{"100-1.\n\u4f9d\u64da\u5be6\u8b49\u91ab\u5b78\uff0c2010\u5e74\u7f8e\u570b\u5fc3\u81df\u5354\u6703(American Heart Association)\u9812\u4f48\u7684\u5c08\u5bb6\u6703\u8b70\u5efa\u8b70\uff0c\u4e0b\u5217\u6709\u95dc\u9662\u5916\u5fc3\u81df\u9589\u6b62(Out-Hospital Cardiac Arrest, OHCA)\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u6b63\u78ba\uff1f\nA. \u5916\u884c\u4eba(Lay person)\u65bd\u884cCPR\u4ecd\u61c9\u9075\u5faa\u80f8\u8154\u58d3\u7e2e(Chest compression)\u53ca\u6301\u7e8c\u6216\u4e2d\u65b7\u6027\u4eba\u5de5\u547c\u5438(Ventilation)\nB. \u53ef\u53ea\u65bd\u884c\u80f8\u8154\u58d3\u7e2e\uff0c\u4ee5\u865f\u53ec\u66f4\u591a\u7684\u5916\u884c\u4eba\u5bb9\u6613\u53c3\u8207CPR\nC. \u53ef\u53ea\u65bd\u884c\u4eba\u5de5\u547c\u5438\uff0c\u4ee5\u865f\u53ec\u66f4\u591a\u7684\u5916\u884c\u4eba\u5bb9\u6613\u53c3\u8207CPR\nD. \u65b0\u5f0f\u7684\u6cbb\u7642-\u4f4e\u6eab\u6cbb\u7642(Therapeutic hypothermia)\u3001\u7d93\u76ae\u51a0\u8108\u963b\u4ecb(PCI)\u53ca\u7559\u7f6e\u5fc3\u81df\u53bb\u986b\u5668(ICD)\u7b49\u4e26\u7121\u5be6\u8cea\u7642\u6548\nE. \u904e\u5ea6\u5f37\u8abf\u55ae\u4e00\u7684\u4eba\u5de5\u547c\u5438\u6216\u80f8\u8154\u58d3\u7e2e\uff0c\u6050\u5f0a\u591a\u65bc\u5229\n": "(B)", "100-2.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u5167\u819c\u708e(Infective Endocarditis)\u7684\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684\uff1f\nA. \u9032\u6b65\u570b\u5bb6\u7684\u5fc3\u5167\u819c\u708e\u8fd1\u5e74\u591a\u589e\uff0c\u56e0\u975e\u6cd5\u4f7f\u7528\u7981\u85e5\u3001\u591a\u7528\u5fc3\u5167\u5668\u68b0(Intracardiac device)\u3001\u591a\u589e\u9000\u5316\u6027\u5fc3\u74e3\u819c\u75c5\u4eba\u3001\u53ca\u91ab\u8b77\u76f8\u95dc\u7684\u611f\u67d3\u75c5\u4e5f\u589e\u591a\nB. \u8d05\u751f\u7269(Vegetation)\u96c6\u8840\u5c0f\u677f\u3001\u7e96\u7dad\u7d20\u3001\u75c5\u83cc\u53ca\u5c11\u6578\u7684\u767c\u708e\u7d30\u80de\uff0c\u591a\u898b\u65bc\u4f4e\u58d3\u8154\u5ba4\u7684\u5fc3\u81df\u7d50\u69cb\nC. \u80c3\u8178\u606f\u8089\u6216\u61a9\u5ba4(Diverticuli)\u5e38\u662f\u93c8\u7403\u83cc\u682a\u7684\u4f86\u6e90\uff0c\u800c\u5927\u8178\u7403\u83cc(Enterococci)\u5e38\u4f86\u81ea\u6ccc\u5c3f\u9053\nD. \u793e\u5340\u611f\u67d3\u5fc3\u5167\u819c\u708e\u591a\u56e0\u93c8\u7403\u83cc(S. viridian)\u3001Staphylococci\u53caHACEK\u75c5\u83cc\u800c\u8d77\nE. \u98df\u9053\u8d85\u97f3\u6ce2\u5fc3\u5716\u6aa2\u67e5\u53ef\u63d0\u9ad8\u5fc3\u5167\u819c\u708e\u7684\u8a3a\u65b7\n": "(A)", "100-3.\n\u6025\u6027\u5fc3\u808c\u6897\u585e\u767c\u75c5\u5f8c\uff0c\u767c\u751f\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\u6642\uff0c\u4f9d\u64da\u5be6\u8b49\u91ab\u5b78\uff0c\u4e0b\u5217\u4f55\u8005\u6c92\u6709\u7f6e\u653e\u6c38\u4e45\u6027\u5fc3\u5f8b\u8abf\u6574\u5668(Permanent pacemaker implantation)\u7684\u5fc5\u8981\uff1f\nA. \u6301\u7e8c\u6027\u7b2c\u4e8c\u6216\u4e09\u5ea6His\u6c0f\u675f\u4ee5\u4e0b\u4e4b\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\nB. \u77ed\u9663\u6027\u7b2c\u4e8c\u6216\u4e09\u5ea6AV node\u4ee5\u4e0b\u4e4b\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\uff0c\u540c\u6642\u4f34\u6709\u675f\u679d\u50b3\u5c0e\u963b\u6eef(BBB)\nC. \u77ed\u9663\u6027\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\u540c\u6642\u4f34\u6709\u5de6\u524d\u675f\u679d\u50b3\u5c0e\u963b\u6eef(Left anterior fascicular block)\nD. \u6301\u7e8c\u6027\u4e14\u6709\u75c7\u72c0\u7684\u7b2c\u4e8c\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\nE. \u6301\u7e8c\u6027\u4e14\u6709\u75c7\u72c0\u7684\u7b2c\u4e09\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\n": "(C)", "100-4.\n\u816b\u7624\u75c5\u4eba\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u65e5\u591a\uff0c\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u85e5\u7269\u4e4b\u5fc3\u8840\u7ba1\u6bd2\u5bb3\u7684\u5be6\u8b49\u91ab\u5b78\u8ad6\u9ede\uff0c\u54ea\u4e9b\u662f\u932f\u8aa4\u7684\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1. \u6bcf\u7a2e\u816b\u7624\u6cbb\u7642\u85e5\u7269\u90fd\u5177\u540c\u6a23\u5fc3\u81df\u6bd2\u5bb3\r\n2. \u51fa\u73fe\u6bd2\u5bb3\u8207\u5e74\u9f61\u7121\u95dc\r\n3 .\u6bd2\u5bb3\u7684\u7522\u751f\u8207\u5291\u91cf\u7684\u5927\u5c0f\u53ca\u670d\u7528\u7684\u6642\u9593\u9577\u77ed\u6709\u95dc\r\n4 .\u4f7f\u7528Beta-Blockers\u53ef\u6539\u5584\u5fc3\u81df\u529f\u80fd\r\n5.\u5118\u65e9\u4f7f\u7528Angiotensin converting enzyme inhibitors\u53ef\u9810\u9632\u5fc3\u808c\u75c5\u8b8a\u4e4b\u767c\u751f\nA. 1+2+3\nB. 1+3+5\nC. 1+2\nD. 2+3\nE. 3+5\n": "(C)", "100-5.\n\u4e0b\u5217\u7684\u5e8a\u908a\u5c64\u6b21\u5fb5\u5146\uff0c\u54ea\u4e9b\u4e0d\u8db3\u4f5c\u70ba\u5224\u5b9a\u50e7\u5e3d\u74e3\u819c\u72f9\u7a84(Mitral stenosis)\u56b4\u91cd\u5ea6\u4e4b\u6839\u64da\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1. \u7b2c\u4e8c\u5fc3\u97f3(P2)-open snap(OS)\u6642\u9593\u5ef6\u9577\r\n2. \u51fa\u73fe\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u540c\u6642\u5408\u4f75\u5fc3\u5ba4\u5feb\u61c9(Rapid ventricular response)\r\n3. \u5fc3\u81df\u8d85\u97f3\u6ce2\u6e2c\u5b9a\u4e4b\u50e7\u5e3d\u74e3\u53e3\u9762\u7a4d(Mitral valvular area)\u5c0f\u65bc1cm2\r\n4. \u51fa\u73fe\u80ba\u52d5\u8108\u9ad8\u58d3(Pulmonary hypertension)\u540c\u6642\u6709\u4e09\u5c16\u74e3\u9589\u92b7\u4e0d\u5168(Tricuspid regurgitation)\r\n5. \u51fa\u73feAustin-Flint murmur\nA. 1+2+3\nB. 1+3+5\nC. 1+3\nD. 1+5\nE. 2+4\n": "(D)", "100-6.\n\u6709\u95dc\u6025\u6027\u5fc3\u808c\u6897\u585e\u7684\u81e8\u5e8a\u6307\u5f15(Guideline)\u61c9\u5305\u62ec\u4e0b\u5217\u8af8\u9ede\u6025\u8a3a\u8655\u7f6e\uff0c\u4f46\u4f55\u8005\u9664\u5916\uff1f\nA. \u6aa2\u50b7\u5206\u985e\u4ee5\u78ba\u4fdddoor-to-needle time\u5c0f\u65bc30\u5206\u9418\u6216door-to-balloon time\u5c0f\u65bc90\u5206\u9418\nB. \u4f7f\u7528Aspirin\nC. \u9664\u4f4e\u8840\u58d3\u3001\u5fc3\u8df3\u5c0f\u65bc60/min\u53ca\u91cd\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\u5916\uff0c\u61c9\u4f7f\u7528Beta-Blockers\u6cbb\u7642\nD. \u9664\u4f4e\u8840\u58d3\u53ca\u53f3\u5fc3\u5ba4\u5fc3\u808c\u6897\u585e\uff0c\u820c\u4e0bNitroglycerin\u78ba\u6709\u4f7f\u7528\u7684\u9700\u8981\nE. \u53ef\u4ee5dihydropyridines\u9223\u96e2\u5b50\u963b\u65b7\u5291\u64f4\u5f35\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u4ee5\u6539\u5584\u5fc3\u808c\u8840\u6db2\u5faa\u74b0\n": "(E)", "100-7.\n\u5973\u6027\u75c5\u4eba68\u6b72\u5728\u6d17\u814e\u4e2d\uff0c\u6709\u982d\u660f\u3001\u5168\u8eab\u7121\u529b\u3001\u51b7\u6c57\u53ca\u5fae\u5598\u6c23\uff0c\u4e43\u8f49\u6025\u8a3a\u8655\u7f6e\u3002\u9019\u4f4d\u592a\u592a\u670910\u5e74\u9ad8\u8840\u58d3\u53ca20\u591a\u5e74\u7684\u7cd6\u5c3f\u75c5\u53f2\uff0c\u4e5f\u5728\u6578\u5e74\u524d\u56e0\u51a0\u5fc3\u75c5\u66fe\u63a5\u53d7\u7d93\u76ae\u51a0\u8108\u4ecb\u5165\u6cbb\u7642(PCI)\uff0c\u4e8c\u5e74\u524d\u56e0\u814e\u75c5\u672b\u671f\uff0c\u6bcf\u9031\u4e09\u6b21\u8840\u6db2\u900f\u6790(Hemodialysis)\u3002\u7406\u5b78\u6240\u898b\uff0cBT\uff1a35.4\u00b0C, RR\uff1a16 min, HR\uff1a43 min, BP\uff1a84/50 mmHg\uff0c\u81c9\u8272\u84bc\u767d\uff0c\u6709\u8ca7\u8840\uff0c\u9838\u975c\u8108\u6012\u5f35\uff0c\u80f8\u90e8\u6709\u6fd5\u56c9\u97f3\uff0c\u5de6\u5fc3\u64f4\u5927\uff0cS1\u504f\u5f31\uff0c\u5728\u5fc3\u5c16\u8655\u6709Gr II Systolic murmur\uff0c\u672a\u8f49\u79fb\uff0c\u4e5f\u7121S3\u6216S4\uff0c\u8179\u90e8\u5fae\u80d6\uff0c\u809d\u813e\u672a\u89f8\u89ba\uff0c\u96d9\u8173\u8f15\u5ea6\u6c34\u816b\u3002\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8\uff38\u5149\u5982\u5716\uff0c\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Uremic cardiomyopathy\nB. Acute myocardial infarction\nC. Hyperkalemia\nD. Complete AV block\nE. Sick sinus syndrome\n": "(C)", "100-8.\n27\u6b72\u7537\u6027\u4e00\u5411\u5065\u5eb7\u53c8\u6d3b\u8e8d\uff0c\u8fd1\u65e5\u4e26\u7121\u50b7\u98a8\u6216\u611f\u5192\uff0c\u8207\u6578\u4f4d\u597d\u53cb\u805a\u9910\u98f2\u9152\uff0c\u6642\u8fd1\u5348\u591c\uff0c\u7a81\u7136\u5931\u53bb\u77e5\u89ba\u5012\u5730\uff0c\u5927\u5925\u4e00\u9663\u614c\u5f35\uff0c\u4f46\u4ecd\u9032\u884cCPR\uff0c\u5f8c\u6025\u96fb\u6551\u8b77\u8eca\u8f49\u9001\u6700\u8fd1\u6025\u8a3a\u8655\uff0c\u7dca\u6025\u6551\u8b77\u54e1\u63a5\u7e8c\u6025\u6551\uff0c\u4e03\u5206\u9418\u9001\u62b5\u91ab\u9662\uff0c\u4f9d\u7167Out-Hospital Cardiac Arrest(OHCA)\u8655\u7f6e\u3002Pupil\uff1a5/5 \u660f\u8ff7\u6307\u6578\uff1aE1V1M1\uff1b\u8eab\u9ad8\uff1a160cm\uff1b\u9ad4\u91cd\uff1a70kg\uff1b\u9ad4\u6eab\uff1a37.2\u2103\uff1b\u7121\u5fc3\u8df3\uff0c\u7121\u8840\u58d3\u53ca\u7121\u547c\u5438\u3002\u8840\u6db2\u53ca\u751f\u5316\u6aa2\u67e5\uff1a WBC\uff1a24000/uL\uff1bHb\uff1a15.2 gm/dL\uff1bPlt:378000/uL\uff1bSeg/Lym\uff1a40.6%/52.3%\uff1bBUN\uff1a10.9 mg/dL\uff1bCr\uff1a1.23 mg/dL\uff1bGOT:58 IU/L\uff1bGlucose\uff1a309 mg/dL\uff1bNa/K/Cl/Mg\uff1a140/3.1/103/0.8 mol/L\uff1bCa7.7\r\nmg/dL\uff1bCKMB/CPK\uff1a2.6/87 U/L Tropnin I 0.19ng/mL\uff1bABG:PH\uff1a6.928\uff1bPCO2\uff1a89.9mmHg\uff1b PO2\uff1a154.6mmHg\uff1bHCO3\uff1a18.4 mEq/L\uff1bSaO2\uff1a97.2%\u3002\u7d93\u6025\u6551\u5f8c\uff0c\u5448\u73fe\u9ad8\u71d2>42\u2103\uff0c\u5fc3\u8df3120bpm\u53ca\u8840\u58d3BP117/76 mmHg\u53ca\u6bcf\u520640\u6b21\u4e4b\u6025\u4fc3\u547c\u5438\uff0c\u5fc3\u97f3\u5fae\u5f31\uff0c\u6574\u500b\u80ba\u547c\u5438\u8072\u6fc1\uff0c\u56db\u80a2\u8edf\u5f31\u3002\u5fc3\u96fb\u5716\u5982\u793a\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684OHCA\u539f\u56e0\u662f\uff1a\nA. Acute anterior myocardial infarction\nB. Acute myocarditis\nC. Alcoholic intoxication\nD. Brugada's syndrome\nE. Long QT syndrome\n": "(D)", "100-9.\n56\u6b72\u7537\u6027\u516c\u52d9\u4eba\u54e1\u56e0\u7a81\u767c\u5fc3\u80f8\u524d\u5340\u5287\u75db\uff0c\u6709\u5de6\u624b\u7684\u8f49\u79fb\u9178\u75bc\uff0c\u4e26\u5b58\u5192\u6c57\u53ca\u81c9\u8272\u84bc\u767d\uff0c\u96a8\u5373\u62b5\u9054\u6025\u8a3a\u8655\u8a3a\u7642\uff0c\u75c5\u4eba\u6709\u4e09\u5341\u5e74\u6bcf\u59291.5\u5305\u9999\u7159\u53ca\u4e09\u5e74\u8f15\u5ea6\u7cd6\u5c3f\u75c5\uff0c\u8fd1\u4e09\u500b\u6708\u6709\u9593\u6b47\u6027\u5fc3\u7d5e\u75bc\u767c\u751f\u3002\u7406\u5b78\uff1a\u6025\u75c5\u72c0\uff0c\u8840\u58d3165/106 mmHg\uff1b \u5fc3\u8df396/min\uff1b\u9ad4\u6eab36.7\u2103\uff0c\u5176\u4ed6\u4e26\u7121\u986f\u8457\u7570\u5e38\u3002\u5fc3\u96fb\u5716\u5982\u793a\uff0c\u8acb\u554f\u9019\u5f35\u5fc3\u96fb\u5716\u6240\u8868\u73fe\u6700\u53ef\u80fd\u7684\u51a0\u72c0\u52d5\u8108\u5b8c\u5168\u963b\u585e\u4f4d\u7f6e\u662f\uff1a\nA. Left main coronary artery\nB. Left anterior descending artery proximal to septal branch\nC. Proximal left circumflex artery\nD. Proximal right coronary artery\nE. Left anterior descending artery to Diagonal branch\n": "(D)", "100-10.\n\u4e0b\u5217\u6709\u95dc\u7121\u75c7\u72c0\u9ad8\u8840\u58d3(>180/120mmHg)\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f\r\n1. \u6b63\u898f\u4f7f\u7528\u6cbb\u7642\u91cf\u7684\u591a\u7a2e\u964d\u8840\u58d3\u85e5\u7684\u75c5\u4eba\u4ecd\u820a\u7121\u6548\uff0c\u5176\u9ad8\u8840\u58d3\u591a\u56e0\u651d\u53d6\u98df\u9e7d\u9ad8\u6240\u800c\u8d77\uff0c\u61c9\u5f37\u5236\u9650\u7528\u98df\u9e7d\u98f2\u98df\r\n2. \u4ecd\u61c9\u7dca\u6025\u964d\u4f4e\u8840\u58d3\u5230160/100mmHg\u4ee5\u4e0b\uff0c\u4ee5\u7b56\u5b89\u5168\r\n3. \u4f7f\u7528\u820c\u4e0bNifedipine\u964d\u58d3\u662f\u9019\u985e\u75c5\u4eba\u4e4b\u9996\u9078\r\n4. \u4f9d\u64da\u5be6\u8b49\u91ab\u5b78\uff0c\u5b55\u5a66\u7684\u9ad8\u8840\u58d3\u61c9\u5373\u6ce8\u5c04\u975c\u8108Nicardipine\r\n5. \u4e0d\u61c9\u7acb\u5373\u4f4f\u9662\nA. 1+2+3\nB. 2+3+4\nC. 1+3+5\nD. 1+4\nE. 1+5\n": "(E)", "100-11.\n\u5fc3\u8840\u7ba1\u7cfb\u7d71\u7406\u5b78\u6aa2\u67e5\u4e4b\u7368\u7279\u6027\u70ba\u8996\u8a3a (\u5167\u9838\u975c\u8108)\u3001\u89f8\u8a3a (\u9838\u52d5\u8108\u6216\u6a48\u9aa8\u8108\u640f)\u8207\u807d\u8a3a\u53ef\u540c\u6b65\u57f7\u884c (\u6240\u8b023\u54081\u6aa2\u67e5)\u3002\u4e0b\u5217\u5fc3\u96fb\u5716 (1 - 4) \u6240\u793a\u4e4b\u4e0d\u6574\u8108,\u5982\u53ea\u9760\u52d5\u8108\u628a\u8108\uff0c\u4f55\u8005\u6703\u88ab\u8aa4\u5224\u70ba\u7ac7\u623f\u6027\u5f90\u8108 (sinus bradycardia)?\nA. 1\nB. 2\nC. 3\nD. 4\nE. 1-4 \u7686\u6703\u88ab\u8aa4\u5224\u70ba\u7ac7\u623f\u6027\u5f90\u8108\n": "(E)", "100-12.\n\u80f8\u90e8\u2169\u5149\u4e0b\u5217\u7570\u5e38\u6240\u898b\uff0c\u4f55\u8005\u70ba\u975e?\nA. \u5de6\u5fc3\u623f\u64f4\u5927\nB. \u5de6\u5fc3\u5ba4\u64f4\u5927\nC. \u53f3\u5fc3\u5ba4\u64f4\u5927\nD. \u80ba\u975c\u8108\u58d3\u4e0a\u6607\nE. \u80ba\u4e3b\u52d5\u8108\u64f4\u5927\n": "(B)", "100-13.\n\u4e00\u4f4d40\u6b72\u7537\u6027\u60a3\u6709 primary pulmonary hypertension, \u56e0\u5e73\u6642\u547c\u5438\u56f0\u96e3\u3001\u8173\u6d6e\u816b\u670d\u7528\u5229\u5c3f\u5291\u3002\u56e0\u6700\u8fd1\u5169\u9031\u8d70\u8def\u6642\u4e0a\u8179\u90e8\u6f32\u75db\u63d0\u524d\u81f3\u9580\u8a3a\u8907\u8a3a\u3002\u554f\u8a3a\u767c\u73fe\u5176\u8179\u90e8\u75c7\u72c0\u8173\u816b\u52a0\u5287\u6642\u66f4\u660e\u986f\uff0c\u53cd\u4e4b\u5982\u52a0\u91cd\u4f7f\u7528\u5229\u5c3f\u5291\u6d6e\u816b\u6e1b\u8f15\u5f8c\u5247\u6539\u5584\u3002\u75c5\u4eba\u7121\u809d\u75c5\u6216\u809d\u529f\u80fd\u7570\u5e38\u4e4b\u75c5\u53f2\u3002\u7406\u5b78\u6aa2\u67e5\u986f\u793a\u610f\u8b58\u6e05\u6670\uff0c\u8840\u58d3118/76 mmHg\uff0c\u8108\u640f\u6bcf\u5206\u941898\u3001\u898f\u5247\uff0c\u547c\u5438\u7a0d\u6dfa\u5feb\u3001\u624b\u8173\u7a0d\u51b0\u51b7\uff0c\u5750\u4f4d\u6642\u53f3\u8033\u5782\u96a8\u5fc3\u6536\u7e2e\u671f\u640f\u52d5\u3002\u5fc3\u81df\u53f3\u5fc3\u5ba4\u64f4\u5927 (\u80f8\u9aa8\u4e0b\u5de6\u7de3\u81f3\u5fc3\u5c16\u90e8\u4f4d\uff0c\u7030\u6f2b\u6027\u6536\u7e2e\u671f\u640f\u52d5(systolic heave)\uff0c\r\n\u7b2c\u4e8c\u5fc3\u97f3P2\u4ea2\u9032\uff0c\u80f8\u9aa8\u5de6\u7de3\u4e0b\u7b2c\u4e09\u5ea6\u6536\u7e2e\u671f\u96dc\u97f3\u96a8\u5438\u6c23\u589e\u5f37\u3002\u80ba\u90e8\u7121\u660e\u986f\u56c9\u97f3\uff0c\u809d\u660e\u986f\u816b\u5927\u8868\u9762\u5e73\u6ed1\u3001\u96a8\u5fc3\u6536\u7e2e\u671f\u640f\u52d5\u3001\u7a0d\u6709\u58d3\u75db\u3002\u6709\u95dc\u6b64\u75c5\u4eba\u75c5\u60c5\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1.\u6709\u53f3\u5fc3\u5ba4\u8870\u7aed\u53ca\u56b4\u91cd\u4e09\u5c16\u74e3\u9589\u9396\u4e0d\u5168\uff0c\u809d\u975c\u8108/\u6bdb\u7d30\u7ba1\u975c\u6c34\u58d3\u4e0a\u5347\uff0c\u5c0e\u81f4\u809d\u5145\u8840 (congested liver) \u3002\r\n2.\u6709\u52de\u4f5c\u6027\u72f9\u5fc3\u75c7 (exertional angina)\u3002\r\n3.\u9810\u671f\u6b64\u75c5\u4eba\u809d\u529f\u80fd\u6aa2\u67e5\u7570\u5e38AST\u3001ALT\uff0c\u4e14ALT\u4e0a\u5347\u8f03AST\u4e0a\u5347\u591a\r\n4.\u4e0a\u8ff0\u809d\u529f\u80fd\u6aa2\u67e5\u7570\u5e38\u8207 shock liver\u6642\u96f7\u540c\u3002\r\n5.\u6709\u57f7\u884c\u809d\u8d85\u97f3\u6ce2\u6aa2\u67e5\u4e4b\u9069\u61c9\u75c7\u3002\nA. 1+3+4\nB. 1+2+3+4+5\nC. 1+3+4+5\nD. 1+2+3+4\nE. 1+5\n": "(A)", "100-14.\n\u4ee5\u4e0b\u53ef\u80fd\u9020\u6210\u4ea4\u4e92\u4f5c\u7528(interaction) \u4e4b\u914d\u5c0d\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. Amiodarone - calcium channel blocker.\nB. Statin - grape fruits (\u8461\u8404\u67da)\nC. Amiodarone - warfarin\nD. Nitrates - sildenafil\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(E)", "100-15.\n50\u6b72\u7537\u6027\uff0c\u60a3\u6709\u7cd6\u5c3f\u75c5\uff0c\u80f0\u81df\u764c\u53ca\u6050\u614c\u75c7\uff0c\u56e0\u7a81\u767c\u6027\u547c\u5438\u56f0\u96e3\u81f3\u6025\u8a3a\u6c42\u8a3a\u3002\u75c5\u60a3\u4e26\u7121\u660e\u986f\u80f8\u75db\u6216\u5192\u51b7\u6c57\uff0c\u610f\u8b58\u6e05\u695a\u4f46\u60c5\u7dd2\u7dca\u5f35\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u9ad4\u6eab36.5\u2103\uff0c\u8840\u58d3 145/95 mmHg\uff0c\u8108\u535a112/min\u7bc0\u5f8b\u898f\u5247, \u547c\u5438 24/min\u5feb\u4e14\u6df1\uff1b\u56db\u80a2\u51b0\u51b7\u6709\u8f15\u5fae\u767c\u7d3a\u73fe\u8c61\u3002\u9838\u975c\u8108\u58d312 cm H2O\uff0c\u7121\u660e\u986f\u5fc3\u96dc\u97f3\u3002\u547c\u5438\u97f3\u96d9\u5074\u6b63\u5e38\uff0c\u8179\u90e8\u5e73\u5766\u7121\u58d3\u75db\uff0c\u56db\u80a2\u6d3b\u52d5\u6b63\u5e38\u4ea6\u7121\u6c34\u816b\u3002\u8b77\u7406\u4eba\u54e1\u7d66\u4e88\u8108\u885d\u8840\u6c27\u5b9a\u91cf\u8a08 (pulse oximeter) \u5075\u6e2c\u767c\u73feSpO2 84%\uff0c\u6025\u8a3a\u91ab\u5e2b\u96a8\u5373\u6307\u793a\u4f7f\u7528Venturi mask O2 35%\u3002\u7d04\u534a\u5c0f\u6642\u5f8c\uff0c\u75c5\u4eba\u81ea\u89ba\u75c7\u72c0\u7565\u70ba\u6e1b\u7de9\uff0c\u6b64\u6642\u4e4b\u52d5\u8108\u6c23\u9ad4\u5206\u6790: PH 7.50, PaO2 70mmHg, PaCO2 25 mmHg, HCO3 23\r\nmEq/L, one touch blood glucose 320 mg/dl. EKG\u9664\u7ac7\u6027\u983b\u8108\u5916\u5176\u9918\u6b63\u5e38\uff0c\u80f8\u90e8\u2169\u5149\u5982\u9644\u5716\uff0c\u4e0b\u5217\u8a3a\u65b7\u4f55\u8005\u6700\u6709\u53ef\u80fd?\nA. Acute pulmonary embolism\nB. Panic disorder related hyperventilation syndrome\nC. Diabetic ketoacidosis\nD. Endobronchial foreign body\nE. Bronchial asthma\n": "(A)", "100-16.\n\u4e0b\u5217\u6709\u95dc\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4 (obstructive sleep apnea, OSA) \u6240\u7522\u751f\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6709\u8aa4?\nA. \u5bb9\u6613\u5f15\u767c\u5fc3\u8840\u7ba1\u75be\u75c5\uff0c\u5982\u8166\u4e2d\u98a8\u548c\u5fc3\u808c\u6897\u585e\nB. \u8207\u4ee3\u8b1d\u75c7\u5019\u7fa4\u4e2d\u7684\u80f0\u5cf6\u7d20\u6297\u6027(insulin resistance)\u7121\u95dc\nC. OSA\u4e5f\u548c\u9ad8\u8840\u58d3\u53ca\u80ba\u52d5\u8108\u9ad8\u58d3\u76f8\u95dc\nD. OSA\u5f15\u8d77\u4e4b\u5fc3\u5f8b\u4e0d\u6574\uff0c\u6700\u5e38\u898b\u70ba\u623f\u5ba4\u963b\u65b7\u53ca\u5fc3\u623f\u986b\u52d5 (Atrial fibrillation)\nE. \u56b4\u91cd\u4e4bOSA\u7d93\u9023\u7e8c\u547c\u5438\u9053\u6b63\u58d3\u547c\u5438\u5668 (CPAP) \u6210\u529f\u6cbb\u7642\u5f8c\uff0c\u5fc3\u808c\u6897\u585e\u53ca\u8166\u4e2d\u98a8\u4e4b\u98a8\u96aa\u53ef\u6062\u5fa9\n": "(B)", "100-17.\n\u75c7\u72c0\u4e4b\u8d77\u59cb\u767c\u4f5c\u578b\u614b (mode of onset) \u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u6975\u70ba\u91cd\u8981\uff0c\u4e0b\u5217\u53ef\u80fd\u4ee5\u80f8\u75db\u8868\u73fe\u4e4b\u6025\u75c7\u4e2d\uff0c\u5176\u75db\u4e4b\u8d77\u59cb\u767c\u4f5c\u578b\u614b\u70ba\u8d85\u6025\u6027(abrupt or dramatic onset) - \u5373\u5176\u75db\u7a81\u7136\u767c\u751f\uff0c\u5176\u7a0b\u5ea6\u77ac\u9593\u6216\u8fc5\u901f\u9054\u5230\u6975\u9ede (\u6674\u5929\u9739\u9742\u5f0f) \u8005\uff0c\u4f55\u8005\u70ba\u4f8b\u5916\uff1f\nA. \u6025\u6027\u5fc3\u808c\u6897\u585e\nB. \u4e3b\u52d5\u8108\u525d\u96e2\u75c7\nC. \u6c23\u80f8 (pneumothorax)\nD. Boerhaave's syndrome\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(A)", "100-18.\n\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u5f15\u8d77\u4e4b\u547c\u5438\u56f0\u96e3\u7684\u767c\u75c5\u578b\u614b (onset mode) \u662f\u70ba\u7a81\u767c\u6027 (sudden onset)? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1. Pneumothorax\r\n2. Acute pulmonary embolism\r\n3. Acute severe mitral regurgitation due to chordae tendineae rupture\r\n4. Panic disorder related hyperventilation syndrome\r\n5. ARDS (acute respiratory distress syndrome)\nA. 1+2\nB. 1+2+3\nC. 1+2+3+4\nD. 1+2+3+4+5\nE. 1+2+4\n": "(C)", "100-19.\n\u80ba\u6c34\u816b\u7684\u75c5\u614b\u751f\u7406\u5b78\uff0c\u5c0e\u56e0\u65bc\u6c34/\u9209\u96e2\u5b50\u7559\u6eef\u5728\u6bdb\u7d30\u7ba1\u5916\u9593\u8cea\u5167\u6240\u5f15\u8d77\u3002\u4f9d\u7167\u5176\u539f\u56e0\u53ef\u5206\u70ba\u5169\u5927\u985e\uff0c\u5373\u5fc3\u56e0\u6027 (cardiogenic) \u548c\u975e\u5fc3\u56e0\u6027 (non-cardiogenic)\uff0c\u6cbb\u7642\u65b9\u5411\u4e0d\u76e1\u76f8\u540c\uff0c\u6545\u5176\u9451\u5225\u8a3a\u65b7\u6975\u70ba\u91cd\u8981\u3002\u4e0b\u5217\u5404\u7a2e\u75be\u75c5\u5f15\u8d77\u4e4b\u80ba\u6c34\u816b\u70ba\u975e\u5fc3\u56e0\u6027\u80ba\u6c34\u816b? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1. \u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (Acute respiratory distress syndrome)\r\n2. \u6bd2\u7269\u5438\u5165\u5f15\u8d77\u4e4b\u80ba\u640d\u50b7 (toxic inhalation lung injury)\r\n3. \u518d\u64f4\u5f35\u6027\u80ba\u6c34\u816b (re-expansion pulmonary edema)\r\n4. \u9ad8\u5c71\u75c7\r\n5. \u4e8c\u5c16\u74e3\u72f9\u7a84\r\n6. \u5de6\u5fc3\u5ba4\u8870\u7aed\nA. 1+2\nB. 1+2+3\nC. 1+2+3+4\nD. 1+2+3+4+5\nE. 1+2+3+4+5+6\n": "(C)", "100-20.\n\u59ff\u52e2\u8207\u9ad4\u4f4d\u7684\u8b8a\u5316\u6703\u9020\u6210\u5fc3\u81df\u524d\u8ca0\u8377\u8207\u7cfb\u7d71\u6027\u52d5\u8108\u8840\u7ba1\u963b\u529b (systemic vascular resistance) \u4e4b\u6539\u8b8a\u3002\u4e0b\u5217\u5404\u7a2e\u60c5\u6cc1\u8207\u751f\u7406\u5b78\u4e4b\u914d\u5c0d\u4f55\u8005\u6709\u8aa4?\nA. \u7576\u75c5\u4eba\u767c\u751fVasovagal syncope\u6642\uff0c\u8b93\u75c5\u4eba\u5e73\u8eba\u4e26\u4f7f\u5176\u5448knee-chest position (\u819d\u84cb\u5411\u80f8\u53e3\u5f4e\u66f2) \u53ef\u5e6b\u52a9\u75c5\u4eba\u7526\u9192\nB. \u80a5\u539a\u6027\u963b\u585e\u578b\u5fc3\u808c\u75c5\u8b8a (hypertrophic obstructive cardiomyopathy) \u7684\u75c5\u4eba\uff0c\u4ee4\u5176\u8e72\u4e0b\uff0c\u53ef\u4f7f\u5f8c\u8ca0\u8377\u6e1b\u5c11\u800c\u8b93\u96dc\u97f3\u6e1b\u5f31\nC. \u6cd5\u6d1b\u6c0f\u56db\u5408\u75c7 (tetralogy of Fallot) \u4e4b\u75c5\u7ae5\uff0c\u7576\u5176\u767c\u751fhypoxic spell (\u7f3a\u6c27\u6027\u767c\u4f5c) \u547c\u5438\u56f0\u96e3\u3001\u767c\u7d3a\u60e1\u5316\u6642\uff0c\u5e38\u81ea\u4e3b\u6027\u8e72\u4e0b\uff0c\u56e0\u4f7f\u53f3\u5fc3\u5ba4\u524d\u8ca0\u8377\u589e\u52a0\u4e14\u5de6\u3001\u53f3\u5fc3\u5ba4\u58d3\u529b\u589e\u52a0\u800c\u80ba\u8840\u6d41\u589e\u52a0\uff0c\u81f3\u5de6\u5fc3\u5ba4\u5206\u6d41\u6e1b\u5c11\uff0c\u4ee5\u6e1b\u7de9\u75c7\u72c0\nD. \u5fc3\u7d5e\u75db\u4e4b\u75c5\u4eba\u82e5\u7ad9\u7acb\u6642\u4f7f\u7528\u785d\u9178\u9e7d\u820c\u4e0b\u542b\u9320\u53ef\u80fd\u5c0e\u81f4\u6688\u53a5\uff0c\u662f\u7531\u65bc\u59ff\u52e2\u6539\u8b8a\u53ca\u975c\u8108\u64f4\u5f35\uff0c\u9020\u6210\u524d\u8ca0\u8377\u6025\u907d\u6e1b\u5c11\u6240\u9020\u6210\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(B)", "100-21.\n\u5fc3\u623f\u986b\u52d5 (atrial fibrillation) \u70ba\u6700\u5e38\u898b\u4e4b\u6301\u7e8c\u6027\u983b\u8108 (sustained tachycardia) \uff0c\u5176\u767c\u751f\u7387\u96a8\u5e74\u9f61\u800c\u589e\u52a0\u3002\u6709\u95dc\u8001\u5e74\u4eba\u767c\u751f\u5fc3\u623f\u986b\u52d5\u6642\u4e4b\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u5e38\u60a3\u6709\u5de6\u5fc3\u5ba4\u8212\u5f35\u671f\u529f\u80fd\u7570\u5e38 (left ventricular dysfunction)\uff0c\u800c\u5de6\u5fc3\u5ba4\u8212\u5f35\u671f\u9806\u61c9\u6027\u964d\u4f4e\uff0c\u56e0\u6b64\u8108\u5dee(pulse deficit) \u6bd4\u5de6\u5fc3\u5ba4\u8212\u5f35\u671f\u529f\u80fd\u6b63\u5e38\u8005\u76f8 \u5c0d\u589e\u52a0\nB. \u4f7f\u7528\u63a7\u901f\u85e5\u7269\uff0c\u5291\u91cf\u8abf\u6574\u61c9\u4ee5\u9069\u7576\u5fc3\u5ba4\u7387\u70ba\u6e96\nC. \u56e0\u5e38\u53ef\u80fd\u814e\u529f\u80fd\u7570\u5e38\uff0c\u4f7f\u7528amiodarone\u63a7\u901f\uff0c\u61c9\u76e3\u63a7\u5176\u8840\u4e2d\u6fc3\u5ea6\nD. \u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032 (hyperthyroidism) \u6709\u53ef\u80fd\u55ae\u4ee5\u5fc3\u623f\u986b\u52d5\u8868\u73fe\nE. \u82e5\u6709\u767c\u751ftransient ischemia attack\uff0c\u5247\u5efa\u8b70\u4f7f\u7528Warfarin.\n": "(C)", "100-22.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u56e0\u6027\u4f11\u514b(Cardiogenic Shock, CS)\u7684\u81e8\u5e8a\u8aaa\u6cd5\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba\u7684?\nA. \u5fc3\u96fb\u5716\u53ef\u80fd\u770b\u5230 Q wave \u53ca ST elevation>2mm\u6216LBBB\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e\u76f8\u95dc\u4e4bCS\u56e0\u65e9\u671f\u8840\u7ba1\u8108\u518d\u901a(Revascularization)\u5176\u767c\u751f\u7387\u5df2\u5f9e20%\u964d\u523010%\u4ee5\u4e0b\nC. \u61c9\u96a8\u5373\u65bd\u884c\u8d85\u97f3\u6ce2\u5fc3\u5716\u4ee5\u78ba\u5b9a\u75c5\u56e0\nD. \u4f9d\u64daSHOCK Trial, Coronary artery bypass graft surgery(CABGS)\u6216Percutaneous intervention(PCI)\u6bd4IABP(Intra aoric balloon counterpulsation)\u4f75\u7528\u8840\u6813\u6eb6\u89e3\u6cbb\u7642\u70ba\u4f73\nE. \u5927\u65bc75\u6b72\u4e0d\u9069\u5b9c\u65bd\u884cCABG\u6216PCI\n": "(E)", "101-1.\n\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u4e0d\u9069\u5fc3\u81df\u78c1\u6838\u5171\u632f\u5f71\u50cf(Cardiovascular magnetic resonance imaging)\u6aa2\u67e5\uff1f\nA. \u51a0\u8108\u7ba1\u5167\u652f\u67b6(Coronary stents)\nB. \u6b98\u7559\u5fc3\u81df\u51672000\u5e74\u5f8c\u4e4b\u5fc3\u5f8b\u8abf\u6574\u5668\u7684\u7ba1\u7dda(Pacemaker leads)\nC. \u80f8\u9aa8\u5207\u88c2\u91d1\u5c6c\u5d4c\u5408\u7dda(Sternotomy wires)\nD. \u80f8\u8154\u5167\u8840\u7ba1\u9257\u593e(Vascular clip)\nE. \u751f\u7269\u6027\u53ca\u91d1\u5c6c\u6027\u4eba\u5de5\u5fc3\u81df\u74e3\u819c(Bioprosthetic & mechanical heart valve)\n": "(E)", "101-2.\n\u4fb5\u5165\u6027\u7684\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u67093-7%\u767c\u751f\u986f\u5f71\u5291\u5c0e\u767c\u814e\u75c5\u8b8a(Contrast-induced nephropathy)\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u9810\u9632\u8655\u7f6e\u932f\u8aa4\uff1f\nA. \u5728\u8853\u524d\u53ca\u8853\u5f8c\u7d66\u4e88Normal saline 50 cc/hour x 24 hours\nB. \u8853\u524d\u4e8c\u5929\u958b\u59cb Acetylcysteine 600 mg bid\nC. \u7cd6\u5c3f\u75c5\u4eba\u6212\u7528Metformin\nD. \u4f7f\u7528\u53e3\u670d\u4f4e\u6fc3\u5ea6\u9e7d\u9178\u4ee5\u589e\u52a0\u986f\u5f71\u5291\u4e4b\u6eb6\u89e3\u5ea6\uff0c\u65e9\u671f\u6392\u51fa\u9ad4\u5916\nE. \u4f7f\u7528\u4f4e\u6ef2\u900f\u58d3\u986f\u5f71\u5291(Low-osmolar contrast media)\uff0c\u9650\u91cf\u5728100 cc \u4ee5\u4e0b\n": "(D)", "101-3.\n\u8a3a\u65b7\u50e7\u5e3d\u74e3\u72f9\u7a84(Mitral stenosis)\u4e4b\u56b4\u91cd\u5ea6\u9664\u5305\u62ec\u81e8\u5e8a\u7684\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3\u3001\u5fc3\u60b8\u53ca\u8840\u75f0\u5916\uff0c\u53ca\u7406\u5b78\u986f\u73fe\u7684\u53f3\u5fc3\u64f4\u5927\uff0c\u5f37\u5ea6S1\uff0c\u5f37\u5ea6\u5fc3\u8212\u4e2d\u671f\u9686\u55da\u96dc\u97f3(Mid-diastolic rumbling murmur)\u53ca\u5fc3\u7e2e\u524d\u671f\u96dc\u97f3\u3002\u5f9e\u8840\u884c\u529b\u5b78\u7684\u89d2\u5ea6\uff0c\u4ee5\u4e0b\u5217\u4f55\u8005\u6700\u6703\u5f71\u97ff\u50e7\u5e3d\u74e3\u72f9\u7a84\u4e4b\u81e8\u5e8a\u75c7\u72c0\u7684\u56b4\u91cd\u5ea6\uff1f\nA. \u5fc3\u8df3(Heart rate)\nB. \u7a7f\u8d8a\u50e7\u5e3d\u74e3\u8840\u58d3\u95a5\u5dee(Trans-mitral valvular pressure gradient)\nC. \u5fc3\u81df\u6392\u8840\u91cf(Cardiac output)\nD. \u50e7\u5e3d\u74e3\u958b\u53e3\u9762\u7a4d(Mitral valvular area)\nE. S2 to OS(Open snap)\u6642\u9593\u7e2e\u77ed\n": "(A)", "101-4.\n\u75c5\u4eba82\u6b72\u8001\u592a\u5927\u56e0\u7a81\u6f38\u56b4\u91cd\u6027\u547c\u5438\u56f0\u96e3\u800c\u4f4f\u9662\uff0c\u5979\u4e09\u5341\u5e74\u524d\u5c31\u6709\u5fc3\u96dc\u97f3\u53ef\u805e\u77e5\uff0c\u552f\u672a\u66fe\u9032\u4e00\u6b65\u8a3a\u7642\u3002\u5f9e\u4e94\u5e74\u524d\u958b\u59cb\u5c31\u6709\u904b\u52d5\u96e3\u53d7\uff0c\u4f34\u6709\u904b\u52d5\u6027\u5fc3\u60b6\uff0c\u6642\u5728\u516c\u4fdd\u4e2d\u5fc3\u78ba\u8a8d\u5fc3\u81df\u64f4\u5927\uff0c\u5728\u4ee5\u5f8c\u7684\u6b72\u6708\uff0c\u75c7\u72c0\u9010\u6f38\u52a0\u5287\uff0c\u7279\u5225\u5728\u904b\u52d5\u6216\u6500\u767b\u6a13\u68af\u4e2d\uff0c\u4f11\u606f\u5373\u53ef\u6539\u5584\u3002\u4f4f\u9662\u524d\u4e09\u65e5\uff0c\u7a81\u7136\u5728\u51cc\u6668\u767c\u4f5c\u547c\u5438\u56f0\u96e3\u3002\u6642\uff0cT/P/R\uff1a36.4/90/16\uff1b BP\uff0c110/62 mmHg\uff1bjugular vein engorgement\uff1bbilateral basal chest with crackles\uff1bheart\uff0cnormal heart border\uff0cGr.III systolic murmur over RUSB with carotid transmission\uff0cS2 diminished\uff1botherwise unremarkable\u3002 Chest X- ray &\rECG\u5982\u57164-1\u53ca\u57164-2\u6240\u793a\u3002\r\u8acb\u554f\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. \u50e7\u5e3d\u74e3\u72f9\u7a84(Mitral stenosis)\nB. \u50e7\u5e3d\u74e3\u9589\u9396\u4e0d\u5168(Mitral regurgitation)\nC. \u4e3b\u52d5\u8108\u74e3\u72f9\u7a84(Aortic stenosis)\nD. \u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168(Aortic regurgitation)\nE. \u6b63\u5e38\u5fc3\u81df\n": "(C)", "101-5.\n\u6709\u95dc\u51a0\u5fc3\u75c5\u8fd1\u56db\u5341\u5e74\u7684\u6d41\u884c\u75c5\u5b78\u6f14\u5316\uff0c\u6709\u4e0b\u5217\u8af8\u9ede\u4e4b\u6027\u5225\u5dee\u7570(Gender difference)\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u51a0\u5fc3\u75c5\u4e4b\u767c\u751f\uff0c\u4e00\u5411\u7537\u591a\u65bc\u5973\nB. \u7d93\u5e74\u9f61\u6821\u6b63(Age-adjusted)\u5f8c\uff0c\u5973\u6027\u75c5\u4eba\u7684\u5fc3\u8840\u7ba1\u75c5\u6b7b\u4ea1\u7387\u8f03\u4f4e\nC. \u4ee5\u904b\u52d5\u5fc3\u96fb\u5716\u8a3a\u65b7\u51a0\u5fc3\u75c5\uff0c\u7537\u6027\u75c5\u4eba\u6709\u8f03\u9ad8\u7684\u53ef\u9760\u5ea6\nD. \u5973\u6027\u4e4b\u51a0\u5fc3\u75c5\u767c\u751f\u6a5f\u8f49\u591a\u8207\u767c\u708e\u3001\u80a5\u80d6\u3001\u7cd6\u5c3f\u75c5\u53ca\u4ee3\u8b1d\u75c7\u5019\u7fa4\u6709\u95dc\nE. \u5973\u6027\u7684\u51a0\u5fc3\u75c5\u591a\u56e0\u51a0\u8108\u5fae\u5faa\u74b0(micro-circulation)\u5931\u80fd\u800c\u8d77\n": "(B)", "101-6.\n\u6709\u95dc\u6211\u570b\u96d9\u8449\u6027(bicuspid)\u4e3b\u52d5\u8108\u74e3\u7684\u81ea\u7136\u75c5\u53f2\u4e4b\u7814\u7a76\u5c1a\u5c6c\u6b20\u7f3a\uff0c\u552f\u4f9d\u64da\u7f8e\u570bMayo Clinic\u5728Olmstead County\u768441,687\u4f4d\u5c45\u6c11\u6b77\u6642\u4e09\u5341\u5e74\u4e4b\u7cfb\u5217\u8ffd\u8e64\uff0c\u6709\u4e0b\u5217\u8af8\u591a\u7279\u9ede\u53ef\u8cc7\u53c3\u8003\uff0c\u4f46\u4f55\u8005\u7684\u8ad6\u8ff0\u662f\u932f\u8aa4\u7684\uff1f\nA. \u65e5\u5f8c\u767c\u751f\u4e3b\u52d5\u8108\u525d\u96e2(aortic dissection)\u4f75\u767c\u75c7\u4e4b\u76f8\u5c0d\u5371\u96aa\u5ea6\u9ad8\u90548.4\u500d\nB. \u65e5\u5f8c\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84(aortic stenosis)\u7684\u767c\u751f\u7387\u6bd4\u4e3b\u52d5\u8108\u74e3\u9589\u92b7\u4e0d\u5168(aortic regurgitation)\u591a\u8fd1\u4e00\u500d\nC. \u96d9\u8449\u6027\u4e3b\u52d5\u8108\u74e3\u75c5\u591a\u898b\u65bc\u7537\u6027\u75c5\u4eba\nD. \u4e00\u65e6\u4f34\u767c\u4e3b\u52d5\u8108\u7624(Aortic aneurysm)\uff0c\u5982\u5176\u76f4\u5f91\u5927\u65bc50 mm \u6642\uff0c\u5e38\u6613\u81f4\u8840\u7ba1\u7834\u88c2\nE. \u96d9\u8449\u6027\u4e3b\u52d5\u8108\u74e3\u8005\u591a\u898b\u56ca\u80de\u6027\u4e2d\u5c64\u58de\u6b7b(Cystic medial necrosis)\n": "(B)", "101-7.\n\u75c5\u4eba67\u6b72\u5973\u6027\uff0c\u4f4f\u5b89\u990a\u8001\u4eba\u9662\uff0c\u4e0b\u5e8a\u8dcc\u50b7\u53f3\u8173\uff0c\u4e94\u5929\u5f8c\u56e0\u610f\u8b58\u4e0d\u6e05\u4f34\u6709\u6c23\u4fc3\u3001\u767c\u71d2\u3001\u5bd2\u986b(chills)\u800c\u4f4f\u9662\u3002\u75c5\u4eba\u6709\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\uff0c\u4e5f\u6709\u9ad8\u8840\u58d3\u5408\u4f75\u5fc3\u81df\u8870\u7aed\u7684\u75c5\u53f2\u3002\u4f4f\u9662\u6642\uff0cGCS E2V2M3\uff1bBP\uff0c112/57 mmHg\uff1bHR\uff0c85/min\uff0cregular\uff1bRR\uff0c25/min\uff1b\u9ad4\u6eab\uff0c\u651d\u6c0f37\u5ea6\uff1b\u5fc3\u81df\u5448\u73fe\u898f\u5f8b\uff0c\u4f46\u5728\u5fc3\u5c16\u90e8\u6709Gr.III/VI Systolic murmur\uff1b\u5728\u80ba\u57fa\u8655\u6fc1\u6fd5\u547c\u5438\u8072\uff1b\u56db\u80a2\u591a\u8655\u7600\u8840\uff0c\u6b64\u5916\u5c1a\u7121\u7570\u5e38\u6240\u898b\u3002\u5be6\u9a57\u5ba4\u6240\u898b\uff1a\u767d\u8840\u7403\uff0c15350/\u03bcL\uff1bC-\u53cd\u61c9\u86cb 44.20 mg/dl(\u6b63\u5e38<1.9)\uff1b\u808c\u9178\u9150 0.98mg/dl\uff1b\u4f4f\u9662\u7b2c\u4e8c\u5929\u6709\u5169\u5957\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u5448\u73fe\u9769\u862d\u967d\u6027\u75c5\u83cc\u3002\u81e8\u5e8a\u8a3a\u65b7\u70ba\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e(infective\rendocarditis)\u5f8c\uff0c\u8acb\u554f\u5728\u6b64\u523b\uff0c\u4e0b\u5217\u4f55\u7a2e\u8655\u7f6e\u70ba\u5b9c\uff1f\nA. \u9032\u884c\u4ecb\u5165\u6027\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\nB. \u5916\u79d1\u624b\u8853\u4ee5\u7372\u5f97\u7d44\u7e54\u8a3a\u65b7\nC. \u4f7f\u7528 IV dopamine 0.5 \u03bcgkg/min \u6ce8\u5c04\uff0c\u4ee5\u589e\u52a0\u5c3f\u91cf\nD. \u4f5c24\u5c0f\u6642\u5fc3\u96fb\u5716\u6aa2\u67e5\u4ee5\u78ba\u5b9a\u5fc3\u5f8b\u4e0d\u6574\nE. \u4f5c\u8d85\u97f3\u6ce2\u5fc3\u5716\u6aa2\u67e5\u4ee5\u78ba\u5b9a\u5fc3\u81df\u75c5\u8b8a\n": "(E)", "101-8.\n\u75c5\u4eba\u662f28\u6b72\u5bb6\u5ead\u4e3b\u5a66\uff0c\u66fe\u6709\u5b55\u671f\u9ad8\u8840\u58d3\u53ca\u6d41\u7522\u5169\u6b21\u3002\u4f4f\u9662\u524d\u6709\u4e00\u500b\u591a\u6708\u958b\u59cb\u547c\u5438\u56f0\u96e3\uff0c\u5176\u5f8c\u9010\u6f38\u52a0\u91cd\u4e14\u4f34\u6709\u98df\u617e\u4e0d\u632f\uff0c\u5076\u6709\u7aef\u7acb\u6027\u547c\u5438\u56f0\u96e3\uff0c\u54b3\u55fd\uff0c\u7d42\u81f3\u96d9\u8173\u6c34\u816b\u53ca\u6e1b\u5c11\u5c3f\u91cf\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3\uff0c98/54 mmHg\uff1b\u5fc3\u8df3\uff0c131/min\uff1b\u9ad4\u6eab\uff0c37.3\u5ea6\uff1b\u547c\u543836/min\uff1b\u6025\u75c5\u72c0\uff0c\u8ca7\u8840\u773c\u77bc\uff1b\u96d9\u5074\u80ba\u90e8\u6709\u6fd5\u56c9\u8072\uff1b\u5fc3\u81df\u64f4\u5927\uff0c\u6709Gr.III/VI pansystolic murmur\u5728apex\u53caGr.II/IV early diastolic murmur over right upper sternal\rborder\uff0c\u6709S3\u53ef\u805e\uff1b\u8179\u90e8\u672a\u6709\u809d\u813e\u816b\u5927\uff1b\u96d9\u8173\u6c34\u816b\uff0c\u76ae\u819a\u51b7\u6c57\uff0c\u6709\u7d2b\u6591\u53ca\u51fa\u8840\u75d5\u6591\uff0c\u5982\u57168-1\u53ca\u57168-2\u6240\u793a\u3002\u5728\u6025\u6027\u5fc3\u5167\u819c\u708e(IE)\u4e4b\u81c6\u8a3a\u4e0b\uff0c\u4e43\u5728\u4e09\u5c0f\u6642\u5167\u5206\u5225\u5728\u5de6\u53f3\u624b\u63a2\u8840\u7d30\u83cc\u57f9\u990a\u90fd\u5448\u73fe\uff1aviridans streptococci\u3002\u8acb\u554f\u672c\u75c5\u4eba\u4f9d\u64daDuke Criteria\u8a3a\u65b7IE\u7684\u6839\u64da\u662f\uff1a\nA. 2 major criteria\nB. 1 major criterion &  3 minor criteria\nC. 1 major criterion &  2 minor criteria\nD. 1 major criterion &  1 minor criterion\nE. 2 major criteria &  2 minor criteria\n": "(B)", "101-9.\n\u7537\u6027\u75c5\u4eba\uff0c72\u6b72\uff0c\u56e0\u5c16\u92b3\u6027\u4e0a\u80cc\u90e8\u75bc\u75db\u7a81\u7136\u767c\u4f5c\uff0c\u540c\u6642\u4f34\u6709\u6025\u4fc3\u547c\u5438\u53ca\u7729\u6688\uff0c\u4e43\u5f80\u6025\u8a3a\u6c42\u6cbb\u3002\u6642\uff0c\u8840\u58d3149/91 mmHg\uff1b\u5fc3\u8df3\uff0c70/min; RR, 20/min\uff1b\u5176\u4ed6\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u4efb\u4f55\u7570\u5e38\u3002\u75c5\u4eba\u6bcf\u5929\u62bd\u7159\u4e00\u5305\uff0c\u5df2\u6709\u4e94\u5341\u591a\u5e74\u3002Chest X-ray\u3001ECG\u53caCT\uff0c\u5982\u57169-1\u3001\u57169-2\u3001\u57169-3A\u53ca\u57169-3B\u5f8c\uff0c\u53ca\u5176\u521d\u6b65\u8655\u7f6e\uff0c\u5f8c\u8f49\u9001\u52a0\u8b77\u75c5\u623f\u9014\u4e2d\uff0c\u53c8\u7a81\u767c\u5f8c\u80cc\u75bc\uff0c\u540c\u6642\u96d9\u8173\u9ebb\u53ca\u75bc\u75db\uff0c\u4e26\u5448\u73fe\u96d9\u8173\u767c\u7d3a\uff0c\u4e43\u6025\u7167\u53e6\u6b21CT\u5982\u57169-4\u6240\u793a\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u6c7a\u7b56\u4e0d\u6070\u7576\uff1f\nA. \u63a7\u5236\u5fc3\u6536\u7e2e\u8840\u58d3\u5728100-120 mmHg\u53ca\u5fc3\u8df360-80/min\nB. \u975c\u8108\u6ce8\u5c04Labetalol 30 mg/min\nC. \u53e3\u670dPropranolol 20 mg tid po\nD. \u53e3\u670dAspirin 100 mg qd \u53caClopidogrel 75 mg qd\nE. \u5916\u79d1\u6703\u8a3a\uff0c\u7dca\u6025\u624b\u8853\n": "(D)", "101-10.\n\u75c5\u4eba62\u6b72\u7537\u6027\uff0c\u65bc9\u67084\u67083:30AM\u56e0\u7a81\u767c\u6027\u5fc3\u80f8\u524d\u5340\u75bc\u75db\u4e00\u500b\u5c0f\u6642\u800c\u6c42\u6551\u6025\u8a3a\uff0c\u6642\u4f34\u6709\u51b7\u6c57\u3001\u81c9\u8272\u84bc\u767d\u3002\u6642\uff0c\u8840\u58d3\uff0c135/82\uff1b\u5fc3\u8df3\uff0c76/min\uff1b\u547c\u5438\uff0c18/min\uff1b\u9ad4\u6eab\uff0c35.9\u5ea6\uff1b\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u91cd\u5927\u7570\u5e38\u3002\u75c5\u4eba\u6709\u9ad8\u8102\u8840\u75c5\u53f2\uff0cStatin\u6cbb\u7642\u4e2d\u3002\u5176\u80f8\u90e8X\u5149\u3001\u5fc3\u96fb\u5716\u53ca\u5fc3\u808c\u9175\u7d20\u6aa2\u67e5\uff0c\u5982\u571610-1\u3001\u571610-2\u3001\u571610-3\u6240\u793a\u3002\u8acb\u554f\u672c\u75c5\u4eba\u4e4b\u51a0\u72c0\u52d5\u8108\u963b\u585e\u75c5\u8b8a\u6700\u53ef\u80fd\u7684\u4f4d\u7f6e\u662f\uff1a\nA. \u5de6\u4e3b\u5e79\nB. \u5de6\u524d\u4e0b\u884c\u679d\nC. \u5de6\u8ff4\u65cb\u679d\nD. \u53f3\u51a0\u8108\u679d\nE. \u6b63\u5e38\u51a0\u72c0\u52d5\u8108\n": "(D)", "101-11.\n\u75c5\u4eba82\u6b72\u7537\u6027\uff0c\u4e3b\u8a34\u6709\u5bd2\u986b(chills)\u53ca\u6f38\u9032\u6027\u547c\u5438\u56f0\u96e3\u7684\u5169\u5929\u75c5\u7a0b\uff0c\u540c\u6642\u4f34\u6709\u5496\u5561\u8272\u5614\u5410\u7269\u3002\u4ed6\u6709\u9ad8\u8840\u58d3\u3001\u5de6\u8ff4\u65cb\u679d\u652f\u67b6\u7f6e\u653e\u4e4b\u51a0\u5fc3\u75c5\u53ca\u8166\u4e2d\u98a8\u800c\u5de6\u534a\u908a\u9ebb\u75fa\u7684\u591a\u5e74\u75c5\u53f2\u3002\u8840\u58d3 125/64\uff1b\u5fc3\u8df3 100/min\uff1b\u9ad4\u6eab 38.6\u5ea6\uff1b\u547c\u5438 24/min\uff1b\u5fc3\u5c16\u90e8\u6709Gr 4/6 systolic murmur\uff1b\u80ba\u90e8\u6709\u6fd5\u6027\u6fc1\u97f3\uff0c\u96d9\u8173\u6c34\u816b\uff1b\u5176\u4ed6\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u3002\u5be6\u9a57\u5ba4\uff1aWBC 9610/mm3\uff0csegment neutrophils 88%\uff1bHb 10.0 g/dL\uff1bC-Reactive protein 1.69 ng/mL\uff1bCK 221 ng/mL\uff1b CK-MB 16 U/L\uff1bTroponin I 1.36\r\u03bcg/L\uff1b\u5c3f\u6aa2\u6709\u86cb\u81ea\u5c3f(++)\uff0c\u5927\u4fbf\u6f5b\u8840\uff0c(++)\uff1b\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u571611-1\u53ca\u571611-2\u6240\u793a\u3002\u4e09\u3001\u516b\u53ca\u5341\u4e8c\u5c0f\u6642\u5f8c\u4e4bCK\u53caCK-MB\uff0c\u5206\u5225\u70ba1340\u30011462\u30011422\u53ca40\u300144\u300138\u3002\u4e14\u5728\u7fcc\u65e5\u8ffd\u8e64\u80f8\u90e8X\u5149\u5982\u571611-3\u6240\u793a\u3002\u96a8\u5373\r(1).\u9015\u884c\u8840\u6db2\u53ca\u75f0\u7d30\u83cc\u57f9\u990a\u53ca\u555f\u7528Unasyn 1g q8h\u53caazithromycin 500 mg qd\r(2)\u8f382u packed cell RBC\r(3).\u975c\u8108\u6ce8\u5c04Furosemide 20 mg\r(4)\u4f7f\u7528Clopidogrel 150 mg & then 75 mg qd \u53caAspirin 80 mg qd\r(5)Heparin25,000 u/day\r(6)\u6703\u8a3a\u5fc3\u81df\u79d1\r\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u7d44\u7684\u8655\u7f6e\u8f03\u6070\u7576\uff1f\nA. (1)+(2)+(5)\nB. (1)+(3)+(6)\nC. (1)+(4)+(6)\nD. (2)+(5)+(6)\nE. (3+(4)+(5)\n": "(B)", "101-12.\n\u4e86\u89e3\u5fc3\u81df\u7d50\u69cb\u6709\u52a9\u65bc\u57f7\u884c\u5fc3\u81df\u5224\u8b80\u7406\u5b78\u6aa2\u67e5\u4e26\u5224\u8b80\u5fc3\u96fb\u5716\u53ca\u5f71\u50cf\u6aa2\u67e5(\u5305\u62ec\u80f8\u90e8X\u5149\u3001CT\u53ca\u5fc3\u81df\u8d85\u97f3\u6ce2\u7b49)\u4e4b\u6240\u898b\u3002\u6709\u95dc\u4e0b\u5217\u5fc3\u81df\u69cb\u9020\u4e4b\u76f8\u5c0d\u4f4d\u7f6e\u95dc\u4fc2\u4f55\u8005\u932f\u8aa4?\nA. \u4e09\u5c16\u74e3\u4f4d\u65bc\u4e8c\u5c16\u74e3\u4e4b\u524d\u65b9\u3001\u53f3\u65b9\u53ca\u4e0b\u65b9\nB. \u53f3\u5fc3\u623f\u4f4d\u65bc\u5de6\u5fc3\u623f\u4e4b\u524d\u65b9\u3001\u53f3\u65b9\u53ca\u4e0b\u65b9\nC. \u53f3\u5fc3\u5ba4\u4f4d\u65bc\u5de6\u5fc3\u5ba4\u4e4b\u524d\u65b9\u3001\u53f3\u65b9\nD. \u80ba\u52d5\u8108\u74e3\u4f4d\u65bc\u4e3b\u52d5\u8108\u74e3\u4e4b\u524d\u65b9\u3001\u5de6\u65b9\u53ca\u4e0a\u65b9\nE. \u80ba\u52d5\u8108\u74e3\u4f4d\u65bc\u4e3b\u52d5\u8108\u74e3\u4e4b\u524d\u65b9\u3001\u53f3\u65b9\u53ca\u4e0a\u65b9\n": "(E)", "101-13.\n\u975e\u767c\u7d3a\u6027\u6775\u72c0\u6307 (non-cyanotic clubbing fingers)\u53ef\u80fd\u51fa\u73fe\u5728\u6162\u6027\u5fc3\u3001\u80ba\u75be\u75c5\u4e4b\u75c5\u60a3\u3002\u4e0b\u5217\u4f55\u8005\u9664\u5916?\nA. Subacute infective endocarditis\nB. Non-small cell lung cancer\nC. Bronchiectasis\nD. Atrial myxoma\nE. Atrial septal defect\n": "(E)", "101-14.\n\u808b\u819c\u8154\u7a4d\u6c34\u70ba\u5de6\u5fc3\u8870\u7aed\u5f15\u8d77\u4e4b\u5fc3\u56e0\u6027\u80ba\u6c34\u816b(cardiogenic pulmonary edema) \u5e38\u898b\u7684\u4f75\u767c\u75c7\uff0c\u82e5\u7121\u75c7\u72c0\u4e0d\u4e00\u5b9a\u9700\u8981\u80f8\u8154\u7a7f\u523a\u5f15\u6d41\u6216\u6aa2\u67e5\uff0c\u4f46\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u5373\u4f7f\u7121\u75c7\u72c0\u4e5f\u5efa\u8b70\u9700\u8981\u80f8\u8154\u7a7f\u523a\u6aa2\u67e5?\r(1)\u96d9\u5074\u808b\u819c\u7a4d\u6c34\r(2)\u55ae\u7368\u53f3\u5074\u808b\u819c\u7a4d\u6c34\r(3)\u55ae\u7368\u5de6\u5074\u808b\u819c\u7a4d\u6c34\r(4).\u591a\u9694\u9593\u6027 (multi-loculated ) \u808b\u819c\u7a4d\u6c34\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (2)+(4)\nE. (1)+(3)\n": "(C)", "101-15.\n64\u6b72\u7537\u6027\uff0c\u904e\u53bb\u7121\u5df2\u77e5\u5fc3\u80ba\u75be\u75c5\uff0c\u56e0\u7a81\u767c\u6027\u547c\u5438\u56f0\u96e3\u81f3\u6025\u8a3a\u6c42\u8a3a\u3002\u75c5\u60a3\u4e26\u7121\u660e\u986f\u80f8\u75db\u6216\u5192\u51b7\u6c57\uff0c\u610f\u8b58\u6e05\u695a\u4f46\u60c5\u7dd2\u7dca\u5f35\uff0c\u521d\u6b65\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u9ad4\u6eab37.2\u2103\uff0c\u8840\u58d3 150/95 mmHg\uff0c\u8108\u535a110/min\u7bc0\u5f8b\u898f\u5247,\u547c\u5438\u5feb(24/min)\u4e14\u6df1\uff1b\u56db\u80a2\u8f15\u5fae\u51b0\u51b7\u6709\u767c\u7d3a\u73fe\u8c61\u3002\u9838\u975c\u8108\u58d313 cm H2O\uff0c\u8108\u885d\u8840\u6c27\u5b9a\u91cf\u8a08 (pulse oximeter) \u5075\u6e2c\u767c\u73feSpO2 83%\u4e0b\u5217\u8a3a\u65b7\u4f55\u8005\u6700\u6709\u53ef\u80fd?\nA. Panic disorder related hyperventilation syndrome\nB. Metabolic acidosis\nC. Pneumothorax\nD. Acute pulmonary embolism\nE. Bronchial asthma\n": "(D)", "101-16.\n\u4ee5\u4e0b\u53ef\u80fd\u548cWarfarin\u9020\u6210\u4ea4\u4e92\u4f5c\u7528 (drug interaction) \u4e4b\u85e5\u7269\u4f55\u8005\u932f\u8aa4?\nA. Amiodarone\nB. Herb drugs - ginkgo etc.\nC. Antiepileptic-phenytoin\nD. Cimetidine\nE. Digoxin\n": "(E)", "101-17.\n\u5728\u6b63\u5e38\u4eba\uff0c\u4e0b\u5217\u975c\u8108\u8840:1) \u51a0\u72c0\u975c\u8108\u7ac7(coronary sinus); 2)\u814e\u975c\u8108(renal veins); 3) \u4e0a\u8154\u975c\u8108 (superior vena cava); and 4) \u4e0b\u8154\u975c\u8108 (inferior vena cava) \u8840\u4e2d\u4e4b\u7d05\u8840\u7403\u8840\u7d05\u7d20\u6c27\u6c23\u98fd\u548c\u5ea6(hemoglobin O2 saturation)\u9ad8\u4f4e\u4f9d\u5e8f\u70ba?\nA. 4) > 1) > 3) > 2)\nB. 2) > 4) > 3) > 1)\nC. 2) > 3) > 4) > 1)\nD. 1) > 2) > 3) > 4)\nE. 2) > 4) > 1) > 3)\n": "(B)", "101-18.\n\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4 (obstructive sleep apnea, OSA)\u8207\u4e0b\u5217\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u95dc\u806f\u6027\u7522\u751f\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u8166\u4e2d\u98a8\u3001\u5fc3\u808c\u6897\u585e\nB. \u4ee3\u8b1d\u75c7\u5019\u7fa4\u4e2d\u7684\u80f0\u5cf6\u7d20\u6297\u6027(insulin resistance)\nC. \u9ad8\u8840\u58d3\u3001\u80ba\u52d5\u8108\u9ad8\u58d3\nD. \u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (Atrial fibrillation)\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(E)", "101-19.\n\u4e00\u4f4d36\u6b72\u5973\u6027\u88ab\u8a3a\u65b7\u60a3\u6709\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032(hyperthyroidism)\uff0c\u4e8c\u9031\u524d\u958b\u59cb\u670d\u7528propylthiouracil\uff0c\u56e0\u8207\u4ee5\u524d\u7570\u6a23\u4e4b\u5fc3\u60b8(\u4e0d\u898f\u5247\u5feb\u901f\u8df3\u52d5\u7684\u611f\u89ba)\u6c42\u8a3a\u3002\u807d\u8a3a\u767c\u73fe\u5fc3\u8df3\u6578\u6bcf\u5206\u9418150\uff0c\u5b8c\u5168\u4e0d\u898f\u5247(irregularly irregular)\uff0c\u540c\u6b65\u89f8\u8a3a\u6a48\u9aa8\u52d5\u8108 (radial pulse)\uff0c\u8108\u640f\u6578\u6bcf\u5206\u9418110\uff0c\u9838\u52d5\u8108\u8996\u8a3a\u7121a\u6ce2\u3002\u70ba\u63a7\u5236\u5fc3\u901f\u7387\u4e0b\u5217\u85e5\u7269\u6700\u9069\u5408\u8005\u70ba?\nA. Verapamil\nB. Diltiazem\nC. Propranolol\nD. Digoxin\nE. \u4ee5\u4e0a\u7686\u9069\u5408\n": "(C)", "101-20.\n\u6025\u6027\u7f3a\u8840\u6027\u809d\u75c5\u8b8a (ischemic liver) -\u5305\u62ec\u7531\u6025\u6027\u53f3\u5fc3\u8870\u7aed\u5c0e\u81f4\u4e4b\u9b31\u8840\u6027\u809d\u75c5\u8b8a(congestive liver)\u53ca\u4f4e\u8840\u58d3\u5f15\u767c\u4e4b\u4f11\u514b\u6027\u809d\u75c5\u8b8a (shock liver)\uff0c\u5176\u809d\u529f\u80fd\u7570\u5e38\u6709\u5225\u65bc\u75c5\u6bd2\u6027\u6025\u6027\u809d\u708e\u4e4b\u809d\u529f\u80fd\u7570\u5e38\u3002 \u7f3a\u8840\u6027\u809d\u75c5\u8b8a\u809d\u529f\u80fd\u7570\u5e38\u4e4b\u4e0b\u5217\u7279\u5fb5\uff0c\u4f55\u8005\u932f\u8aa4?\nA. AST \u53ca ALT\u6607\u9ad8\uff0c\u800c\u6bd4\u7387\u4e0aALT(\u7d30\u80de\u8cea\u9175\u7d20)\u9ad8\u65bcAST(\u7c92\u817a\u9ad4\u9175\u7d20)\u3002\nB. Bilirubin \u7e3d\u6578\u503c\u7570\u5e38\u6607\u9ad8\uff0c\u800c indirect bilirubin \u6bd4\u7387\u4e0a\u9ad8\u65bc direct bilirubin\u3002\nC. \u4e0a\u8ff0B\u9805\u7570\u5e38\u8d77\u56e0\u65bcuridine diphosphate glucuronosyltransferase \u529f\u80fd\u56e0\u7f3a\u6c27\u800c\u529f\u80fd\u964d\u4f4e\u3002\nD. \u53f3\u5fc3\u8870\u7aed\u6216\u4f11\u514b\u7d93\u6cbb\u7642\u6539\u5584\u5f8c\uff0c\u809d\u529f\u80fd\u7570\u5e38\u4ea6\u96a8\u4e4b\u5feb\u901f\u6539\u5584\u3002\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(E)", "101-21.\n\u5fc3\u623f\u9707\u986b (atrial fibrillation) \u60a3\u8005\u53ef\u4ee5\u5229\u7528CHADS2\u91cf\u8868\u8a55\u4f30\u767c\u751f\u4e2d\u98a8\u98a8\u96aa\uff1a\u4ee5\u4e0aC\uff0cH\uff0cA\uff0cD\u54041\u5206\uff0c\u6709S\u5247\u4ee52\u5206\u8a08\uff0c\u5f9e\u52a0\u7e3d\u5f8c\u7684CHADS2\u5206\u6578\u5373\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\u98a8\u98a8\u96aa\u3002\u82e5\u5206\u6578\u662f0\u5206\u5c31\u5c6c\u4f4e\u98a8\u96aa\uff1b1\u5206\u662f\u4e2d\u5ea6\u98a8\u96aa\uff1b\u22672\u5206\uff0c\u5247\u5c6c\u91cd\u5ea6\u8166\u4e2d\u98a8\u96aa\u60a3\u8005\u3002\u5982\u679cCHADS2\u5206\u6578\u662f0\u62161\u5206\uff0c\u53ef\u4ee5\u53ea\u7528 aspirin \u9810\u9632\uff0c\u5982\u679c\u5206\u6578 \u22672\u5206\uff0c\u5247\u61c9\u8a72\u9577\u671f\u670d\u7528warfarin \u4ee5\u6e1b\u4f4e\u8166\u4e2d\u98a8\u6a5f\u6703\u3002\u8acb\u554f CHADS\u5404\u5b57\u6bcd\u6240\u4ee3\u8868\u4e4b\u610f\u7fa9\uff0c\u4ee5\u4e0b\u4f55\u8005\u932f\u8aa4?\nA. C\u4ee3\u8868Congestive heart failure (\u5fc3\u8870\u7aed)\nB. H\u4ee3\u8868Hyperlipemia\uff08\u9ad8\u8840\u8102\uff09\nC. A\u4ee3\u8868Age (\u5e74\u7d00)7 5\u6b72\u4ee5\u4e0a\nD. D\u4ee3\u8868Diabetes (\u7cd6\u5c3f\u75c5)\nE. S\u4ee3\u8868 Stroke\uff08\u4e2d\u98a8\uff09\u53f2\u6216\uff0c\u66ab\u6642\u6027\u8166\u7f3a\u8840(TIA)\n": "(B)", "101-22.\n\u60a3\u6709\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032(hyperthyroidism)\u60a3\u8005\u6240\u4f5c\u5fc3\u96fb\u5716\u4e2d\u9664\u6700\u5e38\u898b\u4e4b\u7ac7\u6027\u983b\u8108(sinus tachycardia)\u5916\uff0c\u9084\u53ef\u80fd\u6709\u4e0b\u5217\u4e4b\u8868\u73fe\uff0c\u4f55\u8005\u9664\u5916?\nA. \u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (atrial fibrillation)\nB. \u75c5\u4eba\u4ee5\u4e0a\u3001\u4e0b\u80a2\u8fd1\u7aef\u7121\u529b(proximal muscle weakness)\u8868\u73fe\u6642\uff0c\u6709\u4f4e\u8840\u9240\u4e4b\u6240\u898b\nC. \u9577\u671f\u5de6\u5fc3\u5ba4\u5bb9\u91cf\u8ca0\u8377\u589e\u52a0(chronic volume overload)\uff0c\u5c0e\u81f4\u4e4bLVH (left ventricular hypertrophy)\nD. \u80ba\u52d5\u8108\u9ad8\u58d3\u75c7(PAH)\u5c0e\u81f4\u4e4bRVH (right ventricular hypertrophy)\nE. \u4ee5\u4e0a\u7686\u53ef\u80fd\n": "(E)", "102-1.\n\u4e0b\u5217\u6578\u5247\u6709\u95dc\u5fc3\u623f\u64b2\u52d5(Atrial flutter) \u7684\u81e8\u5e8a\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u767c\u751f\u5fc3\u623f\u64b2\u52d5\u7684\u5fc3\u623f\u6027\u5feb\u8df3\u6a5f\u8f49\u901a\u5e38\u662f\u529f\u80fd\u6027\u7684\r\n (functional)\uff0c\u800c\u4e0d\u662f\u5668\u8cea\u6027(organic)\nB. \u5178\u578b\u5fc3\u623f\u64b2\u52d5\u591a\u898b\"sawtooth\" \u5f62\u72c0,\u5728II,III,aVF\u53caV1\u5448\u6b63\u5411\u6216\u8ca0\u5411\u6ce2\nC. \u5fc3\u623f\u64b2\u52d5\u53ef\u5728\u4f7f\u7528\u6297\u5fc3\u5f8b\u4e0d\u6574\u85e5\u6cbb\u7642\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation,AF)\u5f8c\u767c\u751f\nD. \u5fc3\u623f\u64b2\u52d5\u4e5f\u53ef\u5728\u5de6\u5fc3\u623f\u71d2\u707c\u624b\u8853\u6cbb\u7642\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(AF)\u5f8c\u51fa\u73fe\nE. \u96fb\u6fc0\u65b9\u5f0f(electric cardioversion)\u70ba\u6cbb\u7642\u5fc3\u623f\u64b2\u52d5\u6700\u6709\u6548\u7684\u65b9\u6cd5\n": "(A)", "102-2.\n\u4f9d\u64da\u4eca\u5e74ACCF/AHA guideline for the management of heart failure\uff0c\u5176\u6307\u5f15\u5c0e\u5411\u5167\u79d1\u7642\u6cd5(Guideline-directed medical therapy)\u6709\u8af8\u9ede\u91cd\u8981\u4fee\u6b63\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u6307\u5f15\u4e3b\u5f35?(1)ACE inhibitors, Angiotensin-II receptor blockers, \u53ca\u03b2-blockers\u4ecd\u820a\u662f\u5408\u5b9c\u5167\u79d1\u7642\u6cd5  (2)B-type naturetic peptide(BNP)\u53ef\u4f5c\u70ba\u9810\u5f8c\u53ca\u75c5\u50b7\u5206\u985e\u4e4b\u6839\u64da\uff0c\u5c24\u5176\u6cbb\u7642\u5f8cBNP\u7684\u964d\u4f4e, \u66f4\u53ef\u4f5c\u9810\u5f8c\u7684\u53c3\u8003 (3)\u53ea\u6709\u6c34\u816b\u75c5\u4eba\u624d\u9700\u8981\u56b4\u683c\u9650\u5236\u9e7d\u5206 (4)\u61c9\u8a72\u4f7f\u7528Inotropic therapy (5)Cardiac resynchronization therapy\u9650\u5b9a\u5728\u5fc3\u8870\u7aedFunction class 3\u4ee5\u4e0a\u53caLBBB\r>150msec\u7684\u75c5\u4eba\uff0c\u624d\u6709\u7f6e\u653e\u7684\u9069\u61c9(indications)\u689d\u4ef6 \u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (3)+(4)+(5)\n": "(D)", "102-3.\n\u4e0b\u5217\u6709\u95dcDigoxin\u6cbb\u7642\u5fc3\u8870\u7aed\u7684\u5be6\u8b49\u91ab\u5b78\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684?\nA. Digoxin\u53ef\u6291\u5236\u5fc3\u808c\u7d30\u80de\u819cNa-K ATPase pump\uff0c\u589e\u52a0\u7d30\u80de\u6f3f\u6db2(Cytosol)\u5167Ca++\uff0c\u800c\u589e\u5f37\u5fc3\u808c\u6536\u7e2e\u529b(Inotropism)\uff0c\u56e0\u6b64\u98fd\u548c\u5291\u91cf\u662f\u6025\u6ce8\u539f\u5247\nB. \u4f9d\u64daDIG\u81e8\u5e8a\u8a66\u9a57\uff0c\u5728\u975e\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u75c5\u4eba\uff0c\u7d93Digoxin \u6cbb\u7642\u5f8c\uff0c\u4e26\u672a\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\u6216\u4f4f\u9662\u65e5\u6578\nC. \u5728\u81e8\u5e8a\u4e0aDigoxin\u4e26\u975e\u6cbb\u7642\u5fc3\u8870\u7aed\u7684\u4e3b\u8ef8\uff0c\u53ea\u80fd\u8207\u03b2-blocker, diuretic, Angiotensin converting enzyme inhibitor \u6216Angiotensin receptor blockade\u4f75\u7528\nD. Digoxin\u53ef\u7528\u65bc\u5fc3\u8870\u7aed\u4f75\u6709\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u53ca\u5fc3\u64f4\u5927\u8005\nE. Digoxin \u4e2d\u6bd2\u4e4b\u81e8\u5e8a\u8868\u73fe\uff0c\u4ee5\u5fc3\u5f8b\u53ca\u5fc3\u50b3\u5c0e\u7570\u5e38\u6700\u591a\u898b\uff0c\u80c3\u8178\u75c7\u72c0\u6b21\u4e4b\n": "(A)", "102-4.\n\u75c5\u4eba78\u6b72\u9000\u4f11\u7684\u7537\u516c\u52d9\u54e1\uff0c\u4e3b\u8a34\u5fc3\u60b8\u6709\u516b\u5c0f\u6642\u4e4b\u4e45\uff0c\u4e26\u6709\u8d77\u4f0f\u4e0d\u5b9a\u4e4b\u9ad8\u8840\u58d3\u8b8a\u5316\uff0c\u4e43\u6025\u901f\u9001\u91ab\u9662\u6c42\u8a3a\u3002\u5c31\u8a3a\u6642\uff0c\u75c5\u4eba\u8868\u73fe\u614c\u5f35\u4e0d\u5b89\u3002\u64da\u7a31\u6709\u4e00\u5e74\u4e4b\u9ad8\u8840\u58d3\uff0c\u53c8\u6709\u80ba\u6c23\u816b\uff0c\u6bcf\u5929\u670d\u7528Theophylline 200 mg\uff1b\u8166\u90e8\u6709Lacunar infarct\uff0c\u6bcf\u5929\u670d\u7528Clopidogrel 75 mg\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3166/86 mmHg\uff1b\u5fc3\u8df395/ min\uff1b\u9918\u7121\u4e0d\u6b63\u5e38\u3002\u5fc3\u96fb\u5716\u5982\u5716\u793a\u3002\u8840\u6db2\u6aa2\u67e5\uff1aSugar\uff0c165 mg/dL\uff1bCPK\uff0c74 IU/L\uff1bCK-MB\uff0c1.2U/L\u53caTroponin I\uff0c0.02 ng/mL\u3002\u8acb\u554f\u672c\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. \u9ad8\u8840\u58d3\nB. STEMI(ST Elevation Myocardial Infarction)\nC. NSTEMI(Non ST Elevation Myocardial Infarction)\nD. Brugada syndrome\nE. Long QT syndrome\n": "(D)", "102-5.\n\u75c5\u4eba\u73fe\u5e7468\u6b72\u7537\u6027\u8fb2\u592b\uff0c\u65bc\uff16\u6708\uff17\u65e5\u6e05\u6668\u7a81\u6709\u80f8\u60b6\uff0c\u540c\u6642\u4f34\u6709\u5641\u5fc3\u3001\u5614\u5410\u3001\u5fc3\u60b8\u53ca\u51b7\u6c57\uff0c\u4e43\u6025\u5f80\u6025\u8a3a\u90e8\u6c42\u8a3a\u3002\u75c5\u4eba\u6bcf\u5929\u62bd\u83f8\u4e8c\u5305\uff0c\u5df2\u6709\u4e09\u5341\u591a\u5e74\uff0c\u7121\u9ad8\u8840\u58d3\u3001\u9ad8\u8102\u8840\u6216\u7cd6\u5c3f\u75c5\u75c5\u53f2\u3002\u7406\u5b78\u6aa2\u67e5TPR \uff1a35.6/82/16\uff1bBP\uff1a146/93 mmHg\uff0c\u610f\u8b58\u6e05\u695a\uff0c\u5fc3\u81df\u5927\u5c0f\u53ca\u5fc3\u97f3\u6b63\u5e38\uff0c\u80ba\u90e8\u7121\u6fd5\u56c9\u97f3\uff0c\u5176\u4ed6\u90e8\u4f4d\u4ea6\u7121\u7570\u5e38\u6240\u898b\u3002CKMB 35 U/L \u6b63\u5e38\u503c[7-25] \uff0cTroponin-T 0.009 ng/ml\uff0cCreatinine(\u8840) 1.0 mg/dL\uff0ceGFR 79 mL/min/1.73M2\u3002 \u80f8\u90e8\uff38\u5149\u6b63\u5e38\uff0c\u5176\u5fc3\u96fb\u5716\u5982\u5716\u793a\uff0c\u8acb\u554f\u6700\u6b63\u78ba\u75be\u75c5\u8a3a\u65b7\u662f\uff1a\nA. Angina pectoris\nB. Non-ST Elevation Myocardial infarction\nC. Right coronary artery occlusion with inferior ST-elevation infarction\nD. Left circumflex artery occlusion with posterior ST-elevation infarction\nE. Left anterior descending artery occlusion with anterior myocardial ischemic injury\n": "(C)", "102-6.\n48\u6b72\u7537\u6027\u5f9e\u6628\u65e5\u4e0b\u53484:30 pm\u7a81\u767c\u5de6\u80f8\u75db\uff0c\u4e26\u6709\u5f8c\u80cc\u50b3\u75db\uff0c\u4f34\u6709\u51b7\u6c57\u3001\u6c23\u4fc3\u53ca\u547c\u5438\u56f0\u96e3\u7b49\u75c7\u72c0\uff0c\u5df2\u6b77\u7d93\u4e00\u5929\u672a\u7de9\u89e3\uff0c\u4e43\u65bc7 PM\u9001\u9054\u91ab\u9662\u6c42\u6cbb\u3002\u75c5\u4eba\u4e00\u5411\u5065\u58ef\uff0c\u672a\u6709\u9ad8\u8840\u58d3\u6216\u5176\u4ed6\u51a0\u5fc3\u75c5\u76f8\u95dc\u5371\u96aa\u56e0\u7d20\u3002\u7406\u5b78\u6240\u898b\uff1a\u6025\u75c5\u72c0\uff0c\u5de6\u53f3\u5169\u624b\u8840\u58d3\u5206\u5225\u70ba182/126\u53ca193/125 mmHg\uff0c\u5de6\u53f3\u5169\u817f\u8840\u58d3\u70ba211/112\u53ca205/112 mmHg\uff1b\u5fc3\u8df371/min\uff0c\u6b63\u5e38\u5f8b\u52d5\uff0c\u5fc3\u81df\u5fae\u5927\uff0c\u7121\u7570\u5e38\u96dc\u97f3\u53ef\u805e\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u793a\uff0c\u751f\u5316\u6aa2\u67e5CK\u3001CK-MB\u53caTroponin I\u90fd\u6b63\u5e38\uff1bBNP,246 pg/mL\u5fae\u9ad8\u3002\u75c5\u4eba\u6b64\u523b\u4e4b\u75be\u75c5\u8a3a\u65b7\u53ca\u5176\u8655\u7f6e\uff0c\u4ee5\u4f55\u8005\u6700\u59a5\u9069?\nA. Acute myocardial infarction, anteroseptal STEMI\nB. Hypertensive cardiovascular disease complication\nC. Acute pericarditis\nD. Hyperkalemia\nE. Myocarditis\n": "(B)", "102-7.\n\u75c5\u4eba\u7537\u602765\u6b72\u751f\u610f\u4eba\uff0c\u6709\u4e00\u5929\u7684\u80f8\u9aa8\u4e0b\u80f8\u60b6\uff0c\u9010\u6f38\u52a0\u5287\uff0c\u540c\u6642\u53c8\u6709\u51b7\u6c57\u3001\u7729\u6688\u53ca\u547c\u5438\u56f0\u96e3\uff0c\u4e43\u5f80\u6025\u8a3a\u6c42\u91ab\u3002\u75c5\u4eba\u7121\u4efb\u4f55\u75be\u75c5\uff0c\u50c5\u53ea\u62bd\u83f8\u6bcf\u5929\u4e00\u5305\u670920\u5e74\uff0c\u6212\u83f8\u5df210\u5e74\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3110/67\uff1b\u5fc3\u8df345/min\uff1b\u5fc3\u81df\u898f\u5247\u5f8b\u8df3\uff0c\u7121\u5fc3\u96dc\u97f3\uff1b\u5176\u4ed6\u6240\u898b\u4e26\u7121\u4efb\u4f55\u4e0d\u6b63\u5e38\u3002\u5176\u751f\u5316\u6aa2\u67e5\uff1aCK,622 IU/L\uff1bCKMB, 32.6IU/L\uff1bTroponin I, 2.30 ng/ml\uff1bSugar,105 mg/dL\uff1bCholesterol,161 mg/dL\uff1bLDL-C,93 mg/dL\uff1bHDL-C,37  mg/dL\uff0c\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u793a\u3002\u5728\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7\u8a3a\u65b7\uff0c\u75c5\u4eba\u63a5\u53d7\u4e0b\u5217\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. iv Atropine, 0.5 mg\u53ca Aspirin,100 mg qd p o\nB. Atorvastatin 10 mg qd / hs\nC. Clopidogrel 300 mg followed by 75 mg qd\nD. Enoxaparin 60 mg subcutaneous injection\nE. Carvedilol (6.25 mg),1# bid po\n": "(E)", "102-8.\n\u75c5\u4eba\u5973\u6027\u73fe\u5e7444\u6b72\uff0c\u6709\u5168\u8eab\u6d6e\u816b2\u500b\u6708\u3002\u81ea2010\u5e74\u5c31\u56e0\u96d9\u8173\u6c34\u816b\u6c42\u91ab\uff0c\u5176\u5f8c\u5169\u5e74\u9593\u5148\u5f8c\u56e0\u8179\u6c34\u3001\u5168\u8eab\u6c34\u816b\u53ca\u9ad4\u91cd11\u516c\u65a4\u7684\u6025\u5287\u589e\u52a0\uff0c\u4f4f\u9662\u6aa2\u67e5\u767c\u73fe\u809d\u786c\u5316\u53ca\u4f4e\u8840\u6e05\u767d\u86cb\u767d(1.2-1.6 g/dL)\u3002\u6700\u8fd1\u534a\u5e74\u66f4\u6709\u6c34\u6027\u8179\u7009\u3001\u8179\u75db\u548c\u591c\u9593\u547c\u5438\u56f0\u96e3\uff0c\u662f\u4e43\u4f4f\u9662\u8a3a\u7642\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3\uff0c108/71\rmmHg\uff1b\u5fc3\u8df3\uff0c88/min\uff0c\u4e0d\u898f\u5247\uff1b\u9838\u975c\u8108\u6012\u5f35\uff1b\u96d9\u5074\u80ba\u90e8\u6709\u6fd5\u6fc1\u547c\u5438\u8072\uff1b\u5fc3\u81df\u64f4\u5927\uff0c\u5728\u5fc3\u5c16\u53ca\u5de6\u4e0b\u80f8\u7de3(LLSB)\u6709\u4e09\u5ea6\u5fc3\u7e2e\u6027\u96dc\u97f3\u53caS3\u53ef\u805e\uff1b\u8179\u90e8\u6709\u5fae\u91cf\u8179\u6c34\u53ca\u8f15\u5ea6\u809d\u816b\uff1b\u96d9\u8173\u4e2d\u5ea6\u6c34\u816b\uff0c\u4f46\u5176\u52d5\u8108\u8108\u8df3\u5c1a\u5c6c\u6b63\u5e38\u3002\u8178\u5167\u8996\u93e1\u53ef\u898b\u6dcb\u5df4\u7ba1\u6d6e\u816b(lymphangiectasia)\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u793a\u3002\u8acb\u554f\u672c\u75c5\u4eba\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u662f\uff1a\nA. \u5fc3\u5167\u819c\u708e(Endocarditis)\nB. \u5fc3\u808c\u708e(Myocarditis)\nC. \u7a84\u7e2e\u6027\u5fc3\u5305\u819c\u708e(Constrictive pericarditis)\nD. \u51a0\u5fc3\u75c5(Coronary artery syndrome)\nE. \u50e7\u5e3d\u74e3\u9589\u9396\u4e0d\u5168(Mitral regurgitation)\n": "(C)", "102-9.\n\u75c5\u4eba53\u6b72\u7537\u6027\uff0c\u6709\u547c\u5438\u56f0\u96e3\u4f75\u6709\u591a\u75f0\u3001\u591c\u9593\u54b3\u55fd\u53ca\u591c\u9593\u547c\u5438\u56f0\u96e3\u3001\u80f8\u60b6\u53ca\u8173\u816b\u7b49\u6b77\u6642\u4e00\u500b\u591a\u6708\u4e0d\u89e3\u3002\u75c5\u4eba\u6709\u591a\u5e74\u5fc3\u667a\u9072\u920d\uff0c\u4e26\u6709\u7cd6\u5c3f\u75c5\u53ca\u9ad8\u8840\u58d3\u7684\u81f3\u5c11\u4e00\u5e74\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3103/56 mmHg\uff1b\u5fc3\u8df398/min;\u547c\u543818/min\uff1b\u9838\u975c\u8108\u6b63\u5e38\uff1b\u5fc3\u81df\u5fae\u5927\uff0c\u5fc3\u97f3\u6b63\u5e38\uff0c\u7121\u96dc\u97f3\uff1b\u80f8\u90e8\u5de6\u5f8c\u5074\u6fd5\u6fc1\u547c\u5438\u97f3\uff0c\u809d\u4e26\u7121\u816b\u5927\uff0c\u4f46\u96d9\u8173\u6d6e\u816b\u3002\u751f\u5316\u6aa2\u9a57\uff1aCK,204 U/L\uff1bCK-MB,35 U/L\uff1bTroponin I,0.655 mg/L\uff1bSugar,216 mg/dl\uff1bHbA1C,8.0%\uff1bBUN,18 mg/dL\uff1bcreatinine,0.84mg/dL\uff1bALT,90 IU/L\uff1bTriglyceride,100 mg/dL\uff1bHDL-C,58.5 mg/dL\uff1bLDL-C,178.1\rmg/dL\u3002\u5176\u5fc3\u96fb\u5716\u3001\u80f8\u90e8X\u5149\u53ca\u51a0\u8108\u651d\u5f71\u5982\u5716\u793a\u3002\u8acb\u554f\u6b64\u75c5\u4eba\u5728\u73fe\u968e\u6bb5\uff0c\u5f9e\u5e74\u9f61\u3001\u6027\u5225\u3001\u51a0\u5fc3\u75c5\u5371\u96aa\u56e0\u7d20\u53ca\u81e8\u5e8a\u75c7\u72c0\u7b49\u8003\u91cf\uff0c\u6700\u5177\u91ab\u5b78\u5be6\u8b49\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\uff1a\nA. \u63a1\u7528\u6700\u5408\u9069\u7684\u5167\u79d1\u7642\u6cd5(Optimal medical therapy)\nB. \u63a1\u7528\u7d93\u51a0\u8108\u963b\u4ecb(PCI),\u7f6e\u653e\u652f\u67b6(Coronary stent)\nC. \u63a1\u7528\u5916\u79d1\u7e5e\u9053\u624b\u8853(CABGS)\nD. \u5148\u4ee5\u6700\u5408\u9069\u5167\u79d1\u7642\u6cd5\uff0c\u723e\u5f8c\u4f9d\u75c5\u60c5\u518d\u63a1\u884cPCI\nE. \u5148\u4ee5\u6700\u5408\u9069\u5167\u79d1\u7642\u6cd5\uff0c\u723e\u5f8c\u4f9d\u75c5\u60c5\u518d\u63a1\u884cCABGS\n": "(E)", "102-10.\nWPW syndrome\u6709\u5fc3\u60b8\u3001\u7729\u6688\u3001\u660f\u53a5\u53ca\u731d\u6b7b\u5371\u96aa\uff0c\u6709\u95dc\u5c0e\u7ba1\u71d2\u707c\u624b\u8853(Catheter ablation)\u6cbb\u7642\u7684\u9069\u61c9\u75c7\uff0c\u6709\u8af8\u591a\u7814\u7a76\u5be6\u8b49\uff1a(1)\u6709\u5fc3\u5feb\u8df3\u75c7\u72c0\u8005 (2) \u7121\u75c7\u72c0\uff0c\u4f46\u65b7\u65b7\u7e8c\u7e8c\u51fa\u73fepreexcitation(short PR & delta wave) (3)WPW syndrome \u75c5\u4eba\u4f34\u6709\u96e3\u6cbb\u7684\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(atrial fibrillation) (4)WPW syndrome \u75c5\u4eba\u7d93\u96fb\u751f\u7406\u5b78\u6aa2\u8a98\u767c\u5fc3\u5feb\u8df3\u8005 (5)\u7121\u75c7\u72c0\uff0cpreexcitation \u767c\u751f\u5728\u904b\u52d5\u54e1\u3001\u98db\u884c\u54e1\u53ca\u5e7c\u5b69\u3002\r\u4e0b\u5217\u4f55\u9805\u624d\u662f\u6b63\u78ba\u4e4b\u9078\u64c7?\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (1)+(2)+(5)\nE. (2)+(3)+(4)\n": "(C)", "102-11.\n\u75c5\u4eba46\u6b72\u5361\u8eca\u53f8\u6a5f\uff0c\u56e0\u6025\u767c\u80f8\u75bc\u4e09\u5c0f\u6642\u6c42\u91ab\u3002\u75c5\u4eba\u7121\u91cd\u5927\u75be\u75c5\u3002\u65e9\u6668\u767b\u5c71\u4e2d\u7a81\u7136\u80f8\u75db\u4f34\u6709\u5de6\u80a9\u9178\u75db\u8207\u6ce0\u6c57\u3002\u5c31\u8fd1\u91ab\u9662\u6c42\u8a3a\uff0c\u5fc3\u96fb\u5716\u5982\u5716\u793a\uff0c\u8840\u6e05CPK=240\uff0c \u4e00\u5929\u5f8c\u4e0a\u5347\u81f34224IU/L\uff0cCK-MB=9.8U/L\uff0c\u4e00\u5929\u5f8c\u4e0a\u5347\u81f3172.5U/L\u3002\u8840\u58d3\uff0c117/76 mmHg\uff1b\u5fc3\u8df3,56/min\uff0c\u5176\u4ed6\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u91cd\u5927\u7570\u5e38\uff0c\u8655\u7f6e\u5f8c\u8f49\u9001\u91ab\u5b78\u4e2d\u5fc3\u3002\u8acb\u554f\u6b64\u91ab\u9662\u7684\u4f55\u7d44\u8655\u7f6e\uff0c\u624d\u7b26\u5408\u6307\u5f15\u898f\u5b9a\u4e4b\u521d\u59cb\u8655\u7f6e(Initial management)\uff1f(1)Carvedilol 3.125 mg qd / po (2)Atorvastatin 20 mg qd (3)Aspirin 80 mg qd and Clopidogrel 300 mg loading followed by 75 mg qd (4)IV nitroglycerin (5)IV Heparin 5000 u\rbolus followed by 1000u/hr (6)rTissue plasminogen activator IV, 15mg bolus followed by 85 mg / 90 min\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (2)+(3)+(5)\nD. (3)+(4)+(5)\nE. (4)+(5)+(6)\n": "(C)", "102-12.\n\u4e0b\u5217\u6709\u95dc\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e(Infective endocarditis)\u7684\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u5e74\u8f15\u7684\u5fc3\u5167\u819c\u708e\u75c5\u4eba\u4ee5\u5973\u6027\u70ba\u591a\nB. \u91ab\u8b77\u7167\u9867\u76f8\u95dc\u7684\u5fc3\u5167\u819c\u708e(healthcare-associated)\u4ee5S. aureus \u70ba\u6700\u3002\u793e\u5340\u6027\u5fc3\u5167\u819c\u708e(community-acquired endocarditis)\u5247\u4ee5Streptococcal species \u6700\u5e38\u898b\nC. \u50e7\u5e3d\u74e3\u819c\u5fc3\u5167\u819c\u708e\u5f9e\u4f86\u6700\u591a\u898b\nD. \u74e3\u819c\u7f6e\u63db\u8853\u5f8c>12\u6708\u7684\u4eba\u5de5\u5fc3\u74e3\u819c\u5fc3\u5167\u819c\u708e\uff0c\u4ee5S aureus\u6700\u591a\u898b\nE. Enterococcal septicemia\u53ef\u5728\u793e\u5340\u6027\u53ca\u91ab\u8b77\u7167\u9867\u76f8\u95dc\u5fc3\u5167\u819c\u708e\u51fa\u73fe\n": "(D)", "102-13.\n\u5a66\u7522\u79d1\u8f49\u4f86\u4e00\u4f4d\u7522\u5a66\uff0c\u5728\u5979\u9806\u5229\u5730\u7528\u81ea\u7136\u7522\u751f\u4e0b\u7b2c\u4e8c\u500b\u5bf6\u5bf6\u4e4b\u5f8c\u4e00\u500b\u6708\uff0c\u5979\u51fa\u73fe\u4e86\u5bb9\u6613\u75b2\u4e4f\u548c\u8f15\u5ea6\u904b\u52d5\u5c31\u6703\u5f88\u5598\u7684\u60c5\u6cc1\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u9838\u975c\u8108\u64f4\u5f35\uff0c\u96d9\u5074\u4e0b\u80a2\u6709\u6c34\u816b\uff0c\u6700\u5927\u5fc3\u640f\u9ede(PMI)\u4e5f\u5411\u5916\uff0c\u5411\u4e0b\u4f4d\u79fb\u3002\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5de6\u5fc3\u5ba4\u640f\u51fa\u7387\u662f30%\uff0c\u5fc3\u5ba4\u6709\u64f4\u5927\u3002\u95dc\u65bc\u5979\u7684\u60c5\u6cc1\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6070\u7576\uff1f\nA. \u9019\u7a2e\u60c5\u6cc1\u53ef\u4ee5\u5728\u751f\u7522\u6578\u5e74\u4e4b\u5f8c\u624d\u7a81\u7136\u51fa\u73fe\nB. \u5927\u7d04\u4e00\u534a\u7684\u985e\u4f3c\u60a3\u8005\u6703\u75ca\u7652\nC. \u9019\u7a2e\u60c5\u5f62\u4e00\u65e6\u51fa\u73fe\uff0c\u4e26\u4e0d\u6703\u589e\u52a0\u4e0b\u4e00\u80ce\u61f7\u5b55\u6216\u662f\u751f\u7522\u9031\u671f\u7684\u5fc3\u8870\u7aed\u98a8\u96aa\nD. \u6b64\u60c5\u6cc1\u7684\u6cbb\u7642\u65b9\u5f0f\u4e0d\u540c\u65bc\u5176\u4ed6\u64f4\u5f35\u6027\u5fc3\u808c\u75c5\u8b8a\u60a3\u8005\nE. \u8a3a\u65b7\u6b64\u60c5\u6cc1\u4e00\u5b9a\u8981\u9032\u884c\u5fc3\u808c\u63a1\u6a23(Endomyocardial biopsy)\n": "(B)", "102-14.\n68\u6b72\u7537\u6027\u60a3\u8005\u6709\u7cd6\u5c3f\u75c5\u548c\u5fc3\u8870\u7aed\u7684\u6b77\u53f2\uff0c\u6700\u8fd1\u5e38\u56e0\u591c\u9593\u60b6\u8207\u5598\u800c\u9192\u4f86\uff0c\u4ed6\u5e73\u6642\u56e0\u70ba\u6703\u5598\u800c\u7121\u6cd5\u9023\u7e8c\u884c\u8d7050\u516c\u5c3a\u4ee5\u4e0a\uff0c\u82e5\u722c\u6a13\u68af\u8d85\u904e\u4e00\u5c64\u6a13\u4e5f\u6703\u5f88\u5598\u3002\u6aa2\u67e5\u6642\u767c\u73fe\u8840\u58d3\u6b63\u5e38\uff0c\u96d9\u5074\u80ba\u5e95\u6709\u56c9\u97f3\uff0c\u9838\u975c\u8108\u9f13\u8139\u3002\u4e0a\u500b\u6708\u4ed6\u525b\u63a5\u53d7\u4e86\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u767c\u73fe\u5de6\u5fc3\u5ba4\u5c04\u51fa\u7387\u662f30%\uff0c\u76ee\u524d\u4ed6\u670d\u7528\u4e59\u578b\u963b\u65b7\u5291\u3001\u5229\u5c3f\u5291\u3001\u8f49\u5316\ufffdC\u6291\u5236\u5291(Angiotensin Coverting enzyme inhibitor)\u548c\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u3002\u4f9d\u64da\u75c5\u60a3\u7684\u7279\u6027\u8207\u76ee\u524d\u7684\u72c0\u6cc1\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6700\u53ef\u80fd\u662f\u9020\u6210\u9019\u4f4d\u60a3\u8005\u5fc3\u8870\u7aed\u7684\u539f\u56e0\uff1f\nA. \u6bd2\u6027\u7269\u8cea\u6216\u85e5\u7269\nB. \u6d78\u6f64\u6027\u75be\u75c5\nC. \u51a0\u72c0\u52d5\u8108\u75be\u75c5\nD. \u74e3\u819c\u6027\u5fc3\u81df\u75c5\nE. \u611f\u67d3\u6027\u75be\u75c5\n": "(C)", "102-15.\n\u4e00\u4f4d48\u6b72\u6709\u8f15\u5fae\u9ad8\u8840\u58d3\u548c\u62bd\u83f8\u7684\u7537\u6027\u60a3\u8005\uff0c\u56e0\u70ba\u6e05\u6668\u7a81\u767c\u6027\u80f8\u53e3\u58d3\u8feb\u75bc\u75db\u5408\u4f75\u5641\u5fc3\u8207\u5192\u6c57\uff0c\u547c\u5438\u8b8a\u5598\uff0c\u7d93\u7531\u6025\u8a3a\u5165\u9662\u3002\u5728\u525b\u5230\u9054\u6025\u8a3a\u7684\u5fc3\u96fb\u5716\u6709\u80f8\u524d\u6975\u5c0e(precordial leads)\u7684ST\u7bc0\u6bb5\u4e0a\u5347\uff0c\u7cfb\u5217\u62bd\u8840\u7684\u5fc3\u81df\u9175\u7d20\u503c\u6b63\u5e38\uff0c\u75c5\u4eba\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u767c\u73fe\u5de6\u524d\u4e0b\u964d\u679d\u51a0\u72c0\u52d5\u810825%\u72f9\u7a84\uff0c\u75c5\u4eba\u6c92\u6709\u9032\u884c\u652f\u67b6\u653e\u7f6e\u6216\u6c23\u7403\u64f4\u5f35\u6cbb\u7642\uff0c\u5f8c\u7e8c\u7684\u4f4f\u9662\u904e\u7a0b\u4e2d\u4e5f\u6c92\u6709\u51fa\u73fe\u5371\u96aa\u6027\u7684\u5fc3\u5f8b\u4e0d\u6574\u3002\u4e0b\u5217\u7684\u8655\u7f6e\uff0c\u54ea\u4e00\u9805\u662f\u9069\u5408\u4e5f\u53ef\u4ee5\u6e1b\u5c11\u672a\u4f86\u53cd\u8986\u767c\u751f\u985e\u4f3c\u80f8\u75db\u7684\u60c5\u6cc1\uff1f\nA. \u653e\u7f6e\u5857\u85e5\u652f\u67b6(drug-eluting coronary artery stent)\u5728\u51a0\u72c0\u52d5\u8108\u4e0a\nB. \u653e\u7f6e\u975e\u5857\u85e5\u652f\u67b6\u5728\u51a0\u72c0\u52d5\u8108\nC. \u958b\u59cb\u4f7f\u7528\u8f49\u5316\ufffdC\u6291\u5236\u5291(ACEI)\u85e5\u54c1\u6cbb\u7642\nD. \u958b\u59cb\u4f7f\u7528\u4e59\u578b\u963b\u65b7\u5291\u6cbb\u7642\nE. \u958b\u59cb\u4f7f\u7528\u9223\u96e2\u5b50\u963b\u65b7\u5291\u6cbb\u7642\n": "(E)", "102-16.\n\u9580\u8a3a\u4f86\u4e86\u4e00\u4f4d15\u6b72\u7684\u7537\u5b78\u751f\uff0c\u966a\u540c\u7684\u6559\u7df4\u8868\u793a\u4ed6\u5728\u6628\u5929\u7684\u4f8b\u884c\u6392\u7403\u6821\u968a\u8a13\u7df4\u4e2d\u5148\u662f\u611f\u89ba\u982d\u6688\uff0c\u7136\u5f8c\u6688\u5012\u4e26\u8dcc\u843d\u5730\u9762\uff0c\u540c\u6642\u55aa\u5931\u610f\u8b58\u5927\u7d041\u5206\u9418\uff0c\u6c92\u6709\u5168\u8eab\u62bd\u6410\u6216\u662f\u53e3\u5410\u767d\u6cab\u3002\u4eca\u5e74\u662f\u4ed6\u52a0\u5165\u6821\u968a\u7684\u7b2c\u4e00\u5e74\uff0c\u4ed6\u4e4b\u524d\u4e26\u4e0d\u66fe\u6688\u5012\uff0c\u56e0\u70ba\u4ed6\u53d7\u4eba\u9818\u990a\uff0c\u5bb6\u65cf\u53f2\u6c92\u6709\u9032\u4e00\u6b65\u7684\u8cc7\u8a0a\u3002\u8eab\u9ad4\u6aa2\u67e5\u4e2d\u4f60\u767c\u73fe\u4e86\u5de6\u80f8\u9aa8\u7de3\u5230\u5fc3\u5c16\u6709\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\uff0c\u5fc3\u96fb\u5716\u6aa2\u67e5\u662f\u7ac7\u6027\u5fc3\u5f8b\uff0c\u4f46\u6709\u5de6\u5fc3\u5ba4\u80a5\u5927\u3002\u4f9d\u64da\u524d\u8ff0\u72c0\u6cc1\u5224\u65b7\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u7406\u5b78\u6aa2\u67e5\u6703\u662f\u6bd4\u8f03\u5408\u7406\u7684\u65b9\u5f0f\u4f86\u9032\u4e00\u6b65\u91d0\u6e05\u9019\u500b\u904b\u52d5\u54e1\u5728\u904b\u52d5\u8a13\u7df4\u4e2d\u6688\u5012\u548c\u5fc3\u96dc\u97f3\u51fa\u73fe\u7684\u53ef\u80fd\u539f\u56e0\uff1f\nA. \u5fc3\u5c16\u5340\u57df\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\u96a8\u8457\u8e72\u4e0b\u6216\u7528\u529b\u63e1\u62f3\u800c\u6e1b\u5c11\uff0c\u96a8\u8457\u7ad9\u7acb\u8d77\u4f86\u6216\u9032\u884cValsalva maneuver\u800c\u589e\u52a0\nB. \u6536\u7e2e\u4e2d\u671f\u7684\u6ef4\u7b54\u97f3(systolic click)\u548c\u6536\u7e2e\u96dc\u97f3\uff0c\u96a8\u8457\u8e72\u4e0b\u6216\u7528\u529b\u63e1\u62f3\u800c\u63d0\u65e9\uff0c\u96a8\u8457\u7ad9\u7acb\u8d77\u4f86\u6216\u9032\u884cValsalva maneuver\u800c\u5ef6\u5f8c\nC. \u6536\u7e2e\u5168\u6642\u671f\u7684\u96dc\u97f3\u5728\u5fc3\u5c16\u807d\u5f97\u6700\u6e05\u695a\uff0c\u6703\u50b3\u5230\u5de6\u814b\u4e0b\uff0c\u96a8\u8457\u8e72\u4e0b\u6216\u7528\u529b\u63e1\u62f3\u800c\u589e\u5f37\uff0c\u96a8\u8457\u7ad9\u7acb\u8d77\u4f86\u6216\u9032\u884cValsalva maneuver\u800c\u6e1b\u5c11\nD. \u5439\u6c23\u578b\u6536\u7e2e\u671f\u96dc\u97f3(Blowing systolic murmur)\u51fa\u73fe\u5728\u5de6\u4e0b\u80f8\u9aa8\u7de3\uff0c\u96a8\u8457\u8e72\u4e0b\u6216\u7528\u529b\u63e1\u62f3\u800c\u589e\u5f37\uff0c\u96a8\u8457\u7ad9\u7acb\u8d77\u4f86\u6216Valsalva maneuver\u800c\u6e1b\u5c11\nE. \u51fa\u73fe\u4f4e\u983b\u6536\u7e2e\u4e2d\u671f\u5fc3\u96dc\u97f3\u6703\u50b3\u5230\u9838\u52d5\u8108\u5340\u57df\n": "(A)", "102-17.\n\u9580\u8a3a\u6709\u4e00\u4f4d\u5bb9\u6613\u5fc3\u60b8\u768436\u6b72\u5973\u6027\u60a3\u8005\uff0c\u5979\u525b\u63a5\u53d7\u4e86\u6392\u5b9a\u768424\u5c0f\u6642\u5fc3\u96fb\u5716\u6aa2\u67e5\uff0c\u5831\u544a\u5448\u73fe\u5979\u6709\u5c11\u91cf\u7684\u5fc3\u5ba4\u671f\u5916\u6536\u7e2e\u548c\u5fc3\u623f\u671f\u5916\u6536\u7e2e\uff0c\u6c92\u6709\u5176\u4ed6\u7684\u5fc3\u5f8b\u4e0d\u6574\u3002\u5fc3\u81df\u8d85\u97f3\u6ce2\u5de6\u5fc3\u5ba4\u640f\u51fa\u7387\u5927\u65bc60%\uff0c\u6c92\u6709\u5176\u4ed6\u74e3\u819c\u6216\u5c40\u90e8\u6536\u7e2e\u529f\u80fd\u7570\u5e38\uff0c\u75c5\u4eba\u6c92\u6709\u5176\u4ed6\u7684\u7cfb\u7d71\u6027\u75be\u75c5\uff0c\u4e5f\u4e0d\u66fe\u6688\u5012\u3002\u91dd\u5c0d\u5979\u7684\u72c0\u6cc1\uff0c\u4e0b\u5217\u54ea\u4e00\u7a2e\u6cbb\u7642\u6bd4\u8f03\u5408\u9069\uff1f\nA. \u7d66\u4e88\u6297\u7126\u616e\u85e5\u54c1\nB. \u7d66\u4e88\u4e59\u578b\u963b\u65b7\u5291\nC. \u7d66\u4e88\u6bdb\u5730\u9ec3(Digoxin)\nD. \u7d66\u4e88\u594e\u5be7(Quinidine)\nE. \u7d66\u4e88\u518d\u4fdd\u8b49\uff0c\u5efa\u8b70\u89c0\u5bdf\uff0c\u76ee\u524d\u4e0d\u7528\u7d66\u85e5\u3002\n": "(E)", "102-18.\n\u4e00\u4f4d80\u6b72\u6709\u9577\u671f\u7f3a\u8840\u6027\u5fc3\u81df\u8870\u7aed\u7684\u7537\u6027\u60a3\u8005\u56e0\u70ba\u5931\u4ee3\u511f\u7684\u5fc3\u8870\u7aed\uff08Decompensated congestive heart failure\uff09\u4f4f\u9032\u52a0\u8b77\u75c5\u623f\uff0c\u5fc3\u96fb\u5716\u6709\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u8207\u5de6\u5074\u675f\u679d\u50b3\u5c0e\u963b\u65b7\u3002\u80f8\u90e8X\u5149\u6709\u514b\u96f7\u6c0fB\u7dda(Kerley's B-lines)\u548c\u96d9\u5074\u80ba\u6ce1\u6d78\u6f64\u8b8a\u5316(Alveolar infiltrates)\u3002\u5728\u7406\u5b78\u6aa2\u67e5\u4e0a\u61c9\u8a72\u53ef\u4ee5\u767c\u73fe\u4e0b\u5217\u54ea\u4e00\u500b\u7d44\u5408\uff1f(1)\u7b2c\u4e8c\u5fc3\u97f3\u5206\u88c2\u97f3  (2)\u7b2c\u56db\u5fc3\u97f3  (3)\u7b2c\u4e09\u5fc3\u97f3  (4)\u4e0d\u898f\u5247\u7684\u8108\u640f  (5)\u9838\u975c\u8108\u51fa\u73fe\u898f\u5247\u7684a\u6ce2\nA. (1)+(2)+(4)\nB. (3)+(4)+(5)\nC. (1)+(2)+(3)\nD. (2)+(3)+(5)\nE. (1)+(3)+(4)\n": "(E)", "102-19.\n\u6709\u4e00\u4f4d75\u6b72\u7537\u6027\u5373\u5c07\u63a5\u53d7\u5e38\u898f\u8ffd\u8e64\u7684\u51a0\u72c0\u52d5\u8108\u5c0e\u7ba1\u6aa2\u67e5\uff0c\u76ee\u7684\u662f\u8a55\u4f30\u4ed6\u5c0d\u65bc\u53e3\u670d\u85e5\u54c1\u53cd\u61c9\u4e0d\u592a\u597d\u7684\u72f9\u5fc3\u75c7\u3002\u4ed6\u554f\u5230\u6709\u95dc\u65bc\u51a0\u72c0\u52d5\u8108\u651d\u5f71\u6aa2\u67e5\u6700\u5e38\u898b\u5230\u7684\u4f75\u767c\u75c7\uff0c\u4f9d\u64da\u4e0a\u8ff0\u60c5\u6cc1\uff0c\u4f60\u8a8d\u70ba\u4e0b\u5217\u54ea\u4e00\u9805\u7684\u6bd4\u4f8b\u6700\u9ad8\uff1f\nA. \u6025\u6027\u814e\u8870\u7aed\nB. \u7de9\u6162\u6027\u5fc3\u5f8b\u4e0d\u6574(Bradyarrhythmias)\nC. \u5fc3\u808c\u6897\u585e\nD. \u8840\u7ba1\u6ce8\u5c04\u90e8\u4f4d(vascular access site)\u51fa\u8840\nE. \u5feb\u901f\u6027\u5fc3\u5f8b\u4e0d\u6574\n": "(D)", "102-20.\n\u4e0b\u5217\u54ea\u4e00\u9805\u76ee\u60c5\u6cc1\uff0c\u5728\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u7684\u60a3\u8005\uff0c\u76ee\u524d\u4ecd\u4e0d\u666e\u904d\u88ab\u7576\u4f5c\u662f\u8166\u8840\u7ba1\u4e2d\u98a8\u7684\u5371\u96aa\u56e0\u5b50\uff1f\nA. \u5de6\u5fc3\u623f\u5927\u5c0f4.0\u516c\u5206\nB. \u7cd6\u5c3f\u75c5\nC. \u66fe\u6709\u9b31\u8840\u6027\u5fc3\u8870\u7aed\nD. \u6709\u9ad8\u8840\u58d3\nE. \u66fe\u7d93\u6709\u8166\u8840\u7ba1\u4e2d\u98a8\n": "(A)", "102-21.\n\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u5728\u6bcf\u4f4d\u60a3\u8005\u8eab\u4e0a\u7684\u81e8\u5e8a\u8868\u73fe\u5dee\u7570\u5f88\u5927\uff0c\u5728\u5177\u6709\u4e0b\u5217\u5e7e\u7a2e\u81e8\u5e8a\u60c5\u6cc1\u7684\u60a3\u8005\uff0c\u5982\u679c\u4ed6\u5011\u8eab\u4e0a\u5982\u679c\u51fa\u73fe\u4e86\u65b0\u7684\u6301\u7e8c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\uff0c\u54ea\u4e00\u7a2e\u6703\u6709\u76f8\u5c0d\u66f4\u660e\u986f\u7684\u75c7\u72c0(\u4f8b\u5982\uff1a\u5598)\uff1f\nA. \u6025\u6027\u9152\u7cbe\u4e2d\u6bd2\nB. \u80a5\u539a\u6027\u5fc3\u808c\u75c5\u8b8a\nC. \u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\nD. \u4f4e\u9ad4\u6eab\nE. \u958b\u80f8\u624b\u8853\u5f8c\u7684\u75c5\u4eba\n": "(B)", "102-22.\n\u6709\u95dc\u5fc3\u81df\u74e3\u819c\u75be\u75c5\u9700\u63a5\u53d7\u74e3\u819c\u7f6e\u63db\u624b\u8853\u7684\u60c5\u6cc1\uff0c\u4e0b\u5217\u8aaa\u660e\u54ea\u4e9b\u662f\u6b63\u78ba\u7684\uff1f(1)\u8207\u6a5f\u68b0\u74e3\u819c\u6bd4\u8f03\uff0c\u751f\u7269\u74e3\u819c(Bioprosthetic valve) \u6bd4\u8f03\u4e0d\u6703\u7522\u751f\u8840\u6813 (2)\u540c\u6a23\u4f7f\u7528\u6a5f\u68b0\u74e3\u819c\uff0c\u653e\u7f6e\u5728\u4e3b\u52d5\u8108\u74e3\u4f4d\u7f6e\u7684\u74e3\u819c\u6bd4\u653e\u7f6e\u5728\u4e8c\u5c16\u74e3\u7684\u74e3\u819c\u8840\u6813\u7522\u751f\u6a5f\u6703\u66f4\u9ad8 (3)\u5982\u679c\u60a3\u8005\u60f3\u8981\u61f7\u5b55\u751f\u5b50\uff0c\u6574\u9ad4\u7684\u8eab\u9ad4\u72c0\u6cc1\u53ef\u4ee5\u63a5\u53d7\uff0c\u4f7f\u7528\u6a5f\u68b0\u74e3\u819c\u6703\u6bd4\u751f\u7269\u74e3\u819c\u66f4\u597d (4)\u8003\u616e\u4f7f\u7528\u8010\u4e45\u6027\uff0c\u5728\u5e74\u8f15\u4eba\u8eab\u4e0a\u61c9\u4f7f\u7528\u751f\u7269\u74e3\u819c\u6703\u6bd4\u6a5f\u68b0\u74e3\u819c\u66f4\u597d (5)\u96d9\u76e4\u5f0f\u7684\u6a5f\u68b0\u74e3\u819c(Double-disk valves)\u6bd4\u7403\u72c0\u74e3\u819c(Ball valve)\u6709\u6bd4\u8f03\u597d\u7684\u8840\u884c\u52d5\u529b\u5b78\u8868\u73fe(Hemodynamic parameters)\nA. (1)+(4)\nB. (2)+(5)\nC. (1)+(5)\nD. (3)+(4)\nE. (2)+(3)\n": "(C)", "103-1.\n\u4f9d\u64da2014\u5e74\u65b0\u7248\u7684JNC 8\u6cbb\u7642\u9ad8\u8840\u58d3\uff0c\u5f37\u8abf\u5be6\u8b49\u91ab\u5b78\uff0c\u4e0b\u5217\u4f55\u9805\u7684\u8aaa\u6cd5\u4e0d\u662f\u5c08\u5bb6\u5c0f\u7d44\u7684\u5efa\u8b70\uff1f\nA. \u5927\u65bc60\u6b72\u7684\u9ad8\u8840\u58d3\u75c5\u4eba\u4ee5\u4f4e\u65bc160/90 mmHg \u70ba\u6cbb\u7642\u76ee\u6a19\u3002\nB. \u4ecb\u65bc30-59\u6b72\u7684\u9ad8\u8840\u58d3\u75c5\u4eba\u4ee5\u5fc3\u8212\u8840\u58d3\u4f4e\u65bc90 mmHg \u70ba\u6cbb\u7642\u76ee\u6a19\u3002\nC. 60\u6b72\u4ee5\u4e0b\u7cd6\u5c3f\u75c5\u53ca\u6162\u6027\u814e\u75c5\u8b8a\u75c5\u4eba\u7684\u8840\u58d3\u6cbb\u7642\u4ee5140/90 mmHg\u70ba\u6cbb\u7642\u76ee\u6a19\u3002\nD. \u7cd6\u5c3f\u75c5\u4eba\u964d\u58d3\u8d77\u59cb\u6cbb\u7642\u4ee5Angiotensin-converting enzyme inhibitor, Angiotensin receptor blocker, Calcium channel blocker\u53caThiazides-type diuretics\u70ba\u9650\u3002\nE. \u964d\u58d3\u5291\u52a0\u7528Angiotensin-converting enzyme inhibitor, Angiotensin receptor blocker\u53ef\u6539\u5584\u6162\u6027\u814e\u75c5\u4eba\u4e4b\u814e\u529f\u80fd\u3002\n": "(A)", "103-2.\n\u6839\u64da\"2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults\"\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u5efa\u8b70\u7684\u6307\u5f15\uff1f\nA. \u5df2\u77e5\u7ca5\u72c0\u786c\u5316\u75c5\u8b8a\u76f8\u95dc\u7684\u5fc3\u8840\u7ba1\u75c5\u4eba\u61c9\u7d66\u4e88\u9ad8\u5f37\u5ea6\u4e4bStatin\u6cbb\u7642\u3002\nB. LDL-C >190 mg/dl\u7684\u4eba\u61c9\u7d66\u4e88\u9ad8\u5f37\u5ea6\u4e4bStatin\u6cbb\u7642\u3002\nC. \u5e74\u9f6140-75\u7684\u7cd6\u5c3f\u75c5\u4eba\uff0c\u5176LDL-C\u5927\u65bc70 mg/dl\u5c31\u61c9\u7d66\u4e88\u4e2d\u7b49\u5ea6\u4e4bStatin\u6cbb\u7642\u3002\nD. \u5e74\u9f6140-75\u75c5\u4eba\uff0c\u5176\u6574\u9ad410\u5e74\u98a8\u96aa\u9ad8\u65bc7.5%\u53caLDL-C 70-189 mg/dl\u5c31\u61c9\u7d66\u4e88\u4e2d\u7b49\u5ea6\u4e4bStatin\u6cbb\u7642\u3002\nE. LDL-C\u4e4b\u6cbb\u7642\u76ee\u6a19\uff1a\u5fc3\u8840\u7ba1\u75c5\u4eba\u53ca\u7cd6\u5c3f\u75c5\u4eba\u61c9\u4f4e\u65bc70mg/dl\uff1b\u6709\u5fc3\u8840\u7ba1\u75c5\u5371\u96aa\u56e0\u5b50\u8005\u61c9\u4f4e\u65bc100mg/dl\uff1b\u5176\u4ed6\u8005\u61c9\u4f4e\u65bc160 mg/dl\u3002\n": "(E)", "103-3.\n82\u6b72\u8001\u5a66\u4eba\u5230\u9662\u4e3b\u8a34\u4e94\u5929\u4f86\u6709\u65e5\u8da8\u56b4\u91cd\u7684\u547c\u5438\u56f0\u96e3\u3002\u75c5\u53f2\u986f\u793a30\u5e74\u524d\u5c31\u6709\u91ab\u5e2b\u544a\u77e5\u5fc3\u81df\u96dc\u97f3\uff0c\u56e0\u7121\u75c7\u72c0\uff0c\u672a\u66fe\u6709\u4efb\u4f55\u6cbb\u7642\u3002\u8fd1\u4e94\u5e74\u4f86\u904b\u52d5\u8010\u53d7\u9010\u6f38\u4e0d\u4f73\uff0c\u4e14\u5076\u6709\u7a81\u767c\u6027\u60b8\u52d5\u53ca\u5fc3\u7d5e\u75db\uff0c\u7279\u5225\u5728\u6b65\u884c\u6a13\u68af\u9593\u66f4\u52a0\u60e1\u5316\u3002\u4f4f\u9662\u7576\u65e5\u6e05\u66683\u9ede\u7a81\u7136\u91cd\u5ea6\u547c\u5438\u56f0\u96e3\uff0c\u56e0\u800c\u6025\u8a3a\u4f4f\u9662\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3110/62 mmHg\uff1b\u5fc3\u8df390/\u5206\uff1b\u9838\u975c\u8108\u6012\u5f35\u3002\u5fc3\u81df\u5927\u5c0f\u6b63\u5e38\uff0c\u4f46\u5728\u53f3\u4e0a\u80f8\u9aa8\u7de3\u53ca\u5fc3\u5c16\u90e8\u6709Gr III/VI systolic murmur, S2\u6e1b\u8f15\uff1a\u5176\u4ed6\u6240\u898b\u5c1a\u7121\u7570\u5e38\u3002\u5176\u80f8\u90e8X\u5149\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ca\u5fc3\u96fb\u5716\u5982\u5716\u3002WBC,5.2 k/micro L\uff1bAST,21U/L\uff1bCK,111U/L\uff1bCK-MB,14.6U/L\uff1bTroponin I,0.06 ng/ml\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u8655\u7f6e\u6700\u6070\u7576?\nA. Percutaneous coronary intervention\nB. Aortic valve replacement\nC. Nitroglycerin IV infusion at the rate of 15mcg/min\nD. Titrate PO carvedilol starting from 3.125 mg and reassess in 3 months\nE. Treating with IV digoxin 0.125mg in conjunction with IV bolus Furosemide 20mg and then 20 mg BID\n": "(B)", "103-4.\n\u75c5\u4eba67\u6b72\u7537\u6027\uff0c\u81ea7\u6708\u8d77\u6709\u8f15\u5ea6\u54b3\u55fd\u53ca\u9593\u65b7\u6027\u767c\u71d2\u9ad8\u905438\u5ea6\uff0c\u574a\u9593\u8a3a\u6240\u8a3a\u65b7\u70ba\u4e0a\u547c\u5438\u9053\u611f\u67d3\u3002\u723e\u5f8c\uff0c\u767c\u71d2\u4ecd\u820a\u8d77\u4f0f\u8b8a\u52d5\uff0c\u5076\u6709\u5bd2\u986b(chillness)\uff0c\u4e26\u6709\u5168\u8eab\u5026\u6020\u53ca\u4e8c\u516c\u65a4\u9ad4\u91cd\u6e1b\u8f15\uff0c\u76f4\u523011\u6708\u624d\u5230\u9662\u6c42\u8a3a\u3002\u75c5\u4eba\u50c5\u6709\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u670d\u85e5\u4e2d\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3\uff0c132/70 mmHg\uff1b\u5fc3\u8df3\uff0c78/\u5206\uff0c\u6b63\u5e38\u5f8b\u52d5\uff1b\u5fc3\u81df\u6709Gr II/IV Systolic murmur over left lower sternum border\uff1b\u5176\u4ed6\u5c1a\u7121\u7570\u5e38\u6240\u898b\u3002Blood cultures \u9001\u6aa2\u4e2d\u3002\r\u8acb\u554f\u672c\u75c5\u4eba\u7684\u8a3a\u65b7\u4ee5\u4f55\u9805\u6aa2\u67e5\u6700\u6070\u7576?\nA. Cardiac MRI\nB. Chest CT\nC. Gallium Scan\nD. Transesophageal echocardiography\nE. Exploratory chest operation\n": "(D)", "103-5.\n\u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u5e38\u6709\u809d\u3001\u814e\u529f\u80fd\u7b49\u591a\u91cd\u5668\u5b98\u7570\u5e38\u53ca\u5e38\u8981\u4f75\u7528\u591a\u7a2e\u85e5\u7269\uff0c\u53ef\u5f71\u97ff\u85e5\u7269\u7684\u5438\u6536\u53ca\u6392\u6cc4\uff0c\u5c0e\u81f4\u7528\u85e5\u4ea4\u4e92\u4f5c\u7528\u7981\u5fcc\u7684\u767c\u751f\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u5f97\u4f7f\u7528?\nA. Thiazolidinediones\nB. Dronedarone\nC. Amlodipine\nD. Cyclooxygenase 2 inhibitors\nE. Metformin\n": "(C)", "103-6.\n72\u6b72\u8001\u5148\u751f\uff0c\u591c\u9593\u7761\u89ba\u4e2d\u7a81\u56e0\u80f8\u75bc\u4f34\u6709\u5bd2\u986b\u3001\u51b7\u6c57\u800c\u9a5a\u9192\uff0c\u75bc\u75db\u9010\u6f38\u52a0\u5287\uff0c\u4e26\u5ef6\u4f38\u5f8c\u80cc\u90e8\uff0c\u4e43\u6025\u8d74\u6025\u8a3a\u90e8\u6c42\u8a3a\u3002\u7576\u6642\u8840\u58d3\u5de6\u624b176/98 mmHg\uff1b\u53f3\u624b164/97 mmHg\uff1b\u8108\u8df378/\u5206\uff0c\u898f\u5247\u8df3\u52d5\u3002\u75c5\u4eba\u8ffd\u61b6\u8fd1\u500b\u6708\u4f86\uff0c\u6642\u6709\u9593\u6b47\u6027\u7684\u80f8\u75db\uff0c\u6709\u6642\u751a\u81f3\u75db\u904e\u500b\u628a\u5c0f\u6642\u3002 \u75c5\u4eba\u559c\u597d\u62bd\u7159\uff0c\u4f46\u5c1a\u7121\u5176\u4ed6\u75be\u75c5\u3002\u7406\u5b78\u53ea\u898b\u8eab\u9ad8 176 cm\u53ca\u9ad4\u91cd64.6 kg\uff0c\u8840\u58d3\u53ca\u5fc3\u8df3\u5982\u524d\u6240\u8ff0\uff0c\u4e0a\u4e0b\u80a2\u52d5\u8108\u8df3\u52d5\u6b63\u5e38\uff0c\u5176\u4ed6\u90e8\u4f4d\u4e26\u7121\u7570\u5e38\u53ef\u898b\u3002\u5176\u80f8\u90e8X\u5149\u3001\u5fc3\u96fb\u5716\u53ca\u96fb\u8166\u65b7\u5c64\u5982\u5716\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5982\u4e0b\u3002\u7d93\u4f7f\u7528IV morphine\u53ca\u93ae\u975c\u5291\u5f8c\uff0c\u75c5\u6cc1\u5927\u6709\u6539\u5584\u3002\u8acb\u554f\u6b64\u523b\u75c5\u4eba\u6700\u5408\u5b9c\u7684\u6cbb\u7642\u7b56\u7565\u662f?\nA. Endovascular stenting\nB. Urgent aortic repair\nC. Labetalol IV titration\nD. Catheter-based fenestration\nE. Dopamine IV infusion\n": "(C)", "103-7.\n\u6709\u95dc\u5fc3\u5ba4\u5feb\u8df3(Ventricular tachycardia, VT)\u7684\u8aaa\u6cd5\uff0c\u4e0b\u5217\u4f55\u8005\u7684\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684\uff1f\nA. Monomorphic VT \u591a\u898b\u65bc\u975e\u5668\u5b98\u8b8a\u7570\u6027\u5fc3\u81df\u75c5\u3002\nB. Polymorphic VT\u5728EP \u5be6\u9a57\u5ba4\u4e0d\u6613\u96fb\u6fc0\u5c0e\u8a98\u767c(Electric stimulation)\u3002\nC. \u8840\u884c\u529b\u5b78\u7570\u5e38\u53ca\u53bb\u986b\u96fb\u6fc0\u6709\u6548\u7684VT\u591a\u662f\u6301\u7e8c\u6027VT(Sustained VT)\u3002\nD. \u5728\u5fc3\u524d\u5340\u96fb\u6975(Precordial leads) \u51fa\u73fe\u540c\u81f4\u6027(Concordant)QRS\u578b\u614b\u3002\nE. Monomorphic VT \u4f7f\u7528\u975c\u6ce8\u7684Procainamide,Lidocaine \u6216Amiodarone \u5c31\u6709\u6548\uff0c\u4e0d\u5fc5\u96fb\u64ca\u3002\n": "(E)", "103-8.\n\u4f9d\u64da\u7f8e\u570b\u91ab\u5e2b\u5b78\u9662(American College of Physicians)\u57fa\u65bc\u91ab\u7642\u6210\u672c\u3001\u81e8\u5e8a\u5be6\u6548\u53ca\u75c5\u4eba\u5b89\u5168\uff0c\u6709\u4e0b\u5217\u8af8\u9805\u7167\u8b77\u8655\u7f6e\uff1a(1)\u4e2d\u5e74\u5973\u6027\uff0c\u6709\u6b63\u5e38\u6708\u7d93\u9031\u671f\uff0c\u4e5f\u6c92\u6709\u4efb\u4f55\u5fc3\u81df\u75c7\u72c0\uff0c\u672a\u6709\u4e09\u9ad8\u75c5\u53f2\uff0c\u70ba\u65e9\u671f\u8a3a\u65b7\uff0c\u9054\u5230\u5b8c\u5168\u6cbb\u7642\u6548\u679c\uff0c\u61c9\u5efa\u8b70\u96fb\u8166\u65b7\u5c64\u51a0\u72c0\u52d5\u8108\u9020\u5f71\u6aa2\u67e5\uff0c\u4ee5\u77ad\u89e3\u51a0\u8108\u72f9\u7a84\u53ca\u51a0\u72c0\u52d5\u8108\u9223\u5316\u5206\u6578 (2)\u4e8c\u5c16\u74e3\u812b\u5782\u75c5\u4eba\u9032\u884c\u62d4\u7259\u624b\u8853\u6642\uff0c\u9664\u6709\u5fc3\u5167\u819c\u708e\u75c5\u53f2\u5916\uff0c\u53ef\u4e0d\u5fc5\u670d\u7528\u6297\u751f\u7d20\u9810\u9632\u5fc3\u5167\u819c\u708e\u4e4b\u767c\u751f (3)\u6162\u6027\u51a0\u5fc3\u75c5\u4eba\uff0c\u5728\u85e5\u7269\u670d\u7528\u4e2d\uff0c\u672a\u6709\u4efb\u4f55\u5fc3\u81df\u75c7\u72c0\u6642\uff0c\u4e0d\u5fc5\u4ee5\u51a0\u72c0\u52d5\u8108\u9020\u5f71\u8ffd\u8e64\u7ca5\u72c0\u786c\u5316\u4e4b\u9032\u5c55\r(4)\u6025\u6027\u4e0b\u58c1\u5fc3\u808c\u6897\u585e\u4f34\u767c\u5b8c\u5168\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef\uff0c\u61c9\u5019\u7b49\u6578\u5929\uff0c\u624d\u53ef\u6c7a\u5b9a\u7f6e\u653e\u6c38\u4e45\u6027\u5fc3\u5f8b\u8abf\u6574\u5668 (5)\u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u4f75\u6709\u547c\u5438\u56f0\u96e3\u6642\uff0c\u4ecd\u820a\u61c9\u6709BNP\u6aa2\u6e2c\uff0c\u4ee5\u70ba\u6cbb\u7642\u4e4b\u53c3\u8003\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u7684\u8655\u7f6e\u624d\u6709\u9ad8\u50f9\u503c\u7684\u7167\u8b77\uff1f\nA. (1)+(3)+(5)\nB. (1)+(4)+(5)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (3)+(4)+(5)\n": "(C)", "103-9.\n\u6797\u5148\u751f\u5e7427\u6b72\uff0c\u65bc2013\u5e7410\u6708\u521d\u5f9e\u4e2d\u570b\u5de5\u4f5c\u56de\u53f0\u5f8c\uff0c\u958b\u59cb\u6709\u54b3\u55fd\u3001\u9593\u6b47\u6027\u5bd2\u986b\u3001\u7009\u809a\u53ca\u8f15\u5ea6\u547c\u5438\u56f0\u96e3\uff0c\u7d93\u904e\u4e8c\u9031\uff0c\u75c5\u72c0\u65e5\u5287\uff0c\u5168\u8eab\u5026\u6020\uff0c\u4e26\u6709\u7aef\u5750\u547c\u5438\u56f0\u96e3\uff0c\u8179\u8139\u3001\u5641\u5fc3\u53ca\u9ad4\u91cd\u5287\u589e\uff0c\u4e43\u4f4f\u9662\u8a3a\u7642\u3002\u7406\u6aa2\u986f\u793a\uff1a\u8eab\u9ad8\uff0c179\u516c\u5206\uff1b\u9ad4\u91cd\uff0c84.6\u516c\u65a4\uff1b\u9ad4\u6eab36.9\u5ea6\uff1a\u5fc3\u8df3 110/\u5206\uff1b\u547c\u5438 24/\u5206\u53ca\u8840\u58d3 159/119 mmHg\uff1b\u9838\u975c\u8108\u6012\u5f35\uff1b\u96d9\u5074\u80ba\u6709\u6df7\u6fc1\u547c\u5438\u8072\uff1b\u5fc3\u81df\uff0cS3\u53caleft lift\uff0c\u4f46\u7121\u5fc3\u81df\u96dc\u97f3\u53ef\u805e\uff1b\u8179\u90e8\u6709shifting dullness\uff0c\u4f46\u7121\u809d\u816b\uff1b\u96d9\u8173\u6d6e\u816b\u3002\u5176\u5fc3\u96fb\u5716\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u3002\r\u8acb\u554f\u9019\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Acute myocardial infarction\nB. Hypertensive cardiovascular disease\nC. Hypertrophic cardiomyopathy\nD. Acute aortic disease\nE. Acute heart failure\n": "(E)", "103-10.\n\u675c\u5148\u751f73\u6b72\uff0c\u56e0H1N1\u6d41\u884c\u6027\u611f\u5192\u4f75\u767c\u80ba\u708e\u53ca\u547c\u5438\u8870\u7aed\u800c\u65bc1\u670824\u65e5\u4f4f\u9662\u3002\u6709\u62bd\u7159\u75c5\u53f2\uff0c\u4f46\u7121\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u6216\u8840\u8102\u7570\u5e38\u75c5\u53f2\u3002\u4f4f\u9662\u4e2d\u547c\u5438\u4ecd\u820a\u4e0d\u9069\uff0c1\u670826\u65e5\u6e05\u6668\u8840\u6c27\u964d\u4f4e\uff0c\u6642T/P/R 36.8/123/26\uff1bCVP=8mmHg\uff0cBP 140/73mmHg\uff0cbilateral crackles\uff0c\u555f\u7528 PEEP\u8f14\u52a9\u547c\u5438\u3002\u7dca\u6025\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X-\u5149\u6aa2\u67e5\u5982\u5716\u3002\u8acb\u554f\u672c\u75c5\u4eba\u4e4b\u8a3a\u65b7\u662f\uff1a\nA. Acute respiratory failure\nB. Acute lungs edema\nC. STEMI, proximal left anterior descending artery occlusion\nD. STEMI, proximal right coronary artery occlusion\nE. NSTEMI, left circumflex artery occlusion\n": "(C)", "103-11.\n72\u6b72\u7537\u6027\u8001\u4eba\uff0c\u4f4f\u9662\u4e3b\u8a34\u7a81\u767c\u6027\u547c\u5438\u56f0\u96e3\u3002\u75c5\u4eba\u57282007\u5e74\u6709\u9ad8\u8840\u58d3\u670d\u7528Bisoprolol(5mg)1/2 #,qd\u53ca Amlodipine(5mg) 1#,qd\u30022009\u5e747\u67086\u65e5\u8fd1\u4e4e\u660f\u53a5\u6c42\u91ab\uff0c\u5fc3\u96fb\u5716\u5982(A)\u30022003\u5e744\u67081\u65e5\u6709\u5de6\u773c\u5931\u660e\u53ca\u5de6\u624b\u8edf\u5f31\u7121\u529b\uff0c\u6642\u8840\u58d3164/79 mmHg\u53ca\u5fc3\u8df393/min\uff0c\u4e0d\u898f\u5247\u5f8b\u8df3\uff0c\u5fc3\u96fb\u5716\u5982(B)\u3002\u57282014\u5e748\u67086\u65e5\u6e05\u6668\u7a81\u7136\u547c\u5438\u56f0\u96e3\uff0c\u4e43\u6025\u5f80\u6025\u8a3a\u90e8\u6c42\u8a3a\uff0c\u64da\u7a31\u75c5\u4eba\u5df2\u6709\u5fc3\u60b8\u3001\u80f8\u60b6\u53ca\u9593\u6b47\u6027\u547c\u5438\u56f0\u96e3\u4e00\u9031\u3002\u7406\u5b78\u6aa2\u67e5\uff1aT/P/R= 36.9/79/18\uff1bBP 119/73 mmHg\uff1b\u6025\u75c5\u72c0\uff0c\u80ba\u90e8\u6df7\u6fc1\u547c\u5438\u97f3\uff0c\u5fc3\u81df\u5927\u5c0f\u5c1a\u53ef\uff0c\u672a\u6709\u5fc3\u96dc\u97f3\u53caS3\u6216S4\uff0c\u9918\u4e4b\u7406\u6aa2\u5c1a\u7121\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716(C)\r\u53ca\u80f8\u90e8X\u5149\u548c\u8840\u6db2\u6aa2\u67e5\u5982\u5716\u3002\u8acb\u554f\u6b64\u75c5\u4eba\u4e4b\u5fc3\u5f8b\u4e0d\u6574\u8a3a\u65b7\u662f\uff1a\nA. Short-run ventricular tachycardia\nB. Torsades de pointes\nC. Atrial fibrillation\nD. Wolff-Parkinson-White (WPW) syndrome with atrial fibrillation\nE. Ventricular fibrillation\n": "(D)", "103-12.\n\u73fe\u5e7452\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u6025\u767c\u80f8\u75bc\u4e26\u6709\u96d9\u8173\u9ebb\u6728\u6025\u5f80\u6025\u8a3a\u90e8\u6c42\u8a3a\u3002\u6642\u6709\u5408\u4f75\u51b7\u6c57\uff0c\u4f46\u7121\u5641\u5fc3\u6216\u5614\u5410\uff0c\u4e5f\u672a\u6709\u653e\u6563\u6027\u80f8\u75bc\u3002\u8840\u58d365/52mmHg; \u5fc3\u8df352/\u5206\uff1b\u9ad4\u6eab36.7\u5ea6\uff1b\u547c\u543818/\u5206\uff1b\u5176\u4ed6\u7406\u5b78\u6240\u898b\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u3002\u75c5\u4eba\u65e2\u5f80\u75c5\u53f2\u6709\u5341\u591a\u5e74\u9ad8\u8840\u58d3\uff0c\u4e0d\u898f\u5247\u7528\u85e5\uff0c\u5bb6\u65cf\u6709\u51a0\u5fc3\u75c5\u3002\u5176\u7dca\u6025\u751f\u5316\u6aa2\u67e5\uff1aCK 78\uff1bCK-MB 26.3\uff1bTroponin I 0.012\u3002\u8acb\u554f\u672c\u75c5\u4eba\u7684STEMI\u6700\u53ef\u80fd\u7684\u51a0\u72c0\u52d5\u8108\u963b\u585e\u4f4d\u7f6e\u5728\uff1a\nA. Proximal left anterior descending artery(LAD)\nB. Proximal LAD beyond septal branch\nC. Posterolateral right coronary artery(RCA)\nD. Proximal RCA with Bezold-Jarish reaction\nE. Proximal left circumflex artery\n": "(D)", "103-13.\n\u4e00\u4f4d42\u6b72\u7684\u7537\u6027\u4e0a\u73ed\u65cf\u4f86\u770b\u9ad4\u6aa2\u5831\u544a\uff0c\u4ed6\u6bcf\u5468\u6162\u8dd1\u4e09\u6b21\uff0c\u6bcf\u6b21\u8dd135\u5206\u9418\uff0c\u8dd1\u6b65\u6642\u4e0d\u66fe\u89ba\u5f97\u80f8\u60b6\u6216\u6c23\u5598\u3002\u5728\u5de5\u4f5c\u58d3\u529b\u5927\u7684\u6642\u5019\u5076\u723e\u6703\u89ba\u5f97\"\u5fc3\u81df\u5c11\u4e86\u4e00\u8df3\"\u7684\u611f\u89ba\uff0c\u800c\u9019\u7a2e\u611f\u89ba\u4e0d\u6703\u6301\u7e8c\uff0c\u4e5f\u4e0d\u6703\u6709\u982d\u6688\u3002\u4ee5\u524d\u6c92\u6709\u4f4f\u9662\u6216\u958b\u5200\uff0c\u81ea\u5df1\u611f\u89ba\u5065\u5eb7\uff0c\u6c92\u6709\u62bd\u83f8\u6216\u559d\u9152\u3002\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3 126/72 mmHg\uff0c\u5fc3\u8df3\u6bcf\u5206\u941868\u6b21\uff0c\u547c\u5438\u6bcf\u5206\u941814\u6b21\uff0c\u8eab\u9ad4\u8cea\u91cf\u6307\u6578(BMI)\u662f23 kg/m2\u3002\u5fc3\u97f3\u807d\u8a3a\u5728\u5de6\u4e0b\u80f8\u9aa8\u908a\u7de3\u6709\u4e0d\u6703\u653e\u5c04\u7684\u7b2c2/6\u5ea6\u6536\u7e2e\u5fc3\u96dc\u97f3\uff0c\u80ba\u90e8\u547c\u5438\u97f3\u6b63\u5e38\uff0c\u56db\u80a2\u8108\u640f\u5c0d\u7a31\u6b63\u5e38\uff0c\u5fc3\u96fb\u5716\u6aa2\u67e5\u6b63\u5e38\u3002 \u4e0b\u4e00\u6b65\u8981\u5b89\u6392\u7684\u6aa2\u67e5\u662f\uff1f\nA. 24\u5c0f\u6642\u5fc3\u96fb\u5716\nB. \u98df\u9053\u5fc3\u81df\u8d85\u97f3\u6ce2\nC. \u80f8\u524d\u5fc3\u81df\u8d85\u97f3\u6ce2\nD. \u904b\u52d5\u5fc3\u96fb\u5716\nE. \u4e0d\u7528\u9032\u4e00\u6b65\u6aa2\u67e5\n": "(E)", "103-14.\n63\u6b72\u7537\u6027\u6709\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u548c\u9ad8\u8840\u58d3\uff0c\u540c\u6642\u6709\u9663\u767c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u7684\u75c5\u53f2\u800c\u63a5\u53d7\u5305\u542b\u6709metoprolol\uff0cmetformin\u548cwarfarin\u7684\u85e5\u7269\u6cbb\u7642\u3002\u56e0\u70ba\u7cde\u4fbf\u6f5b\u8840\u7be9\u6aa2\u967d\u6027\u5b89\u6392\u5927\u8178\u93e1\u6aa2\u67e5\uff0c\u56e0\u70ba\u53ef\u80fd\u6703\u6709\u63a1\u6aa2 (biopsy)\u7684\u9700\u8981\uff0c\u8981\u5148\u505c\u7528warfarin\u3002\u4ed6\u4e0d\u66fe\u62bd\u83f8\uff0c\u6c92\u6709\u4e2d\u98a8\u6216\u56db\u80a2\u52d5\u975c\u8108\u8840\u7ba1\u963b\u585e\u7684\u904e\u53bb\u53f2\uff0c\u9ad4\u6aa2\u6642\u8840\u58d3\u5fc3\u8df3\u5728\u6b63\u5e38\u503c\uff0c\u5fc3\u5f8b\u5247\u5448\u73fe\u4e0d\u898f\u5247(irregularly irregular)\uff0c\u62bd\u8840\u6aa2\u67e5INR\u662f2.3\u3002\u5728\u6b64\u6642\u9700\u8981\u505c\u6b62warfarin\u7684\u60c5\u6cc1\u4e0b\uff0c\u6703\u63a1\u53d6\u7684\u8f03\u6070\u7576\u6b65\u9a5f\u662f\uff1f\nA. \u6539\u7528aspirin\nB. \u6539\u7528clopidogrel\nC. \u6539\u7528\u4f4e\u5206\u5b50\u91cf\u809d\u7d20(low molecular weight heparin)\nD. \u6539\u7528\u809d\u7d20(unfractionated heparin)\nE. \u4e0d\u9808\u4f7f\u7528\u66ab\u6642\u7684\u66ff\u4ee3\u85e5\u54c1\n": "(E)", "103-15.\n70\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u56b4\u91cd\u7684\u5931\u4ee3\u511f\u9b31\u8840\u6027\u5fc3\u8870\u7aed(decompensated congestive heart failure)\u4f4f\u9662\u63a5\u53d7\u6cbb\u7642\uff0c\u56e0\u70ba\u7a81\u767c\u6027\u7684\u5fc3\u5ba4\u7e96\u7dad\u986b\u52d5(Vf)\u6b63\u5728\u9032\u884c\u6025\u6551\uff0c\u76ee\u524d\u525b\u9032\u884c\u5b8c200\u7126\u8033\u7684\u975e\u540c\u6b65\u9ad4\u5916\u53bb\u986b\u96fb\u64ca\uff0c\u7dca\u63a5\u8457\u53bb\u986b\u96fb\u64ca\u4e4b\u5f8c\u7acb\u523b\u9032\u884c\u8f03\u6070\u7576\u7684\u52d5\u4f5c\u662f\uff1f\nA. \u7e7c\u7e8c\u9ad4\u5916\u6309\u6469CPR\nB. \u7d66\u4e88epinephrine\nC. \u7d66\u4e88amiodarone\nD. \u78ba\u8a8d\u8108\u640f\nE. \u7d66\u4e88vasopressin\n": "(A)", "103-16.\n52\u6b72\u6709\u9ad8\u8840\u58d3\u7684\u7537\u6027\u60a3\u8005\uff0c\u6392\u5c3f\u6b63\u5e38\uff0c\u56e0\u70ba\u5927\u65bc\u4e00\u5468\u7684\u96d9\u4e0b\u80a2\u6c34\u816b\u548c\u547c\u5438\u6703\u5598\uff0c\u722c2\u5c64\u6a13\u68af\u66f4\u5598\u800c\u4f4f\u9662\u6cbb\u7642\u3002\u4f4f\u9662\u6642\u4ed6\u63a5\u53d7\u975c\u8108\u6ce8\u5c04\u5229\u5c3f\u5291furosemide\u4e4b\u5f8c\u75c7\u72c0\u9032\u6b65\uff0c\u4e94\u5929\u5f8c\u85e5\u7269\u8abf\u6574\u5230\u53e3\u670d\u7684 enalapril\u548cfurosemide\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5de6\u5fc3\u5ba4\u5c04\u51fa\u738735%\uff0c\u6c92\u6709\u74e3\u819c\u75be\u75c5\uff0c\u6574\u500b\u5de6\u5fc3\u5ba4\u904b\u52d5\u4e0d\u826f(global hypokinesia); \u6838\u5b50\u91ab\u5b78\u704c\u6d41\u6aa2\u67e5\u6c92\u6709\u660e\u986f\u7684\u5c40\u90e8\u7f3a\u8840\u3002\u76ee\u524d\u4ed6\u7684\u8840\u58d3\u662f136/88mmHg\uff0c\u5fc3\u8df3\u6bcf\u5206\u941880\u6b21\uff0c\u547c\u5438\u6bcf\u5206\u941815\u6b21\uff0c\u8eab\u9ad4\u6aa2\u67e5\u6c92\u6709\u9838\u975c\u8108\u6012\u5f35\uff0c\u6c92\u6709\u7b2c\u4e09\u5fc3\u97f3\uff0c\u6c92\u6709\u80ba\u90e8\u56c9\u97f3(moist\rrales)\uff0c\u96d9\u4e0b\u80a2\u5df2\u7d93\u6c92\u6709\u6c34\u816b\u3002\u7532\u72c0\u817a\u6578\u503c\u6b63\u5e38\uff0c\u5fc3\u96fb\u5716\u6b63\u5e38\u7ac7\u6027\u7bc0\u5f8b\uff0c\u6c92\u6709\u75c5\u7406\u6027Q\u6ce2\u3002\u6b64\u6642\u52a0\u4e0a\u4e0b\u5217\u54ea\u4e00\u7a2e\u85e5\u7269\u8f03\u5408\u9069\uff1f\nA. Amlodipine\nB. Carvedilol\nC. Hydralazine + isosorbide dinitrate\nD. Doxazosin\nE. Spironolactone\n": "(B)", "103-17.\n76\u6b72\u5973\u6027\u9ad8\u8840\u58d3\u75c5\u4eba\u7d93\u6b77\u80f8\u53e3\u75bc\u75db\u4e09\u5929\u4e4b\u5f8c\u7531\u5bb6\u4eba\u966a\u540c\u5c31\u91ab\uff0c\u7576\u5979\u5230\u91ab\u9662\u6025\u8a3a\u6642\u80f8\u75db\u5df2\u7d93\u7de9\u89e3\uff0c\u521d\u6b65\u767c\u73fe\u5979\u6709ST\u7bc0\u6bb5\u4e0a\u5347\u578b\u524d\u58c1\u5fc3\u808c\u6897\u585e\u3002\u5230\u9662\u5169\u5c0f\u6642\u4e4b\u5f8c\u5979\u7a81\u7136\u767c\u751f\u547c\u5438\u4e0d\u9806\uff0c\u5287\u70c8\u5598\u606f\u548c\u8840\u58d3\u4e0b\u964d\u800c\u7dca\u6025\u9032\u884c\u6c23\u7ba1\u63d2\u7ba1\uff0cX\u5149\u6aa2\u67e5\u767c\u73fe\u66f4\u64f4\u5927\u7684\u5fc3\u81df\u8207\u80ba\u6c34\u816b\uff0c\u4e26\u9700\u8981\u7528Dopamine\u958b\u59cb\u5e6b\u5fd9\u7dad\u6301\u8840\u58d3\u3002\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3\u662f90/60mmHg\uff0c\u5fc3\u8df3\u6bcf\u5206\u9418122\u6b21\uff0c\u547c\u5438\u6bcf\u5206\u941816\u6b21\uff0c\u5728\u5979\u7684\u5de6\u53f3\u80f8\u9aa8\u908a\u7de3\u807d\u5230\u7b2c4/6\u7d1a\u5168\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\uff0c\u53ef\u4ee5\u89f8\u8a3a\u5230\u9707\u986b(thrill)\uff0c\u96d9\u5074\u80ba\u90e8\u51fa\u73fe\u56c9\u97f3(rales)\u3002\u4e0b\u5217\u54ea\u4e00\u500b\u8a3a\u65b7\u6bd4\u8f03\u53ef\u80fd\u8981\u5148\u8003\u616e\uff1f\nA. \u4e3b\u52d5\u8108\u525d\u96e2\nB. \u5de6\u5fc3\u5ba4\u7624\nC. \u5fc3\u5ba4\u4e2d\u8188\u7f3a\u640d\nD. \u53f3\u5fc3\u5ba4\u6897\u585e\nE. \u5fc3\u5305\u586b\u585e(cardiac tamponade)\n": "(C)", "103-18.\n68\u6b72\u5973\u6027\u60a3\u8005\u56e0\u70ba\u7a81\u7136\u51fa\u73fe\u7684\u5fc3\u60b8\u5408\u4f75\u982d\u6688\uff0c\u547c\u5438\u6703\u5598\u7b49\u72c0\u6cc1\u4f86\u5230\u6025\u8a3a\u5ba4\u3002\u5979\u6709\u9ad8\u8840\u58d3\u7684\u75c5\u53f2\uff0c\u524d\u4e00\u500b\u6708\u525b\u9032\u884c\u7684\u6aa2\u67e5\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5de6\u5fc3\u5ba4\u6536\u7e2e\u529f\u80fd\u6b63\u5e38\uff0c\u5fc3\u8df3\u662f\u7ac7\u6027\u5fc3\u5f8b\u3002\u76ee\u524d\u6b63\u4f7f\u7528ACE inhibitor\uff0c\u5229\u5c3f\u5291\u548c\u963f\u65af\u5339\u9748\u6cbb\u7642\u3002\u5e73\u65e5\u8840\u58d3\u63a7\u5236\u5728\u6b63\u5e38\u6578\u503c\u3002\u7576\u5979\u5230\u9054\u6025\u8a3a\u6642\uff0c\u6e2c\u5f97\u7684\u751f\u547d\u5fb5\u8c61\uff1a\u8840\u58d380/60mmHg\uff0c\u5fc3\u8df3150\u6b21/\u5206\u9418\uff0c\u547c\u543830\u6b21/\u5206\u9418\uff0c\u4f7f\u752840%\u6c27\u6c23\u9762\u7f69\u7684SpO2\u662f80%\u3002\u5fc3\u81df\u7684\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u4e0d\u898f\u5247\u7684\u5feb\u901f\u5fc3\u8df3\uff0cS1\u5fc3\u97f3\u807d\u8a3a\u6642\u8072\u97f3\u51fa\u73fe\u5927\u5c0f\u8b8a\u5316\uff0c\u96d9\u5074\u4e0b\u4e09\u5206\u4e4b\u4e00\u7684\u80ba\u90e8\u6709\u6fd5\u56c9\u97f3\uff0c\u5fc3\u96fb\u5716\u5448\u73fe\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u3002\u6b64\u6642\u7684\u7dca\u6025\u8655\u7406\u4e0b\u5217\u6bd4\u8f03\u5408\u9069\u7684\u4e00\u9805\u662f\uff1f\nA. Adenosine\nB. Amiodarone\nC. Cardioversion\nD. Diltiazem\nE. Metoprolol\n": "(C)", "103-19.\n60\u6b72\u7684\u7537\u6027\u56e0\u70ba\u5de6\u5074\u808b\u819c\u75bc\u75db\u611f\u89ba\u800c\u5c31\u91ab\uff0c\u4ed6\u7684\u75bc\u75db\u51fa\u73fe\u5927\u7d04\u4e00\u9031\u4e86\uff0c\u6bcf\u6b21\u767c\u751f\u6642\u6703\u75db\u6578\u500b\u5c0f\u6642\uff0c\u5982\u679c\u8eba\u4e0b\u6703\u66f4\u75bc\u75db\u3002\u4ed6\u66fe\u8a66\u8457\u670d\u7528\u666e\u62ff\u75bc\uff0c\u53ea\u80fd\u7a0d\u5fae\u6e1b\u8f15\u75bc\u75db\u611f\uff0c\u4f46\u4ed6\u767c\u73fe\u5982\u679c\u5750\u8457\u5c07\u4e0a\u534a\u8eab\u50be\u5411\u524d\u65b9\u80fd\u66ab\u6642\u8b93\u75bc\u75db\u611f\u6d88\u5931\u3002\u4ed6\u56de\u61b6\u81ea\u5df1\u5728\u4e03\u500b\u6708\u4e4b\u524d\u66fe\u88ab\u8a3a\u65b7\u6709\u6025\u6027\u5fc3\u5305\u819c\u708e\uff0c\u90a3\u6642\u5403\u4e86\u91ab\u5e2b\u958b\u7684\u6b62\u75db\u85e57\u5929\u4e4b\u5f8c\u5c31\u597d\u4e86\u3002\u60a3\u8005\u5728\u6700\u8fd1\u4e09\u5929\u6709\u8f15\u5fae\u767c\u71d2\uff0c\u4f46\u6c92\u6709\u54b3\u55fd\u6216\u6d41\u9f3b\u6c34\uff0c\u4e5f\u6c92\u6709\u65c5\u884c\u3002\u8eab\u9ad4\u6aa2\u67e5\u6642\u751f\u547d\u5fb5\u8c61\uff1a\u8840\u58d3128/68mmHg\uff0c\u547c\u543816\u6b21/\u5206\u9418\uff0c\u5fc3\u8df398\u6b21/\u5206\u9418\uff0c\u6c92\u6709\u9838\u975c\u8108\u9f13\u8139\uff0c\u4f46\u6709\u5de6\u5074\u80f8\u9aa8\u7de3\u807d\u5230\u6709\u4e8c\u500b\u7d44\u6210\u6210\u4efd\u7684\u5fc3\u5305\u6469\u64e6\u97f3\uff0c\u80ba\u90e8\u807d\u8a3a\u6c92\u6709\u54ee\u9cf4\u97f3\uff0c\u624b\u8173\u6c92\u6709\u6c34\u816b\uff0c\u5fc3\u96fb\u5716\u662f\u7ac7\u6027\ufffd\r\u8456\u8144A\u6c92\u6709ST\u7bc0\u6bb5\u8b8a\u5316\u3002\u6b64\u6642\u6703\u8003\u616e\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f55\u8005\u6bd4\u8f03\u6070\u7576\uff1f\nA. \u6aa2\u67e5\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\nB. \u5fc3\u5305\u5207\u9664\u8853\nC. Azathioprine\nD. Prednisolone\nE. Colchicine\u548caspirin\n": "(E)", "103-20.\n73\u6b72\u5973\u6027\u6709\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\uff0c\u9ad8\u8840\u58d3\uff0c\u9ad8\u8840\u8102\u597d\u591a\u5e74\u4e86\uff0c\u5979\u524d\u4f86\u56de\u8a3a\u770b\u6700\u8fd1\u7684\u6aa2\u67e5\u5831\u544a\u3002\u76ee\u524d\u5979\u6b63\u63a5\u53d7olmesartan, metformin\u548cpravastatin\u7684\u6cbb\u7642\u3002\u5979\u6709\u63a5\u53d7\u91ab\u5e2b\u7684\u5efa\u8b70\u7dad\u6301\u56fa\u5b9a\u904b\u52d5\uff0c\u9ad8\u7e96\u4f4e\u8102\u98f2\u98df\uff0c\u540c\u6642\u5e38\u651d\u53d6\u6c34\u679c\u8207\u852c\u83dc\u3002\u6c92\u6709\u85e5\u7269\u904e\u654f\u53f2\u3002\u56de\u8a3a\u6642\u751f\u547d\u5fb5\u8c61\u662f\uff1a\u8840\u58d3122/72mmHg\uff0c\u5fc3\u8df372\u6b21/\u5206\u9418\uff0c\u547c\u543815\u6b21/\u5206\u9418\uff0c\u5fc3\u3001\u80f8\u3001\u8179\u90e8\u8207\u56db\u80a2\u7684\u8eab\u9ad4\u6aa2\u67e5\u5247\u6c92\u6709\u7279\u6b8a\u767c\u73fe\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u6578\u503c\u5982\u4e0b\uff1aHbA1c :\r6.5%\uff0c\u7e3d\u81bd\u56fa\u9187116mg/dL\uff0c\u4f4e\u5bc6\u5ea6\u81bd\u56fa\u9187(LDL-C)51mg/dL\uff0c\u9ad8\u5bc6\u5ea6\u81bd\u56fa\u9187(HDL-C)57mg/dL\uff0c\u4e09\u9178\u7518\u6cb9\u8102(TG)40mg/dL\u3002\u75c5\u4eba\u5e0c\u671b\u63a5\u53d7\u5b8c\u5584\u7684\u7167\u9867\uff0c\u8acb\u554f\u6703\u7d66\u4e88\u7684\u7528\u85e5\u5efa\u8b70\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u4f73\uff1f\nA. \u4f7f\u7528clopidogrel\nB. \u589e\u52a0\u964d\u8840\u8102\u7684\u85e5\u7269\nC. \u4f7f\u7528aspirin\u548cdipyridamole\nD. \u4f7f\u7528aspirin\nE. \u4f7f\u7528aspirin\u548cclopidogrel\n": "(D)", "103-21.\n50\u6b72\u7684\u5973\u6027\u66fe\u572813\u5e74\u524d\u56e0\u4e73\u764c\u63a5\u53d7\u624b\u8853\u5207\u9664\u53f3\u5074\u4e73\u623f\u4ee5\u53ca\u8853\u5f8c\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u5728\u5916\u79d1\u8853\u5f8c\u7684\u898f\u5247\u8ffd\u8e64\u88e1\uff0c\u5979\u7684\u72c0\u6cc1\u7a69\u5b9a\uff0c\u6c92\u6709\u8b8a\u5316\u3002\u76f4\u5230\u5979\u6700\u8fd1\u4e09\u500b\u6708\u88e1\uff0c\u5979\u611f\u5230\u904b\u52d5\u6642\u6703\u7565\u70ba\u80f8\u60b6\uff0c\u6700\u8fd1\u4e8c\u500b\u6708\u5167\u5247\u6162\u6162\u51fa\u73fe\u722c\u4e09\u5c64\u6a13\u68af\u6642\u6709\u4e00\u9ede\u5598\u3002\u8eab\u9ad4\u6aa2\u67e5\u6642\u5979\u7684\u9ad4\u6eab\u6b63\u5e38\uff0c\u8840\u58d3\uff1a150/43mmHg\uff0c\u5fc3\u8df380\u6b21/\u5206\u9418\uff0c\u547c\u543814\u6b21/\u5206\u9418\u3002\u9838\u975c\u8108\u6c92\u6709\u9f13\u8139\uff0c\u4f46\u6703\u89c0\u5bdf\u5230\u52a0\u5f37\u800c\u5feb\u901f\u7684\u9838\u52d5\u8108\u6ce2\u4e0a\u5347\u8207\u4e0b\u964d\uff0c\u5fc3\u97f3\u767c\u73fe\u6e1b\u5c0f\u7684S2\u5fc3\u97f3\uff0c\u4f46\u6c92\u6709S3\uff0c\u5de6\u5074\u7b2c\u4e09\u808b\u9593\u80f8\u9aa8\u7de3\u5247\u51fa\u73fe\u9ad8\u983b\u7387\uff0c\u7b2c2/6\u7d1a\u7684\u8212\u5f35\u671f\u6f38\u6e1b\u6027\u5fc3\u96dc\u97f3\uff0c\u6700\u5927\u5fc3\u5c16\u640f\u52d5\u9ede\u5247\u5411\u5916\u5411\u4e0b\u504f\u79fb\uff0c\u6c92\u6709\u51fa\u73fe\u809d\uff0d\u9838\u975c\u8108\u53cd\u5c04\u6ce2(Hepatojugular\rreflux)\u3002\u4e0b\u5217\u54ea\u4e00\u500b\u60c5\u6cc1\u8f03\u80fd\u89e3\u91cb\u524d\u8ff0\u767c\u73fe\uff1f\nA. \u4e3b\u52d5\u8108\u74e3\u8ff4\u6d41(Aortic valve regurgitation)\nB. \u5fc3\u5305\u586b\u585e(Cardiac tamponade)\nC. \u9650\u5236\u6027\u5fc3\u808c\u75c5\u8b8a(Constrictive pericarditis)\nD. \u4fb7\u9650\u6027\u5fc3\u5305\u819c\u708e(Restrictive cardiomyopathy)\nE. \u56b4\u91cd\u4e09\u5c16\u74e3\u8ff4\u6d41(Severe tricuspid valve regurgitation)\n": "(A)", "103-22.\n22\u6b72\u7684\u7537\u6027\uff0c\u51fa\u751f\u6642\u662f\u500b\u65e9\u7522\u5152\uff0c\u4ed6\u8a18\u5f97\u7236\u6bcd\u8aaa\u4ed6\u5f9e\u5c0f\u5c31\u88ab\u91ab\u5e2b\u8a3a\u65b7\u6709\u5fc3\u96dc\u97f3\u4f46\u6c92\u6709\u958b\u904e\u5200\uff0c\u4f46\u6c42\u5b78\u4e2d\u8207\u540c\u73ed\u5b78\u751f\u5728\u9ad4\u80fd\u904b\u52d5\u4e0a\u7684\u8868\u73fe\u76f8\u8fd1\uff0c\u6c92\u6709\u7279\u5225\u7684\u5730\u65b9\uff0c\u4e0d\u66fe\u56e0\u80f8\u90e8\u7684\u75c7\u72c0\u6216\u4e0d\u8212\u670d\u770b\u904e\u75c5\u3002\u8eab\u9ad4\u6aa2\u67e5\u6642\u8840\u58d3\uff1a116/82mmHg\uff0c\u6700\u5927\u5fc3\u5c16\u640f\u52d5\u9ede\u6c92\u6709\u660e\u986f\u4f4d\u79fb\uff0c\u5728\u5de6\u5074\u80f8\u9aa8\u7de3\u7b2c\u4e8c\u808b\u9593\u8655\u6709\u4e00\u500b\u7b2c3/6\u7d1a\u7684\u9023\u7e8c\u7684\uff0c\u50cf\u6a5f\u68b0\u7684( continuous-machinery )\u7684\u8072\u97f3\u51fa\u73fe\uff0c\u9019\u500b\u8072\u97f3\u8de8\u8d8a\u4e86\u6536\u7e2e\u548c\u8212\u5f35\u671f\uff0c\u9019\u500b\u8072\u97f3\u5728\u5de6\u5074\u9396\u9aa8\u4e0b\u65b9\u4e5f\u53ef\u4ee5\u807d\u898b\u3002\u4ed6\u7684\u624b\u8173\u8108\u640f\u5f37\u5f31\u662f\u6b63\u5e38\u5c0d\u7a31\uff0c\u4e5f\u6c92\u6709\u51fa\u73fe\u8108\u640f\u5ef6\u9072\uff0c\u6c92\u6709\u6775\u72c0\u6307\u6216\u767c\u7d3a\u3002\u80f8\u90e8X\u5149\u548c\u5fc3\u96fb\u5716\u6aa2\u67e5\u5247\u6b63\u5e38\u3002\u4e0b\u5217\u54ea\u4e00\u500b\u72c0\u6cc1\u8f03\u7b26\u5408\u9019\u500b\u767c\u73fe\uff1f\nA. Ventricular septal defect\nB. Aortic coarctation\nC. Atrial septal defect\nD. Aortic valve stenosis\nE. Patent ductus arteriosus\n": "(E)", "104-1.\n\u6709\u95dc\u5fc3\u81df\u807d\u8a3a(Cardiac auscultation)\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684?\nA. \u50e7\u5e3d\u74e3\u9589\u9396\u4e0d\u5168(Mitral regurgitation)\u3001\u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168(Aortic regurgitation)\u53ca\u5fc3\u5ba4\u4e2d\u9694\u7f3a\u640d(Ventricular septal defect) \u7b49\u5fc3\u81df\u96dc\u97f3\u90fd\u53ef\u56e0\u8840\u7ba1\u64f4\u5f35\u5291\u4e4b\u975c\u6db2\u6ce8\u5c04\u5f8c\u800c\u66f4\u52a0\u589e\u5f37\nB. \u8e72\u5750(Squatting)\u53ef\u81f4\u80a5\u539a\u6027\u5fc3\u808c\u75c5\u8b8a\u6240\u81f4\u5fc3\u81df\u96dc\u97f3\u66f4\u8da8\u5f37\nC. \u5f9e\u81e5\u8eba\u800c\u7ad9\u7acb\u5f8c\uff0c\u4e8c\u5c16\u74e3\u812b\u5782(Prolapse of mitral valve)\u6240\u81f4\u5fc3\u7e2e\u671f\u6572\u64ca\u6027\u5fc3\u97f3(Systolic click)\u66f4\u8da8\u8fd1\u7b2c\u4e00\u5fc3\u97f3(S1)\nD. \u4e3b\u52d5\u8108\u74e3\u72f9\u7a84(Aortic stenosis) \u7684\u5fc3\u7e2e\u671f\u96dc\u97f3\u5e38\u5728\u8e72\u5750\u5f8c\u5fc3\u96dc\u97f3\u66f4\u5f37\u5316\nE. \u4e09\u5c16\u74e3\u9589\u9396\u4e0d\u5168\u7684\u5fc3\u96dc\u97f3\u5e38\u5728\u6df1\u5438\u6c23\u6642\u66f4\u52a0\u5f37\u5316\n": "(A)", "104-2.\n\u6709\u95dc\u51a0\u5fc3\u75c5\u7684\u5e7e\u7a2e\u8aaa\u6cd5\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u7576\u4eca\u5be6\u8b49\u91ab\u5b78\u7684\u8aaa\u6cd5 ?\nA. \u7537\u6027\u6bd4\u5973\u6027\u8f03\u591a\u56e0\u5fc3\u8840\u7ba1\u75c5\u800c\u6b7b\u4ea1\nB. \u8fd1\u6578\u5341\u5e74\u5728\u7537\u6027\u56e0\u5fc3\u8840\u7ba1\u800c\u6b7b\u4ea1\u4eba\u6578\u5df2\u5927\u5e45\u5ea6\u964d\u4f4e\uff0c\u4f46\u5973\u6027\u75c5\u4ea1\u4eba\u6578\u537b\u4e0d\u6e1b\u53cd\u5347\nC. \u51a0\u5fc3\u75c5\u4e4b\u767c\u751f\u5e38\u8207\u51a0\u8108\u5fae\u5faa\u74b0(Coronary microcirculation)\u4e4b\u7570\u5e38\u6709\u95dc\uff0c \u5c24\u65bc\u5973\u6027\u75c5\u4eba\u6700\u70ba\u56b4\u91cd\nD. \u5973\u6027\u8f03\u7537\u6027\u597d\u767c\u51a0\u5fc3\u75c5\uff0c\u7814\u7a76\u986f\u793a\u8207\u80a5\u80d6\u3001\u7cd6\u5c3f\u75c5\u3001\u767c\u708e\u53ca\u4ee3\u8b1d\u75c7\u5019\u7fa4\u7b49\u51a0\u5fc3\u75c5\u5371\u96aa\u56e0\u7d20\u4e4b\u591a\u767c\u6709\u95dc\nE. \u5973\u6027\u904b\u52d5\u5fc3\u96fb\u5716\u6709\u8f03\u591a\u7684\u507d\u967d\u6027\u7f3a\u6c27\u8b8a\u5316\uff0c\u4ee5\u81f4\u81e8\u5e8a\u8a3a\u7642\u5e38\u898b\u8aa4\u8a3a\n": "(A)", "104-3.\n77\u6b72\u8001\u592a\u592a\u4e00\u5411\u5065\u6717\uff0c\u672a\u6709\u4efb\u4f55\u4e0d\u9069\u75c7\u72c0\uff0c\u56e0\u4e3b\u52d5\u8108\u5340\u6709\u5fc3\u7e2e\u6027\u5fc3\u96dc\u97f3\u800c\u8f49\u8a3a\u5167\u79d1\u3002\u7406\u5b78\u6aa2\u67e5\uff1aHeight: 160cm/ Weight: 55kg; BP:142/82 mmHg; T/P/R: 36.2 /60 /20, SpO2: 99% under room air; Pulsus paradoxicus (-),PMI: 5th ICS, around left mid-clavicular line, aortic ejection sound (+),Gr. III/VI Mid-systolic murmur over Aortic area and left lower sternal border, no neck radiation; Lungs: No crackles; No hepatosplenomegaly and no ascites; No legs edema. \u5176\u5fc3\u96fb\u5716\u3001\u80f8\u90e8X\u5149\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ca\u5fc3\u5c0e\u7ba1\u5831\u544a\u5982\u5217\u3002\r\u672c\u75c5\u4eba\u96a8\u5373\u6709\u4e0b\u5217\u8af8\u9805\u81e8\u5e8a\u6c7a\u7b56\uff1a\r(1)\u521d\u6b65\u8a3a\u65b7\u662f\u9ad8\u8840\u58d3\u53ca\u9ad8\u8840\u58d3\u6027\u5fc3\u81df\u75c5\r(2)\u521d\u6b65\u8a3a\u65b7\u662f\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u5fc3\u81df\u75c5\r(3)\u5728\u73fe\u968e\u6bb5\u6700\u597d\u7684\u5167\u79d1\u6cbb\u7642\u662f\u9069\u91cf\u7684Beta-blocker,Calcium channel blocker,ACE inhibitors or Angiotensin receptor blocker\uff0c\u4ee5\u964d\u4f4e\u8840\u58d3\r(4)\u7531\u65bc\u672a\u6709\u660e\u986f\u7684\u5fc3\u7d5e\u75db\u3001\u7729\u6688\u6216\u547c\u5438\u56f0\u96e3\uff0c\u5728\u73fe\u968e\u6bb5\u6700\u6070\u7576\u7684\u6cbb\u7642\u662f\u4ee5Statin\u3001Angiotensin receptor blocker\u53ca Beta-blocker\u70ba\u5b9c\r(5)\u5167\u79d1\u53ca\u5916\u79d1\u7684\u6cbb\u7642\uff0c\u5c0d\u5176\u9810\u5f8c\u7121\u6709\u6539\u9032\uff0c\u672c\u75c5\u4eba\u7684\u552f\u4e00\u9078\u64c7\u662f\u4e3b\u52d5\u8108\u74e3\u819c\u7f6e\u63db\u624b\u8853\u6216\u7d93\u5c0e\u7ba1\u4e3b\u52d5\u8108\u74e3\u819c\u7f6e\u653e\u624b\u8853\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u6c7a\u7b56\u662f\u6b63\u78ba\u7684 ?\nA. (1)+(3)+(5)\nB. (1)+(3)+(4)\nC. (2)+(3)+(5)\nD. (1)+(4)+(5)\nE. (2)+(4)+(5)\n": "(C)", "104-4.\n\u5433\u5148\u751f\u73fe\u5e7420\u6b72\uff0c\u4e00\u5411\u5065\u58ef\uff0c\u5f9e\u4e8b\u5efa\u7bc9\u7c97\u5de5\uff0c\u65bc3\u670822\u65e5\u6709\u611f\u5192\u6d41\u9f3b\u6c34\u3001\u767c\u71d2\u53ca\u54b3\u55fd\u75c7\u72c0\uff0c\u4e09\u5929\u5f8c\u66f4\u6709\u5168\u8eab\u5026\u6020\u53ca\u6688\u53a5\uff0c\u4e43\u81f3\u5fc3\u75bc\uff0c\u56e0\u5fc3\u96fb\u5716\u53ca\u80f8X\u5149\u7570\u5e38(\u5982\u5716)\uff0c\u800c\u5f9e\u6025\u8a3a\u4f4f\u9662\u3002\u7406\u5b78\u6aa2\u67e5\uff1aConsciousness: drowsy, E3VTM4;T:37.5 P:93 R:16\u53caBP:82/65 mmHg; \u9838\u975c\u8108\u6012\u5f35; \u80f8\u90e8\u6709\u6fd5\u6fc1\u547c\u5438\u97f3; \u5fc3\u81df\u672a\u6709\u64f4\u5927\uff0c\u5fc3\u97f3\u7565\u70ba\u5fae\u5f31\uff0c\u5c1a\u7121S3\u6216S4\u53ca\u5fc3\u81df\u96dc\u97f3\u53ef\u805e; \u8179\u90e8\u672a\u6709\u8179\u6c34\u6216\u809d\u813e\u816b\u5927; \u96d9\u8173\u672a\u898b\u6c34\u816b\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\uff1aWBC,8.37 K/uL;RBC,4.35 M/uL;Plt,128 K/uL; Hb, 13.0 gm/dL;CK,514 U/L;CK-MB,43 U/L; Troponin I, 2.6 ug/L; CRP, 5.6 mg/dL\u3002\r\u672c\u75c5\u4eba\u96a8\u5373\u9032\u884c\u4e0b\u5217\u81e8\u5e8a\u6c7a\u7b56\uff1a\r(1) Continuous IV infusion of Dopamine at the dose of 7.8 mcg/kg/min\uff0c\u4ee5\u7a69\u5b9a\u8840\u58d3\u53ca\u5fc3\u8df3\u53ca\u8840\u6c27\r(2) \u4f7f\u7528IV Heparin at the dose of 1000 u/hour\uff0c\u4ee5\u9810\u9632\u8840\u6813\u7684\u5f62\u6210\r(3) 3\u670827\u65e5\u56e0\u6301\u7e8c\u6027Ventricular tachycardia\uff0c\u63a1\u7528Electric cardioversion\u4e0d\u76e1\u6709\u6548\uff0c\u800c\u7f6e\u653eV-A ECMO\u53caIABP\r(4) 3\u670828\u65e5\u9032\u884cLeft ventricular assisted device\uff0c\u4ee5\u7dad\u6301\u5de6\u5fc3\u5ba4\u529f\u80fd\r(5) 3\u670829\u65e5Myocardial biopsy\u4e4b\u75c5\u7406\u78ba\u8a3a\u5f8c\uff0c\u4f7f\u7528IVIG\uff0c\u4e5f\u4f7f\u7528Prednisolone\u3001Cyclosporine\u53caAzathioprine\r(6) \u75c5\u60c5\u57283\u670831\u65e5\u5f8c\u65bc\u7109\u7a69\u5b9a\r\u5f9e\u8a3a\u65b7\u53ca\u8655\u7f6e\uff0c\u672c\u75c5\u4f8b\u7684\u8655\u7f6e\u5c1a\u7a31\u6210\u529f\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u624d\u662fEvidence-based management?\nA. \u5f9e\u75c5\u53f2\u3001\u7406\u5b78\u6aa2\u67e5\u53caTroponin I \u6216CRP\u7684\u6578\u503c\u53ef\u78ba\u5b9a\u8a3a\u65b7\nB. \u5f9e\u80f8\u90e8X\u5149\u53ca\u5fc3\u96fb\u5716\u53ef\u78ba\u5b9a\u8a3a\u65b7\nC. \u5f9e\u75c5\u7a0b\u8840\u884c\u529b\u5b78\u4e4b\u4e0d\u7a69\u5b9a\uff0c\u61c9\u9015\u884cMyocardial biopsy\nD. \u4f7f\u7528Immunosuppressive agents:Prednisolone\u53caCyclosporine\u662f\u672c\u4f8b\u6cbb\u7642\u6210\u529f\u7684\u91cd\u8981\u56e0\u7d20\nE. \u4f7f\u7528IVIG(Intravenous immunoglobulin)\u624d\u662f\u6551\u547d\u7684\u8981\u8a23\n": "(C)", "104-5.\n\u75c5\u4eba\u7537\u602759\u6b72\u65bc\u5348\u591c24\u6642\uff0c\u7a81\u56e0\u80f8\u60b6\u4e26\u6709\u7259\u5e8a\u7dca\u75bc\uff0c\u4e43\u76f4\u5f80\u6025\u8a3a\u90e8\u6c42\u8a3a\uff0c\u6642\u75c5\u4eba\u4e4bT/P/R = 35.1/51/18, BP 137/74 mmHg; \u7406\u5b78\u6aa2\u67e5\uff0c\u672a\u898b\u4efb\u4f55\u7570\u5e38\u3002\u75c5\u53f2\u8ffd\u5c0b\uff0c\u672c\u75c5\u4eba\u66fe\u7d93\u91ab\u5e2b\u78ba\u5b9a\u9ad8\u8840\u58d3\u3001\u9ad8\u8102\u8840\u3001\u7cd6\u5c3f\u75c5\u53ca\u651d\u8b77\u817a\u80a5\u5927\uff0c\u552f\u50c5\u53ea\u670d\u7528Bisoprolol 2.5 mg/day\u3002\u7d93\u7dca\u6025\u6aa2\u67e5\uff1a\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u986f\u793a\u5982\u5716\uff1a\u751f\u5316\u6aa2\u67e5: CK,96 U/L;CK-MB,20 U/L;TnI <0.0012 ng/ml;Sugar 252 mg/dL; Na,137 mmol/L; K, 3.7 mmol/L; TG,182 mg/dL and Total cholesterol, 222 mg/dL ; \u8840\u6db2\u6aa2\u67e5: Hb,13.9 g/dl; Platelet, 203 K/uL; WBC,9.45 K/uL; Cre,1.3 mg/dL\r\u8acb\u554f\u672c\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u6025\u8a3a\u8a3a\u65b7\u662f\uff1a\nA. Printzmetal's angina\nB. Aortic dissection\nC. Acute anterior myocardial infarction\nD. Hypertension\nE. Acute periodontitis disease\n": "(C)", "104-6.\n\u4f9d\u64da\u4eca\u5e741\u6708\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u53ca\u9ad8\u8840\u58d3\u5b78\u6703\u6240\u516c\u544a\u4e4b\u9ad8\u8840\u58d3\u8655\u7f6e\u6307\u5f15 (2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension)\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684?\nA. \u53f0\u7063\u7684\u9ad8\u8840\u58d3\u8655\u7f6e\u6307\u5f15\u8207\u6700\u8fd1\u6b50\u6d32\u53ca\u7f8e\u570b\u7684\u6307\u5f15\u4e0d\u76e1\u76f8\u540c\nB. 80\u6b72\u4ee5\u4e0a\u7684\u8001\u5e74\u4eba\u964d\u58d3\u4ee5\u4f4e\u65bc150/90 mmHg\u70ba\u6cbb\u7642\u76ee\u6a19\nC. \u7cd6\u5c3f\u75c5\u3001\u51a0\u5fc3\u75c5\u3001\u6162\u6027\u814e\u75c5\u8b8a\u4f75\u6709\u86cb\u767d\u5c3f\u75c5\u4eba\u4e4b\u9ad8\u8840\u58d3\uff0c\u4ee5\u4f4e\u65bc140/80 mmHg\u70ba\u6cbb\u7642\u76ee\u6a19\nD. \u670d\u7528\u6297\u8840\u6813\u85e5\u7269\u9632\u6cbb\u8166\u4e2d\u98a8\u767c\u4f5c\u4e4b\u964d\u58d3\u76ee\u6a19\uff0c\u4ee5\u4e0d\u9ad8\u65bc130/80 mmHg\nE. \u6240\u6709\u75c5\u4eba(40-80\u6b72)\u4e4b\u9ad8\u8840\u58d3\u6cbb\u7642\u76ee\u6a19\u5728140/90 mmHg\u4ee5\u4e0b\n": "(C)", "104-7.\n\u4e00\u5411\u4e3b\u5c0e\u5168\u4e16\u754c\u9ad8\u8102\u8840\u8655\u7f6e\u4e4bNCEP ATP III\uff0c\u65bc2013\u5e7411\u6708\u516c\u5e03\u65b0\u7684\u6307\u5f15\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u65b0\u7684\u898f\u5b9a?\nA. \u6709\u51a0\u5fc3\u75c5\u3001\u8166\u8840\u7ba1\u6216\u9031\u908a\u8840\u7ba1\u75c5\u4e4b\u75c5\u4eba\u61c9\u670d\u7528Statin\u6cbb\u7642\nB. 40-75\u6b72\u7684\u4eba\u53ea\u8981LDL-C\u9ad8\u65bc190 mg/dL\u61c9\u670d\u7528Statin\u6cbb\u7642\nC. 40-75\u6b72\u7cd6\u5c3f\u75c5\u4eba\u61c9\u670d\u7528Statin\u6cbb\u7642\nD. \u6240\u6709\u75c5\u4eba\u4e4b\u8840\u8102\u6fc3\u5ea6\uff1aLDLC\u4ee5\u4f4e\u65bc100 mg/dL\uff0c\u800cCholesterol 180 mg/dL\u70ba\u6cbb\u7642\u76ee\u6a19\nE. \u53ea\u9650\u5b9aStatin\u4e00\u85e5\uff0c\u6392\u9664Fibric acid \u53caCholestyramine \u70ba\u964d\u8102\u8840\u85e5\u7269\n": "(D)", "104-8.\n\u81e8\u5e8a\u8655\u7f6e\u6307\u5f15\u5e38\u4f9d\u64da\u5be6\u8b49\u4fee\u8a02\uff0c\u6709\u95dc\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e(Infective endocarditis) \u6709\u4e0b\u5217\u8af8\u591a\u7684\u8a18\u8ff0\uff1a\r(1)\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u61c9\u572824\u5c0f\u6642\u5167\u63a1\u8840\u4e09\u6b21\uff0c\u5728\u4e0d\u540c\u8840\u7ba1\u8655\u63a1\u8840\uff0c\u4e14\u61c9\u76f8\u9694\u81f3\u5c11\u4e00\u5c0f\u6642\u5be6\u65bd\r(2)\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u662f\u5fc5\u8981\u7684\u8a3a\u65b7\u5de5\u5177\uff0c\u7d93\u98df\u9053\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u9069\u7528\u65bc\u5fc3\u808c\u81bf\u816b\u3001\u74e3\u819c\u7834\u6d1e\u3001\u5fc3\u5167\u5ed4\u7ba1\u53ca\u4eba\u5de5\u74e3\u819c\u5fc3\u5167\u8108\u708e\u7684\u8a3a\u65b7\r(3)\u4e8c\u5c16\u74e3\u812b\u5782\u75c5\u4eba\u63a5\u53d7\u7259\u79d1\u6cbb\u7642\u61c9\u4f5c\u9810\u9632\u6027\u6297\u751f\u7d20\u4f7f\u7528\r(4)\u6709\u767c\u7d3a\u5148\u5929\u6027\u5fc3\u81df\u75c5\u4eba\u3001\u4eba\u5de5\u74e3\u819c\u7f6e\u63db\u624b\u8853\u5f8c\u75c5\u4eba\u3001\u66fe\u6709\u5fc3\u5167\u819c\u708e\u75c5\u53f2\u53ca\u63db\u5fc3\u4eba\u6709\u4e3b\u52d5\u8108\u74e3\u75c5\u8b8a\u8005\u61c9\u9810\u9632\u6027\u6297\u751f\u7d20\u4f7f\u7528\r(5)\u75c5\u4eba\u88dd\u7f6eICD(Intra-cardiac device) \u63a5\u53d7\u5927\u8178\u93e1\u6aa2\u67e5\u61c9\u9810\u9632\u6027\u6297\u751f\u7d20\u4f7f\u7528\r\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u662f\u6b63\u78ba\u7684\u8655\u7f6e\u6307\u5f15?\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (2)+(3)+(5)\n": "(B)", "104-9.\n\u7537\u6027\u75c5\u4eba\u73fe\u5e7460\u6b72\uff0c\u65bc\u6e05\u66686\u6642\u7a81\u7136\u80f8\u60b6\u3001\u51b7\u6c57\uff0c\u81ea\u89ba\u4f34\u6709\u5f8c\u80cc\u53ca\u8179\u90e8\u9178\u75bc\uff0c\u75c5\u4eba\u7531\u5bb6\u5c6c\u6025\u9001\u91ab\u9662\u3002\u75c5\u4eba\u6709\u591a\u5e74\u9ad8\u8840\u58d3\u53ca\u75db\u98a8\u75c5\uff0c\u670d\u7528Losartan(50mg) 1tabQD; Amlodipine(5mg) 1tabQD;Colchicine(0.5mg)1 tabQD;Benzbromarone(100mg) 1tabQD;Atorvastatin 0.5 Tab /HS\u7b49\u85e5\u4e2d\u3002\u8eab\u9ad4\u6aa2\u67e5\uff0c\u5448\u73fe\u6025\u75c5\u72c0\uff0c\u81c9\u8272\u84bc\u767d\uff0c\u9ad4\u6eab: 36.2\u2103\uff0c\u8108\u8df3: 66/min\uff0c\u547c\u5438: 23/min\uff1bBP: 252/114mmHg\uff1b\u610f\u8b58\u6e05\u695a\uff1b\u80f8\u90e8\u53ca\u8179\u90e8\u5c1a\u7121\u7570\u5e38\uff0c\u5fc3\u5f8b\u6b63\u5e38\uff0cS1\u53caS2\u6b63\u5e38\uff0c\u672a\u6709S3\u6216S4\uff0c\u7121\u5fc3\u81df\u96dc\u97f3\u53ef\u805e\uff0c\u4e5f\u7121paradoxical split of S2\uff0c\u795e\u7d93\u6aa2\u67e5\u6b63\u5e38\u3002\u5176\u6642\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5982\u5716\u8868\u3002\u4e0b\u5217\u4f55\u8005\u662f\u6b63\u78ba\u7684\u8a3a\u65b7?\nA. Acute myocardial infarction\nB. Aortic dissection\nC. Hypertensive crisis\nD. Pulmonary embolism\nE. Aortic stenosis\n": "(B)", "104-10.\n\u5973\u6027\u75c5\u4eba\u73fe\u5e7447\u6b72\uff0cG2P2\uff0c\u4e3b\u8a34\u8fd1\u4f86\u4e00\u500b\u6708\u9593\u6642\u6709\u982d\u660f\uff0c\u4e26\u6709\u6f38\u9032\u5f0f\u547c\u5438\u56f0\u96e3\u3002\u4f4f\u9662\u524d\u56db\u5929\u75c7\u72c0\u66f4\u5f62\u60e1\u5316\uff0c\u662f\u4e43\u7d93\u6025\u8a3a\u4f4f\u52a0\u8b77\u75c5\u623f\u3002\u7406\u5b78\u6240\u898b: \u8eab\u9ad8163cm; \u9ad4\u91cd 67.4kg; BMI = 25.37; \u9ad4\u6eab:36.5\u2103 ;BP(mmHg): 128/60; PR(/min): 104; RR(/min): 24; \u81c9\u8840\u84bc\u767d; \u5fc3\u8df3\u5feb\u901f\u4f46\u6b63\u5e38\u5f8b\u52d5, \u5728\u4e09\u5c16\u74e3\u5340\u6709Grade 3/6 systolic murmur\u53ef\u805e \uff0c\u5176\u4ed6\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u548cComputer tomography\u5982\u5716\u3002\rD-Dimer, 3.56 mg/L;Blood gas:pH,7.534;PaO2,57 mmHg;PaCO2,20.9 mmHg;HCO2 std 22.0 mmol/L;\u75c5\u4eba\u4f4f\u9662\u5f8c\u96a8\u5373\u975c\u6ce8\u5927\u65b9\u5291\u91cf(Bolus dose) Unfractionated Heparin 3000u \u53ca\u6bcf\u5c0f\u66421000u\u975c\u8108\u8f38\u6ce8\u3002\u75c5\u7a0b\u4e2d\u5148\u5f8c\u9032\u884c\u4e0b\u5217\u8655\u7f6e\uff1a\r(1)\u901a\u77e5\u5fc3\u81df\u79d1\u555f\u52d5PCI\u5718\u968a\r(2) \u67e5Protein C \uff0cProtein S\u548canti-thrombin III, \u548cAnticardiolipin IgG\r(3)Tumor biomarkers :CEA, CA-199,CA-125,CA-153\r(4)Heparin bolus 3000 unitIV stat and then IV pump 6~12 U/kg/hr according to the aPTT\r(5)Digoxin o.25 mg + 20% glucose in water for IV to control tachycardia\r\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u8655\u7f6e\u624d\u662f\u6b63\u78ba\u7684?\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (2)+(4)+(5)\n": "(D)", "104-11.\n\u75c5\u4eba\u662f\u4f4d47\u6b72\u5bb6\u5ead\u4e3b\u5a66\uff0c\u81ea7\u6b72\u8d77\u5c31\u8a3a\u65b7\u6709\u5fc3\u81df\u75c5\uff0c18\u6b72\u61f7\u5b55\u751f\u6709\u4e00\u5b50\uff0c\u904e\u7a0b\u5c1a\u7a31\u9806\u5229\uff0c\u8fd1\u5341\u5e74\u4f86\u5076\u6709\u5fc3\u60b8\u53ca\u80f8\u60b6\uff0c\u8fd1\u4e8c\u5e74\u66fe\u6709\u4e94\u6b21\u660f\u53a5\uff0c\u56e0\u6b64\u4f4f\u9662\u3002\u7406\u5b78\u6aa2\u67e5\u53ca\u751f\u5316\u6aa2\u9a57\u90fd\u6b63\u5e38\u3002\u80f8X\u5149\u53ca\u5fc3\u96fb\u5716(\u5982\u5716)\u3002\u672c\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Supraventricular tachycardia\nB. WPW syndrome with AVRT\nC. Long QT syndrome with Torsade de pointes\nD. Monomorphic ventricular tachycardia from outflow tract\nE. Polymorphic ventricular tachycardia with Torsade de pointes\n": "(D)", "104-12.\n38\u6b72\u5973\u6027\u56e0\u70ba\u5f88\u5bb9\u6613\u51fa\u73fe\u904b\u52d5\u5598\u800c\u4f86\u6aa2\u67e5\uff0c\u4e0b\u5217\u54ea\u4e00\u500b\u8eab\u9ad4\u6aa2\u67e5\u7684\u767c\u73fe\u6700\u5bb9\u6613\u61f7\u7591\u662f\u5426\u6709\u80ba\u52d5\u8108\u9ad8\u58d3\uff1f\nA. \u9838\u975c\u8108\u9f13\u8139\uff0c\u5fc3\u97f3S1\uff0cS2\u6b63\u5e38\u3002\u5728\u53f3\u4e0a\u80f8\u9aa8\u7de3\u6709 II/VI\u7b49\u7d1a\u7684\u8212\u5f35\u671f\u5fc3\u96dc\u97f3\u3002\nB. \u9838\u975c\u8108\u9f13\u8139\uff0c\u5927\u8072\u7684S2\u5fc3\u97f3\u3002\u5728\u5de6\u4e0b\u80f8\u9aa8\u7de3\u6709 II/VI\u7b49\u7d1a\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\u3002\nC. \u9838\u975c\u8108\u9f13\u8139\uff0c \u5927\u8072\u4e14\u56fa\u5b9a\u800c\u5206\u88c2\u7684S2\u5fc3\u97f3\u3002\u5728\u5de6\u4e0b\u80f8\u9aa8\u7de3\u6709 III/VI\u7b49\u7d1a\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\u3002\nD. \u9838\u975c\u8108\u9f13\u8139\uff0c\u5410\u6c23\u6642S2\u5fc3\u97f3\u5206\u88c2\u3002\u5728\u5de6\u4e0a\u80f8\u9aa8\u7de3\u6709 \u5927\u8072\u800c\u5c16\u92b3\u7684II/VI\u7b49\u7d1a\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\u3002\nE. \u9838\u975c\u8108\u9f13\u8139\uff0c\u6876\u578b\u80f8\u8154\u8b8a\u5f62\u3002\u547c\u5438\u9031\u671f\u7684\u5410\u6c23\u671f\u7279\u5225\u9577\u3002\n": "(B)", "104-13.\n60\u6b72\u5973\u6027\u56e0\u70ba\u9010\u6f38\u51fa\u73fe\u7684\u5598\u6c23\u9020\u6210\u7121\u6cd5\u884c\u8d70\u6b63\u5e38\u8ddd\u96e2\u800c\u5230\u6025\u8a3a\uff0c\u4ed6\u6c92\u6709\u80f8\u75db\u3001\u652f\u6c23\u7ba1\u54ee\u5598\u3001\u75f0\u6216\u662f\u767c\u71d2\u3002\u80f8\u90e8X\u5149\u6aa2\u67e5\u767c\u73fe\u96d9\u5074\u80ba\u52d5\u8108\u64f4\u5f35\uff0c\u5de6\u5fc3\u623f\u64f4\u5927\uff0c\u96d9\u5074\u80ba\u90e8\u6c92\u6709\u6d78\u6f64\u73fe\u8c61\u3002\u5fc3\u96fb\u5716\u51fa\u73feV1\u5c0e\u6975\u6709\u9ad8\u7684R\u6ce2\uff0c\u5fc3\u8ef8\u53f3\u504f\u3002\u6b64\u6642\u5e6b\u60a3\u8005\u9032\u884c\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u6700\u53ef\u80fd\u6703\u51fa\u73fe\u4e0b\u9762\u54ea\u4e00\u7a2e\u8b8a\u5316\uff1f\nA. \u4e3b\u52d5\u8108\u74e3\u8ff4\u6d41\nB. \u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\nC. \u5de6\u5fc3\u5ba4\u6536\u7e2e\u529f\u80fd\u4f4e\u4e0b\nD. \u4e8c\u5c16\u8108\uff08\u50e7\u5e3d\u74e3\uff09\u74e3\u72f9\u7a84\nE. \u4e8c\u5c16\u8108\uff08\u50e7\u5e3d\u74e3\uff09\u74e3\u8ff4\u6d41\n": "(D)", "104-14.\n\u9ad8\u8840\u9240\u7684\u5fc3\u96fb\u5716\u8b8a\u5316\uff0c\u8acb\u5728\u4e0b\u5217\u9805\u76ee\u4e2d\u9078\u64c7\u6700\u9069\u5408\u7684\u767c\u73fe\uff1a(1) P\u6ce2\u8b8a\u5e73\u800c\u53ef\u80fd\u6d88\u5931 ; (2) ST segment\u5ef6\u9577 ; (3) U\u6ce2\u660e\u986f\u8b8a\u5927 ; (4) QRS\u6ce2\u8b8a\u5bec ; (5) T\u6ce2\u8b8a\u9ad8 ; (6) PR interval\u7e2e\u77ed\nA. (3)+(5)+(6)\nB. (1)+(2)+(3)\nC. (3)+(4)+(6)\nD. (1)+(4)+(5)\nE. (2)+(4)+(5)\n": "(D)", "104-15.\n\u6240\u8b02\u300c\u5b8c\u6574\u7684\u5fc3\u81df\u75c5\u8a3a\u65b7\u300d(Complete cardiac diagnosis)\r\u61c9\u4f9d\u5e8f\u5305\u62ec\u54ea\u4e9b\u9805\u76ee\u7d44\u5408?\nA. \u75c5\u56e0\u3001\u75c5\u7406\u3001\u751f\u5316\u53ca\u529f\u80fd\u7570\u5e38(Functional disability)\u7684\u8a3a\u65b7\nB. \u54b3\u8840\u751f\u7406\u3001\u89e3\u5256\u3001\u75c5\u7406\u53ca\u529f\u80fd\u7570\u5e38\u7684\u8a3a\u65b7\nC. \u75c5\u7406\u3001\u751f\u7406\u3001\u529f\u80fd\u53ca\u751f\u5316\u7570\u5e38\u7684\u8a3a\u65b7\nD. \u75c5\u56e0\u3001\u89e3\u5256\u3001\u751f\u7406\u53ca\u529f\u80fd\u7570\u5e38\u7684\u8a3a\u65b7\nE. \u75c5\u56e0\u3001\u75c5\u7406\u3001\u751f\u7406\u53ca\u529f\u80fd\u7570\u5e38\u7684\u8a3a\u65b7\n": "(D)", "104-16.\n\u7576\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u51fa\u73fe\uff0c\u4e0b\u5217\u54ea\u4e00\u4e9b\u56e0\u5b50\u6703\u52a0\u91cd\u60a3\u8005\u7684\u8166\u8840\u7ba1\u8840\u6813\u4e8b\u4ef6\u7684\u53ef\u80fd\u6027\uff1f(1) \u7cd6\u5c3f\u75c5 ; (2) \u5de6\u5fc3\u623f4.2\u516c\u5206 ; (3) \u66fe\u7d93\u6709\u66ab\u6642\u7f3a\u8840\u6027\u8166\u4e2d\u98a8\u767c\u4f5c ; (4) \u9ad8\u8840\u8102 ; (5) \u9b31\u8840\u6027\u5fc3\u8870\u7aed ; (6) \u5e74\u9f6162\u6b72\nA. (1)+(3)+(5)\nB. (2)+(4)+(6)\nC. (1)+(2)+(3)\nD. (4)+(5)+(6)\nE. (2)+(3)+(4)\n": "(A)", "104-17.\n\u9580\u8a3a\u6642\u6709\u4f4d\u64d4\u5fc3\u7684\u6bcd\u89aa\u4f86\u5411\u4f60\u8a62\u554f\u6709\u95dc\u4ed6\u5152\u5b50\u7684\u554f\u984c\uff0c\u5152\u5b50\u5728\u570b\u4e00\u7684\u65b0\u751f\u5165\u5b78\u6aa2\u67e5\u4e2d\u767c\u73fe\u6709\u5fc3\u623f\u4e2d\u9694\u7f3a\u640d\u3002\u95dc\u65bc\u5982\u679c\u6c92\u6709\u4fee\u5fa9\u5fc3\u623f\u4e2d\u9694\u7f3a\u640d\uff0c\u5728\u6210\u5e74\u6216\u591a\u5e74\u4e4b\u5f8c\uff0c\u6700\u4e0d\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u54ea\u4e00\u7a2e\u60c5\u6cc1\uff1f\nA. \u56e0\u70ba\u91ab\u7642\u76ee\u7684\u800c\u9032\u884c\u4e2d\u5fc3\u975c\u8108\u7ba1\u7f6e\u5165\u8853\uff08CVC\uff09\u800c\u7522\u751f\u6c23\u6813\uff08Air emboli\uff09\nB. \u4e0d\u7a69\u5b9a\u6027\u72f9\u5fc3\u75c7\nC. \u6813\u585e\u6027\u8166\u8840\u7ba1\u4e8b\u4ef6\nD. \u80ba\u9ad8\u58d3\nE. \u904b\u52d5\u4e2d\u6c27\u52d5\u8108\u5206\u58d3\u96a8\u4e4b\u4e0b\u964d\n": "(B)", "104-18.\n42\u6b72\u5973\u6027\u5728\u6210\u4eba\u5065\u6aa2\u4e2d\u767c\u73fe\u6709\u6536\u7e2e\u4e2d\u671f\u7570\u5e38\u5fc3\u97f3- Mid-systolic click\uff0c\u6c92\u6709\u767c\u73fe\u5fc3\u96dc\u97f3\u3002\u9664\u6b64\u4e4b\u5916\u7684\u8eab\u9ad4\u6aa2\u67e5\u6b63\u5e38\uff0c\u8840\u6db2\u6aa2\u67e5\u9805\u76ee\u6578\u503c\u6b63\u5e38\uff0c\u5e73\u65e5\u4e5f\u6c92\u6709\u4e0d\u8212\u670d\u3002\u5979\u9084\u662f\u64d4\u5fc3\u76f8\u95dc\u7684\u767c\u73fe\uff0c\u4f9d\u7167\u4e0a\u8ff0\u60c5\u6cc1\uff0c\u4e0b\u5217\u54ea\u4e00\u76f8\u6558\u8ff0\u8f03\u9069\u7576\uff1f\nA. \u8aaa\u660e\u5927\u591a\u6578\u7684\u9019\u985e\u60a3\u8005\u5b58\u6709\u7d50\u7de0\u7d44\u7e54\u75be\u75c5\uff0c\u9032\u884c\u6aa2\u67e5\nB. \u89e3\u91cb\u4e26\u544a\u77e5\u75c5\u4eba\u91dd\u5c0d\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e\u9032\u884c\u76f8\u95dc\u9632\u7bc4\u63aa\u65bd\nC. \u5927\u90e8\u5206\u6b64\u7a2e\u767c\u73fe\u6703\u4e00\u76f4\u5b58\u5728\uff0c\u4f46\u4e0d\u9700\u6cbb\u7642\nD. \u5efa\u8b70\u5979\u4f7f\u7528Aspirin 100mg/day \u4f86\u9810\u9632\u8840\u6813\u4e8b\u4ef6\nE. \u9019\u985e\u554f\u984c\u7121\u6cd5\u5f9e\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u4e0d\u8981\u8981\u6c42\u505a\u8d85\u97f3\u6ce2\u6aa2\u67e5\n": "(C)", "104-19.\n\u4e0b\u5217\u54ea\u4e00\u4e9b\u8eab\u9ad4\u6aa2\u67e5\u7684\u767c\u73fe\u6703\u61f7\u7591\u56b4\u91cd\u7684\u4e3b\u52d5\u8108\u74e3\u8ff4\u6d41\uff1f (1) Corrigan's pulse ; (2) Pulsus bigeminus ; (3) Quincke's pulse ; (4) Traube's sign ; (5) Pulsus parvus et tardus ; (6) Pulsus paradoxus\nA. (2)+(4)+(6)\nB. (1)+(2)+(3)\nC. (1)+(3)+(4)\nD. (3)+(5)+(6)\nE. (4)+(5)+(6)\n": "(C)", "104-20.\n78\u6b72\u7537\u6027\uff0c\u6709\u9577\u671f\u5438\u83f8\uff0c\u80a5\u80d6\u548c\u5341\u5e74\u5de6\u53f3\u7684\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u3002\u4ed6\u56e0\u70ba\u6700\u8fd1\u5169\u500b\u6708\u51fa\u73fe\u7684\u904b\u52d5\u5598\u524d\u4f86\u9580\u8a3a\u3002\u76ee\u524d\u4ed6\u4f7f\u7528\u7684\u85e5\u54c1\u5305\u542b aspirin, metformin \u548c\u5076\u723e\u6703\u56e0\u70ba\u95dc\u7bc0\u75bc\u75db\u670d\u7528 ibuprofen\u3002\u4ed6\u7684\u8eab\u9ad4\u6aa2\u767c\u73fe\u5ef6\u9072\u51fa\u73fe-- \u8108\u640f\u5c16\u5cf0\uff08delayed peak in peripheral pulse\uff09\uff0cleft ventricular heave\u3002\u4ed6\u7684\u5fc3\u8df3\u898f\u5247\uff0c\u5728\u5fc3\u81df\u57fa\u5e95\u90e8\u4f4d(cardiac base)\u6709 VI/VI \u7d1a\u7684\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\uff0c\u6b64\u96dc\u97f3\u6703\u50b3\u5411\u9838\u52d5\u8108\u5340\u57df\u3002\u540c\u6642\u51fa\u73fe\u7b2c\u56db\u5fc3\u97f3\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ea\u6709\u56b4\u91cd\u7684\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u3002\u8acb\u554f\u4f9d\u64da\u75c5\u53f2\u8207\u76f8\u95dc\u767c\u73fe\uff0c\u9020\u6210\u9019\u500b\u75c5\u4eba\u5fc3\u81df\u8b8a\u5316\u7684\u6700\u53ef\u80fd\u539f\u56e0\u662f\uff1f\nA. \u5148\u5929\u6027\u4e8c\u74e3\u7684\u4e3b\u52d5\u8108\u74e3\u819c\uff08bicuspid aortic valve\uff09\nB. \u7cd6\u5c3f\u75c5\nC. \u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\nD. \u75c5\u4eba\u6709\u6f5b\u85cf\u7684\u7d50\u7de0\u7d44\u7e54\u75be\u75c5\nE. \u4ee5\u4e0a\u7686\u975e\n": "(B)", "104-21.\n\u7576\u60a3\u8005\u7684\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u6709\u56b4\u91cd\u7684\u4e8c\u5c16\u74e3\u8ff4\u6d41\uff0c\u8003\u91cf\u624b\u8853\u9069\u61c9\u75c7\uff0c\u4f75\u767c\u75c7\u8207\u624b\u8853\u9810\u5f8c\uff0c\u4e0b\u9762\u54ea\u4e00\u500b\u6558\u8ff0\u7684\u60a3\u8005\u6703\u6709\u6700\u4f73\u7684\u8853\u5f8c\u9032\u6b65\u548c\u624b\u8853\u6cbb\u7642\u6548\u679c\uff1f\nA. 52\u6b72\u7537\u6027\uff0cLVEF=25%\uff0c\u5fc3\u8870\u7aed\u75c7\u72c0NYHA class III\uff0c\u5de6\u5fc3\u5ba4\u6536\u7e2e\u672b\u671f\u5167\u5f9160mm\u3002\nB. 54\u6b72\u7537\u6027\uff0cLVEF=30%\uff0c\u5fc3\u8870\u7aed\u75c7\u72c0NYHA class II\uff0c\u6709\u80ba\u9ad8\u58d3\u3002\nC. 63\u6b72\u7537\u6027\uff0c\u7ac7\u6027\u898f\u5247\u5fc3\u5f8b\uff0cLVEF=65%\uff0c\u6c92\u6709\u81e8\u5e8a\u75c7\u72c0\uff0c\u53f3\u5fc3\u5ba4\u5c0e\u7ba1\u6aa2\u67e5\u58d3\u529b\u6b63\u5e38\u3002\nD. 72\u6b72\u5973\u6027\uff0c\u6c92\u6709\u81e8\u5e8a\u75c7\u72c0\uff0c\u65b0\u767c\u73fe\u9663\u767c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\uff0cLVEF=60%\uff0c \u5de6\u5fc3\u5ba4\u6536\u7e2e\u672b\u671f\u5167\u5f9135mm\u3002\nE. 66\u6b72\u5973\u6027\uff0cLVEF=50%\uff0c\u6c92\u6709\u81e8\u5e8a\u75c7\u72c0\uff0c\u5de6\u5fc3\u5ba4\u6536\u7e2e\u672b\u671f\u5167\u5f9145mm\u3002\n": "(E)", "104-22.\n30\u6b72\uff0cBMI=23\uff0c\u5728\u5efa\u7bc9\u5de5\u5730\u5de5\u4f5c\u7684\u7537\u6027\u9ad8\u8840\u58d3\u60a3\u8005\uff0c\u56e0\u70ba\u5df2\u7d93\u670d\u7528\u56db\u7a2e\u85e5\u7269\u4e4b\u5f8c\u4ecd\u51fa\u73fe180/110mmHg\u7684\u8840\u58d3\u524d\u4f86\u9580\u8a3a\u3002\u4f9d\u60a3\u8005\u6240\u8aaa\uff0c\u4ed6\u5f9e17\u6b72\u5c31\u767c\u73fe\u6709\u9ad8\u8840\u58d3\uff0c\u96d6\u7136\u91ab\u5e2b\u5728\u904e\u53bb\u7d66\u4ed6\u56db\u7a2e\u63a7\u5236\u8840\u58d3\u7684\u85e5\u7269\uff0c\u4ed6\u4e26\u6c92\u6709\u89ba\u5f97\u7279\u5225\u4e0d\u8212\u670d\u3002\u5e73\u65e5\u4e0d\u5e38\u91cf\u8840\u58d3\uff0c\u53ea\u5728\u5076\u723e\u767c\u73fe\u8840\u58d3\u5f88\u9ad8\u6642\u5f9e\u85e5\u623f\u52a0\u8cb7\u85e5\u7269\u670d\u7528\u3002\u9580\u8a3a\u6642\u8eab\u9ad4\u6aa2\u67e5\u6c92\u6709\u7570\u5e38\uff0c\u62bd\u8840\u7684\u6578\u64da\u5982\u4e0b\uff1a Na: 145mEq/L; Cl: 110mEq/L; K: 3.0mEq/L; HCO3: 30 mEq/L; Glucose: 90mg/dL\u3002\u8acb\u554f\u63a5\u4e0b\u4f86\u5982\u4f55\u8655\u7f6e\u8f03\u6d3d\u7576\uff1f\nA. \u52a0\u7b2c\u4e94\u7a2e\u85e5\u7269\uff0c\u8acb\u60a3\u8005\u5bc6\u5207\u8ffd\u8e64\u8840\u58d3\nB. \u6e2c\u91cf\u5c3f\u6db2\u4e2d\u7684 VMA; metanephrines; catecholamines\nC. \u5b89\u6392\u96d9\u5074\u814e\u52d5\u8108\u7684\u90fd\u535c\u52d2\u8d85\u97f3\u6ce2\u6aa2\u67e5\nD. \u6aa2\u67e5 plasma renin activity (PRA) \u8207 plasma aldosterone concentration (PAC)\nE. \u5b89\u6392\u7761\u7720\u91ab\u5b78\u6aa2\u67e5\n": "(D)", "105-1.\n\u5728\u5fc3\u96fb\u5716\u5448\u73fe\uff1a\u5fc3\u8ef8\u5de6\u504f-45\u5ea6\uff0cqR \u5728I\u53caaVL\u7b49\u8b8a\u5316\u662f\u6240\u8b02\"\u5de6\u524d\u675f\u679d\u50b3\u5c0e\u963b\u6eef\" (Left anterior fascicular block)\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u8aaa\u6cd5\u4e0d\u6b63\u78ba\uff1f\nA. \u5de6\u524d\u675f\u679d\u7d30\u9577\uff0c\u7a7f\u884c\u5de6\u5fc3\u5ba4\u51fa\u53e3\u901a\u9053\u5730\u5e36\uff0c\u6613\u53d7\u5fc3\u7e2e\u58d3\u529b\u50b7\u5bb3\uff0c\u662f\u4ee5\u81e8\u5e8a\u591a\u898b\u3002\nB. \u5de6\u524d\u964d\u652f\u51a0\u8108(Left anterior descending artery)\u4f9b\u8840\u5de6\u524d\u675f\u679d\uff0c\u4e0d\u82e5\u5de6\u5f8c\u675f\u679d\u4f9b\u8840\u4f86\u81ea\u5de6\u53f3\u96d9\u689d\u51a0\u8108\uff0c\u662f\u4ee5\u6613\u56e0\u5fc3\u808c\u7f3a\u8840\u50b7\u8b8a\uff0c\u767c\u751f\u50b3\u5c0e\u963b\u6eef\u3002\nC. \u6025\u6027\u524d\u58c1\u5fc3\u808c\u6897\u585e\u5982\u82e5\u4f34\u767c\u53f3\u675f\u679d\u50b3\u5c0e\u963b\u6eef(RBBB)\u53ca\u5de6\u524d\u675f\u679d\u50b3\u5c0e\u963b\u6eef\uff0c\u6613\u81f4\u5b8c\u5168\u50b3\u5c0e\u963b\u6eef(Complete heart block)\u3002\nD. \u6240\u8b02\"\u96d9\u675f\u679d\u50b3\u5c0e\u963b\u6eef\"\u6cdb\u6307RBBB + Left anterior fascicular block\u3001RBBB+ Left posterior fascicular block\u6216LBBB\u3002\nE. \u5de6\u524d\u675f\u679d\u50b3\u5c0e\u963b\u6eef\u82e5\u4f34\u767c\u7b2c\u4e00\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u6eef(First degree A-V block)\uff0c \u4e5f\u6613\u81f4\u5b8c\u5168\u50b3\u5c0e\u963b\u6eef(Complete heart block)\u3002\n": "(E)", "105-2.\n\u75c5\u4eba\u73fe\u5e7463\u6b72\u5bb6\u5ead\u4e3b\u5a66\uff0c\u56e0\u6709\u80f8\u60b6\u53ca\u6c23\u4fc3\u6c42\u91ab\uff0c\u516d\u5e74\u524d\u66fe\u6709\u9152\u7cbe\u6027\u809d\u786c\u5316\uff0c\u809d\u81df\u79fb\u690d\u3002\u4e94\u5e74\u524d\u56e0\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e\u4ee5\u81f4\u65bd\u884c\u50e7\u5e3d\u74e3\u7f6e\u63db(Hancock 27)\uff0c\u6301\u7e8c\u9580\u8a3a\u8ffd\u8e64\u4e2d\u3002\u8840\u58d3148/109 mmHg\uff1b\u5fc3\u8df3152/min\uff1b\u547c\u5438\u6bcf\u520627\u6b21\uff1b\u9ad4\u6eab37.5\u5ea6\u3002\u5176\u4ed6\u8eab\u9ad4\u6aa2\u67e5\u4e26\u7121\u91cd\u5927\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716(A.\u6cbb\u7642\u524d\uff1bB.\u6cbb\u7642\u5f8c)\u5982\u5217\u3002\u6aa2\u67e5\u78ba\u5b9a\u5fc3\u81df\u5feb\u8df3\uff0c\u6709\u4e0b\u5217\u6578\u9805\u8655\u7f6e\u63aa\u65bd\uff1a\r1.\u7dca\u6025\u6ce8\u5c04Adenosine \u6ce8\u5c04\u5291\u91cf150 mg IV\u3002\r2.\u975c\u8108\u6ce8\u8f38 amiodarone 150 mg\u3002\r3.Rapid atrial pacing\u3002\r4.\u7dca\u6025Synchronized cardioversion 50-100 J\u3002\r5.\u7dca\u6025\u7167\u6703\u5fc3\u81df\u79d1\u65bd\u884c\u96f7\u5c04\u71d2\u707c\u624b\u8853 (Radio-frequency catheter ablation)\u3002\r\u4f9d\u64da2015 ACC/AHA/HRS guideline\uff0c\u8acb\u554f\u6709\u95dc\u672c\u75c5\u4f8b\u5feb\u8df3\u4e4b\u8655\u7f6e\uff0c\u4f55\u9805\u6700\u7b26\u5408\" Class of recommendation I\u301e?\nA. 1+2+3\nB. 1+2+4\nC. 1+3+5\nD. 2+3+5\nE. 3+4+5\n": "(B)", "105-3.\n\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u4f7f\u7528\u6297\u8840\u6813\u6cbb\u7642\uff0c\u5728\u81e8\u5e8a\u4e0a\u6709\u8a31\u591a\u76f8\u95dc\u7684\u6558\u8ff0\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684\uff1f\nA. Atrial fibrillation (Af)\u591a\u898b\u8af8\u8001\u4eba\uff0c80\u6b72\u4ee5\u4eba\u7d04\u670910%\u3002\nB. \u5fc3\u81df\u75c5\u4eba\u5982\u82e5\u4f34\u6709Af\uff0c\u90fd\u5c6c\u75c5\u72c0\u56b4\u91cd\u3002\nC. \u6709Af\u75c5\u4eba\uff0c\u8166\u4e2d\u98a8\u591a\u589e\u4e94\u500d\u3002\nD. \u5be6\u8b49\u91ab\u5b78\u8a8d\u5b9aAspirin\u7528\u65bc\u6cbb\u7642\u6c92\u6709\u75c7\u72c0\u7684Af\uff0c\u4e5f\u53ef\u9810\u9632\u8840\u6813\u585e\u3002\nE. \u8001\u5e74\u3001\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u5fc3\u81df\u75c5\u53ca\u547c\u5438\u4e2d\u6b62\u75c7\u90fd\u662fAf\u7684\u5371\u96aa\u56e0\u7d20\u3002\n": "(D)", "105-4.\n\u6709\u95dc\u5fc3\u81df\u8870\u7aed (Heart failure) \u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u9805\u4e0d\u6b63\u78ba\uff1f\nA. \u4e0d\u7ba1\u5fc3\u7e2e\u6216\u5fc3\u8212\u6027\u5fc3\u81df\u8870\u7aed\uff0c\u6709\u8fd1\u534a\u75c5\u4eba\u4ecd\u820a\u6709\u6b63\u5e38\u5de6\u5fc3\u5ba4\u5c04\u51fa\u7387(Left ventricular ejection fraction,LVEF)\uff0c\u662f\u4ee5\u5c07\u5fc3\u81df\u8870\u7aed\u5206\u62101).HF reduced EF(HFrEF)\u53ca2).HF preserved EF(HFpEF)\u5169\u7a2e\u3002\nB. \u5c31\u63a7\u5236\u5fc3\u81df\u8870\u7aed\u4e4b\u5feb\u8df3(Tachycardia)\uff0cIvabradine\u9060\u6bd4Digoxin\u70ba\u4f73\u3002\nC. \u9811\u56fa\u6027\u5fc3\u81df\u8870\u7aed\u61c9\u540c\u6642\u4f75\u7528Captopril + Valsartan + Carvedilol + Spironolactone\u3002\nD. \u6025\u6027\u5931\u8abf\u6027\u5fc3\u81df\u8870\u7aed(Acute decompensated heart failure\uff0cADHF)\u670930%\u4f75\u767c\u5fc3\u814e\u75c7\u5019\u7fa4(Cardio-renal syndrome)\uff0c\u4f7f\u7528\u5229\u5c3f\u91cf\u589e\u52a0\u6b64\u985e\u75c5\u4eba\u4e4b\u5fc3\u81df\u6392\u8840\u91cf(Cardiac output) \u6cbb\u7642\uff0c\u4e0d\u76e1\u6709\u6548\u3002\nE. \u4f75\u7528ACEI\u53caBeta-blocker\u4e0d\u76e1\u6709\u76ca\u65bc\u91cd\u5ea6ADHF\u4e4b\u6cbb\u7642\u3002\n": "(C)", "105-5.\n\u6709\u95dc\u75c5\u6bd2\u6027\u5fc3\u808c\u708e(Viral myocarditis) \u6558\u8aaa\uff0c\u5728\u81e8\u5e8a\u4e0a\u6642\u6709\u7684\u8a18\u8ff0\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u8aaa\u6cd5\u662f\u6b63\u78ba\u7684\uff1f\nA. \u75c5\u6bd2\u6027\u5fc3\u808c\u708e\u591a\u767c\u751f\u5728\u8001\u5f31\u75c5\u4eba\uff0c\u591a\u7a2e\u75be\u75c5\u7e8f\u8eab\u3002\nB. \u4f34\u767c\u91cd\u5ea6\u547c\u5438\u8870\u7aed\u53ca\u5fc3\u56e0\u6027\u4f11\u514b\u7684\u731b\u66b4\u6027\u5fc3\u808c\u708e(Fulminant myocarditis)\uff0c\u5e38\u6703\u4f75\u767c\u591a\u5668\u5b98\u8870\u7aed\u3002\u4f46\u53ca\u6642\u7684\u8a3a\u65b7\u53ca\u6cbb\u7642\u53ef\u6551\u547d\u904e\u534a\u4ee5\u4e0a\u3002\nC. \u5fc3\u808c\u6d3b\u9ad4\u5207\u7247\u6aa2\u67e5(Endomyocardial biopsy)\u78ba\u5b9a\u8a3a\u65b7\u7387\u9ad8\u3002\nD. \u8fc4\u4eca\u70ba\u6b62\u7684\u5be6\u8b49\u91ab\u5b78\u90fd\u8a8d\u5b9a\u6297\u75c5\u6bd2\u85e5\u53ca\u514d\u75ab\u58d3\u5236\u7642\u6cd5(Immunosuppressive therapy)\u662f\u6709\u6548\u7684\u7642\u6cd5\u3002\nE. \u9452\u65bc\u5fc3\u808c\u75c5\u6bd2\u78ba\u5b9a\u4e0d\u6613\uff0c\u53ea\u8981\u4f75\u6709\u808c\u8089\u9178\u75db\u53ca\u547c\u5438\u75c7\u72c0\u7684\u611f\u67d3\uff0c\u540c\u6642\u6709\u5fc3\u808c\u640d\u50b7\u7684\u6aa2\u5b9a\uff0c\u5c31\u53ef\u78ba\u8a3a(Definite diagnosis)\u5fc3\u808c\u708e\u3002\n": "(B)", "105-6.\n\u8acb\u554f\u6709\u95dc\u6025\u6027\u5fc3\u808c\u6897\u585e(Acute Myocardial Infarction) \u7684\u81e8\u5e8a\u8aaa\u6cd5\uff0c\u4ee5\u4e0b\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u6c7a\u5b9a\u6025\u6027\u5fc3\u808c\u6897\u585e\u7684\u5fc3\u96fb\u5716Q\u6ce2\u5728\u75c5\u7406\u5b78\u5fc5\u5b9a\u662f\u5168\u58c1\u6027\u5fc3\u808c\u75c5\u8b8a(Transmural infarction)\u3002\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e\u75c5\u4eba\u4e0d\u5b9c\u4f7f\u7528\u77ed\u6548\u7684Dihydropyridine\uff0c\u56e0\u591a\u589e\u6b7b\u4ea1\u7387\u3002\nC. NSTEMI\u7684\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c5\u4eba\uff0c\u4e0d\u5b9c\u4f7f\u7528\u8840\u6813\u6eb6\u89e3\u5291\u6cbb\u7642(Fibrinolytic therapy)\u3002\nD. \u985e\u56fa\u9187(Glucocorticoid )\u53caNSAID(Non-steroidal anti-inflammatory agents)\u90fd\u4e0d\u5408\u9069\u5728STEMI\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c5\u4eba\u4f7f\u7528\u3002\nE. Coronary care \u7684\u85e5\u7269\u5305\u62ecStatin, Angiotensin receptor blockade, Beta-blockade\uff0c\u9664\u975e\u6709\u7981\u5fcc\u3002\n": "(A)", "105-7.\n\u75c5\u4eba62\u6b72\u7537\u6027\u5546\u4eba\uff0c7:30AM\u65e9\u98ef\u5f8c\u80f8\u75bc\u4f75\u6709\u51b7\u6c57\uff0c\u65bc8:11AM\u5230\u6025\u8a3a\u6c42\u91ab\u3002\u75c5\u4eba\u6709\u62bd\u7159\u4e8c\u5341\u5e74\u53ca\u9ad8\u8102\u8840\u7570\u5e38\u7684\u75c5\u53f2\u3002\u8eab\u9ad4\u6aa2\u67e5\uff1a\u8840\u58d3138/74 mmHg,\u5fc3\u8df396/\u5206\uff0c\u898f\u5247\uff0c\u5fc3\u81df\u5fae\u5927\uff0cS1\u5fb5\u5f31\uff0c\u6c92\u6709S3\u6216\u5fc3\u81df\u96dc\u97f3\uff0c\u5176\u4ed6\u6240\u898b\u4ea6\u7121\u91cd\u5927\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716\u5982\u5716\uff0c\u751f\u5316\u6aa2\u67e5\u57288:39AM\uff1aCK,204U/L\uff1bCK-MB,12U/L\uff1bTnI,<0.012ng/mL\u3002\r\u8acb\u4e0b\u5217\u4f55\u9805\u8655\u7f6e\u6700\u4e0d\u7b26\u5408\u7576\u4eca\u6307\u5f15?\nA. \u5fc3\u96fb\u5716\u53ca\u5fc3\u808c\ufffdC\u90fd\u6b63\u5e38\uff0c\u7559\u89c0\u5373\u53ef\u3002\nB. \u4f7f\u7528Morphine 3 mg IV\u3002\nC. \u5148\u670d\u7528Ticagrelor 180 mg \u4f75 90 mg BID + Chewable Aspirin 300mg loading and then 100 mg QD\u3002\nD. IV Heparin 5000 u bolus and then 600-1000 u/hour, depending on aPTT\u3002\nE. Atorvastatin 20 mg BID\u3002\n": "(A)", "105-8.\n\u75c5\u4eba64\u6b72\u5973\u6027\uff0c\u57284\u670811\u65e5\u6e05\u6668\u6025\u6027\u80f8\u75db\u767c\u4f5c\uff0c4AM\u9001\u9054\u91ab\u9662\uff0c\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u591a\u5e74\uff0c\u85e5\u7269\u6cbb\u7642\u4e2d\u3002\u8eab\u9ad4\u6aa2\u67e5\uff1a\u8840\u58d3216/114 mmHg\uff1b\u5fc3\u8df388/\u5206\uff0c\u898f\u5247\uff0c\u5728\u4e3b\u52d5\u74e3\u5340\u6709\u4e8c\u5ea6\u5fc3\u7e2e\u96dc\u97f3\uff0c\u9918\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u3002\u751f\u5316\u6aa2\u67e5\uff1aCK 832 U/L, CK-MB 41 U/L, TnI 5.32 ng/mL(\u5fc3\u96fb\u5716\u5982\u5716\u793a)\u3002\u6025\u8a3a\u91ab\u5e2b\u96a8\u5373\u884cDAPT loading\u53caHeparination\uff0c\u4e26\u555f\u52d5PCI\u5718\u968a\u9032\u884c\u51a0\u8108\u8840\u7ba1\u8a3a\u65b7\u53ca\u6cbb\u7642\u3002\u8acb\u554f\u672c\u75c5\u4f8b\u4e4bCulprit lesion \u6700\u53ef\u80fd\u5728\u4f55\u8655\uff1f\nA. Proximal left anterior descending artery\nB. Proximal left circumflex artery\nC. Distal left circumflex artery\nD. Proximal right coronary artery\nE. Distal right coronary artery\n": "(D)", "105-9.\n\u75c5\u4eba22\u6b72\u5973\u6027\u5916\u7c4d\u770b\u8b77\u56e0\u6709\u6578\u5929\u7684\u9593\u6b47\u6027\u5fc3\u60b8\u53ca\u7729\u6688\uff0c\u96c7\u4e3b\u6025\u9001\u6025\u8a3a\u90e8\u6c42\u91ab\u3002\u5176\u8eab\u9ad4\u6aa2\u67e5\uff1a\u6025\u75c5\u7665\uff0c\u8840\u58d3\uff0c88/72mmHg\uff1b\u8108\u8df3\uff0c144/\u5206\uff0c\u4e0d\u898f\u5247\uff1b\u547c\u5438\uff0c28/\u5206\uff1b\u80ba\u90e8\u7121\u6fc1\u97f3\uff1b\u5fc3\u81df\uff0c\u6709RV heaving\uff0cWide-splitting of S2\u53ef\u805e\uff1b\u6307\u5c16\u767c\u7d3a\uff1b\u9918\u5747\u6b63\u5e38\u6240\u898b\u3002\u5fc3\u96fb\u5716\u5982\u5716\u793a\u3002\u8acb\u554f\u4f9d\u64da\u6700\u65b0ACC/AHA/HRS\u4e4bGuideline\uff0c\u6b64\u5feb\u8df3\u5728\u6025\u8a3a\u8655\u7f6e\uff0c\u61c9\u4ee5\u4f55\u7a2e\u8655\u7f6e\u6700\u6070\u7576\uff1f\nA. Electric cardioversion 200 J after sedation\nB. Adenosine 300 mg IV\nC. Verapamil 5 mg IV\nD. Amiodarone 150 mg in 10 min IV\nE. Digoxin 0.25 mg in 5%D/W 20 ml for 5 min\n": "(A)", "105-10.\n\u4f9d\u64da2015 Guideline of Taiwan Society of Cardiology and Taiwan Hypertension Society for the Management of Hypertension\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u662fTaiwan Guideline\u7684\u4e3b\u5f35\uff1f\nA. \u9650\u9209\u9e7d\u57282.0 gm/day\u4ee5\u4e0b\u3002\nB. \u4f75\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u75c5\u4eba\u4e4b\u8840\u58d3\uff0c\u61c9\u63a7\u5236\u5728130/80 mmHg\u4ee5\u4e0b\u3002\nC. \u9ad8\u9f61\u8001\u4eba(>80\u6b72)\u7684\u8840\u58d3\u63a7\u5236\u76ee\u6a19\u5f97\u5347\u81f3150/90 mmHg\u3002\nD. \u6709\u86cb\u767d\u5c3f\u7684\u6162\u6027\u814e\u75c5\u4eba\u5b9c\u7dad\u6301\u8840\u58d3\u5728140/90 mmHg \u4ee5\u4e0a\uff0c\u4ee5\u589e\u5f37\u814e\u5c0f\u7403\u904e\u6ffe\u7387(Glomerular filtration rate)\u3002\nE. \u4f7f\u7528\u6297\u8840\u6813\u6cbb\u7642\u7684\u8166\u4e2d\u98a8\u75c5\u4eba\uff0c\u61c9\u63a7\u5236\u8840\u58d3\u5728130/80 mmHg \u4ee5\u4e0b\uff0c\u4ee5\u514d\u8166\u51fa\u8840\u3002\n": "(D)", "105-11.\n58\u6b72\u7537\u6027\u6025\u6027\u767c\u4f5c\u52d5\u5598\u8207\u7aef\u5750\u547c\u5438\u4f86\u6025\u8a3a\uff0c\u75c7\u72c0\u5df2\u6709\u4e09\u5929\uff0c\u8eab\u9ad4\u6aa2\u67e5\u5728\u5fc3\u5c16\u90e8\u4f4d\u5448\u73fe\u7b2c\u4e09\u7d1a\u6536\u7e2e\u671f\u96dc\u97f3,\u4e26\u8f3b\u5c04\u81f3\u5de6\u5f8c\u80cc.\u80f8\u90e8X\u5149\u7247\u5448\u73fe\u80ba\u6c34\u816b\uff1b\u5fc3\u81df\u8d85\u97f3\u6ce2\u5448\u73fe\u4e8c\u5c16\u74e3\u8d05\u751f\u7269(vegetation)\uff0c \u4e8c\u5c16\u74e3\u8171\u7d22\u65b7\u88c2\u8207\u91cd\u5ea6\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\u5168\uff0c\u8840\u4e2d\u7d30\u83cc\u57f9\u990a3\u5957\u5448\u73feStreptococcus bovis. \u8acb\u554f\u9664\u4e86\u5fc3\u5167\u819c\u708e\u5916\uff0c\u4e0b\u5217\u75be\u75c5\u4f55\u8005\u61c9\u5217\u5165\u8a3a\u65b7\u8003\u91cf?\nA. \u80ba\u764c\nB. \u5927\u8178\u764c\nC. \u7532\u72c0\u817a\u764c\nD. \u9f3b\u54bd\u764c\nE. \u4e73\u764c\n": "(B)", "105-12.\n\u6709\u95dc24\u5c0f\u6642\u8840\u58d3\u91cf\u6e2c\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u591c\u9593\u8840\u58d3\u901a\u5e38\u6bd4\u65e5\u9593\u8840\u58d3\u4f4e10-20%\nB. \u752824\u5c0f\u6642\u8840\u58d3\u91cf\u6e2c\u8a3a\u65b7\u9ad8\u8840\u58d3\u6642,\u5e73\u5747\u6e05\u9192\u8840\u58d3 (awake average blood pressure)\u662f\u4ee5\u5927\u65bc\u7b49\u65bc135/85 \u6beb\u7c73\u6c5e\u67f1\u70ba\u8a3a\u65b7\u9ad8\u8840\u58d3\u6a19\u6e96\nC. \u752824\u5c0f\u6642\u8840\u58d3\u91cf\u6e2c\u8a3a\u65b7\u9ad8\u8840\u58d3\u6642,\u5e73\u5747\u7761\u7720\u8840\u58d3(asleep blood pressure) \u662f\u4ee5\u5927\u65bc\u7b49\u65bc130/80\u6beb\u7c73\u6c5e\u67f1\u70ba\u8a3a\u65b7\u9ad8\u8840\u58d3\u6a19\u6e96\nD. 24\u5c0f\u6642\u8840\u58d3\u91cf\u6e2c\u63d0\u4f9b\u66f4\u591a\u7684\u65e5\u9593\u8207\u591c\u9593\u8840\u58d3\u6578\u503c,\u6bd4\u8a3a\u9593\u8840\u58d3(office blood pressure)\u66f4\u80fd\u53ef\u9760\u9810\u6e2c\u5668\u5b98\u50b7\u5bb3( target organ damage).\nE. \u7576\u591c\u9593\u8840\u58d3\u964d\u5e45(dip)\u6e1b\u5c11\u6642,\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\u5347\u9ad8.\n": "(C)", "105-13.\n\u4e59\u578b\u53d7\u9ad4\u963b\u65b7\u5291(beta-blocker)\u53ef\u7528\u65bc\u5de6\u5fc3\u5ba4\u5c04\u51fa\u5206\u7387\u6e1b\u5c11\u6642\u4e4b\u5fc3\u81df\u8870\u7aed\u85e5\u7269\u6cbb\u7642,\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r1. \u53ef\u4ee5\u4f7f\u7528xamoterol\r2. \u53ef\u4ee5\u4f7f\u7528bisoprolol\r3. \u53ef\u4ee5\u4f7f\u7528carvedilol\r4. \u53ef\u4ee5\u4f7f\u7528propranolol\r5. \u7576\u75c5\u4eba\u6c92\u6709\u51fa\u73fe\u4f4e\u8840\u58d3\u5c0e\u81f4\u982d\u6688\u6216\u5026\u6020\u6642,\u6bcf\u9694\u4e00\u9031\u53ef\u4ee5\u5f80\u4e0a\u8abf\u6574\u5291\u91cf\nA. 1+5\nB. 2+3\nC. 2+3+5\nD. 2+4\nE. 3+5\n": "(B)", "105-14.\n\u539f\u767c\u6027\u919b\u56fa\u916e\u589e\u591a\u75c7 (primary aldosteronism)\u5e38\u9020\u6210\u9ad8\u8840\u58d3,\u6709\u95dc\u5176\u8a3a\u65b7\u63cf\u8ff0,\u4f55\u8005\u6b63\u78ba?\r1. \u5728\u975e\u81e5\u5e8a(ambulatory)\u7684\u75c5\u4eba,\u6e05\u6668\u62bd\u8840\u6642; \u8840\u6e05\u4e2d\u919b\u56fa\u916e/\u814e\u7d20\u6d3b\u6027(plasma aldosterone/ plasma renin activity) >30:1\r2. \u5728\u975e\u81e5\u5e8a\u7684\u75c5\u4eba,\u6e05\u6668\u62bd\u8840;\u8840\u6e05\u4e2d\u919b\u56fa\u916e>555pmol/L (>20ng/dL)\r3. \u5728\u6709\u9ad8\u8840\u58d3\u800c\u672a\u4f7f\u7528\u5229\u5c3f\u5291\u75c5\u60a3,\u8840\u6e05\u4e2d\u9240\u96e2\u5b50\u964d\u4f4e\u8005,\u6709\u9ad8\u905490%\u6709\u539f\u767c\u6027\u919b\u56fa\u916e\u589e\u591a\u75c7\r4. \u5728\u62bd\u8840\u524d4~6\u9031\u8981\u505c\u6389\u919b\u56fa\u916e\u62ee\u6297\u5291(aldosterone antagonists)\r5. \u5728\u8840\u6e05\u919b\u56fa\u916e/\u814e\u7d20\u6bd4\u503c\u5347\u9ad8\u60a3\u8005,\u7d66\u4e88\u975c\u8108\u6ce8\u5c042\u516c\u5347\u751f\u7406\u98df\u9e7d\u6c34\u56db\u5c0f\u6642\u5f8c,\u8840\u6e05\u4e2d\u7684\u919b\u56fa\u916e\u964d\u81f3138pmol/L (5ng/dL)\u4ee5\u4e0b\nA. 2+3+4\nB. 1+2+3\nC. 1+2+4\nD. 1+2+5\nE. 1+4+5\n": "(C)", "105-15.\n\u4e00\u4f4d70\u6b72\u7537\u6027\u75c5\u60a3\u56e0\u5fc3\u623f\u986b\u52d5\u5c31\u8a3a,\u8a72\u5fc3\u5f8b\u4e0d\u6574\u75c5\u53f2\u5df2\u67091\u5e74\u4ee5\u4e0a.\u904e\u53bb\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u53f2,\u6700\u8fd1\u6709\u9663\u767c\u6027\u591c\u9593\u547c\u5438\u56f0\u96e3\u8207\u8173\u90e8\u6c34\u816b;\u5fc3\u81df\u8d85\u97f3\u6ce2\u5de6\u5fc3\u5c04\u51fa\u5206\u7387\u70ba29%.\u7121\u5fc3\u808c\u6897\u585e,\u4e2d\u98a8\u6216\u9031\u908a\u8840\u7ba1\u963b\u585e\u75be\u75c5\u75c5\u53f2.\u5728\u6c7a\u5b9a\u8981\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u8840\u5291\u6642;\u6703\u4f30\u7b97CHA2DS2-VASc \u5206\u6578,\u8acb\u554f\u8a72\u75c5\u60a3\u4e4b\u5206\u6578\u70ba?\nA. 2\nB. 3\nC. 4\nD. 5\nE. 6\n": "(C)", "105-16.\n\u4e00\u4f4d25\u6b72\u7537\u6027\u75c5\u60a3,\u56e0\u660f\u53a5\u800c\u9001\u81f3\u6025\u8a3a.\u5728\u6025\u8a3a\u4e4b\u5fc3\u96fb\u5716\u5982\u5716A. \u56de\u9867\u8a72\u75c5\u60a3\u5148\u524d\u9580\u8a3a12\u5c0e\u7a0b\u5fc3\u96fb\u5716\u7684\u7b2c\u4e00\u81f3\u7b2c\u4e09\u80f8\u524d\u5c0e\u5982\u5716B.\u8a72\u75c5\u60a3\u4e4b\u5fc3\u81df\u8d85\u97f3\u6ce2\u7121\u7d50\u69cb\u6027\u5fc3\u81df\u75c5;\u8840\u6e05\u96fb\u89e3\u8cea\u7121\u7570\u5e38,\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u7d66\u4e88\u8a72\u75c5\u60a3flecainide\u6703\u8b93\u7b2c\u4e00\u81f3\u7b2c\u4e09\u80f8\u524d\u5c0e\u7a0bST\u7bc0\u6bb5\u8b8a\u5316\u66f4\u660e\u986f\nB. \u6709\u90e8\u5206\u75c5\u4eba\u6709\u9209\u96e2\u5b50\u901a\u9053(sodium channel)\u7a81\u8b8a\u7570\u5e38\nC. \u75c5\u4eba\u5e38\u56e0\u767c\u71d2\u6216\u7761\u7720\u8a98\u767c\u5fc3\u640f\u505c\u6b62(cardiac arrest)\nD. \u9019\u985e\u75c5\u4eba\u6709\u6642\u9700\u8981\u88dd\u7f6e\u5fc3\u5167\u53bb\u986b\u6574\u6d41\u5668(ICD)\nE. \u9240\u96e2\u5b50\u901a\u9053( potassium channel)\u7570\u5e38\u662f\u7d55\u5927\u90e8\u5206\u7684\u539f\u56e0\n": "(E)", "105-17.\n\u6709\u95dc\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u7684\u96dc\u97f3\u807d\u8a3a\u63cf\u8ff0,\u4f55\u8005\u932f\u8aa4?\r1.\u7576\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u8d8a\u56b4\u91cd,\u7b2c\u4e8c\u5fc3\u97f3A2\u8207\u4e8c\u5c16\u74e3\u958b\u74e3\u97f3(opening snap)\u7684\u9593\u8ddd\u6703\u7e2e\u77ed\r2.\u7576\u4e8c\u5c16\u74e3\u819c\u9762\u7a4d\u8d8a\u4f86\u8d8a\u72f9\u7a84,\u6703\u5f15\u8d77\u6b21\u767c\u6027\u80ba\u52d5\u8108\u9ad8\u58d3,\u6b64\u6642\u7b2c\u4e8c\u5fc3\u97f3P2\u6703\u8b8a\u5927\u8072\r3.\u7576\u4e8c\u5c16\u74e3\u819c\u9762\u7a4d\u8d8a\u4f86\u8d8a\u72f9\u7a84,\u6703\u5f15\u8d77\u6b21\u767c\u6027\u80ba\u52d5\u8108\u9ad8\u58d3,\u6b64\u6642A2\u8207P2\u9593\u8ddd\u6703\u8b8a\u5bec\r4.\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u662f\u8212\u5f35\u671f\u96dc\u97f3(diastolic rumble)\r5.Austin-Flint murmur \u662f\u7528\u4f86\u63cf\u8ff0\u4e8c\u5c16\u74e3\u72f9\u7a84\u7684\u96dc\u97f3\nA. 1+3+5\nB. 1+4\nC. 2+3\nD. 3+4\nE. 3+5\n": "(E)", "105-18.\n\u6709\u95dc\u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3(bicuspid aortic  valve)\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u7684\u60a3\u8005,\u5176\u4e00\u7b49\u89aa\u7f79\u60a3\u8a72\u75be\u75c5\u7684\u76db\u884c\u7387(prevalence)\u70ba10%\nB. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u7684\u60a3\u8005\u4e3b\u52d5\u8108\u6703\u64f4\u5927,\u6709\u6642\u5019\u6703\u5f62\u6210\u4e3b\u52d5\u8108\u7624\u6216\u4e3b\u52d5\u8108\u525d\u96e2\nC. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u60a3\u8005\u7684\u4e3b\u52d5\u8108\u75c5\u8b8a\u8207\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u8840\u578b\u529b\u5b78\u7684\u56b4\u91cd\u7a0b\u5ea6\u4e0d\u4e00\u5b9a\u6709\u76f8\u95dc( independent of the severity of hemodynamic severity  of the valve lesions)\nD. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u7684\u7537\u5973\u6bd4\u70ba1:2~4\nE. \u4e8c\u8449\u5f0f\u4e3b\u52d5\u8108\u74e3\u6703\u8207\u5176\u4ed6\u5148\u5929\u6027\u5fc3\u81df\u75c5\u5408\u4f75\u767c\u751f\n": "(D)", "105-19.\n\u4e00\u4f4d82\u6b72\u7537\u6027\u75c5\u60a3\u56e0\u9aa8\u982d\u58d3\u75db\uff0c\u5598\u8207\u8173\u816b\u81f3\u9580\u8a3a\u5c31\u8a3a\uff0c\u8840\u58d3\u70ba96/60\u6beb\u7c73\u6c5e\u67f1\uff0c\u5fc3\u8df3\u6bcf\u5206\u9418\u70ba80\u6b21\uff0c\u8eab\u9ad4\u6aa2\u67e5\u5448\u73fe\uff1a\u7d50\u819c\u84bc\u767d\uff0c\u9838\u975c\u8108\u6012\u5f35\uff0c\u5169\u5074\u547c\u5438\u97f3\u6e1b\u5f31\uff0c\u5fc3\u81df\u807d\u8a3a\u5de6\u4e0b\u80f8\u9aa8\u5448\u73fe\u7b2c\u4e09\u7d1a\u6536\u7e2e\u671f\u96dc\u97f3\uff0c\u4e26\u96a8\u5438\u6c23\u52a0\u91cd\uff0c\u5fc3\u5c16\u90e8\u5448\u73fe\u7b2c\u4e09\u7d1a\u6536\u7e2e\u671f\u96dc\u97f3\uff0c\u5169\u5074\u4e0b\u80a2\u660e\u986f\u6c34\u816b\u3002\u62bd\u8840\u6aa2\u67e5\u5448\u73feBUN 70 mg/dl, cre 5.5mg/dl, Na 140 mmol/L, K 4.2 mmol/L, calcium 2.8 mmol/L, phosphate 5.3 mg/dL, Hb 10.7 g/dl, MCV 85.2 fL, WBC 9.61 k/uL,  platelet 197 k/uL, albumin 3.1 g/dl, total protein 7.6 g/dl, \u9a57\u5c3f\u5c3f\u86cb\u767d\u5448\u73fe3+, \u982d\u9aa8X\u5149\u5448\u73fe\rpunched-out\u75c5\u7076.\u9aa8\u9ad3\u5207\u7247\u6aa2\u67e5\u5448\u73fe\u660e\u986fplasma cell neoplasm.\u91ab\u5e2b\u61f7\u7591\u5fc3\u81df\u4e5f\u6709\u88ab\u6b64\u75be\u75c5\u6ce2\u53ca.\u8acb\u554f\u4e0b\u5217\u5fc3\u81df\u6aa2\u67e5\u7d50\u679c,\u4f55\u8005\u8207\u9019\u500b\u61f7\u7591\u8f03\u4e0d\u543b\u5408?\nA. \u5fc3\u96fb\u5716A\nB. \u5fc3\u96fb\u5716B\nC. \u5fc3\u81df\u8d85\u97f3\u6ce2\u5448\u73fe\u5fc3\u808c\u80a5\u539a\u8207sparkling\nD. \u5fc3\u81df\u8d85\u97f3\u6ce2\u5de6\u5fc3\u5ba4\u51fa\u73ferestrictive filling pattern\nE. \u5fc3\u81df\u8d85\u97f3\u6ce2\u5448\u73fe\u4e2d\u81f3\u91cd\u5ea6\u4e09\u5c16\u74e3\u819c\u9589\u9396\u4e0d\u5168\n": "(B)", "105-20.\n\u6709\u95dc\u65b0\u578b\u53e3\u670d\u6297\u51dd\u8840\u5291\u7684\u63cf\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. apixaban\u662f\u4f5c\u7528\u5728thrombin\nB. rivaroxaban\u662f\u4f5c\u7528\u5728factor Xa\nC. dabigatran 80%\u7531\u814e\u81df\u4ee3\u8b1d\nD. edoxaban half life\u662f 9~11 \u5c0f\u6642\nE. \u7121\u6cd5\u85c9\u7531 prothrombin time\u4f86\u76e3\u63a7\u8a72\u85e5\u7269\u6297\u51dd\u8840\u6548\u679c\n": "(A)", "105-21.\n\u4e00\u4f4d65\u6b72\u5973\u6027\u9ad6\u9aa8\u9aa8\u6298\u958b\u5200\u5f8c7\u5929,\u4e3b\u8a34\u547c\u5438\u7a98\u8feb;\u958b\u5200\u524d\u8840\u58d3\u70ba130/80\u6beb\u7c73\u6c5e\u67f1,\u547c\u5438\u7a98\u8feb\u6642\u6e2c\u91cf\u4e4b\u8840\u58d3\u70ba80/50\u6beb\u7c73\u6c5e\u67f1.\u8840\u6c27\u6fc3\u5ea6\u753198%\u964d\u81f370%.\u5fc3\u96fb\u5716\u5982\u5716.\u503c\u73ed\u91ab\u5e2b\u6c92\u62bd\u8840\u6e2cD- dimer \u4fbf\u76f4\u63a5\u5b89\u6392\u5f71\u50cf\u6aa2\u67e5;\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5982\u9644\u5716.\u8acb\u554f\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u8a72\u75c5\u60a3\u5f88\u6709\u53ef\u80fd\u56e0\u958b\u5200\u5f8c\u81e5\u5e8a\u800c\u5c0e\u81f4\u6df1\u90e8\u975c\u8108\u6813\u585e\nB. \u8a72\u503c\u73ed\u91ab\u5e2b\u61c9\u8a72\u62bd\u8840\u7b49D- dimer\u6578\u503c\u6aa2\u6e2c\u51fa\u4f86\u5f8c,\u518d\u9032\u884c\u5b89\u6392\u5f71\u50cf\u6aa2\u67e5\nC. \u8a72\u75c5\u60a3\u4e4b\u8840\u58d3\u964d\u4f4e\u7684\u539f\u56e0\u4e4b\u4e00\u662f\u7531\u65bc\u53f3\u5fc3\u8840\u6db2\u7121\u6cd5\u56de\u5230\u5de6\u5fc3,\u4f86\u63d0\u4f9b\u8db3\u5920\u5fc3\u8f38\u51fa\u91cf\u6240\u81f4\nD. \u6b64\u6642\u62bd\u8840,\u8840\u4e2d\u4e73\u9178\u6703\u5347\u9ad8\nE. D-dimer\u5c0d\u6b64\u80ba\u90e8\u8840\u7ba1\u8b8a\u5316\u7684\u8a3a\u65b7\u654f\u611f\u5ea6(sensitivity)>95%\n": "(B)", "105-22.\n\u4e00\u4f4d75\u6b72\u7537\u6027,\u904e\u53bb\u7f79\u60a3\u7cd6\u5c3f\u75c5,\u4f46\u8840\u7cd6\u63a7\u5236\u4e0d\u4f73.\u62bd\u83f8\u670940\u5e74.\u8840\u58d3\u9ad8\u4f46\u9577\u5e74\u672a\u6cbb\u7642.\u6700\u8fd13\u500b\u6708\u51fa\u73fe\u9593\u6b47\u6027\u8ddb\u884c,\u91ab\u5e2b\u61f7\u7591\u4ed6\u6709\u9031\u908a\u52d5\u8108\u963b\u585e\u6027\u75be\u75c5 (peripheral arterial occlusive disease),\u56e0\u6b64\u958b\u7acb\u8173\u8e1d\u8207\u80b1\u52d5\u8108\u8840\u58d3\u6bd4\u503c(ankle brachial index, ABI)\u6aa2\u67e5,\u8acb\u554f\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. ABI \u6b63\u5e38\u503c\u57281.0~1.4\nB. ABI<1.0 \u53ef\u4ee5\u78ba\u7acb\u8a3a\u65b7\u9031\u908a\u52d5\u8108\u963b\u585e\u6027\u75be\u75c5\nC. \u904b\u52d5\u5f8c\u7acb\u5373\u6e2c\u91cfABI,\u5982\u679cABI \u6578\u503c\u660e\u986f\u4e0b\u964d,\u53ef\u4ee5\u5354\u52a9\u75c7\u72c0\u6a21\u7a1c\u5169\u53ef\u7684\u75c5\u4eba\u8a3a\u65b7\u9031\u908a\u52d5\u8108\u963b\u585e\u6027\u75be\u75c5\nD. \u9664\u975e\u75c5\u4eba\u6709\u898f\u5283\u9032\u884c\u8840\u7ba1\u91cd\u5efa\u6cbb\u7642 (revascularization), \u78c1\u632f\u8840\u7ba1\u9020\u5f71( Magnetic  Resonance Angiography) \u4e0d\u8981\u88ab\u7576\u6210\u5e38\u898f\u7be9\u6aa2\u5de5\u5177.\nE. ABI\u5c0d\u7f79\u60a3\u9031\u908a\u52d5\u8108\u963b\u585e\u6027\u75be\u75c5\u4e4b\u75c5\u4eba,\u9664\u4e86\u8a3a\u65b7\u7684\u529f\u7528;\u9084\u53ef\u4ee5\u5354\u52a9\u627e\u51fa\u53ef\u80fd\u767c\u751f\u51a0\u72c0\u52d5\u8108\u7ca5\u6a23\u786c\u5316\u75be\u75c5(atherothrombotic event)\u98a8\u96aa\u7684\u4eba\n": "(B)", "106-1.\n53\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u80f8\u75bc\u53ca\u51b7\u6c57\u6025\u5f80\u6025\u8a3a\u6c42\u91ab\u3002\u75c5\u4eba\u6c92\u6709\u4efb\u4f55\u65e2\u5f80\u75c5\u53f2\uff0c\u53ea\u6709\u6bcf\u5929\u4e00\u5305\u7159\u7684\u5eff\u4e94\u5e74\u55dc\u597d\u3002\u5c31\u8a3a\u6642\u8840\u58d3165/109 mmHg; \u5fc3\u8df382/min\u3002\u75c5\u53f2\u63a2\u8a62\u6642\u7a81\u7136\u5fc3\u8df3\u505c\u6b62\uff0c\u5fc3\u96fb\u5716\u986f\u793a\u5982\u5716\u3002\u60a8\u7368\u81ea\u5728\u73fe\u5834\uff0c\u8acb\u554f\u60a8\u7684\u7b2c\u4e00\u6b65\u8655\u7f6e\uff0c\u4ee5\u4f55\u8005\u70ba\u5148\uff1f\nA. Amiodarone 150 mg in 50 ml D5W \u975c\u8108\u6ce8\u5c0420\u5206\nB. \u9032\u884cCPR, \u5fc3\u81df\u58d3\u8feb\u6bcf\u5206\u9418100\u6b21\nC. \u7dca\u6025\u7f6e\u653e\u4eba\u5de5\u652f\u6c23\u7ba1\uff0c\u7dad\u6301\u547c\u5438\nD. Intra-cardiac injection, bosmin 1 mg\nE. \u555f\u7528\u8449\u514b\u819c\u652f\u6301\u8840\u58d3\u53ca\u5fc3\u8df3\n": "(B)", "106-2.\n\u5c31\u81e8\u5e8a\u89c0\u5bdf\u800c\u8a00\uff0c\u5fc3\u5f8b\u5feb\u8df3(Tachyarrhythmia)\u8207\u7672\u7647(Seizure)\u6240\u81f4\u4e4b\u6688\u7729(Syncope)\u4e0d\u6613\u9451\u5225\u8a3a\u65b7\uff0c\u552f\u4e0b\u5217\u6578\u9ede\u5177\u6709\u5f37\u5ea6\u53c3\u8003\u50f9\u503c:(1)\u904b\u52d5\u4e2d\u7684\u6688\u7729\uff1b (2)\u5c3f\u5931\u7981\u53ca\u54ac\u820c\uff1b(3)\u75c5\u4eba\u5728\u610f\u8b58\u56de\u5fa9\u5f8c\uff0c\u8fc5\u5373\u56de\u5fa9\u5c0d\u4eba\u3001\u5730\u4e4b\u8fa8\u8b58\u80fd\u529b\uff1b (4)\u54b3\u55fd\u3001\u9589\u6b62\u5438\u6c23\u4e0d\u80fd\u91cb\u89e3\u75c7\u72c0\uff1b(5)\u5e73\u8eba\u9593\u7a81\u767c\u6688\u7729\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u75c5\u53f2\u75c7\u72c0\u504f\u5411\u5fc3\u5f8b\u5feb\u8df3\u81f4\u6688\u7729\u4e4b\u8a3a\u65b7\uff1f\nA. (1)+(2)+(3)\nB. (3)+(4)+(5)\nC. (2)+(3)+(4)\nD. (1)+(4)+(5)\nE. (1)+(3)+(5)\n": "(E)", "106-3.\n\u8a31\u591a\u5fc3\u96fb\u5716\u6240\u898b\uff0c\u5e38\u5177\u6709\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u81e8\u5e8a\u610f\u7fa9\uff1a(1)PR\u9593\u9694(PR interval) \u5ef6\u9577\u6c92\u6709\u767c\u751f\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u7684\u5371\u96aa\uff1b(2)QRS duration > 0.12 mSec\u7684\u53f3\u675f\u679d\u50b3\u5c0e\u963b\u6eef(Right bundle branch block)\u4e0d\u5177\u751f\u7406\u75c5\u7406\u7684\u610f\u7fa9\uff1b(3)QTc\u5ef6\u9577\u53ef\u767c\u751f\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u53ca\u60e1\u6027\u5fc3\u5ba4\u6027\u5fc3\u5f8b\u4e0d\u6574(Ventricular tachyarrhythmia)\u4e4b\u5371\u96aa\uff1b(4)\u53cd\u5411QRS\u6ce2\u7684J\u6ce2\u53ef\u5728\u4f4e\u6eab\u3001\u9ad8\u9223\u8840\u53ca\u8166\u90e8\u50b7\u8b8a\u767c\u751f\uff0c\u5177\u9ad8\u5ea6\u60e1\u6027\u5fc3\u5f8b\u4e0d\u6574\u767c\u751f\u7684\u5371\u96aa\uff1b(5)QTc\u7e2e\u77ed\u53ef\u767c\u751f\u60e1\u6027\u5fc3\u5ba4\u6027\u5fc3\u5f8b\u4e0d\u6574\u6216\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u8aaa\u6cd5\u662f\u6b63\u78ba\u7684\uff1f\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "106-4.\n88\u6b72\u7537\u6027\u8001\u5e74\u4e3b\u8a34\u8fd1\u4e09\u500b\u6708\u6642\u6709\u80f8\u60b6\uff0c\u7729\u660f\u53ca\u5fc3\u60b8\u3002\u5f9e\u53bb\u5e74\u5e74\u5e95\u8d77\u65e5\u6f38\u4e0d\u80fd\u81ea\u7406\u751f\u6d3b\uff0c\u4e26\u6709\u8fd1\u671f\u7684\u5931\u61b6\uff0c\u4e0d\u80fd\u8a00\u8a9e\u53ca\u9032\u98df\uff0c\u9010\u65e5\u52a0\u91cd\u5f8c\u4f4f\u9662\u3002\u8eab\u9ad4\u6aa2\u67e5\uff1aBP:112/53 mmHg; HR:46 bpm\uff1bRR,18/min\uff1bSpO2, 98%\uff1b\u610f\u8b58E4M4V5; Muscle power, Normal\uff1b\u9838\u975c\u8108\u6b63\u5e38\uff0c\u7532\u72c0\u817a\u6b63\u5e38\uff1b\u80f8\u90e8\u6709\u7c97\u6fc1\u547c\u5438\u97f3\uff1b\u5fc3\u81df\uff1aS1\u504f\u91cd\uff0c\u5728\u5fc3\u5c16\u53ca\u4e3b\u52d5\u8108\u5340\u6709Grade 2/6 Diastolic murmur\uff1b\u8179\u90e8\u672a\u6709\u809d\u813e\u816b\uff1b\u8173\u6c92\u6709\u6c34\u816b\u3002\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u9644\uff1b\u8d85\u97f3\u6ce2\u5fc3\u5716\u986f\u793a\u4e3b\u52d5\u8108\u74e3\u53ca\u4e09\u5c16\u74e3\u4e2d\u5ea6\u9589\u9396\u4e0d\u5168\u3002\u8acb\u554f\u672c\u75c5\u4eba\u6700\u53ef\u80fd\u8a3a\u65b7\u662f\uff1a\nA. \u5de6\u5fc3\u5ba4\u8870\u7aed\nB. \u53f3\u5fc3\u5ba4\u8870\u7aed\nC. \u7532\u72c0\u817a\u6a5f\u80fd\u4f4e\u4e0b\nD. \u6bdb\u5730\u9ec3\u4e2d\u6bd2\nE. \u4f4e\u9209\u8840\u75c7\n": "(D)", "106-5.\n\u6709\u95dc\u64f4\u5927\u6027\u5fc3\u808c\u75c5(Dilated cardiomyopathy\uff0c DCM)\u7684\u8fd1\u5e74\u8a3a\u7642\u9032\u5c55\uff0c\u6709\u4e0d\u5c11\u5b9a\u8ad6\uff0c\u8acb\u554f\u4f55\u9ede\u662f\u932f\u8aa4\u7684\uff1f\nA. \u5e7e\u8fd1\u4e00\u534a(20-50%)\u7684DCM\u5177\u6709\u5bb6\u65cf\u6027\uff0c\u5176\u4e2d68%\u662f\u81ea\u9ad4\u986f\u6027\u907a\u50b3(Autosomal dominant inheritance)\u3002\nB. \u81e8\u5e8a\u4e0a\uff0cDCM\u6709\u5169\u7a2e\uff0c\u4e00\u4ee5\u5fc3\u81df\u8870\u7aed\u8868\u73fe\u7684\u55ae\u7d14\u6027(Isolated)DCM, \u53e6\u4e00\u662f\u4f34\u6709\u5fc3\u5f8b\u4e0d\u6574\u6216\u50b3\u5c0e\u963b\u6eef\uff0c\u4e14\u6709\u9aa8\u9abc\u808c\u57fa\u56e0\u75c5\u8b8a\u7684DCM\u3002\nC. X-\u76f8\u9023\u6027DCM(X-linked DCM)\u67092-5%\uff0c\u5982\u6709\u8840\u6e05CK\u5347\u9ad8\uff0c\u5c31\u6709\u53ef\u80fd\u662fDystrophin gene \u7a81\u8b8a\u6240\u81f4\u3002\nD. \u6240\u6709\u7684DCM\uff0c\u4e0d\u8ad6\u5148\u5929\u6216\u5f8c\u5929\u56e0\u7d20\u90fd\u4e0d\u80fd\u5fa9\u539f\uff0c\u5fc3\u81df\u79fb\u690d\u662f\u552f\u4e00\u7684\u6cbb\u7642\u9078\u64c7\u3002\nE. \u6709\u8b02DCM, Hypertrophic cardiomyopathy, Restrictive cardiomyopathy, \u6216 Arrhythmogenic RV cardiomyopathy \u90fd\u6709\u5171\u540c\u7684\u57fa\u56e0\u7570\u5e38\uff0c\u56e0\u6b64\u8a8d\u5b9a\u5fc3\u808c\u75c5\u662f\u4e00\u500b\u75c5\u56e0\uff0c\u4e0d\u540c\u7684\u81e8\u5e8a\u5178\u578b\u3002\n": "(D)", "106-6.\n\u75c5\u4eba\uff0c64\u6b72\u5085\u5148\u751f\u5728\u4e0b\u53483:00 PM \u7a81\u7136\u6c23\u4fc3(dyspnea)\uff0c\u5230\u6025\u8a3a\u6c42\u91ab\u3002\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\u3001\u6162\u6027B\u578b\u809d\u708e\u53ca\u75db\u98a8\u75c5\u53f2\u3002\u5230\u9662\u6642\u8840\u58d3102/73mm Hg; ventricular rate 100/min;\u572810 L/min O2 mask \u4f7f\u7528\u4e0bSpO2 100%\u3002\u5728\u6025\u8a3a\u4e4b\u8eab\u9ad4\u6aa2\u67e5\u672b\u898b\u91cd\u5927\u7570\u5e38\u3002\u5176\u5fc3\u96fb\u5716\u53caCxR\u5982\u5716\u3002\u975c\u8108\u8840\u6c27\u6c23\u53ca\u751f\u5316\u6aa2\u67e5\u5982\u8868\uff0c\u8d85\u97f3\u6ce2\u5fc3\u5716\u986f\u793a\u53f3\u5fc3\u64f4\u5927\u53ca\u4e2d\u91cd\u5ea6\u4e09\u5c16\u74e3\u9589\u9396\u4e0d\u5168\u3002\u672c\u75c5\u4eba\u4e4b\u8a3a\u65b7\u53ca\u6cbb\u7642\u4e4b\u7dca\u6025\u8655\u7f6e\uff0c\u4ee5\u4f55\u65b9\u6848\u6700\u9069\u7576\uff1f\nA. \u6557\u8840\u6027\u4f11\u514b\uff0c\u555f\u7528\u5347\u58d3\u5291\u7dad\u6301\u8840\u58d3\uff0c\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u81f3\u5c11\u4e09\u5957\u5f8c\uff0c\u4f7f\u7528Empirical antibiotics\u3002\nB. \u53f3\u5fc3\u8870\u7aed\uff0c\u63a1\u7528\u5bb9\u7a4d\u91cf\u88dc\u5145\u6cd5\uff0c\u5fc5\u8981\u914d\u7528Dopamine infusion at the rate of 2.5-5.0 microgram/Kg/min\u3002\nC. \u80ba\u6813\u585e\uff0c\u6e2c\u5b9aD-dimer\u53ca\u80f8\u90e8CT\uff0c\u4f9d\u7d50\u679c\u4f7f\u7528\u8840\u6813\u6eb6\u89e3\u7642\u6cd5\u53ca\u809d\u7d20\u6ce8\u5c04\u3002\nD. \u6025\u6027\u4e0b\u58c1\u5fc3\u808c\u6897\u585e\uff0c\u7cfb\u5217\u5fc3\u96fb\u5716\u53ca\u5fc3\u808c\u9175\u7d20\u6aa2\u67e5\uff0c\u6309\u7d50\u679c\u6703\u8a3a\u5fc3\u81df\u79d1\u9015\u884cpercutaneous coronary intervention\u3002\nE. \u7e7c\u7e8c\u89c0\u5bdf\uff0c\u7dad\u6301\u751f\u547d\u75c7\u72c0\u7a69\u5b9a\u3002\n": "(C)", "106-7.\n\u6709\u95dc\u9810\u9632\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial Fibrillation\uff1bAf)\u53ef\u81f4\u7684\u8166\u4e2d\u98a8\u7684\u6cbb\u7642\u6307\u5f15\uff0c\u5f9e2014 AHA/ACC,2016 ESC \u53ca2016 CCS\u3002\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u6307\u5f15\u4e3b\u5f35\uff0c\u7528\u4ee5\u9810\u9632Af-related stroke?\nA. Aspirin\u6c92\u6709\u9810\u9632\u8166\u4e2d\u98a8\u7684\u89d2\u8272\u3002\nB. AF\u75c5\u4eba\u7684CHA2DS2-VASc\u8a08\u52060\u5206(\u7537)\u6216\u4f4e\u65bc1\u4ee5\u4e0b(\u5973)\uff0c\u5f97\u4e0d\u7528\u6297\u51dd\u8840\u85e5\u7269\u3002\nC. \u4f34\u6709\u814e\u529f\u80fd\u5931\u5168\u7684AF\u5f97\u7528Apixaban\u3002\nD. Apixaban, Edoxaban, \u53caDabigatran 110 mg \u8f03\u591a\u8166\u5167\u51fa\u8840\u3002\nE. \u6b63\u5e38\u74e3\u819c\u6027\u6216\u975e\u74e3\u819c\u6027(Native or non-valvular)AF\u90fd\u5f97\u4f7f\u7528Warfarin \u53caNon-Vitamin K antagonist oral anticoagulation (NOAC)\n": "(D)", "106-8.\n\u4e0b\u5217\u6709\u95dc\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e(Infective endocarditis\uff0cIE)\u7684\u65b0\u8ad6\u8aaa\u6cd5\uff0c\u4e0d\u662f\u6b63\u78ba\u7684\uff1f\nA. \u8fd1\u5e74IE\u591a\u898b\u65bc\u4e94\u5341\u6b72\u5f8c\u7684\u4e2d\u8001\u4eba\uff0c\u4e14\u4ee5\u7537\u6027\u70ba\u591a\u3002\nB. \u88fd\u9020\u4e82\u6d41\u7684\u5fc3\u81df\u7570\u5e38\u7d50\u69cb\uff0c\u5c0e\u81f4\u5fc3\u5167\u819c\u50b7\u8b8a\uff0c\u805a\u7d50\u8840\u5c0f\u677f\u3001\u7e96\u7dad\u7d20\u5f62\u6210\u7121\u83cc\u8d05\u751f\u7269\uff0c\u518d\u7d50\u5408\u83cc\u8840\u75c7\u53ca\u7d30\u83cc\u6027\u884d\u751f\u548c\u4fb5\u900f\u6027\u7d44\u7e54\u8b8a\u5316\u662f\u91cd\u8981\u7684\u75c5\u7406\u751f\u7406\u5b78\u3002\nC. \u5178\u578b\u7684Osler nodes, Janeway\u6216 Roth spots\u5728\u7576\u4eca\u7684\u81e8\u5e8a\u5be6\u4f8b\u4e26\u4e0d\u591a\u898b\u3002\nD. \u5178\u578b\u7684\u967d\u6027\u83cc\u682a\u7d30\u83cc\u57f9\u990a\u5982Streptococcus\u3001 Staphylococcus \u6216HACEK \u8981\u6709\u4e8c\u5957\uff1b\u5176\u4ed6\u6301\u7e8c\u6027\u83cc\u8840\u57f9\u990a\u8981\u6709\u8ddd\u664212\u5c0f\u6642\u4e8c\u5957\u967d\u6027\uff0c\u6216\u56db\u5957\u4ee5\u4e0a\u57f9\u990a\u6709\u4e09\u5957\u967d\u6027\u3002\nE. \u4efb\u4f55IE\u75c5\u4f8b\u90fd\u61c9\u5feb\u901f\u4f7f\u7528Empirical antibiotics,\u4e0d\u5fc5\u4e45\u7b49\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u7d50\u679c\uff1b\u4f7f\u7528\u6297\u751f\u7d20\u5f8c\u4e09\u5929\u672a\u9000\u71d2\u61c9\u8003\u616e\u66ff\u63db\u6297\u751f\u7d20\u3002\n": "(E)", "106-9.\n\u6839\u636e2016\u5e74\u53f0\u7063\u5fc3\u81df\u5b78\u6703\uff0c\u4ee52013- 2014\u5e74\u767b\u9304\u76841509\u540d\u5931\u511f\u6027\u5fc3\u8870\u7aed(Decompensated systolic heart failure, DSHF) \u7684\u5206\u6790\uff0c\u6709\u4e0b\u5217\u8af8\u591a\u7279\u9ede\uff0c\u4f55\u8005\u9664\u5916?\nA. \u5fc3\u808c\u7f3a\u6c27\u3001\u98f2\u98df\u53ca\u7528\u85e5\u9075\u56d1\u6027\u964d\u4f4e\u3001\u611f\u67d3\u53ca\u814e\u5931\u80fd\u90fd\u662f\u89f8\u767c\u5fc3\u8870\u7aed\u7684\u91cd\u8981\u539f\u56e0\u3002\nB. \u9ad8\u905452.3 %\u7684\u5fc3\u8870\u7aed\u4f34\u6709\u4e2d\u7b49\u5ea6\u548c\u56b4\u91cd\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\u5168(Moderate and severe mitral regurgitation) \u3002\nC. \u53f0\u7063\u7684DSHF\u75c5\u4eba\u9060\u6bd4\u6b50\u3001\u7f8e\u3001\u65e5\u591a\u662f\u8001\u4eba\uff0c\u4e14\u4ee5\u5973\u6027\u75c5\u4eba\u70ba\u591a\u3002\nD. \u53f0\u7063\u7684DSHF\u75c5\u4eba\u8f03\u5c11\u6709\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation) \u53ca\u9ad8\u8840\u58d3\u3002\nE. \u81e8\u5e8a\u91ab\u5e2b\u5c0d\u53f0\u7063\u7684DSHF\u75c5\u4eba\u8f03\u5c11\u4f7f\u7528mineralocorticoid receptor antagonists\u53caBeta-blockers\u3002\n": "(C)", "106-10.\n\u75c5\u4eba68\u6b72\u7537\u6027\uff0c\u6709\u591a\u5e74\u7cd6\u5c3f\u75c5\u53ca\u9ad8\u8840\u58d3\uff0c\u6cbb\u7642\u4e2d\u3002\u6709\u5bb6\u65cf\u51a0\u5fc3\u75c5\u3002\u5728\u6e05\u6668\u5065\u8eab\u8d70\u8def\u6642\uff0c\u7a81\u7136\u80f8\u60b6\uff0c\u6301\u7e8c\u4e09\u500b\u591a\u5c0f\u6642\uff0c\u4e43\u6025\u8a3a\u8655\u6c42\u91ab\u3002\u6642T/P/R: 36/75/20;BP: 148/85 mmHg\uff0c\u5176\u4ed6\u8eab\u9ad4\u6aa2\u67e5\u672a\u898b\u91cd\u5927\u7570\u5e38\u3002\u5176\u80f8\u90e8X\u5149\u53ca\u5fc3\u96fb\u5716\u5982\u5716\uff0c\u751f\u5316\u53ca\u8840\u6db2\u6aa2\u67e5\u5982\u8868\u3002\u8acb\u554f\u672c\u75c5\u4f8b\u6700\u53ef\u80fd\u7684\u6b63\u78ba\u8a3a\u65b7: (1)STEMI\uff1b(2)NSTEMI ACS\uff1b (3)RCA occlusion\uff1b(4) LAD occlusion\uff1b(5)Inferior wall MI\uff1b(6)Postero-inferior wall MI\nA. (1)+(3)+(5)\nB. (1)+(3)+(6)\nC. (2)+(3)+(5)\nD. (2)+(3)+(6)\nE. (2)+(4)+(6)\n": "(B)", "106-11.\n\u6709\u95dc\u6025\u6027\u4e3b\u52d5\u8108\u75c7\u5019\u7fa4(Acute aortic syndrome)\u7684\u63cf\u8ff0,\u4f55\u8005\u70ba\u8aa4?\nA. \u6025\u6027\u4e3b\u52d5\u8108\u58c1\u5167\u8840\u816b(intraluminal hematoma)\u6210\u56e0\u662f\u71df\u990a\u7ba1\u58c1\u7684\u5c0f\u8840\u7ba1(vasa vasorum)\u7834\u88c2\u6240\u81f4\nB. \u6025\u6027\u4e3b\u52d5\u8108\u58c1\u5167\u8840\u816b\u4e3b\u8981\u767c\u751f\u65bc\u5347\u4e3b\u52d5\u8108 (ascending aorta)\nC. \u7a7f\u900f\u6027\u7ca5\u72c0\u52d5\u8108\u786c\u5316\u6f70\u760d(penetrating atherosclerotic ulcer)\u6210\u56e0\u662f\u7ca5\u72c0\u52d5\u8108\u786c\u5316\u6591\u584a\u4fb5\u8755\u81f3\u4e3b\u52d5\u8108\u58c1\u4e2d\u819c (aortic media)\nD. \u7a7f\u900f\u6027\u7ca5\u72c0\u52d5\u8108\u786c\u5316\u6f70\u760d\u5e38\u767c\u751f\u65bc\u964d\u80f8\u4e3b\u52d5\u8108\u7684\u4e2d\u7aef\u8207\u9060\u7aef\u90e8(middle and distal portions of descending thoracic aorta)\nE. \u6025\u6027\u4e3b\u52d5\u8108\u58c1\u5167\u8840\u816b\u53ef\u4ee5\u6f14\u8b8a\u6210\u4e3b\u52d5\u8108\u525d\u96e2\u751a\u81f3\u7834\u88c2\n": "(B)", "106-12.\n\u4e00\u4f4d60\u6b72\u5973\u6027\u6709\u80ba\u764c\u75c5\u53f2,\u4f86\u5230\u6025\u8a3a\u6642,\u5438\u6c23\u6642\u6536\u7e2e\u58d3\u6bd4\u547c\u6c23\u6642\u6536\u7e2e\u58d3\u4e0b\u964d\u8d85\u904e10mmHg\u4ee5\u4e0a,\u5fc3\u96fb\u5716\u5982\u9644\u5716,\u8acb\u554f\u4f55\u8005\u63cf\u8ff0\u70ba\u8aa4?\nA. \u6b64\u75c5\u4eba\u81e8\u5e8a\u4e0a\u61c9\u6709\u4f4e\u8840\u58d3,\u5fc3\u97f3\u5fae\u5f31,\u8207\u9838\u975c\u8108\u6012\u5f35 (Beck's triad )\nB. \u9838\u975c\u8108\u6ce2\u5f62\u6703\u6709\u660e\u986f\u7684 y descent\nC. \u8eab\u9ad4\u6aa2\u67e5\u6642,\u8a72\u75c5\u60a3\u7121Kussmaul's sign\nD. \u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5982\u5716\nE. \u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u6642\u6703\u51fa\u73fe\u8212\u5f35\u672b\u671f\u53f3\u5fc3\u5ba4\u584c\u9677\u5fb5\u8c61 (right ventricular collapse sign)\n": "(B)", "106-13.\n\u6709\u95dc\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed(Heart failure with preserved ejection fraction)\u7684\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u6839\u64da\u6587\u737b[The Candesartan in Heart Failure-Assessment of Mortality and Morbidity (CHARM) Preserved study], Candesartan \u53ef\u4ee5\u6539\u5584\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u75c5\u60a3\u4e4b\u6240\u6709\u539f\u56e0\u6b7b\u4ea1\u7387(all-cause mortality)\nB. \u6839\u64da\u6587\u737b[ Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial], Irbesartan\u7121\u6cd5\u660e\u986f\u6539\u5584\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u75c5\u60a3\u4e4b\u81e8\u5e8a\u9810\u5f8c\nC. \u6839\u64da\u6587\u737b[Digitalis Investigation Group (DIG) trial],\u6bdb\u5730\u9ec3 (digoxin)\u5728\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u75c5\u60a3\u7684\u6cbb\u7642\u4e0a,\u4e26\u7121\u5e6b\u52a9.\nD. \u6839\u64da\u6587\u737b[Study of The Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure (SENIORS) trial], Nebivolol[\u4e00\u7a2e\u4e59\u72c0\u53d7\u9ad4\u963b\u65b7\u5291 (beta-blocker)] , \u7121\u6cd5\u6539\u5584\u66fe\u56e0\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u4f4f\u9662\u5e74\u9577\u75c5\u60a3\u4e4b\u6240\u6709\u539f\u56e0\u6b7b\u4ea1\u7387(all-cause mortality)\nE. \u6839\u64da\u6587\u737b [the Aldosterone Receptor Blockade in Diastolic Heart Failure (ALDO-DHF) study], Spironolactone \u7121\u6cd5\u6539\u5584\u6b63\u5e38\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u75c5\u60a3\u7684\u904b\u52d5\u91cf,\u5fc3\u8870\u7aed\u75c7\u72c0\u8207\u751f\u6d3b\u54c1\u8cea.\n": "(A)", "106-14.\n\u6709\u95dc\u5229\u7528\u6539\u5584\u751f\u6d3b\u6a21\u5f0f(Life Style Modification)\u4ee5\u9054\u6210\u9ad8\u8840\u58d3\u63a7\u5236\u76ee\u7684\u63cf\u8ff0,\u4f55\u8005\u70ba\u8aa4?(1)\u9ad4\u91cd\u4e0b\u964d9.2\u516c\u65a4,\u7d04\u53ef\u4ee5\u4e0b\u964d\u6536\u7e2e\u58d316.3 mmHg\uff1b(2)\u9ad4\u91cd\u4e0b\u964d9.2\u516c\u65a4,\u7d04\u53ef\u4ee5\u964d\u4f4e\u8212\u5f35\u58d33.1 mmHg\uff1b(3)\u9650\u5236\u98df\u9e7d(NaCl)\u6bcf\u65e5\u651d\u53d6\u91cf4.4~7.4 \u514b[75~125meq],\u53ef\u4ee5\u4e0b\u964d\u6536\u7e2e\u58d3\u7d043.7~4.9 mmHg\uff1b(4)\u9650\u5236\u98df\u9e7d(NaCl)\u6bcf\u65e5\u651d\u53d6\u91cf4.4~7.4\u514b[75~125meq],\u53ef\u4ee5\u4e0b\u964d\u8212\u5f35\u58d3\u7d040.9~2.9 mmHg\uff1b(5)\u6839\u64da\u6587\u737b\u300cDietary Approaches to Stop Hypertension (DASH) trial\u300d,\u98df\u7528\u5bcc\u542b\u6c34\u679c,\u852c\u83dc\u8207\u9ad8\u6cb9\u8102\u985e\u98df\u7269\u6709\u52a9\u65bc\u6539\u5584\u8f15\u75c7\u9ad8\u8840\u58d3\u60a3\u8005\u8840\u58d3\u63a7\u5236\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(5)\nD. (3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "106-15.\n\u6709\u95dc\u8840\u58d3\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u817f(leg)\u7684\u6536\u7e2e\u58d3\u901a\u5e38\u6bd4\u4e0a\u81c2(upper arm)\u7684\u6536\u7e2e\u58d3\u9ad8 20 mmHg\nB. \u817f\u8207\u4e0a\u81c2\u7684\u8840\u58d3\u5dee\u589e\u52a0\u5e38\u898b\u65bc\u91cd\u5ea6\u4e3b\u52d5\u8108\u9589\u9396\u4e0d\u5168(aortic regurgitation)\u6216\u56b4\u91cd\u4e0b\u80a2\u9031\u908a\u8840\u7ba1\u75be\u75c5\nC. \u56b4\u91cd\u4e3b\u52d5\u8108\u9589\u9396\u4e0d\u5168\u60a3\u8005,\u8212\u5f35\u58d3\u6e2c\u91cf\u503c\u6709\u53ef\u80fd\u70ba0 \u6beb\u7c73\u6c5e\u67f1\nD. \u5169\u5074\u4e0a\u81c2\u7684\u6536\u7e2e\u8840\u58d3\u5dee,\u6b63\u5e38\u572810\u6beb\u7c73\u6c5e\u67f1\u4ee5\u5167\nE. \u59ff\u52e2\u6027\u4f4e\u8840\u58d3(Orthostatic hypotension)\u7684\u5b9a\u7fa9\u70ba:\u5f9e\u81e5\u59ff(supine position)\u8b8a\u70ba\u7acb\u59ff(upright posture)\u4e09\u5206\u9418\u5167,\u6536\u7e2e\u58d3\u4e0b\u964d15\u6beb\u7c73\u6c5e\u67f1\u6216\u8212\u5f35\u58d3\u4e0b\u964d5\u6beb\u7c73\u6c5e\u67f1\n": "(E)", "106-16.\n\u6709\u95dc\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84(mitral stenosis)\u7684\u63cf\u8ff0,\u4f55\u8005\u70ba\u8aa4?\nA. \u7576\u4e8c\u5c16\u74e3\u819c\u9762\u7a4d\u964d\u81f31~1.5\u5e73\u65b9\u516c\u5206\u6642,\u975c\u6b62\u72c0\u614b\u4e0b\u4e4b\u5fc3\u8f38\u51fa\u91cf(cardiac output)\u63a5\u8fd1\u6b63\u5e38\nB. \u7576\u4e8c\u5c16\u74e3\u819c\u9762\u7a4d\u5c0f\u65bc1\u5e73\u65b9\u516c\u5206\u6642,\u975c\u6b62\u72c0\u614b\u4e0b\u4e4b\u5fc3\u8f38\u51fa\u91cf\u4fbf\u5df2\u7d93\u4f4e\u65bc\u6b63\u5e38(subnormal)\nC. \u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u665a\u671f\u7684\u75c5\u4eba,\u53cd\u8986\u6027\u80ba\u52d5\u8108\u6813\u585e (recurrent pulmonary embolization)\u4e0d\u662f\u9020\u6210\u7f79\u75c5\u8207\u6b7b\u4ea1(morbidity and mortality)\u7684\u91cd\u8981\u539f\u56e0\u4e4b\u4e00\nD. \u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u5408\u4f75\u5fc3\u623f\u986b\u52d5\u7684\u75c5\u4eba,\u5168\u8eab\u6027\u6813\u585e(systemic embolization) \u7684\u767c\u751f\u7387(incidence)\u70ba10~20%\nE. \u8f15\u5ea6\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u4e14\u81e8\u5e8a\u7121\u75c7\u72c0\u7684\u75c5\u4eba,\u5168\u8eab\u6027\u6813\u585e\u6709\u53ef\u80fd\u662f\u81e8\u5e8a\u51fa\u73fe\u7684\u8868\u5fb5 (presenting feature)\n": "(C)", "106-17.\n\u4e00\u540d30\u6b72\u7537\u6027\u5230\u9580\u8a3a\u6c42\u8a3a;\u7121\u5fc3\u60b8\u6642\u9580\u8a3a\u5fc3\u96fb\u5716\u5982\u9644\u5716A,\u5fc3\u60b8\u6642\u5fc3\u96fb\u5716\u5982\u9644\u5716B. \u8acb\u554f\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?(1)\u9644\u5716A \u5fc3\u96fb\u5716\u5448\u73fe\u7e2e\u77ed\u7684PR\u9593\u8ddd (shortened PR interval)\uff1b(2)\u9644\u5716A\u5fc3\u96fb\u5716\u5448\u73fe Epsilon \u6ce2 (Epsilon wave)\uff1b(3)\u9644\u5716B\u70ba\u5fc3\u5ba4\u983b\u8108 (ventricular tachycardia)\uff1b(4)\u7576\u75c5\u4eba\u5fc3\u60b8\u5448\u73fe\u9644\u5716B\u4e4b\u5fc3\u5f8b\u4e0d\u6574\u6642,\u4e0d\u53ef\u4ee5\u65bd\u6253verapamil\uff1b(5)\u7576\u75c5\u4eba\u5fc3\u60b8\u5448\u73fe\u9644\u5716B\u4e4b\u5fc3\u5f8b\u4e0d\u6574\u6642,\u53ef\u4ee5\u65bd\u6253adenosine\nA. (1)+(5)\nB. (2)+(4)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)\nE. (2)+(3)+(5)\n": "(E)", "106-18.\n\u6839\u64da\u7d71\u5408\u5206\u6790(meta-analysis),\u904b\u52d5\u5fc3\u96fb\u5716\u7684\u654f\u611f\u5ea6(sensitivity)\u70ba66%, \u5c08\u4e00\u5ea6(specificity)\u70ba84%. \u6709\u4e00\u4f4d\u75c5\u60a3\u4e4b\u51a0\u5fc3\u75c7\u6e2c\u524d\u6a5f\u7387(pretest probability)\u70ba10%; \u8acb\u554f\u6839\u64da\u8c9d\u6c0f\u5b9a\u7406 (Bayes' Rule), \u7576\u904b\u52d5\u5fc3\u96fb\u5716\u5448\u967d\u6027\u7d50\u679c\u6642,\u8a72\u75c5\u60a3\u4e4b\u6e2c\u5f8c\u6a5f\u7387(posttest probability)\u7d04\u70ba?\nA. 95%\nB. 70%\nC. 50%\nD. 30%\nE. 10%\n": "(D)", "106-19.\n\u6709\u95dcHACEK(Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae) \u5fc3\u5167\u819c\u767c\u708e\u7684\u63cf\u8ff0,\u4f55\u8005\u70ba\u8aa4?\nA. \u9019\u4e9b\u683c\u862d\u6c0f\u9670\u6027\u7d30\u83cc\u7684\u57f9\u990a\u74b0\u5883\u9700\u8981\u4e8c\u6c27\u5316\u78b3\nB. \u6700\u5e38\u4fb5\u72af\u4e3b\u52d5\u8108\u74e3\u8207\u4e8c\u5c16\u74e3(mitral valve)\nC. \u8207\u975eHACEK\u611f\u67d3\u4e4b\u5fc3\u5167\u819c\u708e(Non-HACEK endocarditis)\u6bd4\u8f03, HACEK\u5fc3\u5167\u819c\u708e\u8f03\u4e0d\u5bb9\u6613\u7522\u751f\u6813\u585e (embolization)\nD. \u7d04\u670985%\u7684HACEK\u5fc3\u5167\u819c\u708e\u75c5\u60a3\u505a\u5fc3\u81df\u8d85\u97f3\u6ce2\u6642,\u53ef\u4ee5\u898b\u5230\u8d05\u751f\u7269(vegetation)\nE. \u96a8\u8457\u57f9\u990a\u6280\u8853\u7684\u6539\u826f,\u5927\u90e8\u5206HACEK\u7d30\u83cc\u7684\u57f9\u990a,\u4e00\u822c\u5728\u7b2c\u4e00\u9031\u4fbf\u6703\u5448\u73fe\u967d\u6027.\n": "(C)", "106-20.\n\u4e00\u4f4d42\u6b72\u5973\u6027\u75c5\u60a3,\u4e3b\u8a34\u8eba\u81e5\u6642\u67d0\u7279\u5b9a\u59ff\u52e2\u6703\u4f34\u96a8\u773c\u524d\u767c\u9ed1\u7684\u5fb5\u5146(black out)\u3002\u81e8\u5e8a\u4e0a\u75c7\u72c0\u9084\u5305\u62ec\u5026\u6020,\u9ad4\u91cd\u6e1b\u8f15\u8eab\u9ad4\u6aa2\u67e5\u6642,\u5fc3\u81df\u807d\u8a3a\u65bc\u5fc3\u5c16\u90e8\u8212\u5f35\u4e2d\u671f\u6709\u4e00\u4f4e\u983b\u5fc3\u97f3,\u4e26\u6709\u8f15\u5fae\u6775\u72c0\u6307 (digital clubbing)\u3002\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5982\u9644\u5716,A\u5716\u70ba\u5fc3\u5ba4\u6536\u7e2e\u671f\u5448\u50cf,B\u5716\u70ba\u5fc3\u5ba4\u8212\u5f35\u671f\u5448\u50cf [RA=\u53f3\u5fc3\u623f;RV=\u53f3\u5fc3\u5ba4;LV=\u5de6\u5fc3\u5ba4]\u3002\u8acb\u554f\u8a72\u75c5\u60a3\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba?\nA. \u98a8\u6fd5\u6027\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84(Rheumatic mitral stenosis)\nB. \u5de6\u5fc3\u5ba4\u5047\u6027\u5ba4\u58c1\u7624(left ventricular pseudoaneurysm)\nC. \u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e\u5408\u4f75\u4e8c\u5c16\u74e3\u8d05\u751f\u7269(mitral vegetation)\nD. \u5de6\u5fc3\u623f\u9ecf\u6db2\u7624 (left atrial myxoma)\nE. \u809d\u7d30\u80de\u764c\u5408\u4f75\u53f3\u5fc3\u623f\u8f49\u79fb\n": "(D)", "106-21.\n\u4e0b\u5217\u54ea\u4e9b\u4e59\u72c0\u53d7\u9ad4\u963b\u65b7\u5291(beta-blocker)\u53ef\u4ee5\u7528\u4f86\u6539\u5584\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed (heart failure with reduced ejection fraction)\u4e4b\u9810\u5f8c?(1)carvedilol\uff1b(2)bisoprolol\uff1b(3)metoprolol succinate\uff1b(4)xamoterol\uff1b(5)propranolol\nA. (3)+(4)+(5)\nB. (1)+(2)+(3)\nC. (1)+(2)+(5)\nD. (2)+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(B)", "106-22.\n\u6709\u95dc\u6025\u6027\u5fc3\u808c\u6897\u585e\u5f8c\u5fc3\u5ba4\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u5728\u6025\u6027\u5fc3\u808c\u6897\u585e\u767c\u751f24\u5c0f\u6642\u5167,\u75c5\u60a3\u5e38\u5e38\u7121\u9810\u8b66\u7684\u767c\u751f\u5fc3\u5ba4\u983b\u8108(ventricular tachycardia) \u6216\u5fc3\u5ba4\u986b\u52d5 (ventricular fibrillation)\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e\u767c\u751f24\u5c0f\u6642\u5167,\u5373\u4f7f\u672a\u767c\u751f\u5fc3\u5ba4\u5fc3\u5f8b\u4e0d\u6574,\u4ecd\u61c9\u5e38\u898f\u9810\u9632\u6027\u7d66\u4e88\u75c5\u60a3lidocaine\nC. \u6025\u6027\u5fc3\u808c\u6897\u585e48\u5c0f\u6642\u5f8c,\u5982\u679c\u75c5\u60a3\u56e0\u5fc3\u81df\u8870\u7aed\u800c\u767c\u751f\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u986b\u52d5;\u5176\u4f4f\u9662\u6b7b\u4ea1\u7387\u6216\u9577\u671f\u8ffd\u8e64\u4e4b\u6b7b\u4ea1\u7387\u5747\u589e\u52a0\nD. Torsades des pointes \u9019\u7a2e\u5fc3\u5ba4\u983b\u8108,\u53ef\u4ee5\u5728\u6025\u6027\u5fc3\u808c\u6897\u585e\u5f8c\u767c\u751f\nE. \u6025\u6027\u5fc3\u808c\u6897\u585e\u5f8c\u767c\u751f\u4e4b\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u986b\u52d5,\u5982\u679c\u5c0d\u96fb\u64ca(electroshock)\u7121\u6548\u6642,\u7d66\u4e88\u75c5\u60a3amiodarone, \u6709\u53ef\u80fd\u6539\u5584\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u986b\u52d5\u5c0d\u96fb\u64ca\u6cbb\u7642\u7684\u53cd\u61c9\n": "(B)", "107-1.\n\u6709\u95dc\u5fc3\u56e0\u6027\u4f11\u514b (cardiogenic shock) \u7684\u81e8\u5e8a\u8a8d\u77e5\uff0c \u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684\uff1f\nA. \u5fc3\u56e0\u6027\u4f11\u514b\u8d85\u904e50%\u767c\u751f\u5728\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7\u7684\u7b2c\u4e00\u5929\uff0c\u5176\u5f8c\u7684\u4f11\u514b\u591a\u8207\u5fc3\u808c\u6897\u585e\u64f4\u5927\u3001\u5fc3\u8870\u7aed\u6216\u6a5f\u68b0\u6027\u4f75\u767c\u75c7\u6709\u95dc\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7\u767c\u751f\u5fc3\u56e0\u6027\u4f11\u514b\u6642\uff0c\u5118\u65e9\u63a1\u7528\u4e3b\u52d5\u8108\u5167\u6c23\u7403\u5e6b\u6d66\u7642\u6cd5(Intra-aortic balloon counter-pulsation)\uff0c\u624d\u80fd\u964d\u4f4e\u6b7b\u4ea1\u7387\nC. \u53f3\u5fc3\u5ba4\u5fc3\u808c\u6897\u585e\u5408\u4f75\u4f11\u514b\u61c9\u7a4d\u6975\u4f7f\u7528\u5152\u8336\u915a\u80fa (catecholamine)\uff0c\u66a2\u901a\u6813\u585e\u8840\u7ba1\u53ca\u5145\u5206\u6c34\u5206\u88dc\u91cf\nD. \u5fc3\u5ba4\u4e2d\u9694\u7834\u640d(ventricular septal rupture) \u7684\u4f11\u514b\u591a\u767c\u751f\u5728\u5fc3\u808c\u6897\u585e\u5f8c\u6578\u5929\uff0c\u800c\u975e\u6975\u65e9\u7684\u6578\u5c0f\u6642\u5167\nE. \u904e\u534a\u7684\u5fc3\u56e0\u6027\u4f11\u514b\u591a\u56e0\u524d\u58c1\u5fc3\u808c\u6897\u585e\u800c\u8d77\n": "(B)", "107-2.\n\u88dd\u7f6e\u690d\u5165\u5f0f\u53bb\u986b\u5668(Implantable Cardioverter Defibrillator, ICD) \u53ef\u521d\u7d1a\u9810\u9632 (primary prevention)\u5fc3\u731d\u6b7b (Sudden Cardiac Death, SCD) \u7684\u767c\u4f5c\uff0c\u552f\u4e0b\u5217\u4f55\u8005\u4e4b\u8655\u7f6e\u4e0d\u7b26\u5408\u5be6\u8a3c\u91ab\u5b78\uff1f\nA. \u6025\u6027\u5fc3\u808c\u6897\u585e40\u5929\u5f8c\uff0c\u75c5\u4eba\u67092-3\u7d1aNYHA Heart failure\u4e4b\u75c7\u72c0\uff0c\u4e14\u5de6\u5fc3\u5ba4\u5c04\u51fa\u7387 (Left Ventricular Ejection Fraction, LVEF) <=35%\nB. \u6025\u6027\u5fc3\u808c\u6897\u585e40\u5929\u5167\u7684\u75c5\u4eba\u5982\u6709\u975e\u6301\u7e8c\u6027\u5fc3\u5ba4\u983b\u8108\r\n(non-sustained ventricular tachycardia), LVEF <40%\u53ca\u96fb\u8a98\u6301\u7e8c\u6027\u5fc3\u5ba4\u983b\u8108 (sustained VT) \u5f97\u88dd\u7f6eICD\nC. \u516d\u5341\u6b72\u75c5\u4eba\u51a0\u72c0\u52d5\u8108\u7e5e\u9053\u624b\u8853\u4e00\u500b\u6708\u5167\uff0cLVEF < 35%\nD. \u975e\u7f3a\u8840\u6027\u64f4\u5927\u6027\u5fc3\u808c(dilated cardiomyopathy)\u75c5\u4eba\u5176LVEF <= 35% \u76842-3\u7d1aNYHA\u5fc3\u8870\u7aed\uff0c\u85e5\u7269\u6cbb\u7642\u4e2d\nE. \u80a5\u539a\u6027\u5fc3\u808c\u75c5\u4f75\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u4eba\uff0c\u4e14\u6709\u975e\u6301\u7e8c\u6027\u5fc3\u5ba4\u983b\u8108\u8a18\u9304\n": "(C)", "107-3.\n\u6709\u95dc\u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (atrial fibrillation, AF) \u7684\u81e8\u5e8a\u89c0\u5bdf\uff0c\u4e0b\u5217\u4f55\u7d44\u7684\u6558\u8ff0\u662f\u6b63\u78ba\u7684\uff1f(1).\tAF\u767c\u4f5c\u6642\u9593\u4e0d\u660e\u6216\u5927\u65bc\u4e8c\u65e5\uff0c\u61c9\u5728\u96fb\u64ca(electric cardioversion)\u524d\u5c31\u555f\u7528\u6297\u51dd\u8840\u85e5\u7269\uff0c\u4ee5\u9632\u8840\u6813\u7684\u7a81\u767c (2).\t\u4e8c\u5c16\u74e3\u72f9\u7a84(mitral stenosis)\u4f75\u6709AF\u7684\u75c5\u4eba\u50c5\u53eawarfarin\u6cbb\u7642\u6709\u6548 (3). warfarin\u9060\u6bd4aspirin + clopidogrel\u66f4\u80fd\u9810\u9632AF\u76f8\u95dc\u8166\u4e2d\u98a8 (4). \u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269\u9060\u6bd4wafarin\u5b89\u5168\u6709\u6548 (5).\tAF\u7d93\u96fb\u64ca\u56de\u5fa9\u6b63\u5e38\u5fc3\u5f8b\uff0c\u81f3\u5c11\u61c9\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269\u56db\u9031\uff0c\u5176\u5f8c\u4f9d\u7167CHADS2-VASc\u6c7a\u5b9a\u6297\u51dd\u8840\u85e5\u7269\u4e4b\u4f7f\u7528\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(2)+(5)\nD. (2)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "107-4.\n\u6709\u95dcST\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e(ST Elevation Myocardial Infarction,STEMI)\u7684\u81e8\u5e8a\u6240\u898b\uff0c\u4e0b\u5217\u4f55\u8005\u8a18\u8ff0\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u75c5\u4eba\u4f4f\u966248\u5c0f\u6642\u5f8c\u5982\u4f75\u5fc3\u5ba4\u6027\u986b\u52d5\u6216\u983b\u8108\uff0c\u5728\u5f8c\u4f86\u7684\u75c5\u7a0b\u6703\u6709\u6975\u9ad8\u7684\u6b7b\u4ea1\u7387\uff0c\u61c9\u7a4d\u6975\u96fb\u6c23\u751f\u7406\u6aa2\u67e5\u53ca\u7f6e\u653e\u690d\u5165\u5f0f\u53bb\u986b\u5668(Implantable Cardioverter Defibrillator)\nB. \u5fc3\u5ba4\u6027\u986b\u52d5\u591a\u767c\u751f\u5728\u6025\u75c5\u5f8c\u7b2c\u4e00\u5929\uff0c\u6709\u904e\u534a\u5728\u7b2c\u4e00\u5c0f\u6642\uff0c\u662f\u9662\u5916\u6025\u6027\u731d\u6b7b\u7684\u4e3b\u56e0\nC. STEMI\u662f\u5fc3\u96fb\u5716\u8a3a\u65b7\uff0c\u5176\u75c5\u7406\u751f\u7406\u7684\u610f\u7fa9\u662f\u8840\u7ba1\u5b8c\u5168\u963b\u585e(complete occlusion)\uff0c\u4e14\u662f\u5fc3\u5ba4\u5fc3\u808c\u7684\u5168\u58c1\u58de\u6b7b(transmural necrosis)\nD. \u80a5\u539a(thick)\u7684\u8102\u8cea\u6838\u5fc3\u6591\u584a(lipid core plaque)\u8f03\u6613\u7834\u88c2\uff0c\u4ee5\u81f4STEMI\u7684\u767c\u751f\nE. \u6025\u6027\u5fc3\u808c\u6897\u585e\u767c\u4f5c\u4e00\u5c0f\u6642\u5167, \u524d\u58c1\u6897\u585e\u67091/4\u4f34\u767c\u5feb\u8df3\u53ca\u9ad8\u8840\u58d3\u7684\u4ea4\u611f\u795e\u7d93\u4ea2\u5f35\uff0c\u800c\u4e0b\u58c1\u6897\u585e\u67091/2\u6703\u6709\u6162\u8df3\u53ca\u4f4e\u8840\u58d3\u7684\u526f\u4ea4\u611f\u795e\u7d93\u4ea2\u5f35\n": "(D)", "107-5.\n\u80ba\u52d5\u8108\u9ad8\u58d3\uff08pulmonary hypertension)\u7684\u75c7\u72c0\u4e0d\u4e00\uff0c\u9032\u5c55\u7de9\u6162\uff0c\u81e8\u5e8a\u8a3a\u7642\u6700\u6613\u5ffd\u7565\uff0c\u552f\u65e9\u671f\u75c5\u7a0b\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u662d\u7136\u82e5\u63ed\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u8a3a\u5bdf\u8981\u9ede\uff1f\nA. \u9838\u975c\u8108\u6d6e\u5f35\u3001\u4e0b\u80a2\u6c34\u816b\u53ca\u8179\u6c34\nB. P2\u5fc3\u97f3\u91cd\u97ff\uff08accentuation\uff09\u53ca\u53f3\u5fc3S3\u6216S4\nC. \u6709\u4e09\u5c16\u74e3\u9589\u9396\u4e0d\u5168\u7684\u5168\u5fc3\u7e2e\u671f\u96dc\u97f3\u53ef\u805e\nD. \u5de6\u5fc3\u5ba4\u58d3\u529b\u904e\u5ea6\u8ca0\u8f09\uff08left ventricular pressure overloading\uff09\nE. \u6bdb\u7d30\u7ba1\u64f4\u5f35\uff08telangiectasia\uff09\u3001\u767c\u7d3a\uff08clubbing\uff09\u6216\u786c\u76ae\u75c7\uff08sclerodactylia)\n": "(D)", "107-6.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u81df\u96fb\u98a8\u66b4\uff08electrical storm\uff09\u7684\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u7642\u6cd5\u662f\u4e0d\u9700\u8981\u7684\uff1f\nA. \u6025\u7528beta-blocker, amiodarone, lidocaine\nB. \u5fc3\u96fb\u5716\u5448\u73feQT prolongation \u76f8\u95dc\u7684 torsade de pointes \u6642\u53ef\u7528\u975c\u6ce8magnesium\nC. \u6c92\u6709QT prolongation \u7684\u96fb\u98a8\u66b4\u53ef\u4ee5quinidine \u6216isoproterenol\u6cbb\u7642\nD. \u53ef\u63a1\u7528\u5de6\u661f\u72c0\u795e\u7d93\u7d50\u7bc0\u5207\u65b7\u8853(left satellite ganglion block)\nE. \u61c9\u4f7f\u7528\u5de6\u5fc3\u5ba4\u8f14\u52a9\u5668(left ventricular assist device)\n": "(E)", "107-7.\n76\u6b72\u8001\u5148\u751f\u56e0\u6709\u4e00\u500b\u6708\u547c\u5438\u56f0\u96e3\u53ca\u5de6\u4e0b\u8173\u6c34\u816b\u800c\u4f4f\u9662\uff0c\u75c7\u72c0\u56e0\u7528\u529b\u5de5\u4f5c\u800c\u52a0\u5287\uff0c\u8981\u4f11\u606f\u624d\u80fd\u7de9\u89e3\uff0c\u8a3a\u9593\u767c\u73fe\u5de6\u9838\u6709\u816b\u584a\u53ca\u5de6\u9838\u975c\u8108\u6012\u5f35\uff0c\u540c\u6642\u8072\u555e\u72c0\u3002BP:179/79 mmHg; VR:76/min; RR:18/min; SpO2=93%\uff0c\u5fc3\u5c16\u8655\u6709Gr 2/6 systolic murmur;\u80ba\u90e8\u6b63\u5e38\u547c\u5438\u8072\uff0c\u96d9\u4e0b\u80a2\u6c34\u816b\uff0c\u5de6\u908a\u6bd4\u53f3\u908a\u56b4\u91cd\u3002\u8840\u6db2\u6c23\u9ad4\u5206\u6790\u986f\u793a pH\uff1a7.384; pO2: 87.8mmHg; pCO2\uff1a46.7 mmHg; HCO3\uff1a27.2 mmol/L\u3002\u4f4f\u9662\u8840\u6db2\u6aa2\u67e5\uff1aWBC\uff1a3.77x10*3/uL; RBC\uff1a5.1x10*6/uL; Hb:16.4 gm/dL; Platelet: 49x10*3/ul; (\u8a73\u898b\u9644\u8868)\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u3002\u5fc3\u81df\u8d85\u97f3\u6ce2\u986f\u793a\uff1aLVEDD 56mm; LVESD 34mm; LVEF: 70%; LA:\r40mm; TR max PG: 35 mmHg; \u9838\u7624\u5207\u7247\u6aa2\u67e5\u75c5\u7406\u8a3a\u65b7\uff1aLymphoma\u3002\r\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u81e8\u5e8a\u8a3a\u65b7\uff1f\nA. Acute myocardial infarction\nB. May-Thurner syndrome with pulmonary thromboembolism\nC. Thoracic aortic dissection\nD. Tumor-associated hypercoagulopathy and pulmonary embolism.\nE. Hypertensive cardiovascular disease with HFpEF\n": "(D)", "107-8.\n\u6709\u95dc\u5fc3\u5167\u819c\u708e\u7684\u81e8\u5e8a\u8a3a\u7642\u8aaa\u6cd5\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u8840\u6db2\u7d30\u83cc\u57f9\u990a\u81f3\u5c11\u9700\u8981\u67093~4\u6b21\u4ee5\u4e0a\u5728\u4e0d\u540c\u4f4d\u7f6e\u7684\u8840\u7ba1\u63a1\u8840\uff0c\u4e14\u7b2c\u4e00\u53ca\u6700\u5f8c\u4e00\u6b21\u81f3\u5c11\u9593\u9694\u4e00\u5c0f\u6642\nB. \u5148\u5929\u6027\u5fc3\u81df\u75c5\u3001\u5fc3\u74e3\u819c\u7f6e\u653e\u624b\u8853\u5f8c\u6216\u6709\u5fc3\u5167\u819c\u708e\u75c5\u53f2\u8005\u9032\u884c\u690d\u7259\u624b\u8853\u6642\uff0c\u5b9c\u6709\u9810\u9632\u6027\u6297\u751f\u7d20\u6cbb\u7642\nC. S. aureus \u53caCoagulase negative staphylococcus \u4e0d\u61c9\u50c5\u53ea\u4f7f\u7528methicillin \u6cbb\u7642\nD. \u8840\u6813\u75c7\u72c0\u662f\u5fc3\u5167\u819c\u708e\u7684\u8a3a\u65b7\u91cd\u9ede\uff0c\u5176\u767c\u751f\u90fd\u5728\u6cbb\u7642\u524d\u767c\u751f\uff0c\u76e1\u65e9\u4f7f\u7528\u6709\u6548\u6297\u751f\u7d20\u5c31\u4e0d\u6703\u767c\u751f\u6b64\u4f75\u767c\u75c7\nE. \u5fc3\u5167\u819c\u708e\u4f75\u767c\u8166\u6813\u585e\u61c9\u67094-6\u9031\u6297\u751f\u7d20\u4f7f\u7528\uff0c\u624d\u53ef\u9032\u884c\u5fc5\u8981\u7684\u5916\u79d1\u624b\u8853\n": "(D)", "107-9.\n\u4f9d\u7167\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u53ca\u53f0\u7063\u9ad8\u8840\u58d3\u5b78\u6703\u65bc2017\u5ea6\u516c\u4f48\u91cd\u9ede\u66f4\u65b0\u9ad8\u8840\u58d3\u6cbb\u7642\u6307\u5f15,\u8acb\u554f\u4ee5\u4e0b\u9805\u76ee\u4f55\u8005\u4e0d\u662f\u53f0\u7063\u91ab\u754c\u964d\u58d3\u76ee\u6a19(Target)\u7684\u4e3b\u5f35\uff1f\nA. \u4e0d\u56e0\u6027\u5225\u6216\u5e74\u9f61\uff0c\u964d\u58d3\u76ee\u6a19\u8a2d\u5728130/80 mmHg\nB. \u521d\u7d1a\u9810\u9632(Primary prevention)\u8a2d\u5728140/90 mmHg \u4ee5\u4e0b\nC. \u8166\u4e2d\u98a8\u75c5\u4eba\u4e4b\u6b21\u7d1a\u9810\u9632(Secondary prevention) \u8a2d\u5728140/90 mmHg \u4ee5\u4e0b\nD. \u7cd6\u5c3f\u75c5\u4eba\u4e4b\u6b21\u7d1a\u9810\u9632\u8a2d\u5728130/80 mmHg\u4ee5\u4e0b\nE. \u51a0\u5fc3\u75c7\u75c5\u4eba\u7684\u6b21\u7d1a\u9810\u9632\u5728130/80  mmHg\u4ee5\u4e0b\n": "(A)", "107-10.\n42\u6b72\u7537\u6027\uff0c\u81ea\u5e74\u8f15\u6642\u5019\u6642\u6709\u611f\u5192\u75c7\u72c0\uff0c\u8fd1\u4f86\u6f38\u6709\u547c\u5438\u56f0\u96e3\uff0c\u9032\u800c\u5c0b\u91ab\u6cbb\u75c5\uff0c\u7d93\u5fc3\u81df\u8d85\u97f3\u6ce2\u8a3a\u65b7\u4e26\u4f4f\u9662\u8655\u7f6e\u3002\u8eab\u9ad4\u6aa2\u67e5: BP\uff1a116/61 mmHg; PR\uff1a61/min; RR\uff1a18/min; \u9838\u975c\u8108\u6b63\u5e38\uff1b\u80ba\u547c\u5438\u97f3\u6b63\u5e38\u6e05\u6f88\uff1b\u5fc3\u81df\u6b63\u5e38\u5927\u5c0f\uff0cS1\u91cd\u97ff\uff0c\u5728\u5fc3\u5c16\u6709 Gr 2-3/6 mid-diastolic murmur \uff1b\u8179\u90e8\u672a\u898b\u809d\u3001\u813e\u816b\u5927\uff1b\u96d9\u817f\u672a\u6709\u6c34\u816b\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u5982\u5716\u3002\u5176\u8840\u6db2\u53ca\u751f\u5316\u6aa2\u67e5\u672a\u6709\u7570\u5e38\u3002\u552f\u5176\u5fc3\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5982\u5716\u3002\u7d93\u904e\u56db\u5929\u904e\u7a0b\u5e73\u9806\u51fa\u9662\u3002\u8acb\u554f\u4e0b\u5217\u6709\u95dc\u672c\u75c5\u4eba\u7684\u8655\u7f6e\u662f\u6b63\u78ba\u7684\uff1f (1). \u75c5\u4eba\u61c9\u4f7f\u7528beta-blocker \u63a7\u5236\u5fc3\u8df3 (2). \u53e3\u670d\u6297\u751f\u7d20\u9810\u9632\u5fc3\u5167\u819c\u708e\u4e4b\u767c\u751f\u662f\u5fc5\u8981\u7684 (3). \u53e3\u670dwarfarin\u8abf\u63a7INR\r(iInternational normalized ratio) \u4ecb\u65bc1\u00b75 -2\u00b75 \u70ba\u5b9c (4). \u6709\u9ad8\u51fa\u8840\u5371\u96aa\u8005\u5f97\u6309\u7167\u5be6\u8a3c\u91ab\u5b78\uff0c\u4f7f\u7528DOAC(direct oral anti-coagulant)   \u9810\u9632\u8840\u6813\u4e4b\u767c\u751f (5). \u672c\u75c5\u4eba\u4ee5\u9580\u8a3a\u8ffd\u8e64\u8655\u7f6e\u5373\u53ef (6). \u672c\u75c5\u4eba\u4ee5\u5916\u79d1\u7d44\u7e54\u74e3\u819c(tissue valve)\u7f6e\u63db\u624b\u8853\u70ba\u5b9c\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(4)+(6)\nD. (2)+(3)+(5)\nE. (2)+(3)+(6)\n": "(A)", "107-11.\n\u7121\u75c7\u72c0\u7684\u4e3b\u52d5\u8108\u74e3\u819c\u9589\u9396\u4e0d\u5168(aortic regurgitation)\uff0c\u53ef\u4f9d\u64da\u5e8a\u908a\u6240\u898b\u5224\u5b9a\u5176\u56b4\u91cd\u5ea6\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u53ef\uff1f\nA. \u5bec\u5927\u8108\u58d3 (pulse pressure)\u8d85\u904e\u5fc3\u7e2e\u8840\u58d3\u4e4b\u534a\u4ee5\u4e0a\nB. high-pitched blowing decrescendo diastolic murmur \u589e\u5f37\nC. \u51fa\u73feAustin-Flint murmur\nD. \u807d\u5230\u9ad8\u5f37\u5ea6\u7684ejection systolic murmur\nE. \u53f3\u5fc3\u5ba4\u5c04\u51fa\u7387\u4f4e\u65bc50% \u6216\u5de6\u5fc3\u5ba4\u5fc3\u7e2e\u76f4\u5f91\u5927\u65bc5cm\u53ca\u5fc3\u8212\u76f4\u5f91\u5927\u65bc6.5cm\n": "(D)", "107-12.\n\u55dc\u927b\u7d30\u80de\u7624(pheochromocytoma)\u53ef\u51fa\u73fe\u5728\u4e0b\u5217\u75c7\u5019\u7fa4\uff0c\u4f55\u8005\u9664\u5916?\nA. \u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624\u75c7\u5019\u7fa4\u7b2c\u4e8c\u578bA (multiple endocrine neoplasia type 2A)\nB. \u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624\u75c7\u5019\u7fa4\u7b2c\u4e8c\u578b B (multiple endocrine neoplasia, type 2B)\nC. \u9022\u5e0c\u4f2f-\u6797\u9053\u75c7\u5019\u7fa4 (von Hippel-Lindau disease)\nD. \u7b2c\u4e00\u578b\u795e\u7d93\u7e96\u7dad\u7624 (neurofibromatosis type 1)\nE. \u7b2c\u4e8c\u578b\u795e\u7d93\u7e96\u7dad\u7624 (neurofibromatosis type 2)\n": "(E)", "107-13.\n\u5c0e\u81f4\u6025\u6027\u5fc3\u808c\u6897\u585e\u7684\u7ca5\u72c0\u52d5\u8108\u786c\u5316\u6591\u584a\u75c5\u7406\u6709\u4e0b\u5217\u7279\u5fb5\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. \u8584\u7684\u7e96\u7dad\u8868\u76ae\u84cb (thin fibrous cap)\nB. \u6591\u9ede\u72c0\u9223\u5316 (spotty calcification)\nC. \u5411\u5167\u91cd\u5851 (inward  remodeling)\nD. \u5927\u91cf\u7684\u5de8\u566c\u7d30\u80de (a high content of macrophages)\nE. \u76f8\u5c0d\u5927\u91cf\u7684\u8102\u80aa\u6838\u5fc3(relatively large lipid cores)\n": "(C)", "107-14.\n\u6709\u95dc\u98a8\u6fd5\u6027\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u7684\u7406\u5b78\u6aa2\u67e5\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u521d\u671f,\u7b2c\u4e00\u5fc3\u97f3\u6703\u52a0\u91cd\nB. \u7b2c\u4e8c\u5fc3\u97f3\u8207\u958b\u74e3\u97f3(opening snap, OS)\u7684\u9593\u8ddd(A2-OS interval), \u8207\u5de6\u5fc3\u623f\u8ddf\u5de6\u5fc3\u5ba4\u8212\u5f35\u671f\u58d3\u529b\u5dee\u6210\u6b63\u6bd4\nC. \u60a3\u8005\u81c9\u90e8\u53ef\u4ee5\u51fa\u73fe\u9874\u9830\u6f6e\u7d05 (malar rush)\nD. \u5728\u5fc3\u5c16\u90e8\u53ef\u4ee5\u807d\u5230\u4f4e\u983b\u7684\u9686\u9686\u8212\u5f35\u671f\u96dc\u97f3 (a low pitched, rumbling, diastolic murmur)\nE. \u7576\u5408\u4f75\u53f3\u5fc3\u8870\u7aed\u6642\uff0c\u53ef\u4ee5\u51fa\u73fe\u809d\u816b\u5927\u8207\u8173\u8e1d\u6c34\u816b\n": "(B)", "107-15.\n\u6709\u95dc\u4e3b\u52d5\u8108\u74e3\u819c\u72f9\u7a84\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4\uff1f\nA. \u901a\u5e38\u4e3b\u52d5\u8108\u74e3\u958b\u53e3\u9762\u7a4d\u5c0f\u65bc1\u5e73\u65b9\u516c\u5206\u4ee5\u4e0b\u624d\u6703\u6709\u75c7\u72c0\nB. \u5230\u4e3b\u52d5\u8108\u74e3\u819c\u72f9\u7a84\u672b\u671f\u6642,\u8108\u58d3 (pulse pressure)\u6703\u8b8a\u7a84\nC. \u807d\u8a3a\u6642,\u6709\u6642\u6703\u51fa\u73fe\u7b2c\u4e8c\u5fc3\u97f3\u5947\u7570\u5206\u88c2 (paradoxical splitting of S2),\u610f\u5373\u4e3b\u52d5\u819c\u74e3\u9589\u5408\u5fc3\u97f3\u6703\u6bd4\u80ba\u52d5\u8108\u74e3\u9589\u5408\u5fc3\u97f3\u665a\nD. \u807d\u8a3a\u6642,\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u7684\u6536\u7e2e\u671f\u96dc\u97f3\u6703\u50b3\u905e\u81f3\u5fc3\u5c16\u90e8\u4f4d,\u9020\u6210\u8207\u4e8c\u5c16\u74e3\u819c\u72f9\u7a84\u7684\u96dc\u97f3\u4e0d\u5bb9\u6613\u5340\u5225\uff0c\u7a31\u4e4b\u70baGallavardin effect\nE. \u9223\u5316\u6027\u4e3b\u52d5\u8108\u74e3\u819c\u72f9\u7a84(calcified aortic stenosis)\u662f\u4e00\u500b\u6f38\u9032\u60e1\u5316\u7684\u75be\u75c5, \u6bcf\u5e74\u5e73\u5747\u4e3b\u52d5\u8108\u74e3\u58d3\u529b\u5dee(mean aortic valvular pressure gradient)\u589e\u52a07\u6beb\u7c73\u6c5e\u67f1\n": "(D)", "107-16.\n\u6709\u95dc\u653e\u5c04\u7dda\u6cbb\u7642\u764c\u75c7\u6642\uff0c\u7167\u5c04\u5230\u5fc3\u81df\u7684\u5f71\u97ff\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4\uff1f\nA. \u653e\u5c04\u7dda\u5291\u91cf\u8d85\u904e 6000 cGy\u53c8\u5408\u4f75\u5fc3\u6bd2\u6027\u5316\u5b78\u6cbb\u7642\u85e5\u7269\u6709\u8f03\u9ad8\u6a5f\u7387\u767c\u751f\u5fc3\u81df\u50b7\u5bb3\nB. \u6025\u6027\u653e\u5c04\u6027\u5fc3\u5305\u819c\u767c\u708e\u5e38\u5728\u653e\u5c04\u7dda\u6cbb\u76429\u500b\u6708\u5f8c\u767c\u751f\nC. \u6162\u6027\u675f\u7e2e\u6027\u5fc3\u5305\u819c\u708e (constrictive pericarditis)\u4e00\u822c\u5728\u653e\u5c04\u7dda\u6cbb\u76425-10\u5e74\u5f8c\u767c\u751f\nD. \u5e38\u9020\u6210\u4e3b\u52d5\u8108\u74e3\u6216\u4e8c\u5c16\u74e3\u74e3\u819c\u75be\u75c5\nE. \u4e0a\u534a\u8eab\u6597\u7bf7\u5f0f\u653e\u5c04\u7dda\u6cbb\u7642(mantle field radiation)\u4e0d\u6703\u589e\u52a0\u5fc3\u808c\u6897\u585e\u7684\u98a8\u96aa\n": "(E)", "107-17.\n\u4e00\u4f4d70\u6b72\u5973\u6027\u75c5\u60a3\u80f8\u75db1\u5c0f\u6642\u5230\u6025\u8a3a,\u904e\u53bb\u75c5\u53f2\u6709\u9ad8\u8840\u58d3\u8207\u9ad8\u8840\u7cd6;\u4f46\u8840\u58d3\u63a7\u5236\u4e0d\u826f\uff0c\u81f3\u6025\u8a3a\u6642\u8840\u58d3\u70ba160/100\u6beb\u7c73\u6c5e\u67f1\uff0c\u7cd6\u5316\u8840\u8272\u7d20\u6700\u8fd1\u6578\u503c\u70ba8.0%\uff0c\u6700\u8fd1\u7121\u51fa\u8840\u50be\u5411\u6216\u4e0a\u6d88\u5316\u51fa\u8840\u7d00\u9304\uff0c\u8840\u6c27\u98fd\u548c\u6fc3\u5ea6(SpO2) \u70ba98%.\u807d\u8a3a\u5fc3\u81df\u7121S3\u5954\u99ac\u97f3\uff0c\u80ba\u90e8\u807d\u8a3a\u7121\u6fd5\u56c9\u97f3(moist rales)\u6216\u5598\u9cf4\u97f3(wheezing)\uff0c\u56db\u80a2\u76ae\u819a\u6eab\u6696\u4e14\u4e0b\u80a2\u7121\u6c34\u816b\uff0c\u5fc3\u96fb\u5716\u8207\u80f8\u90e8X\u5149\u7247\u5982\u5716\u4e00\u53ca\u5716\u4e8c\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u662f\uff1f (1). \u8a72\u75c5\u60a3\u61c9\u8a72\u7acb\u523b\u81f3\u5fc3\u81df\u79d1\u4e00\u822c\u75c5\u623f\u4f4f\u9662,\u4f4f\u9662\u5f8c\u61c9\u7167\u6703\u5fc3\u81df\u79d1\u91ab\u5e2b (2). \u7d66\u4e88\u8a72\u75c5\u60a3\u963f\u65af\u5339\u9748 (aspirin) (3). \u56e0\u8840\u58d3\u904e\u9ad8,\u7d66\u4e88\u77ed\u6548\u9223\u96e2\u5b50\u963b\u65b7\u5291nifedipine 5mg \u4f86\u964d\u8840\u58d3 (4).\r\u53ef\u7d66\u4e88\u75c5\u4eba\u820c\u4e0bnitroglycerin (5).\u53ef\u7d66\u4e88\u75c5\u4eba\u4e59\u578b\u53d7\u9ad4\u963b\u65b7\u5291(beta-blocker)\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(3)+(4)+(5)\nC. (2)+(4)+(5)\nD. (2)+(3)+(4)+(5)\nE. (1)+(2)+(4)+(5)\n": "(C)", "107-18.\n\u627f\u4e0a\u984c\uff0c\u8a72\u540d\u75c5\u60a3\u65bc\u51fa\u9662\u5f8c3\u500b\u6708\u5fc3\u81df\u8d85\u97f3\u6ce2\u5de6\u5fc3\u5ba4\u5c04\u51fa\u5206\u7387 (LVEF)\u70ba25%\uff0c\u8840\u6e05\u808c\u9150\u9178\u70ba1.1 mg/dl\uff0c\u8840\u6e05\u96fb\u89e3\u8cea\u7121\u7570\u5e38\uff0c\u722c\u4e00\u5c64\u6a13\u68af\u4e0d\u5230\u4fbf\u6703\u767c\u751f\u80f8\u60b6\u8ddf\u52d5\u5598\uff0c\u57282\u9031\u5f8c\u767c\u751f\u5230\u9662\u524d\u55aa\u5931\u751f\u547d\u5fb5\u72c0(out of hospital cardiac arrest)\uff0c\u7d93\u9001\u81f3\u6025\u8a3a\u56de\u5fa9\u751f\u547d\u8de1\u8c61\u8207\u610f\u8b58\uff0c\u4f4f\u9662\u5f8c\u505a\u4e86\u5fc3\u81df\u6838\u78c1\u5171\u632f\u6383\u63cf(late gadolinium enhancement)\u5982\u9644\u5716\u3002\u6709\u95dc\u9019\u4f4d\u75c5\u4eba\u7684\u8655\u7406\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u9019\u500b\u75c5\u4eba\u660f\u5012\u7684\u539f\u56e0\u662f\u56e0\u5fc3\u5167\u819c\u4e0b\u7d50\u75a4 (subendocardial scar)\u800c\u767c\u751f\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u986b\u52d5\nB. \u8a72\u75c5\u4eba\u63a5\u53d7\u53e3\u670d\u6bcf\u5929amiodarone 200 mg\u5f8c\u5373\u53ef\u56de\u5bb6\nC. \u8a72\u75c5\u4eba\u5982\u6301\u7e8c\u6709\u80f8\u60b6\u75c7\u72c0\uff0c\u61c9\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u51a0\u72c0\u52d5\u8108\u651d\u5f71.\nD. \u8a72\u75c5\u4eba\u61c9\u8a72\u63a5\u53d7\u690d\u5165\u5f0f\u53bb\u986b\u5668 (implantable cardioverter-defibrillator)\nE. \u8a72\u75c5\u60a3\u518d\u767c\u5fc3\u56e0\u6027\u731d\u6b7b\u6a5f\u7387\u9817\u9ad8\n": "(B)", "107-19.\n\u8acb\u554f\u6709\u95dc\u53e3\u670d\u6297\u51dd\u8840\u5291\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f(1). rivaroxaban \u4f5c\u7528\u65bcfactor Xa (2). apixaban\u4f5c\u7528\u65bcThrombin (3). edoxaban\u4f5c\u7528\u65bc factor Xa (4). dabigatran\u4f5c\u7528\u65bcfactor Xa (5).warfarin\u904e\u91cf\u5c0e\u81f4\u51fa\u8840\u4e0d\u6b62\u6642,\u53ef\u4ee5\u4f7f\u7528protamine sulfate\u4f86\u4e2d\u548cwarfarin\u4f5c\u7528\nA. (1)+(2)+(4)\nB. (1)+(3)+(5)\nC. (2)+(4)\nD. (2)+(3)+(4)\nE. (2)+(4)+(5)\n": "(E)", "107-20.\n\u4e00\u4f4d54\u6b72\u5973\u6027\u56e0\u7a81\u767c\u6027\u5fc3\u60b8\u5230\u6025\u8a3a\u6c42\u8a3a\uff0c\u8840\u58d3\u70ba120/80\u6beb\u7c73\u6c5e\u67f1\uff0c\u5148\u524d\u7121\u75c7\u72c0\u6642\uff0c\u5fc3\u96fb\u5716\u5982\u5716\u4e00.\u5230\u6025\u8a3a\u6642\u5fc3\u96fb\u5716\u5982\u5716\u4e8c\u3002\u8acb\u554f\u6709\u95dc\u6b64\u5fc3\u5f8b\u4e0d\u6574\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f (1). \u8a72\u5fc3\u5f8b\u4e0d\u6574\u7684\u8a3a\u65b7\u70ba\u5fc3\u5ba4\u983b\u8108(ventricular tachycardia) (2). \u623f\u5ba4\u7d50\u6298\u8fd4 (atrio-ventricular nodal reentry)\u53ef\u4ee5\u662f\u5c0e\u81f4\u8a72\u5fc3\u5f8b\u4e0d\u6574\u7684\u6a5f\u8f49\u4e4b\u4e00 (3). \u8a72\u5fc3\u5f8b\u4e0d\u6574\u53ef\u4ee5\u7528adenosine\u4f86\u6cbb\u7642 (4). \u8a72\u5fc3\u5f8b\u4e0d\u6574\u53ef\u4ee5\u7528verapamil\u4f86\u6cbb\u7642 (5). \u8a72\u5fc3\u5f8b\u4e0d\u6574\u7684\u6cbb\u7642\u61c9\u8a72\u7acb\u5373\u65bd\u884c100\u7126\u8033\u540c\u6b65\u96fb\u64ca\nA. (1)+(2)+(3)+(4)\nB. (2)+(5)\nC. (2)+(3)+(4)\nD. (1)+(5)\nE. (4)+(5)\n": "(D)", "107-21.\n\u4e00\u540d70\u6b72\u5a66\u5973\uff0c\u904e\u53bb\u75c5\u53f2\u6709\u9ad8\u8840\u58d3\uff0c\u9ad8\u8840\u8102\u4f46\u8840\u8102\u63a7\u5236\u4e0d\u826f (\u7e3d\u81bd\u56fa\u9187246 mg/dl\uff0c\u4e09\u9178\u7518\u6cb9\u8102411 mg/dl\uff0c\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 39 mg/dl) \u7cd6\u5c3f\u75c5\u4f46\u8840\u7cd6\u63a7\u5236\u4e0d\u826f(\u98ef\u524d\u8840\u7cd6134 mg/dl\uff0c\u98ef\u5f8c\u8840\u7cd6304 mg/dl\uff0c\u7cd6\u5316\u8840\u8272\u7d20 8.1%)\uff0c\u904e\u53bb\u7121\u6d88\u5316\u9053\u6f70\u760d\u75be\u75c5\u75c5\u53f2\u6216\u51fa\u8840\u50be\u5411\uff0c\u65bc\u672c\u65e5\u6e05\u6668\u767c\u751f\u5de6\u80f8\u75db\u8f3b\u5c04\u81f3\u4e0b\u5df4\uff0c\u4f34\u96a8\u76dc\u6c57\uff0c\u670d\u7528\u4e09\u9846\u820c\u4e0b\u542b\u7247\u4ecd\u4e0d\u80fd\u7de9\u89e3\u80f8\u75db\uff0c4\u5c0f\u6642\u5f8c\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u5e73\u65e5\u5fc3\u96fb\u5716\u5982\u5716\u4e00\uff0c\u81f3\u6025\u8a3a\u5fc3\u96fb\u5716\u5982\u5716\u4e8c\uff0c\u80f8\u90e8X\u5149\u7247\u5982\u5716\u4e09\uff0c\u81f3\u6025\u8a3a\u7b2c\u4e00\u6b21troponin T \u70ba560 ng/L(normal <14)\uff0cMB isoform of  creatine kinase (CKMB) \u70ba10.35 U/L (normal\r<4.88)\uff0c\u5230\u6025\u8a3a\u5f8c\u8840\u58d3\u70ba144 /86 mmHg\uff0c\u8840\u6c27\u6fc3\u5ea6\u70ba96 %\uff0c\u7406\u5b78\u6aa2\u67e5\u5fc3\u81df\u807d\u8a3a\u7121\u7b2c\u4e09\u5fc3\u97f3\uff0c\u80ba\u90e8\u807d\u8a3a\u7121\u56c9\u97f3\uff0c\u4e0b\u80a2\u4e26\u7121\u6c34\u816b\uff0c\u91dd\u5c0d\u6b64\u75c5\u60a3\u63cf\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u8a72\u75c5\u60a3\u8a3a\u65b7\u70ba\u4e0d\u7a69\u5b9a\u578b\u5fc3\u7d5e\u75db\uff0c\u800c\u975e\u5fc3\u808c\u6897\u585e\nB. \u8a72\u75c5\u60a3\u4e4b\u8a3a\u65b7\u7121\u6cd5\u78ba\u5b9a\u662f\u5426\u70ba\u6025\u6027\u51a0\u5fc3\u75c7 (acute coronary syndrome)\u56e0\u6b64\u61c9\u8a72\u5b89\u6392\u4e00\u500b\u904b\u52d5\u5fc3\u96fb\u5716\u6aa2\u67e5\nC. \u91dd\u5c0d\u6b64\u75c5\u60a3\u4e4b\u5fc3\u81df\u75be\u75c5\u8a3a\u65b7\uff0c\u8840\u6e05\u5fc3\u808c\u751f\u7269\u6a19\u8a18(serum cardiac biomarker)\u4e2d\uff0cCKMB\u654f\u611f\u5ea6\u9060\u9ad8\u65bctroponin  T\nD. \u8a72\u75c5\u60a3\u61c9\u8a72\u5728\u75c7\u72c0\u767c\u751f6\u5c0f\u6642\u5167\u7acb\u5373\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u8207\u51a0\u72c0\u52d5\u8108\u4ecb\u5165\u6027\u6cbb\u7642\nE. \u8a72\u75c5\u60a3\u61c9\u8a72\u63a5\u53d7\u96d9\u91cd\u6297\u8840\u5c0f\u677f\u85e5\u7269\u6cbb\u7642(dual anti-platelet therapy)\n": "(E)", "107-22.\n\u6709\u95dc\u4eba\u985e\u514d\u75ab\u7f3a\u9677\u75c5\u6bd2(human immunodeficiency virus; HIV)\u611f\u67d3\u5f8c\uff0c\u5fc3\u81df\u8840\u7ba1\u7cfb\u7d71\u5f71\u97ff\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u51a0\u5fc3\u75c7(coronary heart disease)\u662f\u6700\u5e38\u898b\u7684\u5f62\u5f0f (most common form)\nB. \u5728\u611f\u67d3\u665a\u671f\uff0c\u5e38\u767c\u751f\u64f4\u5f35\u6027\u5fc3\u808c\u75c5\u8b8a\u5408\u4f75\u9b31\u8840\u6027\u5fc3\u81df\u8870\u7aed\nC. \u53ef\u4ee5\u5fc3\u5305\u819c\u7a4d\u6c34\u4f86\u8868\u73fe\nD. \u53ef\u4ee5\u975e\u7d30\u83cc\u6027\u6813\u585e\u5fc3\u5167\u819c\u708e(nonbacterial thrombotic endocarditis)\u8868\u73fe\nE. \u5728\u6709HIV\u611f\u67d3(advanced HIV infection)\u5408\u4f75\u5fc3\u808c\u75c5\u8b8a\u7684\u75c5\u4eba,\u61c9\u5217\u5165\u8166\u90e8\u5f71\u50cf\u6aa2\u67e5(MRI\u6216CT)\uff0c\u4f86\u6aa2\u67e5\u4e2d\u6a1e\u795e\u7d93\u5f13\u6f3f\u87f2\u611f\u67d3( CNS toxoplamosis)\n": "(B)", "108-1.\n\u6709\u95dc\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7(Acute myocardial infarction, AMI)\u5408\u4f75\u5fc3\u56e0\u6027\u4f11\u514b(Cardiogenic shock, CS)\u4f75\u767c\u75c7\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5?\nA. \u5408\u4f75CS\u7684AMI\u670970%\u7684\u75c5\u4f8b\u5e38\u5448\u73fe\u591a\u689d\u5fc3\u8840\u7ba1\u7684\u56b4\u91cd\u75c5\u8b8a\uff0c\u5176\u4e00\u5e74\u5b58\u6d3b\u7387\u4e5f\u4e0d\u53ca50%\uff0c\u56e0\u6b64\u7dca\u6025\u7d93\u76ae\u51a0\u8108\u963b\u4ecb(PCI) \u6642\uff0c\u61c9\u5c07\u8087\u798d\u75c5\u8b8a(Culprit lesion)\u53ca\u975e\u8087\u798d\u75c5\u8b8a\uff0c\u4e00\u4f75\u540c\u6642\u5be6\u65bd\u5b8c\u6574\u6027\u8840\u7ba1\u518d\u901a\u8853(Complete revascularization)\nB. 80% CS\u90fd\u56e0\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c7\u800c\u8d77\uff0c STEMI \u6bd4NSTEMI\u591a\u898b\u53c8\u65e9\u898b\u4f75\u767cCS\nC. \u4f7f\u7528\u8449\u514b\u819c(ECMO), \u6709\u52a9\u975e\u8087\u798d\u75c5\u8b8a\u8840\u7ba1\u4e4b\u5fc3\u808c\u704c\u6ce8\uff0c\u53ef\u6e1b\u5c11\u50b7\u8b8a\uff0c\u4f46\u6cbb\u7642CS\u7684\u5b58\u6d3b\u5be6\u8a3c\u53ea\u6709IIb C\nD. \u4f7f\u7528\u4e3b\u52d5\u8108\u5167\u6c23\u7403\u5e6b\u6d66(Intra-aortic balloon counter-pulsation,IABP) \u7121\u52a9AMI\u7684CS\uff0c\u56e0\u6b64\u5fc3\u81df\u5b78\u6703\u4e0d\u63a8\u85a6\u5e38\u898f\u4f7f\u7528\nE. \u4f7f\u7528\u6a5f\u68b0\u6027\u8f14\u52a9\u5668(Mechanical support device)\u5982 Impella , TandemHeart\u6cbb\u7642CS\u4ecd\u820a\u672a\u5b9a\u8ad6\n": "(A)", "108-2.\n\u4f9d\u64da\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u53ca\u9ad8\u8840\u58d3\u5b78\u67032017\u5e74\u516c\u4f48\u7684\u6307\u5f15\uff0c\u6709\u95dc\u9ad8\u8840\u58d3\u7684\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u53d7SPRINT\u81e8\u5e8a\u8a66\u9a57\u7d50\u8ad6\u7684\u5f71\u97ff,\u5169\u6703\u4e3b\u5f35\u63a1\u5f37\u5ea6\u8840\u58d3\u63a7\u5236\u7b56\u7565\nB. \u6210\u5e74\u4eba\u4e4b\u8840\u58d3\u9ad8\u65bc130/80 mmHg\u8996\u70ba\u9ad8\u8840\u58d3\nC. \u51a0\u8108\u786c\u5316\u6027\u5fc3\u81df\u75c5\u53ca\u7cd6\u5c3f\u75c5\u75c5\u4eba\u61c9\u63a7\u5236\u5728\u5c0f\u65bc130/80 mmHg\nD. \u5927\u65bc75\u6b72\u8001\u4eba\u5176\u8840\u58d3\u61c9\u63a7\u5236\u5728140/90 mmHg\u4ee5\u4e0b\u70ba\u5b9c\nE. \u8166\u4e2d\u98a8\u75c5\u4eba\u73fe\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269\u8005\uff0c\u4ee5\u63a7\u5236\u5728130/80 mmHg \u4ee5\u4e0b\u70ba\u5b9c\n": "(B)", "108-3.\n\u6709\u95dc\u5fc3\u81df\u731d\u6b7b\uff08Sudden cardiac death)\u7684\u8aaa\u6cd5\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684?\nA. \u731d\u6b7b\u591a\u898b\u65bc\u6709\u51a0\u5fc3\u75c5\u7684\u7537\u6027\u75c5\u4eba\nB. \u731d\u6b7b\u7684\u767c\u751f\u591a\u898b\u65bc\u5fc3\u808c\u7f3a\u6c27\u6027\u5fc3\u5ba4\u6027\u7e96\u7dad\u986b\u52d5\uff08Ventricular fibrillation)\nC. \u51a0\u5fc3\u75c5\u4eba\u4e00\u500b\u6708\u524d\u7d93\u53d7\u76ae\u51a0\u8108\u4ecb\u5165\u6cbb\u7642(PCI) \uff0c\u5176\u5de6\u5fc3\u5ba4\u5c04\u51fa\u91cf\uff08Left ventricular ejection fraction, LVEF) 35%,\u5728\u96fb\u6c23\u751f\u7406\u6aa2\u67e5\u53c8\u672a\u6709\u8a98\u5c0e\u5fc3\u5f8b\u4e0d\u6574\uff0c\u5bb6\u65cf\u672a\u6709\u731d\u6b7b\u75c5\u53f2\u3002\u4f46\u70ba\u9810\u9632\u731d\u6b7b\u7684\u767c\u751f\uff0c\u5f97\u4ee5ICD (Intra-cardiac defibrillator) \u4f5c\u521d\u7d1a\u6cbb\u7642(Primary prevention)\nD. \u6d3b\u547d\u9810\u671f\u4e0d\u8db3\u4e00\u5e74\u7684\u75c5\u4eba\uff0c\u4e0d\u5fc5ICD \u6cbb\u7642\nE. \u5c31\u731d\u6b7b\u4e4b\u521d\u7d1a\u9810\u9632\uff0c\u4e00\u822c\u76f8\u4fe1\u751f\u6d3b\u65b9\u5f0f\u7684\u6539\u9020\u512a\u65bcICD\n": "(C)", "108-4.\n67\u6b72\u7537\u6027\u75c5\u4eba\u8207\u597d\u53cb\u71ac\u591c\u73a9\u9ebb\u5c07\uff0c\u7fcc\u65e59:13AM\u7a81\u7136\u5012\u5730\u6025\u6551\uff0c\u7d93119 EMT\u65bd\u884cCPR\uff0c26\u5206\u5167\u9001\u62b5\u6025\u8a3a\u8655\u3002\u4e2d\u9593\u6709\u591a\u6b21VT/VF\uff0c\u65bd\u884cDC shock 5\u6b21\uff0c\u5176\u5f8c\u7684\u75c5\u7a0b\u6709CPCR\u517156\u5206\u53ca\u96fb\u64ca9\u6b21\uff0c\u4f7f\u7528amiodarone + Lidocaine+ MgSO4\uff0c\u4e5f\u572850\u5206\u9418\u5167\u653e\u7f6eVA-ECMO\u3002\u7406\u5b78\u6aa2\u67e5: BT 35.4 \u00b0C; HR: 55 /min; RR: 20 /min; BP: 125/68mmHg\u81c9\u8272\u84bc\u767d\uff0c\u7121\u8ca7\u8840\uff0c\u80f8\u90e8\u7121\u7570\u5e38\uff0c\u5fc3\u81df\u5927\u5c0f\u6b63\u5e38\uff0c\u5fc3\u5c16\u640f\u672a\u5916\u79fb\uff0cS1\u6b63\u5e38\uff0c\u552f\u5728\u5fc3\u5c16\u53caLLSB\u6709Grade 3/6 systolic murmur\uff0c\u5176\u4ed6\u90e8\u4f4d\u672a\u898b\u7570\u5e38\u3002\r\u65e2\u5f80\u75c5\u53f2:1.2007\u5e74\u8a3a\u65b7\u5fc3\u81df\u75c5\u53ca\u5fc3\u5f8b\u4e0d\u6574\uff0c\u670d\u7528Propranolol\u7528\u30022. \u6bcf\u5929\u62bd\u71591.5\u5305,\u670940\u5e74\u4e4b\u4e45\u30023. \u559c\u597d\u9ad8\u6881\u9152\uff0c\u6bcf\u592930cc\u30024. \u7121\u5bb6\u65cf\u985e\u4f3c\u75c5\u53f2\u3002\u5176\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u651d\u5f71: \u51a0\u72c0\u52d5\u8108\u9020\u5f71\u6aa2\u67e5\u986f\u793a\u4e3b\u5e79\u53ca\u4e09\u5206\u679d\u66a2\u901a\uff0c\u672a\u6709\u8840\u6813\u963b\u585e\u3002\u5fc3\u96fb\u5716\u3001\u80f8\u90e8X\u5149\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u8207\u62bd\u8840\u8cc7\u6599(\u5982\u5716)\u6240\u793a\u3002\u4f9d\u4e0a\u8ff0\u75c5\u72c0\u53ca\u521d\u6b65\u6aa2\u67e5\uff0c\u5982\u60a8\u61c9\u6703\u8a3a\u7167\u6703\uff0c\u8acb\u554f\u9019\u4f4d\u75c5\u4eba\u767c\u751fOHCA(Out-hospital cardiac arrest) \u6700\u53ef\u80fd\u7684\u539f\u56e0\u662f:\nA. Acute myocardial infarction\nB. Septic shock\nC. Dilated cardiomyopathy\nD. Hypertrophic cardiomyopathy\nE. Brugada syndrome\n": "(D)", "108-5.\n44\u6b72\u7537\u4eba\u6709\u80f8\u75bc\u534a\u5c0f\u6642\u4e4b\u4e45\uff0c\u516b\u5c0f\u6642\u5f8c\u53c8\u6709\u80f8\u75bc\u4e43\u81f3\u91ab\u9662\u6c42\u8a3a\uff0c\u6025\u8a3a\u5167\u79d1\u91ab\u5e2b\u5728\u5fc3\u96fb\u5716(\u5982\u5716) \uff0c\u96a8\u5373\u555f\u52d5PCI team \u4e26\u7d66\u4e8eTicagrelor + Aspirin + Heparin \u3002\u75c5\u4eba\u6709\u5e73\u65e5\u591a\u62bd\u83f8\uff0c\u4e5f\u6b20\u7f3a\u904b\u52d5\u3002\u7406\u5b78\u6aa2\u67e5:BH: 174 cm, BW: 135 kg, BMI: 44.6 kg/m2; T: 36.3 \u00b0C, P: 97 bpm, R: 16 /min; BP:121/79 mmHg; \u5176\u4ed6\u4e26\u7121\u986f\u8457\u7570\u72c0\u3002\r\u8acb\u554f\u4e0b\u5217\u4f55\u689d\u51a0\u72c0\u52d5\u8108\u6700\u53ef\u80fd\u7684\u8087\u798d\u8840\u7ba1\u8b8a\u5316(Culprit)\u6240\u5728\u662f?\nA. Normal coronary artery\nB. Left main lesion\nC. Left anterior descending artery\nD. Left circumflex artery\nE. Right coronary artery\n": "(C)", "108-6.\n52 \u6b72\u7537\u6027\u75c5\u4eba\u5f9e\u6628\u665a\u958b\u59cb\u9593\u6b47\u6027\u80f8\u75bc\u75db\uff0c\u521d\u6642\u8f15\u5ea6\u6b77\u7d93\u6578\u5206\u9418\uff0c\u8eab\u9ad4\u904b\u52d5\u53ef\u8a98\u767c\u80f8\u60b6\uff0c\u4eca\u66686:48 AM\u8f49\u6210\u91cd\u5ea6\u80f8\u75bc\uff0c\u540c\u6642\u4f34\u6709\u9838\u9178\u53ca\u5de6\u80a9\u75bc\u800c\u9192\u5e8a\uff0c\u96a8\u5f8c\u81ea\u89ba\u547c\u5438\u56f0\u96e3\u53ca\u982d\u6688\uff0c\u4e43\u6025\u5f80\u91ab\u9662\u3002\u6642\u7406\u5b78\u6aa2\u67e5\u986f\u793a\u6709\u6025\u75c5\u72c0\uff0c\u8eab\u9ad8166cm\uff0c\u9ad4\u91cd80Kg\uff0cBMI 29.07\uff0c\u8840\u58d386/66mmHg\uff0c\u5fc3\u8df370/min\uff0c\u547c\u543820/min\uff0c\u4f53\u6eab35.7\u2103\uff0cSaO2 98%\u3002\u6b64\u5916\u4e26\u7121\u91cd\u5927\u7570\u5e38\u3002\u5176\u751f\u5316\u6aa2\u67e5\u3001\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u7d50\u679c(\u5982\u5716)\u6240\u793a\u3002\u6025\u8a3a\u5167\u79d1\u91ab\u5e2b\u91dd\u5c0d\u75c5\u4eba\u7684\u73fe\u6cc1\uff0c\u96a8\u5373\u555f\u52d5PCI team code\u4e26\u9032\u884c\u4e0b\u5217\u8af8\u7a2e\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u7b26\u5408\u6307\u5f15\u8655\u7f6e?(1)O2 inhalation 6 L/min\uff1b(2)IV Nitroglycerin 3\rmcg/min\uff1b(3)Aspirin\u901f\u6548\u5291\u91cf300 mg\u5f8c 100 mg QD\uff1b(4)Atorvastatin 40 mg HS\uff1b(5)Ticagrelor\u901f\u6548\u5291\u91cf180 mg\u5f8c\uff0c90mg/Tab 1# BID PC\uff1b(6)IV bolus Morphine 3mg\uff0c\u8996\u5fc3\u7d5e\u75bc\u75db\u7528\u85e5\uff1b(7)Bisoprolol 1.25mg QD PC\uff1b(8)Amlodipine 5mg BID\nA. (1)+(2)+(3)\nB. (2)+(4)+(6)\nC. (3)+(4)+(5)\nD. (1)+(3)+(7)\nE. (2)+(4)+(8)\n": "(C)", "108-7.\n\u4f9d\u64da\u7f8e\u570b\u5169\u500b\u5fc3\u81df\u5b78\u6703(AHA/ACC)\u6700\u8fd1\u6709\u95dc\u5fc3\u74e3\u819c\u6027\u5fc3\u81df\u75c5\u4e4b\u5fc3\u5167\u819c\u708e\u8655\u7f6e\u6307\u5f15\u5efa\u8b70\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u61c9\u4f5c\u9810\u9632\u6027\u6297\u751f\u7d20\u7684\u4f7f\u7528?\nA. 56\u6b72\u51a0\u5fc3\u75c5\u4eba\u66fe\u5728\u4e09\u500b\u6708\u524d\uff0c\u7f6e\u653e\u4e94\u652f\u51a0\u8108\u652f\u67b6\uff0c\u5c07\u65bc\u8fd1\u65e5\u5167\u4f5c\u7259\u79d1\u6cbb\u7642\uff0c\u7f6e\u63dborthodontic brackets\u6216orthodontic appliances\nB. 28\u6b72\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u4eba\u5c07\u65bd\u884c\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\nC. 68\u6b72\u75c5\u4eba\u56e0\u5fc3\u5ba4\u6027\u5fc3\u5f8b\u5feb\u8df3\u4e4b\u731d\u6b7b\u6025\u6551\uff0c\u653e\u7f6eIntra-cardiac defibrillater(ICD) \uff0c\u73fe\u5728\u53f3\u4e0a\u80ba\u6709\u73bb\u7483\u72c0\u9670\u5f71(GGO,Ground glass opacity)\uff0c\u5c07\u5be6\u884c\u6c23\u7ba1\u5167\u6d3b\u9ad4\u5207\u7247\u6aa2\u67e5\nD. 28\u6b72\u5973\u6027\u6709\u80f8\u75bc\u4e3b\u8a34\uff0c\u552f\u7406\u5b78\u6aa2\u67e5\u6b63\u5e38\uff0c\u4f46\u8d85\u97f3\u6ce2\u5fc3\u5716\u5448\u73fe\u4e8c\u5c16\u74e3\u819c\u812b\u5782\u4f75\u6709\u8f15\u5ea6\u9589\u9396\u4e0d\u5168\nE. \u6bd2\u766e\u8005\u5341\u500b\u6708\u524d\u66fe\u6709\u767c\u71d2\uff0c\u552f\u8fd1\u65e5\u8d85\u97f3\u6ce2\u5fc3\u5716\u672a\u6709\u7570\u5e38\u8b8a\u5316\uff0c\u73fe\u5728\u5be6\u65bd\u8180\u80f1\u93e1\u6aa2\u67e5\n": "(C)", "108-8.\n\u4e0b\u9762\u6709\u95dc\u5fc3\u8870\u7aed\u7684\u8655\u7f6e\u6839\u64da\u8aaa\u6cd5\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5?\nA. \u5fc3\u8870\u7aed\u5408\u4f75\u4f4e\u8840\u58d3\u7684\u75c5\u4eba\uff0c\u4e0d\u5fc5\u6025\u7528Dopamine, Dobutamine\u6216Nor-epinephrine\uff0c\u56e0\u53ef\u80fd\u591a\u589e\u6b7b\u4ea1\u7387\nB. \u5c31\u75c5\u7406\u751f\u7406\u5b78\u800c\u8a00\uff0c\u53ea\u8981\u80ba\u6c34\u816b\uff0c\u4f7f\u7528\u6301\u7e8c\u6027\u6b63\u58d3\u547c\u5438\u5668(CPAP) \u6709\u52a9\u6539\u5584\u8840\u6db2\u542b\u6c27\u91cf\u53ca\u547c\u5438\u56f0\u96e3\uff0c\u4f46\u7121\u52a9\u4f4f\u9662\u7642\u7a0b\u7684\u6b7b\u4ea1\u7387\nC. \u4f9d\u5de6\u5fc3\u5ba4\u5fc3\u81df\u529f\u80fd\u6aa2\u67e5\uff0c\u5fc3\u8870\u7aed\u5206\u62101. HFrEF (Heart failure reduced ejection fraction) 2. HFpEF(Heart failure preserved ejection fraction)\uff0c\u4e0d\u7ba1\u4f4f\u9662\u6216\u51fa\u9662\u7642\u7a0b\uff0c\u524d\u8005\u90fd\u6bd4\u5f8c\u8005\u7684\u6b7b\u4ea1\u7387\u66f4\u9ad8\nD. \u5fc3\u8870\u7aed\u5408\u4f75\u80ba\u6c34\u816b\u5982\u82e5\u8840\u58d3\u504f\u4f4e\uff0c\u8840\u7ba1\u64f4\u5f35\u5291\u4e0d\u662f\u9069\u7576\u7684\u85e5\u7269\u9078\u64c7\nE. \u7dca\u6025\u975c\u8108\u6ce8\u5c04\u5229\u5c3f\u5291\u6709\u52a9\u80ba\u6c34\u816b\u7684\u6539\u5584\n": "(C)", "108-9.\n64\u6b72\u7537\u6027\u96fb\u5b50\u5de5\u7a0b\u5e2b\u57282003\u5e74\u56e0\u5065\u5eb7\u6aa2\u67e5\u767c\u73fe\u5fc3\u808c\u7f3a\u6c27\uff0c\u5fc3\u5916\u91ab\u5e2b\u96a8\u5373\u9032\u884c\u51a0\u72c0\u52d5\u8108\u7e5e\u9053\u624b\u8853\uff0c\u8ffd\u8e64\u767c\u73fe\u7e5e\u9053\u8840\u7ba1\u963b\u585e\u4e0d\u901a\uff0c\u6539\u4ee5\u5857\u85e5\u652f\u67b6\u6cbb\u7642\u3002\u81ea2019\u5e741\u6708\u8d77\uff0c\u6642\u6709\u80f8\u75db\uff0c\u7d93\u4fb5\u5165\u6027\u6aa2\u67e5\u767c\u73fe\u5de6\u4e3b\u5e79\u53ca\u5176\u4ed6\u4e09\u689d\u51a0\u72c0\u52d5\u8108\u8840\u7ba1\u90fd\u6709\u56b4\u91cd\u72f9\u7a84\uff0c\u5efa\u8b70\u5fc3\u81df\u79fb\u690d\u30022019\u5e747\u670824\u65e5\u56e0\u80f8\u60b6\u53ca\u547c\u5438\u56f0\u96e3\uff0c\u4e43\u5230\u6025\u8a3a\u6c42\u6cbb\u3002\u9ad4\u6eab37.1\u5ea6\uff1b\u8840\u58d3133/93 mmHg; \u5fc3\u8df3130/\u5206\uff1bSpO2 97%\uff1b \u5176\u5fc3\u96fb\u5716(\u5982\u5716)\u3002\u5176\u7dca\u6025\u751f\u5316\u6aa2\u67e5\uff1a CK :117 U/L; CKMB: 4.25 mg/mL,  Troponin T: 10.41 ng/L\u3002\u8ca0\u8cac\u91ab\u5e2b\u96a8\u5373\u9032\u884c\u4e0b\u5217\u8655\u7f6e\uff0c\u4e5f\u56e0\u6b64\u75c5\u60c5\u7a69\u5b9a\u3002(1)Amiodarone 150 mg IV\uff0c\u96a8\u5f8c 1 mg/ min\r\u6301\u7e8c\u975c\u6ce8\uff1b(2)nitroglycerin 100mg in 500 cc Normal saline ,\u4ee52.5 mcg/Kg/min \u6301\u7e8c\u975c\u6ce8\uff1b(3)\u975c\u8108\u6ce8\u5c04Lanoxin 0.5 mg in 10ml  5% glucose in water\uff1b(4)Heparin 4000U bonus \u5f8c\u6301\u7e8c\u975c\u6ce8\u65e5\u91cf25000U\uff1b(5)DC electric shock 200 joules\uff1b(6)IV 2 Gm Magnesium sulfate\uff1b(7)IV Lasix 20 mg\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u8655\u7f6e\u624d\u7b26\u5408\u7576\u4eca\u5fc3\u81df\u5b78\u6703\u5efa\u8b70\u7684\u6307\u5f15\uff1f\nA. (1)+(2)+(3)\nB. (3)+(4)+(5)\nC. (5)+(6)+(7)\nD. (1)+(2)+(4)\nE. (2)+(3)+(7)\n": "(D)", "108-10.\n\u4e0b\u9762\u6709\u95dc\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\uff08Atrial fibrillation \uff0cAF)\u7684\u8aaa\u6cd5\uff0c\u8acb\u554f\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u4e0d\u7ba1\u9663\u767c\u6027(paroxysmal)\u6216\u6c38\u4e45(permanent)\u5982\u82e5\u518d\u767cAF\uff0c\u6709\u75c7\u72c0\u7684AF\u6bd4\u6c92\u6709\u75c7\u72c0\u7684AF\u591a12\u500d\nB. \u5c31\u5be6\u8b49\u91ab\u7642\u800c\u8a00\uff0c\u5fc3\u5f8b\u63a7\u5236(Rhythm control)\u4e0d\u6bd4\u5fc3\u8df3\u63a7\u5236(Rate control)\u91cd\u8981\nC. \u80a5\u80d6\u5e38\u6709AF\u7684\u767c\u4f5c\uff0c\u6e1b\u80a5\u6216\u4f7f\u7528ACEi \u6216ARB \u4e5f\u591a\u6703\u6709\u6e1b\u5c11\u767c\u4f5c\u7684\u6548\u679c\nD. \u6025\u6027\u767c\u4f5c\u7684AF\u670940%\u53ef\u81ea\u5df1\u7de9\u89e3\uff0c\u4f46\u670960%\u6703\u6301\u7e8c\u8d85\u904e\u4e00\u5929\uff0c\u5982\u6709\u9700\u8981\u5fc3\u5f8b\u8f49\u6b63\uff08Cardioversion),\u61c9\u6709\u98df\u9053\u8d85\u97f3\u6ce2\u5fc3\u5716\u6392\u9664\u5de6\u5fc3\u623f\u8840\u6813\u4e4b\u53ef\u80fd\uff0c\u6216\u4f7f\u7528\u6297\u51dd\u8840\u85e5\u7269\u4e09\u9031\u5f8c\u518d\u8655\u7406\nE. \u6162\u6027AF\u7684\u75c5\u4eba\uff0c\u5176CHADS2VASc\u5927\u65bc2\uff0c\u5c31\u9810\u9632\u8840\u6813\u963b\u585e\u767c\u4f5c\uff0c\u5f9e\u5be6\u8a3c\u91ab\u5b78\u800c\u8a00\uff0c\u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269(New oral anticoagulants) \u6bd4Warfarin \u5c11\u898b\u8166\u51fa\u8840\n": "(A)", "108-11.\n78\u6b72\u8001\u592a\u592a\u6709\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u53ca\u6162\u6027\u814e\u75c5\u8b8a\u53ca\u53f3\u4e0a\u80ba\u764c\uff0c\u65bc\u662f\u4f4f\u9662\u505aVATS RUL lobectomy\u958b\u5200, \u8853\u5f8c\u9010\u6f38\u9ad4\u91cd\u589e\u52a0\u3001\u8173\u816b\u3001\u54b3\u55fd\u53ca\u547c\u5438\u56f0\u96e3\uff0c\u7d93\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73feAortic valve area 0.7 cm2, Mean aortic pressure gradient 41 mmHg, LVEF 67%,\u6703\u8a3a\u5167\u79d1\u91ab\u5e2b\u3002\u8840\u58d3180/57 mmHg\uff1b \u5fc3\u8df381/min\uff0c\u6162\u6027\u75c5\u5bb9\u3002\r\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u4e3b\u52d5\u74e3\u819c\u72f9\u7a84\uff08Aortic stenosis\uff09\u61c9\u6709\u7684\u7406\u5b78\u6aa2\u67e5\u6240\u898b\uff1f\nA. Mid-systolic; in crescendo-decrescendo at Aortic area\nB. Soft S2 over Aortic area\nC. Bifid apical impulse\nD. S4 audible over the apex\nE. Intensity of cardiac murmur attenuated while on squatting\n": "(E)", "108-12.\n\u4e00\u4f4d\u75c5\u60a3\u56e0\u80f8\u60b6\u5230\u6025\u8a3a,\u80f8\u60b6\u90e8\u4f4d\u70ba\u5de6\u524d\u80f8, \u80f8\u60b6\u6642\u9593\u8d85\u904e30\u5206\u9418,\u91ab\u5e2b\u60f3\u9451\u5225\u8a3a\u65b7\u8a72\u80f8\u75db\u662f\u5426\u70ba\u5fc3\u5305\u819c\u708e\u6216\u5fc3\u808c\u6897\u585e,\u8acb\u554f\u4e0b\u5217\u9673\u8ff0\u4f55\u8005\u932f\u8aa4?(1)\u7576\u60b6\u75db\u5728\u8eba\u4e0b\u6642\u53ef\u4ee5\u8f03\u70ba\u7de9\u89e3;\u5750\u8d77\u4e26\u8eab\u9ad4\u5411\u524d\u50be\u6642\u6703\u52a0\u91cd(1)\u5fc3\u5305\u819c\u708e\u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u8981\u5217\u5165\u8003\u616e\uff1b(2)\u5fc3\u5305\u819c\u708e\u4e4b\u80f8\u75db\u4e0d\u6703\u8f3b\u5c04\u81f3\u5de6\u4e0a\u81c2\u6216\u4e0b\u5df4\uff1b(3)\u5fc3\u96fb\u5716\u5448\u73fe\u7030\u6f2b\u6027ST -segment elevation,\u5fc3\u5305\u819c\u708e\u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u8981\u5217\u5165\u8003\u616e\uff1b(4)\u7576\u5fc3\u96fb\u5716ST segment elevation\u70ba\u51f8\u51fa\u72c0(convex pattern),\u5fc3\u5305\u819c\u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u8981\u512a\u5148\u5217\u5165\u8003\u616e\uff1b(5)\u5fc3\u96fb\u5716\u4e0a\u6709PR segment depression,\u5fc3\u5305\u819c\u708e\u5728\u9451\u5225\u8a3a\u65b7\u4e0a\u8981\u5217\u5165\u8003\u616e\u3002\nA. (1)+(2)+(4)\nB. (3)+(4)+(5)\nC. (1)+(2)+(3)+(5)\nD. (2)+(4)\nE. (4)+(5)\n": "(D)", "108-13.\n\u6709\u95dc\u4f4e\u5c04\u51fa\u5206\u7387\u578b\u5fc3\u81df\u8870\u7aed(heart failure with reduced ejection fraction)\u4e4b\u85e5\u7269\u6cbb\u7642\u63cf\u8ff0,\u4e0b\u5217\u4f55\u8005\u6709\u8aa4?\nA. \u4f7f\u7528beta-blocker \u61c9\u512a\u5148\u65bc angiotensin-converting enzyme inhibitors (ACEI)\nB. Aldosterone antagonist (eplerenone) \u53ef\u4ee5\u6539\u5584\u6b7b\u4ea1\u7387\nC. Direct renin inhibitor (aliskiren)\u4e0d\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\nD. Propranolol  \u4e0d\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\nE. Endothelin antagonist (bosentan) \u4e0d\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\n": "(A)", "108-14.\n\u4e0b\u5217\u5728\u6025\u6027\u5fc3\u81df\u8870\u7aed\u6cbb\u7642\u4e4b\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u6025\u6027\u5fc3\u81df\u8870\u7aed\u6642,\u4f7f\u7528ultrafiltration\u4f86\u79fb\u9664\u6c34\u5206 \u53ef\u4ee5\u6e1b\u5c11\u5fc3\u81df\u8870\u7aed\u518d\u4f4f\u9662\u7387\nB. \u6025\u6027\u5fc3\u81df\u8870\u7aed\u6642,\u4f7f\u7528ultrafiltration \u4f86\u79fb\u9664\u6c34\u5206\u4e0d\u80fd\u6539\u5584\u814e\u81df\u529f\u80fd\nC. \u6025\u6027\u5fc3\u81df\u8870\u7aed\u6642, \u4f7f\u7528Vasopressin-2 antagonist (tolvaptan) \u53ef\u4ee5\u6539\u5584\u6b7b\u4ea1\u7387\nD. \u6025\u6027\u5fc3\u81df\u8870\u7aed\u6642, \u4f7f\u7528Calcium sensitizer (levosimendan) \u4e0d\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\nE. \u6cbb\u7642\u6025\u6027\u5fc3\u81df\u8870\u7aed,\u4f7f\u7528milrinone\u7576\u4f5c\u5f37\u5fc3\u5291\u6642;\u8981\u6839\u64da\u814e\u529f\u80fd\u4f86\u8abf\u6574\u5291\u91cf.\n": "(C)", "108-15.\n\u4e00\u4f4d46\u6b72\u5973\u6027\u75c5\u60a3\u5448\u73fe\u660f\u53a5\u4f86\u9580\u8a3a\u6c42\u8a3a,\u8a72\u75c7\u72c0\u8207\u7279\u5b9a\u59ff\u52e2\u6709\u95dc.\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5982(\u9644\u5716),\u5de6\u5716\u70ba\u5fc3\u5ba4\u6536\u7e2e\u4e8c\u5c16\u74e3\u95dc\u9589\u6642,\u53f3\u5716\u70ba\u5fc3\u5ba4\u8212\u5f35\u6642\u5716\u50cf.\u6709\u95dc\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u5fc3\u81df\u807d\u8a3a\u6642,\u6709\u6642\u53ef\u4ee5\u807d\u5230\u4f4e\u983b\u7684\u816b\u7624\u64b2\u843d\u97f3(tumor-plop)\nB. \u75c5\u4eba\u53ef\u4ee5\u6709\u767c\u71d2,\u9ad4\u91cd\u6e1b\u8f15\u7b49\u75c7\u72c0\nC. \u75c5\u4eba\u53ef\u4ee5\u6709\u96f7\u8afe\u6c0f\u73fe\u8c61 (Raynauld's phenomenon)\nD. \u75c5\u4eba\u4e0d\u6703\u6709\u6775\u72c0\u6307(clubbing finger)\u7684\u75c7\u72c0\nE. \u5efa\u8b70\u5176\u4ed6\u4e00\u7b49\u89aa\u4e4b\u89aa\u5c6c(first-degree relatives)\u4e5f\u9032\u884c\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\n": "(D)", "108-16.\n\u690e\u52d5\u8108\u4e00\u5171\u5206\u6210\u56db\u6bb5,\u7b2c\u4e00\u6bb5(V1)\u5f9e\u53f3\u7121\u540d\u52d5\u8108(innominate artery)\u6216\u5de6\u9396\u9aa8\u4e0b\u52d5\u8108\u5206\u51fa\u5f8c\u81f3\u7b2c\u4e94\u6216\u7b2c\u516d\u9838\u690e\u6a6b\u7a81\u5b54(transverse foramen).\u7b2c\u4e8c\u6bb5(V2)\u5f9e\u4e0a\u8ff0\u9838\u690e\u6a6b\u7a81\u5b54\u81f3\u7b2c\u4e8c\u9838\u690e(C2)\u6a6b\u7a81\u5b54.\u7b2c\u4e09\u6bb5\u5f9e\u7b2c\u4e8c\u9838\u690e\u6a6b\u7a81\u5b54\u7d93\u7b2c\u4e00\u9838\u690e\u7a7f\u904e\u6795\u9aa8\u5927\u5b54(foramen Magnum)\u4e4b\u786c\u8166\u819c,\u7b2c\u56db\u6bb5(V4)\u8207\u5c0d\u5074\u690e\u52d5\u8108\u5408\u6210\u57fa\u5e95\u52d5\u8108(Basilar artery)\u3002\u6709\u95dc\u690e\u52d5\u8108\u5206\u679d\u75be\u75c5\u6558\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u52d5\u8108\u786c\u5316\u8840\u6813\u75c5\u7076 (atherothrombotic lesions)\u6700\u5e38\u5728V1\u53caV4\u767c\u751f.\nB. V2\u8207V3\u8f03\u5e38\u767c\u751f\u690e\u52d5\u8108\u525d\u96e2\nC. V4\u4f9b\u61c9\u8166\u5e79\u8207\u5c0f\u8166\u4e4b\u8840\u6d41\nD. \u52d5\u8108\u72f9\u7a84\u5728V3\u8655\u6703\u9020\u6210subclavian steal syndrome\nE. V4\u767c\u751f\u8840\u7ba1\u963b\u585e\u53ef\u4ee5\u7522\u751fWallenberg's syndrome\n": "(D)", "108-17.\n\u6709\u95dc\u5fc3\u81df\u8eab\u9ad4\u8a3a\u5bdf\u7684\u63cf\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4? (1)\u5fc3\u81df\u89f8\u8a3a\u51fa\u73fe\u9707\u986b (thrill )\u4ee3\u8868\u5fc3\u96dc\u97f3\u5f37\u5ea6\u70ba\u7b2c\u4e09\u7d1a\uff1b(2)\u5fc3\u623f\u4e2d\u8188\u7f3a\u640d\u6642,\u53ef\u4ee5\u807d\u5230\u5438\u6c23\u8207\u547c\u6c23\u6642\u56fa\u5b9a\u7b2c\u4e00\u5fc3\u97f3\u5206\u5c94(fixed split of S1)\uff1b(3)\u4e3b\u52d5\u8108\u80ba\u52d5\u8108\u958b\u653e\u6027\u5c0e\u7ba1(patent ductus arteriosus)\u53ef\u4ee5\u807d\u5230continuous murmur\uff1b(4)\u80a5\u539a\u6027\u5fc3\u808c\u75c5\u8b8a\u75c5\u60a3\u5728\u4f5cValsalva maneuver \u6642,\u6536\u7e2e\u671f\u96dc\u97f3\u6703\u8b8a\u5927\u8072\uff1b(5)\u4e8c\u5c16\u74e3\u812b\u5782(mitral valve prolapse)\u6703\u807d\u5230\u8212\u5f35\u671f\u96dc\u97f3(diastolic click)\nA. (2)+(4)+(5)\nB. (3)+(4)\nC. (3)+(5)\nD. (1)+(2)+(3)\nE. (1)+(2)+(5)\n": "(E)", "108-18.\n\u6709\u95dc\u5fc3\u81df\u8870\u7aed\u8840\u6e05\u6a19\u8a18B-type natriuretic peptide (BNP) \u8207N-terminal pro-BNP  (NT-proBNP)\u7684\u63cf\u8ff0,\u4f55\u8005\u932f\u8aa4?\nA. \u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u60a3\u8005\u4f7f\u7528ARNI (angiotensin receptor neprilysin inhibitor) \u5f8c, BNP\u7684\u6fc3\u5ea6\u6703\u964d\u4f4e\nB. \u5e74\u9f61\u589e\u52a0\u6642,NT-proBNP\u8840\u6e05\u6fc3\u5ea6\u6703\u589e\u52a0\nC. \u814e\u529f\u80fd\u8b8a\u5dee\u6642, NT-proBNP\u8840\u6e05\u6fc3\u5ea6\u6703\u589e\u52a0\nD. \u80a5\u80d6\u6703\u9020\u6210BNP\u6fc3\u5ea6\u5047\u6027\u964d\u4f4e(falsely low)\nE. \u9019\u4e9b\u8840\u6e05\u6a19\u8a18\u5728\u53f3\u5fc3\u8870\u7aed\u6642,\u4e5f\u6703\u5347\u9ad8.\n": "(A)", "108-19.\n\u4e00\u4f4d75\u6b72\u62bd\u83f8\u7537\u6027\u75c5\u60a3\u81f3\u9580\u8a3a,\u904e\u53bb\u75c5\u53f2\u6709\u9ad8\u8840\u58d3\u8207\u9ad8\u8840\u8102,\u4e3b\u8a34\u9593\u6b47\u6027\u8ddb\u884c.\u767c\u751f\u7684\u90e8\u4f4d\u70ba\u81c0\u90e8\u8207\u4e0b\u80a2\u808c\u8089.\u75c5\u4eba\u53e6\u6709\u967d\u840e(impotence)\u7684\u75c7\u72c0.\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u96d9\u5074\u80a1\u52d5\u8108\u7121\u8108\u640f.\u8acb\u554f\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u8a72\u75c5\u60a3\u7b26\u5408Leriche's syndrome\nB. \u8a72\u75c5\u7076\u662f\u56e0left common iliac vein  \u53d7\u5230right common iliac artery \u58d3\u8feb\u6240\u81f4\nC. \u807d\u8a3a\u6642,\u5728\u809a\u81cd\u4e0b\u65b9\u7684\u8179\u90e8\u5e38\u53ef\u4ee5\u807d\u5230bruit\nD. \u75c5\u4eba\u7684\u75c7\u72c0\u56b4\u91cd\u5ea6\u8207\u5074\u679d\u5faa\u74b0(collateral circulation)\u6709\u95dc\nE. \u8eab\u9ad4\u8a3a\u5bdf\u53ef\u89c0\u5bdf\u5230\u4e0b\u80a2\u76ae\u819a\u840e\u7e2e\u8207\u4e0b\u80a2\u51b0\u51b7\n": "(B)", "108-20.\n\u4e00\u4f4d65\u6b72\u7537\u6027,\u6709\u9ad8\u8840\u58d3,\u7cd6\u5c3f\u75c5\u8207B\u578b\u809d\u708e\u5408\u4f75\u809d\u786c\u5316\u75c5\u53f2.\u6b64\u6b21\u5c31\u8a3a\u4e4b\u4e3b\u8a34\u70ba\u975c\u6b62\u6642\u5598\u4e0d\u904e\u6c23\u4f86,\u4e14\u6709\u7aef\u5750\u547c\u5438\u8207\u4e0b\u80a2\u6c34\u816b.\u904e\u53bb4\u500b\u6708\u6709\u4e7e\u54b3,\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\u8207\u5026\u6020\u611f.\u9ad4\u6eab\u70ba\u651d\u6c0f37\u5ea6,\u5fc3\u8df3\u70ba\u898f\u5247\u5fc3\u5f8b,\u6bcf\u5206\u941878\u8df3,\u547c\u5438\u70ba\u6bcf\u5206\u941817\u6b21.\u8840\u58d3\u70ba158/95\u6beb\u7c73\u6c5e\u67f1.\u80f8\u90e8X \u5149\u5448\u73fe\u5fc3\u81df\u64f4\u5927,\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5448\u73fe\u5927\u91cf\u5fc3\u5305\u819c\u7a4d\u6db2.\u5fc3\u5305\u819c\u7a7f\u523a\u53d6\u5fc3\u5305\u819c\u6db2\u9001\u6aa2\u5f8c\u5448\u73fe\u5982(\u9644\u8868). 3\u5929\u4e4b\u5f8c, \u5fc3\u5305\u819c\u6db2adenosine deaminase \u6fc3\u5ea6\u70ba118.1 U/L (\u6b63\u5e380.0~11.3 U/L).\u8acb\u554f\u5efa\u8b70\u4e0b\u5217\u4f55\u8005\u8655\u7f6e?\nA. \u9032\u884c\u53e6\u4e00\u6b21\u5fc3\u5305\u819c\u7a7f\u523a,\u518d\u9001\u4e00\u6b21\u5fc3\u5305\u6db2\u7d30\u80de\u5b78\u6aa2\u67e5\u8207\u7d30\u83cc\u57f9\u990a\nB. \u7d66\u4e88\u6297\u7d50\u6838\u83cc\u85e5\u7269\u6cbb\u7642\nC. \u7d66\u4e88\u79cb\u6c34\u4ed9\u7d20\u6cbb\u7642\nD. \u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642\nE. \u9032\u884c Interferon-gamma  release assay\n": "(B)", "108-21.\n\u6709\u95dc\u7c92\u7dda\u9ad4\u75be\u75c5(mitochondria disease)\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u75c5\u60a3\u53ef\u4ee5\u6709\u807d\u529b\u969c\u7919 (sensorineural hearing impairment)\nB. \u75c5\u60a3\u53ef\u4ee5\u5448\u73fe\u7cd6\u5c3f\u75c5\nC. \u75c5\u60a3\u53ef\u4ee5\u5448\u73fe\u4e73\u9178\u4e2d\u6bd2 (lactic acidosis)\nD. \u75c5\u60a3\u53ef\u4ee5\u6709\u5fc3\u81df\u50b3\u5c0e\u969c\u7919\nE. \u7c92\u7dda\u9ad4\u75c5\u60a3\u7684\u5152\u5b50\u4e5f\u6703\u7f79\u60a3\u9019\u500b\u75be\u75c5,\u4e26\u6703\u5c07\u6b64\u907a\u50b3\u75be\u75c5\u50b3\u905e\u81f3\u4ed6\u7684\u4e0b\u4e00\u4ee3\n": "(E)", "108-22.\n\u4e00\u540d65\u6b72\u7537\u6027,\u56e0\u51a0\u72c0\u52d5\u8108\u75c5\u63a5\u53d7\u7e5e\u9053\u624b\u8853.\u75c5\u4eba\u56e0\u5fc3\u60b8\u81f3\u6025\u8a3a\u5c31\u8a3a,\u5fc3\u96fb\u5716(\u5982\u5716).\u75c5\u4eba\u8840\u58d3\u70ba100/50\u6beb\u7c73\u6c5e\u67f1,\u610f\u8b58\u6e05\u695a\u4f46\u865b\u5f31,\u4e0d\u6642\u6253\u5475\u6b20.\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u8aa4?\nA. \u8a72\u75c5\u60a3\u5fc3\u96fb\u5716\u80f8\u524d\u5c0e\u6975\u6c92\u6709\u540c\u76f8 (concordance)\u8b8a\u5316\nB. \u8a72\u75c5\u60a3\u5fc3\u96fb\u5716\u6709\u623f\u5ba4\u89e3\u96e2(AV dissociation)\nC. \u8a72\u75c5\u60a3\u5fc3\u96fb\u5716QRS duration >140 msec\nD. \u8a72\u75c5\u60a3\u5fc3\u96fb\u5716\u5224\u8b80\u70ba\u5fc3\u5ba4\u4e0a\u5fc3\u640f\u904e\u901f (supraventricular tachycardia) \u5408\u4f75\u53f3\u675f\u652f\u50b3\u5c0e\u963b\u65b7\nE. \u6b64\u75c5\u60a3\u4e4b\u62bd\u8840\u6aa2\u67e5\u61c9\u6db5\u84cbtroponin T, creatine kinase , \u8207 creatine kinase  MB\n": "(D)", "109-1.\u5c31\u75be\u75c5\u4e4b\u9810\u9632\u53ca\u8655\u7f6e\uff0c\u8acb\u554f\u4e0b\u5217\u500b\u6848\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u4e0d\u7576\u4e4b\u8209\uff1f    \nA.78\u6b72\u8001\u7fc1\u6709\u5fc3\u96fb\u5716\u5448\u73feST -T\u8b8a\u5316\uff0c\u75c5\u4eba\u8840\u58d3128 /74 mmHg, \u5fc3\u8df374 /min, \u6b63\u5e38\u5f8b\u52d5 \uff0c\u5c1a\u7121\u80f8\u75db\u6216\u5fc3\u60b8\n\u7b49\u75c5\u72c0\uff0c\u53ef\u505a\u5167\u79d1\u9580\u8a3a\u6cbb\u7642 \uff0c\u4e0d\u5fc5\u7acb\u523b\u505a\u7d93\u76ae\u51a0\u72c0\u52d5\u8108\u4ecb\u5165\u6cbb\u7642 (Percutaneous coronary \nintervention )\nB.32\u6b72\u5a66\u4eba\u6bcf\u9022\u6708\u7d93\u4f86\u81e8\u90fd\u6709\u5fc3\u60b6\u75c7\u72c0 \uff0c\u7d93\u51a0\u72c0\u52d5\u8108\u9020\u5f71\u53ca\u8d85\u97f3\u6ce2\u5fc3\u5716\u90fd\u986f\u793a\u6b63\u5e38\u7d50\u69cb\u53ca\u529f\u80fd \uff0c\u70ba\u5b89\n\u5168\u8d77\u898b\u4ecd\u61c9\u8acb\u6bcf\u516d\u500b\u6708\u56de\u8a3a\u8ffd\u8e64\nC.56\u6b72\u7537\u6027\u516c\u53f8\u7d93\u7406\u4eba \uff0c\u6709\u9ad8\u8840\u58d3\u53ca\u9ad8\u8102\u8840 \u3002\u4f46\u70ba\u9632\u6cbb\u5fc3\u8840\u7ba1\u75c5 \uff0c\u61c9\u505a\u98a8\u96aa\u8a55\u4f30 \uff0c\u4e26\u5728\u9580\u8a3a\u8ffd\u8e64\u4f5c\u751f\n\u6d3b\u65b9\u5f0f\u77ef\u6b63 (Lifestyle  modification )\nD.48\u6b72\u7537\u6027\u5f9e\u5546 \uff0c\u80f8\u60b6\u7d93\u7531\u7406\u5b78\u6aa2\u67e5\u53ca\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5f8c \uff0c\u4e26\u7121\u4efb\u4f55\u5fc3\u8840\u7ba1\u75be\u75c5\u53ca\u98a8\u96aa \uff0c\u4e0d\u5fc5\u5efa\u8b70\u4f5c\u5168\u8eab\n\u5065\u5eb7\u6aa2\u67e5\nE.102\u6b72\u8001\u5a66\u4eba30\u5e74\u524d\u56e0\u9ad8\u8840\u58d3\u5230\u9580\u8a3a\u6cbb\u7642 \uff0c\u4e94\u5e74\u524d\u958b\u59cb\u6709\u9ad4\u529b\u4e0d\u652f \u3001\u5bb9\u6613\u75b2\u5026 \u3001\u672a\u6709\u80f8\u60b6 \u3001\u7729\u6688\u3001\u547c\n\u5438\u56f0\u96e3\u7b49\u75c7\u72c0 \uff0c\u7d93\u78ba\u8a3a\u70ba\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\u5168 \uff0c\u4f7f\u7528\u85e5\u7269\u6cbb\u7642 \uff0c\u75c7\u72c0\u6539\u5584 \u3002\u61c9\u5efa\u8b70\u9019\u4f4d\u8001\u5a66\u4eba\u6bcf 6\u621612\u500b\n\u6708\u56de\u8a3a\u8a55\u4f30 \uff0c\u5982\u6709\u60e1\u5316 \uff0c\u624d\u5efa\u8b70\u4f4f\u9662\u505a\u5916\u79d1\u624b\u8853\u6cbb\u7642\n": "[B]", "109-2.\u6709\u4f4d38\u6b72\u6797\u5c0f\u59d0\u56e0\u5fc3\u60b8\u53ca\u5931\u7720\u591a\u500b\u6708\u800c\u6c42\u8a3a \uff0c\u7d93\u8eab\u9ad4\u6aa2\u67e5\u4e26\u7121\u91cd\u5927\u7570\u5e38 \uff0c\u552f\u6709\u5de6\u80f8\u9aa8\u4e0b\u7de3\u8655\u6709\u8f15\u5ea6 (Gr \n1-2/6)\u4e2d\u671f\u5fc3\u7e2e\u96dc\u97f3 (Mid-systolic murmur )\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u662f\u78ba\u5b9a\u8a3a\u65b7\u7684\u5fc5\u8981\u8655\u7f6e \uff1f\n(1) \u5fc3\u96fb\u5716(Electrocardiogram )\n(2) \u80f8\u90e8X\u5149(Chest X-ray)\n(3) \u8d85\u97f3\u6ce2\u5fc3\u5716 (Echocardiogram )\n(4) \u5fc3\u81df\u78c1\u632f\u9020\u5f71 (Cardiac MRI )\n(5) Thallium 201 \u5fc3\u808c\u704c\u6ce8\u5f71\u50cf (Thallium 201 Perfusion Scan )\n(6) \u5fc3\u81df\u5c08\u79d1\u6703\u8a3a   \nA.(1)+(2)+(3)\nB.(2)+(4)+(6)\nC.(1)+(3)+(5)\nD.(4)+(5)+(6)\nE.(1)+(2)+(5)\n": "[A]", "109-3.\u5fc3\u8870\u7aed(Heart failure, HF )\u662f\u81e8\u5e8a\u5f88\u91cd\u8981\u7684\u8ab2\u984c \uff0c\u53ef\u5206\u6210\u5de6\u5fc3\u5ba4\u5c04\u51fa\u6bd4\u7387\u4f4e\u9000\u5fc3\u8870\u7aed (Heart Failure reduced \nEjection Fraction ,HFrEF)\u53ca\u5c04\u51fa\u6bd4\u7387\u6b63\u5e38\u5fc3\u8870\u7aed (Heart Failure preserved Ejection Fraction ,HFpEF) \uff0c\u8acb\n\u554f\u4e0b\u5217\u4f55\u9805\u7684\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684 \uff1f   \nA.\u516b\u5341\u4e94\u6b72\u4ee5\u4e0a\u8001\u4eba\u7d0440%\u6709\u5404\u7a2e\u4e0d\u540c\u7a0b\u5ea6\u7684\u5fc3\u8870\u7aed\nB.\u6025\u6027\u5fc3\u8870\u7aed\u75c5\u4eba\u7684\u75c5\u6cc1\u60e1\u5316\u591a\u8207\u539f\u59cb\u75c5\u56e0\u8f49\u5287\u6709\u95dc \uff0c\u4f46\u4e0d\u80fd\u5ffd\u8996\u75c5\u4eba\u56e0\u5176\u4ed6\u6162\u6027\u75be\u75c5\u8a98\u767c \uff0c\u7528\u85e5\u9806\u5f9e\n\u6027\u4e0d\u4f73\u6216\u85e5\u7269\u4ea4\u4e92\u4f5c\u7528\u5c0e\u81f4\nC.\u5de6\u5fc3\u5ba4HFrEF \u7d04\u4f54\u5fc3\u8870\u7aed\u7684\u534a\u6578\u4ee5\u4e0a\nD.\u5de6\u5fc3\u5ba4HFrEF\uff0c\u591a\u898b\u5728\u5973\u6027\u3001\u8001\u5e74\u4eba\u7279\u5225\u5408\u4f75\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u53f2\u8005\nE.\u5de6\u5fc3\u5ba4HFpEF \u4e4b\u6b7b\u4ea1\u7387\u9060\u6bd4\u5de6\u5fc3\u5ba4HFrEF\u70ba\u4f4e\uff0c\u4f46\u4ecd\u6bd4\u540c\u5e74\u9f61\u7684\u6b63\u5e38\u4eba\u70ba\u9ad8\n": "[D]", "109-4.\u96a8\u8457\u91ab\u7642\u74b0\u5883\u53ca\u91ab\u5b78\u7684\u9032\u6b65 \uff0c\u6709\u95dc\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e (Infective endocarditis ,IE )\u7684\u81e8\u5e8a\u5be6\u6cc1\u6709\u8a31\u591a\u8b8a\u5316 \uff0c\u8acb\n\u554f\u4ee5\u4e0b\u7684\u8aaa\u6cd5\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684 \uff1f   \nA.\u96a8\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u76db\u884c\u4e4b\u6e1b\u5c11\uff0c\u7f79\u60a3IE\u7684\u75c5\u4eba\u591a\u504f\u5411\u8001\u9f61\u5316\nB.\u5fc3\u81df\u74e3\u819c\u75c5\u8b8a\u7522\u751f\u7684\u5fc3\u5167\u4e82\u6d41(Turbulent flow) \u8207IE\u767c\u751f\u8d05\u751f\u7269(Vegetation)\u7684\u5f62\u6210\u6709\u95dc\nC.\u4e8c\u5c16\u74e3\u812b\u5782\u53ca\u80a5\u539a\u6027\u5fc3\u808c\u75c5\u90fd\u6709\u767c\u751fIE\u7684\u98a8\u96aa\nD.\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621 (Systemic lupus erythematosus, SLE )\u7684\u6d88\u8017\u6027\u8d05\u7269 (Marantic vegetation )\u4e0d\u5177\u8840\u7ba1\n\u71df\u990a, \u53ef\u662f\u4e00\u65e6\u7d30\u83cc\u9644\u7740\u611f\u67d3 \uff0c\u4e0d\u6613\u6297\u751f\u7d20\u6cbb\u597d   \nE.46\u6b72\u5973\u6027\u75c5\u4eba\u4e3b\u8a34\u611f\u5192 \u3001\u767c\u71d2\u53ca\u8f15\u5ea6\u547c\u5438\u56f0\u96e3 \uff0c\u6709\u5169\u9031\u4e4b\u4e45 \uff0c\u8eab\u9ad4\u6aa2\u67e5\u6709\u5fc3\u81df\u96dc\u97f3, \u624b\u638c\u6709\u985e\u4f3c\n\u7684Osler node, \u7d93\u63a1\u8840\u4e00\u6b21 ,\u7d30\u83cc\u57f9\u990a\u6709\u91d1\u9ec3\u8272\u8461\u8404\u7403\u7d30\u83cc \uff0c\u6309Duke criteria \uff0c\u672c\u75c5\u4f8b\u61c9\u53ef\u78ba\u8a3a\u611f\u67d3\u6027\n\u5fc3\u5167\u819c\u708e\n": "[E]", "109-5.\u5fc3\u5ba4\u983b\u8108 (Ventricular tachycardia, VT) \u662f\u5a01\u8105\u751f\u547d\u6027\u5fc3\u5f8b\u4e0d\u6574 (Life-threatening arrhythmia )\uff0c\u6709\u95dc\u5176\u8a3a\u65b7\n\u53ca\u6cbb\u7642\u7684\u8aaa\u6cd5 \uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u6b63\u78ba \uff1f   \nA.\u6709\u5668\u8cea\u6027\u5fc3\u81df\u75c5 (Organic heart disease )\u7684\u6301\u7e8c\u6027 (Sustained )VT\u6642\uff0c\u61c9\u7f6e\u653e\u5fc3\u5167\u53bb\u986b\u5668 (Intra-cardiac \ndefibrillator )\nB.\u9577\u671f\u4f7f\u7528\u6297\u5fc3\u5f8b\u4e0d\u6574\u85e5\u7269\u53ef\u6cbb\u7642\u7279\u767c\u6027\u5fc3\u5ba4\u5feb\u8df3 (Idiopathic VT )\uff0c\u552f\u5b9c\u5148\u63a1\u7528\u5c0e\u7ba1\u71d2\u707c\u8853 (Catheter \nablation)\nC.\u6709VT\u767c\u4f5c\u75c5\u4eba\uff0c\u4e00\u5b9a\u6709\u91cd\u5ea6\u5668\u8cea\u6027\u5fc3\u81df\u75c5\nD.\u5bec\u95ca\u5947\u7570\u72c0QRS \u6ce2(Wide,Bizarre QRS waves )\uff0c\u878d\u548c\u8df3(Fusion beat) \u3001\u6355\u6349\u8df3(Capture beat) \u53ca\u623f\u5ba4\n\u8df3\u89e3\u96e2 (A-V dissociation )\u662f\u8a3a\u65b7VT\u7684\u5fc3\u96fb\u5716\u689d\u4ef6 (Criteria) \uff0c\u4f46\u50c5\u53ea\u623f\u5ba4\u8df3\u89e3\u96e2\u662f\u552f\u4e00\u53ef\u9760\u7684\u6839\u64da\nE.\u96a8\u8457\u51a0\u8108\u8840\u7ba1\u518d\u901a\u8853\u4e4b\u767c\u9054 \uff0cST\u6ce2\u4e0a\u6607\u578b\u7684\u6025\u6027\u5fc3\u808c\u6897\u585eST elevation acute myocardial \ninfarction )\u4f75\u767cVT\u591a\u5728\u6025\u6027\u51a0\u5fc3\u75c7\u4e00\u9031\u5167\n": "[C]", "109-6.\u7531\u65bc\u91ab\u7642\u79d1\u6280\u7684\u9032\u6b65\u53ca\u81e8\u5e8a\u5be6\u4f8b\u7684\u7d93\u9a57\u7d2f\u7a4d \uff0c\u4e0b\u5217\u6709\u95dc\u80a5\u539a\u6027\u5fc3\u808c\u75c5 (Hypertrophic cardiomyopathy) \u7684\u81e8\n\u5e8a\u7279\u8cea\uff0c\u4f55\u9805\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5 \uff1f   \nA.\u5176\u5728\u4eba\u53e3\u7684\u76db\u884c\u7387\u662f1/500\uff1b\u6b7b\u4ea1\u7387< 1%\nB.\u4e09\u5206\u4e4b\u4e00\u7684\u5e74\u8f15\u4eba\u731d\u6b7b (sudden cardiac deaths) \u662f\u56e0\u80a5\u539a\u6027\u5fc3\u808c\u75c5\u800c\u8d77 \uff0c\u4e14\u591a\u898b\u5fc3\u5ba4\u983b\u8108\u6216\u5fc3\u5ba4\u7e96\u7dad\n\u986b\u52d5(Ventricular tachycardia or fibrillation )\nC.\u5229\u7528\u96fb\u6c23\u751f\u7406\u53ca\u57fa\u56e0\u6aa2\u6e2c\u5df2\u80fd\u9810\u671f\u5176\u731d\u6b7b\u4e4b\u98a8\u96aa\nD.\u904b\u52d5\u5f8c\u4f4e\u8840\u58d3 \u3001\u5fc3\u5ba4\u4e2d\u9694\u539a\u5ea6 >3cm\u3001\u6709\u7729\u6688\u75c5\u53f2\u6216\u5fc3\u5ba4\u5feb\u8df3\u4e4b\u5fc3\u96fb\u5716\u8a18\u9304 \uff0c\u90fd\u662f\u5224\u5b9a\u731d\u6b7b\u98a8\u96aa\u7684\u6307\n\u6a19\nE.Gadolinium\u78c1\u632f\u5f71\u50cf\u53ef\u986f\u793a\u5fc3\u808c\u7e96\u7dad\u5316(Fibrosis) \u7a0b\u5ea6\u662f\u56b4\u91cd\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u53ef\u9760\u9810\u6e2c\u6307\u6a19\n": "[C]", "109-7.\u75c5\u4eba58\u6b72\u5a66\u5973 \uff0c\u4e3b\u8a34\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \u3001\u9ad4\u91cd\u4e00\u661f\u671f\u9593\u5f9e84\u516c\u65a4\u589e\u52a0\u81f387\u516c\u65a4 \uff0c\u96d9\u8173\u6c34\u816b\u6709\u4e00\u9031\u4e4b\u4e45 \uff0c\u6b65\n\u5c65\u96e3\u884c\uff0c\u521d\u6b65\u6aa2\u67e5\u5448\u73fe\u5fc3\u81df\u64f4\u5927 \uff0c\u4e43\u524d\u5f80\u91ab\u5b78\u4e2d\u5fc3\u8a3a\u7642 \uff0c\u5728\u6025\u8a3a\u521d\u6b65\u6aa2\u67e5Chest X -ray\u3001\u5fc3\u81df\u8d85\u97f3\u6ce2\u548c\u5fc3\n\u96fb\u5716(\u5982\u5716)\uff0c\u65cb\u5373\u4f4f\u9662 \u3002\u75c5\u4eba\u4e03\u5e74\u524d\u6709\u5de6\u4e73\u764c\u7d93\u5207\u9664\u624b\u8853 \uff0c\u81f3\u4eca\u4e26\u672a\u5b8c\u5168\u7de9\u89e3 \u3002\u75c5\u4eba\u8fd1\u4e94\u5e74\u4f86 \uff0c\u6709\u9ad8\u8840\u58d3\n\u53ca\u7cd6\u5c3f\u75c5 \uff0c\u90fd\u85e5\u7269\u6cbb\u7642\u4e2d \u3002\u751f\u547d\u5fb5\u8c61 \uff1aT: 36.2\u00b0C,P:81/min,R:20/min,BP:150/84mmHg ,Pain score :0\u3002\u75c5\n\u53f2\u8a62\u554f\u53ca\u8eab\u9ad4\u7406\u5b78\u6aa2\u67e5 \uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u5fc3\u8840\u7ba1\u75c5\u7406\u5b78\u6aa2\u67e5 (Cardiovascular approach )\uff0c\u662f\u60a8\u61c9\u8a72\u89c0\u5bdf\u7684\u6a19\n\u7684\uff1f\n(1) \u6d88\u6c88\u7684S1 and /or S2\n(2) S3 and S4\n(3) Pericardial friction\n(4) Mid-systolic murmur and pansystolic murmur\n(5) Kussmaul sign\n(6) Pulsating congestive liver   \nA.(1)+(2)+(3)\nB.(2)+(4)+(6)\nC.(1)+(3)+(5)\nD.(4)+(5)+(6)\nE.(3)+(4)+(5)   \n": "[C]", "109-8.86\u6b72\u8001\u592a\u592a\u56e0\u6709\u4e8c\u5c0f\u6642\u7684\u80f8\u60b6\u524d\u5f80\u91ab\u9662\u6025\u8a3a\u6c42\u6cbb \u3002\u75c5\u4eba\u5728\u5341\u5e74\u524d\u56e0\u6025\u6027\u5fc3\u808c\u6897\u585e\u800c\u4f4f\u9662 \uff0c\u5728\u5de6\u524d\u964d\u652f\u51a0\u72c0\n\u52d5\u8108(Left anterior descending artery )\u7f6e\u653e\u51a0\u72c0\u52d5\u8108\u652f\u67b6 \u3002\u75c5\u4eba\u5c1a\u6709\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u53ca\u8001\u9f61\u5931\u667a\u8a3a\u65b7 \u3002\u7406\u5b78\n\u6aa2\u67e5\u767c\u73fe \uff1aBH\uff1a156 cm, BW \uff1a48 kg\uff1bBMI\uff1a19.7 kg/m\u00b2\uff1bT/P/R\uff1a 36.2/66/22\uff1bBP\uff1a158/90 mmHg \uff1b\u5728\n\u6025\u8a3a\u7684\u5176\u4ed6\u6aa2\u9a57\u5c1a\u7121\u91cd\u5927\u7570\u5e38 \uff0c\u5176\u7cfb\u5217\u7684\u751f\u5316\u6aa2\u9a57 \u3001Chest X ray \u3001\u5fc3\u96fb\u5716\u5982\u9644\u5716 \uff1a   \nA.\u9ad8\u8840\u58d3\u6027\u5fc3\u81df\u75c5\nB.\u5de6\u8ff4\u65cb\u51a0\u8108\u6813\u585e\u4e4bNon-STE acute myocardial infarction\nC.\u5de6\u524d\u964d\u652f\u51a0\u8108\u6813\u585e\u4e4bNon-STE acute myocardial infarction\nD.\u5de6\u524d\u964d\u652f\u51a0\u8108\u6813\u585e\u4e4bSTE acute myocardial infarction\nE.\u5de6\u8ff4\u65cb\u51a0\u8108\u6813\u585e\u4e4bSTE acute myocardial infarction\n": "[D]", "109-9.\u6709\u95dc\u4e8c\u5c16\u74e3\u819c\u9589\u9396\u4e0d\u5168 (Mitral regurgitation, MR) \u53ef\u5206\u539f\u59cb\u6027\u53ca\u7e8c\u767c\u6027 (Primary and Secondary MR )\u5169\n\u7a2e\uff0c\u5f9e\u8af8\u591a\u81e8\u5e8a\u5be6\u8a3c \uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u7e8c\u767c\u6027MR\u7684\u6b63\u78ba\u8aaa\u6cd5 \uff1f   \nA.\u5de6\u5fc3\u5ba4\u5c04\u51fa\u6bd4\u7387\u4f4e\u9000\u7684\u5fc3\u8870\u7aed (Heart Failure reduced Ejection Fraction, HFrEF) \u7684\u75c5\u4eba\u5927\u670975 %\u7684\u6709\n\u7e8c\u767c\u6027MR\nB.\u7e8c\u767c\u6027MR\u591a\u8087\u56e0\u65bc\u4e8c\u5c16\u74e3\u74b0\u64f4\u5927 (Mitral annular dilatation )\u53ca\u4e73\u982d\u808c\u7570\u5e38 \uff0c\u5f71\u97ff\u4e8c\u5c16\u74e3\u9589\u5408 \uff0c\u5916\u79d1\u5fa9\n\u539f\u624b\u8853\u6709\u826f\u597d\u6cbb\u7642\u6210\u7e3e\nC.\u5f9e\u81e8\u5e8a\u75c7\u72c0\u4e4b\u60e1\u5316\u53ca\u807d\u8a3a\u7570\u5e38\u4e4b\u5f37\u5ea6\u4e0d\u53ef\u70baMR\u7684\u56b4\u91cd\u5ea6\u53c3\u8003\nD.\u4e8c\u5c16\u74e3\u819c\u7684\u75c5\u8b8a\u4e0d\u662f\u6c7a\u5b9a\u7e8c\u767c\u6027MR\u7684\u95dc\u9375\u56e0\u7d20\nE.\u4f7f\u7528\u5fc3\u81df\u518d\u540c\u6b65\u5316\u6cbb\u7642 (Cardiac resynchronization therapy) \u6539\u5584\u5de6\u5fc3\u5ba4\u5fc3\u808c\u5931\u80fd \uff0c\u6709\u52a9\u7e8c\u767c\u6027MR \u7684\n\u56b4\u91cd\u5ea6\n": "[B]", "109-10.\u4f9d\u636e2016 \u5e74Taiwan Society of Cardiology\u6709\u95dc\u975e\u74e3\u819c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (Atrial fibrillation) \u75c5\u4eba\u4e4b\u9810\u9632\u8166\u4e2d\u98a8\n\u7684\u6cbb\u7642\u6307\u5f15 \uff0c\u8acb\u554f\u4f55\u7a2e\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684 \uff1f   \nA.Aspirin\u5c0d\u8166\u4e2d\u98a8\u7684\u9810\u9632\u662f\u7121\u7642\u6548\nB.\u5305\u62ec\u53f0\u7063\u5728\u5167\u7684\u4e9e\u6d32\u4eba \uff0c\u81e8\u5e8a\u5be6\u8a3c\u767c\u73fe\u4ee5\u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269 (New Oral Anti -Coagulants, NOACs) \n\u6bd4 Warfarin \u5c0d\u8166\u4e2d\u98a8\u7684\u9810\u9632\u66f4\u5177\u7642\u6548\nC.\u4e03\u5341\u4e94\u6b72\u8001\u5e74\u4eba\u5408\u4f75\u6709\u4e2d -\u91cd\u5ea6\u6162\u6027\u814e\u8870\u7aed\u6642 \uff0c\u5efa\u8b70\u53ef\u4f7f\u7528\u4f4e\u5291\u91cfNOAC \uff0c\u4f46\u82e5\u4f7f\u7528Warfarin \uff0cTime \nto therapeutic range > 70 %\u6642\uff0c\u53ef\u6539\u7528Warfarin\nD.\u5c31\u4e9e\u6d32\u75c5\u4eba\u800c\u8a00\uff0c\u4f7f\u7528\u4f4e\u5291\u91cfNOACs \u53ef\u4f5c\u70ba\u5982Warfarin\u4e00\u6a23\u5b89\u5168\u7684\u6cbb\u7642\u9078\u64c7\nE.\u4e9e\u6d32\u75c5\u4eba\u4f7f\u7528Warfarin \u6216NOAC\u90fd\u6709\u8f03\u9ad8\u8166\u4e2d\u98a8 \u3001\u5927\u51fa\u8840\u53ca\u9871\u5167\u51fa\u8840\u7684\u767c\u751f \uff0c\u662f\u4ee5\u5efa\u8b70\u542bAspirin \u53ca \nClopidogrel\u7684\u96d9\u91cd\u6297\u8840\u5c0f\u677f\u6cbb\u7642 (Dual antiplatelet therapy, DAPT) \u4ee3\u66ff\n": "[E]", "109-11.\u6709\u95dc\u5fc3\u808c\u708e(Myocarditis)\u7684\u6700\u8fd1\u9032\u5c55\uff0c\u4e0b\u5217\u4f55\u5247\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5\u7684\uff1f    \nA.\u5f9e\u4eba\u53e3\u63a8\u4f30\uff0c\u5fc3\u808c\u708e\u7684\u767c\u751f\u7387\u7d04\u842c\u5206\u4e4b\u4e00\u81f3\u5341\u842c\u5206\u4e4b\u4e00\uff0c\u4f46\u5728\u5e74\u9752\u731d\u6b7b\u75c5\u4eba\u7684\u75c5\u7406\u89e3\u5256\u537b\u9ad8\u905412%\nB.\u75c5\u7406\u8a3a\u65b7\u5fc3\u808c\u708e\u5fc5\u9808\u5fc3\u808c\u7121\u7f3a\u8840\u6027\u7684\u7d30\u80de\u640d\u50b7 \u3001\u9000\u5316\u6216\u58de\u6b7b (Injury, degeneration or necrosis )\u53ca\u767c\u708e\n\u7d30\u80de\u4fb5\u6f64\u8b8a\u5316 \uff0c\u4f46\u771f\u5be6\u7684\u81e8\u5e8a\u4e16\u754c\u88e1 \uff0c\u5927\u90e8\u4efd\u5fc3\u808c\u708e\u662f\u81e8\u5e8a\u8a3a\u65b7 \uff0c\u4e0d\u662f\u75c5\u7406\u8a3a\u65b7\nC.\u975c\u8108\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d (Intravenous immunoglobulin, IVIG )\u5c0d\u5e74\u9752\u4eba\u7684\u6025\u6027\u5fc3\u808c\u708e\u6709\u6548 \uff0c\u552f\u5176\u7d50\u8ad6\u6709\u5f85\n\u5b8c\u6574\u7684\u81e8\u5e8a\u8a66\u9a57\u7684\u9a57\u8a3c\nD.\u611b\u6ecb\u75c5\u6bd2\u53ca\u6dcb\u5df4\u5fc3\u808c\u708e\u90fd\u662f\u9810\u5f8c\u56b4\u91cd\u7684\u5fc3\u808c\u708e\nE.\u5de8\u7d30\u80de\u5fc3\u808c\u708e\u591a\u898b\u8001\u5e74\u4eba \uff0c\u6642\u4ee5\u80f8\u75db \u3001\u5fc3\u8870\u7aed\u3001\u60e1\u6027\u5fc3\u5f8b\u4e0d\u6574\u6216\u50b3\u5c0e\u963b\u6eef \uff0c\u6709\u8cf4\u81e8\u5e8a\u8b66\u89ba\u65e9\u671f\u5207\u7247\u8a3a\n\u65b7\uff0c\u76e1\u65e9\u514d\u75ab\u6cbb\u7642\u6709\u6548 \uff0c\u552f\u6b7b\u4ea1\u7387\u9ad8 \uff0c\u6709\u8cf4\u5fc3\u81df\u79fb\u690d\u6cbb\u7642\n": "[E]", "109-12.\u8acb\u554f\u4e0b\u5217\u6709\u95dc\u5fc3\u56e0\u6027\u4f11\u514b(Cardiogenic shock)\u7684\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f    \nA.\u6025\u6027\u5fc3\u808c\u6897\u585e\u7684\u5fc3\u56e0\u6027\u4f11\u514b\u767c\u751f\u7387\u5df2\u56e0\u65e9\u671f\u4f7f\u7528\u518d\u704c\u6ce8\u6cbb\u7642\uff08Reperfusion therapy)\u800c\u6e1b\u5c11\u4e865-10%   \nB.\u6709\u5fc3\u56e0\u6027\u4f11\u514b\u7684\u5fc3\u808c\u6897\u585e\u75c5\u4eba\u4ee5\u591a\u689d\u51a0\u72c0\u52d5\u8108\u75c5\u8b8a\u70ba\u591a \uff0c\u4e14\u7d0480%\u662f\u4ee5ST\u6ce2\u6bb5\u4e0a\u6607\u5fc3\u808c\u6897\u585e \uff08ST \nelevation myocardial infarction \uff09\u7684\u5fc3\u96fb\u5716\u8868\u73fe\nC.\u5728\u81e8\u5e8a\u5be6\u8b49\u4e0a\uff0c\u6cbb\u7642\u5fc3\u56e0\u6027\u4f11\u514b\u4ee5\u7dca\u6025\u5916\u79d1\u51a0\u8108\u7e5e\u9053\u624b\u8853\u70ba\u5b9c\nD.\u5728\u8af8\u591a\u7684\u5927\u578b\u81e8\u5e8a\u8a66\u9a57 \uff0c\u5229\u7528\u8840\u7ba1\u4f5c\u7528\u5291 \uff08Vasoactive agents) \u5982Norepinephrine, Dopamine, \nDobutamine \u6cbb\u7642\u5fc3\u56e0\u6027\u4f11\u514b \uff0c\u7121\u52a9\u9810\u5f8c\u4e4b\u6539\u5584\nE.\u4f7f\u7528\u4e3b\u52d5\u8108\u5167\u6c23\u7403\u5e6b\u6d66 \uff08Intra-aortic balloon pump \uff0cIABP\uff09\u6cbb\u7642\u5fc3\u56e0\u6027\u4f11\u514b \uff0c\u5728\u81e8\u5e8a\u8a66\u9a57\u8cc7\u6599\u4e26\u4e0d\n\u986f\u793a\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\n": "[C]", "109-13.\u9ad8\u5b89\u6c0f\u8840\u7ba1\u708e(Takayasu arteritis)\uff0c\u6700\u5e38\u5f71\u97ff\u7684\u8840\u7ba1\u70ba\uff1f    \nA.\u814e\u52d5\u8108(renal artery)\nB.\u8179\u4e3b\u52d5\u8108(abdominal aorta)\nC.\u9396\u9aa8\u4e0b\u52d5\u8108(subclavian artery)\nD.\u51a0\u72c0\u52d5\u8108(coronary artery)\nE.\u4e3b\u52d5\u8108\u5f13(aortic arch)\n": "[C]", "109-14.\u6709\u95dc\u7ae0\u9b5a\u58fa\u5fc3\u808c\u75c7(Takotsubo cardiomyopathy)\u4e4b\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u81e8\u5e8a\u8868\u73fe\u5305\u62ec\u80ba\u6c34\u816b\uff0c\u4f4e\u8840\u58d3\u8207\u5178\u578b\u5fc3\u7d5e\u75db\nB.\u5fc3\u81df\u6536\u7e2e\u529f\u80fd\u7570\u5e38\u53ef\u4ee5\u5728\u6578\u5929\u5230\u6578\u9031\u5f8c\u7de9\u89e3\nC.\u60a3\u8005\u4e4b\u5fc3\u96fb\u5716\u5e38\u5448\u73fe\u5178\u578b\u5fc3\u808c\u6897\u585e\u4e4b\u8b8a\u5316\nD.\u9020\u6210\u4e4b\u56e0\u7d20\u5e38\u70ba\u5f37\u70c8\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u6216\u5152\u82ef\u915a\u80fa\u6bd2\u6027(catecholamine toxicity)\nE.\u53e3\u670d\u6297\u51dd\u8840\u5291\u662f\u5fc5\u8981\u4e4b\u85e5\u7269\u6cbb\u7642\n": "[E]", "109-15.\u6709\u95dc\u6297\u51dd\u8840\u5291\u7684\u89e3\u85e5(antidote)\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.Heparin\u7684antidote\u662fprotamine\nB.Warfarin \u7684antidote\u662fvitamin K\nC.Dabigatran \u7684antidote\u662fidarucizumab\nD.Rivaroxaban \u7684antidote\u662fandexanet\nE.Apixaban \u7684antidote\u662fidarucizumab\n": "[E]", "109-16.\u6709\u95dc\u80ba\u52d5\u8108\u9ad8\u58d3\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u4e00\u6c27\u5316\u78b3\u7030\u6f2b\u91cf (Diffusing capacities of the lungs for carbon monoxide DLCO) \u5728\u80ba\u52d5\u8108\u9ad8\u58d3\u60a3\u8005\u6703\n\u4e0b\u964d\nB.\u5fc3\u81df\u8d85\u97f3\u6ce2\u7684\u5f71\u50cf(\u5982\u9644\u5716)\nC.\u5728\u7121\u7761\u7720\u547c\u5438\u969c\u7919\u7684\u80ba\u52d5\u8108\u9ad8\u58d3\u60a3\u8005,\u591c\u9593\u7f3a\u6c27(nocturnal desaturation)\u4e26\u4e0d\u5e38\u898b\nD.\u80ba\u52d5\u8108\u9ad8\u58d3\u60a3\u8005\u5747\u61c9\u63a5\u53d7\u6297\u6838\u6297\u9ad4 (antinuclear antibody )\uff0c\u985e\u98a8\u6fd5\u56e0\u5b50 (rheumatoid factor )\uff0cScl \n70\u6297\u9ad4 (anti-scl-70 antibody )\u6aa2\u6e2c\nE.\u5fc3\u97f3\u807d\u8a3a\u6642\uff0c\u7b2c\u4e8c\u5fc3\u97f3\u80ba\u52d5\u8108\u74e3\u6210\u5206\u6703\u52a0\u91cd(accentuated P2)\n": "[C]", "109-17.\u6709\u95dc\u6025\u6027\u814e\u640d\u50b7(acute kidney injury)\u9020\u6210\u5fc3\u81df\u8870\u7aed\u4e4b\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u51fa\u9662\u5f8c\uff0c\u56e0\u5fc3\u81df\u8870\u7aed\u518d\u4f4f\u9662\u98a8\u96aa\u660e\u986f\u589e\u52a0\nB.\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u51fa\u9662\u5f8c\uff0c\u56e0\u5fc3\u8840\u7ba1\u75be\u75c5\u6b7b\u4ea1\u6216\u6162\u6027\u5fc3\u81df\u8870\u7aed\u6bd4\u7387\u660e\u986f\u589e\u52a0\nC.\u6025\u6027\u814e\u640d\u50b7\u91cd\u75c7\u60a3\u8005\uff0c\u534a\u4e73\u7cd6\u51dd\u96c6\u7d20-3 (galectin 3)\u8207\u5fc3\u808c\u50b7\u5bb3\u6709\u76f8\u95dc\nD.\u5728\u6025\u6027\u814e\u640d\u50b7\u6642\uff0c\u7528\u6c28\u57fa\u672b\u7aef\u8166\u9209\u80bd\u524d\u9ad4(NT-proBNP)\u53ef\u4ee5\u8a3a\u65b7\u5fc3\u81df\u8870\u7aed\u7684\u56b4\u91cd\u5ea6   \nE.\u55dc\u4e2d\u6027\u767d\u8840\u7403\u660e\u81a0\u76f8\u95dc\u6027\u8102\u8cea\u904b\u8f09\u86cb\u767d (neutrophil gelatinase \u2013associated lipocalin /NGAL)\u8207\u6025\u6027\u814e\n\u640d\u50b7\u9020\u6210\u4e4b\u5fc3\u808c\u7e96\u7dad\u5316\u6709\u76f8\u95dc\n": "[D]", "109-18.\u6709\u95dc\u5fc3\u81df\u7406\u5b78\u6aa2\u67e5\u4e4b\u63cf\u8ff0 ,\u4e0b\u5217\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u5fc3\u623f\u986b\u52d5\u6642 ,\u807d\u8a3a\u6642\u4e0d\u6703\u51fa\u73fe\u7b2c\u56db\u5fc3\u97f3 (S4)\n(2) \u807d\u8a3a\u6642,\u7b2c\u4e09\u5fc3\u97f3 (S3)\u5728\u53ea\u5728\u6536\u7e2e\u529f\u80fd\u7570\u5e38\u4e4b\u5fc3\u81df\u8870\u7aed\u60a3\u8005\u51fa\u73fe ,\u6536\u7e2e\u529f\u80fd\u6b63\u5e38\u4e4b\u5fc3\u81df\u8870\u7aed\u60a3\u8005\u4e0d\u6703\u51fa\u73fe\n(3) Allen's test\u662f\u7528\u4f86\u5075\u6e2c\u80b1\u52d5\u8108 (brachial artery) \u8840\u6db2\u5faa\u74b0\n(4) \u5927\u6d41\u91cf\u4e4b\u52d5\u975c\u8108\u5ed4\u7ba1 (arteriovenous fistula )\u53ef\u4ee5\u9020\u6210\u975e\u5e38\u4f4e\u4e4b\u8212\u5f35\u58d3\n(5) \u5728\u64f4\u5f35\u6027\u5fc3\u808c\u75c5\u8b8a\u60a3\u8005 ,\u628a\u8108\u6642\u53ef\u4ee5\u6478\u5230\u96d9\u5cf0\u8108\u6ce2 (bifid pulse )\n(6) \u4e3b\u52d5\u8108\u74e3\u72f9\u7a84\u4e4b\u6536\u7e2e\u671f\u96dc\u97f3\u807d\u8a3a\u5340\u5728\u80f8\u9aa8\u53f3\u5074\u7b2c\u4e8c\u808b\u9593 ,\u5fc3\u96dc\u97f3\u6703\u50b3\u905e\u81f3\u9838\u52d5\u8108   \nA.(1)+(2)+(3)+(6)\nB.(1)+(4)+(6)\nC.(2)+(4)+(5)\nD.(1)+(2)+(4)\nE.(4)+(5)+(6)\n": "[B]", "109-19.\u4e0b\u5217\u54ea\u4e00\u500b\u4e59\u72c0\u53d7\u9ad4\u963b\u65b7\u5291 (beta-blocker)\uff0c\u9664\u4e86\u4ea4\u611f\u795e\u7d93\u6291\u5236\u5916 \uff0c\u9084\u5177\u5099\u8840\u7ba1\u64f4\u5f35\u529f\u80fd (additional \nvasodilator actions )   \nA.Nebivolol\nB.Atenolol\nC.Metoprolol\nD.Propranolol\nE.Bisoprolol\n": "[A]", "109-20.\u4e00\u4f4d70\u6b72\u5973\u6027 \uff0c\u4e3b\u8a34\u660f\u53a5\u75c5\u53f2 \uff0c24 \u5c0f\u6642Holter ECG (\u5982\u9644\u5716)\uff0c\u7121\u75c7\u72c0\u4e4b\u5fc3\u96fb\u5716\u70ba\u4e0a\u5716 \uff0c\u767c\u751f\u660f\u53a5\u4e4b\u5fc3\u96fb\n\u5716\u70ba\u4e0b\u5716 \u3002\u8a72\u5fc3\u96fb\u5716\u4e4b\u5fc3\u81df\u7bc0\u5f8b\u6b63\u78ba\u8a3a\u65b7\u70ba \uff1f   \nA.\u7b2c\u4e00\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u65b7\nB.\u7b2c\u4e8c\u5ea6\u7b2c\u4e00\u578b\u623f\u5ba4\u50b3\u5c0e\u963b\u65b7\uff08Mobitz I\uff09\nC.\u7b2c\u4e8c\u5ea6\u7b2c\u4e8c\u578b\u623f\u5ba4\u50b3\u5c0e\u963b\u65b7\uff08Mobitz II\uff09\nD.\u7b2c\u4e09\u5ea6\u623f\u5ba4\u50b3\u5c0e\u963b\u65b7\nE.\u75c5\u7ac7\u75c7\u5019\u7fa4\n": "[D]", "109-21.\u6709\u95dc\u5fc3\u623f\u986b\u52d5\u8207\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed (heart failure with reduced ejection fraction)\u4e4b\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u5fc3\u623f\u986b\u52d5\u8207\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u5169\u8005\u5408\u4f75\u767c\u751f\u6642\uff0c\u6703\u5c0e\u81f4\u5fc3\u81df\u8870\u7aed\u60a3\u8005\u9810\u5f8c\u4e0d\u826f\nB.\u5728\u4e2d\u81f3\u91cd\u5ea6\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed\u60a3\u8005\uff0c\u4f7f\u7528dronedarone \u4e0d\u6703\u5c0e\u81f4\u6b7b\u4ea1\u7387\u589e\u52a0\nC.\u53ef\u4ee5\u4f7f\u7528dofetilide\u4f86\u9032\u884c\u7bc0\u5f8b\u63a7\u5236(rhythm control)\nD.\u53ef\u9032\u884c\u5c0e\u7ba1\u71d2\u707c\u8853(catheter ablation and pulmonary vein isolation)\nE.\u53ef\u4ee5\u4f7f\u7528amiodarone\u4f86\u9032\u884c\u7bc0\u5f8b\u63a7\u5236(rhythm control)\n": "[B]", "109-22.\u6709\u95dc\u611f\u67d3\u6027\u4e3b\u52d5\u8108\u708e (infective aortitis )\u7684\u63cf\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4 \uff1f\n(1) \u7d30\u83cc\u611f\u67d3\u6027\u4e3b\u52d5\u8108\u708e\u9020\u6210\u611f\u67d3\u6027\u52d5\u8108\u7624 (mycotic aneurysm )\u597d\u767c\u90e8\u70ba\u5728infrarenal abdominal aorta\n(2) \u7d30\u83cc\u611f\u67d3\u6027\u4e3b\u52d5\u8108\u708e\u9020\u6210\u611f\u67d3\u6027\u52d5\u8108\u7624\u597d\u767c\u65bc\u5e74\u8f15\u4eba\n(3) \u7d30\u83cc\u611f\u67d3\u6027\u4e3b\u52d5\u8108\u708e\u9020\u6210\u611f\u67d3\u6027\u52d5\u8108\u7624\u597d\u767c\u65bc\u7537\u6027\n(4) \u6885\u6bd2\u6027\u4e3b\u52d5\u8108\u708e (syphilitic aortitis) \u597d\u767c\u65bc\u5347\u4e3b\u52d5\u8108 (ascending aorta )\uff0c\u5c24\u5176\u662f\u4e3b\u52d5\u8108\u6839\u90e8 (aortic root )\n(5) \u6885\u6bd2\u6027\u4e3b\u52d5\u8108\u708e\u6703\u9020\u6210\u8840\u7ba1\u6ecb\u990a\u7ba1 (vasa vasorum) \u7684\u9589\u585e\u6027\u52d5\u8108\u5167\u819c\u708e( obliterative endarteritis )      \nA.(1)+(2)\nB.(2)+(3)\nC.(2)+(4)\nD.(1)+(4)\nE.(3)+(5)\n": "[A]", "110-1.\u4f9d\u64da2019\u5e74\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u9812\u4f48\u6cbb\u7642\u6307\u5f15\uff0c\u4e0b\u5217\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u7684\u8655\u7f6e\u662f\u4e0d\u6b63\u78ba\u7684?    \nA.\u50e7\u5e3d\u74e3\u72f9\u7a84 (Mitral stenosis) \u53ca\u91d1\u5c6c\u985e\u74e3\u819c\u61c9\u4f7f\u7528Warfarin\u4f5c\u6297\u51dd\u8840\u85e5\u7269 (Anti-coagulant) \u4ee5\u6cbb\u7642\u5fc3\u623f\n\u7e96\u7dad\u986b\u52d5 \u3002\nB.\u672b\u671f\u814e\u75c5\u4eba\u6216\u4f7f\u7528\u8840\u6db2\u900f\u6790\u75c5\u4eba\u4e0d\u5408\u9069\u4f7f\u7528Dabigatran \uff0cRivaroxaban \u6216Edoxaban\u6cbb\u7642\u5fc3\u623f\u7e96\u7dad\u986b\n\u52d5\u3002\nC.\u6cbb\u7642\u975e\u74e3\u819c\u6027\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u4ee5\u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269 (NOACs, \u5982dabigatran, rivaroxaban, apixaban, \n\u53ca edoxaban) \u6bd4warfarin\u66f4\u597d \u3002\nD.\u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (Atrial fibrillation, AF )\u6709\u77ed\u9663\u5f0f (paroxysmal ), \u6301\u7e8c\u5f0f(persistent ), \u53ca\u6c38\u4e45\u5f0f (permanent) \n\u7b49\u4e09\u7a2e\uff0c\u53ea\u6709permanent AF\u624d\u9700\u8981\u4f7f\u7528\u6297\u51dd\u8840\u85e5\u7269\u6cbb\u7642 \u3002\nE.\u5973\u6027\u75c5\u4eba\u6709\u5fc3\u623f\u64b2\u52d5 (Atrial flutter) \u5176CHA\u2082DS\u2082VASc\u662f 2\u5206\u6642\uff0c\u53ef\u4e0d\u5fc5\u4f7f\u7528\u6297\u51dd\u8840\u85e5\u7269\u6cbb\u7642 \u3002\n": "[D]", "110-2.\u4f9d\u64da2020\u53f0\u7063\u9ad8\u8840\u58d3\u5b78\u6703\u53ca\u53f0\u7063\u5fc3\u81df\u5b78\u6703\u7684\u5c08\u5bb6\u5171\u8b58\u800c\u9812\u4f48\u7684\u8a3a\u7642\u6307\u5f15\uff0c\u4e0b\u5217\u4f55\u9805\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5?    \nA.\u9996\u6b21\u4f7f\u7528\u85e5\u7269\u6cbb\u7642\u9ad8\u8840\u58d3 \uff0c\u61c9\u65bc2\u500b\u661f\u671f\u5f8c\u56de\u8a3a \uff0c\u5982\u82e5\u8840\u58d3\u4e0d\u7372\u5f97\u63a7\u5236 \uff0c\u61c9\u5728\u4e00\u500b\u6708\u5f8c\u56de\u8a3a \uff0c\u5982\u82e5\u8840\n\u58d3\u7372\u5f97\u63a7\u5236 \uff0c\u5f97\u5728\u4e09\u500b\u6708\u5f8c\u56de\u8a3a \u3002\nB.\u9ad8\u8840\u58d3\u5408\u4f75\u4e09\u7a2e\u4ee5\u4e0a\u5371\u96aa\u56e0\u7d20(\u5982\u7cd6\u5c3f\u75c5\u3001\u51a0\u5fc3\u75c5)\uff0c\u61c9\u5c07\u8840\u58d3\u63a7\u5236\u5728130/80 mmHg \u4ee5\u4e0b\u3002\nC.\u5927\u65bc75\u6b72\u7684\u8001\u5e74\u9ad8\u8840\u58d3\u75c5\u4eba\uff0c\u8840\u58d3\u61c9\u63a7\u5236\u5728140/90 mmHg\u4ee5\u4e0b\u3002\nD.\u9ad8\u8840\u58d3\u5408\u4f75\u8166\u4e2d\u98a8\u6216\u6162\u6027\u814e\u75c5\u8b8a\u7684\u75c5\u4eba\uff0c\u5b9c\u5c07\u8840\u58d3\u63a7\u5236\u5728140/90 mmHg \u4ee5\u4e0b\u3002\nE.\u5e74\u8f15\u4eba(<30\u6b72)\u7121\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u8a3a\u9593\u8840\u58d3120/75 mmHg\uff0c\u5f97\u5efa\u8b70\u4e0d\u5fc5\u5b9a\u671f\u56de\u8a3a\u3002\n": "[D]", "110-3.\u6709\u95dcCOVID-19\u7684\u5fc3\u8840\u7ba1\u4f75\u767c\u7684\u75c5\u60c5\u5831\u544a\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5?    \nA.\u611f\u67d3COVID-19\u75c5\u4eba\u6bd4\u6d41\u884c\u6027\u611f\u5192(Influenza)\u8005\u70ba\u591a\u3002\nB.COVID-19\u75c5\u6bd2\u9032\u5165\u4eba\u9ad4\u7d30\u80de\u63a1\u5167\u541e\u65b9\u5f0f (Endocytosis) \uff0c\u90fd\u7d93\u7d30\u80de\u819c\u4e0aACE -2\u86cb\u767d\u4e4b\u5f15\u4ecb \uff0c\u5fc3\u808c\u7d30\u80de\n\u4ea6\u67097.5%\u7684ACEI-2 Expression \uff0c\u662f\u4ee5\u5fc3\u808c\u50b7\u8b8a\u5728\u6240\u96e3\u514d \u3002\nC.\u5fc3\u808cTroponin T\u53ef\u56e0\u4f75\u767c\u51a0\u8108\u8840\u7ba1\u50b7\u8b8a\u3001\u5fc3\u808c\u708e\u6216\u5fc3\u8840\u7ba1\u75d9\u6523\u800c\u6607\u9ad8\u3002\nD.\u6709\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u80a5\u80d6\u75c7\u53ca\u5fc3\u8840\u7ba1\u75c5\u7684COVID-19\u75c5\u4eba\u6b7b\u4ea1\u7387\u504f\u9ad8\u3002\nE.\u5fc3\u5f8b\u4e0d\u6574\uff0cSTEMI \u53caNSTEMI\uff0c\u4f11\u514b\u90fd\u53ef\u80fd\u767c\u751f\u5728COVID-19\u75c5\u4eba\uff0c\u7279\u5225\u5e74\u8001\u591a\u75c5\u8005\u3002\n": "[A]", "110-4.73\u6b72\u8001\u592a\u592a\u5728\u4e09\u5929\u524d\u6642\u6709\u77ed\u9663\u80f8\u60b6\u5f8c\u81ea\u7136\u7de9\u89e3\u4e0d\u75db \uff0c\u4e0d\u610f\u6709\u6b21\u904b\u52d5\u5f8c\u7a81\u767c\u80f8\u75db\u6301\u7e8c\u4e8c\u5c0f\u6642\u4e0d\u505c \uff0c\u540c\u6642\u4f34\u6709\n\u76dc\u6c57\u53ca\u5641\u5fc3 \uff0c\u4e43\u524d\u5f80\u6025\u8a3a\u6c42\u91ab \u3002\u6642TPR 35.9\u2070C / 75/min / 22/min; BP 152 / 70 mmHg; SpO2 100 %\u3002\u75c5\u4eba\n\u5144\u5f1f\u59ca\u59b9\u591a\u4eba\u6709\u9ad8\u8102\u8840\u75c7 \uff0c\u4f46\u672a\u6709\u9ad8\u8840\u58d3\u6216\u7cd6\u5c3f\u75c5 \u3002\u8eab\u9ad4\u7406\u5b78\u6aa2\u67e5\u5c1a\u7121\u91cd\u5927\u7570\u5e38\u767c\u73fe \u3002\u63a1\u8840\u9032\u884c\u751f\u5316\u53ca\u8840\n\u6db2\u6aa2\u67e5\u4e2d \uff0c\u96a8\u5373\u4f5c\u5fc3\u96fb\u5716\u6aa2\u67e5 \uff0c\u5982\u5716\u3002\u8acb\u554f\u9019\u4f4d\u75c5\u4eba\u7684\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f :   \nA.\u5de6\u524d\u964d\u679d\u51a0\u8108\u8fd1\u7aef\u8840\u7ba1\u5b8c\u5168\u963b\u585e\u7684ST elevation myocardial infarction(STEMI)\u3002\nB.\u5de6\u524d\u964d\u679d\u51a0\u8108\u9060\u7aef\u8840\u7ba1\u5b8c\u5168\u963b\u585e\u7684STEMI\u3002\nC.\u5de6\u8ff4\u65cb\u679d\u51a0\u8108\u9060\u7aef\u8840\u7ba1\u963b\u585e\u7684STEMI\u3002\nD.\u53f3\u51a0\u8108\u8fd1\u7aef\u8840\u7ba1\u963b\u585e\u7684STEMI\u3002\nE.\u591a\u8840\u7ba1\u51a0\u5fc3\u75c5\u4ee5(non-STEMI)\u81e8\u5e8a\u8868\u73fe\u3002\n": "[A]", "110-5.\u6709\u95dc\u4e3b\u52d5\u8108\u7624 (Aortic aneurysms \uff0cAA)\u4e43\u6cdb\u6307\u4e3b\u52d5\u8108\u76f4\u5f91\u64f4\u592750 %\u4e4b\u8b02\uff0c\u81e8\u5e8a\u7684\u8a8d\u77e5\u5e38\u662f\u7a2e\u7121\u75c7\u72c0 \uff0c\u4f46\u537b\n\u9032\u884c\u64f4\u5c55\u4e2d\u7684\u75be\u75c5 \uff0c\u6709\u4e3b\u52d5\u8108\u7834\u88c2\u6025\u6551\u7684\u5371\u96aa \uff0c\u4e0b\u5217\u4f55\u9805\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684 \uff1f   \nA.\u6700\u8fd1\u7814\u7a76\u8a8d\u5b9a AA\u8207\u8102\u86cb\u767d\uff0c\u7279\u5225\u904e\u4f4e\u7684\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187(HDL-C)\u6709\u95dc\u3002\nB.\u4f9d\u64da\u7814\u7a76\u767c\u73fe\u7cd6\u5c3f\u75c5\u4eba\u7684AA\u8f03\u4e0d\u6613\u64f4\u5927\uff0c\u4e14\u8207HbA1c\u7684\u60aa\u5316\u5ea6\u6210\u53cd\u6bd4\u95dc\u4fc2\u3002\nC.\u8179\u90e8AA\u591a\u898b\u65bc\u7537\u6027\u53ca\u5e74\u8001\u75c5\u4eba\u3002   \nD.\u81e8\u5e8a\u7814\u7a76 \uff0c\u80f8\u90e8AA\u6bd4\u8179\u90e8AA\u591a\u898b ,\u524d\u8005\u8207\u57fa\u56e0 \u3001\u62bd\u7159\u3001\u9ad8\u8840\u58d3\u53ca\u6162\u6027\u80ba\u963b\u585e\u75c5\u7b49\u98a8\u96aa\u6709\u95dc \uff0c\u5f8c\u8005\u8207\u5e74\n\u9f61\u3001\u7537\u6027\u3001\u62bd\u7159\u53ca\u8840\u7ba1\u7ca5\u72c0\u786c\u5316\u7b49\u98a8\u96aa\u6709\u95dc \u3002\nE.\u8179\u90e8AA\u61c9\u5b9a\u671f\u6aa2\u67e5, 3-3.9\u516c\u5206\u76f4\u5f91\u6642\u6bcf\u4e09\u5e74\u8ffd\u8e64\u4e00\u6b21 \uff0c4-4.4\u516c\u5206\u6642\u6bcf\u4e8c\u5e74\u8ffd\u67e5\u4e00\u6b21 \uff0c\u800c4.5-5.4 \u516c\u5206\n\u8005\u6bcf\u5e74\u4e00\u6b21\u8ffd\u67e5 \uff0c\u8d85\u904e5.5\u516c\u5206\u61c9\u4e8e\u6cbb\u7642 \u3002\n": "[D]", "110-6.\u6025\u6027\u5fc3\u808c\u6897\u585e\u4f75\u767c\u5fc3\u56e0\u6027\u4f11\u514b (Cardiogenic shock )\u7684\u767c\u751f\u7387\u7d04\u5728 3-13%\uff0c\u76ee\u524d\u63a1\u884c\u76e1\u65e9\u51a0\u8108\u518d\u901a\u624b\n\u8853(Coronary Revascularization )\u4f7f\u6b7b\u4ea1\u7387\u5f9e70 -80%\u4e0b\u964d\u523040 -50%\uff0c\u4f46\u8fd1\u5e74\u7684\u7814\u7a76\u986f\u793a\u6b7b\u4ea1\u7387\u4e0d\u964d\u53cd\u800c\u5fae\n\u5347\uff0c\u4ecd\u6709\u6539\u5584\u7684\u7a7a\u9593 \u3002\u4e0b\u5217\u6709\u95dc\u5fc3\u56e0\u6027\u4f11\u514b\u7684\u5be6\u8a3c\u91ab\u5b78\u7684\u8655\u7f6e \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u4f9d\u64da2018\u5e74\u6b50\u6d32\u5fc3\u81df\u91ab\u5b78\u6703\u7684\u6307\u5f15\u5efa\u8b70 \uff0c\u50c5\u53ea\u8655\u7406\u8087\u59cb\u75c5\u8b8a (Culprit lesion )\uff0c\u4e0d\u5efa\u8b70\u5e38\u898f\u540c\u6642\u591a\u689d\u51a0\n\u8108\u518d\u901a\u624b\u8853 \u3002\nB.\u4f9d\u64da\u73fe\u6709\u7684\u6578\u500b\u81e8\u5e8a\u7814\u7a76 \uff0c\u7dca\u6025\u51a0\u8108\u8840\u7ba1\u7e5e\u9053\u624b\u8853 \uff08CABG)\u6216\u7d93\u76ae\u51a0\u8108\u518d\u901a\u8853 (PCI)\u6cbb\u7642\u5fc3\u56e0\u6027\u4f11\n\u514b\uff0c\u4f55\u8005\u70ba\u4f73 \uff0c\u96e3\u6709\u7d50\u8ad6 \u3002\nC.\u5fc3\u808c\u6897\u585e\u4f75\u5fc3\u56e0\u6027\u4f11\u514b\u75c5\u4eba\u4e4b\u8840\u6d41\u7570\u5e38\u53ca\u7121\u6cd5\u53e3\u670d\u6297\u8840\u677f\u85e5\u7269 \uff0c\u5f97\u975c\u8108\u6ce8\u5c04GP IIb /IIIb-inhibitors or \nCangrelor \u3002\nD.\u5e7e\u4e4e90%\u5fc3\u56e0\u6027\u4f11\u514b\u75c5\u4eba\u5927\u591a\u4f7f\u7528\u8840\u7ba1\u4f5c\u7528\u5291 (Vasoactive agents ),\u7531\u65bc\u8840\u7ba1\u6536\u7e2e\u5f71\u97ff\u5fae\u8840\u7ba1\u5faa\u74b0\u53ca\n\u589e\u52a0\u5fc3\u808c\u8017\u6c27\u91cf \uff0c\u61c9\u4ee5\u4f4e\u91cf\u6ce8\u5c04\u70ba\u4e3b \u3002\nE.\u4e3b\u52d5\u8108\u5167\u9006\u5411\u5e6b\u9001\u8f14\u52a9\u7642\u6cd5(IABP)\u662f\u5fc3\u56e0\u6027\u4f11\u514b\u8655\u7f6e\u7684\u5fc5\u8981\u9078\u64c7\u3002\n": "[E]", "110-7.\u904e\u53bb20-30\u5e74\u6709\u95dc\u6025\u6027\u5fc3\u808c\u708e(Myocarditis)\u7684\u8a3a\u7642\u8ad6\u9ede\u5df2\u6709\u91cd\u5927\u7684\u6539\u8b8a\uff0c\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u6b63\u78ba\u7684\u505a\u6cd5\uff1f    \nA.\u4e0d\u8ad6\u9ad8\u6216\u4f4e\u98a8\u96aa\u7684\u5fc3\u8870\u75c5\u4f8b\uff0c\u5fc3\u808c\u6d3b\u9ad4\u5207\u7247\u6aa2\u67e5\u662f\u5fc5\u9808\u7684\u8a3a\u65b7\u65b9\u6cd5\u3002\nB.\u5fc3\u808c\u78c1\u632f\u9020\u5f71\u7528\u65bc\u8fa8\u8b58\u5fc3\u808c\u6c34\u816b\u53ca\u7e96\u7dad\u75c5\u8b8a\uff0c\u53ef\u5e6b\u52a9\u5fc3\u808c\u708e\u9451\u5225\u3002\nC.\u514d\u75ab\u7642\u6cd5\u5c0d\u5de8\u7d30\u80de\u5fc3\u808c\u708e (Giant Cell myocarditis )\u6216\u55dc\u7d05\u767d\u8840\u7403\u5fc3\u808c\u708e (Eosinophilic myocarditis )\u6709\n\u6548\u3002\nD.\u5fc3\u808c\u6d3b\u9ad4\u5207\u7247\u6aa2\u67e5\u767c\u73fe\u75c5\u6bd2\u57fa\u56e0\u9ad4(Virus genome)\u4e0d\u4e00\u5b9a\u80fd\u78ba\u5b9a\u5fc3\u808c\u708e\u7684\u8a3a\u65b7\u3002\nE.\u5553\u7528\u8af8\u5982IABP \u53caECMO\u6709\u52a9\u8655\u7406\u6025\u6027\u5fc3\u808c\u708e\u65e9\u671f\u4e4b\u8840\u884c\u529b\u5b78(Hemodynamic)\u4e4b\u7570\u5e38\u3002\n": "[A]", "110-8.40\u6b72\u4f01\u696d\u4e3b\u7ba1\u56e0\u6709\u5fc3\u60b8\u53ca\u547c\u5438\u56f0\u96e3\u6709\u4e00\u500b\u661f\u671f\u4e4b\u4e45 \uff0c\u4e43\u524d\u5f80A\u9662\u6c42\u8a3a\uff0c\u8a8d\u5b9a\u662f\u4e0a\u547c\u5438\u9053\u611f\u67d3 \uff0c\u4f46\u8655\u7f6e\u7121\n\u6548\uff0c\u4e09\u5929\u5f8c\u81f3 B\u9662\u3002\u75c5\u4eba\u57282009\u5e74\u8a3a\u65b7\u7a81\u767c\u6027\u4e0a\u5fc3\u5ba4\u5feb\u8df3 \uff0c\u4e14\u6709\u591a\u5e74\u80a5\u80d6 (BMI=41.5 Kg/m\u00b2,) \u3002\u7406\u5b78\u6aa2\u67e5: \nBP: 156/91  mmHg, HR :141/min, RR:28/min, Temp: 36 .90\u2103, SpO2: 97%\uff0c\u7121\u8ca7\u8840\uff0c\u9838\u975c\u8108\u6b63\u5e38 \uff0c\u7532\u72c0\n\u817a\u672a\u6709\u7570\u5e38 \uff0c\u80f8\u90e8\u6709\u6df7\u6fc1\u547c\u5438\u8072 \uff0c\u5fc3\u81df\u7a0d\u5927 \uff0c\u4e0d\u6b63\u5e38\u5f8b\u52d5 \uff0c\u672a\u6709S3\u53ca\u5fc3\u96dc\u97f3 \uff0c\u809d\u813e\u4e0d\u5927 \uff0c\u7121\u8179\u6c34\uff0c\u96d9\u4e0b\n\u80a2\u5fae\u816b\u3002\u6642\uff0c\u5fc3\u96fb\u5716\u3001\u80f8\u90e8X-\u5149\u53ca\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716 \u3002\u5176\u751f\u5316\u53ca\u8840\u6db2\u6c23\u9ad4\u6aa2\u9a57\u5982\u8868 \u3002\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u8a3a\u65b7\u6700\n\u6b63\u78ba?   \nA.\u51a0\u72c0\u52d5\u8108\u6813\u585e\u75c7\u3002\nB.\u9ad8\u8840\u58d3\u5fc3\u8840\u7ba1\u75c5\u3002\nC.\u64f4\u5f35\u6027\u5fc3\u808c\u75c5\u3002\nD.\u80ba\u52d5\u8108\u6813\u585e\u75c7\u3002\nE.\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u3002\n": "[D]", "110-9.\u75c5\u4eba\u738b\u5148\u751f\u73fe\u5e7488 \u6b72\uff0c\u6709\u5169\u500b\u6708\u7684\u96d9\u8173\u6d6e\u816b\u53ca\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u6578\u5ea6\u524d\u5f80\u591a\u5bb6\u91ab\u9662\u6c42\u8a3a \uff0c\u8a3a\u7642\u7f54\u6548 \u3002\u75c5\u4eba\n\u6709\u591a\u5e74\u9ad8\u8840\u58d3 \u3001\u9ad8\u8102\u8840\u3001\u6162\u6027\u814e\u81df\u75c5\u53ca\u651d\u8b77\u817a\u80a5\u5927\u7b49\u904e\u5f80\u75c5\u53f2 \u3002\u5230\u8a3a\u6642\u610f\u8b58\u6e05\u9192\uff0c T/P/R: 35.5 \u00b0C/99/18; \nBP: 121/73 mmHg; SpO 2: 92%\u3002(ambient air ); BH: 165 cm; BW: 66 kg; BMI: 24 .2 kg/m2   \u7406\u5b78\u6aa2\u67e5\u5b8c\n\u6210\u5f8c\uff0c\u6709\u5fc3\u96fb\u5716 \u3001\u80f8\u90e8X\u5149\u53ca\u5176\u4ed6\u5f71\u50cf\u6aa2\u67e5\u5982\u5716 :\u8acb\u554f\u4e0b\u5217\u6578\u500b\u6a19\u7684\u4e4b\u7406\u5b78\u6aa2\u67e5 (Targeted physical \nexamination) \u6240\u898b: ( 1)\u5168\u8eab\u6c34\u816b (2)\u80ba\u6c34\u816b\u986f\u8457 (3)\u5927\u8108\u58d3(Pulse pressure) ( 4)\u809d\u813e\u816b\u5927 (5)Pericardial \nknock (6)Kussmaul sign \u3002\u90a3\u7d44\u662f\u6b63\u78ba\u8a3a\u65b7\u7684\u6839\u64da ?   \nA.(1)+(2)+(3)\u3002\nB.(1)+(3)+(5)\u3002   \nC.(1)+(4)+(6)\u3002\nD.(2)+(3)+(4)\u3002\nE.(2)+(4)+(6)\u3002\n": "[C]", "110-10.\u6709\u95dc\u8eab\u9ad4\u8a3a\u5bdf\u5167\u9838\u975c\u8108\u7684\u8108\u5716,\u4e0b\u5217\u54ea\u4e00\u500b\u6558\u8ff0\u932f\u8aa4?    \nA.\u5728\u5fc3\u623f\u5fc3\u5ba4\u89e3\u96e2(AV dissociation)\u6642,\u6703\u51fa\u73fe\u5de8\u5927\u7684 A\u6ce2(Cannon A wave)\u3002\nB.\u5fc3\u623f\u986b\u52d5\u6642,\u6703\u51fa\u73feA \u6ce2\u3002\nC.Wide QRS complex tachycardia\u6642\u51fa\u73feA wave,\u4ee3\u8868\u662f\u8a72\u5fc3\u5f8b\u4e0d\u6574\u7684\u8d77\u6e90\u4f86\u81ea\u5fc3\u5ba4\u3002\nD.\u4e09\u5c16\u74e3\u91cd\u5ea6\u9589\u9396\u4e0d\u5168\u6642,V \u6ce2\u6703\u8b8a\u5927\u3002\nE.\u6b63\u5e38\u5438\u6c23\u6642,\u9838\u975c\u8108\u58d3\u61c9\u4e0b\u964d\u7d043\u6beb\u7c73\u6c5e\u67f1\u3002\n": "[B]", "110-11.\u60a3\u8005\u5fc3\u808c\u6897\u585e\u5408\u4f75\u5fc3\u56e0\u6027\u4f11\u514b\u6642,\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?    \nA.\u5fc3\u808c\u6897\u585e\u5408\u4f75\u5fc3\u56e0\u6027\u4f11\u514b\u6642,\u7d04\u670980%\u75c5\u4eba\u5448\u73fe\u5de6\u5fc3\u8870\u7aed\u3002\nB.\u5728\u524d\u80f8\u9396\u9aa8\u4e0b\u807d\u5230\u7b2c\u4e09\u7d1a\u8212\u5f35\u671f\u96dc\u97f3 ,\u8981\u8003\u616e\u5fc3\u5ba4\u4e2d\u8188\u808c\u8089\u56e0\u5fc3\u808c\u6897\u585e ,\u9020\u6210\u6025\u6027\u5fc3\u5ba4\u4e2d\u8188\u88c2\n\u640d(ventricular septal rupture )\u3002\nC.\u6025\u6027\u5fc3\u5ba4\u4e2d\u8188\u88c2\u640d\u6642,\u53f3\u5fc3\u623f\u8207\u53f3\u5fc3\u5ba4\u8212\u5f35\u671f\u7684\u58d3\u529b\u6703\u4e0a\u5347\u3002\nD.\u5fc3\u81df\u8d85\u97f3\u6ce2\u53ef\u4ee5\u5354\u52a9\u5206\u8fa8\u662f\u5426\u6709\u5fc3\u5305\u819c\u586b\u585e,\u4e8c\u5c16\u74e3\u8171\u7d22\u65b7\u88c2\u3002\nE.Lead aVR \u5448\u73feST segment elevation ,\u540c\u6642\u6709\u591a\u5c0e\u6975\u5448\u73feST depression \u6642,\u8981\u8003\u616e\u5de6\u4e3b\u51a0\u72c0\u52d5\u8108\u91cd\u5ea6\n\u72f9\u7a84\u3002\n": "[B]", "110-12.\u4e0b\u5217\u54ea\u4e00\u7a2e\u5fc3\u5305\u819c\u767c\u708e\u75c7\u72c0\u8f03\u5e38\u6709\u660e\u986f\u80f8\u75db?    \nA.\u80ba\u7d50\u6838\u5fc3\u5305\u819c\u708e (tuberculous pericarditis)\u3002\nB.\u816b\u7624\u5fc3\u5305\u819c\u767c\u708e(neoplastic pericarditis)\u3002\nC.\u5c3f\u6bd2\u6027\u5fc3\u5305\u819c\u767c\u708e (uremic pericarditis)\u3002\nD.\u653e\u5c04\u6cbb\u7642\u5f8c\u5fc3\u5305\u819c\u767c\u708e( post-irradiation pericarditis)\u3002\nE.\u5fc3\u808c\u6897\u585e\u5f8c\u5fc3\u5305\u819c\u767c\u708e (Dressler's syndrome)\u3002\n": "[E]", "110-13.\u6162\u6027\u91cd\u5ea6\u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168\u4e4b\u75c5\u60a3,\u4e0b\u5217\u54ea\u4e00\u7a2e\u7406\u5b78\u6aa2\u67e5\u4e4b\u63cf\u8ff0\u70ba\u932f\u8aa4?    \nA.\u6703\u51fa\u73fewater-hammer pulse\u3002\nB.\u6703\u5728\u6307\u5c16\u51fa\u73fe Quincke's pulse\u3002\nC.\u6703\u51fa\u73feTraube's sign\u3002\nD.\u7576\u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168 ,\u662f\u7531\u4e3b\u52d5\u8108\u6839\u90e8\u7624\u72c0\u64f4\u5f35 (aneurysmal dilation of the aortic root )\u6240\u5c0e\u81f4\u6642 ,\u8212\u5f35\n\u671f\u4e4b\u96dc\u97f3\u5728\u80f8\u9aa8\u5de6\u5074\u6bd4\u53f3\u5074\u660e\u986f \u3002\nE.\u6703\u51fa\u73feDuroziez's sign\u3002\n": "[D]", "110-14.\u6709\u95dc\u9209-\u8461\u8404\u7cd6\u5171\u540c\u8f49\u904b\u86cb\u767d\u6291\u5236\u5291 (Sodium-Glucose Co -Transporter 2 [SGLT2] inhibitor )\u7684\u63cf\u8ff0,\u4e0b\u5217\u4f55\n\u8005\u6b63\u78ba?(1)SGLT2 inhibitor\u662f\u6291\u5236\u9060\u7aef\u814e\u5c0f\u7ba1\u7684\u9209 -\u8461\u8404\u7cd6\u5171\u540c\u8f49\u904b\u86cb\u767d (2)SGLT2 inhibitor\u6703\u5c0e\u81f4\u5c3f\u4e2d\u8461\n\u8404\u7cd6\u6392\u51fa\u91cf\u964d\u4f4e (3)SGLT2 inhibitor\u7684\u964d\u8840\u7cd6\u6548\u679c\u662finsulin independent (4)SGLT2 inhibitor \u6703\u5c0e\u81f4\u9ad4\u91cd\u964d\n\u4f4e (5)SGLT2 inhibitor (Empagliflozin and canagliflozin )\u5728\u6709\u7cd6\u5c3f\u75c5\u5408\u4f75\u5fc3\u8840\u7ba1\u75be\u75c5\u60a3\u8005 ,\u6703\u589e\u52a0\u5fc3\u81df\u8870\u7aed\n\u7684\u518d\u4f4f\u9662\u7387   \nA.(3)+(4)\u3002\nB.(1)+(5)\u3002\nC.(4)+(5)\u3002   \nD.(1)+(2)+(3)\u3002\nE.(2)+(3)+(5)\u3002\n": "[A]", "110-15.ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e (ST segment elevation myocardial infarction )\u75c5\u60a3\u63a5\u53d7\u8840\u6813\u6eb6\u89e3\u5291\u7684\u6558\u8ff0\u4f55\u8005\u932f\n\u8aa4?   \nA.\u4f7f\u7528\u8840\u6813\u6eb6\u89e3\u5291\u5f8c ,\u9020\u6210\u6897\u585e\u4e4b\u51a0\u72c0\u52d5\u8108\u5982\u80fd\u9054TIMI (Thrombolysis in Myocardial Infarction )\u5206\u985e\u7b2c\u4e09\n\u7d1a\u8840\u6d41,\u5176\u9810\u5f8c\u8f03\u4f73 .\u76f8\u8f03\u65bcstreptokinase ,\u4f7f\u7528tPA ( tissue plasminogen activator )\u80fd\u66f4\u6709\u6548\u7387\u8b93\u9020\u6210\n\u6897\u585e\u4e4b\u51a0\u72c0\u52d5\u8108\u9054TIMI \u5206\u985e\u7b2c\u4e09\u7d1a\u8840\u6d41 \u3002\nB.\u7528\u8840\u6813\u6eb6\u89e3\u5291\u4f86\u6cbb\u7642ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e\u8981\u6ce8\u610f\u51fa\u8840\u7684\u98a8\u96aa ,\u5927\u898f\u6a21\u7814\u7a76 (large-scale trials )\u986f\u793a:\u76f8\n\u8f03\u65bcstreptokinase ,\u4f7f\u7528tPA\u6cbb\u7642ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e\u9020\u6210\u9871\u5167\u51fa\u8840\u4e4b\u98a8\u96aa\u660e\u986f\u964d\u4f4e \u3002\nC.\u7528\u8840\u6813\u6eb6\u89e3\u5291\u4f86\u6cbb\u7642ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e ,\u572870\u6b72\u4ee5\u4e0a\u9020\u6210\u9871\u5167\u51fa\u8840\u7684\u98a8\u96aa\u7d04\u70ba65\u6b72\u4ee5\u4e0b\u75c5\u60a3\n\u76842\u500d\u3002\nD.\u4f7f\u7528streptokinase\u8981\u6ce8\u610f\u904e\u654f\u53cd\u61c9\u3002\nE.\u7528\u8840\u6813\u6eb6\u89e3\u5291\u4f86\u6cbb\u7642ST \u7bc0\u6bb5\u4e0a\u5347\u578b\u5fc3\u808c\u6897\u585e\u8981\u6ce8\u610f\u75c5\u60a3\u8840\u58d3\u4e0d\u80fd\u904e\u9ad8 (\u5982\u6536\u7e2e\u58d3 >180 mmHg ,\u8212\u5f35\n\u58d3>110mmHg )\u3002\n": "[B]", "110-16.\u4e00\u4f4d55\u6b72\u5973\u6027\u75c5\u60a3\u56e0\u7aef\u5750\u547c\u5438\u8207\u52d5\u5598\u4e00\u9031\u800c\u4f86\u4f4f\u9662 \u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8840\u58d390 /56\u6beb\u7c73\u6c5e\u67f1 ,\u5fc3\u8df3\u6bcf\u5206\n\u9418102\u4e0b,\u9838\u975c\u8108\u6012\u5f35 ,\u5fc3\u97f3\u4f4e\u9060\u4f75\u7b2c\u4e09\u5fc3\u97f3 \uff0c\u80ba\u90e8\u6709\u56c9\u97f3 \uff0c\u96d9\u4e0b\u80a2\u5c0f\u817f\u8207\u8173\u90e8\u6c34\u816b \u3002\u5fc3\u96fb\u5716\u5982\u5716\u4e00 \u3002\u5fc3\u81df\n\u8d85\u97f3\u6ce2\u5448\u73fe\u5de6\u5fc3\u5ba4\u64f4\u5927 ,\u7030\u6f2b\u6027\u5de6\u5fc3\u5ba4\u6536\u7e2e\u529f\u80fd\u7570\u5e38 ,\u5de6\u5fc3\u5ba4\u5c04\u51fa\u5206\u7387 (left ventricle ejection \nfraction)\u70ba25%\u3002\u5fc3\u81df\u78c1\u632f\u9020\u5f71\u6aa2\u67e5\u5982\u5716\u4e8c A\u8207B\u3002\u7d93\u98df\u9053\u5fc3\u81df\u8d85\u97f3\u6ce2\u5982\u5716\u4e8c C\u8207D\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\n\u8aa4?(1)\u8a72\u75c5\u60a3\u7684\u5fc3\u96fb\u5716\u5448\u73fe low voltage in frontal leads (2)\u8a72\u75c5\u60a3\u5fc3\u96fb\u5716\u5448\u73fe\u5fc3\u623f\u986b\u52d5 (3)\u8a72\u75c5\u60a3\u4e4b\u5fc3\u81df\u78c1\n\u632f\u9020\u5f71\u5f71\u50cf\u6aa2\u67e5\u5448\u73fe\u5de6\u5fc3\u5ba4\u5fc3\u808c\u7dfb\u5bc6\u5316\u4e0d\u5168 (left ventricular non -compaction) ( 4)\u8a72\u75c5\u60a3\u4e4b\u5fc3\u81df\u78c1\u632f\u9020\u5f71\u5f71\n\u50cf\u6aa2\u67e5\u5448\u73fe\u6025\u6027\u5fc3\u808c\u767c\u708e (5)\u8a72\u75c5\u60a3\u61c9\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u8840\u5291 (6)\u9019\u7a2e\u75be\u75c5\u6709\u6642\u662f\u56e0\u808c\u7bc0 (sarcomere )\u57fa\u56e0\u7570\u5e38\n\u5f15\u8d77   \nA.(1)+(3)+(6)\u3002\nB.(2)+(3)+(5)\u3002\nC.(2)+(4)\u3002\nD.(2)+(4)+(5)\u3002\nE.(2)+(6)\u3002\n": "[C]", "110-17.\u6709\u95dc\u5229\u7528\u5fc3\u81df\u518d\u540c\u6b65\u5316\u7bc0\u5f8b\u5668 (cardiac resynchronization therapy, CRT )\u6cbb\u7642\u4f4e\u6536\u7e2e\u5206\u7387\u5fc3\u81df\u8870\u7aed (heart \nfailure with reduced ejection fraction )\u7684\u6558\u8ff0,\u4f55\u8005\u6b63\u78ba ?   \nA.Cardiac Resynchronization in Heart Failure Study (CARE-HF) trial \u986f\u793aCRT \u4e0d\u80fd\u6539\u5584\u6240\u6709\u539f\u56e0\u6b7b\u4ea1\n\u7387(all cause mortality )\u3002\nB.\u5728\u5fc3\u96fb\u5716 QRS complex width  >149 ms \u4e14\u5408\u4f75\u53f3\u675f\u652f\u50b3\u5c0e\u963b\u65b7\u60a3\u8005\u6548\u679c\u6700\u597d\u3002\nC.\u5de6\u53f3\u5fc3\u5ba4\u7684\u4e0d\u540c\u6b65\u6536\u7e2e,\u5e38\u5c0e\u81f4\u529f\u80fd\u6027\u7684\u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168,\u9032\u800c\u52a0\u91cd\u5fc3\u81df\u6536\u7e2e\u529f\u80fd\u7570\u5e38\u3002\nD.\u7576\u4f7f\u7528CRT \u5728\u9019\u985e\u75c5\u4eba\u6539\u5584\u5de6\u5fc3\u5ba4\u6536\u7e2e\u5206\u7387\u5f8c,\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\u5168\u7684\u56b4\u91cd\u5ea6\u537b\u5e38\u7121\u6cd5\u6539\u5584\u3002\nE.CRT\u7684\u5de6\u5fc3\u5ba4\u5c0e\u7dda\u5e38\u7d93\u7531\u51a0\u72c0\u975c\u8108\u7ac7(coronary sinus)\u7f6e\u653e\u3002\n": "[E]", "110-18.\u6709\u95dcMarfan syndrome\u7684\u63cf\u8ff0,\u4f55\u8005\u932f\u8aa4?    \nA.\u7576\u5b55\u5a66\u5408\u4f75 Marfan syndrome\u6642,\u5982\u679c\u4e3b\u52d5\u8108\u6839\u90e8>40 mm,\u5247\u4e3b\u52d5\u8108\u525d\u96e2\u7684\u98a8\u96aa\u589e\u52a0\u3002\nB.Marfan syndrome\u60a3\u8005\u4f7f\u7528propranolol\u4f86\u964d\u8840\u58d3,\u7121\u6cd5\u6e1b\u7de9\u6216\u9810\u9632\u4e3b\u52d5\u8108\u64f4\u5927\u3002\nC.\u88c2\u9699\u71c8\u6aa2\u67e5(slit-lamp examination) \u5c0d\u8a3a\u65b7Marfan syndrome\u5f88\u91cd\u8981\u3002\nD.\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5c0d\u8a3a\u65b7Marfan syndrome\u5f88\u91cd\u8981\u3002\nE.\u6839\u64daGhent criteria\u8a3a\u65b7\u7684Marfan syndrome\u60a3\u8005,\u8d85\u904e90% \u90fd\u6709FBN1\u57fa\u56e0\u7684\u7a81\u8b8a\u3002   \n": "[B]", "111-1.\u75c5\u4eba58\u6b72\u7537\u6027 \uff0c\u6709\u50f5\u76f4\u6027\u810a\u690e\u708e \uff0c\u8fd1\u6708\u4f86\u9010\u6f38\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u4e43\u81f3\u91ab\u9662\u6c42\u8a3a \u3002\u7d93\u7cfb\u5217\u5fc3\u81df\u6aa2\u67e5\u78ba\u8a3a\u4e3b\u52d5\n\u8108\u9589\u9396\u4e0d\u5168 (Aortic regurgitation )\uff0c\u4f9d\u64da\u6a19\u7684\u7406\u5b78\u6aa2\u67e5 (Targeted physical examination) \uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u624d\n\u662f\u6b63\u78ba\u7684\u807d\u8a3a ?\n(1) \u5728\u5fc3\u5c16\u8655 (Apical area )\u6709Gr 2/6 mid-systolic click and late systolic murmur \uff0c\n(2) \u5728\u53f3\u80f8\u9aa8\u7de3 (Right sternal border )\u6709Gr3/6 decrescendo, early diastolic murmur\uff0c \n(3) \u5728\u5fc3\u5c16\u8655\u6709Gr 1-2/6 mid-diastolic murmur \uff0c\n(4) \u5728\u53f3\u80f8\u9aa8\u7de3\u4e0b\u7aef\u6709 S3 gallop\uff0c\n(5) \u5728\u5fc3\u5c16\u8655\u6709Open Snap \uff0c\n(6) \u5728\u4e3b\u52d5\u8108\u5340 (Aortic area )\u6709Ejection click \u3002   \nA.(1)+(2)+(3)\u3002\nB.(2)+(4)+(6)\u3002\nC.(1)+(3)+(5)\u3002\nD.(2)+(3)+(4)\u3002\nE.(1)+(4)+(5)\u3002\n": "[D]", "111-2.\u4f9d\u64da1991\u5e74\u4e16\u754c\u885b\u751f\u7d44\u7e54\u7684\u8a8d\u5b9a \uff0c\u9ad8\u8840\u58d3\u662f\u5168\u7403\u75be\u75c5\u8ca0\u64d4\u4e4b\u91cd \uff0c\u6709\u95dc\u9ad8\u8840\u58d3\u7684\u8a3a\u7642\u4e4b\u81e8\u5e8a\u8a66\u9a57\u7684\u7d50\n\u8ad6\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7d44\u662f\u4e0d\u6b63\u78ba\u7684\u8aaa\u6cd5 ?\n(1) SARS-CoV-2 \u7684\u611f\u67d3\u8207\u68d8\u86cb\u767d (Spike protein) \u7684ACE\u6709\u95dc \uff0c\u4f46ACEi \u53caARB\u7684\u4f7f\u7528 \uff0c\u4e26\u672a\u6709\u6703\u5f71\u97ff\u8a72\u75c5\n\u6bd2\u611f\u67d3\u53ca\u75c5\u60c5\u60e1\u5c55\n(2) Sodium glucose co -transporter 2 (SGLT2) inhibitors \u53ca Glucagon -like peptide -1 receptor agonists \n(GLP1-RA) \u662f\u7cd6\u5c3f\u75c5\u53ca\u975e\u7cd6\u5c3f\u75c5\u4eba\u7684\u6709\u5229\u964d\u58d3\u5291\n(3) \u5e74\u9f61\u9ad8\u65bc85\u6b72\u8001\u4eba\u4e4b\u8840\u58d3\u76ee\u6a19\u662f <150/90 mmHg \uff0c\u592a\u9ad8\u53ca\u592a\u4f4e\u90fd\u589e\u52a0\u5fc3\u8840\u7ba1\u75c5 \u3001\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u53ca\u5fc3\u8870\n\u7684\u767c\u751f\u7387  \n(4) \u814e\u795e\u7d93\u5207\u9664\u624b\u8853 (Renal nerve denervation )\u662f\u9811\u56fa\u6027\u9ad8\u8840\u58d3 (Resistant hypertension) \u6cbb\u7642\u7684\u552f\u4e00\u9078\u64c7\n(5) \u4f9d\u64da\u6301\u7e8c\u602724\u5c0f\u6642\u8840\u58d3\u8a18\u9304 \uff0c\u5982\u82e5\u55aa\u5931\u591c\u9593\u8840\u58d3\u4e0b\u964d (Night dipping) \u8207\u5fc3\u8870\u53ca\u5fc3\u8840\u7ba1\u75c5\u6709\u91cd\u5927\u7684\u76f8\u95dc \n(6) \u6b63\u5e38\u8840\u58d3\u8005\u5982\u82e5\u6709\u904b\u52d5\u6027\u5fc3\u7e2e\u9ad8\u8840\u58d3 >200 mmHg \uff0c\u4e5f\u4e0d\u5177\u5fc3\u8840\u7ba1\u75c5\u7684\u98a8\u96aa   \nA.(1)+(3)+(5)\u3002\nB.(2)+(4)+(6)\u3002\nC.(2)+(3)+(5)\u3002\nD.(1)+(2)+(3)\u3002\nE.(1)+(3)+(6)\u3002\n": "[B]", "111-3.\u5fc3\u623f\u7e96\u7dad\u986b\u52d5 (Atrial fibrillation, AF) \u662f\u500b\u9032\u5c55\u6027\u7684\u5fc3\u5f8b\u4e0d\u6574 \uff0c\u5e38\u898b\u65bc\u8001\u4eba \u3001\u5fc3\u81df\u75c5\u3001\u5fc3\u8870\u3001\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\n\u9032\u75c7\u75c5\u4eba \uff0c\u4e14\u6642\u8207\u9ad8\u8840\u58d3 \u3001\u7cd6\u5c3f\u75c5\u3001\u80a5\u80d6\u75c7\u547c\u5438\u4e2d\u6b62\u75c5\u76f8\u4f34 \uff0c\u5176\u8207\u4e2d\u98a8 \u3001\u5931\u667a\u7684\u767c\u751f\u53ca\u6b7b\u4ea1\u7387\u7684\u591a\u898b\u6709\n\u95dc\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u6709\u95dcAF\u7684\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684 ?   \nA.\u5728\u5be6\u8a3c\u91ab\u5b78\u986f\u793a\u65b0\u5f0f\u53e3\u670d\u6297\u51dd\u8840\u85e5\u7269 (NOAC)\u5982dabigatran, rivaroxaban, apixaban, \u53ca edoxaban \u6bd4 \nWarfarin \u5c0d\u975e\u74e3\u819c\u6027AF (Nonvalvular AF) \u75c5\u4f8b\u6709\u6548\u6e1b\u5c11\u6b7b\u4ea1\u7387 \uff0c\u4e5f\u5c11\u6709\u4e2d\u98a8 \u3001\u5927\u51fa\u8840\u6216\u9871\u5167\u51fa\u8840\u7684\n\u526f\u4f5c\u7528\u3002\nB.AF\u6301\u7e8c\u8d85\u904e30\u79d2\u5c31\u6709\u8840\u6813\u5f62\u6210\u7684\u53ef\u80fd \uff0c\u662f\u4ee5\u8655\u7f6e\u6307\u5f15\u8a8d\u5b9aAF\u767c\u751f\u572848\u5c0f\u6642\u5167 \uff0c\u5f97\u4ee5\u96fb\u64ca\u6216\u85e5\u7269\u5f8b\u52d5\n\u8f49\u56de(Cardioversion) \uff0c\u552f\u61c9\u5148\u78ba\u5b9a\u5de6\u5fc3\u8033\u672a\u6709\u8840\u6813\u7684\u5b58\u5728 \u3002\nC.\u5fc3\u623f\u7570\u5e38\u5feb\u8df3\u7d93\u6b77\u591a\u6642\u6050\u81f4\u5fc3\u808c\u7d30\u80de\u8b8a\u7570 \uff0c\u884d\u6210\u7d44\u7e54\u518d\u5851 (Remodeling) \uff0c\u81f4\u6709\u7570\u5e38\u50b3\u5c0e \uff0c\u6539\u8b8a\u5fc3\u623f\n\u7d44\u7e54\u4e4b\u4e0d\u61c9\u671f \uff0c\u9020\u6210\u591a\u8655\u518d\u8ff4\u5165 (Re-entry)\u7684\u96fb\u6c23\u751f\u7406\u8b8a\u5316 \uff0c\u662f\u5fc3\u623f\u5fc3\u808c\u75c5 (Atrial cardiomyopathy )\u7684\n\u75c5\u56e0\u3002\nD.\u75c5\u4eba\u6709\u50e7\u5e3d\u74e3\u72f9\u7a84\u7f6e\u63db\u91d1\u5c6c\u6027\u4eba\u5de5\u74e3\u819c\uff0c\u4f7f\u7528Clopidogrel + Aspirin \u6bd4 Warfarin\u66f4\u5b89\u5168\u6709\u6548\u3002\nE.\u96fb\u6c23\u71d2\u707c(Electric ablation) \u5408\u9069\u5e74\u8f15\u4eba\u7684\u9663\u767c\u6027AF\u3002   \n": "[D]", "111-4.\u75c5\u4eba36\u6b72\u7537\u6027\u7a81\u7136\u55aa\u5931\u610f\u8b58\u6709\u4e00\u500b\u5c0f\u6642\u4e4b\u4e45 \uff0c\u4e43\u6025\u5f80\u91ab\u9662\u6c42\u8a3a \uff0c\u6642\u8840\u58d396 /56 mmHg \u5fc3\u8df3: 105 /min\uff0c\u547c\n\u5438: 20/min\u53ca\u9ad4\u6eab: 36 .2\u2103\u3002\u75c5\u4eba\u65e5\u524d\u7259\u75bc\u81f3\u8a3a\u6240\u6cbb\u7642 \uff0c\u4f7f\u7528ibuprofen, cephalexin \u53ca\u80c3\u85e5 \uff0c\u5341\u9ede\u5165\u7761 \uff0c\u5728\n\u6df1\u591c\u88e1\u807d\u898b\u547c\u5438\u5598\u9cf4 \uff0c4 AM\u4e0d\u9192\u4eba\u4e8b\u4e26\u6709\u7672\u7647\u767c\u4f5c\u53ca\u5c3f\u5931\u7981 \u3002\u7406\u5b78\u6aa2\u67e5\u986f\u793a E1M4V2\uff0c \u534a\u5c0f\u6642\u5f8c\u6e05\n\u9192\uff0c\u6709\u5614\u5410\u53ca\u982d\u75db\u4e4b\u8868\u793a \uff0c\u672a\u6709\u795e\u7d93\u53ca\u5176\u4ed6\u7570\u5e38\u6240\u898b \u3002CXR \u53ca\u5fc3\u96fb\u5716\u5982\u5716 \uff0c\u524d\u5f8c\u76f8\u9694\u4e8c\u5c0f\u6642 \u3002\u8840\u6db2\u751f\u5316\n\u6709K\u207a 2.8 mEq/L, Na\u207a 141 mEq /L,  AST 79 U/L,  ALT 98 U/L,  Cr 0.97 mg/dL, BUN 13 mg /dL, Sugar 132 \nmg/dL, Troponin I 0.04 ng/mL\u3002(\u9644\u5fc3\u96fb\u5716 \u3001\u80f8\u90e8X\u5149)\u3002\u5f9e\u75c5\u4eba\u7684\u5e74\u9f61 \u3001\u6027\u5225\u3001\u75c5\u53f2\u3001\u767c\u4f5c\u6642\u9593 \u3001\u5fc3\u96fb\u5716\n\u6240\u898b\u3001\u751f\u5316\u6aa2\u9a57\u548c\u7406\u5b78\u6240\u898b \uff0c\u672c\u75c5\u4f8b\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f \uff1a   \nA.Long QT syndrome with Torsades de Pointes\u3002\nB.Brugada syndrome with Electrical Storm and Incessant Ventricular Tachycardia\u3002\nC.Wolf-Parkinson-White syndrome with event of atrial fibrillation\u3002\nD.Early Repolarization J Wave Syndromes\u3002\nE.Arrhythmogenic RV cardiomyopathy\u3002\n": "[B]", "111-5.\u6709\u95dc\u6025\u6027\u5fc3\u8870\u7aed\u7684\u6cbb\u7642\u6307\u5f15\u4e26\u4e0d\u591a\u898b\uff0c\u90e8\u4efd\u7814\u7a76\u7684\u4e3b\u5f35\u6709\u81e8\u5e8a\u5be6\u7528\u50f9\u503c\uff0c\u4e0b\u5217\u7684\u4f55\u8005\u8aaa\u6cd5\u662f\u4e0d\u6b63\u78ba\u7684?    \nA.\u96a8\u91ab\u5b78\u7684\u9032\u6b65 \uff0c\u6025\u6027\u5fc3\u8870\u6b7b\u4ea1\u7387\u4ecd\u820a\u5c45\u9ad8\u4e0d\u4e0b \uff0c\u5c24\u5176\u4e00\u500b\u6708\u5167\u53ca\u534a\u5e74\u5167\u518d\u4f4f\u9662\u7387\u5206\u5225\u9ad8\n\u905425%\u53ca50%\uff0c\u8017\u8cbb\u91ab\u7642\u8cc7\u6e90\u9817\u5927 \u3002\nB.\u6162\u6027\u5fc3\u8870\u6025\u6027\u60e1\u5316 \uff0c\u6bd4\u6025\u6027\u521d\u767c\u5fc3\u8870\u66f4\u591a \uff0c\u56e0\u6b64\u627e\u51fa\u8a98\u767c\u5fc3\u8870\u7684\u539f\u56e0\u8af8\u5982\u6025\u6027\u7f3a\u8840\u8b8a\u5316 \u3001\u611f\u67d3\u3001\u5fc3\u81df\n\u7d50\u69cb\u8b8a\u5316 \u3001\u5fc3\u5f8b\u4e0d\u6574 \u3001\u6216\u75c5\u4eba\u7528\u85e5\u9806\u5f9e\u7b49\u56e0\u7d20\u6700\u662f\u91cd\u8981 \u3002\nC.\u5f37\u529b\u7684\u5229\u5c3f\u5291\u662f\u5145\u8840\u6027\u5fc3\u8870\u7684\u95dc\u9375\u6cbb\u7642\u3002\nD.\u5c31\u5be6\u8a3c\u91ab\u5b78\uff0c\u73fe\u7528\u7684\u8840\u7ba1\u4f5c\u7528\u5291(Vasoactive agents)\u53ca\u5f37\u5fc3\u5291(Inotropes) \u90fd\u662f\u5dee\u5f37\u4eba\u610f\u7684\u6cbb\u7642\u3002\nE.\u6c27\u6c23\u7642\u6cd5\u6700\u70ba\u91cd\u8981 \uff0c\u7dad\u6301\u6108\u9ad8\u6c27\u6c23\u6fc3\u5ea6\u6709\u52a9\u7d44\u7e54\u6d3b\u529b \uff0c\u9ad8\u6d41\u91cf\u6c27\u6c23\u5438\u5165 \uff0c\u751a\u81f3\u5167\u7f6e\u6c23\n\u7ba1(Endotracheal intubation )\u4f9b\u6c27\u90fd\u662f\u61c9\u8a72\u7684\u8655\u7f6e \u3002\n": "[E]", "111-6.\u75c5\u4eba64\u6b72\u5bb6\u5ead\u4e3b\u5a66 \uff0c\u8fd1\u4e09\u500b\u6708\u4f86\u6709\u9593\u6b47\u6027\u80f8\u60b6\u53ca\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \u3002\u75c5\u4eba\u6709\u6c23\u5598\u53ca\u9ad8\u8840\u58d310\u5e74\u75c5\u53f2 \uff0c\u898f\u5247\n\u670d\u7528Ipratropium \u6216Furosemide + Aldactone + Digoxin + Aspirin \u3002\u4e8b\u5be6\u4e0a\u75c5\u4eba\u904e\u53bb10\u5e74\u524d\u5c31\u6709\u985e\u4f3c\u75c7\n\u72c0\uff0c\u518d\u591a\u52a0\u670d\u7528\u4e0a\u5217\u85e5\u7269 \uff0c\u4e5f\u5c31\u6539\u5584 \u3002\u53ea\u662f\u8fd1\u6708\u4f86\u5168\u8eab\u5026\u6020 \uff0c\u98df\u617e\u4e0d\u632f \uff0c\u4e0a\u8179\u5fae\u75db\u53ca\u9ad4\u91cd\u6e1b\u8f15\u4e03\u516c\u65a4 \uff0c\u4e43\n\u65bc\u4e03\u6708\u5eff\u516d\u65e5\u4f4f\u9662\u8a3a\u7642 \u3002\u75c5\u4ebaHeight: 156 cm  Weight: 68kg ; T/P/R:37.1/88/16;\u3002 BP: 110 /73 \nmmHg\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u5fc3\u81df\u5927\u5c0f\u6b63\u5e38 \uff0c\u898f\u5247\u5f8b\u8df3 \uff0c\u552f\u5fc3\u5c16\u8655 (Apical area) \u6709\u96d9\u5cf0\u8108\u6ce2bifid pulse) \u53ca\u5728\u5de6\u4e0a\n\u80f8\u7de3\u53ca\u5fc3\u5c16\u8655\u6709Gr 4/6 Pansystolic murmur \uff0c\u4e0b\u80a2\u67092\u5ea6\u6d6e\u816b\uff0c\u4f46\u5176\u4ed6\u5668\u5b98\u4e26\u672a\u6709\u7570\u5e38 \u3002\u8840\u7403\u6aa2\n\u67e5:WBC,10.14k/uL; RBC, 4.79 M/uL; Platelet, 169 K/uL\u3002\u8840\u6db2\u751f\u5316\u7d50\u679c: Albumin, 4.2 gm/dL; T-Bil, 0.86 \nmg/dL; BUN, 16 .8 mg/dL; Cre1.0 mg/dL; ALT, 90 U/L\u3002\u5176\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8 \uff38\u5149\u5982\u5716\u3002\u7d93\u5fc3\u5c0e\u7ba1\u6aa2\u67e5: \u5927\u52d5\u8108\n\u8840\u58d3, 142 /68 mmHg; \u5de6\u5fc3\u5ba4\u51fa\u53e3\u90e8( LVOT ), 158/28 mmHg; \u5de6\u5fc3\u5ba4\u5fc3\u5c16\u90e8, 198 /32 mmHg. \u5176\u5de6\u5fc3\u5ba4\u9020\u5f71\n\u53caCardiac CT\u5982\u5716 \u3002\u8acb\u554f\u75c5\u4eba\u7684\u6b63\u78ba\u5fc3\u81df\u8a3a\u65b7\u662f \uff1a   \nA.\u9ad8\u8840\u58d3\u6027\u5fc3\u81df\u75c5(Hypertensive cardiovascular disease)\u3002\nB.\u5de6\u5fc3\u5ba4\u5fc3\u5c16\u80a5\u539a\u6027\u5fc3\u808c\u75c5(LV apical hypertrophic cardiomyopathy)\u3002\nC.\u5de6\u5fc3\u5ba4\u4e2d\u90e8\u5fc3\u808c\u80a5\u539a\u75c5(Mid-LV hypertrophic cardiomyopathy)\u3002\nD.\u7f3a\u8840\u6027\u5fc3\u81df\u75c5(Ischemic cardiomyopathy)\u3002\nE.\u64f4\u5927\u6027\u5fc3\u808c\u75c5(Dilated cardiomyopathy)\u3002\n": "[C]", "111-7.\u96a8\u8457\u75c5\u7406\u751f\u7406\u6a5f\u8f49\u7684\u8a8d\u77e5 \uff0c\u5fc3\u8870\u6cbb\u7642\u53ca\u5fc3\u81df\u5f71\u50cf\u9032\u6b65 \uff0c\u5fc3\u5167\u5916\u624b\u8853\u6cbb\u7642\u7684\u6f14\u9032 \uff0c\u6709\u95dc\u4e8c\u5c16\u74e3\u9589\u9396\u4e0d\n\u5168(Mitral regurgitation, MR) \u6709\u8af8\u591a\u65b0\u5c55 \uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u7684\u4e3b\u5f35\u662f\u4e0d\u5408\u7576\u4eca\u6642\u5b9c ?   \nA.\u56e0\u4e8c\u5c16\u74e3\u74b0 (Mitral annulus )\u3001\u4e73\u7a81\u808c(Papillary muscles )\u53ca\u5de6\u5fc3\u5ba4\u7570\u5e38\u9020\u6210\u7684\u9589\u9396\u4e0d\u5168\u662f\u539f\u767c\n\u6027MR(Primary MR )\uff0c\u800c\u56e0\u4e8c\u5c16\u74e3\u8449 (Mitral leaflet )\u53ca\u8171\u7d22\u7570\u5e38 (Chordae tendineae )\u800c\u81f4\u7684\u9589\u9396\u4e0d\u5168\u662f\n\u7e8c\u767c\u6027MR (Secondary MR )\u3002   \nB.\u4e0d\u8ad6\u75c7\u72c0\u4e4b\u6709\u7121 \uff0c\u5de6\u5fc3\u5ba4\u6536\u7e2e\u672b\u671f\u76f4\u5f91 >40 mm\u53ca\u5de6\u5fc3\u5ba4\u5c04\u51fa\u91cf <60%\u662f\u5167\u5916\u79d1\u4ecb\u5165\u624b\n\u8853(Intervention )\u7684\u95dc\u9375\u6839\u64da \u3002\nC.\u7f3a\u8840\u6027MR (Ischemic MR )\u5e38\u56e0\u5de6\u5fc3\u5ba4\u5f8c\u58c1\u5931\u80fd \uff0c\u5de6\u5fc3\u5ba4\u64f4\u5927 \uff0c\u5c0e\u81f4\u8171\u7d22\u53ca\u4e73\u982d\u808c\u5931\u80fd\u800c\u8d77 \uff0c\u662f\u6df7\u5408\n\u6027MR(\uff2dixed MR) \uff0c\u4ee5\u5916\u79d1\u7e5e\u9053\u624b\u8853\u53ca\u4e8c\u5c16\u74e3\u819c\u7f6e\u63db\u70ba\u4f73 \u3002\nD.\u7d93\u5c0e\u7ba1\u7de3\u5c0d\u7de3\u593e\u5408(Trans-catheter edge to edge mitral clip) \u5c0d\u539f\u767c\u6027\u53ca\u7e8c\u767c\u6027MR\u90fd\u662f\u5408\u9069\u7684\u6cbb\u7642\u3002\nE.\u56e0\u5de6\u5fc3\u623f\u64f4\u5927\u5c0e\u81f4\u7684\u80ba\u52d5\u8108\u9ad8\u8840\u58d3\u53ca\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u90fd\u662f\u6c7a\u5b9a\u5fc3\u81df\u5167\u5916\u79d1\u624b\u8853\u7684\u6839\u64da\u3002\n": "[A]", "111-8.\u731d\u6b7b\u7684\u767c\u751f \uff0c\u4f54\u5fc3\u8840\u7ba1\u75c5\u6b7b\u4ea1\u768450 %\uff0c \u4e5f\u662f\u5065\u5eb7\u4eba\u7684\u7b2c\u4e00\u6b21\u5fc3\u81df\u75c5\u767c\u4f5c\u768450 %\u3002\u5728\u53f0\u7063\u6bcf\u5e74\u6709\u9662\u5916\u731d\u6b7b\n\u5728\u9662\u5167\u7684\u6551\u6d3b\u800c\u7121\u795e\u7d93\u50b7\u8b8a\u8005\u50c5\u53ea21 .7%\uff0c\u8acb\u554f\u4e0b\u5217\u6709\u95dc\u731d\u6b7b\u7684\u8aaa\u6cd5 \uff0c\u4f55\u8005\u4e0d\u6b63\u78ba ?   \nA.\u51a0\u5fc3\u75c5\u53ca\u5fc3\u8870\u662f\u731d\u6b7b\u6700\u91cd\u8981\u7684\u5371\u96aa\u56e0\u7d20\u3002\nB.\u731d\u6b7b\u5e38\u898b\u7684\u5fc3\u8df3\u9589\u6b62 (Asystole) \u53ca\u7121\u8108\u6027\u96fb\u6c23\u6d3b\u6027 (Pulseless electric activity) \uff0c\u524d\u8005\u5e38\u56e0\u96fb\n\u64ca(Electric cardioversion )\u7d50\u679c\uff0c\u5f8c\u8005\u591a\u56e0\u5931\u8840 \u3001\u7f3a\u6c27\u3001\u4ee3\u8b1d\u7570\u5e38\u6216\u80ba\u52d5\u8108\u6813\u585e\u800c\u8d77 \u3002\nC.\u5bec\u8f3bQRS\u578b\u5feb\u8df3\u5e38\u662f\u5fc3\u5ba4\u6027\u7570\u8df3\uff0c\u61c9\u7dca\u6025\u8655\u7f6e\u3002\nD.\u6b63\u5e38QRS\u578b\u5feb\u8df3\u5982\u82e5\u4f34\u6709\u7729\u6688\u6216\u4f4e\u8840\u58d3\uff0c\u4ea6\u61c9\u7dca\u6025\u8655\u7f6e\u3002\nE.\u4ee5\u85e5\u7269\u4e4b\u6cbb\u7642\u6162\u6027\u5fc3\u5ba4\u6027\u671f\u5916\u6536\u7e2e\u53ef\u9632\u6b62\u731d\u6b7b\u767c\u751f\u3002\n": "[E]", "111-9.\u75c5\u4eba\u738b\u5148\u751f\u73fe\u5e7488 \u6b72\uff0c\u6709\u5169\u500b\u6708\u7684\u96d9\u8173\u6d6e\u816b\u53ca\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u6578\u5ea6\u524d\u5f80\u591a\u5bb6\u91ab\u9662\u6c42\u8a3a \uff0c\u8a3a\u7642\u7f54\u6548 \u3002\u75c5\u4eba\n\u6709\u591a\u5e74\u9ad8\u8840\u58d3 \u3001\u9ad8\u8102\u8840\u3001\u6162\u6027\u814e\u81df\u75c5\u53ca\u524d\u5217\u817a\u80a5\u5927\u7b49\u904e\u5f80\u75c5\u53f2 \u3002\u5230\u8a3a\u6642\u610f\u8b58\u6e05\u9192\uff0c T/P/R: 35.5 \u00b0C/99/18; \nBP: 106/83 mmHg; SpO 2: 92%\u3002(ambient air ); BH: 165 cm; BW: 66 kg; BMI: 24 .2 kg/m2 \u7406\u5b78\u6aa2\u67e5\u767c\u73fe\n\u984f\u9762\u5fae\u816b \uff0c\u9838\u975c\u8108\u4e2d\u5ea6\u6012\u5f35 \uff0c\u8108\u640f\u7a0d\u5f31 \uff0c\u4e26\u672a\u6709\u986f\u8457Paradoxical pulse, \u53caKussmaul sign \uff0c\u547c\u5438\u8072\u6e05\n\u6de8\uff0c\u5fc3\u81df\u5927\u5c0f\u6b63\u5e38 \uff0c\u5fc3\u97f3\u7565\u9060 \uff0cP2\u7a0d\u5f37\uff0cPericardial friction\u53ef\u7591 \uff0c\u7121\u809d\u3001\u813e\u816b\u5927\uff0c\u96d9\u8173\u5fae\u816b \u3002\u5176\u5fc3\u96fb\n\u5716\u3001\u80f8\u90e8X\u5149\u53ca\u5176\u4ed6\u5f71\u50cf\u6aa2\u67e5\u5982\u5716 \uff1a\u8acb\u554f\u4f9d\u7167\u4e0a\u5217\u6578\u500b\u6a19\u7684\u4e4b\u7406\u5b78\u6aa2\u67e5 (Targeted physical examination) \n\u53ca\u5be6\u9a57\u5ba4\u6240\u898b \uff0c\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f   \nA.Non-ST elevation myocardial infarction\u3002\nB.Pericardial disease\u3002\nC.Hypertrophic cardiomyopathy\u3002\nD.Dilated cardiomyopathy\u3002\nE.Fabry disease\u3002\n": "[B]", "111-10.65\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u81ea\u5e74\u8f15\u6642\u5373\u8a3a\u65b7WPW\u75c7\u5019\u7fa4 (Wolff-Parkinson -White syndrome )\uff0c\u591a\u5e74\u4f86\u76f8\u5b89\u7121\u4e8b \u3002\u4e00\u500b\n\u5c0f\u6642\u524d\u7a81\u767c\u5fc3\u623f\u986b\u52d5\u5408\u4f75\u5fc3\u640f\u904e\u901f\u4f86\u6025\u8a3a \u3002\u6025\u8a3a\u6aa2\u67e5\u767c\u73fe\u8840\u58d3\u7a69\u5b9a \uff0c\u5fc3\u8df3\u901f\u5ea6\u7d04\u6bcf\u5206\u9418180 \u4e0b\u3002\u4f60\u70ba\u7576\u65e5\n\u503c\u73ed\u91ab\u5e2b \uff0c\u4ee5\u4e0b\u8655\u7f6e\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u975c\u8108\u6ce8\u5c04adenosine\u3002\nB.\u975c\u8108\u6ce8\u5c04digoxin\u3002\nC.\u975c\u8108\u6ce8\u5c04amiodarone\u3002\nD.\u7d66\u4e88\u53e3\u670dbeta-blockers\u3002\nE.\u7d66\u4e88\u93ae\u975c\u9ebb\u9189\u5f8c\uff0c\u5be6\u65bd\u96fb\u64ca(electric cardioversion)\u3002\n": "[E]", "111-11.\u5fc3\u81df\u8870\u7aed\u5408\u4f75\u5fc3\u623f\u986b\u52d5 (atrial fibrillation )\u7684\u75c5\u4eba\uff0c\u5982\u679c\u63a1\u53d6\u5fc3\u5f8b\u63a7\u5236 (rhythm control )\u7b56\u7565\uff0c\u4ee5\u4e0b\u4f55\u8005\u662f\u9996\n\u9078\u85e5\u7269\uff1f   \nA.Propafenone\u3002\nB.Flecainide\u3002\nC.Dronedarone\u3002\nD.Amiodarone\u3002   \nE.Quinidine\u3002\n": "[D]", "111-12.\u5c0d\u65bc\u5fc3\u81df\u6536\u7e2e\u529f\u80fd\u7570\u5e38\u4e4b\u5fc3\u8870\u7aed\u4e4b\u6cbb\u7642\uff0c\u4f55\u7a2e\u85e5\u7269\u7121\u6cd5\u589e\u52a0\u5b58\u6d3b\u7387\uff1f    \nA.\u8840\u7ba1\u6536\u7e2e\u7d20\u8f49\u5316\u9176\u6291\u5236\u5291 \uff08angiotensin -converting enzyme inhibitor \uff0c\nACEI\uff09\u3002\nB.\u74b0\u7ba1\u5229\u5c3f\u5291 (loop diuretic)\u3002\nC.\u4e59\u578b\u4ea4\u611f\u795e\u7d93\u62ee\u6297\u5291\uff08\u03b2-blockers\uff09\u3002\nD.\u919b\u56fa\u916e\u62ee\u6297\u5291\uff08spironolactone\uff09\u3002\nE.\u8840\u7ba1\u6536\u7e2e\u7d20\u53d7\u9ad4\u963b\u65b7\u5291(angiotensin receptor blocker)\u3002\n": "[B]", "111-13.\u4e0b\u5217\u6709\u95dcST\u7bc0\u6bb5\u4e0a\u5347\u7684\u5fc3\u808c\u6897\u585e\uff08ST-elevation myocardial infarction\uff0cSTEMI\uff09\u7684\u654d\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u4e3b\u8981\u7684\u767c\u75c5\u6a5f\u8f49\u70ba\u8840\u7ba1\u5167\u7ca5\u72c0\u786c\u5316\u6591\u7470\u7834\u88c2\uff0c\u7522\u751f\u6025\u6027\u8840\u6813\u5c07\u8840\u7ba1\u5b8c\u5168\u963b\u585e\u3002\nB.\u6297\u8840\u677f\u85e5\u7269clopidogrel\u6548\u679c\u7684\u81e8\u5e8a\u6548\u679c\u8207ticargrelor, prasugrel\u76f8\u4f3c\u3002\nC.\u75c5\u767c\u5982\u572812\u5c0f\u6642\u5167\uff0c\u8981\u7167\u6703\u5fc3\u81df\u79d1\u5118\u5feb\u9032\u884c\u5fc3\u5c0e\u7ba1\u6253\u901a\u8840\u7ba1\u3002\nD.\u53ef\u4f7f\u7528\u809d\u7d20(heparin)\u6216\u4f4e\u5206\u5b50\u91cf\u809d\u7d20(low-molecular-weigth heparin, LMWH)\u6cbb\u7642\u3002\nE.\u4e0b\u58c1\u5fc3\u808c\u6897\u585e\u5408\u4f75\u53f3\u5fc3\u6897\u585e\u6642\uff0c\u5982\u8840\u58d3\u4e0d\u7a69\uff0c\u53ef\u8003\u616e\u8f38\u6db2\u6cbb\u7642\u3002\n": "[B]", "111-14.\u6709\u95dc\u5fc3\u623f\u7e96\u7dad\u986b\u52d5(Atrial fibrillation)\u76f8\u95dc\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u8aaa\u6cd5\u662f\u932f\u8aa4\u7684\uff1f    \nA.\u6700\u5e38\u898b\u7684\u6301\u7e8c\u6027\u5fc3\u5f8b\u4e0d\u6574\uff0c\u4e00\u822c\u800c\u8a0080\u6b72\u4ee5\u4e0a\u76db\u884c\u7387\u7d0410\uff05\u3002\nB.\u5f15\u8d77\u5fc3\u623f\u986b\u52d5\u7684\u5371\u96aa\u56e0\u5b50\u5305\u62ec\u5e74\u8001\uff0c\u9ad8\u8840\u58d3\uff0c\u7cd6\u5c3f\u75c5\uff0c\u80a5\u80d6\uff0c\u547c\u5438\u7d42\u6b62\u75c7\u7b49\u3002\nC.\u5fc3\u623f\u986b\u52d5\u7d04\u589e\u52a05\u500d\u4e2d\u98a8\u7684\u6a5f\u6703\u3002\nD.\u6297\u51dd\u8840\u5291\u5982aspirin\u7b49\u80fd\u6709\u6548\u9810\u9632\u4e2d\u98a8\u767c\u751f\u3002\nE.\u7d0430\uff05\u7684\u958b\u5fc3\u624b\u8853\u60a3\u8005\u8853\u5f8c\u53ef\u80fd\u7522\u751f\u9577\u77ed\u4e0d\u7b49\u7684\u9663\u767c\u6027\u5fc3\u623f\u986b\u52d5\u3002\n": "[D]", "111-15.70\u6b72\u9673\u5148\u751f \uff0c\u56e0\u70ba\u767c\u71d2\u5408\u4f75\u5598\u8207\u7aef\u5750\u547c\u5438\u81f3\u6025\u8a3a \uff0c\u8eab\u9ad4\u6aa2\u67e5\u5728\u5fc3\u5c16\u90e8\u4f4d\u807d\u5230\u7b2c\u56db\u7d1a\u6536\u7e2e\u671f\u96dc\u97f3 \uff0c\u4e14\u80ba\u90e8\u6709\n\u56c9\u97f3(rales\uff09\u3002 \u5fc3\u81df\u8d85\u97f3\u6ce2\u5728\u4e8c\u5c16\u74e3\u767c\u73fe\u8d05\u751f\u7269 (vegetation )\uff0c\u4e09\u5957\u8840\u6db2\u57f9\u990a\u5448\u73festreptococcus \ngallolyticus \u3002\u8acb\u554f\u9664\u4e86\u5fc3\u5167\u819c\u708e\u5916 \uff0c\u4e0b\u5217\u75be\u75c5\u5fc5\u9808\u5217\u5165\u8003\u616e \uff1f   \nA.\u8166\u819c\u75c5\u8b8a\u3002\nB.\u814e\u7d50\u77f3\u5f15\u767c\u814e\u6c34\u816b\u3002\nC.\u5927\u8178\u606f\u8089\u6216\u5927\u8178\u764c\u3002\nD.\u80ba\u90e8\u75c5\u8b8a\u3002\nE.\u651d\u8b77\u817a\u767c\u708e\u3002\n": "[C]", "111-16.\u738b\u8001\u592a\u592a\u4e09\u500b\u6708\u524d\u63a5\u53d7\u5fc3\u81df\u74e3\u819c\u7f6e\u63db\u624b\u8853 \uff0c\u8fd1\u4e00\u500b\u6708\u4f86 \uff0c\u904b\u52d5\u6642\u547c\u5438\u56f0\u96e3\u9010\u6f38\u52a0\u91cd\u4e14\u6709\u4e0b\u80a2\u6c34\u816b \u3002\u7d93\u6aa2\u67e5\n\u809d\u814e\u529f\u80fd\u6b63\u5e38 \uff0c\u7d66\u4e88\u5229\u5c3f\u5291\u6cbb\u7642\u4f46\u9838\u975c\u8108\u4ecd\u6709\u986f\u8457\u64f4\u5f35 \u3002\u9580\u8a3a\u80f8\u90e8 X\u5149\u986f\u793a\u5fc3\u81df\u4e26\u672a\u64f4\u5927 \uff0c\u8eab\u9ad4\u8a3a\u5bdf\u7121\u5fc3\n\u96dc\u97f3\uff0c\u809d\u81df\u7a0d\u816b\u5927 \uff0c\u6709\u8179\u6c34\u53ca\u96d9\u5074\u4e0b\u80a2\u6c34\u816b \u3002\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u53f3\u5fc3\u623f\u5e73\u5747\u58d3\u529b\u589e\u52a0\u4e14\u53f3\u5fc3\u623f\u58d3\u529b\u66f2\u7dda\u5448\u73fe\u660e\u986f\n\u7684Y\u4e0b\u964d\u6ce2\u3002\u4ee5\u4e0b\u6709\u95dc\u672c\u75c5\u4eba\u7684\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u8840\u58d3\u4e0a\u5347\u4e14\u8108\u640f\u58d3\u8b8a\u5bec\u3002\nB.\u80f8\u90e8X\u5149\u7247\u5448\u73fe\u80ba\u9b31\u8840\uff08lung congestion\uff09\u73fe\u8c61\u3002\nC.\u5de6\u53f3\u5fc3\u5ba4\u8212\u5f35\u672b\u671f\u58d3\u529b(end-diastolic pressure)\u4e0d\u7b49\u3002\nD.\u807d\u8a3a\u6642\u6709\u53ef\u80fd\u6703\u6709\u5fc3\u5305\u6572\u64ca\u97f3\uff08pericardial knock\uff09\uff0c\u6709\u4e9b\u6703\u51fa\u73fe\uff62\u5947\u8108\uff63\uff08paradoxical pulse\uff09\u3002\nE.\u547c\u6c23\u6642\uff0c\u9838\u52d5\u8108\u64f4\u5f35\u53ef\u80fd\u66f4\u5f62\u986f\u8457\u3002\n": "[D]", "111-17.\u6709\u95dc\u5fc3\u81df\u8870\u7aed (Heart failure) \u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u9805\u4e0d\u6b63\u78ba\uff1f       \nA.\u5de6\u5fc3\u5ba4\u5c04\u51fa\u7387\u4fdd\u7559\u5fc3\u81df\u8870\u7aed (heart failure with preserved ejection fraction, HFpEF )\u75c5\u60a3\uff0c\u7d66\u4e88\u8840\u7ba1\u6536\n\u7e2e\u7d20\u8f49\u5316\u9176\u6291\u5236\u5291 \uff08angiotensin -converting enzyme inhibitor \uff0cACEI\uff09\u53ef\u6709\u6548\u6539\u5584\u9810\u5f8c \u3002\nB.\u6bdb\u5730\u9ec3(digoxin)\u56e0\u7121\u6cd5\u6539\u5584\u75c5\u4eba\u9810\u5f8c\uff0c\u76ee\u524d\u50c5\u5728\u5176\u5b83\u85e5\u7269\u5145\u5206\u4f7f\u7528\u5f8c\u4ecd\u6709\u660e\u986f\u75c7\u72c0\u6642\u8003\u616e\u7d66\u4e88\u3002\nC.\u5f37\u5fc3\u85e5\u7269 (inotropic agents )\u7121\u6cd5\u6539\u5584\u9810\u5f8c \uff0c\u751a\u81f3\u53ef\u80fd\u589e\u52a0\u6b7b\u4ea1\u7387\u53ca\u4f75\u767c\u75c7 \uff0c\u76e1\u91cf\u5728\u6709\u9700\u8981\u6642\u77ed\u671f\u4f7f\n\u7528\u3002\nD.\u6025\u6027\u5931\u8abf\u6027\u5fc3\u81df\u8870\u7aed (Acute decompensated heart failure \uff0cADHF)\u53ef\u80fd\u6703\u4f75\u767c\u5fc3\u814e\u75c7\u5019\n\u7fa4(Cardio-renal syndrome )\uff0c\u4f7f\u7528\u5229\u5c3f\u91cf\u589e\u52a0\u6b64\u985e\u75c5\u4eba\u4e4b\u6392\u5c3f\u91cf\u4e0d\u76e1\u6709\u6548 \u3002\nE.\u5728\u5de6\u5fc3\u5ba4\u5c04\u51fa\u6e1b\u5c11\u5fc3\u81df\u8870\u7aed (heart failure with reduced ejection fraction, HFrEF )\u75c5\n\u60a3\uff0cLCZ696(Sacubitril /Valsartan )\u8f03Ramipril\u66f4\u80fd\u6709\u6548\u6e1b\u5c11\u6b7b\u4ea1\u7387 \u3002\n": "[A]", "111-18.\u5433\u5148\u751f\u70ba\u6162\u6027\u814e\u81df\u75c5\u75c5\u4eba \uff0c\u56e0\u70ba\u5168\u8eab\u7121\u529b\u5c31\u8a3a \uff0c\u62bd\u8840\u767c\u73fe\u8840\u6e05\u808c\u9178\u9150 \uff08creatinine \uff09\u70ba5.0 mg/dL \uff0c\u8840\n\u9240\uff08K\uff097. 2 mmol/L\uff0c\u6709\u95dc\u5fc3\u96fb\u5716\u53ef\u80fd\u7684\u8b8a\u5316\u4e0b\u5217\u4f55\u8005\u6709\u8aa4 \uff1f   \nA.\u9ad8\u5c16T\u6ce2\uff08peaked T wave\uff09\u3002\nB.PR\u671f\u9593\u8b8a\u9577\u3002\nC.QRS\u6ce2\u8b8a\u5bec\u3002\nD.QT\u671f\u9593\u8b8a\u9577\u3002\nE.P\u6ce2\u8b8a\u6241\u3002\n": "[D]", "100-1.\n\u4e00\u4f4d\u75c5\u4eba\u7684\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\u986f\u793a pH:7.62, PaCO2:32mmHg, HCO3-:29mEq/L\uff0c\u8acb\u554f\u662f\u4f55\u7a2e\u60c5\u6cc1\uff1f\nA. \u547c\u5438\u9e7c\u8840\u75c7\uff0c\u6709\u90e8\u4efd\u4ee3\u8b1d\u4ee3\u511f\nB. \u547c\u5438\u9e7c\u8840\u75c7\uff0c\u7121\u4ee3\u8b1d\u4ee3\u511f\nC. \u547c\u5438\u9e7c\u8840\u75c7\u5408\u4f75\u4ee3\u8b1d\u9e7c\u8840\u75c7\nD. \u4ee3\u8b1d\u9e7c\u8840\u75c7\uff0c\u7121\u547c\u5438\u4ee3\u511f\nE. \u4ee3\u8b1d\u9e7c\u8840\u75c7\uff0c\u6709\u90e8\u4efd\u547c\u5438\u4ee3\u511f\n": "(C)", "100-2.\n\u4e0b\u5217\u6709\u95dc\u4e00\u822c\u81e8\u5e8a\u4f7f\u7528\u4e4b\u8108\u885d\u5f0f\u8840\u6c27\u5075\u6e2c\u5100\uff08pulse oximetry\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u7576\u5fc3\u81df\u8f38\u51fa\u91cf\u660e\u986f\u4e0b\u964d\u6642\uff0c\u6240\u6e2c\u503c\u66f4\u6e96\u78ba\nB. \u7121\u6cd5\u5206\u8fa8methemoglobin\u8207Oxyhemoglobin\nC. \u7576\u6e2c\u5f97SpO2 > 90% \u6642\uff0c\u4e5f\u8868\u793aPaCO2\u4e0d\u6703\u592a\u9ad8\nD. \u5176\u6e2c\u503c\u4e0d\u53d7\u662f\u5426\u4f7f\u7528\u8840\u7ba1\u6536\u7e2e\u5291\u4e4b\u5f71\u97ff\nE. \u8840\u4e2dPaO2\u8207\u6240\u6e2cSpO2\u6210\u7dda\u6027\u6b63\u76f8\u95dc\n": "(B)", "100-3.\n66\u6b72\u5a66\u4eba\u56e0\u54b3\u8840\u548c\u547c\u5438\u56f0\u96e3\u6c42\u8a3a\uff0c\u80f8\u90e8X\u5149\u5982\u5716\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u5c0d\u8a3a\u65b7\u6700\u6709\u52a9\u76ca\uff1f\nA. \u62bd\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\nB. \u505a\u80f8\u8154\u7a7f\u523a\u62bd\u6c34\u6aa2\u67e5\nC. \u505a\u75f0\u6aa2\u67e5\u7d30\u83cc\u8207\u764c\u7d30\u80de\nD. \u505a\u652f\u6c23\u7ba1\u93e1\u6aa2\u67e5\nE. \u505a\u6838\u91ab\u80ba\u90e8\u6383\u7784\n": "(D)", "100-4.\n60\u6b72B\u7d30\u80de\u6dcb\u5df4\u7624\u75c5\u4eba\uff0c\u5316\u7642\u4e2d\u51fa\u73fe\u767c\u71d2\u3001\u4e7e\u54b3\u548c\u5598\uff0c\u5176\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u7a2e\u611f\u67d3\u6700\u53ef\u80fd\uff1f\nA. Pneumocystis jirovecii\nB. Hemophilus influenzae\nC. Nontuberculosis Mycobacterium\nD. Cryptococcus neoformans\nE. Pseudomonas aeruginosa\n": "(A)", "100-5.\n\u4e0b\u5217\u6709\u95dc\u80ba\u7d50\u6838\u75c5\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u4e00\u822c\u6a19\u6e96\u6cbb\u7642\u662fHERZ 6\u500b\u6708\nB. \u6cbb\u7642\u4e00\u500b\u6708\u5f8c\u7684\u75f0\u57f9\u990a\u4ecd\u7136\u967d\u6027\uff0c\u61c9\u5c6c\u6cbb\u7642\u5931\u6557\nC. \u5c0dIsoniazid \u548cRifampin\u7686\u6297\u85e5\u6027\u8005\uff0c\u7a31\u70ba\u591a\u91cd\u6297\u85e5\u6027(MDR)\nD. Pyrazinamide \u4e4b\u4e3b\u8981\u526f\u4f5c\u7528\u662f\u8996\u795e\u7d93\u840e\u7e2e\nE. \u4e00\u822c\u6a19\u6e96\u6cbb\u7642\u5c0dHIV\u967d\u6027\u8005\u4e4b\u7642\u6548\u751a\u5dee\n": "(C)", "100-6.\n\u4e0b\u5217\u6709\u95dc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\uff08COPD\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u80ba\u90e8\u5fa9\u5065\u7121\u6cd5\u6539\u5584\u80ba\u529f\u80fd\nB. \u53ea\u8981\u9577\u671f\u7d66\u4e88\u6c27\u6c23\u7686\u53ef\u6e1b\u5c11\u6b7b\u4ea1\u7387\nC. \u53ea\u8981\u5438\u7159\u8d85\u904e60\u5e74(pack years)\u5fc5\u6703\u5f97COPD\nD. \u9808\u7d66\u4e88\u9577\u671f\u4f4e\u5291\u91cf\u53e3\u670d\u985e\u56fa\u9187\u4ee5\u6e1b\u7de9\u80ba\u529f\u80fd\u4e4b\u8870\u9000\nE. \u767c\u71d2 > 38.5\u2103 \u5373\u8868\u793a\u6025\u6027\u60e1\u5316\uff08acute exacerbation)\n": "(A)", "100-7.\n\u4e0b\u5217\u6709\u95dc\u6c23\u5598\u75c5\u85e5\u7269\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u77ed\u6548beta 2-agonist \u5438\u5165\u5291\u53ea\u53ef\u9593\u6b47\u4f7f\u7528\nB. \u75c5\u60c5\u7a69\u5b9a\u6642\uff0c\u53ef\u63a1\u7528\u9577\u6548bata 2-agonist\u5438\u5165\u5291\u55ae\u7368\u4f7f\u7528\nC. \u5438\u5165\u5f0f\u985e\u56fa\u9187\u662f\u76ee\u524d\u6700\u6709\u6548\u7684\u63a7\u5236\u5291 (controller)\nD. \u53e3\u670d\u8336\u9e7c\u88fd\u5291\u4e0d\u53ef\u7576\u4f5c\u7b2c\u4e00\u7dda\u6cbb\u7642\u85e5\nE. \u767d\u4e09\u70ef(leukotriene)\u53d7\u9ad4\u62ee\u6297\u5291\u4e4b\u526f\u4f5c\u7528\u6975\u5c11\n": "(B)", "100-8.\n68\u6b72\u7537\u6027\u4e3b\u8a34\u6162\u6027\u54b3\u548c\u5598\uff0c\u80f8\u90e8X\u5149\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u7a2e\u5f71\u50cf\u6aa2\u67e5\u6700\u6709\u52a9\u65bc\u8a3a\u65b7\uff1f\nA. \u80f8\u90e8\u78c1\u632f\u9020\u5f71\uff08MRI\uff09\nB. \u8d85\u97f3\u6ce2\u6383\u63cf\nC. \u6ce8\u5c04\u986f\u5f71\u5291\u4e4b\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\nD. \u9ad8\u89e3\u6790\u5ea6\u4e4b\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\nE. \u6b63\u5b50\u96fb\u8166\u65b7\u5c64(PET-CT)\n": "(D)", "100-9.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u81df\u8870\u7aed\u5f15\u8d77\u80ba\u6c34\u816b\u5c0e\u81f4\u547c\u5438\u8870\u7aed\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r1.\u5e38\u6709\u63db\u6c23-\u704c\u6ce8\uff08V/Q\uff09\u4e0d\u914d\u5408\r2.\u5e38\u5408\u4f75dead space\u589e\u52a0\r3. \u901a\u5e38PaCO2\u660e\u986f\u6607\u9ad8\r4.\u5e38\u6709\u80ba\u5167\u5206\u6d41(shunt)\nA. 1+2\nB. 1+4\nC. 2+3\nD. 2+4\nE. 3+4\n": "(B)", "100-10.\n\u4e0b\u5217\u6709\u95dc\u8f38\u8840\u5f15\u8d77\u6025\u6027\u80ba\u640d\u50b7\uff08TRALI\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r1.\u8f38\u8840\u904e\u91cf\u6216\u904e\u5feb\u6240\u81f4.\r2.\u6709\u5fc3\u81df\u75c5\u8005\u6613\u767c\u751f.\r3.\u56e0\u4f9b\u8840\u8005\u8840\u6f3f\u542b\u9ad8\u6297HLA\u6297\u9ad4\u6240\u81f4.\r4.\u53ea\u9808\u4fdd\u5b88\u7642\u6cd5\u5373\u53ef\r5.\u9700\u4f7f\u7528\u9ad8\u5291\u91cf\u985e\u56fa\u9187\nA. 1+2\nB. 1+4\nC. 2+5\nD. 3+4\nE. 3+5\n": "(D)", "100-11.\n\u4e0b\u5217\u6709\u95dc\u54b3\u55fd\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r1.\u670d\u7528\u8840\u7ba1\u7dca\u7e2e\u7d20\u8f49\u5316\u9175\u7d20\u6291\u5236\u5291(ACEI)\u5f15\u8d77\u7684\u54b3\u55fd\u5e38\u5728\u670d\u7528\u6eff6\u500b\u6708\u624d\u51fa\u73fe\r2.\u5982\u679c\u61f7\u7591\u662f\u80ba\u764c\u5f15\u8d77\uff0c\u61c9\u505a\u9ad8\u89e3\u6790\u5ea6\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\r3.\u7a69\u5b9a\u7684\u6162\u6027\u652f\u6c23\u7ba1\u708e\u75c5\u4eba\uff0c\u4e0d\u5b9c\u670d\u7528\u6b62\u54b3\u85e5\r4.\u6240\u8b02 \"cough syncope\" \u662f\u56e0\u5fc3\u81df\u8f38\u51fa\u91cf\u6e1b\u5c11\u6240\u81f4\nA. 1+2\nB. 1+3\nC. 2+3\nD. 2+4\nE. 3+4\n": "(E)", "100-12.\n\u4e0b\u5217\u95dc\u65bcMDR-TB\u7684\u6558\u8ff0\u54ea\u4e00\u500b\u4e0d\u6b63\u78ba\uff1f\nA. MDR-TB\u6307\u81f3\u5c11\u5c0dIsoniazid\u53caRifampicin\u5177\u6297\u85e5\u6027\u7684\u60a3\u8005\nB. MDR-TB\u7684\u75c5\u60a3\u4ee5\u4e00\u958b\u59cb\u5373\u611f\u67d3\u5177\u6297\u85e5\u6027\u7684\u83cc\u682a\u70ba\u6700\u5e38\u898b\u7684\u539f\u56e0\nC. \u81f3\u5c11\u9700\u4f7f\u75284\u7a2e\u6709\u6548\u7684\u85e5\u7269\u6cbb\u764218\u500b\u6708\u4ee5\u4e0a\uff0c\u4e14\u9700\u6703\u8a3a\u5177\u6cbb\u7642\u591a\u91cd\u6297\u85e5\u7d50\u6838\u6709\u7d93\u9a57\u7684\u91ab\u5e2b\nD. \u75c5\u60a3\u4e0d\u898f\u5247\u670d\u85e5\u3001\u670d\u85e5\u671f\u9593\u4e0d\u8db3\u5373\u81ea\u884c\u505c\u85e5\u662f\u9020\u6210MDR-TB\u7684\u539f\u56e0\u4e4b\u4e00\nE. Isoniazid\u9810\u9632\u6027\u6cbb\u7642\u4e0d\u9069\u7528\u65bcMDR-TB\u75c5\u4eba\u4e4b\u89aa\u5bc6\u63a5\u89f8\u8005\n": "(B)", "100-13.\n\u4f9d\u64da\u300c\u50b3\u67d3\u75c5\u9632\u6cbb\u6cd5\u300d\u7684\u898f\u5b9a\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6240\u6709\u63a5\u53d7\u6297\u7d50\u6838\u85e5\u7269\u6cbb\u7642\u4e4b\u7d50\u6838\u75c5\u4eba\u7686\u61c9\u901a\u5831\nB. \u7d30\u83cc\u5b78\u78ba\u8a3a\u4e4b\u7d50\u6838\u75c5\u4eba\u5728\u78ba\u8a3a\u524d\u6b7b\u4ea1\uff0c\u4e14\u672a\u63a5\u53d7\u6297\u7d50\u6838\u85e5\u7269\u6cbb\u7642\u4e0d\u9700\u901a\u5831\nC. \u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u5c6c\u7b2c\u4e8c\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u9808\u5728\u4e03\u5929\u5167\u901a\u5831\nD. \u80ba\u5916\u7d50\u6838\u75c5\u4e0d\u5177\u50b3\u67d3\u6027\uff0c\u4e0d\u9700\u901a\u5831\nE. \u63a5\u53d7\u9810\u9632\u6027\u6cbb\u7642\u4e4b\u6f5b\u4f0f\u6027\u7d50\u6838\u611f\u67d3\u60a3\u8005\u5fc5\u9808\u901a\u5831\n": "(A)", "100-14.\n\u6c23\u5598\u7684\u75c7\u72c0\u6709\u53ef\u80fd\u6642\u597d\u6642\u58de\uff0c\u4f46\u662f\u547c\u5438\u9053\u7684\u767c\u708e\u53cd\u61c9\u537b\u662f\u6162\u6027\u6301\u7e8c\u5b58\u5728\u7684\u3002\u56e0\u6b64\uff0c\u5c0d\u65bc\u5927\u90e8\u5206\u7684\u6c23\u5598\u60a3\u8005\uff0c\u9700\u8981\u6bcf\u5929\u898f\u5f8b\u4f7f\u7528\u300c\u63a7\u5236\u578b\u85e5\u7269\u300d\uff0c\u9810\u9632\u75c7\u72c0\u7684\u51fa\u73fe\u3001\u6539\u5584\u80ba\u529f\u80fd\u3002\u76ee\u524d\u7684\u85e5\u7269\u5df2\u7d93\u80fd\u5920\u8b93\u5927\u591a\u6578\u7684\u6c23\u5598\u75c5\u4eba\u7372\u5f97\u826f\u597d\u7684\u63a7\u5236\u3002\u7576\u6c23\u5598\u63a7\u5236\u826f\u597d\u6642\uff0c\u75c5\u4eba\u5c31\u80fd\u5920\u9054\u5230\u4ee5\u4e0b\u7684\u76ee\u6a19\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. \u767d\u5929\u3001\u591c\u665a\u90fd\u6c92\u6709\u75c7\u72c0\nB. \u4e0d\u9700\u8981\u4f7f\u7528\u7de9\u89e3\u578b\u85e5\u7269\nC. \u4e0d\u5f71\u97ff\u5e73\u65e5\u6d3b\u52d5\nD. \u80ba\u529f\u80fd\u6b63\u5e38\uff08\u6216\u63a5\u8fd1\u6b63\u5e38\uff09\nE. \u6c92\u6709\u56b4\u91cd\u767c\u4f5c\u6216\u6025\u6027\u60e1\u5316\n": "(B)", "100-15.\n\u6709\u95dc\u9000\u4f0d\u8ecd\u4eba\u75c7(Legionnaire's disease)\u7684\u8840\u6e05\u5b78\u6aa2\u67e5\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6297\u9ad4\u503c 1:128 \u5373\u53ef\u78ba\u8a3a\nB. \u6297\u9ad4\u5728\u611f\u67d3\u5f8c4-6\u9031\u624d\u6703\u5347\u9ad8\nC. \u6297\u9ad4\u503c\u5927\u65bc 1:256 \u8868\u793a\u6025\u6027\u611f\u67d3\nD. \u6297\u9ad4\u5347\u9ad8\u53ef\u6301\u7e8c\u8d85\u904e\u4e00\u5e74\nE. \u5c3f\u6297\u539f\u5c0d\u7b2c\u4e00\u578b\u55dc\u80ba\u9000\u4f0d\u8ecd\u4eba\u83cc\u611f\u67d3\u6709\u5f88\u597d\u7684\u8a3a\u65b7\u654f\u611f\u6027 (>80%) \u53ca\u5c08\u4e00\u6027 (100%)\uff0c\u81e8\u5e8a\u5e38\u7528\u4f86\u4f5c\u70ba\u5176\u4ed6\u8840\u6e05\u578b\u9000\u4f0d\u8ecd\u4eba\u83cc\u611f\u67d3\u4e4b\u5075\u6e2c\u7528\n": "(D)", "100-16.\n\u4e00\u4f4d50\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u660f\u8ff7\u88ab\u9001\u81f3\u6025\u8a3a\u6c42\u8a3a\uff0c\u52d5\u8108\u6c23\u9ad4\u5206\u6790\u5448\u73fepH 7.10\uff0cPCO2 80 mmHg\uff0cPO2 40 mmHg\u3002\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba\u4f55\uff1f\uff1f\nA. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\nB. \u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (ARDS)\nC. \u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2\nD. \u56b4\u91cd\u80ba\u7e96\u7dad\u5316\nE. \u670d\u7528\u904e\u91cf\u93ae\u975c\u5291\n": "(E)", "100-17.\n\u4e00\u4f4d40\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6700\u8fd1\u4e00\u9031\u6301\u7e8c\u767c\u71d2\u81f339\u5ea6\uff0c\u54b3\u55fd\u5e36\u81bf\u75f0\uff0c\u5de6\u5074\u80f8\u75db\u5f15\u767c\u9593\u6b47\u6027\u547c\u5438\u56f0\u96e3\u800c\u5230\u6025\u8a3a\u6c42\u8a3a\u3002\u80f8\u90e8X\u5149\u5448\u73fe\u5de6\u4e0a\u80ba\u8449\u6d78\u6f64\u6027\u75c5\u8b8a\u8207\u5de6\u5074\u808b\u819c\u7a4d\u6c34\u3002\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u80f8\u7ba1\u5f15\u6d41\u6cbb\u7642\u4e4b\u9069\u61c9\u75c7\uff1f\nA. \u5f62\u6210\u8154\u5ba4\u5316\u808b\u819c\u7a4d\u6db2(loculated effusion)\nB. \u808b\u819c\u6db2pH<7.2\nC. \u808b\u819c\u6db2 glucose<60 mg/dl\nD. \u808b\u819c\u6db2Gram's stain\u767c\u73fe\u7d30\u83cc\nE. \u808b\u819c\u6db2\u4e4b\u767d\u8840\u7403\u4e2d\uff0c\u6dcb\u5df4\u7403\u6bd4\u4f8b >50%\n": "(E)", "100-18.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u5c0f\u7d30\u80de\u80ba\u764c(small cell carcinoma of lung)\u5e38\u898b\u4e4b\u4f34\u96a8\u816b\u7624\u65b0\u751f\u5f15\u8d77\u7684\u9ad4\u5167\u7cfb\u7d71\u5931\u8abf (paraneoplastic phenomena)\uff1f\nA. \u6297\u5229\u5c3f\u6fc0\u7d20\u4e0d\u9069\u7576\u5206\u6ccc\u75c7\u5019\u7fa4 (SIADH)\nB. Lamber-Eaton myasthenic syndrmoe\nC. Cushing's syndrome\nD. Humoral hypercalcemia\nE. Coagulopathy\n": "(E)", "100-19.\n\u5927\u591a\u6578\u9593\u8cea\u6027\u80ba\u75c5\u7684\u81f4\u75c5\u539f\u56e0\u4e0d\u660e\uff0c\u4e0b\u5217\u4f55\u8005\u9664\u5916\uff1f\nA. Hypersensitivity pneumonitis\nB. Eosinophilic pneumonia\nC. Pulmonary hemorrhage syndrome\nD. Lymphomatoid granulomatosis\nE. Sarcoidosis\n": "(A)", "100-20.\n\u81e8\u5e8a\u8a3a\u65b7\u80ba\u6813\u585e\u75c7\u5e38\u7528\u4e4b\u300cVirchow's Triad\u300d\u5305\u542b\u54ea\u4e9b\u8b8a\u5316\uff1f\r1.Stasis.\r2.Hyperventilation.\r3.Nocturnal hemoglobinuria.\r4.Vessel wall injury.\r5.Hypercoagulability.\nA. 1+2+3\nB. 2+3+4\nC. 1+3+5\nD. 1+4+5\nE. 2+3+5\n": "(D)", "100-21.\n\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u6297\u85e5\u6027\u7d50\u6838\u75c5\u7684\u539f\u5247\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\r1.\u82e5\u767c\u73fe\u6cbb\u7642\u7121\u6548\u6642\uff0c\u61c9\u518d\u52a0\u5165\u4e00\u7a2e\u672a\u66fe\u4f7f\u7528\u904e\u7684\u6297\u7d50\u6838\u85e5\u7269.\r2.\u82e5\u611f\u67d3\u591a\u91cd\u6297\u85e5\u7d50\u6838\u83cc\u6642\uff0c\u9700\u4f7f\u7528\u81f3\u5c11\u4e09\u7a2e\u4ee5\u4e0a\u654f\u611f\u4e4b\u6297\u7d50\u6838\u85e5\u7269.\r3.\u53ef\u8003\u616e\u5916\u79d1\u624b\u8853\u5207\u9664\u4e3b\u8981\u75c5\u7076\u90e8\u4efd\uff0c\u518d\u63a5\u53d7\u5b8c\u6574\u6297\u7d50\u6838\u85e5\u7269\u6cbb\u7642.\r4.\u9700\u6cbb\u7642\u81f3\u57f9\u990a\u7d50\u679c\u8f49\u9670\u6027\u81f3\u5c1112\u500b\u6708\u624d\u53ef\u8003\u616e\u505c\u85e5.\r5.\u4e0d\u9069\u5408\u4f7f\u7528\u76f4\u63a5\u89c0\u5bdf\u7d66\u85e5\u65b9\u5f0f(directly observed therapy, DOT).\nA. 1+2+3\nB. 2+4+5\nC. 1+3+5\nD. 1+4+5\nE. 2+3+5\n": "(D)", "100-22.\n\u7761\u7720\u547c\u5438\u7d42\u6b62\u75c7\u5019\u7fa4 (sleep apnea syndrome) \u7684\u75c5\u4eba\u767c\u4f5c\u6642\uff0c\u8840\u6c27\u4e0b\u964d\u3001\u4e8c\u6c27\u5316\u78b3\u4e0a\u5347\u3001\u9178\u9e7c\u503c\u504f\u4f4e\uff0c\u53ef\u5c0e\u81f4\u54ea\u4e9b\u751f\u7406\u5b78\u8b8a\u5316\u8207\u81e8\u5e8a\u8868\u5fb5\uff1f\r1.\u808b\u819c\u58d3\u529b\u964d\u4f4e\uff0c\u589e\u52a0\u5fc3\u81df\u4e4b\u5f8c\u8ca0\u8377(afterload)\uff0c\u5c0e\u81f4\u53f3\u5fc3\u5ba4\u8870\u7aed\r2.\u5fc3\u8df3\u6e1b\u6162\uff0c\u5fc3\u5f8b\u4e0d\u6574\uff0c\u5c0e\u81f4\u7121\u9810\u8b66\u4e4b\u591c\u9593\u6b7b\u4ea1 (nocturnal death)\r3.\u80ba\u90e8\u8840\u7ba1\u7e2e\u6536\uff0c\u5c0e\u81f4\u80ba\u52d5\u8108\u58d3\u4e0a\u5347\r4.\u5168\u8eab\u8840\u7ba1\u64f4\u5f35\uff0c\u9020\u6210\u8840\u58d3\u964d\u4f4e\uff0c\u5f15\u767c\u4f11\u514b\r5.\u4e8c\u6c27\u5316\u78b3\u6eef\u7559\uff0c\u5f15\u8d77\u6162\u6027\u901a\u6c23\u4e0d\u8db3 (chronic hypoventilation)\nA. 1+2+3\nB. 2+3+4\nC. 1+3+4\nD. 2+3+5\nE. 1+4+5\n": "(D)", "101-1.\n\u5973\u602721\u6b72,\u672a\u5438\u7159,\u4e3b\u8a34\u9577\u671f\u547c\u5438\u56f0\u96e3\u3002\u80f8\u90e8X\u5149\u5982\u5716\u3002\r\u53ef\u9810\u671f\u6703\u51fa\u73fe\u4e0b\u5217\u80ba\u90e8\u7570\u5e38\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. \u4fb7\u9650\u6027\u80ba\u90e8\u75be\u75c5\nB. \u80ba\u6ce1\u63db\u6c23\u4f4e\u4e0b (hypoventilation)\nC. \u963b\u585e\u6027\u80ba\u90e8\u75be\u75c5\nD. \u63db\u6c23-\u704c\u6ce8 (V-Q) \u7570\u5e38\nE. \u80ba\u52d5\u8108\u9ad8\u58d3\u75c7\n": "(C)", "101-2.\n\u4e0b\u5217\u6709\u95dc\u80ba\u7d50\u6838\u75c5\u85e5\u7269\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\r( R= Rifampin, Z= Pyrazinamide, E= Ethambutol, H= INH )\nA. Pyrazinamide \u5c0d\u5b55\u5a66\u61c9\u5c6c\u5b89\u5168\nB. \u5c0d INH\u6709\u6297\u85e5\u6027\u8005\uff0c\u53ea\u670dRZE 6\u500b\u6708\u4ea6\u53ef\nC. \u7121\u6cd5\u670d\u7528 Pyrazinamide \u8005\uff0c\u53ef\u670d HRE 9\u500b\u6708\nD. \u5c0d INH\u548cRifampin \u6709\u6297\u85e5\u6027\u8005\uff0c\u61c9\u670dZE 18\u500b\u6708\nE. Ethambutol \u6709\u5f15\u8d77\u8996\u795e\u7d93\u708e\u4e4b\u526f\u4f5c\u7528\n": "(D)", "101-3.\n\u4e0b\u5217\u6709\u95dc\u7b2c\u4e00\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u65b0TNM\u5206\u985e\u6cd5\uff0cT1a\u8207T1b\u4e4b\u5206\u5225\u754c\u7dda\u662f\u816b\u7624\u76f4\u5f913\u516c\u5206\nB. \u5728\u80ba\u8449\u5207\u9664\u5f8c\uff0c\u9808\u52a0\u5c40\u90e8\u653e\u5c04\u7dda\u6cbb\u7642\nC. \u5728\u80ba\u8449\u5207\u9664\u5f8c\uff0c\u9808\u8f14\u52a9cisplatin-based\u5316\u7642\nD. \u5728\u80ba\u8449\u5207\u9664\u5f8c\uff0c\u9808\u8f14\u52a9\u6a19\u9776\u6cbb\u7642\nE. \u5c11\u6709\u9ad8\u8840\u9223 ( hypercalcemia )\u4e4b\u60c5\u5f62\n": "(E)", "101-4.\n\u7537\u6027\uff0c61\u6b72\uff0c\u6709\u5438\u7159\u53f2\uff0c\u4e3b\u8a34\u54b3\u55fd\u548c\u5598\uff0c\u80f8\u90e8X\u5149\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u7a2e\u8a3a\u65b7\u6700\u53ef\u80fd\uff1f\nA. \u9c57\u72c0\u7d30\u80de\u80ba\u764c\nB. \u5c0f\u7d30\u80de\u80ba\u764c\nC. \u6dcb\u5df4\u7624\nD. \u4e3b\u52d5\u8108\u7624\nE. \u7532\u72c0\u817a\u816b\n": "(E)", "101-5.\n\u4e0b\u5217\u6709\u95dc\u963b\u585e\u6027\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4 ( OSAHS ) \u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u7761\u7720\u4e2d\u51fa\u73fe apnea \u6216 hypopnea \u81f3\u5c11\u6bcf\u5c0f\u664220\u6b21\nB. \u5176\u591c\u9593\u7761\u7720\u6642\u9593\u6703\u660e\u986f\u5ef6\u9577\nC. \u61c9\u5148\u7528\u85e5\u7269\u6cbb\u7642\uff0c\u7121\u6548\u5f8c\u624d\u5617\u8a66\u547c\u5438\u5668 CPAP\nD. \u82e5\u5408\u4f75\u7cd6\u5c3f\u75c5\u6642\uff0c\u8f03\u5e38\u51fa\u73fe\u80f0\u5cf6\u7d20\u6297\u6027 ( resistance )\nE. \u5176\u5e73\u5747\u8840\u58d3\u6703\u8f03\u9ad8\uff0c\u4f46\u8207\u591c\u9593\u7f3a\u6c27\u7121\u95dc\n": "(D)", "101-6.\n\u7537\u602738\u6b72\uff0c\u6709\u5438\u7159\u53f2\uff0c\u56e0\u767c\u71d2\u3001\u54b3\u3001\u5598\u4f86\u6025\u8a3a\uff0c\u80f8\u90e8X\u5149\u5982\u57161\uff0c\u9694\u5929\u5598\u52a0\u5287\u3001\u80f8\u90e8X\u5149\u5982\u57162\uff0c\u5176\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u6d41\u611f\u80ba\u708e\nB. \u8461\u8404\u7403\u83cc\u80ba\u708e\nC. \u7da0\u81bf\u687f\u83cc\u80ba\u708e\nD. \u514b\u96f7\u767d ( Klebsiella ) \u83cc\u80ba\u708e\nE. \u9000\u4f0d\u8ecd\u4eba\u75c7\u80ba\u708e\n": "(A)", "101-7.\n\u7d30\u83cc\u6027\u80ba\u708e\u5408\u4f75\u808b\u819c\u7a4d\u6db2\uff0c\u4e0b\u5217\u4f55\u7a2e\u808b\u819c\u7a4d\u6db2\u4e4b\u6578\u64da\u8868\u793a\u9808\u63d2\u80f8\u7ba1\u5f15\u6d41\uff1f\nA. PMN > 90%\nB. WBC > 1000/mm3\nC. Glucose < 100 mg/dL\nD. pH < 7.2\nE. LDH > 300 IU/L\n": "(D)", "101-8.\n\u4e0b\u5217\u6709\u95dc\u6c23\u5598\u75c5\u5b55\u5a66\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u61f7\u5b55\u671f\u9593\uff0c\u6c23\u5598\u90fd\u6703\u6539\u5584\uff0c\u53ef\u6e1b\u85e5\nB. \u61f7\u5b55\u671f\u9593\uff0c\u61c9\u5118\u91cf\u907f\u514d\u4f7f\u7528\u5438\u5165\u6027\u985e\u56fa\u9187\nC. \u8336\u9e7c\u88fd\u5291\u53ef\u80fd\u5f15\u8d77\u7578\u80ce\uff0c\u61c9\u907f\u514d\u670d\u7528\nD. \u8981\u5118\u91cf\u907f\u514d\u5f15\u8d77\u6025\u6027\u60e1\u5316\uff0c\u5176\u4ed6\u6cbb\u7642\u540c\u4e00\u822c\u4eba\nE. \u7522\u5f8c\u61c9\u907f\u514d\u54fa\u4e73\uff0c\u4ee5\u514d\u5b30\u5152\u5403\u5230\u6c23\u5598\u7528\u85e5\n": "(D)", "101-9.\n\u7537\u6027\uff0c83\u6b72\uff0c\u6709\u5438\u7159\u53f2\uff0c\u56e0\u767c\u71d2\u3001\u54b3\u55fd\u6709\u75f0\u4f86\u8a3a\uff0c\u80f8\u90e8X\u5149\u548c\u65b7\u5c64\u5982\u5716\u6240\u793a\uff0c\u5176\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u7a7a\u6d1e\u6027\u80ba\u764c\u4f75\u963b\u585e\u6027\u80ba\u708e\nB. \u80ba\u708e\u4f75\u80ba\u81bf\u760d ( abscess )\nC. \u80ba\u708e\u4f75\u6c23\u56ca ( pneumatocele )\nD. \u80ba\u56ca\u816b ( lung cyst ) \u4f75\u80ba\u708e\nE. \u80ba\u7d50\u6838\n": "(B)", "101-10.\n\u4e0b\u5217\u4f55\u8005\u662f\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 ( COPD )\u6709 air trapping \u4e4b\u80ba\u529f\u80fd\u8b8a\u5316\uff1f\r(1)TV \u6e1b\u5c11\r(2)FRC \u6e1b\u5c11\r(3)RV \u589e\u52a0\r(4) RV/TLC \u4e0a\u5347\nA. (1)+(2)\nB. (1)+(3)\nC. (2)+(3)\nD. (2)+(4)\nE. (3)+(4)\n": "(E)", "101-11.\n\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u53ef\u898b\u65bc\u767b\u4e0a\u9ad8\u5c71\u4e0a\u7684\u4eba\uff1f\r(1) PaO2 \u4e0b\u964d\r(2)PaCO2 \u4e0b\u964d\r(3)PaCO2 \u4e0a\u5347\r(4)PAO2-PaO2 \u4e0a\u5347\r(5) PAO2-PaO2 \u4e0b\u964d\nA. (1+)(2)\nB. (1)+(3)\nC. (2)+(4)\nD. (3)+(4)\nE. (3)+(5)\n": "(A)", "101-12.\n\u6839\u64da\u5be6\u8b49\u91ab\u5b78\uff0c\u6210\u4eba\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (ARDS)\u521d\u671f\u6cbb\u7642\u4e4b\u901a\u6c23\u547c\u5438\u8a2d\u5b9a\u70ba\u4f55\uff1f\r(1)\u6f6e\u6c50\u5bb9\u7a4d (TV) <= 6mL/kg PBW\r(2)PEEP 10-20 cmH2O,\r(3)\u9ad8\u539f (plateau )\u58d3\u529b <= 30 cm H2O\r(4) \u547c\u5438\u6b21\u6578<= 20 \u6b21/\u5206\nA. (1)+(2)\nB. (1)+(3)\nC. (2)+(3)\nD. (2)+(4)\nE. (3)+(4)\n": "(B)", "101-13.\n\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u5e38\u898b\u7684\u9593\u8cea\u6027\u80ba\u75c5(interstitial lung disease, ILD)\nA. \u985e\u8089\u7624(Sarcoidosis)\nB. \u85e5\u7269\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5(Drug-induced ILD)\nC. \u8077\u696d\u6216\u74b0\u5883\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5(Occupational and environmental-related ILD)\nD. \u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5(Connective tissue disease-related ILD)\nE. \u81ea\u767c\u6027\u9593\u8cea\u6027\u80ba\u708e(Idiopathic interstitial pneumonia)\n": "(E)", "101-14.\n\u4ee5\u4e0b\u95dc\u65bc\u5404\u985e\u708e\u75c7\u7d30\u80de\u5728\u6c23\u5598(asthma)\u81f4\u75c5\u6a5f\u8f49\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u80a5\u80d6\u7d30\u80de(mast cell)\u548c\u904e\u654f\u539f\u9020\u6210\u7684\u6025\u6027\u7d30\u652f\u6c23\u7ba1\u6536\u7e2e\u6709\u95dc\nB. \u55dc\u4e2d\u6027\u767d\u8840\u7403(neutrophil)\u5728\u6c23\u5598\u767c\u4f5c\u7684\u65e9\u671f\u53cd\u61c9\u4e2d\u626e\u6f14\u91cd\u8981\u89d2\u8272\nC. \u55dc\u4f9d\u7d05\u767d\u8840\u7403(eosinophil)\u5728\u6c23\u5598\u767c\u4f5c\u7684\u665a\u671f\u53cd\u61c9\u4e2d\u626e\u6f14\u91cd\u8981\u89d2\u8272\nD. \u76f8\u8f03\u65bc\u6b63\u5e38\u4eba\u7684\u6c23\u9053\uff0c\u6c23\u5598\u75c5\u60a3\u7684T helper 2 \u7d30\u80de\u6bd4\u65bcT helper 1 \u7d30\u80de\u6d3b\u5316\nE. \u547c\u5438\u4e0a\u76ae\u7d30\u80de\u4e5f\u53c3\u8207\u4e86\u6c23\u5598\u7684\u708e\u75c7\u53cd\u61c9\n": "(B)", "101-15.\n\u4e0b\u5217\u95dc\u65bc\u80ba\u81bf\u760d\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u662f\u4e00\u7a2e\u4e9e\u6025\u6027\uff0c\u9032\u5c55\u8f03\u7de9\u6162\u7684\u611f\u67d3\u75c7\nB. \u75c5\u60a3\u7684\u81e8\u5e8a\u8868\u73fe\u5e38\u898b\u662f\u6162\u6027\u54b3\u55fd\uff0c\u6fc3\u75f0\uff0c\u75b2\u5026\uff0c\u9ad4\u91cd\u6e1b\u8f15\u53ca\u8ca7\u8840\nC. \u75c5\u60a3\u5728\u767c\u71d2\u524d\u5e38\u6703\u5148\u51fa\u73fe\u51b7\u986b\nD. \u5e38\u898b\u65bc\u53e3\u8154\u885b\u751f\u4e0d\u597d\u6216\u662f\u5bb9\u6613\u55c6\u5230\u7684\u75c5\u60a3\nE. \u901a\u5e38\u662f\u53ad\u6c27\u6027\u7d30\u83cc\n": "(C)", "101-16.\n\u4e0b\u5217\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u5168\u4e16\u754c\uff0c\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u662f\u7b2c\u516d\u5927\u6b7b\u4ea1\u539f\u56e0\nB. \u5438\u83f8\u662f\u6700\u91cd\u8981\u7684\u81f4\u75c5\u539f\u56e0\uff0c\u548c\u5438\u83f8\u91cf\u53ca\u958b\u59cb\u5438\u83f8\u7684\u5e74\u9f61\u6709\u95dc\nC. \u6709\u6c23\u9053\u654f\u611f\u6027(airway hyperresponsiveness)\u7684\u5438\u83f8\u8005\uff0c\u66f4\u5bb9\u6613\u767c\u751f\nD. \u9999\u83f8\u5c0d\u6c23\u9053\u7684\u5f71\u97ff\u4e3b\u8981\u767c\u751f\u5728\u7d30\u652f\u6c23\u7ba1\uff0c\u4e0d\u6703\u5230\u9054\u80ba\u6ce1\nE. \u9664\u6212\u83f8\u548c\u63d0\u4f9b\u6c27\u6c23\u7d66\u9577\u671f\u7f3a\u6c27\u8005\uff0c\u78ba\u77e5\u53ef\u4ee5\u63d0\u9ad8\u75c5\u60a3\u7684\u5b58\u6d3b\u671f\uff1b\u76ee\u524d\u6240\u6709\u85e5\u7269\u5c0d\u75c5\u60a3\u5b58\u6d3b\u671f\u7684\u6539\u5584\u90fd\u4ecd\u6709\u722d\u8b70\n": "(D)", "101-17.\n\u4e0b\u5217\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u7684\u80ba\u529f\u80fd\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7528\u529b\u5410\u6c23\u7684\u6c23\u9ad4\u6d41\u901f\u4e0b\u964d\nB. \u6b98\u9918\u80ba\u5bb9\u7a4d(residual volume)\u589e\u52a0\nC. \u6b98\u9918\u80ba\u5bb9\u7a4d\u4f54\u7e3d\u80ba\u5bb9\u7a4d(total lung capacity)\u7684\u6bd4\u4f8b\u4e0a\u5347\nD. \u529f\u80fd\u6027\u6b98\u6c23\u91cf(functional residual capacity)\u6e1b\u5c11\nE. \u5e38\u898b\u901a\u6c23\u53ca\u704c\u6d41\u4e0d\u5747(ventilation-perfusion mismatching)\n": "(D)", "101-18.\n\u4e0b\u5217\u95dc\u65bc\u808b\u819c\u7a4d\u6db2\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u808b\u819c\u7a4d\u6db2\u5c0d\u8840\u6e05\u7684\u86cb\u767d\u8cea\u6bd4\u4f8b\u5927\u65bc0.5\uff0c\u808b\u819c\u7a4d\u6db2\u5c0d\u8840\u6e05\u7684LDH\u6bd4\u4f8b\u5927\u65bc0.6\uff0c\u6216\u662f\u808b\u819c\u7a4d\u6db2\u7684LDH\u5927\u65bc\u8840\u6e05LDH\u6b63\u5e38\u503c\u4e0a\u9650\u7684\u4e09\u5206\u4e4b\u4e8c\uff0c\u7b26\u5408\u4ee5\u4e0a\u81f3\u5c11\u4e8c\u500b\u689d\u4ef6\u8005\uff0c\u5373\u70baLight's criteria\u5b9a\u7fa9\u7684exudate\nB. Light's criteria\u7684\u654f\u611f\u6027\u5f88\u9ad8\uff0c\u4f46\u7279\u7570\u6027\u8f03\u5dee\nC. \u7576\u4f9d\u7167Light's criteria\u7684\u5b9a\u7fa9\u70baexudate\uff0c\u4f46\u81e8\u5e8a\u61f7\u7591\u70batransudate\u6642\uff0c\u53ef\u7528\u8840\u6e05\u5c0d\u808b\u819c\u7a4d\u6db2\u86cb\u767d\u8cea\u7684\u5dee\u503c\u5927\u65bc3.1 g/dL\u4f86\u6392\u9664\u5176\u70baexudate\nD. \u808b\u819c\u7a4d\u6db2\u4e2d\u7684NT-proBNP\u82e5\u5927\u65bc1500 pg/mL\uff0c\u5373\u5f88\u53ef\u80fd\u662f\u9b31\u8840\u6027\u5fc3\u8870\u7aed\u6240\u9020\u6210\u7684\u808b\u819c\u7a4d\u6db2\nE. \u809d\u6e90\u6027\u808b\u819c\u7a4d\u6db2(hepatic hydrothorax)\u4e3b\u8981\u767c\u751f\u5728\u53f3\u5074\n": "(A)", "101-19.\n\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u63a5\u53d7\u5668(epidermal growth factor receptor, EGFR)\u5728\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4f54\u6709\u4e00\u500b\u975e\u5e38\u91cd\u8981\u7684\u89d2\u8272\uff0c\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. EGFR\u916a\u80fa\u9178\u6fc0\u8122\u7684\u7a81\u8b8a\u5e7e\u4e4e\u53ea\u51fa\u73fe\u5728\u80ba\u817a\u764c\nB. \u5177\u6709\u9019\u985e\u7a81\u8b8a\u7684\u75c5\u60a3\u7d93\u5e38\u662f\u4e0d\u5438\u83f8\uff0c\u5973\u6027\u53ca\u6771\u65b9\u4eba\nC. \u6700\u5e38\u898b\u7684\u7a81\u8b8a\u662fexon 19 deletion\u548cL858R point mutation\nD. \u5177\u6709\u9019\u985e\u7a81\u8b8a\u7684\u80ba\u764c\u5c0d\u53e3\u670d\u7684EGFR\u916a\u80fa\u9178\u6fc0\u8122\u6291\u5236\u5291\u7684\u6709\u6548\u7387(Objective response rate)\u8d85\u904e\u4e5d\u6210\nE. T790M\u7a81\u8b8a\u662f\u9019\u4e9b\u75c5\u60a3\u5f8c\u4f86\u51fa\u73fe\u6297\u85e5\u6027\u6700\u91cd\u8981\u7684\u539f\u56e0\n": "(D)", "101-20.\n\u9ad8\u89e3\u50cf\u5ea6\u96fb\u8166\u65b7\u5c64(high resolution computed tomography, HRCT)\u5728\u9593\u8cea\u6027\u80ba\u75c5\u7684\u9451\u5225\u8a3a\u65b7\u4e0a\u5177\u6709\u76f8\u7576\u5927\u7684\u50f9\u503c\uff0c\u5728\u67d0\u4e9b\u60c5\u6cc1\u4e0b\uff0c\u751a\u81f3\u8db3\u4ee5\u8a3a\u65b7\u800c\u4e0d\u9700\u8981\u75c5\u60a3\u5192\u96aa\u505a\u80ba\u5207\u7247\u3002\u4ee5\u4e0b\u5e7e\u7a2e\u75be\u75c5\u4e2d\uff0c\u54ea\u4e00\u4e9b\u5373\u662f\u5728HRCT\u4e0a\u5177\u6709\u8868\u5fb5\u6027\u7684\u5f71\u50cf\u8b8a\u5316\u3002\r(1)\u81ea\u767c\u6027\u9593\u8cea\u6027\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fiborsis)\r(2)\u7d30\u652f\u6c23\u7ba1\u80ba\u6ce1\u7d30\u80de\u764c(bronchioloalveolar cell carcinoma)\r(3)\u985e\u8089\u7624(sarcoidosis)\r(4)\u80ba\u862d\u683c\u7f55\u6c0f\u7d30\u80de\u7d44\u7e54\u7403\u589e\u751f\u75c7(pulmonary Langerhans cell histiocytosis)\r(5)\u5de8\u7d30\u80de\u80ba\u708e(cytomegalovirus pneumonitis)\r(6)\u514b\u96f7\u4f2f\u6c0f\u80ba\u708e(Klebsiella pneumonia)\nA. (1)+(3)+(4)\nB. (2)(3)+(6)\nC. (1)+(2)+(4)\nD. (2)+(4)+(6)\nE. (3)+(5)+(6)\n": "(A)", "101-21.\n\u4e0b\u5217\u54ea\u4e9b\u662f\u5728\u9580\u8a3a\u6cbb\u7642\u7684\u793e\u5340\u578b\u80ba\u708e(outpatient community-acquired pneumonia)\u6700\u5e38\u898b\u7684\u81f4\u75c5\u539f\r(1)Streptococcus pneumoniae\r(2)Klebsiella pneumoniae\r(3)Mycoplasma pneumoniae\r(4)Chlamydia pneumoniae\r(5)Staphylococcus aureus\r(6)Haemophilus influenzae\nA. (1)+(2)+(5)+(6)\nB. (1)+(3)+(4)+(6)\nC. (2)+(3)+(4)+(5)\nD. (1)+(2)+(4)+(5)\nE. (1)+(4)+(5)+(6)\n": "(B)", "101-22.\n\u8acb\u554f\u6839\u64daWHO\u5c0d\u8d85\u7d1a\u6297\u85e5\u6027\u7d50\u6838\u83cc(Extensively drug-resistant tuberculosis\uff0cXDR-TB)\u7684\u5b9a\u7fa9\uff0c\u5fc5\u9808\u81f3\u5c11\u5c0d\u4e0b\u5217\u54ea\u4e9b\u85e5\u7269\u6709\u6297\u85e5\u6027\uff1f\r(1)Isoniazid\r(2)Rifampicin\r(3)Ethambutol\r(4)Pyrazinamide\r(5)\u6240\u6709\u7a2e\u985e\u7684fluoroquinolones\r(6)kanamycin\uff0ccapreomycin\uff0camikacin\u5176\u4e2d\u4e00\u7a2e\nA. (1)+(2)\nB. (1)+(2)+(3)+(4)\nC. (1)+(2)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(4)+(6)\nE. (1)+(2)+(5)+(6)\n": "(E)", "102-1.\n\u4e0b\u5217\u5404\u7a2e\u904e\u654f\u6027\u80ba\u708e(hypersensitivity pneumonitis, HP)\u548c\u904e\u654f\u539f\u7684\u76f8\u95dc\u6027\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8fb2\u592b\u80ba\u708eFarmer's lung - Thermophilic actinomycetes\nB. \u5be6\u9a57\u5ba4\u5de5\u4f5c\u8005\u80ba\u708eLaboratory worker's HP - Male rat urine\nC. \u71b1\u6c34\u6c60\u80ba\u708eHot tub lung - Mycobacterium avium complex\nD. \u81ea\u4f86\u6c34\u80ba\u708eTap water lung - Legionella spp.\nE. \u98fc\u990a\u8005\u80ba\u708eBreeder's lung - Pigeon proteins\n": "(D)", "102-2.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u904e\u654f\u6027\u80ba\u652f\u6c23\u7ba1\u9eb4\u83cc\u75c5(allergic bronchopulmonary aspergillosis)\u7684\u4e3b\u8981\u8a3a\u65b7\u689d\u4ef6\uff1f\nA. \u75f0\u6db2Aspergillus fumigatus\u57f9\u990a\u967d\u6027\nB. \u5c0dAspergillus fumigatus\u7684\u76ae\u819a\u654f\u611f\u8a66\u9a57\u967d\u6027\nC. \u8840\u6e05IgE\u4e0a\u5347\nD. \u4e2d\u592e\u578b\u652f\u6c23\u7ba1\u64f4\u5f35\nE. \u652f\u6c23\u7ba1\u6c23\u5598\n": "(A)", "102-3.\n\u80ba\u764c\u764c\u578b\u7684\u5224\u65b7\uff0c\u5c0d\u80ba\u764c\u6cbb\u7642\u85e5\u7269\u7684\u9078\u64c7\u5177\u6709\u76f8\u7576\u5927\u7684\u5f71\u97ff\uff0c\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5c0f\u7d30\u80de\u80ba\u764c\u7684\u9996\u9078\u8655\u65b9\u70bacisplatin + etoposide\nB. Gemcitabine\u5c0d\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u6cbb\u7642\u6548\u679c\u6bd4Pemetrexed\u597d\nC. Pemetrexed\u5c0d\u975e\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u6cbb\u7642\u6548\u679c\u6bd4Gemcitabine\u597d\nD. Bevacizumab\u5c0d\u817a\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u6cbb\u7642\u6548\u679c\u6bd4\u5c0d\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u597d\nE. Gefitinib\u5c0d\u817a\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u6cbb\u7642\u6548\u679c\u6bd4\u5c0d\u9c57\u72c0\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u597d\n": "(D)", "102-4.\n\u4e0b\u5217\u95dc\u65bc\u54b3\u55fd\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8ca0\u8cac\u54b3\u55fd\u7684\u611f\u89ba\u795e\u7d93\u662fC-fiber\nB. \u8188\u795e\u7d93(phrenic nerve)\u662f\u8ca0\u8cac\u50b3\u5c0e\u54b3\u55fd\u611f\u89ba\u7684\u4e3b\u8981\u795e\u7d93\nC. \u9f3b\u6d95\u5012\u6d41\u662f\u6162\u6027\u54b3\u55fd\u7684\u5e38\u898b\u539f\u56e0\nD. \u6c23\u5598\u8a98\u767c\u8a66\u9a57\u5982\u679c\u662f\u9670\u6027\uff0c\u5927\u81f4\u53ef\u4ee5\u6392\u9664\u6c23\u5598\u662f\u75c5\u60a3\u6162\u6027\u54b3\u55fd\u7684\u539f\u56e0\nE. \u80c3\u98df\u9053\u9006\u6d41\u4e5f\u6703\u5f15\u8d77\u54b3\u55fd\n": "(B)", "102-5.\n\u81e8\u5e8a\u4e0a\u6703\u9020\u6210\u75c5\u60a3\u7684\u4e00\u6c27\u5316\u78b3\u80ba\u7030\u6563\u91cf(diffusion capacity of carbon monoxide\uff0cDLCO)\u4e0b\u964d\u7684\u5e38\u898b\u539f\u56e0\u4e0d\u5305\u62ec\uff1a\nA. \u80ba\u6c23\u816b\nB. \u80ba\u52d5\u8108\u9ad8\u58d3\nC. \u6c23\u5598\u6025\u6027\u767c\u4f5c\nD. \u80ba\u7e96\u7dad\u5316\nE. \u8ca7\u8840\n": "(C)", "102-6.\n\u4e00\u540d60\u6b72\u7537\u6027\u56e0\u70ba\u6557\u8840\u75c7\u5408\u4f75\u547c\u5438\u8870\u7aed\u81f3\u6025\u8a3a\u6c42\u8a3a\uff0c\u5165\u9662\u6642\u7684\u8840\u6db2\u6aa2\u67e5\u767c\u73fe\u767d\u8840\u7403\u6578\u70ba15900/\u03bcL\uff0c\u8840\u7d05\u7d20\u70ba11.0 g/dl\uff0c\u8840\u5bb9\u6bd4\u70ba33.3%\uff0c\u8840\u5c0f\u677f\u6578\u70ba457000/\u03bcL\u3002\u75c5\u60a3\u5728\u4f7f\u7528\u975e\u518d\u5438\u5165\u6027\u9762\u7f69(non-rebreathing mask)\u6642\u52d5\u8108\u8840\u7684pH\u503c\u70ba7.196\uff0c\u6c27\u6c23\u5206\u58d3\u70ba352.3 mmHg\uff0c\u4e8c\u6c27\u5316\u78b3\u5206\u58d3\u70ba40.1 mmHg\uff0c\u78b3\u9178\u6c2b\u9e7d\u6fc3\u5ea6\u70ba15.2 mmol/L\uff0c\u6c27\u6c23\u98fd\u548c\u5ea6\u70ba100%\u3002\u8acb\u554f\u6b64\u75c5\u60a3\u52d5\u8108\u8840\u6db2\u4e2d\u7684\u542b\u6c27\u91cf(oxygen content\uff0cCaO2) \u4f30\u8a08\u7d04\u70ba\u591a\u5c11(mL O2/dL)\uff1f\nA. 15.8\nB. 296.6\nC. 14.9\nD. 45.3\nE. 76.3\n": "(A)", "102-7.\n\u80ba\u52d5\u8108\u6813\u585e(pulmonary thromboembolism)\u5e38\u5f15\u8d77\u7684\u80ba\u751f\u7406\u7570\u5e38\u4e0d\u5305\u62ec\uff1a\nA. \u80ba\u8840\u7ba1\u963b\u529b\u589e\u52a0 (increased pulmonary vascular resistance)\nB. \u6c23\u9053\u963b\u529b\u589e\u52a0 (increased airway resistance)\nC. \u80ba\u6ce1\u904e\u5ea6\u63db\u6c23 (alveolar hyperventilation)\nD. \u6c23\u9ad4\u4ea4\u63db\u969c\u7919 (impaired gas exchange)\nE. \u80ba\u9806\u5f9e\u6027\u589e\u52a0 (increased pulmonary compliance)\n": "(E)", "102-8.\n\u4e0b\u5217\u4f55\u8005\u5c0d\u65bc\u6539\u5584\u6210\u4eba\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(ARDS)\u7684\u9810\u5f8c\u5177\u6709\u6700\u660e\u78ba\u7684\u8b49\u64da\uff1f\nA. \u4f4e\u6f6e\u6c23\u5bb9\u7a4d(low tidal volume)\u7684\u547c\u5438\u5668\u8a2d\u5b9a\nB. \u8f03\u9ad8\u7684\u5410\u6c23\u672b\u967d\u58d3(PEEP)\u7684\u547c\u5438\u5668\u8a2d\u5b9a\nC. \u4fef\u81e5\u901a\u6c23(prone position)\nD. \u5168\u8eab\u6027\u985e\u56fa\u9187\nE. \u8449\u514b\u819c\u9ad4\u5916\u7dad\u751f\u7cfb\u7d71(ECMO)\n": "(A)", "102-9.\n\u67d0\u4e9b\u80ba\u90e8\u75be\u75c5\u7684\u767c\u751f\u7387\u6709\u6027\u5225\u4e0a\u7684\u5dee\u7570\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1)\u6dcb\u5df4\u8840\u7ba1\u5e73\u6ed1\u808c\u589e\u751f\u75c7(Lymphangioleiomyomatosis)\u8f03\u5e38\u898b\u65bc\u5973\u6027 (2)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5\u8f03\u5e38\u898b\u65bc\u5973\u6027 (3)\u7d50\u7bc0\u6027\u786c\u5316\u75c7(Tuberous sclerosis)\u76f8\u95dc\u7684\u9593\u8cea\u6027\u80ba\u75c5\u8f03\u5e38\u898b\u65bc\u7537\u6027 (4)\u81ea\u767c\u6027\u9593\u8cea\u6027\u80ba\u7e96\u7dad\u5316(Idiopathic pulmonary fibrosis)\u8f03\u5e38\u898b\u65bc\u7537\u6027 (5)\u5875\u80ba\u75c7(Pneumoconiosis)\u8f03\u5e38\u898b\u65bc\u7537\u6027\nA. (1)+(2)+(3)\nB. (1)+(4)+(5)\nC. (2)+(3)+(4)\nD. (1)+(2)+(5)\nE. (2)+(4)+(5)\n": "(B)", "102-10.\n\u4e0b\u5217\u95dc\u65bc\u54b3\u8840\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1)\u5728\u5df2\u958b\u767c\u570b\u5bb6\uff0c\u75c5\u6bd2\u6216\u7d30\u83cc\u6027\u652f\u6c23\u7ba1\u708e\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (2)\u5728\u5df2\u958b\u767c\u570b\u5bb6\uff0c\u80ba\u764c\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (3)\u4ee5\u5168\u7403\u800c\u8a00\uff0c\u80ba\u7d50\u6838\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (4)\u4ee5\u5168\u7403\u800c\u8a00\uff0c\u80ba\u764c\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (5)\u80ba\u52d5\u8108\u51fa\u8840\u6642\u7684\u51fa\u8840\u91cf\u6bd4\u8f03\u5927 (6)\u652f\u6c23\u7ba1\u52d5\u8108\u51fa\u8840\u6642\u7684\u51fa\u8840\u91cf\u6bd4\u8f03\u5927\nA. (1)+(3)+(5)\nB. (2)+(3)+(6)\nC. (1)+(4)+(5)\nD. (2)+(3)+(5)\nE. (1)+(3)+(6)\n": "(E)", "102-11.\n\u514d\u75ab\u7d44\u7e54\u67d3\u8272\u662f\u9451\u5225\u60e1\u6027\u816b\u7624\u764c\u578b\u7684\u91cd\u8981\u5de5\u5177\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u7d44\u5408\u6b63\u78ba? (1)\u80ba\u817a\u764c-TTF-1 (2)\u80ba\u817a\u764c-CK7 (3)\u9c57\u72c0\u4e0a\u76ae\u764c-CK20 (4)\u9c57\u72c0\u4e0a\u76ae\u764c-CK56 (5)\u5c0f\u7d30\u80de\u80ba\u764c-TTF-1 (6)\u5c0f\u7d30\u80de\u80ba\u764c-CK56 (7)\u808b\u819c\u9593\u76ae\u7624-TTF-1 (8)\u808b\u819c\u9593\u76ae\u7624-WT-1\nA. (1)+(3)+(6)+(8)\nB. (1)+(4)+(5)+(8)\nC. (2)+(3)+(5)+(7)\nD. (1)+(2)+(6)+(8)\nE. (1)+(2)+(5)+(8)\n": "(E)", "102-12.\n\u4e0b\u5217\u6709\u95dc\u547c\u5438\u56f0\u96e3(dyspnea)\u4e4b\u6558\u8ff0,\u4f55\u8005\u6b63\u78ba?\nA. \u547c\u5438\u56f0\u96e3\u901a\u5e38\u8207\u6240\u6e2c\u91cf\u4e4b\u8840\u6c27\u5206\u58d3(PO2)\u6709\u95dc\nB. \u547c\u5438\u56f0\u96e3\u901a\u5e38\u8207\u547c\u5438\u901f\u7387\u6210\u6b63\u76f8\u95dc\nC. \u8108\u885d\u5f0f\u8840\u6c27\u5075\u6e2c\u5100(pulse oximetry) \u7121\u6cd5\u4f5c\u70ba\u547c\u5438\u56f0\u96e3\u4e4b\u6cbb\u7642\u6307\u5f15\nD. \u53ef\u5f85\u56e0(codeine)\u662f\u4e00\u7a2e\u5f37\u7684\u9d09\u7247\u985e\u85e5,\u53ef\u7de9\u89e3\u56b4\u91cd\u7684\u547c\u5438\u56f0\u96e3\u3002\nE. \u55ce\u5561(morphine)\u4e0d\u53ef\u4f5c\u70ba\u7de9\u89e3\u547c\u5438\u56f0\u96e3\u4e4b\u7528\n": "(C)", "102-13.\n\u4e0b\u5217\u6709\u95dc\u6210\u4eba\u6c23\u5598\u75c5\u8a3a\u7642\u4e4b\u6558\u8ff0,\u4f55\u8005\u932f\u8aa4?\nA. \u65b0\u7248\u8a3a\u7642\u6307\u5f15\u662f\u4ee5\u63a7\u5236\u662f\u5426\u826f\u597d\u70ba\u6cbb\u7642\u4f9d\u64da\nB. \u82e5\u591c\u9593\u56e0\u75c7\u72c0\u9192\u4f86\u4e4b\u6b21\u6578\u6bcf\u6708\u4e0d\u591a\u65bc2\u6b21,\u8868\u793a\u63a7\u5236\u826f\u597d\nC. \u6c23\u5598\u4e4b\u56b4\u91cd\u5ea6\u5206\u985e\u4ecd\u7136\u662f\u521d\u59cb\u6cbb\u7642\u4e4b\u91cd\u8981\u4f9d\u64da\nD. \u904e\u53bb\u4e00\u5e74\u5167\u66fe\u56e0\u6025\u6027\u60e1\u5316\u9700\u53e3\u670d\u985e\u56fa\u9187\u4e8c\u6b21\u4ee5\u4e0a,\u5373\u5c6c\u63a7\u5236\u4e0d\u826f\nE. \u80ba\u529f\u80fd\u4e4b\u8ffd\u8e64\u53ef\u4ee5\u4f7f\u7528peak expiratory flow rate(PEFR)\u4e5f\u53ef\u7528FEV1\n": "(C)", "102-14.\n\u7537\u6027,70\u6b72,\u56e0\u6025\u6027\u547c\u5438\u56f0\u96e3\u88ab\u9001\u5230\u6025\u8a3a,\u5176\u80f8\u90e8X\u5149\u548c\u96fb\u8166\u65b7\u5c64\u5982\u5716\u793a ,\u5176\u8a3a\u65b7\u70ba\u4f55?\nA. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\nB. \u80ba\u52d5\u8108\u9ad8\u58d3\u75c7\u6025\u6027\u60e1\u5316\nC. \u6025\u6027\u80ba\u6813\u585e(thromboembolism)\nD. \u5927\u6ce1\u6027(bullous)\u80ba\u6c23\u816b\nE. \u6dcb\u5df4\u7624(lymphoma)\u58d3\u8feb\u6c23\u9053\n": "(C)", "102-15.\n\u4e0b\u5217\u7b56\u7565\u53ef\u4ee5\u907f\u514d\u6a5f\u68b0\u901a\u6c23\u547c\u5438\u6216\u4f7f\u5176\u4f7f\u7528\u6642\u9593\u6e1b\u5c11,\u4f55\u8005\u9664\u5916?\nA. \u5c0d\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\u8005,\u53ef\u5148\u63a1\u7528\u975e\u4fb5\u8972\u6027\u901a\u6c23(noninvasive ventilation)\nB. \u5c0d\u67d0\u4e9b\u6025\u6027\u5fc3\u56e0\u6027\u80ba\u6c34\u816b\u8005,\u53ef\u5148\u63a1\u7528\u975e\u4fb5\u8972\u6027\u901a\u6c23\nC. \u5c0d\u6210\u4eba\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(ARDS)\u8005,\u5b9c\u63a1\u7528\u4f4e\u6f6e\u6c23\u5bb9\u7a4d(tidal volume)\nD. \u5c0d\u6025\u6027\u80ba\u640d\u50b7\u8005,\u4f7f\u7528\u6db2\u9ad4\u8f38\u6ce8\u61c9\u8a72\u4fdd\u5b88\nE. \u5728\u5617\u8a66\u81ea\u4e3b\u547c\u5438\u524d,\u5b9c\u7e7c\u7e8c\u4f7f\u7528\u93ae\u975c\u5291(sedative)\u8f38\u6ce8\n": "(E)", "102-16.\n\u4ee5\u4f4e\u5291\u91cf\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf(LDCT)\u7be9\u6aa2\u80ba\u764c,\u4f9d\u76ee\u524d\u6240\u5f97\u8cc7\u8a0a,\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u78ba\u53ef\u63d0\u9ad8\u65e9\u671f\u80ba\u764c\u4e4b\u8a3a\u65b7\u7387\nB. \u5c0d\u9ad8\u5371\u96aa\u7fa4\u8005, \u53ef\u6e1b\u5c11\u80ba\u764c\u6b7b\u4ea1\u7387\nC. \u662f\u5426\u53ef\u666e\u904d\u65bd\u884c\u65bc\u4f4e\u5371\u96aa\u6027\u65cf\u7fa4,\u5c1a\u7121\u5b9a\u8ad6\nD. \u6700\u5927\u7684\u7f3a\u9ede\u548c\u5371\u96aa\u662f\u8cbb\u7528\u592a\u8cb4\u548c\u8f3b\u5c04\nE. \u9ad8\u507d\u967d\u6027\u662f\u76ee\u524d\u6700\u5927\u7684\u56f0\u64fe\u548c\u5371\u96aa\n": "(D)", "102-17.\n\u7537\u602773\u6b72,\u6709\u5438\u83f8\u53ca\u9ad8\u8840\u58d3\u53f2,\u56e0\u80f8\u75db\u524d\u4f86,\u80f8\u90e8X\u5149\u5982\u5716\u793a,\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4f55?\nA. \u5c0f\u7d30\u80de\u80ba\u764c\nB. \u6dcb\u5df4\u7624\nC. \u80f8\u817a\u7624\nD. \u98df\u9053\u816b\u7624\nE. \u4e3b\u52d5\u8108\u7624\n": "(E)", "102-18.\n\u5973\u6027,31\u6b72,\u4e3b\u8a34\u54b3\u55fd\u4e8c\u500b\u6708,\u80f8\u90e8X\u5149\u5982\u5716\u6240\u793a,\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4f55?\nA. \u80ba\u7d50\u6838\nB. \u96b1\u7403\u83cc(Cryptococcus)\u611f\u67d3\nC. \u9ef4\u6f3f\u83cc(Mycoplasma)\u611f\u67d3\nD. \u80ba\u708e\u7403\u83cc(S. pneumoniae)\u611f\u67d3\nE. \u80ba\u817a\u764c\n": "(A)", "102-19.\n\u7537\u6027,35\u6b72,\u9577\u671f\u54b3\u55fd\u591a\u75f0,\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716\u793a,\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55?\nA. \u6162\u6027\u652f\u6c23\u7ba1\u708e\nB. \u652f\u6c23\u7ba1\u64f4\u5f35\u75c7\nC. \u80ba\u56ca\u866b(Pneumocystis jirovecii)\u611f\u67d3\nD. \u96b1\u7403\u83cc(Cryptococcus)\u611f\u67d3\nE. \u8f49\u79fb\u764c\n": "(B)", "102-20.\n\u7537\u6027,30\u6b72,\u4e2d\u5ea6\u80a5\u80d6,\u7121\u5438\u83f8\u53f2,\u4e5f\u7121\u547c\u5438\u7cfb\u7d71\u75be\u75c5,\u4e0b\u5217\u80ba\u529f\u80fd\u6578\u503c,\u90a3\u4e9b\u8f03\u7b26\u5408\u5176\u8eab\u6750?  (\u6578\u503c\u662f\u4ee5\u9810\u4f30\u503c\u4e4b%\u8868\u793a)\r(1)FEV1 65% (2) TLC 95% (3)RV 100% (4)DLco 70% (5)Raw 120%\nA. (1)+(2)\nB. (1)+(3)\nC. (2)+(3)\nD. (3)+(4)\nE. (4)+(5)\n": "(C)", "102-21.\n\u4e0b\u5217\u6240\u8ff0,\u90a3\u4e9b\u53ef\u80fd\u8207\u670d\u7528\u6297\u7d50\u6838\u85e5pyrazinamide (PZA)\u6709\u95dc?\r(1)\u8840\u4e2d\u5c3f\u9178\u589e\u52a0 (2)\u8840\u4e2daminotransferase\u589e\u9ad8 (3)\u8840\u4e2d\u5c3f\u7d20\u6c2e(BUN)\u589e\u52a0 (4)\u8840\u4e2dpyridoxine\u529b\u50f9\u6e1b\u5f31 (5)\u8840\u4e2d\u8449\u9ec3\u7d20(lutein)\u529b\u50f9\u4e0b\u964d\nA. (1)+(2)\nB. (1)+(4)\nC. (2)+(3)\nD. (2)+(5)\nE. (3)+(5)\n": "(A)", "102-22.\n\u7576\u52d5\u8108\u8840\u6c27\u5206\u58d3(PaO2)\u964d\u4f4e\u6642, \u5982\u679c\u4f5c\u904e\u5ea6\u63db\u6c23(hyperventilation), \u4f7f\u8840\u4e2d\u4e8c\u6c27\u5316\u78b3\u5206\u58d3(PaCO2)\u4e5f\u4e0b\u964d, \u6b64\u6642\u8166\u8840\u7ba1\u6703\u6709\u4f55\u8b8a\u5316?\r(1)\u963b\u529b\u589e\u52a0 (2)\u963b\u529b\u964d\u4f4e (3)\u8840\u6d41\u589e\u52a0 (4)\u8840\u6d41\u6e1b\u5c11 (5)\u8840\u6d41\u4e0d\u8b8a (6)\u963b\u529b\u4e0d\u8b8a\nA. (1)+(3)\nB. (1)+(4)\nC. (2)+(5)\nD. (3)+(6)\nE. (4)+(6)\n": "(B)", "103-1.\n\u4e0b\u5217\u95dc\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome,ARDS)\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. severe ARDS\u5176PaO2/FiO2<100mmHg\nB. \u56e0\u5916\u50b7\u800c\u9020\u6210\u7684ARDS\u9810\u5f8c\u6700\u597d\nC. \u4fef\u81e5(prone position)\u53ef\u6e1b\u5c1190\u5929\u6b7b\u4ea1\u7387\nD. \u80ba\u52d5\u8108\u5c0e\u7ba1\u5728\u8a3a\u65b7\u4e0a\u5f88\u91cd\u8981\nE. \u4f7f\u7528PEEP\u53ef\u6539\u5584shunt-associated hypoxemia\n": "(D)", "103-2.\n\u4e0b\u5217\u4f55\u8005\u6bd4\u8f03\u4e0d\u9069\u5408\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668(noninvasive positive pressure ventilation)?\nA. \u4e2d\u6216\u91cd\u5ea6COPD\u6025\u6027\u60e1\u5316\nB. \u5fc3\u56e0\u6027\u80ba\u6c34\u816b(cardiogenic pulmonary edema)\nC. \u6557\u8840\u6027\u4f11\u514b\nD. \u514d\u75ab\u4e0d\u5168\u75c5\u4eba\u4f75\u767c\u547c\u5438\u8870\u7aed\nE. \u8179\u90e8\u624b\u8853\u5f8c\u4f75\u767c\u7f3a\u6c27\u6027\u547c\u5438\u8870\u7aed\n": "(C)", "103-3.\n\u4e0b\u5217\u95dc\u65bc\u7d50\u6838\u6027\u808b\u819c\u708e\u9020\u6210\u7684\u808b\u819c\u7a4d\u6c34\u751f\u5316\u53ca\u93e1\u6aa2\u4e4b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. lymphocyte predominant exudate\nB. adenosine deaminase>40 IU/L\nC. Interferon gamma (INF-r) >140 pg/ml\nD. mesothelial cell\u7684\u6bd4\u7387\u9ad8\nE. smear \u7684acid fast stain \u967d\u6027\u7387 <5%\n": "(D)", "103-4.\n\u6709\u95dcparapneumonic effusion\u4e4b\u751f\u5316\u53ca\u93e1\u6aa2\u9700\u8981\u9032\u4e00\u6b65\u8003\u616e\u80f8\u7ba1\u5f15\u6d41\u7684\u72c0\u6cc1\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. glucose <60mg/dl.\nB. PH<7.3\nC. positive Gram stain\nD. positive culture\nE. presence of gross pus.\n": "(B)", "103-5.\n\u5728\u4e00\u4f4d\u5065\u5eb7\u7684\u5e74\u8f15\u4eba,\u611f\u67d3\u6d41\u611f\u75c5\u6bd2\u5f8c\u4f75\u767c\u6025\u6027\u80ba\u81bf\u760d\u6700\u53ef\u80fd\u7684\u75c5\u539f\u83cc\u70ba?\nA. Legionella pneumophila\nB. Pseudomonas aeruginosa\nC. M. tuberculosis\nD. Aspergillus spp.\nE. Staphylococcus aureus\n": "(E)", "103-6.\n\u4e0b\u5217\u95dc\u65bcCOPD\u75c5\u751f\u7406\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4? (\u61c9\u9078\u51fa\u6240\u6709\u7b54\u6848) (1)\u589e\u52a0residual volume \u548c\u589e\u52a0residual volume/total lung capacity\u4ee3\u8868air  trapping. (2)\u589e\u52a0total lung capacity\u4ee3\u8868hyperinflation of thorax. (3)\u4e00\u79d2\u91cf(FEV1)\u5c0f\u65bc50%\u9810\u6e2c\u503c\u6642PaCO2\u624d\u6703\u4e0a\u5347 (4)PaO2\u4e0b\u964d\u7684\u4e3b\u56e0\u662fshunting (5)nonuniform ventilation \u4e5f\u662fCOPD\u6c23\u9ad4\u4ea4\u63db\u969c\u7919\u7684\u539f\u56e0\u4e4b\u4e00\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (3)+(4)\nE. (3)+(4)+(5)\n": "(D)", "103-7.\n\u4e0b\u5217\u95dc\u65bcCOPD\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u6c23\u9053\u7684\u904e\u5ea6\u53cd\u61c9\u6027(airway hyperresponsiveness)\u4e0d\u61c9\u8a72\u662fCOPD\u6240\u5177\u6709\u7684\u7279\u5fb5\nB. \u5438\u83f8\u662fCOPD\u7684\u5371\u96aa\u56e0\u5b50\nC. \u71c3\u71d2\u751f\u8cea\u71c3\u6599(biomass combustion)\u662f\u4e0d\u62bd\u83f8\u5973\u6027\u7f79\u60a3COPD\u7684\u5371\u96aa\u56e0\u5b50\nD. \u03b11 antitrypsin \u7f3a\u4e4f\u75c7\u662fCOPD\u7684\u5371\u96aa\u56e0\u5b50.\nE. \u662f\u4e00\u7a2e\u6162\u6027\u6c23\u9053\u767c\u708e\n": "(A)", "103-8.\n\u4e0b\u5217\u95dc\u65bc\u5167\u56e0\u6027\u6c23\u5598(intrinsic asthma)\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?  (\u61c9\u9078\u51fa\u6240\u6709\u7b54\u6848)  (1)\u5167\u56e0\u6027\u6c23\u5598\u7d04\u4f5410%\u7684\u6c23\u5598\u75c5\u4eba (2)\u5167\u56e0\u6027\u6c23\u5598\u5e38\u5408\u4f75\u9f3b\u606f\u8089\u4e14\u5c0d\u963f\u65af\u5339\u6797\u654f\u611f (3)\u8207atopy\u76f8\u95dc\u7684\u57fa\u56e0\u57286q (4)\u5167\u56e0\u6027\u6c23\u5598\u8207IgE\u76f8\u95dc\u7684\u514d\u75ab\u6a5f\u8f49\u8f03\u7121\u95dc (5)\u6c23\u5598\u662f\u591a\u57fa\u56e0\u63a7\u5236\u7684\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(3)\nD. (3)+(4)\nE. (3)+(4)+(5)\n": "(D)", "103-9.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u5c0e\u81f4\u6c23\u5598(asthma)\u6b7b\u4ea1\u7684\u4e3b\u8981\u5371\u96aa\u56e0\u5b50?\nA. \u6210\u4eba\u6642\u671f\u624d\u767c\u751f\u7684\u6c23\u5598\nB. \u63a7\u5236\u4e0d\u4f73\u6c23\u5598\u800c\u9700\u7d93\u5e38\u4f7f\u7528\u5438\u5165\u578b\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u7684\u75c5\u4eba\nC. \u672a\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187(inhaled corticosteroids)\u7684\u75c5\u4eba\nD. \u4e4b\u524d\u56e0\u7015\u6b7b\u578b\u6c23\u5598(near-fatal asthma)\u800c\u4f4f\u9662\u7684\u75c5\u4eba\nE. \u4ee5\u4e0a\u7686\u975e\n": "(A)", "103-10.\n\u4e0b\u5217\u95dc\u65bc\u80ba\u81bf\u760d(lung abscess)\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. nonspecific lung abscess\u8207aspiration \u6709\u95dc\nB. \u96fb\u8166\u65b7\u5c64\u82e5\u5408\u4f75\u51fa\u73fe\u6dcb\u5df4\u817a\u816b\u5927(lymphadenopathy),\u61c9\u8003\u616e\u5176\u4ed6\u8a3a\u65b7.\nC. \u75f0\u6db2\u57f9\u990a\u7684\u7d50\u679c,\u5e38\u53ef\u4ee3\u8868\u611f\u67d3\u7684\u75c5\u539f\u83cc\nD. \u70ba\u4e86\u78ba\u7acb\u7d30\u83cc\u5b78\u8a3a\u65b7,\u96fb\u8166\u65b7\u5c64\u6307\u5f15\u7d93\u80f8\u7a7f\u523a\u5438\u5f15\u8853,\u5df2\u6f38\u53d7\u91cd\u8996\nE. \u6709\u81ed\u5473\u7684\u75f0\u6db2\u4ee3\u8868\u53ef\u80fd\u6709\u53ad\u6c27\u83cc\u611f\u67d3\n": "(C)", "103-11.\n\u4ee5\u4e0b\u95dc\u65bc\u54b3\u55fd\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8ca0\u8cac\u54b3\u55fd\u7684\u611f\u89ba\u795e\u7d93\u662fC-fiber\nB. \u6025\u6027\u548c\u6162\u6027\u54b3\u55fd\u5b9a\u7fa9\u7684\u6642\u9593\u754c\u9650\u4e00\u822c\u5b9a\u70ba\u516b\u9031\nC. \u80c3\u98df\u9053\u9006\u6d41\u662f\u6162\u6027\u54b3\u55fd\u5e38\u898b\u7684\u539f\u56e0\u4e4b\u4e00\nD. \u9223\u96e2\u5b50\u963b\u65b7\u5291\u964d\u8840\u58d3\u85e5\u7269\u662f\u6162\u6027\u54b3\u55fd\u5e38\u898b\u7684\u539f\u56e0\u4e4b\u4e00\nE. methacholine\u8a98\u767c\u8a66\u9a57\u53ef\u7528\u4f86\u6392\u9664\u652f\u6c23\u7ba1\u6c23\u5598\u6240\u9020\u6210\u6162\u6027\u54b3\u55fd\u7684\u539f\u56e0\n": "(D)", "103-12.\n\u4ee5\u4e0b\u95dc\u65bc\u80ba\u89e3\u5256\u751f\u7406\u7684\u63cf\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u4eba\u985e\u547c\u5438\u9053\u5927\u7d04\u670940\u7a2e\u6b63\u5e38\u7d30\u80de\nB. \u5f9e\u6c23\u7ba1\u958b\u59cb\u7d04\u524d14\u500b\u5206\u652f\u7684\u547c\u5438\u9053\u4e0d\u5177\u6c23\u9ad4\u4ea4\u63db\u529f\u80fd\nC. \u80ba\u5c16\u7684\u901a\u6c23\u91cf(ventilation)\u6bd4\u80ba\u5e95\u5927\nD. \u8ca7\u8840\u6703\u964d\u4f4e\u80ba\u5f4c\u6563\u91cf(diffusion capacity)\nE. \u80ba\u6c23\u816b(emphysema)\u75c5\u60a3\u7684\u529f\u80fd\u80ba\u9918\u91cf(functional residual capacity)\u6703\u504f\u9ad8\n": "(C)", "103-13.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u963b\u585e\u6027\u547c\u5438\u7761\u7720\u4e2d\u6b62\u75c7\u75c5\u60a3\u5e38\u898b\u7684\u81e8\u5e8a\u8868\u5fb5\nA. \u9ad4\u91cd\u904e\u91cd\nB. \u4e0b\u5df4\u8f03\u5c0f\u6216\u5f8c\u7e2e\nC. \u6241\u6843\u817a\u6216\u61f8\u96cd\u5782\u904e\u5927\nD. \u6253\u9f3e\nE. \u7121\u6027\u5225\u5dee\u7570\n": "(E)", "103-14.\n78\u6b72\u7537\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u53ca\u5fc3\u81df\u75c5\u75c5\u53f2\uff0c\u9577\u671f\u4f7f\u7528\u9223\u96e2\u5b50\u963b\u65b7\u5291\u53ca\u5229\u5c3f\u5291\u3002\u6b64\u6b21\u56e0\u9019\u4e00\u9031\u547c\u5438\u8d8a\u4f86\u8d8a\u56f0\u96e3\u800c\u81f3\u80f8\u8154\u79d1\u9580\u8a3a\u6c42\u91ab\u3002\u80f8\u90e8X\u5149\u6aa2\u67e5\u767c\u73fe\u96d9\u5074\u808b\u819c\u7a4d\u6c34\uff0c\u4f46\u53f3\u5074\u8f03\u660e\u986f\u3002\u4ee5\u7d30\u91dd\u62bd\u5438\u5f8c\u6aa2\u9a57\u767c\u73fe\u53f3\u5074\u808b\u819c\u7a4d\u6db2\u7684total protein\u70ba2.8 g/dL\uff0cLDH\u70ba112 U/L\uff0c\u540c\u6642\u75c5\u60a3\u8840\u6db2\u4e2d\u7684total protein\u70ba6.2 g/dL(\u6b63\u5e38\u7bc4\u570d\u70ba6.4 - 8.4 g/dL)\uff0cLDH\u70ba150 U/L(\u6b63\u5e38\u7bc4\u570d\u70ba131 - 250 U/L)\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u95dc\u65bc\u4f7f\u7528Light's criteria\u7684\u5224\u65b7\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u56e0\u70ba\u7b26\u5408\u4e09\u500bcriteria\u4e2d\u7684\u4e00\u500b\uff0c\u6240\u4ee5\u662fexudate\nB. \u56e0\u70ba\u7b26\u5408\u56db\u500bcriteria\u4e2d\u7684\u5169\u500b\uff0c\u6240\u4ee5\u662fexudate\nC. \u56e0\u70ba\u7b26\u5408\u4e09\u500bcriteria\u4e2d\u7684\u4e00\u500b\uff0c\u6240\u4ee5\u662ftransudate\nD. \u56e0\u70ba\u7b26\u5408\u56db\u500bcriteria\u4e2d\u7684\u5169\u500b\uff0c\u6240\u4ee5\u662ftransudate\nE. \u56e0\u70ba\u8840\u6db2\u8207\u808b\u819c\u7a4d\u6db2\u7684total protein\u5dee\u503c\u5927\u65bc3.1 g/dL\uff0c\u6240\u4ee5\u662ftransudate\n": "(A)", "103-15.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u80ba\u6813\u585e\u5e38\u898b\u7684\u5371\u96aa\u56e0\u5b50?\nA. \u9157\u9152\nB. \u62bd\u83f8\nC. \u5973\u6027\u8cc0\u723e\u8499\u88dc\u5145\u6cbb\u7642\nD. \u764c\u75c7\nE. \u9577\u9014\u98db\u884c\n": "(A)", "103-16.\n\u8acb\u554f\u4e0b\u5217\u95dc\u65bc\u5438\u5165\u6027\u985e\u56fa\u9187\u5728\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6cbb\u7642\u7684\u89d2\u8272\uff0c\u4f55\u8005\u722d\u8b70\u6700\u5c0f?\nA. \u964d\u4f4e\u6b7b\u4ea1\u7387\nB. \u6e1b\u7de9\u80ba\u529f\u80fd\u4e0b\u964d\u7684\u901f\u7387\nC. \u6e1b\u5c11\u6bcf\u5e74\u6025\u6027\u60e1\u5316\u7684\u6b21\u6578\nD. \u589e\u52a0\u80ba\u708e\u7684\u6a5f\u7387\nE. \u6e1b\u5c11\u80ba\u764c\u767c\u751f\u7387\n": "(C)", "103-17.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u958b\u6d1e\u6027\u80ba\u90e8\u611f\u67d3\u7684\u5e38\u898b\u81f4\u75c5\u83cc?\nA. \u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc(Staphylococcus aureus)\nB. A\u578b\u93c8\u7403\u83cc(Group A Streptococcus)\nC. \u514b\u96f7\u767d\u6c0f\u80ba\u708e\u83cc(Klebsiella pneumoniae)\nD. \u55dc\u80ba\u6027\u9000\u4f0d\u8ecd\u4eba\u687f\u83cc(Legionella pneumophila)\nE. \u80ba\u708e\u9ef4\u6f3f\u83cc(Mycoplasma pneumoniae)\n": "(E)", "103-18.\n67\u6b72\u7537\u6027\uff0c\u904e\u53bb\u7121\u62bd\u83f8\u53f2\uff0c\u6b64\u6b21\u56e0\u767c\u71d2\u6578\u65e5\u81f3\u9580\u8a3a\u5c31\u91ab\uff0c\u80f8\u90e8X\u5149\u986f\u793a\u53f3\u4e0a\u80ba\u5be6\u8cea\u5316\u9670\u5f71\uff0c\u6295\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u5f8c\u7121\u660e\u986f\u8b8a\u5316\uff0c\u6545\u5b89\u6392\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5(\u5982\u5716)\uff0c\u7d93\u652f\u6c23\u7ba1\u93e1\u5207\u7247\u75c5\u7406\u767c\u73fe\u70ba\u80ba\u817a\u764c\u3002\u5f8c\u4f86\u5b89\u6392\u5168\u8eab\u6b63\u5b50\u6383\u63cf\u4ee5\u53ca\u8166\u90e8\u6838\u78c1\u5171\u632f\uff0c\u767c\u73fe\u53f3\u4e0a\u80ba\u816b\u7624\u7684SUVmax\u70ba4.5\uff0c\u53f3\u4e0b\u6c23\u7ba1\u65c1\u6dcb\u5df4\u7d50\u7684SUVmax\u70ba2.7\uff0c\u6b64\u5916\u7121\u5176\u4ed6\u75c5\u7076\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u7684\u8655\u7f6e\u70ba\u4f55\uff1f\nA. \u6aa2\u9a57EGFR\u57fa\u56e0\u662f\u5426\u6709\u7a81\u8b8a\nB. \u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u5207\u7247\u75c5\u7406\u6aa2\u67e5\nC. \u624b\u8853\u5207\u9664\nD. \u5316\u5b78\u6cbb\u7642\nE. \u540c\u6b65\u6027\u5316\u5b78\u53ca\u653e\u5c04\u7dda\u6cbb\u7642\n": "(B)", "103-19.\n78\u6b72\u7537\u6027\uff0c\u670925\u5e74\u7684\u62bd\u83f8\u53f2\uff0c\u4f46\u81ea\u5f9e55\u6b72\u5c31\u6212\u83f8\u4e86\uff0c\u6b64\u6b21\u56e0\u8fd1\u4e09\u500b\u6708\u4f86\u51fa\u73fe\u4e7e\u54b3\u53ca\u547c\u5438\u56f0\u96e3\u4e14\u65e5\u6f38\u56b4\u91cd\uff0c\u6545\u81f3\u9580\u8a3a\u5c31\u91ab\u3002\u75c5\u60a3\u904e\u53bb\u6709\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c\u6700\u5f8c\u4e00\u6b21\u767c\u751frapid ventricular response\u662f\u56db\u500b\u6708\u524d\uff0c\u75c5\u60a3\u9577\u671f\u4f7f\u7528\u7684\u85e5\u7269\u5305\u62ecmetoprolol\u548cwarfarin\uff0c\u4ee5\u53ca\u81ea\u56db\u500b\u6708\u524d\u958b\u59cb\u52a0\u4e0a\u7684amiodarone\u3002\u75c5\u60a3\u7684\u80f8\u90e8X\u5149\u6aa2\u67e5\u7121\u767c\u73fe\u660e\u986f\u7570\u5e38\uff0c\u7406\u5b78\u6aa2\u67e5\u9664\u80ba\u5e95\u90e8\u807d\u5230\u4e00\u4e9bcrackles\u4ee5\u5916\u4ea6\u7121\u660e\u986f\u7570\u5e38\u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b: FEV1= 72%\uff0cFEV1/FVC= 78%\uff0cVC= 72%\uff0cTLC= 65%\uff0cDLCO=50%\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u7684\u6aa2\u67e5\u70ba\u4f55\uff1f\nA. \u9ad8\u89e3\u6790\u5ea6\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nB. \u652f\u6c23\u7ba1\u93e1\u6aa2\u67e5\nC. \u75f0\u6db2\u7d30\u80de\u5b78\u6aa2\u67e5\nD. \u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\nE. \u6838\u91ab\u80ba\u81df\u704c\u6ce8(perfusion)\u8207\u901a\u6c23(ventilation)\u6383\u63cf\n": "(A)", "103-20.\n\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u80ba\u764c\u7684\u9ad8\u5371\u96aa\u7fa4 (1)\u62bd\u83f8 (2)\u4e8c\u624b\u83f8 (3)\u7cd6\u5c3f\u75c5 (4)\u9ad8\u8840\u58d3 (5)\u7d50\u6838\u75c5\u53f2 (6)\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(7)\u505c\u7d93 (8)\u80ba\u764c\u5bb6\u65cf\u53f2 (9)\u77f3\u7dbf\u88fd\u9020\u5de5\u4eba\nA. (1)+(2)+(5)+(6)+(7)+(8)\nB. (1)+(2)+(5)+(6)+(8)+(9)\nC. (1)+(2)+(3)+(6)+(8)+(9)\nD. (1)+(2)+(6)+(7)+(8)+(9)\nE. (1)+(2)+(4)+(5)+(6)+(8)\n": "(B)", "103-21.\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u60c5\u6cc1\u53ef\u80fd\u5c0e\u81f4\u808b\u819c\u7a4d\u6db2\u4e2d\u7684\u55dc\u4f0a\u7d05\u6027\u767d\u8840\u7403\u6bd4\u4f8b\u589e\u52a0 (1)\u6c23\u80f8 (2)\u4e73\u7cdc\u80f8 (3)\u809d\u6027\u808b\u819c\u7a4d\u6c34 (4)\u85e5\u7269 (5)\u7d50\u6838\u6027\u808b\u819c\u708e (6)\u5fc3\u81df\u624b\u8853\u5f8c (7)\u6dcb\u5df4\u764c (8)\u80ba\u764c (9)\u77f3\u7dbf\u808b\u819c\u708e\nA. (1)+(2)+(4)+(6)+(8)\nB. (3)+(5)+(6)+(7)+(9)\nC. (2)+(3)+(4)+(5)+(9)\nD. (2)+(4)+(5)+(7)+(9)\nE. (1)+(4)+(6)+(7)+(9)\n": "(E)", "103-22.\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u60c5\u6cc1\u5c0e\u81f4\u547c\u5438\u56f0\u96e3\u7684\u6a5f\u8f49\u5305\u62ec\u547c\u5438\u529f(work of breath)\u589e\u52a0 (1)\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (2)\u6c23\u5598 (3)\u9593\u8cea\u6027\u80ba\u75c5 (4)\u80ba\u52d5\u8108\u9ad8\u58d3 (5)\u5fc3\u56e0\u6027\u80ba\u6c34\u816b (6)\u975e\u5fc3\u56e0\u6027\u80ba\u6c34\u816b (7)\u8ca7\u8840 (8)\u5931\u7528(deconditioning)\nA. (3)+(4)+(5)+(6)+(8)\nB. (1)+(2)+(4)+(6)+(8)\nC. (3)+(4)+(6)+(7)+(8)\nD. (1)+(2)+(3)+(5)+(6)\nE. (1)+(2)+(4)+(6)+(7)\n": "(D)", "104-1.\n\u95dc\u65bc\u80ba\u90e8\u807d\u8a3a\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u6b63\u78ba?\r\n(1)\u54ee\u9cf4\u97f3(wheezes)\u4ee3\u8868\u6c23\u9053\u963b\u585e\r\n(2)\u56c9\u97f3(crackles)\u4ee3\u8868\u80ba\u6ce1\u75be\u75c5\r\n(3)\u80ba\u9593\u8cea\u7e96\u7dad\u5316(interstitial fibrosis)\u6703\u51fa\u73feegophony\r\n(4)\u80ba\u5be6\u8cea\u5316(consolidation)\u4e0d\u6703\u51fa\u73fewhispered pectoriloquy\r\n(5)\u80ba\u6c23\u816b(emphysema)\u53ef\u51fa\u73fe\u547c\u5438\u97f3\u964d\u4f4e\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (4)+(5)\nE. (3)+(4)+(5)\n": "(C)", "104-2.\n\u95dc\u65bc\u6c23\u5598\u968e\u68af\u5f0f\u6cbb\u7642(stepwise therapy)\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u6b63\u78ba?\r\n(1)\u6bcf\u5468\u4f7f\u7528\u7de9\u89e3\u85e5\u7269(reliever medication)\u5927\u65bc\u5169\u6b21\u4ee5\u4e0a, \u5c31\u9700\u898f\u5f8b\u4f7f\u7528\u63a7\u5236\u85e5\u7269(controller medication)\r\n(2)\u63a7\u5236\u85e5\u7269\u7684\u9996\u9078\u70ba\u5438\u5165\u578b\u985e\u56fa\u9187(inhaled corticosteroids)\r\n(3)\u7b2c\u4e00\u968e\u75c5\u4eba\u50c5\u4f7f\u7528\u5438\u5165\u578b\u77ed\u6548\u4e4b\u4e59\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5c31\u53ef\u4ee5\r\n(4)\u5438\u5165\u578b\u985e\u56fa\u9187\u7684\u8d77\u59cb\u5291\u91cf\u70ba\u4e2d\u5291\u91cf(\u76f8\u7576200 \u03bcg BID/day beclomethasone dipropionate )\r\n(5)\u4f7f\u7528\u63a7\u5236\u85e5\u7269\u5f8c\u5169\u500b\u6708\u5c31\u53ef\u8a55\u4f30\u6cbb\u7642\u6548\u679c\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (4)+(5)\nE. (3)+(4)+(5)\n": "(B)", "104-3.\n\u95dc\u65bc\u7279\u6b8a\u56e0\u5b50\u548c\u793e\u5340\u6027\u80ba\u708e\u53ef\u80fd\u75c5\u539f\u83cc\u7684\u7d44\u5408,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. Bronchiectasis--P.aeruginosa\nB. \u80ba\u81bf\u760d--oral anaerobes\nC. \u6d41\u611f(influenza)--Klebsiella pneumoniae\nD. COPD--Haemophilus influenzae\nE. \u9ce5\u985e\u63a5\u89f8--Chlamydia psittaci\n": "(C)", "104-4.\n\u95dc\u65bc\u547c\u5438\u5668\u76f8\u95dc\u80ba\u708e(ventilator-associated pneumonia)\u75c5\u7406\u6a5f\u8f49\u548c\u76f8\u95dc\u9810\u9632\u7b56\u7565\u7684\u7d44\u5408,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u6b63\u5e38\u83cc\u7684\u6e1b\u5c11(elimination of normal flora)--\u907f\u514d\u6297\u751f\u7d20\u4f7f\u7528\u6642\u9593\u904e\u9577\nB. \u4e0b\u547c\u5438\u9053\u62b5\u6297\u529b\u6539\u8b8a(altered lower respiratory  host defense)--\u964d\u4f4e\u8f38\u8840\u6642\u8840\u7d05\u7d20\u7684\u95be\u503c(hemoglobin transfusion threshold)\nC. \u6c23\u7ba1\u5167\u7ba1\u5468\u570d\u7269\u8cea\u7684\u5438\u5165(microaspiration around endotracheal tube)--\u52a0\u5f37\u93ae\u975c\nD. \u547c\u5438\u5668\u4f7f\u7528\u6642\u9593\u904e\u9577--\u547c\u5438\u5668\u812b\u96e2\u6d41\u7a0b(weaning protocols)\nE. \u80c3\u98df\u9053\u9006\u6d41--prokinetic agents\n": "(C)", "104-5.\n\u95dc\u65bc\u9020\u6210\u808b\u819c\u7a4d\u6db2(pleural effusion)\u7684\u539f\u56e0,\u4e0b\u5217\u4f55\u8005\u662f\u6f0f\u51fa\u6db2(transudate)?\nA. Meig's syndrome\nB. ovarian hyperstimulation syndrome\nC. myxedema\nD. uremia\nE. rheumatoid pleuritis\n": "(C)", "104-6.\n\u4e0b\u5217\u72c0\u6cc1\u6700\u9069\u5408\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668(noninvasive ventilation)\u8005\u70ba?\nA. \u5fc3\u8df3\u505c\u6b62\nB. \u56b4\u91cd\u8178\u80c3\u9053\u51fa\u8840\nC. \u4e0d\u7a69\u5b9a\u5fc3\u7d5e\u75db\nD. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\nE. \u4e0a\u547c\u5438\u9053\u963b\u585e\n": "(D)", "104-7.\n\u95dc\u65bc\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7(obstructive sleep apnea)\u7684\u6558\u8ff0\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u53ef\u589e\u52a0\u5fc3\u808c\u6897\u585e\u7684\u5371\u96aa\nB. \u53ef\u5f15\u8d77\u809d\u529f\u80fd\u7570\u5e38\nC. \u53ef\u9020\u6210\u80f0\u5cf6\u7d20\u6297\u6027(insulin resistance)\nD. \u6cbb\u7642\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u53ef\u6539\u5584\u4e2d\u98a8\u75c5\u4eba\u7684\u9810\u5f8c\nE. \u6703\u589e\u52a0\u9ebb\u9189\u98a8\u96aa\n": "(D)", "104-8.\n\u5be6\u884c\u8eab\u9ad4\u6aa2\u67e5\u6642,\u65bc\u80ba\u90e8\u807d\u8a3a,\u767c\u73fe\u547c\u5438\u97f3\u6e1b\u5c11,\u6263\u8a3a\u6642\u70badullness\u8005,\u6700\u53ef\u80fd\u70ba\u4e0b\u5217\u4f55\u8005?\nA. \u6c23\u80f8(pneumothorax)\nB. \u808b\u819c\u7a4d\u6db2(pleural effusion)\nC. \u5927\u8449\u6027\u80ba\u708e(lobar pneumonia)\nD. \u80ba\u6c23\u816b(emphysema)\nE. \u7e31\u8188\u6c23\u816b(pneumomediastinum)\n": "(B)", "104-9.\n\u95dc\u65bc\u7d50\u6838\u6027\u808b\u819c\u708e(tuberculous pleuritis)\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u7d93\u5e38\u8207primary TB \u6709\u95dc\nB. \u70ba\u6dcb\u5df4\u7403\u70ba\u4e3b\u7684\u6ef2\u51fa\u6db2(exudate)\nC. \u5c0d\u7d50\u6838\u83cc\u86cb\u767d(tuberculous protein) \u7684\u4e00\u7a2e\u904e\u654f\u53cd\u61c9(hypersensitivity reaction)\nD. \u808b\u819c\u7a4d\u6db2\u70baadenosine deaminase >40 IU/L\u6216interferon- r<140pg/ml\nE. \u808b\u819c\u5207\u7247\u5c0d\u8a3a\u65b7\u6709\u5e6b\u52a9\n": "(D)", "104-10.\n\u95dc\u65bc\u80ba\u708e\u56b4\u91cd\u5ea6\u8a55\u4f30CURB-65\u7684\u9805\u76ee,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u5e74\u9f61\nB. \u610f\u8b58\u4e0d\u6e05\nC. BUN\nD. CRP(C-reactive protein)\nE. \u547c\u5438\u6b21\u6578\n": "(D)", "104-11.\n\u95dc\u65bc\u6c23\u5598\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u5438\u5165\u578b\u985e\u56fa\u9187\u662f\u6cbb\u7642\u7684\u4e3b\u8981\u85e5\u7269\nB. \u5408\u4f75\u6cbb\u7642(ICS+LABA,inhaled corticosteroid+long acting beta adrenergic agonist)\u5efa\u8b70\u65bcstep2 (\u542b)\u4ee5\u4e0a\u4e4b\u75c5\u4eba\u4f7f\u7528\nC. \u6297\u767d\u4e09\u70ef\u7d20(antileukotrienes)\u53ef\u4f5c\u70bacontroller \u85e5\u7269\nD. \u6025\u6027\u60e1\u5316\u6642\u53ef\u4f7f\u7528\u5168\u8eab\u6027\u985e\u56fa\u9187(systemic steroid)\nE. \u5c11\u90e8\u5206\u56b4\u91cd\u75c5\u4eba\u53ef\u4f7f\u7528anti-IgE\n": "(B)", "104-12.\n\u4e0b\u5217\u54ea\u4e00\u500b\u4e0d\u662f\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291\u7684\u4f5c\u7528\uff1f\nA. \u653e\u9b06\u547c\u5438\u9053\u7684\u5e73\u6ed1\u808c\nB. \u6e1b\u7de9\u54b3\u55fd\nC. \u6291\u5236\u6162\u6027\u767c\u708e\u53cd\u61c9\nD. \u589e\u52a0\u547c\u5438\u9053\u7e96\u6bdb\u904b\u52d5\nE. \u589e\u52a0\u547c\u5438\u9053\u9ecf\u6db2\u5206\u6ccc\n": "(C)", "104-13.\n\u4e0b\u5217\u95dc\u65bc\u904e\u654f\u6027\u80ba\u708e(hypersensitivity pneumonitis)\u81e8\u5e8a\u8868\u5fb5\u7684\u6558\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u6210\u56e0\u662f\u7576\u5177\u6709\u7279\u7570\u9ad4\u8cea\u7684\u4eba\uff0c\u5438\u5165\u904e\u654f\u6709\u6a5f\u6027\u7269\u8cea\u6642\u6240\u81f4\nB. \u53ef\u80fd\u51fa\u73fe\u767c\u51b7\u3001\u767c\u71b1\nC. \u5728\u63a5\u89f8\u904e\u654f\u539f\u5f8c\u7684\u4e00\u5230\u5169\u500b\u5c0f\u6642\u5167\u51fa\u73fe\u547c\u5438\u56f0\u96e3\u75c7\u72c0\nD. \u652f\u6c23\u7ba1\u80ba\u6ce1\u704c\u6d17\u6db2\u4e2d\u7684CD4\u8207CD8\u6dcb\u5df4\u7403\u7d30\u80de\u7684\u6bd4\u4f8b\u5e38\u5c0f\u65bc1\nE. \u652f\u6c23\u7ba1\u80ba\u6ce1\u704c\u6d17\u6db2\u4e2d\u80a5\u5927\u7d30\u80de\u7684\u91cf\u53ef\u80fd\u548c\u75be\u75c5\u56b4\u91cd\u5ea6\u6210\u6b63\u6bd4\n": "(C)", "104-14.\n\u4e0b\u5217\u4f55\u8005\u662f\u76ee\u524d\u570b\u969b\u9593\u505a\u55ae\u80ba\u80ba\u81df\u79fb\u690d\u6700\u5e38\u898b\u7684\u9069\u61c9\u75c7\uff1f\nA. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(COPD)\nB. \u56ca\u816b\u7e96\u7dad\u5316(cystic fibrosis)\nC. \u539f\u767c\u6027\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fibrosis)\nD. \u985e\u8089\u7624(sarcoidosis)\nE. \u539f\u767c\u6027\u80ba\u52d5\u8108\u9ad8\u58d3(idiopathic pulmonary hypertension)\n": "(A or C)", "104-15.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u963b\u585e\u6027\u547c\u5438\u7761\u7720\u4e2d\u6b62\u75c7\u6709\u95dc\u7684\u8a98\u767c\u56e0\u5b50\uff1f\nA. \u80a5\u80d6\nB. \u7537\u6027\nC. \u4e0b\u5df4\u8f03\u5c0f\nD. \u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\nE. \u9f3b\u606f\u8089\n": "(E)", "104-16.\n\u4e0b\u5217\u6709\u95dc\u539f\u767c\u81ea\u767c\u6027\u6c23\u80f8(primary spontaneous pneumothorax)\u7684\u63cf\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u75c5\u60a3\u7121\u904e\u53bb\u80ba\u90e8\u75be\u75c5\nB. \u5e38\u662f\u80ba\u5c16\u7684bleb\u7834\u88c2\u6240\u81f4\nC. \u521d\u6b21\u767c\u751f\u5f8c\uff0c\u7d04\u670910%\u7684\u6a5f\u6703\u518d\u5fa9\u767c\nD. \u521d\u6b21\u767c\u751f\u7684\u4e00\u822c\u6cbb\u7642\u539f\u5247\u662fsimple aspiration\nE. \u75c5\u60a3\u5e38\u6709\u5438\u83f8\u53f2\n": "(C)", "104-17.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u5f8c\u7e31\u9694\u8154\u816b\u7624\u5e38\u898b\u7684\u539f\u56e0\uff1f\nA. neurogenic tumor\nB. meningocele\nC. gastroenteric cyst\nD. bronchogenic cyst\nE. esophageal diverticulum\n": "(D)", "104-18.\n\u4e0b\u5217\u95dc\u65bc\u539f\u767c\u6027\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fibrosis)\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5178\u578b\u7684\u75c5\u7406\u8b8a\u5316\u662fusual interstitial pneumonia\nB. \u5178\u578b\u7684\u9ad8\u89e3\u6790\u5ea6\u96fb\u8166\u65b7\u5c64\u8b8a\u5316\u662f\u9031\u908a\u4e0b\u80ba\u91ce\u7684\u8702\u7aa9\u72c0\u7dda\u689d\u5f71\u50cf\nC. \u5178\u578b\u7684\u80ba\u529f\u80fd\u8b8a\u5316\u662f\u4fb7\u9650\u578b\u6c23\u9ad4\u4ea4\u63db\u969c\u7919\nD. \u5438\u5165\u6027\u985e\u56fa\u9187\u662f\u85e5\u7269\u6cbb\u7642\u7684\u9996\u9078\nE. \u662f\u80ba\u81df\u79fb\u690d\u7684\u9069\u61c9\u75c7\u4e4b\u4e00\n": "(D)", "104-19.\n62\u6b72\u7537\u6027\uff0c\u904e\u53bb\u7121\u5438\u83f8\u53f2\uff0c\u6b64\u6b21\u56e0\u54b3\u55fd\u4e09\u500b\u6708\u90fd\u6c92\u6539\u5584\uff0c\u6545\u81f3\u9580\u8a3a\u5c31\u91ab\uff0c\u80f8\u90e8X\u5149\u6aa2\u67e5\u986f\u793a\u53f3\u5074\u6709\u4e2d\u91cf\u808b\u819c\u7a4d\u6db2\uff0c\u4ee5\u7d30\u91dd\u62bd\u5438\u5f8c\u6aa2\u9a57\u767c\u73fe\u808b\u819c\u7a4d\u6db2\u7684total protein\u70ba4.8 g/dL\uff0cLDH\u70ba298 U/L\uff0c\u540c\u6642\u75c5\u60a3\u8840\u6db2\u4e2d\u7684total protein\u70ba5.8 g/dL(\u6b63\u5e38\u7bc4\u570d\u70ba6.4 - 8.4 g/dL)\uff0cLDH\u70ba273 U/L(\u6b63\u5e38\u7bc4\u570d\u70ba131 - 250 U/L)\uff1b\u808b\u819c\u7a4d\u6db2\u4e2d\u7684\u767d\u8840\u7403\u7e3d\u6578\u70ba2300 /cumm\uff0c\u55dc\u4e2d\u6027\u7403\u70ba3%\uff0c\u6dcb\u5df4\u7403\u70ba97%\uff0c\u7d30\u80de\u5b78\u53ca\u6297\u9178\u6027\u67d3\u8272\u6aa2\u67e5\u7686\u70ba\u9670\u6027\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6700\u4e0d\u9069\u7576\uff1f\nA. \u6839\u64daLight's criteria\uff0c\u6b64\u808b\u819c\u7a4d\u6db2\u61c9\u70baexudate\nB. \u82e5\u7d30\u80de\u5b78\u6a19\u672c\u4e2d\u7684\u9593\u76ae\u7d30\u80de(methoselial cell)\u6bd4\u4f8b\u4e0d\u52303%\uff0c\u5247\u7d50\u6838\u6027\u808b\u819c\u7a4d\u6db2\u7684\u6a5f\u6703\u5f88\u5927\nC. \u56e0\u70ba\u8981\u5728\u808b\u819c\u7a4d\u6db2\u4e2d\u76f4\u63a5\u627e\u5230\u7d50\u6838\u83cc\u7684\u654f\u611f\u6027\u4e0d\u523010%\uff0c\u6240\u4ee5\u6297\u9178\u6027\u67d3\u8272\u6aa2\u67e5\u70ba\u9670\u6027\uff0c\u4e26\u4e0d\u80fd\u6392\u9664\u7d50\u6838\u6027\u808b\u819c\u7a4d\u6db2\u7684\u8a3a\u65b7\nD. \u56e0\u70ba\u8981\u5728\u808b\u819c\u7a4d\u6db2\u7d30\u80de\u5b78\u6aa2\u67e5\u4e2d\u767c\u73fe\u60e1\u6027\u7d30\u80de\u7684\u654f\u611f\u6027\u8d85\u904e90%\uff0c\u6240\u4ee5\u7d30\u80de\u5b78\u6aa2\u67e5\u70ba\u9670\u6027\uff0c\u61c9\u53ef\u6392\u9664\u60e1\u6027\u808b\u819c\u7a4d\u6db2\u7684\u8a3a\u65b7\nE. \u53ef\u8003\u616e\u505a\u808b\u819c\u5207\u7247\u4ee5\u5e6b\u52a9\u8a3a\u65b7\n": "(D)", "104-20.\n\u4e0b\u5217\u4f55\u8655\u6709\u54b3\u55fd\u63a5\u53d7\u9ad4(cough receptor)\uff1f (1)\u4e0a\u773c\u77bc\uff0c(2)\u978f\u819c\uff0c(3)\u984d\u982d\uff0c(4)\u53e3\u8154\uff0c(5)\u54bd\uff0c(6)\u5589\uff0c(7)\u5916\u8033\u9053\uff0c(8)\u98df\u9053\uff0c(9)\u7d30\u652f\u6c23\u7ba1\nA. (4)+(5)+(6)+(8)+(9)\nB. (2)+(5)+(6)+(8)+(9)\nC. (1)+(5)+(6)+(7)+(9)\nD. (5)+(6)+(7)+(8)+(9)\nE. (2)+(5)+(6)+(7)+(9)\n": "(D)", "104-21.\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u60c5\u6cc1\u5c0e\u81f4\u547c\u5438\u56f0\u96e3\u7684\u6a5f\u8f49\u548c\u547c\u5438\u529f(work of breath)\u589e\u52a0\u7121\u95dc\uff1f(1)\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\uff0c(2)\u6c23\u5598\uff0c(3)\u80ba\u52d5\u8108\u9ad8\u58d3\uff0c(4)\u8ca7\u8840\uff0c(5)\u5fc3\u56e0\u6027\u80ba\u6c34\u816b\uff0c(6)\u975e\u5fc3\u56e0\u6027\u80ba\u6c34\u816b\uff0c(7)\u9593\u8cea\u6027\u80ba\u75c5\uff0c(8)\u53bb\u689d\u4ef6\u5316(deconditioning)\nA. (4)+(6)+(8)\nB. (3)+(4)+(8)\nC. (2)+(5)+(7)\nD. (3)+(4)+(5)\nE. (1)+(2)+(7)\n": "(B)", "104-22.\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u539f\u56e0\u9020\u6210\u7684\u808b\u819c\u7a4d\u6db2\u901a\u5e38\u662ftransudate\uff1f(1)\u9b31\u8840\u6027\u5fc3\u8870\u7aed\uff0c(2)\u809d\u786c\u5316\uff0c(3)\u80ba\u6813\u585e\uff0c(4)\u85e5\u7269\uff0c(5)\u4e73\u7cdc\u80f8\uff0c(6)\u4e0a\u8154\u975c\u8108\u963b\u585e\uff0c(7)Dressler's syndrome\uff0c(8)Meigs' syndrome\nA. (1)+(2)+(3)+(6)\nB. (1)+(2)+(6)+(7)\nC. (1)+(3)+(5)+(6)\nD. (2)+(5)+(6)+(8)\nE. (1)+(2)+(5)+(6)\n": "(A)", "105-1.\n\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (chronic obstructive pulmonary disease\uff0cCOPD)\u7684\u7406\u5b78\u6aa2\u67e5\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u56b4\u91cd\u7684\u60a3\u8005\u6703\u51fa\u73fecachexia\uff0c\u6b64\u8207\u9ad4\u5167\u767c\u708e\u7269\u8ceaTGF-\u03b2\u5347\u9ad8\u6709\u95dc\u3002\nB. \u6775\u72c0\u6307(Clubbing of the digits)\u8207COPD\u7121\u95dc\uff0c\u5728COPD\u60a3\u8005\u8eab\u4e0a\u65b0\u767c\u73fe\u5230\u6775\u72c0\u6307\uff0c\u9808\u5c0b\u627e\u5176\u4ed6\u7684\u539f\u56e0\u3002\nC. \u6709\u4e9b\u60a3\u8005\u6703\u56e0\u70ba\u80ba\u90e8\u904e\u5ea6\u5145\u6c23(hyperinflation)\uff0c\u4f7f\u6a6b\u8188\u819c\u8b8a\u5e73\uff0c\u5728\u5438\u6c23\u6642\u808b\u9aa8\u4e0b\u7de3\u6703\u7570\u5e38\u5730\u5411\u5167\u79fb\u52d5(paradoxical inward movement)\uff0c\u7a31\u70baHoover\u2032s sign\u3002\nD. \u6709\u4e9b\u60a3\u8005\u6703\u56e0\u70bahyperinflation\uff0c\u5448\u73fe\u51fa\u6876\u72c0\u80f8(barrel chest) \u3002\nE. \u91cd\u5ea6\u60a3\u8005\u5e38\u63a1\"tripod\"\u5750\u59ff\uff0c\u4ee5\u5229\u8f14\u52a9\u547c\u5438\u808c(accessory respiratory muscle)\u7684\u4f7f\u7528\u3002\n": "(A)", "105-2.\n\u6709\u95dc\u9020\u6210\u4f4e\u8840\u6c27\u75c7 (hypoxemia)\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u9ad8\u6d77\u62d4(high altitude)\u5f15\u8d77hypoxemia\uff0c\u80ba\u6ce1-\u52d5\u8108\u6c27\u6c23\u58d3\u529b\u5dee\uff08P(A-a)O2\uff0cAlveolar-arterial oxygen tension gradient\uff09\u6703\u4e0a\u5347\nB. \u63db\u6c23\u91cf\u4e0d\u8db3(hypoventilation)\uff0c\u52d5\u8108\u8840\u4e2d\u7684\u4e8c\u6c27\u5316\u78b3\u58d3\u529b(PaCO2)\u6703\u5347\u9ad8\nC. \u9593\u8cea\u6027\u80ba\u75c5(interstitial lung disease)\u60a3\u8005\uff0c\u6c27\u6c23\u7684\u64f4\u6563\u7570\u5e38(diffusion limitation)\uff0c\u5438\u5165\u9ad8\u6fc3\u5ea6\u7684\u6c27\u6c23\u7121\u6cd5\u6539\u5584hypoxemia\nD. \u80ba\u6813\u585e(pulmonary embolism)\u6703\u9020\u6210\u5206\u6d41(shunt)\uff0c\u5c0e\u81f4hypoxemia\nE. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (COPD) \u60a3\u8005\uff0c\u6703\u56e0\u901a\u6c23\u8207\u8840\u6db2\u704c\u6d41\u4e0d\u5339\u914d(V/Q mismatch) \u9020\u6210\u4f4e\u8840\u6c27\uff0c\u6b64\u6642\u5438\u5165\u9ad8\u6fc3\u5ea6\u7684\u6c27\u6c23\u7121\u6cd5\u6539\u5584hypoxemia\n": "(B)", "105-3.\n\u95dc\u65bc\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7 (Obstructive Sleep Apnea/Hypopnea Syndrome\uff0cOSAHS)\uff0c\u4e0b\u5217\u54ea\u4e9b\u63cf\u8ff0\u662f\u6b63\u78ba\u7684\uff1f\r1. \u80a5\u80d6(obesity)\u8207\u7537\u6027\u70ba\u6700\u91cd\u8981\u7684\u5371\u96aa\u56e0\u5b50\r2. \u6a19\u6e96\u7684\u8a3a\u65b7\u65b9\u6cd5(gold standard)\u70ba overnight oximetry\r3. \u548c\u5fc3(\u8166)\u8840\u7ba1\u75be\u75c5\u3001\u4ee3\u8b1d\u6027\u75be\u75c5\u6709\u95dc\r4. \u5c0d\u5065\u5eb7\u9020\u6210\u7684\u4e0d\u5229\u5f71\u97ff\u662f\u900f\u904esleep fragmentation\u3001cortical arousal \u8207 chronic intermittent hypercapnia (increase in PaCO2)\u9020\u6210\r5. \u6301\u7e8c\u967d\u58d3\u547c\u5438\u5668(continuous positive airway pressure\uff0cCPAP) \u70ba\u6a19\u6e96\u7684\u6cbb\u7642\u65b9\u6cd5\r6. CPAP \u53ef\u4f7f\u8840\u58d3\u4e0b\u964d\u5e73\u5747\u9054\u5230 12~14 mmHg\nA. 2+3+6\nB. 2+3+5\nC. 1+3+6\nD. 1+3+5\nE. 1+5+6\n": "(D)", "105-4.\n\u80ba\u529f\u80fd\u6aa2\u67e5\u4e2d\u7684\u4e00\u6c27\u5316\u78b3\u7030\u6f2b\u91cf(DLCO\uff0cthe diffusion capacity of the lungs for carbon monoxide)\u662f\u6e2c\u91cfCO\u5f9e\u80ba\u6ce1\u64f4\u6563\u5165\u5fae\u8840\u7ba1\u7684\u80fd\u529b\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4:\nA. \u6e2c\u91cf\u6642\u82e5\u75c5\u60a3\u9589\u6c23\u4e0d\u8db3\u5341\u79d2\uff0c\u6e2c\u5f97\u7684\u6578\u503c\u53ef\u80fd\u6703\u504f\u4f4e\u3002\nB. \u5207\u9664\u80ba\u8449\u7684\u60a3\u8005\uff0c\u82e5\u5269\u9918\u80ba\u90e8\u662f\u5065\u5eb7\u7684\uff0c\u6e2c\u5f97\u7684DLCO\u96d6\u7136\u7d55\u5c0d\u503c\u53ef\u80fd\u504f\u4f4e\uff0c\u4f46\u6821\u6b63\u80ba\u6ce1\u63db\u6c23\u91cf(alveolar volume)\u5f8c\u5247\u6703\u6b63\u5e38\u3002\nC. \u53ef\u4ee5\u7528\u4f86\u76e3\u6e2c\u85e5\u7269\u6bd2\u6027\uff0c\u5982:Bleomycin\u3002\nD. \u80ba\u6c23\u816b(emphysema)\u8207\u6c23\u5598(asthma)\u6703\u4e0b\u964d\u3002\nE. \u904b\u52d5\u8207\u6025\u6027\u80ba\u51fa\u8840 (acute pulmonary hemorrhage)\u6703\u4e0a\u5347\n": "(D)", "105-5.\n45\u6b72\u7537\u6027\uff0c\u56e0\u547c\u5438\u4e0d\u9069\uff0c\u6aa2\u67e5\u51fa\u53f3\u5074\u808b\u819c\u7a4d\u6db2 (pleural effusion)\u3002\u808b\u819c\u7a4d\u6db2\u7d93\u62bd\u53d6\u5f8c\u5206\u6790\u7d50\u679c\u5982\u4e0b: \u9ec3\u8272, LDH: 180 U/L, total protein: 4 g/dL\u3002\u8840\u6e05(serum)\u7684\u6aa2\u9a57\u503c\u70ba: LDH: 200 U/L, total protein: 6.2 g/dL\u3002\u5247\u6b64\u75c5\u60a3\u7684\u75c5\u56e0\u6700\u4e0d\u53ef\u80fd\u662f:\nA. Pneumonia\nB. Hepatic hydrothorax\nC. Malignancy\nD. Methothelioma\nE. Pulmonary embolus\n": "(B)", "105-6.\n80\u6b72\u7537\u6027\u6709\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(chronic obstructive pulmonary disease\uff0cCOPD)\u8207\u5fc3\u8870\u7aed\u75c5\u53f2\uff0c\u4e00\u5468\u4f86\u547c\u5438\u56f0\u96e3\u4f86\u6025\u8a3a\uff0c\u5728\u6025\u8a3a\u6cbb\u7642\u4e09\u5929\u5f8c\u4f4f\u9662\u3002\u5230\u75c5\u623f\u6642\uff0c\u610f\u8b58\u6e05\u9192\uff0c\u8840\u58d3160/90 mmHg\uff0c\u5fc3\u8df3108/min\uff0c\u547c\u5438\u901f\u738720/min\u3002\u5728\u672a\u7528\u6c27\u6c23\u7684\u72c0\u614b\u4e0b\uff0c\u52d5\u8108\u6c23\u9ad4\u5206\u6790(arterial blood gas): pH =7.50, PaO2= 65 mmHg, PaCO2 =43 mmHg, HCO3= 35 mEq/L, SaO2 93%\u3002urine [Cl-] =10 mEq/L\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u6b63\u78ba?\nA. \u662f\u4ee3\u8b1d\u6027\u9e7c\u8840\u75c7(metabolic alkalosis)\u5408\u4f75\u547c\u5438\u9178\u8840\u75c7(respiratory acidosis)\nB. \u70ba\u6025\u6027\u547c\u5438\u8870\u7aed\nC. Oxygen-Hemoglobin Dissociation Curve\u5de6\u79fb\uff0c\u7d44\u7e54\u6216\u5668\u5b98\u5bb9\u6613\u7f3a\u6c27\u3002\nD. \u6613\u5408\u4f75\u9ad8\u8840\u9240\u75c7(hyperkalemia)\u3002\nE. \u5728\u6025\u8a3a\u4e00\u5b9a\u6709\u4f7f\u7528\u985e\u56fa\u9187(corticosteroid)\u6cbb\u7642\u3002\n": "(C)", "105-7.\n\u95dc\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome\uff0cARDS)\uff0c\u4e0b\u5217\u54ea\u4e9b\u63cf\u8ff0\u662f\u932f\u8aa4\u7684\uff1f\nA. \u5fc5\u9808\u662f\u6025\u6027\u767c\u4f5c\uff08acute onset\uff09\u3001X \u5149\u70ba\u5169\u5074\u6d78\u6f64\u3001\u80ba\u5fae\u8840\u7ba1\u6954\u58d3( PCWP, pulmonary capillary wedge pressure)\u2266 18 mm Hg\u6216\u7121\u5de6\u5fc3\u623f\u58d3\u529b\u5347\u9ad8\u4e4b\u81e8\u5e8a\u8b49\u64da\u3002\nB. \u6839\u64daBerlin definition\uff0cPaO2 /FiO2 \u9700\u5c0f\u65bc 300 mm Hg\uff0c\u56b4\u91cd\u5ea6\u518d\u4f9dPaO2 /FiO2\u503c\u5340\u5206\u70ba\u8f15(200~300)\u3001\u4e2d(100~200)\u3001\u91cd\u5ea6(<100)\uff0c\u800c\u4e14\u4e0d\u5efa\u8b70\u4f7f\u7528acute lung injury\u9019\u500b\u540d\u8a5e\u3002\nC. \u5e38\u898b\u539f\u56e0\u70ba\u6557\u8840\u75c7(sepsis)\u3001\u80ba\u708e( pneumonia) \u3001\u55c6\u5165\u80c3\u5167\u7269(aspiration)\u3001\u5916\u50b7\u7b49\u3002\nD. \u5e38\u9808\u63d2\u7ba1\u53ca\u547c\u5438\u5668\u652f\u6301\u3002\u96a8\u6a5f\u5206\u6d3e\u7814\u7a76\u7684\u7d50\u679c\u5f37\u70c8\u5efa\u8b70\u4f7f\u7528\u4f4e\u6f6e\u6c23\u5bb9\u7a4d(low tidal volume)\u548c\u4f4e\u5410\u6c23\u672b\u967d\u58d3(low PEEP, positive end-expiratory pressure)\u3002\nE. \u96a8\u6a5f\u5206\u6d3e\u7814\u7a76\u7684\u7d50\u679c\u5f37\u70c8\u5efa\u8b70\u4f7f\u7528\u547c\u5438\u5668\u60a3\u8005\uff0c\u9664sedation\u4ee5\u5916\uff0c\u65e9\u671f\u7d66\u4e88cisatracurium besylate (early neuromuscular blockade)\u3002\u5c0d\u65bcsevere ARDS\u60a3\u8005\uff0c\u53ef\u589e\u52a0\u5b58\u6d3b\u7387\n": "(D)", "105-8.\n\u95dc\u65bc\u9811\u56fa\u578b\u6c23\u5598(Refractory Asthma)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u9996\u8981\u4e4b\u52d9\u70ba\u78ba\u8a8d\u75c5\u4eba\u7528\u85e5\u7684\u9075\u5f9e\u6027(complicance)\u8207\u6e1b\u5c11\u53ef\u80fd\u7684\u8a98\u767c\u56e0\u5b50(trigger factors)\nB. \u4f4e\u5291\u91cf theophylline \u5b8c\u5168\u6c92\u6548\uff0c\u4e0d\u5b9c\u5617\u8a66\nC. \u5927\u90e8\u5206\u7684\u75c5\u4eba\u9700\u8981\u53e3\u670d\u7684\u985e\u56fa\u9187\u6cbb\u7642(oral corticosteroid)\nD. Omalizumab\u5c0d\u65bc\u67d0\u4e9ballergic asthma\u60a3\u8005\uff0c\u5177\u6709\u7642\u6548\uff0c\u7279\u5225\u662f\u5f88\u983b\u7e41\u60e1\u5316\u767c\u4f5c\u60a3\u8005\nE. Anti-TNF (tumor necrosis factor) \u5c0d\u65bcsevere asthma\u60a3\u8005\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\uff0c\u4e0d\u61c9\u4f7f\u7528\n": "(B)", "105-9.\n\u4e0b\u5217\u4f55\u8005\u5c0d\u65bc\u6cbb\u7642\u6c23\u5598\u6025\u6027\u767c\u4f5c(acute exacerbations)\uff0c\u6c92\u6709\u89d2\u8272\uff1f\nA. Systemic corticosteroids\nB. Supplemental oxygen\nC. Inhaled heliox\nD. IV magnesium sulfate (MgSO4)\nE. Antibiotics\n": "(E)", "105-10.\n35\u6b72\u5e74\u8f15\u5973\u6027\uff0c\u56e0\u5065\u6aa2\u7167\u4e86\u4e00\u5f35\u80f8\u90e8X\u5149\uff0c\u5982\u4e0b\u5716\u6240\u793a\uff0c\u6b64\u5916\uff0c\u60a3\u8005\u5728\u5c0f\u817f\u4e0a\u6709\u76ae\u819a\u75c5\u5146\uff0c\u7d93\u8a3a\u65b7\u70ba\u7d50\u7bc0\u6027\u7d05\u6591(erythema nodosum)\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u6558\u8ff0\u6b63\u78ba\r1. \u9700\u8981\u8f49\u4ecb\u773c\u79d1\u91ab\u5e2b\u9032\u884c\u773c\u775b\u7684\u8a55\u4f30\r2. \u8a72\u75be\u75c5\u7684\u5206\u671f\u9700\u8981\u9032\u4e00\u6b65\u4f7f\u7528\u96fb\u8166\u65b7\u5c64\u9032\u884c\u5206\u671f\r3. \u6240\u6709\u60a3\u8005\u5747\u9700\u63a5\u53d7\u6cbb\u7642\r4. \u8a72\u75be\u75c5\u5bb9\u6613\u9020\u6210\u591a\u91cd\u5668\u5b98\u4fb5\u72af\r5. \u6240\u6709\u60a3\u8005\u7684\u8a3a\u65b7\u5747\u9700\u8981\u75c5\u7406\u5207\u7247\u7684\u6aa2\u67e5\nA. 1+3+4+5\nB. 1+2+4\nC. 1+4\nD. 2+3\nE. 2+4+5\n": "(C)", "105-11.\n57\u6b72\u7537\u6027\uff0c\u53f3\u4e0a\u80ba\u8449\u816b\u7624\uff0c\u7d93\u8b49\u5be6\u70ba\u80ba\u817a\u764c\u3002\u96fb\u8166\u65b7\u5c64\u986f\u793a\uff0c\u8a72\u816b\u7624\u7d044\u516c\u5206\u5927\uff0c\u53f3\u4e0b\u80ba\u8449\u53e6\u6709\u4e00\u5c0f\u816b\u7624\u7d041.5\u516c\u5206\u5927\uff0c\u4e5f\u8b49\u5be6\u70ba\u540c\u4e00\u7d44\u7e54\u578b\u7684\u80ba\u817a\u764c\uff0c\u540c\u5074\u814b\u4e0b\u6dcb\u5df4\u7d50\u7d93\u5207\u7247\u8b49\u5be6\u70ba\u8f49\u79fb\uff0c\u9664\u6b64\u4e4b\u5916\u7121\u5176\u4ed6\u6dcb\u5df4\u7d50\u4fb5\u72af\uff0c\u4e5f\u7121\u5176\u4ed6\u5668\u5b98\u9060\u7aef\u8f49\u79fb\uff0c\u8acb\u554f\u6839\u64da\u7b2c\u4e03\u7248\u7684\u80ba\u764cTNM\u5206\u671f\u7cfb\u7d71\uff0c\u75c5\u60a3\u7684\u80ba\u817a\u764c\u5206\u671f\u70ba\uff1f\nA. T2aN1M0, stage IIB\nB. T2aN3M0, stage IIIB\nC. T3N1M0, stage IIIA\nD. T4N3M0, stage IIIB\nE. T4N0M1b, stage IV\n": "(E)", "105-12.\n71\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u70ba\u54b3\u55fd\u4e09\u5468\uff0c\u80f8\u90e8X\u5149\u610f\u5916\u767c\u73fe\u5de6\u80ba\u6709\u9670\u5f71\u3002\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u986f\u793a(\u5982\u5716\u793a)\u5de6\u4e0b\u8449\u6709\u4e00\u9846\u816b\u7624\u53ca\u53f3\u6c23\u7ba1\u524d\u6709\u4e00\u98461\u516c\u5206\u6dcb\u5df4\u7d50\uff0c\u982d\u90e8\u96fb\u8166\u65b7\u5c64\u53ca\u9aa8\u9abc\u6383\u63cf\u7686\u7121\u7570\u5e38\u3002\u8acb\u554f\u63a5\u4e0b\u4f86\u7684\u6aa2\u67e5\u4f55\u8005\u6700\u6709\u6548\u7387\uff0c\u53ef\u4ee5\u5728\u6700\u77ed\u7684\u6642\u9593\u5f97\u5230\u6cbb\u7642\u6240\u9700\u8981\u7684\u8cc7\u8a0a\uff1f\nA. \u5148\u505a\u96fb\u8166\u65b7\u5c64\u63a5\u7247\u6aa2\u67e5\u78ba\u8a8d\u70ba\u60e1\u6027\u5f8c\uff0c\u518d\u505a\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\uff0c\u6dcb\u5df4\u7d50\u6709\u7570\u5e38\u518d\u505a\u7e31\u8188\u8154\u93e1\u6dcb\u5df4\u53d6\u6a23\u3002\nB. \u5148\u505a\u96fb\u8166\u65b7\u5c64\u63a5\u7247\u6aa2\u67e5\u78ba\u8a8d\u70ba\u60e1\u6027\u5f8c\uff0c\u518d\u505a\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\uff0c\u6dcb\u5df4\u7d50\u6709\u7570\u5e38\u518d\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u7d93\u6c23\u7ba1\u6dcb\u5df4\u7d50\u62bd\u5438\u3002\nC. \u5148\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u5468\u908a\u816b\u7624\u5207\u7247\uff0c\u518d\u505a\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\u3002\u6dcb\u5df4\u7d50\u6709\u7570\u5e38\u518d\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u7d93\u6c23\u7ba1\u6dcb\u5df4\u7d50\u62bd\u5438\u3002\nD. \u5148\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u7d93\u6c23\u7ba1\u6dcb\u5df4\u7d50\u62bd\u5438\uff0c\u78ba\u8a8d\u70ba\u60e1\u6027\u816b\u7624\uff0c\u5982\u679c\u70ba\u826f\u6027\u540c\u6642\u505a\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u5468\u908a\u816b\u7624\u5207\u7247\u5f8c\uff0c\u518d\u8003\u616e\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\u3002\nE. \u5148\u505a\u6b63\u5b50\u65b7\u5c64\u9020\u5f71\uff0c\u78ba\u8a8d\u7121\u5176\u4ed6\u8f49\u79fb\u518d\u505a\u96fb\u8166\u65b7\u5c64\u5207\u7247\u6aa2\u67e5\u3002\n": "(D)", "105-13.\n65\u6b72\u7537\u6027\u75c5\u4eba\u814e\u7d72\u7403\u814e\u708e\u9577\u671f\u6d17\u814e\uff0c\u6700\u8fd1\u56e0\u98df\u617e\u4e0d\u632f\u4f86\u9580\u8a3a\uff0c\u75f0\u6db2\u6aa2\u67e5\u767c\u73fe\u70ba\u958b\u653e\u6027\u80ba\u7d50\u6838\uff0c\u9ad4\u91cd\u7d0460\u516c\u65a4\uff0c\u6297\u7d50\u6838\u85e5\u7269\u8a72\u5982\u4f55\u7d66\u4e88\uff1f\r1. INH (100mg) \u6bcf\u59293\u9846\r2. RIF (150 mg) \u6bcf\u59294\u9846\r3. Rifater \u6bcf\u59295\u9846\r4. EMB (400mg) \u6bcf\u59292.5 \u9846\r5. PZA (500mg) \u6bcf\u59293\u9846\r6. EMB\u6d17\u814e\u5f8c2.5 \u9846\r7. PZA\u6d17\u814e\u5f8c3\u9846\u3002\nA. 1+2+3+4\nB. 1+2+6+7\nC. 3+6\nD. 1+2+4+7\nE. 1+2+5+6\n": "(B)", "105-14.\n\u5728\u56b4\u91cd\u6c23\u5598\u767c\u4f5c\u7015\u81e8\u547c\u5438\u8870\u7aed\u7684\u75c5\u4eba\u53ef\u4ee5\u8003\u616e\u4e0b\u5217\u54ea\u4e9b\u6cbb\u7642\uff1f\r1. Noninvasive Ventilator\r2. \u9810\u9632\u6027\u7684\u63d2\u7ba1\u6cbb\u7642\uff0c\u7279\u5225\u662fCO2 \u6b63\u5e38\u6216\u7a0d\u9ad8\u7684\u75c5\u4eba\r3. \u975c\u8108\u6ce8\u5c04 \u03b22 agonist\r4. \u5438\u5165\u5f0f\u526f\u4ea4\u611f\u795e\u7d93\u62ee\u6297\u5291\uff08anticholinergic\uff09\r5. \u975c\u8108\u6ce8\u5c04 Aminophylline\uff08\u8336\u9e7c\uff09\r6. \u975c\u8108\u6ce8\u5c04 anti IgE antibody \uff08Omalizumab\uff09\nA. 1+3+4+5\nB. 2+3+4+5\nC. 2+4+5+6\nD. 1+3+5+6\nE. 2+3+4+6\n": "(B)", "105-15.\n79\u6b72\u5973\u6027\uff0c\u5f9e\u4e0d\u62bd\u83f8\uff0c\u5c0f\u6642\u5019\u7121\u6c23\u5598\u75c5\u53f2\uff0c\u70ba\u5bb6\u5ead\u4e3b\u5a66\uff0c30\u6b72\u4ee5\u5f8c\uff0c\u5076\u723e\u6703\u6709\u547c\u5438\u56f0\u96e3\u7684\u60c5\u6cc1\uff0c\u7279\u5225\u662f\u5728\u611f\u5192\u5f8c\u75c7\u72c0\u52a0\u5287\uff0c\u5728\u4e00\u822c\u8a3a\u6240\u670d\u7528\u85e5\u7269\u5f8c\u5373\u6539\u5584\u3002\u95dc\u65bc\u547c\u5438\u56f0\u96e3\u7684\u60c5\u6cc1\u96a8\u8457\u5e74\u9f61\u589e\u52a0\u800c\u8d8a\u4f86\u8d8a\u56b4\u91cd\uff0c\u8fd1\u5e74\u4f86\u5e38\u6709\u5598\u9cf4\u8072\uff0c\u80ba\u529f\u80fd\u6aa2\u67e5\u986f\u793a FVC 65.7 %\uff0c FEV1 43.1%\uff0c FEV/FVC 54.3%\uff0c Bronchodilator test negative to Fenoterol 100 mcq 4puff\uff0c \u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5178\u578b\u7684 COPD\u61c9\u8a72\u7d66\u4e88long-acting muscarinic antagonist\nB. \u53ef\u4ee5\u662f\u9577\u671f\u7684Asthma\u7684\u7d50\u679c\nC. \u53ef\u4ee5\u662fAsthma COPD overlap syndrome\nD. \u53ef\u4ee5\u7e7c\u7e8c\u7d66\u4e88Inhaled corticosteroid\nE. \u8003\u616e\u80ba\u90e8\u5fa9\u5065\u53ca\u6d41\u611f\u80ba\u708e\u93c8\u7403\u83cc\u75ab\u82d7\n": "(A)", "105-16.\n\u80ba\u9ad8\u58d3\uff08Pulmonary Hypertension\uff09\u6839\u64da\u6700\u65b0\u7684\u5b9a\u7fa9\u5206\u70ba\u4e94\u985e\uff0c\u5176\u4e2d\u54ea\u4e00\u985e\u88ab\u885b\u798f\u90e8\u5065\u4fdd\u7f72\u8a02\u7fa9\u70ba\u7f55\u898b\u75be\u75c5\uff1f\nA. \u80ba\u52d5\u8108\u9ad8\u58d3\uff08Pulmonary Arterial Hypertension\uff09\nB. \u5de6\u5fc3\u75be\u75c5\u5f15\u8d77\u7684\u80ba\u9ad8\u58d3\nC. \u6162\u6027\u80ba\u75c5\u5f15\u8d77\u7684\u80ba\u9ad8\u58d3\nD. \u6162\u6027\u8840\u6813\u6216\u6813\u585e\u75be\u75c5\u9020\u6210\u7684\u80ba\u9ad8\u58d3\nE. \u4e0d\u660e\u6216\u591a\u91cd\u539f\u56e0\u4e4b\u80ba\u9ad8\u58d3\n": "(A)", "105-17.\n63\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u63db\u904e\u4e8c\u5c16\u74e3\u74e3\u819c\uff0c\u5fc3\u5f8b\u4e0d\u6574\u9577\u671f\u4f7f\u7528\u85e5\u7269\u3002\u56e0\u70ba\u5598\u7684\u60c5\u5f62\u52a0\u5287\uff0cCXR\u53ca\u96fb\u8166\u65b7\u5c64\u5982\u5716\u793a\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1f\nA. \u70ba\u5178\u578b\u7684 Interstitial Lung Disease\uff0c\u53ef\u4ee5\u662fidiopathic pulmonary fibrosis\u3002\nB. \u80ba\u90e8\u6709\u8a31\u591a\u5c0f\u9ede\uff0cMiliary TB\u7121\u6cd5\u6392\u9664\u3002\nC. X\u5149\u53ca\u96fb\u8166\u65b7\u5c64\u6709\u8a31\u591a\u7684\u7dda\u689d\uff0c\u53ef\u4ee5\u662fkerley line \u61c9\u70ba\u80ba\u6c34\u816b\u3002\nD. \u7121\u986f\u5f71\u5291\u809d\u81df\u537b\u660e\u986f\u8f03\u4eae\u8981\u8003\u616eAmiodarone \u9020\u6210\u7684 Interstitial Lung Disease\u3002\nE. \u6709\u8a31\u591a\u7684\u9ede\u8ddf\u7dda\uff0c\u61c9\u8003\u616e\u80ba\u764c\u5408\u4f75 lymphangitis carcinomatosis\u3002\n": "(D)", "105-18.\n\u5c0d\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (ARDS)\uff0c\u4e0b\u5217\u54ea\u4e00\u7a2e\u8655\u7f6e\u65b9\u5f0f\u5c0d\u65bc\u9810\u5f8c\uff08survival\uff09\u662f\u6c92\u6709\u5e6b\u52a9\u7684\uff1f\nA. \u4e00\u6c27\u5316\u6c2e\u7684\u5438\u5165\u4f7f\u7528\uff08inhaled NO\uff09\u3002\nB. \u4fef\u81e5\uff08prone position\uff09\u3002\nC. \u4f4e\u6f6e\u6c23\u91cf\u8a2d\u5b9a\uff08Low tidal volume\uff09\u3002\nD. \u9ad8\u5410\u6c23\u672b\u7aef\u6b63\u58d3\uff08High PEEP or open Lung\uff09\u3002\nE. \u65e9\u671f\u795e\u7d93\u808c\u8089\u963b\u65b7\uff08early Neuromuscular Blockade\uff09\u3002\n": "(A)", "105-19.\n57\u6b72\u6cb9\u6f06\u5de5\u56e0\u80f8\u60b6\u4f86\u91ab\u9662\u5c31\u8a3a\uff0c\u5fc3\u81df\u76f8\u95dc\u6aa2\u67e5\u7121\u554f\u984c\uff0cCXR\u5982\u5716\uff0c\u4ed4\u7d30\u8a62\u554f\u904e\u53bb\u7684\u8077\u696d\uff0c\u66fe\u5728\u62c6\u8239\u5ee0\u5de5\u4f5c\u5341\u591a\u5e74\uff0c\u5176\u4ed6\u5668\u5b98\u4e26\u7121\u8f49\u79fb\u7684\u8de1\u8c61\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\u80ba\u817a\u764c\u3002\nB. \u504f\u5149\u986f\u5fae\u93e1\u53ef\u4ee5\u770b\u5230\u7d44\u7e54\u5207\u7247\u5167\u7684\u7d50\u6676\u3002\nC. \u514d\u75ab\u7d44\u7e54\u67d3\u8272TTF-1 \u61c9\u70ba Negative\u3002\nD. \u53ef\u4ee5\u8003\u616e\u5916\u79d1\u5207\u9664\u3002\nE. \u7b2c\u4e00\u7dda\u7684\u5316\u5b78\u6cbb\u7642\u70ba\u611b\u5be7\u9054\uff08pemetrexed\uff09\u52a0\u9251\u91d1\u3002\n": "(A)", "105-20.\n\u5c0d\u65bc\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u4f4e\u901a\u6c23\u75c7\u5019\u7fa4\uff08obstructive sleep apnea hypopnea syndrome OSAHS\uff09\u4e0b\u5217\u4f55\u8005\u70ba\u662f \ufe56\nA. \u5e38\u4f75\u767c\u8840\u58d3\u3001\u5fc3\u81df\u3001\u8166\u8840\u7ba1\u75be\u75c5\uff0c\u4f46\u8207\u7cd6\u5c3f\u75c5\u7121\u95dc\u3002\nB. \u6771\u65b9\u4eba\u767c\u751f\u6b64\u75c5\u7684\u5e73\u5747BMI\u8f03\u897f\u65b9\u4eba\u70ba\u4f4e\uff0c\u4e3b\u8981\u662f\u907a\u50b3\u75be\u75c5\u9020\u6210\u3002\nC. \u8a3a\u65b7\u56b4\u91cdOSAHS\u7684\u6a19\u6e96\u662fApnea hypoxia index \uff08AHI\uff09\u226715 events\uff0fH\u3002\nD. OSAHS \u5728\u7761\u7720\u5feb\u901f\u52d5\u773c\u671f\uff08REM\uff09\u75c7\u72c0\u6700\u56b4\u91cd\u3002\nE. \u75c5\u4eba\u6700\u5e38\u62b1\u6028\u75b2\u7d2f\u3001\u7121\u6cd5\u96c6\u4e2d\u7cbe\u795e\u3002\n": "(D)", "105-21.\n\u5c0d\u65bc\u6557\u8840\u75c7\u7684\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e \ufe56\nA. Early goal directed therapy \u4e3b\u8981\u662f\u70ba\u4e86\u63d0\u4f9b\u8db3\u5920\u7684\u704c\u6d41\uff0c\u5efa\u8b70\u5728\u8840\u58d3\u4f4e\u7684\u75c5\u4eba\uff0c\u524d\u4e00\u5230\u5169\u5c0f\u6642\u7d66\u4e881~2\u5347\u7684Normal Saline\u3002\nB. \u8d8a\u5feb\u7d66\u4e88\u8db3\u5920\u4e14\u9069\u7576\u7684\u6297\u751f\u7d20\u662f\u63d0\u9ad8\u5b58\u6d3b\u7387\u7684\u6c7a\u5b9a\u56e0\u7d20\u3002\nC. \u63d0\u5347\u7d44\u7e54\u6c27\u6c23\u7684\u4f7f\u7528\u662f\u6cbb\u7642\u7684\u76ee\u7684\u4e4b\u4e00\uff0c\u56e0\u6b64\u5fc5\u9808\u7dad\u6301\u975c\u8108\u6c27\u542b\u91cf\uff08\u6c27\u6c23\u98fd\u548c\u5ea6\uff09>70%\u3002\nD. \u70ba\u4e86\u7dad\u6301\u8db3\u5920\u8840\u6db2\u704c\u6d41\u53ca\u907f\u514d\u80ba\u6c34\u816b\uff0c\u4e2d\u5fc3\u975c\u8108\u58d3\u8981\u7dad\u6301\u57288~12cm H2O \u3002\nE. \u76e1\u91cf\u7dad\u6301\u5c3f\u91cf\u57280.5ml\uff0fKg\u4ee5\u4e0a\uff0c\u5982\u679c\u5c3f\u91cf\u4e0d\u8db3\u53ef\u4ee5\u8003\u616e\u5229\u5c3f\u5291furosemide\u4f7f\u7528\u3002\n": "(C)", "105-22.\n\u5c0d\u65bcCOPD\u7684\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\ufe56\nA. \u5c0d\u65bc\u904b\u52d5\u6703\u5598\u7684\u75c5\u4eba\uff0c\u904b\u52d5\u6642\u7d66\u4e88\u6c27\u6c23\u662f\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\u3002\nB. \u5438\u5165\u6027\u985e\u56fa\u9187\u5c0d\u65bc\u6b7b\u4ea1\u7387\u7684\u964d\u4f4e\u4ecd\u6709\u722d\u8b70\uff0c\u5c0d\u65bc\u6025\u6027\u767c\u4f5c\u4e00\u5e74\u8d85\u904e\u5169\u6b21\u7684\u75c5\u4eba\uff0c\u53ef\u4ee5\u8003\u616e\u4f7f\u7528\u3002\nC. \u80ba\u90e8\u5fa9\u5065\u662f\u6cbb\u7642COPD\u91cd\u8981\u7684\u6cbb\u7642\u4e4b\u4e00\uff0c\u53ef\u4ee5\u6709\u6548\u964d\u4f4e\u4f4f\u9662\u7387\u3002\nD. \u9810\u9632\u6027\u7684\u6297\u751f\u7d20\u4f7f\u7528\uff0c\u7121\u6cd5\u964d\u4f4e\u6025\u6027\u767c\u4f5c\u7684\u6b21\u6578\uff0c\u4f46azithromycin\u4f3c\u4e4e\u53ef\u4ee5\u5ef6\u9577\u6025\u6027\u518d\u767c\u4f5c\u7684\u5929\u6578\u3002\nE. \u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\u53ef\u4ee5\u5e6b\u5fd9COPD\u547c\u5438\u8870\u7aed\u7684\u75c5\u4eba\uff0c\u4f46\u610f\u8b58\u4e0d\u6e05\u6216\u75f0\u91cf\u592a\u591a\u7684\u75c5\u4eba\u4e0d\u5efa\u8b70\u4f7f\u7528\u3002\n": "(A)", "106-1.\n\u95dc\u65bc\u80ba\u90e8\u7684\u7406\u5b78\u6aa2\u67e5\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. Velcro crackles \u53ef\u898b\u65bc\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fibrosis, IPF) \u60a3\u8005\u3002\nB. Pulsus paradoxus \u51fa\u73fe\u5728\u963b\u585e\u6027\u80ba\u75c5(obstructive lung disease)\u60a3\u8005\u6642\uff0c\u662f\u4e00\u500b\u4e0d\u597d\u7684\u5fb5\u8c61\uff0c\u53ef\u80fd\u662f\u7015\u81e8\u547c\u5438\u8870\u7aed (impending respiratory failure)\u7684\u5fb5\u5146\u3002\nC. Egophony\u662f\u6307\u75c5\u4eba\u767c\u51fa\"AH\"\u7684\u8072\u97f3\uff0c\u7d93\u7531\u5be6\u8cea\u5316\u5340\u57df\u7684\u7570\u5e38\u50b3\u5c0e\uff0c\u91ab\u5e2b\u5728\u807d\u8a3a\u6642\u807d\u5230 \"EEE\"\u7684\u8072\u97f3\uff0c\u53ef\u898b\u65bc\u80ba\u708e (pneumonia)\u60a3\u8005\u3002\nD. Wheezes \u5e38\u898b\u65bc\u6c23\u5598( asthma)\u60a3\u8005\uff0c\u4f46\u5728\u9b31\u8840\u6027\u5fc3\u8870\u7aed (congestive heart failure)\u7684\u60a3\u8005\u4e5f\u53ef\u898b\u5230\u3002\nE. stridor\u662f\u5438\u6c23\u6642\u9ad8\u983b\u7684\u8072\u97f3\uff0c\u5e38\u70baupper airway obstruction\u7684\u8868\u73fe\u3002\n": "(C)", "106-2.\n\u95dc\u65bc\u547c\u5438\u529f\u80fd\u65b9\u9762\u7684\u6aa2\u67e5\uff0c\u4ee5\u4e0b\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4e00\u6c27\u5316\u78b3\u80ba\u64f4\u6563\u529b\u6aa2\u67e5(DLCO\uff0cdiffusion capacity of CO in lung)\u5728\u80ba\u6c23\u816b  (emphysema)\u7684\u60a3\u8005\u6703\u4e0b\u964d\uff0c\u5728\u6709\u5de6\u81f3\u53f3\u5fc3\u5167\u5206\u6d41(left-to-right intracardiac shunt)\u7684\u60a3\u8005\u6703\u4e0a\u5347\u3002\nB. \u80ba\u91cf\u8a08\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u8a66\u9a57 (spirometry with bronchodilator reversibility test)\u662f\u5728\u5438\u5165\u652f\u6c23\u7ba1\u64f4\u5f35\u5291(\u5982:albuterol\u6216ipratropium)\u7684\u524d\u5f8c\uff0c\u9032\u884c\u80ba\u91cf\u8a08(spirometry)\u7684\u6e2c\u8a66\u3002\u524d\u5f8c\u80ba\u529f\u80fd\u7684\u8b8a\u5316\u7a0b\u5ea6\uff0c\u7531\u65bc\u91cd\u73fe\u6027\u4e0d\u4f73\uff0c\u7121\u6cd5\u826f\u597d\u5730\u9810\u6e2c\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u6cbb\u7642\u7684\u9577\u671f\u6548\u679c\u3002\nC. \u547c\u6c23\u4e2d\u4e00\u6c27\u5316\u6c2e\u7684\u6fc3\u5ea6(fraction of exhaled nitric oxide, FeNO)\u662f\u55dc\u4f0a\u7d05\u6027\u7d30\u80de\u547c\u5438\u9053\u767c\u708e(Eosinophilic Airway Inflammation) \u7684\u6307\u6a19\uff0c\u53ef\u7528\u65bc\u9810\u6e2c\u547c\u5438\u9053\u963b\u585e\u5c0d\u985e\u56fa\u9187\u6cbb\u7642(corticosteroid)\u7684\u53cd\u61c9\u3002\nD. \u6e2c\u91cf\u6700\u5927\u547c\u5438\u58d3\u529b(maximal respiratory pressures)\u6709\u52a9\u65bc\u627e\u51fa\u808c\u8089\u7121\u529b(muscle weakness)\u5c0e\u81f4\u7684\u4fb7\u9650\u6027\u901a\u6c23\u969c\u7919(restrictive ventilator impairment)\u75c5\u60a3\uff0c\u4e5f\u5bb9\u6613\u5340\u5206\u808c\u8089\u7121\u529b\u8207\u6e2c\u8a66\u914d\u5408\u5ea6\u4e0d\u4f73(poor test performance)\u7684\u60a3\u8005\u3002\nE. \u6fc0\u767c\u8a66\u9a57(provocation test)\u662f\u6e2c\u91cf\u6c23\u9053\u904e\u5ea6\u53cd\u61c9(airway hyperresponsiveness)\u53ef\u7528methacholine\u6216\u51b7\u7a7a\u6c23\u6216\u8eab\u9ad4\u523a\u6fc0(physical stimuli)\u3002\n": "(D)", "106-3.\n\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(chronic obstructive pulmonary disease, COPD)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8a3a\u65b7COPD\u4e00\u5b9a\u9700\u8981\u80ba\u91cf\u8a08(spirometry)\u8207\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u8a66\u9a57 (bronchodilator reversibility test)\u3002\nB. \u8f15\u5ea6\u5230\u4e2d\u5ea6\u7684COPD\u60a3\u8005\uff0c\u82e5\u6709\u547c\u5438\u9053\u9ad8\u53cd\u61c9\u6027(airway hyperresponsiveness\uff0cAHR)\uff0c\u53ef\u4ee5\u9810\u6e2c\u80ba\u529f\u80fd\u6703\u52a0\u901f\u4e0b\u964d\uff0c\u7279\u5225\u662f\u6301\u7e8c\u5438\u83f8\u8005\u3002\nC. \u5408\u4e4e\u6162\u6027\u652f\u6c23\u7ba1\u708e(chronic bronchitis)\u5b9a\u7fa9\u7684\u60a3\u8005\u90fd\u5c6c\u65bcCOPD\u3002\nD. Centriacinar emphysema\u4e3b\u8981\u5f71\u97ffrespiratory bronchiole\uff0c\u5e38\u898b\u65bc\u03b11-antitrypsin deficiency\u60a3\u8005\u3002\nE. \u80ba\u6c23\u816b(emphysema)\u662f\u75c5\u7406\u8a3a\u65b7\uff0c\u800c\u6162\u652f\u6c23\u7ba1\u708e(chronic bronchitis)\u70ba\u81e8\u5e8a\u8a3a\u65b7\u3002\n": "(D)", "106-4.\n\u80ba\u529f\u80fd\u6aa2\u67e5\u7684\u6c23\u6d41\u5bb9\u7a4d\u95dc\u4fc2(flow-volume volume/loop)\u8207\u75be\u75c5\u7684\u914d\u5c0d(\u5982\u5716)\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1a(X\u8ef8\u70ba\u5bb9\u7a4d\uff0cY\u8ef8\u70ba\u6c23\u6d41\uff0cY\u8ef8\u6b63\u5411\u70ba\u5410\u6c23\u3001\u8ca0\u5411\u70ba\u5438\u6c23, TLC:total lung capacity, RV: residual volume)\nA. \u8072\u5e36\u9ebb\u75fa(vocal cord paralysis)\uff0c\u9020\u6210\u547c\u5438\u9053\u963b\u585e(variable extra-thoracic obstruction)\u3002\nB. \u5fa9\u767c\u6027\u591a\u8edf\u9aa8\u708e(relapsing polychondritis)\uff0c\u9020\u6210\u547c\u5438\u9053\u963b\u585e(variable intra-thoracic obstruction)\u3002\nC. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(chronic obstructive pulmonary disease, COPD)\u9020\u6210\u7684\u963b\u585e\u6027\u901a\u6c23\u969c\u7919(obstructive ventilatory impairment)\u3002\nD. \u80ba\u7e96\u7dad\u5316(pulmonary fibrosis)\u9020\u6210\u7684\u4fb7\u9650\u6027\u901a\u6c23\u969c\u7919(restrictive ventilatory impairment)\u3002\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(A)", "106-5.\n\u75c5\u60a3\u80f8\u90e8X\u5149\u7247\u8207\u96fb\u8166\u65b7\u5c64\u5f71\u50cf\u5982\u5716\uff0c \u4ee5\u4e0b\u8a3a\u65b7\u4f55\u8005\u6700\u70ba\u53ef\u80fd:\nA. Small cell lung cancer\nB. Septic emboli\nC. Sarcoidosis\nD. Bronchiolitis obliterans organizing pneumonia\nE. Pulmonary fibrosis\n": "(B)", "106-6.\n\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (chronic obstructive pulmonary disease\uff0cCOPD)\u7684\u8a55\u4f30\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u90a3\u4e9b\u63cf\u8ff0\u932f\u8aa4\uff1f(1) 2011-2016\u5e74\u4fee\u8a02\u4e4bGOLD (Global Initiative for Chronic Obstructive Lung Disease) COPD guideline\uff0c\u9664\u4e86FEV1 (forced expiratory volume in one second\uff0c\u7528\u529b\u547c\u6c23\u4e00\u79d2\u91cf)\u4e4b\u5916\uff0c\u52a0\u5165\u4e86\u524d\u4e00\u5e74\u6025\u6027\u60e1\u5316(acute exacerbation)\u767c\u4f5c\u6b21\u6578\u8207\u81e8\u5e8a\u75c7\u72c0\uff0c\u5c07\u75c5\u60a3\u5206\u70baABCD\u56db\u985e\u3002\u6b64\u5206\u985e\u65b9\u5f0f\u6bd4FEV1\u66f4\u80fd\u9810\u6e2c\u75c5\u60a3\u7684\u6b7b\u4ea1\u7387\u8207\u6025\u6027\u60e1\u5316\u7684\u98a8\u96aa\uff1b(2) GOLD 2017 COPD guideline\uff0c\u4f9d\u7167\u75c5\u60a3\u524d\u4e00\u5e74\u6025\u6027\u60e1\u5316(acute\r\nexacerbation)\u767c\u4f5c\u6b21\u6578\u8207\u81e8\u5e8a\u75c7\u72c0\u4f86\u5efa\u8b70\u6cbb\u7642\u7684\u85e5\u7269\uff0c\u4e0d\u5fc5\u518d\u8003\u616eFEV1\uff1b(3) \u4ee5\u5438\u5165\u6027\u7528\u85e5\u800c\u8a00\uff0c\u9577\u6548\u578b\u7684\u4e59\u578b\u81f4\u6548\u5291(long-acting beta2-agonist\uff0cLABA) \u8207\u5438\u5165\u6027\u985e\u56fa\u9187(ICS) \u7684\u7d44\u5408\uff0c\u6bd4LABA\u8207\u9577\u6548\u578b\u7684\u6bd2\u8548\u9e7c\u62ee\u6297\u5291(long-acting anti-muscarinic antagonist\uff0cLAMA)\u7684\u7d44\u5408\u66f4\u80fd\u6e1b\u5c11\u60e1\u5316\u7684\u98a8\u96aa\uff1b(4) LABA/LAMA\u7684\u7d44\u5408\u8207LABA/ICS\u7684\u7d44\u5408\uff0c\u5169\u8005\u80ba\u708e\u4f75\u767c\u75c7\u767c\u751f\u7684\u6bd4\u4f8b\u6709\u986f\u8457\u5dee\u7570\uff1b(5)\u91dd\u5c0dC\u985e\u7684\u75c7\u72c0\u8f15\u4f46\u662f\u60e1\u5316\u98a8\u96aa\u9ad8\u7684COPD\u75c5\u60a3\uff0cGOLD 2017 COPD guideline\u5efa\u8b70\u512a\u5148\u8003\u616e\u4f7f\u7528LABA\u6cbb\u7642\u3002\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(5)\nE. (1)+(4)+(5)\n": "(D)", "106-7.\n\u95dc\u65bc\u63db\u6c23\u63a7\u5236(ventilatory control)\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. heyne-Stokes\u547c\u5438\u7d04\u4f54\u547c\u5438\u4e2d\u6b62\u75c7(sleep apnea)\u60a3\u8005\u76845~10%\uff0c\u5728\u6c92\u6709\u5fc3\u8870\u7aed(heart failure)\u60a3\u8005\u8eab\u4e0a\uff0c\u4e26\u4e0d\u5e38\u898b\u3002\nB. Hypoventilation syndrome\u5b9a\u7fa9\u70ba\u7f3a\u4e4f\u8db3\u5920\u7684\u901a\u6c23\u91cf\u4ee5\u7dad\u6301\u6b63\u5e38\u52d5\u8108\u8840\u4e2dCO2\u5206\u58d3(PaCO2)\u3002\u6700\u5e38\u898b\u7684\u60c5\u5f62\u70ba\u56b4\u91cd\u7684\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (chronic obstructive pulmonary disease\uff0cCOPD)\u6216\u75c5\u614b\u80a5\u80d6(morbid obesity)\u3002\nC. Central congenital hypoventilation syndrome\u4e4b\u524d\u88ab\u7a31\u70baOndine curse\uff0c\u662f\u7b2c\u56db\u5c0d\u67d3\u8272\u9ad4\u4e0a\u7684PHOX2B\u57fa\u56e0\u767c\u751f\u7a81\u8b8a\uff0c\u9020\u6210\u5c0dCO2\u7684\u901a\u6c23\u53cd\u61c9\u4e0d\u8db3\u3002\nD. \u5973\u6027\u3001PaCO2\u57fa\u790e\u503c\u8f03\u9ad8\u3001\u5fc3\u623f\u64b2\u52d5(atrial flutter)\u90fd\u662fCheyne-Stokes\u547c\u5438\u7684\u5371\u96aa\u56e0\u5b50\u3002\nE. 90% \u7684obesity-hypoventilation syndrome\u60a3\u8005\u5408\u4f75\u6709\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7( obstructive sleep apnea)\u3002\n": "(D)", "106-8.\n\u95dc\u65bc\u963b\u585e\u578b\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7 (Obstructive Sleep Apnea/Hypopnea Syndrome\uff0cOSAHS)\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\nA. GOLD 2017 COPD guideline\u5c07OSAHS\u7d0d\u5165COPD\u7684\u5171\u75c5\u75c7\u4e4b\u4e00\u3002\nB. \u5408\u4f75\u6709COPD\u8207OSAHS\u7684\u60a3\u8005\uff0c\u6bd4\u53ea\u6709\u55ae\u4e00\u75be\u75c5\u7684\u60a3\u8005\u9810\u5f8c\u8f03\u5dee\uff0c\u767d\u5929\u4e5f\u66f4\u5bb9\u6613\u767c\u751f\u80ba\u9ad8\u58d3(pulmonary hypertension)\u3002\nC. 2016\u5e74\u5927\u578b\u7684\u96a8\u6a5f\u5206\u6d3e\u5be6\u9a57SAVE study\u8b49\u5be6\u6301\u7e8c\u967d\u58d3\u6cbb\u7642(continuous positive airway pressure\uff0cCPAP)\u53ef\u4ee5\u9810\u9632\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u767c\u751f\u3002\nD. OSAHS\u5c0d\u5065\u5eb7\u9020\u6210\u7684\u4e0d\u5229\u5f71\u97ff\u662f\u900f\u904echronic intermittent hypoxemia \u8207sleep fragmentation\u6240\u9020\u6210\nE. \u4ee5\u9023\u7e8c\u967d\u58d3\u547c\u5438\u5668\u6cbb\u7642(CPAP)\u6cbb\u7642overlap syndnome\u53ef\u4ee5\u6539\u5584COPD\u9810\u5f8c\n": "(C)", "106-9.\n\u95dc\u65bc\u6c23\u5598 (asthma)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5438\u5165methacholin\u6216histamine\u6703\u9020\u6210\u652f\u6c23\u7ba1\u6536\u7e2e(bronchoconstriction)\u7a31\u70ba\u547c\u5438\u9053\u904e\u5ea6\u53cd\u61c9\u6027(airway hyperresponsiveness\uff0cAHR)\u3002\u9019\u662f\u6c23\u5598(asthma)\u7684\u7279\u5fb5\uff0c\u4f46\u5728\u5f88\u591aCOPD\u60a3\u8005\u8eab\u4e0a\u4e5f\u53ef\u898b\u5230\u3002\nB. \u547c\u6c23\u4e2d\u4e00\u6c27\u5316\u6c2e\u7684\u6fc3\u5ea6(fraction of exhaled nitric oxide, FeNO)\u5df2\u88ab2017 GINA (Global Initiative for Asthma) guideline \u5efa\u8b70\u53ef\u4ee5\u7528\u4f86\u5f15\u5c0e\u6cbb\u7642asthma (FENO-guided treatment)\u3002\nC. \u5c0d\u65bc\u540c\u6642\u6709\u6162\u6027\u9f3b\u7ac7\u708e(chronic rhinosinusitis)\u7684\u60a3\u8005\uff0c\u6cbb\u7642\u9f3b\u7ac7\u708e\u50c5\u80fd\u6539\u5584\u9f3b\u5b50\u548c\u547c\u5438\u9053\u7684\u75c7\u72c0\uff0c\u5c0d\u65bcasthma outcome\u4e26\u7121\u5e6b\u52a9\u3002\nD. Asthma with obesity\u662fasthma\u7684\u8868\u73fe\u578b(phenotype)\u4e4b\u4e00\uff0c\u6709\u8f03\u660e\u986f\u7684\u547c\u5438\u9053\u75c7\u72c0\uff0c\u4f46\u5f88\u5c11\u55dc\u4f0a\u7d05\u6027\u547c\u5438\u9053\u767c\u708e(eosinophilic airway inflammation)\u3002\nE. \u6c23\u5598\u75c5\u4eba\u7684\u8a55\u4f30\u4e2d\u5305\u62ec\u5171\u75c5\u5982\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7(obstructive sleep apnea)\u3002\n": "(BorC)", "106-10.\n\u95dc\u65bc\u6c23\u5598 (asthma)\u8a55\u4f30\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u75c7\u72c0\u662f\u5426\u63a7\u5236\u8981\u8a55\u4f30\u65e5\u591c\u9593\u75c7\u72c0\u3001\u662f\u5426\u9700\u8981\u7de9\u89e3\u7528\u85e5(reliever)\u548c\u6709\u6c92\u6709\u56e0\u70ba\u6c23\u5598\u65e5\u5e38\u7684\u6d3b\u52d5\u53d7\u9650\u3002\nB. \u6bcf\u5468\u767d\u5929\u767c\u4f5c\u5169\u6b21\u4ee5\u4e0a\u5c31\u5fc5\u9808\u8981\u898f\u5f8b\u7684controller(\u5438\u5165\u6027\u985e\u56fa\u9187)\u6cbb\u7642\u3002\nC. \u6c23\u5598\u63a7\u5236\u4e0d\u4f73\u6700\u5e38\u898b\u7684\u539f\u56e0\u662f\u7528\u85e5\u7684compliance\u4e0d\u597d\uff0c\u7279\u5225\u662f\u5438\u5165\u6027\u985e\u56fa\u9187\u3002\nD. \u6c23\u5598\u5b8c\u5168\u63a7\u52363\u500b\u6708\u5f8c\uff0c\u53ef\u4ee5\u505c\u7528controller\u6cbb\u7642\u3002\nE. \u5728\u6c23\u5598\u75c5\u4eba\u7684\u8a55\u4f30\u61c9\u5305\u62ec\u5171\u75c5\u5982\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7(obstructive sleep apnea)\n": "(D)", "106-11.\n80\u6b72\u7537\u6027\u6709\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(chronic obstructive pulmonary disease\uff0cCOPD)\uff0c\u547c\u5438\u56f0\u96e3\u3001\u54b3\u55fd\u6709\u9ec3\u75f0\u5df2\u6301\u7e8c\u4e00\u5468\uff0c\u5f8c\u4f86\u610f\u8b58\u8b8a\u5dee\u88ab\u9001\u5230\u6025\u8a3a\u3002\u5728\u6025\u8a3a\u6642\u6aa2\u67e5\u986f\u793a\uff0c\u610f\u8b58E1V1M3\uff0c\u8840\u58d3102/62 mmHg\uff0c\u5fc3\u8df3118/min\uff0c\u547c\u5438\u901f\u738712/min\uff0c\u80ba\u90e8\u6709\u660e\u986f\u6d78\u6f64\uff0cKUB\u5448\u73febowel loop dilatation\uff0c\u5c3f\u91cf\u6709\u6e1b\u5c11\u3002\u7121\u8178\u8815\u52d5\u97f3\uff0c\u7121\u8179\u819c\u708e\u7684\u5fb5\u8c61\u3002\u5728\u672a\u7528\u6c27\u6c23\u7684\u72c0\u614b\u4e0b\uff0c\u52d5\u8108\u6c23\u9ad4\u5206\u6790(arterial blood gas): pH =7.2, PaO2= 65 mmHg, PaCO2 =60 mmHg, HCO3= 18 mEq/L, SaO2 93%\u3002\u8840\u6e05\u4e2d[Na+]=140 mmol/L, [K+] = 2.8 mmol/L , [Cl-] =96 mmol/L, [BUN]=36 mg/dL, [Creatinin] =1.6\r\nmg/dL\u3002\u4ee5\u4e0b\u54ea\u4e9b\u63cf\u8ff0\u6216\u8655\u7f6e\u662f\u6b63\u78ba\u7684\uff1a\r\n(1) \u75c5\u60a3\u7684\u72c0\u614b\u662f\u4ee3\u8b1d\u6027\u9178\u8840\u75c7(metabolic acidosis)\u5408\u4f75\u547c\u5438\u9178\u8840\u75c7(respiratory acidosis)\u3002\r\n(2) \u70baCOPD\u5408\u4f75\u6025\u6027\u547c\u5438\u8870\u7aed\uff0c\u61c9\u512a\u5148\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u96d9\u76f8\u967d\u58d3\u547c\u5438\u5668(bi-level positive airway pressure\uff0cBiPAP)\u3002\r\n(3) \u70ba\u9ad8\u9670\u96e2\u5b50\u9593\u9699(Anion Gap)\u4e4b\u9178\u8840\u75c7\uff0c\u53ef\u80fd\u6709\u6557\u8840\u75c7\u5408\u4f75\u4f11\u514b\u5728\u9032\u884c\u3002\r\n(4) \u6613\u6709\u5fc3\u5ba4\u6027\u5fc3\u640f\u904e\u901f(ventricular tachycardia)\u767c\u751f\u3002\r\n(5) \u6709\u8178\u963b\u585e\u7684\u5fb5\u8c61\uff0c\u61c9\u6703\u8a3a\u5916\u79d1\u91ab\u5e2b\u9032\u884c\u6025\u8a3a\u624b\u8853\u3002\nA. (1)+(2)+(3)\nB. (3)+(4)+(5)\nC. (1)+(3)+(4)\nD. (1)+(2)+(5)\nE. (1)+(3)+(5)\n": "(C)", "106-12.\n70\u6b72\u4e4b\u7537\u6027\u75c5\u4eba\uff0c\u4e00\u5929\u5169\u5305\u83f8\u3002\u6700\u8fd1\u5341\u5e74\u4f86\u5e38\u6709\u75f0\u53ca\u54b3\u55fd\uff0c\u6700\u8fd1\u4e00\u5e74\u4f86\u4e26\u6709\u904b\u52d5\u5f8c\u547c\u5438\u56f0\u96e3\u4e4b\u75c7\u72c0\u3002\u5c31\u8a3a\u6642\u7406\u5b78\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b\uff1a\u8840\u58d3\u53ca\u8108\u640f\u6b63\u5e38\uff0c\u547c\u5438\u6bcf\u5206\u941822\u6b21\uff0c\u7121\u767c\u7d3a\u73fe\u8c61\uff0c\u80f8\u5ed3\u4e4b\u524d\u5f8c\u5f91\u8f03\u6b63\u5e38\u589e\u52a0\u3002\u53e9\u8a3a\u6642\u5448\u793a\u300c\u904e\u5ea6\u56de\u97ff\u300d\u4e4b\u73fe\u8c61\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u4e4b\u90e8\u4efd\u7d50\u679c\u5982\u4e0b\uff1apH7.36\uff0cPaO2 74mmHg\uff0cPaCO2 58mmHg\u3002\u75c5\u4eba\u70ba\u4ec0\u9ebc\u89ba\u5f97\u5598?\nA. \u56e0\u70ba\u8840\u6db2\u6c27\u6c23\u6fc3\u5ea6\u4e0d\u5920 (PaO2 74mmHg)\nB. \u56e0\u70ba\u8840\u6db2\u9178\u9e7c\u503c\u8d85\u904e\u6b63\u5e38\u503c\nC. \u56e0\u70ba\u4e8c\u6c27\u5316\u78b3\u6fc3\u5ea6\u592a\u9ad8 (PaCO2 58mmHg)\nD. \u80f8\u5ed3\u4e4b\u524d\u5f8c\u5f91\u589e\u52a0\uff0c\u547c\u5438\u808c\u7121\u6cd5\u6709\u6548\u904b\u4f5c\nE. \u54b3\u55fd\u75f0\u592a\u591a\u6240\u4ee5\u89ba\u5f97\u5598\n": "(C)", "106-13.\n\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(COPD\u7c21\u7a31\u80ba\u963b\u585e)\u75c5\u4eba\u80ba\u529f\u80fd\u6aa2\u67e5FVC 3600\u6beb\u5347\uff08\u9810\u6e2c\u503c3880\u6beb\u5347\uff09\uff0cFEV1 2160\u6beb\u5347\uff08\u9810\u6e2c\u503c3100\u6beb\u5347\uff09\u76ee\u524d\u75c5\u60c5\u7121\u986f\u8457\u8b8a\u5316\uff0c\u6b64\u6642\u75c5\u4eba\u6700\u4e0d\u9700\u8981\u7684\u6cbb\u7642\u70ba\u4f55?\nA. \u80ba\u708e\u93c8\u7403\u83cc\u75ab\u82d7\u53ca\u6d41\u611f\u75ab\u82d7\nB. \u6212\u83f8\nC. \u5438\u5165\u578b\u6c23\u7ba1\u64f4\u5f35\u5291\nD. \u80ba\u5fa9\u539f(\u80ba\u5fa9\u5065)\nE. \u53e3\u670d\u6297\u751f\u7d20\n": "(E)", "106-14.\n77\u6b72\u7537\u6027\u8001\u7159\u69cd\u4e00\u59291\u81f32\u5305\u83f8\uff0c\u8d85\u904e50\u5e74\uff0c\u56e0\u70ba\u8116\u5b50\u6478\u5230\u4e00\u9846\u6dcb\u5df4\u7d50\u4f86\u5230\u91ab\u9662\u3002\u4e00\u7cfb\u5217\u7684\u6aa2\u67e5\u767c\u73fe\u70ba\u5206\u5316\u4e0d\u597d\u7684\u80ba\u817a\u764c\uff0c\u5177\u6709KRAS Mutation\uff0c\u6709\u9aa8\u9abc\u53ca\u76ae\u4e0b\u7684\u8f49\u79fb\uff0c\u75c5\u4eba\u8a62\u554f\u514d\u75ab\u6cbb\u7642\u7684\u53ef\u80fd\u6027\uff0c\u4ee5\u4e0b\u4f55\u8005\u70ba\u662f\uff1f(1)\u5efa\u8b70\u505a\u751f\u7269\u6a19\u8a8c\u7d30\u80de\u7a0b\u5f0f\u6b7b\u4ea1-\u914d\u9ad41 (PD-L1)\u514d\u75ab\u7d44\u7e54\u67d3\u8272\uff0c\u816b\u7624\u7d30\u80de\u67d3\u8272\u8d85\u904e50%\uff0c\u53ef\u4ee5\u8003\u616e\u7b2c\u4e00\u7dda\u4f7f\u7528\uff1b(2)\u62bd\u83f8\u7684\u75c5\u4eba\u5c0d\u65bc\u514d\u75ab\u6cbb\u7642\u6548\u679c\u8f03\u597d\uff1b(3)KRAS Mutation \u5c0d\u65bc\u514d\u75ab\u6cbb\u7642\u6548\u679c\u8f03\u597d\uff1b(4)\u514d\u75ab\u6cbb\u7642\u5728\u80ba\u817a\u764c\u7684\u75c5\u4eba\u4e5f\u6709\u5e6b\u52a9\uff0c\u4f46\u8207\u5316\u7642\u7684\u5dee\u7570\uff0c\u8f03\u9c57\u72c0\u7d30\u80de\u764c\u4e0d\u660e\u986f\uff1b(5)\u80ba\u764c\u7684\u514d\u75ab\u6cbb\u7642\u6cd5\u662f\u5c07\u75c5\u4eba\u7684 T \u7d30\u80de\u5206\u96e2\u51fa\u4f86\u8207\u6297\u539f\u4e00\u8d77\u57f9\u990a\u5f8c\u518d\u6ce8\u5c04\u56de\u53bb\u3002\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(4)\nC. (1)+(2)+(3)\nD. (1)+(2)+(4)\nE. (1)+(2)\n": "(B)", "106-15.\n\u4e0b\u5217\u5c0d\u53f0\u7063\u80ba\u764c\u7684\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f(1)\u53f0\u7063\u5973\u6027\u80ba\u817a\u764c\uff0c\u62bd\u83f8\u7684\u6bd4\u4f8b\u4e0d\u523010%\uff1b(2)\u7537\u6027\u75c5\u4eba\u6700\u5e38\u898b\u7684\u662f\u9c57\u72c0\u7d30\u80de\u764c\uff1b(3)\u8207\u5c0f\u7d30\u80de\u80ba\u764c\u76f8\u8f03\uff0c\u9c57\u72c0\u7d30\u80de\u764c\u8207\u62bd\u83f8\u7684\u95dc\u806f\u6027\u66f4\u9ad8\uff1b(4)\u81fa\u7063\u80ba\u764c\u7684\u7537\u5973\u6bd4\u4f8b\u76f8\u8f03\u897f\u65b9\u570b\u5bb6\uff0c\u5973\u6027\u80ba\u764c\u6bd4\u4f8b\u504f\u9ad8\uff1b(5)\u56e0\u70ba\u6a19\u9776\u85e5\u7269\u53ca\u514d\u75ab\u6cbb\u7642\u7684\u767c\u5c55\uff0c\u80ba\u764c\u7684\u9810\u5f8c\u6bd4\u80c3\u764c\u53ca\u8178\u764c\u597d\u3002\nA. (1+)(3)+(4)\nB. (2)+(3)+(5)\nC. (1)+(3)+(5)\nD. (3)+(4)+(5)\nE. (2)+(4)+(5)\n": "(B)", "106-16.\n72\u6b72\u5973\u6027\u80a1\u9aa8\u9aa8\u6298\u958b\u5200\u4f4f\u9662\uff0c\u4e09\u5929\u5f8c\u7a81\u767c\u5598\uff0c\u7406\u5b78\u6aa2\u67e5\u5448\u73fe\u5fc3\u8df3\u6bcf\u5206\u9418120\u4e0b\uff0c\u547c\u5438\u6bcf\u5206\u941825\u6b21\uff0c\u8840\u6c27\u6fc3\u5ea694%(Room air)\uff0c\u6c92\u6709\u767c\u71d2\uff0c\u5fc3\u80ba\u6aa2\u67e5\u7121\u7570\u5e38\u3002\u5fc3\u96fb\u5716\u986f\u793a\u7ac7\u6027\u5fc3\u8df3\u904e\u901f(sinus tachycardia)\uff0c\u52d5\u8108\u8840\u6aa2\u67e5:\u9178\u9e7c\u503c7.52\uff0c\u4e8c\u6c27\u5316\u78b3\u5206\u58d3 (PaCO2)25mmHg\uff0c\u4e0b\u4e00\u6b65\u8a72\u505a\u751a\u9ebc\u6aa2\u67e5\u6216\u6cbb\u7642\uff1f\nA. \u5b89\u6170\u75c5\u4eba\u5598\u662f\u9aa8\u6298\u6b63\u5e38\u75c5\u7a0b\nB. \u7d66\u4e88\u93ae\u5b9a\u5291\nC. \u5b89\u6392\u5fc3\u81df\u8d85\u97f3\u6ce2\nD. \u5b89\u6392\u96fb\u8166\u65b7\u5c64\u80ba\u8840\u7ba1\u9020\u5f71\nE. \u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u6c23\u7ba1\u767c\u708e\n": "(D)", "106-17.\n32\u6b72\u5973\u6027\u88ab\u8a3a\u65b7\u70ba\u4e2d\u5ea6\u6301\u7e8c\u6027\u6c23\u5598\u3002\u4e09\u500b\u6708\u4f86\u6c23\u5598\u63a7\u5236\u826f\u597d\uff0c\u77ed\u6548\u6c23\u7ba1\u64f4\u5f35\u5291\u4e00\u9031\u4f7f\u7528\u4e0d\u5230\u4e00\u6b21\uff0c\u4e00\u500b\u6708\u665a\u4e0a\u6703\u56e0\u6c23\u5598\u9192\u4f86\u5169\u6b21\uff0c\u904b\u52d5\u6642\u4e0d\u6703\u53d7\u5230\u9650\u5236\u3002\u76ee\u524d\u7528\u85e5\u5305\u62ec\u5438\u5165\u985e\u56fa\u9187 fluticasone 50 ug/puff 2puff\u4e00\u5929\u5169\u6b21\uff0c\u9577\u6548\u6c23\u7ba1\u64f4\u5f35\u5291salmeterol 50 ug/puff\u4e00\u5929\u5169\u6b21\uff0cFEV1 \u76ee\u524d\u70ba83% predict value\uff0c\u63a5\u4e0b\u4f86\u8a72\uff1f\nA. \u52a0\u4e0a\u767d\u4e09\u70ef\u62ee\u6297\u5291(leukotriene antagonist) montelukast 10mg \u6bcf\u5929\u4e00\u6b21\nB. \u964d\u4f4e\u5438\u5165\u6027\u985e\u56fa\u9187 fluticasone \u523050ug/puff 1puff\u4e00\u5929\u4e00\u6b21\nC. \u505c\u6b62\u5438\u5165\u6027\u985e\u56fa\u9187\u4f7f\u7528\nD. \u505c\u6b62\u9577\u6548\u6c23\u7ba1\u64f4\u5f35\u5291 salmeterol \u4f7f\u7528\nE. \u7dad\u6301\u76ee\u524d\u6cbb\u7642\n": "(D)", "106-18.\n\u5168\u4e16\u754c\u9020\u6210\u652f\u6c23\u7ba1\u64f4\u5f35\u6700\u5e38\u898b\u7684\u539f\u56e0\uff1f\nA. \u56ca\u6027\u7e96\u7dad\u5316 cystic fibrosis\nB. \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\nC. \u80ba\u7d50\u6838\nD. \u5206\u679d\u687f\u83cc\u611f\u67d3(MAC infection)\nE. \u514d\u75ab\u7403\u86cb\u767d\u7f3a\u4e4f\u75c7\n": "(C)", "106-19.\n\u80ba\u7d50\u6838\u7684\u63a7\u5236\u6700\u91cd\u8981\u7684\u5c31\u662f\u53ca\u6642\u6aa2\u6e2c\uff0c\u4e26\u63d0\u4f9b\u6709\u6548\u7684\u77ed\u671f\u6cbb\u7642\u3002\u9032\u4e00\u6b65\u7684\u9810\u9632\u662f\u627e\u51fa\u6f5b\u4f0f\u7d50\u6838\u611f\u67d3\u7684\u7fa4\u7d44\u4e26\u7d66\u4e88\u6cbb\u7642\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u662f\uff1f(1)\u75be\u75c5\u7ba1\u5236\u7f72\u5df2\u57282016\u5e74\u63a8\u52d5\u5168\u5e74\u9f61\u5c64\u6f5b\u4f0f\u7d50\u6838\u5168\u90fd\u6cbb\u8a08\u756b\uff1b(2)\u6f5b\u4f0f\u7d50\u6838\u7684\u5075\u6e2c\uff0c\u4e94\u6b72\u4ee5\u4e0a\u4ee5\u7d50\u6838\u83cc\u76ae\u819a\u6e2c\u9a57(TST)\u70ba\u4e3b\uff0c\u4e94\u6b72\u4ee5\u4e0b\u4ee5\u4e19\u578b\u5e72\u64fe\u7d20\u91cb\u653e\u8a66\u9a57(IGRA)\u70ba\u4e3b\uff1b(3)\u9700\u505aCXR \uff0c\u6392\u9664\u80ba\u90e8\u6709\u6d3b\u52d5\u6027\u80ba\u7d50\u6838\uff1b(4)\u6cbb\u7642\u7684\u8655\u65b9\u572812\u6b72\u4ee5\u4e0b\u53ef\u4ee5\u8003\u616e9\u500b\u6708\u7684 Isoniazid \u62163\u500b\u6708\u7684 Isoniazid \u52a0 Rifapentine\uff1b(5)\u5efa\u8b70\u4ee5\u90fd\u6cbb\u8a08\u756b\u7d66\u85e5(Directly Observed Treatment Short-Course\uff0cDOTS)\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(4)+(5)\nD. (1)+(3)+(4)\nE. (3)+(4)+(5)\n": "(B)", "106-20.\n62\u6b72\u7537\u6027 COPD\u5728\u9580\u8a3a\u8ffd\u8e64\u6cbb\u7642\u3002\u5728\u4e00\u6b21\u91cd\u611f\u5192\u5f8c\uff0c\u75c5\u4eba\u89ba\u5f97\u8d8a\u4f86\u8d8a\u5598\uff0c\u54b3\u55fd\u52a0\u5287\uff0c\u5408\u4f75\u5c11\u8a31\u9ec3\u75f0\uff0c\u56e0\u6b64\u4f86\u5230\u6025\u8a3a\u3002\u672a\u767c\u4f5c\u6642\uff0c\u6700\u5f8c\u4e00\u6b21\u7684\u80ba\u529f\u80fdFEV1 42%\u3002\u5728\u6025\u8a3a\uff0c\u4e8c\u6c27\u5316\u78b3\u5206\u58d3 (PaCO2)78mmHg\uff0c\u75c5\u4eba\u5448\u73feaccessory muscle use \u53ca\u8f15\u5fae\u795e\u667a\u4e0d\u6e05\uff0c\u5169\u5074\u7030\u6f2b\u6027\u5598\u9cf4\u97f3\uff0c\u80f8\u90e8X\u5149\u7121\u80ba\u708e\u8de1\u8c61\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u61c9\u8a72\u505a\u751a\u9ebc\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\uff1f\nA. \u4f7f\u7528\u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\nB. \u63d2\u7ba1\u4f7f\u7528\u547c\u5438\u5668\nC. \u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20\nD. \u975c\u8108\u6ce8\u5c04\u985e\u56fa\u9187\nE. \u589e\u52a0\u6c23\u7ba1\u64f4\u5f35\u5291\u7684\u5291\u91cf\n": "(A)", "106-21.\n57\u6b72\u7537\u6027\uff0c\u5e74\u8f15\u6642\u505a\u904e\u7164\u7926\u5de5\u5341\u591a\u5e74\u3002\u6700\u8fd1\u56e0\u70ba\u5598\u3001\u54b3\u52a0\u5287\u4f86\u91ab\u9662\u6c42\u8a3a\uff0c\u4e0b\u5217\u54ea\u7a2e\u75be\u75c5\u8207\u4ed6\u7684\u8077\u696d\u7121\u95dc\uff1f\nA. \u80ba\u764c\nB. \u80ba\u7d50\u6838\nC. \u6162\u6027\u80ba\u963b\u585e\u6027\u80ba\u75be\nD. \u5875\u80ba\u75c7\nE. \u9593\u76ae\u7624(mesothelioma)\n": "(E)", "106-22.\n\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\uff0c\u4e0b\u5217\u54ea\u4e00\u500b\u6558\u8ff0\u70ba\u975e\uff1f\nA. \u6709\u4e9b\u75c5\u4eba\u53ef\u80fd\u5f9e\u5c0f\u5c31\u6709\u6253\u547c\u7684\u554f\u984c\uff0c\u800c\u9ad4\u91cd\u589e\u52a0\u5247\u6703\u52a0\u901f\u75be\u75c5\u9032\u884c\u3002\nB. \u4e3b\u8981\u7684\u5371\u96aa\u56e0\u5b50\u70ba\u5973\u6027\u53ca\u80a5\u80d6\nC. \u96a8\u8457\u5e74\u7d00\u589e\u52a0\uff0c\u767c\u75c5\u7684\u6a5f\u6703\u4e5f\u589e\u52a0\nD. \u5e38\u4f34\u96a8\u5fc3\u8840\u7ba1\u75be\u75c5\u53ca\u4ee3\u8b1d\u75be\u75c5\nE. \u8a3a\u65b7\u9700\u8981\u9760\u904e\u591c\u591a\u5c0e\u7761\u7720\u76e3\u6e2c(overnight polysomnography)\n": "(B)", "107-1.\n\u95dc\u65bc\u80ba\u764c\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e9b\u662f\u6b63\u78ba\u7684\uff1f (1). \u80ba\u764c\u514d\u75ab\u7d44\u7e54\u67d3\u8272\uff0cP63 \u4ee5\u53ca cytokeratin 5/6 \u662f\u967d\u6027\uff0c\u800cthyroid transcription factor-1 (TTF-1)\u662f\u9670\u6027\uff0c\u901a\u5e38\u6703\u8a3a\u65b7\u70ba \u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c (squamous cell carcinoma) (2). \u5728\u7b2c\u56db\u671f\u80ba\u764c\u7684\u6cbb\u7642\uff0c\u9a45\u52d5\u57fa\u56e0\u7a81\u8b8a (driver mutation)\u662f\u6c7a\u5b9a\u6a19\u9776\u6cbb\u7642\u6548\u679c\u7684\u91cd\u8981\u56e0\u5b50\uff0c\u4f46\u5176\u4ed6\u5171\u540c\u51fa\u73fe\u7684\u7a81\u8b8a (concurrent mutation)\u4e5f\u6703\u5f71\u97ff\u6a19\u9776\u6cbb\u7642\u7684\u6548\u679c (3). \u7b2c\u56db\u671f\u80ba\u817a\u764c\u7684\u6cbb\u7642\uff0c\u9808\u57f7\u884c\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4(epidermal growth factor receptor(EGFR)) \u7a81\u8b8a\u53caALK\uff08anaplastic lymphoma kinase\uff09\u57fa\u56e0\u8f49\u7f6e(translocation)\r\u7b49\u57fa\u56e0\u6aa2\u6e2c\u4ee5\u5916\uff0c\u514d\u75ab\u7d44\u7e54\u67d3\u8272\u6e2c\u5b9aPD-L1\u8868\u73fe\u91cf\uff0c\u4e5f\u662f\u6c7a\u5b9a\u85e5\u7269\u6cbb\u7642\u7684\u6839\u64da (4). EGFR \u7a81\u8b8a\u967d\u6027\u4e4b\u80ba\u817a\u764c\u75c5\u60a3\u4f7f\u7528erlotinib \u4e00\u5e74\u5f8c\u7522\u751f\u6297\u85e5\u6027\uff0c\u518d\u6b21\u816b\u7624\u5207\u7247\u767c\u73feEGFR T790M\u7a81\u8b8a\uff0c\u53ef\u4ee5\u4f7f\u7528afatinib\u4f86\u6cbb\u7642\u6297\u85e5\u7684\u816b\u7624 (5). \u7b2c\u56db\u671f\u80ba\u817a\u764c\uff0c\u6709\u57fa\u56e0\u7a81\u8b8a\u4e14\u4f7f\u7528\u9069\u5408\u6a19\u9776\u6cbb\u7642\u7684\u75c5\u60a3\uff0c\u6bd4\u6c92\u6709\u57fa\u56e0\u7a81\u8b8a\u7684\u75c5\u60a3\uff0c\u5b58\u6d3b\u8f03\u9577\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(3)+(5)\nC. (1)+(2)+(4)+(5)\nD. (2)+(3)+(5)\nE. (1)+(4)+(5)\n": "(B)", "107-2.\n\u95dc\u65bc\u9ad8\u6d77\u62d4\u75be\u75c5(high altitude illness)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u9ad8\u6d77\u62d4\u75be\u75c5\u767c\u751f\u539f\u56e0\uff0c\u662f\u56e0\u70ba\u9ad8\u5c71\u4e0a\u6c27\u6c23\u6fc3\u5ea6\u8f03\u4f4e\nB. \u6025\u6027\u9ad8\u5c71\u75c5(acute mountain sickness; AMS)\uff0c\u56e0\u7f3a\u6c27\u51fa\u73fe\u982d\u75db\u3001\u982d\u6688\u3001\u75b2\u5026\u3001\u5641\u5fc3\u3001\u5614\u5410\u7b49\u975e\u7279\u7570\u6027\u75c7\u72c0\nC. \u9ad8\u6d77\u62d4\u8166\u6c34\u816b(high-altitude cerebral edema; HACE)\u7684\u75c7\u72c0\u5305\u62ec\u56b4\u91cd\u982d\u75db\u3001\u55dc\u7761\u3001\u610f\u8b58\u4e0d\u6e05\u3001\u6b65\u614b\u4e0d\u7a69\u3001\u751a\u81f3\u660f\u8ff7\nD. \u722c\u5347\u7684\u901f\u5ea6\u53ca\u4ee5\u524d\u767c\u751f\u904e\u9ad8\u6d77\u62d4\u75be\u75c5\uff0c\u662f\u9ad8\u6d77\u62d4\u75be\u75c5\u767c\u751f\u7684\u91cd\u8981\u98a8\u96aa\u56e0\u5b50(risk factors)\nE. acetazolamide \u53ef\u4ee5\u7528\u4f86\u9810\u9632\u9ad8\u5c71\u75c5\n": "(A)", "107-3.\n\u95dc\u65bc\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\uff08obstructive sleep apnea syndrome\uff09\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\u662f\u6700\u5e38\u898b\u7684\u7761\u7720\u547c\u5438\u969c\u7919\uff08sleep-disordered breathing\uff09\uff0c\u7279\u5fb5\u662f\u54bd\u90e8\u7684\u547c\u5438\u9053\uff0c\u5728\u7761\u7720\u6642\u53cd\u8986\u963b\u585e\nB. \u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\u6700\u4e3b\u8981\u7684\u98a8\u96aa\u56e0\u5b50\uff08risk factors\uff09\u662f\u80a5\u80d6\u548c\u7537\u6027\nC. \u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\u6703\u589e\u52a0\u51a0\u72c0\u52d5\u8108\u5fc3\u81df\u75c5\u3001\u5fc3\u5f8b\u4e0d\u6574\u3001\u5fc3\u81df\u8870\u7aed\u3001\u4e2d\u98a8\u53ca\u7cd6\u5c3f\u75c5\u7684\u98a8\u96aa\nD. \u6574\u665a\u7684\u7761\u7720\u591a\u9805\u751f\u7406\u6aa2\u67e5(overnight polysomnogram) \u662f\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\u7684\u6a19\u6e96\u6aa2\u67e5\nE. \u6574\u665a\u7684\u7761\u7720\u591a\u9805\u751f\u7406\u6aa2\u67e5\uff0c\u767c\u73fe\u75c5\u60a3\u547c\u5438\u4e2d\u6b62\u6307\u6578\uff08apnea- hypopnea index\uff0cAHI\uff09\u5927\u65bc15\u6642\uff0c\u9700\u518d\u52a0\u4e0a\u591c\u9593\u547c\u5438\u969c\u7919\uff08nocturnal breathing disturbances \uff09\u6216\u767d\u5929\u55dc\u7761\u3001\u75b2\u5026\u7b49\u75c7\u72c0\uff0c\u624d\u80fd\u8a3a\u65b7\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\n": "(E)", "107-4.\n\u95dc\u65bc\u80f8\u817a\u7624(thymoma)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7d04\u4e00\u534a\u7684\u80f8\u817a\u7624\uff0c\u8a3a\u65b7\u6642\u4e26\u7121\u81e8\u5e8a\u75c7\u72c0\nB. \u80f8\u817a\u7624\u53ef\u6709\u816b\u7624\u4f34\u751f\u75c7\u5019\u7fa4(parapneoplastic syndrome)\uff0c\u5305\u62ec\u91cd\u75c7\u808c\u7121\u529b(myasthenia gravis)\uff0c\u7d14\u7d05\u8840\u7403\u518d\u751f\u4e0d\u826f (pure red cell aplasia)\uff0c\u4f4e\u4e19\u578b\u7403\u86cb\u767d\u8840\u75c7(hypogammaglobulinemia) \u7b49\nC. \u4f34\u6709\u91cd\u75c7\u808c\u7121\u529b\u7684\u80f8\u817a\u7624\u75c5\u60a3\uff0c\u5176\u9810\u5f8c\u6bd4\u7121\u91cd\u75c7\u808c\u7121\u529b\u7684\u80f8\u817a\u7624\u75c5\u60a3\u4f86\u5f97\u5dee\nD. \u80f8\u817a\u7624\u5c6c\u65bc\u653e\u5c04\u7dda\u6cbb\u7642\u654f\u611f(radiation sensitive)\u816b\u7624\uff0c\u56e0\u6b64\u653e\u5c04\u7dda\u6cbb\u7642\u5ee3\u6cdb\u4f7f\u7528\u65bc\u6cbb\u7642\u80f8\u817a\u7624\nE. \u5b8c\u5168\u624b\u8853\u5207\u9664\u662f\u6cbb\u7652\u80f8\u817a\u7624\u6700\u4f73\u7684\u65b9\u5f0f\n": "(C)", "107-5.\n\u95dc\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome,ARDS)\u7684\u80ba\u4fdd\u8b77\u547c\u5438\u5668\u7b56\u7565(lung-protective ventilator strategies)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6f6e\u6c23\u5bb9\u7a4d(tidal volume; TV)\u3000\u8a2d\u5b9a10 mL/kg\u7406\u60f3\u9ad4\u91cd\uff08ideal body weight\uff1bIBW\uff09\uff0c\u4ee5\u907f\u514d\u80ba\u6ce1\u584c\u9677\nB. \u9ad8\u539f\u58d3(plateau pressure)\u6700\u597d\u5c0f\u65bc30 cmH2O\nC. \u4e0d\u5b9c\u4f7f\u7528\u5410\u6c23\u672b\u7aef\u6b63\u58d3(positive end expiratory pressure)\uff0c\u4ee5\u514d\u9020\u6210\u547c\u5438\u5668\u5c0e\u81f4\u7684\u80ba\u640d\u50b7(ventilator-induced lung injury)\nD. \u589e\u52a0CO2 \u6392\u9664\u91cf\uff0c\u4ee5\u514d\u7522\u751f\u547c\u5438\u6027\u9178\u4e2d\u6bd2\uff08repiratory acidosis\uff09\nE. \u7d66\u4e88100% \u6c27\u6c23\n": "(B)", "107-6.\n\u95dc\u65bc\u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2(carbon monoxide poisoning)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e9b\u662f\u6b63\u78ba\u7684\uff1f (1). \u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790(arterial blood gas)\u6642\uff0c\u52d5\u8108\u8840\u6c27\u5206\u58d3\uff08arterial PaO2\uff09\u503c\u4e0b\u964d (2). \u8108\u640f\u8840\u6c27\u98fd\u548c\u5ea6\u5206\u6790(pulse oximetry)\uff0c\u6c27\u98fd\u548c\u5ea6\uff08oxygen saturation\uff09\u6b63\u5e38 (3). \u91cd\u5ea6\u5438\u83f8\u8005\uff0c\u5176\u78b3\u6c27\u8840\u7d05\u86cb\u767d\uff08carboxyhemoglobin\uff09 \u6e2c\u5f9712%\uff0c\u53ef\u8a3a\u65b7\u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2 (4). \u6cbb\u7642\u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2\u75c5\u60a3\uff0c\u7d66\u4e88\u6c27\u6c23\u6cbb\u7642\uff0c\u6fc3\u5ea6\u4e0d\u5b9c\u8d85\u904e60%\uff0c\u4ee5\u514d\u9020\u6210\u6c27\u4e2d\u6bd2\uff08oxygen toxicity\uff09(5). \u6cbb\u7642\u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2\u75c5\u60a3\uff0c\u8981\u6ce8\u610f\u6025\u6027\u5fc3\u808c\u7f3a\u6c27\uff08acute myocardial ischemia\uff09\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (2)+(5)\n": "(E)", "107-7.\n\u95dc\u65bc\u808b\u819c\u7a4d\u6db2(pleural effusion)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e9b\u662f\u6b63\u78ba\u7684\uff1f (1). \u808b\u819c\u7a4d\u6db2\u5e38\u898b\u7684\u539f\u56e0\u70ba\uff1b\u5fc3\u81df\u8870\u7aed (heart failure)\u3001\u80ba\u708e\u53ca\u60e1\u6027\u816b\u7624 (2). \u7576\u808b\u819c\u7a4d\u6db2\u8d85\u904e\u534a\u500b\u80f8\u5ed3\u6642\uff0c\u56e0\u70ba\u9ad8\u5ea6\u61f7\u7591\u60e1\u6027\u816b\u7624\u6240\u9020\u6210\uff0c\u6240\u4ee5\u76f4\u63a5\u505a\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\uff0c\u4ee5\u770b\u6e05\u695a\u7a4d\u6db2\u5167\u7684\u816b\u7624  (3).\u3000adenosine deaminase <40 IU/L\uff0c\u8981\u8003\u616e\u7d50\u6838\u6027\u80f8\u819c\u708e(tuberculosis pleuritis) (4). \u808b\u819c\u7a4d\u6db2\u4e4b\u8840\u6bd4\u5bb9\uff08hematocrit\uff09\u9054\u8840\u6db2\u4e4b\u8840\u6bd4\u5bb9\u768450%\u4ee5\u4e0a\uff0c\u8981\u8003\u616e\u8840\u80f8\uff08hemothorax\uff09(5). \u5c3f\u80f8\uff08urinothorax\uff09\u662f\u5c6c\u65bcexudate\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(4)+(5)\nD. (2)+(3)+(5)\nE. (3)+(4)+(5)\n": "(C)", "107-8.\n\u95dc\u65bc\u80ba\u9ad8\u58d3(pulmonary hypertension)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u80ba\u9ad8\u58d3\u7684\u5b9a\u7fa9\u70ba\uff1a\u65bc\u4f11\u606f\u72c0\u614b\uff0c\u5e73\u5747\u80ba\u52d5\u8108\u58d3\u5927\u65bc25\u6beb\u7c73\u6c5e\u67f1\nB. \u80ba\u52d5\u8108\u58d3\u529b\u53ef\u7d93\u7531\u7f6e\u5165\u80ba\u52d5\u8108\u5c0e\u7ba1(pulmonary artery catheter)\u76f4\u63a5\u6e2c\u5f97\uff0c\u6216\u8005\u85c9\u7531\u7d93\u80f8\u524d\u5fc3\u81df\u8d85\u97f3\u6ce2\u4f30\u7b97\nC. \u80ba\u81df\u8840\u6813\u52d5\u8108\u5167\u819c\u5207\u9664\u8853\uff08pulmonary thromboendarterectomy\uff09\u662f\u6cbb\u7642\u6162\u6027\u8840\u7ba1\u6813\u585e\u9020\u6210\u4e4b\u80ba\u52d5\u8108\u9ad8\u58d3(chronic thromboembolic pulmonary hypertension; CTEPH)\u7684\u65b9\u6cd5\nD. CTEPH \u8a3a\u65b7\u5e38\u4f7f\u7528\u80ba\u90e8\u704c\u6d41\u901a\u6c23\u6838\u91ab\u6383\u63cf (lung perfusion/ventilation scan)\nE. portopulmonary hypertension\u662f\u5c6c\u65bc\u809d\u80ba\u75c7\u5019\u7fa4(hepatopulmonary syndrome)\n": "(E)", "107-9.\n62\u6b72\u7537\u6027\uff0c\u662f\u4f4d\u8001\u83f8\u69cd(\u83f8\u9f61\u8d85\u904e30\u5305\u5e74)\uff0c\u4e3b\u8a34\u54b3\u55fd\u3001\u8d70\u5e73\u8def\u6703\u5598(\u6162\u6162\u8d70\u9084\u662f\u9700\u8981\u505c\u4e0b\u4f86\u4f11\u606f)\u3001\u6709\u6642\u6709\u5598\u9cf4\u8072(wheezing)\uff0c \u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u5169\u5074\u547c\u5438\u8072\u6e1b\u4f4e\u53ca\u5410\u6c23\u672b\u7aef\u5598\u9cf4\u8072\u3002\u80ba\u529f\u80fd\u6aa2\u67e5\uff1aFEV1 \u662f\u9810\u6e2c\u503c\u768465%\u3001FEV1/FVC 65%\u3002\u6839\u64da\u76ee\u524d\u7684\u6cbb\u7642\u6307\u5f15\uff0c\u4e0b\u5217\u54ea\u9805\u6cbb\u7642\u6700\u9069\u7576\uff1f\nA. \u5438\u5165\u578b\u985e\u56fa\u9187\u53ca\u80ba\u90e8\u5fa9\u5065\nB. \u9700\u8981\u6642\u4f7f\u7528\u77ed\u6548\u578b\u7684\u4e59\u578b\u81f4\u6548\u5291( short-acting beta2-agonist, SABA) \u53ca\u80ba\u90e8\u5fa9\u5065\nC. \u9577\u6548\u578b\u7684\u6bd2\u8548\u9e7c\u62ee\u6297\u5291(long-acting muscarinic antagonist, LAMA) \u53ca\u80ba\u90e8\u5fa9\u5065\nD. phosphodiesterase-4 inhibitor\u53ca\u80ba\u90e8\u5fa9\u5065\nE. \u975c\u8108\u6ce8\u5c04 aminophyline\u53ca\u80ba\u90e8\u5fa9\u5065\n": "(C)", "107-10.\n31\u6b72\u5973\u6027\uff0c\u5f9e\u5c0f\u5c31\u88ab\u8a3a\u65b7\u6c23\u5598\uff0c\u9577\u5927\u5f8c\u75c7\u72c0\u6539\u5584\u3002\u4f46\u6bcf\u5e74\u90fd\u6703\u767c\u4f5c\uff0c\u6700\u8fd1\u534a\u5e74\u8f03\u5e38\u611f\u5230\u80f8\u60b6\u53ca\u6c23\u4fc3\uff0c\u5230\u8a3a\u6240\u5c31\u8a3a\u5f8c\uff0c\u91ab\u5e2b\u7d66\u4e88\u77ed\u6548\u578b\u7684\u4e59\u578b\u81f4\u6548\u5291( short-acting beta2-agonist\uff0cSABA)\uff0c\u4f46\u5979\u5076\u800c\u624d\u7528\u3002\u6703\u56e0\u70ba\u5598\u534a\u591c\u9192\u4f86\uff0c\u7d04\u6bcf\u5468\u4e00\u6b21\u5230\u4e8c\u6b21\uff0c\u4f86\u5230\u4f60\u7684\u8a3a\u9593\u3002\u80ba\u529f\u80fd\u6aa2\u67e5\uff1aFEV1 \u662f\u9810\u6e2c\u503c\u768470%\u3001FEV1/FVC 75%\uff0c\u652f\u6c23\u7ba1\u64f4\u5f35\u8a66\u9a57(bronchodilator test) FEV1 \u6539\u558416%\u3002\u6839\u64da\u76ee\u524d\u7684\u6cbb\u7642\u6307\u5f15\uff0c\u4e0b\u5217\u54ea\u9805\u6cbb\u7642\u6700\u9069\u7576?\nA. \u5438\u5165\u578b\u985e\u56fa\u9187 +\u9577\u6548\u578b\u7684\u4e59\u578b\u81f4\u6548\u5291( long-acting beta2-agonist\uff0cLABA)\nB. \u9577\u6548\u578b\u7684\u6bd2\u8548\u9e7c\u62ee\u6297\u5291(long-acting muscarinic antagonist, LAMA)\nC. \u53e3\u670d\u985e\u56fa\u9187 +\u53e3\u670d\u4e59\u578b\u81f4\u6548\u5291\nD. omalizumab\nE. \u767d\u4e09\u70ef\u62ee\u6297\u5291(leukotriene antagonist) montelukast 10mg \u6bcf\u5929\u4e00\u6b21\n": "(A)", "107-11.\n31\u6b72\u5973\u6027\uff0c\u7121\u75c7\u72c0\uff0c\u5065\u5eb7\u6aa2\u67e5\u80f8\u90e8X\u5149\u5982\u5716\u6240\u793a\uff0c\u5b89\u6392\u96fb\u8166\u65b7\u5c64\u5982\u5716\u6240\u793a\uff0c\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4f55?\nA. Sarcoidosis\nB. Lymphoma\nC. Lung cancer\nD. Esophageal cancer\nE. Bronchogenic cyst\n": "(A)", "107-12.\n68\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u83f8\u9f6150\u5e74\uff0c\u54b3\u55fd\u3001\u5598\u52a0\u5287\u4f86\u5230\u9580\u8a3a\uff0cCXR\u986f\u793a\u5de6\u5074\u816b\u7624\u5408\u4f75\u7a4d\u6c34\uff0c\u5207\u7247\u6aa2\u67e5\u53ca\u62bd\u6c34\u6aa2\u67e5\u78ba\u8a8d\u662f\u80ba\u817a\u764c\u5408\u4f75\u60e1\u6027\u808b\u819c\u7a4d\u6c34\u3002\u57fa\u56e0\u6aa2\u6e2c\u70baKRAS\u7a81\u8b8a\uff0cPD-L1\u67d3\u827260%\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u6cbb\u7642\u6548\u679c\u6700\u597d\nA. \u6a19\u9776\u85e5\u7269\u6cbb\u7642\nB. \u514d\u75ab\u6cbb\u7642\nC. \u5316\u5b78\u6cbb\u7642 + \u6a19\u9776\u6cbb\u7642\nD. \u5316\u5b78\u6cbb\u7642\nE. \u514d\u75ab\u6cbb\u7642 + \u6a19\u9776\u6cbb\u7642\n": "(B)", "107-13.\n\u52a0\u8b77\u75c5\u623f\u4e2d\u8d85\u97f3\u6ce2\u53ef\u4ee5\u7528\u4f86\uff1a(1). \u8a55\u4f30\u8840\u7ba1\u5167\u9ad4\u6db2\u91cf (2). \u8a55\u4f30\u808b\u819c\u7a4d\u6db2 (3). \u5e6b\u5fd9 central line insertion (4). \u8a55\u4f30\u6c23\u80f8\u7bc4\u570d (5). \u8a55\u4f30\u5fc3\u5305\u819c\u7a4d\u6db2\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(4)+(5)\nC. (1)+(2)+(3)+(5)\nD. (2)+(4)+(5)\nE. (2)+(3)+(4)+(5)\n": "(C)", "107-14.\n\u4e0b\u5217\u5c0d\u6162\u6027\u963b\u585e\u6027\u80ba\u75be COPD \u7684\u6cbb\u7642\u4f55\u8005\u70ba\u5c0d\uff1f\nA. \u6839\u64da NEJM \u6700\u65b0\u7684\u7814\u7a76, triple therapy LABA + LAMA + ICS \u6bd4 Dual therapy LABA + LAMA \u53ef\u4ee5\u964d\u4f4e\u6025\u6027\u767c\u4f5c\u7684\u6b21\u6578\uff0c\u6240\u4ee5\u91cd\u5ea6COPD \u7684\u75c5\u4eba\u90fd\u61c9\u8a72\u63a5\u53d7 triple therapy\nB. phosphodiesterase-4 inhibitor roflumilast \u53ef\u4ee5\u7528\u4f86\u6cbb\u7642\u4ee5\u6162\u6027\u6c23\u7ba1\u708e\u8868\u73fe\u70ba\u4e3b\u7684\u56b4\u91cdCOPD\u75c5\u4eba\nC. \u9577\u6548\u6c23\u7ba1\u64f4\u5f35\u5291\u53ef\u4ee5\u6539\u5584\u75c5\u4eba\u75c7\u72c0\uff0c\u589e\u52a0FEV1\uff0c\u964d\u4f4e\u6025\u6027\u767c\u4f5c\u6b21\u6578\u53ca\u964d\u4f4e\u6b7b\u4ea1\u7387\nD. \u5438\u5165\u6027\u85e5\u5291\u662f\u6cbb\u7642COPD\u7684\u9996\u9078\u85e5\u7269\uff0c\u5982\u679c\u75c5\u4eba\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\uff0c\u8003\u616e\u76f4\u63a5\u63db\u85e5\nE. COPD\u6025\u6027\u767c\u4f5c\u9700\u8981\u4f4f\u9662\u6cbb\u7642\uff0c\u907f\u514d\u4f75\u767c\u75c7\u767c\u751f\n": "(B)", "107-15.\n70 \u6b72\u5973\u6027\u56e0\u70ba\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4\uff08ARDS\uff09\u4f4f\u9032\u52a0\u8b77\u75c5\u623f\uff0c\u5979\u56e0\u70ba\u5de6\u817f\u5927\u817f\u9aa8\u6298\uff0c\u525b\u525b\u63a5\u53d7\u624b\u8853\u3002\u624b\u8853\u76f8\u7576\u6210\u529f\uff0c\u8853\u4e2d\u63a5\u53d7PRBC 2U\uff0c\u8eab\u9ad8150cm\uff0c\u9ad4\u91cd80Kg\uff0c\u624b\u8853\u5b8c\u5f8c\u547c\u5438\u5668\u7121\u6cd5\u79fb\u9664\uff0c\u4e14\u6c27\u6c23\u9700\u8981\u91cf\u9010\u6f38\u589e\u52a0\uff0cPEEP 15 cmH2O \u4e14plateau pressure \u8d8a\u4f86\u8d8a\u9ad8\u3002\u8eab\u9ad4\u6aa2\u67e5\u9664\u4e86\u5169\u5074\u4e0b\u80ba\u91ce\u6709\u5438\u6c23\u671f\u56c9\u97f3\uff0c\u5fc3\u8df3\u8f03\u5feb\uff0c\u4e26\u7121\u5176\u5b83\u767c\u73fe\uff0c\u6700\u6709\u53ef\u80fd\u9020\u6210ARDS\u7684\u539f\u56e0\u70ba\u4f55 ?\nA. \u547c\u5438\u5668\u9020\u6210\u7684\u80ba\u640d\u50b7\nB. \u80a5\u80d6\u5f15\u8d77\u7684\u547c\u5438\u529f\u80fd\u4f4e\u4e0b\uff08hypoventilation syndrome\uff09\nC. \u8f38\u8840\u9020\u6210\u7684\u80ba\u640d\u50b7\nD. \u80ba\u6813\u585e\nE. \u5438\u5165\u6027\u80ba\u708e\n": "(D)", "107-16.\n71\u6b72\u7537\u6027\u56e0\u70ba\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (COPD) \u6025\u6027\u767c\u4f5c\u63d2\u7ba1\u5165\u52a0\u8b77\u75c5\u623f\uff0c\u5728\u7d66\u4e88\u985e\u56fa\u9187\u3001\u6c23\u7ba1\u64f4\u5f35\u5291\u53ca\u6297\u751f\u7d20\u5f8c\uff0c\u75c5\u60c5\u9010\u6f38\u6539\u5584\u3002\u4e94\u5929\u5f8c\u5617\u8a66\u62d4\u7ba1\u4f46spontaneous breathing trial (SBT) \u5931\u6557\u3002\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab\u6b63\u5e38\uff0c\u8840\u58d3132/85\u6beb\u7c73\u6c5e\u67f1\uff0c\u5fc3\u738775/min\uff0c\u547c\u5438\u97f3\u5169\u5074\u7686\u4e0b\u964d\u3002\u5728SBT\u5f8c\u75c5\u4eba\u770b\u8d77\u4f86\u6709\u9ede\u5026\u6020\u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u4f73\uff1f\nA. \u7e7c\u7e8c\u547c\u5438\u5668\u4f7f\u7528\u76f4\u5230SBT \u6210\u529f\u518d\u62d4\u7ba1\nB. \u76f4\u63a5\u62d4\u7ba1\u6539\u7528\u6b63\u58d3\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668\uff08bilevel noninvasive positive pressure ventilation\uff09\nC. \u76f4\u63a5\u62d4\u7ba1\u7d66\u4e88\u8db3\u5920\u6c27\u6c23\nD. \u5efa\u8b70\u6c23\u5207\nE. \u547c\u5438\u5668full support \u8b93\u75c5\u4eba\u4f11\u606f\uff0c\u5f85\u75c5\u4eba\u8212\u670d\u518d\u91cd\u65b0\u812b\u96e2\u8a13\u7df4\n": "(B)", "107-17.\n83\u6b72\u5973\u6027\u56e0\u70ba\u5598\u4f86\u9580\u8a3a\u5c31\u8a3a\uff0c\u9664\u4e86\u9ad8\u8840\u58d3\u53ca\u5076\u800c\u5fc3\u5f8b\u4e0d\u6574\u5916\uff0c\u6c92\u6709\u5176\u4ed6\u75be\u75c5\u3002\u6700\u8fd1\u66fe\u88ab\u8a3a\u65b7\u6709\u5fc3\u8870\u7aed\u3002\u80f8\u90e8X\u5149\u986f\u793a\u5de6\u5074\u55ae\u5074\u5927\u91cf\u7a4d\u6db2\u3002\u62bd\u6c34\u6aa2\u67e5\u7b26\u5408\u6ef2\u6db2\uff08exudate\uff09\uff0c\u7d30\u83cc\u57f9\u990a\u7121\u7d30\u83cc\uff0c\u4f46\u7d50\u6838\u83cc\u57f9\u990a\u9577\u51faMycobacterium tuberculosis\uff0c\u4ee5\u4e0b\u8655\u7f6e\u4f55\u8005\u6b63\u78ba\uff1a(1). \u653e\u7f6e\u80f8\u7ba1\u5f15\u6d41\uff0c\u907f\u514d\u81bf\u80f8\u60e1\u5316 (2). \u958b\u59cb\u56db\u5408\u4e00\u6cbb\u7642 (3). \u7167\u6703\u5916\u79d1\u505a\u525d\u812b\u8853(decortication) (4). \u653e\u7f6e\u8c6c\u5c3e\u578b\u5c0e\u7ba1\u5f15\u6d41 (5). \u80f8\u8154\u7a7f\u523a\u8853\u55ae\u6b21\u5f15\u6d41\nA. (1)+(2)+(3)\nB. (2)+(3)\nC. (2)+(4)\nD. (2)+(5)\nE. (2)+(3)+(4)\n": "(D)", "107-18.\n49\u6b72\u75c5\u4eba\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (COPD) \u4ee5\u652f\u6c23\u7ba1\u708e\u4f86\u8868\u73fe\u5e38\u6709\u9ec3\u75f0\u3002\u6578\u5468\u524d\u958b\u59cb\u75f0\u91cf\u589e\u52a0\uff0c\u4f86\u6025\u8a3a\u524d\u54b3\u4e86\u7d04 100ml \u7684\u9bae\u8840\u3002\u8eab\u9ad4\u6aa2\u67e5\u9664\u4e86\u8f15\u5fae\u7684\u5598\u9cf4\u8072\u5916\uff0c\u6c92\u6709\u5176\u4ed6\u7570\u5e38\uff0c\u62bd\u8840\u6aa2\u67e5 WBC\u3001 PT\u3001PTT\u3001Platelet\u3001Hb\u3001BUN\u3001Cre\u3001ALT\u5168\u90e8\u6b63\u5e38\uff0c\u9664\u4e86CXR\u5728\u5de6\u4e0b\u80ba\u8449\u6709\u4e9b\u6bdb\u73bb\u7483\u72c0\u7684\u6d78\u6f64\u3002\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u5c40\u90e8\u7684\u6bdb\u73bb\u7483\u6d78\u6f64\u5728\u5de6\u4e0b\u8449  \u3002\u8acb\u554f\u63a5\u4e0b\u4f86\u61c9\u8a72\u505a\u751a\u9ebc\uff1f\nA. \u96fb\u8166\u65b7\u5c64\u5f15\u5c0e\u5207\u7247\nB. \u7d66\u4e88\u6297\u751f\u7d20 ciprofloxacin\nC. \u80ba\u90e8\u9ad8\u89e3\u50cf\u5ea6\u96fb\u8166\u65b7\u5c64\nD. \u652f\u6c23\u7ba1\u93e1\u6aa2\u67e5\nE. \u8840\u6db2\u57f9\u990a\n": "(D)", "107-19.\n75\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(COPD)\u6025\u6027\u767c\u4f5c\u63d2\u7ba1\u9032\u52a0\u8b77\u75c5\u623f\u3002\u5728ICU\u7d66\u4e88\u93ae\u975c\u5291\u53ca\u547c\u5438\u5668\u652f\u6301\u3002\u958b\u59cb\u7684\u5c16\u5cf0\u5438\u6c23\u58d3\u529b\uff08Peak inspiratory pressure\uff09\u70ba30 cmH2O\uff0c\u9ad8\u539f\u671f\u58d3\u529b15 cmH2O\u3002\u4e00\u500b\u5c0f\u6642\u5f8c\uff0c\u5c16\u5cf0\u5438\u6c23\u58d3\u529b\u70ba42 cmH2O\uff0c\u9ad8\u539f\u671f\u58d3\u529b26 cmH2O\uff0c FiO2 0.5\uff0cSaturation 90%\u3002\u8eab\u9ad4\u6aa2\u67e5\u5f8c\u6c92\u6709\u767c\u71d2\uff0c\u8840\u58d3100/60 mmHg\uff08\u5728\u6025\u8a3a\u70ba150/100 mmHg\uff09\uff0c\u5fc3\u8df3110/min\uff0c\u547c\u5438\u6b21\u657830/min\uff0c\u9838\u975c\u8108\u6012\u5f35\uff0c\u5fc3\u97f3\u8f03\u5c0f\u8072\uff0c\u547c\u5438\u97f3\u5c0d\u7a31\u4f46\u5c0f\u8072\u3002\u4ee5\u4e0b\u54ea\u7a2e\u60c5\u6cc1\u6700\u80fd\u89e3\u91cb\u75c5\u4eba\u6c23\u9053\u58d3\u529b\u7684\u8b8a\u5316\uff1f\nA. \u75f0\u591a\uff0c\u75f0\u584a\u5361\u4f4f\nB. \u6c23\u7ba1\u5167\u7ba1\u6298\u5230\nC. \u93ae\u975c\u5291\u904e\u91cf\nD. \u6c23\u80f8\nE. \u81ea\u767c\u6027\u5410\u6c23\u6027\u6b63\u58d3(Auto PEEP)\n": "(E)", "107-20.\n75\u6b72\u7537\u6027\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5severe emphysema group D\uff0c\u8f15\u5fae\u7684\u6d3b\u52d5\u5c31\u5bb9\u6613\u5598\u3002\u5e73\u6642\uff08Ambient air\uff09\u7684\u8840\u6c27\u6fc3\u5ea6\u70ba 90%\uff0c\u5076\u723e\u6389\u5230 88%\u4ee5\u4e0b\uff0c\u4f46\u5f88\u5feb\u5c31\u56de\u523090%\uff0c\u904b\u52d5\u6642\u8840\u6c27\u6fc3\u5ea6\u7d04\u70ba 88\u223c90%\uff0c\u5076\u723e\u6389\u5230 88%\u4ee5\u4e0b\uff0c\u5bb6\u5c6c\u8a62\u554f\u9700\u4e0d\u9700\u8981\u4f7f\u7528\u6c27\u6c23\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u4e0d\u9700\u9577\u671f\u4f7f\u7528\uff0c\u56e0\u70ba\u4e0d\u6703\u5f71\u97ff\u4f4f\u9662\u5929\u6578\nB. \u4e0d\u9700\u9577\u671f\u4f7f\u7528\uff0c\u56e0\u70ba\u4e0d\u6703\u5f71\u97ff\u6b7b\u4ea1\u7387\nC. \u9808\u9577\u671f\u4f7f\u7528\uff0c\u6703\u964d\u4f4e\u6b7b\u4ea1\u7387\nD. \u8003\u616e\u8840\u6c27\u6fc3\u5ea6\u4f4e\u65bc88% \u6642\u518d\u4f7f\u7528\nE. \u4e0d\u9700\u9577\u671f\u4f7f\u7528\uff0c\u4e0d\u6703\u5f71\u97ff\u80ba\u529f\u80fd\n": "(C)", "107-21.\n71\u6b72\u7537\u6027\u8001\u83f8\u69cd\uff0c\u4e00\u5929\u4e00\u5305\u83f8\u5df2\u7d9350\u5e74\uff0c\u62b1\u6028\u75f0\u591a\uff0c\u8d70\u8def\u6703\u5598\uff0c\u54b3\u55fd\u52a0\u5287\uff0c\u9580\u8a3a\u91ab\u5e2b\u5b89\u6392\u80ba\u529f\u80fd\u6aa2\u67e5\uff0cFVC 3600\u6beb\u5347\uff08\u9810\u6e2c\u503c3880\u6beb\u5347\uff09\uff0cFEV1  2160\u6beb\u5347\uff08\u9810\u6e2c\u503c3100\u6beb\u5347\uff09\uff0c\u4e26\u958b\u59cb\u7d66\u4e88tiotropium\uff08spiriva respimat\uff09\u3002\u75c7\u72c0\u96d6\u6709\u6539\u5584\uff0c\u4f46\u4ecd\u5e38\u6709\u5598\u54b3\u7684\u60c5\u5f62\u3002\u9580\u8a3a\u91ab\u5e2b\u8003\u616e\u6539\u8b8a\u8655\u65b9\uff0c\u4e0b\u5217\u4f55\u8005\u6703\u512a\u5148\u8003\u616e\uff1f\nA. \u7dad\u6301\u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u589e\u52a0\u4f4e\u5291\u91cf\u53e3\u670d\u985e\u56fa\u9187\nB. \u7dad\u6301\u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u52a0\u5438\u5165\u578b\u77ed\u6548\u03b22 agonist (LAMA + SABA)\nC. \u8003\u616e\u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u52a0\u5438\u5165\u578b\u985e\u56fa\u9187\uff08LAMA+ICS\uff09\nD. \u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u52a0\u5438\u5165\u578b\u9577\u6548\u03b22 agonist (LAMA + LABA)\nE. \u5438\u5165\u578b\u9577\u6548\u03b22 agonist\uff0c\u52a0\u5438\u5165\u578b\u985e\u56fa\u9187 (LABA + ICS)\n": "(D)", "107-22.\n\u6709\u95dc\u80ba\u764c\uff0c\u4e0b\u5217\u54ea\u500b\u63cf\u8ff0\u662f\u932f\u8aa4\uff1f\nA. \u5728\u53f0\u7063\u80ba\u764c\u7684\u75c5\u4eba\uff0c\u76f8\u8f03\u4e16\u754c\u5176\u4ed6\u570b\u5bb6\uff0c\u5973\u6027\u6709\u8f03\u9ad8\u7684\u6bd4\u4f8b\nB. \u53f0\u7063\u7537\u6027\u75c5\u4eba\u9c57\u72c0\u7d30\u80de\u764c\u7684\u4eba\u6578\u6bd4\u80ba\u817a\u764c\u4f86\u7684\u9ad8\nC. \u5728\u53f0\u7063\uff0c\u5973\u6027\u80ba\u817a\u764c\u5438\u83f8\u6bd4\u4f8b\u751a\u4f4e\nD. \u7f8e\u570b\u6709\u4e00\u7a2e\u8da8\u52e2\u5c31\u662f\u80ba\u817a\u764c\u6bd4\u4f8b\u589e\u52a0\uff0c\u7279\u5225\u662f\u5e74\u8f15\u5973\u6027\u4e0d\u62bd\u83f8\u7684\u65cf\u7fa4\nE. \u5c0f\u7d30\u80de\u80ba\u764c\u8207\u5438\u83f8\u9ad8\u5ea6\u76f8\u95dc\n": "(B)", "108-1.\n\u6709\u95dc\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598(Aspirin-sensitive asthma)\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba? (1)\u901a\u5e38\u5148\u767c\u751f\u904e\u654f\u6027\u9f3b\u708e(Perennial rhinitis)\u8207\u9f3b\u606f\u8089(Nasal polyps)\u4e4b\u75c5\u5fb5\uff1b(2)\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598\u6bd4\u8f03\u4e0d\u6703\u88ab\u75c5\u6bd2\u611f\u67d3\u5f15\u767c\u6025\u6027\u767c\u4f5c (Exacerbations of asthma)\uff1b(3)\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598\u5e38\u5e38\u5728\u540c\u4e00\u5bb6\u5ead\u4e2d\u6703\u6709\u591a\u4f4d\u6210\u54e1\u767c\u751f\uff1b(4)cyclooxygenase 1 (COX-1) \u6291\u5236\u5291\u8f03COX-2 \u6291\u5236\u5291\u5bb9\u6613\u5f15\u767c\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598\uff1b(5)\u6cbb\u7642\u6548\u679c\u4ee5\u6297\u767d\u4e09\u70ef\u7d20(Antileukotrienes)\u8f03\u4f73\uff0c\u5438\u5165\u6027\u985e\u56fa\u9187 (Inhaled corticosteroids)\u4e0d\u5efa\u8b70\u4f7f\u7528\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(2)+(4)\nD. (1)+(4)\nE. (3)+(4)+(5)\n": "(D)", "108-2.\n\u6709\u95dc\u5438\u5165\u6027\u80ba\u708e(Aspiration pneumonia)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4? (1)\u81f4\u75c5\u7684\u83cc\u7a2e\u5728\u6700\u8fd1\u9019\u5e7e\u5e74\u4f86\uff0c\u53ad\u6c27\u83cc(Anaerobes)\u7684\u91cd\u8981\u6027\u6f38\u6f38\u9ad8\u65bc\u597d\u6c27\u83cc(aerobes)\uff1b(2)\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(Chronic obstructive pulmonary disease)\u662f\u5176\u4e2d\u4e00\u500b\u5371\u96aa\u56e0\u5b50\uff1b(3)\u7ba1\u704c\u98f2\u98df(Tube feeding)\u5f88\u5b89\u5168\uff0c\u53ef\u4ee5\u907f\u514d\u541e\u56a5\u529f\u80fd\u4e0d\u4f73\u7684\u75c5\u60a3\u767c\u751f\u5438\u5165\u6027\u80ba\u708e\uff1b(4)\u53ea\u6709\u5728\u5438\u5165\u5927\u91cf\u8207\u9178\u6027\u7684\u80c3\u5bb9\u7269(Gastric contents)\u6642\uff0c\u624d\u5bb9\u6613\u767c\u751fChemical pneumonitis\uff1b(5)\u4f86\u81ea\u793e\u5340(Community -acquired)\u7684\u75c5\u60a3\u767c\u751f\u5438\u5165\u6027\u80ba\u708e\uff0c\u53ef\u8003\u616e\u7d66\u4e88ampicillin\u2013sulbactam,\rcarbapenem (ertapenem), \u6216fluoroquinolone (levofloxacin or moxifloxacin)\u7684\u6cbb\u7642\nA. (1)+(2)+(3)\nB. (1)+(3)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (3)+(4)\n": "(B)", "108-3.\n\u6709\u95dc\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316(Idiopathic Pulmonary Fibrosis, IPF)\u4e4b\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba? (1)\u80ba\u529f\u80fd\u6aa2\u67e5\u7d50\u679c\u901a\u5e38\u5448\u73fe\u4e00\u6c27\u5316\u78b3\u80ba\u7030\u6563\u91cf(Diffusing capacity of the lung for carbon monoxide, DLco)\u964d\u4f4e\uff1b(2)\u5371\u96aa\u56e0\u5b50\u5305\u62ec\u9ad8\u9f61, \u7537\u6027\u8207\u62bd\u83f8\u7b49\uff1b(3)\u8a3a\u65b7IPF\u4ee5\u81e8\u5e8a\u8207\u80ba\u90e8\u9ad8\u89e3\u50cf\u5ea6\u96fb\u8166\u65b7\u5c64\u6383\u63cf(HRCT\uff0cHigh Resolution Computed Tomography )\u70ba\u4e3b\uff0c\u4e0d\u4e00\u5b9a\u9700\u8981\u9032\u884c\u80ba\u5207\u7247Lung biopsy)\u6aa2\u67e5\uff1b(4)IPF\u60a3\u8005\u4e0d\u5efa\u8b70\u63a5\u53d7\u80ba\u79fb\u690d(Lung transplantation)\u624b\u8853\uff0c\u56e0\u70ba\u6709\u5f88\u9ad8\u7684\u6bd4\u4f8b\u6703\u5fa9\u767c\uff1b(5)\u4f7f\u7528Nintedanib \u6216 Pirfenidone\u6cbb\u7642IPF\uff0c\u7121\u6cd5\u964d\u4f4e\u6b7b\u4ea1\u7387\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(2)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(A)", "108-4.\n\u95dc\u65bc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome, ARDS)\u7684\u67cf\u6797\u5b9a\u7fa9(Berlin definition)\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u5f9e\u5371\u96aa\u56e0\u5b50\u7684\u66b4\u9732\u5230ARDS\u7684\u767c\u751f\u70ba7\u5929\u5167\nB. \u5f71\u50cf\u5b78\u8a3a\u65b7\u5305\u62ec\u80f8\u90e8X\u5149\u6216\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\nC. \u9700\u5b8c\u5168\u6392\u9664\u5fc3\u81df\u8870\u7aed\u6216Volume overload\nD. \u91cd\u5ea6ARDS\u5b9a\u7fa9\u70ba PaO2/FiO2 \u2266 100 mmHg\nE. \u53d6\u6d88\u6025\u6027\u80ba\u640d\u50b7(Acute lung injury, ALI)\u4e00\u8a5e\n": "(C)", "108-5.\n\u4e0b\u5217\u6709\u95dc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(Acute respiratory distress syndrome, ARDS)\u7684\u6cbb\u7642\u4f55\u8005\u6709\u8aa4?\nA. \u53ca\u65e9\u627e\u5230\u4e26\u6cbb\u7642\u9020\u6210ARDS\u7684\u75c5\u56e0\nB. \u547c\u5438\u5668\u4f7f\u7528\u4f4e\u6f6e\u6c23\u91cf(Tidal volume, 6ml/kg)\uff0c\u4ee5\u6e1b\u5c11\u547c\u5438\u5668\u5c0e\u81f4\u80ba\u640d\u50b7(Ventilator-induced lung injury)\nC. \u4fef\u81e5\u59ff(Prone position)\u53ef\u6e1b\u5c11\u4e2d\u91cd\u5ea6ARDS\u60a3\u8005(PaO2/FiO2 < 120 mmHg)\u4e4b\u6b7b\u4ea1\u7387\nD. \u9ad4\u5916\u819c\u6c27\u5408(Extracorporeal Membrane Oxygenation\uff0cECMO)\u7684\u65e9\u671f\u4f7f\u7528\uff0c\u53ef\u6539\u5584\u56b4\u91cdARDS\u60a3\u8005\u7684\u5b58\u6d3b\u7387\nE. \u4e0d\u5efa\u8b70\u5e38\u898f\u4f7f\u7528\u985e\u56fa\u9187(Glucocorticoids)\n": "(D)", "108-6.\n\u4e0b\u5217\u4f55\u8005\u975e\u6557\u8840\u6027\u4f11\u514b(Septic shock)\u6216\u6557\u8840\u75c7(Sepsis)\u7684\u6700\u65b0\u5b9a\u7fa9(Sepsis-3)?\nA. \u7591\u4f3c\u6216\u78ba\u8a3a\u75c5\u83cc\u611f\u67d3(Suspected or documented infection)\nB. \u51fa\u73fe\u5927\u65bc\u6216\u7b49\u65bc\u5169\u9805\u5168\u8eab\u6027\u708e\u6027\u53cd\u61c9\u75c7\u5019\u7fa4\u8981\u7d20(Systemic inflammatory response syndrome criteria)\nC. \u51fa\u73fe\u5927\u65bc\u6216\u7b49\u65bc\u5169\u9805\u76f8\u7e7c\u5668\u5b98\u8870\u7aed\u8a55\u5206(Sequential organ failure assessment, SOFA, point)\nD. \u9700\u4f7f\u7528\u8840\u7ba1\u589e\u58d3\u5291(Vasopressor)\u4ee5\u7dad\u6301\u5e73\u5747\u52d5\u8108\u8840\u58d3\u226765 mmHg\nE. \u5728\u7d66\u4e88\u9069\u7576\u8f38\u6db2\u6cbb\u7642\u60c5\u6cc1\u4e0b\uff0c\u8840\u6f3f\u4e73\u9178(Serum lactate)\u4ecd>2.0 mmol/L\n": "(B)", "108-7.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u9ecf\u6db2\u963b\u585e\u6027\u80ba\u75be\u75c5(Muco-obstructive lung diseases)?\nA. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(Chronic obstructive pulmonary disease)\nB. \u6c23\u5598(Asthma)\nC. \u56ca\u72c0\u7e96\u7dad\u5316 (Cystic fibrosis)\nD. \u5148\u5929\u6027\u7e96\u6bdb\u904b\u52d5\u7570\u5e38\u75c7(Primary ciliary dyskinesia)\nE. \u975e\u56ca\u72c0\u7e96\u7dad\u5316\u652f\u6c23\u7ba1\u64f4\u5f35\u75c7(Non\u2013cystic fibrosis bronchiectasis)\n": "(B)", "108-8.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668(Noninvasive ventilation)\u7684\u4f7f\u7528\u7981\u5fcc(Contraindication)\nA. \u5fc3\u8df3\u6216\u547c\u5438\u505c\u6b62(Cardiac or respiratory arrest)\nB. \u56b4\u91cd\u8178\u80c3\u9053\u51fa\u8840(Severe gastrointestinal bleeding)\nC. \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316(Chronic obstructive pulmonary disease with acute exacerbation)\nD. \u4e0a\u547c\u5438\u9053\u963b\u585e(Upper airway obstruction)\nE. \u8840\u6db2\u52d5\u529b\u4e0d\u7a69\u5b9a(Hemodynamic instability)\n": "(C)", "108-9.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u6ffe\u51fa\u6027\u808b\u819c\u7a4d\u6c34(Transudative pleural effusion) \u5f62\u6210\u4e4b\u75c5\u56e0?\nA. \u814e\u75c5\u75c7\u5019\u7fa4(Nephrotic syndrome)\nB. \u80ba\u584c\u9677(Atelectasis)\nC. \u4e0a\u8154\u975c\u8108\u963b\u585e(Superior vena cava obstruction)\nD. \u80ba\u6813\u585e(Pulmonary embolism)\nE. \u809d\u786c\u5316(Cirrhosis)\n": "(D)", "108-10.\n\u4e0b\u5217\u6709\u95dcParapneumonic effusions\u4e4b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u662f\u6700\u5e38\u898b\u9020\u6210\u6ef2\u51fa\u6027\u808b\u819c\u7a4d\u6db2(Exudative pleural effusions)\u7684\u539f\u56e0\nB. \u6700\u91cd\u8981\u7684\u6cbb\u7642\u662f\u7d66\u4e88\u9069\u7576\u7684\u6297\u751f\u7d20(Antibiotics)\nC. \u9662\u5167\u611f\u67d3(Hospital-acquired infection)\u6b7b\u4ea1\u7387\u9ad8\u65bc\u793e\u5340\u611f\u67d3(Community-acquired infection)\nD. \u81bf\u80f8(empyema)\u5efa\u8b70\u4f7f\u752816-French\u4ee5\u4e0a\u7684\u80f8\u7ba1(Chest tube)\u6216\u8c6c\u5c3e\u5df4\u5c0e\u7ba1(Pigtail catheter)\u5f15\u6d41\nE. \u82e5\u51fa\u73fe\u8154\u5ba4\u5316\u808b\u819c\u7a4d\u6db2(Loculated pleural fluid)\u5c31\u8981\u8003\u616e\u7167\u6703\u80f8\u8154\u5916\u79d1\u9032\u884c\u5f71\u50cf\u8f14\u52a9\u80f8\u8154\u93e1\u624b\u8853(Video-assisted thoracoscopic surgery , VATS)\n": "(D)", "108-11.\n\u4e0b\u5217\u6709\u95dc\u7f8e\u570b\u570b\u5bb6\u80ba\u764c\u7be9\u6aa2\u8a66\u9a57(The National Lung Screening Trial, NLST)\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u63a5\u53d7\u7be9\u6aa2\u7684\u9ad8\u5371\u96aa\u65cf\u7fa4\u5fc5\u9808\u7b26\u540855-74\u6b72\u4e14\u5438\u83f8\u53f2\u5927\u65bc30\u5305\u83f8-\u5e74(Pack-year )\uff0c\u800c\u6212\u83f8\u8005\u5247\u9700\u6212\u83f8\u5341\u4e94\u5e74\u5167\nB. \u8a66\u9a57\u7d44\u4f7f\u7528\u4f4e\u5291\u91cf\u80f8\u90e8\u96fb\u8166\u65b7\u7be9\u6aa2, \u4e0d\u9700\u6253\u986f\u5f71\u5291\nC. \u5c0d\u7167\u7d44\u70ba\u4f7f\u7528\u80f8\u90e8X\u5149\u7be9\u6aa2\nD. \u8a66\u9a57\u7d44\u7684\u5047\u967d\u6027\u7387(False-positive rate)\u4f4e\u65bc\u5c0d\u7167\u7d44\nE. \u8a66\u9a57\u7d44\u76f8\u8f03\u65bc\u5c0d\u7167\u963b\u53ef\u964d\u4f4e\u80ba\u764c\u6b7b\u4ea1\u738720%\n": "(D)", "108-12.\n\u7b2c\u4e09\u671f\u7121\u6cd5\u63a5\u53d7\u624b\u8853\u5207\u9664\u4e4b\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005(Unresectable non-small-cell lung cancer), \u5728\u9032\u884c\u5b8c\u540c\u6b65\u5316\u5b78\u653e\u5c04\u6cbb\u7642(Concurrent chemoradiotherapy, CCRT)\u5f8c\uff0c\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\u53ef\u5ef6\u9577\u75c5\u60a3\u6574\u9ad4\u5b58\u6d3b(Overall survival)\nA. \u5bc6\u5207\u8ffd\u8e64\uff0c\u4e0d\u9700\u8ffd\u52a0\u4efb\u4f55\u6cbb\u7642\nB. \u978f\u56fa\u6027\u5316\u5b78\u6cbb\u7642(Consolidation chemotherapy)\u56db\u500b\u7642\u7a0b\nC. \u6a19\u9776\u6cbb\u7642(Targeted therapy)\u4f7f\u7528\u4e00\u5e74\nD. \u65bd\u6253Pembrolizumab\u4e00\u5e74\nE. \u65bd\u6253Durvalumab\u4e00\u5e74\n": "(E)", "108-13.\n18\u6b72\u5e74\u8f15\u7537\u6027\uff0c\u5065\u5eb7\u72c0\u6cc1\u826f\u597d\uff0c\u5728\u6253\u7403\u6642\u7a81\u767c\u6027\u5598\u53ca\u80f8\u60b6\uff0c\u4f86\u5230\u6025\u8a3a\uff0c\u521d\u6b65\u8a3a\u65b7\u7591\u4f3c\u6c23\u80f8\uff0c\u4f60\u9810\u671f\u6703\u6709\u90a3\u4e9b\u767c\u73fe(1)\u80f8\u90e8 X-ray \u770b\u5230pleural line\uff1b(2)\u807d\u8a3a\u60a3\u5074\u547c\u5438\u97f3\u4e0b\u964d\uff1b(3)\u6263\u8a3a\u60a3\u5074\u6fc1\u97f3(dullness)\u660e\u986f\uff1b(4)\u89f8\u8a3a\u5169\u5074\u5c0d\u7a31\u64f4\u5f35\uff1b(5)\u80f8\u8154\u8d85\u97f3\u6ce2\u60a3\u5074\u770b\u4e0d\u5230\u808b\u819c\u6ed1\u52d5\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(4)\nC. (1)+(2)+(3)\nD. (1)+(2)+(3)+(5)\nE. (1)+(2)+(5)\n": "(E)", "108-14.\n40\u6b72\u5973\u6027\uff0c\u5c0f\u6642\u5019\u6709\u6c23\u5598\u75c5\u53f2\uff0c\u9ad8\u4e2d\u4e4b\u5f8c\u5f88\u9577\u4e00\u6bb5\u6642\u9593\u6c92\u6709\u767c\u4f5c\uff0c10\u5e74\u524d\uff0c\u6c23\u5598\u518d\u5ea6\u767c\u4f5c\uff0c\u9019\u5e7e\u5e74\u63a7\u5236\u4e0d\u4f73\u3002\u5df2\u7d93\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187+\u9577\u6548\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291\uff0c\u5438\u5165\u578b\u9577\u6548\u6297\u81bd\u9e7c\u85e5\u7269\uff0c\u767d\u4e09\u70ef\u7d20\u53d7\u9ad4\u62ee\u6297\u5291\u53ca\u53e3\u670d\u985e\u56fa\u9187\uff0c\u4e0b\u5217\u4f55\u8005\u5c0d\u5979\u53ef\u80fd\u6703\u6709\u5e6b\u52a9\u3002(1)\u6aa2\u8996\u5438\u85e5\u7684\u6b63\u78ba\u6027\uff1b(2)\u627e\u51fa\u904e\u654f\u539f\uff0c\u4e26\u9060\u96e2\u904e\u654f\u539f\uff1b(3)\u6aa2\u67e5IgE\uff0c\u8003\u616e\u4f7f\u7528\u6297IgE\u7403\u86cb\u767d\u6297\u9ad4\uff1b(4)\u589e\u52a0\u53e3\u670d\u985e\u56fa\u9187\u7684\u5291\u91cf\uff1b(5)\u5982\u679c\u8840\u6db2\u53ca\u75f0\u6db2\u55dc\u9178\u6027\u767d\u8840\u7403\u589e\u52a0\uff0c\u53ef\u4ee5\u8003\u616e\u6297IL-5\u85e5\u7269\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(4)+(5)\nC. (1)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(5)\nE. (2)+(3)+(4)+(5)\n": "(D)", "108-15.\n80\u6b72\u7537\u6027\u8001\u83f8\u69cd\u9ad8\u8840\u58d3\u898f\u5247\u670d\u85e5\uff0c\u56e0\u70ba\u54b3\u55fd\u3001\u5598\u4f86\u9580\u8a3a\u8a55\u4f30\u3002\u80f8\u90e8X-ray\u986f\u793a\u5169\u5074\u4e0b\u80ba\u91ce\u6709\u7db2\u72c0\u9670\u5f71\uff0c\u80ba\u529f\u80fd\u6aa2\u67e5 FVC 79 % of prediction\uff0c FEV1 82% of prediction\uff0cFEV1/FVC 75%\uff0cDLCO 56% of prediction\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. \u6c23\u5598\nB. \u80ba\u6c23\u816b\nC. \u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316\nD. \u6162\u6027\u652f\u6c23\u7ba1\u708e\nE. \u652f\u6c23\u7ba1\u64f4\u5f35\n": "(C)", "108-16.\n\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u7684\u75c5\u4eba\u5728\u8a3a\u6240\u8ffd\u8e64\u6642\uff0c\u82e5\u6709\u6025\u6027\u767c\u4f5c\uff0c\u91ab\u5e2b\u901a\u5e38\u6703\u4f7f\u7528\u6297\u751f\u7d20\u53ca\u985e\u56fa\u9187\uff0c\u7279\u5225\u662f\u75c5\u4eba\u5598\u3001\u75f0\u91cf\u589e\u52a0\u3001\u75f0\u8b8a\u9ec3\u3002\u4e0b\u5217\u54ea\u4e00\u7a2e\u5feb\u901f\u6aa2\u67e5\uff0c\u53ef\u4ee5\u5e6b\u52a9\u8a3a\u6240\u91ab\u5e2b\u6e1b\u5c11\u6297\u751f\u7d20\u7684\u4f7f\u7528\uff1f\nA. Interleukin-1\u03b2 (IL-1\u03b2)\nB. Tumor necrotic factor alpha (TNF-\u03b1)\nC. C-reactive protein (CRP)\nD. Procalcitonin\nE. Ferritin\n": "(C)", "108-17.\n88\u6b72\u7537\u6027\u56e0\u81bd\u7d50\u77f3\uff0c\u4f4f\u9662\u958b\u5200\u3002\u8853\u5f8c\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u767c\u4f5c\uff0c\u4e0b\u5217\u90a3\u4e00\u9805\u4e0d\u662f\u6025\u6027\u767c\u4f5c\u7684\u75c7\u72c0\u6216\u5fb5\u5019 (symptoms or signs)\nA. \u5410\u6c23\u6642\u547c\u5438\u97f3\u964d\u4f4e\u6216\u807d\u4e0d\u5230\nB. \u75f0\u91cf\u8b8a\u591a\nC. \u547c\u5438\u6b21\u6578\u589e\u52a0\nD. \u55ae\u5074\u547c\u5438\u97f3\u964d\u4f4e\nE. \u5438\u6c23\u53ca\u5410\u6c23\u6642\uff0c\u80f8\u5ed3\u8b8a\u5316\u4e0d\u660e\u986f\n": "(D)", "108-18.\n88\u6b72\u7537\u6027\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u767c\u4f5c\uff0c\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790(ABG)\u986f\u793apH7.30, CO2 80mmHg\uff0c\u4e0b\u5217\u54ea\u7a2e\u8655\u7f6e\u5c0d\u4ed6\u6700\u597d?\nA. \u6c23\u7ba1\u63d2\u7ba1\uff0c\u958b\u59cb\u4f7f\u7528\u547c\u5438\u5668(\u6a5f\u68b0\u901a\u6c23mechanical ventilation)\nB. \u975e\u4fb5\u8972\u6027\u901a\u6c23(non-invasive ventilation, NIV)\nC. \u7acb\u5373\u7d66\u4e88\u9577\u6548\u652f\u6c23\u7ba1\u64f4\u5f35\u5291(Long-acting bronchodilator)\nD. \u6297\u751f\u7d20(antibiotic)\nE. \u4eba\u5de5\u6025\u6551\u7526\u9192\u7403\u7d66\u6c27 (AMBU Bagging)\n": "(B)", "108-19.\n90\u6b72\u5973\u6027\u56e0\u70ba\u767c\u71d2\u4f86\u5230\u6025\u8a3a\uff0c\u5c3f\u6db2\u6aa2\u67e5\u986f\u793a\u81bf\u5c3f\uff0c\u8840\u58d3\u4e0d\u7a69\u5b9a\uff0c\u5408\u4f75\u814e\u529f\u80fd\u53d7\u640d\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e?\nA. \u6557\u8840\u75c7Sepsis \u5b9a\u7fa9\u662f\u78ba\u5b9a\u6216\u7591\u4f3c\u611f\u67d3\u6e90\u5408\u4f75SOFA score \u22672\nB. \u6557\u8840\u75c7\u4f11\u514bseptic shock\uff0c\u5247\u662f\u6557\u8840\u75c7\u9700\u5347\u58d3\u85e5(vasopressor)\u4f7f\u7528\u53ca\u4e73\u9178(lactate) >2 mmol/L\nC. \u8d8a\u65e9\u7d66\u4e88\u6709\u6548\u7684\u6297\u751f\u7d20\uff0c\u9810\u5f8c\u8d8a\u597d\nD. \u5c0e\u5c3f\u7ba1\u4f7f\u7528\uff0c\u5f15\u6d41\u5c3f\u6db2\nE. Norepinephrine \u662f\u9996\u9078\u7684\u5347\u58d3\u85e5(vasopressor)\n": "(D)", "108-20.\n35\u6b72\u7537\u6027\uff0c\u8eab\u9ad8172\u516c\u5206\uff0c\u9ad4\u91cd110\u516c\u65a4\uff0c\u56e0\u70ba\u7d93\u5e38\u5728\u767d\u5929\u6253\u778c\u7761\uff0c\u665a\u4e0a\u7761\u89ba\u6642\u6253\u547c\u8072\u8b93\u592a\u592a\u7121\u6cd5\u5165\u7761\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e?\nA. \u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\u662f\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u66ab\u505c/\u4f4e\u901a\u6c23\u7d9c\u5408\u75c7(Obstructive sleep apnea/hypopnea syndrome)\u7684\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nB. \u75c5\u4eba\u7761\u7720\u54c1\u8cea\u4e0d\u4f73\uff0c\u5e38\u5e38\u56e0\u7f3a\u6c27\u800c\u9192\u4f86\nC. \u4e0b\u984e\u7a81\u51fa\u662f\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nD. \u8a3a\u65b7\u4e3b\u8981\u9760\u904e\u591c\u7684\u591a\u5c0e\u7761\u7720\u5716 (overnight polysomnogram)\nE. \u5e38\u5408\u4f75\u5fc3\u81df\u3001\u8166\u8840\u7ba1\u53ca\u4ee3\u8b1d\u75be\u75c5\n": "(C)", "108-21.\n\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e?\nA. \u80ba\u764c\u57281900\u5e74\u4ee5\u524d\u70ba\u7f55\u898b\u75be\u75c5\nB. \u5c0f\u7d30\u80de\u80ba\u764c\u3001\u9c57\u72c0\u7d30\u80de\u764c\u7684\u6bd4\u4f8b\u9010\u5e74\u6e1b\u5c11\u662f\u5168\u4e16\u754c\u5171\u901a\u7684\u8da8\u52e2\nC. \u4e0d\u62bd\u83f8\u5973\u6027\u80ba\u817a\u764c\u7684\u4eba\u6578\u5927\u65bc\u62bd\u83f8\u5973\u6027\u80ba\u817a\u764c\u7684\u4eba\u6578\u662f\u5404\u500b\u5730\u5340\u4e00\u81f4\u7684\u73fe\u8c61\nD. \u7537\u6027\u80ba\u764c\u4eba\u6578\u53ca\u4f54\u4eba\u53e3\u6bd4\u4f8b\u8f03\u5973\u6027\u80ba\u764c\u4eba\u6578\u53ca\u4f54\u4eba\u53e3\u6bd4\u4f8b\u9ad8\u662f\u5168\u4e16\u754c\u4e00\u81f4\u7684\u73fe\u8c61\nE. \u53f0\u7063\u5973\u6027\u80ba\u764c\u4f54\u80ba\u764c\u7684\u6bd4\u4f8b\u9060\u9ad8\u65bc\u4e16\u754c\u5e73\u5747\u503c\n": "(C)", "108-22.\n\u80ba\u7d50\u6838\u7684\u63a7\u5236\u6700\u91cd\u8981\u7684\u5c31\u662f\u53ca\u6642\u6aa2\u6e2c\uff0c\u53ca\u63d0\u4f9b\u6709\u6548\u7684\u77ed\u671f\u6cbb\u7642\u3002\u9032\u4e00\u6b65\u7684\u9810\u9632\u662f\u627e\u51fa\u6f5b\u4f0f\u7d50\u6838\u611f\u67d3\u7684\u7fa4\u7d44\u4e26\u7d66\u4e88\u6cbb\u7642\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u662f? (1)\u75be\u75c5\u7ba1\u5236\u7f72\u5df2\u57282016\u5e74\u63a8\u52d5\u5168\u5e74\u9f61\u5c64\u6f5b\u4f0f\u7d50\u6838\u5168\u90fd\u6cbb\u8a08\u756b\uff1b(2)\u6f5b\u4f0f\u7d50\u6838\u7684\u5075\u6e2c\uff0c\u4e94\u6b72\u4ee5\u4e0a\u4ee5\u7d50\u6838\u83cc\u76ae\u819a\u6e2c\u9a57(TST)\u70ba\u4e3b\uff0c\u4e94\u6b72\u4ee5\u4e0b\u4ee5\u4e19\u578b\u5e72\u64fe\u7d20\u91cb\u653e\u8a66\u9a57(IGRA)\u70ba\u4e3b\uff1b(3)\u9700\u505aCXR \uff0c\u6392\u9664\u80ba\u90e8\u6709\u6d3b\u52d5\u6027\u80ba\u7d50\u6838\uff1b(4)\u7d50\u6838\u83cc\u76ae\u819a\u6e2c\u9a57(TST)\u5e38\u53d7\u975e\u7d50\u6838\u5206\u679d\u687f\u83cc(NTM)\u7684\u5e72\u64fe\uff1b(5)\u5efa\u8b70\u4ee5\u90fd\u6cbb\u8a08\u756b\u7d66\u85e5(Directly Observed Treatment Short-Course\uff0cDOTS)\u3002\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(4)+(5)\nC. (2)+(3)+(4)+(5)\nD. (1)+(2)+(4)+(5)\nE. (2)+(4)+(5)\n": "(B)", "109-23.78\u6b72\u8001\u83f8\u69cd \uff0cCOPD\u8a3a\u65b7\u5df2\u7d93\u597d\u5e7e\u5e74 \uff0c\u56e0\u70ba\u80ba\u529f\u80fd\u4e0d\u4f73\u53ca\u54b3\u5598 \uff0c\u9577\u671f\u4f7f\u7528\u5438\u5165\u578b\u6c23\u7ba1\u64f4\u5f35\u5291 \u3002\u4e0d\u5e78\u7684\u662f\u5de6\n\u4e0a\u80ba\u8449\u767c\u73fe\u4e00\u9846\u816b\u7624 \uff0c\u5207\u7247\u8b49\u5be6\u662f\u9c57\u72c0\u7d30\u80de\u764c \uff0c\u6c92\u6709\u6dcb\u5df4\u7d50\u53ca\u9060\u7aef\u8f49\u79fb \uff0c\u5916\u79d1\u91ab\u5e2b\u60f3\u8981\u958b\u5200\u5207\u9664 \uff0c\u4f60\u6703\u5efa\n\u8b70\u54ea\u7a2e\u6aa2\u67e5\u4f86\u8a55\u4f30\u8853\u5f8c\u7684\u80ba\u529f\u80fd \uff1f   \nA.\u96fb\u8166\u65b7\u5c64\nB.\u6838\u78c1\u5171\u632f\nC.\u652f\u6c23\u7ba1\u93e1\nD.\u80ba\u81df\u8840\u6d41\u704c\u6ce8\u6383\u63cf\nE.\u80f8\u90e8\u8d85\u97f3\u6ce2\n": "[D]", "109-24.\u5e74\u8f15\u5973\u6027\u5728\u5065\u6aa2\u6642\u80f8\u90e8 X-ray \u6709\u7591\u4f3c\u816b\u7624\u7684\u9670\u5f71 \uff0c\u65bc\u662f\u4f86\u5230\u5927\u91ab\u9662\u9580\u8a3a\u9032\u4e00\u6b65\u6aa2\u67e5 \u3002\u5979\u807d\u670b\u53cb\u8aaa\u6838\u78c1\u5171\u632f\n\u6aa2\u67e5\u6bd4\u8f03\u6602\u8cb4 \u3001\u6bd4\u8f03\u7cbe\u5bc6 \uff0c\u65bc\u662f\u8981\u6c42\u5b89\u6392\u80f8\u90e8\u6838\u78c1\u5171\u632f\u6aa2\u67e5 \uff0c\u4e0b\u5217\u4f55\u8005\u8aaa\u660e\u662f\u4e0d\u5408\u7406\u7684 \uff1f   \nA.\u6838\u78c1\u5171\u632f\u5c0d\u65bc\u80ba\u81df\u7684\u89e3\u6790\u5ea6\u6bd4\u96fb\u8166\u65b7\u5c64\u4f73\uff0c\u53ef\u4ee5\u7528\u4f86\u6aa2\u6e2c\u80ba\u816b\u7624\nB.\u96fb\u8166\u65b7\u5c64\u5728\u80ba\u81df\u7684\u89e3\u6790\u5ea6\u6bd4\u6838\u78c1\u5171\u632f\u597d\nC.\u5c0d\u65bc\u80f8\u8154\u5165\u53e3\u816b\u7624\uff08pancoast tumor\uff09\u6838\u78c1\u5171\u632f\u6709\u8f03\u4f73\u7684\u89e3\u6790\u5ea6\nD.\u80ba\u52d5\u975c\u8108\u7578\u578b\uff0c\u6838\u78c1\u5171\u632f\u80fd\u63d0\u4f9b\u8db3\u5920\u7684\u8a0a\u606f\nE.\u810a\u690e\u6216\u795e\u7d93\u6839\u7684\u4fb5\u72af\uff0c\u6838\u78c1\u5171\u632f\u7684\u89e3\u6790\u5ea6\u6bd4\u96fb\u8166\u65b7\u5c64\u4f73\n": "[A]", "109-25.\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u652f\u6c23\u7ba1\u93e1\u642d\u914d\u652f\u6c23\u7ba1\u8d85\u97f3\u6ce2\u5e45\u5c04\u578b\u5fae\u5c0f\u63a2\u982d\u6aa2\u67e5\u53ef\u4ee5\u53d6\u5f97\u80ba\u5468\u908a\u7684\u816b\u7624\u7d44\u7e54 \uff0c\u8a3a\u65b7\u6e96\u78ba\u7387\u4f9d\u64cd\u4f5c\u8005\u7684\n\u7d93\u9a57\u6709\u6240\u4e0d\u540c\nB.\u80f8\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u53ef\u4ee5\u8a55\u4f30\u80ba\u9580\u9644\u8fd1\u7684\u75c5\u8b8a\nC.\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u53d6\u6a23\u6aa2\u67e5\uff0c\u7e31\u8188\u8154\u93e1\u4ecd\u7136\u662f\u6a19\u6e96\u65b9\u5f0f\nD.\u808b\u819c\u8154\u93e1\u53ef\u4ee5\u7528\u4f86\u8a55\u4f30\u808b\u819c\u75c5\u8b8a\uff0c\u4e0d\u9700\u8981\u9032\u958b\u5200\u623f\u5168\u8eab\u9ebb\u9189\nE.\u65e9\u671f\u7684\u6c23\u7ba1\u9ecf\u819c\u75c5\u8b8a\u53ef\u4ee5\u7528\u87a2\u5149\u652f\u6c23\u7ba1\u93e1\u6aa2\u6e2c\n": "[B]", "109-26.59\u6b72\u7537\u6027\u56e0\u70ba\u4e45\u54b3\u4e0d\u7652 \u3001\u5927\u91cf\u7684\u9ec3\u75f0\u4f86\u9580\u8a3a\u5c31\u8a3a \u3002\u80f8\u90e8X\u5149\u6709 Tram tracks sign \uff0c\u56de\u9867\u75c5\u53f2 \uff0c\u4ed6\u6709\u6162\u6027\u9f3b\n\u7ac7\u708e\uff0c\u53cd\u8986\u767c\u4f5c \uff0c\u7d50\u5a5a\u6578\u5341\u5e74\u819d\u4e0b\u7121\u5b50 \uff0c\u4e0b\u5217\u8a3a\u65b7\u4f55\u8005\u6700\u6709\u53ef\u80fd \uff1f   \nA.\u56ca\u6027\u7e96\u7dad\u5316\uff08cystic fibrosis\uff09\nB.\u80ba\u6c23\u816b\uff08emphysema\uff09\nC.\u6c23\u5598\uff08asthma\uff09\nD.\u652f\u6c23\u7ba1\u64f4\u5f35\uff0c\u7e96\u6bdb\u904b\u52d5\u969c\u7919\u75c7\u5019\u7fa4\uff08dyskinetic cilia syndrome\nE.\u975e\u7d50\u6838\u5206\u679d\u687f\u83cc\uff08NTM\uff09\u611f\u67d3\n": "[D]", "109-27.\u4e0b\u5217\u75be\u75c5\u7684\u80ba\u529f\u80fd\u8868\u73fe\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u80a5\u80d6\uff1a\u80f8\u58c1\u7570\u5e38\u5c0e\u81f4\u901a\u6c23\u53d7\u9650\uff08ventilatory restriction\uff09\nB.\u91cd\u75c7\u808c\u7121\u529b\uff1a\u547c\u5438\u808c\u7121\u529b\u5c0e\u81f4\u901a\u6c23\u53d7\u9650\uff08ventilatory restriction\uff09   \nC.\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316 \uff08idiopathic pulmonary fibrosis\uff09\uff1a \u80ba\u6ce1\u58c1\u8b8a\u539a \u3001\u56de\u5f48\u529b\uff08elastic recoil \uff09\u589e\u52a0\u5c0e\u81f4\u6c23\n\u6d41\u963b\u585e\nD.\u6c23\u5598\u767c\u4f5c\uff1a\u6c23\u9053\u76f4\u5f91\u6e1b\u5c0f\u5c0e\u81f4\u6c23\u6d41\u963b\u585e\nE.\u56b4\u91cd\u80ba\u6c23\u816b\uff08emphysema\uff09\u80ba\u6ce1\u58c1\u7834\u58de\u3001\u56de\u5f48\u529b\u4e0b\u964d\u5c0e\u81f4\u6c23\u6d41\u963b\u585e\n": "[C]", "109-28.\u95dc\u65bc\u7d50\u6838\u75c5\u85e5\u7269\u526f\u4f5c\u7528\u7684\u8655\u7406\u539f\u5247 \uff0c\u4e0b\u5217\u54ea\u4e9b\u6558\u8ff0\u662f\u6b63\u78ba\u7684 \uff1f\n(1) \u8840\u4e2d\u5c3f\u9178\u589e\u9ad8\u6642 \uff0c\u540c\u6642\u670d\u7528allopurinol \uff0c\u964d\u5c3f\u9178\u6548\u679c\u901a\u5e38\u5f88\u986f\u8457\n(2) \u56e0\u56b4\u91cd\u76ae\u819a\u526f\u4f5c\u7528\u800c\u4e2d\u65b7\u6cbb\u7642\u8005 \uff0c\u5f85\u526f\u4f5c\u7528\u6d88\u5931\u5f8c \uff0c\u61c9\u8003\u616e\u7531\u4f4e\u5291\u91cf\u81f3\u9ad8\u5291\u91cf\u9010\u4e00\u52a0\u5165\u6297\u7d50\u6838\u85e5\u7269\n(3) \u56b4\u91cd\u526f\u4f5c\u7528\u6642 \uff0c\u4f8b\u5982\u809d\u708e \u3001\u56b4\u91cd\u8996\u529b\u6a21\u7cca \u3001\u56b4\u91cd\u8840\u7403\u964d\u4f4e \u3001\u56b4\u91cd\u76ae\u819a\u526f\u4f5c\u7528\u6642 \uff0c\u61c9\u540c\u6642\u505c\u6b62\u6240\u6709\u6297\u7d50\n\u6838\u85e5\u7269\u6cbb\u7642 \n(4) \u8178\u80c3\u4e0d\u9069 \u3001\u76ae\u75b9\u3001\u6414\u7662\u3001\u95dc\u7bc0\u75e0\u75db\u7b49\u526f\u4f5c\u7528 \uff0c\u901a\u5e38\u5728\u670d\u7528\u6297\u7d50\u6838\u85e5\u7269\u5169\u5468\u5f8c\u6703\u81ea\u7136\u6e1b\u8f15 \u3002\u56e0\u6b64\uff0c\u82e5\u75c7\n\u72c0\u4e0d\u56b4\u91cd \uff0c\u61c9\u7d66\u4e88\u75c5\u4eba\u9069\u7576\u885b\u6559 \u3001\u5fc3\u7406\u6cbb\u7642 \uff0c\u5fc5\u8981\u6642\u7d66\u4e88\u85e5\u7269\u75c7\u72c0\u6cbb\u7642\u5373\u53ef   \nA.(1)+(2)+(3)+(4)\nB.(1)+(2)+(3)\nC.(1)+(2)+(4)\nD.(1)+(3)+(4)\nE.(2)+(3)+(4)\n": "[E]", "109-29.54\u6b72\u7537\u6027\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u53f2 \uff0c\u65e5\u524d\u8207\u570b\u5916\u56de\u4f86\u7684\u670b\u53cb\u804a\u5929\u559d\u5496\u5561 \uff0c\u6578\u65e5\u5f8c\u56e0\u70ba\u547c\u5438\u9053\u75c7\u72c0\u5408\u4f75\u767c\u71d2 \uff0c\u4f86\n\u91ab\u9662\u6025\u8a3a \u3002\u80f8\u90e8X -ray \u986f\u793a\u5169\u5074\u80ba\u6d78\u6f64 (\u6bdb\u73bb\u7483\u72c0\u70ba\u4e3b )\uff0c\u8840\u6c27\u98fd\u548c\u5ea6 <90%\uff0c\u7acb\u523b\u88ab\u9001\u9032\u52a0\u8b77\u75c5\u623f\u9694\n\u96e2\u300224\u5c0f\u6642\u5167 \uff0c\u80ba\u6d78\u6f64\u8b8a\u56b4\u91cd \uff0c\u63a5\u53d7\u6c23\u7ba1\u63d2\u7ba1\u53ca\u958b\u59cb\u547c\u5438\u5668\u4f7f\u7528 \u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u5c0d\u65bc\u75c5\u4eba\u6709\u5e6b\u52a9 \uff1f\n(1) \u70ba\u78ba\u4fdd\u8db3\u5920\u8840\u6c27\u6fc3\u5ea6 \uff0c\u547c\u5438\u5668\u6f6e\u6c23\u5bb9\u7a4d\u898110 ml /kg  \u4ee5\u4e0a\n(2) \u547c\u5438\u5668\u5410\u6c23\u672b\u671f\u6b63\u58d3 (PEEP)\u6108\u4f4e\u8d8a\u597d\n(3) \u4fef\u81e5\u901a\u6c23 (Prone Positioning )\u53ef\u4ee5\u964d\u4f4e\u6c27\u6c23\u9700\u6c42\u91cf\n(4) \u7d66\u4e88\u93ae\u975c\u53ca\u795e\u7d93\u808c\u8089\u963b\u65b7\u5291\n(5) \u6c34\u5206\u9650\u5236 (fluid restriction )   \nA.(1)+(2)+(3)+(4)+(5)\nB.(2)+(3)+(4)+(5)\nC.(3)+(4)+(5)\nD.(1)+(3)+(4)+(5)\nE.(1)+(2)+(3)\n": "[C]", "109-30.72\u6b72\u6d77\u8ecd\u9000\u4f11\u8f2a\u6a5f\u58eb\u5b98\u9577 \uff0c\u9577\u5e74\u5728\u8ecd\u8266\u8f2a\u6a5f\u623f\u5de5\u4f5c \u3002\u6700\u8fd1\u56e0\u70ba\u5598 \uff0c\u5728\u9580\u8a3a\u5c31\u8a3a \uff0c\u80f8\u90e8X\u5149\u7570\u5e38\uff0c\u65bc\u662f\u63a5\u53d7\n\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u5982\u9644\u5716 \uff0c\u4e0b\u5217\u4f55\u8005\u6558\u8ff0\u70ba\u662f \uff1f\n(1) \u96fb\u8166\u65b7\u5c64\u986f\u793a\u70ba\u80f8\u819c\u6591 \uff08pleural plaques \uff09\n(2) \u8207\u5de5\u4f5c\u74b0\u5883\u606f\u606f\u76f8\u95dc\n(3) \u4e0d\u6703\u5f15\u8d77\u80ba\u764c\n(4) \u8207\u80f8\u8154\u9593\u76ae\u7624\u9ad8\u5ea6\u76f8\u95dc\n(5) \u62bd\u7159\u5c0d\u65bc\u764c\u75c7\u7684\u767c\u751f\u7387\u4e0d\u6703\u6709\u52a0\u6210\u6548\u679c   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(3)+(4)+(5)\nD.(1)+(2)+(4)\nE.(1)+(2)+(5)   \n": "[D]", "109-31.40\u6b72\u7537\u6027\u56e0\u70ba\u55dc\u7761 \u3001\u6ce8\u610f\u529b\u7121\u6cd5\u96c6\u4e2d \uff0c\u670b\u53cb\u5efa\u8b70\u4ed6\u4f86\u7761\u7720\u547c\u5438\u66ab\u505c \uff08sleep apnea \uff09\u9580\u8a3a\u3002\u8eab\u9ad4\u6aa2\n\u67e5BMI>30\uff0c\u8116\u5b50\u77ed\uff0c\u4e0b\u5df4\u5167\u7e2e \uff0c\u4f3c\u4e4e\u70ba\u5178\u578bobstractive sleep apnea/ Hypopnea \nsyndrome \uff08OSAHS\uff09\u7684\u75c5\u4eba\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u975e \uff1f   \nA.OSAHS\u5e38\u5408\u4f75\u5176\u4ed6\u6162\u6027\u75be\u75c5\uff0c\u4f8b\u5982\uff1a\u5fc3\u8840\u7ba1\u75be\u75c5\u3001\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u7b49\nB.\u53ef\u4ee5\u5f9e\u75c7\u72c0\u53ca\u75c5\u53f2\u4f86\u8a3a\u65b7\nC.\u5f97\u5230OSAHS\u7684\u75c5\u4eba\u5bb9\u6613\u82f1\u5e74\u65e9\u901d\nD.\u75c5\u4eba\u56e0\u7761\u7720\u54c1\u8cea\u4e0d\u4f73\uff0c\u9577\u671f\u7f3a\u6c27\uff0c\u5bb9\u6613\u9020\u6210\u795e\u7d93\u529f\u80fd\u7684\u9000\u5316\nE.\u6301\u7e8c\u6c23\u9053\u6b63\u58d3\u547c\u5438\u5668\u6cbb\u7642\u662f\u76ee\u524d\u7684\u4e3b\u6d41\n": "[B]", "109-32.18\u6b72\u7537\u6027\u7121\u7279\u6b8a\u75be\u75c5\uff0c\u67d0\u5929\u5728\u6253\u7c43\u7403\u6642\u7a81\u7136\u80f8\u75db\u3001\u80f8\u60b6\u4f86\u5230\u6025\u8a3a\u3002\u80f8\u90e8 X\u5149\u5982\u9644\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1a    \nA.\u597d\u767c\u5e74\u8f15\u7537\u6027\u8eab\u6750\u77ee\u80d6\nB.\u5e38\u662f\u6162\u6027\u80ba\u90e8\u75be\u75c5\u5f15\u8d77\nC.\u6cbb\u7642\u9996\u9078\u662f\u958b\u5200\nD.\u8207\u62bd\u83f8\u95dc\u4fc2\u5bc6\u5207\nE.\u6cbb\u7642\u6210\u529f\u5f8c\u5e7e\u4e4e\u4e0d\u6703\u5fa9\u767c\n": "[D]", "109-33.72\u6b72\u7537\u6027\u8001\u7159\u69cd\u4e00\u5929\u5169\u5305\u83f8\u81f3\u5c1130 \u5e74\uff0c\u6709\u7cd6\u5c3f\u75c5 \u3001\u9ad8\u8840\u58d3\uff0c\u63a5\u53d7\u53e3\u670d\u85e5\u7269\u6cbb\u7642 \uff0c\u4f46\u9806\u5f9e\u6027\u4e0d\u4f73 \u3002\u6162\u6027\u963b\n\u585e\u6027\u80ba\u75c5\u5df2\u670910\u5e74\u6b77\u53f2 \uff0c\u96d6\u7136\u4f7f\u7528\u5438\u5165\u578b\u9577\u6548\u578b\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291 \uff08LABA\uff09\u53ca\u9577\u6548\u578b\u6297\u81bd\u9e7c\n\u5291\uff08LAMA\uff09\uff0c \u4f46\u5e38\u5e38\u56e0\u70ba\u80ba\u708e\u5408\u4f75\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u60e1\u5316\u4f4f\u9662 \u3002\u6700\u8fd1\u65b0\u82f1\u683c\u862d\u96dc\u8a8c\u767c\u8868\u4e00\u7bc7\u5927\u578b\u7814\n\u7a76\uff0c\u8a8d\u70ba\u52a0\u4e0a\u5438\u5165\u578b\u985e\u56fa\u9187\u53ef\u4ee5\u6e1b\u5c11\u60e1\u5316\u6b21\u6578 \uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f \uff1a   \nA.\u5438\u5165\u578b\u985e\u56fa\u9187\u6703\u589e\u52a0\u80ba\u708e\u6a5f\u6703\uff0c\u4e0d\u9069\u5408\u6b64\u4f4d\u75c5\u4eba\nB.\u4f4e\u5291\u91cf\u985e\u56fa\u9187\u5c0d\u65bc\u964d\u4f4e\u6025\u6027\u767c\u4f5c\u66f4\u6709\u5e6b\u52a9\uff0c\u61c9\u8a72\u4f7f\u7528\u4f4e\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187\nC.\u56e0\u70ba\u7cd6\u5c3f\u75c5\u63a7\u5236\u4e0d\u4f73\uff0c\u4f7f\u7528\u4f4e\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187\u5373\u53ef\nD.\u4f7f\u7528\u9ad8\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187\u53ca\u9577\u6548\u578b\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291\u6548\u679c\u6700\u4f73\nE.\u4f7f\u7528\u9ad8\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187\u53ca\u9577\u6548\u578b\u6297\u81bd\u9e7c\u5291\u6700\u597d\n": "[A]", "109-34.71\u6b72\u7537\u6027\u6709\u5438\u7159\u53f2 \uff0c\u4e00\u5929\u4e00\u530530 \u5e74\uff0c\u6212\u4e8620\u5e74\u3002\u6700\u8fd1\u56e0\u70ba\u8d70\u8def\u6703\u5598 \u3001\u54b3\u55fd\u52a0\u91cd\u4f86\u5230\u9580\u8a3a \u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u986f\n\u793a\u4fb7\u9650\u6027\u80ba\u529f\u80fd\u7f3a\u640d \uff08restrictive deficit\uff09\uff0c \u80f8\u90e8 X\u5149\u9ad8\u5ea6\u61f7\u7591\u80ba\u7e96\u7dad\u5316 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u662f\u5fc5\u8981\u7684\u6aa2\u67e5\nB.\u5fc5\u9808\u6392\u9664\u7d50\u7de0\u7d44\u7e54\u75be\u75c5\uff08connective tissue disease\uff09\u9020\u6210\u7684\u80ba\u7e96\u7dad\u5316\nC.\u5207\u7247\u6aa2\u67e5\u662f\u5fc5\u8981\u7684\uff0c\u5373\u4f7f\u662f\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316\u4e5f\u5fc5\u9808\u5207\u7247\u8b49\u5be6\nD.\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316\uff0c\u76ee\u524d\u5df2\u6709\u6297\u7e96\u7dad\u5316\u7642\u6cd5\uff08pirfenidone \u53canintedanib\uff09\nE.\u514d\u75ab\u6291\u5236\u53ef\u80fd\u6703\u589e\u52a0\u6b7b\u4ea1\u7387\n": "[C]", "109-35.\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668 \uff08noninvasive ventilator, NIV \uff09\u4e0d\u9069\u5408\u7528\u65bc\u4e0b\u5217\u54ea\u4e9b\u75c5\u4eba \uff1f\n(1) \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u767c\u4f5c\u5408\u4f75\u4e8c\u6c27\u5316\u78b3\u84c4\u7a4d\n(2) \u795e\u7d93\u808c\u8089\u75be\u75c5\u6240\u5c0e\u81f4\u7684\u6162\u6027\u547c\u5438\u8870\u7aed\n(3) \u610f\u8b58\u4e0d\u6e05\u7121\u6cd5\u5408\u4f5c\n(4) \u5fc3\u808c\u6897\u585e\u5408\u4f75\u80ba\u6c34\u816b\n(5) \u4f11\u514b\u7684\u75c5\u4eba   \nA.(1)+(2)+(3)+(4)+(5)\nB.(1)+(3)+(4)+(5)\nC.(2)+(3)+(4)   \nD.(1)+(3)+(4)\nE.(3)+(4)+(5)\n": "[E]", "109-36.\u6162\u6027\u963b\u585e\u6027\u80ba\u75be\u75c5COPD (Chronic Obstructive Pulmonary Disease )\u60a3\u8005\u5728\u4e0b\u5217\u54ea\u4e9b\u60c5\u6cc1\u6703\u53ef\u8003\u616e\u52a0\u4e0a\u5438\n\u5165\u6027\u985e\u56fa\u9187 (inhaled glucocorticoid )\u7684\u6cbb\u7642\uff1f\n(1) \u7576\u60a3\u8005\u540c\u6642\u6709\u6c23\u5598 (asthma)\u4e4b\u75c5\u53f2\n(2) \u7576\u60a3\u8005\u4e00\u5e74\u5167\u6709\u5169\u6b21\u6216\u4ee5\u4e0a\u6162\u6027\u963b\u585e\u6027\u80ba\u75be\u75c5\u6025\u6027\u767c\u4f5c\u4e4b\u75c5\u53f2\n(3) \u7576\u60a3\u8005\u4e00\u5e74\u5167\u6709\u4e00\u6b21\u6216\u4ee5\u4e0a\u6162\u6027\u963b\u585e\u6027\u80ba\u75be\u75c5\u6025\u6027\u767c\u4f5c\u9700\u8981\u4f4f\u9662\u4e4b\u75c5\u53f2\n(4) \u8840\u6db2\u55dc\u9178\u6027\u767d\u8840\u7403\u8a08\u7b97 (eosinophil count )\u5927\u65bc150/mm3\n(5) \u7576\u60a3\u8005\u4e0d\u9069\u5408\u4f7f\u7528\u9577\u6548\u578b\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u6642\u53ef\u55ae\u7368\u4f7f\u7528   \nA.(1)+(2)+(4)\nB.(1)+(3)+(4)\nC.(1)+(2)+(3)+(4)\nD.(1)+(2)+(3)+(5)\nE.(1)+(2)+(3)+(4)+(5)\n": "[C]", "109-37.\u738b\u5148\u751f40\u6b72\u6709\u6c23\u5598 (asthma)\u75c5\u53f2\uff0c\u5e73\u6642\u4e0d\u898f\u5247\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187 (inhaled corticosteroid, ICS )\u3002\u6700\u8fd1\u591c\u54b3\n\u4ee5\u53ca\u591c\u9593\u5598\u9cf4 (wheezes )\u72c0\u6cc1\u52a0\u5287 \uff0c\u65bc\u662f\u4f86\u5230\u6025\u8a3a\u5c31\u91ab \uff0c\u8840\u6c27\u98fd\u548c\u5ea6 (SpO2)96%(\u7121\u4f7f\u7528\u6c27\u6c23 )\uff0c\u8eab\u9ad4\u8a3a\u67e5\n\u767c\u73fe\u80ba\u90e8\u6709\u7030\u6f2b\u6027\u5598\u9cf4\u8072 \uff08diffuse wheezes\uff09\uff0c \u5c16\u7aef\u547c\u6c23\u6d41\u91cf (peak expiratory flow rate, PEFR )\u70ba\u9810\u6e2c\u503c\n\u768450%\uff0c\u53ef\u8003\u616e\u7d66\u4e88\u4e0b\u5217\u54ea\u4e9b\u8655\u7f6e \uff1f\n(1) \u5438\u5165\u578b\u77ed\u6548\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291 (short-acting \u03b22 agonist, SABA )\n(2) \u5438\u5165\u578b\u77ed\u6548\u6297\u81bd\u9e7c\u85e5\u7269 (short-acting muscuarinic antagonist \uff0cSAMA)\n(3) \u5168\u8eab\u6027\u985e\u56fa\u9187 (systemic corticosteroids )\n(4) \u786b\u9178\u9382\u6ce8\u5c04\u6db2 (magnesium sulfate )\n(5) Azithromycin   \nA.(1)+(2)\nB.(1)+(2)+(3)\nC.(1)+(3)+(4)\nD.(1)+(2)+(3)+(4)\nE.(1)+(2)+(3)+(4)+(5)\n": "[D]", "109-38.\u6709\u95dc\u6c23\u5598(asthma)\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u8f15\u5ea6\u6c23\u5598\u7684\u75c5\u60a3The Global initiative against asthma (GINA) 2020 \u4e0d\u518d\u5efa\u8b70\u55ae\u7368\u4f7f\u7528\u5438\u5165\u578b\u77ed\u6548\u4e59\u4e8c\n\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291 (short-acting \u03b22 agonist, SABA )\u4f5c\u70ba\u63a7\u5236\u85e5\u7269 (controller )\uff0c\u9700\u8981\u4f7f\u7528SABA\u6642\u5efa\u8b70\n\u8207\u4f4e\u5291\u91cf\u5438\u5165\u578b\u985e\u56fa\u9187 (inhaled corticosteroid, ICS )\u4e26\u7528\nB.\u9577\u6548\u578b\u6297\u81bd\u9e7c\u5291(long-acting muscarinic antagonists; LAMA)\u65bc\u4e2d\u91cd\u5ea6\u6c23\u5598\u7684\u63a7\u5236\u6c92\u6709\u89d2\u8272\nC.\u767d\u4e09\u70ef\u7d20\u62ee\u6297\u5291 (leukotriene receptor antagonist )\u5728\u63a7\u5236\u6c23\u5598\u6548\u679c\u8207\u9810\u9632\u6025\u6027\u767c\u4f5c\u4e0a\u8f03\u5438\u5165\u578b\u985e\u56fa\n\u9187(inhaled corticosteroid, ICS )\u5dee\nD.\u8f15\u5ea6\u6c23\u5598\u7684\u75c5\u60a3\u53ef\u65bc\u6709\u75c7\u72c0\u6642\u9593\u6b47\u6027\u4f7f\u7528budesonide-formoterol\nE.\u5438\u5165\u578b\u985e\u56fa\u9187 (inhaled corticosteroid, ICS )\u8207\u5438\u5165\u578b\u9577\u6548\u4e59\u4e8c\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5291 (long-acting \u03b22 \nagonist, SABA )\u4f75\u7528\u8f03\u55ae\u7368\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187\u65bc\u4e2d\u5ea6\u6c23\u5598\u60a3\u8005\u53ef\u9054\u5230\u8f03\u5feb\u901f\u7684\u75c7\u72c0\u6539\u5584\n": "[B]", "109-39.\u9ad4\u5916\u751f\u547d\u652f\u6301(Extracorporeal life support, ECLS)\u4f7f\u7528\u5728\u547c\u5438\u8870\u7aed\u75c5\u60a3\u53ef\u4ee5\u9054\u5230\u7684\u6548\u679c\uff0c\u4ee5\u4e0b\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u6539\u5584\u4f4e\u8840\u6c27(hypoxemia)\nB.\u6539\u5584\u9ad8\u78b3\u9178\u8840\u75c7(hypercapnia)   \nC.\u6e1b\u5c11\u547c\u5438\u5668\u5c0e\u81f4\u80ba\u640d\u50b7(ventilator-induced lung injury, VILI)\nD.\u6e1b\u5c11\u6a6b\u8188\u819c\u640d\u50b7(diaphragm myotrauma)\nE.\u6e1b\u5c11\u6cdb\u767c\u6027\u8840\u7ba1\u5167\u8840\u6db2\u51dd\u56fa\u75c7(disseminated intravascular coagulation,DIC)\u7684\u6a5f\u6703\n": "[E]", "109-40.65\u6b72\u7537\u6027\u6709\u9ad8\u8840\u58d3 \u3001\u7cd6\u5c3f\u75c5\u75c5\u53f2 \u3002\u56e0\u70ba\u767c\u71d2 \uff0c\u54b3\u55fd\u6709\u9ec3\u75f0\u4f86\u5230\u6025\u8a3a \u3002\u5728\u6025\u8a3a\u6642\u610f\u8b58\u6e05\u695a \uff0c\u8840\u58d3120/80 \nmmHg\uff0c\u5fc3\u8df3\u901f\u7387100 /min\uff0c\u9ad4\u6eab38.8\u00b0C\uff0c\u547c\u5438\u901f\u738726 /min\uff0c\u8840\u6c27\u98fd\u548c\u5ea6 (SpO2)95%(\u7121\u4f7f\u7528\u6c27\u6c23 )\uff0c\u8eab\u9ad4\n\u8a3a\u67e5\u767c\u73fe\u53f3\u4e0b\u80ba\u91ce\u6709\u7c97\u7206\u88c2\u97f3 (coarse crackles )\u3002\u80f8\u90e8X\u5149\u986f\u793a\u53f3\u4e0b\u80ba\u8449\u6d78\u6f64 \uff0c\u7121\u660e\u986f\u808b\u819c\u7a4d\u6c34 \u3002\u4ee5\u4e0b\u8655\n\u7f6e\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u53ef\u8003\u616e\u7d66\u4e88\u53e3\u670d\u6297\u751f\u7d20\u9580\u8a3a\u6cbb\u7642\nB.\u6d41\u884c\u6027\u611f\u5192\u6d41\u884c\u5b63\u7bc0\u61c9\u9032\u884c\u6d41\u611f\u6aa2\u6e2c\nC.\u53ef\u8003\u616e\u55ae\u7368\u7d66\u4e88azithromycin \u6216clarithromycin\nD.\u53ef\u8003\u616e\u7d66\u4e88Amoxicillin-clavulanate\u52a0\u4e0amacrolide\nE.\u53ef\u8003\u616e\u55ae\u7368\u7d66\u4e88respiratory fluoroquinolone\n": "[C]", "109-41.\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u9032\u5c55\u6210\u70ba\u56b4\u91cd\u65b0\u578b\u51a0\u72c0\u80ba\u708e(severe coronavirus disease 2019,Covid-19)\u7684\u5371\u96aa\u56e0\u5b50\uff1f    \nA.\u5e74\u9f61\u5c0f\u65bc65\u6b72\nB.\u6162\u6027\u80ba\u75be\u75c5\nC.\u7cd6\u5c3f\u75c5\nD.\u80a5\u80d6\nE.\u672b\u671f\u814e\u75c5(End Stage Renal Disease, ESRD)\n": "[A]", "109-42.\u4e0b\u5217\u9020\u6210\u6ffe\u51fa\u6027\u808b\u819c\u7a4d\u6c34 (Transudative pleural effusion) \u4e4b\u75c5\u56e0 \uff0c\u4f55\u8005\u6839\u64daLight 's criteria\u6700\u5e38\u88ab\u8aa4\u5224\u70ba\u6ef2\n\u51fa\u6db2(Exudate)\uff1f   \nA.\u9b31\u8840\u6027\u5fc3\u81df\u8870\u7aed(Congestive heart failure)\u60a3\u8005\u4f7f\u7528\u5229\u5c3f\u5291\u6cbb\u7642\nB.\u809d\u786c\u5316(cirrhosis)\nC.\u814e\u75c5\u75c7\u5019\u7fa4(nephrotic syndrome)\nD.\u4f4e\u767d\u86cb\u767d\u8840\u75c7(hypoalbuminemia)\nE.\u80ba\u584c\u9677(atelectasis)\n": "[A]", "109-43.50\u6b72\u7537\u6027\u56e0\u70ba\u767c\u71d2 \uff0c\u54b3\u55fd\u6709\u9ec3\u75f0\u4f34\u96a8\u5de6\u5074\u80f8\u75db\u4f86\u5230\u6025\u8a3a \u3002\u5728\u6025\u8a3a\u6642\u610f\u8b58\u6e05\u695a \uff0c\u8840\u58d3130/70 mmHg \uff0c\u5fc3\u8df3\n\u901f\u7387110/min\uff0c\u9ad4\u6eab39\u00b0C \uff0c\u547c\u5438\u901f\u738728 /min\uff0c\u8840\u6c27\u98fd\u548c\u5ea6 (SpO2)95%(\u7121\u4f7f\u7528\u6c27\u6c23 )\uff0c\u8eab\u9ad4\u8a3a\u67e5\u767c\u73fe\u5de6\u4e0b\u80ba\n\u91ce\u6709\u7c97\u7206\u88c2\u97f3 (coarse crackles )\u4e14\u547c\u5438\u97f3\u6e1b\u5c11 \u3002\u80f8\u90e8X\u5149\u986f\u793a\u5de6\u4e0b\u80ba\u8449\u6d78\u6f64 \uff0c\u540c\u6642\u6709\u808b\u819c\u7a4d\u6c34 \u3002\u4e0b\u5217\u6558\u8ff0\n\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u62bd\u51fa\u7684\u808b\u819c\u7a4d\u6db2\u5728\u9769\u862d\u6c0f\u67d3\u8272(Gram stain)\u4e0b\u770b\u5230\u7d30\u83cc\u5c31\u53ef\u8a3a\u65b7\u70ba\u81bf\u80f8\nB.\u80f8\u8154\u8d85\u97f3\u6ce2\u662f\u8a55\u4f30\u808b\u819c\u7a4d\u6db2\u662f\u5426\u6709\u9694\u9593(septations)\u6700\u4f73\u7684\u5de5\u5177\nC.\u82e5\u611f\u67d3\u6027\u808b\u819c\u7a4d\u6db2\u6709\u9694\u9593 (septations )\uff0c\u53ca\u65e9\u9032\u884c\u5f71\u50cf\u8f14\u52a9\u80f8\u8154\u93e1\u624b\u8853 (Video-Assisted Thoracoscopic \nSurgery ,VATS)\u53ef\u6e1b\u5c11\u624b\u8853\u4f75\u767c\u75c7\nD.\u82e5\u62bd\u51fa\u7684\u808b\u819c\u7a4d\u6db2\u70ba\u81bf (frank pus )\uff0c\u4f7f\u7528\u80f8\u7ba1\u5f15\u6d41\u52a0\u4e0atissue plasminogen activator (t-PA)\u4ee5\n\u53caDNase\u6bd4\u4e0a\u55ae\u7d14\u80f8\u7ba1\u5f15\u6d41\u53ef\u964d\u4f4e\u6b7b\u4ea1\u7387\nE.\u5982\u679c\u75c5\u60a3\u4e0d\u9069\u5408\u958b\u5200\uff0c\u5f15\u6d41\u81bf\u80f8\u4f7f\u752814-French\u80f8\u7ba1(chest tube)\u6216\u8c6c\u5c3e\u5c0e\u7ba1(pigtail catheter)\u5373\u53ef\n": "[D]", "109-44.\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u65bc\u665a\u671f\u767c\u5c0f\u7d30\u80de\u80ba\u764c\u7b2c\u4e00\u7dda\u6cbb\u7642\u9069\u5408\u55ae\u4e00\u4f7f\u7528pembrolizumab\u6ce8\u5c04\uff1f    \nA.EGFR mutations\nB.ALK gene rearrangements   \nC.\u75c5\u60a3\u6709\u63a7\u5236\u4e0d\u4f73\u7684\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\nD.PD-L1 tumor proportion score less than 1%\nE.PD-L1 tumor proportion score of 50% or greater\n": "[E]", "110-19.35\u6b72\u5973\u6027\u7591\u4f3c\u7e31\u8188\u8154\u816b\u7624 \uff0c\u56e0\u70ba\u5598\u4f86\u5230\u80f8\u8154\u5167\u79d1\u9580\u8a3a \u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u767c\u73fe TLC 75 %, FRC 100 %, RV 120 %, \nFVC 60%, FEV\u2081 60 %, Raw 1.0, DLco80% (TLC total lung capacity; FRC functional residual capacity; RV \nresidual volume; FVC forced vital capacity; FEV1 forced expiratory volume in 1 s; Raw airway \nresistance; DLco diffusion capacity of lung for carbon monoxide )\uff0c\u5982\u4f55\u89e3\u91cb\u5979\u7684\u80ba\u529f\u80fd ?   \nA.\u56e0\u70ba\u80a5\u80d6\u9020\u6210\u7684\u4fb7\u9650\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\nB.\u56e0\u70ba\u6c23\u5598\u9020\u6210\u7684\u963b\u585e\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\nC.\u56e0\u70ba\u80ba\u6c23\u816b\u9020\u6210\u7684\u963b\u585e\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\nD.\u56e0\u70ba\u547c\u5438\u808c\u8089\u7121\u529b\u9020\u6210\u7684\u4fb7\u9650\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\nE.\u56e0\u70ba\u80ba\u7e96\u7dad\u5316\u9020\u6210\u7684\u4fb7\u9650\u6027\u80ba\u529f\u80fd\u969c\u7919\u3002\n": "[D]", "110-20.\u5982\u679c\u628a\u80ba\u90e8\u554f\u984c\u5206\u6210\u4e09\u90e8\u5206 \uff0c\u963b\u585e\u6027\u554f\u984c \uff0c\u9650\u5236\u6027\u554f\u984c \uff0c\u53ca\u80ba\u8840\u7ba1\u554f\u984c \u3002\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u9650\u5236\u6027\u554f\u984c\n(1)\u985e\u8089\u7624(Sarcoidosis) ( 2)\u652f\u6c23\u7ba1\u64f4\u5f35 (3)\u91cd\u75c7\u808c\u7121\u529b (Myasthenia Gravis) ( 4)\u6162\u6027\u808b\u819c\u7a4d\u6c34 (5)\u5c0f\u652f\u6c23\u7ba1\u708e   \nA.(1)+(3)\u3002\nB.(2)+(5)\u3002\nC.(1)+(2)\u3002\nD.(2)+(4)\u3002\nE.(3)+(5)\u3002\n": "[B]", "110-21.\u80ba\u90e8\u60e1\u6027\u816b\u7624\u7684\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u5206\u671f\uff0c\u5c0d\u65bc\u6cbb\u7642\u5f71\u97ff\u5f88\u5927\u3002\u4e0b\u5217\u6558\u8ff0\u5c0d\u65bc\u5224\u65b7\u6dcb\u5df4\u7d50\u5206\u671f\u4f55\u8005\u70ba\u975e?    \nA.\u6b63\u5b50\u6383\u63cf\u5c0d\u65bc\u6dcb\u5df4\u7d50\u5206\u671f(\u5206\u8fa8\u826f\u6027\u6216\u60e1\u6027\u6dcb\u5df4\u7d50)\u7684\u654f\u611f\u5ea6(sensitivity)\u8d85\u904e95%\u3002\nB.\u7e31\u8188\u8154\u93e1\u662f\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u5206\u671f\u7684\u6a19\u6e96\u505a\u6cd5 \uff0c\u76ee\u524d\u5df2\u88ab\u652f\u6c23\u7ba1\u5167\u8d85\u97f3\u6ce2\u5c0e\u5f15\u7d93\u6c23\u7ba1\u7d30\u91dd\u7a7f\u523a\u8853 (EBUS \nTBNA)\u53d6\u4ee3\u3002\nC.\u6b63\u5b50\u6383\u63cf\u5c0d\u65bc\u826f\u6027\u6216\u60e1\u6027\u6dcb\u5df4\u7d50\u5224\u5225\u7684\u6e96\u78ba\u6027\u6bd4\u4e0d\u4e0a\u7e31\u8188\u8154\u93e1\u3002\nD.\u7e31\u8188\u8154\u93e1\u7121\u6cd5\u53d6\u6a23\u80ba\u9580\u6dcb\u5df4\u7d50\u3002\nE.\u7e31\u8188\u8154\u93e1\u53ca\u652f\u6c23\u7ba1\u5167\u8d85\u97f3\u6ce2\u5c0e\u5f15\u7d93\u6c23\u7ba1\u7d30\u91dd\u7a7f\u523a\u8853 (EBUS TBNA )\u7686\u7121\u6cd5\u53d6\u6a23\u4e3b\u52d5\u8108\u65c1\u6dcb\u5df4\u7d50 (Level \n5,6)\u3002\n": "[A]", "110-22.35\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u5c0f\u6642\u5019\u88ab\u8a3a\u65b7\u70ba\u6c23\u5598 \u3002\u6700\u8fd1\u5e7e\u5e74\u5e38\u5e38\u767c\u4f5c \uff0c\u5373\u4f7f\u7528\u4e86\u9ad8\u5291\u91cf\u5438\u5165\u6027\u985e\u56fa\u9187 \uff0c\u9577\u6548\u652f\u6c23\u7ba1\u64f4\n\u5f35\u5291\uff0c\u53e3\u670d\u985e\u56fa\u9187 \uff0c\u53e3\u670d\u6297\u767d\u4e09\u70ef (leukotriene )\uff0c\u4ecd\u4e0d\u6642\u767c\u4f5c \u3002\u4e0b\u5217\u54ea\u4e00\u7a2e\u6cbb\u7642\u65b9\u5f0f\u4e0d\u9069\u7576 ?   \nA.\u5982\u679c\u75c5\u4eba\u8840\u6db2Ig E\u589e\u52a0\uff0c\u53ef\u4ee5\u8003\u616eanti-IgE omalizumab\u3002\nB.\u55dc\u4f0a\u7d05\u6027\u767d\u8840\u7403\u589e\u52a0\uff0c\u53ef\u4ee5\u8003\u616ecyclosporin A\uff0c\u6291\u5236\u767c\u708e\u53cd\u61c9\u3002\nC.\u91cd\u65b0\u6aa2\u8996\u75c5\u4eba\u4f7f\u7528\u85e5\u7269\u7684\u9806\u5f9e\u6027\uff0c\u53ca\u5438\u5165\u578b\u85e5\u7269\u7684\u4f7f\u7528\u65b9\u5f0f\u3002\nD.\u5728\u6c92\u6709\u56b4\u91cd\u767c\u708e\u7684\u75c5\u4eba\uff0c\u8003\u616e\u7528\u652f\u6c23\u7ba1\u71b1\u6210\u5f62\u8853\u4f86\u71d2\u707c\u6c23\u9053\u4e0a\u7684\u5e73\u6ed1\u808c\u3002\nE.\u53ef\u4ee5\u8003\u616e\u4f7f\u7528theophylline\uff0c\u96d6\u7136\u6548\u679c\u6709\u9650\u3002\n": "[B]", "110-23.\u4e0b\u5217\u5c0d\u80ba\u764c\u7684\u63cf\u8ff0\u4f55\u8005\u70ba\u662f?    \nA.\u80ba\u764c\u7684\u9a45\u52d5\u7a81\u8b8a(driver mutation)\u4e0d\u5305\u62ecNTRK \u57fa\u56e0\u3002\nB.\u5c0f\u7d30\u80de\u80ba\u764c\u90fd\u5177\u6709P53, RB1\u7684\u7a81\u8b8a\u3002\nC.\u5229\u7528Chest X-ray\u7be9\u6aa2\u80ba\u764c\uff0c\u53ef\u4ee5\u6709\u6548\u964d\u4f4e20%\u80ba\u764c\u6b7b\u4ea1\u7387\u3002\nD.\u65e9\u671f\u80ba\u764c\u5efa\u8b70\u624b\u8853\u6cbb\u7642\uff0c\u5982\u7121\u6cd5\u624b\u8853\uff0c\u53ef\u4ee5\u8003\u616e\u6a19\u9776\u85e5\u7269\u6cbb\u7642\u3002\nE.\u5c0d\u65bc\u7b2c\u4e09\u671f\u7684\u75c5\u4eba\u5982\u679c\u7121\u6cd5\u958b\u5200 \uff0c\u5efa\u8b70\u540c\u6642\u5316\u5b78\u6cbb\u7642\u53ca\u653e\u5c04\u6cbb\u7642 \uff0c\u4e26\u65bc\u7642\u7a0b\u7d50\u675f\u5f8c\u4f7f\u7528\u514d\u75ab\u6cbb\u7642\u4e00\n\u5e74\u3002   \n": "[E]", "110-24.72\u6b72\u7537\u6027 \uff0c\u80ba\u764c\u7b2c\u56db\u671f\u63a5\u53d7\u514d\u75ab\u6cbb\u7642\u5408\u4f75\u5316\u5b78\u6cbb\u7642 \u3002\u56e0\u70ba\u514d\u75ab\u6cbb\u7642 \uff0c\u9020\u6210\u9593\u8cea\u6027\u80ba\u75c5 \uff0c\u4f4f\u9662\u4f7f\u7528\u9ad8\u5291\u91cf\u7684\n\u985e\u56fa\u9187\u3002\u56e0\u70ba\u56b4\u91cd\u7684\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u5e7e\u4e4e\u6574\u5929\u81e5\u5e8a \u3002\u6709\u4e00\u5929\u4ed6\u7684\u5973\u5152\u5728\u5e6b\u4ed6\u6309\u6469\u817f\u90e8\u6642 \uff0c\u7a81\u7136\u8840\u58d3\u98fd\u548c\n\u5ea6\u4e0b\u964d\u523050 %\uff0c\u8840\u58d3\u4e0b\u964d40mmHg \uff0c\u4e0b\u5217\u4f55\u8005\u662f\u9020\u6210\u4f11\u514b\u6700\u6709\u53ef\u80fd\u7684\u539f\u56e0 \uff1f   \nA.\u80ba\u52d5\u8108\u6813\u585e\u3002\nB.\u5fc3\u5f8b\u4e0d\u6574\u3002\nC.\u904e\u654f\u6027\u4f11\u514b\u3002\nD.\u5927\u91cf\u5167\u51fa\u8840\u3002\nE.\u6557\u8840\u75c7\u4f11\u514b\u3002\n": "[A]", "110-25.\u611f\u67d3SARS -CoV-2\u7684\u75c5\u4eba\u6b7b\u4ea1\u7387\u504f\u9ad8 \uff0c\u5c0d\u65bcCOVID -19\u91cd\u75c7\u7684\u75c5\u4eba\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u662f ?\n(1)\u6c89\u9ed8\u7f3a\u6c27 (silent hypoxia )\u4e3b\u8981\u662f\u80ba\u6813\u585e\u9020\u6210 \uff0c\u5efa\u8b70\u5e38\u898f\u7528\u6297\u51dd\u8840\u5291\u6cbb\u7642\n(2)HFNC (high flow nasal cannula )\uff0c\u88ab\u7a31\u70ba\u6551\u547d\u795e\u5668 \uff0c\u4e3b\u8981\u7528\u4f86\u964d\u4f4e\u547c\u5438\u808c\u505a\u5de5\n(3)\u4f7f\u7528\u985e\u56fa\u9187\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\n(4)\u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\u53ef\u4ee5\u5e38\u898f\u7528\u4f86\u6cbb\u7642COVID -19\u9020\u6210\u7684\u547c\u5438\u8870\u7aed\n(5)\u4fef\u81e5\u901a\u6c23 (Prone Positioning )\u53ef\u4ee5\u964d\u4f4e\u6c27\u6c23\u9700\u6c42\u91cf   \nA.(1)+(2)+(3)+(5)\u3002\nB.(3)+(4)+(5)\u3002\nC.(3)+(5)\u3002\nD.(1)+(3)+(5)\u3002\nE.(2)+(3)+(5)\u3002\n": "[C]", "110-26.63\u6b72\u5973\u6027\u75c5\u4eba\u80ba\u764c\u7b2c\u56db\u671f\u6b63\u5728\u63a5\u53d7\u5316\u5b78\u6cbb\u7642 \uff0c\u6700\u8fd1\u56e0\u5598 \u3001\u808b\u819c\u7a4d\u6c34\u589e\u52a0 \uff0c\u4f4f\u9662\u63a5\u53d7\u6cbb\u7642 \u3002\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u9664\n\u4e86\u808b\u819c\u7a4d\u6c34\u5916 \uff0c\u4e5f\u6709\u5c11\u91cf\u5230\u4e2d\u91cf\u5fc3\u5305\u819c\u7a4d\u6c34 \uff0c\u53ca\u5fc3\u5305\u819c\u589e\u539a \u3002\u808b\u819c\u7a4d\u6c34\u6aa2\u67e5 \uff0c\u6de1\u9ec3\u8272\uff0c\u6ef2\u51fa\n\u6db2(exudate)\uff0c\u7d30\u80de\u5b78\u6aa2\u67e5\u7121\u764c\u7d30\u80de \uff0c\u4ee5\u6dcb\u5df4\u7403\u70ba\u4e3b \u3002\u7a4d\u6c34\u57f9\u990a\u70ba\u7d50\u6838\u83cc \u3002\u4ee5\u4e0b\u8655\u7f6e\u4f55\u8005\u4e0d\u9069\u7576 ?   \nA.\u61c9\u7acb\u5373\u7d66\u4e88\u6297\u7d50\u6838\u6cbb\u7642\u3002\nB.\u5982\u679c\u75f0\u6db2\u62b9\u7247\u70ba\u9670\u6027\uff0c\u4e0d\u9808\u9694\u96e2\u3002\nC.\u56e0\u70ba\u591a\u91cd\u75be\u75c5\u5efa\u8b70\u52a0\u4e0avit B6\u3002\nD.\u5fc3\u5305\u819c\u589e\u539a\u4e0d\u662f\u7d50\u6838\u611f\u67d3\u9020\u6210\uff0c\u61c9\u8a72\u63a5\u53d7\u5fc3\u5305\u819c\u5207\u9664\u8853\uff0c\u7e7c\u7e8c\u80ba\u764c\u6cbb\u7642\u3002\nE.\u56e0\u70ba\u5598\u3001\u808b\u819c\u7a4d\u6c34 \uff0c\u53ca\u5fc3\u5305\u819c\u7a4d\u6c34\u589e\u52a0 \uff0c\u53ef\u4ee5\u662f\u7d50\u6838\u611f\u67d3\u5f15\u8d77 \uff0c\u53ef\u4ee5\u66ab\u505c\u5316\u7642 \uff0c\u89c0\u5bdf\u6297\u7d50\u6838\u6cbb\u7642\u6548\n\u679c\u3002\n": "[D]", "110-27.70\u6b72\u7537\u6027 COPD\u5728\u9580\u8a3a\u8ffd\u8e64\u6cbb\u7642 \u3002\u5728\u4e00\u6b21\u91cd\u611f\u5192\u5f8c \uff0c\u75c5\u4eba\u89ba\u5f97\u8d8a\u4f86\u8d8a\u5598 \uff0c\u54b3\u55fd\u52a0\u5287 \uff0c\u5408\u4f75\u5c11\u8a31\u9ec3\u75f0 \uff0c\u56e0\n\u6b64\u4f86\u5230\u6025\u8a3a \u3002\u672a\u767c\u4f5c\u6642 \uff0c\u6700\u5f8c\u4e00\u6b21\u7684\u80ba\u529f\u80fdFEV\u2081 42 %\u3002\u5728\u6025\u8a3a\uff0c\u4e8c\u6c27\u5316\u78b3\u5206\u58d3 (PaCO\u2082)55mmHg \uff0c\u5169\u5074\n\u7030\u6f2b\u6027\u5598\u9cf4\u97f3 \uff0c\u80f8\u90e8X\u5149\u7121\u80ba\u708e\u8de1\u8c61 \u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u4f55\u8005\u8f03\u4e0d\u9069\u7576 \uff1f   \nA.\u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20\u3002\nB.\u8d95\u5feb\u63d2\u7ba1\u4f7f\u7528\u547c\u5438\u5668\uff0c\u6cbb\u7642\u7b2c\u4e8c\u578b\u547c\u5438\u8870\u7aed\u3002\nC.\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u6b63\u58d3\u547c\u5438\u5668\u3002\nD.\u975c\u8108\u6ce8\u5c04\u985e\u56fa\u9187\u3002\nE.\u589e\u52a0\u6c23\u7ba1\u64f4\u5f35\u5291\u7684\u4f7f\u7528\u3002   \n": "[B]", "110-28.\u6797\u5148\u751f60 \u6b72\uff0c\u6bcf\u5929\u62bd\u4e00\u5305\u83f8\u5230\u76ee\u524d\u5171\u62bd30 \u5e74\u3002\u5927\u7d04\u534a\u5e74\u524d\u958b\u59cb\u51fa\u73fe\u722c\u6a13\u68af\u547c\u5438\u6025\u4fc3 \uff0c\u5927\u7d04\u722c\u5230\u4e8c\u6a13\u5c31\u8981\n\u4f11\u606f\u3002\u6162\u6162\u7684\u9023\u7a0d\u5fae\u8d70\u4e00\u9ede\u5e73\u8def\u90fd\u6703\u89ba\u5f97\u5598 \uff0c\u540c\u6642\u4f34\u96a8\u54b3\u55fd\u8207\u767d\u75f0 \u3002\u4ed6\u5230\u9644\u8fd1\u91ab\u9662\u5c31\u91ab \uff0c\u80f8\u90e8X\u5149\u5448\u73fe\u5169\n\u5074\u80ba\u5bb9\u7a4d\u8207\u900f\u5149\u5ea6\u589e\u52a0 \u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u7d50\u679c\u70ba \uff1aFEV\u2081/FVC=50%\uff0cFEV\u2081\u70ba\u9810\u6e2c\u503c\u768435 %\uff0c\u7d66\u4e88\u77ed\n\u6548\u03b2\u2082-agonist 15\u5206\u9418\u5f8cFEV \u2081\u6539\u55845%\u3002\u5169\u500b\u6708\u524d\u9084\u56e0\u70ba\u5598\u7684\u75c7\u72c0\u6025\u901f\u60e1\u5316\u4f4f\u9662\u6cbb\u7642\u4e00\u661f\u671f \uff0c\u5f8c\u7e8c\u53ef\u8003\u616e\u4e0b\n\u5217\u54ea\u4e9b\u6cbb\u7642\u65b9\u5f0f \uff1f(1) \u5efa\u8b70\u6212\u83f8 \uff0c(2) \u7d66\u4e88\u5438\u5165\u578bLong -acting Muscarinic Antagonists (LAMA)\uff0c(3) \u5408\u4f75\u5438\n\u5165\u578bLAMA \u8207Long-acting \u03b2\u2082-agonist(LABA)\uff0c(4) \u55ae\u7368\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187 \uff0c(5) \u5408\u4f75\u5438\u5165\n\u578bLAMA\uff0cLABA\u4ee5\u53ca\u5438\u5165\u578b\u985e\u56fa\u9187 \u3002   \nA.(1)+(2)+(3)\u3002\nB.(1)+(2)+(3)+(4)\u3002\nC.(1)+(2)+(3)+(4)+(5)\u3002\nD.(1)+(2)+(3)+(5)\u3002\nE.(1)+(3)+(4)+(5)\u3002\n": "[D]", "110-29.\u63a5\u7e8c\u4e0a\u984c \uff0c\u6797\u5148\u751f\u5728\u63a5\u53d7\u85e5\u7269\u6cbb\u7642\u5f8c \uff0c\u75c7\u72c0\u7a0d\u6709\u6539\u5584 \u3002\u4f46\u5169\u500b\u6708\u5f8c \uff0c\u6797\u5148\u751f\u547c\u5438\u6025\u4fc3\u7684\u75c7\u72c0\u52a0\u5287 \uff0c\u4e14\u54b3\u51fa\n\u7684\u75f0\u8b8a\u6210\u9ec3\u8272 \u3002\u7531\u65bc\u4f11\u606f\u6642\u4ecd\u7136\u6709\u547c\u5438\u6025\u4fc3\u7684\u73fe\u8c61 \uff0c\u56e0\u6b64\u738b\u5148\u751f\u4f86\u5230\u6025\u8a3a\u5c31\u91ab \u3002\u5728\u6025\u8a3a\u6642\u547c\u5438\u901f\u7387\u6bcf\u5206\n\u941828\u6b21\uff0c\u8840\u6c27\u98fd\u548c\u5ea6\u70ba89 %\u7121\u4f7f\u7528\u6c27\u6c23 \uff0c\u80f8\u90e8X\u5149\u8207\u5148\u524d\u7121\u660e\u986f\u5dee\u7570 \u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u4e0d\u6070\u7576 \uff1f   \nA.\u7d66\u4e88\u5438\u5165\u578b\u77ed\u6548 \u03b2\u2082-agonist\u3002\nB.\u7d66\u4e88\u5438\u5165\u578b\u77ed\u6548Anticholinergic agent\u3002\nC.\u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u3002\nD.\u61c9\u907f\u514d\u7d66\u4e88\u6c27\u6c23\u4ee5\u9810\u9632\u8840\u4e2d\u4e8c\u6c27\u5316\u78b3\u4e0a\u5347\u3002\nE.\u7d66\u4e88\u53e3\u670d\u985e\u56fa\u9187\uff0c\u4f7f\u75285-10\u5929\u3002\n": "[D]", "110-30.\u95dc\u65bc\u6c23\u5598\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u5167\u6e90\u6027\u6c23\u5598(intrinsic asthma)\u8840\u6e05\u4e2dIgE\u7684\u6fc3\u5ea6\u901a\u5e38\u8f03\u9ad8\u3002\nB.\u898f\u5247\u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187\u53ef\u9810\u9632\u904b\u52d5\u8a98\u767c\u6c23\u5598 (exercise-induced asthma, EIA)\u3002\nC.Long-acting \u03b2\u2082-agonist\uff08LABA\uff09\u61c9\u8207\u5438\u5165\u578b\u985e\u56fa\u9187\u5408\u4f75\u4f7f\u7528 \uff0c\u4e0d\u5b9c\u55ae\u7368\u4f7f\u7528 \u3002\nD.Long-acting Muscarinic Antagonists (LAMA)\uff0c\u65bc\u4f7f\u7528LABA\u5408\u4f75\u5438\u5165\u578b\u985e\u56fa\u9187\u6cbb\u7642\u4e0d\u4f73\u4e4b\u60a3\u8005 \uff0c\u53ef\u6539\n\u5584\u60a3\u8005\u80ba\u529f\u80fd \u3002\nE.\u60a3\u6709\u963f\u65af\u5339\u9748\u654f\u611f\u578b\u6c23\u5598 (aspirin sensitive asthma )\u4e4b\u75c5\u60a3\uff0c\u61c9\u907f\u514d\u670d\u7528 nonselective COX \ninhibitors \u3002\n": "[A]", "110-31.\u7576\u6c23\u5598\u63a7\u5236\u4e0d\u7406\u60f3\u6642 \uff0c\u9808\u8003\u91cf\u4ee5\u4e0b\u54ea\u4e9b\u56e0\u7d20\u4e4b\u5f71\u97ff \uff1f(1) \u4f7f\u7528\u5438\u5165\u578b\u985e\u56fa\u9187\u9806\u5f9e\u6027\u4e0d\u4f73 \uff0c(2) \u662f\u5426\u6709\u8077\u696d\u5834\n\u6240\u904e\u654f\u539f\u4e4b\u66b4\u9732 \uff0c(3) \u662f\u5426\u540c\u6642\u60a3\u6709\u6162\u6027\u9f3b\u7ac7\u708e (chronic rhinosinusitis )\uff0c(4) \u662f\u5426\u6709\u8072\u5e36\u529f\u80fd\u7570\n\u5e38(Vocal-cord dysfunction )\uff0c(5) \u662f\u5426\u540c\u6642\u4f7f\u7528beta -adrenergic blockers, aspirin\u7b49\u85e5\u7269 \u3002   \nA.(1)+(2)\u3002\nB.(1)+(2)+(3)\u3002\nC.(1)+(2)+(5)\u3002\nD.(1)+(2)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[E]", "110-32.\u95dc\u65bc\u80ba\u6813\u585e (pulmonary embolism) \u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f    \nA.\u5fc3\u96fb\u5716\u6700\u5e38\u898b\u7684\u7570\u5e38\u662fS1Q3T3 sign\u3002\nB.\u75c5\u60a3\u8840\u6f3f\u4e2dD-dimer\u82e5\u4e0a\u5347\uff0c\u53ef\u7528\u4f86\u78ba\u8a3a\u80ba\u6813\u585e\u3002\nC.\u80ba\u704c\u6ce8-\u901a\u6c23\u6383\u63cf (ventilation-perfusion lung scanning)\u662f\u8a3a\u65b7\u80ba\u6813\u585e\u9996\u9078\u7684\u5f71\u50cf\u6aa2\u67e5\u3002   \nD.Rivaroxaban \u4ee5\u53ca apixaban\u53ef\u4ee5\u55ae\u7368\u4f7f\u7528\u65bc\u6cbb\u7642\u80ba\u6813\u585e\uff0c\u4e0d\u9808\u5148\u6ce8\u5c04\u6297\u51dd\u8840\u5291\u3002\nE.\u82e5\u75c5\u60a3\u767c\u751fSubmassive pulmonary embolism, \u4f46\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5448\u73fe\u53f3\u5fc3\u5ba4\u529f\u80fd\u4e0d\u5168 \uff0c\u61c9\u8003\u616e\u6ce8\n\u5c04recombinant tissue plasminogen activator (tPA)\u3002\n": "[D]", "110-33.\u95dc\u65bc\u7279\u767c\u6027\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fibrosis, IPF) \u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u597d\u767c\u65bc\u7537\u6027\u3002\nB.\u8207\u62bd\u83f8\u4ee5\u53ca\u74b0\u5883\u7684\u66b4\u9732\u6709\u95dc\u3002\nC.Usual interstitial pneumonia (UIP) \u70ba\u4e3b\u8981\u7684\u75c5\u7406\u8b8a\u5316\u3002\nD.\u9700\u6392\u9664connective tissue diseases (CTDs) associated interstitial lung diseases (ILDs)\u3002\nE.\u6cbb\u7642\u4ee5\u514d\u75ab\u6291\u5236\u5291\u70ba\u4e3b\u3002\n": "[E]", "110-34.\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\u53ef\u964d\u4f4e\u9700ICU\u7167\u8b77\u4e4bCOVID-19\u75c5\u60a3\u6b7b\u4ea1\u7387\uff1f    \nA.Remdesivir\u3002\nB.Baricitinib plus Remdesivir\u3002\nC.Interleukin-6 Receptor Antagonists (tocilizumab or sarilumab)\nD.Covid-19 convalescent plasma\u3002\nE.SARS-CoV-2 Neutralizing Antibody\u3002\n": "[C]", "110-35.\u4e0b\u5217\u4f55\u7a2e\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u7684\u9a45\u52d5\u7a81\u8b8a \uff08driver mutations\uff09\uff0c \u76ee\u524d\u4ecd\u672a\u6709\u6709\u6548\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291\u53ef\u7528\u65bc\u665a\u671f\u975e\u5c0f\n\u7d30\u80de\u80ba\u764c\u60a3\u8005\u4e4b\u6cbb\u7642 \uff1f   \nA.EGFR mutations\u3002\nB.ALK rearrangements\u3002\nC.KRAS G12A mutation\u3002\nD.KRAS G12C mutation\u3002\nE.BRAF V600E mutation\u3002\n": "[C]", "110-36.\u6709\u95dcEGFR exon 19 deletion\u4ee5\u53caL858R\u967d\u6027\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u75c5\u60a3\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?    \nA.\u7b2c\u4e8c\u3001\u4e09\u671f\u7684\u75c5\u60a3\u8853\u5f8c\u670d\u7528Osimertinib\u4e09\u5e74\u8f14\u52a9\u6027\u6cbb\u7642\u76f8\u8f03\u65bc\u5b89\u6170\u5291 \uff0c\u53ef\u5ef6\u9577\u75c5\u60a3\u7121\u75be\u75c5\u5b58\u6d3b\n\u7387(disease-free survival )\u3002\nB.Afatinib\u65bc\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e00\u7dda\u6cbb\u7642\u76f8\u8f03\u65bcGefitinib \uff0c\u53ef\u5ef6\u9577\u75be\u75c5\u7121\u60e1\u5316\u5b58\u6d3b\u671f \uff08progression -free \nsurvival\uff09\u3002\nC.Osimertinib\u65bc\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e00\u7dda\u6cbb\u7642\u76f8\u8f03\u65bcGefitinib or Erlotinib \uff0c\u53ef\u5ef6\u9577\u6574\u9ad4\u5b58\u6d3b (Overall \nsurvival)\u3002\nD.\u665a\u671f\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u4e00\u7dda\u6cbb\u7642\u4f7f\u7528Gefitinib or Erlotinib\u6cbb\u7642\u5f8c \uff0c\u6700\u5e38\u898b\u4e4b\u6297\u85e5\u6a5f\u8f49\u70ba\u7522\u751fsecondary \nT790M mutation \u3002\nE.\u7576\u7522\u751fsecondary T790M mutation \u5f8c\uff0c\u6700\u4f73\u7684\u6cbb\u7642\u65b9\u5f0f\u662f\u7d66\u4e88\u7b2c\u4e8c\u4ee3EGFR\u5c0f\u5206\u5b50\u6291\u5236\u5291Afatinib \u6cbb\n\u7642\u3002   \n": "[E]", "111-19.\u95dc\u65bc\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(Chronic obstructive pulmonary disease, COPD)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.COPD\u60a3\u8005\u82e5\u4f11\u606f\u6642\u8840\u6c27\u98fd\u548c\u5ea6 \u226488%\uff0c\u63a5\u53d7\u9577\u671f\u6c27\u7642 (long-term oxygen therapy, LTOT )\u53ef\u6539\u5584\u5b58\n\u6d3b\u3002\nB.\u4e0d\u5efa\u8b70\u9577\u671f\u4f7f\u7528\u53e3\u670d\u985e\u56fa\u9187\u3002\nC.\u6025\u6027\u767c\u4f5c(COPD exacerbation) \u5927\u7d04\u67091/3\u662f\u547c\u5438\u9053\u75c5\u6bd2\u611f\u67d3\u5f15\u8d77\u7684\u3002\nD.\u6025\u6027\u767c\u4f5c\u6642\uff0c\u8840\u6c27\u4e0d\u8db3\u6642\u61c9\u7d66\u4e88\u6c27\u6c23\u4ee5\u7dad\u6301\u8840\u6c27\u98fd\u548c\u5ea6\u226590%\u3002\nE.\u6025\u6027\u767c\u4f5c\u6642\uff0c\u7d66\u4e88\u5168\u8eab\u6027\u985e\u56fa\u9187(systemic corticosteroid)\u6cbb\u7642\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\u3002\n": "[E]", "111-20.\u5468\u5148\u751f65 \u6b72\uff0c\u6bcf\u5929\u62bd\u5169\u5305\u83f8\u5171\u62bd30 \u5e74\uff0c\u4e94\u5e74\u524d\u7531\u65bc\u8f03\u5287\u70c8\u904b\u52d5\u5f8c\u6703\u547c\u5438\u6025\u4fc3 \uff0c\u56e0\u6b64\u6212\u83f8 \u3002\u6700\u8fd1\u4e00\u5e74\u5927\u7d04\n\u722c\u5230\u4e8c\u6a13\u5c31\u8981\u4f11\u606f \uff0c\u6162\u6162\u7684\u9023\u7a0d\u5fae\u8d70\u4e00\u9ede\u5e73\u8def\u90fd\u6703\u89ba\u5f97\u5598 \uff0c\u5e38\u5e38\u9700\u8981\u505c\u4e0b\u4f86\u4f11\u606f \u3002\u4ed6\u5230\u9644\u8fd1\u91ab\u9662\u5c31\u91ab \uff0c\u80f8\n\u90e8X\u5149\u5448\u73fe\u5169\u5074\u80ba\u4e0a\u8449\u5927\u80ba\u6ce1 (bullae)\u3002\u80ba\u529f\u80fd\u6aa2\u67e5\u7d50\u679c\u70ba \uff1aFEV1/FVC=50%\uff0cFEV1\u70ba\u9810\u6e2c\u503c\u768435 %\uff0c\u7d66\n\u4e88\u77ed\u6548\u03b22-agonist 15\u5206\u9418\u5f8cFEV 1\u6539\u55843%\u3002\u6700\u8fd1\u534a\u5e74\u56e0\u70ba\u5598\u7684\u75c7\u72c0\u52a0\u91cd\u5230\u91ab\u9662\u6025\u8a3a\u5c31\u91ab\u4e09\u6b21 \uff0c\u9580\u8a3a\u85e5\u7269\u6cbb\n\u7642\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u6070\u7576 \uff1f   \nA.\u55ae\u7368\u7d66\u4e88\u5438\u5165\u578bLong-acting \u03b22-agonist (LABA)\u3002\nB.\u55ae\u7368\u7d66\u4e88\u5438\u5165\u578bLong-acting Muscarinic Antagonists (LAMA)\u3002\nC.\u5408\u4f75\u5438\u5165\u578bLAMA \u8207LABA\u3002\nD.\u5408\u4f75LABA\u8207\u5438\u5165\u578b\u985e\u56fa\u9187\u3002\nE.\u5408\u4f75\u5438\u5165\u578bLAMA\uff0cLABA\u4ee5\u53ca\u5438\u5165\u578b\u985e\u56fa\u9187\u3002\n": "[A]", "111-21.\u4e0b\u5217\u54ea\u4e00\u9805\u4e0d\u5c6c\u65bc\u7b2c\u4e8c\u578b\u6c23\u5598(Type 2 high-inflammation asthma)\u76f8\u95dc\u4e4b\u751f\u7269\u6a19\u8a18\uff1f    \nA.\u55dc\u9178\u6027\u767d\u8840\u7403 (eosinophils)\u3002\nB.\u55dc\u4e2d\u6027\u767d\u8840\u7403 (neutrophils)\u3002\nC.\u767d\u8840\u7403\u4ecb\u7d20-4 (Interleukin-4)\u3002\nD.\u767d\u8840\u7403\u4ecb\u7d20-5 (Interleukin-5)\u3002\nE.\u767d\u8840\u7403\u4ecb\u7d20-13 (Interleukin-13)\u3002   \n": "[B]", "111-22.\u4ee5\u4e0b\u54ea\u4e9b\u56e0\u7d20\u6709\u53ef\u80fd\u5f15\u767c\u6c23\u5598\u6025\u6027\u767c\u4f5c \uff1f\n(1)\u904b\u52d5 (2) \u904e\u5ea6\u63db\u6c23 (3) \u51b7\u7a7a\u6c23 (4) SARS-CoV-2 \u75c5\u6bd2\u611f\u67d3 (5) \u4f7f\u7528beta -adrenergic blockers, aspirin\u7b49\u85e5\n\u7269\u3002   \nA.(1)+(2)+(3)\u3002\nB.(1)+(2)+(5)\u3002\nC.(1)+(2)+(3)+(4)\u3002\nD.(1)+(3)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[E]", "111-23.\u95dc\u65bc\u793e\u5340\u6027\u80ba\u708e (Community-acquired pneumonia) \u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f    \nA.\u80f8\u8154\u8d85\u97f3\u6ce2\u8a3a\u65b7\u80ba\u708e\u7684\u9748\u654f\u5ea6\u8f03\u80f8\u90e8 X\u5149\u9ad8\u3002\nB.\u6162\u6027\u80ba\u75be\u75c5 (chronic lung diseases, structure lung diseases )\u662f\u7da0\u81bf\u687f\u83cc\u793e\u5340\u6027\u80ba\u708e (Pseudomonas \naeruginosa caused community -acquired pneumonia )\u7684\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00 \u3002\nC.\u5c3f\u6db2Streptococcus pneumoniae \u8207 Legionella pneumophila\u6297\u539f\u6aa2\u9a57\u90fd\u6709\u5f88\u9ad8\u7684\u8a3a\u65b7\u9748\u654f\u5ea6\u3002\nD.CURB-65\u8f03The Pneumonia Severity Index (PSI)\u7c21\u4fbf\u4e14\u6709\u6548\u5730\u5224\u65b7\u75c5\u60a3\u9700\u8981\u4f4f\u9662\u6216\u53ea\u8981\u63a5\u53d7\u9580\u8a3a\u6cbb\n\u7642\u3002\nE.\u63a5\u53d7\u9580\u8a3a\u6cbb\u7642\u7684\u75c5\u60a3 \uff0c\u53ea\u6709\u5728pneumococcal resistant to macrolide\u5c0f\u65bc50 %\u7684\u5730\u5340\u65b9\u53ef\u55ae\u7368\u4f7f\n\u7528macrolide\u6cbb\u7642 \u3002\n": "[B]", "111-24.\u95dc\u65bc\u6c27\u6c23\u6cbb\u7642(Oxygen Therapy)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u9f3b\u5c0e\u7ba1\uff08Nasal cannula\uff09\u7684\u6c27\u6c23\u6d41\u91cf\u4ee5\u4e0d\u8d85\u904e 6 liters/min\u70ba\u539f\u5247\u3002\nB.\u4f7f\u7528\u7c21\u55ae\u5f0f\u9762\u7f69 \uff08Simple face mask \uff09\u6642\uff0c\u82e5\u56fa\u5b9a\u6c27\u6c23\u6d41\u901f( 5 liters /min)\uff0c\u7576\u75c5\u60a3\u6bcf\u5206\u9418\u63db\u6c23\u91cf\u5347\n\u9ad8\uff0c\u5247FiO2\u6703\u96a8\u4e4b\u4e0b\u964d \u3002\nC.\u975e\u518d\u5438\u5165\u6027\u9762\u7f69\uff08nonrebreather face mask\uff09\u7d66\u4e88\u75c5\u60a3\u7684\u6c27\u6c23FiO2\u53ef\u90540.6-1.0\u3002\nD.Venturi mask\u7684\u597d\u8655\u662f\u53ef\u4ee5\u63d0\u4f9b\u75c5\u60a3\u76f8\u5c0d\u56fa\u5b9a\u7684FiO2\u3002\nE.\u9ad8\u6d41\u91cf\u9f3b\u5c0e\u7ba1 \uff08High-flow nasal cannula \uff09\u53ef\u7522\u751f\u5410\u6c23\u672b\u6b63\u58d3 (positive end -expiratory pressure )\uff0c\u4ee5\n\u907f\u514d\u80ba\u6ce1\u584c\u9677 \u3002\n": "[C]", "111-25.\u4e0b\u5217\u6709\u95dc\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(acute respiratory distress syndrome, ARDS)\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u6839\u64daBerlin definition\uff0c\u56b4\u91cd\u5ea6\u662f\u4ee5PaO2/FiO2 ratio\u4f86\u5340\u5206\u3002\nB.\u6700\u5e38\u898b\u9020\u6210ARDS\u7684\u539f\u56e0\u662f\u80ba\u708e\u53ca\u6557\u8840\u75c7\u3002\nC.\u547c\u5438\u5668\u7684\u8a2d\u5b9a\u61c9\u63a1\u7528\u80ba\u4fdd\u8b77\u901a\u6c23\u7b56\uf976 (lung protective strategy )\uff0c\u4f7f\u7528\u8f03\u4f4e\u7684\u6f6e\u6c23\u5bb9\u7a4d (Tidal Volume; \n6 mL/kg)\uff0c\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387 \u3002\nD.Mild to moderate ARDS\u61c9\u8003\u616e\u4f7f\u7528\u4fef\u81e5\u5f0f\u901a\u6c23\u6a21\u5f0f(Prone positioning) \u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\u3002\nE.\u985e\u56fa\u9187\u7684\u4f7f\u7528\u7121\u6cd5\u964d\u4f4eARDS\u7684\u6b7b\u4ea1\u7387\u3002\n": "[D]", "111-26.\u4e0b\u5217\u54ea\u4e9b\u539f\u56e0\u6703\u9020\u6210\u6ef2\u51fa\u808b\u819c\u7a4d\u6db2 (exudative pleural effusion )?(1) Peritoneal dialysis (2) Superior vena \ncava obstruction (3) Asbestos exposure (4) Meigs' syndrome (5) Radiation therapy \u3002   \nA.(1)+(2)+(3)\u3002\nB.(1)+(2)+(4)\u3002\nC.(2)+(3)+(4)\u3002\nD.(3)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002   \n": "[D]", "111-27.\u95dc\u65bc\u60e1\u6027\u808b\u819c\u9593\u76ae\u7624(Malignant Pleural Mesothelioma)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u5f9e\u77f3\u7dbf\u66b4\u9732\u5230\u767c\u75c5\u6642\u9593\u53ef\u4ee5\u9577\u905420-50\u5e74\u3002\nB.\u6700\u5e38\u898b\u7684\u7d44\u7e54\u578b\u614b\u662fepithelioid mesothelioma\u3002\nC.Sarcomatoid mesothelioma\u53ef\u4ee5\u900f\u904e\u808b\u819c\u6db2\u7684\u6aa2\u9a57\u7372\u5f97\u8a3a\u65b7\u3002\nD.\u808b\u819c\u7a4d\u6db2\u7684\u63a7\u5236\u53ef\u4ee5\u5229\u7528\u5c0e\u7ba1\u5f15\u6d41\u8207\u6ed1\u77f3\u7c89\u808b\u819c\u6cbe\u9ecf\u8853(talc pleurodesis)\u3002\nE.\u653e\u5c04\u7dda\u6cbb\u7642\u7121\u6cd5\u6539\u5584\u75c5\u60a3\u5b58\u6d3b\u3002\n": "[C]", "111-28.\u67d078\u6b72COPD\u75c5\u4eba\u767c\u751f\u6025\u6027\u60e1\u5316 (acute exacerbation )\u3002\u610f\u8b58\u6e05\u695a \uff0c\u8840\u58d3140/78 mmHg \u3002\u807d\u8a3a\u5169\u5074\u80ba\u90e8\u6709\n\u5598\u9cf4\u8072\u3002\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790 (ABG) \u4f7f\u7528\u9f3b\u5c0e\u7ba1\u6c27\u6c232 L/min\u6642\u986f\u793a: pH 7.33, PaCO\u2082 58 mmHg, PaO\u2082 64 \nmmHg\u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u4e0d\u9069\u7576 ?   \nA.\u7d66\u4e88\u975e\u4fb5\u8972\u6027\u96d9\u967d\u58d3\u547c\u5438\u5668(BiPAP)\u652f\u6301\u3002\nB.\u7acb\u5373\u63d2\u7ba1(endotracheal intubation)\u53ca\u4f7f\u7528\u547c\u5438\u5668\u3002\nC.\u7d66\u4e88\u5438\u5165\u6027\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u3002\nD.\u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u3002\nE.\u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642\u3002\n": "[B]", "111-29.\u67d030\u6b72\u652f\u6c23\u7ba1\u64f4\u5f35\u75c7 (bronchiectasis )\u75c5\u60a3\u56e0\u53cd\u8986\u54b3\u8840\u81f3\u6025\u8a3a\u5c31\u91ab \u3002\u8840\u58d3 105 /80 mmHg \uff0c\u8840\u6c27(SpO\u2082) \n94%\uff0c\u4f46\u4ecd\u6301\u7e8c\u54b3\u55fd\u4e26\u5927\u91cf\u54b3\u8840 \uff0c\u80f8\u90e8X\u5149\u986f\u793a\u53f3\u4e0b\u80ba\u8f15\u5fae\u6d78\u6f64 \u3002\u6b64\u6642\u5728\u6025\u8a3a\u61c9\u512a\u5148\u5b89\u6392\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u6216\n\u8655\u7f6e\u6700\u70ba\u9069\u7576 ?   \nA.\u8f38\u8840\u3002\nB.\u652f\u6c23\u7ba1\u93e1\u6aa2\u3002\nC.\u6838\u91ab\u80ba\u704c\u6d41\u986f\u5f71(perfusion scan)\u3002\nD.\u96fb\u8166\u65b7\u5c64\u80ba\u8840\u7ba1\u651d\u5f71(CT angiography)\u3002\nE.\u7d66\u4e88\u975e\u4fb5\u8972\u6027\u96d9\u967d\u58d3\u547c\u5438\u5668(BiPAP)\u652f\u6301\u3002\n": "[D]", "111-30.\u6839\u64da\u6700\u65b0\u6c23\u5598GINA\u6307\u5f15\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u56b4\u91cd\u6c23\u5598\u7b2c\u4e94\u968e\u53ef\u8003\u616e\u7684\u6cbb\u7642\u9078\u9805?    \nA.Anti-IgE (Omalizumab)\u3002\nB.Anti-IL5 ( \u5982Mepolizumab \u6216Benralizumab)\u3002\nC.\u8336\u9e7c(theophyllines)\u3002\nD.\u9ad8\u5291\u91cf\u5438\u5165\u6027\u985e\u56fa\u9187-\u9577\u6548\u4e59\u4e8c\u578b\u523a\u6fc0\u5291(ICS-LABA)\u3002\nE.Tiotropium\u3002\n": "[C]", "111-31.\u67d080\u6b72COPD\u75c5\u4eba \uff0c\u5438\u5165\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\u524dFEV 1\u70ba\u9810\u6e2c\u503c\u4e4b71 %\uff0c\u5438\u5165\u652f\u6c23\u7ba1\u64f4\u5f35\u5291\n\u5f8cFEV1\u70ba78%\uff0cCOPD\u8a55\u4f30\u6e2c\u9a57 (CAT)\u5206\u6578\u70ba8\u5206\uff0c  \u904e\u53bb\u4e00\u5e74\u6709 1\u6b21COPD\u6025\u6027\u60e1\u5316\u4f4f\u9662 \u3002\u8acb\u554f\u6839\n\u64daGOLD\u6307\u5f15 \uff0c\u5176\u80ba\u529f\u80fd\u5206\u7d1a\u8207COPD\u56b4\u91cd\u5ea6\u5206\u7fa4\u70ba\u4f55 \uff1f   \nA.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 1\uff0cCOPD\u56b4\u91cd\u5ea6\u70ba A\u7fa4\u3002\nB.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 2\uff0cCOPD\u56b4\u91cd\u5ea6\u70ba B\u7fa4\u3002\nC.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 1\uff0cCOPD\u56b4\u91cd\u5ea6\u70ba C\u7fa4\u3002\nD.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 2\uff0cCOPD\u56b4\u91cd\u5ea6\u70ba C\u7fa4\u3002\nE.\u80ba\u529f\u80fd\u5206\u7d1a\u70baGOLD 3\uff0cCOPD\u56b4\u91cd\u5ea6\u5206\u7fa4\u70ba D\u7fa4\u3002\n": "[D]", "111-32.\u67d090\u6b72\u75c5\u4eba\u56e0\u4e7e\u54b3\u8207\u547c\u5438\u56f0\u96e3\u5c31\u91ab \uff0c\u904e\u53bb\u672a\u66fe\u5438\u83f8 \u3002\u807d\u8a3a\u6642\u4e0b\u80ba\u8449\u6709 crackles \uff0c\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716\u6240\n\u793a\u3002\u4e0b\u5217\u80ba\u529f\u80fd\u8207\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\u7d50\u679c\u4f55\u8005\u6700\u7b26\u5408\u5176\u8a3a\u65b7 ?      \nA.FVC 67%\uff0cFEV\u2081 70%\uff0cFEV\u2081/FVC 0.81\uff0cDLCO 40 %\uff0cPaO\u2082 75 mmHg \uff0cPaCO\u2082 40 mmHg \u3002\nB.FVC 92%\uff0cFEV\u2081 70%\uff0cFEV\u2081/FVC 0.70\uff0cDLCO 78 %\uff0cPaO\u2082 75 mmHg \uff0cPaCO\u2082 40 mmHg \u3002\nC.FVC 77%\uff0cFEV\u2081 90%\uff0cFEV\u2081/FVC 0.87\uff0cDLCO 80 %\uff0cPaO\u2082 75 mmHg \uff0cPaCO\u2082 55 mmHg \u3002\nD.FVC 100 %\uff0cFEV\u2081 70%\uff0cFEV\u2081/FVC 0.55\uff0cDLCO 40 %\uff0cPaO\u2082 65 mmHg \uff0cPaCO\u2082 40 mmHg \u3002\nE.FVC 57%\uff0cFEV\u2081 89%\uff0cFEV\u2081/FVC 0.75\uff0cDLCO 87 %\uff0cPaO\u2082 75 mmHg \uff0cPaCO\u2082 58 mmHg \u3002\n": "[A]", "111-33.\u67d0\u4f4d\u9ad4\u91cd60\u516c\u65a4\u4e4b65\u6b72\u7537\u6027\u75c5\u60a3\u56e0COVID -19\u4f75\u767c\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4 (ARDS)\u63a5\u53d7\u547c\u5438\u5668\u6cbb\u7642 \u3002\u5176\u547c\u5438\n\u5668\u8a2d\u5b9a(VC mode )\u70ba: FiO\u2082 0.55\u3001\u547c\u5438\u901f\u738716 \u6b21/min\u3001\u6f6e\u6c23\u5bb9\u7a4d (tidal volume) 600 mL \u3001\u6700\u9ad8\u5438\u6c23\u6d41\u901f70 \nL/min\u3001\u5410\u6c23\u672b\u967d\u58d3 (PEEP) 10 cmH \u2082O\u3002\u5176\u52d5\u8108\u8840\u6db2\u6c23\u9ad4\u5206\u6790\u70ba \uff1apH 7.34\u3001PaO\u2082 72 mmHg \u3001PaCO\u2082 51 \nmmHg\u3001HCO\u2083 28 mEq /L\u3002\u8acb\u554f\u61c9\u8abf\u6574\u90a3\u500b\u547c\u5438\u5668\u53c3\u6578\u503c\u6700\u70ba\u59a5\u7576 \uff1f   \nA.\u589e\u52a0\u547c\u5438\u901f\u7387\u3002\nB.\u6e1b\u5c11FiO\u2082\u3002\nC.\u6e1b\u5c11\u6f6e\u6c23\u5bb9\u7a4d(tidal volume)\u3002\nD.\u589e\u52a0\u5438\u6c23\u6700\u5927\u6d41\u901f\u3002\nE.\u6e1b\u5c11\u5410\u6c23\u672b\u967d\u58d3(PEEP)\u3002\n": "[C]", "111-34.\u67d0\u80ba\u708e\u5c0e\u81f4\u547c\u5438\u8870\u7aed\u75c5\u60a3\u63a5\u53d7\u547c\u5438\u5668\u6cbb\u7642\u6642\u7a81\u7136\u7522\u751f\u8840\u6c27\u8207\u8840\u58d3\u4e0b\u964d \uff0c\u807d\u8a3a\u6642\u53f3\u5074\u80ba\u90e8\u547c\u5438\u97f3\u6e1b\u4f4e \u3002\u4e0b\u5217\n\u4f55\u8005\u70ba\u9069\u7576\u4e4b\u8655\u7f6e ?(1) \u589e\u52a0\u5410\u6c23\u672b\u967d\u58d3 (PEEP) (2) \u589e\u52a0\u5438\u5165\u6c27\u6c23\u5206\u7387 (FiO\u2082)\u81f3100% (3) \u66ab\u6642\u812b\u96e2\u547c\u5438\n\u5668\uff0c\u4f7f\u7528\u7526\u9192\u7403\u6025\u6551 (Ambu) (4) \u7528\u80f8\u8154\u8d85\u97f3\u6ce2\u78ba\u8a8d\u8a3a\u65b7 (5) \u5982\u70ba\u5f35\u529b\u6027\u6c23\u80f8 \uff0c\u61c9\u7acb\u523b\u7528\u7d30\u91dd\u6216\u5f15\u6d41\u5c0e\u7ba1\u63d2\n\u5165\u808b\u819c\u8154\u6e1b\u58d3   \nA.(1)+(2)+(3)+(4)\u3002\nB.(2)+(3)+(4)\u3002\nC.(3)+(4)+(5)\u3002\nD.(2)+(3)+(4)+(5)\u3002\nE.(1)+(3)+(5)\u3002\n": "[D]", "111-35.\u67d0\u61f7\u5b5535\u9031\u4e4b\u786c\u76ae\u75c7\u7522\u5a66\u7dca\u6025\u5256\u8179\u7522\u5f8c\u547c\u5438\u56f0\u96e3\u52a0\u91cd\u8f49\u4f86\u5167\u79d1\u52a0\u8b77\u75c5\u623f \uff0c\u610f\u8b58\u6e05\u695a \uff0c\u8840\u58d3\u7531\u5256\u8179\u7522\n\u524d134/88 mmHg\u4e0b\u964d\u81f3 92 /50 mmHg \uff0c\u5fc3\u8df3 110 /min\uff0cSpO\u2082 90% (NRM )\u3002\u53f3\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u986f\u793a\u53f3\u5fc3\u623f\n\u58d3(RAP)\u70ba12 mmHg \uff0c\u5e73\u5747\u80ba\u52d5\u8108\u58d3 (mean PAP )\u70ba44 mmHg \uff0c\u80ba\u52d5\u8108\u6954\u58d3 (PA wedge pressure \n(PAWP))\u70ba14 mmHg \uff0c\u5fc3\u8f38\u51fa\u91cf\u70ba 3.0 L/min\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u932f\u8aa4 \uff1f   \nA.\u75c5\u60a3\u80ba\u8840\u7ba1\u963b\u529b\u70ba14 Wood units\u3002\nB.\u786c\u76ae\u75c7\u80ba\u52d5\u8108\u9ad8\u58d3(PAH)\u5982\u672a\u6cbb\u7642\u5247\u4e09\u5e74\u5b58\u6d3b\u7387\u4f4e\u65bc50%\u3002\nC.\u53ef\u4f7f\u7528\u80ba\u8840\u7ba1\u64f4\u5f35\u5291\u4ee5\u964d\u4f4e\u80ba\u8840\u7ba1\u963b\u529b\u3002\nD.\u4e0d\u61c9\u8a72\u7d66\u4e88\u5927\u91cf\u8f38\u6db2\u4f86\u63d0\u9ad8\u8840\u58d3\u3002\nE.\u53ef\u4f7f\u7528\u5438\u5165\u4e00\u6c27\u5316\u6c2e\u4ee5\u964d\u4f4e\u80ba\u8840\u7ba1\u963b\u529b\u3002\n": "[A]", "111-36.\u5c0d\u65bc\u80ba\u708e\u4f75\u767c\u4e4b\u808b\u819c\u7a4d\u6db2(parapneumonic pleural effusion), \u4e0b\u8ff0\u4f55\u8005\u4e0d\u662f\u9032\u884c\u80f8\u7ba1\u5f15\u6d41\u4e4b\u689d\u4ef6?    \nA.\u808b\u819c\u7a4d\u6db2\u7684\u767d\u8840\u7403\u6578\u76ee> 1000/uL\u3002\nB.\u808b\u819c\u7a4d\u6db2\u7684\u9769\u862d\u6c0f\u67d3\u8272(Gram stain)\u62b9\u7247\u767c\u73fe\u7d30\u83cc\u3002\nC.\u808b\u819c\u7a4d\u6db2\u7684pH\u503c\u70ba6.9\u3002\nD.\u808b\u819c\u7a4d\u6db2\u7684glucose\u503c\u70ba8 mg/dL\u3002\nE.\u808b\u819c\u7a4d\u6db2\u6709\u60e1\u81ed\u5473\u3002   \n": "[A]", "100-1.\n60\u6b72\u5973\u6027\u56e0\u89e3\u8840\u4fbf\u81f3\u6025\u8a3a\uff0c\u7d93\u8f38\u6db2\u6cbb\u7642\u7a69\u5b9a\u751f\u547d\u5fb5\u8c61\u5f8c\u5b89\u6392\u5927\u8178\u93e1\u53ca\u80c3\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u4e26\u7121\u767c\u73fe\u53ef\u7591\u7684\u51fa\u8840\u75c5\u7076\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6b64\u7a2e\u51fa\u8840\u578b\u614b\u7a31\u70baoccult GI bleeding\nB. \u5c0f\u8178\u662f\u6700\u53ef\u80fd\u7684\u75c5\u7076\u4f4d\u7f6e\nC. \u53ef\u4ee5\u662f\u8840\u7ba1\u6027\u75c5\u7076\nD. \u60a3\u8005\u82e5\u6301\u7e8c\u56b4\u91cd\u6027\u51fa\u8840\u53ef\u8003\u616eTc-RBC scan\u6216angiography\nE. \u82e5\u51fa\u8840\u505c\u6b62\u5247\u8003\u616e\u9032\u884cvideo capsule\u6216enteroscopy\u6aa2\u67e5\n": "(A)", "100-2.\n20\u6b72\u7537\u6027\u5065\u5eb7\u6aa2\u67e5\u6642\u767c\u73feBilirubin (total/direct)\u70ba2.0/0.2 mg/dL\uff0c\u5176\u8a3a\u65b7\u53ef\u80fd\u70ba\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.Gilbert's syndrome.\r2.Rotor's syndrome.\r3.glucose-6-phosphate dehydrogenase and pyruvate kinase deficiency.\r4..Dubin-Johnson syndrome.\r5.Crigler-Najjar syndrome.\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 2+3+5\nE. 1+3+5\n": "(E)", "100-3.\n\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u9ad4\u58c1\u8179\u819c(parietal peritoneum)\u767c\u708e\u5f15\u8d77\u7684\u75bc\u75db\u5b9a\u4f4d\u8f03\u81df\u58c1\u8179\u819c(visceral peritoneum)\u767c\u708e\u6e05\u695a\r2.\u9ad4\u58c1\u8179\u819c\u6613\u56e0\u81df\u5668\u62c9\u626f\u64f4\u5f35\u6536\u7e2e\u800c\u5f15\u8d77\u75d9\u6523\u75db\u4e14\u5408\u4f75\u76dc\u6c57\u3001\u5641\u5fc3\u53ca\u5fc3\u8df3\u8b8a\u5316\u7b49\u81ea\u5f8b\u795e\u7d93\u75c7\u72c0\r3.\u89f8\u75db\u4e43\u56e0\u81df\u58c1\u8179\u819c\u800c\u8d77\uff0c\u5177\u7279\u7570\u6027\u53ca\u8f03\u4f73\u4e4b\u5b9a\u4f4d\u4f5c\u7528\r4.\u8178\u7f3a\u8840\u56b4\u91cd\u60a3\u8005\u6709\u6642\u7406\u5b78\u6aa2\u67e5\u5fb5\u5019\u8f15\u5fae\r5.\u80f0\u81df\u708e\u8179\u75db\u5287\u70c8\u5fb5\u5019\u660e\u986f\u6613\u88ab\u8a8d\u70basurgical abdomen\nA. 1+2+3\nB. 1+4+5\nC. 1+3+4\nD. 2+3+4\nE. 2+4+5\n": "(B)", "100-4.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u4f7f\u7528\u975c\u8108\u71df\u990a(parenteral nutrition)\u60a3\u8005\u5e38\u898b\u7684\u4ee3\u8b1d\u6027\u554f\u984c?\nA. Hyponatremia\nB. Hypocalcemia\nC. Hyperphosphatemia\nD. Hypermagnesemia\nE. Azotemia\n": "(D)", "100-5.\n55\u6b72\u7537\u6027\u60a3\u8005\uff0c\u6709\u62bd\u7159\u3001\u559d\u9152\u3001\u559d\u5496\u5561\u7fd2\u6163\uff0c\u4e3b\u8a34\u80c3\u9178\u9006\u6d41\u53ca\u80f8\u53e3\u707c\u71b1\uff0c\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\u7d50\u679c\u5982\u9644\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u670d\u7528\u9223\u96e2\u5b50\u963b\u65b7\u5291(calcium channel blocker)\u53ef\u4f7f\u75c7\u72c0\u7de9\u89e3\nB. \u670d\u7528\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291(proton pump inhibitor)\u53ef\u4f7f\u5df2\u767c\u751f\u7684\u9ecf\u819c\u5316\u751f(metaplasia)\u5b8c\u5168\u6062\u5fa9\u6b63\u5e38\nC. \u6e1b\u91cd\u7121\u6cd5\u4f7f\u75c7\u72c0\u7de9\u89e3\nD. \u5207\u7247\u6aa2\u67e5\u82e5\u6709\u9ecf\u819c\u9ad8\u5ea6\u5316\u751f\u4e0d\u826f(high-grade dysplasia)\uff0c\u5247\u5167\u8996\u93e1\u8ffd\u8e64\u983b\u7387\u70ba\u6bcf\u5e741\u6b21\nE. \u6bcf\u5e74\u767c\u751f\u764c\u75c7\u7684\u6a5f\u6703\u70ba0.5%\n": "(E)", "100-6.\n\u80c3\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(Helicobacter pylori)\u662f\u9020\u6210\u6d88\u5316\u6027\u6f70\u760d\u548c\u80c3\u764c\u7684\u91cd\u8981\u539f\u56e0\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u4e0d\u9069\u7528\u65bc\u9664\u83cc\u6cbb\u7642\uff1f\nA. Lansoprazole\nB. Cephalexin\nC. Bismuth subsalicylate\nD. Clarithromycin\nE. Amoxicillin\n": "(B)", "100-7.\n\u6709\u95dc\u85e5\u7269\u9020\u6210\u80c3\u8178\u9053\u9ecf\u819c\u50b7\u5bb3\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Alendronate\u53ef\u4ee5\u9020\u6210\u98df\u9053\u6f70\u760d\nB. Cyclooxygenase-1(COX-1)\u70ba\u7dad\u6301\u80c3\u8178\u9ecf\u819c\u529f\u80fd\u6240\u5fc5\u9700\nC. Cyclooxygenase-2(COX-2)\u6291\u5236\u5291\u4e0d\u6703\u9020\u6210\u80c3\u6f70\u760d\nD. \u4f4e\u5291\u91cf\u7684aspirin(75~100mg)\u4e5f\u6703\u9020\u6210\u80c3\u6f70\u760d\nE. \u540c\u6642\u4f7f\u7528glucocorticoid\u6703\u589e\u52a0non-steroidal anti-inflammatory drug (NSAID)\u7522\u751f\u6f70\u760d\u7684\u6a5f\u6703\n": "(C)", "100-8.\n30\u6b72\u5973\u6027\u56e0\u6025\u6027\u8179\u75db\u5408\u4f75\u5641\u5fc3\u3001\u5614\u5410\u81f3\u6025\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u6709\u53f3\u4e0b\u8179\u89f8\u75db\uff0c\u9ad4\u6eab37.5\u2103\uff1b\u8840\u6db2\u6aa2\u67e5\u6709\u767d\u8840\u7403\u4e0a\u5347\u73fe\u8c61(13000cells/uL)\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u7d50\u679c\u5982\u9644\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. Fecolith\u662f\u5e38\u898b\u7684\u539f\u56e0\nB. \u5bc4\u751f\u87f2\u9020\u6210\u963b\u585e\u4e5f\u662f\u53ef\u80fd\u7684\u8d77\u56e0\nC. \u53f3\u4e0b\u8179\u75db\u7684\u5973\u6027\u60a3\u8005\u5fc5\u9808\u8207twisted ovarian cyst, endometriosis\u6216corpus luteum rupture\u505a\u9451\u5225\u8a3a\u65b7\nD. Acute mesenteric lymphadenitis\u4e5f\u662f\u53ef\u80fd\u7684\u9451\u5225\u8a3a\u65b7\nE. \u55ae\u7528\u6297\u751f\u7d20\u5373\u53ef\u670980%\u4ee5\u4e0a\u7684\u6cbb\u7642\u6210\u529f\u7387\uff0c\u4e14\u5fa9\u767c\u7387\u8f03\u624b\u8853\u70ba\u4f4e\n": "(E)", "100-9.\n75\u6b72\u5973\u6027\u56e0\u75b2\u5026\u3001\u8d70\u8def\u6c23\u5598\u3001\u982d\u6688\u3001\u4e0b\u8179\u75bc\u75db\u3001\u767c\u71d2\u548c\u9ad4\u91cd\u6e1b\u8f15\u81f3\u6025\u8a3a\uff0c\u8840\u6db2\u6aa2\u67e5Hb:5.0g/dL\uff0c\u5168\u5927\u8178\u93e1\u6aa2\u67e5\u5982\u9644\u5716\uff0c\u8840\u6db2\u57f9\u990a\u9577\u51fa\u7d30\u83cc\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u767c\u73fe\u4f55\u7a2e\u7d30\u83cc\uff1f\nA. Staphylococcus aureus\nB. Clostridium difficile\nC. Streptococcus bovis\nD. Salmonella typhi\nE. E. coli\n": "(C)", "100-10.\n\u52a0\u8b77\u75c5\u623f\u60a3\u8005\u51fa\u73fe\u8179\u7009\u3001\u8840\u4fbf\u548c\u767c\u71d2\u60c5\u5f62\uff0c\u8178\u93e1\u6aa2\u67e5\u7d50\u679c\u5982\u9644\u5716\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u4e0d\u9069\u5408\u7528\u65bc\u6b64\u60a3\u8005\u7684\u6cbb\u7642\uff1f\nA. Metronidazole\nB. Clindamycin\nC. Vancomycin\nD. Teicoplanin\nE. Fusidic acid\n": "(B)", "100-11.\n40\u6b72\u5bb6\u5ead\u4e3b\u5a66\u56e0\u4e0a\u8179\u75db\u3001\u5614\u5410\u81f3\u6025\u8a3a\uff0c\u809d\u751f\u5316\u6aa2\u67e5\u986f\u793aAST:1090 IU/L, ALT:1870 IU/L, Bil(T/D):3.2/1.8 mg/dL, WBC:12500 cells/uL\uff0c\u8179\u90e8\u8d85\u97f3\u6ce2\u548c\u96fb\u8166\u65b7\u5c64\u5982\u5716\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u624b\u8853\u662f\u4e3b\u8981\u7684\u6cbb\u7642\u65b9\u5f0f.\r2.\u53ef\u5148\u7528morphine\u6b62\u75db.\r3.\u5167\u79d1\u6cbb\u7642\u53ef\u4ee5\u4f7f75%\u75c5\u4eba\u7de9\u89e3\u4f46\u4e00\u5e74\u5fa9\u767c\u7387\u670925%\r4.ileus\u548cbiliary-enteric fistula\u662f\u53ef\u80fd\u7684\u4f75\u767c\u75c7\r5.\u624b\u8853\u5f8c\u7684\u4f75\u767c\u75c7\u5305\u62ecbile salt-induced constipation\nA. 1+2+3\nB. 1+3+4\nC. 1+4+5\nD. 2+3+4\nE. 3+4+5\n": "(B)", "100-12.\n52\u6b72\u5973\u59d3\u75c5\u4eba\u56e0\u98df\u9053\u975c\u8108\u66f2\u5f35\u51fa\u8840\u800c\u4f4f\u9662\u3002\u63a2\u8a0e\u5176\u75c5\u56e0\u6642\u767c\u73fe\u5176\u8840\u4e2dBil(T)=1.0 mg/dL (< 1.2)\uff0cAST=100 IU/L (< 31)\uff0cALT=95 IU/L (< 31)\uff0cALP=1200 IU/L (< 220)\uff0cgamma-GT:850 IU/L (< 50)\uff1b\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u4e26\u7121\u809d\u5167\u81bd\u7ba1\u64f4\u5927\u73fe\u8c61\uff0c\u4e5f\u7121\u809d\u5167\u816b\u7624\u3002\u95dc\u65bc\u9019\u4f4d\u75c5\u4eba\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7d0430%\u4e4b\u6b64\u985e\u75c5\u4eba\u6703\u51fa\u73fepruritus\u4e4b\u75c7\u72c0\nB. \u6b64\u7a2e\u75c5\u4eba\u53ef\u80fd\u5408\u4f75sicca syndrome\u53caautoimmune thyroid dysfunction\u7b49\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\nC. \u62bd\u8840\u6aa2\u9a57microsomal antibody\u4f86\u8a3a\u65b7\u6b64\u75c5\u4e4bsensitivity\u53caspecificity \u7686> 95%\nD. UDCA (ursodeoxycholic acid) 12~15 mg/kg (body weight)\u53ef\u5ef6\u7de9\u75c5\u60c5\u4e4b\u60e1\u5316\nE. \u82e5\u4e00\u518d\u51fa\u73fe\u56b4\u91cd\u4e4b\u4f75\u767c\u75c7\uff0c\u61c9\u5b89\u6392\u809d\u81df\u79fb\u690d\n": "(C)", "100-13.\nGastroesophageal reflux disease (GERD) \u8fd1\u5e74\u4f86\u5df2\u662f\u4e00\u7a2e\u5e38\u898b\u7684\u75be\u75c5\uff0c\u4e14\u88ab\u8a8d\u70ba\u53ef\u80fd\u6703\u5c0e\u81f4Barrett esophagus\uff0c\u751a\u81f3\u884d\u751f\u98df\u9053\u764c\u3002\u95dc\u65bcBarrett esophagus\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. Barrett esophagus\u5e38\u898b\u65bc\u6709large hiatal hernia, low lower esophageal pressure\u53caabnormal esophageal motility\u4e4b\u75c5\u4eba\r2. Short-segment Barrett esophagus (< 3 cm) \u8f03long-segment\u8005\u6613\u5c0e\u81f4esophageal adenocarcinoma\r3. \u5927\u591a\u6578\u5c08\u5bb6\u8a8d\u70basymptomatic GERD\u60a3\u8005\u61c9\u63a5\u53d7\u5167\u8996\u93e1\u8ffd\u8e64\u6aa2\u67e5\u81f3\u5c115\u5e74\r4. Barrett esophagus\u75c5\u4eba\u958b\u59cb\u63a5\u53d7\u5167\u8996\u93e1\u7be9\u6aa2\u6642\uff0c\u524d\u5169\u6b21\uff08\u76f8\u9694\u4e00\u5e74\uff09\u7686\u8981\u884cmultiple biopsies\r5. \u4ee5proton pump inhibitors (PPIs) \u6cbb\u7642\u53ef\u4f7f\u7570\u5e38\u4e4b\u98df\u9053\u7c98\u819c\u56de\u5fa9\u6b63\u5e38\uff0c\u9032\u800c\u5ef6\u7de9Barrett esophagus\u4e4b\u60e1\u5316\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 1+3+4\nE. 2+4+5\n": "(D)", "100-14.\n\u4e00\u4f4d40\u6b72\u5973\u6027\u75c5\u4eba\u88ab\u8a3a\u65b7\u6709ulcerative colitis\u5df2\u67096\u5e74\uff0c\u76ee\u524d\u63a5\u53d7azathioprine\u53catopical mesalamine\u6cbb\u7642\uff0c\u75c5\u60c5\u5c1a\u7a69\u5b9a\uff0c\u6bcf\u5929\u6392\u4fbf1~2\u6b21\uff0c\u5927\u4fbf\u6210\u5f62\u3002\u904e\u53bb\u5169\u9031\uff0c\u5979\u56e0\u4e0a\u547c\u5438\u9053\u611f\u67d3\u4f75\u6709\u9ec3\u8272\u81bf\u75f0\u800c\u670d\u7528\u6297\u751f\u7d20\u3002\u4e09\u5929\u524d\uff0c\u5979\u958b\u59cb\u51fa\u73fe\u8179\u90e8\u7d5e\u75db\uff0c\u5927\u4fbf\u6b21\u6578\u589e\u81f3\u6bcf\u59298~10\u6b21\uff0c\u591a\u4e0d\u6210\u5f62\uff0c\u767c\u71d2\u81f338.1\u00b0C\uff0c\u8840\u4e2dWBC\u4e0a\u5347\u81f320,000/uL\uff0c\u6709postural hypotension\u53catachycardia\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8179\u90e8\u6709tenderness\uff0c\u4f46\u7121rebound tenderness\u53camuscle guarding\u3002\u6025\u8a3a\u8655\u91ab\u5e2b\u958b\u59cb\u7d66\u4e88IV fluid\uff0c\u4e26\u63a1\u96c6\u5927\u4fbf\u9001\u6aa2\u3002\u4e0b\u5217\u4f55\u8005\u61c9\u99ac\u4e0a\u63a5\u8457\u53bb\u505a\uff1f\nA. \u7d66\u4e88IV corticosteroid\nB. \u7d66\u4e88cyclosporine\nC. \u7d66\u4e88infliximab (\u4e00\u7a2eanti-TNF-alpha\u85e5\u7269)\nD. \u589e\u52a0azathioprine\u4e4b\u5291\u91cf\nE. \u7d66\u4e88\u53e3\u670dvancomycin\n": "(E)", "100-15.\n\u4e0b\u5217\u95dc\u65bcdiarrhea\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6aa2\u67e5\u5927\u4fbf\u4e2d\u7684fat\u4e43\u662f\u7be9\u6aa2malabsorption\u6700\u4f73\u65b9\u5f0f\nB. Malabsorption\u60a3\u8005\u4e00\u5b9a\u6703\u6709diarrhea\nC. Non-inflammatory chronic watery diarrhea\u4e2d\uff0csecretory diarrhea\u65bcfasting\u5f8c\u6703\u505c\u6b62\nD. Irritable bowel syndrome\u60a3\u8005\u4e4bdiarrhea\u65bcfasting\u5f8c\u6703\u6301\u7e8c\nE. \u5c0dsevere diarrhea\u60a3\u8005\uff0c\u61c9\u5118\u5feb\u7d66\u4e88opiates\u85e5\u7269\u6cbb\u7642\n": "(A)", "100-16.\n\u6162\u6027\uff23\u578b\u809d\u708e\u76ee\u524d\u5df2\u6709\u76f8\u7576\u6709\u6548\u4e4b\u6cbb\u7642\u85e5\u7269\uff0c\u53f0\u7063\u7684\u5065\u4fdd\u5c40\u5728\u7d66\u4ed8\u65b9\u9762\u4ea6\u5927\u5e45\u653e\u5bec\uff0c\u56e0\u6b64\u6709\u6108\u4f86\u6108\u591a\u7684\u75c5\u4eba\u63a5\u53d7\u6cbb\u7642\u3002\u4e0b\u5217\u6709\u95dc\u6162\u6027\uff23\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u76ee\u524d\u4e4b\u4e3b\u6d41\u6cbb\u7642\u65b9\u5f0f\u70bapegylated IFN-alpha2a or IFN-alpha2b\u4f75\u7528ribavirin\r2. \u82e5\u75c5\u4eba\u65bc\u958b\u59cb\u6cbb\u76424\u5468\u5f8c\uff0c\u8840\u4e2dHCV RNA\u5df2\u6e2c\u4e0d\u5230\uff0c\u4e14\u6cbb\u7642\u524d\u4e4bHCV RNA < 400000 IU/mL\uff0c\u7642\u7a0b\u53ea\u898124\u5468\r3. \u75c5\u4eba\u958b\u59cb\u6cbb\u7642\u5f8c12\u5468\uff0c\u8840\u4e2dHCV RNA\u4ecd\u6e2c\u5f97\u5230\uff0c\u4e14\u5176\u91cf\u6e1b\u5c11\u4e0d\u5230100\u500d\uff08\u5982\uff1a\u81ea1000000\u6e1b\u81f310000 IU/mL)\u5373\u61c9\u505c\u6b62\u6cbb\u7642\r4. Ribavirin\u4e4b\u526f\u4f5c\u7528\u5305\u62ec\u6eb6\u8840\r5. \u82e5\u75c5\u4eba\u5df2\u51fa\u73feliver decompensation\uff0c\u61c9\u8d95\u5feb\u65bd\u4ee5\u6cbb\u7642\nA. 1+2+3+4\nB. 1+2+3+5\nC. 2+4+5\nD. 3+4+5\nE. 1+4+5\n": "(A)", "100-17.\n\u6162\u6027\uff22\u578b\u809d\u708e\u4e4b\u6cbb\u7642\u5305\u62ecpegylated IFN-alpha\u53ca\u53e3\u670d\u6297\uff22\u578b\u809d\u708e\u75c5\u6bd2\u85e5\u7269\uff0c\u53f0\u7063\u7684\u5065\u4fdd\u5c40\u5728\u7d66\u4ed8\u65b9\u9762\u5df2\u5927\u5e45\u653e\u5bec\uff0c\u80fd\u63a5\u53d7\u6cbb\u7642\u4e4b\u75c5\u4eba\u5927\u589e\u3002\u4e0b\u5217\u6709\u95dc\u6162\u6027\uff22\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u82e5\u75c5\u4eba\u5df2\u51fa\u73feliver decompensation\uff0c\u61c9\u8d95\u5feb\u63a5\u53d7pegylated IFN-alpha\u4e4b\u6cbb\u7642\r2. HBeAg (+)\u75c5\u4eba\u4e4bALT\u6578\u503c\u6301\u7e8c\u4e0a\u5347\u57281\u500d\u223c2\u500d\u4e4b\u9593\uff0c\u4e14\u8840\u4e2dHBV DNA > 20,000 IU/mL\uff0c\u53ef\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\r3. HBeAg (-)\u75c5\u4eba\u4e4bALT\u6578\u503c\u57283\u500b\u6708\u5167\u81f3\u5c11\u6709\u5169\u6b21\u4e0a\u5347\u81f32\u500d\u4ee5\u4e0a\uff0c\u4e14\u8840\u4e2dHBV DNA > 2,000 IU/mL\uff0c\u53ef\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\r4. \u53e3\u670d\u6297\uff22\u578b\u809d\u708e\u75c5\u6bd2\u85e5\u7269\u4e2d\uff0ctelbivudine\u53ef\u80fd\u5c0e\u81f4myopathy\uff0cadefovir\u53ef\u80fd\u50b7\u814e\r5. HBeAg (+)\u75c5\u4eba\u82e5\u51fa\u73fe\u8840\u4e2dHBeAg seroconversion\u6642\uff0c\u5373\u53ef\u65bc3\u500b\u6708\u5167\u505c\u85e5\nA. 1+2\nB. 3+4\nC. 4+5\nD. 1+2+4\nE. 3+4+5\n": "(B)", "100-18.\n\u4e00\u4f4d35\u6b72\u7537\u6027\u75c5\u4eba\u5230\u91ab\u9662\u5c31\u91ab\uff0c\u4e3b\u8a34\u70ba\u6700\u8fd1\u5e38\u611f\u75b2\u5026\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feALT=200 (< 41) IU/L\uff0cAST=180 (< 37) IU/L\uff0c\u5176\u5b83\u809d\u529f\u80fd\u9805\u76ee\u7686\u5728\u6b63\u5e38\u7bc4\u570d\u5167\uff1bHBsAg (-)\uff0cAnti-HCV (-)\uff0cANA (-)\u3002\u4ed6\u7684\u9ad4\u91cd\u70ba110 \u516c\u65a4\uff0c\u8eab\u9ad8165\u516c\u5206\uff0c\u6c92\u6709\u9157\u9152\u7fd2\u6163\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u50c5\u767c\u73fe\u53f3\u4e0a\u8179\u6709\u8f15\u5fae\u58d3\u75db\u3002\u95dc\u65bc\u9019\u4f4d\u75c5\u4eba\u4e4b\u8a3a\u65b7\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u6b64\u7a2e\u75c5\u4eba\u53ef\u80fd\u6703\u884d\u8b8a\u6210\u809d\u786c\u5316\uff0c\u751a\u81f3\u7522\u751f\u809d\u7d30\u80de\u764c\r2. \u6b64\u7a2e\u75c5\u4eba\u8840\u4e2dAST\u503c\u901a\u5e38\u5927\u65bcALT\u503c\uff0c\u4e14AST\u6578\u503c\u5f88\u5c11\u5927\u65bc250 IU/L\r3. \u6b64\u985e\u809d\u75c5\u4e4b\u4e3b\u8981\u75c5\u7406\u751f\u7406\u7f3a\u9677\u70bainsulin resistance\r4. Lifestyle modification\u70ba\u6700\u4f73\u6cbb\u7642\u65b9\u5f0f\r5. Coronary artery disease\u662f\u6b64\u7a2e\u75c5\u4eba\u6700\u5e38\u898b\u7684\u55ae\u4e00\u6b7b\u56e0\nA. 1+2+3+4\nB. 2+3+4+5\nC. 1+3+4+5\nD. 2+4+5\nE. 2+3\n": "(C)", "100-19.\n\u95dc\u65bc\u98df\u9053\u764c\u4e4b\u5371\u96aa\u56e0\u5b50\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. Barrett esophagus\u70basquamous cell cancer\u4e4b\u5371\u96aa\u56e0\u5b50\r2. Bile reflux\u70baadenocarcinoma\u4e4b\u5371\u96aa\u56e0\u5b50\r3. Cigarette smoking\u70baadenocarcinoma\u4e4b\u5371\u96aa\u56e0\u5b50\r4.  Achalasia\u70basquamous cell carcinoma\u4e4b\u5371\u96aa\u56e0\u5b50\r5. Human papilloma virus (HPV)\u611f\u67d3\u70basquamous cell carcinoma\u4e4b\u5371\u96aa\u56e0\u5b50\nA. 1+2+3\nB. 2+3+4\nC. 1+3+4\nD. 2+4+5\nE. 1+2+5\n": "(D)", "100-20.\n\u95dc\u65bc\u80f0\u81df\u764c\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. Genetic predisposition\u8207\u80f0\u81df\u764c\u4e4b\u767c\u751f\u5bc6\u5207\u76f8\u95dc\r2. 50\u6b72\u4ee5\u5f8c\u624d\u767c\u751f\u7cd6\u5c3f\u75c5\uff0c\u8981\u8a73\u67e5\u80f0\u81df\u764c\u4e4b\u53ef\u80fd\u6027\r3. \u8840\u4e2dCA19-9\u5c0d\u65bc\u80f0\u81df\u764c\u4e4b\u8a3a\u65b7\u5177\u6709\u76f8\u7576\u597d\u7684sensitivity\u53caspecificity\r4. \u82e5\u75c5\u4eba\u767c\u751f\u963b\u585e\u6027\u9ec3\u75b8\uff0c\u81e8\u5e8a\u5224\u65b7\u53ef\u80fd\u662f\u80f0\u81df\u982d\u90e8\u764c\u75c7\uff0c\u4f46multidetector CT with dynamic contrast\u770b\u4e0d\u5230\u816b\u7624\uff0c\u6b64\u6642\u61c9\u8003\u616e\u8840\u7ba1\u651d\u5f71\r5. \u5167\u8996\u93e1\u8d85\u97f3\u6ce2\uff08endoscopic ultrasound\uff09\u5c0d\u76f4\u5f912\u516c\u5206\u4ee5\u4e0b\u80f0\u81df\u764c\u4e4b\u5075\u6e2c\u7387\u53ef\u80fd\u6bd4CT\u70ba\u4f73\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 2+4+5\nE. 1+2+5\n": "(E)", "100-21.\n\u4e00\u4f4d42\u6b72\u75c5\u4eba\u56e0\u4e0a\u8179\u75db\u6c42\u91ab\uff0c\u61f7\u7591\u6709\u80c3\u6f70\u760d\uff0c\u91ab\u5e2b\u70ba\u5176\u5b89\u6392\u5167\u8996\u93e1\u6aa2\u67e5\u3002\u9019\u4f4d\u75c5\u4eba\u5e73\u6642\u5c0d\u91ab\u5b78\u77e5\u8b58\u6709\u6240\u6d89\u7375\uff0c\u77e5\u9053\u80c3\u6f70\u760d\u8207H. pylori \u6709\u5bc6\u5207\u95dc\u4fc2\uff0c\u4e14\u8207\u80c3\u764c\u6709\u95dc\uff0c\u56e0\u6b64\u8acb\u91ab\u5e2b\u8a73\u52a0\u8aaa\u660eH. pylori\u6709\u95dc\u4e4b\u8a3a\u65b7\u53ca\u6cbb\u7642\u72c0\u6cc1\u3002\u82e5\u60a8\u662f\u5176\u4e3b\u6cbb\u91ab\u5e2b\uff0c\u4e0b\u5217\u8aaa\u6cd5\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u62bd\u8840\u6aa2\u9a57H. pylori\u4e4b\u6297\u9ad4\uff08antibody test\uff09\u53c8\u4fbf\u5b9c\u53c8\u6709good negative predictive value\uff0c\u56e0\u6b64\u5c07\u7528\u65bc\u6cbb\u7642\u5f8c\u5224\u65b7H. pylori\u662f\u5426\u5df2\u6839\u9664\r2. Urea breath test\u6709good positive and negative predictive value\uff0c\u65bc\u6cbb\u7642\u5f8c\u4e8c\u5468\u5373\u53ef\u7528\u4f86\u5224\u65b7H. pylori\u662f\u5426\u5df2\u6839\u9664\r3. \u63a5\u53d7H. pylori\u4e4b\u6839\u9664\u6cbb\u7642\u5f8c\uff0c\u6700\u597d\u518d\u505a\u4e00\u6b21\u5167\u8996\u93e1\uff0c\u53d6\u80c3\u7c98\u819c\u884cculture\u4ee5\u78ba\u5b9aH. pylori\u662f\u5426\u5df2\u6839\u9664\r4. Triple therapy (PPI + Clarithromycin + Amoxicillin) \u662f\u76ee\u524d\u6700\u5e38\u7528\u7684\u6cbb\u7642\u65b9\u5f0f\uff0c\u4f46\u82e5\u75c5\u4eba\u5c0dPenicillin\u66fe\u6709\u904e\u654f\u73fe\u8c61\uff0c\u61c9\u4ee5Metronidazole\u53d6\u4ee3Amoxicillin\r5.  \u82e5Triple therapy\u6cbb\u7642\u5931\u6557\uff0c\u53ef\u6539\u7528Bismuth-based quadruple therapy 7-14\u5929 (PPI + Bismuth + Metronidazole + Tetracycline) \u6cbb\u7642\nA. 1+2+3\nB. 4+5\nC. 2+3+4\nD. 3+4+5\nE. 1+5\n": "(B)", "100-22.\n\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1. \u6025\u6027\u767c\u4f5c\u4e4b\u5614\u5410\uff0c\u82e5\u4f34\u96a8\u6709\u56b4\u91cd\u4e4b\u8179\u75db\uff0c\u53ef\u80fd\u6709intestinal\u6216gastric obstruction\r2. \u6025\u6027\u767c\u4f5c\u4e4b\u5614\u5410\uff0c\u82e5\u7121\u5408\u4f75\u8179\u75db\uff0c\u53ef\u80fd\u662fdiabetic ketoacidosis\u6240\u9020\u6210\r3.\u6162\u6027\u6301\u7e8c\u6216\u53cd\u8986\u767c\u4f5c\u4e4b\u5614\u5410\uff0c\u82e5\u4f34\u96a8\u6709\u8179\u75db\uff0c\u53ef\u80fd\u662fhypothyroidism\u6240\u9020\u6210\r4. \u6162\u6027\u6301\u7e8c\u6216\u53cd\u8986\u767c\u4f5c\u4e4b\u5614\u5410,\u82e5\u6c92\u6709\u5408\u4f75\u8179\u75db,\u53ef\u80fd\u662f\u8166\u90e8\u9577\u7624\nA. 1+2+3\nB. 2+3+4\nC. 3+4+1\nD. 1+2+4\nE. 1+2+3+4\n": "(D)", "101-1.\n\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u53ef\u80fd\u662f\u4e0a\u8179\u75db(epigastralgia)\u4e4b\u75c5\u56e0\uff1f\nA. Reflux esophagitis\nB. Ruptured aortic aneurysm\nC. Myocardial infarction\nD. Mesenteric lymphadenitis\nE. Peptic ulcer disease\n": "(D)", "101-2.\n\u8179\u6c34\uff08ascites\uff09\u75c5\u56e0\u4e4b\u9451\u5225\u8a3a\u65b7\u6709\u8cf4SAAG (Serum-Ascites Albumin Gradient)\uff0c\u4e0b\u5217\u6709\u95dcSAAG\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\r(1)Nephrotic syndrome > 1.1 g/dL\r(2)Tuberculous peritonitis < 1.1 g/dL\r(3)Cirrhosis > 1.1 g/dL\r(4)Peritoneal carcinomatosis < 1.1 g/dL\r(5)Constrictive pericarditis < 1.1 g/dL\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (1)+(4)+(5)\n": "(B)", "101-3.\n\u4e0b\u5217\u6709\u95dcpancreatic neuroendocrine tumor\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r(1)Glucagonoma\u53ef\u80fd\u5c0e\u81f4\u7cd6\u5c3f\u75c5\r(2)VIPoma (VIP: vasoactive intestinal peptide)\u53ef\u80fd\u5c0e\u81f4peptic ulcers\r(3)Insulinoma\u5e38\u70ba\u60e1\u6027\u816b\u7624\r(4)EUS (endoscopic ultrasound)\u662f\u5075\u6e2c\u9019\u985e\u816b\u7624\u4e4b\u6700\u4f73\u5de5\u5177\r(5) Liver metastasis\u5c0d\u60a3\u8005\u4e4b\u9810\u5f8c\u5f71\u97ff\u751a\u5927\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (2)+(3)+(5)\nE. (1)+(4)+(5)\n": "(E)", "101-4.\n\u4e0b\u5217\u6709\u95dcjaundice\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\uff08\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848\uff09\r(1)Isolated elevation of serum bilirubin,\u3000\u4e14direct bilirubin\u4f5470%\u4ee5\u4e0a\uff0c\u53ef\u80fd\u70baCrigler-Najjar syndrome\r(2)Isolated elevation of serum bilirubin\uff0c\u4e14indirect bilirubin\u4f5470%\u4ee5\u4e0a\uff0c\u53ef\u80fd\u70bahemolysis\r(3)Serum bilirubin \u2191\u2191\uff0cAST\u53caALT \u2191\u2191 \uff0cALP\u7121\u660e\u986f\u4e0a\u5347\uff0c\u53ef\u80fd\u70bahepatic decompensation\r(4)Serum bilirubin \u2191\u2191\uff0cAST\u53caALT \u2191\uff0cALP \u2191\u2191\uff0c Gamma-GT \u2191\u2191 \uff0c\u53ef\u80fd\u70baobstructive jaundice\nA. (1)+(2)\nB. (1)+(2)+(3)\nC. (2)+(3)+(4)\nD. (1)+(3)+(4)\nE. (1)+(4)\n": "(C)", "101-5.\n\u4e0b\u5217\u6709\u95dcgastric polyp\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Adenomatous polyps\u5927\u5c0f\u4e0d\u4e00\uff0cdysplasia\u51fa\u73fe\u6a5f\u7387\u4ea6\u4e0d\u4e00\uff0c\u4f46\u6709\u764c\u5316\u98a8\u96aa\nB. Hyperplastic polyps\u82e5\u540c\u6642\u4f75\u6709H. pylori\u611f\u67d3\uff0c\u65bc\u6839\u9664H. pylori\u5f8c\uff0c\u6b64\u7b49polyps\u53ef\u80fd\u6703\u8b8a\u5c0f\nC. Fundic gland polyps\u591a\u57281~5 mm\u5927\u5c0f\uff0c\u5e38\u70basporadic\u767c\u751f\uff0c\u8207gastric cancer\u5f88\u5c11\u6709\u95dc\u806f\nD. Fundic gland polyps\u767c\u751f\u65bcfamilial adenomatous polyposes\u60a3\u8005\u6642\uff0c\u50c5\u67091% dysplasia\u6a5f\u7387\uff0c\u4e0d\u5fc5\u5b9a\u671f\u8ffd\u8e64\nE. Submucosal lesions\u61c9\u8003\u616e\u4ee5endoscopic ultrasound\u505a\u9451\u5225\u8a3a\u65b7\n": "(D)", "101-6.\n\u4e0b\u5217\u5404\u9805\u95dc\u65bc\u6162\u6027\u809d\u75c5\u4e4b\u75c5\u56e0\u8a3a\u65b7\u7d44\u5408\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Primary biliary cirrhosis---Antimicrosomal antibody\nB. Autoimmune hepatitis---Antinuclear antibody\nC. Fasting transferrin saturation > 60% & elevated serum ferritin---Hemochromatosis\nD. Decreased serum ceruloplasmin & increased urine copper excretion---Wilson disease\nE. Wilson disease---Kayser-Fleischer ring\n": "(A)", "101-7.\n\u6240\u8b02postcholecystectomy syndrome\u662f\u6307\u56e0disorders of extrahepatic bile duct\u800c\u9020\u6210\u53f3\u4e0a\u8179\u75c7\u72c0\u65bc\u8853\u5f8c\u4ecd\u6301\u7e8c\u5b58\u5728\u3002\u4e0b\u5217\u5404\u9805\u75c5\u6cc1\uff0c\u4f55\u8005\u8207postcholecystectomy syndrome\u7121\u95dc\uff1f\nA. Bile salt-induced diarrhea or gastritis\nB. Stenosis or dyskinesia of the sphincter of Oddi\nC. Cystic duct stump syndrome\nD. Retained biliary calculi\nE. Common bile duct dilatation\n": "(E)", "101-8.\n\u4e0b\u5217\u6709\u95dc\u85e5\u7269\u6027\u809d\u50b7\u5bb3\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u85e5\u7269\u5728\u809d\u7d30\u80de\u5167\u4e4b\u4ee3\u8b1d\uff0c\u5206\u70baphase I\u53caphase II reaction\uff0c\u5176\u4e2dphase I reaction\u4e4b\u4e2d\u9593\u7522\u7269\u53ef\u80fd\u6703\u50b7\u5bb3\u809d\u7d30\u80de\nB. Cytochrome p450\u8207phase II reaction\u76f8\u95dc\uff0cglucuronidation\u5247\u8207phase I reaction\u76f8\u95dc\nC. \u85e5\u7269\u50b7\u809d\u4e4b\u6a5f\u8f49\u4e3b\u8981\u5206direct toxicity\u53caidiosyncratic reaction\u5169\u7a2e\nD. \u85e5\u7269\u6027\u809d\u50b7\u5bb3\u4e4b\u8868\u73fe\u5305\u542bhepatotoxicity (hepatocyte necrosis)\u53cacholestasis\nE. \u7b2c\u4e00\u4ee3TZD (Thiozolidinedione)\u767c\u751f\u809d\u50b7\u5bb3\u4e4b\u6a5f\u7387\u8f03\u9ad8\uff0c\u7b2c\u4e8c\u4ee3TZD\u5247\u8f03\u5c11\u898b\n": "(B)", "101-9.\n\u4e0b\u5217\u95dc\u65bcdiverticular disease of the colon\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5927\u8178\u4e4bdiverticulosis\u662f\u4e00\u7a2e\u8001\u5316\u7684\u75be\u75c5\nB. \u8179\u75db\u3001\u767c\u71d2\u53ca\u767d\u8840\u7403\u7570\u5e38\u589e\u591a\u4e43\u662facute uncomplicated diverticulitis\u6700\u5e38\u898b\u4e4b\u8868\u73fe\nC. \u5927\u8178\u93e1\u6aa2(colonoscopy)\u5728\u6025\u6027\u671f\u57f7\u884c\u6700\u6709\u8a3a\u65b7\u6548\u76ca\nD. \u5728\u5973\u6027\u60a3\u8005\uff0c\u6b64\u75c5\u61c9\u8207ovarian cyst, endometriosis\u6216pelvic inflammatory disease\u884c\u9451\u5225\u8a3a\u65b7\nE. uncomplicated\u75c5\u60a3\u61c9\u4ee5\u6297\u751f\u7d20\u6cbb\u7642\u4e4b\n": "(C)", "101-10.\n\u4e0b\u5217\u6709\u95dc\u6025\u6027\u80f0\u81df\u708e\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6025\u6027\u80f0\u81df\u708e\u4e4b\u75c5\u7a0b\u53ef\u5206\u5169\u500bphases\uff0c\u7b2c\u4e00\u500bphase\u4fc2\u767c\u75c5\u5f8c1~2\u9031\u5167\uff0c\u5176\u56b4\u91cd\u5ea6 (severity)\u61c9\u4ee5morphologic findings\u70ba\u4e3b\u8981\u5224\u65b7\u4f9d\u64da\nB. CT Severity Index (CTSI)\u4e4b\u5224\u65b7\u53ca\u8a08\u5206\u5305\u542bunenhanced \u53caenhanced CT\u6240\u898b\nC. \u8840\u4e2damylase level\u7570\u5e38\u5347\u9ad8\u4e5f\u53ef\u898b\u65bcrenal insufficiency\u6216lung cancer\u60a3\u8005\nD. \u82e5\u6709\u4f75\u767chemoperitoneum\uff0c\u5728\u809d\u81cd\u5468\u570d\u53ef\u80fd\u898b\u5230faint blue discoloration\uff0c\u7a31\u70baCullen's sign\nE. \u672c\u5730\u6700\u5e38\u898b\u4e4b\u75c5\u56e0\u70bagallstone \u53caalcoholism\n": "(A)", "101-11.\n\u4e0b\u5217\u6709\u95dc\u75c5\u6bd2\u6027\u809d\u708e\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. E\u578b\u809d\u708e\u75c5\u6bd2\u4e4b\u6f5b\u4f0f\u671f\u7d04\u70ba14~60\u5929 (mean\uff0c5~6\u9031\uff09\nB. D\u578b\u809d\u708e\u4e4b\u50b3\u67d3\u9014\u5f91\u4e3b\u8981\u70bapaid sex\nC. \u6162\u6027\uff22\u578b\u809d\u708e\u60a3\u8005\u8840\u4e2d\u767c\u751f\u81ea\u767c\u6027\uff08spontaneous\uff09HBeAg seroconversion (HBeAg (+) \u8b8a (-)\uff0cAnti-HBe (-) \u8b8a (+)\uff09\uff0c\u662f\u4e00\u500b\u597d\u73fe\u8c61\nD. \u6162\u6027\uff23\u578b\u809d\u708e\u4ee5\u5e72\u64fe\u7d20 + Ribavirin\u6cbb\u7642\u81f3\u5c11\u516d\u500b\u6708\uff0c\u53ef\u80fd\u75ca\u7652\nE. \u76ee\u524d\u53f0\u7063\u4e09\u5341\u6b72\u4ee5\u4e0b\u7684\u5e74\u8f15\u4eba\u7686\u61c9\u63a5\u53d7A\u578b\u809d\u708e\u75ab\u82d7\u63a5\u7a2e\uff0c\u4e00\u500b\u5b8c\u6574\u7684\u7642\u7a0b\u5171\u61c9\u63a5\u53d7\u4e09\u5291\u75ab\u82d7\n": "(E)", "101-12.\n\u6709\u4f4d\u60a3\u8005\u8179\u7009\u8d85\u904e4\u9031\uff0c\u5176\u7279\u5fb5\u70ba\u6c34\u6a23\u6027\u7cde\u4fbf\u4e14\u91cf\u76f8\u7576\u5927\uff0c\u4e26\u6c92\u6709\u8179\u75db\u73fe\u8c61\uff0c\u5373\u4f7f\u7981\u98df\u4ecd\u7136\u8179\u7009\u4e0d\u6b62\uff0c\u7cde\u4fbf\u7684osmotic gap\u6b63\u5e38\uff0c\u5176\u8a3a\u65b7\u53ef\u80fd\u70ba\u4e0b\u5217\u5404\u7a2e\u75be\u75c5\uff0c\u9664\u4e86\uff1a\nA. \u9577\u671f\u98f2\u9152(chronic ethanol ingestion)\nB. \u5927\u8178\u7d68\u6bdb\u817a\u7624(villous adenoma)\nC. \u670d\u7528lactulose\nD. \u611b\u8fea\u751f\u75c5(Addison's disease)\nE. \u80c3\u6ccc\u7d20\u7624(gastrinoma)\n": "(C)", "101-13.\n\u9ad4\u91cd\u7684\u8abf\u63a7\u8207\u9032\u98df\u884c\u70ba\u6709\u95dc\uff0c\u6b63\u5e38\u72c0\u6cc1\u4e0b\u4f55\u8005\u662f\u6e90\u65bc\u80c3\u8178\u9053\u4e14\u53ef\u5f71\u97ff\u9032\u98df\u7684\u8377\u723e\u8499?\r(1)gastrin\r(2)ghrelin\r(3)glucagon\r(4)cholecystokinin\r(5)ciliary neurotrophic factor\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(B)", "101-14.\n50\u6b72\u7537\u6027\u56e0\u4e0a\u8179\u75db\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5(\u57161)\u4e26\u505a\u4e86\u75c5\u7406\u5207\u7247(\u57162)\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u9069\u5408\u505a\u70ba\u6cbb\u7642\u85e5\u7269?\nA. bismuth subcitrate\nB. omeprazole\nC. cephalexin\nD. amoxicillin\nE. clarithromycin\n": "(C)", "101-15.\n60\u6b72\u7537\u6027\u809d\u786c\u5316\u60a3\u8005\uff0c\u56e0\u5410\u8840\u89e3\u9ed1\u4fbf\u81f3\u6025\u8a3a\uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u7d50\u679c\u4e4b\u98df\u9053\u8868\u73fe\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u9069\u7528\u65bc\u6b64\u4f4d\u60a3\u8005\u7684\u8655\u7f6e?\nA. terlipressin\nB. antibiotic\nC. endoscopic variceal ligation\nD. doxazosin\nE. octreotide\n": "(D)", "101-16.\n20\u6b72\u7537\u6027\uff0c\u56e0\u541e\u56a5\u56f0\u96e3\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\uff0c\u5831\u544a\u7d50\u679c\u70ba\u6b63\u5e38\uff0c\u5176\u98df\u9053\u651d\u5f71\u7d50\u679c\u5982\u5716\uff0c\u4e0b\u5217\u6cbb\u7642\u65b9\u5f0f\u53ef\u7de9\u89e3\u5176\u75c7\u72c0\uff0c\u9664\u4e86\uff1a\nA. isosorbide dinitrate\nB. atenolol\nC. nifedipine\nD. endoscopic botulinum toxin injection\nE. endoscopic ballon dilatation\n": "(B)", "101-17.\n22\u6b72\u7537\u6027\uff0c\u56e0\u89e3\u8840\u4fbf\u63a5\u53d7\u5168\u5927\u8178\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u5982\u5716\uff0c\u75c5\u7406\u5207\u7247\u7d50\u679c\u70bagranulomatous inflammation\uff0c\u4e14acid-fast stain\u70ba\u9670\u6027\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u771f\uff1f\r(1)\u62bd\u7159\u53ef\u6e1b\u5c11\u6b64\u75c5\u7684\u767c\u751f\r(2)\u8178\u9053\u5167\u53ad\u6c27\u83cc\uff0c\u4f8b\u5982Bacteroides\uff0c\u53ef\u8a98\u767c\u75c5\u4eba\u7684\u8178\u9053\u767c\u708e\u53cd\u61c9\r(3)\u8d85\u904e50%\u4ee5\u4e0a\u7684\u60a3\u8005\u8840\u4e2dperinuclear antineutrophil cytoplasmic antibodies (PANCAs)\u5448\u73fe\u967d\u6027\u53cd\u61c9\r(4)\u6b64\u75c5\u53ef\u5408\u4f75\u9031\u908a\u95dc\u7bc0\u708e(peripheral arthritis)\u6216\u50f5\u76f4\u6027\u810a\u690e\u708e(ankylosing spondylitis)\r(5)\u53ef\u5408\u4f75\u81bd\u9053\u75be\u75c5\u7684\u767c\u751f\uff0c\u4f8b\u5982primary sclerosing cholangitis\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(E)", "101-18.\n\u500b\u6848\u5065\u5eb7\u6aa2\u67e5\u6642\uff0c\u767c\u73feAST:20 IU/L\uff0cALT:18 IU/L\uff0cALP:95 IU/L\uff0cr-GT:25 IU/L\uff0cbilirubin(total/direct):2.0/0.4 mg/dL\uff0c\u4e14\u8d85\u97f3\u6ce2\u6aa2\u67e5\u6b63\u5e38\uff0c\u500b\u6848\u7528phenobarbital\u5f8cbilirubin\u53ef\u6062\u5fa9\u6b63\u5e38\u3002\u6709\u95dc\u6b64\u500b\u6848\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u6b64\u75c5\u7684\u767c\u751f\u5973\u591a\u65bc\u7537\nB. \u8207\u907a\u50b3\u6709\u95dc\uff0c\u4e14\u70ba\u81ea\u9ad4\u986f\u6027\u907a\u50b3(autosomal dominant)\nC. \u5176bilirubin uridine diphosphate glucuronosyltransferase (UGT) \u9175\u7d20\u6d3b\u6027\u5448\u73fe\u6b63\u5e38\nD. \u5f88\u5c11\u767c\u751f\u6eb6\u8840(hemolysis)\u73fe\u8c61\nE. \u8207UGT1\u57fa\u56e0\u7a81\u8b8a\u6709\u95dc\n": "(E)", "101-19.\n38\u6b72\u7537\u6027\u70baHBsAg(+)\u548cHBeAg(-)\u5e36\u539f\u8005\uff0c\u4f4f\u9662\u524d\u4e00\u9031\u6709\u5026\u6020\u611f\u53ca\u8179\u8139\u73fe\u8c61\uff0c\u63a5\u8457\u51fa\u73fe\u6709\u6df1\u8272\u5c3f\u73fe\u8c61\uff0c\u4f4f\u9662\u6642\u6aa2\u67e5AST:1250 IU/L\u3001ALT:1460 IU/L\uff0cbilirubin (total/direct):11.2/7.1 mg/dL, HBV-DNA:1500000 copies/mL\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8a3a\u65b7\u53ef\u80fd\u70baB\u578b\u809d\u708e\u6025\u6027\u60e1\u5316\nB. \u60a3\u8005\u9ad4\u5167\u75c5\u6bd2\u53ef\u80fd\u5728pre-S region \u7684nucleotide 1896\u8655\u767c\u751fG-->A\u7a81\u8b8a\nC. \u9810\u5f8c\u8f03\u6c92\u6709\u767c\u751f\u7a81\u8b8a\u7684wild-type\u5dee\nD. \u6b64\u578b\u662f\u76ee\u524d\u6b50\u6d32\u6700\u5e38\u898b\u7684B\u578b\u809d\u708e\u767c\u4f5c\u578b\u5f0f\nE. \u7531\u65bc\u79fb\u6c11\u7684\u95dc\u4fc2\uff0c\u76ee\u524d\u7f8e\u570b\u6b64\u578b\u7684\u767c\u751f\u7387\u4e5f\u6709\u589e\u52a0\u7684\u8da8\u52e2\n": "(B)", "101-20.\n45\u6b72\u80a5\u80d6\u7537\u6027\uff0c\u904e\u53bb\u4e00\u5e74\u4f86\u809d\u529f\u80fd\u6301\u7e8c\u7570\u5e38\uff0c\u5176AST/ALT\u5747\u5728\u6b63\u5e38\u503c\u76842\u500d\u81f35\u500d\u6ce2\u52d5\uff0c\u6aa2\u67e5\u767c\u73feHBsAg(-), anti-HCV(+), HCV-RNA: 3500000 copies/mL\uff0c\u75c5\u6bd2\u57fa\u56e0\u578b\u70ba\u7b2c1\u578b,\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r(1)\u500b\u6848\u61c9\u63a5\u53d724\u9031\u7684PEG-IFN\u5408\u4f75ribavirin\u6cbb\u7642,\u6548\u679c\u6700\u597d\r(2)\u500b\u6848\u56e0\u5e74\u9f61\u95dc\u4fc2\uff0c\u6cbb\u7642\u53cd\u61c9\u8f03\u4f73\r(3)\u500b\u6848\u56e0\u75c5\u6bd2\u57fa\u56e0\u578b\u95dc\u4fc2\uff0c\u6cbb\u7642\u53cd\u61c9\u8f03\u5dee\r(4)\u6cbb\u764212\u9031\u6642\u6aa2\u6e2cHCV-RNA\u503c\u6709\u52a9\u65bc\u53cd\u61c9\u7684\u5224\u65b7\r(5)\u500b\u6848\u56e0\u80a5\u80d6\u95dc\u4fc2\uff0c\u6cbb\u7642\u53cd\u61c9\u8f03\u5dee\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "101-21.\n40\u6b72\u5973\u6027\uff0c\u56e0\u6025\u6027\u8179\u75db\u81f3\u6025\u8a3a\u8655\u6c42\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u53f3\u4e0a\u8179\u6709\u660e\u986f\u58d3\u75db\uff0c\u9ad4\u6eab38\u2103\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5AST:1070 IU/L, ALT:1810 IU/L, bilirubin (total/direct) 3.2/1.8 mg/dL\uff0cWBC:12400/\u03bcl\uff0cseg:84%\uff0c\u8d85\u97f3\u6ce2\u53ca\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u5982\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u8a3a\u65b7\u70ba\u6025\u6027\u809d\u708e\nB. \u5e38\u5408\u4f75\u809d\u5167\u81bd\u7ba1\u7d50\u77f3\nC. Morphine\u662f\u6b64\u60a3\u8005\u6b62\u75db\u4e4b\u9996\u9078\nD. \u5167\u79d1\u6cbb\u7642\u70ba\u9996\u9078,\u4e1490%\u4ee5\u4e0a\u60a3\u8005\u5747\u53ef\u5f97\u5230\u75c7\u72c0\u6539\u5584\nE. \u8fd1\u4f86\u4e4b\u8da8\u52e2\u70ba\u5118\u65e9\u624b\u8853\n": "(E)", "101-22.\n37\u6b72\u7537\u6027\u60a3\u8005\uff0c\u4e3b\u8a34\u6162\u6027\u8179\u75db\u4e00\u5e74\u4ee5\u4e0a\uff0c\u6709\u6b62\u75db\u85e5\u4f7f\u7528\u7fd2\u6163\uff0c\u4e14\u6700\u8fd1\u6709\u8179\u7009\u3001\u9ad4\u91cd\u6e1b\u8f15\u73fe\u8c61\uff0c\u8179\u90e8\u8d85\u97f3\u6ce2(\u57161)\u53ca\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u7d50\u679c(\u57162)\uff0c\u6b64\u60a3\u8005\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u7684\u4f75\u767c\u75c7(complication)\uff0c\u9664\u4e86\nA. \u9ec3\u75b8\nB. \u80c3\u8178\u51fa\u8840\nC. \u7dad\u751f\u7d20B1\u5438\u6536\u4e0d\u826f\nD. \u8461\u8404\u7cd6\u8010\u53d7\u7570\u5e38(impaired glucose tolerance)\nE. \u76ae\u4e0b\u8102\u80aa\u58de\u6b7b(subcutaneous fat necrosis)\n": "(C)", "102-1.\n\u4e00\u4f4d50\u6b72\u75c5\u4eba\u81f3\u9580\u8a3a\u5c31\u91ab\uff0c\u81ea\u8a34\u6700\u8fd1\u5065\u6aa2\u4e2d\uff0c\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u4e00\u9846\u809d\u5167\u816b\u7624\uff0c\u4e0d\u77e5\u8a72\u600e\u9ebc\u8fa6\uff0c\u56e0\u6b64\u4ed6\u4f86\u8acb\u6559\u4f60\u7684\u5c08\u696d\u770b\u6cd5\u3002\u4e0b\u5217\u6709\u95dc\u809d\u5167\u816b\u7624\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4e09\u76f8\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff08triphasic CT scan\uff09\u6709\u52a9\u65bc\u809d\u5167\u816b\u7624\u4e4b\u9451\u5225\u8a3a\u65b7\nB. \u809d\u7d30\u80de\u764c\uff08hepatocellular carcinoma\uff09\u5e38\u5408\u4f75\u809d\u786c\u5316\nC. \u809d\u8840\u7ba1\u7624\uff08hemangioma\uff09\u901a\u5e38\u4e0d\u5fc5\u52a0\u4ee5\u8655\u7f6e\nD. \u5c40\u90e8\u7d50\u7bc0\u6027\u589e\u751f\uff08focal nodular hyperplasia, FNH\uff09\u4e4b\u767c\u751f\u8207\u53e3\u670d\u907f\u5b55\u4e38\u6709\u95dc\nE. \u817a\u7624\uff08adenoma\uff09\u53ef\u80fd\u6703\u6709\u816b\u7624\u5167\u51fa\u8840\u4e4b\u98a8\u96aa\n": "(D)", "102-2.\n\u807d\u8aaa50\u6b72\u4ee5\u4e0a\u5c31\u662f\u764c\u75c7\u6613\u767c\u5e74\u9f61\uff0c\u4e00\u4f4d\u75c5\u4eba\u627e\u4f60\u5c31\u91ab\uff0c\u5e0c\u671b\u80fd\u63a5\u53d7\u4e00\u4e9b\u764c\u75c7\u7be9\u6aa2\u63aa\u65bd\u3002\u4e0b\u5217\u5404\u9805\u6709\u95dc\u764c\u75c7\u7be9\u6aa2\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u809d\u7d30\u80de\u764c\uff08hepatocellular carcinoma\uff09\u4e4b\u7be9\u6aa2\u61c9\u5305\u62ec\u8179\u90e8\u8d85\u97f3\u6ce2\u6383\u63cf\u53ca\u62bd\u8840\u6aa2\u9a57\u7532\u7a2e\u80ce\u5152\u86cb\u767d\uff08\u03b1 -fetoprotein\uff09\nB. CA19-9\u53caCEA (carcinoembryonic antigen) \u5169\u7a2e\u816b\u7624\u6a19\u8a18\u52a0\u4e0a\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u80fd\u65e9\u671f\u767c\u73fe\u80f0\u81df\u764c\nC. \u7f8e\u570b\u764c\u75c7\u5b78\u6703\uff08American Cancer Society\uff09\u5efa\u8b7050\u6b72\u4ee5\u4e0a\u7121\u7279\u6b8a\u9ad8\u98a8\u96aa\u56e0\u5b50\u4e4b\u4e00\u822c\u6c11\u773e\uff0c\u6bcf\u5e74\u6aa2\u67e5fecal hemoccult screening\u52a0\u4e0a5\u5e74\u4e00\u6b21sigmoidoscopic examination\nD. \u9577\u671f\u7279\u5225\u559c\u6b61\u9032\u98df\u542b\u6709\u9ad8\u6fc3\u5ea6nitrates\u4e4b\u98df\u7269\u7684\u4eba\uff0c\u61c9\u5b9a\u671f\u63a5\u53d7\u80c3\u90e8\u6aa2\u67e5\uff0c\u5305\u62ecdouble-contrast radiographic examination\u6216\u5167\u8996\u93e1\u6aa2\u67e5\nE. \u540c\u6027\u6200\u7537\u4eba\u6216\u611b\u6ecb\u75c5\u4eba\uff0c\u61c9\u5b9a\u671f\u63a5\u53d7\u809b\u9580\u6307\u8a3a\uff08digital rectal examination\uff09\n": "(B)", "102-3.\n\u4e00\u4f4d\u809d\u786c\u5316\u75c5\u4eba\u5e73\u6642\u8eab\u9ad4\u611f\u5230\u4e0d\u8212\u670d\u6642\uff0c\u5927\u591a\u5148\u627e\u5bb6\u5ead\u91ab\u5e2b\u8655\u7406\u3002\u5982\u679c\u4f60\u662f\u4ed6\u7684\u5bb6\u5ead\u91ab\u5e2b\uff0c\u4e0b\u5217\u5404\u9805\u91ab\u7642\u554f\u984c\u4e4b\u8655\u7f6e\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5176Child's score\u5df2\u81f3B\u7d1a\uff0cprothrombin time (INR)= 1.50\uff0c\u60f3\u8acb\u4f60\u958bVitamin K \u7d66\u4ed6\u6cbb\u7642\nB. \u4ed6\u525b\u56e0\u98df\u9053\u975c\u8108\u66f2\u5f35\u7834\u88c2\u51fa\u8840\u4f4f\u9662\uff0c\u63a5\u53d7variceal band ligation\u8655\u7406\u4e14\u75c5\u60c5\u7a69\u5b9a\u5f8c\u51fa\u9662\u3002\u91ab\u9662\u7684\u4e3b\u6cbb\u91ab\u5e2b\u53eb\u4ed6\u8981\u53e3\u670dpropranolol\uff0c\u6e1b\u5c11\u518d\u5ea6\u51fa\u8840\u4e4b\u6a5f\u7387\u3002\nC. \u62bd\u8840\u6aa2\u9a57\u767c\u73feplatelet count = 72 K/\u03bcL(\u6b63\u5e38 > 150 K) \uff0c\u8207\u809d\u9580\u8108\u9ad8\u58d3 (portal hypertension) \u6709\u95dc\u3002\nD. \u5176\u809d\u786c\u5316\u662f\u56e0\u6162\u6027B\u578b\u809d\u708e\u6240\u9020\u6210\uff0c\u76ee\u524d\u8840\u4e2dALT (alanine aminotransferase)= 89\uff0cAST (aspartate aminotransferase) = 100\uff0cHBV DNA = 100,000 IU/mL\uff0c\u60f3\u8acb\u4f60\u7528interferon \u03b1 \u7d66\u4e88\u6cbb\u7642\uff0c\u4f60\u8a8d\u70ba\u4e0d\u5408\u5b9c\u3002\nE. \u75c5\u4eba\u7f79\u60a3primary biliary cirrhosis\uff0c\u5df2\u6709\u5341\u5e74\u75c5\u53f2\uff0c\u4f60\u8981\u7279\u5225\u6ce8\u610f\u4ed6\u662f\u5426\u6709osteoporosis\u3002\n": "(A)", "102-4.\n\u95dc\u65bc\u809d\u786c\u5316\u4e4b\u4f75\u767c\u75c7\uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u98df\u9053\u975c\u8108\u66f2\u5f35\u7834\u88c2\u51fa\u8840\uff0c\u65bc\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a\u5f8c\u61c9\u5118\u5feb\u65bd\u884cband ligation\u3002\nB. \u82e5\u8179\u90e8\u8139\u5927\u4e14\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8179\u90e8\u6709shifting dullness\uff0c\u61c9\u9650\u5236\u5176\u6bcf\u65e5\u7d0d\u651d\u53d6\u91cf\u4f4e\u65bc2 g\u3002\nC. \u82e5\u6709\u8179\u75db\uff0c\u62bd\u53d6\u8179\u6c34\u6aa2\u9a57\u767c\u73feneutrophils > 250/\u03bcL\uff0c\u61c9\u7acb\u5373\u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u3002\nD. \u82e5\u75c5\u4eba\u884c\u70ba\u7570\u65bc\u5e73\u6642\uff0c\u62bd\u8840\u6aa2\u9a57\u767c\u73feNH3 =100 (\u6b63\u5e38 < 37)\uff0c\u61c9\u512a\u5148\u4ee5neomycin\u6216metronidazole\u7b49\u8178\u9053\u5438\u6536\u751a\u5c11\u4e4b\u6297\u751f\u7d20\u7d66\u4e88\u6cbb\u7642\u3002\nE. \u82e5\u75c5\u4eba\u525b\u5f9e\u809d\u6027\u8166\u75c5\u8b8a (hepatic encephalopathy) \u6062\u5fa9\uff0c\u61c9\u9650\u5236\u5176\u6bcf\u65e5\u86cb\u767d\u8cea\u651d\u53d6\u91cf\uff0c\u5c24\u5176\u662f\u52d5\u7269\u6027\u86cb\u767d\u8cea\u3002\n": "(D)", "102-5.\n\u4e00\u4f4d\u6162\u6027\uff22\u578b\u809d\u708e\u75c5\u4eba\uff0c\u61c9\u9577\u671f\u5b9a\u671f\u63a5\u53d7\u8ffd\u8e64\u6aa2\u67e5\u4ee5\u77ad\u89e3\u4e26\u638c\u63e1\u5176\u75c5\u60c5\u3002\u4e0b\u5217\u5404\u9805\u7d44\u5408\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1) ALT (alanine aminotransferase)\u53caAST (aspartate aminotransferanse) <->\u809d\u767c\u708e\u6307\u6578 (2) albumin <-> \u809d\u6b98\u5b58\u529f\u80fd (3) bilirubin <-> \u809d\u89e3\u6bd2\u529f\u80fd\r\n(4) hemoglobin <-> \u809d\u7e96\u7dad\u5316\u7a0b\u5ea6 (5) AFP (a-fetoprotein) <-> \u81bd\u7ba1\u7d30\u80de\u764c\u816b\u7624\u6a19\u8a18 (6) \u8d85\u97f3\u6ce2\u6aa2\u67e5 <-> \u809d\u7d30\u80de\u764c (7) \u8d85\u97f3\u6ce2\u6aa2\u67e5 <-> \u809d\u786c\u5316 (8) HBV DNA <-> \u809d\u7d30\u80de\u764c\u816b\u7624\u6a19\u8a18\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (1)+(2)+(6)+(7)\nD. (3)+(4)+(6)+(7)\nE. (2)+(4)+(5)+(8)\n": "(C)", "102-6.\n\u5c0d\u65bc\u6162\u6027\uff22\u578b\u809d\u708e\u75c5\u4eba\uff0c\u73fe\u5728\u6709\u5404\u7a2e\u7279\u7570\u6027\u6cbb\u7642\u85e5\u7269\u53ef\u4f9b\u4f7f\u7528\u3002\u9762\u5c0d\u4e0b\u5217\u5404\u7a2e\u81e8\u5e8a\u60c5\u5883\uff0c\u4f55\u8005\u4e0d\u5fc5\u6cbb\u7642\uff1f\nA. HBeAg (+), HBV DNA: 108IU/mL, ALT < 2X ULN (Upper Limits of Normal)\nB. HBeAg (+), HBV DNA: 105IU/mL, ALT > 5X ULN\nC. HBeAg (-), HBV DNA: 106IU/mL, ALT > 2X ULN \u5df2\u8d85\u904e6\u500b\u6708\nD. HBeAg (-), HBV DNA: 30000 IU/mL, ALT < 2X ULN, \u6709\u4ee3\u511f\u6027\u809d\u786c\u5316 (compensated liver cirrhosis)\nE. HBeAg (+), HBV DNA: 106IU/mL, ALT > 5X ULN, Cr (creatinine) = 2.5 mg/dL\n": "(A)", "102-7.\n\u5c0d\u65bc\u6162\u6027C\u578b\u809d\u75c5\u4eba\uff0c\u73fe\u5728\u5df2\u6709\u6210\u529f\u7387\u76f8\u7576\u9ad8\u7684\u6cbb\u7642\u65b9\u5f0f\u3002\u4e0b\u5217\u5404\u9805\u76f8\u95dc\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f (1) \u4e3b\u6d41\u7642\u6cd5\u70ba\u6ce8\u5c04\u9577\u6548\u578binterferon \u03b1 (pegylated IFN \u03b1)\u5408\u4f75\u53e3\u670d\u8db3\u91cf\u7684ribavirin (\u81f3\u5c11800 mg/\u5929) (2) anti-HCV (+)\u4e14ALT\u53caAST\u4e0a\u5347\u81f31.5X ULN (Upper Limits of Normal)\u6301\u7e8c\u90546\u500b\u6708\u4ee5\u4e0a\uff0c\u5373\u61c9\u8a72\u63a5\u53d7pegylated IFN \u03b1 + ribavirin\u6cbb\u7642 (3) \u75c5\u4ebaIL-28B SNP (Single Nucleotide Polymorphism) at rs12979860\u5c6cT/T\u8005 (\u6709 T/T\uff0cC/T\uff0cC/C\u4e09\u7a2egenotypes )\uff0c\u6cbb\u7642\u6210\u529f\u7387\u8f03\u9ad8 (4) HCV\u82e5\u70bagenotype 1\u62164\uff0c\u6cbb\u7652\u7387\u905480%\u4ee5\u4e0a (5) \u6cbb\u7642\u524d\u8840\u4e2dHCV RNA level\u4f4e\u65bc800,000\r\nIU/mL\u8005\uff0c\u6cbb\u7652\u7387\u8f03\u9ad8 (6) \u6cbb\u7642\u524d\u809d\u5167\u7e96\u7dad\u5316 (fibrosis)\u6108\u53b2\u5bb3\uff0c\u6cbb\u7652\u7387\u6108\u9ad8\u3002\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(5)+(6)\nC. (2)+(4)+(6)\nD. (2)+(4)+(5)\nE. (1)+(2)+(5)\n": "(E)", "102-8.\n\u6709\u95dc\uff22\u578b\u809d\u708e\u75c5\u6bd2 (HBV) \u6cbb\u7642\u85e5\u7269\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. Interferon \u03b1\u53ef\u80fd\u5c0e\u81f4bone marrow suppression, autoimmune thyroiditis\u53caemotional lability\nB. \u55ae\u7368\u4f7f\u7528lamivudine\uff11\u5e74\uff0cHBV\u5c0d\u5b83\u7522\u751f\u6297\u85e5\u6027\u4e4b\u6a5f\u7387\u53ef\u905430%\nC. \u53ef\u80fd\u7522\u751f\u814e\u6bd2\u6027\u4e4b\u53e3\u670d\u85e5\u7269\u70batelbivudine\nD. \u814e\u529f\u80fd\u7570\u5e38\u6642\uff0c\u61c9\u8abf\u6574\u53e3\u670d\u6297\uff22\u809d\u75c5\u6bd2\u85e5\u7269\u4e4b\u670d\u7528\u5291\u91cf\u3002\nE. Telbivudine\u53ef\u80fd\u5c0e\u81f4asymptomatic creatine kinase elevation\u53caperipheral neuropathy\u3002\n": "(C)", "102-9.\n\u67d0\u4f4d\u75c5\u4eba\u6700\u8fd1\u4e00\u5468\u5fc3\u7aa9\u8655 (epigastric region) \u5e38\u611f\u60b6\u75db\uff0c\u4eca\u5929\u56e0\u75bc\u75db\u7a81\u7136\u52a0\u5287\u800c\u88ab\u9001\u81f3\u6025\u8a3a\u5ba4\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u4e0a\u8179\u90e8\u808c\u8089\u7dca\u7e43 (rigid)\uff0c\u89f8\u8a3a\u6642\u611f\u5230\u76f8\u7576\u786c\uff1b\u7ad9\u7acb\u80f8\u90e8X\u5149\u7167\u76f8\u7d50\u679c\u5982\u5716\u793a\u3002\u4e0b\u5217\u5404\u9805\u81e8\u5e8a\u8a3a\u65b7\uff0c\u4f55\u8005\u6700\u53ef\u80fd\uff1f\nA. Reflux esophagitis\nB. Mallory-Weiss tear\nC. Acute cholecystitis\nD. Perforated peptic ulcer\nE. Myocardial infarction\n": "(D)", "102-10.\n\u4e0b\u5217\u95dc\u65bc\u6d88\u5316\u7cfb\u7d71\u75be\u75c5\u4e4b\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7947\u5c0d\u56fa\u614b\u98df\u7269\u541e\u56a5\u56f0\u96e3\uff0c\u4e14\u6642\u597d\u6642\u58de\uff0c\u6301\u7e8c\u4e00\u5e74\u4ee5\u4e0a\uff0c\u9ad4\u91cd\u672a\u660e\u986f\u6e1b\u8f15\uff0c\u5176\u8a3a\u65b7\u53ef\u80fd\u70baachalasia\nB. Indigestion\u4e4b\u6700\u5e38\u898b\u75c5\u56e0\u70bagastroesophageal reflux\u53cafunctional dyspepsia\nC. \u6703\u5f15\u767c\u5641\u5fc3\u5614\u5410\u4e4b\u85e5\u7269\u5305\u62ec\uff1a\u6297\u751f\u7d20\u3001\u5fc3\u5f8b\u4e0d\u6574\u85e5\u7269\u3001\u964d\u8840\u58d3\u85e5\u7269\u53ca\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\nD. \u5c0d\u65bc\u4e3b\u8a34\u8179\u8139\u7684\u75c5\u4eba\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u4e00\u5b9a\u8981\u78ba\u5b9a\u75c5\u4eba\u662f\u5426\u6709shifting dullness\nE. 90%\u4ee5\u4e0a\u6025\u6027\u8179\u7009\u662f\u50b3\u67d3\u6027\u75c5\u56e0 (infectious agents) \u6240\u81f4\n": "(A)", "102-11.\n\u6839\u9664\u80c3\u5167\u7684\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\uff0c\u53ef\u4ee5\u6e1b\u5c11\u4e0b\u5217\u90a3\u4e9b\u75be\u75c5\u4e4b\u767c\u751f\uff1f\uff08\u61c9\u9078\u51fa\u5168\u90e8\u6b63\u78ba\u7b54\u6848\uff09(1) Gastroesophageal reflux disease (GERD) (2) Esophageal cancer (3) Duodenal ulcer (4) Gastric ulcer (5) Zollinger-Ellison syndrome (6) Gastric mucosa-associated lymphoid tissue (MALT) lymphoma (7) Gastric adenocarcinoma\nA. (1)+(3)+(5)+(7)\nB. (2)+(4)+(6)\nC. (3)+(4)+(6)+(7)\nD. (4)+(5)+(6)\nE. (1)+(3)+(6)+(7)\n": "(C)", "102-12.\n\u6709\u95dc\u9152\u7cbe\u6027\u809d\u75c5(alcoholic liver disease)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f(1)\u7537\u6027\u8f03\u5973\u6027\u6613\u611f\u6027\u9ad8(increased susceptibility) (2)\u71df\u990a\u4e0d\u826f(malnutrition)\u6703\u52a0\u91cd\u75c5\u60c5 (3)\u91cd\u5ea6\u9152\u7cbe\u6027\u809d\u708e(severe alcoholic hepatitis)\u4e0d\u53ef\u4f7f\u7528prednisolone\u6cbb\u7642 (4)\u91cd\u5ea6\u9152\u7cbe\u6027\u809d\u708e\u7528\u6297TNF-\u03b1\u55ae\u682a\u6297\u9ad4\u6cbb\u7642\u6210\u6548\u826f\u597d (5)\u91cd\u5ea6\u9152\u7cbe\u6027\u809d\u708e\u53ef\u8003\u616e\u7528pentoxifylline\u6cbb\u7642\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(B)", "102-13.\n\u6709\u95dc\u611f\u67d3\u6027\u8179\u7009(infectious diarrhea)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1)Yersinia\u611f\u67d3\u53ef\u4fb5\u72af\u672b\u7aef\u8ff4\u8178\uff0c\u800c\u51fa\u73fe\u985e\u4f3c\u6025\u6027\u76f2\u8178\u708e\u73fe\u8c61 (2)Campylobacter\u611f\u67d3\u53ef\u51fa\u73fe\u5408\u4f75\u95dc\u7bc0\u708e\u3001\u5c3f\u9053\u708e\u548c\u7d50\u819c\u708e\u7684\u7684Reiter's syndrome (3)Shigella\u611f\u67d3\u53ef\u5f15\u8d77hemolytic-uremic syndrome (4)\u61f7\u7591\u7d30\u83cc\u611f\u67d3\u6700\u5e38\u4f7f\u7528\u7684empirical treatment\u70baamoxicillin (5)\u61f7\u7591giardiasis\u6700\u5e38\u4f7f\u7528\u7684\u6297\u751f\u7d20\u70bacephalexin\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(2)+(4)\nE. (2)+(3)+(5)\n": "(A)", "102-14.\n60\u6b72\u7537\u6027\u5de5\u4eba\u56e0\u541e\u56a5\u56f0\u96e3\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u5728\u98df\u9053\u4e2d\u6bb5\u767c\u73fe\u75c5\u7076(\u5982\u5716\u793a)\uff0c\u4e0b\u5217\u4f55\u8005\u8207\u6b64\u75c5\u7684\u767c\u751f\u7121\u95dc\uff1f\nA. \u62bd\u7159\nB. \u559d\u9152\nC. \u80c3\u98df\u9053\u9006\u6d41\nD. \u559d\u71b1\u8336\nE. \u98df\u9053\u5f1b\u7de9\u4e0d\u5f35(achalasia)\n": "(C)", "102-15.\n20\u6b72\u5973\u6027\u670d\u7528\u76ae\u819a\u79d1\u7528\u85e5\u5f8c\uff0c\u51fa\u73fe\u541e\u56a5\u75bc\u75db\u53ca\u56f0\u96e3\u73fe\u8c61\uff0c\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\u65bc\u98df\u9053\u767c\u73fe\u5982\u5716\u4e4b\u75c5\u7076\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5f88\u53ef\u80fd\u662f\u670d\u7528doxycycline\nB. \u505c\u6b62\u670d\u7528\u85e5\u7269\u53ef\u80fd\u6539\u5584\nC. \u4ee5\u5f8c\u767c\u751f\u98df\u9053\u764c\u7684\u6a5f\u6703\u589e\u52a0\nD. \u9664\u6297\u751f\u7d20\u5916\uff0cnonsteroidal anti-inflammatory  agents\uff0c\u5982aspirin\u548cindomethacin\u7b49\u4e5f\u53ef\u9020\u6210\u540c\u6a23\u98df\u9053\u50b7\u5bb3\nE. \u670d\u85e5\u6642\u559d\u5927\u91cf\u7684\u6c34\u4e26\u4e14\u63a1\u7ad9\u6216\u5750\u59ff\u53ef\u4ee5\u9810\u9632\u6b64\u75c5\u7684\u767c\u751f\n": "(C)", "102-16.\n70\u6b72\u5973\u6027\u6709\u4e2d\u98a8\u75c5\u53f2\uff0c\u56e0\u89e3\u9ed1\u4fbf\u81f3\u6025\u8a3a\uff0c\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\u6709\u5982\u5716\u4e4b\u75c5\u7076\uff0cbiopsy urease test\u70ba\u9670\u6027\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6700\u9069\u7576\u7684\u7dca\u6025\u8655\u7f6e\uff1f\nA. \u6ce8\u5c04\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291(proton pump inhibitor)\nB. \u6ce8\u5c04\u4e59\u578b\u7d44\u7e54\u80fa\u53d7\u9ad4\u7d50\u6297\u5291(H2 receptor antagonist)\nC. \u5167\u8996\u93e1\u6b62\u8840\u6cbb\u7642\nD. \u5167\u8996\u93e1\u6b62\u8840\u52a0\u4e0a\u6ce8\u5c04\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291\nE. \u624b\u8853\u6cbb\u7642\n": "(D)", "102-17.\n(\u627f\u4e0a\u984c)\u60a3\u8005\u6709\u670d\u7528aspirin\uff0c\u4f4f\u9662\u4e09\u5929\u5f8c\u9806\u5229\u6062\u5fa9\u9032\u98df\uff0c\u51fa\u9662\u5f8c\u8003\u616e\u5fc3\u8840\u7ba1\u53ca\u80c3\u8178\u98a8\u96aa\u7684\u6700\u4f73\u8655\u7f6e\u70ba\uff1f\nA. \u5c07aspirin\u6539\u70baclopidogrel\nB. \u53e3\u670d\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291\u4e26\u5408\u7528aspirin\nC. \u505c\u7528aspirin\uff0c\u4e26\u7d66\u4e88\u53e3\u670d\u8cea\u5b50\u5e6b\u6d66\u6291\u5236\u5291\nD. \u6c38\u4e45\u505c\u7528aspirin\u53ca\u985e\u4f3c\u7684\u6297\u8840\u5c0f\u677f\u85e5\u7269\nE. \u6839\u9664\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\n": "(B)", "102-18.\n45\u6b72\u9157\u9152\u7537\u6027\u56e0\u6162\u6027\u8179\u75db\u53ca\u89e3\u8102\u80aa\u4fbf(steatorrhea)\u63a5\u53d7\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5(\u5982\u5716\u793a)\uff0c\u4e0b\u5217\u4f55\u7a2e\u4f75\u767c\u75c7\u767c\u751f\u7387\u6700\u4f4e\uff1f\nA. \u8461\u8404\u7cd6\u8010\u53d7\u4e0d\u826f(impaired glucose tolerance)\nB. \u7cd6\u5c3f\u75c5\u916e\u9178\u8840\u75c7(diabetic ketoacidosis)\nC. \u80c3\u8178\u51fa\u8840\nD. \u507d\u56ca\u816b(pseudocyst)\nE. \u9ec3\u75b8\n": "(B)", "102-19.\n\u60a3\u8005\u56e0\u5c62\u6b21\u53f3\u4e0a\u8179\u75db\u5408\u4f75\u767c\u71d2\uff0c\u7d93\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u8a3c\u5be6\u6709\u81bd\u7d50\u77f3\uff0c\u8179\u8154\u93e1\u81bd\u56ca\u5207\u9664\u8853(laparoscopic cholecystectomy)\u5f8c\u767c\u73fe\u70ba\u8272\u7d20\u7d50\u77f3(pigment stone)\uff0c\u4e0b\u5217\u4f55\u8005\u8207\u6b64\u7d50\u77f3\u7684\u5f62\u6210\u7121\u95dc\uff1f(1)\u80a5\u80d6(2)\u5973\u6027\u8cc0\u723e\u8499(3)\u85e5\u7269\u4f7f\u7528\uff0c\u5982clofibrate(4)\u809d\u786c\u5316(5)\u60e1\u6027\u8ca7\u8840(pernicious anemia)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(5)\nE. (1)+(2)+(4)\n": "(A)", "102-20.\n\u6709\u95dc\u8178\u963b\u585e(intestinal obstruction)\u7684\u8eab\u9ad4\u8a3a\u5bdf\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u5c0f\u8178\u963b\u585e\u8f03\u5927\u8178\u963b\u585e\u8179\u8139\u60c5\u5f62\u56b4\u91cd\nB. \u963b\u585e\u65e9\u671f\u5e38\u898b38\u5ea6\u4ee5\u4e0a\u7684\u9ad8\u71d2\nC. Strangulating obstruction\u807d\u8a3a\u5e38\u51fa\u73feloud, high-pitched borborygmi\nD. Quiet abdomen\u5373\u53ef\u6392\u9664\u963b\u585e\u4e4b\u53ef\u80fd\u6027\nE. \u767c\u751fclosed-loop strangulating small-bowel obstruction\u6709\u6642\u53ef\u6478\u5230\u8179\u90e8\u816b\u584a\n": "(E)", "102-21.\n30\u6b72\u5973\u6027\u81ea\u5370\u5ea6\u65c5\u904a\u56de\u570b4\u9031\u5f8c\u51fa\u73fe\u8179\u75db\u3001\u8179\u7009\u3001\u9ad4\u91cd\u6e1b\u8f15\uff0c\u5927\u8178\u93e1\u6aa2\u67e5\u767c\u73fe\u6f70\u760d\uff0c\u5f9e\u6f70\u760d\u8655\u7684\u75c5\u7406\u5207\u7247\u7d50\u679c\u5982\u5716\u793a\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u9996\u9078\u6cbb\u7642\uff1f\nA. Ciprofloxacin\nB. Amoxicillin\nC. Metronidazole\nD. Ceftriaxone\nE. Erythromycin\n": "(C)", "102-22.\n22\u6b72\u7537\u6027\u56e0\u8840\u4fbf\u63a5\u53d7\u5927\u8178\u93e1\u6aa2\u67e5\uff0c\u767c\u73fe\u76f4\u8178\u53ca\u4e59\u72c0\u7d50\u8178\u6709\u5982\u5716\u4e4b\u75c5\u7076\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u53ef\u51fa\u73fetoxic megacolon\u4e4b\u4f75\u767c\u75c7\nB. perinuclear anti-neutrophil cytoplasimc antibodies (pANCAs)\u53ef\u4ee5\u5448\u73fe\u967d\u6027\u7d50\u679c\nC. \u76f2\u8178\u5207\u9664\u589e\u52a0\u6b64\u75c5\u7684\u767c\u751f\u7387\nD. \u76ae\u819a\u53ef\u51fa\u73feerythema nodosum\nE. \u76ae\u819a\u53ef\u51fa\u73fepyoderma gangrenosum\n": "(C)", "103-1.\n\u541e\u56a5\u56f0\u96e3(dysphagia)\u53ef\u4f9d\u98df\u7269\u5728\u4e0d\u540c\u90e8\u4f4d\u53d7\u963b\u60c5\u5f62\u5206\u6210\u53e3\u54bd\u578b(oropharyngeal)\u548c\u98df\u9053\u578b(esophageal)\u5169\u5927\u985e\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u9020\u6210\u53e3\u54bd\u578b\u541e\u56a5\u56f0\u96e3\u7684\u539f\u56e0\uff1f\nA. \u5df4\u91d1\u68ee\u75c5(Parkinson's disease)\nB. \u6241\u6843\u817a\u5468\u570d\u81bf\u760d(peritonsillar abscess)\nC. Schatzki's ring\nD. Plummer-Vinson syndrome\nE. Zenker's diverticulum\n": "(C)", "103-2.\n\u6709\u95dc\u5df4\u745e\u7279\u6c0f\u98df\u9053(Barrett's esophagus)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u662f\u98df\u9053\u817a\u764c(esophageal adenocarcinoma)\u7684\u5371\u96aa\u56e0\u5b50\nB. \u6bcf\u5e74\u67095%\u9032\u5c55\u6210\u764c\u75c7\nC. \u4f9d\u9577\u5ea6\u5206\u6210long-segment\u548cshort-segment\uff0c\u81e8\u5e8a\u4e0a\u5f8c\u8005\u8f03\u5e38\u898b\nD. \u53ef\u5c0e\u81f4\u98df\u9053\u6f70\u760d\u53ca\u72f9\u7a84\nE. \u75c5\u7406\u5207\u7247\u6709\u9ad8\u5ea6\u5316\u751f\u4e0d\u826f\u8005(high grade dysplasia)\u670920%\u9032\u5c55\u6210\u764c\u75c7\u6a5f\u6703\n": "(B)", "103-3.\n\u4e00\u4f4d\u4e0a\u8179\u60b6\u75db\u60a3\u8005\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\uff0c\u4e26\u65bc\u80c3\u7ac7\u90e8(antrum)\u5207\u7247\uff0c\u5176\u75c5\u7406\u5982\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u771f\uff1f (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)\u56e0\u70ba\u767c\u708e\u5728\u80c3\u7ac7\u90e8\uff0c\u6240\u4ee5\u53c8\u7a31A\u578b(type A)\u80c3\u708e(2)\u5bb9\u6613\u56e0\u6b64\u800c\u9020\u6210\u9006\u6d41\u6027\u98df\u9053\u708e(3)\u5f97\u5230\u5341\u4e8c\u6307\u8178\u6f70\u760d\u6a5f\u6703\u589e\u52a0(4)\u8207\u80c3\u6dcb\u5df4\u7624\u767c\u751f\u6709\u95dc(5)\u6703\u96a8\u6642\u9593\u589e\u9577\u800c\u9020\u6210\u80c3\u9ecf\u819c\u840e\u7e2e\uff0c\u4e14\u9020\u6210\u8a72\u80c3\u708e\u4e4b\u7d30\u83cc\u91cf\u6703\u56e0\u9ecf\u819c\u840e\u7e2e\u800c\u589e\u52a0\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(C)", "103-4.\n\u627f\u4e0a\u984c\uff0c\u4e0a\u8ff0\u60a3\u8005\u63a5\u53d7\u4e00\u500b\u7642\u7a0b\u7684\u6297\u751f\u7d20\u6cbb\u7642\uff0c\u6cbb\u7642\u5f8c\u505c\u85e54\u9031\uff0c\u6700\u5408\u9069\u7528\u65bc\u78ba\u8a8d\u6cbb\u7642\u6210\u6548\u7684\u6aa2\u67e5\u70ba\u4f55\uff1f\nA. serologic test\nB. urea breath test\nC. endoscopy\nD. histologic examination\nE. endoscopy plus histology\n": "(B)", "103-5.\n\u6709\u95dc\u81bd\u9178(bile acid)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)\u4e3b\u8981\u7531\u98f2\u98df\u800c\u4f86(2)\u809d\u81df\u5408\u6210\u81bd\u9178\u8207\u81bd\u56fa\u9187\u4ee3\u8b1d\u6709\u95dc(3)\u81bd\u9178\u53ef\u65bc\u7a7a\u8178(jejum)\u518d\u5438\u6536\uff0c\u7a31\u70baenterohepatic circulation(4)\u809d\u81df\u5408\u6210\u7684\u81bd\u9178\u6709primary\u53casecondary\u5169\u7a2e\uff0c\u524d\u8005\u4ee5lithocholic acid\u53cachenodeoxycholic acid\u70ba\u4e3b(5)\u81bd\u9178\u7684enterohepatic circulation\u7570\u5e38\u53ef\u5c0e\u81f4\u8179\u7009\uff0c\u751a\u81f3steatorrhea\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(D)", "103-6.\n\u4e00\u4f4d\u6162\u6027\u8179\u7009\u60a3\u8005\uff0c\u5448\u73fe\u6c34\u816b\uff0c\u4f4e\u86cb\u767d\u8840\u75c7(albumin: 2.1g/dL\u3001globulin: 1.8g/dL)\uff0c\u8840\u6db2\u7684AST/ALT/PT/PTT/BUN/Cr\u53ca\u5c3f\u6db2\u6aa2\u67e5\u7686\u6b63\u5e38\u3002\u63a5\u53d7\u5c0f\u8178\u5167\u8996\u93e1\u5408\u4f75\u5207\u7247\u6aa2\u67e5\uff0c\u5207\u7247\u7d44\u7e54\u67d3\u8272\u7d50\u679c\u5982\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4f4e\u86cb\u767d\u8840\u75c7\u8207\u8178\u9053\u904e\u5ea6\u6d41\u5931\u86cb\u767d\u6709\u95dc\nB. \u9664\u4e86\u4f4e\u86cb\u767d\u5916\uff0c\u6b64\u500b\u6848\u4e4b\u5468\u908a\u8840\u6db2\u6dcb\u5df4\u7403\u6578\u76ee\u4e5f\u53ef\u80fd\u6e1b\u5c11\nC. \u53ef\u7528\u03b11-antitrypsin clearance\u5354\u52a9\u78ba\u8a8d\u86cb\u767d\u6d41\u5931\nD. \u8102\u80aa\u6027\u8179\u7009\u5728\u6b64\u7a2e\u75c5\u4eba\u4e5f\u5e38\u767c\u751f\nE. \u6cbb\u7642\u4e0a\u9664\u4e86low fat diet\u5916\uff0c\u61c9\u88dc\u5145long-chain fatty acids\n": "(E)", "103-7.\n23\u6b72\u7537\u6027\u56e0\u5c62\u6b21\u4e0d\u660e\u539f\u56e0\u8179\u75db\u81f3\u6025\u8a3a\uff0c\u5176\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u7d50\u679c\u5982\u5716\uff0c\u5168\u5927\u8178\u93e1\u6aa2\u67e5\u767c\u73fe\u53f3\u5074\u7d50\u8178\u53ca\u672b\u7aef\u8ff4\u8178\u6709\u6f70\u760d\uff0c\u5207\u7247\u75c5\u7406\u70bagranulomatous inflammation\uff0c\u7cde\u4fbf\u6aa2\u67e5\u53ca\u5404\u9805\u57f9\u990a\u4e26\u7121\u7d30\u83cc\u548c\u7d50\u6838\u83cc\u611f\u67d3\u3002\u6709\u95dc\u6b64\u60a3\u8005\u4e4b\u6cbb\u7642\u4f55\u8005\u932f\u8aa4\uff1f\nA. 5-ASA\u4e2d\u7684sulfasalazine\u53ef\u65bc\u80c3\u3001\u8ff4\u8178\u3001\u7d50\u8178\u91cb\u653e\u53ca\u4f5c\u7528\uff0c\u6700\u9069\u5408\u4f5c\u7b2c\u4e00\u7dda\u6cbb\u7642\nB. \u985e\u56fa\u9187\u53ef\u4f7f60~70%\u60a3\u8005\u5f97\u5230\u7de9\u89e3\nC. \u8655\u65b9metronidazole\u6216ciprofloxacin\u5c0d\u6b64\u4f4d\u60a3\u8005\u80fd\u767c\u63ee\u6709\u76ca\u6548\u679c\nD. azathioprine\u53ef\u7528\u65bc\u7dad\u6301\u7de9\u89e3\u6642\u7684\u6cbb\u7642\nE. \u5c0d\u514d\u75ab\u6291\u5236\u85e5\u7269\u7121\u6548\u8005\u53ef\u8003\u616e\u7528anti-TNF antibody\u6cbb\u7642\n": "(A)", "103-8.\n\u6709\u95dc\u5927\u8178\u76f4\u8178\u764c(colorectal cancer)\u7be9\u6aa2(screening)\u7b56\u7565\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1)\u4e0d\u8ad6\u7537\u5973\uff0c50\u6b72\u4ee5\u4e0a\u5373\u5fc5\u9700\u7be9\u6aa2(2)\u67091\u500b\u5c0f\u65bc1\u516c\u5206\u7684\u7ba1\u72c0\u817a\u7624(tubular adenoma)\u8005\uff0c\u61c9\u57281\u5e74\u5f8c\u91cd\u505a\u5927\u8178\u93e1(3)1\u7d1a\u8840\u89aa\u6709\u5927\u8178\u764c\u75c5\u53f2\u8005\uff0c\u7be9\u6aa2\u5e74\u9f61\u70ba50\u6b72(4)\u76ee\u524d\u53f0\u7063\u662f\u4f7f\u7528\u7cde\u4fbf\u6f5b\u8840\u514d\u75ab\u53cd\u61c9\u6cd5\u505a\u7be9\u6aa2(5)\u6709\u907a\u50b3\u6027\u5927\u8178\u764c\u75c7\u5019\u7fa4(hereditary nonpolyposis colorectal cancer)\u5bb6\u65cf\u53f2\u8005\u53ef\u65bc30\u6b72\u5373\u958b\u59cb\u7be9\u6aa2\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(2)+(4)\nE. (1)+(4)+(5)\n": "(E)", "103-9.\n40\u6b72\u5973\u6027\u5065\u5eb7\u4e00\u5411\u826f\u597d\uff0c\u53c3\u52a0\u516c\u53f8\u5065\u5eb7\u6aa2\u67e5\uff0c\u8d85\u97f3\u6ce2\u767c\u73fe\u81bd\u56ca\u6709\u5982\u5716\u4e4b\u7570\u5e38\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u56e0\u70ba\u7121\u75c7\u72c0\uff0c\u53ef\u63a1\u8ffd\u8e64\u7b56\u7565\nB. \u5feb\u901f\u6e1b\u91cd\u662f\u9020\u6210\u6b64\u7570\u5e38\u53ef\u80fd\u539f\u56e0\u4e4b\u4e00\nC. \u81bd\u56ca\u8815\u52d5\u5feb\u901f(gallbladder hypermotility)\u4e5f\u6703\u9020\u6210\u6b64\u7570\u5e38\nD. \u6b64\u7570\u5e38\u8207\u907a\u50b3\u56e0\u5b50\u4e5f\u6709\u95dc\nE. \u6162\u6027\u81bd\u9053\u611f\u67d3\u4e5f\u662f\u53ef\u80fd\u75c5\u56e0\n": "(C)", "103-10.\n\u627f\u4e0a\u984c\uff0c\u4e0a\u8ff0\u60a3\u8005\u56e0\u6025\u6027\u8179\u75db\u3001\u767c\u71d2\u81f3\u6025\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u9ec3\u75b8\uff0c\u8179\u90e8\u8d85\u97f3\u6ce2\u5448\u73fe\u81bd\u7ba1\u64f4\u5f35\uff0c\u8840\u6db2\u57f9\u990a\u6709\u845b\u862d\u6c0f\u9670\u6027\u83cc\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u55ae\u7528\u6297\u751f\u7d20\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\nB. ERCP with endoscopic sphincteromy\u517c\u5177\u8a3a\u65b7\u53ca\u6cbb\u7642\u6548\u679c\nC. laparoscopic cholecystectomy\u70ba\u6700\u4f73\u6cbb\u7642\u65b9\u5f0f\nD. \u6709\u53ef\u80fd\u4f75\u767c\u6025\u6027\u80f0\u81df\u708e\nE. \u7121\u60e1\u6027\u816b\u7624\u72c0\u6cc1\u4e0b\uff0c\u81bd\u7d05\u7d20(bilirubin)\u5f88\u5c11\u8d85\u904e20mg/dL\n": "(C)", "103-11.\n\u60a3\u8005\u56e0\u4e0a\u8179\u75db\u3001\u9ad4\u91cd\u6e1b\u8f15\u3001\u9ec3\u75b8\u63a5\u53d7\u5982\u5716(A\u3001B)\u4e4b\u6aa2\u67e5\u3002\u4e0b\u5217\u4f55\u8005\u8207\u6b64\u75be\u75c5\u7684\u767c\u751f\u8f03\u7121\u95dc\u806f\uff1f\nA. \u80a5\u80d6\nB. \u62bd\u7159\nC. \u7cd6\u5c3f\u75c5\nD. \u5496\u5561\nE. \u6162\u6027\u80f0\u81df\u708e\n": "(D)", "103-12.\n\u4e00\u4f4d60\u6b72\u5973\u6027\u75c5\u60a3\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u4e3b\u8a34\u70ba\u7a81\u7136\u611f\u5230\u56b4\u91cd\u8179\u75db\uff0c\u75bc\u75db\u6307\u6578\u9054\u5230\u4e5d\u5206\uff08\u6eff\u5206\u5341\u5206\uff09\u3002\u75c5\u4eba\u6c92\u767c\u71d2\u3002\u91ab\u5e2b\u5728\u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u767c\u73fe\u5176\u8179\u90e8\u6478\u8d77\u4f86\u4e26\u4e0d\u786c\uff0c\u50c5\u6709\u8f15\u5ea6\u58d3\u75db\uff0c\u4f46\u4e26\u7121\u56fa\u5b9a\u90e8\u4f4d\uff0c\u5176\u8840\u58d3\u6b63\u5e38\u3002\u4ed6\u81ea\u8ff0\u904e\u53bb\u6709\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u73fe\u8c61\u3002\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u8207\u6b64\u75c5\u4eba\u5bc6\u5207\u76f8\u95dc\uff0c\u9664\u4e86\uff1a\nA. \u61c9\u6e2c\u767d\u8840\u7403\u6578\u76ee\u3001\u8840\u6db2\u9178\u9e7c\u5ea6\u3001\u53ca\u8840\u6e05 lactate \u6578\u503c\nB. \u61c9\u8d95\u5feb\u5b89\u6392\u50b3\u7d71\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u56e0\u5176\u8f03\u65b9\u4fbf\u4e14\u8a3a\u65b7\u6548\u76ca\u8f03\u9ad8\nC. CT angiography \u5c0d\u8a3a\u65b7\u6709\u6975\u5927\u52a9\u76ca\nD. \u50b3\u7d71 angiography \u662f\u9ec3\u91d1\u8a3a\u65b7\u4e4b\u4f9d\u64da\nE. \u7acb\u5373\u5b89\u6392 ECG\uff0c\u5fc5\u8981\u6642\u4e5f\u8981\u5b89\u6392 24 hr Holter monitor recording\n": "(B)", "103-13.\n\u4e00\u4f4d50\u6b72\u7537\u6027\u56e0\u76ae\u819a\u6cdb\u9ec3\u4f4f\u9662\u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aBilirubin (T) : 8.5 mg/dL (\u22661.0), Bilirubin (D) : 7.0 mg/dL (\u2266 0.2), ALT : 70 (\u2266 41), AST : 80 (\u2266 31), ALP : 380 (\u2266104), GGT : 500 (\u2266 52)\u3002\u4ed6\u6700\u8fd1\u6c92\u6709\u8179\u75db\u72c0\u6cc1\uff0c\u98df\u617e\u5c1a\u4f73\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u5169\u5074\u809d\u5167\u81bd\u7ba1\uff0c\u8fd1\u809d\u9580\u5340\u4e4b\u7e3d\u81bd\u7ba1\u53ca\u4e3b\u80f0\u7ba1\u7686\u8139\u5927\u3002\u6253\u986f\u5f71\u5291\u4e4b\u96fb\u8166\u65b7\u5c64\u651d\u5f71 (contrat-enhanced spiral CT) \u4ea6\u6709\u540c\u6a23\u767c\u73fe\uff0c\u4f46\u672a\u770b\u5230\u4efb\u4f55\u816b\u7624\u3002\u4e0b\u5217\u5404\u9805\u9032\u4e00\u6b65\u4e4b\u6aa2\u67e5\uff0c\u4f55\u8005\u6700\u6709\u6548\u76ca\uff1f\nA. \u8840\u6e05CA 199\u6aa2\u6e2c\nB. \u78c1\u632f\u9020\u5f71 (MRI)\nC. \u5167\u8996\u93e1\u8d85\u97f3\u6ce2 (EUS)\nD. \u6b63\u5b50\u6383\u7784\u96fb\u8166\u65b7\u5c64 (PET-CT)\nE. 99mTc HIDA scan\n": "(C)", "103-14.\n\u4f60\u7684\u75c5\u4eba\u61f7\u5b55\u5df226\u5468\uff0c\u56e0\u8fd1\u671f\u76ae\u819a\u767c\u7662\uff0c\u751a\u81f3\u7662\u5230\u5f71\u97ff\u7761\u7720\u800c\u4f86\u6c42\u91ab\u3002\u5979\u7947\u6709\u670d\u7528vitamin \u53cafolic acid\uff0c\u672a\u670d\u7528\u4efb\u4f55\u85e5\u7269\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u76ae\u819a\u6709\u6293\u75d5\uff0c\u6c92\u6709petechiae\u6216ecchymoses\u3002\u75c5\u4eba\u610f\u8b58\u6e05\u695a\uff0c\u751f\u547d\u5fb5\u8c61\u6b63\u5e38\uff0c\u6c92\u6709\u767c\u71d2\u3002\u6709mildly icteric sclera\u3002\u8179\u90e8\u6572\u8a3a\u7121shifting dullness\u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aHb=12.0 (\u226710.8); WBC=4800 (\u22674000), platelet=280K (\u2267130K), PT (INR)=1.1 (0.8-1.1), Bilirubin (T)=3.8 mg/dL (\u22661.0), Bilirubin (D)=3.2 mg/dL (\u22660.3), ALT=38 (\u2266 41), AST=29 (\u226631), ALP (Alkaline phosphatase)=330 (\u2266104), GGT=400 (\u226652),\rAlbumin=3.5 g/dL (\u22673.5)\u3002\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5b50\u5bae\u53ca\u80ce\u5152\u6b63\u5e38\u3002\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4e0b\u5217\u90a3\u4e00\u9805\uff1f\nA. HELLP (Hemolysis, Elevated Liver enzymes, and Low Platelets) syndrome\nB. Acute fatty liver of pregnancy\nC. Intrahepatic cholestasis of pregnancy\nD. Hyperemesis gravidarum\nE. Drug-induced liver injury\n": "(C)", "103-15.\n\u4e0b\u5217\u5404\u9805\u4f55\u8005\u53ef\u80fd\u662f\u809d\u786c\u5316\u7684\u4f75\u767c\u75c7\uff1f\uff08\u8acb\u9078\u51fa\u5168\u90e8\u53ef\u80fd\u7b54\u6848\uff09(1) Esophageal varices (2) Spontaneous bacterial peritonitis (3) Hepatic encephalopathy (4) Hepatic failure (5) Hepatorenal syndrome (6) Hepatopulmonary syndrome (7) Portopulmonary hypertension (8) Hepatoovary syndrome\nA. (1)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(4)+(5)\nC. (1)+(2)+(3)+(4)+(5)+(6)\nD. (1)+(2)+(3)+(4)+(5)+(6)+(7)\nE. \u6bcf\u9805\u7686\u53ef\u80fd\u3002\n": "(D)", "103-16.\n\u4e00\u4f4d55 \u6b72\u5973\u6027\u75c5\u4eba\u4f4f\u9662\u4e4b\u4e3b\u8a34\u70ba\u8179\u75db\u5169\u5929\uff0c\u5c0f\u4fbf\u8b8a\u5c11\u3002\u904e\u53bb\u75c5\u53f2\u4e0d\u6e05\u695a\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73femildly icteric sclera\u53cashifting dullness with tenderness of abdomen\u3002\u624b\u81c2\u67092\u8655ecchymoses\u3002\u9ad4\u6eab38\u2103 \uff08\u8033\u6eab\uff09\uff0cB.P.=100/60 mmHg, P.R.=90/min, regular. \u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aAlbumin=2.5 g/dL (\u2267 3.5), Bilirubin (T)=3.8 mg/dL (\u22661), ALT=70 (\u2266 41), AST=80 (\u226631), ALP=380 (\u2266104), GGT=600 (\u226652), Cr=3.0 mg/dL (\u22661.3), PT=17\" (\u226611\")\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u809d\u786c\u5316\u3001\u813e\u816b\u5927\u53ca\u8179\u6c34\u3002\u6709\u95dc\u672c\u75c5\u4eba\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(1)\u61c9\u5118\u5feb\u62bd\u8179\u6c34\u9001\u9a57\u767d\u8840\u7403\u7e3d\u6578\u53ca\u5206\u985e\r(2)\u61c9\u5118\u5feb\u6e2c\u91cfFeNa (fractional excretion of sodium) (3)\u670d\u7528UDCA (ursodeoxycholic acid)\u5c0d\u5176\u75c5\u60c5\u6709\u5e6b\u52a9 (4)\u61c9\u5118\u5feb\u4ee5\u4f4e\u5291\u91cfDopamin\u6cbb\u7642\u4e4b (5)\u6ce8\u5c04Albumin\u5c0d\u5176\u75c5\u60c5\u6709\u5e6b\u52a9 (6)Spironolactone (aldosterone inhibitor)\u53cafurosemide (loop diruetics)\u4e4b\u4f7f\u7528\u4e0d\u5fc5\u8003\u616e\uff08\u8acb\u9078\u51fa\u5168\u90e8\u6b63\u78ba\u7b54\u6848\uff09\nA. (1)+(2)+(3)+(4)+(5)+(6)\nB. (1)+(2)+(4)+(5)\nC. (1)+(3)+(5)+(6)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(5)\n": "(E)", "103-17.\n54\u6b72\u5973\u6027\u81f3\u9580\u8a3a\u505a\u5065\u5eb7\u8aee\u8a62\u3002\u5979\u6bcd\u89aa\u572872\u6b72\u7f79\u60a3\u5927\u8178\u764c\u3002\u5979\u76ee\u524d\u5df2\u505c\u7d93\uff0c\u7121\u4efb\u4f55\u4e0d\u9069\u3002\u8eab\u9ad4\u8a3a\u5bdf\u7121\u7570\u5e38\uff0c\u4e00\u822c\u6aa2\u9a57\uff08\u5305\u542bCEA\u6578\u503c\uff09\u4e4b\u7d50\u679c\u7686\u6b63\u5e38\uff0c\u5927\u8178\u93e1\u6aa2\u67e5\u7121polyp\u53cacancer\u3002\u5979\u5e0c\u671b\u80fd\u670d\u7528\u4e00\u4e9b\u85e5\u7269\u4f86\u9810\u9632\u5927\u8178\u764c\u4e4b\u767c\u751f\u3002\u8acb\u554f\u4e0b\u5217\u5404\u7a2e\u85e5\u7269\uff0c\u4f55\u8005\u5df2\u88ab\u8b49\u5be6\u6709\u6548\u4e14\u88ab\u61c9\u7528\u65bc\u6c11\u773e\uff1f\nA. Aspirin\nB. Celecoxib\nC. Estrogen-replacement therapy\nD. Vitmin D\nE. \u4ee5\u4e0a\u7686\u975e\n": "(E)", "103-18.\n\u5abd\u5abd\u5e36\u845719\u6b72\u5973\u5152\u81f3\u9580\u8a3a\u5c31\u91ab\uff0c\u5979\u81ea\u5df1\u53ca\u5169\u4f4d\u5e74\u7d00\u8f03\u5927\u7684\u5b69\u5b50\u7686\u70baB\u578b\u809d\u708e\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\u3002\u9019\u500b\u5973\u5152\u51fa\u751f\u6642\u63a5\u53d7\u904eB\u578b\u809d\u708e\u75ab\u82d7\u6ce8\u5c04\uff0c\u76ee\u524d\u6aa2\u9a57\u7d50\u679c\u70ba\uff1aHBsAg (+), Anti-HBs (-), Anti-HBc (+), HBeAg (+), Anti-HBe (-), ALT: 22 (\u226641), AST: 25 (\u226631), Bilirubin (T) = 2.5 mg/dL (\u22661.0), Bilirubin (D)=0.3 mg/dL (\u22660.2), Albumin=4.5 g/dL (\u22663.5), PT (INR)=1.05 (0.8-1.2)\u3002\u4e0b\u5217\u4f55\u8005\u662f\u76ee\u524d\u6700\u5408\u9069\u4e4b\u8655\u7f6e\uff1f\nA. \u518d\u8ffd\u52a0B\u809d\u75ab\u82d7\u6ce8\u5c04\nB. \u99ac\u4e0a\u505a\u809d\u5207\u7247 (liver biopsy)\u77ad\u89e3\u75c5\u60c5\nC. \u5118\u901f\u4ee5\u53e3\u670dB\u578b\u809d\u708e\u75c5\u6bd2\u6291\u5236\u85e5\u7269\uff0c\u5982\uff1aentecavir \u6216tenofovir\uff0c\u6cbb\u7642\nD. \u5118\u901f\u5efa\u8b70\u63a5\u53d7 alpha interferon\u6cbb\u7642\nE. \u5b9a\u671f\uff08\u4e8c\u223c\u4e09\u500b\u6708\u4e00\u6b21\uff09\u8ffd\u8e64\u8840\u6e05ALT\u53caAST\u5373\u53ef\n": "(E)", "103-19.\n\u4e00\u4f4d\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\u62bd\u8840\u6aa2\u9a57\u4e4b\u7d50\u679c\u70ba\uff1aALT=53 (\u226641), AST=48 (\u226631), HCV RNA=380,000 IU/mL\u3002Hb=15 (\u226713), WBC=5,000 (\u22674,000), Platelet=110,000 (\u2267130,000)\u3002\u75c5\u4eba\u904e\u53bb\u6c92\u6709\u7532\u72c0\u817a\u75be\u75c5\uff0c\u4e5f\u6c92\u6709depression\u3002\u809d\u5207\u7247\u767c\u73fe\u6162\u6027\u767c\u708e\u4f75\u6709fibrosis\uff0c\u7121\u660e\u986fcirrhosis\u3002\u4e0b\u5217\u4f55\u8005\u662f\u76ee\u524d\u6700\u5408\u5b9c\u4e4b\u8655\u7f6e\uff1f\nA. \u672a\u4f86\u6bcf\u5e74\u63a5\u53d7\u4e00\u6b21\u809d\u5207\u7247\u6aa2\u67e5\uff0c\u8ffd\u8e64\u5176fibrosis\u9032\u884c\u72c0\u6cc1\uff0c\u6c7a\u5b9a\u6cbb\u7642\u6642\u6a5f\u3002\nB. \u672a\u4f86\u6bcf6\u500b\u6708\u6aa2\u67e5\u4e00\u6b21\u8840\u4e2dHCV RNA viral load\uff0c\u6c7a\u5b9a\u6cbb\u7642\u6642\u6a5f\u3002\nC. \u672a\u4f86\u6bcf2\u500b\u6708\u6aa2\u67e5\u4e00\u6b21\u8840\u4e2dALT\u53caAST\uff0c\u6c7a\u5b9a\u6cbb\u7642\u6642\u6a5f\u3002\nD. \u672a\u4f86\u6bcf3\u500b\u6708\u6aa2\u67e5\u4e00\u6b21complete blood count\uff0c\u6c7a\u5b9a\u6cbb\u7642\u6642\u6a5f\u3002\nE. \u7a4d\u6975\u5efa\u8b70\u75c5\u4eba\u958b\u59cb\u63a5\u53d7interfron-based therapy\u3002\n": "(E)", "103-20.\n\u4e0b\u5217\u6709\u95dc\u5614\u5410\u4e4b\u75c5\u56e0\u63a8\u6e2c\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5614\u5410\u7269\u4e3b\u8981\u70ba\u672a\u6d88\u5316\u4e4b\u98df\u7269\uff0c\u53ef\u80fd\u6709achalasia\nB. \u5614\u5410\u7269\u542b\u6709\u81bd\u6c41\uff0c\u4e0d\u53ef\u80fd\u70bagastric obstruction\nC. \u5614\u5410\u7269\u5e36\u6709\u7cde\u5473\uff0c\u53ef\u80fd\u6709distal intestinal or colonic obstruction\nD. \u5614\u5410\u901a\u5e38\u767c\u751f\u65bc\u98ef\u5f8c1\u5c0f\u6642\u5167\uff0c\u53ef\u80fd\u70bapyloric stenosis\nE. \u5614\u5410\u5f8c\u8179\u75db\u6d88\u5931\uff0c\u8868\u793a\u53ef\u80fd\u70baacute pancreatitis\n": "(E)", "103-21.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u6025\u6027\u5fc3\u7aa9\u75db\u800c\u88ab\u9001\u81f3\u6025\u8a3a\u5ba4\u3002\u5fc3\u7aa9\u75db\u6703\u5ef6\u4f38\u81f3\u80cc\u90e8\u3002\u75c5\u4eba\u56e0\u96e3\u53d7\u800c\u986f\u5f97\u7126\u8e81\u4e0d\u5b89\uff0c\u547c\u5438\u6025\u4fc3\u3002\u8eab\u9ad4\u8a3a\u5bdf\u986f\u793a\uff1a\u9ad4\u6eab 39.1\u2103\uff0c\u8840\u58d3 150/90 mmHg\uff0c\u8108\u6476 104/\u5206\uff0c\u898f\u5f8b\uff0c\u547c\u5438\u901f\u7387 24/\u5206\u3002\u5de6\u4e0b\u80ba\u547c\u5438\u97f3\u8f03\u5f31\u3002\u5fc3\u7aa9\u8655\u6709\u8f15\u5fae\u58d3\u75db\u3002\u4ed6\u6700\u8fd1\u6c92\u6709\u4f7f\u7528\u65b0\u85e5\u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aHb=15.0 (\u226713), WBC=16,300 (> 4,000, < 10,000), Amylase=20,000, Lipase=8,000, BUN=68 (\u226624), Cr=2.4 (\u22661.0)\u3002\u6253\u986f\u5f71\u5291\u4e4bCT (contrast-enhanced CT)\u986f\u793a\u80f0\u81df\u5468\u906d\u6709\u6c34\u816b\uff0c\u7121\u7d44\u7e54\u58de\u6b7b\u3001\u4ea6\u7121\u8179\u6c34\u3002\u4e0b\u5217\u5404\u9805\uff0c\u4f55\u8005\u6700\u80fd\u53cd\u6620\u51fa\u672c\u75c5\u4eba\u75c5\u60c5\u4e4b\u56b4\u91cd\u5ea6\uff1f\nA. \u9ad4\u6eab (39.1\u2103)\nB. Amylase \u53ca Lipase serum level\nC. \u80f0\u81df\u5468\u906d\u6c34\u816b\nD. BUN\u6578\u503c\nE. \u5fc3\u7aa9\u75db\u4e14\u5ef6\u4f38\u81f3\u80cc\u9762\n": "(D)", "103-22.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u95dc\u7bc0\u708e\u800c\u9700\u4f7f\u7528NSAIDs\u85e5\u7269\u6cbb\u7642\uff0c\u75c5\u4eba\u5f88\u6015\u6703\u6709\u80c3\u8178\u526f\u4f5c\u7528\u3002\u4e0b\u5217\u5404\u9805\u6709\u95dc\u9810\u9632NSAID-induced gastrointestinal (GI) injury\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Standard-dose proton pump inhibitors (PPI) \u70ba\u9996\u9078\u85e5\u7269\nB. Misoprostol (synthetic prostaglandin E1 analogue) \u4ea6\u53ef\u8003\u616e\u4f7f\u7528\uff0c\u4f46\u5291\u91cf\u4e0d\u5b9c\u904e\u9ad8\u4ee5\u6e1b\u5c11\u8179\u7009\u4e4b\u526f\u4f5c\u7528\nC. High-dose H2 blockers \u6548\u679c\u8207PPI \u6216 Misoprostol \u76f8\u4f3c\uff0c\u6545\u53ef\u505a\u70ba\u66ff\u4ee3\u85e5\u7269\nD. \u82e5\u75c5\u4eba\u5c6clow GI risk \u4e14 low cardiovascular (CV) risk \u8005\uff0c\u4f7f\u7528\u4f4e\u5291\u91cf\u55ae\u4e00\u7a2e NSAID \u6642\u4e0d\u9700\u9810\u9632\u5176\u53ef\u80fd\u7522\u751f\u4e4b GI \u53ca CV toxicity\nE. Enteric-coated NSAIDs \u53ca Aspirin\u7121\u6cd5\u6709\u6548\u9810\u9632\u5176 GI injury\n": "(C)", "104-1.\n\u60a3\u8005\u4e3b\u8a34\u70ba\u541e\u56a5\u56f0\u96e3(dysphagia)\uff0c\u800c\u4e14\u4e00\u958b\u59cb\u767c\u751f\u5373\u5305\u62ec\u56fa\u9ad4(solid)\u548c\u6d41\u8cea(liquid)\u98df\u7269\u7686\u6709\u554f\u984c\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u53ef\u80fd\u662f\u6b64\u4f4d\u60a3\u8005\u541e\u56a5\u56f0\u96e3\u7684\u539f\u56e0\uff1f\nA. achalasia\nB. scleroderma\nC. gastroesophageal reflux disease with weak peristalsis\nD. Schatzki ring\nE. diffuse esophageal spasm\n": "(D)", "104-2.\n\u75c5\u60a3\u4e3b\u8a34\u8179\u70093\u500b\u6708\uff0c\u7cde\u4fbf\u6aa2\u67e5\u986f\u793a\u7121\u767d\u8840\u7403\u3001\u8102\u80aa\u5247\u70ba\u967d\u6027\u3002\u4e0b\u5217\u4f55\u8005\u6700\u6709\u53ef\u80fd\u662f\u9020\u6210\u6b64\u4f4d\u60a3\u8005\u8179\u7009\u7684\u75c5\u56e0\uff1f\nA. \u5927\u8178\u6fc0\u71e5\u75c7(irritable bowel syndrome)\nB. \u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032(hyperthyroidism)\nC. \u5927\u8178\u7d68\u6bdb\u6027\u817a\u7624(villous adenoma)\nD. \u611b\u8fea\u751f\u6c0f\u75c5(Addison's disease)\nE. \u7d30\u83cc\u904e\u5ea6\u589e\u751f(bacterial overgrowth)\n": "(E)", "104-3.\n\u60a3\u8005\u5728\u5634\u5507\u6709\u9ed1\u8272\u7684\u8272\u7d20\u6c88\u6fb1(\u5982\u5716)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8178\u80c3\u9053\u5bb9\u6613\u6709\u606f\u8089\u767c\u751f\nB. \u606f\u8089\u7684\u75c5\u7406\u578b\u614b\u70ba\u817a\u7624(adenoma)\nC. \u70ba\u81ea\u9ad4\u986f\u6027\u907a\u50b3(autosomal dominant)\nD. \u767c\u751f\u5375\u5de2\u816b\u7624\u6a5f\u6703\u589e\u52a0\nE. \u767c\u751f\u80f0\u81df\u816b\u7624\u6a5f\u6703\u589e\u52a0\n": "(B)", "104-4.\n\u8001\u5e74\u60a3\u8005\u4e3b\u8a34\u70ba\u670d\u7528\u85e5\u7269\u5f8c\uff0c\u6709\u6025\u6027\u767c\u4f5c\u7684\u80f8\u75db\u5408\u4f75\u541e\u56a5\u75bc\u75db(odynophagia)\uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u5728\u98df\u9053\u767c\u73fe\u5982\u5716\u7684\u8b8a\u5316(\u5982\u5716)\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8d77\u56e0\u65bc\u4e0d\u826f\u7684\u670d\u85e5\u7fd2\u6163\nB. \u6700\u5bb9\u6613\u767c\u751f\u65bc\u98df\u9053\u4e0b\u7aef\nC. \u670d\u7528nonsteroidal anti-inflammatory drugs\u662f\u53ef\u80fd\u7684\u75c5\u56e0\nD. \u670d\u7528bisphosphonates\u4e5f\u53ef\u4ee5\u9020\u6210\nE. \u53ef\u4ee5\u8655\u65b9antisecretory medications\n": "(B)", "104-5.\n\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(Helicobacter pylori)\u662f\u9020\u6210\u6162\u6027\u80c3\u708e\uff0c\u6d88\u5316\u6027\u6f70\u760d\u548c\u80c3\u764c\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u4e0b\u5217\u4f55\u9805\u85e5\u7269\u4e0d\u9069\u5408\u7528\u65bc\u9664\u83cc\u7684\u5408\u4f75\u6cbb\u7642\uff1f\nA. omeprazole\nB. bismuth subsalicylate\nC. erythromycin\nD. metronidazole\nE. amoxicillin\n": "(C)", "104-6.\n\u6709\u95dc\u81bd\u9178(bile acid)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1)\u98f2\u98df\u6210\u5206\u4e2d\u4e0d\u542b\u81bd\u9178(2)\u8178\u5b50\u5408\u6210\u7684\u81bd\u9178\u70ba\u521d\u7d1a\u81bd\u9178(primary bile acid) (3)\u7d93\u7531\u8178\u5b50\u5438\u6536\u7684\u81bd\u9178\u6703\u56de\u5230\u809d\u81df\uff0c\u6b64\u904e\u7a0b\u6709\u554f\u984c\u6703\u5c0e\u81f4steatorrhea (4)cholestyramine\u53ef\u7528\u65bcbile acid diarrhea (5)deoxycholic acid\u548clithocholic acid\u70ba\u521d\u7d1a\u81bd\u9178\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(D)", "104-7.\n\u767c\u708e\u6027\u5927\u8178\u75be\u75c5(inflammatory bowel disease)\u5305\u62ec\u514b\u9686\u6c0f\u75c7(Crohn's disease\u7c21\u7a31CD)\u548c\u6f70\u760d\u6027\u8178\u708e(ulcerative colitis\u7c21\u7a31UC)\uff0c\u5bb9\u6613\u6709\u8178\u9053\u4ee5\u5916\u7684\u8868\u73fe(extraintestinal manifestation)\u3002\u4e0b\u5217\u4f55\u7a2e\u8178\u9053\u5916\u8868\u73fe\u8f03\u5e38\u898b\u65bcCD\uff1f(1)pyoderma gangrenosum (2)ankylosing spondylitis (3)primary sclerosing cholangitis (4)episcleritis (5)peripheral arthritis\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (2)+(4)+(5)\nE. (1)+(3)+(4)\n": "(D)", "104-8.\n\u6025\u6027\u80f0\u81df\u708e\u7684\u56b4\u91cd\u5ea6\u5224\u65b7\u5c0d\u60a3\u8005\u8655\u7f6e\u548c\u9810\u5f8c\u76f8\u7576\u91cd\u8981\uff0c\u904e\u53bb\u7684Ranson's sign(\u22673)\u548cAPACHE II score (\u22678)\u7531\u65bc\u8f03\u7e41\u7463\uff0c\u76ee\u524d\u6709\u7528bedside index severity\u53d6\u800c\u4ee3\u4e4b\u7684\u8da8\u52e2\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u5c6c\u65bcbedside index severity of acute pancreatitis (BISAP)\uff1f\nA. age>60years\nB. SIRS\nC. pleural effusion\nD. creatinine>2.0mg/dL\nE. impaired mental status\n": "(D)", "104-9.\n\u85e5\u7269\u5f15\u8d77\u7684\u809d\u81df\u50b7\u5bb3(drug-induced hepatic injury)\uff0c\u53cd\u61c9\u6709direct\u53caidiosyncratic\u5169\u7a2e\uff0c\u4e0b\u5217\u85e5\u7269\u4f55\u8005\u5c6c\u65bcidiosyncratic\u53cd\u61c9\uff1f(1)oral contraceptive agents (2)acetaminophen (3)halothane (4)isoniazid (5)chlorpromazine\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "104-10.\n\u6709\u95dc\u80c3\u5206\u6ccc(gastric secretion)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u57fa\u790e\u80c3\u9178\u5206\u6ccc\u91cf\u5728\u65e9\u4e0a\u6700\u9ad8\nB. \u9664\u80c3\u9178\u5916\uff0c\u80c3\u53ef\u5206\u6cccpepsinogen\nC. \u9435\u8cea\u548cB12\u7684\u5438\u6536\u8207\u80c3\u5206\u6ccc\u6709\u95dc\nD. somatostatin\u53ef\u6291\u5236\u80c3\u9178\u5206\u6ccc\nE. parietal cell\u4e0a\u6709histamine, gastrin\u548cacetylcholine\u53d7\u9ad4\n": "(A)", "104-11.\n\u9577\u671f\u9157\u9152\u7684\u60a3\u8005\u56e0\u89e3\u9ed1\u4fbf\u3001\u5410\u8840\u5230\u6025\u8a3a\u8655\uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u7d50\u679c(\u5982\u5716)\uff0c\u4e0b\u5217\u4f55\u7a2e\u8655\u7f6e\u4e0d\u9069\u5408\u6025\u6027\u51fa\u8840\u7684\u63a7\u5236\uff1f\nA. octreotide\nB. propranolol\nC. injection therapy(sclerotherapy)\nD. transjugular intrahepatic portosystemic shunt\nE. somatostatin\n": "(B)", "104-12.\n\u4fbf\u79d8\uff08constipation\uff09\u53ef\u80fd\u767c\u751f\u65bc\u4e0b\u5217\u60c5\u6cc1\uff0c\u4f55\u8005\u9664\u5916\uff1f\r\u0010\nA. Hypothyroidism\nB. \u670d\u7528Bismuth\nC. Hypocalcemia\nD. \u670d\u7528calcium channel blockers\nE. \u670d\u7528opiates\n": "(C)", "104-13.\n\u5927\u8178\u7684diverticular diseases\u5728\u4e2d\u8001\u5e74\u4eba\u76f8\u7576\u5e38\u898b\uff0c\u4e0b\u5217\u76f8\u95dc\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Diverticulitis\u4e4b\u5178\u578b\u75c7\u72c0\u5305\u62ec\uff1a\u5de6\u6216\u53f3\u4e0b\u8179\u75db\u3001\u767c\u71d2\u53caleukocytosis\nB. \u7528\u4f86\u6cbb\u7642diverticulitis\u4e4b\u6297\u751f\u7d20\u61c9\u5305\u62ec\u5c0d\u6297aerobic gram-negative \u53cagram-positive\u7d30\u83cc\nC. Diverticulitis\u6025\u6027\u767c\u4f5c\u671f\u4e0d\u5b9c\u505a\u5167\u8996\u93e1\u6aa2\u67e5\nD. \u82e5\u8a3a\u65b7\u4e0d\u662f\u5f88\u78ba\u5b9a\uff0cabdominopelvic CT\u662f\u9996\u9078\u6aa2\u67e5\u5de5\u5177\nE. Diverticula of colon \u662f\u8840\u4fbf\u7684\u5e38\u898b\u75c5\u56e0\u4e4b\u4e00\n": "(B)", "104-14.\n\u4e00\u4f4d72\u6b72\u7537\u6027\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u4e3b\u8a34\u70ba\u904e\u53bb\u4e8c\u5468\u6709\u5fc3\u7aa9\u75db\uff0c6\u5c0f\u6642\u524d\u6709\u5410\u51fa\u5496\u5561\u8272\u7269\u8cea\u3002\u4ed6\u904e\u53bb\u66fe\u63a5\u53d7\u624b\u8853\u63db\u904emitral valve\uff0c\u4e5f\u66fe\u6709\u904etransient ischemic attack\uff0c\u73fe\u5728\u4e00\u76f4\u670d\u7528warfarin\u3002\u904e\u53bb\u7121\u809d\u75c5\u53f2\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8840\u58d3\u70ba170/88 mmHg\uff0c\u7121\u59ff\u52e2\u6027\u4f4e\u8840\u58d3\uff0c\u5fc3\u8df3\u70ba92/\u5206\uff0c\u547c\u5438\u901f\u738717/\u5206\uff0c\u9ad4\u6eab\u6b63\u5e38\uff0c\u8179\u90e8\u6aa2\u67e5\u5728\u5fc3\u7aa9\u8655\u6709\u8f15\u5fae\u58d3\u75db\u3002\u62bd\u8840\u6aa2\u67e5INR=2.3 (0.8-1.2), Hb : 13 g/dL (\u2267 13.2), Albumin: 3.8 (\u2267 3.7) g/dL, Bilirubin (total): 0.9 (\u2266 1.0) mg/dL, AST: 31U/L (\u2266 31), ALT: 25U/L (\u2266 41)\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u8feb\u5207\u5408\u5b9c\u4e4b\u8655\u7f6e\uff1f\nA. \u8f38\u6ce8Fresh frozen plasma\nB. \u8f38\u6ce8Vitamin K\nC. \u8f38\u6ce8Platelet\nD. \u7d66\u4e88\u9810\u9632\u6027\u6297\u751f\u7d20\nE. \u5b89\u6392\u5167\u8996\u93e1\u6aa2\u67e5\n": "(E)", "104-15.\n\u4e00\u4f4d60\u6b72\u5973\u6027\u75c5\u4eba\u81ea\u8ff0\u8fd12\u500b\u6708\u6709\u9010\u6f38\u52a0\u91cd\u7684\u6d3b\u52d5\u6027\u6c23\u4fc3\uff08progressive exertional dyspnea\uff09\uff0c\u5979\u4e26\u7121\u80f8\u75db\u6216\u5fc3\u60b8\u7b49\u73fe\u8c61\uff0c\u975c\u6b62\u6216\u7761\u89ba\u6642\u4ea6\u7121\u6c23\u4fc3\u60c5\u6cc1\u3002\u8eab\u9ad4\u8a3a\u5bdf\u50c5\u5728\u80f8\u524d\u767c\u73fespider angiomata\uff0c\u5176\u5b83\u7121\u7570\u5e38\u767c\u73fe\u3002\u62bd\u8840\u6aa2\u9a57\u767c\u73fe\uff1aPaO2=62 mmHg\uff0coxygen saturation 90%\uff0cAST=110 (\u2266 31)\uff0cALT=130 (\u2266 41)\uff0cAlb=3.5 (\u2267 3.7) g/dL\uff0cBil(T)=0.9 (\u2266 1) mg/dL\uff0cINR=0.95 (0.8-1.2)\uff0cWBC=4500 (\u2267 3500)\uff0cPlatelet=103K ( > 140K)\uff0cHBsAg (-)\uff0cAntiHCV (+)\u3002\u5fc3\u96fb\u5716\u53ca\u80f8\u90e8X\u5149\u7686\u6b63\u5e38\u3002\u4e0b\u5217\u4f55\u7a2e\u8a3a\u65b7\u6700\u53ef\u80fd\uff1f\nA. Hepatopulmonary syndrome\nB. Portopulmonary hypertension\nC. Ischemic heart disease\nD. Decompensated liver cirrhosis\nE. Idiopathic portal hypertension\n": "(A)", "104-16.\n\u4e00\u4f4d\u809d\u786c\u5316\u75c5\u4eba\u6700\u8fd1\u767c\u751f\u809d\u6027\u8166\u75c5\u8b8a\uff08hepatic encephalopathy\uff09\u3002\u4f4f\u9662\u5f8c\u4e26\u672a\u767c\u73fe\u6709\u8178\u80c3\u9053\u51fa\u8840\u3001\u611f\u67d3\u53ca\u4f4e\u8840\u9240\u7b49\u75c5\u60c5\uff0c\u4ed6\u5728\u5bb6\u4e2d\u6bcf\u5929\u65bc\u670d\u7528lactulose\u4e0b\u89e3\u4fbf\u7d044\u6b21\uff0c\u751f\u75c5\u524d\u4ea6\u7121\u9032\u98df\u904e\u591a\u86cb\u767d\u8cea\u3002\u589e\u52a0\u4e0b\u5217\u4f55\u8005\u7d66\u75c5\u4eba\u670d\u7528\uff0c\u6709\u52a9\u65bc\u9810\u9632\u672a\u4f86\u518d\u767c\u751f\u809d\u6027\u8166\u75c5\u8b8a\u4e14\u4e0d\u6703\u6709\u660e\u986f\u53ef\u9810\u671f\u4e4b\u526f\u4f5c\u7528\uff1f\nA. Dulcolax\nB. Neomycin\nC. Metronidazole\nD. Rifaximin\nE. Anticholinergic drug\n": "(D)", "104-17.\n\u4e0b\u5217\u95dc\u65bcacute intestinal obstruction\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\r(1) \u521d\u671f\u5e38\u6709\u9663\u767c\u6027cramping mid-abdominal pain\r(2) Strangulation\u767c\u751f\u6642\uff0c\u8179\u75db\u8f03\u6703\u56fa\u5b9a\u65bc\u67d0\u4e00\u90e8\u4f4d\uff0c\u4e14\u8b8a\u6210\u6301\u7e8c\u6027\uff0c\u4e5f\u8f03\u4e0d\u6703cramping\r(3) Colon obstruction\u4e4b\u8179\u75db\u8f03\u4e0d\u56b4\u91cd\r(4) \u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u8179\u90e8\u8139\u6c23\u8d8a\u53b2\u5bb3\uff0c\u8868\u793a\u5176\u963b\u585e\u90e8\u4f4d\u8f03\u53ef\u80fd\u5728\u8fd1\u7aef\u5c0f\u8178\u8655\r(5) \u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u807d\u4e0d\u5230bowel sound\uff0c\u53ef\u6392\u9664acute intestinal obstruction\u4e4b\u53ef\u80fd\u6027\r(6) \u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u807d\u4e0d\u5230bowel sound\uff0c\u8868\u793a\u4e00\u5b9a\u662f\u767c\u751fadynamic (paralytic) ileus\r(7) Barium meal study\u662f\u5224\u65b7\u963b\u585e\u90e8\u4f4d\u4e4b\u6700\u597d\u65b9\u5f0f\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (2)+(3)+(6)+(7)\nD. (3)+(4)+(5)+(6)\nE. (4)+(5)+(6)+(7)\n": "(E)", "104-18.\n\u4e0b\u5217\u95dc\u65bcAcute Appendicitis\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r(1) \u5178\u578b\u4e4b\u8179\u75db\u662f\u7531periumbilical/epigastric region\u79fb\u884c\u81f3right lower quadrant of abdomen\r(2) \u5e38\u6709bowel habit change\r(3) \u5e38\u6709anorexia\r(4) \u8eab\u9ad4\u8a3a\u5bdf\u6642\uff0c\u5728\u53f3\u4e0b\u8179\u6c92\u6709\u767c\u73fetenderness\uff0c\u5373\u53ef\u6392\u9664acute appendicitis\u4e4b\u8a3a\u65b7\r(5) psoas/obturator sign\u5c0d\u5224\u65b7acute appendicitis\u4e4b\u6709\u7121\u6975\u5177\u50f9\u503c\r(6) \u4f7f\u7528CT with contrast agent enhancement\u8a3a\u65b7acute appendicitis\u4e4b\u6e96\u78ba\u7387\uff08accuracy\uff09\u76f8\u7576\u9ad8\uff0c\u53ef\u905490%\nA. (1)+(2)+(3)\nB. (2)+(3)+(5)\nC. (1)+(3)+(6)\nD. (3)+(4)+(5)\nE. (4)+(5)+(6)\n": "(C)", "104-19.\n\u4e0b\u5217\u95dc\u65bc\u809d\u81df\u5c40\u9650\u6027\u75c5\u7076\uff08focal lesion\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r(1) \u5927\u7684cyst\u82e5\u6709wall irregularity\uff0c\u61c9\u8003\u616e\u5207\u9664\u4e4b\r(2)  Focal Nodular Hyperplasia (FNH)\u6709malignant potential\uff0c\u6545\u61c9\u5207\u9664\u4e4b\r(3) \u76f4\u5f915\u516c\u5206\u4ee5\u4e0a\u7684adenoma\u53ef\u80fd\u6703spontaneous rupture\u6216\u6f14\u8b8a\u6210\u60e1\u6027\u816b\u7624\uff0c\u6545\u61c9\u5207\u9664\u4e4b\r(4) \u63a5\u89f8ameba\u81f3\u958b\u59cb\u6709liver abscess\u4e4b\u81e8\u5e8a\u75c7\u72c0\uff0c\u5176\u6f5b\u4f0f\u671f\u7d042-4 weeks\r(5) \u63a5\u53d7CT scan\u6aa2\u67e5\uff0c\u6ce8\u5c04\u986f\u5f71\u5291\u5f8c\uff0c\u5728\u8840\u7ba1\u7624\u6703\u6709\u6240\u8b02 \"fill-in\"\u73fe\u8c61\uff0c\u5373\u662f\u986f\u5f71\u5291\u6703\u96a8\u6642\u9593\u5f9e\u8840\u7ba1\u7624\u4e4b\u5468\u908a\u5411\u5176\u4e2d\u592e\u6ef2\u5165\u3002\nA. (3)+(4)+(5)\nB. (2)+(3)+(4)\nC. (1)+(2)+(3)\nD. (2)+(3)+(5)\nE. (1)+(3)+(5)\n": "(E)", "104-20.\n\u76ee\u524d\u5df2\u6709\uff21\u578b\u809d\u708e\u53ca\uff22\u578b\u809d\u708e\u75ab\u82d7\uff0c\u5e74\u8f15\u4e00\u4ee3\u4e4b\u570b\u4eba\u61c9\u63a5\u53d7\u4e4b\u3002\u4e0b\u5217\u76f8\u95dc\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u82e5\u6bcd\u89aa\u70baHBeAg (-)\u4e4b\uff22\u578b\u809d\u708e\u5e36\u539f\u8005\uff0c\u5176\u65b0\u751f\u5152\u61c9\u65bc24\u5c0f\u6642\u5167\u63a5\u53d7HBIG (hepatitis B immune globulin) \u6ce8\u5c04\uff0c\u4e26\u65bc\u4e00\u5468\u5167\u5b8c\u6210\u7b2c\u4e00\u5291\uff22\u578b\u809d\u708e\u75ab\u82d7\u6ce8\u5c04\nB. \u76ee\u524d\u4e4b\uff22\u578b\u809d\u708e\u75ab\u82d7\uff0c\u61c9\u65bc\u516d\u500b\u6708\u5167\u5b8c\u6210\u4e09\u5291\u6ce8\u5c04\nC. \u76ee\u524d\u4e4b\uff21\u578b\u809d\u708e\u75ab\u82d7\uff0c\u61c9\u65bc\u516d\u500b\u6708\u223c\u4e00\u5e74\u5167\u5b8c\u6210\u5169\u5291\u6ce8\u5c04\nD. \u5b8c\u6210\u4e09\u5291\u6ce8\u5c04\u4e14\u7522\u751fanti-HBs\u5f8c\uff0c60%\u4ee5\u4e0a\u53ef\u6301\u7e8c\u7dad\u6301\u5177\u4fdd\u8b77\u6027\u4e4b\u6fc3\u5ea6\u81f3\u5c1110\u5e74\nE. \u5b8c\u6210\u4e8c\u5291\u6ce8\u5c04\u4e14\u7522\u751fanti-HAV\u5f8c\uff0c\u61c9\u53ef\u6301\u7e8c\u7dad\u6301\u5177\u4fdd\u8b77\u6027\u4e4b\u6fc3\u5ea6\u81f3\u5c1120\u5e74\n": "(A)", "104-21.\n\u5728\u65e5\u5e38\u91ab\u7642\u4e4b\u60c5\u6cc1\u4e0b\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6700\u4e0d\u6703\u7522\u751f\u809d\u81df\u50b7\u5bb3\uff1f\nA. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u6fc3\u5ea6\u7684allopurinol\nB. \u9000\u71d2\u6642\u4f7f\u7528acetaminophen\uff08\u9152\u7cbe\u6210\u766e\u8005\u9664\u5916\uff09\nC. \u6cbb\u7642\u7d50\u6838\u75c5\u4e4bisoniazid\nD. \u6cbb\u7642\u8db3\u766c\u4e4bketoconazole\u985e\u85e5\u7269\nE. \u964d\u4f4e\u8840\u4e2d\u81bd\u56fa\u9187\u4e4bstatin\u985e\u85e5\u7269\n": "(B)", "104-22.\n\u4e00\u4f4d45\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u53f3\u4e0a\u8179\u75db\u53ca\u76ae\u819a\u7662\u800c\u5c31\u91ab\uff0c\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aALT=60U/L (\u226641)\uff0cAST=70U/L (\u226631)\uff0cALP=700 (\u2266104)\uff0cr-GT=450U/L (\u226650)\uff0cBil(T)=1.2mg/dL\uff0cBil(D)=0.8mg/dL\u3002\u4f4f\u9662\u5f8c\u63a5\u53d7\u78c1\u632f\u9020\u5f71\u53ca\u81bd\u80f0\u7ba1\u651d\u5f71\uff08MRCP, magnetic resonance cholangio pancreatography\uff09\u767c\u73fe\u809d\u5167\u81bd\u7ba1\u6709\u5206\u5e03\u4e0d\u4e00\u4e4b\u72f9\u7a84\u53ca\u64f4\u5927\u73fe\u8c61\uff08segmental stricture with saccular dilatation\uff09\u3002\u75c5\u4eba\u63a5\u53d7\u809d\u5207\u7247\uff0c\u5176\u7d44\u7e54\u986f\u73feportal tract expansion with ductular proliferation and lymphocytic\rinfiltration\uff0c\u6b64\u75c5\u4eba\u4e4b\u8a3a\u65b7\u56e0\u800c\u5df2\u7d93\u78ba\u7acb\u3002\u95dc\u65bc\u672c\u75c5\u4eba\u4e4b\u75c5\u60c5\uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5e38\u5408\u4f75\u6709\u6162\u6027\u767c\u708e\u6027\u8178\u9053\u75be\u75c5\uff08inflammatory bowel disease\uff09\nB. \u61c9\u96a8\u6642\u6ce8\u610f\u5176\u662f\u5426\u4f75\u767ccholangiocarcinoma\nC. \u9ad8\u5291\u91cf (25 mg/Kg/d) UDCA (ursodeoxycholic acid) \u80fd\u6709\u6548\u63a7\u5236\u5176\u75c5\u60c5\nD. \u82e5\u75c5\u60c5\u60e1\u5316\uff0c\u53ef\u8003\u616e\u809d\u81df\u79fb\u690d\nE. MRCP\u7528\u65bc\u8a3a\u65b7\u6b64\u7b49\u75c5\u4eba\uff0c\u5176\u6e96\u78ba\u7387\u53ef\u905490%\n": "(C)", "105-1.\n25\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u541e\u56a5\u56f0\u96e3\u3001\u80f8\u75db\u53ca\u9ad4\u91cd\u6e1b\u8f15\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u70ba\u6b63\u5e38\u3002\u500b\u6848\u9032\u4e00\u6b65\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u651d\u5f71\u7d50\u679c\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\u8a3a\u65b7\uff1f\nA. \u98df\u9053\u5ee3\u6cdb\u6027\u75d9\u6523(diffuse esophageal spasm)\nB. \u80c3\u98df\u9053\u9006\u6d41\u6027\u75be\u75c5(gastroesophageal reflux disease)\nC. \u98df\u9053\u5f1b\u7de9\u4e0d\u80fd(achalasia)\nD. \u55dc\u4f0a\u7d05\u6027\u98df\u9053\u708e(eosinophilic esophagitis)\nE. \u98df\u9053\u764c(esophageal cancer)\n": "(C)", "105-2.\n60\u6b72\u7537\u6027\u56e0\u80c3\u9178\u9006\u6d41\u3001\u80f8\u53e3\u707c\u71b1\u63a5\u53d7\u80c3\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u767c\u73fe\u98df\u9053\u6709\u5982\u5716\u4e4b\u8b8a\u5316\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u9020\u6210\u6b64\u98df\u9053\u75c5\u8b8a\u4e4b\u4fc3\u767c\u56e0\u5b50\uff1f\nA. acid\nB. pepsin\nC. bile\nD. pancreatic ezyme\nE. Helicobacter pylori infection\n": "(E)", "105-3.\n\u9664\u4e86\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u611f\u67d3\u5916\uff0c\u85e5\u7269\u4e5f\u662f\u9020\u6210\u6d88\u5316\u6027\u6f70\u760d\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u8f03\u4e0d\u6703\u9020\u6210\u6f70\u760d\uff1f\nA. bisphosphonate\nB. clopidogrel\nC. potassium chloride\nD. acetaminophen\nE. chemotherapeutic agent\n": "(D)", "105-4.\n65\u6b72\u7537\u6027\u60a3\u800525\u5e74\u524d\u56e0\u80c3\u51fa\u8840\u63a5\u53d7\u5716\u793a\u4e4b\u624b\u8853\uff0c\u51fa\u73fe\u98ef\u5f8c\u8179\u75db\u3001\u8179\u8139\u3001\u8179\u7009\uff0c\u540c\u6642\u6709\u8102\u80aa\u53ca\u7dad\u751f\u7d20B12\u5438\u6536\u4e0d\u826f\uff0c\u9019\u4e9b\u75c7\u72c0\u5728\u4f7f\u7528\u6297\u751f\u7d20\u5f8c\u5f97\u5230\u6539\u5584\uff0c\u8a66\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. recurrent ulceration\nB. afferent loop syndrome\nC. postvagotomy diarrhea\nD. bile reflux gastropathy\nE. remnant gastric cancer\n": "(B)", "105-5.\n\u6709\u95dc\u81bd\u9178(bile acids)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r\n1. \u98f2\u98df\u4e2d\u6c92\u6709\uff0c\u5176\u4e3b\u8981\u4f86\u6e90\u662f\u809d\u81df\u5408\u6210\r\n2. lithocholic acid\u5c6c\u521d\u7d1a\u81bd\u9178(primary bile acid)\r\n3. \u6b21\u7d1a\u81bd\u9178(secondary bile acid)\u4f8b\u5982deoxycholic acid\u4e4b\u7522\u751f\u662f\u7531\u65bc\u5927\u8178\u5167\u7d30\u83cc\u9175\u7d20\u5206\u89e3\u521d\u7d1a\u81bd\u9178\u800c\u4f86\r\n4. \u81bd\u9178\u7570\u5e38\u6703\u9020\u6210\u6bd4\u8102\u80aa\u9178\u7570\u5e38\u66f4\u56b4\u91cd\u7684\u8102\u80aa\u8179\u7009(steatorrhea)\r\n5. \u81bd\u9178\u5f15\u8d77\u4e4b\u8179\u7009\u5c0d\u4f4e\u8102\u98f2\u98df\u6cbb\u7642\u6548\u679c\u4e0d\u4f73\nA. 1+2+3\nB. 1+3+4\nC. 1+3+5\nD. 2+4+5\nE. 2+3+5\n": "(C)", "105-6.\n20\u6b72\u7537\u6027\u56e0\u53cd\u8986\u6027\u8179\u75db\u4f4f\u9662\uff0c\u5c0f\u8178\u651d\u5f71\u6aa2\u67e5\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. irritable bowel syndrome\nB. celiac sprue\nC. jejunal diverticulosis\nD. Crohn's disease\nE. Whipple's disease\n": "(D)", "105-7.\n\u6709\u95dc\u767c\u708e\u6027\u5927\u8178\u75be\u75c5(inflammatory bowel disease)\u4e2d\u6f70\u760d\u6027\u8178\u708e(ulcerative colitis)\u548c\u514b\u9686\u6c0f\u75c5(Crohn's disease)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\r\n1. \u62bd\u7159\u6703\u589e\u52a0\u6f70\u760d\u6027\u8178\u708e\u7684\u767c\u751f\r\n2. \u76f2\u8178\u5207\u9664\u624b\u8853(appendectomy)\u53ef\u4ee5\u6e1b\u5c11\u6f70\u760d\u6027\u8178\u708e\u7684\u767c\u751f\r\n3. \u4f7f\u7528\u53e3\u670d\u907f\u5b55\u85e5(oral contraceptive)\u6703\u589e\u52a0\u514b\u9686\u6c0f\u75c5\u767c\u751f\r\n4. \u9664\u4e8615-30\u6b72\u5916\uff0c\u5169\u8005\u572860-80\u6b72\u6709\u53e6\u4e00\u597d\u767c\u9ad8\u5cf0\r\n5. \u514b\u9686\u6c0f\u75c5\u5973\u6027\u767c\u751f\u6a5f\u6703\u9ad8\u65bc\u7537\u6027\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 1+4+5\nE. 2+4+5\n": "(B)", "105-8.\n60\u6b72\u7537\u6027\u4e00\u5e74\u524d\u63a5\u53d7\u5927\u8178\u93e1\u6aa2\u67e5\u5728\u4e59\u72c0\u7d50\u8178\u767c\u73fe\u4e00\u4e9b\u61a9\u5ba4(diverticulum)\u3002\u56e0\u70ba\u5de6\u4e0b\u8179\u75bc\u75db\u3001\u767c\u71d2\u81f3\u6025\u8a3a\u8655\uff0c\u8840\u6db2\u6aa2\u67e5WBC: 15000 /\u03bcL\uff0cSeg: 88%\uff0c\u4e14\u8179\u90e8\u53ca\u9aa8\u76c6\u8154\u96fb\u8166\u65b7\u5c64\u4e26\u7121\u6e38\u96e2\u7a7a\u6c23\u6216\u81bf\u760d\u3002\u4e0b\u5217\u4f55\u9805\u8655\u65b9\u8f03\u4e0d\u9069\u5408\u6b64\u60a3\u8005\u7684\u6cbb\u7642\uff1f\nA. penicillin / clavulanic acid\nB. cephalexin\nC. ciprofloxacin / metronidazole\nD. piperacillin\nE. trimethoprim / sulfamethoxazole\n": "(B)", "105-9.\n\u6709\u95dc\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(Helicobacter pylori)\u6aa2\u6e2c\uff0c\u4f55\u8005\u6b63\u78ba?\r\n1. \u547c\u6c23\u6e2c\u8a66(urea breath test)\u654f\u611f\u5ea6\u6700\u9ad8\r\n2. \u7cde\u4fbf\u6297\u539f\u6e2c\u8a66(stool antigen)\u50f9\u683c\u6700\u6602\u8cb4\r\n3. \u8840\u6e05\u6e2c\u8a66\u53ef\u7528\u65bc\u6bba\u83cc\u5f8c\u7684\u65e9\u671f\u8ffd\u8e64\r\n4. \u670d\u7528bismuth\u6216proton pump inhibitor\u6703\u4f7f\u5feb\u901f\u5c3f\u7d20\u9175\u7d20\u6e2c\u8a66(rapid urease test)\u5448\u73fe\u507d\u9670\u6027\u7d50\u679c\r\n5. \u4e8c\u6b21\u4ee5\u4e0a\u6bba\u83cc\u5931\u6557\u5f8c\u53ef\u8003\u616e\u7d30\u83cc\u57f9\u990a\u6e2c\u6297\u85e5\u6027\nA. 1+2+3\nB. 2+3+4\nC. 3+4+5\nD. 1+4+5\nE. 2+4+5\n": "(D)", "105-10.\n\u6025\u6027\u80f0\u81df\u708e\u572824\u5c0f\u6642\u5167\u6709\u6240\u8b02\u7684bedside index of severity in acute pancreatitis\uff0c\u7c21\u7a31BISAP\uff0c\u4f86\u5354\u52a9\u56b4\u91cd\u5ea6\u7684\u5224\u5b9a\u3002\u4e0b\u5217\u4f55\u9805\u4e0d\u5c6c\u65bcBISAP\uff1f\nA. BUN>22mg/dL\nB. impaired mental status\nC. hemoconcentration\nD. age>60years\nE. pleural effusion\n": "(C)", "105-11.\n\u81bd\u7d50\u77f3\u6709\u81bd\u56fa\u9187\u7d50\u77f3(cholesterol stone)\u548c\u8272\u7d20\u7d50\u77f3(pigment stone)\u5169\u7a2e\uff0c\u4e0b\u5217\u4f55\u9805\u4e0d\u662f\u8272\u7d20\u7d50\u77f3\u4e4b\u4fc3\u767c\u56e0\u5b50(predisposing factors)\uff1f\nA. \u8001\u5e74\u4eba\nB. \u61f7\u5b55\nC. \u9152\u7cbe\u6027\u809d\u786c\u5316\nD. \u60e1\u6027\u8ca7\u8840(pernicious anemia)\nE. \u6162\u6027\u6eb6\u8840(chronic hemolysis)\n": "(B)", "105-12.\n\u4e0b\u5217\u4f55\u9805\u6aa2\u6e2c\u4e3b\u8981\u7528\u65bcprimary biliary cirrhosis\uff1f\nA. antinuclear antibody\nB. anti-smooth-muscle antibody\nC. antimitochondrial antibody\nD. C3/C4\nE. IgG4\n": "(C)", "105-13.\n\u809d\u7d30\u80de\u764c\uff08hepatocellular carcinoma, HCC\uff09\u540d\u5217\u570b\u4eba\u764c\u75c7\u5341\u5927\u6b7b\u56e0\u524d\u8305\uff0c\u5176\u9810\u9632\u53ca\u6cbb\u7642\u5c0d\u570b\u4eba\u5065\u5eb7\u5f71\u97ff\u751a\u5927\u3002\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7f79\u60a3HCC\u7684\u75c5\u4eba\uff0c\u5176\u8840\u4e2dalpha-fetoprotein (AFP) \u90fd\u6703\u7570\u5e38\u4e0a\u5347\nB. \u5b9a\u671f\u5c0d\u9ad8\u5371\u96aa\u7fa4\u6aa2\u9a57\u8840\u4e2dAFP\u6578\u503c\u662f\u5fc5\u8981\u7684\nC. \u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u662f\u767c\u73feHCC\u4e4b\u5229\u5668\nD. \u809d\u786c\u5316\u60a3\u8005\u662fHCC\u6700\u9ad8\u5371\u96aa\u7fa4\nE. \u65e9\u671f\u63a7\u5236\u6162\u6027\uff22\u578b\u809d\u708e\u4e4b\u75c5\u60c5\u6709\u52a9\u65bc\u9810\u9632HCC\u4e4b\u767c\u751f\n": "(A)", "105-14.\n\u4e00\u4f4d\u6162\u6027\u809d\u708e\u60a3\u8005\uff0c\u5b9a\u671f\u63a5\u53d7\u8d85\u97f3\u6ce2\u6aa2\u67e5\uff0c\u6700\u8fd1\u4e00\u6b21\u88ab\u544a\u77e5\u809d\u5167\u7591\u4f3c\u6709\u4e00\u500b\u816b\u7624\uff0c\u60f3\u5fb5\u8a62\u60a8\u7684\u770b\u6cd5\u3002\u4e0b\u5217\u6709\u95dc\u809d\u5167\u816b\u7624\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\r\n1. \u809d\u5167\u8840\u7ba1\u7624\uff08hemangioma\uff09\u6709\u60e1\u5316\u4e4b\u53ef\u80fd\uff0c\u6700\u597d\u4e88\u4ee5\u8655\u7406\r\n2. \u809d\u5167\u6c34\u6ce1\uff08cyst\uff09\u901a\u5e38\u4e0d\u9700\u8655\u7406\r\n3. \u817a\u7624\uff08adenoma\uff09\u4e0d\u5177hormone responsiveness\r\n4. \u5c40\u90e8\u7d50\u7bc0\u589e\u751f\uff08focal nodular hyperplasia\uff09\u82e5\u5927\u65bc5\u516c\u5206\uff0c\u4e14\u60a3\u8005\u70ba\u5e74\u8f15\u5973\u751f\uff0c\u672a\u4f86\u53ef\u80fd\u6703\u61f7\u5b55\uff0c\u6700\u597d\u4e88\u4ee5\u5207\u9664\r\n5. \u809d\u7d30\u80de\u764c\uff08hepatocellular carcinoma\uff09\u5927\u591a\u70bahypervascular\r\n6. \u8f49\u79fb\u6027\u809d\u764c\uff08metastatic liver cancer\uff09\u5927\u591a\u70bahypovascular\r\n7. \u809d\u5167\u81bd\u7ba1\u764c\uff08cholangiocarcinoma\uff09\u9810\u5f8c\u76f8\u7576\u4e0d\u932f\nA. 3+4+5+6\nB. 1+4+5+6\nC. 2+4+5+6\nD. 2+3+6+7\nE. 1+3+4+7\n": "(E)", "105-15.\n\u4e0b\u5217\u6709\u95dcNSAID (Nonsteroidal Anti-inflammatory Drugs)-induced gastrointestinal complications\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. NSAID\u6703\u6291\u5236prostaglandin synthesis\uff0c\u56e0\u6b64\u53ef\u7528misoprostol\u6cbb\u7642\nB. H. pylori\u611f\u67d3\u8207NSAID-induced\u80c3\u90e8\u6f70\u760d\u6beb\u7121\u95dc\u806f\nC. \u66fe\u6709\u80c3\u6f70\u760d\u51fa\u8840\u65e2\u5f80\u75c5\u53f2\u8005\u5c6c\u65bc\u9ad8\u5371\u96aa\u7fa4\nD. 65\u6b72\u4ee5\u4e0a\u8001\u5e74\u75c5\u4eba\u4f7f\u7528\u9ad8\u5291\u91cfNSAIDs\uff0c\u4ea6\u6709\u8f03\u9ad8\u98a8\u96aa\u6703\u767c\u751f\u6b64\u7b49\u4f75\u767c\u75c7\nE. \u6a19\u6e96\u5291\u91cfproton pump inhibitors (PPIs)\u70ba\u9810\u9632\u6b64\u7b49\u4f75\u767c\u75c7\u4e4b\u9996\u9078\n": "(B)", "105-16.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u76ae\u819a\u767c\u7662\u800c\u5c31\u91ab\uff0c\u62bd\u8840\u6aa2\u9a57\u4e4b\u7d50\u679c\u5982\u4e0b\uff1aALT=105 U/L (<41), AST=100U/L (<37), ALP (alkaline phosphatase)=700 U/L (<104), GGT (gamma-glutamyl transpeptidase)=500 U/L (<50), Bilirubin (total)=1.0 mg/dL  (<1.0)\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \uff22\u578b\u809d\u708e\u4e4b\u53ef\u80fd\u6027\u5f88\u4f4e (hepatitis B)\nB. \uff23\u578b\u809d\u708e\u4e4b\u53ef\u80fd\u6027\u5f88\u4f4e (hepatitis C)\nC. \u85e5\u7269\u6027\u809d\u708e\u4e4b\u53ef\u80fd\u6027\u5f88\u4f4e (drug-induced hepatitis)\nD. \u81bd\u6c41\u9b31\u7a4d\u6027\u809d\u75c5\u4e4b\u53ef\u80fd\u6027\u5f88\u9ad8 (cholestatic liver disease)\nE. Wilson's disease\u4e4b\u53ef\u80fd\u6027\u5f88\u9ad8\n": "(D)", "105-17.\n\u6709\u95dc\u81bd\u56ca\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u7121\u75c7\u72c0\u4e4b\u81bd\u56ca\u7d50\u77f3\u60a3\u8005\uff0c\u4ecd\u61c9\u5118\u65e9\u4e88\u4ee5\u65bd\u884c\u81bd\u56ca\u5207\u9664\nB. \u9ad4\u5916\u9707\u6ce2\u788e\u77f3\u8853\uff08extracorporeal shock wave lithotripsy\uff09\u50c5\u9069\u7528\u65bc\u6cbb\u7642\u5c11\u8a31\u75c5\u4eba\nC. \u76f4\u5f91\u5c0f\u65bc0.5\u516c\u5206\u4e4b\u591a\u767c\u6027\u81bd\u56ca\u606f\u8089\uff0c\u61c9\u52a0\u4ee5\u5207\u9664\nD. \u6709\u76f4\u5f91\u5927\u65bc3\u516c\u5206\u4e4b\u81bd\u56ca\u7d50\u77f3\u60a3\u8005\uff0c\u82e5\u7121\u75c7\u72c0\uff0c\u4e0d\u5fc5\u8003\u616e\u81bd\u56ca\u5207\u9664\nE. Cholechochal cyst\u4e26\u975e\u767c\u751f\u81bd\u56ca\u764c\u4e4b\u9ad8\u98a8\u96aa\u56e0\u5b50\n": "(B)", "105-18.\n\u4e0b\u5217\u6709\u95dcgastroesophageal reflux disease (GERD)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Asthma\u53ef\u80fd\u662f GERD \u7684 extraesophageal syndrome\u4e4b\u4e00\nB. \u904e\u5ea6\u80a5\u80d6\u4e4bGERD\u60a3\u8005\uff0c\u6e1b\u80a5\u6709\u52a9\u65bc\u6539\u5584\u5176GERD\u4e4b\u75c7\u72c0\nC. \u82e5GERD\u5df2\u6210\u6162\u6027\u72c0\u6cc1\uff0c\u9577\u671f\u4f7f\u7528\u4f4e\u5291\u91cfproton pump inbihitors (PPIs) \u901a\u5e38\u9700\u8981\nD. \u52a0\u4e0ametoclopramide\uff08\u5982\uff1aPrimperan\u7b49\uff09\u901a\u5e38\u6709\u52a9\u65bc\u5f37\u5316GERD\u4e4b\u6cbb\u7642\nE. Barrett's esophagus\u4e4b\u75c5\u4eba\u61c9\u5b9a\u671f\u63a5\u53d7\u5167\u8996\u93e1\u6aa2\u67e5\n": "(D)", "105-19.\n\u4e00\u4f4d50\u6b72\u7537\u6027\u4e4b\u5065\u6aa2\u4e2d\u6709\u95dc\u809d\u708e\u75c5\u6bd2\u6a19\u8a18\u4e4b\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aHBsAg (-), Anti-HBs (-), Anti-HBc (+), Anti-HCV (+)\u3002\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\r\n1. \u4ecd\u53ef\u80fd\u662f\uff22\u578b\u809d\u708e\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\r\n2. \u672a\u66fe\u63a5\u89f8\u904e\uff22\u578b\u809d\u708e\u75c5\u6bd2\r\n3. \u61c9\u5118\u5feb\u63a5\u53d7\uff22\u578b\u809d\u708e\u75ab\u82d7\u6ce8\u5c04\r\n4. \u904e\u53bb\u53ef\u80fd\u66fe\u6709Anti-HBs (+)\uff0c\u76ee\u524d\u6fc3\u5ea6\u5df2\u964d\u4f4e\u81f3\u6e2c\u4e0d\u5230\r\n5. \u66fe\u611f\u67d3\u904e\uff23\u578b\u809d\u708e\u75c5\u6bd2\r\n6. \uff23\u578b\u809d\u708e\u53ef\u80fd\u5df2\u75ca\u7652\nA. 1+2+4+5\nB. 2+3+5+6\nC. 1+4+5+6\nD. 3+4+5+6\nE. 2+3+4+5\n": "(C)", "105-20.\n\u95dc\u65bcIBD (inflammatory bowel disease)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Ulcerative colitis \u60a3\u8005\u8f03\u5e38\u6709proctitis\nB. Ulcerative colitis\u60a3\u8005\u4e4b\u75c7\u72c0\u8f03\u70baacute onset, Crohn disease\u60a3\u8005\u5247\u8f03\u5e38indolent onset\nC. Ulcerative colitis\u60a3\u8005\u8f03\u5e38\u6709enterocutaneous fistula\nD. Crohn disease\u60a3\u8005\u8f03\u5e38\u6709perianal abscess\nE. \u5169\u8005\u4e4b\u767c\u751f\u7686\u53ef\u80fd\u6d89\u53cagenetic predisposition, immune dysregulation\u53caenvironmental triggers\n": "(C)", "105-21.\n\u76ee\u524d\u5c0d\u6162\u6027\uff23\u578b\u809d\u708e\u60a3\u8005\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4ee5\u5e72\u64fe\u7d20\uff08interferon)\u70ba\u57fa\u790e\u4e4b\u6cbb\u7642\u5df2\u975e\u512a\u5148\u65b9\u5f0f\nB. \u53e3\u670d\u4e0d\u542b\u5e72\u64fe\u7d20\u4e4b\u65b0\u85e5\uff08direct acting antiviral agents, DAA\uff09\u4e4b\u6cbb\u7652\u7387\u5927\u591a\u53ef\u9054\u4e5d\u6210\u4ee5\u4e0a\nC. DAA\u4e4b\u7642\u7a0b\u591a\u572812-24\u9031\nD. DAA\u4e4b\u526f\u4f5c\u7528\u8f03\u5c11\u4e14\u8f15\u5fae\uff0c\u75c5\u4eba\u4e4b\u9806\u5f9e\u6027\u9ad8\nE. DAA\u8207\u5176\u5b83\u85e5\u7269\u5f88\u5c11\u6709drug interaction\n": "(E)", "105-22.\n\u76ee\u524d\u5c0d\u6162\u6027\uff22\u578b\u809d\u708e\u60a3\u8005\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\r\n1. Pegylated interferon (PEG-interferon) alpha-2\u03b1\u5df2\u4e0d\u5efa\u8b70\u4f7f\u7528\r\n2. Tenofovir\u53caEntecavir\u662f\u5169\u7a2e\u88ab\u63a8\u85a6\u512a\u5148\u4f7f\u7528\u4e4b\u53e3\u670d\u6297\uff22\u809d\u75c5\u6bd2\u85e5\u7269\r\n3. Tenofovir\u53caEntecavir\u4e4b\u4f7f\u7528\u4e0d\u9700\u56e0\u814e\u529f\u80fd\u72c0\u6cc1\u800c\u8abf\u6574\u5291\u91cf\r\n4. \u5c0dTenofovir\u53caEntecavir\u4e4b\u6297\u85e5\u6027\uff22\u809d\u75c5\u6bd2\u51fa\u73fe\u7387\u6975\u4f4e\r\n5. \u5931\u4ee3\u511f\u6027\uff08decompensated\uff09\u809d\u75c5\u60a3\u8005\u61c9\u5118\u901f\u4f7f\u7528PEG-interferon\r\n6. \u82e5\u75c5\u4eba\u5c0dEntecavir\u7522\u751f\u6297\u85e5\u6027\uff0c\u53ef\u6539\u7528Tenofovir\nA. 1+2+3+4\nB. 1+2+5+6\nC. 2+4+6\nD. 3+4+5\nE. 1+3+5\n": "(E)", "106-1.\n\u4e00\u4f4d\u75c5\u4eba\u88ab\u5bb6\u5c6c\u9001\u81f3\u6025\u8a3a\u5ba4\uff0c\u81ea\u8a34\u4e0a\u8179\u4e2d\u592e\u75bc\u75db\u5df2\u67093\u5929\uff0c\u5e73\u8eba\u6703\u66f4\u75db\uff0c\u4f34\u6709\u5614\u5410\u73fe\u8c61\u3002\u95dc\u65bc\u9019\u4f4d\u75c5\u4eba\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u62bd\u8840\u6aa2\u9a57 Liapse \u8f03\u5177\u8a3a\u65b7\u6027\nB. \u82e5\u8840\u4e2d Amylase \u6b63\u5e38,\u5373\u53ef\u6392\u9664\u6025\u6027\u80f0\u81df\u708e\u4e4b\u53ef\u80fd\u6027\nC. \u61c9\u6ce8\u610f\u5176\u8840\u4e2d triglyceride \u662f\u5426\u8d85\u904e1000 mg/dL\nD. \u61c9\u6ce8\u610f\u5176\u8170\u90e8\u662f\u5426\u6709 Turner's sign\nE. \u61c9\u8a62\u554f\u5176\u76ee\u524d\u662f\u5426\u6709\u670d\u7528 Furosemide, Hydrochlorothiazide, 6-Mercaptopurine/azathioprine \u7b49\u85e5\u7269\n": "(B)", "106-2.\n\u6709\u95dc Macroamylasemia\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u9019\u662f\u7531\u65bc amylase multimers \u7121\u6cd5\u7531\u8840\u4e2d\u6392\u81f3\u5c3f\u4e2d\u6240\u81f4\nB. \u8840\u4e2d amylase \u6fc3\u5ea6\u6703\u7570\u5e38\u4e0a\u5347\nC. \u8840\u4e2d Lipase \u901a\u5e38\u4e5f\u6703\u7570\u5e38\u5347\u9ad8\nD. Macroamylase \u53ef\u7528 chromatography \u5075\u6e2c\u51fa\u4f86\nE. \u75c5\u4eba\u901a\u5e38\u6c92\u6709\u8179\u75db\n": "(C)", "106-3.\n\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6025\u6027\u8179\u7009( < 2\u9031) \u75c5\u4eba\u82e5\u6709bloody stool \u6216\u767c\u71d2 >38.5 C \u6642\uff0c\u61c9\u8a73\u67e5\u5176\u539f\u56e0\nB. \u6700\u8fd1\u670d\u7528\u6297\u751f\u7d20\u800c\u5c0e\u81f4\u6025\u6027\u8179\u7009\uff0c\u4e0d\u5fc5\u9032\u4e00\u6b65\u8a73\u67e5\u75c5\u56e0\nC. Osmotic diarrhea \u75c5\u4eba\u4e4b\u5927\u4fbf\u91cf\u901a\u5e38\u5927\u65bc 1L/\u5929\uff0c\u7981\u98df\u5373\u6703\u505c\u6b62\u8179\u7009\nD. Secretory diarrhea \u75c5\u4eba\u4e4b\u5927\u4fbf\u91cf\u901a\u5e38\u5c0f\u65bc 1L/\u5929\uff0c\u5373\u4fbf\u7981\u98df\u4ecd\u6703\u51fa\u73fe\u8179\u7009\nE. Small intestinal bacterial overgrowth \u8f03\u5c11\u767c\u751f\u65bcintestinal motility\u7570\u5e38(dysmotility) \u4e4b\u75c5\u4eba\uff0c\u5982\uff1aautonomic neuropathy\n": "(A)", "106-4.\n\u6709\u95dcC\u578b\u809d\u708e\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1)\u7d93\u7531\u9ad4\u6db2\u50b3\u67d3\uff1b(2)\u6025\u6027C\u578b\u809d\u708e\u591a\u6578\u6c92\u75c7\u72c0\uff0c\u4e0d\u6613\u5bdf\u89ba\uff1b(3)\u76ee\u524d\u5df2\u6709\u75ab\u82d7\u53ef\u4f9b\u9810\u9632\uff1b(4)\u5065\u5eb7\u6210\u5e74\u4eba\u7f79\u60a3\u6025\u6027C\u578b\u809d\u708e\uff0c\u82e5\u672a\u6cbb\u7642\uff0c\u7d0420% \u6703\u8b8a\u6210\u6162\u6027\u809d\u708e\uff1b(5)\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\uff0c\u82e5\u672a\u6cbb\u7642\uff0c20-30\u5e74\u5f8c\u7d04\u670920-30% \u6703\u6f14\u8b8a\u6210\u809d\u786c\u5316\uff1b(6)\u76ee\u524d\u809d\u764c\u75c5\u4eba\u4e4b\u75c5\u56e0\u70ba\u6162\u6027C\u578b\u809d\u708e\u4e4b\u6bd4\u4f8b\u6108\u4f86\u6108\u9ad8\uff1b(7)\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\u4e4b\u81e8\u5e8a\u75c5\u72c0\u50c5\u4fb7\u9650\u5728\u809d\u81df\nA. (1)+(2)+(3)+(4)\nB. (2)+(4)+(5)+(7)\nC. (3)+(5)+(6)+(7)\nD. (1)+(2)+(5)+(6)\nE. (4)+(5)+(6)+(7)\n": "(D)", "106-5.\n\u6709\u95dc\u6162\u6027C\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f(1)\u9577\u6548\u578b\u5e72\u64fe\u7d20 (PEG IFN) \u4f75\u7528Ribavirin \u76ee\u524d\u4ecd\u662f\u6cbb\u7642\u4e3b\u6d41\uff0c\u7279\u5225\u662f\u5728C\u809d\u75c5\u6bd2\u57fa\u56e0\u578b\u7b2c\u4e00\u578b\u60a3\u8005\uff1b(2)\u9577\u6548\u578b\u5e72\u64fe\u7d20 (PEG IFN) \u4f75\u7528Ribavirin\u4e4b\u526f\u4f5c\u7528\u5305\u62ec\uff1a\u985e\u4f3c\u6d41\u611f\u4e4b\u75c7\u72c0\uff0c\u767d\u8840\u7403 (\u4e2d\u6027\u7403) \u964d\u4f4e\u3001\u8ca7\u8840\uff1b(3)\u9577\u6548\u578b\u5e72\u64fe\u7d20 (PEG IFN) \u4f75\u7528Ribavirin\u4e4b\u526f\u4f5c\u7528\u4e0d\u5305\u62ec\uff1a\u81ea\u9ad4\u514d\u75ab\u75be\u75c5 (\u5c24\u5176\u662f\u7532\u72c0\u817a\u708e)\u3001\u6182\u9b31\uff1b(4)\u514d\u5e72\u64fe\u7d20\u5168\u53e3\u670dC\u809d\u85e5\u7269\u985e (Direct Acting Antiviral Agents, DAAs)\r\u4e4b\u526f\u4f5c\u7528\u8f03\u5c11\u4e14\u8f15\u5fae\uff0c\u5305\u62ec\uff1a\u5026\u6020\u3001\u982d\u75db\u3001\u76ae\u819a\u708e\u3001\u7761\u7720\u969c\u7919\uff1b(5)DAAs\u5c0dC\u809d\u75c5\u6bd2\u57fa\u56e0\u578b\u7b2c\u4e8c\u578b\u60a3\u8005\u4e4b\u6cbb\u7652\u7387\u53ef\u9054\u4e5d\u6210\u4e94\u4ee5\u4e0a\uff1b(6)\u6bcf\u4e00\u7a2eDAA\u7686\u53ef\u7528\u65bc\u809d\u529f\u80fd\u5df2\u5931\u4ee3\u511f\u4e4b\u809d\u786c\u5316\u75c5\u4eba(decompensated cirrhotic patients)\uff1b(7)DAAs\u4e4b\u4f7f\u7528\u9700\u7279\u5225\u6ce8\u610f\u85e5\u7269\u4ea4\u4e92\u4f5c\u7528(Drug-Drug Interactions)\nA. (7)+(6)+(5)+(3)\nB. (1)+(3)+(4)+(7)\nC. (1)+(3)+(5)+(6)\nD. (2)+(4)+(6)+(7)\nE. (3)+(4)+(6)+(7)\n": "(C)", "106-6.\n\u95dc\u65bc\u6025\u6027\u809d\u708e\u53ef\u80fd\u75c5\u56e0\u4e4b\u8a3a\u65b7\uff0c\u4e0b\u5217\u7d44\u5408\u4f55\u8005\u6b63\u78ba\uff1f(1)A\u578b\u809d\u708e\uff1aIgG Anti-HAV\uff1b(2)B\u578b\u809d\u708e\uff1aHBsAg, HBV DNA\uff1b(3)C\u578b\u809d\u708e\uff1aAnti-HCV\uff0c HCV RNA\uff1b(4)Wilson's disease: ferritin, transferrin saturation\uff1b(5)Autoimmune hepatitis: Antinuclear antibody (ANA), smooth muscle antibody\uff1b(6)Primary biliary cirrhosis: Mitochondrial antibody\nA. (1)+(3)+(5)+(6)\nB. (2)+(3)+(4)+(5)\nC. (3)+(4)+(5)+(6)\nD. (2)+(3)+(5)+(6)\nE. (1)+(2)+(3)+(5)\n": "(D)", "106-7.\n\u4e00\u4f4d\u6162\u6027B\u578b\u809d\u708e\u5973\u6027\u60a3\u8005\uff0c\u56e0\u75c5\u60c5\u6240\u9700\u670d\u7528 Entecavir (Baraclude) \u6cbb\u7642\u5df2\u6709\u5169\u5e74\u4e4b\u4e45\uff0c\u5176ALT\u53caAST\u4e5f\u4e00\u76f4\u7dad\u6301\u5728\u6b63\u5e38\u7bc4\u570d\u5167\u3002\u4f46\u662f\u6700\u8fd1\u4e00\u6b21\u6aa2\u9a57\u767c\u73feALT=100 (<41) U/L, AST=70 (< 31) U/L, HBV viral load: undetectable, Anti-HCV (+); HCV RNA: undetectable, Anti-HDV (-)\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6b64\u75c5\u4eba\u9ad4\u5167\u4e4bB\u578b\u809d\u708e\u75c5\u6bd2\u5c0d entecavir \u5df2\u7522\u751f\u6297\u85e5\u6027\nB. \u6b64\u75c5\u4eba\u4e0d\u662fC\u578b\u809d\u708e\u75c5\u6bd2 (HCV) superinfection\nC. \u6b64\u75c5\u4eba\u4e0d\u662fD\u578b\u809d\u708e\u75c5\u6bd2 (HDV) superinfection\nD. \u61c9\u52a0\u9a57 IgM Anti-HAV\nE. \u61c9\u52a0\u9a57 Antinuclear antibody (ANA)\u53caSmooth muscle antibody\n": "(A)", "106-8.\n\u6709\u95dc\u6162\u6027B\u578b\u809d\u708e\u7279\u7570\u6027\u6cbb\u7642 (PEG Interferon\u53ca\u53e3\u670d\u6297B\u809d\u75c5\u6bd2\u85e5\u7269) \u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f(1)HBeAg (+) \u60a3\u8005\uff0c\u7121\u809d\u786c\u5316\uff0cULN < ALT < 2X ULN (upper limit of normal range)\uff0c\u61c9\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff1b(2)HBeAg (-) \u60a3\u8005\uff0c\u82e5 HBV DNA \u2267 2000 IU/mL\uff0c\u4e14\u534a\u5e74\u5167\u6709\u5169\u6b21 ALT > 2X ULN (\u5f7c\u6b64\u9593\u96943\u500b\u6708\u4ee5\u4e0a)\uff0c\u61c9\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff1b(3)\u809d\u786c\u5316\u60a3\u8005\uff0c\u82e5HBV DNA  \u2267 10000 IU/mL\uff0c\u61c9\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff1b(4)\u809d\u786c\u5316\u60a3\u8005\uff0c\u5df2\u5931\u53bb\u4ee3\u511f(decompensated liver cirrhosis)\uff0c\u4e0d\u8ad6HBV\rDNA\u6aa2\u6e2c\u7d50\u679c\u70ba\u4f55\uff0c\u61c9\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff1b(5)\u5e74\u8f15\u751f\u80b2\u5e74\u9f61\u4e4b\u60a3\u8005\uff0c\u512a\u5148\u8003\u616e\u53e3\u670d\u6297B\u809d\u75c5\u6bd2\u85e5\u7269\uff1b(6)\u82e5\u6709\u6025\u6027\u767c\u4f5c\u75c5\u60c5\uff0c\u4e14Bilirubin (T)=10.5 (< 1.0), PT=17.5 (< 11), \u61c9\u5118\u901f\u7d66\u4e88PEG Interferon\u6cbb\u7642\nA. (1)+(3)+(5)\nB. (2)+(3)+(4)+(6)\nC. (3)+(4)+(5)\nD. (2)+(3)+(5)+(6)\nE. (1)+(4)+(5)+(6)\n": "(E)", "106-9.\n\u809d\u786c\u5316\u5df2\u6709\u591a\u5e74\u7684\u75c5\u4eba\u6700\u8fd1\u5e38\u56e0\u809d\u6027\u8166\u75c5\u8b8a\u4f4f\u9662\u3002\u5176\u809d\u81df\u6b98\u5b58\u529f\u80fd (liver reserve) \u4e26\u7121\u660e\u986f\u60e1\u5316\uff1b\u4f4f\u9662\u4e2d\u4ea6\u67e5\u4e0d\u51fa\u5404\u7a2e\u8a98\u56e0 (precipitating factor)\u3002\u4ed6\u4e00\u76f4\u56fa\u5b9a\u559d lactulose \u6bcf\u59293\u6b21\uff0c\u6bcf\u6b2120 ml\uff0c\u4e00\u5929\u67093~4\u6b21\u5927\u4fbf\uff1b\u6bcf\u5929\u98df\u7528\u7684\u86cb\u767d\u8cea\u4ea6\u9069\u4e2d\u3002\u52a0\u7528\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\uff0c\u4f55\u8005\u6709\u52a9\u65bc\u6e1b\u5c11\u809d\u6027\u8166\u75c5\u8b8a\u767c\u751f\u4e4b\u983b\u7387\u4e14\u4e0d\u6703\u6709\u660e\u986f\u526f\u4f5c\u7528\uff1f\nA. Rifaximin\nB. Metronidazole\nC. Neomycin\nD. Ciprofloxain\nE. Dulcocax\n": "(A)", "106-10.\n\u95dc\u65bc Ischemic Bowel Disease \u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\r(1)Ischemic colitis \u901a\u5e38\u4e0d\u6703\u4fb5\u72afrectum\uff1b(2)Ischemic colitis \u5e38\u4fb5\u72af\u53f3\u908a\u5927\u8178\uff1b(3)Systemic Lupus Erythematosis \u75c5\u4eba\u53ef\u80fd\u7f79\u60a3ischemic colitis\uff1b(4)Chronic mesenteric ischemia\u0013\u75c5\u4eba\u4e4b\u8179\u75db\u901a\u5e38\u8207\u9032\u98df\u7121\u95dc\uff1b(5)Chronic mesenteric ischemia \u53c8\u7a31intestinal angina\uff1b(6)Acute mesenteric ischemia \u5e38\u767c\u751f\u65bc\u4e2d\u8001\u5e74\u4eba( > 50\u6b72)\uff1b(7)SMA (superior mesenteric artery) embolus \u5c0e\u81f4\u7684acute mesenteric ischemia \u75c5\u4eba\uff0c\u767c\u75c5\u671f\u9593\u5176plain abdomen \u90fd\u4e0d\u6703\u6709\u4efb\u4f55\u7570\u5e38\u8868\u73fe\u3002\nA. (1)+(2)+(4)\nB. (2)+(3)+(6)\nC. (3)+(5)+(7)\nD. (2)+(4)+(7)\nE. (1)+(5)+(6)\n": "(D)", "106-11.\n\u95dc\u65bc obscure gastrointestinal bleeding \u4e4b\u78ba\u8a3a\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u61c9\u518d\u4ee5 colonoscopy\u53caesophagogastroduodenoscopy \u6392\u9664\u5e38\u898b\u7684\u51fa\u8840\u75c5\u7076\nB. Technetium-99m (Tc-99m) labeled nuclear scan \u7528\u65bc\u5075\u6e2c actively bleeding lesions\u5f88\u6709\u7528\uff0c\u53ea\u8981\u51fa\u8840\u91cf\u9054 0.1-0.5 mL/min \u5373\u53ef\uff0c\u4e5f\u80fd\u5224\u65b7\u70ba\u4f55\u7a2e\u75c5\u7076\u53ca\u5176\u89e3\u5256\u4f4d\u7f6e\u3002\nC. Angiography (celiac & mesenteric arteries) \u50c5\u80fd\u7528\u65bc active overt bleeding ( \u9700 > 1 mL/min) \u4e4b\u75c5\u4eba\uff0c\u9664\u4e86\u8a3a\u65b7\uff0c\u4e5f\u80fd\u63d0\u4f9barterial embolization \u6cbb\u7642\u3002\nD. Small-bowel barium study with enteroclysis \u73fe\u5728\u8f03\u5c11\u88ab\u7528\u70ba\u7b2c\u4e00\u7dda\u8a3a\u65b7\u5de5\u5177\nE. Single- and Double-Balloon Enterscopy\u4e0d\u9069\u7528\u65bc\u6709 radiation enteritis, severe ulceration \u53ca recent bowel surgery \u4e4b\u75c5\u4eba\n": "(B)", "106-12.\n28\u6b72\u7537\u6027\u75c5\u60a3\u56e0\u70ba\u541e\u56a5\u56f0\u96e3(dysphagia)\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u651d\u5f71\u6aa2\uff0c\u7d50\u679c\u5982\u5716\u3002\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\uff1f(1)\u53ea\u6709\u5c0d\u56fa\u614b\u98df\u7269\u6703\u6709\u541e\u56a5\u56f0\u96e3\u73fe\u8c61\uff1b(2)\u6b64\u75c5\u7684\u7522\u751f\u53ef\u80fd\u8207\u907a\u50b3\u6613\u611f\u6027(genetic susceptibility)\u52a0\u4e0a\u7b2c\u4e00\u578bHerpes simplex virus\u611f\u67d3\uff1b(3)\u98df\u9053\u6aa2\u58d3\u6e2c\u8a66(manometry)\u70ba\u6b64\u75c5\u6700\u654f\u611f\u7684\u6aa2\u67e5\uff1b(4)\u5f97\u5230\u98df\u9053\u764c\u7684\u6a5f\u7387\u548c\u4e00\u822c\u4eba\u76f8\u540c\uff1b(5)\u4ee5Calcium channel blocker\u6cbb\u7642\u6548\u679c\u826f\u597d\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(4)+(5)\nD. (2)+(3)+(4)\nE. (2)+(4)+(5)\n": "(C)", "106-13.\n\u60a3\u8005\u56e0\u4e0a\u8179\u60b6\u75db\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\uff0c\u767c\u73fe\u5341\u4e8c\u6307\u8178\u6f70\u760d\uff0c\u80c3\u93e1\u5207\u7247\u5feb\u901f\u5c3f\u7d20\ufffdC\u6aa2\u67e5(rapid urease test)\u5448\u73fe\u967d\u6027\uff0c\u75c5\u60a3\u4e26\u672a\u670d\u7528\u6d88\u708e\u6b62\u75db\u5291\uff0c\u4f46\u5c0d\u76e4\u5c3c\u897f\u6797(penicillin)\u904e\u654f\u3002\u7d93\u670d\u752814\u5929omeprazole\u3001metronidazole\u53caclarithromycin\u5f8c\uff0c\u63a5\u53d7\u5c3f\u7d20\u547c\u5438\u6e2c\u8a66(urea breath test)\u7d50\u679c\u967d\u6027\uff0c\u9664\u4e86\u518d\u5ea6\u7d66\u4e88\u8cea\u5b50\u5e6b\u6d66\u6291\u5291(proton pump inhibitor)\u5916\uff0c\u4e0b\u5217\u4f55\u9805\u8655\u65b9\u6700\u9069\u5408\u6b64\u4f4d\u60a3\u8005\uff1f\nA. amoxicilin\u548clevofloxacin\nB. bismuth subsalicylate, metronidazole\u548ctetracycline\nC. clarithromycin\u548camoxicillin\nD. clarithromycin\u548cmetronidazole\nE. trimethoprim-sulfamethoxazole\u548cerythromycin\n": "(B)", "106-14.\n\u6709\u95dc\u81bd\u9178(bile acid)\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u662f\uff1f(1)\u81bd\u9178\u4e3b\u8981\u7531\u809d\u81df\u5408\u6210\u800c\u4f86\uff0c\u81b3\u98df(diet)\u4e2d\u4e26\u7121\u81bd\u9178\u6210\u4efd\uff1b(2)\u6b21\u7d1a(secodary)\u81bd\u9178\u5305\u62ecchenodeoxycholic acid\u548clithocholic acid\u5169\u7a2e\uff1b(3)\u81bd\u9178\u5206\u6ccc\u81f3\u8178\u9053\u5f8c\u4e3b\u8981\u5728\u5927\u8178\u518d\u5438\u6536\uff1b(4)\u6162\u6027\u809d\u75c5\uff0c\u5982\u539f\u767c\u6027\u81bd\u9053\u809d\u786c\u5316(primary biliary cirrhosis)\uff0c\u53ef\u56e0\u70ba\u81bd\u9178\u5408\u6210\u53ca\u5206\u6ccc\u7570\u5e38\u9020\u6210\u8102\u80aa\u6027\u8179\u7009(steatorrhea)\uff1b(5)\u81bd\u9178\u5408\u6210\u4e3b\u8981\u53d7\u81bd\u56fa\u9187degradation\u9175\u7d207\u03b1-hydroxylase\u8abf\u63a7\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(4)+(5)\nD. (2)+(3)+(4)\nE. (2)+(3)+(5)\n": "(C)", "106-15.\n20\u6b72\u7537\u6027\uff0c\u8179\u7009\u8d85\u904e1\u500b\u6708\uff0c\u5927\u4fbf\u5e36\u9ecf\u6db2\u53ca\u8840\u6db2\uff0c\u4e14\u51fa\u73fe\u95dc\u7bc0\u75bc\u75db\u73fe\u8c61\uff0c\u6709\u76ae\u819a\u75c5\u7076(\u5982\u5716)\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1f\nA. \u5927\u8178\u6fc0\u71e5\u75c7(irritable bowel syndrome)\nB. \u670d\u7528\u6297\u751f\u7d20\u5f15\u8d77\u4e4b\u8178\u708e\nC. \u6162\u6027\u80f0\u81df\u708e\nD. \u5c0f\u8178\u5bc4\u751f\u87f2\u611f\u67d3\uff0c\u5982Giardia\nE. \u514b\u9686\u6c0f\u75c7(Crohn's disease)\n": "(E)", "106-16.\n34\u6b72\u5973\u6027\u56e0\u6301\u7e8c\u6027\u4e0a\u8179\u75db\u53cd\u5c04\u81f3\u80cc\u90e8\u3001\u5641\u5fc3\u3001\u5614\u54105\u5929\uff0c\u8a3a\u65b7\u70ba\u9152\u7cbe\u76f8\u95dc\u80f0\u81df\u708e\u800c\u4f4f\u9662\u63a5\u53d7\u9032\u4e00\u6b65\u8a55\u4f30\u3002\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab38.2\u2103\uff0c\u8840\u58d3132/84mmHg\u3001\u8108\u640f101/min\u3001\u547c\u543820/min\u3001\u978f\u819c\u7121\u9ec3\u81bd\u3001\u8179\u90e8\u7030\u6f2b\u6027\u58d3\u75db\u4e14\u8178\u97f3\u70bahypoactive\u3002\u8840\u6db2\u6aa2\u67e5WBC:15400/\u03bcL\u3001AST:189U/L\u3001ALT:151U/L\u3001Bilirubin(total):1.1mg/dL\u3001amylase:388U/L\u3001lipase:924U/L\u3002\u96fb\u8166\u65b7\u5c64\u986f\u793a\u80f0\u81df\u7030\u6f2b\u6027\u6c34\u816b\uff0c\u4e14\u6709peripancreatic fluid collection\uff0c\u4f46\u7121\u58de\u6b7b\u73fe\u8c61\u3002\u6700\u9069\u5408\u7684\u4e0b\u4e00\u6b65\u6cbb\u7642\u70ba\u4f55\uff1f\nA. enteral nutrition by nasojejunal feeding tube\nB. intravenous imipenem\nC. pancreatic debridemet\nD. parenteral nutrition\nE. oral metronidazole\n": "(A)", "106-17.\n68\u6b72\u7537\u6027\u6709\u9157\u9152\u75c5\u53f2\uff0c\u56e0\u9593\u6b47\u6027\u8179\u75db\u5408\u4f75\u8179\u70097\u500b\u6708\u81f3\u6025\u8a3a\uff0c\u75c5\u60a3\u4e26\u672a\u670d\u7528\u4efb\u4f55\u85e5\u7269\u3002\u8eab\u9ad4\u6aa2\u67e5\u4e26\u7121\u767c\u71d2\uff0cBP:108/72mmHg\u3001\u8108\u640f:80/min\u3001\u547c\u543816/min\uff0c\u809a\u5b50\u4e26\u7121\u58d3\u75db\u4e5f\u672a\u6709\u8179\u8139\u3002\u8840\u6db2\u6aa2\u67e5AST:155U/L\u3001ALT:88U/L\u3001ALP:96U/L\u3001Bilirubin(total):1.1mg/dL\u3001amylase:65U/L\u3001lipase:70U/L\u3002\u7cde\u4fbf\u6aa2\u67e5\u6709\u8102\u80aa\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\u6cbb\u7642\uff1f\nA. fiber\nB. cholestyramine\nC. loperamide\nD. pancreatic enzyme\nE. ciprofloxacin\n": "(D)", "106-18.\n81\u6b72\u5a66\u5973\u67093\u500b\u6708\u8179\u75db\u53ca\u80cc\u75db\uff0c\u5408\u4f75\u98df\u617e\u4e0d\u632f\u53ca\u9ad4\u91cd\u6e1b\u8f1511\u516c\u65a4\uff0c\u6700\u8fd12\u9031\u51fa\u73fe\u9ec3\u75b8\u53ca\u76ae\u819a\u6414\u7662\u3002\u8840\u6db2\u6aa2\u67e5WBC:13200/\u03bcL\u3001Bilirubin(total):12.4mg/dL\u3001ALP:784U/L\u3001CA19-9:822U/L\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u65bc\u80f0\u81df\u982d\u67093.2\u516c\u5206\u816b\u7624\u5408\u4f75\u80f0\u7ba1\u548c\u81bd\u7ba1\u64f4\u5f35\u53ca\u809d\u81df\u591a\u9846\u816b\u7624\uff0c\u5167\u8996\u93e1\u8d85\u97f3\u6ce2\u5408\u4f75\u80f0\u81df\u982d\u90e8\u816b\u7624\u5207\u7247\u4e4b\u75c5\u7406\u70ba\u817a\u764c(adenocarcinoma)\u3002\u4e0b\u5217\u4f55\u9805\u8655\u7f6e\u5c0d\u75c5\u60a3\u6700\u6070\u7576\uff1f\nA. \u809d\u81df\u5207\u7247\nB. \u81bd\u9053\u652f\u67b6\u7f6e\u653e\nC. \u80f0\u81df\u548c\u809d\u81df\u653e\u5c04\u6cbb\u7642\nD. \u624b\u8853\u5207\u9664\u80f0\u81df\u816b\u7624\nE. \u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\n": "(B)", "106-19.\n57\u6b72\u5973\u6027\u56e0\u6025\u6027\u5de6\u4e0b\u8179\u75db\u3001\u8179\u7009\u3001\u5641\u5fc3\u81f3\u6025\u8a3a\uff0c\u9ad4\u6eab38.1\u2103\uff0cBP:115/76mmHg\u3001\u8108\u640f:98/min\uff0c\u5de6\u4e0b\u8179\u6709\u6309\u58d3\u75db\uff0c\u4f46\u7121\u53cd\u5f48\u75db\u4e5f\u7121\u816b\u584a\u3002WBC:14900/\u03bcL\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u4e59\u72c0\u7d50\u8178\u6709diverticula\u4e14\u6709pericolic fatty infiltration\u53cabowel wall thickening\u3002\u4f46\u7121\u81bf\u760d\u3001\u963b\u585e\u6216\u5ed4\u7ba1\u3002\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u8655\u7f6e\u70ba\uff1f\nA. \u4e59\u72c0\u7d50\u8178\u93e1\u6aa2\u67e5\nB. \u5168\u5927\u8178\u93e1\u6aa2\u67e5\nC. \u53e3\u670dcephalexin\u6cbb\u7642\nD. \u53e3\u670dciprofloxacin\u548cmetronidazole\u6cbb\u7642\nE. \u5916\u79d1\u5207\u9664\n": "(D)", "106-20.\n30\u6b72\u7537\u6027\uff0c4\u5e74\u524d\u88ab\u8a3a\u65b7B\u578b\u809d\u708e\uff0c\u6700\u8fd13\u9031\u6709\u75b2\u5026\u3001\u9ec3\u81bd\u73fe\u8c61\u3002\u75c5\u60a3\u5076\u723e\u559d\u4e00\u74f6\u5564\u9152\uff0c\u4e26\u7121\u670d\u7528\u4efb\u4f55\u85e5\u7269\u3002\u8eab\u9ad4\u6aa2\u67e5:\u9ad4\u6eab36.1\u2103\u3001\u8840\u58d3120/65mmHg\u3001\u8108\u640f100/min\u3001\u547c\u543816/min\uff0c\u53f3\u4e0a\u8179\u6709\u8f15\u5ea6\u58d3\u75db\u3002\u8840\u6db2\u6aa2\u67e5:Bilirubin(T)/(D):3.8/1.8mg/dL\u3001AST:1100U/L\u3001ALT:1450U/L\u3001PT INR:1.2\u3001HBsAg(+)\u3001IgG-anti-HBc(+)\u3001IgM-anti-HBc(-)\u3001HBV-DNA<20U/L\u3001anti-HCV(-)\uff0c\u8d85\u97f3\u6ce2\u50c5\u767c\u73fe\u809d\u81df\u5be6\u8cea\u70baheterogeneous echotexture\uff0c\u7121\u5176\u5b83\u7570\u5e38\u3002\u6b64\u75c5\u60a3\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\uff1f\nA. \u6025\u6027\u9152\u7cbe\u6027\u809d\u708e\nB. \u6025\u6027\u81bd\u56ca\u708e\nC. \u809d\u7d30\u80de\u764c\nD. B\u578b\u809d\u708e\u75c5\u6bd2\u518d\u6d3b\u5316(reactivated HBV infection)\nE. D\u578b\u809d\u708e\u75c5\u6bd2superinfection\n": "(E)", "106-21.\n51\u6b72\u7537\u6027\u56e0\u534a\u5e74\u5641\u5fc3\u3001\u8179\u8139\u3001\u548c\u8179\u7009\u5165\u9662\u6aa2\u67e5\u3002\u5641\u5fc3\u548c\u8179\u8139\u5728\u98ef\u5f8c\u4e00\u5c0f\u6642\u767c\u751f\u4e14\u5408\u4f75\u6fc0\u70c8\u8178\u5b50\u8815\u52d5\u53ca\u5fc3\u60b8\u3002\u9ad8\u8102\u98f2\u98df\u4e26\u4e0d\u6703\u52a0\u91cd\u75c7\u72c0\u7522\u751f\uff0c\u4e5f\u6c92\u6709\u8179\u75db\u6216\u9ad4\u91cd\u6e1b\u8f15\u3002\u500b\u68489\u500b\u6708\u524d\u56e0perforated peptic ulcer\u63a5\u53d7distal gastrectomy\u624b\u8853\uff0c\u8853\u5f8c\u4e26\u672a\u670d\u7528\u85e5\u7269\u3002\u8eab\u9ad4\u6aa2\u67e5BMI:24\uff0c\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a\u4e14\u6b63\u5e38\uff0c\u8178\u97f3\u70bahyperactive\u3002\u8840\u6db2\u6aa2\u67e5\u5305\u62ecCBC\u548c\u751f\u5316\u5747\u6b63\u5e38\u3002\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u767c\u73fe\u624b\u8853\u543b\u5408\u8655\u6b63\u5e38\u4e14\u66a2\u901a\uff0c\u5207\u7247\u53ca\u5c0f\u8178\u6db2\u5206\u6790\u4e5f\u6b63\u5e38\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1f\nA. carcinoid syndrome\nB. chronic mesenteric ischemia\nC. dumping syndrome\nD. gastrinoma\nE. irritable bowel syndrome\n": "(C)", "106-22.\n75\u6b72\u5973\u6027\u4e00\u65e9\u8d77\u5e8a\u6709\u8179\u90e8\u7d5e\u75db\u3001\u8179\u7009\u4e8c\u6b21\uff0c\u4e14\u5408\u4f75\u89e3\u51fa\u9bae\u8840\u3002\u75c5\u60a3\u6709\u9ad8\u8840\u58d3\u53ca\u51a0\u72c0\u52d5\u8108\u75be\u75c5\u75c5\u53f2\uff0c\u670d\u7528\u85e5\u7269\u5305\u62ecaspirin, ramipril, metoprolol\u548csimvastatin\u30026\u500b\u6708\u524d\u5927\u8178\u93e1\u6aa2\u67e5\u6b63\u5e38\u3002\u81f3\u6025\u8a3a\u4e4b\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab36.8\u2103\u3001\u8840\u58d3130/80mmHg\u3001\u8108\u640f70/min\u3001\u547c\u543814/min\uff0c\u5de6\u4e0b\u8179\u6709\u58d3\u75db\uff0c\u76f4\u8178\u809b\u8a3a\u6709\u9bae\u8840\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u4e4b\u4e59\u72c0\u7d50\u8178\u6709\u5c40\u90e8\u589e\u539a\u73fe\u8c61\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. Crohn's disease\nB. ulcerative colitis\nC. microscopic colitis\nD. ischemic colitis\nE. CMV colitis\n": "(D)", "107-1.\n\u95dc\u65bc\u6839\u9664\u80c3\u90e8\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u80c3\u90e8\u7684MALT (Mucosa-Associated Lymphoid Tissue) \u6dcb\u5df4\u7624\uff0c\u65bc\u6839\u9664\u80c3\u90e8\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u5f8c\uff0c\u6709\u6a5f\u6703\u6d88\u5931\nB. \u9006\u6d41\u6027\u98df\u9053\u708e\u4e4b\u75c5\u4eba\uff0c\u8981\u7a4d\u6975\u6839\u9664\u5176\u80c3\u90e8\u4e4b\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\uff0c\u4ee5\u514d\u884d\u751f\u98df\u9053\u764c\nC. Probiotics\uff0c\u5982\uff1aLactobacillus spp \u53ca Saccharomyces spp\uff0c \u4e4b\u670d\u7528\u53ef\u589e\u52a0\u80c3\u90e8\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u6839\u6cbb\u4e4b\u6a5f\u7387\nD. \u7d50\u675f\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u6839\u9664\u6cbb\u7642\u5f8c\uff0c\u81f3\u5c11\u8981\u7b49 2 \u9031\u5f8c\u624d\u80fd\u63a5\u53d7 urea breath test \u4f86\u78ba\u8a8d\u662f\u5426\u5df2\u6839\u9664\nE. \u80c3\u90e8\u5e7d\u9580\u87ba\u65cb\u687f\u83cc\u6839\u9664\u5f8c\uff0c\u518d\u611f\u67d3\u7387\u7d04\u670940%\n": "(A)", "107-2.\n\u6709\u95dc\u80c3\u5167Helicobacter pylori (H. pylori) \u4e4b\u5075\u6e2c\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u670d\u7528\u6297\u751f\u7d20\u6703\u5f71\u97ff rapid urease test (CLO test) \u4e4b\u6e96\u78ba\u5ea6\nB. \u670d\u7528 PPI (Proton Pump Inhibitors) \u6703\u5f71\u97ff urea breath test \u4e4b\u6e96\u78ba\u5ea6\nC. \u8840\u6e05 H. pylori \u4e4b IgG antibody test \u6709\u5f88\u597d\u7684 negative predictive value\nD. urea breath test \u53ef\u8fa8\u8a8d\u80c3\u5167 H. pylori \u4e4b\u5b58\u5728 (active infection)\uff0cfecal antigen test \u5247\u5426\nE. \u8840\u6e05 H. pylori \u4e4bIgG antibody test \u4e0d\u9069\u5408\u7528\u4f86\u5224\u65b7 H. pylori \u6839\u9664\u6cbb\u7642\u4e4b\u6548\u679c\n": "(D)", "107-3.\n\u76ee\u524d\u5c0d\u6162\u6027\uff23\u578b\u809d\u708e\u60a3\u8005\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4ee5\u5e72\u64fe\u7d20\uff08interferon)\u70ba\u57fa\u790e\u4e4b\u6cbb\u7642\u5df2\u975e\u512a\u5148\u65b9\u5f0f\nB. \u53e3\u670d\u4e0d\u542b\u5e72\u64fe\u7d20\u4e4b\u65b0\u85e5\uff08direct acting antiviral agents, DAA\uff09\u4e4b\u6cbb\u7652\u7387\u5927\u591a\u53ef\u9054\u4e5d\u6210\u4ee5\u4e0a\nC. DAA\u4e4b\u7642\u7a0b\u591a\u572812-24\u9031\nD. DAA\u4e4b\u526f\u4f5c\u7528\u8f03\u5c11\u4e14\u8f15\u5fae\uff0c\u75c5\u4eba\u4e4b\u9806\u5f9e\u6027\u9ad8\nE. DAA\u8207\u5176\u5b83\u85e5\u7269\u5f88\u5c11\u6709drug interaction\n": "(E)", "107-4.\n\u4e0b\u5217\u5404\u9805\u4f55\u8005\u975e\u80c3\u817a\u764c(gastric adenocarcinoma)\u4e4b\u5371\u96aa\u56e0\u5b50(risk factors)\uff1f(1). Peutz-Jeghers syndrome (2). hereditary hemorrhagic telangiectasia (3). Helicobacter pylori infection (4). subtotal gastrectomy (5). drinking\nA. (1)+(4)+(5)\nB. (2)+(5)\nC. (3)+(4)\nD. (4)+(5)\nE. (2)+(3)\n": "(B)", "107-5.\n\u6162\u6027B\u578b\u809d\u708e\u73fe\u5728\u5df2\u6709\u8a31\u591a\u5177\u7279\u7570\u7642\u6548\u4e4b\u85e5\u7269\u53ef\u7528\u4f86\u63a7\u5236\u75c5\u60c5\uff0c\u4e0b\u5217\u76f8\u95dc\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f (1). PEG IFN \u6709\u76f8\u7576\u4e0d\u932f\u7684\u7642\u6548(\u8840\u6e05 e \u6297\u539f\u8f49\u63db\u6210 e \u6297\u9ad4\uff0c\u4e14 ALT\u503c\u6062\u5fa9\u6b63\u5e38)\uff0c\u4f46\u5fa9\u767c\u7387\u905440% (2). PEG IFN \u4e0d\u80fd\u7528\u65bc decompensated patients (3). \u53e3\u670d\u6297B\u809d\u75c5\u6bd2\u85e5\u7269 (nucleot(s)ide analogues) \u526f\u4f5c\u7528\u5c11\u4e14\u5c0f\uff0c\u4f46\u7642\u7a0b\u9577\u77ed\u4e0d\u80fd\u4e8b\u524d\u78ba\u5b9a (4). \u8840\u6e05 HBeAg (-)\u3001HBV DNA < 1,000 IU/mL\u3001ALT\u503c\u6b63\u5e38\u4e14\u7121\u809d\u786c\u5316\u4e4b\u75c5\u4eba\uff0c\u4e0d\u5efa\u8b70\u63a5\u53d7\u6cbb\u7642 (5). \u5df2\u6709\u809d\u786c\u5316\u4e4bB\u809d\u75c5\u4eba\u7686\u61c9\u63a5\u53d7\u7279\u7570\u6027\u6cbb\u7642 (6). cytotoxic chemotherapy\r\u53ef\u80fd\u5c0e\u81f4\u672c\u4f86\u4e0d\u6d3b\u52d5\u7684\u6162\u6027B\u578b\u809d\u708e\u51fa\u73fe\u6025\u6027\u767c\u4f5c\uff0c\u76ee\u524d\u5efa\u8b70\u65bc\u6cbb\u7642\u671f\u9593\u5bc6\u5207\u8ffd\u8e64B\u809d\u75c5\u60c5\uff0c\u4e00\u65e6\u767c\u751f\u6025\u6027\u767c\u4f5c\u518d\u958b\u59cb\u4f7f\u7528\u53e3\u670d\u6297B\u809d\u75c5\u6bd2\u85e5\u7269\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)+(6)\nE. (1)+(4)+(5)+(6)\n": "(C)", "107-6.\n\u95dc\u65bc\u81bd\u56ca\u75be\u75c5\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f (1). porcelain gallbladder \u4e00\u822c\u5efa\u8b70\u63a5\u53d7 cholecystectomy (2). gallbladder polyp > 10 mm \u4f75\u6709 gallstones\uff0c\u5373\u4f7f\u6c92\u6709\u75c7\u72c0\uff0c\u4ecd\u61c9\u8003\u616e\u63a5\u53d7 cholecystectomy (3). pure cholesterol gallstones \u7686\u53ef\u7528UDCA (ursodeoxycholic acid) \u5c07\u4e4b\u5b8c\u5168\u6d88\u9664 (4). \u76f4\u5f91\u5927\u65bc3\u516c\u5206\u4e4b gallstones\uff0c\u7947\u8981\u6c92\u6709\u75c7\u72c0\uff0c\u4e0d\u5fc5\u63a5\u53d7 cholecystectomy (5). 60 \u6b72\u4ee5\u5f8c\u624d\u767c\u751f gallstone\uff0c\u8f03\u6703\u51fa\u73fe\u75c7\u72c0\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(3)+(4)\n": "(A)", "107-7.\n\u4e0b\u5217\u5404\u9805\u95dc\u65bc\u98df\u9053\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. esophageal diverticulum \u901a\u5e38\u56e0\u4f75\u6709\u5176\u5b83\u98df\u9053\u72c0\u6cc1(\u5982\uff1aachalasia) \u624d\u6703\u51fa\u73fe\u75c7\u72c0\uff0c\u8207\u5176\u5927\u5c0f\u7121\u95dc\nB. \u7a4d\u6975\u4f7f\u7528PPI therapy \u53ef\u660e\u986f\u6e1b\u5c11 Barrett's esophagus \u884d\u751f adenocarcinoma \u4e4b\u6a5f\u7387\nC. Barrett's esophagus with high-grade dysplasia \u61c9\u8003\u616e\u4ee5endoscopic mucosal resection\u3001radiofrequency ablation \u6216 photodynamic therapy \u9664\u53bb\u4e4b\nD. \u98df\u9053\u7684 motor disorders \u53ca diverticula \u53ef\u80fd\u6703\u5c0e\u81f4 Candida esophagitis\nE. \u98df\u9053\u7684 hypotensive disorders \u53ef\u80fd\u6703\u52a0\u91cd gastroesophageal reflux disease\n": "(B)", "107-8.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u809d\u529f\u80fd\u7570\u5e38\u6c42\u91ab\uff0c\u5176\u62bd\u8840\u6578\u503c\u5982\u4e0b\uff1aAST (GOT) = 80 (< 31) U/L\uff0cALT (GPT) = 70 (< 41) U/L\uff0cALP = 450 (< 104) U/L\uff0cGGT = 400 (< 64) U/L\uff0cBil(T) = 0.9 (< 1.0) mg/dL\uff0cBil(D) = 0.2 (< 0.18) mg/dL\u3002\u6700\u8fd13\u500b\u6708\u4ed6\u611f\u5230\u5026\u6020\uff0c\u4f46\u81ea1\u5e74\u524d\u958b\u59cb\u5373\u4e0d\u5b9a\u6642\u6709\u8179\u7009\uff0c\u6709\u6642\u6df7\u6709\u8840\u4fbf\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u7121\u7570\u5e38\u767c\u73fe\uff1b\u96fb\u8166\u65b7\u5c64\u4ea6\u672a\u767c\u73fe\u809d\u3001\u81bd\u3001\u80f0\u816b\u7624\uff0c\u4ea6\u7121\u809d\u5167\u81bd\u7ba1\u53ca\u809d\u5916\u81bd\u7ba1\u7570\u5e38\u64f4\u5927\u73fe\u8c61\uff1b\u4f46\u78c1\u632f\u9020\u5f71 (MRI + MRCP)\u5247\u986f\u793a\u7b26\u5408\u539f\u767c\u6027\u786c\u5316\u6027\u81bd\u7ba1\u708e\u4e4b\u8868\u73fe (primary sclerosing cholangitis)\u3002\r\u5c0d\u9019\u4f4d\u75c5\u4eba\uff0c\u76ee\u524d\u6700\u8feb\u5207\u9700\u8981\u5b89\u6392\u7684\u6aa2\u67e5\u70ba\u4e0b\u5217\u4f55\u8005\uff1f\nA. Liver biopsy\nB. Endoscopic ultrasound (EUS)\nC. Endoscopic retrograde cholangiopancreatography (ERCP)\nD. Colonoscopy\nE. Serum IgG4 measurement\n": "(D)", "107-9.\n\u4e00\u4f4d40\u6b72\u5973\u6027\u75c5\u4eba\u70ba\u6162\u6027B\u578b\u809d\u708e\u75c5\u6bd2\u611f\u67d3\u8005\uff0c\u5728\u9580\u8a3a\u8ffd\u8e64\u4e2d\u88ab\u767c\u73fe\u6709\u8179\u6c34\uff0c\u4e14\u9010\u6f38\u8b8a\u591a\uff0c\u6162\u6162\u7684\u5169\u908a\u5c0f\u817f\u53ca\u8173\u80cc\u4e5f\u51fa\u73fe\u6c34\u816b\uff0c\u76ee\u524d\u6c92\u6709exertional dyspnea\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u5169\u908a\u9838\u975c\u8108\u660e\u986f\u8139\u5927\uff0c\u5fc3\u81df\u7121\u96dc\u97f3\u3002\u8179\u90e8\u5fae\u8139\uff0c\u6572\u4e4b\u6709shifting dullness\u3002\u5169\u908a\u4e0b\u80a2\u6709pitting edema\u3002\u8840\u6db2\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aAlbumin = 3.5 ( > 3.5) g/dL\uff0cAST = 25 (< 31) U/L\uff0c ALT = 30 (< 41) U/L\uff0cBil(T) = 0.9 (< 1.0) mg/dL\uff0cProthrombin time = 10.0\" (INR = 0.99)\uff0cPlatelet = 175 (> 150) K/ul\u3002\u8179\u6c34\u62bd\u53d6\u9001\u9a57\u4e4b\u7d50\u679c\u70ba Albumin = 2.3 g/dL\uff0cTotal protein = 3.5 g/dL\uff0c WBC =\r120/uL\uff0cneutrophil 30%\u3002\r\u9019\u4f4d\u75c5\u4eba\u8179\u6c34\u6700\u53ef\u80fd\u7684\u75c5\u56e0\u70ba\u4e0b\u5217\u4f55\u8005\uff1f\nA. Postnecrotic cirrhosis\nB. Alcoholic cirrhosis\nC. Tuberculous peritonitis\nD. Constrictive pericarditis\nE. Congestive heart failure\n": "(D)", "107-10.\n\u4e00\u4f4d\u6162\u6027C\u578b\u809d\u708e\u4f75\u6709\u809d\u786c\u5316\u7684\u60a3\u8005\u56e0\u610f\u8b58\u4e0d\u6e05\u800c\u5165\u9662\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8179\u90e8\u8139\u5927\u4e14\u6709shifting dullness\uff0c\u53f3\u80f8\u4e0b\u534a\u547c\u5438\u97f3\u807d\u4e0d\u898b\uff0c\u5169\u5074\u4e0b\u80a2\u6709pitting edema\u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1aAmmonia N (NH3) = 130 (< 37) umol/L\uff0cAlbumin = 2.4 (> 3.5) g/dL\uff0cAST = 50 ( < 31) U/L\uff0cALT = 35 (<41) U/L\uff0cBil(T) = 1.5 (< 1.0) mg/dL\uff0cBil(D) = 0.8 (<0.18) mg/dL\uff0cNa = 125 (> 135) mmol/L\uff0c Cr = 1.6 (<1.3) mg/dL (\u672c\u75c5\u4eba\u904e\u53bb\u2266 1.2 mg/dL)\uff0cBUN = 40 (< 25) mg/dL\uff0cPT = 13.0\" (INR = 1.25)\u3002\u62bd\u53d6\u8179\u6c34\u9001\u7d50\u679c\u5982\u4e0b\uff1aAlb = 1.0 g/dL\uff0cWBC = 900\r/ul\uff0cneutrophil\u4f5470%\u3002\u4e0b\u5217\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u5408\u5b9c\u7684\uff1f (1). intravenous cefotaxime (2). 3% saline solution (3). albumin infusion (4). lactulose (5). anticholinergic agent\nA. (1)+(3)+(4)\nB. (1)+(4)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (2)+(4)+(5)\n": "(A)", "107-11.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u7a81\u767c\u53f3\u4e0a\u8179\u75db\u53ca\u767c\u71d2\u800c\u9001\u81f3\u6025\u8a3a\u5ba4\uff0c\u904e\u53bb\u5076\u800c\u6703\u6709\u53f3\u4e0a\u8179\u75db\u4e4b\u75c5\u60c5\u3002\u5176\u9ad4\u6eab\u9ad8\u905439.0C\uff0c\u8108\u640f\u6578\u70ba105\u4e0b/\u5206\u9418\uff0c\u8840\u58d3120/80 mmHg\uff0c\u978f\u819c\u53ca\u76ae\u819a\u6cdb\u9ec3\uff0c\u53f3\u4e0a\u8179\u90e8\u6709\u58d3\u75db\uff0c\u7121shifting dullness\u3002\u62bd\u8840\u6aa2\u9a57\u4e4b\u7d50\u679c\u5982\u4e0b\uff1aWBC = 15,000/ ul\uff0cSeg. 85%\uff0cAST = 250 (<31) U/L\uff0cALT = 220 (<41) U/L\uff0cALP = 220 (<104) U/L\uff0cGGT = 300 (< 64) U/L\uff0cBil(T) = 5.0 (< 1.0) mg/dL\uff0cBil(D) = 3.4 (< 0.18)\rmg/dL\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u809d\u5167\u81bd\u7ba1\u53ca\u8fd1\u7aef\u7e3d\u81bd\u7ba1\u8139\u5927\uff0c\u4f46\u9060\u7aef\u7e3d\u81bd\u7ba1\u88ab\u8178\u6c23\u906e\u4f4f\u800c\u770b\u4e0d\u5230\uff0c\u4e3b\u80f0\u7ba1\u76f4\u5f91\u6b63\u5e38\u3002\u81bd\u56ca\u5167\u6709\u7d50\u77f3\uff0c\u4f46\u81bd\u56ca\u58c1\u6b63\u5e38\u4e14\u81bd\u56ca\u5468\u570d\u6c92\u6709\u7570\u5e38\u6db2\u9ad4\u3002\u91dd\u5c0d\u75c5\u4eba\u76ee\u524d\u75c5\u60c5\uff0c\u4e0b\u5217\u5404\u9805\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u8feb\u5207\u4e14\u5408\u5b9c\u7684\uff1f (1). Endoscopic retrograde cholangiopancreatography (ERCP) (2). Percutaneous cholecystostomy (3). Cholecystectomy (4). Percutaneous transhepatic cholangiography & drainage (PTCD) (5). Intravenous broad-spectrum antibiotics\nA. (1)+(2)\nB. (2)+(4)\nC. (1)+(5)\nD. (3)+(4)\nE. (3)+(5)\n": "(C)", "107-12.\n22\u6b72\u7537\u6027\u670910\u5e74\u80f8\u9aa8\u5f8c\u707c\u71b1\u611f(retrosternal burning)\u75c5\u53f2\uff0c\u61f7\u7591\u80c3\u98df\u9053\u9006\u6d41\u75be\u75c5\uff0c\u96d6\u7136\u65e9\u9910\u524d30\u5206\u9418\u7d66\u4e88omeprazole 20mg\uff0c\u4e5f\u907f\u514d\u523a\u6fc0\u6027\u98df\u7269\uff0c\u4e14\u7761\u89ba\u6642\u6795\u982d\u588a\u9ad8\uff0c\u4f46\u662f\u707c\u71b1\u611f\u53ca\u9006\u6d41\u4ecd\u6301\u7e8c\u3002\u6700\u8fd12\u5e74\u56fa\u9ad4\u98df\u7269\u6709\u541e\u56a5\u56f0\u96e3(dysphagia)\u73fe\u8c61\uff0c\u4f46\u4e26\u7121\u9ad4\u91cd\u6e1b\u8f15\u3002\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\u98df\u9053\u5207\u7247\u6b63\u5e38\uff0c\u56e0\u75c7\u72c0\u6301\u7e8c\u63a5\u53d7\u98df\u9053high-resolution manometry\u6aa2\u67e5\u7d50\u679c\u5982\u9644\u8868\u6240\u793a\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u5408\u9069\u4e4b\u6cbb\u7642\uff1f\nA. 360\u5ea6Nissen fundoplication\nB. Heller myotomy & partial fundoplication\nC. omeprazole\u6539\u621020mg bid\nD. omeprazole\u63db\u6210esomeprazole\nE. omeprazole\u63db\u6210nortriptyline\n": "(B)", "107-13.\n60\u6b72\u80a5\u80d6\u7537\u6027\u6709\u9577\u671f\u80f8\u53e3\u707c\u71b1\u75c5\u53f2\uff0c\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u5176\u98df\u9053\u4e0b\u7aef\u4e4b\u8b8a\u5316\u5982\u5716\u6240\u793a\uff0c\u6b64\u75c5\u4eba\u6bcf\u5e74\u767c\u751f\u98df\u9053\u764c\u4e4b\u6a5f\u6703\u70ba\uff1f\nA. 0.01~0.03%\nB. 0.1~0.3%\nC. 0.6~1%\nD. 1~3%\nE. 3~5%\n": "(B)", "107-14.\n\u80c3\u58c1\u7d30\u80de(gastric parietal cell)\u975c\u614b\u53ca\u523a\u6fc0\u72c0\u614b\u5982\u5716\u793a\uff0c\u6839\u64da\u6b64\u5716\uff0c\u4e0b\u5217\u90a3\u9805\u85e5\u7269\u70ba\u6700\u5f37\u80c3\u9178\u6291\u5236\u5291\uff1f\nA. famotidine\nB. hyoscine butylbromide\nC. lansoprazole\nD. dexlansoprazole\nE. vonoprazan\n": "(E)", "107-15.\n\u4e0b\u5217\u6709\u95dc\u81bd\u9178(bile acid)\u53ca\u5176\u8178\u809d\u5faa\u74b0(enterohepatic circulation)\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u662f\uff1f (1). \u81bd\u9178\u4e3b\u8981\u7531\u98f2\u98df\u800c\u4f86 (2). chenodoxycholic acid\u70ba\u6b21\u7d1a\u81bd\u9178 (3). \u81bd\u9178\u5206\u6ccc\u5f8c\u4e3b\u8981\u65bc\u8ff4\u8178(ileum)\u5438\u6536 (4). \u963b\u65b7\u81bd\u9178\u4e4b\u8178\u809d\u5faa\u74b0\u53ef\u6e1b\u5c11\u8840\u4e2d\u81bd\u56fa\u9187\u503c (5).\u81bd\u9178\u6392\u6cc4\u7570\u5e38\u53ef\u9020\u6210\u8102\u80aa\u4fbf(steatorrhea)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)\nE. (2)+(3)+(5)\n": "(C)", "107-16.\n\u4e0b\u5217\u6709\u95dc\u767c\u708e\u6027\u8178\u9053\u75be\u75c5(inflammatory bowel disease)\u4e4b\u6d41\u884c\u75c5\u5b78\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\uff1f (1). \u767d\u4eba\u8f03\u4e9e\u6d32\u4eba\u767c\u751f\u7387\u70ba\u9ad8 (2). \u62bd\u7159\u53ef\u9810\u9632\u514b\u9686\u6c0f(Crohn's disease) (3). \u76f2\u8178\u5207\u9664(appendectomy)\u53ef\u589e\u52a0\u6f70\u760d\u6027\u8178\u708e(ulcerative colitis)\u767c\u751f\u7387 (4). \u65e9\u5e74\u4f7f\u7528\u6297\u751f\u7d20\u53ef\u589e\u52a0\u6f70\u760d\u6027\u8178\u708e\u767c\u751f\u7387 (5). \u7336\u592a\u4eba\u7684\u767c\u751f\u7387\u5168\u7403\u6700\u9ad8\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (2)+(4)\n": "(B)", "107-17.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u767c\u708e\u6027\u8178\u9053\u75be\u75c5\u5e38\u898b\u7684\u8178\u9053\u5916\u8868\u73fe(extraintestinal manifestation)\uff1f\nA. erythema nodosum\nB. ankylosing spondylitis\nC. uveitis\nD. primary biliary cirrhosis\nE. metabolic bone disorders\n": "(D)", "107-18.\n\u6709\u95dc\u5927\u8178\u61a9\u5ba4\u75c7(Diverticulosis)\u4e4b\u6558\u8ff0\u4f55\u8005\u70ba\u662f\uff1f (1). \u4e9e\u6d32\u4eba70%\u7684\u61a9\u5ba4\u767c\u751f\u65bc\u53f3\u5074\u5927\u8178 (2). 60\u6b72\u4ee5\u4e0a\u7684\u75c5\u4eba\u4e0b\u6d88\u5316\u9053\u51fa\u8840(hematochezia\u8868\u73fe\u70ba\u4e3b)\u6700\u5e38\u898b\u7684\u75c5\u56e0\u70ba\u61a9\u5ba4\u51fa\u8840 (3). \u61a9\u5ba4\u708e\u7684\u8a3a\u65b7\u4ee5\u5927\u8178\u93e1\u70ba\u4e3b (4). \u61a9\u5ba4\u708e\u7684\u6cbb\u7642\u4ee5\u624b\u8853\u70ba\u4e3b (5). \u542bLactobacillus acidophilus\u548cbifidobacterium strains\u4e4bprobiotics\u53ef\u6709\u6548\u9810\u9632\u61a9\u5ba4\u708e\u7684\u5fa9\u767c\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(2)+(5)\nE. (2)+(4)+(5)\n": "(D)", "107-19.\n\u6709\u95dc\u5927\u8178\u764c\u5728\u53f0\u7063\u7684\u73fe\u6cc1\uff0c\u4f55\u8005\u70ba\u932f\uff1f\nA. \u6574\u9ad4\u767c\u751f\u7387\u9ad8\u5c45\u764c\u75c7\u7b2c\u4e00\u4f4d\nB. \u6574\u9ad4\u6b7b\u4ea1\u7387\u9ad8\u5c45\u764c\u75c7\u7b2c\u4e00\u4f4d\nC. \u5168\u570b\u6027\u7be9\u6aa2\u70ba50\u6b72\u4ee5\u4e0a\u6bcf\u4e8c\u5e74\u4e00\u6b21\u7cde\u4fbf\u6aa2\u67e5\nD. \u7cde\u4fbf\u6aa2\u67e5\u4ee5\u514d\u75ab\u6cd5\u70ba\u4e3b\nE. \u7be9\u6aa2\u5df2\u6709\u6548\u964d\u4f4e\u6b7b\u4ea1\u7387\n": "(B)", "107-20.\n\u6709\u95dcGilbert's syndrome\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f?\nA. \u4ee5\u8f15\u5ea6conjugated hyperbilirubinemia\u70ba\u4e3b\u8981\u8868\u73fe\nB. \u5927\u90e8\u5206\u500b\u6848\u4e4bbilirubin< 3mg/dL\nC. \u53ef\u56e0\u58d3\u529b\u3001\u559d\u9152\u7b49\u56e0\u7d20\u800c\u8b93bilirubin\u66f4\u9ad8\nD. \u4e3b\u56e0\u70baUGT1A1\u6d3b\u6027\u6e1b\u5c11\nE. \u6b64\u7a2e\u500b\u6848\u4f7f\u7528irinotecan\u8f03\u6613\u767c\u751fintractable diarrhea\u53camyelosuppression\u7684\u526f\u4f5c\u7528\n": "(A)", "107-21.\n\u6709\u95dc\u75c5\u6bd2\u6027\u809d\u708e\u7684\u809d\u5916\u8868\u73fe(extrahepatic manifestation),\u4f55\u8005\u932f\u8aa4\uff1f\nA. serum sickness-like syndrome\u597d\u767c\u65bc\u6162\u6027B\u578b\u809d\u708e\nB. immune-complex glomerulonephritis\u53ef\u898b\u65bc\u6162\u6027C\u578b\u809d\u708e\nC. mixed cryoglobulinemia\u53ef\u898b\u65bc\u6162\u6027B\u578b\u809d\u708e\nD. C\u578b\u809d\u708e\u8840\u4e2d\u7684immune complex\u5167\u542bHCV-RNA\nE. polyarteritis nodosa\u53ef\u898b\u65bc\u6162\u6027B\u578b\u809d\u708e\n": "(A)", "107-22.\n\u4e0b\u5217B\u578b\u809d\u708e\u7684\u6cbb\u7642\u85e5\u7269\uff0c\u4f55\u8005\u7522\u751f\u75c5\u6bd2\u6297\u85e5\u6027\u7684\u6a5f\u6703\u6700\u9ad8\uff1f\nA. PEG IFN\nB. lamivudine\nC. adefovir\nD. entecavir\nE. telbivudine\n": "(B)", "108-1.\n\u95dc\u65bcacute intestinal obstruction\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1)Hyperparathyroidism\u53ef\u80fd\u9020\u6210ilues (pseudo-obstruction)\uff1b(2)Hypokalemia \u53cahypomagnesemia\u53ef\u80fd\u9020\u6210ilues\uff1b(3)\u8179\u8154\u93e1\u624b\u8853\u4e0d\u53ef\u80fd\u9020\u6210obstructive adhesion\uff1b(4)Bezoars\u53ef\u80fd\u9020\u6210acute intestinal obstruction\uff1b(5)Ileus\u767c\u751f\u6642\uff0c\u75c5\u4eba\u901a\u5e38\u6703\u6709\u8179\u8139\u3001\u7d5e\u75db\u53ca\u53b2\u5bb3\u7684\u5614\u5410\uff1b(6)\u9060\u7aef\u5927\u8178\u767c\u751f\u6025\u6027\u963b\u585e\u6642\uff0c\u7ad9\u7acb\u7684plain films of the abdomen\u6703\u986f\u793aair-fluid levels\u65bc\u5927\u8178\u548c\u5c0f\u8178\u4e2d\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (2)+(4)+(5)\nD. (3)+(5)+(6)\nE. (4)+(5)+(6)\n": "(B)", "108-2.\n\u4e0b\u5217\u4f55\u8005\u662f\u80c3\u817a\u764c(gastric adenocarcinoma)\u4e4b\u5371\u96aa\u56e0\u5b50\uff1f(1)Alcoholism\uff1b(2)Helicobacter pylori infection\uff1b(3)Diet high in salted and preserved food\uff1b(4)Subtotal gastrectomy\uff1b(5) Hereditary hemorrhagic telangiectasia\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (2)+(3)+(5)\nE. (3)+(4)+(5)\n": "(C)", "108-3.\n\u4e00\u4f4d20\u6b72B\u578b\u809d\u708e\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\uff0c\u5176\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b\uff1a\rHBsAg (+), HBeAg (+), ALT: 48 (\u226641), AST: 31 (\u226631), Bilirubin (T)/(D)=1.8/0.3 mg/dL, Albumin: 4.1 g/dL (\u22673.5), Prothrombin time (PT) INR= 1.0 (0.8~1.2) \u3002\u4e0b\u5217\u4f55\u8005\u662f\u76ee\u524d\u6700\u5408\u5b9c\u7684\u8655\u7f6e\uff1f\nA. \u61c9\u7acb\u5373\u5b89\u6392\u809d\u5207\u7247 (liver biopsy)\u4ee5\u77ad\u89e3\u75c5\u60c5\nB. \u6bcf2~3\u500b\u6708\u5b9a\u671f\u8ffd\u8e64\u8840\u6e05ALT \u53ca AST\u5373\u53ef\nC. \u82e5\u8840\u6e05HBV viral load \u90541,000,000 IU/mL, \u61c9\u958b\u59cb\u4ee5\u5e72\u64fe\u7d20\u6ce8\u5c04\u6cbb\u7642\nD. \u82e5\u8840\u6e05HBV viral load \u9054100,000 IU/mL, \u61c9\u958b\u59cb\u4ee5\u53e3\u670d\u6291\u5236B\u809d\u75c5\u6bd2\u4e4b\u85e5\u7269\u6cbb\u7642\nE. \u61c9\u5118\u5feb\u5b89\u6392\u6aa2\u67e5\u4ee5\u91d0\u6e05\u963b\u585e\u6027\u9ec3\u75b8\u4e4b\u539f\u56e0\n": "(B)", "108-4.\n\u4e0b\u5217\u6709\u95dc\u809d\u786c\u5316\u53ca\u5176\u4f75\u767c\u75c7\u4e4b\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u809d\u786c\u5316\u75c5\u4eba\u5df2\u5728\u53e3\u670dLactulose\uff0c\u4ecd\u4e00\u518d\u767c\u751f\u809d\u8166\u75c5\u8b8a (hepatic encephalopathy)\uff0c\u4f46\u627e\u4e0d\u5230\u4efb\u4f55\u8a98\u767c\u56e0\u7d20\uff0c\u6b64\u6642\u7d66\u4e88\u670d\u7528Rifaximin\u53ef\u6e1b\u5c11\u767c\u4f5c\u6a5f\u7387\nB. \u809d\u786c\u5316\u4f75\u809d\u9580\u8108\u9ad8\u58d3\u75c5\u4eba\u53ef\u80fd\u51fa\u73feplatypnea \u53ca orthodeoxia \u4e4b\u75c7\u72c0\nC. \u809d\u786c\u5316\u4f75\u809d\u9580\u8108\u9ad8\u58d3\u75c5\u4eba\u53ef\u80fd\u4f75\u767c\u80ba\u52d5\u8108\u9ad8\u58d3\uff0c\u61c9\u5148\u5617\u8a66\u4ee5prostacyclin analogues\u6216endothelin antagonists\u6cbb\u7642\u4e4b\nD. \u8179\u6c34\u75c5\u56e0\u4e4b\u9451\u5225\u8a3a\u65b7\u6709\u8cf4\u62bd\u53d6\u8179\u6c34\u9001\u53bb\u6aa2\u9a57Albumin\u6578\u503c\uff0c\u4e26\u8207\u8840\u6e05Albumin\u6578\u503c\u505a\u6bd4\u8f03\uff0c\u82e5\u8840\u6e05Albumin < 2.5 g/dL\uff0c\u4e14Serum-Ascites Albumin Gradient (SAAG) < 1.1 g/dL\uff0c\u61c9\u8003\u616e\u764c\u75c7\u8f49\u79fb\u81f3\u8179\u819c\u9020\u6210\u4e4b\u8179\u6c34\nE. Type I hepatorenal syndrome\u61c9\u4ee5vasoconstrictor\u4f75Albumin\u6cbb\u7642\n": "(D)", "108-5.\nC\u578b\u809d\u708e\u4e4b\u6cbb\u7642\u5df2\u6709\u7a81\u7834\u6027\u9032\u5c55\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u53f0\u7063\u5065\u4fdd\u5df2\u6709\u7d66\u4ed8Direct Acting Anti-virals (DAAs)\u7528\u65bc\u6cbb\u7642\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\nB. \u53f0\u7063\u4f7f\u7528DAAs\u6cbb\u7642\u6162\u6027C\u578b\u809d\u708e\u75c5\u4eba\u4e4bC\u809d\u75c5\u6bd2\u6839\u9664\u7387(SVR12: Sustained Virologic Response 12 weeks after end of treatment)\u9ad8\u9054\u4e5d\u6210\u4e94\u4ee5\u4e0a\nC. \u73fe\u5728\u7947\u8981\u8840\u4e2d\u6e2c\u5f97\u5230C\u578b\u809d\u708e\u75c5\u6bd2\uff0c\u5373\u53ef\u670d\u7528\u5065\u4fdd\u7d66\u4ed8\u4e4bDAAs\nD. DAAs\u4e4b\u7642\u7a0b\uff0c\u4e00\u822c\u7947\u89818\u9031~12\u9031\nE. \u76ee\u524d\u5065\u4fdd\u6709\u7d66\u4ed8\u4e4bHarvoni (Sofosbuvir+Ledipasvir) \u53ca Epclusa (Sofosbuvir+Velpatasvir)\u5169\u7a2eDAAs\uff0c\u4e0d\u5b9c\u7528\u65bc\u5931\u4ee3\u511f\u6027\u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\n": "(E)", "108-6.\n\u6703\u4fc3\u4f7f\u55ae\u7d14\u8102\u80aa\u809d\u4e4b\u75c5\u60c5\u60e1\u5316\uff0c\u671d\u975e\u9152\u7cbe\u6027\u8102\u80aa\u809d\u708e (Non-Alcoholic Steatohepatitis, NASH)\u9032\u884c\u4e4b\u5371\u96aa\u56e0\u5b50\uff0c\u5305\u62ec\u4e0b\u5217\u5404\u9805\uff0c\u4f55\u8005\u4e0d\u662f\uff1f\nA. \u80a5\u80d6\nB. \u80f0\u5cf6\u7d20\u6297\u6027 (insulin resistance)\nC. \u65b0\u9673\u4ee3\u8b1d\u75c7\u5019\u7fa4 (metabolic syndrome)\nD. \u8840\u8102\u7570\u5e38 (dyslipidemia)\nE. \u9ad8\u8840\u58d3\n": "(E)", "108-7.\n\u95dc\u65bcUlcerative Colitis (UC) \u548cCrohn's Disease (CD) \u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u5404\u9805\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8f03\u5e38\u898b\u5230gross blood in stool \u7684\u662fUC\nB. \u6703\u5f62\u6210 enterocutaneous fistula \u7684\u662f CD\nC. \u53ef\u80fd\u6478\u5230\u53f3\u4e0b\u8179\u90e8\u6709 mass formation \u7684\u662f UC\nD. \u6703\u9020\u6210 small bowel obstruction \u7684\u662f CD\nE. \u6703\u9020\u6210 colon obstruction \u7684\u662f CD\n": "(C)", "108-8.\n\u95dc\u65bcCrohn's Disease \u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7d04\u6709 10% \u6703\u9020\u6210 colon stricture\uff0c\u4f46\u5728\u5927\u8178\u93e1\u6aa2\u67e5\u78b0\u5230\u72f9\u7a84\u800c\u904e\u4e0d\u53bb\u6642\uff0c\u4ecd\u9700\u6392\u9664\u5927\u8178\u764c\u4e4b\u53ef\u80fd\u6027\nB. \u6700\u5e38\u4fb5\u72af\u4e4b\u90e8\u4f4d\u662f terminal ileum\nC. \u670910~20% \u6703\u6709\u9ad4\u91cd\u6e1b\u8f15\u7684\u60c5\u6cc1\nD. \u53ef\u80fd\u9020\u6210 fistula (\u5982\uff1aenterocutaneous \u3001enterovesical)\nE. \u5e38\u6703\u9020\u6210 perforation of intestine\u5c0e\u81f4\u8179\u8154\u5167\u6709\u660e\u986f\u4e4b\u6e38\u96e2\u7a7a\u6c23\n": "(E)", "108-9.\n\u4e0b\u5217\u6709\u95dc\u80f0\u81df\u708e\u4e4b\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6162\u6027\u80f0\u81df\u708e\u75c5\u4eba\uff0c\u8840\u6e05 amylase \u53ca lipase \u6578\u503c\u901a\u5e38\u4e0d\u6703\u7570\u5e38\u5347\u9ad8\nB. \u521d\u671f\u6162\u6027\u80f0\u81df\u708e\uff0c\u53ef\u80fd\u9023\u5f71\u50cf\u6aa2\u67e5\u90fd\u770b\u4e0d\u51fa\u4f86\uff0c\u6b64\u6642\u53ef\u7528 fecal elastase test \u5354\u52a9\u5224\u65b7\nC. \u660e\u986f\u4e0a\u8179\u75db\u7591\u4f3c\u6025\u6027\u80f0\u81df\u708e\uff0c\u4f46\u8840\u6e05amylase \u6578\u503c\u6b63\u5e38\uff0c\u53ef\u80fd\u662fhypertriglyceridemia\u4e4b\u5e72\u64fe\nD. \u6162\u6027\u814e\u81df\u75c5\u60a3\u8005\u82e5\u88ab\u61f7\u7591\u6709\u6025\u6027\u80f0\u81df\u708e\uff0c\u61c9\u76f4\u63a5\u62bd\u8840\u6aa2\u9a57lipase\u4f86\u52a0\u4ee5\u5224\u65b7\nE. \u808b\u819c\u7a4d\u6c34\u88ab\u9a57\u51fa\u7570\u5e38\u5347\u9ad8\u4e4b amylase \u6578\u503c\uff0c\u6709\u53ef\u80fd\u662f\u80ba\u764c\u6240\u9020\u6210\n": "(B)", "108-10.\n\u6709\u95dc Hyperbilirubinemia \u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f(1)\u6eb6\u8840 (hemolysis) \u5c0e\u81f4\u7684 hyperbilirubinemia \u901a\u5e38 Bilirubin (total) \u2266 4 mg/dL, Bilirubin (direct) < 15%\uff1b(2)\u5927\u578b\u7684 hematoma \u53ef\u80fd\u5c0e\u81f4\u4ee5 direct (conjugated) bilirubin \u70ba\u4e3b\u7684 hyperbilirubinemia\uff1b(3)Megaloblastic anemia \u53ef\u80fd\u5c0e\u81f4 indirect (unconjugated) bilirubin \u70ba\u4e3b\u7684 hyperbilirubinemia\uff1b(4)Rotor syndrome \u75c5\u4eba\u6703\u51fa\u73fe tea-colored urine\uff1b(5)Dubin-Johnson syndrome \u75c5\u4eba\u4e4b hyperbilirubinemia \u901a\u5e38 \u2267 20 mg/dL\uff0c\u4e14\u4ee5 direct bilirubin \u70ba\u4e3b\uff1b(6)Gilbert's\rsyndrome\u5c0e\u81f4\u4e4bhyperbilirubinemia \u4ee5 indirect bilirubin \u70ba\u4e3b\uff0ctotal bilirubin \u901a\u5e38\u2266 4 mg/dL\uff0c\u670d\u7528 phenobarbital \u6703\u8b93 total bilirubin\uff0c\u964d\u81f3\u6b63\u5e38\u7bc4\u570d\nA. (2)+(3)+(4)\nB. (1)+(3)+(5)\nC. (4)+(5)+6)\nD. (3)+(6)\nE. (2)+(5)\n": "(E)", "108-11.\n\u95dc\u65bc\u5927\u8178\u76f4\u8178\u764c\u53ca\u5927\u8178\u606f\u8089\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\r(1) \u7d55\u5927\u591a\u6578\u5927\u8178\u76f4\u8178\u764c\u6e90\u81ea\u5927\u8178 adenomatous polyps\r(2) \u7d0430% adenomatous polyps \u6703\u884d\u751f\u5927\u8178\u76f4\u8178\u764c\r(3) tubular adenoma \u6bd4villous adenoma\u8f03\u6613\u8f49\u8b8a\u6210\u5927\u8178\u76f4\u8178\u764c\r(4) \u6709 adenomatous polyp \u7684\u75c5\u4eba\uff0c < 5%\u4e4b\u7cde\u4fbf\u6703\u51fa\u73fe\u6f5b\u8840\u4e4b\u967d\u6027\u53cd\u61c9\r(5) > 2.5 \u516c\u5206\u7684\u5927\u8178\u606f\u8089\uff0c\u6709 30% \u6703\u4f75\u6709 invasive cancer\r(6) \u5927\u8178\u606f\u8089\u7d93\u5207\u9664\u5f8c\uff0c\u5927\u591a\u6578\u4eba\u7d93\u904e 3 \u5e74\u5f8c\u518d\u63a5\u53d7\u8ffd\u8e64\u6027\u5927\u8178\u93e1\u6aa2\u67e5\u5373\u53ef\nA. (1)+(2)+(3)\nB. (2)+(4)+(5)\nC. (3)+(4)+(6)\nD. (2)+(3)+(5)\nE. (4)+(5)+(6)\n": "(D)", "108-12.\n55\u6b72\u5973\u60278\u5e74\u524d\u63a5\u53d7\u6e1b\u91cd\u7684\u7e5e\u9053\u624b\u8853\uff0c\u8853\u5f8c\u9ad4\u91cd\u6e1b\u5c1168kg\uff0c\u6700\u8fd1\u5e7e\u5e74\u4f86\u9ad4\u91cd\u7a69\u5b9a\uff0c\u4f46\u662f\u8853\u5f8c\u6709\u6162\u6027\u975e\u51fa\u8840\u6027\u8179\u7009\uff0c\u5bb9\u6613\u75b2\u5026\u3001\u53cd\u819a\u4e7e\u71e5\u3001\u773c\u775b\u4e7e\u7662\uff0c\u665a\u4e0a\u958b\u8eca\u770b\u4e0d\u6e05\u695a\u8def\u6a19\u7b49\u60c5\u5f62\u3002\u53e6\u5916\u56e0\u7cd6\u5c3f\u75c5\u548c\u9ad8\u8840\u58d3\u670d\u7528metformin\u53calisinopril\uff0c\u4e5f\u81ea\u884c\u670d\u7528\u591a\u7a2e\u7dad\u4ed6\u547d\u548c\u9435\u5291\uff0c5\u5e74\u524d\u7684\u5927\u8178\u93e1\u6aa2\u67e5\u6b63\u5e38\u3002\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3\u70ba140/79 mmHg\uff0c\u8108\u640f63/min\uff0cBMI:25\u3002\u8840\u6db2\u6aa2\u67e5Hb:10.5g/dL\uff0cMCV:95fL\u3002\u4e0b\u5217\u4f55\u7a2e\u71df\u990a\u7d20\u7f3a\u4e4f\u662f\u5c0e\u81f4\u6b64\u75c5\u60a3\u81e8\u5e8a\u8868\u73fe\u7684\u539f\u56e0?\nA. Copper\nB. Iron\nC. Vitamin A\nD. Vitamin B12\nE. Vitamin B1\n": "(C)", "108-13.\n57\u6b72\u5973\u6027\u63a5\u53d7\u7be9\u6aa2\u6027\u5927\u8178\u93e1\u6aa2\u67e5\uff0c\u7d50\u679c\u5728\u5347\u7d50\u8178\u767c\u73fe\u4e00\u984612mm\u606f\u8089\uff0c\u5207\u9664\u5f8c\u75c5\u7406\u5831\u544a\u70baserrated polyp\u3002\u5979\u4e0b\u6b21\u5927\u8178\u93e1\u6aa2\u67e5\u7684\u6700\u9069\u7576\u6642\u9593\u70ba\u4f55?\nA. 1\u5e74\nB. 2\u5e74\nC. 3\u5e74\nD. 5\u5e74\nE. 10\u5e74\n": "(C)", "108-14.\n28\u6b72\u7537\u6027\u8179\u7009\u5df23\u5e74\uff0c\u6700\u8fd13\u500b\u6708\u611f\u5230\u75b2\u5026\uff0c\u7406\u5b78\u6aa2\u67e5\u986f\u793aBMI:24\uff0c\u6709\u809d\u81df\u816b\u5927\u4f46\u813e\u81df\u6c92\u6709\u816b\u5927\uff0c\u4e5f\u7121\u8179\u6c34\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5AST:87 U/L\uff0cALT:75 U/L\uff0cALP:456 U/L\uff0cBilirubin (T/D):1.2/0.4 mg/dL\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u809d\u5916\u81bd\u7ba1\u58c1\u589e\u539a\u4f46\u7121\u809d\u5167\u81bd\u7ba1\u64f4\u5f35\uff0cMRCP\u6aa2\u67e5\u7591\u4f3c\u539f\u767c\u786c\u5316\u6027\u81bd\u7ba1\u708e(primary sclerosing cholangitis)\uff0c\u8a66\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6aa2\u67e5\u5c0d\u75c5\u60c5\u91d0\u6e05\u6700\u6070\u7576?\nA. colonoscopy\nB. ERCP\nC. Liver biopsy\nD. Serum IgG4\nE. ANA\n": "(A)", "108-15.\n55\u6b72\u7537\u6027\u67098\u5e74\u5fc3\u707c\u71b1(heartburn)\u53ca\u80c3\u9178\u9006\u6d41(acid reflux)\uff0c\u6bcf\u65e5\u670d\u7528\u4e00\u9846pantoprazole\uff0c\u75c7\u72c0\u63a7\u5236\u826f\u597d\uff0c10\u9031\u524d\u56e0\u591c\u9593\u5fc3\u707c\u71b1\u800c\u63d0\u9ad8\u5291\u91cf\u81f3\u4e00\u65e5\u4e8c\u6b21\u3002\u75c5\u4eba\u78ba\u8a8d\u5728\u98ef\u524d30\u5206\u9418\u670d\u85e5\uff0c\u4f46\u75c7\u72c0\u4ecd\u53ea\u6709\u4e9b\u5fae\u6539\u5584\uff0c\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u7d50\u679c\u6b63\u5e38\uff0c\u63a5\u4e0b\u4f86\u61c9\u5b89\u6392\u4f55\u9805\u8655\u7f6e?\nA. Ambulatory pH impedance monitoring\nB. Barium esophagogram\nC. Esophageal manometry\nD. Abdominal computed tomography\nE. Fundoplication\n": "(A)", "108-16.\n63\u6b72\u7537\u6027\u6709\u4e09\u500b\u6708\u7f3a\u9ad4\u6027\u8ca7\u8840\u75c5\u53f2\uff0c\u63a5\u53d7\u904e\u4e8c\u6b21\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u53ca\u4e00\u6b21\u4e0b\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\u5747\u7121\u767c\u73fe\u80c3\u8178\u51fa\u8840\u75c5\u7076\uff0c\u75c5\u4eba\u56e0\u6162\u6027\u5fc3\u623f\u986b\u52d5\u670d\u7528diltiazem\u53cawarfarin\uff0c\u53e6\u5916\u4e5f\u53e3\u670d\u9435\u5291\uff0c\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3130/78 mmHg\uff0c\u8108\u640f80/min\uff0c\u547c\u543818/min\uff0c\u8840\u6db2\u6aa2\u67e5Hb:9.2 g/dL\uff0cINR:2.5\uff0c\u7cde\u4fbf\u6f5b\u8840\u53cd\u61c9\u5448\u73fe\u967d\u6027\uff0c\u61c9\u5b89\u6392\u4e0b\u5217\u4f55\u9805\u6aa2\u67e5\u4ee5\u9032\u4e00\u6b65\u8655\u7f6e?\nA. Angiography\nB. Capsule endoscopy\nC. Intraoperative endoscopy\nD. Technetium-labeled nuclear scan\nE. Abdominal computed tomogrphy\n": "(B)", "108-17.\n68\u6b72\u7537\u6027\u56e0\u4e0b\u80a2\u6c34\u816b\u53ca\u65b0\u767c\u751f\u7684\u8179\u6c34\u63a5\u53d7\u6aa2\u67e5\uff0c\u75c7\u72c0\u5728\u904e\u53bb4\u9031\u9010\u6f38\u52a0\u91cd\uff0c\u4ed6\u6709\u559d\u9152\u75c5\u53f2\uff0c8\u500b\u6708\u524d\u63a5\u53d7\u51a0\u72c0\u52d5\u8108\u7e5e\u9053\u624b\u8853\uff0c\u670d\u7528\u4f4e\u5291\u91cfaspirin\uff0catorvastatin\u53cametoprolol\u3002\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab36.8\u2103\uff0c\u8840\u58d3122/84 mmHg\uff0c\u8108\u640f64/min\uff0c\u547c\u543816/min\u3002\u5fc3\u81df\u6aa2\u67e5jugular venous presscure\u589e\u52a0\uff0c\u6709\u6b63\u5e38\u7684S1\u53caS2\u5fc3\u97f3\uff0c\u4e26\u7121\u5fc3\u96dc\u97f3\u3002\u80f8\u8154\u6aa2\u67e5\u6b63\u5e38\u8179\u90e8\u6aa2\u67e5\u6709\u809d\u816b\u5927\uff0cfluid wave\u5448\u73fe\u967d\u6027\uff0c\u4e0b\u80a2\u67092+\u7684pitting edema\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5albumin:3.5 g/dL\uff0cAST/ALT\u6b63\u5e38\u3002\u8179\u6c34\u6aa2\u67e5\u5982\u4e0b\uff1aWBC:120/ L\uff0c30%\u70baPMN\uff0calbumin:2.3g/dL\uff0c\u86cb\u767d\u7e3d\u91cf3.5g/dL\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba?\nA. Alcoholic cirrhosis\nB. Constrictive pericarditis\nC. Nonalcoholic cirrhosis\nD. Tuberculous peritonitis\nE. Spontaneous bacterial peritonitis\n": "(B)", "108-18.\n\u6709\u95dc\u80c3\u8178\u9593\u8cea\u7624(gastrointestinal stromal tumor-GIST)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u662f? (1)\u80c3\u6700\u5e38\u767c\u751f\uff0c\u7d04\u536070% (2)\u80c3\u7684\u9593\u8cea\u7624\u751f\u9577\u5feb\u901f (3)\u5e38\u6709K-ras\u57fa\u56e0\u7a81\u8b8a (4)\u816b\u7624\u5927\u5c0f\u548c\u9810\u5f8c\u7121\u95dc (5)\u9664\u624b\u8853\u5916\uff0c\u76ee\u524d\u6709tyrosine kinase inhititor\u53ef\u7528\u65bc\u6cbb\u7642\u8f49\u79fb\u6027GIST\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (1)+(5)\nE. (2)+(5)\n": "(D)", "108-19.\n\u6709\u95dcmultiple endocrine neoplasia(MEN)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e? (1)\u53ef\u5408\u4f75Zollinger-Ellison syndrome\u4e4b\u767c\u751f (2)parathyroid, pituitary\u548cpancreas\u662f\u816b\u7624\u5e38\u767c\u751f\u8655 (3)\u5c6cautosomal recessive\u907a\u50b3 (4)\u81e8\u5e8a\u8868\u73fe\u9664\u6d88\u5316\u6027\u6f70\u760d\u5916\uff0c\u53ef\u4ee5\u6709\u814e\u7d50\u77f3\u548c\u9ad8\u8840\u7cd6 (5)\u80c3\u548c\u5341\u4e8c\u6307\u8178\u6613\u767c\u751fneuroendocrine tumors\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (3)+(5)\nE. (2)+(5)\n": "(C)", "108-20.\n\u4e0b\u5217\u4f55\u7a2e\u80c3\u764c\u8f03\u4e0d\u9069\u5408\u505a\u5167\u8996\u93e1\u9ecf\u819c\u5207\u9664\u8853(endoscopic mucosal resection)?\nA. \u8178\u9053\u578b(intestinal type)\nB. \u5167\u8996\u93e1\u8d85\u97f3\u6ce2\u986f\u793a\u70bamucosal cancer\u4e14\u7121\u6dcb\u5df4\u7d50\u8f49\u79fb\nC. \u55ae\u4e00\u816b\u7624\nD. \u7a81\u8d77\u578b\u816b\u76242\u516c\u5206\nE. \u6f70\u760d\u7d50\u75a4\u4e4b\u51f9\u9650\u578b1.5\u516c\u5206\n": "(E)", "108-21.\n\u6709\u95dc\u5927\u8178\u61a9\u5ba4\u75c7\u4e4b\u6558\u8ff0\uff0c\u4ee5\u4e0b\u4f55\u8005\u70ba\u6b63\u78ba? (1)\u4f75\u767c\u75c7\u5305\u62ecAbscess\uff0cFistula\u53caPerforation (2)\u5728\u53f0\u7063\u5e38\u898b\u65bcsigmoid colon\u53caascending colon (3)\u4e00\u822cDiverticula\u767c\u751f\u65bcMesenteric\u53caAntimesenteric taeniae\u4e4b\u9593 (4)\u5927\u8178\u5167\u8996\u93e1\u70ba\u6700\u4f73\u4e4b\u8a3a\u65b7\u5de5\u5177 (5)\u5927\u8178\u764c\u4e4b\u81e8\u5e8a\u75c7\u72c0\uff0c\u8207\u6b64\u75c5\u6700\u4e0d\u50cf\uff0c\u4f46\u548c\u7f3a\u8840\u6027\u5927\u8178\u708e\u6700\u50cf\nA. (1)+(3)+(4)\nB. (1)+(2)+(3)\nC. (2)+(4)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(B)", "108-22.\n\u4e00\u4f4d60\u6b72\u5a66\u5973\uff0c\u4e3b\u8a34\u53f3\u4e0a\u8179\u75bc\u75db\u3001\u5641\u5fc3\u3001\u5614\u5410\u3001\u767c\u71d2\uff0c\u9019\u4e9b\u75c7\u72c0\u6301\u7e8c8\u5c0f\u6642\u3002\u8eab\u9ad4\u6aa2\u67e5\uff0c\u9ad4\u6eab39\u2103\uff0c\u8108\u640f105\u4e0b\uff0c\u8840\u58d3120/76\uff0c\u8179\u90e8\u6aa2\u67e5\u53f3\u4e0a\u8179\u6709\u58d3\u75db\uff0c\u53ef\u81f4\u547c\u5438\u505c\u6b62\uff0c\u5979\u6c92\u6709\u9ec3\u75b8\u3002\u4e0b\u5217\u5f71\u50cf\u5b78\u6aa2\u67e5\u7d50\u679c\uff0c\u4e0d\u50cf\u662f\u5979\u7684?\nA. \u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u81bd\u56ca\u58c1\u539a\uff0c\u5468\u570d\u6709\u6db2\u9ad4\u6eef\u7559\nB. \u96fb\u8166\u65b7\u5c64\u651d\u5f71\u986f\u793a\u81bd\u56ca\u816b\u8139\nC. \u6838\u91ab\u9020\u5f71(hepatobiliary scintigraphy)\u770b\u4e0d\u5230\u81bd\u56ca\nD. \u8179\u90e8X\u5149(KUB)\u53ef\u4ee5\u770b\u5230\u81bd\u56ca\u5167\u6709\u7a7a\u6c23\nE. \u8d85\u97f3\u6ce2\u4e0a\u770b\u5230\u809d\u5167\u53ca\u809d\u5916\u81bd\u7ba1\u816b\u8139\uff0c\u81bd\u56ca\u5167\u6709\u8a31\u591a\u5c0f\u77f3\u982d\n": "(E)", "109-45.\u75c5\u4eba\u56e0\u611f\u5230\u5026\u6020\u800c\u5c31\u91ab \uff0c\u5176\u62bd\u8840\u6aa2\u9a57\u5982\u4e0b \uff1aAST=70 (<31) U/L\uff0cALT=35 (<41) U/L\uff0cALP (Alkaline \nphosphatase)=105 (<104) U/L\u3002\u4e0b\u5217\u75c5\u6cc1\u4f55\u8005\u4e0d\u80fd\u89e3\u91cb\u5176\u7d50\u679c \uff1f   \nA.\u6eb6\u8840 (hemolysis)\nB.\u5fc3\u808c\u6897\u585e (myocardial infarction)\nC.\u91cd\u8a13 (heavy muscle exercise)\nD.\u9157\u9152 (alcoholism)\nE.\u5065\u5eb7\u7684B\u578b\u809d\u708e\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\uff08\u5065\u5eb7\u5e36\u539f\u8005\uff09\n": "[E]", "109-46.\u75c5\u4eba\u56e0\u4e0a\u8179\u75bc\u75db\u4e00\u5929\u88ab\u9001\u81f3\u6025\u8a3a\u5ba4 \uff0c\u62bd\u8840\u6aa2\u9a57 Amylase\u4e0a\u5347\u81f31000 U/L\u3002\u4f4f\u9662\u7b2c\u4e09\u5929 \uff0c\u8840\u6e05 amylase \u964d\n\u81f3\u6b63\u5e38\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u6aa2\u6e2c\u8840\u6e05 triglyceride \u6fc3\u5ea6\u53ef\u80fd >1000 mg /dL\n(2) \u8981\u91d0\u6e05\u6709\u7121\u81bd\u7d50\u77f3\n(3) \u8eab\u9ad4\u8a3a\u5bdf\u53ef\u80fd\u6709Obturator sign\n(4) \u4f4f\u9662\u5f8c24\u5c0f\u6642\u9700\u6ce8\u610f serum Creatinie level\n(5) \u9700\u6392\u9664 perforated peptic ulcer\n(6) \u9700\u6392\u9664 mesenteric vascular occlusion\n(7) \u6bcf\u5929\u505a\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u662f\u6700\u4f73\u5224\u65b7 severity \u4e4b\u65b9\u5f0f   \nA.(2)+(3)+(4)+(7)\nB.(3)+(4)+(5)+(6)\nC.(1)+(2)+(4)+(5)+(7)\nD.(1)+(3)+(5)+(6)\nE.(1)+(2)+(4)+(5)+(6)\n": "[E]", "109-47.\u75c5\u4eba\u6700\u8fd1\u56e0\u95dc\u7bc0\u708e\u800c\u9700\u670d\u7528NSAID (Non-steroidal Anti -inflammatory Drug )\u3002\u67d0\u5929\u534a\u591c\u7a81\u7136\u611f\u5230\u5287\u70c8\u7684\u80f8\n\u9aa8\u5f8c\u75bc\u75db\u800c\u9192\u4f86 \u3002\u95dc\u65bc\u9019\u500b\u75c5\u4eba\u7684\u75c5\u60c5 \uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.Anti-secretory drugs \u5e38\u88ab\u7528\u4f86\u52a0\u901f\u75c5\u60c5\u4e4b\u6539\u5584\nB.\u670d\u85e5\u5f8c\u8981\u559d\u8db3\u5920\u7684\u6c34\u4e14\u907f\u514d\u65bc 30 \u5206\u9418\u5167\u8eba\u5e73\u7761\u89ba\nC.\u6700\u5bb9\u6613\u767c\u751f\u65bc\u98df\u9053\u4e2d\u6bb5\nD.\u670d\u7528 potassium chloride \u53ca quinidine \u4ea6\u53ef\u80fd\u9020\u6210\u985e\u4f3c\u75c5\u60c5\nE.\u6b64\u7a2e\u75c5\u60c5\u50c5\u6703\u6301\u7e8c\u5e7e\u5929\uff0c\u4e14\u4e0d\u6703\u6709\u5f8c\u907a\u75c7\n": "[E]", "109-48.\u4e00\u500b\u75c5\u4eba\u88ab\u8a3a\u65b7\u809d\u786c\u5316\u5df2\u6709\u4e09\u5e74 \uff0c\u6700\u8fd1\u809a\u5b50\u9010\u6f38\u9f13\u6f32 \uff0c\u5c31\u91ab\u6642\u91ab\u5e2b\u5728\u8eab\u9ad4\u8a3a\u5bdf\u5176\u8179\u90e8\u6642\u767c\u73fe\u6709shifting \ndullness\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u61c9\u5118\u53ef\u80fd\u5b89\u6392\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\nB.\u8840\u6db2\u6aa2\u9a57\u5f88\u53ef\u80fd\u767c\u73fe thrombocytosis\nC.\u75c5\u4eba\u6bcf\u65e5\u6240\u98df\u7528\u7684\u9209\u61c9\u4f4e\u65bc 2 gm\nD.\u5fc5\u8981\u6642\u9700\u958b\u7acb spironolactone +/- furosemide\nE.\u8981\u6aa2\u6e2c\u5176\u8840\u6e05 Albumin \u6fc3\u5ea6\n": "[B]", "109-49.\u6709\u95dcC\u578b\u809d\u708e\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f       \nA.\u809d\u529f\u80fd\u5931\u4ee3\u511f\u4e4b\u60a3\u8005\uff0c\u4e0d\u80fd\u670d\u7528\u542b Protease Inhibitor (PI) \u985e\u4e4b\u85e5\u7269\nB.eGFR < 15 \u4e4b\u672b\u671f\u814e\u75c5\u60a3\u8005\uff0c\u4e0d\u5b9c\u670d\u7528\u542bNS5B \u6291\u5236\u5291\u4e4b\u85e5\u7269\nC.\u76ee\u524d\u53f0\u7063\u5065\u4fdd\u7d66\u4ed8\u898f\u7bc4 \uff0c\u7947\u8981\u75c5\u4eba\u8840\u4e2d\u6e2c\u5230 C\u809d\u75c5\u6bd2\uff0c\u5373\u53ef\u63a5\u53d7 Direct Acting Antivirals (DAAs) \u4e4b\u6cbb\n\u7642\nD.\u76ee\u524d DAAs \u4e4b\u7642\u7a0b\uff0c\u591a\u572812~24\u9031\nE.\u53f0\u7063\u904e\u53bb\u5169\u5e74\u4f7f\u7528 DAAs \u6cbb\u7642 C\u809d\u75c5\u4eba\uff0c\u53ea\u8981\u75c5\u60c5\u5c1a\u4f73 \uff08\u7121\u809d\u786c\u5316\u6216\u50c5\u6709\u4ee3\u511f\u6027\u809d\u786c\u5316\uff09\uff0c \u5176 \nSVR12 ( sustained virologic response at 12 weeks after end of treatment) \u6a5f\u7387\u9ad8\u9054 98 %\u3002\n": "[D]", "109-50.\u95dc\u65bc\u809d\u7d30\u80de\u764c (hepatocellular carcinoma, HCC) \u4e4b\u4e0b\u5217\u5404\u9805\u6558\u8ff0 \uff0c\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u5728\u53f0\u7063\uff0cB\u578b\u809d\u708e\u75c5\u6bd2\u548c C\u578b\u809d\u708e\u75c5\u6bd2\u662f\u5f15\u767c HCC \u7684\u4e3b\u8981\u5371\u96aa\u56e0\u5b50\n(2) \u65b0\u751f\u5152\u5168\u9762 B\u578b\u809d\u708e\u75ab\u82d7\u63a5\u7a2e \uff0c\u5df2\u660e\u986f\u964d\u4f4e HCC \u4e4b\u767c\u751f\u7387\n(3) \u6162\u6027C\u578b\u809d\u708e\u60a3\u8005\u9ad4\u5167\u4e4b C\u809d\u75c5\u6bd2\u88ab\u53e3\u670d\u6297 C\u809d\u75c5\u6bd2\u85e5\u7269 (Direct Acting Antirivrals) \u6839\u9664\u4e4b\u5f8c \uff0cHCC \u4e4b\n\u767c\u751f\u7387\u5df2\u660e\u986f\u964d\u4f4e\n(4) Statins \u53ca Metformin \u5df2\u88ab\u8b49\u5be6\u53ef\u964d\u4f4e HCC \u4e4b\u767c\u751f\u7387\n(5) \u76f4\u5f91\u5927\u65bc 2 \u516c\u5206\u4e4b HCC \uff0c\u5728 contrast -enhanced computed tomography (CECT) \u4e2d\u5448\u73fe\u5178\u578b\u7684\u8868\n\u73fe\uff0c\u5373\u53ef\u78ba\u8a3a \uff0c\u4e0d\u9700\u505a\u5207\u7247\u6aa2\u67e5\n(6) BCLC (Barcelona -Clinic-Liver-Cancer) staging system 0\u671f\u8005\uff0c\u4ee5 RFA ( Radiofrequency Ablation) \u6cbb\n\u7642\u7684\u6210\u529f\u7387\u8207\u958b\u5200\u5207\u9664\u5dee\u4e0d\u591a   \nA.(1)+(2)+(3)+(4)\nB.(1)+(2)+(4)+(5)\nC.(2)+(4)+(5)+(6)\nD.(3)+(4)+(5)+(6)\nE.(1)+(2)+(5)+(6)\n": "[E]", "109-51.\u95dc\u65bc\u5927\u8178\u764c\u8207\u5927\u8178\u606f\u8089\u4e4b\u6558\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u8001\u5e74\u4eba\u7d04 50% \u6709 adenomatous polyp \u65bc\u5176\u5927\u8178\u4e2d \uff0c\u5176\u4e2d < 1% \u6703\u6f14\u8b8a\u6210\u5927\u8178\u764c\n(2) \u6709\u5927\u8178\u606f\u8089\u8005 \uff0c\u7d04 20% \u6703\u9a57\u51fa\u7cde\u4fbf\u6709\u6f5b\u8840\u53cd\u61c9\n(3) Sessile villous adenomas \u884d\u751f\u764c\u8b8a\u4e4b\u6a5f\u7387\u7d04\u70ba tubular adenoma \u4e4b 3 \u500d\n(4) \u767c\u708e\u6027\u8178\u9053\u75be\u75c5 (Inflammatory Bowel Disease) \u60a3\u8005\u767c\u75c5\u5f8c \uff0c\u524d10\u5e74\u767c\u751f\u5927\u8178\u76f4\u8178\u764c\u4e4b\u6a5f\u7387\u76f8\u7576\u4f4e\n(5) \u7f79\u60a3\u5927\u8178\u76f4\u8178\u764c\u4e4b\u60a3\u8005 \uff0c\u7d04 50% \u5176\u7cde\u4fbf\u6f5b\u8840\u70ba\u9670\u6027\u53cd\u61c9\n(6) < 1 cm \u4e4b sessile serrated polyp \u88ab\u5207\u9664\u5f8c \uff0c\u5176\u5f8c\u61c9\u6bcf\u5e74\u6aa2\u67e5\u4e00\u6b21\u5927\u8178\u93e1   \nA.(1)+(2)+(3)+(4)\nB.(1)+(3)+(4)+(5)\nC.(2)+(3)+(4)+(5)\nD.(2)+(4)+(5)+(6)\nE.(3)+(4)+(5)+(6)\n": "[B]", "109-52.\u4e0b\u5217\u95dc\u65bc\u80c3\u8178\u9053\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f    \nA.Hypocalcemia \u53ef\u80fd\u9020\u6210 constipation\nB.\u6cbb\u7642\u6025\u6027\u5927\u8178\u61a9\u5ba4\u708e (diverticulitis) \u76ee\u524d\u6700\u5e38\u4f7f\u7528\u5c0d\u6297 aerobic gram -negative rods \u53ca anaerobic \nbacteria \u4e4b\u6297\u751f\u7d20 \uff0c\u5305\u62ec\u7b2c\u4e09\u4ee3 cephalosporin \u53ca metronidazole\nC.\u6025\u6027\u80c3\u8178\u9053\u51fa\u8840\u75c5\u4eba\u6709\u5fc3\u640f\u904e\u901f\u73fe\u8c61 (tachycardia) \u6642\uff0c\u61c9\u4f7f\u7528 \u03b2 blockers \u63a7\u5236\u4e4b\nD.Secretory diarrhea \u75c5\u4eba\u4e4b\u5927\u4fbf\u91cf\u901a\u5e38\u5c0f\u65bc 1L/\u5929\uff0c\u7981\u98df\u5373\u6703\u505c\u6b62\u8179\u7009\nE.Chronic mesenteric ischemia (intestinal angina) \u75c5\u4eba\u4e4b\u8179\u75db\u901a\u5e38\u8207\u9032\u98df\u7121\u95dc   \n": "[B]", "109-53.\u95dc\u65bc\u5e7d\u9580\u87ba\u65cb\u687f\u83cc (H. pylori) \u4e4b\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f    \nA.Eradication of H. pylori \u6e1b\u5c11\u5341\u4e8c\u6307\u8178\u6f70\u760d\u5fa9\u767c\u9054 80% \u4ee5\u4e0a\nB.\u8840\u6e05 H. pylori \u4e4b IgG antibody test \u53ef\u7528\u4f86\u5224\u65b7 H. pylori eradication \u4e4b\u6548\u679c\nC.\u80c3\u90e8 H. pylori \u88ab\u6839\u9664\u5f8c\uff0c\u518d\u611f\u67d3\u7387\u751a\u4f4e\nD.NSAID (Nonsteroidal Anti-inflammatory Drugs)- induced \u80c3\u6f70\u760d\u8207 H. pylori \u6709\u95dc\nE.H. pylori eradication \u9700\u4f7f\u7528\u7d44\u5408\u7642\u6cd5 \uff0c\u6297\u751f\u7d20\u70ba\u5176\u4e2d\u91cd\u8981\u9805\u76ee \uff0c\u5e38\u7528\u8005\u5305\u62ec \nclarithromycin \u3001amoxicillin\n": "[B]", "109-54.\u75c5\u4eba\u904e\u53bb\u6709\u6162\u6027\u809d\u708e\u75c5\u53f2 \uff0c\u4f46\u4e00\u76f4\u6c92\u6709\u7372\u5f97\u660e\u78ba\u8a3a\u65b7 \u3002\u6b64\u6b21\u5c31\u91ab\u62bd\u8840\u6aa2\u9a57\u6240\u5f97\u7d50\u679c\u5982\u4e0b \uff1aAST=100 (<31) \nU/L\uff0cALT=100 (<41) U/L\uff0cALP=500 (<104) U/L\uff0cGGT=450 (<50) U/L\uff0cBil (T)/(D)=4.0/3.1 mg/dL\uff0cPT \nINR=1.05\u3002\u8acb\u554f\u5176\u8a3a\u65b7\u6700\u4e0d\u53ef\u80fd\u70ba\u4e0b\u5217\u4f55\u8005 \uff1f   \nA.Primary Biliary Cholangitis\nB.Primary Sclerosing Cholangitits\nC.Drug-induced liver injury\nD.Hepatic failure\nE.Stone impaction at common bile duct\n": "[D]", "109-55.\u75c5\u4eba\u81ea\u8a34\u5026\u6020 \u3001\u5641\u5fc3\u3001\u98df\u617e\u4e0d\u632f\u5df2\u6709\u4e94\u5929 \uff0c\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u767c\u73fe \uff1aALT=300 (<41) U/L\uff0cAST=210 (< 31) \nU/L\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u82e5\u62bd\u8840\u6aa2\u9a57 IgM Anti-HAV \u5448\u9670\u6027\uff0c\u5c31\u4e0d\u662f\u6025\u6027 A\u578b\u809d\u708e\nB.\u82e5\u62bd\u8840\u6aa2\u9a57 HBsAg \u5448\u967d\u6027\uff0c\u5c31\u53ef\u78ba\u5b9a\u662f\u6025\u6027 B\u578b\u809d\u708e\u6216 B\u809d\u75c5\u6bd2\u6162\u6027\u611f\u67d3\u8005\u4f75\u6025\u6027\u809d\u708e\u767c\u4f5c\nC.\u82e5\u62bd\u8840\u6aa2\u9a57 Anti-HCV \u5448\u967d\u6027\uff0c\u4e0d\u4e00\u5b9a\u662f\u6025\u6027 C\u578b\u809d\u708e\nD.\u82e5\u6700\u8fd1\u6709\u56e0\u7070\u6307\u7532\u670d\u7528 Ketoconazole\uff0c\u61c9\u7acb\u5373\u505c\u85e5\uff0c\u901a\u5e38\u505c\u85e5\u5f8c 1~2 \u9031\uff0cALT\u503c\u53ef\u80fd\u6703\u660e\u986f\u4e0b\u964d\nE.\u82e5\u6700\u8fd1\u6709\u53f3\u4e0a\u8179\u75db\uff0c\u9700\u6ce8\u610f\u81bd\u7d50\u77f3\u662f\u5426\u6389\u81f3\u7e3d\u81bd\u7ba1\u4e2d\n": "[B]", "109-56.60\u6b72\u5973\u6027\u56e0\u541e\u56a5\u75bc\u75db (odynophagia )\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5 \uff0c\u7d50\u679c\u5982\u9644\u5716 \uff0c\u5efa\u8b70\u7528\u4e0b\u5217\u4f55\u7a2e\u85e5\u53e3\u670d\u6cbb\n\u7642\uff1f   \nA.Acyclovir\nB.Valganciclovir\nC.Fluconazole\nD.Ganciclovir\nE.Dexlansoprazole\n": "[C]", "109-57.50\u6b72\u4e2d\u5e74\u7537\u6027\u6709\u80f8\u75db\u75c7\u72c0 \uff0c\u5fc3\u81df\u6aa2\u67e5\u7121\u7570\u5e38 \uff0c\u56e0\u70ba\u541e\u56a5\u56f0\u96e3\u63a5\u53d7\u92c7\u5291\u98df\u9053\u651d\u5f71 \uff0c\u7d50\u679c\u5982\u9644\u5716 \u3002\u4e0b\u5217\u6558\u8ff0\u4f55\n\u8005\u6b63\u78ba\uff1f\n(1) \u98df\u9053\u58d3\u529b (esophageal manometry )\u53ef\u5448\u73fehypotense lower esophageal sphincter \u53capoor peristaltic \nactivity\n(2) \u53ef\u4ee5\u5408\u4f75\u9006\u6d41 (reflux)\u75c7\u72c0\n(3) \u53ef\u4ee5\u9032\u5c55\u6210\u98df\u9053\u5f1b\u7de9\u4e0d\u80fd (achalasia )\n(4) \u53ef\u4ee5\u7528calcium channel blockers\u6cbb\u7642\n(5) \u4e0d\u80fd\u7528botulinum toxin injections\u6cbb\u7642   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(3)+(4)+(5)   \nD.(1)+(3)+(4)\nE.(2)+(3)+(5)\n": "[B]", "109-58.55\u6b72\u7537\u6027 \uff0c\u9577\u671f\u6709\u80c3\u9178\u9006\u6d41\u53ca\u80f8\u53e3\u707c\u71b1\u75c7\u72c0 \uff0cBMI:30\uff0c\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5 \uff0c\u7d50\u679c(\u5982\u9644\u5716)\u3002\u4e0b\u5217\u6558\n\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u62bd\u7159\u589e\u52a0\u7f79\u75c5\u98a8\u96aa\nB.\u591a\u5403\u852c\u679c\u53ef\u6e1b\u5c11\u7f79\u75c5\u98a8\u96aa\nC.\u6bcf\u5e74\u67090.12~0.5%\u7f79\u764c\u98a8\u96aa\nD.\u589e\u52a0\u98df\u9053\u4e0a\u76ae\u7d30\u80de\u764c(esophageal squamous cell carcinoma)\u98a8\u96aa\nE.\u6297\u9006\u6d41\u624b\u8853(antireflux surgery)\u7121\u6cd5\u9810\u9632\u5176\u9032\u5c55\u6210\u764c\u75c7\n": "[D]", "109-59.\u6709\u95dc\u5e7d\u9580\u87ba\u65cb\u687f\u83cc (Helicobacter pylori )\u611f\u67d3\u7684\u6558\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4 \uff1f\n(1) \u4e16\u754c\u885b\u751f\u7d44\u7e54\u5b9a\u5176\u70badefinite carcinogen\n(2) \u8207\u80c3\u9ecf\u819c\u76f8\u95dc\u6dcb\u5df4\u7d44\u7e54 (gastric mucosa -associated lymphoid tissue -MALT)\u6dcb\u5df4\u764c\u7684\u767c\u751f\u6709\u95dc\n(3) \u8207\u80c3\u98df\u9053\u9006\u6d41\u6027\u75be\u75c5\u7684\u767c\u751f\u6709\u95dc\n(4) \u8207\u4e0d\u660e\u539f\u56e0\u8840\u5c0f\u677f\u6e1b\u5c11\u7d2b\u6591\u75c7 (idiopathic thrombocytopenic purpura )\u7684\u767c\u751f\u6709\u95dc\n(5) \u7b2c\u4e00\u7dda\u6cbb\u7642\u61c9\u7528\u6a19\u6e96\u5291\u91cfproton pump inhibitor twice daily\u52a0\u4e0alevoflaxacin 500mg /d\u53caamoxicilliin \n1000mg twice daily   \nA.(1)+(2)\nB.(3)+(4)\nC.(1)+(5)\nD.(3)+(5)\nE.(2)+(3)\n": "[D]", "109-60.\u4e0b\u5217\u6709\u95dc\u80c3\u606f\u8089(gastric polyp)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f    \nA.Sporadic fundic gland polyp (FGP)\u8207proton pump inhibitor\u4f7f\u7528\u6709\u95dc \uff0c\u606f\u8089\u6578\u76ee\u5c0f\u65bc10 \uff0c\u5927\u5c0f\n\u57281-5mm\uff0c\u6bcb\u9700\u5207\u9664\nB.\u907a\u50b3\u6027FGPs\u606f\u8089\u6578\u76ee\u5e38\u5927\u65bc30 \uff0c\u8207familial adenomatous polyposis (FAP)\u6216MYH-associated \npolyposis\u6709\u95dc \uff0c\u6613\u6709\u4e0d\u826f\u5316\u751f (dysplasia )\nC.\u61f7\u7591FAP \u6216MYH-associated polyposis\u5fc5\u9808\u9032\u884c\u5927\u8178\u93e1\u6aa2\u67e5\nD.Hyperplastic polyps\u4e0d\u6703\u6709\u4e0d\u826f\u5316\u751f(dysplasia)\nE.Adenomatous polyps\u8207\u840e\u7e2e\u6027\u80c3\u708e (atrophic gastritis )\u3001\u8178\u5316\u751f(intestinal metaplasia )\u3001\u53ca\u5e7d\u9580\u87ba\u65cb\u687f\n\u83cc\u611f\u67d3\u6709\u95dc\n": "[D]", "109-61.55\u6b72\u7537\u6027\u56e0\u6025\u6027\u8179\u75db \u3001\u5641\u5fc3\u548c\u5614\u5410\u81f3\u6025\u8a3a\u8655\u5c31\u91ab \uff0c6\u9031\u5167\u4ed6\u6709\u5169\u6b21\u98ef\u5f8c\u7684\u53f3\u4e0a\u8179\u75db \uff0c\u9664\u6b64\u5916\u4ed6\u904e\u53bb\u4e26\u7121\u4efb\n\u4f55\u91ab\u85e5\u53f2 \u3002\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab36 .8\u2103\u3001\u8840\u58d3130/75 mmHg \u3001\u8108\u640f89/min\u3001\u547c\u5438\u901f\u738717 /min\u3001BMI:29\uff0c\u978f\u819c\u6709\n\u9ec3\u75b8\uff0c\u8179\u90e8\u6aa2\u67e5\u6709tenderness \uff0c\u4f46\u4e26\u7121guarding \u6216rebound pain \uff0c\u8178\u97f3\u5448\u73fehypoactive \u3002\u4f4f\u9662\u5f8c\uff0c\u7d66\n\u4e88fluid resuscitation \u5f8c\uff0c\u5be6\u9a57\u5ba4\u6578\u64da (\u5982\u9644\u8868)\uff1a\u8179\u90e8\u8d85\u97f3\u6ce2\u6709\u81bd\u7d50\u77f3\u4f46\u4e26\u7121\u81bd\u56ca\u58c1\u589e\u5f8c\u6216\u7a4d\u6c34\u73fe\u8c61 \uff0c\u7e3d\u81bd\n\u7ba1\u4e26\u7121\u64f4\u5f35 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u9069\u7576\u8655\u7f6e \uff1f   \nA.\u51fa\u9662\u524d\u9032\u884cCholecystectony\nB.\u9032\u884ccholecystokin hepatobiliary (CCK-HIDA)scintigraphy\nC.\u9032\u884cendoscopic retrograde cholangiopancreaticography with bitiary sphincterotomy\nD.Intravenous imipenem\nE.Total parenteral nutirition   \n": "[A]", "109-62.43\u6b72\u5973\u6027\u56e0\u70ba 4\u5929\u7684\u8179\u75db\u81f3\u6025\u8a3a\u8655 \uff0c\u4e00\u9031\u524d\u5979\u63a5\u53d7\u8179\u8154\u93e1\u81bd\u56ca\u5207\u9664\u8853 (laparoscopic cholecystectomy )\uff0c\u624b\n\u8853\u5f88\u9806\u5229 \uff0c\u4e26\u7121\u660e\u986f\u4f75\u767c\u75c7 \uff0c\u5979\u65bc\u540c\u65e5\u51fa\u9662 \u3002\u624b\u8853\u5f8c3\u5929\u958b\u59cb\u6709\u6301\u7e8c30\u5206\u9418\u81f3 2\u5c0f\u6642\u7684\u4e0a\u8179\u75db \uff0c\u5408\u4f75\u5641\n\u5fc3\u3002\u8eab\u9ad4\u6aa2\u67e5 \uff1a\u9ad4\u6eab:36.8\u2103\uff0c\u8840\u58d3106/60 mmHg \u3001\u8108\u640f82/min\u3001\u547c\u5438\u901f\u738716 /min\uff0c\u8179\u90e8\u6aa2\u67e5\u4e26\u7121\u7570\u5e38\n\u73fe\uff0c\u624b\u8853\u50b7\u53e3\u5fa9\u539f\u826f\u597d \uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5ALT: 84 U/L\u3001AST: 62U/L\u3001CBC\u3001ALP\u548camylase\u6578\u503c\u5747\u65bc\u6b63\u5e38\u7bc4\n\u570d\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u4e26\u7121\u8179\u6c34 \uff0c\u809d\u5167\u53ca\u809d\u5916\u81bd\u7ba1\u6709\u64f4\u5f35\u73fe\u8c61 \u300224\u5c0f\u6642\u5f8cAST \u53caALT\u6062\u5fa9\u6b63\u5e38 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\n\u6700\u53ef\u80fd\u7684\u8a3a\u65b7 \uff1f   \nA.Acute pancreatitis\nB.Bile leak\nC.Cholangitis\nD.Choledocholitihiasis\nE.Sphincter of Oddi dysfunction\n": "[D]", "109-63.80\u6b72\u7537\u6027\u904e\u53bb 3\u500b\u6708\u6709\u9593\u6b47\u6027\u89e3\u9ed1\u4fbf (intermittent melena )\uff0c\u5165\u9662\u6642\u8eab\u9ad4\u6aa2\u67e5 \uff1a\u9ad4\u6eab:37\u2103\uff0c\u8840\u58d3135/80 \nmmHg\u3001\u8108\u640f80/min\u3001\u547c\u5438\u901f\u738718 /min\uff0cHb: 8.2 g/dL\u3002\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u53ca\u5168\u5927\u8178\u93e1\u6aa2\u67e5\u4e26\u7121\u7570\u5e38\u767c\n\u73fe\u3002\u81a0\u56ca\u5167\u8996\u93e1 (Capsule endoscopy )\u6aa2\u67e5\u767c\u73feproximal jejunum\u6709\u9bae\u8840 \uff0c\u4e26\u6709\u4e00\u4e9bangiodysplasia \u3002\u4e0b\u4e00\n\u6b65\u6700\u9069\u7576\u7684\u8655\u7f6e\u70ba\u4f55 \uff1f   \nA.Intraoperative endoscopy\nB.Push enteroscopy\nC.Repeat upper endoscopy\nD.Repeat colonoscopy\nE.Technetium labeled nuclean scan\n": "[B]", "109-64.38\u6b72\u7537\u6027\u6f70\u760d\u6027\u8178\u708e\u60a3\u800510\u5929\u524d\u958b\u59cb\u6bcf\u65e5\u670d\u7528prednisolone 60mg \uff0c\u4f46\u662f\u4ecd\u6bcf\u65e5\u6709 6\u81f39\u6b21\u7684\u8840\u4fbf\u5408\u4f75\u8179\n\u75db\uff0c\u56e0\u70ba\u9032\u98df\u52a0\u91cd\u75bc\u75db\u548c\u8179\u7009 \uff0c\u4ed6\u4e3b\u52d5\u6e1b\u5c11\u7d93\u53e3\u9032\u98df \u3002\u8eab\u9ad4\u6aa2\u67e5 \uff1a\u9ad4\u6eab:37\u2103\uff0c\u8840\u58d3110/56 mmHg \u3001\u8108\n\u640f96/min\uff0c\u8179\u90e8\u6709diffuse tenderness\u4f46\u4e26\u7121guarding \u6216rebound pain\u73fe\u8c61 \u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u986f\u793aHb: 9.7 \ng/dL\u3001WBC: 6300 /\u03bcL\uff0c\u7cde\u4fbf\u57f9\u990a\u548cClostridium difficile\u6aa2\u67e5\u7686\u70ba\u9670\u6027 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6b64\u60a3\u8005\u76ee\u524d\u6700\u9069\u7576\u7684\u6cbb\n\u7642\uff1f   \nA.\u589e\u52a0prednisolone\u81f3\u6bcf\u65e580mg\nB.\u4f7f\u7528adalimumab\nC.\u4f7f\u7528ciprofloxacin \u548cmetronidazole\nD.\u4f7f\u7528mesalamine\nE.\u4f7f\u7528sulfasalazine\n": "[B]", "109-65.28\u6b72\u5973\u6027\u56e0 8\u9031\u7684\u4e0b\u8179\u7d5e\u75db\u5408\u4f75\u8179\u7009\u75c5\u53f2 \uff0c\u63a5\u53d7\u9032\u4e00\u6b65\u8a55\u4f30 \uff0c\u5979\u6bcf\u5929\u6392\u4fbf 6\u81f310\u6b21\uff0c\u5176\u4e2d\u6709\u4e00\u81f3\u4e8c\u6b21\u5728\u534a\n\u591c\uff0c\u5927\u4fbf\u7279\u5fb5\u70baloose to watery with intermittent blood streaking \u3002\u53e6\u5916\u5979\u6709\u5641\u5fc3\u53ca\u98df\u617e\u8b8a\u5dee\u73fe\u8c61 \uff0c\u4f46\u7121\u5614\n\u5410\u3001\u767c\u71d2\uff0c\u4e5f\u7121\u670d\u7528\u85e5\u7269\u75c5\u53f2 \u3002\u8eab\u9ad4\u6aa2\u67e5 \uff1a\u9ad4\u6eab:37.8\u2103\uff0c\u8840\u58d3100/54 mmHg \u3001\u8108\u640f96/min\uff0c\u8179\u90e8\u5448\n\u73fediffuse tenderness\u4f46\u7121rigidity, guarding \u6216rebound pain \u3002\u5927\u8178\u93e1\u6aa2\u67e5\u5728\u5347\u7d50\u8178 \u3001\u6a6b\u7d50\u8178\u53ca\u964d\u7d50\u8178\u6709\u5982\n\u9644\u5716\u4e4b\u767c\u708e\u75c5\u7076 \uff0c\u4f46\u662fterminal ileum \u53carectum\u4e26\u7121\u767c\u708e\u73fe\u8c61 \uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7 \uff1f   \nA.Collagenous colitis\nB.Crohn colitis\nC.Ischemic colitis\nD.Ulcerative colitis\nE.Tuberculous colitis   \n": "[B]", "109-66.\u6709\u95dcCOVID -19\u7684\u80c3\u8178\u8207\u809d\u81df\u7570\u5e38\u8868\u73fe\u6558\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u5641\u5fc3(nausea)\u6bd4\u98df\u617e\u4e0d\u632f (anorexia )\u5e38\u898b\n(2) \u8179\u7009\u662f\u6700\u5e38\u898b\u7684\u80c3\u8178\u8868\u73fe\n(3) \u4ee5\u55c5\u89ba\u6216\u5473\u89ba\u505a\u70ba\u9810\u6e2cCOVID -19\u8868\u73fe\uff0c\u654f\u611f\u5ea6\u6bd4\u7279\u7570\u5ea6\u9ad8\n(4) \u8f15\u5ea6AST /ALT\u4e0a\u6607\u70ba\u6700\u5e38\u898b\u4e4b\u809d\u81df\u7570\u5e38\n(5) \u80c3\u8178\u7570\u5e38\u8f03\u809d\u81df\u7570\u5e38\u66f4\u5e38\u898b   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(3)+(4)+(5)\nD.(1)+(3)+(5)\nE.(2)+(4)+(5)\n": "[E]", "110-37.\u75c5\u4eba\u56e0\u8179\u75db\u5c31\u91ab \uff0c\u5176\u75c5\u53f2\u5df2\u6709 6-7\u500b\u6708\uff0c\u8179\u75db\u6c92\u6709\u56fa\u5b9a\u90e8\u4f4d \uff0c\u672c\u4f86\u6bcf\u9031\u4e00\u6b21 \uff0c\u8fd1\u4f86\u983b\u7387\u589e\u52a0\u81f3\u6bcf\n\u90312-3\u6b21\uff0c \u6bcf\u6b21\u8179\u75db\u6301\u7e8c\u6642\u9593\u9577\u77ed\u4e0d\u4e00 \u3002\u5728\u9019\u6bb5\u671f\u9593 \uff0c\u5927\u4fbf\u6b21\u6578\u81ea\u904e\u53bb\u7684\u6bcf\u5929\u4e00\u6b21\u589e\u81f3\u6bcf\u5929 3-4\u6b21\uff0c\u91cf\u4e0d\n\u591a\uff0c\u4e14\u591a\u4e0d\u6210\u5f62 \u3002\u75c5\u4eba\u64d4\u5fc3\u662f\u5426\u5df2\u7f79\u60a3\u5927\u8178\u764c \u3002\u95dc\u65bc\u9019\u500b\u75c5\u4eba\u7684\u75c5\u60c5 \uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u82e5\u6b64\u75c5\u4eba\u6709\u8ca7\u8840\u73fe\u8c61 \uff0c\u61c9\u5b89\u6392\u5927\u8178\u93e1\u6aa2\u67e5\n(2) \u6b64\u7a2e\u75c5\u4eba\u4e00\u822c\u4e0d\u6703\u6709\u9ad4\u91cd\u6e1b\u8f15\u60c5\u6cc1\n(3) \u6b64\u7a2e\u75c5\u4eba\u665a\u4e0a\u5e38\u6703\u88ab\u8179\u75db\u5435\u9192\n(4) \u6b64\u7a2e\u75c5\u4eba\u9700\u5b89\u6392\u98df\u7269\u904e\u654f\u539f\u6aa2\u6e2c\n(5) \u6b64\u7a2e\u75c5\u4eba\u6709\u6642\u6703\u6392\u51fa\u7c98\u6db2 \uff0c\u4f46\u4e00\u822c\u4e0d\u6703\u89e3\u51fa\u9bae\u8840\n(6) \u6b64\u7a2e\u75c5\u4eba\u5e38\u5408\u4f75\u6709dyspepsia \u3001heartburn \u6216 nausea   \nA.(1) + (2) + (3) + (4)\u3002\nB.(1) + (3) + (5) + (6)\u3002\nC.(2) + (3) + (4) + (6)\u3002\nD.(3) + (4) + (5) + (6)\u3002\nE.(1) + (2) + (5) + (6)\u3002\n": "[E]", "110-38.70\u6b73\u5973\u6027\u75c5\u4eba\u56e0\u7a81\u767c\u5de6\u4e0b\u8179\u75db\u53ca\u767c\u71d2\u81f338 .5\u2070C\u800c\u5c31\u91ab\uff0c\u62bd\u8840\u6aa2\u9a57\u6709\u767d\u8840\u7403\u7570\u5e38\u5347\u9ad8\u73fe\u8c61 \uff0c\u5de6\u4e0b\u8179\u89f8\u6478\u6703\u75db \n(tenderness) \u4f46\u6c92\u6709\u53cd\u5f48\u75db (rebound pain )\uff0c\u96b1\u7d04\u6478\u5230\u4e00\u5718\u5c0f\u5c0f\u7684\u816b\u584a \uff0c\u75c5\u4eba\u8840\u58d3\u6b63\u5e38 \u3002\u91dd\u5c0d\u9019\u500b\u75c5\u4eba\u4e4b\n\u75c5\u60c5\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u61c9\u5118\u5feb\u5b89\u6392\u5927\u8178\u93e1\u6aa2\u67e5\n(2) \u61c9\u5b89\u6392contrast -enhanced computed tomography (CECT)\n(3) \u61c9\u99ac\u4e0a\u7167\u6703\u5916\u79d1\u6e96\u5099emergent operation\n(4) \u61c9\u7167\u6703\u5a66\u7522\u79d1\u4ee5\u6392\u9664\u5375\u5de2\u56ca\u816b\u76f8\u95dc\u75be\u75c5\n(5) \u5148\u7981\u98df\uff0c\u4e26\u7d66\u4e88\u6297\u751f\u7d20 \uff0c\u5305\u62ec\u7b2c\u4e09\u4ee3cephalosporin \u6216 ciprofloxacin \u4f75 metronidzole\n(6) \u75c5\u4eba\u53ef\u80fd\u6709 abscess   \nA.(1) + (2) + (3) + (4)\u3002\nB.(1) + (3) + (5) + (6)\u3002\nC.(2) + (4) + (5) + (6)\u3002\nD.(2) + (3) + (5) + (6)\u3002\nE.(3) + (4) + (5) + (6)\u3002\n": "[C]", "110-39.\u75c5\u4eba\u56e0\u8336\u8272\u5c3f\u4e09\u5929\u53ca\u53f3\u4e0a\u8179\u75db\u800c\u4f86\u5c31\u91ab \uff0c\u6c92\u6709\u767c\u71d2 \u3002\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b \uff1aAST=300 U/L (<31)\uff0cALT=345 \nU/L (<41)\uff0cALP=430 U/L (<104)\uff0c\u03b3-GT=450 U/L (<50)\uff0cBil (T)/(D)=4.5/3.5 mg/dL \n(<1.1/<0.4)\uff0c Albumin=4.0 g/dL (>3.5)\uff0cProthrombin time =10.1\"\uff0cINR=1.01\n\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u61c9\u5118\u5feb\u5b89\u6392\u8d85\u97f3\u6ce2\u6aa2\u67e5\u3002\nB.\u5f71\u50cf\u6aa2\u67e5\u5f88\u53ef\u80fd\u767c\u73fe\u5169\u5074\u809d\u5167\u81bd\u7ba1\u64f4\u5f35\u3002\nC.\u5f71\u50cf\u6aa2\u67e5\u5f88\u53ef\u80fd\u767c\u73fe\u7e3d\u81bd\u7ba1\u64f4\u5f35\u3002\nD.\u5f8c\u7e8c\u53ef\u80fd\u9700\u5b89\u6392\u5167\u8996\u93e1\u9006\u884c\u6027\u81bd\u80f0\u7ba1\u651d\u5f71\u53ca\u76f8\u95dc\u4ecb\u5165\u8655\u7f6e\u3002\nE.\u75c5\u4eba\u7f79\u60a3\u539f\u767c\u6027\u81bd\u6c41\u6eef\u7559\u6027\u809d\u75c5 (primary biliary cirrhosis)\u3002\n": "[E]", "110-40.\u75c5\u4eba\u56e0\u5026\u6020\u53ca\u98df\u617e\u4e0d\u632f\u800c\u4f86\u5c31\u91ab \uff0c\u62bd\u8840\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b \uff1aFree T4=1.00ng/dL (0.7-1.48)\uff0cTSH=1.85mU/L \n(0.35-4.94)\uff0cBUN=15mg/dL (<25)\uff0cCr=0.6mg/dL (<1.2)\uff0cALT=450 U/L (<41)\uff0cAST=350 U/L \n(<31)\uff0cALP=650 U/L (<104)\uff0c\u03b3-GT=790 U/L (<50)\uff0cBil(T)/(D)=2.5/1.85 mg/dL \n(<1.1/<0.4)\uff0c Albumin=3.9 g/dL (>3.5)\uff0cProthrombin time INR =1.05\uff0cAnti-HCV (+)\uff0cHCV RNA: Not \ndetected \uff0cHBsAg (+) \uff0cHBV DNA =500 IU/mL\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u75c5\u4eba\u6709hypothyroidism\u3002   \nB.\u75c5\u4eba\u6709\u6025\u6027\u809d\u708e\u767c\u4f5c\uff0c\u61c9\u8207 B\u578b\u809d\u708e\u75c5\u6bd2\u6709\u95dc\u3002\nC.\u75c5\u4eba\u6709\u6025\u6027\u809d\u708e\u767c\u4f5c\uff0c\u61c9\u8207 C\u578b\u809d\u708e\u75c5\u6bd2\u6709\u95dc\u3002\nD.\u75c5\u4eba\u6709\u6025\u6027\u809d\u708e\u767c\u4f5c\uff0c\u5176\u75c5\u56e0\u5f88\u53ef\u80fd\u70ba\u81bd\u6c41\u6eef\u7559\u6027\u809d\u75c5 (cholestatic liver disease)\u3002\nE.\u75c5\u4eba\u5df2\u6709\u809d\u81df\u5931\u4ee3\u511f\u73fe\u8c61 (liver decompensation)\u3002\n": "[D]", "110-41.\u6709\u95dc\u53f0\u7063 C\u578b\u809d\u708e\u4e4b\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u76ee\u524d\u53f0\u7063\u5065\u4fdd\u7d66\u4ed8 Direct Acting Antivirals (DAAs) \u4e4b\u6cbb\u7642\u50c5\u9650\u7528\u65bc\u6162\u6027 C\u578b\u809d\u708e\u75c5\u4eba\u3002\nB.\u76ee\u524dDAAs\u4e4b\u7642\u7a0b\uff0c\u591a\u57288-12\u9031\u3002\nC.\u670d\u7528\u542bNS 3/4A Protease Inhibitors\u985e\u4e4bDAAs \u6642\uff0c\u4e00\u65e6\u767c\u73fe prothrombin time \u660e\u986f\u5ef6\u9577 \uff0c\u61c9\u7acb\u5373\u505c\u6b62\n\u670d\u85e5\u3002\nD.\u76ee\u524d\u53f0\u7063\u4f7f\u7528\u4e4bDAAs \u85e5\u7269\u4e3b\u8981\u662f pangenotypic drugs\u3002\nE.\u53f0\u7063\u8981\u57282025\u5e74\u6839\u9664 C\u809d\uff0c\u5176\u4e3b\u8981\u95dc\u9375\u5728\u65bc\u5f37\u5316\u7be9\u6aa2\u627e\u51fa\u6f5b\u5728\u7684 C\u809d\u75c5\u4eba\u3002\n": "[A]", "110-42.\u95dc\u65bc\u53f0\u7063\u5065\u4fdd\u5c0d B\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u7d66\u4ed8\u898f\u7bc4\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u76ee\u524d\u7684\u5171\u8b58\u662f \uff1a\u7947\u8981\u8840\u4e2d B\u809d\u75c5\u6bd2\u91cf (viral load) \u5927\u65bc 1,000,000 IU/mL\uff0c\u5c31\u61c9\u8a72\u958b\u59cb\u4ee5\u53e3\u670d\u6297 B\u809d\u75c5\n\u6bd2\u85e5\u7269\u6cbb\u7642 \u3002\nB.\u521d\u6b21\u88ab\u767c\u73fe\u8840\u4e2d HBsAg \u967d\u6027\uff0c IgM Anti -HBc \u4ea6\u967d\u6027\u4e14\u6578\u503c\u76f8\u7576\u9ad8 \uff0cALT=400 U/L (<41)\uff0cBil (T)\n=0.9 mg/dL (<1.1)\uff0cProthrombin time =11.0\"\uff0cINR=1.1\uff0c\u4e0d\u5fc5\u6025\u8457\u958b\u59cb\u7d66\u4e88\u53e3\u670d\u6297 B\u809d\u75c5\u6bd2\u85e5\u7269 \u3002\nC.30\u6b72\u7684\u6162\u6027 B\u578b\u809d\u708e\u60a3\u8005\uff0c\u6cbb\u7642\u7684\u512a\u5148\u8003\u91cf\u85e5\u7269\u662f pegylated interferon\u3002\nD.\u7f79\u60a3\u809d\u7d30\u80de\u764c\u4e4b B\u809d\u60a3\u8005\uff0c\u7947\u8981\u8840\u4e2d\u6e2c\u5f97\u5230 B\u809d\u75c5\u6bd2\uff0c\u5c31\u53ef\u4ee5\u9577\u671f\u670d\u7528\u6297 B\u809d\u75c5\u6bd2\u85e5\u7269\u3002\nE.\u4f7f\u7528\u53e3\u670d\u6297 B\u809d\u75c5\u6bd2\u85e5\u7269\u6642\uff0c\u61c9\u96a8\u6642\u6ce8\u610f\u75c5\u4eba\u4e4b\u814e\u529f\u80fd\u3002\n": "[A]", "110-43.\u8179\u90e8\u8d85\u97f3\u6ce2\u4e4b\u4f7f\u7528\u6108\u4f86\u6108\u983b\u7e41 \uff0c\u56e0\u6b64\u816b\u7624\u610f\u5916\u88ab\u767c\u73fe\u7684\u6a5f\u7387\u4e5f\u6108\u4f86\u6108\u9ad8 \u3002\u95dc\u65bc\u809d\u816b\u7624\u7684\u8a3a\u65b7\u8207\u6cbb\u7642 \uff0c\u4e0b\u5217\n\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u8840\u7ba1\u7624 (hemangioma) \u662f\u6700\u5e38\u898b\u7684\u826f\u6027\u809d\u816b\u7624\uff0c\u901a\u5e38\u7947\u8981\u5b9a\u671f\u8ffd\u8e64\u5373\u53ef\u3002\nB.\u809d\u81df\u817a\u7624 (hepatic adenoma) \u76f8\u7576\u5c11\u898b \uff0c\u5176\u5f62\u6210\u8207 oral contraceptives \u6216 anabolic androgenic \nsteroids \u5bc6\u5207\u76f8\u95dc \u3002\nC.B\u809d\u75c5\u6bd2\u53ca C\u809d\u75c5\u6bd2\u5c0e\u81f4\u7684\u809d\u786c\u5316\u75c5\u4eba\uff0c\u662f\u7f79\u60a3\u809d\u7d30\u80de\u764c\u7684\u6700\u9ad8\u5371\u96aa\u7fa4\u3002\nD.\u809d\u786c\u5316\u7684\u809d\u81df\u5167\u6709\u4e00\u9846\u76f4\u5f91 2\u516c\u5206\u7684\u7d50\u7bc0 \uff0c\u60a3\u8005\u8840\u4e2dAFP (Alpha-fetoprotein) \u53ca PIVKA -II (Protein \ninduced by Vitamin K absence or antagonists -II) \u6578\u503c\u7686\u5728\u6b63\u5e38\u7bc4\u570d\u5167 \uff0c\u4e14\u8207\u904e\u53bb\u5dee\u4e0d\u591a \uff0c\u6545\u4e0d\u53ef\u80fd\n\u70ba\u809d\u7d30\u80de\u764c \u3002\nE.\u81bd\u7ba1\u7d30\u80de\u764c (cholangiocarcinoma) \u4e4b\u9810\u5f8c\uff0c\u4e00\u822c\u6bd4\u809d\u7d30\u80de\u764c\u5dee\u3002\n": "[D]", "110-44.\u975e\u9152\u7cbe\u6027\u8102\u80aa\u809d\u75c5 (Non-alcoholic fatty liver disease, NAFLD) \u6108\u4f86\u6108\u666e\u904d \uff0c\u5df2\u6210\u70ba\u6162\u6027 B\u809d\u53caC\u809d\u4ee5\u5916\u6700\n\u5e38\u898b\u7684\u809d\u75c5 \u3002\u4e0b\u5217\u6709\u95dc NAFLD \u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u7f8e\u570b\u98df\u85e5\u5c40 (FDA) \u5df2\u901a\u904e Thiazolidinedions \u985e\u85e5\u7269\u53ef\u7528\u4f86\u6cbb\u7642 NAFLD\u3002\nB.\u7f8e\u570b\u7684\u8cc7\u6599\u986f\u793a\uff0cNAFLD \u75c5\u4eba\u4e2d\u7d04 20-25% \u5df2\u6709 NASH (non-alcoholic steatohepatitis)\u3002\nC.Metformin \u96d6\u80fd\u6539\u5584 hepatic insulin resistance\uff0c\u4f46\u4ecd\u7121\u6cd5\u6539\u5584 NASH\u3002\nD.Transient elastography (Fibroscan) \u53ef\u7528\u4f86\u9577\u671f\u8ffd\u8e64 NAFLD \u75c5\u4eba\u4e4b\u809d\u5167\u8102\u80aa\u91cf\u53ca\u7e96\u7dad\u5316\u72c0\u614b\u3002\nE.\u8102\u80aa\u809d\u4f75\u6709\u7cd6\u5c3f\u75c5\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u4e4b\u75c5\u4eba\u4e5f\u662f\u7f79\u60a3\u809d\u7d30\u80de\u764c\u7684\u5371\u96aa\u7fa4\u3002\n": "[A]", "110-45.Acute intestinal obstruction \u53ef\u5206 mechanical blockage \u53ca functional dysmotility (ileus) \u5169\u7a2e\u75c5\u60c5 \u3002\u4e0b\u5217\u6709\n\u95dc acute intestinal obstruction \u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.Upright plain films of the abdomen \u5c0d\u8a3a\u65b7\u5f88\u6709\u5e6b\u52a9\uff0c\u5fc5\u8981\u6642\u518d\u5b89\u6392\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002   \nB.\u82e5 Upright plain films of the abdomen \u986f\u793a\u5927\u8178\u53ca\u5c0f\u8178\u7686\u6f32\u5927\u4e14\u5145\u6eff\u6c23\u9ad4 \uff0c\u5373\u53ef\u8a3a\u65b7\u70ba colon \nobstruction \u3002\nC.ileus \u7684\u75c5\u4eba\u901a\u5e38\u4e0d\u6703\u5614\u5410\u3002\nD.\u6108\u9060\u7aef\u7684\u8178\u5b50\u767c\u751f mechanical blockage\uff0c\u809a\u5b50\u8139\u5f97\u6108\u53b2\u5bb3\u3002\nE.Mechanical blockage \u767c\u751f\u521d\u671f \uff0c\u75c5\u4eba\u6613\u6709 colicky abdominal pain \uff0cbowel sound \u8f03 \nhyperactive \uff0c\u5176\u5f8c colicky pain \u53ef\u80fd\u6162\u6162\u6e1b\u8f15\uff0c bowel sound \u53ef\u80fd\u8b8a\u6210 hypoactive \u3002\n": "[B]", "110-46.\u60a3\u8005\u4ee5\u541e\u56a5\u56f0\u96e3 (dysphagia )\u4e3b\u8a34\u4f86\u8a3a \uff0c\u4e4b\u524d\u6709\u8072\u97f3\u6c99\u555e (hoarseness )\u73fe\u8c61\uff0c\u76ee\u524d\u5408\u4f75\u6709\u9f3b\u8fd4\u6d41 (nasal \nregurgitation )\u53ca\u5bb9\u6613\u55c6\u5230 (aspiration )\uff0c\u4e0b\u5217\u4f55\u9805\u8a3a\u65b7\u6700\u4e0d\u53ef\u80fd\u662f\u6b64\u4f4d\u60a3\u8005\u7684\u75c5\u56e0 \uff1f   \nA.Pakinson\u2019s disease\u3002\nB.Schatzki ring\u3002\nC.Zenker\u2019s diverticulum\u3002\nD.Guillain-Barre syndrome\u3002\nE.Post head and neck surgery\u3002\n": "[B]", "110-47.\u8179\u6c34\u75c5\u60a3 \uff0c\u8840\u6db2\u767d\u86cb\u767d (albumin) 3.0g/dL\uff0c\u8179\u6c34\u4e2d\u86cb\u767d\u7e3d\u91cf 2.0g/dL\uff0c\u767d\u86cb\u767d1.2g/dL\uff0c\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\n\u4e0b\u5217\u4f55\u8005 \uff1f   \nA.nephrotic syndrome\u3002\nB.pancreatitis\u3002\nC.constrictive pericarditis\u3002\nD.tuberculosis\u3002\nE.liver cirrhosis\u3002\n": "[E]", "110-48.\u60a3\u8005\u56e0\u9577\u671f\u80f8\u53e3\u707c\u71b1 (heartburn )\u53ca\u80f8\u75db\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5 \uff0c\u7d50\u679c\u5982\u5716 \uff0c\u4e0b\u5217\u4f55\u8005\u548c\u6b64\u75c5\u7076\u7684\u767c\u751f\u7121\n\u95dc\uff1f   \nA.Lower esophageal sphincter hypotension\u3002\nB.Hiatal hernia\u3002\nC.Helicobacter pylori infection\u3002\nD.Pepsin\u3002\nE.Bile\u3002\n": "[C]", "110-49.\u6709\u95dc\u6162\u6027\u840e\u7e2e\u6027\u80c3\u708e (chronic atrophic gastritis )\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4 \uff1f(1)\u5206\u6210A\u578b\u53caB\u578b\uff0c\u5e7d\u9580\u687f\u83cc\u611f\u67d3\n\u548cB\u578b\u6709\u95dc (2)pepsinogen I \u548cpepsinogen II\u7684\u6578\u503c\u7686\u6e1b\u5c11 (3)\u548c\u60e1\u6027\u8ca7\u8840 (pernicious anemia )\u7121\u95dc \n(4)gastrin\u6578\u503c\u964d\u4f4e (5)\u6709\u4e9b\u60a3\u8005\u53ef\u6e2c\u5230\u91dd\u5c0dthyroid antigen\u4e4b\u6297\u9ad4   \nA.(1)+(2)+(3)\u3002\nB.(1)+(2)+(4)\u3002\nC.(2)+(3)+(4)\u3002\nD.(2)+(3)+(5)\u3002\nE.(3)+(4)+(5)\u3002\n": "[C]", "110-50.23\u6b72\u7537\u6027\u56e0\u89e3\u9ecf\u6db2\u4fbf \u3001\u8179\u90e8\u7d5e\u75db\u5408\u4f75\u76f4\u8178\u51fa\u8840 \uff0c\u63a5\u53d7\u5168\u5927\u8178\u93e1\u6aa2\u67e5 (\u7d50\u679c\u5982\u5716\u4e00 )\uff0c\u5207\u7247\u6aa2\u67e5\u75c5\u7406\u5716\u50cf (\u5716\n\u4e8c)\uff0c\u4e0b\u5217\u6709\u95dc\u6b64\u75c5\u7684\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u975e \uff1f(1)\u897f\u73ed\u7259\u88d4\u7f8e\u570b\u4eba\u767c\u751f\u7387\u8f03\u767d\u4eba\u70ba\u9ad8 (2)\u62bd\u7159\u53ef\u964d\u4f4e\u6b64\u75c5\u7684\u767c\u751f\u7387 \n(3)\u53e3\u670d\u907f\u5b55\u85e5\u6703\u589e\u52a0\u98a8\u96aa (4)\u5207\u9664\u76f2\u8178 (appendectomy )\u6703\u589e\u52a0\u98a8\u96aa (5)\u51fa\u751f\u4e00\u5e74\u5167\u4f7f\u7528\u6297\u751f\u7d20\u6703\u589e\u52a0\u98a8\u96aa   \nA.(1)+(2)+(3)\u3002   \nB.(1)+(3)+(4)\u3002\nC.(2)+(3)+(4)\u3002\nD.(2)+(3)+(5)\u3002\nE.(3)+(4)+(5)\u3002\n": "[B]", "110-51.\u60a3\u8005\u56e0\u770b\u7259\u91ab\u767c\u73fe\u65bc\u5634\u5507 \u3001\u53e3\u8154\u6709\u6df1\u68d5\u8272\u8272\u7d20\u6c88\u7a4d \uff0c\u800c\u8f49\u8a3a\u6d88\u5316\u5167\u79d1 \uff0c\u7d93\u4e0a\u3001\u4e0b\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5 \uff0c\u767c\u73fe\n\u65bc\u80c3\u53ca\u5927\u8178\u6709\u606f\u8089 \uff0c\u6709\u95dc\u6b64\u75c5\u75c7\u7684\u6558\u8ff0\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u606f\u8089\u75c5\u7406\u70bahamartoma\u3002\nB.\u6bd4\u8d77familial adenomatous polyposis\uff0c\u6b64\u7a2e\u606f\u8089\u8f49\u6210\u60e1\u6027\u6a5f\u6703\u8f03\u4f4e\u3002\nC.\u8207\u5375\u5de2\u816b\u7624\u767c\u751f\u6709\u95dc\u3002\nD.\u8207\u80f0\u81df\u816b\u7624\u767c\u751f\u6709\u95dc\u3002\nE.\u8207\u53e3\u8154\u816b\u7624\u767c\u751f\u6709\u95dc\u3002\n": "[E]", "110-52.\u6709\u95dc\u5927\u8178\u61a9\u5ba4\u75c7(diverticulosis)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u901a\u5e38\u5728\u4e59\u72c0\u7d50\u8178(sigmoid colon)\uff0c\u4f46\u5728\u4e9e\u6d32\u65cf\u7fa4\uff0c\u670970%\u767c\u751f\u5728\u53f3\u5074\u7d50\u8178\u3002\nB.\u662f60\u6b72\u4ee5\u4e0a\u75c5\u60a3\u767c\u751f\u4e0b\u6d88\u5316\u9053\u51fa\u8840\u6700\u5e38\u898b\u65f3\u539f\u56e0\u3002\nC.aspirin\u53caNSAID\u4e0d\u6703\u589e\u52a0\u6b64\u985e\u60a3\u8005\u4e0b\u6d88\u5316\u9053\u51fa\u8840\u7684\u98a8\u96aa\u3002\nD.\u4ee5\u8179\u75db\u3001\u767c\u71d2\u3001\u767d\u8840\u7403\u589e\u52a0\u70ba\u8868\u73fe\u7684\u61a9\u5ba4\u708e\u53ef\u4ee5\u5148\u7528\u6297\u751f\u7d20\u6cbb\u7642\u3002\nE.\u61a9\u5ba4\u708e\u53ef\u9032\u5c55\u6210\u7a7f\u5b54\u53ca\u8179\u819c\u708e\u3002\n": "[C]", "110-53.\u60a3\u8005\u56e0\u8179\u75db \u3001\u5641\u5fc3\u3001\u5614\u5410\u53ca\u767c\u71d2\u5230\u6025\u8a3a \uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u5982\u5716 \uff0c\u6309\u58d3\u6b64\u75c5\u60a3\u5de6\u4e0b\u8179\u6642\u9020\u6210\u53f3\u4e0b\u8179\u660e\u986f\u75bc\n\u75db\uff0c\u6b64\u73fe\u8c61\u7a31\u70ba ?   \nA.Rovsing\u2019s sign\u3002\nB.Obturator sign\u3002\nC.Iliopsoas sign\u3002\nD.Murphy\u2019s sign\u3002\nE.Cullen\u2019s sign\u3002\n": "[A]", "110-54.\u60a3\u8005\u56e0\u4e0a\u8179\u75db\u53cd\u5c04\u81f3\u80cc\u90e8 \uff0c\u5408\u4f75\u5641\u5fc3 \u3001\u5614\u5410\u81f3\u6025\u8a3a \uff0c\u8840\u6db2\u6aa2\u67e5amylase \u548clipase\u503c\u5747\u6709 3\u500d\u4ee5\u4e0a\u7684\u589e\u52a0 \uff0c\u4e0b\n\u5217\u4f55\u8005\u4e0d\u5c6c\u65bc\u5224\u65b7\u6b64\u75c5\u56b4\u91cd\u5ea6\u7684BISAP score \uff1f   \nA.BUN>25mg/dL\u3002\nB.Impaired mental status\u3002\nC.SIRS:2 \u2267 of 4 present\u3002\nD.Amylase>2000 IU/L\u3002\nE.Pleural effusion\u3002\n": "[D]", "111-37.\u809d\u751f\u6aa2(liver biopsy )\u4e4b\u76f8\u95dc\u6558\u8ff0 \uff0c\u4e0b\u5217\u5404\u9805\u90a3\u4e9b\u6b63\u78ba \uff1f\n(1) Cholestasis\u75c5\u4eba\u8a3a\u65b7\u4e4b\u9996\u9078\u6aa2\u67e5\u662f\u809d\u751f\u6aa2\n(2) Budd-Chiari syndrome\u75c5\u4eba\u8a3a\u65b7\u4e4b\u9996\u9078\u6aa2\u67e5\u662f\u809d\u751f\u6aa2\n(3) \u809d\u751f\u6aa2\u6709\u52a9\u65bc\u809d\u7e96\u7dad\u5316\u7a0b\u5ea6\u4e4b\u5224\u65b7\n(4) \u73fe\u5728\u6709\u6578\u7a2e\u975e\u4fb5\u8972\u6027\u65b9\u5f0f (non-invasive tests )\u53ef\u7cbe\u6e96\u5224\u65b7\u809d\u7e96\u7dad\u5316\u7a0b\u5ea6 \uff0c\u5df2\u53ef\u53d6\u4ee3\u809d\u751f\u6aa2\n(5) \u809d\u751f\u6aa2\u6709\u52a9\u65bc\u4e0d\u660e\u539f\u56e0\u809d\u708e\u4e4b\u8a3a\u65b7\n(6) \u6709\u660e\u986f\u8179\u6c34\u4e4b\u75c5\u4eba \uff0c\u61f7\u7591\u6709\u809d\u5167\u7030\u6f2b\u6027\u816b\u7624 \uff0c\u7947\u80fd\u4ee5\u7d93\u76ae\u809d\u751f\u6aa2\u8a3a\u65b7\n(7) \u809d\u751f\u6aa2\u6709\u52a9\u65bc\u81ea\u9ad4\u514d\u75ab\u809d\u708e\u4e4b\u78ba\u8a3a   \nA.(1) + (3) + (5)\u3002\nB.(2) + (4) + (6)\u3002\nC.(3) + (4) + (5)\u3002\nD.(3) + (5) + (7)\u3002\nE.(4) + (5) + (6)\u3002\n": "[D]", "111-38.\u53f0\u7063\u73fe\u884c\u5065\u4fdd\u7d66\u4ed8\u6709\u95dc\u6162\u6027 B\u578b\u809d\u708e\u53e3\u670d\u6297\u75c5\u6bd2\u85e5\u7269\u7684\u4f7f\u7528\u898f\u7bc4\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.HBeAg\u967d\u6027\u60a3\u8005\u61c9\u63a5\u53d7\u6cbb\u7642\u81f3HBeAg\u6d88\u5931\u5f8c\uff0c\u518d\u7e7c\u7e8c\u670d\u7528\u4e00\u5e74\u3002\nB.HBeAg\u9670\u6027\u60a3\u8005\u61c9\u63a5\u53d7\u6cbb\u7642\u81f3\u8840\u4e2dHBV DNA\u6e2c\u4e0d\u5230 \uff08\u6bcf\u534a\u5e74\u6e2c\u4e00\u6b21 \uff0c\u9023\u7e8c\u4e09\u6b21\u6e2c\u4e0d\u5230\uff09\uff0c \u7642\u7a0b\u81f3\u5c11\n\u5169\u5e74\uff0c\u81f3\u591a\u4e09\u5e74 \u3002\nC.\u8b49\u5be6\u6709\u809d\u786c\u5316\u7684\u60a3\u8005\uff0c\u7947\u8981\u8840\u4e2d\u6e2c\u5f97\u5230 B\u809d\u75c5\u6bd2\uff0c\u5f97\u9577\u671f\u670d\u7528\u6297\u75c5\u6bd2\u85e5\u7269\u3002\nD.\u809d\u7d30\u80de\u764c\u60a3\u8005\uff0c\u7947\u8981\u8840\u4e2d\u6e2c\u5f97\u5230 B\u809d\u75c5\u6bd2\uff0c\u5f97\u7d42\u751f\u670d\u7528\u6297\u75c5\u6bd2\u85e5\u7269\u3002\nE.\u6e96\u5099\u63a5\u53d7\u5316\u5b78\u7642\u6cd5\u7684\u6162\u6027 B\u809d\u60a3\u8005\uff0c\u53ef\u65bc\u5316\u7642\u555f\u52d5\u524d\u4e00\u5468\u958b\u59cb\u9810\u9632\u6027\u7528\u85e5 \uff0c\u76f4\u81f3\u5316\u7642\u7d50\u675f\u518d\u670d\u7528\u534a\n\u5e74\u3002\n": "[D]", "111-39.\u95dc\u65bc\u53f0\u7063 C\u578b\u809d\u708e\u6cbb\u7642\u4e4b\u5065\u4fdd\u7d66\u4ed8\u898f\u7bc4 \uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f\n(1) \u73fe\u5728\u662f\u4ee5\u5168\u53e3\u670d\u85e5\u7269 \uff08Direct-Acting Antivirals, DAAs \uff09\u70ba\u6cbb\u7642\u4e3b\u6d41\n(2) C\u809d\u75c5\u4eba\u8981\u7b49 6\u500b\u6708\u624d\u80fd\u63a5\u53d7DAAs\u6cbb\u7642\n(3) \u73fe\u5728\u53f0\u7063\u7684\u57f7\u696d\u897f\u91ab\u5e2b\u7686\u53ef\u958b\u7acbDAAs\u6cbb\u7642 C\u809d\u75c5\u4eba\n(4) \u6709\u809d\u529f\u80fd\u5931\u4ee3\u511f\u7684\u60a3\u8005 \uff0c\u7947\u80fd\u7528Maviret \uff08Glecaprevir + Pibrentasvir \uff0c\u542bNS3/4A protease \ninhibitor\uff09\u6cbb\u7642\n(5) \u7d76\u5927\u591a\u6578 C\u809d\u75c5\u4eba\uff08\u542b\u4ee3\u511f\u6027\u809d\u786c\u5316 )\u63a5\u53d7\u73fe\u5728\u6240\u7528\u7684DAAs\u6cbb\u7642 \uff0cC\u809d\u75c5\u6bd2\u6839\u9664\u7387\u53ef\u905498 %\n(6) \u88ab\u5075\u6e2c\u51fa\u6709\u4e00\u500b\u76f4\u5f91 3\u516c\u5206\u809d\u764c\u7684\u75c5\u4eba \uff0c\u540c\u6642\u88ab\u767c\u73fe\u70ba C\u809d\u60a3\u8005\uff0c\u4ed6\u61c9\u8a72\u5148\u63a5\u53d7DAAs\u6cbb\u7642\n(7) \u5408\u4f75\u6709B\u809d\u548cC\u809d\u4e4b\u60a3\u8005 \uff0c\u65bc\u63a5\u53d7DAAs\u6cbb\u7642\u4e2d \uff0c\u5176\u4e26\u5b58\u4e4b B\u809d\u75c5\u6bd2\u53ef\u80fd\u6703\u88ab\u6fc0\u6d3b   \nA.(1)+(3) + (5)\u3002\nB.(2) + (4) + (6)\u3002\nC.(3) + (6) + (7)\u3002\nD.(2) + (5) + (7)\u3002\nE.(3) + (4) + (5)\u3002\n": "[B]", "111-40.\u95dc\u65bc\u81bd\u56ca\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u82e5\u7121\u4f75\u767c\u75c7\uff0c\u6025\u6027\u81bd\u56ca\u708e\u4e00\u822c\u5efa\u8b70\u5728\u78ba\u7acb\u8a3a\u65b7\u5f8c48-72\u5c0f\u6642\u5167\u65bd\u884c\u81bd\u56ca\u5207\u9664\u8853\u3002\nB.\u7cd6\u5c3f\u75c5\u4eba\u6709\u81bd\u56ca\u7d50\u77f3\uff0c\u82e5\u7121\u4efb\u4f55\u75c7\u72c0\uff0c\u4e0d\u5fc5\u5efa\u8b70\u63a5\u53d7\u9810\u9632\u6027\u81bd\u56ca\u5207\u9664\u8853\u3002\nC.\u81bd\u56ca\u5167\u7684radiolucent cholesterol stones\u4e0d\u8ad6\u5927\u5c0f \uff0c\u7686\u670950%\u6a5f\u6703\u80fd\u4ee5Ursodeoxycholic acid (UDCA) \n\u5c07\u4e4b\u5b8c\u5168\u6eb6\u5316 \u3002\nD.\u5728\u8d85\u97f3\u6ce2\u6aa2\u67e5\u610f\u5916\u767c\u73fe\u7684\u81bd\u56ca\u7d50\u77f3 \uff0c\u82e5\u53d7\u6aa2\u8005\u904e\u53bb\u5f9e\u7121\u76f8\u95dc\u75c7\u72c0 \uff0c\u9577\u671f\u8ffd\u8e64\u5f8c \uff0c60-80%\u4e0d\u6703\u7522\u751f\u75c7\n\u72c0\u3002   \nE.50\u6b72\u4ee5\u4e0a\u82e5\u7d93\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u6709\u5927\u65bc1 cm\u7684\u81bd\u56ca\u606f\u8089\uff0c\u4e00\u822c\u6703\u5efa\u8b70\u63a5\u53d7\u81bd\u56ca\u5207\u9664\u8853\u3002\n": "[C]", "111-41.\u5716A\u53ca\u5716B\u6240\u793a\u92c7\u5291\u986f\u5f71\u4e0b\u4e4b\u98df\u9053\u5f62\u50cf\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u5169\u8005\u7686\u53ef\u80fd\u4ee5\u80f8\u75db\u53ca\u541e\u56a5\u7570\u5e38\u70ba\u75c5\u4eba\u7684\u75c7\u72c0\u3002\nB.\u5728Manometry\u6aa2\u67e5\u6642\uff0c\u6703\u6709\u4e0d\u540c\u7684esophageal pressure topography\u5448\u73fe\u3002\nC.\u91dd\u5c0d\u5716A\u4e4b\u75c5\u6cc1\uff0c\u901a\u5e38\u6703\u5148\u5617\u8a66\u4ee5\u85e5\u7269\u6cbb\u7642\uff0c\u6709\u76f8\u7576\u9ad8\u7684\u6a5f\u6703\u80fd\u9577\u671f\u6539\u5584\u75c5\u4eba\u4e4b\u75c7\u72c0\u3002\nD.\u91dd\u5c0d\u5716B\u4e4b\u75c5\u6cc1\uff0c\u96d6\u7136manometry\u4e4b\u7d50\u679c\u662f\u4e3b\u8981\u7684\u8a3a\u65b7\u4f9d\u64da \uff0c\u4f46\u4ecd\u9700\u4ee5\u5167\u8996\u93e1\u6aa2\u67e5\u6392\u9664\u5176\u5b83\u53ef\u80fd\u7522\u751f\n\u985e\u4f3c\u75c7\u72c0\u4e4b\u75be\u75c5 \u3002\nE.\u7f79\u60a3\u5716A\u4e4b\u75c5\u4eba\uff0c\u82e5\u672a\u52a0\u4ee5\u8655\u7406\uff0c\u8d85\u904e\u5341\u5e74\u4ee5\u4e0a\uff0c\u6709\u8f03\u9ad8\u6a5f\u7387\u6703\u7522\u751fsquamous cell carcinoma\u3002\n": "[C]", "111-42.Barrett's metaplasia \u662fgastroesophageal reflux disease\u7684\u4f75\u767c\u75c7\u4e4b\u4e00\uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u73fe\u5728\u5167\u8996\u93e1\u8a3a\u65b7\u53ca\u5f37\u800c\u6709\u6548\u4e4b\u6291\u5236\u80c3\u9178\u5206\u6ccc\u85e5\u7269\u7686\u6709\u5f88\u5927\u7684\u9032\u5c55 \uff0c\u56e0\u6b64 Barrett 's metaplasia\u4e4b\u767c\u751f\n\u7387\u9010\u6f38\u6e1b\u5c11 \u3002\nB.\u9157\u9152\u4e0d\u662fBarrett's metaplasia\u4e4b\u98a8\u96aa\u56e0\u5b50\u3002\nC.Long-segment Barrett's metaplasia \u662fesophageal adenocarcinoma \u4e4bprecursor lesion\u3002\nD.Barrett's metaplasia\u672a\u4f75\u6709dysplasia\u8005\uff0c\u7d04\u6bcf3-5\u5e74\u63a5\u53d7\u4e00\u6b21\u5167\u8996\u93e1\u6aa2\u67e5\u5373\u53ef\u3002\nE.Barrett's metaplasia\u4f75\u6709high-grade dysplasia\u8005\uff0c\u61c9\u63a5\u53d7endoscopic eradication therapy\u3002\n": "[A]", "111-43.\u95dc\u65bcpeptic ulcer disease (PUD) \u4e4b\u6cbb\u7642 \uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\u90a3\u4e9b\u932f\u8aa4 \uff1f\n(1) Refractory PUD\u63a5\u53d7\u8f03\u9ad8\u5291\u91cfproton pump inhibitors (PPIs) \u6cbb\u7642 8\u9031\u6709 90% \u4ee5\u4e0a\u6703\u7652\u5408\n(2) \u9577\u671f\u670d\u7528PPIs \u53ef\u80fd\u589e\u52a0 community -acquired pneumonia\u767c\u751f\u6a5f\u7387\n(3) \u65b0\u958b\u767c\u7684 K-competitive acid pump antagonist (P-CAPs) \u4e4b\u7642\u6548\u5c1a\u4e0d\u660e\u78ba\n(4) Gastric maltoma (MALT) lymphoma \u61c9\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\n(5) Helicobacter pylori (HP) \u5b58\u5728\u80c3\u4e2d\u4e4b\u5075\u6e2c\u65b9\u6cd5\u5305\u62ec \uff1astool antigen\u6aa2\u6e2c, urea breath test (UBT) \n\u53caserological testing\n(6) \u6b32\u8b49\u5be6 HP eradication therapy \u5df2\u6210\u529f \uff0c\u9700\u5728eradication therapy \u7d50\u675f 4\u9031\u5f8c\u70ba\u4e4b   \nA.(1) + (2) + (3)\u3002\nB.(2) + (4) + (5)\u3002\nC.(3) + (4) + (5)\u3002\nD.(4) + (5) + (6)\u3002\nE.(3) + (4) + (6)\u3002\n": "[C]", "111-44.\u5728\u53f0\u7063\uff0c\u5927\u8178\u76f4\u8178\u764c\u4e4b\u6bcf\u5e74\u767c\u751f\u4eba\u6578\u76ee\u524d\u9ad8\u5c45\u9996\u4f4d \uff0c\u5982\u4f55\u65e9\u671f\u767c\u73fe\u53ca\u9810\u9632\u5f88\u91cd\u8981 \uff0c\u4e0b\u5217\u5404\u9805\u76f8\u95dc\u6558\u8ff0 \uff0c\u4f55\n\u8005\u932f\u8aa4\uff1f   \nA.\u7cde\u4fbf\u6f5b\u8840\u6aa2\u6e2c\u8207\u5167\u8996\u93e1\u6aa2\u67e5\u5df2\u6210\u7be9\u6aa2\u4e4b\u4e3b\u8981\u5de5\u5177\u3002\nB.Air contrast\u92c7\u5291\u986f\u5f71\u53cavirtual colonoscopy\uff08\u96fb\u8166\u65b7\u5c64\uff09\u5df2\u5c11\u7528\u4e86\u3002\nC.\u7f8e\u570bMulti -Society Task Force\u91dd\u5c0d\u4e00\u822c\u98a8\u96aa\u6210\u5e74\u4eba \uff0c\u5efa\u8b7050\u6b72 (\u6700\u8fd1\u6539\u621045 \u6b72) \u4ee5\u4e0a\u4e4b\u5927\u8178\u76f4\u8178\u764c\u7be9\n\u6aa2\u65b9\u5f0f\u70ba\u6bcf\u5e74\u7cde\u4fbf\u6f5b\u8840\u6aa2\u6e2c+ \u6bcf\u4e94\u5e74\u4e00\u6b21flexible sigmoidoscopy\u6216\u6bcf\u5341\u5e74\u4e00\u6b21total colon \ncolonoscopy \u3002\nD.\u7f8e\u570bMulti -Society Task Force\u5c0d\u65bc\u521d\u6b21\u5927\u8178\u93e1\u6aa2\u67e5\u767c\u73fe\u6709\u4e0d\u542b\u60e1\u6027\u6210\u5206\u4e4bpolyp (s) \u4e14\u5df2\u4e88\u4ee5\u5b8c\u5168\u5207\u9664\n\u8005\u4e4b\u5f8c\u7e8c\u8ffd\u8e64 \uff0c\u9664\u4e86adenomas\u8d85\u904e10\u9846\u4ee5\u4e0a\u8005 \uff0c\u82e5\u5f8c\u7e8c\u7cde\u4fbf\u6f5b\u8840\u6aa2\u6e2c\u5448\u9670\u6027\u6642 \uff0c\u4e00\u822c\u5efa\u8b70 3\u5e74\u5f8c\u518d\n\u4ee5\u5927\u8178\u93e1\u8ffd\u8e64 \u3002\nE.Peutz-Jeghers syndrome\u60a3\u8005\u4e4b\u8178\u9053\u606f\u8089\u8f49\u70ba\u60e1\u6027\u4e4b\u6a5f\u7387\u6975\u9ad8\uff0c\u61c9\u5bc6\u96c6\u8ffd\u8e64\u7be9\u6aa2\u3002   \n": "[E]", "111-45.\u4e00\u4f4d70\u6b72\u7537\u6027\u75c5\u4eba\u4e3b\u8a34\u6700\u8fd1\u4e00\u5e74\u8001\u662f\u89ba\u5f97\u98ef\u5f8c\u6703\u6709\u5fc3\u7aa9\u8655\u75bc\u75db \uff0c\u8b93\u4ed6\u5c0d\u9032\u98df\u5fc3\u751f\u6050\u61fc \uff0c\u9ad4\u91cd\u5df2\u6e1b\u8f15\u4e86 6\u516c\n\u65a4\u3002\u5c31\u91ab\u6642\u8eab\u9ad4\u8a3a\u5bdf\u986f\u793a\u8f03\u6d88\u7626 \uff0c\u8179\u90e8\u6aa2\u67e5\u7121\u660e\u986f\u7570\u5e38 \u3002\u5b89\u6392\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\u4e26\u672a\u767c\u73fe\u6d88\u5316\u6027\u6f70\n\u760d\u3001\u80c3\u764c\u6216\u9006\u6d41\u6027\u98df\u9053\u708e \u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u672a\u767c\u73fe\u81bd\u7d50\u77f3 \u3002\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u4e5f\u78ba\u8a8d\u6c92\u6709\u80f0\u81df\u764c \u3002\u5fc3\u96fb\u5716\u986f\u793a\n\u6709\u5fc3\u623f\u632f\u986b \uff08atrial fibrillation\uff09\u3002 \u6709\u95dc\u9019\u4f4d\u75c5\u4eba\u4e4b\u6558\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u5176\u75c5\u60c5\u6709\u6642\u6703\u6709\u6025\u6027\u75c5\u6cc1\uff0c\u6b7b\u4ea1\u7387\u53ef\u80fd\u9ad8\u9054 50% \u4ee5\u4e0a\u3002\nB.Duplex ultrasound \u5728\u6025\u8a3a\u5ba4\u5e38\u88ab\u62ff\u4f86\u505a\u70ba\u9019\u7a2e\u75c5\u4eba\u4e4b\u521d\u6b65\u7be9\u6aa2\u5de5\u5177 \uff0c\u5176\u8a3a\u65b7\u4e4b\u654f\u611f\u5ea6\u53ca\u7279\u7570\u6027\u76f8\u7576\n\u4e0d\u932f\u3002\nC.Duplex ultrasound \u6aa2\u67e5\u8981\u5728\u98ef\u5f8c\u70ba\u4e4b\u6548\u679c\u6700\u4f73\u3002\nD.\u82e5\u8a3a\u65b7\u5df2\u5927\u81f4\u78ba\u7acb\uff0c\u9032\u4e00\u6b65\u8655\u7f6e\u524d\u52d9\u5fc5\u8981\u6709 CT angiogram\u3002\nE.\u5176\u8655\u7f6e\u5305\u62ec endovascular or open surgical revascularization\u3002\n": "[C]", "111-46.30\u6b72\u7537\u6027\u60a3\u8005\u6709\u591a\u5e74\u7684\u55c6\u54b3\u53ca\u541e\u56a5\u56f0\u96e3 \uff0c\u63a5\u53d7\u98df\u9053\u651d\u5f71\u53ca\u6aa2\u58d3\u8853 (manometry )\uff0c\u7d50\u679c\u5982\u5716 1\u3001\u57162\uff0c \u4e0b\u5217\u6558\n\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f(1)\u6b64\u75c5\u53ef\u4ee5\u9810\u9632 (2)\u8d77\u56e0\u70ba\u4e0b\u98df\u9053\u62ec\u7d04\u808c\u58d3\u529b\u592a\u4f4e (3)\u53ef\u4ee5\u7528nitrate \u6216calcium channel \nblocker\u6cbb\u7642 \uff0c\u4f46\u6548\u679c\u6709\u9650 (4)\u53ef\u4ee5\u7528\u5167\u8996\u93e1\u64f4\u5f35\u8853 (pneumatic dilation )\u6cbb\u7642\uff0c\u4f46\u4e0d\u540c\u4e2d\u5fc3\u6709\u6548\u7d50\u679c\u5831\u544a\n\u5f9e30~90% (5)per oral esophageal myotomy (POES)\u6548\u679c\u4e0d\u932f \uff0c\u4e14\u8f03\u50b3\u7d71\u5916\u79d1\u624b\u8853\u6062\u5fa9\u5feb   \nA.(1)+(2)\u3002\nB.(2)+(3)\u3002\nC.(3)+(4)\u3002\nD.(4)+(5)\u3002\nE.(1)+(5)\u3002\n": "[A]", "111-47.\u4e0b\u5217\u4e0d\u9069\u7528\u65bc\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(Helicobacter pylori)\u4e4b\u6551\u63f4\u6cbb\u7642(salvage therapy)\u7684\u8655\u65b9(regimen)?    \nA.bismuth quadruple regimen\u3002\nB.clarithromycin triple regimen\u3002\nC.concomitant regimen\u3002\nD.levofloxacin triple regimen\u3002\nE.rifabutin triple regimen\u3002\n": "[B]", "111-48.\u6709\u95dc\u81bd\u9178 (bile acid)\u548c\u8178\u809d\u5faa\u74b0 (enterohepatic circulation )\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba (1)\u81bd\u9178\u7531\u81bd\u56fa\u9187 (cholesterol )\u5728\n\u809d\u81df\u5408\u6210 \uff0c\u6bcf\u59295\u516c\u514b (2)\u5f9e\u809d\u81df\u5408\u6210\u7684\u521d\u7d1a (primary)\u81bd\u9178\u6709cholic acid \u548clithocholic acid (3)\u81bd\u9178\u5408\u6210\n\u75317\u03b1-hydrxylase\u81ea\u4e3b\u8abf\u63a7 (autoregulated) ( 4)\u6b21\u7d1a(secondary )\u81bd\u9178\u7684\u5f62\u6210\u9808\u8981\u5927\u8178\u5167\u7684\u7d30\u83cc\u5354\u52a9 (5)\u81bd\u9178\n\u900f\u904e\u9580\u975c\u8108\u56de\u5230\u809d\u81df \uff0c\u7136\u5f8c\u518d\u5ea6\u5206\u6ccc\u5230\u5c0f\u8178   \nA.(1)+(2)+(3)\u3002\nB.(2)+(3)+(4)\u3002\nC.(3)+(4)+(5)\u3002\nD.(1)+(3)+(5)\u3002\nE.(2)+(4)+(5)\u3002\n": "[C]", "111-49.25\u6b72\u7537\u6027\u56e0\u9577\u671f\u8840\u4fbf \u3001\u9ad4\u91cd\u6e1b\u8f15 \uff0c\u7d93\u91ab\u5e2b\u8a3a\u65b7\u70ba\u514b\u9686\u6c0f\u75c5 (Crohn\u2019s disease )\uff0c\u4e0b\u5217\u56db\u5f35\u92c7\u5291\u8178\u9053\u651d\u5f71\u7d50\n\u679c\uff0c\u4f55\u8005\u7279\u5fb5\u7b26\u5408\u6b64\u75c5 ?   \nA.\u5716A\u3002\nB.\u5716B\u3002\nC.\u5716C\u3002   \nD.\u5716D\u3002\nE.\u4ee5\u4e0a\u7686\u975e\u3002\n": "[D]", "111-50.\u4e00\u4f4d\u6025\u6027\u8179\u75db\u60a3\u8005\uff0c\u5728\u6025\u8a3a\u8655\u63a5\u53d7\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\uff0c\u7d50\u679c\u5982\u5716\uff0c\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f    \nA.\u6b64\u75c5\u767c\u751f\u7387\u5448\u589e\u52a0\u8da8\u52e2\u3002\nB.\u8d85\u904e\u516b\u6210\u7684\u60a3\u8005\u53ef\u767c\u73fe\u7cde\u77f3(fecalith)\u3002\nC.\u4e00\u534a\u4ee5\u4e0a\u60a3\u8005\u8eab\u9ad4\u6aa2\u67e5\u51fa\u73fepsoas sign\u3002\nD.\u5e74\u8001\u60a3\u8005\u6613\u6709\u975e\u5178\u578b\u8868\u73fe\u3002\nE.\u6cbb\u7642\u4ee5\u5167\u79d1\u4fdd\u5b88\u6027\u65b9\u5f0f\u70ba\u4e3b\u3002\n": "[D]", "111-51.74\u6b72\u5973\u6027\u56e0\u76ae\u819a\u9ec3 \u3001\u8336\u8272\u5c3f\u548c\u7070\u767d\u4fbf\u5341\u5929\u81f3\u6025\u8a3a\u8655 \uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u9ec3\u75b8 \u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b \uff1aALP: \n175 U/L\uff0cALT: 57 U/L\uff0cAST: 49 U/L\uff0cBil(T/D): 6.0/4.6 mg/dL\u3002\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u986f\u793a\u6709\u5f8c\u8179\u8154\u7e96\u7dad\n\u5316(retroperitoneal fibrosis )\u53ca\u80f0\u81df\u816b\u5927\u5982\u9999\u8178\u72c0 (sausage-shaped)\u4f75\u80f0\u7ba1\u72f9\u7a84 \uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u4f75\u7d30\u91dd\u62bd\u53d6\u7d30\n\u80de\u5b78\u6aa2\u67e5\u5728\u9ad8\u500d\u4e0b\u767c\u73fe10\u500b\u4ee5\u4e0a\u7684IgG 4-positive\u7d30\u80de \uff0c\u4e14\u6c92\u6709\u60e1\u6027\u7d30\u80de \u3002\u4ee5\u4e0b\u4f55\u8005\u70ba\u6700\u9069\u7576\u6cbb\u7642 ?   \nA.azathioprine\u3002\nB.ERCP with biliary stent placement\u3002\nC.prednisolone\u3002\nD.methotrexate\u3002\nE.totoal pancreatectomy\u3002\n": "[C]", "111-52.45\u6b72\u5973\u6027\u56e0alkaline phosphatase (ALP)\u6301\u7e8c\u7570\u5e38\u8ffd\u8e64\u4e00\u6bb5\u6642\u9593 \uff0c\u75c7\u72c0\u53ea\u6709\u8f15\u5fae\u76ae\u7662 (pruritus)\uff0c\u4e26\u7121\u5bb6\u65cf\n\u53f2\u6216\u5176\u5b83\u7cfb\u7d71\u6027\u75be\u75c5 \uff0c\u8eab\u9ad4\u6aa2\u67e5\u6b63\u5e38 \uff0c\u8840\u6db2\u6aa2\u67e5\u5305\u62ecCBC \uff0cAST/ALT\uff0calbumin\uff0cbilirubin\u548ctotal \nprotein\u5747\u70ba\u6b63\u5e38 \uff0c\u53ea\u6709ALP 212 U/L\u4e0a\u5347\u3002\u4e0b\u5217\u4f55\u9805\u662f\u8a3a\u65b7\u7684\u6700\u9069\u7576\u6aa2\u67e5 ?   \nA.anti-smooth muscle antibody\u3002\nB.antinuclear antibody\u3002\nC.anti-mitochondria antibody\u3002\nD.serum IgG4\u3002\nE.liver biopsy\u3002\n": "[C]", "111-53.60\u6b72\u7537\u6027 \uff0c\u65bc\u9580\u8a3a\u8ffd\u8e64\u6642\u767c\u73feAST /ALT\u503c\u4e0a\u5347 \u3002\u672c\u8eab\u6709\u7cd6\u5c3f\u75c5 \u3001\u9ad8\u8840\u58d3\u53ca\u9ad8\u8840\u8102 \uff0c\u76ee\u524d\u670d\u7528metformin, \nhydrochlorothiazide, losartan \u548catorvastatin \u3002\u4ed6\u6709social drinking \uff0cBP: 143/80 mmHg \uff0cBMI: 37\uff0c\u8179\u90e8\u6aa2\n\u67e5\u6709\u809d\u816b\u5927\u4f46\u7121\u58d3\u75db\u6216\u89f8\u75db \uff0c\u4e5f\u7121\u813e\u816b\u5927 \u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5ALP: 180 U/L\uff0cAST: 42 U/L\uff0cALT: 64 \nU/L\uff0cCBC\u3001albumin\u548cbilirubin\u5747\u6b63\u5e38 \u3002\u8d85\u97f3\u6ce2\u6aa2\u67e5\u53ea\u6709\u81bd\u606f\u8089 \uff0c\u809d\u81df\u816b\u5927 \uff0c\u4e14echogenicity\u589e\u52a0 \uff0c\u4f46\u81bd\u7ba1\n\u6b63\u5e38\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6b64\u75c5\u60a3\u6700\u9069\u7576\u7684\u6cbb\u7642 ?   \nA.\u6212\u9152\u3002\nB.\u505c\u7528atorvastatin\u3002\nC.\u52a0\u7528pioglitazone\u3002\nD.\u6e1b\u91cd\u3002\nE.\u505c\u7528losartan\u3002\n": "[D]", "111-54.40\u6b72\u5973\u6027\u5728\u98ef\u5f8c30 \u81f360\u5206\u9418\u5f8c \uff0c\u6709\u4e0a\u8179\u75db \u3001\u8179\u8139\u3001\u5641\u5fc3\u548c\u8179\u7009 \uff0c\u5df2\u767c\u751f\u4e09\u500b\u6708 \uff0c\u6709\u6642\u5927\u9910\u5f8c\u5408\u4f75\u982d\n\u75db\u3001\u6d41\u6c57\u73fe\u8c61 \uff0c\u4e0a\u8ff0\u75c7\u72c0\u5728\u98ef\u5f8c30\u5206\u9418\u81f3 2\u5c0f\u6642\u6703\u7de9\u89e3 \u3002\u672c\u8eab\u70ba\u80a5\u80d6 \u3001\u9ad8\u8840\u58d3\u548c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u56db\u500b\n\u6708\u524d\u63a5\u53d7\u6e1b\u91cd\u624b\u8853sleeve gastrectomy \u3002\u80c3\u93e1\u6aa2\u67e5\u9664sleeve gastrectomy\u5916\u4e26\u7121\u7570\u5e38 \uff0c\u80c3\u5207\u7247\u7121\u5e7d\u9580\u87ba\u65cb\n\u687f\u83cc\uff0c\u5341\u4e8c\u6307\u8178\u5207\u7247\u53ca\u80c3\u6392\u7a7a\u6aa2\u67e5\u5747\u70ba\u6b63\u5e38 \u3002\u6b64\u4f4d\u60a3\u8005\u6700\u6070\u7576\u7684\u6cbb\u7642\u70ba ?   \nA.acarbose\u3002   \nB.metformin\u3002\nC.metoclopramide\u3002\nD.rifaximin\u3002\nE.\u5c11\u91cf\u591a\u9910\u3002\n": "[E]", "100-1.\n\u96a8\u8457\u814e\u529f\u80fd\u60e1\u5316\uff0c\u8f03\u56b4\u91cd\u7684CKD\uff08chronic kidney disease\uff09\u75c5\u4eba\u6703\u767c\u751f\u9178\u9e7c\u5e73\u8861\u7684\u7570\u5e38\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u5927\u90e8\u5206\u7684\u75c5\u4eba\u6703\u7522\u751f\u6bd4\u6b63\u5e38\u4eba\u66f4\u591a\u91cf\u7684ammonia\u4ee5\u6392\u9664\u591a\u9918\u7684H\uff0b(\u6c2b\u96e2\u5b50)\nB. \u82e5\u6709\u9ad8\u8840\u9240\uff0c\u6703\u4f7fammonia\u88fd\u9020\u66f4\u589e\u52a0\uff0c\u4ee5\u5229\u6392\u9178.\nC. \u9ad8\u8840\u9240 (hyperkalemia)\u53cahyperchloremic metabolic acidosis \u53c8\u7a31type III RTA, \u5e38\u898b\u65bc\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a(DM nephropathy), \u6216\u814e\u5c0f\u7ba1\u9593\u8cea\u6027\u75be\u75c5 (tubulo-interstitial disease).\nD. \u7576\u8840\u4e2dbicarbonate\u4f4e\u65bc 20-23mmol/L\u5c31\u53ef\u8003\u616e\u88dc\u5145alkali.\nE. \u7576\u814e\u529f\u80fd\u6108\u4f86\u6108\u60e1\u5316, \u5e38\u5e38\u7531anion-gap metabolic acidosis\u8b8a\u6210non-anion-gap metabolic acidosis.\n": "(D)", "100-2.\n\u6709\u4e00\u4f4d70\u6b72\u5973\u6027, \u8173\u816b\u5df2\u5169\u9031, \u4eba\u53ef\u4ee5\u6d3b\u52d5. \u6bcf\u5929\u5c3f\u86cb\u767d\u6392\u6cc4\u7d046 gm , \u8840\u4e2d\u767d\u86cb\u767d(albumin)\u70ba2.8 g/dL,\u4e0b\u5217\u4f55\u7a2e\u63cf\u8ff0\u4e0d\u6b63\u78ba\uff1f\nA. \u9019\u985e\u75c5\u4eba\u6bcf\u4f4d\u90fd\u61c9\u5118\u65e9\u7d66\u4ee5\u6297\u51dd\u5291\uff08warfarin\uff09.\nB. \u5c3f\u6db2\u6aa2\u67e5\u53ef\u80fd\u4f34\u6709\u986f\u5fae\u8840\u5c3f\uff08microscopic hematuria\uff09.\nC. \u6709\u4e9b\u75c5\u4eba\u53ef\u80fd\u75c5\u60c5\u6703\u81ea\u52d5\u6539\u5584\uff08remission\uff09\nD. \u5982\u679c\u70ba\u539f\u767c\u6027\u814e\u708e\uff0c\u6700\u5e38\u898b\u7684\u53ef\u80fd\u6027\u70bamembranous nephropathy\u6240\u9020\u6210.\nE. \u80ba\u764c\u53ef\u80fd\u6703\u9020\u6210\u6b64\u7a2e\u4f75\u767c\u75c7.\n": "(A)", "100-3.\n\u6709\u4e00\u4f4d65\u6b72\u7537\u6027, \u61f7\u7591\u814e\u7d50\u77f3, \u63a5\u53d7IVU ( intravenous urography) \u6aa2\u67e5, \u7b2c\u4e09\u5929\u767c\u73feBUN\u753133 mg/dL\u5347\u81f360 mg/dL, \u8840\u4e2dcreatinine\u75312.1 mg/dL\u5347\u81f34.6 mg/dL,\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u986f\u5f71\u5291\u4e43\u7531\u8840\u7ba1\u64f4\u5f35\u4e4b\u6a5f\u8f49\u5c0e\u81f4\u814e\u640d\u50b7.\nB. \u5fc3\u81df\u8870\u7aed\uff08congestive heart failure\uff09\u75c5\u4eba\u8f03\u5bb9\u6613\u767c\u751f\u6b64\u4f75\u767c\u75c7,\nC. \u986f\u5f71\u5291\u4e4b\u5291\u91cf\u8207\u814e\u640d\u50b7\u4e4b\u7a0b\u5ea6\u901a\u5e38\u7121\u95dc.\nD. \u986f\u5f71\u5291\u53ef\u7d93\u904ereactive oxygen species\u4e4b\u6a5f\u8f49, \u4e3b\u8981\u50b7\u5bb3\u814e\u5c0f\u7403\uff08glomerular cells).\nE. \u901a\u5e38\u70ba\u53ef\u9006\u6027, \u5dd4\u5cf0\u671f(peak)\u70ba10-12\u5929, \u5927\u7d042 \u661f\u671f\u5167\u6062\u5fa9.\n": "(B)", "100-4.\n\u6709\u4e00\u500b\u5916\u570b\u4eba\u5230\u53f0\u7063\u65c5\u904a, \u56e0\u5c3f\u5f88\u591a\u4f86\u505a\u6aa2\u67e5, \u767c\u73fe\u5c3f\u6db2\u4e2dWBC 20-25/HPF, RBC 15-20/HPF, protein\uff0b, \u8840\u4e2dBUN 45 mg/dL, creatinine 3.8 mg/dL, \u5169\u5e74\u524d\u6aa2\u67e5\u8840\u4e2dcreatinine\u70ba2.5mg/dL, \u4ed6\u8aaa\u5e38\u5e38\u5403\u6b62\u75db\u8907\u65b9\uff08aspirin\uff0bphenacetin\uff0bacetaminophen\uff09\u5df2\u670915\u5e74\u4ee5\u4e0a\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u75c5\u4eba\u7684\u814e\u75c5\u548c\u6b62\u75db\u85e5\u53ef\u80fd\u6709\u95dc.\nB. \u4ed6\u82e5\u7167IVU\uff08intravenous urography\uff09\u53ef\u80fd\u51fa\u73fe \u301dring sign\u301e.\nC. \u5c07\u4f86\u53ef\u80fd\u767c\u751f\u7684\u4f75\u767c\u75c7\u70barenal cell carcinoma.\nD. \u6b64\u7a2e\u75c5\u8b8a\u4e4b\u7279\u9ede\u70bapapillary necrosis\u53catubulo-interstitial inflammation.\nE. \u767c\u751f\u8ca7\u8840\u7684\u7a0b\u5ea6\u5f80\u5f80\u8207\u814e\u529f\u80fd\u8870\u7aed\u4e4b\u7a0b\u5ea6\u4e0d\u6210\u6bd4\u4f8b.\n": "(C)", "100-5.\n\u6709\u4e00\u4f4d62\u6b72\u5973\u6027, \u63a5\u53d7\u5316\u7642\uff08chemotherapy\uff09\u5f8c, \u767c\u73feBUN\u70ba42 mg/dL, creatinine 3.8 mg/dL, hemoglobin\u70ba9.0 g/dL, platelet 31 k/\u03bcl \uff08\u534a\u5e74\u524d4\u9805\u90fd\u6b63\u5e38\uff09, \u8840\u6db2\u62b9\u7247\u51fa\u73fefragmented RBC. \u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6b64\u75c5\u4e4b\u6b7b\u4ea1\u7387\u6975\u4f4e,\u5927\u591a\u6578\u53ef\u4ee5\u6cbb\u7652.\nB. \u6700\u5e38\u5f15\u8d77\u6b64\u73fe\u8c61\u7684\u5316\u7642\u85e5\u7269\u70bacyclophosphamide.\nC. \u767c\u751f\u904e\u7a0b\u5341\u5206\u7de9\u6162, \u4e0d\u6703\u7a81\u7136\u767c\u751f.\nD. \u7528\u985e\u56fa\u9187, \u8840\u6f3f\u4ea4\u63db\uff08plasma exchange\uff09\u53ca\u514d\u75ab\u6291\u5236\u5291\u53ef\u6210\u529f\u6cbb\u7652\u5927\u591a\u6578\u75c5\u60a3.\nE. \u75c5\u7406\u7d44\u7e54\u4e0a\u5448\u73fethrombotic microangiopathy.\n": "(E)", "100-6.\n\u4e00\u4f4d45\u6b72\u5973\u6027,\u75c5\u4eba\u610f\u8b58\u7a0d\u5fae\u4e0d\u6e05\u695a, \u5728\u6025\u8a3a\u8655\u88ab\u767c\u73fe\u8840\u9209\u70ba118mmol/L, \u4e0b\u5217\u90a3\u4e9b\u301d\u5168\u90e8\u6b63\u78ba\u301e\uff1f\r1.\u5927\u90e8\u5206\u4f4e\u8840\u9209\u7684\u6210\u56e0\u5e38\u4f34\u96a8\u4f4e\u8840\u6f3f\u6ef2\u900f\u58d3 (hypo-osmolality) .\r2.\u6240\u8b02SIADH\u4e43\u9ad8\u9ad4\u6db2\uff08hypervolemic\uff09hyponatremia \u4e2d\u6700\u5e38\u898b\u7684\u4e00\u7a2e\u539f\u56e0.\r3.\u4f4e\u8840\u9209\u53ef\u80fd\u56e0\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\uff08hyperthyroidism\uff09\u5f15\u8d77.\r4.\u75c5\u4eba\u610f\u8b58\u4e0d\u6b63\u5e38, \u5176\u6a5f\u8f49\u70ba\u8166\u6c34\u816b\uff08cerebral edema\uff09\r5.\u8840\u9209\u7a81\u7136\u964d\u4f4e\u81f3120 mmol/L\u4ee5\u4e0b, \u75c5\u4eba\u53ef\u80fd\u767c\u751f\u660f\u8ff7(coma)\u6216\u62bd\u6410\uff08seizure\uff09\r6.\u814e\u4e0a\u817a\u6a5f\u80fd\u4ea2\u9032\u4e5f\u53ef\u4ee5\u5f15\u767c\u6b64\u60c5\u6cc1\r7.\u559d\u4e0b\u5927\u91cf\u5564\u9152\u800c\u98df\u7269\u5403\u5f88\u5c11\u53ef\u80fd\u5f15\u767c\u6b64\u60c5\u6cc1, \u7a31\u70babeer potomania\nA. 1+2+3\nB. 2+6+7\nC. 1+2+6\nD. 3+6+7\nE. 4+5+7\n": "(E)", "100-7.\n\u4e00\u4f4d62\u6b72\u5a66\u4eba, \u8840\u9223\u70ba2.8 mmol/L, \u4eba\u6c92\u6709\u660e\u986f\u75c7\u72c0,\u4e0b\u5217\u90a3\u4e9b\u63cf\u8ff0\u301d\u5168\u90e8\u6b63\u78ba\u301e\uff1a\r1.\u5979\u7684\u8840\u4e2d\u526f\u7532\u72c0\u817a\u8377\u723e\u8499\uff08PTH\uff09\u4e0d\u4e00\u5b9a\u5347\u9ad8.\r2.\u6709\u5f88\u591a\u816b\u7624\u6703\u5206\u6cccPTH\u9020\u6210\u9ad8\u8840\u9223\r3.sarcoidosis\u9020\u6210\u9ad8\u9223\u662f\u56e0\u70ba\u5206\u6cccPTH\u4e4b\u6545\r4.\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\uff08hypothyroidism\uff09\u4fc3\u4f7f\u9aa8\u9abc\u4e4b\u9223\u79fb\u51fa\u800c\u9020\u6210\u9ad8\u9223\u8840\u75c7\r5.\u56b4\u91cd\u9ad8\u9223\u8840\u75c7\u53ef\u4ee5\u5f15\u8d77\u5fc3\u8df3\u6162\uff08bradycardia\uff09, \u5fc3\u623f\u5fc3\u5ba4\u50b3\u5c0e\u963b\u65b7\uff08AV block\uff09\r6.\u8a55\u4f30\u8840\u9223\u7570\u5e38\u7b2c\u4e00\u6b65\u9700\u5148\u77e5\u9053\u8840\u4e2d\u767d\u86cb\u767d\uff08Albumin\uff09\u7684\u6fc3\u5ea6.\r7.\u9ad8\u8840\u9223\u540c\u6642\u4f75\u6709\u4f4e\u8840PTH\u6fc3\u5ea6(hypercalcemia with suppessed PTH level)\u6700\u5e38\u898b\u7684\u539f\u56e0\u70ba\u60e1\u6027\u816b\u7624\uff08malignancy\uff09.\nA. 1+2+3\nB. 2+4+5\nC. 3+4+6\nD. 1+5+6\nE. 4+6+7\n": "(D)", "100-8.\n\u90a3\u4e00\u7a2e\u60c5\u5f62\u5bb9\u6613\u767c\u751f\u9ad8\u8840\u9240\uff08hyperkalemia\uff09\uff1f\nA. \u9ad4\u6eab\u904e\u4f4e\uff08Hypothermia\uff09\nB. Thyrotoxic periodic paralysis\nC. \u9382 (Magnesium) \u7f3a\u4e4f\nD. \u4f7f\u7528COX-2\u6291\u5236\u5291\nE. Total parenteral nutrition\n": "(D)", "100-9.\n\u4e00\u4f4d65\u6b72\u7537\u6027, \u6709\u5341\u4e8c\u6307\u8178\u6f70\u760d\u75c5\u53f2, \u7a81\u7136\u5410\u51fa\u5927\u91cf\u9bae\u8840, \u88ab\u9001\u5230\u6025\u8a3a\u8655\u6642\u8840\u58d3\u91cf\u523060/20mmHg, \u64da\u5bb6\u5c6c\u63cf\u8ff0, \u75c5\u4eba\u4f4f\u5728\u504f\u9060\u5730\u5340, \u82b1\u6578\u5c0f\u6642\u624d\u9001\u5230\u91ab\u9662, \u7d93\u6e2c\u91cf\u8840\u4e2d\u4e73\u9178(lactic acid) \u504f\u9ad8, \u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u4e73\u9178\u4e2d\u6bd2\uff08lactic acidosis\uff09\u70ba\u4e00\u7a2e\u6b63\u5e38anion gap\u4e4b\u9178\u4e2d\u6bd2 (acidosis).\nB. \u5206\u70batype A,B,C\u4e09\u7a2e.\nC. \u7d66\u4e88\u8840\u7ba1\u6536\u7e2e\u5291\uff08vasoconstrictor\uff09\u6709\u76ca\u7121\u5bb3.\nD. \u61c9\u6ce8\u5c04\uff08NaHCO3\uff09\u4f7f\u8840\u6db2PH\u5118\u5feb\u6062\u5fa9\u81f3\u6b63\u5e38.\nE. \u7528NaHCO3\u6cbb\u7642\u6709\u6642\u6703\u5f15\u8d77\u9ad8\u8840\u58d3\u53ca\u9ad4\u6db2\u904e\u591a\uff08fluid overload\uff09\n": "(E)", "100-10.\n\u4e0b\u5217\u90a3\u4e00\u9805\u4e0d\u662fhypercholemic metabolic acidosis \u7684\u6210\u56e0\uff1f\nA. \u8179\u7009 (diarrhea)\nB. \u6162\u6027mild to moderate\u814e\u75c5\uff08CKD\uff09\u3010\u7576\u814e\u5c0f\u7403\u904e\u6ffe\u7387\uff08GFR\uff09\u7d04\u4ecb\u65bc20-50ml/min\u6642\u3011\nC. \u7b2c\u4e8c\u578b\uff08type II\uff09\u814e\u5c0f\u7ba1\u9178\u5316\u75c7 (proximal RTA)\nD. \u4f4e\u814e\u7d20\u4f4e\u76ae\u8cea\u919b\u916e\u75c7\uff08hyporeninemic hypoaldosteronism\uff09\nE. \u916e\u9178\u4e2d\u6bd2\uff08ketoacidosis\uff09\n": "(E)", "100-11.\n44\u6b72\u7537\u6027\uff0c\u56e0\u70ba\u6025\u6027\u51a0\u5fc3\u75c7(acute coronary syndrome)\u4f4f\u9662\u3002\u4f4f\u9662\u8840\u58d3 162/100 mm Hg, \u4e0b\u80a2\u6c34\u816b(2+), \u5be6\u9a57\u5ba4\u6aa2\u67e5: [Albumin] 2.6 g/dL, t-Chol 320 mg/dL, LDL 178 mg/dL, \u86cb\u767d\u5c3f(4+). \u5982\u679c\u9032\u4e00\u6b65\u6aa2\u67e5\uff0c\u4f55\u7a2e\u6307\u6a19\u7684\u6578\u503c\u6700\u53ef\u80fd\u6703\u6bd4\u6b63\u5e38\u4eba\u504f\u4f4e?\nA. anti-thrombin III\nB. fibrinogen antigen and activity\nC. factor VII\nD. alpha-2 macroglobulin\nE. protein C and protein S levels\n": "(A)", "100-12.\n48\u6b72\u5973\u6027\u6700\u8fd1\u534a\u5e74\u56e0\u70ba\u7cd6\u5c3f\u75c5\u3001\u8840\u58d3\u504f\u9ad8\uff0c\u958b\u59cb\u63a5\u53d7\u4e0b\u5217\u85e5\u7269\u6cbb\u7642\uff0c\u8fd1\u4e09\u9031\u4ee5\u4f86\u81ea\u6211\u767c\u89ba\u6709\u96d9\u4e0b\u80a2\u8db3\u8e1d\u6309\u58d3\u5f0f\u6c34\u816b\u3002\u75c5\u4eba\u672c\u8eab\u9ad4\u91cd\u7121\u986f\u8457\u589e\u52a0\uff0c\u6c92\u6709exertional dyspnea, \u4e5f\u7121\u809d\u75be\u60a3\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: \u86cb\u767d\u5c3f(-)\uff0c\u8840\u6e05albumin 4.1 g/dL, \u808c\u9178\u91501.1 mg/dL, AST 20 IU/L, ALT 18 IU/L, C3 \u8207 ANA \u7686\u6b63\u5e38\u3002\u6709\u95dc\u6b64\u75c5\u4eba\u7684\u8655\u7f6e\u5efa\u8b70\uff0c\u9664\u4e86\u63a7\u5236\u9e7d\u5206\u651d\u53d6\u4e4b\u5916\uff0c\u4f55\u8005\u61c9\u8a72\u7121\u95dc\uff1f\nA. \u66ab\u505c minoxidil\nB. \u66ab\u505c nifedipine (calcium channel blocker)\nC. \u66ab\u505c metformin\nD. \u66ab\u505c\u6216\u6e1b\u5c11\u4f7f\u7528 NSAID (nonsteroidal anti-inflammatory drugs)\nE. \u66ab\u505c thiazolidinediones\n": "(C)", "100-13.\n31\u6b72\u5973\u6027\u56e0\u767c\u71d2\u3001\u5026\u6020\u3001\u6c34\u816b\u3001\u9ad4\u91cd\u77ed\u671f\u5167\u66b4\u589e5\u516c\u65a4\u4f4f\u9662\u3002\u7406\u5b78\u6aa2\u67e5: \u9ad4\u6eab37.8\u00b0C\uff0c\u8840\u58d3153/110 mmHg\uff0c\u4e0b\u80a2\u6c34\u816b(3+)\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: \u86cb\u767d\u5c3f(4+)\uff0c\u8840\u6e05C3 34 mg/dL\uff0canti-dsDNA \u5448\u73fe\u9ad8\u50f9\u6578; \u5c3f\u7d20\u6c2e 40 mg/dL\uff0c\u808c\u9178\u91502.5 mg/dL\u3002\u814e\u81df\u5207\u7247\u5728\u5f97\u5230\u768411\u500b\u814e\u7d72\u7403\u67097\u500b\u985e\u4f3c\u7684(\u5982\u5716)\u75c5\u7406\u8b8a\u5316 \u3002\u6709\u95dc\u6b64\u75c5\u4eba\u7684\u8a3a\u65b7\u53ca\u6cbb\u7642:\r1.\u75c5\u7406\u7d50\u679c\u986f\u793a\u70ba\u6162\u6027\u7684\u7b2c\u4e94\u7d1a\uff08class V\uff09lupus nephritis\u3002\r2.\u901a\u5e38\u9019\u6a23\u7684\u75c5\u7406\u8b8a\u5316\u9700\u8981\u8108\u885d\u7642\u6cd5\uff08pulse therapy)\uff0c\u5982: \u985e\u56fa\u9187\u8108\u885d\u7642\u6cd5\u3002\r3.\u4e5f\u53ef\u4f7f\u7528cyclophosphamide\u8108\u885d\u7642\u6cd5\uff0c\u5efa\u8b70\u5728\u524d6\u500b\u6708\u61c9\u6bcf\u6708\u7d66\u4e88\u975c\u8108\u6ce8\u5c040.5-1 g/m2\u3002\r4.\u61c9\u8a72\u5148\u5f9e\u53e3\u670d\u4f4e\u5291\u91cf\u985e\u56fa\u9187(prednisolone 0.5 mg/kg/day)\u958b\u59cb\u6cbb\u7642\u3002\r5.\u6b64\u985e\u75c5\u4eba\u6709\u6108\u986f\u8457\u7684interstitial fibrosis\uff0c\u9577\u671f\u9810\u5f8c\u6bd4\u8f03\u5dee\u3002\r6.\u5fc5\u8981\u6642\uff0c\u53ef\u4ee5\u642d\u914d\u5229\u5c3f\u5291\u6216aspirin\u3002\r\u4e0b\u5217\u4f55\u7a2e\u7d44\u5408\u662f\u6b63\u78ba\u7684\uff1f\nA. 1+2+3\nB. 1+3+4\nC. 2+3+6\nD. 1+4+6\nE. 4+5\n": "(C)", "100-14.\n\u4e00\u4f4d38\u6b72\u8077\u696d\u5a66\u5973\uff0c\u904e\u53bb\u8840\u58d3\u7d04138/84 mm Hg\uff0c\u5728\u61f7\u5b55\u7d0426\u9031\u7522\u524d\u6aa2\u67e5\u6642\u767c\u73fe: \u8840\u58d3 150/94 mm Hg\uff0c\u6709\u86cb\u767d\u5c3f (3+)\uff0c\u548c\u8f15\u5ea6\u8db3\u80cc\u6c34\u816b\u3002\u6709\u95dc\u8840\u58d3\u6cbb\u7642\uff0c\u4f55\u8005\u85e5\u7269\u8f03\u9069\u7576?\r1.hydralazine\r2.labetalol\r3.clonidine\r4.methyldopa\r5.captopril\r6.losartan\r7.aliskiren\nA. 1+4+5\nB. 1+2+4\nC. 2+5+7\nD. 3+4+6\nE. 1+3+6\n": "(B)", "100-15.\n\u4e00\u4f4d46\u6b72\u672b\u671f\u814e\u81df\u75c5\u7537\u6027\uff0c\u56e0\u70baHb 8.4 g/dL\u6545\u91ab\u5e2b\u958b\u7acberythropoietin (EPO, 2000 unit biweekly)\u6ce8\u5c04\u77ef\u6b63\u814e\u6027\u8ca7\u8840\u3002\u96a8\u5f8c\u7684\u516b\u500b\u6708\u671f\u9593\uff0c\u96d6\u7136\u589e\u52a0EPO\u5291\u91cf\u81f3 5000 unit biweekly\uff0c\u75c5\u4eba\u7684Hb\u537b\u9010\u6b65\u964d\u4f4e\u81f36.4 g/dL\u3002\u671f\u9593: \u814e\u529f\u80fd\u7121\u986f\u8457\u60e1\u5316\uff0c\u98f2\u98df\u6b63\u5e38\uff0c\u4e5f\u7121\u7f3a\u9435\u6027\u8ca7\u8840\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: Reticulocyte count\u504f\u4f4e\uff0c\u800c\u9aa8\u96a8\u6aa2\u67e5\u70ba: Normal cellularity except diminished RBC precursors\u3002\u6709\u95dc\u75c5\u4eba\u7684\u8a3a\u65b7\u4e88\u8655\u7f6e\u5efa\u8b70\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u518d\u589e\u52a0EPO\u81f35000 units three times per week\nB. \u8003\u616e\u7d66\u4e88immunosuppressive agents\nC. \u5982\u679c\u63a5\u53d7\u814e\u81df\u79fb\u690d\uff0c\u8ca7\u8840\u61c9\u8a72\u6703\u6539\u5584\nD. \u6aa2\u67e5\u662f\u5426\u6709anti-erythropoietin antibody\nE. \u9593\u6b47\u6027\u8f38\u8840RBC\u88dc\u5145\uff0c\u77ef\u6b63\u8ca7\u8840\n": "(A)", "100-16.\n\u4e00\u4f4d58\u6b72\u5973\u6027\u56e0\u8179\u75db\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u75c5\u4eba\u6709\u7cd6\u5c3f\u75c5\u9577\u671f\u63a5\u53d7\u4e0b\u5217\u85e5\u7269\u6cbb\u7642\uff0c\u4e00\u5e74\u534a\u524d\u5be6\u9a57\u5ba4\u6aa2\u67e5: creatinine 1.4 mg/dL\uff0c\u4e94\u500b\u6708\u524d\u5347\u81f3 3.5 mg/dL\u3002\u5728\u6025\u8a3a\u7684\u91cd\u8981\u6578\u64da:\u5982\u4e0b: BP 162/88 mm Hg, HR 120 beats/min, respiratory rate 26 breaths/min, BT 35.2\u00b0C, PaO2 96% (room air)\u3002\u8179\u90e8\u89f8\u8a3a\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5\u6709 metabolic acidosis: pH 7.01; HCO3- 2.3  mmol/L; [Na] 145 mEq/L, [K] 5.2 mEq/L, [Cl] 99 mEq/L; glucose 78 mg/dL  \u60a8\u8a8d\u70ba: \u6700\u53ef\u80fd\u8ddf\u76ee\u524d\u6240\u4f7f\u7528\u7684\u4f55\u7a2e\u85e5\u7269\u6709\u95dc?\nA. furosemide\nB. metformin\nC. atenolol\nD. losartan\nE. amlodipine\n": "(B)", "100-17.\n\u4e00\u4f4d54 \u6b72\u5973\u6027\uff0c\u6c92\u6709\u7cd6\u5c3f\u75c5\u6216\u6709\u9ad8\u8840\u58d3\uff0c\u4f46\u662f\u6709 proteinuria (2.4 g/24 hr), microscopic hematuria, \u53capolymyalgia\u3002\u5176\u4ed6\u5be6\u9a57\u5ba4\u6aa2\u67e5: , Hb 8.6, MCV 90 (fL), MCHC 32 g/dL. serum creatinine 2.2 mg/dL, hypercalcemia ([Ca] 11.8 mg/dL), \u53ca urinary monoclonal protein\u3002\u814e\u81df\u751f\u6aa2(renal biopsy\uff0c\u7d50\u679c\u5982\u9644\u5716)\u3002\u75c5\u4eba\u7684\u8a3a\u65b7\u6700\u53ef\u80fd\u662f:\nA. Wegener's granulomatosis\nB. multiple myeloma\nC. Hemolytic Uremic Syndrome\nD. systemic lupus erythematosus (SLE)\nE. Henoch-Schonlein Purpura\n": "(B)", "100-18.\n\u4e00\u4f4d\u7d0440\u6b72\u7537\u6027\uff0c\u904e\u53bb\u5065\u5eb7\u60c5\u5f62\u826f\u597d\uff0c\u7121\u7cd6\u5c3f\u75c5\u3002\u672c\u6b21\u56e0\u5026\u6020\u3001\u8179\u75db\u3001\u8170\u9178\u5230\u6025\u8a3a\u3002\u7406\u5b78\u8207\u5be6\u9a57\u5ba4\u6aa2\u67e5: BP 132/82 mm Hg, edema (-), creatinine 3.0 mg/dL\u3002\u5c3f\u6db2\u6aa2\u67e5\u6709: proteinuria (+/-), O.B. (+), WBC 30-50/HPF \uff0c\u534a\u5e74\u524d\u5065\u5eb7\u6aa2\u67e5\u7684creatinine\u503c\u662f 1.0 mg/dL\u3002\u8acb\u554f: \u4e0b\u4e00\u6b65\u61c9\u8a72\u5148\u9032\u884c\u54ea\u7a2e\u6aa2\u67e5\u8a3a\u65b7\u6b65\u9a5f?\nA. \u6aa2\u6e2c \u6297\u6838\u6297\u9ad4 (ANA , anti-nuclear antibody)\nB. \u6aa2\u6e2c anti-GBM (glomerular basement membrane) antibody\nC. \u5b89\u6392\u505a renal sonography\nD. \u4f30\u7b97 eGFR \u8207\u62bd\u8840\u6aa2\u6e2c [Na], [K], [Ca]\nE. \u5b89\u6392\u505a renal biopsy\n": "(C)", "100-19.\n\u4e00\u4f4d\u7d0480\u6b72\u5c45\u4f4f\u5728\u990a\u8b77\u4e2d\u5fc3\u7684\u8001\u4eba\uff0c\u56e0\u70ba\u865b\u5f31\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u6aa2\u67e5\u767c\u73fe: BP 88/64 mm Hg, HR 100/min, BT 37.6\u00b0C, [Albumin] 3.0 g/dL, BUN 32 mg/dL, creatinine 0.8 mg/dL, [Na] 134 mEq/L, [K] 2.7 mEq/L, [Cl] 107 mEq/L\u3002ABG\u70ba pH 7.30, PaO2 90 mm Hg, PaCO2 23 mm Hg, HCO3- 11 mEq/L. \u6025\u8a3a\u91ab\u5e2b\u7684\u8a3a\u65b7\u70ba:\r1.metabolic acidosis\r2.respiratory acidosis\r3.anion-gap (+)\r4.non-anion-gap\r5.\u7b26\u5408hypoaldosteronism\r6.\u53ef\u80fd\u6709\u6f5b\u5728\u611f\u67d3\u75c7\r7.\u53ef\u80fd\u6709severe diarrhea \u6216\u4f7f\u7528diuretics\r\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba?\nA. 1+3+6\nB. 2+3+5+7\nC. 1+4+5+7\nD. 1+3+7\nE. 1+4+6+7\n": "(A)", "100-20.\n\u6162\u6027\u814e\u81df\u75c5(CKD)\u662f\u570b\u4eba\u91cd\u8981\u7684\u91ab\u7642\u7d93\u6fdf\u8207\u5065\u5eb7\u8b70\u984c\u3002\u6839\u64daCKD\u7167\u8b77\u65b9\u6848\u8207\u570b\u5167\u6d41\u884c\u75c5\u5b78\u5c08\u5bb6\u7684\u591a\u9805\u7814\u7a76\uff0c\u4ee5\u53ca2010\u5e74\u6240\u51fa\u7248\u7684\u9ad8\u8840\u58d3\u6cbb\u7642\u6307\u5f15\u986f\u793a: \u63a7\u5236\u4ee5\u4e0b\u5371\u96aa\u56e0\u5b50\u8207\u6cbb\u7642\u5efa\u8b70\uff0c\u53ef\u4ee5\u5ef6\u7de9\u6216\u6e1b\u5c11 CKD\u9032\u5c55\u81f3\u672b\u671f\u814e\u81df\u75c5(ESRD)\u6216\u6d17\u814e(dialysis)\uff0c\u4f55\u8005\u9664\u5916?\nA. DM-CKD\u75c5\u4eba\uff0c\u5b9a\u671f\u6aa2\u6e2c\u86cb\u767d\u5c3f\nB. DM-CKD\u75c5\u4eba\uff0c\u5982\u679c\u6709\u86cb\u767d\u5c3f(> 1.0 g/day)\uff0c\u8840\u58d3\u63a7\u5236\u4ee5140/90 mm Hg\u70ba\u76ee\u6a19\nC. DM-CKD\u75c5\u4eba\uff0c\u5b9a\u671f\u6aa2\u6e2cHbA1C\uff0c\u63a7\u5236\u57287.0 %\u6216\u4ee5\u4e0b\nD. \u8840\u8102\u7570\u5e38(dyslipidemia)\u4e5f\u662f\u4e00\u500b\u5371\u96aa\u56e0\u5b50\uff0c\u5982: high LDL-cholesterol level\nE. \u5efa\u8b70\u4f4e\u9e7d(low salt)\u98f2\u98df\u7fd2\u6163\n": "(B)", "100-21.\n\u4e00\u4f4d70\u6b72\u5973\u6027\uff0c\u672c\u8eab\u6709\u9ad8\u8840\u58d3\uff0c\u4f7f\u7528atenolol \u548c furosemide\uff0c\u56e0\u70ba\u8fd1\u4e00\u9031\u4f86\u6709\u982d\u6688\u3001\u865b\u5f31\u60c5\u5f62\uff0c\u6240\u4ee5\u5df2\u7d93\u66ab\u505c\u8840\u58d3\u7528\u85e5\u3002\u5230\u6025\u8a3a\u6642: \u8840\u58d3 114/68 mm Hg, HR 100/min, BT 36.5\u00b0C, edema (-). \u5be6\u9a57\u5ba4\u6aa2\u67e5: Hb 10.5 g/dL, Hct 29%, albumin 3.8 g/dL, creatinine 1.1 mg/dL, [Na] 119 mEq/L, [K] 3.6 mEq/L, [Cl] 84 mEq/L, ABG\u70ba: pH 7.47, PaO2 98 mm Hg, PaCO2 44 mm Hg, HCO3- 27 mEq/L. \u6aa2\u6e2c\u5c3f\u4e2d\u96fb\u89e3\u8cea: [Na]urine 6 mEq/L, [K]urine 14 mEq/L. \u8acb\u554f: \u4ee5\u4e0b\u8a3a\u65b7\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u98f2\u98df\u4e2d\u9e7d\u5206(salt)\u651d\u53d6\u53ef\u80fd\u4e0d\u8db3\nB. \u7b26\u5408SIADH (syndrome of inappropriate antidiuretic hormone hypersecretion)\nC. ABG\u986f\u793a\u75c5\u4eba\u6709metabolic alkalosis\nD. \u53ef\u80fd\u8207\u4e4b\u524d\u4f7f\u7528diuretics (furosemide)\u6709\u95dc\nE. \u61c9\u8a72\u6aa2\u6e2cserum \u548c urine osmolality\uff0c\u6709\u52a9\u65bc\u9451\u5225\u8a3a\u65b7\n": "(B)", "100-22.\n\u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD, hemodialysis)\uff0c\u6709\u95dc\u8179\u819c\u900f\u6790(PD, peritoneal dialysis)\u7684\u6558\u8ff0\u8207\u9577\u671f\u5408\u4f75\u75c7\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. PD\u75c5\u4eba\u4f7f\u7528\u9ad8\u7cd6\u900f\u6790\u6db2\u662f\u70ba\u4e86\u8981\u9054\u5230\u900f\u6790\u6e05\u9664\u5c3f\u6bd2\u7d20(uremic toxin)\u7684\u6548\u679c\nB. PD\u75c5\u4eba\u5bb9\u6613\u51fa\u73fehypertriglyceridemia\uff0c\u662f\u56e0\u70ba\u4f7f\u7528\u9ad8\u7cd6\u900f\u6790\u6db2\nC. \u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD)\uff0c\u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u8f03\u5bb9\u6613\u767c\u751f\u8179\u819c\u708e(peritonitis)\nD. \u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD)\uff0c\u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u6bcf\u65e5\u86cb\u767d\u8cea\u6d41\u5931\u91cf\u8f03\u9ad8\nE. \u76f8\u8f03\u65bc\u8179\u819c\u900f\u6790(PD)\uff0c\u8840\u6db2\u900f\u6790(HD)\u75c5\u4eba\u8f03\u51fa\u73fe\u900f\u6790\u4e2d\u4f4e\u8840\u58d3\n": "(A)", "101-1.\n\u4e00\u4f4d65\u6b72\u7cd6\u5c3f\u75c5\u4eba\uff0c\u6709\u9ad8\u8840\u58d3\uff0c\u6e96\u5099\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u3002\u7406\u5b78\u6aa2\u67e5:BP 118/74, edema (-), serum [creatinine] 1.5 mg/dL\u3002\u76ee\u524d\u7528\u85e5\u70ba: metformin 500 mg bid, irbesartan 75 mg qd, trichlormethiazide 1 mg qd. \u70ba\u4e86\u964d\u4f4e\u767c\u751fcontrast nephropathy\u7684\u5371\u96aa\uff0c\u4ee5\u4e0b\u54ea\u9805\u63aa\u65bd\u6700\u4e0d\u5efa\u8b70\u3002\nA. \u505c\u7528metformin, \u66f4\u63db\u6210\u5176\u4ed6\u964d\u8840\u7cd6\u85e5\nB. volume expansion with saline, \u53ef\u4ee5\u52a0\u4e0a bicarbonate\nC. \u505c\u7528irbesartan, \u66f4\u63db\u6210fenoldopam\u964d\u8840\u58d3\u85e5\u6bd4\u8f03\u5b89\u5168\nD. \u7d66\u4e88 N-acetylcysteine\nE. \u6253radiocontrast agent\u524d\uff0c\u7d66\u4e88aminophylline\n": "(C)", "101-2.\n\u4e00\u4f4d24\u6b72\u5973\u6027\uff0c\u904e\u53bb\u7121\u75c5\u53f2\u3002\u7d042\u500b\u6708\u524d\u958b\u59cb\u6ce8\u610f\u51fa\u73fe\u6c34\u816b\uff0c\u9ad4\u91cd\u57282\u500b\u6708\u5167\u589e\u52a08\u516c\u65a4\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: Albumin 2.8 g/dL, creatinine 0.8 mg/dL, t-Chol 280 mg/dL, LDL 163 mg/dL, urine protein-creatinine (P/C) ratio \u7d049 mg/mg, urinalysis O.B. (-), serum [K] 4 mEq/L, [Ca] 9.2 mg/dL, Hb 12 g/dL\u3002\u672c\u75c5\u4eba\u7684\u8a3a\u65b7\uff0c\u6700\u53ef\u80fd\u70ba?\nA. IgA nephropathy\nB. minimal change disease\nC. multiple myeloma with nephropathy\nD. systemic lupus erythromatous (SLE) with nephropathy\nE. membranoproliferative glomerulonephritis (MPGN)\n": "(B)", "101-3.\n\u6709\u95dchyperuricemia\u7684\u6cbb\u7642\uff0c\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u6558\u8ff0\u7684\u7d44\u5408\u662f\u6b63\u78ba\u7684?\r(1) asymptomatic hyperuricemia\u75c5\u4eba\u4f7f\u7528allopurinol\u53ef\u4ee5\u9810\u9632\u814e\u529f\u80fd\u60e1\u5316\r(2) asymptomatic hyperuricemia\u75c5\u4eba\u4f7f\u7528\u9810\u9632\u6027allopurinol\u53ef\u4ee5\u9810\u9632acute uric acid nephropathy\u767c\u751f\r(3) \u5df2\u7d93\u6709gouty arthritis\u7684\u75c5\u4eba\uff0c\u5efa\u8b70\u7d66\u4e88allopurinol\u9810\u9632uric acid stone\u6216calcium oxalate stone\u767c\u751f\r(4)\u5c0d\u65bc\u53cd\u8986\u767c\u751furic acid stone\u7684\u75c5\u4eba\uff0c\u4e5f\u53ef\u4ee5\u4f7f\u7528potassium-citrate\u6cbb\u7642\r(5) \u5df2\u4f7f\u7528allopurinol\u7684\u75c5\u4eba\u5982\u679c\u53c8\u767c\u751facute gouty arthritis, \u61c9\u8a72\u505c\u7528allopurinol, \u6539\u7528 colchicine\u4f86\u53d6\u4ee3\nA. (3)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (1)+(3)+(5)\n": "(A)", "101-4.\n\u4e00\u4f4dscleroderma (systemic sclerosis)\u7684\u75c5\u4eba\uff0c\u904e\u53bb\u8840\u58d3\u63a7\u5236\u826f\u597d\uff0c\u6709\u8f15\u5ea6\u86cb\u767d\u5c3f(+)\uff0ccreatinine\u7d041.8 mg/dL. \u6700\u8fd1\u4e00\u9031\u8840\u58d3\u5347\u9ad8(BP 158/92 mmHg), creatinine\u4e0a\u5347\u52303.0 mg/dL, \u5c3f\u6db2\u6aa2\u67e5protein (+++), O.B. (2+). \u91ab\u5e2b\u8a3a\u65b7\u75c5\u4eba\u53ef\u80fd\u4f75\u767c scleroderma renal crisis (SRC), \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. Scleroderma\u7684\u75c5\u4eba\u5927\u591a\u6709 Anti-nuclear Antibody (ANA) \u967d\u6027\nB. anti-Scl-70 antibody\u662fSRC\u7684risk predictor\nC. \u6709anti-RNA polymerase III (anti-RNA POL3) antibody\u7684\u4eba\u6bd4\u8f03\u4e0d\u6703\u767c\u751fSRC\nD. \u8840\u58d3\u63a7\u5236\u6700\u91cd\u8981\uff0c\u4f46\u61c9\u76e1\u91cf\u907f\u514d\u4f7f\u7528ACEI (angiotensin converting enzyme inhibitor)\uff0c\u52a0\u91cd\u814e\u81df\u60e1\u5316\nE. Scleroderma\u7684\u75c5\u4eba\u82e5\u4f7f\u7528prophylaxis glucocorticoid, \u53ef\u80fd\u6703\u6e1b\u5c11\u4f75\u767cSRC\n": "(A)", "101-5.\n\u4e00\u4f4dCKD(chronic kidney disease) Stage 4\u75c5\u4eba\uff0ccreatinine 3.8 mg/dL, Hb 8.6 g/dL. \u82e5\u8981\u4f7f\u7528erythropoiesis-stimulating agent, \u5982: erythropoietin (EPO). \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u61c9\u6ce8\u610f\u662f\u5426\u6709\u9435\u8cea\u7f3a\u4e4f\uff0c\u4e00\u822c\u5efa\u8b70ferritin > 200 ng/mL, transferrin saturation (TS) > 20%\nB. Hb \u76ee\u6a19\u70ba>13 g/dL, \u4ee5\u6e1b\u5c11\u5fc3\u8840\u7ba1\u5408\u4f75\u75c7\uff0c\u4e26\u4fdd\u8b77\u814e\u529f\u80fd\nC. \u63a7\u5236\u6216\u6539\u5584secondary hyperparathyroidism, \u6709\u52a9\u65bcEPO\u6548\u679c\nD. \u5c11\u6578\u4eba\u82e5\u51fa\u73feanti-EPO antibody, \u6703\u6709pure RBC aplasia\nE. \u4f75\u7528ACEI (angiotensin converting enzyme inhibitor)\u53ef\u80fd\u6703\u5e72\u64fe\u6216\u964d\u4f4eEPO\u6548\u679c\uff1b\u800c\u4f7f\u7528statin\u985e\u964d\u4f4echronic inflammation\u53ef\u80fd\u6709\u52a9\u65bcEPO\u6548\u679c\n": "(B)", "101-6.\n\u6709\u95dc\u8179\u819c\u900f\u6790(peritoneal dialysis, \u7c21\u7a31PD)\u75c5\u4eba\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u767c\u751f\u8179\u819c\u708e(peritonitis)\u6700\u5e38\u898b\u7684\u83cc\u7a2e\u662f Gram negative \u83cc\u7a2e\nB. Pseudomonas\u6216fungal peritonitis, \u901a\u5e38\u4e0d\u6613\u6cbb\u7642,\u6709\u6642\u9700\u8981\u62d4\u9664PD \u5c0e\u7ba1 (remove PD catheter)\nC. \u5c0dPD\u75c5\u4eba, \u4f7f\u7528mupirocin\u5c0d\u65bc\u6709Staphylococcus aureus nasal carriage\u8005\uff0c\u53ef\u4ee5\u6709\u6548\u964d\u4f4eexit site infection\nD. \u8179\u819c\u708e\u7684\u8a3a\u65b7\u6a19\u6e96\u4e4b\u4e00\u662fcloudy peritoneal fluid, \u4e14\u5176\u4e2dWBC > 100 cells/mm3,\u4e00\u822c\u4ee5neutrophil\u70ba\u4e3b\nE. \u7531\u65bc\u900f\u6790\u65b9\u5f0f\u7684\u7279\u6027, PD\u75c5\u4eba\u6bd4\u8840\u6db2\u900f\u6790\u75c5\u4eba\u8f03\u5e38\u6709hypertriglyceridemia\u53cahypoproteinemia\n": "(A)", "101-7.\n35\u6b72\u5973\u6027\uff0c\u672c\u8eab\u6709CKD (chronic kidney disease) stage 5, \u56e0\u5de5\u4f5c\u4e2d\u8dcc\u5012\u767c\u751ftibia\u9aa8\u6298, \u5be6\u9a57\u5ba4\u6aa2\u67e5: creatinine 4.8 mg/dL, Hb 10.0 g/dL, [Ca] 8.2 mg/dL, [P] 5.9 mg/dL, iPTH 680 pg/mL (\u6b63\u5e38\u503c 10-65 pg/mL), \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u9019\u662fCKD\u4f75\u767cadynamic bone disease\nB. \u53ef\u4ee5\u7d66\u4e88\u9069\u7576 active Vitamin D3 \u6cbb\u7642\nC. \u98f2\u98df\u885b\u6559\uff0c\u6307\u5c0ediet phosphate restriction (800-1000 mg/day)\nD. \u9019\u4f4d\u75c5\u4eba\u5982\u679c\u6aa2\u67e5alkaline phsphatase (ALP), \u6578\u503c\u61c9\u8a72\u6703\u6bd4\u6b63\u5e38\u503c\u504f\u9ad8\nE. \u5982\u679c\u505a\u9aa8\u75c5\u7406\u6aa2\u67e5\uff0c\u578b\u614b\u6bd4\u8f03\u50cfosteitis fibrosa, \u800c\u4e0d\u662favascular necrosis\n": "(A)", "101-8.\n\u4e00\u4f4d30\u6b72\u61f7\u5b55\u5973\u6027\uff0c\u56e0\u70ba\u8840\u58d3\u504f\u9ad8(BP 154/102 mm Hg), \u86cb\u767d\u5c3f(2+), \u4e0b\u80a2\u6c34\u816b\u4f86\u8a3a\u3002\u91dd\u5c0d\u8840\u58d3\u63a7\u5236\uff0c\u4ee5\u4e0b\u54ea\u4e00\u500b\u85e5\u7269\u6bd4\u8f03\u4e0d\u5408\u9069?\nA. labetalol\nB. hydralazine\nC. ramipril\nD. methyldopa\nE. \u5982\u679c\u51fa\u73fepre-eclampsia\u53capulmonary edema, \u53ef\u4ee5\u4f7f\u7528Intravenous nitroglycerin\n": "(C)", "101-9.\n\u4e00\u4f4d32\u6b72\u5973\u6027\u904e\u53bb\u7121\u9ad8\u8840\u58d3\u75c5\u53f2\u3002\u67d0\u65e5\u4e0a\u5348\u9192\u4f86\u767c\u73fe\u56db\u80a2\u7121\u529b\uff0c\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u7406\u5b78\u8207\u5be6\u9a57\u5ba4\u6aa2\u67e5: BP 128/68 mmHg, edema (-), [creatinine] 1.0 mg/dL, [Na] 138 mEq/L, [K] 2.8 mEq/L, [Mg]  1.0 mg/dL, ABG\u70ba pH 7.48, [HCO3-] 28 mEq/L, thyroid hormone (T3, T4, TSH)\u90fd\u6b63\u5e38. \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u53ef\u80fd\u662ftype I renal tubular acidosis (RTA), \u61c9\u8a72\u6aa2\u67e5urine anion-gap\nB. \u53ef\u80fd\u662ftype 2 renal tubular acidosis (RTA), \u61c9\u8a72\u6aa2\u67e5urine osmolality gap\nC. \u53ef\u80fd\u662fBartter's syndrome, \u53ef\u4ee5\u4f7f\u7528spironolactone \u6cbb\u7642hypokalemia\nD. \u53ef\u80fd\u662fGitelman's syndrome, \u53ef\u4ee5\u4f7f\u7528NSAIDs \u6cbb\u7642 polyuria \u548c salt wasting\nE. \u53ef\u80fd\u662frenin-secreting tumor,  \u61c9\u8a72\u5b89\u6392\u505a\u814e\u4e0a\u817a(adrenal gland)\u5f71\u50cf\u6aa2\u67e5\n": "(C)", "101-10.\n\u4e00\u4f4d54\u6b72\u5973\u6027\uff0c\u56e0\u5026\u6020\u3001\u86cb\u767d\u5c3f\u3001\u4e0b\u80a2\u6c34\u816b\u4f86\u8a3a\u3002\u7d93\u814e\u81df\u751f\u6aa2(renal biopsy)\u986f\u793a\u6709immune-complex\u53caC3 \u6c89\u7a4d\uff0c\u8a3a\u65b7\u70bamembranoproliferative glomerulonephritis (MPGN)\u3002\u6709\u95dcMPGN\u7684\u81e8\u5e8a\u8868\u73fe\u8207\u6cbb\u7642\uff0c\u4f55\u8005\u6558\u8ff0\u7d44\u5408\u662f\u6b63\u78ba\u7684?\r(1) \u8840\u6e05\u6aa2\u67e5\uff0c\u75c5\u4eba\u7684\u8840\u6e05C3\u503c\u901a\u5e38\u6703\u964d\u4f4e\r(2) \u8981\u7be9\u6aa2\u6709\u6c92\u6709infectious disease, \u5982: C\u578b\u809d\u708e\r(3) monoclonal gammopathy\u7b49chronic inflammation\u4e5f\u6703\u5408\u4f75MPGN\r(4) \u6cbb\u7642\u4ee5glucocorticoid \u6216cytotoxic agent\u70ba\u4e3b, \u4e14\u56e0\u70ba\u814e\u529f\u80fd\u9810\u5f8c\u4e0d\u597d\uff0c\u6545\u4e0d\u4f7f\u7528ACEI (angiotensin-converting enzyme inhibitor) \u6216angiotensin II-receptor blocker (ARB)\r(5) MPGN\u672b\u671f\u814e\u75c5\u8b8a\u75c5\u4eba\uff0c\u5982\u63a5\u53d7\u505a\u814e\u81df\u79fb\u690d\u4e4b\u5f8c\uff0c\u5f88\u5c11\u518d\u5fa9\u767c\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (2)+(3)+(5)\nD. (2)+(3)+(4)+(5)\nE. (1)+(4)+(5)\n": "(A)", "101-11.\n\u4e00\u4f4d70\u6b72\u7537\u6027\u56e0lymphoma\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u5f8c\uff0c\u51fa\u73fe\u6578\u65e5\u5641\u5fc3\u3001\u5614\u5410\u3002\u4e09\u5929\u5f8c\u88ab\u9001\u81f3\u6025\u8a3a\u767c\u73feWBC 11,000/mm3, Hb 8.0 g/dL, \u6709\u812b\u6c34\u75c7\u72c0\uff0c\u521d\u6b65\u8a3a\u65b7\u70batumor lysis syndrome\u53caacute kidney injury. \u4ee5\u4e0b\u54ea\u4e00\u7a2e\u72c0\u6cc1\uff0c\u6700\u4e0d\u5e38\u51fa\u73fe?\nA. hyperuricemia\nB. hypercalcemia\nC. hyperkalemia\nD. hyperphosphatemia\nE. serum creatinine level \u4e0a\u5347\n": "(B)", "101-12.\n\u6709\u4e0051\u6b72\u7537\u6027\uff0c\u4f4f\u9662\u4e2d\u767c\u73fe\u8840\u9209\uff08Na\uff09138 mmol/L\uff0c\u8840\u6c2f\uff08CL\u203e\uff09103 mmol/L\uff0c\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\uff1apH 7.3\uff0cPCO2 30mmHg\uff0cPO2 92 mmHg\uff0cHCO3\u203e 14 mEq/L\u3002\u4e0b\u5217\u90a3\u4e00\u7a2e\u70ba\u53ef\u80fd\u4e4b\u539f\u56e0\uff1f\nA. \u4f7f\u7528amphotericin B\nB. \u4f7f\u7528 magnesium sulfate\nC. \u98e2\u9913\uff08starvation\uff09\nD. \u4f7f\u7528cholestyramine\nE. \u814e\u529f\u80fd\u4e0d\u5168\uff08renal insufficiency\uff09\u4e4b\u75c5\u4eba\u4f7f\u7528\u975e\u985e\u56fa\u9187\u6297\u767c\u708e\u85e5\u7269\uff08NSAID\uff09\n": "(C)", "101-13.\n\u6709\u4e0072\u6b72\u7684\u8001\u5148\u751f\uff0c\u56e0\u5c3f\u9053\u611f\u67d3\u800c\u4f4f\u9662\uff0c3\u5e74\u524d\u5df2\u77e5\u8840\u4e2d\u808c\u9178\u9150\u7d042~3mg/dl\uff0c\u4f4f\u9662\u7528\u85e5\u7269\u6cbb\u7642\u6578\u5929\u5f8c\uff0c\u8840\u808c\u9178\u9150\u5347\u81f35.0mg/dl\uff0cBUN\u9ad8\u523098mg/dl\u3002\u4e26\u7121\u767c\u73fe\u660e\u986f\u814e\u8870\u7aed\u4e4b\u539f\u56e0\uff0c\u75c5\u4eba\u7121\u767c\u71d2\u3001\u76ae\u75b9(rash)\uff0c\u8840\u58d3130/80mmHg\uff0c\u5fc3\u8df378/min\uff0c\u5c3f\u91cf1100 cc/day\u3002\u4e0b\u5217\u4f55\u8005\u63cf\u8ff0\u4e0d\u5c0d?\nA. \u61c9\u61f7\u7591\u6025\u6027\u9593\u8cea\u6027\u814e\u708e(acute interstitial nephritis, AIN)\u4e4b\u53ef\u80fd\u6027\nB. AIN\u4ee5\u904e\u654f\u6027\u9593\u8cea\u6027\u814e\u708e( allergic interstitial nephritis) \u6700\u5e38\u898b\nC. \u975e\u985e\u56fa\u9187\u6297\u767c\u708e\u85e5\u7269(NSAID)\u5f15\u8d77\u4e4bAIN\u5e38\u7121\u767c\u71d2\uff0c\u76ae\u75b9\uff0c\u4f46\u5e38\u898b\u6025\u6027\u814e\u8870\u7aed\u4f75\u6709\u56b4\u91cd\u86cb\u767d\u5c3f\nD. \u5c3f\u4e2d\u55dc\u4f0a\u7d05\u767d\u8840\u7403(eosinophil) \u662f\u5426\u589e\u52a0\u5c0d\u8a3a\u65b7AIN\u5927\u6709\u5e6b\u52a9\uff0c\u5176\u654f\u611f\u5ea6\u53ca\u7279\u7570\u6027\u7686\u4f73\uff0c\u61c9\u8a72\u90fd\u8981\u4f5c\u6b64\u6aa2\u67e5\nE. AIN\u4e0d\u4e00\u5b9a\u8981\u9760\u814e\u7a7f\u524c\u8a3a\u65b7\n": "(D)", "101-14.\n\u6709\u4e0049\u6b72\u7537\u6027, \u56e0\u814e\u75c5\u75c7\u5019\u7fa4(nephrotic syndrome)\u4f4f\u9662\uff0c\u5ffd\u7136\u767c\u751f\u53f3\u8170\u75bc\u75db\uff0c\u9a57\u5c3f\u767c\u73fe\u8840\u5c3f\uff0c\u86cb\u767d\u5c3f\u3001\u814e\u529f\u80fd\u4e0b\u964d\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u61c9\u61f7\u7591\u814e\u975c\u8108\u6813\u585e(renal vein thrombosis)\nB. \u6b64\u7a2e\u75c5\u4eba\u56e0\u51dd\u8840\u7570\u5e38\u9020\u6210\u6613\u51dd\u8840\u72c0\u614b\uff08hypercoagulable state\uff09\u800c\u5bb9\u6613\u767c\u751f\u6b64\u75c7.\nC. \u75c5\u7406\u8b8a\u5316\u70ba\u819c\u6027\u814e\u75c5\u8b8a(membranous nephropathy)\u8005\u6700\u6613\u767c\u751f\u6b64\u4f75\u767c\u75c7.\nD. \u6700\u654f\u611f\uff08\u5e7e\u4e4e100%\uff09\u4e4b\u6aa2\u67e5\u65b9\u6cd5\u70ba\u675c\u535c\u52d2\u8d85\u97f3\u6ce2(doppler ultrasound)\nE. \u78ba\u5b9a\u8a3a\u65b7\u70ba\u814e\u975c\u8108\u6813\u585e\u5f8c\u61c9\u4f7f\u7528\u6297\u51dd\u8840\u5291(anticoagulant)\u6cbb\u7642\n": "(D)", "101-15.\n\u6709\u4e0042\u6b72\u5973\u6027\uff0c\u5065\u6aa2\u767c\u73fe\u5c3f\u6db2\u4e2d\u86cb\u767d( - )\uff0c\u7d05\u8840\u74035-7/HPF\uff0c\u767d\u8840\u74030-3/ HPF\uff0c\u8868\u76ae\u7d30\u80de0-2/ HPF\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u55ae\u7d14\u6027\u986f\u5fae\u8840\u5c3f(isolated microscopic hematuria)\u53ef\u4ee5\u662f\u814e\u5c0f\u7403\u75be\u75c5\u4e4b\u8868\u73fe\u3002\nB. \u8089\u773c\u6027\u8840\u5c3f(gross hematuria) \u901a\u5e38\u4ee3\u8868\u6709\u6bd4\u8f03\u91cd\u8981\u7684\u814e\u6ccc\u5c3f\u9053\u75be\u75c5\u3002\nC. \u8840\u5c3f\u4f75\u6709\u5c3f\u4e2d\u767d\u8840\u7403 >5/ HPF\u53ca\u83cc\u5c3f(bacteriuria) \u4ee3\u8868\u53ef\u80fd\u6709\u611f\u67d3\u3002\nD. \u5973\u6027\u4e4b\u6025\u6027\u8180\u80f1\u708e\u6216\u5c3f\u9053\u708e\u6709\u6642\u6703\u767c\u751f\u8089\u773c\u6027\u8840\u5c3f\u3002\nE. \u75c5\u4eba\u53ea\u8981\u6709\u4e00\u6b21\u8840\u5c3f\uff08RBC\uff1e2/HPF\uff09\u5c31\u8868\u793a\u814e\u6ccc\u5c3f\u9053\u4e00\u5b9a\u6709\u75c5\u3002\n": "(E)", "101-16.\n\u4e00\u4f4d84\u6b72\u5973\u6027\uff0c\u56e0\u95dc\u7bc0\u75db\u53bb\u85e5\u623f\u8cb7\u85e5\uff0c\u5403\u4e86\u5e7e\u5929\u5f8c\u767c\u751f\u5614\u5410\uff0c\u5728\u6025\u8a3a\u8655\u767c\u73fe\u5c3f\u7d20\u6c2e\uff08BUN\uff09\u70ba84 mg/dl\uff0c\u808c\u9178\u9150\uff08creatinine\uff09\u70ba6.1 mg/dl\u3002\u904e\u53bb\u4e26\u7121\u814e\u81df\u75c5\u53f2\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u53ef\u80fd\u6709\u6025\u6027\u814e\u640d\u50b7\uff08acute kidney injury, AKI\uff09\nB. \u6b62\u75db\u85e5\u53ef\u80fd\u626e\u6709\u91cd\u8981\u89d2\u8272\u3002\nC. \u5927\u591a\u6578\u814e\u81df\u5c08\u5bb6\u6cbb\u7642AKI\u5728BUN 60 mg/dl\u5c31\u958b\u59cb\u505a\u900f\u6790\uff08dialysis\uff09\u4ee5\u907f\u514d\u4f75\u767c\u75c7\uff0c\u592a\u665a\u505a\u6703\u589e\u52a0\u6b7b\u4ea1\u7387\u3002\nD. \u900f\u6790\u65b9\u6cd5\u4e4b\u4f7f\u7528\u8981\u8003\u616e\u7576\u5730\u53ef\u63d0\u4f9b\u7684\u8a2d\u5099\u3002\nE. \u5c0d\u8840\u58d3\u504f\u4f4e\u7684\u75c5\u4eba\uff0c\u7528\u8179\u819c\u900f\u6790\u6bd4\u8840\u6db2\u900f\u6790\u5b89\u5168\u3002\n": "(C)", "101-17.\n\u4e00\u500b35\u6b72\u7537\u6027\uff0c\u5728\u6bcf\u6b21\u611f\u5192\u5f8c\u6703\u767c\u73fe\u8089\u773c\u53ef\u898b\u4e4b\u8840\u5c3f\uff08gross hematuria\uff09\uff0c\u814e\u7a7f\u524c\u8a3a\u65b7\u70baIgA\u814e\u75c5\u8b8a\uff08IgA nephropathy\uff09\uff0c\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u5e38\u5e38\u4ee5\u814e\u75c5\u75c7\u5019\u7fa4\uff08nephrotic syndrome\uff09\u8868\u73fe\u3002\nB. \u5728\u75c5\u7a0b\u4e2d\u5e38\u5e38\u767c\u751f\u6025\u6027\u814e\u8870\u7aed\u3002\nC. \u5c0d\u5927\u90e8\u4efd\u75c5\u4eba\u800c\u8a00\uff0c\u662f\u4e00\u76f8\u5c0d\u826f\u6027\u4e4b\u75be\u75c5\uff0c\u67095-30%\u6703\u5b8c\u5168\u7de9\u89e3\uff08complete remission\uff09\u3002\nD. \u6709\u76f8\u7576\u9ad8\u6bd4\u4f8b\u7684\u75c5\u4eba\uff08\u7d0440%\uff09\u572810\u5e74\u5167\u6703\u767c\u751f\u814e\u8870\u7aed\u3002\nE. \u5f88\u591a\u5927\u898f\u6a21\u7814\u7a76\u986f\u793a\u5207\u9664tonsil\uff0c\u4f7f\u7528\u985e\u56fa\u9187\u53ca\u9b5a\u6cb9\uff08fish oil\uff09\u53ef\u4ee5\u6539\u5584\u6240\u6709IgA\u814e\u75c5\u8b8a\u4e4b\u75c5\u4eba\u3002\n": "(C)", "101-18.\n\u5728\u503c\u73ed\u6642\u770b\u5230\u4e00\u500b58\u6b72\u5973\u6027\uff0c\u8840\u9209108 mmole/L\uff0c\u75c5\u4eba\u610f\u8b58\u4e0d\u6e05\u695a\uff0c\u5c0d\u6b64\u75c5\u4eba\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u75c5\u4eba\u4e4b\u4f4e\u8840\u9209\u61c9\u8a72\u8d95\u5feb\u6cbb\u7642\u3002\nB. \u9664\u7cfe\u6b63\u5176\u4f4e\u8840\u9209\u5916\u4ea6\u61c9\u627e\u51fa\u539f\u56e0\u5c0d\u75c7\u6cbb\u7642\u3002\nC. \u70ba\u907f\u514d\u767c\u751f\u56e0\u6ef2\u900f\u58d3\u5287\u70c8\u8b8a\u5316\u5f15\u8d77\u4e4b\u8166\u75c5\u8b8a\uff0dosmotic demyelination syndrome\uff08ODS\uff09\uff0c\u7cfe\u6b63\u4e4b\u901f\u5ea6\u6108\u6162\u6108\u4f73\uff0c\u4e0d\u5fc5\u8003\u616e\u63d0\u5347\u8840\u9209\u4e4b\u901f\u7387\u3002\nD. \u6cbb\u7642\u592a\u5feb\u5f15\u8d77\u8166\u90e8\u4e4b\u4f75\u767c\u75c7ODS\u6700\u591a\u767c\u751f\u5728Pons\uff0c\u4f46\u5176\u4ed6\u8166\u90e8\u7d44\u7e54\u4ea6\u53ef\u767c\u751f\u5982\u5c0f\u8166\u3001\u5927\u8166\u76ae\u8cea\u2026\u7b49\u3002\nE. \u82e5\u7cfe\u6b63\u592a\u5feb\u4f7f\u8840\u9209\u904e\u5ea6\u77ef\u6b63\u6642\uff0c\u60f3\u9810\u9632ODS\u6216\u60f3\u9006\u8f49\uff08reverse\uff09ODS\u4e4b\u767c\u751f\uff0c\u53ef\u4ee5\u4f7f\u7528\u975c\u8108\u6ce8\u5c045%\u8461\u8404\u7cd6\u8f38\u6db2\uff0c\u91cd\u65b0\u5f15\u767c\u4f4e\u8840\u9209\u3002\n": "(C)", "101-19.\n\u4e0068\u6b72\u5973\u6027\uff0c\u77e5\u9053\u6709\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u3001\u53ca\u6162\u6027\u814e\u81df\u75c5\uff08CKD\uff09\u5df2\u7d933\u5e74\uff0c\u5176\u8840\u4e2d\u5c3f\u7d20\u6c2e\uff08BUN\uff09\u70ba39mg/dl\uff0c\u808c\u9178\u9150\uff08creatinine\uff09\u70ba2.1mg/dl\u3002\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6709\u7cd6\u5c3f\u75c5\u6216\u6bcf\u5929\u5c3f\u86cb\u767d\u5927\u65bc1\u514b\u4e4bCKD\u75c5\u4eba\uff0c\u8840\u58d3\u61c9\u63a7\u5236\u81f3125/75 mmHg\u3002\nB. \u8840\u7ba1\u5f35\u529b\u7d20\u8f49\u63db\ufffdC\u963b\u65b7\u5291\uff08ACE inhibitor\uff09\u6216\u8840\u7ba1\u5f35\u529b\u7d20\u53d7\u9ad4\u963b\u65b7\u5291\uff08ARB\uff09 \u53ef\u4ee5\u6e1b\u7de9\u814e\u529f\u80fd\u60e1\u5316\u3002\nC. ACE inhibitors\u6216ARB\u5c0d\u6709\u7f3a\u8840\u6027\u814e\u8840\u7ba1\u75be\u75c5\u4e4b\u75c5\u4eba\uff08ischemic renovascular disease\uff09\u8005\u53ef\u5f15\u767c\u6025\u6027\u814e\u640d\u50b7\uff08acute kidney injury\uff09\u3002\nD. ACE inhibitor\u6216ARB\u4e4b\u5916\u518d\u52a0\u7528\u7559\u9240\u5229\u5c3f\u5291\uff08potassium-sparing diuretics \uff09\u5c0d\u75c5\u4eba\u66f4\u6709\u5e6b\u5fd9\u800c\u4e14\u5b89\u5168\uff0c\u6240\u4ee5\u6bcf\u500b\u75c5\u4eba\u90fd\u53ef\u653e\u5fc3\u4f75\u7528\u3002\nE. \u8840\u8102\u80aa\u82e5\u5347\u9ad8\u61c9\u7a4d\u6975\u6cbb\u7642\u3002\n": "(D)", "101-20.\n\u6709\u4e0040\u6b72\u5973\u6027\uff0c\u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\u5448\u73fe\uff1apH 7.55\u3001PCO2 50mmHg\u3001HCO3\u203e 42 mEq/L\u3001PO2 94 mmHg\uff0c\u8acb\u554f\u4e0b\u5217\u90a3\u4e9b\u70ba\u53ef\u80fd\u4e4b\u75c5\u56e0\uff1f\r(1)\u4f7f\u7528estrogen\r(2)\u4f7f\u7528amphotericin B\r(3)\u9382\u7f3a\u4e4f\uff08magnesium deficiency\uff09\r(4)\u4f7f\u7528acetazolamide\r(5)\u8f38\u5c3f\u7ba1\u4e59\u72c0\u7d50\u8178\u9020\u53e3\u8853\uff08ureterosigmoidostomy\uff09\nA. (2)+(4)\nB. (4)+(5)\nC. (1)+(3)\nD. (2)+(5)\nE. (2)+(3)\n": "(C)", "101-21.\n\u6709\u4e0051\u6b72\u7537\u6027\uff0c\u4e3b\u8a34\u8173\u816b\u5df1\u7d93\u6578\u5929\uff0c\u6aa2\u67e5\u767c\u73fe\u8840\u9209\uff08Na\uff09\u70ba128mmol/L\uff0c\u5176\u8840\u58d3\u70ba150/92mmHg\uff0c\u5fc3\u8df384/min\uff0c\u5169\u8173\u7686\u6709\u6c34\u816b\uff0c\u5c1a\u672a\u7528\u85e5\u6642\uff0c\u9a57\u5176\u5c3f\u9209\u6fc3\u5ea6\u70ba42mmol/L\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u53ef\u80fd\u4e4b\u539f\u56e0\uff1f\r(1)\u814e\u75c5\u75c7\u5019\u7fa4\uff08nephrotic syndrome\uff09\r(2)\u6025\u6027\u814e\u8870\u7aed\uff08acute renal failure\uff09\r(3)\u809d\u786c\u5316\uff08cirrhosis\uff09\r(4)\u6162\u6027\u814e\u8870\u7aed\uff08chronic renal failure\uff09\r(5)\u5fc3\u81df\u8870\u7aed\uff08cardiac failure\uff09\nA. (1)+(3)\nB. (3)+(5)\nC. (1)+(5)\nD. (2)+(4)\nE. (3)+(4)\n": "(D)", "101-22.\n\u6025\u8a3a\u8655\u4f86\u4e86\u4e00\u4f4d55\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u8840\u4e2d\u9240K\u70ba3.1mEg/L\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u53ef\u80fd\u539f\u56e0\uff1f\r(1)\u4f7f\u7528mannitol\r(2)\u816b\u7624\u5feb\u901f\u5206\u89e3\uff08rapid tumor lysis\uff09\r(3)\u9382\u7f3a\u4e4f\uff08magnesium deficiency\uff09\r(4)\u4f7f\u7528amiloride\r(5)\u9ad4\u6eab\u904e\u4f4e\uff08hypothermia\uff09\nA. (1)+(2)\nB. (3)+(5)\nC. (1)+(4)\nD. (2)+(4)\nE. (2)+(3)\n": "(B)", "102-1.\n\u6162\u6027\u814e\u81df\u75c5(chronic kidney disease, CKD)\u7684\u75c5\u4eba\uff0c\u6703\u767c\u751f\u9aa8\u75c5\u8b8a(osteodystrophy)\uff0c\u4ee5\u4e0b\u6a5f\u8f49\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)1,25-vitamin D3 deficiency (2)Hypophosphatemia (3)Hypocalcemia (4)Low serum FGF-23 (fibroblast growth factor-23) (5)Klotho deficiency\nA. (1)+(2)+(3)+(4)\nB. (2)+(4)+(5)\nC. (1)+(3)+(5)\nD. (1)+(3)+(4)+(5)\nE. (1)+(3)+(4)\n": "(C)", "102-2.\n\u4e00\u4f4d\u4e2d\u5e74\u5973\u6027\uff0c\u6709\u86cb\u767d\u5c3f(+)\uff0c creatinine 1.8 mg/dL\uff0c\u5026\u6020\uff0c\u8207serum C3 level\u964d\u4f4e\u3002\u5c1a\u672a\u505a\u814e\u81df\u75c5\u7406\u6aa2\u67e5\u524d\uff0c\u6700\u53ef\u80fd\u662f\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u814e\u708e\u75be\u75c5?\nA. Focal segmental glomerulosclerosis (FSGS)\nB. cryoglobulinemia\nC. Henoch-Schonlein purpura\nD. Wegner's granulomatosis\nE. IgA nephropathy\n": "(B)", "102-3.\n\u6709\u95dc\u591a\u56ca\u814e(autosomal dominant polycystic kidney disease, ADPKD)\u7684\u6558\u8ff0\uff0c\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba?\nA. \u6e90\u81eaPKD2 gene mutation (\u7d04\u4f5480%)\uff0c\u6bd4PKD1 gene mutation (\u7d04\u4f5420%)\u70ba\u591a\nB. \u76f8\u8f03\u5176\u4ed6\u75c5\u56e0\u6240\u5c0e\u81f4\u7684\u6162\u6027\u814e\u81df\u75c5(chronic kidney disease, CKD)\uff0cADPKD\u7684\u7279\u5fb5\u662f\u66f4\u65e9\u767c\u751f\u8ca7\u8840(anemia)\u75c7\u72c0\nC. \u96d6\u7136\u5c11\u6578(4-15%)\u53ef\u80fd\u5408\u4f75cerebral aneurysm, \u4f46\u662f\u5c0d\u65bc\u7121\u75c7\u72c0\u8005\uff0c\u4e0d\u5efa\u8b70\u505aroutine screening\u3002\nD. \u67d0\u4e9bADPKD\u6703\u5408\u4f75\u5fc3\u81df\u74e3\u819c\u7570\u5e38\uff0c\u5176\u4e2d\u4ee5aortic value regurgitation\u6700\u5e38\u898b\u3002\nE. \u9810\u9632ADPKD\u60e1\u5316\uff0c\u8840\u58d3\u63a7\u5236\u5f88\u91cd\u8981\uff0c\u4f46\u61c9\u907f\u514d\u4f7f\u7528ACEI\u6216ARB\u85e5\u7269\u3002\n": "(C)", "102-4.\n\u61f7\u5b55\u5973\u6027\u6cbb\u7642\u9ad8\u8840\u58d3\uff0c\u6216\u662f\u9810\u9632\u8207\u6cbb\u7642pre-eclampsia\u7684\u8840\u58d3\u7570\u5e38\uff0c\u4e0b\u5217\u4f55\u8005\u85e5\u7269\u4e0d\u5efa\u8b70\u4f7f\u7528?\nA. Methyldopa\nB. ACEI \u6216ARB\u985e\u85e5\u7269\nC. Hydralazine\nD. Labetaolol\nE. Pre-eclampsia\u6642\u7d66\u4e88MgSO4\u6216nifedipine\n": "(B)", "102-5.\n\u6709\u95dc\u8179\u819c\u900f\u6790(peritoneal dialysis, PD)\u7684\u6558\u8ff0\uff0c\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba?\nA. \u8840\u6db2\u900f\u6790(hemodialysis, HD)\u5c0d\u4e2d\u5927\u5206\u5b50\u7684\u6e05\u9664\u7387\uff0c\u6bd4\u8179\u819c\u900f\u6790\u597d\nB. \u8179\u819c\u708e(peritonitis)\u662fPD\u5e38\u898b\u7684\u5408\u4f75\u75c7\uff0c\u6700\u5e38\u898b\u7684\u83cc\u7a2e\u662fPseudomonas species\nC. PD\u767c\u751f\u51fa\u53e3\u611f\u67d3(exit-site infection)\u6642\uff0c\u6700\u5e38\u898b\u7684\u83cc\u7a2e\u662fStaphylococcus aureus\nD. 4.25%\u7684PD\u900f\u6790\u6db2(dialysate)\uff0c\u6bd42.5% dialysate\u53ef\u4ee5\u6709\u66f4\u4f73\u7684\u6bd2\u7d20\u6e05\u9664(clearance)\u8207\u71df\u990a\u88dc\u5145\u6548\u679c\nE. \u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u7684\u9577\u671f\u5b58\u6d3b\u7387\u6bd4\u8840\u6db2\u900f\u6790(HD)\u75c5\u4eba\u597d\n": "(C)", "102-6.\n\u67d0\u4e2d\u5e74\u7537\u6027\u88ab\u8a3a\u65b7\u6709systemic sclerosis (scleroderma)\uff0c\u8fd1\u5169\u9031\u51fa\u73fe\u9ad8\u8840\u58d3(182/110 mm Hg)\uff0c\u86cb\u767d\u5c3f(+)\uff0c\u8840\u5c3f(2+)\uff0c\u53cacreatinine 2.1 mg/dL (\u4e09\u500b\u6708\u524d\u503c\u70ba1.0 mg/dL)\u3002\u91dd\u5c0d\u8840\u58d3\u63a7\u5236\uff0c\u512a\u5148\u9996\u9078\u85e5\u7269\u70ba:\nA. ACEI \u985e\u964d\u58d3\u5291\nB. \u03b2-blocker\nC. \u03b1-blocker\nD. Direct vasodilator\nE. Diuretics\n": "(A)", "102-7.\n\u5c0dstage II/III\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\u7684\u75c5\u4eba\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u662f\u6700\u9069\u5408\u7684\u8655\u7f6e\u7b56\u7565\u7d44\u5408?  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1) \u958b\u59cb\u4f7f\u7528erythropoietin (EPO)\u9810\u9632\u8ca7\u8840(anemia) (2)\u4f7f\u7528ACEI/ARB\u63a7\u5236\u8840\u58d3 (3)\u5efa\u8b70\u4f4e\u86cb\u767d\u98f2\u98df(0.8 g/\u6bcfkg\u7406\u60f3\u9ad4\u91cd/day) (4)\u6212\u83f8\u3001\u6e1b\u91cd (5) \u63a7\u5236\u8840\u7cd6\uff0cthe lower the better (6)\u5982\u679c\u6709\u8840\u8102\u7570\u5e38(dyslipidemia)\uff0c\u53ef\u4ee5\u7d66\u4e88\u964d\u8840\u8102\u85e5\u7269(\u5982: statin)\nA. (1)+(2)+(3)+(4)+(5)+(6)\nB. (2)+(4)+(5)\nC. (2)+(3)+(4)+(6)\nD. (1)+(4)+(5)+(6)\nE. (1)+(2)+(3)+(4)+(6)\n": "(C)", "102-8.\n\u521d\u6b21\u88ab\u767c\u73fe\u6709\u9ad8\u8840\u58d3\u7684\u75c5\u4eba\uff0c\u5728screen\u7684\u8a3a\u65b7\u6aa2\u67e5\u9805\u76ee\u4e0a\uff0c\u9664\u4e86\u5efa\u8b70\u8981\u505a: BUN, creatinine, Na, K, Ca, urinalysis\u6aa2\u9a57\u4e4b\u5916\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u662f\u6700\u9069\u5408\u7684\u8a3a\u65b7\u7d44\u5408? (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)(1)total cholesterol (T-Chol), low density lipoprotein (LDL) (2)fasting glucose (AC) level (3)hematocrit (Hct) (4)electrocardiogram (ECG) (5) chest x-ray study (6)renal ultrasonography\nA. (1)+(2)+(3)+(4)+(5)+(6)\nB. (1)+(2)+(3)+(4)\nC. (1)+(2)+(3)+(5)\nD. (1)+(2)+(4)+(6)\nE. (1)+(2)+(6)\n": "(B)", "102-9.\n\u67d054\u6b72\u5973\u6027\uff0c\u6709\u5c3f\u6bd2\u75c7\u72c0(creatinine 4.0 mg/dL)\u3001\u8ca7\u8840(Hct 8.5 g/dL)\u3001\u5026\u6020\u3001\u591c\u5c3f(nocturia)\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u6709metabolic acidosis\uff0c\u8f15\u5ea6\u86cb\u767d\u5c3f(<1.0 g/day)\uff0c\u5c3f\u6db2\u4e2d\u6709WBC cast, granular cast, pyuria\u53caglycosuria\u3002\u75c5\u4eba\u814e\u75c5\u8b8a\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba:\nA. Aristolochic acid nephropathy (Chinese herbal nephropathy)\nB. Focal segmental glomerulosclerosis (FSGS)\nC. Membranoproliferative glomerulonephritis (MPGN)\nD. IgA nephropathy\nE. ADPKD (autosomal dominant polycystic kidney disease)\n": "(A)", "102-10.\n\u4e00\u4f4d21\u6b72\u9752\u5e74\uff0c\u5728\u9177\u71b1\u74b0\u5883\u4e2d\u5287\u70c8\u52de\u52d5\uff0c\u51fa\u73fe\u610f\u8b58\u8b6b\u5984\u3001\u62bd\u6410\uff0c\u88ab\u8a3a\u65b7\u70ba\u4e2d\u6691\u3002\u8655\u7f6e\u4e0a\u9700\u6ce8\u610f\u4ee5\u4e0b\u4f75\u767c\u75c7\uff0c\u4f55\u8005\u6700\u5c11\u898b?:\nA. Hyperglycemia\nB. Acute kidney injury\nC. DIC (disseminated intravascular coagulation)\nD. Rhabdomyolysis\nE. Cardiac arrhythmia\n": "(A)", "102-11.\n\u4e00\u4f4d60\u6b72DM\u53ca\u6162\u6027\u814e\u81df\u75c5(chronic kidney disease)\u75c5\u4eba\uff0c\u4e09\u9031\u524d\u7684AC\u8840\u7cd6\u662f160 mg/dL\uff0cHbA1C\u662f8.2%\uff0ccreatinine 2.0 mg/dL\u3002\u56db\u5929\u524d\u958b\u59cb\u6709\u54b3\u55fd\u3001\u63a5\u8457\u6709\u5598\u3001\u547c\u5438\u56f0\u96e3\u3001\u5c3f\u91cf\u6e1b\u5c11\uff0c\u56e0\u6b64\u4f4f\u9662\u3002\u4f4f\u9662\u6642: WBC 12,500/mm3, Hct 28%, BUN 78 mg/dL, creatinine 2.8 mg/dL, AC 190 mg/dL. \u80f8\u90e8X-\u5149\u6aa2\u67e5\u6709\u53f3\u4e0b\u8449\u75c5\u7076\u3002\u52d5\u8108\u8840\u6db2\u6c23\u9ad4\u6aa2\u67e5(ABG): pH 7.22, PO2 92 mm Hg, PCO2 32 mm Hg, HCO3- 10 mEq/L, BE -15 mEq/L. \u5f9e\u75c5\u53f2\u8207ABG\u8cc7\u6599\u4f86\u770b\uff0c\u4ee5\u4e0b\u6700\u9069\u5408\u7684\u8a3a\u65b7?\nA. Simple metabolic acidosis, with well compensation\nB. Simple respiratory acidosis, with well compensation\nC. Metabolic acidosis + respiratory acidosis\nD. Metabolic acidosis + respiratory alkalosis\nE. Respiratory acidosis + metabolic alkalosis\n": "(C)", "102-12.\n\u4e0b\u5217\u814e\u75c5\u8b8a\u7279\u5fb5\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?:\nA. \u5152\u7ae5\u539f\u767c\u6027\u814e\u75c5\u75c7\u5019\u7fa4(primary nephrotic syndrome)\u6700\u5e38\u898b\u7684\u814e\u75c5\u8b8a\u662fminimal change disease\nB. \u6210\u4eba\u539f\u767c\u6027\u814e\u75c5\u75c7\u5019\u7fa4\u6700\u5e38\u898b\u7684\u814e\u75c5\u8b8a\u662ffocal segmental glomerulosclerosis (FSGS)\nC. \u6700\u5bb9\u6613\u4f75\u767c\u814e\u975c\u8108\u963b\u585e(renal vein thrombosis)\u7684\u539f\u767c\u6027\u814e\u75c5\u8b8a\u662fmembranous nephropathy (MN)\nD. \u6700\u5e38\u898b\u7684\u539f\u767c\u6027\u814e\u708e(glomerulonephritis, \u7c21\u7a31GN)\u662fIgA nephropathy\nE. \u548cC\u578b\u809d\u708e(hepatitis C)\u76f8\u95dc\u7684\u814e\u708e\uff0c\u8f03\u5e38\u898b\u662f: membranous nephropathy (MN) \u6216membranoproliferative glomerulonephritis (MPGN)\n": "(B)", "102-13.\n\u4e0b\u5217\u4f55\u8005\u85e5\u7269\u5bb9\u6613\u5f15\u8d77\u6162\u6027\u814e\u75c5\u8b8a\u8207\u6ccc\u5c3f\u9053\u4e0a\u76ae\u7d30\u80de\u764c(uroepithelial carcinoma) (1)Analgesics (2)Chinese herb (3)Calcineurin inhibitors (4)Lithium (5)Lead (\u61c9\u5beb\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)+(5)\nB. (2)+(3)+(5)\nC. (2)+(5)\nD. (1)+(2)\nE. (2)+(4)\n": "(D)", "102-14.\n\u67d0\u5973\u6027\u75c5\u4eba\u56e0\u808c\u8089\u7121\u529b\u6c42\u8a3a, \u7d93\u6aa2\u67e5\u767c\u73fe\u8840\u58d3\u6b63\u5e38, \u4f46\u6709\u4f4e\u8840\u9240 (K 3.0 mmol/L) , metabolic alkalosis, high renin \u53cahigh aldosterone level. \u8acb\u554f\u53ef\u80fd\u70ba\u5e95\u4e0b\u4f55\u8005\u75be\u75c5 ? (1)Bartter's syndrome (2)Unilateral renal artery stenosis (3)Liddle's syndrome (4)Gitelman's syndrome (5)Loop diuretics  (\u61c9\u5beb\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (1)+(3)+(4)\nC. (1)+(3)+(4)+(5)\nD. (1)+(4)+(5)\nE. (2)+(5)\n": "(D)", "102-15.\n\u67d070\u6b72\u75c5\u4eba\u56e0\u75db\u98a8\u8207\u819d\u95dc\u7bc0\u9000\u5316\u6027\u95dc\u7bc0\u708e\u6642\u5e38\u670d\u7528\u6b62\u75db\u85e5, \u7d93\u6aa2\u67e5serum creatinine\u70ba 2.5 mg/dL, \u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u4e0d\u9069\u5408\u7e7c\u7e8c\u7d66\u4e88thiazide\u7576\u964d\u8840\u58d3\u85e5.\nB. \u9ad4\u6db2\u4e0d\u8db3\u8207\u6162\u6027\u814e\u81df\u75c5\u5747\u662fAnalgesic nephropathy\u4e4b\u9ad8\u5371\u96aa\u65cf\u7fa4.\nC. \u6838\u78c1\u5171\u632f\u6aa2\u67e5\u70ba\u6700\u5408\u9069\u4e4b\u5f71\u50cf\u6aa2\u67e5.\nD. Acetaminophen\u5f15\u8d77analgesic nephropathy \u7684\u53ef\u80fd\u6027\u6bd4\u8f03\u5c0f\nE. \u56e0analgesic nephropathy\u81f4\u672b\u671f\u814e\u8870\u7aed\u8005,\u7f79\u60a3uroepithelial malignancy \u4e4b\u6a5f\u7387\u589e\u52a0\n": "(C)", "102-16.\n\u67d0\u4f4d\u4e2d\u5e74\u5a66\u5973\u6709\u9ad8\u8840\u58d3\u800c\u4e14\u814e\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5de6\u5074\u814e\u81df\u8f03\u5c0f(\u9577\u5f918.5\u516c\u5206),\u53f3\u5074(10\u516c\u5206),\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6aa2\u67e5\u76ee\u524d\u88ab\u8a8d\u70ba\u6bd4\u8f03\u4e0d\u80fd\u78ba\u5207\u986f\u793a\u7570\u5e38?\nA. Captopril renal scintigraphy\nB. Renal Doppler ultrasonography\nC. CT angiography\nD. Magnetic resonance angiography\nE. Digital substraction angiography\n": "(A)", "102-17.\n\u67d060\u6b72\u75c5\u4eba\u5177\u7cd6\u5c3f\u75c5\u5341\u5e74, \u9ad8\u8840\u58d3\u4e09\u5e74, \u73fe\u5728\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\u70ba\u5c3f\u86cb\u767d\u70ba 3+ (300 mg/dL) \u8207serum creatinine 1.4 mg/dL. \u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u75c5\u4eba\u65bc\u4e09\u5e74\u524d\u5c31\u61c9\u6aa2\u6e2cmicroalbuminuria\u6216\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\nB. \u75c5\u4eba\u5e38\u5728\u60e1\u5316\u5230\u672b\u671f\u814e\u8870\u7aed\u524d, \u5c31\u5148\u5fc3\u8840\u7ba1\u75be\u75c5\u767c\u4f5c\u6216\u6b7b\u4ea1\nC. \u75c5\u4eba\u814e\u529f\u80fd\u53ef\u80fd\u65bc\u4e94\u81f3\u5341\u5e74\u5167\u7e7c\u7e8c\u60e1\u5316\u6210\u672b\u671f\u814e\u8870\u7aed\nD. \u82e5\u5176\u5b50\u5973\u4ea6\u907a\u50b3\u5f97\u7cd6\u5c3f\u75c5, \u5176\u7f79\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\u4e4b\u6a5f\u7387\u6703\u8f03\u9ad8\nE. \u5176\u814e\u7d72\u7403\u4e4b\u75c5\u7406\u8b8a\u5316\u53ea\u6709\u5c11\u90e8\u5206\u662fKimmelstiel-Wilson nodular lesions\n": "(A)", "102-18.\n\u7576\u61f7\u7591\u6709light chain disease \u6642, \u8acb\u554f\u4f55\u9805\u70ba\u78ba\u5b9a\u8a3a\u65b7\u654f\u611f\u5ea6\u6700\u9ad8(1-4)\u53ca\u5224\u65b7\u9810\u5f8c(5-6) ? (1)Serum protein electrophoresis (2)24hr Urine protein electrophoresis (3)Immunofixation (4)Serum free light chain assay (5)Serum \u03b2-2 microglobulin (6)Serum albumin.\nA. (1)+(2)+(5)\nB. (2)+(5)+(6)\nC. (2)+(3)+(6)\nD. (4)+(5)+(6)\nE. (2)+(3)+(4)+(5)\n": "(D)", "102-19.\n\u8acb\u554f\u9e7c\u5316\u6cbb\u7642, \u5c0d\u4e0b\u5217\u54ea\u7a2e\u814e\u7d50\u6642\u77f3\u6c92\u6709\u5e6b\u5fd9?  (1)Hypocitraturia (2)Hyperuricemia (3)Distal renal tubular acidosis (4)Primary hyperparathyroidism (5) Struvite stones  (\u61c9\u5beb\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)+(5)\nB. (2)+(4)\nC. (4)+(5)\nD. (3)+(4)\nE. (1)+(5)\n": "(C)", "102-20.\n\u95dc\u65bc\u964d\u5c3f\u9178\u85e5\u7269allopurinol\u8207colchicine\u4e4b\u81e8\u5e8a\u4f7f\u7528,\u4e0b\u5217\u4f55\u8005\u70ba\u8aa4?\nA. \u75c5\u4eba\u82e5\u5177HLA-B5801\u8f03\u5bb9\u6613\u5c0dallopurinol\u7522\u751f\u56b4\u91cd\u904e\u654f\u53cd\u61c9\nB. Allopurinol\u6703\u964d\u4f4etheophylline\u4e4bclearance\nC. Allopurinol\u6703\u589e\u52a0\u8207azathioprine\u62166-mercaptopurine\u6bd2\u6027\nD. Thiazide diuretics\u6703\u964d\u4f4eallopurinol\u4e4b\u6bd2\u6027\nE. Clarithromycin\u6703\u589e\u52a0colchicine\u4e4b\u6bd2\u6027\n": "(D)", "102-21.\n\u67d030\u6b72\u5973\u6027\u65bc\u65bc\u61f7\u5b55\u5169\u500b\u6708\u6642\u5f97\u5230\u5c3f\u8def\u611f\u67d3, \u8acb\u554f\u5728\u9078\u64c7\u6297\u751f\u7d20\u6642,\u4e0b\u5217\u4f55\u8005\u4e0d\u9069\u5408\u4f7f\u7528?\nA. Ampicillin\nB. Levofloxacin\nC. Nitrofurantoin\nD. Aminoglycoside\nE. Cephalosporins\n": "(B)", "102-22.\n\u95dc\u65bcscleroderma renal crisis,\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba?\nA. \u767c\u751frenal crisis\u6642, \u8840\u58d3\u6b63\u5e38\u6216\u4e0d\u9ad8\u4ee3\u8868\u9810\u5f8c\u8f03\u4f73\nB. \u82e5\u6709anti-centromere antibodies,\u8868\u793a\u8f03\u5bb9\u6613\u767c\u751frenal crisis.\nC. \u70ba\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u61c9\u4f7f\u7528\u5927\u91cf\u985e\u56fa\u9187\nD. \u53ef\u4ee5\u4f7f\u7528ACEI\u4f86\u9810\u9632renal crisis\u4e4b\u767c\u751f\nE. \u76ae\u819a\u786c\u5316\u5feb\u901f\u9032\u884c\u6216\u5177anti-RNA polymerase I \u8207 III \u6297\u9ad4\u4e4b\u7537\u6027\u75c5\u60a3\u8f03\u5bb9\u6613\u767c\u751frenal crisis.\n": "(E)", "103-1.\n\u4e2d\u5e74\u7537\u6027\uff0c\u6700\u8fd1\u4e09\u500b\u6708\u5728\u9580\u8a3a\u525b\u88ab\u78ba\u8a3a\u6709\u9ad8\u8840\u58d3\u3002\u70ba\u4e86\u89e3\u9ad8\u8840\u58d3\u7684\u75c5\u56e0\u8207\u76f8\u95dc\u5f71\u97ff\uff0c\u9664\u4e86\u4e00\u822c\u75c5\u53f2\u8207\u7406\u5b78\u6aa2\u67e5\u4e4b\u5916\uff0c\u60a8\u6703\u5efa\u8b70\u512a\u5148\u505a\u4ee5\u4e0b\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7be9\u6aa2\uff0c\u4f55\u8005\u9664\u5916?\nA. Hemoglobin or hematocrit\nB. Urinalysis\nC. Fasting glucose level\nD. HbA1C level\nE. Electrocardiogram (ECG) or chest X-ray\n": "(D)", "103-2.\n\u4e00\u4f4d49\u6b72\u7537\u6027\uff0c\u5916\u50b7\u5f8c\u7b2c\u4e09\u5929\u51fa\u73fe\u5c3f\u91cf\u6e1b\u5c11(350 mL/day)\u3002\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5: \u814e\u81df\u5927\u5c0f\u7121\u7570\u5e38\uff0c\u4e5f\u7121\u6c34\u814e(hydronephrosis)\u3002\u4ee5\u4e0b\u6578\u64da\u4f55\u8005\u652f\u6301ATN (acute tubular necrosis)\uff0c\u800c\u975e\u814e\u524d\u6027\u6025\u6027\u814e\u640d\u50b7(pre-renal acute kidney injury)?\nA. BUN 78 mg/dL, creatinine 1.8 mg/dL\nB. Urine [Na] 41 mEq/L\nC. Urine osmolality 390 mosmol/L\nD. Plasma [Na] 140 mEq/L, plama [creatinine] 1.8 mg/dL, urine [Na] 28 mEq/L, urine [creatinine] 72 mg/dL\nE. urine sediment normal, occasional hyaline cast. No granular or brown cast\n": "(B)", "103-3.\n\u4e00\u4f4d58\u6b72\u5973\u6027\uff0c\u4f8b\u884c\u6027\u5065\u5eb7\u6aa2\u67e5\u6642\u767c\u73fe: \u5c3f\u6db2\u6aa2\u67e5\u5831\u544a\u7570\u5e38\u3002Urinalysis: protein (-), occult blood (2+), RBC 15-20/(HPF, high power field), WBC cast (-), dysmorphic RBC (-), RBC cast (-). \u75c5\u4eba\u81ea\u8ff0\u7121\u5176\u4ed6\u4e0d\u9069\uff0c\u7406\u5b78\u6aa2\u67e5\u4e5f\u7121\u7570\u72c0\u3002\u60a8\u63a5\u8457\u6703\u512a\u5148\u505a\u4ee5\u4e0b\u4f55\u7a2e\u6aa2\u67e5?\nA. Urine cytology test\nB. Check serum cryoglobulin, complement (C3, C4)\nC. Check myoglobulinuria\nD. Arrange renal biopsy\nE. Do urine bacterial culture\n": "(A)", "103-4.\n\u4ee5\u4e0b\u662f\u4e00\u4f4dICU\u75c5\u4eba\u7684\u52d5\u8108\u6c23\u9ad4\u5206\u6790\u8207\u8840\u6db2\u96fb\u89e3\u8cea\u5831\u544a: pH 7.42, PaO2 88 mmHg, PaCO2 67 mmHg, [Na] 140 mEq/L, [K] 3.5 mEq/L, [Cl] 88 mEq/L, HCO3 42 mEq/L\u3002\u4f9d\u64da\u4e0a\u8ff0\u6578\u503c\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u4f55\u7a2e\u75c5\u4eba\u72c0\u6cc1?\nA. Sepsis in ICU\nB. Uremia, long-term use of diuretics\nC. COPD with diuretics\nD. Methanol intoxication, with secondary lactic acidosis\nE. Pneumonia, on ventilator support for pulmonary edema\n": "(C)", "103-5.\n\u4ee5\u4e0b\u6709\u95dc\u8179\u819c\u900f\u6790(peritoneal dialysis, \u7c21\u7a31PD)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)  (1)PD\u75c5\u4eba\u767c\u751f\u8179\u819c\u708e(peritonitis)\uff0c\u6700\u5e38\u898b\u7684\u662fStaphylococcus aureus (2)\u8981\u8a3a\u65b7PD\u75c5\u4eba\u767c\u751f\u8179\u819c\u708e(peritonitis)\uff0c\u4e09\u500b\u6700\u4e3b\u8981\u7684\u75c7\u72c0(triad)\u662f: \u8179\u75db(abdominal pain), \u900f\u6790\u6db2\u6df7\u6fc1(cloudy dialysate), \u53ca\u6df7\u6fc1\u7684\u900f\u6790\u6db2\u4e2dWBC\u9700 >100 /\u03bcL (3)PD\u75c5\u4eba\u767c\u751f\u8179\u819c\u708e(peritonitis)\uff0c\u82e5\u662f\u900f\u6790\u6db2\u6df7\u6fc1(cloudy dialysate), \u800c\u6df7\u6fc1\u7684\u900f\u6790\u6db2\u4e2dWBC >100  /\u03bcL\uff0c\u4e14\u4ee5lymphocyte\u70ba\u4e3b(> 50%)\u6642\uff0c\u8981\u8003\u616eTB (tuberculosis)\u6216\u662ffungal peritonitis\r(4)\u8001\u5e74PD\u75c5\u4eba\u767c\u751f\u8179\u819c\u708e(peritonitis)\uff0c\u6700\u5e38\u898b\u7684\u662fPseudomonas species\u83cc\u7a2e (5)PD\u75c5\u4eba\u767c\u751f\u5c0e\u7ba1\u51fa\u53e3(exit-site)\u611f\u67d3\uff0c\u6700\u5e38\u898b\u7684\u662fStaphylococcus epidermidis\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(5)\nC. (1)+(2)+(4)\nD. (1)+(2)+(5)\nE. (2)+(3)\n": "(E)", "103-6.\n\u4e00\u4f4d44\u6b72\u5973\u6027\uff0c\u4e3b\u8ff0\u6700\u8fd1\u516d\u9031\u4f86\u5169\u5074\u811b\u9aa8\u524d(pre-tibial)\u8207\u8173\u8e1d(ankle)\u6709\u9593\u6b47\u6027\u6c34\u816b(edema)\u3002\u508d\u665a\u6642\u8f03\u816b\uff0c\u8173\u62ac\u9ad8\u6216\u65e9\u6668\u7761\u9192\u6642\u6c34\u816b\u6703\u7a0d\u6539\u5584\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5831\u544a\u70ba: albumin 3.0 g/dL, BUN 26 mg/dL, creatinine 1.0 mg/dL, total cholesterol (t-Chol) 284 mg/dL, LDL 168 mg/dL. C3 48 mg/dL (normal range, 75-135 mg/dL)\u3002\u5c3f\u6db2\u6aa2\u67e5\u986f\u793a: protein (2+), occult blood (1+)\u3002\u4f9d\u64da\u4e0a\u8ff0\u6578\u503c\uff0c\u6700\u4e0d\u7b26\u5408\u4ee5\u4e0b\u4f55\u7a2e\u8a3a\u65b7?\nA. \u53ef\u80fd\u662f lupus nephritis\nB. \u53ef\u80fd\u662f post-infectious glomerulonephritis\nC. \u53ef\u80fd\u662f membranous nephropathy\nD. \u53ef\u80fd\u662f cryoglobulinemia\nE. \u53ef\u80fd\u662f membranoproliferative glomerulonephritis\n": "(C)", "103-7.\n\u4e00\u4f4d54\u6b72\u7537\u6027\uff0c\u56e0\u70ba\u8fd1\u4e09\u5468\u4f86\u6709\u547c\u5438\u4e0d\u9069(dyspnea)\u3001\u75f0\u4e2d\u6709\u8840\u7d72(hemoptysis)\u5230\u6025\u8a3a\u5c31\u91ab\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5831\u544a\u70ba: albumin 3.9 g/dL, BUN 46 mg/dL, creatinine 5.8 mg/dL, Hb 9.4 g/dL. \u80f8\u90e8X-\u5149\u986f\u793a: \u5169\u5074\u80ba\u6709\u7030\u6f2b\u578b\u6d78\u6f64(diffuse alveolar infiltration)\u3002\u514d\u75ab\u5b78\u6aa2\u67e5\uff0c\u542b: anti-GBM antibody, ANCA-antibody, C3, C4, ANA\uff0c\u7686\u7121\u660e\u986f\u7570\u5e38\u3002\u4f9d\u64da\u4e0a\u8ff0\u6578\u503c\uff0c\u75c5\u4eba\u7684\u80ba\u90e8\u8207\u814e\u81df\u75c5\u56e0\uff0c\u8f03\u53ef\u80fd\u662f?\nA. Uremic lung\nB. SLE \u5408\u4f75pulmonary-renal syndrome\nC. Wegener's granulomatosis\nD. Goodpasture's syndrome\nE. Microscopic polyarthritis\n": "(A)", "103-8.\n\u4e00\u4f4d70\u6b72\u7537\u6027\uff0c\u904e\u53bb\u75c5\u53f2\u6709\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u3001\u8207\u6162\u6027\u814e\u81df\u75c5(CKD)\u3002\u9810\u5b9a\u5169\u5929\u5f8c\u9032\u884c\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5831\u544a\u70ba: albumin 4.0 g/dL, BUN 42 mg/dL, creatinine 3.1 mg/dL, total cholesterol (t-Chol) 224 mg/dL, LDL 128 mg/dL. \u5c3f\u6db2\u6aa2\u67e5\u986f\u793a: protein (2+)\u3002\u76ee\u524d\u7528\u85e5\u6709: losartan, carvedilol, furosemide, rosuvastatin, aspirin, insulin\u548csaxagliptin\u3002\u4f9d\u64da\u75c5\u4eba\u72c0\u6cc1\uff0c\u70ba\u6e1b\u5c11\u6216\u9810\u9632contrast-induced nephropathy or acute kidney injury (AKI)\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u63aa\u65bd\u6b63\u78ba?  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)Hydration with isotonic saline, \u53ef\u52a0\u4e0a sodium\rbicarbonate (2)\u56e0\u70baserum creatinine\u9ad8\uff0c\u505a\u5b8c\u5fc3\u5c0e\u7ba1\u7576\u65e5\uff0c\u61c9\u5b89\u6392\u505a\u9810\u9632\u6027\u8840\u6db2\u900f\u6790(prophylactic hemodialysis) (3)\u5c0e\u7ba1\u524d\u4e00\u5929\u8207\u7576\u5929\u5404\u7d66\u4e88N-acetylcysteine (600 mg, bid) (4)\u5c07ARB (losartan)\u63db\u6210cyclosporin-A\uff0c\u4ee5\u6e1b\u5c11\u814e\u6bd2\u6027 (5)\u5982\u679c\u814e\u529f\u80fd\u5c1a\u53ef(< 1.5 mg/dL)\uff0c\u61c9\u8a72\u76e1\u91cf\u5c07insulin\u63db\u56demetformin\uff0c\u53ef\u4ee5\u589e\u52a0\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\u3002\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(3)+(4)+(5)\nC. (1)+(3)+(4)\nD. (1)+(3)+(5)\nE. (1)+(3)\n": "(E)", "103-9.\n\u4e00\u4f4d34\u6b72\u5973\u6027\uff0c\u904e\u53bb\u7121\u91cd\u5927\u75be\u75c5\u6216\u6162\u6027\u75c5\u3002\u4e3b\u8ff0\u6700\u8fd1\u5169\u5929\u6709\u983b\u5c3f\u3001\u6392\u5c3f\u75bc\u75db\u4e0d\u9069(dysuria)\uff0c\u4f46\u662f\u6c92\u6709\u767c\u71d2\u6216\u8170\u75db\u60c5\u5f62\uff0c\u4e5f\u6c92\u6709vaginal discharge\u3002\u4f60\u67e5\u95b1\u75c5\u4f8b\uff0c\u767c\u73fe\u9019\u662f\u5979\u8fd1\u516d\u500b\u6708\u4f86\u7b2c\u4e09\u5ea6\u56e0\u70ba\u76f8\u540c\u4e3b\u8ff0\u5c31\u91ab\u3002\u800c\u4e00\u500b\u6708\u524d\uff0c\u91ab\u5e2b\u66fe\u958b\u4e88trimethoprim-sulfamethoxazole (TMP-SMX)\u4e09\u65e5\u4efd\uff0c\u7576\u6642\u6709\u6548\u4e14\u75c7\u72c0\u75ca\u7652\u3002\u91ab\u5e2b\u5efa\u8b70\u4ee5\u4e0b\u8655\u7f6e\uff0c\u4e0b\u5217\u4f55\u8005\u9664\u5916?\nA. \u4e00\u6a23\u958b\u4e883-5\u65e5\u4efd\u4e4bTMP-SMX \u505a\u75c7\u72c0\u6cbb\u7642\nB. \u5982\u679c\u75c7\u72c0\u672a\u7de9\u89e3\u6216\u60e1\u5316\uff0c\u91cd\u65b0\u505aurine culture\uff0c\u4e26\u4f9d\u7d50\u679c\u9078\u64c7\u6297\u751f\u7d20\u6cbb\u7642\nC. \u5b89\u6392\u505aIVP\u6216\u96fb\u8166\u65b7\u5c64(CT)\u6aa2\u67e5\nD. \u7d66\u4e88\u9810\u9632\u6027\u6297\u751f\u7d20\uff0c\u6bcf\u5929\u7761\u524d\u4f4e\u5291\u91cfTMP-SMX\uff0c\u6216cephalexin\uff0c\u7d043-6\u500b\u6708\u70ba\u671f\u3002\u4e4b\u5f8c\u505c\u85e5\u89c0\u5bdf\nE. \u9f13\u52f5\u591a\u559d\u6c34\u3001\u914d\u5408\u990a\u6210\u9069\u6642\u89e3\u5c3f\u7684\u7fd2\u6163\n": "(C)", "103-10.\n\u4e00\u4f4d28\u6b72\u7537\u6027\uff0c\u4e3b\u8ff0\u5169\u5929\u4f86\u5c3f\u6db2\u984f\u8272\u6df1\u6697(tea-colored urine)\uff0c\u4e14\u611f\u89ba\u5c3f\u91cf\u660e\u986f\u6e1b\u5c11\u4e86\u3002\u75c5\u4eba\u904e\u53bb\u7121\u91cd\u5927\u75be\u75c5\u6216\u6162\u6027\u75c5\uff0c\u7d045\u5929\u524d\u5148\u6709\u611f\u5192\u75c7\u72c0\u3001\u8f15\u5ea6\u767c\u71d2\u3001\u808c\u8089\u8207\u8170\u90e8\u9178\u75db\uff0c\u66fe\u81ea\u884c\u81f3\u85e5\u5c40\u8cb7\u611f\u5192\u6210\u85e5\u670d\u7528\u3002\u4f46\u662f\u7121\u5614\u5410\u3001\u8179\u7009\u3001\u6216\u983b\u5c3f\u7b49\u75c7\u72c0\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe: \u8840\u58d3135/86 mm Hg, \u5589\u56a8\u8f15\u5ea6\u7d05\u816b\uff0c\u547c\u5438\u97f3\u6b63\u5e38\uff0c\u7121\u6c34\u816b\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: Hb 9.9 g/dL, WBC 9700/mm3, albumin 4.1 g/dL, BUN 38 mg/dL, creatinine 1.9 mg/dL. C3, C4 \u6578\u503c\u7686\u6b63\u5e38\u3002\u5c3f\u6db2\u6aa2\u67e5\u986f\u793a: protein (2+), occult blood (3+)\u3002\u814e\u81df\u8d85\u97f3\u6ce2\u986f\u793a: \u5169\u5074\u814e\u81df\u5927\u5c0f\u6b63\u5e38\uff0c\u7121\u963b\u585e\u60c5\u5f62\u3002\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f?\nA. Membranous nephropathy\nB. IgA nephropathy\nC. Microscopic polyarteritis\nD. Membranoproliferative glomerulonephritis\nE. Focal segmental glomerulosclerosis\n": "(B)", "103-11.\n\u4e00\u4f4d\u6162\u6027\u814e\u81df\u75c5\u4eba\uff0c4\u5e74\u4f86\u6301\u7e8c\u63a5\u53d7\u898f\u5247\u8840\u6db2\u900f\u6790\u6cbb\u7642\u3002\u67d0\u65e5\uff0c\u56e0\u8dcc\u5012\u9aa8\u6298\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u7d93\u8a3a\u65b7\u6709\u9aa8\u8cea\u758f\u9b06\uff0c\u591a\u8655\u8840\u7ba1\u9223\u5316\uff0c\u8207\u76ae\u819a\u8840\u7ba1\u75c5\u8b8a(calciphylaxis)\u3002\u9020\u6210\u4e0a\u8ff0\u75c5\u56e0\u8207\u75c7\u72c0\uff0c\u8207\u4f55\u7a2e\u4e0b\u5217\u6a5f\u8f49\u7121\u95dc?\nA. High parathyroid hormone\nB. High [Calcium] x [Phosphate] product\nC. High fetuin-A\nD. High FGF-23 (fibroblast growth factor)\nE. Vascular wall (media and intima) calcification\n": "(C)", "103-12.\n\u95dc\u65bc\u6162\u6027\u814e\u81df\u75c5(Chronic kidney disease)\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5(Cardiovascular disease)\uff0c\u5e95\u4e0b\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f (\u8acb\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848\u4e4b\u7d44\u5408) (1)\u4e09\u5230\u56db\u6210\u4ee5\u4e0a\u6162\u6027\u814e\u81df\u75c5\u60a3\u8005\u5728\u9032\u5c55\u81f3\u7b2c\u4e94\u671f\u524d\uff0c\u5df2\u7f79\u60a3\u5fc3\u8840\u7ba1\u75be\u75c5\u6216\u5df2\u56e0\u4e4b\u6b7b\u4ea1 (2)\u53ea\u6709\u5728\u7b2c\u4e09\u81f3\u7b2c\u4e94\u671f\u6162\u6027\u814e\u81df\uff0c\u5fc3\u8840\u7ba1\u75be\u75c5\u624d\u662f\u5c45\u524d\u7684\u7f79\u75c5\u6216\u81f4\u6b7b\u7684\u539f\u56e0 (3)\u900f\u6790\u75c5\u4eba\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u6b7b\u4ea1\u7387\u4e4b\u660e\u986f\u589e\u52a0\uff0c\u4e3b\u8981\u662f\u6025\u6027\u5fc3\u808c\u6897\u585e\u9020\u6210 (4)\u4f4e\u8840\u6e05\u767d\u86cb\u767d\u8840\u75c7\u8207\u900f\u6790\u75c5\u4eba\u4e4b\u6b7b\u4ea1\u7387\u6709\u95dc (5)\u4f4e\u58d3\u529b\u80ba\u6c34\u816b (low-pressure pulmonary edema)\u5e38\u898b\u65bc\u665a\u671f\u6162\u6027\u814e\u81df\u75c5\uff0c\u4fc2\u7531\u80ba\u6ce1\u58c1\u5fae\u8840\u7ba1\u901a\u900f\u5ea6\u589e\u52a0\u6240\u81f4,\u6240\u4ee5\u900f\u6790\u6cbb\u7642\u5e38\u7121\u6548\u679c\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(4)\nC. (1)+(3)+(4)\nD. (1)+(4)\nE. (1)+(4)+(5)\n": "(D)", "103-13.\n\u67d049\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6162\u6027\u814e\u7d72\u7403\u814e\u708e\u81f4\u5c3f\u6bd2\u75c7\uff0c\u65bc\u8840\u6db2\u900f\u6790\u4e94\u5e74\u5f8c\u63a5\u53d7\u7531\u89aa\u59b9\u59b9\u6350\u8d08\u814e\u81df\u7684\u814e\u81df\u79fb\u690d\u624b\u8853\uff0c\u4f46\u65bc\u79fb\u690d\u624b\u8853\u4e09\u500b\u6708\u5f8c\u767c\u751f\u5c3f\u91cf\u6e1b\u5c11\u53ca\u8840\u6e05\u808c\u9178\u9150\u4e0a\u5347(1.1 mg/dL -> 2.9 mg/dL),\u5728\u8d85\u97f3\u6ce2\u6392\u9664\u7121\u8840\u7ba1\u6216\u5c3f\u9053\u554f\u984c\u5f8c\uff0c\u814e\u81df\u7a7f\u523a\u75c5\u7406\u5982\u5716(A\u3001B\u3001C) \u986f\u793aC4d\u4e4b\u87a2\u5149\u514d\u75ab\u67d3\u8272\u70ba\u967d\u6027\uff0c\u8acb\u554f\u6700\u597d\u5982\u4f55\u8655\u7f6e\uff1f (\u8acb\u9078\u51fa\u6240\u6709\u9069\u7576\u7d44\u5408\u7684\u7b54\u6848)(1)Plasmapheresis (2)Immunoglobulin infusion (3)OKT3 monoclonal antibody (4)Daclizumab (5)Anti-CD20 monoclonal antibody\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)\nC. (2)+(3)+(5)\nD. (1)+(3)+(4)\nE. (1)+(2)+(5)\n": "(E)", "103-14.\n\u67d066\u6b72\u75c5\u4eba\u56e0\u5c3f\u86cb\u767d3+\uff0c\u8840\u6e05\u767d\u86cb\u767d2.9 gm/dL\uff0cBUN 27 mg/dL, Cre 1.5 mg/dL\uff0c \u7d93\u814e\u81df\u7a7f\u523a\u6aa2\u67e5\u70ba\u819c\u6027\u814e\u75c5\u8b8a\uff0c\u5176\u75c5\u7406\u5982\u9644\u5716(A\u3001B\u3001C\u3001D)\uff0c \u8acb\u554f\u5176\u814e\u81df\u75c5\u8207\u4e0b\u5217\u4f55\u8005\u6c92\u6709\u95dc\u806f\uff1f\nA. \u6885\u6bd2\nB. B\u578b\u6216C\u578b\u809d\u708e\nC. \u6297Phospholipase A2 receptor\u6297\u9ad4\nD. \u6297Soluble urokinase plasminogen activator receptor\u6297\u9ad4\nE. \u60e1\u6027\u816b\u7624\n": "(D)", "103-15.\n\u5c31\u5168\u4e16\u754c\u800c\u8a00\uff0c \u8207\u611f\u67d3\u76f8\u95dc\u4e4b\u814e\u7d72\u7403\u708e\u4e2d\uff0c\u6700\u4e3b\u8981\u8207\u6700\u5e38\u898b\u7684\u70ba\u54ea\u5169\u500b\uff1f(1)\u7627\u75be(Malaria) (2)\u8840\u5438\u866b(Schistosomiasis) (3)\u4eba\u985e\u514d\u75ab\u7f3a\u9677\u75c5\u6bd2(HIV) (4)B\u578b\u809d\u708e (5)C\u578b\u809d\u708e\nA. (1)+(2)\nB. (3)+(4)\nC. (4)+(5)\nD. (3)+(4)\nE. (1)+(3)\n": "(A)", "103-16.\n34\u6b72\u7537\u6027\u525b\u53bb\u6771\u5357\u4e9e\u65c5\u904a\u5169\u9031\u4e26\u627f\u8a8d\u5176\u9593\u6709\u6027\u4ea4\u6613\u884c\u70ba\u6578\u6b21\uff0c\u56de\u570b\u4e00\u9031\u5f8c\u51fa\u73fe\u5c0f\u4fbf\u6642\u75bc\u75db\u8207\u5c3f\u9053\u53e3\u6709\u5206\u6ccc\u7269\uff0c\u7d93\u5c3f\u9053\u5206\u6ccc\u7269\u62b9\u7247\u6aa2\u67e5\u6709\u770b\u5230\u767d\u8840\u7403\u5167\u6709\u683c\u862d\u6c0f\u9670\u6027\u4e4b\u96d9\u7403\u83cc\uff0c\u8acb\u554f\u4e0b\u5217\u8005\u70ba\u932f\u8aa4 ?\nA. \u75be\u75c5\u7ba1\u5236\u7f72\u898f\u5b9a\u70ba\u7b2c\u4e09\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\nB. FDA\u5df2\u901a\u904e\u53ef\u7528Nucleic acid amplification tests\u4f86\u78ba\u5b9a\u8a3a\u65b7\nC. \u5f88\u53ef\u80fd\u540c\u6642\u6709\u62ab\u8863\u83cc\u4e4b\u611f\u67d3,\u6545\u6700\u597d\u540c\u6642\u7d66Doxycycline\u6216Azithromycin\u4f86\u6cbb\u7642\nD. \u6b64\u83cc\u56e0\u9ad8\u5ea6\u7a81\u8b8a\u6027,\u5c0e\u81f4\u5176\u6297\u85e5\u6027\u76f8\u7576\u9ad8\nE. CDC\u4e0d\u5efa\u8b70\u7d66\u4e88Quinolone\u985e\u6297\u751f\u7d20\u4f86\u6cbb\u7642\n": "(D)", "103-17.\n20\u6b72\u7537\u6027\u5b78\u751f\u5176\u5144\u5f1f\u8207\u7236\u89aa\u7684\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u5169\u5074\u814e\u81df\u5747\u6709\u814e\u81df\u56ca\u816b(Renal cysts)\u8207\u8840\u7ba1\u5e73\u6ed1\u808c\u8102\u80aa\u7624(Angiomyolipoma) \uff0c \u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4e2d\u4f55\u8005\u70ba\u932f\u8aa4 ?\nA. \u544a\u8a34\u5b78\u751f\u8207\u5176\u7236\u5144\u5011\u9808\u8981\u5b9a\u671f\u8d85\u97f3\u6ce2\uff0c\u96fb\u8166\u65b7\u5c64\uff0c\u6216\u6838\u78c1\u5171\u632f\u7684\u8ffd\u8e64\u6aa2\u67e5\nB. \u544a\u77e5\u5176\u7236\u5144\u5176\u814e\u529f\u80fd\u6975\u53ef\u80fd\u6703\u8870\u9000\u5230\u9808\u8981\u900f\u6790\u6cbb\u7642\nC. \u7576\u816b\u7624\u5927\u65bc\u4e09\u516c\u5206\u4ee5\u4e0a\uff0c\u5efa\u8b70\u6700\u597d\u8655\u7406\u6389\nD. \u6709\u53ef\u80fd\u4e5f\u6703\u6709CNS\u7684\u554f\u984c\nE. \u6709\u53ef\u80fd\u6703\u6709Pheochromocytoma\n": "(B)", "103-18.\n\u5e95\u4e0b\u95dc\u65bc\u6162\u6027\u814e\u81df\u75c5\u8207Vitamin D\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4 ?\nA. \u6162\u6027\u814e\u81df\u75c5\u75c5\u4eba\u82e5\u8840\u4e2d 25-hydroxyvitamin D\u504f\u4f4e\uff0c\u5176\u5168\u539f\u56e0\u6b7b\u4ea1\u7387(all-cause mortality)\u6703\u589e\u52a0\nB. Fibroblast growth factor-23 (FGF-23)\u6703\u4fc3\u9032\u814e\u81df\u78f7\u7684\u6392\u6cc4\u8207vitamin D\u7684\u88fd\u9020\nC. Vitamin D\u6b20\u7f3a\u6703\u589e\u52a0\u7f79\u60a3\u7cd6\u5c3f\u75c5\uff0c\u5fc3\u81df\u75c5\uff0c\u9ad8\u8840\u58d3\u7b49\u4e4b\u6a5f\u7387\nD. \u6162\u6027\u814e\u81df\u75c5\u56e0Vitamin D\u4e0d\u8db3\uff0c\u6703\u6e1b\u5c11\u526f\u7532\u72c0\u7dda\u4e0aVitamin D receptor\u800c\u4f7f\u526f\u7532\u72c0\u817a\u7d20\u589e\u52a0\nE. Vitamin D \u662f\u5728\u814e\u81df\u8fd1\u7aef\u814e\u5c0f\u7ba1\u76841 alfa-hydroxylase\u5c0725-OH  cholecalciferol\u6d3b\u5316\n": "(B)", "103-19.\n\u4e0b\u5217\u4f55\u8005\u662f\u7a81\u767c\u6027\u591c\u9593\u8840\u7d05\u7d20\u5c3f\u4e2d\u7684\u6700\u7f55\u898b\u7684\u81e8\u5e8a\u8868\u73fe\nA. \u5f8c\u5929\u5f62\u6210\u7684\u6eb6\u8840\u6027\u8ca7\u8840(Acquired hemolytic anemia)\nB. \u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840 (aplastic anemia)\nC. \u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5(Acute myeloid leukemia)\nD. \u975c\u8108\u8840\u6813 (venous thrombosis)\nE. Hemoglobinuria and hemosiderinuria\n": "(C)", "103-20.\n\u95dc\u65bc\u7cd6\u5c3f\u75c5\u4eba\u986f\u5fae\u5c3f\u86cb\u767d\u51fa\u73fe\u4e4b\u610f\u7fa9,\u4e0b\u5217\u4f55\u8005\u70ba\u932f\u8aa4 ?\nA. \u986f\u5fae\u5c3f\u86cb\u767d\u7684\u51fa\u73fe, \u4ee3\u8868\u814e\u7d72\u7403\u8d85\u9ad8\u904e\u6ffe(glomerlar hyperfiltration)\u5df2\u7d93\u5b58\u5728\u4e26\u5f9e\u6b64\u958b\u59cb\u8870\u9000\nB. \u986f\u5fae\u5c3f\u86cb\u767d\u7684\u51fa\u73fe, \u4ee3\u8868\u75c5\u4eba\u767c\u751f\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u7f79\u75c5\u6216\u6b7b\u4ea1\u6a5f\u7387\u5df2\u7d93\u589e\u52a0\nC. \u986f\u5fae\u5c3f\u86cb\u767d\u7684\u51fa\u73fe, \u4ee3\u8868\u81f3\u5c11\u6709\u4e94\u6210\u4ee5\u4e0a\u7684\u75c5\u4eba\u5176\u773c\u5e95\u6709\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u75c5\u8b8a\nD. \u986f\u5fae\u5c3f\u86cb\u767d\u4e4b\u51fa\u73fe, \u4e26\u4e0d\u5177\u907a\u50b3\u6027.\nE. \u986f\u5fae\u5c3f\u86cb\u767d\u7684\u51fa\u73fe, \u4ee3\u8868\u81f3\u5c11\u6709\u4e94\u6210\u4ee5\u4e0a\u7684\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\n": "(D)", "103-21.\n\u95dc\u65bc\u5fc3\u814e\u75c7\u5019\u7fa4\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u70ba\u932f\u8aa4 ?\nA. \u5fc3\u814e\u75c7\u5019\u7fa4\u5f88\u5c11\u767c\u751f\u5728\u5de6\u5fc3\u5ba4\u6536\u7e2e\u529f\u80fd\u6b63\u5e38\u7684\u75c5\u4eba\nB. \u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u53ef\u80fd\u56e0\u814e\u975c\u8108\u58d3\u529b\u589e\u52a0, \u81f4\u4f7f\u814e\u7d72\u7403\u904e\u6ffe\u7387\u4e0b\u964d\nC. \u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u6297\u5229\u5c3f\u6fc0\u7d20(Anti-diuretic hormone,ADH)\u5206\u6ccc\u589e\u52a0\nD. \u6162\u6027\u814e\u81df\u75c5\u4e2d\u7dad\u4ed6\u547dD\u7684\u7f3a\u4e4f\u6703\u9020\u6210\u5fc3\u808c\u80a5\u539a\nE. \u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u8840\u6db2\u4e2dadenosine\u4e0a\u5347,\u6703\u9020\u6210\u814e\u7d72\u7403\u904e\u6ffe\u7387\u4e0b\u964d, \u9209\u56de\u6536\u589e\u52a0\n": "(A)", "103-22.\n\u67d030\u6b72\u5973\u6027\u56e0\u9ad8\u8840\u58d3(BP 210/130 mmHg)\u8207\u4f4e\u8840\u9240(K =2.8 mmol/L), \u52d5\u8108\u8840\u6c23\u9ad4\u5206\u6790\u70bapH 7.45, PaCO2 53mmHg , HCO3 32.7mEq/L . \u5176\u57fa\u6e96\u7684\u8840\u6f3f\u814e\u7d20\u6d3b\u6027 (Plasma renin activity, PRA  0.07 ng.mL/hr;) \u8840\u6f3f\u7559\u9e7d\u6fc0\u7d20(Plasma aldosterone; PA 43.7 ng/mL);\u7d93\u56db\u5c0f\u6642\u4e8c\u516c\u5347\u751f\u7406\u9e7d\u6c34\u8f38\u6ce8\u5f8c: PRA\u70ba0.2 ng/mL/hr, PA \u70ba19 ng/mL);\u8acb\u554f\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\u4f55?\nA. Diuretic use\nB. Congenital adrenal hyperplasia\nC. Primary aldosteronism\nD. Cushing syndrome\nE. Licorice ingestion\n": "(C)", "104-1.\n24\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u808c\u8089\u62bd\u7b4b\u8207\u5168\u8eab\u4e4f\u529b\u5f71\u97ff\u6253\u96fb\u8166\u8207\u8d70\u8def\u800c\u6c42\u8a3a\u3002\u7406\u5b78\u6aa2\u67e5\u70ba\uff1a\u8840\u58d3 112/70 mmHg; HR 80/min, \u547c\u543814/min,\u5168\u8eab\u808c\u529b\u7d044\u5206\u3002BUN 13.2 mg/dL, Cre 0.9 mg/dL, Uric acid 9.6 mg/dL, Na 136 mmol/L, K 2.6 mmol/L, Cl 85 mmol/L, Ca 2.38 mmol/L, Mg 0.9 mmol/L. Urine K 33.4 mmol/24/h , TTKG 11.74. Blood gas pH 7.53, PaCO2 49.3 mmHg, PaO2 98.0 mmHg, HCO3- 41.2 mEq/L, BE 15.8 mEq/L. Plasma renin activity 25.8 ng/ml/h (normal <5); Plasma aldosterone 64.4 ng/dL (normal <30)., \u814e\u81df\u8d85\u97f3\u6ce2(\u5982\u5716)\u3002\u8acb\u554f\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\r(1) Fanconi syndrome, (2) Bartter syndrome, (3) Gilteman syndrome, (4) \u9577\u671f\u904e\u5ea6\u4f7f\u7528Thiazide, (5) \u9577\u671f\u904e\u5ea6\u4f7f\u7528Loop diuretics.\nA. (1)+(2)\nB. (2)+(5)\nC. (3)+(4)\nD. (2)+(4)\nE. (3)+(5)\n": "(B)", "104-2.\n73\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6700\u8fd1\u4e94\u5929\u773c\u7736\u5468\u906d\u81ea\u7136\u51fa\u73fe\u7d2b\u6591\uff0c\u81ea\u8ff0\u4e4b\u524d\u7121\u5916\u50b7\u6216\u8dcc\u5012\uff0c\u904e\u53bb\u7121\u7cd6\u5c3f\u75c5\u6216\u9ad8\u8840\u58d3\uff0c\u4e5f\u7121\u670d\u7528\u6b62\u75db\u85e5\u3001\u963f\u65af\u5339\u6797\u3001\u6297\u51dd\u5291\u7b49\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u5168\u8eab\u4ed6\u8655\u76ae\u819a\u7121\u96f7\u540c\u75c7\u72c0\uff0c\u4e0b\u80a2\u7121\u6c34\u816b\u3002\u4f46\u5c3f\u6db2\u6aa2\u67e5\u6709\u5c3f\u86cb\u767d3+,RBC 0-2/HPF\uff0cBUN 30 mg/dL, Cre 1.5 mg/dL, Albumin 3.3 gm/dL\uff0c.\u8d85\u97f3\u6ce2\u986f\u793a\u814e\u81df\u5927\u5c0f\u6b63\u5e38\uff0c\u76ae\u8cea\u56de\u97f3\u5ea6\u7a0d\u589e\u5f37\uff0c\u5176\u4ed6\u7121\u7570\u5e38\u3002\u8acb\u554f\u5728\u5efa\u8b70\u505a\u4fb5\u8972\u6027\u6aa2\u67e5\u524d\uff0c\u6700\u597d\u80fd\u9078\u64c7\u5e95\u4e0b\u54ea\u5e7e\u9805\u6aa2\u67e5\u6bd4\u8f03\u80fd(\u63a5\u8fd1\u767e\u5206\u4e4b\u767e\u7684\u9748\u654f\u5ea6)\u4f86\u78ba\u5b9a\u81c6\u65b7\u4e4b\u6b63\u78ba\u5426\uff1f\r(1) Immunofixation of serum; (2) Immunofixation of urine, (3) Serum protein electrophoresis, (4) Urine Bence Jones Protein detection, (5) Serum immunoglobulin free light chain assay.\nA. (3)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(5)\nD. (1)+(2)+(5)\nE. (3)+(4)+(5)\n": "(D)", "104-3.\n\u8acb\u554f\u5e95\u4e0b\u6240\u5217\u964d\u8840\u58d3\u4e4b\u85e5\u7269\uff0c\u54ea\u4e9b\u53ef\u5e6b\u5fd9\u8f38\u5c3f\u7ba1\u7d50\u77f3\u4e4b\u6392\u51fa\uff1f\r(1) Thiazide, (2) Loop diuretics, (3) Beta blockers, (4) alpha blockers (tamsulosin), (5) calcium blockers (nifedipine)\nA. (1)+(2)\nB. (3)+(4)\nC. (4)+(5)\nD. (1)+(3)\nE. (2)+(5)\n": "(C)", "104-4.\n58\u6b72\u7537\u6027\u75c5\u4eba\u6709\u7cd6\u5c3f\u75c512\u5e74\uff0c\u9ad8\u8840\u58d3\u8207\u8173\u90e8\u6c34\u816b\u7d04\u534a\u5e74\u3002\u7406\u5b78\u6aa2\u67e5 BMI 29\uff0c\u8840\u58d3 154/88 mmHg\uff0c\u811b\u9aa8\u524d\u6c34\u816b +\u3002 \u5c3f\u86cb\u767d 3+, URBC 0-2/HPF\u3002Albumin 3.3 g/dL, BUN 33 mg/dL, Cre 1.8 mg/dL (eGFR 42 ml/min), Na 132 mmol/L, K 5.2 mmol/L, HbA1C 7.3. .\u8acb\u554f\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u662f\u932f\u8aa4\uff1f\r(1) \u56e0\u662f\u6162\u6027\u814e\u81df\u75c5\u7b2c3b\u671f\uff0c\u5c1a\u7121\u9808\u8f49\u8a3a\u81f3\u814e\u81df\u5c08\u79d1\u91ab\u5e2b\u3002(2) \u9ad8\u8840\u58d3\u4e4b\u51fa\u73fe\u4ee3\u8868\u814e\u529f\u80fd\u5c07\u6301\u7e8c\u7e7c\u7e8c\u60e1\u5316\u3002(3) \u82e5\u8840\u7cd6\u80fd\u56b4\u683c\u63a7\u5236\uff0c\u4ea6\u96e3\u4ee5\u964d\u4f4e\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u767c\u751f\u3002(4) \u82e5\u9ad8\u8840\u58d3\u80fd\u56b4\u683c\u63a7\u5236(\u5305\u62ec\u4f7f\u7528ACEI\u6216ARB)\u53ef\u4ee5\u6e1b\u7de9\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\u8207\u8996\u7db2\u819c\u75c5\u8b8a\u3002(5) \u75c5\u4eba\u8840\u7cd6\u5728\u9ad8\u8840\u58d3\u8207\u5c3f\u86cb\u767d\u51fa\u73fe\u5c07\u66f4\u96e3\u63a7\u5236\u3002\nA. (1)+(3)\nB. (2)+(5)\nC. (2)+(3)\nD. (4)+(5)\nE. (3)+(5)\n": "(A)", "104-5.\n\u8acb\u554f\u6162\u6027\u814e\u81df\u75c5\u4eba\u4e2d\u4f7f\u7528\u5e95\u4e0b\u4e4b\u85e5\u7269\uff0c\u4f55\u8005\u6216\u54ea\u4e9b\u4e0d\u6703\u52a0\u91cd\u8840\u7ba1\u9223\u5316\uff1f\r(1) Calcium containing phosphate binders; (2) non-ion based phosphate binders, (3) Vitamin D, (4)  High calcium dialysate, (5) Warfarin \u3002\nA. (2)\nB. (2)+(3)\nC. (2)+(5)\nD. (2)+(3)+(4)\nE. (2)+(3)+(5)\n": "(A)", "104-6.\n\u8acb\u554f\u5e95\u4e0b\u85e5\u7269\u4f55\u8005\u662f\u4e3b\u8981\u7531\u814e\u81df\u6392\u6cc4\u4e14\u814e\u529f\u80fd\u6b20\u4f73\u6642\u9700\u8abf\u6574\u5291\u91cf\uff0c\u4f46\u5728\u85e5\u7269\u904e\u91cf\u6642\u537b\u7121\u6cd5\u4ee5\u8840\u6db2\u900f\u6790\u4f86\u6392\u9664\uff1f\r(1) Aspirin ; (2) Digoxin ;(3)  Lithium (4)Tobramycin; (5)Vancomycin.\nA. (1)+(2)\nB. (2)+(3)\nC. (2)+(5)\nD. (2)+(4)\nE. (3)+(5)\n": "(C)", "104-7.\n45\u6b72\u5973\u6027\u66fe\u63a5\u53d7\u814e\u81df\u79fb\u690d\uff0c\u6b63\u5728\u670d\u7528 Tacrolimus\u53caSirolimus\uff0c\u6b64\u5916\u6709\u670d\u7528\u907f\u5b55\u85e5\u53ca\u56e0\u51a0\u72c0\u52d5\u8108\u963b\u585e\u66fe\u653e\u652f\u67b6\u800c\u670d\u7528Clopidogrel\uff0c\u8acb\u554f\u6b64\u75c5\u4eba\u5bb9\u6613\u7f79\u60a3\u5e95\u4e0b\u54ea\u4e00\u7a2e\u814e\u81df\u75be\u75c5\uff1f\r(1) Thrombotic thrombocytopenic purpura ; (2) Hemolytic uremic syndrome ; (3) Goodpasture syndrome ; (4) Henoch-Schonlein purpura ; (5)Microscopic polyangitis\nA. (1)+(2)\nB. (3)+(4)\nC. (3)+(5)\nD. (2)+(3)\nE. (2)+(5)\n": "(A)", "104-8.\n63\u6b72\u5973\u6027\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\u3001\u9000\u5316\u6027\u95dc\u7bc0\u708e\u4e4b\u904e\u53bb\u53f2\uff0c\u56e0\u814e\u529f\u80fd\u6b20\u4f73\u6c42\u8a3a\u7d93\u6aa2\u67e5\u6709\u5c3f\u86cb\u767d++\u8207\u5c3f\u7d05\u8840\u74035-10/HPF\u3002\u8840\u6e05\u808c\u9178\u9150 2.2 mg/dL\uff0c\u8840\u7d05\u7d2010 gm/dL\u3002\u8d85\u97f3\u6ce2\u986f\u793a\u5169\u5074\u814e\u81df\u5747\u8f15\u5ea6\u840e\u7e2e\u5404\u7d049\u516c\u5206(\u5982\u5716)\uff0c\u8acb\u554f\u4e0d\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\uff1f\r(1) Myeloma kidney ; (2)nephropathy ; (3)DM nephropathy; (4) Chinese herb nephropathy ; (5)Lithium nephropathy\nA. (1)+(2)\nB. (1)+(3)\nC. (2)+(3)\nD. (3)+(5)\nE. (2)+(5)\n": "(B)", "104-9.\n\u4f9d\u64da\u76ee\u524d\u4e4b\u81e8\u5e8a\u8b49\u64da\uff0c\u65bc\u7b2c\u56db\u671f\u7d05\u6591\u6027\u72fc\u7621\u4e4b\u8a98\u767c\u671f\uff0c\u5efa\u8b70\u5982\u4f55\u9078\u64c7\u514d\u75ab\u6291\u5236\u5291\u800c\u80fd\u6709\u8f03\u4f73\u7642\u6548\u4e14\u8f03\u5c11\u526f\u4f5c\u7528\uff1f\r(1) Monthly i.v. high dose cyclophosphamide;\r(2) Monthly i.v. high dose methylprednisolone,\r(3) Monthly i.v. Rituxumab, anti-CD20 monoclonal antibody.\r(4) Daily oral mycophenolate mofetil\r(5) Daily oral cyclosporine\r(6) Daily oral azathioprine\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(5)\nD. (1)+(3)+(6)\nE. (2)+(5)+(6)\n": "(B)", "104-10.\n\u75c5\u4eba\u56e0Transient Ischemia attack \u6b63\u9577\u671f\u670d\u7528\u4f4e\u5291\u91cfAspirin, \u8acb\u554f\u8207\u4e0b\u5217\u54ea\u4e9b\u85e5\u7269\u6703\u6709\u4ea4\u4e92\u4f5c\u7528\uff1f\r(1) naproxen\r(2) Ibuprofrn\r(3) COX-2 inhibitor\r(4) Acetaminophen\r(5) Diclofenac\nA. (1)+(2)\nB. (1)+(2)+(4)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (2)+(3)+(4)+(5)\n": "(A)", "104-11.\n66\u6b72\u5a66\u4eba\u56e0\u6182\u9b31\u75c7\u541e\u670d\u9223\u96e2\u5b50\u963b\u65b7\u5291\u8207\u4e59\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291(\u4e0d\u77e5\u9053\u5e7e\u7c92)\uff0c\u7d93\u6025\u8a3a\u5f8c\u7be9\u6aa2\u767c\u73fe\u8840\u58d3 70/50 mmHg, \u5fc3\u8df3 45/min\uff0c\u5fc3\u96fb\u5716\u6709AV block \u73fe\u8c61\u3002\u8acb\u554f\u5e95\u4e0b\u54ea\u4e9b\u662f\u4e0d\u9069\u7576\u7684\u7279\u6b8a\u6cbb\u7642\u6216\u8655\u7f6e\uff1f\r(1) \u7d66\u4e88\u5927\u91cf\u751f\u7406\u9e7d\u6c34; (2) Glucacon ; (3) Vasopressors or inotropic agents; (4) Magnesium; (5) Electric pacing ; (6) High dose insulin (with glucose and potassium) ; (7) \u9700\u8981\u96a8\u6642\u6aa2\u6e2c\u8840\u7cd6\u53ca\u9240\u96e2\u5b50\nA. (1)+(2)+(7)\nB. (2)+(6)+(7)\nC. (1)+(4)\nD. (6)+(7)\nE. (1)+(2)+(6)\n": "(C)", "104-12.\n\u4e00\u4f4d30\u6b72\u5973\u6027\uff0c\u904e\u53bb\u6709IgA nephropathy\u8207\u8f15\u5ea6\u86cb\u767d\u5c3f\uff0c\u5b9a\u671f\u5728\u9580\u8a3a\u5c31\u91ab\u3002\u6700\u8fd1\u61f7\u5b55\u4e26\u51fa\u73fe\u9ad8\u8840\u58d3\uff0c\u4ee5\u4e0b\u9ad8\u8840\u58d3\u76f8\u95dc\u85e5\u7269\u8655\u7f6e\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u5408?\nA. \u4f7f\u7528methyldopa\nB. \u4f7f\u7528ACEI \u985e\u964d\u4f4e\u86cb\u767d\u5c3f\uff0c\u9810\u9632\u767c\u751fpre-eclampsia\nC. \u4f7f\u7528 labetalol\nD. \u4f7f\u7528Long-acting nifedipine\nE. \u4f7f\u7528hydralazine\n": "(B)", "104-13.\n\u4e00\u4f4d52\u6b72\u7537\u6027\uff0c\u6709\u4e09\u5e74\u7684nephrotic syndrome\u75c5\u53f2\uff0c\u5b9a\u671f\u5728\u9580\u8a3a\u5c31\u91ab\u3002\u6700\u8fd1\u4e00\u500b\u6708\u51fa\u73fe\u96d9\u4e0b\u80a2\u6c34\u816b\uff0c\u9ad4\u91cd\u589e\u52a0\u4e864\u516c\u65a4\uff0c\u5c3f\u86cb\u767d\u5f9e2.8 g/day\u589e\u52a0\u523010.6 g/day\u3002\u91ab\u5e2b\u61f7\u7591\u6709venous thromboembolism\u5408\u4f75\u75c7\u3002\u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u53ef\u80fd\u662f\u767c\u751fdeep vein thrombosis\u6216renal vein thrombosis\nB. \u539f\u56e0\u901a\u5e38\u662fplatelet \u6578\u76ee\u589e\u52a0\u6216antithrombin III activity\u589e\u52a0\u6240\u81f4\nC. \u53ef\u80fd\u539f\u56e0\u662fprotein C\u6216protein S\u6e1b\u5c11\u6240\u81f4\nD. \u901a\u5e38\u5148\u4ee5\u8d85\u97f3\u6ce2\u505a\u7be9\u6aa2(screening test)\uff0c\u5fc5\u8981\u6642\u518d\u5b89\u6392CT \u6216MRI\u6aa2\u67e5\nE. \u4f7f\u7528 heparin \u6216warfarin\u6cbb\u7642\n": "(B)", "104-14.\n\u4e00\u4f4d24\u6b72\u5916\u8868\u5065\u5eb7\u5973\u6027\uff0c\u5065\u5eb7\u6aa2\u67e5\u767c\u73fe: urine protein (2+)\uff0curine occult blood test (2+), Hb 9.4 g/dL\uff0cWBC 7,650/mm3\uff0cserum creatinine 1.8 mg/dL\uff0c\u88dc\u9ad4C3\u8207C4\u8f03\u6b63\u5e38\u503c\u504f\u4f4e\u3002\u75c5\u4eba\u6700\u53ef\u80fd\u662f\u4ee5\u4e0b\u4f55\u7a2e\u814e\u7d72\u7403\u814e\u708e(glomerulonephritis)?\nA. IgA nephropathy\nB. Henoch-Schonlein purpura\nC. Acute poststreptococcal nephritis\nD. Mesangial proliferative glomerulonephritis\nE. Focal segmental glomerulosclerosis (FSGS)\n": "(C)", "104-15.\n\u4e00\u4f4d\u591a\u56ca\u814e(polycystic kidney disease)\u7684\u75c5\u4eba\uff0c\u56e0\u767c\u71d2\u3001\u8170\u75db\u4f4f\u9662\uff0c\u8a3a\u65b7\u70bacystic infection\u3002\u8003\u91cf\u6297\u751f\u7d20\u5c0d\u500b\u5225\u814e\u81df\u56ca\u6ce1(cyst)\u7684\u7a7f\u900f\u6027\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u6297\u751f\u7d20\u8f03\u4e0d\u9069\u7528?\nA. Aminoglycoside\nB. Clindamycin\nC. Ampicillin\u6216Erythromycin\nD. Fluoroquinolone\nE. Metronidazole\n": "(A)", "104-16.\n\u4e00\u4f4d\u4f4f\u9662\u75c5\u4eba\uff0c\u62bd\u8840\u767c\u73fe[Na] 120 mmol/L\uff0c\u91dd\u5c0d\u4f4e\u8840\u9209\u75c7(hyponatremia)\uff0c\u9032\u4e00\u6b65\u6aa2\u67e5\u5c3f\u6db2\u6ef2\u900f\u58d3(urine osmolality) \u5927\u65bc 280 mOsm/L\uff0c\u5c3f\u6db2\u7684\u9209\u96e2\u5b50\u6fc3\u5ea632 mmol/L\u3002\u75c5\u4eba\u7684\u4f4e\u8840\u9209\u75c7\u6700\u53ef\u80fd\u662f\u4ee5\u4e0b\u4f55\u7a2e\u75c5\u56e0?\nA. SIADH (Syndrome of inappropriate antidiuretic hormone secretion)\nB. Primary polydipsia\nC. Liver cirrhosis\nD. Heart failure\nE. Nephrotic syndrome\n": "(A)", "104-17.\n\u4e00\u4f4d54\u6b72\u75c5\u4eba\uff0c\u4e00\u5e74\u524d\u56e0\u70ba\u86cb\u767d\u5c3f\uff0c\u63a5\u53d7\u814e\u81df\u5207\u7247(renal biopsy)\u75c5\u7406\u6aa2\u67e5\uff0c\u8a3a\u65b7\u662fMembranous nephropathy (MN)\uff0c\u4e4b\u5f8c\u6301\u7e8c\u65bc\u9580\u8a3a\u8ffd\u8e64\u3002\u6700\u8fd1\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7d50\u679c(\u548c\u4e00\u5e74\u524d\u985e\u4f3c)\uff0c\u70ba: [Albumin] 3.8 g/dL\uff0c[creatinine] 1.2 mg/dL\uff0c\u86cb\u767d\u5c3f1.6 g/day\u3002\u75c5\u4eba\u6709\u8f15\u5ea6\u9ad8\u8840\u58d3\uff0c\u4f46\u662f\u6c92\u6709\u6c34\u816b\u3002\u73fe\u968e\u6bb5\u91dd\u5c0d\u6b64\u75c5\u4eba\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u8f03\u5408\u9069?\nA. \u4f7f\u7528\u4f4e\u5291\u91cfprednisolone\uff0c\u7d042.5 mg/kg/day\uff0c\u9810\u9632\u75be\u75c5\u60e1\u5316\nB. \u61c9\u8a72\u4f7f\u7528Cyclosporine \u6216 tacrolimus\uff0c\u53ef\u4ee5\u4fc3\u9032\u7de9\u89e3(remission)\nC. \u55ae\u7368\u4f7f\u7528Mycophenolate mofetil (MMF)\uff0c\u53ef\u4ee5\u66f4\u964d\u4f4e\u86cb\u767d\u5c3f\uff0c\u4fdd\u8b77\u814e\u81df\nD. \u5c1a\u7121\u9700\u4f7f\u7528prednisolone\u6216\u5176\u4ed6\u514d\u75ab\u6291\u5236\u5291\uff0c\u53ef\u4ee5\u4f7f\u7528ACEI\u985e\u85e5\u7269\u63a7\u5236\u8840\u58d3\nE. \u61c9\u8a72\u518d\u5b89\u6392\u4e00\u6b21\u814e\u81df\u5207\u7247(renal biopsy)\uff0c\u8ffd\u8e64\u75c5\u7406\u8b8a\u5316\n": "(D)", "104-18.\n\u4e00\u4f4d48\u6b72\u6162\u6027\u814e\u81df\u75c5\u4eba(CKD stage IV, eGFR 18)\uff0c\u56e0\u70ba\u6709\u7591\u4f3c\u8179\u90e8\u816b\u7624\uff0c\u63a5\u53d7\u6838\u78c1\u5171\u632f(MRI, with Gadolinium-contrast)\uff0c\u5169\u65e5\u5f8c\u51fa\u73fe\u5be1\u5c3f(oliguria)\uff0c\u5168\u8eab\u808c\u8089\u8207\u76ae\u819a\u75bc\u75db\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u662f\u767c\u751f\u54ea\u7a2e\u75c5\u72c0?\nA. Acute tubular necrosis\nB. Rhabdomyolysis\nC. Nephrogenic systemic fibrosis\nD. Obstructive acute kidney injury\nE. Dehydration-induced acute kidney injury\n": "(C)", "104-19.\n\u6709\u95dcchronic tubulointerstitial nephritis\u75c5\u4eba\u7684\u5c3f\u6db2\u6aa2\u9a57\uff0c\u4ee5\u4e0b\u6558\u8ff0\u7d44\u5408\u4f55\u8005\u6700\u6b63\u78ba?\r(1) \u7528Hansel stain\u53ef\u4ee5\u898b\u5230eosinophiluria\r(2) \u6c92\u898b\u5230WBC cast\r(3) \u898b\u5230granular cast\r(4) \u86cb\u767d\u5c3f(proteinuria) > 1-2 g/day\r(5) \u6709\u6f5b\u8840\u53cd\u61c9[occult blood test (+)], \u53caWBC 40-50/HPF\uff0c\u4f46\u662f\u75c5\u4eba\u4e26\u7121\u6ccc\u5c3f\u9053\u4e0d\u9069\u75c7\u72c0\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (1)+(3)+(4)\n": "(B)", "104-20.\n\u4e00\u4f4d52\u6b72\u5973\u6027\uff0c\u4e3b\u8a34\u767c\u71d2\u3001\u5641\u5fc3\u5614\u5410\u3001\u80c3\u53e3\u8b8a\u5dee\u548c\u8179\u75db\u6301\u7e8c\u4e86\u4e00\u500b\u661f\u671f\u3002\u75c5\u4eba\u56e0\u7d05\u6591\u6027\u72fc\u7621\u814e\u708e\u53ca\u5c3f\u6bd2\u75c7\uff0c\u63a5\u53d7\u8179\u819c\u900f\u6790\u7d0415\u5e74\u3002\u900f\u6790\u6db2\u5916\u89c0\u6e05\u6f88\uff0c\u8179\u6c34\u5316\u9a57\u767d\u8840\u7403\u5c0f\u65bc100 cells/uL\u3002\u81e8\u5e8a\u4e0a\u51fa\u73fe\u8178\u963b\u585e\u4e4b\u75c7\u72c0\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64(CT)\u53ef\u770b\u5230\u6709\u8178\u9053\u64f4\u5f35\u53ca\u8178\u58c1\u9223\u5316\uff0c\u4e14\u88ab\u9223\u5316\u7684\u81df\u5c64\u8179\u819c\u5305\u8986\u8d77\u4f86\u3002\u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\r(1) \u53ef\u80fd\u662f\u8179\u819c\u900f\u6790\u767c\u751f\u7d30\u83cc\u6027\u8179\u819c\u708e(bacterial peritonitis), \u6216\u9ef4\u83cc\u6027\u8179\u819c\u708e(fungal peritonitis)\r(2) \u53ef\u80fd\u662f\u767c\u751f\u5305\u56ca\u6027\u8179\u819c\u786c\u5316\u75c7(encapsulating peritoneal sclerosis)\r(3) \u53ef\u4ee5\u7528tamoxifen\uff0c\u6216\u514d\u75ab\u6291\u5236\u5291(\u5982\u985e\u56fa\u9187\uff0ccorticosteroid)\u6cbb\u7642\r(4) \u53ef\u4ee5\u7528\u4e59\u578b\u963b\u65b7\u5291(beta-blocker)\u6cbb\u7642\r(5) \u4f7f\u7528\u9ad8\u7cd6\u6fc3\u5ea6\u900f\u6790\u6db2\uff0c\u589e\u52a0\u704c\u6d17\u6b21\u6578\uff0c\u53ef\u9810\u9632\u8179\u8154\u5167\u6cbe\u9ecf\uff0c\u4e26\u88dc\u5145\u71df\u990a\nA. (1)+(2)+(5)\nB. (1)+(3)+(5)\nC. (2)+(3)\nD. (2)+(3)+(4)\nE. (2)+(3)+(5)\n": "(C)", "104-21.\n\u4e00\u4f4d51\u6b72\u7537\u6027\uff0c\u8eab\u6750\u5fae\u80d6\uff0c\u5169\u500b\u6708\u524d\u4f8b\u884c\u6027\u5065\u6aa2\u767c\u73fe\u6709\u9ad8\u8840\u58d3(152/94 mm Hg)\u3002\u75c5\u4eba\u81f3\u4f60\u7684\u9580\u8a3a\u5c31\u91ab\uff0c\u6e2c\u5f97\u8840\u58d3\u503c148/90 mm Hg\uff0c\u4f9d\u71672015\u5e74\u51fa\u7248\u7684\u53f0\u7063\u9ad8\u8840\u58d3\u6307\u5f15\uff0c\u9664\u4e86\u6aa2\u67e5serum creatinine\uff0curinalysis\u7b49\uff0c\u53calipid parameters\u4e4b\u5916\uff0c\u5efa\u8b70\u5b89\u6392\u4ee5\u4e0b\u5be6\u9a57\u5ba4\u4f8b\u884c\u6aa2\u67e5\uff0c\u4f55\u8005\u9664\u5916?\nA. Renal ultrasonography\nB. Hemoglobin or hematocrit\nC. Serum uric acid level\nD. Fasting glucose level\nE. Electrocardiogram (ECG) or chest X-ray\n": "(A)", "104-22.\n\u4f4e\u8840\u9240\u7684\u539f\u56e0\u53ef\u4ee5\u5927\u81f4\u6b78\u985e\u70baThyrotoxic periodic paralysis (TPP)\u8207hypokalemic non-periodic paralysis (HNPP)\u5169\u985e\u3002\u9019\u4e9b\u75c5\u4eba\u5728\u88dc\u5145\u9240\u7684\u8f38\u6db2\u6cbb\u7642\u4e2d\uff0c\u8840\u6e05\u9240\u6fc3\u5ea6\u6709\u6642\u53cd\u800c\u66f4\u4f4e\uff0c\u9019\u7a31\u4e4b\u70ba\"Paradoxical hypokalemia\". \u4ee5\u4e0b\u6709\u95dcParadoxical hypokalemia\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u4e00\u822c\u800c\u8a00\uff0c\u7576\u8981\u77ef\u6b63\u4f4e\u8840\u9240\uff0cTPP\u6bd4HNPP\u7684\u75c5\u4eba\u9700\u8981\u88dc\u5145\u66f4\u591a\u7684\u9240\nB. \u4e00\u822c\u800c\u8a00\uff0c\u7576\u77ef\u6b63\u4f4e\u8840\u9240\u6642\uff0cTPP\u6bd4HNPP\u7684\u75c5\u4eba\u66f4\u5e38\u767c\u751frebound hyperkalemia.\nC. \u4e00\u822c\u800c\u8a00\uff0c\u7576\u77ef\u6b63\u4f4e\u8840\u9240\u6642\uff0cTPP\u6bd4HNPP\u7684\u75c5\u4eba\u66f4\u5e38\u767c\u751fParadoxical hypokalemia\nD. TPP\u7684\u75c5\u4eba\u767c\u751fParadoxical hypokalemia\u7684\u539f\u56e0\uff0c\u901a\u5e38\u8207\u9ad4\u6db2\u5bb9\u7a4d\u4e0d\u8db3(hypovolemia)\u6216renin-aldosterone \u6d3b\u6027\u904e\u9ad8\u6709\u95dc\nE. HNPP\u7684\u75c5\u4eba\u767c\u751fParadoxical hypokalemia\u7684\u539f\u56e0\uff0c\u901a\u5e38\u8207\u8840\u58d3\u9ad8\u6709\u95dc\uff0c\u6240\u4ee5\u53ef\u4ee5\u4f7f\u7528beta-blocker\u4f86\u9810\u9632\n": "(B)", "105-1.\n54\u6b72\u80a5\u80d6\u7537\u5b50(BMI 27.6)\uff0c\u56e0\u9ad8\u8840\u58d3\u4e00\u76f4\u63a7\u5236\u4e0d\u4f73\u800c\u88ab\u8f49\u8a3a\uff0c\u5176\u964d\u58d3\u85e5\u7269\u958b\u59cb\u6709Verapamil\u3001Metoprolol\u3001Clonidine\uff0c\u5f8c\u4f86\u8abf\u6574\u6210Amlodipine\u3001Atenolol\u3001Valsartan\u3001Doxazosin\u3001Minoxidil\u4e94\u7a2e\uff0c\u4f46\u662f\u8840\u58d3\u4ecd\u7136\u5728160-180/100-110 mmHg\u3002\u4ed6\u5e38\u56e0\u982d\u75db\u8207\u95dc\u7bc0\u9178\u75bc\u670d\u7528Ibuprofen\uff0c\u6700\u8fd1\u6aa2\u6e2c\u8840\u6e05\u808c\u9178\u9150\u70ba2.9mg/dL\uff1b\u53e6\u5916\u6709\u547c\u5438\u4e2d\u6b62\u75c7\u5019\u7fa4\uff0c\u56e0\u914d\u6234\u5100\u5668\u7761\u89ba\u4e0d\u8212\u670d\uff0c\u6c92\u6709\u6bcf\u5929\u63a5\u53d7continuous positive airway pressure (CPAP)\u6cbb\u7642\u3002\r\u70ba\u4e86\u80fd\u5c07\u8840\u58d3\u597d\u597d\u63a7\u5236\uff0c\u8acb\u554f\u5e95\u4e0b\u8655\u7f6e\u54ea\u4e9b\u70ba\u6b63\u78ba\uff1f\r1. \u61c9\u8a72\u6539\u7528Selective COX2  inhibitor\uff0c\u5c0d\u8840\u58d3\u8f03\u7121\u5f71\u97ff\u3002\r2. \u61c9\u8a72\u5b89\u639224\u5c0f\u6642\u52d5\u614b\u8840\u58d3\u76e3\u6e2c(24 hour ambulatory blood pressure monitor) \u7684\u6aa2\u67e5\u3002\r3. \u61c9\u8a72\u52a0\u4e0a\u5229\u5c3f\u5291\u4e4b\u4f7f\u7528\u4ee5\u53ca\u7be9\u6aa2\u5176\u4ed6\u6b21\u767c\u6027\u9ad8\u8840\u58d3\u3002\r4. \u61c9\u8a72\u6e1b\u91cd\u53ca\u5f37\u8abf\u6bcf\u5929\u4f7f\u7528CPAP\u6cbb\u7642\u3002\r5. \u61c9\u8a72\u63a8\u85a6\u505a\u814e\u52d5\u8108\u4ea4\u611f\u795e\u7d93\u71d2\u707c\u8853\u6cbb\u7642\u3002\nA. 1+2+3\nB. 1+3+4\nC. 1+3+5\nD. 2+3+4\nE. 1+2+3+4\n": "(D)", "105-2.\n63\u6b72\u7537\u6027\u75c5\u4eba\u5169\u5929\u524d\u63a5\u53d7\u8180\u80f1\u93e1\u6aa2\u67e5\uff0c\u9010\u6f38\u51fa\u73fe\u754f\u5bd2\u767c\u71d2\u3001\u89e3\u5c3f\u4e0d\u6613\u3001\u89e3\u5c3f\u75bc\u75db\u3001\u983b\u5c3f\u3001\u6703\u9670\u8655\u7a0d\u5fae\u4e0d\u9069\uff1b\u9ad4\u6eab\u651d\u6c0f38.3\u5ea6\u3001\u5176\u4ed6\u751f\u547d\u73fe\u8c61\u7a69\u5b9a\uff0cCostophrenic angle\u7121\u6572\u64ca\u75db\u3001\u5c3f\u9053\u53e3\u7121\u5206\u6ccc\u7269\uff1b\u5c3f\u6db2\u6aa2\u67e5\u670910 WBC/HPF\u3001Nitrite 1+, Leukocyte esterase 1+\uff1b\u62bd\u8840\u6aa2\u67e5\u814e\u529f\u80fd\u6b63\u5e38\uff0cPSA \u5347\u9ad8\u81f325ng/ml\u3002\r\u8acb\u554f\u5e95\u4e0b\u54ea\u4e9b\u6558\u8ff0\u662f\u6b63\u78ba\u7684\uff1f\r1.\u61c9\u8a72\u8981\u505a\u5c3f\u6db2\u8207\u8840\u6db2\u7d30\u83cc\u57f9\u990a\r2. \u56e0\u70ba\u5c3f\u6db2Nitrite\u5448\u967d\u6027\uff0c\u6975\u53ef\u80fd\u662fPseudomonas\u611f\u67d3\r3. \u61c9\u8a72\u5b89\u6392\u814e\u81df\u8180\u80f1\u651d\u8b77\u817a\u8d85\u97f3\u6ce2\u6aa2\u67e5\r4..\u53ef\u7d66\u4e88\u53e3\u670dFluoroquinolone\u4e8c\u81f3\u56db\u9031\r5. \u53ef\u7d66\u4e88\u53e3\u670dNitrofuratoin\u4e8c\u81f3\u56db\u9031\nA. 1+2+4\nB. 1+3+4\nC. 2+3+4\nD. 1+3+5\nE. 2+3+5\n": "(B)", "105-3.\n58\u6b72\u7537\u6027\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\u3001\u9ad8\u8840\u8102\u3001\u6162\u6027\u814e\u81df\u75c5\u3001\u75db\u98a8(\u8fd1\u534a\u5e74\u767c\u4f5c\u4e09\u6b21\uff0c\u6700\u5f8c\u4e00\u6b21\u70ba\u4e09\u5468\u524d\uff0c\u5728\u624b\u6307\u3001\u8173\u8dbe\u3001\u624b\u8098\u3001\u8033\u6735\u7b49\u591a\u8655\u95dc\u7bc0\u6709Subcutaneous tophi)\u3002\u76ee\u524d\u62bd\u8840\u6aa2\u67e5\u8840\u6e05\u808c\u9178\u91502.1 mg/dL(eGFR 33)\uff1b\u5c3f\u9178 9 mg/dL\u3002\u5176\u76ee\u524d\u670d\u7528\u85e5\u7269\u6709Thiazide\u3001Losartan\u3001Amlodipine\u3001Fenofibrate\u3001 low dose aspirin\u3002\r\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u8655\u7f6e\u70ba\u6070\u7576\uff1f\r1.\u958b\u59cb\u4f7f\u7528Allopurinol\u6216Febuxostat\uff0c\u4f46\u9808\u964d\u4f4e\u5291\u91cf\u3002\r2.\u505c\u7528Thiazide\uff0c\u56e0\u70ba\u6703\u52a0\u5c3f\u9178\u800c\u4e14\u589e\u52a0Allopurinol\u7684\u6bd2\u6027\u3002\r3. Losartan\u3001Amlodopine\u3001 Low dose aspirin \u5747\u6703\u4fc3\u9032\u5c3f\u9178\u6392\u6cc4\u3002\r4.\u5df2\u975e\u6025\u6027\u75db\u98a8\u671f\uff0c\u4e0d\u5fc5\u518d\u4f7f\u7528Colchicine\u3002\r5.\u6b64\u75c5\u4eba\u964d\u4f4e\u5c3f\u9178\u4e4b\u9810\u671f\u76ee\u6a19\u70ba6 mg/dL\u4ee5\u4e0b\u3002\nA. 1+2+3\nB. 2+3+5\nC. 1+2+5\nD. 1+3+5\nE. 1+4+5\n": "(C)", "105-4.\n62\u6b72\u5973\u59d3\uff0c\u904e\u53bb\u7121\u9ad8\u8840\u58d3\u6216\u7cd6\u5c3f\u75c5\uff0c\u8fd1\u4e94\u5e74\u96d9\u624b\u624b\u6307\u78b0\u51b7\u6c34\u6703\u8b8a\u7d05\u7d2b\uff0c\u6700\u8fd1\u56db\u500b\u6708\u9010\u6f38\u51fa\u73fe\u4ee5\u4e0b\u75c7\u72c0\uff1a\u9762\u5b54\u8207\u624b\u6307\u6d6e\u816b\u3001\u541e\u56a5\u4e0d\u9806\u3001\u8aaa\u8a71\u9072\u7de9\u3001\u4e0b\u80a2\u816b\u8139\u3001\u8840\u58d3\u8b8a\u9ad8\u3001\u547c\u5438\u6025\u4fc3\u3001\u547c\u5438\u56f0\u96e3\u3001\u7aef\u5750\u547c\u5438\u3002BP160/83 mmHg, Urine protein 3+, RBC 40-50/HPF;Hb 7.4 gm/dL,Alb 2.8 gm/dL,Cre 2.8 mg/dL(\u534a\u5e74\u524d1.2 mg/dL) \u3002( \u5982\u5716\u793a)\r\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u99ac\u4e0a\u4f4f\u9662\u4e26\u958b\u59cb\u985e\u56fa\u9187\u7684\u6cbb\u7642\u3002\nB. \u82e5\u5728\u767c\u75c5\u524d\u7d66\u4e88ACE inhibitor\uff0c\u5373\u53ef\u6709\u6548\u5730\u9810\u9632\u6b64\u75c5\u4e4b\u767c\u4f5c\u3002\nC. \u82e5\u75c5\u4eba\u6c92\u6709\u51fa\u73fe\u9ad8\u8840\u58d3(\u5373Normotensive)\uff0c\u5176\u75c5\u60c5\u8207\u9810\u5f8c\u6703\u8f03\u597d\u3002\nD. \u82e5\u75c5\u4eba\u4e4bautoantibody against topoisomerase I (Scl70)\u5448\u967d\u6027\uff0c\u5176\u9810\u5f8c\u8f03\u597d\u3002\nE. \u82e5\u5169\u5e74\u5f8c\u4ecd\u7121\u6cd5\u812b\u96e2\u900f\u6790\u6cbb\u7642\uff0c\u53ef\u5efa\u8b70\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u79fb\u690d\uff0c\u56e0\u70ba\u5176\u5b58\u6d3b\u7387\u9084\u597d\u4e14\u5f88\u5c11\u5fa9\u767c\u3002\n": "(E)", "105-5.\n\u8ffd\u8e64\u7cd6\u5c3f\u75c5\u75c5\u4eba\u8840\u7cd6\u63a7\u5236\u60c5\u5f62\u7684\u7cd6\u5316\u8840\u8272\u7d20(Glycosylated hemoglobin, HbA1C)\uff0c\u8acb\u554f\u6709\u54ea\u4e9b\u72c0\u6cc1\u6703\u5047\u6027\u589e\u9ad8(fasle high)?\r1. Hemolytic anemia\r2. Iron dficiency anemia.\r3. High dose Vitamin A or C\r4. Chronic kidney disease\r5. Chronic liver dsease.\nA. 1+2\nB. 1+3\nC. 2+4\nD. 3+5\nE. 4+5\n": "(C)", "105-6.\n\u95dc\u65bc\u651d\u8b77\u817a\u7279\u5b9a\u6297\u539f(Prostate specific antigen,PSA)\u4e4b\u6e2c\u91cf\u8207\u7be9\u6aa2\uff0c\u5e95\u4e0b\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\r1. PSA\u4e4b\u7be9\u6aa2\u5177\u6975\u4f73\u4e4b\u654f\u611f\u5ea6(Sensitivity)\u8207\u7279\u7570\u6027(Specificity)\u3002\r2. PSA\u4e4b\u8840\u4e2d\u6fc3\u5ea6\u8ddf\u651d\u8b77\u817a\u764c\u4e4b\u767c\u751f\u6a5f\u7387\u53ca\u9810\u5f8c\u7121\u660e\u986f\u76f8\u95dc\u3002\r3. PSA\u4e4b\u7be9\u6aa2\u5efa\u8b70\u53ea\u5728\u5e74\u9f6155\u523069\u6b72\u7684\u7537\u6027\uff0c\u624d\u6709\u5229\u591a\u65bc\u5f0a\u3002\r4. PSA\u4e4b\u7be9\u6aa2\u5efa\u8b70\u53ea\u5728\u9810\u4f30\u58fd\u547d\u6709\u8d85\u904e15\u5e74\u7684\u7537\u6027\u624d\u9700\u8003\u616e\u3002\r5. PSA\u4e4b\u7be9\u6aa2\u82e5\u5305\u62ec\u6e2c\u91cffree PSA\uff0c\u53ef\u589e\u52a0\u6e2c\u5f97\u651d\u8b77\u817a\u764c\u7684\u6a5f\u7387\u3002\nA. 1+2\nB. 2+5\nC. 1+2+3\nD. 2+3+4\nE. 3+4+5\n": "(E)", "105-7.\n\u7576\u7d2b\u6591\u75c7Purpura \u51fa\u73fe\u6642\uff0c\u5176\u91cd\u8981\u7684\u9451\u5225\u8a3a\u65b7\u70ba\u662f\u5426Palpable\uff0c \u8acb\u554f\u5e95\u4e0b\u90a3\u4e9b\u814e\u81df\u75be\u75c5\u51fa\u73fe\u7684purpura\u662f\u70baPalpable?\r1. Uremia\r2. Thrombotic thrombocytopenic purpura\r3. Henoch- Schonlein Purpura\r4. Waldenstrom's hypergammaglobulinemic purpura\r5. Polyarteritis nodosa\nA. 1+3\nB. 2+4\nC. 2+3+4\nD. 1+3+5\nE. 3+5\n": "(E)", "105-8.\n65\u6b72\u5973\u6027\u56e0\u814e\u75c5\u75c7\u5019\u7fa4(\u819c\u6027\u814e\u75c5\u8b8a)\u904e\u53bb\u66fe\u63a5\u53d7\u985e\u56fa\u9187\u8207\u5229\u5c3f\u5291\u5df2\u6709\u4e94\u5e74\u6642\u9593\uff0c\u4f46\u76ee\u524d\u70ba\u7de9\u89e3\u72c0\u6cc1\uff0c\u985e\u56fa\u9187\u4ecd\u7dad\u6301(Prednisolone 10mg QD)\uff0c\u8acb\u554f\u95dc\u65bc\u75c5\u4eba\u9aa8\u8cea\u758f\u9b06\u65b9\u9762\uff0c\u5e95\u4e0b\u8655\u7f6e\u90a3\u4e9b\u8996\u70ba\u6070\u7576\uff1f\r1. \u985e\u56fa\u9187\u5291\u91cf\u5f88\u4f4e\u4e0d\u6703\u6709\u5f71\u97ff\uff0c\u4e0d\u5fc5\u8003\u616e\u505c\u7528\u3002\r2. \u61c9\u8a72\u78ba\u5b9a\u6bcf\u5929\u6709\u53e3\u670d\u8db3\u91cf\u7684\u9223\u7247\u8207\u7dad\u4ed6\u547dD\u3002\r3. \u53ef\u8003\u616e\u7d66\u4e88Bisphosphonate\u4f86\u9810\u9632\u9aa8\u6298\u3002\r4. \u61c9\u8a72\u4e0d\u7528\u6bcf\u5e74\u5b89\u6392\u6aa2\u6e2c\u9aa8\u5bc6\u5ea6(DXA)\u4e4b\u6aa2\u67e5\r5. \u5982\u6709\u9aa8\u8cea\u758f\u9b06\uff0c\u53ef\u8003\u616e\u65bd\u6253\u5408\u6210\u7684\u526f\u7532\u72c0\u817a\u7d20\u3002\nA. 1+2\nB. 1+2+3\nC. 1+2+4\nD. 1+4+5\nE. 2+3+5\n": "(E)", "105-9.\n30\u6b72\u7537\u6027\u521d\u6b21\u53c3\u52a0\u99ac\u62c9\u677e\u8cfd\u8dd1\u5f8c\u4e0d\u652f\u5012\u5730\uff0c\u808c\u8089\u75e0\u75bc\u4e14\u5c3f\u6db2\u5448\u68d5\u7d05\u8272\uff0c\u9001\u81f3\u6025\u8a3a\u521d\u6b65\u6aa2\u67e5\u91cf\u5f97\u9ad4\u6eab\u70ba38.8\u5ea6(\u651d\u6c0f)\uff0c\u8840\u58d3\u6b63\u5e38\uff0c\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\u6709\u6f5b\u88402+\u4f46\u96e2\u5fc3\u6c89\u6e23\u7121\u7d05\u8840\u7403\uff0c\u808c\u9178\u91501.3mg/dL\uff0cCPK 13000u/L \u8acb\u554f\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\r1. \u50cf\u71b1\u4e2d\u6691\uff0c\u56e0\u6b64\u767c\u751f\u6025\u6027\u814e\u8870\u7aed\u6a5f\u7387\u5927\u3002\r2.\u5fc5\u9808\u4f9d\u9760\u8840\u6db2\u6216\u5c3f\u6db2myoglobin\u7684\u5b9a\u91cf\u6aa2\u67e5\u624d\u53ef\u78ba\u5b9a\u662f\u6a6b\u7d0b\u808c\u6eb6\u89e3\u75c7\u3002\r3.\u5176\u4e0a\u8ff0\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\u7d50\u679c\u4ee3\u8868\u53ef\u80fd\u6703\u767c\u751f\u6025\u6027\u814e\u8870\u7aed\u3002\r4.\u61c9\u8a72\u7a4d\u6975\u88dc\u5145\u5927\u91cf\u9ad4\u6db2\uff0c\u7dad\u6301\u5c3f\u6db23ml/kg/hr\uff0c\u76f4\u5230\u5c3f\u6db2\u8a66\u7d19\u6f5b\u8840\u53cd\u61c9\u5448\u9670\u6027\u3002\r5.\u5982\u679c\u5c3f\u6db2pH<6.5\uff0c\u4e00\u5b9a\u8981\u9ede\u6ef4\u52a0\u4e0aBicarbonate\u9e7c\u5316\u5c3f\u6db2\u3002\nA. 1+2+3\nB. 1+3+4\nC. 2+4+5\nD. 3+4+5\nE. 1+4+5\n": "(B)", "105-10.\nWhich patient may have the highest risk and progression of CKD ?\nA. CKD stage 1, with normal albuminuria\nB. CKD stage 3b, with normal albuminuria\nC. CKD stage 2, with severely increased albuminuria\nD. CKD stage 3a, with moderately increased albuminuria\nE. CKD stage 3, no matter the status of albuminuria, will have similar risk of CKD progression\n": "(D)", "105-11.\nSystemic diseases may induce thrombotic microangiopathy in the kidney, with the pathological picture of secondary focal segmental glomerulosclerosis.  Which does not belong to this category ?\nA. hemolytic-uremic syndrome (HUS)\nB. Hepatitis B virus infection\nC. Malignant hypertension\nD. Antiphospholipid syndrome\nE. Radiation nephropathy after bone marrow transplantation\n": "(B)", "105-12.\nA 38-year-old woman who had been diagnosed as membranous nephropathy with heavy proteinuria (4.5 g/day). One day she presented with flank pain, tenderness, hematuria, and rapid decline in renal function.  Which is the most likely diagnosis ?\nA. Renal stone with urinary tract infection\nB. Renal vein thrombosis\nC. Renal artery stenosis\nD. Malignant hypertension\nE. Thrombotic microangiopathy\n": "(B)", "105-13.\nSeveral nutrients have been implicated to increase risk for nephrolithiasis formation. Except ?\nA. Higher intake of animal protein\nB. Higher intake of potassium-rich or magnesium-rich food\nC. Higher sodium intake\nD. Vitamin C supplement is associated with an increased risk of calcium oxalate stone\nE. Higher consumption of sugar-sweetened carbonated beverage\n": "(B)", "105-14.\nA 48 y/o male was found to develop acute renal failure after 7 days of drug therapy. His clinical presentation were: fever, rash, peripheral eosinophilia, and oliguric renal failure, but without proteinuria. Which statement is correct?\r1.A possible etiology of acute interstitial nephritis (AIN)\r2.His manifestation is compatible with nonsteroidal anti-inflammatory drug (NSAID)-induced AIN\r3.Peripheral blood eosinophilia is common in most of AIN patients\r4.Urinary eosinophils are sensitive and specific for diagnosis of AIN, therefore, this testing is highly recommended\r5.Renal biopsy is generally not required for diagnosis of AIN\nA. 1+3+4+5\nB. 1+5\nC. 1+3+4\nD. 1+2\nE. 1+2+3+4+5\n": "(B)", "105-15.\nWhich statement regarding Lithium-associated nephropathy is not correct ?\nA. Most of the patients presented as oliguric acute renal failure\nB. Prolonged (>10-20 years) lithium use, or those experienced repeated episodes of toxic lithium levels, may develop chronic tubulointerstitial nephritis\nC. The most prudent approach is to monitor lithium levels frequently and adjust dosing to avoid toxic levels\nD. In patients with significant proteinuria, ACEI or ARB treatment should be helpful\nE. typical findings on renal biopsy are interstitial fibrosis and tubular atrophy\n": "(A)", "105-16.\nWhich statement regarding mineral metabolism in CKD is correct?\r1.increased production of parathyroid hormone\r2.reduced production of fibroblast growth factor-23 (FGF-23)\r3.increased renal excretion of phosphate\r4.reduced produce of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]\r5.reduction in serum calcium\nA. 1+3+4+5\nB. 1+2+4\nC. 1+2+3+4\nD. 1+2+4+5\nE. 1+4+5\n": "(E)", "105-17.\nPrimary glomerular diseases with reduced complement levels is:\nA. Cryoglobulinemia\nB. Minimal-change disease\nC. IgA nephropathy\nD. focal segmental glomerular sclerosis\nE. Wegener's granulomatosis\n": "(A)", "105-18.\nWhich test has the highest sensitivity of screening renovascular hypertension ?\nA. Duplex ultrasonography\nB. Computed tomography angiography\nC. Captopril renogram\nD. Magnetic resonance angiography (MRA)\nE. Captopril plus diuretics renogram\n": "(D)", "105-19.\nFor diagnosis of acute renal failure, which urinary indices indicating prerenal azotemia rather than acute tubular necrosis or obstruction ?\nA. Urine Na > 40 mEq/L\nB. Urine osmolarity < 400\nC. Urine/plasma creatinine ratio < 20\nD. Renal failure index < 1\nE. FENa > 2%\n": "(D)", "105-20.\nA 52-year-old man with a 20-year history of cigarette smoking is admitted to the hospital because of cough and weakness. On admission, his serum electrolyte levels are: serum [Na] 112 mEq/L; [K] 4.5 mEq/L; [Cl] 80 mEq/L; and HCO3-, 26 mEq/L. The BUN was 8 mg/dL , serum creatinine 0.8 mg/dL and serum uric acid 3.0 mg/dL. These data are most consistent with which of the following?\nA. SIADH (syndrome of inappropriate antidiuretic hormone secretion)\nB. Congestive heart failure\nC. Cirrhosis and ascites\nD. Severe salt and water depletion\nE. Adrenal insufficiency\n": "(A)", "105-21.\nA 28 y/o young male visited your outpatient clinic with an elevated blood pressure of 148/100 mmHg. He denies taking any medications, but has a family history of hypertension. His laboratory values were: [Na] 140 mEq/L, [K] 3.1 mEq/L, [Cl] 98 mEq/L, BUN 25 mg/dL, Creatinine 0.9 mg/dL, Glucose: 85 mg/dL. The arterial blood gas (ABG) test reveals: Arterial pH: 7.48, PCO2: 46 mm Hg, HCO3-: 34 mEq/L. What is the most appropriate characterization of his acid-base disorder?\nA. Metabolic alkalosis\nB. Metabolic alkalosis and respiratory acidosis\nC. Respiratory alkalosis and metabolic acidosis\nD. Metabolic alkalosis and respiratory alkalosis\nE. Respiratory alkalosis\n": "(A)", "105-22.\n\u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD, hemodialysis)\uff0c\u6709\u95dc\u8179\u819c\u900f\u6790(PD, peritoneal dialysis)\u7684\u6558\u8ff0\u8207\u9577\u671f\u5408\u4f75\u75c7\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. PD\u75c5\u4eba\u4f7f\u7528\u9ad8\u7cd6\u900f\u6790\u6db2\u662f\u70ba\u4e86\u8981\u9054\u5230\u900f\u6790\u6e05\u9664\u5c3f\u6bd2\u7d20(uremic toxin)\u7684\u6548\u679c\nB. PD\u75c5\u4eba\u5bb9\u6613\u51fa\u73fehypertriglyceridemia\uff0c\u662f\u56e0\u70ba\u4f7f\u7528\u9ad8\u7cd6\u900f\u6790\u6db2\nC. \u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD)\uff0c\u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u8f03\u5bb9\u6613\u767c\u751f\u8179\u819c\u708e(peritonitis)\nD. \u76f8\u8f03\u65bc\u8840\u6db2\u900f\u6790(HD)\uff0c\u8179\u819c\u900f\u6790(PD)\u75c5\u4eba\u6bcf\u65e5\u86cb\u767d\u8cea\u6d41\u5931\u91cf\u8f03\u9ad8\nE. \u76f8\u8f03\u65bc\u8179\u819c\u900f\u6790(PD)\uff0c\u8840\u6db2\u900f\u6790(HD)\u75c5\u4eba\u8f03\u51fa\u73fe\u900f\u6790\u4e2d\u4f4e\u8840\u58d3\n": "(A)", "106-1.\n\u4e00\u4f4d48\u6b72\u5973\u6027\uff0c\u60a3\u6709bipolar affective disorder\uff0c\u9577\u671f\u670d\u7528\u92f0\u9e7d(Lithium)\u8fd1\u5341\u5e74\u3002\u6700\u8fd1\u51fa\u73fe:  polyuria \u548c polydipsia\u3002 \u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u75c5\u4eba\u53ef\u80fd\u662f Lithium intoxication\nB. \u75c7\u72c0\u53ef\u80fd\u662f central diabetes insipidus (DI)\nC. \u6162\u6027 Lithium nephropathy\u53ef\u4f34\u96a8\u6709\u86cb\u767d\u5c3f\nD. \u53ef\u4f34\u96a8\u51fa\u73fe hypernatremia\nE. Lithium \u82e5\u5f15\u8d77\u6162\u6027\u814e\u75c5\u8b8a\u6703\u6709 interstitial fibrosis \u548c tubular atrophy\n": "(B)", "106-2.\n\u4e00\u4f4d62\u6b72\u5973\u6027\uff0c\u56e0\u7d93\u5e38\u982d\u75db\u8207\u95dc\u7bc0\u75e0\u75db\uff0c\u81ea\u884c\u670d\u7528\u591a\u7a2e\u6b62\u75db\u85e5\uff0c\u6709aspirin, caffeine, acetaminophen\u53ca\u4e0d\u540c\u7a2e\u985e\u7684 NSAID (non-steroid anti-inflammatory drug)\u7b49\uff0c\u6df7\u5408\u8457\u4f7f\u7528\u3002\u6700\u8fd1\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u6709\u814e\u529f\u80fd\u4e0d\u5168\u8207\u86cb\u767d\u5c3f(2+)\u3002\u4ee5\u4e0b\u6558\u8ff0\u7684\u75c7\u72c0\u6216\u8a3a\u65b7\uff0c\u4f55\u8005\u6700\u6b63\u78ba?\nA. \u75c5\u4eba\u7684\u8a3a\u65b7\u7b26\u5408 renal infarction and cortical necrosis\nB. \u75c5\u4eba\u7684\u8a3a\u65b7\u6700\u53ef\u80fd\u662f glomerulosclerosis\nC. \u5176\u4ed6\u53ef\u80fd\u4f34\u96a8\u51fa\u73fe polyuria and metabolic alkalosis\u75c7\u72c0\nD. \u672c\u8a3a\u65b7\u53ef\u80fd\u4f34\u96a8\u51fa\u73fe papillary necrosis and papillary calcification\nE. \u4e0a\u8ff0\u85e5\u7269\u4e2d\uff0c\u6700\u53ef\u80fd\u5f15\u8d77\u6b64\u75c5\u75c7\u7684\u662facetaminophen\n": "(D)", "106-3.\n\u4e00\u4f4d42\u6b72\u7537\u6027\uff0c\u56e0\u767c\u73fe\u6700\u8fd1\u6578\u6b21\u91cf\u5230\u8840\u58d3\u5347\u9ad8(148/88 mmHg)\uff0c\u800c\u81ea\u884c\u5230\u91ab\u9662\u5c31\u8a3a\u3002\u91dd\u5c0d\u521d\u6b21\u5c31\u91ab\uff0c\u4e14\u591a\u6b21\u7d00\u9304\u8b49\u5be6\u78ba\u6709\u9ad8\u8840\u58d3\u7684\u75c5\u4eba\uff0c\u6703\u5b89\u6392\u512a\u5148\u505a\u4ee5\u4e0b\u8a55\u4f30(initial evaluation)\uff0c\u4ee5\u4e0b\u4f55\u8005\u6700\u4e0d\u5177\u512a\u5148\u6027?\nA. Urinalysis\nB. Serum BUN and creatinine\nC. Serum uric acid\nD. Fasting blood glucose, total cholesterol and LDL cholesterol\nE. Hematocrit\n": "(C)", "106-4.\n\u9577\u671f\u7cd6\u5c3f\u75c5\u6703\u5f15\u8d77\u591a\u7a2e\u814e\u81df\u75c5\u8b8a\uff0c\u5305\u62ec: \u86cb\u767d\u5c3f\u3001\u814e\u529f\u80fd\u4e0d\u5168\u3001\u611f\u67d3\u75c7\uff0c\u6216\u814e\u5c0f\u7ba1\u9178\u8840\u75c7(renal tubular acidosis, \u7c21\u7a31RTA)\u8207\u4ee3\u8b1d\u6027\u9178\u8840\u75c7\u3002\u6709\u95dc\u9019\u7a2eRTA\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\nA. \u6b64\u7a2eRTA\u7684\u7279\u9ede\u662f\u51fa\u73fehyperkalemia\nB. \u6700\u5e38\u5f15\u8d77\u7684\u662ftype II RTA\nC. \u6b64\u7a2eRTA\u5f15\u8d77\u7684\u9178\u8840\u75c7\uff0c\u901a\u5e38serum pH\u503c\u6703\u5f88\u4f4e\uff0c\u9700\u8981\u975c\u8108\u6ce8\u5c04\u88dc\u5145bicarbonate\nD. \u6b64\u7a2eRTA\u662f\u56e0\u70ba\u8840\u4e2daldosterone\u6fc3\u5ea6\u5f88\u9ad8\u6240\u5f15\u8d77\nE. \u4e3b\u8981\u75c5\u8b8a\u662f\u5728collecting tubule\uff0c\u7121\u6cd5\u6392\u51fa\u6c2b\u96e2\u5b50(hydrogen ion)\n": "(A)", "106-5.\n\u4e00\u4f4d62\u6b72\u5973\u6027\uff0c\u9577\u671f\u670d\u7528amitriptyline\u6cbb\u7642\u6182\u9b31\u75c7(depression)\uff0c\u6700\u8fd1\u56e0stroke\u4f4f\u9662\u3002\u75c5\u4eba\u7121\u541e\u56a5\u56f0\u96e3\uff0c\u98f2\u98df\u6b63\u5e38\uff0c\u4e5f\u6c92\u6709\u6c34\u816b\u3002\u4f4f\u9662\u4e00\u9031\u5f8c\u62bd\u8840\u6aa2\u67e5\u767c\u73feserum [Na] 126 mEq/L\uff0cosmolality 262 mOsm/kg\u3002urine [Na] 40 mEq/L\uff0curine osmolality 398 mOsm/kg\u3002\u75c5\u4ebahyponatremia\u7684\u539f\u56e0\uff0c\u6700\u53ef\u80fd\u662f?\nA. \u767c\u751fRenal sodium loss and dehydration\nB. \u767c\u751fExtra-renal loss of sodium, and fluid overload\nC. \u767c\u751f lung cancer\nD. \u767c\u751f SIADH (syndrome of inappropriate anti-diuretic hormone secretion)\nE. \u767c\u751f stroke-induced central diabetes insipidus (DI)\n": "(D)", "106-6.\n\u4e00\u4f4d22\u6b72\u5973\u6027\uff0c\u6709\u4e09\u5e74SLE (Systemic Lupus Erythematosus)\u75c5\u53f2\uff0c\u4f46\u6c92\u6709\u898f\u5247\u670d\u85e5\u3002\u6700\u8fd1\u4e00\u9031\u51fa\u73fe\u5598\u3001\u6c34\u816b\u3001\u5c3f\u91cf\u6e1b\u5c11\uff0c\u9ad4\u91cd\u589e\u52a0\u8fd17\u516c\u65a4\u3002\u4f4f\u9662\u8840\u58d3154/94 mmHg\uff0c\u62bd\u8840\u6aa2\u67e5: BUN 98 mg/dL\uff0ccreatinine 3.6 mg/dL, urine protein (4+)\u3002\u56e0\u70ba\u6025\u6027\u814e\u640d\u50b7(acute kidney injury, AKI)\uff0c\u5b89\u6392\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u751f\u6aa2(renal biopsy)\uff0c\u4ee5\u4e0b\u75c5\u7406\u8b8a\u5316\uff0c\u4f55\u8005\u6700\u4e0d\u53ef\u80fd?\nA. Focal segmental glomerulosclerosis (FSGS)\nB. Diffuse proliferative nephritis with diffuse subendothelial deposit\nC. Membranous glomerulonephritis with subepithelial immune complex deposit\nD. Global endocapillary proliferation, crescent formation\nE. Glomerular necrotizing lesion, may present with vascular lesion\n": "(A)", "106-7.\n\u4e00\u4f4d48\u6b72\u7537\u6027\uff0c\u904e\u53bb\u6709C\u578b\u809d\u708e\uff0c\u5b9a\u671f\u5728\u9580\u8a3a\u8ffd\u8e64\u3002\u6700\u8fd1\u4e00\u500b\u6708\u4f86\uff0c\u51fa\u73fe\u86cb\u767d\u5c3f\uff0c\u811b\u524d\u8207\u8db3\u8e1d\u6c34\u816b\uff0c\u9ad4\u91cd\u7565\u589e\u52a0\u8fd13\u516c\u65a4\uff0c\u8840\u58d3150/92 mmHg\u3002\u62bd\u8840\u6aa2\u67e5: \u6709\u8840\u6e05\u88dc\u9ad4(complement, C3\u8207C4)\u504f\u4f4e\u60c5\u5f62\u3002\u56e0\u70ba\u4e0d\u660e\u539f\u56e0\u814e\u75c5\uff0c\u5b89\u6392\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u751f\u6aa2(renal biopsy)\u3002\u4ee5\u4e0b\u75c5\u7406\u8b8a\u5316\uff0c\u4f55\u8005\u6700\u53ef\u80fd?\nA. Membranoproliferative glomerulonephritis (MPGN)\nB. Membranous nephropathy (MN)\nC. IgA nephropathy\nD. Focal segmental glomerulosclerosis (FSGS)\nE. Henoch-Schonlein purpura (HSP)\n": "(A)", "106-8.\n\u4e00\u4f4d46\u6b72\u7537\u6027\uff0c\u904e\u53bb\u7d93\u5e38\u6709\u9f3b\u7ac7\u708e\u75c7\u72c0\uff0c\u6700\u8fd1\u4e00\u500b\u6708\u4f86\uff0c\u51fa\u73fe\u80f8\u60b6\u3001\u6c23\u5598\u3001\u54b3\u55fd\u3001\u5580\u8840\u3002\u4f4f\u9662\u5f8c\u5c3f\u6db2\u6aa2\u67e5\u6709: hematuria, \u8207 RBC cast\u3002\u62bd\u8840\u6aa2\u67e5: antineutrophil cytoplasmic antibody (ANCA)\u967d\u6027\u53cd\u61c9\u3002\u75c5\u4eba\u5982\u679c\u63a5\u53d7\u814e\u81df\u751f\u6aa2(renal biopsy)\uff0c\u6700\u53ef\u80fd\u7684\u81e8\u5e8a\u8a3a\u65b7\u8207\u75c5\u7406\u8b8a\u5316\u662f:\nA. Goodpasture's syndrome\nB. Granulomatosis with polyangiitis (Wegener's granulomatosis)\nC. Polyarteritis nodosa (PNA)\nD. Microscopic polyangitis (MPA)\nE. Behcet's syndrome\n": "(B)", "106-9.\n\u5c3f\u6db2\u6c89\u6e23(cast, sediment)\u6aa2\u9a57\uff0c\u6709\u6642\u5019\u4e5f\u53ef\u4ee5\u63d0\u4f9b\u91cd\u8981\u7684\u8a0a\u606f\uff0c\u5e6b\u52a9\u81e8\u5e8a\u8a3a\u65b7\u3002\u4ee5\u4e0b\u6709\u95dc\u5404\u7a2e\u75be\u75c5\u8207urine cast\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. Dysmorphic RBC\u8207erythrocyte casts\u901a\u5e38\u8868\u793ahematuria\u4f86\u81ea\u65bcglomerulus\nB. \u5287\u70c8\u904b\u52d5\u53c8\u9ad4\u6db2\u4e0d\u8db3(dehydration)\u5f8c\u7684\u5c3f\u6db2\u7570\u5e38\uff0c\u53ef\u80fd\u6703\u51fa\u73fehyaline cast\nC. Granular cast\u901a\u5e38\u8868\u793a\u6709tubular injury \u6216 chronic kidney disease\nD. Allergic interstitial nephritis\u6703\u51fa\u73fe WBC cast \u6216 urine eosinophil, \u4f46\u5f88\u5c11\u51fa\u73fe RBC cast\nE. \u7cd6\u5c3f\u75c5(DM)\u75c5\u4eba\u82e5\u5408\u4f75\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\uff0c\u7d93\u5e38\u6703\u4f34\u96a8\u51fa\u73feRBC cast\n": "(E)", "106-10.\n\u4e00\u4f4d64\u6b72\u7537\u6027\uff0c\u63a5\u53d7\u51a0\u72c0\u52d5\u8108\u7e5e\u9053\u624b\u8853\u5f8c\u7b2c\u4e8c\u5929\uff0c\u51fa\u73fe\u5be1\u5c3f(oliguria)\uff0c\u814e\u529f\u80fd\u7570\u5e38\u3002\u75c5\u4eba\u7684\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u81e8\u5e8a\u6558\u8ff0\uff0c\u6700\u7b26\u5408\u624b\u8853\u5f8c\u767c\u751fpre-renal azotemia (AKI)\u7684\u81e8\u5e8a\u8a3a\u65b7?\nA. Hypotension or cardiogenic shock\nB. Functional excretion of sodium is 3.5%\nC. Urine sodium is 40 mEq/L\nD. BUN/creatinine ratio is 10\nE. Low urine specific gravity (< 1.015), and active urinary sediment (+)\n": "(A)", "106-11.\n\u4e00\u4f4d44\u6b72\u7537\u6027\uff0c\u6709\u80ba\u7d50\u6838(pulmonary tuberculosis)\u63a5\u53d7rifampin\u8207isoniazid\u6cbb\u7642\u3002\u67d0\u65e5\u56e0\u610f\u8b58\u6a21\u7cca\uff0c\u547c\u5438\u6025\u4fc3\uff0c\u56db\u80a2\u6709\u8f15\u5fae\u986b\u6296\u62bd\u6410\u60c5\u5f62\uff0c\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u62bd\u8840\u6aa2\u67e5:\u52d5\u8108\u6c23\u9ad4\u5206\u6790\u3001\u8840\u6e05\u96fb\u89e3\u8cea\u5982\u4e0b: ABG: pH 7.26\uff0cHCO3- 11 mEg/L\uff0cPCO2 21 mmHg ; glucose 160 mg/dL, BUN 34 mg/dL, Cr 1.8 mg/dL ; Na 133 mEq/L , K 6.1 mEq/L, Cl 94mEq/L\u3002\u7531\u4ee5\u4e0a\u6578\u64da\u5206\u6790\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u4f55\u7a2e\u8a3a\u65b7? (1)Metabolic acidosis\uff1b(2)Respiratory acidosis\uff1b(3)adequate secondary (respiratory or renal) compensation\uff1b(4)inadequate secondary (respiratory or renal)\rcompensation\uff1b(5)normal anion gap\uff1b(6)increased or high anion gap\nA. (1)+(3)+(5)\nB. (1)+(3)+(6)\nC. (1)+(4)+(5)\nD. (1)+(4)+(6)\nE. (2)+(4)+(6)\n": "(B)", "106-12.\n\u67d045\u6b72\u7537\u6027\u5df2\u6709\u9ad8\u8840\u58d35\u5e74\uff0c\u6700\u8fd1\u6aa2\u67e5\u6709\u8840\u5c3fRBC 10-20/HPF\u3001Cre 1.2 mg/dL\u3001\u8d85\u97f3\u6ce2\u6aa2\u67e5\u767c\u73fe\u5169\u5074\u814e\u81df\u9577\u5f91\u8d85\u904e15\u516c\u5206(\u5982\u5716)\u53ca\u5404\u6709\u56ca\u816b\u6578\u76ee\u8d85\u904e\u5341\u500b\uff1b\u5bb6\u65cf\u53f2\u70ba\u7236\u89aa\u81ea60\u6b72\u958b\u59cb\u8840\u6db2\u900f\u6790\uff0c\u4e0d\u66fe\u9871\u5167\u51fa\u8840\uff0c\u7236\u89aa\u7684\u814e\u81df\u8d85\u97f3\u6ce2\u4ea6\u6709\u96f7\u540c\u7684\u767c\u73fe\u3002\r\u8acb\u554f\u95dc\u65bc\u5176\u814e\u81df\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\uff1f(1)\u6bcf\u5e74\u5b9a\u671f\u8ffd\u8e64\u814e\u529f\u80fd\uff0c\u5373\u70ba\u9810\u4f30\u65e5\u5f8c\u662f\u5426\u9700\u8981\u900f\u6790\u6cbb\u7642\u4e4b\u6700\u654f\u611f\u65b9\u6cd5\uff1b(2)\u82e5\u5176\u592a\u592a\u61f7\u5b55\u53ef\u505a\u7522\u524d\u7be9\u6aa2\uff0c\u5176\u5b50\u5973\u907a\u50b3\u6b64\u814e\u81df\u75be\u75c5\u7684\u6a5f\u6703\u70ba50%\uff1b(3) \u4ee5\u5f71\u50cf\u5b78\u6aa2\u67e5\u4f30\u7b97\u5176\u814e\u81df\u9ad4\u7a4d\uff0c\u82e5\u8d85\u904e600\u7acb\u65b9\u516c\u5206\uff0c\u5176\u814e\u529f\u80fd\u6975\u53ef\u80fd\u6301\u7e8c\u9010\u5e74\u60e1\u5316\uff1b(4) \u96d6\u7121\u75c7\u72c0\uff0c\u61c9\u6bcf\u5e74\u5b89\u6392\u8166\u90e8\u8840\u7ba1Magnetic resonance angiography\u7684\u6aa2\u67e5\uff1b(5)\u5b9c\u5efa\u8b70\u505c\u6b62\u670d\u7528\u542b\u5973\u6027\u8377\u723e\u8499\u4e4b\u907f\u5b55\u85e5\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (2)+(4)\nD. (4)+(5)\nE. (2)+(3)+(5)\n": "(E)", "106-13.\n\u67d050\u6b72\u53f0\u96fb\u54e1\u5de5\u65bc\u98b1\u98a8\u5f8c\u66fe\u81f3\u6c34\u707d\u5730\u5340\u8655\u7406\u5012\u584c\u96fb\u7dda\u687f\uff0c\u7d0410\u5929\u5f8c\u51fa\u73fe\u9ad8\u71d2\u3001\u982d\u75db\u3001\u808c\u8089\u75e0\u75db\u3001\u54b3\u55fd\u5e36\u8840\u3001\u547c\u5438\u6025\u4fc3\uff0c\u4f4f\u9662\u6aa2\u67e5\u5f8c\u767c\u73fe\uff1a\u7d50\u819c\u4e0b\u51fa\u8840(\u5982\u5716\u4e00)\u3001\u9ec3\u75b8\u3001\u814e\u529f\u80fd\u5931\u5e38\u3001\u4f4e\u8840\u9240\u7b49\u3002\u80f8\u90e8X\u5149(\u5982\u5716\u4e8c)\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u6b63\u78ba\uff1f(1)\u6b64\u75c5\u70ba\u4ee5\u52d5\u7269\u70ba\u5bbf\u4e3b\u4e4b\u5bc4\u751f\u87f2\u6240\u5f15\u8d77\uff1b(2)\u5fc5\u9808\u7b49\u5f85\u75c5\u539f\u9ad4\u4e4b\u8840\u6db2\u57f9\u990a\u7d50\u679c\u70ba\u967d\u59d3\uff0c\u65b9\u80fd\u78ba\u5b9a\u8a3a\u65b7\u8207\u958b\u59cb\u6cbb\u7642\uff1b(3)\u767c\u75c5\u5341\u5929\u5f8c\u9ad4\u5167\u5df2\u7522\u751f\u6297\u9ad4\uff0c\u4f46\u5c3f\u6db2\u4e2d\u4ecd\u53ef\u80fd\u6709\u75c5\u539f\u9ad4\u4e4b\u5b58\u5728\uff1b(4)\u6b64\u75c5\u5373Weil's disease\uff0c\u6709\u9ad8\u6b7b\u4ea1\u7387\u4e4b\u5371\u96aa\uff1b(5)\u6b64\u75c5\u9760\u81e8\u5e8a\u8a3a\u65b7\uff0c\u9808\u7acb\u5373\u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u3002\nA. (2)+(3)+(4)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (3)+(4)+(5)\nE. (1)+(4)+(5)\n": "(D)", "106-14.\n\u67d070\u6b72\u75c5\u4eba\u5df2\u7d93\u6b63\u5728\u670d\u7528\u5229\u5c3f\u5291\u53caValsartan\uff0c\u8acb\u554f\u4e0b\u5217NSAIDs\u4e2d\u54ea\u4e00\u500b\u6700\u4e0d\u6703\u5f71\u97ff\u9019\u5169\u7a2e\u964d\u58d3\u85e5\u4e4b\u6548\u679c\uff1f\nA. Acetaminophen\nB. Etoricoxib\nC. Diclofenac\nD. Celecoxib\nE. Nimesulide\n": "(A)", "106-15.\n\u67d040\u6b72\u7537\u6027\u7121\u7cd6\u5c3f\u75c5\u6216\u9ad8\u8840\u58d3\u75c5\u53f2\u3001\u904e\u53bb\u5e38\u6709\u9593\u6b47\u6027\u80a2\u9ad4\u75bc\u75db\u3001\u76ae\u819a\u75c5\u8b8a(\u5982\u5716)\u3001\u4e0d\u6613\u6d41\u6c57\u3001\u5c3f\u86cb\u767d(++)\u3001\u814e\u529f\u80fd\u5931\u5e38(Cre 3.0 mg/dL)\uff0c\u5176\u5bb6\u65cf\u53f2\u70ba\u5169\u4f4d\u5144\u9577\u5144\u5206\u5225\u6b7b\u65bc\u5fc3\u81df\u8870\u7aed\u53ca\u8166\u8840\u7ba1\u610f\u5916\u53ca\u8840\u6db2\u900f\u6790\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f(1) \u61c9\u70baGaucher disease\uff1b(2)\u5b9c\u5b89\u6392\u773c\u79d1\u3001\u5fc3\u81df\u65b9\u9762\u6aa2\u67e5\uff1b(3)\u5176\u59ca\u59b9\u61c9\u8a72\u90fd\u4e0d\u6703\u6709\u75c7\u72c0\uff1b(4)\u5c3f\u6db2\u6aa2\u67e5\u53ef\u51fa\u73fe \"Maltese crosses\"\u7684\u6c89\u6fb1\u7269\uff1b(5) \u814e\u81df\u75c5\u7406\u591a\u70bafocal segmental glomerulosclerosis(FSGS)\u3002\nA. (1)+(3)\nB. (2)+(3)\nC. (3)+(5)\nD. (1)+(3)+(5)\nE. (2)+(4)+(5)\n": "(E)", "106-16.\n\u7167\u9867\u6162\u6027\u814e\u81df\u75c5\u7684\u75c5\u4eba\uff0c(1)\u65bc\u4f55\u6642\u671f \u61c9\u8f49\u4ecb\u7d66\u814e\u81df\u5c08\u79d1\u91ab\u5e2b\uff0c(2)\u65bc\u4f55\u671f\u61c9\u8ddf\u75c5\u4eba\u4ecb\u7d39\u814e\u81df\u66ff\u4ee3\u6cbb\u7642 (\u8840\u6db2\u900f\u6790\u3001\u8179\u819c\u900f\u6790\u3001\u814e\u81df\u79fb\u690d)\uff1f\rI-\u7b2c\u4e00\u671f\uff1bII:\u7b2c\u4e8c\u671f\uff1bIII\uff1a\u7b2c\u4e09\u671f\uff1bIV\uff1a\u7b2c\u56db\u671f\uff1a Va : \u7b2c\u4e94\u671f\u900f\u6790\u524d\nA. (1)I\uff1b (2) III\nB. (1) I\uff1b (2) Va\nC. (1)III\uff1b(2) IV\nD. (1)IV\uff1b(2) Va\nE. (1)Va\uff1b(2)Va\n": "(C)", "106-17.\n\u95dc\u65bc\u6162\u6027\u814e\u81df\u75c5\u4e4b\u86cb\u767d\u98f2\u98df\u9650\u5236 \uff0c\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u4e0d\u6b63\u78ba\uff1f\nA. \u7576\u51fa\u73fe\u5c3f\u6bd2\u75c7\u72c0\u6642\uff0c\u86cb\u767d\u98f2\u98df\u9650\u5236\u6700\u4f4e\u70ba\u86cb\u767d\u8cea\u6bcf\u59290.6\u516c\u514b/\u516c\u65a4(\u7406\u60f3\u9ad4\u91cd)\u53ca\u71b1\u91cf\u6bcf\u592930 kcal/\u516c\u65a4(\u7406\u60f3\u9ad4\u91cd)\u3002\nB. \u4f4e\u86cb\u767d\u98f2\u98df\u9650\u5236\u672c\u8eab\u78ba\u5be6\u53ef\u4ee5\u6e1b\u7de9\u814e\u529f\u80fd\u60e1\u5316\uff0c\u56e0\u5176\u53ef\u6e1b\u4f4e\u5c3f\u6bd2\u75c7\u72c0\u8207\u5ef6\u7de9\u958b\u59cb\u900f\u6790\u6cbb\u7642\u4e4b\u6642\u9593\u3002\nC. \u4f4e\u86cb\u767d\u98f2\u98df\u53ef\u7531\u6e2c\u91cf\u9ad4\u91cd\u8b8a\u5316\u3001\u8840\u6e05\u767d\u86cb\u767d\u300124\u5c0f\u6642urea nitrogen\u6392\u6cc4\u91cf\u7b49\u4f86\u5224\u65b7\u4f4e\u86cb\u767d\u98f2\u98df\u9650\u5236\u662f\u5426\u9069\u5ea6\u3002\nD. \u9ad8\u86cb\u767d\u98f2\u98df\u5e38\u4e5f\u6703\u589e\u52a0\u78f7\u8207\u9209\u4e4b\u651d\u53d6\uff0c\u800c\u62b5\u92b7angiotensin-converting enzyme inhibitor (ACEi)\u8207angiotensin-receptor blocker (ARB)\u4e4b\u814e\u81df\u4fdd\u8b77\u4f5c\u7528\u3002\nE. \u4f4e\u86cb\u767d\u98f2\u98df\u63a7\u5236\u9700\u88dc\u5145\u6c34\u6eb6\u6027\u7dad\u751f\u7d20\u3002\n": "(B)", "106-18.\n\u95dc\u65bc\u8840\u58d3\u4e4b\u6e2c\u91cf\uff1a \u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u61c9\u9f13\u52f5\u5c45\u5bb6\u8840\u58d3\u76e3\u6e2c(Home blood pressure monitoring)\uff0c\u6bcf\u5929\u6e2c\u91cf\u8207\u7d00\u9304\u4e8c\u81f3\u4e09\u56de\u3002\nB. \u9ad8\u8840\u58d3\u6cbb\u7642\u7684\u76ee\u6a19\uff1a\u4e00\u822c\u75c5\u60a3\u70ba\u5c45\u5bb6\u8840\u58d3\u5e73\u5747\u8981\u4f4e\u65bc135/85 mmHg\uff1b\u6162\u6027\u814e\u81df\u75c5\u5247\u4f4e\u65bc130/80 mmHg\u3002\nC. \u6d3b\u52d5\u5f0f\u8840\u58d3\u76e3\u6e2c(Ambulatory blood pressure monitoring)\u7684\u6b63\u5e38\u503c\uff1a\u767d\u5929\u5e73\u5747\u4f4e\u65bc135/85 mmHg:\uff1b\u591c\u9593\u5e73\u5747\u4f4e\u65bc130/80 mmHg\u3002\nD. \u8207\u8a3a\u9593\u8840\u58d3\u6e2c\u91cf\u76f8\u8f03\uff0c\u6d3b\u52d5\u5f0f\u8840\u58d3\u6e2c\u91cf\u66f4\u80fd\u9810\u6e2c\u5fc3\u808c\u6897\u585e\u6216\u4e2d\u98a8\u3002\nE. \u5c31\u6d3b\u52d5\u5f0f\u8840\u58d3\u76e3\u6e2c\u800c\u8a00\uff0c\u82e5\u8207\u767d\u5929\u7684\u8840\u58d3\u76f8\u6bd4\u8f03\uff0c\u591c\u9593\u9ad8\u8840\u58d3\u6703\u589e\u52a0\u5fc3\u8840\u7ba1\u7684\u8ca0\u64d4\uff0c\u70ba\u5fc3\u8840\u7ba1\u75be\u75c5\u9810\u5f8c\u4e4b\u5f37\u70c8\u56e0\u5b50\u3002\n": "(C)", "106-19.\n\u95dc\u65bc\u9aa8\u9ad3\u79fb\u690d\u814e\u75c5\u8b8a(Bone marrow transplant nephropathy)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u5e38\u5728\u79fb\u690d\u5f8c\u767e\u65e5\u5167\u767c\u751f\nB. \u8207Cyclosporine\u6709\u95dc\nC. \u8207Sirolimus\u6709\u95dc\nD. \u8207Radiation\u6709\u95dc\nE. \u9808\u7a4d\u6975\u505a\u8840\u6f3f\u7f6e\u63db\u6cbb\u7642\u3002\n": "(D)", "106-20.\n\u4e0b\u5217\u54ea\u4e00\u500b\u514d\u75ab\u6291\u5236\u85e5\u7269\uff0c\u53ef\u80fd\u5f15\u8d77\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u53ca\u814e\u81df\u75c5(Thrombotic microangiopathy) \u4e09\u7a2e\u75be\u75c5\uff1f\nA. Prednisolone\nB. Cyclosporine\nC. Tacrolimus\nD. Sirolimus\nE. Mycophenolate mofetil\n": "(C)", "106-21.\n\u67d050\u6b72\u7537\u6027\u6709\u9152\u7cbe\u6210\u766e\u75c5\u53f2\uff0c\u88ab\u767c\u73fe\u8eba\u5728\u65c5\u9928\u623f\u9593\u5730\u677f\u4e0a\u800c\u88ab\u9001\u81f3\u6025\u8a3a\u8655\u3002\u8840\u58d3120/66 mmHg\uff0c\u5fc3\u8df3\u6bcf\u5206\u9418100\u4e0b\uff0c\u547c\u5438\u6bcf\u5206\u941830\u4e0b\u3002\u62bd\u8840\u6aa2\u67e5\uff1aSerum Na 140 mEq/L\uff0cK 5.8 mEq/L\uff0cCl 103 mEq/L\uff0cBUN 25 mg/dL\uff0cCre 1.4 mg/dL\uff0cAC glucose 150 mg/L\uff0c pH 7.16\uff0c PaCO2 23 mmHg, HCO3- 8 mEq/L\uff0cSerum osmolarity 332 mOsm/L\uff0c\u8840\u4e2d\u9152\u7cbe\u6fc3\u5ea6\u70ba\u9670\u6027\u3002\u8acb\u554f\u80fd\u70ba\u5e95\u4e0b\u4f55\u8005\uff1f\nA. Diabetic ketoacidosis\nB. Starvation ketoacidosis\nC. Alcohol ketoacidosis\nD. Methanol intoxication\nE. Salicylates\n": "(D)", "106-22.\n\u95dc\u65bc\u6025\u6027\u814e\u81df\u50b7\u5bb3(Acute kidney injury; AKI) \u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f\nA. \u7d55\u5927\u591a\u6578\u6025\u6027\u814e\u81df\u50b7\u5bb3\u5728\u91ab\u9662\u5167\u767c\u751f\uff0c\u5c24\u5176\u5728\u52a0\u8b77\u75c5\u623f\u3002\nB. \u6025\u6027\u814e\u81df\u50b7\u5bb3\u4e2d\u5927\u591a\u6578\u70baPrerenal AKI\u3002\nC. NSAIDs\u3001ACEi\u3001ARB\u7b49\u5bb9\u6613\u5f15\u8d77Prerenal AKI\u3002\nD. \u793e\u5340\u578b\u6025\u6027\u814e\u81df\u5bb3\u5927\u90e8\u5206\u70baPrerenal AKI\u3002\nE. \u4f4e\u8840\u6e05\u767d\u86cb\u767d\u5bb9\u6613\u597d\u767cPrerenal AKI\u3002\n": "(E)", "107-1.\n\u91dd\u5c0d\u65b0\u8a3a\u65b7\u7684\u78ba\u8a3a\u9ad8\u8840\u58d3\u7684\u75c5\u4eba\uff0c\u5efa\u8b70\u512a\u5148\u505a\u521d\u671f\u8a55\u4f30(initial evaluation)\uff0c\u5305\u62ec: BUN, creatinine, urinalysis\uff0c\u53ca\u4ee5\u4e0b\u9805\u76ee\uff0c\u4f55\u8005\u9664\u5916?\nA. Serum lipid panel\nB. Electrocardiogram (ECG)\nC. Fasting plasma glucose\nD. Serum potassium, calcium\nE. Serum uric acid level\n": "(E)", "107-2.\n\u4e00\u4f4d55\u6b72\u5973\u6027\uff0c\u4e3b\u8a34\u9577\u671f\u6709\u95dc\u7bc0\u75bc\u75db\u3001\u4e7e\u773c\u75c7\u3001\u53ca\u4f7f\u7528NSAID\u7684\u7fd2\u6163\u3002\u67d0\u65e5\u56e0\u75b2\u52de\u7121\u529b\u81f3\u6025\u8a3a\u5c31\u8a3a\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe: serum creatinine 1.0 mg/dL, Na 139 mEq/L, K 3.3 mEq/L, Cl 115 mEq/L, ABG: pH 7.26, HCO3- 14 mEq/L. \u5c3f\u6db2\u6aa2\u67e5: pH 7.0, glucose (-), protein (-), \u5c3f\u6db2\u96fb\u89e3\u8cea: Na 35 mEq/L, K 40.0 mEq/L, Cl 18 mEq/L  \u75c5\u4eba\u7684\u9178\u8840\u75c7(acidosis)\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u54ea\u4e00\u500b\u8a3a\u65b7?\nA. Chronic diarrhea\nB. Type 1 RTA (renal tubular acidosis)\nC. Type 2 RTA (renal tubular acidosis)\nD. Type 4 RTA (renal tubular acidosis)\nE. Diabetic keto-acidosis\n": "(B)", "107-3.\n\u67d0\u4f4dCKD stage 5\u7684\u75c5\u4eba\uff0c[Ca] 8.7 mg/dL, [P] 6.8 mg/dL\u3002 \u4e0b\u5217\u6709\u95dc\u814e\u6027\u9aa8\u75c5\u8b8a\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. Hyperphosphatemia stimulates increasing plasma level of PTH (parathyroid hormone)\nB. Low serum [Ca] level, and reduced FGF-23 (fibroblast growth factor 23)production contribute to renal bone disease\nC. Nephron loss reduces synthesis of 1,25-Vitamin D3\nD. Low level of 1,25-Vitamin D3 results in lower intestine resorption of Ca\nE. Phosphate retention contributes to hypo[Ca]\n": "(B)", "107-4.\n\u4e00\u4f4d70\u6b72\u5973\u6027\uff0c\u904e\u53bb\u6c92\u6709CAD\u6216DM\u75c5\u53f2\uff0c\u4e5f\u6c92\u6709\u898f\u5247\u5c31\u91ab\u3002\u6700\u8fd1\u56e0\u70ba\u5026\u6020\u3001\u80c3\u53e3\u4e0d\u4f73\u4f86\u8a3a\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u767c\u73fe: serum creatinine 6.2 mg/dL, eGFR 14 mL/min\uff0cHb 11.4 g/dL, serum ferritin 500 ng/mL\u3002\u4e0b\u5217\u8655\u7f6e\uff0c\u4f55\u8005\u6700\u9069\u5b9c?\nA. \u7d66\u4e88ESA (erythropoiesis stimulating agent)\uff0c\u5c07Hb \u63d0\u5347\u81f3\u76ee\u6a19\u503c13-14 g/dL\nB. Check serum level of erythropoietin\nC. Give intravenous iron for anemia\nD. Give oral iron dose for correcting anemia\nE. Measure blood level of transferrin saturation\n": "(E)", "107-5.\n\u4e00\u4f4d48\u6b72\u5973\u6027\uff0c\u8a3a\u65b7\u6709high grade lymphoma\uff0c\u9810\u5b9a\u63a5\u53d7cytotoxic chemotherapy\u3002\u75c5\u4eba\u76ee\u524d\u7684serum creatinine level\u662f2.1 mg/d\u3002\u70ba\u4e86\u9810\u9632\u767c\u751ftumor lysis syndrome\u53ca\u814e\u81df\u60e1\u5316\uff0c\u4e0b\u5217\u8655\u7f6e\uff0c\u4f55\u8005\u6700\u9069\u5b9c?\nA. Give allopurinol or febuxostat, if not contraindicated, for preventing hyperuricemia\nB. Give acetylcysteine for preventing acute kidney injury\nC. Give large amount of 5% glucose water solution for volume expansion\nD. Give 1,25-activated Vitamin D3 for preventing hyperphosphatemia\nE. Arrange dialysis immediately after chemotherapy for preventing occurrence of chronic interstitial nephritis\n": "(A)", "107-6.\n\u4e0b\u5217\u8655\u7f6e\u6709\u52a9\u65bc\u6e1b\u7de9\u591a\u56ca\u814e(adult polycystic kidney)\u75c5\u4eba\u7684\u814e\u529f\u80fd\u60e1\u5316\uff0c\u4f55\u8005\u9664\u5916?\nA. \u4f7f\u7528ACEI \u6216 ARB\uff0c\u63a7\u5236\u8840\u58d3\u5728130-140/80-90 mmHg\u4e4b\u4e0b\nB. \u4f7f\u7528vasopressin antagonist (tolvaptan), \u6216\u5efa\u8b70\u9069\u7576\u589e\u52a0\u6bcf\u65e5\u98f2\u6c34\u91cf (> 3 L/day)\nC. \u5982\u679c\u6709cyst infection, \u4f7f\u7528lipid-soluble antibiotics, \u5982: quinolones, \u56e0\u70bacyst penetration \u4f73\uff0c\u6548\u679c\u8f03\u597d\nD. \u9650\u5236\u4f4e\u9e7d(low salt, < 5 g/day)\u98f2\u98df\nE. \u4f7f\u7528\u4f4e\u86cb\u767d\u98f2\u98df (low protein diet, < 0.6 g/kg/day)\n": "(E)", "107-7.\n\u4e00\u4f4d72\u6b72\u7537\u6027\uff0c\u56e0\u70ba\u9ad8\u8840\u58d3\uff0c\u86cb\u767d\u5c3f\uff0c\u4e0b\u80a2\u8f15\u5ea6\u6c34\u816b\uff0c\u4f86\u9580\u8a3a\u5c31\u8a3a\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5:  serum creatinine1.8 mg/dL, \u6709proteinuria (2+), hematuria (-), \u9032\u4e00\u6b65\u505aurine protein electrophoresis\u6709monoclonal band (+)\uff0cC3\u8207C4 \u7686\u6b63\u5e38\u3002\u4f4f\u9662\u505a\u814e\u81df\u751f\u6aa2(renal biopsy)\u767c\u73fe\u6709\u7269\u8cea\u6c89\u6fb1\u5728glomerulus\uff0ctubule\u90e8\u5206\u6b63\u5e38\u3002\u4ee5\u7279\u6b8a\u67d3\u8272\uff0c\u5448\u73feCongo red (-) \u3002\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba:\nA. Amyloidosis\nB. Light-chain deposit disease\nC. Myeloma cast nephropathy\nD. Fibrillary glomerulonephritis\nE. Type II cryoglobulinemia\n": "(B)", "107-8.\n\u9577\u671f\u8840\u6db2\u900f\u6790(hemodialysis)\u7684\u75c5\u4eba\uff0c\u70ba\u505a\u597d\u9632\u8b77\uff0c\u9810\u9632\u611f\u67d3\uff0c\u9664\u4e86\u6aa2\u6e2cHIV \uff0cviral hepatitis (B and C) profile\u4e4b\u5916\uff0c\u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba? (1). \u5c0d\u65bc HBV (-)\u7684\u75c5\u4eba\uff0c\u5efa\u8b70\u65bd\u6253 HBV vaccine (2).\u5efa\u8b70\u6bcf\u4e94\u5e74\u5167\uff0c\u61c9\u65bd\u6253 23\u50f9/13\u50f9 pneumococcal vaccine (3). \u5efa\u8b70\u6bcf\u5e74\u6d41\u611f\u5b63\u7bc0\uff0c\u61c9\u65bd\u6253  inactivated influenza vaccine (4). \u5efa\u8b70\u65bd\u6253 Herpes Zoster vaccine\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(3)\nC. (1)+(2)\nD. (1)+(3)\nE. (2)+(3)+(4)\n": "(B)", "107-9.\n56\u6b72\u7537\u6027\uff0c\u7121\u7cd6\u5c3f\u75c5\uff0c\u6709\u8f15\u5ea6\u9ad8\u8840\u58d3\uff0cBMI 26Kg/\u33a1\uff0cserum creatinine 3.2 mg/dL\uff0ceGFR 18 mL/min\uff0c\u5c0d\u65bcCKD\u5c1a\u672a\u900f\u6790\u7684\u75c5\u4eba\uff0c\u86cb\u767d\u8cea\u651d\u53d6\u91cf\uff0c\u4ee5\u4e0b\u5efa\u8b70\uff0c\u4f55\u8005\u6700\u5408\u9069?\nA. 1.4-1.5 g/kg/day\nB. 1.2-1.4 g/kg/day\nC. 1.0-1.2 g/kg/day\nD. 0.6-0.8 g/kg/day\nE. < 0.4-0.6 g/kg/day\n": "(D)", "107-10.\n\u6162\u6027\u814e\u81df (CKD) \u60a3\u8005\u61c9\u907f\u514d\u6216\u5c0f\u5fc3\u4f7f\u7528OTC (over-the-counter)\u85e5\u7269,\u4f46\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u4e0b\u53ef\u4ee5\u4f7f\u7528?\nA. NSAID as analgesics\nB. Aspirin for CV protection\nC. Ephedrine for weight reduction\nD. MgO for constipation\nE. Aluminum hydroxide long-term use as antacid\n": "(B)", "107-11.\n\u4e00\u4f4d39\u6b72\u5973\u6027\uff0c\u672c\u8eab\u7121DM\uff0c\u9019\u6b21\u662f\u7b2c\u4e00\u6b21\u61f7\u5b55\u3002\u5728\u61f7\u5b55\u7b2c26\u9031\u6642\u51fa\u73fe\u9ad8\u8840\u58d3(150/96 mmHg)\uff0c\u6709\u96d9\u4e0b\u80a2\u8db3\u8e1d\u9644\u8fd1\u6c34\u816b\u3002\u5c3f\u6db2\u8a66\u7d19(dipstick)\u6aa2\u67e5\u6709\u86cb\u767d\u5c3f (2+)\uff0c\u56e0\u6b64\u88ab\u8f49\u4ecb\u4f86\u5167\u79d1\u9580\u8a3a\u3002\u6b32\u5b89\u6392\u9451\u5225\u8a3a\u65b7\uff0c\u4e0b\u5217\u9078\u9805\uff0c\u4f55\u8005\u6700\u9069\u5b9c? (1). Liver function test (AST, ALT) (2). Check platelet count (3). Check anti-phospholipid antibody titer (4).Arrange CT/MRI for central vein thrombosis (5). Give ACEI/ARB for hypertension control and for renal protection\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)\nC. (1)+(4)+(5)\nD. (1)+(3)+(5)\nE. (3)+(4)\n": "(B)", "107-12.\n\u4e00\u4f4d48\u6b72\u88ab\u65b0\u8a3a\u65b7\u6709\u9ad8\u8840\u58d3\u7684\u7537\u6027\uff0c\u672c\u8eab\u7121DM\u3002\u670d\u7528\u91ab\u5e2b\u7d66\u4e88\u7684ACEI\u964d\u8840\u58d3\u85e5\u7269\uff0c\u5169\u500b\u6708\u5f8c\u8fd4\u8a3a\uff0c\u767c\u73feserum creatinine\u5f9e 1.4 mg/dL\u4e0a\u5347\u81f32.6 mg/dL\u3002\u91cd\u65b0\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u8179\u90e8\u5728\u809a\u81cd\u53f3\u5074\u90e8\u4f4d\u6709\u56c9\u97f3(bruit)\u3002\u6b32\u5b89\u6392\u9451\u5225\u8a3a\u65b7\uff0c\u4e0b\u5217\u9078\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba? (1). \u5982\u679c\u6aa2\u67e5\u75c5\u4eba\u7684renin, aldosterone level\uff0c\u9810\u671frenin\u61c9\u8a72\u504f\u4f4e\uff0c\u800caldosterone\u6703\u5f88\u9ad8 (2). \u53ef\u5b89\u6392duplex Doppler \u6216CT/MRI\u6aa2\u67e5renal artery (3). \u61c9\u8a72\u63a5\u8457\u5b89\u6392\u505a\u5c0e\u7ba1\u6aa2\u67e5renal vein sampling (4). \u5982\u679c\u6aa2\u67e5\u8840\u6e05[K]\uff0c\u7d93\u5e38\u6703\u4f34\u96a8\u6709\u9ad8\u8840\u9240(hyperkalemia) (5).\r\u5982\u679c\u6aa2\u67e5\u5c3f\u6db2catecholamines\uff0c\u6703\u767c\u73fe\u5c3f\u6db2catecholamines\u5347\u9ad8\nA. (1)+(2)\nB. (1)+(3)+(4)\nC. (3)+(4)+(5)\nD. (2)\nE. (1)+(2)+(5)\n": "(D)", "107-13.\n\u9580\u8a3a\u8f49\u8a3a48\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u4e3b\u8a34\u70ba\u534a\u5e74\u524d\u4f4e\u5291\u91cf\u80ba\u90e8\u96fb\u8166\u65b7\u5c64\u610f\u5916\u767c\u73fe\u5de6\u908a\u814e\u4e0a\u817a\u67092\u516c\u5206\u5927\u5c0f\u4e4b\u7d50\u7bc0\uff0c\u904e\u53bb\u7121\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u8acb\u554f\u95dc\u65bc\u814e\u4e0a\u817a\u7624\u4e4b\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u9805\u70ba\u6b63\u78ba\uff1f(1). \u82e5\u7121\u9ad8\u8840\u58d3\u6216\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u75c7\u72c0\uff0c\u5c31\u4e0d\u7528\u505a\u8377\u723e\u8499\u65b9\u9762\u7684\u7be9\u6aa2 (2). \u7531\u5f71\u50cf\u5b78\u6aa2\u67e5\uff0c\u82e5\u5927\u65bc4\u516c\u5206\u60e1\u6027\u816b\u7624\u4e4b\u53ef\u80fd\u6027\u8f03\u9ad8 (3). \u82e5\u70ba\u814e\u4e0a\u817a\u76ae\u8cea\u764c\uff0c\u5927\u90e8\u5206\u6703\u88fd\u9020\u904e\u591a\u7684\u985e\u56fa\u9187 (4). \u82e5 Low CT density <10 HU in unenhanced CT \u8207 Contrast washout after 15 min. >50%\uff0c\u5247\u70ba\u826f\u6027\u5076\u898b\u7624(Incidentaloma)\u4e4b\u6a5f\u7387\u8f03\u5927 (5). MRI\u70ba\u9996\u9078\u6aa2\u67e5\u9805\u76ee\uff0c\u56e0\u80fd\u6bd4\u96fb\u8166\u65b7\u5c64\u63d0\u4f9b\u66f4\u591a\u8cc7\u8a0a\nA. (1)+(2)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (2)+(3)+(5)\nE. (2)+(4)+(5)\n": "(C)", "107-14.\n\u4ee5\u4e0b\u4e0d\u540c\u6642\u671f\u7684\u6162\u6027\u814e\u81df\u75c5(CKD)\u60a3\u8005\uff0c\u9996\u5ea6\u62bd\u8840\u6e2c\u5f97\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 (CHO 260 mg/dL,HDL 30 mg/dL, LDL 160 mg/dL)\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u5efa\u8b70\u7d66\u4e88Statin\uff1f (1). \u5e74\u9f6155\u6b72\u4e4b\u7b2c\u4e8c\u671fCKD\u60a3\u8005 (2). \u5e74\u9f6155\u6b72\uff0c\u5c1a\u672a\u958b\u59cb\u900f\u6790\u4e4b\u7b2c\u4e94\u671fCKD \u60a3\u8005 (3). \u5e74\u9f6140\u6b72\uff0c\u6709\u5c3f\u86cb\u767d\u8207\u7cd6\u5c3f\u75c5\u4e4b\u7b2c\u56db\u671fCKD\u60a3\u8005 (4). \u5e74\u9f6140\u6b72\u3001\u958b\u59cb\u900f\u6790\u6cbb\u7642\u5169\u5e74\u4e4b\u7b2c\u4e94\u671fCKD\u60a3\u8005 (5). \u5e74\u9f6140\u6b72\u3001\u814e\u81df\u79fb\u690d\u6210\u529f\u5169\u5e74\u4e4b\u7b2c\u4e8c\u671fCKD\u60a3\u8005\nA. (3)+(4)+(5)\nB. (2)+(4)+(5)\nC. (4)+(5)\nD. (2)+(4)\nE. (4)\n": "(E)", "107-15.\n\u5c3f\u5931\u7981\u70ba\u8001\u4eba\u5e38\u898b\u4e4b\u56f0\u64fe\u554f\u984c\uff0c\u8acb\u554f\u5e95\u4e0b\u54ea\u4e9b\u5e38\u898b\u7684\u85e5\u7269\u53ef\u80fd\u52a0\u91cd\u591c\u5c3f\u800c\u5118\u91cf\u907f\u514d\uff1f (1). Doxazocin (2). Dihydropyridine calcium-channel blockers (3). NSAIDs (4). Thiazolidinediones (5). Anthistamines\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (2)+(3)+(4)\nD. (2)+(3)+(5)\nE. (1)+(3)+(5)\n": "(C)", "107-16.\n\u95dc\u65bc\u6d3b\u52d5\u5f0f\u8840\u58d3\u91cf\u6e2c(Ambulatory blood pressure mesurement)\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u96b1\u533f\u578b\u9ad8\u8840\u58d3(Masked hypertension)\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\u660e\u986f\u4f4e\u65bc\u8a3a\u9593\u6216\u5c45\u5bb6\u4e4b\u6301\u7e8c\u6027\u9ad8\u8840\u58d3\nB. \u591c\u9593\u578b\u9ad8\u8840\u58d3(Nocturnal hypertension)\u662f\u6bd4\u767d\u5929\u9ad8\u8840\u58d3\u6216\u8a3a\u9593\u9ad8\u8840\u58d3\u66f4\u5f37\u4e4b\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\u9810\u5f8c\u56e0\u5b50\nC. \u96b1\u533f\u578b\u9ad8\u8840\u58d3\u5e38\u898b\u65bc\u7537\u6027\u3001\u8001\u4eba\u3001\u7cd6\u5c3f\u75c5\nD. \u8001\u4eba\u5e38\u898b\u6709\u767d\u888d\u9ad8\u8840\u58d3(White coat hypertension) \u6216\u96b1\u533f\u578b\u9ad8\u8840\u58d3\nE. \u6162\u6027\u814e\u81df\u75c5\u7279\u5225\u5e38\u898b\u6709\u591c\u9593\u9ad8\u8840\u58d3\u8207\u96b1\u533f\u578b\u9ad8\u8840\u58d3\n": "(A)", "107-17.\n55\u6b72\u75c5\u4eba\uff0c\u7cd6\u5c3f\u75c5\u4e03\u5e74\u75c5\u53f2\u6bcf\u5929\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u63a7\u5236\uff0c\u4eca\u5e74\u56e0\u51fa\u73fe\u5c3f\u86cb\u767d\u8207\u9ad8\u8840\u58d3\u958b\u59cb\u670d\u7528 Thiazide/Valsartan\uff0c\u8fd1\u5169\u500b\u6708\u53c8\u80c3\u9178\u9006\u6d41\u670d\u7528Proton pump inhibitor\uff0c\u9019\u6b21\u9580\u8a3a\u75c5\u4eba\u62b1\u6028\u5bb9\u6613\u624b\u8db3\u62bd\u6410(tetany)\uff0c\u8acb\u6b64\u65b0\u75c7\u72c0\u53ef\u80fd\u8ddf\u54ea\u4e00\u96fb\u89e3\u8cea\u4e4b\u7570\u5e38\u76f8\u95dc\uff1f\nA. \u4f4e\u9209\u8840\u75c7\nB. \u4f4e\u9240\u8840\u75c7\nC. \u4ee3\u8b1d\u6027\u9e7c\u4e2d\u6bd2\nD. \u4f4e\u9382\u8840\u75c7\nE. \u4f4e\u9223\u8840\u75c7\n": "(D)", "107-18.\n\u5728\u665a\u671f\u6162\u6027\u814e\u81df\u75c5\u6216\u900f\u6790\u75c5\u4eba\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805 \u8207\u5176\u9ad8\u51fa\u8a31\u591a\u7684\u5fc3\u8840\u7ba1\u75be\u75c5\u6216\u6b7b\u4ea1\u98a8\u96aa\u4e0d\u898b\u5f97\u6709\u76f4\u63a5\u76f8\u95dc\uff1f\nA. \u4f4e\u8840\u58d3 (Low blood pressure)\nB. \u66fe\u6709\u6025\u6027\u5fc3\u808c\u6897\u585e (Documented AMI)\nC. \u5fc3\u81df\u8870\u7aed (Congestive heart failure)\nD. \u5de6\u5fc3\u5ba4\u80a5\u539a (Left ventricular hypertrophy)\nE. \u64f4\u5f35\u578b\u5fc3\u808c\u80a5\u539a (Dilated cardiomyopathy)\n": "(B)", "107-19.\n\u95dc\u65bc\u814e\u81df\u7d30\u80de\u764c(Renal cell carcinoma)\uff0c\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u814e\u81df\u7d30\u80de\u764c\u4e2d\u4ee5Clear cell carcinoma\u70ba\u6700\u591a\u800c\u4e14\u6700\u6703\u8f49\u79fb\nB. Clear cell carcinoma\u70ba von Hippel-Lindau gene \u4e4b \"loss of function\" mutation\nC. \u7d04\u756530%\u814e\u81df\u7d30\u80de\u764c\u767c\u73fe\u6642\u5df2\u6709\u8f49\u79fb\uff0c\u800c\u814e\u81df\u5207\u9664\u624b\u8853\u5f8c\u4ecd\u670920-30%\u6703\u6709\u8f49\u79fb\u5fa9\u767c\nD. \u814e\u81df\u7d30\u80de\u764c\u5c24\u5176\u662fClear cell carcinoma\u767c\u73fe\u6642\u6709\u8f49\u79fb\uff0c\u4ecd\u61c9\u5efa\u8b70\u505a\u7f79\u764c\u5074\u4e4b\u5168\u90e8\u6216\u5c40\u90e8\u814e\u81df\u5207\u9664\nE. \u5e38\u4f34\u6709Paraneoplastic syndrome\uff0c\u5305\u62ec\u6709\u809d\u81df\u8f49\u79fb\u53ca\u809d\u529f\u80fd\u7570\u5e38\u4e4bStauffer's syndrome\n": "(E)", "107-20.\n68\u6b72\u7537\u6027 \u7121\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u3001\u5fc3\u808c\u7f3a\u6c27\u7b49\u75c5\u53f2\uff0c\u8fd1\u516d\u500b\u6708\u9010\u6f38\u51fa\u73fe\u547c\u5438\u56f0\u96e3\u3001\u884c\u52d5\u56f0\u96e3\u3001\u7ad9\u7acb\u6642\u982d\u6688\u3001\u4e0b\u80a2\u6c34\u816b\u3001\u4e0b\u80a2\u6709\u9ebb\u6728\u53ca\u75bc\u75db\u611f\u89ba\u7570\u5e38\u3002 \u7d93\u6aa2\u67e5\uff1a\u8840\u58d3102/70 mmHg\u3001\u8108\u535a96/min\u3001\u547c\u543820/min\u3001\u80f8\u90e8Cardiac dullness\u589e\u52a0\u3001\u547c\u5438\u97f3\u6e1b\u5c11\uff0c\u8179\u90e8\u6709shifting dullness\uff0c\u4e0b\u80a2\u56b4\u91cd\u6c34\u816b\u81f3\u819d\u84cb\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u4e0b\u80a2\u5c0d\u89f8\u6478\u8207\u9707\u52d5\u4e4b\u611f\u89ba\u6709\u4e0b\u964d\u3002\u62bd\u8840\u6aa2\u67e5\uff1aHb 10.2 gm/dL, Albumin 2.4 gm/dL, Cre 1.6 mg/dL, CHO 280 mg/dL, HbA1C 5.9%, Urine Protein/ Creatinine ratio 4800 mg/g, \u53caUrine\u6709Bence Jones protein\u7684\u5b58\u5728\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u9032\u4e00\u6b65\u6aa2\u67e5immunofixation of serum and urine\u53caserum immunoglobulin free light chain assay\uff0c\u78ba\u5b9a\u70ba \u03ba \u6216 \u03bb light chain \u8207\u5176\u91cf\nB. \u5efa\u8b70\u53ef\u5148\u505a\u76ae\u4e0b\u8102\u80aa\u8207\u9aa8\u9ad3\u7a7f\u523a\uff0c\u78ba\u5b9a\u662f\u5426\u6709Amyloidosis \u4ee5\u53ca\u9aa8\u96a8\u5167plasma cell \u7684\u767e\u5206\u6bd4\nC. \u8a3a\u65b7\u4e0a\u9084\u662f\u9700\u8981\u505a\u814e\u81df\u5207\u7247\uff0c\u4e26\u514d\u75ab\u67d3\u8272\u8b49\u660e\u6709light chain\u7684\u5b58\u5728\nD. \u6b64\u75c5\u63a5\u53d7\u81ea\u9ad4\u9020\u8840\u5e79\u7d30\u80de\u9aa8\u9ad3\u79fb\u690d\u4e26\u4e0d\u6703\u6bd4\u50b3\u7d71\u5316\u7642\u6548\u679c\u597d\nE. \u75c5\u4eba\u7d50\u5c40(outcome)\u6c7a\u5b9a\u65bc\u814e\u529f\u80fd\u662f\u5426\u60e1\u5316\u81f3\u900f\u6790\u6cbb\u7642\n": "(E)", "107-21.\n\u67d050\u6b72\u7537\u6027\u4f86\u9662\u524d\u4e94\u5929\u525b\u9a0e\u8173\u8e0f\u8eca\u74b0\u5cf6\u7d50\u675f\uff0c\u4e3b\u8a34: \u8f15\u5fae\u5641\u5fc3\u3001\u5169\u8173\u808c\u8089\u75e0\u75bc\u7121\u529b\u3001\u5c0f\u4fbf\u5448\u53ef\u6a02\u984f\u8272\u5df2\u5169\u5929\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3130/80 mmHg\uff0c\u8108\u640f 82/min\uff0c\u547c\u543818/min\uff0c\u80f8\u90e8\u8179\u90e8\u7121\u6059\uff0c\u5169\u5074\u5c0f\u817f\u5927\u817f\u6709\u58d3\u75db\u53ca\u808c\u8089\u8f15\u5fae\u7121\u529b~+4\u3002\u62bd\u8840\u6aa2\u67e5\uff1a WBC 10200/ul, Hb 11.6g/dL,BUN 128mg/dL, Cre 6.7mg/dL, Na 138mmol/L, K 5.6mmol/L, ABG pH 7.26, HCO3- 16mEq/L. CK 25000 U/L, AST 703U/L, ALT 238 U/L, Bil-T 1.2 mg/dL, LDH 2013 U/dL, Haptoglobin 58 mg/dL, \u5c3f\u6aa2 pH 5.8, protein (2+), OB(3+), RBC 2-5/HPF, WBC\r0-3/HPF.\u814e\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5169\u5074\u814e\u81df\u5747\u70ba10\u516c\u5206\u5de6\u53f3\uff0c\u7121\u840e\u7e2e\u73fe\u8c61\u3002\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u5176AKI\u70ba\u7531Hypovolemia\u4e4bprerenal AKI\uff0c\u6240\u4ee5\u6cbb\u7642\u4e0a\u4ee5Hydration\u70ba\u4e3b\nB. \u61c9\u4e5f\u8981\u6aa2\u67e5\u8840\u6e05\u9223\u8207\u78f7\u6fc3\u5ea6\uff0c\u56e0\u5e38\u6703\u6709\u4f4e\u9223\u8840\u75c7\u8207\u9ad8\u78f7\u8840\u75c7\nC. \u61c9\u6301\u7e8c\u7d66\u4e88\u751f\u7406\u9e7d\u6c34\u81f3\u5c11\u6bcf\u5c0f\u6642200\u6beb\u5347\u4ee5\u4e0a\uff0c\u81f3\u5c3f\u8a66\u7d19\u6f5b\u8840\u8b8a\u6210\u9670\u6027\u70ba\u6b62\nD. \u82e5\u5c3f\u6db2pH<6.5\uff0c\u53ef\u8003\u616e\u5728\u751f\u7406\u9e7d\u6c34\u4e2d\u52a0\u5165Sodium bicarbonate\nE. \u5982\u679c\u51fa\u73fe\u5be1\u5c3f\u3001\u9ad8\u8840\u9240\u4f75EKG\u8b8a\u5316\u3001\u56b4\u91cd\u9178\u4e2d\u6bd2\uff0c\u5c31\u61c9\u5373\u65e9\u7dca\u6025\u8840\u6db2\u900f\u6790\u6cbb\u7642\n": "(A)", "107-22.\n\u4ee5\u4e0b\u662f\u4e00\u4f4dICU\u75c5\u4eba\u7684\u52d5\u8108\u6c23\u9ad4\u5206\u6790\u8207\u8840\u6db2\u96fb\u89e3\u8cea\u5831\u544a: pH 7.42, PaO2 88 mmHg, PaCO2 67 mmHg, [Na] 140 mEq/L, [K] 3.5 mEq/L, [Cl] 88 mEq/L, HCO3 42 mEq/L\u3002\u4f9d\u64da\u4e0a\u8ff0\u6578\u503c\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u4f55\u7a2e\u75c5\u4eba\u72c0\u6cc1?\nA. Sepsis in ICU\nB. Uremia, long-term use of diuretics\nC. COPD with diuretics\nD. Methanol intoxication, with secondary lactic acidosis\nE. Pneumonia, on ventilator support for pulmonary edema\n": "(C)", "108-1.\n\u6162\u6027\u814e\u81df\u75c5(CKD)\u75c5\u4eba\u5e38\u5408\u4f75\u6709\u9223\u78f7\u7570\u5e38\uff0c\u4ee5\u4e0b\u6709\u95dc\u6cbb\u7642\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u63a1\u7528\u4f4e\u78f7\u98f2\u98df(low phosphate diet)\uff0c\u6709\u52a9\u65bc\u9810\u9632\u526f\u7532\u72c0\u817a\u9ad8\u80fd\u75c7(secondary hyperparathyroidism)\nB. \u4f7f\u7528\u6d3b\u6027\u7dad\u4ed6\u547dD(\u5982: calcitriol)\u53ef\u4ee5\u6291\u5236\u526f\u7532\u72c0\u817a\u7d20(parathyroid hormone)\u5206\u6ccc\uff0c\u526f\u4f5c\u7528\u4e4b\u4e00\u662f\u5f15\u8d77\u9ad8\u8840\u9223(hypercalcemia)\nC. \u4f7f\u7528calcimimetic agent(\u5982: cinacalcet)\u53ef\u4ee5\u6291\u5236\u526f\u7532\u72c0\u817a\u7d20(parathyroid hormone)\u5206\u6ccc\uff0c\u526f\u4f5c\u7528\u4e4b\u4e00\u662f\u5f15\u8d77\u9ad8\u8840\u9223(hypercalcemia)\nD. \u4f7f\u7528\u78f7\u7d50\u5408\u5291(\u5982: \u5404\u5f0f\u9223\u7247)\u53ef\u4ee5\u6291\u5236\u526f\u7532\u72c0\u817a\u7d20(parathyroid hormone)\u5206\u6ccc\uff0c\u526f\u4f5c\u7528\u4e4b\u4e00\u662f\u5f15\u8d77\u9ad8\u8840\u9223(hypercalcemia)\nE. \u4f7f\u7528sevelamer\u6216lanthanum\uff0c\u53ef\u4ee5\u6291\u5236\u8178\u80c3\u9053\u5c0d\u78f7\u7684\u5438\u6536\uff0c\u4f46\u4e0d\u6703\u5f15\u8d77\u9ad8\u8840\u9223(hypercalcemia)\n": "(C)", "108-2.\n\u9ad8\u8840\u58d3\u7684\u75c5\u4eba\u521d\u6b21\u5c31\u91ab\u6642\uff0c\u61c9\u5b89\u6392\u512a\u5148\u505a\u4ee5\u4e0b\u8a55\u4f30(initial evaluation)\uff0c\u4f55\u8005\u9664\u5916?\nA. Hematocrit\nB. Serum uric acid level\nC. ECG (electrocardiogram)\nD. Urinalysis \u6216 urine albumin excretion\nE. Serum BUN and Cr, Sodium, potassium\n": "(B)", "108-3.\n\u59b3(\u4f60)\u662f\u5167\u79d1\u91ab\u5e2b\uff0c\u4e00\u4f4d\u5e74\u8f15\u9ad8\u8840\u58d3\u75c5\u4eba\u61f7\u5b5520\u9031\uff0c\u8f49\u4ecb\u5230\u59b3(\u4f60)\u7684\u9580\u8a3a\u8ffd\u8e64\u3002\u4ee5\u4e0b\u91dd\u5c0d\u61f7\u5b55\u9ad8\u8840\u58d3\u7684\u6cbb\u7642\u5efa\u8b70\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba?\nA. \u8a72\u5b55\u5a66\u7684\u8840\u58d3\u63a7\u5236\u76ee\u6a19\uff0c\u5efa\u8b70\u4e0d\u9ad8\u65bc140/90 mmHg\nB. \u53ef\u7d66\u4e88\u4f4e\u5291\u91cf(80-100 mg/day)aspirin\uff0c\u9810\u9632\u767c\u751f\u5b50\u7672\u524d\u75c7(pre-eclampsia)\nC. \u8840\u58d3\u85e5\uff0c\u5efa\u8b70\u4ee5ACEI\u6216ARB\u985e\u512a\u5148\nD. \u8840\u58d3\u85e5\uff0c\u53ef\u4ee5\u4f7f\u7528labetalol\nE. \u8840\u58d3\u85e5\uff0c\u53ef\u4ee5\u4f7f\u7528nifedipine\n": "(C)", "108-4.\n\u81e8\u5e8a\u4e0a\u53ef\u4ee5\u4f7f\u7528eGFR\u8207urine ACR(albumin creatinine ratio)\u4f86\u5224\u65b7\u814e\u81df\u75c5\u7684\u56b4\u91cd\u7a0b\u5ea6\uff0c\u8207\u8a55\u4f30\u9032\u5c55\u5230\u672b\u671f\u814e\u81df\u75c5(ESRD)\u7684\u5371\u96aa\u5ea6\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u60c5\u6cc1\u6700\u56b4\u91cd?\nA. eGFR 30 (ml/min/1.73 m2)\uff0c urine ACR<30 mg/g\nB. eGFR 60 (ml/min/1.73 m2)\uff0c urine ACR>300 mg/g\nC. eGFR 50 (ml/min/1.73 m2)\uff0c urine ACR 30-300 mg/g\nD. eGFR 70 (ml/min/1.73 m2)\uff0c urine ACR<30 mg/g\nE. eGFR 40 (ml/min/1.73 m2)\uff0c urine ACR 30-300 mg/g\n": "(E)", "108-5.\n\u4e0d\u660e\u539f\u56e0\u7684\u6025\u6027\u814e\u640d\u50b7(AKI)\uff0c\u5c3f\u6db2\u6aa2\u67e5\u767c\u73fe: protein (2+), RBC cast (+), WBC cast (-), WBC 0-5/HPF, eosinophil (-), bacteria (-), Muddy brown cast (-), FENa > 1% \u75c5\u4eba\u767c\u751fAKI\u6700\u53ef\u80fd\u7684\u75c5\u56e0\u70ba:\nA. Glomerulonephritis (GN) or vasculitis\nB. Interstitial nephritis\nC. Acute tubular necrosis (ATN)\nD. Pyelonephritis or papillary necrosis\nE. Renal arterial or vein occlusion\n": "(A)", "108-6.\n\u4e00\u4f4d36\u6b72\u5973\u6027\uff0c\u4e3b\u8a34\u5065\u5eb7\u6aa2\u67e5\u767c\u73fe\u8840\u5c3f(hematuria)\u3002\u9580\u8a3a\u518d\u4e00\u6b21\u5c3f\u6db2\u6aa2\u67e5\u767c\u73fe: protein (3+), O.B. (2+), dysmorphic RBC (+), RBC cast (+)\u3002\u57fa\u65bc\u9019\u4e9b\u8cc7\u6599\uff0c\u59b3(\u4f60)\u6703\u5b89\u6392\u4ee5\u4e0b\u9032\u4e00\u6b65\u6aa2\u67e5\uff0c\u4f55\u8005\u6700\u4e0d\u5408\u9069?\nA. IVP (intravenous pyelography)\u6216RP (retrograde pyelography)\nB. \u505aserology tests, \u5305\u62ec: ant-GBM Ab, ANCA, ASLO (anti-strytolysin O)\nC. \u6aa2\u6e2c\u8840\u4e2d complement levels (C3, C4), cryoglobulin\nD. Renal sonography, \u5fc5\u8981\u6642\u8003\u616erenal biopsy\nE. Urine cytology test\n": "(A)", "108-7.\n\u4e00\u4f4d\u75c5\u4eba\u4e3b\u8a34\u983b\u5c3f\uff0c\u800c\u4e14\u6bcf\u6b21\u5c3f\u91cf\u90fd\u5f88\u591a\u3002\u75c5\u4eba\u4e26\u672a\u4f7f\u7528\u5229\u5c3f\u5291\uff0c\u8eab\u9ad4\u6aa2\u67e5: \u8840\u58d3\u6b63\u5e38\uff0c\u7121\u7570\u72c0\u3002\u6536\u96c624\u5c0f\u6642\u5c3f\u6db2\u7d50\u679c\u5982\u4e0b: \u7e3d\u5c3f\u91cf 3600 mL/day, urine osmolality 550 mOsm/kg\u3002\u75c5\u4eba\u7684\u6aa2\u67e5\u6578\u503c\uff0c\u6700\u7b26\u5408\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u591a\u5c3f\u75c7\u7684\u8a3a\u65b7:\nA. \u767c\u751fsolute diuresis\nB. Primary polydipsia\nC. \u767c\u751f central diabetes insipidus (DI)\nD. \u767c\u751f nephrogenic diabetes insipidus (DI)\nE. \u767c\u751f SIADH (syndrome of inappropriate anti-diuretic hormone secretion)\n": "(A)", "108-8.\n\u4e0b\u5217\u539f\u767c\u6027\u814e\u75c5\u8b8a\u5f15\u8d77\u7684\u814e\u75c5\u75c7\u5019\u7fa4(nephrotic syndrome)\uff0c\u54ea\u4e00\u7a2e\u6700\u5bb9\u6613\u5408\u4f75\u814e\u975c\u8108\u6813\u585e(renal vein thrombosis)?\nA. Focal segmental glomerulosclerosis (FSGS)\nB. IgA nephropathy\nC. Membranous nephropathy (MN)\nD. Minimal change disease (MCD)\nE. Type I MPGN (membranoproliferative glomerulonephritis)\n": "(C)", "108-9.\n\u6162\u6027\u814e\u81df\u75c5(CKD)\u75c5\u4eba\u7684\u98f2\u98df\uff0c\u5efa\u8b70\u53ef\u4f75\u7528\u4f4e\u86cb\u767d\u98f2\u98df(low protein diet, LPD)\uff0c\u4ee5\u4fdd\u8b77\u814e\u529f\u80fd\uff0c\u6e1b\u7de9CKD\u60e1\u5316\u3002\u4ee5\u4e0b\u5c0d\u65bcLPD\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. CKD\u98f2\u98df\u6cbb\u7642\u6307\u5f15\u6240\u8b02\u7684LPD\uff0c\u5efa\u8b70\u6bcf\u65e5\u86cb\u767d\u8cea\u651d\u53d6\u7d040.6-0.8 g/kg/day\nB. LPD\u53ef\u4ee5\u8b93\u814e\u5c0f\u7403\u5165\u7403\u5c0f\u52d5\u8108(afferent arteriole)\u6536\u7e2e\uff0c\u964d\u4f4e\u814e\u5c0f\u7403\u5167\u58d3\u529b(intra-glomerular pressure)\uff0c\u6e1b\u7de9CKD\u60e1\u5316\nC. LPD\u53ef\u4ee5\u589e\u5f37\u814e\u5c0f\u7403\u51fa\u7403\u5c0f\u52d5\u8108(efferent arteriole)\u64f4\u5f35\u7684\u6a5f\u8f49\uff0c\u964d\u4f4e\u814e\u5c0f\u7403\u5167\u58d3\u529b(intra-glomerular pressure)\uff0c\u6e1b\u7de9CKD\u60e1\u5316\nD. LPD\u8981\u642d\u914d\u71b1\u91cf\u9650\u5236\uff0c\u5efa\u8b70 < 30 Kcal/kg/day\uff0c\u9019\u6a23\u624d\u80fd\u6709\u6548\u6539\u5584\u6e1b\u7de9CKD\u60e1\u5316\nE. LPD\u53ef\u4ee5\u6e1b\u5c11\u542b\u6c2e(nitrogen, N)\u4ee3\u8b1d\u7269\u7522\u751f\uff0c\u964d\u4f4e\u76f8\u95dcuremic toxins, \u5982: p-cresol sulfate\u7522\u751f\n": "(D)", "108-10.\n\u9810\u9632contrast-induced acute kidney injury (AKI)\uff0c\u4ee5\u4e0b\u6cbb\u7642\u7b56\u7565\u7d44\u5408\uff0c\u4f55\u8005\u6b63\u78ba? (1)\u9069\u7576\u7684volume expansion, \u5efa\u8b70\u512a\u5148\u9078\u64c7isotonic saline (2)\u52a0\u4e0aurinary alkalization, \u6548\u679c\u548c\u55ae\u7d14\u4f7f\u7528isotonic saline\u6548\u679c\u7121\u5dee\u5225 (3)\u73fe\u5728\u7684\u6307\u5f15\u5efa\u8b70: routine \u7d66\u4e88 N-acetylcysteine\uff0c\u53ef\u4ee5\u6709\u6548\u9810\u9632AKI\u767c\u751f (4)\u5982\u679c\u75c5\u4eba\u6b63\u5728\u4f7f\u7528metformin, \u5efa\u8b70\u4e0d\u8981\u96a8\u610f\u7d42\u6b62\u505c\u7528\uff0c\u4ee5\u907f\u514d\u767c\u751flactic acidosis (5)\u5982\u679c\u75c5\u4eba\u6b63\u5728\u4f7f\u7528diuretics, \u6216Angiotensin-converting enzyme inhibitors (ACEI) \u6216angiotensin-receptor blockers (ARB), \u5efa\u8b70\u8981\u66ab\u505c\u4f7f\u7528\uff0c\u4ee5\u9810\u9632\u767c\u751fAKI\nA. (1)+(2)\nB. (1)+(2)+(3)\nC. (1)+(2)+(3)+(4)\nD. (1)+(2)+(3)+(5)\nE. (1)+(2)+(5)\n": "(A)", "108-11.\n\u91dd\u5c0d\u591a\u56ca\u814e(autosomal dominant polycystic kidney disease, ADPKD)\uff0c\u4ee5\u4e0b\u4f55\u7a2e\u6cbb\u7642\u7b56\u7565\u53ef\u4ee5\u9810\u9632\u814e\u7d72\u7403\u904e\u6ffe\u7387(GFR)\u4e0b\u964d? (1)Low salt diet (2)Cyclic adenosine monophosphate (cAMP) raising agent, \u4f8b\u5982 dipyridamole (3)Vasopressin-receptor antagonist, \u4f8b\u5982: somatostatin (4)Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB) (5)Water restriction, to prevent cyst growth\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)+(5)\nD. (1)+(3)+(5)\nE. (2)+(3)+(5)\n": "(B)", "108-12.\n\u4ee5\u4e0b\u7684\u7cd6\u5c3f\u75c5\u6cbb\u7642\u85e5\u7269\uff0c\u54ea\u4e00\u985e\u53ef\u4ee5\u6709\u6548\u9810\u9632\u814e\u75c5\u8b8a\u7684\u767c\u751f? (1)Insulin (2)Metformin (3)Biguanides (4)Dipeptidyl peptidase 4 (DPP-4) inhibitors (5)glucagon-like peptide 1 (GLP-1) agonist (6)sodium-glucose cotransporter 2 (SGLT2) inhibitors\nA. (5)+(6)\nB. (1)+(5)+(6)\nC. (3)+(5)+(6)\nD. (3)+(4)+(5)+(6)\nE. (1)+(2)+(5)+(6)\n": "(A)", "108-13.\n63\u6b72\u7537\u6027\u75c5\u4eba\u56e0 Chronic kidney disease stage 3 (eGFR 50ml/min/1.73m^2)\uff0c\u814e\u75c5\u75c7\u5019\u7fa4(\u814e\u81df\u5207\u7247\u75c5\u7406\u70ba\u5c40\u90e8\u786c\u5316\u578b\u814e\u708e)\u3001\u9ad8\u8840\u58d3\u3001\u9000\u5316\u6027\u95dc\u7bc0\u708e\u7b49\u75be\u75c5\u670d\u7528\u5e95\u4e0b\u85e5\u7269\uff0c\u4f46\u662f\u904e\u53bb\u534a\u5e74\u8840\u9240\u90fd\u7dad\u6301\u57285.5-6.0 mmol/L\u4e4b\u9593\uff0c\u8acb\u554f\u9ad8\u8840\u9240\u53ef\u80fd\u8207\u5e95\u4e0b\u85e5\u7269\u6709\u95dc? (1)ARB (2)Doxazosin (3)Cyclosporin (4)Predinisolone (5)COX-2 inhibitor.\nA. (1)+(3)+(4)\nB. (1)+(3)+(5)\nC. (1)+(2)+(4)\nD. (1)+(2)+(5)\nE. (1)+(4)+(5)\n": "(B)", "108-14.\n\u95dc\u65bc\u814e\u81df\u66ff\u4ee3\u7642\u6cd5\uff0c\u5e95\u4e0b\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u65e9\u9ede\u958b\u59cb\u900f\u6790(eGFR 10-14 ml/min/1.73m^2) \u8ddf\u665a\u9ede\u958b\u59cb\u900f\u6790 (5-7 ml/min/1.73m2)\u5728\u6b7b\u4ea1\u7387\u6709\u986f\u8457\u5dee\u7570\nB. \u589e\u52a0\u6bcf\u6b21\u8840\u6db2\u900f\u6790\u4e2d\u5c3f\u7d20\u6c2e\u7684\u6e05\u9664\u7387\uff0c\u53ef\u4ee5\u6539\u5584\u6b7b\u4ea1\u7387\nC. \u6bcf\u9031\u4e09\u6b21\u7684\u8840\u6db2\u900f\u6790\u6539\u70ba\u6bcf\u9031\u516d\u6b21\uff0c\u53ef\u4ee5\u6e1b\u5c11\u6b7b\u4ea1\u7387\nD. \u4f4e\u767d\u86cb\u767d\u8840\u75c7\u70ba\u900f\u6790\u75c5\u4eba\u4e4b\u91cd\u8981\u4e0d\u826f\u9810\u5f8c\u56e0\u5b50\nE. \u8840\u6db2\u900f\u6790\u6539\u70ba\u8179\u819c\u900f\u6790\u53ef\u4ee5\u964d\u4f4e\u6b7b\u4ea1\u7387\n": "(D)", "108-15.\n\u67d0\u7537\u6027\u6709\u9ad8\u8840\u58d3\u75c5\u4eba\uff0c\u56e0\u4e0b\u80a2\u6c34\u816b\u516d\u500b\u6708\uff0c\u7d93\u6aa2\u67e524\u5c0f\u6642\u5c3f\u86cb\u767d\u70ba5\u516c\u514b\uff0c\u8840\u6e05\u767d\u86cb\u767d3 gm/L\uff0cCreatinine 1.7 mg/dL\uff0c\u7d93\u814e\u81df\u7a7f\u523a\u5207\u7247\u75c5\u7406\u5831\u544a\u70ba\u7b2c\u4e8c\u671f\u819c\u6027\u814e\u708e\u3002\u8acb\u554f\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u5b9c? (1)\u61c9\u6aa2\u6e2c\u8840\u6e05Anti-M-Phospholipase A2 recptor (Anti-PLA2R) antibody titer (2)\u53ef\u7531\u814e\u81df\u5207\u7247\u4e2d\u814e\u7d72\u7403\u5e95\u819c\u4e4b\u589e\u539a\u8207\u767c\u708e\u7d30\u80de\u4e4b\u6d78\u6f64\u591a\u5be1\u5f97\u77e5\u5176\u9810\u5f8c (3)\u82e5\u75c5\u4ebaAnti-PLA2R antibody titer\u4e0d\u9ad8\uff0c\u5c31\u8868\u793a\u5176\u5c31\u6703\u81ea\u884c\u7de9\u89e3 (4)\u82e5\u75c5\u4ebaAnti-PLA2R antibody titer\u6709\u9ad8\uff0c\u5c31\u61c9\u5efa\u8b70\u63a5\u53d7\u514d\u75ab\u6291\u5236\u7642\u6cd5 (5)\u82e5\u75c5\u4ebaAnti-PLA2R antibody\rtiter\u6709\u9ad8\u4e14\u958b\u59cb\u63a5\u53d7\u6cbb\u7642\uff0c\u5efa\u8b70\u9084\u662f\u7e7c\u7e8c\u8ffd\u8e64\u6b64\u6297\u9ad4\u4e4btiter\u3002\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(4)+(5)\nC. (1)+(4)+(5)\nD. (1)+(2)+(3)\nE. (1)+(3)+(4)\n": "(C)", "108-16.\n\u95dc\u65bc\u53f0\u7063\u814e\u81df\u79fb\u690d\u7684\u73fe\u6cc1\uff0c\u4f55\u8005\u70ba\u932f\uff1f\nA. \u53f0\u7063\u814e\u81df\u79fb\u690d\u75c5\u4eba\u7b2c\u4e00\u3001\u4e94\u3001\u5341\u5e74\u7684\u5b58\u6d3b\u7387\u8207\u7f8e\u570b\u76f8\u7576\nB. \u53f0\u7063\u814e\u81df\u79fb\u690d\u75c5\u4eba\u4e94\u3001\u5341\u5e74\u5b58\u6d3b\u7387\u6bd4\u53f0\u7063\u900f\u6790\u7684\u75c5\u4eba\u660e\u986f\u9ad8\u5f88\u591a\nC. \u53f0\u7063\u814e\u81df\u79fb\u690d\u5f8c\u6b7b\u4ea1\u539f\u56e0\u6392\u540d\u4f9d\u5e8f\u70ba\u5fc3\u8840\u7ba1\u75be\u75c5\u3001\u611f\u67d3\u3001\u60e1\u6027\u816b\u7624\nD. \u53f0\u7063\u814e\u81df\u79fb\u690d\u5f8c\u60e1\u6027\u816b\u7624\u767c\u751f\u7387\u70ba\u6b63\u5e38\u4eba\u76843-5\u500d\uff0c\u4e14\u9010\u5e74\u589e\u52a0\nE. \u53f0\u7063\u814e\u81df\u79fb\u690d\u5f8c\u816b\u7624\u8ddf\u5916\u570b\u4e00\u6a23\u4ee5\u6dcb\u5df4\u764c\u5c45\u591a\n": "(E)", "108-17.\n\u8acb\u554f\u5728\u5e95\u4e0b\u90a3\u4e00\u7a2e\u72c0\u6cc1\u505a\u5927\u91cf\u8f38\u6db2\u6cbb\u7642\uff0c\u4ecd\u8981\u5c0f\u5fc3\u53ef\u80fd\u6703\u9020\u6210\u7f3a\u8840\u6027\u814e\u50b7\u5bb3\uff1f\nA. \u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2 Diabetic ketoacidosis\nB. \u6a6b\u7d0b\u808c\u6eb6\u89e3\u75c7 Rhabdomyolysis\nC. \u71d2\u50b7 Burns\nD. \u5c3f\u8def\u963b\u585e\u88ab\u89e3\u9664\u5f8c\u5c3f\u91cf\u589e\u52a0  Post-obstruction diuresis\nE. \u986f\u5f71\u5291\u7d66\u4e88\u5f8c After administration of constrast medium\n": "(C)", "108-18.\n\u95dc\u65bc\u814e\u81df\u79fb\u690d\u5f8c\u591a\u7624\u6027\u75c5\u6bd2(Polyomaviruses BK virus) \u611f\u67d3\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u932f\uff1f\nA. \u901a\u5e38\u5728\u814e\u81df\u79fb\u690d\u4e00\u500b\u6708\u5f8c\u624d\u767c\u751f\nB. \u7d66\u4e88Acyclovir\u53ef\u4ee5\u6709\u6548\u5730\u9810\u9632\u5176\u767c\u751f\nC. \u65e9\u671f\u767c\u73fe\u8207\u964d\u4f4e\u8abf\u6574\u514d\u75ab\u6291\u5236\u85e5\u7269\u6975\u70ba\u9069\u7576\u4e4b\u8655\u7f6e\nD. BK \u75c5\u6bd2\u611f\u67d3\u53ef\u898b\u65bc\u814e\u81df\u79fb\u690d\nE. BK\u75c5\u6bd2\u53ef\u5728\u75c5\u4eba\u7684\u5c3f\u6db2\u8207\u8840\u6db2\u4e2d\u6aa2\u6e2c\u6216\u57f9\u990a\u51fa\u4f86\n": "(B)", "108-19.\n65\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u904e\u53bb\u7121\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\uff0c\u4e00\u5e74\u524d\u5065\u6aa2\u5c3f\u6db2\u814e\u529f\u80fd\u5747\u6b63\u5e38\uff0c\u4f46\u6700\u8fd1\u516d\u9031\u5c3f\u6db2\u984f\u8272\u8b8a\u6df1\uff0c\u8173\u8e1d\u6c34\u816b\uff0c\u8d70\u8def\u6703\u5fae\u5598\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3 152/98 mmHg\uff0c\u4e0b\u80a2\u6c34\u816b\u81f3\u5c0f\u817f\u524d\u811b\u9aa8\u8655\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\uff1a\u5c3f\u86cb\u767d3+\uff0cOB 3+\uff0cURBC 50-70/HPF\uff0cHb 10g/dL\uff0cBUN 53 mg/dL\uff0cCre 3.6 mg/dL\uff0c\u514d\u75ab\u5b78\u6aa2\u67e5C-ANCA (+) \u4e14titer\u9ad8\u904e\u6b63\u5e38\u503c\uff0c\u8acb\u554f\u5176\u814e\u81df\u5207\u7247\u4e4b\u75c5\u7406\u5831\u544a\u6bd4\u8f03\u53ef\u80fd\u70ba\u5e95\u4e0b\u4f55\u8005? (1)Goodpasture syndrome (2)Wegner granulomatosis (3)Eosonophilic granulomatosis (4)Churg-Strauss disease (5)Microscopic polyangitis.\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (2)+(4)+(5)\nE. (1)+(3)+(5)\n": "(B)", "108-20.\n\u95dc\u65bc\u8001\u5e74\u6642\uff0c\u814e\u81df\u6ccc\u5c3f\u7cfb\u7d71\u4e4b\u9000\u5316\uff0c\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u932f\u8aa4\uff1f\nA. \u814e\u7d72\u7403\u904e\u6ffe\u7387\u6bcf\u5e74\u8870\u90001%\uff0c\u81f370\u6b72\u6642\u5e73\u5747\u7d04\u70ba70 ml/min/1.73m2\u5de6\u53f3\nB. \u814e\u81df\u5c3f\u6db2\u6700\u5927\u6fc3\u7e2e\u80fd\u529b\u4e0b\u964d\uff0c\u4e14\u591c\u9593\u5c3f\u91cf\u589e\u52a0\nC. \u8180\u80f1\u4fbf\u5bb9\u6613\u8e81\u52d5\uff0c\u4e14\u8180\u80f1\u6536\u7e2e\u529b\u4e0b\u964d\nD. \u8180\u80f1\u9918\u5c3f\u91cf\u589e\u52a0\uff0c\u4e14\u8180\u80f1\u5bb9\u91cf\u6e1b\u5c11\nE. \u903c\u5c3f\u808c\u904e\u5ea6\u53cd\u61c9(Detrusor overactivity)\u662f\u5c3f\u5931\u7981\u6700\u5e38\u898b\u4e4b\u539f\u56e0\n": "(D)", "108-21.\n36\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u4e3b\u8a34\u6700\u8fd1\u5169\u9031\u6709\u7d93\u5e38\u53e3\u6e34\u3001\u5c3f\u91cf\u589e\u52a0\u53ca\u51fa\u73fe\u982d\u75db\u73fe\u8c61\u3002\u7406\u5b78:\u8840\u58d3\u6b63\u5e38\uff0c\u76ae\u819a\u5f48\u529b\u6b63\u5e38\u3002\u7d93\u521d\u6b65\u6aa2\u9a57\u5f97\u814e\u529f\u80fd\u5c3f\u8a66\u7d19\u6aa2\u67e5\u5747\u6b63\u5e38\uff0c\u4f46 [Na+] 155 mmol/L; plasma osmolarity 330 mOsm/L\u3002\u8acb\u554f\u5e95\u4e0b\u4e4b\u81e8\u5e8a\u8655\u7f6e\uff0c\u4f55\u9805\u70ba\u932f\u8aa4\uff1f\nA. \u61c9\u5148\u5728\u4e0d\u9650\u6c34\u72c0\u6cc1\u4e0b\uff0c\u8acb\u75c5\u4eba\u8490\u96c624\u5c0f\u6642\u4e4b\u5c3f\u6db2\u4e26\u8a18\u9304\u5c3f\u91cf\nB. \u598224\u5c0f\u6642\u5c3f\u91cf\u8d85\u904e50 ml/Kg\uff0c\u800c\u4e14Urine osmolarity < 300 mOsm/L\uff0c\u6709\u53ef\u80fd\u662fDiabete insipidus.(DI)\nC. \u61c9\u8981\u5148\u6392\u9664Hypokalemia\u53caHypercalcemia\nD. \u53ef\u6253 DDAVP\uff0c\u770bPlasm osmolarity\u4e4b\u8b8a\u5316\u4f86\u5224\u5b9a\u662fcentral\u6216Nephrogenic DI\nE. \u6cbb\u7642\u6642\uff0c\u6bcf\u5929 [Na+] \u4e4b\u4e0b\u964d\u91cf\u6700\u597d\u4e0d\u8981\u8d85\u904e 10 mmol/L\n": "(D)", "108-22.\n\u757670\u6b72\u75c5\u4eba\u56e0\u814e\u75c5\u75c7\u5019\u7fa4\u53caCre 2.0 mg/dL\uff0c\u9032\u4e00\u6b65\u7d93\u6aa2\u67e5Serum and urine immunofixation \u3001 Free light chain assay\u3001\u814e\u81df\u7a7f\u523a\u5f8c\u5df2\u78ba\u5b9a\u662f Renal AL Amyloidosis\u3002\u8acb\u554f\u63a5\u4e0b\u4f86\u4e4b\u81e8\u5e8a\u8655\u7f6e\uff0c\u5e95\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u932f\u8aa4\uff1f\nA. \u5efa\u8b70\u9032\u4e00\u6b65\u505aBone marrow biopsy\nB. \u7e7c\u7e8c\u8ffd\u8e64Free light chain assay \u505a\u70ba\u75c5\u60c5\u8207\u6cbb\u7642\u4e4b\u6307\u6a19\nC. \u82e5\u4e5f\u6709Cardiac involvement\uff0c\u4e5f\u61c9\u8ffd\u8e64Troponin\u8207 N-termial pro-BNP\nD. \u6b64\u75c5\u4eba\u5c31\u662f\u63a5\u53d7\u5316\u5b78\u7642\u6cd5\uff0c\u7d42\u7a76\u9084\u662f\u6703\u6b7b\u65bcRenal failure\nE. \u75c5\u4eba\u63a5\u53d7\u81ea\u9ad4\u9020\u8840\u5e79\u7d30\u80de\u79fb\u690d\u4e0d\u898b\u5f97\u6703\u6bd4\u5316\u7642\u597d\n": "(D)", "109-67.49\u6b72\u7537\u6027\u56e0\u8fd1\u5e7e\u5e74\u91cd\u8986\u6392\u51fa\u5c3f\u8def\u7d50\u77f3 \uff0c\u6b64\u5916\uff0c\u660e\u986f\u7121\u5176\u4ed6\u81e8\u5e8a\u75c7\u72c0\u8207\u7cfb\u7d71\u75be\u75c5 \uff0c\u7d93\u6aa2\u67e5\u6709\u8840\u6e05\u808c\u9178\u9150 1.4 \nmg/dL (eGFR 57 ml /min/1.73m2)\u3001\u9ad8\u8840\u9223(13mg/dL)\u3001\u53ca\u9ad8\u526f\u7532\u72c0\u817aiPTH (150 \npg/mL)\uff0ctechnetium -99m sestamibi scintigraphy (MIBI)\u986f\u793a\u5728\u53f3\u7532\u72c0\u817a\u8655\u4f4d\u7f6e\u6709intense uptake \uff0c\u8acb\u554f\u5176\n\u4e4b\u8655\u7f6e\u4f55\u8005\u70ba\u6b63\u78ba \uff1f\n(1) \u5efa\u8b70\u5b9c\u4f4e\u9223\u9ad8\u78f7\u7684\u98f2\u98df  \n(2) \u5efa\u8b70\u5b9c\u4f7f\u7528Thiazide\u9810\u9632\u5c3f\u8def\u7d50\u77f3\n(3) \u5efa\u8b70\u5b9c\u4f7f\u7528Biphosphate\u9810\u9632\u9aa8\u8cea\u758f\u9b06 \n(4) \u5efa\u8b70\u5b9c\u4f7f\u7528cinacalcet\u964d\u4f4e\u8840\u9223\u6fc3\u5ea6\n(5) \u5efa\u8b70\u5b9c\u63a5\u53d7\u526f\u7532\u72c0\u817a\u5207\u9664   \nA.(1)+(2)+(3)+(4)+(5)\nB.(1)+(3)+(5)\nC.(1)+(2)+(3)+(4)\nD.(2)+(3)+(4)\nE.(3)+(4)+(5)\n": "[E]", "109-68.\u65bc\u6162\u6027\u814e\u75c5\u4e4b\u5206\u671f\u4e2d \uff0c\u5e95\u4e0b\u54ea\u4e9b\u70ba\u53ef\u80fd\u8fc5\u901f\u56b4\u91cd\u60e1\u5316 (\u5373\u7d05\u8272\u8b66\u6212 )\u7684\u72c0\u6cc1\uff1furinary albumin to creatinine \nratio (UACR)\n(1) eGFR 45 -59 + UACR 100 mg /g \n(2) eGFR 45 -59 + UACR > 300 mg /g\n(3) eGFR 30 -44 + UACR < 30 mg /g \n(4) eGFR 30 -44 + UACR 100 mg /g\n(5) eGFR 15 -29 + UACR < 30 mg /g   \nA.(2)+(3)+(4)+(5)\nB.(1)+(3)+(5)\nC.(2)+(4)+(5)\nD.(3)+(4)+(5)\nE.(1)+(2)+(3)+(4)+(5)   \n": "[C]", "109-69.72\u6b72\u7537\u6027\u6709\u591a\u5e74\u9ad8\u8840\u58d3 \u3001\u9ad8\u81bd\u56fa\u9187\u8840\u75c7 \u3001\u6162\u6027\u814e\u75c5\u7b2c\u4e09\u671f (\u7a69\u5b9a\u7121\u60e1\u5316 )\uff0c\u8fd1\u534a\u5e74\u56e0\u8f15\u5fae\u8840\u5c3feGFR 46 \nmL/min/1.73m2\uff0c\u505a\u814e\u81df\u8d85\u97f3\u6ce2\u767c\u73fe\u5de6\u5074\u814e\u81df (\u9577\u5f918\u516c\u5206)\u6bd4\u53f3\u5074\u5c0f 2\u516c\u5206\uff0c\u9032\u4e00\u6b65\u7684MR angiography (\u5982\n\u5716) \u767c\u73fe \u5728\u5de6\u5074\u814e\u52d5\u8108\u5165\u53e3\u8655\u6709\u4e00\u72f9\u7a84 \uff0c\u8acb\u554f\u5e95\u4e0b\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u6b63\u78ba \uff1f\n(1) \u5176\u9ad8\u8840\u58d3\u8207\u6162\u6027\u814e\u75c5\u6975\u53ef\u80fd\u70ba\u52d5\u8108\u786c\u5316\u5f15\u8d77\u814e\u52d5\u8108\u72f9\u7a84\u6240\u9020\u6210\n(2) \u53ef\u5b89\u6392\u505acaptopril renogram \u770b\u5de6\u5074\u814e\u81df\u8840\u6d41\u662f\u5426\u6709\u6e1b\u5c11\n(3) \u56e0\u814e\u529f\u80fd\u5df2\u4e0d\u6b63\u5e38 \uff0c\u61c9\u5efa\u8b70\u653e\u652f\u67b6\u6216\u6c23\u7403\u64f4\u5f35\u8853\u4f86\u6539\u5584\n(4) \u82e5\u90fd\u535c\u52d2\u8d85\u97f3\u6ce2\u986f\u793a\u5de6\u5074\u814e\u81df\u4e4bresistive index\u5c0f\u65bc80 \uff0c\u61c9\u8a72\u8981\u9700\u8981\u9032\u4e00\u6b65\u6aa2\u67e5\n(5) ACEi/ARB \u8207 Statins\u7684\u85e5\u7269\u6cbb\u7642\u5373\u53ef   \nA.(1)+(2)+(5)\nB.(1)+(3)+(5)\nC.(2)+(4)+(5)\nD.(1)+(3)+(4)\nE.(1)+(4)+(5)\n": "[C]", "109-70.\u95dc\u65bc\u5e38\u7528\u7684\u6c2b\u96e2\u5b50\u5e6b\u6d66\u963b\u65b7\u5291\u5c0d\u814e\u81df\u7684\u4e0d\u826f\u4f5c\u7528\u4e2d\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.Chronic kidney disease\nB.Acute kidney injury\nC.Acute interstitial nephritis\nD.Metabolic alkalosis\nE.Hypomagnesemia\n": "[D]", "109-71.\u5e95\u4e0b\u4e0d\u540c\u6e2c\u91cf\u8840\u58d3\u4e4b\u65b9\u5f0f\uff0c\u5176\u9ad8\u8840\u58d3\u7684\u5b9a\u7fa9\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f    \nA.\u8a3a\u9593\u6c34\u9280\u8840\u58d3\u8a08 \u6536\u7e2e\u58d3 \u2265140 and/or \u8212\u5f35\u58d3 \u226590  mmHg\nB.\u81ea\u91cf\u8a3a\u9593\u81ea\u52d5\u8840\u58d3\u8a08 \u6536\u7e2e\u58d3\u2265140 and/or\u8212\u5f35\u58d3\u226590 mmHg\nC.\u5c45\u5bb6\u8840\u58d3\u91cf\u6e2c \u6536\u7e2e\u58d3\u2265135 and/or\u8212\u5f35\u58d3\u226585 mmHg\nD.24 \u5c0f\u6642\u52d5\u614b\u8840\u58d3\u76e3\u6e2c (\u5168\u5929) \u6536\u7e2e\u58d3\u2265130 and/or \u8212\u5f35\u58d3\u226580 mmHg\nE.24 \u5c0f\u6642\u52d5\u614b\u8840\u58d3\u76e3\u6e2c (\u591c\u9593) \u6536\u7e2e\u58d3\u2265120 and/or \u8212\u5f35\u58d3\u226570 mmHg\n": "[B]", "109-72.\u95dc\u65bc\u75db\u98a8\u6d41\u884c\u75c5\u5b78\u8207\u81e8\u5e8a\u8868\u5fb5\uff0c\u5e95\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u70ba\u4e0d\u6b63\u78ba\uff1f    \nA.\u53f0\u7063\u539f\u4f4f\u6c11\u6bcf\u5341\u4eba\u81f3\u5c11\u6709\u4e00\u4eba\u6709\u75db\u98a8\uff0c\u5373\u76db\u884c\u7387\u8d85\u904e10%\nB.\u75db\u98a8\u75c5\u4eba\u4e5d\u6210\u662f\u56e0\u70ba\u814e\u81df\u7121\u6cd5\u6392\u51fa\u5c3f\u9178\u6240\u9020\u6210\nC.\u5973\u6027\u8f03\u5c11\u7f79\u60a3\u75db\u98a8\uff0c\u4e14\u5e38\u5728\u505c\u7d93\u4e4b\u5f8c\u5c31\u9bae\u5c11\u767c\u4f5c\nD.\u82e525\u6b72\u524d\u5c31\u6709\u75db\u98a8\u767c\u4f5c\uff0c\u53ef\u80fd\u6709\u5c3f\u9178\u4ee3\u8b1d\u4e4b\u57fa\u56e0\u7570\u5e38\nE.Thiazide\u3001low dose aspirin\u3001\u4eba\u5de5\u751c\u5473\u5291\uff0c\u90fd\u6703\u589e\u52a0\u75db\u98a8\u4e4b\u767c\u4f5c\n": "[C]", "109-73.\u6709\u4f4d39\u6b72\u5973\u6027\u56e0\u591a\u65e5\u8179\u7009 \u3001\u5168\u8eab\u7121\u529b \u3001\u547c\u5438\u77ed\u4fc3\u800c\u5230\u6025\u8a3a \uff0c\u904e\u53bb\u53f2\u6709\u7d93\u5e38\u6027\u4fbf\u79d8\u4f7f\u7528\u7009\u5291\u53ca\u8207\u5c0f\u4fbf\u56f0\u96e3\u81ea\n\u884c\u670d\u7528\u5229\u5c3f\u5291 \u3002\u7406\u5b78\u6aa2\u67e5 \uff1a\u7a0d\u55dc\u7761\u4f46\u53ef\u6e05\u9192 \u3001\u8840\u58d385/55,\u5fc3\u8df375/min.\u76ae\u819a\u5f35\u529b\u7a0d\u5dee \uff0c\u5176\u4ed6\u7121\u751a\u7570\u5e38 \u3002\u5be6\u9a57\n\u5ba4\u6aa2\u67e5\uff1aNa+ 125 mmol /l. , K+ 2.8 mmol/l., Cl 101- mmol /l., Glucose 94mg /dL, BUN 34 mg /dL, Cre 1.6 \nmg/dL\u3002Arterial Blood Gases  (pH 7.29; pCO2 25 .6 mmHg; pO2 111 mmHg; HCO 3\u207b  14.0 mmol/l)\u3002\u5c31\n\u5176Blood gas\u65b9\u9762\u800c\u8a00 \uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u9805\u70ba\u6b63\u78ba \uff1f   \nA.\u61c9\u70ba High anion gap metabolic acidosis\nB.\u61c9\u70ba High anion gap acidosis + metabolic alkalosis\nC.\u660e\u986f\u70baLactic acidosis\u9020\u6210\uff0c\u61c9\u6aa2\u6e2cserum lactate level   \nD.\u61c9\u7e7c\u7e8c\u6aa2\u6e2c Urine Anion Gap (UAG)\nE.\u61c9\u7e7c\u7e8c\u6aa2\u6e2c Osmolar gap \u53ca Delta ratio\n": "[D]", "109-74.\u95dc\u65bc\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3(Contrast-associated AKI)\uff0c\u8fd1\u5e74\u6587\u737b\u56de\u9867\u6307\u51fa\u5e95\u4e0b\u63cf\u8ff0\u4f55\u8005\u70ba\u4e0d\u6b63\u78ba\uff1f    \nA.\u56b4\u91cd\u6162\u6027\u814e\u75c5\u662f\u767c\u751f\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3\u4e4b\u6700\u5f37\u70c8\u4e4b\u7368\u7acb\u98a8\u96aa\u56e0\u5b50\nB.\u82e5\u975e\u5408\u4f75\u6162\u6027\u814e\u75c5\uff0c\u7cd6\u5c3f\u75c5\u672c\u8eab\u4e26\u4e0d\u662f\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3\u4e4b\u7368\u7acb\u98a8\u96aa\u56e0\u5b50\nC.\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3\u96d6\u7136\u7a0b\u5ea6\u8f15\u5fae\uff0c\u4f46\u4e5f\u6703\u589e\u52a0\u75c5\u4eba\u4e4b\u6b7b\u4ea1\u7387\nD.\u986f\u5f71\u5291\u76f8\u95dc\u6025\u6027\u814e\u50b7\u5bb3\u4e4b\u56b4\u91cd\u7a0b\u5ea6\uff0c\u8207\u96a8\u5f8c\u814e\u529f\u80fd\u6301\u7e8c\u60e1\u5316\u6709\u95dc\nE.\u6162\u6027\u814e\u75c5\u75c5\u4eba\u56e0\u986f\u5f71\u5291\u5c0e\u81f4\u56b4\u91cd\u6025\u6027\u814e\u50b7\u5bb3\u6216\u5c0e\u81f4\u900f\u6790\u7684\u6a5f\u7387\u9084\u662f\u660e\u986f\u9ad8\u51fa\u5f88\u591a\n": "[E]", "109-75.70 y/o\u5973\u6027\u9ad8\u8840\u58d3\u75c5\u4eba \uff0c\u56e0\u4e2d\u98a8\u9577\u5e74\u81e5\u75c5\u5728\u5e8a\u4e14\u9808\u9760\u9f3b\u80c3\u7ba1\u9935\u98df \uff0c\u5e73\u5e38\u53ea\u6709\u670d\u7528\u964d\u58d3\n\u85e5(Thiazide \u3001Beta/calcium blocer) (\u4ea6\u7121\u5176\u4ed6\u7cbe\u795e\u79d1\u85e5\u7269 )\uff0c\u8fd1\u65e5\u9023\u7e8c\u5929\u6c23\u9ad8\u6eab\u800c\u5bb6\u4e2d\u6c92\u6709\u7a7a\u8abf\u4e14\u901a\u98a8\u6b20\u4f73\n\u4e14\u672a\u88ab\u770b\u8b77\u597d\u597d\u7167\u9867 \uff1b\u5bb6\u5c6c\u63a2\u671b\u624d\u767c\u73fe\u6709\u767c\u71d2 \u3001\u610f\u8b58\u5446\u6eef\u53cd\u61c9\u9072\u920d \u3001\u5fc3\u60b8\u547c\u5438\u6025\u4fc3\u7b49\u800c\u88ab\u9001\u81f3\u6025\u8a3a \uff0c\u521d\u6b65\n\u6aa2\u67e5\uff1a\u809b\u6eab\u651d\u6c0f41 \u5ea6\uff0c\u8840\u58d390/66, \u5fc3\u8df3110 /min, Resp: 22 /min, \u76ae\u819a\u7121\u767c\u6c57 \u3001\u6392\u5c3f\u6e1b\u5c11 \u3002\u521d\u6b65\u4ea6\u7121\u660e\u986f\u611f\n\u67d3\u8de1\u8c61\uff0c\u8acb\u554f\u5176\u53ef\u80fd\u4e4b\u521d\u6b65\u8a3a\u65b7\u70ba \uff1f   \nA.Heat cramps\nB.Heat edema\nC.Heat syncope\nD.Heat stroke\nE.Heat exhaustion\n": "[D]", "109-76.\u5e95\u4e0b\u54ea\u4e00\u500b\u6297\u751f\u7d20\u85e5\u7269\u7576\u4f7f\u7528\u5291\u91cf\u8f03\u5927\u6642\uff0c\u6709\u53ef\u80fd\u7522\u751f\u808c\u8089\u6bd2\u6027\u751a\u81f3\u767c\u751f\u808c\u8089\u6eb6\u89e3\u75c7\u4e4b\u4e0d\u826f\u5f8c\u679c\uff1f    \nA.Erythromycin\nB.Colistin\nC.Quinolone\nD.Daptomycin.\nE.Vancomycin\n": "[D]", "109-77.\u95dc\u65bc\u814e\u81df\u7d30\u80de\u764c\u7684\u81e8\u5e8a\u8868\u73fe\uff0c\u5e95\u4e0b\u4f55\u8005\u70ba\u6b63\u78ba\uff1f    \nA.\u75c5\u4eba\u5e38\u56e0\u660e\u986f\u75c7\u72c0\u5982\u8840\u5c3f\u3001\u8179\u90e8\u816b\u584a\u3001\u75bc\u75db\u800c\u88ab\u6aa2\u67e5\u767c\u73fe\uff0c\u6545\u88ab\u7a31\u70ba\u201cinternist's tumor\u201d\nB.\u82e5\u8f49\u79fb\u81f3\u809d\u81df\u9020\u6210\u809d\u529f\u80fd\u5931\u5e38\uff0c\u5373Stauffer syndrome\nC.\u82e5\u5df2\u6709\u8f49\u79fb\uff0c\u814e\u81df\u5167\u816b\u7624\u6216\u8f49\u79fb\u4ed6\u8655\u816b\u7624\u4e4b\u5207\u9664\u53ef\u4ee5\u5ef6\u9577\u5b58\u6d3b\nD.\u8fd1\u5e74\u65b0\u7684\u751f\u7269\u88fd\u5291\u7121\u6cd5\u6539\u5584\u665a\u671f\u814e\u81df\u7d30\u80de\u764c\u7684\u4e94\u5e74\u5b58\u6d3b\u7387>70%\nE.\u814e\u81df\u7d30\u80de\u764c\u865f\u767c\u5e74\u9f61\u5c64\u70ba\u56db\u5341\u5230\u4e94\u5341\u6b72\u4e4b\u524d\n": "[C]", "109-78.\u9577\u671f\u7cd6\u5c3f\u75c5\u6703\u5f15\u8d77\u591a\u7a2e\u814e\u81df\u75c5\u8b8a \uff0c\u5305\u62ec: \u86cb\u767d\u5c3f \u3001\u814e\u529f\u80fd\u4e0d\u5168\u6216\u814e\u5c0f\u7ba1\u9178\u8840\u75c7 (renal tubular acidosis, \u7c21\n\u7a31RTA)\u3002\u6709\u95dc\u9019\u7a2e\u7cd6\u5c3f\u75c5\u6703\u5f15\u8d77\u7684RTA \uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u6b64\u7a2eRTA\u7d93\u5e38\u51fa\u73fehyperkalemia\nB.\u6700\u5e38\u5f15\u8d77\u7684\u662ftype 2 RTA\nC.\u6b64\u7a2eRTA\u5f15\u8d77\u7684\u9178\u8840\u75c7\uff0c\u901a\u5e38serum pH\u503c\u6703\u5f88\u4f4e\uff0c\u9700\u8981\u975c\u8108\u6ce8\u5c04\u88dc\u5145bicarbonate\nD.\u6b64\u7a2eRTA\u662f\u56e0\u70ba\u8840\u4e2drenin \u8207 aldosterone\u6fc3\u5ea6\u5f88\u9ad8\u6240\u5f15\u8d77\nE.\u6b64\u7a2eRTA\uff0c\u56e0\u70ba\u5c3f\u6db2\u7121\u6cd5\u9178\u5316\uff0c\u901a\u5e38urine pH\u503c\u6703 > 6.5   \n": "[A]", "109-79.\u4e00\u4f4d\u5e74\u8f15\u5973\u6027 \uff0c\u6709\u9811\u56fa\u6027\u9ad8\u8840\u58d3 \uff0c\u9700\u540c\u6642\u4f7f\u7528\u4ee5\u4e0b\u591a\u7a2e\u964d\u8840\u58d3\u85e5\u7269 \u3002\u91ab\u5e2b\u56e0\u61f7\u7591\u662f\u6b21\u767c\u6027\u9ad8\u8840\u58d3 \uff0c\u6b32\u6aa2\n\u67e5renin-angiotensin -aldosterone system \u3002\u6aa2\u67e5\u524d\u53ef\u4ee5\u4fdd\u7559\u4f7f\u7528\u4ee5\u4e0b\u4f55\u7a2e\u85e5\u7269 \uff0c\u800c\u66ab\u505c\u5176\u4ed6\u7684 \uff0c\u624d\u80fd\u5920\u5c40\n\u90e8\u63a7\u5236\u8840\u58d3 \uff0c\u53c8\u4e0d\u81f4\u5f71\u97ff\u6aa2\u67e5\u7d50\u679c\u8207\u5224\u8b80 \uff1f\n(1) Alpha-blocker, \u5982: prazosin\n(2) Beta-blocker, \u5982: propranolol\n(3) Calcium channel blocker, \u5982: nifedipine\n(4) Diuretics, \u5982: aldosterone antagonists\n(5) ACEI (angiotensin- converting enzyme inhibitors ), \u5982: ramipril   \nA.(1)+(3)\nB.(1)+(5)\nC.(1)+(3)+(4)\nD.(2)+(3)+(4)\nE.(2)+(3)+(5)\n": "[A]", "109-80.28\u6b72\u5b55\u5a66 \uff0c\u9ad4\u91cd82KG, \u9577\u671f\u62bd\u83f8 \u3002\u9019\u6b21\u56e0\u61f7\u5b5522\u9031\u51fa\u73fe\u9ad8\u8840\u58d3 \u3001\u4e0b\u80a2\u6c34\u816b(+), \u91ab\u5e2b\u5df2\u7d93\u7d66\n\u4e88methyldopa \uff0c\u4f46\u662f\u8840\u58d3\u9084\u662f\u504f\u9ad8 \uff0c\u4ee5\u4e0b\u85e5\u7269\u4e5f\u53ef\u4ee5\u77ed\u671f\u5408\u4f75\u4f7f\u7528\u5728\u61f7\u5b55\u671f\u9593\u63a7\u5236\u8840\u58d3 \uff0c\u4f55\u8005\u9664\u5916 \uff1f   \nA.Ramipril, an angiotensin-converting enzyme (ACE) inhibitors\nB.hydralazine\nC.Labetalol , a beta-blocker\nD.Clonidine\nE.Sustained-release nifedipine, a calcium channel blocker\n": "[A]", "109-81.\u4e00\u4f4d38\u6b72\u7537\u6027 \uff0cnon-DM, non-obese, \u4e5f\u6c92\u6709\u65e9\u767c\u6027\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u5bb6\u65cf\u53f2 \u3002\u537b\u56e0\u70ba\u6025\u6027\u51a0\u5fc3\u75c7\u63a5\u53d7\u5fc3\u5c0e\u7ba1\n\u624b\u8853\u8207\u653e\u7f6e\u5169\u6839\u652f\u67b6 \u3002\u4f4f\u9662\u5f8c\u6aa2\u67e5\u7d50\u679c\u5982\u4e0b: BP 142 /90 mmHg, HR 86 /min and regular, pedal edema \n(2+), t-Chol 400 mg /dL, LDL 285 mg /dL, albumin 2.8 g/dL, AST 40 IU /L, ALT 38 IU /L, creatinine 1.2 \nmg/dL, HbA1C 6.8%, WBC 7400 /mm3\u3002\u70ba\u4e86\u9032\u4e00\u6b65\u63a2\u67e5\u75c5\u56e0 \uff0c\u60a8\u6703\u512a\u5148\u5b89\u6392\u4ee5\u4e0b\u54ea\u7a2e\u6aa2\u67e5 \uff1f   \nA.Serum protein electrophoresis\nB.Urine protein electrophoresis\nC.Urine albumin/creatinine ratio\nD.Urine total protein/creatinine ratio\nE.Hs-CRP, ANA (antinuclear antibody)\n": "[D]", "109-82.\u4e00\u4f4d24\u6b72\u5973\u6027 \uff0c\u6709\u591a\u5e74SLE (Systemic Lupus Erythematosus )\u75c5\u53f2\uff0c\u4f46\u6c92\u6709\u898f\u5247\u8ffd\u8e64\u8207\u6cbb\u7642 \u3002\u6700\u8fd1\u5169\u9031\u51fa\n\u73fe\u75b2\u5026\u3001\u4e0b\u80a2\u6c34\u816b \uff0c\u9ad4\u91cd\u589e\u52a0\u8fd1 7\u516c\u65a4\u800c\u4e14\u611f\u89ba\u5c3f\u91cf\u6e1b\u5c11 \u3002\u4f4f\u9662\u5f8c\u62bd\u8840\u6aa2\u67e5: BUN 74 mg /dL\uff0ccreatinine \n2.8 mg/dL, urine protein (4+)\uff0c\u8a3a\u65b7\u70ba\u6025\u6027\u814e\u708e (acute glomerulonephritis, AGN )\uff0c\u5b89\u6392\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u751f\n\u6aa2(renal biopsy )\uff0c\u4ee5\u4e0b\u75c5\u7406\u8b8a\u5316 \uff0c\u4f55\u8005\u6700\u4e0d\u53ef\u80fd \uff1f   \nA.Diffuse proliferative nephritis with diffuse subendothelial deposit\nB.Membranous glomerulonephritis with subepithelial immune complex deposit\nC.Global endocapillary proliferation, with crescent formation\nD.Focal segmental glomerulosclerosis\nE.Glomerular necrotizing lesion of renal arteriole\n": "[D]", "109-83.\u4e00\u4f4d65\u6b72\u5973\u6027 \uff0c\u56e0\u5c3f\u6bd2\u75c7 \uff0c9\u500b\u6708\u524d\u958b\u59cb\u9577\u671f\u63a5\u53d7\u8179\u819c\u900f\u6790 (CAPD)\u6cbb\u7642\u3002\u6700\u8fd1\u5169\u5929\u56e0\u70ba\u767c\u71d2 \u3001\u8179\u75db\uff0c\u900f\u6790\n\u5f15\u6d41\u6db2(effluent)\u6df7\u6fc1\u800c\u88ab\u9001\u81f3\u6025\u8a3a \u3002\u8eab\u9ad4\u6aa2\u67e5: \u9ad4\u6eab37 .6\u2103, \u8179\u90e8tenderness (+). \u60a8\u6703\u512a\u5148\u5b89\u6392\u505a\u4ee5\u4e0b\u4f55\u7a2e\n\u8a55\u4f30(initial evaluation )\uff1f      \nA.Abdominal CT\nB.PD effluent: for culture, cytology and Gram staining\nC.\u7167\u6703\u5916\u79d1\uff0c\u66f4\u63db PD catheter\nD.Empirical antibiotics and stopping PD, shift to HD\nE.\u6e2c\u91cf CAPD Kt/V, \u4e26\u5b89\u6392\u8179\u819c\u529f\u80fd\u6e2c\u8a66 (peritoneal equilibration test, PET)\n": "[B]", "109-84.\u4e00\u4f4d58\u6b72\u7537\u6027 \uff0c\u904e\u53bb\u75c5\u53f2\u6709\u591a\u5e74\u814e\u75c5\u5fb5\u5019\u7fa4 (nephrotic syndrome )\uff0c\u5f8c\u4f86\u9032\u5c55\u6210\u5c3f\u6bd2\u75c7 \uff0c\u4e09\u5e74\u524d\u958b\u59cb\u6bcf\u9031\n\u4e09\u6b21\u63a5\u53d7\u8840\u6db2\u900f\u6790\u6cbb\u7642 (hemodialysis )\u3002\u534a\u5e74\u524d\u56e0\u51a0\u5fc3\u75c7 \uff0c\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u624b\u8853\u4e26\u653e\u7f6e\u8840\u7ba1\u5167\u652f\u67b6 \u3002\u6700\u8fd1\u4e00\u6b21\n\u7684\u8eab\u9ad4\u6aa2\u67e5\u6578\u64da\u5982\u4e0b: BUN 138 mg /dL, creatinine 13 .5 mg/dL, K 6.4 mEq/L, P 8.7 mg/dL, albumin 4.6 \ng/dL, Hb 9.6 g/dL, ferritin 364 mg /dL. \u4e0b\u80a2\u6709\u8f15\u5ea6\u6c34\u816b(+). \u6bcf\u6b21\u900f\u6790 4\u5c0f\u6642\u671f\u9593\u5e73\u5747\u9700\u812b\u6c344 KG  \u4ee5\u4e0b\u5e7e\u9805\n\u8a3a\u65b7\uff0c\u4f55\u8005\u8f03\u4e0d\u5408\u9069 \uff1f   \nA.Dialysis inadequacy\nB.Protein energy wasting (PEW) and ongoing nephrotic syndrome\nC.Excessive protein intake\nD.Volume overload\nE.Renal anemia\n": "[B]", "109-85.\u4e00\u4f4d52\u6b72\u591a\u5e74\u9ad8\u8840\u58d3\u7684\u75c5\u4eba \uff0c\u9019\u6b21\u56e0malignant hypertension (systolic BP 210 mmHg )\u88ab\u9001\u81f3\u6025\u8a3a \uff0c\u8eab\u9ad4\n\u6aa2\u67e5: edema (3+), creatinine 1.4 mg/dL\u3002\u75c5\u4eba\u63a5\u53d7\u814e\u81df\u751f\u6aa2 (renal biopsy )\uff0c\u4ee5\u4e0b\u81e8\u5e8a\u8207\u75c5\u7406\u8b8a\u5316\u6558\n\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba \uff1f\n(1) \u814e\u81df\u75c5\u7406\u5207\u7247: Fibrinoid necrosis and medial hypertrophy of small vessels\n(2) \u814e\u81df\u75c5\u7406\u5207\u7247: mesangial proliferation and cellular crescent formation\n(3) \u814e\u81df\u75c5\u7406\u5207\u7247: global sclerosis of glomerulus with pericapillary fibrosis\n(4) \u814e\u81df\u75c5\u7406\u5207\u7247: IgA or IgM immune deposition at glomerular area\n(5) \u8840\u6db2\u6aa2\u67e5: hypocomplementemia (low serum C 3, low serum C 4)\n(6) Urinalysis \u6709heavy proteinuria, \u4f46\u5f88\u5c11\u6709hematuria   \nA.(1)+(3)+(6)\nB.(1)+(2)+(3)+(4)+(6)\nC.(1)+(2)+(5)+(6)\nD.(1)+(4)+(5)\nE.(1)+(2)+(3)+(4)+(5)\n": "[A]", "109-86.\u4e00\u4f4d72\u6b72\u5973\u6027 \uff0c\u8fd1\u4f86\u56e0\u53cd\u61c9\u8b8a\u9072\u920d \u3001\u55dc\u7761\uff0c\u88ab\u5bb6\u4eba\u9001\u81f3\u9580\u8a3a\u5c31\u91ab \u3002\u8eab\u9ad4\u6aa2\u67e5: BP 138 /84 mmHg, edema \n(-), \u5fc3\u640f88 /min (\u4e0d\u898f\u5247\uff0c\u6709atrial fibrillation )\u3002\u6aa2\u8996\u9577\u671f\u7528\u85e5\u6e05\u55ae\u6709 \uff1aamiodarone, carbamazepine \n(selective serotonin reuptake inhibitors ), haloperidol (a antipsychotics )\u3002\u8840\u6db2\u6aa2\u67e5 \uff1aNa 118 mEq /L, K \n3.9 mEq/L, creatinine 0.8 mg/dL, glucose 118 mg /dL, albumin 3.4 g/dL, globulin 3.7 g/dL, t-Chol 164 \nmg/dL, TG 180 mg /d, serum osmolality 250 mOsm /kg\u3002\u5c3f\u6db2\u6aa2\u67e5 \uff1aNa 34 mEq /L, K 4.0 mEq/L, urine \nosmolality 436 mOsm /kg\u3002\u4ee5\u4e0b\u8a3a\u65b7\u8207\u6cbb\u7642\u7684\u6558\u8ff0 \uff0c\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u8a3a\u65b7\u7b26\u5408pseudo -hyponatremia\n(2) \u8a3a\u65b7\u7b26\u5408 SIADH (syndrome of inappropriate antidiuretic hormone secretion )\n(3) \u8a3a\u65b7\u7b26\u5408 Reset Osmostat\n(4) \u53ef\u80fd\u8207\u76ee\u524d\u7528\u85e5amiodarone, carbamazepine\u6216 haloperidol\u6709\u95dc\n(5) \u7531\u8840\u6db2\u8207\u5c3f\u6db2\u7684Na, K, \u53ca osmolality \u6578\u503c \uff0c\u53ef\u80fd\u8207\u9577\u671f\u81ea\u884c\u4f7f\u7528\u5229\u5c3f\u5291\u6709\u95dc\n(6) \u6cbb\u7642\uff1a\u5efa\u8b70\u9069\u91cf\u9650\u6c34 800 -1000 mL /day\n(7) \u6cbb\u7642\uff1a\u5efa\u8b70diuretics + 0.9% saline (NaCl) solution infusion   \nA.(1)+(4)+(7)   \nB.(2)+(4)+(6)\nC.(3)+(4)+(5)+(6)\nD.(1)+(5)+(6)\nE.(2)+(5)+(7)\n": "[B]", "109-87.53\u6b72\u7537\u6027 \uff0c\u904e\u53bb\u6709\u9ad8\u8840\u58d3\u8207 C\u578b\u809d\u708e\u75c5\u53f2 \u3002\u6700\u8fd1\u4e09\u500b\u6708\u4f86 \uff0c\u51fa\u73fe\u86cb\u767d\u5c3f \uff0c\u811b\u524d\u8207\u8db3\u8e1d\u8f15\u5ea6\u6c34\u816b \uff0c\u9ad4\u91cd\u7565\u589e\n\u52a0\u7d043\u516c\u65a4\u3002\u62bd\u8840\u6aa2\u67e5: \u6709\u8840\u6e05\u88dc\u9ad4 (complement, C3\u8207C4) \u504f\u4f4e\u60c5\u5f62 \u3002\u56e0\u70ba\u4e0d\u660e\u539f\u56e0\u814e\u75c5 \uff0c\u5b89\u6392\u75c5\u4eba\u63a5\u53d7\n\u814e\u81df\u751f\u6aa2 (renal biopsy )\u3002\u4ee5\u4e0b\u75c5\u7406\u8b8a\u5316 \uff0c\u4f55\u8005\u6700\u53ef\u80fd \uff1f   \nA.Cryoglobulinemia, especially type II\nB.Polyarteritis nodosa\nC.IgA nephropathy or idiopathic chronic interstitial nephritis\nD.Membranous nephropathy\nE.Henoch-Sch\u00f6nlein purpura (HSP)\n": "[A]", "109-88.ACEI/ARB\u985e\u85e5\u7269 \uff0c\u5728\u81e8\u5e8a\u4e0a\u5177\u6709\u4fdd\u8b77\u814e\u81df\u8207\u6cbb\u7642\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u6548\u679c \u3002\u5728COVID-19\u75ab\u60c5\u671f\u9593 \uff0c\u7531\u6d41\u884c\u75c5\n\u5b78\u8cc7\u6599\u767c\u73fe \uff1a\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u53ca\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u4eba \uff0c\u662f\u5bb9\u6613\u611f\u67d3COVID -19\u7684\u9ad8\u5371\u96aa\u7fa4 \uff0c\u800c\u9019\u4e09\u985e\u75c5\u4eba\u6070\u597d\n\u4e5f\u662f\u6700\u5e38\u4e14\u9577\u671f\u4f7f\u7528ACEI /ARB\u985e\u85e5\u7269\u7684\u65cf\u7fa4 \u3002\u91dd\u5c0d\uff1a\u300cCOVID -19\u75ab\u60c5\u671f\u9593 \uff0c\u662f\u5426\u61c9\u505c\u7528ACEI /ARB\u985e\u85e5\n\u7269\uff1f\u300d\uff0c \u8acb\u9078\u51fa\u76ee\u524d\u8f03\u88ab\u63a5\u53d7\u7684\u5171\u8b58\u89c0\u9ede \uff1f   \nA.COVID-19 virus\u6703\u85c9\u7531\u7d50\u5408\u4eba\u985e\u7d30\u80de\u8868\u9762\u7684angiotensin receptor\u800c\u611f\u67d3\u7d30\u80de \u3002ACEI/ARB\u985e\u85e5\u7269\u6703\u589e\n\u52a0angiotensin receptor \uff0c\u6240\u4ee5\u6703\u589e\u52a0\u611f\u67d3COVID -19\u7684\u98a8\u96aa \uff0c\u56e0\u6b64\u9084\u662f\u61c9\u8a72\u5168\u9762\u4f7f\u7528\u6bd4\u8f03\u597d\nB.\u7e7c\u7e8c\u4f7f\u7528ACEI /ARB\u985e\u85e5\u7269 \uff0c\u7684\u78ba\u6703\u589e\u52a0\u611f\u67d3COVID -19\u7684\u98a8\u96aa\u8207\u75be\u75c5\u56b4\u91cd\u5ea6 \uff0c\u4f46\u662f\u4e0d\u6703\u589e\u52a0\u6b7b\u4ea1\n\u7387\u3001\u56e0\u6b64\u5df2\u7d93\u611f\u67d3COVID -19\u7684\u75c5\u4eba\u518d\u505c\u7528\u5c31\u597d\nC.\u5982\u679c\u662f\u5973\u6027\u3001\u5e74\u9f61\u5927\u65bc65\u6b72\u3001\u6709\u5fc3\u81df\u8870\u7aed(CHF)\u7684\u75c5\u4eba\uff0c\u61c9\u8a72\u7acb\u5373\u505c\u6b62\u4f7f\u7528\nD.\u7d9c\u5408\u6240\u6709\u89c0\u5bdf\u578b\u7814\u7a76\u7684\u8cc7\u6599\u5206\u6790\uff0c\u8fc4\u4eca\u4ecd\u652f\u6301ACEI/ARB\u985e\u85e5\u7269\u53ef\u4ee5\u7e7c\u7e8c\u4f7f\u7528\uff0c\u7121\u9808\u505c\u7528\nE.\u904e\u53bb\u672a\u66fe\u4f7f\u7528ACEI /ARB\u985e\u85e5\u7269\u7684\u75c5\u4eba \uff0c\u5982\u679c\u611f\u67d3COVID -19\uff0c\u57fa\u65bc\u4fdd\u8b77\u814e\u81df\u8207\u5fc3\u8840\u7ba1 \uff0c\u5efa\u8b70\u91ab\u5e2b\u61c9\n\u8a72\u65b0\u958b\u7acb\u6b64\u985e\u85e5\u7269 \uff0c\u9810\u9632\u5668\u5b98\u8870\u7aed\n": "[D]", "110-55.Statement on management strategy for patients with autosomal dominant polycystic kidney disease \n(ADPKD), which is incorrect :   \nA.Dietary salt restriction may be beneficial in the management of ADPKD\u3002\nB.Angiotensin -converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are the \nfirst-line antihypertensive drugs in ADPKD \u3002\nC.Nonsteroidal anti -inflammatory drugs (NSAIDs) is more effective and safe than acetaminophen or \ntramadol for cystic pain relief in ADPKD patients \u3002   \nD.Oral tolvaptan can slow the increase in total kidney volume and the decline in kidney function of \nADPKD patients \u3002\nE.ADPKD patients can be a recipient for renal transplantation\u3002\n": "[C]", "110-56.A 54 y/o diabetic female patient with 4 days of fever, respiratory symptoms and dyspnea. At emergency \nservice, physical examination revealed postural hypotension, tachycardia, and Kussmaul respiration. \nLaboratory tests were: blood glucose level of 385 mg /dL. The arterial pH is 7.35, pCO\u2082 is 22 mm Hg, \npO\u2082 86 mmHg, HCO \u2083\u207b 14 mEq /L. Serum electrolyte values were: Na 130 meq /L; K 5.1 meq/L; Cl 96 \nmeq/L; Chest x -ray film indicated consolidation of bilateral lower lobe. \nWhich of the following statements is most likely to be true ?\n(1)The patient has respiratory acidosis, possibly related to pneumonia\n(2)The patient has metabolic acidosis, possibly related to diabetes\n(3)The patient has respiratory alkalosis, possibly related to pneumonia\n(4)The anion gap is still within normal range\n(5)Be cautious with hyperphospatemia during combined insulin and glucose therapy   \nA.(1)+(2)+(5)\u3002\nB.(1)+(2)+(4)+(5)\u3002\nC.(2)+(3)+(5)\u3002\nD.(2)+(3)\u3002\nE.(2)+(3)+(4)\u3002\n": "[D]", "110-57.A middle aged woman was referred to renal clinic for evaluation of her renal disorder. She had \nintermittent pre -tibial swelling for almost 3 months. She has mild hypertension, but no diabetes. Neither \nviral hepatitis B nor C history. Laboratory tests were: albumin 3.1 g/dL, creatinine 1.7 mg/dL, Both \nserum complement levels (C3 and C4) are low, with a particularly depressed C4 compared with C 3.  \nWhich of the following should be considered ?   \nA.Cryoglobulinemia\u3002\nB.Post-streptococcal glomerulonephritis\u3002\nC.Membranoproliferative glomerulonephritis\u3002\nD.Lupus nephritis, stage III or V\u3002\nE.Infectious endocarditis or shunt nephritis\u3002\n": "[A]", "110-58.Struvite stones occurs in patients of repeated urinary tract infections (UTI) from bacteria that produce \nthe enzyme urease, including both gram -positive and gram -negative species.  \nWhich is the least possible micropathogen causing struvite stone and repeated UTI ?   \nA.Klebsiella spp\u3002\nB.Escherichia coli\u3002\nC.Mycoplasma spp\u3002\nD.Staphylococcus epidermidis\u3002\nE.Proteus\u3002   \n": "[B]", "110-59.Which are correct statements regarding hyperuricemia and related nephropathy? \n(1)The renal tubular transporters responsible for determining how much of the filtered uric acid is \nactually excreted are located in the distal nephron\n(2)Renal clearance of uric acid can be inhibited by the angiotensin -converting -enzyme inhibitors or by \n\u03b2-Blockers .\n(3)Initiation of colchicine can induce acute flares of gout\n(4)Initiation of allopurinol or febuxostat can induce acute flares of gout\n(5)Routine use of allopurinol (100-300 mg/day) in patients with stage 3-4 CKD can slow kidney disease \nprogression   \nA.(1)+(2)+(4)+(5)\u3002\nB.(1)+(4)+(5)\u3002\nC.(2)+(3)\u3002\nD.(2)+(4)\u3002\nE.(2)+(4)+(5)\u3002\n": "[D]", "110-60.A 26-year-old girl of type I diabetes had poor appetite and body weight loss for 3 kg (6%) in recent one \nmonth. After admission, she received partial parenteral nutrition due to anorexia and poor oral intake. \nHypophosphatemia (0.8 mg/dL) was notcied on the third day of admission . \nThe most likely mechanism for her acute hypophosphatemia is :   \nA.Acute stage of diabetic ketoacidosis\u3002\nB.Hungry bone syndrome\u3002\nC.Primary hypoparathyroidism\u3002\nD.Renal phosphate wasting\u3002\nE.Shift of phosphorus into intracellular stores\u3002\n": "[E]", "110-61.A 50-year-old male visited outpatient clinic due to difficult -to-control hypertension. After initial work up, \nhypokalemic hypertensive disorder was impressed, Further laboratory evaluation of adrenal hormones \nincluding plasma renin, aldosterone, cortisol, and androgen levels were arranged to distinguish among \nspecific diagnoses. The results are: high renin level, high aldosterone level, an aldosterone -to-renin ratio \nof 10 : 1 ; and a normal serum cortisol level \nWhich is the most possible diagnosis ?   \nA.ACTH-secreting tumor\u3002\nB.Bartter syndrome\u3002\nC.Liddle syndrome\u3002\nD.Primary hyperaldosteronism\u3002\nE.Unilateral renal artery stenosis\u3002\n": "[E]", "110-62.Laboratory indices for differentiation of prerenal versus Intrinsic renal azotemia. \nWhich of the followings prefers pre -renal azotemia ?   \nA.High urine Na concentration >20 (mmol/L)\u3002\nB.High Urine specific gravity >1.020\u3002\nC.Low urine osmolality <300 (mosmol/kg H\u2082O)\u3002\nD.High renal failure index (UNa/UCr/PCr)  >1\u3002   \nE.Urinary sediment analysis reveals a lot of muddy -brown granular casts and casts containing tubular \nepithelial cells \u3002\n": "[B]", "110-63.\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u6703\u9020\u6210\u9ad8\u8840\u78f7\u75c7 \uff08Hyperphosphatemia \uff09? (1)\u7dad\u751f\u7d20D\u4e2d\u6bd2 (2)\u4ee3\u8b1d\u6027\u9e7c\u4e2d\u6bd2 (3)\u539f\u767c\u6027\u526f\u7532\n\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032 (4)\u56b4\u91cd\u4f4e\u8840\u9382\u75c7 \uff08Severe hypomagnesemia )\uff09 (5)\u816b\u7624\u6eb6\u89e3\u75c7\u5019\u7fa4 (tumor lysis syndrome, \nTLS)   \nA.(1)+(2)+(4)\u3002\nB.(1)+(3)+(5)\u3002\nC.(2)+(3)+(4)\u3002\nD.(2)+(3)+(5)\u3002\nE.(1)+(4)+(5)\u3002\n": "[E]", "110-64.\u4e00\u4f4d74\u6b72\u7cd6\u5c3f\u75c5\u5973\u6027\u60a3\u8005\u5408\u4f75\u6162\u6027\u814e\u81df\u75c5\u7b2c\u56db\u671f \uff0c\u9577\u671f\u670d\u7528\u53e3\u670d\u964d\u8840\u7cd6\u7528\u85e5\u642d\u914d\u80f0\u5cf6\u7d20\u63a7\u5236 \uff0c\u7531\u65bc\u610f\u8b58\u4e0d\n\u6e05\u9192\u88ab\u9001\u5230\u6025\u8a3a\u5c31\u91ab \uff0c\u7d93\u6aa2\u67e5\u6709\u4ee3\u8b1d\u6027\u9178\u4e2d\u6bd2 (metabolic acidosis )\uff0c\u5176\u9670\u96e2\u5b50\u9699 (anion gap )\u70ba26 \nmmol/L\uff0c\u7d93\u7a4d\u6975\u4f7f\u7528\u78b3\u9178\u6c2b\u9209 \uff08sodium bicarbonate )\u77ef\u6b63\uff0c\u4ecd\u7121\u6cd5\u63a7\u6b63 \uff0c\u4e0b\u5217\u4f55\u7a2e\u7528\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u53ef\n\u80fd\u70ba\u8a98\u767c\u7684\u539f\u56e0 \uff1f   \nA.\u4e8c\u80bd\u57fa\u80bd\u9176-4\u6291\u5236\u5291\uff08Dipeptidyl peptidase-4 inhibitor\uff09\u3002\nB.\u904e\u6c27\u5316\u7269\u9176\u9ad4\u589e\u6b96\u7269\u6d3b\u5316\u53d7\u9ad4\u03b3\uff08PPAR-\u03b3\uff09\u3002\nC.\u03b1-\u8461\u8404\u7cd6\u82f7\u9176\u6291\u5236\u5291(\u03b1-glucosidase inhibitor)\u3002\nD.\u4e8c\u7532\u96d9\u80cd\u985e\u964d\u8840\u7cd6\u85e5\u7269 (Metformin)\u3002\nE.\u78fa\u91af\u57fa\u5c3f\u7d20(sulfonylurea)\u3002\n": "[D]", "110-65.\u4e00\u4f4d60\u6b72\u7537\u6027\u9ad8\u8840\u58d3\u80a5\u80d6\u60a3\u8005 \uff0c\u8fd1\u5e7e\u500b\u6708\u8840\u58d3\u5347\u9ad8\u4ee5 4\u7a2e\u964d\u58d3\u5291\u63a7\u5236 \uff0c\u8840\u58d3\u70ba166 /92 mm Hg \u3002\u75c5\u60a3\u7121\u5bb6\n\u65cf\u9ad8\u8840\u58d3\u75c5\u53f2 \uff0c\u4e00\u5e74\u524d\u6aa2\u67e5\u96d9\u5074\u814e\u5728\u5927\u5c0f\u4e00\u81f4\u7d0411cm \uff0c\u814e\u81df\u529f\u80fd\u6b63\u5e38 \u3002\u5b89\u6392\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u5f8c\u767c\u73fe: \u53f3\n\u814e10.6 cm, \u5de6\u814e 8.6 cm\uff0c\u8840\u6db2\u751f\u5316\u6aa2\u9a57\u986f\u793a \uff1a\u808c\u9178\u9150(Creatinine) 2.0 mg/dL\u3002\u4ee5\u4e0b\u6558\u8ff0 \uff0c\u4f55\u8005\u6700\u6b63\u78ba ?   \nA.9\u6210\u4ee5\u4e0a\u60a3\u8005\u5728\u7406\u5b78\u6aa2\u67e5\u6709\u8179\u90e8\u96dc\u97f3(bruit)\u4e14\u6aa2\u67e5\u8840\u9240[K]\u901a\u5e38\u6703\u5347\u9ad8\u3002\nB.\u5982\u679c\u8179\u90e8\u96dc\u97f3\u504f\u5074\u5316\u6216\u5ef6\u4f38\u5230\u6574\u500b\u6536\u7e2e\u671f\u5230\u8212\u5f35\u671f\uff0c\u5247\u5b83\u66f4\u6709\u53ef\u80fd\u5728\u8840\u6d41\u52d5\u529b\u5b78\u4e0a\u5177\u6709\u986f\u8457\u610f\u7fa9\u3002\nC.\u7528\u6838\u78c1\u5171\u632f\u8840\u7ba1\u651d\u5f71 (MRA)\u5f71\u50cf\u6aa2\u67e5 \uff0c\u5982\u679c\u767c\u73ferenal artery stenosis \uff0c\u901a\u5e38\u4ee5fibromuscular \ndysplasia (FMD)\u578b\u6700\u5e38\u898b \u3002\nD.\u964d\u58d3\u5291\u4e2d\uff0c\u4ee5ACEI \u6216ARB\u985e\u70ba\u9996\u9078\u7528\u85e5\u3002\nE.\u9ad8\u8840\u58d3\u7684\u539f\u56e0\u5c6c\u5148\u5929\u6027\u7570\u5e38 \uff0c\u8207\u8840\u6e05\u81bd\u56fa\u9187\u8f03\u7121\u95dc\u4fc2 \uff0c\u7121\u9700\u4f7f\u7528HMG -CoA \u9084\u539f\u9176\u6291\u5236\u5291( statins )\u63a7\n\u5236\u81bd\u56fa\u9187 \u3002\n": "[B]", "110-66.\u6709\u95dc\u6162\u6027\u9593\u8cea\u6027\u814e\u81df\u75c5\u5e38\u898b\u4e4b\u81e8\u5e8a\u8868\u73fe \uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba (\u61c9\u9078\u51fa\u6240\u6709\u7b54\u6848) ( 1)\u8303\u5eb7\u5c3c\u6c0f\u75c7\u5019\u7fa4 (Fanconi \nsyndrome)  ( 2)\u5be1\u5c3f\uff08Oliguria\uff09\u8207\u7b49\u5f35\u5c3f \uff08isosthenuria \uff09(3)\u8ca7\u8840 (4)\u9ad8\u9670\u96e2\u5b50\u9593\u9699\u4ee3\u8b1d\u6027\u9178\u4e2d\u6bd2\u5408\u4f75\u4f4e\u8840\n\u9240 (5)\u814e\u75c5\u75c7\u5019\u7fa4   \nA.(1)+(4)+(5)\u3002\nB.(1)+(2)+(3)\u3002\nC.(2)+(3)+(4)\u3002\nD.(4)+(5)\u3002\nE.(1)+(3)\u3002\n": "[E]", "110-67.\u4e00\u540d45 \u6b72\u5973\u6027\u60a3\u6709\u7cd6\u5c3f\u75c5 \uff0c\u56e0\u660e\u986f\u75b2\u52de\u800c\u5c31\u8a3a \u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a \uff1a\u8840\u6e05\u5c3f\u7d20\u6c2e (BUN) \u70ba 100 mg /dL\uff0c\u8840\u6e05\n\u808c\u9150\u9178\u70ba 2.5 mg/dL\u3002 \u8a55\u4f30\u9700\u8981\u54ea\u4e9b\u521d\u6b65\u8655\u7f6e \uff1f   \nA.\u5b89\u6392\u814e\u81df\u8d85\u97f3\u6ce2\u53ca\u814e\u81df\u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u3002   \nB.\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57\u3002\nC.\u8f49\u4ecb\u5230\u904b\u52d5\u5fa9\u5065\u4e2d\u5fc3\u935b\u934a\u3002\nD.\u8840\u7d05\u7d20\uff08Hb\uff09\u53ca\u5927\u4fbf\u6f5b\u8840\u6aa2\u67e5\u3002\nE.\u9650\u5236\u75c5\u53cb\u86cb\u767d\u651d\u53d6\u3002\n": "[D]", "110-68.\u4e00\u540d 23 \u6b72\u7684\u7537\u6027\u7814\u7a76\u751f \uff0c\u56e0\u4e00\u6b21\u7121\u75db\u6027\u660e\u986f\u8840\u5c3f\u7531\u5b78\u6821\u4fdd\u5065\u4e2d\u5fc3\u8f49\u8a3a\u5230\u814e\u81df\u79d1\u9580\u8a3a \u3002\u4ed6\u8eab\u9ad4\u5065\u5eb7 \uff0c\u6c92\u6709\n\u660e\u986f\u7684\u5bb6\u65cf\u53f2 \u3002\u8eab\u9ad4\u8a3a\u5bdf\u6642\u8840\u58d3\u6b63\u5e38 \uff0c\u7121\u5176\u4ed6\u7570\u5e38 \u3002\u8ffd\u8e64\u5be6\u9a57\u5ba4\u6aa2\u67e5\u986f\u793a\u751f\u5316\u53ca\u8840\u6db2\u5b78\u6b63\u5e38 \u3001\u814e\u529f\u80fd\u6aa2\u67e5\n\u6b63\u5e38\uff0c\u4ee5\u53ca\u5c3f\u57f9\u990a\u9670\u6027 \u3002\u8840\u6e05\u514d\u75ab\u5b78\u6aa2\u6e2c\u5305\u62ec\u88dc\u9ad4 \u3001\u6297\u6838\u6297\u9ad4 (ANA)\u3001\u6297\u4e2d\u6027\u7c92\u7d30\u80de\u80de\u6f3f\u6297\u9ad4 (ANCA)\u548c\n\u809d\u708e\u6aa2\u6e2c\u5747\u5448\u9670\u6027 \u3002\u5c3f\u6db2\u8a66\u7d19\u6aa2\u67e5\u986f\u793a :\u6f5b\u8840(2+)\u548c\u86cb\u767d\u8cea(+) \uff0c\u986f\u5fae\u93e1\u6aa2\u67e5\u4e2d\u6709\u5c11\u8a31\u578b\u8b8aRBC\u4f46\u4e26\u7121RBC \ncast\u3002\u4ed6\u7684\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u662f\u6b63\u5e38\u7684 \u30021 \u9031\u5f8c\u91cd\u8907\u9ad4\u6aa2\u548c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u986f\u793a\u5c3f\u6db2\u6f5b\u8840 1+ \u548c\u7d05\u8840\u7403\u7d30\n\u80de5\u81f38\u500b\u7d05\u7d30\u80de\u548c\u5fae\u91cf\u5c3f\u86cb\u767d \uff0c\u5b9a\u91cf\u70ba 150 \u6beb\u514b /\u5929\u3002\u4e0b\u5217\u4f55\u8005\u662f\u6700\u9069\u7576\u5efa\u8b70   \nA.\u7e7c\u7e8c\u8ffd\u8e64\u89c0\u5bdf\u3002\nB.\u814e\u81df\u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u3002\nC.\u5c0d\u60a3\u8005\u53ca\u5176\u5bb6\u5c6c\u9032\u884c\u57fa\u56e0\u6aa2\u6e2c\u3002\nD.\u958b\u59cb\u985e\u56fa\u9187\u7d93\u9a57\u6027\u6cbb\u7642\u3002\nE.\u6ccc\u5c3f\u79d1\u8f49\u8a3a\u67e5\u660e\u539f\u56e0\u3002\n": "[A]", "110-69.\u4e00\u540d68\u6b72\u60a3\u6709\u814e\u75c5\u75c7\u5019\u7fa4\u5973\u6027 \uff08\u5c3f\u86cb\u767d 3.5 g/\u5929\uff0c\u814e\u529f\u80fd\u6b63\u5e38 \uff0c\u8840\u6e05\u767d\u86cb\u767d 2.2 g/dL\uff09\u6700\u8fd1\u7d93\u814e\u81df\u5207\u7247\u8a3a\n\u65b7\u70ba\u819c\u6027\u814e\u75c5\u8b8a \uff08membranous nephropathy\uff09\u3002 \u8840\u6e05PLA 2R\u6aa2\u6e2c\u548c\u814e\u7d44\u7e54\u67d3\u8272\u5448\u5747\u70ba\u9670\u6027 \u3002\u4ee5\u4e0b\u76f8\u95dc\u7684\n\u6558\u8ff0\u4f55\u8005 \u300c\u932f\u8aa4\u300d\uff1a   \nA.\u9032\u4e00\u6b65\u8abf\u67e5\u61c9\u5305\u62ec\u60e1\u6027\u816b\u7624\u6aa2\u67e5\u3002\nB.\u60a3\u8005\u61c9\u958b\u59cb\u4ea4\u66ff\u4f7f\u7528\u74b0\u78f7\u91af\u80fa\uff08cyclophosphamide\uff09\u548c\u985e\u56fa\u9187\u3002\nC.\u767c\u751f\u8840\u6813\u4e8b\u4ef6\u7684\u98a8\u96aa\u5f88\u5927\uff0c\u51fa\u8840\u98a8\u96aa\u4f4e\u7684\u60a3\u8005\u53ef\u4ee5\u8003\u616e\u9810\u9632\u6027\u6297\u51dd\u5291\u3002\nD.\u5979\u61c9\u8a72\u63a5\u53d7 B\u578b\u809d\u708e\u7be9\u67e5\uff0c\u5df2\u77e5 B\u578b\u809d\u708e\u8207\u819c\u6027\u814e\u75c5\u6709\u95dc\u3002\nE.\u5982\u679c\u7d93\u904e 6 \u500b\u6708\u5f8c\u5176\u86cb\u767d\u5c3f\u4ecd\u4fdd\u6301\u76ee\u524d\u72c0\u6cc1\uff0c\u5979\u7684\u814e\u81df\u529f\u80fd\u53ef\u80fd\u51fa\u73fe\u9032\u884c\u6027\u814e\u75c5\u7684\u98a8\u96aa\u3002\n": "[B]", "110-70.\u814e\u524d\u6027\u6c2e\u8840\u75c7 \uff08Prerenal azotemia \uff09\u7684\u8a3a\u65b7\u5fc5\u9808\u7d93\u7531\u9069\u7576\u7684\u75c5\u53f2\u8a62\u554f\u548c\u7406\u5b78\u6aa2\u67e5\u5f8c\u78ba\u7acb\uff0c \u4e0b\u5217\u5c3f\u6db2\u548c\u8840\n\u6e05\u6aa2\u9a57\u53ef\u7528\u65bc\u5e6b\u52a9\u78ba\u8a8d\u814e\u524d\u6027\u6c2e\u8840\u75c7\u7684\u8a3a\u65b7 \uff1f   \nA.\u5c3f\u7d20\u6c2e\uff08BUN\uff09\u8207\u808c\u9178\u9150\uff08creatinine\uff09\u7684\u6bd4\u503c\u5927\u65bc 20\u3002\nB.\u9209\u6392\u6cc4\u5206\u7387\uff08fractional excretion of sodium\uff0cFeNa\uff09\u5c0f\u65bc 1%\u3002\nC.\u5c3f\u6db2\u6ef2\u900f\u58d3\uff08urine osmolality\uff09\u5927\u65bc500 (mOsm/kg H2O)\u3002\nD.\u5c3f\u6db2\u9209\u6fc3\u5ea6\u5927\u65bc 20 (mEq/L)\u3002\nE.\u5c3f\u6db2\u6bd4\u91cd\u5927\u65bc1.020\u3002\n": "[B]", "110-71.\u6025\u6027\u814e\u640d\u50b7\u5f8c\u9700\u8981\u7dca\u6025\u900f\u6790\u662f\u56b4\u91cd\u814e\u81df\u640d\u50b7\u7684\u6307\u6a19 \uff0c\u60a3\u8005\u7684\u5408\u4f75\u75c7\u548c\u6b7b\u4ea1\u7387\u589e\u52a0 \u3002\u95dc\u65bc\u6025\u6027\u814e\u640d\u50b7\u7684\u900f\u6790\n\u6cbb\u7642\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u662f\u6b63\u78ba\u7684 \uff1f   \nA.\u61c9\u8a72\u9700\u8981\u9ad8\u5f37\u5ea6\u7684\u900f\u6790\u983b\u7387\u548c\u6642\u9593\uff0c\u4ee5\u4fbf\u70ba\u60a3\u8005\u63d0\u4f9b\u6700\u5408\u9069\u7684\u9ad4\u5167\u6046\u5b9a\u74b0\u5883\u3002\nB.\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u958b\u59cb\u900f\u6790\u7684\u4e3b\u8981\u539f\u56e0\u5305\u62ec\u9178\u4e2d\u6bd2\u3001\u9ad8\u8840\u9240\u548c\u5168\u8eab\u9ad4\u6db2\u904e\u591a\u3002\nC.\u8207\u9593\u6b47\u6027\u8840\u6db2\u900f\u6790\u76f8\u6bd4\uff0c\u9023\u7e8c\u814e\u81df\u66ff\u4ee3\u6cbb\u7642\u5df2\u88ab\u8b49\u660e\u5c0d\u60a3\u8005\u6709\u66f4\u597d\u7684\u7d50\u679c\u3002\nD.\u900f\u6790\u958b\u59cb\u6642\u7684\u8840\u6e05\u808c\u9150\u9ad8\u4f4e\u8207\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u7684\u9810\u5f8c\u8ca0\u76f8\u95dc\u3002\nE.\u6557\u8840\u75c7\uff08sepsis\uff09\u60a3\u8005\u65e9\u671f\u958b\u59cb\u900f\u6790\u53ef\u6539\u5584\u9810\u5f8c\u3002\n": "[B]", "110-72.\u6709\u95dc\u814e\u5c0f\u7ba1\u814e\u7d72\u7403\u56de\u994b\uff08Tubuloglomerular Feedback\uff0cTGF\uff09\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?       \nA.\u814e\u5c0f\u7ba1\u814e\u7d72\u7403\u56de\u994b\u662f\u6307\u9060\u5074\u814e\u5c0f\u7ba1\u5c0d\u5c3f\u6db2\u6ef2\u900f\u58d3\u7684\u611f\u89ba\u4fe1\u865f\u5c0d\u55ae\u500b\u814e\u5143\u55ae\u4f4d\u814e\u7d72\u7403\u904e\u6ffe\n\u7387\uff08glomerular filtration rate \uff0cGFR\uff09\u7684\u56de\u994b\u8abf\u7bc0 \u3002\nB.\u7cd6\u5c3f\u75c5\u521d\u671f\u6703\u9020\u6210\u51fa\u7403\u5c0f\u52d5\u8108\u58c1\u4e2d\u7684\u9846\u7c92\u7d30\u80de\u5c07\u814e\u7d20\u5927\u91cf\u91cb\u653e\u5230\u5faa\u74b0\u4e2d\u3002\nC.\u814e\u7d20\u5206\u6ccc\u5f8c \uff0c\u9032\u4e00\u6b65\u6d3b\u5316\u814e\u7d20 -\u8840\u7ba1\u6536\u7e2e\u7d20\u7cfb\u7d71 \uff08renin-angiotensin system \uff0cRAS\uff09\u6536\u7e2e\u5165\u7403\u5c0f\u52d5\n\u8108\u3002\nD.\u7dfb\u5bc6\u6591\uff08macula densa \uff09\u7d30\u80de\uff0c\u611f\u77e5\u5230\u5927\u91cf\u9209 /\u6c2f\u96e2\u5b50\u6642 \uff0c\u4ee3\u8b1d\u589e\u52a0\u817a\u82f7 \uff08Adenosine \uff09\u542b\u91cf\uff0c\u8b93\u5165\n\u7403\u5c0f\u52d5\u8108\u8212\u5f35 \u3002\nE.\u7cd6\u5c3f\u75c5\u60a3\u8005\u4f7f\u7528SGLT -2 \u6291\u5236\u5291\u963b\u65b7\u8461\u8404\u7cd6\u8207\u9209\u518d\u5438\u6536 \uff0c\u6703\u4f7f\u5165\u7403\u5c0f\u52d5\u8108\u6536\u7e2e \uff0c\u5f9e\u800c\u4f7f\u540c\u4e00\u814e\u5143\u55ae\u4f4d\n\u7684\u814e\u5c0f\u7403\u904e\u6ffe\u7387\u6e1b\u5c11 \u3002\n": "[E]", "111-55.\u8840\u6db2\u900f\u6790\u75c5\u4eba\u7684\u8840\u7ba1\u901a\u8def (AVF, arterio -venous fistula )\uff0c\u900f\u904e\u4f8b\u884c\u6aa2\u8996 (physical examination )\u53ef\u4ee5\u53ca\u65e9\u767c\n\u73fe\u963b\u585e\u6216\u8840\u6d41\u7570\u5e38 \uff0c\u53ca\u6642\u8655\u7406 \u3002\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u5fb5\u5146\u7b26\u5408AVF \u52d5\u8108\u7aef\u72f9\u7a84 (inflow stenosis )\u8207\u8840\u6d41\u704c\u6ce8\u4e0d\u8db3 ?\n(1) increased pulsatility or water hammer pulse during systole\n(2) reduced pulsatility during systole\n(3) reduced softening and\u201cempty\u201d access during diastole\n(4) a high pitch, discontinuous bruit \n(5) weak thrill\n(6) Increased pulse intensity (augmentation) test   \nA.(1) + (4) + (6)\u3002\nB.(1) + (3) + (5)\u3002\nC.(2) + (3) + (5) + (6)\u3002\nD.(2) + (3) + (4) + (5)\u3002\nE.(2) + (3) + (4) + (5) + (6)\u3002\n": "[D]", "111-56.\u4e00\u4f4d60\u6b72\u7537\u6027 \uff0c\u814e\u529f\u80fd\u6b63\u5e38 \u3002\u4f8b\u884c\u6027\u8d85\u97f3\u6ce2\u6aa2\u67e5\u7121\u610f\u9593\u767c\u73fe\u6709\u826f\u6027\u524d\u5217\u817a\u80a5\u5927 (BPH)\uff0c\u5169\u5074\u4e2d\n\u5ea6hydronephrosis \uff0c\u5169\u5074\u814e\u81df\u5927\u5c0f\u4ecd\u5728\u6b63\u5e38\u7bc4\u570d \u3002\u91ab\u5e2b\u64ec\u5b89\u6392\u9032\u4e00\u6b65\u6aa2\u67e5\u53ef\u80fd\u7684\u75c5\u56e0 \uff0c\u4e26\u5e0c\u671b\u80fd\u85c9\u6b64\u9805\u6aa2\n\u67e5\u4f86\u9078\u64c7\u54ea\u4e00\u5074\u5148\u505a\u7d93\u76ae\u814e\u81df\u9020\u763b (Percutaneous Nephrostomy, PCN) \u4f86\u66ab\u6642\u7de9\u89e3\u814e\u81df\u50b7\u5bb3\u3002   \u4ee5\u4e0b\u4f55\u9805\n\u6aa2\u67e5\u6700\u5408\u9069 ?   \nA.high-resolution multidetector row computed tomography (CT) scan\u3002\nB.retrograde urography\u3002\nC.radionuclide renal scan with furosemide\u3002\nD.Magnetic resonance urography\u3002\nE.endoscopic voiding cystourethrography\u3002\n": "[C]", "111-57.\u4ee5\u4e0b\u6709\u95dc\u591a\u56ca\u814e (ADPKD\uff0cAutosomal Dominant Polycystic Kidney Disease )\u7684\u6558\u8ff0\uff0c\u4f55\u7a2e\u7d44\u5408\u662f\u6b63\u78ba\u7684 ?\n(1) \u8840\u58d3\u5efa\u8b70\u4ee5140 /90 mmHg \u70ba\u76ee\u6a19 \uff0c\u53ef\u964d\u4f4e\u5fc3\u8840\u7ba1\u4f75\u767c\u75c7 \uff0c\u800c\u82e5\u662f\u80fd\u9032\u4e00\u6b65\u63a7\u5236\u6536\u7e2e\u58d3\u76ee\u6a19\u9054110 \nmmHg\uff0c\u53ef\u4ee5\u5ef6\u7de9\u814e\u529f\u80fd\u60e1\u5316 \u3002\n(2) \u9078\u64c7\u8102\u6eb6\u6027\u6297\u751f\u7d20 [\u5982trimethoprim -sulfamethoxazole, quinolones, \u53ca chloramphenicol] \u5c0d\u56ca\u6ce1 (cyst)\u611f\n\u67d3\uff0c\u7a7f\u900f\u6027\u8207\u6cbb\u7642\u6548\u679c\u8f03\u4f73 \u3002\n(3 )\u559d\u6c34\u91cf\u4e0d\u5efa\u8b70\u904e\u591a (> 2500 mL /day)\uff0c\u4ee5\u514d\u4fc3\u9032\u56ca\u6ce1\u751f\u9577 (cyst growth )\n(4)\u6291\u5236\u814e\u7d20 -\u8840\u7ba1\u5f35\u529b\u7d20\u7cfb\u7d71 (RAA\uff0c renin -angiotensin -aldosterone system )\uff0c\u53ef\u63a7\u5236\u8840\u58d3\u8207\u6e1b\u7de9\u814e\u529f\u80fd\n\u60e1\u5316\u3002\n(5) tolvaptan, \u4e00\u7a2evasopressin V2 receptor (V2R) antagonists \uff0c\u53ef\u4ee5\u6291\u5236\u56ca\u6ce1 (cyst)\u7d30\u80de\u589e\u751f \u3002\u5efa\u8b70\u65e9\u671f\n\u4f7f\u7528tolvaptan \uff0c\u9810\u9632\u56ca\u6ce1\u751f\u9577\u8207\u9032\u5c55\u81f3\u5c3f\u6bd2\u75c7 \u3002   \nA.(1) + (2) + (3) + (4) + (5)\u3002\nB.(2) + (3) + (4) + (5)\u3002\nC.(2) + (3) + (4)\u3002\nD.(2) + (4) + (5)\u3002\nE.(2) + (4)\u3002   \n": "[E]", "111-58.\u5065\u6aa2\u767c\u73fe\u7121\u81e8\u5e8a\u75c7\u72c0\u8840\u5c3f (asymptomatic hematuria )\u75c5\u4eba\uff0c 2020 \u5e74AUA guideline\u5efa\u8b70 \uff0c\u4f9d\u64da\u5371\u96aa\u7b49\u7d1a\u7a0b\n\u5ea6\u9032\u884c\u8ffd\u8e64\u8655\u7f6e\u5efa\u8b70\u3002    \u4ee5\u4e0b\u4f55\u7a2e\u75c5\u4eba \uff0c\u5efa\u8b70\u61c9\u5b89\u6392CT scan \u6216cystoscopy \u4ee5\u6392\u9664\u6ccc\u5c3f\u9053\u816b\u7624 (urological \nmalignancy )\u7684\u98a8\u96aa ?   \nA.< 50 \u6b72\u5973\u6027\uff0c\u7121\u62bd\u83f8\u75c5\u53f2\u3002\nB.< 60\u6b72\u7537\u6027\uff0c\u6709\u62bd\u83f8\u75c5\u53f2\u3002\nC.> 60 \u6b72\uff0c\u4e0d\u8ad6\u7537\u5973\uff0c\u66fe\u5408\u4f75\u6709gross hematuria\u75c5\u53f2\u3002\nD.\u6709dysmorphic RBC, cellular cast \u53caproteinuria\u7684\u75c5\u4eba\u3002\nE.\u5df2\u7d93\u9023\u7e8c\u591a\u5e74\uff0c\u6bcf\u5e74\u5065\u6aa2\u90fd\u662fasymptomatic hematuria\uff0c\u814e\u81df\u8d85\u97f3\u6ce2\u4e5f\u672a\u767c\u73fe\u7570\u5e38\u3002\n": "[C]", "111-59.\u8840\u58d3\u63a7\u5236\u5c0d\u65bc\u56b4\u91cd\u5b50\u7647\u524d\u75c7(severe preeclampsia)\u7684\u5a66\u5973\u5f88\u95dc\u9375\u3002\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u85e5\u7269\u8f03\u4e0d\u5408\u9069?    \nA.oral renin \u2013angiotensin \u2013aldosterone inhibitors\u3002\nB.oral nifedipine\u3002\nC.oral methyldopa\u3002\nD.parenteral hydralazine\u3002\nE.oral or parenteral labetalol\u3002\n": "[A]", "111-60.\u4ee5\u4e0b\u6709\u95dclupus nephritis\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?    \nA.Class IV lupus nephritis\u82e5\u662f\u5728renal biopsy\u6642\u767c\u73fe\u6709crescent \uff0c\u61c9\u7a4d\u6975\u6cbb\u7642 \uff0c\u907f\u514d\u9032\u5c55\u81f3rapidly \nprogressive glomerulonephritis (RPGN) \u8207renal fibrosis \u3002\nB.\u6709anti-phospholipid antibody\u967d\u6027\u7684\u75c5\u4eba \uff0c\u6709\u8f03\u9ad8\u6a5f\u6703\u767c\u751fthrombotic microangiopathy \uff0c\u61c9\u7d66\n\u4e88anticoagulant\u53ef\u4ee5\u6709\u6548\u9810\u9632lupus nephritis\u60e1\u5316 \u3002\nC.\u8a3a\u65b7\u70baClass I, II\u7684\u75c5\u4eba \uff0c\u61c9\u76e1\u65e9\u7d66\u4e88moderate or high dose steroid\u4ee5\u9810\u9632\u75c5\u60c5\u9032\u5c55\u81f3Class IV or V \n\u7684lupus nephritis \u8207renal fibrosis \u3002\nD.\u81e8\u5e8a\u9810\u5f8c\u8207ANA level \u53cacomplement levels\u5bc6\u5207\u76f8\u95dc \uff0c\u5b9c\u5b9a\u671f\u8ffd\u8e64ANA \u8207C3, C4 levels\uff0c\u8a55\u4f30\u6cbb\u7642\u6548\n\u679c\u3002\nE.Class IV lupus nephritis\u75c5\u4eba \uff0c\u5efa\u8b70\u5118\u65e9\u4f7f\u7528rituximab or tacrolimus \uff0c\u53ef\u8f03\u50b3\u7d71high dose steroid \u66f4\n\u6709\u6548\u9054\u5230\u53ca\u7dad\u6301renal remission \u3002\n": "[A]", "111-61.\u6709\u95dcasymptomatic bacteriuria (\u5b9a\u7fa9: voided urine specimen > 10\u2075 cfu /ml of an uropathogen isolated, \nabsence of signs and symptoms of UTI )\uff0c\u4f9d\u64da2019 IDSA (Infectious Diseases of America )\uff0c\u4e00\u822c\u662f\u4e0d\n\u9700\u8981\u4f8b\u884c\u6027\u7be9\u6aa2\u8207\u6cbb\u7642 (screen and treatment )\u7684\uff0c\u4ee5\u514d\u7522\u751f\u4e0d\u5fc5\u8981\u7684\u6297\u85e5\u6027 \u3002\u4ee5\u4e0b\u4f55\u7a2e\u60c5\u6cc1IDSA\u624d\u5efa\u8b70\n\u4f8b\u884c\u6027\u7be9\u6aa2\u8207\u5fc5\u8981\u6642\u7684\u6cbb\u7642 ?   \nA.pregnant woman\u3002\nB.older patients with cognitive impairment, delirium\u3002\nC.diabetes\u3002\nD.kidney transplant patients\u3002\nE.patients with spinal cord injury\u3002\n": "[A]", "111-62.\u4e00\u4f4d40\u6b72\u7537\u6027 \uff0c\u8f15\u5ea6\u9ad8\u8840\u58d3 (sBP 148 mmHg )\uff0cserum creatinine 1.0 mg/dL, urine protein 0.6 g/24-Hr \nurine, renal biopsy\u70ba IgA nephropathy, without advanced tubulointerstitial fibrosis, nor crescent \nformation. \u91ab\u5e2b\u5148\u7d66\u4e88 RAAS blocker, \u6301\u7e8c\u8ffd\u8e64 6\u500b\u6708\uff0c\u518d\u6aa2\u6e2c\u5be6\u9a57\u5ba4\u6578\u503c\u70ba: serum creatinine 1.4 \nmg/dL, urine protein 1.3 g/24-Hr urine, sBP 120 mmHg.  \u8acb\u554f: \u4ee5\u4e0b\u8655\u7f6e \uff0c\u4f55\u8005\u6700\u9069\u5b9c ?   \nA.intravenous methylprednisolone (500-1000 mg /day, for 3 days) followed by oral azathioprine for \ndeclining renal function \u3002   \nB.add on oral steroid 0.4 mg/kg/day\u3002\nC.add on fish oil\u3002\nD.arrange tonsillectomy + add on fish oil\u3002\nE.hold RAAS blocker, shift to SGLT2i (sodium glucose cotransporter 2 inhibitor)\u3002\n": "[B]", "111-63.\u4e00\u4f4d56\u6b72\u7537\u6027 \uff0c15\u500b\u6708\u524d\u6709lung cancer, liver metastasis, \u7d93cisplatin \u6cbb\u7642 \uff0c\u66fe\u767c\u751fAKI (acute kidney \ninjury\uff0c\u6700\u9ad8serum creatinine 4.6 mg/dL)\u3002\u672c\u6b21\u56e0\u75b2\u618a\u7121\u529b\u88ab\u9001\u81f3\u6025\u8a3a \u3002\u8840\u58d3 150 /88 mmHg \uff0c\u5be6\u9a57\u5ba4\u6578\n\u64da\u5982\u4e0b: albumin 3.2 g/dL, creatinine 2.5 mg/dL, Na 145 mEq /L, K 2.0 mEq/L, Cl 84 mEq /L, ABG (pH \n7.48, paCO\u2082 60, PaO\u2082 97, HCO \u2083\u207b  40, BE 10 .5)\uff0cplasma osmolality 298 mOsm /kg, urine data \n(osmolality 388 mOsm /kg, Na 35 mEq /L, K 26 mEq /L)\u3002\u9032\u4e00\u6b65\u6aa2\u67e5plasma renin activity (PRA) \n\u8207plasma aldosterone concentration (PAC)\u90fd\u5728\u6b63\u5e38\u7bc4\u570d\u3002 \u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \u3002   \nA.\u75c5\u4eba\u767c\u751fmetabolic alkalosis with adequate respiratory compensation\u3002\nB.\u75c5\u4eba\u767c\u751fmixed type acid-base disorder, metabolic alkalosis with respiratory alkalosis\u3002\nC.\u7b26\u5408 Bartter-Gitelman syndrome \u7684\u8a3a\u65b7\u3002\nD.Ectopic ACTH: Cushing syndrome\u53ef\u4ee5\u6709\u5982\u4e0a\u7684\u8868\u73fe\u3002\nE.\u75c5\u4eba\u7684TTKG (\u5c0d\u7167\u7576\u6642serum [K] 2.0 mEq/L)\u4ecd\u5c6c\u9069\u7576\uff0c\u5224\u5b9a\u975erenal loss\u3002\n": "[D]", "111-64.\u6709\u95dc\u65e9\u671f\u5075\u6e2c\u6025\u6027\u814e\u640d\u50b7\u767c\u751f\u7684\u751f\u7269\u6a19\u8a8c\u7269\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u8840\u5c3f\u7d20\u6c2e\uff08BUN\uff09\u3002\nB.\u767d\u7d30\u80de\u4ecb\u7d20-18 \uff08IL-18\uff09\u3002\nC.\u814e\u640d\u50b7\u5206\u5b50-1 (KIM-1)\u3002\nD.\u4e2d\u6027\u7c92\u7d30\u80de\u660e\u81a0\u9176\u76f8\u95dc\u8f09\u8102\u86cb\u767d (NGAL)\u3002\nE.\u809d\u81df\u578b\u8102\u80aa\u9178\u7d50\u5408\u86cb\u767d(L-FABP)\u3002\n": "[A]", "111-65.\u6162\u6027\u814e\u75c5\u60a3\u8005\u6b7b\u4ea1\u7684\u4e3b\u8981\u539f\u56e0\u662f\u4ec0\u9ebc\uff1f    \nA.\u5fc3\u8840\u7ba1\u75be\u75c5\u3002\nB.\u9ad8\u9240\u8840\u75c7\u3002\nC.\u611f\u67d3\u3002\nD.\u60e1\u6027\u816b\u7624\u3002\nE.\u5c3f\u6bd2\u75c7\u3002\n": "[A]", "111-66.\u4e00\u540d\u60a3\u6709\u672b\u671f\u814e\u75c5\u7684 27 \u6b72\u5973\u6027\u6b63\u5728\u63a5\u53d7\u8840\u6db2\u900f\u6790 \uff0c\u5728\u6cbb\u7642\u671f\u9593\u88ab\u767c\u73fe\u51fa\u73fe\u4f4e\u8840\u58d3\u3002 \u6709\u95dc\u8840\u6db2\u900f\u6790\u671f\u9593\u4f4e\n\u8840\u58d3\uff0c\u4e0b\u5217\u6f5b\u5728\u6a5f\u5236\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u964d\u58d3\u85e5\u3002\nB.\u904e\u5ea6\u8d85\u6ffe\u812b\u6c34\u3002\nC.\u81ea\u5f8b\u795e\u7d93\u53cd\u61c9\u53d7\u640d\u3002\nD.\u6ef2\u900f\u58d3\u8b8a\u5316\u3002\nE.\u52d5\u975c\u8108\u5ed4\u7ba1\u8840\u6d41\u8f03\u5927\u3002\n": "[E]", "111-67.\u4e00\u540d 28 \u6b72\u7684\u5973\u6027 \uff0c\u5728\u5979\u7b2c\u4e8c\u6b21\u61f7\u5b55\u7684\u7b2c 30 \u9031\u5167 \uff0c\u7531\u65bc\u8f15\u5ea6\u9ad8\u8840\u58d3\u800c\u5bc6\u5207\u8ffd\u8e64\u3002 \u7b2c\u4e00\u6b21\u61f7\u5b55\u66fe\u56e0\u5b50\u7647\u524d\n\u75c7\u800c\u51fa\u73fe\u5408\u4f75\u75c7\uff0c \u73fe\u5728\u75b2\u52de\u52a0\u5287\u3002 \u8840\u58d3\u70ba 140 /90 mmHg \uff0c\u5fc3\u7387\u70ba 84 bpm \uff0c\u8840\u6c27\u98fd\u548c\u5ea6\u70ba 95 %\u3002 \u80ce\u5152\n\u76e3\u6e2c\u986f\u793a\u6c92\u6709\u7570\u5e38\u3002 \u5be6\u9a57\u5ba4\u6aa2\u9a57\u986f\u793a\u8840\u7d05\u7d20\u70ba 6 g/dL\uff081 \u9031\u524d\u70ba 10 g/dL\uff09\u548c\u8840\u5c0f\u677f\u70ba 80 K/\u03bcL\uff081 \u9031\u524d\u70ba \n180K/\u03bcL\uff09\u3002  \u5468\u908a\u8840\u6db2\u62b9\u7247\u986f\u793a\u7834\u88c2\u7d05\u8840\u7403\u7d30\u80de \u3002\u6709\u95dc\u65bc\u5979\u7684\u60c5\u6cc1\u7684\u9673\u8ff0 \uff0c\u4e0b\u5217\u4f55\u8005\u662f\u932f\u8aa4\u7684 \uff1a   \nA.\u7cd6\u76ae\u8cea\u6fc0\u7d20\uff08Glucocorticoids\uff09\u53ef\u6709\u6548\u964d\u4f4e\u767c\u75c5\u7387\u548c\u6b7b\u4ea1\u7387\u3002   \nB.\u809d\u529f\u80fd\u9176\u53ef\u80fd\u5347\u9ad8\u3002\nC.\u5b50\u7647\u524d\u75c7\u662f\u6b64\u75c5\u7684\u524d\u9a45\u75c5\u5fb5\u3002\nD.\u5f88\u5e38\u898b\u814e\u8870\u7aed\u3002\nE.\u5206\u5a29\u5f8c\u75c5\u60c5\u53ef\u80fd\u6703\u597d\u8f49\u3002\n": "[A]", "111-68.\u4e00\u540d35 \u6b72\u5973\u6027\u60a3\u6709\u9ad8\u8840\u58d3\u6162\u6027\u814e\u81df\u75c5\u60a3\u8005 \uff0c\u9032\u5c55\u70ba\u672b\u671f\u814e\u75c5\u8b8a\u3002 \u4e26\u65bc 1 \u5e74\u524d\u958b\u59cb\u9032\u884c\u8179\u819c\u900f\u6790 \uff0c\u5c3f\u6bd2\u75c7\n\u75c7\u72c0\u7372\u5f97\u660e\u986f\u6539\u5584\u3002 \u8fd1\u65e5 \uff0c\u56e0\u767c\u71d2\u3001\u7cbe\u795e\u72c0\u614b\u6539\u8b8a \u3001\u7030\u6f2b\u6027\u8179\u75db\u548c\u900f\u6790\u6db2\u6df7\u6fc1\u88ab\u9001\u5f80\u6025\u8a3a\u5ba4\u3002 \u5979\u7684\u8179\u819c\n\u900f\u6790\u6db2\u5be6\u9a57\u5ba4\u5206\u6790\u986f\u793a\uff1a \u767d\u8840\u7403\u7d30\u80de\u8a08\u6578\u70ba 125 /\u03bcL\uff0c\u542b\u6709 85% \u7684\u591a\u5f62\u6838\u4e2d\u6027\u9846\u7c92\u767d\u8840\u7403\u7d30\u80de\u3002 \u8179\u819c\u6db2\n\u57f9\u990a\u4e2d\u6700\u6709\u53ef\u80fd\u767c\u73fe\u54ea\u7a2e\u5fae\u751f\u7269 \uff1f   \nA.\u767d\u8272\u5ff5\u73e0\u83cc\uff08Candida albicans\uff09\u3002\nB.\u5947\u7570\u8b8a\u5f62\u687f\u83cc\uff08Proteus mirabilis\uff09\u3002\nC.\u7d50\u6838\u5206\u679d\u687f\u83cc \uff08Mycobacterium tuberculosis\uff09\u3002\nD.\u7da0\u81bf\u55ae\u80de\u687f\u83cc\uff08Pseudomonas aeruginosa\uff09\u3002\nE.\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc \uff08Staphylococcus aureus\uff09\u3002\n": "[E]", "111-69.\u4ee5\u4e0b\u54ea\u4e9b\u6025\u6027\u814e\u640d\u50b7\u60a3\u8005\u5728\u814e\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u4e2d\u6700\u6709\u53ef\u80fd\u6709\u300e\u96d9\u5074\u300f\u814e\u7a4d\u6c34\u7684\u8b49\u64da\uff1f    \nA.\u4e00\u540d 22 \u6b72\u7537\u6027\u60a3\u6709\u731b\u66b4\u6027\u7d2b\u6591\u75c7\u5408\u4f75\u6dcb\u7403\u83cc\u6557\u8840\u75c7\u3002\nB.\u4e00\u540d 42 \u6b72\u7684\u5973\u6027\uff0c\u56e0\u665a\u671f\u5b50\u5bae\u9838\u764c\u6b63\u5728\u63a5\u53d7\u5316\u7642\u548c\u653e\u7642\u3002\nC.\u4e00\u540d48 \u6b72\u7537\u6027\uff0c\u56e0\u9ad8\u8840\u58d3\u800c\u60a3\u6709\u6162\u6027\u814e\u81df\u75c5\uff0c\u63a5\u53d7\u63a5\u53d7\u542b\u7898\u986f\u5f71\u5291\u6ce8\u5c04\u7684\u8179\u90e8\u8840\u7ba1\u9020\u5f71\u3002\nD.\u4e00\u540d 56 \u6b72\u7537\u6027\u60a3\u6709\u5927\u8178\u687f\u83cc 0157:H7 \u76f8\u95dc\u6eb6\u8840\u6027\u5c3f\u6bd2\u75c7\u3002\nE.\u4e00\u540d85 \u6b72\u4f4f\u5728\u5b89\u990a\u4e2d\u5fc3\u5973\u6027\uff0c\u56e0\u814e\u76c2\u814e\u708e\u548c\u6557\u8840\u75c7\u7684\u60a3\u8005\u3002\n": "[B]", "111-70.\u4e00\u540d 28 \u6b72\u7684\u5973\u6027\u5728\u4e00\u6b21\u8840\u5c3f\u5f8c \uff0c\u88ab\u8a3a\u65b7\u70ba\u5e38\u67d3\u8272\u9ad4\u986f\u6027\u591a\u56ca\u814e\u75c5 \uff08autosomal dominant polycystic \nkidney disease \uff0cADPCKD\uff09\uff0c \u5979\u64d4\u5fc3\u9871\u5167\u52d5\u8108\u7624\u7684\u98a8\u96aa\u3002 \u95dc\u65bc\u9019\u7a2e\u98a8\u96aa \uff0c\u4e0b\u5217\u54ea\u9805\u9673\u8ff0\u662f\u6b63\u78ba\u7684 \uff1f   \nA.\u9871\u5167\u52d5\u8108\u7624\u7834\u88c2\u5bb6\u65cf\u53f2\u4e0d\u6703\u589e\u52a0\u7834\u88c2\u98a8\u96aa\u3002\nB.\u65e2\u5f80\u9871\u5167\u51fa\u8840\u4e0d\u6703\u589e\u52a0\u96a8\u5f8c\u51fa\u8840\u7684\u98a8\u96aa\u3002\nC.\u52d5\u8108\u7624\u7684\u5927\u5c0f\u8207\u5176\u81ea\u767c\u7834\u88c2\u7684\u98a8\u96aa\u7121\u95dc\u3002\nD.\u6709\u591a\u56ca\u814e\u75c5\u4eba\uff0c\u9871\u5167\u52d5\u8108\u7624\u7684\u98a8\u96aa\u4e0d\u6703\u589e\u52a0\u3002\nE.\u4e0d\u53d7\u63a7\u5236\u7684\u9ad8\u8840\u58d3\u6703\u589e\u52a0\u81ea\u767c\u7834\u88c2\u7684\u98a8\u96aa\u3002\n": "[E]", "111-71.\u4e00\u540d 48\u6b72\u7684\u80a5\u80d6\u5973\u6027 \uff0c\u6709 5 \u5e74\u7684\u8f15\u5ea6\u9ad8\u8840\u58d3\u75c5\u53f2 \uff0c\u4f7f\u7528\u9223\u96e2\u5b50\u901a\u9053\u963b\u65b7\u5291 (Calcium-channel Blockers )\u63a7\n\u5236\uff0c\u5728\u5979\u6bcf\u5e74\u7684\u5065\u5eb7\u6aa2\u67e5\u6642 \uff0c\u5c3f\u8a66\u7d19\u4e0a\u986f\u793a\u6709\u86cb\u767d\u5c3f \u3002\u9ad4\u683c\u6aa2\u67e5\u986f\u793a\u8eab\u9ad8 167 .6 \u516c\u5206\uff0c\u9ad4\u91cd 91 \u516c\u65a4 \uff0c\u8840\n\u58d3 130/80 \u6beb\u7c73\u6c5e\u67f1 \uff0c\u9838\u975c\u8108\u58d3\u5347\u9ad8 \uff0c\u7b2c\u56db\u5fc3\u97f3\u548c\u5fae\u91cf\u8db3\u90e8\u6c34\u816b \u3002\u5be6\u9a57\u5ba4\u6578\u503c\u5982\u4e0b \uff1a\n\u2022 \u8840\u6e05\u808c\u9150 \uff1a0.9mg/dL\uff1b eGFR \uff1a79 \u6beb\u5347/\u5206\u9418\n\u2022 BUN\uff1a18 \u6beb\u514b/\u5206\u5347\n\u2022 \u5c3f\u6db2\u5206\u6790 \uff1apH 5.0\uff1b\u6bd4\u91cd1.018\uff1b\u86cb\u767d\u8cea 3+; \u6c92\u6709\u8461\u8404\u7cd6 \uff1b\u900f\u660e\u5713\u67f1\u9ad4 (Hyaline cast )\n\u2022 \u5c3f\u6db2 PCR (protein-creatinine ratio )\uff1a5.9 g/g\n\u814e\u81df\u5207\u7247\u7d50\u679c\u986f\u793a 60% \u7684\u814e\u7d72\u7403 \uff0c\u5728\u5149\u5b78\u986f\u5fae\u93e1\u4e0b\u6709\u7bc0\u6bb5\u6027\u7622\u75d5 \uff0c\u5176\u9918\u7684\u814e\u5c0f\u7403\u770b\u8d77\u4f86\u6c92\u6709\u660e\u986f\u8b8a\n\u5316\uff08\u57161\uff09\u3002 \u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\u4ec0\u9ebc \uff1f   \nA.\u9ad8\u8840\u58d3\u6027\u814e\u786c\u5316\u3002\nB.\u5c40\u90e8\u7bc0\u7d50\u6027\u814e\u7d72\u7403\u786c\u5316\u75c7\u3002\nC.\u5fae\u5c0f\u6027\u814e\u75c5\u8b8a\u3002\nD.\u819c\u6027\u814e\u75c5\u8b8a\u3002\nE.\u65b0\u6708\u578b\u814e\u7d72\u7403\u814e\u708e\u3002   \n": "[B]", "111-72.\u4ee5\u4e0b\u6240\u6709\u95dc\u65bc\u5728\u6162\u6027\u814e\u75c5\u60a3\u8005\u4e2d\u4f7f\u7528\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u662f\u6b63\u78ba\u9673\u8ff0 \uff1a(1).\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u61c9\u4ee5 \n10-11.5 g/dL \u7684\u76ee\u6a19\u8840\u7d05\u86cb\u767d\u6fc3\u5ea6\u7d66\u85e5 \u3002(2).\u4f7f\u7528\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u8207\u6539\u5584\u5fc3\u8840\u7ba1\u9810\u5f8c\u76f8\u95dc \u3002(3).\u4f7f\u7528\n\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u8207\u5408\u4f75 2 \u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u589e\u52a0\u8166\u4e2d\u98a8\u96aa\u6709\u95dc \u3002(4).HIF\u52a0\u5f37\u5291 \uff0chypoxia-inducible \nfactors enhancer \uff0c\u53ef\u80fd\u6210\u70ba\u4e00\u500b\u53e3\u670d\u7684\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20 \u3002(5).\u4f7f\u7528\u5916\u6e90\u6027\u4fc3\u7d05\u8840\u7403\u751f\u6210\u7d20\u8207\u8840\u6813\u6813\n\u585e\u4e8b\u4ef6\u7684\u767c\u751f\u7387\u589e\u52a0\u6709\u95dc \u3002   \nA.(1)+ (2)+ (3)+ (4)\u3002\nB.(2)+ (3)+ (4)+ (5)\u3002\nC.(1)+ (2)+ (4)+ (5)\u3002\nD.(1)+ (2)+ (3)+ (5)\u3002\nE.(1)+ (3)+ (4)+ (5)\u3002\n": "[E]", "100-1.\n\u8840\u6e05Troponin I\u4e4b\u6607\u9ad8\u662f\u5fc3\u81df\u6025\u75c7\u91cd\u8981\u7684\u751f\u7269\u6a19\u8a18(bio-marker), \u4e0b\u5217\u4f55\u8005\u4e0d\u6703\u767c\u751f\u8840\u6e05Troponin I\u4e0a\u5347?\nA. Congestive heart failure\nB. Pulmonary embolism\nC. Acute myocardial infarction\nD. Acute myocarditis\nE. Pneumonia\n": "(E)", "100-2.\n65\u6b72\u7537\u6027\u7f79\u60a3\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u591a\u5e74\uff0c\u56e0\u547c\u5438\u56f0\u96e3\u52a0\u5287\u88ab\u9001\u4f86\u6025\u8a3a\uff0c\u7576\u6642\u610f\u8b58\u6e05\u9192\u3001\u4e5f\u6703\u5408\u4f5c\uff0c\u547c\u543826 \u6b21/\u5206\uff0c\u52d5\u8108\u8840\u5206\u6790\uff1apH7.24\u3001PaCO2 60mm Hg\uff0cPaO2 60 mmHg\u3002\u8a66\u554f\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u80ba\u6ce1\u548c\u52d5\u8108\u8840\u7684\u6c27\u5206\u58d3\u5dee P(A-a)O2\u70ba30 mm Hg\nB. \u61c9\u7acb\u5373\u7d66\u4e88\u6c23\u7ba1\u5167\u63d2\u7ba1\u53ca\u6c27\u6c23\u5438\u5165\nC. \u53ef\u5148\u7d66\u4e88\u975e\u4fb5\u8972\u6027\u6a5f\u68b0\u901a\u6c23(non-invasive ventilation, NIV)\nD. \u53ea\u8981\u7d66\u4e88\u6c27\u6c23\u5438\u5165 3-4 L/min\uff0c\u518d\u89c0\u5bdf\nE. \u53ea\u8981\u7d66\u4e88\u975c\u6ce8\u751f\u7406\u98df\u9e7d\u6c34\u548c\u6c27\u6c23\u5438\u5165 2 L/min\uff0c\u518d\u89c0\u5bdf\n": "(C)", "100-3.\n\u4e00\u4f4d63\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u9ec3\u75b8\u4f4f\u9662\uff0c\u7121\u8179\u75db\u53ca\u767c\u71d2\u75c5\u53f2\uff0c\u5176\u6aa2\u9a57\u6578\u503c\u5982\u4e0b\uff1aHb:14.5 g/dL; Platelet:225K/uL; Bil (T): 8 mg/dL, Bil (D): 5.8 mg/dL, AST: 120 (< 37) U/L, ALT: 145 (<41) U/L, Alkaline phosphatase (ALP): 700 (<230) U/L, CA19-9: 1200 ( <37 ) U/mL, Alfa-fetoprotein : 9 ( < 20 ) ng/mL. \u4ed62\u5e74\u524d\u88ab\u8a3a\u65b7\u51faprimary sclerosing cholangitis\u3002\u7406\u5b78\u6aa2\u67e5\u9664\u76ae\u819a\u53ca\u978f\u819c\u5448\u9ec3\u75b8\u4e4b\u5916\uff0c\u7121\u7279\u5225\u767c\u73fe\u3002\u4e0b\u5217\u8a3a\u65b7\uff0c\u4f55\u8005\u6700\u53ef\u80fd\uff1f\nA. \u6025\u6027\u81bd\u56ca\u708e\nB. \u6025\u6027\u81bd\u7ba1\u708e\nC. \u809d\u81bf\u760d\nD. Primary sclerosing cholangitis\u60e1\u5316\nE. \u81bd\u7ba1\u7d30\u80de\u764c (Cholangiocarcinoma)\n": "(E)", "100-4.\n\u4e00\u4f4d68\u6b72\u7537\u6027\u9ad4\u91cd60\u516c\u65a4\uff0c\u8eab\u9ad8172\u516c\u5206\uff0c\u62bd\u8840\u9a57\u808c\u9178\u9150(Cr)\u70ba1.5mg/dL\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\nA. \u4f9dCockcroft-Gault\u516c\u5f0f\uff0c\u5176\u4f30\u8a08\u814e\u7d72\u7403\u904e\u6ffe\u7387\u4ecb\u65bc55-65ml/min\nB. \u4f9d\u4e0a\u8ff0\u516c\u5f0f\uff0c\u5176\u4f30\u8a08\u814e\u7d72\u7403\u904e\u6ffe\u7387\u4ecb\u65bc45-55ml/min\nC. \u4f9d\u6162\u6027\u814e\u81df\u75c5\u5206\u671f\u70ba\u7b2c1\u671f\nD. \u4f9d\u6162\u6027\u814e\u81df\u75c5\u5206\u671f\u70ba\u7b2c2\u671f\nE. \u4f9d\u6162\u6027\u814e\u81df\u75c5\u5206\u671f\u70ba\u7b2c3\u671f\n": "(E)", "100-5.\n\u5df2\u7d93\u4f7f\u7528\u591a\u7a2e\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u4ecd\u63a7\u5236\u4e0d\u826f\u4e4b\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\uff0c\u4e0b\u5217\u90a3\u4e00\u8655\u7f6e\u8f03\u4f73?\nA. \u589e\u52a0\u6ce8\u5c04\u9910\u524dRegular insulin\nB. \u589e\u52a0\u65e9\u9910\u524dNPH insulin\nC. \u589e\u52a0\u665a\u9910\u524dLispro insulin\nD. \u589e\u52a0\u7761\u524dGlargine insulin\nE. \u589e\u52a0\u7761\u524dMixtard insulin(NPH 70%+Regular 30%)\n": "(D)", "100-6.\n\u6709\u4e0045\u6b72\u7537\u6027\u8fb2\u592b\uff0c\u56e0\u5026\u6020\u3001\u9ad4\u91cd\u6e1b\u8f15\u4f86\u8a3a\uff0c\u75c5\u4eba\u904e\u53bb\u75c5\u53f2\u6709B\u578b\u809d\u708e\uff0c\u8eab\u9ad4\u6aa2\u67e5\u8eab\u9ad8180\u516c\u5206\uff0c\u9ad4\u91cd102\u516c\u65a4\uff0c\u8840\u58d3136/83 mmHg\u3001\u8108\u640f 88/min\uff0cregular\uff0c\u53e3\u8154\u9ecf\u819c\u3001\u624b\u6307\u95dc\u7bc0\u53ca\u624b\u638c\u7d0b\u6709\u9ed1\u8272\u6c88\u7a4d\uff0c\u9838\u3001\u80f8\u3001\u8179\u6aa2\u67e5\u7121\u7279\u5225\u7570\u5e38\uff0c\u62bd\u8840\u6aa2\u67e5Na 138 mM\u3001K 4.5 mM\u3001Cl 104 mM\u3001Ca 2.27 mM\u3001P 4.4 mg/dl\u3001GOT 30 U/L\u3001GPT 56 U/L\uff0c\u8a66\u554f\u54ea\u4e00\u9805\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u8f03\u4f73\uff1f\nA. \u8179\u90e8\u8d85\u97f3\u6ce2\nB. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nC. 8 AM ACTH\uff0ccortisol\u8840\u6f3f\u6fc3\u5ea6\nD. \u8840\u6e05ceruloplasmin\nE. \u8840\u7cd6\u3001\u7cd6\u5316\u8840\u8272\u7d20\n": "(C)", "100-7.\n\u4e0b\u5217\u6709\u95dc\u7f3a\u6c27(hypoxia)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7576\u6b63\u5e38\u6210\u4eba\u5728\u6d77\u62d410,000\u82f1\u544e\u9ad8\u7a7a\u6642\uff0c\u5176\u80ba\u6ce1\u4e4bPO2 \u7d0460 mmHg\nB. \u56e0\u80ba\u4e4b\u53f3\u5411\u5de6\u5206\u6d41(shunt)\u5f15\u8d77\u4e4b\u7f3a\u6c27\uff0c\u5373\u4f7f\u5438\u5165\u7d14\u6c27\u4e5f\u7121\u6cd5\u4f7fPaO2\u9054\u5230\u6b63\u5e38\nC. \u7531\u8ca7\u8840\u5f15\u8d77\u4e4b\u7f3a\u6c27\uff0c\u5176PaO2\u6b63\u5e38\uff0c\u800cPvO2\u6703\u964d\u4f4e\nD. \u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u4e4b\u56db\u80a2\u6703\u56e0\u8840\u7ba1\u6536\u7e2e\u5c0e\u81f4\u7f3a\u6c27\nE. \u7576\u75c5\u4ebaPaO2\u4e0b\u964d\uff0c\u82e5\u540c\u6642\u6709\u63db\u6c23\u904e\u5ea6\u6642\uff0c\u5176PaCO2\u4e0d\u6703\u4e0b\u964d\n": "(E)", "100-8.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u5169\u5074\u814e\u52d5\u8108\u963b\u585e\u5c0e\u81f4\u672b\u671f\u814e\u75c5\u800c\u63a5\u53d7\u9577\u671f\u8840\u6db2\u900f\u67903\u5e74\u3002\u75c5\u4eba\u51fa\u73fe\u8840\u9240\u9ad8(6.0mmol/L)\u4e14\u5fc3\u96fb\u5716\u51fa\u73fe\u9ad8\u800c\u72f9\u7a84\u7684T\u6ce2\u3002\u7d93\u4f4f\u9662\u6aa2\u67e5\u3001\u71df\u990a\u8aee\u8a62\u53ca\u85e5\u7269\u8abf\u6574\uff0c\u5176\u8840\u9240\u4f9d\u820a\u504f\u9ad8\uff0c\u6700\u5408\u9069\u7684\u4e0b\u4e00\u6b65\ufe55\nA. \u6bcf\u5929\u53e3\u670d\u4ea8\u6c0f\u74b0(loop)\u5229\u5c3f\u5291\nB. \u900f\u6790\u6642\u5be6\u65bdsodium modeling\uff0c\u5373\u900f\u6790\u6db2Na\u6fc3\u5ea6\u7531\u8d77\u521d\u7684145 mmol/L\u6f38\u964d\u81f3\u7d04135 mmol/L\nC. \u8abf\u6574\u900f\u6790\u6db2\u6210\u5206\u6fc3\u5ea6\nD. \u57f7\u884c\u5169\u5074\u814e\u5207\u9664\u624b\u8853\nE. \u690d\u5165\u81ea\u52d5\u53bb\u986b\u5668(defibrillator)\n": "(C)", "100-9.\n\u6709\u95dc\u9ad8\u8840\u58d3\u7684\u8ff0\u8aaa\uff0c\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1a\nA. \u96a8\u8457\u8840\u58d3\u7684\u589e\u52a0\uff0c\u5176\u5c0d\u8840\u7ba1\u4e4b\u50b7\u5bb3\u662f\u9010\u6f38\u53ca\u6301\u7e8c\u52a0\u91cd\nB. \u9ad8\u5fc3\u7e2e\u8840\u58d3(Systolic BP)\u6bd4\u9ad8\u5fc3\u8212\u8840\u58d3(Diastolic BP)\u5c0d\u8840\u7ba1\u58c1\u50b7\u5bb3\u66f4\u5927\nC. \u85e5\u7269\u6cbb\u7642\u9ad8\u8840\u58d3\u4e0d\u80fd\u5ffd\u8996\u5176\u4ed6\u5371\u96aa\u56e0\u7d20\uff0c\u5426\u5247\u8840\u58d3\u4e0d\u6613\u63a7\u5236\nD. \u76ee\u524d\u85e5\u7269\u767c\u9054\uff0c\u5728\u6211\u570b\u81e8\u5e8a\u6cbb\u7642\u9ad8\u8840\u58d3\u5df2\u6709\u8fd1\u534a\u7684\u9ad8\u8840\u58d3\u75c5\u4eba\u9054\u5230\u63a7\u5236\u76ee\u6a19\nE. \u65b0\u8fd1\u6709\u6b50\u6d32\u570b\u5bb6\u6cbb\u7642\u6307\u5f15\u4e3b\u5f35\uff0c\u5c07\u03b2-\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291\u53ca\u03b1-\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291\u5254\u9664\u5728\u7b2c\u4e00\u7dda\u9ad8\u8840\u58d3\u6cbb\u7642\u7684\u85e5\u7269\u4e4b\u5916\n": "(D)", "100-10.\n\u4e00\u4f4d65\u6b72\u75c5\u4eba\u4eca\u5929\u4e0a\u5348\u7a81\u7136\u611f\u5230\u8179\u90e8\u5287\u70c8\u7d5e\u75db\uff0c\u5f9e\u809a\u81cd\u9644\u8fd1\u958b\u59cb\u800c\u5f8c\u64f4\u5c55\u81f3\u6574\u500b\u809a\u5b50\uff0c\u4ee4\u4ed6\u5750\u7acb\u96e3\u5b89\uff0c\u66fe\u5410\u904e\u4e00\u6b21\uff0c\u4f46\u6c92\u6709\u767c\u71d2\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u6574\u500b\u809a\u5b50\u8f03\u70ba\u9f13\u8139\uff0c\u4e14\u6709\u58d3\u75db\uff0c\u8178\u5b50\u8815\u52d5\u8072\u97f3\u6b63\u5e38\u3002\u4ed6\u88ab\u767c\u73featrial fibrillation \u5df2\u6709\u6578\u5e74\u3002\u8acb\u554f\u5176\u8a3a\u65b7\u6700\u53ef\u80fd\u70ba\u4e0b\u5217\u90a3\u4e00\u9805\uff1a\nA. \u6025\u6027\u5927\u8178\u61a9\u5ba4\u708e (acute diverticulitis of colon)\nB. \u7f3a\u8840\u6027\u5927\u8178\u708e (ischemic colitis)\nC. \u6025\u6027\u80f0\u81df\u708e (acute pancreatitis)\nD. \u6025\u6027\u8178\u7e6b\u819c\u52d5\u8108\u6813\u585e (acute mesenteric artery embolus)\nE. \u8178\u9053\u7d5e\u75db\u75c7 (intestinal angina)\n": "(D)", "100-11.\n\u8a55\u4f30\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u4e4b\u75be\u75c5\u6d3b\u6027(disease activities),\u4e0b\u5217\u90a3\u4e00\u9805\u6700\u4e0d\u5177\u6d3b\u6027\u6307\u6a19?\nA. \u985e\u98a8\u6fd5\u56e0\u5b50\u6fc3\u5ea6\nB. \u816b\u8139\u95dc\u7bc0\u4e4b\u6578\u76ee\nC. ESR\u4e0a\u5347\u7a0b\u5ea6\nD. \u75c5\u4eba\u81ea\u8eab\u4e4b\u56b4\u91cd\u5ea6\u8a55\u4f30(patient's global assessment)\nE. \u58d3\u75db\u95dc\u7bc0\u4e4b\u6578\u76ee\n": "(A)", "100-12.\n\u4e00\u4f4d21\u6b72\u7537\u6027\u75c5\u4eba\u4e3b\u8a34\u904b\u52d5\u5f8c\u547c\u5438\u6025\u4fc3\uff0c\u5c3f\u6db2\u5448\u6df1\u8910\u8272\u4f46\u7121bilirubinuria\u4ea6\u7121\u7d05\u8840\u7403\u3002\u8840\u6db2\u6aa2\u67e5\u986f\u793aHb 8.6 g/dL\uff0cWBC 4,750/\u03bcL\uff0cplatelet 156,000/\u03bcL\uff0ctotal bilirubin3.5 mg/dL\uff0cdirect biliubin 0.7 mg/dL\uff0cAST105 U/L(\u6b63\u5e38<31)\uff0cALT 32U/L(\u6b63\u5e38<31)\uff0cLDH 1,250 U/L(\u6b63\u5e38230-460)\u3002\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u662f\u6700\u4e0d\u5fc5\u8981\u7684\uff1f\nA. HBsAg\nB. Reticulocyte\nC. Coombs' test\nD. Glucose-6-phosphate dehydrogenase\nE. Flow cytometry for CD55 and CD59 expression of blood cells\n": "(A)", "101-1.\n64\u6b72\u7537\u6027\uff0c\u56e0\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5\u6025\u6027\u767c\u4f5c\uff0c\u547c\u5438\u8870\u7aed\u4f4f\u9662\uff0c\u5165\u9662\u524d\u80ba\u529f\u80fd\u6aa2\u67e5FEV1=1.2L\uff08<30%\u9810\u6e2c\u503c\uff09\u3002\u75c5\u4eba\u63d2\u7ba1\u4f7f\u7528\u547c\u5438\u5668\uff0c\u521d\u59cb\u8840\u58d3\u70ba80/60 mmHg\uff0c\u7d93\u7d66\u4e88500mL\u751f\u7406\u98df\u9e7d\u6c34\u5f8c\u70ba90/60 mmHg\uff0c\u80ba\u52d5\u8108\u6954\u58d3\u70ba20cmH2O\u3002\u7576\u8b77\u58eb\u89e3\u958b\u75c5\u60a3\u8207\u547c\u5438\u5668\u9023\u63a5\u7ba1\u8def\u4e88\u4ee5\u62bd\u75f0\u6642\uff0c\u8840\u58d3\u6210\u70ba140/80mmHg\uff0c\u80ba\u52d5\u8108\u6954\u58d313cmH2O\u3002\u75c5\u4eba\u547c\u5438\u5668\u8a2d\u5b9a\u503c\u5982\u4e0b\uff1a\u6f6e\u6c23\u5bb9\u7a4d500mL\uff0c\u547c\u5438\u901f\u738720/min\uff0c\u5410\u6c23\u672b\u6b63\u58d3\u503c\uff08PEEP\uff095cmH2O\uff0cFiO2 0.5\u3002\u52d5\u8108\u8840\u6c27\u6c23\u9ad4\u5206\u6790\u7d50\u679c\u70bapH 7.38\uff0cPaCO2 48mmHg\uff0cPaO2 65mmHg\u3002\u61c9\u5982\u4f55\u8abf\u6574\u547c\u5438\u5668\uff1f\nA. \u589e\u52a0FiO2\nB. \u589e\u52a0\u6f6e\u6c23\u5bb9\u7a4d\nC. \u964d\u4f4e\u547c\u5438\u901f\u7387\nD. \u589e\u52a0\u547c\u5438\u901f\u7387\nE. \u4f7f\u5410\u6c23\u6642\u9593\u7e2e\u77ed\n": "(C)", "101-2.\n\u5c0d\u65bc\u61f7\u7591\u6709intestinal obstruction\u4e4b\u60a3\u8005\uff0c\u8179\u90e8\uff38\u5149\u7167\u76f8\uff08plain abdomen\uff09\u53ef\u63d0\u4f9b\u76f8\u7576\u6709\u7528\u7684\u8cc7\u6599\u3002\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Plain abdomen\u7528\u4f86\u5224\u65b7nonstrangulating complete small-bowel obstruction\u76f8\u7576\u53ef\u9760\nB. Partial mechanical small-bowel obstruction\u8207adynamic ileus\u4e0d\u592a\u5bb9\u6613\u5340\u5206\uff0c\u4f46colonic distension\u5728adynamic ileus\u901a\u5e38\u8f03\u660e\u986f\nC. \u8139\u5927\u7684\u5c0f\u8178\u4e2d\u53ef\u898bair-fluid levels\uff0c\u5e38\u6392\u5217\u6210\u201cstepladder\u201d pattern\uff0c\u5c11\u898b\u5167\u542b\u7a7a\u6c23\u7684\u5927\u8178\uff0c\u9019\u4e9b\u767c\u73fe\u5e38\u898b\u65bcstrangulating small-bowel obstruction\nD. \u82e5\u81e8\u5e8a\u75c7\u72c0\u5f88\u50cfsmall intestine obstruction\uff0c\u4f46plain abdomen\u770b\u8d77\u4f86\u6b63\u5e38\uff0c\u6b64\u6642\u5b89\u6392\u8179\u90e8CT\u6aa2\u67e5\u6709\u52a9\u65bc\u8a3a\u65b7\nE. \u559d\u92c7\u5291\u4f86\u5e6b\u5fd9\u5224\u65b7\u5c0f\u8178\u7684\u963b\u585e\u90e8\u4f4d\u662f\u76f8\u7576\u5b89\u5168\u7684\n": "(C)", "101-3.\n42\u6b72\u5973\u6027\uff0c\u5176\u8840\u4e2d\u5c3f\u7d20\u6c2e\uff08BUN\uff09\u70ba45mg/dL\uff0c\u8840\u4e2d\u808c\u9178\u9150\u70ba3.8mg/dL\uff0c\u7570\u5e38\u814e\u529f\u80fd\u5df2\u77e5\u67093\u5e74\uff0c\u5169\u5074\u814e\u81df\u5728\u8d85\u97f3\u6ce2\u4e0b\u5df2\u7e2e\u5c0f\u3002\u70ba\u63a7\u5236\u5176\u9aa8\u75c5\u8b8a\u4e4b\u9032\u884c\uff0c\u61c9\u4f5c\u5982\u4f55\u8655\u7406\uff1f\uff08\u8aaa\u660e\uff1aPTH\uff1a\u526f\u7532\u72c0\u817a\u8377\u723e\u8499\uff09\nA. \u8840\u9223\u53ca\u8840\u78f7\u7dad\u6301\u6b63\u5e38\uff0cPTH\u7dad\u6301\u6b63\u5e38\u4e0a\u96504-6\u500d\nB. \u8840\u9223\u53ca\u8840\u78f7\u7dad\u6301\u6b63\u5e38\uff0cPTH\u7dad\u6301\u6b63\u5e38\u4e0a\u9650\u4e4b1-2\u500d\nC. \u8840\u9223\u3001\u8840\u78f7\u53caPTH\u5168\u5728\u6b63\u5e38\u7bc4\u570d\nD. \u8840\u9223\u53ca\u8840\u78f7\u5fc5\u9808\u6b63\u5e38\uff0cPTH\u6c92\u6709\u95dc\u4fc2\nE. \u8840\u9223\u53ca\u8840\u78f7\u6c92\u6709\u95dc\u4fc2\uff0cPTH\u5fc5\u9808\u5728\u6b63\u5e38\u7bc4\u570d\n": "(B)", "101-4.\n\u51fa\u570b\u65c5\u904a\u6700\u5e38\u767c\u751f\u7684\u75be\u75c5\u4e4b\u4e00\u70baTraveller's diarrhea\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u9020\u6210Traveller's diarrhea\u6700\u5e38\u898b\u7684\u81f4\u75c5\u83cc\uff1f\nA. Toxigenic E. coli\nB. Salmonella\nC. Shigella\nD. Rotavirus\nE. Norwalk agent\n": "(A)", "101-5.\n\u6709\u4e0026\u6b72\u5973\u6027\u75c5\u4eba\u4e3b\u8a34\u6ea2\u4e73\uff0c\u4e0b\u5217\u4e4b\u6558\u8ff0\u4f55\u8005\u70ba\u8aa4\uff08\u4e0b\u5217\u6558\u8ff0\u53ef\u70ba\u4e0d\u540c\u4e4b\u75c5\u4eba)\uff1f\nA. \u75c5\u4eba\u6700\u5f8c\u4e00\u6b21\u6708\u7d93\u662f2\u500b\u6708\u524d\uff0c\u9700\u505a\u61f7\u5b55\u6e2c\u8a66\nB. \u75c5\u4eba\u670d\u7528 metoclopramide \u53ca sulpride \u6cbb\u7642\u80c3\u75c5\uff0c\u61c9\u505c\u85e5\u5169\u661f\u671f\u5f8c\u518d\u6aa2\u67e5\u4e73\u4fc3\u7d20\nC. \u75c5\u4eba\u6708\u7d93\u898f\u5247\u6b63\u5e38\u4e5f\u7121\u4e73\u4fc3\u7d20\u6297\u9ad4\uff0c\u53ef\u9810\u6e2c\u8840\u6e05\u4e73\u4fc3\u7d20\u6fc3\u5ea6\u4e00\u5b9a\u5347\u9ad8\nD. \u8840\u6e05\u4e73\u4fc3\u7d20\u503c\u8d85\u904e300 \u03bcg/L\uff0c\u75c5\u4eba\u6709\u4e73\u4fc3\u7d20\u7624\nE. \u6838\u78c1\u5171\u632f\u767c\u73fe1.2\u516c\u5206\u8166\u5782\u817a\u7624\uff0c\u8996\u91ce\u6b63\u5e38\uff0c\u7d66\u4e88 Bromocriptine \u662f\u6cbb\u7642\u9996\u9078\n": "(C)", "101-6.\n\u90a3\u4e9b\u85e5\u6703\u4fc3\u9032\u9aa8\u751f\u6210\r(1)Bisphosphonate\r(2)PTH\r(3)NaF\r(4)Vit D\r(5)Estrogen\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(B)", "101-7.\n40\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u4e3b\u8a34\u9f3b\u6a11\u75bc\u75db\u53ca\u6d41\u9f3b\u8840\u5df2\u4e8c\u500b\u591a\u6708\u3002\u6700\u8fd1\u54b3\u55fd\u5e36\u8840\u75f0\u3002\u8d70\u8def\u6c23\u5598\u3002\u80f8\u90e8X\u5149\u767c\u73fe\u80ba\u90e8\u5169\u5074\u6709\u8a31\u591a\u958b\u6d1e\u75c5\u7076\uff08cavitary lesions\uff09\uff0c\u9f3b\u5b50\u6aa2\u67e5\u767c\u73fe\u9f3b\u4e2d\u9694\u7834\u6d1e\uff08septal perforation\uff09\u3002\u5f9e\u9f3b\u9ecf\u819c\u505a\u5207\u7247\uff0c\u75c5\u7406\u5831\u544a\u70banecrotizing granulomatous vasculitis\uff0c\u8acb\u554f\u6700\u63a8\u85a6\u7684\u6cbb\u7642\u65b9\u5f0f\u70ba\u4e0b\u5217\u90a3\u4e00\u7a2e\uff1f\nA. Oral cyclophosphamide 2 mg/kg/day + Prednisolone 1 mg/kg/day\nB. Intravenous immunoglobulin\uff08IVIG\uff09\nC. Pulse methylprednisolone 1 gm I.V.\nD. Pulse cyclophosphamide 1 gm I.V.\nE. Oral azathioprine 150 mg/day + prednisolone 60 mg/day\n": "(A)", "101-8.\n\u4e00\u4f4d54\u6b72\u5973\u6027\u6700\u8fd14\u500b\u6708\u4f86\u6709\u773c\u4e7e\u3001\u53e3\u4e7e\u53ca\u591a\u8655\u95dc\u7bc0\u9178\u75db\u3002\u5728\u9ad8\u5ea6\u61f7\u7591\u6709\u201c\u4e7e\u71e5\u75c7\u5019\u7fa4\u201d\u7684\u8a3a\u65b7\u4e0b\uff0c\u8acb\u554f\u4e0b\u5217\u90a3\u7a2e\u6aa2\u67e5\u5728\u78ba\u5b9a\u8a3a\u65b7\u4e0a\u662f\u5fc5\u8981\u7684\uff1f\r(1)Schirmer's test\r(2)serum rheumatoid factor\r(3)Sialoscintigraphy\r(4)ANA\r(5)serum electrophoresis\r(6)Anti-SSA/SSB test\nA. (1)+(2)+(4)\nB. (4)+(5)+(6)\nC. (2)+(4)+(6)\nD. (1)+(2)+(3)\nE. (1)+(3)+(6)\n": "(E)", "101-9.\n\u56b4\u91cd\u8840\u53cb\u75c5\u4eba\u82e5\u767c\u73fe\u6709\u6297\u7b2c\u516b\u51dd\u8840\u56e0\u5b50\u7684\u6297\u9ad4\uff0c\u5247\u5728\u51fa\u8840\u6642\u53ef\u63a1\u7528\u4f55\u7a2e\u6cbb\u7642\uff1f\r(1)Factor VIIa\r(2)Porcine factor VIII\r(3)Activated prothrombin complex concentrate\nA. (1)\nB. (2)\nC. (3)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(E)", "101-10.\n\u4e0070\u6b72\u7537\u6027\uff0c\u6bcf\u5929\u62bd\u5169\u5305\u7159\uff0c\u81ea\u534a\u5e74\u8d77\u6709\u80c3\u53e3\u8b8a\u5dee\u53ca\u9ad4\u91cd\u6e1b\u8f15\u7684\u73fe\u8c61\uff0c\u81ea\u4e00\u500b\u6708\u524d\u8d77\u62b1\u6028\u5f37\u70c8\u4e0a\u8179\u75bc\u75db\uff0c\u6b64\u75bc\u75db\u5728\u8eab\u9ad4\u5411\u524d\u50be\u6642\u53ef\u7372\u5f97\u8212\u7de9\uff1b\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u7e3d\u81bd\u8272\u7d20 (total bilirubin) \u70ba4.2 mg/dl\uff1b\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u6709\u81bd\u56ca\u6f32\u5927\u4f46\u7121\u5c40\u90e8\u58d3\u75db\uff0c\u53e6\u6709\u4e003\u516c\u5206\u816b\u7624\u4f4d\u65bc\u80f0\u81df\u982d\u90e8\u3002\u4e0b\u5217\u95dc\u65bc\u6b64\u75c5\u60a3\u7684\u75c5\u75c7\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u96d6\u7136\u6709\u9ec3\u75b8\uff0c\u4f46\u56e0\u4f34\u96a8\u7121\u58d3\u75db\u4e4b\u81bd\u56ca\u816b\u5927\uff0c\u6b64\u75c5\u60a3\u70ba\u826f\u6027\u75be\u75c5\u7684\u6a5f\u6703\u8f03\u9ad8\nB. \u82e5\u5207\u7247\u6aa2\u67e5\u70ba\u80f0\u81df\u764c\uff0c\u591a\u6578\u75c5\u60a3\u4ecd\u53ef\u63a5\u53d7\u624b\u8853\u5207\u9664\nC. \u5c0d\u65bc\u7121\u6cd5\u63a5\u53d7\u624b\u8853\u5207\u9664\u4e4b\u75c5\u60a3\uff0c\u53ef\u8003\u616e\u7f6e\u653e\u652f\u67b6\u6216\u7d93\u76ae\u7a7f\u809d\u81bd\u9053\u651d\u5f71\u53ca\u5f15\u6d41 (percutaneous transhepatic cholangiography and drainage: PTCD) \u4ee5\u8212\u7de9\u75c5\u60a3\u4e4b\u9ec3\u75b8\nD. \u5c0d\u65bc\u8f49\u79fb\u6027\u80f0\u81df\u764c\u75c5\u60a3\uff0c\u514d\u75ab\u7642\u6cd5\u5982 Interferon \u70ba\u76ee\u524d\u4e3b\u8981\u6cbb\u7642\u65b9\u5f0f\nE. \u8fd1\u671f\u5927\u898f\u6a21\u81e8\u5e8a\u8a66\u9a57\u986f\u793a\uff0c\u55ae\u7368\u4f7f\u7528\u55ae\u682a\u6297\u9ad4\u5982 bevacizumab \u6216 cetuximab \u53ef\u5c07\u8f49\u79fb\u6027\u80f0\u81df\u764c\u75c5\u60a3\u4e4b\u5e73\u5747\u5b58\u6d3b\u5ef6\u9577\u5169\u5e74\n": "(C)", "101-11.\n30\u6b72\u5973\u6027\uff0c\u7a81\u767c\u56b4\u91cd\u7684\u8179\u75db\u8207\u5614\u5410\uff0c2\u5e74\u524d\u66fe\u6709\u8f03\u8f15\u5fae\u3001\u985e\u4f3c\u7684\u8179\u75db\uff0c\u7dca\u6025\u8179\u90e8\u8d85\u97f3\u6ce2\u8207\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\u70ba\u6b63\u5e38\u3002\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u75c5\u60a3\u6709\u4e9b\u55dc\u7761\uff0c\u9871\u795e\u7d93\u8207\u80a2\u9ad4\u611f\u89ba\u529f\u80fd\u6b63\u5e38\uff0c\u4f46\u4e0a\u80a2\u7684\u808c\u529b\u4e0b\u964d\u3002\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Fabry's disease\nB. Guillain-Barre syndrome\nC. Pyridoxine deficiency\nD. Thiamine deficiency\nE. Acute intermittent porphyria\n": "(E)", "101-12.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u5ba4\u6027\u671f\u5916\u6536\u7e2e(Ventricular premature contraction, VPC)\u7684\u8aaa\u6cd5\uff0c\u4f55\u8005\u624d\u662f\u6b63\u78ba\u7684\u8aaa\u6cd5;\nA. \u9810\u9632\u6027\u5730\u4f7f\u7528\u6297\u4e0d\u6574\u8108\u85e5\u7269(Antiarrhythmic agents)\u6cbb\u7642\u6025\u6027\u5fc3\u808c\u6897\u585e\u75c5\u4eba\u662f\u5408\u7406\u7684\nB. \u6709\u75c7\u72c0\u7684VPCs\u5c31\u9700\u8981\u4f7f\u7528\u6297\u4e0d\u6574\u8108\u85e5\u7269\nC. \u4e59\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291(\u03b2-adrenergic blocking agents)\u9069\u7528\u6cbb\u7642\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u6216\u4e8c\u5c16\u74e3\u812b\u5782\u75c7\u4f34\u6709VPCs\u7684\u5e74\u8f15\u75c5\u4eba\nD. \u6297\u4e0d\u6574\u8108\u85e5\u7269\u6709\u52a9\u65bc\u6539\u5584VPCs\u76f8\u95dc\u7684\u731d\u6b7b\nE. VPCs\u4e4b\u767c\u751f\u6b21\u6578\uff0cQRS\u5f62\u72c0\u53ca\u6301\u7e8c\u9577\u77ed\u8207\u9810\u5f8c\u6709\u95dc\n": "(C)", "102-1.\n\u5f9e\u75c5\u56e0\u800c\u8a00\uff0c\u4e0b\u5217\u4f55\u7a2e\u539f\u56e0\u8207\u50e7\u5e3d\u74e3\u72f9\u7a84\u7684\u81f4\u75c5\u6a5f\u8f49\u7121\u95dc\uff1f\nA. \u98a8\u6fd5\u71b1\nB. \u5fc3\u5167\u819c\u708e\nC. \u5148\u5929\u7578\u5f62\u7570\u5e38\nD. \u50e7\u5e3d\u74e3\u74b0\u91cd\u5ea6\u9223\u5316(Severe mitral annular calcification)\nE. \u7d05\u6591\u6027\u72fc\u7621\u75c7(SLE)\n": "(B)", "102-2.\n\u5927\u91cf\u54b3\u8840(24\u5c0f\u6642\u5167\u54b3\u8840\u91cf\u8d85\u904e500\u6beb\u5347)\u8f03\u4e0d\u5e38\u767c\u751f\u5728\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5?\nA. \u80ba\u764c(bronchogenic carcinoma)\nB. \u80ba\u7d50\u6838(pulmonary tuberculosis)\nC. \u652f\u6c23\u7ba1\u64f4\u5f35\u75c7(bronchiectasis)\nD. \u80ba\u81bf\u760d(lung abscess)\nE. \u80ba\u6813\u585e(pulmonary embolism)\n": "(E)", "102-3.\n\u4e0b\u5217\u75be\u75c5\u53ef\u4f7f\u80c3\u6392\u7a7a\u6642\u9593\u52a0\u901f\uff0c\u9664\u4e86\nA. Pancreatic insufficiency\nB. Celiac Sprue\nC. Zolllinger-Ellison Syndrome\nD. Duodenal ulcer\nE. Reflux esophagitis\n": "(E)", "102-4.\n\u809d\u75c5\u672b\u671f\u6613\u4f75\u767c\u809d\u814e\u75c7\u5019\u7fa4\uff08hepatorenal syndrome\uff09\uff0c\u6b64\u75c7\u4e4b\u8087\u56e0\u8207\u4e0b\u5217\u90a3\u7a2e\u72c0\u6cc1\u7121\u95dc\uff1f\nA. \u51fa\u8840\u3002\nB. \u4f7f\u7528\u5229\u5c3f\u5291\uff08diuretics\uff09\u3002\nC. \u4f7f\u7528\u8840\u7ba1\u6536\u7e2e\u5291\uff08systemic vasoconstrictors\uff09\u3002\nD. \u4f7f\u7528\u6291\u5236cyclooxygenase\u4e4b\u85e5\u7269\u3002\nE. \u62bd\u8179\u6c34\u3002\n": "(C)", "102-5.\n\u6d41\u884c\u6027\u611f\u5192\u5f8c\u4f75\u767c\u7e8c\u767c\u6027\u7d30\u83cc\u6027\u80ba\u708e\uff0c\u5176\u4e3b\u8981\u75c5\u539f\u83cc\u70ba\uff1a(1)Staphylococcus aureus (2)Pseudomonas aeruginosa (3)Streptococcus pneumoniae (4)Haemophilus influenzae (5)Legionella pneumophila\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(4)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(B)", "102-6.\n\u6709\u95dc\u7cd6\u5c3f\u75c5\u8db3\u6f70\u760d\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u4e3b\u8981\u539f\u56e0\u662f\u8840\u7ba1\u75c5\u8b8a\u5c0e\u81f4\u7f3a\u6c27\uff0c\u56e0\u6b64\u9ad8\u58d3\u6c27\u6cbb\u7642\u662f\u5fc5\u9808\u7684\nB. \u4e3b\u8981\u539f\u56e0\u662f\u795e\u7d93\u75c5\u8b8a\u5c0e\u81f4\u58d3\u529b\u4e0d\u5747\u52fb\u6240\u81f4\nC. \u4e3b\u8981\u662f\u56e0\u62b5\u6297\u529b\u4e0d\u8db3\uff0c\u611f\u67d3\u9020\u6210\nD. \u9664\u4e86\u5728\u5ba4\u5167\uff0c\u4e0d\u61c9\u8d64\u8173\u8d70\u8def\nE. \u61c9\u9f13\u52f5\u75c5\u4eba\u591a\u8d70\u52d5\u4ee5\u4fc3\u9032\u8840\u6db2\u5faa\u74b0\n": "(B)", "102-7.\n\u6709\u4e0030\u6b72\u7537\u6027\u5de5\u7a0b\u5e2b\u56e0\u7a81\u7136\u4e0b\u80a2\u7121\u529b\u8dcc\u5012\u88ab\u9001\u4f86\u6025\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u4e0b\u80a2paralysis\uff0cdeep tendon reflex \u6d88\u5931\uff0c\u8108\u640f132/min\uff0c\u8840\u58d3150/50 mmHg\uff0c\u9ad4\u6eab\u6b63\u5e38\uff0c\u62bd\u8840\u6aa2\u67e5\uff1aK2.0 mM\uff0cfree T4 2.5 ng/dl\uff0c\u4ee5\u4e0b\u6709\u95dc\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4e0d\u5b9c\u591a\u5403\u6d77\u5e36\u3001\u7d2b\u83dc\u542b\u7898\u98df\u7269\nB. \u4e0d\u5b9c\u591a\u5403\u751c\u98df\u6216\u904e\u65bc\u98fd\u98df\nC. \u6b64\u75c5\u70ba\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u5f15\u8d77\uff0c\u53ea\u8981\u7532\u72c0\u817a\u6a5f\u80fd\u63a7\u5236\u4fbf\u4e0d\u518d\u767c\nD. \u5b9c\u591a\u5403\u542b\u9240\u98df\u7269\nE. \u5efa\u8b70\u75c5\u4eba\u5373\u523b\u4f7f\u7528\u653e\u5c04\u7898\u6cbb\u7642\n": "(E)", "102-8.\n\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e (rheumatoid arthritis) \u6700\u5c11\u4fb5\u72af\u7684\u95dc\u7bc0\u662f\u4e0b\u5217\u54ea\u4e00\u500b\uff1f\nA. Hip joints\nB. Shoulder joints\nC. Cervical spine\nD. Distal interphalangeal joints of fingers\nE. Temporomandibular joint\n": "(D)", "102-9.\n\u4e0b\u5217\u4f55\u8005\u662f\u5f15\u767c\u72fc\u7621\u75c5\u60c5\u60e1\u5316\u7684\u6700\u91cd\u8981\u74b0\u5883\u56e0\u5b50\uff1f\nA. \u7d2b\u5916\u7dda\u7684\u7167\u5c04\nB. \u5bd2\u51b7\u6f6e\u6fd5\u7684\u5929\u6c23\nC. \u8207vinyl chloride\u63a5\u89f8\nD. \u670d\u7528\u542b\u96cc\u6fc0\u7d20\u7684\u907f\u5b55\u7d20\nE. \u75c5\u6bd2\u611f\u67d3\n": "(A)", "102-10.\n\u5927\u8178\u817a\u764c\u82e5\u5728\u8853\u5f8c\u75c5\u7406\u767c\u73fe\u4fb5\u72af\u81f3\u6f3f\u819c (serosa)\uff0c\u6c92\u6709\u5c40\u90e8\u6dcb\u5df4\u7d50\u4fb5\u72af\uff0c\u5168\u8eab\u6aa2\u67e5\u7121\u8f49\u79fb\u73fe\u8c61\uff0c\u6b64\u75c5\u4eba\u61c9\u5c6c\u65bc Dukes staging\u4e4b\u90a3\u4e00\u5206\u671f\uff1f\nA. A2\nB. B1\nC. B2\nD. C1\nE. C2\n": "(C)", "102-11.\n\u4e0b\u5217\u54ea\u4e00\u7a2e\u60c5\u6cc1\u51fa\u73fe\u8840\u5c0f\u677f\u4f4e\u4e0b\u7684\u6a5f\u6703\u6700\u5c0f\uff1f\nA. Evans syndrome\nB. Liver cirrhosis\nC. HIV infection\nD. Uremia\nE. Penicillin treatment\n": "(D)", "102-12.\n75\u6b72\u7537\u6027\uff0c\u5df2\u77e5\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u53ca\u5fc3\u623f\u986b\u52d5\u591a\u5e74\uff0c\u56e0\u7a81\u767c\u5de6\u5074\u80a2\u9ad4\u504f\u7671\u8207\u610f\u8b58\u4e0d\u6e05\u800c\u81f3\u6025\u8a3a\u3002\u7406\u5b78\u6aa2\u67e5\u75c5\u60a3\u70ba\u55dc\u7761\u72c0\u6cc1\u3001\u8840\u58d3220/112 mmHg\u3001\u5fc3\u8df3105\u6b21/\u5206\u3001\u9ad4\u6eab38.5\u0002\u2103\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u5de6\u5074\u504f\u7671\u8207\u504f\u76f2\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u70ba\u8840\u7cd6280 mg/dL\u3001INR\u70ba1.08\u3001\u8840\u8272\u7d20\u70ba13.3 g/dL\uff0c\u8166\u90e8MRI\u986f\u793a\u53f3\u5074\u4e2d\u5927\u8166\u52d5\u8108\u5340\u57df\u5b8c\u5168\u8166\u6897\u585e\u3002\u8acb\u554f\u4e0b\u5217\u90a3\u4e9b\u8655\u7f6e\u4e0d\u9069\u7576  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\uff1a(1) \u7d66\u4e88\u964d\u58d3\u85e5\u7269\uff08\u5982labetalol\uff09\u5c07\u8840\u58d3\u964d\u81f3140/90 mmHg(2) \u4f7f\u7528\u80f0\u5cf6\u7d20\u5c07\u8840\u7cd6\u964d\u81f3120 mg/dL(3) \u4f7f\u7528\u6297\u51dd\u8840\u5291\uff08heparin\uff09(4) \u7d66\u4e88\u975c\u8108\u6ce8\u5c04\u9ad8\u5f35\u6eb6\u6db2\uff08mannitol\uff09(5) \u7d66\u4e88acetaminophen\u5c07\u9ad4\u6eab\u964d\u81f337\u2103\nA. (1)+(2)+(3)\nB. (1)+(5)\nC. (2)+(3)\nD. (2)+(3)+(5)\nE. (1)+(3)\n": "(E)", "103-1.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u5167\u819c\u708e(Infective Endocarditis)\u7684\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684\uff1f\nA. \u5148\u9032\u570b\u5bb6\u7684\u5fc3\u5167\u819c\u708e\u8fd1\u5e74\u589e\u591a\uff0c\u56e0\u975e\u6cd5\u4f7f\u7528\u7981\u85e5\u3001\u591a\u7528\u5fc3\u5167\u5668\u68b0(intracardiac device)\u3001\u589e\u52a0\u9000\u5316\u6027\u5fc3\u74e3\u819c\u75c5\u4eba\u3001\u53ca\u91ab\u8b77\u76f8\u95dc\u7684\u611f\u67d3\u75c5\u4e5f\u589e\u591a\nB. \u8d05\u751f\u7269(vegetation)\u96c6\u8840\u5c0f\u677f\u3001\u7e96\u7dad\u7d20\u3001\u75c5\u83cc\u53ca\u5c11\u6578\u7684\u767c\u708e\u7d30\u80de\uff0c\u591a\u898b\u65bc\u4f4e\u58d3\u8154\u5ba4\u7684\u5fc3\u81df\u7d50\u69cb\nC. \u53e3\u8154\u3001\u80c3\u8178\u606f\u8089\u6216\u61a9\u5ba4(diverticuli)\u5e38\u662f\u93c8\u7403\u83cc\u682a\u7684\u4f86\u6e90\uff0c\u800c\u5927\u8178\u7403\u83cc(enterococci)\u5e38\u4f86\u81ea\u6ccc\u5c3f\u9053\nD. \u793e\u5340\u611f\u67d3\u5fc3\u5167\u819c\u708e\u591a\u56e0\u8349\u7da0\u8272\u93c8\u7403\u83cc(viridans streptococci)\u3001staphylococci\u53caHACEK\u75c5\u83cc\u800c\u8d77\nE. \u98df\u9053\u8d85\u97f3\u6ce2\u5fc3\u5716\u6aa2\u67e5\u53ef\u63d0\u9ad8\u5fc3\u5167\u819c\u708e\u7684\u8a3a\u65b7\n": "(A)", "103-2.\n\u4e0b\u5217\u95dc\u65bcMDR-TB\u7684\u6558\u8ff0\u54ea\u4e00\u500b\u4e0d\u6b63\u78ba\uff1f\nA. MDR-TB\u6307\u81f3\u5c11\u5c0disoniazid\u53carifampicin\u5177\u6297\u85e5\u6027\u7684\u60a3\u8005\nB. MDR-TB\u7684\u75c5\u60a3\u4ee5\u4e00\u958b\u59cb\u5373\u611f\u67d3\u5177\u6297\u85e5\u6027\u7684\u83cc\u682a\u70ba\u6700\u5e38\u898b\u7684\u539f\u56e0\nC. \u81f3\u5c11\u9700\u4f7f\u75284\u7a2e\u6709\u6548\u7684\u85e5\u7269\u6cbb\u764218\u500b\u6708\u4ee5\u4e0a\uff0c\u4e14\u9700\u6703\u8a3a\u5177\u6cbb\u7642\u591a\u91cd\u6297\u85e5\u7d50\u6838\u6709\u7d93\u9a57\u7684\u91ab\u5e2b\nD. \u75c5\u60a3\u4e0d\u898f\u5247\u670d\u85e5\u3001\u670d\u85e5\u671f\u9593\u4e0d\u8db3\u5373\u81ea\u884c\u505c\u85e5\u662f\u9020\u6210MDR-TB\u7684\u539f\u56e0\u4e4b\u4e00\nE. \u5c0d\u65bcMDR-TB\u75c5\u4eba\u4e4b\u89aa\u5bc6\u63a5\u89f8\u8005\uff0cisoniazid\u4e0d\u9069\u7528\u65bc\u6cbb\u7642\u6f5b\u4f0f\u671f\u7d50\u6838\u83cc\u611f\u67d3(latent tuberculosis)\n": "(B)", "103-3.\n\u4e0b\u5217\u95dc\u65bcdiarrhea\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6aa2\u67e5\u5927\u4fbf\u4e2d\u7684fat\u4e43\u662f\u7be9\u6aa2malabsorption\u6700\u4f73\u65b9\u5f0f\nB. Malabsorption\u60a3\u8005\u4e00\u5b9a\u6703\u6709diarrhea\nC. Non-inflammatory chronic watery diarrhea\u4e2d\uff0csecretory diarrhea\u65bcfasting\u5f8c\u6703\u505c\u6b62\nD. Irritable bowel syndrome\u60a3\u8005\u4e4bdiarrhea\u65bcfasting\u5f8c\u6703\u6301\u7e8c\nE. \u5c0dsevere diarrhea\u60a3\u8005\uff0c\u61c9\u5118\u5feb\u7d66\u4e88opiates\u85e5\u7269\u6cbb\u7642\n": "(A)", "103-4.\n\u6709\u4e00\u4f4d65\u6b72\u7537\u6027, \u61f7\u7591\u814e\u7d50\u77f3, \u63a5\u53d7IVU ( intravenous urography) \u6aa2\u67e5, \u7b2c\u4e09\u5929\u767c\u73feBUN\u753133 mg/dL\u5347\u81f360 mg/dL, \u8840\u4e2dcreatinine\u75312.1 mg/dL\u5347\u81f34.6 mg/dL,\u4e0b\u5217\u63cf\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u986f\u5f71\u5291\u4e43\u7531\u8840\u7ba1\u64f4\u5f35\u4e4b\u6a5f\u8f49\u5c0e\u81f4\u814e\u640d\u50b7.\nB. \u5fc3\u81df\u8870\u7aed\uff08congestive heart failure\uff09\u75c5\u4eba\u8f03\u5bb9\u6613\u767c\u751f\u6b64\u4f75\u767c\u75c7\nC. \u986f\u5f71\u5291\u4e4b\u5291\u91cf\u8207\u814e\u640d\u50b7\u4e4b\u7a0b\u5ea6\u901a\u5e38\u7121\u95dc.\nD. \u986f\u5f71\u5291\u53ef\u7d93\u904ereactive oxygen species\u4e4b\u6a5f\u8f49, \u4e3b\u8981\u50b7\u5bb3\u814e\u5c0f\u7403\uff08glomerular cells).\nE. \u901a\u5e38\u70ba\u4e0d\u53ef\u9006\u6027, \u5927\u7d042 \u661f\u671f\u5f8c\u9032\u5c55\u81f3\u9700\u900f\u6790\u6cbb\u7642\n": "(B)", "103-5.\n\u4e0b\u5217\u6709\u95dc\u76ae\u819a\u8edf\u7d44\u7e54\u611f\u67d3\u7684\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5728\u53f0\u7063\uff0c\u81f4\u75c5\u83ccKlebsiella pneumoniae\u7684\u6bd4\u4f8b\u6bd4\u6b50\u7f8e\u570b\u5bb6\u9ad8\u51fa\u8a31\u591a\nB. \u58de\u6b7b\u6027\u7b4b\u819c\u708e\u662f\u6cbf\u8457fascia\u5feb\u901f\u8513\u5ef6\u7684\u4e00\u7a2e\u76ae\u819a\u53ca\u76ae\u4e0b\u7d44\u7e54\u611f\u67d3\uff0c\u6b7b\u4ea1\u7387\u53ef\u905426%\nC. \u58de\u6b7b\u6027\u7b4b\u819c\u708e\u7684\u6cbb\u7642\u9700\u8981\u5118\u65e9\u7684\u624b\u8853\u6e05\u5275\u53ca\u6709\u6548\u7684\u6297\u751f\u7d20\u6cbb\u7642\nD. \u767c\u751f\u5728\u80a2\u9ad4\u7684\u58de\u6b7b\u6027\u7b4b\u819c\u708e\u53c8\u7a31\u70baFournier's gangrene\nE. Primary pyomyositis\u662f\u6307\u9aa8\u9abc\u808c\u5167\u7684\u767c\u708e\u53cd\u61c9\u4e26\u4e14\u5f62\u6210\u81bf\u760d\uff0c\u6700\u5e38\u898b\u7684\u81f4\u75c5\u83cc\u7a2e\u662f Staphylococcus aureus\n": "(D)", "103-6.\n65\u6b72\u7537\u6027\u56e0\u5026\u6020\u3001\u98df\u617e\u4e0d\u632f\u3001\u591a\u5c3f\u4e8c\u500b\u6708\uff0c\u4eca\u65e9\u660f\u8ff7\u4f86\u6025\u8a3a\uff0c6\u500b\u6708\u524d\u75c5\u4eba\u88ab\u8a3a\u65b7\u80ba\u764c\uff0c\u8eab\u9ad4\u6aa2\u67e5\uff1a\u8840\u58d388/60 mmHg \u3001PR 108/min\u3001regular\uff0cRR20/min\uff0c\u6b64\u5916\u7121\u7279\u5225\u7570\u5e38\uff0c\u62bd\u8840\u6aa2\u67e5BUN 66 mg/dL\u3001Cr 2.9 mg/dL\u3001Ca 13 mg/dL\u3002\u7d93\u904e\u98df\u9e7d\u6c34\u8f38\u6db2\u6cbb\u7642\u5f8c\u6e05\u9192\uff0ciPTH\u6e2c\u4e0d\u5230\uff0c\u8981\u7dad\u6301\u8840\u9223\u6b63\u5e38\uff0c\u4e0b\u5217\u90a3\u4e00\u85e5\u7269\u6700\u4f73\nA. Calcitonin\nB. Bisphosphonate\nC. Diuretic\nD. Prednisolone\nE. EDTA\n": "(B)", "103-7.\n30\u6b72\u5973\u6027\u5e73\u5e38\u8eab\u9ad4\u5065\u5eb7\uff0c\u56e02\u500b\u6708\u4f86\u5e38\u65e9\u4e0a\u7121\u6cd5\u53eb\u9192\u88ab\u9001\u4f86\u6025\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u9664\u8840\u58d390/60 mmHg\u3001 PR 120/min\uff0c regular\u3001 \u76dc\u6c57\u5916\uff0c\u7121\u7279\u6b8a\u7570\u5e38\u3002\u7d93\u8461\u8404\u7cd6\u6ce8\u5c04\u6062\u5fa9\u6b63\u5e38\uff0c\u6ce8\u5c04\u524d\u62bd\u8840\u6aa2\u67e5\u8840\u7cd656 mg/dL\u3001 insulin level 18 \u03bcU/mL \uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u5728\u8a3a\u65b7\u4e0a\u6700\u6070\u7576\uff1f\nA. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nB. \u4f4f\u9662\u505a72\u5c0f\u6642\u7a7a\u8179\u8a66\u9a57\nC. \u5bb6\u4e2d\u8461\u8404\u7cd6\u76e3\u6e2c\nD. \u5168\u8eab\u6b63\u5b50\u6383\u63cf\nE. \u80f0\u81df\u5167\u8996\u93e1\u8d85\u97f3\u6ce2\u6aa2\u67e5\n": "(B)", "103-8.\n\u624b\u90e8\u95dc\u7bc0\u4fb5\u72af\u7684\u4f4d\u7f6e\u5c0d\u4e00\u4e9b\u98a8\u6fd5\u75c5\u4e4b\u9451\u5225\u8a3a\u65b7\u5177\u6709\u4e0d\u932f\u7684\u50f9\u503c.\u8b6c\u5982\u5927\u62c7\u6307\u7684Carpometacarpal joint (1st CMC)\u4e4b\u4fb5\u72af\u6700\u53ef\u80fd\u7684\u98a8\u6fd5\u75c5\u70ba\u4f55?\nA. Psoriatic arthritis\nB. Rheumatoid arthritis\nC. Osteoarthritis\nD. Pseudogout\nE. Gonococcal arthritis\n": "(C)", "103-9.\n23\u6b72\u7537\u6027\u60a3\u8005\u65e9\u6668\u7761\u9192\u6642\u6709\u4e0b\u80cc\u50f5\u786c\u53ca\u7a0d\u5fae\u75bc\u75db\u3002\u53e6\u5916\uff0c\u80a9\u95dc\u7bc0\u53ca\u9838\u90e8\u4ea6\u6642\u5e38\u6709\u50f5\u786c\u767c\u751f\uff0c\u7d93\u7a0d\u5fae\u904b\u52d5\u4e4b\u5f8c\u50f5\u786c\u6703\u7de9\u89e3\u3002\u6709\u6642\u8d70\u8def\u6703\u6709\u5169\u5074\u9f20\u8e4a\u90e8\u75bc\u75db\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Pelvis X-film (AP view)\nB. Sonogram of neck and bilateral shoulder joint areas\nC. HLA-B27\nD. C-spine X-film (AP and lateral view)\nE. Autoimmune profile\n": "(A)", "103-10.\n\u4e0b\u5217\u5bb9\u6613\u5f15\u767c\u6813\u585e\u4e4b\u907a\u50b3\u6027\u7f3a\u9677\u4e2d\uff0c\u4f55\u8005\u5728\u53f0\u7063\u6700\u5e38\u898b\uff1f\nA. Antithrombin III deficiency\nB. Protein C deficiency\nC. Protein S deficiency\nD. Factor\uff36 Leiden mutation\nE. Prothrombin 20210A mutation\n": "(C)", "103-11.\nGefitinib (Iressa)\u8207Erlotinib (Tarceva)\u662f\u4e8c\u500b\u91cd\u8981\u7684\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC, non-small cell lung cancer)\u7684\u6a19\u9776\u85e5\u7269\uff0c\u5c0d\u6771\u65b9\u5973\u6027\uff0c\u975e\u5438\u83f8\u4e4b\u817a\u764c(adenocarcinoma)\u60a3\u8005\uff0c\u5c24\u5176\u6709\u6548\u3002\u4ee5\u85e5\u7269\u57fa\u56e0\u5b78\u7684\u89c0\u9ede\uff0c\u6b64\u4e00\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u63a5\u53d7\u9ad4(EGFR, epidermal growth factor receptor)\u916a\u80fa\u9178\u78f7\u9178\u5316\u6fc0\ufffdC(TK, tyrosine kinase)\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291\uff0c\u7576\u300cEGFR\u57fa\u56e0\u300d\u7522\u751f\u4f55\u7a2e\u8b8a\u7570\u6642\uff0c\u5f88\u53ef\u80fd\u6703\u8868\u73fe\u5c0dGefitinib\u6216Erlotinib\u85e5\u7269\u4e4b\"\u6297\u85e5\u6027\" (resistance)\uff1f\nA. L858R (\u7b2c858\u80fa\u57fa\u9178\u4f4d\u9ede\u4e4bLysine \u88abArginine\u53d6\u4ee3)\nB. L747-S752 \u4e4b\u4e00\u6bb5\u80fa\u57fa\u9178\u4e4b\u57fa\u56e0\u88ab\u522a\u9664(deletion)\nC. T790M (\u7b2c790\u80fa\u57fa\u9178\u4f4d\u9ede\u4e4bThreonine\u88abMethionine\u53d6\u4ee3)\nD. E746-A750\u4e4b\u4e00\u6bb5\u80fa\u57fa\u9178\u4e4b\u57fa\u56e0\u88ab\u522a\u9664(deletion)\nE. \u4ee5\u4e0aEGFR\u4e4b\u57fa\u56e0\u8b8a\u7570\uff0c\u5747\u5c0dGefitinib\u6216Erlotinib\u5177\u9ad8\u654f\u611f\u6027\uff0c\u4e26\u7121\u6297\u85e5\u6027\n": "(C)", "103-12.\n42\u6b72\u5973\u6027\uff0c\u7a81\u767c\u5de6\u9838\u90e8\u75bc\u75db\uff0c\u5de6\u81c9\u8207\u53f3\u5074\u80a2\u9ad4\u9ebb\u6728\uff0c\u5de6\u5074\u80a2\u9ad4\u5931\u8abf\uff08dysmetria\uff09\u8207\u69cb\u97f3\u56f0\u96e3\uff08dysarthria\uff09\uff0c\u5247\u6700\u6709\u53ef\u80fd\u90a3\u4e00\u689d\u52d5\u8108\u963b\u585e\uff1f\nA. \u57fa\u5e95\u52d5\u8108\uff08basilar artery\uff09\nB. \u690e\u52d5\u8108\uff08vertebral artery\uff09\nC. \u524d\u4e0b\u5c0f\u8166\u52d5\u8108\uff08anterior inferior cerebellar artery\uff09\nD. \u5f8c\u5927\u8166\u52d5\u8108\uff08posterior cerebral artery\uff09\nE. \u524d\u810a\u52d5\u8108\uff08anterior spinal artery\uff09\n": "(B)", "104-1.\n\u5177\u6709\u9ad8\u5ea6\u731d\u6b7b\u5371\u96aa\u6027\u7684\u80a5\u539a\u5fc3\u808c\u75c5\u5305\u62ec\u6709\uff1a (1)\u5fc3\u5c16\u5de8\u5927T\u6ce2\u5fc3\u808c\u80a5\u539a (2)\u5bb6\u65cf\u6709\u731d\u6b7b\u75c5\u4eba (3)\u5de6\u5fc3\u5ba4\u51fa\u53e3\u9ad8\u58d3\u95be\u5dee\uff08pressure gradient\uff09> 50 mmHg (4)\u6210\u5e74\u4eba\u80a5\u539a\u5fc3\u808c\u75c5 (5)\u5fc3\u808c\u80a5\u539a > 20 mm\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(5)\nE. (2)+(3)+(5)\n": "(E)", "104-2.\n\u5341\u516b\u6b72\u5973\u6027\uff0c\u7a81\u7136\u767c\u71d2\u3001\u982d\u75db\u53ca\u5614\u5410\uff0c8\u5c0f\u6642\u5f8c\u4f4f\u9662\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u75c5\u4eba\u55dc\u7761\u3001\u9ad4\u6eab40\u2103\uff0c\u5728\u4e0b\u80a2\u53ef\u898b\u7d2b\u6591\u6027\u76ae\u75b9\u4ee5\u53ca\u9838\u9805\u50f5\u76f4\u3001\u672b\u68a2\u8840\u767d\u8840\u740323x1000/\u03bcL\u5206\u985e\u660e\u986f\u5de6\u79fb\uff0cCSF\u6aa2\u67e5\u767c\u73fe\u767d\u8840\u740310x1000/\u03bcL\uff0c\u591a\u5f62\u6838\u4f5495%\uff0c\u8461\u8404\u7cd610 mg/dL\uff0c\u86cb\u767d\u8cea90 mg/dL\uff0cCSF\u6c88\u6e23\u62b9\u7247\u67d3\u8272\u93e1\u6aa2\u767c\u73fe\u9769\u862d\u9670\u6027\u96d9\u7403\u83cc\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. \u6dcb\u83cc\u6027\u8166\u819c\u708e\nB. \u8166\u819c\u708e\u7403\u83cc\u6027\u8166\u819c\u708e\nC. \u55dc\u8840\u6d41\u884c\u611f\u5192\u687f\u83cc\u6027\u8166\u819c\u708e\nD. \u7d50\u6838\u6027\u8166\u819c\u708e\nE. \u80ba\u708e\u7403\u83cc\u6027\u8166\u819c\u708e\n": "(B)", "104-3.\n72\u6b72\u7537\u6027\u7cd6\u5c3f\u75c520\u5e74\uff0c\u6700\u8fd1\u5c3f\u7d20\u6c2e\uff08BUN\uff0932 mg/dl\u3001\u808c\u9178\u9150\uff08creatinine\uff091.8 mg/dl\uff0c\u5176\u814e\u7d20(renin)\u53ca\u76ae\u8cea\u919b\u916e(aldosterone)\u7686\u504f\u4f4e\uff0c\u60a8\u9810\u6e2c\u6b64\u4eba\u9178\u9e7c\u5e73\u8861\u5982\u4f55\uff1f\nA. \u5b8c\u5168\u6b63\u5e38\nB. \u9240\u4f4e\uff0c\u4ee3\u8b1d\u6027\u9178\u4e2d\u6bd2(Hypokalemia, metabolic acidosis)\nC. \u9240\u4f4e\uff0c\u4ee3\u8b1d\u6027\u9e7c\u4e2d\u6bd2(Hypokalemia, metabolic alkalosis)\nD. \u9240\u9ad8\uff0c\u4ee3\u8b1d\u6027\u9e7c\u4e2d\u6bd2(Hyperkalemia, metabolic alkalosis)\nE. \u9240\u9ad8\uff0c\u4ee3\u8b1d\u6027\u9178\u4e2d\u6bd2(Hyperkalemia, metabolic acidosis)\n": "(E)", "104-4.\n\u4e0b\u5217\u6709\u95dc\u66b4\u98df\u75c7 (bulimia)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u60a3\u8005\u5728\u66b4\u98df\u5f8c\u6703\u611f\u5230\u8212\u66a2\nB. \u66b4\u98df\u7684\u5167\u5bb9\u4e3b\u8981\u662f\u78b3\u6c34\u5316\u5408\u7269\u985e\u98df\u7269\nC. \u5e38\u6703\u4f75\u767c\u4f4e\u8840\u9240\u75c7\nD. \u66b4\u98df\u75c7\u846f\u7269\u6cbb\u7642\u4e4b\u4e3b\u7dda\u846f\u70ba\u6297\u9b31\u5291\nE. \u66b4\u98df\u75c7\u60a3\u8005\u4e4b\u9ad4\u91cd\u591a\u5728\u6b63\u5e38\u7bc4\u570d\n": "(A)", "104-5.\n\u4e0b\u5217\u56e0\u7d20\u5747\u53ef\u80fd\u5f15\u8d77\u8001\u5e74\u4eba\u7684\u8b6b\u5984(delirium)\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. \u5c3f\u9053\u708e\nB. \u4ee3\u8b1d\u969c\u7919\nC. \u80ba\u708e\nD. \u846f\u7269\nE. \u5fc3\u7406\u58d3\u529b\n": "(E)", "104-6.\n\u4e0b\u5217\u6709\u95dc\u80ba\u708e\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. Legionella pneumophila \u5f15\u8d77\u8005\uff0c\u5c3f\u6db2\u6297\u539f\u6aa2\u67e5\u53ef\u65e9\u671f\u8a3a\u65b7\nB. Pneumocystis carinii\u5f15\u8d77\u8005\uff0c\u75f0\u57f9\u990a\u662f\u6700\u4f73\u78ba\u8a8d\u65b9\u6cd5\nC. Mycoplasma pneumoniae\u5f15\u8d77\u8005\uff0c\u75f0\u62b9\u7247\u5373\u53ef\u78ba\u5b9a\u8a3a\u65b7\nD. SARS\u51a0\u72c0\u75c5\u6bd2\u5f15\u8d77\u8005\uff0c\u8d77\u59cb\u90fd\u5448\u73fe\u5927\u8449\u6027\u80ba\u708e\nE. Aspergillus fumigatus\u53ea\u6703\u767c\u751f\u5728\u672c\u4f86\u6709\u7a7a\u6d1e\u7684\u80ba\u75c5\u7076\n": "(A)", "104-7.\n\u6709\u95dc\u80c3\u8178\u9053\u51fa\u8840\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6025\u6027\u51fa\u8840\u6642\uff0c\u51fa\u8840\u91cf\u591a\u5c11\u4e4b\u5224\u65b7\uff0c\u4e3b\u8981\u4f9d\u9760\u8840\u4e2d\u7684hemoglobin\u6578\u503c\nB. \u9f3b\u80c3\u7ba1\u62bd\u53d6\u6db2\u4e0d\u542b\u8840\u6db2\uff08non-bloody\uff09\u6642\uff0c\u8868\u793a\u4e0a\u6d88\u5316\u9053\u51fa\u8840\u4e4b\u6a5f\u7387\u4e0d\u5927\nC. \u6025\u6027\u51fa\u8840\u6642\uff0c\u61c9\u6ce8\u610f\u75c5\u4eba\u6709\u7121\u59ff\u52e2\u6027\uff08postural\uff09\u4f4e\u8840\u58d3\u6216\u5fc3\u8df3\u8b8a\u5feb\nD. \u6162\u6027\u51fa\u8840\u60a3\u8005\uff0c\u53ef\u80fd\u8840\u7d05\u7d20\u6578\u503c\u5df2\u660e\u986f\u964d\u4f4e\uff0c\u4f46\u75c5\u4eba\u7684\u8840\u58d3\u8207\u5fc3\u8df3\u4ecd\u7dad\u6301\u6b63\u5e38\nE. \u89e3\u8840\u4fbf\u6642\uff0c\u5927\u591a\u4f86\u81ea\u4e0b\u6d88\u5316\u9053\u51fa\u8840\n": "(A)", "104-8.\n\u5728\u52a0\u8b77\u75c5\u623f\u4e2d\u4f7f\u7528\u4eba\u5de5\u547c\u5438\u5668\u4e26\u767c\u751f\u8b6b\u5984(delirium)\u7684\u500b\u6848\uff0c\u8207\u6c92\u6709\u767c\u751f\u8b6b\u5984\u7684\u500b\u6848\u76f8\u8f03\uff0c\u524d\u8005\u6bd4\u8f03\u5bb9\u6613\u767c\u751f\u4e0b\u5217\u4f55\u7a2e\u73fe\u8c61\uff1f(1) \u4f4f\u9662\u65e5\u6578\u589e\u52a0\u3002(2) \u516d\u500b\u6708\u5167\u6b7b\u4ea1\u7387\u4e0a\u5347\u3002(3) \u51fa\u9662\u6642\u8a8d\u77e5\u529f\u80fd\u7f3a\u640d\u8f03\u56b4\u91cd\u3002(4) \u4f7f\u7528\u8f03\u5c11\u7684\u93ae\u975c\u85e5(sedatives)\u3002(5) \u4f4f\u9662\u671f\u9593\u4f7f\u7528\u547c\u5438\u5668\u65e5\u6578\u8f03\u77ed\u3002\nA. (2)+(3)+(4)\nB. (2)+(3)+(5)\nC. (1)+(3)+(5)\nD. (1)+(2)+(3)\nE. (2)+(4)+(5)\n": "(D)", "104-9.\n\u4e0b\u5217\u6709\u95dc\u9aa8\u4ee3\u8b1d\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f\nA. BMPs\uff08bone morphogenic proteins\uff09\u70ba\u6210\u9aa8\u7d30\u80de\uff08osteoblast\uff09\u4e4b\u5206\u5316\u6240\u9700\nB. M-CSF\uff08macrophage colony-stimulating factor\uff09\u662f\u7834\u9aa8\u7d30\u80de\uff08osteoclast\uff09\u5206\u5316\u6240\u9700\nC. RANK\uff08receptor activator of nuclear Factor \u03baB\uff09ligand\u662f\u7834\u9aa8\u7d30\u80de\u5206\u6ccc\nD. Osteocalcin\uff0cOsteopontin\uff0cAlkaline Phosphatase\u662f\u6210\u9aa8\u7d30\u80de\u5206\u6ccc\nE. Cross-linked N-telopeptide\u8840\u6fc3\u5ea6\u53ef\u4ee3\u8868\u9aa8\u5438\u6536\u4e4b\u5f37\u5ea6\n": "(C)", "104-10.\n\u6709\u4e0021\u6b72\u5973\u6027\u56e0\u9ad4\u91cd\u65bc\u4e00\u500b\u6708\u5167\u4e0b\u964d5\u516c\u65a4\uff0c\u5fc3\u60b8\u3001\u624b\u6296\u4f86\u5c31\u8a3a\uff0c\u9ad4\u6aa2\u767c\u73fe\u624b\u6296\u3001\u591a\u6c57\u3001 Gr \u2160\u7532\u72c0\u817a\u816b\u3001free T4 3.8ng/ml\u3001hsTSH<0.1\u03bcU/ml\u3001AMA1:56000x(+)\uff0c\u53e3\u670dpropylthiouracil 300 mg per day\u3001inderal 30mg per day\u5f8c\u4e00\u661f\u671f\uff0c\u75c5\u4eba\u56e0\u76ae\u819a\u7662\u518d\u4f86\u6c42\u8a3a\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6070\u7576\uff1f (1)\u76ae\u819a\u7662\u662f\u6297\u7532\u72c0\u817a\u85e5\u7269\u6700\u5e38\u898b\u4e4b\u526f\u4f5c\u7528 (2)\u5c07propylthiouracil\u6539\u6210 methimazole\u5373\u53ef (3)\u6e1b\u5c11propylthiouracil\u5291\u91cf\u5373\u53ef (4)\u53ea\u8981\u52a0\u4e0a\u6297\u7d44\u7e54\u80fa\u5373\u53ef\u3002\nA. (1)+(2)\nB. (2)+(6)\nC. (3)+(4)\nD. (4)+(1)\nE. (1)+(3)\n": "(D)", "104-11.\n\u6709\u90a3\u4e9b\u75c5\u539f\u83cc\u7684\u611f\u67d3\uff0c\u5728\u5e36\u6709HLA-B27\u6216\u5176\u4ed6\u7279\u6b8a\u907a\u50b3\u80cc\u666f\u7684\u4eba\u6709\u53ef\u80fd\u5f15\u8d77reactive arthritis? (1) TB bacilli (2) Yersinia (3) Salmonella (4) Shigella (5) E. coli\nA. (1)+(2)+(4)\nB. (1)+(2)+(3)\nC. (2)+(3)+(5)\nD. (2)+(4)+(5)\nE. (2)+(3)+(4)\n": "(E)", "104-12.\n\u4e00\u4f4d70\u6b72\u7684\u5a66\u4eba\uff0c\u4e3b\u8a34\u53f3\u5074\u819d\u95dc\u7bc0\u816b\u75db\u5df23\u5929\uff0cX\u5149\u6aa2\u67e5\u770b\u5230osteophytes\u53ca\u95dc\u7bc0\u8154\u6709\u7dda\u72c0\u9223\u5316\u9ede\u3002\u95dc\u7bc0\u6db2\u6aa2\u67e5\uff0c\u521d\u6b65\u7d50\u679c\u662f\u767d\u8840\u740326000 cells/mm3\uff0c\u5176\u4e2dPMN\u4f5480%\uff0cGram's stain\u70ba\u9670\u6027\u3002\u8acb\u554f\u6700\u4e0d\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Avascular necrosis\nB. Gouty arthritis\nC. Calcium pyrophosphate dihydrate deposition arthritis\nD. Bacterial septic arthritis\nE. Reactive arthritis\n": "(A)", "105-1.\n30\u6b72\uff0cBMI=23\uff0c\u5728\u5efa\u7bc9\u5de5\u5730\u5de5\u4f5c\u7684\u7537\u6027\u9ad8\u8840\u58d3\u60a3\u8005\uff0c\u56e0\u70ba\u5df2\u7d93\u670d\u7528\u56db\u7a2e\u85e5\u7269\u4e4b\u5f8c\u4ecd\u51fa\u73fe180/110mmHg\u7684\u8840\u58d3\u524d\u4f86\u9580\u8a3a\u3002\u4f9d\u60a3\u8005\u6240\u8aaa\uff0c\u4ed6\u5f9e17\u6b72\u5c31\u767c\u73fe\u6709\u9ad8\u8840\u58d3\uff0c\u96d6\u7136\u91ab\u5e2b\u5728\u904e\u53bb\u7d66\u4ed6\u56db\u7a2e\u63a7\u5236\u8840\u58d3\u7684\u85e5\u7269\uff0c\u4ed6\u4e26\u6c92\u6709\u89ba\u5f97\u7279\u5225\u4e0d\u8212\u670d\u3002\u5e73\u65e5\u4e0d\u5e38\u91cf\u8840\u58d3\uff0c\u53ea\u5728\u5076\u723e\u767c\u73fe\u8840\u58d3\u5f88\u9ad8\u6642\u5f9e\u85e5\u623f\u52a0\u8cb7\u85e5\u7269\u670d\u7528\u3002\u9580\u8a3a\u6642\u8eab\u9ad4\u6aa2\u67e5\u6c92\u6709\u7570\u5e38\uff0c\u62bd\u8840\u7684\u6578\u64da\u5982\u4e0b\uff1a Na: 145mEq/L; Cl: 110mEq/L; K: 3.0mEq/L; HCO3: 30 mEq/L; Glucose: 90mg/dL\u3002\u8acb\u554f\u63a5\u4e0b\u4f86\u5982\u4f55\u8655\u7f6e\u8f03\u6d3d\u7576\uff1f\nA. \u52a0\u7b2c\u4e94\u7a2e\u85e5\u7269\uff0c\u8acb\u60a3\u8005\u5bc6\u5207\u8ffd\u8e64\u8840\u58d3\nB. \u6e2c\u91cf\u5c3f\u6db2\u4e2d\u7684 VMA; metanephrines; catecholamines\nC. \u5b89\u6392\u96d9\u5074\u814e\u52d5\u8108\u7684\u90fd\u535c\u52d2\u8d85\u97f3\u6ce2\u6aa2\u67e5\nD. \u6aa2\u67e5 plasma renin activity (PRA) \u8207 plasma aldosterone concentration (PAC)\nE. \u5b89\u6392\u7761\u7720\u91ab\u5b78\u6aa2\u67e5\n": "(D)", "105-2.\n\u4e0b\u5217\u95dc\u65bc\u539f\u767c\u6027\u80ba\u7e96\u7dad\u5316(idiopathic pulmonary fibrosis)\u7684\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5178\u578b\u7684\u75c5\u7406\u8b8a\u5316\u662fusual interstitial pneumonia\nB. \u5178\u578b\u7684\u9ad8\u89e3\u6790\u5ea6\u96fb\u8166\u65b7\u5c64\u8b8a\u5316\u662f\u9031\u908a\u4e0b\u80ba\u91ce\u7684\u8702\u7aa9\u72c0\u7dda\u689d\u5f71\u50cf\nC. \u5178\u578b\u7684\u80ba\u529f\u80fd\u8b8a\u5316\u662f\u4fb7\u9650\u578b\u6c23\u9ad4\u4ea4\u63db\u969c\u7919\nD. \u5438\u5165\u6027\u985e\u56fa\u9187\u662f\u85e5\u7269\u6cbb\u7642\u7684\u9996\u9078\nE. \u662f\u80ba\u81df\u79fb\u690d\u7684\u9069\u61c9\u75c7\u4e4b\u4e00\n": "(D)", "105-3.\n\u4fbf\u79d8\uff08constipation\uff09\u53ef\u80fd\u767c\u751f\u65bc\u4e0b\u5217\u60c5\u6cc1\uff0c\u4f55\u8005\u9664\u5916\uff1f \u0010\nA. Hypothyroidism\nB. \u670d\u7528Bismuth\nC. Hypocalcemia\nD. \u670d\u7528calcium channel blockers\nE. \u670d\u7528opiates\n": "(C)", "105-4.\n\u4e00\u4f4d30\u6b72\u5973\u6027\uff0c\u904e\u53bb\u6709IgA nephropathy\u8207\u8f15\u5ea6\u86cb\u767d\u5c3f\uff0c\u5b9a\u671f\u5728\u9580\u8a3a\u5c31\u91ab\u3002\u6700\u8fd1\u61f7\u5b55\u4e26\u51fa\u73fe\u9ad8\u8840\u58d3\uff0c\u4ee5\u4e0b\u9ad8\u8840\u58d3\u76f8\u95dc\u85e5\u7269\u8655\u7f6e\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u5408?\nA. \u4f7f\u7528methyldopa\nB. \u4f7f\u7528ACEI \u985e\u964d\u4f4e\u86cb\u767d\u5c3f\uff0c\u9810\u9632\u767c\u751fpre-eclampsia\nC. \u4f7f\u7528 labetalol\nD. \u4f7f\u7528Long-acting nifedipine\nE. \u4f7f\u7528hydralazine\n": "(B)", "105-5.\n\u75c5\u4eba67\u6b72\u7537\u6027\uff0c\u81ea7\u6708\u8d77\u6709\u8f15\u5ea6\u54b3\u55fd\u53ca\u9593\u65b7\u6027\u767c\u71d2\u9ad8\u905438\u5ea6\uff0c\u574a\u9593\u8a3a\u6240\u8a3a\u65b7\u70ba\u4e0a\u547c\u5438\u9053\u611f\u67d3\u3002\u723e\u5f8c\uff0c\u767c\u71d2\u4ecd\u820a\u8d77\u4f0f\u8b8a\u52d5\uff0c\u5076\u6709\u5bd2\u986b(chillness)\uff0c\u4e26\u6709\u5168\u8eab\u5026\u6020\u53ca\u4e8c\u516c\u65a4\u9ad4\u91cd\u6e1b\u8f15\uff0c\u76f4\u523011\u6708\u624d\u5230\u9662\u6c42\u8a3a\u3002\u75c5\u4eba\u50c5\u6709\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u670d\u85e5\u4e2d\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u8840\u58d3\uff0c132/70 mmHg\uff1b\u5fc3\u8df3\uff0c78/\u5206\uff0c\u6b63\u5e38\u5f8b\u52d5\uff1b\u5fc3\u81df\u6709Gr II/IV Systolic murmur over left lower sternum border\uff1b\u5176\u4ed6\u5c1a\u7121\u7570\u5e38\u6240\u898b\u3002Blood cultures \u9001\u6aa2\u4e2d\u3002 \u8acb\u554f\u672c\u75c5\u4eba\u7684\u8a3a\u65b7\u4ee5\u4f55\u9805\u6aa2\u67e5\u6700\u6070\u7576?\nA. Cardiac MRI\nB. Chest CT\nC. Gallium Scan\nD. Transesophageal echocardiography\nE. Exploratory chest operation\n": "(D)", "105-6.\n\u4e0b\u5217\u95dc\u65bc\u7d50\u6838\u6027\u808b\u819c\u708e\u9020\u6210\u7684\u808b\u819c\u7a4d\u6c34\u751f\u5316\u53ca\u93e1\u6aa2\u4e4b\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. lymphocyte predominant exudate\nB. adenosine deaminase>40 IU/L\nC. Interferon gamma (INF-r) >140 pg/ml\nD. mesothelial cell\u7684\u6bd4\u7387\u9ad8\nE. smear \u7684acid fast stain \u967d\u6027\u7387 <5%\n": "(D)", "105-7.\n\u4e0b\u5217\u6709\u95dc\u5614\u5410\u4e4b\u75c5\u56e0\u63a8\u6e2c\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5614\u5410\u7269\u4e3b\u8981\u70ba\u672a\u6d88\u5316\u4e4b\u98df\u7269\uff0c\u53ef\u80fd\u6709achalasia\nB. \u5614\u5410\u7269\u542b\u6709\u81bd\u6c41\uff0c\u4e0d\u53ef\u80fd\u70bagastric obstruction\nC. \u5614\u5410\u7269\u5e36\u6709\u7cde\u5473\uff0c\u53ef\u80fd\u6709distal intestinal or colonic obstruction\nD. \u5614\u5410\u901a\u5e38\u767c\u751f\u65bc\u98ef\u5f8c1\u5c0f\u6642\u5167\uff0c\u53ef\u80fd\u70bapyloric stenosis\nE. \u5614\u5410\u5f8c\u8179\u75db\u6d88\u5931\uff0c\u8868\u793a\u53ef\u80fd\u70baacute pancreatitis\n": "(E)", "105-8.\n\u4e00\u4f4d30\u6b72\u7537\u6027\uff0c\u5728\u53c3\u52a0\u559c\u5bb4\u5f8c3\u5c0f\u6642\u958b\u59cb\u767c\u751f\u4e0a\u5410\u4e0b\u7009\u4e4b\u75c7\u72c0\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u8207\u4e0b\u5217\u4f55\u7a2e\u75c5\u539f\u76f8\u95dc\uff1f\nA. Staphylococcus aureus\nB. Shigella spp.\nC. Vibrio cholerae\nD. Salmonella spp.\nE. Enterohemorrhagic E.coli\n": "(A)", "105-9.\n48\u6b72\u5973\u6027\u56e0\u5065\u6aa2\u767c\u73fe\u7532\u72c0\u817a\u816b\u4f86\u6c42\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u75c5\u4eba\u7532\u72c0\u817a\u5448\u7b2c\u4e00\u5ea6\u816b\u5927\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30free T4 1.07 ng/dl\u3001hsTSH 7.5\u03bcU/ml\u3001thyroglobulin 100 ng/ml\u3001antiTPO 400 IU/ml\u3002\u4e0b\u5217\u8655\u7f6e\u53ca\u5176\u7406\u7531\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u75c5\u4eba\u7532\u72c0\u817a\u6a5f\u80fd\u4f4e\u4e0b\u5373\u523b\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u88dc\u5145\nB. \u75c5\u4eba\u7532\u72c0\u817a\u816b\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nC. \u75c5\u4ebaantiTPO\u9ad8\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\u4ee5\u6e1b\u5c11\u767c\u708e\nD. \u75c5\u4ebathyroglobulin\u9ad8\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nE. \u7532\u72c0\u817a\u7d20\u6cbb\u7642\u7121\u76ca\uff0c\u89c0\u5bdf\u5373\u53ef\n": "(E)", "105-10.\n37\u6b72\u5973\u6027\u70ba\u7b2c1\u578b\u7cd6\u5c3f\u75c519\u5e74\uff0c\u56e0\u5de6\u8db3\u7121\u6cd5\u80cc\u5c48 ( dorsiflex ) \u4f86\u8a3a\uff0c\u6700\u8fd1\u8ffd\u8e64\u9664\u4e86\u773c\u5e95\u6709\u4e00\u4e9b\u5c0f\u8840\u7ba1\u7624\u4ee5\u5916\u7121\u5176\u4ed6\u4f75\u767c\u75c7\uff0c\u9ad4\u6aa2\u767c\u73fe\u7532\u72c0\u817a2\u5ea6\u816b\u5927\uff0c\u5de6\u8db3\u7121\u6cd5\u80cc\u5c48\uff0c\u611f\u89ba\u4e5f\u55aa\u5931\uff0c\u53f3\u4e0b\u80a2\u5247\u70ba\u6b63\u5e38\uff1b \u819d\u53cd\u5c04\u4e8c\u5074\u7686\u6b63\u5e38\uff0c\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u6700\u6070\u7576?\nA. \u7532\u72c0\u817a\u529f\u80fd\u6aa2\u67e5\nB. \u795e\u7d93\u50b3\u5c0e\u6aa2\u67e5\nC. \u8166\u810a\u9ad3\u6db2\u86cb\u767d\u96fb\u6cf3\nD. \u8170\u90e8\u6838\u78c1\u5171\u632f\nE. \u985e\u98a8\u6fd5\u56e0\u5b50\u6e2c\u5b9a\n": "(B)", "105-11.\n\u4e00\u4f4d\u4e2d\u5e74\u5973\u6027\uff0c\u6709\u86cb\u767d\u5c3f(+)\uff0c creatinine 1.8 mg/dL\uff0c\u5026\u6020\uff0c\u8207serum C3 level\u964d\u4f4e\u3002\u5c1a\u672a\u505a\u814e\u81df\u75c5\u7406\u6aa2\u67e5\u524d\uff0c\u6700\u53ef\u80fd\u662f\u4ee5\u4e0b\u54ea\u4e00\u7a2e\u814e\u708e\u75be\u75c5?\nA. Focal segmental glomerulosclerosis (FSGS)\nB. cryoglobulinemia\nC. Henoch-Schonlein purpura\nD. Wegner's granulomatosis\nE. IgA nephropathy\n": "(B)", "105-12.\n\u6709\u95dc\u50f5\u76f4\u6027\u810a\u690e\u708e\u7684\u8840\u6db2\u53ca\u8840\u6e05\u5b78\u6aa2\u67e5\u6578\u64da\u5982\u4e0b\uff0c\u8acb\u554f\u4f55\u8005\u6700\u70ba\u6b63\u78ba?(1) ANA(+) (2) ESR\u4e0a\u5347( 3) CRP\u4e0a\u5347 (4) RF (+) (5)Anti-CCP (-) (6) HLA-B27(+) (7) ANCA(+)\nA. 1+2+3\nB. 4+5+6\nC. 2+4+7\nD. 3+4+5\nE. 3+5+6\n": "(E)", "106-1.\n\u95dc\u65bc\u6c23\u5598\u968e\u68af\u5f0f\u6cbb\u7642(stepwise therapy)\u7684\u6558\u8ff0,\u4e0b\u5217\u4f55\u8005\u6b63\u78ba? (1)\u6bcf\u5468\u4f7f\u7528\u7de9\u89e3\u85e5\u7269(reliever medication)\u5927\u65bc\u5169\u6b21\u4ee5\u4e0a, \u5c31\u9700\u898f\u5f8b\u4f7f\u7528\u63a7\u5236\u85e5\u7269(controller medication)\uff1b(2)\u63a7\u5236\u85e5\u7269\u7684\u9996\u9078\u70ba\u5438\u5165\u578b\u985e\u56fa\u9187(inhaled corticosteroids)\uff1b(3)\u7b2c\u4e00\u968e\u75c5\u4eba\u50c5\u4f7f\u7528\u5438\u5165\u578b\u77ed\u6548\u4e4b\u4e59\u578b\u4ea4\u611f\u795e\u7d93\u523a\u6fc0\u5c31\u53ef\u4ee5\uff1b(4)\u5438\u5165\u578b\u985e\u56fa\u9187\u7684\u8d77\u59cb\u5291\u91cf\u70ba\u4e2d\u5291\u91cf(\u76f8\u7576200 \u03bcg BID/day beclomethasone dipropionate )\uff1b(5)\u4f7f\u7528\u63a7\u5236\u85e5\u7269\u5f8c\u5169\u500b\u6708\u5c31\u53ef\u8a55\u4f30\u6cbb\u7642\u6548\u679c\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (4)+(5)\nE. (3)+(4)+(5)\n": "(B)", "106-2.\n\u8840\u6e05Troponin I\u4e4b\u6607\u9ad8\u662f\u5fc3\u81df\u6025\u75c7\u91cd\u8981\u7684\u751f\u7269\u6a19\u8a18(bio-marker), \u4e0b\u5217\u4f55\u8005\u4e0d\u6703\u767c\u751f\u8840\u6e05Troponin I\u4e0a\u5347?\nA. Congestive heart failure\nB. Pulmonary embolism\nC. Acute myocardial infarction\nD. Acute myocarditis\nE. Pneumonia\n": "(E)", "106-3.\n\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5(multidrug-resistant tuberculosis, MDRTB)\u662f\u76ee\u524d\u5168\u7403\u7d50\u6838\u75c5\u9632\u6cbb\u7684\u91cd\u5927\u6311\u6230\u3002\u4e0b\u5217\u7d44\u5408\u4f55\u8005\u70ba\u662f\uff1f (1)\u53f0\u7063\u7684\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u76e3\u6e2c\u767c\u73fe\uff1a\u5728\u7d50\u6838\u75c5\u65b0\u75c5\u4eba\u70ba1%\uff0c\u518d\u6cbb\u75c5\u4eba(\u5305\u542b\u5fa9\u767c\u3001\u6cbb\u7642\u5931\u6557\u548c\u5931\u843d)\u70ba6-8%\u3002\u76f8\u8f03\u65bc\u5468\u908a\u7684\u4e2d\u570b\u5927\u9678(\u5206\u5225\u70ba5.7%\u548c25.6%)\u53ca\u6771\u5357\u4e9e\uff0c\u53f0\u7063\u75ab\u60c5\u8f03\u8f15\u5fae\u3002 (2)\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u7684\u5be6\u9a57\u5ba4\u6aa2\u67e5\u53ea\u80fd\u4f9d\u8cf4\u50b3\u7d71\u85e5\u7269\u654f\u611f\u6027\u8a66\u9a57\u7d50\u679c\uff0c\u76ee\u524d\u65b0\u7684\u5206\u5b50\u5feb\u901f\u8a3a\u65b7\u7684\u65b9\u6cd5\uff0c\u5982\uff1aHain test \u6216Xpert\uff0c\u4ecd\u5c1a\u5728\u8a55\u4f30\u4e2d\u3002 (3)\u4e00\u822c\u7d50\u6838\u75c5\u7684\u6cbb\u7642\u61c9\u5408\u4f75\u591a\u7a2e\u85e5\u7269\u3001\u5291\u91cf\u8db3\u5920\u3001\u4e14\u6709\u8db3\u5920\u7684\u6cbb\u7642\u671f\uff0c\u4e26\u52f8\u75c5\u4eba\u52a0\u5165\u90fd\u6cbb(directly observed therapy)\r\u78ba\u4fdd\u670d\u85e5\u9806\u5f9e\u6027\uff0c\u53ef\u6e1b\u5c11\u7522\u751f\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u7684\u98a8\u96aa\u3002 (4)\u4e00\u65e6\u70ba\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u4eba\uff0c\u6cbb\u7642\u9700\u8003\u616e\u5408\u4f754\u7a2e\u4ee5\u4e0a\u7684\u6709\u6548\u85e5\u7269\uff0c\u4f46\u4e0d\u9808\u5ef6\u9577\u6cbb\u7642\u8d85\u904e\u75f0\u9670\u8f4918\u500b\u6708\u3002 (5)\u591a\u91cd\u6297\u85e5\u7d50\u6838\u75c5\u4eba\u4f7f\u7528\u7684\u4e8c\u7dda\u85e5\u7269\u526f\u4f5c\u7528\u6bd4\u4e00\u7dda\u6297\u7d50\u6838\u85e5\u7269\u591a\uff0c\u5efa\u8b70\u75c5\u4eba\u8f49\u4ecb\u7d66\u5177\u7d93\u9a57\u7684\u591a\u91cd\u6297\u85e5\u75c5\u4eba\u7167\u8b77\u5718\u968a\u91ab\u9662\u3002\nA. (1)+(3)+(5)\nB. (2)+(4)\nC. (2)+(3)+(4)\nD. (1)+(2)+(5)\nE. (1)+(4)+(5)\n": "(A)", "106-4.\n55\u6b72\u7537\u6027\u6700\u8fd13\u500b\u6708\u958b\u59cb\u6709\u6f6e\u7d05\u3001\u6d41\u6c57\u3001\u547c\u5438\u56f0\u96e3\u4e4b\u767c\u4f5c\uff0c\u8d77\u521d\u5f88\u8f15\u5fae\uff0c\u4f46\u8fd11\u500b\u6708\u4f86\u89ba\u5f97\u52a0\u91cd\uff0c\u66fe\u56e0\u4e0a\u8ff0\u75c7\u72c0\u5230\u904e\u6025\u8a3a\uff0c\u4f46\u7d93\u75c7\u72c0\u6cbb\u7642\u5373\u6062\u5fa9\uff0c\u4e09\u661f\u671f\u524d\u9084\u56e0\u61f7\u7591\u6025\u6027\u76f2\u8178\u708e\u958b\u5200\u4f46\u75c7\u72c0\u7686\u7121\u6539\u5584\uff0c\u4e8c\u5929\u524d\u5167\u8996\u93e1\u6aa2\u67e5\u767c\u73fe\u5341\u4e8c\u6307\u8178\u6f70\u760d\u3001\u80c3\u708e\uff0c\u8179\u8d85\u767c\u73fe\u809d\u5be6\u8cea\u6027\u75be\u75c5 ( parenchymal disease ) \uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u767c\u73fe\u53f3\u814e\u4e0a\u817a\u67093.5 cm\u816b\u7624\uff0c\u7d93\u5167\u5206\u6ccc\u6aa2\u67e5\uff0ccortisol\u3001ACTH\u3001catecholamine\u3001aldosterone\u3001plasma renin activity\u3001 DHEAS\u7686\u70ba\u6b63\u5e38\uff0c\u8acb\u554f\u60a8\u5982\u4f55\u8655\u7f6e\uff1f\nA. \u6b64\u70ba\u7121\u529f\u80fd\u6027\u816b\u7624\uff0c\u53ef\u63a1\u75c7\u72c0\u6cbb\u7642\nB. \u4e0d\u8ad6\u6709\u7121\u529f\u80fd\uff0c\u7167\u6703\u958b\u5200\u6cbb\u7642\nC. \u5148\u7167\u6703\u7cbe\u795e\u79d1\u6392\u9664\u7cbe\u795e\u65b9\u9762\u75be\u75c5\nD. \u6b64\u70ba\u7537\u6027\u66f4\u5e74\u671f\u53ef\u7d66\u4e88\u96c4\u6027\u7d20\u6cbb\u7642\nE. 6\u500b\u6708\u5f8c\u518d\u505a\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(B)", "106-5.\n\u4e00\u500b30\u6b72\u7537\u6027\u4e3b\u8a34\u4e0b\u80cc\u75db\u5df2\u534a\u5e74,X\u5149\u6aa2\u67e5\u4e26\u7121\u660e\u986f\u8b8a\u5316.\u4f46ESR\u53caCRP\u7686\u660e\u986f\u4e0a\u5347.\u6700\u8fd13\u500b\u6708\u5176\u8173\u5f8c\u8ddf(heel)\u4e5f\u6642\u5e38\u75bc\u75db.\u9a57\u5176HLA-B27\u57fa\u56e0\u70ba\u967d\u6027.\u5176\u7236\u89aa\u70ba\u50f5\u76f4\u6027\u810a\u690e\u708e\u4e4b\u60a3\u8005.\u75c5\u4eba\u5f9e\u672a\u63a5\u53d7\u904e\u4efb\u4f55\u85e5\u7269\u6cbb\u7642,\u8acb\u554f\u6700\u9069\u7576\u7684\u8655\u65b9\u70ba\u90a3\u4e00\u9805\u85e5\u7269?\nA. Glucocorticoid\nB. Etanercept\nC. Sulfasalazine\nD. Methotrexate\nE. Non-steroidal anti-inflammatory drugs\n": "(E)", "106-6.\n58\u6b72\u7537\u6027\uff0c2\u5e74\u524d\u56e0\u8166\u5782\u817a 1.6 \u516c\u5206\u7121\u529f\u80fd\u816b\u7624\u958b\u5200\u5207\u9664\uff0c\u6b64\u5f8c\u5373\u670d\u7528\u7532\u72c0\u817a\u7d20\u6cbb\u7642\uff0c\u75c5\u4eba\u5728\u5065\u6aa2\u767c\u73fe\u8170\u690eBone nineral Density(BMD) -2.6\u3001\u5de6\u81c0BMD -2.7\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u7121\u7279\u6b8a\u7570\u5e38\uff0c\u62bd\u8840free T4 1.2 ng/dL \u3001hsTSH \uff1c0.1 \u03bcU/mL\uff0cFSH\u3001LH\u7686\uff1c1.0 mIU/mL\uff0cTestosterone 50 ng/dL\uff0c\u9664\u4e86Vit D \u53ca\u9223\u4e4b\u88dc\u5145\u5916\uff0c\u4e0b\u5217\u90a3\u4e00\u6cbb\u7642\u6700\u6070\u7576 ?\nA. Calcitonin\nB. Carbergoline\nC. Testosterone\nD. \u6e1b\u5c11\u7532\u72c0\u817a\u7d20\u5291\u91cf\nE. Bisphosphonate\n": "(C)", "106-7.\n\u5c0d\u65bc\u61f7\u7591\u6709intestinal obstruction\u4e4b\u60a3\u8005\uff0c\u8179\u90e8\uff38\u5149\u7167\u76f8\uff08plain abdomen\uff09\u53ef\u63d0\u4f9b\u76f8\u7576\u6709\u7528\u7684\u8cc7\u6599\u3002\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Plain abdomen\u7528\u4f86\u5224\u65b7nonstrangulating complete small-bowel obstruction\u76f8\u7576\u53ef\u9760\nB. Partial mechanical small-bowel obstruction\u8207adynamic ileus\u4e0d\u592a\u5bb9\u6613\u5340\u5206\uff0c\u4f46colonic distension\u5728adynamic ileus\u901a\u5e38\u8f03\u660e\u986f\nC. \u8139\u5927\u7684\u5c0f\u8178\u4e2d\u53ef\u898bair-fluid levels\uff0c\u5e38\u6392\u5217\u6210\u201cstepladder\u201d pattern\uff0c\u5c11\u898b\u5167\u542b\u7a7a\u6c23\u7684\u5927\u8178\uff0c\u9019\u4e9b\u767c\u73fe\u5e38\u898b\u65bcstrangulating small-bowel obstruction\nD. \u82e5\u81e8\u5e8a\u75c7\u72c0\u5f88\u50cfsmall intestine obstruction\uff0c\u4f46plain abdomen\u770b\u8d77\u4f86\u6b63\u5e38\uff0c\u6b64\u6642\u5b89\u6392\u8179\u90e8CT\u6aa2\u67e5\u6709\u52a9\u65bc\u8a3a\u65b7\nE. \u559d\u92c7\u5291\u4f86\u5e6b\u5fd9\u5224\u65b7\u5c0f\u8178\u7684\u963b\u585e\u90e8\u4f4d\u662f\u76f8\u7576\u5b89\u5168\u7684\n": "(C)", "106-8.\n\u4e00\u4f4d68\u6b72\u7537\u6027\u9ad4\u91cd60\u516c\u65a4\uff0c\u8eab\u9ad8172\u516c\u5206\uff0c\u62bd\u8840\u9a57\u808c\u9178\u9150(Cr)\u70ba1.5mg/dL\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\nA. \u4f9dCockcroft-Gault\u516c\u5f0f\uff0c\u5176\u4f30\u8a08\u814e\u7d72\u7403\u904e\u6ffe\u7387\u4ecb\u65bc55-65ml/min\nB. \u4f9d\u4e0a\u8ff0\u516c\u5f0f\uff0c\u5176\u4f30\u8a08\u814e\u7d72\u7403\u904e\u6ffe\u7387\u4ecb\u65bc45-55ml/min\nC. \u4f9d\u6162\u6027\u814e\u81df\u75c5\u5206\u671f\u70ba\u7b2c1\u671f\nD. \u4f9d\u6162\u6027\u814e\u81df\u75c5\u5206\u671f\u70ba\u7b2c2\u671f\nE. \u4f9d\u6162\u6027\u814e\u81df\u75c5\u5206\u671f\u70ba\u7b2c3\u671f\n": "(E)", "106-9.\n\u4e0b\u5217\u6709\u95dc\u6025\u91cd\u75c7\u75c5\u4eba\u5728\u52a0\u8b77\u75c5\u623f\u4e4b\u8655\u7f6e\uff0c\u4f55\u8005\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. \u547c\u5438\u8870\u7aed\u75c5\u60a3\u8f38\u6ce8albumin\uff0c\u53ef\u964d\u4f4e\u6b7b\u4ea1\u738720%\nB. \u4f7f\u7528ventilator\u75c5\u4eba\u63a1\u7528H2 blocker\uff0c\u5e38\u4f75\u767c\u80ba\u708e\nC. \u5982\u7121\u7981\u5fcc\uff0c\u53ef\u7528low molecular weight heparin\u6ce8\u5c04\uff0c\u4ee5\u9810\u9632deep vein thrombosis\nD. \u63a1\u7528\u975c\u8108\u6ce8\u5c04\u93ae\u975c\u5291\uff0c\u53ef\u7e2e\u77ed\u547c\u5438\u5668\u4f7f\u7528\u6642\u9593\nE. \u4f7f\u7528corticosteroids\u53ef\u80fd\u5c0e\u81f4\u591a\u767c\u6027\u795e\u7d93\u75c5\u8b8a(polyneuropathy)\n": "(A)", "106-10.\n\u4e00\u4f4d64\u6b72\u7537\u6027\u75c5\u4eba\u6709\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u73fe\u814e\u529f\u80fd\u8b8a\u5dee\uff0c\u814e\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u6709\u814e\u6c34\u816b(hydronephrosis)\u73fe\u8c61\uff0c\u8179\u90e8\u53ca\u9aa8\u76c6\u8154\u96fb\u8166\u65b7\u5c64\u986f\u793a\u5982\u5716\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u75c5\u56e0?\nA. \u5169\u5074\u5c3f\u8def\u7d50\u77f3\nB. \u651d\u8b77\u817a\u80a5\u5927\nC. \u591a\u56ca\u814e\nD. \u767c\u708e\u6027\u4e3b\u52d5\u8108\u7624\nE. \u814e\u79fb\u884c\u4e0a\u76ae\u7d30\u80de\u764c(Transitional cell carcinoma)\n": "(D)", "106-11.\n\u95dc\u65bc\u809d\u786c\u5316\u4e4b\u4f75\u767c\u75c7\uff0c\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u98df\u9053\u975c\u8108\u66f2\u5f35\u7834\u88c2\u51fa\u8840\uff0c\u65bc\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a\u5f8c\u61c9\u5118\u5feb\u65bd\u884cband ligation\u3002\nB. \u82e5\u8179\u90e8\u8139\u5927\u4e14\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u8179\u90e8\u6709shifting dullness\uff0c\u61c9\u9650\u5236\u5176\u6bcf\u65e5\u7d0d\u651d\u53d6\u91cf\u4f4e\u65bc2 g\u3002\nC. \u82e5\u6709\u8179\u75db\uff0c\u62bd\u53d6\u8179\u6c34\u6aa2\u9a57\u767c\u73feneutrophils > 250/\u03bcL\uff0c\u61c9\u7acb\u5373\u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\u3002\nD. \u82e5\u75c5\u4eba\u884c\u70ba\u7570\u65bc\u5e73\u6642\uff0c\u62bd\u8840\u6aa2\u9a57\u767c\u73feNH3 =100 (\u6b63\u5e38 < 37)\uff0c\u61c9\u512a\u5148\u4ee5neomycin\u6216metronidazole\u7b49\u8178\u9053\u5438\u6536\u751a\u5c11\u4e4b\u6297\u751f\u7d20\u7d66\u4e88\u6cbb\u7642\u3002\nE. \u82e5\u75c5\u4eba\u525b\u5f9e\u809d\u6027\u8166\u75c5\u8b8a (hepatic encephalopathy) \u6062\u5fa9\uff0c\u61c9\u9650\u5236\u5176\u6bcf\u65e5\u86cb\u767d\u8cea\u651d\u53d6\u91cf\uff0c\u5c24\u5176\u662f\u52d5\u7269\u6027\u86cb\u767d\u8cea\u3002\n": "(D)", "106-12.\n\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u6709\u53ef\u80fd\u9020\u6210\u5168\u8840\u7403\u6e1b\u5c11\uff1f(1)\u56b4\u91cd Vit B12 deficiency\uff1b(2) Myelodysplastic syndrome\uff1b(3) Liver cirrhosis\uff1b(4) Autoimmune disease\nA. (4)\nB. (2)+(4)\nC. (2)+(3)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(E)", "107-1.\n\u75c5\u4eba67\u6b72\u5973\u6027\uff0c\u4f4f\u5b89\u990a\u8001\u4eba\u9662\uff0c\u4e0b\u5e8a\u8dcc\u50b7\u53f3\u8173\uff0c\u4e94\u5929\u5f8c\u56e0\u610f\u8b58\u4e0d\u6e05\u4f34\u6709\u6c23\u4fc3\u3001\u767c\u71d2\u3001\u5bd2\u986b(chills)\u800c\u4f4f\u9662\u3002\u75c5\u4eba\u6709\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\uff0c\u4e5f\u6709\u9ad8\u8840\u58d3\u5408\u4f75\u5fc3\u81df\u8870\u7aed\u7684\u75c5\u53f2\u3002\u4f4f\u9662\u6642\uff0cGCS E2V2M3\uff1bBP\uff0c112/57 mmHg\uff1bHR\uff0c85/min\uff0cregular\uff1bRR\uff0c25/min\uff1b\u9ad4\u6eab\uff0c\u651d\u6c0f37\u5ea6\uff1b\u5fc3\u81df\u5448\u73fe\u898f\u5f8b\uff0c\u4f46\u5728\u5fc3\u5c16\u90e8\u6709Gr.III/VI Systolic murmur\uff1b\u5728\u80ba\u57fa\u8655\u6fc1\u6fd5\u547c\u5438\u8072\uff1b\u56db\u80a2\u591a\u8655\u7600\u8840\uff0c\u6b64\u5916\u5c1a\u7121\u7570\u5e38\u6240\u898b\u3002\u5be6\u9a57\u5ba4\u6240\u898b\uff1a\u767d\u8840\u7403\uff0c15350/\u03bcL\uff1bC-\u53cd\u61c9\u86cb 44.20 mg/dl(\u6b63\u5e38<1.9)\uff1b\u808c\u9178\u9150 0.98mg/dl\uff1b\u4f4f\u9662\u7b2c\u4e8c\u5929\u6709\u5169\u5957\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u5448\u73fe\u9769\u862d\u967d\u6027\u75c5\u83cc\u3002\u81e8\u5e8a\u8a3a\u65b7\u70ba\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e(infective\rendocarditis)\u5f8c\uff0c\u8acb\u554f\u5728\u6b64\u523b\uff0c\u4e0b\u5217\u4f55\u7a2e\u8655\u7f6e\u70ba\u5b9c\uff1f\nA. \u9032\u884c\u4ecb\u5165\u6027\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\nB. \u5916\u79d1\u624b\u8853\u4ee5\u7372\u5f97\u7d44\u7e54\u8a3a\u65b7\nC. \u4f7f\u7528 IV dopamine 0.5 \u03bcgkg/min \u6ce8\u5c04\uff0c\u4ee5\u589e\u52a0\u5c3f\u91cf\nD. \u4f5c24\u5c0f\u6642\u5fc3\u96fb\u5716\u6aa2\u67e5\u4ee5\u78ba\u5b9a\u5fc3\u5f8b\u4e0d\u6574\nE. \u4f5c\u8d85\u97f3\u6ce2\u5fc3\u5716\u6aa2\u67e5\u4ee5\u78ba\u5b9a\u5fc3\u81df\u75c5\u8b8a\n": "(E)", "107-2.\n\u7d30\u83cc\u6027\u80ba\u708e\u5408\u4f75\u808b\u819c\u7a4d\u6db2\uff0c\u4e0b\u5217\u4f55\u7a2e\u808b\u819c\u7a4d\u6db2\u4e4b\u6578\u64da\u8868\u793a\u9808\u63d2\u80f8\u7ba1\u5f15\u6d41\uff1f\nA. PMN > 90%\nB. WBC > 1000/mm3\nC. Glucose < 100 mg/dL\nD. pH < 7.2\nE. LDH > 300 IU/L\n": "(D)", "107-3.\n\u4e0b\u5217\u6709\u95dcpancreatic neuroendocrine tumor\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f (1)glucagonoma\u53ef\u80fd\u5c0e\u81f4\u7cd6\u5c3f\u75c5 (2)VIPoma (VIP: vasoactive intestinal peptide)\u53ef\u80fd\u5c0e\u81f4peptic ulcers (3)insulinoma\u5e38\u70ba\u60e1\u6027\u816b\u7624 (4)EUS (endoscopic ultrasound)\u662f\u5075\u6e2c\u9019\u985e\u816b\u7624\u4e4b\u6700\u4f73\u5de5\u5177 (5) liver metastasis\u5c0d\u60a3\u8005\u4e4b\u9810\u5f8c\u5f71\u97ff\u751a\u5927\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (2)+(3)+(5)\nE. (1)+(4)+(5)\n": "(E)", "107-4.\n\u4e00\u4f4d24\u6b72\u5973\u6027\uff0c\u904e\u53bb\u7121\u75c5\u53f2\u3002\u7d042\u500b\u6708\u524d\u958b\u59cb\u6ce8\u610f\u51fa\u73fe\u6c34\u816b\uff0c\u9ad4\u91cd\u57282\u500b\u6708\u5167\u589e\u52a08\u516c\u65a4\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5: albumin 2.8 g/dL, creatinine 0.8 mg/dL, t-Chol 280 mg/dL, LDL 163 mg/dL, urine protein-creatinine (P/C) ratio \u7d049 mg/mg, urinalysis O.B. (-), serum [K] 4 mEq/L, [Ca] 9.2 mg/dL, Hb 12 g/dL\u3002\u672c\u75c5\u4eba\u7684\u8a3a\u65b7\uff0c\u6700\u53ef\u80fd\u70ba?\nA. IgA nephropathy\nB. minimal change disease\nC. multiple myeloma with nephropathy\nD. systemic lupus erythromatous (SLE) with nephropathy\nE. membranoproliferative glomerulonephritis (MPGN)\n": "(B)", "107-5.\n\u6709\u95dc\u6d41\u611f\u75ab\u82d7\u63a5\u7a2e\u526f\u4f5c\u7528\u8207\u7981\u5fcc\u75c7\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f (1)\u5c0d\u96de\u86cb\u56b4\u91cd\u904e\u654f\u8005\u70ba\u63a5\u7a2e\u6d41\u611f\u75ab\u82d7\u4e4b\u7981\u5fcc\u3002 (2)\u9664\u4e86\u7f8e\u570b1976\u5e74H1N1\u8c6c\u6d41\u611f\u75ab\u82d7\u5916\uff0c\u63a5\u7a2e\u5b63\u7bc0\u6d41\u611f\u75ab\u82d7\u5f8c\u767c\u751fGuillain-Barre syndrome\u4e4b\u6a5f\u7387\u6975\u4f4e\u3002 (3)\u5c0f\u65bc6\u500b\u6708\u4e4b\u5b30\u5152\u4e0d\u5b9c\u63a5\u53d7\u6d41\u611f\u75ab\u82d7\u65bd\u6253\u3002 (4)\u90e8\u5206\u6d41\u611f\u75ab\u82d7\u4e2d\u542b\u6709\u7532\u57fa\u6c5e\u8207\u4e59\u57fa\u6c5e\u7528\u4ee5\u4fdd\u5b58\u75ab\u82d7\uff0c\u7532\u57fa\u6c5e\u8207\u4e59\u57fa\u6c5e\u5747\u53ef\u70ba\u4eba\u9ad4\u6240\u4ee3\u8b1d\u3002 (5)\u5728\u5224\u65b7\u6d41\u611f\u75ab\u82d7\u63a5\u7a2e\u5f8c\u4e0d\u826f\u4e8b\u4ef6\u8207\u75ab\u82d7\u63a5\u7a2e\u4e4b\u56e0\u679c\u95dc\u4fc2\u6642\uff0c\u8a72\u4e0d\u826f\u4e8b\u4ef6\u4e4b\u6b7b\u4ea1\u6216\u91cd\u75c7\u6bd4\u7387\u662f\u91cd\u8981\u7684\u89c0\u5bdf\u6307\u6a19\u3002\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (1)+(3)+(5)\nE. (1)+(2)+(3)+(5)\n": "(E)", "107-6.\n45\u6b72\u5973\u6027\u56e0\u5026\u6020\u3001\u7121\u529b\u3001\u4fbf\u79d8\u3001\u9ad4\u91cd\u589e\u52a0\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u8eab\u9ad8160\u516c\u5206\u3001\u9ad4\u91cd60\u516c\u65a4\u3001\u81c9\u90e8\u7565\u70ba\u6d6e\u816b\u3001\u84bc\u767d\uff0c\u8840\u58d3 146/92 mmHg\u3001PR 58/min\uff0c regular \u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u98ef\u524d\u8840\u7cd6100 mg/dl\u3001\u81bd\u56fa\u9187 260 mg/dl\u3001\u4f4e\u5bc6\u5ea6\u81bd\u56fa\u9187 160 mg/dl\uff0cNa 128 mM\u3001K 4.0 mM\u3001CK 1500 U/L\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u6070\u7576\ufe30\nA. \u7d66\u4e88statin\u6cbb\u7642\nB. \u7d66\u4e88angiotensin receptor blocker\nC. \u6e2cUrine sodium\u3001protein\nD. \u6e2c\u8840\u4e2d free T4\u3001hsTSH\nE. \u6e2c\u8840\u4e2d ACTH\u3001cortisol\n": "(D)", "107-7.\n\u4e0b\u5217\u90a3\u4e00\u9805\u975e\u8a3a\u65b7\u7b2c1\u578b\u7cd6\u5c3f\u75c5\u7684\u5fc5\u8981\u689d\u4ef6\ufe30\nA. \u7a7a\u8179\u8840\u6e05C-\u80dc\ufffdT\u6fc3\u5ea6 < 0.5 ng/ml\nB. \u5347\u7cd6\u7d20\u523a\u6fc0\u5f8c6\u5206\u9418\u8840\u6e05C-\u80dc\ufffdT\u6fc3\u5ea6 < 1.8 ng/ml\nC. \u5347\u7cd6\u7d20\u523a\u6fc0\u8a66\u9a576\u5206\u82070\u5206\u8840\u6e05C-\u80dc\ufffdT\u6fc3\u5ea6\u76f8\u5dee < 0.7 ng/ml\nD. \u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2\nE. Anti-GAD65 \u967d\u6027\n": "(D)", "107-8.\n50\u6b72\u4e4b\u7537\u75c5\u4eba,\u7f79\u60a3\u75db\u98a8\u77f3\u6027\u95dc\u7bc0\u708e(tophaceous gout)\u5df21\u5e74\u591a,\u5169\u4e0b\u80a2\u6709\u8a31\u591a\u5927\u5c0f\u4e0d\u4e00\u7684\u75db\u98a8\u77f3(tophi);\u540c\u6642\u6709\u6162\u6027\u814e\u529f\u80fd\u4e0d\u5168,\u8840\u4e2dcreatinine\u503c\u70ba2.5 mg/ml,\u4e26\u6709\u814e\u7d50\u77f3.\u5176HLA-B5801\u57fa\u56e0\u70ba\u967d\u6027.\u8acb\u554f\u6700\u5408\u9069\u7684\u964d\u5c3f\u9178\u85e5\u7269\u70ba\u4f55?\nA. febuxostat\nB. probenecid\nC. benzbramarone\nD. sulfinpyrazone\nE. allopurinol\n": "(A)", "107-9.\n\u4e00\u4f4d27\u6b72\u7684\u7537\u6027\uff0c\u5f9e\u5c0f\u5c31\u6709\u4e2d\u7b49\u5ea6\u6301\u7e8c\u578b\u7684\u904e\u654f\u6027\u9f3b\u708e(Allergic rhinitis)\uff0c\u5176\u8840\u4e2dtotal IgE 325IU/ml\uff0c\u904e\u654f\u539f\u6aa2\u67e5\u767c\u73fe\u5c0dhouse dust mite Der.P \u5448+++\u3002\u8acb\u554f\u9664\u4e86immunotherapy\u4e4b\u5916\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u9996\u9078\u85e5\u7269?\nA. intranasal glucocorticoids spray\nB. moderate dose of oral prednisolone\nC. anti-IgE antibody injection\nD. oral pseudoephedrine\nE. oral H1 antihistamine\n": "(A)", "107-10.\n\u4e00\u4f4d50\u6b72\u5973\u6027\u88ab\u8a3a\u65b7\u6709portal vein thrombosis\u3002\u5468\u908a\u8840\u6db2\u6aa2\u67e5\u767c\u73fe\u6709JAK2\u57fa\u56e0\u7a81\u8b8a\uff0c\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u6709\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\uff1f\nA. myeloproliferative neoplasm\nB. paroxysmal nocturnal hemoglobinuria\nC. protein S deficiency\nD. protein C deficiency\nE. antithrombin III deficiency\n": "(A)", "107-11.\n\u816b\u7624\u6a19\u8a18(tumor markers)\u7684\u61c9\u7528\uff0c\u53ef\u904b\u7528\u5728\u60e1\u6027\u816b\u7624\u7684\u6cbb\u7642\u671f\u9593\uff0c\u4f5c\u70ba\u6cbb\u7642\u6210\u6548\u7684\u8f14\u52a9\u8a55\u4f30\u3002\u4ee5\u4e0b\u5404\u7a2e\u816b\u7624\u6a19\u8a18\u8207\u816b\u7624\u7684\u914d\u5c0d\uff0c\u54ea\u4e9b\u662f\u6b63\u78ba\u7684? (1)catecholamines\u8207pheochromocytoma (2)calcitonin\u8207papillary cancer of the thyroid (3)human chorionic gonadotropin (hCG)\u8207gestational trophoblastic disease (4)\u03b1-fetoprotein\u8207gonadal germ cell tumor\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(C)", "107-12.\n\u5c0d\u65bc\u61f7\u7591\u6709intestinal obstruction\u4e4b\u60a3\u8005\uff0c\u8179\u90e8\uff38\u5149\u7167\u76f8\uff08plain abdomen\uff09\u53ef\u63d0\u4f9b\u76f8\u7576\u6709\u7528\u7684\u8cc7\u6599\u3002\u4e0b\u5217\u5404\u9805\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. plain abdomen\u7528\u4f86\u5224\u65b7nonstrangulating complete small-bowel obstruction\u76f8\u7576\u53ef\u9760\nB. partial mechanical small-bowel obstruction\u8207adynamic ileus\u4e0d\u592a\u5bb9\u6613\u5340\u5206\uff0c\u4f46colonic distension\u5728adynamic ileus\u901a\u5e38\u8f03\u660e\u986f\nC. \u8139\u5927\u7684\u5c0f\u8178\u4e2d\u53ef\u898bair-fluid levels\uff0c\u5e38\u6392\u5217\u6210\u201cstepladder\u201d pattern\uff0c\u5c11\u898b\u5167\u542b\u7a7a\u6c23\u7684\u5927\u8178\uff0c\u9019\u4e9b\u767c\u73fe\u5e38\u898b\u65bcstrangulating small-bowel obstruction\nD. \u82e5\u81e8\u5e8a\u75c7\u72c0\u5f88\u50cfsmall intestine obstruction\uff0c\u4f46plain abdomen\u770b\u8d77\u4f86\u6b63\u5e38\uff0c\u6b64\u6642\u5b89\u6392\u8179\u90e8CT\u6aa2\u67e5\u6709\u52a9\u65bc\u8a3a\u65b7\nE. \u559d\u92c7\u5291\u4f86\u5e6b\u5fd9\u5224\u65b7\u5c0f\u8178\u7684\u963b\u585e\u90e8\u4f4d\u662f\u76f8\u7576\u5b89\u5168\u7684\n": "(C)", "108-1.\n64\u6b72\u7537\u6027\uff0c\u904e\u53bb\u7121\u5df2\u77e5\u5fc3\u80ba\u75be\u75c5\uff0c\u56e0\u7a81\u767c\u6027\u547c\u5438\u56f0\u96e3\u81f3\u6025\u8a3a\u6c42\u8a3a\u3002\u75c5\u60a3\u4e26\u7121\u660e\u986f\u80f8\u75db\u6216\u5192\u51b7\u6c57\uff0c\u610f\u8b58\u6e05\u695a\u4f46\u60c5\u7dd2\u7dca\u5f35\uff0c\u521d\u6b65\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u9ad4\u6eab37.2\u2103\uff0c\u8840\u58d3 150/95 mmHg\uff0c\u8108\u535a110/min\u7bc0\u5f8b\u898f\u5247,\u547c\u5438\u5feb(24/min)\u4e14\u6df1\uff1b\u56db\u80a2\u8f15\u5fae\u51b0\u51b7\u6709\u767c\u7d3a\u73fe\u8c61\u3002\u9838\u975c\u8108\u58d313 cm H2O\uff0c\u8108\u885d\u8840\u6c27\u5b9a\u91cf\u8a08 (pulse oximeter) \u5075\u6e2c\u767c\u73feSpO2 83%\u4e0b\u5217\u8a3a\u65b7\u4f55\u8005\u6700\u6709\u53ef\u80fd?\nA. Panic disorder related hyperventilation syndrome\nB. Metabolic acidosis\nC. Pneumothorax\nD. Acute pulmonary embolism\nE. Bronchial asthma\n": "(D)", "108-2.\n\u4e0b\u5217\u95dc\u65bc\u54b3\u8840\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1)\u5728\u5df2\u958b\u767c\u570b\u5bb6\uff0c\u75c5\u6bd2\u6216\u7d30\u83cc\u6027\u652f\u6c23\u7ba1\u708e\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (2)\u5728\u5df2\u958b\u767c\u570b\u5bb6\uff0c\u80ba\u764c\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (3)\u4ee5\u5168\u7403\u800c\u8a00\uff0c\u80ba\u7d50\u6838\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (4)\u4ee5\u5168\u7403\u800c\u8a00\uff0c\u80ba\u764c\u662f\u9020\u6210\u75c5\u60a3\u54b3\u8840\u6700\u5e38\u898b\u7684\u539f\u56e0 (5)\u80ba\u52d5\u8108\u51fa\u8840\u6642\u7684\u51fa\u8840\u91cf\u6bd4\u8f03\u5927 (6)\u652f\u6c23\u7ba1\u52d5\u8108\u51fa\u8840\u6642\u7684\u51fa\u8840\u91cf\u6bd4\u8f03\u5927\nA. (1)+(3)+(5)\nB. (2)+(3)+(6)\nC. (1)+(4)+(5)\nD. (2)+(3)+(5)\nE. (1)+(3)+(6)\n": "(E)", "108-3.\n\u4e00\u4f4d\u75c5\u4eba\u5728\u62bd\u8840\u6aa2\u67e5\u4e2d\u767c\u73fePT\u70ba16.3\"(\u6b63\u5e389.8~11.5\")\uff0cINR 1.52\uff0cPTT\u70ba54.3\"(\u6b63\u5e3825.6~32.6\")\u3002\u75c5\u4eba\u6700\u4e0d\u53ef\u80fd\u6709\u4ee5\u4e0b\u4f55\u7a2e\u72c0\u6cc1\uff1f\nA. Warfarin treatment\nB. Rivaroxaban treatment\nC. Aspirin treatment\nD. Factor XII deficiency\nE. Liver disease\n": "(D)", "108-4.\n\u4e0b\u5217\u75be\u75c5\u5e38\u4ee5\u55ae\u4e00\u95dc\u7bc0\u708e\u8868\u73fe? (1) \u9000\u5316\u6027\u95dc\u7bc0\u708e; (2)\u75db\u98a8\u95dc\u7bc0\u708e ; (3)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e ; (4)\u7d30\u83cc\u611f\u67d3\u6027\u95dc\u7bc0\u708e ; (5)\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (3)+(4)+(5)\n": "(B)", "108-5.\nClostridium difficile\u611f\u67d3\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. C. difficile\u662f\u4e0d\u6703\u7522\u751f\u5b62\u5b50\u7684\u9769\u862d\u6c0f\u967d\u6027\u687f\u83cc\uff0c\u654570%\u9152\u7cbe\u5177\u6709\u6b64\u83cc\u826f\u597d\u4e4b\u6bba\u83cc\u529b\nB. \u4ee5\u5927\u8178\u93e1\u6aa2\u67e5\u507d\u819c\u6027\u8178\u708e(Pseudomembranous colitis)\u4e4b\u654f\u611f\u6027\u5f88\u9ad8\uff0c\u56e0\u6b64\u8178\u93e1\u6aa2\u67e5\u82e5\u7121\u51fa\u73fe\u75c5\u7076\u5247\u53ef\u6392\u9664\u6b64\u8a3a\u65b7\nC. \u81f4\u75c5\u529b\u53ef\u80fd\u548cToxin A\u548cToxin B\u76f8\u95dc\uff0ctoxin A\u662fcytotoxin, toxin B\u662fenterotoxin\nD. \u5c0d\u65bc\u9996\u6b21\u8f15\u5ea6C. difficile\u8178\u708e\uff0c\u9996\u9078\u6cbb\u7642\u85e5\u7269\u70ba\u53e3\u670dmetronidaozle\u6cbb\u764210\u523014\u5929\nE. \u5c0d\u65bc\u9996\u6b21C. difficile\u8178\u708e\u91cd\u5ea6\u60a3\u8005\uff0c\u9996\u9078\u6cbb\u7642\u85e5\u7269\u70ba\u91dd\u5291vancomycin\u6cbb\u764210\u523014\u5929\n": "(D)", "108-6.\n\u9673\u5148\u751f\uff0c82\u6b72\uff0c\u8eab\u9ad8168\u516c\u5206\uff0c\u9ad4\u91cd58\u516c\u65a4\uff0c\u7cd6\u5c3f\u75c5\u75c5\u53f220\u5e74\uff0c\u76ee\u524d\u63a5\u53d7 \u4e09\u9910\u524d\u901f\u6548\u53ca\u7761\u524d\u57fa\u790e\u80f0\u5cf6\u7d20\u6cbb\u7642\u3002\u4f46\u7d93\u5e38\u6703\u6f0f\u6253\u9910\u524d\u80f0\u5cf6\u7d20\uff0c\u4e00\u500b\u6708\u524d\u4e4bHbA1c\u70ba8.8 %\uff0c\u8fd1\u4e00\u5468\u51fa\u73fe\u611f\u5192\u4e4b\u75c7\u72c0\uff0c\u6c92\u6709\u767c\u71d2\u4e4b\u7d00\u9304\uff0c\u4f46\u662f\u80c3\u53e3\u4e0d\u4f73\u3002\u6b64\u6b21\u56e0\u610f\u8b58\u72c0\u6cc1\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u6025\u8a3a\u4e4b\u8840\u7cd6\u70ba525 mg/dL\uff0c\u9209\u96e2\u5b50\u70ba151 mEq/L\uff0c'\u9240\u96e2\u5b50\u70ba3.5 mEq/L\uff0c\u5c3f\u7d20\u6c2eBUN\u70ba62 mg/dL\uff0c\u808c\u9178\u9150Cr\u70ba 2.6 mg/dL\u3002\u5230\u6025\u8a3a\u5f8c\u4e4b\u8840\u58d3\u70ba98/60 mmHg\uff0c\u8108\u640f\u70ba96 bpm\u3002\u4e0b\u5217\u4e4b\u8f38\u6db2\uff0c\u4f55\u8005\u6700\u9069\u65bc\u6b64\u75c5\u60a3\u8f38\u6ce8\u53ca\u76e3\u6e2c\u5176\u5c3f\u6db2\u6392\u51fa\u91cf (Urine output)?\nA. 0.45% Half saline solution\nB. Lactate Ringer solution\nC. 0.9 % Normal Saline solution\nD. 5% Glucose solution with regular insulin intravenous infusion\nE. 0.45% Half saline solution with regular insulin intravenous infusion\n": "(C)", "108-7.\n65\u6b72\u7537\u6027\u56e0\u5026\u6020\u3001\u98df\u617e\u4e0d\u632f\u3001\u591a\u5c3f\u4e8c\u500b\u6708\uff0c\u4eca\u65e9\u660f\u8ff7\u4f86\u6025\u8a3a\uff0c6\u500b\u6708\u524d\u75c5\u4eba\u88ab\u8a3a\u65b7\u80ba\u764c\uff0c\u8eab\u9ad4\u6aa2\u67e5\uff1a\u8840\u58d388/60 mmHg \u3001PR 108/min\u3001regular\uff0cRR20/min\uff0c\u6b64\u5916\u7121\u7279\u5225\u7570\u5e38\uff0c\u62bd\u8840\u6aa2\u67e5BUN 66 mg/dL\u3001Cr 2.9 mg/dL\u3001Ca 13 mg/dL\u3002\u7d93\u904e\u98df\u9e7d\u6c34\u8f38\u6db2\u6cbb\u7642\u5f8c\u6e05\u9192\uff0ciPTH\u6e2c\u4e0d\u5230\uff0c\u8981\u7dad\u6301\u9577\u4e45\u8840\u9223\u6b63\u5e38\uff0c\u4e0b\u5217\u90a3\u4e00\u85e5\u7269\u6700\u4f73\nA. Calcitonin\nB. Bisphosphonate\nC. Diuretic\nD. Prednisolone\nE. EDTA\n": "(B)", "108-8.\n\u4e0b\u5217\u6709\u95dc\u4ee5\u751f\u7269\u88fd\u5291\u6cbb\u7642\u75be\u75c5\u7684\u9069\u61c9\u75c7\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6070\u7576\uff1f\nA. IVIG--leukocytoclastic vasculitis\nB. Anti-IgE monoclonal antibody--anaphylactic shock\nC. Anti-TNF- monoclonal antibody--rheumatoid arthritis\nD. Anti-CD20 monoclonal antibody--CREST syndrome\nE. Anti-CD3 monoclonal antibody--systemic lupus erythematosus\n": "(C)", "108-9.\n\u0002\u0002\u4e0b\u5217\u7d44\u5408\uff0c\u4f55\u8005\u6b63\u78ba\uff1f1. Behcet's syndrome2. Peutz-Jeghers syndrome3. Heavy metal pigmentation4. Hairy leukoplakia\ra. \u5507\u53ca\u53e3\u8154\u7c98\u819c\u4e0a\u6709\u6697\u8910\u8272\u6591\u9edeb. \u820c\u982d\u5074\u9762\u6709\u767d\u8272\u75c5\u7076\uff0c\u53ef\u80fd\u5c0f\u800c\u5e73\uff0c\u4e5f\u53ef\u80fd\u5927\u7bc4\u570d\u800c\u6709\u7a81\u8d77c. \u53e3\u8154\u5167\u6709\u591a\u767c\u6027\u9d5d\u53e3\u7621\uff0c\u4f75\u6709\u767c\u708e\u6027\u8178\u9053\u75be\u75c5d. \u6cbf\u8457\u7259\u9f66\u8207\u7259\u9f52\u9593\u7684\u85cd\u9ed1\u8272\u7d30\u7dda\nA. 1-d, 2-a, 3-c, 4-d\nB. 1-c, 2-d, 3-a, 4-b\nC. 1-a, 2-b, 3-c, 4-d\nD. 1-b, 2-c, 3-d, 4-a\nE. 1-c, 2-a, 3-d, 4-b\n": "(E)", "108-10.\n\u4e0b\u5217\u4f55\u7a2e\u60c5\u6cc1\u5bb9\u6613\u9020\u6210\u9ad8\u8840\u9240\u75c7\ufe55 1.\u4f7f\u7528amiloride\u5229\u5c3f\u5291 2.\u4f7f\u7528amphotericin B 3.\u4f7f\u7528thiazide\u5229\u5c3f\u5291 4.\u4f7f\u7528trimethoprim 5.\u5df4\u7279\u6c0f(Bartter)\u75c7\u5019\u7fa4\nA. 1+4\nB. 1+2+4\nC. 1+3+4\nD. 2+3+5\nE. 2+4+5\n": "(A)", "108-11.\n\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u7684\u8f49\u79fb\u6027\u4e0a\u76ae\u764c(carcinoma of unknown primary, CUP)\uff0c\u75c5\u7406\u7d44\u7e54\u5e38\u9700\u8981\u984d\u5916\u9032\u884c\u514d\u75ab\u7d44\u7e54\u67d3\u8272(immunohistochemical stains)\uff0c\u63d0\u4f9b\u81e8\u5e8a\u4e0a\u5206\u8fa8\u764c\u75c7\u5668\u5b98\u539f\u767c\u4f86\u6e90\u7684\u53c3\u8003\u4f9d\u64da\u3002cytokeratin(CK)\u662f\u7d93\u5e38\u4f7f\u7528\u7684intermediate filaments\u67d3\u8272\uff0c\u4eba\u9ad4\u670920\u591a\u7a2eCK\u4e9e\u578b\uff0c\u7576\u986f\u793a\u764c\u7d30\u80deCK20\u67d3\u8272\u967d\u6027\u4e14CK7\u67d3\u8272\u9670\u6027(CK20+/ CK7-)\u6642\uff0c\u76f8\u5c0dCUP\u6700\u53ef\u80fd\u7684\u539f\u767c\u5668\u5b98\u70ba\u4e0b\u5217\u4f55\u8005?\nA. lung\nB. breast\nC. endometrium\nD. pancreas\nE. colon\n": "(E)", "108-12.\n55\u6b72\u7537\u6027\uff0c\u56e0\u5de6\u773c\u816b\u8139\u8207\u9b31\u8840\u5c31\u8a3a\uff0c\u982d\u90e8\u78c1\u632f\u7167\u5f71\u986f\u793a\u5de6\u5074\u6d77\u7dbf\u7ac7\uff08cavernous sinus\uff09\u6709\u4e0d\u6b63\u5e38\u986f\u5f71\uff0c\u81e8\u5e8a\u8a3a\u65b7\u70ba\u773c\u7aa9\u9802\u75c7\u5019\u7fa4\uff08orbital apex syndrome\uff09\uff0c\u90a3\u4e00\u689d\u9871\u795e\u7d93\u5b78\u4e0d\u6703\u53d7\u5f71\u97ff\uff1f\nA. \u7b2c\u4e8c\u9871\u795e\u7d93\nB. \u7b2c\u4e09\u9871\u795e\u7d93\nC. \u7b2c\u56db\u9871\u795e\u7d93\nD. \u7b2c\u516d\u9871\u795e\u7d93\nE. \u7b2c\u4e03\u9871\u795e\u7d93\n": "(E)", "109-89.\u4e0b\u5217\u95dc\u65bcdiarrhea\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f    \nA.\u6aa2\u67e5\u5927\u4fbf\u4e2d\u7684fat\u4e43\u662f\u7be9\u6aa2malabsorption\u6700\u4f73\u65b9\u5f0f\nB.Malabsorption\u60a3\u8005\u4e00\u5b9a\u6703\u6709diarrhea\nC.Non-inflammatory chronic watery diarrhea\u4e2d\uff0csecretory diarrhea \u65bcfasting\u5f8c\u6703\u505c\u6b62\nD.Irritable bowel syndrome\u60a3\u8005\u4e4bdiarrhea \u65bcfasting\u5f8c\u6703\u6301\u7e8c\nE.\u5c0dsevere diarrhea\u60a3\u8005\uff0c\u61c9\u5118\u5feb\u7d66\u4e88opiates\u85e5\u7269\u6cbb\u7642\n": "[A]", "109-90.\u4f7f\u7528\u9023\u7e8c\u6b63\u58d3\u547c\u5438\u8f14\u52a9 (CPAP)\u6cbb\u7642\u963b\u585e\u6027\u7761\u7720\u547c\u5438\u4e2d\u6b62 (obstructive sleep apnea )\u7684\u6548\u679c\uff0c\u4e0b\u5217\u4f55\u8005\u9664\n\u5916\uff1f   \nA.\u964d\u4f4eAHI (apnea-hypopnea index)\nB.\u6539\u5584\u7761\u7720\u54c1\u8cea\nC.\u63d0\u9ad8\u8840\u6c27\u98fd\u548c\u5ea6\nD.\u5c0d\u5fc3\u81df\u8870\u7aed\u75c5\u4eba\u7684\u6548\u679c\u8f03\u5dee\nE.\u6e1b\u8f15\u65e5\u9593\u55dc\u7761\u75c7\u72c0   \n": "[D]", "109-91.\u4e00\u4f4d65\u6b72\u7cd6\u5c3f\u75c5\u4eba \uff0c\u6709\u9ad8\u8840\u58d3 \uff0c\u6e96\u5099\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u6aa2\u67e5 \u3002\u7406\u5b78\u6aa2\u67e5 :BP 118/74, edema (-), serum  \ncreatinine 1.5 mg/dL\u3002\u76ee\u524d\u7528\u85e5\u70ba: metformin 500 mg bid, irbesartan 75 mg qd, trichlormethiazide 1 mg \nqd. \u70ba\u4e86\u964d\u4f4e\u767c\u751fcontrast nephropathy\u7684\u5371\u96aa \uff0c\u4ee5\u4e0b\u54ea\u9805\u63aa\u65bd\u6700\u4e0d\u5efa\u8b70 \u3002   \nA.\u505c\u7528metformin, \u66f4\u63db\u6210\u5176\u4ed6\u964d\u8840\u7cd6\u85e5\nB.volume expansion with saline, \u53ef\u4ee5\u52a0\u4e0a bicarbonate\nC.\u505c\u7528irbesartan, \u66f4\u63db\u6210fenoldopam\u964d\u8840\u58d3\u85e5\u6bd4\u8f03\u5b89\u5168\nD.\u7d66\u4e88 N-acetylcysteine\nE.\u6253radiocontrast agent\u524d\uff0c\u7d66\u4e88aminophylline\n": "[C]", "109-92.\u4e0b\u5217\u6709\u95dcDigoxin\u6cbb\u7642\u5fc3\u8870\u7aed\u7684\u5be6\u8b49\u91ab\u5b78\u8aaa\u6cd5\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684?    \nA.Digoxin\u53ef\u6291\u5236\u5fc3\u808c\u7d30\u80de\u819cNa -K ATPase pump \uff0c\u589e\u52a0\u7d30\u80de\u8cea\u6db2 (Cytosol)\u5167Ca++\uff0c\u800c\u589e\u5f37\u5fc3\u808c\u6536\u7e2e\n\u529b(Inotropism )\uff0c\u56e0\u6b64\u4ee5\u98fd\u548c\u5291\u91cf\u6025\u6027\u6ce8\u5c04\u70ba\u539f\u5247\nB.\u4f9d\u64daDIG\u81e8\u5e8a\u8a66\u9a57\uff0c\u5728\u975e\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u75c5\u4eba\uff0c\u7d93Digoxin \u6cbb\u7642\u5f8c\uff0c\u4e26\u672a\u80fd\u6539\u5584\u6b7b\u4ea1\u7387\u6216\u4f4f\u9662\u65e5\u6578\nC.\u5728\u81e8\u5e8a\u4e0aDigoxin\u4e26\u975e\u6cbb\u7642\u5fc3\u8870\u7aed\u7684\u4e3b\u8ef8 \uff0c\u53ea\u80fd\u8207\u03b2-blocker, diuretic, Angiotensin converting enzyme \ninhibitor \u6216Angiotensin receptor blockade\u4f75\u7528\nD.Digoxin\u53ef\u7528\u65bc\u5fc3\u8870\u7aed\u4f75\u6709\u5fc3\u623f\u7e96\u7dad\u986b\u52d5\u53ca\u5fc3\u64f4\u5927\u8005\nE.Digoxin \u4e2d\u6bd2\u4e4b\u81e8\u5e8a\u8868\u73fe\uff0c\u4ee5\u5fc3\u5f8b\u53ca\u5fc3\u50b3\u5c0e\u7570\u5e38\u6700\u591a\u898b\uff0c\u80c3\u8178\u75c7\u72c0\u6b21\u4e4b\n": "[A]", "109-93.48\u6b72\u5973\u6027\u56e0\u5065\u6aa2\u767c\u73fe\u7532\u72c0\u817a\u816b\u4f86\u6c42\u8a3a \uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u75c5\u4eba\u7532\u72c0\u817a\u5448\u7b2c\u4e00\u5ea6\u816b\u5927 \uff0c\u62bd\u8840\u6aa2\u67e5 \u2025free T4 1 .07 \nng/dl\u3001hsTSH 7.5\u03bcU/ml\u3001thyroglobulin 100 ng /ml\u3001antiTPO 400 IU /ml\u3002\u4e0b\u5217\u8655\u7f6e\u53ca\u5176\u7406\u7531\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u75c5\u4eba\u7532\u72c0\u817a\u6a5f\u80fd\u4f4e\u4e0b\u5373\u523b\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u88dc\u5145\nB.\u75c5\u4eba\u7532\u72c0\u817a\u816b\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nC.\u75c5\u4ebaantiTPO\u9ad8\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\u4ee5\u6e1b\u5c11\u767c\u708e\nD.\u75c5\u4ebathyroglobulin\u9ad8\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nE.\u7532\u72c0\u817a\u7d20\u6cbb\u7642\u7121\u76ca\uff0c\u89c0\u5bdf\u5373\u53ef\n": "[E]", "109-94.\u4e0b\u5217\u90a3\u4e00\u9805\u975e\u8a3a\u65b7\u7b2c1\u578b\u7cd6\u5c3f\u75c5\u7684\u5fc5\u8981\u689d\u4ef6\u2025    \nA.\u7a7a\u8179\u8840\u6e05 C-\u80dc\n\u6fc3\u5ea6 < 0.5 ng/ml\nB.\u5347\u7cd6\u7d20\u523a\u6fc0\u5f8c 6\u5206\u9418\u8840\u6e05 C-\u80dc\n\u6fc3\u5ea6 < 1.8 ng/ml\nC.\u5347\u7cd6\u7d20\u523a\u6fc0\u8a66\u9a57 6\u5206\u82070\u5206\u8840\u6e05C-\u80dc\n\u6fc3\u5ea6\u76f8\u5dee < 0.7 ng/ml\nD.\u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2\nE.Anti-GAD65 \u967d\u6027\n": "[D]", "109-95.\u4e0b\u5217\u6709\u95dc\u751f\u7269\u88fd\u5291\u8207\u75be\u75c5\u6cbb\u7642\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.Soluble CTLA-4 protein - T cell lymphoma\nB.Anti-TNF-\u03b1 monoclonal antibody - rheumatoid arthritis\nC.IVIG - multiple myeloma\nD.Anti - CD20 monoclonal antibody - acute B cell leukemia\nE.Anti-IL-6 receptor monoclonal antibody - SLE\n": "[B]", "109-96.\u4e0b\u5217\u95dc\u7bc0\u708e\u5e38\u9700\u505a\u95dc\u7bc0\u8154\u6db2\u6aa2\u67e5(Synovial fluid analysis)\u4ee5\u78ba\u5b9a\u8a3a\u65b7    \nA.\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e (RA)\nB.\u7d05\u6591\u6027\u72fc\u7621 (SLE)   \nC.\u611f\u67d3\u6027\u95dc\u7bc0\u708e (septic arthritis)\nD.\u9000\u5316\u6027\u95dc\u7bc0\u708e (OA)\nE.\u7e96\u7dad\u808c\u75db\u75c7 (fibromyalgia)\n": "[C]", "109-97.\u4e0b\u5217\u95dc\u65bcHIV\u611f\u67d3\u8207\u816b\u7624\u7684\u95dc\u4fc2\u4f55\u8005\u932f\u8aa4\uff1f    \nA.Kaposi\u2019s sarcoma \u8207Human Herpes virus \u2013 8 (HHV-8) \u7684\u611f\u67d3\u6709\u95dc\nB.Anogenital carcinoma \u8207Human papilloma virus (HPV) \u7684\u611f\u67d3\u6709\u95dc\nC.Primary CNS lymphoma (\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u6dcb\u5df4\u7624) \u8207Epstein-Barr virus ( EBV )\u7684\u611f\u67d3\u6709\u95dc\nD.Burkitt\u2019s lymphoma \u8207Cytomegalovirus ( CMV ) \u7684\u611f\u67d3\u6709\u95dc\u4fc2\nE.HIV\u611f\u67d3\u76f8\u95dc\u4e4blymphoma\u4e3b\u8981\u662fB cell lymphoma\n": "[D]", "109-98.\u4e00\u4f4d58\u6b72\u5a66\u5973 \uff0c\u56e0\u70ba\u5169\u908a\u5c0f\u817f\u7600\u9752\u53ca\u816b\u8139\u75bc\u75db\u61c9\u8a3a \uff0c\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20 12 .1 g/dL\uff0c\u767d\u8840\u7403 \n8,290/\u03bcL\uff0c\u8840\u5c0f\u677f 225 ,000/\u03bcL\uff0cPT 11.3\"(\u6b63\u5e388.0-12.2)\uff0cINR 1.02\uff0caPTT 77 .3\"(\u6b63\u5e3826.9-36.3)\u3002\u5c07\u75c5\n\u4eba\u8207\u6b63\u5e38\u4e4b\u8840\u6f3f\u4ee5 1:1\u505a\u6df7\u5408\u8a66\u9a57 \uff0c\u958b\u59cb\u6642aPTT \u70ba39.2\"\uff0c1\u5c0f\u6642\u5f8c51 .2\"\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.Antiphospholipid antibody syndrome\nB.Acquired hemophilia\nC.von Willebrand disease\nD.Warfarin overdose\nE.Liver function impairment\n": "[B]", "109-99.\u4e00\u500b\u8eab\u9ad4\u72c0\u6cc1\u5927\u81f4\u6b63\u5e38\u768465\u6b72\u5973\u6027\u9032\u884c\u5065\u5eb7\u6aa2\u67e5 \uff0ccolonoscope\u5728\u5347\u7d50\u8178\u90e8\u4f4d\u767c\u73fe 2\u500b\u5927\u5c0f\u5206\u5225\u70ba 1.2\u516c\n\u5206\u30011.4\u516c\u5206\u7684\u6241\u5e73\u6a23sessile (flat-based)\u606f\u8089\uff0c\u5167\u8996\u93e1\u6aa2\u540c\u6642\u9032\u884c\u5167\u8996\u93e1\u606f\u8089\u5207\u9664 \uff0c\u75c5\u7406\u5831\u544a\u5747\u70ba\u7d68\u6bdb\u6a23\n\u817a\u7624(villous adenoma )\uff0c\u4e26\u7121\u7d50\u8178\u764c \u3002\u4ee5\u4e0b\u5efa\u8b70\u4f55\u7a2e\u6700\u9069\u7576 ?   \nA.Abdominal and Pelvic CT scan\nB.Partial colectomy\nC.Reassurance only\nD.Follow-up colonoscopy in 3 years\nE.Follow-up colonoscopy in 10 years\n": "[D]", "109-100.55\u6b72\u7537\u6027 \uff0c\u9577\u671f\u65bc\u67d0\u4e00\u5de5\u5ee0\u5de5\u4f5c \uff0c\u8fd16\u500b\u6708\u6709\u6f38\u9032\u7684\u6b65\u5c65\u8b8a\u5c0f \u3001\u52d5\u4f5c\u8b8a\u6162 \u3001\u5e73\u8861\u8b8a\u5dee \uff0c\u8a3a\u65b7\u70ba\u5df4\u91d1\u68ee\u6c0f\n\u75c7\uff08parkinsonism\uff09\uff0c \u67092\u4f4d\u5de5\u5ee0\u540c\u4e8b\u6709\u985e\u4f3c\u4f46\u8f03\u8f15\u7684\u75c7\u72c0 \uff0c\u6700\u9700\u8981\u61f7\u7591\u70ba\u4f55\u7a2e\u4e2d\u6bd2 \uff1f   \nA.\u925b\uff08lead\uff09\nB.\u9333\uff08manganese\uff09\nC.\u6c5e\uff08mercury\uff09\nD.\u7837\uff08arsenic\uff09\nE.\u9285\uff08copper\uff09\n": "[B]", "110-73.\u75c5\u4eba82\u6b72\u8001\u592a\u592a\u56e0\u7a81\u6f38\u56b4\u91cd\u6027\u547c\u5438\u56f0\u96e3\u800c\u4f4f\u9662 \uff0c\u5979\u4e09\u5341\u5e74\u524d\u5c31\u6709\u5fc3\u96dc\u97f3\u53ef\u805e\u77e5 \uff0c\u552f\u672a\u66fe\u9032\u4e00\u6b65\u8a3a\u7642 \u3002\u5f9e\u4e94\n\u5e74\u524d\u958b\u59cb\u5c31\u6709\u904b\u52d5\u96e3\u53d7 \uff0c\u4f34\u6709\u904b\u52d5\u6027\u5fc3\u60b6 \uff0c\u7d93\u6aa2\u67e5\u78ba\u8a8d\u5fc3\u81df\u64f4\u5927 \uff0c\u5728\u4ee5\u5f8c\u7684\u6b72\u6708 \uff0c\u75c7\u72c0\u9010\u6f38\u52a0\u5287 \uff0c\u7279\u5225\u5728\n\u904b\u52d5\u6216\u6500\u767b\u6a13\u68af\u4e2d \uff0c\u4f11\u606f\u5373\u53ef\u6539\u5584 \u3002\u4f4f\u9662\u524d\u4e09\u65e5 \uff0c\u7a81\u7136\u5728\u51cc\u6668\u767c\u4f5c\u547c\u5438\u56f0\u96e3 \u3002\u6642\uff0cT/P/R\uff1a 36.4/90/16\uff1b \nBP\uff0c110/62 mmHg \uff1bjugular vein engorgement \uff1bbilateral basal chest with crackles \uff1bheart\uff0cnormal \nheart border \uff0cGr.III systolic murmur over RUSB with carotid transmission \uff0cS2 diminished \uff1botherwise \nunremarkable\u3002 Chest X- ray & ECG\u5982\u5716\u6240\u793a\u3002 \u8acb\u554f\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f \uff1a   \nA.\u50e7\u5e3d\u74e3\u72f9\u7a84(Mitral stenosis)\u3002\nB.\u50e7\u5e3d\u74e3\u9589\u9396\u4e0d\u5168(Mitral regurgitation)\u3002\nC.\u4e3b\u52d5\u8108\u74e3\u72f9\u7a84(Aortic stenosis)\u3002\nD.\u4e3b\u52d5\u8108\u74e3\u9589\u9396\u4e0d\u5168(Aortic regurgitation)\u3002\nE.\u6b63\u5e38\u5fc3\u81df\u3002\n": "[C]", "110-74.\u81e8\u5e8a\u4e0a\u6703\u9020\u6210\u75c5\u60a3\u7684\u4e00\u6c27\u5316\u78b3\u80ba\u7030\u6563\u91cf (diffusion capacity of carbon monoxide \uff0cDLCO)\u4e0b\u964d\u7684\u5e38\u898b\u539f\u56e0\n\u4e0d\u5305\u62ec\uff1a   \nA.\u80ba\u6c23\u816b\u3002\nB.\u80ba\u52d5\u8108\u9ad8\u58d3\u3002\nC.\u6c23\u5598\u6025\u6027\u767c\u4f5c\u3002\nD.\u80ba\u7e96\u7dad\u5316\u3002\nE.\u8ca7\u8840\u3002\n": "[C]", "110-75.\u6709\u95dc\u5927\u8178\u76f4\u8178\u764c (colorectal cancer )\u7be9\u6aa2(screening )\u7b56\u7565\uff0c\u4f55\u8005\u6b63\u78ba \uff1f(1)\u4e0d\u8ad6\u7537\u5973 \uff0c50\u6b72\u4ee5\u4e0a\u5373\u5fc5\u9700\u7be9\n\u6aa2(2)\u67091 \u500b\u5c0f\u65bc1\u516c\u5206\u7684\u7ba1\u72c0\u817a\u7624 (tubular adenoma )\u8005\uff0c\u61c9\u57281\u5e74\u5f8c\u91cd\u505a\u5927\u8178\u93e1 (3)\u4e00\u7d1a\u8840\u89aa\u6709\u5927\u8178\u764c\u75c5\u53f2\n\u8005\uff0c\u7be9\u6aa2\u5e74\u9f61\u70ba50 \u6b72(4)\u76ee\u524d\u53f0\u7063\u662f\u4f7f\u7528\u7cde\u4fbf\u6f5b\u8840\u514d\u75ab\u53cd\u61c9\u6cd5\u505a\u7be9\u6aa2 (5)\u6709\u907a\u50b3\u6027\u5927\u8178\u764c\u75c7\u5019\u7fa4 (hereditary \nnonpolyposis colorectal cancer )\u5bb6\u65cf\u53f2\u8005\u53ef\u65bc30\u6b72\u5373\u958b\u59cb\u7be9\u6aa2   \nA.(1)+(2)+(3)\u3002\nB.(2)+(3)+(4)\u3002\nC.(3)+(4)+(5)\u3002\nD.(1)+(2)+(4)\u3002\nE.(1)+(4)+(5)\u3002\n": "[E]", "110-76.\u4e00\u4f4d30\u6b72\u5973\u6027 \uff0c\u904e\u53bb\u6709IgA nephropathy\u8207\u8f15\u5ea6\u86cb\u767d\u5c3f \uff0c\u5b9a\u671f\u5728\u9580\u8a3a\u5c31\u91ab \u3002\u6700\u8fd1\u61f7\u5b55\u4e26\u51fa\u73fe\u9ad8\u8840\u58d3 \uff0c\u4ee5\u4e0b\n\u9ad8\u8840\u58d3\u76f8\u95dc\u85e5\u7269\u8655\u7f6e \uff0c\u4f55\u8005\u6700\u4e0d\u9069\u5408 ?   \nA.\u4f7f\u7528methyldopa\u3002\nB.\u4f7f\u7528ACEI \u985e\u964d\u4f4e\u86cb\u767d\u5c3f\uff0c\u9810\u9632\u767c\u751fpre-eclampsia\u3002   \nC.\u4f7f\u7528 labetalol\u3002\nD.\u4f7f\u7528Long-acting nifedipine\u3002\nE.\u4f7f\u7528hydralazine\u3002\n": "[B]", "110-77.Clostridium difficile\u611f\u67d3\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f    \nA.C. difficile\u662f\u4e0d\u6703\u7522\u751f\u5b62\u5b50\u7684\u9769\u862d\u6c0f\u967d\u6027\u687f\u83cc\uff0c\u654570%\u9152\u7cbe\u5177\u6709\u6b64\u83cc\u826f\u597d\u4e4b\u6bba\u83cc\u529b\u3002\nB.\u4ee5\u5927\u8178\u93e1\u6aa2\u67e5\u507d\u819c\u6027\u8178\u708e (Pseudomembranous colitis )\u4e4b\u654f\u611f\u6027\u5f88\u9ad8 \uff0c\u56e0\u6b64\u8178\u93e1\u6aa2\u67e5\u82e5\u7121\u51fa\u73fe\u75c5\u7076\u5247\n\u53ef\u6392\u9664\u6b64\u8a3a\u65b7 \u3002\nC.\u81f4\u75c5\u529b\u53ef\u80fd\u548ctoxin A \u548ctoxin B\u76f8\u95dc\uff0ctoxin A \u662fcytotoxin, toxin B \u662fenterotoxin\u3002\nD.\u5c0d\u65bc\u9996\u6b21\u8f15\u5ea6C. difficile\u8178\u708e\uff0c\u9996\u9078\u6cbb\u7642\u85e5\u7269\u70ba\u53e3\u670dmetronidaozle\u6cbb\u764210\u523014\u5929\u3002\nE.\u5c0d\u65bc\u9996\u6b21C. difficile\u8178\u708e\u91cd\u5ea6\u60a3\u8005\uff0c\u9996\u9078\u6cbb\u7642\u85e5\u7269\u70ba\u91dd\u5291vancomycin\u6cbb\u764210\u523014\u5929\u3002\n": "[D]", "110-78.\u7cd6\u5c3f\u75c5\u60a3\u8005\u6cbb\u7642\u4e2d\uff0c\u4f4e\u8840\u7cd6\u662f\u975e\u5e38\u9700\u8981\u6ce8\u610f\u7684\u8b8a\u5316\u3002\u4e0b\u5217\u6709\u95dc\u7cd6\u5c3f\u75c5\u4f4e\u8840\u7cd6\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?    \nA.\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4ee5\u80f0\u5cf6\u7d20\u7a4d\u6975\u63a7\u5236\u8840\u7cd6 \uff0c\u53ef\u4ee5\u6709\u6548\u5730\u964d\u4f4e\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u53ca\u814e\u75c5\u8b8a \uff0c\u4f46\u662f\u4f4e\u8840\u7cd6\u56e0\u80f0\n\u5cf6\u7d20\u4e4b\u7a4d\u6975\u4f7f\u7528 \uff0c\u767c\u751f\u7387\u4e5f\u8f03\u9ad8 \u3002\nB.\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u6700\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\u4e4b\u53e3\u670d\u85e5\u7269\u70ba\u786b\u80fa\u985e (Sulfonylurea)\u85e5\u7269\u3002\nC.\u65b0\u578b\u7684\u7cd6\u5c3f\u75c5\u85e5\u7269\u5982DPP -4 inhibitor \u53ca SGLT -2 inhibitor \uff0c\u56e0\u5176\u85e5\u7269\u6a5f\u8f49\u7279\u6b8a \uff0c\u56e0\u6b64\u4e0d\u6703\u767c\u751f\u4f4e\u8840\n\u7cd6\u3002\nD.\u4f7f\u7528\u591a\u6b21\u9910\u524d\u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\uff0c\u767c\u751f\u4f4e\u8840\u7cd6\u4e4b\u6a5f\u7387\uff0c\u8f03\u57fa\u790e\u80f0\u5cf6\u7d20\u70ba\u9ad8\u3002\nE.\u7cd6\u5c3f\u75c5\u60a3\u7684\u7cd6\u5c3f\u75c5\u53f2\u6108\u4e45 \uff0c\u53ef\u80fd\u56e0\u81ea\u4e3b\u795e\u7d93\u75c5\u8b8a \uff0c\u7522\u751f Hypoglycemia unawareness \uff0c\u800c\u7121\u660e\u986f\u81ea\u89ba\n\u6027\u7684\u75c7\u72c0 \u3002\n": "[C]", "110-79.\u4e00\u4f4d40\u6b72\u75c5\u4eba\u62b1\u6028\u80c3\u75db \uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u767c\u73fe\u80c3\u7ac7 (gastric antrum )\u6709\u4e00\u816b\u7624 \uff0c\u75c5\u7406\u5207\u7247\u6aa2\u67e5\u986f\u793a\n\u70bamucosa-associated lymphoid tissue lymphoma \uff0cCD20\u967d\u6027\u53ca H. pylori\u967d\u6027 \uff0c\u5206\u671f\u6aa2\u67e5\u672a\u767c\u73fe\u5176\u4ed6\u7570\n\u5e38\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u7b2c\u4e00\u7dda\u6cbb\u7642 \uff1f   \nA.Eradication of H. pylori\u3002\nB.Rituximab\u3002\nC.Chemotherapy\u3002\nD.Rituximab + Chemotherapy\u3002\nE.Local irradiation\u3002\n": "[A]", "110-80.\u4e00\u4f4d40\u6b72\u7537\u6027 \uff0c\u767c\u71d2\u905439 \u2103\uff0c\u9ad4\u91cd\u6e1b\u8f15 5\u516c\u65a4\uff0c\u808c\u8089\u53ca\u95dc\u7bc0\u75bc\u75db\u53ca\u6dcb\u5df4\u817a\u816b\u8139\u800c\u6c42\u91ab \uff0c\u6709\u4e00\u500b\u6708\u95dc\u7bc0\u75db\u5305\n\u62ec\u80a9\u90e8\u3001\u624b\u8155\u3001\u96d9\u819d\uff0c\u4e14\u6709\u65e9\u6668\u50f5\u786c\u73fe\u8c61 \uff0c\u4e14\u66fe\u5728\u8eab\u9ad4\u53ca\u56db\u80a2\u6709\u7c89\u8272\u7d05\u6591 \uff0c\u7406\u5b78\u6aa2\u67e5\u9ad4\u6eab38 .8\u2103\uff0c\u9838\u90e8\u6dcb\n\u5df4\u817a\u816b\u5927 \uff0c\u813e\u816b\u5927\uff0c\u8eab\u9ad4\u53ca\u56db\u80a2\u6709\u7d05\u75b9 \uff0c\u624b\u8155\u53ca\u96d9\u819d\u816b\u8139\u53ca\u58d3\u75db \uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5ESR 100 mm /h\uff0c\u767d\u8840\n\u740330,000/mm\u00b3\uff0cC\u53cd\u61c9\u86cb\u767d (CRP)18mg/dl\uff0c\u9435\u86cb\u767d(Ferritin)20,000 ng/ml\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7 ?   \nA.\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621(SLE)\u3002\nB.\u5168\u8eab\u6027\u786c\u5316\u75c7(SSc)\u3002\nC.\u6210\u4eba\u578bStill's \u75c5(Adult Onset Still's Disease)\u3002\nD.\u6025\u6027\u9aa8\u9ad3\u767d\u8840\u75c5(AML)\u3002\nE.\u50f5\u76f4\u6027\u810a\u690e\u708e(AS)\u3002   \n": "[C]", "111-73.60\u6b72\u5973\u6027\u56e0\u89e3\u8840\u4fbf\u81f3\u6025\u8a3a \uff0c\u7d93\u8f38\u6db2\u6cbb\u7642\u7a69\u5b9a\u751f\u547d\u5fb5\u8c61\u5f8c\u5b89\u6392\u5927\u8178\u93e1\u53ca\u80c3\u93e1\u6aa2\u67e5 \uff0c\u7d50\u679c\u4e26\u7121\u767c\u73fe\u53ef\u7591\u7684\u51fa\u8840\n\u75c5\u7076\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u6b64\u7a2e\u51fa\u8840\u578b\u614b\u7a31\u70baoccult GI bleeding\u3002\nB.\u5c0f\u8178\u662f\u6700\u53ef\u80fd\u7684\u75c5\u7076\u4f4d\u7f6e\u3002\nC.\u53ef\u4ee5\u662f\u8840\u7ba1\u6027\u75c5\u7076\u3002\nD.\u60a3\u8005\u82e5\u6301\u7e8c\u56b4\u91cd\u6027\u51fa\u8840\u53ef\u8003\u616eTc-RBC scan \u6216angiography\u3002\nE.\u82e5\u51fa\u8840\u505c\u6b62\u5247\u8003\u616e\u9032\u884cvideo capsule \u6216enteroscopy\u6aa2\u67e5\u3002\n": "[A]", "111-74.\u6709\u95dc\u7d50\u6838\u83cc(Mycobacterium tuberculosis)\u611f\u67d3\u4e4b\u9673\u8ff0\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u6f5b\u4f0f\u6027\u7d50\u6838\u83cc\u611f\u67d3\u8005\u7d42\u5176\u4e00\u751f\u767c\u75c5\u7684\u6a5f\u6703\u7d04\u70ba5~10%\u3002\nB.\u521d\u6b21\u611f\u67d3\u7d50\u6838\u83cc\u5f8c\uff0c\u4ee5\u611f\u67d3\u5f8c\u524d\u4e00\u81f3\u4e8c\u5e74\u767c\u75c5\u7684\u53ef\u80fd\u6a5f\u6703\u6700\u9ad8\u3002\nC.\u5178\u578b\u4e4b\u7d50\u6838\u83cc\u6dcb\u5df4\u817a\u708e\u75c7\u72c0\u70ba\u7121\u75db\u6027(painless)\u9838\u5f8c\u6dcb\u5df4\u817a\u708e\u6216\u9396\u9aa8\u4e0a\u6dcb\u5df4\u817a\u708e\u3002\nD.\u7d50\u6838\u75c5\u60a3\u8005\u5373\u4f7f\u5728\u5b8c\u6210\u6cbb\u7642\u5f8c\uff0c\u4ecd\u6709\u7d0450%\u60a3\u8005\u6dcb\u5df4\u7d50\u6709\u7d50\u6838\u83cc\u6f5b\u4f0f\uff0c\u4e0d\u6613\u6839\u6cbb\uff0c\u5fa9\u767c\u6a5f\u7387\u9ad8\u3002\nE.\u7d50\u6838\u83cc\u75f0\u62b9\u7247\u967d\u6027\u767c\u75c5\u4e4b\u60a3\u8005\uff0c\u82e5\u672a\u63a5\u53d7\u6cbb\u7642\uff0c5\u5e74\u5167\u7684\u6b7b\u4ea1\u7387\u7d04\u70ba65%\u3002\n": "[D]", "111-75.\u4e0b\u5217\u4f55\u8005\u6bd4\u8f03\u4e0d\u9069\u5408\u4f7f\u7528\u975e\u4fb5\u8972\u6027\u547c\u5438\u5668(noninvasive positive pressure ventilation)?    \nA.\u4e2d\u6216\u91cd\u5ea6COPD\u6025\u6027\u60e1\u5316\u3002\nB.\u5fc3\u56e0\u6027\u80ba\u6c34\u816b(cardiogenic pulmonary edema)\u3002\nC.\u6557\u8840\u6027\u4f11\u514b\u3002\nD.\u514d\u75ab\u4e0d\u5168\u75c5\u4eba\u4f75\u767c\u547c\u5438\u8870\u7aed\u3002\nE.\u8179\u90e8\u624b\u8853\u5f8c\u4f75\u767c\u7f3a\u6c27\u6027\u547c\u5438\u8870\u7aed\u3002\n": "[C]", "111-76.\u8acb\u554f\u5e95\u4e0b\u85e5\u7269\u4f55\u8005\u662f\u4e3b\u8981\u7531\u814e\u81df\u6392\u6cc4\u4e14\u814e\u529f\u80fd\u6b20\u4f73\u6642\u9700\u8abf\u6574\u5291\u91cf \uff0c\u4f46\u5728\u85e5\u7269\u904e\u91cf\u6642\u537b\u7121\u6cd5\u4ee5\u8840\u6db2\u900f\u6790\u4f86\u6392\n\u9664\uff1f (1) Aspirin ; (2) Digoxin ;(3) Lithium (4)Tobramycin; (5)Vancomycin   \nA.(1)+(2)\u3002\nB.(2)+(3)\u3002\nC.(2)+(5)\u3002\nD.(2)+(4)\u3002\nE.(3)+(5)\u3002   \n": "[C]", "111-77.\u4e00\u4f4d45\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u4e3b\u8a34\u70ba\u524d\u9838\u90e8\u75bc\u75db \u3002\u4ed6\u7d04\u5169\u9031\u524d\u6709\u611f\u5192 \uff0c\u6c92\u6709\u767c\u71d2 \uff0c\u7532\u72c0\u817a\u6709\u5c40\u90e8\u816b\u5927\u4f75\u58d3\u75db \u3002\u4ed6\u7684\n\u767d\u8840\u7403\u70ba 5.1 K/\u03bcL\uff0cfT4 \u70ba 1.9 ng/dL (\u53c3\u8003\u503c 0.89 ~ 1.76 ng/dL)\uff0cTSH\u70ba 0.36 \u03bcIU/mL (\u53c3\u8003\u503c 0.4 ~ \n4\u03bcIU/mL) \uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u500b\u9078\u9805\u6700\u6b63\u78ba ?   \nA.\u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\u3002\nB.\u7d66\u4e88\u6297\u751f\u7d20\u3002\nC.\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u3002\nD.\u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\u53ca\u6297\u751f\u7d20\u3002\nE.\u7d66\u4e88\u985e\u56fa\u9187\u6216\u975e\u985e\u56fa\u9187\u6297\u767c\u708e\u85e5\u7269(NSAID)\u3002\n": "[E]", "111-78.\u4e00\u4f4d\u75c5\u4eba\u56e0\u8840\u5c0f\u677f\u4f4e\u4e0b\u61c9\u8a3a\uff0c\u4e0b\u5217\u5404\u9805\u6aa2\u9a57\u4e2d\u4f55\u8005\u70ba\u9451\u5225\u8840\u5c0f\u677f\u4f4e\u4e0b\u539f\u56e0\u5e6b\u5fd9\u6700\u5c0f\u8005\uff1f    \nA.H. pylori infection\u3002\nB.Serology tests for SLE\u3002\nC.Hepatitis C infection\u3002\nD.HIV infection\u3002\nE.Platelet antibodies\u3002\n": "[E]", "111-79.\u4e00\u4f4d32\u6b72\u5a66\u5973\u56e0\u5169\u5074\u96d9\u624b\u53ca\u96d9\u8173\u816b\u75db\u7d04 2\u9031\u5230\u91ab\u9662\u4f4f\u9662 \uff0c\u5979\u6709\u5169\u624b\u65e9\u6668\u50f5\u786c\u73fe\u8c61 \uff0c\u6c92\u6709\u5176\u4ed6\u7684\u7279\u5225\u75c5\n\u53f2\uff0c\u7406\u5b78\u6aa2\u67e5\u986f\u793a\u96d9\u624b\u7b2c\u4e09 \u3001\u7b2c\u56db\u53ca\u7b2c\u4e94\u8fd1\u7aef\u6307\u9593\u95dc\u7bc0\u58d3\u75db\u53ca\u816b\u8139\u53ca\u5169\u5074\u7b2c\u4e8c \u3001\u7b2c\u4e09\u638c\u6307\u95dc\u7bc0\u816b\u8139\u53ca\u58d3\n\u75db\uff0c\u624b\u90e8\u53ca\u8173\u90e8 X-\u5149\u6b63\u5e38\uff0c\u4e0b\u5217\u90a3\u4e9b\u6aa2\u67e5\u5c0d\u75c5\u4eba\u662f\u6700\u6709\u5e6b\u5fd9\u8a3a\u65b7 \uff1f(1). \u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6 (ESR) (2). C\u53cd\u61c9\n\u86cb\u767d(CRP) (3).\u6297\u74dc\u80fa\u9178\u86cb\u767d\u6297\u9ad4 (ACPA) (4). \u985e\u98a8\u6fd5\u6027\u56e0\u5b50 (RF) (5). \u6297\u6838\u6297\u9ad4 (ANA)   \nA.(1)+(2)\u3002\nB.(2)+(3)\u3002\nC.(3)+(4)\u3002\nD.(4)+(5)\u3002\nE.(1)+(5)\u3002\n": "[C]", "111-80.\u4e0068\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u8a3a\u65b7\u7f79\u60a3\u4e59\u72c0\u7d50\u8178\u764c (adenocarcinoma, sigmoid colon )\uff0c\u4ee5\u6839\u6cbb\u6027\u624b\u8853\u5207\u9664\u5de6\u5074\u4e59\u72c0\u7d50\n\u8178\u8207\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853 \uff0c\u75c5\u7406\u7d44\u7e54\u78ba\u5b9a\u624b\u8853\u908a\u7de3\u6c92\u6709\u764c\u7d30\u80de \uff0c\u6e05\u9664\u6dcb\u5df4\u7d50\u517125\u9846\u4e2d\u75c5\u7406\u6aa2\u67e5\u6709 6\u9846\u5df2\u6709\u764c\u7d30\n\u80de\uff0c\u6c92\u6709\u9060\u8655\u5668\u5b98\u8f49\u79fb \uff0c\u91ab\u5e2b\u5efa\u8b70\u624b\u8853\u5f8c\u9032\u884c 6\u500b\u6708\u5316\u5b78\u6cbb\u7642\u4ee5\u964d\u4f4e\u5fa9\u767c\u7387\u8207\u589e\u52a0\u5b58\u6d3b \u3002\u5404\u7a2e\u81e8\u5e8a\u6307\u5f15\u5747\n\u4e00\u81f4\u5efa\u8b70\u4e4b\u6700\u9069\u5408\u4e4b\u8f14\u52a9\u6027 (adjuvant )\u6cbb\u7642\u8655\u65b9\u70ba\u4f55\u8005 \uff1f   \nA.Irinotecan added to 5-FU and Leucovorin (FOLFIRI)\u3002\nB.Oxaliplatin added to 5-FU and Leucovorin (FOLFOX)\u3002\nC.Bevacizumab added to FOLFOX\u3002\nD.Cetuximab added to FOLFOX\u3002\nE.Panitumumab added to FOLFOX\u3002\n": "[B]", "100-1.\n\u8afe\u7f85\u75c5\u6bd2 (Norovirus) \u5728\u5404\u7d1a\u5b78\u6821\u3001\u8001\u4eba\u4e4b\u5bb6\u3001\u547c\u5438\u7167\u8b77\u75c5\u623f\u3001\u7cbe\u795e\u79d1\u75c5\u623f\u548c\u8eab\u5fc3\u969c\u7919\u6a5f\u69cb\u7b49\u55ae\u4f4d\u53ef\u9020\u6210\u4f4f\u6c11\u96c6\u9ad4\u767c\u751f\u6025\u6027\u8178\u80c3\u708e\u7684\u75ab\u60c5\u3002\u4e0b\u5217\u6709\u95dc\u8afe\u7f85\u75c5\u6bd2\u611f\u67d3\u53ca\u7ba1\u5236\u63aa\u65bd\u4e4b\u6558\u8ff0\u4e2d\uff0c\u4f55\u8005\u6b63\u78ba\uff1f (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1. \u8afe\u7f85\u75c5\u6bd2\u611f\u67d3\u5c6c\u65bc\u7b2c\u4e09\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u5fc5\u9700\u65bc\u4e00\u9031\u5167\u5411\u75be\u75c5\u7ba1\u5236\u5c40\u901a\u5831\u3002\r\n2. \u8afe\u7f85\u75c5\u6bd2\u901a\u5e38\u70ba\u81ea\u9650\u6027 (self-limited)\u3001\u8f15\u4e2d\u5ea6\u7684\u8178\u80c3\u9053\u611f\u67d3\u75c7\uff0c\u611f\u67d3\u75c5\u6bd2\u91cf\u5fc5\u9700\u9ad8\u65bc1000 particles\u4ee5\u4e0a\u624d\u6709\u9020\u6210\u81e8\u5e8a\u75c7\u72c0\u7684\u53ef\u80fd\u3002\r\n3. \u8afe\u7f85\u75c5\u6bd2\u5c6c\u65bc\u55ae\u93c8RNA\u75c5\u6bd2\uff0c\u5c6c\u65bcCaliciviridae\uff0c\u56e0\u5177\u6709\u5916\u5957\u819c (envelope)\uff0c\u56e0\u6b64\u9069\u7576\u6fc3\u5ea6\u4e4b\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u80fd\u6709\u6548\u7684\u6bba\u6b7b\u8afe\u7f85\u75c5\u6bd2\u3002\r\n4. \u611f\u67d3\u8afe\u7f85\u75c5\u6bd2\u60a3\u8005\u4e4b\u7cde\u4fbf\u3001\u5614\u5410\u7269\u5747\u61c9\u4f7f\u7528\u6f02\u767d\u6c34\u8655\u7406\u5f8c\u518d\u6c96\u5165\u4e0b\u6c34\u9053\u3002\r\n5. \u6f02\u767d\u6c34\u6d88\u6bd2\u6db2\u6fc3\u5ea6\u61c9\u4ee51000ppm\u64e6\u62ed\u5730\u9762\u53ca\u74b0\u5883\uff1b\u82e5\u6709\u8840\u6db2\u9ad4\u6db2\u4e4b\u6c61\u67d3\uff0c\u5247\u4f7f\u75285000ppm\u6d88\u6bd2\u3002\nA. 1+3+4\nB. 4+5\nC. 1+4+5\nD. 2+3+4\nE. 3+4+5\n": "(B)", "100-2.\n\u6709\u95dc\u4e16\u754c\u885b\u751f\u7d44\u7e54 (WHO) \u8207\u53f0\u7063\u75be\u75c5\u7ba1\u5236\u5c40\u76ee\u524d\u5728\u63a8\u52d5\u4e4b\u624b\u90e8\u885b\u751f\u904b\u52d5\u4e2d\uff0c\u6240\u8b02\u6d17\u624b5\u6642\u6a5f\uff0c\u5305\u62ec\u4e0b\u5217\u90a3\u4e9b\u60c5\u5f62\uff1f (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1.\u5e6b\u75c5\u4eba\u505a\u8eab\u9ad4\u6aa2\u67e5\u524d\u3002\r\n2.\u53ea\u63a5\u89f8\u75c5\u4eba\u8eab\u9ad4\u9ad4\u8868\u4e4b\u4e00\u822c\u6aa2\u67e5\u4e4b\u5f8c\u3002\r\n3.\u63a5\u89f8\u5230\u75c5\u4eba\u8840\u6db2\u6216\u9ad4\u6db2\u4e4b\u5f8c\u3002\r\n4.\u57f7\u884c\u4fb5\u5165\u6027\u6aa2\u67e5\u6234\u7121\u83cc\u624b\u5957\u4e4b\u524d\u3002\r\n5.\u9032\u5165\u75c5\u4eba\u623f\u9593\u53ea\u89f8\u78b0\u5230\u5e8a\u6b04\u687f\u5c31\u96e2\u958b\u75c5\u4eba\u623f\u9593\nA. 1+2+3+4+5\nB. 1+2+3+4\nC. 1+3+4\nD. 2+3+4\nE. 3+4\n": "(A)", "100-3.\n\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u53ef\u7b26\u5408\"\u611b\u6ecb\u75c5\"\u7684\u8a3a\u65b7\u6a19\u6e96? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1.\u767c\u751f\u80ba\u56ca\u87f2\u80ba\u708e\uff0c\u4f46\u611b\u6ecb\u75c5\u6bd2\u6297\u9ad4\u9670\u6027\u3002\r\n2. \u7121\u81e8\u5e8a\u75c7\u72c0\uff0c\u4f46\u611b\u6ecb\u75c5\u6bd2\u6297\u9ad4\u967d\u6027\uff0c\u4e14\u8840\u6db2\u4e2dCD4+\u6dcb\u5df4\u7403\u6578\u5df2\u6301\u7e8c\u5c0f\u65bc200/uL\u3002\r\n3.\u611b\u6ecb\u75c5\u6bd2\u6297\u9ad4\u967d\u6027\uff0c\u8840\u6db2\u4e2dCD4+\u6dcb\u5df4\u7403\u6578\u5927\u65bc200/uL\uff0c\u4f46\u8840\u4e2d\u75c5\u6bd2\u91cf\u5927\u65bc1,000,000 copies/mL\u3002\r\n4.\u611b\u6ecb\u75c5\u6bd2\u6297\u9ad4\u967d\u6027\uff0c\u8840\u6db2\u4e2dCD4+\u6dcb\u5df4\u7403\u6578\u5927\u65bc200/uL\uff0c\u81e8\u5e8a\u4e0a\u50c5\u51fa\u73fe\u6709\u53e3\u8154\u5ff5\u73e0\u83cc\u611f\u67d3\u3002\nA. 2+3+4\nB. 2+3\nC. 2\nD. 1+2+3\nE. 1+2+3+4\n": "(C)", "100-4.\n\u5f9e\u906d\u5230\u611b\u6ecb\u75c5\u6bd2\u611f\u67d3\uff0c\u5230\u4ee5\u6aa2\u6e2c\u8a66\u5291\u53ef\u5075\u6e2c\u5230\u611f\u67d3\u7684\u9019\u7d04\u4e00\u500b\u6708\u7684\u671f\u9593\uff0c\u7a31\u70ba\uff1a\nA. \u7a7a\u7a97\u671f\u3002\nB. \u6f5b\u4f0f\u671f\u3002\nC. \u6062\u5fa9\u671f\u3002\nD. \u60e1\u5316\u671f\u3002\nE. \u4ee5\u4e0a\u7686\u975e\u3002\n": "(A)", "100-5.\n\u4e0b\u5217\u6709\u95dc\u6d41\u884c\u6027\u611f\u5192 (Influenza) \u4e4b\u6558\u8ff0\u4e2d\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6d41\u611f\u75c5\u6bd2 (Influenza virus) \u7684\u57fa\u56e0\u662f\u7531\u516b\u6bb5DNA\u6240\u7d44\u6210\u7684\uff0c\u6545\u5f88\u5bb9\u6613\u91cd\u7d44\u800c\u9020\u6210\u75c5\u6bd2\u767c\u751f\u8b8a\u7570\u3002\nB. 2009\u5e74\u6d41\u884c\u4e4bH1N1\u6d41\u611f\u75c5\u6bd2\uff0c\u5176\u57fa\u56e0\u7247\u6bb5\u662f\u7531\u8c6c\u8207\u4eba\u5169\u7a2e\u6d41\u611f\u75c5\u6bd2\u6240\u7d44\u5408\u800c\u6210\u7684\u65b0\u578b\u6d41\u611f\u75c5\u6bd2\u3002\nC. H5N1\u6d41\u611f\u75c5\u6bd2\u52302011\u5e74\u4ecd\u7136\u6709\u9020\u6210\u4eba\u985e\u7684\u611f\u67d3\u3002\nD. 2010\u5e74\u79cb\u51ac\u5929\u6240\u4f7f\u7528\u4e4b\u5b63\u7bc0\u6027\u6d41\u611f\u75ab\u82d7\u4e26\u672a\u5305\u542b2009\u5e74\u958b\u59cb\u6d41\u884c\u4e4b\u65b0\u578bH1N1\u6d41\u611f\u75c5\u6bd2\u3002\nE. 2009\u5e74\u6d41\u884c\u4e4bH1N1\u6d41\u611f\u75c5\u6bd2\uff0c\u52302011\u5e746\u6708\u5e95\u70ba\u6b62\u5c1a\u672a\u6709Oseltamivir (Tamiflu) \u6297\u85e5\u6027\u4e4b\u75c5\u6bd2\u682a\u51fa\u73fe\u3002\n": "(C)", "100-6.\n\u4e0b\u5217\u5404\u7a2e\u85e5\u7269\u8207\u6cbb\u7642\u4e4b\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Daptomycin \uff0d MRSA\u4e4b\u6cbb\u7642\u3002\nB. Mefloquine \uff0d Malaria\u4e4b\u6cbb\u7642\u3002\nC. Micafungin \uff0d Candida\u4e4b\u6cbb\u7642\u3002\nD. Efavirenz \uff0d HIV\u4e4b\u6cbb\u7642\u3002\nE. Atazanavir \uff0d Influenza virus\u4e4b\u6cbb\u7642\u3002\n": "(E)", "100-7.\n\u4e0b\u5217\u6709\u95dc\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc (Staphylococcus aureus) \u53ca\u5176\u611f\u67d3\u7684\u6558\u8ff0\u4e2d\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. penicillin\u6297\u85e5\u6027\u4e4b\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc\u4e3b\u8981\u662f\u56e0\u70ba\u6703\u88fd\u9020penicillinase\u800c\u9020\u6210\u3002\nB. \u5c0d\u65bcmethicillin-susceptible\u7684\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc\u611f\u67d3\uff0cvancomycin\u7684\u7642\u6548\u4e0d\u5982oxacillin\u3002\nC. \u81e8\u5e8a\u4e0a\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc\u6240\u5c0e\u81f4\u7684\u611f\u67d3\u4e2d\uff0c\u76ae\u819a\u8207\u76ae\u4e0b\u7d44\u7e54\u662f\u6700\u5e38\u898b\u7684\u611f\u67d3\u90e8\u4f4d\u3002\nD. methicillin\u6297\u85e5\u6027\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc (MRSA)\u4e4b\u611f\u67d3\u5df2\u7d93\u4e5f\u51fa\u73fe\u5728\u793e\u5340\u611f\u67d3\u7684\u500b\u6848\u4e2d\u3002\nE. \u4ee5\u4e0a\u7686\u662f\u3002\n": "(E)", "100-8.\n\u4e0b\u5217\u6709\u95dc\u9b91\u6c0f\u4e0d\u52d5\u687f\u83cc (Acinetobacter baumannii) \u7684\u6558\u8ff0\u4e2d\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u81f4\u75c5\u6bd2\u529b (virulence)\u5f37\uff0c\u57281970\u5e74\u4ee3\u521d\u671f\uff0c\u5373\u88ab\u8a8d\u5b9a\u70ba\u4eba\u985e\u7684\u771f\u5be6\u81f4\u75c5\u83cc (true pathogen)\u3002\nB. \u5728\u4e7e\u71e5\u7684\u74b0\u5883\u8868\u9762\u7121\u6cd5\u5b58\u6d3b\u3002\nC. \u5728\u53f0\u7063\u8a31\u591a\u7684\u91ab\u5b78\u4e2d\u5fc3\u3001\u5340\u57df\u91ab\u9662\uff0ccarbapenem\u6297\u85e5\u6027\u7684\u9b91\u6c0f\u4e0d\u52d5\u687f\u83cc\uff0c\u5df2\u9020\u6210\u56b4\u91cd\u7684\u81e8\u5e8a\u554f\u984c\u3002\nD. \u5c0d\u65bccarbapenem\u6297\u85e5\u6027\u7684\u9b91\u6c0f\u4e0d\u52d5\u687f\u83cc\u611f\u67d3\u53ef\u9078\u64c7Linezolid\u52a0\u4ee5\u6cbb\u7642\u3002\nE. \u4ee5\u4e0a\u7686\u662f\u3002\n": "(C)", "100-9.\n\u5c0d\u65bc\u6297\u751f\u7d20\u7684\u4f5c\u7528\u6a5f\u8f49\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u76e4\u5c3c\u897f\u6797 (penicillin) \u985e\u6297\u751f\u7d20\u4f5c\u7528\u65bc\u7d30\u83cc\u7684\u7d30\u80de\u819c\u3002\nB. fluoroquinolone\u985e\u6297\u751f\u7d20\u4f5c\u7528\u65bc\u7d30\u83cc\u7684DNA gyrase\u548ctopoisomerase IV\u3002\nC. aminoglycoside\u985e\u7684\u6297\u751f\u7d20\u4e3b\u8981\u4f5c\u7528\u572850S ribosomal subunit\u4e0a\u3002\nD. vancomycin\u4e3b\u8981\u4f5c\u7528\u6a5f\u8f49\u5728\u6291\u5236\u7d30\u83cc\u7684\u6c27\u5316\u50b3\u905e\u93c8\u3002\nE. \u4ee5\u4e0a\u7686\u662f\u3002\n": "(B)", "100-10.\n\u4e00\u4f4d36\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u5e73\u65e5\u8eab\u9ad4\u5065\u5eb7\u72c0\u6cc1\u826f\u597d\uff0c\u559c\u6b61\u91ce\u5916\u65c5\u904a\uff0c3\u5929\u524d\u525b\u5f9e\u82b1\u6771\u65c5\u904a\u56de\u5230\u53f0\u5317\uff0c2\u5929\u524d\u958b\u59cb\u51fa\u73fe\u767c\u71d2\u3001\u5026\u6020\u611f\u53ca\u982d\u75db\uff0c\u524d\u5f80\u67d0\u8a3a\u6240\u5c31\u8a3a\u5f8c\uff0c\u670d\u7528\u4e00\u4e9b\u611f\u5192\u85e5\u4f46\u4e26\u672a\u9000\u71d2\uff0c\u65bc\u662f\u5230\u67d0\u91ab\u9662\u5c31\u8a3a\uff0c\u8840\u6db2\u6aa2\u67e5\u767c\u73fe\u767d\u8840\u7403\u70ba3,600/\u03bcL\uff0cAST\uff1a66 IU/L\uff0cALT\uff1a58 IU/L\uff0c\u65bc\u53f3\u5074\u814b\u7aa9\u9644\u8fd1\u767c\u73fe\u6709\u4e00eschar\uff0c\u8acb\u554f\u6b64\u6642\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u9069\u7576\u4e4bempirical antibiotic\u9078\u64c7\uff1f\nA. Oxacillin\u3002\nB. Ampicillin\u3002\nC. \u7b2c\u4e09\u4ee3cephalosporin\u3002\nD. Minocycline\u3002\nE. \u7b2c\u4e00\u4ee3cephalosporin\u3002\n": "(D)", "100-11.\n\u9264\u7aef\u87ba\u65cb\u83cc(Leptospires)\u53ca\u5176\u6240\u9020\u6210\u7684\u75be\u75c5(Leptospirosis)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1.\u4eba\u755c\u5171\u901a\u75c5\uff0c\u9f20\u985e\u3001\u91ce\u751f\u54fa\u4e73\u52d5\u7269\u6216\u5bb6\u755c\u7686\u53ef\u70ba\u5bbf\u4e3b\u3002\r\n2.\u8a72\u83cc\u7d93\u5c3f\u6392\u51fa\uff0c\u5728\u6c34\u4e2d\u53ef\u5b58\u6d3b\u9054\u6578\u6708\u3002\r\n3.\u4eba\u7f79\u60a3\u8a72\u75c5\u6f5b\u4f0f\u671f\u901a\u5e38\u57285\u81f314\u5929\u3002\u5927\u591a\u6578\u75c5\u4eba\u6c92\u75c7\u72c0\uff0c\u6709\u75c7\u72c0\u7684\u75c5\u4eba\u4e2d\u7d045~15%\u6703\u5f88\u56b4\u91cd\u3002\r\n4.\u9810\u9632\u65b9\u6cd5\u662f\u907f\u514d\u63a5\u89f8\u6c61\u67d3\u542b\u83cc\u7684\u6c34\u6216\u6ce5\u571f\uff0c\u5c24\u5176\u662f\u6d2a\u6c34\u6216\u662f\u98b1\u98a8\u904e\u5f8c\u7684\u6c34\u60a3\u3002\r\n5.\u5728\u75c5\u767c3\u5929\u5f8c\u4ecd\u7136\u53ef\u4ee5\u6cbb\u7642\uff0c\u56b4\u91cd\u8005\u4ee5penicillin\u6cbb\u7642\uff0c\u8f15\u8005\u4ee5doxycycline\u6cbb\u7642\u3002\nA. 1+2+3+4\nB. 1+3+4\nC. 1+3+4+5\nD. 1+4+5\nE. 1+2+3+4+5\n": "(E)", "100-12.\n\u6d41\u611f\u4f75\u767c\u75c7\u7684\u9ad8\u5371\u96aa\u7fa4\uff1a (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1.\u5c0f\u5b69\u5f9e\u51fa\u751f\u52304\u6b72\r\n2.\u61f7\u5b55\u5a66\u5973\r\n3.\u6709\u6162\u6027\u5fc3\u80ba\u75be\u75c5\u8005\u3001\u5927\u65bc65\u6b72\u7684\u8001\u5e74\u4eba\u53ca\u5b89\u7642\u990a\u9662\u4f4f\u6c11\r\n4.\u5c0f\u5b78\u751f\r\n5.\u8ecd\u4eba\nA. 1+2+3+4\nB. 1+3+4\nC. 2+3+4+5\nD. 2+3+4\nE. 1+2+3\n": "(E)", "100-13.\n\u8089\u6bd2\u687f\u83cc(Clostridium botulinum)\u53ca\u5176\u4e2d\u6bd2\u75c7(Botulism)\uff1a (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1.\u662f\u53ad\u6c27\u9769\u862d\u6c0f\u967d\u6027\u83cc\uff0c\u53ef\u5b58\u5728\u571f\u58e4\u548c\u6c34\u4e2d\u3002\r\n2.\u4e2d\u6bd2\u53ef\u56e0\u98df\u7528\u5230\u542b\u83cc\u5b62\u5b50\u6216\u53d7\u6bd2\u7d20\u6c61\u67d3\u7684\u98df\u7269\uff0c\u6216\u50b7\u53e3\u6c61\u67d3\u5230\u75c5\u83cc\u800c\u9020\u6210\uff0c\u81f4\u75c5\u662f\u7531\u795e\u7d93\u6bd2\u7d20(neurotoxin)\u6240\u81f4\u3002\r\n3.\u9020\u6210\u98df\u7269\u4e2d\u6bd2\u7684\u4e3b\u8981\u662f\u5bb6\u5ead\u81ea\u88fd\u852c\u679c\u3001\u8abf\u5473\u4f50\u6599\u4e4b\u7f50\u88dd\u7269\uff0c\u9810\u9632\u7684\u65b9\u6cd5\u662f\u98df\u7528\u524d\u572885\u2103\u52a0\u71b15\u5206\u9418\uff0c\u4ee5\u7834\u58de\u6bd2\u7d20\u3002\u81f3\u65bc\u8981\u5c07\u8089\u6bd2\u687f\u83cc\u5b62\u5b50\u6bba\u6b7b\u5247\u9700\u5728\u9ad8\u58d3\u53ca116~121\u2103\u9ad8\u6eab\u8655\u740610\u5206\u9418\u4ee5\u4e0a\u3002\r\n4.\u8a72\u795e\u7d93\u6bd2\u7d20\u9032\u5165\u8840\u6d41\u7cfb\u7d71\u6703\u88ab\u50b3\u9001\u5230\u672b\u68a2\u795e\u7d93\u53ca\u795e\u7d93\u808c\u8089\u4ea4\u6703\u8655\uff0c\u7d93\u7531\u5206\u89e3\u86cb\u767d\u8cea\u800c\u963b\u65b7\u4eba\u9ad4acetylcholine\u4e4b\u91cb\u653e\uff0c\u9020\u6210\u7531\u9871\u795e\u7d93\u9032\u5c55\u5230\u80a2\u9ad4\u4e4b\u904b\u52d5\u795e\u7d93\u7671\u7613\u3002\r\n5.\u6cbb\u7642\u8457\u91cd\u76e3\u63a7\u547c\u5438\u3001\u8840\u6c27\u53ca\u6297\u6bd2\u7d20\u3002\nA. 1+2+3\nB. 1+2+4\nC. 1+2+4+5\nD. 1+2+3+5\nE. 1+2+3+4+5\n": "(E)", "100-14.\n\u4eba\u985e\u8178\u75c5\u6bd2\u8d85\u904e65\u7a2e\u8840\u6e05\u578b\uff1a (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r\n1.\u8178\u75c5\u6bd2\u5305\u62ecCoxsackievirus A\u3001Coxsackievirus B\u3001Poliovirus\u3001echovirus\u53caEnterovirus\u7b49\u3002\r\n2.\u662f\u55ae\u80a1RNA\u75c5\u6bd2\uff0c\u7121\u8102\u8cea\u5916\u9798\uff0c\u5c0d\u9178\u7a69\u5b9a\uff0c\u53ef\u5728\u5ba4\u6eab\u5b58\u6d3b\u591a\u5929\u3002\r\n3.\u597d\u7684\u6d17\u624b\u7fd2\u6163\uff0c\u4f7f\u7528\u624b\u5957\u3001\u9694\u96e2\u8863\uff0c\u53ef\u9810\u9632\u50b3\u64ad\u3002\r\n4.\u8a72\u75c5\u6bd2\u5c0d\u9152\u7cbe\u654f\u611f\uff0c\u4ee5\u9152\u7cbe\u4e7e\u6d17\u624b\u6db2\u5373\u53ef\u6709\u6548\u6bba\u6b7b\u3002\r\n5.\u5c11\u6578\u91cd\u75c7\u60a3\u8005\u9808\u52a0\u8b77\u652f\u6301\u6cbb\u7642\u3002\nA. 1+2+3\nB. 1+2+3+4\nC. 1+3+5\nD. 1+2+3+5\nE. 1+2+3+4+5\n": "(D)", "100-15.\n\u53f0\u7063\u75be\u75c5\u7ba1\u5236\u5c40\u57282010\u5e74\u70ba\u5f37\u5316\u6297\u85e5\u6027\u7d30\u83cc\u76e3\u6e2c\uff0c\u5c07NDM-1\u8178\u9053\u83cc\u611f\u67d3\u75c7\u5217\u70ba\u7b2c\u56db\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u9019\u985e\u7d30\u83cc\u9020\u6210\u7684\u6297\u85e5\u6027\u57fa\u56e0\u4e3b\u8981\u900f\u904eplasmid\u88fd\u9020\u53ca\u6563\u64ad\uff0cNDM-1\u662f\u4ec0\u9ebc\uff1f\nA. Extended spectrum \u03b2-lactamase\uff0c\u9020\u6210\u5c0d\u7b2c\u4e09\u4ee3\u982d\u5b62\u7d20\u4e4b\u6297\u85e5\u6027\u3002\nB. DNA gyrase\uff0c\u9020\u6210\u5c0dquinolone\u4e4b\u6297\u85e5\u6027\u3002\nC. Metallo-\u03b2-lactamase\uff0c\u9020\u6210\u5c0dcarbapenem\u4e4b\u6297\u85e5\u6027\u3002\nD. Penicillinase\uff0c\u9020\u6210\u5c0dpenicillin\u4e4b\u6297\u85e5\u6027\u3002\nE. \u6539\u8b8a outer membrane protein (porin)\u4e4b\u7d50\u69cb\uff0c\u9020\u6210\u6297\u85e5\u6027\u3002\n": "(C)", "100-16.\n\u624b\u90e8\u885b\u751f\u662f\u9810\u9632\u91ab\u9662\u5167\u4ea4\u53c9\u611f\u67d3\u6700\u6709\u6548\u4e4b\u55ae\u4e00\u65b9\u6cd5\uff0c\u4ee5\u4e0b\u6709\u95dc\u6d17\u624b\uff0c\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba\uff1f\nA. \u5728\u63a5\u89f8\u75c5\u4eba\u6216\u75c5\u4eba\u65c1\u908a\u74b0\u5883\u524d\u5f8c\u61c9\u8a72\u6d17\u624b\u3002\nB. \u624b\u90e8\u6709\u660e\u986f\u5f04\u9ad2\u6216\u6709\u8840\u6db2\u6c61\u67d3\uff0c\u4ee5\u80a5\u7682\u6d17\u624b\u70ba\u539f\u5247\u3002\nC. \u75c5\u623f\u6709Clostridium difficile\u7fa4\u805a\u611f\u67d3\uff0c\u61c9\u8a72\u7528\u80a5\u7682\u6d17\u624b\u3002\nD. \u8178\u75c5\u6bd2\u6d41\u884c\u6642\uff0c\u4ee5\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u6d17\u624b\u3002\nE. \u5927\u90e8\u5206\u7684\u60c5\u6cc1\u53ef\u63a1\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u3002\n": "(D)", "100-17.\n\u51fa\u570b\u65c5\u904a\u6108\u4f86\u6108\u666e\u904d\uff0c\u4ee5\u4e0b\u6709\u95dc\u65c5\u904a\u5230\u843d\u5f8c\u570b\u5bb6\u7684\u6558\u8ff0\u662f\u932f\u8aa4\u7684\uff1f\nA. \u559d\u716e\u904e\u7684\u6c34\u6216\u74f6\u88dd\u6c34\uff0c\u907f\u514d\u98df\u7528\u751f\u7684\u3001\u672a\u719f\u7684\u98df\u7269\u6216\u51b0\u88fd\u54c1\uff0c\u53ef\u9810\u9632\u8179\u7009\u3002\nB. \u82e5\u4e0d\u80fd\u907f\u514d\u6027\u95dc\u4fc2\uff0c\u5247\u5168\u7a0b\u4f7f\u7528\u4fdd\u96aa\u5957\uff0c\u53ef\u907f\u514d\u6027\u75c5\u3002\nC. \u5728\u6de1\u6c34\u6e56\u6216\u6cb3\u5ddd\u6d17\u6fa1\u6e38\u6cf3\u4e26\u4e0d\u6703\u589e\u52a0\u7f79\u60a3\u8840\u5438\u87f2\u75c5(schistosomiasis)\u4e4b\u5371\u96aa\u3002\nD. \u6253\u8d64\u8173\u8d70\u8def\uff0c\u6703\u589e\u52a0\u9264\u87f2\u548c\u7cde\u7dda\u87f2(Strongyloides)\u611f\u67d3\u5371\u96aa\u3002\nE. \u9810\u9632\u868a\u54ac\u53ca\u7627\u75be\u9810\u9632\u7528\u85e5\uff0c\u53ef\u907f\u514d\u7627\u75be\u548c\u87f2\u5a92\u75be\u75c5\u3002\n": "(C)", "100-18.\n2011\u5e74\u5728\u6b50\u6d32\u767c\u751f\u8de8\u8d8a\u591a\u570b\u7684\u8178\u51fa\u8840\u578b(enterohemorrhagic)\u5927\u8178\u687f\u83cc(EHEC)\u611f\u67d3\u75c7\uff0c\u9020\u6210\u4e0d\u5c11\u4eba\u6b7b\u4ea1\u3002\u4ee5\u4e0b\u6558\u8ff0\uff0c\u54ea\u4e00\u9805\u932f\u8aa4\uff1f\nA. \u9019\u6b21EHEC\u4e3b\u8981\u662f\u8840\u6e05\u578bO111\u6240\u9020\u6210\u3002\nB. \u56b4\u91cd\u7684\u75c5\u4eba\u9664\u4e86\u6709\u8840\u5c0f\u677f\u6578\u6e1b\u5c11\u4e4b\u5916\uff0c\u6709\u4e9b\u4f75\u767c\u6eb6\u8840\u6027\u5c3f\u6bd2\u75c7\u5019\u7fa4\u3002\nC. \u6cbb\u7642\u9700\u7528Ampicillin\u3002\nD. EHEC\u6703\u5206\u6cccshiga-like toxin\u3002\nE. \u8d77\u56e0\u8207\u7cde\u4fbf\u6c61\u67d3\u548c\u751f\u98df\u852c\u83dc\u6709\u95dc\u3002\n": "(C)\u6216(A)", "100-19.\n\u6709\u95dc\u767b\u9769\u71b1\u4e4b\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u932f\u8aa4\uff1f\nA. \u75c5\u5a92\u868a\u4e3b\u8981\u662f\u57c3\u53ca\u6591\u868a\uff0c\u767d\u7dda\u6591\u868a\u6b21\u4e4b\u3002\nB. \u9810\u9632\u4e3b\u8981\u9760\u5674\u7051\u6bba\u87f2\u5291\u3002\nC. \u6e05\u9664\u5b73\u751f\u6e90\u548c\u7a4d\u6c34\u5bb9\u5668\u662f\u6700\u91cd\u8981\u7684\u9810\u9632\u65b9\u6cd5\u3002\nD. \u6c23\u5019\u8b8a\u9077\u5f71\u97ff\u868a\u5b50\u5206\u5e03\u5340\u57df\uff0c\u4e5f\u6539\u8b8a\u75c5\u6bd2\u5728\u868a\u87f2\u9ad4\u5167\u4e4b\u8907\u88fd\u6642\u9593\u3002\nE. 50%\u81f390%\u7684\u75c5\u4eba\u611f\u67d3\u4e4b\u75c7\u72c0\u4e0d\u660e\u986f\u3002\n": "(B)", "101-1.\n\u4ee5\u4e0b\u6709\u95dc\u767c\u71d2\u548c\u76ae\u75b9\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r(1)\u4e8c\u671f\u6885\u6bd2\u7684\u76ae\u75b9\u6700\u5e38\u51fa\u73fe\u5728\u624b\u638c\u5fc3\u548c\u8173\u5e95\r(2)\u5c48\u516c\u75c5\uff08Chikungunya fever\uff09\u6700\u5e38\u898b\u76ae\u75b9\u5728\u4e0a\u80a2\u548c\u81c9\u90e8\uff0c\u5e38\u4f34\u96a8\u5c0f\u95dc\u7bc0\u75bc\u75db\r(3)\u767b\u9769\u71b1\u7d0450%\u6703\u6709\u76ae\u75b9\uff0c\u5e38\u7531\u8ec0\u5e79\u958b\u59cb\uff0c\u7e7c\u800c\u6563\u81f3\u80a2\u9ad4\u548c\u81c9\u90e8\r(4)\u6059\u87f2\u75c5\u7684\u76ae\u75b9\u5e38\u7531\u80a2\u7aef\u958b\u59cb\uff0c\u800c\u5f8c\u64f4\u53ca\u8ec0\u5e79\u548c\u81c9\u90e8\r(5)\u9ebb\u75b9\u7684\u76ae\u75b9\u5e38\u7531\u81c9\u90e8\u5f80\u4e0b\u64f4\u5c55\uff0c\u6700\u7d42\u5230\u624b\u638c\u5fc3\u548c\u8173\u638c\u5fc3\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(3)+(5)\nC. (1)+(2)+(4)+(5)\nD. (1)+(2)+(3)\nE. (1)+(3)+(4)\n": "(D)", "101-2.\n\u4e00\u540d\u7537\u5b50\u5728\u5927\u9678\u5de5\u4f5c\u6642\u56e0\u5916\u51fa\u906d\u91ce\u72ac\u54ac\u50b7\u8173\u8dbe\uff0c\u7576\u6642\u672a\u5c31\u91ab\uff0c\u4e00\u500b\u591a\u6708\u5f8c\u51fa\u73fe\u4e0b\u534a\u8eab\u7570\u5e38\u7662\u3001\u9ebb\u75db\u3001\u5614\u5410\u3001\u541e\u56a5\u56f0\u96e3\u53ca\u5589\u56a8\u816b\u75db\u7b49\u75c7\u72c0\uff0c\u4e26\u6709\u6050\u6c34\u4e4b\u73fe\u8c61\uff0c\u5c31\u91ab\u5f8c\u56e0\u7591\u4f3c\u72c2\u72ac\u75c5(rabies) \u800c\u5165\u9662\uff0c\u95dc\u65bc\u6b64\u75c5\uff0c\u8acb\u554f\u4ee5\u4e0b\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u75c5\u60a3\u6050\u6c34\u4e4b\u73fe\u8c61\u662f\u56e0\u54bd\u5589\u90e8\u808c\u8089\u4e4b\u75d9\u6523\u6240\u5f15\u8d77\u3002\nB. \u53f0\u7063\u81ea\u6c11\u570b\u56db\u5341\u516b\u5e74\u8d77\u53f0\u7063\u5730\u5340\u5373\u4e0d\u518d\u6709\u4eba\u7684\u672c\u571f\u75c5\u4f8b\uff0c\u6c11\u570b\u4e94\u5341\u5e74\u4e00\u6708\u5f8c\u5373\u672a\u518d\u51fa\u73fe\u52d5\u7269\u7684\u75c5\u4f8b\u3002\u76ee\u524d\u5728\u53f0\u7063\u88ab\u672c\u5730\u7684\u72d7\u3001\u8c93\u54ac\u50b7\uff0c\u539f\u5247\u4e0a\u4e0d\u5fc5\u65bd\u6253\u4eba\u7528\u72c2\u72ac\u75c5\u514d\u75ab\u7403\u86cb\u767d\u6216\u75ab\u82d7\u3002\nC. \u5982\u9700\u524d\u5f80\u72c2\u72ac\u75c5\u75ab\u5340\uff0c\u5efa\u8b70\u884c\u524d\u81f3\u5c11\u4e00\u500b\u6708\uff0c\u63a5\u7a2e\u4e09\u5291\u75ab\u82d7\u4ee5\u7522\u751f\u514d\u75ab\u4fdd\u8b77\u3002\nD. \u5728\u75ab\u5340\u88ab\u52d5\u7269\u54ac\u50b7\u5f8c\uff0c\u5b9c\u5fb9\u5e95\u5730\u6e05\u6d17\u3001\u6d88\u6bd2\u50b7\u53e3\uff0c\u8fc5\u901f\u63a5\u53d7\u4eba\u7528\u72c2\u72ac\u75c5\u514d\u75ab\u7403\u86cb\u767d\u53ca\u63a5\u7a2e4\u5291\u75ab\u82d7\u3002\nE. \u82e5\u672a\u6cbb\u7642\uff0c\u6b64\u75c5\u81f4\u6b7b\u7387\u7d04\u70ba45%\u3002\n": "(E)", "101-3.\n\u738b\u5927\u660e\u662f\u4e00\u4f4d20\u6b72\u7684\u5927\u5b78\u4e8c\u5e74\u7d1a\u5b78\u751f\uff0c\u7531\u65bc\u4ed6\u662f\u5728\u6821\u5712\u5167\u4e00\u4f4d\u50b3\u67d3\u6027\u7d50\u6838\u75c5\u4eba(\u8010\u9178\u62b9\u7247\u967d\u6027\u4e14\u7d50\u6838\u83cc\u57f9\u990a\u967d\u6027)\u7684\u5bc6\u5207\u63a5\u89f8\u8005\uff0c\u67d0\u65e5\u4ed6\u62ff\u8457\u516c\u5171\u885b\u751f\u7684\u8f49\u4ecb\u55ae\u4e14\u5305\u542b\u7d50\u6838\u83cc\u7d20\u6e2c\u9a57\u7d50\u679c\u70ba20 mm\u4f86\u5230\u4f60\u7684\u9580\u8a3a\uff0c\u8a62\u554f\u4f60\u6709\u95dc\u7d50\u6838\u75c5\u548c\u6f5b\u4f0f\u611f\u67d3(latent tuberculosis infection)\u7684\u554f\u984c\u3002\u4e0b\u5217\u7d44\u5408\u4f55\u8005\u6b63\u78ba\uff1f\r(1)\u9019\u4f4d\u540c\u5b78\u7684\u7d50\u6838\u83cc\u7d20\u6e2c\u9a57\u7d50\u679c\u70ba\u967d\u6027\uff0c\u53ef\u4ee5\u8a8d\u70ba\u4ed6\u5c31\u662f\u7d50\u6838\u75c5\u767c\u75c5\u500b\u6848\uff0c\u4e5f\u6703\u50b3\u67d3\u7d66\u5176\u4ed6\u4eba\u3002\r(2)\u51fa\u751f\u6642\u7684\u5361\u4ecb\u82d7\u63a5\u7a2e\u4e00\u5b9a\u6703\u8b93\u9019\u4f4d\u540c\u5b78\u7684\u7d50\u6838\u83cc\u7d20\u6e2c\u9a57\u7d50\u679c\u5448\u73fe\u507d\u967d\u6027\uff0c\u6240\u4ee5\u4e0d\u7528\u64d4\u5fc3\u7d50\u6838\u75c5\u767c\u75c5\u98a8\u96aa\u3002\r(3)\u512a\u5148\u9032\u884c\u75c5\u53f2\u8a62\u554f\u662f\u5426\u6709\u6162\u6027\u54b3\u55fd\u8d85\u904e\u4e09\u9031\u7b49\u75c7\u72c0\u3001\u7406\u5b78\u6aa2\u67e5\u548c\u80f8\u90e8X\u5149\u4f86\u8a55\u4f30\u662f\u5426\u70ba\u6d3b\u52d5\u6027\u7d50\u6838\u75c5\u75c5\u4eba\u3002\r(4)\u5047\u8a2d\u738b\u540c\u5b78\u6c92\u6709\u75c7\u72c0\u4e14\u80f8\u90e8X\u5149\u6b63\u5e38\uff0c\u53ef\u4f7f\u7528isoniazid 300 mg \u6cbb\u76429\u500b\u6708\u4ee5\u6e1b\u5c11\u767c\u75c5\u98a8\u96aa\uff0c\u662f\u76ee\u524d\u5c0d\u65bc\u6f5b\u4f0f\u611f\u67d3\u6cbb\u7642\u7684\u5efa\u8b70\u3002\r(5)\u885b\u6559\u9019\u4f4d\u540c\u5b78\u63a5\u89f8\u8005\u767c\u75c5\u7684\u98a8\u96aa\u548c\u4e00\u4f46\u51fa\u73fe\u7d50\u6838\u75c5\u76f8\u95dc\u75c7\u72c0\uff0c\u76e1\u901f\u5c31\u91ab\u4e26\u61c9\u63d0\u9192\u91ab\u5e2b\u66fe\u70ba\u63a5\u89f8\u8005\u3002\nA. (1)+(3)\nB. (2)\nC. (3)+(4)\nD. (3)+(4)+(5)\nE. (4)+(5)\n": "(D)", "101-4.\n\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5(multidrug-resistant tuberculosis, MDRTB)\u662f\u76ee\u524d\u5168\u7403\u7d50\u6838\u75c5\u9632\u6cbb\u7684\u91cd\u5927\u6311\u6230\u3002\u4e0b\u5217\u7d44\u5408\u4f55\u8005\u70ba\u662f\uff1f\r(1)\u53f0\u7063\u7684\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u76e3\u6e2c\u767c\u73fe\uff1a\u5728\u7d50\u6838\u75c5\u65b0\u75c5\u4eba\u70ba1%\uff0c\u518d\u6cbb\u75c5\u4eba(\u5305\u542b\u5fa9\u767c\u3001\u6cbb\u7642\u5931\u6557\u548c\u5931\u843d)\u70ba6-8%\u3002\u76f8\u8f03\u65bc\u5468\u908a\u7684\u4e2d\u570b\u5927\u9678(\u5206\u5225\u70ba5.7%\u548c25.6%)\u53ca\u6771\u5357\u4e9e\uff0c\u53f0\u7063\u75ab\u60c5\u8f03\u8f15\u5fae\u3002\r(2)\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u7684\u5be6\u9a57\u5ba4\u6aa2\u67e5\u53ea\u80fd\u4f9d\u8cf4\u50b3\u7d71\u85e5\u7269\u654f\u611f\u6027\u8a66\u9a57\u7d50\u679c\uff0c\u76ee\u524d\u65b0\u7684\u5206\u5b50\u5feb\u901f\u8a3a\u65b7\u7684\u65b9\u6cd5\uff0c\u5982\uff1aHain test \u6216Xpert\uff0c\u4ecd\u5c1a\u5728\u8a55\u4f30\u4e2d\u3002\r(3)\u4e00\u822c\u7d50\u6838\u75c5\u7684\u6cbb\u7642\u61c9\u5408\u4f75\u591a\u7a2e\u85e5\u7269\u3001\u5291\u91cf\u8db3\u5920\u3001\u4e14\u6709\u8db3\u5920\u7684\u6cbb\u7642\u671f\uff0c\u4e26\u52f8\u75c5\u4eba\u52a0\u5165\u90fd\u6cbb(directly observed therapy) \u78ba\u4fdd\u670d\u85e5\u9806\u5f9e\u6027\uff0c\u53ef\u6e1b\u5c11\u7522\u751f\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u7684\u98a8\u96aa\u3002\r(4)\u4e00\u65e6\u70ba\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u4eba\uff0c\u6cbb\u7642\u9700\u8003\u616e\u5408\u4f754\u7a2e\u4ee5\u4e0a\u7684\u6709\u6548\u85e5\u7269\uff0c\u4f46\u4e0d\u9808\u5ef6\u9577\u6cbb\u7642\u8d85\u904e\u75f0\u9670\u8f4918\u500b\u6708\u3002\r(5)\u591a\u91cd\u6297\u85e5\u7d50\u6838\u75c5\u4eba\u4f7f\u7528\u7684\u4e8c\u7dda\u85e5\u7269\u526f\u4f5c\u7528\u6bd4\u4e00\u7dda\u6297\u7d50\u6838\u85e5\u7269\u591a\uff0c\u5efa\u8b70\u75c5\u4eba\u8f49\u4ecb\u7d66\u5177\u7d93\u9a57\u7684\u591a\u91cd\u6297\u85e5\u75c5\u4eba\u7167\u8b77\u5718\u968a\u91ab\u9662\u3002\nA. (1)+(3)+(5)\nB. (2)+(4)\nC. (2)+(3)+(4)\nD. (1)+(2)+(5)\nE. (1)+(4)+(5)\n": "(A)", "101-5.\n\u6709\u95dc\u6d41\u611f\u75ab\u82d7\u63a5\u7a2e\u526f\u4f5c\u7528\u8207\u7981\u5fcc\u75c7\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\r(1)\u5c0d\u96de\u86cb\u56b4\u91cd\u904e\u654f\u8005\u70ba\u63a5\u7a2e\u6d41\u611f\u75ab\u82d7\u4e4b\u7981\u5fcc\u3002\r(2)\u9664\u4e86\u7f8e\u570b1976\u5e74H1N1\u8c6c\u6d41\u611f\u75ab\u82d7\u5916\uff0c\u63a5\u7a2e\u5b63\u7bc0\u6d41\u611f\u75ab\u82d7\u5f8c\u767c\u751fGuillain-Barre syndrome\u4e4b\u6a5f\u7387\u6975\u4f4e\u3002\r(3)\u5c0f\u65bc6\u500b\u6708\u4e4b\u5b30\u5152\u4e0d\u5b9c\u63a5\u53d7\u6d41\u611f\u75ab\u82d7\u65bd\u6253\u3002\r(4)\u90e8\u5206\u6d41\u611f\u75ab\u82d7\u4e2d\u542b\u6709\u7532\u57fa\u6c5e\u8207\u4e59\u57fa\u6c5e\u7528\u4ee5\u4fdd\u5b58\u75ab\u82d7\uff0c\u7532\u57fa\u6c5e\u8207\u4e59\u57fa\u6c5e\u5747\u53ef\u70ba\u4eba\u9ad4\u6240\u4ee3\u8b1d\u3002\r(5)\u5728\u5224\u65b7\u6d41\u611f\u75ab\u82d7\u63a5\u7a2e\u5f8c\u4e0d\u826f\u4e8b\u4ef6\u8207\u75ab\u82d7\u63a5\u7a2e\u4e4b\u56e0\u679c\u95dc\u4fc2\u6642\uff0c\u8a72\u4e0d\u826f\u4e8b\u4ef6\u4e4b\u6b7b\u4ea1\u6216\u91cd\u75c7\u6bd4\u7387\u662f\u91cd\u8981\u7684\u89c0\u5bdf\u6307\u6a19\u3002\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (1)+(3)+(5)\nE. (1)+(2)+(3)+(5)\n": "(E)", "101-6.\n\u95dc\u65bc\u897f\u5c3c\u7f85\u71b1\uff08West Nile Fever\uff09\u53ca\u5c48\u516c\u71b1\uff08Chikungunya fever\uff09\uff0c\u4ee5\u4e0b\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f\nA. \u6b64\u5169\u7a2e\u75be\u75c5\u53ef\u7d93\u7531\u75c5\u5a92\u868a\u53ee\u54ac\u50b3\u67d3\u7d66\u4eba\u985e\u3002\u65c5\u904a\u9632\u868a\u53ef\u9078\u64c7\u542b\u6575\u907f(DEET)\u7684\u9632\u868a\u7522\u54c1\uff0c\u6548\u679c\u6700\u597d\u3002\nB. \u9ce5\u985e\u662f\u897f\u5c3c\u7f85\u75c5\u6bd2\u65bc\u81ea\u7136\u754c\u4e3b\u8981\u5bbf\u4e3b\u3002\nC. \u53ef\u80fd\u50b3\u64ad\u897f\u5c3c\u7f85\u71b1\u53ca\u5c48\u516c\u71b1\u7684\u75c5\u5a92\u868a\uff0c\u4e5f\u5927\u91cf\u5206\u4f48\u65bc\u53f0\u7063\u3002\nD. \u65c5\u5ba2\u81ea\u897f\u5c3c\u7f85\u75c5\u6bd2\u6d41\u884c\u5340\u96e2\u5883\u56de\u53f0\u4e00\u500b\u6708\u5167\uff0c\u61c9\u66ab\u7de9\u6350\u8840\uff0c\u4ee5\u9632\u7bc4\u8f38\u8840\u50b3\u67d3\u897f\u5c3c\u7f85\u75c5\u6bd2\u3002\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(E)", "101-7.\n\u8fd1\u5e74\u4e2d\u570b\u5927\u9678\u5728\u6cb3\u5357\u3001\u5c71\u6771\u3001\u6e56\u5317\u3001\u5b89\u5fbd\u3001\u6c5f\u8607\u548c\u907c\u5be7\u7701\u88ab\u767c\u73fe\u5c0e\u81f4\u300c\u767c\u71d2\u4f34\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\u5019\u7fa4\uff08severe fever with thrombocytopenia syndrome\uff09\u300d\uff0c\u6709\u95dc\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u81f4\u75c5\u539f\u5c6c\u65bc\u5e03\u5c3c\u4e9e\u75c5\u6bd2\u79d1\uff08Bunyaviridae\uff09\u3002\nB. \u6b64\u75c5\u6bd2\u7684\u50b3\u64ad\u6a21\u5f0f\u53ef\u900f\u904e\u8731\uff08tick\uff09\u7684\u53ee\u54ac\u3002\nC. \u50b3\u64ad\u4ea6\u53ef\u900f\u904e\u76f4\u63a5\u63a5\u89f8\u60a3\u8005\u7684\u8840\u6db2\u6216\u542b\u8840\u5206\u6ccc\u7269\u3002\nD. \u60a3\u8005\u4ee5\u8077\u696d\u8fb2\u6c11\u70ba\u4e3b\uff0c\u6b7b\u4ea1\u7387\u905410%\u4ee5\u4e0a\u3002\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\u3002\n": "(E)", "101-8.\n\u611b\u6ecb\u75c5\u6bd2\uff08HIV\uff09\u50b3\u64ad\u4e4b\u98a8\u96aa\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u662f\uff1f\nA. \u7531\u65bc\u76f4\u8178\u9ecf\u819c\u7684\u89e3\u5256\u7d50\u69cb\u5f88\u8584\uff0c\u5177\u6613\u53d7\u50b7\u4e4b\u7279\u6027\uff0c\u672a\u63a1\u4fdd\u8b77\u63aa\u65bd\u7684\u7537\u6027\u6216\u5973\u6027\u809b\u9580\u6027\u4ea4\u63a5\u53d7\u8005\uff0c\u5176\u611f\u67d3HIV\u4e4b\u98a8\u96aa\u6700\u9ad8\u3002\nB. \u672a\u63a1\u4fdd\u8b77\u4e4b\u9670\u9053\u6027\u4ea4\u63a5\u53d7\u8005\uff0c\u4ea6\u662f\u611f\u67d3HIV\u4e4b\u9ad8\u5371\u96aa\u8005\u3002\nC. \u7576\u6709\u751f\u6b96\u5668\u5b98\u6027\u75c5\u3001\u7522\u751f\u5c3f\u9053\u708e\u3001\u526f\u776a\u708e\u6216\u6f70\u760d\u7b49\u60c5\u6cc1\uff0c\u7531\u65bc\u767c\u708e\u90e8\u4f4d\u6703\u4f7f\u6dcb\u5df4\u7403\u548c\u55ae\u6838\u7403\u6578\u76ee\u589e\u52a0\uff0c\u6703\u589e\u52a0\u7cbe\u6db2\u4e2d\u7684HIV\u75c5\u6bd2\u91cf\u3002\nD. \u50b3\u64adHIV\u6a5f\u7387\u6700\u9ad8\u7684\u6642\u6a5f\u662fHIV\u65e9\u671f\u611f\u67d3\u53caHIV\u672b\u671f\u611f\u67d3\u3002\nE. \u4ee5\u4e0a\u7686\u6b63\u78ba\n": "(E)", "101-9.\n\u6709\u95dc\u7d50\u6838\u83cc(Mycobacterium tuberculosis)\u611f\u67d3\u4e4b\u9673\u8ff0\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u7d50\u6838\u83cc\u611f\u67d3\u8005\u7d42\u5176\u4e00\u751f\u767c\u75c5\u7684\u6a5f\u6703\u7d04\u70ba10%\u3002\nB. \u521d\u6b21\u611f\u67d3\u7d50\u6838\u83cc\u5f8c\uff0c\u4ee5\u611f\u67d3\u5f8c\u524d\u4e00\u5e74\u767c\u75c5\u7684\u53ef\u80fd\u6a5f\u6703\u6700\u9ad8\u3002\nC. \u5178\u578b\u4e4b\u7d50\u6838\u83cc\u6dcb\u5df4\u817a\u708e\u75c7\u72c0\u70ba\u7121\u75db\u6027(painless)\u9838\u5f8c\u6dcb\u5df4\u817a\u708e\u6216\u9396\u9aa8\u4e0a\u6dcb\u5df4\u817a\u708e\u3002\nD. \u7d50\u6838\u75c5\u60a3\u8005\u5373\u4f7f\u5728\u5b8c\u6210\u6cbb\u7642\u5f8c\uff0c\u4ecd\u6709\u7d0450%\u60a3\u8005\u6dcb\u5df4\u7d50\u6709\u7d50\u6838\u83cc\u6f5b\u4f0f\uff0c\u4e0d\u6613\u6839\u6cbb\uff0c\u5fa9\u767c\u6a5f\u7387\u9ad8\u3002\nE. \u7d50\u6838\u83cc\u75f0\u62b9\u7247\u967d\u6027\u767c\u75c5\u4e4b\u60a3\u8005\uff0c\u82e5\u672a\u63a5\u53d7\u6cbb\u7642\uff0c5\u5e74\u5167\u7684\u6b7b\u4ea1\u7387\u7d04\u70ba65%\u3002\n": "(D)", "101-10.\n\u75a5\u7621(scabies)\u662f\u5e38\u767c\u751f\u65bc\u5b89\u990a\u4e2d\u5fc3\u6216\u7cbe\u795e\u91ab\u7642\u9662\u6240\u7684\u50b3\u67d3\u6027\u75be\u75c5\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r(1)Burrow(\u5730\u9053)\u5e38\u4f4d\u65bc\u624b\u8155\u5167\u5074\u3001\u6307\u9593\u53ca\u751f\u6b96\u5668(\u9670\u8396)\u90e8\u5206\u3002\r(2)Burrow\u4e2d\u6709\u96cc\u6027\u75a5\u87f2\uff0c\u7d44\u7e54\u75c5\u7406\u6aa2\u67e5\u4e3b\u8981\u70ba\u4e2d\u6027\u767d\u8840\u7403(neutrophil)\u4e4b\u6d78\u6f64\u3002\r(3)\u632a\u5a01\u578b\u75a5\u7621(Norwegian scabies)\u597d\u767c\u65bc\u514d\u75ab\u4e0d\u5168\u75c5\u60a3\uff0c\u75a5\u87f2\u6578\u91cf\u4e0d\u591a\uff0c\u6cbb\u7642\u5bb9\u6613\u3002\r(4)\u611f\u67d3\u75a5\u87f2\u5f8c\u81f3\u767c\u75c5\u75c7\u72c0\u51fa\u73fe\u4e4b\u6f5b\u4f0f\u671f\u53ef\u9577\u90546\u9031\u3002\r(5)\u514d\u75ab\u6b63\u5e38\u7684\u65cf\u7fa4\u611f\u67d3\u75a5\u87f2\u7684\u6578\u91cf\u7d04\u5728\u6bcf\u4eba15\u96bb\u4ee5\u4e0b\u3002\nA. (1)+(4)+(5)\nB. (1)+(2)+(4)\nC. (2)+(3)+(5)\nD. (2)+(3)+(4)\nE. (2)+(4)+(5)\n": "(A)", "101-11.\n19\u6b72\u7537\u6027\u5728\u53f0\u7063\u767b\u5c71\u65c5\u904a\u5f8c\u958b\u59cb\u51fa\u73fe\u767c\u71d2\u3001\u982d\u75db\u3001\u5168\u8eab\u808c\u8089\u9178\u75db\uff0c\u65bc\u9580\u8a3a\u6642\u767c\u73fe\u75c5\u4eba\u53f3\u817f\u5167\u5074\u6709\u4e00\u7126\u75c2(eschar)\uff0c\u4e14\u9f20\u8e4a\u6dcb\u5df4\u817a\u816b\u5927\uff0c\u8840\u6db2\u6aa2\u67e5\u767d\u8840\u7403\u6578\u70ba3150/\u03bcL\u3001GOT 112 IU/L\u3001GPT184 IU/L\uff0c\u5c0d\u65bc\u6b64\u75c5\u4f8b\u4e4b\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u6b64\u75be\u75c5\u70ba\u6059\u87f2\u75c5scrub typhus\uff0c\u81f4\u75c5\u83cc\u70baOrientia tsutsugamushi\nB. \u6b64\u81f4\u75c5\u83cc\u662f\u7531\u8768(louse)\u6240\u50b3\u64ad\nC. \u53f0\u7063\u6d41\u884c\u6b64\u611f\u67d3\u7684\u5730\u5340\u5728\u6771\u90e8\u5730\u5340\u53ca\u96e2\u5cf6\nD. \u6cbb\u7642\u7684\u9996\u9078\u85e5\u7269\u662fdoxycycline\nE. \u6b64\u75c5\u4e4b\u6f5b\u4f0f\u671f(incubation period)\u7d04\u70ba9\u81f318\u5929\n": "(B)", "101-12.\n\u6709\u95dc\u56b4\u91cd\u6557\u8840\u75c7\u6642\u75c5\u60a3\u4e4b\u81e8\u5e8a\u8655\u7406\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u4e2d\u5fc3\u975c\u8108\u58d3(central venous pressure)\u61c9\u7dad\u6301\u57288-12 cmH2O\u3002\nB. \u975c\u8108\u8f38\u6db2\u6ef4\u6ce8\u61c9\u4f7f\u6bcf\u5c0f\u6642\u5c3f\u6db2\u51fa\u7dad\u6301\u5927\u65bc0.5 ml/kg\u9ad4\u91cd\uff0c\u5fc5\u8981\u6642\u4f7f\u7528\u5229\u5c3f\u5291\u3002\nC. \u4f4e\u8840\u58d3\u4f11\u514b\u767c\u751f\u6642\uff0c\u7de9\u6162\u7d66\u4e88\u751f\u7406\u98df\u9e7d\u6c341000 ml\u81f32000 ml\uff0c\u6ef4\u6ce8\u6642\u9593\u7dad\u6301\u7d043\u5c0f\u6642\u4ee5\u907f\u514d\u80ba\u6c34\u816b\u3002\nD. \u6210\u4eba\u8840\u7d05\u7d20\u4f4e\u65bc7 g/dL\u6642\uff0c\u5408\u7406\u7684\u8f38\u8840\u76ee\u6a19\u61c9\u9054\u52309 g/dL\u4ee5\u4e0a\u3002\nE. Bicarbonate \u5728\u4ee3\u8b1d\u6027\u9178\u4e2d\u6bd2(\u52d5\u8108\u8840pH<7.2)\u53ef\u8003\u616e\u7d66\u4e88\uff0c\u4f46\u76ee\u524d\u4ecd\u7f3a\u4e4f\u53ef\u6539\u5584\u8840\u5faa\u52d5\u529b(hemodynamics)\u7684\u5be6\u8b49\u3002\n": "(C)", "101-13.\n\u4e00\u4f4d35\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u767c\u71d2\u754f\u5bd22\u5929\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u624b\u8155\u6709\u8a31\u591a\u904e\u53bb\u6ce8\u5c04\u91dd\u5b54\u7684\u50b7\u53e3\uff0c\u5fc3\u81df\u807d\u8a3a\u6709\u660e\u986f\u6536\u7e2e\u5fc3\u96dc\u97f3\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u767c\u73fe\u4e09\u5c16\u74e3\u4e0a\u6709\u8d05\u751f\u7269(vegetation)\uff0c\u8840\u6db2\u57f9\u990a2\u5957\u5747\u70ba\u70ba\u9769\u862d\u6c0f\u9670\u6027\u83cc\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u6709\u53ef\u80fd\u7684\u81f4\u75c5\u83cc?\nA. Staphylococcus aureus(\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc)\nB. Klebsiella pneumoniae(\u514b\u96f7\u67cf\u6c0f\u687f\u83cc)\nC. Listeria monocytogenes(\u674e\u65af\u7279\u83cc)\nD. Pseudomonas aeruginosa(\u7da0\u81bf\u687f\u83cc)\nE. Acinetobacter baumannii(\u9b91\u66fc\u4e0d\u52d5\u687f\u83cc)\n": "(D)", "101-14.\n\u4e0b\u5217\u6709\u95dc\u5316\u81bf\u6027\u809d\u81bf\u760d\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u53f0\u7063\u5730\u5340\u539f\u767c\u6027\u5316\u81bf\u6027\u809d\u81bf\u760d\u81f4\u75c5\u83cc\u4ee5Klebsiella pneumoniae\u6700\u5e38\u898b\nB. \u53f0\u7063\u5730\u5340\u539f\u767c\u6027\u5316\u81bf\u6027\u809d\u81bf\u760d\u75c5\u60a3\u5e38\u6709\u7cd6\u5c3f\u75c5\u6216\u9157\u9152\u75c5\u53f2\nC. \u5316\u81bf\u6027\u809d\u81bf\u760d\u81f4\u75c5\u539f\u53ef\u80fd\u8840\u5faa\u8f49\u79fb\u81f3\u8166\u90e8\u3001\u9aa8\u9abc\u7b49\u8655\nD. \u8840\u6db2\u751f\u5316\u6aa2\u67e5\u4ee5\u809d\u8f49\u63db\ufffdCALT\u3001AST\u7d04\u670970%\u60a3\u8005\u5347\u9ad8\u6700\u70ba\u5e38\u898b\nE. \u6297\u751f\u7d20\u52a0\u4e0a\u7d93\u76ae\u5c0e\u7ba1\u5f15\u6d41\u70ba\u6709\u6548\u6cbb\u7642\u65b9\u6cd5\n": "(D)", "101-15.\n\u6709\u95dc\u91ab\u7642\u7167\u8b77\u611f\u67d3\u75c5\u539f\u4e4b\u50b3\u64ad\u9014\u5f91\uff0c\u4e0b\u5217\u914d\u5c0d\u4f55\u8005\u932f\u8aa4?\nA. \u591a\u91cd\u6297\u85e5\u6027\u83ccAcinetobacter baumannii - \u63a5\u89f8\u6c61\u67d3\u7684\u807d\u8a3a\u5668\u6216\u8840\u58d3\u8a08\nB. B\u578b\u53caC\u578b\u809d\u708e\u75c5\u6bd2 - \u611f\u67d3\u8005\u8840\u7ba1\u5c0e\u7ba1\u7559\u7f6e\u91dd\u982d\u76ae\u819a\u91dd\u624e\nC. Legionella pneumophila(\u9000\u4f0d\u8ecd\u4eba\u83cc) - \u6c61\u67d3\u7684\u6c34\u6e90\u6216\u6c23\u9727\u5438\u5165\nD. Group A Streptococcus(A\u578b\u93c8\u7403\u83cc) - \u63a2\u8a2a\u8005\u3001\u7167\u9867\u8005\u4e4b\u54b3\u55fd\u98db\u6cab\nE. Aspergillus fumigatus(\u771f\u83cc) - \u6c61\u67d3\u7684\u91ab\u7642\u4eba\u54e1\u624b\u63a5\u89f8\u50b3\u67d3\n": "(E)", "101-16.\n\u4e00\u4f4d70\u6b72\u7537\u6027\u60a3\u8005\uff0c\u56e0\u8166\u4e2d\u98a8\u5e38\u7559\u7f6e\u5c3f\u6db2\u5c0e\u7ba1(Foley catheter)\uff0c\u56e0\u8840\u5c3f\u53ca\u767c\u71d2\u4e09\u5929\u81f3\u672c\u9662\u6025\u8a3a\uff0c\u5169\u5957\u8840\u6db2\u57f9\u990a\u5747\u9577\u51faEnterococcus faecalis\uff0c\u82e5\u5c0d\u6297\u751f\u7d20\u7686\u5177\u6709\u611f\u53d7\u6027\u6642(susceptible)\uff0c\u6b64\u6642\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6cbb\u7642\u662f\u6700\u4f73\u8003\u616e\u9996\u9078?\nA. Oxacillin + gentamicin\nB. Ceftriaxone (3rd generation cephalosporin)\nC. Ampicillin + gentamicin\nD. Cefazolin + gentamicin (1st generation cephalosporin)\nE. Vancomycin\n": "(C)", "101-17.\n\u4e00\u4f4d29\u6b72\u61f7\u5b55\u5a66\u5973\uff0c\u56e0\u767c\u71d2\u4f4f\u9662\u9700\u4f7f\u7528\u6297\u5fae\u751f\u7269\u88fd\u5291\uff0c\u8acb\u554f\u4e0b\u5217\u6297\u5fae\u751f\u7269\u88fd\u5291\u4f55\u8005\u662f\u5c6c\u65bc\u61f7\u5b55\u85e5\u7269\u5b89\u5168\u5206\u985eClass C\u6216D\u7d1a\u85e5\u7269\uff0c\u61c9\u907f\u514d\u4f7f\u7528?\r(1)Erythromycin estolate\r(2)Metronidazole\r(3)Meropenem\r(4)Clarithromycin\r(5)Gentamicin\nA. (1)+(5)\nB. (2)+(3)\nC. (2)+(5)\nD. (3)+(4)\nE. (4)+(5)\n": "(E)", "101-18.\n18\u6b72\u5973\u6027\uff0c\u7a81\u7136\u767c\u71d2\u3001\u982d\u75db\u53ca\u5614\u5410\uff0c\u4f4f\u9662\u5f8c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u75c5\u4eba\u55dc\u7761\u53ca\u9838\u90e8\u50f5\u786c\uff0c\u56db\u80a2\u53ef\u898b\u591a\u8655\u7d2b\u6591\u51fa\u8840\u75b9\u3001\u8840\u6db2\u767d\u8840\u7403\u70ba18000/\u03bcl\uff0c\u8166\u810a\u9ad3\u6db2\u6aa2\u67e5\u767c\u73fe\u767d\u8840\u74031100/\u03bcl\uff0cneutrophil\u4f5492\uff05\uff0c\u8461\u8404\u7cd611 mg/dl\u3002\u4ee5\u4e0b\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u81f4\u75c5\u539f?\nA. Neisseria meningitidis\nB. Enterovirus type 71\nC. Haemophilus influenzae\nD. Listeria monocytogenes\nE. Herpes simplex virus\n": "(A)", "101-19.\n\u4e0b\u5217\u6709\u95dcVaricella-zoster virus \u75c5\u6bd2\u611f\u67d3\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u6b64\u75c5\u6bd2\u70ba\u96d9\u80a1RNA\u75c5\u6bd2\uff0c\u521d\u6b21\u611f\u67d3\u9014\u5f91\u4e3b\u8981\u70ba\u547c\u5438\u9053\u50b3\u64ad\nB. \u521d\u6b21\u611f\u67d3\u5f8c\u6f5b\u4f0f\u5728\u810a\u9ad3\u8179\u6839\u795e\u7d93(ventral root ganglia)\uff0c\u6613\u5fa9\u767c\u65bc\u80f8\u690e\u81f3\u8170\u690e\u76ae\u7bc0\nC. \u76ee\u524d\u5c1a\u7121\u9069\u7576\u7684\u75ab\u82d7\u53ef\u7528\u65bc\u9810\u9632Varicella zoster virus\u4e4b\u611f\u67d3\nD. \u8166\u708e\u767c\u751f\u6642\u5bb9\u6613\u6709\u5c40\u90e8\u51fa\u8840\u6027\u58de\u6b7b\uff0c\u8207Herpes simplex virus\u8166\u708e\u81e8\u5e8a\u8868\u73fe\u985e\u4f3c\uff0c\u6b7b\u4ea1\u7387\u9ad8\nE. Ramsay-Hunt syndrome\u53ef\u5728\u5916\u8033\u9053\u898b\u5230\u6c34\u6ce1\uff0c\u820c\u982d\u524d\u4e09\u5206\u4e4b\u4e8c\u5931\u53bb\u5473\u89ba\n": "(E)", "102-1.\n\u6709\u95dc\u80ba\u708e\u81f4\u75c5\u539f\u4e4b\u8a3a\u65b7\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\r(1)\u6709\u81e8\u5e8a\u610f\u7fa9\u4e4b\u75f0\u6db2\u53d6\u6a23\uff0c\u5fc5\u9808\u7b26\u5408\u6bcf\u4e00\u986f\u5fae\u93e1\u9ad8\u500d\u8996\u91ce(high power field\uff0cHPF 400X) \u53ef\u898b\u9769\u862d\u6c0f\u67d3\u8272\uff1e25\u500b\u55dc\u4e2d\u6027\u767d\u8840\u7403/HPF\uff0c\uff1c10\u500b\u4e0a\u76ae\u7d30\u80de/HPF (2)\u5373\u4f7f\u8840\u6db2\u57f9\u990a\u78ba\u8a8d\u967d\u6027\u4e4b\u80ba\u708e\u7403\u83cc (Streptococcus pneumoniae) \u80ba\u708e\uff0c\u5728\u75f0\u6db2\u57f9\u990a\u7387\u4e5f\u50c5\u6709\u6700\u591a50\uff05\u967d\u6027\u7387 (3)\u5c3f\u6db2Legionella\u6297\u539f\u967d\u6027\u4f86\u8a3a\u65b7\u70ba\u9000\u4f0d\u8ecd\u4eba\u75c7\u4e4b\u654f\u611f\u6027(sensitivity)\u53ca\u7279\u7570\u6027(specificity)\u53ef\u905490\uff05 (4)\u5c3f\u6db2Legionella antigen\u53ef\u4ee5\u6aa2\u9a57\u51fa\u591a\u7a2eLegionella serogroups (5)\u4ee5\u6c23\u7ba1\u5167\u75f0\u6db2\u5206\u6ccc\u7269\u62bd\u5438(endotracheal\raspirate)\u65b9\u5f0f\u57f7\u884c\u5b9a\u91cf\u7d30\u83cc\u57f9\u990a\u5206\u6790\uff0c\u914d\u5408\u81e8\u5e8a\u75c7\u72c0\uff0c\u53ef\u4ee5\u7528\u4f86\u5340\u5206\u611f\u67d3(infection)\u6216\u79fb\u751f(colonization)  (\u61c9\u5beb\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)+(5)\nB. (1)+(3)+(4)\nC. (1)+(2)+(3)\nD. (2)+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "102-2.\n\u6709\u95dc\u56b4\u91cd\u6557\u8840\u6027\u4f11\u514b\u75c5\u60a3\u4e4b\u8655\u7406\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\r(1).\u70ba\u4f7f\u5668\u5b98\u704c\u6d41\u8db3\u5920\uff0c\u5e73\u5747\u52d5\u8108\u58d3(mean arterial blood pressure) \u76ee\u6a19\u61c9\u7dad\u6301\u572865mmHg\u4ee5\u4e0a\uff0c\u6536\u7e2e\u58d3(systolic pressure)\u572890mmHg\u4ee5\u4e0a (2).\u7d66\u4e88\u975c\u8108\u8f38\u6db2\u7dad\u6301\u5728\u4e2d\u5fc3\u975c\u8108\u58d3(central venous pressure)\u572815 - 20mmHg\uff0c\u4ee5\u907f\u514d\u80ba\u6c34\u816b (3).\u7d66\u4e88\u975c\u8108\u8f38\u6db2\u7dad\u6301\u5728\u5c3f\u6db2\u8f38\u51fa\u91cf(urine output rate)\u5927\u65bc0.5ml/kg/hr\uff0c\u5fc5\u8981\u6642\u7d66\u4e88\u5229\u5c3f\u5291(furosemide) (4).\u82e5\u56e0\u5fc3\u808c\u6536\u7e2e\u529f\u80fd\u4e0d\u5168(myocardial dysfunction)\u800c\u5c0e\u81f4\u4f4e\u5fc3\u81df\u8f38\u51fa\u91cf(low cardiac output)\uff0c\u53ef\u4ee5\u512a\u5148\u4f7f\u7528norepinephrine\u6ef4\u6ce8\uff0c\u4ee5\u52a0\u5f37\u5fc3\u81df\u8f38\u51fa\u91cf\r(5).\u8655\u7406\u4f4e\u8840\u58d3\u6557\u8840\u6027\u4f11\u514b\u6642\uff0c\u751f\u7406\u98df\u9e7d\u6c341000ml\u81f32000ml\u61c9\u7de9\u6162\u975c\u8108\u6ef4\u6ce83\u5c0f\u6642\uff0c\u4ee5\u907f\u514d\u80ba\u6c34\u816b\u767c\u751f\nA. (1)+(3)\nB. (1)+(2)\nC. (3)+(4)\nD. (2)+(3)\nE. (4)+(5)\n": "(A)", "102-3.\n\u6709\u95dc\u65b0\u8208\u50b3\u67d3\u75c5H7N9\u6d41\u611f\u4e4b\u6d41\u884c\u75c5\u5b78\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6839\u64da\u4e2d\u570b\u5927\u9678\u516c\u4f48\u4e4bH7N9\u75c5\u4f8b\uff0c\u611f\u67d3\u5f8c\u9020\u6210\u80ba\u708e\u4e4b\u6b7b\u4ea1\u7387\u7d04\u70ba30\uff05\u3002\nB. \u53f0\u7063\u5df2\u6709\u5883\u5916\u79fb\u5165\u4e4bH7N9\u611f\u67d3\u500b\u6848\u3002\nC. H7N9\u611f\u67d3\u500b\u6848\u8d85\u904e\u534a\u6578\u6709\u6162\u6027\u7cfb\u7d71\u6027\u75be\u75c5\uff0c\u5982\uff1a\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u6162\u6027\u80ba\u708e\u6216\u6162\u6027\u5fc3\u80ba\u75be\u75c5\u7b49\u3002\nD. H7N9\u611f\u67d3\u500b\u6848\u4ee5\u5bb6\u65cf\u7fa4\u805a\u70ba\u4e3b\uff0c\u5c11\u6578\u500b\u6848\u70ba\u63a5\u89f8\u6d3b\u79bd\u53f2\u3002\nE. H7N9\u6d41\u611f\u8a3a\u65b7\u4e4b\u78ba\u5b9a\u9700\u4f9d\u8cf4\u75c5\u6bd2\u6838\u9178\u9451\u5b9a\u5206\u6790(rRT-PCR)\u3002\n": "(D)", "102-4.\n\u6709\u95dc\u65b0\u8208\u50b3\u67d3\u75c5H7N9\u6d41\u611f\u4e4b\u81e8\u5e8a\u8868\u73fe\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6b64\u75c5\u4e4b\u6f5b\u4f0f\u671f\u53ef\u905410 - 14\u5929\u3002\nB. \u75c7\u72c0\u4e3b\u8981\u70ba\u767c\u9ad8\u71d2\u3001\u54b3\u55fd\u3001\u547c\u5438\u5598\uff0c\u5c11\u6578\u6709\u8179\u7009\u75c7\u72c0\u3002\nC. \u80f8\u90e8X\u5149\u51fa\u73fe\u96d9\u5074\u80ba\u90e8\u6d78\u6f64\u70ba\u91cd\u75c7\u8868\u73fe\u3002\nD. \u8840\u6db2\u6aa2\u67e5\u53ef\u898b\u767d\u8840\u7403\u589e\u591a(leukocytosis)\u53ca\u8840\u5c0f\u677f\u4f4e\u4e0b(thrombocytopenia)\uff0c\u6dcb\u5df4\u7403\u4ea6\u5448\u589e\u52a0(lymphocytosis)\u3002\nE. \u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7(ARDS)\u9020\u6210\u4e4b\u7f3a\u6c27\u5c0e\u81f4\u591a\u91cd\u5668\u5b98\u8870\u7aed\u70ba\u4e3b\u8981\u6b7b\u56e0\u3002\n": "(D)", "102-5.\n\u4e00\u4f4d30\u6b72\u7537\u6027\uff0c\u5728\u53c3\u52a0\u559c\u5bb4\u5f8c3\u5c0f\u6642\u958b\u59cb\u767c\u751f\u4e0a\u5410\u4e0b\u7009\u4e4b\u75c7\u72c0\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u8207\u4e0b\u5217\u4f55\u7a2e\u75c5\u539f\u76f8\u95dc\uff1f\nA. Staphylococcus aureus\nB. Shigella spp.\nC. Vibrio cholerae\nD. Salmonella spp.\nE. Enterohemorrhagic E.coli\n": "(A)", "102-6.\n\u6709\u95dc\u5bbf\u4e3b\u4e4b\u514d\u75ab\u529b\u8207\u6613\u611f\u53d7\u81f4\u75c5\u539f\u611f\u67d3\u4e4b\u914d\u5c0d\u95dc\u4fc2\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u80c3\u9178\u5206\u6ccc\u6e1b\u5c11 \uff0d \u6c99\u9580\u6c0f\u83cc (Salmonella) \u611f\u67d3\nB. \u767d\u8840\u7403\u541e\u566c\u80fd\u529b\u4e0b\u964d \uff0d \u80ba\u708e\u7403\u83cc(Streptococcus pneumoniae) \u611f\u67d3\nC. \u813e\u81df\u5207\u9664 \uff0d \u79bd\u578b\u5206\u679d\u687f\u83cc(Mycobacterium avium complex) \u611f\u67d3\nD. C5-C8\u88dc\u9ad4\u7f3a\u4e4f \uff0d \u5948\u745f\u6c0f\u8166\u819c\u708e\u7403\u83cc(Neisseria meningitidis) \u611f\u67d3\nE. T\u6dcb\u5df4\u7d30\u80de\u7f3a\u9677 \uff0d \u674e\u65af\u7279\u83cc(Listeria monocytogenes) \u611f\u67d3\n": "(C)", "102-7.\n\u6709\u95dc\u6ccc\u5c3f\u9053\u611f\u67d3(urinary tract infection; UTI)\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(1)\u65b0\u751f\u5152\u968e\u6bb5(neonatal period)\uff0c\u6ccc\u5c3f\u9053\u611f\u67d3\u7684\u767c\u751f\u7387\u5973\u6027\u9060\u9ad8\u65bc\u7537\u6027 (2)E.coli\u662f\u6700\u5e38\u898b\u7684\u8907\u96dc\u6027\u6ccc\u5c3f\u9053\u611f\u67d3(complicated UTI)\u81f4\u75c5\u539f (3)\u6709\u75c7\u72c0\u7684\u6025\u6027\u8180\u80f1\u708e(acute cystitis)\uff0c\u82e5\u5c3f\u6db2\u57f9\u990a\u83cc\u843d\u5927\u65bc100 \u83cc\u843d\u6578/ml\u5c3f\u6db2\uff0c\u53ef\u8a3a\u65b7\u70ba\u81f4\u75c5\u539f (4)\u814e\u79fb\u690d\u4e4b\u63a5\u53d7\u8005\uff0c\u82e5\u6aa2\u9a57\u70ba\u7121\u75c7\u72c0\u4e4b\u83cc\u5c3f\u75c7(\u2267100,000\u83cc\u843d\u6578/ml\u5c3f\u6db2)\uff0c\u9700\u8981\u9032\u884c\u6297\u751f\u7d20\u6cbb\u7642 (5)\u6025\u6027\u814e\u76c2\u814e\u708e\u4e4b\u75c5\u60a3\u670960\uff05\u81f370\uff05\u60a3\u8005\u6703\u5408\u4f75\u83cc\u8840\u75c7(bacteremia)\nA. (1)+(2)+(3)\nB. (3)+(4)+(5)\nC. (2)+(4)+(5)\nD. (1)+(2)+(5)\nE. (2)+(3)+(4)\n": "(E)", "102-8.\n\u4e00\u4f4d\u53f0\u5546\u81f3\u5927\u9678\u5de5\u4f5c\uff0c\u5728\u91ce\u5916\u5c71\u5340\u88ab\u91ce\u72d7\u54ac\u50b7\u624b\u6307\uff0c\u7576\u6642\u4e26\u672a\u5c31\u91ab\uff0c\u4e09\u9031\u5f8c\u56de\u570b\u51fa\u73fe\u982d\u75db\u3001\u767c\u71d2\u3001\u54ac\u50b7\u80a2\u9ad4\u9ebb\u75fa\u3001\u541e\u56a5\u56f0\u96e3\u3001\u6050\u6c34\u7b49\u75c7\u72c0\u800c\u81f3\u6025\u8a3a\uff0c\u6709\u95dc\u6b64\u75be\u75c5\u4e4b\u9810\u9632\u8207\u6cbb\u7642\u7167\u8b77\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u53f0\u7063\u6b64\u75be\u75c5\u5c6c\u65bc\u7b2c\u4e00\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u9700\u65bc24\u5c0f\u6642\u5167\u901a\u5831\u3002\nB. \u82e5\u81f3\u6b64\u75be\u75c5\u4e4b\u611f\u67d3\u98a8\u96aa\u4e4b\u75ab\u5340\u53ef\u80fd\u6709\u63a5\u89f8\u91ce\u751f\u52d5\u7269\u767c\u751f\u98a8\u96aa\uff0c\u61c9\u65bc\u51fa\u767c\u524d\u4e00\u500b\u6708\u63a5\u7a2e\u4e09\u5291\u75ab\u82d7\u3002\nC. \u75c5\u60a3\u5728\u6025\u8a3a\u4e4b\u7167\u8b77\u671f\u9593\u91ab\u8b77\u4eba\u54e1\u61c9\u56b4\u7981\u63a5\u89f8\u60a3\u8005\u4e4b\u547c\u5438\u9053\u5206\u6ccc\u7269\u3002\nD. \u75c5\u60a3\u61c9\u65bc\u53d7\u50b7\u5f8c\uff0c\u5118\u901f\u6e05\u6d17\u6d88\u6bd2\u50b7\u53e3\u3001\u65bd\u6253\u75ab\u82d7\u53ca\u4f7f\u7528\u514d\u75ab\u7403\u86cb\u767d\u65bc\u50b7\u53e3\u6d78\u6f64(infiltration)\u8207\u6ce8\u5c04\u3002\nE. Ribavirin\u53ef\u505a\u70ba\u6b64\u75c5\u4e4b\u6cbb\u7642\u85e5\u7269\u3002\n": "(E)", "102-9.\n\u627f\u4e0a\u984c\uff0c\u6b64\u75be\u75c5\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u767c\u751f\u6025\u6027\u795e\u7d93\u75c7\u5019\uff0c80\uff05\u500b\u6848\u81e8\u5e8a\u8868\u73fe\u70ba\u8166\u708e(encephalitic)\u70ba\u4e3b\uff0c20\uff05\u500b\u6848\u70ba\u80a2\u9ad4\u9ebb\u75f9(paralytic)\u70ba\u4e3b\u3002\nB. \u6b64\u75c5\u4e4b\u6f5b\u4f0f\u671f\u4e00\u822c\u70ba20\u81f390\u5929\u3002\nC. \u60a3\u8005\u8166\u810a\u9ad3\u6db2(cerebrospinal fluid)\u5206\u6790\u5e38\u898b\u767d\u8840\u7403(pleocytosis)\u9ad8\u65bc1000/\u03bcL\u4ee5\u4e0a\u3002\nD. \u5e38\u898b\u81e8\u5e8a\u75c7\u72c0\u70ba\u6025\u6027\u8166\u810a\u9ad3\u708e\uff0c\u75c7\u72c0\u70ba\u982d\u75db\u3001\u767c\u71d2\u3001\u7126\u8e81\uff0c\u96a8\u5f8c\u4f75\u6709\u7cbe\u795e\u932f\u4e82\u53ca\u62bd\u6410\u3002\nE. \u60a3\u8005\u553e\u6db2\u5206\u6ccc\u904e\u591a(hypersalivation)\u539f\u56e0\u70ba\u81ea\u4e3b\u795e\u7d93\u53d7\u75c5\u6bd2\u4fb5\u72af\u5c0e\u81f4\u529f\u80fd\u7570\u5e38(autonomic dysfunction)\u3002\n": "(C)", "102-10.\n\u4e00\u4f4d60\u6b72\u764c\u75c7\u75c5\u4eba\u4f4f\u9662\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\uff0c\u56e0\u6ccc\u5c3f\u9053\u611f\u67d3\u4f7f\u7528\u6297\u751f\u7d20Ceftriaxone\u4e8c\u9031\uff0c\u51fa\u9662\u5f8c\u75c5\u60a3\u958b\u59cb\u51fa\u73fe\u767c\u71d2\u3001\u8179\u75db\u53ca\u8179\u7009\u7684\u75c7\u72c0\uff0c\u7d93\u5927\u8178\u93e1\u6aa2\u67e5\u5982\u5716\u793a\uff0c\u6709\u95dc\u6b64\u75be\u75c5\u4e4b\u767c\u751f\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u6b64\u83cc\u53ef\u5728\u793e\u5340\u4eba\u7fa4\u5e36\u539f\uff0c\u65b0\u751f\u5152\u7121\u75c7\u72c0\u8178\u9053\u5e36\u83cc\u7387\u53ef\u9ad8\u905450%\u3002\nB. \u6b64\u83cc\u7522\u751f\u4e4b\u6bd2\u7d20A\u70ba\u7d30\u80de\u6bd2\u7d20(cytotoxin)\uff0c\u70ba\u4e3b\u8981\u6bd2\u529b\u56e0\u5b50(virulence factor)\u3002\nC. \u6b64\u75be\u75c5\u5e38\u5408\u4f75\u8089\u773c\u53ef\u898b\u4e4b\u8840\u4fbf\u8179\u7009\u3002\nD. \u6ce8\u5c04\u842c\u53e4\u9ef4\u7d20(vancomycin)\u70ba\u7b2c\u4e00\u7dda\u85e5\u7269metronidazole\u6cbb\u7642\u5931\u6557\u5f8c\u4e4b\u9996\u9078\u6cbb\u7642\u3002\nE. \u4ee5\u6838\u9178\u9451\u5b9a(PCR)\u65b9\u5f0f\u5075\u6e2c\u7cde\u4fbftoxin C gene\u53ef\u5feb\u901f\u8a3a\u65b7\u6b64\u75c5\u3002\n": "(A)", "102-11.\n\u4e00\u4f4d50\u6b72\u7684\u5a66\u5973\u5403\u4e86\u81ea\u5df1\u9183\u88fd\u7684\u852c\u83dc\uff0c2\u5929\u5f8c\u958b\u59cb\u51fa\u73fe\u8178\u80c3\u4e0d\u9069\u3001\u4fbf\u79d8\u4ee5\u53ca\u80a2\u9ad4\u9ebb\u75fa(descending flaccid paralysis)\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u60a3\u8005\u4e26\u88ab\u767c\u73fe\u6709\u8907\u8996(diplopia)\u3001\u53e3\u9f52\u4e0d\u6e05(dysarthria)\u53ca\u541e\u56a5\u56f0\u96e3(dysphagia)\uff0c\u7406\u5b78\u6aa2\u67e5\u5728\u54bd\u5589\u53cd\u5c04(gag reflex)\u53ca\u6df1\u90e8\u808c\u8171\u53cd\u5c04(deep tendon reflexes)\u6e1b\u5f31\uff0c\u5c0d\u6b64\u75be\u75c5\u7684\u6558\u8ff0\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u57f7\u884c\u8840\u6db2\u57f9\u990a\uff0c\u5927\u591a\u53ef\u57f9\u990a\u51fa\u6b64\u81f4\u75c5\u83cc\u3002\nB. \u6b64\u75c5\u60a3\u4e4b\u4fbf\u7955\u662f\u56e0\u70ba\u8178\u80c3\u7684\u795e\u7d93\u9ebb\u75fa(paralytic ileus)\u6240\u5c0e\u81f4\u3002\nC. \u81e8\u5e8a\u75c7\u72c0\u901a\u5e38\u5408\u4f75\u767c\u9ad8\u71d2\u53ca\u754f\u5bd2\u3002\nD. \u6b64\u83cc\u7522\u751f\u4e4b\u6bd2\u7d20(toxin)\u8207\u795e\u7d93\u5143\u7d50\u5408\u5c6c\u65bc\u4e0d\u53ef\u9006\u6027(irreversible)\u4e4b\u8b8a\u5316\uff0c\u56e0\u6b6495\uff05\u4ee5\u4e0a\u7684\u75c5\u60a3\u6703\u767c\u751f\u6c38\u4e45\u4e0d\u53ef\u9006\u7684\u795e\u7d93\u5b78\u7570\u5e38\u3002\nE. \u6b64\u75be\u75c5\u4e4b\u4e3b\u8981\u6cbb\u7642\u65b9\u5f0f\u70ba\u7d66\u4e88\u9ad8\u5291\u91cfPenicillin\u6ce8\u5c04\u3002\n": "(B)", "102-12.\n\u842c\u53e4\u9ef4\u7d20\u6297\u85e5\u6027\u8178\u7403\u83cc(Vancomycin-resistant Enterococcus)\u662f\u9662\u5167\u611f\u67d3\u5e38\u898b\u7684\u81f4\u75c5\u83cc\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2(70\uff05-80\uff05 Alcohol)\u7121\u6cd5\u6bba\u6b7b\u6b64\u83cc\u3002\nB. \u82e5\u7121ampicillin\u4e4b\u6297\u85e5\u6027\u5247\u4ee5ampicillin\u9ad8\u5291\u91cf(12g/\u5929)\u55ae\u4e00\u6cbb\u7642Enterococcus\u5fc3\u5167\u819c\u708e\u53ef\u4ee5\u6709\u5f88\u597d\u7684\u6cbb\u7642\u7387\u3002\nC. E. faecium\u6bd4E. faecalis\u5c0dampicillin\u6216vancomycin\u4e4b\u6297\u85e5\u6027\u66f4\u5e38\u898b\u3002\nD. \u982d\u5b62\u5b50\u83cc\u7d20(cephalosporin)\u985e\uff0c\u5982cefepime\uff0c\u662f\u6b64\u83cc\u611f\u67d3\u7684\u4e3b\u8981\u6cbb\u7642\u85e5\u7269\u3002\nE. \u6b64\u83cc\u4e4b\u611f\u67d3\u7ba1\u5236\u70ba\u843d\u5be6\u98db\u6cab\u9694\u96e2\u9632\u8b77(droplet isolation precaution)\u3002\n": "(C)", "102-13.\n\u4e0b\u5217\u95dc\u65bc\u6d41\u884c\u6027\u8166\u810a\u9ad3\u819c\u708e\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?\nA. \u53f0\u7063\u548c\u5176\u4ed6\u570b\u5bb6\u6d41\u884c\u7684\u578b\u5225\u985e\u4f3c\uff0c\u7686\u4ee5A, C, Y, W135\u8840\u6e05\u578b\u70ba\u4e3b\uff0c\u53f0\u7063\u7684\u767c\u751f\u7387\u548c\u975e\u6d32\u7684\"\u6d41\u8166\u5e36(meningitis belt)\"\u6492\u54c8\u62c9\u6c99\u6f20\u4ee5\u5357\u5340\u57df\u63a5\u8fd1\u3002\nB. \u6f5b\u4f0f\u671f\u5c0f\u65bc\u4e03\u5929\uff0c\u50c5\u6709\u5b69\u7ae5\u6703\u51fa\u73fe\u56b4\u91cd\u7684\u75c7\u72c0\uff0c\u4e14\u767c\u751f\u8166\u819c\u708e\u7684\u98a8\u96aa\u8f03\u767c\u751f\u83cc\u8840\u75c7\u70ba\u4f4e\u3002\nC. \u76ee\u524d\u53f0\u7063\u6709\u591a\u91a3\u9ad4\u56db\u50f9\u75ab\u82d7\u53ef\u4f7f\u7528\uff0c\u800c\u4e14\u5c0d\u65bcSerogroup B\u4e5f\u6709\u6709\u6548\u4fdd\u8b77\u4f5c\u7528\u3002\nD. \u904e\u53bb\u66fe\u6709\u81f3\u9ea5\u52a0\u671d\u8056\u9020\u6210\u6d41\u884c\u6027\u8166\u810a\u9ad3\u819c\u708e\u7fa4\u805a\u4e8b\u4ef6\u7684\u767c\u751f\uff0c\u56e0\u6b64\u524d\u5f80\u9ea5\u52a0\u671d\u8056\u7684\u65c5\u5ba2\u9808\u51fa\u793a\u4e09\u5e74\u5167\u63a5\u7a2e\u6d41\u884c\u6027\u8166\u810a\u9ad3\u819c\u708e\u75ab\u82d7\u4e4b\u63a5\u7a2e\u8b49\u660e\u3002\nE. \u5c0d\u65bc\u5bc6\u5207\u63a5\u89f8\u8005\u7684\u66b4\u9732\u5f8c\u9810\u9632\uff0c\u50c5\u6709rifampin \u53ef\u4f7f\u7528\uff0c\u4e14\u9808\u4f7f\u7528\u8d85\u904e\u5169\u9031\u4ee5\u4e0a\u3002\n": "(D)", "102-14.\n\u95dc\u65bc\u9ec3\u71b1\u75c5\u6bd2\u5c6c(Flavivirus)\u6240\u5f15\u8d77\u7684\u4eba\u985e\u75be\u75c5\u4e4b\u6b63\u78ba\u63cf\u8ff0\uff0c\u9664\u4e86:\nA. \u5305\u542b\u9ec3\u71b1\u75c5\u3001\u767b\u9769\u71b1\u3001\u65e5\u672c\u8166\u708e\u3001\u897f\u5c3c\u7f85\u71b1\u7b49\u3002\nB. \u9ec3\u71b1\u75c5\u5df2\u6709\u6709\u6548\u7684\u6e1b\u6bd2\u6d3b\u6027\u75ab\u82d7\u53ef\u4ee5\u4f7f\u7528\uff0c\u76ee\u524d\u7684\u7814\u7a76\u8a8d\u70ba\u5176\u6297\u9ad4\u4fdd\u8b77\u529b\u53ef\u7dad\u6301\u5341\u5e74\u4ee5\u4e0a\u6216\u7d42\u8eab\u3002\nC. \u9ec3\u71b1\u75c5\u3001\u767b\u9769\u71b1\u3001\u53ca\u65e5\u672c\u8166\u708e\u4e3b\u8981\u7d93\u7531\u57c3\u53ca\u6591\u868a\u53ca\u767d\u7dda\u6591\u868a\u50b3\u64ad\u3002\nD. \u767b\u9769\u71b1\u4f9d\u8840\u6e05\u578b\u5206\u70ba\u2160\u3001\u2161\u3001\u2162\u3001\u2163\u56db\u7a2e\u578b\u5225\uff0c\u5373\u4fbf\u611f\u67d3\u904e\u5176\u4e2d\u67d0\u7a2e\u8840\u6e05\u578b\uff0c\u4e5f\u7121\u6cd5\u5c0d\u5176\u4ed6\u578b\u5225\u7522\u751f\u4ea4\u53c9\u7684\u4fdd\u8b77\u529b\u800c\u7d42\u8eab\u514d\u75ab\u3002\nE. \u767b\u9769\u71b1\u76ee\u524d\u5c1a\u672a\u6709\u75ab\u82d7\u6216\u9810\u9632\u6027\u85e5\u7269\u4f7f\u7528\uff0c\u56e0\u6b64\u5047\u5982\u6c11\u773e\u524d\u5f80\u6771\u5357\u4e9e\u570b\u5bb6\uff0c\u5982\u6cf0\u570b\u3001\u65b0\u52a0\u5761\u7b49\uff0c\u4ecd\u61c9\u8a72\u885b\u6559\u6c11\u773e\u5982\u4f55\u9032\u884c\u9632\u868a\u63aa\u65bd,\u4f8b\u5982: \u4f7f\u7528\u542b\u6709DEET\u6210\u5206\u7684\u9632\u868a\u7522\u54c1\u3002\n": "(C)", "102-15.\n\u6709\u95dcH7N9\u6d41\u611f\u611f\u63a7\u63aa\u65bd\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u4ee5\u7a7a\u6c23\u9632\u8b77\u53ca\u63a5\u89f8\u50b3\u64ad\u9632\u8b77\u63aa\u65bd\u70ba\u539f\u5247\u3002\nB. \u57f7\u884c\u53ef\u80fd\u5f15\u767c\u98db\u6cab\u5fae\u7c92 (aerosol)\u7522\u751f\u7684\u6aa2\u9ad4\u63a1\u96c6\u6216\u6cbb\u7642\u63aa\u65bd\u6642\uff0c\u61c9\u914d\u6234N95\u7b49\u7d1a(\u542b)\u4ee5\u4e0a\u53e3\u7f69\u3002\nC. H7N9\u6d41\u611f\u75c5\u60a3\u6536\u6cbb\u4f4f\u9662\u6642\uff0c\u61c9\u512a\u5148\u7f6e\u65bc\u8ca0\u58d3\u75c5\u623f\u6216\u55ae\u4eba\u75c5\u5ba4\u4e26\u7dad\u6301\u623f\u9580\u95dc\u9589\u3002\nD. H7N9\u6d41\u611f\u75c5\u60a3\u9000\u71d2\u5f8c3\u5929\uff0c\u4e14\u9023\u7e8c2\u6b21\u547c\u5438\u9053\u6aa2\u9ad4PCR\u9670\u6027(\u9700\u9593\u969424\u5c0f\u6642)\uff0c\u59cb\u53ef\u89e3\u9664\u9694\u96e2\u3002\nE. \u901a\u5831\u7591\u4f3cH7N9\u6d41\u611f\u75c5\u60a3\u5373\u4f7f\u7576\u5929\u6aa2\u9a57\u7d50\u679c\u9670\u6027\uff0c\u91ab\u5e2b\u4ecd\u53ef\u8996\u75c5\u60c5\u8b8a\u5316\u518d\u5ea6\u63a1\u6aa2\u9001\u6aa2\uff0c\u4e26\u76e1\u91cf\u63a1\u96c6\u75f0\u6db2\u6216\u4e0b\u547c\u5438\u9053\u62bd\u53d6\u6db2\u3002\n": "(A)", "102-16.\n\u6709\u95dc\u72c2\u72ac\u75c5\u514d\u75ab\u7403\u86cb\u767d\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba? (1)\t\u72c2\u72ac\u75c5\u514d\u75ab\u7403\u86cb\u767d\u9700\u5118\u91cf\u5728\u52d5\u7269\u6293\u54ac\u50b77\u65e5\u5167\u4f7f\u7528 (2)\t\u4e0d\u53ef\u4ee5\u548c\u75ab\u82d7\u540c\u4e00\u5929\u65bd\u6253\uff0c\u4ee5\u907f\u514d\u5f71\u97ff\u75ab\u82d7\u7684\u6548\u679c (3)\u4f7f\u7528\u72c2\u72ac\u75c5\u514d\u75ab\u7403\u86cb\u767d\u6642\uff0c\u9808\u6ce8\u610f\u53ef\u80fd\u5f15\u8d77\u4e4b\u7acb\u5373\u904e\u654f\u53cd\u61c9 (4)\u4f7f\u7528\u6642\u4ee5\u808c\u8089\u6ce8\u5c04\u70ba\u4e3b\uff0c\u5982\u679c\u6709\u5269\u9918\u7684\u514d\u75ab\u7403\u86cb\u767d\uff0c\u518d\u6ce8\u5c04\u65bc\u50b7\u53e3\u5468\u570d (5)\u82e5\u54ac\u50b7\u4eba\u7684\u52d5\u7269\u7d93\u6aa2\u9a57\u70ba\u72c2\u72ac\u75c5\u967d\u6027\uff0c\u7121\u8ad6\u4ee5\u524d\u6709\u7121\u63a5\u7a2e\u904e\u72c2\u72ac\u75c5\u75ab\u82d7\uff0c\u7686\u9700\u7d66\u4e88\u514d\u75ab\u7403\u86cb\u767d  (\u61c9\u5beb\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(4)+(5)\nB. (1)+(3)+(5)\nC. (1)+(3)\nD. (3)+(5)\nE. (1)+(2)+(3)+(5)\n": "(C)", "102-17.\n\u4eba\u985e\u514d\u75ab\u4e0d\u5168\u75c5\u6bd2(Human immunodeficiency virus, HIV)\u611f\u67d3\u7684\u6709\u6548\u9810\u9632\u63aa\u65bd\uff0c\u9664\u4e86?\nA. \u53ef\u7528\u7522\u524d\u7be9\u6aa2\u3001\u5206\u5a29\u524d\u6301\u7e8c\u670d\u85e5\u3001\u9078\u64c7\u5256\u8179\u7522\u3001\u65b0\u751f\u5152\u51fa\u751f\u5f8c\u6295\u85e5\u3001\u63d0\u4f9b\u6bcd\u4e73\u66ff\u4ee3\u54c1\u7b49\u65b9\u5f0f\u9810\u9632\u6bcd\u5b50\u5782\u76f4\u611f\u67d3HIV\u3002\nB. \u53ef\u7528\u53e3\u670d\u66ff\u4ee3\u85e5\u7269(\u5982\u7f8e\u6c99\u51ac)\u3001\u63d0\u4f9b\u6e05\u6f54\u91dd\u5177\u7b49\u65b9\u5f0f\u9810\u9632\u975c\u8108\u6ce8\u5c04\u85e5\u766e\u8005\u611f\u67d3HIV\u3002\nC. \u82e5HIV\u611f\u67d3\u8005\u4f7f\u7528\u96de\u5c3e\u9152\u7642\u6cd5\u59a5\u5584\u63a7\u5236\u75c5\u6bd2\u91cf\uff0c\u53ef\u5927\u5e45\u964d\u4f4e\u6027\u4f34\u4fb6\u611f\u67d3HIV\u6a5f\u7387\u3002\nD. \u7537\u6027HIV\u611f\u67d3\u8005\u5272\u5305\u76ae\uff0c\u53ef\u964d\u4f4e\u5176\u7570\u6027\u6027\u4f34\u4fb6\u6216\u540c\u6027\u6027\u4f34\u4fb6\u611f\u67d3HIV\u6a5f\u7387\u3002\nE. \u56e0\u91ab\u7642\u884c\u70ba\u906dHIV\u6c61\u67d3\u91dd\u5668\u91dd\u624e\u5f8c\u8fc5\u901f\u7d66\u4e88\u66b4\u9732\u5f8c\u9810\u9632\u6027\u6295\u85e5\uff0c\u53ef\u5927\u5e45\u964d\u4f4e\u611f\u67d3HIV\u6a5f\u7387\u3002\n": "(D)", "102-18.\n\u95dc\u65bc\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u75f0\u6aa2\u9ad4\u5206\u5b50\u5feb\u901f\u8a3a\u65b7\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u7684\u5b9a\u7fa9\u70baisoniazid\u3001rifampin \u548cpyrazinamide\u540c\u6642\u6297\u85e5\u3002\nB. \u82e5\u8a3a\u6cbb\u7684\u7d50\u6838\u75c5\u4eba\uff0c\u75c5\u4eba\u5206\u985e\u70ba\u5fa9\u767c, \u5931\u6557\u6216\u8005\u5931\u843d\u7b49\u518d\u6cbb\u75c5\u4eba\u6642\uff0c\u70ba\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u4e4b\u9ad8\u98a8\u96aa\u65cf\u7fa4\uff0c\u61c9\u9001\u9a57 \u3002\nC. \u76ee\u524d\u53f0\u7063\u7684\u7d50\u6838\u75c5\u63a5\u89f8\u8005\uff0c\u5df2\u9010\u6b65\u5efa\u7f6e\u540d\u55ae\u65bc\u75be\u7ba1\u7f72\u7cfb\u7d71\u4e2d\uff0c\u82e5\u5df2\u77e5\u75c5\u4eba\u70ba\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u63a5\u89f8\u8005\u767c\u75c5\uff0c\u61c9\u76e1\u901f\u9032\u884c\u6297\u85e5\u6027\u5feb\u901f\u7be9\u6aa2\u3002\nD. \u82e5\u75c5\u4eba\u5c45\u4f4f\u5728\u82b1\u84ee\u7e23\u5353\u6eaa\u3001\u842c\u69ae\u3001\u79c0\u6797\u9109\u6216\u75c5\u4eba\u4e00\u5e74\u5167\u66fe\u505c\u7559\u65bc\u5f9e\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u9ad8\u8ca0\u64d4\u570b\u5bb6\u8d85\u904e\u4e00\u500b\u6708\u4ee5\u4e0a\uff0c\u61c9\u76e1\u901f\u9032\u884c\u6297\u85e5\u6027\u5feb\u901f\u7be9\u6aa2\u3002\nE. \u5c0d\u65bc\u591a\u91cd\u6297\u85e5\u6027\u7d50\u6838\u75c5\u7684\u6cbb\u7642\uff0c\u61c9\u6cbb\u7642\u81f3\u75f0\u9670\u8f49\u5f8c\u6eff18\u500b\u6708\u70ba\u6b62\u3002\n": "(A)", "102-19.\n\u4e16\u754c\u885b\u751f\u7d44\u7e54\u65bc2012\u5e749\u6708\u516c\u4f48\u4e2d\u6771\u547c\u5438\u75c7\u5019\u7fa4\uff08Middle East Respiratory Syndrome\uff09\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7\u6848\u4f8b\uff0c\u73fe\u5728\u5df2\u5728\u6c99\u70cf\u5730\u963f\u62c9\u4f2f\u3001\u7d04\u65e6\u3001\u5361\u9054\u3001\u82f1\u570b\u3001\u5fb7\u570b\u3001\u6cd5\u570b\u7b49\u570b\u5bb6\u9678\u7e8c\u767c\u73fe\u78ba\u8a3a\u75c5\u4f8b\uff0c\u4e0b\u4f8b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba? (1)\u53ef\u900f\u904e\u547c\u5438\u9053\u98db\u6cab\u9846\u7c92\uff0c\u76f4\u63a5\u6216\u9593\u63a5\u63a5\u89f8\u611f\u67d3\u8005\u5206\u6ccc\u7269\u50b3\u64ad\uff0c\u800c\u9020\u6210\u7fa4\u805a\u611f\u67d3\u4e8b\u4ef6 (2)\u81e8\u5e8a\u75c7\u72c0\u5305\u62ec\u767c\u71d2\u3001\u54b3\u55fd\u3001\u547c\u5438\u6025\u4fc3\u8207\u547c\u5438\u56f0\u96e3\u4e4b\u80ba\u708e\u8868\u73fe\uff0c\u90e8\u5206\u75c5\u4eba\u51fa\u73fe\u814e\u8870\u7aed\u3001\u5fc3\u5305\u819c\u708e\u3001\u7030\u6f2b\u6027\u8840\u7ba1\u5167\u51dd\u8840\uff0c\u6b7b\u4ea1\u7387\u7d0450\uff05 (3)\u6f5b\u4f0f\u671f\u4e00\u822c\u70ba9\u81f312\u5929 (4)\u91ab\u7642\u5de5\u4f5c\u4eba\u54e1\u662f\u53ef\u80fd\u53d7\u611f\u67d3\u4e4b\u9ad8\u5371\u96aa\u7fa4\r(5)\u6211\u570b\u5217\u70ba\u7b2c\u4e94\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u91ab\u8b77\u4eba\u54e1\u5982\u9047\u300c\u91ab\u8b77\u4eba\u54e1\u767c\u751f\u4e0d\u660e\u539f\u56e0\u80ba\u708e\u300d\u3001\u300c\u81e8\u5e8a\u51fa\u73fe\u80ba\u708e\u4e14\u767c\u75c5\u524d14\u65e5\u5167\u5177\u6709\u4e2d\u6771\u5730\u5340\u65c5\u904a\u53f2\u300d\u3001\u300c\u4e0d\u660e\u539f\u56e0\u80ba\u708e\u7fa4\u805a\u4e8b\u4ef6\u300d\uff0c\u61c9\u63a1\u9069\u7576\u611f\u67d3\u7ba1\u5236\u63aa\u65bd\uff0c\u63a1\u96c6\u547c\u5438\u9053\u53ca\u8840\u6db2\u6aa2\u9ad4\u9001\u75be\u75c5\u7ba1\u5236\u7f72\uff0c\u4e26\u901a\u5831\u6cd5\u50b3(\u5fc5\u9808\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(4)+(5)\nB. (2)+(3)+(4)+(5)\nC. (1)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(4)\nE. (1)+(2)+(3)+(4)+(5)\n": "(E)", "103-1.\n\u6709\u4e00\u4f4d21\u6b72\u7537\u6027\u56e0\u5589\u75db\uff0c\u6bcf\u5929\u767c\u71d2\uff0c\u524d\u984d\u982d\u75db\uff0c\u5168\u8eab\u808c\u8089\u548c\u95dc\u7bc0\u75db6\u5929\u800c\u6c42\u8a3a\u3002\u4ed6\u65bc\u767c\u75c5\u524d\u4e00\u9031\u653e\u5b8c\u6691\u5047\u7531\u9ad8\u96c4\u56de\u5230\u53f0\u5317\u3002\u8eab\u9ad4\u8a3a\u5bdf\u9ad4\u6eab38.7\u00b0C\uff0c\u8840\u58d3 102/70 mmHg\uff0c\u8108\u640f 100/min\uff0c\u547c\u5438 16/min\uff0c\u5f8c\u54bd\u6709\u5145\u8840\u73fe\u8c61\uff0c\u4f46\u7121\u5206\u6ccc\u7269\uff0c\u80f8\u90e8\u3001\u624b\u81c2\u548c\u4e0b\u80a2\u6709 maculopapular rash\uff0c\u800c\u624b\u638c\u548c\u8173\u638c\u5247\u7121\u76ae\u75b9\uff0c\u4e0b\u80cc\u6709\u9178\u75db\uff0c\u5176\u4ed6\u5fc3\u80ba\u548c\u8179\u90e8\u6aa2\u67e5\u5247\u7121\u7570\u5e38\u3002\u5be6\u9a57\u8840\u6db2\u6aa2\u67e5\u767c\u73fe\u767d\u8840\u74033000/uL (3.0x10 9/L)\uff0c\u8840\u5c0f\u677f86000/uL (86.0x10 9/L)\uff0c\u8840\u7d05\u7d2013.8 g/dL\uff0cALT 116 units/L\uff0ctotal billirubin 1.2 mg/dL\u3002 \u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55?\nA. Leptospirosis\nB. Syphilis\nC. Dengue fever\nD. \u6c34\u75d8\nE. Melioidosis\n": "(C)", "103-2.\n\u6709\u4e00\u4f4d81\u6b72\u5973\u6027\u56e0\u767c\u71d2\u3001\u754f\u5bd2\u53ca\u5614\u5410\u4e00\u5929\u800c\u88ab\u9001\u5230\u6025\u8a3a\u5ba4\u3002\u8eab\u9ad4\u8a3a\u5bdf\u9ad4\u6eab39\u2103\uff0c\u8840\u58d3120/72mmHg\uff0c\u8108\u640f110/min\uff0c\u547c\u543816/min\uff0c\u5fc3\u80ba\u53ca\u8179\u90e8\u6aa2\u67e5\u5448\u73fe\u4e0b\u8179\u90e8\u8f15\u5fae\u58d3\u75db\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u8840\u6db2\u767d\u8840\u740318000/uL(18.0x10 9/L)\uff0cneutrophil 88%\uff1b\u5c3f\u6db2\u6aa2\u67e5\uff1aWBC 100/HPF \u4e14leukocyte esterase (+)\uff0c\u9769\u862d\u6c0f\u9670\u6027\u687f\u83cc\uff1b\u80f8\u90e8X\u5149\u6b63\u5e38\u3002\u75c5\u4eba\u4f4f\u9662\u63a5\u53d7\u7a4d\u6975\u8f38\u6db2\u53ca\u7d93\u9a57\u6027piperacillin-tazobactam\u975c\u8108\u6ce8\u5c04\u6cbb\u7642\u3002\u5165\u9662\u5f8c\u4e09\u5929\uff0c\u8840\u6db2\u53ca\u5c3f\u6db2\u57f9\u990a\u51faKlebsiella pneumoniae\uff0c\u5176\u6297\u751f\u7d20\u611f\u53d7\u6027\u8a66\u9a57\u5448\u73fe\u5c0dpiperacillin-tazobactam, imipenem, ciprofloxacin,\rcefazolin\u548ctrimethoprim/sulfamethoxazole\u654f\u611f\u3002 \u6b64\u6642\u6297\u751f\u7d20\u6cbb\u7642\u6700\u6070\u7576\u7684\u9078\u64c7\u662f\u4ec0\u9ebc\uff1f\nA. \u6301\u7e8c\u7d66\u4e88piperacillin-tazobactam\nB. \u505c\u7528piperacillin-tazobactam\u800c\u6539\u7528cefazolin\nC. \u505c\u7528piperacillin-tazobactam\u800c\u6539\u7528ciprofloxacin\nD. \u505c\u7528piperacillin-tazobactam\u800c\u6539\u7528imipenem\nE. \u505c\u7528piperacillin-tazobactam\u800c\u6539\u7528trimethoprim/sulfamethoxazole\n": "(B)", "103-3.\n\u4e00\u4f4d22\u6b72\u7537\u6027\uff0c\u65bc4\u5929\u524d\u958b\u59cb\u89e3\u5c3f\u6709\u707c\u71b1\u611f\uff0c\u5c31\u8a3a\u524d\u5169\u5929\u5de6\u773c\u6709\u9ec3\u8272\u6db2\u9ad4\u6d41\u51fa\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u9664\u767c\u73fe\u5de6\u773c\u773c\u76ae\u6709\u7d05\u816b\u3001\u5de6\u773c\u6709\u9ec3\u8272\u5206\u6ccc\u7269\u6d41\u51fa\u5916\uff0c\u751f\u6b96\u5668\u4ea6\u53ef\u898b\u9ec3\u8272\u6db2\u9ad4 (\u5982\u5716)\uff0c\u8acb\u554f\u81f4\u75c5\u539f\u6700\u53ef\u80fd\u662f\u4ec0\u9ebc?\nA. \u80ba\u708e\u514b\u96f7\u767d\u6c0f\u687f\u83cc (Klebsiella pneumoniae)\nB. \u5927\u8178\u687f\u83cc (Escherichia coli)\nC. A\u65cf\u93c8\u7403\u83cc (group A streptococcus )\nD. \u6dcb\u75c5\u96d9\u7403\u83cc (Neisseria gonorrhoeae)\nE. \u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc (Staphylococcus aureus)\n": "(D)", "103-4.\n\u4e00\u540d45\u6b72\u7684\u7537\u6027\uff0c\u81f3\u6025\u8a3a\u5ba4\u5c31\u91ab\uff0c\u6709\u4f4e\u5ea6\u767c\u71d2\uff0c\u5168\u8eab\u5026\u6020\u548c\u95dc\u7bc0\u75db\u3002\u5c31\u8a3a6\u9031\u4e4b\u524d\u66fe\u8207\u7537\u6027\u6027\u5de5\u4f5c\u8005\u767c\u751f\u4e0d\u5b89\u5168\u7684\u6027\u884c\u70ba\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u6709\u591a\u767c\u6027\u4e18\u75b9 (maculopapular rash)\uff0c\u6db5\u84cb\u4ed6\u7684\u6574\u500b\u8eab\u9ad4\uff0c\u5305\u62ec\u624b\u638c (\u5982\u5716)\u548c\u8173\u638c\u3002\u8acb\u554f\u75c5\u60a3\u7684\u8a3a\u65b7\u6700\u53ef\u80fd\u7531\u4e0b\u5217\u7684\u4f55\u7a2e\u6e2c\u8a66\u5f97\u5230\uff1a\nA. HIV Western blot antibody test\nB. Tzanck smear\nC. Gram stain\nD. Fluorescent treponemal antibody absorption test\nE. India ink stain\n": "(D)", "103-5.\n\u4e00\u4f4d65\u6b72\u7537\u6027\u6709\u7cd6\u5c3f\u75c5\u75c5\u53f2\uff0c\u56e0\u70ba\u9ad8\u71d2\u548c\u5bd2\u986b\u88ab\u9001\u81f3\u6025\u8a3a\u5ba4\uff0c\u53f3\u5074\u9f20\u8e4a\u90e8\u4f4d\u51fa\u73fe\u7d05\u816b\u7d04\u56db\u5929\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\uff1a\u9ad4\u6eab39.4\u2103\uff0c\u8840\u58d3100/60mmHg\uff0c\u8108\u640f108/min\u3002\u65bc\u53f3\u5074\u9f20\u8e4a\u90e8\u4f4d\u5ef6\u4f38\u81f3\u53f3\u5074\u5927\u817f\u670912x9 \u516c\u5206\u7684\u767c\u7d05\uff0c\u8b8a\u786c\uff0c\u816b\u8139\u75bc\u75db\u7684\u75c5\u7076\u3002\u5728\u8a72\u75c5\u7076\u4e0a\u7de3\u9084\u6709\u5169\u500b\u51fa\u8840\u6027\u7684\u6c34\u6ce1(\u5982\u5716)\u3002\u9aa8\u76c6\u8154\u7684\u96fb\u8166\u65b7\u5c64\u986f\u793a\uff1a\u5927\u817f\u8655\u8edf\u7d44\u7e54\u7684\u58de\u6b7b\u53ca\u5c11\u91cf\u6c23\u9ad4\u7522\u751f\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6b64\u75c5\u60a3\u6700\u6025\u8feb\u7684\u6cbb\u7642?\nA. Surgical exploration and debridement\nB. Anti-staphylococcal antibiotics\nC. Anti-pseudomonal antibiotics\nD. Hyperbaric oxygen therapy\nE. Blood transfusion\n": "(A)", "103-6.\n2014\u5e74\u897f\u975e\u4f0a\u6ce2\u62c9\u75c5\u6bd2\u611f\u67d3 (Ebola virus disease)\u901a\u5831\u8d85\u904e1700\u4f8b\uff0c\u6b7b\u4ea1\u903e900\u4f8b\uff0c\u903e50\u4f4d\u91ab\u7642\u4eba\u54e1\u611f\u67d3\uff0c\u4e0b\u5217\u76f8\u95dc\u6558\u8ff0\u4f55\u8005\u6b63\u78ba? (1) \u6b64\u75be\u75c5\u5728\u6211\u570b\u5217\u70ba\u7b2c\u4e94\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u901a\u5831\u6642\u6548\u70ba24\u5c0f\u6642\u5167\u5b8c\u6210 (2) \u81f4\u75c5\u75c5\u6bd2\u4e4b\u5929\u7136\u5bbf\u4e3b\u4e3b\u8981\u662f\u99f1\u99dd\u548c\u9f20\u985e (3) \u6b64\u75c5\u6bd2\u53ef\u7d93\u7531\u53d7\u611f\u67d3\u52d5\u7269\u76f4\u63a5\u50b3\u7d66\u4eba\uff0c\u800c\u4eba\u50b3\u4eba\u4e3b\u56e0\u662f\u76f4\u63a5\u63a5\u89f8\u5230\u88ab\u611f\u67d3\u8005\u6216\u5176\u5c4d\u9ad4\u4e4b\u8840\u6db2\u3001\u5206\u6ccc\u7269\u3001\u5668\u5b98\uff0c\u6216\u9593\u63a5\u63a5\u89f8\u88ab\u6c59\u67d3\u4e4b\u74b0\u5883\u800c\u611f\u67d3 (4) \u75be\u75c5\u6f5b\u4f0f\u671f2\u81f321\u5929\uff0c\u7576\u75c5\u4eba\u4e09\u9031\u5167\u6709\u76f8\u95dc\u65c5\u904a\u6216\u63a5\u89f8\u53f2\uff0c\u4e00\u65e6\u6709\u767c\u71d2\u3001\u982d\u75db\u3001\u808c\u8089\u75db\u3001\u5641\u5fc3\u3001\u5614\u5410\u3001\u8179\u7009\u3001\u8179\u75db\uff0c\u6216\u4e0d\u660e\u539f\u56e0\u51fa\u8840\u3001\u6b7b\u4ea1\u7b49\u4efb\u4e00\u9805\u6642\uff0c\u5373\u61c9\u901a\u5831\u4e14\u63a1\u6aa2\u9001\u9a57  (5)\r\u6536\u6cbb\u75c5\u4eba\u65bc\u8ca0\u58d3\u9694\u96e2\u75c5\u623f\uff0c\u91ab\u8b77\u4eba\u54e1\u6234N95\u53e3\u7f69\u6700\u70ba\u91cd\u8981  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(3)+(4)\nD. (1)+(4)+(5)\nE. (1)+(5)\n": "(C)", "103-7.\n\u4e0b\u5217\u6709\u95dc\u75c5\u4eba\u8179\u7009\u5371\u96aa\u56e0\u7d20/\u75c7\u72c0\u53ca\u75c5\u56e0\u4e4b\u7d44\u5408\uff0c\u6b63\u78ba\u70ba\u4f55\u8005? (1) \u8840\u4fbf--- Shigella, Salmonella, E. coli O157 (2) \u5c0f\u5b69\u990a\u70cf\u9f9c\u3001\u8725\u8734--- Salmonella (3) \u5403\u751f\u86cb--- Salmonella (4) \u642d\u90f5\u8f2a\u65c5\u904a--- Norovirus (5) \u5bb6\u4e2d\u5c0f\u8c93\u5c0f\u72d7\u8179\u7009--- Campylobacter (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(2)+(3)+(4)\nE. ()1+(2)+(3)+(4)+(5)\n": "(E)", "103-8.\n\u70ba\u964d\u4f4e\u91ab\u7642\u6a5f\u69cb\u5167\u591a\u91cd\u6297\u85e5\u6027\u75c5\u539f\u4e4b\u4ea4\u53c9\u611f\u67d3\uff0c\u75be\u75c5\u7ba1\u5236\u7f72\u97ff\u61c9\u4e16\u754c\u885b\u751f\u7d44\u7e54 (WHO)\u4e4b\u5021\u5c0e\u91ab\u8b77\u4eba\u54e1\u624b\u90e8\u885b\u751f\u904b\u52d5\u3002\u6709\u95dc\u624b\u90e8\u885b\u751f\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r(1) \u4f9d\u6587\u737b\u53ca\u5be6\u9a57\u986f\u793a\uff0c\u4f7f\u7528\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u9032\u884c\u624b\u90e8\u885b\u751f\uff0c\u5728\u6e05\u6f54\u6548\u679c\u3001\u4f7f\u7528\u6642\u6a5f\u3001\u82b1\u8cbb\u6642\u9593\u3001\u5c0d\u76ae\u819a\u7684\u5f71\u97ff\u3001\u5b89\u5168\u6027\u8003\u91cf\u53ca\u6d17\u624b\u9075\u5f9e\u6027\u7b49\u65b9\u9762\uff0c\u5747\u6bd4\u4f7f\u7528\u80a5\u7682\u6216\u6db2\u614b\u7682\u9032\u884c\u6fd5\u6d17\u624b\u7684\u6548\u679c\u70ba\u4f73\u3002\r(2) WHO\u63a8\u52d5\u7684\u91ab\u8b77\u4eba\u54e1\u624b\u90e8\u885b\u751f\u904b\u52d5\uff0c\u5f37\u8abf\u91ab\u8b77\u4eba\u54e1\u5728\u624b\u90e8\u7121\u660e\u986f\u9ad2\u6c59\u6642\uff0c\u512a\u5148\u4f7f\u7528\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u6e05\u6f54\u624b\u90e8\uff0c\u4e7e\u6d17\u624b\u4e4b\u6d17\u624b\u6280\u8853\u5168\u7a0b\u970040-60\u79d2\u3002\r(3) \u624b\u90e8\u6709\u660e\u986f\u9ad2\u6c61\u6216\u6cbe\u6709\u8840\u6db2/\u9ad4\u6db2\u6642\uff0c\u5efa\u8b70\u4f7f\u7528\u80a5\u7682\u548c\u6e05\u6c34\u4e4b\u6fd5\u6d17\u624b\u6280\u8853\u6d17\u624b\u3002\r(4) \u70ba\u63d0\u9ad8\u624b\u90e8\u885b\u751f\u8a2d\u5099\u7684\u53ef\u8fd1\u6027\uff0c WHO\u5ba3\u5c0e\u5728\u7167\u8b77\u9ede\u666e\u904d\u8a2d\u7f6e\u6216\u96a8\u8eab\u651c\u5e36\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u65b9\u5f0f\uff0c\u53ef\u9054\u5230\u7b26\u5408\u5728\u7167\u8b77\u9ede\u4f38\u624b\u53ef\u53ca\u61c9\u6709\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u7684\u76ee\u6a19\u3002\r(5) \u70ba\u907f\u514d\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u4e4b\u7522\u54c1\u9152\u7cbe\u6fc3\u5ea6\u4e0d\u8db3\uff0c\u5f71\u97ff\u91ab\u8b77\u4eba\u54e1\u57f7\u884c\u624b\u90e8\u885b\u751f\u4e4b\u6210\u6548\uff0c\u91ab\u7642\u6a5f\u69cb\u65bc\u8cfc\u8cb7\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\uff0c\u61c9\u9078\u64c7\u9152\u7cbe\u6210\u5206\u8d8a\u9ad8\u7684\u8d8a\u597d\u3002\r (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)\nC. (2)+(4)+(5)\nD. (2)+(3)+(4)\nE. (1)+(3)+(4)\n": "(E)", "103-9.\n\u767c\u71d2\u4f75\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\u5019\u7fa4 (severe fever with thrombocytopenia syndrome)\u5728\u4e2d\u570b\u5927\u9678\u53ca\u65e5\u672c\u5df2\u6709\u5831\u544a\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u6b63\u78ba?  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1) \u81f4\u75c5\u539f\u662f\u65b0\u5e03\u5c3c\u4e9e\u75c5\u6bd2 (novel bunyavirus)\r(2) \u7531\u9577\u89d2\u8840\u8731 (Haemaphysalis longicornis)\u53ee\u54ac\u800c\u50b3\u64ad\r(3) \u6025\u6027\u671f\u75c5\u4eba\u53ca\u5c4d\u9ad4\u8840\u6db2\u3001\u8840\u6027\u5206\u6ccc\u7269\u5177\u50b3\u67d3\u6027\uff0c\u76f4\u63a5\u63a5\u89f8\u75c5\u4eba\u8840\u6db2\u6216\u8840\u6027\u5206\u6ccc\u7269\u53ef\u5c0e\u81f4\u611f\u67d3\uff0c\u56e0\u6b64\u53ef\u4ee5\u4eba\u50b3\u4eba\u3002\r(4) \u81e8\u5e8a\u8868\u73fe\u5305\u62ec\u767c\u71d2\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u3001\u8178\u80c3\u9053\u75c7\u72c0\u3001\u591a\u91cd\u5668\u5b98\u529f\u80fd\u5931\u8abf\uff0c\u521d\u671f\u6b7b\u4ea1\u7387\u53ef\u905410-30%\u3002\r(5) \u8a72\u75c5\u6b63\u78ba\u540d\u7a31\u70ba Granulocytic anaplasmosis\u3002\nA. (1)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(4)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "103-10.\n\u4e16\u754c\u885b\u751f\u7d44\u7e54\u65bc2012\u5e749\u6708\u9996\u5ea6\u516c\u5e03\u4e2d\u6771\u547c\u5438\u75c7\u5019\u7fa4 (Middle East Respiratory Syndrome)\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7\u6848\u4f8b\u5f8c\uff0c\u73fe\u5728\u5df2\u5728\u6c99\u70cf\u5730\u963f\u62c9\u4f2f\u3001\u7d04\u65e6\u3001\u5361\u9054\u3001\u82f1\u570b\u3001\u5fb7\u570b\u3001\u6cd5\u570b\u7b49\u570b\u5bb6\u9678\u7e8c\u767c\u73fe\u78ba\u8a3a\u75c5\u4f8b\u6578\u767e\u4f8b\uff0c\u5176\u4e2d80%\u4ee5\u4e0a\u96c6\u4e2d\u5728\u6c99\u70cf\u5730\u963f\u62c9\u4f2f\u3002\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba? (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1)\u53ef\u900f\u904e\u547c\u5438\u9053\u98db\u6cab\u9846\u7c92\uff0c\u76f4\u63a5\u6216\u9593\u63a5\u63a5\u89f8\u611f\u67d3\u8005\u5206\u6ccc\u7269\u50b3\u64ad\uff0c\u800c\u9020\u6210\u7fa4\u805a\u611f\u67d3\u4e8b\u4ef6\uff0c\u91ab\u7642\u5de5\u4f5c\u8005\u5177\u6f5b\u5728\u906d\u53d7\u611f\u67d3\u98a8\u96aa\u3002\r(2) \u81e8\u5e8a\u75c7\u72c0\u5305\u62ec\u767c\u71d2\u3001\u54b3\u55fd\u3001\u547c\u5438\u6025\u4fc3\u8207\u547c\u5438\u56f0\u96e3\u4e4b\u80ba\u708e\u8868\u73fe\uff0c\u90e8\u5206\u75c5\u4eba\u51fa\u73fe\u814e\u8870\u7aed\u3001\u5fc3\u5305\u819c\u708e\u3001\u7030\u6f2b\u6027\u8840\u7ba1\u5167\u51dd\u8840\u3001\u6b7b\u4ea1\u7387\u7d0450%\u3002\r(3) \u6f5b\u4f0f\u671f\u4e00\u822c\u70ba9-12\u5929\u3002\r(4) \u8d74\u4e2d\u6771\u671d\u89c0\u4fe1\u5f92\u53ca\u65c5\u5ba2\u61c9\u7279\u5225\u6ce8\u610f\u624b\u90e8\u885b\u751f\u53ca\u547c\u5438\u9053\u9632\u8b77\u63aa\u65bd\u3002\r(5) \u6211\u570b\u5217\u70ba\u7b2c\u4e94\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u91ab\u8b77\u4eba\u54e1\u5982\u9047\u300c\u91ab\u8b77\u4eba\u54e1\u767c\u751f\u4e0d\u660e\u539f\u56e0\u80ba\u708e\u300d\u3001\u300c\u81e8\u5e8a\u51fa\u73fe\u80ba\u708e\u4e14\u767c\u75c5\u524d14\u65e5\u5167\u5177\u6709\u4e2d\u6771\u65c5\u904a\u53f2\u300d\u3001\u300c\u4e0d\u660e\u539f\u56e0\u80ba\u708e\u7fa4\u805a\u4e8b\u4ef6\u300d\uff0c\u61c9\u63a1\u53d6\u9069\u7576\u611f\u67d3\u8005\u7ba1\u5236\u63aa\u65bd\uff0c\u63a1\u96c6\u547c\u5438\u9053\u53ca\u8840\u6db2\u6aa2\u9ad4\u9001\u75be\u75c5\u7ba1\u5236\u7f72\u4e26\u901a\u5831\u6cd5\u50b3\u3002\nA. (1)+(2)+(4)+(5)\nB. (2)+(3)+(4)+(5)\nC. (1)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(4)\nE. (1)+(2)+(3)+(4)+(5)\n": "(E)", "103-11.\n\u4e00\u4f4d36\u6b72\u7537\u6027\uff0c\u5e73\u65e5\u6709\u5ad6\u5993\u7684\u7fd2\u6163\uff0c\u6b64\u6b21\u56e0\u5168\u8eab\u5026\u6020\uff0c\u8ec0\u5e79\u53ca\u56db\u80a2\u51fa\u73fe\u7d05\u75b9\u800c\u5c31\u91ab\uff0c\u62bd\u8840\u6aa2\u9a57\u7d50\u679c\u8840\u6e05TPHA\uff08Treponema hemagglutination\uff09assay\u70ba1\uff1a5120\uff0cRPR\uff08rapid plasma reagin\uff09assay titer\u70ba128\uff0b\uff0c\u8acb\u554f\u6b64\u6642\u6700\u9069\u7576\u7684\u9996\u9078\u91ab\u7642\u8655\u7f6e\u70ba\u4f55\uff1f\nA. aqueous crystalline penicillin-G\uff0818-24MU/day\uff09\u975c\u8108\u6ce8\u5c0410\u81f314\u5929\u3002\nB. \u808c\u8089\u6ce8\u5c04\u4e00\u5291penicillin-G benzathine 2.4MU\u3002\nC. \u53e3\u670ddoxycycline 100mg bid\u6cbb\u7642\u5169\u9031\u3002\nD. \u6bcf\u9031\u808c\u8089\u6ce8\u5c04\u4e00\u5291penicillin-G benzathine 2.4MU\u9023\u7e8c\u4e09\u9031\u3002\nE. \u808c\u8089\u6ce8\u5c04\u4e00\u5291ceftriaxone 500mg\u3002\n": "(B)", "103-12.\n\u4e00\u4f4d19\u6b72\u7537\u6027\uff0c\u81ea\u8a34\u70ba\u7537\u540c\u6027\u6200\uff0c\u6709\u591a\u6b21\u672a\u4fdd\u8b77\u4e4b\u5371\u96aa\u6027\u884c\u70ba\uff0c\u6700\u8fd110\u5929\u982d\u75db\u3001\u767c\u71d2\u3001\u9838\u90e8\u6dcb\u5df4\u7d50\u816b\u5927\u3001\u56db\u80a2\u95dc\u7bc0\u9178\u75db\u800c\u5c31\u91ab\uff0c\u7406\u5b78\u6aa2\u67e5\u9ad4\u6eab\u70ba39.1\u2103\uff0c\u9838\u90e8\u50f5\u786c\u89f8\u8a3a\u9838\u90e8\u6dcb\u5df4\u7d50\u58d3\u75db\uff0c\u591a\u8655\u8ec0\u5e79\u76ae\u75b9\u53ca\u809d\u813e\u816b\u5927\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u8840\u6e05\u5b78EBV\u3001Anti-HIV\u3001Mycoplasma IgM\u3001Anti-CMV IgM\u5747\u70ba\u9670\u6027\u53cd\u61c9\u3002\u91ab\u5e2b\u61f7\u7591\u75c5\u60a3\u6709\u521d\u671fHIV\u611f\u67d3\uff0c\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u9805\u8a66\u9a57\u6700\u80fd\u65e9\u671f\u5075\u6e2c\u662f\u5426\u6709HIV\u611f\u67d3\uff1f\nA. \u8840\u6db2\u9031\u908a\u55ae\u6838\u7403\uff08PBMC\uff09HIV\u57f9\u990a\u3002\nB. \u8840\u6f3f\u75c5\u6bd2\u91cfHIV RNA\uff08RT-PCR\uff09\u3002\nC. \u518d\u505a\u4e00\u6b21\u8840\u6db2Anti-HIV\u6297\u9ad4\u3002\nD. \u8840\u6db2HIV Western-Blot\uff08\u897f\u65b9\u58a8\u9ede\u6e2c\u8a66\uff09\u3002\nE. \u8840\u6db2CD4\u6dcb\u5df4\u7403\u6578\u3002\n": "(B)", "103-13.\n\u4e0b\u5217\u6709\u95dc\u9264\u7aef\u87ba\u65cb\u9ad4\u611f\u67d3\uff08Leptospirosis\uff09\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1) Leptospirosis\u5c6c\u65bc\u4eba\u755c\u5171\u901a\u50b3\u67d3\u75c5\uff08zoonosis\uff09\uff0c\u5176\u81f4\u75c5\u539f\u6700\u91cd\u8981\u7684\u8caf\u5b58\u7aa9\uff08reservoir\uff09\u662f\u9f20\u985e\u3002\r(2) Leptospira\u611f\u67d3\u4eba\u9ad4\u53ef\u7d93\u7531\u6709\u50b7\u53e3\u7684\u76ae\u819a\u6216\u5b8c\u6574\u7684\u9ecf\u819c\u9032\u5165\uff0c\u4e26\u4e14\u53ef\u4eba\u50b3\u4eba\uff08human-to-human transmission\uff09\u3002\r(3) Leptospirosis\u611f\u67d3\u8005\u53ef\u4ee5\u50cf\u662f\u6d41\u884c\u6027\u611f\u5192\u7684\u81e8\u5e8a\u8868\u73fe\uff0c\u51fa\u73fe\u767c\u71d2\u3001\u754f\u5bd2\u3001\u982d\u75db\u3001\u808c\u8089\u9178\u75db\u7b49\uff0c\u767c\u71d2\u53ef\u6301\u7e8c3-10\u5929\u3002\r(4) Weil's syndrome\u75c5\u4eba\u6703\u6709\u9ec3\u75b8\u3001\u6025\u6027\u814e\u529f\u80fd\u640d\u50b7\u969c\u7919\u3001\u80ba\u90e8\u51fa\u8840\u53ca\u9ad8\u6b7b\u4ea1\u7387\u3002\r(5) \u9996\u9078\u85e5\u7269\u6cbb\u7642\u70baazithromycin\u3002\nA. (1)+(2)+(4)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(5)\nE. (1)+(3)+(4)\n": "(E)", "103-14.\n\u4e00\u4f4d46\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u56e0\u767c\u71d2\u53ca\u754f\u5bd2\u4e00\u9031\u81f3\u672c\u9662\u6025\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u6709\u4e8c\u5c16\u74e3\u6536\u7e2e\u671f\u5fc3\u96dc\u97f3\uff0c\u5169\u5957\u8840\u6db2\u57f9\u990a\u5747\u9577\u51faEnterococcus faecalis\uff0c\u5c0d\u6240\u6e2c\u8a66\u4e4b\u6297\u751f\u7d20\u5747\u5177\u654f\u611f\u6027\uff08susceptible\uff09\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6cbb\u7642\u65b9\u5f0f\u662f\u6700\u5408\u9069\u4e4b\u9078\u64c7\uff1f\nA. Cefazolin + gentamicin\u3002\nB. Ampicillin + gentamicin\u3002\nC. high dose Penicillin alone\u3002\nD. high dose Ceftriaxone alone\u3002\nE. Vancomycin alone\u3002\n": "(B)", "103-15.\n\u6709\u95dc\u65b0\u578b\u6d41\u611fH5N1\u53caH10N8\u6d41\u611f\u75c5\u6bd2\u611f\u67d3\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1) H5N1\u8207H10N8\u7686\u5177\u6709\u5c0d\u4eba\u985e\u4e0b\u547c\u5438\u9053\u03b12,3-linked sialic acid\u63a5\u53d7\u5668\u7d50\u5408\u4e4b\u80fd\u529b\uff0c\u6613\u9020\u6210\u6025\u6027\u80ba\u640d\u50b7\u3002\r(2) H10N8\u75c5\u6bd2\u516d\u6bb5\u5167\u90e8\u57fa\u56e0\u4f86\u81ea\u65bcH9N2\u79bd\u6d41\u611f\u75c5\u6bd2\u3002\r(3) H5N1\u8207H10N8\u6d41\u611f\u75c5\u6bd2\u66fe\u5728\u4e2d\u570b\u5927\u9678\u767c\u751f\u4eba\u50b3\u4eba\u7fa4\u7a81\u767c\u6d41\u884c\u3002\r(4) H5N1\u8207H10N8\u6d41\u611f\u75c5\u6bd2\u7686\u5c0d\u65bc\u9ce5\u79bd\u985e\u70ba\u9ad8\u81f4\u75c5\u6027\u53ca\u9ad8\u81f4\u6b7b\u7387\u611f\u67d3\u3002\r(5) H10N8\u8207H5N1\u5927\u90e8\u4efd\u75c5\u6bd2\u682a\u5c0d\u73fe\u884c\u85e5\u7269neuraminidase inhibitor\uff08\u5982oseltamivir\uff09\u5747\u5177\u6709\u6297\u85e5\u6027\u3002\nA. (2)+(4)+(5)\nB. (3)+(4)+(5)\nC. (1)+(2)+(3)\nD. (1)+(3)+(5)\nE. (2)+(3)+(4)\n": "(B)", "103-16.\n\u6709\u95dc\u65b0\u578b\u6d41\u611fH7N9\u611f\u67d3\u4e4b\u6d41\u884c\u75c5\u5b78\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6839\u64da\u4e2d\u570b\u5927\u9678\u516c\u4f48\u4e4bH7N9\u75c5\u4f8b\uff0c\u611f\u67d3\u5f8c\u9020\u6210\u80ba\u708e\u4e4b\u6b7b\u4ea1\u7387\u7d04\u70ba30-40\uff05\u3002\nB. \u53f0\u7063\u5df2\u6709\u5883\u5916\u79fb\u5165\u4e4bH7N9\u611f\u67d3\u500b\u6848\u3002\nC. H7N9\u611f\u67d3\u500b\u6848\u670990\uff05\u500b\u6848\u81e8\u5e8a\u8868\u73fe\u70ba\u80ba\u708e\uff0c\u6709\u63a5\u8fd160\uff05\u70baARDS\u547c\u5438\u8870\u7aed\u3002\nD. H7N9\u611f\u67d3\u500b\u6848\u6709\u8d85\u904e80\uff05\u66fe\u6709\u63a5\u89f8\u6d3b\u79bd\u53f2\u3002\nE. \u7d55\u5927\u90e8\u5206H7N9\u6d41\u611f\u85c9\u7531\u8840\u6e05\u5b78\uff08serology\uff09\u6aa2\u5b9a\u3002\n": "(E)", "103-17.\nAIDS\u75c5\u60a3\u70baT\u6dcb\u5df4\u7d30\u80de\u529f\u80fd\u7f3a\u640d\u4e4b\u6613\u611f\u53d7\u4e3b\uff0c\u4e0b\u5217\u4f55\u7a2e\u75c5\u539f\u4e26\u975e\u70ba\u6b64\u985e\u75c5\u60a3\u5e38\u898b\u4e4b\u611f\u67d3\u75c7\u81f4\u75c5\u539f\uff1f\nA. Pneumocystis jirovecii\u3002\nB. Cytomegalovirus\u3002\nC. Herpes simplex virus\u3002\nD. Candida albicans\u3002\nE. Shigella flexneri\u3002\n": "(E)", "103-18.\n\u4e00\u4f4d40\u6b72\u8840\u6db2\u75be\u75c5\u60a3\u8005\uff0c\u63a5\u53d7\u5168\u813e\u81df\u5207\u9664\u8853\uff08splenectomy\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5927\u90e8\u4efd\u611f\u67d3\u767c\u751f\u65bc\u813e\u81df\u5207\u9664\u5f8c\u7684\u524d2\u5e74\u5167\u3002\nB. \u91cd\u75c7\u611f\u67d3\u4e4b\u6b7b\u4ea1\u7387\u53ef\u9ad850\uff05\u3002\nC. \u4e3b\u8981\u611f\u67d3\u7684\u81f4\u75c5\u83cc\u70ba\u6709\u83a2\u819c\u6027\u7d30\u83cc\uff0c\u4f8b\u5982\uff1aNeisseria meningitidis\u3002\nD. Salmonella\u70ba\u6700\u5e38\u898b\u4e4b\u81f4\u75c5\u539f\uff0c\u7d04\u536050-70\uff05\u3002\nE. \u5152\u7ae5\u63a5\u53d7\u813e\u81df\u5207\u9664\u5f8c\u767c\u751f\u611f\u67d3\u7684\u98a8\u96aa\u9ad8\u65bc\u6210\u4eba\u63a5\u53d7\u813e\u81df\u5207\u9664\u8005\u4e4b\u611f\u67d3\u98a8\u96aa\u3002\n": "(D)", "103-19.\n\u6709\u95dc\u793e\u5340\u7d30\u83cc\u6027\u8166\u819c\u708e\u611f\u67d3\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6210\u4eba\u6700\u5e38\u898b\u7684\u81f4\u75c5\u83cc\u70baStreptococcus pneumoniae\u3002\nB. 60\u6b72\u4ee5\u4e0a\u60a3\u8005\u6216\u514d\u75ab\u7f3a\u9677\u60a3\u8005\uff0c\u9700\u8003\u616eListeria monocytogenes\u3002\nC. Streptococcus pneumoniae\u8166\u819c\u708e\u5373\u4f7f\u7d66\u4e88\u9069\u7576\u7684\u6297\u751f\u7d20\u6cbb\u7642\uff0c\u6b7b\u4ea1\u7387\u4ecd\u7d04\u70ba20\uff05\u3002\nD. \u7814\u7a76\u986f\u793adexamethasone 10mg q6h \u7d66\u4e884\u5929\u53ef\u6539\u5584\u6210\u4ebaStreptococcus pneumoniae\u8166\u819c\u708e\u9810\u5f8c\u3002\nE. \u56db\u50f9Neisseria meningitidis\u75ab\u82d7\u6ce8\u5c04\u53ef\u9810\u9632serogroup B\u5948\u745f\u6c0f\u8166\u819c\u708e\u96d9\u7403\u83cc\u8166\u819c\u708e\u3002\n": "(E)", "104-1.\n\u53f0\u7063\u5730\u5340\u590f\u5929\u767b\u9769\u71b1\u75ab\u60c5\u589e\u6eab\uff0c\u75c5\u4f8b\u6578\u5feb\u901f\u4e0a\u6607\uff0c\u4e0b\u5217\u95dc\u65bc\u767b\u9769\u71b1\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576?\nA. \u767b\u9769\u75c5\u6bd2\u70ba\u9ec3\u75c5\u6bd2\u79d1(Flaviviridae)\uff0c\u70baRNA\u75c5\u6bd2\uff0c\u76db\u884c\u65bc\u9130\u8fd1\u8d64\u9053\u5340\u57df\uff0c\u5305\u62ec\u4e2d\u5357\u7f8e\u6d32\u3001\u6771\u5357\u4e9e\u53ca\u975e\u6d32\nB. \u5728\u53f0\u7063\uff0c\u767b\u9769\u71b1\u4e3b\u8981\u7684\u50b3\u67d3\u75c5\u5a92\u70ba\u767d\u7dda\u6591\u868a\u53ca\u57c3\u53ca\u6591\u868a\u3002\u57c3\u53ca\u6591\u868a\u591a\u5206\u4f48\u5728\u5357\u90e8\uff0c\u559c\u6b61\u68f2\u606f\u5728\u5ba4\u5167\uff1b\u767d\u7dda\u6591\u868a\u5168\u5cf6\u5206\u4f48\uff0c\u559c\u6b61\u68f2\u606f\u5728\u5ba4\u5916\u3002\nC. \u767b\u9769\u4f11\u514b\u75c7\u5019\u7fa4\u539f\u56e0\u70ba\u75c5\u4eba\u51fa\u73fe\u8840\u6f3f\u6ef2\u6f0f\u5c0e\u81f4\u8840\u58d3\u4e0b\u964d\uff0c\u5373\u4f7f\u65e9\u671f\u7d66\u4e88\u75c5\u60a3\u9069\u7576\u7684\u975c\u8108\u8f38\u6db2\u53ca\u652f\u6301\u6027\u6cbb\u7642\uff0c\u767b\u9769\u4f11\u514b\u75c7\u5019\u7fa4\u4e4b\u6b7b\u4ea1\u7387\u4ecd\u670940%~50%\u3002\nD. \u6aa2\u9a57\u767b\u9769\u71b1\u53ef\u6e2c\u75c5\u4eba\u8840\u6e05\u767b\u9769\u75c5\u6bd2\u7279\u7570\u6027IgM\u967d\u6027\u6216IgG\u6297\u9ad4\u967d\u8f49\u6216\u67094\u500d\u4e0a\u5347\u78ba\u8a3a\u3002\nE. \u767b\u9769\u71b1\u75c5\u6bd2\u5206\u70ba4\u7a2e\u8840\u6e05\u578b\uff0c\u611f\u67d3\u8840\u6e05\u578b\u7b2c\u4e00\u578b\u5f8c\u518d\u611f\u67d3\u7b2c\u4e8c\u578b\u75c5\u75c7\u6700\u70ba\u56b4\u91cd\u3002\n": "(C)", "104-2.\n\u6885\u6bd2\u70ba\u7531\u6885\u6bd2\u87ba\u65cb\u9ad4\u6240\u5f15\u81f4\u4e4b\u4e00\u7a2e\u6027\u50b3\u67d3\u75c5\uff0c\u4ee5\u4e0b\u6558\u8ff0\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576?\nA. \u6cbb\u7642\u9996\u9078\u70baPenicillin\uff0c\u82e5\u75c5\u60a3\u70baPenicillin\u904e\u654f\u6642\uff0c\u53ef\u6539\u7528Doxycycline\u6cbb\u7642\nB. \u80ce\u5152\u5148\u5929\u6027\u6885\u6bd2\u5927\u591a\u6e90\u81ea\u6885\u6bd2\u87ba\u65cb\u9ad4\u5728\u80ce\u5152\u51fa\u751f\u901a\u904e\u7522\u9053\u6642\u50b3\u67d3\nC. \u8461\u8404\u819c\u708e(Uveitis)\u70ba\u6885\u6bd2\u5728\u773c\u775b\u611f\u67d3\u53ef\u898b\u7684\u8868\u73fe\nD. \u96b1\u6027(latent)\u6885\u6bd2\u662f\u6307\u6885\u6bd2\u9032\u5165\u5b8c\u5168\u7121\u81e8\u5e8a\u75c7\u72c0\u7684\u6642\u671f\u3002\u65e9\u671f\u96b1\u6027\u6885\u6bd2\u70ba\u611f\u67d3\u5f8c\u672a\u8d85\u904e1\u5e74\u4e4b\u7121\u75c7\u72c0\u671f\uff0c\u75c5\u60a3\u4ecd\u5177\u8f03\u9ad8\u50b3\u67d3\u6027\uff1b\u665a\u671f\u96b1\u6027\u6885\u6bd2\u5247\u6307\u611f\u67d3\u8d85\u904e1\u5e74\u4e4b\u7121\u75c7\u72c0\u671f\uff0c\u50b3\u67d3\u529b\u8f03\u5f31\nE. \u65e9\u671f\u5148\u5929\u6027\u6885\u6bd2\u81e8\u5e8a\u75c7\u72c0\u4f3c\u5f8c\u5929\u6027\u4e8c\u671f\u6885\u6bd2\uff0c\u800c\u665a\u671f\u5148\u5929\u6027\u6885\u6bd2\u5178\u578b\u75c7\u72c0\u70ba\u6885\u6bd2\u816b\u3001\u9593\u8cea\u6027\u89d2\u819c\u708e\u3001\u8033\u807e\u3001Hutchinson\u6c0f\u9f52\u7b49\n": "(B)", "104-3.\n\u4e00\u4f4d32\u6b72\u7537\u6027\u65bc10\u5929\u524d\u81f3\u967d\u660e\u5c71\u904a\u73a9\uff0c2\u5929\u524d\u958b\u59cb\u51fa\u73fe\u767c\u71d2\u3001\u982d\u75db\u3001\u9f20\u8e4a\u90e8\u6dcb\u5df4\u817a\u816b\uff0c\u76ae\u819a\u51fa\u75b9\uff0c\u4e26\u65bc\u8179\u80a1\u6e9d\u4e0b\u7de3\u767c\u73fe\u6709\u4e00\u7126\u75c2\u75c5\u7076(\u5982\u5716)\uff0c\u6b64\u6642\u4e0b\u5217\u4f55\u7a2e\u8a3a\u65b7\u53ca\u6cbb\u7642\u662f\u6700\u932f\u8aa4\u7684\uff1f\nA. \u6b64\u70baScrub typhus\uff0c\u75c5\u539f\u9ad4\u70baOrientia tsutsugamushi\u3002\nB. \u6b64\u75c5\u539f\u662f\u7531\u6059\u87f2(chigger)\u53ee\u54ac\u6240\u5f15\u8d77\uff1b\u79cb\u5929\u6700\u5e38\u898b\uff0c\u8a3a\u65b7\u53ef\u5229\u7528\u8840\u6e05\u514d\u75ab\u53cd\u61c9(IFA)\u6216PCR\u8a3a\u65b7\u3002\nC. \u6f5b\u4f0f\u671f\u70ba6\u81f321 \u5929\uff0c\u8d85\u904e90%\u60a3\u8005\u81e8\u5e8a\u75c7\u72c0\u6703\u51fa\u73fe\u6b64\u7126\u75c2\u75c5\u7076\u53ca\u76ae\u75b9\u3002\nD. \u6cbb\u7642\u53ef\u7528doxycycline 100mg Bid\u6cbb\u76427-15\u5929\u3002\nE. \u82e5\u75c5\u60a3\u5c0ddoxycycline\u904e\u654f\uff0c\u53ef\u4ee5\u4f7f\u7528azithromycin 500mg QD\u4e09\u5929\u6cbb\u7642\u3002\n": "(C)", "104-4.\n\u4e0b\u5217\u4f55\u8005\u6297\u83cc\u85e5\u7269\u5c6c\u65bc\u61f7\u5b55\u5206\u985eCategory B\u53ef\u4ee5\u9069\u5408\u5b55\u5a66\u4f7f\u7528\uff1f\nA. Aminoglycoside\nB. Fluoroquinolone\nC. Clarithromycin\nD. Erythromycin estolate\nE. Sulfonamide\n": "(D)", "104-5.\n\u4e0b\u5217\u6297\u83cc\u85e5\u7269\u4e4b\u526f\u4f5c\u7528\u914d\u5c0d\uff0c\u4f55\u8005\u70ba\u975e\uff1f\nA. Aminoglycosides - 8th Cranial nerve toxicity\nB. Clindamycin - Clostridium difficile colitis\nC. Levofloxacin - \u5fc3\u96fb\u5716 QTc prolongation\nD. Metronidazole - \u8207Alcohol\u4f75\u7528\u5f15\u8d77Disulfiram reaction\nE. Macrolides - Renal toxicity\n": "(E)", "104-6.\n\u4e0b\u5217\u6709\u95dcListeria monocytogenes\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u517c\u6027\u53ad\u6c27\uff0c\u7fd2\u6163\u65bc\u8f03\u51b7\u74b0\u5883\u5b58\u6d3b\u7684\u683c\u862d\u6c0f\u967d\u6027\u687f\u83cc\u3002\nB. \u61f7\u5b55\u5a66\u5973\u3001\u5668\u5b98\u79fb\u690d\u75c5\u60a3\u548c\u4eba\u985e\u514d\u75ab\u4e0d\u5168\u75c5\u6bd2\u611f\u67d3\u60a3\u8005\u662f\u611f\u67d3\u9ad8\u5371\u96aa\u7fa4\u3002\nC. \u63a5\u89f8\u53ca\u98df\u7528\u6c59\u67d3\u7684\u98df\u7269\u662f\u4e3b\u8981\u611f\u67d3\u9014\u5f91\u3002\nD. \u9996\u9078\u6cbb\u7642\u85e5\u7269\u662fampicillin\uff0c\u5c0d\u65bcampicillin\u904e\u654f\u8005\u53ef\u512a\u5148\u9078\u64c7trimethoprim-sulfomethoxazole(TMP-SMX)\u6cbb\u7642\u3002\nE. \u82e5\u70ba\u8166\u819c\u708e\u500b\u6848\u53ef\u4f7f\u7528IV Ceftriaxone 2g Q12H\u6cbb\u7642\u3002\n": "(E)", "104-7.\n\u4e0b\u5217\u6297\u83cc\u85e5\u7269\u4f55\u8005\u975e\u4e3b\u8981\u7d93\u7531\u814e\u81df\u4ee3\u8b1d\uff0c\u6545\u4e0d\u9700\u4f9d\u814e\u529f\u80fd\u8abf\u6574\u5291\u91cf\uff1f\nA. Cefazolin\nB. Levofloxacin\nC. Penicillin\nD. Metronidazole\nE. Vancomycin\n": "(D)", "104-8.\n\u6709\u95dc\u80ba\u7d50\u6838(Tuberculosis)\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\r(1). \u521d\u611f\u67d3\u4e4b\u5f8c\uff0c\u4e00\u822c\u4eba\u7d42\u5176\u4e00\u751f\u9ad4\u5167\u7d50\u6838\u83cc\u518d\u5ea6\u6d3b\u5316\u800c\u767c\u75c5\u7684\u6a5f\u7387\u7d04\u70ba5~10%\uff0c\u5176\u4e2d\u7d04\u6709\u4e00\u534a\u662f\u5728\u611f\u67d3\u5f8c\u7684\u524d\u4e94\u5e74\u767c\u75c5\uff0c\u800c\u4ee5\u7b2c\u4e00\u5e74\u7684\u5371\u96aa\u6027\u6700\u5927\u3002\r(2). \u7d93\u7531\u9a57\u75f0\u767c\u73fe\u7d50\u6838\u83cc\uff0c\u662f\u80ba\u7d50\u6838\u6700\u70ba\u91cd\u8981\u7684\u8a3a\u65b7\u4f9d\u64da\u3002\r(3). \u518d\u6d3b\u5316\u80ba\u90e8\u611f\u67d3\u75be\u75c5(reactivation)\u597d\u767c\u65bc\u80ba\u5c16(apical)\u53ca\u80ba\u4e0a\u8449(upper lobes)  \u4e4b\u524d\u7bc0(anterior segments)\u3002\r(4). \u7576\u75f0\u6db2\u4e2d\u627e\u4e0d\u5230\u7d50\u6838\u83cc\u6642\uff0c\u4ea6\u53ef\u7531\u80f8\u90e8X\u5149\u6aa2\u67e5\u7d50\u679c\u52a0\u4e0a\u75c5\u4eba\u7684\u81e8\u5e8a\u75c7\u72c0\uff0c\u505a\u70ba\u80ba\u7d50\u6838\u7684\u81e8\u5e8a\u8a3a\u65b7\u4f9d\u64da\u3002\r(5). \u767c\u71d2\u3001\u591c\u9593\u76dc\u6c57\u53ca\u9ad4\u91cd\u6e1b\u8f15\u662f\u80ba\u7d50\u6838\u5e38\u898b\u7684\u75c7\u72c0\uff0c\u7d04\u670950%~60%\u7684\u80ba\u7d50\u6838\u500b\u6848\u6703\u51fa\u73fe\u54b3\u8840\u3002\nA. (2)+(3)+(4)\u3002\nB. (1)+(3)+(5)\u3002\nC. (3)+(4)+(5)\u3002\nD. (1)+(2)+(4)\u3002\nE. (1)+(2)+(3)+(4)+(5)\u3002\n": "(D)", "104-9.\n\u4e00\u4f4d40\u6b72\u5973\u6027\uff0c\u98b1\u98a8\u904e\u5f8c\u65bc\u5bb6\u4e2d\u6e05\u7406\u6de4\u6c34\uff0c\u4e00\u9031\u5f8c\u51fa\u73fe\u767c\u71d2\uff0c\u982d\u75db\uff0c\u5168\u8eab\u75e0\u75db\uff0c\u98df\u617e\u4e0d\u632f\uff0c\u9001\u91ab\u9662\u5f8c\uff0c\u767c\u73fe\u773c\u7d50\u819c\u5145\u8840\uff0c\u4e14\u6709\u9ec3\u75b8\u548c\u6025\u6027\u814e\u8870\u7aed\uff0c\u4e0b\u5217\u8a3a\u65b7\u53ca\u8655\u7f6e\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\r(1) \u512a\u5148\u8003\u616e\u9264\u7aef\u87ba\u65cb\u9ad4\u75c5(Leptospirosis)\u3002\r(2) \u8a3a\u65b7\u4e3b\u8981\u4f9d\u64da\u7d30\u83cc\u57f9\u990a\u53caPCR\u3002\r(3) \u9996\u9078\u6cbb\u7642\u85e5\u7269\u53ef\u4f7f\u7528Penicillin\u3002\r(4) \u91cd\u75c7\u8005\u53ef\u4f7f\u7528Ceftriaxone\u6cbb\u7642\u3002\nA. (2)+(3)+(4)\u3002\nB. (1)+(2)+(4)\u3002\nC. (1)+(2)+(3)\u3002\nD. (1)+(3)+(4)\u3002\nE. (1)+(2)+(3)+(4)\u3002\n": "(D)", "104-10.\n\u4ee5\u4e0b\u95dc\u65bc\u72c2\u72ac\u75c5\u7684\u76f8\u95dc\u63cf\u8ff0\u4f55\u8005\u70ba\u6b63\u78ba\uff1a\r(1) \u81f4\u75c5\u539fRabies virus\u662f\u4e00\u7a2eRNA \u75c5\u6bd2\uff0c\u70ba Lyssavirus \u5c6c\u3002\r(2) \u72c2\u72ac\u75c5\u70ba\u7b2c\u4e00\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u61c9\u65bc24\u5c0f\u6642\u5167\u901a\u5831\u3002\r(3) \u4eba\u985e\u611f\u67d3\u4e4b\u6f5b\u4f0f\u671f\u7d04\u70ba 3\u9031\u81f33\u500b\u6708\uff0c\u767c\u75c5\u6642\u6703\u6709\u7126\u616e\u3001\u982d\u75db\u3001\u767c\u71d2\u3001\u54ac\u50b7\u90e8 \u4f4d\u7570\u6a23\u611f\u3001\u6050\u6c34\u3001\u808c\u8089\u9ebb\u75fa\u3001\u62bd\u6410\u7b49\u8166\u708e\u75c7\u72c0,\u6700\u5f8c\u56e0\u5fc3\u80ba\u6216\u591a\u91cd\u5668\u5b98\u8870\u7aed\u800c\u5c0e\u81f4\u6b7b\u4ea1\u3002\r(4) \u7576\u75be\u75c5\u7684\u75c7\u72c0\u4e00\u65e6\u767c\u5c55\u51fa\u4f86\u6642\uff0c\u75ab\u82d7\u548c\u72c2\u72ac\u75c5\u514d\u75ab\u7403\u86cb\u767d\u53ef\u5c07\u81f4\u6b7b\u7387\u964d\u81f360%\u3002\r(5) \u65c5\u904a\u5230\u83f2\u5f8b\u8cd3\u3001\u8d8a\u5357\u3001\u5370\u5ea6\u3001\u6cf0\u570b\u7b49\u570b\u5bb6\uff0c\u5efa\u8b70\u63a5\u53d7\u66b4\u9732\u524d\u9810\u9632\u4e09\u5291\u72c2\u72ac\u75c5\u75ab\u82d7\u3002\nA. (1)+(2)+(4)\nB. (1)+(2)+(3)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (1)+(2)+(4)+(5)\n": "(B)", "104-11.\n\u5728\u4e0b\u5217\u95dc\u65bc\u8089\u6bd2\u687f\u83cc\u7684\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u9769\u862d\u6c0f\u967d\u6027\uff0c\u6975\u53ad\u6c27\u4e4b\u7522\u5b62\u687f\u83cc\uff0c\u6bd2\u7d20\u662f\u5176\u81f4\u75c5\u56e0\u5b50\u3002\nB. \u4ee5\u98df\u56e0\u578b\u8089\u6bd2\u687f\u83cc\u4e2d\u6bd2\u6700\u70ba\u5e38\u898b\u3002\u901a\u5e38\u5728\u98df\u5165\u53d7\u6bd2\u7d20\u6c61\u67d3\u7684\u98df\u7269\u5f8c\uff0c\u7d0412 \u81f3 36\u5c0f\u6642\u5f8c\u767c\u75c5\u3002\nC. \u982d\u9838\u90e8\u7684\u795e\u7d93\u75c7\u5982\u8996\u529b\u6a21\u7cca\u6216\u8907\u8996\u3001\u773c\u77bc\u4e0b\u5782\u3001\u984f\u9762\u795e\u7d93\u9ebb\u75fa\u3001\u541e\u56a5\u56f0\u96e3\u53ca\u8b1b\u8a71\u56f0\u96e3\u7b49\u3002\nD. \u56b4\u91cd\u75c5\u4eba\u9001\u5230\u6025\u8a3a\u4e3b\u8981\u5448\u73fe\u4ee3\u8b1d\u6027\u9178\u8840\u75c7\uff0c\u6cbb\u7642\u4ee5intensive care\u548c\u6297\u6bd2\u7d20\u70ba\u4e3b\u8ef8\u3002\nE. \u7b2c\u56db\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u767c\u73fe\u500b\u6848\u65bc24\u5c0f\u6642\u5167\u901a\u5831\u75be\u7ba1\u7f72\u3002\n": "(D)", "104-12.\n\u6709\u4e00\u4f4d45\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u767c\u71d2\u53ca\u4e0b\u80a2\u8edf\u7d44\u7e54\u611f\u67d3\u800c\u81f3\u6025\u8a3a\u8655\u5c31\u8a3a\u63a5\u53d7\u50b7\u53e3\u6e05\u5275\uff0c\u611f\u67d3\u75c5\u7076\u4e4b\u81bf\u6db2\u57f9\u990a\u9577\u51fa\u793e\u5340\u578bmethicillin-resistant Staphylococcus aureus\uff08MRSA\uff09\uff0c\u4e0b\u5217\u4f55\u7a2e\u53e3\u670d\u85e5\u7269\u6700\u4e0d\u9069\u5408\u7528\u65bc\u6cbb\u7642\u6b64\u75c5\u4eba\uff1f\nA. Ciprofloxacin\nB. Fusidic acid\nC. Linezolid\nD. Sulfamethoxazole/ trimethoprim\nE. Doxycycline\n": "(A)", "104-13.\n\u6709\u95dc\u65b0\u578b\u6d41\u611fH5N1\u53caH7N9 \u6d41\u611f\u75c5\u6bd2\u611f\u67d3\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f(1) H5N1\u5177\u6709\u5c0d\u4eba\u985e\u4e0b\u547c\u5438\u9053\u7d30\u80de\u03b12,3-linked sialic acid\u63a5\u53d7\u5668\u7d50\u5408\u4e4b\u80fd\u529b\uff0c\u6613\u9020\u6210\u6025\u6027\u80ba\u640d\u50b7 ;  (2) H7N9\u5177\u6709\u5c0d\u4eba\u985e\u547c\u5438\u9053\u4e0a\u76ae\u7d30\u80de\u03b12,6-linked sialic acid\u63a5\u53d7\u5668\u7d50\u5408\u4e4b\u80fd\u529b; (3) H5N1\u8207H7N9\u6d41\u611f\u75c5\u6bd2\u7686\u66fe\u5728\u4e2d\u570b\u5927\u9678\u767c\u751f\u4eba\u50b3\u4eba\u7fa4\u7a81\u767c\u6d41\u884c; (4) H5N1\u8207H7N9\u6d41\u611f\u75c5\u6bd2\u7686\u5c0d\u65bc\u9ce5\u79bd\u985e\u70ba\u9ad8\u81f4\u75c5\u6027\u53ca\u9ad8\u81f4\u6b7b\u7387\u611f\u67d3; (5) H7N9\u8207H5N1\u5927\u90e8\u4efd\u75c5\u6bd2\u682a\u5c0d\u73fe\u884c\u85e5\u7269neuraminidase inhibitor\uff08\u5982oseltamivir\uff09\u5177\u6709\u611f\u53d7\u6027\uff0c\u800c\u5c0damantadine\u5247\u5177\u6709\u6297\u85e5\u6027\u3002\nA. (2)+(4)+(5)\nB. (3)+(4)+(5)\nC. (1)+(2)+(3)\nD. (1)+(3)+(5)\nE. (2)+(3)+(4)\n": "(E)", "104-14.\n\u5728\u53f0\u7063\uff0c\u4e0b\u5217\u75be\u75c5\u8207\u6297\u751f\u7d20\u6cbb\u7642\u9078\u64c7\u4e4b\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u662f\u6070\u7576\u4e4b\u6cbb\u7642\u9078\u64c7\uff1f(1) Actinomycosis - Cephalexin ;  (2) Nocardiosis - Trimethoprim\uff0fsulfamethoxazole ; (3) Listeria monocytogenes infection - ceftriaxone ; (4) Cat-scratch disease - azithromycin ; (5) Legionellosis - Azithromycin\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (2)+(4)+(5)\nD. (3)+(4)+(5)\nE. (1)+(4)+(5)\n": "(C)", "104-15.\n\u4e0b\u5217\u6709\u95dcVaricella-zoster virus (VZV)\u75c5\u6bd2\u611f\u67d3\u6216\u9810\u9632\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba?  (1) \u6b64\u75c5\u6bd2\u70ba\u96d9\u80a1DNA\u75c5\u6bd2\uff0c\u521d\u6b21\u611f\u67d3\u9014\u5f91\u4e3b\u8981\u70ba\u547c\u5438\u9053\u50b3\u64ad; (2) \u521d\u6b21\u611f\u67d3\u5f8c\u6f5b\u4f0f\u5728\u810a\u9ad3\u80cc\u6839\u795e\u7d93(dorsal root ganglia)\uff0c\u6613\u5fa9\u767c\u65bc\u80f8\u690e\u81f3\u8170\u690e\u76ae\u7bc0; (3) \u5927\u65bc60\u6b72\u8005\uff0c\u82e5\u63a5\u53d7VZV\u75ab\u82d7\uff0c\u53ef\u6e1b\u5c11\u5e36\u72c0\u76b0\u75b9\u7684\u767c\u751f\u53ca\u6e1b\u8f15\u76b0\u75b9\u5f8c\u7684\u795e\u7d93\u75bc\u75db(post-herpetic neuralgia); (4) \u5c0d\u65bc\u56b4\u91cd\u514d\u75ab\u4e0d\u5168\u60a3\u8005\uff08\u5982\u5668\u5b98\u79fb\u690d\u60a3\u8005\uff09\uff0c\u767c\u751f\u6c34\u75d8\u6216\u5e36\u72c0\u76b0\u75b9\u7686\u61c9\u6cbb\u7642\uff0c\u975c\u6ce8Acyclovir\u53ef\u964d\u4f4e\u5167\u81df\u4fb5\u72af\u4e4b\u5408\u4f75\u75c7; (5) \u5e36\u72c0\u76b0\u75b9\u795e\u7d93\u75db\u5f88\u96e3\u6cbb\u7642\uff0c\u82e5\u8981\u4f7f\u7528\u985e\u56fa\u9187\uff0c\u5247\u61c9\u540c\u6642\u7528\u6297\u75c5\u6bd2\u85e5\u3002\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(2)+(5)\nD. (1)+(2)+(3)+(4)\nE. (1)+(2)+(3)+(4)+(5)\n": "(E)", "104-16.\n\u4e00\u4f4d38\u6b72\u53f0\u5546\u81ea\u5927\u9678\u8fd4\u53f0\u5f8c\uff0c\u767c\u73feHIV\u611f\u67d3\u53ca\u80ba\u90e8\u611f\u67d3M. tuberculosis\uff0c CD4\u6aa2\u67e5\u70ba100 cell/mm3\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1) \u9664\u7acb\u5373\u6295\u8207\u6297\u7d50\u6838\u85e5\u7269\u5916\uff0c\u4ea6\u61c9\u540c\u6642\u958b\u59cbhighly active anti-retroviral therapy (HAART);  (2) \u60a3\u8005\u6b64\u6642\u5df2\u662fAIDS ; (3) \u7acb\u5373\u6295\u8207\u6297\u7d50\u6838\u85e5\u7269\uff0c\u4e26\u5c07\u60a3\u8005\u8f49\u81f3\u8ca0\u58d3\u9694\u96e2\u75c5\u623f; (4) \u60a3\u8005\u9700\u5118\u5feb\u63a5\u53d7\u6297\u75c5\u6bd2\u85e5\u7269\u6cbb\u7642\uff0c\u6539\u5584\u514d\u75ab\u7cfb\u7d71; (5) \u60a3\u8005\u5148\u63a5\u53d7\u81f3\u5c116\u500b\u6708\u6297\u7d50\u6838\u85e5\u7269\u6cbb\u7642\u5f8c\uff0c\u624d\u80fd\u958b\u59cb\u63a5\u53d7\u6297\u75c5\u6bd2\u85e5\u7269\u6cbb\u7642\u3002\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (2)+(3)\nE. (2)+(3)+(5)\n": "(D)", "104-17.\n\u6709\u95dc\u4f0a\u6ce2\u62c9\u75c5\u6bd2\u611f\u67d3\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u521d\u671f\u75c7\u72c0\u70ba\u7a81\u7136\u51fa\u73fe\u9ad8\u71d2\u3001\u56b4\u91cd\u5026\u6020\u3001\u808c\u8089\u75db\u3001\u982d\u75db\u8207\u54bd\u5589\u75db\u7b49\uff0c\u63a5\u8457\u51fa\u73fe\u5614\u5410\u3001\u8179\u7009\u3001\u76ae\u819a\u6591\u9ede\u72c0\u4e18\u75b9\u8207\u51fa\u8840\u73fe\u8c61\u3002\u91cd\u75c7\u8005\u5e38\u4f34\u6709\u809d\u81df\u53d7\u640d\u3001\u814e\u8870\u7aed\u3001\u4e2d\u6a1e\u795e\u7d93\u640d\u50b7\u3001\u4f11\u514b\u4f75\u767c\u591a\u91cd\u5668\u5b98\u8870\u7aed\u3002\nB. \u50b3\u67d3\u6e90\u4e3b\u8981\u70ba\u679c\u8760\nC. \u4e3b\u8981\u900f\u904e\u63a5\u89f8\u50b3\u67d3\uff0c\u4eba\u8207\u4eba\u4e4b\u50b3\u67d3\u662f\u56e0\u76f4\u63a5\u63a5\u89f8\u5230\u88ab\u611f\u67d3\u8005\u6216\u5176\u5c4d\u9ad4\u4e4b\u8840\u6db2\u3001\u5206\u6ccc\u7269\u3001\u5668\u5b98\u3001\u7cbe\u6db2\uff1b\u6216\u662f\u9593\u63a5\u63a5\u89f8\u88ab\u611f\u67d3\u8005\u9ad4\u6db2\u6c61\u67d3\u7684\u74b0\u5883\u800c\u611f\u67d3\uff0c\u4e14\u5e38\u898b\u6709\u7a7a\u6c23\u5fae\u7c92(aerosols)\u50b3\u64ad\u6848\u4f8b\u3002\nD. \u91ab\u8b77\u4eba\u54e1\u88ab\u611f\u67d3\u4e4b\u60c5\u6cc1\u5728\u975e\u6d32\u9817\u70ba\u5e38\u898b\uff0c\u4e3b\u8981\u662f\u56e0\u70ba\u91ab\u8b77\u4eba\u54e1\u7167\u9867\u75c5\u60a3\u6642\u672a\u9075\u5b88\u9069\u7576\u7684\u9632\u8b77\u63aa\u65bd\uff08\u5982\u6d17\u624b\u3001\u914d\u6234\u6a19\u6e96\u9632\u8b77\u88dd\u5099\u7b49\uff09\u3002\nE. \u4f0a\u6ce2\u62c9\u75c5\u6bd2\u76ee\u524d (up to March 2015) \u5c1a\u7121\u78ba\u5b9a\u6709\u6548\u4eba\u7528\u75ab\u82d7\u53ef\u4f9b\u9810\u9632\u63a5\u7a2e\u3002\n": "(C)", "104-18.\n\u6709\u95dc\u6d41\u611f\u91cd\u75c7\u597d\u767c\u5c0d\u8c61\u548c\u793e\u5340\u611f\u67d3\u80ba\u708e\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(1) \u6d41\u611f\u91cd\u75c7\u597d\u767c\u65bc\u51fa\u751f\u52304\u6b72\u7684\u5152\u7ae5; (2) \u6d41\u611f\u91cd\u75c7\u597d\u767c\u65bc\u5b55\u5a66;  (3) \u6d41\u611f\u91cd\u75c7\u597d\u767c\u65bc65\u6b72\u4ee5\u4e0a\u6709\u6162\u6027\u5fc3\u80ba\u75be\u75c5\u8005; (4) \u793e\u5340\u611f\u67d3\u80ba\u708e\u7531\u80ba\u708e\u93c8\u7403\u83cc\u9020\u6210\u8005\u5e74\u9f61\u6108\u5927\u767c\u751f\u7387\u6108\u9ad8\uff0c\u800c\u975e\u5178\u578b\u80ba\u708e\uff08\u9ef4\u6f3f\u83cc\u3001\u62ab\u8863\u83cc\u548c\u9000\u4f0d\u8ecd\u4eba\u83cc\uff09\u5247\u597d\u767c\u65bc\u5c0f\u5b69; (5)\u9020\u6210\u56b4\u91cd\u793e\u5340\u611f\u67d3\u80ba\u708e\u4e3b\u8981\u81f4\u75c5\u539f\u662f\u80ba\u708e\u93c8\u7403\u83cc\u548c\u9000\u4f0d\u8ecd\u4eba\u83cc\u3002\nA. (1)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(5)\nC. (1)+(2)+(3)+(4)\nD. (2)+(3)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(B)", "104-19.\n\u4ee5\u4e0b\u6709\u95dc\u6297\u5fae\u751f\u7269\u88fd\u5291\u4e4b\u526f\u4f5c\u7528\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Vancomycin\u975c\u8108\u6ce8\u5c04\u82e5\u592a\u5feb\u53ef\u80fd\u5c0e\u81f4Red man syndrome\nB. Fluoroquinolones\u82e5\u7528\u65bc\u4f7f\u7528\u6297\u5fc3\u5f8b\u4e0d\u6574\u85e5\u7269\u7684\u60a3\u8005\u6216\u96fb\u89e3\u8cea\u4e0d\u5e73\u8861\u8005\uff0c\u61c9\u7559\u610fQTc\u5ef6\u9577\u4e4b\u4e0d\u826f\u53cd\u61c9\u3002\nC. \u964d\u4f4eaminoglycoside\u814e\u6bd2\u6027\u7684\u65b9\u5f0f\u662f\u63a1\u4e00\u65e5\u591a\u6b21\u5291\u91cf\u7d66\u4e88\u3002\nD. Amphotericin B\u6700\u4e3b\u8981\u7684\u526f\u4f5c\u7528\u662f\u814e\u6bd2\u6027\uff0c\u6bcf\u6b21\u8f38\u6ce8\u524d\u5404\u7d66\u4e88500ml\u751f\u7406\u98df\u9e7d\u6c34\u53ca\u6e1b\u7de9\u8f38\u6ce8\u901f\u5ea6\u53ef\u964d\u4f4e\u526f\u4f5c\u7528\u3002\nE. Terbinafine\u7528\u65bc\u6cbb\u7642\u7532\u766c\uff0c\u6709\u6642\u9020\u6210\u56b4\u91cd\u85e5\u7269\u6027\u809d\u708e\uff0c\u5c0d\u65bc\u809d\u814e\u75be\u75c5\u60a3\u8005\u61c9\u907f\u514d\u4f7f\u7528\u3002\n": "(C)", "105-1.\n\u4e00\u4f4d20\u6b72\u7537\u6027\u65bc\u4e8c\u9031\u524d\u81f3\u91d1\u9580\u65c5\u904a\uff0c4\u5929\u524d\u958b\u59cb\u51fa\u73fe\u767c\u71d2\u3001\u982d\u75db\u3001\u76ae\u819a\u75b9\uff0c\u4e26\u65bc\u8179\u90e8\u767c\u73fe\u6709\u4e00\u75c5\u7076(\u5982\u5716)\uff0c\u6b64\u6642\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6b64\u70baScrub typus\uff0c\u75c5\u539f\u9ad4\u70baOrientia tsutsugamushi\u3002\nB. Serology\u662f\u826f\u597d\u7684\u8a3a\u65b7\u5de5\u5177\uff1b\u4e5f\u53ef\u6aa2\u9a57\u4e0a\u8ff0\u75c5\u7076\u505a\u6838\u9178(PCR)\u5206\u6790\u8a3a\u65b7\u3002\nC. \u81e8\u5e8a\u75c7\u72c0\u767c\u751f\u5728\u88abChigger\u53ee\u54ac\u5f8c6\u81f321\u5929(\u6f5b\u4f0f\u671f)\u3002\nD. \u6b64\u75c5\u539f\u611f\u67d3\u7684\u6b7b\u4ea1\u7387\u7d04\u70ba25%\u81f330%\u3002\nE. \u75be\u75c5\u7684\u65e9\u671f\uff0c\u6703\u51fa\u73fe\u76f8\u5c0d\u6027\u7de9\u8108(relative bradycardia)\u3002\n": "(D)", "105-2.\n\u4e0b\u5217\u95dc\u65bcHIV\u611f\u67d3\u8207\u816b\u7624\u7684\u95dc\u4fc2\u4f55\u8005\u932f\u8aa4\uff1f\nA. Kaposi\u2019s sarcoma\u8207Human Herpes virus \u2013 8(HHV-8)\u7684\u611f\u67d3\u6709\u95dc\u3002\nB. Anogenital carcinoma\u8207Human papilloma virus(HPV)\u7684\u611f\u67d3\u6709\u95dc\u3002\nC. Primary CNS lymphoma(\u539f\u767c\u6027\u4e2d\u6a1e\u795e\u7d93\u6dcb\u5df4\u7624)\u8207Epstein-Barr virus ( EBV )\u7684\u611f\u67d3\u6709\u95dc\u3002\nD. Burkitt\u2019s lymphoma\u8207Cytomegalovirus ( CMV )\u7684\u611f\u67d3\u6709\u95dc\u4fc2\u3002\nE. HIV\u611f\u67d3\u76f8\u95dc\u4e4blymphoma\u4e3b\u8981\u662fB cell lymphoma\u3002\n": "(D)", "105-3.\n\u4e00\u4f4d50\u6b72\u7537\u6027\uff0c\u65bc9\u500b\u6708\u524d\u56e0sick sinus sysdrome\u63a5\u53d7\u5fc3\u5f8b\u8abf\u7bc0\u5668(CIED, Cardiovascular implantable electronic device )\u690d\u5165\uff0c\u60c5\u6cc1\u7a69\u5b9a\uff0c\u4f46\u6700\u8fd1\u56e0\u53cd\u8986\u767c\u71d2\u5df2\u56db\u9031\u800c\u4f4f\u9662\u3002\u4f4f\u9662\u8840\u6db2\u57f9\u990a\u5169\u5957\u7686\u6709\u7d30\u83cc\u9577\u51fa\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u767c\u73fe\u5fc3\u5f8b\u8abf\u7bc0\u5668wire\u7684\u524d\u7aef\u6709vegetation\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u8840\u6db2\u57f9\u990a\u83cc\u682a\u7a2e\u985e\uff1f\nA. Staphylococcus aureus\nB. Viridans streptococcus\nC. Staphylococcus epidermidis\nD. Enterococcus faecalis\nE. Escherichia coli\n": "(C)", "105-4.\n\u4e0b\u5217\u6297\u5fae\u751f\u7269\u88fd\u5291\u8207\u526f\u4f5c\u7528\u4e4b\u7d44\u5408\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. Daptomycin \u2013 Myopathy (\u808c\u8089\u75c5\u8b8a)\nB. Chloramphenicol \u2013 Aplastic anemia (\u518d\u751f\u4e0d\u80fd\u6027\u8ca7\u8840 )\nC. Amikacin - Hepatic failure (\u809d\u8870\u7aed)\nD. Tetracycline - Photosensitivity (\u5149\u654f\u611f\u75c7)\nE. Metronidazole \u2013 Peripheral neuropathy (\u5468\u908a\u795e\u7d93\u75c5\u8b8a)\n": "(C)", "105-5.\n\u6709\u95dc\u91ab\u7642\u7167\u8b77\u4eba\u54e1\u9810\u9632\u63a5\u7a2e\u5efa\u8b70\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u73fe\u884c\u5efa\u8b70\u9700\u6ce8\u5c04\u7684\u75ab\u82d7\uff1f\nA. \u75f2\u75b9 - \u816e\u817a\u708e - \u5fb7\u570b\u9ebb\u75b9\u75ab\u82d7 ( Measles-Mumps-Rubella vaccine )\nB. \u6d41\u884c\u6027\u611f\u5192\u75ab\u82d7 ( Influenza vaccine )\nC. \u72c2\u72ac\u75c5\u75ab\u82d7 ( Rabies vaccine )\nD. B\u578b\u809d\u708e\u75ab\u82d7 ( Hepatitis B vaccine )\nE. \u6c34\u75d8\u75ab\u82d7 ( Chickenpox vaccine)\n": "(C)", "105-6.\nClostridium difficile\u611f\u67d3\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. C. difficile\u662f\u4e0d\u6703\u7522\u751f\u5b62\u5b50\u7684\u9769\u862d\u6c0f\u967d\u6027\u687f\u83cc\uff0c\u654570%\u9152\u7cbe\u5177\u6709\u6b64\u83cc\u826f\u597d\u4e4b\u6bba\u83cc\u529b\u3002\nB. \u4ee5\u5927\u8178\u93e1\u6aa2\u67e5\u507d\u819c\u6027\u8178\u708e(Pseudomembranous colitis)\u4e4b\u654f\u611f\u6027\u5f88\u9ad8\uff0c\u56e0\u6b64\u8178\u93e1\u6aa2\u67e5\u82e5\u7121\u51fa\u73fe\u75c5\u7076\u5247\u53ef\u6392\u9664\u6b64\u8a3a\u65b7\u3002\nC. \u81f4\u75c5\u529b\u53ef\u80fd\u548cToxin A\u548cToxin B\u76f8\u95dc\uff0ctoxin A\u662fcytotoxin, toxin B\u662fenterotoxin\u3002\nD. \u5c0d\u65bc\u9996\u6b21\u8f15\u5ea6C. difficile\u8178\u708e\uff0c\u9996\u9078\u6cbb\u7642\u85e5\u7269\u70ba\u53e3\u670dmetronidaozle\u6cbb\u764210\u523014\u5929\u3002\nE. \u5c0d\u65bc\u9996\u6b21C. difficile\u8178\u708e\u91cd\u5ea6\u60a3\u8005\uff0c\u9996\u9078\u6cbb\u7642\u85e5\u7269\u70ba\u91dd\u5291vancomycin\u6cbb\u764210\u523014\u5929\u3002\n": "(D)", "105-7.\n\u4e00\u4f4d40\u6b72\u7537\u6027\u51fa\u570b\u81f3\u4e2d\u6771\u9ea5\u52a0\u53c3\u52a0\u56de\u6559\u671d\u8056\u4e4b\u65c5\uff0c\u65c5\u904a\u4e2d\u4e26\u6709\u751f\u98f2\u99f1\u99dd\u5976\uff0c\u8fd4\u570b\u5f8c\u51fa\u73fe\u767c\u71d2\u53ca\u547c\u5438\u5598\uff0c\u80f8\u90e8X\u5149\u51fa\u73fe\u5169\u5074\u4e0b\u8449\u6d78\u6f64\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8a62\u554f\u51fa\u570b\u65c5\u904a\u53f2\uff0c\u82e5\u5728\u4e2d\u6771\u5730\u5340\u96e2\u958b\u5f8c14\u5929\u4e4b\u5167\u767c\u71d2\uff0c\u81e8\u5e8a\u53ca\u5f71\u50cf\u6aa2\u67e5\u8a3a\u65b7\u80ba\u708e\uff0c\u61c9\u65bc24\u5c0f\u6642\u5167\u901a\u5831\u4e2d\u6771\u547c\u5438\u75c7\u72c0\u7fa4\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7(MERS - CoV)\u3002\nB. \u4e2d\u6771\u547c\u5438\u75c7\u72c0\u7fa4\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7\u5c6c\u65bc\u7b2c\u4e94\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u5df2\u6709\u51fa\u73fe\u5c40\u9650\u6027\u4eba\u50b3\u4eba\u7684\u7fa4\u805a\u611f\u67d3\u4e8b\u4ef6\u3002\nC. \u4e2d\u6771\u547c\u5438\u75c7\u72c0\u7fa4\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7\u81e8\u5e8a\u8868\u73fe\u5305\u62ec\u767c\u71d2\u3001\u54b3\u55fd\u3001\u547c\u5438\u6025\u4fc3\u8207\u547c\u5438\u56f0\u96e3\u3001\u901a\u5e38\u6703\u6709\u80ba\u708e\uff0c\u90e8\u5206\u75c5\u4eba\u6703\u51fa\u73fe\u814e\u8870\u7aed\u3001\u5fc3\u5305\u819c\u708e\u3001\u8840\u7ba1\u5167\u7030\u6f2b\u6027\u51dd\u8840(DIC)\u6216\u6b7b\u4ea1\u3002\nD. \u4e2d\u6771\u547c\u5438\u75c7\u72c0\u7fa4\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7\u4f4f\u9662\u91cd\u75c7\u6cbb\u7642\u75c5\u60a3\u6b7b\u4ea1\u7387\u7d04\u70ba10%\u81f312%\u3002\nE. \u76ee\u524d\u4e2d\u6771\u547c\u5438\u75c7\u72c0\u7fa4\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7\u4ecd\u7121\u81e8\u5e8a\u8a66\u9a57\u8b49\u5be6\u6709\u6548\u6cbb\u7642\u4e4b\u85e5\u7269\u53ca\u75ab\u82d7\uff0c\u6cbb\u7642\u4e3b\u8981\u4ee5\u652f\u6301\u6027\u7642\u6cd5\u70ba\u4e3b\u3002\n": "(D)", "105-8.\n\u6709\u95dc\u9000\u4f0d\u8ecd\u4eba\u75c7(Legionellosis)\uff0c\u4e0b\u5217\u4f55\u8005\u6558\u8ff0\u70ba\u975e\uff1f\nA. Legionella\u662f\u55dc\u6c27\u9769\u862d\u6c0f\u9670\u6027\u687f\u83cc\uff0c\u4e3b\u8981\u662fLegionella pneumophila\u8207\u4eba\u985e\u611f\u67d3\u6709\u95dc\u3002\nB. \u50b3\u67d3\u65b9\u5f0f\u662f\u98db\u6cab\u50b3\u67d3\uff0c\u901a\u5e38\u7d93\u7531\u5438\u5165\u53d7\u6c59\u67d3\u6c34\u6e90\u800c\u81f4\u75c5\uff0c\u6f5b\u4f0f\u671f\u70ba2\u81f310\u5929\u3002\nC. \u514d\u75ab\u529b\u4f4e\u4e0b\u611f\u67d3\u75c5\u4eba\u5bb9\u6613\u611f\u67d3\uff0c\u4f7f\u752810\u81f314\u5929\u7b2c\u4e09\u4ee3\u982d\u5b62\u5b50\u7d20(\u5982Ceftriaxone)\u53ef\u6709\u6548\u6cbb\u7642\u3002\nD. \u91ab\u9662\u4f9b\u6c34\u7cfb\u7d71\u4e2d\u767c\u73fe\u8a72\u75c5\u83cc\u6642\uff0c\u53ef\u85c9\u4e8c\u6c27\u5316\u6c2f(chlorine dioxide)\u6d88\u6bd2\uff0c\u6216\u9285-\u9280\u96e2\u5b50\u4ea4\u63db(copper-silver ionization)\u9032\u884c\u6d88\u6bd2\u3002\nE. Legionella\u53ef\u9020\u6210\u80ba\u5916\u611f\u67d3\uff0c\u5982\u8179\u819c\u708e\u6216\u814e\u76c2\u814e\u708e\u3002\n": "(C)", "105-9.\n\u6709\u95dc\u61f7\u5b55\u6642\u671f\u4f7f\u7528\u6297\u751f\u7d20\uff0c\u4e0b\u5217\u4f55\u8005\u5c6c\u65bcPregnancy category D\uff0c\u4e0d\u5efa\u8b70\u4f7f\u7528\uff1f\nA. Azithromycin\nB. Clindamycin\nC. Metronidazole\nD. Vancomycin\nE. Sulfonamide\n": "(E)", "105-10.\n\u6709\u95dc\u8332\u5361\u75c5\u6bd2(Zika virus)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u8332\u5361\u75c5\u6bd2\u8207\u767b\u9769\u71b1\u75c5\u6bd2\u540c\u5c6c\u65bc\u9ec3\u75c5\u6bd2\u79d1(Flaviviridae)\uff0c\u6f5b\u4f0f\u671f\u7d043\u81f37\u5929(\u6700\u9577\u7d0412\u65e5)\u3002\nB. \u53f0\u7063\u75be\u75c5\u7ba1\u5236\u7f72\u516c\u5e03\u8332\u5361\u75c5\u6bd2\u5c6c\u65bc\u7b2c\u4e94\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u970024\u5c0f\u6642\u5167\u901a\u5831\u3002\nC. \u8332\u5361\u75c5\u6bd2\u4ea6\u53ef\u85c9\u7531\u6027\u884c\u70ba\u6216\u8f38\u8840\u611f\u67d3\u3002\nD. \u75c5\u5a92\u868a\u4e3b\u8981\u70ba\u71b1\u5e36\u5bb6\u868a\u8207\u74b0\u7d0b\u5bb6\u868a\u50b3\u64ad\u3002\nE. \u5b55\u5a66\u611f\u67d3\u6b64\u75c5\u6bd2\u53ef\u80fd\u7531\u6bcd\u5b50\u5782\u76f4\u611f\u67d3\u9020\u6210\u80ce\u5152\u51fa\u751f\u5c0f\u982d\u7578\u578b\u75c7\u3002\n": "(D)", "105-11.\n\u6709\u95dc\u6297\u751f\u7d20 - \u6709\u6548\u6cbb\u7642(\u75be\u75c5/\u81f4\u75c5\u539f)-\u6291\u83cc/\u6bba\u83cc\u6a5f\u8f49\u4e4b\u914d\u5c0d\uff0c\u4e0b\u5217\u5404\u7d44\u5408\u4f55\u8005\u70ba\u975e\uff1f\nA. Penicillin \u2013 Syphilis \u2013 \u7d30\u80de\u58c1\u5408\u6210\u6291\u5236\u3002\nB. Clarithromycin \u2013 Legionella \u2013 50S ribosome\u86cb\u767d\u8cea\u5408\u6210\u6291\u5236\u3002\nC. Levofloxacin \u2013 Pseudomonas aeruginosa \u2013 30S ribosome\u86cb\u767d\u8cea\u5408\u6210\u6291\u5236\u3002\nD. Dapomycin \u2013 Staphylococcus aureus \u2013 \u7d30\u80de\u819c\u6291\u5236\u3002\nE. Polymyxin \u2013 Acinetobacter baumannii \u2013 \u7d30\u80de\u819c\u6291\u5236\u3002\n": "(C)", "105-12.\n\u6aa2\u6e2c\u6f5b\u96b1\u6027(latent)\u7d50\u6838\u75c5\u5e38\u7528\u7684\u65b9\u6cd5\u6709\u7d50\u6838\u83cc\u7d20\u76ae\u819a\u8a66\u9a57(Mantoux tuberculin skin test, TST)\u548c\u4e19\u578b\u5e72\u64fe\u7d20\u91cb\u51fa\u5206\u6790(interferon-\u03b3 release assays, IGRAs)\uff0c\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba?\r1. IGRAs\u53ef\u9451\u5225\u6d3b\u52d5\u6027\u611f\u67d3\u548c\u6f5b\u96b1\u6027\u611f\u67d3\uff0c\u800cTST\u5247\u53ea\u53ef\u5075\u6e2c\u6f5b\u96b1\u6027\u611f\u67d3\u3002\r2. TST\u5047\u967d\u6027\u53ef\u767c\u751f\u65bc\u975e\u7d50\u6838\u5206\u679d\u687f\u83cc\u611f\u67d3\u6216\u66fe\u63a5\u7a2e\u5361\u4ecb\u82d7\u8005\u3002\r3. IGRAs\u5728\u8a3a\u65b7\u7d50\u6838\u611f\u67d3\u7684\u5c08\u4e00\u6027\u548c\u654f\u611f\u6027\u7686\u9ad8\u65bcTST\u3002\r4. IGRAs\u6bd4TST\u66f4\u9069\u5408\u7528\u65bc\u66fe\u63a5\u7a2e\u5361\u4ecb\u82d7\u8005\u3002\r5. \u5728\u5075\u6e2c\u6f5b\u96b1\u6027\u7d50\u6838\uff0c\u7576TST\u6216IGRAs\u967d\u6027\u6642\uff0c\u5fc5\u9808\u8a55\u4f30\u662f\u5426\u6709\u6d3b\u52d5\u6027\u7d50\u6838\u611f\u67d3\u3002\nA. 1+2+3\nB. 2+3+4\nC. 2+4+5\nD. 3+4+5\nE. 1+4+5\n": "(C)", "105-13.\n\u9810\u9632\u6d41\u884c\u6027\u611f\u5192\u75c5\u6bd2\u611f\u67d3\u53ca\u5176\u5408\u4f75\u75c7\u6700\u6709\u6548\u7684\u65b9\u6cd5\u662f\u75ab\u82d7\u63a5\u7a2e\uff0c\u4e00\u822c\u5efa\u8b70\u6240\u67096\u500b\u6708\u4ee5\u4e0a\u7684\u4eba\u7686\u53ef\u63a5\u7a2e\uff0c\u4ee5\u4e0b\u6709\u95dc\u6211\u570b\u5b63\u7bc0\u6027\u6d41\u611f\u75ab\u82d7\u572865\u6b72\u4ee5\u4e0a\u8001\u4eba\u53ca\u5168\u4eba\u53e3\u4e4b\u6bcf\u5e74\u65bd\u6253\u7387\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\nA. 65\u6b72\u4ee5\u4e0a\u8001\u4eba\u65bd\u6253\u7387\u7d0480%\uff0c\u5168\u4eba\u53e3\u65bd\u6253\u7387\u7d0450%\nB. 65\u6b72\u4ee5\u4e0a\u8001\u4eba\u65bd\u6253\u7387\u7d0460%\uff0c\u5168\u4eba\u53e3\u65bd\u6253\u7387\u7d0440%\nC. 65\u6b72\u4ee5\u4e0a\u8001\u4eba\u65bd\u6253\u7387\u7d0440%\uff0c\u5168\u4eba\u53e3\u65bd\u6253\u7387\u7d0415-20%\nD. 65\u6b72\u4ee5\u4e0a\u8001\u4eba\u65bd\u6253\u7387\u7d0430%\uff0c\u5168\u4eba\u53e3\u65bd\u6253\u7387<10%\nE. \u4ee5\u4e0a\u7686\u4e0d\u6b63\u78ba\n": "(C)", "105-14.\n\u4e00\u4f4d80\u6b72\u5973\u6027\u4f4f\u5728\u5b89\u990a\u9662\uff0c\u5979\u534a\u5e74\u524d\u56e0\u4e2d\u98a8\u800c\u958b\u59cb\u88ab\u7f6e\u653e\u5c0e\u5c3f\u7ba1\uff0c\u6700\u8fd1\u56e0\u6d41\u9f3b\u6c34\u3001\u54b3\u55fd\u53ca\u8f15\u5fae\u767c\u71d2\u88ab\u9001\u5230\u6025\u8a3a\u5ba4\uff0c\u7d66\u4e88\u75c7\u72c0\u6027\u6cbb\u7642\u5f8c\u9001\u56de\u5b89\u990a\u9662\uff0c\u75c5\u4eba\u57284\u5929\u5f8c\u88ab\u5e36\u56de\u9580\u8a3a\u8ffd\u8e64\uff0c\u6b64\u6642\u75c5\u4eba\u53ea\u6709\u8f15\u5fae\u54b3\u55fd\uff0c\u6c92\u767c\u71d2\uff0c\u9935\u98df\u60c5\u6cc1\u826f\u597d\uff0c\u800c\u5728\u6025\u8a3a\u5ba4\u6240\u505a\u5c3f\u57f9\u990a\u6709Vancomycin\u6297\u85e5\u6027\u8178\u7403\u83cc\uff0c\u8acb\u554f\u6b64\u6642\u5982\u4f55\u6cbb\u7642?\nA. \u7d66\u4e88Linezolid\nB. \u7d66\u4e88Ciprofloxacin\nC. \u7d66\u4e88Daptomycin\nD. \u7d66\u4e88Amoxicillin\nE. \u4ee5\u4e0a\u7686\u975e\n": "(E)", "105-15.\n\u4e00\u4f4d49\u6b72\u7537\u6027\u56e0\u767c\u71d2\u7531A\u91ab\u9662\u8f49\u4f86\uff0c\u4ed6\u66fe\u5728A\u91ab\u9662\u63a5\u53d7\u6aa2\u67e5\u4e26\u63a5\u53d7Ceftriaxone\u53caDoxycycline\u6cbb\u7642\u4e00\u9031\uff0c\u56e0\u672a\u9000\u71d2\u4e14\u8840\u6db2\u57f9\u990a\u5831\u544a\u9670\u6027\uff0c\u5728A\u91ab\u9662\u7cde\u4fbf\u57f9\u990a\u6709MRSA\u3002\u75c5\u4eba\u8f49\u4f86\u6642\u8840\u58d3140/80mmHg\uff0c\u5fc3\u8df378/min\uff0c\u547c\u543818/min\uff0c\u9ad4\u6eab38\u2103\uff0c\u521d\u6b65\u6aa2\u67e5\u4e26\u672a\u767c\u73fe\u611f\u67d3\u90e8\u4f4d\uff0c\u8acb\u554f\u9019\u6642\u8a72\u4ec0\u9ebc\u6297\u751f\u7d20?\nA. Fusidic acid\nB. Sulfamethoxazole-Trimethoprim\nC. Vancomycin\nD. Linezolid\nE. \u4e0d\u4f7f\u7528\u6297\u751f\u7d20\n": "(E)", "105-16.\n\u4ee5\u4e0b\u4f55\u8005\u4e0d\u662f\u4eba\u985e\u514d\u75ab\u7f3a\u4e4f\u75c5\u6bd2(HIV)\u611f\u67d3\u4e4b\u9ad8\u5371\u96aa\u8005?\nA. \u975c\u8108\u85e5\u766e\u8005\nB. \u6709\u6885\u6bd2\u6216\u5176\u4ed6\u6027\u50b3\u67d3\u75c5\u8005\nC. \u591a\u91cd\u6027\u4f34\u4fb6\u8005\nD. \u5e74\u8f15\u7d50\u6838\u75c5\u60a3\u8005\nE. \u4ee5\u4e0a\u7686\u662f\u9ad8\u5371\u96aa\u8005\n": "(E)", "105-17.\nWHO 2009\u5e74\u7248\u7684\u767b\u9769\u71b1\u5206\u985e\u53ca\u6cbb\u7642\u6307\u5f15\u4e3b\u8981\u5728\u63d0\u4f9b\u75ab\u5340\u91ab\u7642\u4eba\u54e1\u5c0d\u75c5\u60a3\u7684\u8a55\u4f30\u53ca\u6309\u81e8\u5e8a\u75c5\u60c5\u8f15\u91cd\u5206\u7d1a\u5206\u6d41\uff0c\u4ee5\u6709\u6548\u6cbb\u7642\u53ca\u8655\u7406\u75c5\u4eba\u3002\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u932f?\nA. \u5c07\u75c5\u4eba\u5206\u985e\u70baGroup A\u3001B\u548cC\uff0c\u800c\u4e0d\u518d\u5340\u5206\u767b\u9769\u71b1\u8207\u767b\u9769\u51fa\u8840\u71b1\u3002\nB. Group B\u75c5\u4eba\u70ba\u6709\u300c\u8b66\u793a\u5fb5\u8c61\u300d(\u5982\u8179\u90e8\u75bc\u75db\u3001\u9ad4\u6db2\u84c4\u7a4d\u3001\u9ecf\u819c\u51fa\u8840\u3001\u55dc\u7761\u3001\u8e81\u52d5\u4e0d\u5b89\u3001\u809d\u816b\u5927\u53ca\u8840\u6bd4\u5bb9\u503c\u589e\u52a0\u4f34\u96a8\u8840\u5c0f\u677f\u6025\u901f\u4e0b\u964d)\u6216\u6709\u6f5b\u5728\u75be\u75c5\u6216\u9867\u53ca\u7279\u5b9a\u793e\u7d93\u72c0\u6cc1\uff0c\u9700\u4f4f\u9662\u6cbb\u7642\u3002\nC. Group C\u75c5\u4eba\u70ba\u6709\u56b4\u91cd\u8840\u6f3f\u6ef2\u6f0f\u5c0e\u81f4\u767b\u9769\u4f11\u514b\u75c7\u5019\u7fa4\u6216\u9ad4\u6db2\u84c4\u7a4d\u4f34\u96a8\u547c\u5438\u7a98\u8feb\u3001\u56b4\u91cd\u51fa\u8840\u3001\u56b4\u91cd\u5668\u5b98\u640d\u50b7\uff0c\u9700\u7dca\u6025\u8f49\u9001\u5230\u8a2d\u5099\u5b8c\u5584\u4e4b\u91ab\u9662\u6216\u5165\u4f4f\u52a0\u8b77\u75c5\u623f\u3002\nD. Group A\u53caGroup B\u9ad4\u6db2\u88dc\u5145\u9f13\u52f5\u53e3\u670d\uff0c\u82e5\u9700\u975c\u8108\u8f38\u6db2\u5247\u4ee5\u751f\u7406\u9e7d\u6c34\u6216Ringer's lactate\u8f38\u6db224\u81f348\u5c0f\u6642\uff0c\u5728Group C\u75c5\u4eba\u6709\u4f4e\u8840\u58d3\u4f11\u514b\u6642\uff0c\u7528\u7b49\u5f35Crystalloid\u6216Colloid\u6eb6\u6db2\uff0c\u4ee520 ml/kg\u572815\u5206\u9418\u5167\u7d66\u4e88\uff0c\u884c\u7dca\u6025\u8f38\u6db2\u3002\nE. \u75c5\u4eba\u61c9\u907f\u514d\u4f7f\u7528aspirin\uff0c\u800c\u6539\u7528NSAID\u4f86\u6e1b\u8f15\u75c7\u72c0\uff0c\u7576\u8840\u5c0f\u677f\u4f4e\u65bc30000/cumm\uff0c\u5c31\u5fc5\u9808\u7acb\u5373\u8f38\u6ce8\u8840\u5c0f\u677f\u3002\n": "(E)", "105-18.\n\u4e0b\u5217\u6709\u95dcClostridium difficile\u611f\u67d3\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4?\nA. \u9810\u9632Clostridium difficile\u5b62\u5b50\u50b3\u64ad\u7684\u9662\u611f\u63aa\u65bd\u5305\u62ec\u6234\u624b\u5957\u3001\u7a7f\u9694\u96e2\u8863\u53ca\u4ee5\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u6d17\u624b\u3002\nB. \u78ba\u5b9a\u8a3a\u65b7Clostridium difficile-associated disease (CDAD)\u6240\u9020\u6210\u7684\u8179\u7009\u9700\u6aa2\u6e2c\u7cde\u4fbftoxin A\u548cB\uff0c\u6216\u8005\u7522\u751ftoxin\u7684\u57fa\u56e0\u3002\nC. CDAD\u75c5\u4eba\u7684\u8868\u73fe\u9664\u4e86\u8179\u7009\u5916\uff0c\u9084\u5305\u62ec\u767c\u71d2\u3001\u8179\u75db\u3001\u767d\u8840\u7403\u5347\u9ad8(leukocytosis)\u3002\nD. \u6cbb\u7642\u8f15\u5fae\u5230\u4e2d\u7b49\u56b4\u91cd\u5ea6CDAD\u7684\u85e5\u7269\u512a\u5148\u9078\u64c7\u70ba\u53e3\u670dmetronidazole 500 mg Q8h\uff0c\u4f7f\u752810\u81f314\u5929\u3002\nE. \u5927\u7d0420%\u7684CDAD\u75c5\u4eba\u6703\u767c\u751frecurrence\n": "(A)", "105-19.\n\u70ba\u964d\u4f4e\u91ab\u7642\u6a5f\u69cb\u5167\u591a\u91cd\u6297\u85e5\u6027\u75c5\u539f\u4e4b\u4ea4\u53c9\u611f\u67d3\uff0c\u97ff\u61c9\u4e16\u754c\u885b\u751f\u7d44\u7e54(WHO)\u4e4b\u5021\u5c0e\u91ab\u8b77\u4eba\u54e1\u624b\u90e8\u885b\u751f\u904b\u52d5\u3002\u6709\u95dc\u624b\u90e8\u885b\u751f\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r1. \u4f7f\u7528\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u9032\u884c\u624b\u90e8\u885b\u751f\uff0c\u5728\u6e05\u6f54\u6548\u679c\u3001\u4f7f\u7528\u6642\u6a5f\u3001\u82b1\u8cbb\u6642\u9593\u3001\u5c0d\u76ae\u819a\u7684\u5f71\u97ff\u3001\u5b89\u5168\u8003\u91cf\u53ca\u6d17\u624b\u9075\u5f9e\u6027\u7b49\u65b9\u9762\uff0c\u5747\u6bd4\u4f7f\u7528\u80a5\u7682\u6216\u6db2\u614b\u7682\u9032\u884c\u6fd5\u6d17\u624b\u7684\u6548\u679c\u70ba\u4f73\u3002\r2. WHO\u63a8\u52d5\u7684\u91ab\u8b77\u4eba\u54e1\u624b\u90e8\u885b\u751f\u904b\u52d5\uff0c\u5f37\u8abf\u91ab\u8b77\u4eba\u54e1\u5728\u624b\u90e8\u7121\u660e\u986f\u9ad2\u6c59\u6642\uff0c\u512a\u5148\u4f7f\u7528\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u6e05\u6f54\u624b\u90e8\u3002\r3. \u624b\u90e8\u6709\u660e\u986f\u9ad2\u6c59\u6216\u6cbe\u6709\u8840\u6db2/\u9ad4\u6db2\u6642\uff0c\u5efa\u8b70\u4f7f\u7528\u80a5\u7682\u548c\u6e05\u6c34\u4e4b\u6fd5\u6d17\u624b\u6280\u8853\u6d17\u624b20\u79d2\u3002\r4. \u70ba\u63d0\u9ad8\u624b\u90e8\u885b\u751f\u8a2d\u5099\u7684\u53ef\u8fd1\u6027\uff0cWHO\u5ba3\u5c0e\u5728\u7167\u8b77\u9ede\u666e\u904d\u8a2d\u7f6e\u6216\u96a8\u8eab\u651c\u5e36\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u3002\r5. \u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u5c0d\u8afe\u7f85\u75c5\u6bd2(norovirus)\u3001\u8178\u75c5\u6bd2\u7686\u6709\u5f88\u597d\u4e4b\u6d88\u6bd2\u6548\u679c\u3002\nA. 1+2+3+4+5\nB. 1+2+4\nC. 2+4+5\nD. 2+3+4\nE. 1+3+4\n": "(B)", "106-1.\n\u6709\u95dcClostridium difficile\u611f\u67d3\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u9664\u4e86\u57f7\u884c\u63a5\u89f8\u9694\u96e2\u9632\u8b77\uff0c\u7167\u8b77C. difficile\u611f\u67d3\u60a3\u8005\u4ee570%\u9152\u7cbe\u9032\u884c\u624b\u90e8\u885b\u751f\uff0c\u53ef\u5177\u6709\u826f\u597d\u4e4b\u6bba\u83cc\u529b\u3002\nB. \u4ee5\u5927\u8178\u93e1\u6aa2\u67e5\u507d\u819c\u6027\u8178\u708e(Pseudomembranous colitis)\u4e4b\u654f\u611f\u6027\u9ad8\u905490%\u4ee5\u4e0a\uff0c\u82e5\u8178\u93e1\u6aa2\u67e5\u7121\u51fa\u73fe\u75c5\u7076\u5247\u5e7e\u4e4e\u53ef\u4ee5\u6392\u9664\u6b64\u8a3a\u65b7\u3002\nC. \u4e3b\u8981\u81f4\u75c5\u529b\u548ctoxin A\u548ctoxin B\u76f8\u95dc\uff0ctoxin A\u662fcytotoxin, toxin B\u662fenterotoxin\uff0c\u5169\u8005\u555f\u52d5\u9020\u6210\u507d\u819c\u6027\u8178\u708e\u3002\nD. \u5c0d\u65bc\u8f15\u5ea6C. difficile\u611f\u67d3\u521d\u6b21\u767c\u4f5c\u8178\u708e\u60a3\u8005\uff0c\u9996\u9078\u6cbb\u7642\u975c\u8108\u6ce8\u5c04\u6216\u53e3\u670dmetronidazole 500 mg TID\u6cbb\u764210\u523014\u5929\u3002\nE. \u5c0d\u65bcC. difficile\u611f\u67d3\u53cd\u8986\u591a\u6b21\u767c\u4f5c\u8178\u708e\u60a3\u8005\uff0c\u9996\u9078\u6cbb\u7642\u70ba\u975c\u8108\u6ce8\u5c04vancomycin 500 mg Q6H\u6cbb\u764210\u523014\u5929\u3002\n": "(D)", "106-2.\n\u4e00\u540d\u7537\u5b50\u5728\u5927\u9678\u5de5\u4f5c\u6642\u56e0\u5916\u51fa\u906d\u91ce\u72ac\u54ac\u50b7\u8173\u8dbe\uff0c\u7576\u6642\u672a\u5c31\u91ab\uff0c\u4e00\u500b\u591a\u6708\u5f8c\u51fa\u73fe\u4e0b\u534a\u8eab\u7570\u5e38\u7662\u3001\u9ebb\u75db\u3001\u5614\u5410\u3001\u541e\u56a5\u56f0\u96e3\u53ca\u5589\u56a8\u816b\u75db\u7b49\u75c7\u72c0\uff0c\u4e26\u6709\u6050\u6c34\u4e4b\u73fe\u8c61\uff0c\u5c31\u91ab\u5f8c\u56e0\u7591\u4f3c\u72c2\u72ac\u75c5(rabies) \u800c\u5165\u9662\uff0c\u95dc\u65bc\u6b64\u75c5\uff0c\u8acb\u554f\u4ee5\u4e0b\u63cf\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u75c5\u60a3\u6050\u6c34\u4e4b\u73fe\u8c61\u662f\u56e0\u54bd\u5589\u90e8\u808c\u8089\u4e4b\u75d9\u6523\u6240\u5f15\u8d77\u3002\nB. \u53f0\u7063\u81ea\u6c11\u570b\u56db\u5341\u516b\u5e74\u8d77\u53f0\u7063\u5730\u5340\u5373\u4e0d\u518d\u6709\u4eba\u7684\u672c\u571f\u75c5\u4f8b\uff0c\u6c11\u570b\u4e94\u5341\u5e74\u4e00\u6708\u5f8c\u5373\u672a\u518d\u51fa\u73fe\u52d5\u7269\u7684\u75c5\u4f8b\u3002\u76ee\u524d\u5728\u53f0\u7063\u88ab\u672c\u5730\u7684\u72d7\u3001\u8c93\u54ac\u50b7\uff0c\u539f\u5247\u4e0a\u4e0d\u5fc5\u65bd\u6253\u4eba\u7528\u72c2\u72ac\u75c5\u514d\u75ab\u7403\u86cb\u767d\u6216\u75ab\u82d7\u3002\nC. \u5982\u9700\u524d\u5f80\u72c2\u72ac\u75c5\u75ab\u5340\uff0c\u5efa\u8b70\u884c\u524d\u81f3\u5c11\u4e00\u500b\u6708\uff0c\u63a5\u7a2e\u4e09\u5291\u75ab\u82d7\u4ee5\u7522\u751f\u514d\u75ab\u4fdd\u8b77\u3002\nD. \u5728\u75ab\u5340\u88ab\u52d5\u7269\u54ac\u50b7\u5f8c\uff0c\u5b9c\u5fb9\u5e95\u5730\u6e05\u6d17\u3001\u6d88\u6bd2\u50b7\u53e3\uff0c\u8fc5\u901f\u63a5\u53d7\u4eba\u7528\u72c2\u72ac\u75c5\u514d\u75ab\u7403\u86cb\u767d\u53ca\u63a5\u7a2e4\u5291\u75ab\u82d7\u3002\nE. \u82e5\u672a\u6cbb\u7642\uff0c\u6b64\u75c5\u81f4\u6b7b\u7387\u7d04\u70ba45%\u3002\n": "(E)", "106-3.\n\u6709\u95dc\u9000\u4f0d\u8ecd\u4eba\u75c7(Legionellosis)\uff0c\u4e0b\u5217\u4f55\u8005\u6558\u8ff0\u70ba\u975e\uff1f\nA. \u5178\u578b\u8840\u6db2\u6aa2\u9a57\u7d50\u679c\u70ba\u767d\u8840\u7403\u589e\u52a0\u3001\u809d\u529f\u80fdAST/ALT\u4e0a\u5347\u3001\u4f4e\u8840\u9209\u3001\u4f4e\u8840\u78f7\u3001Cold agglutinin\u9670\u6027\u3002\nB. \u6b64\u83cc\u6700\u9069\u5408\u65bc\u651d\u6c0f25\u81f342\u5ea6\u6c34\u74b0\u5883\u751f\u9577\uff0c\u50b3\u67d3\u65b9\u5f0f\u662f\u98db\u6cab\u50b3\u67d3\uff0c\u60a3\u8005\u901a\u5e38\u7d93\u7531\u5438\u5165\u53d7\u6c59\u67d3\u6c34\u6e90\u800c\u81f4\u75c5\uff0c\u6f5b\u4f0f\u671f\u70ba2\u81f310\u5929\u3002\nC. \u514d\u75ab\u529b\u4f4e\u4e0b\u611f\u67d3\u75c5\u4eba\u53ca\u6709\u6162\u6027\u80ba\u75c5\u8001\u5e74\u4eba\u5bb9\u6613\u611f\u67d3\uff0c 14\u5929\u81f321\u5929\u7b2c\u4e09\u4ee3\u982d\u5b62\u5b50\u7d20(cephalosporin)\u53ef\u6709\u6548\u6cbb\u7642\u3002\nD. \u79fb\u690d\u5668\u5b98\u60a3\u8005\u5728\u79fb\u690d\u5f8c3\u500b\u6708\u5167\u662f\u5f97\u5230Legionella\u611f\u67d3\u7684\u9ad8\u5371\u96aa\u671f\uff0c\u4e14\u80f8\u90e8X\u5149\u5728\u79fb\u690d\u60a3\u8005\u6613\u898b\u958b\u6d1e\u75c5\u7076(cavitation)\u3002\nE. Legionella\u53ef\u9020\u6210\u80ba\u5916\u611f\u67d3\uff0c\u5982\u8179\u819c\u708e\u6216\u76ae\u819a\u8edf\u7d44\u7e54\u611f\u67d3\u3002\n": "(C)", "106-4.\n\u9000\u4f0d\u8ecd\u4eba\u83cc(Legionella)\u5728\u91ab\u9662\u7684\u51b7\u537b\u6c34\u5854\u53ef\u80fd\u9020\u6210\u6c59\u67d3\uff0c\u6709\u95dc\u9000\u4f0d\u8ecd\u4eba\u83cc\u6d88\u6bd2\u65b9\u5f0f\u4e0b\u5217\u4f55\u8005\u70ba\u975e?\nA. \u52a0\u71b1\u6cd5\uff0c\u63d0\u9ad8\u6c34\u7ba1\u6c34\u6eab\uff0c\u7dad\u6301\u51fa\u6c34\u7ba1\u8def\u6c34\u6eab\u81f3\u651d\u6c0f45~50\u5ea6\u3002\nB. \u6c2f\u5316\u6d88\u6bd2(chlorination)\uff0c\u5982\u52a0\u5165\u4e8c\u6c27\u5316\u6c2f\u3002\nC. \u7d2b\u5916\u7dda\u6d88\u6bd2(UV light)\u3002\nD. \u9285\u9280\u96e2\u5b50\u4ea4\u63db\u6cd5(copper-silver ion exchange)\u3002\nE. \u5fae\u7c73\u5b54\u5f91\u4e4b\u6ffe\u6c34\u5668(microfiltration)\u3002\n": "(A)", "106-5.\n\u4e0b\u5217\u90a3\u4e9b\u6297\u751f\u7d20\u7684\u6291\u83cc\u6a5f\u8f49\u70ba\u7834\u58de\u7d30\u80de\u819c?(1)penicillins\uff1b(2)aminoglycosides\uff1b (3)macrolides\uff1b(4)quinolones \uff1b(5)polymyxins \uff1b(6)daptomycin\nA. (1)+(4)\nB. (2)+(3)\nC. (4)+(5)\nD. (5)+(6)\nE. (3)+(4)\n": "(D)", "106-6.\n\u4e0b\u5217\u6297\u5fae\u751f\u7269\u85e5\u5291\u8207\u526f\u4f5c\u7528\u4e4b\u7d44\u5408\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576\uff1f\nA. Macrolides ---- QTc prolongation(\u5fc3\u96fb\u5716QTc\u5ef6\u9577)\nB. Clindamycin ---- Pseudomembranous colitis(\u507d\u819c\u6027\u8178\u708e)\nC. Metronidazole ----Lipodystrophy(\u8102\u80aa\u75c5\u8b8a)\nD. Sulfonamide ---- Hypersensitivity(\u904e\u654f\u53cd\u61c9)\nE. Fluoroquinolones ---- Dysglycemia(\u8840\u7cd6\u7570\u5e38)\n": "(C)", "106-7.\n\u6709\u95dc\u767b\u9769\u71b1(Dengue fever)\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u9805\u6700\u4e0d\u9069\u7576\uff1f\r(1)\u767b\u9769\u75c5\u6bd2\u5c6c\u65bc\u9ec3\u75c5\u6bd2\u79d1(Flavivirdae)\u6240\u5f15\u8d77\uff0c\u70ba\u55ae\u80a1DNA\u75c5\u6bd2\uff1b (2)\u67094\u7a2e\u578b\u5225\uff0c\u611f\u67d3\u67d0\u4e00\u578b\u767b\u9769\u75c5\u6bd2\u8005\uff0c\u53ef\u5c0d\u5176\u4ed6\u578b\u5225\u4e4b\u75c5\u6bd2\u5177\u6709\u7d42\u8eab\u514d\u75ab\uff1b(3)\u5c48\u516c\u71b1(Chikungunya)\u75c5\u6bd2\u4e5f\u662f\u5c6c\u65bcFlaviviridae(\u9ec3\u75c5\u6bd2\u79d1)\uff0c\u50b3\u64ad\u5a92\u4ecb\u8207\u767b\u9769\u71b1\u76f8\u540c\uff1b(4)\u767b\u9769\u51fa\u8840\u71b1\u82e5\u7121\u9069\u7576\u6cbb\u7642\uff0c\u6b7b\u4ea1\u7387\u53ef\u905420%\uff0c\u65e9\u671f\u8a3a\u65b7\u4e26\u52a0\u4ee5\u9069\u7576\u652f\u6301\u6027\u6cbb\u7642\uff0c\u6b7b\u4ea1\u7387\u53ef\u4f4e\u81f31%\u3002\nA. (1)+(4)\nB. (3)+(4)\nC. (2)+(3)\nD. (2)+(4)\nE. (1)+(2)+(3)\n": "(E)", "106-8.\n\u4ee5\u4e0b\u95dc\u65bc\u767b\u9769\u71b1(Dengue fever)\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u70ba\u6700\u4e0d\u9069\u7576\uff1f\nA. \u5728\u53f0\u7063\u4e3b\u8981\u7684\u75c5\u5a92\u868a\u70ba\u57c3\u53ca\u6591\u868a(Andes aegypti)\u53ca\u767d\u7dda\u6591\u868a(Aedes albopictus)\u3002\nB. \u5e38\u898b\u75c7\u72c0\u70ba\u982d\u75db\u3001\u5f8c\u773c\u7aa9\u75db\u3001\u808c\u8089\u75db\u3001\u51fa\u75b9\u3001\u767d\u8840\u7403\u6e1b\u5c11\u3002\nC. \u88ab\u611f\u67d3\u767b\u9769\u75c5\u6bd2\u7684\u6591\u868a\u53ee\u54ac\u5f8c\uff0c\u5927\u7d04\u7d93\u904e10\u81f314\u5929\uff0c\u6b64\u611f\u67d3\u5bbf\u4e3b\u6703\u958b\u59cb\u51fa\u73fe\u81e8\u5e8a\u767b\u9769\u71b1\u75c5\u75c7\u3002\nD. \u56db\u7a2e\u4e0d\u540c\u8840\u6e05\u578b\u75c5\u6bd2\u7686\u53ef\u81f4\u75c5\uff0c\u5c6c\u7b2c\u4e8c\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u970024\u5c0f\u6642\u5167\u901a\u5831\u3002\nE. \u5728\u75c5\u4eba\u767c\u75c5\u524d1\u5929\u81f3\u767c\u75c5\u5f8c5\u5929\u7a31\u70ba\u300c\u75c5\u6bd2\u8840\u75c7\u671f\u300d\uff0c\u6b64\u6642\u671f\u611f\u67d3\u8005\u82e5\u88ab\u6591\u868a\u53ee\u54ac\uff0c\u5247\u6b64\u6591\u868a\u5c07\u611f\u67d3\u767b\u9769\u75c5\u6bd2\u3002\n": "(C)", "106-9.\n\u6709\u95dc\u4e0b\u5217\u91dd\u5c0d\u6d41\u884c\u6027\u611f\u5192(\u6d41\u611f)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e?\nA. \u6d41\u611f\u75c5\u6bd2\u53ef\u5206\u70baA\u3001B\u3001C\u4e09\u7a2e\u578b\u5225\uff0c\u5176\u4e2dC\u578b\u6d41\u611f\u75c5\u6bd2\u751a\u5c11\u5f15\u8d77\u4eba\u985e\u75be\u75c5\u3002\nB. \u53f0\u7063\u4e3b\u8981\u7684\u5b63\u7bc0\u6027\u6d41\u611f\u75c5\u6bd2\u70baA\u578b\u6d41\u611f\u75c5\u6bd2H3N2\u8207H1N1\u4e9e\u578b\uff0c\u4ee5\u53caB\u578b\u6d41\u611f\u75c5\u6bd2\u7b493\u985e\u3002\nC. \u6d41\u611f\u4e4b\u53ef\u50b3\u67d3\u671f\uff0c\u6210\u4eba\u5927\u7d04\u5728\u75c7\u72c0\u51fa\u73fe\u5f8c3\u81f37\u5929\uff0c\u5e7c\u7ae5\u53ef\u9577\u9054\u6578\u5341\u5929\u3002\nD. \u9810\u9632\u6d41\u611f\u6700\u597d\u7684\u65b9\u6cd5\u5c31\u662f\u65bd\u6253\u75ab\u82d7\uff0c\u7d0470%\u81f380%\u5065\u5eb7\u6210\u5e74\u4eba\u65bd\u6253\u6d41\u611f\u75ab\u82d7\u53ef\u9054\u5177\u6709\u4fdd\u8b77\u529b\u4e4b\u6297\u9ad4\u3002\nE. \u9810\u9632\u6d41\u611f\u4e4b\u6297\u75c5\u6bd2\u85e5\u5291\uff0c\u5982Oseltamivir\u53caZanamivir\u7b49\uff0c\u662f\u51dd\u8840\u539f(Hemagglutinin)\u6291\u5236\u5291\uff0c\u53ef\u540c\u6642\u6cbb\u7642A\u53caB\u578b\u6d41\u611f\u75c5\u6bd2\u3002\n": "(E)", "106-10.\n\u6709\u95dc\u4e0b\u5217\u91dd\u5c0d\u65b0\u578bA\u578b\u6d41\u611f(Novel Influenze A)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e?\nA. \u9ad8\u75c5\u539f\u6027\u79bd\u6d41\u611f\u5305\u62ecH5N1\u3001H5N6\u3001H7N7\u3001H7N9\u75c5\u6bd2\u7b49\u3002\nB. H5N1\u53caH7N9\u66fe\u51fa\u73fe\u5bb6\u5ead\u7fa4\u805a\u6848\u4f8b\uff0c\u6545\u4e0d\u6392\u9664\u6709\u4fb7\u9650\u6027\u4eba\u50b3\u4eba\u7684\u53ef\u80fd\uff0c\u60df\u76ee\u524d\u4ecd\u7121\u8b49\u64da\u986f\u793a\u6709\u6301\u7e8c\u6027\u4eba\u50b3\u4eba\u7684\u73fe\u8c61\u3002\nC. \u65b0\u578bA\u578b\u6d41\u611f\u7684\u6f5b\u4f0f\u671f\u57281\u81f310\u65e5\u4e4b\u9593\uff0c\u76ee\u524d\u63a1\u752810\u65e5\u4f5c\u70ba\u4f30\u8a08\u6f5b\u4f0f\u671f\u4e4b\u4e0a\u9650\u3002\nD. \u4eba\u985e\u611f\u67d3H5N6\u6d41\u611f\u7684\u75c5\u4f8b\u591a\u70ba\u8f15\u75c7\uff0c\u5c11\u6578\u60a3\u8005(\u7d0410%)\u5728\u611f\u67d33\u81f38\u5929\u5f8c\u51fa\u73fe\u80ba\u708e\uff0c\u4e26\u5feb\u901f\u9032\u5c55\u70ba\u6025\u6027\u547c\u5438\u7a98\u8feb\u75c7\u5019\u7fa4(ARDS)\u3002\nE. \u8fd1\u4e94\u6210\u7684H7N9\u6d41\u611f\u75c5\u4f8b\u70ba65\u6b72(\u542b)\u4ee5\u4e0a\u60a3\u8005\uff0c\u81f3\u5c11\u516d\u6210\u4ee5\u4e0a\u75c5\u4f8b\u6709\u6f5b\u5728\u6027\u75be\u75c5\u3002\n": "(D)", "106-11.\n\u6709\u95dc\u8332\u5361\u75c5\u6bd2(Zika virus)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u9069\u7576\uff1f\nA. \u8332\u5361\u75c5\u6bd2\u8207\u767b\u9769\u71b1\u75c5\u6bd2\u540c\u5c6c\u65bc\u9ec3\u75c5\u6bd2\u79d1(Flaviviridae)\uff0c\u6f5b\u4f0f\u671f\u7d043\u81f37\u5929(\u6700\u9577\u7d0412\u65e5)\u3002\nB. \u8332\u5361\u75c5\u6bd2\u611f\u67d3\u75c7\u4e4b\u75c7\u72c0\u8207\u767b\u9769\u71b1\u76f8\u4f3c\u4f46\u8f03\u8f15\u5fae\uff0c\u7d04\u670925%\u7684\u611f\u67d3\u75c5\u4f8b\u6703\u51fa\u73fe\u81e8\u5e8a\u75c7\u72c0\uff0c\u75c7\u72c0\u6301\u7e8c\u7d042\u81f37\u5929\u3002\nC. \u5178\u578b\u7684\u75c7\u72c0\u662f\u767c\u71d2\u3001\u7d05\u75b9\u3001\u95dc\u7bc0\u75db\u3001\u975e\u5316\u81bf\u6027\u7d50\u819c\u708e\uff0c\u75c5\u4f8b\u53ef\u80fd\u51fa\u73fe\u795e\u7d93\u7cfb\u7d71 (\u5982Guillain-Barre Syndrome)\u6216\u514d\u75ab\u7cfb\u7d71 (\u5982Idiopathic Thrombocytopenic Purpura) \u4f75\u767c\u75c7\u3002\nD. \u8332\u5361\u75c5\u6bd2\u75c5\u5a92\u50b3\u64ad\u4e3b\u8981\u70ba\u4e09\u6591\u5bb6\u868a\u8207\u77ee\u5c0f\u5bb6\u868a\uff0c\u4ea6\u53ef\u85c9\u7531\u6027\u884c\u70ba\u6216\u8f38\u8840\u611f\u67d3\u3002\nE. \u5b55\u5a66\u611f\u67d3\u6b64\u75c5\u6bd2\u53ef\u80fd\u7531\u6bcd\u5b50\u5782\u76f4\u611f\u67d3\u9020\u6210\u80ce\u5152\u51fa\u751f\u5c0f\u982d\u7578\u578b\u75c7\uff0c\u5b9a\u7fa9\u70ba\u51fa\u751f24\u5c0f\u6642\u5f8c\u6e2c\u91cf\u5b30\u5152\u982d\u570d\uff0c\u982d\u570d\u5c0f\u65bc\u7b2c3\u500b\u767e\u5206\u4f4d\u3002\n": "(D)", "106-12.\n\u95dc\u8332\u5361\u75c5\u6bd2(Zika virus)\u7684\u611f\u67d3\u7ba1\u5236\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u9069\u7576\uff1f\nA. \u53f0\u7063\u75be\u75c5\u7ba1\u5236\u7f72\u516c\u5e03\u8332\u5361\u75c5\u6bd2\u5c6c\u65bc\u7b2c\u4e94\u985e\u6cd5\u5b9a\u50b3\u67d3\u75c5\uff0c\u9700\u65bc24\u5c0f\u6642\u5167\u901a\u5831\u3002\nB. \u8332\u5361\u75c5\u6bd2\u611f\u67d3\u75c7\u76ee\u524d\u7121\u75ab\u82d7\u53ef\u9810\u9632\uff0c\u5f97\u75c5\u5f8c\u50c5\u80fd\u75c7\u72c0\u652f\u6301\u6027\u6cbb\u7642\uff0c\u907f\u514d\u75c5\u5a92\u868a\u53ee\u54ac\u662f\u6700\u91cd\u8981\u7684\u9810\u9632\u65b9\u6cd5\u3002\nC. \u500b\u6848\u7d93\u6aa2\u9a57\u78ba\u5b9a\u611f\u67d3\u8332\u5361\u75c5\u6bd2\u5f8c\uff0c\u5247\u5f8c\u7e8c\u63a1\u6aa2\u4ee5\u9593\u96947\u65e5\u70ba\u539f\u5247\uff0c\u8840\u6db2\u53ca\u5c3f\u6db2\u6aa2\u9a57\u7d50\u679c\u5206\u5b50\u751f\u7269\u5b78\u6838\u9178\u6aa2\u6e2c\u5747\u70ba\u9670\u6027\uff0c\u624d\u80fd\u505c\u6b62\u8ffd\u8e64\u63a1\u6aa2\u3002\nD. \u7121\u8ad6\u7537\u6027\u6216\u5973\u6027\u4e4b\u611f\u67d3\u8005\uff0c\u5747\u61c9\u63a1\u53d6\u5b89\u5168\u6027\u884c\u70ba\u81f3\u5c116\u500b\u6708\uff0c\u82e5\u7537\u6027\u7684\u6027\u4f34\u4fb6\u70ba\u5b55\u5a66\uff0c\u5247\u6027\u884c\u70ba\u6642\u61c9\u6234\u4fdd\u96aa\u5957\u81f3\u6027\u4f34\u4fb6\u5206\u5a29\u3002\nE. \u63a5\u89f8\u8005\u53ca\u611f\u67d3\u6e90\u7684\u8abf\u67e5\uff0c\u9700\u8abf\u67e5\u6307\u6a19\u500b\u6848\u767c\u75c5\u524d3\u5929\u81f3\u767c\u75c5\u5f8c7\u5929\u7684\u505c\u7559\u5730\u9ede\u53ca\u63a5\u89f8\u8005\u3002\n": "(E)", "106-13.\n\u4e0b\u5217\u6709\u95dc\u5fc3\u5167\u819c\u708e\u4f55\u8005\u6558\u8ff0\u6b63\u78ba\uff1f(1)\u975c\u8108\u85e5\u766e\u8005\u4e4b\u5fc3\u5167\u819c\u708e\u6700\u5e38\u898b\u81f4\u75c5\u83cc\u70baStaphylococcus aureus\uff1b(2)\u8840\u6db2\u57f9\u990a\u9670\u6027\u4e4b\u5fc3\u5167\u819c\u708e\uff0c\u5176\u6700\u91cd\u8981\u6cbb\u7642\u85e5\u7269\u70baDoxycycline\uff1b(3)\u4e00\u5e74\u5167\u5f97\u904e\u5fc3\u5167\u819c\u708e\u8005\uff0c\u5728\u9032\u884c\u547c\u5438\u9053\u6216\u8178\u80c3\u9053\u93e1\u6aa2\u67e5\u4e4b\u524d\uff0c\u5fc5\u9808\u7d66\u4e88\u9810\u9632\u6027\u6297\u751f\u7d20\uff1b(4)\u6709\u534a\u6578\u75c5\u4eba\u53ef\u4ee5\u770b\u5230Osler nodes\uff0cJaneway lesion\u6216subungual hemorrhages\uff1b(5)\u8840\u6db2\u57f9\u990a\u9577\u9ef4\u83cc\u8005\u4e4b\u5167\u819c\u708e\u60a3\u8005\u901a\u5e38\u9810\u5f8c\u5dee\u3002\nA. (1)+(4)\nB. (1)+(3)\nC. (1)+(2)+(3)\nD. (1)+(2)+(4)\nE. (1)+(2)+(5)\n": "(E)", "106-14.\n\u70ba\u964d\u4f4e\u547c\u5438\u5668\u76f8\u95dc\u80ba\u708e\uff0c\u76ee\u524d\u885b\u751f\u798f\u5229\u90e8\u75be\u75c5\u7ba1\u5236\u7f72\u6b63\u5728\u63a8\u52d5\u4e00\u7cfb\u5217\u7d44\u5408\u5f0f\u7167\u8b77\u4ee5\u9810\u9632\u547c\u5438\u5668\u76f8\u95dc\u80ba\u708e\u611f\u67d3\u3002\u8acb\u554f\u4e0b\u5217\u54ea\u4e9b\u9805\u76ee\u5305\u62ec\u5728\u300c\u9810\u9632\u547c\u5438\u5668\u76f8\u95dc\u80ba\u708e\u611f\u67d3\u7684\u7d44\u5408\u5f0f\u7167\u8b77\u300d\u4e4b\u4e2d? (\u8acb\u9078\u51fa\u6240\u6709\u6b63\u78ba\u9078\u9805) (1) \u6bcf\u65e5\u62d4\u7ba1\u8a55\u4f30\uff1b(2) \u5e8a\u982d\u62ac\u9ad830-45\u5ea6\uff1b(3)\u6bcf\u65e5\u57f7\u884c\u53e3\u8154\u6297\u83cc\u7167\u8b77\uff1b(4)\u6bcf\u65e5\u4e2d\u6b62\u93ae\u975c\u5291\uff1b(5)\u88dc\u5145\u547c\u5438\u5668\u7ba1\u8def\u6c34\u5206\u3002\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(3)+(4)\nC. (1)+(2)+(3)+(5)\nD. (1)+(2)+(4)+(5)\nE. (1)+(3)+(4)+(5)\n": "(B)", "106-15.\n\u6709\u95dc2016\u5e74\u7248Surviving Sepsis Campaign guidelines\uff0c\u95dc\u65bc\u6557\u8840\u75c7\u53ca\u6557\u8840\u6027\u4f11\u514b\u7684\u81e8\u5e8a\u8655\u7406\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4? (\u8acb\u9078\u51fa\u6240\u6709\u9078\u9805)(1)\u61c9\u5728\u6700\u521d3\u5c0f\u6642\u5167\u81f3\u5c11\u7d66\u4e88\u6bcf\u516c\u65a4\u9ad4\u91cd30 mL\u7684\u8f38\u6db2\u88dc\u5145\uff1b(2)\u5373\u4f7f\u81e8\u5e8a\u72c0\u6cc1\u5df2\u6539\u5584\uff0c\u6297\u751f\u7d20\u7642\u7a0b\u4e00\u5b9a\u898110-14\u5929\u624d\u8db3\u5920\uff1b(3)\u5efa\u8b70\u5e38\u898f\u4f7f\u7528Hydroxyethyl starches\u4f86\u8655\u7f6e\u6557\u8840\u6027\u4f11\u514b\uff1b(4)\u6557\u8840\u6027\u4f11\u514b\u7684\u7b2c\u4e00\u7dda\u5347\u58d3\u5291\u9078\u64c7\u70ba\u53bb\u7532\u57fa\u814e\u4e0a\u817a\u7d20\uff08Norepinephrine\uff09\uff1b(5)\u5efa\u8b70\u5e38\u898f\u4f7f\u7528\u76ae\u8cea\u9187(hydrocortisone)\u4f86\u6cbb\u7642\u6557\u8840\u6027\u4f11\u514b\u3002\nA. (1)+(2)+(4)\nB. (1)+(2)+(5)\nC. (1)+(3)+(4)\nD. (2)+(3)+(5)\nE. (2)+(4)+(5)\n": "(D)", "106-16.\n\u4e0b\u5217\u95dc\u65bc\u975e\u7d50\u6838\u5206\u679d\u687f\u83cc(Non-Tuberculous Mycobacteria, NTM)\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?(1)\u8fd1\u5e74\u4f86\u88ab\u9451\u5b9a\u51fa\u4f86\u7684\u83cc\u682a\u6578\u6709\u6108\u4f86\u6108\u591a\u7684\u8da8\u52e2\uff0c\u4e3b\u8981\u662f\u56e0\u70ba\u5bb9\u6613\u5728\u4eba\u7fa4\u4e2d\u50b3\u64ad\uff1b(2)\u5e38\u767c\u751f\u5728\u80ba\u90e8\u7d50\u69cb\u7570\u5e38\u6216\u514d\u75ab\u7f3a\u9677\u75c5\u4eba\u8eab\u4e0a\uff1b(3)\u5404\u7a2e\u4e0d\u540cNTM\u83cc\u7a2e\u5c0d\u85e5\u7269\u7684\u611f\u53d7\u6027\u4e0d\u540c\uff0c\u6574\u9ad4\u800c\u8a00NTM\u5c0dClarithromycin\u5177\u611f\u53d7\u6027\uff0c\u800c\u5c0dPyrazinamide\u4e0d\u5177\u611f\u53d7\u6027\uff1b(4)\u6839\u64da\u7f8e\u570b\u80f8\u8154\u79d1\u5b78\u6703\u91dd\u5c0d\u80ba\u90e8NTM\u7684\u8a3a\u65b7\u6a19\u6e96\uff0c\u81e8\u5e8a\u8a3a\u65b7(\u80ba\u90e8\u75c7\u72c0\u53ca\u5f71\u50cf\u5b78\u7570\u5e38)\u4ee5\u53ca\u5fae\u751f\u7269\u5b78\u8a3a\u65b7(\u57f9\u990a\u7d50\u679c\u967d\u6027)\uff0c\u4efb\u4e00\u689d\u4ef6\u5373\u53ef\u8a3a\u65b7\uff1b(5) NTM\u611f\u67d3\u8207\u7d50\u6838\u75c5(tuberculosis)\u7684\u9451\u5225\u8a3a\u65b7\uff0c\u53ef\u63a1\u7528\u7d50\u6838\u83cc\u7d20PPD\u76ae\u5167\u8a66\u9a57\u3002\nA. (1)+(2)\nB. (1)+(3)\nC. (2)+(3)\nD. (2)+(4)\nE. (3)+(5)\n": "(C)", "106-17.\n19\u6b72\u7537\u6027\u5728\u53f0\u7063\u767b\u5c71\u65c5\u904a\u5f8c\u958b\u59cb\u51fa\u73fe\u767c\u71d2\u3001\u982d\u75db\u3001\u5168\u8eab\u808c\u8089\u9178\u75db\uff0c\u65bc\u9580\u8a3a\u6642\u767c\u73fe\u75c5\u4eba\u53f3\u817f\u5167\u5074\u6709\u4e00\u7126\u75c2(eschar)\uff0c\u4e14\u9f20\u8e4a\u6dcb\u5df4\u817a\u816b\u5927\uff0c\u8840\u6db2\u6aa2\u67e5\u767d\u8840\u7403\u6578\u70ba3150/\u03bcL\u3001GOT 112 IU/L\u3001GPT 184 IU/L\uff0c\u5c0d\u65bc\u6b64\u75c5\u4f8b\u4e4b\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4?\nA. \u6b64\u75be\u75c5\u70ba\u6059\u87f2\u75c5(scrub typhus)\uff0c\u81f4\u75c5\u83cc\u70baOrientia tsutsugamushi\nB. \u6b64\u81f4\u75c5\u83cc\u662f\u7531\u8768(louse)\u6240\u50b3\u64ad\nC. \u53f0\u7063\u6d41\u884c\u6b64\u611f\u67d3\u7684\u5730\u5340\u5728\u6771\u90e8\u5730\u5340\u53ca\u96e2\u5cf6\nD. \u6cbb\u7642\u7684\u9996\u9078\u85e5\u7269\u662fdoxycycline\nE. \u6b64\u75c5\u4e4b\u6f5b\u4f0f\u671f(incubation period)\u7d04\u70ba9\u81f318\u5929\n": "(B)", "106-18.\n\u7576\u4f60\u8981\u5e6b\u4e00\u4f4d\u547c\u5438\u56f0\u96e3\u7684\u75c5\u4eba\u9032\u884c\u6c23\u7ba1\u5167\u63d2\u7ba1\u6642\uff0c\u8acb\u554f\u6a19\u6e96\u9632\u8b77\u63aa\u65bd\u662f\u4ec0\u9ebc\uff1f(1)\u6d17\u624b\u3001\u6234\u624b\u5957\uff1b(2)\u6234N95\u53e3\u7f69\uff1b(3)\u7a7f\u9694\u96e2\u8863\uff1b(4)\u6234\u773c\u7f69\uff1b(5)\u6234\u5916\u79d1\u624b\u8853\u53e3\u7f69\nA. (1)+(2)+(3)\nB. (1)+(2)+(3)+(4)\nC. (1)+(3)+(5)\nD. (1)+(3)+(4)+(5)\nE. (1)+(2)+(4)\n": "(B)", "106-19.\n\u6709\u95dc\u6297\u7d50\u6838\u85e5\u7269\u6cbb\u7642\u4e4b\u63cf\u8ff0\uff0c\u4ee5\u4e0b\u4f55\u8005\u932f\u8aa4\uff1f\nA. Pyrazinamide (PZA) \u53ef\u5f15\u8d77\u9ad8\u5c3f\u9178\u8840\u75c7\uff0c\u4f46\u5f88\u5c11\u9020\u6210\u75db\u98a8\u767c\u4f5c\nB. Ethambutol\u53ef\u9020\u6210\u8996\u795e\u7d93\u708e\nC. Rifampicin\u6703\u4f7f\u5c3f\u6db2\u8b8a\u6a58\u7d05\u8272\nD. \u7576\u4f7f\u7528\u6297\u7d50\u6838\u85e5\u5f8c\uff0c\u809d\u529f\u80fd\u8d85\u904e\u6b63\u5e385\u500d\u6642\uff0c\u61c9\u8003\u616e\u505cIsoniazid\u3001PZA\u53carifampicin\nE. \u901a\u5e38\u6297\u7d50\u6838\u6cbb\u7642\u524d\u4e8c\u500b\u6708\u8981\u4f7f\u7528\u56db\u7a2e\u85e5\uff0c\u7a31\u70baIntensive Phase\uff0c\u5982\u82e5\u7121\u6297\u85e5\u554f\u984c\uff0c\u5247PZA\u672a\u5b8c\u6574\u4f7f\u7528\u4e8c\u500b\u6708\u6642\uff0c\u6cbb\u7642\u5168\u7a0b\u53ef\u516d\u500b\u6708\u7d50\u675f\n": "(E)", "107-1.\n\u4e00\u4f4d53\u6b72\u5973\u6027, 8\u670815\u65e5\u56e0\u70ba\u9ad8\u71d2\u3001\u754f\u5bd2\u3001\u982d\u75db\u3001\u808c\u8089\u75e0\u75db\u800c\u5230\u6025\u8a3a\u5ba4\u6c42\u6cbb,\u62bd\u8840\u6aa2\u9a57\u767d\u8840\u740313500/cumm\u3001\u4e2d\u6027\u767d\u8840\u740386%\u3001\u8840\u5c0f\u677f56000/cumm\u3001AST 176 U/L\u3001ALT 152 U/L\u3001Cr 1.4 mg/dL\u3001CRP 10mg/dL\u3001\u8840\u6db2\u57f9\u990a\u9670\u6027, \u5979\u548c\u4e00\u7fa4\u540c\u4f34\u559c\u597d\u6cb3\u5ddd\u6e38\u6cf3\u3002\u8acb\u554f\u4e0b\u5217\u54ea\u9805\u8077\u696d\u6700\u4e0d\u5bb9\u6613\u5f97\u5230\u9019\u500b\u75be\u75c5?\nA. \u7378\u91ab\nB. \u8fb2\u592b\nC. \u5c60\u5bb0\u5834\u5de5\u4eba\nD. \u516c\u8eca\u53f8\u6a5f\nE. \u6c59\u6c34\u9053\u5de5\u4eba\n": "(D)", "107-2.\n\u6709\u95dc\u6885\u6bd2\u7684\u6aa2\u9a57, \u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba?(1). \u7576\u75c5\u4eba\u662fHIV(+)\u6642, \u82e5RPR (\u6216VDRL)\u22671:32\u6216CD4<=350/cumm, \u5247\u61c9\u505aCSF\u6aa2\u67e5RPR (2). primary/secondary\u6885\u6bd2, \u539fRPR\u70ba1:32, \u65bc\u6cbb\u7642\u5f8c6\u81f312\u500b\u6708\u8ffd\u8e64, \u518d\u9a57RPR\u70ba1:8, \u4e43\u8868\u793a\u6cbb\u7642\u53cd\u61c9\u826f\u597d (3). Latent/late syphilis \u65bc\u6cbb\u7642\u5f8c6\u300112\u300124\u500b\u6708\u7686\u61c9\u518d\u9032\u884c\u8ffd\u8e64\u6aa2\u67e5 (4). \u540c\u6642\u6709HIV(+)\u8005, \u6cbb\u7642\u5f8c3\u30016\u30019\u300112\u53ca24\u500b\u6708\u7686\u8981\u8ffd\u8e64\u6aa2\u9a57\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(2)+(4)\nD. (1)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(E)", "107-3.\n\u6c99\u9580\u6c0f\u83cc\u5e38\u6e90\u81ea\u86cb\u3001\u751f\u8089\u3001\u725b\u5976\u7522\u54c1\u3001\u82b1\u751f\u91ac\u3001\u65b0\u9bae\u852c\u83dc\u6216\u63a5\u89f8\u722c\u87f2\u985e\u52d5\u7269,\u53ef\u4ee5\u9020\u6210\u8178\u9053\u611f\u67d3\u75c7\u72c0\u6216\u83cc\u8840\u75c7, \u4ee5\u4e0b\u6709\u95dc\u6cbb\u7642\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f (1). \u5e74\u7d00\u5c0f\u65bc50\u6b72\u4e4b\u5065\u5eb7\u6210\u4eba\u82e5\u6709\u8f15\u5fae\u81f3\u4e2d\u7b49\u5ea6\u8178\u80c3\u75c7\u72c0,\u53ef\u4e0d\u9700\u7528\u6297\u751f\u7d20 (2). \u6210\u4eba\u5e74\u7d00\u5927\u65bc50\u6b72, \u75c7\u72c0\u8f15\u5fae\u5247\u4e0d\u9700\u4f7f\u7528\u6297\u751f\u7d20 (3). \u6709\u4eba\u5de5\u8840\u7ba1\u690d\u5165\u7269\u3001\u4eba\u5de5\u95dc\u7bc0\u8005, \u75c7\u72c0\u8f15\u5fae\u4ea6\u61c9\u4f7f\u7528\u6297\u751f\u7d20 (4). \u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u85e5\u6cbb\u7642\u764c\u75c5\u6216\u514d\u75ab\u6291\u5236\u5291\u8005, \u75c7\u72c0\u8f15\u5fae\u4ea6\u61c9\u4f7f\u7528\u6297\u751f\u7d20\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(4)\nC. (2)+(3)+(4)\nD. (3)+(4)\nE. (4)\n": "(B)", "107-4.\n\u6709\u95dcA\u65cf\u93c8\u7403\u83cc\u9020\u6210\u7684\u6025\u6027\u54bd\u5589\u708e(pharyngitis)\u4e4b\u6558\u8ff0\uff0c\u4ee5\u4e0b\u6709\u95dc\u6cbb\u7642\u4e4b\u6558\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u6cbb\u7642\u53ef\u964d\u4f4e\u98a8\u6fd5\u71b1\u4e4b\u98a8\u96aa\nB. \u6cbb\u7642\u53ef\u7e2e\u77ed\u75be\u75c5\u75c7\u72c0\nC. \u53ef\u964d\u4f4e\u5c0d\u5bc6\u5207\u63a5\u89f8\u8005\u6216\u5728\u64c1\u64e0\u74b0\u5883\u4e2d\u4e4b\u50b3\u64ad\nD. \u6cbb\u7642\u53ef\u63a110\u5929\u4e4b\u53e3\u670dAmoxicillin\nE. \u6cbb\u7642\u63a1moxifloxacin 7\u5929\n": "(E)", "107-5.\n\u4e00\u822c\u5c0d\u7da0\u81bf\u687f\u83cc\u611f\u67d3\u7684\u6cbb\u7642\u53ef\u9078\u4e0b\u5217\u54ea\u4e9b\u6297\u751f\u7d20? (1). Moxifloxacin (2). Cefepime (3). Cefoxitin (4). Ertapenem (5). Ceftazidime\nA. (1)+(2)+(4)\nB. (1)+(4)+(5)\nC. (2)+(4)+(5)\nD. (1)+(4)\nE. (2)+(5)\n": "(E)", "107-6.\n\u4ee5\u4e0b\u54ea\u4e9b\u6297\u85e5\u6027\u7d30\u83cc\u611f\u67d3\u53ef\u88ab\u914d\u5c0d\u6297\u751f\u7d20\u6240\u6cbb\u7642? (1). Extended spectrum beta-lactamase (ESBL)-producing E. coli: Ertapenem (2). KPC carbapenemase-producing K. pneumoniae: Meropenem (3). VRE: Linezolid (4). MRSA: Daptomycin (5). Carbapenem-resistant Pseudomonas aeruginosa: Tigecycline\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(3)+(4)+(5)\nE. (1)+(3)\n": "(B)", "107-7.\n\u8702\u7aa9\u7d44\u7e54\u708e\u5728\u4ee5\u4e0b\u4f55\u7a2e\u60c5\u6cc1\u5b9c\u4f7f\u7528amoxicillin/clavulanic acid\u6cbb\u7642? (1). \u7576\u6709\u6162\u6027\u6dcb\u5df4\u816b\u4f75\u767c\u6025\u6027\u8702\u7aa9\u7d44\u7e54\u708e (2). \u7576\u6709\u52d5\u7269(\u8c93\u3001\u72d7)\u6216\u4eba\u54ac\u50b7 (3). \u7576\u5728\u6cb3\u5ddd\u5de5\u4f5c\u6709\u53d7\u50b7\u4e14\u6d78\u6ce1\u904e\u6cb3\u5ddd\u6c34\u6642 (4). \u7576\u6709\u91d8\u5b50\u523a\u50b7\u6df1\u90e8\u7d44\u7e54\u6642 (5). \u7576\u6709\u88ab\u9b5a\u523a\u50b7\u6642\nA. (2)+(4)\nB. (3)+(5)\nC. (1)+(2)\nD. (2)+(5)\nE. (1)+(2)+(3)+(4)\n": "(C)", "107-8.\n\u4e00\u4f4d75\u6b72\u7537\u6027\u56e0\u767c\u71d2\u4e8c\u5929\uff0c\u547c\u5438\u6025\u4fc3\u53ca\u54b3\u55fd\u52a0\u5287\u800c\u4f4f\u9662\u3002\u4ed6\u66fe\u65bc\u4e09\u5468\u524d\u7f79\u60a3\u6d41\u611f\u80ba\u708e\uff0c\u4f46\u547c\u5438\u9053\u75c7\u72c0\u5df2\u7d93\u5728\u4e94\u5929\u524d\u6062\u5fa9\u4e86\u3002\u7136\u800c\u9019\u4e8c\u5929\u54b3\u55fd\u53ca\u547c\u5438\u6025\u4fc3\u53c8\u7522\u751f\uff0c\u6709\u7070\u9ec3\u8272\u7684\u75f0\u6db2\u3002\u4ed6\u5e73\u6642\u6709\u9ad8\u8840\u58d3\uff0c\u4f4f\u9662\u9ad4\u6eab38.3\u00b0C\uff0c\u8840\u58d3140/86mmHg,\u5fc3\u8df390/min\uff0c\u547c\u543826/min, \u8840\u6c27\u6fc3\u5ea690% (\u5728room air)\uff0c\u80f8\u90e8\u547c\u5438\u97f3\u4e8c\u5074\u7686\u6709\u56c9\u97f3\uff0c \u800c\u80f8\u90e8X\u5149\u5169\u5074\u7686\u6709\u7a7a\u6d1e\u6027\u6d78\u6f64\u73fe\u8c61\uff0c\u8acb\u554f\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u81f4\u75c5\u539f\u662f\u751a\u9ebc\uff1f\nA. Legionella species\nB. Staphylococcus aureus\nC. Pseudomonas aeruginosa\nD. Pneumocystis jirovecii\nE. Streptococcus pneumoniae\n": "(B)", "107-9.\nKlebsiella pneumoniae \u6f38\u6f38\u6210\u70ba\u6700\u91cd\u8981\u7684\u8178\u539f\u6027\u81f4\u75c5\u83cc, \u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba? (1). \u6240\u6709\u7684\u81e8\u5e8a Klebsiella pneumoniae\u83cc\u682a\u7686\u5c0d Ampicillin\u548c Ticarcillin\u5177\u6297\u85e5\u6027 (2). Extended spectrum beta-lactamase (ESBL)-producing K. pneumoniae\u5c0dceftriaxone\u548c ceftazidime\u5177\u6709\u6297\u85e5\u6027\uff0c\u4f46\u5c0d Ertapenem\u548c Fluoroquinolones \u5247\u7686\u5177\u6709\u611f\u53d7\u6027 (3). \u53ef\u7522\u751fNDM-1 carbapenemase \u7684 K. pneumoniae \u83cc\u53ef\u7528Tigecycline\u548cPolymycins\u6cbb\u7642 (4). \u53f0\u7063\u53ef\u7522\u751fKPC carbapenemase \u7684 K. pneumoniae \u83cc\u682a\u662f\u900f\u904e\u8cea\u9ad4\u7522\u751f\u6297\u85e5\u6027\uff0c\u4e26\u900f\u904e\u91ab\u7642\u7167\u8b77\u6a5f\u69cb\u50b3\u64ad (5).\r\u5728\u53f0\u7063\u9020\u6210\u809d\u81bf\u760d\u6216\u773c\u5167\u708e\u4e3b\u8981\u662f ESBL-producing K. pneumoniae\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (1)+(3)+(5)\nE. (1)+(2)+(3)+(4)\n": "(C)", "107-10.\n\u70ba\u964d\u4f4e\u91ab\u7642\u6a5f\u69cb\u5167\u591a\u91cd\u6297\u85e5\u6027\u75c5\u539f\u4e4b\u4ea4\u53c9\u611f\u67d3\uff0c\u5021\u5c0e\u91ab\u8b77\u4eba\u54e1\u624b\u90e8\u885b\u751f\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba? (1). \u4f7f\u7528\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u9032\u884c\u624b\u90e8\u885b\u751f\uff0c\u5728\u6e05\u6f54\u6548\u679c\u3001\u4f7f\u7528\u6642\u6a5f\u3001\u82b1\u8cbb\u6642\u9593\u3001\u5c0d\u76ae\u819a\u7684\u5f71\u97ff\u3001 \u5b89\u5168\u8003\u91cf\u53ca\u6d17\u624b\u9075\u5f9e\u6027\u7b49\u65b9\u9762\uff0c\u5747\u6bd4\u4f7f\u7528\u80a5\u7682\u6216\u6db2\u614b\u7682\u9032\u884c\u6fd5\u6d17\u624b\u7684\u6548\u679c\u70ba\u4f73 (2). \u91ab\u8b77\u4eba\u54e1\u5728\u624b\u90e8\u7121\u660e\u986f\u9ad2\u6c59\u6642\uff0c\u512a\u5148\u4f7f\u7528\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u6e05\u6f54\u624b\u90e8 (3). \u624b\u90e8\u6709\u660e\u986f\u9ad2\u6c59\u6216\u6cbe\u6709\u8840\u6db2/\u9ad4\u6db2\u6642\uff0c\u4f7f\u7528\u80a5\u7682\u548c\u6e05\u6c34\u4e4b\u6fd5\u6d17\u624b15\u79d2 (4).  \u5728\u7167\u8b77\u9ede\u666e\u904d\u8a2d\u7f6e\u6216\u96a8\u8eab\u651c\u5e36\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2 (5). \u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u6db2\u5c0d\u8afe\u7f85\u75c5\u6bd2(norovirus)\u3001\u8178\u75c5\u6bd2\u548cClostridium difficile\u7686\u6709\u5f88\u597d\u4e4b\u6d88\u6bd2\u6548\u679c\nA. (1)+(2)+(3)+(4)+(5)\nB. (1)+(2)+(4)\nC. (2)+(4)+(5)\nD. (2)+(3)+(4)\nE. (1)+(3)+(4)\n": "(B)", "107-11.\n\u4e00\u4f4d20 \u6b72\u7537\u6027\u75c5\u60a3\uff0c\u767c\u71d2\u6578\u5929\u4f4f\u9662\u6cbb\u7642\uff0c\u672a\u4f7f\u7528beta-blocker\uff0c\u4f4f\u9662\u751f\u547d\u5fb5\u8c61\u70ba\u9ad4\u6eab38.5\u81f339.5\u5ea6C\u3001\u5fc3\u8df3\u6bcf\u5206\u941870\u81f380\u4e0b\uff0c\u8acb\u554f\u4e0a\u8ff0\u7d00\u9304\u70ba\u4e0b\u5217\u54ea\u4e9b\u75be\u75c5\u4e4b\u81e8\u5e8a\u8868\u5fb5? (1). \u6c99\u9580\u6c0f\u83cc(Salmonella typhi) (2). \u9000\u4f0d\u8ecd\u4eba\u83cc(Legionella) (3). \u7acb\u514b\u6b21\u9ad4(Rickettsia) (4). \u6d41\u611f\u75c5\u6bd2(Influenza)\nA. (1)+(3)\nB. (2)+(3)\nC. (3)+(4)\nD. (1)+(2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(D)", "107-12.\n\u6709\u95dc\u6557\u8840\u75c7\u81f4\u75c5\u539f\u8207\u6297\u751f\u7d20\u6cbb\u7642\u7684\u914d\u5c0d,\u4e0b\u5217\u54ea\u4e9b\u7d44\u5408\u662f\u6b63\u78ba\u7684? (1). Neisseria meningitidis - ceftriaxone (2). Group A Streptococcus - penicillin (3). Rickettsia - clindamycin (4). Enterococcus - cefazolin\nA. (1)+(2)\nB. (2)+(3)\nC. (1)+(3)\nD. (2)+(4)\nE. (1)+(4)\n": "(A)", "107-13.\n\u4e0b\u5217\u54ea\u4e9b\u75ab\u82d7\u662f\u6b63\u5728\u61f7\u5b55\u7684\u5a66\u5973\u4e0d\u5efa\u8b70\u6ce8\u5c04\u7684(\u5373\u75ab\u82d7\u7981\u5fcc\u75c7)? (1). Influenza (Flu\u75ab\u82d7) (2). MMR (measles-mumps-rubella)\u75ab\u82d7 (3). Varicella (Chickenpox)\u75ab\u82d7 (4). Pneumococcal (PPSV 23)\u75ab\u82d7\nA. (1)+(3)\nB. (2)+(3)\nC. (1)+(4)\nD. (1)+(2)+(3)\nE. (2)+(3)+(4)\n": "(B)", "107-14.\n\u4e00\u4f4d50\u6b72\u4e4b\u5973\u6027\u75c5\u60a3\uff0c10\u5929\u524d\u5230\u6771\u5357\u4e9e\u65c5\u904a\u66fe\u751f\u98df\u6d77\u9bae\uff0c\u8fd4\u570b\u5f8c\u767c\u751f\u8179\u7009\u8179\u75db\uff0c\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u8840\u6db2\u55dc\u4f0a\u7d05\u6027\u767d\u7403\u7570\u5e38\u589e\u52a0(WBC 7800/mm3\u3001eosinophil 38%)\uff0c\u8acb\u554f\u6700\u53ef\u80fd\u662f\u4e0b\u5217\u4f55\u7a2e\u75c5\u539f?\nA. Capillaria (\u97ad\u6bdb\u87f2)\nB. Ascaris (\u86d4\u87f2)\nC. Strongyloides (\u7cde\u5c0f\u687f\u7dda\u87f2)\nD. Hookworm (\u9264\u87f2)\nE. Cryptosporidium (\u96b1\u5b62\u5b50\u87f2)\n": "(A)", "107-15.\n\u6709\u95dc\u58de\u6b7b\u6027\u7b4b\u819c\u708e(necrotizing fasciitis)\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e?\nA. \u53ef\u80fd\u6e90\u81ea\u65bc\u5275\u50b7\u3001\u6c34\u75d8\u611f\u67d3\u76ae\u75c2\u3001\u624b\u8853\u6216\u751f\u7522\u5f8c\u50b7\u53e3\nB. \u7cd6\u5c3f\u75c5\u3001\u975c\u8108\u85e5\u766e\u3001\u6162\u6027\u809d\u814e\u75be\u75c5\u662f\u76f8\u95dc\u7684\u5bbf\u4e3b\u56e0\u7d20\nC. \u767c\u75c5\u5f8c\u7d043\u81f35\u5929\u8868\u76ae\u51fa\u73fe\u6c34\u6ce1(bullae)\u53ca\u76ae\u819a\u58de\u6b7b(necrosis)\nD. \u82e5\u5408\u4f75\u6709\u6bd2\u6027\u4f11\u514b\u75c7\u5019\u7fa4(toxic shock syndrome)\uff0c\u6b7b\u4ea1\u7387\u53ef\u9ad8\u905470%\nE. Clostridium peringens \u5f15\u8d77\u4e4b\u58de\u6b7b\u6027\u7b4b\u819c\u708e\u75c5\u7a0b\u6162\uff0c\u81e8\u5e8a\u75c7\u72c0\u7de9\u548c\uff0c\u6b7b\u4ea1\u7387\u4f4e\n": "(E)", "107-16.\n\u4e0b\u5217\u6709\u95dc\u793e\u5340\u6027\u80ba\u708e\u81f4\u75c5\u539f\u8207\u76f8\u95dc\u5bbf\u4e3b\u56e0\u7d20\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576?\nA. Acinetobacter - \u9152\u766e (alcoholism)\nB. Klebsiella pneumoniae - \u7cd6\u5c3f\u75c5 (diabetes)\nC. Haemophilus influenza - \u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (COPD)\nD. Pseudomonas aeruginosa - \u652f\u6c23\u7ba1\u64f4\u5f35(bronchiectasis)\nE. Legionella - \u6d41\u611f\u611f\u67d3\u5f8c (post - flu)\n": "(E)", "107-17.\n\u4e00\u4f4d30\u6b72\u5973\u6027\uff0c\u5728\u5403\u5b8c\u86cb\u6c99\u62c93\u5c0f\u6642\u5f8c\u51fa\u73fe\u6025\u6027\u8179\u75db\u3001\u5641\u5fc3\u5614\u5410\u53ca\u8179\u7009\uff0c \u8acb\u554f\u6700\u53ef\u80fd\u662f\u4e0b\u5217\u54ea\u4e00\u81f4\u75c5\u83cc\u6240\u5f15\u8d77?\nA. Staphylococcus aureus\nB. Enterotoxigenic E.coli\nC. Campylobacter jejuni\nD. Vibrio parahaemolyticus\nE. Ameoba histolytica\n": "(A)", "107-18.\n\u6709\u95dc\u56f0\u96e3\u68ad\u72c0\u687f\u83cc NAPI/BI/027\u83cc\u682a\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e?\nA. NAPI/BI/027\u83cc\u682a\u662f\u8fd1\u5e74\u4f86\u9020\u6210\u5168\u7403\u6d41\u884c\uff0c\u6b50\u7f8e\u5730\u5340\u91ab\u9662\u7fa4\u7a81\u767c\u7684\u4e3b\u8981\u83cc\u682a\nB. \u6b64\u83cc\u682a\u5c0d\u65bcfluoroquinolones\u985e\u6297\u751f\u7d20\u5177\u6709\u9ad8\u5ea6\u611f\u53d7\u6027(susceptible)\nC. \u8207\u4e00\u822c\u83cc\u682a\u76f8\u6bd4\uff0cNAPI/BI/027\u83cc\u682a\u53ef\u7522\u751f16\u81f323\u500d\u7684toxin A\u8207toxin B\nD. \u6b64\u83cc\u4ea6\u5df2\u88ab\u767c\u73fe\u9664toxin A\u53catoxin B\u5916\uff0c\u53e6\u53ef\u7522\u751f\u7b2c3\u7a2e\u6bd2\u7d20(binary toxin CDT)\nE. \u6b64\u83cc\u682a\u53ef\u4f7f\u7528metronidazole\u6216vancomycin\u4f86\u4f5c\u7b2c\u4e00\u7dda\u53e3\u670d\u6cbb\u7642\n": "(B)", "107-19.\n\u4e00\u4f4d20\u6b72\u5e74\u8f15\u5973\u6027\uff0c\u982d\u75db\u767c\u71d2\u53ca\u9838\u90e8\u50f5\u786c\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u6025\u8a3a\u91ab\u5e2b\u57f7\u884c\u8166\u810a\u9ad3\u6db2\u6aa2\u67e5\uff0c\u8a3a\u65b7\u70ba\u7d30\u83cc\u6027\u8166\u819c\u708e\uff0c\u8acb\u554f\u4e0b\u5217\u6709\u95dc\u8166\u810a\u9ad3\u6db2\u6aa2\u67e5\u7d50\u679c\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e?\nA. \u591a\u578b\u6838\u767d\u8840\u7403(PMN)\u6578 >100 cells/uL\nB. \u8461\u8404\u7cd6\u6fc3\u5ea6 < 40 mg/dL\nC. \u86cb\u767d\u8cea(protein) > 45 mg/dL\nD. \u8166\u810a\u9ad3\u6db2\u7d30\u83cc\u57f9\u990a\u967d\u6027\u7387\u9ad8\uff0c\u7d04\u70ba80%\nE. \u8166\u810a\u9ad3\u6db2\u9769\u862d\u6c0f\u67d3\u8272\u967d\u6027\u7387\u4f4e\uff0c\u7d04\u70ba40%\n": "(E)", "108-1.\n\u4e00\u4f4d76\u6b72\u5a66\u5973\u56e0\u793e\u5340\u611f\u67d3\u80ba\u708e\u4f4f\u9662\uff0c\u63a5\u53d7\u6c27\u6c23\u88dc\u5145\uff0c\u6ce8\u5c04ceftriaxone\u548cazithromycin\u51713\u5929\uff0c\u8840\u6db2\u53ca\u75f0\u6db2\u57f9\u990a\u5747\u7121\u7d30\u83cc\u9577\u51fa\u3002\u5979\u611f\u89ba\u6bd4\u8f03\u8212\u670d\uff0c\u98df\u617e\u826f\u597d\uff0c\u54b3\u55fd\u53ca\u547c\u5438\u6025\u4fc3\u90fd\u6539\u5584\u4e86\uff0c\u5728\u4f4f\u9662\u7b2c2\u5929\u5c31\u9000\u71d2\u4e86\u3002\u5979\u6c92\u6709\u5176\u4ed6\u5171\u75c5\u3002\u8eab\u9ad4\u8a3a\u5bdf\u9ad4\u6eab37.8\u00b0C\uff0c\u8840\u58d3120/74 mmHg\uff0c\u5fc3\u8df390/min\uff0c\u547c\u543818/min\uff0c\u672a\u984d\u5916\u7d66\u6c27\u6c23\u6642\u6c27\u98fd\u548c\u5ea6\u70ba94%\u3002\u5979\u547c\u5438\u5e73\u7a69\uff0c\u807d\u8a3a\u5169\u5074\u80ba\u57fa\u5e95\u547c\u5438\u8072\u964d\u4f4e\uff0c\u53e9\u8a3a\u7121\u6fc1\u97f3(dullness)\uff0c\u5fc3\u81df\u8a3a\u5bdf\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u96d9\u4e0b\u80a2\u7121\u6c34\u816b\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5468\u908a\u8840\u767d\u8840\u740313000/cumm(\u5165\u9662\u664218000/cumm)\uff0c\u751f\u5316\u503c\u6b63\u5e38\u3002\r\u8acb\u554f\u4e0b\u5217\u6700\u5408\u9069\u4e4b\u6297\u751f\u7d20\u6cbb\u7642\u70ba\u4f55\u8005?\nA. \u6301\u7e8cceftriaxone\u6ce8\u5c04\u6cbb\u7642\u3002\nB. \u6539\u6210\u53e3\u670d\u6297\u751f\u7d20\u4e26\u51fa\u9662\u3002\nC. \u6539\u6210\u53e3\u670d\u6297\u751f\u7d20\u4e26\u89c0\u5bdf24\u5c0f\u6642\u3002\nD. \u6539\u6210\u53e3\u670d\u6297\u751f\u7d20\u4e26\u8207\u6ce8\u5c04\u6297\u751f\u7d20\u91cd\u758a24\u5c0f\u6642\u3002\nE. \u505c\u7528\u6297\u751f\u7d20\u4e26\u51fa\u9662\u3002\n": "(B)", "108-2.\n\u4e00\u4f4d83\u6b72\u7537\u6027\uff0c\u56e0\u70ba\u5c3f\u8def\u611f\u67d3\u4f75\u83cc\u8840\u75c7\u800c\u4f4f\u9032\u52a0\u8b77\u75c5\u623f\u3002\u4e09\u5929\u524d\u4ed6\u56e0\u70ba\u9593\u65b7\u6027\u795e\u667a\u6df7\u4e82\u3001\u865b\u5f31\uff0c\u89e3\u5c3f\u75bc\u75db\u548c\u8840\u5c3f\u88ab\u9001\u5230\u6025\u8a3a\uff0c\u56e0\u70ba\u8840\u6d41\u52d5\u529b\u60c5\u6cc1\u4e0d\u7a69\u800c\u5165\u4f4f\u52a0\u8b77\u75c5\u623f\uff0c\u525b\u958b\u59cb\u63a5\u53d7\u975c\u8108\u8f38\u6db2\uff0c\u7d93\u9a57\u6027meropenem\u3002\u4e09\u5929\u5f8c\u4f4e\u8840\u58d3\u548c\u767c\u71d2\u90fd\u7de9\u89e3\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u9ad4\u6eab37.6\u00b0C\uff0c\u8840\u58d3120/80 mmHg\uff0c\u5fc3\u8df394/min\uff0c\u547c\u543818/min\uff0c\u5fc3\u81df\u8a3a\u5bdf\u6b63\u5e38\uff0c\u8170\u5074\u548c\u8179\u90e8\u7121\u58d3\u75db\uff0c\u5c3f\u6db2\u57f9\u990aEnterococcus faecalis\u5927\u65bc100000\u83cc\u843d\uff0c\u800c\u8840\u6db2\u57f9\u990a\u4e5f\u662fE. faecalis\uff0c\u6297\u751f\u7d20\u611f\u67d3\u6027\u8a66\u9a57\u5c0dampicillin\uff0cvancomycin\u548cgentamicin\u5177\u654f\u611f\u6027\u3002\r\u8acb\u554f\u6b64\u6642\u4e0b\u5217\u54ea\u4e00\u9805\u6297\u751f\u7d20\u6cbb\u7642\u662f\u9069\u7576\u7684?\nA. \u6539\u6210ampicillin\nB. \u6539\u6210ampicillin\u548cgentamicin\nC. \u6539\u6210vancomycin\nD. \u6539\u6210vancomycin\u548cgentamicin\nE. \u7e7c\u7e8c\u4f7f\u7528meropenem\n": "(A)", "108-3.\n\u4e00\u4f4d60\u6b72\u7537\u6027\u56e0\u8179\u7009\u548c\u767c\u71d23\u5929\u800c\u4f86\u5c31\u8a3a\uff0c\u4ed6\u6c92\u6709\u8179\u75db\u6216\u5614\u5410\uff0c\u7cde\u4fbf\u6df7\u6709\u9ecf\u6db2\uff0c\u4f46\u6c92\u6709\u770b\u5230\u8840\u4fbf\uff0c\u4ed6\u611f\u89ba\u75b2\u52de\u548c\u98df\u617e\u8b8a\u5dee\uff0c\u4ed6\u5f9e\u4e8b\u5e02\u5834\u5de5\u4f5c\u3002\u8eab\u9ad4\u8a3a\u5bdf\u9ad4\u6eab38\u00b0C\uff0c\u8840\u58d3146/68 mmHg\uff0c\u5fc3\u8df382/min\uff0c\u547c\u543822/min\uff0c\u8179\u90e8\u8a3a\u5bdf\u8178\u97f3\u589e\u5f37\uff0c\u6574\u500b\u8179\u90e8\u6709\u8f15\u5fae\u58d3\u75db\u3002\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5468\u908a\u8840\u767d\u8840\u740311400/mm^3\uff0c\u7cde\u4fbf\u6709\u6f5b\u8840\u53cd\u61c9\u3002\u4ed6\u63a5\u53d7\u7cde\u4fbf\u57f9\u990a\u53ca\u7d93\u9a57\u6027\u6297\u751f\u7d20levofloxacin 3\u5929\u5f8c\uff0c\u7cde\u4fbf\u57f9\u990a\u5448\u73feCampylobacter jejuni\uff0c\u5c0dlevofloxacin\u6709\u6297\u85e5\u6027\u3002\u4ed6\u4f86\u9580\u8a3a\u8907\u67e5\u6642\uff0c\u611f\u89ba\u75c5\u5df2\u597d\uff0c\u8179\u7009\u53ca\u767c\u71d2\u90fd\u5df2\u7de9\u89e3\u3002\r\u8acb\u554f\u9019\u6642\u6700\u9069\u7576\u7684\u8655\u7406\u662f?\nA. \u505clevofloxacin\nB. \u63a1\u8840\u6db2\u57f9\u990a\nC. \u518d\u63a1\u96c6\u7cde\u4fbf\u57f9\u990a\nD. \u6539\u6210azithromycin\nE. \u6539\u6210ciprofloxacin\n": "(A)", "108-4.\n\u4e00\u4f4d60\u6b72\u5973\u6027\u56e0\u70ba\u547c\u5438\u6025\u4fc3\u548c\u8173\u816b\u65bc1\u5929\u524d\u88ab\u9001\u5230\u6025\u8a3a\u5ba4\uff0c\u81e8\u5e8a\u5224\u65b7\u70ba\u5931\u511f\u6027(decompensated)\u5fc3\u8870\u7aed\uff0c\u5979\u63a5\u53d7\u5c0e\u5c3f\u7ba1\u7f6e\u653e\uff0c\u975c\u8108\u6ce8\u5c04\u7d66\u4e88\u5229\u5c3f\u5291\u5e76\u4f4f\u9662\u3002\u5979\u6709\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u548c\u6162\u6027\u814e\u75c5\u7b49\u6f5b\u5728\u75be\u75c5\u3002\u5979\u6240\u4f7f\u7528\u7684\u85e5\u7269\u5305\u62ecaspirin\uff0ccarvedilol\uff0cinsulin\uff0clisinopril\uff0crosuvastatin\uff0cspironolactone\u548c\u8996\u9700\u8981\u7528furosemide\u3002\u8eab\u9ad4\u8a3a\u5bdf\u9ad4\u6eab36.5\u00b0C\uff0c\u8840\u58d3128/72 mmHg\uff0c\u5fc3\u8df396/min\uff0c\u547c\u543818/min\uff0c\u807d\u8a3a\u80ba\u90e8\u96d9\u5074\u57fa\u5e95\u6709\u56c9\u97f3\uff0c\u5fc3\u97f3\u6709S3\uff0c\u4e8c\u5074\u4e0b\u80a2\u6709\u7b2c\u4e8c\u5ea6\u6c34\u816b\uff0c\u7531\u5c3f\u7ba1\u6d41\u51fa\u7684\u5c3f\u6db2\u662f\u6e05\u6f88\u7684\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u8840\u6e05Creatinine 2.8 mg/dL\u3002\r\u8acb\u554f\u6b64\u6642\u5c0d\u75c5\u4eba\u5c0e\u5c3f\u7ba1\u6700\u6070\u7576\u7684\u8655\u7406\u70ba\u4f55?\nA. \u4e09\u5929\u5f8c\u62d4\u5c0e\u5c3f\u7ba1\nB. \u63db\u4e00\u652f\u5c0e\u5c3f\u7ba1\nC. \u62d4\u6389\u5c0e\u5c3f\u7ba1\nD. \u7576\u814e\u529f\u80fd\u56de\u5fa9\u5230\u75c5\u4eba\u57fa\u790e\u503c\u6642\u62d4\u5c0e\u5c3f\u7ba1\nE. \u7b49\u51fa\u9662\u518d\u62d4\u5c0e\u5c3f\u7ba1\n": "(C)", "108-5.\n\u8fd1\u5e74\u53c8\u8208\u8d77\u9ebb\u75b9\u7fa4\u805a\u75ab\u60c5\uff0c\u76f8\u95dc\u6558\u8ff0\u8acb\u9078\u51fa\u6700\u6b63\u78ba\u4e4b\u7d44\u5408\u3002\r(1)\u50b3\u7d71\u521d\u6b21\u611f\u67d3\u9ebb\u75b9\u7684\u81e8\u5e8a\u8868\u73fe\u5305\u62ec\u5168\u8eab\u6027\u76ae\u819a\u6591\u4e18\u75b9\uff0c\u767c\u71d238.3\u00b0C\u4ee5\u4e0a\uff0c\u4ee5\u53cacoryza\uff0ccough\u6216conjunctivitis\uff0c\u800c\u66fe\u65bd\u6253\u904e\u75ab\u82d7\u8005\u5f97\u5230\u9ebb\u75b9\u5247\u75c7\u72c0\u5e38\u5448\u73fe\u4e0d\u5178\u578b (2)\u9ebb\u75b9\u8fc4\u4eca\u4e26\u7121\u6297\u75c5\u6bd2\u85e5\u7269\u53ef\u6cbb\u7642\uff0c\u81e8\u5e8a\u8655\u7406\u63a1\u652f\u6301\u6027\u6cbb\u7642\u5982\u6c34\u4efd\u548c\u9000\u71d2\u85e5\u3002\u800cvitamin A\u6cbb\u7642\u53ef\u964d\u4f4e\u9ebb\u75b9morbidity\u548cmortality (3)\u9ebb\u75b9\u56b4\u91cd\u5408\u4f75\u75c7\u5305\u62ec\u75c5\u6bd2\u76f4\u63a5\u4fb5\u72af\u547c\u5438\u9053\u53ca\u7e8c\u767c\u6027\u7d30\u83cc\u611f\u67d3\u9020\u6210\u80ba\u708e\u6216\u4e2d\u8033\u708e\u3002\u6975\u56b4\u91cd\u7684\u8166\u810a\u9ad3\u708e\u767c\u751f\u7387\u7d04\u70ba\u5343\u5206\u4e4b\u4e00 (4)\u91ab\u8b77\u4eba\u54e1\u82e510\u81f315\u5e74\u5167\u6709\u6253\u904eMMR\u75ab\u82d7\uff0c\u5728\u672a\u9632\u8b77\u60c5\u6cc1\u66b4\u9732\u5230\u5e36\u75c5\u6bd2\u91cf\u8f03\u9ad8\u7684\u514d\u75ab\u6291\u5236\u60a3\u8005\uff0c\u4e0d\u5fc5\u64d4\u5fc3\u906d\u53d7\u611f\u67d3\r(5)\u6025\u6027IgM\u82e5\u5448\u9670\u6027\uff0c\u4e5f\u4e0d\u53ef\u6392\u9664\u611f\u67d3\uff0c\u800c\u9f3b\u54bd\u62ed\u5b50PCR\u6aa2\u6e2c\u4e4b\u967d\u6027\u7387\u6703\u66f4\u9ad8\u3002\nA. (1)+(3)+(5)\nB. (1)+(2)+(3)\nC. (1)+(2)+(3)+(4)\nD. (1)+(2)+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "108-6.\n\u6709\u95dc\u767b\u9769\u71b1\u7684\u63cf\u8ff0\uff0c\u6700\u6b63\u78ba\u7684\u7d44\u5408\u70ba\u4e0b\u5217\u4f55\u8005?\t\r(1)\u767c\u75b9\u7d04\u5728\u982d\u75db\u3001\u767c\u71d2\u7b2c4\u81f3\u7b2c7\u65e5\uff0c\u5f9e\u8ec0\u5e79\u6563\u81f3\u982d\u90e8\u53ca\u56db\u80a2\u3002\r(2)\u767c\u75b9\u6b21\u5e8f\u548c\u9ebb\u75b9\u985e\u4f3c\u3002\r(3)\u76ae\u75b9\u51fa\u73fe\u6642\uff0c\u8840\u5c0f\u677f\u3001\u767d\u8840\u7403\u6578\u76ee\u7d04\u964d\u81f3\u6700\u4f4e\u9ede\uff0c\u800c\u5f8c\u518d\u9010\u6f38\u56de\u5347\u3002\r(4)\u76ae\u75b9\u521d\u767c\u984f\u8272\u8f03\u6f6e\u7d05\uff0c\u800c\u5f8c\u6f38\u6697\u6d88\u9000\uff0c\u7d044-7\u5929\u624d\u6d88\u5931\u3002\r(5)\u7d04\u670950%\u81f390%\u7684\u75c5\u4eba\u611f\u67d3\u75c7\u72c0\u4e0d\u660e\u986f\u3002\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(4)+(5)\nC. (1)+(2)+(3)+(4)+(5)\nD. (3)+(4)+(5)\nE. (1)+(2)+(3)\n": "(B)", "108-7.\n\u6709\u6548\u964d\u4f4e\u4e2d\u5fc3\u975c\u8108\u5c0e\u7ba1\u611f\u67d3\u7684\u7d44\u5408\u5f0f\u65b9\u6cd5\u5df2\u7d93\u5728\u5148\u9032\u570b\u5bb6\u5f97\u5230\u9a57\u8b49\uff0c\u5176\u4e2d\u5305\u62ec: (1)\u624b\u90e8\u885b\u751f\uff0c\u9078\u64c7\u9069\u7576\u7f6e\u5165\u90e8\u4f4d (2)\u4f7f\u75282% chlorhexidine\u6d88\u6bd2\u5291\u6d88\u6bd2\u76ae\u819a (3)\u6700\u5927\u7121\u83cc\u9762\u9632\u8b77 (4)\u6bcf\u65e5\u8a55\u4f30\u5118\u65e9\u62d4\u9664\u4e0d\u9700\u8981\u4e4b\u5c0e\u7ba1 (5)\u7d44\u5957\u5f0f\u7684\u4f9b\u61c9\u5305\u6216\u7f6e\u653e\u8eca\uff0c\u63a1checklist\u4ee5\u78ba\u5b9a\u6bcf\u4e00\u6b65\u9a5f\u4e4b\u9075\u5f9e\u3002\nA. (1)+(2)+(4)\nB. (1)+(3)+(4)\nC. (1)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(4)+(5)\nE. (1)+(2)+(3)+(4)\n": "(D)", "108-8.\n\u624b\u90e8\u885b\u751f\u662f\u9810\u9632\u9662\u5167\u4ea4\u53c9\u611f\u67d3\u6700\u6709\u6548\u4e4b\u65b9\u6cd5\uff0c\u6709\u95dc\u9152\u7cbe\u6027\u4e7e\u6d17\u624b\u4e4b\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba? (1)\u624b\u90e8\u6709\u660e\u986f\u5f04\u9ad2\u6216\u8840\u6db2\u6c59\u67d3\u4e0d\u53ef\u4f7f\u7528\uff0c\u61c9\u63a1\u6d17\u624b\u4e73\u6fd5\u6d17\u624b (2)\u5728\u63a5\u89f8\u75c5\u4eba\u6216\u65c1\u908a\u74b0\u5883\u524d\u5f8c\u4f7f\u7528 (3)\u75c5\u623f\u6709Clostridium difficile\u7fa4\u805a\u611f\u67d3\u6642\u4f7f\u7528 (4)\u8178\u75c5\u6bd2\u6d41\u884c\u6642\u4f7f\u7528 (5)\u5927\u90e8\u5206\u7684\u60c5\u6cc1\u7686\u53ef\u4f7f\u7528\u3002\nA. (1)+(2)+(5)\nB. (1)+(2)+(3)+(5)\nC. (1)+(2)+(4)+(5)\nD. (1)+(2)+(3)+(4)+(5)\nE. (2)+(3)+(4)+(5)\n": "(A)", "108-9.\n\u53f0\u7063\u5730\u534065\u6b72\u4ee5\u4e0a\u8001\u4eba\uff0c\u5efa\u8b70\u63a5\u7a2e\u75ab\u82d7\u70ba\u4f55? (1)\u80ba\u708e\u7403\u83cc\u75ab\u82d7 (2)\u65e5\u672c\u8166\u708e\u75ab\u82d7 (3)\u6d41\u611f\u75ab\u82d7 (4)B\u578b\u55dc\u8840\u687f\u83cc\u75ab\u82d7(Hib vaccine) (5)\u7834\u50b7\u98a8\u53ca\u6e1b\u6bd2\u767d\u5589\u6df7\u5408\u75ab\u82d7(Td)\nA. (2)+(3)+(4)\nB. (2)+(3)+(5)\nC. (1)+(2)+(3)\nD. (1)+(3)+(5)\nE. (1)+(3)\n": "(D)", "108-10.\n\u6709\u95dc\u6297\u751f\u7d20\u4e4b\u63cf\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba?\nA. Fluoroquinolone\u985e\u6297\u751f\u7d20\u5728QTc prolongation\u7684\u75c5\u4eba\u7522\u751f\u5fc3\u5f8b\u4e0d\u6574\u7684\u98a8\u96aa\u589e\u52a0\nB. \u8001\u5e74\u4eba\u548c\u540c\u6642\u7528steroid\u7684\u4eba\u4f7f\u7528fluoroquinolone\u6703\u589e\u52a0tendinitis\u526f\u4f5c\u7528\u4e4b\u98a8\u96aa\nC. \u61f7\u5b55\u5a66\u4eba\u4e0d\u5efa\u8b70\u4f7f\u7528streptomycin\uff0ctetracycline\u6216tigecycline (category D)\nD. \u4f7f\u7528ceftriaxone\u4e0d\u53ef\u52a0\u5165\u542b\u9223\u4e4b\u9ede\u6ef4\u6ce8\u5c04\u6db2\nE. Fluoroquinolone\u5c0dMRSA\u53caVRE\u6cbb\u7642\u6548\u679c\u826f\u597d\n": "(E)", "108-11.\n\u793e\u5340\u6027\u6297\u85e5\u6027\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc(Community-acquired MRSA)\u80ba\u708e\u611f\u67d3\uff0c\u8fd1\u5e74\u4f86\u6709\u6d41\u884c\u7387\u4e0a\u5347\u7684\u8da8\u52e2\uff0c\u4e0b\u5217\u76f8\u95dc\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576?\nA. \u80ba\u90e8\u611f\u67d3\u8f03\u6613\u51fa\u73fe\u958b\u6d1e\u6027\u75c5\u7076(Cavitation)\u6216\u58de\u6b7b\nB. \u75c5\u4eba\u5927\u591a\u70ba\u6162\u6027\u814e\u529f\u80fd\u4e0d\u5168\u63a5\u53d7\u8840\u6db2\u900f\u6790\u60a3\u8005(Chronic dialysis)\nC. \u60a3\u8005\u8f03\u70ba\u5e74\u8f15\uff0c\u4e14\u591a\u534a\u4e4b\u524d\u5065\u5eb7\u72c0\u6cc1\u826f\u597d\nD. \u5408\u4f75\u54b3\u8840\u3001\u808c\u8089\u75e0\u75db\u53ca\u76ae\u75b9\nE. \u9664oxacillin\u6297\u85e5\u4e4b\u5916\uff0c\u5176\u4ed6\u591a\u6578\u6297\u751f\u7d20\u5177\u6709\u611f\u53d7\u6027(susceptible)\n": "(B)", "108-12.\n\u4e0b\u5217\u793e\u5340\u6027\u80ba\u708e\u81f4\u75c5\u539f\u8207\u5bbf\u4e3b\u56e0\u5b50\u4e4b\u914d\u5c0d\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576?\nA. Alcoholism - Streptococcus pneumoniae\nB. Bronchiectasis - Pseudomonas aeruginosa\nC. Post-Influenza illness - Stapylococcus aureus\nD. Exposure to bird - Chlamydia trochomatis\nE. Exposure to sheep - Coxiella burnetii\n": "(D)", "108-13.\n\u4e00\u4f4d30\u6b72\u5973\u6027\uff0c\u958b\u5fc3\u642d\u4e58\u90f5\u8f2a\u51fa\u904a\uff0c\u4f46\u5728\u8239\u4e0a\u9032\u98df\u5f8c24\u5c0f\u6642\u5de6\u53f3\u958b\u59cb\u51fa\u73fe\u767c\u71d2\u3001\u8179\u75db\u3001\u8179\u7009\u4e4b\u75c7\u72c0\uff0c\u5176\u4ed6\u540c\u884c\u8005\u4e5f\u6709\u591a\u4eba\u51fa\u73fe\u8178\u80c3\u4e0d\u9069\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u81f4\u75c5\u539f?\nA. Norovirus\nB. Giardia lamblia\nC. Cryptosporidium\nD. Entameoba histolytica\nE. Escherichia coli\n": "(A)", "108-14.\n\u6709\u95dc\u5178\u578b\u9000\u4f0d\u8ecd\u4eba\u75c7(Legionnaires' disease)\u4e4b\u75c5\u53f2\uff0c\u81e8\u5e8a\u8868\u5fb5\u8207\u6aa2\u9a57\u7d50\u679c\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u9069\u7576?\nA. \u4f75\u6709\u767c\u9ad8\u71d2(>40\u2103)\u3001\u8179\u7009(Diarrhea)\u7b49\nB. \u5c3f\u6db2\u6297\u539f\u53cd\u61c9\u4e4b\u654f\u611f\u5ea6(Sensitivity)\u7d04\u70ba70%\nC. \u4f75\u6709\u9ad8\u8840\u9209\u75c7(hypernatremia)\u53ca\u4f4e\u8840\u9240\u75c7(hypokalemia)\nD. \u5178\u578b\u75f0\u6db2\u53ef\u898b\u4e2d\u6027\u7403(neutrophils)\u6d78\u6f64\u589e\u52a0\u4f46\u9769\u862d\u6c0f\u67d3\u8272\u627e\u4e0d\u5230\u7d30\u83cc\nE. \u8207\u6709\u6c59\u67d3\u7684\u6c34\u6e90\u74b0\u5883\u63a5\u89f8\u6709\u95dc\n": "(C)", "108-15.\n\u4e00\u4f4d30\u6b72\u7684\u5973\u6027\uff0c\u5403\u4e86\u751f\u8c6c\u8089\u4e4b\u5f8c\u767c\u751f\u660e\u986f\u7684\u8178\u80c3\u708e\u75c7\u72c0\uff0c\u4e14\u6709\u767c\u71d2\u3001\u53f3\u4e0b\u8179\u75db\u53ca\u8179\u7009\uff0c\u6025\u8a3a\u5ba4\u8a3a\u67e5\u767c\u73feterminal ileum\u90e8\u4f4d\u767c\u708e(ileitis)\uff0c\u4e26\u6709\u53f3\u4e0b\u8179\u90e8\u53cd\u5f48\u75db\u7591\u4f3c\u76f2\u8178\u708e\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u662f\u4e0b\u5217\u54ea\u4e00\u7a2e\u8178\u9053\u81f4\u75c5\u539f?\nA. Vibrio cholera\nB. Salmonella typhi\nC. Yersinia enterocolitica\nD. E. coli O157\nE. Enterovirus 71 (EV71)\n": "(C)", "108-16.\n\u6709\u95dc\u4e2d\u6771\u547c\u5438\u75c7\u72c0\u7fa4\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7(MERS-CoV)\uff0c\u4e0b\u5217\u4f55\u8005\u6558\u8ff0\u70ba\u975e\uff1f\nA. \u50b3\u67d3\u9014\u5f91\u70ba\u98db\u6cab\u53ca\u63a5\u89f8\u50b3\u67d3\uff0c\u6f5b\u4f0f\u671f\u7d04\u70ba7\u81f314\u5929\uff0c\u5df2\u6709\u51fa\u73fe\u5c40\u9650\u6027\u4eba\u50b3\u4eba\u7684\u7fa4\u805a\u611f\u67d3\u4e8b\u4ef6\nB. \u4e2d\u6771\u547c\u5438\u75c7\u72c0\u7fa4\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7\u81e8\u5e8a\u8868\u73fe\u5305\u62ec\u767c\u71d2\u3001\u54b3\u55fd\u3001\u547c\u5438\u6025\u4fc3\u8207\u547c\u5438\u56f0\u96e3\u3001\u901a\u5e38\u6703\u6709\u80ba\u708e\uff0c\u90e8\u5206\u75c5\u4eba\u6703\u51fa\u73fe\u814e\u8870\u7aed\u3001\u5fc3\u5305\u819c\u708e\u3001\u8840\u7ba1\u5167\u7030\u6f2b\u6027\u51dd\u8840(DIC)\u6216\u6b7b\u4ea1\nC. \u75c5\u60a3\u5c31\u91ab\u6216\u9032\u884c\u6aa2\u67e5\u6642\uff0c\u75c5\u60a3\u9700\u5f37\u5236\u914d\u6234N95\u53e3\u7f69\uff0c\u4f4f\u9662\u91cd\u75c7\u63d2\u7ba1\u75c5\u60a3\u6b7b\u4ea1\u7387\u7d04\u70ba10%\u81f312%\nD. \u75c5\u60a3\u61c9\u5165\u4f4f\u8ca0\u58d3\u9694\u96e2\u75c5\u5ba4\uff0c\u82e5\u7121\u8ca0\u58d3\u9694\u96e2\u75c5\u5ba4\u53ef\u66ab\u6642\u5b89\u7f6e\u6709\u885b\u6d74\u8a2d\u5099\u7684\u55ae\u4eba\u75c5\u5ba4\uff0c\u4e14\u75c5\u5ba4\u623f\u9580\u61c9\u7dad\u6301\u95dc\u9589\nE. \u76ee\u524d\u4ecd\u7121\u6709\u6548\u6cbb\u7642\u85e5\u7269\uff0c\u4e3b\u8981\u4ee5\u652f\u6301\u6027\u7642\u6cd5\u70ba\u4e3b\n": "(C)", "108-17.\n\u6709\u95dc\u81f4\u75c5\u539f\u611f\u67d3\u8207\u6297\u751f\u7d20\u6cbb\u7642\u7684\u914d\u5c0d,\u4e0b\u5217\u54ea\u4e9b\u7d44\u5408\u662f\u6b63\u78ba\u7684?\r(1) Bacteroides - metronidazole\r(2) Meningococcus - ceftriaxone\r(3) Staphylococcus - vancomycin or oxacillin\r(4) Enterococcus - cefazolin\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(3)+(4)\nD. (1)+(2)+(4)\nE. (1)+(2)+(3)+(4)\n": "(A)", "108-18.\n\u6709\u4e00\u4f4d30\u6b72\u5b55\u5a66\uff0c\u60f3\u4f86\u9580\u8a3a\u65bd\u6253\u75ab\u82d7\u9810\u9632\u611f\u67d3\uff0c\u4e0b\u5217\u54ea\u4e9b\u75ab\u82d7\u5c6c\u65bc\u6d3b\u6027\u75ab\u82d7\u662f\u5b55\u5a66\u4e0d\u5efa\u8b70\u6ce8\u5c04\u7684?\r(1) Influenza vaccine \u6d41\u611f\u75ab\u82d7\r(2) MMR vaccine (Measles - Mump - Rubella vaccine) \u9ebb\u75b9-\u816e\u817a\u708e-\u5fb7\u570b\u9ebb\u75b9\u75ab\u82d7\r(3) Varicella vaccine \u6c34\u75d8\u75ab\u82d7\r(4) Pneumococcal vaccine \u80ba\u708e\u93c8\u7403\u83cc\u75ab\u82d7\nA. (1)+(3)\nB. (2)+(3)\nC. (1)+(4)\nD. (1)+(2)+(3)\nE. (2)+(3)+(4)\n": "(B)", "108-19.\n\u6709\u95dc\u9000\u4f0d\u8ecd\u4eba\u75c7(Legionella Infection)\u4e4b\u6cbb\u7642\u85e5\u7269\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6700\u5b8c\u6574\u7684\u53ef\u9078\u64c7\u85e5\u7269\u7d44\u5408?\r(1)Macrolides\r(2)Quinolones\r(3)Tetracyclines\r(4)Cephalosporins\r(5)Trimethoprim/ Sulfamethoxazle\nA. (1)+(2)\nB. (1)+(2)+(3)\nC. (2)+(3)+(4)\nD. (1)+(2)+(3)+(5)\nE. (3)+(4)+(5)\n": "(D)", "109-101.\u9580\u8a3a\u4f86\u4e86\u4e00\u4f4d70\u6b72\u5973\u6027 \uff0c\u5979\u5148\u751f3\u500b\u6708\u524d\u78ba\u8a3a\u958b\u653e\u6027\u80ba\u7d50\u6838 \uff0c\u5979\u65bc2\u500b\u6708\u524d\u7167\u4e00\u5f35\u80f8\u90e8 X\u5149\u7121\u7570\u5e38\u72c0\u6cc1 \uff0c\u5979\n\u73fe\u5728\u6c92\u4efb\u4f55\u75c7\u72c0 \u3002\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u5e6b\u5979\u5b89\u6392\u80f8\u90e8 X\u5149\u6aa2\u67e5\uff0c\u82e5\u6b63\u5e38\uff0c\u5247\u7e7c\u7e8c\u5b9a\u671f\u8ffd\u8e64\nB.\u5e6b\u5979\u5b89\u6392\u80f8\u90e8 X\u5149\u6aa2\u67e5\uff0c\u767c\u73fe\u53f3\u4e0b\u80ba\u6709\u6d78\u6f64\u73fe\u8c61\uff0c\u7d66\u4e88\u8655\u65b9levofloxacin\u6cbb\u76427-10\u5929\nC.\u5e6b\u5979\u5b89\u6392\u80f8\u90e8 X\u5149\u6aa2\u67e5\uff0c\u7121\u7570\u5e38\u767c\u73fe \uff0c\u53ef\u518d\u5b89\u6392\u4e19\u578b\u5e72\u64fe\u7d20\u91cb\u51fa\u5206\u6790 (inferferon -\u03b3 release assay )\u6aa2\n\u6e2c\uff0c\u4ee5\u505a\u70ba\u6f5b\u4f0f\u7d50\u6838\u6cbb\u7642\u6c7a\u7b56\u4e4b\u53c3\u8003\nD.\u76f4\u63a5\u5b89\u6392\u4e19\u578b\u5e72\u64fe\u7d20\u91cb\u51fa\u5206\u6790\u6aa2\u6e2c\uff0c\u82e5\u70ba\u967d\u6027\u7d50\u679c\uff0c\u7d93\u75c5\u4eba\u540c\u610f\u53ef\u76f4\u63a5\u7d66\u4e88\u6f5b\u4f0f\u7d50\u6838\u6cbb\u7642\u8655\u65b9   \nE.\u5e6b\u5979\u5b89\u6392\u80f8\u90e8 X\u5149\u6aa2\u67e5\uff0c\u767c\u73fe\u53f3\u4e0b\u80ba\u6709\u6d78\u6f64\u73fe\u8c61\uff0c\u8490\u96c6\u75f0\u6db2acid fast stain\u9670\u6027\uff0c\u7e7c\u7e8c\u5b9a\u671f\u8ffd\u8e64\u5373\u53ef\n": "[C]", "109-102.\u4f60\u6536\u7642\u7684\u767b\u9769\u71b1\u60a3\u8005\u5373\u5c07\u51fa\u9662\uff0c\u95dc\u65bc\u51fa\u9662\u885b\u6559\uff0c\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba\uff1f    \nA.\u767b\u9769\u71b1\u5e38\u767c\u751f\u5728\u71b1\u5e36\u53ca\u4e9e\u71b1\u5e36\u5730\u5340\uff0c\u5728\u53f0\u7063\u4e3b\u8981\u75c5\u5a92\u868a\u70ba\u7627\u868a\u548c\u767d\u7dda\u6591\u868a\nB.\u5f97\u904e\u767b\u9769\u71b1\u4e4b\u5f8c\u5373\u6703\u51fa\u73fe\u4fdd\u8b77\u6027\u6297\u9ad4\uff0c\u5c0d\u767b\u9769\u71b1\u7d42\u751f\u514d\u75ab\nC.\u767b\u9769\u71b1\u4e00\u5171\u6709 4\u578b\uff0c\u76ee\u524d\u8a8d\u70ba\u7b2c\u4e00\u6b21\u611f\u67d3\u767b\u9769\u71b1\u75c5\u6bd2\u5f8c\u9ad4\u5167\u81ea\u7136\u7522\u751f\u7684\u6297\u9ad4 \uff0c\u53ef\u80fd\u6703\u5728\u611f\u67d3\u5176\u4ed6\u578b\u5225\n\u767b\u9769\u71b1\u6642\u9020\u6210 \u300c\u6297\u9ad4\u4f9d\u8cf4\u6027\u514d\u75ab\u52a0\u5f37\u53cd\u61c9 \u300d(antibody dependent enhancement; ADE )\uff0c\u9020\u6210\u56b4\u91cd\u7684\n\u4f75\u767c\u75c7\nD.\u767b\u9769\u51fa\u8840\u71b1 (dengue hemorrhagic fever) \u8207\u767b\u9769\u71b1\u4f11\u514b\u75c7\u5019\u7fa4 (dengue shock syndrome) \u50c5\u6703\u51fa\u73fe\u5728\n\u7b2c\u4e00\u578b\u767b\u9769\u71b1 \uff0c\u6240\u4ee5\u82e5\u66fe\u5f97\u904e\u767b\u9769\u51fa\u8840\u71b1 \uff0c\u5c31\u6703\u7d42\u751f\u514d\u75ab\u4e86\nE.\u767b\u9769\u71b14\u6548\u50f9\u6e1b\u6bd2\u6d3b\u75ab\u82d7 (Sanofi) \u5efa\u8b70\u4f7f\u7528\u65bc\u672a\u66fe\u611f\u67d3\u904e\u767b\u9769\u71b1\u7684\u4eba\n": "[C]", "109-103.\u6709\u95dc\u8178\u7403\u83cc\u8207\u6297\u751f\u7d20\u4e4b\u6558\u8ff0 \uff0c\u8acb\u9078\u51fa\u6700\u6b63\u78ba\u7684\u7b54\u6848\n(1) Vancomycin\u6297\u85e5\u6027\u8178\u7403\u83cc (VRE) \u6700\u5e38\u898b\u7684\u83cc\u7a2e\u662fEnterococcus faecium\n(2) Enterococcus faecalis\u83cc\u8840\u75c7\u901a\u5e38\u4ee5 vancomycin\u6cbb\u7642\n(3) Enterococcus faecails\u611f\u67d3\u7684\u9996\u9078\u6cbb\u7642\u901a\u5e38\u662f ampicillin\n(4) VRE\u7684\u56b4\u91cd\u611f\u67d3\u5e38\u9700\u4f7f\u7528linezolid \u6216daptomycin\u6cbb\u7642\n(5) \u5c3f\u6db2\u57f9\u990a\u6216\u75f0\u6db2\u57f9\u990a\u6709VRE \uff0c\u9700\u4f7f\u7528linezolid\u6cbb\u7642   \nA.(1)+(2)\nB.(1)+(3)\nC.(2)+(4)\nD.(1)+(3)+(4)\nE.(1)+(2)+(3)+(4)+(5)\n": "[D]", "109-104.\u52a0\u8b77\u75c5\u623f\u6d17\u6c34\u69fd\u540c\u6642\u4f7f\u7528\u65bc\u6c59\u67d3\u7269\u6e05\u6d17\u548c\u6d17\u624b\u7b49\u884c\u70ba \uff0c\u5bb9\u6613\u9020\u6210\u9662\u5167\u611f\u67d3 \uff0c\u56e0\u6b64\u5efa\u8b70\u6c59\u6c34\u8207\u6e05\u6f54\u6c34\u69fd\u9700\u5340\n\u5206\u6e05\u695a\uff0c\u751a\u81f3\u5c07\u6c59\u6c34\u69fd\u79fb\u51fa\u52a0\u8b77\u75c5\u623f \uff0c\u5e38\u898b\u4e4b\u75c5\u539f\u83cc\u4e0b\u5217\u4f55\u8005\u70ba\u975e \uff1f   \nA.Pseudomonas aeruginosa\nB.Nontuberculous Mycobacterium\nC.Chryseobacterium\nD.Stenotrophomonas maltophilia\nE.Aspergillus fumigatus\n": "[E]", "109-105.\u98df\u5a92\u6027\u75be\u75c5\uff0c\u4ee5\u4e0b\u54ea\u4e9b\u914d\u5c0d\u6700\u4e0d\u6b63\u78ba\uff1f    \nA.Listeriosis\u8207\u4e73\u916a\nB.Campylobacter jejuni\u8207\u672a\u716e\u719f\u96de\u8089\nC.Salmonella\u8207\u751f\u96de\u86cb\nD.Norovirus\u8207\u751f\u8814\u6216\u6c61\u67d3\u7684\u6c34\nE.Q fever\u8207\u751f\u725b\u8089\n": "[E]", "109-106.\u66b4\u9732\u5f8c\u9810\u9632\u5efa\u8b70\u4f7f\u7528\u6297\u5fae\u751f\u7269\u88fd\u5291\u8005 \uff0c\u8acb\u9078\u51fa\u6700\u9069\u7576\u7684\u7b54\u6848 \uff1f\n(1) HIV\n(2) \u9ebb\u75b9\n(3) COVID-19\n(4) Influenza\n(5) Meningococcus      \nA.(1)+(2)+(4)\nB.(1)+(3)+(4)\nC.(1)+(4)+(5)\nD.(1)+(3)+(4)+(5)\nE.(1)+(2)+(3)+(4)+(5)\n": "[C]", "109-107.\u4e0b\uf99c\u7528\u65bc\u6cbb\u7642methicillin-resistant Staphylococcus aureus (MRSA)\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f    \nA.MRSA\u8207 methicillin-susceptible Staphylococcus aureus (MSSA) \u5fc3\u5167\u819c\u708e\u6b7b\u4ea1\u7387\u76f8\u8fd1\nB.\u53ea\u6709\u9662\u5167\u611f\u67d3\u624d\u6709MRSA\u7684\u98a8\u96aa\uff0c\u4e00\u822c\u793e\u5340\u578b\u80ba\u708e\u4e0d\u61c9\u5c07MRSA\u5217\u5165\u8003\u91cf\nC.Tigecycline\u5c6c\u65bc\u6bba\u83cc\u578b\u85e5\u7269\uff0c\u53ef\u7528\u65bc\u5fc3\u5167\u819c\u708e\u53ca\u83cc\u8840\u75c7\u4e4b\u6cbb\u7642\uff0c\u9ad8\u5291\u91cf\u4f7f\u7528\u9808\u6ce8\u610f\u8178\u80c3\u9053\u75c7\u72c0\nD.Linezolid\u9577\u6642\u9593\u4f7f\u7528\u53ef\u80fd\u6703\u9020\u6210\u8840\u5c0f\u677f\u6578\u91cf\u964d\u4f4e\uff0c\u4e5f\u53ef\u80fd\u5f15\u767c\u8996\u795e\u7d93\u75c5\u8b8a\uff0c\u9808\u6ce8\u610f\u773c\u5e95\u6aa2\u67e5\nE.Vancomycin\u4f7f\u7528\u6642\u53ea\u9808\u76e3\u6e2c\u8840\u4e2d trough \u6fc3\u5ea6\uff0c\u4ee5\u8a55\u4f30\u5176\u7642\u6548\u53ca\u526f\u4f5c\u7528\n": "[D]", "109-108.\u6709\u95dc\u51a0\u72c0\u75c5\u6bd2 \uff0c\u8acb\u9078\u51fa\u6700\u9069\u7576\u7684\u7b54\u6848\u3002 \n(1) SARS-CoV\u3001MERS-CoV\u3001SARS-CoV-2\u7686\u5c6c\u65bcRNA\u75c5\u6bd2 \uff0c\u6b64\u4e09\u8005\u7686\u5c6c\u65bcBetacoronavirus\n(2) \u51a0\u72c0\u75c5\u6bd2\u4e2d \uff0cE gene\u8ca0\u8cac\u88fd\u9020Envelope protein \uff0c\u5e6b\u52a9\u75c5\u6bd2\u7d50\u5408\u53d7\u9ad4 \uff0c\u9032\u800c\u5165\u4fb5\u4eba\u9ad4\u7d30\u80de\n(3) \u6b64\u4e09\u682a\u75c5\u6bd2\u4ee5SARS -CoV\u611f\u67d3\u8005\u4e4b\u6b7b\u4ea1\u7387\u6700\u9ad8\n(4) SARS-CoV-2\u611f\u67d3\u8005\u53ef\u80fd\u5f15\u767c\u7d30\u80de\u7d20\u98a8\u66b4\u75c7\u5019\u7fa4 (cytokine storm syndrome )\uff0c\u76ee\u524d\u5df2\u767c\u73fe\u91cd\u75c7\u60a3\u8005\u9ad4\n\u5167IL-6\u6fc3\u5ea6\u6703\u504f\u9ad8\n(5) \u5efa\u8b70\u5e38\u898f\u4f7f\u7528hydroxychloroquine\u4ee5\u6709\u6548\u6cbb\u7642SARS -CoV-2\u611f\u67d3\u8005   \nA.(1)+(2)+(3)\nB.(1)+(3)+(4)\nC.(1)+(3)\nD.(1)+(4)\nE.(2)+(3)+(5)\n": "[D]", "109-109.\u8acb\u554f\u7d30\u83cc\u6027\u8166\u819c\u708e\u7684\u8a3a\u65b7\u3001\u6cbb\u7642\u4ee5\u4e0b\u4f55\u8005\u932f\u8aa4\uff1f    \nA.\u9808\u76e1\u5feb\u4f7f\u7528\u6297\u751f\u7d20\nB.\u75c5\u4eba\u53ef\u80fd\u6703\u982d\u75db\u3001\u754f\u5149\nC.\u78ba\u5b9a\u8a3a\u65b7\u9700\u8170\u690e\u7a7f\u523a\uff0c\u5c07\u8166\u810a\u9ad3\u6db2\u9001\u57f9\u990a\nD.\u8170\u690e\u7a7f\u523a\u524d\u9808\u8003\u616e\u505a\u96fb\u8166\u65b7\u5c64\u907f\u514d\u52a0\u91cd\u53ef\u80fd\u5df2\u5347\u9ad8\u4e4b\u8166\u58d3\nE.\u4f7f\u7528\u8f03\u5f8c\u7dda\u4e4bcarbapenem\u985e\u6297\u751f\u7d20\u53ef\u907f\u514d\u6cbb\u7642\u5931\u6557\n": "[E]", "109-110.\u6709\u95dc\u767c\u71d2\u3001\u76ae\u75b9(skin rashes)\u4e4b\u75be\u75c5\u8207\u81f4\u75c5\u539f\u4e4b\u914d\u5c0d\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f    \nA.Measles (\u9ebb\u75b9) - Paramyxovirus\nB.Rubella (\u5fb7\u570b\u9ebb\u75b9) - Togavirus\nC.Erythema infectiosum (\u7b2c\u4e94\u75c5)- Coxsackievirues A9\nD.Roseola (\u73ab\u7470\u71b1\u3001\u7b2c\u516d\u75c5) - Human herpesvirus 6\nE.Dengue fever (\u767b\u9769\u71b1) \u2013Flaviviruses\n": "[C]", "109-111.\u4e00\u4f4d\u5eda\u5e2b \uff0c\u5728\u6e05\u7406\u5eda\u9918\u6642\u4e0d\u614e\u88ab\u8001\u9f20 (Rodent)\u54ac\u50b7\u8173\u8dbe \uff0c\u5e7e\u5929\u5f8c\u958b\u59cb\u51fa\u73fe\u9ad8\u71d2 \u3001\u754f\u5bd2\u3001\u982d\u75db\u3001\u56db\u80a2\u75bc\n\u75db\u3001\u6dcb\u5df4\u816b\u8139 \u3001\u8840\u6db2\u7d30\u83cc\u57f9\u990a\u6709\u5831\u544a\u9577\u83cc \uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u81f4\u75c5\u539f\u70baStreptobacillus moniliformis \u6216Pasteurella multocida   \nB.\u6b64\u611f\u67d3\u81f4\u75c5\u83cc\u5c6c\u65bc\u9769\u862d\u6c0f\u967d\u6027\u687f\u83cc(Gram positive bacilli)\nC.\u6b64\u83cc\u751f\u9577\u7de9\u6162\uff0c\u53ef\u80fd\u9700\u89813\u81f37\u5929\u57f9\u990a\u624d\u6703\u990a\u51fa\nD.\u82e5\u5c0d\u65bcPenicillin\u6709\u904e\u654f\uff0c\u53ef\u4ee5\u4f7f\u7528doxycycline\nE.\u81f4\u75c5\u539f\u4ea6\u53ef\u70baLeptospira\uff0c\u53ef\u5229\u7528\u8840\u6e05\u6297\u9ad4\u529b\u50f9\u8a3a\u65b7\n": "[B]", "109-112.\u6709\u95dc\u9810\u9632\u4e2d\u5fc3\u975c\u8108\u5c0e\u7ba1\u76f8\u95dc\u8840\u6d41\u611f\u67d3\u4e4b\u5be6\u8b49 \uff0c\u4e0b\u5217\u4f55\u8005\u7d44\u5408\u70ba\u6b63\u78ba \uff1f\n(1) \u4f7f\u7528\u6700\u5927\u7121\u83cc\u9762 (maximal barrier precautions )\u505a\u9632\u8b77\n(2) \u76ae\u819a\u6d88\u6bd2\u6548\u679c\u4f7f\u7528 \u03b2-iodine\u512a\u65bcchlorhexidine \n(3) \u7f6e\u653e\u5c0e\u7ba1\u524d\u5f8c\u9700\u57f7\u884c\u624b\u90e8\u885b\u751f (hand hygiene )\n(4) \u4e2d\u5fc3\u975c\u8108\u5c0e\u7ba1\u7f6e\u653e\u6642\u9593\u4ee514\u5929\u70ba\u539f\u5247 \uff0c\u6bcf14\u5929\u9700\u5e38\u898f\u66f4\u63db\u4e00\u6b21 \uff0c\u4ee5\u907f\u514d\u611f\u67d3   \nA.(1)+(2)+(3)+(4)\nB.(1)+(2)+(3)\nC.(2)+(4)\nD.(1)+(3)\nE.(1)+(3)+(4)\n": "[D]", "109-113.\u6709\u95dc\u6297\u751f\u7d20\u6cbb\u7642\u8207\u6557\u8840\u75c7\u81f4\u75c5\u539f\u7684\u914d\u5c0d ,\u4e0b\u5217\u54ea\u4e9b\u7d44\u5408\u662f\u6b63\u78ba\u7684 \uff1f\n(1) Ceftriaxone - Neisseria meningitidis \n(2) Penicillin - Group A Streptococcus \n(3) Clindamycin - Rickettsia \n(4) Ceftazidime- Enterococcus   \nA.(1)+(2)\nB.(2)+(3)\nC.(1)+(3)\nD.(2)+(4)\nE.(1)+(4)\n": "[A]", "109-114.\u6709\u4e00\u4f4d30\u6b72\u5b55\u5a66 \uff0c\u60f3\u4f86\u9580\u8a3a\u65bd\u6253\u75ab\u82d7\u9810\u9632\u611f\u67d3 \uff0c\u4e0b\u5217\u90a3\u4e9b\u75ab\u82d7\u662f\u5b55\u5a66\u4e0d\u5efa\u8b70\u6ce8\u5c04\u7684 \uff1f\n(1) Influenza vaccine \u6d41\u611f\u75ab\u82d7\n(2) MMR vaccine (Measles \u2013 Mump \u2013 Rubella vaccine) \u9ebb\u75b9 -\u816e\u817a\u708e-\u5fb7\u570b\u9ebb\u75b9\u75ab\u82d7\n(3) Varicella vaccine \u6c34\u75d8\u75ab\u82d7\n(4) Pneumococcal vaccine \u80ba\u708e\u93c8\u7403\u83cc\u75ab\u82d7   \nA.(1)+(3)\nB.(2)+(3)\nC.(1)+(4)\nD.(1)+(2)+(3)\nE.(2)+(3)+(4)\n": "[B]", "109-115.\u4e0b\u5217\u6709\u95dc\u793e\u5340\u6027\u80ba\u708e\u81f4\u75c5\u539f\u8207\u76f8\u95dc\u5bbf\u4e3b\u56e0\u7d20\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576\uff1f    \nA.Streptococcus pneumoniae -\u9152\u766e (alcoholism)\nB.Klebsiella pneumoniae \u2013\u7cd6\u5c3f\u75c5 (diabetes)\nC.Haemophilus influenzae \u2013\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5 (COPD)\nD.Pseudomonas aeruginosa \u2013\u652f\u6c23\u7ba1\u64f4\u5f35(bronchiectasis)\nE.Coxiella burnetii \u2013\u8207\u9ce5\u985e\u63a5\u89f8   \n": "[E]", "109-116.\u6709\u95dc2019\u65b0\u578b\u51a0\u72c0\u75c5\u6bd2\u611f\u67d3\u75c7(COVID-19)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f    \nA.COVID-19\u50b3\u67d3\u9014\u5f91\u4e3b\u8981\u70ba\u8fd1\u8ddd\u96e2\u98db\u6cab\u50b3\u67d3\u6216\u63a5\u89f8\u50b3\u67d3\nB.\u5178\u578b\u75c7\u72c0\u70ba\u767c\u71d2\u3001\u4e7e\u54b3\u3001\u5026\u6020\uff0c\u7d04\u6709\u4e09\u5206\u4e4b\u4e00\u6703\u547c\u5438\u6025\u4fc3\nC.\u76ee\u524d\u8a3a\u65b7COVID-19\u4ee5\u5206\u5b50\u6838\u9178RT-PCR\u70ba\u6025\u6027\u671f\u6aa2\u9a57\u9996\u9078\nD.70%\u9152\u7cbe\u4e7e\u6d17\u624b\u6db2\u53ef\u4ee5\u6709\u6548\u6bba\u6b7b\u51a0\u72c0\u75c5\u6bd2\nE.\u5168\u7403COVID-19 \u611f\u67d3\u7684\u6b7b\u4ea1\u7387\u7d04\u70ba0.5%~1%\n": "[E]", "109-117.\u4e00\u4f4d34\u6b72\u9577\u671f\u4f7f\u7528\u975c\u8108\u6ce8\u5c04\u6d77\u6d1b\u82f1\u7684\u7537\u6027 \uff0c\u56e0\u767c\u71d2\u3001\u5598\u3001\u547c\u5438\u56f0\u96e3\u4e00\u9031\u4f86\u6025\u8a3a\u5c31\u8a3a \uff0c\u8eab\u9ad4\u8a3a\u5bdf\u6709\u767c\u73fe\u6536\u7e2e\n\u671f\u5fc3\u96dc\u97f3 \uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e \uff1f\n (1) \u611f\u67d3\u539f\u6700\u5e38\u898b\u70ba\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc (Staphylococcus aureus )\n (2) \u6b64S. aureus \u6975\u5c11\u70bamethicillin\u6297\u85e5 (MRSA)\u6027\u83cc\u682a\n (3) \u6b64\u53f3\u5fc3\u5fc3\u5167\u819c\u708e \uff0c\u4ee5\u4e09\u5c16\u74e3 (tricuspid valve )\u70ba\u4e3b\u8981\u4fb5\u72af\u4f4d\u7f6e\n (4) \u76f8\u5c0d\u65bc\u975e\u975c\u8108\u85e5\u766e\u5fc3\u5167\u819c\u708e \uff0c\u6b64\u75c5\u4eba\u81f4\u75c5\u539f\u66f4\u5e38\u6709\u7da0\u81bf\u687f\u83cc (Pseudomonas aeruginosa )\u6216\u5ff5\u73e0\n\u83cc(Candida)\u611f\u67d3\u7684\u6a5f\u6703\n (5) \u82e5\u70baHIV\u611f\u67d3\u8005 \uff0c\u81f4\u75c5\u539f\u51fa\u73feHACEK group\u7684\u6a5f\u6703\u8f03\u9ad8   \nA.(1)+(2)+(3)\nB.(1)+(3)+(5)\nC.(4)+(5)\nD.(2)+(5)\nE.(1)+(2)+(3)+(4)+(5)\n": "[D]", "109-118.\u4e00\u4f4d50\u6b72\u4f4f\u9662\u63a5\u53d7\u5316\u5b78\u6cbb\u7642\u75c5\u60a3 \uff0c\u56e0\u4e2d\u6027\u7403\u4f4e\u4e0b\u767c\u71d2\u4f7f\u7528\u6297\u751f\u7d20 \uff0c\u6cbb\u7642\u671f\u9593\u767c\u751f\u8179\u7009 \uff0c\u81e8\u5e8a\u91ab\u5e2b\u61f7\u7591\u70ba\u56f0\n\u96e3\u68ad\u72c0\u687f\u83cc (Clostridium difficile )\u8178\u708e\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u81e8\u5e8a\u4e0a\u8a3a\u65b7\u611f\u67d3\u6027\u8179\u7009\uff0c\u9700\u5305\u62ec\u9023\u7e8c2 \u5929\u4ee5\u4e0a\u6bcf\u5929\u67093\u6b21\u4e0d\u6210\u5f62\u7cde\u4fbf\nB.\u53ef\u4ee5\u7528\u6838\u9178\u6aa2\u5b9atoxin A \u6216toxin B\u4f86\u78ba\u8a8d\u611f\u67d3\nC.\u8a3a\u65b7\u9700\u4f9d\u8cf4\u5167\u8996\u93e1\u6aa2\u67e5\u53ca\u7cde\u4fbf\u57f9\u990a\nD.\u5224\u5b9a\u6cbb\u7642\u662f\u5426\u5931\u6557\uff0c\u61c9\u81f3\u5c11\u4f7f\u75286\u5929\u85e5\u7269\u6aa2\u8996\u6cbb\u7642\u6548\u679c\u6c7a\u5b9a\nE.\u5c0d\u8f03\u56b4\u91cd\u611f\u67d3\u75c5\u60a3\uff0c\u5982\u8840\u6db2\u767d\u8840\u7403\u6578>15000/\u03bcL\uff0c\u9996\u9078\u4f7f\u7528\u53e3\u670dVancomycin\n": "[C]", "109-119.\u4e0b\u5217\u6709\u95dc\u816b\u7624\u8207\u611f\u67d3\u81f4\u75c5\u539f\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576\uff1f    \nA.\u5b50\u5bae\u9838\u764c-\u4eba\u985e\u4e73\u7a81\u75c5\u6bd2(HPV)\nB.\u5361\u6ce2\u897f\u6c0f\u7624(Kaposi\u2019s sarcoma) \u2013\u4eba\u985e\u7b2c8\u578b\u76b0\u75b9\u75c5\u6bd2(HHV-8)\nC.T\u7d30\u80de\u8840\u764c(T-cell leukemia) \u2013 HTLV-1\nD.\u809d\u7d30\u80de\u764c- B\u578b\u809d\u708e(HBV)\nE.\u809b\u9580\u9c57\u72c0\u4e0a\u76ae\u764c(squamous cell carcinoma) \u2013\u611b\u6ecb\u75c5\u6bd2(HIV)   \n": "[E]", "110-81.\u6709\u95dcCOVID -19\u7684\u6cbb\u7642 \uff0c\u4ee5\u4e0b\u4f55\u8005\u6b63\u78ba \uff0c\u8acb\u9078\u51fa\u6700\u9069\u7576\u7684\u7b54\u6848\n(1)\u55ae\u7368\u4f7f\u7528\u6297\u75c5\u6bd2\u85e5Remdesivir\u5c0d\u75be\u75c5\u8f15 \u3001\u91cd\u75c7\u60a3\u8005\u4e4b\u9810\u5f8c\u90fd\u6709\u6975\u70ba\u986f\u8457\u4e4b\u6548\u679c \u3002\n(2)\u55ae\u682a\u6297\u9ad4Bamlanivimab + Etesevimab\u4e3b\u8981\u4f5c\u7528\u65bc\u75c5\u6bd2spike glycoprotein \uff0c\u5c0d\u65bc\u75be\u75c5\u8f15\u5fae\u6216\u4e2d\u5ea6\u800c\u6709\u91cd\n\u75c7\u5371\u96aa\u56e0\u7d20\u5982\u5e74\u7d00 \u226565\u6b72\u3001\u80a5\u80d6(BMI \u226535)\uff0c\u6709\u6162\u6027\u814e\u75c5 \u3001\u6162\u6027\u80ba\u75c5 \u3001\u5fc3\u8840\u7ba1\u75be\u75c5 \u3001\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u514d\u75ab\n\u6291\u5236\u60a3\u8005 \uff0c\u65bc\u767c\u75c5\u8a3a\u65b7 3\u5929\u5167\u4f7f\u7528 \uff0c\u53ef\u964d\u4f4e\u4f4f\u9662\u548c\u6b7b\u4ea1\u4e4b\u98a8\u96aa \u3002\n(3)\u55ae\u682a\u6297\u9ad4Bamlanivimab + Etesevimab\u5c0d\u5357\u975e\u8b8a\u7570\u682a (B.1.351, \u03b2)\u548c\u5df4\u897f\u8b8a\u7570\u682a (P.1, \u03b3)\u5728\u9ad4\u5916\u4e2d\u548c\u8a66\u9a57\n\u6548\u679c\u8b8a\u5dee \uff0c\u800c\u55ae\u682a\u6297\u9ad4Casirivimab + Imdevimab\u5247\u5c0d\u524d\u8ff0\u75c5\u6bd2\u8b8a\u7570\u682a\u4e4b\u9ad4\u5916\u4e2d\u548c\u8a66\u9a57\u6548\u679c\u672a\u6539\u8b8a \u3002\n(4)IL-6 receptor blocker \u5982Tocilizumab\u5efa\u8b70\u8207dexamethasone\u5408\u4f75\u4f7f\u7528\u65bc\u56b4\u91cd\u80ba\u708e \u3002\n(5)JAK\u6291\u5236\u5291Baricitinib \uff0c\u4e0d\u53ef\u8207dexamethasone\u5408\u4f75\u4f7f\u7528 \u3002   \nA.(1)+(2)+(3)\u3002\nB.(2)+(3)+(4)\u3002\nC.(1)+(2)+(4)\u3002\nD.(2)+(3)+(5)\u3002\nE.(2)+(4)\u3002\n": "[B]", "110-82.\u63a5\u7a2e\u817a\u75c5\u6bd2\u8f09\u9ad4SARS -COV-2\u75ab\u82d7\u5076\u767c\u8840\u6813\u6027\u8840\u5c0f\u677f\u4f4e\u4e0b (thrombotic thrombocytopenia )\uff0c\u4ee5\u4e0b\u63cf\u8ff0\u4f55\u8005\n\u932f\u8aa4?   \nA.\u5927\u591a\u767c\u751f\u65bc\u63a5\u7a2e\u75ab\u82d7\u5f8c5\u81f330\u5929\u3002\nB.\u5e38\u898b\u8166\u975c\u8108\u8840\u6813\u3001\u8179\u8154\u5167\u975c\u8108\u8840\u6813\u6216\u80ba\u6813\u585e\u3002\nC.\u8868\u73fe\u8207heparin-induced thrombocytopenia\u5f88\u50cf\uff0c\u8207\u75c5\u4eba\u6700\u8fd1\u6709\u4f7f\u7528heparin\u6709\u95dc\u3002\nD.\u75c5\u4eba\u8840\u6e05\u4e2d\u53ef\u6e2c\u5230\u5c0d\u6297\u8840\u5c0f\u677f\u7b2c 4\u56e0\u5b50(platelet factor 4)\u7684\u8840\u5c0f\u677f\u6d3b\u5316\u6297\u9ad4 \uff0c\u8a72\u6297\u9ad4\u53ef\u7d93\u7531\u8207\u8840\u5c0f\n\u677fFc\u03b3\u63a5\u53d7\u5668\u800c\u6d3b\u5316\u8840\u5c0f\u677f \u3002\nE.\u6cbb\u7642\u5efa\u8b70\u4ee5nonheparin\u6297\u51dd\u8840\u5291\u6216IVIG\u3002\n": "[C]", "110-83.\u4e00\u4f4d58\u6b72\u7537\u6027\u56e0\u70ba\u9ad6\u9aa8\u9aa8\u6298\u63a5\u53d7\u624b\u8853 \uff0c\u624b\u8853\u5f8c\u767c\u751fMRSA\u611f\u67d3 \uff0c\u65bc\u4f4f\u9662\u5f8c\u63a5\u53d7\u6e05\u5275\u624b\u8853\u53cavancomycin \u6ce8\n\u5c04\uff0c\u6cbb\u7642\u4e09\u9031\u9032\u6b65\u5f8c\u51fa\u9662 \u3002\u51fa\u9662\u6642\u4f7f\u7528\u53e3\u670dlinezolid\u6cbb\u7642 \uff0c\u8acb\u554f\u5728\u9580\u8a3a\u8ffd\u8e64\u4e0b\u5217\u54ea\u4e00\u9805\u8f03\u4e0d\u91cd\u8981 ?   \nA.Linezolid\u4e0d\u53ef\u8207\u55ae\u80fa\u6c27\u5316\u9176\u6291\u5236\u5291 (monoamine oxidase inhibitor )\u6216selective serotonin re -uptake \ninhibitor\u5171\u540c\u4f7f\u7528 \u3002\nB.\u8981\u6ce8\u610f\u662f\u5426\u6709\u4e73\u9178\u4e2d\u6bd2\u73fe\u8c61\u3002\nC.\u6703\u9020\u6210QTc prolongation\u3002\nD.\u4f7f\u7528\u8d85\u904e2\u9031\u6709\u9aa8\u9ad3\u6291\u5236\u98a8\u96aa\u3002\nE.\u4f7f\u7528\u8d85\u904e4\u9031\u6709\u8996\u795e\u7d93\u548c\u5468\u908a\u795e\u7d93\u75c5\u8b8a\u4e4b\u98a8\u96aa\u3002\n": "[C]", "110-84.\u4e00\u4f4d35\u6b72\u7537\u6027\u5230\u6025\u8a3a\u5c31\u91ab \uff0c\u4e3b\u8a34\u8179\u90e8\u4e0d\u9069 \u3001\u5614\u5410\u548c\u7a00\u5927\u4fbf 5\u5929\uff0c\u767c\u71d2\u4e5f\u8d8a\u4f86\u8d8a\u56b4\u91cd \uff0c\u4e5f\u6709\u982d\u75db\u548c\u76ae\u819a\n\u75b9\u3002\u8eab\u9ad4\u8a3a\u5bdf\u9ad4\u6eab40\u00b0C \uff0c\u8840\u58d3100/70mmHg \uff0c\u5fc3\u640f62/\u5206\uff0c\u5438\u547c20/\u5206\uff0cBMI 26\uff0c\u660e\u986f\u751f\u75c5\u6a23 \u3002\u5728\u4e0b\u80f8\u548c\n\u4e0a\u8179\u90e8\u6709\u8b8a\u6de1\u7684\u7d05\u6591\u75b9 \uff0c\u4ed6\u7684\u978f\u819c\u8b8a\u9ec3 \uff0c\u7d50\u819c\u5145\u8840 \uff0c\u54bd\u90e8\u8f03\u7d05 \uff0c\u800c\u89f8\u8a3a\u6709\u809d\u813e\u816b\u5927\u548c\u58d3\u75db \u3002CBC\u8840\u8272\n\u7d2012 gm/dl\uff0c\u767d\u8840\u74034500 /cumm\uff0c\u591a\u5f62\u6838\u767d\u8840\u740368 %\uff0cband form 10 %\uff0c\u6dcb\u5df4\u740316 %\uff0c\u55ae\u6838\u74036%\uff0c\u8840\u5c0f\n\u677f90000/cumm\uff0cAST 120 u/L\uff0cALT 240 u/L\uff0c\u4e8c\u5957\u8840\u6db2\u57f9\u990a\u70ba\u683c\u862d\u6c0f\u9670\u6027\u83cc \u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u53ca\u5176\u6cbb\u7642 ?   \nA.\u920e\u7aef\u87ba\u65cb\u9ad4\u611f\u67d3\uff0cciprofloxacin\u3002\nB.\u50b7\u5bd2\uff0cceftriaxone\u3002\nC.\u9000\u4f0d\u8ecd\u4eba\u75c5\uff0cciprofloxacin\u3002\nD.\u674e\u65af\u7279\u83cc\u611f\u67d3\uff0campicillin\u3002\nE.\u5e03\u6c0f\u687f\u83cc\u75c5 (brucellosis)\uff0cdoxycycline\u3002\n": "[B]", "110-85.\u88ab\u52d5\u7269\u54ac\u50b7\u6642\u6709\u6240\u805e,\u7576\u75c5\u60a3\u88ab\u54ac\u50b7\u5f8c\u5230\u91ab\u9662\u5c31\u91ab,\u4f60\u9664\u4e86\u8655\u7406\u50b7\u53e3\u5916,\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba?       \nA.\u72d7\u54ac\u548c\u8c93\u54ac\u7684\u81f4\u75c5\u83cc\u5305\u62ec\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc\u3001\u5df4\u58eb\u5fb7\u687f\u83cc(Pasteurella multocida)\u548c\u53ad\u6c27\u83cc\u3002\nB.\u512a\u5148\u8003\u616e\u7684\u6297\u751f\u7d20\u662famoxicillin/clavulanate \u6216ampicillin/sulbactam\u3002\nC.\u5982\u75c5\u4eba\u6709penicillin\u904e\u654f\u53f2,\u53ef\u7528clindamycin + trimethoprim-sulfamethoxazole\u6216 fluoroquinolone\u3002\nD.\u9700\u8003\u616e\u72c2\u72ac\u75c5\u9810\u9632\u3002\nE.\u88ab\u7334\u5b50\u54ac\u50b7\u4e5f\u662f\u9078\u64c7amoxicillin/clavulanate\u6cbb\u7642, \u7121\u9700\u8003\u616e\u6297\u75c5\u6bd2\u85e5\u7684\u4f7f\u7528\u3002\n": "[E]", "110-86.\u75c5\u53f2\u8a62\u554f\u53ef\u63d0\u4f9b\u6557\u8840\u75c7\u75c5\u539f\u91cd\u8981\u7dda\u7d22, \u4ee5\u4e0b\u54ea\u4e9b\u72c0\u6cc1\u8981\u60f3\u5230\u9264\u7aef\u87ba\u65cb\u9ad4\u75c5\u4e4b\u98a8\u96aa ?\n(1)\u6d2a\u6c34\u6c3e\u6feb\u5f8c\n(2)\u5728\u6eaa\u6d41\u6cb3\u5ddd\u6d3b\u52d5\n(3)\u5eda\u5e2b\n(4)\u5f9e\u4e8b\u8fb2\u7530 \u3001\u7378\u91ab\u6216\u755c\u7267\u5de5\u4f5c\n(5)\u5230\u4e09\u6eab\u6696\u6ce1\u8db3\u90e8\u6eab\u6cc9   \nA.(1)+(2)+(4)\u3002\nB.(3)+(4)+(5)\u3002\nC.(1)+(3)+(4)\u3002\nD.(1)+(2)+(3)+(4)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[D]", "110-87.\u8003\u91cf\u6297\u751f\u7d20\u7684\u7279\u6027\u53ca\u6297\u85e5\u6027\u554f\u984c, \u5728\u53f0\u7063\u76ee\u524d\u7d93\u9a57\u6027\u6297\u751f\u7d20\u5728\u4e0b\u5217\u54ea\u4e9b\u60c5\u6cc1\u4e0d\u5efa\u8b70\u4ee5 fluoroquinolone \u7576\u4f5c\n\u7b2c\u4e00\u7dda\u6cbb\u7642 ?(1)\u6025\u6027\u5316\u81bf\u6027\u6241\u6843\u708e (2)\u6025\u6027\u8180\u80f1\u708e (3)\u8db3\u766c\u5408\u4f75\u4e0b\u80a2\u8702\u7aa9\u7d44\u7e54\u708e (4)\u6025\u6027\u8166\u819c\u708e (5)\u6025\u6027\u8179\u7009   \nA.(1)+(4)+(5)\u3002\nB.(1)+(2)+(5)\u3002\nC.(2)+(3)+(5)\u3002\nD.(1)+(2)+(3)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[D]", "110-88.\u6709\u4e00\u4f4d23\u6b72\u7537\u6027\u56e0\u9ad8\u71d2\u4e0d\u9000\u4e00\u9031\u800c\u4f86\u4f4f\u9662, \u4ed6\u65bc\u4e09\u9031\u524d\u5168\u8eab\u9577\u6eff\u6c34\u75d8, \u65bc\u4e8c\u9031\u524d\u6c34\u75d8\u5df2\u6f38\u7d50\u75c2 \u3002\u4f4f\u9662\u8eab\u9ad4\n\u8a3a\u5bdf\u9ad4\u6eab40\u00b0C, \u8840\u58d3140 /50mmHg, \u5fc3\u8df3136 /min,\u547c\u543822/min, \u7d50\u819c\u767c\u7d05, \u80f8\u90e8 X\u5149\u6aa2\u67e5\u6c92\u6709\u660e\u986f\u80ba\u6d78\u6f64\u73fe\n\u8c61, CBC\u5448\u73feHgb 12 gm /dL, WBC18000 /cumm, neutrophil 82 %, band form 6%, lymphocyte 10 %, \nmonocyte 2%, \u5c3f\u6db2\u6aa2\u67e5\u5448\u73feRBC10 -20, WBC 5-10, \u86cb\u767d(-), \u4ee5\u4e0b\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba ?   \nA.\u61c9\u884c\u5b8c\u6574\u7684\u8eab\u9ad4\u8a3a\u5bdf\u3002\nB.\u53ef\u80fd\u6703\u6709\u5fc3\u96dc\u97f3\u3002\nC.\u61c9\u884c\u81f3\u5c11\u5169\u5957\u8840\u6db2\u57f9\u990a\u3002\nD.\u61c9\u884c\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\u3002\nE.\u75c5\u4eba\u6700\u53ef\u80fd\u6709\u8166\u819c\u708e\u3002\n": "[E]", "110-89.\u4e00\u4f4d65\u6b72\u75c5\u4eba\u4f4f\u9662\u9032\u884c\u81bd\u7d50\u77f3\u624b\u8853\uff0c\u8853\u5f8c3\u5929\u767c\u751f\u9662\u5167\u611f\u67d3\u80ba\u708e\uff0c\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6700\u4e0d\u9069\u7576\uff1f    \nA.\u9020\u6210\u75c5\u4eba\u767c\u751f\u9662\u5167\u80ba\u708e\u4e3b\u8981\u4f86\u81ea\u65bc\u53e3\u54bd\u55c6\u54b3(oropharyngeal aspiration)\u3002\nB.\u9032\u884c\u4e0a\u8179\u90e8\u624b\u8853(upper abdominal surgery)\u589e\u52a0\u6b64\u75c5\u4eba\u767c\u751f\u9662\u5167\u80ba\u708e\u7684\u98a8\u96aa\u3002\nC.\u6b64\u75c5\u4eba\u70ba\u767c\u751f\u65e9\u767c\u6027\uff08early onset\uff09\u80ba\u708e\uff0c\u81f4\u75c5\u539f\u4e3b\u8981\u70ba\u547c\u5438\u9053\u5e38\u5728\u83cc\uff0c\u5982\u80ba\u708e\u7403\u83cc\u6216\u611f\u5192\u687f\u83cc\u3002\nD.\u82e5\u6b64\u75c5\u4eba\u63d2\u7ba1\u4f7f\u7528\u547c\u5438\u5668 \uff0c\u5728\u57f9\u990a\u672a\u767c\u73fe\u7279\u5b9a\u6297\u85e5\u81f4\u75c5\u539f\u4e14\u75c5\u4eba\u81e8\u5e8a\u6539\u5584 \uff0c\u5efa\u8b70\u6297\u751f\u7d20\u77ed\u671f\u6cbb\n\u7642\uff088\u5929\uff09 \u4ee5\u6e1b\u5c11\u5f8c\u7e8c\u6297\u85e5\u6027\u83cc\u79fb\u751f \u3002\nE.\u8853\u524d\u4f7f\u7528\u9810\u9632\u6027\u6297\u751f\u7d2072\u5c0f\u6642\u53ef\u4ee5\u964d\u4f4e\u624b\u8853\u75c5\u4eba\u767c\u751f\u9662\u5167\u611f\u67d3\u7684\u6a5f\u6703\u3002   \n": "[E]", "110-90.\u6839\u64da\u7f8e\u570b\u75be\u75c5\u7ba1\u5236\u5c40\u7684\u5efa\u8b70 \uff0c\u5c0d\u65bc\u61f7\u5b55\u8005 \uff0c\u5305\u62ec\u9ad8\u98a8\u96aa\u611f\u67d3\u4e4b\u61f7\u5b55\u5a66\u5973 \uff0c\u4e0b\u5217\u4f55\u8005\u662f\u4e0d\u5efa\u8b70\u63a5\u7a2e\u7684\u75ab\u82d7\u7d44\n\u5408\uff1f\u9078\u9805\uff1a(1)B\u578b\u809d\u708e\u75ab\u82d7 \uff08HBV vaccine \uff09(2)\u5e36\u72c0\u76b0\u75b9\u75ab\u82d7 \uff08Varicella -zoster vaccine \uff09(3)\u9ebb\u75b9\u3001\u5fb7\u570b\n\u9ebb\u75b9\u3001\u816e\u817a\u708e\u75ab\u82d7 \uff08MMR vaccine \uff09(4)\u6d41\u611f\u75ab\u82d7 \uff08Influenza \uff09(5)\u767d\u5589\u3001\u767e\u65e5\u54b3\u3001\u7834\u50b7\u98a8\uff08Td/Tdap \nvaccine\uff09   \nA.(1)+(2)\u3002\nB.(2)+(3)\u3002\nC.(3)+(4)\u3002\nD.(4)+(5)\u3002\nE.(3)+(5)\u3002\n": "[B]", "110-91.\u4e00\u4f4d\u63a5\u53d7\u8840\u6db2\u5e79\u7d30\u80de\u79fb\u690d (Hematopoietic Stem Cell Transplantation )\u7684\u75c5\u4eba\uff0c\u5728\u79fb\u690d\u5f8c100\u5929\u767c\u751f\u611f\n\u67d3\uff0c\u8acb\u554f\u5728\u6b64\u6642\u671f\u4e4b\u5e38\u898b\u4e4b\u81f4\u75c5\u539f\u7d44\u5408 \uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u6b63\u78ba ?(1)Escherichia \ncoli(2)Aspergillus (3)Cytomegalovirus (4)Clostridium difficile (5)Encapsulated \nbacteria(6)Toxoplasma (7)Varicella zoster virus   \nA.(2)+(3)+(6)\u3002\nB.(1)+(3)+(4)+(5)\u3002\nC.(2)+(4)+(5)\u3002\nD.(5)+(6)+(7)\u3002\nE.(1)+(4)+(7)\u3002\n": "[A]", "110-92.\u4e0b\u5217\u6709\u95dc\u65bcHerpesvirus\u7522\u751f\u4e4b\u75be\u75c5\u914d\u5c0d\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576?    \nA.Herpes simplex virus type 1\uff1aHerpangina\u3002\nB.Varicella-zoster virus : Ramsay Hunt syndrome\u3002\nC.Epstein-Barr virus : B cell lymphoma\u3002\nD.Human herpesvirus type 8 : Kaposi\u2019s sarcoma\u3002\nE.Epstein-Barr virus : Oral hairy leukoplakia\u3002\n": "[A]", "110-93.\u4e0b\u5217\u6709\u95dc\u65bc\u6297\u751f\u7d20\u8207\u5176\u4ed6\u85e5\u7269\u7522\u751f\u4e4b\u4ea4\u4e92\u4f5c\u7528\u914d\u5c0d\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576?    \nA.Metronidazole\u4f75\u7528Ethanol\u767c\u751fdisulfiram-like reaction\u3002\nB.Macrolides\u4f75\u7528Fluoroquinolones\u6703\u589e\u52a0\u5fc3\u5f8b\u4e0d\u6574(arrhythmias)\u7684\u98a8\u96aa\u3002\nC.Tetracyclines\u4f75\u7528Warfarin\u6703\u52a0\u5f37Warfarin\u6297\u51dd\u8840\u529f\u80fd\u589e\u52a0\u51fa\u8840\u7684\u98a8\u96aa\u3002\nD.Rifampin\u6703\u52a0\u5f37\u8377\u723e\u8499\u4f5c\u7528\uff0c\u53e3\u670d\u907f\u5b55\u85e5(oral contraceptive)\u61c9\u6e1b\u91cf\u4f7f\u7528\u3002\nE.Linezolid\u6703\u589e\u52a0adrenergic\u5347\u58d3\u85e5\u7684\u4f5c\u7528\uff0c\u767c\u751f\u4e0d\u6613\u63a7\u5236\u7684\u9ad8\u8840\u58d3\u3002\n": "[D]", "110-94.\u6709\u95dc\u65b0\u51a0\u80ba\u708e (Coronavirus disease 2019, COVID-19)\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u9069\u7576?    \nA.\u81f4\u75c5\u539fSARS-CoV-2\u5c6c\u65bcRNA\u75c5\u6bd2\uff0c\u4eba\u985e\u611f\u67d3\u51a0\u72c0\u75c5\u6bd2\u4ee5\u547c\u5438\u9053\u75c7\u72c0\u70ba\u4e3b\u3002\nB.SARS-CoV-2\u6f5b\u4f0f\u671f\u4e00\u822c\u4ecb\u65bc2\u81f314\u5929\uff0c\u5927\u90e8\u5206\u70ba4\u52305\u5929\u3002\nC.\u81e8\u5e8a\u75c7\u72c0\u767c\u751f\u524d\u6975\u5c11\u5177\u6709\u50b3\u67d3\u6027\uff0c\u5927\u591a\u6578\u611f\u67d3\u8005\u662f\u63a5\u89f8\u5230\u6709\u75c7\u72c0\u8005\u800c\u767c\u751f\u50b3\u67d3\u3002\nD.\u7d04\u67095%\u60a3\u8005\u6703\u767c\u751f\u547c\u5438\u8870\u7aed\u6216\u6557\u8840\u6027\u4f11\u514b\u7b49\u6975\u56b4\u91cd\u611f\u67d3\uff0c\u9700\u52a0\u8b77\u6cbb\u7642\u3002\nE.\u5be6\u9a57\u5ba4\u6aa2\u67e5\u6dcb\u5df4\u7403\u6e1b\u5c11(lymphopenia)\u5408\u4f75D-dimer\u5347\u9ad8\u8207\u6b7b\u4ea1\u7387\u5448\u6b63\u76f8\u95dc\u3002\n": "[C]", "110-95.\u6709\u95dc\u547c\u5438\u5668\u76f8\u95dc\u80ba\u708e\u4e4b\u9810\u9632\u63aa\u65bd\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e?    \nA.\u5e8a\u982d\u62ac\u9ad8\uff0c\u4ee5\u6e1b\u5c11\u55c6\u5165\u6a5f\u6703\u3002   \nB.\u5e38\u898f\u5236\u9178\u5291\u4f7f\u7528\uff0c\u589e\u52a0\u80c3pH\u503c\u4ee5\u6e1b\u5c11\u4e0a\u6d88\u5316\u83cc\u53e2\u3002\nC.\u9577\u671f\u63d2\u7ba1\u75c5\u4eba\uff0c\u8a55\u4f30\u93ae\u975c\u5291\u6bcf\u65e5\u4e2d\u65b7\u3002\nD.\u4eba\u54e1\u843d\u5be6\u624b\u90e8\u885b\u751f\u53ca\u7121\u83cc\u64cd\u4f5c\u3002\nE.\u63a7\u5236\u8840\u7cd6\u4ee5\u6539\u5584\u5bbf\u4e3b\u514d\u75ab\u3002\n": "[B]", "110-96.\u4e0b\u5217\u6709\u95dc\u6297\u751f\u7d20\u7684\u4e3b\u8981\u6291\u5236\u6a5f\u8f49\u914d\u5c0d\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576\uff1f    \nA.Cephalosporin \u2013\u6291\u5236\u7d30\u80de\u58c1\uff08Cell wall\uff09\u5408\u6210\u3002\nB.Clindamycin \u2013\u6291\u5236\u86cb\u767d\u8cea\uff08Protein synthesis\uff09\u5408\u6210\u3002\nC.Macrolide \u2013\u6291\u5236DNA\u5408\u6210\u3002\nD.Sulfonamide \u2013\u6291\u5236\u8449\u9178\uff08Folate\uff09\u5408\u6210\u3002\nE.Rifampin - \u6291\u5236RNA\u5408\u6210\u3002\n": "[C]", "111-81.\u4e00\u4f4d46\u6b72\u7537\u6027\u6709\u767c\u71d2 \u3001\u754f\u5bd2\u3001\u54b3\u55fd\u5e36\u9ec3\u75f0 5\u5929\uff0c\u56e0\u547c\u5438\u56f0\u96e3\u52a0\u5287 1\u5929\u7531\u6025\u8a3a\u6536\u5165\u9662 \u3002\u75c5\u4eba\u5728\u6025\u8a3a\u5ba4\u56e0\u547c\u5438\n\u7a98\u8feb\u800c\u88ab\u63d2\u7ba1\u4e14\u63a5\u4e0a\u547c\u5438\u5668 \uff0c\u6025\u8a3a\u5df2\u62bd\u4e8c\u5957\u8840\u6db2\u57f9\u990a \uff0c\u4f7f\u7528\u7d93\u9a57\u6027\u6297\u751f\u7d20\u6cbb\u7642 \u3002\u5165\u9662\u9ad4\u6eab39 \u2103\uff0c\u8840\n\u58d386/50 mmHg \uff0c\u5fc3\u640f132/min\uff0c\u547c\u543828/min\uff0cBMI 28.5\uff0c\u807d\u8a3a\u5728\u5de6\u53f3\u5169\u5074\u4e0b\u80ba\u53ef\u807d\u5230\u652f\u6c23\u7ba1\u97f3 \u3002\u5be6\u9a57\u5ba4\n\u6aa2\u67e5\u8840\u7d05\u7d2011 g/dL\uff0c\u767d\u8840\u74034200 /cumm\uff0c\u8840\u5c0f\u677f95000 /cumm\uff0c\u80f8\u90e8X\u5149\u6aa2\u67e5\u5448\u73fe\u4e8c\u5074\u4e0b\u80ba\u548c\u5de6\u80ba\u4e2d\u8449\u6709\n\u5be6\u8cea\u5316\u73fe\u8c61 \u3002\u9664\u4e86\u6c23\u7ba1\u5167\u62bd\u5438\u75f0\u6db2\u9001Gram stain\u548c\u57f9\u990a\u5916 \uff0c\u6b64\u6642\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u662f\u6700\u5408\u9069\u8981\u518d\u505a\u7684 \uff1f   \nA.\u652f\u6c23\u7ba1\u93e1\u6aa2\u67e5\u53ca\u5b9a\u91cf\u7d30\u83cc\u57f9\u990a\u3002\nB.Legionella \u548cpneumococcus\u5c3f\u6297\u539f\u3002\nC.Legionella\u8840\u6e05\u6297\u9ad4\u3002   \nD.\u80ba\u5207\u7247\u6aa2\u67e5\u3002\nE.\u4e0d\u9700\u8981\u518d\u6aa2\u67e5\u3002\n": "[B]", "111-82.\u6211\u570b2022 \u5e745\u6708\u958b\u59cb\u9762\u5c0d\u5927\u91cfCOVID -19\u793e\u5340\u611f\u67d3\u8005 \uff0c\u9632\u6cbb\u7b56\u7565\u6f38\u6b21\u9032\u5165\u8207\u75c5\u6bd2\u5171\u5b58\u7684\u968e\u6bb5 \uff0c\u6b64\u6642\u6709\n\u95dcCOVID-19\u7684\u6cbb\u7642 \uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba \uff0c\u8acb\u9078\u51fa\u6700\u9069\u7576\u7684\u7b54\u6848\n(1)Remdesivir \u662fRNA-dependent RNA polymerase\u6291\u5236\u5291 \uff0c\u5c0d\u75be\u75c5\u8f15 \u3001\u91cd\u75c7\u60a3\u8005\u55ae\u7368\u4f7f\u7528\u4e4b\u9810\u5f8c\u7686\u6709\u986f\n\u8457\u4e4b\u6548\u679c \u3002\n(2)Nirmatrelvir /ritonavir (Paxlovid )\u80fd\u963b\u6b62\u75c5\u6bd2\u86cb\u767d\u9176\u8907\u88fd \uff0critonavir\u662fcytochrome P450 3 A4 (CYP3A4)\u7684\n\u5f37\u6291\u5236\u5291 \uff0c\u53ef\u6e1b\u7de9Nirmatrelvir\u88ab\u809d\u81dfcytochrome P450\u5206\u89e3\u4ee3\u8b1d\u7684\u901f\u5ea6 \uff0c\u800c\u589e\u5f37\u5176\u6548\u679c \u3002\n(3)Molnupiravir\u5247\u85c9\u7531\u5176\u6210\u4efd\u7684\u6838\u82f7\u985e\u4f3c\u7269 \uff0c\u8b93\u75c5\u6bd2\u7684\u8907\u88fd\u9176\u5728RNA\u8907\u88fd\u6642\u7522\u751f\u6709\u7f3a\u9677\u7684RNA \uff0c\u56e0\u6709\u57fa\u56e0\n\u7a81\u8b8a\u7b49\u8003\u91cf \uff0c\u4e0d\u5efa\u8b70\u4f7f\u7528\u65bc\u5b55\u5a66 \u3002\n(4)Paxlovid \u548cMolnupiravir\u4e3b\u8981\u65bcCOVID -19\u767c\u75c5\u65e9\u671f \uff0c\u75c7\u72c0\u8f15\u5fae\u4f46\u6709\u767c\u751f\u91cd\u75c7\u6216\u6b7b\u4ea1\u4e4b\u9ad8\u98a8\u96aa\u8005 \u3002\n(5)Paxlovid\u6709\u5f88\u591a\u85e5\u7269\u4ea4\u4e92\u4f5c\u7528\u53ca\u7981\u5fcc\u75c7 \uff0c\u60df\u814e\u529f\u80fd\u53ea\u8981eGFR >30\u5c31\u4e0d\u9700\u8abf\u6574\u5291\u91cf \u3002   \nA.(1)+(2)+(3)\u3002\nB.(1)+(2)+(3)+(4)\u3002\nC.(2)+(3)+(4)\u3002\nD.(2)+(3)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[C]", "111-83.\u4e00\u4f4d51\u6b72\u5973\u6027\u65bc 3\u5929\u524d\u56e0\u5641\u5fc3 \u3001\u5614\u5410\u3001\u53f3\u5074\u8170\u808b\u75bc\u75db\u548c\u9ad8\u71d2\u4f4f\u9662 \uff0c\u5728\u6025\u6027\u814e\u76c2\u814e\u708e\u7684\u8a3a\u65b7\u4e0b\u5165\u9662\u5373\u958b\u59cb\u63a5\n\u53d7Ceftriaxone\u6cbb\u7642 \u3002\u56e0\u70ba\u75c5\u4eba\u9ad8\u71d272\u5c0f\u6642\u4e0d\u9000 \uff0c\u4f60\u503c\u73ed\u88ab\u547c\u53eb\u53bb\u770b\u75c5\u4eba \uff0c\u6b64\u6642\u75c5\u4eba\u8eab\u9ad4\u8a3a\u5bdf\u9ad4\n\u6eab39\u2103\uff0c\u8840\u58d3106/60 mmHg \uff0c\u8108\u640f110/min\uff0c\u547c\u543818/min\uff0cBMI 27\uff0c\u53f3\u5074\u808b\u810a\u89d2\u58d3\u75db \u3002\u5165\u9662\u6642\u5c3f\u6db2\u57f9\u990a\n\u767c\u73fe\u5927\u65bc10 \u2075\u83cc\u843d/mL\u7684E. coli\u4e14\u5c0dceftriaxone\u6709\u654f\u611f\u6027 \uff0c\u8840\u6db2\u57f9\u990a\u9670\u6027 \u3002\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u9805\u662f\u6700\u9069\u7576\u7684\u8655\n\u7f6e\uff1f   \nA.\u814e\u81df\u96fb\u8166\u65b7\u5c64\u651d\u5f71\u6aa2\u67e5\u3002\nB.\u5c3f\u6db2\u57f9\u990a\u3002\nC.\u6297\u751f\u7d20\u6539\u70bagentamicin\u3002\nD.\u6297\u751f\u7d20\u6539\u70baamoxicillin/clavulanate\u3002\nE.\u7d66\u9000\u71d2\u85e5\uff0c\u89c0\u5bdf\u5373\u53ef\u3002\n": "[A]", "111-84.\u4e00\u4f4d50\u6b72\u7537\u6027\u56e0\u70ba\u80ba\u7d50\u6838\u75c5\u5df2\u7d93\u63a5\u53d7\u4e8c\u500b\u6708\u7684\u6297\u7d50\u6838\u6cbb\u7642 \uff0c\u4ed6\u4f7f\u7528\u7684\u85e5\u7269\u5305\n\u62ecrifampin\uff0cisoniazid \u548cethambutol \uff0c\u958b\u59cb\u6642\u5c31\u56e0\u75db\u98a8\u767c\u4f5c\u800c\u672a\u4f7f\u7528pyrazinamide \uff0c\u75f0\u6db2\u7d50\u6838\u83cc\u5206\u96e2\u682a\u5c0d\n\u7b2c\u4e00\u7dda\u6297\u7d50\u6838\u85e5\u7269\u90fd\u5177\u654f\u611f\u6027 \u3002\u4ed6\u7684\u904e\u53bb\u75c5\u53f2\u53ea\u6709\u9ad8\u8840\u58d3 \u3001\u6162\u6027\u75db\u98a8\u77f3\u95dc\u7bc0\u708e\u4f75\u53cd\u8986\u6025\u6027\u767c\u4f5c \uff0c\u6709\u4f7f\n\u7528lisinopril\u548callopurinol \u3002\u4f86\u9662\u8eab\u9ad4\u8a3a\u5bdf\u751f\u547d\u5fb5\u8c61\u90fd\u6b63\u5e38 \uff0c\u819d\u548c\u624b\u8173\u4e8c\u5074\u95dc\u7bc0\u6709\u75db\u98a8\u8b8a\u5316 \uff0c\u5728\u624b\u8098\u6709\u75db\u98a8\n\u77f3\u3002\u80f8\u90e8X\u5149\u6aa2\u67e5\u7121\u958b\u6d1e\u75c5\u7076 \uff0c\u6700\u8fd1\u75f0AFB\u662f\u9670\u6027 \u3002\u8acb\u554f\u75c5\u4eba\u8981\u518d\u63a5\u53d7rifampin \u548cisoniazid\u6cbb\u7642\u591a\u4e45 \uff1f   \nA.4\u500b\u6708\u3002\nB.7\u500b\u6708\u3002\nC.10\u500b\u6708\u3002\nD.12\u500b\u6708\u3002\nE.\u53ef\u4ee5\u505c\u85e5\u4e86\u3002   \n": "[B]", "111-85.\u4e00\u4f4d48\u6b72\u7537\u6027\u4e8c\u5929\u524d\u5728\u6d77\u908a\u6d89\u6c34\u8e29\u5230\u9b5a\u9264\u800c\u81f4\u5de6\u8173\u5e95\u53d7\u50b7 \uff0c\u56e0\u767c\u71d2\u53ca\u5de6\u8173 \u3001\u5de6\u8db3\u75bc\u75db\u52a0\u5287\u800c\u7d93\u7531\u6025\u8a3a\u5165\n\u9662\uff0c\u4ed6\u767c\u73fe\u7d05\u816b\u75bc\u75db\u5f80\u4e0a\u64f4\u6563\u81f3\u5de6\u819d \uff0c\u4ed6\u6709C\u578b\u809d\u708e\u4f75\u809d\u786c\u5316 \uff0c\u5e73\u6642\u670d\u7528propranolol\u548c furosemide \u3002\u5165\u9662\n\u8eab\u9ad4\u8a3a\u5bdf\u6eab\u5ea639 .5\u2103\uff0c\u8840\u58d390/60 mmHg \uff0c\u8108\u640f72/min\u547c\u543822 /min\uff0c\u5de6\u8db3\u548c\u5de6\u8173\u81f3\u819d\u90e8\u6709\u6c34\u816b \uff0c\u56b4\u91cd\u58d3\n\u75db\uff0c\u76ae\u819a\u6709\u51fa\u8840\u6027\u6c34\u6ce1 \uff0c\u5468\u908a\u767d\u8840\u740320000 /cumm,\u4e2d\u6027\u740385\uff05\uff0c immature band form 10\uff05\uff0c \u800c\u6dcb\u5df4\n\u74035\uff05\uff0c \u7dca\u6025\u5916\u79d1\u6e05\u5275\u624b\u8853\u986f\u793a\u70ba\u58de\u6b7b\u6027\u808c\u7b4b\u819c\u708e \uff0c\u6e05\u5275\u7d44\u7e54Gram stain \u986f\u793a\u6709\u5f4e\u66f2\u7684\u683c\u862d\u6c0f\u9670\u6027\u83cc \uff0c\u4ee5\n\u4e0b\u54ea\u4e00\u9805\u662f\u6700\u53ef\u80fd\u7684\u81f4\u75c5\u539f ?   \nA.Erysipelothrix rhusiopathiae\u3002\nB.Listeria monocytogenes\u3002\nC.Mycobacterium marinum\u3002\nD.Vibrio vulnificus\u3002\nE.Legionella pneumophila\u3002\n": "[D]", "111-86.\u4e00\u4f4d24\u6b72\u7537\u6027\u5927\u5b78\u751f \uff0c\u5e73\u5e38\u5065\u5eb7 \uff0c\u56e0\u868a\u5b50\u53ee\u54ac\u5f8c \uff0c\u5de6\u8173\u7d05\u816b\u5230\u9580\u8a3a\u4f86 \uff0c\u8eab\u9ad4\u8a3a\u5bdf\u9ad4\u6eab37 .3\u2103 \uff0c\u8840\n\u58d3120/72 mmHg \uff0c\u8108\u640f72/min\uff0c\u547c\u543814/min\uff0c\u5728\u5de6\u8173\u6709 3\u00d75\u516c\u5206\u7d05\u816b \uff0c\u89f8\u6478\u6709\u6eab\u71b1 \uff0c\u4f46\u7121\u5316\u81bf\u73fe\u8c61 \uff0c\u4e5f\u7121\n\u6dcb\u5df4\u7d50\u816b\u75db \u3002\u4e0b\u8ff0\u6700\u5408\u9069\u7684\u6297\u751f\u7d20 :   \nA.moxifloxacin\u3002\nB.ciprofloxacin\u3002\nC.linezolid\u3002\nD.cephalexin\u3002\nE.doxycycline\u3002\n": "[D]", "111-87.\u7334\u75d8 (monkeypox) 2022 \u5e746\u6708\u81f3\u5c11\u572827\u500b\u975e\u6d32\u4ee5\u5916\u570b\u5bb6\u767c\u73fe\u4e26\u901a\u5831\u4e16\u754c\u885b\u751f\u7d44\u7e54 (WHO)\u3002\u4e0b\u5217\u6558\u8ff0 \uff0c\u4f55\n\u9805\u7d44\u5408\u6700\u6b63\u78ba ?\n(1) \u7334\u75d8\u7531DNA\u75c5\u6bd2\u9020\u6210 \uff0c\u75c7\u72c0\u8207\u5929\u82b1\u985e\u4f3c \uff0c\u904e\u53bb\u4e3b\u8981\u767c\u73fe\u65bc\u9130\u8fd1\u71b1\u5e36\u96e8\u6797\u7684\u4e2d\u975e\u548c\u897f\u975e\u570b\u5bb6 \u3002\u5929\u82b1\u75ab\u82d7\n\u5c0d\u7334\u75d8\u670985 %\u4fdd\u8b77\u529b\u3002\n(2) \u50b3\u64ad\u4e3b\u8981\u662f\u900f\u904e\u5bc6\u5207\u63a5\u89f8\u5230\u547c\u5438\u5206\u6ccc\u7269\u611f\u67d3\u7684\u76ae\u819a\u75c5\u7076\u6216\u6c59\u67d3\u7684\u7269\u9ad4 \u3002\u6f5b\u4f0f\u671f\u53ef\u5f9e 5\u81f321\u5929\uff0c\u4f46\u5927\n\u591a6\u81f313\u5929\u3002\n(3) \u75c7\u72c0\u5982\u767c\u71d2 \u3001\u982d\u75db\u3001\u808c\u8089\u816b\u8139\u548c\u9178\u75db \u3001\u865b\u812b\uff0c\u4e00\u822c\u5148\u5f9e\u81c9\u90e8\u51fa\u75b9 \uff0c\u518d\u9010\u6f38\u64f4\u6563\u5230\u624b \u3001\u8db3\u7b49\u8eab\u9ad4\u5176\u4ed6\u90e8\n\u4f4d\u3002\u76ae\u75b9\u5f9e\u6591\u4e18\u75b9 \u3001\u5c0f\u6c34\u76b0\u8f49\u8b8a\u70ba\u81bf\u76b0 \uff0c\u7d0410\u5929\u5f8c\u7d50\u75c2 \uff0c2\u81f33\u9031\u6d88\u5931\u3002\n(4) \u7334\u75d8\u662f\u4eba\u755c\u5171\u901a\u50b3\u67d3\u75c5 \uff0c\u60df\u8fd1\u671f\u5f88\u591a\u65b0\u589e\u500b\u6848\u662f\u7d93\u6027\u884c\u70ba\u50b3\u64ad \uff0c\u5728\u6703\u9670\u90e8\u75c5\u7076\u5e38\u9700\u8207\u6885\u6bd2 \u3001\u8edf\u6027\u4e0b\u75b3\n\u548c\u5e36\u72c0\u6ce1\u75b9\u9451\u5225 \u3002\n(5) \u7334\u75d8\u75c5\u4eba\u5728\u7167\u8b77\u4e0a \uff0c\u53f0\u7063CDC\u5efa\u8b70\u6536\u6cbb\u65bc\u5177\u7368\u7acb\u885b\u6d74\u4e4b\u55ae\u4eba\u75c5\u623f \u3002\u5728\u9032\u884c\u6703\u5f15\u8d77\u6c23\u6eb6\u81a0\u7684\u91ab\u7642\u8655\n\u7f6e(aerosal generating procedues )\u9700\u6709\u7a7a\u6c23\u50b3\u67d3\u9632\u8b77\u63aa\u65bd (airborne precaution )\uff0c\u4e14\u8981\u7a7f\u6234\u9069\u7576\u9632\u8b77\u88dd\n\u5099\u3002   \nA.(1)+(2)+(3)+(5)\u3002\nB.(1)+(2)+(3)\u3002\nC.(1)+(2)+(4)\u3002\nD.(1)+(2)+(3)+(4)+(5)\u3002\nE.(1)+(3)+(4)+(5)\u3002\n": "[D]", "111-88.\u63a8\u5ee3\u9152\u7cbe\u4e7e\u6d17\u624b\u53ef\u4ee5\u5927\u5927\u964d\u4f4e\u9662\u5167\u611f\u67d3\u7684\u767c\u751f\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f    \nA.\u9152\u7cbe\u4e7e\u6d17\u624b\u6bcf\u6b21\u4f7f\u7528\u9152\u7cbe\u91cf1\u6beb\u5347\u5373\u53ef\u3002\nB.\u9152\u7cbe\u4e7e\u6d17\u624b\u53ef\u6e05\u9664\u5bc4\u751f\u87f2\u87f2\u5375\u3002\nC.\u9152\u7cbe\u4e7e\u6d17\u624b\u53ef\u6e05\u9664\u8178\u75c5\u6bd2\u3001\u8afe\u7f85\u75c5\u6bd2\u3002\nD.\u9152\u7cbe\u4e7e\u6d17\u624b\u53ef\u6e05\u9664\u6d41\u611f\u75c5\u6bd2\u3001\u65b0\u51a0\u75c5\u6bd2\u3002   \nE.\u4ee5\u4e0a\u7686\u6b63\u78ba\u3002\n": "[D]", "111-89.\u5728\u53f0\u7063\u8840\u7cd6\u63a7\u5236\u4e0d\u826f\u7684\u60a3\u8005\u4e2d \uff0cKlebsiella pneumoniae\u662f\u91cd\u8981\u4e14\u5e38\u898b\u7684\u8178\u6e90\u6027\u81f4\u75c5\u83cc \uff0c\u7d93\u5e38\u9020\u6210\u809d\u81bf\n\u760d\u3001\u6ccc\u5c3f\u9053\u611f\u67d3\u7b49\u75be\u75c5 \uff0c\u4ee5\u4e0b\u76f8\u95dc\u6558\u8ff0 \uff0c\u4f55\u8005\u6b63\u78ba \uff1f   \nA.\u81e8\u5e8a\u4e0awild type K. pneumoniae \u53ef\u7528Ampicillin\u6cbb\u7642\u3002\nB.\u82e5\u6aa2\u9a57\u7d50\u679c\u70baExtended spectrum beta -lactamase (ESBL) -producing K. pneumoniae \u56e0\u5c0d\u7b2c\u4e00\u7dda\u6297\n\u751f\u7d20\u6709\u6297\u85e5\u6027 \uff0c\u5efa\u8b70\u4f7f\u7528Ceftriaxone\u6cbb\u7642 \u3002\nC.\u81e8\u5e8a\u4e0a\u5c0d\u65bcESBL-producing K. pneumoniae \u611f\u67d3\u5efa\u8b70\u4f7f\u7528imipenem \u6216ertapenem\u6cbb\u7642\u3002\nD.\u53ef\u7522\u751fNDM -1 carbapenemase \u7684K. pneumoniae\u53ef\u7528Tigecycline \u548cTrimethoprim /Sulfamethoxazole \n(TPM-SMX)\u6cbb\u7642\u3002\nE.\u5728\u53f0\u7063\u9020\u6210\u809d\u81bf\u760d\u6216\u773c\u5167\u708e\u7684\u81f4\u75c5\u83cc\u76f8\u5c0d\u6297\u85e5\u6027\u8f03\u9ad8 \uff0c\u5927\u591a\u662f\u5c6c\u65bcESBL -producing K. \npneumoniae \u3002\n": "[C]", "111-90.\u4e0b\u5217\u793e\u5340\u6027\u80ba\u708e\u81f4\u75c5\u539f\u8207\u5bbf\u4e3b\u56e0\u5b50\u4e4b\u914d\u5c0d\uff0c\u4f55\u8005\u6700\u4e0d\u9069\u7576?    \nA.Alcoholism \u2013 Streptococcus pneumoniae\u3002\nB.Bronchiectasis \u2013 Pseudomonas aeruginosa\u3002\nC.Post-Influenza illness \u2013 Stapylococcus aureus\u3002\nD.Exposure to bird \u2013 Chlamydia trochomatis\u3002\nE.Exposure to sheep \u2013 Coxiella burnetii\u3002\n": "[D]", "111-91.\u6709\u95dc\u6297\u751f\u7d20\u6cbb\u7642\u8207\u6557\u8840\u75c7\u81f4\u75c5\u539f\u7684\u914d\u5c0d ,\u4e0b\u5217\u54ea\u4e9b\u7d44\u5408\u662f\u6b63\u78ba\u7684 ?\n(1) Ceftriaxone - Neisseria meningitidis \n(2) Penicillin - Group A Streptococcus \n(3) Clindamycin - Rickettsia \n(4) Ceftazidime- Enterococcus   \nA.(1)+(2)\u3002\nB.(2)+(3)\u3002\nC.(1)+(3)\u3002\nD.(2)+(4)\u3002\nE.(1)+(4)\u3002\n": "[A]", "111-92.\u6709\u95dcFilariae(\u8840\u7d72\u87f2)\u611f\u67d3\u4eba\u9ad4\u9014\u5f91\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f?    \nA.insect vector bite\u3002\nB.larvae skin penetration\u3002\nC.ingest egg from mouth\u3002\nD.metacercaria in fish\u3002\nE.cercariae skin penetration from water\u3002\n": "[A]", "111-93.\u4e0b\u5217\u6709\u95dc\u96b1\u7403\u83cc(Cryptococcus)\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u70ba\u975e?    \nA.C.gattii\u5728\u9ce5\u985e\u7cde\u4fbf(\u5982\u9d3f\u5b50)\u4e0d\u5bb9\u6613\u767c\u73fe\u3002\nB.\u5728HIV\u611f\u67d3\u65cf\u7fa4\uff0cmemory B cell IgM\u7684\u4e0b\u964d\uff0c\u5177\u6709\u8f03\u9ad8\u7684\u611f\u67d3\u98a8\u96aa\u3002\nC.Cryptococcal Ag\u53ef\u4ee5\u6709\u6548\u7684\u8a3a\u65b7\u80ba\u90e8\u611f\u67d3 (pulmonary cryptococcosis )\uff0c\u5177\u6709\u5f88\u597d\u7684\u654f\u611f\u6027\u8207\u5c08\u4e00\n\u6027\u3002\nD.\u80ba\u90e8\u96b1\u7403\u83cc\u611f\u67d3\u7684\u6cbb\u7642\u4ee5fluconazole 200-400mg/\u5929\u70ba\u671f3-6\u500b\u6708\u3002   \nE.\u80ba\u5916\u611f\u67d3(\u5982\u8166\u819c\u708e)\u4ee5amphotericin B deoxycholate 0.5-1 mg/kg/\u5929\uff0c\u505a\u70ba\u8d77\u59cb\u6cbb\u7642\u3002\n": "[C]", "111-94.\u4e0b\u5217\u6709\u95dcCOVID-19\u6cbb\u7642\u85e5\u7269\u8207\u5176\u6a5f\u8f49\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u70ba\u975e?    \nA.Remdesivir\uff1aInhibit viral RNA polymerase\u3002\nB.Tocilizumab\uff1aIL-6 monoclonal Ab\u3002\nC.Molnupiravir\uff1aRibonucleoside analog\u3002\nD.Baricitinib\uff1aTNF-\u03b1 inhibitor\u3002\nE.Nirmatrelvir/Ritonavir\uff1aprotease inhibitor\u3002\n": "[D]", "111-95.\u4e0b\u5217\u6709\u95dc\u8207\u6027\u75c5\u8868\u5fb5(syndrome)\u81f4\u75c5\u539f(pathogen)\u4e4b\u914d\u5c0d\uff0c\u4f55\u9019\u70ba\u975e?    \nA.Epididymitis\uff1aChlamydia trachomatis\u3002\nB.Bartholinitis \uff1aTrichomonas vaginalis\u3002\nC.Infertility \uff1a Neisseria gonorrhoeae\u3002\nD.Genital warts\uff1aHuman herpes virus type 8\u3002\nE.Genital ulcers \uff1a Haemophilus ducreyi\u3002\n": "[D]", "111-96.\u4e00\u4f4d30\u6b72\u7537\u6027\uff0c\u8def\u4e0a\u4e0d\u614e\u88ab\u72d7\u54ac\u50b7\uff0c\u88ab\u9001\u81f3\u6025\u8a3a\u8655\u7f6e\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba?    \nA.\u5e38\u898b\u81f4\u75c5\u539f\u70baStaphylococcus aureus\u3001Pasteurella multocida\u3001Anaerobe\u7b49\u3002\nB.\u82e5\u81f4\u75c5\u539f\u70baCapnocytophaga canimorsus\u5f15\u8d77\u4e4b\u6557\u8840\u75c7\uff0c\u8840\u6db2\u57f9\u990a\u9700\u8981\u81f314\u5929\u3002\nC.\u9996\u9078\u6cbb\u7642\u70baamoxicillin/clavulanate \u6216ampicillin/sulbactam\u3002\nD.\u82e5\u5c0dpenicillin\u904e\u654f\uff0c\u53ef\u4f7f\u7528macrolide\u6cbb\u7642\u505a\u70ba\u66ff\u4ee3\u3002\nE.\u9700\u8a55\u4f30\u662f\u5426\u6709Rabies\u9810\u9632\u8655\u7f6e\u4e4b\u9700\u8981\u3002\n": "[D]", "100-1.\n41\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u9ad4\u91cd\u65bc2\u661f\u671f\u4e0b\u964d4\u516c\u65a4\u4f86\u8a3a\uff0c\u4e3b\u8a342010\u5e746\u6708\u7a81\u767c\u773c\u5167\u982d\u75db\u53ca\u8996\u529b\u6a21\u7cca\uff0c\u53f3\u773c\u8996\u529b\u75311.0\u964d\u70ba0.6\uff0c\u773c\u79d1\u8a3a\u65b7\u70ba\u9752\u5149\u773c\uff0c\u7d93\u9ede\u773c\u85e5\u5f8c\u8996\u529b\u6539\u5584\u70ba0.8 (2010\u5e749\u6708) 2010\u5e7410\u6708\u6ce8\u610f\u5230\u9ad4\u91cd\u4e0b\u964d\u3001\u7121\u529b\uff0c\u5bb6\u91ab\u79d1\u62bd\u8840\u767c\u73feTSH 0.02 \u03bcU/ml \u8a3a\u65b7\u70ba\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u75c7\uff0c\u4e88\u4ee5\u670d\u7528carbimazole 10 mg b.i.d \uff0c\u4f46\u75c5\u60c5\u6709\u60e1\u5316\u4e4b\u73fe\u8c61\u56e0\u6b64\u4f86\u8a3a\u3002\u9ad4\u6aa2\u5305\u542b\u8996\u91ceconfrontation test \uff0c\u4e26\u672a\u6709\u7279\u5225\u7570\u5e38\uff0c\u62bd\u8840CBC\u53caBCS \u542b\u96fb\u89e3\u8cea\u3001HbA1C\u7686\u6b63\u5e38\uff0cfree T4 0.67 ng/dl\u3001hsTSH 0.025\u03bcU/ml \uff0c\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u5c0d\u6b64\u75c5\u4eba\u6700\u6709\u5e6b\u52a9\uff1a\nA. \u505a\u7532\u72c0\u817a\u8d85\u97f3\u6ce2\nB. \u6e2cTSH receptor antibody\nC. \u6e2c\u773c\u58d3\u53caOrbit\u8d85\u97f3\u6ce2\nD. \u6e2c\u5b9apituitary hormone\nE. \u6e1b\u5c11carbimazole\u5291\u91cf\n": "(D)", "100-2.\n37\u6b72\u5973\u6027\u4e3b\u8a34\u9032\u884c\u6027\u547c\u5438\u56f0\u96e3\u3001\u5026\u6020\u3001\u4fbf\u79d8\u4f46\u7121\u767c\u71d2\uff0c\u8eab\u9ad4\u6aa2\u67e5\u81c9\u90e8\u6d6e\u816b\u3001\u8ca7\u8840\uff0cBP 126/94 mmHg\u3001PR 104/min\uff0c\u80f8\u90e8X\u5149\u5982\u5716\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. \u80a5\u80d6\u4f75\u4ee3\u8b1d\u75c7\u5019\u7fa4\nB. \u9ecf\u6db2\u6c34\u816b\u6027\u5fc3\u81df\u75c5\u8b8a\nC. \u7d50\u6838\u6027\u5fc3\u5305\u819c\u708e\nD. \u5145\u8840\u6027\u5fc3\u8870\u7aed\nE. \u9ad8\u8840\u58d3\u5fc3\u81df\u75c5\n": "(B)", "100-3.\n30\u6b72\u7537\u6027\u56e0\u65e9\u4e0a\u8d77\u5e8a\u722c\u4e0d\u8d77\u4f86\u88ab\u9001\u4f86\u6025\u8a3a\uff0c\u75c5\u4eba\u4e3b\u8a34\u6700\u8fd11\u500b\u6708\u4f86\u98df\u617e\u5927\u589e\u4f46\u9ad4\u91cd\u537b\u4e0b\u964d4\u516c\u65a4\uff0c\u6015\u71b1\u6d41\u6c57\u3002\u6628\u591c\u56e0\u6176\u529f\u5bb4\u5927\u5403\u5927\u559d\u4f46\u4e26\u7121\u8179\u7009\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u75c5\u4eba\u610f\u8b58\u6e05\u695aBP 106/60 mmHg \u3001PR 110/min\uff0cregular\uff0c\u7532\u72c0\u817a\u7b2c1\u5ea6\u816b\u5927\uff0c\u96d9\u624b\u8f15\u5faetremor\uff0cDTR\u2193\uff0c\u808c\u529b\u5448\u4e0b\u80a22/5\u3001\u4e0a\u80a23/5\uff0c\u6025\u8a3a\u62bd\u8840CBC\u6b63\u5e38\uff0cNa 142 mM\u3001K 1.4 mM\u3001Ca 2.18 mM\u3001CK 756 U/L\uff0c\u4ee5\u4e0b\u5c0d\u6b64\u75be\u75c5\u7684\u6558\u8ff0\u4f55\u8005\u6700\u6070\u7576\uff1f\nA. \u70ba\u5148\u5929\u6027\u907a\u50b3\u75be\u75c5\nB. \u70bathyrotoxic periodic paralysis\nC. \u75c5\u4eba\u9ad4\u5167K+\u7f3a\u4e4f\u88dc\u5145KCl\u5373\u53ef\nD. \u7537\u3001\u5973\u767c\u751f\u6bd4\u4f8b\u4e00\u6a23\nE. \u70ba\u81ea\u9ad4\u514d\u75ab\u6297\u9ad4\u5c0d\u6297Na/K Channel\u6240\u81f4\n": "(B)", "100-4.\n23\u6b72\u7537\u6027\u5175\u5f79\u9ad4\u6aa2\u767c\u73fe\u6027\u5668\u767c\u80b2\u4e0d\u826f\uff0cMRI\u5982\u5716\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Pseudohermaphroditism\nB. Klinefelter syndrome\nC. Noonan syndrome\nD. Prader-Willi syndrome\nE. Kallmann syndrome\n": "(E)", "100-5.\n55\u6b72\u7537\u602715\u5e74\u4f86\u4e00\u76f4\u6709\u9ad8\u8840\u58d3\uff0c\u76ee\u524d\u4ee5Losartan 50mg qd\u3001Amlodipine 5 mg qd\u63a7\u5236\uff0c\u4f46\u5e38\u6709\u982d\u75db\u3001\u5931\u7720\u3001\u6613\u6d41\u6c57\u3001\u7126\u616e\u3001\u5fc3\u60b8\u3001\u624b\u6296\uff0c\u6700\u8fd12\u5e74\u958b\u59cb\u670d\u7528\u4e2d\u85e5\u3002\u65bc2010\u5e741\u6708\u7a81\u767c\u80f8\u75db\u3001\u5192\u51b7\u6c57\u56e0\u6b64\u9001\u5230\u6025\u8a3a\uff0c\u6b64\u6642\u8840\u58d3205/121 mmHg\uff0cTrandate\u6ce8\u5c04\u5f8c\u8840\u58d3\u6539\u5584\u800c\u4f4f\u9662\u6aa2\u67e5\uff0c\u4f4f\u9662\u6642\u8840\u58d3\u53c8\u4e0a\u5347\u81f3180/110 mmHg\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u6070\u7576\uff1f\nA. \u6aa2\u67e5plasma metanephrine\u53caurine catecholamine\nB. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nC. \u52a0\u4e0a\u03b2-blocker\nD. \u52a0\u4e0a\u03b1-blocker\nE. PET FDG\u6aa2\u67e5\n": "(C)", "100-6.\n\u8a3a\u65b7\u7522\u5f8c\u5a66\u5973\u5e0c\u7f55\u6c0f\u75c7\uff08Sheehan's Syndrome\uff09\u6700\u53ef\u9760\u4e4b\u6307\u6a19\u70ba\uff1a\nA. hypoprolactinemia\nB. hypothyrotropinemia\nC. hypocorticotropinemia\nD. hyposomatotropinemia\nE. hypogonadotropinemia\n": "(A)", "100-7.\n30\u6b72\u5973\u6027\u56e0\u767c\u71d2\u3001\u53f3\u9838\u90e8\u6709\u4e00\u7d05\u816b\u786c\u584a\u4f86\u5c31\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u53f3\u9838\u816b\u584a\u53ef\u96a8\u541e\u56a5\u79fb\u52d5\uff0c\u6709\u5c40\u90e8\u767c\u71b1\u3001\u58d3\u75db\u4e14\u76ae\u819a\u8b8a\u7d05\uff0c\u6b64\u5916\u7121\u7279\u5225\u767c\u73fe\uff0c\u75c5\u4eba\u4e00\u5411\u5065\u5eb7\uff0c\u5c0d\u65bc\u6b64\u75c5\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u6b63\u78ba:\nA. Subacute thyroiditis\uff0c\u53ef\u4ee5Steroid\u6cbb\u7642\nB. Thyroid cancer\uff0c\u5fc5\u9808\u7532\u72c0\u817a\u5168\u5207\u9664\nC. Residual thyroglossal duct\u5f15\u767c\u767c\u708e\nD. Sepsis, hematogenous spread\nE. \u6ce8\u5c04\u6297\u751f\u7d20\u6cbb\u7642\u5373\u53ef\n": "(C)", "100-8.\n32\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u5230\u6025\u8a3a\u3002\u75c5\u4eba\u4e3b\u8a343\u500b\u6708\u4f86\u5e38\u8179\u7009 (1\u59294\u223c5\u6b21)\uff0c\u6700\u8fd1\u4f75\u6709\u8179\u75db\u53ca\u610f\u8b58\u4e0d\u6e05\u3002\u904e\u53bb\u75c5\u53f2\u6709Hepatitis C\uff0c\u5b50\u5bae\u808c\u7624\u8853\u5f8c\uff0c\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u75c7\u53caKetamine \u6feb\u7528\uff0c\u9ad4\u6aa2\u767c\u73fe\u547c\u5438\u6025\u4fc3\u3001\u5fc3\u8df3144/min\u3001\u8840\u58d380/60 mm Hg\uff0c\u5916\u9662WBC 38000/\u03bcL\uff0c\u7532\u72c0\u817a\u7b2c2\u5ea6\u816b\u5927\uff0c\u8179\u90e8\u8edf\u4e14\u7121\u58d3\u75db\uff0c\u6025\u8a3a\u62bd\u8840Hb 10.4 g/dl\u3001WBC 77000/\u03bcl\u3001shift to the left\uff0cPT 35.3 sec\u3001aPTT 60.4 sec\u3001GOT 55 IU/L\u3001GPT 24 IU/L\u3001T-Bilirubin 5.03 mg/dl\u3001ALP 320 IU/L\u3001Na 140 mM/L\u3001K 4.1 mM/L\u3001BUN 25 mg/dl\u3001Cr 1.79 mg/dl\u3001AC glucose 40\rmg/dl\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u6070\u7576\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u4f9dKetamine \u4e2d\u6bd2\u8655\u7f6e\r2.\u4f9dhepatitis C \u5fa9\u767c\u8655\u7f6e\r3.\u4f9d\u7532\u72c0\u817a\u5371\u75c7\u8655\u7f6e\r4.\u4f9d\u6557\u8840\u75c7\u8655\u7f6e\r5.\u4f9d\u814e\u4e0a\u817a\u5371\u75c7\u8655\u7f6e\nA. 1+2+3+4\nB. 2+3+4+5\nC. 3+4+5\nD. 4+5+1\nE. 1+3+5\n": "(C)", "100-9.\n61\u6b72\u7537\u6027\u56e0\u9ad4\u6aa2PET\u767c\u73fe\u53f3\u814e\u4e0a\u817a\u816b\u7624\u4f86\u8a3a\u3002\u75c5\u4eba\u9664\u4e86\u8840\u58d3\u9ad8\u5728\u670d\u7528Carvedilol 25 mg qd\u3001Lercanidipine 10mg qd\u3001Valsartan 60mg qd\u53caIndapamide 1.5 mg qd\u5916\uff0c\u4e26\u7121\u4e0d\u9069\u3002\u8eab\u9ad4\u6aa2\u67e5\u9664BP 150/100 mmHg\uff0c\u7121\u7279\u5225\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5Na 139 mM/L\u3001K 3.1 mM/L\u3001Ca 2.39 mM/L\u3001P 3.1 mg/dl\u3001plasma aldosterone 35 ng/dl\u3001plasma renin activity 0.36 ng/ml/hr\u3002saline infusion test\uff0caldosterone\u70ba28.5 ng/dl\uff0cAdrenal CT\u986f\u793a\u5169\u5074\u7686\u67091~2\u516c\u5206\u7d50\u7bc0\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6700\u9069\u7576\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u70baprimary aldosteronism\r2.\u70baadrenal incidentaloma\u53ea\u9808\u89c0\u5bdf\r3.\u9808\u958b\u5200\u6cbb\u7642\r4.\u9808\u88dc\u5145K+\r5.\u4ee5spironolactone\u6cbb\u7642\u70ba\u4e3b\nA. 1+3\nB. 2+4\nC. 4+5\nD. 1+5\nE. 1+3+4\n": "(D)", "100-10.\n70\u6b72\u5973\u60272007\u5e742\u6708\u9ad4\u6aa2\u9996\u5ea6\u767c\u73feCEA 15.8 ng/ml\u53canodular goiter\u56e0\u7532\u72c0\u817a\u529f\u80fd\u6b63\u5e38\u4e5f\u5c31\u4e0d\u4ecb\u610f\u30022007\u5e749\u6708CEA\u70ba 23.4 ng/ml\uff0c2008\u5e744\u6708\u66f4\u4e0a\u5347\u70ba28.3 ng/ml\uff0c\u5927\u8178\u93e1 \u53ca\u4e73\u623f\u8d85\u97f3\u6ce2\u6aa2\u67e5\u90fd\u7121\u7279\u5225\u767c\u73fe\u3002\u8eab\u9ad4\u6aa2\u67e5BP 105/70 mmHg\u3001PR 86/min\uff0c\u7532\u72c0\u817a\u54482\u5ea6\u816b\u5927\u53ca\u591a\u7d50\u7bc0\uff0c\u5176\u4ed6\u4e26\u7121\u7279\u5225\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5\uff0cCBC\u6b63\u5e38\u3001BUN 12 mg/dl\u3001Cr 1.3 mg/dl\u3001Na 138 mM/L\u3001K 4.5 mM/L\u3001Ca 2.2 mM/L\u3001free T4 0.99 ng/dl\u3001hsTSH 2.87  \u03bcU/ml\uff0c\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6700\u6070\u7576\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u4ee5PETFDG\u5075\u6e2c\u816b\u7624\r2.\u505a\u7532\u72c0\u817a\u7d30\u91dd\u7a7f\u523a\r3.\u505a\u80f8\u81f3\u8179\u90e8CT\r4.CEA\u4e0a\u5347\u7121\u7279\u5225\u610f\u7fa9\r5.\u6aa2\u67e5serum calcitonin\nA. 1+2+3\nB. 2+3\nC. 4\nD. 3+5\nE. 5+1+2\n": "(E)", "100-1.\nThiazolidinediones \u767c\u5c55\u81f3\u4eca\u8207\u5176\u6709\u95dc\u4e4b\u53ef\u80fd\u4e0d\u826f\u53cd\u61c9\u6709\u4e0b\u5217\u6578\u9805\uff0c\u9664\u4e86\nA. \u9020\u6210\u5fc3\u8870\u7aed\u6a5f\u7387\u589e\u52a0\nB. \u9020\u6210\u809d\u6bd2\u6027\u6a5f\u7387\u589e\u52a0\nC. \u9020\u6210\u9aa8\u9b06\u6a5f\u7387\u589e\u52a0\nD. \u9020\u6210\u814e\u8870\u7aed\u6a5f\u7387\u589e\u52a0\nE. \u9020\u6210\u8180\u80f1\u764c\u6a5f\u7387\u589e\u52a0\n": "(D)", "100-2.\n\u9577\u671f\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u8840\u7cd6\u63a7\u5236\u4e0d\u4f73\u6642\uff0c\u4ee5\u54ea\u4e00\u7a2e\u80f0\u5cf6\u7d20\u88fd\u5291\u88dc\u5145\u57fa\u790e\u80f0\u5cf6\u7d20\u4e4b\u4e0d\u8db3\u8f03\u5408\u4e4e\u751f\u7406\u72c0\u614b\nA. Regular insulin\nB. Glargine insulin\nC. NPH insulin\nD. Insulin aspart\nE. Lispro insulin\n": "(B)", "100-3.\n55\u6b72\u7537\u6027\u8a3a\u65b7\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u5df2\u670910\u5e74\uff0c\u6700\u8fd11\u6b21\u62bd\u8840\u6aa2\u67e5\u986f\u793a\uff1aAC 148 mg/dl\u3001 PC 240 mg/dl\u3001 HbA1C 8.0 %\u3001 BUN 30 mg/dl\u3001 Cr 2.0 mg/dl\u3001 Urinalysis protein (+) \uff0c\u76ee\u524d\u4f7f\u7528\u4e4b\u85e5\u7269\u6709 Metformin 500 mg tid\u3001 Glibenclamide 5 mg tid\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u4e0d\u6070\u7576\uff1a\nA. \u5c07 Glibenclamide \u6539\u70ba Gliquidone\nB. \u52a0\u5165Sitagliptin 50 mg qd\nC. \u589e\u52a0 Metformin\u5291\u91cf\u81f31000 mg bid\nD. \u52a0\u5165pioglitazone 15 mg qd\nE. \u589e\u52a0\u6ce8\u5c04basal insulin\n": "(C)", "100-4.\n29\u6b72\u7537\u6027\u56e0\u6700\u8fd1\u5bb6\u4eba\u767c\u73fe\u65e9\u4e0a\u5f88\u96e3\u53eb\u9192\u4f86\u8a3a\uff0c\u75c5\u4eba\u4e3b\u8a34\u5e38\u6709\u60e1\u5922\u4e26\u5192\u6c57\uff0c\u8d77\u5e8a\u89ba\u5f97\u5f88\u865b\u5f31\u3002\u75c5\u4eba\u6709\u7761\u524d\u5c0f\u914c\u4e4b\u7fd2\u6163\u3002\u62bd\u8840\u65e9\u98ef\u524d\u8840\u7cd6\u70ba40 mg/dl\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u4e0d\u6070\u7576\nA. \u809d\u3001\u814e\u529f\u80fd\u70ba\u5fc5\u8981\u6aa2\u67e5\nB. \u7532\u72c0\u817a\u53ca\u814e\u4e0a\u817a\u529f\u80fd\u6aa2\u67e5\u70ba\u5fc5\u8981\nC. \u9577\u6642\u9593(\u53ef\u905472\u5c0f\u6642)\u7a7a\u8179\u8840\u7cd6\u503c\u70ba\u5fc5\u8981\u6aa2\u67e5\nD. Whipple triad \u9451\u5225\u5ea6\u9ad8\nE. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\u8a3a\u65b7\u7387\u9ad8\n": "(E)", "100-5.\nIncretin \u7d93\u7531\u4e0b\u5217\u76f4\u63a5\u6a5f\u8f49\u6539\u5584\u8840\u7cd6\u63a7\u5236\uff0c\u9664\u4e86\nA. \u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\nB. \u6291\u5236\u5347\u7cd6\u7d20\u5206\u6ccc\nC. \u6291\u5236\u80c3\u6392\u7a7a\nD. \u6291\u5236\u98df\u617e\nE. \u6539\u5584\u80f0\u5cf6\u7d20\u6297\u6027\n": "(E)", "100-6.\n\u4e0b\u5217\u6709\u95dc\u80f0\u5cf6\u7d20\u4e4b\u5206\u6ccc\u4f55\u8005\u4e0d\u6b63\u78ba\nA. \u8461\u8404\u7cd6\u70ba\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e3b\u8981\u8abf\u7bc0\u8005\nB. \u8461\u8404\u7cd6\u6fc3\u5ea6\u9ad8\u65bc70 mg/dl\u4ee5\u4e0a\u6642\uff0c\u5c31\u80fd\u523a\u6fc0\u80f0\u5cf6\u7d20\u4e4b\u5408\u6210\nC. \u8461\u8404\u7cd6\u78f7\u5316 ( phosphorylation )\u662f\u8461\u8404\u7cd6\u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e4b\u901f\u7387\u6c7a\u5b9a\u4e4b\u6b65\u9a5f\nD. \u7d93\u7531GLUT2 transportor\u9032\u5165\u03b2\u7d30\u80de\nE. \u7576\u03b2\u7d30\u80de\u819c\u4e0a\u7684ATP-sensitive K+ channel \u53d7\u523a\u6fc0\u6642\uff0c\u6703\u4f7f\u03b2\u7d30\u80de\u5206\u6ccc\u80f0\u5cf6\u7d20\n": "(E)", "100-7.\n\u5c0d\u65bc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u7684\u6cbb\u7642\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u4e0d\u5b9c\nA. \u5c0d\u65bc\u764c\u672b\u75c5\u4eba\u6216\u5b58\u6d3b\u671f\u4e0d\u9577\u7684\u75c5\u4eba\u53ef\u653e\u5bec\u7cd6\u5c3f\u75c5\u4e4b\u63a7\u5236\u6a19\u6e96\nB. \u7cd6\u5c3f\u75c5\u4e4b\u63a7\u5236\u4ee5\u907f\u514d\u4f4e\u8840\u7cd6\u70ba\u9996\u8981\u8003\u91cf\nC. \u5c0d\u65bc\u5e74\u8f15\u7cd6\u5c3f\u75c5\u75c5\u4eba\u4ee5\u6108\u63a5\u8fd1\u6b63\u5e38HbA1C\u70ba\u6a19\u7684\nD. \u5c0d\u65bc\u4f4f\u9662\u75c5\u4eba\u70ba\u907f\u514d\u4f4e\u8840\u7cd6\u4ee5sliding scale\u4f86\u63a7\u5236\nE. \u76ee\u524d\u53f0\u7063\u7cd6\u5c3f\u75c5\u5b78\u6703\u7684\u8840\u7cd6\u6cbb\u7642\u6a19\u7684HbA1C\u70ba6.5%\n": "(D)", "100-8.\n\u6709\u95dc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u5fc3\u8840\u7ba1\u75be\u75c5\u4f75\u767c\u75c7\u4e4b\u6558\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u771f\uff0c\u9664\u4e86\nA. \u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u4e4b\u51a0\u5fc3\u75c7\u4e4b\u767c\u751f\u7387\u53ca\u6b7b\u4ea1\u7387\u7686\u6bd4\u975e\u7cd6\u5c3f\u75c5\u4eba\u591a2-4\u500d\nB. \u8840\u8102\u3001\u8840\u58d3\u4e4b\u63a7\u5236\u9054\u5230\u9810\u9632\u51a0\u5fc3\u75c7\u767c\u751f\u7387\uff0c\u6bd4\u8840\u7cd6\u4e4b\u63a7\u5236\u4f86\u5f97\u91cd\u8981\nC. UKPDS\u7d50\u675f\u5f8c\u5ef6\u9577\u89c0\u5bdf\u8b49\u660e\u65e9\u671f\u8840\u7cd6\u7684\u63a7\u5236\u5c0d\u65bc\u665a\u671f\u51a0\u5fc3\u75c7\u4e4b\u767c\u751f\u6709\u6e1b\u5c11\u4e4b\u6548\u679c\nD. Aspirin\u5c0d\u65bc\u6b21\u7d1a\u9810\u9632\u5fc3\u8840\u7ba1\u75be\u75c5\u6709\u6548\nE. Sulfonylurea\u5df2\u88ab\u8b49\u660e\u53ef\u589e\u52a0\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u98a8\u96aa\n": "(E)", "100-9.\n\u6709\u95dc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u4f75\u9ad8\u8840\u58d3\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u6b63\u78ba\r1) \u9664\u4e86\u751f\u6d3b\u578b\u614b\u4e4b\u6539\u8b8a\u5916\uff0cAngiotensin Converting Enzyme Inhibitor(ACEI)\u6216Angiotensin Receptor Blocker(ARB)\u61c9\u8a72\u512a\u5148\u4f7f\u7528\r2) \u03b2 blocker\u53cathiazide\u5c0d\u80f0\u5cf6\u7d20\u6297\u6027\u53ca\u8840\u8102\u6709\u4e0d\u5229\u5f71\u97ff\r3) Dihydropyridine\u985e\u9223\u96e2\u5b50\u963b\u65b7\u5291\u512a\u65bcNon-Dihydropyridine\u985e\r4) \u5c0d\u6709Macroalbuminuria\u4e4b\u75c5\u4eba\u8840\u58d3\u6a19\u7684\u70ba130/80 mm Hg\r5) Thiazide\u3001\u03b2 blocker\u3001ACEI\u3001ARB\u5c0d\u65bc\u5fc3\u808c\u6897\u585e\u6216stroke\u6709\u6b63\u9762\u6548\u679c\r6) \u03b1 blocker\u5c0d\u6709\u81ea\u5f8b\u795e\u7d93\u75c5\u8b8a\u75c5\u4eba\u6703\u589e\u52a0\u59ff\u614b\u6027\u4f4e\u8840\u58d3\u98a8\u96aa\nA. 1+3+5\nB. 2+4+6\nC. 1+2+6\nD. 2+3+4\nE. 4+5+6\n": "(C)", "100-10.\n\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u4e2d\u90a3\u4e9b\u8f03\u4e0d\u6703\u589e\u52a0\u9ad4\u91cd\r1.Glimepiride\r2.Metformin\r3.Pioglitazone\r4.Sitagliptin\r5.Acarbose\r6.Repaglinide\nA. 1+3+5\nB. 2+4+6\nC. 2+4+5\nD. 1+2+6\nE. 3+4+5\n": "(C)", "101-1.\n45\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6025\u6027\u5fc3\u808c\u6897\u585e\u9032\u5165ICU\uff0c\u55e3\u5f8c\u767c\u73fe\u983b\u767c\u5fc3\u5ba4\u4e0d\u6574\u8108\u4f7f\u7528Amiodarone\uff0c\u7b2c5\u5929\u51faICU\u524d\u62bd\u8840\u6aa2\u67e5T4 3.0 \u03bcg/dl\u3001T3 30 ng/dl\u3001\rTSH 0.6 \u03bcU/ml\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u9069\u7576\uff1a\nA. \u7d66\u4e88thyroxine 25 \u03bcg qd \u6cbb\u7642\nB. \u505c\u7528 Amiodarone\nC. \u53ef\u8f49\u81f3\u666e\u901a\u75c5\u623f\u89c0\u5bdf\u5373\u53ef\nD. \u5b89\u6392\u7532\u72c0\u817aI-131 uptake\u53ca scan\nE. \u5b89\u6392\u7532\u72c0\u817a\u8d85\u97f3\u6ce2\u6aa2\u67e5\n": "(C)", "101-2.\n20\u6b72\u5973\u5927\u5b78\u751f\u56e0\u5fc3\u60b8\u3001\u767c\u71d2\u3001\u5026\u6020\u4e8c\u5929\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u5de6\u9838\u67091.5\u00d72 \u516c\u5206\u786c\u584a\u3001\u58d3\u75db(+)\uff0c\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u9451\u5225\u529b\u6700\u9ad8\ufe30\nA. free T4\u3001hsTSH\nB. I-131 uptake and scan\nC. ESR\u3001CRP\nD. Fine needle aspiration cytology\nE. Ultrasound of thyroid\n": "(D)", "101-3.\n45\u6b72\u5973\u6027\u56e0\u5026\u6020\u3001\u7121\u529b\u3001\u4fbf\u79d8\u3001\u9ad4\u91cd\u589e\u52a0\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u8eab\u9ad8160\u516c\u5206\u3001\u9ad4\u91cd60\u516c\u65a4\u3001\u81c9\u90e8\u7565\u70ba\u6d6e\u816b\u3001\u84bc\u767d\uff0c\u8840\u58d3 146/92 mmHg\u3001PR 58/min\uff0c regular \u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u98ef\u524d\u8840\u7cd6100 mg/dl\u3001\u81bd\u56fa\u9187 260 mg/dl\u3001\u4f4e\u5bc6\u5ea6\u81bd\u56fa\u9187 160 mg/dl\uff0cNa 128 mM\u3001K 4.0 mM\u3001CK 1500 U/L\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u6070\u7576\ufe30\nA. \u7d66\u4e88statin\u6cbb\u7642\nB. \u7d66\u4e88Angiotensin Receptor Blocker\nC. \u6e2cUrine sodium\u3001protein\nD. \u6e2c\u8840\u4e2d free T4\u3001hsTSH\nE. \u6e2c\u8840\u4e2d ACTH\u3001cortisol\n": "(D)", "101-4.\n\u627f\u4e0a\u984c\uff0c\u7d93\u9069\u7576\u6cbb\u7642\u75c5\u4eba\u6062\u5fa9\u826f\u597d\uff0c\u4e09\u500b\u6708\u5f8c\u75c5\u4eba\u56e0\u610f\u8b58\u4e0d\u6e05\u88ab\u5bb6\u4eba\u9001\u4f86\u6025\u8a3a\uff0c\u64da\u5bb6\u4eba\u63cf\u8ff0\u75c5\u4eba3\u5929\u524d\u611f\u5192\u767c\u71d2\u5f8c\uff0c\u98df\u617e\u4e0d\u632f\u9010\u6f38\u865b\u5f31\uff0c\u75c5\u4eba\u6bcf\u5929\u4ecd\u7e7c\u7e8c\u670d\u7528\u4e0a\u6b21\u4f4f\u9662\u4e4b\u85e5\u7269\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73feB.T. 36.5\u2103\u3001BP 90/60 mmHg\u3001PR 112/min\uff0cregular\u62bd\u8840\u6aa2\u67e5 Hb 11 g/dl\u3001WBC 6000/\u03bcl\u3001platelet 200 K/\u03bcl\u3001Na 117 mM/L\u3001K 3.4 mM/L\u3001Ca 2.0 mM/L\u3001P 2.5 mg/dl\u3001CK 40 U/L\u3001\u8840\u7cd6 85 mg/dl\uff0c\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u6700\u9069\u7576\ufe30\nA. \u6e2cUrine sodium\nB. \u6e2c\u8840\u4e2d free T4\u3001hsTSH\nC. \u6e2c\u8840\u4e2d ACTH\u3001cortisol\nD. \u6e2c\u8840\u4e2d 25 Vit D\u3001iPTH\nE. \u6e2c\u8840\u4e2d GOT\u3001GPT\n": "(C)", "101-5.\n55\u6b72\u7537\u6027\u6700\u8fd13\u500b\u6708\u958b\u59cb\u6709\u6f6e\u7d05\u3001\u6d41\u6c57\u3001\u547c\u5438\u56f0\u96e3\u4e4b\u767c\u4f5c\uff0c\u8d77\u521d\u5f88\u8f15\u5fae\uff0c\u4f46\u8fd11\u500b\u6708\u4f86\u89ba\u5f97\u52a0\u91cd\uff0c\u66fe\u56e0\u4e0a\u8ff0\u75c7\u72c0\u5230\u904e\u6025\u8a3a\uff0c\u4f46\u7d93\u75c7\u72c0\u6cbb\u7642\u5373\u6062\u5fa9\uff0c\u4e09\u661f\u671f\u524d\u9084\u56e0\u61f7\u7591\u6025\u6027\u76f2\u8178\u708e\u958b\u5200\u4f46\u75c7\u72c0\u7686\u7121\u6539\u5584\uff0c\u4e8c\u5929\u524d\u5167\u8996\u93e1\u6aa2\u67e5\u767c\u73fe\u5341\u4e8c\u6307\u8178\u6f70\u760d\u3001\u80c3\u708e\uff0c\u8179\u8d85\u767c\u73fe\u809d\u5be6\u8cea\u6027\u75be\u75c5 ( parenchymal disease ) \uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u767c\u73fe\u53f3\u814e\u4e0a\u817a\u67093.5 cm\u816b\u7624\uff0c\u7d93\u5167\u5206\u6ccc\u6aa2\u67e5\uff0ccortisol\u3001ACTH\u3001catecholamine\u3001aldosterone\u3001plasma renin activity\u3001 DHEAS\u7686\u70ba\u6b63\u5e38\uff0c\u8acb\u554f\u60a8\u5982\u4f55\u8655\u7f6e\uff1f\nA. \u6b64\u70ba\u7121\u529f\u80fd\u6027\u816b\u7624\uff0c\u53ef\u63a1\u75c7\u72c0\u6cbb\u7642\nB. \u4e0d\u8ad6\u6709\u7121\u529f\u80fd\uff0c\u7167\u6703\u958b\u5200\u6cbb\u7642\nC. \u5148\u7167\u6703\u7cbe\u795e\u79d1\u6392\u9664\u7cbe\u795e\u65b9\u9762\u75be\u75c5\nD. \u6b64\u70ba\u7537\u6027\u66f4\u5e74\u671f\u53ef\u7d66\u4e88\u96c4\u6027\u7d20\u6cbb\u7642\nE. 6\u500b\u6708\u5f8c\u518d\u505a\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(B)", "101-6.\n42\u6b72\u7537\u6027\u91ab\u5e2b\u65bc22\u5e74\u524d\u88ab\u8a3a\u65b7Graves' \u6c0f\u75c7\uff0c\u4f46\u56e0\u85e5\u7269\u526f\u4f5c\u7528 ( \u7662\u75b9 ) \u4e26\u672a\u898f\u5247\u670d\u85e5\uff0c\u5076\u800c\u6703\u6709\u5fc3\u60b8\u3001\u8e81\u71b1\u60c5\u5f62\uff0c\u4f4f\u9662\u524d3\u5929\u6709\u5fc3\u60b8\u3001\u5641\u5fc3\u3001\u547c\u5438\u56f0\u96e3\u3002\u4f4f\u9662\u524d\u4e00\u5929\u51fa\u73fe\u767c\u71d2\u3001\u5750\u7acb\u547c\u5438\u4f86\u6025\u8a3a\uff0c\u75c5\u4eba\u610f\u8b58\u4e0d\u6e05\uff0cBP 90/59 mmHg\u3001PR 150/min\uff0cLVEF 29 %\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u4e0d\u6070\u7576\ufe30\nA. \u4f7f\u7528\u5927\u5291\u91cfhydrocortisone\nB. \u4f7f\u7528Lugol solution \u5f8c\u52a0\u4e0a\u5927\u5291\u91cf propylthiouracil\nC. \u7d66\u4e88Dopamine infusion + Digoxin IV\nD. Blood culture\u5f8c\u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20\nE. \u8003\u616e\u63a1\u7528ECMO\n": "(B)", "101-7.\n30\u6b72\u5973\u6027\u81ea\u89ba\u9838\u90e8\u816b\u8139\u4f86\u8a3a\uff0c\u75c5\u4eba\u4e26\u7121\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u6216\u4f4e\u4e0b\u4e4b\u75c7\u72c0\uff0c\u89f8\u8a3aThyroid Gr I \u5de6\u5074\u6709\u7c73\u7c92\u5927\u5c0f\u4e4b\u7d50\u7bc0\uff0c\u8acb\u554f\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u975e\u5fc5\u8981\ufe30\nA. free T4\u3001hsTSH\nB. AntiTPO\u3001Antithyroglobulin Ab\nC. I-131 uptake & scan\nD. ultrasound of  thyroid\nE. Fine needle aspiration of  thyroid\n": "(C)", "101-8.\n25\u6b72\u7537\u6027\u5728\u7c43\u7403\u6bd4\u8cfd\u4e2d\u660f\u5012\uff0c\u9001\u4f86\u6025\u8a3a\u5fc3\u96fb\u5716\u5448\u73fe\u5fc3\u623f\u986b\u52d5\uff0c\u8840\u58d3 180/100 mmHg\uff0c\u7d93\u904e10\u5206\u9418\uff0c\u5fc3\u96fb\u5716\u6062\u5fa9\u6b63\u5e38\uff0c\u8840\u58d3 130/80 mmHg\uff0c\u75c5\u4eba\u6558\u8ff06\u500b\u6708\u524d\u6709\u985e\u4f3c\u767c\u4f5c\uff0c\u6700\u8fd1\u9ad4\u91cd\u6e1b\u5c112\u516c\u65a4\uff0c\u5bb6\u65cf\u53f2\u7236\u89aa\u6709\u9ad8\u8840\u58d3\uff0c\u5927\u59ca\u66fe\u63a5\u53d7\u526f\u7532\u72c0\u817a\u816b\u7624\u5207\u9664\uff0c\u4e00\u5144\u4e8c\u59b9\u7686\u5065\u5eb7\uff0c\u8eab\u9ad4\u6aa2\u67e5\u9664\u4e86\u5716127\u6240\u793a\u4e26\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30Na 138 mM/L\u3001K 4.0 mM/L\u3001Cl 102 mM/L \u3001Ca 2.5 mM/L\u3001P 3.5 mg/dl\u3001AC glucose 112 mg/dl\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u70ba\u6700\u9069\u7576\ufe30\r(1)\u62bd\u8840\u6aa2\u67e5Albumin\u3001total protein\u3001BUN\u3001Cr\u3001GOT\u3001GPT\u3001ALP\r(2)\u62bd\u8840\u6aa2\u67e5HbA1C\u3001AC\u3001PC\r(3)\u62bd\u8840\u6aa2\u67e5plasma metanephrine\r(4)\u62bd\u8840\u6aa2\u67e5iPTH\r(5)\u62bd\u8840\u6aa2\u67e5Calcitonin\r(6)\u5b89\u6392Holter EKG \u6aa2\u67e5\nA. (1)+(2)+(3)\nB. (2)+(4)+(6)\nC. (3)+(4)+(5)\nD. (5)+(6)+(1)\nE. (2)+(3)+(4)\n": "(C)", "101-9.\n22\u6b72\u7537\u6027\u5927\u5b78\u751f\u8fd1\u534a\u5e74\u4f86\u89ba\u5f97\u53e3\u6e34\u3001\u591a\u5c3f\uff0c1\u5929\u559d\u51b7\u98f2\u7d045\u516c\u5347\uff0c\u9ad4\u91cd\u589e\u52a0\u8fd110 Kg\uff0c\u4f86\u8a3a\u8eab\u9ad4\u6aa2\u67e5\u7121\u7279\u5225\u767c\u73fe\uff0cBP 126/82 mmHg\u3001PR 80/min regular\uff0c\u62bd\u8840\u6aa2\u67e5 Na 140 mM/L\u3001K 3.5 mM/L\u3001Urinalysis protein ( - )\uff0csugar ( - )\uff0c\u60a8\u89ba\u5f97\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u70ba\u8a3a\u65b7\u6240\u5fc5\u8981\ufe30\r(1)Water deprivation test\r(2)dDAVP test\r(3)plasma Osm.\r(4)HbA1C\r(5)MRI of sella\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(4)+(5)\nE. (1)+(2)+(5)\n": "(E)", "101-10.\n28\u6b72\u7537\u6027\u696d\u52d9\u54e1\u56e0\u4e0b\u80a2\u7121\u529b\u7121\u6cd5\u7ad9\u7acb\u88ab\u9001\u4f86\u6025\u8a3a\uff0c\u75c5\u4eba\u6700\u8fd1\u696d\u52d9\u58d3\u529b\u5927\u5e38\u5931\u7720\uff0c\u4f46\u98df\u617e\u4e0d\u932f\u53ea\u662f\u9ad4\u91cd\u4e26\u672a\u589e\u52a0\uff0c\u6628\u65e5\u53c3\u52a0\u805a\u9910\uff0c\u4eca\u65e9\u672c\u4f86\u8981\u505a\u696d\u52d9\u5831\u544a\u4f46\u4eca\u65e9\u767c\u73fe\u7121\u6cd5\u7ad9\u7acb\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73feBP 140/70 mmHg\u3001PR 100/min regular\uff0c\u7532\u72c0\u817a\u4e26\u7121\u660e\u986f\u816b\u5927\uff0c\u4e0b\u80a2\u808c\u529b1/5\uff0cDTR\u4e0b\u80a2\u7121\u6cd5\u505a\u51fa\uff0c\u4e0a\u80a2 ( + + )\u3001Barbinski sign ( - )\uff0c\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u5fc5\u8981\ufe30\r(1)free T4\u3001hsTSH\r(2)Na\u3001K\r(3)MRI of spinal cord\r(4)Psychiatry consultation\r(5)Neurology consultation\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(A)", "101-1.\n\u4f9d\u64da\u4e2d\u83ef\u6c11\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70\uff0c\u4e0b\u5217\u90a3\u4e9b\u4eba\u5c1a\u4e0d\u9808\u505a\u7cd6\u5c3f\u75c5\u548c\u7cd6\u5c3f\u75c5\u524d\u671f\u7684\u7be9\u6aa2 ?\nA. 28\u6b72\u5973\u6027\u53bb\u5e74\u751f\u7522\uff0c\u5b30\u5152\u91cd4500\u516c\u514b\uff0cBMI\u70ba26 Kg/\u33a1  \uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\nB. 26\u6b72\u5973\u6027\u88ab\u8a3a\u65b7\u70ba\u591a\u56ca\u6ce1\u5375\u5de2\u75c7\uff0cBMI\u70ba24 Kg/\u33a1  \uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\nC. 32\u6b72\u7537\u6027\uff0c\u8fa6\u516c\u5ba4\u5de5\u4f5c\uff0c\u5065\u6aa2\u767c\u73feHbA1C 5.8 %\uff0cBMI\u70ba23 Kg/\u33a1 \uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\nD. 66\u6b72\u7537\u6027\uff0c\u53bb\u5e74\u525b\u9000\u4f11\uff0c\u5065\u6aa2\u767c\u73feHbA1C 5.6 %\uff0cBMI\u70ba23 Kg/\u33a1\uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\nE. 23\u6b72\u5927\u5b78\u751f\uff0c\u7236\u6bcd\u7686\u6709\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0cBMI 25 Kg/\u33a1 \uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\n": "(C)", "101-2.\n\u4e0b\u5217\u90a3\u4e00\u9805\u975e\u8a3a\u65b7\u7b2c1\u578b\u7cd6\u5c3f\u75c5\u7684\u5fc5\u8981\u689d\u4ef6\ufe30\nA. \u7a7a\u8179\u8840\u6e05C-\u80dc\ufffdT\u6fc3\u5ea6 < 0.5 ng/ml\nB. \u5347\u7cd6\u7d20\u523a\u6fc0\u5f8c6\u5206\u9418\u8840\u6e05C-\u80dc\ufffdT\u6fc3\u5ea6 < 1.8 ng/ml\nC. \u5347\u7cd6\u7d20\u523a\u6fc0\u8a66\u9a576\u5206\u82070\u5206\u8840\u6e05C-\u80dc\ufffdT\u6fc3\u5ea6\u76f8\u5dee < 0.7 ng/ml\nD. \u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2\nE. Anti-GAD65 \u967d\u6027\n": "(D)", "101-3.\n\u4e0b\u5217\u90a3\u4e00\u85e5\u7269\u6700\u6613\u5f15\u8d77\u4f4e\u8840\u7cd6\nA. Metformin\nB. Pioglitazone\nC. Glinide \u985e\nD. DDP-4 inhibitor\nE. \u03b1- Glucosidase inhibitor\n": "(C)", "101-4.\n\u76ee\u524d\u8a8d\u70ba\u80c3\u7e5e\u9053\u624b\u8853\u53ef\u4f7f\u7cd6\u5c3f\u75c5\u7de9\u89e3\u4e4b\u6a5f\u8f49\u70ba\u4e0b\u5217\u5404\u9805\uff0c\u9664\u4e86\nA. \u98f2\u98df\u9650\u5236\nB. Ghrelin \u4e0a\u5347\nC. \u5341\u4e8c\u6307\u8178\u9694\u7d55\nD. \u4e0b\u8178\u9053\u8377\u723e\u8499\u4e0a\u5347\nE. \u98df\u617e\u4e0b\u964d\n": "(B)", "101-5.\n\u4e0b\u5217\u90a3\u4e00\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u589e\u52a0\u9aa8\u9b06\u75c7\u98a8\u96aa ?\nA. Metformin\nB. Sulfonylurea\nC. Pioglitazone\nD. DDP - 4 inhibitor\nE. \u03b1- glucosidase inhibitor\n": "(C)", "101-6.\n\u4e0b\u5217\u90a3\u4e9b\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u88ab\u5efa\u8b70\u7528\u4f86\u6cbb\u7642\u9910\u5f8c\u9ad8\u8840\u7cd6\uff0c\u9664\u4e86\nA. Glinide\nB. \u03b1- Glucosidase inhibitor\nC. Metformin\nD. DDP - 4 inhibitor\nE. Ultrashort acting insulin\n": "(C)", "101-7.\n\u6839\u64da\u6211\u570b\u6210\u4eba\u9aa8\u9b06\u75c7\u9632\u6cbb\u6307\u5f15\uff0c\u4e0b\u5217\u90a3\u4e9b\u4eba\u8f03\u6c92\u6709\u505a\u9aa8\u5bc6\u5ea6\u7be9\u6aa2\u4e4b\u5fc5\u8981\u6027\nA. 65\u6b72\u4ee5\u4e0a\u7537\u6027\nB. \u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u75c7\u4e4b30\u6b72\u5973\u6027\nC. \u60a3\u6709\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u4f7f\u7528\u985e\u56fa\u9187\u60a3\u8005\nD. \u672a\u4f8610\u5e74\u4e4b\u9ad6\u90e8\u9aa8\u6298\u98a8\u96aa4%\u4ee5\u4e0a\u8005\nE. 65\u6b72\u4ee5\u4e0a\u5a66\u5973\n": "(A)", "101-8.\n29\u6b72\u5973\u6027\u6709\u50e7\u5e3d\u74e3\u812b\u5782\u53ca\u659c\u8996\u8853\u5f8c\u75c5\u53f2\uff0c\u6700\u8fd18\u500b\u6708\u4f86\u6709\u65b7\u65b7\u7e8c\u7e8c\u660f\u7761\u72c0\u6cc1\uff0c\u767c\u751f\u6642\u4f75\u6709\u6d41\u53e3\u6c34\u3001\u56db\u80a2\u7121\u529b\u986b\u6296\u4e4b\u60c5\u5f62\uff0c\u5403\u904e\u4e00\u4e9b\u6771\u897f\u5f8c\u5c31\u53ef\u6062\u5fa9\uff0c\u8acb\u554f\u60a8\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u6b63\u78ba\ufe30\r(1) \u75c5\u4eba\u7b26\u5408 Whipple's Triad\r(2) \u809d\u3001\u814e\u529f\u80fd\u6aa2\u67e5\u70ba\u5fc5\u8981\r(3) 72\u5c0f\u6642fasting test \u6aa2\u67e5 C- peptide\u3001glucose\u3001insulin \u70ba\u5fc5\u8981\r(4) \u6e2c\u5b9a\u8840\u4e2dsulfonylurea \u6fc3\u5ea6\u70ba\u5fc5\u8981\r(5) \u82e5\u61f7\u7591\u80f0\u5cf6\u7d20\u7624\u6642\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u5927\u90e8\u5206\u53ef\u5b9a\u4f4d\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(4)+(5)\nE. (1)+(2)+(5)\n": "(B)", "101-9.\n40\u6b72\u7537\u6027\u4e3b\u8a34\u5168\u8eab\u9aa8\u982d\u75db\u7121\u6cd5\u884c\u8d70\u4f86\u8a3a\uff0c\u4ed6\u91cf\u8eab\u9ad8\u6642\u767c\u73fe\u534a\u5e74\u4f86\u6e1b\u5c113\u516c\u5206\uff0c\u810a\u690eX - \u5149\u767c\u73feT10\u524d\u5f91 < \u5f8c\u5f91\uff0c\u9aa8\u5bc6\u5ea6 Lumbar spine T score - 2.6\u3001Hip T score ( \u5de6 ) - 2.8\uff0c( \u53f3 ) -2.9 \uff0c\u62bd\u8840\u6aa2\u67e5 Alb 4.0 g/dl\u3001globulin 2.5 g/dl\u3001ALP 150 U/L ( normal < 80 )\u3001Ca 9.0 mg/dl\u3001P 2.0 mg/dl\u3001iPTH 70 pg/ml\uff0curinalysis \u7121glucose\u3001amino acid\u3001\u86cb\u767d, \u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\r(1) \u6b64\u75c5\u4eba\u70ba osteoporosis \u6709 compression fracture\r(2) \u6b64\u75c5\u4eba\u70ba\u9aa8\u9ad3 ( \u8840\u6db2 ) \u75be\u75c5\u9020\u6210osteoporosis\r(3) \u6e2c\u91cf\u5c3f\u78f7\u70ba\u5fc5\u8981\r(4) \u6e2c\u91cf fibroblast growth factor 23\u6709\u52a9\u8a3a\u65b7\r(5) \u6b64\u75c5\u4eba\u70ba\u60e1\u6027\u816b\u7624\u8f49\u79fb\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "101-10.\n\u4e0b\u5217\u6709\u95dc\u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2\u4e4b\u6cbb\u7642\u70ba\u6070\u7576\r(1) \u80f0\u5cf6\u7d20\u5b9c\u4f7f\u75284 - dose intensify \u6cbb\u7642\r(2) \u975c\u8108\u8f38\u6db2\u521d\u59cb\u5b9c\u5feb\u901f\u5927\u91cf\u751f\u7406\u98df\u9e7d\u6c34 ( 10-20 ml/kg )\r(3) \u9240\u96e2\u5b50\u4e4b\u88dc\u5145\u70ba\u5fc5\u8981\uff0c\u9664\u975e\u8840\u9240 > 5 mM/L \u53ef\u66ab\u7de9\r(4) \u4fc3\u767c\u56e0\u5b50\u5fc5\u9808\u7a4d\u6975\u5c0b\u627e\u4e26\u6cbb\u7642\r(5) \u4e00\u822c\u8840\u7cd6\u4e0b\u964d\u5f8c\u8840\u4e2d Ketone \u81ea\u7136\u6d88\u5931\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (4)+(5)+(1)\nE. (5)+(1)+(2)\n": "(B)", "102-1.\n48\u6b72\u5973\u6027\u56e0\u5065\u6aa2\u767c\u73fe\u7532\u72c0\u817a\u816b\u4f86\u6c42\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u75c5\u4eba\u7532\u72c0\u817a\u5448\u7b2c\u4e00\u5ea6\u816b\u5927\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30free T4 1.07 ng/dl\u3001hsTSH 7.5\u03bcU/ml\u3001thyroglobulin 100 ng/ml\u3001antiTPO 400 IU/ml\u3002\u4e0b\u5217\u8655\u7f6e\u53ca\u5176\u7406\u7531\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u75c5\u4eba\u7532\u72c0\u817a\u6a5f\u80fd\u4f4e\u4e0b\u5373\u523b\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u88dc\u5145\nB. \u75c5\u4eba\u7532\u72c0\u817a\u816b\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nC. \u75c5\u4ebaantiTPO\u9ad8\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\u4ee5\u6e1b\u5c11\u767c\u708e\nD. \u75c5\u4ebathyroglobulin\u9ad8\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nE. \u7532\u72c0\u817a\u7d20\u6cbb\u7642\u7121\u76ca\uff0c\u89c0\u5bdf\u5373\u53ef\n": "(E)", "102-2.\n68\u6b72\u5973\u6027\u6709\u9577\u671f\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u4f7f\u7528Glimepiride\u53cametformin\uff0c\u8fd1\u4e00\u5e74\u4f86\u56e0\u814e\u529f\u80fd\u4e0d\u826f\u505c\u7528metformin\uff0c\u53e6\u6709\u9ad8\u8840\u58d3\uff0c\u63a7\u5236\u4e2d\uff0c\u534a\u5e74\u4f86\u67093\u6b21\u610f\u8b58\u4e0d\u6e05\uff0c\u6700\u8fd11\u6b21\u662f6\u661f\u671f\u524d\u67d0\u4e00\u534a\u591c\uff0c\u8840\u7cd6\u70ba20 mg/dl\uff0c\u6b64\u5f8c\u4e0d\u518d\u670d\u7528\u4efb\u4f55\u964d\u8840\u7cd6\u85e5\uff0c1\u5e74\u524d\u56e0\u5fc3\u623f\u986b\u52d5\u958b\u59cb\u670d\u7528Amiodarone\uff0c\u75c5\u4eba\u8acb\u6c42\u5168\u8eab\u6aa2\u67e5\uff0c\u8840\u58d3 176/70 mmHg\uff0c\u4e0b\u80a2\u9707\u52d5\u611f\u89ba\u6d88\u5931\uff0c\u4e26\u6709Romberg's sign\uff0c\u773c\u5e95\u80cc\u666f\u8996\u7db2\u819c\u75c5\u8b8a\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\ufe30\u7a7a\u8179\u8840\u7cd6135 mg/dl\u3001HbA1C 6.5%\u3001Na 141 mM\u3001K 4.4 mM\u3001Cr 1.9 mg/dl\u3001TSH 24 \u03bcU/ml\u3001urine protein +++\u3002 \u60a8\u6703\u5efa\u8b70\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\uff1f\nA. \u958b\u59cbLautus insulin 1\u59291\u6b21\u6cbb\u7642\nB. \u56de\u5fa9Glimepiride\u4f7f\u7528\nC. \u958b\u59cb\u7528Pioglitazone\nD. \u4f7f\u7528Novonorm\nE. \u958b\u59cbthyroxine\u6cbb\u7642\n": "(E)", "102-3.\n54\u6b72\u5973\u6027\uff0c5\u5e74\u524d\u505c\u7d93\uff0c\u7d048\u500b\u6708\u524d\u6015\u71b1\u3001\u5fc3\u60b8\u3001\u9ad4\u91cd\u6e1b\u8f155.5 Kg\u3001\u624b\u6296\uff0c\u9ad4\u6aa2\u767c\u73feGrade 1\u7532\u72c0\u817a\u816b\uff0c\u9aa8\u5bc6\u5ea6\u6aa2\u67e5\u767c\u73fe\u8170\u690eT score -1.8 \u3001\u80a1\u9aa8 -2.4\uff0c\u62bd\u8840\u6aa2\u67e5\uff0c\u90a3\u4e00\u9805\u8f03\u7b26\u5408\u6b64\u75c5\u4eba\u4e4b\u7d50\u679c?\nA. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n      \u2191                 \u2193                    \u2191                           \u2191\nB. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n      \u2193                 \u2191                    \u2191                           \u2193\nC. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n     \u2191                  \u2191                    \u2191                           \u2191\nD. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n     \u2191                  \u2193                    \u2193                           \u2193\nE. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n     \u2193                  \u2193                    \u2193                          \u2191\n": "(A)", "102-4.\n72\u6b72\u5973\u6027\u56e0\u767c\u751f\u610f\u8b58\u4e0d\u6e05\u4f4f\u9662\uff0c\u5979\u5152\u5b50\u6558\u8ff0\u75c5\u4eba3\u5929\u524d\u611f\u5192\u670d\u7528\u666e\u62ff\u75bc(acetaminophen)\u53ca\u5927\u91cf\u6c34\uff0c\u9ad4\u6aa2\u767c\u73fe\u9ad4\u6eab38.5 \u2103\u3001\u8108\u640f100/min\u3001\u8840\u58d3140/85 mmHg\uff0c\u4e8c\u5074\u80ba\u6709\u56c9\u97f3( rales ) \u4e26\u7121\u6c34\u816b\uff0c\u80f8\u90e8X\u5149\u767c\u73fe\u4e8c\u5074\u6709\u6d78\u6f64\u584a\uff0c\u62bd\u8840\ufe30Na 110 mM\u3001BUN 15 mg/dl\u3001glucose 96 mg/dl\u3001\u8840\u6f3f\u6ef2\u900f\u58d3230  mOsm\uff0c\u5c3f\u6db2400 mOsm\uff0c \u5c3f\u6db2 Na 15 mM \u3002\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u7981\u6c34\u89c0\u5bdf\nB. \u7d66\u4e88demeclocycline\nC. \u7d66\u4e88\u751f\u7406\u98df\u9e7d\u6c34\nD. \u7d66\u4e883% \u98df\u9e7d\u6c34\nE. \u7d66\u4e883% \u98df\u9e7d\u6c34\u4f75\u7528furosemide 20 mg q12h\n": "(D)", "102-5.\n16\u6b72\u5c11\u5973\u56e0\u539f\u767c\u6027\u7121\u6708\u7d93\u4f86\u8a3a\uff0c\u8eab\u9ad8165.1\u516c\u5206\uff0c\u9ad4\u91cd85\u516c\u65a4\uff0c\u5169\u624b\u5f35\u958b167\u516c\u5206\uff0c\u8840\u58d3 102/60 mmHg\uff0c\u5916\u9670\u767c\u80b2\u6b63\u5e38\uff0c\u9aa8\u76e4\u8154\u8d85\u97f3\u6ce2\u6c92\u6709\u5b50\u5bae\uff0c\u5169\u5074\u5375\u5de21.5x4.2x1.3 cm (\u5de6)\uff0c 1.3x4.4x1.2 cm (\u53f3)\uff0c\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u53ef\u78ba\u7acb\u8a3a\u65b7?\nA. FSH\u3001LH\nB. Karyotype \u5206\u6790\nC. MRI of Pelvis\nD. ACTH stimulation test\nE. DHEA-S\u53ca17OH-progesterone\n": "(B)", "102-6.\n64\u6b72\u7537\u6027\u5065\u5eb7\u6aa2\u67e5\u5168\u8eabMRI\u767c\u73fe5mm\u8166\u5782\u817a\u816b\u7624\uff0c\u5176\u4ed6\u751f\u5316\u6aa2\u67e5\u7686\u6b63\u5e38\uff0c\u62bd\u8840\ufe30ACTH ( 8AM) 20 pg/ml\u3001cortisol 14 \u03bcg/dl\u3001\rFSH 4 mIU/ml\u3001testosterone 427 ng/dl\u3001free T4 1.1 ng/dl\u3001prolactin 14 ng/ml\u3002\u60a8\u7684\u5efa\u8b70\u662f\nA. \u8f49\u4ecb neurosurgeon\nB. \u8f49\u4ecb radiotherapy\nC. \u7d66\u4e88Octreotide\nD. \u4e0d\u9808\u6cbb\u7642\nE. \u7d66\u4e88Dostinex\n": "(D)", "102-7.\n57\u6b72\u5973\u6027\u9577\u671f\u56e0\u80cc\u75db\u3001\u80a9\u75db\u524d\u5f80\u8a3a\u6240\u6ce8\u5c04\u301d\u6b62\u75db\u91dd\u301e\uff0c1\u5e74\u4f86\u9ad4\u91cd\u589e\u52a09\u516c\u65a4\uff0c\u5448\u73fe\u6708\u4eae\u81c9\uff0c8AM cortisol \u53caACTH\u7686\u6e2c\u4e0d\u5230\uff0c\u76ee\u524d\u4f7f\u7528Dexamethasone 0.5 mg qd\u3001Celebrex 200 mg bid\u3001gabapentin 600 mg qid\u53caNexium 20 mg qd\uff0c\u56e0\u75c5\u4eba\u89ba\u5f97\u6108\u4f86\u6108\u75b2\u5026\u3001\u7121\u529b\u800c\u4f86\u8a3a\u3002\u4e0b\u5217\u90a3\u4e00\u9805\u63aa\u65bd\u662f\u6700\u6070\u7576?\nA. \u505a\u8166\u5782\u817aMRI\u4e86\u89e3\u8166\u5782\u817a\u662f\u5426\u840e\u7e2e\nB. \u6162\u6162\u6e1b\u5c11\u7cd6\u76ae\u7d20\u7528\u91cf\uff0c\u958b\u59cb\u5fa9\u5065\u6cbb\u7642\nC. \u589e\u52a0Dexamethasone \u81f31.0 mg bid\nD. \u505c\u7528gabapentin\nE. \u505aCRH test \u4e86\u89e3\u8166\u5782\u817a\u76ae\u4fc3\u7d20\u7d30\u80de\u4e4b\u529f\u80fd\n": "(B)", "102-8.\n65\u6b72\u7537\u6027\u4e8c\u5e74\u524d\u767c\u73fe\u5de8\u5927\u8166\u5782\u817a\u816b\u7624\uff0c\u63a5\u53d7\u7d93\u8776\u978d\u816b\u7624\u5207\u9664\u8853\uff0c\u8853\u5f8c\u75c5\u7406\u8b49\u5be6\u7121\u529f\u80fd\u6027\u816b\u7624\uff0c\u56e0\u5c1a\u6709\u6b98\u9918\u816b\u7624\u518d\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4e4b\u5f8c\u4fbf\u63a5\u53d7\u6fc0\u7d20\u7f6e\u63db\u6cbb\u7642\u3002\u7d04\u534a\u5e74\u524d\u75c5\u4eba\u611f\u89ba\u5168\u8eab\u9178\u75db\u5c24\u5176\u808b\u9aa8\uff0c\u7d93Tc 99 m \u9aa8\u982d\u6383\u63cf\u767c\u73fe\u591a\u8655\u71b1\u9ede\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30Ca 2.3 mM\u3001P 1.8 mg/dl\u3001iPTH 120 pg/ml\u3001 ALP 658 U/ml\uff0c \u8acb \u554f\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6700\u6070\u7576\uff1f(1)\u5b89\u6392 In-111 Octreotide scan (2)\u62bd\u8840\u6e2c\u5b9aFGF-23 (3)\u62bd\u8840\u6e2c\u5b9a 25 Vit D (4)\u7d66\u4e88Joulie solution (5)\u7d66\u4e881, 25 Vit D3 (6) \u5b89\u6392\u9aa8\u982d biopsy\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(6)\nD. (5)+(6)+(1)\nE. (2)+(4)+(6)\n": "(B)", "102-9.\n32\u6b72\u5973\u6027\u56e0\u767c\u71d2\u3001\u547c\u5438\u56f0\u96e3\u4f86\u9662\u6025\u8a3a\uff0c\u4e3b\u8a34\u4e0a\u8ff0\u75c7\u72c0\u5df2\u4e00\u5929\uff0c\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab39.4 \u2103\u3001\u5fc3\u8df3175/min \u4e0d\u898f\u5247\uff0c \u547c\u5438\u6bcf\u520630\u6b21\uff0c\u8840\u58d3197/127  mmHg\uff0c\u7d50\u819c\u4e0d\u84bc\u767d\uff0c\u7121\u9ec3\u75b8\uff0c\u7532\u72c0\u817a\u7b2c2\u5ea6\u816b\u5927\u3001\u67d4\u8edf\uff0c\u9838\u975c\u8108\u64f4\u5f35\uff0c\u5728\u5fc3\u5c16\u6709\u7b2c2\u5ea6\u5fc3\u6536\u7e2e\u96dc\u97f3\uff0c\u5728\u5de6\u4e0b\u80ba\u6709\u56c9\u97f3\uff0c\u4e26\u7121\u809d\u813e\u816b\u5927\uff0c\u56db\u80a2\u51b0\u51b7\uff0c\u5169\u8173\u6709\u6c34\u816b\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30T4 14 \u03bcg/dl\u3001TSH < 0.001 \u03bcU//ml\u3001cortisol 20\u03bcg/dl \uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6b63\u78ba\uff1f(1)\u96d6\u6709\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u4f46\u53ef\u6392\u9664\u7532\u72c0\u817a\u98a8\u66b4 (2)\u6392\u9664\u814e\u4e0a\u817a\u529f\u80fd\u4f4e\u4e0b\uff0c\u4e0d\u9808\u7d66\u4e88\u7cd6\u76ae\u7d20 (3)\u6b64\u4f8b\u7d66\u4e88 propylthiouracil \u6bd4 Methimazole \u70ba\u4f73 (4)\u6b64\u4f8b\u7d66\u4e88Digoxin \u6bd4Amiodarone \u9069\u7576\r(5)\u62bd\u8840\u6aa2\u67e5epinephrine \u53canorepinephrine\u7686\u5347\u9ad8\u4e14\u8840\u58d3\u9ad8\u61c9\u5148\u7d66\u4e88\u03b1- \u963b\u65b7\u5291\nA. (1)+(3)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "102-10.\n37\u6b72\u7537\u6027\u56e0\u534a\u591c\u767c\u751f\u80f8\u60b6\u3001\u5192\u51b7\u6c57\u4f86\u9662\u6025\u8a3a\uff0c\u4e3b\u8a34\u524d1\u5929 \u665a\u4e0a10\u6642\u767c\u751f\u5641\u5fc3 \u3001\u4e0b\u7009\u4e00\u6b21\uff0c\u534a\u591c2\u6642\u4fbf\u767c\u751f\u4e0a\u8ff0\u75c7\u72c0\u3002\u8eab\u9ad4\u6aa2\u67e5\uff1a\u8840\u58d3175/105 mmHg\u3001  \u8108\u640f88/min\uff0c\u4f46\u505aEKG\u5448sinus tachycardia (\u5fc3\u8df3 141/min )\uff0cST-T depression V4 - V6 \uff0c\u62bd\u8840 WBC 14.4 K/\u03bcl\u3001neutrophil 85.4 %\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5fc3\u623f\u3001\u5fc3\u5ba4\u6b63\u5e38\u5927\u5c0f\uff0c\u4f46LV hypokinesia ( LVEF 50% )\uff0c\u56e0\u6b64\u7d66\u4e88\u6297\u8840\u5c0f\u677f\u85e5\u7269\u53ca\u4f4e\u5206\u5b50\u91cfHeparin\uff0c\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u5728\u5165\u9662\u5f8c8\u5c0f\u6642\u9032\u884c\uff0c\u986f\u793a\u7121\u660e\u986f\u51a0\u72c0\u52d5\u8108\u72f9\u7a84\uff0c\u8853\u5f8c \u75c5\u4eba\u8840\u58d3\u4e0b\u964d\u81f3\u6536\u7e2e\u58d3 70 mmHg\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u9069\u7576\ufe30(1) \u75c5\u4eba\u70ba\u6025\u6027\u75c5\u6bd2\u6027\u5fc3\u808c\u708e\uff0c\u62bd\u8840\u6aa2\u67e5\u75c5\u6bd2\u6297\u9ad4 (2)\r\u521d\u6642\u75c5\u4eba\u8840\u58d3\u9ad8\u3001\u5fc3\u8df3\u5feb\u4ee5\u03b2\u963b\u65b7\u5291\u4f86\u964d\u58d3\u662f\u9996\u9078\uff0c\u6216\u53ef\u907f\u514d\u5f8c\u7e8c\u4f75\u767c\u75c7 (3) \u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u96d6\u70ba\u9670\u6027\u4ecd\u4e0d\u80fd\u6392\u9664\u5fc3\u808c\u6897\u585e(4)\u75c5\u4eba\u8840\u58d3\u3001\u5fc3\u8df3\u6d6e\u52d5\u751a\u5927\uff0c\u55dc\u927b\u7d30\u80de\u7624\u6aa2\u67e5\u70ba\u5fc5\u8981 (5)\u6b64\u4f8b\u5fc3\u56e0\u6027\u4f11\u514b\u70ba\u53ef\u9006\u6027\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(D)", "102-1.\n62\u6b72\u7537\u6027\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u5df214\u5e74\uff0c\u76ee\u524d\u4f7f\u7528metformin 1000 mg bid\uff0cGlimepiride 4 mg qd\uff0c\u9ad8\u8840\u58d3\u4f7f\u7528irbesartan 150 mg qd\u3001trichlormethiazide 2 mg qd\u3001Atenolol 50 mg qd\u3001\u9ad8\u8840\u8102\u4f7f\u7528atorvastatin 40 mg qd \u53c8\u6709\u51a0\u5fc3\u75c7\uff0c\u4f7f\u7528Nitrate\u53caAspirin 80 mg qd \uff0c\u9ad4\u6aa2\u8eab\u9ad8177\u516c\u5206\u3001\u9ad4\u91cd90Kg\u3001\u8840\u58d3 130/82 mmHg\uff0c\u5176\u9918\u7121\u7279\u5225\u767c\u73fe\uff0c\u62bd\u8840\ufe30HbA1C 8.1%\u3001Cr 1.3 mg/dl\u3001LDL 74 mg/dl\uff0c\u75c5\u4eba\u5728\u5bb6\u5076\u800c\u4f7f\u7528\u8840\u7cd6\u6a5f\u76e3\u6e2c\u8840\u7cd6\uff0c\u60a8\u958b\u4e86Lantus 16 u hs\uff0c\u8acb\u554f\u70baLantus\u5291\u91cf\u8abf\u6574\u4e4b\u8840\u7cd6\u76e3\u6e2c\u6700\u6070\u7576\u7684\u662f\ufe30\nA. \u98ef\u524d\u53ca\u98ef\u5f8c2\u5c0f\u6642\nB. \u6709\u4f4e\u8840\u7cd6\u4e4b\u61f7\u7591\u6642\nC. \u98ef\u524d\u53ca\u7761\u524d\nD. \u7a7a\u8179\nE. \u65e9\u3001\u665a\u9910\u524d\n": "(D)", "102-2.\n64\u6b72\u7537\u6027\u7b2c2\u578b\u7cd6\u5c3f\u75c519\u5e74\uff0c\u56e0\u53f3\u8173\u816b\u53ca\u75db\u4f86\u8a3a\uff0c\u5df2\u77e5\u4f75\u767c\u75c7\u6709\u5468\u908a\u795e\u7d93\u75c5\u8b8a\u3001\u975e\u589e\u751f\u6027\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u75c5\u8b8a\u3001\u9ad8\u8840\u58d3\u3001\u9ad8\u8840\u8102\u53ca\u5468\u908a\u8840\u7ba1\u75be\u75c5\u3002\u75c5\u4eba\u4e3b\u8a34\u4e00\u5929\u524d\u53f3\u8173\u8e1d\u75bc\u75db\uff0c\u4eca\u5929\u7d05\u816b\u53ca\u8df3\u8e8d\u6642\u6709\u4e9b\u4e0d\u9069\uff0c\u53bb\u5e74\u66fe\u6709\u7b2c\u4e8c\u8dbe\u53d7\u50b7\u767c\u708e\u7d93\u6cbb\u7642\u5df2\u75ca\u7652\u3002\u76ee\u524d\u85e5\u7269\u6709metformin 500mg t.id\u3001 Glimepiride 4 mg qd\u3001pioglitazone 30 mg qd\u3001hydrochlorothiazide/valsartan 25/80 mg qd\u3001simvastatin 40 mg hs\u3001 Aspirin 100 mg qd\uff0c\u9ad4\u6aa2\u767c\u73fe\u8eab\u9ad8160\u516c\u5206\u3001\u9ad4\u91cd80\u516c\u65a4\u3001\u8840\u58d3140/86 mmHg\uff0c\u5c40\u90e8\u767c\u73fe\u53f3\u8173\u7d05\u816b\uff0c\u5468\u908a\u8108\u640f\u7686\u6b63\u5e38\u7121\u660e\u986f\u5916\u50b7\u4f46\u4e0b\u80a2\u9707\u52d5\u611f\u6d88\u5931\uff0c\u62bd\u8840\ufe30HbA1C 7.6 %\u3001Cr 1.2\rmg/dl\u3001LDL 84 mg/dl\u3001uric acid 6.8 mg/dl\uff0cWBC 12,000/\u03bcL\uff0c\u53f3\u8173X\u5149\u6aa2\u67e5\u7121\u7279\u5225\u767c\u73fe\u4f46\u6709\u4e00\u4e9b\u8840\u7ba1\u9223\u5316\uff0c\u4e0b\u5217\u90a3\u4e00\u6b65\u9a5f\u6700\u6070\u7576\uff1a\nA. \u53f3\u8173\u8e1d\u56fa\u5b9a7\u5929\u4e26\u6e1b\u5c11\u627f\u91cd\nB. \u505a\u53f3\u8173MRI\nC. \u505a\u810a\u690e\u3001\u80a1\u9aa8BMD\u6aa2\u67e5\nD. \u505a\u8840\u6db2\u57f9\u990a\u4e26\u7d66\u6297\u751f\u7d20\nE. Tc 99m\u9aa8\u982d\u6383\u63cf\n": "(B)", "102-3.\n52\u6b72\u7537\u6027\u56e0\u65e9\u6668\u88ab\u5bb6\u4eba\u767c\u73fe\u53e3\u9f52\u4e0d\u6e05\u4f86\u6025\u8a3a\uff0c one-touch\u767c\u73fe\u8840\u7cd645mg/dL\u7d93\u8461\u8404\u7cd6\u6ce8\u5c04\u6062\u5fa9\u6b63\u5e38\uff0c\u80f8\u90e8X\u5149\u767c\u73fe\u53f3\u5074\u6709\u4e00\u808b\u819c\u816b\u7624\u7d045\u516c\u5206\uff0c\u75c5\u4eba\u7981\u98df4\u5c0f\u6642\u5f8c\u53c8\u767c\u751f\u4f4e\u8840\u7cd6\u73fe\u8c61\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30\u8840\u7cd639 mg/dl\u3001Insulin < 0.1\u03bcU/ml\u3001C-peptide < 0.1 ng/ ml\uff0c\u7d93glucagon\u6ce8\u5c04\u5f8c10\u5206\u8840\u7cd6\u5347\u70ba65 mg/dl\u800c\u6062\u5fa9\uff0c\u57fa\u65bc\u4e0a\u8ff0\u6aa2\u67e5\u7d50\u679c\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u6070\u7576\uff1a\nA. Pancreas CT\nB. \u91cd\u6e2cinsulin\uff0cc-peptide\nC. \u6e2c\u5b9a\u8840\u4e2d\u964d\u8840\u7cd6\u85e5\u7269\u6fc3\u5ea6\nD. \u6e2c\u5b9aIGF-2\nE. CT-guided biopsy of pleural lesion\n": "(D)", "102-4.\n81\u6b72\u7537\u6027\u4f4f\u5728\u5b89\u990a\u9662\u6709\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u53f2\u7528\u98f2\u98df\u63a7\u5236\uff0c\u5176\u4ed6\u75c5\u53f2\u6709\u51a0\u5fc3\u75c7\u3001\u5fc3\u8870\u7aed\u3001\u9ad8\u8840\u58d3\u7528Nitrate\u53caACEI\u6cbb\u7642\uff0c\u75c5\u4eba\u56e0\u8840\u58d3\u964d\u4f4e\u53ca\u610f\u8b58\u60e1\u5316\u88ab\u9001\u4f86\u6025\u8a3a\uff0c\u75c5\u4eba\u55dc\u7761\uff0c\u53e3\u4e7e\u3001\u76ae\u4e7e\u3001\u8840\u58d396/74 mmHg\u3001\u8108\u640f104/min\u3001one-touch > 500 mg/dl\uff0c\u56e0\u6b64\u7d66\u4e88IV\u53caSC RI 10u\uff1b\u62bd\u8840\u6aa2\u67e5\ufe30glucose 815 mg/dl\u3001K 6.1 mM\u3001Na 145 mM\u3001BUN 80mg/dl \u3001Cr 3.5 mg/dl \u3001Blood gas\ufe30pH 7.32 \u3001PCO2 33 mmHg\u3001HCO3 19 mEq/L\u3001PO2 78 mmHg\uff0c\u56e0\u6b64\u653e\u7f6e\u4e2d\u592e\u975c\u8108\u5c0e\u7ba1\u5f8c\u958b\u59cb\u751f\u7406\u98df\u9e7d\u6c34\u704c\u6ce8\uff0c2\u5c0f\u6642\u7d66\u4e861.5\u516c\u5347\uff0c\u4f46\u8840\u58d3\u4e0b\u964d\u81f384/70 mmHg\uff0c\u8acb\u554f\u6b64\u75c5\u4eba\u8840\u58d3\u4e0b\u964d\u4e4b\u539f\u56e0\u70ba\ufe30\nA. Insulin\nB. IV fluid\u4e4b\u9ad4\u7a4d\u6d41\u5931\nC. IV fluid\u4e4b\u6ef2\u900f\u58d3\nD. \u6025\u6027\u5fc3\u808c\u6897\u585e\nE. \u4e73\u9178\u4e2d\u6bd2\n": "(A)", "102-5.\n54\u6b72\u7537\u6027\u6700\u8fd1\u9ad4\u6aa2\u767c\u73fe\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u4ed6\u7684\u6bcd\u89aa\u53ca\u59ca\u59ca\u4ea6\u6709\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u7236\u89aa\u572860\u6b72\u6642\u6b7b\u65bc\u5fc3\u808c\u6897\u585e\uff0c\u75c5\u4eba\u9664\u4e86\u670d\u7528\u591a\u7a2e\u7dad\u4ed6\u547d\u5916\u6c92\u6709\u5176\u4ed6\u85e5\u7269\uff0c\u9ad4\u6aa2\uff1aBMI 28.3 Kg/m2 \u3001\u8840\u58d3145/88 mmHg\uff0c\u62bd\u7159\u4e00\u59291\u5305\uff0c\u8840\u6db2\u751f\u5316\uff1a HDL 37 mg/dl\u3001LDL 142 mg/dl\u3001CHO 220 mg/dl\u3001TG 210 mg/dl\u3001 HbA1C 8.2 %\u3001Cr 1.0 mg/dl\u3001fasting glucose 144 mg/dl\u3002\u8acb\u554f\u9664\u4e86\u751f\u6d3b\u578b\u614b(\u98f2\u98df\u3001\u904b\u52d5\u3001\u505c\u6b62\u62bd\u7159)\u5916\uff0c\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6700\u9069\u7576\uff1f\nA. \u7d66\u4e88Metformin 500 mg bid\uff0c\u82e5\u53ef\u8010\u53d7\uff0c\u589e\u81f31000 mg bid\nB. \u7d66\u4e88Glyburide 5 mg bid\nC. \u7d66\u4e88Simvastatin 20 mg hs\nD. \u7d66\u4e88Pioglitazone 30 mg qd\nE. \u7d66\u4e88Exenatide 5 mg sc bid\n": "(C)", "102-6.\n37\u6b72\u5973\u6027\u70ba\u7b2c1\u578b\u7cd6\u5c3f\u75c519\u5e74\uff0c\u56e0\u5de6\u8db3\u7121\u6cd5\u80cc\u5c48 ( dorsiflex ) \u4f86\u8a3a\uff0c\u6700\u8fd1\u8ffd\u8e64\u9664\u4e86\u773c\u5e95\u6709\u4e00\u4e9b\u5c0f\u8840\u7ba1\u7624\u4ee5\u5916\u7121\u5176\u4ed6\u4f75\u767c\u75c7\uff0c\u9ad4\u6aa2\u767c\u73fe\u7532\u72c0\u817a2\u5ea6\u816b\u5927\uff0c\u5de6\u8db3\u7121\u6cd5\u80cc\u5c48\uff0c\u611f\u89ba\u4e5f\u55aa\u5931\uff0c\u53f3\u4e0b\u80a2\u5247\u70ba\u6b63\u5e38\uff1b \u819d\u53cd\u5c04\u4e8c\u5074\u7686\u6b63\u5e38\uff0c\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u6700\u6070\u7576?\nA. \u7532\u72c0\u817a\u529f\u80fd\u6aa2\u67e5\nB. \u795e\u7d93\u50b3\u5c0e\u6aa2\u67e5\nC. \u8166\u810a\u9ad3\u6db2\u86cb\u767d\u96fb\u6cf3\nD. \u8170\u90e8\u6838\u78c1\u5171\u632f\nE. \u985e\u98a8\u6fd5\u56e0\u5b50\u6e2c\u5b9a\n": "(B)", "102-7.\n57\u6b72\u7537\u6027\u88ab\u8a3a\u65b7\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u7d041\u5e74\uff0c\u76ee\u524d\u7528\u85e5\ufe30Metformin 1000mg bid\u3001Glyburide 10 mg bid\u3001rosuvastatin 20 mg qd\uff0c\u4e0d\u62bd\u7159\uff0c\u5076\u800c\u559d1\u7f50\u5564\u9152\uff0c\u9ad4\u6aa2\ufe30\u8840\u58d3126/74 mmHg\u3001\u8108\u640f 84/min\u3001BMI 25 Kg/M2 \uff0c\u62bd\u8840\u6aa2\u67e5\ufe30TSH 1.2\u03bcU/ml\u3001HbA1C 9.6 %\u3001CHO 302 mg/dl\u3001LDL 104 mg/dl\u3001TG 803 mg/dl\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u6070\u7576\uff1f\nA. \u7d66\u4e88Niacin\nB. \u7d66\u4e88Pioglitazone\nC. \u7d66\u4e88Insulin\nD. \u7d66\u4e88Fenofibrate\nE. \u7d66\u4e88Ezetimibe\n": "(C)", "102-8.\n\u4e0b\u5217\u90a3\u4e9b\u4eba\u8f03\u9069\u5408\u7528\u80f0\u5cf6\u7d20\u63a7\u5236\uff0c\u8acb\u9078\u6700\u6070\u7576\u7b54\u6848: (1)\u65b0\u767c\u73fe\u7cd6\u5c3f\u75c5\u6709\u4e09\u591a\u75c7\u72c0 (2)\u7cd6\u5c3f\u75c5\u53f220\u5e74\uff0c\u670d\u7528\u4e09\u7a2e\u53e3\u670d\u964d\u7cd6\u5291\uff0c\u8fd1\u534a\u5e74HbA1C \uff1e 8.0 % (3)\u809d\u786c\u5316 Child A \u75c5\u4eba (4) BMI 36 Kg/M2 \uff0c\u7121\u6cd5\u4ee5metformin + sulfonylurea\u63a7\u5236\u4e4b\u7cd6\u5c3f\u75c5\u75c5\u4eba (5)\u6025\u6027\u5fc3\u808c\u6897\u585e\u5728\u51a0\u5fc3\u75c7\u52a0\u8b77\u75c5\u623f\u75c5\u4eba\uff0c\u65b0\u767c\u73fe\u7cd6\u5c3f\u75c5\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(A)", "102-9.\n\u4e0b\u5217\u90a3\u4e9b\u7cd6\u5c3f\u75c5\u4eba\u8f03\u9069\u5408\u8840\u7cd6\u63a7\u5236\u6307\u6a19\u8a2d\u65bcHbA1C \uff1e 7.0 % (1)65\u6b72\u5973\u6027BMI 28 Kg/M2 \uff0c\u5df2\u6709\u7cd6\u5c3f\u75c510\u5e74\uff0c\u7368\u5c45\u81ea\u4e3b (2)65\u6b72\u5973\u6027\u6709\u8996\u7db2\u819c\u75c5\u8b8a\uff0cCr 2.0 mg/dl\uff0c\u624b\u8173\u9ebb\u6728 (3)65\u6b72\u7537\u6027\u6709\u5fc3\u808c\u6897\u585e\u75c5\u53f2\uff0c\u5fc3\u8870\u7aed\u55dc\u597d\u7f8e\u98df (4)65\u6b72\u5973\u6027\u6709\u5927\u8178\u764c\u4f75\u809d\u8f49\u79fb\uff0c\u8853\u5f8c\u6b63\u63a5\u53d7\u5316\u7642 (5)70\u6b72\u7537\u6027\u53bb\u5e74\u53c3\u52a0\u9ad8\u9f61\u99ac\u62c9\u677e\u8cfd\u5f97\u734e (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)\nB. (2)+(3)\nC. (3)+(4)\nD. (2)+(3)+(4)\nE. (1)+(3)+(5)\n": "(C)", "102-10.\n\u4e0b\u5217\u6709\u95dc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u8207\u9aa8\u8cea\u758f\u9b06\u75c7\u4e4b\u95dc\u4fc2\uff0c\u4f55\u8005\u6b63\u78ba \ufe56(1)\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u80a5\u80d6\u591a\uff0c\u9aa8\u627f\u91cd\u8f03\u5927\uff0c\u4e0d\u6613\u9aa8\u6298 (2)\u7cd6\u5c3f\u75c5\u5728\u9aa8\u6298\u98a8\u96aa\u8a55\u4f30\u5de5\u5177( FRAX ) \u516c\u5f0f\u5167\u52a0\u4ee5\u8003\u616e (3)\u7cd6\u5c3f\u75c5\u7528\u85e5 thiazolidinedione \u6703\u9020\u6210\u9aa8\u8cea\u758f\u9b06\u75c7 (4)\u7cd6\u5c3f\u75c5\u5f15\u8d77\u4e4b\u7cd6\u5316\u7d42\u7aef\u7522\u7269\u9020\u6210\u9aa8\u8cea\u8b8a\u5dee (5)\u4f7f\u7528 metformin\u65e2\u53ef\u6e1b\u5c11\u5fc3\u8840\u7ba1\u75be\u75c5\u4e5f\u6e1b\u5c11\u9aa8\u6298\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "103-1.\n45\u6b72\u7537\u6027\u75c5\u4eba\u5728\u5065\u6aa2\u6642\u767c\u73fe\u6709\u4e00FDG-PET positive \u7684\u9838\u90e8\u71b1\u9ede\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u7532\u72c0\u817a\u5de6\u5074\u7d041 \u516c\u5206\u7d50\u7bc0\uff0c\u62bd\u8840\u6aa2\u67e5free T4\u6b63\u5e38\u3001hsTSH \u504f\u4f4e\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u9996\u5148\u8981\u505a?\nA. \u5efa\u8b70\u958b\u5200\u5207\u9664\nB. \u6e2cAnti TPO\uff0cAntithyroglobulin Ab\nC. Fine needle aspiration (FNA) of thyroid\nD. I-131 uptake and scan\nE. \u5c40\u90e8\u6ce8\u5c04\u9152\u7cbe\n": "(D)", "103-2.\n63\u6b72\u5973\u6027\u56e0\u4e73\u764c\u505a\u8853\u524d\u8a55\u4f30\u767c\u73fe\u8840\u6db2BUN 24 mg/dl\u3001Cr 1.1 mg/dl\u3001Ca 11.1 mg/dl\u3001P 3.5 mg/dl\u3001Alb 3.9 g/dl\u3001iPTH 96 pg/ml(10-65 pg/ml)\uff0cBone scan \u6b63\u5e38\uff0c\u8853\u5f8c\u8840\u9223\u70ba11.3 mg/dl\u3001iPTH 92 pg/ml\u30011,25 Vit D3 61 pg/ml (16-65 pg/mL)\u3001Urine Ca 362 mg/day\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u9ad8\u8840\u9223\u539f\u56e0?\nA. \u4e73\u764c\u8f49\u79fb\nB. \u7570\u4f4d\u6027PTH\u5206\u6ccc\nC. \u539f\u767c\u6027\u526f\u7532\u72c0\u817a\u9ad8\u80fd\u75c7\nD. \u4e73\u764c\u904e\u5ea6\u9032\u884c1\u03b1 hydroxylation\nE. \u5bb6\u65cf\u6027\u4f4e\u5c3f\u9223\u9ad8\u8840\u9223\u75c7\n": "(C)", "103-3.\n47\u6b72\u5973\u6027\u52a0\u62ff\u5927\u56de\u570b\u50d1\u80de\u56e0\u9ad4\u6aa2\u767c\u73feTSH 4.5\u03bcU/ml\uff0c\u7532\u72c0\u817a\u8d85\u97f3\u6ce2\u6709\u591a\u98460.5-0.7cm \u7d50\u7bc0\u800c\u5c31\u8a3a\uff0c\u7532\u72c0\u817a\u89f8\u6478\u6bd4\u6b63\u5e38\u7a0d\u5927\u3001\u7a0d\u786c\uff0c\u62bd\u8840\u6aa2\u67e5Anti TPO 242 IU/ml (< 10 IU/mL)\uff0c\u4e0b\u5217\u90a3\u9805TSH \u6fc3\u5ea6\u4ee5\u4e0a\uff0c\u4f60\u6703\u958b\u59cbthyroxine \u6cbb\u7642\uff1f\nA. 1.5 \u03bcU/ml\nB. 11.5 \u03bcU/ml\nC. 7.5 \u03bcU/ml\nD. 3.9 \u03bcU/ml\nE. 18 \u03bcU/ml\n": "(B)", "103-4.\n32\u6b72\u5973\u6027\u56e0\u8179\u75db\u5728\u6025\u8a3a\u7167\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u767c\u73fe1.5\u516c\u5206\u5de6\u5074\u814e\u4e0a\u817a\u7624(3.5 Hu)\uff0c\u5979\u9ad4\u91cd\u7a69\u5b9a\uff0cBMI 31.2 Kg/M2\uff0c3\u5e74\u524d\u767c\u73fe\u9ad8\u8840\u58d3\uff0c\u76ee\u524d\u670d\u7528Amlodipine 10 mg qd\uff0cRamipril 10 mg qd\uff1b\u8840\u58d3144/82 mmHg\uff0c\u62bd\u8840(4PM)  Na 143 meq/L\u3001K 3.6 meq/L\uff0cplasma metanephrine\u6b63\u5e38\uff0cplasma aldosterone 6.9 ng/dl\uff0cplasma renin activity (PRA) < 0.6  ng/ml/hr\uff0covernight Dexamethasone suppression test cortisol 0.8 \u03bcg/dl\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u4f73\uff1f\nA. \u6aa2\u67e5 midnight cortisol\nB. \u91cd\u6aa28AM plasma aldosterone and PRA\nC. \u6e2c24 urine catecholamine\nD. \u505a\u814e\u4e0a\u817a\u6838\u78c1\u5171\u632f\nE. \u6e2c24 urine cortisol\n": "(B)", "103-5.\n76\u6b72\u5973\u6027\u56e0\u8dcc\u5750\u5730\u4e0a\u81f4T11\u58d3\u8feb\u6027\u9aa8\u6298\u4f86\u8a3a\uff0c\u5979\u6709\u9ad8\u8840\u58d3\u53ca\u98df\u9053\u9006\u6d41\u670d\u85e5\u63a7\u5236\uff0c\u6bcd\u89aa\u572870\u591a\u6b72\u6642\u4e8c\u5074\u5927\u817f\u9aa8\u6298\uff0c\u5979\u6bcf\u5929\u670d\u7528\u9223\u72471000 mg \u4e26\u4f7f\u7528\u591a\u7a2e\u7dad\u4ed6\u547d\uff0c\u5979\u4e3b\u8a34\u5df2\u7d93\u77ee\u4e865-6\u516c\u5206\uff0c\u9ad4\u6aa2\u767c\u73fe\u6709\u4e9b\u99dd\u80cc\u5916\u7121\u5176\u4ed6\u7570\u5e38\uff0c\u62bd\u8840\u6aa2\u67e525 Vit D 33 ng/ml (15-80 ng/ml)\u3001iPTH 32 pg/ml (10-65 pg/ml)\uff0c\u751f\u5316\u6aa2\u67e5\u53ca\u96fb\u89e3\u8cea\u7686\u6b63\u5e38\uff0c\u60a8\u8a8d\u70ba\u6700\u597d\u7684\u6cbb\u7642\u662f?\nA. oral bisphosphonate\nB. \u589e\u52a0\u53e3\u670d\u9223\u7247\nC. \u76ae\u4e0b\u6ce8\u5c04rh PTH\nD. \u4f7f\u7528Nasal calcitonin\nE. \u589e\u52a0Vit D \u5291\u91cf\n": "(C)", "103-6.\n25\u6b72\u5973\u6027\u56e0\u80a5\u80d6\u53ca\u7cd6\u5c3f\u75c5\u75c7\u60e1\u5316\u4f86\u8a3a\uff0c\u76ee\u524dBMI 42 Kg/M2\uff0c18\u6b72\u6642\u88ab\u8a3a\u65b7\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u8d77\u5148\u7528\u98f2\u98df\u63a7\u5236\uff0c\u76f4\u81f32\u5e74\u524d\u9808\u4f7f\u7528metformin\uff0cHbA1C 4\u500b\u6708\u524d\u70ba7.2%\uff0c\u6700\u8fd1\u56e0\u76ae\u75b9\u4f7f\u7528\u985e\u56fa\u9187\uff0c\u9ad4\u6aa2\u767c\u73fe\u8eab\u9ad4\u6709\u591a\u8655\u4e7e\u766c\u75b9\u584a\uff0c\u8840\u58d3150/85 mmHg \uff0c \u7121\u5176\u4ed6\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u7a7a\u8179\u8840\u7cd6204 mg/dl\u3001HbA1C 9.5%\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u91cd\u8981?\nA. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nB. \u6e2c8AM cortisol\nC. \u6e2c\u8840\u6e05 ferritin\u53caTIBC\nD. \u6e2cAnti-insulin\u53caglutamic acid decarboxylase Ab\nE. \u8f49\u4ecb\u505a\u80c3\u7e5e\u9053\u624b\u8853\n": "(B)", "103-7.\n37\u6b72\u7537\u6027\u4e3b\u8a34\u56e0\u4e0b\u80a2\u7121\u529b\u65e9\u4e0a\u7121\u6cd5\u8d77\u5e8a\uff0c\u4f46\u5230\u4e86\u65e9\u4e0a10\u6642\u5c31\u81ea\u7136\u597d\u4e86\u3002\u75c5\u53f2\u4e2d\u75c5\u4eba\u900f\u9732\u8fd12\u500b\u6708\u9ad4\u91cd\u6e1b\u8f153\u516c\u65a4\u4f46\u98df\u617e\u6975\u4f73\uff0c\u4ed6\u5426\u8a8d\u6709\u5fc3\u60b8\uff0c\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3136/56 mmHg\u3001\u8108\u640f90/\u5206\u3001\u898f\u5247\u3001\u7532\u72c0\u817a\u6b63\u5e38\u5927\u5c0f\uff0c\u76ae\u819a\u7d30\u7dfb\u6eab\u6696\uff0c\u808c\u529b\u6aa2\u67e5\u5927\u817f\u808c\u529b4/5\uff0c\u4e0a\u81c24/5\uff0c\u5176\u99185/5\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u662f?\nA. \u539f\u767c\u6027\u919b\u56fa\u916e\u8840\u75c7\nB. \u7532\u72c0\u817a\u9ad8\u80fd\u75c7\u4f75\u808c\u75c5\u8b8a\nC. \u7532\u72c0\u817a\u6bd2\u6027\u5468\u671f\u6027\u7671\u7613\nD. \u7570\u4f4d\u6027\u76ae\u4fc3\u7d20\u75c7\u5019\u7fa4\nE. \u4f7f\u7528\u5229\u5c3f\u5291\u6e1b\u80a5\n": "(C)", "103-8.\n74\u6b72\u7537\u6027\u56e0\u5026\u6020\u3001\u98df\u617e\u5dee\uff0c\u9ad4\u91cd\u6e1b\u8f15\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5BMI 17 Kg/M2\u3001\u8840\u58d3130/70 mmHg\u3001\u8108\u640f 54/min\uff0c\u81c9\u90e8\u7a0d\u6709\u6d6e\u816b\uff0c\u773c\u7d50\u819c\u7a0d\u84bc\u767d\uff0c\u5176\u9918\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5\uff1aHb 9.0 gm/dl\u3001WBC 4000/\u03bcl\u3001platelet 80,000/\u03bcl\u3001Na 125 mM\u3001K 3.6 mM\u3001T-CHO 260 mg/dl\u3001LDL 145 mg/dl\u3001BUN 35 mg/dl\u3001Cr 1.5 mg/dl\u3001free T4 0.6 ng/dl (0.8-2.4ng/dl)\u3001hsTSH 0.1 \u03bcU/ml (0.4-4.2\u03bcU/ml )\uff1b\u5927\u4fbf\u6aa2\u67e5\u7121\u6f5b\u8840\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u6070\u7576\uff1f\r(1)\t\u7d66\u4e883% NaCl solution\r(2)\t\u7d66\u4e88statin \u6cbb\u7642\r(3)\t\u5373\u523b\u88dc\u5145thyroxine 125\u03bcg/day\r(4)\t\u6e2c\u5b9a8AM cortisol\u3001ACTH\r(5)\t\u505asella MRI\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(D)", "103-9.\n50\u6b72\u4e2d\u5e74\u7537\u6027\u4e3b\u8a34\u967d\u840e\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5BMI 27 Kg/M2\u3001\u8840\u58d3140/90 mmHg\uff0c\u5176\u9918\u7121\u7279\u5225\u767c\u73fe\uff0c\u4e0b\u5217\u90a3\u4e9b\u8377\u723e\u8499\u6aa2\u67e5\u6700\u9069\u7576\uff1f(1) FSH (2) LH (3) Testosterone (4) prolactin (5) Dehydroepiandrosterone (DHEAS)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (4)+(5)+(1)\nE. (5)+(1)+(2)\n": "(B)", "103-10.\n25\u6b72\u5973\u6027\u56e0\u9ad4\u6aa2\u767c\u73fe\u9ad8\u8840\u58d3\u4f86\u8a3a\uff0c\u5bb6\u65cf\u53f2\u6bcd\u89aa\u56e0\u7532\u72c0\u817a\u816b\u958b\u5200\u5f8c\uff0c\u76ee\u524d\u4f7f\u7528thyroxine\u88dc\u5145\uff0c\u7236\u89aa\u4ea6\u6709\u9ad8\u8840\u58d3\uff0c\u65bc\u67d0\u6b21\u8eca\u798d\u958b\u5200\u4e2d\u6b7b\u4ea1\uff0c\u4e00\u500b\u59ca\u59ca\u56e0\u526f\u7532\u72c0\u817a\u9ad8\u80fd\u75c7\u958b\u5200\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u8840\u58d3160/100 mmHg\u3001\u8108\u640f 72/min\uff0c\u7532\u72c0\u817a\u6709grade1\u816b\u5927\uff0c\u9918\u8005\u7121\u7279\u5225\u767c\u73fe\uff0c\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6700\u9069\u7576\uff1f(1) \u6e2c\u5b9aNa\u3001K\u3001Cl (2) \u6e2c\u5b9aplasma aldosterone\u53caplasma rennin activity (3) \u6e2c\u5b9aUrine metanephrine (4) \u6e2c\u5b9aAlb\u3001Ca\u3001P\u3001iPTH (5) \u505aRET oncogene\u6aa2\u67e5\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (4)+(5)+(1)\nE. (5)+(1)+(2)\n": "(C)", "103-1.\n58\u6b72\u7537\u6027\uff0c\u670913\u5e74\u7cd6\u5c3f\u75c5\u53f2\u53ca\u9577\u671fCAD\uff0c5\u5e74\u524d\u653e\u7f6e\u652f\u67b6\uff0c\u76ee\u524d\u4f7f\u7528\u85e5\u7269\u6709sulfonylurea\u3001metformin\u3001hydrochlorothiazide\u3001ACEI\u53caAspirin\u3001atorvastatin\u3002\u6700\u8fd11\u5e74\u4ed6\u52a0\u5f37\u98f2\u98df\u53ca\u904b\u52d5\uff0c\u6e1b\u91cd4\u516c\u65a4\uff0c\u9ad4\u6aa2\u767c\u73fe\u8840\u58d3126 / 72 mmHg\uff0cBMI 30 Kg/M2\uff0c\u8170\u570d99\u516c\u5206\uff0c\u5176\u4ed6\u6b63\u5e38\uff1b\u62bd\u8840HbA1C 7.0 %\u3001CHO 174 mg/dl\u3001LDL 66 mg/dl\u3001TG 376 mg/dl\uff0curine ACR (microalbumin creatinine ratio) 25\u03bcg/gm\uff0c\u4e0b\u5217\u54ea\u4e00\u7a2e\u6cbb\u7642\u6700\u6070\u7576\uff1a\nA. Fenofibrate\nB. Pioglitazone\nC. Insulin glargine\nD. Low carbohydrate diet\nE. Exenatide\n": "(A)", "103-2.\n80\u6b72\u7537\u6027\u56e0\u5026\u6020\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\ufe30BMI 26 Kg/M2\uff0c\u8840\u58d3140 / 90 mmHg\uff0c\u4e0b\u80a2\u6709\u8f15\u5fae\u6c34\u816b\uff0c\u9918\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5Cr 2.5 mg/dl\u3001GOT 30u/L\u3001GPT 25u/L\u3001HbA1C 7.8 %\u3001glucose AC150 mg/dl\uff0c\u5c3f\u6aa2protein(++)\uff0c\u9664\u4e86\u751f\u6d3b\u578b\u614b\u3001\u98f2\u98df\u63a7\u5236\u5916\uff0c\u4f55\u8005\u6700 \u9069\u5b9c\uff1f\nA. \u521d\u767c\u73fe\u7cd6\u5c3f\u75c5\u4ee5\u80f0\u5cf6\u7d20\u6ce8\u5c04\u70ba\u4f73\nB. Metformin\nC. Pioglitazone\nD. Linagliptin\nE. Glimepiride\n": "(D)", "103-3.\n29\u6b72\u5973\u6027\u670910\u5e74\u7b2c1\u578b\u7cd6\u5c3f\u75c5\u75c5\u53f2\u4f86\u8a3a\uff0c\u6700\u8fd11-2\u5e74HbA1C 7\u223c8%\uff0c\u773c\u5e95\u6aa2\u67e5\u904e\u6578\u6b21\u4f46\u90fd\u8aaa\u6b63\u5e38\uff0c\u76ee\u524d\u4f7f\u7528\u98ef\u524d\u77ed\u6548\u53ca\u7761\u524dInsulin glargine(Lantus)\uff0c\u6bcf\u661f\u671f\u4ecd\u67093-4\u6b21\u8f15\u5fae\u4f4e\u8840\u7cd6\uff0c\u5176\u4ed6\u85e5\u7269\u53ea\u6709\u907f\u5b55\u4e38\uff0c\u8eab\u9ad4\u6aa2\u67e5BMI 22 Kg/M2\uff0c\u8840\u58d3125/75 mmHg\uff0c\u5de6\u773c\u773c\u5e95\u6709\u4e00microaneurysm \u5468\u908a\u795e\u7d93\u6aa2\u67e5\u6b63\u5e38\uff0c\u62bd\u8840HbA1C 7.4%\uff0cCHOL 156 mg/dl\u3001LDL 95 ng/ dl\u3001TG 78 mg/ dl\u3001urine ACR (microalbumin creatinine ratio) 45 \u03bcg/gm\uff0c\u60a8\u7684\u5efa\u8b70\u662f\uff1a\nA. \u5373\u523b\u7d66\u4e88ACEI\nB. \u5373\u523b\u7d66\u4e88ARB\nC. \u56de\u8a3a\u505a\u5c3f\u6db2\u611f\u67d3\u7be9\u6aa2\nD. 4-6\u661f\u671f\u5f8c\u518d\u505aurine ACR \u6aa2\u67e5\nE. \u505c\u6b62\u53e3\u670d\u907f\u5b55\u4e38\u6539\u7528\u5176\u4ed6\u907f\u5b55\u63aa\u65bd\n": "(D)", "103-4.\n62\u6b72\u7537\u6027\u6709\u4e2d\u98a8\u3001\u5fc3\u623f\u986b\u52d5\u3001\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u7236\u89aa56\u6b72\u6642\u6b7b\u65bc\u5fc3\u808c\u6897\u585e\uff0c\u5f1f\u5f1f58\u6b72\u56e0\u51a0\u5fc3\u75c7\u505a\u7e5e\u9053\u624b\u8853\uff0c\u4ed6\u56e0\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u670d\u7528Simvastatin\u3001Atorvastatin \u90fd \u56e0\u808c\u8089\u9178\u75db\u7121\u6cd5\u4f7f\u7528\uff0c\u4ed6\u4e5f\u56e0\u6f6e\u7d05\u7121\u6cd5\u4f7f\u7528Niacin\u3001gemfibrozil (Lopid)\u9020\u6210\u8178\u80c3\u4e0d\u9069\uff0c\u76ee\u524d\u4f7f\u7528\u85e5\u7269\u70baimipramine hydrochloride (Tofranil)\u3001Lisinopril\u3001Diltiazem\u3001Warfarin\u53cadiuretic\uff0c\u9ad4\u6aa2\u767c\u73fe\u8840\u58d3 114/71 mmHg\u3001BMI 30.4 Kg/M2\u3001\u8170\u570d102\u516c\u5206\uff0c\u4e8c\u5074\u9838\u52d5\u8108\u96dc\u97f3\uff0c\u5de6\u5074\u504f\u7671\uff0c\u62bd\u8840\u7a7a\u8179\u8840\u7cd6 98 mg/dl\u3001TSH 2.7 \u03bcU/ml\u3001CK 57 U/L\u3001CHO 304 mg/dl\u3001LDL 218 mg/dl\u3001TG 258 mg/dl\u3001HDL 34\rmg/dl\uff0c\u4e0b\u5217\u90a3\u4e00\u500b\u63aa\u65bd\u662f\u6700\u4f73\u7684\u7b2c\u4e00\u6b65\uff1f\nA. \u7d66\u4e88Bezafibrate\nB. Therapeutic lifestyle change Diet\nC. \u7d66\u4e88rosuvastatin (Crestor)\nD. \u7d66\u4e88Ezetimibe\nE. \u7d66\u4e88Pravastatin\n": "(E)", "103-5.\nACCORD\u3001ADVANCE\u3001VADT\u81e8\u5e8a\u8a66\u9a57\u767c\u73fe\u5617\u8a66\u964d\u4f4eHbA1C\u63a5\u8fd16% \u6216 6.5%\uff0c\u53cd\u800c\u9020\u6210\u6b7b\u4ea1\u7387\u4e0a\u5347\uff0c\u6700\u4e3b\u8981\u539f\u56e0\u4f55\u5728?\nA. \u524c\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\u8a98\u767c\u764c\u75c7\u767c\u751f\nB. \u5fc3\u808c\u6897\u585e\u767c\u751f\u7387\u589e\u52a0\nC. \u8166\u5352\u4e2d\u767c\u751f\u7387\u589e\u52a0\nD. \u4f4e\u8840\u7cd6\u81f4\u5fc3\u5f8b\u4e0d\u6574\u767c\u751f\u7387\u589e\u52a0\nE. \u75c5\u4eba\u62b5\u6297\u529b\u964d\u4f4e\n": "(D)", "103-6.\n\u76ee\u524d\u5df2\u77e5Pioglitazone\u4e4b\u526f\u4f5c\u7528\u5305\u62ec\u4e0b\u5217\u5404\u9805\uff0c\u9664\u4e86\nA. \u6c34\u816b\nB. \u5fc3\u808c\u6897\u585e\nC. \u809d\u529f\u80fd\u8b8a\u5316\nD. \u9aa8\u9b06\nE. \u9ad4\u8102\u589e\u52a0\n": "(B)", "103-7.\n62\u6b72\u7537\u6027\u56e0\u6025\u6027\u5fc3\u808c\u6897\u585e\u4f4f\u9662\u88ab\u767c\u73fe\u6709\u7cd6\u5c3f\u75c5\uff0c\u51a0\u72c0\u52d5\u8108\u651d\u5f71\u767c\u73fe\u591a\u8840\u7ba1\u75be\u75c5\u9808\u9032\u884c\u7e5e\u9053\u624b\u8853\uff0c\u75c5\u4eba\u5728\u624b\u8853\u524d\u5f8c\u4ee5\u2163.\u80f0\u5cf6\u7d20\u704c\u6ce8\u63a7\u5236\u8840\u7cd6\uff0c\u4f4f\u9662\u4e2dLVEF   \u70ba30%\uff0c\u7121\u5fc3\u5f8b\u4e0d\u6574\u3001HbA1C 12%\u3001Cr 1.0 mg/ dl\uff0c\u4f4f\u9662\u4e2d\u63a5\u53d7\u71df\u990a\u5e2b\u885b\u6559\uff0c\u51fa\u9662\u524d\u6539\u670d\u7528Glipizide 5 mg bid\uff0c\u5176\u4ed6\u85e5\u7269\u5c1a\u6709Carvedilol 12.5 mg bid\u3001Atorvastatin (Lipitor) 20 mg qd\u3001Aspirin 75 mg qd\u3001ramipril (Tritace) 10 mg qd\u3001isosorbide 5-mononitrate (Ismo-20) 1/2\uff03bid\u3001furosemide (Lasix)40 mg qd\uff0c\u8acb\u554f\u6cbb\u7642\u6b64\u75c5\u4eba\u4e4b\u7cd6\u5c3f\u75c5\u61c9\u5982\u4f55\u8f03\u597d\uff1f\nA. \u505c\u7528Glipizide \u6539\u7528Metformin\nB. \u7e7c\u7e8cGlipizide\u53e6\u52a0Pioglitazone\nC. \u7e7c\u7e8cGlipizide\u53e6\u52a0Metformin\nD. \u7e7c\u7e8cGlipizide\u53e6\u52a0Insulin\nE. \u505c\u7528Glipizide\u6539\u7528Insulin\n": "(E)", "103-8.\n\u4e0b\u5217\u6709\u95dcincretin\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1) GIP\u7531duodenum L cell \u5206\u6cccGLP-1\u7531Ileum K cell \u5206\u6ccc (2) GIP\u53ef\u523a\u6fc0insulin \u53caglucagon\u5206\u6ccc (3) GLP-1\u53ef\u523a\u6fc0insulin \u5206\u6ccc\u4f46\u6291\u5236glucagon\u5206\u6ccc (4) GIP\u53caGLP-1\u7686\u53ef\u88abDDP-4\u5206\u89e3 (5)\u5728\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u6ce8\u5c04GIP\u4ecd\u53ef\u964d\u4f4e\u8840\u7cd6\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "103-9.\n\u6709\u95dc\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u75c5\u8b8a\u4e4b\u7167\u8b77\u6307\u5f15\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f (1) \u738b\u5973\u58eb\u5927\u5b781\u5e74\u7d1a\u65b0\u751f\uff0c18\u6b72\uff0c\u9ad4\u6aa2\u767c\u73fe\u70ba\u7b2c1\u578b\u7cd6\u5c3f\u75c5\uff0c\u9808\u7acb\u523b\u505a\u521d\u6b21\u6563\u77b3\u5b8c\u6574\u773c\u79d1\u6aa2\u67e5(2) \u674e\u5973\u58eb50\u6b72\u505c\u7d93\u75c7\u5019\u7fa4\uff0c\u9ad4\u6aa2\u767c\u73fe\u70ba\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u9808\u7acb\u5373\u505a\u521d\u6b21\u6563\u77b3\u5b8c\u6574\u773c\u79d1\u6aa2\u67e5 (3) \u984c(1)\u4e2d\u4e4b\u738b\u5973\u58eb\u5927\u5b78\u7562\u696d\uff0c\u521d\u6b21\u61f7\u5b55\u61c9\u65bcsecond trimester\u505a\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u6aa2\u67e5\uff0c\u4e26\u65bc\u61f7\u5b55\u4e2d\u5bc6\u5207\u8ffd\u8e64\u81f3\u751f\u7522\u5f8c1\u5e74(4) \u4f7f\u7528Aspirin\u589e\u52a0\u8996\u7db2\u819c\u51fa\u8840\u7684\u98a8\u96aa\uff0c\u4f46\u5c0d\u4fdd\u8b77\u6cbb\u7642\u5fc3\u81df\u7684\u75c5\u4eba\u4e26\u975e\u7981\u5fcc(5) \u96f7\u5c04\u5149\u51dd\u56fa\u6cd5\u5c0d\u9ec3\u6591\u90e8\u6c34\u816b\u4e5f\u53ef\u6e1b\u5c11\u8996\u529b\u55aa\u5931\u7684\u98a8\u96aa(6) \u8996\u7db2\u819c\u75c5\u8b8a\u70ba\u5c0f\u8840\u7ba1\u75c5\u8b8a\u8207\u75c5\u4eba\u5927\u8840\u7ba1\u75c5\u8b8a\u7121\u95dc\nA. (1)+(2)\nB. (3)+(4)\nC. (5)+(6)\nD. (1)+(3)\nE. (2)+(5)\n": "(E)", "103-10.\n\u6709\u95dc\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\u4e4b\u7167\u8b77\u6307\u5f15\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(1)\u8840\u58d3\u6b63\u5e38\u4e0b\u4f7f\u7528ACEI\u6216ARB\uff0c\u5c0d\u814e\u75c5\u8b8a\u4e0d\u50c5\u7121\u6548\u4e14\u6613\u6709\u526f\u4f5c\u7528(2)\u61c9\u7a4d\u6975\u6cbb\u7642\u9ad8\u8840\u58d3\u4e26\u7dad\u6301\u5728130/80 mmHg \u4ee5\u4e0b(3)\u61c9\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u4e26\u7dad\u6301HbA1C\u57286.5%\u4ee5\u4e0b(4)\u82e5\u75c5\u4eba\u8840\u6e05\u808c\u9150\u9178\u5df2\u4e0a\u5347\uff0c\u5247\u6bcf\u4e09\u500b\u6708\u5fc5\u9808\u8981\u6aa2\u67e5\u4e00\u6b21\u8840\u6e05\u808c\u9150\u9178(creatrimine)(5)\u82e5\u75c5\u4eba\u767c\u751f\u5de8\u91cf\u86cb\u767d\u5c3f\u61c9\u589e\u52a0\u86cb\u767d\u8cea\u651d\u53d6( >1.0 gm/Kg )\uff0c\u88dc\u5145\u6d41\u5931\u86cb\u767d\u4ee5\u907f\u514d\u6c34\u816b(6)\u5373\u4f7f\u5df2\u662fESRD\u4ecd\u61c9\u7a4d\u6975\u63a7\u5236\u8840\u8102\u7570\u5e38\uff0c\u4f7fLDL\u572870 mg/dl\u4ee5\u4e0b\nA. (1)+(2)\nB. (3)+(4)\nC. (5)+(6)\nD. (2)+(4)\nE. (1)+(5)\n": "(D)", "104-1.\n69\u6b72\u7537\u6027\u6709chronic stable angina pectoris\uff0c\u534a\u5e74\u524d\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u767c\u73fe\u55ae\u4e00\u8840\u7ba1\u51a0\u5fc3\u75c7\uff08\u5de6\u524d\u4e0b\u652f\uff09\uff0c\u75c5\u4eba\u76ee\u524d\u4f7f\u7528Atenolol 100 mg qd \u53caAspirin 80 mg qd\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u76ae\u819a\u4e7e\u71e5\u6709\u4e9b\u6d6e\u816b\uff0c\u62bd\u8840\u767c\u73fe\u81bd\u56fa\u9187320 mg/dl\uff0cLDL 166 mg/dl\uff0c HDL 34 mg/dl\uff0c hsTSH 62 uU/ml\uff0cfree T4 0.4ng/dl\uff0c\u4e0b\u5217\u6cbb\u7642\u65b9\u5f0f\u90a3\u4e00\u7a2e\u6700\u597d\uff1f\nA. \u7d66\u4e88\u9810\u9632\u6027anticoagulant\u6cbb\u7642\u53ca\u7532\u72c0\u817a\u7d20100 ug qd\nB. \u7d66\u4e88\u7532\u72c0\u817a\u7d2075 ug qd\u53ca\u4e09\u7898\u7532\u7d2025 ug qd\nC. \u7d66\u4e88\u7532\u72c0\u817a\u7d20100 ug qd\u53ca Cortisone Acetate 25 mg qd\nD. \u7d66\u4e88\u7532\u72c0\u817a\u7d20100 ug qd\u53castatin\nE. \u7d66\u4e88\u7532\u72c0\u817a\u7d2025ug qd\n": "(E)", "104-2.\n69\u6b72\u5973\u6027\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c520\u5e74\uff0cBMI 41.7 kg/M2\uff0c\u7528Glimepiride 2 mg qd \u63a7\u5236\uff0c\u4f466\u500b\u6708\u5167\u767c\u751f3\u6b21\u4f4e\u8840\u7cd6\uff0c\u9808\u4f4f\u9662\u6cbb\u7642\uff0c\u56e0\u6b64\u505c\u7528Glimepiride\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u6709\u795e\u7d93\u75c5\u8b8a\u53caRomberg's sign(+)\uff0c\u8840\u58d3175/70 mmHg\uff0c\u7532\u72c0\u817a\u6709GrI\u816b\u5927\uff0c\u62bd\u8840\u6aa2\u67e5AC 134 mg/dl\uff0c Cr 1.9mg/dl\uff0c HbA1c 6.8%,\uff0cmicroalb/Cr=3130 mg/g\uff0c K 4.4 mEq/L\uff0c TSH 24.0 uU/ml\u3002\u4e0b\u5217\u6cbb\u7642\u4e2d\uff0c\u60a8\u6703\u5efa\u8b70\u54ea\u4e00\u9805\uff1f\nA. \u6539\u70baNPH insulin hs\nB. \u6062\u5fa9Glimepiride\nC. \u6539\u7528Pioglitazone\nD. \u6539\u7528Repaglinide\nE. \u958b\u59cb\u7532\u72c0\u817a\u7d20\u6cbb\u7642\n": "(E)", "104-3.\n25\u6b72\u7537\u6027\u56e0\u9ad4\u6aa2\u767c\u73fe\u9ad8\u8840\u9223\u4f86\u8a3a\uff0c\u75c5\u4eba\u4e3b\u8a34\u5065\u5eb7\u72c0\u6cc1\u826f\u597d\uff0c\u672a\u66fe\u6709\u5c3f\u8def\u7d50\u77f3\u75c5\u53f2\uff0c\u4ed6\u4e5f\u672a\u670d\u7528\u7dad\u4ed6\u547dD\u53ca\u9223\u7247\uff0c\u9ad4\u6aa2BMI 27.5 kg/M2\uff0c\u8840\u58d3122/84 mmHg\uff0c\u62bd\u8840\u6aa2\u67e5 Alb 4.0 gm/dl\uff0cCr 0.9 mg/dl\uff0cALK phosphatase 120 U/L\uff0c Ca 11.1 mg/dl\uff0c P 3.0 mg/dl\uff0ciPTH 49 pg/ml\uff0cUrine Ca 70 mg/day\uff0c\u6700\u53ef\u80fd\u8a3a\u65b7\u662f\uff1f\nA. Sarcoidosis\nB. VitD intoxication\nC. Primary hyperparathyroidism\nD. Familial hypocalciuric hypercalcemia\nE. Hypercalcemia of malignancy\n": "(D)", "104-4.\n56\u6b72\u5973\u6027\u56e0\u5076\u7136\u767c\u73fe\u53f3\u9838\u6709\u816b\u584a\uff0c\u9ad4\u6aa2\u767c\u73fe\u662f\u53f3\u5074\u7532\u72c0\u817a\u7d50\u7bc0\uff0c\u8d85\u97f3\u6ce2\u767c\u73fe\u70ba2X2\u516c\u5206\u5468\u908a\u5e73\u6ed1\uff0c\u7d30\u91dd\u7a7f\u523a\u662ffollicular neoplasm\uff0c\u62bd\u8840\u6aa2\u67e5free T4  1.71 ng/dl,\uff0chsTSH 0.1 uU/ml\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u70ba\u6700\u9069\u7576\uff1f\nA. I-131 uptake & scan\nB. \u7532\u72c0\u817a\u7d20\u6291\u5236\u6cbb\u7642\nC. \u89c0\u5bdf\u8ffd\u8e64\nD. \u958b\u5200\u5207\u9664\nE. \u9838\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(A)", "104-5.\n36\u6b72\u7537\u6027\u56e0\u4e0b\u80a2\u7121\u529b\u4f86\u6025\u8a3a\uff0c\u4ed6\u6700\u8fd1\u88ab\u767c\u73fe\u6709\u9ad8\u8840\u58d3\uff0c\u4ee5\u5229\u5c3f\u5291\u63a7\u5236\uff0c\u6b64\u5916\u7121\u7279\u5225\u75c5\u53f2\u3002\u9ad4\u6aa2\u767c\u73fe\u8840\u58d3150/90 mmHg\uff0c\u62bd\u8840\u6aa2\u67e5 Na 143 mEq/L\uff0cK 2.6 mEq/L\uff0cCL 100 mEq/L\uff0cplasm Aldosterone\uff08PA\uff09 29 ng/dl\uff0cplasma renin activity \uff08PRA\uff09<0.6 ng/ml/h \uff0c\u4e0b\u5217\u90a3\u4e00\u6aa2\u67e5\u6700\u6070\u7576\uff1f\nA. saline suppression test \u6e2cPA\nB. \u6e2c\u8840\u4e2d18-hydroxycorticosterone\nC. postural stimulation test\u6e2cPA, cortisol, PRA, K\nD. adrenal venous sampling \u6e2cPA\u53ca cortisol\nE. CT of adrenal gland\n": "(A)", "104-6.\n60\u6b72\u7537\u6027\u56e0\u8033\u9cf4\u505a\u4e86\u982d\u90e8\u6838\u78c1\u5171\u632f\uff0c\u767c\u73fe\u8166\u4e0b\u5782\u9ad4\u6709\u4e005mm\u817a\u7624\u800c\u4f86\u8a3a\uff0c\u9664\u4e86\u8033\u9cf4\u5916\u75c5\u4eba\u4e26\u7121\u5176\u4ed6\u4e0d\u9069\uff0c\u5916\u89c0\u4ea6\u7121\u5167\u5206\u6ccc\u75be\u75c5\u5916\u89c0\u3002\u62bd\u8840\u6aa2\u67e5 Cortisol 8 AM 15ug/dl\uff0cplasma ACTH 20 pg/ml\uff0c FSH 4 IU/L\uff0c LH 5 IU/L\uff0cfree T4 1.1 ng/dl\uff0cTestosterone 427 ng/dl\uff0c IGF-1 165 ng/ml\uff0cTSH 1.0 uU/ml\u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u6070\u7576\uff1f\nA. Transsphenoidal surgery\nB. gamma-knife radiotherapy\nC. No treatment\nD. Octreotide therapy\nE. Dostinex therapy\n": "(C)", "104-7.\n55\u6b72\u5973\u6027\u4e00\u5e74\u524d\u958b\u59cb\u56e0\u8170\u9178\u80cc\u75db\u63a5\u53d7\u4e0d\u660e\u85e5\u7269\u6cbb\u7642\uff0c\u6bcf\u6b21\u670d\u7528\u5f8c\u9178\u75db\u6d88\u5931\uff0c\u4e0d\u7528\u5e7e\u5929\u5f8c\u9178\u75db\u53c8\u4f86\uff0c\u4e00\u5e74\u4f86\u9ad4\u91cd\u589e\u52a020\u516c\u65a4\uff0c\u5713\u81c9\uff0c\u76ae\u819a\u8b8a\u8584\uff0c\u6642\u611f\u5026\u6020\uff0c\u62bd\u8840\u6aa2\u67e5ACTH 8AM <10 pg/ml\uff0cCortisol 3.0 ug/dl\uff0c\u76ee\u524d\u4f7f\u7528\u85e5\u7269\u70badexamethasone 0.5mg gd\uff0c Celebrex 200 mg b.i.d.\uff0cNexium 20 mg qd\uff0cgabapentin 600mg q.i.d.\u3002\u4e0b\u5217\u63aa\u65bd\u90a3\u4e00\u9805\u6700\u6070\u7576\uff1f\nA. \u505a\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\nB. \u505aATCH stimulation test\nC. \u589e\u52a0Dexamethasone \u70ba1 mg b.i.d.\nD. \u505c\u6b62\u4f7f\u7528gabapentin\nE. \u6162\u6162tapper \u7cd6\u76ae\u7d20\u4e26\u505a\u5fa9\u5065\n": "(E)", "104-8.\n60\u6b72\u7537\u6027\u6709\u9ad8\u8840\u58d3\u75c5\u53f220\u5e74\uff0c\u6700\u8fd12\u5e74\u8840\u58d3\u96e3\u4ee5\u63a7\u5236\uff0c\u76ee\u524d\u964d\u8840\u58d3\u85e5\u70baamlodipine 10mg\uff0cBetaloc 100 mg qd\uff0cLosartan 100 mg qd\uff0cClonidine 0.1 mg qd\uff0chydrochlorothiazide 25 mg qd\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u767c\u73fe\u53f3\u5074\u814e\u4e0a\u817a3\u516c\u5206\u816b\u7624\u3002\u8acb\u554f\u5728\u8a55\u4f30\u6b64\u816b\u7624\u9808\u505a\u90a3\u4e00\u4e9b\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\r(1) BUN\u3001Cr\r(2) Na\u3001K\u3001CL\r(3) plasma aldosterone\uff0cplasma renin activity\r(4) \u814e\u4e0a\u817a\u816b\u7624\u7d30\u91dd\u7a7f\u523a\r(5) Overnight 1 mg dexamethasone suppression test\r(6) MIBG Scan\r(7) Plasma metanephrine\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (3)+(4)+(5)+(6)\nD. (3)+(5)+(7)\nE. (2)+(4)+(6)\n": "(D)", "104-9.\n58\u6b72\u5973\u6027\u6700\u8fd1\u5fc3\u60b8\u3001\u9ad4\u91cd\u6e1b\u8f155 Kg/3\u6708\uff0c\u6015\u71b1\uff0c\u62bd\u8840\u6aa2\u67e5 Free T4 2.3ng/dl hsTSH<0.01 uU/ml\uff0c\u56e0\u80cc\u75db\u505aBMD\uff08\u8170\u690e\uff09T score -2.7\uff0c\u6b64\u75c5\u4eba\u4e4b\u9aa8\u9b06\u75c7\uff0c\u4e0b\u5217\u8840\u6db2\u6aa2\u67e5\u4f55\u8005\u6b63\u78ba\uff1f\nA. Ionized Ca\u2191    PTH\u2193    Osteocalcin\u2191    N-Telopeptide\u2191\nB. Ionized Ca\u2193    PTH\u2191    Osteocalcin\u2191    N-Telopeptide\u2191\nC. Ionized Ca\u2191    PTH\u2191    Osteocalcin\u2191    N-Telopeptide\u2191\nD. Ionized Ca\u2191    PTH\u2193    Osteocalcin\u2193    N-Telopeptide\u2193\nE. Ionized Ca\u2193    PTH\u2193    Osteocalcin\u2193    N-Telopeptide\u2193\n": "(A)", "104-10.\n29\u6b72\u5973\u6027\u56e0\u9ad4\u91cd\u57282\u5e74\u5167\u589e\u52a030kg\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u6709\u4e2d\u592e\u6027\u80a5\u80d6\uff0c\u5713\u81c9\u53ca\u4e0b\u8179\u7d2b\u8272\u689d\u7d0b\uff0c\u8840\u58d3150/100 mmHg\uff0c\u4e0b\u5217\u54ea\u4e9b\u6aa2\u67e5\u70ba\u5fc5\u8981\r(1) serum ACTH\r(2) Urine free cortisol\r(3) Plasma metanephrine\r(4) overnight dexamethasone suppression test\r(5) low dose dexamethasone suppression test\r(6) high dose dexamethasone suppression test\nA. (1)+(2)+(3)\nB. (2)+(5)+(6)\nC. (1)+(5)+(6)\nD. (3)+(4)+(5)\nE. (2)+(4)+(6)\n": "(B)", "104-1.\n63\u6b72\u7537\u6027\u7b2c2\u578b\u7cd6\u5c3f\u75c514\u5e74\uff0c\u4ee5\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u63a7\u5236\uff0c\u6700\u8fd1\u534a\u5e74\u4f86\u98ef\u524d\u8840\u7cd6150-160 mg/dl\uff0c\u98ef\u5f8c\u8840\u7cd6200 mg/dl\uff0cHbA1c 8.5%\uff0c\u4e3b\u6cbb\u91ab\u5e2b\u4f7f\u7528Lantus 10 u hs\u4f86\u6539\u5584\u8840\u7cd6\uff0c\u8acb\u554f\u8840\u7cd6\u8ffd\u8e64\u4f86\u8abf\u6574\u4ee5\u4f55\u8005\u70ba\u6e96\uff1f\nA. \u65e9\u98ef\u524d\u8840\u7cd6\nB. \u65e9\u98ef\u5f8c\u8840\u7cd6\nC. \u7761\u524d\u8840\u7cd6\nD. \u665a\u98ef\u524d\u8840\u7cd6\nE. \u6253\u91dd\u5f8c2\u5c0f\u6642\n": "(A)", "104-2.\n64\u6b72\u7537\u6027\u7b2c2\u578b\u7cd6\u5c3f\u75c518\u5e74\uff0c\u6709\u8996\u7db2\u819c\u75c5\u8b8a\u3001\u795e\u7d93\u75c5\u8b8a\u3001\u5468\u908a\u8840\u7ba1\u75c5\u8b8a\uff0c2\u5929\u524d\u56e0\u5927\u8173\u8dbe\uff08\u53f3\uff09\u53d7\u50b7\uff0c\u73fe\u8173\u638c\u53ca\u8e1d\u90e8\u7d05\u816b\u75bc\u75db\uff0c\u4e0b\u4e00\u6b65\u8655\u7f6e\u4f55\u8005\u6700\u4f73\uff1f\nA. \u8e1d\u90e8\u56fa\u5b9a7\u5929\uff0c\u4e4b\u5f8c\u8f15\u5ea6\u91cd\u529b\u627f\u64d4\nB. \u505a\u8173\u8e1d\u6838\u78c1\u5171\u632f\nC. \u505a\u810a\u690e\u3001\u4e0b\u80a2\u9aa8\u5bc6\u5ea6\nD. \u505a\u8840\u6db2\u57f9\u990a\u4e26\u7d66\u6297\u751f\u7d20\nE. Tc 99 m\u9aa8\u982d\u6383\u7784\n": "(B)", "104-3.\n56\u6b72\u7537\u602710\u500b\u6708\u524d\u88ab\u767c\u73fe\u7cd6\u5c3f\u75c5\uff0c\u98ef\u524d151 mg/dl\uff0c\u98ef\u5f8c289 mg/dl\uff0c\u8840\u58d3 170/99 mmHg\uff0c BMI 27 kg/M2\uff0cCHO 210 mg/dl\uff0cTG 287 mg/dl\uff0c\uff0cHbA1c 7.4%\uff0c\u7d66\u4e88ACEI\uff0cmetformin\u3001glipizide \u53ca\u98f2\u98df\u6cbb\u7642\uff0c3\u500b\u6708\u5f8c\uff0cHbA1c 8.3\uff05\uff0cBMI 26 kg/M2\uff0c\u7d93\u85e5\u7269\u8abf\u6574\u5f8c\u8840\u58d3\u5df2\u6b63\u5e38\uff0c\u4f46HbA1c 9.1%\uff0c\u76ee\u524d\u4ed6\u4f7f\u7528metformin 1000 mg b.i.d.\uff0crosuvastatin 10 mg qd\uff0c\u4f86\u8a3a\u62bd\u8840\u6aa2\u67e5 TSH 1.2uU/ml\uff0cHbA1c 9.5%\uff0cCHO 302 mg/dl\uff0cHDL 37 mg/dl\uff0cLDL 140 mg/dl\uff0cTG 803 mg/dl\u3002\u4f60\u5efa\u8b70\u7528\u90a3\u4e00\u85e5\u7269\u4f86\u6cbb\u7642\uff1f\nA. Niacin\nB. Pioglitazone\nC. Insulin\nD. Fenofibrate\nE. Ezetimibe\n": "(C)", "104-4.\n35\u6b72\u5973\u6027\u56e0\u65b7\u65b7\u7e8c\u7e8c\u767c\u751f\u4f4e\u8840\u7cd6\u75c7\u72c0\u5df2\u67091\u5e74\u4f86\u8a3a\uff0c\u6700\u8fd1\u4e00\u661f\u671f\u524d\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u6025\u8a3a\uff0c\u8840\u7cd6\u70ba39 mg/dl\u3002\u5728\u9580\u8a3a\u7a7a\u8179\u62bd\u8840\u6aa2\u67e5 AC 61 mg/dl\uff0cinsulin 4uU/ml\uff0cC-peptide 0.9 ng/ml\uff0ccortisol 16 ug/dl\uff0cIGF-1 300 ng/ml\uff0cTSH 1.2uU/ml\uff0c\u6700\u6070\u7576\u8655\u7f6e\u70ba\uff1a\nA. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nB. \u4f4f\u9662\u505a72 hour fasting test\nC. \u53e3\u670d\u8461\u8404\u7cd6\u8010\u6027\u8a66\u9a57\nD. \u8f49\u4ecb\u5916\u79d1\u624b\u8853\nE. Selective arterial calcium stimulation test\n": "(B)", "104-5.\n81\u6b72\u7537\u6027\u6709\u7cd6\u5c3f\u75c5\u53f2\uff0c\u53ea\u4f7f\u7528\u98f2\u98df\u63a7\u5236\uff0c\u76f8\u95dc\u75be\u75c5\u6709CAD\u3001CHF\u3001\u9ad8\u8840\u58d3\uff0c\u4ed6\u88ab\u9001\u4f86\u6025\u8a3a\u56e0\u610f\u8b58\u4e0d\u6e05\u670924\u5c0f\u6642\uff0c\u9ad4\u6aa2BP 96/74 mmHg\uff0cPR 104/min\uff0cone touch \u8840\u7cd6 > 500 mg/dl\uff0c\u62bd\u8840\u6aa2\u67e5\u8840\u7cd6800 mg/dl\uff0cNa 150 mEq/L\uff0cK 6.1 mEq/L\uff0cBUN 80 mg/dl\uff0cCr 3.5 mg/dl\uff0c\u52d5\u8108\u8840PH 7.32\uff0cPCO2 33mg Hg\uff0cPO2 78 mmHg\uff0cBicarbonate 19 meq/L\uff0c\u4e0b\u5217\u8f38\u6db2\u4f55\u8005\u70ba\u4f73\uff1f\nA. Normal saline I.V.\nB. Half saline I.V.\nC. Lactate Ringer I.V.\nD. N/G distilled water\nE. 5% glucose water + Regular insulin IV\n": "(A)", "104-6.\n65\u6b72\u7537\u6027\u56e0\u80ba\u708e\u4f4f\u9662\uff0c\u5728\u9580\u8a3a\u4ed6\u56e0\u7cd6\u5c3f\u75c5\u670d\u7528Amaryl 3mg b.i.d\uff0cmetformin 850 mg b.i.d\uff0c\u9ad8\u8840\u8102\u670d\u7528Lipitor 20 mg qd\uff0c\u9ad8\u8840\u58d3\u670d\u7528Aprovel 150 mg qd\uff0c\u8eab\u9ad4\u6aa2\u67e5\u7a0d\u6709\u6c23\u5598\uff0c\u8840\u58d398/66 mmHg\uff0c\u9ad4\u91cd 80KG\uff0c\u80f8\u90e8X\u5149\u5de6\u5074\u80ba\u708e\uff0c\u5176\u4ed6\u7121\u7279\u5225\u767c\u73fe\u3002\u62bd\u8840\u6aa2\u67e5Random glucose 276 mg/dl\uff0cNa 132 mEq/L\uff0cK 3.8 mEq/L\uff0cCr 1.7 mg/dl\uff0cWBC 18600/uL\uff0cHbA1c \u4e00\u500b\u6708\u524d\u5728\u9580\u8a3a\u70ba8.3%\uff0c\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u8655\u7f6e\u8f03\u6070\u7576\uff1f\nA. \u52a0Lactus 16 u hs.\nB. \u52a0Pioglitazone\nC. \u505c\u7528Metformin\u53caAmaryl\uff0c\u7528Lactus 16 U hs\u53ca\u6bcf\u9910\u524dRI\uff08\u7d04\u7565\u517116 U)\nD. \u505c\u7528Metformin\u53caAmaryl\uff0c\u5168\u90e8\u7528RI sliding scale\u63a7\u5236\u8840\u7cd6\nE. \u505c\u7528Metformin\uff0c\u52a0\u4e0asliding scale regular insulin\uff08\u8840\u7cd6 > 150 mg/dl\uff09\n": "(C)", "104-7.\n65\u6b72\u7537\u6027\u56e0\u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u75c5\u63a5\u53d7\u5316\u7642\uff0c\u4f4f\u9662\u4e2d\u767c\u73fe\u7cd6\u5c3f\u75c5\uff0c\u8840\u7cd6\u4ecb\u65bc230-280 mg/dl\uff0cBMI 19.5 kg/M2\uff0c\u9ad4\u6aa2\u767c\u73fe\u813e\u816b\u5927\uff0cGr 2/6 \u6536\u7e2e\u5fc3\u96dc\u97f3\u53ca\u58d3\u4e0b\u6027\u8173\u6c34\u816b\uff0c\u62bd\u8840\u6aa2\u67e5\u8840\u7d05\u7d208 gm/dl\uff0cHbA1c 6.3\uff05\uff0cWBC 18600/uL\uff0cAlbmin 2.9 g/dl\uff0cCr 1.0 mg/dl\uff0cAC 178 mg/dl\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6700\u6070\u7576\uff1f\nA. \u82e5\u98f2\u98df\u3001\u904b\u52d5\u7121\u6cd5\u65bc1\u500b\u6708\u5167\u6539\u5584\uff0c\u4fbf\u958b\u59cb\u4f7f\u7528\u964d\u8840\u7cd6\u85e5\u7269\nB. HbA1c\u5c1a\u5728\u6b63\u5e38\u7bc4\u570d\uff0c\u66ab\u4e0d\u9808\u6cbb\u7642\nC. \u9ad8\u8840\u7cd6\u662f\u5be6\u9a57\u5ba4\u5931\u8aa4\u5f15\u8d77\nD. HbA1c\u56e0\u8ca7\u8840\u800c\u4e0d\u6e96\u78ba\nE. HbA1c\u56e0\u767d\u8840\u7403\u589e\u52a0\u800c\u4e0d\u6e96\u78ba\n": "(D)", "104-8.\n\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269Pioglitazone\u4f7f\u7528\u4e4b\u7981\u5fcc\u70ba?\r(1) \u9ad8\u8840\u58d3\r(2) \u814e\u8870\u7aed\u7b2c\u4e09\u671f\r(3) \u5fc3\u8870\u7aed\u7b2c\u4e09\u671f\r(4) \u809d\u529f\u80fd\u7570\u5e38\r(5) \u80a5\u80d6\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(C)", "104-9.\n\u6709\u95dc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u4e4b\u6cbb\u7642\u539f\u5247\uff0c\u9664\u751f\u6d3b\u578b\u614b\u3001\u98f2\u98df\u6cbb\u7642\u5916\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r(1) Metformin\u662f\u5927\u90e8\u5206\u75c5\u4eba\u7684\u7b2c\u4e00\u7dda\u7528\u85e5\u3002\r(2) Sulfonylurea\u662f\u5c0d\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u4eba\u4e4b\u7981\u5fcc\u3002\r(3) DDP-4\u6291\u5236\u5291\u5c0d\u5fc3\u81df\u6709\u76ca\u53ef\u4f7f\u7528\u65bc\u5fc3\u8870\u7aed\u7b2c\u4e09\u671f\u75c5\u4eba\r(4) \u7cd6\u5316\u8840\u8272\u7d20\u9054\u52307\uff05\u4ee5\u4e0b\u70ba\u5fc5\u8981\u9054\u6210\u4e4b\u76ee\u6a19\u3002\r(5) Pioglitazone\u662fNon-insulin dependent\u964d\u8840\u7cd6\u85e5\u7269\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(E)", "104-10.\n\u6839\u64da\u53f0\u7063\u7cd6\u5c3f\u75c5\u5b78\u67032012\u7cd6\u5c3f\u75c5\u7167\u8b77\u6307\u5f15\u61c9\u500b\u5225\u5316\u8003\u91cf\u8840\u7cd6\u63a7\u5236\u76ee\u6a19\u7684\u56e0\u7d20\u6709:\r(1) \u9ad4\u91cd\r(2) \u591a\u91cd\u5c0f\u8840\u7ba1\u75c5\u8b8a\r(3) \u8a8d\u77e5\u529f\u80fd\u4e0d\u8db3\r(4) \u764c\u75c7\u672b\u671f\r(5) \u793e\u7d93\u5730\u4f4d\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(4)+(5)\nE. (1)+(2)+(5)\n": "(B)", "105-1.\n\u7121\u75c7\u72c0\u539f\u767c\u6027\u526f\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\uff0c\u82e5\u7b26\u5408\u4e0b\u5217\u54ea\u4e00\u9805\uff0c\u61c9\u5efa\u8b70\u624b\u8853\u6cbb\u7642?\nA. \u5e74\u7d00\u5927\u65bc50\u6b72\nB. \u808c\u9178\u9150\u5ed3\u6e05\u7387(Creatinine clearance) <90 mL/min\nC. \u4efb\u4e00\u8655\u9aa8\u5bc6\u5ea6 T score <-2.5\nD. 24\u5c0f\u6642 \u5c3f\u9223 >= 100 mg\nE. \u8840\u9223\u6bd4\u6b63\u5e38\u53c3\u8003\u503c\u591a 1 mg/dL \u4ee5\u4e0a\n": "(E)", "105-2.\n\u4e00\u4f4d60\u6b72\u5973\u6027\u75c5\u4eba\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u75c5\u4eba\u76ae\u819a\u7c97\u4e7e\uff0c\u4e73\u982d\u984f\u8272\u6de1\uff0c\u5979\u7684\u8840\u58d3\u662f 90/60 mmHg, \u9ad4\u6eab\u70ba\u651d\u6c0f36.5\u5ea6\uff0c\u8108\u640f \u6bcf\u5206\u9418 70 \u4e0b\uff0c \u8840\u9209\u662f125 mmol/L\uff0c\u8840\u7cd6\u662f 60 mg/dL\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba?\r1. \u9808\u7acb\u5373\u62bd\u8840\u6aa2\u67e5 ACTH\u3001cortisol\u3001fT4\u3001TSH\r2. \u512a\u5148\u88dc\u5145 thyroxine\r3. \u512a\u5148\u88dc\u5145 hydrocortisone\r4. \u5b89\u6392\u814e\u4e0a\u817a\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\r5. \u9700\u8a73\u7d30\u8a62\u554f\u6708\u7d93\u53ca\u751f\u7522\u53f2\nA. 1+2+4\nB. 1+2+5\nC. 1+3+4\nD. 1+3+5\nE. 2+3+5\n": "(D)", "105-3.\n\u4e0b\u5217\u6709\u95dc\u65bc\u9ad8\u8102\u8840\u75c7\u7684\u6558\u8ff0\u54ea\u4e00\u9805\u6700\u6b63\u78ba?\r1. \u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (LDL-C)\u4e2d\u7684apolipoprotein \u4ee5 ApoB-100 \u70ba\u4e3b\r2. ApoB-100 \u4e3b\u8981\u5728\u5c0f\u8178\u88fd\u9020\r3. \u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\u6642\uff0c\u5e38\u53ef\u898b\u8840\u6e05\u4e2d LDL-C \u589e\u52a0\r4. \u6162\u6027\u814e\u75c5\u8b8a (chronic kidney disease) \u6642\uff0c\u5e38\u53ef\u898b\u8840\u4e2d\u4e09\u9178\u9150\u6cb9\u916f (triglyceride, TG) \u6fc3\u5ea6\u4e0b\u964d\r5. TG > 400 mg/dL\u6642\uff0c\u61c9\u8a72\u4f7f\u7528Friedewald\u516c\u5f0f\u8a08\u7b97\u8840\u6e05\u4e2d LDL-C\u6fc3\u5ea6\nA. 1+2\nB. 1+3\nC. 2+4\nD. 1+3+5\nE. 3+4+5\n": "(B)", "105-4.\n\u4e00\u4f4d45\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u4e3b\u8a34\u70ba\u524d\u9838\u90e8\u75bc\u75db\u3002\u4ed6\u7d04\u5169\u9031\u524d\u6709\u611f\u5192\uff0c\u6c92\u6709\u767c\u71d2\uff0c\u7532\u72c0\u817a\u6709\u5c40\u90e8\u816b\u5927\u4f75\u58d3\u75db\u3002\u4ed6\u7684\u767d\u8840\u7403\u70ba5.1 K/\u03bcL\uff0cfT4 \u70ba 1.9 ng/dL (\u53c3\u8003\u503c 0.89 ~ 1.76 ng/dL)\uff0cTSH\u70ba 0.36 \u03bcIU/mL (\u53c3\u8003\u503c 0.4 ~ 4\u03bcIU/mL) \uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u500b\u9078\u9805\u6700\u6b63\u78ba?\nA. \u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\nB. \u7d66\u4e88\u6297\u751f\u7d20\nC. \u7d66\u4e88\u7532\u72c0\u817a\u7d20\nD. \u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\u53ca\u6297\u751f\u7d20\nE. \u7d66\u4e88\u985e\u56fa\u9187\u6216\u975e\u985e\u56fa\u9187\u6297\u767c\u708e\u85e5\u7269(NSAID)\n": "(E)", "105-5.\n\u67d0\u4e9b\u85e5\u7269\u53ef\u80fd\u5f71\u97ff\u8840\u6e05\u4e2d\u919b\u56fa\u916e(aldosterone)\u3001\u814e\u7d20(renin)\u3001aldosterone-renin ratio (ARR) \u7684\u6aa2\u6e2c\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u85e5\u7269\u53ef\u80fd\u4f7frenin\u589e\u52a0\u3001aldosterone\u6e1b\u5c11\u3001ARR\u4e0b\u964d?\nA. \u4e59\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291 (\u03b2-blockers)\nB. \u7532\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291 (\u03b1-blockers)\nC. \u8840\u7ba1\u5f35\u529b\u7d20\u8f49\u5316\u6291\u5236\u5291 (ACE inhibitors)\nD. \u9223\u96e2\u5b50\u62ee\u6297\u5291 (calcium antagonists)\nE. \u5229\u5c3f\u5291 (Diuretics)\n": "(C)", "105-6.\n\u4e00\u4f4d55\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u70ba\u80f8\u75db\u53ca\u5192\u6c57\u7d04\u4e00\u5c0f\u6642\u800c\u4f86\u8a3a\uff0c\u4ed6\u7684\u8840\u58d3\u70ba205/120 mmHg\u3002\u75c5\u4eba\u904e\u53bb\u5341\u4e94\u5e74\u6709\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u4ee5Enalapril 5mg 1# qd\u3001Losartan 50mg 0.5# qd\u3001Amlodipine 5mg 1# qd\u63a7\u5236\uff0c\u4e00\u822c\u8840\u58d3\u70ba120/80 mmHg\u3002\u75c5\u4eba\u6700\u8fd13\u500b\u6708\u4f86\u9ad4\u91cd\u6e1b\u8f156\u516c\u65a4\uff0c\u6709\u6642\u6703\u89ba\u5f97\u809a\u5b50\u4e0d\u8212\u670d\uff0c\u4e5f\u51fa\u73fe\u982d\u75db\u3001\u5fc3\u60b8\u3001\u5192\u6c57\u3001\u7126\u616e\u3001\u624b\u6296\u7b49\u75c7\u72c0\u3002\u75c5\u4eba\u7d93\u7dca\u6025\u8655\u7f6e\u5f8c\u8840\u58d3\u70ba140/90 mmHg\uff0c\u5176\u96fb\u8166\u65b7\u5c64\u5982\u9644\u5716\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba?\nA. \u75c5\u4eba24\u5c0f\u6642\u5c3f\u6db2\u4e2d\u4e4bnorepinephrine \u53ef\u80fd\u9060\u9ad8\u65bcepinephrine\nB. \u61c9\u8a72\u4f7f\u7528 \u4e59\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291 (beta-blockers) \u63a7\u5236\u8840\u58d3\nC. \u61c9\u8a72\u9650\u5236\u6c34\u5206\u651d\u53d6\u4ee5\u63a7\u5236\u8840\u58d3\nD. \u75c5\u4eba\u82e5\u6709SDHB gene mutation \u5247\u5176\u816b\u7624\u70ba\u60e1\u6027\u7684\u6a5f\u7387\u5c07\u5927\u6e1b\nE. \u75c5\u4eba\u82e5\u540c\u6642\u6709\u7532\u72c0\u817a\u9ad3\u8cea\u764c\u5247\u5c6c\u65bc\u7b2c\u4e00\u578b\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624 (multiple endocrine neoplasia type 1)\n": "(A)", "105-7.\n\u4e00\u4f4d58\u6b72\u5973\u6027\u75c5\u4eba\u6709\u6708\u4eae\u81c9\u3001\u4e2d\u6a1e\u6027\u80a5\u80d6\u3001\u7d2b\u7d0b\uff0c\u5979\u7684 8 am ACTH\u70ba 90 pg/mL (\u53c3\u8003\u503c 10 ~ 65 pg/mL)\u3001Cortisol\u70ba30 \u03bcg/dL (\u53c3\u8003\u503c 5 - 25\u03bcg/dL)\uff0c4 pm ACTH \u70ba 86 pg/mL\u3001Cortisol\u70ba 28 \u03bcg/dL (\u53c3\u8003\u503c 2.5 - 12.5\u03bcg/dL)\uff0c\u7d66\u4e88 dexamethasone 2 mg qid \u5169\u5929\u5f8c\uff0c\u5176 cortisol level\u70ba25\u03bcg/dL\u3002 \u75c5\u4eba\u7684\u8840\u9240\u6fc3\u5ea6\u70ba 2.8 mmol/L (\u53c3\u8003\u503c 3.5-5.1 mmol/L)\u3001LDH \u70ba400 u/L (\u53c3\u8003\u503c 140~271 u/L)\uff0c\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u54ea\u4e00\u9805\u6700\u9069\u7576?\nA. \u61c9\u5b89\u6392\u814e\u4e0a\u817a\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nB. \u61c9\u5b89\u6392\u8166\u4e0b\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5\nC. \u61c9\u5b89\u6392\u80f8\u90e8\u81f3\u9aa8\u76c6\u8154\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nD. \u61c9\u5b89\u6392bilateral inferior petrosal sinus sampling\nE. \u61c9\u8a73\u7d30\u8a62\u554f\u7528\u85e5\u53f2\u4e26\u505c\u7528\u985e\u56fa\u9187\n": "(C)", "105-8.\n\u91dd\u5c0d\u5c3f\u5d29\u75c7(diabetes insipidus, DI)\u7684\u9451\u5225\u8a3a\u65b7\u6240\u505a\u7684\u9650\u6c34\u6e2c\u9a57 (fluid deprivation test) \u54ea\u4e00\u9805\u63cf\u8ff0\u6b63\u78ba?\nA. \u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI) \u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u4e0d\u6703\u6e1b\u5c11\uff0c\u7d66\u4e88desmopressin\u5f8c\u5c3f\u91cf\u6e1b\u5c11\nB. \u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI) \u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u6e1b\u5c11\uff0c\u7d66\u4e88desmopressin\u5f8c\u5c3f\u91cf\u589e\u52a0\nC. \u814e\u6e90\u6027\u5c3f\u5d29\u75c7 (nephrogenic DI ) \u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u4e0d\u6703\u6e1b\u5c11\uff0c\u7d66\u4e88desmopressin\u5f8c\u5c3f\u91cf\u6e1b\nD. \u814e\u6e90\u6027\u5c3f\u5d29\u75c7 (nephrogenic DI ) \u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u6e1b\u5c11\uff0c\u7d66\u4e88desmopressin\u5f8c\u5c3f\u91cf\u589e\u52a0\nE. \u5fc3\u7406\u56e0\u7d20\u5f15\u8d77\u7684\u5c3f\u5d29\u75c7\u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u4e0d\u6703\u6e1b\u5c11\n": "(A)", "105-9.\n\u9aa8\u8cea\u758f\u9b06\u75c7\u7684\u98a8\u96aa\u56e0\u7d20\u4e0d\u5305\u62ec\u4e0b\u5217\u54ea\u4e00\u9805? \u8acb\u9078\u64c7\u6700\u9069\u7576\u7684\u7b54\u6848\nA. \u8166\u4e0b\u5782\u9ad4\u529f\u80fd\u4f4e\u4e0b\nB. Vitamin D\u904e\u91cf\nC. Primary biliary cirrhosis\nD. Epilepsy\nE. Proton pump inhibitors\n": "(B)", "105-10.\n\u4e0b\u5217\u54ea\u4e00\u9805\u6709\u95dc\u65bc\u80a2\u7aef\u80a5\u5927\u75c7 (acromegaly) \u7684\u63cf\u8ff0\u662f\u6b63\u78ba\u7684?\nA. \u8840\u6e05\u4e2dIGF-1\u6fc3\u5ea6\u6703\u56e0\u5e74\u7d00\u4e0d\u540c\u800c\u6539\u8b8a\uff0c\u4e0d\u9069\u5408\u7528\u505a\u8a3a\u65b7\u4e4b\u4f9d\u64da\nB. \u751f\u9577\u6fc0\u7d20 (growth hormone, GH) \u5206\u6ccc\u6046\u5b9a\uff0c\u6e2c\u91cf\u4e00\u6b21GH\u5373\u8db3\u4ee5\u8a3a\u65b7\nC. \u53e3\u670d75\u516c\u514b\u8461\u8404\u7cd61-2\u5c0f\u6642\u5f8c GH\u6fc3\u5ea6\u70ba1 \u03bcg/L\uff0c\u53ef\u6392\u9664\u80a2\u7aef\u80a5\u5927\u75c7\nD. \u5927\u7d0425%\u7684\u80a2\u7aef\u80a5\u5927\u75c7\u75c5\u4eba\u540c\u6642\u6709\u6ccc\u4e73\u6fc0\u7d20 (prolactin) \u589e\u9ad8\nE. \u5927\u591a\u6578GH-secreting pituitary adenoma\u53ef\u4ee5\u4f7f\u7528\u85e5\u7269\u6cbb\u7642\u4e0d\u9808\u958b\u5200\n": "(D)", "105-1.\n\u674e\u5148\u751f\uff0c45\u6b72\uff0c165\u516c\u5206\uff0c76\u516c\u65a4\uff0c\u7121\u7cd6\u5c3f\u75c5\u5bb6\u65cf\u53ca\u500b\u4eba\u75c5\u53f2\uff0c\u66fe\u5169\u6b21\u65bc\u5de5\u4f5c\u6642\u660f\u5012\uff0c\u90fd\u5728\u4f11\u606f30\u5206\u9418\u5f8c\u9010\u6f38\u7526\u9192\uff0c\u5fc3\u81df\u5167\u79d1\u53ca\u795e\u7d93\u5167\u79d1\u9580\u8a3a\u6aa2\u67e5\u7121\u5fc3\u5f8b\u4e0d\u6574\u6216\u795e\u7d93\u8840\u7ba1\u75c5\u8b8a\u7570\u5e38\u767c\u73fe\u3002\u6b64\u6b21\u5728\u5ea6\u56e0\u660f\u5012\u5f8c\uff0c\u9001\u81f3\u6025\u8a3a\uff0c\u4f46\u610f\u8b58\u6301\u7e8c\u4e0d\u6e05\uff0c\u8840\u58d3\u70ba112/60mmHg\uff0c\u8108\u640f\u898f\u5f8b\u70ba66BPM\uff0c\u6025\u8a3aone-touch\u8840\u7cd6\u70ba28mg/dl\uff0c\u7d66\u4e8850%\u8461\u8404\u7cd6\u6ce8\u5c04\u53ca\u8f38\u6db2\u5f8c\u7526\u9192\uff0c\u7121\u795e\u7d93\u5b78\u8b8a\u5316\u3002\u5efa\u8b70\u4f4f\u9662\u8a3a\u6cbb\u3002\u5728\u75c5\u623f\u672a\u8f38\u6db2\u60c5\u6cc1\u4e0b\uff0c\u7a7a\u81798\u5c0f\u6642\u5f8c\uff0c\u62bd\u8840\u7d50\u679c\u70ba\u7a7a\u8179\u8840\u7cd676mg/dl, Insulin 1.8 mIU/ml, C-peptide 1.8 ng/ml, ACTH 49.5 pg/ml, Cortisol 21.6 ug/dl, IGF-1 182 ng/ml, TSH 2.8\rmIU/ml\u3002\u6b64\u6642\u61c9\u5efa\u8b70\u5148\u9032\u884c\u4f55\u9805\u6aa2\u67e5?\nA. \u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (MRI)\nB. 24\u5c0f\u6642\u5fc3\u96fb\u5716\nC. 72\u5c0f\u6642 Prolong fasting test\nD. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nE. 72 \u516c\u514b\u8461\u7cd6\u7cd6\u8010\u53d7\u8a66\u9a57\n": "(C)", "105-2.\n\u65b0\u9673\u4ee3\u8b1d\u75be\u75c5\u4e2d\uff0c\u7cd6\u5c3f\u75c5\u8207\u80a5\u80d6\u5bc6\u5207\u76f8\u95dc\uff0c\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u53ca\u80a5\u80d6\u95dc\u4fc2\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e?\nA. \u4ee5\u8a08\u756b\u6027\u98f2\u98df\u53ca\u904b\u52d5\u4f86\u964d\u4f4e\u9ad4\u91cd\uff0c\u9810\u9632\u65b0\u9673\u4ee3\u8b1d\u75be\u75c5\u6642\uff0c\u4eba\u9ad4\u771f\u6b63\u6e1b\u5c11\u7684\u9ad4\u91cd\u6210\u5206\u70ba\u8102\u80aa\nB. \u8eab\u9ad4\u4e2d\u5fc3\u6027\u8179\u90e8\u80a5\u80d6 (central abdominal obesity)\uff0c\u8207\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u5bc6\u5207\u76f8\u95dc\nC. \u9577\u671f\u7684\u7814\u7a76\u986f\u793a\uff0c\u8a08\u756b\u6027\u98f2\u98df\u53ca\u904b\u52d5\uff0c\u53ef\u4ee5\u85c9\u7531\u9ad4\u91cd\u63a7\u5236\uff0c\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u4e4b\u6a5f\u7387\nD. \u7814\u7a76\u986f\u793a\uff0c\u904b\u52d5\u7684\u6642\u9593\u6108\u9577\uff0c\u904b\u52d5\u5f37\u5ea6\u6108\u5f37\uff0c\u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u53ca\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u4e4b\u6b7b\u4ea1\u7387\nE. \u7f8e\u570b\u9032\u884c\u4e4bLOOKAHEAD\u9577\u671f\u7cd6\u5c3f\u75c5\u7814\u7a76\u986f\u793a\uff0c\u5c0d\u65bc\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0c\u964d\u4f4e\u9ad4\u91cd\u53ef\u4ee5\u4f7f\u8840\u7cd6\u53caHbA1c\u63a7\u5236\u5f97\u66f4\u597d\uff0c\u4f46\u662f\u7121\u6cd5\u964d\u4f4e\u5176\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u4e4b\u6b7b\u4ea1\u7387\n": "(D)", "105-3.\n\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u7684\u6cbb\u7642\uff0c\u751f\u6d3b\u578b\u614b\u63a7\u5236\u662f\u5fc5\u8981\u9805\u76ee\uff0c\u4f46\u662f\u85e5\u7269\u6cbb\u7642\u5247\u662f\u98f2\u98df\u53ca\u904b\u52d5\u5916\uff0c\u4e0d\u53ef\u7f3a\u7684\u4e00\u74b0\u3002\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u85e5\u7269\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\r1. Metformin\u662f\u4e00\u822c\u9078\u64c7\u6cbb\u7642\u7cd6\u5c3f\u75c5\u7684\u7b2c\u4e00\u7dda\u85e5\u7269\uff0c\u814e\u529f\u80fd\u8870\u7aed\uff0ceGFR < 30\u6642\uff0c\u4ecd\u53ef\u5b89\u5168\u4f7f\u7528\u3002\r2. Sulphonylurea\u985e\u85e5\u7269\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\uff0c\u4ee5\u53ca\u9ad4\u91cd\u4e0a\u5347\u3002\r3. \u570b\u5167\u7cd6\u5c3f\u5b78\u6703\u4e4b\u5efa\u8b70\uff0cHbA1c (\u7cd6\u5316\u8840\u8272\u7d20)\u7684\u63a7\u5236\u76ee\u6a19\u70ba7%\u4ee5\u4e0b\u3002\r4. \u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\u7684\u7642\u6548\u5f88\u597d\uff0c\u4f46\u662f\u4f4e\u8840\u7cd6\u6a5f\u6703\u4e5f\u8f03\u9ad8\u3002\r5. \u5c0d\u65bc\u5bb9\u6613\u767c\u751f\u4f4e\u8840\u7cd6\u4e4b\u75c5\u60a3\uff0c\u61c9\u907f\u514d\u9078\u64c7\u80f0\u5cf6\u7d20\u6216GLP-1 receptor agonist \u985e\u4e4b\u91dd\u5291 \u3002\nA. 1+3\nB. 4+5\nC. 1+5\nD. 2+3\nE. 3+5\n": "(C)", "105-4.\n\u4f9d\u76ee\u524dWHO\u53ca\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70\uff0c\u6709\u95dc\u7cd6\u5c3f\u75c5\u8a3a\u65b7\u4e4b\u5be6\u9a57\u5ba4\u6a19\u6e96\uff0c\u4e0b\u5217\u4f55\u8005\u6709\u8aa4?\nA. \u7a7a\u8179\u8840\u7cd6\u5927\u65bc\u6216\u7b49\u65bc 126 mg/dl\nB. \u53e3\u670d\u8461\u8404\u7cd6\u8a66\u9a57 (OGTT)2\u5c0f\u6642\u5f8c\u4e4b\u8840\u7cd6\u5927\u65bc\u6216\u7b49\u65bc 200mg/dl\nC. \u7cd6\u5316\u8840\u8272\u7d20\u503c\u5927\u65bc\u6216\u7b49\u65bc 6.5 %\nD. \u96a8\u6a5f\u6e2c\u8a66\u8840\u7cd6 (Random blood glucose) \u5927\u65bc\u6216\u7b49\u65bc 160 mg/dl\nE. \u7a7a\u8179\u8840\u7cd6\u4e4b\u5b9a\u7fa9\u70ba\u81f3\u5c118\u5c0f\u6642\u672a\u9032\u98df\u4efb\u4f55\u98df\u7269\n": "(D)", "105-5.\n\u674e\u5148\u751f\uff0c68\u6b72\uff0c\u7cd6\u5c3f\u75c5\u53f210\u5e74\uff0c\u4e0d\u898f\u5247\u4f7f\u7528\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\uff0c\u5728\u9580\u8a3a\u4e5f\u4e0d\u9858\u610f\u63a5\u53d7\u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\u3002\u5fc3\u81df\u8870\u7aed NYHA Class III\uff0c\u65bc\u5fc3\u81df\u5167\u79d1\u8ffd\u8e64\u6cbb\u7642\uff0c\u6700\u8fd1\u534a\u5e74\u7121\u62bd\u8840\u5831\u544a\u3002\u56e0\u610f\u8b58\u72c0\u614b\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u6025\u8a3a\u8840\u7cd6\u70ba628 mg/dl\uff0c\u9209\u96e2\u5b50 148 mEq/L\uff0c\u9240\u96e2\u5b50 3.8 mEq/L\uff0c\u5c3f\u7d20\u6c2e 92 mg/dl\uff0c\u808c\u9178\u9150 3.9 mg/dl\uff0c\u52d5\u8108\u8840\u4e4bPh\u503c\u70ba7.28\uff0cPaO2 82 mmHg\uff0cPaCO2 36 mmHg\uff0cBicarbomate 12 mEq/L\u3002\u8840\u58d3\u70ba 88/58 mmHg\uff0c\u8108\u640f\u70ba 108 bpm\u3002\u5728\u76e3\u8996 urine output \u4e4b\u524d\u63d0\u4e0b\uff0c\u4e0b\u5217\u4e4b\u8f38\u6db2\uff0c\u4f55\u8005\u6700\u9069\u7576?\nA. Lactate Ringer solution\nB. 0.9% Normal saline solution\nC. 0.45% Half saline solution\nD. 5% Glucose/Dextrose solution with regular insulin intravenous  infusion\nE. 0.9% Normal saline solution with regular insuin intravenous infustion\n": "(B)", "105-6.\n\u5f35\u5148\u751f\uff0c55\u6b72\uff0c\u7cd6\u5c3f\u75c5\u53f210\u5e74\uff0c\u66fe\u56e0coronary arter disease\u9032\u884c\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\uff0c\u4e26\u7f6e\u653e\u652f\u67b6\u3002\u76ee\u524d\u4ee5\u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\uff0c\u9ad8\u8840\u58d3\u85e5\u7269\u70baARB + CCB\uff0c\u964d\u8840\u8102\u85e5\u7269\u70ba Atorvasatain 40mg qd\u3002\u76ee\u524d\u4e4b\u9ad4\u91cd\u70ba76\u516c\u65a4\uff0c\u8eab\u9ad8180\u516c\u5206\uff0cLDL\u70ba62 mg/dl\uff0cHDL \u70ba39mg/dl\uff0cTG\u70ba 682 mg/dl\uff0c\u672c\u6b21HbA1c \u70ba6.9%\uff0c\u5c3f\u6db2\u4e4bMicroalbumin/creatinine ratio\u6b63\u5e38\u3002\u5c0d\u6b64\u75c5\u60a3\u800c\u8a00\uff0c\u61c9\u6709\u4f7f\u7528\u4e0b\u5217\u4f55\u9805\u85e5\u7269\u4e4b\u5fc5\u8981?\nA. Ezetimibe\nB. Pioglitazone\nC. Fenofibrate\nD. GLP-1 receptor agonist, Liraglutide\nE. Nicotic acid\n": "(C)", "105-7.\n\u738b\u5973\u58eb\uff0c58\u6b72\uff0c\u56e0\u80ba\u708e\u4f4f\u9662\uff0c\u6297\u751f\u7d20\u4f7f\u75285\u5929\u5f8c\uff0c\u75c5\u6cc1\u7a69\u5b9a\uff0c\u9810\u8a082\u5929\u5f8c\u51fa\u9662\u3002\u76ee\u524d\u9ad4\u6eab\u70ba\u651d\u6c0f36.2\u5ea6\uff0c\u8840\u58d3 126/82 mmHg\uff0c\u8108\u640f\u70ba76 bpm\u3002\u6709\u8840\u7cd6\u7570\u5e38\u4e4b\u500b\u4eba\u53f2\u7d042\u5e74\uff0c\u4f46\u672a\u66fe\u63a5\u53d7\u6cbb\u7642\uff0c\u5165\u9662\u96a8\u6a5f\u62bd\u8840\u8840\u7cd6\u70ba186 mg/dl\uff0cHbA1c \u70ba 8.6 %\uff0c\u4f4f\u9662\u7b2c\u4e94\u5929\u4e4b\u6668\u9593\u7a7a\u8179\u62bd\u8840\u8840\u7cd6\u70ba 154 mg/dl\uff0c\u81ea\u5099\u65e9\u9910\u5f8c2\u5c0f\u6642\u62bd\u8840\u8840\u7cd6\u70ba 216 mg/dl\uff0cCr 0.7 mg/dl (eGFR 78), BUN 16 mg/dl,  Na 135 mEqL, K 3.9 mEq/L\u3002\u76ee\u524d\u4ea6\u7121\u7cd6\u5c3f\u75c5\u81e8\u5e8a\u75c7\u72c0\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6709\u8aa4?\nA. \u5728\u76ee\u524d\u75c5\u6cc1\u7a69\u5b9a\u4e0b\u61c9\u8003\u616e\u7d66\u4e88Metformin\u85e5\u7269\u6cbb\u7642\nB. \u61c9\u5b89\u6392\u7cd6\u5c3f\u75c5\u98f2\u98df\u885b\u6559\u53ca\u57fa\u672c\u904b\u52d5\u6307\u5c0e\nC. \u5efa\u8b70\u75c5\u60a3\u61c9\u6709\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u8840\u7cd6(Self-Monitoring blood glucose, SMBG)\u4e4b\u89c0\u5ff5\nD. \u5efa\u8b70\u5b89\u6392\u53e3\u670d\u8461\u8404\u7cd6\u8010\u53d7\u6e2c\u8a66 (OGTT)\u9032\u4e00\u6b65\u78ba\u8a3a\u7cd6\u5c3f\u75c5\nE. \u5efa\u8b70\u61c9\u5118\u65e9\u5b89\u6392\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u6aa2\u67e5\u53ca\u8db3\u90e8\u795e\u7d93\u5b78\u6aa2\u67e5\n": "(D)", "105-8.\n\u7cd6\u5c3f\u75c5\u60a3\u8005\u6cbb\u7642\u904e\u7a0b\u4e2d\uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u4e4b\u4f75\u767c\u75c7\uff0c\u4e0b\u5217\u6709\u95dc\u7cd6\u5c3f\u75c5\u4e4b\u4f4e\u8840\u7cd6\u72c0\u6cc1\u6558\u8ff0\uff0c\u4f55\u8005\u6709\u8aa4?\nA. \u6839\u64daDCCT (Diabetes Control and COmplications Trial)\uff0c\u4ee5\u80f0\u5cf6\u7d20\u7a4d\u6975\u63a7\u5236\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\uff0c\u53ef\u6709\u6548\u7684\u964d\u4f4e\u7cd6\u5c3f\u75c5\u773c\u75c5\u8b8a\u3001\u814e\u75c5\u8b8a\u53ca\u795e\u7d93\u75c5\u8b8a\uff0c\u4f46\u662f\u4f4e\u8840\u7cd6\u7684\u60c5\u6cc1\u4e5f\u5f88\u5e38\u898b\nB. \u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u4e4bACCORD, ADVANCE\u7814\u7a76\u767c\u73fe\uff0c\u4f7f\u7528\u85e5\u7269\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u6642\uff0c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e4b\u4f4e\u8840\u7cd6\u73fe\u8c61\u4e26\u4e0d\u5e38\u898b\nC. \u7576\u7cd6\u5c3f\u75c5\u60a3\u8005\u4f7f\u7528\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u767c\u751f\u4f4e\u8840\u7cd6\u6642\uff0c\u591a\u6578\u53e3\u670d\u85e5\u7269\u70baSulphonylurea\nD. \u4f7f\u7528Basal insulin (\u57fa\u790e\u80f0\u5cf6\u7d20) \u767c\u751f\u4f4e\u8840\u7cd6\u7684\u60c5\u6cc1\u8f03\u5c11\uff0c\u4f46\u662f\u4f7f\u7528\u9910\u524d\u80f0\u5cf6\u7d20 (Prandial insulin)\u6642\uff0c\u4f4e\u8840\u7cd6\u7684\u6a5f\u6703\u660e\u986f\u589e\u52a0\nE. \u4f4e\u8840\u7cd6\u7684\u75c7\u72c0\uff0c\u5305\u62ec\u5fc3\u5f8b\u4e0d\u6574\u3001\u795e\u7d93\u5b78\u75c7\u72c0\u3001\u751a\u81f3\u62bd\u6410\u3001\u660f\u8ff7\n": "(B)", "105-9.\n\u76ee\u524d\u7cd6\u5c3f\u75c5\u6cbb\u7642\u85e5\u7269\u4e2d\u4e4b\u91dd\u5291\uff0c\u9664\u80f0\u5cf6\u7d20\u5916\uff0c\u4e5f\u6709GLP-1 receptor agonist\u91dd\u5291\u85e5\u7269\uff0c\u8207DPP-4 inhibitors \u5747\u70baIncretin \u985e\u85e5\u7269\u3002\u4ee5\u4e0b\u6709\u95dcIncretin\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u6b63\u78ba?\r1. GLP-1 (Glucagon like peptide-1) \u7531\u8178\u9053\u4e4bL cell\u5206\u6ccc\u3002\r2. GLP-1 \u53ef\u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\uff0c\u4f46\u4e5f\u523a\u6fc0\u6607\u7cd6\u6fc0\u7d20 (Glucagon)\u5206\u6ccc\u3002\r3. \u4f7f\u7528GLP-1 receptor agonist\u6cbb\u7642\u7cd6\u5c3f\u75c5\u60a3\u8005\u6642\uff0c\u4e5f\u6709\u660e\u986f\u6e1b\u8f15\u9ad4\u91cd\u4e4b\u6548\u679c\u3002\r4. \u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e5f\u9069\u7528GLP-1 receptor agonist\u3002\r5. \u4f7f\u7528GLP-1 receptor agonist\u53ef\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u4e4b\u98df\u617e\u53ca\u5ef6\u7de9\u672a\u6392\u7a7a\u6642\u9593\u3002\nA. 1+2+3\nB. 2+3+5\nC. 1+3+5\nD. 3+4+5\nE. 1+2+4\n": "(C)", "105-10.\nTZD\u985e\u85e5\u7269\uff0c\u662f\u4e00\u7a2e\u80f0\u5cf6\u7d20\u589e\u654f\u5291\uff0c\u4f46\u662f\u4f7f\u7528\u6642\uff0c\u9808\u6ce8\u610f\u5176\u526f\u4f5c\u7528\uff0c\u4ee5Pioglitazone\u800c\u8a00\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u5176\u4f7f\u7528\u6642\uff0c\u5fc5\u9808\u7559\u610f\u4e4b\u526f\u4f5c\u7528?\r1. \u6c34\u816b (edema)\r2. \u5fc3\u808c\u6897\u585e\r3. \u9ad4\u91cd\u53ca\u8eab\u9ad4\u8102\u80aa\u589e\u52a0\r4. \u5931\u61b6\r5. \u9aa8\u8cea\u758f\u9b06\u3002\nA. 1+3+4\nB. 2+3+5\nC. 3+4+5\nD. 1+3+5\nE. 1+2+5\n": "(D)", "106-1.\n\u4e00\u4f4d53\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u5176\u8840\u9223\u503c\u70ba2.7 mmol/L (\u53c3\u8003\u503c 2.15~2.58 mmol/L), \u526f\u7532\u72c0\u817a\u8377\u723e\u8499\u70ba 45 pg/mL (\u53c3\u8003\u503c12.0~65.0 pg/mL)\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u9808\u5217\u70ba\u9451\u5225\u8a3a\u65b7?(1)\u6162\u6027\u8089\u82bd\u816b\u75c5 (Chronic granulomatous disease)\uff1b(2)\u5bb6\u65cf\u6027\u4f4e\u5c3f\u9223\u9ad8\u8840\u9223\u75c7 (familial hypocalciuric hypercalcemia)\uff1b(3)\u725b\u5976\uff0d\u9e7c\u5291\u75c7 (Milk-alkali syndrome)\uff1b(4)\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b (Hypothyroidism)\uff1b(5)\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 (Cushing's syndrome)\nA. (1)+(2)+(4)\nB. (2)+(3)+(5)\nC. (1)+(2)+(3)\nD. (3)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(C)", "106-2.\n\u6709\u95dc\u7532\u72c0\u817a\u9ad3\u8cea\u764c\u7684\u7279\u6027\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6b63\u78ba?(1)\u7532\u72c0\u817a\u9ad3\u8cea\u764c(Medullary thyroid carcinoma)\u7d04\u4f54\u6240\u6709\u7532\u72c0\u817a\u764c\u7684 5 ~ 10% \uff1b(2)\u7d0420% \u7532\u72c0\u817a\u9ad3\u8cea\u764c\u75c5\u4eba\u6709\u5bb6\u65cf\u75c5\u53f2\uff1b(3)\u7b2c\u4e8c\u578b\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624(Multiple endocrine neoplasia, MEN, type 2) \u75c5\u4eba\u5e38\u898b\u6709 \u7532\u72c0\u817a\u9ad3\u8cea\u764c\u3001\u814e\u4e0a\u817a\u76ae\u8cea\u816b\u7624\u3001\u526f\u7532\u72c0\u817a\u816b\u7624\uff1b(4)\u7b2c\u4e8c\u578b\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624 (MEN type2)\u7684\u5bb6\u4eba\u61c9\u8a72\u505a\u57fa\u56e0\u7be9\u6aa2\uff0c\u82e5\u6709RET\u57fa\u56e0\u7a81\u8b8a\uff0c\u61c9\u7b49\u75c5\u4eba\u6210\u5e74\u5f8c\u5efa\u8b70\u7532\u72c0\u817a\u5207\u9664\uff1b(5)\u7532\u72c0\u817a\u9ad3\u8cea\u764c\u53ef\u80fd\u6709\u7570\u4f4d\u6027\u4fc3\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20(ectopic ACTH) \u5206\u6ccc\u800c\u5c0e\u81f4\u5eab\u6b23\u5f0f\u75c7\u5019\u7fa4 (Cushing's syndrome)\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (1)+(5)\n": "(B)", "106-3.\n\u4e00\u4f4d64\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u5df2\u6709\u591a\u5e74\u9ad8\u8840\u58d3\uff0c\u6700\u8fd1\u534a\u5e74\u4f86\u8840\u58d3\u4e0d\u6613\u63a7\u5236\uff0c\u4e14\u5e38\u6709\u9663\u767c\u6027\u5fc3\u60b8\u3001\u982d\u75db\u3001\u5192\u6c57\u7b49\u75c7\u72c0\uff0c\u4f60\u61f7\u7591\u75c5\u4eba\u6709\u55dc\u916a\u7d30\u80de\u7624(pheochromocytoma)\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6b63\u78ba?\nA. \u75c5\u4eba\u539f\u4f86\u6709\u4f7f\u7528\u7684\u5229\u5c3f\u5291(diuretics)\u53ca\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7269(tricyclic antidepressants)\u5c0d\u6aa2\u9a57\u4e0d\u6703\u5f71\u97ff\uff0c\u6240\u4ee5\u4e0d\u9700\u8981\u5148\u66ab\u505c\u4f7f\u7528\nB. \u6e2c\u91cf\u8840\u6f3f\u4e2d\u7684\u6e38\u96e2\u5f8c\u814e\u4e0a\u817a\u9ad3\u7d20(Plasma free metanephrines)\u5177\u6709\u6700\u9ad8\u7684\u7279\u7570\u6027\uff0c\u4f46\u5e38\u6703\u6709\u56e0\u975c\u8108\u62bd\u8840\u6642\u9020\u6210\u7684\u507d\u967d\u6027(venipuncture-induced false-positive)\u7d50\u679c\nC. \u75c5\u4eba\u6709\u5fc3\u60b8\u75c7\u72c0\uff0c\u61c9\u8a72\u512a\u5148\u4f7f\u7528\u4e59\u578b\u814e\u4e0a\u817a\u53d7\u9ad4\u6291\u5236\u5291 (\u03b2-adrenergic blockers)\uff0c\u4ee5\u907f\u514d\u5fc3\u8df3\u904e\u901f\uff0c\u9020\u6210\u5371\u96aa\nD. \u7d04\u670910%\u7684\u55dc\u916a\u7d30\u80de\u7624\u662f\u60e1\u6027\u7684\uff0c\u9664\u4e86\u958b\u5200\u4ee5\u5916\uff0c\u53ef\u4ee5\u8003\u616e\u4ee5200 mCi\u7684131 I-MIBG \u6cbb\u7642\nE. \u5927\u7d04\u670925-33% \u7684\u55dc\u916a\u7d30\u80de\u7624\u75c5\u4eba\u6709\u8ddf\u907a\u50b3\u6709\u95dc\u7684\u57fa\u56e0\u7a81\u8b8a\uff0c\u5176\u4e2d\u6709SDHB\u57fa\u56e0\u7a81\u8b8a\u7684\uff0c\u7522\u751f\u60e1\u6027\u8b8a\u5316\u7684\u53ef\u80fd\u6027\u6700\u4f4e\n": "(D)", "106-4.\n\u4e0b\u5217\u54ea\u4e00\u9805\u964d\u8840\u58d3\u85e5\u6703\u4f7f\u8840\u6f3f\u919b\u56fa\u916e\u6fc3\u5ea6 (Plasma aldosterone concentration , PAC)\u8207\u8840\u6e05\u5f35\u529b\u7d20\u6d3b\u6027(plasma renin activity, PRA)\u6bd4\u503c(Aldosterone-renin-ratio, ARR) \u4e0a\u5347?\nA. \u4e59\u578b\u814e\u4e0a\u817a\u53d7\u9ad4\u6291\u5236\u5291 (\u03b2-adrenergic blockers)\nB. \u7532\u578b\u814e\u4e0a\u817a\u53d7\u9ad4\u6291\u5236\u5291 (\u03b1-adrenergic blockers)\nC. \u8840\u7ba1\u7dca\u5f35\u7d20\u8f49\u63db\ufffdC\u6291\u88fd\u5291 (angiotensin-converting enzyme inhibitors, ACEi)\nD. \u9223\u96e2\u5b50\u62ee\u6297\u5291 (calcium antagonists)\nE. \u5229\u5c3f\u5291 (diuretics)\n": "(A)", "106-5.\n\u6709\u95dc\u8166\u4e0b\u5782\u9ad4\u529f\u80fd\u6aa2\u67e5\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u662f\u6b63\u78ba\u7684\uff1f\r(\u53c3\u8003\u503c: \u6ccc\u4e73\u6fc0\u7d20\uff08Prolactin\uff091.9~25 ng/m\uff2c\uff1b\u751f\u9577\u6fc0\u7d20\uff08Growth hormone, GH\uff09 < 8 ng/mL\uff1b\u76ae\u8cea\u9187\uff08cortisol\uff098 am 5~25 \u03bcg/dL\u30014 pm 2.5~12.5 \u03bcg/dL\uff1b\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20\uff08ACTH\uff097.4~57.3 pg/mL; \u9240\uff08potassium, K\uff093.5~5.1 mmol/L\uff1b\u6e38\u96e2\u578b\u7532\u72c0\u817a\u7d20 (fT4) 0.89~1.76 ng/dL\uff1b\u7532\u72c0\u817a\u523a\u6fc0\u7d20 (TSH) 0.4~4 \u03bcIU/mL)\nA. \u7d66\u4e88\u53e3\u670d75\u514b\u8461\u8404\u7cd6\uff0cGH\u57280\u5206\u300130 \u5206\u300160\u5206\u5225\u70ba15 ng/mL\u300114 ng/mL\u300112 ng/mL\uff0c\u53ef\u4ee5\u6392\u9664\u80a2\u7aef\u80a5\u5927\u75c7(acromegaly)\u3002\nB. \u75c5\u4eba\u7684\u6ccc\u4e73\u6fc0\u7d20\u503c\u70ba 50 ng/mL\uff0c\u53ef\u4ee5\u8a3a\u65b7\u70ba\u6ccc\u4e73\u6fc0\u7d20\u7624(prolactinoma)\u3002\nC. \u75c5\u4eba\u76848 am cortisol \u70ba30 \u03bcg/dL\uff0c\u665a\u4e0a 11 pm \u7d66\u4e88 \u53e3\u670ddexamethasone 1 mg \u5f8c\uff0c\u7b2c\u4e8c\u5929\u4e0a\u5348 8 am \u7684cortisol \u503c\u70ba 18 \u03bcg/dL\uff0c\u53ef\u4ee5\u6392\u9664\u5eab\u6b23\u6c0f\u75c7\u3002\nD. \u75c5\u4eba8 am ACTH 96 pg/mL\u3001cortisol 28 \u03bcg/dL\uff1b4 pm cortisol 25 \u03bcg/dL\uff1b\uff2b 2.7 mmol/L\uff1b\u9808\u5c0f\u5fc3\u662f\u5426\u6709 ectopic ACTH syndrome\u3002\nE. \u75c5\u4eba\u7684 fT4 \u70ba 0.86 ng/dL\u3001TSH 9 \u03bcIU/mL\uff0c\u6b64\u75c5\u4eba\u53ef\u80fd\u6709\u7532\u72c0\u817a\u523a\u6fc0\u7d20\u7624\u3002\n": "(D)", "106-6.\n\u6709\u95dc\u5c3f\u5d29\u75c7\uff08diabetes insipidus, DI\uff09\u7684\u8a3a\u65b7\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6b63\u78ba\uff1f\nA. \u5c3f\u5d29\u75c7\u7684\u5b9a\u7fa9\u70ba\u5728\u4e0d\u9650\u6c34\u7684\u60c5\u6cc1\u4e0b\uff0c\u6bcf\u5929\u6bcf\u516c\u65a4\u9ad4\u91cd\u5c3f\u91cf\u5927\u65bc60 mL (\u4f8b\u5982: 70\u516c\u65a4\u91cd\uff0c\u5c3f\u91cf\u8d85\u904e\u6bcf\u5929 4200 mL)\u4e14\u5c3f\u6ef2\u900f\u58d3\u5c0f\u65bc250 mosmol/L\u3002\nB. \u75c5\u4eba\u6709\u5c3f\u5d29\u75c7\uff0c\u4e14\u5176plasma arginine vasopressin (AVP) < 1 pg/mL\uff0c\u61c9\u8a72\u5b89\u6392\u8166\u4e0b\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5\u3002\nC. \u5c3f\u5d29\u75c7\u7684\u75c5\u4eba\u5982\u679c\u5176\u8166\u4e0b\u5782\u9ad4\u6838\u78c1\u5171\u632f\u5f71\u50cf\u986f\u793a\u5176\u5f8c\u8449\u6709\u767d\u767d\u4eae\u9ede\uff0c\u4e00\u5b9a\u662f\u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI)\u3002\nD. \u61f7\u7591\u6709\u5c3f\u5d29\u75c7\u7684\u75c5\u4eba\u5728\u505a\u9650\u6c34\u6e2c\u8a66\u6642\uff0c\u5c3f\u91cf\u6e1b\u5c11\uff0c\u5c3f\u6ef2\u900f\u58d3\u589e\u52a0\uff0c\u6b64\u75c5\u4eba\u6bd4\u8f03\u50cf\u662f\u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI)\u3002\nE. \u814e\u6e90\u6027\u5c3f\u5d29\u75c7(nephrogenic DI)\u61c9\u8a72\u4f7f\u7528desmopressin (DDAVP)\u6cbb\u7642\u3002\n": "(B)", "106-7.\n\u4e00\u4f4d70 \u6b72\u5973\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u4f11\u514b\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u5176\u6aa2\u9a57\u503c\u5982\u4e0b: Na 125 mmol/L\u3001glucose AC 68 mg/dL\u3001ACTH 20 pg/mL\u3001cortisol 10 \u03bcg/dL\u3001fT4 0.5 ng/dL\u3001TSH 0.1 \u03bcIU/mL\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6cbb\u7642\u61c9\u8a72\u512a\u5148\u7d66\u4e88\uff1f\r(\u53c3\u8003\u503c: \u76ae\u8cea\u9187\uff08cortisol\uff098 am 5~25 \u03bcg/dL\u30014 pm 2.5~12.5 \u03bcg/dL\uff1b\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20\uff08ACTH\uff097.4~57.3 pg/mL; \u9209 (sodium, Na) 136~145 mmol/L\uff1b \u7a7a\u8179\u8840\u7cd6 (glucose AC) 70~100 mg/dL\uff1b\u6e38\u96e2\u578b\u7532\u72c0\u817a\u7d20 (fT4) 0.89~1.76 ng/dL\uff1b\u7532\u72c0\u817a\u523a\u6fc0\u7d20 (TSH) 0.4~4 \u03bcIU/mL)\nA. Hydrocortisone, intravenous\nB. Thyroxine\nC. 3% NaCl\nD. 50% glucose water (G/W)\nE. Prednisolone, per os\n": "(A)", "106-8.\n\u4e0b\u5217\u56e0\u7d20\u53ef\u80fd\u9020\u6210euthyroid hyperthyroxinemia\uff0c\u9664\u4e86?\nA. Resistance to thyroid hormone\nB. Pregnancy\nC. Amiodarone\nD. Liver cirrhosis\nE. Malnutrition\n": "(E)", "106-9.\n\u4e00\u4f4d25\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u524d\u9838\u90e8\u816b\u75db\u4f86\u8a3a\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u7532\u72c0\u817a\u6709\u816b\u584a\u3001\u5177\u58d3\u75db\uff0c\u4f46\u7121\u76ae\u819a\u7d05\u71b1\u73fe\u8c61\u3002\u75c5\u4eba\u5169\u9031\u524d\u6709\u4e0a\u547c\u5438\u9053\u611f\u67d3\u75c7\u72c0\u3002\u5979\u7684\u6aa2\u9a57\u6578\u503c\u5982\u4e0b: fT4 2.0 ng/dL (\u53c3\u8003\u503c: 0.89~1.76 ng/dL)\u3001TSH 0.3 \u03bcIU/mL (\u53c3\u8003\u503c 0.4~4 \u03bcIU/mL)\u3001WBC 7800 /\u03bcL\u3002\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u58d3\u75db\u8655\u6709\u5c40\u90e8\u4f4e\u8ff4\u97f3\u5ea6\u8b8a\u5316\u3001\u7d30\u91dd\u7a7f\u523a\u7d30\u80de\u5b78\u6aa2\u67e5\u986f\u793a\u6709\u591a\u6838\u6027\u5de8\u7d30\u80de (multinucleated giant cell)\uff0c\u8acb\u554f\u61c9\u8a72\u7d66\u4e88\u4e0b\u5217\u54ea\u4e9b\u8655\u7f6e?\nA. \u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\nB. \u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\u6cbb\u7642\nC. \u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642\nD. \u61c9\u8a72\u7acb\u5373\u5b89\u6392\u98df\u9053\u651d\u5f71 (esophagogram)\nE. \u61c9\u8a72\u7acb\u5373\u5b89\u6392\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(C)", "106-10.\n\u4e00\u4f4d43\u6b72\u7537\u6027\u75c5\u4eba\u88ab\u8a3a\u65b7\u6709\u7532\u72c0\u817a\u4e73\u7a81\u764c(thyroid papillary cancer)\uff0c\u5176\u816b\u7624\u67092.5\u516c\u5206\uff0c\u5df2\u7d93\u6709\u5c40\u90e8\u8edf\u7d44\u7e54\u4fb5\u72af\u53ca\u9838\u90e8\u6dcb\u5df4\u817a\u8f49\u79fb\u4f46\u7121\u9060\u7aef\u8f49\u79fb\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6558\u8ff0\u6b63\u78ba?\nA. \u6b64\u75c5\u4eba\u7684\u764c\u75c7\u5206\u671f\u5c6c\u65bc\u7b2c\u4e09\u671f\nB. \u6b64\u75c5\u4eba\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\u5927\u7d04\u70ba70%\nC. \u624b\u8853\u5f8c\u61c9\u8a72\u7d66\u4e882-5 mCi\u7684\u653e\u5c04\u6027\u7898\u505a\u6383\u63cf\uff0c\u78ba\u5b9a\u662f\u5426\u6709\u9060\u7aef\u8f49\u79fb\u5f8c\u518d\u8003\u616e\u662f\u5426\u9700\u8981\u7d66\u4e88\u653e\u5c04\u6027\u7898\u6cbb\u7642\nD. \u7d93\u904e\u624b\u8853\u53ca\u5fc5\u8981\u7684\u653e\u5c04\u6027\u7898\u6cbb\u7642\u5f8c\uff0c\u61c9\u8a72\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u88dc\u5145\uff0c\u4ee5\u7dad\u6301\u75c5\u4eba\u7684\u7532\u72c0\u817a\u529f\u80fd\u65bc\u6b63\u5e38\u7bc4\u570d\uff0c\u5176TSH\u61c9\u8a72\u8d8a\u4f4e\u8d8a\u597d\nE. \u75c5\u4eba\u63a5\u53d7\u6cbb\u7642\u5291\u91cf\u7684\u653e\u5c04\u6027\u7898\u5f8c\u4e4b\u6383\u63cf\u6c92\u6709\u770b\u5230\u6709\u651d\u53d6\u653e\u5c04\u6027\u7898\u7684\u75c5\u7076\uff0c\u5176thyroglobulin \u70ba 20 ng/mL\uff0c\u6b64\u75c5\u4eba\u53ef\u4ee5\u78ba\u5b9a\u6c92\u6709\u7532\u72c0\u817a\u764c\u518d\u767c\n": "(D)", "106-1.\n\u9673\u5973\u58eb\uff0c56\u6b72\uff0c160\u516c\u5206\uff0c80\u516c\u65a4\uff0c\u8fd1\u5e74\u4f86\u5e38\u767c\u751f\u98e2\u9913\u611f\uff0c\u4f46\u662f\u5403\u6771\u897f\u5373\u53ef\u6539\u5584\u98e2\u9913\u4e4b\u4e0d\u9069\u3002\u5169\u5e74\u5167\u9ad4\u91cd\u589e\u52a015\u516c\u65a4\u3002\u6700\u8fd1\u4e09\u6b21\u56e0\u7121\u610f\u8b58\u660f\u5012\uff0c\u88ab\u9001\u5230\u6025\u8a3a\u5c31\u91ab\uff0c\u5728\u8f38\u6ce850%\u8461\u8404\u7cd6\u6db2\u5f8c\u5373\u7526\u9192\u3002\u672c\u6b21\u70ba\u7b2c\u4e09\u6b21\u5230\u6025\u8a3a\uff0c\u6025\u8a3a\u8840\u7cd6\u7d00\u9304\u70ba32 mg/dL\uff0c\u8840\u58d3\u70ba116/68 mmHg\uff0c\u8108\u640f\u70ba66 bpm\uff0c\u56e0\u6b64\u5efa\u8b70\u6536\u6cbb\u4f4f\u9662\u3002\u5728\u672a\u6ce8\u5c04\u8f38\u6db2\u4e4b\u4e0b\uff0c\u7a7a\u81798\u5c0f\u6642\u4e4b\u6e05\u6668\u7a7a\u8179\u8840\u7cd6\u70ba88 mg/dL\uff0cInsulin \u70ba10.6 \u03bcIU/mL (reference range, <28.8 \u03bcIU/mL)\uff0cC-peptide\u70ba 3.6  ng/mL (reference range, 0.34-4.25 mIU/mL)\u3002\u6e05\u66688\u9ede\u4e4bACTH 55.8 pg/mL (reference range, 6.0-76.0 pg/mL)\uff0cCortisol 25.6\r\u03bcg/dL (reference range, 5-25 \u03bcg/dL)\uff0cIGF-1 \u70ba 198 ng/mL (reference range, 81-225 ng/mL)\uff0cTSH \u70ba 4.8 mIU/mL (reference range, 0.34-4.25 mIU/mL)\u3002\u76ee\u524d\u61c9\u5148\u9032\u884c\u4e0b\u5217\u54ea\u4e00\u9805\u6aa2\u67e5?\nA. 75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57 (OGTT)\nB. \u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (MRI)\nC. 24\u5c0f\u6642\u9023\u7e8c\u5fc3\u96fb\u5716\u6aa2\u67e5\nD. 72\u5c0f\u6642\u4e4b Prolonged fasting test\nE. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(D)", "106-2.\nBiguanides \u985e\u7684\u85e5\u7269\uff0cMetformin\u662f\u76ee\u524d\u570b\u969b\u4e0a\u5927\u591a\u6578\u7cd6\u5c3f\u75c5\u6cbb\u7642\u6307\u5f15\u4e4b\u9996\u9078\u85e5\u7269\u5efa\u8b70\u3002\u4ee5\u4e0b\u6709\u95dcMetformin\u4e4b\u6558\u8ff0\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. \u4e73\u9178\u4e2d\u6bd2\u662f\u7f55\u898b\u7684Metformin\u85e5\u7269\u526f\u4f5c\u7528\uff0c\u4f46\u662f\u6b7b\u4ea1\u7387\u53ef\u905450%\nB. Metformin\u4e5f\u53ef\u80fd\u9020\u6210\u7dad\u4ed6\u547dB12 (Vitamin B12)\u4e4bmalabsorption\nC. Metfmornin\u4e4b\u4f7f\u7528\u53ef\u4ee5\u5ef6\u7de9\u7cd6\u5c3f\u75c5\u4e4b\u767c\u75c5\u75c5\u7a0b\nD. \u814e\u529f\u80fd\u4e0d\u4f73\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0c\u5373\u4f7feGFR\u5c0f\u65bc30 ml/min/1.73\u33a1\uff0c\u4f7f\u7528Metformin\u4ecd\u7136\u662f\u5b89\u5168\u7684\nE. \u7cd6\u5c3f\u75c5\u4e4b\u5b55\u5a66\u61f7\u5b55\u6642\uff0cMetformin\u662f\u5b89\u5168\u7684\u7cd6\u5c3f\u75c5\u7528\u85e5\u9078\u64c7\u4e4b\u4e00\n": "(D)", "106-3.\n\u7cd6\u5c3f\u75c5\u65b0\u578b\u7528\u85e5\u4e2d\uff0cSGLT-2\u6291\u5236\u5291 (Sodium-glucose Co-transporter 2 inhibitor)\uff0c\u6700\u8fd1\u5169\u5e74\u5ee3\u6cdb\u4f7f\u7528\u7684\u65bc\u7cd6\u5c3f\u75c5\u4e4b\u6cbb\u7642\u3002\u4e0b\u5217\u6709\u95dcSGLT-2\u6291\u5236\u5291\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684?\nA. \u6b64\u985e\u85e5\u7269\u4e0d\u6703\u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\nB. SGLT-2\u6291\u5236\u5291\u7684\u4f5c\u7528\u6a5f\u8f49\uff0c\u4e3b\u8981\u662f\u6291\u5236\u5c3f\u7cd6\u4e4b\u518d\u5438\u6536\uff0c\u8b93\u8461\u8404\u7cd6\u5927\u91cf\u7684\u5f9e\u5c3f\u4e2d\u6392\u51fa\nC. \u814e\u529f\u80fdeGFR<45 ml/min/1.73\u33a1\u4ee5\u4e0b\u6642\uff0c\u4e0d\u61c9\u4f7f\u7528\u6b64\u985e\u85e5\u7269\nD. \u6b64\u985e\u85e5\u7269\u589e\u52a0\u5c3f\u7cd6\u6392\u51fa\uff0c\u56e0\u6b64\u5973\u6027\u5bb9\u6613\u6709\u6ccc\u5c3f\u9053\u611f\u67d3\u4e4b\u53ef\u80fd\u6027\uff0c\u4f46\u662f\u7537\u6027\u5247\u7121\u6b64\u56f0\u64fe\nE. \u6b64\u985e\u85e5\u7269\u5728\u964d\u8840\u7cd6\u7684\u904e\u7a0b\u4e2d\uff0c\u7cd6\u5c3f\u75c5\u60a3\u8005\u9ad4\u91cd\u4e5f\u6703\u96a8\u4e4b\u6e1b\u8f15\n": "(D)", "106-4.\n\u9673\u5148\u751f\uff0c82\u6b72\uff0c\u8eab\u9ad8168\u516c\u5206\uff0c\u9ad4\u91cd58\u516c\u65a4\uff0c\u7cd6\u5c3f\u75c5\u75c5\u53f220\u5e74\uff0c\u76ee\u524d\u63a5\u53d7 \u4e09\u9910\u524d\u901f\u6548\u53ca\u7761\u524d\u57fa\u790e\u80f0\u5cf6\u7d20\u6cbb\u7642\u3002\u4f46\u7d93\u5e38\u6703\u6f0f\u6253\u9910\u524d\u80f0\u5cf6\u7d20\uff0c\u4e00\u500b\u6708\u524d\u4e4bHbA1c\u70ba8.8 %\uff0c\u8fd1\u4e00\u5468\u51fa\u73fe\u611f\u5192\u4e4b\u75c7\u72c0\uff0c\u6c92\u6709\u767c\u71d2\u4e4b\u7d00\u9304\uff0c\u4f46\u662f\u80c3\u53e3\u4e0d\u4f73\u3002\u6b64\u6b21\u56e0\u610f\u8b58\u72c0\u6cc1\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u6025\u8a3a\u4e4b\u8840\u7cd6\u70ba525 mg/dL\uff0c\u9209\u96e2\u5b50\u70ba151 mEq/L\uff0c'\u9240\u96e2\u5b50\u70ba3.5 mEq/L\uff0c\u5c3f\u7d20\u6c2eBUN\u70ba62 mg/dL\uff0c\u808c\u9178\u9150Cr\u70ba 2.6 mg/dL\u3002\u5230\u6025\u8a3a\u5f8c\u4e4b\u8840\u58d3\u70ba98/60 mmHg\uff0c\u8108\u640f\u70ba96 bpm\u3002\u4e0b\u5217\u4e4b\u8f38\u6db2\uff0c\u4f55\u8005\u6700\u9069\u65bc\u6b64\u75c5\u60a3\u8f38\u6ce8\u53ca\u76e3\u6e2c\u5176\u5c3f\u6db2\u6392\u51fa\u91cf (Urine output)?\nA. 0.45% Half saline solution\nB. Lactate Ringer solution\nC. 0.9 % Normal Saline solution\nD. 5% Glucose solution with regular insulin intravenous infusion\nE. 0.45% Half saline solution with regular insulin intravenous infusion\n": "(C)", "106-5.\n\u5f35\u5148\u751f\uff0c50\u6b72\uff0c\u96fb\u8166\u516c\u53f8\u526f\u7e3d\u7d93\u7406\uff0c\u7cd6\u5c3f\u75c5\u53f25\u5e74\uff0c\u53bb\u5e74\u56e0\u51a0\u72c0\u52d5\u8108\u75be\u75c5\u4f4f\u9662\uff0c\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u5f8c\uff0c\u7f6e\u653e\u652f\u67b6\u3002\u76ee\u524d\u5df2\u9810\u6df7\u578b\u80f0\u5cf6\u7d20(Premix insulin) \u63a7\u5236\u8840\u7cd6\uff0c\u9ad8\u8840\u58d3\u85e5\u7269\u70ba\u6bcf\u65e5Valsartan 160 mg\u53caAmlodipine 5 mg\uff0c\u964d\u8840\u8102\u85e5\u7269\u70ba\u6bcf\u65e5Atorvastatin 20 mg\u3002\u6700\u8fd1HbA1c \u70ba6.5 %\uff0cLDL cholesterol\u70ba 55 mg/dL\uff0cHDL cholesterol\u70ba 35 mg/dL\uff0ctriglyceride \u70ba 756 mg/dL\uff0c\u6c92\u6709\u5fae\u91cf\u767d\u86cb\u767d\u5c3f\uff0c\u4f46\u662f\u5df2\u7d93\u51fa\u73fe\u80cc\u666f\u578b\u8996\u7db2\u819c\u75c5\u8b8a\u3002\u4e0b\u5217\u4e4b\u85e5\u7269\uff0c\u61c9\u6709\u4f7f\u7528\u4e4b\u5fc5\u8981?\nA. Sitagliptin\nB. Pioglitazone\nC. Nicotic acid\nD. Fenofibrate\nE. Acarbose\n": "(D)", "106-6.\nThiazolidinedione (TZD) \u985e\u7684\u85e5\u7269\uff0c\u5c6c\u65bc\u80f0\u5cf6\u7d20\u589e\u654f\u5291 (Insulin sensitizer)\uff0c\u7814\u7a76\u986f\u793a\u5c0d\u65bc\u5fc3\u81df\u8840\u7ba1\u53ca\u8166\u4e2d\u98a8\uff0c\u53ef\u80fd\u6709\u76f8\u7576\u9810\u9632\u6027\u7684\u610f\u7fa9\u3002\u4ee5Pioglitazone\u800c\u8a00\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u4f7f\u7528\u6b64\u85e5\u6642\uff0c\u5fc5\u9808\u7559\u610f\u7684\u526f\u4f5c\u7528?(1) \u9ad4\u91cd\u53ca\u8102\u80aa\u7d44\u7e54\u589e\u52a0\uff1b(2)\u60c5\u7dd2\u6cae\u55aa\uff1b(3)\u6c34\u816b\uff1b(4)\u9aa8\u8cea\u758f\u9b06\uff1b(5) \u5931\u7720\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (1)+(3)+(4)\nE. (3)+(4)+(5)\n": "(D)", "106-7.\n\u4f4e\u8840\u7cd6\u662f\u7cd6\u5c3f\u75c5\u6cbb\u7642\u904e\u7a0b\u4e2d\u3001\u975e\u7cd6\u5c3f\u75c5\u60a3\u8005\u76f8\u95dc\u75be\u75c5\u6216\u4f7f\u7528\u7279\u5b9a\u85e5\u7269\u6cbb\u7642\u6642\u5e38\u898b\u7684\u4f75\u767c\u75c7\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u767c\u751f\u4f4e\u8840\u7cd6\u7684\u539f\u56e0?(1) \u4e0d\u7576\u4f7f\u7528\u80f0\u5cf6\u7d20\u6216\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\uff1b(2)\u80a2\u7aef\u80a5\u5927\u75c7\uff1b(3)\u80c3\u5207\u9664\u624b\u8853\u5f8c (Post-gastric bypass surgery)\uff1b(4)\u814e\u4e0a\u817a\u6a5f\u80fd\u4e0d\u8db3 (Adrenal insufficiency)\uff1b(5)\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 (Cushing's syndrome)\nA. (1)+(2)+(4)\nB. (2)+(3)+(4)\nC. (1)+(3)+(4)\nD. (1)+(2)+(5)\nE. (1)+(3)+(5)\n": "(C)", "106-8.\n\u7cd6\u5c3f\u75c5\u60a3\u8005\u6cbb\u7642\u4e2d\uff0c\u4f4e\u8840\u7cd6\u662f\u975e\u5e38\u9700\u8981\u6ce8\u610f\u7684\u8b8a\u5316\u3002\u4e0b\u5217\u6709\u95dc\u7cd6\u5c3f\u75c5\u4f4e\u8840\u7cd6\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. \u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4ee5\u80f0\u5cf6\u7d20\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\uff0c\u53ef\u4ee5\u6709\u6548\u5730\u964d\u4f4e\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u53ca\u814e\u75c5\u8b8a\uff0c\u4f46\u662f\u4f4e\u8840\u7cd6\u56e0\u80f0\u5cf6\u7d20\u4e4b\u7a4d\u6975\u4f7f\u7528\uff0c\u767c\u751f\u7387\u4e5f\u8f03\u9ad8\nB. \u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u6700\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\u4e4b\u53e3\u670d\u85e5\u7269\u70ba\u786b\u80fa\u985e (Sulfonylurea)\u85e5\u7269\nC. \u65b0\u578b\u7684\u7cd6\u5c3f\u75c5\u85e5\u7269\u5982DPP-4 inhibitor \u53ca SGLT-2 inhibitor\uff0c\u56e0\u5176\u85e5\u7269\u6a5f\u8f49\u7279\u6b8a\uff0c\u56e0\u6b64\u4e0d\u6703\u767c\u751f\u4f4e\u8840\u7cd6\nD. \u4f7f\u7528\u591a\u6b21\u9910\u524d\u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\uff0c\u767c\u751f\u4f4e\u8840\u7cd6\u4e4b\u6a5f\u7387\uff0c\u8f03\u57fa\u790e\u80f0\u5cf6\u7d20\u70ba\u9ad8\nE. \u7cd6\u5c3f\u75c5\u60a3\u7684\u7cd6\u5c3f\u75c5\u53f2\u6108\u4e45\uff0c\u53ef\u80fd\u56e0\u81ea\u4e3b\u795e\u7d93\u75c5\u8b8a\uff0c\u7522\u751f Hypoglycemia unawareness\uff0c\u800c\u7121\u660e\u986f\u81ea\u89ba\u6027\u7684\u75c7\u72c0\n": "(C)", "106-9.\n\u7cd6\u5c3f\u75c5\u7684\u6cbb\u7642\u4e2d\uff0c\u751f\u6d3b\u578b\u614b\u63a7\u5236\u662f\u5fc5\u8981\u7684\u3002\u4f46\u662f\u85e5\u7269\u6cbb\u7642\u4e5f\u4e0d\u53ef\u6216\u7f3a\u3002\u4e0b\u5217\u6558\u8ff0\u4e2d\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?(1)Metformin\u70ba\u7cd6\u5c3f\u75c5\u7b2c\u4e00\u7dda\u7528\u85e5\uff0ceGFR < 30 ml/min/1.73\u33a1\u6642\uff0c\u4ecd\u53ef\u5b89\u5168\u4f7f\u7528\uff1b(2)\u53f0\u7063\u7cd6\u5c3f\u75c5\u6cbb\u7642\u6307\u5f15\u5efa\u8b70HbA1c\u7cd6\u5316\u8840\u8272\u7d20\u7684\u63a7\u5236\u76ee\u6a19\u70ba 7.0 %\u4ee5\u4e0b\uff1b(3)\u5bb9\u6613\u767c\u751f\u4f4e\u8840\u7cd6\u4e4b\u60a3\u8005\uff0c\u61c9\u8003\u616e\u907f\u514d\u4f7f\u7528\u80f0\u5cf6\u7d20\uff1b(4)Glucagon-like peptide-1 (GLP-1)\u985e\u7684\u91dd\u5291\u7cd6\u5c3f\u75c5\u85e5\u7269\u767c\u751f\u4f4e\u8840\u7cd6\u7684\u6a5f\u6703\u6bd4\u80f0\u5cf6\u7d20\u91dd\u5291\u70ba\u4f4e\uff1b(5)SGLT-2\u6291\u5236\u5291\u9020\u6210\u6ccc\u5c3f\u9053\u611f\u67d3\u7684\u6a5f\u6703\u8f03\u9ad8\nA. (1)+(4)\nB. (3)+(5)\nC. (2)+(5)\nD. (1)+(3)\nE. (3)+(4)\n": "(D)", "106-10.\n\u7cd6\u5c3f\u75c5\u6cbb\u7642\u85e5\u7269\u4e2d\uff0cGlucagon-like peptide-1\u91dd\u5291\u85e5\u7269\u53caDPP-4 inhibitor\u5747\u5c6c\u65bc\u8178\u6ccc\u7d20 (Incretin)\u985e\u85e5\u7269\uff0c\u4e0b\u5217\u6709\u95dc\u8178\u6ccc\u7d20\u53ca\u76f8\u95dc\u85e5\u7269\u7684\u6558\u8ff0\uff0c\u54ea\u4e00\u500b\u662f\u932f\u8aa4\u7684?\nA. \u4eba\u9ad4\u751f\u7406\u5b78\u4e0a\u5206\u6ccc\u7684GLP-1\u4f86\u81ea\u8178\u9053\u7684L-\u7d30\u80de\nB. DPP-4 inhibitor \u7684\u7814\u7a76\u4e2d\u767c\u73fe\uff0cDPP-4 ihbibitor \u53ef\u80fd\u6709\u9020\u6210\u75c5\u60a3\u5fc3\u81df\u8870\u7aed\u7684\u98a8\u96aa\nC. \u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u4e4b\u60a3\u8005\u4e5f\u9069\u5408\u4f7f\u7528GLP-1\u985e\u7684\u91dd\u5291\u85e5\u7269\nD. \u8178\u6ccc\u7d20\u985e\u7684\u85e5\u7269\u767c\u751f\u4f4e\u8840\u7cd6\u7684\u6a5f\u6703\u6bd4\u786b\u80fa\u985e (Sulfonylurea)\u985e\u85e5\u7269\u70ba\u4f4e\nE. \u7814\u7a76\u986f\u793a\uff0c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4f7f\u7528GLP-1\u985e\u85e5\u7269\u6642\uff0c\u53ef\u4ee5\u6e1b\u8f15\u75c5\u60a3\u9ad4\u91cd\n": "(C)", "107-1.\n\u4e00\u4f4d56\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u4ed6\u6709\u591a\u5e74\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u53f2\uff0c\u4f7f\u7528\u85e5\u7269\u63a7\u5236\u4e2d\u3002\u5bb6\u5c6c\u63d0\u53ca\u75c5\u4eba\u4f5c\u606f\u53ca\u98f2\u98df\u6b63\u5e38\uff0c\u5728\u610f\u8b58\u6539\u8b8a\u524d\uff0c\u75c5\u4eba\u8868\u793a\u6709\u6025\u6027\u5287\u70c8\u982d\u75db\u53ca\u8996\u91ce\u6a21\u7cca\uff0c\u5176\u4ed6\u4e26\u7121\u7570\u72c0\u3002\u75c5\u4eba\u5916\u89c0\u6709\u80a2\u7aef\u80a5\u5927\u75c7\u7279\u5fb5\uff0c\u5176\u8840\u58d3\u70ba90/60 mmHg\u3001\u8840\u7cd6\u503c\u70ba65 mg/dL\u3001\u8840\u9209\u70ba125 mmol/L\u3002\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba\uff1f (1). \u75c5\u4eba\u7684\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u53ef\u80fd\u767c\u73fe\u8166\u4e0b\u5782\u9ad4\u816b\u7624\u5167\u51fa\u8840 (2).\t\u61c9\u8a72\u512a\u5148\u4f7f\u7528\u7532\u72c0\u817a\u7d20\u6cbb\u7642 (3).\t\u61c9\u7acb\u5373\u4f7f\u7528\u9ad8\u5291\u91cf\u985e\u56fa\u9187\u6cbb\u7642 (4).\t\u61c9\u5118\u901f\u5b89\u6392\u624b\u8853\u6e1b\u58d3 (5). \u75c5\u4eba\u672a\u4f86\u53ef\u80fd\u7522\u751f\u7a7a\u8776\u978d\u75c7 (empty sella)\nA. (1)+(3)+(4)\nB. (2)+(3)+(5)\nC. (2)+(4)+(5)\nD. (1)+(3)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "107-2.\n\u7121\u75c7\u72c0\u7684\u539f\u767c\u6027\u526f\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u75c7(asymptomatic primary hyperparathyroidism)\u6709\u4e0b\u5217\u54ea\u4e9b\u73fe\u8c61\u61c9\u8a72\u5efa\u8b70\u958b\u5200?\u8acb\u9078\u64c7\u6700\u9069\u7576\u7684\u7b54\u6848\u3002(1). \u8840\u6e05\u4e2d\u9223\u6fc3\u5ea6\u9ad8\u65bc\u6b63\u5e38\u503c 1.2 mg/dL (2). 24\u5c0f\u6642\u5c3f\u9223\u70ba 200 mg (3). \u808c\u9150\u6e05\u9664\u7387 (creatinine clearance) \u70ba 50 mL/min (4). \u810a\u690e (spine)\u4e4b\u9aa8\u5bc6\u5ea6\u6aa2\u67e5 T score < - 2.5 (5). \u75c5\u4eba\u5e74\u7d00 \u70ba55 \u6b72\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(5)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (1)+(3)+(4)\n": "(E)", "107-3.\n\u6709\u95dc\u7532\u72c0\u817a\u75be\u75c5\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6700\u6b63\u78ba\uff1f(1). \u4f7f\u7528 Amiodarone \u6cbb\u7642\u5fc3\u5f8b\u4e0d\u6574\u53ef\u80fd\u9020\u6210\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u6216\u4f4e\u4e0b (2).\t34\u6b72\u7537\u6027\u75c5\u4eba\u5ffd\u7136\u6709\u7532\u72c0\u817a\u816b\u5927\uff0c\u61c9\u8a72\u7acb\u5373\u4f7f\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269\u6cbb\u7642 (3).\t\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u6642\u7d55\u5c0d\u7981\u6b62\u4f7f\u7528\u542b\u7898\u85e5\u7269 (4).\t\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u4e4b\u5973\u6027\u75c5\u4eba\u82e5\u61f7\u5b55\u6642\u61c9\u8a72\u7acb\u5373\u505c\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269 (5).\t\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\u4e4b\u5973\u6027\u75c5\u4eba\u5982\u679c\u61f7\u5b55\u53ef\u80fd\u9700\u8981\u589e\u52a0\u7532\u72c0\u817a\u7d20\u5291\u91cf\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(5)\nD. (1)+(4)\nE. (1)+(3)+(5)\n": "(C)", "107-4.\n\u4e0b\u5217\u6709\u95dc\u8178\u80c3\u9053\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624(gastrointestinal neuroendocrine tumor, GI-NETs)\u53ca\u80f0\u81df\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624 (pancreatic neuroendocrine tumor, pNETs)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba?\nA. GI-NETs\u5c6c\u65bcAPUDomas (amine precursor uptake and decarboxylation tumor)\uff0c\u4f46 pNETs\u4e0d\u5c6c\u65bcAPUDomas\nB. \u8840\u6e05\u4e2d chromogranin A \u6fc3\u5ea6\u53ef\u4ee5\u505a\u70baGI-NETs\u53ca pNETs\u4e4b\u816b\u7624\u6a19\u8a8c (tumor marker)\nC. GI-NETs \u5c11\u6709\u9ad4\u6291\u7d20\u63a5\u53d7\u9ad4(somatostatin receptor)\uff0c\u800cpNETs\u5247\u5e38\u898b\u6709\u9ad4\u6291\u7d20\u63a5\u53d7\u9ad4\nD. \u514d\u75ab\u7d30\u80de\u5316\u5b78\u6aa2\u67e5(immunocytochemical studies) \u53ef\u4ee5\u9810\u6e2cGI-NETs\u53ca pNETs\u4e4b\u81e8\u5e8a\u8868\u5fb5\nE. GI-NETs\u5927\u591a\u6578\u9032\u5c55\u7de9\u6162\uff0cpNETs\u7d55\u5927\u591a\u6578\u9032\u5c55\u6975\u70ba\u5feb\u901f\n": "(B)", "107-5.\n\u4e0b\u5217\u6709\u95dc\u55dc\u927b\u7d30\u80de\u7624(pheochromocytoma)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba?\nA. \u55dc\u927b\u7d30\u80de\u7624\u7684\u75c5\u4eba\u5e38\u4ee5\u5fc3\u60b8\u3001\u982d\u75db\u3001\u5192\u6c57\u7b49\u75c7\u72c0\u8868\u73fe\uff0c\u4f46\u4e5f\u6709\u75c5\u4eba\u53ef\u80fd\u591a\u5e74\u6beb\u7121\u75c7\u72c0\nB. \u61f7\u7591\u6709\u55dc\u927b\u7d30\u80de\u7624\u7684\u75c5\u4eba\uff0c\u70ba\u907f\u514d\u8a98\u767c\u9ad8\u8840\u58d3\uff0c\u4ee5\u96fb\u8166\u65b7\u5c64\u6216\u6838\u78c1\u5171\u632f\u505a\u5f71\u50cf\u6aa2\u67e5\u6642\u61c9\u8a72\u7981\u7528\u986f\u5f71\u5291\nC. \u4e00\u4f4d28\u6b72\u5973\u6027\u75c5\u4eba\u5728\u61f7\u5b55\u521d\u671f\u88ab\u8a3a\u65b7\u6709\u55dc\u927b\u7d30\u80de\u7624\uff0c\u70ba\u5b55\u5a66\u53ca\u53ca\u80ce\u5152\u5b89\u5168\u8003\u91cf\uff0c\u6700\u597d\u5728\u751f\u7522\u5f8c\u624d\u5b89\u6392\u986f\u5fae\u624b\u8853\u5207\u9664\nD. \u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624\u7b2c\u4e8c\u578b(multiple endocrine neoplasia type 2, MEN 2)\u7684\u75c5\u4eba\uff0c\u5176\u55dc\u927b\u7d30\u80de\u7624\u901a\u5e38\u70ba\u5169\u5074\u814e\u4e0a\u817a\u7684\u60e1\u6027\u816b\u7624\nE. \u55dc\u927b\u7d30\u80de\u7624\u75c5\u4eba\u5982\u679c\u6709\u8ddf\u907a\u50b3\u6709\u95dc\u7684\u57fa\u56e0\u7a81\u8b8a\uff0c\u5176\u767c\u75c5\u5e74\u9f61\u5e73\u5747\u8f03\u5076\u767c\u578b(sporadic type)\u75c5\u4eba\u665a10\u6b72\n": "(A)", "107-6.\n\u4e0b\u5217\u6709\u95dc\u65bc\u539f\u767c\u6027\u9ad8\u919b\u56fa\u916e\u75c7(primary aldosteronism)\u7684\u63cf\u8ff0\u54ea\u4e00\u9805\u6b63\u78ba?\nA. \u70ba\u589e\u52a0\u6aa2\u67e5\u4e4b\u6b63\u78ba\u6027\uff0c\u5df2\u4f7f\u7528spironolactine\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u61c9\u8a72\u5148\u505c\u85e5\u4e00\u9031\u624d\u6aa2\u67e5\u8840\u6e05\u919b\u56fa\u916e\u6fc3\u5ea6\u8207\u814e\u7d20\u6d3b\u6027\u4e4b\u6bd4\u503c(aldosterone-renin ratio, ARR)\nB. \u4e59\u578b\u4ea4\u611f\u795e\u7d93\u7d20\u963b\u65b7\u5291(\u03b2-blockers)\u6703\u4f7fARR\u4e0a\u5347\nC. \u57284\u5c0f\u6642\u5167\u704c\u6ce8\u751f\u7406\u98df\u9e7d\u6c342\u516c\u5347 (saline infusion test)\u5f8c\uff0c\u8840\u6e05\u919b\u56fa\u916e (aldosterone)\u6fc3\u5ea6\u70ba10 ng/dL \u53ef\u4ee5\u6392\u9664\u539f\u767c\u6027\u9ad8\u919b\u56fa\u916e\u75c7\nD. \u70ba\u78ba\u4fdd\u8a3a\u65b7\u53ca\u6cbb\u7642\u6b63\u78ba\uff0c\u6240\u6709\u61f7\u7591\u70ba\u539f\u767c\u6027\u9ad8\u919b\u56fa\u916e\u75c7\u7684\u75c5\u4eba\u90fd\u61c9\u8a72\u63a5\u53d7\u5169\u5074\u814e\u4e0a\u975c\u8108\u53d6\u6a23\u6aa2\u67e5(selective adrenal vein sampling, AVS)\nE. \u505aAVS\u6aa2\u67e5\u6642\uff0c\u55ae\u5074\u814e\u4e0a\u817a\u975c\u8108\u7684aldosterone/cortisol\u6bd4\u503c\u81f3\u5c11\u9700\u70ba\u5c0d\u5074\u76844\u500d\u4ee5\u4e0a\u624d\u80fd\u505a\u70ba\u8a3a\u65b7\u8a72\u5074\u816b\u7624\u7684\u4f9d\u64da\n": "(B)", "107-7.\n\u4e00\u4f4d32\u6b72\u672a\u5a5a\u5973\u6027\u4e3b\u8a34\u6700\u8fd14\u500b\u6708\u6c92\u6709\u6708\u7d93\uff0c\u5979\u6c92\u6709\u6027\u884c\u70ba\u4e5f\u6c92\u6709\u670d\u7528\u4efb\u4f55\u85e5\u7269\u3002\u8eab\u9ad4\u8a3a\u5bdf\u9664\u4e86\u6709\u4e73\u6c41\u5206\u6ccc\u53ca\u7532\u72c0\u817a\u7565\u70ba\u816b\u5927\u5916\uff0c\u5176\u9918\u7686\u6b63\u5e38\u3002\u8377\u723e\u8499\u6aa2\u67e5\u986f\u793a\u6ccc\u4e73\u6fc0\u7d20(prolactin\uff0960 ng/mL; \u751f\u9577\u6fc0\u7d20\uff08growth hormone, GH\uff096 ng/mL; \u76ae\u8cea\u9187(cortisol) 8 am \u70ba16 \u03bcg/dL\u3001 4 pm\u70ba9 \u03bcg/dL\uff1b\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20\uff08ACTH\uff0946 pg/mL\uff1b\u6e38\u96e2\u578b\u7532\u72c0\u817a\u7d20 (fT4) 0.9 ng/dL\uff1b\u7532\u72c0\u817a\u523a\u6fc0\u7d20 (TSH) 0.6 \u03bcIU/mL\u3002\u4e0b\u5217\u54ea\u4e00\u9805\u6aa2\u67e5\u5c0d\u65bc\u8a3a\u65b7\u6216\u6cbb\u7642\u6700\u53ef\u80fd\u6709\u5e6b\u52a9?\r (\u53c3\u8003\u503c: Prolactin 1.9~25 ng/m\uff2c\uff1bGH < 8 ng/mL\uff1bcortisol 8 am 5~25 \u03bcg/dL\u30014 pm 2.5~12.5 \u03bcg/dL\uff1bACTH 7.4~57.3 pg/mL; fT4 0.89~1.76 ng/dL\uff1bTSH 0.4~4 \u03bcIU/mL)\nA. Insulin hypoglycemia test\nB. Oral glucose tolerance test\nC. TRH stimulation test\nD. Bromocriptine test\nE. ACTH stimulation test\n": "(D)", "107-8.\n\u4e00\u4f4d50\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u4f11\u514b\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u5979\u7684\u610f\u8b58\u4e0d\u6e05\uff0c\u8840\u58d3\u3001\u8840\u9209\u3001\u8840\u7cd6\u7686\u504f\u4f4e\u3002\u8377\u723e\u8499\u6aa2\u67e5\u5df2\u62bd\u8840\u9001\u6aa2\uff0c\u4f46\u5c1a\u7121\u5831\u544a\u3002\u6709\u95dc\u9451\u5225\u8a3a\u65b7\u4ee5\u53ca\u8655\u7f6e\u7684\u63cf\u8ff0\u54ea\u4e00\u9805\u6700\u6b63\u78ba?\nA. \u75c5\u4eba\u6709\u6708\u4eae\u81c9\u3001\u6c34\u725b\u80a9\u3001\u4e2d\u6a1e\u6027\u80a5\u80d6\uff0c\u5979\u6700\u53ef\u80fd\u7684\u6aa2\u67e5\u7d50\u679c\u70ba ACTH\u9ad8\u3001cortisol\u9ad8\nB. \u5148\u4ee55% G/W\u5efa\u7acb\u975c\u8108\u8f38\u6db2\uff0c\u7b49\u5019\u8377\u723e\u8499\u6aa2\u67e5\u5831\u544a\u5f8c\u518d\u9032\u4e00\u6b65\u6cbb\u7642\nC. \u4ee53% Nacl \u6821\u6b63\u5176\u4f4e\u8840\u9209\nD. \u75c5\u4eba\u5916\u8868\u70ba\u9ed1\u4e7e\u7626\uff0c\u61c9\u8a72\u5b89\u6392\u8166\u4e0b\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5\nE. \u75c5\u4eba\u4e73\u6688\u984f\u8272\u6de1\u3001\u7121\u814b\u6bdb\uff0c\u5979\u6700\u53ef\u80fd\u7684\u6aa2\u67e5\u7d50\u679c\u70ba ACTH\u4f4e\u3001cortisol\u4f4e\n": "(E)", "107-9.\n\u4e0b\u5217\u6709\u95dc\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba?\nA. \u7f79\u60a3\u5eab\u6b23\u6c0f\u75c7(Cushing's disease)\u7684\u7537\u5973\u6bd4\u4f8b\u7d04\u70ba1:1; \u800c\u7f79\u60a3\u7570\u4f4d\u6027\u4fc3\u814e\u4e0a\u817a\u76ae\u8cea\u7d20\u75c7\u4faf\u7fa4(ectopic ACTH syndrome)\u7684\u7537\u5973\u6bd4\u7d04\u70ba4:1\nB. \u5c0d\u65bc\u5916\u8868\u6709\u6708\u4eae\u81c9\u3001\u6c34\u725b\u80a9\u3001\u7d2b\u8272\u82b1\u7d0b\u7b49\u7279\u5fb5\u7684\u75c5\u4eba\uff0c\u5982\u679c\u517624\u5c0f\u6642\u5c3f\u6db2\u4e2d\u7684free cortisol \u70ba\u53c3\u8003\u503c\u76841.5\u500d\uff0c\u5c31\u53ef\u4ee5\u78ba\u8a8d\u6b64\u75c5\u4eba\u6709\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\nC. \u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u75c5\u56e0\u7684\u9451\u5225\u8a3a\u65b7\u6d41\u7a0b\u4e2d\uff0c\u5982\u679c\u8840\u6e05\u4e2d\u7684ACTH\u6fc3\u5ea6<5 pg/mL\u5247\u61c9\u8a72\u9032\u4e00\u6b65\u5b89\u6392\u76ae\u8cea\u91cb\u7d20\u8a66\u9a57(corticotropin-releasing hormone (CRH) test)\nD. \u4e0b\u5ca9\u6a23\u7ac7\u63a1\u6a23(inferior petrosal sinus sampling)\u53ef\u4ee5\u5e6b\u52a9\u5206\u8fa8\u662f\u5426\u70ba\u5eab\u6b23\u6c0f\u75c7(Cushing's disease)\uff0c\u4f46\u5c0d\u65bc\u8166\u4e0b\u5782\u9ad4\u816b\u7624\u7684\u5b9a\u4f4d(lateralization)\u5247\u4e0d\u4e00\u5b9a\u53ef\u9760\nE. \u6cbb\u7642\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u7684\u85e5\u7269\uff0cmetyrapone \u7684\u4f5c\u7528\u6a5f\u8f49\u70ba\u6291\u5236cortisol\u8207\u5176\u63a5\u53d7\u5668\u7684\u7d50\u5408\uff0c\u800cketoconazole \u5247\u6703\u6291\u5236cortisol \u7684\u5408\u6210\n": "(D)", "107-10.\n\u4e00\u4f4d54\u6b72\u7532\u72c0\u817a\u4e73\u7a81\u764c\u7537\u6027\u75c5\u4eba\uff0c\u7d93\u904e\u96d9\u8449\u5168\u7532\u72c0\u817a\u5207\u9664(bilateral total thyroidectomy)\u53ca\u591a\u6b21\u653e\u5c04\u6027\u7898 (I-131\uff0c\u7e3d\u91cf\u70ba 600 mCi)\u6cbb\u7642\uff0c\u6bcf\u65e5\u88dc\u5145100 \u03bcg levothyroxine sodium\uff0c\u5176\u7532\u72c0\u817a\u529f\u80fd\u70ba fT4 1.0 dL (\u53c3\u8003\u503c 0.89~1.76 ng/dL)\u3001 TSH 0.1 \u03bcIU/mL (\u53c3\u8003\u503c 0.4~4 \u03bcIU/mL)\uff0c\u8840\u6e05thyroglobulin 50 ng/mL (\u6b63\u5e38\u53c3\u8003\u503c < 55 ng/mL)\uff0canti-thyroglobulin antibody 156.7 IU/mL (\u53c3\u8003\u503c <14.4 IU/mL)\u3002\u75c5\u4eba\u6c92\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\uff0c\u4e5f\u6c92\u6709\u4efb\u4f55\u4e0d\u9069\uff0c\u75c5\u4eba\u6700\u8fd1\u4e00\u6b21\u4ee5 I-131 150 mCi\u6cbb\u7642\u5f8c\u7684\u6383\u63cf\u6c92\u6709\u986f\u793a\u6709\u4efb\u4f55uptake\u3002\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6558\u8ff0\u6b63\u78ba?\nA. \u75c5\u4eba\u6709\u81e8\u5e8a\u524d\u671f\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032(subclinical hyperthyroidism)\uff0c\u61c9\u8a72\u7acb\u5373\u505c\u7528\u7532\u72c0\u817a\u7d20\u3002\nB. \u75c5\u4eba\u7684anti-thyroglobulin antibody \u8f03\u53c3\u8003\u503c\u9ad8\uff0c\u53ef\u4ee5\u589e\u52a0thyroglobulin \u7576\u4f5ctumor marker\u7684\u81e8\u5e8a\u6307\u6a19\u610f\u7fa9\nC. \u61c9\u8a72\u5b89\u6392\u6b63\u5b50\u6383\u63cf\u6aa2\u67e5 (positron emission tomography, PET)\nD. \u518d\u5b89\u6392\u4e00\u6b21\u9ad8\u5291\u91cf\u7684 I-131 \u6cbb\u7642\nE. \u7acb\u5373\u4f7f\u7528\u6a19\u9776\u6cbb\u7642\n": "(C)", "107-1.\n\u9673\u5c0f\u59d0\uff0c36\u6b72 \uff0c\u8eab\u9ad8160\u516c\u5206\uff0c\u9ad4\u91cd73\u516c\u65a4\uff0c\u6700\u8fd1\u5169\u5e74\uff0c\u9ad4\u91cd\u81ea58\u516c\u65a4\u589e\u52a0\u81f3\u76ee\u524d\u4e4b\u9ad4\u91cd\u3002\u7121\u500b\u4eba\u6216\u5bb6\u65cf\u4e4b\u7cd6\u5c3f\u75c5\u53f2\u3002\u6700\u8fd1\u5169\u5e74\uff0c\u6578\u6b21\u5728\u5bb6\u4e2d\u6216\u5de5\u4f5c\u5834\u6240\uff0c\u56e0\u660f\u5012\u610f\u8b58\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u66fe\u65bc\u6025\u8a3a\u767c\u73fe\u8840\u7cd6\u503c\u70ba32mg/dL\uff0c\u5728\u6ce8\u5c0450%\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58\u3002\u4e4b\u5f8c\uff0c\u66fe\u65bc\u795e\u7d93\u5167\u79d1\u53ca\u5bb6\u5ead\u91ab\u5b78\u79d1\u5c31\u91ab\u8907\u67e5\uff0c\u4e26\u672a\u767c\u73fe\u795e\u7d93\u5b78\u7570\u5e38\u6216\u7cd6\u5c3f\u75c5\u3002\u672c\u6b21\u518d\u5ea6\u56e0\u610f\u8b58\u72c0\u614b\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u6025\u8a3a\u8840\u7cd6\u503c\u70ba28 mg/dL\uff0c\u6ce8\u5c04\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58\uff0c\u6e05\u9192\u5f8c\uff0c\u5728\u6025\u8a3a\u4ea6\u7121\u795e\u7d93\u5b78\u7570\u5e38\u75c7\u72c0\uff0c\u56e0\u6b64\u5efa\u8b70\u4f4f\u9662\u9032\u4e00\u6b65\u8ffd\u67e5\u539f\u56e0\u3002\u5728\u75c5\u623f\u4f4f\u9662\u6642\uff0c\u7a7a\u81798\u5c0f\u6642\uff0c\u4e26\u7121\u8f38\u6db2\u4e0b\uff0c\u7a7a\u8179\u8840\u7cd6\u70ba86mg/dL\uff0cACTH 36.5pg/mL,\rCortisol 16.8 ug/dL, Insulin 1.6 mIU/mL, C-peptide 2.2 ng/mL, TSH 1.62 mIU/mL\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u61c9\u8a72\u5efa\u8b70\u90a3\u4e00\u9805\u6aa2\u67e5?\nA. 75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57\nB. Overnight 1mg Dexamathasone suppression\u6e2c\u8a66\nC. \u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (Pituitary MRI)\nD. 72 \u5c0f\u6642\u4e4b Prolonged fasting test\nE. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(D)", "107-2.\n\u5728\u53f0\u7063\uff0c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u773e\u591a\uff0c\u9664\u4e86\u751f\u6d3b\u578b\u614b\u3001\u98f2\u98df\u53ca\u904b\u52d5\u4f86\u9810\u9632\u4e4b\u5916\uff0c\u4e00\u65e6\u78ba\u8a3a\u70ba\u7cd6\u5c3f\u75c5\u4e4b\u5f8c\uff0c\u85e5\u7269\u6cbb\u7642\u4e5f\u662f\u975e\u5e38\u91cd\u8981\u7684\u4e00\u74b0\u3002\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u4e4b\u6558\u8ff0\uff0c\u90a3\u4e00\u4e9b\u662f\u932f\u8aa4\u7684\uff1f(1). Biguanide\u4e4bMetformin\u662f\u7cd6\u5c3f\u75c5\u6cbb\u7642\u539f\u5247\u7684\u7b2c\u4e00\u7dda\u7528\u85e5\uff0c\u4f46\u662f\u82f1\u570b\u4e4b\u6cbb\u7642\u6307\u5f15\u5efa\u8b70\uff0c\u7576eGFR < 45 \u6642\uff0c\u5373\u4e0d\u61c9\u4f7f\u7528Metformin (2). \u76ee\u524d\u570b\u5167\u53ca\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70\uff0cHbA1c (\u7cd6\u5316\u8840\u7d05\u7d20)\u4e4b\u63a7\u5236\u76ee\u6a19\u70ba 7% \u4ee5\u4e0b (3). Sulphonylurea\u985e\u85e5\u7269\uff0c\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\u53ca\u9ad4\u91cd\u4e0a\u5347 (4). \u80f0\u5cf6\u7d20\u96d6\u7136\u53ef\u4ee5\u8fc5\u901f\u964d\u4f4e\u8840\u7cd6\uff0c\u4f46\u9577\u671f\u4f7f\u7528\u6642\uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u4e4b\u85e5\u7269\u526f\u4f5c\u7528 (5). \u65b0\u578b\u4e4b\u7cd6\u5c3f\u75c5\u53e3\u670d\u85e5\u7269\uff0c\u5982DPP-4\rinhibitor\u53caSGLT-2 inhibitor\uff0c\u4e0d\u4f46\u53ef\u4ee5\u964d\u4f4e\u8840\u7cd6\uff0c\u4e5f\u90fd\u6709\u6e1b\u8f15\u7cd6\u5c3f\u75c5\u60a3\u9ad4\u91cd\u7684\u6548\u679c\nA. (1)+(3)\nB. (3)+(5)\nC. (2)+(5)\nD. (1)+(5)\nE. (3)+(4)\n": "(D)", "107-3.\n\u80f0\u5cf6\u7d20\u662f\u6cbb\u7642\u7cd6\u5c3f\u75c5\uff0c\u63a7\u5236\u8840\u7cd6\u7684\u91cd\u8981\u91dd\u5291\u85e5\u7269\uff0c\u4ee5\u4e0b\u6709\u95dc\u80f0\u5cf6\u7d20\u6cbb\u7642\u7684\u8aaa\u660e\u53ca\u5176\u751f\u7406\u6a5f\u8f49\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684?\nA. \u8eab\u9ad4\u80f0\u81df\u5206\u6ccc\u4e4b\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\uff0c\u76f4\u63a5\u5206\u6ccc\u9032\u5165\u9580\u975c\u8108\u7cfb\u7d71\uff0c\u4f46\u662f\u6ce8\u5c04\u578b\u4e4b\u5916\u6e90\u6027\u80f0\u5cf6\u7d20\uff0c\u5247\u5728\u6ce8\u5c04\u5f8c\u9032\u5165\u5168\u8eab\u7cfb\u7d71\u5faa\u74b0\uff0c\u56e0\u6b64\u6ce8\u5c04\u4e4b\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u6642\uff0c\u8f03\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u7684\u6fc3\u5ea6\u70ba\u4f4e\uff0c\u5c6c\u65bcsubphysiologic insulin level\u3002\nB. \u5c31\u7cd6\u5c3f\u75c5\u63a7\u5236\u8840\u7cd6\u800c\u8a00\uff0c\u6bd4\u8f03\u7b26\u5408\u4eba\u9ad4\u751f\u7406\u6027\u9700\u6c42\u7684\u80f0\u5cf6\u7d20\u6ce8\u5c04\u65b9\u5f0f\u662f\u4e00\u5929\u4e00\u6b21\u7684\u57fa\u790e\u80f0\u5cf6\u7d20(basal insulin)\nC. \u5982\u679c\u9700\u8981\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u6642\uff0c\u591a\u6b21\u80f0\u5cf6\u7d20\u6ce8\u5c04\uff0c\u662f\u9054\u6210\u63a7\u5236\u6a19\u7684\u7684\u91cd\u8981\u65b9\u6cd5\uff0c\u4f46\u662f\u9700\u8981\u914d\u5408\u66f4\u983b\u7e41\u4e4b\u81ea\u6211\u8840\u7cd6\u76e3\u6e2c\nD. \u5c31\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u4e4b\u60a3\u8005\u800c\u8a00\uff0c\u6bcf\u5929\u9700\u8981\u4e4b\u80f0\u5cf6\u7d20\u6ce8\u5c04\u7e3d\u91cf\u5927\u7d04\u5728 0.5-1 \u55ae\u4f4d/\u6bcf\u516c\u65a4/\u6bcf\u5929\nE. \u7576\u4e00\u5929\u5167\u9700\u591a\u6b21\u6ce8\u5c04\u80f0\u5cf6\u7d20\u6642\uff0c\u80f0\u5cf6\u7d20\u7e3d\u5291\u91cf\u768450%\uff0c\u61c9\u4ee5\u57fa\u790e\u80f0\u5cf6\u7d20(basal insulin) \u7684\u65b9\u5f0f\u7d66\u85e5\n": "(B)", "107-4.\n\u6839\u64da\u4e16\u754c\u885b\u751f\u7d44\u7e54(WHO)\u53ca\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u81e8\u5e8a\u5efa\u8b70\uff0c\u7cd6\u5c3f\u75c5\u8a3a\u65b7\u4e4b\u6a19\u6e96\uff0c\u4ee5\u4e0b\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. \u7a7a\u8179\u8840\u7cd6\u5927\u65bc\u6216\u7b49\u65bc 126 mg/dL\nB. \u7cd6\u5316\u8840\u8272\u7d20\u503c\u5728NGSP (National Glycohemoglobin Standardization Program)\u6aa2\u6e2c\u6a19\u6e96\u4e0b\uff0c\u5927\u65bc\u6216\u7b49\u65bc6.5%\nC. \u7a7a\u8179\u8840\u7cd6\u4e4b\u57fa\u672c\u5b9a\u7fa9\u70ba\u81f3\u5c118\u5c0f\u6642\u672a\u9032\u98df\nD. \u96a8\u6a5f\u8840\u7cd6\u6aa2\u9a57 (random blood glucose)\u5927\u65bc\u6216\u7b49\u65bc140 mg/dL\uff0c\u540c\u6642\u4f75\u6709\u7cd6\u5c3f\u75c5\u4e4b\u5178\u578b\u75c7\u72c0\nE. \u53e3\u670d\u8461\u8404\u7cd6\u8a66\u9a57 (oral glucose tolerance test) \u4e4b\u5f8c\u7684\u5169\u5c0f\u6642\u8840\u7cd6\u5927\u65bc\u6216\u7b49\u65bc200 mg/dL\n": "(D)", "107-5.\n\u7d71\u8a08\u4e0a\u986f\u793a\u81f3\u5c117%\u4e4b\u61f7\u5b55\u5a66\u5973\u70ba\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\uff0c\u96d6\u7136\u7522\u5f8c\u5927\u591a\u6578\u4e4b\u5a66\u5973\uff0c\u8840\u7cd6\u90fd\u53ef\u4ee5\u6062\u5fa9\u5230\u6b63\u5e38\u7bc4\u570d\u4e4b\u5167\uff0c\u4f46\u4ecd\u670935-60%\u7684\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973\uff0c\u572810\u81f320\u5e74\u671f\u9593\u4ecd\u6703\u9032\u5c55\u70ba\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5\u60a3\u3002\u4ee5\u4e0b\u6709\u95dc\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u4e4b\u76f8\u95dc\u6558\u8ff0\uff0c\u90a3\u4e00\u4e9b\u662f\u932f\u8aa4\u7684\uff1f (1). \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u589e\u52a0\u7684\u8da8\u52e2\uff0c\u8207\u5a66\u5973\u80a5\u80d6\u7387\u7684\u589e\u52a0\uff0c\u5bc6\u5207\u76f8\u95dc (2). \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u7684\u8868\u73fe\uff0c\u4e3b\u8981\u8207\u60a3\u8005\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e0d\u8db3\u76f8\u95dc (3). \u5728\u61f7\u5b55\u671f\u9593\uff0c\u521d\u6b21\u767c\u73fe\u4e4b\u8840\u7cd6\u7570\u5e38\uff0c\u5982\u679c\u7b26\u5408\u7cd6\u5c3f\u75c5\u4e4b\u8a3a\u65b7\uff0c\u61c9\u6b78\u985e\u65bc\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5 (overt diabetes) (4). \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5728\u61f7\u5b55\u4e4b\u5f8c\u671f\u5b55\u671f\u6642 (late\rpregnancy)\uff0c\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u6703\u660e\u986f\u964d\u4f4e\uff0c\u8840\u7cd6\u6bd4\u8f03\u5bb9\u6613\u63a7\u5236\u3002\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (1)+(4)\nE. (2)+(4)\n": "(E)", "107-6.\n\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u6839\u6e90\u5728\u65bc\u8102\u86cb\u767d (lipoprotein)\u7684\u4ee3\u8b1d\u7570\u5e38\uff0c\u4e00\u822c\u5e38\u898b\u7684\u75be\u75c5\u72c0\u614b\u8207\u81bd\u56fa\u9187/\u4e09\u9178\u7518\u6cb9\u916f(TG)\u589e\u52a0\uff0c\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d (HDL)\u6e1b\u5c11\u76f8\u95dc\uff0c\u4ee5\u4e0b\u6709\u95dc\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u72c0\u614b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. \u5927\u591a\u6578\u75c5\u60a3\u7f79\u75c5\u6642\u7684\u8840\u8102\u7570\u5e38\uff0c\u540c\u6642\u53d7\u5230\u907a\u50b3\u56e0\u5b50(genetic predisposition)\u53ca\u74b0\u5883\u56e0\u7d20(environmental contribution)\u7684\u5f71\u97ff\nB. \u8840\u8102\u7570\u5e38\u6642\uff0c\u4f4e\u5bc6\u5ea6\u53ca\u6975\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d(LDL & VLDL)\u7684\u589e\u52a0\u662f\u91cd\u8981\u7684\u81f4\u75c5\u56e0\u5b50\uff0c\u591a\u6578\u8207\u80a5\u80d6\u3001\u80f0\u5cf6\u7d20\u963b\u6297\u53ca\u907a\u50b3\u76f8\u95dc\nC. \u9577\u671f\u651d\u53d6\u9ad8\u71b1\u91cf\u7684\u91a3\u985e\u98df\u7269\u53ca\u6301\u7e8c\u7684\u98f2\u9152\uff0c\u5176\u8840\u8102\u7570\u5e38\u53ef\u767c\u73fe\u589e\u52a0VLDL\u53caTG\uff0c\u4e26\u964d\u4f4eHDL\u4e4b\u8840\u4e2d\u6fc3\u5ea6\nD. \u80a5\u80d6\u53ca\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u589e\u52a0\u6642\uff0c\u8840\u8102\u7570\u5e38\u7684\u8868\u73fe\u7d93\u5e38\u662fTG\u589e\u52a0\uff0c\u4f46\u662fHDL \u964d\u4f4e\nE. \u5167\u5206\u6ccc\u7532\u72c0\u817a\u6a5f\u80fd\u4e0d\u8db3 (Hypothyroidism) \u7d93\u5e38\u5c0e\u81f4LDL\u589e\u52a0\uff0c\u56e0\u70ba\u7532\u72c0\u817a\u7d20\u53ef\u589e\u52a0\u809d\u81df\u4e4bLDL\u53d7\u5668\uff0c\u964d\u4f4e\u8840\u4e2d\u4e4bLDL\uff0c\u4f46\u7532\u72c0\u817a\u7d20\u4e0d\u8db3\u6642\uff0c\u8840\u4e2d\u4e4bLDL\u4e4b\u6e05\u9664\u6548\u7387\u4e5f\u6703\u660e\u986f\u4e0b\u964d\n": "(C)", "107-7.\n\u9673\u5148\u751f\uff0c72\u6b72\uff0c\u7cd6\u5c3f\u75c5\u53f220\u5e74\uff0c\u76ee\u524d\u63a5\u53d7\u53e3\u670d\u7cd6\u5c3f\u75c5\u85e5\u7269\u53ca\u57fa\u790e\u80f0\u5cf6\u7d20\u6cbb\u7642\uff0c\u6700\u8fd1\u4e00\u6b21\u4e4bHbA1c\u70ba7.5%\uff0c\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u4e4b\u65e9\u6668\u7a7a\u8179\u8840\u7cd6\u5728140-160 mg/dL\u5de6\u53f3\u3002\u75c5\u60a3\u4e5f\u56e0\u5fc3\u81df\u8870\u7aed\u75c5\u53f2\u65bc\u5fc3\u81df\u5167\u79d1\u898f\u5f8b\u6cbb\u7642\u3002\u672c\u6b21\u56e0\u547c\u5438\u5598\u53ca\u4e0b\u80a2\u6c34\u816b\uff0c\u81f3\u6025\u8a3a\u5c31\u91ab\u3002\u6025\u8a3a\u4e4b\u96a8\u6a5f\u8840\u7cd6\u70ba226 mg/dL\uff0c\u9209\u96e2\u5b50\u70ba146mEq/dL\uff0c\u9240\u96e2\u5b50\u70ba3.2 mEq/dL\uff0c\u808c\u9178\u9150\u70ba1.8 mg/dL\uff0c\u8840\u58d3\u70ba98/62 mmHg\uff0c\u8108\u640f\u70ba108 bpm\u3002\u5728\u8003\u91cf\u672c\u75c5\u60a3\u4e4b\u60c5\u6cc1\u4e0b\uff0c\u8003\u616e\u8f38\u6db2\u53ca\u76e3\u8996\u5c3f\u6392\u51fa\u91cf (urine output)\uff0c\u8acb\u554f\u4e0b\u5217\u4e4b\u8f38\u6db2\uff0c\u4f55\u8005\u70ba\u6700\u662f\u7576\u4e4b\u9078\u9805?\nA. Lactate Ringer solution\nB. 0.45% Half Saline solution\nC. 0.9% Normal Saline solution\nD. 5% Dextrose solution plus regular insulin with intravenous infusion\nE. Lactate Ringer solution plus regular insulin with intravenous infusion\n": "(C)", "107-8.\n\u5c31\u7cd6\u5c3f\u75c5\u4e4b\u8840\u7cd6\u63a7\u5236\u800c\u8a00\uff0c\u80f0\u5cf6\u7d20\u963b\u6297 (insulin resistance)\u662f\u91cd\u8981\u7684\u81f4\u75c5\u6a5f\u8f49\uff0cThiazolidinedione (TZD)\u662f\u589e\u52a0\u80f0\u5cf6\u7d20\u654f\u611f\u5ea6\u7684\u91cd\u8981\u85e5\u7269\uff0c\u4f46\u662f\u85e5\u7269\u5fc5\u9808\u7559\u610f\u5176\u526f\u4f5c\u7528\uff0c\u76ee\u524d\u570b\u5167TZD\u985e\u85e5\u7269\uff0c\u50c5\u6709pioglitazone\uff0c\u4e0b\u5217\u4e4b\u9078\u9805\u4e2d\uff0c\u90a3\u4e9b\u662f\u5fc5\u9808\u7559\u610f\u7684\u85e5\u7269\u526f\u4f5c\u7528\uff1f (1). \u9aa8\u8cea\u758f\u9b06 (2). \u6c34\u816b (3). \u9ad4\u91cd\u589e\u52a0 (4). \u5c3f\u9053\u611f\u67d3 (5). \u8166\u4e2d\u98a8\nA. (1)+(3)+(5)\nB. (2)+(3)+(4)\nC. (1)+(4)+(5)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)\n": "(E)", "107-9.\n\u7cd6\u5c3f\u75c5\u6cbb\u7642\u4e2d\uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u7684\u4f75\u767c\u75c7\u4e4b\u4e00\uff0c\u9810\u9632\u53ca\u6cbb\u7642\u7cd6\u5c3f\u75c5\u7684\u4f75\u767c\u75c7\uff0c\u662f\u4e00\u822c\u91ab\u5b78\u4e2d\u7684\u91cd\u8981\u8ab2\u984c\uff0c\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u4f4e\u8840\u7cd6\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6709\u8aa4?\nA. \u4e00\u822c\u7d71\u8a08\u4e0a\uff0c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u7684\u4f4e\u8840\u7cd6\u767c\u751f\u7387\u4f4e\u65bc\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\nB. \u904e\u53bb\u7684\u7814\u7a76\u986f\u793a6-10%\u7684\u7684\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u7684\u6b7b\u4ea1\u539f\u56e0\u662f\u4f4e\u8840\u7cd6\nC. \u96d6\u7136sulphonylurea\u53cainsulin\u985e\u7684\u85e5\u7269\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\uff0c\u4f46\u662f\u7576\u4e0a\u8ff0\u5169\u985e\u85e5\u7269\u5408\u4f75\u65b0\u578b\u85e5\u7269\uff0c\u5982\u53e3\u670d\u4e4bDPP-4 inhibitor \u6216 \u6ce8\u5c04\u4e4bGLP-1 receptor agonist\u85e5\u7269\u6642\uff0c\u53ef\u4ee5\u6709\u6548\u7684\u964d\u4f4e\u4f4e\u8840\u7cd6\u7684\u767c\u751f\nD. \u6839\u64daACCORD\u53caADVANCE\u7684\u7814\u7a76\u767c\u73fe\uff0c\u4f7f\u7528\u85e5\u7269\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u662f\u9020\u6210\u4f4e\u8840\u7cd6\u767c\u751f\u7684\u91cd\u8981\u539f\u56e0\u4e4b\u4e00\nE. \u7d71\u8a08\u4e0a\uff0c\u7576\u75c5\u60a3\u4f7f\u7528\u4e00\u5929\u4e00\u6b21\u4e4b\u57fa\u790e\u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\u6642\uff0c\u767c\u751f\u4f4e\u8840\u7cd6\u4e4b\u6a5f\u6703\uff0c\u4f4e\u65bc\u4e00\u5929\u9700\u591a\u6b21\u6ce8\u5c04\u9910\u524d\u80f0\u5cf6\u7d20\u4f86\u63a7\u5236\u8840\u7cd6\u7684\u75c5\u4eba\n": "(C)", "107-10.\n\u674e\u5973\u58eb\uff0c62\u6b72\uff0c\u53ef\u81ea\u7531\u6d3b\u52d5\uff0c\u8207\u5bb6\u4eba\u540c\u4f4f\uff0c\u6578\u6b21\u56e0\u80ba\u708e\u6216\u6ccc\u5c3f\u9053\u611f\u67d3\u4f4f\u9662\u6cbb\u7642\uff0c\u8840\u7cd6\u7570\u5e38\u75c5\u53f22\u5e74\u3002\u76ee\u524d\u4e26\u672a\u63a5\u53d7\u53e3\u670d\u85e5\u7269\u63a7\u5236\u8840\u7cd6\u3002\u672c\u6b21\u56e0\u80ba\u708e\u4f4f\u9662\uff0c\u6297\u751f\u7d20\u4f7f\u75285\u5929\u5f8c\uff0c\u8a55\u4f30\u60c5\u6cc1\u7a69\u5b9a\uff0c\u9810\u8a082\u5929\u5f8c\u51fa\u9662\u3002\u76ee\u524d\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a\uff0c\u5165\u9662\u96a8\u6a5f\u4e4bHbA1c \u70ba8.2 %\uff0c\u4f4f\u9662\u4e4b\u7b2c\u4e94\u5929\u6668\u9593\u7a7a\u8179\u8840\u7cd6\u70ba168 mg/dL\uff0c\u7576\u65e5\u65e9\u9910\u5f8c\u5169\u5c0f\u6642\u62bd\u8840\u6aa2\u67e5\u4e4b\u8840\u7cd6\u70ba223 mg/dL\uff0c\u808c\u9178\u9150\u70ba 0.6 mg/dL\u3002\u96d6\u7136\u76ee\u524d\u7121\u660e\u986f\u7cd6\u5c3f\u75c5\u75c7\u72c0\uff0c\u4f46\u4ecd\u61c9\u591a\u52a0\u6ce8\u610f\u75c5\u7a0b\u767c\u5c55\u3002\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u5b89\u6392\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u61c9\u5efa\u8b70\u5728\u51fa\u9662\u75c5\u6cc1\u7a69\u5b9a\u4e4b\u5f8c\uff0c\u7d66\u4e88Metformin\u85e5\u7269\u6cbb\u7642\nB. \u5efa\u8b70\u5118\u65e9\u5b89\u6392\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u53ca\u8db3\u90e8\u795e\u7d93\u5b78\u6aa2\u67e5\nC. \u5efa\u8b70\u5b89\u6392\u53e3\u670d\u8461\u8404\u7cd6\u6e2c\u8a66 (OGTT)\u9032\u4e00\u6b65\u78ba\u8a3a\u5176\u7cd6\u5c3f\u75c5\nD. \u5efa\u8b70\u61c9\u5b89\u6392\u7cd6\u5c3f\u75c5\u98f2\u98df\u53ca\u904b\u52d5\u885b\u6559\nE. \u5efa\u8b70\u75c5\u60a3\u53ef\u65bc\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u8840\u7cd6 (Self Monitoring of Blood Glucose)\n": "(C)", "108-1.\n\u4ee5Amiodarone\u6cbb\u7642\u5fc3\u5f8b\u4e0d\u6574\u53ef\u80fd\u5f71\u97ff\u7532\u72c0\u817a\u529f\u80fd\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba? (1)\u56e0\u70ba\u4f7f\u7528amiodarone\u800c\u4e0a\u5347\u7684\u7898\u542b\u91cf\uff0c\u5728\u505c\u7528amiodarone\u5169\u9031\u5f8c\u53ef\u4ee5\u4e0b\u964d\u81f3\u6b63\u5e38 (2)\u4f7f\u7528\u6bcf\u5929\u4e00\u6b21 200 mg amiodarone\u5c31\u53ef\u80fd\u4f7f\u8840\u7898\u53ca\u5c3f\u7898\u4e0a\u534740\u500d (3)\u8207\u7898\u7f3a\u4e4f\u5730\u5340\u6bd4\u8f03\uff0c\u7898\u5145\u8db3\u5730\u5340\u56e0\u70ba\u4f7f\u7528amiodarone \u800c\u9020\u6210\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b(hypothyroidism)\u7684\u767c\u751f\u7387\u6bd4\u8f03\u9ad8 (4)\u4f7f\u7528 amiodarone \u5f8c\u9020\u6210\u7684\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032 ( amiodarone-induced thyrotoxicosis (AIT) )\u7b2c\u4e8c\u578b\u5176\u767c\u751f\u7387\u8207amidarone \u7684\u7d2f\u7a4d\u5291\u91cf\u7121\u95dc (5)\u4f7f\u7528amiodarone\u9020\u6210\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\uff0c\u4e0d\u9700\u8981\u505c\u7528amiodarone\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (2)+(3)+(5)\nD. (1)+(2)+(4)\nE. (1)+(3)+(5)\n": "(C)", "108-2.\n\u4e00\u4f4d28\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u5df2\u61f7\u5b558\u9031\uff0c\u6709\u5fc3\u60b8\u3001\u6015\u71b1\u3001\u9ad4\u91cd\u4e0b\u964d\u7b49\u75c7\u72c0\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u986f\u793a\u6709\u51f8\u773c\u3001\u7532\u72c0\u817a\u7030\u6f2b\u6027\u816b\u5927\uff0c\u62bd\u8840\u6aa2\u67e5\u986f\u793a free thyroxine (fT4) 2.92 ng/ dL\u3001thyroid stimulating hormone (TSH) <0.001 \u03bcIU/mL (\u53c3\u8003\u503c: fT4 0.70~1.48 ng/dL\u3001hsTSH 0.35~4.94 \u03bcIU/mL)\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u9078\u64c7\u6700\u6b63\u78ba? (1)\u61f7\u5b55\u524d\u671f\u4f7f\u7528methimazole \u6216carbimazole\u53ef\u80fd\u5f71\u97ff\u80da\u80ce\u767c\u80b2\uff0c\u56e0\u6b64\u6700\u597d\u9078\u64c7\u4f7f\u7528 propylthiouracil \u6cbb\u7642 (2)propylthiouracil \u53ef\u80fd\u6709\u809d\u6bd2\u6027\uff0c\u56e0\u6b64\u61f7\u5b55\u4e2d\u671f\u4ee5\u5f8c\u82e5\u4ecd\u9700\u8981\u6297\u7532\u72c0\u817a\u85e5\u7269\uff0c\u6700\u597d\u6539\u7528methimazole \u6216 carbimazole (3)\u6297\u7532\u72c0\u817a\u85e5\u7269\u4e0d\u6703\u7a7f\u900f\u80ce\u76e4\u5f71\u97ff\u80ce\u5152\r(4)\u6388\u4e73\u671f\u7981\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269\u4ee5\u514d\u5f71\u97ff\u5b30\u5152 (5)\u70ba\u907f\u514d\u6297\u7532\u72c0\u817a\u85e5\u7269\u4e4b\u526f\u4f5c\u7528\uff0c\u5efa\u8b70\u5b89\u6392\u7532\u72c0\u817a\u5207\u9664\u624b\u8853\nA. (1)+(2)\nB. (3)+(4)\nC. (2)+(3)+(4)\nD. (1)+(2)+(5)\nE. (1)+(3)+(5)\n": "(A)", "108-3.\n\u85e5\u7269\u53ef\u80fd\u5f71\u97ffrenin\u3001aldosterone\u7684\u5b9a\u91cf\u4ee5\u53caAldosterone-renin ratio (ARR)\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba?? (1)\u03b2-blocker \u53ef\u80fd\u4f7f renin \u4e0b\u964d\u3001aldosterone \u4e0a\u5347\u3001ARR\u4e0a\u5347 (2)\u03b1-blocker \u4e0d\u6703\u5f71\u97ff renin\u3001aldosterone\u3001ARR (3)Angiotensin-converting enzyme inhibitors (ACEI) \u53ef\u80fd\u4f7f renin \u4e0b\u964d\u3001aldosterone \u4e0a\u5347\u3001ARR\u4e0a\u5347 (4)Calcium antagonists\u61c9\u8a72\u5148\u505c\u7528\u4e00\u9031\uff0c\u4ee5\u907f\u514d\u5f71\u97ffrenin\u3001aldosterone\u7684\u5b9a\u91cf (5)Saline infusion test\u6642\uff0c\u5982\u679c aldosterone \u70ba10 ng/dL\uff0c\u53ef\u4ee5\u6392\u9664\u539f\u767c\u6027\u9ad8\u919b\u56fa\u916e\u75c7 (primary aldosteronism)\nA. (1)+(3)+(5)\nB. (2)+(4)\nC. (1)+(2)\nD. (3)+(5)\nE. (1)+(2)+(4)\n": "(C)", "108-4.\n\u4e00\u4f4d58\u6b72\u7537\u6027\u75c5\u4eba\u6709\u9ad4\u91cd\u4e0b\u964d\u3001\u5026\u6020\u3001\u59ff\u614b\u6027\u4f4e\u8840\u58d3\u7b49\u75c7\u72c0\uff0c\u4ed6\u7684\u8840\u9209\u662f125 mmol/L\uff0c\u8840\u7cd6\u662f60 mg/dL\uff0c\u61f7\u7591\u6709\u814e\u4e0a\u817a\u529f\u80fd\u4e0d\u5168\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba?\nA. \u5982\u679c\u75c5\u4eba\u5916\u8868\u9ed1\u3001\u4e7e\u3001\u7626\uff0c\u5247\u5176ACTH\u3001cortisol \u90fd\u61c9\u8a72\u6bd4\u6b63\u5e38\u503c\u4f4e\nB. \u5982\u679c\u75c5\u4eba\u7684\u4e73\u982d\u984f\u8272\u8f03\u6de1\uff0c\u61c9\u8a72\u540c\u6642\u4f7f\u7528glucocorticoid \u53ca mineralocorticoid \u6cbb\u7642\nC. \u5982\u679c\u75c5\u4eba\u6709\u6708\u4eae\u81c9\u3001\u4e2d\u6a1e\u6027\u80a5\u80d6\u3001\u7d2b\u6591\u3001\u8179\u90e8\u7d2b\u8272\u6591\u7d0b\u7b49\u5916\u8868\u7279\u5fb5\uff0c\u5247\u5176ACTH\u3001cortisol \u90fd\u61c9\u8a72\u6bd4\u6b63\u5e38\u503c\u9ad8\nD. \u5982\u679c\u75c5\u4eba\u7684 fT4\u53caTSH\u90fd\u504f\u4f4e\uff0c\u61c9\u8a72\u512a\u5148\u4f7f\u7528\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nE. \u4e0d\u7ba1\u662f\u539f\u767c\u6027\u6216\u6b21\u767c\u6027\u814e\u4e0a\u817a\u529f\u80fd\u4e0d\u5168\uff0c\u814e\u4e0a\u817a\u96c4\u6027\u7d20( adrenal androgen) \u7684\u5206\u6ccc\u90fd\u6709\u53ef\u80fd\u53d7\u5230\u5f71\u97ff\n": "(E)", "108-5.\n\u4e00\u4f4d38\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u9663\u767c\u6027\u9ad8\u8840\u58d3\u3001\u982d\u75db\u3001\u5fc3\u60b8\u4f86\u8a3a\uff0c\u61f7\u7591\u6709\u55dc\u927b\u7d30\u80de\u7624 (pheochromocytoma)\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u9069\u7576?\nA. \u56e0\u70ba\u8840\u58d3\u592a\u9ad8\uff0c\u4e0b\u80a2\u6709\u8f15\u5fae\u6c34\u816b\uff0c\u61c9\u8a72\u9650\u5236\u6c34\u5206\u651d\u53d6\nB. \u6aa2\u67e5\u5c3f\u6db2\u4e2d\u7684fractionated metanephrines \u53ca catecholamine \u5c0d\u65bc\u55dc\u927b\u7d30\u80de\u7624\u7684\u8a3a\u65b7\u6709\u6700\u9ad8\u7684\u7279\u7570\u6027( specificity)\nC. \u75c5\u4eba\u66fe\u7d93\u4f7f\u7528\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7269\u53ca\u5229\u5c3f\u5291\uff0c\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7269\u53ef\u80fd\u9020\u6210\u507d\u967d\u6027(false positive)\u7684catecholamine\u6aa2\u9a57\u7d50\u679c\uff0c\u4f46\u5229\u5c3f\u5291\u5247\u4e0d\u6703\u5f71\u97ff\u6aa2\u9a57\u7d50\u679c\nD. \u70ba\u6e1b\u5c11\u58d3\u529b\uff0c\u505a\u96fb\u8166\u65b7\u5c64\u6216\u6838\u78c1\u5171\u632f\u7b49\u5f71\u50cf\u5b78\u6aa2\u67e5\u6642\u61c9\u8a72\u907f\u514d\u4f7f\u7528\u986f\u5f71\u5291\nE. \u55dc\u927b\u7d30\u80de\u7624\u6216\u526f\u795e\u7d93\u7bc0\u7d30\u80de\u7624 ( paragangliomas) \u5927\u7d04\u67095-10% \u662f\u60e1\u6027\u7684\n": "(E)", "108-6.\n\u4e00\u4f4d50\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u6709\u80a2\u7aef\u80a5\u5927\u3001\u95dc\u7bc0\u708e\u3001\u7761\u7720\u547c\u5438\u4e2d\u6b62\u7b49\u75c7\u72c0\uff0c\u4ed6\u7684\u751f\u9577\u6fc0\u7d20\uff08Growth hormone, GH\uff09\u70ba10 ng/mL (\u53c3\u8003\u503c < 8 ng/mL)\u3001insulin-like growth factor-1 (IGF-1) \u70ba 300 ng/mL (\u53c3\u8003\u503c48.1~209 ng/mL)\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6b63\u78ba?\nA. \u9752\u6625\u671f\u6642IGF-1 \u7684\u53c3\u8003\u503c\u901a\u5e38\u8f03\u5e74\u7d00\u5927\u6642\u70ba\u9ad8\nB. \u55ae\u6b21\u96a8\u610f(single random) \u7684\u8840\u6e05GH\u503c\u8207\u80a2\u7aef\u80a5\u5927\u75c7\u75be\u75c5\u56b4\u91cd\u5ea6\u6709\u6b63\u76f8\u95dc\nC. \u7d66\u4e88\u53e3\u670d75\u516c\u514b\u8461\u8404\u7cd6\u5f8cGH\u7684\u6700\u4f4e\u503c\u70ba4 ng/mL\uff0c\u53ef\u4ee5\u6392\u9664\u80a2\u7aef\u80a5\u5927\u75c7\nD. \u751f\u9577\u6fc0\u7d20\u7624\u7684\u9996\u9078\u6cbb\u7642\u70ba\u624b\u8853\u5207\u9664\uff0c\u8853\u524d\u7981\u5fcc\u7d66\u4e88somatostatin analogues\nE. \u751f\u9577\u6fc0\u7d20\u7624\u7684\u653e\u5c04\u6027\u6cbb\u7642(radiotherapy)\uff0c\u901a\u5e38\u5728\u4e00\u5e74\u5de6\u53f3\u53ef\u4ee5\u770b\u5230\u751f\u5316\u6307\u6a19(biochemical parameter)\u6b63\u5e38\u5316\n": "(A)", "108-7.\n\u4e0b\u5217\u54ea\u4e00\u9805\u53ef\u80fd\u4f7f\u526f\u7532\u72c0\u817a\u8377\u723e\u8499\u6fc3\u5ea6(parathyroid hormone, PTH)\u4e0a\u5347?\nA. Calcium-sensing receptor (CaSR) agonists such as cinacalcet\nB. Vitamin D\nC. Fibroblast growth factor 23 (FGF23)\nD. Phosphates\nE. Severe intracellular magnesium deficiency\n": "(D)", "108-8.\n\u4e00\u4f4d25\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u70ba\u7b2c\u4e8c\u6027\u5fb5\u4e0d\u660e\u986f\u4f86\u6c42\u8a3a\uff0c\u7d93\u75c5\u53f2\u8a62\u554f\u53ca\u8eab\u9ad4\u8a3a\u5bdf\u5f8c\u78ba\u8a8d\u6709\u6027\u817a\u529f\u80fd\u4f4e\u4e0b(hypogonadism)\u3001\u55c5\u89ba\u7570\u5e38\u3001\u8272\u76f2\u3001\u984e\u88c2\uff0c\u8acb\u554f\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u6b63\u78ba?\nA. \u6b64\u75c5\u4eba\u4e4b\u776a\u4e38\u5c0f\u800c\u786c\nB. \u6b64\u75c5\u4eba\u4e4b\u6ffe\u6ce1\u523a\u6fc0\u7d20\uff08follicle-stimulating hormone, FSH\uff09\u53ca\u9ec3\u9ad4\u5316\u6fc0\u7d20 (luteinizing hormone, LH) \u8f03\u53c3\u8003\u503c\u9ad8\nC. \u6b64\u75c5\u4eba\u53ef\u80fd\u6709X-linked KAL gene \u7a81\u8b8a\nD. \u82e5\u6b64\u75c5\u4eba\u6025\u65bc\u7d50\u5a5a\u751f\u5b50\uff0c\u61c9\u8a72\u8d95\u5feb\u7d66\u4e88testosterone \u6cbb\u7642\nE. \u6838\u78c1\u5171\u632f\u6aa2\u67e5\u767c\u73fe\u6709\u8166\u4e0b\u5782\u9ad4\u5fae\u5c0f\u816b\u7624(microadenoma)\n": "(C)", "108-9.\n\u4e0b\u5217\u6709\u95dc\u6ccc\u4e73\u6fc0\u7d20\u7624(prolactinoma)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba\uff1f\nA. \u4e00\u516c\u5206\u4ee5\u4e0a\u7684prolactinoma,\u7537\u5973\u6bd4\u7d04\u70ba1:3\nB. \u5973\u6027\u75c5\u4eba\u6709prolactin microadenoma (< 1 cm) \u4f46\u7121\u75c7\u72c0\uff0c\u4e0d\u9808\u6cbb\u7642\uff0c\u8ffd\u8e64\u5373\u53ef\nC. \u8840\u6db2\u4e2d\u6ccc\u4e73\u6fc0\u7d20(Prolactin)\u6fc3\u5ea6\u8207\u816b\u7624\u5927\u5c0f\u7121\u95dc\nD. Prolactinoma\u75c5\u4eba\u5982\u679c\u4ee5dopamine agonists\u6cbb\u7642\uff0c\u6700\u597d\u7dad\u6301\u5176prolactin \u6fc3\u5ea6\u65bc\u53c3\u8003\u503c\u4e4b1\u81f31.5\u500d\nE. \u5973\u6027\u75c5\u4eba\u6709\u5c0f\u65bc1\u516c\u5206\u7684prolactinoma\uff0c\u5982\u679c\u4ee5dopamine agonists\u6cbb\u7642\u5f8c\u61f7\u5b55\uff0c\u4e0d\u53ef\u4ee5\u505c\u85e5\uff0c\u61c9\u8a72\u6301\u7e8c\u4f7f\u7528dopamine agonists\n": "(B)", "108-10.\n\u81ea\u9ad4\u514d\u75ab\u591a\u767c\u6027\u5167\u5206\u6ccc\u75c7\u5019\u7fa4\u7b2c\u4e00\u578b(Autoimmune Polyendocrine Syndromes type 1, APS-1) \u6709\u4e0b\u5217\u7279\u5fb5\uff0c\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba?\nA. Candidiasis\nB. \u7259\u91c9\u8cea\u589e\u751f (Hyperplasia of the dental enamel)\nC. Hypoparathyroidism\nD. Addison's disease\nE. \u70baAIRE gene \u7684\u9ad4\u67d3\u8272\u9ad4\u96b1\u6027\u7a81\u8b8a\n": "(B)", "108-1.\n\u7cd6\u5c3f\u75c5\u8207\u80a5\u80d6\u7d44\u6210\u7cd6\u80d6\u75c7(Diabesity)\uff0c\u5728\u65b0\u9673\u4ee3\u8b1d\u75be\u75c5\u7684\u7bc4\u7587\u5167\uff0c\u5f7c\u6b64\u5bc6\u5207\u76f8\u95dc\uff0c\u4e0b\u5217\u4e4b\u6709\u95dc\u6b64\u5169\u985e\u75be\u75c5\u6558\u8ff0\u4e2d\uff0c\u4f55\u8005\u6709\u8aa4?\nA. \u9577\u671f\u7684\u7814\u7a76\u4e2d\uff0c\u8a08\u756b\u6027\u98f2\u98df\u53ca\u898f\u5f8b\u4e4b\u8db3\u91cf\u904b\u52d5\uff0c\u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u4e4b\u6a5f\u7387\uff0c\u5176\u95dc\u9375\u6a5f\u8f49\u70ba\u63a7\u5236\u9ad4\u91cd\nB. \u904b\u52d5\u5c0d\u65bc\u9ad4\u91cd\u4e4b\u63a7\u5236\u975e\u5e38\u91cd\u8981\uff0c\u904b\u52d5\u5f37\u5ea6\u6108\u5f37\uff0c\u7814\u7a76\u4e4b\u8cc7\u6599\u986f\u793a\u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u7387\uff0c\u4e5f\u53ef\u4ee5\u964d\u4f4e\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u4e4b\u6b7b\u4ea1\u7387\nC. \u9664\u4e86\u8eab\u9ad4\u8cea\u91cf(body mass index, BMI)\u4e4b\u5916\uff0c\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u5bc6\u5207\u76f8\u95dc\u7684\u80a5\u80d6\u578b\u614b\u662f\u4e2d\u5fc3\u6027\u8179\u90e8\u80a5\u80d6 (central abdominal obesity)\nD. \u4f9d\u7167\u7cd6\u5c3f\u75c5\u98f2\u98df\u63a7\u5236\u539f\u5247\uff0c\u9810\u9632\u75be\u75c5\u9032\u5c55\u6642\uff0c\u8a08\u756b\u6027\u98f2\u98df\u53ca\u904b\u52d5\u964d\u4f4e\u7684\u9ad4\u91cd\uff0c\u4e3b\u8981\u662f\u8102\u80aa\u7d44\u7e54\nE. \u7f8e\u570b\u570b\u885b\u9662\u9032\u884c\u4e4b\u751f\u6d3b\u578b\u614b\u7814\u7a76LOOKAHEAD\uff0c\u91dd\u5c0d\u7cd6\u5c3f\u75c5\u7684\u60a3\u8005\u5b89\u6392\u71df\u990a\u8aee\u8a62\u53ca\u9ad4\u91cd\u7ba1\u7406\uff0c\u96d6\u7136\u53ef\u4ee5\u6539\u5584\u8840\u7cd6\u53caHbA1c\u4e4b\u63a7\u5236\uff0c\u4f46\u662f\u7814\u7a76\u7d50\u679c\u986f\u793a\u4e26\u7121\u6cd5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e4b\u5fc3\u81df\u8840\u7ba1\u75be\u75c5 \u6b7b\u4ea1\u7387\n": "(B)", "108-2.\n\u7cd6\u5c3f\u75c5\u7528\u85e5\u7684\u6a5f\u8f49\uff0c\u8207\u75c5\u60a3\u7a7a\u8179\u6216\u98ef\u5f8c\u8840\u7cd6\u63a7\u5236\u5bc6\u5207\u76f8\u95dc\uff0c\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u4e2d\uff0c\u6709\u4e9b\u8207\u80f0\u5cf6\u7d20\u5206\u6ccc\u6216\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u6709\u95dc\uff0c\u6709\u4e9b\u5247\u7121\u76f4\u63a5\u95dc\u806f(non-insulin dependent)\uff0c\u4ee5\u4e0b\u964d\u8840\u7cd6\u85e5\u7269\u4e2d\uff0c\u4f55\u9805\u85e5\u7269\u70ba\u975e\u80f0\u5cf6\u7d20\u76f8\u95dc(non-insulin dependent)\u4e4b\u6a5f\u8f49?\nA. Sulfonylurea\nB. Biguanide\nC. Dipeptidyl dipeptidase 4 inhibitor (DPP4 inhibitor)\nD. Sodium-glucose co-transporter 2 inhibitor (SGLT 2 inhibitor)\nE. Glucagon like peptide 1 receptor agonist (GLP 1 RA)\n": "(D)", "108-3.\n\u7cd6\u5c3f\u75c5\u7684\u6cbb\u7642\uff0c\u751f\u6d3b\u578b\u614b\u7ba1\u63a7\u98f2\u98df\u53ca\u904b\u52d5\u4e4b\u5916\uff0c\u53e3\u670d\u6216\u6ce8\u5c04\u578b\u85e5\u7269\u4e5f\u662f\u95dc\u9375\u63a7\u5236\u56e0\u5b50\uff0c\u4e0b\u5217\u6709\u95dc\u7cd6\u5c3f\u75c5\u85e5\u7269\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u4e4b\u63cf\u8ff0? (1) Metformin\u53ef\u4ee5\u5b89\u5168\u5730\u4f7f\u7528\u65bceGFR < 30\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005 (2)Sulfobnylurea\u985e\u4e4b\u964d\u8840\u7cd6\u85e5\u7269\uff0c\u5bb9\u6613\u9020\u6210\u75c5\u60a3\u4e4b\u4f4e\u8840\u7cd6\u53ca\u9ad4\u91cd\u4e0a\u5347 (3) \u570b\u5167\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70\u4e2d\uff0cHbA1c\u7cd6\u5316\u8840\u8272\u7d20\u61c9\u63a7\u5236\u65bc < 6% (4) Sodium glucose co-transporter 2 inhibitor (SGLT2 inhibitor) \u5728\u964d\u4f4e\u8840\u7cd6\u4e4b\u6642\uff0c\u901a\u5e38\u4e5f\u6703\u4f34\u96a8\u6e1b\u8f15\u75c5\u60a3\u4e4b\u9ad4\u91cd (5) \u814e\u529f\u80fd\u4e0d\u4f73\uff0ceGFR < 60\u6642\uff0c\u61c9\u907f\u514d\u4f7f\u7528\u80f0\u5cf6\u7d20\u53caGLP-1 receptor agonist\u4e4b\u91dd\u5291\u85e5\u7269\u3002\nA. (2)+(4)+(5)\nB. (1)+(3)+(4)\nC. (1)+(4)+(5)\nD. (1)+(3)+(5)\nE. (3)+(4)+(5)\n": "(D)", "108-4.\nSodium glucose co-transporter 2 inhibitor (SGLT 2 inhibitor) \u662f\u8fd1\u5e7e\u5e74\u4f86\u4f7f\u7528\u65bc\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e4b\u65b0\u578b\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\uff0c\u964d\u8840\u7cd6\u4e4b\u6a5f\u8f49\u662f\u7d93\u7531\u5c3f\u6db2\u5c07\u8461\u8404\u7cd6\u6392\u51fa\u9ad4\u5916\uff0c\u4ee5\u4e0b\u6709\u95dc\u672c\u9805\u85e5\u54c1\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. SGLT 2 inhibitor \u6240\u5f62\u6210\u4e4b\u9ad8\u5c3f\u7cd6\uff0c \u589e\u52a0\u6ccc\u5c3f\u9053\u53ca\u751f\u6b96\u5668\u611f\u67d3\u4e4b\u98a8\u96aa\nB. \u81e8\u5e8a\u8a66\u9a57\u7814\u7a76\u986f\u793aSGLT 2 inhibitor \u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u8005\u56e0\u5fc3\u81df\u8870\u7aed\u4f4f\u9662\u7684\u6a5f\u7387\nC. SGLT 2 inhibitor \u5c0d\u7cd6\u5c3f\u75c5\u60a3\u8005\u800c\u8a00\uff0c\u5728\u964d\u4f4e\u8840\u7cd6\u4e4b\u969b\uff0c\u4e5f\u540c\u6642\u964d\u4f4e\u4e86\u75c5\u60a3\u7522\u751f\u916e\u9178\u4e2d\u6bd2(diabetic ketoacidosis) \u7684\u6a5f\u7387\nD. \u76ee\u524d\u4e4b\u7814\u7a76\u986f\u793aSGLT 2 inhibitor\u53ef\u4ee5\u8207\u80f0\u5cf6\u7d20\u540c\u6642\u5408\u4f75\u4f7f\u7528\u4f86\u63a7\u5236\u8840\u7cd6\nE. eGFR > 60 \u4ee5\u4e0a\u4e4b\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0c\u90fd\u53ef\u4ee5\u4f7f\u7528SGLT 2 inhibitor\n": "(C)", "108-5.\n\u5728\u5167\u79d1\u7cd6\u5c3f\u75c5\u8840\u7cd6\u4e4b\u63a7\u5236\u4e2d\uff0c\u80f0\u5cf6\u7d20(lnsulin)\u53caGLP-1 receptor agonist  (GLP-1 RA)\u6ce8\u5c04\u578b\u88fd\u5291\u662f\u91cd\u8981\u7684\u63a7\u5236\u85e5\u7269\uff0c\u4ee5\u4e0b\u6709\u95dc\u80f0\u5cf6\u7d20\u53caGLP-1 RA\u6cbb\u7642\u4e4b\u63cf\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. Basal insulin (\u57fa\u790e\u80f0\u5cf6\u7d20) \u4f7f\u7528\u4e4b\u8d77\u59cb\u5291\u91cf(initial dose) \u7684\u539f\u5247\u70ba 0.2 unit/kg/day\nB. Basal insulin \u53ef\u4ee5\u5408\u4f75GLP-1 RA\uff0c\u5354\u540c\u63a7\u5236\u75c5\u60a3\u4e4b\u8840\u7cd6\nC. GLP-1 RA \u5e38\u898b\u7684\u526f\u4f5c\u7528\u70ba\u8179\u8139\u5641\u5fc3\u611f\uff0c\u80f0\u5cf6\u7d20\u6700\u5e38\u898b\u4e4b\u526f\u4f5c\u7528\u70ba\u4f4e\u8840\u7cd6\nD. GLP-1 RA \u53ef\u4ee5\u5408\u4f75\u80f0\u5cf6\u7d20\u6cbb\u7642\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\uff0c\u4e26\u53ef\u6e1b\u5c11\u80f0\u5cf6\u7d20\u4f7f\u7528\u4e4b\u5291\u91cf\nE. \u81e8\u5e8a\u8a66\u9a57\u7814\u7a76\u4e4b\u7d50\u679c\u986f\u793a\uff0cGLP-1 RA  \u4e4b\u4f7f\u7528\uff0c\u5728\u964d\u4f4e\u8840\u7cd6\u6642\uff0c\u4e5f\u6703\u540c\u6642\u6e1b\u8f15\u75c5\u60a3\u4e4b\u9ad4\u91cd\n": "(D)", "108-6.\n\u9673\u5148\u751f\uff0c40 \u6b72\uff0c\u8eab\u9ad8173\u516c\u5206\uff0c\u9ad4\u91cd 84 \u516c\u65a4\uff0c\u8fd1\u4e00\u5e74\u4f86\uff0c\u9ad4\u91cd\u589e\u52a0\u4e866 \u516c\u65a4\u3002\u4e26\u7121\u7cd6\u5c3f\u75c5\u4e4b\u5bb6\u65cf\u53ca\u500b\u4eba\u75c5\u53f2\uff0c\u534a\u5e74\u4f86\uff0c\u66fe\u7d93\u6709\u6578\u6b21\u4e0d\u660e\u539f\u56e0\u7684\u660f\u5012\uff0c\u90fd\u572830 \u5206\u9418\u5167\u7526\u9192\u904e\u4f86\u3002\u9580\u8a3a\u75c5\u7121\u5fc3\u5f8b\u4e0d\u6574\u6216\u7570\u5e38\u795e\u7d93\u8840\u7ba1\u4e4b\u7570\u5e38\u72c0\u6cc1\u3002\u672c\u6b21\u56e0\u518d\u5ea6\u65bc\u5de5\u4f5c\u6642\u660f\u5012\uff0c\u4f46\u662f\u610f\u8b58\u6301\u7e8c\u4e0d\u6e05\uff0c\u56e0\u6b64\u9001\u5230\u6025\u8a3a\u3002\u6025\u8a3a\u4e4b\u8840\u58d3\u70ba110/68 mmHg\uff0c\u8108\u640f\u70ba\u898f\u5f8b\u768472 bpm\uff0c\u6025\u8a3a\u4e4b\u8840\u7cd6\u986f\u793a\u70ba35 mg/dL\uff0c\u7d66\u4e8850%\u4e4b\u8461\u8404\u7cd6\u8f38\u6db2\u5f8c\uff0c\u6062\u5fa9\u610f\u8b58\u3002\u5efa\u8b70\u4f4f\u9662\u8a3a\u5bdf\uff0c\u5728\u75c5\u623f\u7121\u9ede\u6ef4\u8f38\u6db2\u7684\u524d\u63d0\u4e0b\uff0c\u7a7a\u81798 \u5c0f\u6642\u5f8c\uff0c\u62bd\u8840\u5831\u544a\u70ba: \u7a7a\u8179\u8840\u7cd6 84 mg/dL\uff0c Insulin 3.6 mIU/mL \uff0cC-peptide 2.6 ng/mL\uff0cACTH 62.2 pg/mL\uff0cCortisol\r24.3 ug/dL\uff0cIGF-1 198 ng/mL\uff0cTSH 1.2 mIU/mL\uff0c\u6b64\u6642\u61c9\u8003\u616e\u4e4b\u512a\u5148\u6aa2\u67e5\u9805\u76ee\u70ba\u4f55?\nA. 24\u5c0f\u6642\u5fc3\u96fb\u5716\nB. \u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71(MRI)\nC. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nD. 75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57 (Oral glucose tolerance test)\nE. 72\u5c0f\u6642\u4e4b Prolonged fasting test\n": "(E)", "108-7.\nGlitazone(TZD)\u985e\u4e4b\u964d\u8840\u7cd6\u85e5\u7269\uff0c\u5c6c\u65bc\u80f0\u5cf6\u7d20\u589e\u654f\u5291\uff0c\u53ef\u4ee5\u6539\u5584\u80f0\u5cf6\u7d20\u5728\u4eba\u9ad4\u5167\u4e4b\u654f\u611f\u5ea6\uff0c\u4f46\u662f\u4e5f\u6709\u4e9b\u85e5\u7269\u4e4b\u526f\u4f5c\u7528\uff0c\u4ee5Pioglitazone\u70ba\u4f8b\uff0c\u4f7f\u7528\u76f8\u95dc\u85e5\u7269\u526f\u4f5c\u7528\u5305\u62ec\u4e0b\u5217\u4f55\u8005?  (1)\u9aa8\u8cea\u758f\u9b06 (2)\u8a8d\u77e5\u969c\u7919 (cognitive dysfunction) (3)\u6c34\u816b (4)\u8166\u4e2d\u98a8 (Storke) (5)\u9ad4\u91cd\u53ca\u8102\u80aa\u7d44\u7e54\u589e\u52a0\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (3)+(4)+(5)\nD. (1)+(2)+(5)\nE. (2)+(3)+(5)\n": "(B)", "108-8.\n\u674e\u5148\u751f\uff0c56\u6b72\uff0c\u7cd6\u5c3f\u75c5\u75c5\u53f2\u70ba10\u5e74\uff0c\u5169\u5e74\u524d\u56e0\u51a0\u72c0\u52d5\u8108\u75be\u75c5\u9032\u884c\u5fc3\u5c0e\u7ba1\u7f6e\u653e\u652f\u67b6\uff0c\u76ee\u524d\u4f7f\u7528\u85e5\u7269\u5305\u62ec: \u9810\u6df7\u578b\u80f0\u5cf6\u7d20 (Premix insulin)\uff0c\u9ad8\u8840\u58d3\u85e5\u7269\u70ba\u6bcf\u65e5valsatan 160mg \u53caamlodipine 5mg \uff0c\u81bd\u56fa\u9187\u85e5\u7269\u70ba rosuvastatin \u6bcf\u65e520mg\u3002\u76ee\u524dHbA1c \u70ba 6.8%\uff0cLDL cholesterol \u70ba 50 mg/dL\uff0cHDL cholesterol 31 mg/dL\uff0cTriglyceride \u70ba 828 mg/dL\uff0c\u5c3f\u6db2\u6aa2\u67e5\u6b63\u5e38\uff0c\u7121\u5fae\u91cf\u767d\u86cb\u767d\u5c3f\uff0c\u8f15\u5fae\u80cc\u666f\u578b\u8996\u7db2\u819c\u75c5\u8b8a (Background retinopathy)\uff0c\u76ee\u524d\u61c9\u8a72\u589e\u52a0\u4f7f\u7528\u4e0b\u5217\u54ea\u4e00\u9805\u85e5\u7269?\nA. Pioglitazone\nB. Nicotic acid\nC. Fenofibrate\nD. Acarbose\nE. Cholestyramine\n": "(C)", "108-9.\n\u4f4e\u8840\u7cd6\u7684\u767c\u751f\uff0c\u6709\u6642\u8207\u7cd6\u5c3f\u75c5\u4e4b\u6cbb\u7642\u5bc6\u5207\u76f8\u95dc\uff0c\u4f46\u975e\u7cd6\u5c3f\u75c5\u4e4b\u75be\u75c5\u4e5f\u53ef\u80fd\u767c\u751f\u4f4e\u8840\u7cd6\uff0c\u4e0b\u5217\u6558\u8ff0\u7684\u75c5\u75c7\u4e2d\uff0c\u4f55\u8005\u70ba\u4f4e\u8840\u7cd6\u767c\u751f\u7684\u539f\u56e0? (1)\u4f7f\u7528\u80f0\u5cf6\u7d20\u6216sulfonylurea \u985e\u964d\u8840\u7cd6\u85e5\u7269 (2)\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 (Cushing's Syndrome) (3)\u80c3\u5207\u9664\u624b\u8853\u5f8c (Post-gastric bypass survey) (4)\u814e\u4e0a\u817a\u6a5f\u80fd\u4e0d\u8db3 (Adrenal insufficiency) (5) \u80a2\u7aef\u80a5\u5927\u75c7 (Acromegaly)\u3002\nA. (1)+(2)+(3)\nB. (3)+(4)+(5)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (1)+(3)+(4)\n": "(E)", "108-10.\n\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u53ca\u9ad8\u8840\u8102\u6cbb\u7642\u85e5\u7269\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?  (1)\u96a8\u8457\u5e74\u9f61\u7684\u8001\u5316\uff0c\u8840\u7cd6\u63a7\u5236\u7684HbA1c\u53ca\u8840\u58d3\u63a7\u5236\u7bc4\u570d\uff0c\u9ad8\u9f61\u7684\u7cd6\u5c3f\u75c5\u75c5\u60a3\u6703\u8f03\u5e74\u8f15\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005\u5bec\u9b06\u4e9b (2)\u76ee\u524d\u7cd6\u5c3f\u75c5\u9ad8\u8840\u58d3\u6cbb\u7642\u7684\u9996\u9078\u85e5\u7269\u70ba Angiotensin converting enzyme inhibitor (ACEI)\u6216 angiotension receptor blocker (ARB) (3)\u7cd6\u5c3f\u75c5\u60a3\u8005\u5982\u9700\u85e5\u7269\u63a7\u5236\u6cbb\u7642\u9ad8\u8840\u8102\uff0c\u5176\u4f4e\u5bc6\u5ea6\u81bd\u56fa\u9187(LDL-cholestrol) \u4e4b\u6cbb\u7642\u6a19\u7684\u70ba\u4f4e\u65bc130 mg/mL (4)\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e4b\u9ad8\u8840\u58d3\u63a7\u5236\u76ee\u6a19\uff0c\u57fa\u672c\u4e0a\u5b9a\u5728\u4f4e\u65bc120/80 mmHg\uff0c\u5982\u679c\u5408\u4f75\u86cb\u767d\u5c3f\u6642\uff0c\u8840\u58d3\u63a7\u5236\u5efa\u8b70\u70ba\u4f4e\u65bc110/70 mmHg\r(5)\u7576HbA1c\u3001\u8840\u58d3\u53ca\u8840\u8102\u5747\u9054\u5230\u63a7\u5236\u6a19\u6e96\u6642\uff0c\u6212\u83f8\u5df2\u7121\u52a9\u65bc\u9032\u4e00\u6b65\u964d\u4f4e\u7cd6\u5c3f\u75c5\u8840\u7ba1\u4f75\u767c\u75c7\u4e4b\u98a8\u96aa\u3002\nA. (3)+(4)+(5)\nB. (1)+(3)+(5)\nC. (1)+(2)+(3)\nD. (1)+(4)+(5)\nE. (2)+(4)+(5)\n": "(A)", "109-120.58\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u56e0\u70ba\u8840\u58d3\u4f4e\u53ca\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a \u3002\u5979\u7684\u5167\u5206\u6ccc\u6aa2\u67e5\u986f\u793a fT4 0 .65 ng/dL, hsTSH 0.32 \nuIU/mL, cortisol (8 am) 5 ug /dL, ACTH 40 pg /mL, GH 2.5 ng/mL, prolactin 6 ng /mL\u3002\u4e0b\u5217\u54ea\u4e00\u500b\u9078\u9805\uff0c \n\u6700\u652f\u6301\u8166\u5782\u9ad4\u529f\u80fd\u4e0d\u5168 (hypopituitarism) \u8a3a\u65b7 \uff1f(\u53c3\u8003\u503c: fT4 0 .70~1.48 ng/dL; hsTSH 0.35~4.94 uIU/mL; \ncortisol (8am) 5~25 ug/dL; cortisol (4pm) 2.5~12.5 ug/dL; ACTH 7.4~57.3 pg/mL; GH <8 ng/dL; \nprolactin 5~23 ng/mL)\n(1) insulin hyoglycemia test, \u7576 glucose <40 mg/dL\u6642, GH \u70ba 6 ng /mL.\n(2) Insulin hypoglycemia test, \u7576 glucose < 40 mg /dL\u6642, cortisol \u70ba 9 ug /dL.\n(3) TRH stimulation test, peak TSH 4.25 uIU/mL.\n(4) TRH stimulation test, peak prolactin 19 ng /mL.\n(5) CRH stimulation test, peak ACTH 90 pg /mL.   \nA.(1)+(2)\nB.(2)+(3)\nC.(3)+(4)\nD.(1)+(2)+(3)\nE.(2)+(3)+(5)\n": "[B]", "109-121.\u4e00\u4f4d65\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u4e3b\u8a34\u6709\u591a\u5c3f\u591c\u5c3f \uff0c\u4ed6\u6c92\u6709\u7cd6\u5c3f\u75c5 \uff0c\u8003\u616e\u6b64\u75c5\u4eba\u662f\u5426\u6709\u5c3f\u5d29\u75c7 (diabetes insipidus, \nDI)\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u601d\u8003\u6700\u6b63\u78ba \uff1f\n(1) \u8b93\u75c5\u4eba\u96a8\u610f\u559d\u6c34\u7684\u60c5\u6cc1\u4e0b, \u5982\u679c24\u5c0f\u6642\u5c3f\u91cf , < 40 mL /kg,  \u5c3f\u6ef2\u900f\u58d3 > 300 mosm /L, \u61c9\u8a72\u5148\u6aa2\u67e5\u6ccc\u5c3f\u7cfb\n\u7d71\u662f\u5426\u6709\u7570\u5e38 \u3002\n(2) \u5982\u679c24\u5c0f\u6642\u5c3f\u91cf > 40 mL /kg,  \u5c3f\u6ef2\u900f\u58d3 < 300 mosm /L, basal plasma arginine vasopressin (AVP) < 1 \npg/mL, \u61c9\u8a72\u8003\u616e central DI \u6216 primary polydipsia \u3002\n(3) \u5982\u679c\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5\u986f\u793a\u5f8c\u8449\u6c92\u6709\u4eae\u9ede, \u53ef\u4ee5\u6392\u9664 central DI \u3002\n(4) \u75c5\u4eba\u7684\u5c3f\u6ef2\u900f\u58d3\u5728\u9650\u6c34 4\u5c0f\u6642\u5f8c, \u7531 250 mOsm /L \u4e0a\u5347\u70ba 400 mOsm /L, \u75c5\u4eba\u53ef\u80fd\u662f central DI \u3002\n(5) \u75c5\u4eba\u5728\u9650\u6c34 4\u5c0f\u6642\u4ee5\u5f8c, \u7d66\u4e88 desmopressin (DDAVP), \u5176\u5c3f\u6ef2\u900f\u58d3\u70ba 250 mOsm /L, \u75c5\u4eba\u53ef\u80fd\u662f \nnephrogenic DI \u3002   \nA.(1)+(2)+(4)\nB.(2)+(3)+(5)\nC.(1)+(2)+(5)\nD.(3)+(4)+(5)\nE.(2)+(4)\n": "[C]", "109-122.\u4e00\u4f4d35\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u70ba\u61f7\u7591\u6709\u5eab\u6b23\u6c0f\u75c7\u800c\u63a5\u53d7\u8166\u5782\u9ad4\u624b\u8853 \uff0c\u4f46\u958b\u5200\u4e09\u500b\u6708\u5f8c \uff0c\u6708\u4eae\u81c9\uff0c\u8179\u90e8\u7d2b\u8272\u6591\u7d0b \uff0c\u5026\n\u6020\uff0c\u4e0a\u80a2\u7121\u529b\u7b49\u75c7\u72c0\u5747\u672a\u6539\u5584 \uff0c\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\u672a\u898b\u660e\u986f\u816b\u7624 \uff0c\u5979\u7684\u6aa2\u9a57\u7d50\u679c\u70ba cortisol (8am) 28 ug /dL, \n4pm 26 ug /dL, ACTH 96 pg /mL, K 2.8 mmol/L, LDH 864 U/L\u3002\u8acb\u554f\u54ea\u4e00\u9805\u6aa2\u67e5\u6216\u8655\u7f6e\u6700\u6070\u7576 \uff1f(\u53c3\u8003\u503c \ncortisol (8sm) 5 ~25 ug/dL, cortisol (4pm) 2.5 ~12.5 ug/dL, ACTH 7.4 ~ 57.3 pg/mL, K 3.5 ~5.1 mmol/L, \nLDH 140 ~271 U/L)   \nA.High dose dexamethasone suppression test\nB.\u8ffd\u8e64, \u4e09\u500b\u6708\u5f8c\u518d\u505a\u4e00\u6b21\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\nC.\u96d9\u5074infeiror petrosal sinus sampling\nD.\u80f8\u8179\u9aa8\u76c6\u8154\u96fb\u8166\u65b7\u5c64\nE.\u7533\u8acb\u5065\u4fdd\u7d66\u4ed8\uff0c \u4ee5 pasireotide \u6cbb\u7642   \n": "[D]", "109-123.\u4e00\u4f4d49\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u70ba B\u578b\u809d\u708e\u5e36\u539f\u8ffd\u8e64\u8179\u90e8\u8d85\u97f3\u6ce2\u767c\u73fe\u6709\u53f3\u5074\u814e\u4e0a\u817a\u816b\u7624 \uff0c\u814e\u4e0a\u817a\u96fb\u8166\u65b7\u5c64\u986f\u793a\u816b\u7624\u5927\n\u5c0f\u70ba4\u516c\u5206\uff0c CT density \u70ba10 HU\u3002\u5979\u7684\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b \uff1acortisol (8am) 16.0 ug/dL, cortisol (4pm) 12.2 \nug/dL, ACTH 13 .7 pg/mL, aldosterone 18 ng /dL, plasma renin activity 0.95 ng/mL/hr, urine VMA 4.7 \nmg/24hr, urine dopamine 254 .5 ug/24 hr, urine epinephrine 9.3 ug/24hr, urine norepinephrine 83 .5 \nug/24hr\u3002\u8acb\u554f\u4ee5\u4e0b\u54ea\u4e00\u9805\u6558\u8ff0\u6b63\u78ba \uff1f(\u53c3\u8003\u503c; cortisol (8am) 5.0~25.0 ug/dL, cortisol (4pm) 2.5~12.5 \nug/dL, ACTH 7.4~57.3 pg/mL, plasma renin activity 1~5 ng/mL/hr, aldosterone 5~30 ng/dL, urine \ndopamine 50 ~450 ug/24 hr, urine epinephrine < 22 .4 ug/24hr, urine norepinephrine 12 .1~85.5 ug/24hr, \nurine VMA 1~7 mg/24hr)   \nA.\u7d55\u5927\u591a\u6578\u55ae\u5074\u814e\u4e0a\u817a\u816b\u7624\u70ba\u5206\u6ccccortisol\u7684\u826f\u6027\u816b\u7624\nB.\u6b64\u75c5\u4eba\u61c9\u8a72\u512a\u5148\u8003\u616eprimary aldosteronism\nC.\u4f7f\u7528\u5229\u5c3f\u5291\u6216\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7269\u53ef\u80fd\u5f15\u8d77urine catecholamine \u5047\u6027\u504f\u4f4e\nD.\u61c9\u8a72\u52a0\u6e2c17-hydroxyprogesterone \u53caDHEAS\nE.\u5efa\u8b70\u624b\u8853\u5207\u9664\u6b64\u814e\u4e0a\u817a\u816b\u7624\n": "[D]", "109-124.\u67d0\u4e9b\u975e\u7532\u72c0\u817a\u75be\u75c5 (nonthyroidal illness )\u53ef\u80fd\u9020\u6210\u7532\u4fc3\u7d20 (TSH)\u6216\u7532\u72c0\u817a\u8377\u723e\u8499\u6fc3\u5ea6\u7570\u5e38\u7684sick euthyroid \nsyndrome \u3002\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u4e0d\u6b63\u78ba \uff1f   \nA.\u7981\u98df\u53ef\u80fd\u5f71\u97ff5-deiodinase\u7684\u4f5c\u7528\uff0c\u4f7f T4 \u8b8a\u6210 rT3, \u9020\u6210 low T3 syndrome\nB.\u5982\u679c\u75c5\u4eba\u6709low T4, low T3, \u4ee3\u8868\u75c5\u60c5\u6975\u70ba\u56b4\u91cd\uff0c\u9810\u5f8c\u4e0d\u4f73\nC.\u6025\u6027\u809d\u75c5\u8b8a (acute liver disease) \u53ef\u80fd\u91cb\u653ethyroxine -binding globulin (TBG)\u800c\u4f7ftotal T 3\u53caT4 \u589e\n\u52a0\uff0c\u4f46unbound T 3\u53ca T4\u5247\u4e0d\u6703\u589e\u52a0\nD.\u4f7f\u7528dopamine \u6216 glucocorticoid \u6cbb\u7642\u53ef\u80fd\u4f7fTSH \u504f\u4f4e\nE.\u5728HIV\u611f\u67d3\u521d\u671f\uff0c\u5373\u4f7f\u75c5\u4eba\u6709\u9ad4\u91cd\u4e0b\u964d\uff0cT3 \u53caT4\u4ecd\u7136\u53ef\u80fd\u589e\u9ad8\n": "[A]", "109-125.\u4e00\u4f4d28\u6b72\u7537\u6027\u75c5\u4eba\u63a5\u53d7\u96d9\u5074\u7532\u72c0\u817a\u5168\u5207\u9664\u624b\u8853\uff0c \u5176\u75c5\u7406\u5831\u544a\u5982\u4e0b \uff1a\u5de6\u5074\u7532\u72c0\u817a\u6709 4*2.2*1.8 \u516c\u5206\u7532\u72c0\u817a\u4e73\n\u7a81\u764c\uff0c\u53f3\u5074\u7532\u72c0\u817a\u7121\u764c\u75c5\u8b8a \u3002\u5de6\u5074level II, III, IV\u6dcb\u5df4\u7d50\u5171\u5207\u966411 \u500b\uff0c\u5176\u4e2d5\u500b\u6709\u7532\u72c0\u817a\u4e73\u7a81\u764c\u8f49\u79fb \u3002\u8acb\u554f\n\u6709\u95dc\u9019\u4f4d\u75c5\u4eba\u7684\u8a3a\u65b7\u8207\u8655\u7f6e \uff0c\u54ea\u4e00\u9805\u6b63\u78ba \uff1f   \nA.\u4f9d\u64da\u7f8e\u570b\u806f\u5408\u764c\u75c7\u59d4\u54e1\u6703 (American Joint Commiottee on Cancer staging ), \u6b64\u75c5\u4eba\u70ba T2N1bMx, \nstage IVA\nB.\u75c5\u4eba\u7684\u518d\u767c\u98a8\u96aa\u9ad8\uff0c\u624b\u8853\u5f8c\u4e8c\u9031\u5167\u61c9\u8a72\u7d66\u4e88\u653e\u5c04\u6027\u7898(I -131)\u6cbb\u7642\nC.\u4f7f\u7528\u653e\u5c04\u6027\u7898\u6cbb\u7642\u524d \uff0c\u61c9\u8a72\u5148\u4ee5\u4f4e\u5291\u91cf (3mCi)\u653e\u5c04\u6027\u7898\u6383\u63cf \uff0c\u4ee5\u4e86\u89e3\u6b98\u9918\u7532\u72c0\u817a\u7d44\u7e54\u6709\u591a\u5c11\u4e26\u4f30\u7b97\u9069\n\u7576\u7684\u653e\u5c04\u6027\u7898\u6cbb\u7642\u5291\u91cf\nD.\u75c5\u4eba\u5728\u63a5\u53d7\u653e\u5c04\u6027\u7898\u6cbb\u7642\u5f8c \uff0c\u61c9\u8a72\u88dc\u5145\u7532\u72c0\u817a\u7d20 \u4ee5\u7dad\u6301\u5176\u7532\u72c0\u817a\u529f\u80fd\u5728subclinical \nhyperthyroidism\u7684\u7bc4\u570d\nE.\u8840\u6e05\u4e2dthyroglobulin\u53ef\u505a\u70ba\u7532\u72c0\u817a\u764c\u8ffd\u8e64\u6307\u6a19\uff0c\u6700\u597d\u7dad\u6301\u572810 ng/ML \u4ee5\u4e0b (\u6b63\u5e38\u53c3\u8003\u503c< 55 ng/mL)\n": "[D]", "109-126.\u9ad8\u8840\u9223(hypercalcemia)\u7684\u9451\u5225\u8a3a\u65b7\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba\uff1f    \nA.Vitamin A intoxication\u53ef\u80fd\u9020\u6210\u526f\u7532\u72c0\u817a\u8377\u723e\u8499(PTH)\u4f4e\u7684\u9ad8\u8840\u9223\u75c7\nB.\u5982\u679c\u77ed\u671f\u6025\u6027\u51fa\u73fe\u9ad8\u8840\u9223\u75c7\u4e14PTH\u503c\u504f\u4f4e\uff0c\u61c9\u8a72\u5148\u8003\u616e\u60e1\u6027\u816b\u7624\nC.\u7d04\u6709 10% \u4ee5lithium \u6cbb\u7642 bipolar depression \u7684\u75c5\u4eba\u53ef\u80fd\u7522\u751f\u9ad8\u8840\u9223\u75c7\nD.Calcimimetics\u53ef\u4ee5\u4e0b\u964dPTH\u7684\u5206\u6ccc\uff0c\u964d\u4f4e\u8840\u9223, \u589e\u52a0\u9aa8\u5bc6\u5ea6\nE.\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u6216\u814e\u4e0a\u817a\u529f\u80fd\u4f4e\u4e0b\u90fd\u53ef\u80fd\u5f15\u8d77\u9ad8\u8840\u9223\u75c7\n": "[D]", "109-127.\u4e0b\u5217\u6709\u95dc\u9aa8\u8cea\u758f\u9b06(osteroporosis)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba\uff1f       \nA.\u4ee5DXA\u6e2c\u91cf\u9aa8\u5bc6\u5ea6 (bone minearal density, BMD ), T-score\u662f\u8207\u76f8\u540c\u6027\u5225 \u3001\u76f8\u540c\u7a2e\u65cf \u3001\u76f8\u540c\u5e74\u7d00\u7684\u4eba\n\u505a\u6bd4\u8f03\nB.Klinefelter's syndrome\u6703\u589e\u52a0\u9aa8\u8cea\u758f\u9b06\u98a8\u96aa\nC.\u5982\u679c\u5176\u4ed6\u689d\u4ef6\u90fd\u76f8\u540c, \u9aa8\u5bc6\u5ea6 T-score <-2.5\u7684\u4eba\u767c\u751f\u9aa8\u6298\u7684\u98a8\u96aa \uff13\u500d\u65bcT-score \u4ecb\u65bc -1.0 \u53ca -2.5\u4e4b\u9593\n\u7684\u4eba\nD.\u4ee5 Fracture risk assessment tool (FRAX)\u4f30\u7b97\uff0c\u5982\u679c\u7236\u6bcd\u6709\u8170\u690e\u9aa8\u6298\u75c5\u53f2\uff0c\u5247\u9aa8\u6298\u98a8\u96aa\u6703\u589e\u52a0\nE.Denosumab\u53ef\u80fd\u589e\u52a0osteonecrosis of the jaw (ONJ)\u7684\u98a8\u96aa\uff0c\u4f46\u4e0d\u6703\u589e\u52a0atypical femur fracture\u7684\u98a8\n\u96aa\n": "[B]", "109-128.\u4e0b\u5217\u6709\u95dc\u7537\u6027\u5065\u5eb7\u7684\u8ad6\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba\uff1f    \nA.\u6210\u4eba\u7537\u6027\u8377\u723e\u8499testosterone \u6fc3\u5ea6\u96a8\u5e74\u7d00\u589e\u52a0\u800c\u4e0b\u964d\u7684\u901f\u5ea6\u8207\u9ad4\u91cd\u76f8\u95dc\uff0c\u80a5\u80d6\u8005\u4e0b\u964d\u901f\u5ea6\u8f03\u6162\nB.\u5e74\u8001\u8005\u7684 sex-hormone binding globulin (SHBG) \u6bd4\u5e74\u8f15\u4eba\u9ad8\nC.Total testosterone \u6fc3\u5ea6\u8207\u80f0\u5cf6\u7d20\u963b\u6297 (insulin resistance )\u7121\u95dc\uff0c\u4f46bioavailable testosterone\u6fc3\u5ea6\u8d8a\u4f4e\n\u5247insulin resistance \u8d8a\u9ad8\nD.Testosterone \u6cbb\u7642\u53ef\u4ee5\u589e\u52a0\u8170\u690e\u53ca\u80a1\u9aa8\u7684\u9aa8\u5bc6\u5ea6\nE.\u524d\u5217\u817a\u764c(Prostate cancer)\u7684\u75c5\u4eba\u63a5\u53d7 androgen deprivation therapy \u53ef\u4ee5\u6e1b\u5c11\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\n": "[B]", "109-129.Medullary thyroid cancer (MTC) \u53ef\u4ee5\u8868\u73fe\u65bc\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624 (multiple endocrine neoplasia, MEN )\uff0c\u4ee5\n\u4e0b\u54ea\u4e00\u9805\u6b63\u78ba \uff1f   \nA.\u6709MTC\u5bb6\u65cf\u75c5\u53f2\u7684\u5e7c\u5152\uff0c\u6700\u597d\u57285\u6b72\u4ee5\u524d\u63a5\u53d7\u9810\u9632\u6027\u7684\u7532\u72c0\u817a\u5207\u9664\u624b\u8853\nB.MEN2A \u4e2d\u7684 MTC \u6bd4 MEN2B\u4e2d\u7684MTC \u66f4\u5177\u4fb5\u8972\u6027 (more aggressive)\nC.Calcitonin\u53ef\u4ee5\u7576\u4f5c MTC \u8853\u524d\u8a3a\u65b7\u53ca\u8853\u5f8c\u8ffd\u8e64\u7684tumor marker\nD.MTC\u8853\u5f8c\u518d\u767c\u9838\u90e8\u6dcb\u5df4\u817a\u8f49\u79fb\u61c9\u8a72\u4f7f\u7528\u653e\u5c04\u6027\u7898\u6cbb\u7642\nE.MTC\u82e5\u6709\u9060\u90e8\u8f49\u79fb\uff0c\u517610\u5e74\u5b58\u6d3b\u7387\u7d04\u70ba 50%\n": "[C]", "109-130.\u8fd1\u5e74\u4f86\uff0c\u7cd6\u5c3f\u75c5\u4e4b\u65b0\u85e5\u767c\u5c55\u8fc5\u901f \uff0c\u5176\u4e2dSGLT2 inhibitor (\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\uff0csodium \nglucose co -transporter 2 inhibitor )\u5c6c\u65bc\u65b0\u6a5f\u8f49\u4e4b\u85e5\u7269 \u3002\u4e0b\u5217\u7684\u6709\u95dcSGLT2 inhibitor\u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u932f\u8aa4 \uff1f   \nA.\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\u4e4b\u57fa\u672c\u6a5f\u8f49\uff0c\u8207\u80f0\u5cf6\u7d20\u4e4b\u4f5c\u7528\u7121\u95dc\nB.\u5927\u578b\u7cd6\u5c3f\u75c5\u4e4b\u9810\u5f8c\u7814\u7a76\u7d50\u679c\u986f\u793a \uff0c\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\u53ef\u4ee5\u6e1b\u5c11\u7cd6\u5c3f\u75c5\u60a3\u8005\u767c\u751f\u8166\u4e2d\n\u98a8\nC.\u76ee\u524d\u7684\u7814\u7a76\u7d50\u679c\u986f\u793a \uff0c\u6b64\u985e\u85e5\u7269\u81e8\u5e8a\u4e0a\u6700\u4ee4\u4eba\u64d4\u5fc3\u7684\u7cfb\u7d71\u6027\u526f\u4f5c\u7528\u70ba\u916e\u9178\u4e2d\u6bd2 (Ketoacidosis )\uff0c\u5176\u81f4\n\u75c5\u6a5f\u8f49\u63a8\u8ad6\u8207\u672c\u9805\u85e5\u7269\u4f7f\u7528\u4e4b\u5f8c \uff0c\u6703\u589e\u52a0\u75c5\u60a3\u8840\u4e2d\u6607\u7cd6\u6fc0\u7d20 (glucagon )\u4e4b\u6fc3\u5ea6\nD.\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\u4f7f\u7528\u5f8c\u4e4b\u9ad4\u91cd\u6e1b\u8f15\u73fe\u8c61 \uff0c\u4e3b\u8981\u7684\u539f\u56e0\u4f86\u81ea\u65bc\u672c\u9805\u85e5\u54c1\u53ef\u5c07\u8840\u4e2d\u8461\n\u8404\u7cd6\u6392\u9664\u65bc\u5c3f\u6db2\u4e2d\nE.\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\u7684\u7814\u7a76\u767c\u73fe \uff0c\u672c\u9805\u85e5\u7269\u53ef\u4ee5\u6539\u5584\u86cb\u767d\u5c3f\u7684\u73fe\u8c61 \uff0c\u5177\u6709\u5ef6\u7de9\u7cd6\u5c3f\u75c5\n\u814e\u75c5\u8b8a\u7684\u85e5\u7406\u6548\u61c9\n": "[B]", "109-131.\u53f0\u7063\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5\u4eba\u53e3 \uff0c\u96a8\u8457\u5e73\u5747\u58fd\u547d\u4e4b\u5ef6\u9577 \uff0c\u5448\u73fe\u5feb\u901f\u589e\u52a0\u7684\u73fe\u8c61 \uff0c\u5176\u4e2d\u7cd6\u5c3f\u75c5\u814e\u81df\u7167\u8b77 \uff0c\u5fc5\u9808\u91cd\n\u8996\uff0c\u4e0b\u5217\u6709\u95dc\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5\u814e\u81df\u7167\u8b77\u7684\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u932f\u8aa4 \uff1f   \nA.\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5\u814e\u81df\u75c5\u8b8a\u6642 \uff0c\u75c5\u60a3\u8ca7\u8840\u7684\u7a0b\u5ea6 \u3001\u5de6\u5fc3\u5ba4\u80a5\u5927\u73fe\u8c61 \u3001\u5fc3\u8840\u7ba1\u75be\u75c5\u767c\u751f\u7387\u53ca\u6b7b\u4ea1\u7387\u4e4b\u9593 \uff0c\u5448\n\u73fe\u7d71\u8a08\u5b78\u4e0a\u986f\u8457\u7684\u76f8\u95dc\u6027\nB.\u96d6\u7136\u7cd6\u5c3f\u63a7\u5236\u6307\u6a19\u7cd6\u5316\u8840\u8272\u7d20 (HbA1c) \u4e00\u822c\u5efa\u8b70\u7684\u6a19\u7684\u662f 7%\uff0c\u4f46\u662f\u91dd\u5c0d\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5 \uff0c\u5408\u4f75\u814e\u75c5\u8b8a\n\u6642\uff0c\u9700\u8003\u616e\u75c5\u60a3\u4e4b\u8eab\u9ad4\u5065\u5eb7\u72c0\u6cc1\u53ca\u6d3b\u52d5\u80fd\u529b \uff0c\u76ee\u524d\u8001\u5e74\u7cd6\u5c3f\u75c5\u7167\u8b77\u4e4b\u5efa\u8b70 \uff0c\u91dd\u5c0d\u6d3b\u52d5\u529b\u8f03\u5dee\u4e4b\u60a3\n\u8005\uff0c\u63a7\u5236\u6a19\u7684\u70baHbA 1c < 8 %   \nC.\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u6216\u5176\u4ed6\u5f71\u50cf\u5b78\u6aa2\u67e5\u6642 \uff0c\u986f\u5f71\u5291\u53ef\u80fd\u662f\u9020\u6210\u814e\u81df\u529f\u80fd\u6025\u901f\u60e1\u5316\u7684\u539f\u56e0\u4e4b\n\u4e00\nD.\u76ee\u524d\u5df2\u77e5\u7684\u5927\u578b\u81e8\u5e8a\u7814\u7a76\u5747\u986f\u793a \uff0c\u70ba\u4e86\u964d\u4f4e\u5fc3\u8840\u7ba1\u6b7b\u4ea1 \uff0c\u4ee5\u53ca\u9810\u9632\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u767c\u751f \uff0c\u5728\u75c5\u60a3\u814e\u529f\u80fd\u7121\n\u865e\u7684\u524d\u63d0\u4e0b \uff0c\u5e74\u7d00\u6108\u9577\u7684\u7cd6\u5c3f\u75c5\u60a3 \uff0c\u61c9\u5c07HbA 1c\u63a7\u5236< 6.5%\u4ee5\u4e0b\uff0c\u624d\u662f\u9577\u671f\u7684\u91ab\u7642\u6a21\u5f0f\nE.\u8001\u5e74\u7cd6\u5c3f\u75c5, \u60a3\u814e\u529f\u80fd\u4e0d\u4f73\u6642, \u78fa\u8132\u985e\u85e5\u7269(Sulfonylureas)\u4e4b\u4f7f\u7528, \u53ef\u80fd\u662f\u4f4e\u8840\u7cd6\u7684\u91cd\u8981\u539f\u56e0\u4e4b\u4e00\n": "[D]", "109-132.\u5f35\u8001\u5e2b\uff0c48\u6b72 \uff0c\u8eab\u9ad8173\u516c\u5206 \uff0c\u9ad4\u91cd90\u516c\u65a4 \uff0c\u6700\u8fd1\u5169\u5e74 \uff0c\u9ad4\u91cd\u81ea75\u516c\u65a4\u589e\u52a0\u81f3\u76ee\u524d\u4e4b\u9ad4\u91cd \u3002\u7121\u500b\u4eba\u6216\u5bb6\n\u65cf\u4e4b\u7cd6\u5c3f\u75c5\u53f2 \u3002\u6700\u8fd1\u5e7e\u5e74 \uff0c\u597d\u5e7e\u6b21\u5728\u6e05\u6668\u4e0a\u73ed\u6216\u4e0a\u8ab2\u4e2d\u660f\u5012 \uff0c\u660f\u5012\u6642\u610f\u8b58\u4e0d\u6e05 \uff0c\u66fe\u65bc\u8f49\u9001\u6025\u8a3a\u5f8c \uff0c\u767c\u73fe\u8840\n\u7cd6\u503c\u70ba28mg /dL\uff0c\u5728\u6ce8\u5c0450 %\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58 \u3002\u4e26\u672a\u767c\u73fe\u795e\u7d93\u5b78\u7570\u5e38\u6216\u7cd6\u5c3f\u75c5 \u3002\u672c\u6b21\u518d\u5ea6\u56e0\u610f\u8b58\u72c0\u614b\n\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab \uff0c\u6025\u8a3a\u8840\u7cd6\u503c\u70ba38 mg /dL\uff0c\u6ce8\u5c04\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58 \uff0c\u6e05\u9192\u5f8c\uff0c\u5728\u6025\u8a3a\u4ea6\u7121\u795e\u7d93\u5b78\n\u7570\u5e38\u75c7\u72c0 \uff0c\u56e0\u6b64\u5efa\u8b70\u4f4f\u9662\u9032\u4e00\u6b65\u8ffd\u67e5\u539f\u56e0 \u3002\u56de\u9580\u8a3a\u8ffd\u8e64\u6642 \uff0c\u5728\u63a5\u53d7\u4efb\u4f55\u8f38\u6db2\u4e0b \uff0c\u7a7a\u8179\u8840\u7cd6\u70ba 98 \nmg/dL\uff0c\u6e05\u66688\u9ede\u6642\u4e4bACTH  42 .2 pg/mL, Cortisol 21 .8 ug/dL, \u7a7a\u8179\u4e4bInsulin \u70ba  2.12  mIU/mL, \nC-peptide\u70ba 1.40 ng/mL, \u7532\u72c0\u817a\u529f\u80fd\u7be9\u6aa2TSH\u70ba 4.20 mIU/mL\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u61c9\u8a72\u5efa\u8b70\u90a3\u4e00\u9805\u6aa2\u67e5 \uff1f   \nA.\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nB.72 \u5c0f\u6642\u4e4b Prolonged fasting test (\u5ef6\u9577\u98e2\u9913\u6e2c\u8a66)\nC.75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57 (Oral glucose tolerance test)\nD.\u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (Pituitary MRI)\nE.Overnight 1mg Dexamathasone suppression\u6e2c\u8a66\n": "[B]", "109-133.\u7d71\u8a08\u4e0a\uff0c\u53f0\u7063\u76ee\u524d\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u9054230\u842c\u4eba \uff0c\u9664\u4e86\u751f\u6d3b\u578b\u614b \u3001\u98f2\u98df\u53ca\u904b\u52d5\u4f86\u9810\u9632\u4e4b\u5916 \uff0c\u4e00\u65e6\u78ba\u8a3a\u70ba\u7cd6\n\u5c3f\u75c5\u4e4b\u5f8c \uff0c\u85e5\u7269\u6cbb\u7642\u4e5f\u662f\u975e\u5e38\u91cd\u8981\u7684\u4e00\u74b0 \u3002\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u4e4b\u6558\u8ff0 \uff0c\u90a3\u4e00\u4e9b\u662f\u932f\u8aa4\u7684 \uff1f\n(1) Biguanide \u4e4bMetformin\u662f\u53f0\u7063\u53ca\u7f8e\u570b\u5efa\u8b70\u7cd6\u5c3f\u75c5\u6cbb\u7642\u7684\u7b2c\u4e00\u7dda\u7528\u85e5\n(2) \u76ee\u524d\u570b\u5167\u53ca\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70 \uff0cHbA1c (\u7cd6\u5316\u8840\u7d05\u7d20 )\u4e4b\u63a7\u5236\u76ee\u6a19\u61c9\u8a72\u70ba 6 % \u4ee5\u4e0b \n(3) Sulphonylurea\u985e\u85e5\u7269 \uff0c\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\u53ca\u9ad4\u91cd\u4e0a\u5347 \n(4) \u80f0\u5cf6\u7d20\u96d6\u7136\u53ef\u4ee5\u8fc5\u901f\u964d\u4f4e\u8840\u7cd6 \uff0c\u4f46\u9577\u671f\u4f7f\u7528\u6642 \uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u4e4b\u85e5\u7269\u526f\u4f5c\u7528 \n(5) \u65b0\u578b\u4e4b\u7cd6\u5c3f\u75c5\u53e3\u670d\u85e5\u7269 \uff0c\u5982DPP-4 inhibitor \u53caSGLT-2 inhibitor \uff0c\u9664\u4e86\u964d\u4f4e\u8840\u7cd6\u4e4b\u5916 \uff0c\u4e5f\u6709\u6e1b\u8f15\u7cd6\u5c3f\u75c5\n\u60a3\u9ad4\u91cd\u7684\u85e5\u7406\u6548\u61c9   \nA.(1)+(2)\nB.(2)+(5)\nC.(3)+(4)\nD.(2)+(4)\nE.(4)+(5)\n": "[B]", "109-134.2020\u5e74\u4e4bCovid -19 \u65b0\u578b\u51a0\u72c0\u75c5\u6bd2\u7684\u8086\u8650 \uff0c\u5c0d\u65bc\u7cd6\u5c3f\u75c5\u60a3\u800c\u8a00 \uff0c\u5728\u7d71\u8a08\u5b78\u4e0a \uff0c\u986f\u7136\u662f\u91cd\u5927\u7684\u96b1\u6182 \uff0c\u56e0\u70ba\u7cd6\n\u5c3f\u75c5\u60a3\u7f79\u60a3\u65b0\u51a0\u80ba\u708e \uff0c\u7522\u751f\u4f75\u767c\u75c7\u5f8c\u4e4b\u6b7b\u4ea1\u7387 \uff0c\u660e\u986f\u9ad8\u65bc\u975e\u7cd6\u5c3f\u75c5\u60a3\u8005 \u3002\u4f9d\u71672020\u4e0a\u534a\u5e74\u4e4b\u7814\u7a76\u5831\n\u544a\uff0c\u4e0b\u5217\u6709\u95dc\u4e4b\u56e0\u5b50\u4e2d\u4f55\u8005 \uff0c\u4e26\u975e\u78ba\u8a8d\u4e4b\u75be\u75c5\u60e1\u5316\u98a8\u96aa\u56e0\u5b50 \uff1f   \nA.\u5e74\u9f61\u6108\u5927\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005 (Aging)\nB.\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u5408\u4f75\u9ad8\u8840\u58d3 \uff0c\u5728\u7f79\u60a3\u65b0\u51a0\u80ba\u708e\u524d \uff0c\u5373\u5df2\u4f7f\u7528angiotensin -converting enzyme inhibitor \n(ACEI) \u6216 Angiotnensin receptor blocker (ARB)\uff0c\u63a7\u5236\u9ad8\u8840\u58d3\u8005\nC.\u539f\u672c\u5373\u5df2\u7f79\u60a3\u78ba\u8a3a\u4e4b\u5fc3\u81df\u8840\u7ba1\u75be\u75c5(ASCVD, atherosclerotic cardiovascular disease) \u8005\nD.Body mass index (BMI) \u504f\u9ad8\u4e4b\u80a5\u80d6\u7cd6\u5c3f\u75c5\u60a3\u8005 (Obesity)\nE.\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005 (Type 1 diabetes mellitus)   \n": "[B]", "109-135.\u8fd1\u5e74\u4e4b\u7814\u7a76\u986f\u793a\u61f7\u5b55\u8207\u7cd6\u5c3f\u75c5\u4e4b\u95dc\u4fc2\u91d0\u6e05 \uff0c\u662f\u5b89\u5168\u6210\u529f\u751f\u80b2\u7684\u95dc\u9375\u56e0\u5b50\u4e4b\u4e00 \u3002\u5b55\u524d\u672a\u8a3a\u65b7\u7cd6\u5c3f\u4e4b\u5a66\u5973 \uff0c\u61f7\n\u5b55\u6642\u7522\u751f\u4e4b\u8840\u7cd6\u7570\u5e38\u70ba\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5 \uff0c\u96d6\u7136\u7522\u5f8c\u5927\u591a\u6578\u4e4b\u5a66\u5973 \uff0c\u8840\u7cd6\u90fd\u53ef\u4ee5\u6062\u5fa9\u5230\u6b63\u5e38\u7bc4\u570d\u4e4b\u5167 \uff0c\u4f46\u4ecd\n\u670935-60%\u7684\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973 \uff0c\u572810\u81f320\u5e74\u671f\u9593\u4ecd\u6703\u9032\u5c55\u70ba\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5\u60a3 \u3002\u4ee5\u4e0b\u6709\u95dc\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u4e4b\n\u76f8\u95dc\u6558\u8ff0 \uff0c\u90a3\u4e00\u4e9b\u662f\u932f\u8aa4\u7684 \uff1f\n(1) \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u7684\u8868\u73fe \uff0c\u4e3b\u8981\u8207\u60a3\u8005\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e0d\u8db3 (insulin deficiency) \u76f8\u95dc\n(2) \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u589e\u52a0\u7684\u8da8\u52e2 \uff0c\u8207\u5a66\u5973\u80a5\u80d6\u7387\u7684\u589e\u52a0\u5bc6\u5207\u76f8\u95dc \n(3) \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5728\u61f7\u5b55\u4e4b\u5f8c\u671f\u5b55\u671f\u6642 (late pregnancy )\uff0c\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u6703\u660e\u986f\u964d\u4f4e \uff0c\u8840\u7cd6\u6bd4\u8f03\u5bb9\u6613\u63a7\u5236 \n(4) \u5728\u61f7\u5b55\u671f\u9593 \uff0c\u521d\u6b21\u767c\u73fe\u4e4b\u8840\u7cd6\u7570\u5e38 \uff0c\u5982\u679c\u7b26\u5408\u7cd6\u5c3f\u75c5\u4e4b\u8a3a\u65b7 \uff0c\u61c9\u6b78\u985e\u65bc\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5 (overt diabetes )   \nA.(1)+(2)\nB.(2)+(4)\nC.(2)+(3)\nD.(1)+(4)\nE.(1)+(3)\n": "[E]", "109-136.\u9673\u5976\u5976\uff0c78\u6b72\uff0c\u53ef\u81ea\u7531\u6d3b\u52d5 \uff0c\u4e3b\u8981\u7167\u8b77\u8005\u70ba\u5bb6\u4eba \uff0c\u540c\u4f4f\u3002\u6578\u6b21\u56e0\u80ba\u708e\u6216\u6ccc\u5c3f\u9053\u611f\u67d3\u4f4f\u9662\u6cbb\u7642 \uff0c\u7cd6\u5c3f\u75c5\u75c5\u53f2\n\u5df210\u5e74\u3002\u76ee\u524d\u63a5\u53d7\u53e3\u670d\u85e5\u7269\u63a7\u5236\u8840\u7cd6 \uff0c\u4f46\u672a\u898f\u5f8b\u56de\u8a3a\u8ffd\u8e64\u6025\u7be9\u6aa2\u4f75\u767c\u75c7 \u3002\u672c\u6b21\u56e0\u80ba\u708e\u4f4f\u9662 \uff0c\u6297\u751f\u7d20\u4f7f\n\u75285\u5929\u5f8c\uff0c\u8a55\u4f30\u60c5\u6cc1\u7a69\u5b9a \uff0c\u9810\u8a082\u5929\u5f8c\u51fa\u9662 \u3002\u76ee\u524d\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a \uff0c\u5165\u9662\u96a8\u6a5f\u4e4bHbA 1c \u70ba 9.5 %\uff0c\u4f4f\u9662\u4e4b\u7b2c\n\u4e94\u5929\u6668\u9593\u7a7a\u8179\u8840\u7cd6\u70ba220 mg /dL\uff0c\u7576\u65e5\u65e9\u9910\u5f8c\u5169\u5c0f\u6642\u4e4b\u8840\u7cd6\u70ba268 mg /dL\uff0c\u808c\u9178\u9150\u70ba 0.9 mg/dL\u3002\u96d6\u7136\u76ee\n\u524d\u7121\u660e\u986f\u591a\u5c3f\u6216\u5176\u4ed6\u4e0d\u9069\u75c7\u72c0 \u3002\u5c31\u75c5\u7a0b\u767c\u5c55\u800c\u8a00 \uff0c\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u5b89\u6392\u6558\u8ff0 \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u5c31\u4f4f\u9662\u8840\u7cd6\u8b8a\u5316\uff0c\u61c9\u5efa\u8b70\u81f3\u5c11\u52a0\u5165basal Insulin\u91dd\u5291\u985e(\u57fa\u790e\u80f0\u5cf6\u7d20)\u85e5\u7269\u6cbb\u7642\nB.\u5efa\u8b70\u5118\u65e9\u5b89\u6392\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u53ca\u8db3\u90e8\u795e\u7d93\u5b78\u6aa2\u67e5\nC.\u5efa\u8b70\u61c9\u5b89\u6392\u7cd6\u5c3f\u75c5\u98f2\u98df\u53ca\u904b\u52d5\u885b\u6559\nD.\u672a\u4f86\u7cd6\u5c3f\u75c5HbA1c\u6307\u6a19\uff0c\u63a7\u5236\u6a19\u7684\u70ba < 6.5 % \u4ee5\u4e0b\nE.\u5efa\u8b70\u75c5\u60a3\u672a\u4f86\u61c9\u65bc\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u8840\u7cd6 (Self Monitoring of Blood Glucose)\n": "[D]", "109-137.\u4e0d\u8ad6\u7cd6\u5c3f\u75c5\u6216\u975e\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u6839\u6e90\u5728\u65bc\u80f0\u5cf6\u7d20\u963b\u6297\u6027 (Insulin resistance) \u53ca \u8102\u86cb\u767d \n(lipoprotein )\u7684\u4ee3\u8b1d\u7570\u5e38 \uff0c\u4e00\u822c\u5e38\u898b\u7684\u75be\u75c5\u72c0\u614b\u70ba\u81bd\u56fa\u9187 /\u4e09\u9178\u7518\u6cb9\u916f (TG)\u589e\u52a0\uff0c\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d (HDL)\u6e1b\u5c11\n\u76f8\u95dc\uff0c\u4ee5\u4e0b\u6709\u95dc\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u72c0\u614b\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684 \uff1f   \nA.\u8840\u8102\u7570\u5e38\u6642 \uff0c\u4f4e\u5bc6\u5ea6\u53ca\u6975\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL & VLDL )\u7684\u589e\u52a0\u662f\u91cd\u8981\u7684\u81f4\u75c5\u56e0\u5b50 \uff0c\u591a\u8207\u80a5\u80d6 \u3001\u80f0\u5cf6\u7d20\n\u963b\u6297\u53ca\u907a\u50b3\u76f8\u95dc \uff0c\u56e0\u6b64\u80a5\u80d6\u60a3\u8005 \uff0c\u5728\u6e1b\u8f15\u9ad4\u91cd\u4e4b\u5f8c \uff0c\u76f8\u95dc\u6aa2\u67e5\u6578\u503c\u90fd\u6703\u6539\u5584\nB.\u907a\u50b3\u56e0\u5b50(genetic predisposition)\u53ca\u74b0\u5883\u56e0\u7d20(environmental contribution)\u6703\u540c\u6642\u5f71\u97ff\u75c5\u60a3\u8840\u8102\u4e4b\u8b8a\u5316\nC.\u80a5\u80d6\u53ca\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u589e\u52a0\u6642\uff0c\u8840\u8102\u7570\u5e38\u7684\u8868\u73fe\u7d93\u5e38\u662fTG\u589e\u52a0\uff0c\u4f46\u662fHDL \u964d\u4f4e\nD.\u9577\u671f\u651d\u53d6\u9ad8\u71b1\u91cf\u7684\u91a3\u985e\u98df\u7269\u53ca\u6301\u7e8c\u7684\u98f2\u9152 \uff0c\u5176\u8840\u8102\u7570\u5e38\u53ef\u767c\u73fe\u70ba\u589e\u52a0VLDL \u53caTG\uff0c\u4f46\u662f\u964d\u4f4eHDL\u4e4b\u8840\n\u4e2d\u6fc3\u5ea6\nE.\u7532\u72c0\u817a\u6a5f\u80fd\u4e0d\u8db3 (Hypothyroidism) \u6642\uff0c\u75c5\u60a3\u4e4bLDL\u589e\u52a0 \uff0c\u56e0\u70ba\u539f\u672c\u7532\u72c0\u817a\u7d20\u53ef\u589e\u52a0\u809d\u81df\u4e4bLDL \u53d7\n\u5668\uff0c\u964d\u4f4e\u8840\u4e2d\u4e4bLDL \uff0c\u4f46\u7532\u72c0\u817a\u7d20\u4e0d\u8db3\u6642 \uff0c\u8840\u4e2d\u4e4bLDL\u4e4b\u6e05\u9664\u6548\u7387\u4e5f\u6703\u660e\u986f\u4e0b\u964d\n": "[D]", "109-138.\u80f0\u5cf6\u7d20\u662f\u6cbb\u7642\u7cd6\u5c3f\u75c5 \uff0c\u63a7\u5236\u8840\u7cd6\u7684\u91cd\u8981\u91dd\u5291\u85e5\u7269 \uff0c\u4ee5\u4e0b\u6709\u95dc\u80f0\u5cf6\u7d20\u6cbb\u7642\u7684\u8aaa\u660e\u53ca\u5176\u751f\u7406\u6a5f\u8f49 \uff0c\u4f55\u8005\u662f\u6b63\u78ba\n\u7684\uff1f   \nA.\u5c31\u7cd6\u5c3f\u75c5\u63a7\u5236\u8840\u7cd6\u800c\u8a00 \uff0c\u6bd4\u8f03\u7b26\u5408\u4eba\u9ad4\u751f\u7406\u6027\u9700\u6c42\u7684\u80f0\u5cf6\u7d20\u6ce8\u5c04\u65b9\u5f0f\u662f\u4e00\u5929\u4e00\u6b21\u7684\u57fa\u790e\u80f0\u5cf6\u7d20 (basal \ninsulin)\nB.\u5982\u679c\u9700\u8981\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u6642 \uff0c\u591a\u6b21\u80f0\u5cf6\u7d20\u6ce8\u5c04 \uff0c\u662f\u9054\u6210\u63a7\u5236\u6a19\u7684\u7684\u91cd\u8981\u65b9\u6cd5 \uff0c\u4f46\u662f\u9700\u8981\u914d\u5408\u66f4\u983b\u7e41\u4e4b\u81ea\n\u6211\u8840\u7cd6\u76e3\u6e2c \uff0c\u672a\u4f86\u7684\u8da8\u52e2\u662f\u9023\u7e8c\u8840\u7cd6\u5075\u6e2c\u6a21\u5f0f (continuous glucose monitoring )   \nC.\u8eab\u9ad4\u80f0\u81df\u5206\u6ccc\u4e4b\u5167\u6e90\u6027\u80f0\u5cf6\u7d20 \uff0c\u76f4\u63a5\u5206\u6ccc\u9032\u5165\u809d\u975c\u8108\u7cfb\u7d71 \uff0c\u4f46\u662f\u6ce8\u5c04\u578b\u4e4b\u5916\u6e90\u6027\u80f0\u5cf6\u7d20 \uff0c\u5247\u5728\u6ce8\u5c04\u5f8c\n\u9032\u5165\u5168\u8eab\u7cfb\u7d71\u5faa\u74b0 \uff0c\u56e0\u6b64\u6ce8\u5c04\u4e4b\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u6642 \uff0c\u8f03\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u7684\u6fc3\u5ea6\u70ba\u9ad8 \uff0c\u5c6c\n\u65bcsupraphysiologic insulin level \u3002\nD.\u5c31\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u4e4b\u60a3\u8005\u800c\u8a00 \uff0c\u6bcf\u5929\u9700\u8981\u4e4b\u80f0\u5cf6\u7d20\u6ce8\u5c04\u7e3d\u91cf \uff0c\u4e00\u822c\u5728 1.5 - 2.0 \u55ae\u4f4d/\u6bcf\u516c\u65a4/\u6bcf\u5929 \n(unit/kg/day) \u5de6\u53f3\nE.GLP-1 RA (Glucgon like peptide -1 receptor agonist) \u662f\u4e00\u7a2e\u57fa\u790e\u80f0\u5cf6\u7d20 \uff0c\u4f46\u662f\u537b\u6c92\u6709\u50b3\u7d71\u80f0\u5cf6\u7d20\u6703\n\u589e\u52a0\u75c5\u60a3\u9ad4\u91cd\u7684\u526f\u4f5c\u7528\n": "[B]", "109-139.\u4f9d\u7167 2017\u53f0\u7063\u9ad8\u5371\u96aa\u75c5\u60a3\u8840\u8102\u6cbb\u7642\u6307\u5f15 \uff0c\u7cd6\u5c3f\u75c5\u60a3\u8005\u4ee5\u751f\u6d3b\u578b\u614b\u53ca\u85e5\u7269\u6cbb\u7642\u70ba\u57fa\u672c\u6a19\u7684 \uff0c\u4e0b\u5217\u6558\u8ff0 \uff0c\u4f55\n\u8005\u70ba\u932f\u8aa4\u7684 \uff1f   \nA.\u7cd6\u5c3f\u75c5\u60a3\u8005\u5408\u4f75\u6025\u6027\u51a0\u72c0\u52d5\u8108\u75c7\u5019\u7fa4 (acute coronary syndrome )\u6642\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL-C)\u7684\u63a7\u5236\u6a19\n\u7684\u70ba < 55 mg /dL\nB.\u7cd6\u5c3f\u75c5\u60a3\u8005\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u63a7\u5236\u4e4b\u5efa\u8b70\u9996\u9078\u85e5\u7269\u70baStatins\nC.\u7cd6\u5c3f\u75c5\u60a3\u8005\u5408\u4f75\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\u6642\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL-C)\u7684\u63a7\u5236\u6a19\u7684\u70ba < 70 mg/dL\nD.40\u6b72\u4ee5\u4e0a\u4e4b\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0c\u5728\u7121\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u53f2\u6642\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL-C)\u7684\u63a7\u5236\u6a19\u7684\u70ba < 100 mg/dL\nE.\u4e00\u822c\u63a7\u5236\u539f\u5247 \uff0c40\u6b72\u4ee5\u4e0b\u4e4b\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u7121\u8ad6\u662f\u5426\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u53f2 \uff0c\u5747\u4e0d\u5b9c\u4f7f\u7528Statins\u985e\u85e5\u7269\u63a7\n\u5236\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL-C)\n": "[E]", "110-97.81\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u75c5\u53f2 \u3002\u56e0\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a \uff0c\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u986f\u793a\u6709\u8166\u4e0b\u5782\u9ad4\u816b\u7624 \uff0c\u62bd\n\u8840\u6aa2\u67e5\u986f\u793a: \u8840\u9209126 mmol /L\u3001\u8840\u92404.1 mmol/L\u3001\u8840\u7cd6126 mg /dL\u3001fT4 0.78 ng/dL\u3001hsTSH 4.59 \n\u00b5IU/mL\u3001cortisol (8 am) 18 .9 \u03bcg/dL\u3001ACTH 7.5 pg/mL\u3001LH 0.67 mIU/mL\u3001FSH 7.2 mIU/mL\u3001GH 0.19 \nng/mL\u3001IGF-1 60.3 ng/mL\u3001prolactin 56 .3 ng/mL \u3002\u4e0b\u5217\u54ea\u4e00\u500b\u63cf\u8ff0\u6700\u6b63\u78ba ?\n\uff08\u53c3\u8003\u503c\uff1afT4 0.93~1.70 ng/dL\u3001hsTSH 0.27~4.20 \u00b5IU/mL\u3001cortisol: 8 am 5.27~22.45 \u03bcg/dL\u3001ACTH: \n7.9~47.1 pg/mL\u3001GH 0.01-3.61 ng/mL\u3001prolactin 1.8-20.3 ng/mL\u3001LH (\u505c\u7d93\u5f8c)15.9-54.0 mIU/mL\u3001FSH \n(\u505c\u7d93\u5f8c) 23 .0-116.3 mIU/mL\u3001IGF-1 30.6-208 ng/mL\uff09\u3002\n(1)\u75c5\u4eba\u7684TSH \u8f03\u53c3\u8003\u503c\u9ad8 \uff0c\u61c9\u8a72\u8003\u616eTSHoma\u3002 \n(2)\u75c5\u4eba\u7684prolactin \u8f03\u53c3\u8003\u503c\u9ad8 \uff0c\u61c9\u8a72\u8a3a\u65b7\u70baprolactinoma .\n(3)\u75c5\u4eba\u7684LH \u53caFSH \u8f03\u53c3\u8003\u503c\u4f4e \uff0c\u61c9\u8a72\u8003\u616e\u6709hypopituitarism \u3002\n(4)\u61c9\u8a72\u5148\u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642 \u3002\n(5)\u61c9\u8a72\u5148\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642 \u3002   \nA.1\u3002\nB.2\u3002\nC.3\u3002\nD.(3)+(4)\u3002\nE.(2)+(5)\u3002\n": "[D]", "110-98.\u4e0b\u5217\u54ea\u4e00\u9805\u6709\u95dc\u6ccc\u4e73\u6fc0\u7d20\u7624 (prolactinoma )\u7684\u63cf\u8ff0\u6700\u6b63\u78ba \uff1f\n(1)\u6ccc\u4e73\u6fc0\u7d20\u7624 (prolactinoma )\u662f\u6700\u5e38\u898b\u7684\u8166\u4e0b\u5782\u9ad4\u816b\u7624 \uff0c\u7d04\u4f54\u6709\u529f\u80fd\u7684\u8166\u4e0b\u5782\u9ad4\u816b\u7624 (functioning pituitary \ntumor)\u768470%\u4ee5\u4e0a\u3002 \n(2)\u8166\u4e0b\u5782\u9ad4\u816b\u7624\u53ef\u80fd\u540c\u6642\u5206\u6ccc\u5169\u7a2e\u4ee5\u4e0a\u7684\u8377\u723e\u8499 \uff0c\u4f8b\u5982: GH\u53ca prolactin (PRL), ACTH\u53ca PRL, TSH\u53ca \nPRL\u7b49\u3002\n(3)\u5c0f\u65bc1\u516c\u5206\u7684\u6ccc\u4e73\u6fc0\u7d20\u7624 \uff0c\u7537\u5973\u6bd4\u4f8b\u7d04\u70ba 1:20\uff1b\u5927\u65bc1\u516c\u5206\u7684\u6ccc\u4e73\u6fc0\u7d20\u7624\u7537\u5973\u6bd4\u4f8b\u7d04\u70ba 2:1\u3002\n(4)\u8840\u4e2d\u6ccc\u4e73\u6fc0\u7d20\u6fc3\u5ea6\u901a\u5e38\u8207\u6ccc\u4e73\u6fc0\u7d20\u816b\u7624\u5927\u5c0f\u6210\u6b63\u76f8\u95dc \uff0cPRL> 250 \u03bcg/L \u901a\u5e38\u5176\u816b\u7624\u5927\u65bc 1\u516c\u5206 \u3002\n(5)\u6709\u6ccc\u4e73\u6fc0\u7d20\u7624\u7684\u5a66\u5973\u82e5\u8003\u616e\u61f7\u5b55 \uff0c\u61c9\u4f7f\u7528cabergoline\u6cbb\u7642 \u3002   \nA.(1)+(2)+(4)\u3002\nB.(2)+(3)+(5)\u3002\nC.(1)+(3)+(5)\u3002\nD.(1)+(4)+(5)\u3002\nE.(2)+(4)\u3002   \n": "[E]", "110-99.\u6709\u95dc\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u7684\u8a3a\u65b7\u53ca\u6cbb\u7642 \uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6700\u6b63\u78ba ?\n(1)\u6297\u7532\u72c0\u817a\u85e5\u7269\u53ef\u80fd\u901a\u904e\u80ce\u76e4\u5f71\u97ff\u80ce\u5152\u767c\u80b2 \u3002\n(2)\u54fa\u4e73\u671f\u7d55\u5c0d\u7981\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269 \u3002\n(3)\u4ee5carbimazole \u6cbb\u7642\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032 \uff0c\u82e5\u6b32\u7d66\u4e88\u653e\u5c04\u6027\u7898\u6cbb\u7642 \uff0c\u5728\u7d66\u4e88\u653e\u5c04\u6027\u7898\u524d 2-3\u5929\u61c9\u5148\u66ab\n\u505ccarbimazole \uff0c\u82e5\u6709\u9700\u8981 \uff0c\u5728\u7d66\u4e88\u653e\u5c04\u6027\u7898 3-7\u5929\u5f8c\u518d\u7d66\u4e88carbimazole \u3002\u4f7f\u7528propylthiouracil \u5f8c\u82e5\u8981\u7d66\n\u4e88\u653e\u5c04\u6027\u7898\u6cbb\u7642 \uff0c\u5247\u53ef\u4ee5\u4e0d\u9700\u8981\u505c\u7528propylthiouracil \u3002\n(4)\u75c5\u4eba\u5982\u679c\u6709\u7532\u72c0\u817a\u6bd2\u75c7 (thyrotoxicosis )\u7684\u81e8\u5e8a\u8868\u73fe \uff0c\u5176TSH\u504f\u4f4e\u4f46fT 4\u6b63\u5e38\uff0c\u61c9\u8a72\u6aa2\u6e2cfT 3\u4ee5\u78ba\u5b9a\u662f\u5426\u70ba \nT3 toxicosis \u3002\n(5)fT4 \u9ad8\u3001TSH \u6b63\u5e38\u6216\u9ad8 \uff0c\u9808\u8003\u616eTSH -secreting pituitary adenoma \u6216\u7532\u72c0\u817a\u8377\u723e\u8499\u62ee\u6297\u75c7\u5019\u7fa4 (thyroid \nhormone resistance syndrome )\u3002   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(3)+(5)\u3002\nD.(1)+(4)+(5)\u3002\nE.(2)+(3)+(4)\u3002\n": "[D]", "110-100.\u4e00\u4f4d58\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u6709\u7cd6\u5c3f\u75c5 \u3001\u9ad8\u8840\u58d3\u53ca\u9aa8\u8cea\u758f\u9b06\u75c5\u53f2 \u3002\u5979\u6709\u76ae\u4e0b\u7600\u9752 \u3001\u8179\u90e8\u7d2b\u8272\u6591\u7d0b \u3002\u6aa2\u9a57\u767c\u73fe\u76ae\u8cea\n\u9187\uff08cortisol\uff098 am 20.86 \u03bcg/dL\u30014 pm 20.97 \u03bcg/dL\uff1b\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20 \uff08ACTH\uff098 am <5 pg/mL\uff0c\u96fb\u8166\n\u65b7\u5c64\u986f\u793a\u5de6\u5074\u814e\u4e0a\u817a\u6709 3.3\u516c\u5206\u7684\u816b\u7624 \uff0c\u5982\u679c\u5b89\u6392\u5de6\u5074\u814e\u4e0a\u817a\u5207\u9664 \uff0c\u4e0b\u5217\u54ea\u4e00\u500b\u63cf\u8ff0\u6700\u9069\u7576 \uff1f\n(\u53c3\u8003\u503c: cortisol: 8 am 5.77~22.45 \u03bcg/dL\u30014 pm 3.44-16.9 \u03bcg/dL ; ACTH; 7.9~47.1 pg/mL )   \nA.\u6b64\u75c5\u4eba\u8853\u524d\u7684cortisol\u6c92\u6709\u589e\u9ad8\uff0c\u56e0\u6b64\u5de6\u5074\u814e\u4e0a\u817a\u5207\u9664\u8853\u5f8c\u4e0d\u9808\u7d66\u4e88hydrocortisone\u3002\nB.\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u53ef\u80fd\u589e\u52a0\u6df1\u90e8\u975c\u8108\u6813\u585e\u6216\u80ba\u6813\u585e\u7684\u98a8\u96aa\u3002\nC.\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u5728\u7d66\u4e88\u9069\u7576\u7684\u6cbb\u7642\u5f8c \uff0chypothalamus -pituitary-adrenal (HPA) axis\u6062\u5fa9\u6b63\u5e38\u7684\u6a5f\u6703\u56e0\u70ba\n\u75c5\u56e0\u4e0d\u540c\u6703\u6709\u5dee\u5225 \u3002\u4e00\u822c\u800c\u8a00 \uff0c\u814e\u4e0a\u817a\u816b\u7624\u9020\u6210\u7684\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u5728\u814e\u4e0a\u817a\u816b\u7624\u5207\u9664\u5f8c \uff0c\u5176HPA \naxis\u6062\u5fa9\u6b63\u5e38\u7684\u6bd4\u7387\u70ba80 %\uff0c\u9060\u9ad8\u65bcectopic ACTH syndrome \u6216Cushing\u2019s disease\u6cbb\u7642\u5f8c HPA axis \n\u6062\u5fa9\u6b63\u5e38\u7684\u6bd4\u7387 \u3002\nD.\u75c5\u4eba\u63a5\u53d7\u814e\u4e0a\u817a\u816b\u7624\u5207\u9664\u8853\u5f8c\uff0c\u9808\u589e\u52a0\u964d\u8840\u58d3\u53ca\u964d\u8840\u7cd6\u85e5\u7269\u5291\u91cf\u3002\nE.\u5eab\u6b23\u6c0f\u75c7\u4faf\u7fa4\u7684\u75c5\u4eba\u5982\u679c\u4e0d\u9069\u5408\u624b\u8853 \uff0c\u53ef\u4ee5\u8003\u616e\u4f7f\u7528metyraponec \u6216ketoconazole \u3002Mitotane \u53ef\u4ee5\u7528\n\u65bc\u6cbb\u7642\u814e\u4e0a\u817a\u76ae\u8cea\u764c \uff0c\u4f46\u4e0d\u5efa\u8b70\u7528\u65bc\u826f\u6027\u814e\u4e0a\u817a\u816b\u7624\u7684\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 \u3002\n": "[B]", "110-101.\u4e00\u4f4d53\u6b72\u7537\u6027\u56e0\u70ba\u524d\u9838\u90e8\u816b\u5927\u7d04\u4e00\u500b\u6708 \u3002\u4ed6\u9664\u4e86\u56e0\u70ba\u814e\u7d50\u77f3\u63a5\u53d7\u904e\u591a\u6b21\u9ad4\u5916\u9707\u6ce2\u788e\u77f3\u8853\u6cbb\u7642\u5916\u7121\u5176\u4ed6\u75c5\n\u53f2\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u5176\u524d\u9838\u90e8\u6709\u7d04 3\u516c\u5206\u7684\u816b\u5927 \uff0c\u53ef\u96a8\u541e\u56a5\u6ed1\u52d5 \uff0c\u8868\u9762\u76ae\u819a\u6b63\u5e38 \u3002\u4ed6\u7684\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b: fT4 \n1.13 ng/dL\u3001TSH 0.31 \u03bcIU/mL\u3001PTH 125 .3 pg/mL\u3001\u8840\u922311.9 mg/dL\u3001creatinine 1.2 mg/dL\u3002\u8d85\u97f3\u6ce2\u986f\n\u793a\u7532\u72c0\u817a\u56ca\u816b\u6027\u7d50\u7bc0 \u3002\u7d30\u91dd\u7a7f\u523a\u7d30\u80de\u5b78\u6aa2\u67e5\u986f\u793asheet of follicular cells with macrophages and \ncolloid\u3002\u7d30\u91dd\u7a7f\u523a\u62bd\u5230\u768417 ml\u6db2\u9ad4\u4e2d \uff0cPTH\u6fc3\u5ea6> 3000 pg /mL\uff0cthyroglobulin \u6fc3\u5ea6\u70ba211 ng /mL\u3002Tc99m \nsestamibi scintigraphy \u986f\u793alocal hot spots at left upper and left lower thyroid beds, and a large cold area \nat right lobe of thyroid \u3002\n(\u8840\u4e2d\u6fc3\u5ea6\u53c3\u8003\u503c: fT4 0 .93-1.70 ng/dL\u3001TSH 0.27-4.20 \u03bcIU/mL\u3001PTH 18.4-80.1 pg/mL\u3001Ca 8.6-10.2 \nmg/dL\u3001thyroglobulin <55 ng/mL\u3001creatinine 0.7-1.2 mg/dL)\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u662f\u6700\u53ef\u80fd\u7684\u6b63\u78ba\u8a3a\u65b7 ?   \nA.\u7532\u72c0\u817a\u56ca\u816b\u6027\u7d50\u7bc0\u3002\nB.\u7532\u72c0\u817a\u764c\u3002\nC.\u55ae\u4e00\u526f\u7532\u72c0\u817a\u816b\u7624\u3002\nD.\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624 (multiple endocrine neoplasia)\u3002\nE.\u6b21\u767c\u6027\u526f\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\n": "[D]", "110-102.\u4e0b\u5217\u6709\u95dc\u55dc\u927b\u7d30\u80de\u7624(pheochromocytoma)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba?       \nA.\u4e09\u74b0\u6297\u6182\u616e\u85e5\u7269(tricyclic antidepressants) \u53caopiates\u90fd\u53ef\u80fd\u8a98\u767c\u9ad8\u8840\u58d3\u3001\u5fc3\u60b8\u3001\u5192\u6c57\u7b49\u75c7\u72c0\u3002\nB.\u55dc\u927b\u7d30\u80de\u7624\u7d04\u67095-10%\u662f\u60e1\u6027\u7684\u3002\u5982\u679c\u6709SDHC\u7a81\u8b8a\uff0c\u6700\u5bb9\u6613\u6709\u8f49\u79fb\u3002\nC.\u55dc\u927b\u7d30\u80de\u7624\u7684\u8a3a\u65b7 \uff0c\u6aa2\u9a57\u8840\u4e2d\u7684free metanephrines \u6bd4\u6aa2\u9a57\u8840\u4e2d\u7684catecholamines \u6709\u66f4\u9ad8\u7684\u654f\u611f\u6027\n\u53ca\u7279\u7570\u6027 \u3002\nD.\u55dc\u927b\u7d30\u80de\u7624\u7684\u624b\u8853\u6aa2\u9ad4\u4ee5\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272 (immunohistochemistry )\u53ef\u4ee5\u770b\u5230\n\u6709chromogranin \u3001synaptophysin \u7684\u967d\u6027\u53cd\u61c9 \u3002\nE.\u60e1\u6027\u55dc\u927b\u7d30\u80de\u7624\u5408\u4f75\u8f49\u79fb\u53ef\u4ee5\u8003\u616e\u7528\u653e\u5c04\u6027\u6838\u7a2e(radionuclide)\u6cbb\u7642\uff0c\u4f8b\u5982 \u00b9\u00b3\u00b9I-MIBG \u3002\n": "[B]", "110-103.\u6709\u95dc\u539f\u767c\u6027\u76ae\u8cea\u919b\u916e\u75c7(primary aldosteronism, PA) \u7684\u63cf\u8ff0\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba?    \nA.Primary aldosteronism\u75c5\u4eba\u5e38\u8868\u73fe\u9ad8\u8840\u58d3\u53ca\u4f4e\u8840\u9240 \uff0c\u6703\u589e\u52a0\u7cd6\u5c3f\u75c5\u7f79\u60a3\u7387 \uff0c\u4f46\u53ef\u4ee5\u6e1b\u5c11\u9aa8\u8cea\u758f\u9b06\u98a8\n\u96aa\u3002\nB.\u5927\u591a\u6578\u7684\u826f\u6027aldosterone -producing adenoma \u901a\u5e38\u5c0f\u65bc 2\u516c\u5206\uff0c\u5e74\u8f15\u4eba\u6709\u8f03\u5927\u7684\u816b\u7624\u61c9\u8a72\u8981\u5c0f\u5fc3\u662f\n\u5426\u6709\u60e1\u6027\u8b8a\u5316 \u3002\nC.Glucocorticoid -remediable aldosteronsim (GRA)\u6709\u5bb6\u65cf\u907a\u50b3 \uff0c\u53ef\u80fd\u6703\u6709\u65e9\u767c\u6027\u7684\u9ad8\u8840\u58d3\u53ca\u4e2d\u98a8 \u3002\u4f7f\n\u7528glucocorticoid \u53ef\u4ee5\u6e1b\u5c11aldosterone\u7684\u7522\u751f \u3002\nD.\u6aa2\u6e2caldosterone \u53carenin \u6fc3\u5ea6\u524d \uff0c\u61c9\u8a72\u5148\u5c07\u8840\u9240\u8abf\u81f3\u6b63\u5e38\u7bc4\u570d \uff0c\u4e26\u505c\u7528 minerocorticoid receptor \nantagonist \u81f3\u5c11 4\u9031\u3002\nE.\u4f7f\u7528thiazide\u6cbb\u7642\u5176\u9ad8\u8840\u58d3\u53ef\u80fd\u5c0e\u81f4\u4f4e\u8840\u9240\u60e1\u5316\u3002\n": "[A]", "110-104.\u4e00\u4f4d50\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u4e3b\u8a34\u56db\u6708\u521d\u56e0\u70ba\u5de6\u5074\u524d\u9838\u90e8\u816b\u75db\u5728\u5916\u5c31\u8a3a \uff0c\u7576\u6642\u7684\u7532\u72c0\u817a\u529f\u80fd\u6aa2\u67e5\u70ba: T4 10.85 \n\u03bcg/dL\u3001TSH 0.153 \u03bcIU/mL\uff0c\u672a\u505a\u5176\u4ed6\u6aa2\u67e5\u53ca\u6cbb\u7642 \u3002\u4e94\u6708\u521d\u75c5\u4eba\u4f86\u8a3a \uff0c\u8868\u793a\u5de6\u5074\u524d\u9838\u90e8\u75bc\u75db\u7a0d\u6e1b \uff0c\u4f46\u53f3\u5074\n\u524d\u9838\u90e8\u958b\u59cb\u75bc\u75db \u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u7532\u72c0\u817a\u816b\u5927 \uff0c\u53f3\u5074\u5c40\u90e8\u58d3\u75db\u6bd4\u5de6\u5074\u660e\u986f \uff0c\u8868\u9762\u76ae\u819a\u6b63\u5e38 \u3002\u6aa2\u67e5\u7d50\u679c\u986f\u793a \nfT4 3.01 ng/dL\u3001 TSH \u2266 0.005\u03bcIU/mL\u3001anti-thyroglobulin antibody 292 IU /mL\u3001anti-TPO 414 \nIU/mL\u3001ESR 36 mm /hr\u3001CRP 7.0 mg/L\u3001WBC 4.58*10\u00b3/\u03bcL\uff1b\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba ?\n(\u53c3\u8003\u503c: T4: 5.1-14.1\u03bcg/dL\u3001fT4 0.93~1.70 ng/dL\u3001TSH 0.270 ~ 4.200 \u00b5IU/mL\u3001anti-thyroglobulin \nantibody <60 IU/mL\u3001anti-TPO <60 IU/mL\u3001ESR 0-20 mm/hr\u3001CRP <5 mg/L\u3001WBC 4.00-10.80*10\u00b3/\u03bcL \n)   \nA.\u75c5\u4eba\u6709\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\uff0c\u61c9\u8a72\u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\u3002\nB.\u75c5\u4eba\u6709\u81ea\u9ad4\u514d\u75ab\u7532\u72c0\u817a\u75be\u75c5\uff0c\u61c9\u8a72\u7d66\u4e88\u985e\u56fa\u9187\u3002\nC.\u75c5\u4eba\u6709\u4e9e\u6025\u6027\u7532\u72c0\u817a\u708e\uff0c\u53ef\u4ee5\u7d66\u4e88non-steroid anti-inflammatory drug\u3002\nD.\u75c5\u4eba\u6709\u6025\u6027\u7532\u72c0\u817a\u708e\uff0c\u61c9\u8a72\u7d66\u4e88\u6297\u751f\u7d20\u3002\nE.\u7532\u72c0\u817a\u8d85\u97f3\u6ce2\u6bd4\u653e\u5c04\u6027\u7898\u6383\u63cf\u66f4\u6709\u52a9\u65bc\u9451\u5225fT4\u9ad8\u7684\u539f\u56e0\u3002\n": "[C]", "110-105.\u7cd6\u5c3f\u75c5\u7684\u8840\u7cd6\u63a7\u5236 \uff0c\u80f0\u5cf6\u7d20\u963b\u6297 (insulin resistance )\u662f\u91cd\u8981\u7684\u81f4\u75c5\u6a5f\u8f49 \uff0cThiazolidinedione (TZD)\u53ef\u4ee5\u6539\n\u5584\u589e\u52a0\u589e\u52a0\u80f0\u5cf6\u7d20\u654f\u611f\u5ea6 \uff0c\u76ee\u524d\u570b\u5167TZD\u985e\u85e5\u7269 \uff0c\u50c5\u6709Pioglitazone \uff0c\u4e0b\u5217\u4e4b\u9078\u9805\u4e2d \uff0c\u4f55\u8005\u70ba\u5fc5\u9808\u7559\u610f\u7684\n\u85e5\u7269\u526f\u4f5c\u7528\uff1f (1)\u9aa8\u6298 (2)\u5c3f\u9053\u611f\u67d3  (3)\u5fc3\u81df\u8870\u7aed (4)\u8166\u4e2d\u98a8 (5)\u773c\u775b\u9ec3\u6591\u90e8\u6c34\u816b \u3002   \nA.(1)+(2)+(3)\u3002\nB.(3)+(4)+(5)\u3002\nC.(1)+(3)+(5)\u3002\nD.(2)+(3)+(4)\u3002\nE.(1)+(2)+(5)\u3002   \n": "[C]", "110-106.\u9673\u5148\u751f\uff0c70\u6b72\uff0c\u9ad4\u91cd76\u516c\u65a4 \uff0c\u8eab\u9ad8160\u516c\u5206 \uff0cBMI \u70ba29.7\uff0c\u7cd6\u5c3f\u75c5\u8a3a\u65b7\u903e\u5341\u5e74 \uff0c\u672c\u6b21\u4f4f\u9662\u524d\u534a\u5e74 \uff0c\u66fe\u56e0\u5fc3\n\u808c\u6897\u585e\uff0c\u4f4f\u9662\u9032\u884c\u5fc3\u5c0e\u7ba1\u53ca\u7f6e\u653e\u652f\u67b6\u6cbb\u7642 \uff0c\u76ee\u524d\u751f\u6d3b\u4f5c\u606f\u53ef\u81ea\u7406 \uff0c\u4e3b\u8981\u7167\u9867\u8005\u70ba\u540c\u4f4f\u4e4b\u5152\u5b50 \u3002\u4f4f\u9662\u524d\u50c5\u63a5\n\u53d7\u6bcf\u5929\u65e9 \u3001\u665a\u9910\u5f8c\u53e3\u670d\u4e00\u9846Metformin (500mg/tab) \u6cbb\u7642 \uff0c\u4f4f\u9662\u4e2d\u63a5\u53d7\u80f0\u5cf6\u7d20\u6ce8\u5c04\u6cbb\u7642 \u3002\u672c\u6b21\u56e0\u793e\u5340\u578b\u80ba\n\u708e\u4f4f\u9662\u6cbb\u7642 \uff0c\u6297\u751f\u7d20\u4f7f\u7528 7\u5929\u5f8c\uff0c\u8a55\u4f30\u60c5\u6cc1\u7a69\u5b9a \uff0c\u76ee\u524d\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a \uff0c\u4e26\u9810\u5099\u51fa\u9662 \u3002\u4f4f\u9662\u4e2d\u4e4bHbA 1c \n\u70ba7.6 %\uff0c\u808c\u9178\u9150\u70ba 2.3 mg/dL (eGFR\u70ba 28mL /min/1.73m\u00b2)\u3002\u9810\u51fa\u9662\u524d\u4e4b\u6668\u9593\u7a7a\u8179\u8840\u7cd6\u70ba122 mg /dL\uff0c\u7576\n\u65e5\u65e9\u9910\u5f8c\u5169\u5c0f\u6642\u6307\u5c16\u624e\u91dd\u8840\u4e4b\u8840\u7cd6\u70ba166 mg /dL\u3002\u4e0b\u5217\u6709\u95dc\u51fa\u9662\u5f8c\u7cd6\u5c3f\u75c5\u6cbb\u7642\u5b89\u6392\u6558\u8ff0 \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u4f9d\u7167\u75c5\u60a3\u4e4beGFR\u8b8a\u5316\uff0cMetfromin\u5df2\u4e0d\u5b9c\u4f7f\u7528\u3002\nB.\u70ba\u9810\u9632\u7cd6\u5c3f\u75c5\u814e\u529f\u80fd\u7e7c\u7e8c\u60e1\u5316\u53ca\u75c5\u60a3\u66fe\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u53f2\uff0c\u61c9\u52a0\u4e0aDPP-4 inhibitor \u985e\u85e5\u7269\u6cbb\u7642\u3002\nC.\u4f9d\u64da\u76ee\u524d\u814e\u529f\u80fd\u4e4b\u8b8a\u5316\uff0c\u51fa\u9662\u5f8c\u4e0d\u5b9c\u4f7f\u7528SGLT-2 inhibitor\u3002\nD.\u5efa\u8b70\u51fa\u9662\u5f8c\u4e4bHbA1c\u63a7\u5236\u61c9\u4ee57.0 %\u4ee5\u4e0b\u70ba\u76ee\u6a19\u3002\nE.\u5efa\u8b70\u75c5\u60a3\u61c9\u65bc\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u8840\u7cd6 (Self Monitoring of Blood Glucose)\u3002\n": "[B]", "110-107.\u6709\u95dc\u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2 (Diabetic ketoacidosis)\u8a3a\u65b7\u53ca\u8655\u7f6e\uff0c\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?    \nA.\u75c5\u60a3\u591a\u6703\u5408\u4f75\u9ad8\u8840\u7cd6\u53ca\u4ee3\u8b1d\u9178\u4e2d\u6bd2 (Metabolic acidosis)\u3002\nB.\u75c5\u60a3\u8840\u4e2d\u51fa\u73fe\u916e\u9ad4 (serum ketone)\u662f\u8a3a\u65b7\u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2\u7684\u91cd\u8981\u95dc\u9375\u3002\nC.\u88dc\u5145\u6b64\u985e\u75c5\u60a3\u4e4b\u9ad4\u6db2\uff0c\u61c9\u540c\u6642\u78ba\u8a8d\u96fb\u89e3\u8cea\u5e73\u8861\uff0c\u4e00\u822c\u6703\u4f7f\u7528 0.9% Normal saline \u53ca 0.45% Saline\u3002\nD.\u898f\u5f8b\u6ce8\u5c04\u57fa\u790e\u80f0\u5cf6\u7d20\u662f\u6821\u6b63\u53ca\u907f\u514d\u75c5\u60a3\u916e\u9178\u4e2d\u6bd2\u60e1\u5316\u7684\u91cd\u8981\u6b65\u9a5f\u3002\nE.\u7576\u4f7f\u7528\u80f0\u5cf6\u7d20\u6821\u6b63\u8840\u7cd6\u81f3250 mg /dL \u6642\uff0c\u9664\u7e7c\u7e8c\u6ce8\u610f\u9ad4\u6db2\u91cf\u4e4b\u5e73\u8861\u4e4b\u5916 \uff0c\u61c9\u540c\u6b65\u52a0\u4e0a 5% Glucose \u4e4b\n\u8f38\u6db2\u3002\n": "[D]", "110-108.\u6709\u95dc\u7cd6\u5c3f\u75c5\u85e5\u7269\u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u662f\u932f\u8aa4\u7684 \uff1f\n(1)Metformin\u662f\u7cd6\u5c3f\u75c5\u6cbb\u7642\u539f\u5247\u7684\u7b2c\u4e00\u7dda\u7528\u85e5 \uff0c\u4f46\u7576eGFR < 45 \u6642\uff0c\u5373\u4e0d\u61c9\u4f7f\u7528Metformin \n(2)\u7814\u7a76\u986f\u793a \uff0cGLP-1 receptor agonist\u985e\u4e4b\u85e5\u7269\uff0c \u5177\u6709\u7cd6\u5c3f\u75c5\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u4fdd\u8b77\u7642\u6548\n(3)\u4f7f\u7528 Sulphonylurea\u985e\u85e5\u7269\u53ca\u80f0\u5cf6\u7d20 \uff0c\u5bb9\u6613\u51fa\u73fe\u4f4e\u8840\u7cd6\u53ca\u9ad4\u91cd\u4e0a\u5347 \n(4)Thiazolidinediones (TZD)\u9577\u671f\u4f7f\u7528\u6642 \uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u4e4b\u85e5\u7269\u526f\u4f5c\u7528 \n(5)\u7cd6\u5c3f\u75c5\u53e3\u670d\u85e5\u7269\u4e2d \uff0cDPP-4 inhibitor \u53caSGLT-2 inhibitor \uff0c\u5177\u6709\u7cd6\u5c3f\u75c5\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u4fdd\u8b77\u7642\u6548   \nA.(1)+(2)+(5)\u3002\nB.(1)+(3)+(4)\u3002\nC.(2)+(3)+(5)\u3002\nD.(2)+(3)+(4)\u3002\nE.(1)+(4)+(5)\u3002\n": "[E]", "110-109.\u4e00\u4f4d48\u6b72 \u7684\u5973\u6027 \uff0c\u8eab\u9ad8155\u516c\u5206 \uff0c\u9ad4\u91cd70\u516c\u65a4 \uff0c\u7121\u500b\u4eba\u6216\u5bb6\u65cf\u4e4b\u7cd6\u5c3f\u75c5\u53f2 \u3002\u6700\u8fd1\u5169\u5e74 \uff0c\u9ad4\u91cd\u81ea58\u516c\u65a4\u589e\n\u52a0\u81f3\u76ee\u524d\u4e4b\u9ad4\u91cd \u3002\u6700\u8fd1\u5169\u5e74 \uff0c\u6578\u6b21\u56e0\u660f\u5012\u610f\u8b58\u4e0d\u6e05 \uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab \uff0c\u4e26\u66fe\u65bc\u6025\u8a3a\u767c\u73fe\u6307\u5c16\u624e\u8840\u4e4b\u8840\u7cd6\n\u503c40mg/dL\uff0c\u5728\u6ce8\u5c0450 %\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58 \u3002\u75c5\u60a3\u65bc\u795e\u7d93\u5167\u79d1\u53ca\u5bb6\u5ead\u91ab\u5b78\u79d1\u5c31\u91ab\u8907\u67e5 \uff0c\u4e26\u672a\u767c\u73fe\u795e\u7d93\u5b78\n\u7570\u5e38\u6216\u7cd6\u5c3f\u75c5 \u3002\u672c\u6b21\u518d\u5ea6\u56e0\u610f\u8b58\u72c0\u614b\u4e0d\u6e05 \uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab \uff0c\u6025\u8a3a\u8840\u7cd6\u503c\u70ba 36mg /dL\uff0c\u6ce8\u5c04\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\n\u5fa9\u610f\u8b58\uff0c\u6e05\u9192\u5f8c\uff0c\u5728\u6025\u8a3a\u4ea6\u7121\u795e\u7d93\u5b78\u7570\u5e38\u75c7\u72c0 \uff0c\u5efa\u8b70\u4f4f\u9662\u9032\u4e00\u6b65\u8ffd\u67e5\u539f\u56e0 \u3002\u5728\u75c5\u623f\u4f4f\u9662\u6642 \uff0c\u7a7a\u81798\u5c0f\n\u6642\uff0c\u7121\u8f38\u6db2\u4e0b \uff0c\u6e05\u66688\u9ede\u7a7a\u8179\u8840\u7cd6\u70ba 82mg /dL\uff0c\u540c\u6642\u4e4b\u5167\u5206\u6ccc\u6aa2\u67e5\u986f\u793a \uff0cACTH 38 .6 pg/mL, Cortisol 19 .6 \nug/dL, Insulin 2.2 mIU/mL, C-peptide 2.0 ng/mL, TSH 3.82 mIU/mL\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u61c9\u8a72\u5efa\u8b70\u90a3\u4e00\u9805\u6aa2\u67e5 ?   \nA.\u53e3\u670d75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57\u3002\nB.\u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (Pituitary MRI)\u3002\nC.\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002\nD.Overnight 1mg Dexamathasone suppression\u6e2c\u8a66\u3002\nE.72 \u5c0f\u6642\u4e4b Prolonged fasting test\u3002   \n": "[E]", "110-110.\u6709\u95dc\u65bc\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5 \uff0c\u7814\u7a76\u986f\u793a35 -60%\u7684\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973 \uff0c\u572810\u81f320\u5e74\u671f\u9593\u4ecd\u6703\u9032\u5c55\u70ba\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5\n\u60a3\u3002\u4ee5\u4e0b\u6709\u95dc\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u4e4b\u76f8\u95dc\u6558\u8ff0 \uff0c\u90a3\u4e00\u9805\u662f\u932f\u8aa4\u7684 \uff1f   \nA.\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u7684\u8868\u73fe\uff0c\u4e3b\u8981\u8207\u6b64\u985e\u60a3\u8005\u61f7\u5b55\u6642\u7684\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e0d\u8db3\u76f8\u95dc\u3002\nB.\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u589e\u52a0\u7684\u8da8\u52e2\uff0c\u8207\u5a66\u5973\u80a5\u80d6\u7387\u7684\u589e\u52a0\u76f8\u95dc\u3002\nC.\u5982\u679c\u61f7\u5b55\u7b2c\u4e00\u671f\u5b55\u7a0b (first trimester )\u6642\uff0c\u5373\u51fa\u73fe\u8840\u7cd6\u7570\u5e38\u4e4b\u7cd6\u5c3f\u75c5\u8a3a\u65b7 \uff0c\u4ee3\u8868\u6b64\u75c5\u60a3\u65bc\u61f7\u5b55\u524d \uff0c\u5df2\u662f\n\u7cd6\u5c3f\u75c5\u7684\u60a3\u8005 \u3002\nD.\u76ee\u524d\u81e8\u5e8a\u5efa\u8b70\uff0c\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973\u7522\u5f8c\uff0c\u4ecd\u61c9\u6bcf\u4e09\u5e74\u9032\u884c\u8840\u7cd6\u7be9\u6aa2\u3002\nE.\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973\u7522\u4e0b\u4e4b\u65b0\u751f\u5152 \uff0c\u6bd4\u8d77\u6b63\u5e38\u598a\u5a20\u5a66\u5973\u4e4b\u4e0b\u4e00\u4ee3 \uff0c\u9577\u5927\u5f8c\u6709\u66f4\u9ad8\u7684\u98a8\u96aa \uff0c\u6210\u70ba\u7cd6\u5c3f\u75c5\u7684\n\u75c5\u60a3\u3002\n": "[A]", "110-111.\u6709\u95dc\u7cd6\u5c3f\u75c5\u80f0\u5cf6\u7d20\u7684\u751f\u7406\u6a5f\u8f49\u53ca\u85e5\u7269\u6cbb\u7642\uff0c\u4e0b\u5217\u4e4b\u6558\u8ff0\u4f55\u8005\u662f\u932f\u8aa4\u7684?    \nA.\u4eba\u9ad4\u80f0\u81df\u5206\u6ccc\u4e4b\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\uff0c\u5206\u6ccc\u5f8c\u76f4\u63a5\u9032\u5165\u9580\u975c\u8108\u7cfb\u7d71\u3002\nB.\u6ce8\u5c04\u578b\u4e4b\u5916\u6e90\u6027\u80f0\u5cf6\u7d20 \uff0c\u65bc\u6ce8\u5c04\u5f8c\u9032\u5165\u5168\u8eab\u7cfb\u7d71\u5faa\u74b0 \uff0c\u76f8\u8f03\u65bc\u4eba\u9ad4\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u7684\u6fc3\u5ea6\u70ba\n\u4f4e\uff0c\u5c6c\u65bcsubphysiologic insulin level \u3002\nC.\u5728\u75c5\u60a3\u6b63\u5e38\u4f5c\u606f\u4e0b\uff0c\u6bcf\u65e5\u6ce8\u5c04\u9577\u6548\u578b\u57fa\u790e\u80f0\u5cf6\u7d20\u7684\u6642\u6a5f\u70ba\u508d\u665a (evening)\u6216\u7761\u524d (before bedtime)\u3002\nD.\u5c31\u7cd6\u5c3f\u75c5\u63a7\u5236\u8840\u7cd6\u800c\u8a00 \uff0c\u6700\u7b26\u5408\u4eba\u9ad4\u751f\u7406\u6027\u9700\u6c42\u7684\u80f0\u5cf6\u7d20\u6ce8\u5c04\u65b9\u5f0f\u662f\u4e00\u5929\u4e00\u6b21\u7684\u9577\u6548\u578b\u57fa\u790e\u80f0\u5cf6\n\u7d20(basal insulin )\u3002\nE.\u75c5\u60a3\u4f4f\u9662\u6642 \uff0c\u5982\u679c\u9700\u8981\u6bcf\u65e5\u591a\u6b21\u6ce8\u5c04\u80f0\u5cf6\u7d20 \uff0c\u7d93\u9ad4\u91cd\u8a08\u7b97\u4e4b\u80f0\u5cf6\u7d20\u7e3d\u5291\u91cf\u768450 %\uff0c\u61c9\u4ee5\u57fa\u790e\u80f0\u5cf6\n\u7d20(basal insulin) \u7684\u65b9\u5f0f\u7d66\u85e5 \u3002\n": "[D]", "110-112.\u4ee5\u4e0b\u6709\u95dc\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u72c0\u614b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?    \nA.\u4f4e\u5bc6\u5ea6\u53ca\u6975\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d(LDL & VLDL)\u7684\u589e\u52a0\u662f\u91cd\u8981\u7684\u81f4\u75c5\u56e0\u5b50\uff0c\u4e26\u4e14\u8207\u80a5\u80d6\u3001\u80f0\u5cf6\u7d20\u963b\u6297\u76f8\u95dc\u3002\nB.\u9577\u671f\u651d\u53d6\u5927\u91cf\u7684\u91a3\u985e\u98df\u7269\u53ca\u6301\u7e8c\u7684\u98f2\u9152 \uff0c\u5176\u8840\u8102\u7570\u5e38\u8868\u73fe\u70baVLDL \u53caTG\u589e\u52a0\uff0c\u4ee5\u53ca\u8840\u4e2d\u4e4bHDL\u6fc3\u5ea6\u964d\n\u4f4e\u3002\nC.\u80a5\u80d6\u53ca\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u589e\u52a0\u6642\uff0c\u8840\u8102\u7570\u5e38\u7684\u8868\u73fe\u4e3b\u8981\u662fTG\u589e\u52a0\u3002\nD.\u7532\u72c0\u817a\u6a5f\u80fd\u4e0d\u8db3 (Hypothyroidism) \u6642\uff0c\u8840\u4e2d\u4e4bLDL\u6fc3\u5ea6\u6703\u660e\u986f\u5347\u9ad8\uff0c\u9020\u6210\u5fc3\u8840\u7ba1\u75be\u75c5\u3002\nE.\u8840\u8102\u7570\u5e38\u75be\u75c5 \uff0c\u540c\u6642\u53d7\u5230\u907a\u50b3\u56e0\u5b50 (genetic predisposition )\u53ca\u74b0\u5883\u56e0\u7d20 (environmental contribution )\u7684\n\u5f71\u97ff\u3002\n": "[B]", "111-97.\u4ee5\u4e0b\u6709\u95dc\u61f7\u5b55\u8207\u7532\u72c0\u817a\u75be\u75c5\u7684\u63cf\u8ff0 \uff0c\u54ea\u5e7e\u9805\u6700\u6b63\u78ba ?\n(1) \u61f7\u5b55\u5a66\u5973\u9ad4\u5167\u7684\u7532\u72c0\u817a\u523a\u6fc0\u7403\u86cb\u767d (thyroid stimulating immunoglobulins )\u53ef\u4ee5\u904e\u80ce\u76e4\u9020\u6210\u80ce\u5152\u7684\u7532\u72c0\u817a\n\u6bd2\u75c7\u3002\n(2) \u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (Food and Drug Administration) \u5efa\u8b70\u4e0d\u8ad6\u61f7\u5b55\u9031\u671f \uff0c\u61f7\u5b55\u5a66\u5973\u7684\u9996\u9078\u6297\u7532\u72c0\u817a\u85e5\n\u7269\u5747\u70bapropylthiouracil \u3002\n(3) \u4e00\u822c\u800c\u8a00 \uff0c\u4f7f\u7528\u653e\u5c04\u6027\u7898\u6cbb\u7642\u516d\u500b\u6708\u4ee5\u5f8c\u53ef\u4ee5\u5b89\u5168\u53d7\u5b55 \uff0c\u4f46\u5728\u61f7\u5b55\u53ca\u54fa\u4e73\u671f\u4f7f\u7528\u653e\u5c04\u6027\u7898\u6cbb\u7642\u662f\u7d55\u5c0d\n\u7981\u5fcc\u3002\n(4) \u80ce\u5152\u7532\u72c0\u817a\u6bd2\u75c7\u7684\u5fb5\u5019\u5305\u62ec\u5b50\u5bae\u5167\u751f\u9577\u9072\u7de9 (poor intrauterine  growth) \u3001\u5fc3\u8df3\u8d85\u904e\u6bcf\u5206\u9418160 \u4e0b\u3001\u9aa8\u9f61\n\u8d85\u904e(advanced bone age )\u3001\u7532\u72c0\u817a\u816b\u7b49 \u3002\n(5) \u7522\u5f8c\u5f88\u5bb9\u6613\u6709\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u7684\u5fa9\u767c \uff0c\u4f46\u82e5\u54fa\u4e73 \uff0c\u5247\u4e0d\u61c9\u8a72\u4f7f\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269 \u3002   \nA.(1)+(2)\u3002\nB.(3)+(4)\u3002\nC.(4)+(5)\u3002\nD.(1)+(3)+(4)\u3002\nE.(2)+(3)+(5)\u3002   \n": "[D]", "111-98.\u4e0b\u5217\u56e0\u7d20\u53ef\u80fd\u9020\u6210\u9ad8\u8840\u9223\u75c7 \uff0c\u54ea\u5e7e\u9805\u63cf\u8ff0\u6700\u6b63\u78ba ?\n(1) \u8207\u526f\u7532\u72c0\u817a\u8377\u723e\u8499 (parathyroid hormone, PTH )\u76f8\u95dc\uff0c\u5305\u62ec\u526f\u7532\u72c0\u817a\u764c \u3001\u4f7f\u7528\u92f0\u9e7d\u6cbb\u7642 \u3001\u5bb6\u65cf\u6027\u4f4e\u5c3f\u9223\n\u9ad8\u8840\u9223\u7b49 \u3002\n(2) 24-hydroxylase\u7f3a\u4e4f\u4f7f 1,25(OH)\u2082D\u4ee3\u8b1d\u8b8a\u6162\u53ef\u80fd\u5c0e\u81f4\u9ad8\u8840\u9223 \u3002\n(3) \u7dad\u751f\u7d20A\u7f3a\u4e4f\u3001\u4f7f\u7528Thiazides \u3001\u8102\u80aa\u6d88\u89e3 (fat necrosis )\u7b49\u53ef\u80fd\u52a0\u5feb\u9aa8\u4ee3\u8b1d\u800c\u9020\u6210\u9ad8\u8840\u9223 \u3002\n(4) \u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b \u3001\u4e0d\u52d5(immobilization) \u4f7f\u4ee3\u8b1d\u8b8a\u6162 \uff0c\u9223\u4e0d\u6613\u6392\u51fa \uff0c\u56e0\u6b64\u53ef\u80fd\u9020\u6210\u9ad8\u8840\u9223 \u3002\n(5) \u60e1\u6027\u816b\u7624\u53ef\u80fd\u56e0\u70ba\u8f49\u79fb (metastasis )\u6216\u5206\u6ccc\u67d0\u4e9b\u56e0\u5b50 (humoral mediation )\u800c\u9020\u6210\u9ad8\u8840\u9223 \u3002   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(5)\u3002\nD.(2)+(3)+(5)\u3002\nE.(1)+(2)+(5)\u3002\n": "[E]", "111-99.\u4e0b\u5217\u6709\u95dc\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4(Cushing's syndrome)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6700\u6b63\u78ba?    \nA.\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u75c5\u56e0\u4e0d\u540c \uff0c\u7537\u5973\u597d\u767c\u6bd4\u4f8b\u5404\u7570 \u3002\u5176\u4e2d\uff0c\u6613\u4f4d\u6027\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 (ectopic ACTH \nsyndrome )\u4ee5\u5973\u6027\u5c45\u591a \uff1b\u4f46\u814e\u4e0a\u817a\u76ae\u8cea\u816b\u7624\u7684 \uff0c\u5247\u4ee5\u7537\u6027\u5c45\u591a \u3002\nB.\u5728\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u7684\u8a3a\u65b7\u6d41\u7a0b\u4e2d \uff0c\u4f4e\u5291\u91cfdexamethasone \u58d3\u6291\u6e2c\u8a66 (low dose dexamethasone \nsuppression test )\uff0c\u7d66\u4e880.5 mg dexamethasone q 6h \u5169\u5929\u5f8c \uff0c\u5982\u679c\u8840\u6e05\u4e2d\u7684cortisol \u6fc3\u5ea6\u4f4e\u65bc 50 \nnmol/L\uff0c\u61c9\u8a72\u53ef\u4ee5\u5148\u6392\u9664\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 \u3002\nC.40%\u5eab\u6b23\u6c0f\u75c7 (Cushing's disease)\u75c5\u4eba\u7684\u8166\u5782\u9ad4\u816b\u7624\u5927\u65bc1\u516c\u5206\u3002\nD.\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u7684\u75c5\u4eba\u901a\u5e38\u767d\u8840\u7403\u6578\u4e0b\u964d\uff0c\u4e14\u55dc\u9e7c\u6027\u7d30\u80de(basophil)\u589e\u52a0\u3002\nE.\u5eab\u6b23\u6c0f\u75c7\u7684\u75c5\u4eba\u6709\u9ad8\u51dd\u8840 (hypercoagulation )\uff0c\u80ba\u6813\u585e(pulmonary embolism )\u7684\u98a8\u96aa\u589e\u52a0 \uff0c\u4f46\u6df1\u90e8\u975c\n\u8108\u6813\u585e(deep vein thromobosis )\u7684\u98a8\u96aa\u4e26\u672a\u589e\u52a0 \u3002\n": "[B]", "111-100.\u4e0b\u5217\u6709\u95dc\u65bc\u539f\u767c\u6027\u919b\u56fa\u916e\u75c7(primary aldosteronism, PA)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6700\u6b63\u78ba?    \nA.PA\u7684\u75c5\u4eba\u53ef\u80fd\u589e\u52a0\u9aa8\u8cea\u758f\u9b06\u3001\u7cd6\u5c3f\u75c5\u3001\u8a8d\u77e5\u969c\u7919\u7b49\u75be\u75c5\u98a8\u96aa\uff0c\u4e5f\u53ef\u80fd\u4f7fcortisol\u7684\u5206\u6ccc\u6e1b\u5c11\u3002\nB.PA\u7684\u9451\u5225\u8a3a\u65b7\u904e\u7a0b\u4e2d \uff0c\u6aa2\u6e2c\u919b\u56fa\u916e /\u814e\u7d20\u6bd4\u503c (aldosterone /renin ratio, ARR )\u6642, \u9664\u4e86\u9700\u8981\u505c\n\u7528spironolactone 4\u9031\u5916\uff0c\u53ef\u4ee5\u6301\u7e8c\u539f\u6709\u7684\u8840\u58d3\u85e5 \u3002\u4f46\u56e0\u70ba\u03b2-blocker\u53ef\u80fd\u4f7fARR\u4e0b\u964d \uff0c\u56e0\u6b64\u82e5\u6aa2\u6e2c\u7d50\n\u679c\u4e0d\u78ba\u5b9a (equivocal )\u6642\uff0c\u6700\u597d\u505c\u7528 \u03b2-blocker\u5169\u9031\u5f8c\u518d\u91cd\u8907\u6e2c\u91cf\u4e00\u6b21 \u3002\nC.\u751f\u7406\u98df\u9e7d\u6c34\u975c\u6ce8\u6e2c\u8a66 (saline infusion test )\uff0c\u57284\u5c0f\u6642\u5167\u975c\u8108\u8f38\u6ce8 2\u516c\u5347\u751f\u7406\u98df\u9e7d\u6c34\u5f8c \uff0caldosterone \u6fc3\n\u5ea6\u70ba280 pmol /L (10 ng/dL)\u53ef\u6392\u9664PA \u3002\nD.\u814e\u4e0a\u817a\u975c\u8108\u53d6\u6a23 (adrenal vein sampling )\u6642\uff0c\u5982\u679c\u53f3\u3001\u5de6\u814e\u4e0a\u817a\u975c\u8108\u4e2d\u7684aldosterone /cortisone\u6fc3\u5ea6\u6bd4\n\u5dee\u8ddd\u70ba1.8\uff0c\u53ef\u63a1\u4fe1\u662f\u53f3\u814e\u4e0a\u817a\u9020\u6210PA \u3002\nE.\u7cd6\u76ae\u8cea\u985e\u56fa\u9187\u53ef\u6291\u5236\u6027\u919b\u56fa\u916e\u589e\u591a\u75c7 \uff08glucocorticoid remediable aldosteronism, GRA \uff09\u61c9\u5148\u4ee5\u4f4e\u5291\n\u91cfdexamethasone\u63a7\u5236\u8840\u58d3 \u3002\u82e5\u9700\u8981\uff0c\u53ef\u52a0\u4e0a\u919b\u56fa\u916e\u53d7\u9ad4\u62ee\u6297\u5291 \u3002\n": "[E]", "111-101.\u55dc\u927b\u7d30\u80de\u7624 (pheochromocytoma) \u88ab\u8996\u70ba \u201c\u5049\u5927\u7684\u507d\u88dd\u8005 (the great masquerader )\u201d\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\n\u78ba?   \nA.\u55dc\u927b\u7d30\u80de\u7624\u7684\u75c7\u72c0\u5305\u62ec\u9ad8\u8840\u58d3\u53ca\u9663\u767c\u6027\u7684\u5fc3\u60b8 \u3001\u5192\u6c57\u3001\u982d\u75db\u7b49\u3002\u901a\u5e38\u5176\u75c7\u72c0\u660e\u986f \uff0c\u4f46\u4e5f\u6709\u67d0\u4e9b\u75c5\u4eba\u53ef\n\u4ee5\u7121\u75c7\u72c0\u9054\u6578\u5e74\u4e4b\u4e45 \u3002\nB.\u55dc\u927b\u7d30\u80de\u7624\u7684\u75c7\u72c0\u767c\u4f5c\u983b\u7387\u4e0d\u5b9a\uff0c\u4f46\u6bcf\u6b21\u767c\u4f5c\u6642\u9593\u901a\u5e38\u5927\u65bc\u5169\u5c0f\u6642\u3002\nC.\u4e09\u74b0\u6297\u6182\u9b31\u85e5 (tricyclic antidepressants )\u3001opiates\u3001metoclopramide\u7b49\u85e5\u6703\u6e1b\u5c11\u55dc\u927b\u7d30\u80de\u7624\u7684\u75c7\u72c0\u8868\n\u73fe\uff0c\u5ef6\u7de9\u8a3a\u65b7 \u3002\nD.\u75c5\u4eba\u61f7\u7591\u6709\u55dc\u927b\u7d30\u80de\u7624\u9700\u8981\u505a\u96fb\u8166\u65b7\u5c64\u6216\u6838\u78c1\u5171\u632f\u7b49\u5f71\u50cf\u5b78\u6aa2\u67e5\u6642 \uff0c\u70ba\u6e1b\u5c11\u523a\u6fc0 \uff0c\u6700\u597d\u4e0d\u8981\u65bd\u6253\u986f\u5f71\n\u5291\u3002   \nE.\u8207\u5176\u4ed6\u6aa2\u9a57\u65b9\u5f0f\u6bd4\u8f03 \uff0c\u6aa2\u6e2c\u8840\u4e2d\u7684metanephrine \u5177\u6709\u9ad8\u654f\u611f\u5ea6 \uff0c\u4f46\u56e0\u5f88\u5bb9\u6613\u53d7\u5230\u975c\u8108\u7a7f\n\u523a(venipuncture )\u7b49\u58d3\u529b\u5f71\u97ff \uff0c\u800c\u6709\u8f03\u9ad8\u7684\u507d\u967d\u6027 \u3002\n": "[A]", "111-102.\u8166\u5782\u9ad4\u816b\u7624 (pituitary adenomas) \u53ef\u80fd\u4f34\u96a8\u8166\u5782\u9ad4\u8377\u723e\u8499\u5206\u6ccc\u7570\u5e38\u3002\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u4e0d\u6b63\u78ba?    \nA.\u8166\u5782\u9ad4\u816b\u7624\u901a\u5e38\u6e90\u81ea\u55ae\u4e00\u578b\u614b\u7d30\u80de\uff0c\u4f46\u53ef\u80fd\u6709\u5169\u7a2e\u4ee5\u4e0a\u8377\u723e\u8499\u7684\u904e\u591a\u5206\u6ccc\u3002\nB.\u6ccc\u4e73\u6fc0\u7d20\u7624 (prolactinoma )\u7684\u5927\u5c0f\u8207\u6ccc\u4e73\u6fc0\u7d20 (prolactin, PRL )\u6fc3\u5ea6\u76f8\u95dc \u3002PRL\u6fc3\u5ea6\u5927\u65bc150 \u03bcg/L\uff0c\u5176\n\u816b\u7624\u7686\u5927\u65bc1 \u516c\u5206 \u3002\nC.\u751f\u9577\u6fc0\u7d20 (growth hormone, GH )\u6709\u8108\u52d5\u6027 (pulsatile)\u5206\u6ccc\uff0c\u55ae\u4e00\u96a8\u610f (single, random )\u6aa2\u6e2c\u7684GH\u6fc3\u5ea6\u7121\n\u6cd5\u7528\u4ee5\u78ba\u5b9a (\u6216\u6392\u9664)\u80a2\u7aef\u80a5\u5927\u75c7 (acromegaly )\u7684\u8a3a\u65b7\uff0c\u4e5f\u7121\u6cd5\u4ee3\u8868\u75be\u75c5\u7684\u56b4\u91cd\u5ea6 \u3002\nD.\u985e\u80f0\u5cf6\u7d20\u751f\u9577\u56e0\u5b501 (insulin-like growth factor 1\uff0cIGF-1)\u7684\u6fc3\u5ea6\u6703\u56e0\u5e74\u7d00\u4e0d\u540c\u800c\u7570 \u3002GH\u53ef\u4ee5\n\u4f7fIGF-1\u7684\u6fc3\u5ea6\u589e\u52a0 \uff0c\u9650\u5236\u71b1\u91cf\u651d\u53d6 (caloric restriction )\u6703\u4f7f IGF -1\u6fc3\u5ea6\u4e0b\u964d \u3002\nE.\u5927\u591a\u6578\u5eab\u6b23\u6c0f\u75c7(Cushing's disease)\u7684\u8166\u5782\u9ad4\u816b\u7624\u662f\u5c0f\u65bc0.5 \u516c\u5206\u7684 microadenoma\u3002\n": "[B]", "111-103.\u6709\u95dc\u6027\u817a\u529f\u80fd\u7570\u5e38\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6700\u6b63\u78ba?    \nA.Turner's syndrome \u6703\u8868\u73fe hypogonadotropic hypogonadism\u3002\nB.\u9871\u54bd\u7624(Craniopharygioma)\u53ef\u5c0e\u81f4hypergonadotropic hypogonadism\u3002\nC.\u8840\u6db2\u4e2d\u7684\u776a\u56fa\u916e (testosterone )\u7d0480%\u8207\u767d\u86cb\u767d\u6216\u6027\u8377\u723e\u8499\u7d50\u5408\u7403\u86cb\u767d (sex hormone -binding globulin, \nSHBG)\u7d50\u5408\uff0c\u7d0420%\u5c6c\u6e38\u96e2\u578b \u3002\nD.Klinefelter syndrome\u75c5\u4eba\u7f79\u60a3\u4e73\u764c \u3001\u7cd6\u5c3f\u75c5\u3001\u9aa8\u8cea\u758f\u9b06 \u3001\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621 (systemic lupus \nerythematosus, SLE )\u7b49\u75be\u75c5\u7684\u98a8\u96aa\u589e\u52a0 \uff0c\u4f46\u7f79\u60a3\u651d\u8b77\u817a\u764c\u7684\u98a8\u96aa\u964d\u4f4e \u3002\nE.Ketoconazole\u53ef\u4ee5\u523a\u6fc0\u6291\u5236\u776a\u56fa\u916e (testosterone )\u7684\u751f\u6210\uff0c\u800cspironolactone\u53ef\u4ee5\u963b\u65b7\u96c4\u6fc0\n\u7d20(androgen )\u7684\u4f5c\u7528\u3002\n": "[D]", "111-104.\u4e0b\u5217\u6709\u95dc\u5c3f\u5d29\u75c7(diabetes insipidus, DI)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6700\u6b63\u78ba?    \nA.\u5c3f\u5d29\u75c7\u7684\u5b9a\u7fa9\u70ba24 \u5c0f\u6642\u5c3f\u91cf\u8d85\u904e30 ml/\u516c\u65a4\u9ad4\u91cd\uff0c\u4e14\u5c3f\u6ef2\u900f\u58d3 <250 mosmol/L\u3002\nB.\u6b63\u5e38\u4eba\u7684\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5 \uff0c\u5f8c\u8449\u5728T1-weighted midsagittal images \u6703\u5448\u73fe\u4eae\u9ede \u3002\u6b64\u4eae\u9ede\u5728\u539f\u767c\n\u6027\u591a\u98f2\u75c7 \uff08primary polydipsia \uff09\u6216\u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI )\u6703\u6d88\u5931\u3002\nC.\u67d0\u4e9b\u85e5\u7269 \uff0c\u4f8b\u5982lithium \u3001amphotericin B \u3001aminoglycosides\u7b49\u53ef\u80fd\u5c0e\u81f4\u814e\u6027\u5c3f\u5d29\u75c7 (nephrogenic \nDI)\u3002\nD.\u61f7\u5b55\u671f\u5c3f\u5d29\u75c7(gestational DI) \u5e38\u8868\u73fe\u65bc\u61f7\u5b55\u7684\u982d\u4e09\u500b\u6708\uff0c\u96a8\u5b55\u671f\u4e4b\u589e\u52a0\u800c\u9010\u6f38\u6539\u5584\u3002\nE.Desmopressin (DDAVP)\u53ef\u6cbb\u7642\u539f\u767c\u6027\u591a\u98f2\u75c7 (primary polydipsia )\u6216\u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI )\u3002\u814e\u6027\n\u5c3f\u5d29\u75c7 (nephrogenic DI )\u61c9\u4ee5thiazide\u5229\u5c3f\u5291\u3001 amiloride \u3001indomethacin \u7b49\u85e5\u7269\u6cbb\u7642 \u3002\n": "[C]", "111-105.\u7cd6\u5c3f\u75c5\u8207\u80a5\u80d6\u7d44\u6210\u7cd6\u80d6\u75c7 (Diabesity )\uff0c\u5728\u65b0\u9673\u4ee3\u8b1d\u75be\u75c5\u7684\u7bc4\u7587\u5167 \uff0c\u80a5\u80d6\u5df2\u7d93\u6210\u70ba\u63a7\u5236\u7cd6\u5c3f\u75c5\u8840\u7cd6\u4e4b\u91cd\u8981\u969c\n\u7919\uff0c\u4e0b\u5217\u4e4b\u6709\u95dc\u7cd6\u80d6\u75c7\u4e4b\u63cf\u8ff0 \uff0c\u4f55\u8005\u6709\u8aa4 ?   \nA.\u904b\u52d5\u5c0d\u65bc\u9ad4\u91cd\u63a7\u5236\u975e\u5e38\u91cd\u8981 \uff0c\u5be6\u8b49\u7814\u7a76\u986f\u793a\u904b\u52d5\u5f37\u5ea6\u6108\u5f37\u6642 \uff0c\u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u7387 \uff0c\u4e5f\u53ef\u4ee5\u964d\u4f4e\u5fc3\n\u81df\u8840\u7ba1\u75be\u75c5\u4e4b\u6b7b\u4ea1\u7387 \u3002\nB.\u7f8e\u570b\u570b\u885b\u9662\u9032\u884c\u4e4b\u751f\u6d3b\u578b\u614b\u7814\u7a76LOOKAHEAD \uff0c\u91dd\u5c0d\u7cd6\u5c3f\u75c5\u7684\u60a3\u8005\u5b89\u6392\u71df\u990a\u8aee\u8a62\u53ca\u9ad4\u91cd\u7ba1\u7406 \uff0c\u96d6\u7136\n\u53ef\u4ee5\u6539\u5584\u8840\u7cd6\u53caHbA 1c\u4e4b\u63a7\u5236\uff0c\u4f46\u662f\u6700\u7d42\u7814\u7a76\u7d50\u679c \uff0c\u537b\u986f\u793a\u7121\u6cd5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u8005\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u6b7b\u4ea1\n\u7387\u3002\nC.\u751f\u6d3b\u578b\u614b\u4e4b\u65bc\u7cd6\u5c3f\u75c5\u98f2\u98df\u63a7\u5236\u539f\u5247 \uff0c\u8a08\u756b\u6027\u98f2\u98df\u53ca\u904b\u52d5\u964d\u4f4e\u7684\u9ad4\u91cd\u53ca\u8102\u80aa\u7d44\u7e54 \uff0c\u53ef\u4ee5\u9810\u9632\u75be\u75c5\u4e4b\u9032\n\u5c55\u3002\nD.\u76ee\u524d\u5be6\u8b49\u91ab\u5b78\u4e0a \uff0c\u91dd\u5c0d\u7cd6\u80d6\u75c7\u4e4b\u8840\u7cd6\u63a7\u5236 \uff0c\u4ee5\u53ca\u6709\u6548\u964d\u4f4e\u9ad4\u91cd \uff0c\u4f7f\u7528Glucagon -like peptide -1 \nreceptor agonist (GLP-1 RA)\u662f\u6cbb\u7642\u4e0a\u5e38\u898b\u7684\u8003\u91cf\u4e4b\u4e00 \u3002   \nE.\u904e\u53bb\u4e8c\u5341\u5e74\u4e4b\u6e1b\u91cd\u624b\u8853\u7814\u7a76 \uff0c\u986f\u793a\u9ad4\u91cd\u6e1b\u8f15\u4e4b\u904e\u7a0b\u4e2d \uff0c\u7cd6\u5c3f\u75c5\u9032\u5c55\u53ca\u5fc3\u81df\u8840\u7ba1\u6b7b\u4ea1\u7387\u5747\u5f97\u5230\u7d71\u8a08\u5b78\n\u4e0a\uff0c\u6709\u610f\u7fa9\u4e4b\u6539\u5584 \u3002\n": "[A]", "111-106.\u694a\u5148\u751f\uff0c56\u6b72\uff0c\u8eab\u9ad8164\u516c\u5206 \uff0c\u9ad4\u91cd 77 \u516c\u65a4 \uff0c\u4e26\u7121\u7cd6\u5c3f\u75c5\u4e4b\u5bb6\u65cf\u53ca\u500b\u4eba\u75c5\u53f2 \uff0c\u6700\u8fd1\u534a\u5e74 \uff0c\u9ad4\u91cd\u589e\u52a0\u4e86 4\u516c\n\u65a4\u3002\u8fd1\u4e00\u5e74\u4ee5\u4f86 \uff0c\u6578\u6b21\u56e0\u4e0d\u660e\u539f\u56e0\u660f\u5012 \uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab \u3002\u75c5\u53f2\u6709\u9ad8\u8840\u58d3 \uff0c\u6bcf\u65e5\u898f\u5247\u670d\u7528Losartan \n50mg\u53caAmlodipine 5mg\uff0c\u904e\u53bb\u9580\u8a3a\u7121\u7570\u5e38\u795e\u7d93\u8840\u7ba1\u4e4b\u7570\u5e38\u72c0\u6cc1 \u3002\u672c\u6b21\u5c45\u5bb6\u6642 \uff0c\u518d\u5ea6\u660f\u5012 \uff0c\u4e26\u4e14\u610f\u8b58\u6301\u7e8c\n\u4e0d\u6e05\uff0c\u56e0\u6b64\u9001\u5230\u6025\u8a3a \u3002\u672c\u6b21\u6025\u8a3a\u4e4b\u8840\u58d3\u70ba98 /60 mmHg \uff0c\u8108\u640f\u70ba\u898f\u5f8b\u768484 bpm \uff0c\u6025\u8a3a\u4e4b\u8840\u7cd6\u986f\u793a\u70ba22 \nmg/dL\uff0c\u7d66\u4e8850%\u4e4b\u8461\u8404\u7cd6\u8f38\u6db2\u5f8c \uff0c\u6062\u5fa9\u610f\u8b58 \u3002\u56e0\u6b64\u5efa\u8b70\u4f4f\u9662\u8a3a\u5bdf \uff0c\u5728\u75c5\u623f\u7121\u9ede\u6ef4\u8f38\u6db2\u7684\u524d\u63d0\u4e0b \uff0c\u7a7a\u81798 \n\u5c0f\u6642\u5f8c\uff0c\u62bd\u8840\u5831\u544a\u70ba: \u7a7a\u8179\u8840\u7cd6 76 mg /dL \uff0cInsulin 3.6 mIU/mL \uff0cC-peptide 2.6 ng/mL\uff0cACTH 62 .2 \npg/mL\uff0cCortisol 16 .3 ug/dL\uff0cIGF-1 106 ng /mL\uff0cTSH 4.32 mIU/mL\uff0c\u65bc\u6b64\u6642\u61c9\u8003\u616e\u4e4b\u512a\u5148\u6aa2\u67e5\u9805\u76ee\u70ba\n\u4f55?   \nA.\u8179\u90e8\u809d\u80f0\u78c1\u632f\u651d\u5f71 (Magnetic resonance image, MRI)\u3002\nB.72\u5c0f\u6642\u5ef6\u9577\u7981\u98df\u6e2c\u8a66 ( Prolonged fasting test)\u3002\nC.24\u5c0f\u6642\u5fc3\u96fb\u5716 (Holter ECG monitor)\u3002\nD.\u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71(MRI)\u3002\nE.\u7d93\u98df\u9053\u5167\u8996\u93e1\u8d85\u97f3\u6ce2 (Endoscopic ultrasound, EUS)\u3002\n": "[B]", "111-107.\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\u85e5\u7269\u773e\u591a \uff0c\u4e0b\u5217\u4e4b\u964d\u8840\u7cd6\u85e5\u7269\u4e2d \uff0c\u5be6\u8b49\u7814\u7a76\u986f\u793a\u90a3\u4e9b\u85e5\u7269 \uff0c\u6709\u660e\u78ba\u53ef\u964d\u4f4e Major adverse \ncardiovascular events (cardiovascular death, non -fatal myocardial infarctiomn, non -fatal stroke) \u4e4b\u7d50\u679c ?\n(1) Alpha-glucosidase inhibitors\n(2) Glucagon -like peptide 1 receptor agonists\n(3) Sulfonylurea\n(4) Dipepetidyl peptidase inhibitor\n(5) Sodium -glucose co -transporter -2 inhibitors   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(3)+(5)\u3002\nE.(2)+(5)\u3002\n": "[E]", "111-108.Thiazolidinedione (TZD)\u985e\u4e4b\u80f0\u5cf6\u7d20\u589e\u654f\u5291 \uff0c\u53ef\u4ee5\u6539\u5584\u80f0\u5cf6\u7d20\u5728\u4eba\u9ad4\u5167\u4e4b\u654f\u611f\u5ea6 \uff0c\u6587\u737b\u5831\u544a\u986f\u793a\u4e5f\u53ef\u4ee5\u6539\n\u5584\u86cb\u767d\u5c3f \uff0c\u4f46\u662f\u672c\u985e\u85e5\u7269\u4e5f\u6709\u4e9b\u526f\u4f5c\u7528 \u3002\u4ee5Pioglitazone\u70ba\u4f8b \uff0c\u4f7f\u7528\u76f8\u95dc\u85e5\u7269\u526f\u4f5c\u7528\u5305\u62ec\u4e0b\u5217\u4f55\u8005? \n(1) \u6c34\u816b (edema)\n(2) \u8a8d\u77e5\u969c\u7919 (cognitive dysfunction) \n(3 )\u8106\u5f31\u6027\u9aa8\u6298 (fragility frcuture )\n(4) \u8166\u4e2d\u98a8 (Storke) \n(5) \u9ad4\u91cd\u53ca\u8102\u80aa\u7d44\u7e54\u589e\u52a0   \nA.(1)+(2)+(4)\u3002\nB.(1)+(2)+(3)\u3002\nC.(1)+(3)+(5)\u3002\nD.(2)+(3)+(5)\u3002\nE.(3)+(4)+(5)\u3002   \n": "[C]", "111-109.\u674e\u5148\u751f\uff0c64\u6b72\uff0c\u7cd6\u5c3f\u75c5\u75c5\u53f2\u70ba 8\u5e74\uff0c\u4e00\u5e74\u524d\u56e0\u51a0\u72c0\u52d5\u8108\u75be\u75c5 (three vessles disease )\u9032\u884c\u5fc3\u5c0e\u7ba1 \uff0c\u4e26\u7f6e\u653e\n\u652f\u67b6\uff0c\u76ee\u524d\u4f7f\u7528\u4e4b\u8840\u7cd6\u63a7\u85e5\u7269\u70ba\u80f0\u5cf6\u7d20 insulin degludec (70%)/aspart (30%)\u3002\u9ad8\u8840\u58d3\u85e5\u7269\u70ba\u6bcf\n\u65e5Valsatan 160mg \u53caAmlodipine 5mg \uff0c\u81bd\u56fa\u9187\u85e5\u7269\u70ba Atorvastatin \u6bcf\u65e540mg \u3002\u76ee\u524d\u4e4b\u7a7a\u8179\u8840\u7cd6\u70ba 132 \nmg/dL\uff0cHbA1c \u70ba 7.0 %\uff0cLDL cholesterol \u70ba 55 mg /dL\uff0cHDL cholesterol 48 mg /dL\uff0cTriglyceride \u70ba \n628 mg/dL\uff0c\u5c3f\u6db2\u986f\u793a\u6709\u5de8\u91cf\u767d\u86cb\u767d\u5c3f (macroalbuminuria )\uff0c\u4e14\u6709\u975e\u589e\u6b96\u578b\u8996\u7db2\u819c\u75c5\u8b8a (Non-proliferative \nretinopathy )\uff0c\u76ee\u524d\u61c9\u8a72\u589e\u52a0\u4f7f\u7528\u4e0b\u5217\u54ea\u4e00\u9805\u85e5\u7269 ?   \nA.Ezetimibe\u3002\nB.Cholestyramine\u3002\nC.PCSK9 (Proprotein convertase subtilisin/kexin type9) inhibitor\u3002\nD.Fenofibrate\u3002\nE.Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors\u3002\n": "[D]", "111-110.GLP-1 receptor agonist \u8207DPP-4 inhibitors\u5c6c\u65bcIncretin \u8178\u6ccc\u7d20\u985e\u985e\u85e5\u7269 \u3002\u4ee5\u4e0b\u6709\u95dc \u8178\u6ccc\u7d20\u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\n\u70ba\u6b63\u78ba? \n(1) GLP-1 (Glucagon like peptide -1) \u7531\u8178\u9053\u4e4bL cell\u5206\u6ccc\n(2) GLP-1 \u53ef\u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc \uff0c\u4f46\u4e5f\u523a\u6fc0\u6607\u7cd6\u6fc0\u7d20 (Glucagon )\u5206\u6ccc\n(3) \u4f7f\u7528GLP -1 receptor agonist\u6cbb\u7642\u7cd6\u5c3f\u75c5\u60a3\u8005\u6642 \uff0c\u4e5f\u6709\u660e\u986f\u6e1b\u8f15\u9ad4\u91cd\u4e4b\u6548\u679c\n(4) \u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e5f\u9069\u7528GLP -1 receptor agonist\n(5) \u4f7f\u7528GLP -1 receptor agonist\u53ef\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u4e4b\u98df\u617e\u53ca\u5ef6\u7de9\u80c3\u6392\u7a7a\u6642\u9593   \nA.(1)+(2)+(3)\u3002\nB.(2)+(3)+(4)\u3002\nC.(2)+(3)+(5)\u3002\nD.(1)+(4)+(5)\u3002\nE.(1)+(3)+(5)\u3002\n": "[E]", "111-111.Biguanides \u985e\u7684\u85e5\u7269 \uff0c\u662f\u76ee\u524d\u5168\u4e16\u754c\u5927\u591a\u6578\u7cd6\u5c3f\u75c5\u6cbb\u7642\u6307\u5f15\u7684\u5efa\u8b70\u9996\u9078\u7528\u85e5 \uff0c\u4ee5\u4e0b\u6709\u95dcMetformin\u4e4b\u6558\u8ff0\n\u4f55\u8005\u70ba\u932f\u8aa4\u7684 ?   \nA.\u814e\u529f\u80fd\u4e0d\u4f73\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0ceGFR\u5c0f\u65bc30 ml/min/1.73 \u33a1\u6642\uff0c\u4e0d\u61c9\u4f7f\u7528Metformin\u3002\nB.Metformin\u53ef\u80fd\u9020\u6210\u7dad\u4ed6\u547dB12 (Vitamin B12) \u4e4bmalabsorption\u3002\nC.\u96d6\u7136Metfmornin\u4e4b\u4f7f\u7528\u53ef\u4ee5\u964d\u4f4e\u8840\u7cd6 \uff0c\u4f46\u662f\u6839\u64daDiabetes Prevention Program\u4e4b\u7814\u7a76 \uff0cMetformin \u4e26\n\u7121\u6cd5\u5ef6\u7de9\u7cd6\u5c3f\u75c5\u4e4b\u767c\u75c5\u75c5\u7a0b \u3002\nD.\u4e73\u9178\u4e2d\u6bd2\u662f\u7f55\u898b\u7684Metformin\u85e5\u7269\u526f\u4f5c\u7528\uff0c\u7d71\u8a08\u4e0a\uff0c\u5ef6\u9072\u8a3a\u65b7\u4e4b\u6b7b\u4ea1\u7387\u53ef\u905450%\u3002\nE.\u76ee\u524d\u7cd6\u5c3f\u75c5\u4e4b\u5b55\u5a66\u61f7\u5b55\u6642\uff0c\u4f9d\u64da\u7f8e\u570b\u53ca\u53f0\u7063\u4e4b\u6cbb\u7642\u6307\u5f15\uff0cMetformin\u662f\u5b89\u5168\u7684\u7cd6\u5c3f\u75c5\u7528\u85e5\u9078\u64c7\u4e4b\u4e00\u3002\n": "[C]", "111-112.\u7cd6\u5c3f\u75c5\u65b0\u578b\u7528\u85e5\u4e2d \uff0cSGLT-2\u6291\u5236\u5291 (Sodium-glucose Cotransporter 2 inhibitor )\uff0c\u6700\u8fd1\u6578\u5e74\u5ee3\u6cdb\u4f7f\u7528\u7684\u65bc\n\u7cd6\u5c3f\u75c5\u4e4b\u65b0\u8208\u6cbb\u7642\u85e5\u7269 \u3002\u4e0b\u5217\u6709\u95dcSGLT -2\u6291\u5236\u5291\u7684\u6558\u8ff0 \uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684 ?   \nA.SGLT-2\u6291\u5236\u5291\u7684\u4f5c\u7528\u6a5f\u8f49\uff0c\u4e3b\u8981\u662f\u6291\u5236\u5c3f\u7cd6\u4e4b\u518d\u5438\u6536\uff0c\u56e0\u6b64\u8461\u8404\u7cd6\u5927\u91cf\u7684\u5f9e\u5c3f\u4e2d\u6392\u51fa\u3002\nB.\u76ee\u524d\u5927\u591a\u6578\u7684SGLT-2\u6291\u5236\u5291\uff0c\u4f7f\u7528\u4e4b\u814e\u529f\u80fd\u4e4b\u9650\u5236\u70ba eGFR > 45 ml/min/1.73 \u33a1\u4ee5\u4e0a\u3002\nC.\u6b64\u985e\u85e5\u7269\u5728\u964d\u8840\u7cd6\u7684\u904e\u7a0b\u4e2d\uff0c\u7cd6\u5c3f\u75c5\u60a3\u8005\u9ad4\u91cd\u591a\u534a\u4e5f\u6703\u96a8\u4e4b\u6e1b\u8f15\u3002\nD.\u5be6\u8b49\u91ab\u5b78\u7814\u7a76\u986f\u793a\uff0cSGLT-2\u6291\u5236\u5291\u4e5f\u53ef\u4ee5\u4f7f\u7528\u65bc\u975e\u7cd6\u5c3f\u75c5\u4e4b\u6162\u6027\u814e\u81df\u75c5\u60a3\u8005\u3002\nE.\u7531\u65bc\u6b64\u985e\u85e5\u7269\u589e\u52a0\u5c3f\u7cd6\u6392\u51fa\uff0c\u56e0\u6b64\u5bb9\u6613\u767c\u751f\u6ccc\u5c3f\u9053\u611f\u67d3\uff0c\u800c\u4e14\u53ef\u80fd\u767c\u751f\u56b4\u91cd\u4e4b\u751f\u6b96\u5668\u611f\u67d3\u3002\n": "[B]", "100-1.\n24\u6b72\u7537\u75c5\u4eba\u7f79\u60a3\u50f5\u76f4\u6027\u810a\u690e\u708e\u5df22\u5e74\u591a,\u6700\u8fd1\u534a\u5e74\u4f7f\u7528\u4e0d\u540c\u7a2e\u985e\u4e4b\u975e\u985e\u56fa\u9187\u6d88\u708e\u6b62\u75db\u5291(NSAIDs)\u52a0\u4e0a\u6bcf\u59292\u514b\u4e4bsulfasalazine\u6cbb\u7642,\u75c7\u72c0\u4ecd\u7121\u6cd5\u7372\u5f97\u63a7\u5236,\u8acb\u554f\u6700\u5408\u9069\u4e4b\u4e0b\u4e00\u6b65\u6cbb\u7642\u85e5\u7269\u70ba\u4f55?\nA. Adalimumab\nB. Glucocorticoid\nC. Methotrexate\nD. Thalidomide\nE. Rituximab\n": "(A)", "100-2.\n\u4e00\u4f4d28\u6b72\u7537\u75c5\u60a3,\u6700\u8fd1\u56e0\u5c0f\u4fbf\u707c\u71b1\u75bc\u75db\u5c31\u91ab,\u5c3f\u6db2\u6aa2\u9a57\u8b49\u5be6\u70ba\u62ab\u8863\u83cc(Chlamydia trachomatis)\u5c3f\u9053\u708e.\u7d93\u6297\u751f\u7d20\u6cbb\u7642\u5f8c\u75ca\u7652.\u63a5\u4e0b\u7684\u5e7e\u9031\u4e4b\u9593,\u75c5\u4eba\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u4e4b\u75c7\u72c0,\u8acb\u554f\u54ea\u4e00\u7a2e\u53ef\u80fd\u6027\u6700\u5c0f?\nA. \u53f3\u5074\u8db3\u8e1d\u95dc\u7bc0\u708e\nB. \u8461\u8404\u819c\u708e(uveitis)\nC. \u9999\u8178\u6307(dactylitis)\nD. \u8db3\u5e95\u76ae\u819a\u589e\u539a\u89d2\u5316\u75c7(keratodermia)\nE. \u5169\u5074\u624b\u6307proximal interphalangeal joint \u95dc\u7bc0\u708e\n": "(E)", "100-3.\n40\u6b72\u4e4b\u5973\u75c5\u60a32\u500b\u6708\u524d\u5728\u624b\u4e0a\u95dc\u7bc0\u8655(knuckle)\u51fa\u73fe\u8a31\u591a\u7d05\u75b9,\u4e0d\u75db\u4e5f\u4e0d\u7662,\u5f8c\u4f86\u76ae\u819a\u7d05\u75b9\u4e5f\u51fa\u73fe\u5728\u773c\u77bc,\u5169\u9830,\u984d\u982d\u53ca\u80a9\u9838\u90e8.\u53bb\u8a3a\u6240\u5c31\u91ab,\u4e5f\u767c\u73fe\u8ca7\u8840\u53ca\u809d\u6307\u6578(AST/ALT)\u7570\u5e38.\u6700\u8fd1\u5169\u661f\u671f\u51fa\u73fe\u56b4\u91cd\u7121\u75f0\u6027\u4e4b\u54b3\u55fd\u53ca\u547c\u5438\u56f0\u96e3.\u521d\u6b65\u80f8\u90e8X\u5149\u767c\u73fe\u5169\u5074\u80ba\u90e8\u6709\u53b2\u5bb3\u4e4b\u6d78\u6f64\u73fe\u8c61;\u8acb\u554f\u8a72\u75c5\u4eba\u6700\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u90a3\u4e00\u7a2e\u81ea\u9ad4\u6297\u9ad4?\nA. Anti-Scl-70\nB. Anti-Sm\nC. Anti-histone\nD. Anti-Jo-1\nE. Anti-SSA\n": "(D)", "100-4.\n\u4e00\u4e9b\u8edf\u7d44\u7e54\u98a8\u6fd5\u75c7(soft tissue rheumatism)\u5bb9\u6613\u56e0\u67d0\u7279\u6b8a\u6d3b\u52d5\u7528\u529b\u4e0d\u7576\u9020\u6210.\u8acb\u554f\u4e0b\u5217\u4e4b\u914d\u5c0d\u4e2d,\u90a3\u4e00\u9805\u8f03\u4e0d\u6070\u7576?\nA. lateral epicondylitis  <------->   carry heavy suitcase\nB. plantar fasciitis <--------> run in hard surface\nC. medial epicondylitis <--------> swing golf club\nD. patellar tendinitis  <-------> jump too much\nE. adhesive capsulitis <-------->mother holds her baby\n": "(E)", "100-5.\n35\u6b72\u4e4b\u7537\u75c5\u4eba\u6bcf\u5e74\u9ad4\u6aa2\u7686\u767c\u73fe\u6709\u5c3f\u9178\u9ad8\u4e4b\u73fe\u8c61(8-9 mg/dl),\u4f46\u5f9e\u7121\u95dc\u7bc0\u708e\u4e4b\u73fe\u8c61.\u6628\u5929\u534a\u591c\u7a81\u7136\u53f3\u8173\u80cc\u53ca\u5927\u8173\u8dbe\u5287\u70c8\u75bc\u75db,\u7121\u6cd5\u5165\u7720.\u5176\u5f9e\u7121\u814e\u81df\u75c5\u53f2.\u8acb\u554f\u6b64\u6642\u4e0b\u5217\u4e4b\u85e5\u7269\u6cbb\u7642\u90a3\u4e00\u9805\u6700\u4e0d\u6070\u7576?\nA. Allopurinol 300mg qd\nB. Colchicine(0.6 mg/tab.) 2 tab. q 8h\nC. Prednisolone 10 mg tid\nD. Diclofenac 75mg bid\nE. ACTH 80 IU intramuscularly\n": "(A)", "100-6.\n\u4e00\u500b60\u6b72\u4e4b\u5973\u75c5\u4eba\u4e3b\u8a34\u624b\u6307\u9047\u51b7\u6703\u8b8a\u7d2b\u8272\u6216\u767d\u8272,\u4e14\u6709\u56b4\u91cd\u53e3\u4e7e\u53ca\u773c\u4e7e\u5df2\u534a\u5e74\u591a,\u4f46\u4e26\u7121\u76ae\u819a\u75c5\u8b8a,\u7121\u95dc\u7bc0\u75db,\u816e\u817a\u53ca\u6dcb\u5df4\u817a\u4e0d\u816b,\u4e5f\u7121\u6162\u6027\u54b3\u55fd\u73fe\u8c61.\u5be6\u9a57\u5ba4\u6aa2\u67e5\u51fa\u73feANA\u53caAnti-SSA(Ro)\u9ad8\u6fc3\u5ea6\u967d\u6027;\u8840\u6e05\u751f\u5316\u53ca\u5c0f\u4fbf\u6aa2\u67e5\u6b63\u5e38;\u80f8\u90e8X\u5149\u4e5f\u6b63\u5e38.\u9664\u7d66\u4e88\u4eba\u5de5\u6dda\u6db2\u5916,\u8acb\u554f\u4e0b\u5217\u4e4b\u6cbb\u7642\u90a3\u4e00\u7a2e\u6700\u6070\u7576?\nA. Prednisolone 10 mg/day + plaquenil 400 mg/day\nB. Methotrexate 10 mg/week + plaquenil 400 mg/day\nC. Pilocaripine 5mg qid + nifedipine 10mg tid.\nD. Rituximab therapy\nE. Cevimelline + azathioprine 100 mg/day\n": "(C)", "100-7.\n\u738b\u5c0f\u59d0\u7f79\u60a3\u5168\u8eab\u6027\u7d05\u6591\u72fc\u7621\u75c7\u4f75\u814e\u7d72\u7403\u708e\u5df24\u5e74\u591a;\u6700\u8fd1\u75c5\u60c5\u7a69\u5b9a,\u7136\u800c\u53f3\u5074\u80a1\u6e9d\u8655(inguinal area)\u6642\u5e38\u75bc\u75db\u5df2\u4e00\u500b\u591a\u6708,\u5c24\u5176\u8d70\u8def\u6642\u66f4\u611f\u4e0d\u9069,\u521d\u6b65\u9aa8\u76e4\u8154(pelvis) X\u5149\u4e26\u7121\u7570\u5e38\u73fe\u8c61;\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u6700\u53ef\u80fd\u5e6b\u52a9\u8a3a\u65b7\u5176\u554f\u984c?\nA. \u8d85\u97f3\u6ce2(ultrasound)\nB. \u9aa8\u9abc\u6383\u63cf(bone scan)\nC. \u6838\u78c1\u5171\u632f(MRI)\nD. \u62bd\u8840\u6aa2\u9a57ALP\u53caCK\u503c\nE. \u8840\u7ba1\u651d\u5f71(Angiography)\n": "(C)", "100-8.\n\u738b\u5c0f\u59d0\u7f79\u60a3\u5168\u8eab\u6027\u7d05\u6591\u72fc\u7621\u5df23\u5e74\u591a,\u6700\u8fd1\u534a\u5e74\u4f86,\u5b8c\u5168\u8655\u65bc\u7121\u75c7\u72c0\u4e4b\u7de9\u89e3\u72c0\u614b(remission).\u6bcf3\u500b\u6708\u56de\u9580\u8a3a\u8ffd\u8e64\u4e00\u6b21,\u9664\u4e86\u5b8c\u6574\u4e4b\u75c5\u53f2\u8a62\u554f\u53ca\u7406\u5b78\u6aa2\u67e5\u5916,\u4e0b\u5217\u90a3\u4e9b\u5be6\u9a57\u5ba4\u4e4b\u6aa2\u67e5\u4e5f\u662f\u8a55\u4f30\u75be\u75c5\u6d3b\u6027\u4e4b\u5fc5\u8981\u6aa2\u9a57.(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.ANA\r2.Urinalysis\r3.Anti-dsDNA\r4.Anti-Sm\r5.C3 and C4\nA. 1+3+5\nB. 1+4+5\nC. 2+3+5\nD. 3+4+5\nE. 2+3+4\n": "(C)", "100-9.\n38\u6b72\u4e4b\u5973\u75c5\u60a3,\u6700\u8fd12\u661f\u671f\u591a\u6301\u7e8c\u54b3\u55fd\u5e36\u8840\u7d72,\u6f38\u6f38\u611f\u5230\u547c\u5438\u6025\u4fc3\u56f0\u96e3;\u4e00\u661f\u671f\u524d\u51fa\u73fe\u5169\u4e0b\u80a2\u6c34\u816b\u4e14\u5c3f\u91cf\u6e1b\u5c11;\u5be6\u9a57\u5ba4\u6aa2\u67e5\u767c\u73fe\u814e\u529f\u80fd\u4e0d\u5168,\u5c3f\u4e2d\u51fa\u73fe\u86cb\u767d\u5c3f\u53ca\u8840\u5c3f,\u4e14\u80f8\u90e8X\u5149\u51fa\u73fe\u5169\u5074\u80ba\u90e8\u6d78\u6f64\u80ba\u708e\u73fe\u8c61.\u8acb\u554f\u51fa\u73fe\u4e0b\u5217\u90a3\u4e00\u4e9b\u81ea\u9ad4\u6297\u9ad4\u53ef\u4ee5\u89e3\u91cb\u5176\u81e8\u5e8a\u75c7\u5019,\u4e26\u5e6b\u52a9\u8a3a\u65b7? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.Anti-proteinase 3\r2.Anti-Jo-1\r3.Anti-myeloperoxidase\r4.Anti-basement membrane\r5.Anti-beta 2 glycoprotein 1\nA. 1+2+3\nB. 1+3+4\nC. 2+3+4\nD. 2+4+5\nE. 3+4+5\n": "(B)", "100-10.\n\u81e8\u5e8a\u8541\u9ebb\u75b9(urticaria)\u4e4b\u767c\u751f,\u56e0\u4e0d\u540c\u539f\u56e0\u6709\u4e0d\u540c\u4e4b\u81f4\u75c5\u6a5f\u8f49,\u8acb\u554f\u4e0b\u5217\u90a3\u4e9b\u539f\u56e0\u9020\u6210\u4e4b\u8541\u9ebb\u75b9,IgE\u6297\u9ad4\u626e\u6f14\u91cd\u8981\u89d2\u8272? (\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.sunlight.\r2.seafood.\r3.radiocontrast media.\r4.anti-C1q inhibitor deficiency.\r5.aspirin and NSAIDs.\nA. 1+2\nB. 1+2+3\nC. 2+4+5\nD. 3+5\nE. 2+5\n": "(A)", "100-1.\n\u4e0b\u5217\u6709\u95dc\u514d\u75ab\u75be\u75c5\u8207\u81ea\u9ad4\u6297\u539f\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. Systemic sclerosis--fibronectin\nB. Rheumatoid arthritis--collagen type II\nC. Hashimoto's thyroiditis--asialoglycoprotein receptor.\nD. Sjogren's syndrome--fibrillarin\nE. Dilated cardiomyopathy--F-actin\n": "(B)", "100-2.\n\u4e0b\u5217\u6709\u95dc\u4ee5\u751f\u7269\u88fd\u5291\u6cbb\u7642\u75be\u75c5\u7684\u9069\u61c9\u75c7\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6070\u7576\uff1f\nA. IVIG--leukocytoclastic vasculitis\nB. Anti-IgE monoclonal antibody--anaphylactic shock\nC. Anti-TNF-  monoclonal antibody--rheumatoid arthritis\nD. Anti-CD20 monoclonal antibody--CREST syndrome\nE. Anti-CD3 monoclonal antibody--systemic lupus erythematosus\n": "(C)", "100-3.\n\u7576\u91ab\u5e2b\u61f7\u7591\u60a3\u8005\u7684T\u7d30\u80de\u514d\u75ab\u529f\u80fd\u6709\u554f\u984c\u6642\uff0c\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u6700\u91cd\u8981\uff1f\nA. Anergy panel skin test\nB. \u8840\u6db2\u4e2dCD3+T\u7d30\u80de\u7684\u6578\u76ee\nC. \u8840\u6e05\u4e2d\u514d\u75ab\u7403\u86cb\u767d\u7684\u6fc3\u5ea6\nD. \u8840\u6db2\u4e2dCD4/CD8 T\u7d30\u80de\u7684\u6bd4\u503c\nE. \u8840\u6e05\u4e2dTNF-alpha \u7684\u6fc3\u5ea6\n": "(A)", "100-4.\n48\u6b72\u7684\u738b\u5c0f\u59d0\u6700\u8fd1\u534a\u5e74\u4f86\uff0c\u6bcf\u5929\u508d\u665a\u958b\u59cb\u6703\u5168\u8eab\u8d77\u8541\u9ebb\u75b9\u3002\u7d93\u91ab\u5e2b\u6aa2\u67e5\u767c\u73fetotal IgE\u53catotal eosinophil count\u5747\u5c6c\u6b63\u5e38\u3002\u8acb\u554f\u4e0b\u5217\u5c0d\u65bc\"\u6162\u6027\u539f\u56e0\u4e0d\u660e\u6027\u8541\u9ebb\u75b9\"\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. \u91cd\u8907\u76ae\u4e0b\u6ce8\u5c04\u81ea\u9ad4\u8840\u6e05\u6709\u6548\nB. \u6bcf\u5929\u5b9a\u671f\u670d\u7528H1 anti-histamine\u53ef\u4ee5\u75ca\u7652\nC. \u767c\u4f5c\u6642\u5c40\u90e8\u61c9\u5857\u62b9\u8f03\u5f37\u529b\u7684corticosteroid ointment\nD. \u4f7f\u7528hydroxychloroquine \u53cacolchicine\u6709\u52a9\u65bc\u75be\u75c5\u7684\u7de9\u89e3\nE. \u5373\u4f7f\u6c92\u6709urticaric vasculitis\u4e5f\u5fc5\u9808\u670d\u7528\u9ad8\u5291\u91cf\u7684\u985e\u56fa\u9187\n": "(D)", "100-5.\n32\u6b72\u7684\u6797\u5148\u751f\u70baHBV carrier\u3002\u5728\u5169\u9031\u524d\u56e0\u5169\u624b\u7b2cII \u53ca\u7b2cIII\u6307\u7684PIP\u548c MCP\u53ca\u5de6\u624b\u7755\u95dc\u7bc0\u75bc\u75db\u5230\u91ab\u9662\u6c42\u8a3a\u3002\u62bd\u8840\u767c\u73feESR=34 mm/1h, CRP=1.87mg/ml, RF=28.4U/ml (normal<20U/ml)\u3002\u91ab\u5e2b\u61f7\u7591\u70ba\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\uff0c\u70ba\u4f5c\u9451\u5225\u8a3a\u65b7\uff0c\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u6700\u6709\u5e6b\u52a9\uff1f\nA. Bilateral hands X-film (AP and Lat. view)\nB. Synovial fluid examination\nC. Soft tissue sonography\nD. Serum anti-CCP antibody\nE. Serum IgG4\n": "(D)", "100-6.\n51\u6b72\u7684\u674e\u592a\u592a\u6700\u8fd13\u5e74\u4f86\uff0c\u5728\u51ac\u5929\u6216\u590f\u5929\u5439\u51b7\u6c23\u6642\uff0c\u624b\u6307\u7532\u6703\u8b8a\u767d\u5f8c\u8b8a\u7d2b\u3002\u6700\u8fd1\u5169\u500b\u6708\u4f86\u559d\u6c34\u6642\u5e38\u6703\u55c6\u5230\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\uff1aANA=1:1280 nucleolar+ centromere pattern, C3=107mg/ml, C4=21.4 mg/ml, anti-dsDNA =16 IU/ml (normal <120 IU/ml). hemogram \u53caurinalysis\u5747\u6b63\u5e38\uff0ccryoglobulin (-), RFs=25 IU/ml (normal<20 IU/ml)\u3002\u8acb\u554f\u9019\u4f4d\u60a3\u8005\u7684\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Systemic sclerosis\nB. Systemic lupus erythematosus\nC. Rheumatoid arthritis\nD. Raynaud's phenomenon\nE. Cutaneous vasculitis\n": "(A)", "100-7.\n\u4e0b\u5217\u6709\u95dc\u50f5\u76f4\u6027\u810a\u690e\u708e\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. HLA-B27\u967d\u6027\u662f\u75be\u75c5\u8a3a\u65b7\u7684\u6700\u91cd\u8981\u4f9d\u64da\nB. \u6ce8\u5c04IL-1 receptor antagonist \u6700\u5177\u7642\u6548\nC. \u7167pelvis X-ray (AP-view)\u767c\u73febilateral S-I joint sacroiliitis GrII \u4ee5\u4e0a\u6642\uff0c\u53ef\u4ee5\u78ba\u5b9a\u8a3a\u65b7\nD. \u4e0b\u80cc\u75db\u5728\u904b\u52d5\u6642\u6703\u52a0\u5287\nE. \u521d\u59cb\u75c7\u72c0\u5927\u90fd\u767c\u751f\u572840\u6b72\u4ee5\u4e0a\u7684\u4e2d\u5e74\u4eba\n": "(C)", "100-8.\n\u4e0b\u5217\u6709\u95dc\u9000\u5316\u6027\u95dc\u7bc0\u708e(osteoarthritis, OA)\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. \u6771\u65b9\u4eba\u7684OA\u5e38\u767c\u751f\u5728\u624b\u8155\u90e8\u53ca\u9ad6\u95dc\u7bc0\nB. \u624b\u90e8OA\u6703\u6709\u907a\u50b3\u56e0\u7d20\u7684\u5b58\u5728\nC. \u624b\u90e8X-\u5149\u6aa2\u67e5\u5e38\u5e38\u53ef\u4ee5\u767c\u73fe\u5728\u95dc\u7bc0\u5468\u908a\u6709\u9aa8\u982d\u4fb5\u8755(bone erosion)\u73fe\u8c61\nD. \u75c5\u7406\u7d44\u7e54\u53ef\u4ee5\u767c\u73fe\u8edf\u9aa8\u7684proteoglycan\u589e\u52a0\uff0c\u4f46\u662f\u8edf\u9aa8\u7d30\u80de\u6578\u76ee\u6e1b\u5c11\nE. \u95dc\u7bc0\u8154\u5167\u6ce8\u5c04hyaluronic acid\u6703\u4f7f\u8edf\u9aa8\u7d44\u7e54\u6062\u5fa9\u6b63\u5e38\n": "(B)", "100-9.\n\u4e0b\u5217\u6709\u95dc\u95dc\u7bc0\u6db2(synovial fluid, SF)\u7684\u6aa2\u67e5\u6240\u898b\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\r1.rheumatoid arthritis(RA)\u7684SF\u4e2dWBC\u6578\u76ee\u901a\u5e38>2000/\u03bcl\r2.RA\u7684SF\u4e2dC3\u53caC4\u6fc3\u5ea6\u6703\u4e0a\u5347\r3.gouty arthritis\u7684SF\u4e2d\u6703\u6709needle-shaped crystal\u5b58\u5728\r4.\u5047\u6027\u75db\u98a8(pseudogout)\u7684SF\u4e2d\u6709birefringency (\u4e00)\u7684 \u83f1\u72c0\u5f62\u7d50\u6676\u9ad4\u5b58\u5728\r5.osteoarthritis\u7684SF\u7684\u7684\u7c98\u7a20\u5ea6\u6703\u964d\u4f4e\r6.\u611f\u67d3\u6027\u95dc\u7bc0\u708e(septic arthritis)\u7684SF\u7684\u7c98\u7a20\u5ea6\u6703\u589e\u52a0\r7.RA\u7684SF\u4e2dmucin test\u6703\u5448\u967d\u6027\u53cd\u61c9\nA. 1+2+3\nB. 4+5+6\nC. 5+6+7\nD. 1+3+7\nE. 2+4+6\n": "(D)", "100-10.\n\u4e0b\u5217\u4f55\u7a2e\u95dc\u7bc0\u75be\u75c5\u6703\u5448\u73feacute monoarthritis\uff1f\r1.rheumatoid arthritis\r2.septic arthritis\r3.osteoarthritis\r4.gouty arthritis\r5.polymyalgia rheumatica\r6.reactive arthritis\r7.psoriatic arthritis\r8.osteonecrosis\nA. 1+3+5\nB. 3+7+8\nC. 2+4+6\nD. 1+6+7\nE. 2+3+4\n": "(C)", "101-1.\n60\u6b72\u4e4b\u5973\u75c5\u4eba,\u4e3b\u8a34\u53f3\u80a9\u75bc\u75db\u50f5\u786c\u5df22\u500b\u6708,\u665a\u4e0a\u6703\u75db\u5f97\u4e0d\u80fd\u5b89\u7720,\u4e26\u7121\u767c\u71d2\u4e4b\u73fe\u8c61,\u4ee5\u524d\u4e5f\u7121\u95dc\u7bc0\u708e\u75c5\u53f2.\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u53f3\u80a9\u8180\u6709\u58d3\u75db,\u4e14\u4e3b\u52d5\u6216\u88ab\u52d5\u7684\u80a9\u95dc\u7bc0\u9748\u6d3b\u5ea6\u7686\u53d7\u9650(restricted active and passive movement)\u3002X\u5149\u6aa2\u67e5\u4e26\u7121\u7279\u5225\u8b8a\u5316.\u8acb\u554f\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u53d7\u4fb5\u72af\u4e4b\u95dc\u7bc0\u7d50\u69cb\u70ba\u4f55?\nA. Bursa\nB. Capsule\nC. Cartilage\nD. Supraspinatus tendon\nE. Synovium\n": "(B)", "101-2.\n50\u6b72\u4e4b\u7537\u75c5\u4eba,\u7f79\u60a3\u75db\u98a8\u77f3\u6027\u95dc\u7bc0\u708e(tophaceous gout)\u5df21\u5e74\u591a,\u5169\u4e0b\u80a2\u6709\u8a31\u591a\u5927\u5c0f\u4e0d\u4e00\u7684\u75db\u98a8\u77f3(tophi);\u540c\u6642\u6709\u6162\u6027\u814e\u529f\u80fd\u4e0d\u5168,\u8840\u4e2dcreatinine\u503c\u70ba2.5 mg/ml,\u4e26\u6709\u814e\u7d50\u77f3.\u5176HLA-B5801\u57fa\u56e0\u70ba\u967d\u6027.\u8acb\u554f\u6700\u5408\u9069\u7684\u964d\u5c3f\u9178\u85e5\u7269\u70ba\u4f55?\nA. Febuxostat\nB. Probenecid\nC. Benzbramarone\nD. Sulfinpyrazone\nE. Allopurinol\n": "(A)", "101-3.\n\u95dc\u7bc0\u708e\u4e4b\u9451\u5225\u8a3a\u65b7\u4e4b\u8981\u9ede\u5305\u62ec\u5176\u70ba\u75c5\u7a0b\u70ba\u6025\u6027(acute)\u6216\u6162\u6027(chronic);\u5176\u4fb5\u72af\u95dc\u7bc0\u6578\u76ee\u70ba\u55ae\u4e00\u95dc\u7bc0(mono-),\u5be1\u95dc\u7bc0(oligo-)\u6216\u591a\u95dc\u7bc0(poly-).\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u7a2e\u81e8\u5e8a\u95dc\u7bc0\u708e\u985e\u578b(pattern),\u505a\u95dc\u7bc0\u62bd\u6db2(arthrocentesis)\u70ba\u6700\u5fc5\u8981\u7684,\u6700\u6709\u8a3a\u65b7\u50f9\u503c(essential)\u7684\u6aa2\u67e5?\nA. Acute monoarthritis\nB. Acute polyarthritis\nC. Chronic monoarthritis\nD. Chronic polyarthritis\nE. Acute oligoarthritis\n": "(A)", "101-4.\n\u751f\u7269\u88fd\u5291(biologicals)\u4e4b\u7814\u767c\u6210\u529f,\u4f7f\u5f97\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u4e4b\u6cbb\u7642\u6709\u9577\u8db3\u4e4b\u9032\u6b65.\u8acb\u554f\u4e0b\u5217\u4e4b\u751f\u7269\u88fd\u5291\u53ca\u4f5c\u7528\u6a5f\u5236\u4e4b\u914d\u5c0d\u4e2d\uff0c\u90a3\u4e00\u9805\u662f\u932f\u8aa4\uff1f\nA. adalimumab : TNF-alpha inhibition\nB. abatacept : T cell costimulation blockage\nC. etanercept : TNF-alpha inhibition\nD. rituximab : B cell depletion\nE. tocilizumab : IL-1 inhibition\n": "(E)", "101-5.\n\u70ba\u4f7f\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u80fd\u66f4\u65e9\u671f\u8a3a\u65b7,\u66f4\u65e9\u4f7f\u7528\"\u75c5\u7a0b\u4fee\u98fe\u85e5\u7269\"(DMARDs),\u7f8e\u570b\u53ca\u6b50\u76df\u98a8\u6fd5\u75c5\u91ab\u5b78\u6703\u65bc\u897f\u51432010\u5e74\u63a8\u51fa\u65b0\u5206\u985e\u8a3a\u65b7\u6a19\u6e96(classification criteria),\u63a1\u8a08\u5206\u6cd5(score),\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u9805\u4e4b\u7d66\u5206\u6700\u9ad8?\nA. \u75c7\u72c0\u8d85\u904e6\u661f\u671f\nB. CRP\u53caESR\u503c\u7686\u4e0a\u5347\nC. \u5169\u5074\u819d\u95dc\u7bc0\u816b\u75db\u767c\u708e\nD. \u4f4e\u6fc3\u5ea6rheumatoid factor\u967d\u6027\nE. \u5169\u5074wrists\u53ca\u5169\u50743rd proximal interphangeal joints \u767c\u708e\n": "(E)", "101-6.\n\u8541\u75f2\u75b9(urticaria)\u6216\u8840\u7ba1\u6c34\u816b(angioedema)\u6709\u8a31\u591a\u4e0d\u540c\u7684\u81f4\u75c5\u6a5f\u5236;\u8acb\u554f\u4e0b\u5217\u4e4b\u914d\u5c0d\u4e2d,\u90a3\u4e00\u9805\u662f\u932f\u8aa4\uff1f\nA. dermographism : IgE-dependent\nB. C1 inhibitor deficiency : bradykinin-mediated\nC. reaction to blood products : complement-mediated\nD. aspirin : altered arachidonic acid metabolism\nE. solar urticaria : direct mast cell-releasing effect\n": "(E)", "101-7.\n28\u6b72\u5973\u6027\u75c5\u4eba,\u4e3b\u8a34\u96d9\u5074\u624b\u6307\u95dc\u7bc0\u75bc\u75db\u5df2\u4e00\u500b\u591a\u6708,\u9664\u5916\u4e26\u7121\u5176\u4ed6\u75c7\u72c0.\u6700\u8fd1\u516c\u53f8\u9ad4\u6aa2,\u767c\u73fe\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u76ee\u7a0d\u4f4e,\u5176\u4ed6\u6b63\u5e38.\u5176\u6642\u5e38\u6709\u53e3\u8154\u6f70\u760d\u60c5\u5f62.\u6297\u6838\u6297\u9ad4(ANA)\u6aa2\u9a57\u70ba\u9670\u6027.\u8acb\u554f\u70ba\u78ba\u8a8d\u662f\u5426\u7f79\u60a3\u5168\u8eab\u6027\u7d05\u6591\u72fc\u7621,\u4e0b\u6b21\u7684\u81ea\u9ad4\u6297\u9ad4\u6aa2\u67e5\u90a3\u4e00\u7d44\u662f\u6700\u9069\u7576\u7684?\nA. Repeat ANA + anti-dsDNA + anti-Ro\nB. Repeat ANA + anti-Sm + anti-Ro\nC. Repeat ANA + anti-Sm +anti-RNP\nD. Anti-dsDNA + anti-ribosomal  P + anti-cardiolipin\nE. Anti-Sm + anti-histone +anti-La\n": "(A)", "101-8.\n\u4e00\u500b30\u6b72\u7537\u6027\u4e3b\u8a34\u4e0b\u80cc\u75db\u5df2\u534a\u5e74,X\u5149\u6aa2\u67e5\u4e26\u7121\u660e\u986f\u8b8a\u5316.\u4f46ESR\u53caCRP\u7686\u660e\u986f\u4e0a\u5347.\u6700\u8fd13\u500b\u6708\u5176\u8173\u5f8c\u8ddf(heel)\u4e5f\u6642\u5e38\u75bc\u75db.\u9a57\u5176HLA-B27\u57fa\u56e0\u70ba\u967d\u6027.\u5176\u7236\u89aa\u70ba\u50f5\u76f4\u6027\u810a\u690e\u708e\u4e4b\u60a3\u8005.\u75c5\u4eba\u5f9e\u672a\u63a5\u53d7\u904e\u4efb\u4f55\u85e5\u7269\u6cbb\u7642,\u8acb\u554f\u6700\u9069\u7576\u7684\u8655\u65b9\u70ba\u90a3\u4e00\u9805\u85e5\u7269?\nA. Glucocorticoid\nB. Etanercept\nC. Sulfasalazine\nD. Methotrexate\nE. Non-steroidal anti-inflammatory drugs\n": "(E)", "101-9.\n42\u6b72\u5973\u6027\u75c5\u4eba\u4e3b\u8a34\u5026\u6020,\u5076\u800c\u767c\u71d2\u53ca\u9ad4\u91cd\u6e1b\u8f15\u5df23\u500b\u591a\u6708.\u4e0a\u80a2\u624b\u81c2\u6d3b\u52d5\u7a0d\u4e45,\u5e38\u767c\u4f5c\u6fc0\u70c8\u75bc\u75db.\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u6709\u9ad8\u8840\u58d3\u73fe\u8c61,\u5de6\u5074\u624b\u8155\u8108\u535a(radial pulse)\u6478\u4e0d\u5230.\u62bd\u8840ESR(>100 mm)\u53caCRP\u660e\u986f\u4e0a\u5347,\u4e14\u8840\u4e2dcreatinine\u503c\u504f\u9ad8.\u8acb\u554f\u75c5\u4eba\u6700\u53ef\u80fd\u7f79\u60a3\u4e0b\u5217\u90a3\u4e00\u7a2e\u75be\u75c5?\nA. Henoch-Schonlein purpura\nB. Churg-Strauss syndrome\nC. Takayasu's arteritis\nD. Temporal arteritis\nE. Microscopic polyangitis\n": "(C)", "101-10.\n\u98a8\u6fd5\u75c5\u4e4b\u9451\u5225\u8a3a\u65b7,\u8a73\u7d30\u75c5\u53f2\u8a62\u554f\u53ca\u7406\u5b78\u6aa2\u67e5\u76f8\u7576\u91cd\u8981.\u8acb\u554f\u4e0b\u5217\u90a3\u4e9b\u98a8\u6fd5\u75c5\u4e3b\u8981\u9760\u75c5\u53f2\u53ca\u7406\u5b78\u6aa2\u67e5\u505a\u8a3a\u65b7\u4f9d\u64da,\u62bd\u8840\u6aa2\u9a57\u7121\u751a\u5e6b\u52a9?\r(1)dermatomyositis\r(2)fibromyalgia\r(3)relapsing polychondritis\r(4)Behcet's disease\r(5)Wegener's granulomatosis\nA. (1)+(2)+(3)\nB. (1)+(4)+(5)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (2)+(3)+(5)\n": "(C)", "101-1.\n\u98a8\u6fd5\u53ca\u514d\u75ab\u75be\u75c5\u7684\u81f4\u75c5\u6a5f\u8f49\u8207\u514d\u75ab\u907a\u50b3\u5b78(immunogenetics)\u6709\u76f8\u95dc\u3002\u8acb\u554f\u4e0b\u5217\u7684\u76f8\u95dc\u6027\u4e2d,\u4f55\u8005\u6700\u70ba\u5f37\u70c8?\nA. SLE\u8207HLA-DR2\nB. Ankylosing spondylitis\u8207HLA-B2704\nC. Behcet's disease\u8207HLA-B51\nD. Graves' disease\u8207HLA-B8\nE. Chronic active hepatitis\u8207DR3\n": "(B)", "101-2.\n\u4e00\u4f4d27\u6b72\u7684\u7537\u6027\uff0c\u5f9e\u5c0f\u5c31\u6709\u4e2d\u7b49\u5ea6\u6301\u7e8c\u578b\u7684\u904e\u654f\u6027\u9f3b\u708e(Allergic rhinitis)\uff0c\u5176\u8840\u4e2dtotal IgE 325IU/ml\uff0c\u904e\u654f\u539f\u6aa2\u67e5\u767c\u73fe\u5c0dhouse dust mite Der.P \u5448+++\u3002\u8acb\u554f\u9664\u4e86immunotherapy\u4e4b\u5916\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u9996\u9078\u85e5\u7269?\nA. Intranasal glucocorticoids spray\nB. Moderate dose of oral prednisolone\nC. Anti-IgE antibody injection\nD. Oral pseudoephedrine\nE. Oral H1 antihistamine\n": "(A)", "101-3.\n\u4e00\u4f4d42\u6b72\u5973\u6027\u4e3b\u8a34\u70ba\u6162\u6027\u8541\u9ebb\u75b9\u6709\u5169\u5e74\u4e4b\u4e45\uff0c\u8fd1\u65e5\u4f86\u76ae\u819a\u98a8\u75b9\u584a\u52a0\u5287 ,      \u800c\u4e14\u58d3\u4e86\u4e4b\u5f8c\u4e5f\u4e0d\u6703\u6d88\u5931\uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u70ba\u301dvasculitic urticaria\u301e\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6700\u70ba\u9069\u7576?\nA. Topical glucocorticoids\nB. Topical H1 type anti-histamine\nC. Systemic glucocorticoids\nD. Hydroxychloroquine\nE. Cyclosporine\n": "(C)", "101-4.\n\u4e00\u4f4d28\u6b72SLE\u60a3\u8005\u7522\u4e0b\u4e00\u4f4d\u5973\u5b30\uff0c\u4f46\u5176\u5fc3\u8df3\u53ea\u670964\u4e0b/\u5206\uff0c\u8acb\u554f\u4e0b\u5217\u7684\u54ea\u4e00\u7a2e\u81ea\u9ad4\u6297\u9ad4\u6703\u5f15\u8d77\u65b0\u751f\u5152\u7684congenital heart block?\nA. Anti-RNP\nB. Anti-Sm\nC. Anti-histone\nD. Anti-dsDNA\nE. Anti-SSA/Ro\n": "(E)", "101-5.\n\u4e00\u4f4d30\u6b72\u7684\u5973\u6027\u904e\u53bb\u6c92\u6709\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u6216\u9ad8\u8840\u8102\u7684\u75c5\u53f2\u3002\u6709\u4e00\u5929\u7a81\u7136\u767c\u751f\u53f3\u4e0b\u80a2\u6df1\u90e8\u975c\u8108\u6813\u585e\uff0c\u88ab\u91ab\u5e2b\u8a3a\u65b7\u70ba\u301d\u6297\u78f7\u8102\u8cea\u6297\u9ad4\u75c7\u5019\u7fa4\u301e(Anti-phospholipid antibody syndrome)\u3002\u8acb\u554f\u4f55\u7a2e\u75c7\u72c0\u6216\u6aa2\u6e2c\u8207\u672c\u75c7\u5019\u7fa4\u6709\u95dc\uff1a\r(1)pulmonary embolism\r(2)anti-B2GPI\r(3)protein C\u7f3a\u4e4f\r(4) recurrent fetal loss\r(5) protein S\u904e\u591a\r(6) livedo reticularis\r(7)aPTT shortening\r(8)increase DRVVT\r(9)subacute cutaneous lupus skin lesion\r(10)interstitial nephritis\nA. (1)+(2)+(5)\nB. (2)+(3)+(4)\nC. (5)+(6)+(7)\nD. (1)+(2)+(9)\nE. (2)+(4)+(6)\n": "(E)", "101-6.\n\u6709\u95dc\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u7684\"\u95dc\u7bc0\u5916\u75c7\u72c0\"\u5f88\u591a\uff0c\u4e0b\u5217\u90a3\u4e9b\u75c7\u72c0\u5305\u62ec\u5728\u5167\uff1f\r(1)iritis\r(2)episcleritis\r(3)subcutaneous nodule\r(4)keratoconjunctivitis sicca\r(5)pleural effusion\r(6)thrombocytopenia\r(7)glomerulonephritis\r(8)ischemic necrosis of femoral head\r(9)interstitial lung disease\r(10)cervical myelopathy\nA. (1)+(3)+(5)\nB. (2)+(4)+(9)\nC. (6)+(7)+(8)\nD. (8)+(9)+(10)\nE. (3)+(6)+(9)\n": "(B)", "101-7.\n\u5728\u5065\u4fdd\u7684\u4f7f\u7528\u898f\u7bc4\u4e0a\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u6cbb\u7642\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u7684\u7b2c\u4e00\u7dda\u751f\u7269\u88fd\u5291\uff1f\nA. Soluble TNF-\u03b1 receptor\nB. Anti-CD20 antibody\nC. Soluble CTLA4\nD. Anti-IL-6 receptor antibody\nE. Anti-LFA1 antibody\n": "(A)", "101-8.\n\u4e0b\u5217\u54ea\u4e00\u7a2e\u8840\u6e05\u5b78\u6216\u5f71\u50cf\u5b78\u6aa2\u67e5\u5728\u8a3a\u65b7\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u7684\u7279\u7570\u6027\uff08specificity\uff09\u6700\u9ad8\uff1f\nA. Rheumatoid factors\nB. Anti-collagen antibodies\nC. X-ray findings of hands\nD. Anti-CCP antibodies\nE. Soft tissue sonography\n": "(D)", "101-9.\n\u54ea\u4e9b\u81e8\u5e8a\u75c7\u72c0\u6216\u6aa2\u67e5\u8207\u5168\u8eab\u6027\u786c\u5316\u75c7\uff08systemic sclerosis\uff09\u6700\u6709\u76f8\u95dc\uff1f\r(1)anti-centromere antibody\r(2)Raynaud's phenomenon\r(3)active synovitis\r(4)decrease in DLCO\r(5)Gottron's sign\r(6)anti-Scl70 antibody\r(7)photosensitivity\r(8)swallowing disturbance\r(9)uveitis\r(10)peripheral neuropathy\nA. (1)+(2)+(3)\nB. (2)+(4)+(6)\nC. (5)+(6)+(7)\nD. (8)+(9)+(10)\nE. (3)+(6)+(8)\n": "(B)", "101-10.\n\u4e0b\u5217\u4f55\u8005\u53ef\u4ee5\u4f5c\u70ba\u7be9\u9078\u8840\u7ba1\u708e\u7684biomarker\uff1f\nA. Rheumatoid factors\nB. ESR\nC. Thrombocytopenia\nD. Anti-neutrophil cytoplasmic antibodies\nE. Complement C3 levels\n": "(D)", "102-1.\n\u738b\u5973\u58eb45\u6b72\u60a3SLE(systemic lupus erythematosus)\u591a\u5e74\u5408\u4f75\u56b4\u91cd\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7,\u7d93\u985e\u56fa\u9187\u53ca\u5176\u5b83\u7a4d\u6975\u6cbb\u7642\u5f8c\u7121\u6548,\u91ab\u5e2b\u5efa\u8b70\u5979\u63a5\u53d7\u813e\u81df\u5207\u9664\u8853,\u5979\u5728\u624b\u8853\u524d2\u9031\u61c9\u63a5\u53d7\u4f55\u7a2e\u75ab\u82d7\u9810\u9632\u6ce8\u5c04?\nA. A\u578b\u809d\u708e(Hepatitis A)\u75ab\u82d7\nB. \u6c34\u75d8(Varicella)\u75ab\u82d7\nC. \u80ba\u708e(Pneumococcal)\u75ab\u82d7\nD. \u5e36\u72c0\u76b0\u75b9(Herpes zoster)\u75ab\u82d7\nE. \u7834\u50b7\u98a8(Tetanus)\u75ab\u82d7\n": "(C)", "102-2.\n\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u6700\u5177\u8a3a\u65b7\u7279\u7570\u6027\u4e4b\u6aa2\u67e5\u70ba\nA. ESR\nB. CRP\nC. Antibodies to cyclic citrullinated peptide\nD. Anti-topoisomerase I antibody\nE. Anti-histone antibody\n": "(C)", "102-3.\n\u738b\u5148\u751f55\u6b72\u6bcf\u5e74\u75db\u98a8\u767c\u4f5c4-5\u6b21,\u6bcf\u6b21\u767c\u4f5c\u6642\u624d\u627e\u91ab\u5e2b\u6cbb\u7642,\u9664\u751f\u6d3b\u7fd2\u6163\u6539\u5584\u5916,\u4e0b\u5217\u4f55\u7a2e\u5efa\u8b70\u662f\u4ed6\u7684\u6700\u597d\u6cbb\u7642\u6216\u6cbb\u7642\u76ee\u6a19?\nA. \u9577\u671fColchicine\u9810\u9632\nB. \u9577\u671fNon-steroid anti-inflammatory drugs\u4f7f\u7528\nC. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u6fc3\u5ea6\u52309-10mg/dl\nD. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u6fc3\u5ea6\u52308-9mg/dl\nE. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u6fc3\u5ea6\u52305-6mg/dl\n": "(E)", "102-4.\n\u6839\u64da2010\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u8a3a\u65b7(ACR&EULAR 2010 criteria)\uff0c\u9700\u67096\u5206\u4ee5\u4e0a\u624d\u80fd\u8a3a\u65b7\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u3002\u738b\u5c0f\u59d0\u5728\u5169\u624bmetacarpophalangeal\u53caproximal interphalangeal\u5171\u67099\u500b\u5c0f\u95dc\u7bc0\u767c\u708e\uff0c\u5176\u5206\u6578(score)\u6709\uff1a\nA. 1\nB. 2\nC. 3\nD. 4\nE. 5\n": "(C)", "102-5.\n\u738b\u5973\u58eb45\u6b72\u60a3\u6709\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u591a\u5e74,\u7d93\u50b3\u7d71Disease-modified anti-rheumatic drugs (DMARD)\u6cbb\u7642\u7121\u6548\u5f8c,\u6c7a\u5b9a\u4f7f\u7528\u751f\u7269\u88fd\u5291TNF-\u03b1\u6291\u5236\u5291,\u5979\u4f7f\u7528\u751f\u7269\u88fd\u5291\u524d\u6700\u91cd\u8981\u4e4b\u6aa2\u67e5\u70ba\nA. \u8166\u6ce2(EEG)\nB. \u5fc3\u96fb\u5716(EKG)\nC. Purified peptide derivative (PPD) skin test\nD. \u80ba\u529f\u80fd(pulmonary function tests)\nE. \u808c\u96fb\u5716(EMG)\n": "(C)", "102-6.\nAllopurinol\u5e38\u88ab\u4f7f\u7528\u65bc\u964d\u8840\u4e2d\u5c3f\u9178,\u5176\u526f\u4f5c\u7528\u70ba\u5e38\u767c\u751f\u904e\u654f\u53cd\u61c9,\u53f0\u7063\u5b78\u8005\u5df2\u767c\u73fe\u57fa\u56e0\u8207Allopurinol\u904e\u654f\u6709\u5bc6\u5207\u95dc\u4fc2,\u6b64\u57fa\u56e0\u70ba\nA. HLA DR1\nB. HLA B*5701\nC. HLA B*5801\nD. HLA B*1502\nE. HLA B*1501\n": "(C)", "102-7.\n\u738b\u5148\u751f40\u6b72\u7537\u6027\u6709\u50f5\u76f4\u6027\u810a\u690e\u708e8\u5e74,HLA-B27\u967d\u6027,\u904e\u53bb\u4ed6\u4e26\u6c92\u63a5\u53d7\u9069\u7576\u4e4b\u6cbb\u7642,\u4e8c\u5929\u5f8c\u958b\u59cb\u773c\u775b\u7d05,\u71b1,\u75db\u53ca\u754f\u5149,\u4ed6\u6700\u6709\u53ef\u80fd\u5f97\u5230\u4e0b\u5217\u75be\u75c5\nA. \u904e\u654f\u6027\u7d50\u819c\u708e(Allergic conjunctivitis)\nB. \u524d\u623f\u8461\u8404\u819c\u708e(Anterior uveitis)\nC. \u8996\u7db2\u819c\u7624(Retina tumor)\nD. \u9752\u5149\u773c(Glaucoma)\nE. \u767d\u5167\u969c(Cataract)\n": "(B)", "102-8.\n\u4e0b\u5217\u54ea\u4e9b\u8840\u7ba1\u708e\u75be\u75c5\u8f03\u6613\u7522\u751fanti-neutrophil cytoplasmic antibodies (ANCA) (1)Granulomatosis with polyangiitis (Wegener's) (2)Behcet's disease (3)Microscopic polyangiitis (4)Giant cell arteritis (5)Takayasu's arteritis\nA. (1)+(3)\nB. (2)+(4)\nC. (3)+(5)\nD. (2)+(4)\nE. (4)+(5)\n": "(A)", "102-9.\n\u4e0b\u5217\u4e8c\u7a2e\u5371\u96aa\u56e0\u5b50(Risk factors)\u8207\u9000\u5316\u6027\u95dc\u7bc0\u708e(Osteoarthritis arthritis)\u4e4b\u767c\u751f\u6709\u95dc: (1)\u62bd\u83f8 (2)\u98f2\u98df (3)\u6c23\u5019 (4)\u5e74\u9f61 (5)\u80a5\u80d6\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(D)", "102-10.\n\u4e0b\u5217\u7d30\u80de\u6fc0\u7d20(cytokine)\u662f\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u4e4b\u4e3b\u8981\u7d30\u80de\u6fc0\u7d20:(1)IL-2 (2)TNF-\u03b1 (3)IL-4 (4)IL-10 (5)IL-17\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (2)+(5)\n": "(E)", "102-1.\n\u4e0b\u5217\u6709\u95dc\u904e\u654f\u6027\u9f3b\u708e\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. \u5b63\u7bc0\u578b\u7684\u60a3\u8005\u8207\u9ef4\u83cc(mold)\u904e\u654f\u539f\u6700\u6709\u95dc\u4fc2\nB. \u7d93\u5e74\u578b\u7684\u60a3\u8005\u8207\u5875\ufffdu(house dust mite)\u904e\u654f\u539f\u6700\u6709\u95dc\u4fc2\nC. \u62bd\u8840\u6aa2\u67e5\u904e\u654f\u539f\u7684\u7279\u7570\u6027\u6297\u9ad4\u6700\u5177\u8a3a\u65b7\u7279\u7570\u6027\nD. \u5b63\u7bc0\u578b\u7684\u60a3\u8005\u8840\u6e05\u4e2d\u7684IgE\u901a\u5e38\u4e0d\u6703\u9ad8\nE. \u5f15\u8d77\u904e\u654f\u6027\u9f3b\u708e\u7684\u904e\u654f\u539f\u7c92\u5b50\u901a\u5e38\u6bd4\u6c23\u5598\u904e\u654f\u539f\u70ba\u5c0f\n": "(B)", "102-2.\n24\u6b72\u7684\u5973\u6027\u60a3\u8005\u7f79\u60a3\u8541\u9ebb\u75b9\u6a23\u7684\u76ae\u819a\u6414\u7662\u6709\u4e00\u5e74\u56db\u500b\u6708\u4e4b\u4e45\uff0c\u6bcf\u6b21\u767c\u4f5c\u6642\u76ae\u819a\u6703\u81a8\u8d77\uff0c\u7d93\u56db\u5929\u4e4b\u5f8c\u624d\u6703\u6d88\u5931\u3002\u76ae\u819a\u5207\u7247\u6aa2\u67e5\u767c\u73fe\u5c0f\u975c\u8108\u6709\u767c\u708e\u7d30\u80de\u7684\u6d78\u6f64\u53cafibrinoid necrosis\u3002\u8acb\u554f\u9577\u671f\u4f7f\u7528\u4e0b\u5217\u4f55\u8005\u85e5\u7269\u6700\u70ba\u9069\u7576\uff1f\nA. H1 anti-histamine\nB. Local application of corticosteroid ointment\nC. Methotrexate\nD. Anti-IgE therapy\nE. Hydroxychloroquine\n": "(E)", "102-3.\n27\u6b72\u7537\u6027\u60a3\u8005\u8fd1\u534a\u5e74\u4f86\u6709\u91cd\u8907\u6027\u7684\u53e3\u8154\u53ca\u820c\u982d\u9ecf\u819c\u7684\u75bc\u75db\u6027\u6f70\u760d\u3002\u4e26\u4e14\u6703\u6709\u591a\u8655\u95dc\u7bc0\u9178\u75db\uff0c\u5176\u9593\u5076\u800c\u4e0b\u80a2\u6703\u51fa\u73fe\u58d3\u75db\u6027\u7684\u7d05\u6591\u3002\u6b64\u7d05\u6591\u75c5\u8b8a\u66fe\u88ab\u91ab\u5e2b\u61f7\u7591\u70ba\u8840\u7ba1\u708e\u3002\u53c8\uff0c\u60a3\u8005\u70ba\u6162\u6027B\u809d\u5e36\u539f\u8005\uff0c\u62bd\u8840\u6aa2\u67e5\u767c\u73feANA 1:160 speckled pattern\u3001rheumatoid factor(RF) 108 IU/ml (normal < 10 IU/ml)\u3001C3\u53caC4\u6b63\u5e38\u3001 HLA-B27 (+)\u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Behcet's disease\nB. SLE\nC. Rheumatoid arthratis (RA)\nD. Leukocytoclastic vasculitis\nE. Chronic urticaria\n": "(A)", "102-4.\n28\u6b72\u7684\u5973\u6027SLE\u60a3\u8005\u6709\u4e09\u6b21\u6d41\u7522\u53ca\u4e00\u6b21\u6b7b\u7522\u4e4b\u61f7\u5b55\u53f2\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6297\u9ad4\u8207\u7fd2\u6163\u6027\u6d41\u7522\u6700\u6709\u76f8\u95dc\uff1f\nA. Anti-dsDNA\nB. Anti-SSB/La\nC. Anti-Sm/anti-RNP\nD. Anti-\u03b22GPI\nE. Anti-PCNA\n": "(D)", "102-5.\n\u4e00\u4f4d\u7f79\u60a3\u72fc\u7621\u814e\u708e\u7684\u60a3\u8005\u6bcf\u65e5\u6295\u4e88prednisolone 10mg\u53caazathioprine 100mg\u3002\u6709\u4e00\u5929\u5176serum creatinine\u7531\u539f\u672c\u76841.8mg/dL\u5728\u4e8c\u500b\u6708\u4e4b\u5167\u5feb\u901f\u4e0a\u6607\u81f35.3mg/dL\uff0c\u800c\u4e14\u6709\u4e0b\u80a2\u6d6e\u816b\u51fa\u73fe\u3002\u8acb\u554f\u61c9\u8a72\u99ac\u4e0a\u7d66\u4e88\u4f55\u7a2e\u85e5\u7269\u6cbb\u7642\u6700\u70ba\u6070\u7576\uff1f\nA. Methylprednisolone pulse therapy\nB. Oral mycophenolate mofetil\nC. Cyclophosphamide pulse therapy\nD. Rituximab IV infusion\nE. Belimumab IV infusion\n": "(C)", "102-6.\n\u4e00\u4f4d31\u6b72\u7684\u5973\u6027\u5728\u4e8c\u5929\u524d\u53f3\u4e0b\u817f\u7a81\u7136\u767c\u751f\u816b\u8139\u5287\u75db\u3002\u7d93\u62bd\u8840\u6aa2\u67e5\u767c\u73feESR 41 mm/h\u3001CRP 2.3mg/dL\u3001ANA 1:80 speckled pattern, blood culture (-)\u3001PT\u6b63\u5e38\uff0c\u4f46PTT\u5ef6\u9577\u81f353\u79d2\uff08\u6b63\u5e3836\u79d2\uff09\u3001Anti-SSA 34.6 AU/mL (normal < 1.2)\uff0canti-SSB < 1.2 AU/ml\u3001DRVVT\u4e0a\u5347\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u7684\u53ca\u6642\u6cbb\u7642\u6700\u70ba\u6070\u7576\uff1f\nA. Intravenous antibiotics\nB. Low molecular weight heparin infusion\nC. Corticosteroid 1mg/kg/day IV infusion\nD. Oral cylophosphamide 100mg/day\nE. Intravenous immunoglobulin for 5 days\n": "(B)", "102-7.\n58\u6b72\u7684\u5973\u6027\u60a3\u8005\u4e3b\u8a34\u70baRaynaud's phenomenon\u6709\u4e00\u5e74\u4e4b\u4e45\u3002\u8fd1\u4e09\u500b\u6708\u4f86\u5169\u624b\u80cc\u7684\u76ae\u819a\u9010\u6f38\u8b8a\u786c\u3002\u53e6\u5916\uff0c\u5403\u6771\u897f\u5bb9\u6613\u55c6\u5230\u3002\u91ab\u5e2b\u61f7\u7591\u5979\u7f79\u60a3\u786c\u76ae\u75c7\u3002\u514d\u75ab\u5b78\u6aa2\u67e5\u767c\u73feanti-Scl-70\u70ba 126 AU/mL (normal<1.5 AU/mL)\uff0c\u80ba\u529f\u80fd\u53cadiffusion capacity of carbon monoxide(DLCO)\u6aa2\u67e5\u6b63\u5e38\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u9996\u9078\u85e5\u7269?\nA. Cyclophosphamide pulse therapy\nB. High dose oral corticosteroids\nC. Colchicine\nD. D-penicillamine\nE. Methotrexate\n": "(D)", "102-8.\n\u6709\u95dc\u50f5\u76f4\u6027\u810a\u690e\u708e\u7684\u8840\u6db2\u53ca\u8840\u6e05\u5b78\u6aa2\u67e5\u6578\u64da\u5982\u4e0b\uff0c\u8acb\u554f\u4f55\u8005\u6700\u70ba\u6b63\u78ba?(1) ANA(+)  (2) ESR\u4e0a\u5347( 3) CRP\u4e0a\u5347  (4) RF (+) (5)Anti-CCP (-)  (6) HLA-B27(+)  (7) ANCA(+)\nA. (1)+(2)+(3)\nB. (4)+(5)+(6)\nC. (2)+(4)+(7)\nD. (3)+(4)+(5)\nE. (3)+(5)+(6)\n": "(E)", "102-9.\n\u4e0b\u5217\u6709\u95dc\u5404\u7a2evasculitis syndromes\u7684\u75be\u75c5\u7279\u5fb5\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f(1)Granulomatosis with polyangiitis--cANCA (+) (2)\tHenoch-Schonlein purpura--serum IgE\u4e0a\u5347 (3)Polyarteritis nodosa-paranasal sinusitis (4)Takayasu's arteritis--pulseless disease (5)Leukocytoclastic vasculitis--pANCA (+) (6)Churg-Strauss syndrome--allergic manifestations (7)Temporal arteritis--serum IgA\u4e0a\u5347\nA. (1)+(4)+(6)\nB. (1)+(2)+(3)\nC. (3)+(4)+(5)\nD. (2)+(6)+(7)\nE. (3)+(5)+(7)\n": "(A)", "102-10.\n\u4e0b\u5217\u6709\u95dc\u5404\u7a2e\u95dc\u7bc0\u708e\u7684\u75be\u75c5\u7279\u5fb5\u63cf\u8ff0\uff0c\u4f55\u7a2e\u7d44\u5408\u6700\u70ba\u6b63\u78ba\uff1f\r(1)\tOsteoarthritis--osteophyte formation\r(2)\tRheumatoid arthritis--marginal bone erosion\r(3)\tPsoriatic arthropathy--osteonecrosis\r(4)\tPseudogout--monosodium urate deposit\r(5)\tAnkylosing spondylitis--chronic synovitis\r(6)\tFrozen shoulder--tendinitis\r(7)\tReactive arthritis--enthesitis\nA. (1)+(3)+(5)\nB. (2)+(6)+(7)\nC. (3)+(4)+(5)\nD. (1)+(4)+(7)\nE. (2)+(5)+(6)\n": "(B)", "103-1.\n\u9673\u5c0f\u59d0\uff0c 28\u6b72\uff0c\u672a\u5a5a\uff0c\u56e0\u70ba\u4e0b\u80a2\u6c34\u816b\u4f86\u4f4f\u9662\uff0c \u4e26\u7121\u5176\u4ed6\u81e8\u5e8a\u8868\u5fb5 (\u5305\u62ec:\u96d9\u9830\u7d05\u75b9\u3001\u5634\u7834\u53ca\u6389\u9aee\u7b49)\uff0c\u6aa2\u9a57\u5831\u544a\u53ea\u670924\u5c0f\u6642\u86cb\u767d\u5c3f3.2g\uff0c \u8840\u6db2\u767d\u86cb\u767d2.0 mg/dl , ANA(+) (Antinuclear antibodies) 1:1280X speckled pattern\uff0canti-double strand DNA Ab(-) \u8acb\u554f\u63a5\u4e0b\u4f86\u8981\u505a\u4ec0\u9ebc\u6aa2\u67e5\u4f86\u8a3a\u65b7\u8f03\u70ba\u5408\u9069?\nA. \u4e09\u5929\u5f8c\u518d\u62bd\u4e00\u6b21anti-double strand DNA Ab, \u8981\u9023\u7e8c3\u6b21.\nB. \u5b89\u6392\u814e\u81df\u5207\u7247\nC. \u5b89\u6392\u773c\u5e95\u93e1\u6aa2\u67e5\nD. \u62bd\u8840\u6aa2HLA typing\nE. \u4ee5\u4e0a\u7686\u5fc5\u8981.\n": "(B)", "103-2.\n\u5433\u5c0f\u59b9\u59b9\uff0c16 \u6b72\uff0c 1 \u5e74\u524d\u8a3a\u65b7\u6709SLE\uff0c\u6700\u8fd13\u5929\u5abd\u5abd\u767c\u73fe\u5979\u6027\u683c\u6539\u8b8a\uff0c \u958b\u59cb\u4e82\u7f75\u4eba\uff0c\u53c8\u6709\u4e9b\u767c\u71d2\uff0c \u4f46\u7121\u8116\u5b50\u50f5\u786c\uff0c \u56e0\u6b64\u4f86\u4f4f\u9662\u3002 \u8acb\u554f\u63a5\u4e0b\u4f86\u8981\u505a\u4ec0\u9ebc\u8840\u6e05\u6aa2\u67e5\u4f86\u8a3a\u65b7\u8f03\u70ba\u5408\u9069?\nA. Anti-cardiolipin Ab + Anti-Ribosomal P Ab\nB. Anti-Ribosomal P Ab + Anti-Smith Ab\nC. Anti-smooth-muscle antibody (ASMA)\nD. Antithyroglobulin antibody\nE. \u4ee5\u4e0a\u7686\u5c0d\n": "(A)", "103-3.\n42\u6b72\u5973\u6027\u75c5\u60a3\u6709primary systemic sclerosis\u75c5\u53f23\u5e74\uff0c\u56e0\u5168\u8eab\u62bd\u6410\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u5230\u9662\u6642\u8840\u58d3200/106 mmHg\uff0c\u8a3a\u65b7\u70bastatus epilepticus\u3002\u75c5\u60a3\u524d\u4e00\u9031\u66fe\u81f3\u773c\u79d1\u9580\u8a3a\u5c31\u91ab\uff0c\u4e3b\u8a34\u70ba\u8996\u529b\u6a21\u7cca\uff0c\u773c\u5e95\u93e1\u6240\u898b\u70ba\u8996\u7db2\u819c\u51fa\u8840\u4e26\u6709cotton wool spots\u3002\rHb\t10.1 g/dL\rWBC\t6450/\u03bcL\rPlatelets\t204,000/\u03bcL\rBUN\t50 mg/dL\rCreatinine\t2.0 mg/dL\rESR\t77 mm/hr\rUrine protein\t+++\rUrine RBC\t10-20/HPF\r\u4ee5\u4e0b\u54ea\u7a2e\u6cbb\u7642\u6700\u9069\u7576\uff1f\nA. \u7d66\u4e88oral captopril\nB. \u7d66\u4e88IV labetalol (Trandate)\nC. \u7d66\u4e88oral methotrexate\nD. \u7d66\u4e88IV phenytoin\nE. \u5b89\u6392plasma exchange\n": "(A)", "103-4.\n69\u6b72\u9000\u4f11\u8b77\u7406\u5e2b\uff0c\u5973\u6027\uff0c\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u75c5\u53f215\u5e74\uff0c\u65bc\u534a\u5e74\u524d\u63a5\u53d7\u751f\u7269\u88fd\u5291adalimumab Q2W\u4f75\u7528methotrexate 15mg QW\u53caprednisolone 10mg QD\u6cbb\u7642\u3002\u8fd1\u4e09\u9031\u51fa\u73fe\u75b2\u5026\u3001\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\u3001\u53ca\u591c\u9593\u76dc\u6c57\u4e4b\u60c5\u5f62\u3002\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u95dc\u7bc0\u767c\u708e\u53caDAS28\u70ba3.1\u5206\u3002\u5176\u4ed6\u7406\u5b78\u6aa2\u67e5\u4e26\u7121\u76ae\u75b9\u6dcb\u5df4\u816b\u5927\u6216\u809d\u813e\u816b\u5927\u3002\u80f8\u90e8\uff38\u5149\u7121\u767c\u73fe\u7570\u5e38\u3002\rHb\t13.1 g/dL\rWBC\t7200/\u03bcL\rPlatelets\t204,000/\u03bcL\rRF\t320 U/L\rANA\tnegative\rESR\t72 mm/hr\rCRP\t5.5 mg/dL\rLDH\u53cabeta-2 microglobulin\tBoth within normal ranges\r\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u9069\u7576\u4e4b\u6aa2\u67e5\uff1f\nA. bone marrow biopsy\nB. CT scan of thorax, abdomen and pelvis\nC. PPD test\nD. QuantiFeron test for tuberculous infection\nE. Creatine kinase (CK)\n": "(D)", "103-5.\n27\u6b72\u5973\u6027\uff0c\u67095\u5e74\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u75c5\u53f2\uff0c\u65bc1\u5e74\u524d\u958b\u59cb\u63a5\u53d7\u751f\u7269\u88fd\u5291etanercept\u6cbb\u7642\uff0c\u76ee\u524d\u4e26\u7121\u95dc\u7bc0\u816b\u75db\u53ca\u6668\u9593\u50f5\u786c\uff0cDAS28\u70ba2.2\u5206\u3002\u6700\u8fd1\u4e00\u500b\u6708\u767c\u73fe\u81c9\u4e0a\u6709\u7d05\u6591\u53ca\u6389\u9aee\u60c5\u5f62\uff0c\u81c9\u4e0a\u7d05\u6591\u65bc\u65e5\u66ec\u5f8c\u66f4\u70ba\u660e\u986f\u3002\u8fd1\u5169\u9031\u51fa\u73fe\u5de6\u80f8\u75bc\u75db\uff0c\u5c24\u5176\u5728\u5438\u6c23\u6642\u66f4\u70ba\u75db\u695a\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u6700\u70ba\u6709\u8a3a\u65b7\u6027\uff1f\nA. anti-cardiolipin antibodies\nB. anti-dsDNA\nC. anti-histone antibodies\nD. ANCA\nE. anti-SSA and anti-SSB\n": "(B)", "103-6.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u8ef8\u5fc3\u578b\u810a\u690e\u95dc\u7bc0\u708eAxial spondyloarthritis\u7684\u8a3a\u65b7\u689d\u4ef6\u4e4b\u4e00\uff1f\nA. \u5bb6\u65cf\u53f2\u6709\u810a\u690e\u95dc\u7bc0\u708e\u4e4b\u4efb\u4e00\u7a2e\nB. \u4f7f\u7528NSAID\u5f8c\u6709\u9032\u6b65\nC. MRI\u6709sacroiliitis\nD. ESR\u5347\u9ad8\nE. HLA-B27\u967d\u6027\n": "(D)", "103-7.\n\u4e00\u4f4d40\u6b72\u5bb6\u5ead\u4e3b\u5a66\uff0c\u56e0\u5de6\u53f3\u624b\u8108\u640f\u5f37\u5ea6\u4e0d\u540c\u800c\u5230\u91ab\u9662\uff0c10\u5e74\u524d\u4ed6\u66fe\u6709\u4e09\u500b\u6708\u7684\u767c\u71d2\u3001\u5b50\u5bae\u808c\u7624\u8207\u9ad4\u91cd\u6e1b\u8f15\u4e4b\u75c5\u53f2\uff0c\u7576\u6642\u8840\u58d3120/70 mmHg\uff0c\u9ad4\u6eab37.8\u2103\uff0c\u8108\u640f80/min\uff0c\u76ae\u819a\u6c92\u7d05\u6591\uff0c\u7121\u53e3\u8154\u6f70\u760d\uff0c\u5fc3\u81df\u7121\u96dc\u97f3\uff0c\u4f46\u5728\u5de6\u908asupraclavicular fossa\u6709Bruit\uff0c\u5176\u4ed6\u6b63\u5e38\uff0c10\u5e74\u4f86\u5979\u4e26\u4e0d\u518d\u770b\u91ab\u5e2b\uff0c10\u5e74\u524d\u7684\u5be6\u9a57\u5ba4\u6aa2\u67e5\u70ba\uff1a\u8840\u6bd4\u5bb928 %\uff0c\u767d\u8840\u74037,600/\u03bcL\uff0c\u8840\u5c0f\u677f480,000/\u03bcL\uff0cESR 80 mm/hr\uff0c CRP 4.5mg/dL\uff0cCK\u3001serum creatinine\u3001RF\u3001ANCA\u3001ANA\u7686\u9670\u6027\u3002\u9019\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u662f\u4f55\u7a2e\u75be\u75c5\nA. Adult onset Still's disease\nB. Microscopic polyangiitis\nC. polyarteritis nodosa\nD. Rheumatoid arthritis\nE. Takayasu's arteritis\n": "(E)", "103-8.\n\u767c\u708e\u6027\u4e0b\u80cc\u75db(Inflammatory low back pain)\u7684\u7279\u5fb5\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f(1)\u767c\u75c5\u5e74\u9f61\u5c0f\u65bc40\u6b72 (2)\u6f38\u9032\u767c\u751f (3)\u904b\u52d5\u904e\u5f8c\u53ef\u6e1b\u8f15 (4)\u6668\u9593\u50f5\u786c (5)\u53d7\u50b7\u5f15\u8d77 (6)high CRP\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (5)+(6)\nE. (1)+(6)\n": "(D)", "103-9.\n\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621\u75c5\u4eba\u9808\u61f7\u5b55\u6642\u4f7f\u7528\u4e0b\u5217\u85e5\u7269\u5c0d\u5f71\u97ff\u80ce\u5152\u6700\u5c0f(1)Glucocorticoid (2)Tacrolimus (3)Rituximab (4)Cyclosporine (5)Methotrexate (6)Low-dose aspirin\nA. (1)+(2)\nB. (3)+(4)\nC. (5)+(6)\nD. (1)+(3)\nE. (1)+(6)\n": "(E)", "103-10.\n\u4e0b\u5217\u85e5\u7269\u6700\u5e38\u898b\u5f15\u8d77\u7d05\u6591\u6027\u72fc\u7621\uff08Lupus-like disease\uff09\u70ba(1)Procainamide (2)Disopyramide (3)Furosemide (4)Glucocorticoid\r(5)Azathioprine (6)Methotrexate\nA. (1)+(2)\nB. (3)+(4)\nC. (5)+(6)\nD. (1)+(5)\nE. (1)+(6)\n": "(A)", "103-1.\n\u4e0b\u5217\u6709\u95dc\u75be\u75c5\u8207\u514d\u75ab\u529f\u80fd\u7570\u5e38\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Mycobacterial infection - antibody deficiency\nB. Recurrent Streptococcus pneumoniae infection- cellular deficiency\nC. Recurrent skin pyogenic infections - phagocytic defect\nD. Recurrent Neisseria infection - antibody deficiency\nE. Inflammatory diseases - complement deficiency\n": "(C)", "103-2.\n\u4e0b\u5217\u6709\u95dc\u751f\u7269\u88fd\u5291\u8207\u75be\u75c5\u6cbb\u7642\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Soluble CTLA-4 protein - T cell lymphoma\nB. Anti-TNF-\u03b1 monoclonal antibody - rheumatoid arthritis\nC. IVIG - multiple myeloma\nD. Anti - CD20 monoclonal antibody - acute B cell leukemia\nE. Anti-IL-6 receptor monoclonal antibody - SLE\n": "(B)", "103-3.\n\u4e0b\u5217\u6709\u95dc\u904e\u654f\u6027\u9f3b\u708e\u6cbb\u7642\u7684\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Immunotherapy\u5c0d\u4efb\u4f55\u5c6c\u6027\u7684\u904e\u654f\u6027\u9f3b\u708e\u90fd\u662f\u6700\u597d\u7684\u6cbb\u7642\u9078\u64c7\nB. \u55ae\u682a\u6297IgE\u6297\u9ad4\u5c0dallergen-specific IgE\u5347\u9ad8\u7684\u9f3b\u708e\u60a3\u8005\u6700\u6709\u6548\nC. \u53e3\u670d\u03b1-adrenergic agonist\u662f\u9996\u9078\u6cbb\u672c\u7684\u85e5\u7269\nD. Intra-nasal high-potency glucocorticoids\u7684\u4f7f\u7528\u5c0d\u904e\u654f\u75c7\u72c0\u6700\u6709\u6548\nE. \u8f15\u5ea6\u3001\u9593\u6b47\u6027\u7684\u904e\u654f\u6027\u9f3b\u708e\u767c\u4f5c\u6642\u53ef\u4ee5\u77ed\u671f\u4f7f\u7528\u9ad8\u5291\u91cf\u7684\u53e3\u670d\u985e\u56fa\u9187\u6cbb\u7642\n": "(D)", "103-4.\n\u4e00\u4f4d57\u6b72\u5973\u6027\uff0c\u8fd1\u4e8c\u5e74\u4f86\u767c\u73fe\u51ac\u5b63\u5929\u51b7\u6642\uff0c\u53f3\u624b\u7b2c\u4e09\u53ca\u7b2c\u56db\u6307\u7684\u6307\u7532\u6703\u8b8a\u767d\u8b8a\u7d2b\u3002\u6700\u8fd1\u4e00\u5e74\u4f86\u5169\u5074\u624b\u80cc\u7684\u76ae\u819a\u8b8a\u539a\u8b8a\u786c\u3002\u559d\u6c34\u6642\u5076\u800c\u6703\u55c6\u5230\u53ca\u6709\u4e7e\u54b3\u767c\u751f\u3002\u5230\u8a3a\u6240\u62bd\u8840\u767c\u73feANA 1:5120 speckled + 1:320 centromere pattern\uff0cC3 109 mg/dL\uff0cC4 21.4 mg/dL\uff0canti-dsDNA 42.5 IU/mL (normal < 120 IU/mL)\u3001anti-SSA 25.4 U/mL (< 12.0 U/mL)\uff0canti-SSB 8.6 U/mL (< 12.0 U/mL)\u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1a\nA. SLE\nB. Systemic sclerosis\nC. Sjogren's syndrome\nD. Psoriasis\nE. Cutaneous vasculitis\n": "(B)", "103-5.\n\u4e00\u4f4d46\u6b72\u7684\u7537\u6027\uff0c\u904e\u53bb\u6709\u91cd\u8907\u6027\u7684\u5de6\u5074\u816e\u817a\u816b\u5927\u3002\u6700\u8fd1\u534a\u500b\u6708\u4f86\u6709\u660e\u986f\u7684\u6d88\u5316\u4e0d\u826f\u53ca\u98df\u617e\u4e0d\u632f\u3002\u53e6\u5916\uff0c\u4e5f\u6709\u773c\u4e7e\u53ca\u53e3\u4e7e\u767c\u751f\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feANA: 1:80 speckled\uff0cAST 38 U/L\uff0cALT 62 U/L\uff0canti-SSA 8 U/mL (<12 U/mL)\uff0canti-SSB 11 U/mL (<12 U/mL)\uff0camylase 185 U/L\u3002\u8179\u90e8\u8d85\u97f3\u6ce2\u767c\u73fe\u80f0\u81df\u982d\u90e8\u816b\u5927\u4e14\u6709\u7e96\u7dad\u5316\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Serum IgG4\nB. Serum electrophoresis\nC. Anti-aquaporin 4 antibodies\nD. Minor salivary gland biopsy\nE. Sialoscintigraphy\n": "(A)", "103-6.\n\u4e00\u4f4d21\u6b72\u7684\u7537\u6027\uff0c\u65e9\u6668\u8d77\u4f86\u6709\u4e0b\u80cc\u75db\u90545\u500b\u6708\u4e4b\u4e45\u3002\u8d77\u5e8a\u4ee5\u5f8c\u7a0d\u4e8b\u904b\u52d520\u5206\u4e4b\u5f8c\uff0c\u4e0b\u80cc\u7684\u50f5\u786c\u53ca\u75e0\u75db\u5f88\u5feb\u5c31\u6703\u7de9\u89e3\u3002\u7d93\u591a\u5bb6\u91ab\u9662\u6aa2\u67e5\u5305\u62ec\uff0cESR 2 mm/1h\u3001CRP<0.3 mg/dL\u3001\u9aa8\u76c6X-\u5149\u7167\u76f8\u7121\u660e\u986f\u7684sacroiliitis\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u65bc\u8a3a\u65b7axial spondyloarthropathy\u6700\u6709\u5e6b\u52a9\uff1f\nA. Soft tissue sonography\nB. Inflammatory bone scan\nC. Dynamic MRI test\nD. HLA-B27 genotyping\nE. Lumbar spine mobility test\n": "(C)", "103-7.\n\u4e00\u4f4d69\u6b72\u7684\u75db\u98a8\u60a3\u8005\uff0c\u904e\u53bb\u6709\u5c3f\u8def\u7d50\u77f3\u7684\u75c5\u53f2\u3002\u56e0\u7d93\u5e38\u4f7f\u7528NSAIDS\u4ee5\u81f4\u814e\u529f\u80fd\u53d7\u640d\u3002\u8840\u6db2\u6aa2\u67e5\u767c\u73feBUN 34 mg/dL\uff0ccreatinine 2.3 mg/dL\uff0curic acid 9.1 mg/dL\u3002\u53e6\u5916\u6aa2\u6e2cHLA\u767c\u73fe\u70baHLA-B*5801\u5e36\u539f\u8005\u3002\u8acb\u554f\u4f7f\u7528\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u4f86\u964d\u5c3f\u9178\u6700\u70ba\u9069\u7576\uff1f\nA. Allopurinol\nB. Probenecid\nC. Benzbromarone\nD. Febuxostat\nE. Colchicine\n": "(D)", "103-8.\n\u5728SLE\u60a3\u8005\u7684\u8840\u6e05\u4e2d\u542b\u6709\u5404\u5f0f\u5404\u6a23\u7684\u6297\u9ad4\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u624d\u662f\u6700\u6b63\u78ba\u7684\u7d44\u5408\u6297\u9ad4\uff1f (1) ACPA  (2) ANCA  (3) anti-SSA/anti-SSB  (4) anti-histone  (5) anti-Sm/ anti-RNP  (6) anti-lymphocyte  (7) anti-mitochondria  (8) anti-LKM  (9) anti-centromere\nA. (1)+(3)+(9)\nB. (2)+(6)+(8)\nC. (3)+(4)+(7)\nD. (1)+(5)+(8)\nE. (4)+(5)+(6)\n": "(E)", "103-9.\n\u8207rheumatoid arthritis\u76f8\u95dc\u7684\u56e0\u5b50\u5f88\u591a\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e9bcytokines/ chemokines \u8207rheumatoid pathogenesis\u6700\u6709\u76f8\u95dc\uff1f\r(1) IL-2  (2) IL-1  (3) IL-6  (4) TGF-\u03b2  (5) TNF-\u03b1  (6) IL-4  (7) G-CSF  (8) IFN-\u03b3  (9) IL-10\nA. (1)+(2)+(4)\nB. (3)+(5)+(8)\nC. (4)+(6)+(7)\nD. (2)+(8)+(9)\nE. (1)+(5)+(7)\n": "(B)", "103-10.\n\u4e0b\u5217\u7684\u54ea\u7a2e\u8840\u7ba1\u708e\u6709\u53ef\u80fd\u6703\u7522\u751fanti-neutrophil cytoplasmic antibodies (ANCAs) ? (1) giant cell arteritis  (2) polyarteritis nodosa  (3) idiopathic cutaneous vasculitis (4) granulomatosis with polyangiitis  (5) hepatitis C-associated cryoglobulinemic vasculitis  (6) microscopic polyangiitis  (7) Kawasaki disease (8) Churg-Strauss syndrome  (9) Takayasu's arteritis\nA. (1)+(2)+(4)\nB. (2)+(5)+(7)\nC. (4)+(6)+(8)\nD. (3+(5)+(9)\nE. (5)+(6)+(7)\n": "(C)", "104-1.\n\u4e00\u4f4d65\u6b72\u786c\u76ae\u75c7\u5973\u6027\u75c5\u4eba\uff0c\u9577\u671f\u4ee5\u514d\u75ab\u6291\u5236\u5291\u63a7\u5236\u75c5\u60c5\uff0c\u6700\u8fd1\u958b\u59cb\u611f\u89ba\u8d70\u8def\u6703\u547c\u5438\u56f0\u96e3\u53ca\u75b2\u5026\uff0c\u91ab\u5e2b\u61f7\u7591\u6709\u80ba\u52d5\u8108\u9ad8\u8840\u58d3\uff0c\u4e0b\u5217\u6aa2\u67e5\u662f\u8a3a\u65b7\u80ba\u52d5\u8108\u9ad8\u58d3\u4e4b\u5e38\u7528\u65b9\u6cd5\uff1f\r(1)\u80f8\u90e8X\u5149 (Chest X-ray) ; (2)\u53f3\u5fc3\u5c0e\u7ba1\u6aa2\u67e5 (R't Heart Catheterization) ; (3)\u5de6\u5fc3\u5c0e\u7ba1\u6aa2\u67e5 (L't Heart Catheterization) ; (4)\u6297\u6838\u6297\u9ad4 (ANA) ; (5)\u8d85\u97f3\u6ce2\u6aa2\u67e5 (Echocardiography)\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (1)+(2)+(5)\nD. (1)+(4)+(5)\nE. (3)+(4)+(5)\n": "(C)", "104-2.\n\u4e00\u4f4d28\u6b72\u7537\u6027\u4e3b\u8a34\u767c\u71d2\u3001\u982d\u75db\u3001\u8179\u7009\u53ca\u76ae\u819a\u7d05\u75b9\u6709\u5169\u9031\uff0c\u75c5\u4eba\u4e8c\u500b\u6708\u524d\u5230\u5b5f\u52a0\u62c9\u7d93\u5546\u4e00\u9031\uff0c\u66fe\u6709\u6c34\u72c0\u8179\u7009\u591a\u5929\uff0c\u4e0b\u5217\u6aa2\u67e5\u8f03\u4e0d\u5177\u8a3a\u65b7\u50f9\u503c\uff1f\nA. \u8840\u6db2\u57f9\u990a\nB. \u9aa8\u9ad3\u57f9\u990a\nC. \u672a\u7d93\u6cbb\u7642\u75c5\u4eba\uff0c\u611f\u67d3\u4e00\u9031\u4e4b\u5927\u4fbf\u57f9\u990a\nD. \u672a\u7d93\u6cbb\u7642\u75c5\u4eba\uff0c\u611f\u67d3\u4e09\u9031\u4e4b\u5927\u4fbf\u57f9\u990a\nE. Widal test\n": "(E)", "104-3.\n\u4e0b\u5217\u95dc\u7bc0\u708e\u5e38\u9700\u505a\u95dc\u7bc0\u8154\u6db2\u6aa2\u67e5(Synovial fluid analysis)\u4ee5\u78ba\u5b9a\u8a3a\u65b7\nA. \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e (RA)\nB. \u7d05\u6591\u6027\u72fc\u7621 (SLE)\nC. \u611f\u67d3\u6027\u95dc\u7bc0\u708e (septic arthritis)\nD. \u9000\u5316\u6027\u95dc\u7bc0\u708e (OA)\nE. \u7e96\u7dad\u808c\u75db\u75c7 (fibromyalgia)\n": "(C)", "104-4.\n\u4e0b\u5217\u75be\u75c5\u5e38\u4ee5\u55ae\u4e00\u95dc\u7bc0\u708e\u8868\u73fe?\r(1) \u9000\u5316\u6027\u95dc\u7bc0\u708e; (2)\u75db\u98a8\u95dc\u7bc0\u708e ; (3)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e ; (4)\u7d30\u83cc\u611f\u67d3\u6027\u95dc\u7bc0\u708e ; (5)\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (2)+(3)+(4)\nD. (2)+(4)+(5)\nE. (3)+(4)+(5)\n": "(B)", "104-5.\n\u4e0b\u5217\u4f55\u7a2e\u6297\u9ad4\u8207\u65b0\u751f\u5152\u72fc\u7621 (Neonatal lupus)\u5408\u4f75\u5148\u5929\u6027\u7d05\u6591\u53ca\u5148\u5929\u6027\u5fc3\u81df\u50b3\u5c0e\u969c\u7919\u6709\u95dc?\nA. La\u6297\u9ad4 (anti-La)\nB. Ro\u6297\u9ad4 (anti-Ro)\nC. Scl-70\u6297\u9ad4 (anti-Scl-70)\nD. U1 RNP (anti-U1 RNP)\nE. Sm\u6297\u9ad4 (anti-Sm)\n": "(B)", "104-6.\n\u6709\u95dc\u50f5\u76f4\u6027\u810a\u690e\u708e\u4e4b\u76f8\u95dc\u57fa\u56e0\uff0c\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u76f8\u95dc?\nA. HLA-B27\nB. HLA-B61\nC. DR4\nD. ERAP-1\nE. IL23R\n": "(C)", "104-7.\n40\u6b72\u7537\u6027\uff0c\u53cd\u8986\u767c\u751f\u8e1d\u95dc\u7bc0\u708e\uff0c\u5e38\u4f75\u6709\u53e3\u8154\u6f70\u760d\u53ca\u5c3f\u9053\u708e\uff0c\u5076\u6709\u8ddf\u8171\u816b\u75db\uff0c\u8840\u4e2dESR=30 hr/min, HLA-B27 negative, Rheumatoid factor: negative\uff0c\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1a\nA. \u75db\u98a8\nB. \u7d05\u6591\u6027\u72fc\u7621\nC. \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e (rheumatoid arthritis)\nD. \u810a\u690e\u95dc\u7bc0\u708e (spondyloarthritis)\nE. \u9aa8\u95dc\u7bc0\u708e (osteoarthritis)\n": "(D)", "104-8.\n38\u6b72\u7537\u6027\uff0c\u6709\u767c\u708e\u6027\u4e0b\u80cc\u75db\u7d04\u534a\u5e74\uff0cESR=30 mm/1hr\uff0c\u4f46X-ray\u7121\u660e\u986fSacroiliitis\uff0c\u4e0b\u5217\u8a3a\u65b7\u6b65\u9a5f\u4f55\u8005\u4e0d\u5408\u7406?\nA. \u8a62\u554f\u6709\u7121\u810a\u690e\u95dc\u7bc0\u708e\u5bb6\u65cf\u53f2\nB. \u7406\u5b78\u6aa2\u67e5\nC. \u6838\u91ab\u9aa8\u9abc\u6383\u63cf (Bone Scan)\nD. \u62bd\u8840\u6e2cHLA-B27\nE. \u8003\u616eSI joints MRI\n": "(C)", "104-9.\n\u767c\u708e\u6027\u4e0b\u80cc\u75db (Inflammatory low back pain)\u7684\u7279\u5fb5\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e?\nA. \u767c\u75c5\u5e74\u9f61\u5c0f\u65bc40\nB. \u6f38\u9032\u767c\u751f\nC. \u904b\u52d5\u904e\u5f8c\u53ef\u6e1b\u8f15\nD. \u6668\u9593\u50f5\u786c\nE. \u8840\u4e2dRF\u9670\u6027\n": "(E)", "104-10.\n\u4e0b\u5217\u54ea\u4e9b\u4e0d\u662f\u5c6c\u65bc\u6297\u5438\u6536\u7684 (anti-resorptive)\u6297\u9aa8\u8cea\u758f\u9b06\u85e5\u7269\nA. selective estrogen receptor modulator (raloxifene)\nB. bisphosphonqate\nC. RANKL inhibitor (Denosumab)\nD. parathyroid homone (teriparatide)\nE. hormone replacement therapy\n": "(D)", "104-1.\n\u4e0b\u5217\u6709\u95dcspecific autoantibody\u8207\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. Anti-collagen type II--Goodpasture's syndrome\nB. Anti-aminoacyl-tRNA histidyl synthetase--Myositis\nC. Anti-thyroid peroxidase--Graves' disease\nD. Anti-myeloperoxidase--Granulomatosis with polyangiitis\nE. Anti-keratin--SLE\n": "(B)", "104-2.\n\u4e00\u4f4d23\u6b72\u5973\u6027\uff0c\u5f9e5\u6b72\u958b\u59cb\u76ae\u819a\u6301\u7e8c\u767c\u7662\u81f3\u4eca\u3002\u5c31\u8a3a\u6642\u81c9\u90e8\u3001\u9838\u90e8\u3001\u80cc\u90e8\u3001\u8179\u90e8\u53ca\u56db\u80a2\u76ae\u819a\u5df2\u5448\u82d4\u766c\u5316(lichenification)\u3002\u8acb\u554f\u5c0d\u672c\u60a3\u8005\u6700\u6709\u7528\u7684\u6aa2\u67e5\u9805\u76ee\u70ba\uff1a\nA. Serum specific IgE\nB. Dermatography\nC. Total eosinophil count\nD. Serum complement C1 inhibitor levels\nE. Skin pathology\n": "(A)", "104-3.\n\u4e00\u4f4d26\u6b72\u7684SLE\u60a3\u8005\u904e\u53bb\u66fe\u67093\u6b21\u6d41\u7522\u7d00\u9304\uff0c\u8acb\u554f\u8207\u4e0b\u5217\u7684\u4f55\u7a2e\u81ea\u9ad4\u6297\u9ad4\u6700\u6709\u76f8\u95dc\uff1f\nA. Anti-dsDNA\nB. Anti-SSA/Ro\nC. Anti-Sm\nD. Anti-histone\nE. Anti-phospholipid\n": "(E)", "104-4.\n41\u6b72\u7684\u5973\u6027\u4f86\u9662\u6c42\u8a3a\u7684\u4e3b\u8a34\u70ba\u624b\u3001\u8173\u591a\u8655\u95dc\u7bc0\u75e0\u75db\u6709\u4e09\u5e74\u4e4b\u4e45\u3002\u6700\u8fd1\u4e8c\u500b\u6708\u4f86\u767c\u73fe\u5de6\u624b\u7b2c2\u30013\u6307\u7684\u8fd1\u7aef\u6307\u9593\u95dc\u7bc0\u816b\u8139.\u5728\u8a3a\u6240\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\uff1aESR 32 mm/h\u3001CRP 1.8 mg/dL\u3001C3 89 mg/dL\u53caC4 17.1 mg/dL\uff0c\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\uff0c\u5c0d\u8a3a\u65b7\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u6700\u6709\u5e6b\u52a9\uff1f\nA. Rheumatoid factors\nB. ANAs\nC. Anti-CCP antibodies\nD. Bilateral hand X-ray examination\nE. Bilateral hand sonographic examination\n": "(C)", "104-5.\n48\u6b72\u5973\u6027\u767c\u73fe\u8fd1\u4e09\u5e74\u4f86\u5169\u5074\u624b\u6307\u5728\u51ac\u5929\u6703\u8b8a\u767d\u53ca\u8b8a\u7d2b\uff0c\u7d93\u4fdd\u6696\u4e4b\u5f8c\u6703\u6062\u5fa9\u3002\u6700\u8fd1\u89ba\u5f97\u541e\u56a5\u6709\u9ede\u56f0\u96e3\uff0c\u53ca\u767c\u73fe\u96d9\u5074\u624b\u6307\u7684\u76ae\u819a\u8b8a\u539a\u3001\u8b8a\u786c\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u8a3a\u65b7systemic sclerosis\u6700\u6709\u5e6b\u5fd9\uff1f\nA. Anti-U1RNP\nB. Nailfold capillaroscopy\nC. Pulmonary function test + DLCO\nD. Anti-centromere antibody\nE. Anti-topoisomerase-1\n": "(E)", "104-6.\n68\u6b72\u7684\u7537\u6027\u60a3\u8005\u572815\u5e74\u524d\u56e0\u5169\u624b\u8098\u53ca\u982d\u76ae\u76ae\u819a\u75c5\u8b8a\uff0c\u88ab\u76ae\u819a\u79d1\u91ab\u5e2b\u8a3a\u65b7\u70ba\"\u4e7e\u766c\"\uff0c\u7d93\u6cbb\u7642\u4e4b\u5f8c\u76ae\u819a\u75c7\u72c0\u7a69\u5b9a\u3002\u6700\u8fd1\u4e00\u500b\u6708\u4f86\u767c\u73fe\u5169\u624b\u591a\u6307\u7684\u9060\u7aef\u6307\u9593\u95dc\u7bc0\u816b\u8139\u75bc\u75db\u3002\u800c\u4e14\u6709\u591a\u6839\u624b\u6307\u8b8a\u6210\"\u9999\u8178\u6307\u6a23\"(sausage-like finger)\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feESR 48 mm/1h\u3001CRP 3.8 mg/dL\u3001Rheumatoid factor 14.3 IU/ml (normal < 10 IU/ml)\u3001uric acid 8.1 mg/dL\uff0cX-\u5149\u6aa2\u67e5\u767c\u73fe\u624b\u90e8\u9060\u7aef\u6307\u9593\u95dc\u7bc0\u6709\u7834\u58de\u8b8a\u578b\u3002\u56e0\u53e6\u6709\u8170\u90e8\u75e0\u75db\u7d93pelvic X-ray\u6aa2\u67e5\u767c\u73feS-I\u95dc\u7bc0\u6709\u660e\u986f\u767c\u708e\u53cd\u61c9\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1a\nA. Rheumatoid arthritis\nB. Gouty arthritis\nC. Osteoarthritis\nD. Psoriatic arthropathy\nE. Ankylosing spondylitis\n": "(D)", "104-7.\n\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u98a8\u6fd5\u75c5/\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u7684\u85e5\u7269\u8207\u5176\u526f\u4f5c\u7528\u7684\u914d\u5c0d\u4e2d\uff0c\u5728\u81e8\u5e8a\u4e0a\u4f55\u8005\u6700\u70ba\u56b4\u91cd\uff1f\nA. Glucocorticoids--leukocytosis\nB. Azathioprine--neutropenia\nC. Methotrexate--oral mucosal ulcer\nD. Intravenous cyclophosphamide pulse therapy-teratogenicity\nE. Hydroxychloroquine--retinal detachment\n": "(B)", "104-8.\nRheumatoid arthritis\u7684\u95dc\u7bc0\u5916\u7684\u81e8\u5e8a\u8868\u5fb5\u5f88\u591a\uff0c\u4e0b\u5217\u7684\u4f55\u7a2e\u7d44\u5408\u6700\u70ba\u6b63\u78ba\uff1f(1) keratoconjunctivitis sicca (2) iritis/uveitis (3) periodontitis (4) cerebral vasculitis (5) \u9838\u690eC1-C2 subluxation (6) pleuritis (7) renal tubular acidosis (8) cutaneous vasculitis (9) thrombocytopenia (10) intestinal mucositis\nA. (1)+(4)+(7)\nB. (4)+(6)+(7)\nC. (1)+(5)+(6)\nD. (3)+(5)+(7)\nE. (2)+(9)+(10)\n": "(C)", "104-9.\n\u8840\u7ba1\u708e\u75c7\u5019\u7fa4(vasculitis syndrome)\u7684\u6a19\u5e5f\u6297\u9ad4\u70baANCA\uff0c\u8acb\u554f\u4e0b\u5217\u90a3\u4e9b\u8840\u7ba1\u708e\u662fANCA(+) vasculitis\uff1f(1) drug-induced vasculitis (2) granulomatosis with polyangiitis (3) cancer-associated vasculitis (4) Churg-Strauss syndrome (5) Behcet's disease (6) microscopic polyangiitis (7) Kawasaki disease (8) idiopathic crescentic glomerulonephritis (9) giant cell arteritis (10) polyarteritis nodosa\nA. (1)+(3)+(5)+(7)\nB. (1)+(2)+(3)+(4)\nC. (2)+(5)+(6)+(7)\nD. (2)+(4)+(6)+(8)\nE. (3)+(8)+(9)+(10)\n": "(D)", "104-10.\nChronic polyarthritis\u53ef\u4ee5\u5305\u62ec\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\uff1f(1) gouty arthritis (2) rheumatoid arthritis (3) pyogenic arthritis (4) calcium pyrophosphate deposition disease (5) osteoarthritis (6) Lyme arthritis (7) pigmented villonodular synovitis (8) reactive arthritis (9) hemophilic hemarthrosis (10) sarcoidosis\nA. (1)+(2)+(3)\nB. (2)+(5)+(10)\nC. (3)+(5)+(9)\nD. (4)+(6)+(8)\nE. (5)+(7)+(8)\n": "(B)", "105-1.\n\u50f5\u76f4\u6027\u810a\u690e\u708e(Ankylosing spondylitis ) (AS)\u4e4b\u767c\u751f\u8207\u57fa\u56e0\u6709\u5bc6\u5207\u95dc\u4fc2\uff0c\u4e0b\u5217\u57fa\u56e0\u8207AS\u4e4b\u767c\u751f\u6709\u95dc?\r1. HLA-B27\r2. HLA-DR4\r3. HLA-B8\r4. IL-23R\r5. HLA-B47\nA. 1+2\nB. 1+3\nC. 1+4\nD. 1+5\nE. 3+5\n": "(C)", "105-2.\n\u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e(Rheumatoid arthritis)\u70ba\u56b4\u91cd\u4e4b\u95dc\u7bc0\u708e\uff0c\u4e0b\u5217\u6558\u8ff0\u70ba\u6b63\u78ba?\r1. \u6297\u816b\u7624\u58de\u6b7b\u751f\u7269\u88fd\u5291\u70ba\u5e38\u7528\u4e4b\u6cbb\u7642\r2. \u5e38\u4fb5\u72af\u9060\u7aef\u6307\u95dc\u7bc0\r3. \u6297\u74b0\u74dc\u6c28\u9178\u6297\u9ad4(anti-CCP)\u70ba\u5176\u7279\u5fb5\u4e4b\u4e00\r4. \u5e38\u767c\u751f\u5728HLA-B8\u4e4b\u75c5\r5. \u62bd\u83f8\u7121\u95dc\nA. 1+2\nB. 1+3\nC. 1+4\nD. 1+5\nE. 3+5\n": "(B)", "105-3.\n\u4e0b\u5217\u70ba\u50f5\u76f4\u6027\u810a\u690e\u708e(AS)\u5e38\u898b\u4e4b\u95dc\u7bc0\u5916\u4e4b\u75c7\u72c0\u6216\u75be\u75c5\r1. \u524d\u8461\u8404\u819c\u708e(\u5f69\u8679\u708e)\r2. Giant cell arteritis ( temporal arteritis)\r3. \u904e\u654f\u6027\u76ae\u819a\u708e\r4. \u8178\u708e ( inflammatory bowel disease)\r5. \u80ba\u764c\nA. 1+2\nB. 1+3\nC. 1+4\nD. 1+5\nE. 2+4\n": "(C)", "105-4.\n\u6839\u64da2010\u7f8e\u570b\u98a8\u6fd5\u75c5\u91ab\u5b78\u6703\u8207\u6b50\u6d32\u98a8\u6fd5\u75c5\u806f\u76df\u5236\u5b9a\u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e\u4e4b\u8a3a\u65b7\u5206\u985e\u6e96\u5247\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u8f03\u91cd\u8981\u4e4b\u8a3a\u65b7\u8981\u4ef6\nA. \u4fb5\u72af\u5927\u95dc\u7bc0\nB. \u4fb5\u72af\u5c0f\u95dc\u7bc0\nC. \u53cd\u61c9\u86cb\u767d\u6fc3\u5ea6(C-reactive protein)\nD. \u7d05\u8840\u7403\u4e0b\u964d\u901f\u7387(ESR)\nE. \u767c\u75c5\u6642\u9593\u4e4b\u9577\u77ed\n": "(B)", "105-5.\n\u4e00\u4f4d22\u6b72\u7537\u6027\u9000\u4f0d\u5f8c\uff0c\u56e0\u5026\u6020\u5230\u6aa2\u9a57\u6240\u62bd\u8840\u6aa2\u67e5\uff0c\u767c\u73fe\u6885\u6bd2\u8a66\u9a57(venereal disease research laboratory test) (VDRL)\u967d\u6027\u4e0b\u5217\u4f55\u8005\u70ba\u6709\u53ef\u80fd\u4e4b\u539f\u56e0\nA. \u75c5\u4eba\u6709\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0(RA)\nB. \u75c5\u4eba\u6709\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621(SLE)\nC. \u75c5\u4eba\u6709\u50f5\u76f4\u6027\u810a\u9ad3\u708e(AS)\nD. \u75c5\u4eba\u6709\u4e7e\u766c\nE. \u75c5\u4eba\u6709\u4e7e\u766c\u6027\u95dc\u7bc0\u708e\n": "(B)", "105-6.\n\u4e00\u4f4d55\u6b72\u5973\u6027\u75c5\u4eba\u60a3\u6709\u786c\u76ae\u75c7\u591a\u5e74\uff0c\u6700\u8fd1\u8d70\u8def\u6642\u6703\u5598\uff0c\u4e0b\u5217\u6aa2\u67e5\u8f03\u9069\u7576\nA. \u6aa2\u67e5\u6297\u9ad4anti-Scl-70\nB. \u6e2c\u80ba\u52d5\u8108\u8840\u58d3\nC. \u6aa2\u67e5\u6297\u78f7\u9178\u8102\u6297\u9ad4(anti phospholipid antibody)\nD. \u6e2c\u5fc3\u808c\u9175\u7d20(CK-MB)\nE. \u80ba\u90e8\u5207\u7247\u6aa2\u67e5\n": "(B)", "105-7.\n\u4e00\u4f4d64\u6b72\u7537\u6027\u4e3b\u8a34\u5de6\u624b\u7b2c4\u6307\u816b\u75db\u53ca\u53f3\u624b\u7b2c3\u6307\u9060\u7aef\u6307\u9593\u816b\u75db3\u500b\u6708(\u5982\u5716)\uff0c\u75c5\u4eba\u81ea\u8ff0\u4e0b\u80cc\u75db\u591a\u5e74\uff0c\u4e0b\u5217\u6aa2\u67e5\u6700\u9069\u7576\nA. \u6297\u6838\u6297\u9ad4(ANA)\nB. HLA-B27\nC. \u6297dsDNA\u6297\u9ad4(anti-dsDNA)\nD. Anti-Scl-70 \u6297\u9ad4\nE. \u8840\u4e2d\u5c3f\u9178\n": "(B)", "105-8.\n\u4e0b\u5217\u85e5\u7269\u6cbb\u7642\u5c0d\u7d05\u6591\u6027\u72fc\u7621(SLE)\u4e4bdiffuse proliferative lupus Nephritis\u6700\u9069\u7576\nA. azathioprine\nB. Plasmaphersis\nC. Cyclosporin\nD. Mycophenolate\nE. Methotrexate\n": "(D)", "105-9.\n\u4e0060\u6b72\u7537\u6027\u60a3\u8005\u6709\u7cd6\u5c3f\u75c5\u53f25\u5e74 \u7a81\u7136\u53f3\u5074\u95dc\u7bc0\u816b\u75db3\u5929\uff0cX\u5149\u50c5\u986f\u793a\u51fa\u53f3\u819d\u8edf\u7d44\u7e54\u816b\u8139\uff0c\u95dc\u7bc0\u6db2\u5206\u6790\u986f\u793aWBC 85000\uff0cN/L\uff1a85/15\uff0cMSU(-)\uff0cCPPD(-)\uff0c\u4ee5\u4e0b\u4f55\u8005\u81c6\u6e2c\u8a3a\u65b7\u6700\u6709\u53ef\u80fd\uff1f\nA. \u75db\u98a8\u6027\u95dc\u7bc0\u708e\nB. \u5047\u6027\u75db\u98a8\nC. \u9000\u5316\u6027\u95dc\u7bc0\u708e\nD. \u7d30\u83cc\u6027\u95dc\u7bc0\u708e\nE. \u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e\n": "(D)", "105-10.\nSjogren's syndrome \u5e38\u5408\u4f75\u6dcb\u5df4\u7624(Lymphoma) \u4e4b\u767c\u751f, Sjogren's syndrome\u75c5\u4eba\u6709\u4e0b\u5217\u6aa2\u67e5\u5e38\u5408\u4f75\u6dcb\u5df4\u7624\nA. ANA\u967d\u6027\nB. Anti-SS/A\u6297\u9ad4\u967d\u6027\nC. Anti-SS/B\u6297\u9ad4\u967d\u6027\nD. \u8840\u4e2d\u4f4e\u88dc\u9ad4\nE. \u767d\u8840\u7403\u589e\u52a0\n": "(D)", "105-1.\n21\u6b72\u7684\u5973\u6027\u60a3\u8005\uff0c\u5f9e3\u6b72\u958b\u59cb\u5c31\u6709\u6162\u6027\u5168\u8eab\u76ae\u819a\u6414\u7662\u3002\u5176\u7236\u6bcd\u5747\u6709\u904e\u654f\u6027\u75be\u75c5\u7684\u5bb6\u65cf\u53f2\u3002\u5c31\u8a3a\u6642\u767c\u73fe\u5979\u7684\u81c9\u90e8\u53ca\u5169\u624b\u8098\u7684\u76ae\u819a\u6709\u82d4\u861a\u5316\u73fe\u8c61\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feIgE 3750IU/mL (normal<300IU/mL)\u3002\u76ae\u819a\u6414\u7662\u5c0d\u985e\u56fa\u9187\u85e5\u818f\u7684\u6cbb\u7642\u6709\u6548\uff0c\u4f46\u59cb\u7d42\u7121\u6cd5\u6cbb\u7652\u3002\u8acb\u554f\u9019\u4f4d\u60a3\u8005\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Psoriasis\nB. Chronic urticaria\nC. Atopic dermatitis\nD. Licken planus\nE. Contact dermatitis\n": "(C)", "105-2.\n\u4e0b\u5217\u6709\u95dc\u514d\u75ab\u7570\u5e38\u8207\u7f79\u60a3\u75be\u75c5\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Complement deficiency--autoimmune disorders\nB. Antibody deficiency--frequent influenza infections\nC. Cellular immunodeficiency--chronic skin infections\nD. Phagocytic deficiency--chronic fungal infections\nE. NK cell dysfunction--carcinogenesis\n": "(A)", "105-3.\n\u4e0b\u5217\u6709\u95dc\u5168\u8eab\u6027\u7d05\u6591\u72fc\u7621\u60a3\u8005\u7684\u8840\u6e05\u81ea\u9ad4\u6297\u9ad4\u8207\u81e8\u5e8a\u75c7\u72c0\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55 \u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Anti-Sm--neuropsychiatric manifestation\nB. Anti-ribosomal P--serositis\nC. Anti-SSB/La--lupus nephritis\nD. Anti-histone--drug-induced SLE\nE. Anti-RNP--vasculitis\n": "(D)", "105-4.\n\u4e00\u4f4d41\u6b72\u5973\u6027\u70ba\u6162\u6027\u809d\u708e\u60a3\u8005\u3002\u4e3b\u8a34\u70ba\u5169\u624b\u624b\u6307\u53ca\u5169\u624b\u8098\u95dc\u7bc0\u50f5\u786c\u3001\u9178\u75db\u6709\u5169\u500b\u6708\u4e4b\u4e45\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feESR 28mm/h, CRP 1.4mg/mL\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0dRA\u7684\u9451\u5225\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Rheumatoid factors\nB. Complement C3 and C4\nC. ANA\nD. Anti-neutrophil cytoplasmic antibodies\nE. Anti-citrullinated peptide antibodies\n": "(E)", "105-5.\n54\u6b72\u5973\u6027\u60a3\u8005\u4e3b\u8a34\u51ac\u5929\u6642\u5169\u624b\u591a\u6307\u6703\u8b8a\u767d\u3001\u8b8a\u7d2b\u3002\u53e6\u5916\uff0c\u81c9\u90e8\u6709\u8774\u8776\u6591\u3001\u808c\u8089\u7121\u529b\u3001\u53ca\u559d\u6c34\u6642\u5bb9\u6613\u55c6\u5230\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u6709\u9999\u8178\u6307\u53ca\u624b\u80cc\u76ae\u819a\u8b8a\u786c\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\uff1aC3 65mg/mL, C4 14.6mg/mL, ANA 1:1280 speckled+1:640 nucleoli, RF 54U/mL, anti-dsDNA 354 IU/mL (normal <300IU/mL), anti-Scl-70<20 IU/L, anti-RNP 2476 IU/mL. proteinuria (++), CK 786 IU/mL, ESR 37mm/h, CRP 0.81mg/mL, AST 121 U/mL. ALT 18U/mL. \u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. MCTD\nB. SLE\nC. PSS\nD. RA\nE. DM/PM\n": "(A)", "105-6.\n56\u6b72\u7537\u6027\u60a3\u8005\u4e3b\u8a34\u70ba\u773c\u4e7e\u3001\u53e3\u4e7e\u3001\u5169\u5074\u816e\u817a\u816b\u8139\u3001\u53ca\u773c\u76ae\u6d6e\u816b\u6709\u4e09\u500b\u6708\u4e4b\u4e45\u3002\u4e00\u5e74\u524d\u7684\u5065\u5eb7\u6aa2\u67e5\u767c\u73feserum amylase\u6607\u9ad8\uff0c\u8179\u8d85\u6aa2\u67e5\u767c\u73fe\u80f0\u81df\u982d\u90e8\u816b\u8139\u53ca\u81bd\u7ba1\u3001\u81bd\u56ca\u6709\u7e96\u7dad\u5316\u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73fe\uff1aanti-SSA\u53caanti-SSB\u6b63\u5e38\uff0cANA 1:160 speckled, Schirmer's test: OD 4mm/5min, OS: 6mm/5min. \u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u9451\u5225\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Serum lipase\nB. Sialoscintigraphy\nC. Anti-mitochondrial antibodies\nD. Anti-smooth muscle antibodies\nE. Serum IgG4 level\n": "(E)", "105-7.\n56\u6b72\u7537\u6027\u60a3\u8005\u904e\u53bb\u4e09\u5e74\u4f86\u6642\u5e38\u6709\u9f3b\u7ac7\u708e\u53ca\u5169\u6b21\u6d41\u9f3b\u8840\u3002\u6700\u8fd1\u767c\u73fe\u814e\u529f\u80fd\u6709\u7570\u5e38\u53ca\u5580\u8840\u3002\u80f8\u90e8X\u5149\u6aa2\u67e5\u767c\u73fe\u80ba\u91ce\u6709\u6578\u9846\u7d50\u7bc0\u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73fe\uff1aESR \u53caCRP\u589e\u52a0\uff0cANA 1: 80 speckled, \u8840\u6db2\u5e38\u898f\u6b63\u5e38\uff0cproteinurea (++). Urine RBC 10-15/HPF, WBC 7-9/HPF, cANCA 148 IU/mL (normal<10 IU/ml). \u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Polyarteritis nodosa\nB. Eosinophilia with polyangiitis\nC. Sarcoidosis\nD. Granulomatosis with polyangiitis\nE. Paragonimiasis\n": "(D)", "105-8.\n\u4e0b\u5217\u6709\u95dc\u75c5\u56e0\u8207\u95dc\u7bc0\u708e\u5c6c\u6027\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Staphylococcus aureus--chronic monarticular arthritis\nB. Reactive arthritis--acute monarticular arthritis\nC. Rheumatoid arthritis--chronic polyarticular arthritis\nD. Mycobacterium tuberculosis--acute polyarticular arthritis\nE. Neisseria gonorrhoeae--acute monarticular arthritis\n": "(C)", "105-9.\n\u4e0b\u5217\u6709\u95dcRA\u60a3\u8005\u7684\u95dc\u7bc0\u5916\u8868\u73fe(extra-articular manifestations)\u7684\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\r(1)\tkeratoconjunctivitis sicca (2) pleural effusion (3) thromboembolism (4) oral ulceration (5) panniculitis (6) ascites (7) erythema nodosum (8) uveitis (9) interstitial lung disease (10) IgA nephropathy\nA. 1+3+5\nB. 1+2+9\nC. 3+4+5\nD. 2+7+8\nE. 5+9+10\n": "(B)", "105-10.\n\u4e0b\u5217\u6709\u95dcanti-phospholipid antibody syndrome\u7684\u6558\u8ff0\u4e2d\uff0c\u4f55\u7a2e\u7d44\u5408\u6700\u70ba\u6b63\u78ba\uff1f\r(1) Bleeding tendency (2) aPTT prolongation (3) PT shortening (4) \u6703\u5f15\u8d77deep vein thrombosis (5) \u8207SLE recurrent abortion\u6709\u76f8\u95dc (6) \u5e38\u5e38\u6703\u5f15\u767ccutaneous vasculitis (7) \u5c0dgluco- corticoids\u7684\u6cbb\u7642\u6709\u6548 (8) \u8207SLE\u60a3\u8005\u7684 VDRL (venereal disease research laboratory) false positive\u6709\u95dc (10) \u8207SLE\u60a3\u8005\u7684leukopenia\u6709\u95dc\nA. 1+3+6\nB. 2+4+8\nC. 5+7+9\nD. 2+8+9\nE. 4+5+6\n": "(B)", "106-1.\n\u767d\u7d30\u80de\u4ecb\u7d2017 (Interleukin 17)\u626e\u6f14\u4e0b\u5217\u75be\u75c5\u91cd\u8981\u4e4b\u89d2\u8272\uff1f(1)\u75db\u98a8\u95dc\u7bc0\u708e \uff1b(2)\u9000\u5316\u6027\u95dc\u7bc0\u708e\uff1b(3)\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(Psoriatic arthritis)\uff1b(4)\u50f5\u76f4\u6027\u810a\u690e\u708e(Ankylosing spondylitis)\uff1b(5)\u5168\u8eab\u6027\u786c\u5316\u75c7(Systemic sclerosis)\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "106-2.\n\u95dc\u7bc0\u6db2\u62bd\u53d6\u6aa2\u67e5\u5e38\u5728\u4e0b\u5217\u75be\u75c5\u57f7\u884c\uff1f(1)\u75db\u98a8\u95dc\u7bc0\u708e\uff1b(2)\u611f\u67d3\u6027\u95dc\u7bc0\u708e\uff1b(3)\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621 (SLE)\uff1b(4)\u5168\u8eab\u6027\u786c\u5316\u75c7 ( Systemic sclerosis)\uff1b(5)\u50f5\u76f4\u6027\u810a\u690e\u708e(Ankylosing spondylitis)\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(A)", "106-3.\n\u4e00\u4f4d61\u6b72\u7537\u6027\u6709\u591a\u5e74\u559d\u9152\u7fd2\u6163\uff0c\u5168\u8eab\u6709\u75db\u98a8\u77f3\u7d50\u6676(\u5982\u5716)\uff0c\u6cbb\u7642\u7684\u76ee\u6a19\u662f\uff1f\nA. \u5916\u79d1\u624b\u8853\u53bb\u9664\u75db\u98a8\u77f3\nB. \u98f2\u98df\u63a7\u5236\nC. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u503c\u81f32 mg/dL\u4ee5\u4e0b\nD. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u503c\u81f35 mg/dL\u4ee5\u4e0b\nE. \u964d\u4f4e\u8840\u4e2d\u5c3f\u9178\u503c\u81f37 mg/dL\u4ee5\u4e0b\n": "(D)", "106-4.\n\u514d\u75ab\u7403\u86cb\u767dG4\u76f8\u95dc\u75be\u75c5(IgG4-related disease)\u5728\u7e96\u7dad\u5316\u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u4e2d\u4e3b\u8981\u4e4b\u7d30\u80de\u6d78\u6f64\u70ba\uff1f\nA. \u5de8\u566c\u7d30\u80de (Macrophage)\nB. NK\u7d30\u80de\nC. \u6a39\u72c0\u7a81\u7d30\u80de(Dendritic cell)\nD. \u6f3f\u7d30\u80de(Plasma cell)\nE. B\u7d30\u80de(B cell)\n": "(D)", "106-5.\n\u50f5\u76f4\u6027\u810a\u690e\u708e(Ankylosing spondylitis)\u6700\u5e38\u898b\u7684\u95dc\u7bc0\u5916\u75c7\u72c0(extra-articular symptom)\u662f\uff1f\nA. \u8178\u80c3\u708e\nB. \u524d\u8461\u8404\u819c\u708e(Anterior uveitis)\nC. \u53e3\u8154\u6f70\u760d\nD. \u76ae\u819a\u7d05\u6591\nE. \u80ba\u90e8\u7e96\u7dad\u5316\n": "(B)", "106-6.\n\u6cbb\u7642\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621(SLE)\u4e4b\u85e5\u7269\u4e2d\uff0c\u4e0b\u5217\u662f\u6700\u5c11\u5f15\u8d77\u80ce\u5152\u6bd2\u6027\u4e4b\u526f\u4f5c\u7528\uff1f(1)\u585e\u514b\u7f85\u9081\u5f97Cyclophosphamide (Endoxan)\uff1b(2)\u74b0\u5b62\u9748Cyclosporine\uff1b(3)\u5fc5\u8cf4\u514b\u5ed4Hydroxychloroquine\uff1b(4)\u7cd6\u76ae\u8cea\u6fc0\u7d20Glucocorticoid\uff1b(5)\u83ab\u9808\u7624Rituximab\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "106-7.\n\u4e0b\u5217\u4f55\u7a2e\u6297\u9ad4\u5728\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621(SLE)\u5e38\u5408\u4f75\u6182\u9b31\u75c7(depression)\u6216\u7cbe\u795e\u75c5(psychosis)\uff1f\nA. anti-Sm\nB. anti-RNP\nC. anti-SS-A/Ro\nD. anti-SS-A/La\nE. anti-ribosomal P\n": "(E)", "106-8.\n\u4e00\u4f4d55\u6b72\u5bb6\u5ead\u4e3b\u5a66\u4e3b\u8a34\u54b3\u55fd\u53ca\u547c\u5438\u56f0\u96e31\u500b\u6708\uff0c\u80f8\u90e8X\u5149\u986f\u793a\u9593\u8cea\u6027\u80ba\u75c5(interstitial lung disease)\uff0c\u75c5\u4eba\u66fe\u78ba\u8a3a\u70ba\u591a\u767c\u6027\u808c\u708e(polymyositis)\u3002\u4e0b\u5217\u4f55\u7a2e\u6297\u9ad4\u70ba\u51fa\u73fe\u5728\u6b64\u75be\u75c5\u6700\u5e38\u898b\u7684\u6297\u9ad4\uff1f\nA. anti-dsDNA\nB. anti-histidyl-tRNA synthetase\nC. anti-melanoma differentiation-associated gene 5\nD. anti-DNA topoisomerase 1\nE. anti-centromere\n": "(B)", "106-9.\n\u4e0b\u5217\u767d\u7d30\u80de\u4ecb\u7d20( interleukin)\u53ef\u7528\u4f86\u8a3a\u65b7\u80ba\u7d50\u6838\u611f\u67d3\u4e4b\u53ef\u80fd\uff1f\nA. \u816b\u7624\u58de\u6b7b\u56e0\u5b50-\u03b1 (Tumor Necrosis Factor-\u03b1, TNF-\u03b1)\nB. \u767d\u7d30\u80de\u4ecb\u7d2010 (IL-10)\nC. \u5e72\u64fe\u7d20-\u03b1 (Interferon-\u03b1)\nD. \u5e72\u64fe\u7d20-\u03b2 (Interferon-\u03b2)\nE. \u5e72\u64fe\u7d20-\u03b3 (Interferon-\u03b3)\n": "(E)", "106-10.\nHepcidin\u53ef\u4ee5\u5f15\u8d77\u767c\u708e\u76f8\u95dc\u4e4b\u8ca7\u8840\uff0c\u5176\u4f5c\u7528\u6a5f\u8f49\u662f\u5f71\u97ff\uff1f\nA. \u9435\u4e4b\u5438\u6536\nB. \u8449\u9178\u4e4b\u5438\u6536\nC. \u7dad\u4ed6\u547dB12\u4e4b\u5438\u6536\nD. \u7dad\u4ed6\u547dD\u4e4b\u5438\u6536\nE. \u81bd\u56fa\u9187\n": "(A)", "106-1.\n\u4e0b\u5217\u6709\u95dc\u904e\u654f\u539f\u5f15\u767c\u8541\u75f2\u75b9\u81f4\u75c5\u6a5f\u8f49\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f\nA. Pollens\uff0dbradykinin-mediated\nB. Radiocontrast media\uff0dmast cell-mediated\nC. Opiate\uff0dIgE-dependent\nD. NSAIDs\uff0dcomplement-mediated\nE. Cold exposure\uff0dmacrophage activation\n": "(B)", "106-2.\n32\u6b72\u5973\u59d3\u60a3\u8005\u904e\u53bb\u6709\u4e8c\u6b21\u6d41\u7522\u8a18\u9304\u3002\u4e8c\u5929\u524d\u53f3\u4e0b\u817f\u7a81\u7136\u816b\u8139\u75bc\u75db\uff0c\u88ab\u61f7\u7591\u70ba\u8702\u7aa9\u7d44\u7e54\u708e\u3002\u4f46\u7d93\u6297\u751f\u7d20\u6cbb\u7642\u4e09\u5929\u4e4b\u5f8c\u7121\u986f\u8457\u6539\u5584\u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73feANA1:1280 speckled pattern, C3 57.6 mg/dL, C4 7.5 mg/dL, anti-dsDNA 473 IU/mL, \u8840\u6db2\u5b78\u6aa2\u67e5\u767c\u73fepancytopenia\u3002\u8acb\u554f\u9019\u4f4d\u60a3\u8005\u53f3\u4e0b\u817f\u7a81\u7136\u816b\u8139\u7684\u6700\u53ef\u80fd\u539f\u56e0\u70ba\u4f55\uff1f\nA. Lupus nephritis\nB. Cellulitis\nC. Anti-phospholipid syndrome\nD. Lymphoedema\nE. Sciatica\n": "(C)", "106-3.\n49\u6b72\u5973\u59d3\u60a3\u8005\uff0c\u4e8c\u5e74\u524d\u958b\u59cb\u767c\u73fe\u96d9\u5074\u624b\u6307\u5728\u51ac\u5929\u6703\u8b8a\u767d\u5f8c\u8b8a\u7d2b\u3002\u6700\u8fd1\u4e09\u500b\u6708\u96d9\u624b\u6709\u95dc\u7bc0\u9178\u75db\u53ca\u50f5\u786c\uff0c\u5634\u5df4\u5f35\u958b\u53d7\u9650\u53ca\u5403\u6771\u897f\u6709\u6642\u6703\u55c6\u5230\u3002\u5728\u61f7\u7591\u7f79\u60a3\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u4e4b\u4e0b\uff0c\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u81ea\u9ad4\u6297\u9ad4\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Anti-double stranded DNA\nB. Anti-Sjogren's-syndrome-related antigen A\nC. Anti-cyclic citrullinated peptide antibody (Anti-CCP antibody)\nD. Anti-topoisomerase 1\nE. Anti-phospholipid\n": "(D)", "106-4.\n24\u6b72\u7537\u6027\u60a3\u8005\uff0c\u5728\u9577\u9014\u958b\u8eca\u6642\u6703\u6709\u8170\u9178\u80cc\u75db\u3002\u4e0b\u8eca\u6d3b\u52d520\u5206\u9418\u4e4b\u5f8c\u6703\u6539\u5584\u3002\u53e6\u5916\uff0c\u65e9\u4e0a\u525b\u8d77\u5e8a\u6642\u5168\u8eab\u6703\u50f5\u786c\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. HLA-B27\nB. Whole body bone scan\nC. Rheumatoid factors (RFs)\nD. Anti-nuclear antibodies (ANAs)\nE. MRI\n": "(E)", "106-5.\n61\u6b72\u5973\u59d3\u767c\u89ba\u6700\u8fd1\u81c9\u90e8\u53ca\u624b\u90e8\u6307\u7bc0\u8655\u6709\u7d05\u6591\u51fa\u73fe\u3002\u8d77\u5e8a\u6642\u7121\u6cd5\u7acb\u5373\u7ad9\u8d77\u4f86\uff0c\u5fc5\u9808\u4ee5\u96d9\u624b\u652f\u6490\u624d\u80fd\u7ad9\u8d77\u4f86\u3002\u62bd\u8840\u767c\u73feAST 108U/L, ALT 32U/L, CK 659 U/L\u3002\u8acb\u554f\u8981\u78ba\u5b9a\u8a3a\u65b7\uff0c\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u5177\u6c7a\u5b9a\u6027\uff1f\nA. MRI\nB. Electromyolography (EMG)\nC. Muscle biopsy\nD. Myoglobulin\nE. Whole body CT scan\n": "(C)", "106-6.\n82\u6b72\u7537\u6027\u60a3\u8005\uff0c\u5728\u534a\u591c\u7761\u89ba\u6642\u7a81\u7136\u767c\u751f\u5de6\u819d\u84cb\u5287\u75db\u3002\u5728\u6025\u8a3a\u62bd\u8840\u767c\u73feuric acid 6.1 mg//dL, ESR 42 mm/1h, CRP 4.6 mg/dL\u3002\u95dc\u7bc0\u6db2\u6aa2\u67e5\uff1aWBC 8480/HPF,\u767c\u73fe\u6709 rhomboid and plate-like crystal (+),\u4f46\u7121needle-shaped crystal.\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u75be\u75c5\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Acute gouty arthritis\nB. Pseudo-gout\nC. Septic arthritis\nD. Osteoarthritis\nE. Polymyalgia rheumatica\n": "(B)", "106-7.\n\u4ee5xanthine oxidase inhibitor \"Allopurinol\"\u6cbb\u7642\u75db\u98a8\u6642\uff0c\u5fc5\u9808\u4e8b\u524d\u6aa2\u6e2c\u4f55\u7a2e\u57fa\u56e0\uff1f\nA. HLA-B*5801\nB. HLA-DR4\nC. HLA-B*1502\nD. HLA-B27\nE. HLA-B51\n": "(A)", "106-8.\n45\u6b72\u7537\u6027\u60a3\u8005\u70baB\u809d\u5e36\u539f\u8005\u3002\u6700\u8fd1\u4e94\u5929\u5168\u8eab\u6709\u591a\u8655\u95dc\u7bc0\u75db\u767c\u751f\u3002\u5230\u91ab\u9662\u6aa2\u67e5\u767c\u73feESR 34 mm/1h, CRP 2.1 mg/dL, RF 84 IU/mL\u3002\u88ab\u61f7\u7591\u6709rheumatoid arthritis\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u9451\u5225\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Ferritin\nB. Bilateral hand X-ray film\nC. Cryoglobulin\nD. IgG RFs\nE. Anti-CCP\n": "(E)", "106-9.\n\u4e0b\u5217\u6709\u95dc\u8840\u7ba1\u708e\u75c7\u5019\u7fa4(vasculitis syndrome)\u8207\u81e8\u5e8a\u76f8\u95dc\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u6b63\u78ba\uff1f(1)Granulomatosis with polyangiitis\uff0dusually cANCA (+)\uff1b(2)Takayasu arteritis\uff0ddifference in bilateral. brachial blood pressure\uff1b(3)Giant cell arteritis\uff0dhigh incidence in young age group\uff1b(4)Eosinophilic granulomatosis with polyangiitis\uff0dhigh incidence in old age group\uff1b(5)Henoch-Schonlein purpura\uff0dincrease in serum IgA\uff1b(6)Polyarteritis nodosa\uff0dchronic pancreatitis\uff1b(7)Cryoglobulinemic vasculitis\uff0dassociated with hepatitis\rC\uff1b(8)Behcet's disease\uff0dusually pANCA (+)\uff1b(9)Microscopic polyangiitis\uff0dusually associated with sinusitis\nA. (1)+(2)+(3)\nB. (3)+(4)+(6)\nC. (1)+(5)+(7)\nD. (2)+(7)+(8)\nE. (1)+(3)+(9)\n": "(C)", "106-10.\n\u539f\u767c\u6027Sjogren's syndrome \u6709\u591a\u7a2e\u553e\u6db2\u817a\u4ee5\u5916\u7684\u75c7\u72c0\u8868\u73fe\u3002\u8acb\u554f\u4e0b\u8ff0\u7684\u75c7\u72c0\u7684\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f(1)Interstitial lung fibrosis\uff1b(2)primary biliary cirrhosis\uff1b(3)uveitis\uff1b(4)scleritis\uff1b(5) autoimmune hepatitis\uff1b(6)peripheral neuropathy\uff1b(7)acute pancreatitis\uff1b(8)renal tubular acidosis\uff1b(9)amyloidosis\uff1b(10)atopic dermatitis\nA. (1)+(2)+(3)\nB. (2)+(4)+(5)\nC. (1)+(6)+(7)\nD. (4)+(9)+(1)\nE. (5)+(6)+(8)\n": "(E)", "107-1.\n\u4e00\u4f4d32\u6b72\u5a66\u5973\u56e0\u5169\u5074\u96d9\u624b\u53ca\u96d9\u8173\u816b\u75db\u7d042\u9031\u5230\u91ab\u9662\u4f4f\u9662\uff0c\u5979\u6709\u5169\u624b\u65e9\u6668\u50f5\u786c\u73fe\u8c61\uff0c\u6c92\u6709\u5176\u4ed6\u7684\u7279\u5225\u75c5\u53f2\uff0c\u7406\u5b78\u6aa2\u67e5\u986f\u793a\u96d9\u624b\u7b2c\u4e09\u3001\u7b2c\u56db\u53ca\u7b2c\u4e94\u8fd1\u7aef\u6307\u9593\u95dc\u7bc0\u58d3\u75db\u53ca\u816b\u8139\u53ca\u5169\u5074\u7b2c\u4e8c\u3001\u7b2c\u4e09\u638c\u6307\u95dc\u7bc0\u816b\u8139\u53ca\u58d3\u75db\uff0c\u624b\u90e8\u53ca\u8173\u90e8X-\u5149\u6b63\u5e38\uff0c\u4e0b\u5217\u90a3\u4e9b\u6aa2\u67e5\u5c0d\u75c5\u4eba\u662f\u6700\u6709\u5e6b\u5fd9\u8a3a\u65b7\uff1f(1). \u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR) (2). C\u53cd\u61c9\u86cb\u767d(CRP) (3).\u6297\u74dc\u80fa\u9178\u86cb\u767d\u6297\u9ad4(ACPA) (4). \u985e\u98a8\u6fd5\u6027\u56e0\u5b50(RF) (5). \u6297\u6838\u6297\u9ad4(ANA)\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(C)", "107-2.\n\u4e00\u4f4d28\u6b72\u5973\u6027\u56e0\u96d9\u624b\u53ca\u96d9\u8173\u816b\u8139\u4e00\u500b\u6708\u5230\u91ab\u9662\u6c42\u8a3a\uff0c\u4e00\u500b\u6708\u524d\u5979\u525b\u751f\u7522\u4e00\u4f4d\u6b63\u5e38\u7537\u5b30\uff0c\u75c5\u4eba\u6c92\u7279\u5225\u75c5\u53f2\uff0c\u7406\u5b78\u6aa2\u67e5\u5728\u96d9\u624b\u53ca\u96d9\u8173\u6709\u58d3\u75db\u53ca\u816b\u8139\u73fe\u8c61\uff0c\u8840\u4e2d\u767d\u8840\u74032,800/mm3\uff0c\u4e2d\u6027\u767d\u8840\u7403\u4f5476.24 %\uff0c\u6dcb\u5df4\u7403\u4f5414.64 %\uff0c\u55ae\u6838\u7d30\u80de(monocyte)8.0%\uff0c\u55dc\u9178\u6027\u7c92\u7d30\u80de(eosinophils)0.74%\uff0c\u55dc\u9e7c\u6027\u7c92\u7d30\u80de(basophils)0.54%\uff0c\u7d05\u8840\u7403(RBC)3.47 x 10^6/mm3\uff0c\u8840\u7d05\u7d20(hemoglobin)9.6 g/dl\uff0c\u8840\u7d30\u80de\u6bd4\u5bb9(hematocrit)28\r%\uff0c\u8840\u5c0f\u677f186,000/mm3\uff0c\uff0c\u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR)80/hr\uff0cc-\u53cd\u61c9\u86cb\u767d(CRP)1.28mg/dl\uff0cANA\u6548\u50f91:1280\u967d\u6027\uff0c\u6297\u96d9\u93c8DNA\u6297\u9ad4(Anti-dsDNA)\u967d\u6027\uff0c\u8840\u4e2d\u88dc\u9ad4C3(2.31mg/dl)\u53caC4\u7686\u4e0b\u964d(5.8mg/dl)\uff0c\u81e8\u5e8a\u8a3a\u65b7\u6700\u53ef\u80fd\u70ba\nA. \u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e(RA)\nB. \u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621\nC. \u5168\u8eab\u6027\u786c\u5316\u75c7\nD. \u4e7e\u71e5\u75c7\nE. \u8840\u7ba1\u708e\n": "(B)", "107-3.\n\u5982\u4e0a\u8ff0\u75be\u75c5\uff0c\u5176\u6700\u6709\u53ef\u80fd\u7684\u7d30\u80de\u6fc0\u7d20\u8b8a\u5316\u662f\uff1a\r(1)\u7b2c\u4e00\u578b\u5e72\u64fe\u7d20(Type\u2160interferon)\r(2)\u4ecb\u767d\u7d20-10(interleukin-10)\r(3)\u4ecb\u767d\u7d20-1 (interleukin- 1)\r(4)\u4ecb\u767d\u7d20-2 (interleukin- 2)\r(5)\u8f49\u8b8a\u751f\u9577\u56e0\u5b50\u03b2(transforming growth factor-\u03b2)\nA. (1)\u589e\u52a0+(2)\u589e\u52a0\nB. (1)\u589e\u52a0+(4)\u589e\u52a0\nC. (3)\u589e\u52a0+(4)\u589e\u52a0\nD. (4)\u589e\u52a0+(5)\u589e\u52a0\nE. (5)\u589e\u52a0+(1)\u589e\u52a0\n": "(A)", "107-4.\n\u4e00\u4f4d28\u6b72\u7537\u6027\u8077\u696d\u8ecd\u4eba\u56e0\u70ba\u4e0b\u80cc\u75db\u67095\u5e74\u6642\u9593\uff0c\u5728\u65e9\u6668\u7761\u9192\u5f8c\u7279\u5225\u53b2\u5bb3\u65e9\u4e0a\u50f5\u786c\u6703\u6301\u7e8c2\u5c0f\u6642\uff0c\u4f46\u904b\u52d5\u5f8c\u4e0b\u80cc\u75db\u6703\u6539\u5584\uff0c\u4f7f\u7528\u6d88\u708e\u85e5\u5f8c\u6703\u6709\u4e00\u9ede\u6539\u5584\uff0c\u6b64\u5916\u6c92\u6709\u4efb\u4f55\u95dc\u7bc0\u554f\u984c\uff0c\u96d9\u89aa\u6c92\u6709\u7279\u5225\u75be\u75c5\uff0c\u4f46\u53d4\u7236\u4e5f\u6709\u9577\u671f\u4e0b\u80cc\u75db\u3002\u7406\u5b78\u6aa2\u67e5\uff1a\u6c92\u6709\u7279\u5225\u4e0d\u6b63\u5e38\uff0c\u9664\u5411\u524d\u53ca\u5411\u5f8c\u5f4e\u8170\u6709\u4e00\u4e9b\u9650\u5236\u53ca\u4e0b\u80cc\u58d3\u75db\u5916\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u986f\u793a\uff1a\u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR)48mm/h\uff0cHLA-B27(\u4eba\u985e\u767d\u8840\u7403\u6297\u539f-B27)\u9670\u6027\uff0c\u4e0b\u5217\u6aa2\u67e5\u662f\u6700\u9069\u7576\nA. \u9aa8\u6c0f\u9ac2\u95dc\u7bc0(sacroiliac joint)\u96fb\u8166\u65b7\u5c64(CT)\u6aa2\u67e5\nB. \u9aa8\u6c0f\u9ac2\u95dc\u7bc0(sacroiliac joint)\u6838\u78c1\u5171\u632f(MRI)\u6aa2\u67e5\nC. \u9aa8\u9583\u720d\u986f\u5f71\u6aa2\u67e5(bone scan)\nD. \u8d85\u97f3\u6ce2\u6aa2\u67e5(ultrasonography)\nE. \u95dc\u7bc0\u7d44\u7e54\u5207\u7247\u6aa2\u67e5(join biopsy)\n": "(B)", "107-5.\n\u4e00\u4f4d40\u6b72\u5a66\u5973\u60a3\u6709\u76ae\u808c\u708e(dermatomyositis)2\u5e74\uff0c\u4e14\u75be\u75c5\u63a7\u5236\u5f97\u5f88\u597d\uff0c\u76ee\u524d\u85e5\u7269\u4ee5\u985e\u56fa\u9187(prednisolone)\u53caazathioprine\u6cbb\u7642\uff0c\u8eab\u9ad4\u6aa2\u67e5\u7686\u6b63\u5e38\uff0c\u56db\u80a2\u808c\u8089\u529b\u91cf\u6b63\u5e38\uff0c\u6c27\u6c2398%\u98fd\u548c(O2 saturation)\u76ae\u819a\u6c92\u6709\u7d05\u6591\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5CK 100\u03bc/L\uff0cANA 1:1280\u500d\u967d\u6027\uff0c\u6297Jo-1\u6297\u9ad4\u967d\u6027\uff0c\u76ee\u524d\u4e0b\u5217\u6aa2\u67e5\u662f\u6700\u9069\u5408\u75c5\u4eba\u4e4b\u6aa2\u67e5\nA. 6\u5206\u9418\u8d70\u8def\u6aa2\u67e5\nB. \u5fc3\u81df\u6838\u78c1\u5171\u632f\u6aa2\u67e5(MRI)\nC. \u80f8\u90e8X\u5149(chest radiography)\nD. \u904b\u52d5\u58d3\u529b\u6aa2\u67e5\nE. \u76ae\u819a\u5207\u7247\u6aa2\u67e5\n": "(C)", "107-6.\n\u4e00\u4f4d28\u6b72\u7537\u6027\u67096\u500b\u6708\u7684\u53f3\u8173\u8ddf\u75db\uff0c\u4f11\u606f\u5f8c\u75bc\u75db\u52a0\u5287\uff0c\u65e9\u6668\u7761\u9192\u6709\u6668\u50f5\u73fe\u8c61\u7d042\u5c0f\u6642\uff0c\u5c0dacetaminophen\u6cbb\u7642\u7121\u6548\uff0c\u904e\u53bb\u773c\u775b\u5e38\u6709\u8461\u8404\u819c\u708e\u767c\u751f\uff0c\u8eab\u9ad4\u6aa2\u67e5\uff0c\u8170\u690e\u7121\u58d3\u75db\uff0c\u8170\u690e\u904b\u52d5\u6b63\u5e38\uff0c\u53f3\u8173\u8ddf\u6709\u58d3\u75db\u53ca\u816b\u8139\uff0c\u5176\u4ed6\u7686\u6b63\u5e38\uff0c\u9aa8\u76c6\u8154\u95dc\u7bc0X\u5149\u6b63\u5e38\uff0c\u53f3\u8173\u8ddfX\u5149\u8edf\u7d44\u7e54\u6709\u816b\u8139\uff0cAchillis\u808c\u8171\u63a5\u5408\u8655\u9aa8\u9abc\u6709\u4fb5\u8755\u73fe\u8c61\uff0c\u4e0b\u5217\u6aa2\u67e5\u662f\u6700\u9069\u5408\u4e4b\u6aa2\u67e5\uff0c\r(1)\u985e\u98a8\u6fd5\u6027\u56e0\u5b50(RF)\r(2)\u6297\u6838\u6297\u9ad4(ANA)\r(3)\u6297\u74dc\u80fa\u9178\u86cb\u767d\u6297\u9ad4(ACPA)\r(4)\u4eba\u985e\u767d\u8840\u7403\u6297\u539fB27\u6aa2\u67e5(HLA-B-27)\r(5)\u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR)\nA. (1)+(2)\nB. (1)+(3)\nC. (4)+(5)\nD. (5)+(2)\nE. (5)+(1)\n": "(C)", "107-7.\n\u4e00\u4f4d42\u6b72\u5a66\u5973\u56e0\u70ba\u5c0d\u7a31\u6027\u8fd1\u7aef\u808c\u8089\u7121\u529b\u67093\u500b\u6708\u5230\u91ab\u9662\u8acb\u6c42\u8a55\u4f30\uff0c\u7406\u5b78\u6aa2\u67e5\u9664\u56db\u80a2\u8fd1\u7aef\u808c\u8089\u7121\u529b\u5916\uff0c\u4e26\u7121\u5176\u4ed6\u7570\u5e38\uff0c\u4e5f\u7121\u76ae\u819a\u75c7\u72c0\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u8840\u6e05\u57fa\u9178\u78f7\u9175\u7d20(CK)2000U/L\uff0c\u7532\u72c0\u817a\u6fc0\u7d20(TSH)\u6b63\u5e38\uff0c\u808c\u96fb\u5716\u986f\u793a\u5728\u8fd1\u7aef\u808c\u8089\u6709\u81ea\u767c\u986b\u52d5(spontaneous fibrillation)\uff0c\u591a\u9805\u6027\u904b\u52d5\u96fb\u4f4d(polyphasic motor unit potential)\u589e\u52a0\uff0c\u6838\u78c1\u5171\u632f(MRI)\u986f\u793a\u817f\u90e8\u56db\u982d\u808c\u6709\u767c\u708e\u6539\u8b8a\uff0c\u4e0b\u5217\u662f\u76ee\u524d\u6700\u5408\u9069\u4e4b\u6cbb\u7642?\nA. \u8b77\u9081(adalimumab)\nB. \u74b0\u5b62\u7d20(cyclosporine)\nC. \u4f86\u6c1f\u7c73\u7279(leflunomide)\nD. \u985e\u56fa\u9187(prednisolone)\nE. \u7fa5\u6c2f\u53e3\u594e(hydroxychloroquine)\n": "(D)", "107-8.\n\u4e00\u4f4d25\u6b72\u5973\u6027\u767c\u71d2\u5026\u6020\u53ca\u96d9\u624b\u624b\u8155\u3001\u96d9\u819d\u53ca\u8173\u8e1d\u75db\u4e00\u9031\uff0c\u5979\u66fe\u7d93\u77ed\u66ab\u6709\u76ae\u819a\u7d05\u75b9\uff0c\u50cf\u662f\u81bf\u5305(pustule)\uff0c\u6c92\u6709\u5c3f\u9053\u75c7\u72c0\u6216\u9670\u9053\u5206\u6ccc\u7269\u3002\u5979\u66fe\u4f7f\u7528\u904e\u975e\u6cd5\u85e5\u7269\u4e14\u6027\u6d3b\u52d5\u6d3b\u8000\uff0c\u4f7f\u7528\u53e3\u670d\u907f\u5b55\u85e5\uff0c\u7406\u5b78\u6aa2\u67e5\u9ad4\u6eab38\u2103\uff0c\u624b\u8155\u6709\u58d3\u75db\uff0c\u5de6\u819d\u53ca\u96d9\u8173\u88f8\u6709\u58d3\u75db\u53ca\u816b\u8139\uff0c\u53ca\u5169\u5074\u8ddf\u8171(Achilles tendon)\u58d3\u75db\uff0c\u96d9\u624b\u53ca\u96d9\u8173\u6709\u7d05\u6591\u76ae\u75c7\uff0c\u5be6\u9a57\u6aa2\u67e5\u8840\u6db2\u767d\u8840\u740313,500/mm3\uff0c\u809d\u814e\u529f\u80fd\u6b63\u5e38\uff0c\u4e0b\u5217\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u662f\u6700\u6709\u5e6b\u52a9?\nA. C\u53cd\u61c9\u86cb\u767d(CRP)\nB. \u5b50\u5bae\u9838\u5206\u6ccc\u7269\u57f9\u990a\nC. \u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6(ESR)\nD. \u93c8\u7403\u83cc\u6297\u539f\u6aa2\u67e5\nE. \u624b\u8155\u53ca\u96d9\u819d\u96fb\u8166\u65b7\u5c64(CT scan)\n": "(B)", "107-9.\n\u4e00\u4f4d25\u6b72\u60a3\u67095\u5e74\u4e4b\u7d05\u6591\u6027\u72fc\u7621\uff0c\u6e96\u5099\u61f7\u5b55\uff0c\u904e\u53bb\u4e00\u5e74\u4f86\u4f7f\u7528hydroxychloroquine\u3001mycophenolate mofetil\u53ca\u985e\u56fa\u9187\u63a7\u5236\u7d05\u6591\u6027\u72fc\u7621\uff0c\u75c5\u60c5\u7a69\u5b9a\uff0c\u7406\u5b78\u6aa2\u67e5\u4e00\u5207\u6b63\u5e38\uff0c\u9664\u53f3\u81c9\u6709\u4e00\u4e9b\u7d05\u6591\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7686\u6b63\u5e38\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6cbb\u7642\u75c5\u4eba\u6700\u597d\u7684\u5efa\u8b70\nA. \u505c\u6b62\u4f7f\u7528hydroxychloroquine\nB. \u505c\u6b62\u4f7f\u7528mycophenolate mofetil\nC. \u505c\u6b62\u4f7f\u7528\u985e\u56fa\u9187\nD. \u7e7c\u7e8c\u4f7f\u7528\u6240\u6709\u85e5\u7269\nE. \u505c\u6b62\u4f7f\u7528\u6240\u6709\u85e5\u7269\n": "(B)", "107-10.\n\u4e00\u4f4d40\u6b72\u7537\u6027\uff0c\u767c\u71d2\u905439\u2103\uff0c\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\uff0c\u808c\u8089\u53ca\u95dc\u7bc0\u75bc\u75db\u53ca\u6dcb\u5df4\u817a\u816b\u8139\u800c\u6c42\u91ab\uff0c\u6709\u4e00\u500b\u6708\u95dc\u7bc0\u75db\u5305\u62ec\u80a9\u90e8\u3001\u624b\u8155\u3001\u96d9\u819d\uff0c\u4e14\u6709\u65e9\u6668\u50f5\u786c\u73fe\u8c61\uff0c\u4e14\u66fe\u5728\u8eab\u9ad4\u53ca\u56db\u80a2\u6709\u7c89\u8272\u7d05\u6591\uff0c\u7406\u5b78\u6aa2\u67e5\u9ad4\u6eab38.8\u2103\uff0c\u9838\u90e8\u6dcb\u5df4\u817a\u816b\u5927\uff0c\u813e\u816b\u5927\uff0c\u8eab\u9ad4\u53ca\u56db\u80a2\u6709\u7d05\u75b9\uff0c\u624b\u8155\u53ca\u96d9\u819d\u816b\u8139\u53ca\u58d3\u75db\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5ESR 100 mm/h\uff0c\u767d\u8840\u740330,000/mm3\uff0cC\u53cd\u61c9\u86cb\u767d(CRP)18mg/dl\uff0c\u9435\u86cb\u767d(Ferritin)20,000 ng/ml\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u4e4b\u8a3a\u65b7?\nA. \u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621(SLE)\nB. \u5168\u8eab\u6027\u786c\u5316\u75c7(SSc)\nC. \u6210\u4eba\u578bStill's \u75c5(Adult Onset Still's Disease)\nD. \u6025\u6027\u9aa8\u9ad3\u767d\u8840\u75c5(AML)\nE. \u50f5\u76f4\u6027\u810a\u690e\u708e(AS)\n": "(C)", "107-1.\n\u4e0b\u5217\u6709\u95dcSLE\u7684\u81ea\u9ad4\u6297\u9ad4\u53ca\u5176\u75be\u75c5\u4f75\u767c\u75c7\u7684\u914d\u5c0d\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Anti-phospholipid\u2500fetal loss\nB. Anti-SSB/La\u2500lupus nephritis\nC. Anti-Sm\u2500malar rash\nD. Anti-RNP\u2500arthritis\nE. Anti-ribosomal P\u2500drug-induced lupus-like syndrome\n": "(A)", "107-2.\n53\u6b72\u5973\u6027\u7684\u4e3b\u8a34\u70ba\u8fd1\u4e8c\u5e74\u4f86\u5929\u51b7\u6642\u96d9\u5074\u624b\u6307\u6703\u8b8a\u767d\u53ca\u8b8a\u7d2b\u3002\u6700\u8fd1\u5169\u624b\u80cc\u7684\u76ae\u819a\u6709\u8b8a\u7c97\u3001\u8b8a\u539a\u3002\u800c\u4e14\u6703\u6709\u4e7e\u54b3\u3001\u808c\u8089\u7121\u529b\u53ca\u6392\u4fbf\u4e0d\u9806\u767c\u751f\u3002\u5230\u67d0\u91ab\u9662\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\uff1aANA 1:1280 speckled+nucleolar pattern, anti-Scl-70 (-), anti-CENP-B (-), RF 62 IU/mL, anti-U1RNP 1284 IU/mL, CK 645 U/L (normal<250 U/L)\u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Systemic sclerosis\nB. MCTD (mixed connective tissue disease)\nC. SLE\nD. RA\nE. Polymyositis/dermatomyositis\n": "(B)", "107-3.\n19\u6b72\u7537\u6027\u5728\u6e05\u6668\u6642\u6703\u6709\u4e0b\u80cc\u50f5\u786c\u53ca\u9178\u75db\u6709\u534a\u5e74\u4e4b\u4e45\u3002\u8d77\u4f86\u904b\u52d530\u5206\u4e4b\u5f8c\u6703\u9010\u6f38\u7de9\u89e3\u3002\u5728\u6b64\u671f\u9593\u66fe\u6709\u4e00\u6b21\u53f3\u8173\u5e95\u8d70\u8def\u5287\u75db\uff0c\u7d93\u670d\u7528\u6d88\u708e\u6b62\u75db\u5291\u5f8c\u9010\u6f38\u6062\u5fa9\u6b63\u5e38\u3002\u7d93\u91ab\u5e2b\u8a73\u7d30\u6aa2\u67e5\u5f8c\u8a3a\u65b7\u70ba\u50f5\u76f4\u6027\u810a\u690e\u708e\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6700\u6709\u6548\uff1f\nA. Methotrexate\nB. Anti-B cell therapy\nC. Anti-TNF- alpha therapy\nD. MMF (mycophenolate mofetil)\nE. Cyclophosphamide\n": "(C)", "107-4.\n57\u6b72\u7537\u6027\u75c5\u4eba\u57288\u5e74\u524d\u767c\u73fe\u5169\u624b\u7684\u6307\u7532\u6709\u589e\u751f\u80a5\u539a\u53ca\u6613\u8106\u3002\u800c\u8fd1\u534a\u5e74\u4f86\u6642\u5e38\u6709\u4e0b\u80cc\u9178\u75db\u3002\u6700\u8fd1\u767c\u73fe\u591a\u8655\u9060\u7aef\u6307\u9593\u95dc\u7bc0\u6709\u767c\u708e\u816b\u75db\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73feESR 31mm/1h, CRP1.8mg/dL\u3002\u7167X-\u5149\u767c\u73fe\u591a\u8655\u95dc\u7bc0\u6709marginal erosion\u53ca\u9aa8\u982d\u7834\u58de\u3002\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Inflammatory osteoarthritis\nB. Rheumatoid arthritis\nC. Reactive arthritis\nD. Tinea on the finger nails\nE. Psoriatic arthritis\n": "(E)", "107-5.\n\u4e0b\u5217\u6709\u95dc\u5404\u985e\u8840\u7ba1\u708e\u53ca\u5176\u81f4\u75c5\u56e0\u5b50\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Hepatitis C virus-associated cryoglobulinemic vascultits\u2500T cell response\nB. Granulomatosis with polyangiitis\u2500cANCA\nC. Eosinophilic granulomatosis with polyangiitis\u2500immune complex deposition\nD. Takayasu arteritis\u2500IgA-associated vasculitis\nE. Microscopic polyangiitis\u2500complement activation\n": "(B)", "107-6.\n\u4e00\u4f4d72\u6b72\u5973\u6027\u6700\u8fd1\u56db\u500b\u6708\u4f86\uff0c\u7a81\u7136\u767c\u751f\u96d9\u5074\u80a9\u8180\u808c\u8089\u5287\u75db\uff0c\u4f34\u96a8\u6709\u5fae\u71d2\u767c\u751f\u3002\u6700\u8fd1\u611f\u89ba\u5728\u9873\u9aa8\u90e8\u4f4d\u6709\u982d\u75db\u4e14\u4f34\u96a8\u8996\u529b\u6a21\u7cca\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe: Hb 9.8mg/mL, ESR102mm/1h, CRP 2.1mg/dL, ANA 1:80 speckled, pANCA(-), cANCA (-)\u3002\u7d93\u6bcf\u5929\u670d\u7528prednisolone 40mg \u4e03\u5929\u4e4b\u5f8c\u6709\u660e\u986f\u7642\u6548\u3002\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Giant cell arteritis\nB. Migraine\nC. Adhesive capsulitis\nD. Influenza infection\nE. Glaucoma\n": "(A)", "107-7.\n51\u6b72\u5973\u6027\u8fd1\u4e09\u500b\u6708\u4f86\u6709\u767c\u71d2\u96d9\u5074\u7684\u4e0a\u773c\u77bc\u816b\u8139\u53ca\u51fa\u73fe\u7d2b\u7d05\u8272\u6591\u3002\u8d77\u5e8a\u6642\u5927\u817f\u7121\u529b\uff0c\u5fc5\u9808\u4ee5\u96d9\u624b\u652f\u6490\u624d\u80fd\u5750\u8d77\u3002\u6700\u8fd1\u4e00\u9031\u559d\u6c34\u6709\u6642\u6703\u55c6\u5230\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u96d9\u5074\u5927\u817f\u56db\u982d\u808c\u7121\u529b\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe: ANA 1:160 speckled, \u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u6700\u80fd\u53cd\u61c9\u60a3\u8005\u7684\u75be\u75c5\u6d3b\u52d5\u6027\uff1f\nA. CRP\nB. CK\nC. AST\nD. Anti-tRNA synthetase titer\nE. Myoglobulin\n": "(B)", "107-8.\n\u8acb\u554f\u4f7f\u7528color Doppler ultrasound\u53ef\u4ee5\u6aa2\u67e5\u4e0b\u5217\u4f55\u7a2e\u808c\u8089\u9aa8\u9abc\u7684\u75be\u75c5\uff1f (1).\trotator cuff tears (2). bone marrow edema (3). calcium pyrophosphate deposition (4). chronic osteomyelitis (5). spinal stenosis (6). carpal tunnel syndrome (7). avascular bone necrosis (8). septic arthritis (9). HIVD\nA. (2)+(5)+(8)\nB. (1)+(4)+(9)\nC. (1)+(3)+(6)\nD. (3)+(4)+(5)\nE. (7)+(8)+(9)\n": "(C)", "107-9.\n\u8acb\u554f\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u6703\u5f15\u8d77acute mono-arthritis\uff1f (1). rheumatoid arthritis (2). gouty arthritis (3). osteoarthritis (4). seronegative spondylarthropathy (5). septic arthritis (6). Lyme disease\r(7). acute rheumatic fever (8). pigmented villonodular synovitis\r(9). traumatic arthritis\nA. (1)+(3)+(4)\nB. (2)+(6)+(7)\nC. (7)+(8)+(9)\nD. (4)+(5)+(6)\nE. (2)+(5)+(9)\n": "(E)", "107-10.\n\u4e0b\u5217\u6709\u95dc2012\u5e74Systemic Lupus International Collaborating Clinic (SLICC) classification criteria\u4e2d\u6240\u5217SLE\u7684\u81e8\u5e8a\u8868\u5fb5\u53ca\u8840\u6e05\u5b78\u6aa2\u67e5\uff0c\u4f55\u8005\u5305\u62ec\u5728\u5167\uff1f (1).\tarthritis with deformity (2). chronic cutaneous LE (3). anti-phospholipid antibodies (4). hemoglobulin< 10g/dL (5). anti-SSA/Ro antibodies (6). ANCAs (7). low serum complement levels (8). uveitis (9). vasculitis\nA. (1)+(2)+(9)\nB. (2)+(3)+(7)\nC. (3)+(4)+(5)\nD. (1)+(6)+(8)\nE. (5)+(6)+(7)\n": "(B)", "108-1.\n\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\r(1)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u6613\u808c\u8171\u9aa8\u63a5\u5408\u9ede\u767c\u708e(enthesitis)\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(Psoriatic arthritis,PSA)\u6613\u95dc\u7bc0\u6ed1\u819c\u708e(synovitis)\r(2)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u6613\u4fb5\u72af\u9060\u7aef\u6307\u9593\u95dc\u7bc0(Distal interphalangeal joint,DIP)\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\u6613\u4fb5\u72af\u8fd1\u7aef\u6307\u7aef\u7bc0(proximal interphalangeal join,PIP)\r(3)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u6613\u5f15\u8d77\u9aa8\u4fb5\u8755\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\u6613\u5f15\u8d77\u808c\u8171\u9aa8\u63a5\u5408\u9ede\u767c\u708e\r(4)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u5927\u90e8\u5206\u6703\u7522\u751f\u81ea\u9ad4\u6297\u9ad4\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\u5927\u90e8\u5206\u4e0d\u6703\u7522\u751f\u81ea\u9ad4\u6297\u9ad4\r(5)\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u4e3b\u8981\u662f\u6a5f\u68b0\u6027\u5f15\u8d77\u4e4b\u767c\u708e(Mechanical inflammation)\uff0c\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\u4e3b\u8981\u662f\u81ea\u9ad4\u514d\u75ab\u53cd\u61c9\u9020\u6210(Autoimmune)\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(C)", "108-2.\n\u4e0b\u5217\u85e5\u7269\u88ab\u5efa\u8b70\u5728\u6240\u6709\u7d05\u6591\u6027\u72fc\u7621(SLE)\u75c5\u4eba\u9577\u671f\u4f7f\u7528\uff1f\nA. endoxan\nB. hydroxychloroquine\nC. azathioprine\nD. \u9ad8\u5291\u91cf\u985e\u56fa\u9187glucocorticoid\nE. \u6297\u751f\u7d20\u4ee5\u9810\u9632\u611f\u67d3\n": "(B)", "108-3.\n\u4e0b\u5217\u6297\u9ad4\u5e38\u5408\u4f75\u9593\u8cea\u80ba\u75be\u75c5(interstitial lung disease)\u4e26\u5feb\u901f\u5f71\u97ff\u751f\u547d\u5371\u96aa\uff1f\nA. anti- melanoma differentiation-associated protein 5(MDA5)Ab\nB. anti-Sm Ab\nC. anti-RNP Ab\nD. anti-dsDNA Ab\nE. anti histone Ab\n": "(A)", "108-4.\n\u4e00\u4f4d65\u6b72\u5973\u6027\u56e0\u5168\u8eab\u7121\u529b\u53ca\u865b\u5f31\uff0c\u6df1\u8910\u8272\u5c0f\u4fbf\u53ca\u541e\u56a5\u56f0\u96e3\u800c\u4f4f\u9662\uff0c\u4e09\u5341\u4e94\u5e74\u524d\u75c5\u4eba\u63a5\u53d7\u8b8a\u6027\u624b\u8853\u5f9e\u7537\u8b8a\u5973\uff0c\u6b64\u5f8c\u5c31\u9577\u671f\u4f7f\u7528\u96cc\u6fc0\u7d20\uff0c\u4e00\u5e74\u534a\u524d\u6709\u5fc3\u81df\u5f15\u8d77\u7684\u8166\u4e2d\u98a8\u5f8c\u958b\u59cb\u670d\u7528atorvastatin\u53caAspirin\u53ca\u5229\u5c3f\u5291\uff0c\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u4e0a\u4e0b\u80a2\u8fd1\u7aef\u808c\u8089\u7121\u529b\uff0c\u4e0b\u5217\u4e3b\u8981\u6aa2\u67e5\u5c07\u6700\u6709\u53ef\u80fd\u65bc\u75be\u75c5\u8a3a\u65b7\u6b64\u75c5? (1)CK (2)anti-HMGCR (3)anti-sm (4)anti-topoisomerase 1  (5)anti-Ro Ab\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(4)\nD. (1)+(5)\nE. (2)+(5)\n": "(A)", "108-5.\n\u627f\u63a5\u4e0a\u984c\uff0c\u6b64\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u60a3\u6709\uff1f\nA. \u7d05\u6591\u6027\u72fc\u7621(SLE)\nB. \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\nC. \u611f\u67d3\u5fc3\u5167\u819c\u708e\nD. \u85e5\u7269\u5f15\u8d77\u808c\u708e\nE. \u786c\u76ae\u75c7\n": "(D)", "108-6.\n\u4e00\u4f4d60\u6b72\u7537\u6027\u56e0\u6025\u6027\u75db\u98a8\u591a\u6b21\u4f4f\u9662\uff0c\u4ed6\u6709\u814e\u7d50\u77f3\u3001\u6162\u6027\u814e\u75c5\u4e4b\u75c5\u53f2\uff0c\u7d93\u6aa2\u67e5\u5c6c\u65bc\u5c3f\u9178\u88fd\u9020\u589e\u52a0\u4e4b\u75c5\u4eba\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r(1)\u6700\u597d\u7684\u964d\u5c3f\u9178\u85e5\u7269\u70baallopurinol\r(2)\u6b64\u75c5\u4eba\u76ee\u524d\u6025\u6027\u75db\u98a8\u767c\u4f5c\u61c9\u53ef\u99ac\u4e0a\u7d66\u4e88allopurinol 300mg/day\r(3)\u75c5\u4eba\u958b\u59cb\u4f7f\u7528\u964d\u5c3f\u9178\u85e5\u6642\uff0c\u53ef\u540c\u6642\u7d66\u4e88colchicine\u9810\u9632\u767c\u4f5c\r(4)\u6b64\u75c5\u4eba\u6700\u597d\u7684\u964d\u5c3f\u9178\u85e5\u7269\u662fbenzbromarone\r(5)\u6b64\u75c5\u4eba\u61c9\u9577\u671f\u670d\u7528\u964d\u5c3f\u9178\u85e5\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(4)\nD. (2)+(4)\nE. (2)+(5)\n": "(B)", "108-7.\n\u4e00\u4f4d45\u6b72\u5973\u6027\u56e0\u624b\u6307\u53ca\u8173\u8dbe\u816b\u75db\u4e09\u5e74\uff0c\u5176\u5169\u8173\u5927\u62c7\u6307\u53ca\u53f3\u8173\u7b2c\u4e8c\u8173\u8dbe\u53ca\u5de6\u7b2c\u4e09\u8173\u8dbe\u70ba\u50cf\u9999\u8178\u6a23\u7684\u816b\u8139(Sausage-like)\uff0canti-CCP\u6297\u9ad4\u53ca\u985e\u98a8\u6fd5\u6027\u56fa\u7686\u9670\u6027\uff0c\u5979\u7684\u8173\u8ddf\u8171(Achilles tendon)\u9577\u671f\u816b\u8139\u53ca\u75bc\u75db\uff0c\u6b64\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba \uff1f\nA. \u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e(RA)\nB. \u7d05\u6591\u6027\u72fc\u7621(SLE)\nC. \u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PSA)\nD. \u786c\u76ae\u75c7(SSc)\nE. \u591a\u767c\u6027\u808c\u708e(Polymyositis)\n": "(C)", "108-8.\n\u514d\u75ab\u6291\u5236\u5291\u5e38\u7528\u65bc\u6cbb\u7642\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u53ca\u5668\u5b98\u79fb\u690d\u75c5\u4eba\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u70ba\u6b63\u78ba? (1)\u985e\u56fa\u9187(corticosteroid)\u5e38\u5f15\u8d77\u9aa8\u8cea\u758f\u9b06(Osteoporosis) (2)Tacrolimus\u53cacyclosporine\u6703\u5f15\u8d77\u808c\u8089\u6e1b\u5c11 (3)\u4f7f\u7528\u514d\u75ab\u6291\u5236\u5291\u8f03\u5c11\u5f15\u8d77\u611f\u67d3 (4)\u4f7f\u7528\u514d\u75ab\u6291\u5236\u5291\u8f03\u4e0d\u6703\u5f15\u8d77\u4e7e\u766c (5)\u4f7f\u7528\u514d\u75ab\u6291\u5236\u5291\u8f03\u4e0d\u6703\u9020\u6210\u814e\u81df\u7834\u58de\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(4)\nD. (1)+(5)\nE. (2)+(4)\n": "(A)", "108-9.\n\u4e00\u4f4d30\u6b72\u5973\u6027\u60a3\u6709\u7d05\u6591\u6027\u72fc\u7621(SLE)\u591a\u5e74\uff0c\u6700\u8fd1\u6709\u4e09\u6b21\u6d41\u7522\u4e26\u88ab\u8a3a\u65b7\u6709\u6297\u78f7\u8102\u6297\u9ad4\u75c7\u5019\u7fa4(Antiphospholipid Syndrome)\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba? (1)\u53ef\u4ee5Aspirin 100mg/day \u6cbb\u7642 (2)\u53ef\u4ee5Aspirin 330mg/day \u6cbb\u7642 (3)\u53ef\u4ee5\u670d\u7528\u907f\u5b55\u85e5 (4)\u62bd\u7159\u4e0d\u5f71\u97ff\u75c5\u60c5 (5)\u518d\u6b21\u61f7\u5b55\u6642\u53ef\u6253\u4f4e\u5291\u91cf(heparin)\nA. (1)+(3)\nB. (1)+(4)\nC. (1)+(5)\nD. (2)+(3)\nE. (2)+(5)\n": "(C)", "108-10.\n\u786c\u76ae\u75c7\u814e\u5371\u6025(scleroderma renal crisis, SRC)\u662f\u56b4\u91cd\u4e14\u81f4\u547d\u4e4b\u6025\u75c7\u5176\u9996\u9078\u4e4b\u6cbb\u7642\u85e5\u7269\uff1f\nA. ACE-inhibitors (angiotensin-converting enzyme inhibitor)\nB. corticosteroids\nC. endoxan (cyclophosphamide)\nD. Immuran (azathioprine)\nE. methotrexate (MTX)\n": "(A)", "108-1.\n\u4e0b\u5217\u6709\u95dc SLE\u81ea\u9ad4\u6297\u9ad4\u8207\u81e8\u5e8a\u8868\u73fe\u4e4b\u9593\u7684\u76f8\u95dc\u6027\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Anti-dsDNA\u8207disease activity\u6709\u6b63\u76f8\u95dc\nB. Anti-SSB\u8207nephritis\u6709\u6b63\u76f8\u95dc\nC. Anti-cardiolipin\u8207neonatal lupus\u7684\u767c\u751f\u6709\u95dc\nD. Anti-ribosomal P\u8207mononeuritis multiplex\u6709\u6b63\u76f8\u95dc\nE. Anti-histone\u8207thrombocytopenia\u6709\u6b63\u76f8\u95dc\n": "(A)", "108-2.\n\u4e0b\u5217\u4f55\u7a2e\u6297\u9ad4\u5728\u8a3a\u65b7rheumatoid arthritis\u6700\u5177\u7279\u7570\u6027\uff1f\nA. Anti-IgG\nB. Anti-EB viral nuclear protein\nC. Anti-collagen type II\nD. Anti-CCP\nE. Anti-proteoglycan\n": "(D)", "108-3.\n\u4e0b\u5217\u6709\u95dcsystemic sclerosis\u7684\u63cf\u8ff0\u4e2d,\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. \u6700\u5e38\u51fa\u73fe\u7684\u6297\u9ad4\u70baanti-centromere antibodies\nB. Anti-Jo-1\u8207interstitial lung disease\u7121\u95dc\nC. Anti-topoisomerase 1 antibodies\u70ba\u5176\u751f\u7269\u6a19\u8a8c\nD. \u53e3\u670d\u9ad8\u91cf\u985e\u56fa\u9187\u70ba\u6cbb\u7642\u76ae\u819a\u786c\u5316\u7684\u9996\u9078\u85e5\u7269\nE. Raynaud's phenomenon\u70ba\u5728\u672b\u671f\u624d\u6703\u51fa\u73fe\n": "(C)", "108-4.\n\u4e0b\u5217\u6709\u95dcSjogren's syndrome\u7684extra-glandular manifestations\u7684\u63cf\u8ff0\u4e2d,\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Erosive arthritis\nB. Iritis/uveitis\nC. Leukocytoclastic vasculitis\nD. Oral cavity carcinoma\nE. Primary biliary cholangitis\n": "(E)", "108-5.\n\u4e0b\u5217\u6709\u95dc\u98a8\u6fd5\u514d\u75ab\u75be\u75c5\u7684\u75c5\u56e0\u8207\u7d50\u679c\u7684\u52fe\u914d\u95dc\u4fc2\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Anti-myeloperoxidase\u5f15\u8d77lupus nephritis\nB. Anti-proteinase 3\u5f15\u8d77granulomatosis with polyangiitis\nC. Viral infection\u5f15\u8d77Takayasu's arteritis\nD. Immune complex\u5f15\u8d77giant cell arteritis\nE. IgG4\u5f15\u8d77 microscopic polyangiitis\n": "(B)", "108-6.\n\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u8a3a\u65b7polyarteritis nodosa\u6700\u6709\u5e6b\u52a9\uff1f\nA. Anti-elastase antibodies\nB. Inflammatory parameters\nC. Angiography\nD. Anti-neutrophil cytoplasmic antibodies\nE. Renal function test\n": "(C)", "108-7.\n\u4e0b\u5217\u6709\u95dcinflammatory muscle diseases\u7684\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\nA. Inclusion body myositis\u6703\u5f15\u8d77\u672b\u7aef\u808c\u8089\u7684\u7121\u529b\nB. \u76ae\u808c\u708e\u8207\u816b\u7624\u8f03\u7121\u95dc\u806f\u6027\nC. \u591a\u767c\u6027\u808c\u708e\u8207B\u7d30\u80de\u7522\u751f\u6297\u9ad4\u6709\u5f88\u5927\u7684\u95dc\u4fc2\nD. \u672c\u985e\u75be\u75c5\u5e38\u5e38\u5f15\u8d77\u6025\u6027\u808c\u8089\u7121\u529b\nE. \u80c3\u8178\u9053\u7684\u8815\u52d5\u5e38\u53d7\u5230\u5f71\u97ff\n": "(A)", "108-8.\n\u4e0b\u5217\u6709\u95dcSLE\u7684\u5206\u985e\u57fa\u6e96\u9805\u76ee\u7684\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba? (1)chronic cutaneous vasculitis  (2)  RBC casts in urinalysis (3)    anti-SSA/Ro (4) anti-phospholipid (5) positive direct Coomb's test (6) low serum complements (7) Raynaud's phenomenon (8) malar skin rash\nA. (1)+(2)+(3)+(4)\nB. (5)+(6)+(7)+(8)\nC. (2)+(4)+(5)+(8)\nD. (3)+(5)+(6)+(7)\nE. (4)+(6)+(7)+(8)\n": "(C)", "108-9.\n\u4e0b\u5217\u6709\u95dcrheumatoid arthritis \u7684extra-articular manifestations\u4e2d\uff0c \u4f55\u8005\u6700\u70ba  \u6b63\u78ba\uff1f\r (1)Uveitis (2)cervical myelopathy (3)oral mucosa ulcer (4)Felty's  syndrome (5)mechanical hand (6)rheumatoid nodule (7)inflammatory bowel diseases (8)episcleritis\nA. (2)+(4)+(8)\nB. (1)+(2)+(3)\nC. (4)+(5)+(6)\nD. (6)+(7)+(8)\nE. (2)+(3)+(6)\n": "(A)", "108-10.\n\u4e0b\u5217\u6709\u95dcaxial spondyloarthritis\u7684\u767c\u708e\u6027\u4e0b\u80cc\u75db\u5206\u985e\u57fa\u6e96\u7684\u7d44\u5408\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f\r (1)\tAge>40 year-old (2) HLA-B27 (+)  (3) acute lumbago (4) relief after exercise (5)\u534a\u591c\u6216\u6e05\u6668\u7684\u9178\u75db\u50f5\u786c>30\u5206 (6) \u767d\u5929\u4f11\u606f\u4e4b\u5f8c\u6703\u548c\u7de9 (7) \u8170\u90e8\u810a\u690e\u6703\u8b8a\u76f4 (8)\u7167MRI\u5e6b\u52a9\u4e0d\u5927\nA. (1)+(2)+(3)\nB. (4)+(5)+(7)\nC. (2)+(4)+(8)\nD. (3)+(6)+(7)\nE. (6)+(7)+(8)\n": "(B)", "109-140.\u4e00\u4f4d55\u6b72\u7537\u6027\u4e8c\u5929\u524d\u7a81\u7136\u53f3\u8173\u8e1d\u75db\u53ca\u816b\u8139 \uff0c\u75c5\u4eba\u670920\u5e74\u62bd\u83f8\u7fd2\u6163 \uff0c\u5076\u723e\u559d\u9152 \uff0c\u4e8c\u5468\u524d\u4e26\u66fe\u6709\u5c0f\u4fbf\u5fae\u75db\u53ca\n\u707c\u71b1\u611f\uff0c\u4e0b\u5217\u6aa2\u9a57\u5c0d\u75c5\u4eba\u6700\u6709\u5e6b\u52a9 \uff1f(1) \u6297\u6838\u6297\u9ad4 (antinuclear antibody )\uff1b(2) \u4eba\u985e\u767d\u8840\u7403\u6297\u539f -B27 \n(HLA-B27)\uff1b(3) \u5c3f\u9178\uff1b(4) \u6297\u74dc\u80fa\u9178\u86cb\u767d\u6297\u9ad4 (ACPA)\uff1b(5) \u6297\u55dc\u4e2d\u6027\u767d\u8840\u7403\u7d30\u80de\u8cea\u6297\u9ad4 (ANCA)   \nA.(1)+(5)\nB.(1)+(4)\nC.(2)+(3)\nD.(2)+(4)\nE.(3)+(5)\n": "[C]", "109-141.\u9ad8\u5c3f\u9178\u8840\u75c7\u60a3\u8005\uff0c\u4e0b\u5217\u4f55\u60c5\u6cc1\u4e0d\u9808\u4ee5\u964d\u5c3f\u9178\u85e5\u7269\u6cbb\u7642\uff1f    \nA.\u6709\u75db\u98a8\u77f3\nB.X-ray\u6709\u56e0\u5c3f\u9178\u7834\u58de\u95dc\u7bc0\u6216\u9aa8\u75c5\u8b8a\nC.\u7d93\u5e38\u75db\u98a8\u767c\u4f5c\nD.\u8840\u4e2d\u5c3f\u9178\u5927\u65bc7mg/dL\nE.\u814e\u81df\u56e0\u5c3f\u9178\u5f15\u8d77\u4e4b\u814e\u75c5\u8b8a\n": "[D]", "109-142.\u5168\u7403\u65b0\u51a0\u80ba\u708e\u75c5\u6bd2 (Covid-19)\u611f\u67d3\u5df2\u8d85\u904e\u4e00\u4edf\u67d2\u767e\u842c\u4eba \uff0c\u6b7b\u4ea1\u4eba\u6578\u8d85\u904e\u516d\u5341\u516b\u842c (\u81f3109\u5e747\u6708)\uff0c \u547c\u5438\u8870\u7aed\n\u70ba\u6700\u5927\u6b7b\u4ea1\u539f\u56e0 \uff0c\u5176\u80ba\u90e8\u75c5\u7406\u8b8a\u5316\u6700\u5927\u7279\u5fb5\u70ba\u4f55 \uff1f   \nA.\u5ee3\u6cdb\u80ba\u90e8\u8840\u7ba1\u6813\u585e\u53ca\u80ba\u90e8\u5fae\u8840\u7ba1\u75c5\u8b8a (thrombosis \u53camicroangiopathy)\nB.\u5ee3\u6cdb\u80ba\u8840\u7ba1\u51fa\u8840\nC.\u80ba\u816b\u7624\nD.\u80ba\u52d5\u8108\u9ad8\u8840\u58d3\nE.\u5ee3\u6cdb\u80ba\u8840\u7ba1 B\u7d30\u80de\u6d78\u6f64\n": "[A]", "109-143.\u4e0a\u8ff0\u65b0\u51a0\u80ba\u708e\u75c5\u6bd2 (Covid-19)\u9032\u5165\u4eba\u9ad4\u7d30\u80de\u662f\u7d50\u5408\u4f55\u7a2e\u5206\u5b50\u800c\u611f\u67d3\uff1f    \nA.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d201 (Angiotensin-converting enzyme 1)   \nB.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d202 (Angiotensin-converting enzyme 2)\nC.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d203 (Angiotensin-converting enzyme 3)\nD.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d204 (Angiotensin-converting enzyme 4)\nE.\u8840\u7ba1\u6536\u7e2e\u7d20-\u8f49\u63db\u9175\u7d205 (Angiotensin-converting enzyme 5)\n": "[B]", "109-144.\u4e00\u4f4d45\u6b72\u5973\u662f\u4e3b\u8a34\u96d9\u8173\u6162\u6162\u51fa\u73fe\u7d2b\u6591 \uff0c\u8840\u6e05\u6aa2\u67e5\u6709type II\u51b7\u51dd\u7403\u86cb\u767d\u8840\u75c7 (cryoglobulinemia )\uff0c\u6b64\u75c5\u6700\u5e38\u898b\n\u4e4b\u539f\u56e0\u70ba \uff1f   \nA.\u80ba\u7d50\u6838\u611f\u67d3\nB.C\u809d\u75c5\u6bd2\u611f\u67d3\nC.\u6885\u6bd2\u611f\u67d3\nD.\u6dcb\u75c5\u611f\u67d3\nE.\u5ff5\u73e0\u83cc\u611f\u67d3\n": "[B]", "109-145.B\u7d30\u80de\u5f15\u8d77\u6dcb\u5df4\u589e\u6b96\u75be\u75c5 (B cell lymphoproliferative disorder )\u4e3b\u8981\u5f15\u8d77\u4e4b\u51b7\u51dd\u86cb\u767d\u8840\n\u75c7(cryoglobulinemia )\u662f   \nA.\u7b2c\u4e00\u578b\nB.\u7b2c\u4e8c\u578b\nC.\u7b2c\u4e09\u578b\nD.\u7b2c\u56db\u578b\nE.\u7b2c\u4e94\u578b\n": "[A]", "109-146.\u4e00\u4f4d55\u6b72\u5973\u6027\u4e3b\u8a34\u6709\u5de6\u8170\u75bc\u75db 4\u500b\u6708\uff0c\u7406\u5b78\u6aa2\u67e5\u9664\u5de6\u8170\u89f8\u75db\u5916\u4e26\u672a\u767c\u73fe\u5176\u4ed6\u4e0d\u6b63\u5e38\u73fe\u8c61 \uff0c\u96fb\u8166\u65b7\u5c64\u986f\u793a\u5728\n\u5f8c\u8179\u8154\u6709\u4e00\u500b\u816b\u7624 \uff0c\u4e14\u58d3\u8feb\u8f38\u5c3f\u7ba1\u53ca\u814e\u81df \uff0c\u5207\u7247\u6aa2\u67e5\u70ba\u514d\u75ab\u7403\u86cb\u767dIg G 4\u76f8\u95dc\u75be\u75c5 (IgG4RD)\uff0c\u4e0b\u5217\u4f55\u7a2e\u6aa2\n\u67e5\u662f\u6700\u4e0d\u9069\u5408\u8a3a\u65b7IgG 4RD\uff1f\n(1) \u8840\u6e05IgG 4\u6fc3\u5ea6\u5347\u9ad8   \n(2) \u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u6709\u6dcb\u5df4\u539f\u5f62\u8cea\u7d30\u80de (Lymphoplasmic )\u7d30\u80de\u6d78\u6f64\n(3) \u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u6709plasma\u7d30\u80de\u6d78\u6f64   \n(4) \u7d44\u7e54\u5207\u7247\u6aa2\u67e5\u6709\u4e2d\u6027\u767d\u8840\u7403\u6d78\u6f64 (Neutrophia )\n(5) \u8840\u6e05anti dsDNA\u5347\u9ad8   \nA.(1)+(2)\nB.(1)+(3)\nC.(2)+(3)\nD.(4)+(5)\nE.(2)+(4)\n": "[D]", "109-147.IgG4\u76f8\u95dc\u75be\u75c5(IgG4RD)\u70ba\u4e00\u7a2e\u7e96\u7dad\u5316\u767c\u708e\u75be\u75c5\uff0c\u6700\u5c11\u4fb5\u72af\u4e0b\u5217\u54ea\u7a2e\u5668\u5b98\uff1f    \nA.\u6dda\u817a\nB.\u80ba\nC.\u553e\u6db2\u817a\nD.\u5f8c\u8179\u8154\nE.\u9ad6\u95dc\u7bc0   \n": "[E]", "109-148.\u4e00\u4f4d48\u6b72\u5bb6\u5ead\u4e3b\u5a66\u4e3b\u8a34\u5728\u65e9\u4e0a\u8d77\u5e8a\u5f8c\u56db\u80a2\u50f5\u786c\u6709\u4e03\u500b\u6708 \uff0c\u6bcf\u5929\u50f5\u786c\u6642\u9593\u8d85\u904e\u4e8c\u5c0f\u6642 \uff0c\u4e09\u500b\u6708\u524d\u5979\u958b\u59cb\u6709\u96d9\n\u80a9\u75bc\u75db\u4e14\u975e\u5e38\u75b2\u5026 \uff0c\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u96d9\u624b\u8fd1\u7aef\u6307\u9593\u95dc\u7bc0 (PIP)\u53ca\u624b\u638c\u6307\u95dc\u7bc0 (MCP)\u53ca\u624b\u8155(wrist)\u6709\u816b\u53ca\u58d3\n\u75db\uff0c\u4e0b\u5217\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f\n(1) \u7d05\u8840\u7403\u6c89\u6fb1\u901f\u5ea6 (ESR)\n(2) \u808c\u9178\u9176(CK)\n(3) \u4e73\u9178\u53bb\u6c2b\u9176 (LDH)   \n(4) \u985e\u98a8\u6fd5\u6027\u56e0\u5b50 (RF)\n(5) IL-10   \nA.(1)+(2)\nB.(1)+(3)\nC.(1)+(4)\nD.(1)+(5)\nE.(2)+(5)\n": "[C]", "109-149.\u627f\u63a5\u4e0a\u984c\uff0c\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u4e4b\u8a3a\u65b7\u70ba\uff1f    \nA.PM \u591a\u767c\u6027\u808c\u708e\nB.RA \u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\nC.AS \u50f5\u76f4\u6027\u810a\u690e\u708e\nD.SSC \u786c\u76ae\u75c7\nE.SLE \u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621\n": "[B]", "109-150.\u5341\u4e5d\u6b72\u7684\u6797\u5c0f\u59d0 \uff0c\u6700\u8fd1\u534a\u5e74\u4f86\u6709\u5fae\u71d2 \u3001\u5026\u6020\u3001\u53ca\u5169\u624b\u591a\u6578\u95dc\u7bc0\u9178\u75db \u3002\u8840\u6db2\u5e38\u898f\u6aa2\u67e5\u767c\u73fe \uff1aHb 9.8 g/dL, \nplatelet count 86 ,000/uL, WBC 3450 /uL with normal differential count, ESR 11 mm /1hr, CRP< 0.5 \nmg/dL, proteinuria (++) \u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.Rheumatoid factors\nB.Sonogram of bilateral hands\nC.Autoantibody profile\nD.Viral screen tests\nE.Bone marrow examination\n": "[C]", "109-151.\u56db\u5341\u4e00\u6b72\u7684\u9673\u592a\u592a\u662f B\u809d\u5e36\u539f\u8005 \u3002\u6700\u8fd1\u4e09\u500b\u6708\u5728\u6668\u9192\u4e4b\u5f8c\u611f\u89ba\u5169\u624b \u3001\u5169\u8155\u3001\u53ca\u5169\u8098\u95dc\u7bc0\u50f5\u786c\u9178\u75db \u3002\u62bd\u8840\u6aa2\n\u67e5\u767c\u73fe\uff1a\u8840\u6db2\u5e38\u898f\u6b63\u5e38 \uff0cESR 34mm /1hr, CRP 2.4 mg/dL. ANA 1:160 speckled pattern (normal< 1:40), \n\u96d9\u624bX-\u5149\u6aa2\u67e5\u7121\u7570\u5e38 \u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.Sonogram of the affected joints\nB.RFs\nC.Cryoglobulin\nD.Complements\nE.Anti-CCP\n": "[E]", "109-152.\u4e00\u4f4d54\u6b72\u4e2d\u5e74\u5a66\u5973\u4e3b\u8a34\u70ba\u8fd1\u4e09\u5e74\u4f86 \uff0c\u5728\u51ac\u5929\u5169\u624b\u6307\u6703\u8b8a\u767d \u3002\u6700\u8fd1\u4e09\u9031\u5c62\u6709\u4e7e\u54b3\u53ca\u904b\u52d5\u6642\u547c\u5438\u56f0\u96e3 \uff0c\u559d\u6c34\u6642\n\u5076\u800c\u6703\u55c6\u5230 \u3002\u5c31\u8a3a\u6642\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe: \u5169\u624b\u80cc\u7684\u76ae\u819a\u6697\u6c89\u53ca\u7a0d\u786c \u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73fe: ANA 1:1280 nucleolar \npattern, pulmonary function test\u5448\u73femoderate restrictive pattern, DLCO: 54% of normal value \u3002\u8acb\u554f\u6700\n\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u4f55 \uff1f   \nA.SLE   \nB.Sjogren\u2019s syndrome\nC.Systemic sclerosis\nD.Polymyositis\nE.Anti-phospholipid syndrome\n": "[C]", "109-153.\u4e00\u4f4d51\u6b72\u7684\u7537\u6027\u60a3\u8005 \uff0c\u6700\u8fd1\u4e00\u5e74\u4f86\u6709\u773c\u4e7e\u53ca\u53e3\u4e7e\u75c7\u72c0 \u3002\u904e\u53bb\u4e5f\u6709\u591a\u5e74\u7684\u904e\u654f\u6027\u9f3b\u708e\u767c\u751f \u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\n\u73fe:\u4e0b\u984e\u90e8\u6709\u5c0d\u7a31\u6027\u7684\u816e\u817a\u816b\u584a\u5b58\u5728 \u3002\u96d9\u5074\u773c\u76ae\u6d6e\u816b \u3002\u4f46\u662f\u514d\u75ab\u5b78\u6aa2\u67e5\u767c\u73feanti -SSA/Ro(-)\u53ca \nanti-SSB/La(-)\u3002\u5176\u65e2\u5f80\u6b77\u4e2d\u6709\u88ab\u8178\u80c3\u79d1\u5c08\u79d1\u91ab\u5e2b\u8a3a\u65b7\u70ba\u80f0\u81df\u708e \u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4e0b\u5217\u4f55\u8005 \uff1f   \nA.Sicca syndrome\nB.IgG4-related disease\nC.Chronic pancreatitis\nD.Lymphoma\nE.Sacoidosis\n": "[B]", "109-154.\u4e0b\u5217\u6709\u95dcaxial spondyloarthritis\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.HLA-B27 (+)\nB.ANA (+)\nC.RFs (+)\nD.\u8170\u9178\u80cc\u75db\u5728\u904b\u52d5\u6642\u6703\u52a0\u5287\nE.Anti-TNF-alpha\u6297\u9ad4\u6cbb\u7642\u7121\u6548\n": "[A]", "109-155.\u4e0b\u5217\u6709\u95dc\u8840\u7ba1\u708e\u75c7\u5019\u7fa4(vasculitis syndrome)\u53ca\u5176\u81e8\u5e8a\u5be6\u52d9\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.Granulomatosis with polyangiitis\u2501serum pANCA(+)\u5c45\u591a\nB.Henoch-Schonlein purpura\u2501serum IgA\u4e0a\u5347\u5c45\u591a\nC.Eosinophilic granulomatosis with polyangiitis\u2501serum cANCA(+)\u5c45\u591a\nD.Giant cell arteritis\u2501\u5c0f\u65bc50\u6b72\u7684\u60a3\u8005\u5c45\u591a\nE.Polyarteritis nodosa\u2501\u76ae\u819a\u5e38\u6703\u5448\u73feleukocytoclastic vasculitis\n": "[B]", "109-156.\u4e0b\u5217\u6709\u95dcosteoarthritis\u7684\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.\u624b\u90e8\u6aa2\u67e5\u6642\u5e38\u53ef\u767c\u73feHeberden\u2019s nodules\nB.\u6700\u5e38\u767c\u751f\u65bc\u624b\u8155\u95dc\u7bc0\nC.\u8840\u4e2d\u767d\u8840\u7403\u8a08\u6578\u5e38\u5e38\u6703\u5347\u9ad8\nD.X-\u5149\u6aa2\u67e5\u5e38\u6703\u6709\u9aa8\u982d\u4fb5\u8755\u767c\u751f\nE.\u9577\u671f\u670d\u7528\u5c11\u91cf\u985e\u56fa\u9187\u6700\u70ba\u6709\u6548\n": "[A]", "109-157.\u4e0b\u5217\u6709\u95dc\u6676\u9ad4\u8a98\u767c\u6027\u95dc\u7bc0\u708e(crystal-associated arthropathies)\u7684\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.Calcium pyrophosphate deposition disease\u901a\u5e38\u767c\u751f\u5728\u5e74\u8f15\u4eba\nB.Calcium apatite\u7d50\u6676\u5728\u504f\u6975\u5149\u986f\u5fae\u93e1\u89c0\u5bdf\u4e0b\u5448\u73fe\u8ca0\u96d9\u5c48\u5149\u6027(negative birefringency)\nC.Calcium oxalate\u7d50\u6676\u7684\u5f62\u6210\u8207\u809d\u529f\u80fd\u7570\u5e38\u6709\u95dc\nD.\u4f7f\u7528allopurinol\u6cbb\u7642\u75db\u98a8\u6642\u5fc5\u9808\u5148\u78ba\u5b9aHLA-B*5801(-)\nE.\u79cb\u6c34\u4ed9\u7d20\u5177\u6709\u964d\u5c3f\u9178\u7684\u6548\u679c   \n": "[D]", "109-158.\u4e00\u4f4d65\u6b72\u5973\u6027\u56e0\u6709\u80ba\u90e8\u611f\u67d3 \uff0c\u7d93\u670d\u7528\u6297\u751f\u7d20\u4e00\u5929\u4e4b\u5f8c \uff0c\u5169\u4e0b\u817f\u90e8\u6709\u6414\u7662\u53ca\u7d05\u8272\u5c0f\u9ede\u51fa\u73fe \u3002\u5c31\u8a3a\u6642\u767c\u73fe\u4e0a\u8ff0\n\u76ae\u819a\u9664\u4e86\u81a8\u9686\u4e4b\u5916 \uff0c\u4ee5\u624b\u6307\u58d3\u4e4b\u4e0d\u6703\u8b8a\u767d \u3002\u91ab\u5e2b\u8a3a\u65b7\u70bavasculitic urticaria \u3002\u8acb\u554f\u6700\u9069\u7576\u7684\u85e5\u7269\u6cbb\u7642\u70ba\u4e0b\u5217\n\u4f55\u8005\uff1f   \nA.Anti-histamine injection\nB.Oral colchicine\nC.Hydroxychloroquine\nD.Dapsone\nE.Systemic corticosteroids\n": "[E]", "109-159.\u6709\u95dcAnti-phospholipid syndrome\u7684\u8a3a\u65b7\u57fa\u6e96\u4e2d \uff0c\u4e0b\u5217\u7684\u90a3\u4e9b\u7d44\u5408\u6700\u70ba\u6b63\u78ba \uff1f\n(1) Deep vein thrombosis (2) cutaneous petechia (3) fetal loss (4) hemolytic anemia (5) \nanti-beta2-GPI\u6297\u9ad4\u967d\u6027 (6) prolong bleeding time (7) premature delivery (8) anti-platelet antibody\u967d\u6027 \n(9) epilepsy (10) arthritis (11) leukocytosis (12) pulmonary hypertension   \nA.(1)+(3)+(5)\nB.(2)+(4)+(8)\nC.(3)+(5)+(10)\nD.(5)+(11)+(12)\nE.(6)+(7)+(9)\n": "[A]", "110-113.60\u6b72\u7684\u5973\u75c5\u60a3\u4e3b\u8a34\u53f3\u819d\u95dc\u7bc0\u816b\u8139\u53ca\u8f15\u5fae\u75bc\u75db\u5df2 2\u9031\u3002\u62bd\u51fa\u95dc\u7bc0\u6db2\u6aa2\u9a57 \uff0c\u5176\u5916\u8868\u9ec3\u8272\u900f\u660e \uff0c\u9ecf\u7a20\n\u5ea6\uff08viscosity \uff09\u9ad8\uff0c\u767d\u8840\u7403\u6fc3\u5ea6\u70ba300 cells /mm\u00b3\u3002\u6700\u9069\u5b9c\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.\u75db\u98a8\u6027\u95dc\u7bc0\u708e\u3002\nB.\u9000\u5316\u6027\u95dc\u7bc0\u708e\u3002\nC.\u7d30\u83cc\u6027\u95dc\u7bc0\u708e\u3002\nD.\u4e7e\u766c\u6027\u95dc\u7bc0\u708e\u3002\nE.\u7d05\u6591\u6027\u72fc\u7621(SLE)\u3002\n": "[B]", "110-114.50\u6b72\u5973\u75c5\u4eba\u4e3b\u8a34\u5169\u5074\u624b\u8155\u95dc\u7bc0\u53ca\u624b\u6307\u95dc\u7bc0\u816b\u75db\u5df2 3 \u500b\u591a\u6708 \u3002\u62bd\u8840\u6aa2\u67e5 \uff0cESR \u53ca CRP \u7686\u660e\u986f\u4e0a\u5347 \uff0c\u4e14\u985e\n\u98a8\u6fd5\u56e0\u5b50\u4e5f\u5448\u967d\u6027 \u3002\u96d9\u624bX \u5149\u4e5f\u767c\u73fe\u95dc\u7bc0\u908a\u7de3\u6027\u8150\u8755\u73fe\u8c61 \u3002\u6b64\u6642\uff0c\u9664\u7d66\u4e88\u6d88\u708e\u6b62\u75db\u5291 \uff08NSAID\uff09\u5916\uff0c\u6700\u9069\n\u5b9c\u518d\u7d66\u4e88\u7684\u85e5\u7269\u70ba\u4e0b\u5217\u90a3\u4e00\u7a2e \uff1f   \nA.methotrexate\u3002\nB.cyclosporine\u3002\nC.cyclophosphamide\u3002   \nD.azathioprine\u3002\nE.Mycophenolate mofetil (MMF)\u3002\n": "[A]", "110-115.\u4e00\u4f4d26\u6b72\u7d05\u6591\u6027\u72fc\u7621\u5973\u6027\u75c5\u4eba \uff0c\u56e0\u9ad8\u71d2\u53ca\u76ae\u819a\u7d05\u75b9\u4f4f\u9662 \uff0c\u7030\u6f2b\u6027\u7d05\u6591\u5206\u5225\u5728\u81c9\u53ca\u80f8\u90e8 \uff0ccomputed \ntomography scan\u986f\u793a\u814b\u4e0b \u3001\u9838\u90e8\u53ca\u4e0a\u9396\u9aa8\u6709\u6dcb\u5df4\u817a\u816b\u8139 \uff0c\u9aa8\u9ad3\u5207\u7247\u6709hemophagocytic cells \uff0c\u4e0b\u5217\u6aa2\u67e5\n\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1fa. \u88dc\u9ad4 b. Ferritin (\u9435\u86cb\u767d) c. ANA\u6297\u6838\u6297\u9ad4 d. \u4e73\u9178\u812b\u6c2b\u9176 (lactate \ndehydrogenase ,LDH)  e. \u4e19\u80fa\u9178\u8f49\u80fa\u9176Alanine transaminase (ALT)   \nA.a+b\u3002\nB.a+c\u3002\nC.b+c\u3002\nD.b+d\u3002\nE.c+d\u3002\n": "[D]", "110-116.\u4e00\u540d27\u6b72\u7537\u6027\u6709\u767c\u71d2 \u3001\u547c\u5438\u9053\u611f\u67d3 \u3001\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3\u4e09\u500b\u6708 \uff0c\u7d93\u6297\u751f\u7d20\u6cbb\u7642\u5f8c \uff0c\u6709\u8f15\u5fae\u6539\u5584 \uff0c\u4f46\u547c\u5438\u56f0\u96e3\n\u6301\u7e8c\uff0c\u9ad8\u89e3\u6790\u5ea6\u96fb\u8166\u65b7\u5c64\u986f\u793a\u4e8c\u5074\u4e0b\u80babilateral ground -glass Haziness (\u5ee3\u6cdb\u6bdb\u73bb\u7483\u6a23\u6a21\u7cca )\u4e8c\u500b\u6708\u5f8c\u4ed6\u958b\n\u59cb\u7121\u6cd5\u5f9e\u5ea7\u6905\u53ca\u8e72\u8e1e\u7ad9\u8d77\u4f86 \uff0c\u4e0b\u5217\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u7279\u5225\u6709\u5e6b\u52a9 \uff1f   \nA.\u4e19\u80fa\u9178\u8f49\u80fa\u9176Alanine transaminase (ALT)\u3002\nB.\u4e73\u9178\u812b\u6c2b\u9176(lactate dehydrogenase,LDH)\u3002\nC.\u808c\u9178\u78f7\u5316\u9175\u7d20Creatine phosphokinase (CPK)\u3002\nD.\u6297\u6838\u6297\u9ad4 (ANA)\u3002\nE.\u8840\u4e2d\u88dc\u9ad4\u3002\n": "[C]", "110-117.\u627f\u63a5\u4e0a\u984c\uff0c\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u6703\u51fa\u73fe\u4e0b\u5217\u5178\u578b\u6297\u9ad4\uff1f    \nA.Anti-RNP\u6297\u9ad4\u3002\nB.Anti-Jo1 \u6297\u9ad4\u3002\nC.Anti-histone \u6297\u9ad4\u3002\nD.Anti-dsDNA\u3002\nE.Anti-Ku \u6297\u9ad4\u3002\n": "[B]", "110-118.\u4e00\u4f4d58\u6b72\u7537\u6027\u56e0\u54b3\u8840 8\u5929\u5f8c\u958b\u59cb\u904b\u52d5\u6027\u547c\u5438\u56f0\u96e3 \uff0c\u80f8\u90e8X\u5149\u986f\u793a\u897f\u5074\u80ba\u90e8\u6709\u6d78\u6f64 \uff0c\u8840\u7d05\u7d205.4g/d\uff0c \u5c0f\u4fbf\u6709\u5927\n\u91cf\u86cb\u767d\u5c3f\u53ca\u51fa\u8840 \uff0c\u808c\u9178\u9150\uff08creatinine \uff097.2mg/dl\uff0c\u4e0b\u5217\u6aa2\u67e5\u6700\u5408\u9069 \uff1f\na. \u4e19\u80fa\u9178\u8f49\u80fa\u9176Alanine transaminase (ALT) \nb. \u6297\u55dc\u4e2d\u6027\u767d\u8840\u7403\u7d30\u80de\u8cea\u6297\u9ad4Anti -neutrophil cytoplasmic antibodies (ANCA)\nc. \u6297\u814e\u7d72\u7403\u57fa\u5e95\u819c\u6297\u9ad4Anti -glomerular basement membrane antibody / GBM Antibody \nd. \u6297\u6838\u6297\u9ad4 (ANA) \ne. \u6297\u5fc3\u78f7\u8102\u6297\u9ad4anticardiolipin antibody   \nA.a+b\u3002\nB.b+c\u3002\nC.c+d\u3002\nD.d+e\u3002\nE.e+a\u3002   \n": "[B]", "110-119.\u627f\u63a5\u4e0a\u984c \uff0c\u6cbb\u7642\u6700\u597d\u7684\u9078\u64c7\u70ba \uff1a\na.\u764c\u5fb7\u661fCyclophosphamide (Endoxan) \nb. \u963f\u65af\u5339\u6797Aspirin low dose\nc.\u79cb\u6c34\u4ed9\u7d20Colchicine\nd.\u985e\u56fa\u9187\u8108\u885d\u6cbb\u7642methyl -prednisolone pulse therapy \ne.\u6297\u751f\u7d20Antibiotics   \nA.a+b\u3002\nB.a+c\u3002\nC.a+d\u3002\nD.a+e\u3002\nE.b+c\u3002\n": "[C]", "110-120.\u4e00\u4f4d58\u6b72\u5973\u6027\u6709\u4e09\u5e74\u5de6\u5074\u7b2c\u4e09\u624b\u6307\u816b\u75db \uff0c\u5de6\u624b\u7b2c\u4e94\u6307\u4e5f\u6709\u816b\u8139 \uff0c\u816b\u8139\u662f\u5f9e\u638c\u6307\u95dc\u7bc0 (MCP)\u5230\u8fd1\u7aef\u6307\u9593\u95dc\n\u7bc0(PIP)\u53ca\u8fd1\u7aef\u6307\u9593\u95dc\u7bc0 (PIP)\u5230\u9060\u7aef\u6307\u9593\u95dc\u7bc0 (DIP)\u4e4b\u9593\uff0c\u5979\u7684\u6307\u7532\u6709\u9ede\u72c0\u51f9\u9677 (pittiy)\uff0c\u6307\u7532\u8b8a\u5f62\u840e\u7e2e\u53ca\u5206\n\u96e2(dystrophy onycholysis )\uff0c\u985e\u98a8\u6fd5\u56e0\u5b50 (RF)\u53caCCP\u6297\u9ad4\u7686\u9670\u6027 \uff0cHLA-B27\u4e5f\u70ba\u9670\u6027 \uff0c\u6b64\u75c5\u4eba\u6700\u6709\u53ef\u80fd\u8a3a\n\u65b7\u70ba\uff1f   \nA.\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e(RA)\u3002\nB.\u4e7e\u766c\u6027\u95dc\u7bc0\u708e(PsA)\u3002\nC.\u50f5\u76f4\u6027\u810a\u690e\u708e(AS)\u3002\nD.\u75db\u98a8\u6027\u95dc\u7bc0\u708e (gouty arthritis)\u3002\nE.\u9000\u5316\u6027\u95dc\u7bc0\u708e (osteoarthritis)\u3002\n": "[B]", "110-121.\u514d\u75ab\u7403\u86cb\u767d G\u975c\u773d\u6ce8\u5c04(Intravenous immunoglobulin G injection)\u5c0d\u65bc\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u6700\u70ba\u6709\u6548\uff1f    \nA.Nephrotic syndrome\u3002\nB.Fulminant hepatitis\u3002\nC.Immune thrombocytopenia\u3002\nD.Thyroid storm\u3002\nE.Acute pulmonary hemorrhage\u3002\n": "[C]", "110-122.\u4e0b\u5217\u6709\u95dc\u75be\u75c5\u8207HLA\u6297\u539f\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u7684\u76f8\u95dc\u6027\u6700\u5927\uff1f    \nA.Rheumatoid arthritis\u2501HLA-DR4\u3002\nB.SLE\u2501HLA-B8\u3002\nC.Behcet\u2019s disease\u2501HLA-DR3\u3002\nD.Sjogren\u2019s syndrome\u2501HLA-B27\u3002\nE.Allopurinol hypersensitivity\u2501HLA-DR2\u3002\n": "[A]", "110-123.21\u6b72\u4e4b\u5973\u6027\u60a3\u8005\u4e3b\u8a34\u70ba\u591a\u767c\u6027\u95dc\u7bc0\u75bc\u75db\u53ca\u53e3\u4e7e\u6709\u4e09\u500b\u6708\u4e4b\u4e45 \uff0c\u670d\u7528\u6d88\u708e\u6b62\u75db\u5291\u6709\u6548 \u3002\u6c42\u8a3a\u5f8c\u624b\u90e8 X-\u5149\u6aa2\u67e5\n\u7121\u7570\u5e38\u6216\u9aa8\u982d\u7834\u58de\u8de1\u8c61 \u3002\u8840\u6e05\u5b78\u6aa2\u67e5\u767c\u73fe: ANA 1: 160X speckled pattern, anti -cardiolipin antibody (+), \nanti-dsDNA antibody (-), ESR 48mm /mL, CRP 0.8 mg/dL, RF 94 IU /mL (normal <20 IU/mL), blood \nroutine: platelet count: 88 ,000/uL, AST 24 U/L, ALT 58 U/L\u3002\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4e0b\u5217\u4f55\u8005 \uff1f   \nA.RA\u3002\nB.SLE\u3002\nC.Ankylosing spondylitis\u3002   \nD.Sjogren\u2019s syndrome\u3002\nE.Autoimmune hepatitis\u3002\n": "[B]", "110-124.48\u6b72\u4e2d\u5e74\u5a66\u5973\u81ea\u53bb\u5e74\u51ac\u5929\u958b\u59cb\u6709\u624b\u6307\u982d\u8b8a\u767d \u3001\u8b8a\u7d2b\u767c\u751f \u3002\u800c\u6700\u8fd1\u66f4\u6709\u6ea2\u9178 \uff0c\u6613\u55c6\u53ca\u541e\u56a5\u56f0\u96e3\u767c\u751f \u3002\u8840\u6e05\u5b78\n\u6aa2\u67e5\u767c\u73fe: ANA : 1:640 speckled pattern\u3002 \u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6297\u9ad4\u6aa2\u67e5\u5c0d\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.Anti-dsDNA\u3002\nB.Anti-phospholipid\u3002\nC.Anti-SSA\u3002\nD.Anti-neutrophil cytoplasmic antibodies\u3002\nE.Anti-Scl-70\u3002\n": "[E]", "110-125.53\u6b72\u7537\u6027\u8fd1 1\u5e74\u4f86\u6709\u773c\u4e7e\u53ca\u53e3\u4e7e\u767c\u751f \u3002\u800c\u4e14\uff0c\u767c\u73fe\u5169\u5074\u816e\u817a\u816b\u5927\u53ca\u773c\u76ae\u6d6e\u816b \u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fe \uff1aANA :1: 40 \n(-), CRP 6.4 mg/dL, anti-SSA (-), anti -SSB(-), amylase 354 U/L, lipase 69 U/L\u3002\u8acb\u554f\u4e0b\u5217\u7684\u4f55\u7a2e\u6aa2\u67e5\u5c0d\n\u75be\u75c5\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.\u816e\u817a\u6d78\u6f64\u6dcb\u5df4\u7403\u7684IgG4\u67d3\u8272\u3002\nB.Serum IgG-RFs\u3002\nC.Serum cryoglobulin M\u5b9a\u91cf\u3002\nD.Anti-EB viral antibody\u3002\nE.Sialoscintigraphy\u6aa2\u67e5\u3002\n": "[A]", "110-126.\u4e0b\u5217\u6709\u95dc\u8840\u7ba1\u708e\u53ca\u5176\u75c5\u7406\u6a5f\u5236\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.Microscopic polyangiitis \u2501 immune complex deposition\u3002\nB.Eosinophic granulomatosis with polyangiitis\u2501MPO-ANCA (-)\u3002\nC.Granulomatosis with polyangiitis \u2501 proteinase 3-ANCA (+)\u3002\nD.Henoch-Schonlein purpura\u2501IgM cryoglobulinemia-induced\u3002\nE.Giant cell arteritis\u2501chronic hepatitis C infection\u3002\n": "[C]", "110-127.\u4e0b\u5217\u4f55\u7a2e\u81e8\u5e8a\u8868\u5fb5\u53ca\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7570\u5e38 \uff0c\u53ef\u4ee5\u4f5c\u70baSLE\u7684\u5206\u985e\u57fa\u6e96 (classification criteria )?(1) discoid skin \nrash (2) erosive arthritis (3) anti-beta 2 glycoprotein I antibody  (4) pleural effusion  (5) acute uveitis  (6) \nleukocytosis  (7) bipolar mental disorder (8) acute renal tubular acidosis   \nA.(2)+(4)+(5)\u3002\nB.(3)+(5)+(7)\u3002\nC.(1)+(6)+(8)\u3002\nD.(4)+(5)+(6)\u3002\nE.(1)+(3)+(4)\u3002\n": "[E]", "110-128.\u4e0b\u5217\u4f55\u8005\u662fRheumatoid arthritis\u7684\u95dc\u7bc0\u5916\u75c7\u72c0 (extra-articular manifestations )?(1) xerostomia  (2) \nepiscleritis  (3) osteophyte  (4) hyperthyroidism (5) secondary amyloidosis (6) periodontitis (7) vasculitis  \n(8) polycythemia vera   \nA.(1)+(3)+(4)\u3002\nB.(5)+(6)+(8)\u3002\nC.(2)+(5)+(8)\u3002\nD.(2)+(6)+(7)\u3002   \nE.(4)+(7)+(8)\u3002\n": "[D]", "111-113.\u4e00\u4f4d30\u6b72\u5973\u6027\u6253\u5b8cCOVID -19\u75ab\u82d710\u5929\u5f8c\u958b\u59cb\u982d\u75db \uff0c\u7d93\u6aa2\u67e5\u5f8c\u78ba\u5b9a\u6709\u75ab\u82d7\u5f15\u8d77\u8840\u6813\u585e (thrombosis )\uff0c\u4e0b\u5217\n\u4f55\u7a2e\u75ab\u82d7\u8f03\u6613\u5f15\u8d77\u6b64\u526f\u4f5c\u7528 \uff1f      \nA.\u6838\u9178\u75ab\u82d7(mRNA Vaccine)\u3002\nB.\u75c5\u6bd2\u8f09\u9ad4\u75ab\u82d7(Viral Vector Vaccine)\u3002\nC.\u86cb\u767d\u8cea\u6b21\u55ae\u4f4d\u75ab\u82d7(Protein Subunit Vaccine)\u3002\nD.\u4e0d\u6d3b\u52d5\u75ab\u82d7(Inactivated Vaccine)\u3002\nE.\u6e1b\u6bd2\u75ab\u82d7(Live- Attenuated Vaccine)\u3002\n": "[B]", "111-114.\u627f\u63a5\u4e0a\u984c\uff0c\u6b64\u75c5\u4eba\u56e0\u75ab\u82d7\u5f15\u8d77\u7684\u6813\u585e\u5176\u6a5f\u8f49\u8207\u4e0b\u5217\u4f55\u7a2e\u8840\u6db2\u7d30\u80de\u7684\u6210\u4efd\u6297\u9ad4\u6709\u95dc\uff1f    \nA.\u767d\u8840\u7403(Leukocyte)\u3002\nB.\u8840\u5c0f\u677f(Platelet)\u3002\nC.\u6dcb\u5df4\u7403(Lymphocyte)\u3002\nD.\u5de8\u566c\u7d30\u80de(Macrophage)\u3002\nE.\u55dc\u4f0a\u7d05\u6027\u767d\u8840\u7403(Eosinophil)\u3002\n": "[B]", "111-115.\u4e00\u4f4d30\u6b72\u5973\u6027\u767c\u71d2\u4e00\u500b\u6708\u5408\u4f75\u591a\u8655\u95dc\u7bc0\u75db\u53ca\u53e3\u8154\u6f70\u760d \uff0c\u4f9d\u64da2019 EULAR /ACR\u8a3a\u65b7\u7d05\u6591\u6027\u72fc\u7621\u4e4b\u689d\n\u4ef6\uff0c\u4e0b\u5217\u6297\u9ad4\u6aa2\u67e5\u5c07\u6709\u5e6b\u52a9\u8a3a\u65b7 \uff1f   \nA.\u6297RNP\u6297\u9ad4(Anti-RNP Antibody)\u3002\nB.\u6297\u78f7\u8102\u6297\u9ad4(Anti-Phospholipid Antibody)\u3002\nC.\u6297SS-A/RO\u6297\u9ad4(Anti-SS-A/RO Antibody)\u3002\nD.\u6297SS-B/LA\u6297\u9ad4(Anti-SS-B/LA Antibody)\u3002\nE.\u6297\u7d44\u7e54\u86cb\u767d\u6297\u9ad4(Anti-histone Antibody)\u3002\n": "[B]", "111-116.\u4e00\u4f4d60\u6b72\u5973\u6027\u4e3b\u8a34\u591a\u8655\u95dc\u7bc0\u708e \uff0c\u5305\u62ec\u624b\u8155 \u3001\u8fd1\u7aef\u624b\u6307\u95dc\u7bc0\u708e\u53ca\u819d\u95dc\u7bc0\u708e \uff0c\u4e0b\u5217\u5169\u7a2e\u5be6\u9a57\u5ba4\u6aa2\u67e5\u5df2\u6210\u70ba\u8a3a\u65b7\n\u985e\u98a8\u6fd5\u6027\u95dc\u7bc0\u708e\u4e4b\u5e38\u7528\u6aa2\u67e5 \uff1f\n(1) \u6297\u6838\u6297\u9ad4   \n(2) \u985e\u98a8\u6fd5\u6027\u56e0\u5b50   \n(3) \u6297SS-A/RO\u6297\u9ad4   \n(4) \u6297\u74dc\u6c28\u9178\u6297\u9ad4 (Anti-citrullinated protein Antibodies)   \n(5) \u6297SS-B/LA\u6297\u9ad4   \nA.(1)+(2)\u3002\nB.(1)+(3)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(2)+(4)\u3002\n": "[E]", "111-117.\u4e00\u4f4d30\u6b72\u7537\u6027\u4e3b\u8a34\u4e0b\u80cc\u75db\u4e00\u5e74 \uff0c\u6700\u8fd1\u5de6\u819d\u95dc\u7bc0\u816b\u4e8c\u500b\u6708 \uff0c\u904e\u53bb\u6709\u524d\u8461\u8404\u819c\u708e (anterior uveitis )\u75c5\u53f2\uff0c\u75c5\u4eba\n\u6709\u62bd\u83f8\u4e00\u5929\u4e00\u5305\u5df2\u7d93\u62bd\u83f8\u4e94\u5e74 \uff0c\u4e0b\u5217\u6aa2\u67e5\u5c0d\u6b64\u75c5\u4eba\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f \n(1) \u6297\u6838\u6297\u9ad4 (ANA)   \n(2) \u7279\u5225\u4eba\u985e\u767d\u8840\u7403\u6297\u539f\u6aa2\u67e5 (HLA)   \n(3) C-\u53cd\u61c9\u86cb\u767d (CRP)   \n(4) \u6297RNP\u6297\u9ad4   \n(5) \u5c3f\u9178\u6aa2\u6e2c   \nA.(1)+(2)\u3002\nB.(2)+(3)\u3002\nC.(3)+(4)\u3002   \nD.(4)+(5)\u3002\nE.(1)+(5)\u3002\n": "[B]", "111-118.\u4e00\u4f4d50\u6b72\u5973\u6027\u4e3b\u8a34\u773c\u4e7e\u53ca\u53e3\u4e7e \uff0c\u904e\u53bb\u66fe\u6709\u816e\u817a\u816b\u5927\u4e4b\u75c5\u53f2 \uff0c\u88ab\u8a3a\u65b7\u70ba\u4e7e\u71e5\u75c7 \uff0c\u4e0b\u5217\u4f55\u8005\u7570\u5e38\u6700\u6709\u53ef\u80fd\u6703\u7522\n\u751f\u6dcb\u5df4\u7624 \uff1f   \nA.\u7d05\u8840\u7403\u4e0b\u964d\u901f\u5ea6\u589e\u52a0(ESR)\u3002\nB.\u8ca7\u8840\u3002\nC.\u9577\u671f\u816e\u817a\u816b\u5927\u3002\nD.\u95dc\u7bc0\u75db\u3002\nE.\u809d\u529f\u80fd\u7570\u5e38\u3002\n": "[C]", "111-119.\u4e00\u4f4d45\u6b72\u7537\u6027\u7a81\u7136\u53f3\u8173\u8e1d\u816b\u75db\uff0c\u7121\u6cd5\u8d70\u8def\uff0c\u75c5\u4eba\u7121\u53d7\u50b7\u4e4b\u75c5\u53f2\uff0c\u4e0b\u5217\u6aa2\u67e5\u6700\u6709\u5e6b\u52a9\u8a3a\u65b7\uff1f    \nA.\u985e\u98a8\u6fd5\u6027\u56e0\u5b50\u3002\nB.\u6297\u6838\u6297\u9ad4\u3002\nC.X-Ray\u6aa2\u67e5\u3002\nD.\u95dc\u7bc0\u8154\u6db2\u6aa2\u67e5\u3002\nE.\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002\n": "[D]", "111-120.\u4e00\u4f4d55\u6b72\u5973\u6027\u4e3b\u8a34\u547c\u5438\u56f0\u96e3\u4e8c\u9031 \uff0c\u516d\u500b\u6708\u524d\u5728\u773c\u77bc\u6709\u7d05\u6591\u5408\u4f75\u6c34\u816b \uff0c\u81c9\u90e8\u53ca\u524d\u80f8\u4e5f\u6709\u7d05\u6591 \uff0c\u5728\u624b\u80cc\u3001\u6307\u95dc\n\u7bc0\u6709\u812b\u5c51\u76ae\u75b9 \uff0c\u4e0b\u80a2\u808c\u8089\u7121\u529b \uff0c\u75c5\u4eba\u56e0\u547c\u5438\u56f0\u96e3\u4f4f\u9032ICU\u4f7f\u7528\u547c\u5438\u5668 \uff0c\u4e0b\u5217\u6297\u9ad4\u6aa2\u67e5\u5c0d\u75c5\u4eba\u4e4b\u8a3a\u65b7\u53ca\u75c5\u60c5\n\u9810\u5f8c\u6700\u6709\u5e6b\u52a9 \uff1f   \nA.\u6297RNP\u6297\u9ad4\u3002\nB.\u6297MDA5\u6297\u9ad4\u3002\nC.\u6297Scl-70\u6297\u9ad4\u3002\nD.\u6297SS-A/RO\u6297\u9ad4\u3002\nE.\u6297SS-B/LA\u6297\u9ad4\u3002\n": "[B]", "111-121.\u4e0b\u5217\u6709\u95dcHLA loci\u8207\u514d\u75ab\u76f8\u95dc\u75be\u75c5\u4e4b\u9593\u7684\u95dc\u806f\u6027\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u5f37\u70c8\uff1f    \nA.SLE\u2014HLA-DR2\u3002\nB.Ankylosing spondylitis \u2014HLA-B27\u3002\nC.Myasthenia gravis \u2014HLA-B8\u3002\nD.Behcet's disease \u2014HLA-B51\u3002\nE.Chronic active hepatitis \u2014HLA-DR3\u3002\n": "[B]", "111-122.\u4e0b\u5217\u6709\u95dc\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\u8207\u81ea\u9ad4\u6297\u9ad4\u4e4b\u9593\u7684\u914d\u5c0d\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.Hashimoto's thyroiditis \u2014anti-TSH receptor antibody\u3002\nB.Granulomatosis with polyangiitis--anti-proteinase 3 antibody\u3002\nC.Systemic lupus erythematosis (SLE) \u2014anti-C3 antibody\u3002\nD.Rheumatoid arthritis (RA) \u2014anti-IgM antibody\u3002\nE.Systemic sclerosis \u2014anti-epidermal cadhedin antibody\u3002\n": "[B]", "111-123.\u4e0b\u5217\u4f55\u8005\u662frheumatoid arthritis\u6700\u5e38\u898b\u7684\u95dc\u7bc0\u5916\u8868\u73fe\uff1f    \nA.Vasculitis\u3002   \nB.Non-specific Interstitial pneumonia\u3002\nC.Subcutaneous nodule\u3002\nD.Cervical myelopathy\u3002\nE.Uveitis\u3002\n": "[C]", "111-124.\u4e0b\u5217\u6709\u95dcsystemic sclerosis\u7684\u81e8\u5e8a\u75c7\u72c0\u63cf\u8ff0\u4e2d\uff0c\u4f55\u8005\u6700\u70ba\u6b63\u78ba\uff1f    \nA.\u76ae\u819a\u5e38\u6703\u51fa\u73fe\u6ebc\u75b9\u6027\u8b8a\u5316\u3002\nB.\u6613\u767c\u751f\u5fc3\u8840\u7ba1\u75c5\u8b8a\u3002\nC.\u5e38\u6703\u5f15\u8d77\u9593\u8cea\u6027\u814e\u708e\u3002\nD.\u80ba\u764c\u7684\u6bd4\u4f8b\u589e\u52a0\u3002\nE.\u6700\u5e38\u898b\u7684\u521d\u59cb\u75c7\u72c0\u70baRaynaud's phenomenon\u3002\n": "[E]", "111-125.\u4e0b\u5217\u4f55\u8005\u662fSjogren's syndrome\u7684\u817a\u9ad4\u5916(extra-glandular)\u4f75\u767c\u75c7\u4e4b\u4e00\uff1f    \nA.Uveitis\u3002\nB.Chronic pancreatitis\u3002\nC.Retroperitoneal fibrosis\u3002\nD.Renal tubular acidosis\u3002\nE.Anemia\u3002\n": "[D]", "111-126.\u6cbb\u7642axial spondyloarthritis\u7684\u6700\u6709\u6548\u7684\u85e5\u7269\u70ba\u4e0b\u5217\u4f55\u8005\uff1f    \nA.Salazopyrin\u3002\nB.Methotrexate\u3002\nC.Anti-TNF-alpha therapy\u3002\nD.Corticosteroids\u3002\nE.Cyclosporine\u3002\n": "[C]", "111-127.SLE\u7684\u8a3a\u65b7\u662f\u6839\u64da\u81e8\u5e8a\u75c7\u72c0\u53ca\u514d\u75ab\u8840\u6e05\u5b78\u6aa2\u67e5\u5169\u90e8\u5206 \u3002\u8acb\u554f\u4e0b\u5217\u7684\u90a3\u4e9b \u9805\u76ee\u5305\u62ec\u5728\u5167 \uff1f\n(1) Oral mucosa ulcer (2) scaring alopecia (3) discoid skin lesion (4) pleural effusion (5) myalgia (6) \nschizophrenia (7) low serum complements (8) anti-Sm antibody (9) anti-beta glycoprotein I antibody (10) \nhemolytic anemia (11) anti-ribonuclear protein antibody (12) thrombocytopenia   \nA.(1)+(2)+(7)\u3002\nB.(3)+(4)+(11)\u3002\nC.(5)+(8)+(9)\u3002\nD.(3)+(7)+(10)\u3002\nE.(3)+(11)+(12)\u3002\n": "[D]", "111-128.\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\u5c6c\u65bcanti -neutrophil cytoplasmic antibody (ANCA)\u967d\u6027\u7684\u8840 \u7ba1\u708e\u75c7\u5019\u7fa4 \uff1f\n(1) granulomatosis with polyangiitis (2) hepatitis C virus -associated vasculitis (3) microscopic \npolyangiitis (4) eosinophilic granulomatosis with polyangiitis (5) lupus vasculitis (6) giant cell arteritis (7) \ndrug-induced vasculitis (8) Behcet's disease (9) IgA-induced vasculitis (10) Takayasu arteritis   \nA.(3)+(4)+(5)\u3002\nB.(6)+(7)+(8)\u3002\nC.(1)+(2)+(6)\u3002   \nD.(7)+(8)+(9)\u3002\nE.(1)+(3)+(4)\u3002\n": "[E]", "100-1.\n\u4e00\u4f4d58\u6b72\u5a66\u5973\uff0c\u56e0\u70ba\u5169\u908a\u5c0f\u817f\u7600\u9752\u53ca\u816b\u8139\u75bc\u75db\u61c9\u8a3a\uff0c\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20 12.1 g/dL\uff0c\u767d\u8840\u7403 8,290/\u03bcL\uff0c\u8840\u5c0f\u677f 225,000/\u03bcL\uff0cPT 11.3\"(\u6b63\u5e388.0-12.2)\uff0cINR 1.02\uff0caPTT 77.3\"(\u6b63\u5e3826.9-36.3)\u3002\u5c07\u75c5\u4eba\u8207\u6b63\u5e38\u4e4b\u8840\u6f3f\u4ee51:1\u505a\u6df7\u5408\u8a66\u9a57\uff0c\u958b\u59cb\u6642aPTT\u70ba39.2\"\uff0c1\u5c0f\u6642\u5f8c51.2\"\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Antiphospholipid antibody syndrome\nB. Acquired hemophilia\nC. von Willebrand disease\nD. Warfarin overdose\nE. Liver function impairment\n": "(B)", "100-2.\n\u4e00\u4f4d45\u6b72\u7537\u6027\uff0c\u904e\u53bb\u66fe\u56e0\u70ba\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u63a5\u53d7\u4e8c\u5c16\u74e3\u74e3\u819c\u7f6e\u63db\u8853\uff0c\u5176\u4ed6\u7121\u7279\u6b8a\u75c5\u53f2\u3002\u6700\u8fd1\u62bd\u8840\u767c\u73fe\u8840\u7d05\u7d20 8.2 g/dL\uff0cMCV 108 fL\uff0c\u767d\u8840\u7403 9,650/\u03bcL\uff0c\u8840\u5c0f\u677f 209,000/\u03bcL\uff0cbilirubin\u5168\u91cf(total) 5.1 mg/dL\uff0c\u76f4\u63a5\u578b(direct) 0.80 mg/dL\uff0cGOT 234 IU/L\uff0cGPT 36 IU/L\uff0cLDH 4,300 IU/L\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u3002\u6b64\u75c5\u4eba\u8ca7\u8840\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba\u4f55\uff1f\nA. Anemia related to liver disease\nB. Iron deficiency anemia\nC. Autoimmune hemolytic anemia\nD. Mechanical hemolytic anemia\nE. Thalassemia\n": "(D)", "100-3.\n\u4e00\u4f4d57\u6b72\u75c5\u4eba\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20 5 g/dL\uff0c\u7d05\u8840\u7403 1,655,000/\u03bcL\uff0c\u7db2\u72c0\u7d05\u8840\u7403 0.5%\uff0c\u767d\u8840\u7403 2,450/\u03bcL\uff0c\u4e2d\u6027\u9846\u7c92\u7403 20%\uff0c\u8840\u5c0f\u677f 16,000/\u03bcL\uff0c\u9aa8\u9ad3\u6aa2\u67e5\u8a3c\u5be6\u70ba\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\uff0c\u7d30\u80de\u7d50\u69cb\u4f54 5%\u3002\u5c0d\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\uff1f\nA. Anti-thymocyte globulin plus cyclosporine\nB. Anabolic hormone\nC. Steroids\nD. Azathioprine\nE. Allogeneic hematopoietic stem cell transplantation\n": "(A)", "100-4.\n\u4ee5\u4e0b\u5404\u75be\u75c5\u53ca\u5176\u6cbb\u7642\u85e5\u7269\u4e4b\u914d\u5c0d\u4f55\u8005\u6709\u8aa4\uff1f\nA. Acute promyeloctyic leukemia-tretinoin\nB. Chronic myeloid leukemia-imatinib\nC. Follicular lymphoma-rituximab\nD. Multiple myeloma-bortezomib\nE. Essential thrombocythemia-bevacizumab\n": "(E)", "100-5.\n\u4e0b\u5217\u4f55\u7a2e\u6210\u4eba\u8840\u6db2\u60e1\u6027\u75c5\u5728\u9054\u5230\u7de9\u89e3\u6642\u61c9\u8003\u616e\u79fb\u690d\uff0c\u4ee5\u589e\u52a0\u75c5\u4eba\u7684\u5b58\u6d3b\uff1f\nA. Acute lymphoblastic leukemia with t(9;22)\nB. Acute lymphoblastic leukemia with t(12;21)\nC. Acute lymphoblastic leukemia with t(8;21)\nD. Acute lymphoblastic leukemia with inv(16)\nE. Acute lymphoblastic leukemia with t(15;17)\n": "(A)", "100-6.\n\u4e00\u4f4d62\u6b72\u5973\u6027\uff0c\u904e\u53bb\u7121\u5168\u8eab\u6027\u75be\u75c5\u75c5\u53f2\uff0c\u56e0\u70ba\u75b2\u5026\u53ca\u80cc\u75db\u61c9\u8a3a\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20 8.3 g/dL\uff0c\u767d\u8840\u7403 8,650/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f 165,000/\u03bcL\uff0c\u767d\u86cb\u767d 3.4 g/dL\uff0c\u7403\u86cb\u767d 2.1 g/dL\uff0cCa 2.83 mmol/L\uff0cCr 2.6 mg/dL\uff0cUA 6.6 mg/dL\uff0c\u809d\u529f\u80fd\u6b63\u5e38\uff0c\u5c3f\u86cb\u767d1+\uff0c\u7121\u8840\u5c3f\u6216\u81bf\u5c3f\uff0cX-\u5149\u6aa2\u67e5\u5982\u5716\u6240\u793a\u3002\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u7684\u6aa2\u67e5\u70ba\u4f55\uff1f\nA. Renal sonogram\nB. Kidney biopsy\nC. Bone Scan\nD. Blood and urine immunoelectrophoresis\nE. Parathyroid hormone level\n": "(D)", "100-7.\n\u4e0b\u5217\u8207\u539f\u767c\u6027\u591a\u8840\u75c7(polycythemia vera)\u75c5\u4eba\u76f8\u95dc\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f\nA. \u591a\u6709JAK2\u57fa\u56e0\u7a81\u8b8a\nB. \u8840\u4e2derythropoietin\u6fc3\u5ea6\u4e0b\u964d\nC. \u5e38\u4f34\u96a8\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u76ee\u589e\u52a0\nD. \u767c\u751f\u6813\u585e\u7684\u6a5f\u6703\u8f03\u4e00\u822c\u4eba\u9ad8\nE. LAP\u6578\u503c\u5e38\u4e0b\u964d\n": "(E)", "100-8.\n\u4e00\u4f4d55\u6b72\u5973\u6027\uff0c\u56e0\u76ae\u819a\u7600\u9752\u61c9\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u7121\u5176\u4ed6\u90e8\u4f4d\u51fa\u8840\u73fe\u8c61\u3002\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20 12.5 g/dL\uff0c\u767d\u8840\u7403 4,350/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f 15,000/\u03bcL\u3002\u9aa8\u9ad3\u6aa2\u67e5\u8a3c\u5be6\u70ba\u514d\u75ab\u6027\u8840\u5c0f\u677f\u7f3a\u4e4f\u6027\u7d2b\u6591\u75c7\u3002\u6b64\u6642\u61c9\u9078\u64c7\u4f55\u7a2e\u6cbb\u7642\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r(1)\u8f38\u6ce8\u8840\u5c0f\u677f\u6fc3\u7e2e\u6db2\r(2)\u985e\u56fa\u9187\r(3)\u514d\u75ab\u7403\u86cb\u767d\nA. 1\nB. 2\nC. 3\nD. 1+2\nE. 1+2+3\n": "(B)", "100-9.\n\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u4eba\u6709\u4e0b\u5217\u4f55\u7a2e\u57fa\u56e0\u7570\u5e38\u8005\u9810\u5f8c\u8f03\u597d\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r(1)NPM1mutation\r(2)FLT3-ITD\r(3)CEBPA mutation\r(4)MLL rearrangement\nA. 1\nB. 1+2\nC. 1+3\nD. 1+4\nE. 1+2+3\n": "(C)", "100-10.\n\u4e0b\u5217\u4f55\u8005\u70bahemophagocytic syndrome\u5e38\u898b\u7684\u81e8\u5e8a\u8868\u73fe?(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.fever\r2.pancytopenia\r3.hyperferritinemia\r4.high LDH level\nA. 1\nB. 1+2\nC. 1+4\nD. 1+2+3\nE. 1+2+3+4\n": "(E)", "100-1.\n\u4e0b\u5217\u4f55\u8005\u5c6c\u65bc\u764c\u75c7\u6cbb\u7642\u5f8c\u816b\u7624\u6eb6\u89e3\u75c7\u5019\u7fa4\uff08tumor lysis syndrome\uff09\u7684\u7279\u5fb5\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.hyperuricemia\r2.hyperphosphatemia\r3.hyperkalemia\r4.hypercalcemia\r5.lactic acidosis\nA. 1+2+4\nB. 1+3+4\nC. 1+4+5\nD. 1+2+3+5\nE. 2+3+4+5\n": "(D)", "100-2.\n\u4e0b\u5217\u4f55\u8005\u6703\u5f15\u8d77\u4eba\u985e\u7684\u6dcb\u5df4\u60e1\u6027\u75be\u75c5\uff08lymphoid malignancy\uff09\u7684\u767c\u751f\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.Helicobacter pylori \u611f\u67d3\r2.Hepatitis B virus\uff08HBV\uff09\u611f\u67d3\r3.Celiac sprue\r4.Human herpes virus 8\uff08HHV8\uff09\u611f\u67d3\r5.Epstein-Barr virus\uff08EBV\uff09\u611f\u67d3\nA. 1+2+3\nB. 1+2+4\nC. 1+2+4+5\nD. 1+3+4+5\nE. 1+2+3+4+5\n": "(D)", "100-3.\n\u4ee5\u4e0b\u5404\u75c7\u5019\u7fa4\uff08syndrome\uff09\u8207\u764c\u75c7\u7684\u767c\u751f\u7387\u589e\u52a0\u6709\u95dc\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. von Hippel-Lindau syndrome\nB. Fragile X syndrome\nC. Ataxia telangiectasia\nD. Neurofibromatosis, type II\nE. Bloom syndrome\n": "(B)", "100-4.\n\u4e00\u4f4d\u8eab\u9ad4\u5411\u4f86\u5065\u5eb7\u768460\u6b72\u5973\u6027\u63a5\u53d7\u4f8b\u884c\u6027\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\uff08colonoscopy\uff09\uff0c\u5728\u6a6b\u7d50\u8178\u767c\u73fe\u4e00\u500b1.5\u516c\u5206\u5927\u5c0f\u4e4b\u7121\u67c4\u7684\u6241\u5e73\u6027\uff08sessile, flat-based\uff09\u606f\u8089\uff0c\u9806\u5229\u9032\u884c\u606f\u8089\u5207\u9664\uff0c\u75c5\u7406\u6aa2\u67e5\u7d50\u679c\u70ba\u817a\u7624\u6027\u606f\u8089\uff08villous adenoma\uff09\uff0c\u4e26\u672a\u767c\u73fe\u60e1\u6027\u8b8a\u5316\u3002\u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u8655\u7f6e\u65b9\u5f0f\u8f03\u9069\u7576\uff1f\nA. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\uff08CT\uff09\u6383\u63cf\u6aa2\u67e5\nB. \u90e8\u5206\u7d50\u8178\u5207\u9664\u8853\uff08partial colectomy\uff09\nC. 10\u5e74\u5f8c\uff0c\u518d\u9032\u884c\u4e00\u6b21\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\nD. 3\u5e74\u5f8c\uff0c\u518d\u9032\u884c\u4e00\u6b21\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\nE. 3\u500b\u6708\u5f8c\uff0c\u518d\u9032\u884c\u4e00\u6b21\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\n": "(D)", "100-5.\n\u4e0b\u5217\u54ea\u4e00\u7a2e\u6a19\u9776\u6216\u5316\u5b78\u6cbb\u7642\u8207\u76f8\u95dc\u526f\u4f5c\u7528\u7684\u914d\u5c0d\u662f\u4e0d\u6b63\u78ba\u7684\uff1f\nA. Ifosfamide \uff0d Fanconi-like syndrome\nB. Cyclophosphamide \uff0d hematuria\nC. Trastuzumab plus doxorubicin \uff0d heart failure\nD. Bevacizumab \uff0d hypertension, proteinuria\nE. Cisplatin \uff0d liver toxicity\n": "(E)", "100-6.\n\u764c\u75c7\u75c5\u4eba\u5408\u4f75\u9ad4\u6db2\u6027\u9ad8\u8840\u9223\u75c7\uff08humoral hypercalcemia of malignancy , HHM\uff09\uff0c\u6700\u5e38\u898b\u7684\u539f\u56e0\u70ba\u4f55\uff1f\nA. \u816b\u7624\u7d30\u80de\u5c0d\u9aa8\u9abc\u7684\u76f4\u63a5\u7834\u58de\nB. Parathyroid hormone\uff08PTH\uff09\u7684\u904e\u5ea6\u88fd\u9020\u5206\u6ccc\nC. 1, 25-hydroxyvitamin D\u7684\u6fc3\u5ea6\u4e0a\u5347\nD. Parathyroid hormone-related peptide\uff08PTHrP\uff09\u7684\u904e\u5ea6\u88fd\u9020\u5206\u6ccc\nE. \u9aa8\u9abc\u8f49\u79fb\u5f15\u8d77\u5c40\u90e8TNF\uff08tumor necrosis factor\uff09\u8207IL-6\u7684\u5206\u6ccc\n": "(D)", "100-7.\n\u6709\u95dc\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u7684\u4e0a\u76ae\u764c\uff08Carcinoma of unknown primary, CUP\uff09\uff0c\u6709\u6642\u9664\u4e86\u75c5\u7406\u7d44\u7e54\u7684H&E\u67d3\u8272\u578b\u614b\u4e4b\u5916\uff0c\u9700\u501f\u52a9\u65bc\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272\u4f86\u5354\u52a9\u5224\u65b7CUP\u7684\u539f\u767c\u5668\u5b98\u3002\u4e0b\u5217\u54ea\u4e00\u7a2e\u6a19\u8a18\u7684\u6297\u9ad4\u6838\u67d3\u8272\u7d04\u670968%\u80ba\u817a\u764c(adenocarcinoma of the lung) \u5448\u967d\u6027\u820725%\u7684\u80ba\u9c57\u72c0\u4e0a\u76ae\u764c(squamous cell carcinoma of the lung)\u5448\u967d\u6027\uff0c\u7d93\u5e38\u505a\u70ba\u80ba\u81df\u70baCUP\u539f\u767c\u5668\u5b98\u4e4b\u9451\u5225\u8a3a\u65b7\u8f14\u52a9\u6a19\u8a18\u4e4b\u3127\uff1f\nA. Thyroglobulin\nB. Thyroid transcription factor 1 (TTF-1)\nC. CDX-2 transcription factor (CDX-2)\nD. Cytokeratin (CK)\nE. Leucocyte common antigen (LCA)\n": "(B)", "100-8.\n\u4e0b\u5217\u4f55\u7a2e\u539f\u767c\u5668\u5b98\u7522\u751f\u7684\u764c\u75c7\uff0c\u8f49\u79fb(metastasis)\u81f3\u9aa8\u9abc\u7cfb\u7d71\u76f8\u5c0d\u6a5f\u6703\u6700\u4f4e\uff1f\nA. Lung\nB. Prostate\nC. Colon\nD. Breast\nE. Kidney\n": "(C)", "100-9.\n\u4e0b\u5217\u764c\u75c7\u5747\u7d93\u5e38\u8f49\u79fb(metastasis)\u81f3\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\uff0c\u4f55\u8005\u76f8\u5c0d\u6a5f\u6703\u6700\u4f4e\uff1f\nA. Breast cancer\nB. Melanoma\nC. Acute lymphoblastic leukemia\uff08ALL\uff09\nD. Kidney cancer\nE. Hodgkin's disease\n": "(E)", "100-10.\n\u4e00\u4f4d65\u6b72\u7537\u6027\uff0c\u7121\u5176\u4ed6\u7279\u6b8a\u75be\u75c5\uff0c\u56e0\u61f7\u7591\u7f79\u60a3\u76f4\u8178\u764c(rectal cancer)\uff0c\u800c\u63a5\u53d7\u5927\u8178\u5167\u8996\u93e1\u6aa2\u67e5\uff0c\u767c\u73fe\u6709\u4e004\u00d73\u516c\u5206\u816b\u7624\uff0c\u816b\u7624\u4e0b\u7de3\u8dddanal verge\u50c53\u516c\u5206\uff0c\u75c5\u7406\u5207\u7247\u6aa2\u67e5\u767c\u73fe\u4e2d\u7b49\u5206\u5316\u4e4b\u817a\u764c\uff0c\u4e26\u7121\u5176\u4ed6\u4e4b\u5668\u5b98\u8f49\u79fb\uff0c CEA\u70ba15.0 ng/mL\u3002\u76f4\u8178\u816b\u7624\u7d93\u624b\u8853\u5207\u9664(abdomino-perineal resection)\uff0c\u75c5\u7406\u6aa2\u67e5\u816b\u7624\u5df2\u4fb5\u72af\u81f3\u6f3f\u819c\u5c64 (serosa)\u5916\uff0c15\u9846\u5c40\u90e8\u6dcb\u5df4\u7d50\u5176\u4e2d7\u9846\u6709\u764c\u7d30\u80de\u8f49\u79fb\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u8f03\u70ba\u9069\u7576\uff1f\nA. \u8f14\u52a9\u6027(adjuvant)\u5316\u5b78\u6cbb\u7642\u53ca\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u5747\u4e0d\u61c9\u8003\u616e\u7d66\u8207\nB. \u61c9\u8003\u616e\u7d66\u8207\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\uff0c\u4f46\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\u4e0d\u61c9\u8003\u616e\u7d66\u8207\nC. \u61c9\u8003\u616e\u7d66\u8207\u8f14\u52a9\u6027\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4f46\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u4e0d\u61c9\u8003\u616e\u7d66\u8207\nD. \u61c9\u8003\u616e\u7d93\u809d\u52d5\u8108\u7d66\u8207\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u4ee5\u9810\u9632\u809d\u81df\u8f49\u79fb\nE. \u61c9\u8003\u616e\u7d66\u8207\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u53ca\u8f14\u52a9\u6027\u653e\u5c04\u6cbb\u7642\n": "(E)", "101-1.\n\u4e00\u4f4d23\u6b72\u7537\u6027\u904e\u53bb\u7121\u7279\u6b8a\u4e0d\u9069\uff0c\u5728\u7576\u5175\u524d\u9ad4\u6aa2\u767c\u73fe\u8f15\u5fae\u8ca7\u8840\u53ca\u9ec3\u75b8\uff0cHb 11.1 gm/dL, WBC 5990/uL\uff0cplatelet 172000/uL\uff0cbilirubin\u5168\u91cf4.1 mg/dL\uff0c\u76f4\u63a5\u578b0.61 mg/dL\uff0c\u5468\u908a\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u6b64\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Thalassemia\nB. Hereditary spherocytosis\nC. G6PD deficiency\nD. Chronic hepatitis\nE. Gilbert's disease\n": "(B)", "101-2.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u70ba\u62d4\u7259\u6d41\u8840\u4e0d\u6b62\u4f86\u5230\u6025\u8a3a\u8655\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff0c\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4f55\u7a2e\u75c5\uff1f\nA. Lymphoma\nB. Chronic myeloid leukemia\nC. Acute lymphoblastic leukemia\nD. Acute promyelocytic leukemia\nE. Acute monocytic leukemia\n": "(D)", "101-3.\n\u4e00\u4f4d50\u6b72\u5973\u6027\u88ab\u8a3a\u65b7\u6709portal vein thrombosis\u3002\u5468\u908a\u8840\u6db2\u6aa2\u67e5\u767c\u73fe\u6709JAK2\u57fa\u56e0\u7a81\u8b8a\uff0c\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u6709\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\uff1f\nA. Myeloproliferative neoplasm\nB. Paroxysmal nocturnal hemoglobinuria\nC. Protein S deficiency\nD. Protein C deficiency\nE. Antithrombin III deficiency\n": "(A)", "101-4.\n\u4e00\u4f4d\u75c5\u4eba\u7684\u5468\u908a\u8840\u51fa\u73fe\u82bd\u7d30\u80de\uff0c\u9aa8\u9ad3\u6aa2\u67e5\u767c\u73fe\u82bd\u7d30\u80de\u70ba35%\uff0cmyeloperoxidase\u70ba\u9670\u6027\uff0c\u5176\u7d30\u80de\u8868\u9762\u6297\u539f\u8868\u73fe\u5982\u4e0bCD2(-)CD3(-)CD13(-)CD19(-)CD20(-)CD33(+)CD41(+)CD61(+)\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Early preB acute lymphoblastic leukemia\nB. T-acute lymphoblastic leukemia\nC. Acute erythroleukemia\nD. Acute monocytic leukemia\nE. Acute megakaryoblastic leukemia\n": "(E)", "101-5.\nBortezomib\u76ee\u524d\u5df2\u662f\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u7b2c\u4e00\u7dda\u7528\u85e5\uff0c\u5176\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f\nA. Tyrosine kinase inhibitor\nB. Immunomodulation\nC. Proteosome inhibitor\nD. Anti-angiogenesis\nE. Anti-IL6\n": "(C)", "101-6.\n\u4e0b\u5217\u6709\u95dctransfusion related acute lung injury (TRALI)\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684\uff1f\nA. \u4e00\u822c\u5728\u8f38\u5165\u5e36\u6709\u8840\u6f3f\u7684\u8840\u6db2\u6210\u5206\u5f8c\u767c\u751f\nB. \u591a\u5728\u8f38\u8840\u5f8c6\u81f312\u5c0f\u6642\u4e2d\u767c\u751f\nC. \u75c5\u4eba\u7684\u75c7\u72c0\u70ba\u7a81\u767c\u7684\u547c\u5438\u6025\u4fc3\u4e26\u6709\u80ba\u90e8\u6d78\u6f64\u7684\u73fe\u8c61\nD. \u53ef\u80fd\u7684\u6a5f\u8f49\u70ba\u8f38\u5165\u7684\u8840\u6db2\u6210\u5206\u4e2d\u6709\u5c0d\u6297\u53d7\u8840\u8005\u767d\u8840\u7403\u6297\u539f\u7684\u6297\u9ad4\nE. \u7531\u65bc\u985e\u56fa\u9187\u7684\u6cbb\u7642\u6548\u679c\u4e26\u4e0d\u78ba\u5b9a\uff0c\u4e00\u822c\u4e0d\u5efa\u8b70\u4f5c\u70ba\u4f8b\u884c\u6cbb\u7642\u4e4b\u7528\n": "(B)", "101-7.\n\u4e00\u4f4d25\u6b72\u5973\u6027\u958b\u5200\u5f8c\u51fa\u8840\u4e0d\u6b62\uff0c\u62bd\u8840\u6aa2\u67e5\u767c\u73fe Hb 10.5gm/dL\uff0cWBC 4350/uL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f 247000/uL\uff0cPT 10.1\" (\u6b63\u5e388\"~12.2\")\uff0cINR 0.96\uff0caPTT 46\" (\u6b63\u5e3826.9\"~36.3\")\u3002\u70ba\u8a3a\u65b7\u75c5\u4eba\u51fa\u8840\u50be\u5411\u7684\u539f\u56e0\uff0c\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u6700\u4e0d\u9700\u8981\uff1f\nA. Lupus anticoagulant\nB. Factor VIII\nC. vWF\nD. Platelet function test\nE. Ristocetin cofactor activity\n": "(A)", "101-8.\n\u4e00\u4f4d29\u6b72\u5973\u6027\u7121\u7279\u6b8a\u4e0d\u9069\uff0c\u4e09\u5e74\u524d\u516c\u53f8\u4f8b\u884c\u9ad4\u6aa2\u7684\u8840\u6db2\u76f8\u986f\u793aHb 11.5 gm/dL\uff0cMCV 84fL\uff0cWBC 4750/uL\uff0c\u8840\u5c0f\u677f 325000/uL\u3002\u4eca\u5e74\u7684\u9ad4\u6aa2\u986f\u793aHb 9.8 gm/dL\uff0cMCV 70fL\uff0cWBC 3350/uL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f416000/uL\u3002\u7406\u5b78\u6aa2\u67e5\u9664\u7d50\u819c\u7a0d\u5fae\u84bc\u767d\u5916\uff0c\u7121\u5176\u4ed6\u7570\u5e38\u3002\u6b64\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Thalassemia\nB. Iron deficiency\nC. Anemia of chronic disorder\nD. Essential thrombocythemia\nE. Myelodysplastic syndrome\n": "(B)", "101-9.\n\u4e0b\u5217\u6709\u95dcparoxysmal nocturnal hemoglobinuria(PNH) \u75c5\u4eba\u7684\u6558\u8ff0\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1)\u5468\u908a\u8840\u5e38\u5448\u73fe\u5168\u8840\u7403\u6e1b\u5c11\r(2)\u8840\u7403\u4e0a\u7f3a\u4e4fCD53\u53caCD58\r(3)\u6613\u767c\u751f\u975c\u8108\u6813\u585e\r(4)Eculizumab\u53ef\u6539\u5584\u75c5\u4eba\u7684\u75c7\u72c0\nA. (1)+(4)\nB. (2)+(3)\nC. (1)+(3)+(4)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(C)", "101-10.\n\u4e0b\u5217\u5fae\u751f\u7269\u53ca\u5176\u76f8\u95dc\u4e4b\u6dcb\u5df4\u7624\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f\r(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1)Helicobacter pylori, gastric MALT lymphoma\r(2)EB virus, NK/T cell lymphoma\r(3)HTLV-I, adult T cell lymphoma/leukemia\r(4)HCV, lymphoplasmacytoid lymphoma\nA. (1)\nB. (2)+(3)\nC. (1)+(3)\nD. (1)+(2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(E)", "101-1.\n\u816b\u7624\u6a19\u8a18(tumor markers)\u7684\u61c9\u7528\uff0c\u53ef\u904b\u7528\u5728\u60e1\u6027\u816b\u7624\u7684\u6cbb\u7642\u671f\u9593\uff0c\u4f5c\u70ba\u6cbb\u7642\u6210\u6548\u7684\u8f14\u52a9\u8a55\u4f30\u3002\u4ee5\u4e0b\u5404\u7a2e\u816b\u7624\u6a19\u8a18\u8207\u816b\u7624\u7684\u914d\u5c0d\uff0c\u54ea\u4e9b\u662f\u6b63\u78ba\u7684?\r(1)catecholamines\u8207pheochromocytoma\r(2)calcitonin\u8207papillary cancer of the thyroid\r(3)human chorionic gonadotropin (hCG)\u8207gestational trophoblastic disease\r(4)\u03b1-fetoprotein\u8207gonadal germ cell tumor\nA. (1)+(2)+(3)\nB. (1)+(2)+(4)\nC. (1)+(3)+(4)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(C)", "101-2.\n\u8a31\u591a\u60e1\u6027\u816b\u7624\u5e38\u6709\u81f4\u764c\u57fa\u56e0(oncogene)\u7684\u6539\u8b8a\u6216\u6d3b\u5316\u3002\u4ee5\u4e0b\u5404\u7a2e\u81f4\u764c\u57fa\u56e0\u7684\u6539\u8b8a\u8207\u764c\u75c7\u7684\u914d\u5c0d\uff0c\u54ea\u4e9b\u662f\u6b63\u78ba\u7684?\r(1)BRAF point mutation\u8207melanoma\r(2)CTNNB1 point mutation\u8207prostate cancer\r(3)FOS overexpression\u8207osteosarcomas\r(4)ERBB2 amplification\u6216point mutation\u8207colon cancer\r(5)N-MYC amplification\u8207neuroblastoma\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (1)+(2)+(4)+(5)\nD. (1)+(2)+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "101-3.\n\u80c3\u8178\u9053\u6709\u5df2\u77e5\u7684\u53ef\u907a\u50b3\u6027\u7684(hereditable)\u591a\u767c\u606f\u8089\u75c7\u5019\u7fa4(polyposis syndrome)\uff0c\u751a\u81f3\u6709\u60e1\u6027\u5316\u7684\u53ef\u80fd\u6027(malignant potential)\u3002\u5176\u4e2d\u6709\u4e9b\u591a\u767c\u606f\u8089\u75c7\u5019\u7fa4\uff0c\u606f\u8089\u5207\u9664\u4e4b\u75c5\u7406\u6aa2\u67e5\u70baadenoma\uff0c\u53e6\u5916\u6709\u4e9b\u75c7\u5019\u7fa4\u606f\u8089\u5207\u9664\u606f\u8089\u4e4b\u75c5\u7406\u7d44\u7e54\u6aa2\u67e5\u5247\u70bahamartoma\u3002\u4e0b\u5217\u4f55\u7a2e \"\u53ef\u907a\u50b3\u6027\u591a\u767c\u606f\u8089\u75c7\u5019\u7fa4\" \u591a\u5728\u8178\u9053\u767c\u751f\uff0c\u4e14\u606f\u8089\u5207\u9664\u4e4b\u75c5\u7406\u6aa2\u67e5\u5c6cadenoma?\r(1)Familial adenomatous polyposis (FAP)\r(2)Gardner's syndrome\r(3)Turcot's syndrome\r(4)Peutz-Jeghers syndrome\r(5)Lynch syndrome\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (1)+(3)+(4)+(5)\nD. (1)+(2+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "101-4.\n65\u6b72\u65b0\u8a3a\u65b7\u4e73\u764c\u75c5\u4eba\uff0c\u4e4b\u524d\u6574\u9ad4\u8eab\u9ad4\u72c0\u6cc1\u826f\u597d\uff0c\u7121\u986f\u8457\u5176\u4ed6\u5171\u75c5(co-morbidities)\u75c5\u53f2\uff0c\u7d93modified radical mastectomy\u624b\u8853\u5207\u9664\u53f3\u5074\u4e73\u764c\u8207\u53f3\u5074\u814b\u4e0b\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853\uff0c\u75c5\u7406\u6aa2\u67e5\u986f\u793a\u4e73\u764c\u816b\u584a\u5927\u5c0f4\u516c\u5206\uff0c\u814b\u4e0b\u6dcb\u5df4\u7d5015\u9846\u4e2d\u670910\u9846\u5df2\u6709\u4e73\u764c\u7d30\u80de\u4fb5\u72af\uff0c\u67d3\u8272ER(-)\u3001PR(-)\u3001HER2(-)\u3002\u4f60\u5efa\u8b70\u7d66\u4e88\u4f55\u7a2e\u624b\u8853\u5f8c\u8f14\u52a9\u6027(adjuvant)\u6cbb\u7642\u4f86\u964d\u4f4e\u764c\u75c7\u5fa9\u767c?\nA. tamoxifen\nB. multi-drug chemotherapy\nC. aromatase inhibitors\nD. trastuzumab\nE. no indications for adjuvant therapy\n": "(B)", "101-5.\n\u7121\u6cd5\u624b\u8853\u5207\u9664\u4e14\u7121\u6cd5\u9032\u884c\u52d5\u8108\u6813\u585e\u6cbb\u7642\u7684\u665a\u671f\u809d\u764c(HCC)\u75c5\u4eba\uff0c\u6a19\u9776\u6cbb\u7642\u85e5\u7269(targeted agents)\u8fd1\u5e74\u5df2\u6709\u91cd\u8981\u7684\u9032\u5c55\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u88ab\u8b49\u5be6\u6709\u6548\u4e4b\u665a\u671f\u809d\u764c\u7684\u7b2c\u4e00\u500b\u53e3\u670d\u6a19\u9776\u85e5\u7269? \u7d93\u7531\u7b2c\u4e09\u671f(Phase III)\u81e8\u5e8a\u8a66\u9a57\u8b49\u5be6\u5c0dChild-Pugh A\u4e4b\u665a\u671f\u809d\u764c\u75c5\u4eba\u7b2c\u4e00\u7dda\u4f7f\u7528\u6642\uff0c\u6709\u6574\u9ad4\u5b58\u6d3b\u63d0\u5347\u6548\u679c\uff0c\u76ee\u524d\u5df2\u88ab\u8996\u70ba\u665a\u671f\u809d\u764cstandard of care\u4e4b\u4e00\u3002\nA. sunitinib\nB. sorafenib\nC. brivanib\nD. everolimus\nE. erlotinib\n": "(B)", "101-6.\n\u80c3\u9ecf\u819c\u76f8\u95dc\u6dcb\u5df4\u764c(MALT lymphoma)\u7684\u751f\u6210\u8207\u80c3\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(H. pylori)\u5bc6\u5207\u76f8\u95dc\uff0c\u4e5f\u5df2\u77e5MALT lymphoma\u4e4b\u5e38\u898b\u67d3\u8272\u9ad4\u8b8a\u5316(cytogenetic translocation)\u6613\u9020\u6210API2/MALT\u8207Bcl-10\u7b49\u81f4\u764c\u56e0\u5b50\u4e4b\u6d3b\u5316\u3002\u80c3MALT lymphoma\u6700\u5e38\u898b\u7684\u67d3\u8272\u9ad4\u8f49\u4f4d\u8b8a\u5316\u70ba\u4f55?\nA. t(14;15) (q32;q13)\nB. t(9;22) (q34;q11)\nC. t(4;11) (q21;q23)\nD. t(11;18) (q21;q21)\nE. t(2;5) (p23;q35)\n": "(D)", "101-7.\n\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u7684\u8f49\u79fb\u6027\u4e0a\u76ae\u764c(carcinoma of unknown primary, CUP)\uff0c\u75c5\u7406\u7d44\u7e54\u5e38\u9700\u8981\u984d\u5916\u9032\u884c\u514d\u75ab\u7d44\u7e54\u67d3\u8272(immunohistochemical stains)\uff0c\u63d0\u4f9b\u81e8\u5e8a\u4e0a\u5206\u8fa8\u764c\u75c7\u5668\u5b98\u539f\u767c\u4f86\u6e90\u7684\u53c3\u8003\u4f9d\u64da\u3002cytokeratin(CK)\u662f\u7d93\u5e38\u4f7f\u7528\u7684intermediate filaments\u67d3\u8272\uff0c\u4eba\u9ad4\u670920\u591a\u7a2eCK\u4e9e\u578b\uff0c\u7576\u986f\u793a\u764c\u7d30\u80deCK20\u67d3\u8272\u967d\u6027\u4e14CK7\u67d3\u8272\u9670\u6027(CK20+/ CK7-)\u6642\uff0c\u76f8\u5c0dCUP\u6700\u53ef\u80fd\u7684\u539f\u767c\u5668\u5b98\u70ba\u4e0b\u5217\u4f55\u8005?\nA. lung\nB. breast\nC. endometrium\nD. pancreas\nE. colon\n": "(E)", "101-8.\n\u8f49\u79fb\u6027\u5927\u8178\u764c\u5728\u4f7f\u7528\u6297\u764c\u85e5\u7269\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u6709\u4e00\u91cd\u8981\u7684\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18(predictive biomarker)\u3002\u8b6c\u5982:\u7576\u5927\u8178\u764c\u6aa2\u9ad4K-RAS\u7684codon 12\u57fa\u56e0\u578b\u5c6c\u300c\u7a81\u8b8a\u578b\u300d\u6642\uff0c\u5c0d\u4e0b\u5217\u54ea\u500b\u85e5\u5291\u660e\u986f\u300c\u7121\u6548\u300d(non-responsiveness)\uff0c\u56e0\u6b64\u4e0d\u5efa\u8b70\u9078\u7528\u8a72\u85e5\u5291\u6cbb\u7642\u3002\nA. Bevacizumab (VEGF monoclonal antibody)\nB. Cetuximab (EGFR monoclonal antibody)\nC. 5-fluorouracil (5-FU)\nD. Oxaliplatin\nE. Irinotecan (CPT-11)\n": "(B)", "101-9.\n\u95dc\u65bctesticular cancer\u5206\u70banon-seminoma\u8207seminoma\u5169\u5927\u7d44\u6210\uff0c\u4e14\u9810\u5f8c\u660e\u986f\u6709\u5dee\u5225\u3002\u4e0b\u5217\u4f55\u7a2e\u8840\u6e05\u816b\u7624\u6a19\u8a18(tumor marker)\u986f\u8457\u4e0a\u5347\u6642\uff0c\u4ee3\u8868\u8a72\u75c5\u4eba\u7684testicular cancer\u5fc5\u5b9a\u6709\u300cnon-seminoma\u300d\u6210\u5206?\nA. LDH (lactate dehydrogenase)\nB. beta-hCG (human chorionic gonadotropin)\nC. AFP (\u03b1-fetoprotein)\nD. ALP (alkaline phosphatase)\nE. ALT (alanine aminotransferase)\n": "(C)", "101-10.\n\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624(neuroendocrine tumors)\u4e2d\u4e4b\"\u985e\u764c\"(carcinoid tumor)\u6709\u6642\u4ee5\u8179\u7009(diarrhea)\u3001\u6f6e\u7d05(flushing)\uff0c\u751a\u81f3\u9663\u767c\u6027\u75bc\u75db\u3001\u6c23\u5598\u7b49\"\u985e\u764c\u75c7\u5019\u7fa4\"(carcinoid syndrome)\u4f86\u8868\u73fe\uff0c\u548c\u985e\u764c\u6240\u5206\u6ccc\u7684serotonin\u3001tachykinins\u3001motilin\u7b49\u6d3b\u6027\u7269\u8cea\u6709\u95dc\u3002\u901a\u5e38\u8868\u73fe\"\u985e\u764c\u75c7\u5019\u7fa4\"\u7684\"\u985e\u764c\"\u816b\u7624\u4f4d\u7f6e(location)\u76f8\u5c0d\u6700\u591a\u6578\u8d77\u6e90\u65bc\u80da\u80ce\u5b78\u7684\u54ea\u500b\u90e8\u4f4d?\nA. Foregut\nB. Midgut\nC. Hindgut\nD. Foregut\u3001Midgut\u3001Hindgut \u8868\u73fe\"\u985e\u764c\u75c7\u5019\u7fa4\"\u7684\u6a5f\u6703\u5747\u76f8\u8fd1\nE. Rectum\n": "(B)", "102-1.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u570b\u969b\u4e0a\u8a55\u4f30diffuse large B cell lymphoma\u75c5\u4eba\u9810\u5f8c\u7684\u6307\u6a19IPI (International Prognostic Index)\uff1f\nA. Performance status\nB. Age\nC. Hb\nD. Stage\nE. LDH\n": "(C)", "102-2.\n\u76ee\u524dAzacytidine\u4ee5\u6cbb\u7642\u9aa8\u9ad3\u5316\u751f\u4e0d\u826f\u75c7\u5019\u7fa4(MDS)\u9ad8\u5371\u96aa\u4e4b\u75c5\u60a3\uff0c\u5df2\u6709\u5065\u4fdd\u7d66\u4ed8\u3002\u6b64\u85e5\u4f5c\u7528\u7684\u6a5f\u8f49\u70ba\u4f55\uff1f\nA. Tyrosine kinase inhibitor\nB. DNA methylation inhibitor\nC. Proteosome inhibitor\nD. Immunomodulator\nE. Vascular endothelial growth factor inhibitor\n": "(B)", "102-3.\n\u4e00\u4f4d37\u6b72\u5973\u6027\u75c5\u60a3\u904e\u53bb\u7121\u7279\u6b8a\u75c5\u53f2\uff0c\u6700\u8fd1\u56e0\u70ba\u75b2\u5026\u3001\u9ec3\u75b8\u53ca\u6df1\u8272\u5c3f\u61c9\u8a3a\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793aHb 8.7 g/dL\uff0creticulocyte 4.8%\uff0c\u767d\u8840\u74033560/uL\uff0c\u8840\u5c0f\u677f145000/uL\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff1bbilirubin\u5168\u91cf3.7 mg/dL\uff0c\u76f4\u63a5\u578b0.6 mg/dL\uff0cAST 75 U/L\uff0cALT 31 U/L\uff0cLDH 2350 U/L\uff0cCoombs' test\u9670\u6027\uff1b\u5c0f\u4fbf\u5982\u5716\u6240\u793a\uff0c\u6f5b\u8840\u53cd\u61c9\u5448\u967d\u6027\uff0c\u6c88\u6fb1\u7269\u4e2dRBC 0-2/HPF\uff0cWBC 1-3/HPF\u3002\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. Urine myoglobin\nB. Hb electrophoresis\nC. Bone marrow examination\nD. Hepatitis markers\nE. Flow cytometry for CD55 and CD59 expression\n": "(E)", "102-4.\n\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u9020\u6210iron deficiency anemia\u7684\u6a5f\u6703\u6700\u5c0f\uff1f\nA. Gastrectomy\nB. Paroxysmal nocturnal hemoglobinuria\nC. Thalassemia\nD. Pregnancy\nE. Colon Cancer\n": "(C)", "102-5.\n\u4e0b\u5217\u5316\u5b78\u6cbb\u7642\u6216\u6a19\u9776\u6cbb\u7642\u85e5\u7269\u4e2d\uff0c\u4f55\u8005\u9020\u6210\u795e\u7d93\u5b78\u6bd2\u6027\u7684\u53ef\u80fd\u6027\u6700\u5c0f\uff1f\nA. Vincristine\nB. Cisplatin\nC. Thalidomide\nD. Etoposide\nE. Bortezomib\n": "(D)", "102-6.\n\u4e0b\u5217\u6aa2\u67e5\u70ba\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u8a3a\u65b7\u6216\u5206\u671f\u6240\u5fc5\u9700\uff0c\u4f55\u8005\u70ba\u4f8b\u5916\uff1f\nA. Bone scan\nB. \u03b22-microglobulin\nC. Albumin\nD. Daily urine light chain quantification\nE. Blood M-protein level\n": "(A)", "102-7.\n\u4e00\u4f4d25\u6b72\u6025\u6027\u767d\u8840\u75c5\u4eba\u5468\u908a\u8840\u4e2d\u8840\u7d05\u7d207.5 g/dL\uff0c\u767d\u8840\u7403165000/uL\uff0c\u8840\u5c0f\u677f13000/uL\uff1b\u5c3f\u917810.5 mg/dL\uff0cCr 1.7 mg/dL\uff1b\u70ba\u53ca\u65e9\u964d\u4f4e\u767d\u8840\u7403\u7684\u6578\u76ee\uff0c\u5316\u5b78\u6cbb\u7642\u5fc5\u9808\u5118\u5feb\u958b\u59cb\u3002\u5728\u5316\u5b78\u6cbb\u7642\u524d\uff0c\u70ba\u5feb\u901f\u9054\u5230\u9810\u9632\u53ca\u6cbb\u7642tumor lysis syndrome\u7684\u76ee\u7684\uff0c\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6700\u9069\u7576\uff1f\nA. Allopurinol\nB. Rasburicase\nC. Benzbromarone\nD. Furosemide\nE. Magnexium oxide\n": "(B)", "102-8.\n\u4e00\u4f4d31\u6b72\u5973\u6027\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u6709\u8f15\u5fae\u9ec3\u75b8\uff0c\u76ae\u819a\u5c11\u8a31\u6de4\u9752\uff0c\u7121\u5176\u4ed6\u51fa\u8840\u73fe\u8c61\u3002\u8840\u7d05\u7d209.2 g/dL\uff0c\u7db2\u72c0\u7d05\u8840\u7403(reticulocyte) 4.1%\uff0c\u767d\u8840\u74034750/uL\uff0c\u8840\u5c0f\u677f23000/uL\uff1bPT\u53caPTT\u6b63\u5e38\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff0c\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Thrombotic thrombocytopenic purpura\nB. Disseminated intravascular coagulation\nC. G-6PD deficiency\nD. Evan syndrome\nE. Hypersplenism\n": "(A)", "102-9.\n\u4e00\u4f4d35\u6b72\u75c5\u60a3\uff0c\u88ab\u8a3a\u65b7\u5f97\u4e86\u8cbb\u57ce\u67d3\u8272\u9ad4(Ph)\u967d\u6027\u4e4bacute lymphoblastic leukemia\u3002\u9664\u4e86\u5316\u5b78\u6cbb\u7642\u5916\uff0c\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\u53ef\u9032\u4e00\u6b65\u6539\u5584\u75c5\u4eba\u7684\u9810\u5f8c\uff1f(1)all-trans retinoic acid (2)dasatinib (3)allogeneic hematopoietic stem cell transplantation(\u5fc5\u9808\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)\nB. (3)\nC. (2)+(3)\nD. (1)+(3)\nE. (1)+(2)+(3)\n": "(C)", "102-10.\n\u4e00\u4f4d72\u6b72\u7537\u6027\uff0c\u6709\u9577\u671f\u80ba\u75c5\u75c5\u53f2\uff0c\u6700\u8fd1\u62bd\u8840\u6aa2\u9a57\u767c\u73feHb 18.6 g/dL\uff0cHct 55%\uff0c\u88ab\u8f49\u8a3a\u5230\u8840\u6db2\u79d1\u9580\u8a3a\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u5176\u9762\u8272\u6f6e\u7d05\uff0c\u5634\u5507\u7a0d\u6709\u767c\u9257\u73fe\u8c61\uff0c\u4e26\u6709\u6775\u72c0\u6307\u3002\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u5340\u5206\u6b64\u75c5\u4eba\u662fpolycythemia vera\u6216secondary erythrocytosis\u6709\u5e6b\u52a9\uff1f(\u5fc5\u9808\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1)arterial blood gas (2)JAK2 mutation (3)erythropoietin level\nA. (1)\nB. (2)\nC. (1)+(2)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(E)", "102-1.\n\u4e0b\u5217\u6709\u95dc\u5c0f\u7d30\u80de\u80ba\u764c(small-cell-lung cancer\uff0cSCLC)\uff0c\u76f8\u8f03\u65bc\u975e\u5c0f\u7d30\u80de\u80ba\u764c(non-small-cell lung cancer\uff0cNSCLC)\uff0c\u4f55\u8005\u70ba\u6b63\u78ba\uff1f\nA. \u5c0f\u7d30\u80de\u80ba\u764c\u6bd4\u8f03\u5e38\u898b\u65bc\u80ba\u90e8\u5468\u570d(periphery)\nB. \u5c0f\u7d30\u80de\u80ba\u764c\u6e90\u8d77\u65bc\u80ba\u7d44\u7e54\u7684alveolar\u7d30\u80de\nC. \u5c0f\u7d30\u80de\u80ba\u764c\u5c0d\u5316\u5b78\u6cbb\u7642\u8f03\u4e0d\u654f\u611f (less chemosensitive)\nD. \u5c0f\u7d30\u80de\u80ba\u764c\u5c0d\u653e\u5c04\u7dda\u6cbb\u7642\u8f03\u70ba\u654f\u611f(more radiosensitive)\nE. \u975e\u5c0f\u7d30\u80de\u80ba\u764c\u8f03\u5e38\u898b\u9aa8\u9ad3\u8f49\u79fb\n": "(D)", "102-2.\n\u6709\u4e0028\u6b72\u7537\u6027\uff0c\u8eab\u9ad4\u72c0\u6cc1\u5927\u81f4\u826f\u597d\uff0c\u7121\u767c\u71d2\u3001\u7121\u9ad4\u91cd\u6e1b\u8f15\u7b49\u75c7\u72c0\u3002\u6700\u8fd1\u56e0\u6b32\u52a0\u5165\u4fdd\u96aa\u800c\u63a5\u53d7\u4f8b\u884c\u6027\u80f8\u90e8X\u5149\u651d\u5f71\u6aa2\u67e5\uff0c\u767c\u73fe\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u816b\u5927(mediastinal lymphadenopathy)\u3002\u7576\u7136\uff0c\u6dcb\u5df4\u7d50\u7a7f\u523a\u5207\u7247\u6709\u52a9\u65bc\u78ba\u5b9a\u8a3a\u65b7\uff0c\u9664\u6dcb\u5df4\u7d50\u7a7f\u523a\u5207\u7247\u4e4b\u5916\uff0c\u4e5f\u9700\u8981(indicated)\u4e0b\u5217\u4f55\u7a2e\u62bd\u8840\u6aa2\u9a57\u76f8\u5c0d\u6700\u6709\u52a9\u65bc\u8a3a\u65b7\uff1f\nA. C-reactive protein (CRP)\nB. Prostate-specific antigen (PSA)\nC. Alpha-fetoprotein (AFP)\nD. Thyroid stimulating hormone (TSH)\nE. Angiotensin-converting enzyme (ACE) level\n": "(C)", "102-3.\n\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC)\u75c5\u4eba\u63a5\u53d7\"\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u63a5\u53d7\u9ad4(EGFR)\u5c0f\u5206\u5b50\u6291\u5236\u5291(EGFR-TKI)\"\u4e4b\u6a19\u9776\u6cbb\u7642\u85e5\u7269(gefitinib\u3001erlotinib\u7b49)\uff0c\u5df2\u77e5\u8a72\u985eEGFR-TKI\u6a19\u9776\u6cbb\u7642\u85e5\u7269\u6709\u6cbb\u7642\u816b\u7624\u7de9\u89e3\u7387\u4e4b\u9810\u6e2c\u56e0\u5b50\uff0c\u4ee5\u4e0b\u4f55\u7a2eEGFR\u57fa\u56e0\u7a81\u8b8a\u53ef\u9810\u6e2c\u4f7f\u7528EGFR-TKI\u6cbb\u7642\u6642\u816b\u7624\u7de9\u89e3\u7387\u6700\u9ad8?\nA. EGFR exon 20 duplication (exon 20 dup)\nB. EGFR exon 19 deletion (exon 19 del)\nC. EGFR T790M mutation\nD. EGFR L747S mutation\nE. EGFR T854A mutation\n": "(B)", "102-4.\n\u6bd4\u8f03\u4e0b\u5217\u5404\u7a2e\u6dcb\u5df4\u764c\uff0c\u4f55\u8005\u76f8\u5c0d\u6709\u6700\u4f73\u7684\u9810\u5f8c(prognosis)\uff1f\nA. Burkitt's lymphoma\nB. Lymphoblastic lymphoma\nC. Mantle cell lymphoma\nD. Hodgkin's disease, nodular sclerosis\nE. Diffuse large B cell lymphoma (DLBCL)\n": "(D)", "102-5.\n\u8f49\u79fb\u6027\u5927\u8178\u764c\u5728\u4f7f\u7528\u6297\u764c\u85e5\u7269\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u6709\u4e00\u91cd\u8981\u7684\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18(predictive biomarker)\u3002\u8b6c\u5982:\u7576\u5927\u8178\u764c\u6aa2\u9ad4K-RAS\u7684codon 12\u57fa\u56e0\u578b\u5c6c\u300c\u91ce\u751f\u578b\u300d(wild-type)\u6642\uff0c\u662f\u5c0d\u4e0b\u5217\u54ea\u500b\u85e5\u5291\u6709\u6548 (responsiveness)\u7684\u9810\u6e2c\u56e0\u5b50\uff0c\u56e0\u6b64\u5efa\u8b70\u53ef\u9078\u7528\u8a72\u85e5\u5291\u6cbb\u7642\u3002\nA. 5-Fluorouracil (5-FU)\nB. Oxaliplatin\nC. Irinotecan (CPT-11)\nD. Cetuximab (EGFR monoclonal antibody)\nE. Bevacizumab (VEGF monoclonal antibody)\n": "(D)", "102-6.\n\u4e73\u764c\u7684\u75c5\u7406\u6aa2\u67e5\u7279\u5fb5\uff0c\u4e0b\u5217\u4f55\u8005\u986f\u793a\"\u4e0d\u826f\u7684\u9810\u5f8c\"(poor prognosis)\uff1f\nA. Ki-67 index < 2%\nB. Estrogen receptor (ER)\u967d\u6027 (>95%)\nC. p53\u91ce\u751f\u578b\nD. \u6838\u7684\u60e1\u6027\u5ea6\uff0cgrade I\nE. erbB2 (HER-2/neu)\u904e\u5ea6\u8868\u73fe(3+)\n": "(E)", "102-7.\n\"\u764c\u75c7\u95dc\u806f\u75c7\u5019\u7fa4\"(Paraneoplastic syndrome)\u5e38\u898b\"\u9ad8\u8840\u9223\u8840\u75c7\" (hypercalcemia)\uff0c\u5176\u4e2d\u6709\u4e9b\u60c5\u5f62\u4fc2\u7531\u65bc\u764c\u75c7\u5206\u6ccc\u904e\u591a\u76841,25-dihydroxy-vitamin D\uff0c\u6700\u5178\u578b\u7684\u764c\u75c7\u985e\u5225\u70ba\u4f55\uff1f\nA. \u982d\u9838\u90e8\u9e9f\u72c0\u4e0a\u76ae\u7d30\u80de\u764c\nB. \u4e73\u764c\nC. \u6ccc\u5c3f\u4e0a\u76ae\u764c\nD. \u60e1\u6027\u6dcb\u5df4\u764c\nE. \u76ae\u819a\u764c\n": "(D)", "102-8.\n\u6839\u64da\u7f8e\u570b\u7684\u570b\u5bb6\u80ba\u764c\u7be9\u6aa2\u8a08\u756b(National Lung Cancer Screening Trial)\u7d50\u679c\uff0c\u4f4e\u5291\u91cf\u80f8\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cf(low-dose chest CT scan)\u7be9\u6aa2\uff0c\u53ef\u6709\u6548\u964d\u4f4e\u80ba\u764c\u6b7b\u4ea1\u738720%\u3002\u6b64\u8a08\u756b\u91dd\u5c0d\u7684\u7be9\u6aa2\u5c0d\u8c61\uff1f\nA. \u226715 pack-years of smoking\uff0c\u4e14\u6212\u83f8\u672a\u6eff15\u5e74\u8005\nB. \u226720 pack-years of smoking\uff0c\u4e14\u6212\u83f8\u672a\u6eff15\u5e74\u8005\nC. \u226730 pack-years of smoking\uff0c\u4e14\u6212\u83f8\u672a\u6eff15\u5e74\u8005\nD. \u226740 pack-years of smoking\uff0c\u4e14\u6212\u83f8\u672a\u6eff15\u5e74\u8005\nE. \u6240\u6709smoking\u7684\u6210\u5e74\u4eba\n": "(C)", "102-9.\n\u4e0b\u5217\u816b\u7624\u8207\u75c5\u56e0\u7684\u914d\u5c0d\u4f55\u8005\u4e0d\u6b63\u78ba ?\nA. Burkitt's lymphoma\u8207Epstein-Barr virus (EBV) infection\nB. \u9f3b\u54bd\u764c (Nasopharyngeal carcinoma)\u8207 cytomegalovirus (CMV)infection\nC. \u53e3\u8154\u9e9f\u72c0\u4e0a\u76ae\u7d30\u80de\u764c(oral cavity squamous cell carcinoma)\u8207human papillomavirus(HPV)\nD. \u80c3\u7684mucosa-associated lymphoid tissue (MALT)lymphoma \u8207Helicobactor pylori infection\nE. Adult T-cell leukemia/lymphoma\u8207HTLV-1\n": "(B)", "102-10.\n\u4e0b\u5217\u54ea\u4e9b\u7279\u5fb5\u662f\u5178\u578b\"\u764c\u7d30\u80de\"\u7684phenotypes\u7279\u5fb5\uff1f(1)Success to differentiate (2)Loss of normal apoptosis pathways (3)Genetic stability (4)Loss of replicative senescence (5)Increased angiogenesis  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (2)+(4)+(5)\nD. (2)+(3)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(C)", "103-1.\n\u904e\u53bb\u672a\u66fe\u63a5\u53d7heparin\u6ce8\u5c04\u904e\u4e4b\u75c5\u4eba\uff0c\u6ce8\u5c04heparin\u5f8c\u5f15\u767c\u8840\u5c0f\u677f\u4f4e\u4e0b(Heparin induced thrombocytopenia)\u6700\u5e38\u51fa\u73fe\u7684\u6642\u9593\u70baheparin\u6ce8\u5c04\u5f8c\nA. 1\u5929\u5167\nB. 1\u81f33\u5929\nC. 5\u81f310\u5929\nD. 14\u81f328\u5929\nE. 1\u500b\u6708\u5f8c\n": "(C)", "103-2.\n\u4e0b\u5217\u6709\u95dcTRALI(transfusion-related acute lung injury)\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u8f38\u6ce8\u4efb\u4f55\u8840\u6db2\u6210\u5206\u90fd\u6709\u53ef\u80fd\u767c\u751f\nB. \u4e00\u822c\u5728\u8f38\u8840\u4e2d\u6216\u8f38\u8840\u5f8c6\u5c0f\u6642\u5167\u767c\u751f\nC. \u767c\u751f\u7684\u539f\u56e0\u53ef\u80fd\u8207\u53d7\u8840\u8005\u9ad4\u5167\u6709\u6297\u6350\u8840\u8005\u767d\u8840\u7403\u7684\u6297\u9ad4\u6709\u95dc\nD. \u75c5\u4eba\u7684\u80f8\u90e8X\u5149\u6703\u51fa\u73fe\u5169\u908a\u80ba\u8449\u7684\u6d78\u6f64\nE. \u76ee\u524d\u4e26\u7121\u660e\u78ba\u8b49\u64da\u986f\u793a\u985e\u56fa\u9187\u6cbb\u7642\u6709\u6548\n": "(C)", "103-3.\n\u4e00\u4f4d63\u6b72\u7537\u6027\u5728\u5065\u5eb7\u6aa2\u67e5\u6642\u5076\u7136\u767c\u73fe\u8840\u5c0f\u677f\u6578\u70ba732,000/uL\uff0c\u8840\u7d05\u7d20\u53ca\u767d\u8840\u7403\u7121\u7570\u5e38\uff1b\u8eab\u9ad4\u6aa2\u67e5(physical examination)\u4e26\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u57fa\u56e0\u6aa2\u6e2c\u672a\u767c\u73fe\u6709JAK2\u7a81\u8b8a\u3002\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u7d50\u679c\u5c0d\u539f\u767c\u6027\u8840\u5c0f\u677f\u589e\u751f\u75c7\u7684\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. \u9aa8\u9ad3\u9435\u67d3\u8272\u53ef\u770b\u5230ring sideroblasts\nB. \u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\nC. PDGFRA\u57fa\u56e0\u7a81\u8b8a\nD. EGFR\u57fa\u56e0\u7a81\u8b8a\nE. CALR\u57fa\u56e0\u7a81\u8b8a\n": "(E)", "103-4.\n\u4e00\u4f4d\u75c5\u4eba\u5728\u62bd\u8840\u6aa2\u67e5\u4e2d\u767c\u73fePT\u70ba16.3\"(\u6b63\u5e389.8~11.5\")\uff0cINR 1.52\uff0cPTT\u70ba54.3\"(\u6b63\u5e3825.6~32.6\")\u3002\u75c5\u4eba\u6700\u4e0d\u53ef\u80fd\u6709\u4ee5\u4e0b\u4f55\u7a2e\u72c0\u6cc1\uff1f\nA. Warfarin treatment\nB. Rivaroxaban treatment\nC. Aspirin treatment\nD. Factor XII deficiency\nE. Liver disease\n": "(D)", "103-5.\n\u4e00\u4f4d52\u6b72\u75c5\u4eba\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u767d\u8840\u7403\u6578\u70ba25,500/uL\uff0c\u6dcb\u5df4\u7d30\u80de\u4f5478%\uff0c\u5468\u908a\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff0c\u6d41\u6c0f\u7d30\u80de\u5100\u986f\u793a\u9019\u4e9b\u6dcb\u5df4\u7d30\u80de\u8868\u73feCD19\uff0cCD20\uff0cCD5\uff0cCD23\uff0c\u53ca\u03ba-\u8f15\u93c8\uff0c\u4f46\u7121CD3\uff0cCD10\u53ca\u03bb-\u8f15\u93c8\u8868\u73fe\uff0c\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4ec0\u9ebc\u75c5\uff1f\nA. Chronic lymphocytic leukemia\nB. Large granular lymphocyte leukemia\nC. Reactive lymphocytosis\nD. Acute lymphoblastic leukemia\nE. Follicular lymphoma\n": "(A)", "103-6.\n\u4e00\u4f4d17\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u767c\u71d2\u4f4f\u9662\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u7d05\u8840\u74032,350,000/uL\uff0c\u767d\u8840\u74031,050/uL\uff0c\u5176\u4e2dsegmented forms 10%\uff0cbands 2%\uff0clymphocytes 82%\uff0cmonocytes 6%\uff0c\u8840\u5c0f\u677f16,400/uL\uff0c\u7db2\u72c0\u7d05\u8840\u74031%\uff1b\u4f7f\u7528\u6297\u751f\u7d20\u5f8c\uff0c\u9ad4\u6eab\u56de\u5fa9\u6b63\u5e38\u3002\u9aa8\u9ad3\u6aa2\u67e5\u986f\u793a\u70ba\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\uff0c\u4e0b\u4e00\u6b65\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55\uff1f\nA. Antithymocyte globulin\nB. Cyclosporine\nC. Antithymocyte globulin\u53cacyclosporine\nD. Anabolic hormone\nE. Allogeneic hematopoietic stem cell transplantation from a HLA-matched sibling donor\n": "(E)", "103-7.\n\u4e00\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d2010.5 gm/dL\uff0c\u767d\u86cb\u767d3.6 gm/dL\uff0c\u7403\u86cb\u767d5.1 gm/dL\uff0cCr 1.1 mg/dL\uff0c\u03b22-microglobulin 4.1 mg/L\uff0c\u6b64\u75c5\u4eba\u5728\u570b\u969b\u5206\u671f\u7cfb\u7d71(International Staging System)\u4e4b\u671f\u5225\u70ba\uff1f\nA. 0\nB. I\nC. II\nD. III\nE. IV\n": "(C)", "103-8.\n\u4e00\u4f4d47\u6b72\u7537\u6027\u65b0\u8a3a\u65b7\u51fa\u6709\u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\uff0c\u4e0b\u5217\u6709\u95dc\u6b64\u75c5\u4eba\u7684\u6558\u8ff0\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1)\u6709\u67d3\u8272\u9ad4\u7570\u5e38t(9;22)\r(2)\u6709\u7570\u5e38\u4e4b\u878d\u5408\u57fa\u56e0BCR-ABL\r(3)\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u916a\u80fa\u9178\u6fc0\ufffdC\u6291\u5236\u5291(tyrosine kinase inhibitor)\nA. (1)\nB. (2)\nC. (1)+(2)\nD. (1)+(3)\nE. (1)+(2)+(3)\n": "(E)", "103-9.\n\u4e00\u4f4d58\u6b72\u5973\u6027\uff0c\u56e0\u9838\u90e8\u6dcb\u5df4\u7d50\u816b\u5927\u63a5\u53d7\u5207\u7247\u6aa2\u67e5\uff0c\u75c5\u7406\u521d\u6b65\u5831\u544a\u70ba\u7591\u4f3c\u6ffe\u6ce1\u578b\u6dcb\u5df4\u7624(follicular lymphoma)\u3002\u4e0b\u5217\u4f55\u7a2e\u6aa2\u67e5\u7d50\u679c\u53ef\u4ee5\u5e6b\u5fd9\u8a3a\u65b7\u6ffe\u6ce1\u578b\u6dcb\u5df4\u7624\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1) t(14;18)\r(2) BCL-2\u7570\u5e38\u8868\u73fe\r(3) CD5\u7d30\u80de\u8868\u9762\u6297\u539f\u967d\u6027\nA. (1)\nB. (1)+(2)\nC. (1)+(3)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(B)", "103-10.\n\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u6709\u53ef\u80fd\u9020\u6210\u5168\u8840\u7403\u6e1b\u5c11\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r(1) Vit B12 deficiency\r(2) Myelodysplastic syndrome\r(3) Liver cirrhosis\r(4) Autoimmune disease\nA. (4)\nB. (2)+(4)\nC. (2)+(3)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(E)", "103-1.\n\u95dc\u65bc\u80f8\u817a\u7624(thymoma)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e?\nA. \u7d0490%\u7684thymoma\u767c\u751f\u65bc\u524d\u7e31\u8188\u8154(anterior mediastinum)\nB. \u7d0440%\u7684thymoma\u75c5\u4eba\u53e6\u5408\u4f75\u4e00\u500b\u5168\u8eab\u6027\u7684\u81ea\u9ad4\u514d\u75ab\u75be\u75c5(systemic autoimmune illness)\nC. \u7d0430%\u7684thymoma\u75c5\u4eba\u5408\u4f75\u91cd\u75c7\u808c\u7121\u529b\u75c7(myasthenia gravis)\nD. \u7d045-8%\u7684thymoma\u75c5\u4eba\u5408\u4f75pure red cell aplasia\nE. \u7d045%\u7684thymoma\u75c5\u4eba\u5408\u4f75hypergammaglobulinemia\n": "(E)", "103-2.\n\u4ee5\u4eba\u985e\u4e73\u7a81\u75c5\u6bd2(human papilloma virus, HPV)\u75ab\u82d7\u6ce8\u5c04\uff0c\u53ef\u4ee5\u9810\u9632\u81f3\u5c11\u7d0470%\u7684\u4eba\u985e\u5b50\u5bae\u9838\u764c(cervical cancer)\u3002\u6240\u8b02HPV bivalent\u75ab\u82d7\uff0c\u4e3b\u8981cover HPV\u7684\u82e5\u5e72strains\u4ee5\u9810\u9632\u5b50\u5bae\u9838\u764c?\nA. HPV strains 6, 11\nB. HPV strains 11, 16\nC. HPV strains 16, 18\nD. HPV strains 6, 18\nE. HPV strains 6, 11, 16, 18\n": "(C)", "103-3.\n\u6839\u64da\u4e73\u764c\u7684\u57fa\u56e0\u8868\u73fe\u5716\u8b5c(gene expression profiling)\u70ba\u4e94\u500b\u6b21\u7fa4\u7d44(subclassification)\uff0c\u5206\u5225\u6709\u4e0d\u540c\u7684\u81e8\u5e8a\u9810\u5f8c\u8207\u6cbb\u7642\u9078\u9805\u3002\u4e0b\u5217\u6b21\u7fa4\u7d44\u4f55\u8005\u5c6c\u65bc\u6240\u8b02\u300c\u4e09\u9670\u6027\u300d(triple negative)\u4e73\u764c?\nA. Luminal A\nB. Luminal B\nC. HER2 amplified\nD. Basal\nE. Normal breast-like\n": "(D)", "103-4.\n\u4e0b\u5217\u80c3\u7684\u60e1\u6027\u816b\u7624\u4e2d\uff0c\u4f55\u8005\u8207\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(H. pylori, HP)\u5bc6\u5207\u76f8\u95dc\uff0c\u800c\u4e14\u4f7f\u7528\u5e7d\u9580\u87ba\u65cb\u687f\u83cc(HP)\u5ed3\u6e05\u7642\u6cd5\u5f8c\u81f3\u5c11\u8d85\u904e\u534a\u6578(\u7d0450%\u81f375%)\u7684\u764c\u75c7\u53ef\u9054\u5230\u6301\u7e8c\u6027\u7de9\u89e3(durable remission)?\nA. Gastric adenocarcinomas\nB. Gastric MALT (mucosa-associated lymphoid tissue) lymphomas\nC. Gastric leiomyosarcomas\nD. Gastric GISTs (gastrointestinal stromal tumors)\nE. Gastric NETs (neuroendocrine tumors)\n": "(B)", "103-5.\n\u80c3\u8178\u9053\u6709\u591a\u985e\u5177\u907a\u50b3\u6027\u7684\u591a\u767c\u761c\u8089\u75c7\u5019\u7fa4(hereditable polyposis syndrome)\u3002\u5176\u4e2d\u6709\u4e00\u985esyndrome\uff0c\u75c5\u4eba\u5e38\u5408\u4f75\u9ecf\u819c\u76ae\u819a\u4e4b\u8272\u7d20\u6c88\u8457\u75c7(mucocutaneous pigmentation)\uff0c\u5176\u761c\u8089\u7684\u7d44\u7e54\u75c5\u7406\u5b78\u986f\u793a\u70bahamartoma\uff0c\u800c\u975e\u8f03\u5e38\u898b\u7684\u817a\u7624(adenoma)\uff0c\u761c\u8089\u53ef\u5206\u5e03\u65bc\u5c0f\u8178\u3001\u5927\u8178\u6216\u80c3\u3002\u4ee5\u4e0b\u4f55\u985esyndrome\u7b26\u5408?\nA. Lynch syndrome\nB. Gardner's syndrome\nC. Turcot's syndrome\nD. Peutz-Jeghers syndrome\nE. Familial adenomatous polyposis (FAP)\n": "(D)", "103-6.\n\u651d\u8b77\u817a\u764c(prostate cancer)\u5316\u5b78\u9810\u9632(chemoprevention)\u7684\u5927\u578b\u7b2c\u4e09\u671f\u81e8\u5e8a\u8a66\u9a57\u7684\u7d50\u679c\uff0c\u4e0b\u5217\u4f55\u8005\u5df2\u986f\u793a\u6700\u53ef\u4ee5\u964d\u4f4e\u651d\u8b77\u817a\u764c\u7684\u76db\u884c\u7387(prevalence)?\nA. \u7852 (selenium)\nB. \u776a\u56fa\u916e\u4e4b5\u03b1-\u9084\u539f\u9175\u7d20\u6291\u5236\u5291 (5\u03b1-reductase inhibitor, 5ARI, of testosterone)\nC. \u7dad\u751f\u7d20 E\nD. \u7dad\u751f\u7d20 A\nE. \u7dad\u751f\u7d20 C\n": "(B)", "103-7.\n\u751f\u6b96\u7d30\u80de\u7624(germ cell tumor)\u5206\u70ba\u7cbe\u539f\u7d30\u80de\u7624(seminoma)\u8207\u975e\u7cbe\u539f\u7d30\u80de\u7624(nonseminoma)\u5169\u5927\u985e\u7d44\u6210\u5206\u3002\u4e0b\u5217\u4f55\u7a2e\u816b\u7624\u6a19\u8a18\u4e4b\u4e0a\u5347\uff0c\u50c5\u6703\u767c\u751f\u65bc\u5177\u6709\u975e\u7cbe\u539f\u7d30\u80de\u7624(nonseminoma)\u7d44\u6210\u4e4b\u751f\u6b96\u7d30\u80de\u7624?\nA. AFP (\u03b1-fetoprotein)\nB. hCG (human chorionic gonadotropin)\nC. LDH (lactate dehydrogenase)\nD. ALP (alkaline phosphatase)\nE. ALT (alanine transaminase)\n": "(A)", "103-8.\n\u91dd\u5c0d\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u4e4b\u8f49\u79fb\u764c(carcinoma of unknown primary\uff0cCUP)\uff0c\u4e3b\u8981\u75c5\u7406\u7d44\u7e54\u578b\u614b\u5340\u5206\u70ba\u4e94\u5927\u985e\uff0c\u54ea\u4e00\u5927\u985e\u6700\u70ba\u5e38\u898b?\nA. squamous cell cancer\nB. neuroendocrine\nC. poorly differentiated adenocarcinoma\uff0cpoorly differentiated carcinoma\nD. well to moderately differentiated adenocarcinoma\nE. undifferentiated malignancy\n": "(D)", "103-9.\n\u809d\u7d30\u80de\u764c(\u809d\u764c)\u7684\u816b\u7624\u95dc\u806f\u75c7\u5019\u7fa4(paraneoplastic syndrome)\uff0c\u53ef\u80fd\u5305\u62ec\u4e0b\u5217\u54ea\u4e9b\u75c7\u5019? (1)\u7d05\u8840\u7403\u7d30\u80de\u6578\u76ee\u589e\u591a\u75c7(erythrocytosis) (2)\u9ad8\u8840\u9223\u75c7(hypercalcemia) (3)\u9ad8\u8840\u7cd6\u75c7(hyperglycemia) (4)\u9ad8\u81bd\u56fa\u9187\u8840\u75c7(hypercholesterolemia) (5)\u7537\u6027\u5973\u4e73\u75c7(gynecomastia)\uff0c\u776a\u4e38\u840e\u7e2e\u75c7(testicular atrophy) (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(2)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "103-10.\n\u60e1\u6027\u9aa8\u8089\u7624(osteosarcoma)\u4f54\u4e86\u8fd1\u534a\u6578(\u7d0445%)\u7684\u9aa8\u9abc\u8089\u7624(sarcoma)\uff0c\u96a8\u8457\u6cbb\u7642\u5b78\u7684\u9032\u6b65\uff0c\u5df2\u6709\u8d85\u904e\u7d0480%\u75c5\u4eba\u53ef\u4ee5\u9054\u6210\u80a2\u9ad4\u4fdd\u5168\u624b\u8853(limb-sparing surgery)\u7684\u76ee\u7684\uff0c\u4f7f\u7528\u8853\u524d/\u8853\u5f8c\u7684\u5316\u5b78\u6cbb\u7642\u6642\uff0c\u5c0d\u60e1\u6027\u9aa8\u8089\u7624\u654f\u611f(chemosensitive)\u7684\u5316\u7642\u85e5\u7269\uff0c\u5305\u62ec\u4e0b\u5217\u4f55\u8005?(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848) (1)doxorubicin (2)cisplatin (3)ifosfamide (4)\u9ad8\u5291\u91cfmethotrexate (5)\u4ee5\u4e0a\u7686\u975e\nA. (1)+(2)\nB. (3)+(4)\nC. (1)+(3)+(4)\nD. (1)+(2)+(3)+(4)\nE. (5)\n": "(D)", "104-1.\n\u4e00\u4f4d35\u6b72\u5973\u6027\uff0c\u7121\u7279\u6b8a\u75c5\u53f2\uff0c\u4e94\u5e74\u524d\u7684\u9ad4\u6aa2\u986f\u793a\u8840\u6db2\u76f8\u70ba\u6b63\u5e38\u3002\u6700\u8fd1\u611f\u89ba\u722c\u5761\u6642\u6703\u6709\u547c\u5438\u6025\u4fc3\u7684\u73fe\u8c61\uff1b\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u8840\u58d3\u70ba126/82 mmHg\uff0c\u8108\u640f\u898f\u5247\uff0c\u6bcf\u5206\u941892\u4e0b\uff0c\u81c9\u8272\u84bc\u767d\uff0c\u7121\u5176\u4ed6\u7570\u5e38\uff1b\u8840\u6db2\u6aa2\u67e5\u986f\u793aHb 8.4 g/dL\uff0cMCV 69fL\uff0c\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u7121\u7570\u5e38\u3002\u6b64\u75c5\u4eba\u8ca7\u8840\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba\nA. \u6d77\u6d0b\u6027\u8ca7\u8840 (Thalassemia)\nB. \u7f3a\u9435\u6027\u8ca7\u8840 (Iron deficiency anemia)\nC. \u6162\u6027\u708e\u6027\u53cd\u61c9\u5f15\u767c\u4e4b\u8ca7\u8840 (Anemia of chronic inflammation)\nD. \u7532\u72c0\u817a\u75be\u75c5\nE. \u814e\u81df\u75c5\n": "(B)", "104-2.\n\u4e00\u4f4d27\u6b72\u7537\u6027\u60a3\u6709\u514d\u75ab\u6027\u8840\u5c0f\u677f\u4f4e\u4e0b\u6027\u7d2b\u6591\u75c7(ITP)\uff0c\u5c0d\u65bc\u50b3\u7d71\u6cbb\u7642\u5982prednisolone, azathioprine\u7b49\u7684\u6548\u679c\u4e0d\u4f73\uff0c\u91ab\u5e2b\u5efa\u8b70\u4ed6\u5207\u9664\u813e\u81df\u3002\u5728\u624b\u8853\u524d\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u6cbb\u7642\u662f\u6700\u9069\u7576\u7684\u9078\u64c7\uff1f\nA. Eltrombopag\nB. GM-CSF\nC. Desmopressin\nD. High dose dexamethasone\nE. Tranexamic acid\n": "(A)", "104-3.\n\u4e0b\u5217\u75be\u75c5\u4f55\u8005\u5f15\u767c\u8840\u6813(thromboembolism)\u7684\u53ef\u80fd\u6027\u6700\u5c0f\uff1f\nA. Antiphospholipid antibody syndorme\nB. Paroxysmal nocturnal hemoglobinuria\nC. Hereditary spherocytosis\nD. Myeloproliferative neoplasm\nE. Ovarian cancer\n": "(C)", "104-4.\n\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u7684\u75c5\u4eba\uff0c\u5e36\u6709\u4e0b\u5217\u4f55\u7a2e\u67d3\u8272\u9ad4\u6216\u57fa\u56e0\u8b8a\u7570\u9810\u5f8c\u6700\u5dee\uff1f\nA. -7\nB. t(8;21)\nC. inv(16)\nD. CEBPA mutation\nE. NPM1 mutation\n": "(A)", "104-5.\n\u4e0b\u5217\u5404\u60e1\u6027\u8840\u6db2\u75be\u75c5\u8207\u6a19\u9776\u6cbb\u7642\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u6709\u8aa4\uff1f\nA. Diffuse large B-cell lymphoma : rituximab\nB. Acute promyelocytic leukemia : arsenic trioxide\nC. Multiple myeloma : bortezomib\nD. Myelofibrosis : azacitidine\nE. Acute lymphoblastic leukemia with t(9;22) : imatinib\n": "(D)", "104-6.\n\u4e00\u4f4d19\u6b72\u75c5\u60a3\uff0c\u56e0\u767c\u71d2\u4e0d\u9000\u4f86\u5230\u6025\u8a3a\u8655\u3002\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u5589\u56a8\u767c\u7d05\uff0c\u7121\u51fa\u8840\u50be\u5411\uff0c\u7121\u547c\u5438\u6025\u4fc3\uff1b\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u8840\u7d05\u7d20 8.1 g/dL\uff0c\u7d05\u8840\u7403 2,710,000/uL\uff0c\u7db2\u72c0\u7d05\u8840\u7403 0.5%\uff1b\u767d\u8840\u7403 1,200/uL\uff0c\u5176\u4e2dneutrophils 15%\uff0clymphocytes 80%\uff0cmonocytes 4.5%\uff0ceosinophils 0.5%\uff1b\u8840\u5c0f\u677f 18,000/uL\uff1b\u9aa8\u9ad3\u6aa2\u67e5\u8a3c\u5be6\u70ba\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\u3002\u4ee5\u4e0b\u8655\u7f6e\uff0c\u4f55\u8005\u6700\u4e0d\u9700\u8981\uff1f\nA. Search for HLA-matched sibling donor\nB. Blood culture\nC. Chest X-ray\nD. Platelet concentrate transfusion\nE. Antibiotics treatment\n": "(D)", "104-7.\n\u4e00\u4f4d38\u6b72\u75c5\u60a3\uff0c\u5065\u5eb7\u6aa2\u67e5\u6642\u767c\u73fe\u767d\u8840\u7403\u6578\u76ee\u589e\u9ad8\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\uff0c\u6b64\u75c5\u4eba\u767d\u8840\u7403\u589e\u9ad8\u6700\u53ef\u80fd\u7684\u539f\u56e0\u70ba\u4f55\uff1f\nA. \u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\nB. \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\nC. \u6025\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5\nD. \u6162\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5\nE. \u53cd\u61c9\u6027\u767d\u8840\u7403\u589e\u751f\n": "(B)", "104-8.\n\u985e\u8840\u53cb\u75c5(von Willebrand disease)\u7684\u767c\u751f\u7387\u8f03\u8840\u53cb\u75c5\u9ad8\uff0c\u9019\u7a2e\u75c5\u4eba\u5927\u591a\u6703\u51fa\u73fe\u4e0b\u5217\u4f55\u7a2e\u6aa2\u9a57\u7570\u5e38\uff1f\r(1) \u8840\u5c0f\u677f\u529f\u80fd\u7570\u5e38\r(2) PT\u5ef6\u5e38\r(3) aPTT\u5ef6\u5e38\r(4) Factor VIII\u6fc3\u5ea6\u4e0b\u964d\nA. (3)\nB. (2)+(3)\nC. (1)+(3)\nD. (3)+(4)\nE. (1)+(3)+(4)\n": "(E)", "104-9.\n\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u570b\u969b\u5206\u671f\u7cfb\u7d71(International staging system)\uff0c\u662f\u6839\u64da\u4e0b\u5217\u90a3\u4e9b\u6307\u6a19\uff1f\r(1) \u767d\u86cb\u767d\u7684\u6fc3\u5ea6\r(2) \u514d\u75ab\u7403\u86cb\u767d\u7684\u6fc3\u5ea6\r(3) \u03b22-microglobulin\r(4) \u8840\u7d05\u7d20\nA. (1)+(2)\nB. (2)+(3)\nC. (1)+(3)\nD. (1)+(3)+(4)\nE. (2)+(3)+(4)\n": "(C)", "104-10.\n\u816b\u7624\u6eb6\u89e3\u75c7\u5019\u7fa4(Tumor lysis syndorme)\u5e38\u767c\u751f\u5728\u751f\u9577\u5feb\u901f\u7684\u816b\u7624\uff0c\u5c24\u5176\u662f\u5c0d\u5316\u5b78\u6cbb\u7642\u5f88\u654f\u611f\u7684\u60e1\u6027\u75c5\uff0c\u4ee5\u4e0b\u4f55\u8005\u70ba\u5e38\u898b\u7684\u6aa2\u9a57\u7570\u5e38\uff1f\r(1) Hyperkalemia\r(2) Hyperphosphatemia\r(3) Hyperuricemia\r(4) Hypercalcemia\nA. (1)+(3)\nB. (2)+(3)\nC. (1)+(2)+(3)\nD. (1)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(C)", "104-1.\n\u4e0b\u5217\u4f55\u7d44\u816b\u7624\u6a19\u8a18(tumor markers)\u8207\u7279\u5b9a\u764c\u75c7\u7684\u914d\u5c0d\u6700\u70ba\u5408\u5b9c? \u7576\u8a72\u764c\u75c7\u6cbb\u7642\u671f\u9593\uff0c\u53ef\u6aa2\u6e2c\u8a72\u816b\u7624\u6a19\u8a18\uff0c\u505a\u70ba\u8a55\u4f30\u816b\u7624\u7e3d\u91cf(tumor burden)\u7684\u8f14\u52a9\u5224\u65b7\u53c3\u8003\u3002\nA. CA-125\u8207Colon cancer\nB. CD30\u8207Hairy cell leukemia\nC. CA-153\u8207Gestational trophoblastic disease\nD. Calcitonin\u8207Medullary cancer of the thyroid\nE. Neuron-specific enolase (NSE)\u8207Non-small cell carcinoma of the lung\n": "(D)", "104-2.\n\u4e00\u4f4d63\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u8072\u97f3\u6c99\u555e(hoarseness)\u7d043\u500b\u6708\u800c\u5c31\u91ab\uff0c\u4ed6\u904e\u53bb25\u5e74\u5e73\u5747\u6bcf\u5929\u62bd\u83f8\u4e00\u5305\uff0c\u521d\u6b65\u7406\u5b78\u6aa2\u67e5\u982d\u9838\u90e8\u5927\u81f4\u6b63\u5e38\uff0c\u6c92\u6709\u9838\u90e8\u6dcb\u5df4\u7d50\u816b\u5927\uff0c\u8033\u9f3b\u5589\u93e1\u6aa2\u767c\u73fe\u4e00\u5589\u90e8(laryngeal)\u75c5\u7076\uff0c\u5207\u7247\u6aa2\u67e5\u8b49\u5be6\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c(squamous cell carcinoma)\uff0cCT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u986f\u793a\u4e3b\u8981\u75c5\u7076\u6700\u9577\u5f91\u7d042.2\u516c\u5206\uff0c\u6b63\u5b50\u6383\u63cf(FDG-PET)\u4e26\u6c92\u6709\u767c\u73fe\u61f7\u7591\u7684\u6dcb\u5df4\u7d50\u8f49\u79fb\u3002 \u5efa\u8b70\u6b64\u75c5\u4eba\u6700\u5408\u9069\u7684\u6cbb\u7642\u65b9\u5f0f\u70ba\u4f55?\nA. \u5316\u5b78\u6cbb\u7642\nB. \u624b\u8853\u5207\u9664\u4f75\u7528\u6839\u6cbb\u6027\u9838\u90e8\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853\nC. \u624b\u8853\u5207\u9664\u4f75\u7528\u6839\u6cbb\u6027\u9838\u90e8\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853\uff0c\u8853\u5f8c\u518d\u7528\u540c\u6b65\u5316\u7642\u653e\u5c04\u6cbb\u7642\nD. \u653e\u5c04\u7dda\u6cbb\u7642\nE. \u7de9\u548c\u5b89\u5be7(Hospice)\u6cbb\u7642\n": "(D)", "104-3.\n\u4e00\u4f4d58\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u4ee5\u4e0a\u8154\u975c\u8108\u75c7\u5019\u7fa4(SVC syndrome)\u70ba\u6700\u521d\u8868\u73fe\u800c\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u88ab\u8a3a\u65b7\u7f79\u60a3\u5c0f\u7d30\u80de\u80ba\u764c(small cell lung cancer\uff0cSCLC)\u3002\u70ba\u9032\u4e00\u6b65\u5b8c\u6574\u7684\u764c\u75c7\u5206\u671f\uff0c\u9700\u518d\u5b89\u6392\u54ea\u4e9b\u6aa2\u67e5?\nA. \u80f8\u8154\u8207\u8179\u8154CT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\nB. \u8166\u90e8\u96fb\u8166\u65b7\u5c64\u6383\u63cfCT\uff0c\u6216\u8166\u90e8\u78c1\u632f\u9020\u5f71\u6383\u63cfMRI\u6aa2\u67e5(\u52a0\u4e0a\u975c\u8108\u986f\u5f71\u5291\u6ce8\u5c04)\nC. \u9aa8\u9ad3\u5207\u7247(Bone marrow biopsy)\u6aa2\u67e5\nD. A + B\nE. A + B + C\n": "(D)", "104-4.\n\u4e00\u4f4d41\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u7d93\u75c5\u7406\u5207\u7247\u78ba\u8a3a\u7f79\u60a3\u4e86\u7b2c\u4e8c\u671f\u7684\u5b50\u5bae\u9838\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c(squamous cell carcinoma)\uff0c\u5979\u5148\u63a5\u53d7\u4e86\u8179\u5f0f\u5168\u5b50\u5bae\u5207\u9664\u8853\uff0c\u52a0\u4e0a\u96d9\u5074\u8f38\u5375\u7ba1\u8207\u5375\u5de2\u6458\u9664\u8853\uff0c\u8207\u9aa8\u76c6\u8154\u6dcb\u5df4\u7d50\u63a1\u6a23\u3002\u624b\u8853\u5f8c\u75c5\u7406\u6aa2\u67e5\u5831\u544a\u986f\u793a\u816b\u7624\u6700\u9577\u5f913.3\u516c\u5206\uff0c\u4e26\u5408\u4f75\u591a\u500b\u9ad8\u5371\u96aa\u75c5\u7406\u7d50\u679c\u967d\u6027 (\u5305\u62ecdeep stromal invasion\uff0clymphovascular invasion\uff0c4\u500b\u6dcb\u5df4\u7d50\u816b\u7624\u967d\u6027)\u3002\r\u5efa\u8b70\u4e0b\u4e00\u6b65\u6700\u9069\u5b9c\u7684\u6cbb\u7642\u8a08\u756b\u70ba\u4f55 ?\nA. \u5df2\u5145\u5206\u624b\u8853\uff0c\u50c5\u9700\u5b9a\u671f\u8ffd\u8e64\u89c0\u5bdf\u5373\u53ef\u3002\u81f3\u5c11\u6bcf3-4\u500b\u6708\u8ffd\u8e64\u9aa8\u76c6\u8154\u7406\u5b78\u6aa2\u67e5\uff0c\u8207\u7cfb\u5217CT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\nB. \u8840\u6e05Human papilloma virus (HPV) \u6aa2\u67e5\nC. \u624b\u8853\u5f8c\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u6cbb\u7642\nD. \u624b\u8853\u5f8c\u5316\u5b78\u6cbb\u7642\nE. \u624b\u8853\u5f8c\u9aa8\u76c6\u8154\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u5408\u4f75\u540c\u6b65\u5316\u5b78\u6cbb\u7642\n": "(E)", "104-5.\n\u4e0b\u5217\u5973\u6027\uff0c\u4f55\u8005\u53ef\u80fd\u6709\u300c\u6700\u4f4e\u300d\u7684\u4e73\u764c\u7f79\u60a3\u98a8\u96aa?\nA. \u4e00\u5973\u6027\u521d\u7d93(menarche)\u572816\u6b72\uff0c\u7b2c\u4e00\u80ce\u61f7\u5b55\u751f\u7522\u572818\u6b72\uff0c\u4e4b\u5f8c\u505c\u7d93(menopause)\u572844\u6b72\nB. \u4e00\u5973\u6027\u521d\u7d93(menarche)\u572814\u6b72\uff0c\u7b2c\u4e00\u80ce\u61f7\u5b55\u751f\u7522\u572818\u6b72\uff0c\u4e4b\u5f8c\u505c\u7d93(menopause)\u572852\u6b72\nC. \u4e00\u5973\u6027\u521d\u7d93(menarche)\u572812\u6b72\uff0c\u7b2c\u4e00\u80ce\u61f7\u5b55\u751f\u7522\u572824\u6b72\uff0c\u4e4b\u5f8c\u505c\u7d93(menopause)\u572848\u6b72\nD. \u4e00\u5973\u6027\u521d\u7d93(menarche)\u572816\u6b72\uff0c\u7b2c\u4e00\u80ce\u61f7\u5b55\u751f\u7522\u572832\u6b72\uff0c\u4e4b\u5f8c\u505c\u7d93(menopause)\u572852\u6b72\nE. \u4ee5\u4e0a\u5973\u6027\uff0c\u7f79\u60a3\u4e73\u764c\u7684\u98a8\u96aa\u5747\u76f8\u540c\n": "(A)", "104-6.\n\u4e00\u4f4d68\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u7d04\u4e00\u500b\u6708\u7684\u7121\u75db\u6027\u9ec3\u75b8(painless jaundice)\u9010\u6f38\u60e1\u5316\u800c\u5c31\u91ab\uff0c\u5408\u4f75\u6709\u7d043\u516c\u65a4\u9ad4\u91cd\u6e1b\u8f15\uff0c\u7406\u5b78\u6aa2\u67e5\u7121\u660e\u986f\u5176\u4ed6\u7570\u5e38\u3002\u9032\u884cdual-phase\u986f\u5f71CT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\uff0c\u767c\u73fe\u80f0\u81df\u982d\u90e8\u6709\u4e00\u7591\u4f3c\u816b\u584a\uff0c\u5408\u4f75\u81bd\u7ba1\u64f4\u5f35\u3002 \u8981\u9032\u4e00\u6b65\u8b49\u5be6\u78ba\u8a3a\u300c\u80f0\u81df\u764c\u300d\uff0c\u5efa\u8b70\u6700\u9069\u5b9c\u7684\u6aa2\u67e5\u8a3a\u65b7\u65b9\u5f0f\u70ba\u4f55?\nA. \u5167\u8996\u93e1\u9006\u884c\u81bd\u80f0\u7ba1\u651d\u5f71(ERCP)\u5408\u4f75\u80f0\u6db2\u63a1\u6a23\uff0c\u4ee5\u9032\u884c\u7d30\u80de\u5b78\u6aa2\u67e5(cytology)\nB. CT\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u5c0e\u5f15\u4e0b\uff0c\u7d93\u76ae\u819a(percutaneous)\u9032\u884cneedle biopsy\u5207\u7247\u75c5\u7406\u6aa2\u67e5\nC. \u5167\u8996\u93e1\u8d85\u97f3\u6ce2(endoscopic ultrasound, EUS)\u5c0e\u5f15\u4e0b\uff0c\u9032\u884cneedle biopsy\u5207\u7247\u75c5\u7406\u6aa2\u67e5\nD. FDG-PET \u6b63\u5b50\u6383\u63cf\u651d\u5f71\nE. \u62bd\u8840\u6aa2\u67e5\u8840\u6e05CA19-9\u6578\u503c\n": "(C)", "104-7.\n\u6709\u4e0021\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u7d04\u4e00\u500b\u6708\u524d\u56e0\u53f3\u5c0f\u817f\u811b\u9aa8\u524d\u5074\u816b\u75db\u800c\u5c31\u91ab\uff0c\u5148\u524d\u4e26\u7121\u78b0\u649e\u53d7\u50b7\u7684\u75c5\u53f2\u3002\u53f3\u4e0b\u80a2X\u5149\u986f\u793a\u9aa8\u9abc\u4f3c\u87f2\u86c0\u6a23(moth-eaten)\u7834\u58de\uff0c\u4e14\u5ef6\u4f38\u81f3\u9aa8\u5468\u570d\u7684\u8edf\u7d44\u7e54\uff0c\u4e26\u6709\u91dd\u6a23\u7684\u9aa8\u5468\u570d\u53cd\u61c9(periosteal reaction)\uff0c\u8edf\u7d44\u7e54\u816b\u584a\u548c\u9aa8\u5468\u570d\u53cd\u61c9\uff0c\u7d50\u5408\u5f62\u6210Codman\u6c0f\u4e09\u89d2(Codman's triangle)\u5fb5\u8c61\u3002\r\u91ab\u5e2b\u5224\u65b7\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff0c\u8207\u5efa\u8b70\u4f55\u7a2e\u6700\u5408\u9069\u7684\u6cbb\u7642\u8a08\u756b?\nA. \u6f3f\u7d30\u80de\u816b\u7624(plasma cell tumor\uff0cplasmacytoma)\uff1b\u5316\u5b78\u6cbb\u7642\nB. \u60e1\u6027\u8edf\u9aa8\u8089\u7624(chondrosarcoma)\uff1b\u5316\u5b78\u6cbb\u7642\nC. \u60e1\u6027\u8edf\u9aa8\u8089\u7624(chondrosarcoma)\uff1b\u653e\u5c04\u7dda\u6cbb\u7642\u5408\u4f75\u5c40\u90e8\u5207\u9664\u624b\u8853\nD. \u60e1\u6027\u9aa8\u8089\u7624(osteosarcoma)\uff1b\u624b\u8853\u524d\u5316\u5b78\u6cbb\u7642\uff0c\u4e4b\u5f8c\u9032\u884c\u80a2\u9ad4\u4fdd\u5168(limb-sparing)\u624b\u8853\nE. \u60e1\u6027\u9aa8\u8089\u7624(osteosarcoma)\uff1b\u653e\u5c04\u7dda\u7642\u6cd5\n": "(D)", "104-8.\n\u4ee5\u4e0b\u54ea\u4e9b\u75c5\u75c7\u6216\u75c7\u5019\u7fa4\uff0c\u6703\u589e\u52a0\u60a3\u8005\u7f79\u60a3\u764c\u75c7\u7684\u98a8\u96aa?\r(1) Fanconi's anemia\r(2) Down syndrome\r(3) Von Hippel-Lindau syndrome\r(4) Fragile X syndrome\r(5) Neurofibromatosis\nA. (1+)(2)+(4)\nB. (2)+(3)+(4)\nC. (1)+(3)+(4)+(5)\nD. (1)+(2)+(3)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "104-9.\n\u764c\u75c7\u7684\u6a19\u9776\u6cbb\u7642(targeted therapy)\u85e5\u5291\uff0c\u901a\u5e38\u91dd\u5c0d\u7279\u5b9a\u7684\u8a0a\u606f\u50b3\u905e\u8def\u5f91\u6216\u5206\u5b50\u6a19\u9776\u9032\u884c\u6291\u5236\uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684\u3002 \u4e0b\u5217\u6cbb\u7642\u85e5\u5291\u8207\u5206\u5b50\u6a19\u9776(molecular target) \u7684\u914d\u5c0d\uff0c\u54ea\u4e9b\u6b63\u78ba?\r(1) Erlotinib \u8207 EGFR\r(2) Ipilimumab \u8207 CTLA-4\r(3) Imatinib \u8207 Bcr-Abl\r(4) Vemurafenib \u8207 B-Raf\r(5) Rituximab \u8207 CD30\nA. (1)+(2)+(3)+(5)\nB. (1)+(2)+(3)+(4)\nC. (2)+(3)+(4)+(5)\nD. (3)+(4)+(5)\nE. (2)+(4)+(5)\n": "(B)", "104-10.\n\u4e00\u4f4d70\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u8fd12\u500b\u6708\u53f3\u5074\u8170\u75db\uff0c\u5408\u4f75\u8fd11\u500b\u6708\u8840\u5c3f(hematuria)\u9010\u6f38\u52a0\u91cd\u800c\u5c31\u91ab\u3002\u4e09\u661f\u671f\u524d\uff0c\u5728\u9580\u8a3a\u521d\u8a3a\u65b7\u70ba\u8180\u80f1\u708e\u5148\u9032\u884c\u6cbb\u7642\uff0c\u4f46\u75c7\u72c0\u4e26\u672a\u6539\u5584\uff0c\u4e14\u75c5\u4eba\u5408\u4f75\u98df\u617e\u4e0d\u632f\u8207\u9ad4\u91cd\u6e1b\u8f15\u7d044\u516c\u65a4\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u53f3\u5074\u8170\u90e8\u6709\u4e00\u53ef\u89f8\u8a3a\u7684\u816b\u584a\u7d0410\u516c\u5206\uff0c\u814e\u529f\u80fd\u6aa2\u67e5\u76ee\u524d\u4ecd\u5c6c\u6b63\u5e38\u3002 \u4ee5\u4e0b\u6709\u95dc\u6b64\u75c5\u4eba\u7684\u53ef\u80fd\u8a3a\u65b7\uff0c\u90a3\u4e9b\u6b63\u78ba?\r(1) \u8d85\u904e\u534a\u6578\u7684\u75c5\u7406\u8a3a\u65b7\uff0c\u591a\u5c6c\u4eae\u7d30\u80de\u4e0a\u76ae\u764c(clear cell carcinoma)\r(2) \u62bd\u83f8\u70ba\u5df2\u77e5\u7684\u76f8\u95dc\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\r(3) \u8ca7\u8840(anemia)\u8f03\u7d05\u8840\u7403\u589e\u591a\u75c7(erythrocytosis)\u5e38\u898b\r(4) \u7b2c\u4e00\u671f\u6216\u7b2c\u4e8c\u671f\u7684\u6b64\u7a2e\u764c\u75c7\uff0c\u7d93\u6839\u6cbb\u6027\u624b\u8853\u5207\u9664\u5f8c\uff0c5\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u8d85\u904e80%\r(5) \u7b2c\u56db\u671f\u8f49\u79fb\u6027\u7684\u6b64\u7a2e\u764c\u75c7\uff0c\u7d93\u7531\u5404\u7a2e\u6a19\u9776\u6cbb\u7642(targeted therapy)\u85e5\u5291\u7684\u9032\u5c55\uff0c5\u5e74\u6574\u9ad4\u5b58\u6d3b\u7387\u5df2\u53ef\u8d85\u904e50%\nA. (1)+(3)+(5)\nB. (3)+(4)+(5)\nC. (1)+(2)+(3)+(5)\nD. (1)+(2)+(3)+(4)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "105-1.\n\u4e00\u4f4d\u75c5\u4eba\u88ab\u767c\u73fe\u6709\u7d05\u8840\u7403\u904e\u591a\u75c7\uff0c\u4e0b\u5217\u8b8a\u5316\u5728\u539f\u767c\u6027\u591a\u8840\u75c7\u75c5\u60a3\u8f03\u6b21\u767c\u6027\u591a\u8840\u75c7\u75c5\u60a3\u70ba\u5e38\u898b\uff0c\u4f55\u8005\u4f8b\u5916\uff1f\nA. Leukocytosis\nB. Thrombocytosis\nC. Basophilia\nD. High erythropoietin level\nE. Splenomegaly\n": "(D)", "105-2.\n\u4e00\u4f4d63\u6b72\u7537\u6027\u5728\u5065\u6aa2\u6642\u88ab\u767c\u73fe\u767d\u8840\u7403\u6578\u76ee\u589e\u9ad8\uff0c\u5176\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u9019\u4e9b\u7d30\u80de\u8868\u73feCD5/CD19/CD20/CD23\uff0c\u4f46CD2/CD3/CD10\u70ba\u9670\u6027\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1f\nA. Chronic myeloid leukemia\nB. B cell chronic lymphocytic leukemia\nC. Follicular lymphoma\nD. Mantle cell lymphoma\nE. Adult T cell lymphoma/leukemia\n": "(B)", "105-3.\n\u4e0b\u5217\u85e5\u7269\u8207\u5176\u4f5c\u7528\u6a5f\u8f49\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u6709\u8aa4\uff1f\nA. Bortezomib : proteosome inhibitor\nB. Imatinib : tyrosine kinase inhibitor\nC. Ruxolitinib : JAK inhibitor\nD. Azacitidine : demethylation agent\nE. Ibrutinib : anti-CD30 antibody\n": "(E)", "105-4.\n\u4e00\u4f4d\u75c5\u4eba\u4e3b\u8a34\u547c\u5438\u6025\u4fc3\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793aHb 9.6 gm/dL\uff0c\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u76ee\u6b63\u5e38\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1f\nA. Aplastic anemia\nB. Iron deficiency anemia\nC. Hemolytic anemia\nD. Vit B12 deficiency anemia\nE. Thalassemia\n": "(C)", "105-5.\n\u4e0b\u5217\u6709\u95dcheparin\u5f15\u767c\u8840\u5c0f\u677f\u4f4e\u4e0b\u75c7\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u7b2c\u4e00\u6b21\u4f7f\u7528\u7684\u75c5\u4eba\uff0c\u4e00\u822c\u5728\u4f7f\u7528\u5f8c2\u81f33\u661f\u671f\u767c\u751f\nB. Low-molecular-weight heparin\u767c\u751f\u6a5f\u6703\u8f03unfractionated heparin\u5c0f\nC. \u5bb9\u6613\u4f75\u767c\u6813\u585e\nD. \u8840\u5c0f\u677f\u5f88\u5c11\u6389\u523020000/uL\u4ee5\u4e0b\nE. \u75c5\u4eba\u8840\u4e2d\u53ef\u5075\u6e2c\u5230\u6297heparin/platelet factor 4\u7684\u6297\u9ad4\n": "(A)", "105-6.\n\u5927\u90e8\u5206\u9aa8\u9ad3\u589e\u751f\u4e0d\u826f\u75c7\u5019\u7fa4(Myelodysplastic syndrome, MDS)\u7684\u75c5\u4eba\u90fd\u88ab\u767c\u73fe\u6709\u57fa\u56e0\u7a81\u8b8a\u3002\u5176\u4e2drefractory anemia with ring sideroblasts\u8207\u90a3\u4e00\u7a2e\u7a81\u8b8a\u7279\u5225\u6709\u95dc\uff1f\nA. KIT\nB. JAK2\nC. SFS3B1\nD. DNMT3A\nE. MYC\n": "(C)", "105-7.\n\u6025\u6027\u524d\u9aa8\u9ad3\u82bd\u7d30\u80de\u767d\u8840\u75c5(Acute promyelocytic leukemia, APL)\u5728\u6cbb\u7642\u5f8c\u53ef\u4ee5\u7528\u4f55\u7a2e\u751f\u7269\u6a19\u8a18\u8ffd\u8e64\u5176\u5fae\u91cf\u6b98\u5b58\u75be\u75c5(minimal residual disease)\nA. NPM1 mutant\nB. BCR-ABL\nC. RUNX1-RUNX1T1\nD. PML-RARA\nE. CBFB-MYH11\n": "(D)", "105-8.\n\u4e00\u4f4d55\u6b72\u75c5\u4eba\u6700\u8fd1\u4e00\u661f\u671f\u51fa\u73fe\u5169\u8173\u591a\u8655\u7600\u9752\uff0c\u5176\u4ed6\u7121\u7279\u6b8a\u7570\u5e38\u3002\u8edf\u7d44\u7e54\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u6709\u8840\u816b\u3002\u62bd\u8840\u6aa2\u67e5\u767c\u73fePT\u70ba12\u79d2(\u53c3\u8003\u503c9.8~11.5)\uff0cINR 0.95\uff0cPTT 58\u79d2(\u53c3\u8003\u503c25.6~32.6)\u3002mixing test\u986f\u793a\uff0c0\u5c0f\u6642PTT\u70ba37\u79d2\uff0c2\u5c0f\u6642\u70ba54\u79d2\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1a\nA. Acquired hemophilia\nB. Antiphospholipid syndrome\nC. von Willebrand disease\nD. Factor XII deficiency\nE. Disseminated intravascular coagulation\n": "(A)", "105-9.\n\u4e00\u4f4d45\u6b72\u75c5\u4eba\u56e0\u80c3\u75db\u5c31\u8a3a\uff0c\u80c3\u93e1\u6aa2\u67e5\u986f\u793a\u67092\u516c\u5206\u5927\u816b\u7624\uff0c\u5207\u7247\u53ca\u75c5\u7406\u6aa2\u67e5\u8b49\u5be6\u70bamarginal zone B-cell lymphoma, H. pylori\u967d\u6027\uff1b\u5206\u671f\u6aa2\u67e5\u672a\u767c\u73fe\u5176\u4ed6\u5730\u65b9\u6709\u88ab\u4fb5\u72af\u3002\u5c0d\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55\uff1f\nA. Surgery\nB. Anti-H. pylori treatment\nC. Rituximab\nD. Rituximab plus oral chemotherapeutic drug\nE. Rituximab plus CHOP(Cyclophosphamide, Adriamycin, Vincristine and Prednisolone)\n": "(B)", "105-10.\n\u4e0b\u5217\u4f55\u8005\u70baTumor lysis\u5e38\u898b\u7684\u8b8a\u5316\uff1f(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r1. Hyperuricemia\r2. Hyperkalemia\r3. Hypercalcemia\r4. Renal failure\nA. 1+3\nB. 1+3+4\nC. 1+2+3\nD. 1+2+4\nE. 1+2+3+4\n": "(D)", "105-1.\n\u4e0055\u6b72\u7537\u6027\u75c5\u4eba\u8a3a\u65b7\u6709\u60e1\u6027\u9ed1\u8272\u7d20\u7d30\u80de\u7624(melanoma)\u5408\u4f75\u80ba\u81df\u8207\u9aa8\u9abc\u8f49\u79fb\uff0c\u76ee\u524d\u4e00\u822c\u9ad4\u80fd\u72c0\u6cc1\u826f\u597d\u3002\u4ed6\u7684\u816b\u7624\u57fa\u56e0\u6aa2\u6e2c\u8b49\u5be6BRAF V600E\u7a81\u8b8a\u967d\u6027\u3002\u5efa\u8b70\u6b64\u75c5\u4eba\u63a5\u53d7\u4f55\u7a2e\u6cbb\u7642\u53ef\u4ee5\u6709\u6700\u4f73\u7684\u816b\u7624\u7de9\u89e3\u7387(response rates)?\nA. Cisplatin\nB. Dacarbazine\nC. Vemurafenib\nD. Interleukin-2\nE. Hospice care\n": "(C)", "105-2.\n\u4e0065\u6b72\u7537\u6027\uff0c\u5f9e16\u6b72\u958b\u59cb\u62bd\u83f8\uff0c\u5230\u76ee\u524d\u4ecd\u5e73\u5747\u4e00\u5929\u7d04\u62bd1\u5305\u9999\u83f8\u3002\u4ed6\u5728\u6700\u8fd1\u4e00\u6b21\u5065\u5eb7\u6aa2\u67e5\u4e2d\uff0cCT\u6383\u63cf\u767c\u73fe\u5de6\u4e0b\u80ba\u8449\u5916\u570d(periphery)\u6709\u55ae\u4e00\u500b10mm\u76f4\u5f91\u5927\u5c0f\u7684\u80ba\u7d50\u7bc0(nodule)\uff0c\u4e26\u6c92\u6709\u767c\u73fe\u660e\u986f\u7684\u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u816b\u5927\uff0c\u4ed6\u57282\u5e74\u524d\u6709\u6aa2\u67e5\u904eCXR\uff0c\u4e26\u6c92\u6709\u767c\u73fe\u9019\u4e00\u500b\u7d50\u7bc0\u3002\u76ee\u524d\u4ed6\u4e26\u7121\u4efb\u4f55\u986f\u8457\u7684\u547c\u5438\u7cfb\u7d71\u75c7\u72c0\uff0c\u80ba\u529f\u80fd\u6aa2\u67e5FEV1\u70ba87% predicted\uff0cFVC\u70ba91% predicted\uff0cdiffusion capacity\u70ba81% predicted\u3002\u5efa\u8b70\u4e0b\u5217\u4e0b\u4e00\u6b65\u8655\u7f6e\u4f55\u8005\u6700\u70ba\u9069\u7576?\nA. \u9032\u884cFDG-PET-CT\u6b63\u5b50\u65b7\u5c64\u6383\u63cf\u651d\u5f71\u6aa2\u67e5\nB. \u9032\u884cBronchoscope with biopsy\u4ee5\u78ba\u8a3a\nC. 3\u500b\u6708\u5f8c\u9032\u884cChest MRI\u6383\u63cf\u4ee5\u8a55\u4f30interval growth\nD. \u8f49\u4ecb\u80f8\u8154\u5916\u79d1\u9032\u884cVideo-assisted thoracoscopic (VATS) biopsy\uff0c\u82e5\u8b49\u5be6\u70ba\u60e1\u6027\uff0c\u5247\u5408\u4f75\u75c5\u7076\u5207\u9664\nE. \u8f49\u4ecb\u653e\u5c04\u816b\u7624\u79d1\u9032\u884cStereotactic radiation\n": "(D)", "105-3.\n\u4e00\u4f4d66\u6b72\u7537\u6027\u56e0\u7a81\u7136\u767c\u89ba\u53f3\u5074\u773c\u77bc\u4e0b\u5782\u8207\u8996\u529b\u6a21\u7cca\u800c\u5230\u6025\u8a3a\u5c31\u91ab\uff0c\u75c5\u4eba\u4e3b\u8a34\u904e\u53bb\u90fd\u6c92\u6709\u985e\u4f3c\u7684\u75c7\u72c0\u767c\u751f\uff0c\u53ea\u662f\u904e\u53bb\u7d043\u500b\u6708\u4ee5\u4f86\uff0c\u4ed6\u81ea\u89ba\u53f3\u80a9\u8207\u53f3\u4e0a\u81c2\u75bc\u75db\u7684\u554f\u984c\uff0c\u4ed6\u7684\u5bb6\u5ead\u91ab\u5e2b\u5148\u8a3a\u65b7\u70ba\u767c\u708e\u6027\u75bc\u75db(shoulder bursitis)\u4e26\u7d66\u4e88\u85e5\u7269\uff0c\u4f46\u75bc\u75db\u4e26\u672a\u80fd\u5b8c\u5168\u63a7\u5236\u3002\u4ed6\u5e73\u5747\u6bcf\u5929\u62bd\u83f8\u7d04\u4e00\u5305\uff0c\u5df2\u6709\u8d85\u904e30\u5e74\u4e4b\u4e45\uff0c\u9577\u671f\u6709COPD\u8207\u6162\u6027\u54b3\u75f0\u7684\u554f\u984c\u3002\u6025\u8a3a\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u53f3\u773c\u77bcptosis\u4e14\u5169\u5074pupils\u5927\u5c0f\u4e0d\u7b49\uff0c\u53f3\u5074pupil 2 mm\u4e14not reactive\uff0c\u5de6\u5074pupil 4 mm\u4e14reactive\uff0c\u5169\u773c\u7403\u7684\u5404\u773c\u5916\u808c\u6d3b\u52d5\u7684\u5404\u65b9\u5411\u5747\u6b63\u5e38(full and\rfree)\u3002\u80ba\u90e8\u807d\u8a3a\u5927\u81f4\u6b63\u5e38\u3002\u80a2\u9ad4\u6aa2\u67e5\u767c\u73fe\u53f3\u624b\u638c\u7684intrinsic\u808c\u8089\u5df2\u6709wasting\u73fe\u8c61\u3002\r\u4f60\u63a8\u6e2c\u4ed6\u6700\u53ef\u80fd\u7684\u81e8\u5e8a\u8a3a\u65b7\u70ba\u4f55?\nA. CXR\u53ef\u898b\u5230\u4e00cervical rib\u7684\u5b58\u5728\nB. Eaton-Lambert myasthenic syndrome (Eaton-Lambert\u91cd\u75c7\u808c\u7121\u529b\u75c7\u5019\u7fa4)\nC. \u5c0f\u7d30\u80de\u80ba\u764c(Small cell lung cancer)\u5df2\u6709midbrain\u8f49\u79fb\nD. CXR\u53ef\u898b\u5230\u53f3\u4e0a\u80ba\u5c16(apical)\u808b\u819c\u589e\u539a\u4e14\u5408\u4f75\u6709\u4e00\u500b\u7d042\u516c\u5206\u539a\u5ea6\u7684\u816b\u584a\u9670\u5f71\nE. \u7e31\u8188\u8154\u6dcb\u5df4\u7d50\u816b\u5927\uff0c\u58d3\u8feb\u4e0a\u8154\u975c\u8108(SVC)\uff0c\u9020\u6210SVC\u75c7\u5019\u7fa4\n": "(D)", "105-4.\n\u4e0033\u6b72\u5973\u6027\u56e0\u53f3\u5074\u4e73\u623f\u816b\u584a\u4f86\u5c31\u91ab\u3002\u7d04\u4e00\u9031\u524d\u5979\u5728\u6dcb\u6d74\u6642\u767c\u73fe\u9019\u4e00\u816b\u584a\uff0c\u4e26\u6c92\u6709nipple\u7684\u7570\u5e38\u5206\u6ccc\u7269\uff0c\u4e5f\u6c92\u6709\u4efb\u4f55\u7d05\u816b\u6216\u4e0d\u9069\uff0c\u5979\u904e\u53bb\u4e5f\u6c92\u6709\u7279\u5b9a\u91ab\u7642\u75c5\u53f2\u3002\u7406\u5b78\u6aa2\u67e5\u89f8\u8a3a\u767c\u73fe\u53f3\u5074\u4e73\u623f\u7684\u300c\u53f3\u4e0a\u5916\u5074\u56db\u5206\u4e4b\u4e00\u300d\u90e8\u4f4d\u6709\u4e00\u500b\u7d041.5 x 2.0\u516c\u5206\u7684\u816b\u584a\uff0c\u5de6\u5074\u4e73\u623f\u6b63\u5e38\uff0c\u5169\u5074\u814b\u4e0b\u6dcb\u5df4\u7d50\u5747\u7121\u816b\u5927\u30024\u9031\u5f8c\u518d\u6b21\u7406\u5b78\u6aa2\u67e5\u4f9d\u7136\u4e00\u6a23\u3002\u65bc\u662f\u9032\u884c\u7d30\u91dd\u62bd\u5438\u8853\uff0c\u62bd\u51fa\u7d042.5\u6beb\u5347\u6e05\u6f88\u7684\u6db2\u9ad4\uff0c\u4e4b\u5f8c\u816b\u584a\u5c31\u89f8\u8a3a\u4e0d\u5230\u4e86\u3002\u4e0b\u5217\u5efa\u8b70\u4f55\u8005\u6700\u70ba\u9069\u5b9c?\nA. \u7acb\u5373\u9032\u884cMammography\u9032\u4e00\u6b65\u8a55\u4f30\nB. \u7acb\u5373\u9032\u884cBreast MRI\u5075\u6e2c\u8207\u5206\u8fa8\u6b98\u9918\u6db2\u9ad4\u7684\u5206\u5e03\nC. \u7acb\u5373\u8f49\u4ecbBreast surgeon\u9032\u884c\u5207\u9664\u624b\u8853\nD. \u65e5\u5f8c\u6b64\u75c5\u4eba\u4e0d\u61c9\u9935\u5979\u7684\u5c0f\u5b69\u6bcd\u4e73\nE. \u5b89\u6392\u6b64\u75c5\u4eba1\u500b\u6708\u5f8c\u518d\u56de\u8a3a\u8ffd\u8e64\uff0c\u4ee5\u6c7a\u5b9a\u5f8c\u7e8c\u7684\u6aa2\u67e5\u6216\u6cbb\u7642\u9700\u8981\u8207\u5426\n": "(E)", "105-5.\n\u4e00\u500b\u8eab\u9ad4\u72c0\u6cc1\u5927\u81f4\u6b63\u5e38\u768465\u6b72\u5973\u6027\u9032\u884c\u5065\u5eb7\u6aa2\u67e5\uff0ccolonoscope\u5728\u5347\u7d50\u8178\u90e8\u4f4d\u767c\u73fe2\u500b\u5927\u5c0f\u5206\u5225\u70ba1.2\u516c\u5206\u30011.4\u516c\u5206\u7684\u6241\u5e73\u6a23sessile (flat-based)\u606f\u8089\uff0c\u5167\u8996\u93e1\u6aa2\u540c\u6642\u9032\u884c\u5167\u8996\u93e1\u606f\u8089\u5207\u9664\uff0c\u75c5\u7406\u5831\u544a\u5747\u70ba\u7d68\u6bdb\u6a23\u817a\u7624(villous adenoma)\uff0c\u4e26\u7121\u7d50\u8178\u764c\u3002\u4ee5\u4e0b\u5efa\u8b70\u4f55\u7a2e\u6700\u9069\u7576?\nA. Abdominal and Pelvic CT scan\nB. Partial colectomy\nC. Reassurance only\nD. Follow-up colonoscopy in 3 years\nE. Follow-up colonoscopy in 10 years\n": "(D)", "105-6.\n\u4f4e\u5291\u91cf\u80f8\u8154CT\u6383\u63cf\u767c\u73fe\u55ae\u4e00\u80ba\u7d50\u7bc0(solitary pulmonary nodule)\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u771f?\nA. About 70% of incidentally found pulmonary nodules are benign.\nB. A lobulated and irregular contour is more indicative of malignancy than a smooth one.\nC. Ground-glass nodules should be benign.\nD. Multiple nodules indicate malignant disease.\nE. Absence of growth over a period of 6-12 months is sufficient to determine whether it is benign.\n": "(B)", "105-7.\n\u4e0055\u6b72\u7537\u6027\u63a5\u53d7\u5065\u5eb7\u6aa2\u67e5\uff0c\u809b\u9580\u6307\u6aa2(digital rectal examination\uff0cDRE)\u767c\u73fe\u660e\u986f\u7684\u651d\u8b77\u817a\u816b\u5927\uff0c\u4e14\u89f8\u8a3a\u5df2\u767c\u73fe\u651d\u8b77\u817a\u53f3\u8449\u660e\u986f\u7d50\u7bc0\uff0c\u4ed6\u5df2\u4e0d\u8a18\u5f97\u524d\u4e00\u6b21\u7684DRE\u6642\u9593\uff0c\u4e5f\u5f9e\u672a\u62bd\u8840\u6e2c\u904e\u651d\u8b77\u817a\u7279\u7570\u6027\u6297\u539f(prostate-specific antigen\uff0cPSA)\u6578\u503c\u3002\u6839\u64da\u5065\u5eb7\u6aa2\u67e5\u7684\u7d50\u679c\u8207\u81e8\u5e8a\u6307\u5f15\uff0c\u5efa\u8b70\u4e0b\u4e00\u6b65\u6700\u9069\u5b9c\u7684\u8655\u7f6e\u70ba\u4f55?\nA. \u53ea\u6e2c\u91cf\u4e00\u6b21PSA\u5373\u53ef\nB. \u73fe\u5728\u82076\u500b\u6708\u5f8c\u5404\u6e2c\u91cf\u4e00\u6b21PSA, \u4ee5\u8a08\u7b97PSA velocity\nC. \u5b89\u6392\u5168\u8eab\u6027\u9aa8\u9abc\u540c\u4f4d\u7d20\u6383\u63cf\u4ee5\u8a55\u4f30\u53ef\u80fd\u7684\u8f49\u79fb\nD. \u5b89\u6392\u5728\u300c\u7d93\u76f4\u8178\u8d85\u97f3\u6ce2\u6aa2\u67e5\u300d\u7684\u5c0e\u5f15\u4e0b\uff0c\u9032\u884c\u651d\u8b77\u817a\u5207\u7247\u6aa2\u67e5\nE. \u7b493\u500b\u6708\u5f8c\u518d\u91cd\u8907\u4e00\u6b21DRE\u6aa2\u67e5\n": "(D)", "105-8.\n\u4e0080\u6b72\u7537\u6027\u8f49\u79fb\u6027\u651d\u8b77\u817a\u764c\u75c5\u4eba\uff0c\u56e0\u610f\u8b58\u72c0\u614b\u6539\u8b8a(altered mental status)\u800c\u88ab\u5bb6\u4eba\u9001\u81f3\u6025\u8a3a\u3002\u4ed6\u56e0\u651d\u8b77\u817a\u764c\u5b9a\u6642\u63a5\u53d7goserelin\u808c\u8089\u6ce8\u5c04\u6297\u8377\u723e\u8499\u6cbb\u7642\u3002\u6025\u8a3a\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\uff0c\u8840\u58d3106/52 mmHg\uff0c\u8108\u640f112/min\uff0c\u770b\u4f86\u5341\u5206\u75b2\u5026\u55dc\u7761\u4e14\u5c0d\u80f8\u9aa8\u58d3\u75db\u53cd\u61c9\u6975\u5fae\u5f31\uff0c\u773c\u7aa9\u51f9\u9677\u4e14\u9ecf\u819c\u4e7e\u71e5\uff0cgag reflex\u4ecdintact\uff0c\u56db\u80a2\u5c0d\u5287\u75db\u523a\u6fc0\u7684withdrawal\u5747\u4ecd\u5c0d\u7a31\uff0c\u4e14rectal tone\u4ecd\u6b63\u5e38\u3002\u7570\u5e38\u5be6\u9a57\u5ba4\u6578\u64dacreatinine 4.2 mg/dL\uff0ccalcium 3.25 mmol/L (13.0 mg/dL)\uff0calbumin 2.6 g/dL\u3002\u4e0b\u5217\u5408\u9069\u7684\u8655\u7f6e\uff0c\u4f55\u8005\u70ba\u975e?\nA. Dexamethasone\nB. Normal saline\nC. \u7576\u75c5\u4eba\u6062\u5fa9euvolemic\u72c0\u614b\u6642\uff0c\u7d66\u4e88Furosemide\nD. Calcitonin\nE. Palmidronate\n": "(A)", "105-9.\n\u6709\u4e9b\u764c\u75c7\u75c5\u4eba\u96d6\u7136\u5df2\u7d93\u662f\u8f49\u79fb\u6027\u7684\u764c\u75c7\u671f\u5225(metastatic disease)\uff0c\u4ee5\u624b\u8853\u5207\u9664\u65b9\u5f0f\u6cbb\u7642\uff0c\u4ecd\u6709\"\u5c11\u6578\"\u75c5\u4eba\u6709\u9577\u671f\u5b58\u6d3b\u6216\u751a\u81f3\u300c\u6cbb\u7652\u7684\u53ef\u80fd\u6027\u300d(potentially curable)\u3002 \u4e0b\u5217\u72c0\u6cc1\u4f55\u8005\u70ba\u771f? (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\r1. \u4e00\u4f4d58\u6b72\u5973\u6027\u7d50\u8178\u764c\u75c5\u4eba\u624b\u8853\u6cbb\u7642\u5f8c\uff0c2\u5e74\u5f8c\u67093\u9846\u809d\u81df\u8f49\u79fb\u7684\u7d50\u8178\u764c\uff0c\u5747\u4f4d\u65bc\u809d\u81df\u5de6\u8449\uff0c\u8f49\u4ecb\u81f3\u5916\u79d1\u9032\u884cleft hepatic lobectomy\u624b\u8853\u5207\u9664\r2. \u4e00\u4f4d25\u6b72\u7537\u6027\u75c5\u4eba\u6709\u5de6\u80a1\u9aa8(femur)\u60e1\u6027\u9aa8\u8089\u7624(osteosarcoma)\u75c5\u53f2\uff0c\u5982\u4eca\u767c\u73fe\u53f3\u4e0b\u80ba\u8449\u67091.2\u516c\u5206\u5927\u5c0f\u8f49\u79fb\u75c5\u7076\uff0c\u8f49\u4ecb\u81f3\u5916\u79d1\u9032\u884cright lower lobectomy of lung\u624b\u8853\u5207\u9664\r3. \u4e00\u4f4d75\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u651d\u8b77\u817a\u764c\u8f49\u79fb\u81f3\u591a\u8655\u810a\u67f1\u9aa8\u9abc(vertebrae)\uff0c\u8f49\u4ecb\u81f3\u6ccc\u5c3f\u816b\u7624\u79d1\u5148\u9032\u884corchiectomy\u624b\u8853\u5207\u9664\nA. 1\nB. 1+2\nC. 2+3\nD. 1+2+3\nE. \u4ee5\u4e0a\u7686\u975e\n": "(D)", "105-10.\n\u4e00\u4f4d52\u6b72\u5973\u6027\u7b2c\u4e09\u671f\u4e73\u764c\u75c5\u4eba\uff0c\u6ce8\u5c04\u5305\u542bdoxorubicin\u70ba\u4e3b\u7684CAF\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642\u8655\u65b9\uff0c\u6ce8\u5c04\u5316\u7642\u5f8c\u7b2c8\u5929\u75c5\u4eba\u56e0\u9ad8\u71d239.2\u2103\u4f86\u5230\u6025\u8a3a\uff0c\u5408\u4f75\u5bd2\u986b\u8207\u982d\u75db\u3002\u6025\u8a3a\u521d\u6b65\u6aa2\u67e5\u767d\u8840\u7403\u7e3d\u6578490/\u03bcL (\u5206\u985e10% neutrophils\uff0c20% monocytes\uff0c70% lymphocytes)\uff0c\u80f8\u90e8X\u5149(CXR)\u6aa2\u67e5\uff0c\u5c3f\u6db2\u6aa2\u67e5\uff0c\u8207\u4e2d\u5fc3\u975c\u8108\u5c0e\u7ba1\u5747\u6c92\u6709\u660e\u986f\u611f\u67d3\u7684\u8b49\u64da\uff0c\u5df2\u7531\u5468\u908a\u8207\u4e2d\u5fc3\u975c\u8108\u62bd\u8840\u9032\u884c\u8840\u6db2\u57f9\u990a\u6aa2\u67e5\u3002 \u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u5982\u4f55\u8655\u7f6e\u6700\u9069\u5b9c?\nA. \u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20ceftazidime\u3001vancomycin\u8207voriconazole\nB. \u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20ceftazidime\u8207vancomycin\nC. \u4e0b\u4e00\u500b\u6216\u5f80\u5f8c\u7684\u76f8\u540c\u8655\u65b9\u5316\u5b78\u6cbb\u7642\u7642\u7a0b\uff0c\u53ef\u9810\u9632\u6027\u7d66\u4e88G-CSF (granulocyte colony-stimulating factor)\nD. (A)+(C)\nE. (B)+(C)\n": "(E)", "106-1.\n\u4e0b\u5217\u75be\u75c5\u8207\u76ee\u524d\u5df2\u77e5\u6709\u6548\u4e4b\u6cbb\u7642\u85e5\u7269\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684\uff1f\nA. Multiple myeloma: Lenalidomide\nB. Chronic myeloid leukemia: Dasatinib\nC. Diffuse large B-cell lymphoma: Rituximab\nD. Paroxysmal nocturnal hemoglobinuria: Eculizumab\nE. Polycythemia vera: Prednisolone\n": "(E)", "106-2.\n\u4e00\u4f4d72\u6b72\u75c5\u4eba\u56e0\u70ba\u51fa\u8840\u50be\u5411\u53ca\u75b2\u5026\u61c9\u8a3a\uff0c\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20\u70ba8.2 g/dL\uff0c\u767d\u8840\u740324000/uL\uff0c\u8840\u5c0f\u677f12000/uL\uff1b\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4f55\u7a2e\u75c5\uff1f\nA. Chronic myeloid leukemia\nB. Chronic myelomonocytic leukemia\nC. Chronic lymphocytic leukemia\nD. Acute myeloid leukemia\nE. Acute lymphoblastic leukemia (ALL)\n": "(B)", "106-3.\n\u4e00\u4f4d23\u6b72\u75c5\u4eba\u56e0\u547c\u5438\u6025\u4fc3\u61c9\u8a3a\uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d20\u70ba6.3 g/dL\uff0c\u8840\u5c0f\u677f\u3001\u767d\u8840\u7403\u53ca\u5206\u985e\u6b63\u5e38\uff0c\u7db2\u72c0\u7d05\u8840\u7403(reticulocyte) 3.5%\uff0c\u5168\u81bd\u7d05\u7d20 (total bilirubin) 3.4 mg/dL\uff0c\u76f4\u63a5\u81bd\u7d05\u7d20 (direct bilirubim) 0.7 mg/dL\uff1b\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u6b64\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4ec0\u9ebc\u75c5\uff1f\nA. Iron deficiency anemia\nB. Autoimmune hemolytic anemia\nC. Vit B12 deficiency anemia\nD. Thalassemia\nE. G6PD deficiency\n": "(D)", "106-4.\n\u6a19\u9776\u6cbb\u7642\u85e5\u7269Tyrosine kinase inhibitor, Imatinib, \u5c0d\u4e0b\u5217\u4f55\u7a2e\u6025\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5(ALL)\u6709\u6548\uff1f\nA. B-lineage ALL with t(9;22)\nB. B-lineage ALL with t(4;11)\nC. CD19 positive B-lineage ALL\nD. CD20 positive B-lineage ALL\nE. CD3 positive T-lineage ALL\n": "(A)", "106-5.\nEltrombopag\u76ee\u524d\u70ba\u5065\u4fdd\u7d66\u4ed8\u6cbb\u7642\u514d\u75ab\u6027\u8840\u5c0f\u677f\u4f4e\u4e0b\u6027\u7d2b\u6591\u75c7(immune thrombocytopenic purpura)\u7684\u7b2c\u4e8c\u7dda\u7528\u85e5\uff0c\u5b83\u7684\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f\nA. Anabolic hormone\nB. Corticosteroid\nC. Immunosuppressive agent\nD. Thrombopoietin receptor agonist\nE. JAK inhibitor\n": "(D)", "106-6.\n\u4e00\u4f4d\u75c5\u4eba\u56e0\u8840\u5c0f\u677f\u4f4e\u4e0b\u61c9\u8a3a\uff0c\u4e0b\u5217\u5404\u9805\u6aa2\u9a57\u4e2d\u4f55\u8005\u70ba\u9451\u5225\u8840\u5c0f\u677f\u4f4e\u4e0b\u539f\u56e0\u5e6b\u5fd9\u6700\u5c0f\u8005\uff1f\nA. H. pylori infection\nB. Serology tests for SLE\nC. Hepatitis C infection\nD. HIV infection\nE. Platelet antibodies\n": "(E)", "106-7.\n\u5c0d\u65bc\u591a\u767c\u6027\u9aa8\u9ad3\u7624(multipel myeloma)\u7684\u8a3a\u65b7\u53ca\u5206\u671f\uff0c\u4e0b\u5217\u4f55\u9805\u6aa2\u67e5\u662f\u6700\u4e0d\u9700\u8981\u8005\uff1f\nA. Immunoelectrophoresis\nB. Albumin level\nC. Beta 2-microglobulin level\nD. Bone scan\nE. Plain bone radiography\n": "(D)", "106-8.\n\u4e00\u4f4d40\u6b72\u75c5\u4eba\u62b1\u6028\u80c3\u75db\uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u767c\u73fe\u80c3\u7ac7(gastric antrum)\u6709\u4e00\u816b\u7624\uff0c\u75c5\u7406\u5207\u7247\u6aa2\u67e5\u986f\u793a\u70bamucosa-associated lymphoid tissue lymphoma\uff0cCD20\u967d\u6027\u53caH. pylori\u967d\u6027\uff0c\u5206\u671f\u6aa2\u67e5\u672a\u767c\u73fe\u5176\u4ed6\u7570\u5e38\u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u7b2c\u4e00\u7dda\u6cbb\u7642\uff1f\nA. Eradication of H. pylori\nB. Rituximab\nC. Chemotherapy\nD. Rituximab + Chemotherapy\nE. Local irradiation\n": "(A)", "106-9.\n\u4e0b\u5217\u4f55\u7a2e\u72c0\u6cc1\u5e38\u6703\u51fa\u73feprothrombin time (PT)\u6b63\u5e38\u4f46activated partial thromoplostim time (aPTT)\u5ef6\u5e38\u7684\u73fe\u8c61\uff1f(1) Hepatic failure\uff1b(2) Antiphospholipid syndrome\uff1b(3) von Willebrand disease\uff1b(4) Disseminated intravascular coagulation\nA. (1)+(4)\nB. (2)+(4)\nC. (1)+(2)\nD. (2)+(3)\nE. (1)+(2)+(4)\n": "(D)", "106-10.\n\u4e0b\u5217\u4f55\u8005\u662fB\u7d30\u80de\u6162\u6027\u6dcb\u5df4\u6027\u767d\u8840\u75c5(chronic lymphocytic leukemia)\u7d30\u80de\u7684\u7279\u5fb5\uff0c\u53ef\u8207\u53cd\u61c9\u6027\u6dcb\u5df4\u7d30\u80de\u904e\u591a\u75c7\u505a\u9451\u5225\u8a3a\u65b7\uff1f(1) Monoclonal light chain restriction\uff1b(2) CD5 expression\uff1b(3) CD10 expression\nA. (1)\nB. (1)+(2)\nC. (1)+(3)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(B)", "106-1.\n\u6709\u4e0058\u6b72\u5973\u6027\uff0c\u5728\u4f8b\u884c\u6027\u4e73\u623fX\u5149\u651d\u5f71\u6aa2\u67e5\u767c\u73fe\u53f3\u5074\u4e73\u623f\u7684\u4e0a\u5916\u5074\u56db\u5206\u4e4b\u4e00\u8c61\u9650\u6709\u4e00\u65b0\u7684\u9223\u5316\u816b\u584a\u3002\u5c40\u90e8\u4e73\u623f\u816b\u584a\u5207\u9664(lumpectomy)\u5f8c\uff0c\u8b49\u5be6\u70ba\u4e73\u817a\u764c\uff0c\u6700\u9577\u76f4\u5f91\u70ba2.2\u516c\u5206\uff0c\u4e14Estrogen\u63a5\u53d7\u9ad4(ER)\uff0cProgesterone\u63a5\u53d7\u9ad4(PR)\uff0cHER2\u63a5\u53d7\u9ad4\uff0c\u4e09\u8005\u7686\u70ba\u9670\u6027\u3002\u524d\u54e8(sentinel)\u6dcb\u5df4\u7d50\u5207\u7247\u986f\u793a\u67092\u9846\u6dcb\u5df4\u7d50\u6709\u764c\u7d30\u80de\u4fb5\u72af\u967d\u6027\u3002\u5979\u4e00\u822c\u8eab\u9ad4\u72c0\u6cc1\u5927\u81f4\u826f\u597d\uff0c\u7121\u5df2\u77e5\u5171\u75c5(comorbidities)\u3002\u5b8c\u6574\u7684\u764c\u75c7\u5206\u671f\u5f71\u50cf\u6aa2\u67e5\u4e26\u7121\u5df2\u77e5\u8f49\u79fb\u75c5\u7076\u3002\u653e\u5c04\u816b\u7624\u91ab\u5e2b\u5efa\u8b70\u5b89\u6392\u653e\u5c04\u7dda\u6cbb\u7642\u3002\u4f60\u5efa\u8b70\u75c5\u4eba\u7684\u6cbb\u7642\u8a08\u756b\uff0c\u4e0b\u5217\u9078\u9805\u4f55\u8005\u8f03\u70ba\u5408\u5b9c?\nA. Lumpectomy\u52a0\u4e0aradiation therapy\u5df2\u8db3\u5920\nB. \u9700\u52a0\u4e0acomplete mastectomy\nC. \u9700\u52a0\u4e0aaxillary lymph node dissection, followed by tamoxifen for 5 years\nD. \u9700\u52a0\u4e0a6 cycles of capecitabine chemotherapy\nE. \u9700\u52a0\u4e0a4 cycles of doxorubicin + cyclophosphamide (AC), followed by paclitaxel chemotherapy\n": "(E)", "106-2.\n\u4e00\u4f4d66\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u6700\u8fd1\u88ab\u8a3a\u65b7\u7f79\u60a3\u7b2c\u56db\u671f\u60e1\u6027\u9ed1\u8272\u7d20\u7d30\u80de\u764c\uff0c\u764c\u75c7\u5206\u671f\u6aa2\u67e5\u986f\u793a\u5df2\u6709\u591a\u8655\u809d\u81df\u3001\u80ba\u81df\u8207\u9aa8\u9abc\u8f49\u79fb\u3002\u4ed6\u7684\u81e8\u5e8a\u75c7\u72c0\u5305\u62ec\u547c\u5438\u6025\u4fc3\u3001\u54b3\u55fd\u3001\u9aa8\u9abc\u75bc\u75db\u8207\u9ad4\u91cd\u6e1b\u8f15\u7d045\u516c\u65a4\u3002\u816b\u7624\u6aa2\u9ad4\u4e4b\u57fa\u56e0\u6aa2\u6e2c\u986f\u793aBRAF\u57fa\u56e0\u4e4bV600E\u7a81\u8b8a\u967d\u6027\u3002\u4f60\u5efa\u8b70\u9078\u64c7\u7d66\u4e88\u4f55\u7a2e\u85e5\u5291\u6cbb\u7642\u8f03\u70ba\u9069\u5b9c?\nA. Gefitinib\nB. Vemurafenib\nC. Trametinib\nD. Imatinib\nE. Sorafenib\n": "(B)", "106-3.\n\u4e0084\u6b72\u5973\u6027\u75c5\u4eba\u5728\u904e\u53bb3\u9031\u5167\u7a81\u7136\u6709\u4e00\u9838\u90e8\u5feb\u901f\u9577\u5927\u7684\u816b\u584a\uff0c\u5979\u547c\u5438\u6025\u4fc3\u3001\u8072\u97f3\u6c99\u555e\u3001\u5589\u56a8\u75bc\u75db\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u5979\u7532\u72c0\u817a\u5de6\u8449\u6709\u4e0010\u516c\u5206\u5927\u5c0f\u7684\u786c\u816b\u584a\uff0c\u5589\u93e1\u6aa2\u67e5\u5df2\u767c\u73fe\u816b\u7624\u76f4\u63a5\u64f4\u5c55\u4fb5\u72af\u6c23\u7ba1\uff0c\u80f8\u90e8X\u5149\u7247\u986f\u793a\u5169\u5074\u80ba\u91ce\u5df2\u6709\u8a31\u8a31\u591a\u591a\u5c0f\u65bc1\u516c\u5206\u7684\u80ba\u7d50\u7bc0\u3002\u7d30\u91dd\u62bd\u5438\u7d30\u80de\u5b78\u6aa2\u67e5\u78ba\u8a3a\u70ba\u300c\u5206\u5316\u4e0d\u826f\u7684\u7532\u72c0\u817a\u764c\u300d(anaplastic thyroid cancer)\u3002\u56de\u9867\u4e00\u500b\u6708\u524d\uff0c\u5979\u4ecd\u80fd\u5927\u81f4\u7368\u7acb\u65e5\u5e38\u751f\u6d3b\uff0c\u4f46\u8fd13\u9031\u4f86\u6025\u901f\u60e1\u5316\uff0c\u5df2\u5411\u75c5\u4eba\u53ca\u5bb6\u5c6c\u8aaa\u660e\u6b64\u764c\u75c7\u4e4b\u81e8\u5e8a\u9810\u5f8c\u5341\u5206\u4e0d\u826f\u3002\u4f60\u5efa\u8b70\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\uff0c\u76f8\u5c0d\u8f03\u70ba\u9069\u5b9c?\nA. Bortezomib\u6a19\u9776\u6cbb\u7642\nB. Vandetanib\u6a19\u9776\u6cbb\u7642\nC. Brentuximab vedotin\u55ae\u682a\u6297\u9ad4\u6cbb\u7642\nD. Palliative external beam radiation therapy to the neck\nE. Surgical en bloc resection of the thyroid, anterior tracheal wall with reconstruction, followed by chemotherapy\n": "(D)", "106-4.\n\u6709\u4e0065\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u670970-pack-years\u7684\u62bd\u83f8\u53f2\uff0c\u8207\u6162\u6027\u963b\u585e\u6027\u80ba\u75c5(COPD)\uff0c\u6aa2\u67e5\u767c\u73fe\u5728ambient air\u4e4b\u4e0b\uff0c\u6c27\u6c23\u98fd\u548c\u5ea6\u4ecd\u670997%\uff0c\u4f46\u5410\u6c23expiratory phase\u5247\u5df2\u660e\u986f\u5ef6\u9577\u3002\u5176\u4ed6\u7406\u5b78\u6aa2\u67e5\u5927\u81f4\u826f\u597d(unremarkable)\u3002\u5979\u5e0c\u671b\u5b89\u6392\u80ba\u764c\u7be9\u6aa2(screening)\u6aa2\u67e5\u3002\u4f60\u5efa\u8b70\u4f55\u7a2e\u7be9\u6aa2\u6aa2\u67e5\u8f03\u70ba\u9069\u5b9c?\nA. Chest X-ray\nB. 18-FDG-PET-CT scan\nC. Serum CEA (carcinoembryonic antigen)\nD. Low-dose non-contrast CT scan of the chest\nE. Routine screening for lung cancer should NOT be offered to her\n": "(D)", "106-5.\n\u4e0066\u6b72\u7537\u6027\u7cd6\u5c3f\u75c5\u75c5\u4eba\uff0c\u904e\u53bb\u75c5\u53f2\u4e3b\u8981\u6709\u6162\u6027\u75b2\u5026\u75c7\u5019\u7fa4(chronic fatigue syndrome)\u3002\u6700\u8fd1\uff0c\u4ed6\u7d93\u8a3a\u65b7\u7f79\u60a3\u7b2c\u56db\u671f\u8f49\u79fb\u6027\u814e\u7d30\u80de\u764c(renal cell carcinoma, RCC)\uff0c\u5408\u4f75\u80ba\u81df\u8207\u9aa8\u9abc\u8f49\u79fb\u3002\u4ed6\u4e3b\u8a34\u8f15\u5ea6\u9aa8\u9abc\u75bc\u75db\uff0c\u672a\u958b\u59cb\u6cbb\u7642\u524d\u5df2\u6709\u4e2d\u5ea6\u75b2\u5026(baseline moderate fatigue)\u75c7\u72c0\u3002\u4f60\u70ba\u4ed6\u9078\u64c7\u7b2c\u4e00\u7dda\u6cbb\u7642\u85e5\u5291\uff0c\u5efa\u8b70\u4ee5\u4e0b\u4f55\u8005\u6700\u70ba\u9069\u5b9c?\nA. Erlotinib\nB. Sunitinib\nC. Pazopanib\nD. Everolimus\nE. Axitinib\n": "(C)", "106-6.\n\u4e0029\u6b72\u5e74\u8f15\u5973\u6027\uff0c\u8fd13\u500b\u6708\u4f86\u53f3\u524d\u81c2\u8207\u53f3\u624b\u6f38\u6f38\u611f\u89ba\u9ebb\u6728\u8207\u77e5\u89ba\u7570\u5e38(paresthesia)\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u53f3\u524d\u81c2\u8207\u53f3\u624b\u8155\u4f38\u5c55(extension)\u660e\u986f\u7121\u529b\uff0c\u5979\u8eab\u4e0a\u6709\u591a\u767c\u7684\u5c0f\u5c0f\u795e\u7d93\u7e96\u7dad\u7624(neurofibromas)\u7d50\u7bc0\uff0c\u8a31\u591a\u7684\u5496\u5561\u725b\u5976\u50cf(cafe-au-lait)\u7684\u76ae\u819a\u6591\u584a\uff0c\u814b\u4e0b\u8207\u80a1\u6e9d\u6709\u591a\u767c\u6591\u9ede(freckles)\uff0c\u53f3\u814b\u4e0b\u6709\u4e00\u500b\u5805\u786c\u7684(firm)\u816b\u584a\u3002\u5169\u5074\u4e73\u623f\u6aa2\u67e5\u4e26\u7121\u7570\u5e38\u7684\u767c\u73fe\u3002\u96fb\u8166\u65b7\u5c64(CT)\u6383\u63cf\u986f\u793a\u53f3\u814b\u4e0b\u6709\u4e00\u500b5\u516c\u5206\u76f4\u5f91\u5927\u5c0f\u7684\u816b\u584a\u3002\u5979\u63a5\u53d7\u53f3\u814b\u4e0b\u816b\u584a\u5207\u7247\uff0c\u63a8\u6e2c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55?\nA. Adenocarcinoma\nB. Squamous cell carcinoma\nC. Malignant peripheral nerve sheath tumor\nD. Leiomyosarcoma\nE. Lymphoma\n": "(C)", "106-7.\n\u4e00\u4f4d31\u6b72\u5e74\u8f15\u7537\u6027\u75c5\u4eba\uff0c\u8a3a\u65b7\u7f79\u60a3\u7d50\u8178\u764c(colon cancer)\u3002\u4ed6\u6709\u5df2\u77e5\u7684\u7d50\u8178\u764c\u5bb6\u65cf\u75c5\u53f2\uff0c\u5305\u62ec\uff1a\u4ed6\u6bcd\u89aa\u572823\u6b72\u6642\u66fe\u88ab\u8a3a\u65b7\u7f79\u60a3\u7b2c\u4e00\u671f\u5b50\u5bae\u5167\u819c\u764c(endometrial cancer)\uff0c\u7d93\u6cbb\u7642\u5f8c\u75ca\u7652\uff0c\u4e4b\u5f8c\u53c8\u572846\u6b72\u6642\u8a3a\u65b7\u6709\u7d50\u8178\u764c\u3002\u4ed6\u7684\u5916\u7956\u723655\u6b72\u6642\u56e0\u7d50\u8178\u764c\u53bb\u4e16\u3002\u4ed6\u768436\u6b72\u59ca\u59ca\u6700\u8fd1\u5728\u5927\u8178\u5167\u8996\u93e1\u6aa2\u6642\u4e5f\u767c\u73fe\u7b2c\u4e00\u671f\u7d50\u8178\u764c\uff0c\u4f46\u4e26\u7121\u984d\u5916\u7684\u606f\u8089(polyps)\u88ab\u767c\u73fe\u3002\u9019\u4f4d31\u6b72\u7537\u6027\u7d50\u8178\u764c\u75c5\u4eba\uff0c\u6700\u53ef\u80fd\u6709\u4ee5\u4e0b\u7684\u57fa\u56e0\u8b8a\u7570?\nA. ATM\u57fa\u56e0\u7684loss of heterozygosity\nB. p53\u6291\u764c\u57fa\u56e0\u7684germline mutation\nC. Rb\u6291\u764c\u57fa\u56e0\u7684germline mutation\nD. MSH2\u57fa\u56e0\u7684germline mutation\nE. Nucleotide excision repair\u76f8\u95dc\u57fa\u56e0\u7684somatic mutation\n": "(D)", "106-8.\n\u4e0065\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u9ad4\u80fdperformance status (PS)\u826f\u597d\uff0c\u4e14\u6c92\u6709\u660e\u986f\u5df2\u77e5\u5171\u75c5(comorbidities)\uff0c\u88ab\u78ba\u8a3a\u8f49\u79fb\u6027\u80c3\u817a\u764c\uff0cHER2\u9670\u6027\uff0c\u75c5\u4eba\u5df2\u6709\u809d\u81df\u8207\u8179\u819c\u8f49\u79fb\u3002\u4ed6\u63a5\u53d7\u7b2c\u4e00\u7dda\u5316\u5b78\u6cbb\u7642\u6ce8\u5c04Cisplatin\u4f75\u7528\u6bcf\u903124\u5c0f\u6642\u9ad8\u5291\u91cf5-FU\u52a0\u4e0a\u6d3b\u6027\u8449\u9178(Cisplatin-HDFL\u8655\u65b9)\uff0c\u4e8c\u500b\u6708\u5f8c\u816b\u7624\u9806\u5229\u9054\u5230\u90e8\u5206\u7de9\u89e3(partial response)\uff0c\u4e14\u526f\u4f5c\u7528\u8f15\u5fae\uff0c\u75c5\u4eba\u8010\u53d7\u6027\u826f\u597d\u3002\u75c5\u4eba\u6301\u7e8c\u7b2c\u4e00\u7dda\u5316\u7642\u51718\u500b\u6708\u5f8c\uff0c\u96fb\u8166\u65b7\u5c64(CT)\u6383\u63cf\u986f\u793a\u809d\u81df\u8f49\u79fb\u75c5\u7076\u958b\u59cb\u589e\u5927\u60e1\u5316\uff0c\u7b26\u5408progressive disease (PD)\u3002\u6b64\u6642\u75c5\u4eba\u9ad4\u80fd\u72c0\u6cc1performance status (PS)\u4ecd\u826f\u597d(WHO/ECOG\r0-1)\uff0c\u4e14\u6709\u9ad8\u5ea6\u610f\u9858\u63a5\u53d7\u7b2c\u4e8c\u7dda\u6cbb\u7642\u3002\u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u6cbb\u7642\uff0c\u4f55\u8005\u53ef\u70ba\u5408\u9069\u7684\u9078\u9805?\r(1)\tSecond-line chemotherapy with irinotecan\r(2)\tSecond-line chemotherapy with paclitaxel or docetaxel\r(3)\tSecond-line therapy with ramucirumab (VEGFR2\u55ae\u682a\u6297\u9ad4)\r(4)\tSecond-line therapy with ramucirumab plus paclitaxel\r(5)\tBest supportive care alone\nA. \u50c5(5)\u9069\u5408\nB. \u50c5(1)\u3001(2)\u9069\u5408\nC. \u50c5(1)\u3001(2)\u3001(3)\u9069\u5408\nD. (1)\u3001(2)\u3001(3)\u3001(5)\u5747\u9069\u5408\nE. (1)\u3001(2)\u3001(3)\u3001(4)\u5747\u9069\u5408\n": "(E)", "106-9.\n\u4e0056\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u904e\u53bb15\u5e74\u9678\u7e8c\u6709intermittent diarrhea\u8179\u7009\u7684\u75c7\u72c0\uff0c\u5747\u88ab\u8a3a\u65b7\u70ba\u8178\u8e81\u75c7irritable bowel syndrome\u7d66\u4e88\u75c7\u72c0\u6cbb\u7642\u3002\u6700\u8fd1\u4e00\u5e74\u4f86\uff0c\u5979\u958b\u59cb\u6709\u8173\u8e1d\u6c34\u816bankle edema\uff0c\u4e14\u6f38\u6709\u60e1\u5316\u8da8\u52e2\uff0c\u6f38\u6f38\u9700\u53e3\u670d\u5229\u5c3f\u5291\u624d\u80fd\u7de9\u89e3\u3002\u4ed4\u7d30\u8a62\u554f\u75c5\u53f2\uff0c\u5979\u9593\u65b7\u6709\u71b1\u6f6e\u7d05(hot flashes)\u7684\u60c5\u5f62\u5df2\u6709\u591a\u5e74\uff0c\u4f46\u4e00\u76f4\u7576\u4f5c\u662f\u505c\u7d93\u75c7\u5019\u7fa4\u7684\u4e00\u90e8\u5206\u75c7\u72c0\u3002\u7406\u5b78\u6aa2\u67e5\u6240\u898b\u75c5\u4eba\u767c\u80b2\u8207\u71df\u990a\u72c0\u614b\u826f\u597d\uff0c\u7121\u9ec3\u75b8\uff0c\u7121\u5468\u908a\u6dcb\u5df4\u7d50\u816b\u5927\uff0chepatojugular reflux\u967d\u6027\uff0c\u5fc3\u81df\u807d\u8a3a\u6709\u660e\u986fS3\u5fc3\u97f3\uff0c\u809d\u816b\u5927\u81f3\u53f3\u808b\u7de3\u4e0b\u7d043\u6307\u5e45\uff0c\u4e14\u660e\u986f\u5169\u5074\u8db3\u8e1d\u6c34\u816b\u3002\u4f60\u5efa\u8b70\u9032\u4e00\u6b65\u70ba\u6b64\u75c5\u4eba\u5b89\u6392\u4ee5\u4e0b\u7684\u6aa2\u67e5\uff0c\u4f55\u8005\u9069\u5b9c?\r(1)\t24-hour urine for 5-HIAA (5-hydroxyindoleacetic acid)\r(2)\tCT scan of the abdomen and pelvis\r(3)\tOctreoscan\r(4)\tEchocardiogram\r(5)\t18-FDG-PET scan\nA. \u50c5(1)\u9069\u5408\nB. \u50c5(1)+(2)\u9069\u5408\nC. \u50c5(1)+(2)+(3)\u9069\u5408\nD. (1)+(2)+(3)+(4)\u5747\u9069\u5408\nE. (1)+(2)+(3)+(5)\u5747\u9069\u5408\n": "(D)", "106-10.\n\u764c\u75c7\u7684\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291(immune checkpoint inhibitors)\u6216\u6a19\u9776\u6cbb\u7642\u85e5\u5291(molecular targeted agents)\u901a\u5e38\u91dd\u5c0d\u7279\u5b9a\u7684\u8a0a\u606f\u50b3\u905e\u8def\u5f91\u6216\u5206\u5b50\u6a19\u9776\u9032\u884c\u6291\u5236\uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684\u3002\u6cbb\u7642\u85e5\u5291\u8207\u514d\u75ab\u6216\u5206\u5b50\u6a19\u9776\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u6b63\u78ba?(1)Afatinib\u8207EGFR\uff1b(2)Ipilimumab\u8207CTLA-4\uff1b(3)Trastuzumab\u8207HER-2\uff1b(4)Rituximab\u8207CD30\uff1b(5)Nivolumab\u8207PD-1\nA. (1)+(2)+(3)+(5)\nB. (1)+(2)+(3)+(4)\nC. (2)+(3)+(4)+(5)\nD. (3)+(4)+(5)\nE. (2)+(4)+(5)\n": "(A)", "107-1.\n\u4e00\u4f4d35\u6b72\u75c5\u4eba\u9664\u4e0a\u4e0b\u80a2\u5076\u6709\u6de4\u9752\u5916\u7121\u5176\u4ed6\u4e0d\u9069\u3002\u5728\u5065\u5eb7\u6aa2\u67e5\u6642\u767c\u73fe\u5c0f\u817f\u6709\u4e00\u8655\u6de4\u9752\uff0c\u5176\u4ed6\u7121\u7570\u5e38\u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u5c0f\u677f\u6578\u70ba47000/\u03bcL\uff0c\u8840\u7d05\u7d20\u3001\u767d\u8840\u7403\u6578\u53ca\u5206\u985e\u6b63\u5e38\uff0c\u5176\u4ed6\u809d\u3001\u814e\u529f\u80fd\u7121\u7570\u5e38\uff0cHBsAg(-)\uff0cAnti-HBs(+)\uff0cAnti-HCV(-)\uff1bHIV(-)\uff1bC3\uff0cC4\uff0c\u53caANA\u5728\u6b63\u5e38\u7bc4\u570d\uff0c\u80c3\u93e1\u6aa2\u67e5\u7121\u7279\u6b8a\u767c\u73fe\u3002\u5c0d\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55\uff1f\nA. \u8f38\u6ce8\u8840\u5c0f\u677f\u6fc3\u7e2e\u6db2\nB. \u53e3\u670d\u985e\u56fa\u9187\nC. \u975c\u8108\u6ce8\u5c04\u514d\u75ab\u7403\u86cb\u767d\nD. \u975c\u8108\u6ce8\u5c04Rituximab\nE. \u89c0\u5bdf\u53ca\u8ffd\u8e64\uff0c\u4e0d\u9700\u6cbb\u7642\n": "(E)", "107-2.\n\u4e00\u4f4d68\u6b72\u5a66\u5973\u56e0\u70ba\u8179\u75db\u4f86\u5230\u6025\u8a3a\u8655\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u4e0b\u8179\u90e8\u6709\u4e00\u816b\u584a\uff0c\u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u8179\u5167\u6709\u4e005\u516c\u5206\u5927\u4e4b\u8840\u816b\u3002\u75c5\u4eba\u904e\u53bb\u7121\u51fa\u8840\u50be\u5411\u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d2010.5 gm/dL\uff0c\u767d\u8840\u74039650/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f175000/\u03bcL\uff1bPT 12\u79d2\uff0caPPT 55\u79d2\uff1b\u75c5\u4eba\u8207\u6b63\u5e38\u4eba\u4e4b\u8840\u6f3f\u6df7\u5408\u8a66\u9a57(mixing test)\uff0caPTT\u70ba48\u79d2\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u6297\u78f7\u8102\u75c7\u5019\u7fa4(anti-phospholipid antibody syndrome)\nB. \u809d\u81df\u8870\u7aed\nC. \u5f8c\u5929\u8840\u53cb\u75c5\nD. von Willebrand\u75be\u75c5\nE. \u5f4c\u6f2b\u6027\u8840\u7ba1\u5167\u51dd\u8840(DIC)\n": "(C)", "107-3.\n\u4e00\u4f4d28\u6b72\u5973\u6027\u56e0\u904b\u52d5\u5f8c\u547c\u5438\u6025\u4fc3\u6c42\u8a3a\u3002\u8eab\u9ad4\u6aa2\u67e5\u9664\u81c9\u8272\u84bc\u767d\u5916\u7121\u5176\u4ed6\u7570\u5e38\uff1b\u62bd\u8840\u6aa2\u67e5\u986f\u793a\uff0c\u8840\u7d05\u7d207.2 gm/dL\uff0cMCV 69 fL\uff0c\u767d\u8840\u74034350/\u03bcL\uff0c\u8840\u5c0f\u677f395000/\u03bcL\uff1b\u56de\u9867\u5979\u5728\u5927\u5b78\u5165\u5b78\u6642\u7684\u62bd\u8840\u7d50\u679c\uff0c\u8840\u7d05\u7d20\u70ba11.5 gm/dL\uff0cMCV 88 fL\u3002\u5c0d\u5176\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\u7684\u6aa2\u67e5\u70ba\u4f55\uff1f\nA. \u8840\u7d05\u7d20\u96fb\u6cf3\u5206\u6790(Hb electrophoresis)\nB. \u8840\u6e05\u9435\u6fc3\u5ea6\nC. \u81ea\u9ad4\u514d\u75ab\u6297\u9ad4\u6aa2\u6e2c\nD. \u7532\u72c0\u817a\u529f\u80fd\u6aa2\u6e2c\nE. \u814e\u529f\u80fd\u6aa2\u6e2c\n": "(B)", "107-4.\n\u4e00\u4f4d43\u6b72\u7537\u6027\u62b1\u6028\u9019\u5e7e\u500b\u6708\u4f86\u5c0f\u4fbf\u4e0d\u6642\u6703\u5448\u73fe\u6df1\u7d05\u8272\u3002\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u81c9\u8272\u84bc\u767d\uff0c\u8f15\u5fae\u9ec3\u75b8\uff1b\u8840\u6db2\u6aa2\u67e5\u8840\u7d05\u7d20\u70ba8.2 gm/dL\uff0cMCV 101 fL\uff0c\u7db2\u72c0\u7d05\u8840\u74034.5%\uff0c\u767d\u8840\u74033150/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff0c\u8840\u5c0f\u677f78000/\u03bcL\uff1b\u81bd\u7d05\u7d20(bilirubin)\u5168\u91cf3.5 mg/dL\uff0c\u76f4\u63a5\u578b0.5 mg/dL\uff0cALT 30 U/L\uff0cAST 85 U/L\uff0cLDH 2100 U/L\uff0cCoombs test\u9670\u6027\uff1b\u5c0f\u4fbf\u6f5b\u8840\u967d\u6027(+++)\uff0c\u86cb\u767d(+/-)\uff0c\u5c3f\u6db2\u6c88\u6fb1\u5f8c\u9ad8\u500d\u986f\u5fae\u93e1\u4e0b\u89c0\u5bdf\u7d05\u8840\u74032-3\u500b\uff0c\u767d\u8840\u74030-2\u500b\u3002\u4e0b\u9762\u4f55\u9805\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\nA. \u6d41\u5f0f\u7d30\u80de\u5100(flow cytometry)\u6aa2\u6e2c\u8840\u7403\u4e0aCD55\u53caCD59\u7684\u8868\u73fe\nB. B\u578b\u53caC\u578b\u809d\u708e\u6aa2\u6e2c\nC. \u8840\u6e05\u7dad\u751f\u7d20B12\u6e2c\u5b9a\nD. \u9aa8\u9ad3\u6aa2\u67e5\nE. \u8179\u90e8\u8d85\u97f3\u6ce2\u6aa2\u67e5\n": "(A)", "107-5.\n\u4e00\u4f4d78\u6b72\u75c5\u4eba\u56e0\u5bb9\u6613\u75b2\u5026\u4f86\u8a3a\uff0c\u7121\u5176\u4ed6\u4e0d\u9069\u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d209.1 gm/dL\uff0c\u767d\u8840\u74033250/\u03bcL\uff0c\u5206\u985e\u67092% blasts\uff0c\u8840\u5c0f\u677f32000/\u03bcL\uff1b\u9aa8\u9ad3\u6aa2\u67e5\u986f\u793a\u9020\u8840\u7d30\u80de\u6709\u5316\u751f\u4e0d\u826f(dysplasia)\uff0c\u82bd\u7d30\u80de\u4f54\u6240\u6709\u6709\u6838\u7d30\u80de\u76849%\uff0c\u67d3\u8272\u9ad4\u7570\u5e38\u8d85\u904e3\u500b\u3002\u5c0d\u6b64\u75c5\u4eba\u76ee\u524d\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55\uff1f\nA. Antithymocyte globulin\nB. Azacitidine\nC. Danazol\nD. Allogeneic hematopoietic stem cell transplantation\nE. Platelet concentrate transfusion\n": "(B)", "107-6.\n\u4e00\u4f4d42\u6b72\u7537\u6027\u75c5\u4eba\u904e\u53bb\u7121\u7279\u6b8a\u75c5\u53f2\uff0c\u8eab\u9ad4\u4ea6\u7121\u4e0d\u9069\uff0c\u5728\u4e00\u6b21\u5065\u5eb7\u6aa2\u67e5\u767c\u73fe\u8840\u5c0f\u677f\u6578\u70ba896000/\u03bcL\uff0c\u8840\u7d05\u7d2013.5 gm/dL\uff0c\u767d\u8840\u740310500/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38\uff1b\u5206\u5b50\u6aa2\u9a57\u767c\u73fe\u6709JAK2V617F\u7a81\u8b8a\u3002\u4ee5\u4e0b\u4f55\u8005\u70ba\u76ee\u524d\u6700\u9069\u7576\u7684\u6cbb\u7642\uff1f\nA. Hydroxyurea\nB. Anagrelide\nC. Ruxolitinib\nD. Busulfan\nE. Observation\n": "(E)", "107-7.\n\u4e00\u4f4d65\u6b72\u7537\u6027\u5728\u9ad4\u9a57\u6642\u7121\u610f\u767c\u73fe\u8840\u7d05\u7d2010.5 gm/dL\uff0c\u767d\u8840\u7403130810/\u03bcL\uff0c\u8840\u5c0f\u677f47000/\u03bcL\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Acute myeloid leukemia\nB. Chronic myeloid leukemia\nC. Leukemoid reaction\nD. Hemolytic anemia\nE. Myelodysplastic syndrome\n": "(B)", "107-8.\n\u4e00\u4f4d57\u6b72\u5973\u6027\u56e0\u70ba\u865b\u5f31\uff0c\u610f\u8b58\u6df7\u4e82\u88ab\u5bb6\u4eba\u9001\u5230\u6025\u8a3a\u8655\uff0c\u8eab\u9ad4\u6aa2\u67e5\u986f\u793a\u9ad4\u6eab37.9\u00b0C\uff0c\u8f15\u5fae\u9ec3\u75b8\uff0c\u624b\u8173\u6709\u6de4\u9752\uff0c\u7121\u9ecf\u819c\u51fa\u8840\uff1b\u5c0d\u6642\u3001\u5730\u6709\u4e9b\u6df7\u6dc6\uff0c\u4f46\u53ef\u4ee5\u56de\u7b54\u554f\u984c\uff0c\u4ea6\u7121\u5c40\u90e8\u611f\u89ba\u53ca\u795e\u7d93\u5b78\u5fb5\u72c0\u3002\u8840\u6db2\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d207.5 gm/dL\uff0c\u7db2\u72c0\u7d05\u8840\u74035.4 %\uff0c\u8840\u5c0f\u677f11000/\u03bcL\uff0c\u767d\u8840\u74038500/\u03bcL\uff0c\u5206\u985e\u6709normoblast\uff0c\u5168\u81bd\u7d05\u7d20(bilirubin) 3.1 mg/dL\uff0c\u76f4\u63a5\u578b0.7 mg/dL\uff0cALT 23 U/L\uff0cAST 55 U/L\uff0cLDH 1350 U/L\uff0cCr 1.1 mg/dL\uff0cPT\u53caaPTT\u6b63\u5e38\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u3002\u4e0b\u5217\u90a3\u4e9b\u8655\u7f6e\u5c0d\u75c5\u4eba\u662f\u6709\u5e6b\u52a9\u7684\uff1f (1). platelet concentrate transfusion (2). plasma exchange (3). immunomodulatory therapy\nA. (2)\nB. (3)\nC. (1)+(2)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(D)", "107-9.\n\u4e0b\u5217\u5fae\u751f\u7269\u611f\u67d3\u8207\u5176\u53ef\u80fd\u9020\u6210\u4e4b\u8840\u6db2\u60e1\u6027\u75c5\u7684\u914d\u5c0d\uff0c\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f (1). Ebstein-Barr virus: Nasal type NK/T cell lymphoma (2). Hepatitis C virus: Lymphoplasmacytoid lymphoma (3). Helicobacter pylori: Gastric mucosa associated lymphoid tissue lymphoma (4). HTLV-1: Adult T-cell lymphoma/leukemia\nA. (1)+(2)\nB. (1)+(3)\nC. (3)+(4)\nD. (1)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(E)", "107-10.\n\u4e0b\u5217\u4f55\u8005\u70baInternational Staging System(ISS)\u5c0d\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u5206\u671f\u6240\u6839\u64da\u7684\u9810\u5f8c\u56e0\u5b50\uff1f (1). Serum albumin level (2). Serum monoclonal globulin level (3). Serum beta2-microglobulin (4). Serum lactate dehydrogenase level\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(4)\nD. (1)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(B)", "107-1.\n49\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u7f79\u60a3\u8f49\u79fb\u6027\u80ba\u817a\u764c(NSCLC, adenocarcinoma)\uff0c\u5df2\u63a5\u53d7\u7b2c\u4e00\u7ddacarboplatin\u3001paclitaxel\uff0c\u5408\u4f75bevacizumab\u6cbb\u7642\uff0c\u6709\u6548\"\u7de9\u89e3\"(partial response)\u4e00\u6bb5\u671f\u9593\u4e4b\u5f8c\"\u60e1\u5316\"(progressive disease)\u3002\u4ed6\u7684\u9ad4\u80fd\u72c0\u614bperformance status (PS)\u70ba1\uff0c\u91ab\u5e2b\u91dd\u5c0d\u4ed6\u5468\u908a\u80ba\u91ce\u8f03\u5927\u7684\u75c5\u7076\u5b89\u6392\u91cd\u65b0\u5207\u7247\uff0c\u5206\u5b50\u6aa2\u6e2c\u767c\u73feALK\u57fa\u56e0rearrangement\u967d\u6027\u3002\u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u6cbb\u7642\uff0c\u4f55\u8005\u6700\u70ba\u9069\u5b9c?\nA. Pemetrexed\nB. Gemcitabine\nC. Docetaxel\nD. Erlotinib\nE. Crizotinib\n": "(E)", "107-2.\n68\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u6709\u9ad8\u8840\u58d3\u75c5\u53f2\u820750 pack-years\u7684\u5438\u83f8\u53f2\uff0c\u56e0\u7121\u75db\u6027\u5de8\u89c0\u8840\u5c3f\u75c7(painless gross hematuria)\u6c42\u8a3a\uff0c\u521d\u6b21\u4ee5\u670d\u7528\u4e00\u500b\u7642\u7a0b\u5ee3\u6548\u6027\u6297\u751f\u7d20\u6cbb\u7642\uff0c\u4f46\u8840\u5c3f\u4f9d\u7136\u6301\u7e8c\u5b58\u5728\u3002\u6ccc\u5c3f\u79d1\u91ab\u5e2b\u70ba\u4ed6\u5b89\u6392cystoscopy\u6aa2\u67e5\uff0c\u767c\u73fe\u8180\u80f1\u5f8c\u58c1\u6709\u4e003\u516c\u5206\u7684\u816b\u7624\u3002\u5207\u7247\u75c5\u7406\u6aa2\u67e5\u8b49\u5be6\u70ba\u4e00\u300c\u808c\u8089\u4fb5\u5165\u578b\u6ccc\u5c3f\u4e0a\u76ae\u8180\u80f1\u764c\u300d(muscle-invasive urothelial carcinoma)\u3002\u96fb\u8166\u65b7\u5c64(CT)\u6383\u63cf\u986f\u793a\u5ee3\u6cdb\u7684\u8180\u80f1\u58c1\u6d78\u6f64\u589e\u539a\uff0c\u76ee\u524d\u7121\u5468\u570d\u6dcb\u5df4\u7d50\u589e\u5927\u7684\u8de1\u8c61\u3002\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u6cbb\u7642\u8a08\u756b\uff0c\u4f55\u8005\u70ba\u6700\u9069\u5b9c\u7684\u9078\u9805?\nA. Repeat transurethral biopsy\nB. Intravesical BCG (Bacille Calmette-Guerin)\nC. Neoadjuvant cisplatin-based combination chemotherapy, followed by radical cystectomy\nD. Capecitabine-based chemotherapy\nE. Radiation therapy alone\n": "(C)", "107-3.\n30\u6b72\u5e74\u8f15\u7537\u6027\u75c5\u4eba\uff0c\u8a3a\u65b7\u7f79\u60a3\u7d50\u8178\u764c(colon cancer)\u3002\u4ed6\u6709\u5df2\u77e5\u7684\u7d50\u8178\u764c\u5bb6\u65cf\u75c5\u53f2\uff0c\u5305\u62ec\uff1a\u4ed6\u6bcd\u89aa\u572825\u6b72\u6642\u66fe\u88ab\u8a3a\u65b7\u7f79\u60a3\u7b2c\u4e00\u671f\u5b50\u5bae\u5167\u819c\u764c(endometrial cancer)\uff0c\u7d93\u6cbb\u7642\u5f8c\u75ca\u7652\uff0c\u4e4b\u5f8c\u53c8\u572845\u6b72\u6642\u8a3a\u65b7\u6709\u7d50\u8178\u764c\u3002\u4ed6\u7684\u5916\u7956\u723653\u6b72\u6642\u56e0\u7d50\u8178\u764c\u53bb\u4e16\u3002\u4ed6\u768435\u6b72\u59ca\u59ca\u6700\u8fd1\u5728\u5927\u8178\u5167\u8996\u93e1\u6aa2\u6642\u4e5f\u767c\u73fe\u7b2c\u4e00\u671f\u7d50\u8178\u764c\uff0c\u4f46\u4e26\u6c92\u6709\u984d\u5916\u7684\u606f\u8089(polyps)\u88ab\u767c\u73fe\u3002\u9019\u4f4d30\u6b72\u7537\u6027\u7d50\u8178\u764c\u75c5\u4eba\uff0c\u6700\u53ef\u80fd\u6709\u4ee5\u4e0b\u7684\u57fa\u56e0\u8b8a\u7570?\nA. MSH2\u57fa\u56e0\u7684germline mutation\nB. p53\u6291\u764c\u57fa\u56e0\u7684germline mutation\nC. Rb\u6291\u764c\u57fa\u56e0\u7684germline mutation\nD. Nucleotide excision repair (NER)\u76f8\u95dc\u57fa\u56e0\u7684somatic mutation\nE. ATM\u57fa\u56e0\u7684loss of heterozygosity\n": "(A)", "107-4.\n67\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u4e3b\u8a34\u4e8c\u500b\u6708\u9010\u6f38\u52a0\u91cd\u7684\u53f3\u8170\u75db\uff0c\u5408\u4f75\u4e00\u500b\u6708\u9010\u6f38\u52a0\u91cd\u7684\u8840\u5c3f(hematuria)\u3002\u56e0\u8840\u5c3f\u5230\u4e00\u822c\u8a3a\u6240\u8a3a\u7642\uff0c\u8a3a\u6240\u91ab\u5e2b\u5148\u4ee5\u8180\u80f1\u708e\u6cbb\u7642\u4e09\u9031\uff0c\u4f46\u672a\u898b\u6539\u5584\u3002\u4e14\u81ea\u89ba\u6c92\u6709\u80c3\u53e3\u5728\u4e8c\u500b\u6708\u5167\u9ad4\u91cd\u6e1b\u8f15\u7d04\u4e09\u516c\u65a4\u3002\u75c5\u4eba\u8f49\u81f3\u5927\u91ab\u9662\u6c42\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u89f8\u8a3a\u5df2\u767c\u73fe\u53f3\u8170\u90e8\u6709\u81f3\u5c115\u516c\u5206\u5927\u5c0f\u816b\u584a\uff0c\u814e\u529f\u80fd\u5927\u81f4\u6b63\u5e38\u3002\u5f71\u50cf\u6aa2\u67e5\u767c\u73fe\u53f3\u814e\u6709\u4e009.6\u516c\u5206\u5be6\u9ad4\u816b\u584a\uff0c\u5169\u5074\u80ba\u91ce\u6709\u591a\u767c\u7684\u80ba\u7d50\u7bc0\uff0c\u986f\u793a\u5df2\u6709\u591a\u767c\u80ba\u81df\u8f49\u79fb\u3002\u7d30\u91dd\u7a7f\u523a\u5207\u7247\u75c5\u7406\u8b49\u5be6\u70ba\u814e\u7d30\u80de\u764c(renal cell carcinoma)\u4e4b\u4eae\u7d30\u80de(clear cell)\u4e9e\u578b\u3002 \u5efa\u8b70\u4e0b\u4e00\u6b65\u5982\u4f55\u8655\u7f6e\u6700\u70ba\u5408\u9069?\nA. Radical nephrectomy\nB. Gemcitabine\nC. Sunitinib\nD. Interleukin-2\nE. Interferon-\u03b3\n": "(C)", "107-5.\n55\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u8a3a\u65b7\u7f79\u60a3\u7b2c\u4e8c\u671f\u4e73\u764c\uff0c\u63a5\u53d7\u4e73\u623f\u5207\u9664\u624b\u8853(mastectomy)\u5f8c\uff0c\u75c5\u7406\u6aa2\u67e5\u767c\u73fe\u6709\u5169\u9846\"\u814b\u4e0b\u6dcb\u5df4\u7d50\"\u816b\u7624\u4fb5\u72af\u967d\u6027\uff0c\u816b\u7624\u7d44\u7e54\u514d\u75ab\u67d3\u8272\u986f\u793aestrogen\u63a5\u53d7\u9ad4\u967d\u6027(ER+)\uff0cprogesterone\u63a5\u53d7\u9ad4\u967d\u6027(PR+)\uff0cHER2/Neu\u9ad8\u5ea6\u8868\u73fe(3+)\u3002\u624b\u8853\u5f8c\u63a5\u53d7\"\u8f14\u52a9\u6027\"(adjuvant)\u8907\u65b9\u6cbb\u7642(doxorubicin\u3001cisplatin\u3001trastuzumab)\u3002\u4e0b\u5217\u4f55\u7a2e\u53ef\u80fd\u6bd2\u6027\u548cdoxorubicin\u8f03\u5bc6\u5207\u76f8\u95dc?\nA. Cardiomyopathy\uff0creversible\nB. Cardiomyopathy\uff0cirreversible\nC. Sensorimotor neuropathy\uff0creversible\nD. Sensorimotor neuropathy\uff0cirreversible\nE. Hearing loss\uff0cirreversible\n": "(B)", "107-6.\n40\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u7f79\u60a3\u7b2c\u56db\u671f\u5375\u5de2\u764c(ovarian cancer)\uff0c\u63a5\u53d7carboplatin\u5408\u4f75paclitaxel\u5316\u5b78\u6cbb\u7642\u3002\u7d93\u904e6\u500b\u7642\u7a0bcarboplatin\u5408\u4f75paclitaxel\u8907\u65b9\u5316\u5b78\u6cbb\u7642\u4e4b\u5f8c\uff0c\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u524d\u5f8c\u6bd4\u8f03\u7684\u7d50\u679c\uff0c\u816b\u7624\u7e3d\u91cf(tumor burden)\u5171\u6e1b\u5c11\u4e8625%\u3002\u53ef\u4ee5\u8a55\u4f30\u5979\u7684\u5375\u5de2\u764c\u5c0d\u5316\u5b78\u6cbb\u7642\u7684\"\u53cd\u61c9\"(response)\u70ba\u4f55?\nA. Complete response (CR)\nB. Partial response (PR)\nC. Stable disease (SD)\nD. Progressive disease (PD)\nE. \u4ee5\u4e0a\u7686\u975e\n": "(C)", "107-7.\n48\u6b72\u5973\u6027\u75c5\u4eba\uff0c3\u5e74\u524d\u56e0\u5f8c\u4e0a\u80cc\u90e8\u9ed1\u8272\u7d20\u7624(melanoma)\u624b\u8853\u5207\u9664\uff0c\u764c\u75c7\u5206\u671f\u7b2cIIB\u671f\u3002\u5979\u56e0\u547c\u5438\u6025\u4fc3\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u767c\u73fe\u5169\u5074\u80ba\u91ce\u591a\u767c\u75c5\u7076\uff0c\u5f8c\u7e8c\u6aa2\u67e5\u8b49\u5be6\u60e1\u6027\u9ed1\u8272\u7d20\u7624\u5169\u5074\u80ba\u8f49\u79fb\u3002\u5728\u6c7a\u5b9a\u9078\u64c7\u6a19\u9776\u6cbb\u7642\u3001\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291\u3001\u6216\u5316\u5b78\u6cbb\u7642\u4e4b\u524d\uff0c\u61c9\u6aa2\u9a57\u4f55\u7a2e\u57fa\u56e0\u7a81\u8b8a(genetic mutation)\uff0c\u53ef\u4f5c\u70ba\u9078\u64c7\u6cbb\u7642\u4e4b\u53c3\u8003?\nA. C-KIT\nB. N-RAS\nC. MEK\nD. BRAF\nE. ERK\n": "(D)", "107-8.\n\u6709\u95dc\u80f0\u81df\u764c(pancreatic cancer)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u771f?\nA. \u7531\u65bc\u8d85\u904e85%\u7684\u80f0\u81df\u764c\u8a3a\u65b7\u8f03\u665a\uff0c\u5df2\u5c6c\u7121\u6cd5\u624b\u8853\u5207\u9664(inoperable)\u6216\u5df2\u8f49\u79fb\uff0c\u6240\u4ee5\u5404\u671f\u5225\u5408\u4f75\u8a08\u7b97\u7684\u80f0\u81df\u764c5\u5e74\u5b58\u6d3b\u7387\u6574\u9ad4\u5c0f\u65bc10%\nB. \u80f0\u81df\u764c\u82e5\u80fd\u65e9\u671f\u8a3a\u65b7\uff0c5\u5e74\u5b58\u6d3b\u7387\u53ef\u80fd\u63d0\u5347\u81f3\u7d0420%\uff0c\u751a\u81f3\u66f4\u9ad8\u4e9b\nC. \u904e\u53bb\u5341\u5e74\u4f86\uff0c\u7b2c\u56db\u671f\u8f49\u79fb\u6027\u80f0\u81df\u764c\u76845\u5e74\u5b58\u6d3b\u7387\u6709\u9577\u8db3(3\u500d\u5de6\u53f3)\u7684\u5927\u5e45\u63d0\u5347\nD. \u62bd\u83f8\u662f\u80f0\u81df\u764c\u7684\u5371\u96aa\u56e0\u5b50(risk factor)\u4e4b\u4e00\nE. \u559d\u9152\u672c\u8eab\u4e0d\u662f\u80f0\u81df\u764c\u7684\u91cd\u8981\u5371\u96aa\u56e0\u5b50(risk factor)\n": "(C)", "107-9.\n\u4ee5\u4e0b\u90a3\u4e9b\u75c5\u75c7\u6216\u75c7\u5019\u7fa4(syndrome)\u6703\u589e\u52a0\u60a3\u8005\u7f79\u60a3\u764c\u75c7\u7684\u98a8\u96aa\uff1f(1).\tFanconi's anemia (2). Down syndrome (3). Von Hippel-Lindau syndrome (4). Fragile X syndrome (5). Neurofibromatosis\nA. (1)+(2)+(4)\nB. (2)+(3)+(4)\nC. (1)+(2)+(3)+(5)\nD. (1)+(3)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(C)", "107-10.\n\u764c\u75c7\u7684\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291(immune checkpoint inhibitors)\u6216\u6a19\u9776\u6cbb\u7642\u85e5\u5291(molecular targeted agents)\u901a\u5e38\u91dd\u5c0d\u7279\u5b9a\u7684\u8a0a\u606f\u50b3\u905e\u8def\u5f91\u6216\u5206\u5b50\u6a19\u9776\u9032\u884c\u6291\u5236\uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684\u3002\u6cbb\u7642\"\u85e5\u5291\"\u8207\u514d\u75ab\u6216\u5206\u5b50\"\u6a19\u9776\"\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u771f\uff1f(1). Afatinib\u8207EGFR (2).\tIpilimumab\u8207PD-L1 (3).\tTrastuzumab\u8207HER-2 (4). Rituximab\u8207CD20 (5). Pembrolizumab\u8207PD-1\nA. (1)+(2)+(3)+(4)\nB. (1)+(3)+(4)+(5)\nC. (2)+(3)+(4)+(5)\nD. (2)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(B)", "108-1.\n\u4e00\u4f4d\u75c5\u4eba\u62bd\u8840\u6aa2\u67e5\u986f\u793aHb\u70ba10.2 gm/dL\uff0cMCV 75 fL\uff0creticulocyte 0.8%\uff0cferritin 78 ng/mL(\u53c3\u8003\u503c5-200)\uff0ciron 41 \u03bcg/dL(\u53c3\u8003\u503c50-200)\uff0cTIBC 230 \u03bcg/dL(\u53c3\u8003\u503c260-590)\uff0c\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u6b63\u5e38\u3002\u9019\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\uff1a\nA. Iron deficiency anemia\nB. Thalassemia\nC. Anemia of chronic disease\nD. Folic acid deficiency anemia\nE. Hemolytic anemia\n": "(C)", "108-2.\n\u4e0b\u5217\u6709\u95dc\u9663\u767c\u6027\u591c\u9593\u8840\u8272\u7d20\u5c3f\u7684\u81e8\u5e8a\u8868\u73fe\u4f55\u8005\u662f\u932f\u7684\uff1f\nA. PIG A gene mutation\nB. CD55 and CD59 deficiency on blood cells\nC. Hypercoagulable state\nD. Intravascular hemolysis\nE. Bilirubinuria\n": "(E)", "108-3.\n\u4e00\u4f4d75\u6b72\u75c5\u4eba\u9577\u671f\u56e0\u9ad8\u8840\u58d3\u4e00\u76f4\u898f\u5247\u770b\u8a3a\u3002\u6700\u8fd1\u62bd\u8840\u6aa2\u67e5\u7121\u610f\u4e2d\u767c\u73fe\u8840\u6e05\u4e2d\u6709IgG/kappa\u55ae\u682a\u7403\u86cb\u767d(monoclonal gammopathy)\uff0cIgG 3700 mg/dL\uff0c\u5176\u4ed6\u8840\u6db2\u6aa2\u67e5\u5982\u8840\u7d05\u7d20\u3001\u767d\u8840\u7403\u53ca\u8840\u5c0f\u677f\u6578\u3001\u8840\u9223\u53ca\u814e\u529f\u80fd\u6b63\u5e38\uff1b\u9aa8\u9ad3\u6aa2\u67e5\u986f\u793a\u6f3f\u7d30\u80de\u70ba35%\uff0c\u9aa8\u9abc\u6aa2\u67e5\u7121\u8755\u9aa8\u75c5\u8b8a\u3002\u6b64\u4f4d\u75c5\u4eba\u6700\u6070\u7576\u7684\u8a3a\u65b7\u70ba\uff1f\nA. Monoclonal gammopathy of undetermined significance\nB. Smoldering multiple myeloma\nC. Symptomatic multiple myeloma\nD. Waldenstrom's macroglobulinemia\nE. Light chain disease\n": "(B)", "108-4.\nIbrutinib\u5c0d\u67d0\u4e9b\u6dcb\u5df4\u60e1\u6027\u75be\u75c5\u5982chronic lymphocytic leukemia, mantle cell lymphoma\u7b49\u975e\u5e38\u6709\u6548\u3002\u5b83\u7684\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f\nA. Phosphoinositide-3 kinase (PI3K) inhibitor\nB. Burton tyrosine kinase (BTK) inhibitor\nC. B-cell lymphoma 2 (BCL-2) inhibitor\nD. Anti-CD79a monoclonal antibody\nE. Anti-CD19 monoclonal antibody\n": "(B)", "108-5.\n\u4e00\u4f4d63\u6b72\u75c5\u4eba\u88ab\u8a3a\u65b7\u70ba\u56b4\u91cd\u578b\u518d\u751f\u4e0d\u826f\u6027\u8ca7\u8840\uff0c\u7d93\u904eAnti-thymocyte globulin\u53cacyclosporine\u6cbb\u7642\u5f8c\u53cd\u61c9\u4e0d\u4f73\uff0c\u4ecd\u5168\u8840\u7403\u4f4e\u4e0b\uff0c\u7d93\u5e38\u9700\u8981\u8f38\u8840\u3002\u6b64\u6642\u6700\u6709\u6548\u4e4b\u6cbb\u7642\u65b9\u5f0f\u70ba\u4f55\uff1f\nA. Eltrombopag\nB. Danazol\nC. Steroid\nD. G-CSF\nE. Erythropoietin\n": "(A)", "108-6.\n\u4e00\u4f4d\u75c5\u4eba\u8840\u6db2\u6aa2\u67e5\u767c\u73fe\u8840\u6db2\u76f8\u7570\u5e38\uff0c\u8840\u6db2\u62b9\u7247\u5982\u5716\u6240\u793a\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u5f97\u4e86\u4ec0\u9ebc\u75c5\uff1f\nA. \u6162\u6027\u6dcb\u5df4\u589e\u751f\u6027\u75be\u75c5\nB. \u6162\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\nC. \u6025\u6027\u524d\u9aa8\u9ad3\u7d30\u80de\u767d\u8840\u75c5\nD. \u6025\u6027\u55ae\u6838\u7d30\u80de\u767d\u8840\u75c5\nE. \u6025\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5\n": "(C)", "108-7.\n\u4e00\u4f4d58\u6b72\u75c5\u4eba\u56e0\u5927\u817f\u75bc\u75db\u6709\u786c\u584a\u61c9\u8a3a\uff0c\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u6709\u808c\u8089\u5167\u8840\u816b\u584a\uff0c\u7d93\u5be6\u9a57\u5ba4\u6aa2\u67e5\u8a3a\u65b7\u70ba\u5f8c\u5929A\u578b\u8840\u53cb\u75c5(acquired hemophilia A)\u3002\u4ee5\u4e0b\u8207\u6b64\u75c5\u76f8\u95dc\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f\nA. \u591a\u56e0\u514d\u75ab\u7570\u5e38\u6240\u5f15\u8d77(immune mediated)\nB. Prothrombin time\u6b63\u5e38\nC. Thrombin time\u6b63\u5e38\nD. Mixing test\u5c07\u75c5\u4eba\u8207\u6b63\u5e38\u4eba\u4e4b\u8840\u6f3f\u6df7\u5408\u5f8c2\u5c0f\u6642\u5f8c\u6aa2\u9a57\uff0caPTT\u6703\u6062\u5fa9\u6b63\u5e38\nE. \u53ef\u4ee5\u7528activated prothrombin complex concentrate (aPCC)\u6cbb\u7642\n": "(D)", "108-8.\n\u51b7\u51cd\u6c88\u6fb1(Cryoprecipitate)\u53ef\u7528\u65bc\u6cbb\u7642\u4f55\u7a2e\u75c5\u4eba\uff1f\r(1) Hypofibrinogenemia\r(2) Hypoalbuminemia\r(3) Hemophilia A\r(4) von Willebrand disease\nA. (1)+(2)\nB. (1)+(3)\nC. (1)+(2)+(3)\nD. (1)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(D)", "108-9.\n\u4e0b\u5217\u6709\u95dc\u6dcb\u5df4\u7624\u53ca\u5176\u76f8\u5c0d\u61c9\u4e4b\u67d3\u8272\u9ad4\u8b8a\u7570\uff0c\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f\r(1) Follicular lymphoma : t(14;18)\r(2) Mantle cell lymphoma : t(3;14)\r(3) Burkitt lymphoma : t(8;14)\nA. (1)\nB. (3)\nC. (1)+(3)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(C)", "108-10.\n\u4e00\u4f4d34\u6b72\u7537\u58eb\u56e0\u70ba\u76ae\u819a\u51fa\u73fe\u7d2b\u6591\u61c9\u8a3a\uff0c\u7121\u670d\u85e5\u75c5\u53f2\u6216\u5176\u4ed6\u4e0d\u9069\u3002\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u8840\u7d05\u7d2013.2 gm/dL\uff0c\u8840\u5c0f\u677f12000/\u03bcL\uff0c\u767d\u8840\u7403\u6578\u53ca\u5206\u985e\u6b63\u5e38\uff0c\u809d\u3001\u814e\u529f\u80fd\u3001\u5c3f\u6db2\u53ca\u7cde\u4fbf\u6b63\u5e38\u3002\u4e0b\u5217\u4f55\u8005\u662f\u5c0d\u6b64\u75c5\u4eba\u9069\u7576\u7684\u6cbb\u7642\uff1f\r(1)\u8f38\u6ce8\u8840\u5c0f\u677f\u6fc3\u7e2e\u6db2\r(2) \u670d\u7528\u985e\u56fa\u9187\r(3)\u813e\u81df\u5207\u9664\nA. (1)\nB. (2)\nC. (1)+(2)\nD. (2)+(3)\nE. (1)+(2)+(3)\n": "(B)", "108-1.\n\u80ba\u816b\u7624\u7684\u6cbb\u7642\u9078\u9805\uff0c\u4e0a\u76ae\u751f\u9577\u56e0\u5b50\u63a5\u53d7\u9ad4(EGFR, epidermal growth factor receptor)\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291\u85e5\u7269\u662f\u91cd\u8981\u7684\u9078\u64c7\u3002\u4e0b\u5217\u4f55\u7a2e\u75c5\u4eba\u80ba\u816b\u7624\u6709\u300cEGFR\u7a81\u8b8a\u300d\u7684\u6a5f\u7387\u6700\u9ad8?\nA. A 35-year-old woman with a carcinoid tumor\nB. A 25-year-old man with a hamartoma\nC. A 75-year-old man with squamous cell carcinoma and a history of asbestos exposure\nD. A 58-year-old man with a 100-pack-year history of tobacco use with small-cell lung carcinoma\nE. A 54-year-old woman who has never smoked with an adenocarcinoma\n": "(E)", "108-2.\n\u4e00\u4f4d58\u6b72\u5973\u6027\u56e0\u8173\u4e0a\u6709\u4e00\u9010\u6f38\u9577\u5927\u7684\u9ed1\u75e3\u800c\u81f3\u76ae\u819a\u79d1\u6c42\u8a3a\uff0c\u9ed1\u75e3\u6700\u9577\u76f4\u5f91\u7d049mm\uff0c\u908a\u7de3\u4e0d\u898f\u5247\uff0c\u75c5\u4eba\u81ea\u5df1\u767c\u89ba\u9ed1\u75e3\u9664\u4e86\u9010\u6f38\u8b8a\u5927\u4e4b\u5916\uff0c\u984f\u8272\u4e5f\u6f38\u52a0\u6df1\u8b8a\u9ed1\u3002\u5207\u7247\u6aa2\u67e5\u8b49\u5be6\u662f\u9ed1\u8272\u7d20\u7624(melanoma)\uff0c\u6df1\u5ea6\u7531\u76ae\u819a\u8868\u9762\u4e00\u76f4\u5ef6\u4f38\u5165\u771f\u76ae\u5c64(dermis)\u5171\u6df1\u90540.5mm\uff0c\u8a08\u7b97\u6bcf1mm\u4e4b\u6709\u7d72\u5206\u88c2(mitosis)<1 (<1 mitosis/mm)\u3002\u4e0b\u5217\u56e0\u7d20\u4f55\u8005\u5c0d\u75c5\u4eba\u9ed1\u8272\u7d20\u7624\u7684\u9810\u5f8c(prognosis)\u7684\u5f71\u97ff\u6700\u5927?\nA. Anatomic site\nB. Sex\nC. Number of mitoses\nD. Breslow Depth\nE. Clark level\n": "(D)", "108-3.\n\u4e0069\u6b72\u7537\u6027\uff0c\u75c5\u7406\u5207\u7247\u8a3a\u65b7\u78ba\u8a3a\u7f79\u60a3\u5c0f\u7d30\u80de\u80ba\u764c (SCLC, small-cell lung cancer)\uff0cPET/CT\u6383\u63cf\u7d50\u679c\u986f\u793a\u53f3\u5074\u80ba\u9580(hilar)\u90e8\u4f4d\u6709\u4e004 x 5\u516c\u5206\u816b\u584a\uff0c\u4e14\u540c\u5074\u6709\u4e2d\u7b49\u91cf(moderate)\u7684\u808b\u819c\u7a4d\u6c34\uff0c\u7d93\u808b\u819c\u7a4d\u6c34\u7a7f\u523a\u6aa2\u67e5\uff0c\u808b\u819c\u7a4d\u6c34\u7d30\u80de\u5b78\u8b49\u5be6\u540c\u6a23\u6709SCLC\u764c\u7d30\u80de\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u771f?\nA. Surgical therapy alone has a high curative rate for his stage of SCLC\nB. Radiation plays no palliative role at all in therapy for this disease\nC. Twenty percent of patients with SCLC are diagnosed with the same stage of disease as this patient\nD. The majority of patients with SCLC of this stage respond to chemotherapy alone and go into remission with a very high 3-year survival\nE. This patient has extensive-stage disease\n": "(E)", "108-4.\n\u4e0b\u5217\u5371\u96aa\u56e0\u5b50\uff0c\u4f55\u8005\u8207\u98df\u9053\u9c57\u72c0\u4e0a\u76ae\u7d30\u80de\u764c(squamous cell carcinoma)\u8207\u98df\u9053\u817a\u764c(adenocarcinoma)\u5747\u5bc6\u5207\u76f8\u95dc?\nA. Male sex\nB. Chronic gastroesophageal reflux disease\nC. Barrett's esophagus\nD. Lye ingestion\nE. Cigarette smoking\n": "(E)", "108-5.\n\u82e5\u91dd\u5c0d\u300c\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u4e0a\u76ae\u764c\u300d(CUP, carcinoma of unknown primary)\u7684\u816b\u7624\u6aa2\u9ad4\uff0c\u9032\u884c\u6b21\u4e16\u4ee3\u57fa\u56e0\u5b9a\u5e8f\u5206\u6790(NGS, next generation sequencing)\uff0c\u6700\u5e38\u898b\u767c\u751f\u57fa\u56e0\u8b8a\u7570(GA, genetic alterations)\u7684\u57fa\u56e0\u70ba\u4e0b\u5217\u4f55\u8005?\nA. KRAS\nB. CDKN2A\nC. ARID1A\nD. TP53\nE. MTOR\n": "(D)", "108-6.\n\u4e00\u4f4d31\u6b72\u7537\u6027\uff0c\u82e5\u6709\u4e0b\u5217\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\u6216\u5bb6\u65cf\u75c5\u53f2\uff0c\u6703\u9700\u8981\u5c07\u300c\u907a\u50b3\u6027\u975e\u591a\u767c\u606f\u8089\u6027\u5927\u8178\u764c\u300d (HNPCC\uff0chereditary nonpolyposis colon cancer) \u7a4d\u6975\u5217\u5165\u7be9\u6aa2(screening)\u7684\u8003\u616e?\nA. Innumerable polyps visualized on routine colonoscopy\nB. Mucocutaneous pigmentation\nC. New diagnosis of ulcerative colitis\nD. (A)+(B)+(C)\nE. Father, paternal uncle, and paternal cousin with colon cancer diagnosed at age 50, 66, and 35 years, respectively\n": "(E)", "108-7.\n\u4e0b\u5217\u75c5\u4eba\u60c5\u5f62\uff0c\u4f55\u8005\u8207\u7f79\u60a3\u982d\u9838\u90e8\u764c\u75c7(head and neck cancers)\u7684\u98a8\u96aa\u589e\u52a0\uff0c\u6700\u7121\u95dc\u9023?\nA. Alcohol consumption\nB. Tobacco consumption\nC. Helicobacter pylori infection\nD. Epstein Barr virus infection\nE. Human papillomavirus infection\n": "(C)", "108-8.\n\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u5e38\u898b\u7684\u60e1\u6027\u6dcb\u5df4\u816b\u7624 (lymphoid malignancy)?\nA. Chronic lymphoid leukemia (CLL)\nB. Acute lymphoid leukemia (ALL)\nC. Hodgkin lymphoma (HD)\nD. Non-Hodgkin lymphoma (NHL)\nE. Multiple myeloma (MM)\n": "(D)", "108-9.\n48\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u7f79\u60a3\u7b2c\u56db\u671f\u5375\u5de2\u764c(ovarian cancer)\uff0c\u63a5\u53d76\u500b\u7642\u7a0bcarboplatin\u5408\u4f75paclitaxel\u5316\u5b78\u6cbb\u7642\u5f8c\uff0c\u6bd4\u8f03\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u524d\u5f8c\u7684\u5dee\u7570\uff0c\u5982\u7642\u6548\u8a55\u4f30\u6839\u64daResponse Evaluation Criteria in Solid Tumors (RECIST), \u7b2c1.1\u7248(Ver. 1.1)\u7684\u5b9a\u7fa9\uff0c\u82e5\u816b\u7624\u6cbb\u7642\u5f8c\u53ef\u6e2c\u91cf\u7684\u816b\u7624\u300c\u6700\u9577\u76f4\u5f91\u300d(longest diameters)\u7684\u7e3d\u548c\uff0c\u5171\u7e2e\u5c0f\u4e8615%\uff0c\u4e14\u6548\u679c\u6301\u7e8c\u81f3\u5c114\u9031\u3002\u53ef\u4ee5\u8a55\u4f30\u5979\u7684\u5375\u5de2\u764c\u5c0d\u5316\u5b78\u6cbb\u7642\u7684\"\u53cd\u61c9\" (response)\u70ba\u4f55?\nA. Complete response (CR)\nB. Partial response (PR)\nC. Stable disease (SD)\nD. Progressive disease (PD)\nE. \u4ee5\u4e0a\u7686\u975e\n": "(C)", "108-10.\n\u6709\u95dc\u81bd\u7ba1\u764c(cholangiocarcinoma)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u4e26\u4e0d\u6b63\u78ba?\nA. The incidence of cholangiocarcinoma has been increasing in recent years\nB. Primary sclerosing cholangitis and hepatitis C virus infection are associated with cholangiocarcinoma\nC. Most patients present due to an abnormal screening ultrasound, without symptoms\nD. Asians infected with liver flukes have an increased risk of cholangiocarcinoma\nE. Surgical resection may achieve 40% 5-year Survival with an R0 resection\n": "(C)", "109-160.\u4e00\u4f4d57\u6b72\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u4eba\uff0c\u57fa\u56e0\u6aa2\u6e2c\u767c\u73fe\u6709FLT3-ITD\uff0c\u4e0b\u5217\u4f55\u7a2e\u8a98\u5c0e\u6cbb\u7642\u6700\u70ba\u9069\u7576\uff1f    \nA.Anthracycline \u52a0Cytarabine\nB.Anthracycline \u52a0Cytarabine \u52a0Midostaurin\nC.Anthracycline \u52a0Vetoposide\nD.Anthracycline \u52a0Cytarabine \u52a0Vetoposide\nE.Cyclophosphamide \u52a0Cytarabine\n": "[B]", "109-161.\u4e00\u4f4d65\u6b72\u5973\u6027\u75c5\u4eba\u62bd\u8840\u6aa2\u67e5\u767c\u73feHb \u70ba19.5 gm/dL\uff0cHct 58.5%\uff0cWBC 15400 /\u03bcL\uff0cplatelet 435000 /\u03bcL\u3002\u4ee5\n\u4e0b\u4f55\u7a2e\u57fa\u56e0\u7a81\u8b8a\u53ef\u5e6b\u5fd9\u8a3a\u65b7\u6b64\u75c5\u4eba\u5f97\u4e86\u771f\u6027\u7d05\u8840\u7403\u589e\u591a\u75c7 (PV)\uff1f   \nA.BCR/ABL fusion\nB.ASXL1\nC.CALR\nD.JAK2\nE.RUNX1\n": "[D]", "109-162.Daratumumab\u5df2\u6709\u5065\u4fdd\u7d66\u4ed8\u4f5c\u70ba\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684\u85e5\u7269\uff0c\u5176\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f    \nA.Anti-CD38 antibody\nB.Anti-CD20 antibody\nC.Anti-CD138 antibody\nD.Proteosome inhibitor\nE.Histone deacetylase inhibitor\n": "[A]", "109-163.\u4e00\u4f4d\u6162\u6027\u95dc\u7bc0\u708e\u60a3\u8005\u62bd\u8840\u6aa2\u67e5\u986f\u793a\u6709\u8ca7\u8840 \uff0c\u7d93\u8a73\u7d30\u6aa2\u67e5\u6392\u9664\u5176\u4ed6\u539f\u56e0\u5f8c \uff0c\u88ab\u8a3a\u65b7\u70ba\u6162\u6027\u75be\u60a3\u9020\u6210\u7684\u8ca7\n\u8840(anemia of chronic disease )\uff0c\u4e0b\u5217\u4f55\u8005\u8207\u6b64\u8a3a\u65b7\u4e0d\u7b26\u5408 \uff1f      \nA.Microcytic anemia\nB.Low serum iron\nC.Normal or high serum ferritin\nD.Increased iron stores\nE.Decreased hepcidin production\n": "[E]", "109-164.Double-hit\u5f4c\u6f2b\u6027\u5927 B\u7d30\u80de\u6dcb\u5df4\u7624(DLBCL)\u9810\u5f8c\u5f88\u5dee\uff0c\u9019\u4e9b\u75c5\u4eba\u7684\u6dcb\u5df4\u7624\u7d30\u80de\u6709\u90a3\u5169\u500b\u57fa\u56e0\u91cd\u7d44\uff1f    \nA.MYC, BCL2\nB.BCL2, BCL6\nC.MYC, MCL1\nD.BCL2, MCL1\nE.MYC, BCL1\n": "[A]", "109-165.\u4e0b\u5217\u6a19\u9776\u6cbb\u7642\u8207\u75be\u75c5\u7684\u914d\u5c0d\u4f55\u8005\u662f\u932f\u8aa4\u7684\uff1f    \nA.Eltrombopag- Immune thrombocytopenic purpura\nB.Rituximab- B-cell lymphoma\nC.Brentuximab- Hodgkin\u2019s lymphoma\nD.Ibrutinib- Multiple myeloma\nE.Imatinib- Chronic myeloid leukemia\n": "[D]", "109-166.\u4e0b\u5217\u6709\u95dc\u8f38\u8840\u76f8\u95dc\u4e4b\u6025\u6027\u80ba\u640d\u50b7(Transfusion-related acute lung injury)\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f    \nA.\u767c\u751f\u539f\u56e0\u591a\u70ba\u6350\u8840\u8005\u9ad4\u5167\u6709\u9ad8\u6fc3\u5ea6\u4e4bAnti-HLA class II \u6297\u9ad4\nB.\u4e00\u822c\u767c\u751f\u65bc\u8f38\u8840\u5f8c24\u5c0f\u6642\nC.\u75c5\u4eba\u6709\u7f3a\u6c27\u73fe\u8c61\nD.\u6703\u51fa\u73fe\u80ba\u6c34\u816b\nE.\u8f38\u6ce8\u7537\u6027\u6216\u672a\u66fe\u61f7\u5b55\u5a66\u5973\u7684\u8840\u53ef\u6e1b\u5c11\u767c\u751f\u6a5f\u7387\n": "[B]", "109-167.\u4e00\u4f4d75\u6b72\u7537\u58eb \uff0c\u904e\u53bb\u7121\u7279\u6b8a\u75c5\u53f2 \uff0c\u5728\u4f8b\u884c\u62bd\u8840\u6aa2\u67e5\u6642\u767c\u73feHb 9.2 gm/dL\uff0cWBC 2600 /\u03bcL\uff0cblasts \n2%\uff0csegmented neutrophils 35 %\uff0cmonocytes 8%\uff0clymphocytes 55 %\uff0c\u8840\u5c0f\u677f23000 /\u03bcL\uff1b\u9aa8\u9ad3\u6aa2\u67e5\u986f\n\u793a\u9020\u8840\u7d30\u80de\u5316\u751f\u4e0d\u826f (dysplasia )\uff0cblasts 9%\uff0c\u67d3\u8272\u9ad4\u70ba\u8907\u96dc\u8b8a\u5316 \u3002\u6b64\u75c5\u4eba\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55 \uff1f   \nA.Packed RBC transfusion\nB.Platelet concentrate transfusion\nC.Erythropoietin\nD.Azacitidine\nE.Allogeneic hematopoietic stem cell transplantation\n": "[D]", "109-168.Cryoprecipitate\u4e2d\u5e36\u6709\u90a3\u4e9b\u51dd\u8840\u56e0\u5b50 \uff1f\n(1) fibrinogen\n(2) Factor VII\n(3) Factor VIII\n(4) von Willebrand factor   \nA.(1)\nB.(2)   \nC.(1)+(3)\nD.(1)+(3)+(4)\nE.(1)+(2)+(3)\n": "[D]", "109-169.\u4e00\u4f4d55\u6b72\u7537\u58eb\u904e\u53bb\u7121\u7279\u6b8a\u75c5\u53f2 \uff0c\u56e0\u547c\u5438\u6025\u4fc3\u53ca\u76ae\u819a\u7600\u9752\u61c9\u8a3a \uff0c\u8eab\u9ad4\u6aa2\u67e5\u7121\u809d\u813e\u816b\u5927 \uff0c\u9ad4\u6eab\u6b63\u5e38 \u3002\u62bd\u8840\u6aa2\u67e5\n\u986f\u793aHb 7.8 gm/dL\uff0cWBC 1250 /\u03bcL\uff0cneutrophils 20 %\uff0cmonocytes 6%\uff0clymphocytes 74 %\uff0c\u8840\u5c0f\n\u677f13000/\u03bcL\uff1b\u809d\u814e\u529f\u80fd\u6b63\u5e38 \uff0c\u8840\u6e05\u9435\u3001\u7dad\u5316\u547dB12\u53ca\u8449\u9178\u503c\u6b63\u5e38 \uff1b\u9aa8\u9ad3\u6aa2\u67e5\u986f\u793a\u9020\u8840\u7d30\u80de\u4f54\u6709\u6838\u7d30\u80de\n\u4e4b10%\uff0cblasts\u767e\u5206\u6bd4\u6b63\u5e38 \uff0c\u7121\u5316\u751f\u4e0d\u826f (dysplasia) \u8b8a\u5316 \uff0c\u6b64\u6642\u6700\u9069\u7576\u7684\u6cbb\u7642\u70ba\u4f55 \uff1f\n(1) allogeneic hematopoietic stem cell transplantation\n(2) cyclosporine\n(3) anti-thymocyte globulin\n(4) G-CSF   \nA.(1)\nB.(2)\nC.(2)+(3)\nD.(1)+(4)\nE.(2)+(3)+(4)\n": "[C]", "109-170.\u4e0068\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u8a3a\u65b7\u7f79\u60a3\u4e59\u72c0\u7d50\u8178\u764c (adenocarcinoma, sigmoid colon )\uff0c\u4ee5\u6839\u6cbb\u6027\u624b\u8853\u5207\u9664\u5de6\u5074\u4e59\u72c0\u7d50\n\u8178\u8207\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853 \uff0c\u75c5\u7406\u7d44\u7e54\u78ba\u5b9a\u624b\u8853\u908a\u7de3\u6c92\u6709\u764c\u7d30\u80de \uff0c\u6e05\u9664\u6dcb\u5df4\u7d50\u517125\u9846\u4e2d\u75c5\u7406\u6aa2\u67e5\u6709 6\u9846\u5df2\u6709\u764c\u7d30\n\u80de\uff0c\u6c92\u6709\u9060\u8655\u5668\u5b98\u8f49\u79fb \uff0c\u91ab\u5e2b\u5efa\u8b70\u624b\u8853\u5f8c\u9032\u884c 6\u500b\u6708\u5316\u5b78\u6cbb\u7642\u4ee5\u964d\u4f4e\u5fa9\u767c\u7387\u8207\u589e\u52a0\u5b58\u6d3b \u3002\u5404\u7a2e\u81e8\u5e8a\u6307\u5f15\u5747\n\u4e00\u81f4\u5efa\u8b70\u4e4b\u6700\u9069\u5408\u4e4b\u8f14\u52a9\u6027 (adjuvant )\u6cbb\u7642\u8655\u65b9\u70ba\u4f55\u8005 \uff1f   \nA.Irinotecan added to 5-FU and Leucovorin (FOLFIRI)\nB.Oxaliplatin added to 5-FU and Leucovorin (FOLFOX)\nC.Bevacizumab added to FOLFOX\nD.Cetuximab added to FOLFOX\nE.Panitumumab added to FOLFOX\n": "[B]", "109-171.\u764c\u75c7\u75c5\u4eba\u7684\u8655\u7406\u8a55\u4f30 \uff0c\u9ad4\u80fd\u72c0\u614b (Performance status, PS) \u662f\u4e00\u500b\u91cd\u8981\u7684\u5e38\u7528\u6307\u6a19 \u3002\u9ad4\u80fd\u72c0\u614b\u7684\u8a55\u4f30\u6709\u4e00\n\u500b\u6cbf\u7528\u591a\u5e74\u7684\u6307\u6a19Karnofsky performance status (KPS)\u3002\u4eca\u6709\u4e00\u4f4d60\u6b72\u764c\u75c7\u75c5\u4eba \uff0c\u4ed6\u65e5\u5e38\u751f\u6d3b\u5b8c\u5168\u53ef\u4ee5\n\u81ea\u7406(self-care)\uff0c\u4e0d\u9700\u4eba\u5e6b\u5fd9 \u3002\u4f46\u662f\u4ed6\u5df2\u6c92\u6709\u8fa6\u6cd5\u6b63\u5e38\u7684\u5de5\u4f5c (active work )\uff0c\u4e5f\u6c92\u6709\u8fa6\u6cd5\u53c3\u52a0\u6b63\u5e38\u6d3b\n\u52d5\uff08normal activity )\u3002\u91ab\u5e2b\u4f30\u8a08\u9019\u6a23\u7684\u75c5\u4ebaKPS\u7d04\u70ba\u5e7e\u5206 \uff1f   \nA.KPS 90\nB.KPS 80\nC.KPS 70\nD.KPS 60\nE.KPS 50\n": "[C]", "109-172.\u4e00\u4f4d70\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u7a81\u7136\u56e0\u610f\u8b58\u6df7\u4e82 (confusion )\u88ab\u5bb6\u4eba\u9001\u81f3\u6025\u8a3a\u5ba4 \u3002\u751f\u547d\u5fb5\u8c61 (TPR\u8207\u8840\u58d3 )\u5927\u81f4\u7a69\u5b9a \uff0c\u4e26\n\u6c92\u6709\u5c40\u90e8\u795e\u7d93\u5b78\u5fb5\u8c61 \u3002\u521d\u6b65\u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u8840\u6e05\u9223\u6578\u503c 3.55mmol/L (14.2mg/dL)\uff0cBUN\u8207Cre\u6578\u503c\u8f15\u5fae\u4e0a\n\u5347\u3002\u80f8\u90e8X\u5149\u651d\u5f71(CXR)\u767c\u73fe\u5169\u5074\u80ba\u91ce\u6709\u591a\u767c\u80ba\u7d50\u7bc0 (nodules)\uff0c\u9ad8\u5ea6\u61f7\u7591\u662f\u8f49\u79fb\u7684\u60e1\u6027\u816b\u7624 \u3002\u4e4b\u5f8c\u7684\u5be6\u9a57\n\u5ba4\u6aa2\u67e5\u986f\u793aPTH -rP (parathyroid hormone -related protein )\u6578\u503c\u660e\u986f\u4e0a\u5347 \u3002\u4e0b\u5217\u7684\u9ad8\u8840\u9223\u75c7\u4e4b\u8655\u7f6e\u6700 \"\u4e0d\"\u9700\n\u8981\uff1f   \nA.Normal saline\nB.Pamidronate   \nC.Furosemide\nD.Prednisolone\nE.Calcitonin\n": "[D]", "109-173.\u4e0b\u5217\u75c5\u4eba\u60c5\u5f62\uff0c\u4f55\u8005\u8207\u7f79\u60a3\u809d\u7d30\u80de\u764c(HCC, hepatocellular carcinoma)\u7684\u98a8\u96aa\u589e\u52a0\uff0c\u6700\"\u7121\"\u95dc\u9023\uff1f    \nA.Hepatitis B infection\nB.Nonalcoholic steatohepatitis (NASH)\nC.Hepatitis C infection\nD.Liver flukes (Clonorchis sinensis, Opisthorchis viverrini)\nE.Cirrhosis from any cause\n": "[D]", "109-174.\u81ea2012\u5e74\u4ee5\u4f86 \uff0c\u514d\u75ab\u6cbb\u7642\u7684\u9032\u5165\u5fa9\u8208\u65b0\u6642\u4ee3 \uff0c\u6709\u4e9b\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (immune checkpoint inhibitors )\u8b49\u5be6\n\u53ef\u4ee5\u6709\u6548\u6cbb\u7642\u764c\u75c7 \uff0c\u4e14\u9032\u5165\u81e8\u5e8a\u5be6\u7528\u968e\u6bb5 \uff0c\u9032\u4e00\u6b65\u6709\u4e9b\u764c\u75c7\u6cbb\u7642\u6642\u4e5f\u767c\u73fe\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291\u91cd\u8981\u7684 \"\u9810\u6e2c\n\u6027\u751f\u7269\u6a19\u8a18 \"\u3002\u8f49\u79fb\u6027\u5927\u8178\u764c\u75c5\u4eba\u5728\u63a5\u53d7PD -1\u6297\u9ad4\u85e5\u5291Pembrolizumab (Kytruda)\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u4e0b\u5217\u4f55\n\u7a2e\"\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18 \"\u60c5\u5f62\u4e0b\uff0cPembrolizumab (Kytruda)\u6cbb\u7642\u8f03\u70ba\u6709\u6548 \uff1f   \nA.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cdefective MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\n\u7f3a\u9677)\nB.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027)\uff0cdefective MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u7f3a\u9677)\nC.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cproficient MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\n\u7d20\u5b8c\u6574)\nD.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027)\uff0cproficient MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u5b8c\u6574)\nE.\u4ee5\u4e0a\u7686\u975e\n": "[A]", "109-175.\u8f49\u79fb\u6027\u5927\u8178\u764c\u5728\u4f7f\u7528\u6297\u764c\u85e5\u7269\u6cbb\u7642\u6642 \uff0c\u5df2\u77e5\u6709\u4e00\u91cd\u8981\u7684\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18 (predictive biomarker )\u3002\u8b6c\u5982\uff1a\u7576\n\u5927\u8178\u764c\u6aa2\u9ad4\u57fa\u56e0\u578bExpanded RAS (KRAS, NRAS\u57fa\u56e0\u7684exons 2, 3, 4)\u5c6c\u300c\u91ce\u751f\u578b\u300d(wild-type)\u6642\uff0c\u662f\u5c0d\n\u4e0b\u5217\u54ea\u500b\u85e5\u5291\u6709\u6548 (responsiveness )\u7684\u9810\u6e2c\u56e0\u5b50predictive biomarker \uff0c\u56e0\u6b64\u5efa\u8b70\u53ef\u9078\u7528\u8a72\u85e5\u5291\u6cbb\u7642 \u3002   \nA.5-Fluorouracil (5-FU)\nB.Irinotecan\nC.Oxaliplatin\nD.Cetuximab\nE.Bevacizumab\n": "[D]", "109-176.\u4e0070\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u4e3b\u8a34\u4e00\u500b\u6708\u7684\u7121\u75db\u6027\u9ec3\u75b8\u5408\u4f75\u9ad4\u91cd\u6e1b\u8f15 4\u81f35\u516c\u65a4\u3002\u986f\u5f71\u6ce8\u5c04\u7684\u96fb\u8166\u65b7\u5c64CT\u6383\u63cf \uff0c\u767c\u73fe\n\u80f0\u81df\u982d\u90e8 (head of pancreas )\u6709\u4e00\u7591\u4f3c\u816b\u584a\u4e14\u5408\u4f75\u81bd\u7ba1\u64f4\u5f35 \u3002\u4e0b\u5217\u4f55\u8005\u662f\u70ba\u6b64\u75c5\u4eba\u78ba\u8a3a\u662f\u5426\u70ba\u80f0\u81df\u764c\u7684\u6700\n\u4f73\u8a3a\u65b7\u65b9\u5f0f \uff1f   \nA.CT-guided percutaneous needle biopsy\nB.Endoscopic ultrasound (EUS)-guided needle biopsy\nC.Endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic juice sampling for \ncytopathology\nD.FDG-PET imaging\nE.Serum CA 19-9\n": "[B]", "109-177.\u6709\u95dc\u524d\u5217\u817a\u7279\u7570\u6297\u539f\uff08PSA\uff0cprostate specific antigen\uff09\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u771f?    \nA.Most prostate cancer deaths occur in men with PSA levels below the top quartile.   \nB.PSA is produced by malignant and non-malignant prostate cells.\nC.The US Preventive Services Task Force (USPSTF) recommends PSA screening in men between \n55 and 69 years of age .\nD.The American Urological Association (AUA) recommends PSA screening in men 40 -55 years of \nage.\nE.Asymptomatic men with an elevated PSA should receive a 2-week course of antibiotics before \nrepeating PSA and considering biopsy .\n": "[B]", "109-178.\u764c\u75c7\u7684\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (immune checkpoint inhibitors )\u6216\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (molecular targeted agents )\u901a\u5e38\n\u91dd\u5c0d\u7279\u5b9a\u7684\u8a0a\u606f\u50b3\u905e\u8def\u5f91\u6216\u5206\u5b50\u6a19\u9776\u9032\u884c\u6291\u5236 \uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684 \u3002\u6cbb\u7642\"\u85e5\u5291\"\u8207\u514d\u75ab\u6216\u5206\u5b50 \"\u6a19\n\u9776\"\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u771f \uff1f\n(1) Ipilimumab \u8207 CTLA -4\n(2) Afatinib \u8207 EGFR\n(3) Rituximab \u8207 CD20\n(4) Trastuzumab \u8207 HER -2\n(5) Nivolumab \u8207 PD -L1   \nA.(1)+(2)+(3)+(4)\nB.(1)+(3)+(4)+(5)\nC.(2)+(3)+(4)+(5)\nD.(2)+(4)+(5)\nE.(1)+(2)+(3)+(4)+(5)\n": "[A]", "109-179.\u4e0064\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u904e\u53bb\u5341\u591a\u5e74\u9678\u7e8c\u6709\u9593\u6b47\u6027\u8179\u7009\u7684\u75c7\u72c0 \uff0c\u5747\u50c5\u88ab\u8a3a\u65b7\u70ba\u8178\u8e81\u75c7 (irritable bowel \nsyndrome )\uff0c\u7d66\u4e88\u75c7\u72c0\u6cbb\u7642 \u3002\u6700\u8fd1\u4e00\u5e74\u4f86 \uff0c\u5979\u958b\u59cb\u6709\u8173\u8e1d\u6c34\u816b \uff0c\u4e14\u6f38\u6709\u60e1\u5316\u8da8\u52e2 \uff0c\u6f38\u6f38\u9700\u53e3\u670d\u5229\u5c3f\u5291\u624d\u80fd\n\u7de9\u89e3\u3002\u4ed4\u7d30\u8a62\u554f\u75c5\u53f2 \uff0c\u5979\u9593\u65b7\u6709\u71b1\u6f6e\u7d05\u7684\u60c5\u5f62\u5df2\u6709\u591a\u5e74 \uff0c\u4f46\u4e00\u76f4\u7576\u4f5c\u662f\u505c\u7d93\u75c7\u5019\u7fa4\u7684\u4e00\u90e8\u5206\u75c7\u72c0 \u3002\u7406\u5b78\u6aa2\n\u67e5\u6240\u898b\u75c5\u4eba\u767c\u80b2\u8207\u71df\u990a\u72c0\u614b\u826f\u597d \uff0c\u7121\u9ec3\u75b8\uff0c\u7121\u5468\u908a\u6dcb\u5df4\u7d50\u816b\u5927 \uff0chepatojugular reflux\u967d\u6027 \uff0c\u5fc3\u81df\u807d\u8a3a\u6709\u660e\n\u986fS3\u5fc3\u97f3\uff0c\u809d\u816b\u5927\u81f3\u53f3\u808b\u7de3\u4e0b\u7d04 3\u6307\u5e45\uff0c\u4e14\u660e\u986f\u5169\u5074\u8db3\u8e1d\u6c34\u816b \u3002\u4f60\u5efa\u8b70\u9032\u4e00\u6b65\u70ba\u6b64\u75c5\u4eba\u5b89\u6392\u4ee5\u4e0b\u7684\u6aa2\n\u67e5\uff0c\u4f55\u8005\u9069\u5b9c \uff1f\n(1) 24-hour urine for 5-HIAA (5-hydroxyindoleacetic acid )\n(2) Echocardiogram\n(3) 18-FDG-PET scan\n(4) CT scan of abdomen and pelvis\n(5) Octreoscan   \nA.\u50c51\u9069\u5b9c\nB.\u50c51\u30012\u9069\u5b9c\nC.\u50c51\u30012\u30013\u9069\u5b9c\nD.1\u30012\u30013\u30014\u5747\u9069\u5b9c\nE.1\u30012\u30014\u30015\u5747\u9069\u5b9c\n": "[E]", "110-129.\u76ee\u524dAnti-CD22\u85e5\u7269Inotuzumab\u5df2\u88ab\u6838\u51c6\u7528\u65bc\u4e0b\u5217\u4f55\u7a2e\u75be\u75c5\uff1f    \nA.\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u3002\nB.B\u7d30\u80de\u6025\u6027\u6dcb\u5df4\u82bd\u7d30\u80de\u767d\u8840\u75c5\u3002\nC.\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u3002\nD.\u975e\u4f55\u6770\u91d1\u6c0f\u6dcb\u5df4\u7624\u3002\nE.\u514d\u75ab\u6027\u8840\u5c0f\u677f\u4f4e\u4e0b\u6027\u7d2b\u6591\u75c7\u3002\n": "[B]", "110-130.Venetoclax\u7528\u65bc\u8001\u5e74\u4e0d\u9069\u5408\u63a5\u53d7\u589e\u5f37\u5316\u7642\u7684\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u75c5\u4eba\u5df2\u6709\u5065\u4fdd\u7d66\u4ed8\uff0c\u5b83\u7684\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55\uff1f    \nA.BCL-2 inhibitor\u3002\nB.MCL-1 inhibitor\u3002\nC.Bruton tyrosine kinase inhibito\u3002\nD.RAS inhibitor\u3002\nE.Immunomudulatory agent\u3002\n": "[A]", "110-131.\u4e00\u4f4d25\u6b72\u5973\u6027\u7121\u7279\u6b8a\u4e0d\u9069 \u3002\u5728\u9ad4\u6aa2\u6642\u767c\u73feHb 9.1 gm/dL\uff0cRBC 4.43 M/\u03bcL\uff0cMCV 68 fL \uff0c\u767d\u8840\u7403\u6578\u53ca\u5206\u985e\n\u6b63\u5e38\uff0c\u8840\u5c0f\u677f\u6578\u6b63\u5e38 \uff0c\u7db2\u72c0\u7d05\u8840\u7403 3.1%\uff1b\u8840\u9435\u8cea185 ng /mL (\u6b63\u5e385~148)\uff0ciron 145 \u03bcg/dL (\u6b63\n\u5e3851~209)\uff0cTIBC 420 \u03bcg/dL (\u6b63\u5e38268~593)\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.Iron deficiency anemia\u3002\nB.Anemia of chronic disorder\u3002\nC.Thalassemia\u3002\nD.Myelodysplastic syndrome with ring sideroblasts\u3002\nE.Lead poisoning\u3002\n": "[C]", "110-132.\u4e0b\u5217\u6709\u95dc\u9663\u767c\u6027\u591c\u9593\u8840\u8272\u7d20\u5c3f(PNH)\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f    \nA.Intravascular hemolysis\u3002\nB.Elevation of LDH levels\u3002\nC.Reduced haptoglobin levels\u3002\nD.Loss of membrane CD55 and CD56 expression on RBC\u3002\nE.Responsive to complement 5 (C5) inhibitor treatment\u3002\n": "[D]", "110-133.\u4e00\u4f4d35\u6b72\u7537\u6027\u75c5\u4eba\u767c\u73fe\u624b\u8173\u78b0\u649e\u6642\u5076\u6709\u7d2b\u6591 \uff0c\u4f46\u7121\u5176\u4ed6\u51fa\u8840\u73fe\u8c61 \uff0c\u8840\u6db2\u6aa2\u67e5\u986f\u793aHb 13 .2 gm/dL\uff0c\u767d\u8840\u7403 \n5650/\u03bcL\uff0c\u5206\u985e\u6b63\u5e38 \uff0c\u8840\u5c0f\u677f 36000 /\u03bcL\uff0c\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u662f\u6700\u4e0d\u9700\u8981\u7684 \uff1f   \nA.Hepatitis C\u3002\nB.Autoimmune profile\u3002\nC.Helicobacter pylori\u3002\nD.Antiphospholipid antibodies\u3002\nE.Bone marrow\u3002\n": "[E]", "110-134.\u4e0b\u5217\u4f55\u8005\u662f\u539f\u767c\u6027\u591a\u8840\u75c7(polycythemia vera)\u6700\u5e38\u898b\u7684\u57fa\u56e0\u7a81\u8b8a\uff1f    \nA.JAK2\u7a81\u8b8a\u3002\nB.CALR\u7a81\u8b8a\u3002   \nC.MPL\u7a81\u8b8a\u3002\nD.DNMT3A\u7a81\u8b8a\u3002\nE.IDH\u7a81\u8b8a\u3002\n": "[A]", "110-135.\u4e00\u4f4d45\u6b72\u75c5\u4eba\u62bd\u8840\u767c\u73feaPTT\u5ef6\u9577 \uff0c\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f\n(1) hemophilia  (2) antiphospholipid syndrome  (3) heparin use  (4) von Willebramd disease   \nA.(1)\u3002\nB.(1)+(4)\u3002\nC.(1)+(3)\u3002\nD.(1)+(3)+(4)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[E]", "110-136.\u4e0b\u5217\u4f55\u8005\u70batumor lysis\u7684\u8868\u73fe \uff1f(1) Hyperkalemia  (2) Hypercalcemia  (3) Hyperuricemia  (4) renal \nfunction impairment   \nA.(1)+(3)\u3002\nB.(1)+(2)+(3)\u3002\nC.(1)+(3)+(4)\u3002\nD.(2)+(3)+(4)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[C]", "110-137.\u4e0060\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u8a3a\u65b7\u7f79\u60a3\u4e59\u72c0\u7d50\u8178\u764c (adenocarcinoma, sigmoid colon )\uff0c\u4ee5\u6839\u6cbb\u6027\u624b\u8853\u5207\u9664\u5de6\u5074\u4e59\u72c0\u7d50\n\u8178\u8207\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853 \uff0c\u75c5\u7406\u7d44\u7e54\u78ba\u5b9a\u624b\u8853\u908a\u7de3\u6c92\u6709\u764c\u7d30\u80de \uff0c\u6e05\u9664\u6dcb\u5df4\u7d50\u517121\u9846\u4e2d\u75c5\u7406\u6aa2\u67e5\u6709 8\u9846\u5df2\u6709\u764c\u7d30\n\u80de\uff0c\u6c92\u6709\u9060\u8655\u5668\u5b98\u8f49\u79fb \u3002\u91ab\u5e2b\u5efa\u8b70\u624b\u8853\u5f8c \uff0c\u518d\u7d66\u4e886\u500b\u6708\u300c\u8f14\u52a9\u6027(adjuvant) \u5316\u5b78\u6cbb\u7642 \u300d\u4ee5\u964d\u4f4e\u5fa9\u767c\u7387\u8207\n\u589e\u52a0\u5b58\u6d3b \u3002\u4f9d\u64da\u5404\u7a2e \u300c\u81e8\u5e8a\u6307\u5f15\u300d\uff0c \u91ab\u5e2b\u5efa\u8b70\u4e0b\u5217\u4f55\u8005 \u300c\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642 \u300d\u8655\u65b9\u8f03\u70ba\u5408\u9069 \uff1f   \nA.Oxaliplatin plus 5-FU or Capecitabine (FOLFOX or CAPOX)\u3002\nB.Irinotecan plus 5-FU or Capecitabine (FOLFIRI or CAPIRI)\u3002\nC.Bevacizumab added to (FOLFOX or CAPOX)\u3002\nD.Cetuximab added to (FOLFIRI or CAPIRI)\u3002\nE.Panitumumab added to (FOLFIRI or CAPIRI)\u3002\n": "[A]", "110-138.\u4e00\u4f4d65\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u63a5\u53d7\u4e0a\u6d88\u5316\u9053\u5167\u8996\u93e1\u6aa2\u67e5\u8207\u5207\u7247\u78ba\u5b9a\u7f79\u60a3\u80c3\u7684 \u300c\u795e\u7d93\u5167\u5206\u6ccc\u7624 (Neuroendocrine \ntumor, NET) \u300d\u3002 \u96fb\u8166\u65b7\u5c64\u6383\u63cf\u986f\u793a\u809d\u81df\u5df2\u6709\u591a\u767c\u8f49\u79fb\u75c5\u7076 \u3002\u75c5\u7406\u7d44\u7e54\u9664\u4e86\u78ba\u5b9a\u70ba\u795e\u7d93\u5167\u5206\u6ccc\u7624\u4e4b\u5916 \uff0c\u816b\n\u7624\u7684\u300c\u5206\u5316\u300d(grading)\u5c0d\u75c5\u4eba\u81e8\u5e8a\u9810\u5f8c (prognosis )\u7684\u5224\u5b9a\u8207\u6cbb\u7642\u9078\u9805\u7684\u9078\u64c7 \uff0c\u6709\u91cd\u8981\u7684\u53c3\u8003\u50f9\u503c \u3002\n\u5018\u82e5\u75c5\u7406\u7d44\u7e54\u986f\u5fae\u93e1\u6aa2\u67e5 \uff0c\u6bcf10\u500b\u9ad8\u500d\u6578\u8996\u91ce (10 HPF, high power field ), \u5e73\u5747\u670912\u500b\u6709\u7d72\u5206\u88c2 (mitotic \ncount)\uff0c\u8207Ki-67\u6307\u6578(Ki-67 index )\u8a08\u7b97\u70ba11 %\u3002\u4f9d\u7167\u4e16\u754c\u885b\u751f\u7d44\u7e54 (WHO) NET\u5206\u985e\u7cfb\u7d71\u7684grading \u5efa\n\u8b70\uff0c\u9019\u6a23\u7684\u75c5\u7406\u7d44\u7e54\u7684 \u300c\u5206\u5316\u300d(grading)\u5c6c\u65bc\u7b2c\u5e7e\u7d1a ?   \nA.Gr. 1\u3002\nB.Gr. 2\u3002\nC.Gr. 3\u3002\nD.Gr. 4\u3002\nE.Neuroendocrine carcinoma (NEC)\u3002\n": "[B]", "110-139.\u6709\u4e00\u7814\u7a76\u4f7f\u7528200 \u500b\u300c\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u4e0a\u76ae\u764c \u300d(CUP, carcinoma of unknown primary )\u75c5\u4eba\u7684\u816b\u7624\u6aa2\u9ad4 \uff0c\u9032\n\u884c\u300c\u6b21\u4e16\u4ee3\u57fa\u56e0\u5b9a\u5e8f\u5206\u6790 \u300d(NGS, next generation sequencing )\u3002\u60a8\u63a8\u6e2c\u6700\u5e38\u898b\u767c\u751f\u57fa\u56e0\u8b8a\u7570 (genetic \nalterations )\u7684\u57fa\u56e0\u70ba\u4e0b\u5217\u4f55\u8005 ?      \nA.KRAS\u3002\nB.TP53\u3002\nC.ARID1A\u3002\nD.CDKN2A\u3002\nE.mTOR\u3002\n": "[B]", "110-140.67\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u4e3b\u8a34\u4e8c\u500b\u6708\u9010\u6f38\u52a0\u91cd\u7684\u53f3\u8170\u75db \uff0c\u5408\u4f75\u4e00\u500b\u6708\u9010\u6f38\u52a0\u91cd\u7684\u8840\u5c3f (hematuria )\u3002\u4e14\u81ea\u89ba\u6c92\u6709\u80c3\n\u53e3\uff0c\u5728\u4e8c\u500b\u6708\u5167\u9ad4\u91cd\u6e1b\u8f15\u7d04 3\u516c\u65a4\u3002\u75c5\u4eba\u8f49\u81f3\u5927\u91ab\u9662\u6c42\u8a3a \uff0c\u7406\u5b78\u6aa2\u67e5\u89f8\u8a3a\u5df2\u767c\u73fe\u53f3\u8170\u90e8\u6709\u81f3\u5c11 5\u516c\u5206\u5927\u5c0f\u816b\n\u584a\uff0c\u814e\u529f\u80fd\u5927\u81f4\u6b63\u5e38 \u3002\u5f71\u50cf\u6aa2\u67e5\u767c\u73fe\u53f3\u814e\u6709\u4e0010\u516c\u5206\u5be6\u9ad4\u816b\u584a \uff0c\u5169\u5074\u80ba\u91ce\u6709\u591a\u767c\u7684\u80ba\u7d50\u7bc0 \uff0c\u986f\u793a\u5df2\u6709\u591a\u767c\n\u80ba\u81df\u8f49\u79fb \u3002\u7d30\u91dd\u7a7f\u523a\u5207\u7247\u75c5\u7406\u8b49\u5be6\u70ba\u814e\u7d30\u80de\u764c (renal cell carcinoma )\u4e4b\u4eae\u7d30\u80de (clear cell )\u4e9e\u578b\u3002\u5efa\u8b70\u4e0b\u4e00\n\u6b65\u5982\u4f55\u8655\u7f6e\u6700\u70ba\u5408\u9069 ?   \nA.Radical nephrectomy\u3002\nB.Gemcitabine\u3002\nC.Sunitinib\u3002\nD.Interleukin-2\u3002\nE.Interferon-\u03b3\u3002\n": "[C]", "110-141.58\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u7f79\u60a3\u8f49\u79fb\u6027\u80ba\u817a\u764c (NSCLC, adenocarcinoma )\uff0c\u5df2\u63a5\u53d7\u7b2c\u4e00\u7ddacarboplatin \u3001paclitaxel \uff0c\u5408\n\u4f75bevacizumab\u6cbb\u7642 \uff0c\u6709\u6548\u201d\u7de9\u89e3\u201d(partial response )\u4e00\u6bb5\u671f\u9593\u4e4b\u5f8c \u201d\u60e1\u5316\u201d(disease progression )\u3002\u75c5\u4eba\n\u7684ECOG\u9ad4\u80fd\u72c0\u614b (performance status, PS )\u70ba1\uff0c\u91dd\u5c0d\u75c5\u4eba\u5468\u908a\u80ba\u91ce\u7684\u8f03\u5927\u75c5\u7076\u5b89\u6392\u91cd\u65b0\u5207\u7247 \uff0c\u5206\u5b50\u6aa2\u6e2c\n\u767c\u73feROS 1\u57fa\u56e0rearrangement\u967d\u6027 \u3002\u4f60\u5efa\u8b70\u4e0b\u4e00\u6b65\u7684\u6cbb\u7642 \uff0c\u4f55\u8005\u6700\u70ba\u9069\u5b9c ?   \nA.Pemetrexed\u3002\nB.Docetaxel\u3002\nC.Gemcitabine\u3002\nD.Erlotinib\u3002\nE.Crizotinib\u3002\n": "[E]", "110-142.\u81ea2012\u5e74\u4ee5\u4f86 \uff0c\u514d\u75ab\u6cbb\u7642\u7684\u9032\u5165\u5fa9\u8208\u65b0\u6642\u4ee3 \uff0c\u6709\u4e9b\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (Immune checkpoint inhibitors) \u8b49\n\u5be6\u53ef\u4ee5\u6709\u6548\u6cbb\u7642\u764c\u75c7 \uff0c\u4e14\u9032\u5165\u81e8\u5e8a\u5be6\u7528\u968e\u6bb5 \uff0c\u9032\u4e00\u6b65\u6709\u4e9b\u764c\u75c7\u6cbb\u7642\u6642\u4e5f\u767c\u73fe\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291\u91cd\u8981\u7684 \u300c\u9810\n\u6e2c\u6027\u751f\u7269\u6a19\u8a18\u300d\u3002 \u8f49\u79fb\u6027\u5927\u8178\u764c\u75c5\u4eba\u5728\u63a5\u53d7PD -1\u6297\u9ad4\u85e5\u5291Pembrolizumab (Kytruda)\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u4e0b\u5217\u4f55\n\u7a2e\u201d\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18 \u201d\u60c5\u5f62\u4e0b, Pembrolizumab (Kytruda)\u6cbb\u7642\u8f03\u70ba\u6709\u6548 \uff1f   \nA.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027 )\uff0cdefective MMR (mismatch repair \u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\n\u7d20\u7f3a\u9677)\u3002\nB.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cproficient MMR (mismatch repair \n\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u5b8c\u6574 )\u3002\nC.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cdefective MMR (mismatch repair \n\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u7f3a\u9677 )\u3002\nD.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027 )\uff0cproficient MMR (mismatch repair \u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\n\u7d20\u5b8c\u6574)\u3002\nE.\u4ee5\u4e0a\u7686\u975e\u3002\n": "[C]", "110-143.\u764c\u75c7\u7684\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (molecular targeted agents )\u6216\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (immune checkpoint inhibitors )\u901a\u5e38\n\u91dd\u5c0d\u7279\u5b9a\u7684\u5206\u5b50\u6a19\u9776\u6216\u514d\u75ab\u8def\u5f91\u9032\u884c\u6291\u5236 \uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684 \u3002\u6cbb\u7642\u300c\u85e5\u5291\u300d\u8207\u5206\u5b50\u6216\u514d\u75ab \u300c\u6a19\n\u9776\u300d\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u771f ?(1)Nivolumab \u8207PD-L1 (2)Afatinib\u8207EGFR (3)Trastuzumab \u8207HER-2 \n(4)Rituximab \u8207CD20 (5)Ipilimumab \u8207CTLA-4      \nA.(1)+(2)+(3)+(4)\u3002\nB.(1)+(3)+(4)+(5)\u3002\nC.(2)+(3)+(4)+(5)\u3002\nD.(1)+(2)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[C]", "110-144.\u4e0b\u5217\u90a3\u4e9b\u75c5\u75c7\u6216\u75c7\u5019\u7fa4 (syndrome )\uff0c\u53ef\u80fd\u6703\u589e\u52a0\u75c5\u4eba\u7f79\u60a3\u764c\u75c7\u7684\u98a8\u96aa? (1)Fanconi's anemia (2)Down \nsyndrome (3)Fragile X syndrome (4)von Hippel -Lindau syndrome (5)Neurofibromatosis   \nA.(1)+(3)+(4)\u3002\nB.(2)+(3)+(4)\u3002\nC.(1)+(2)+(3)+(5)\u3002\nD.(1)+(2)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[D]", "111-129.\u6025\u6027\u9aa8\u9ad3\u6027\u767d\u8840\u75c5\u4eba\u5e36\u6709\u4e0b\u5217\u67d3\u8272\u9ad4\u6216\u57fa\u56e0\u8b8a\u7570\u7684\u9810\u5f8c\u5f88\u5dee\uff0c\u4f55\u8005\u70ba\u4f8b\u5916\uff1f    \nA.t(6;9)\u3002\nB.t(3;3)\u3002\nC.NPM1 mutation without FLT3-ITD\u3002\nD.TP53 mutation\u3002\nE.ASXL1 mutation\u3002\n": "[C]", "111-130.Ibrutinib\u5065\u4fdd\u53ef\u7d66\u4ed8\u7528\u65bc\u5e36\u670917 p\u7f3a\u640d\u4e14\u5148\u524d\u66fe\u63a5\u53d7\u6cbb\u7642\u4ecd\u60e1\u5316\u6216\u5fa9\u767c\u7684\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u75c5\u4eba \uff0c\u5b83\u7684\n\u4f5c\u7528\u6a5f\u8f49\u70ba\u4f55 \uff1f   \nA.Bruton tyrosine kinase inhibitor\u3002\nB.BCL-2 inhibitor\u3002\nC.MCL-1 inhibitor\u3002\nD.RAS inhibitor\u3002\nE.Immunomudulatory agent\u3002\n": "[A]", "111-131.\u4e00\u4f4d65\u6b72\u75c5\u60a3\u56e0\u75b2\u618a \u3001\u5931\u53bb\u5473\u89ba \u3001\u624b\u8173\u767c\u9ebb\u4f86\u8a3a \uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u767c\u73fevibration sensation\u7570\u5e38 \uff0c\u820c\u982d\u5149\n\u6ed1\u3001\u5473\u857e\u840e\u7e2e \uff1b\u62bd\u8840\u7d50\u679c\u767c\u73feHb 6.1 gm/dL\uff0cMCV 118 fL \uff0c\u767d\u8840\u74033150 /\u00b5L\uff0c\u5206\u985e\u6b63\u5e38 \uff0c\u8840\u5c0f\n\u677f116,000/\u00b5L\uff0c\u7db2\u72c0\u7d05\u8840\u7403 1.1%\u3002\u6b64\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba \uff1f   \nA.Aplastic anemia\u3002\nB.VitB12 deficiency anemia\u3002\nC.Folic acid deficiency anemia\u3002\nD.Hemolytic anemia\u3002\nE.Lead poisoning\u3002\n": "[B]", "111-132.\u4e0b\u5217\u6709\u95dc\u9663\u767c\u6027\u591c\u9593\u8840\u8272\u7d20\u5c3f(PNH)\u7684\u6558\u8ff0\u4f55\u8005\u6709\u8aa4\uff1f    \nA.PIG-A gene mutation\u3002\nB.Tendency to venous thrombosis\u3002\nC.Reduced haptoglobin levels\u3002\nD.Bilirubinuria\u3002\nE.Responsive to complement 5 (C5) inhibitor treatment\u3002\n": "[D]", "111-133.\u672a\u66fe\u6ce8\u5c04\u904eheparin\u4e4b\u75c5\u4eba \uff0c\u6ce8\u5c04heparin\u5f8c\u5f15\u767c\u8840\u5c0f\u677f\u4f4e\u4e0b (Heparin induced thrombocytopenia )\u6700\u5e38\u51fa\u73fe\n\u7684\u6642\u9593\u70baheparin \u6ce8\u5c04\u5f8c   \nA.1\u5929\u5167\u3002\nB.1\u81f33\u5929\u3002\nC.5\u81f310\u5929\u3002\nD.14\u81f328\u5929\u3002\nE.1\u500b\u6708\u5f8c\u3002\n": "[C]", "111-134.\u4e0b\u5217\u8b8a\u5316\u80fd\u5e6b\u5fd9\u9451\u5225\u75c5\u4eba\u70ba\u539f\u767c\u6027\u591a\u8840\u75c7\u800c\u975e\u6b21\u767c\u6027\u591a\u8840\u75c7\uff0c\u4f55\u8005\u4f8b\u5916?       \nA.JAK2 gene mutation\u3002\nB.Splenomegaly\u3002\nC.Expansion of plasma volume\u3002\nD.Leukocytosis and thrombocytosis\u3002\nE.Elevated erythropoietin level\u3002\n": "[E]", "111-135.\u4e00\u4f4d65\u6b72\u75c5\u4eba\u62b1\u6028\u80c3\u75db \uff0c\u5167\u8996\u93e1\u6aa2\u67e5\u767c\u73fe\u80c3\u7ac7\u6709\u4e00\u816b\u7624 \uff0c\u75c5\u7406\u5207\u7247\u6aa2\u67e5\u986f\u793a\u70bamucosa associated \nlymphoid tissue lymphoma \uff0cCD20\u967d\u6027\u53ca H. Pylori\u967d\u6027 \uff0c\u5206\u671f\u6aa2\u67e5\u672a\u767c\u73fe\u5176\u4ed6\u7570\u5e38 \u3002\u4e0b\u5217\u4f55\u8005\u70ba\u6b64\u75c5\u4eba\u6700\n\u9069\u7576\u7684\u7b2c\u4e00\u7dda\u6cbb\u7642 \uff1f   \nA.Eradication of H. Pylori\u3002\nB.Chemotherapy\u3002\nC.Rituximab\u3002\nD.Rituximab + Chemotherapy\u3002\nE.Watchful waiting\u3002\n": "[A]", "111-136.\u4e0b\u5217\u6709\u95dcTRALI (transfusion -related acute lung injury )\u7684\u654d\u8ff0\u4f55\u8005\u662f\u6b63\u78ba\u7684 ?\n(1) \u591a\u5728\u8f38\u8840 3\u5929\u5f8c\u767c\u751f \n(2) \u767c\u751f\u7684\u539f\u56e0\u5e38\u8207\u6350\u8840\u8005\u9ad4\u5167\u6709\u6297\u53d7\u8840\u8005HLA class II\u4e4b\u6297\u9ad4\u6709\u95dc  \n(3) \u75c5\u4eba\u7684\u80f8\u90e8 X\u5149\u6703\u51fa\u73fe\u5169\u908a\u80ba\u8449\u7684\u6d78\u6f64   \nA.(1)\u3002\nB.(3)\u3002\nC.(2)+(3)\u3002\nD.(1)+(3)\u3002\nE.(1)+(2)+(3)\u3002\n": "[C]", "111-137.\u816b\u7624\u95dc\u806f\u75c7\u5019\u7fa4 (Paraneoplastic syndromes )\u6709\u6642\u7531\u65bc\u816b\u7624\u7522\u88fd \u300c\u7570\u4f4d\u6027\u7684\u8377\u723e\u8499 \u300d(ectopic hormone )\u6240\n\u9020\u6210\u3002\u8b6c\u5982:\u300cSyndrome of inappropriate antidiuretic hormone secretion (SIADH)\u300d\u5e38\u5f15\u767c\u81e8\u5e8a\u7684\u4f4e\u8840\u9209\n\u75c7(hyponatremia )\u3002SIADH\u5e38\u7531\u4e0b\u5217\u4f55\u7a2e \u300c\u7570\u4f4d\u6027\u7684\u8377\u723e\u8499 \u300d(ectopic hormone) \u7522\u88fd\u8207\u5206\u6ccc\u904e\u591a\u6240\u9020\u6210 ?   \nA.Parathyroid hormone-related protein (PTHrP)\u3002\nB.1,25-Dihydroxyvitamin D\u3002\nC.Vasopressin\u3002\nD.Adrenocorticotropic hormone (ACTH)\u3002\nE.Insulin-like growth factor type II (IGF-II)\u3002\n": "[C]", "111-138.\u6709\u95dc\u539f\u767c\u90e8\u4f4d\u4e0d\u660e\u7684\u4e0a\u76ae\u764c (Carcinoma of unknown primary, CUP )\uff0c\u9664\u4e86\u75c5\u7406\u7d44\u7e54\u7684 H&E\u67d3\u8272\u578b\u614b\u4e4b\n\u5916\uff0c\u6709\u6642\u9700\u501f\u52a9\u65bc\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272\u4f86\u5354\u52a9\u5224\u65b7CUP\u7684\u539f\u767c\u5668\u5b98 \u3002\u4e0b\u5217\u54ea\u4e00\u7a2e\u6a19\u8a18\u7684\u6297\u9ad4\u6838\u67d3\u8272 \uff0c\u7d04\n\u670968%\u80ba\u817a\u764c(adenocarcinoma of lung) \u5448\u967d\u6027 \uff0c\u7d04\u6709 25%\u7684\u80ba\u9c57\u72c0\u4e0a\u76ae\u764c (squamous cell carcinoma of \nlung)\u5448\u967d\u6027\uff0c\u7d93\u5e38\u505a\u70ba\u80ba\u81df (lung)\u70baCUP\u539f\u767c\u5668\u5b98\u4e4b\u9451\u5225\u8a3a\u65b7\u8f14\u52a9\u6a19\u8a18\u4e4b \u3127\uff1f   \nA.CDX-2 transcription factor (CDX-2)\u3002\nB.Thyroglobulin\u3002\nC.Thyroid transcription factor 1 (TTF-1)\u3002\nD.Cytokeratin (CK)\u3002\nE.Leucocyte common antigen (LCA)\u3002   \n": "[C]", "111-139.\u5728 COVID -19 \u65b0\u51a0\u75ab\u60c5\u5927\u6d41\u884c (pandemic )\u5371\u6a5f\u671f\u9593 \uff0c\u95dc\u65bc\u764c\u75c7\u75c5\u4eba\u5373\u6642\u63d0\u4f9b\u6cbb\u7642\u7684\u5efa\u8b70\u6307\u5f15 \uff0c\u767c\u8868\u65bc \n(Kutikov A, et al. Ann Intern Med. 2020, DOI: 10 .7326/M20-1133)\u3002\u8a72\u4e00\u6307\u5f15\u5efa\u8b70\u5c0d\u4e0b\u5217\u764c\u75c7\u75c5\u4eba \u201c\u9ad8\u5ea6\n\u512a\u5148\uff08\u7406\u60f3\u60c5\u6cc1\u4e0b, \u4e0d\u61c9\u5ef6\u9072 \uff09\u201d\u5373\u6642\u63d0\u4f9b\u764c\u75c7\u6cbb\u7642 \uff0c\u4f46\u4ee5\u4e0b\u60c5\u6cc1\u53ef\u80fd\u9664\u5916 \uff1a   \nA.Chemotherapy for testicular cancers\u3002\nB.Chronic lymphocytic leukemia\u3002\nC.Small cell lung cancer\u3002\nD.Colon cancer with imminent obstruction\u3002\nE.High-grade soft tissue sarcomas\u3002\n": "[B]", "111-140.\u4e0066\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u8a3a\u65b7\u7f79\u60a3\u4e59\u72c0\u7d50\u8178\u764c (adenocarcinoma, sigmoid colon )\uff0c\u4ee5\u6839\u6cbb\u6027\u624b\u8853\u5207\u9664\u5de6\u5074\u4e59\u72c0\u7d50\n\u8178\u8207\u6dcb\u5df4\u7d50\u5ed3\u6e05\u8853 \uff0c\u75c5\u7406\u7d44\u7e54\u78ba\u5b9a\u624b\u8853\u908a\u7de3\u6c92\u6709\u764c\u7d30\u80de \uff0c\u6e05\u9664\u6dcb\u5df4\u7d50\u517122\u9846\u4e2d\u75c5\u7406\u6aa2\u67e5\u670910\u9846\u5df2\u6709\u764c\u7d30\n\u80de\uff0c\u6c92\u6709\u9060\u8655\u5668\u5b98\u8f49\u79fb \u3002\u91ab\u5e2b\u5efa\u8b70\u624b\u8853\u5f8c \uff0c\u518d\u7d66\u4e886\u500b\u6708\u300c\u8f14\u52a9\u6027(adjuvant) \u5316\u5b78\u6cbb\u7642 \u300d\u4ee5\u964d\u4f4e\u5fa9\u767c\u7387\u8207\n\u589e\u52a0\u5b58\u6d3b \u3002\u4f9d\u64da\u5404\u7a2e \u300c\u81e8\u5e8a\u6307\u5f15\u300d\uff0c \u91ab\u5e2b\u5efa\u8b70\u4e0b\u5217\u4f55\u8005 \u300c\u8f14\u52a9\u6027\u5316\u5b78\u6cbb\u7642 \u300d\u8655\u65b9\u8f03\u70ba\u5408\u9069 \uff1f   \nA.Irinotecan plus 5-FU or Capecitabine (FOLFIRI or CAPIRI/XELIRI)\u3002\nB.Oxaliplatin plus 5-FU or Capecitabine (FOLFOX or CAPOX/XELOX)\u3002\nC.Cetuximab, combined with (FOLFIRI or CAPIRI//XELIRI)\u3002\nD.Bevacizumab, combined with (FOLFOX or CAPOX/XELOX)\u3002\nE.Panitumumab, combined with (FOLFIRI or CAPIRI/XELIRI)\u3002\n": "[B]", "111-141.\u81ea2012\u5e74\u4ee5\u4f86 \uff0c\u514d\u75ab\u6cbb\u7642\u7684\u9032\u5165\u5fa9\u8208\u65b0\u6642\u4ee3 \uff0c\u6709\u4e9b\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (Immune checkpoint inhibitors) \u8b49\n\u5be6\u53ef\u4ee5\u6709\u6548\u6cbb\u7642\u764c\u75c7 \uff0c\u4e14\u9032\u5165\u81e8\u5e8a\u5be6\u7528\u968e\u6bb5 \uff0c\u9032\u4e00\u6b65\u6709\u4e9b\u764c\u75c7\u6cbb\u7642\u6642\u4e5f\u767c\u73fe\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291\u91cd\u8981\u7684 \u300c\u9810\n\u6e2c\u6027\u751f\u7269\u6a19\u8a18\u300d\u3002 \u8f49\u79fb\u6027\u5927\u8178\u764c\u75c5\u4eba\u5728\u63a5\u53d7PD -1\u6297\u9ad4\u85e5\u5291Pembrolizumab (Kytruda)\u6cbb\u7642\u6642\uff0c\u5df2\u77e5\u4e0b\u5217\u4f55\n\u7a2e\"\u9810\u6e2c\u6027\u751f\u7269\u6a19\u8a18 \"\u60c5\u5f62\u4e0b, Pembrolizumab (Kytruda)\u6cbb\u7642\u8f03\u70ba\u6709\u6548 \uff1f   \nA.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027)\uff0cproficient MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u5b8c\u6574)\u3002\nB.MSS (microsatellite stable, \u5fae\u5c0f\u885b\u661f\u9ad4\u7a69\u5b9a\u6027)\uff0cdefective MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\u7f3a\u9677)\u3002\nC.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cproficient MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\n\u7d20\u5b8c\u6574)\u3002\nD.MSI-H (microsatellite instability -high, \u5fae\u5c0f\u885b\u661f\u9ad4\u9ad8\u5ea6\u4e0d\u7a69\u5b9a\u6027 )\uff0cdefective MMR (\u6838\u9178\u8aa4\u914d\u4fee\u5fa9\u9175\u7d20\n\u7f3a\u9677)\u3002\nE.\u4ee5\u4e0a\u7686\u662f\u3002\n": "[D]", "111-142.51\u6b72\u5973\u6027\u75c5\u4eba \uff0c3\u5e74\u534a\u4e4b\u524d \uff0c\u56e0\u5f8c\u4e0a\u80cc\u90e8\u9ed1\u8272\u7d20\u7624 (melanoma )\u624b\u8853\u5207\u9664 \uff0c\u764c\u75c7\u5206\u671f\u7b2cIIB \u671f\u3002\u6700\u8fd1\u56e0\u547c\u5438\n\u6025\u4fc3\u81f3\u6025\u8a3a\u5c31\u91ab \uff0c\u767c\u73fe\u5169\u5074\u80ba\u91ce\u591a\u767c\u75c5\u7076 \uff0c\u5f8c\u7e8c\u6aa2\u67e5\u8b49\u5be6\u60e1\u6027\u9ed1\u8272\u7d20\u7624\u591a\u767c\u5169\u5074\u80ba\u8f49\u79fb \u3002\u5728\u6c7a\u5b9a\u9078\u64c7\u6a19\u9776\n\u6cbb\u7642\u3001\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 \u3001\u6216\u5316\u5b78\u6cbb\u7642\u4e4b\u524d \uff0c\u61c9\u6aa2\u9a57\u4f55\u7a2e\u57fa\u56e0\u7a81\u8b8a (genetic mutation )\u7684\u6709\u7121\uff0c\u5c0d\u65bc\u9078\u64c7\u4f55\n\u7a2e\u6a19\u9776\u6cbb\u7642\u6709\u6700\u91cd\u8981\u7684\u53c3\u8003\u50f9\u503c ?   \nA.C-KIT\u3002\nB.NRAS\u3002\nC.HRAS\u3002\nD.ERK\u3002\nE.BRAF\u3002   \n": "[E]", "111-143.\u764c\u75c7\u5206\u671f\u5c6cBCLC (Barcelona Clinic Liver Cancer staging) \u7b2cC \u671f\u7684\u665a\u671f\u809d\u764c (HCC)\u75c5\u4eba\uff0c\u5df2\u77e5\u53d7\u76ca\u65bc\u5168\n\u8eab\u6027\u85e5\u5291\u6cbb\u7642 \u3002\u5df2\u6709\u6578\u500b\u809d\u764c\u7684\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (molecular targeted agents, MTAs )\u6216\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\n\u5291(immune checkpoint inhibitors, ICIs )\uff0c\u55ae\u7368\u6216\u7d44\u5408\u4f7f\u7528 \uff0c\u7b2c\u4e00\u7dda\u6216\u7b2c\u4e8c\u7dda\u4f7f\u7528 \uff0c\u7531\u81e8\u5e8a\u8a66\u9a57\u8b49\u5be6\u53ef\u6709\u6548\n\u5ef6\u9577\u4e2d\u4f4d\u6578\u7e3d\u5b58\u6d3b\u671f (median overall survival )\u7684\u76ee\u7684\u3002(1) Sorafenib (2)Lenvatinib (3)Atezolizumab \n(4)Bevacizumab (5)Regorafenib \u3002\u4e0b\u5217\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (MTAs)\u8207\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (ICIs)\u7684\u54ea\u4e00\u500b \u300c\u7d44\n\u5408\u300d\uff0c  \u91dd\u5c0d\u7121\u6cd5\u624b\u8853\u6210\u529f\u5207\u9664\u7684\u809d\u764c (unresectable HCC )\u75c5\u4eba\uff0c\u5df2\u7531\u81e8\u5e8a\u8a66\u9a57\u8b49\u5be6 \uff0c\u7b2c\u4e00\u7dda(1st-line)\u7684\u5168\n\u8eab\u6027\u85e5\u5291\u6cbb\u7642 \uff0c\u53ef\u9054\u7d71\u8a08\u4e0a\u986f\u8457\u5ef6\u9577\u4e4b\u4e2d\u4f4d\u6578\u7e3d\u5b58\u6d3b\u671f (\u7d0419.2\u500b\u6708) \u7684\u76ee\u7684 \uff0c\u767c\u8868\u65bc (N Engl J Med \n2020 May 14 ;382(20):1894 -1905)\u3002   \nA.(1)+(3)\u3002\nB.(2)+(3)\u3002\nC.(3)+(4)\u3002\nD.(3)+(5)\u3002\nE.(1)+(5)\u3002\n": "[C]", "111-144.\u764c\u75c7\u7684\u6a19\u9776\u6cbb\u7642\u85e5\u5291 (molecular targeted agents )\u6216\u514d\u75ab\u7bc0\u5236\u9ede\u6291\u5236\u5291 (immune checkpoint inhibitors )\u901a\u5e38\n\u91dd\u5c0d\u7279\u5b9a\u7684\u5206\u5b50\u6a19\u9776\u6216\u514d\u75ab\u8def\u5f91\u9032\u884c\u6291\u5236 \uff0c\u4ee5\u9054\u5230\u6cbb\u7642\u764c\u75c7\u7684\u76ee\u7684 \u3002\u6cbb\u7642\u300c\u85e5\u5291\u300d\u8207\u5206\u5b50\u6216\u514d\u75ab \u300c\u6a19\n\u9776\u300d\u7684\u914d\u5c0d\uff0c\u4e0b\u5217\u90a3\u4e9b\u70ba\u771f ?\n(1) Rituximab \u8207CD20\n(2) Osimertinib \u8207EGFR\n(3) Trastuzumab \u8207HER-2\n(4) Nivolumab \u8207PD-1\n(5) Ipilimumab \u8207CTLA-4   \nA.(1)+(2)+(3)+(4)\u3002\nB.(2)+(3)+(4)+(5)\u3002\nC.(2)+(3)+(4)\u3002\nD.(3)+(4)+(5)\u3002\nE.(1)+(2)+(3)+(4)+(5)\u3002\n": "[E]", "100-1.\n56\u6b72\u5973\u6027\uff0c\u904e\u53bb\u7121\u816b\u7624\u75c5\u53f2\uff0c2\u500b\u6708\u524d\u8d77\u6709\u6f38\u9032\u7684\u982d\u75db\u8207\u6b65\u5c65\u4e0d\u7a69\uff0c\u8166\u90e8\u5f71\u50cf\u6aa2\u67e5\u986f\u793a\u6709\u591a\u9846\u8166\u90e8\u816b\u7624\uff0c\u6700\u6709\u53ef\u80fd\u662f\u7531\u4f55\u8655\u8f49\u79fb\u7684\u816b\u7624\uff1f\nA. \u809d\u81df\uff08liver\uff09\nB. \u4e73\u623f\uff08breast\uff09\nC. \u80ba\u81df\uff08lung\uff09\nD. \u5927\u8178\uff08colon\uff09\nE. \u76ae\u819a\uff08skin\uff09\n": "(C)", "100-2.\n76\u6b72\u7537\u6027\uff0c\u9ad8\u8840\u58d3\u8207\u7cd6\u5c3f\u75c5\u7684\u75c5\u53f2\uff0c\u670d\u7528Amlodipine\u3001Enalapril\u3001Furosemide\u3001Glipizide\u3001Metformin\uff0c\u56e0\u7a81\u767c\u6025\u6027\u8166\u6897\u585e\u4e2d\u98a8\uff0c\u63a5\u53d7\u975c\u8108\u8840\u6813\u6eb6\u89e3\u6cbb\u7642\uff0c\u5728\u6cbb\u7642\u5f8c1\u500b\u5c0f\u6642\u767c\u751f\u820c\u982d\u816b\u8139\u3001\u547c\u5438\u56f0\u96e3\uff0c\u9700\u63d2\u7ba1\u6cbb\u7642\uff0c\u5148\u524d\u6240\u4f7f\u7528\u7684\u4f55\u7a2e\u85e5\u7269\u53ef\u80fd\u8207\u6b64\u526f\u4f5c\u7528\u767c\u751f\u76f8\u95dc\uff1f\nA. Amlodipine\nB. Enalapril\nC. Furosemide\nD. Glipizide\nE. Metformin\n": "(B)", "100-3.\n28\u6b72\u7537\u6027\uff0c\u570b\u5c0f\u6642\u56db\u80a2\u7684\u808c\u529b\u5c31\u8f03\u5dee\uff0c\u570b\u4e2d\u6642\u8e72\u4e0b\u53bb\u7121\u6cd5\u7acb\u5373\u7ad9\u8d77\uff0c\u5408\u4f75\u6709\u5fc3\u5f8b\u4e0d\u6574\uff0c\u8840\u6db2Creatine kinase\u70ba\u6b63\u5e38\u503c5\u500d\uff0c\u5176\u7236\u572840\u6b72\u6642\u56e0\u7a81\u767c\u5fc3\u7387\u4e0d\u6574\u800c\u904e\u4e16\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Limb girdle muscular dystrophy\nB. Myotonic dystrophy\nC. Mitochondrial myopathy\nD. Emery-Dreifuss muscle dystrophy\nE. Becker muscle dystrophy\n": "(D)", "100-4.\n75\u6b72\u7537\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u8207\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c2\u5e74\u524d\u767c\u751f\u53f3\u6795\u8449\u90e8\u8166\u6897\u585e\u5f8c\u958b\u59cb\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u8840\u85e5Warfarin\uff0c\u6b64\u6b21\u56e0\u5de6\u5927\u8166\u6897\u585e\u4e2d\u98a8\u5165\u9662\uff0cINR\u70ba1.3\uff0c\u61c9\u8003\u616e\u5982\u4f55\u8abf\u6574\u85e5\u7269\u4ee5\u9810\u9632\u4e2d\u98a8\u518d\u767c\u751f\uff1f\nA. Warfarin \u8207 Aspirin \u4f75\u7528\nB. Warfarin \u8207 Clopidogrel \u4f75\u7528\nC. \u6539\u7528 Aspirin \u8207 Clopidogrel \u4f75\u7528\nD. Warfarin \u8207 Aspirin \u53ca Clopidogrel \u4f75\u7528\nE. \u8abf\u6574 Warfarin \u4f7f\u7528\u5291\u91cf\n": "(E)", "100-5.\n\u6bd4\u8f03\u591a\u767c\u6027\u808c\u708e\uff08polymyositis\uff09\u8207\u76ae\u808c\u708e\uff08dermatomyositis\uff09\uff0c\u4e0b\u5217\u90a3\u4e9b\u72c0\u6cc1\u70ba\u591a\u767c\u6027\u808c\u708e\u8f03\u76ae\u808c\u708e\u5e38\u898b\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u81ea\u9ad4\u514d\u75ab\u75be\u75c5\r2.\u764c\u75c7\r3.\u85e5\u7269\u76f8\u95dc\r4.\u7cfb\u7d71\u786c\u5316\u75c7\uff08systemic sclerosis\uff09\nA. 1+3\nB. 2+4\nC. 1+4\nD. 2+3\nE. 1+2+3+4\n": "(A)", "100-6.\n50\u6b72\u7537\u6027\uff0c\u6574\u810a\u5f8c\u4e0d\u9069\u81f3\u6025\u8a3a\uff0c\u8166\u90e8\u78c1\u632f\u7167\u5f71\u986f\u793a\u6709\u53f3\u5074\u5ef6\u8166\u5167\u5074\u6897\u585e\uff08right medial medulla infarct\uff09\uff0c\u53ef\u80fd\u6709\u90a3\u4e9b\u75c7\u72c0\u8868\u73fe\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u53f3\u5074\u81c9\u9ebb\r2.\u5de6\u5074\u80a2\u9ad4\u7121\u529b\r3.\u53f3\u5074\u80a2\u9ad4\u5931\u8abf\uff08dysmetria\uff09\r4.\u53f3\u5074\u820c\u982d\u7121\u529b\nA. 1+3\nB. 2+4\nC. 1+4\nD. 2+3\nE. 1+2+3+4\n": "(B)", "100-7.\n\u4e0b\u5217\u90a3\u4e9b\u662f\u4ee5\u75bc\u75db\u8868\u73fe\u70ba\u4e3b\u7684\u5468\u908a\u795e\u7d93\u75be\u75c5\uff08painful neuropathy\uff09\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.amyloidosis \uff08\u985e\u6fb1\u7c89\u75c7\uff09\r2.\u7dad\u4ed6\u547dB12\u795e\u7d93\u75c5\u8b8a\uff08vitamin B12 neuropathy\uff09\r3.\u925b\u4e2d\u6bd2\u795e\u7d93\u75c5\u8b8a\uff08lead neuropathy\uff09\r4.\u6cd5\u5e03\u6c0f\u75c7\uff08Fabry's disease\uff09\nA. 1+3\nB. 2+4\nC. 1+4\nD. 2+3\nE. 1+2+3+4\n": "(C)", "101-1.\n35\u6b72\u5973\u6027\uff0c\u56e0\u80a9\u9838\u9178\u75db\u63a5\u53d7\u6574\u810a\u63a8\u62ff\uff0c\u9694\u65e5\u767c\u751f\u53f3\u9838\u8207\u982d\u90e8\u75bc\u75db\u3001\u6688\u7729\u3001\u5614\u5410\u3001\u7121\u6cd5\u7ad9\u7acb\u75c7\u72c0\uff0c\u6b64\u60a3\u8005\u53ef\u80fd\u5408\u4f75\u4e0b\u5217\u75c7\u72c0\uff0c\u4f55\u8005\u9664\u5916\uff1f\nA. \u53f3\u81c9\u9ebb\u6728\uff08paresthesia\uff09\nB. \u53f3\u5074\u80a2\u9ad4\u7121\u529b\uff08hemiparesis\uff09\nC. \u53f3\u5074\u80a2\u9ad4\u5931\u8abf\uff08dysmetria\uff09\nD. \u5de6\u5074\u80a2\u9ad4\u9ebb\u6728\uff08hemiparesthesia\uff09\nE. \u53f3\u5074\u773c\u77bc\u4e0b\u5782\uff08ptosis\uff09\n": "(B)", "101-2.\n80\u6b72\u7537\u6027\uff0c\u8fd1\u534a\u5e74\u6709\u8a18\u61b6\u6e1b\u9000\uff0c\u8fd11\u500b\u6708\u5168\u8eab\u7121\u529b\u3001\u5026\u6020\u6b65\u614b\u4e0d\u7a69\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u56db\u80a2\u808c\u529b\u5747\u4e0b\u964d\u3001\u80a2\u9ad4\u9060\u7aef\u66f4\u660e\u986f\u3001\u808c\u9375\u53cd\u5c04\u4e0b\u964d\u4e14\u8b8a\u6162\uff0c\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u7dad\u4ed6\u547dB1\u7f3a\u4e4f\nB. \u7dad\u4ed6\u547dB12\u7f3a\u4e4f\nC. \u7532\u72c0\u817a\u4f4e\u4e0b\u75c7\uff08hypothyroidism\uff09\nD. \u5e38\u58d3\u6c34\u8166\u75c7\uff08normal pressure hydrocephalus\uff09\nE. \u4f4e\u8840\u9240\u75c7\uff08hypokalemia\uff09\n": "(C)", "101-3.\n70\u6b72\u7537\u6027\uff0c\u4e3b\u8a34\u8fd11\u9031\u6709\u6578\u6b21\u77ed\u66ab\u9663\u767c\u6027\u53f3\u4e0b\u80a2\u986b\u52d5\uff08limb shaking\uff09\uff0c\u6bcf\u6b21\u6301\u7e8c2\u5206\u9418\uff0c\u591a\u767c\u751f\u5728\u8981\u8d77\u8eab\u884c\u8d70\u6642\uff0c\u767c\u751f\u6642\u610f\u8b58\u6e05\u695a\uff0c\u5408\u4f75\u6709\u51a0\u5fc3\u75c7\u3001\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u8102\u7b49\u3002\u5247\u61c9\u512a\u5148\u5b89\u6392\u4f55\u6aa2\u67e5\uff1f\nA. \u8166\u96fb\u5716\nB. \u80a2\u9ad4\u795e\u7d93\u50b3\u5c0e\u6aa2\u67e5\nC. \u9838\u810a\u9ad3\u78c1\u632f\u7167\u5f71\u6aa2\u67e5\nD. \u9838\u52d5\u8108\u8d85\u97f3\u6ce2\u8207\u9871\u5167\u8d85\u97f3\u6ce2\nE. \u808c\u96fb\u5716\n": "(D)", "101-4.\n25\u6b72\u7537\u6027\uff0c\u4e3b\u8a34\u8fd15\u65e5\u6709\u660e\u986f\u53f3\u8033\u75bc\u75db\u50b3\u5230\u4e0b\u984e\u8655\uff0c\u8fd13\u65e5\u6709\u53f3\u81c9\u7121\u529b\u3001\u8033\u9cf4\u8207\u53f3\u8033\u807d\u529b\u4e0b\u964d\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. Sarcoidosis\nB. Miller-Fisher syndrome\nC. Tolosa-Hunt syndrome\nD. Ramsay-Hunt syndrome\nE. Leprosy\n": "(D)", "101-5.\n\u4f7f\u7528\u8840\u6813\u6eb6\u89e3\u85e5\u7269tissue plasminogen activator\uff0c\u7d041%\u6703\u767c\u751forolingual angioedema\uff08\u820c\u54bd\u8840\u7ba1\u6027\u6c34\u816b\uff09\uff0c\u4f75\u7528\u90a3\u4e00\u985e\u964d\u8840\u58d3\u85e5\u7269\u6700\u53ef\u80fd\u767c\u751f\u6b64\u526f\u4f5c\u7528\uff1f\nA. Beta-blocker\nB. Calcium channel blocker\nC. Alpha-blocker\nD. Diuretics\nE. Angiotensin receptor blocker\n": "(E)", "101-6.\n55\u6b72\u7537\u6027\u56e0\u8b6b\u5984\u5c31\u91ab\uff0c\u6709\u9157\u9152\u53f2\uff0c\u88dc\u5145\u7dad\u4ed6\u547dB1\u8207\u8f38\u6db2\uff0c\u8840\u9209\u8207\u9240\u504f\u4f4e\u7d66\u4e88\u6cbb\u7642\uff0c12\u5c0f\u6642\u5f8c\u767c\u73fe\u56db\u80a2\u660e\u986f\u7121\u529b\u3001\u610f\u8b58\u4e0d\u6e05\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u6025\u6027\u7030\u6f2b\u6027\u8166\u810a\u9ad3\u708e\uff08acute disseminated encephalomyelitis\uff09\nB. \u4e2d\u592e\u6a4b\u8166\u812b\u9ad3\u9798\u75c5\u8b8a\uff08central pontine myelinolysis\uff09\nC. Marchiafava-Bignami\u6c0f\u75c5 \uff08Marchiafava-Bignami disease\uff09\nD. \u7dad\u5c3c\u514b\u8166\u75c7\uff08Wernicke's encephalopathy\uff09\nE. \u9ad8\u8840\u9240\u75c7\uff08Hyperkalemia\uff09\n": "(B)", "101-7.\n60\u6b72\u7537\u6027\uff0c\u6709\u9157\u9152\u7fd2\u6163\uff0c\u8fd13\u500b\u6708\u8a18\u61b6\u660e\u986f\u6e1b\u9000\u3001\u6b65\u5c65\u4e0d\u7a69\u73fe\u8c61\uff0c\u56e0\u9aa8\u6298\u63a5\u53d7\u624b\u8853\u5f8c\u767c\u751f\u610f\u8b58\u4e0d\u6e05\u3002\u5247\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u8f03\u4e0d\u61c9\u7acb\u5373\u9032\u884c\uff1f\r(1) \u7d66\u4e88\u8461\u8404\u7cd6\u9ede\u6ef4\r(2) \u7d66\u4e88Thiamine\r(3) \u9032\u884c\u8170\u690e\u7a7f\u523a\u7684\u810a\u9ad3\u6db2\u6aa2\u67e5\r(4) \u8166\u90e8\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(A)", "102-1.\n65\u6b72\u5973\u6027\uff0c\u56e0\u5fc3\u623f\u986b\u52d5\u767c\u751f\u8166\u6897\u585e\u4e2d\u98a8\uff0c\u4e26\u6709\u7672\u7647\u3001\u9ad8\u5c3f\u9178\u3001\u80ba\u7d50\u6838\uff0c\u5728\u4f7f\u7528\u6297\u51dd\u5291warfarin\uff0c\u5408\u4f75\u4f7f\u7528\u5176\u5b83\u90a3\u4e9b\u85e5\u7269\u53ef\u80fd\u6703\u660e\u986f\u589e\u52a0\u8840\u4e2d\u7684INR\uff08international normalized ratio\uff09\u503c\uff1f(1) carbamazepine (2) valproic acid (3) rifampin (4) allopurinol  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "102-2.\n70\u6b72\u7537\u6027\uff0c\u56e0\u80a2\u9ad4\u5bb9\u6613\u767c\u751f\u75d9\u6523\uff08Tetany\uff09\u800c\u5c31\u8a3a\uff0c\u6aa2\u67e5\u6642\u53ef\u80fd\u6703\u767c\u73fe\u90a3\u4e9b\u5fb5\u5019\uff1f(1) Hoffmann sign (2)Trousseau's sign (3)Chvostek's sign (4)Myotonia  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(D)", "102-3.\n65\u6b72\u5973\u6027\u56e0\u5b50\u5bae\u624b\u8853\u5f8c\u81f4\u56b4\u91cd\u8178\u5b50\u4e0d\u8815\u52d5\uff08ileus\uff09\uff0c\u7121\u6cd5\u9032\u98df\u53ea\u80fd\u63a5\u53d7\u975c\u8108\u8f38\u6db2\u88dc\u5145\uff0c\u8fd1\u4e00\u9031\u6709\u6b65\u5c65\u4e0d\u7a69\uff08ataxia\uff09\u3001\u8907\u8996\uff08diplopia\uff09\u3001\u6f38\u6f38\u610f\u8b58\u4e0d\u6e05\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u767c\u73fe\u6709\u773c\u632f\uff08nystagmus\uff09\u3001\u773c\u7403\u904b\u52d5\u969c\u7919\u8207\u80a2\u9ad4\u5931\u8abf\uff0c\u53ef\u80fd\u662f\u4f55\u7a2e\u7f3a\u4e4f\u6240\u81f4\uff1f\nA. Thiamine\nB. Pyridoxine\nC. Cobalamin\nD. Riboflavin\nE. Vitamin E\n": "(A)", "102-4.\n65\u6b72\u7537\u6027\uff0c\u982d\u75db\u3001\u5026\u6020\uff0c\u7a81\u767c\u5de6\u5074\u8996\u529b\u55aa\u5931\uff0c\u6aa2\u67e5\u986f\u793a\u70ba\u8996\u795e\u7d93\u708e\uff0c\u4e0b\u5217\u4f55\u8a3a\u65b7\u53ef\u80fd\u6027\u8f03\u9ad8\uff1f\nA. Cerebral sinus thrombosis\nB. Antiphospholipid syndrome\nC. Carotid dissection\nD. Giant cell arteritis\nE. Lyme disease\n": "(D)", "102-5.\n\u95dc\u65bcPOEMS\u75c7\u5019\u7fa4\u7684\u81e8\u5e8a\u8868\u73fe\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u70ba\u6162\u6027\u812b\u9ad3\u9798\u795e\u7d93\u75c5\u8b8a\uff0c\u4f46\u591a\u5c0d\u985e\u56fa\u9187\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73\nB. Kappa light chain\u8f03lambda light chain\u5e38\u898b\nC. \u6709\u8996\u4e73\u982d\u6c34\u816b\uff08papilledema\uff09\nD. \u76ae\u819a\u8b8a\u9ed1\u3001\u591a\u6bdb\nE. \u8840\u6e05\u4e2d\u7684\u8840\u7ba1\u5167\u76ae\u751f\u9577\u56e0\u5b50\uff08vascular endothelial growth factor\uff09\u6fc3\u5ea6\u589e\u52a0\n": "(B)", "102-6.\n70\u6b72\u5973\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u7684\u75c5\u53f2\uff0c\u53f3\u6487\uff0c\u5bb6\u4eba\u767c\u73fe\u6700\u8fd1\u4e09\u65e5\u8b8a\u5f97\u4e0d\u6703\u505a\u5bb6\u4e8b\uff0c\u4e5f\u4e0d\u6703\u81ea\u5df1\u7a7f\u8863\u670d\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u8166\u5e79\u529f\u80fd\u6b63\u5e38\u3001\u80a2\u9ad4\u808c\u529b\u6b63\u5e38\u3001\u8a00\u8a9e\u6d41\u66a2\uff0c\u6700\u53ef\u80fd\u7684\u75c5\u8b8a\u4f4d\u7f6e\u5728\u90a3\u88e1\uff1f\nA. \u53f3\u5074\u984d\u8449\uff08frontal lobe\uff09\nB. \u53f3\u5074\u9873\u8449\uff08temporal lobe\uff09\nC. \u53f3\u5074\u9802\u8449\uff08parietal lobe\uff09\nD. \u5de6\u5074\u984d\u8449\uff08frontal lobe\uff09\nE. \u5de6\u5074\u9802\u8449\uff08parietal lobe\uff09\n": "(E)", "102-7.\n\u4e0b\u5217\u4f55\u8005\u975e\u56b4\u91cd\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\uff08hypothyroidism\uff09\u7684\u795e\u7d93\u5b78\u8868\u73fe\uff1f\nA. \u667a\u80fd\u4f4e\u4e0b\nB. \u808c\u8089\u6523\u7e2e\uff08cramp\uff09\nC. \u808c\u8089\u50f5\u786c\uff08stiffness\uff09\nD. \u808c\u8089\u75bc\u75db\nE. \u808c\u8171\u53cd\u5c04\u589e\u5f37\n": "(E)", "103-1.\n55\u6b72\u7537\u6027\uff0c\u56e0\u5de6\u773c\u816b\u8139\u8207\u9b31\u8840\u5c31\u8a3a\uff0c\u982d\u90e8\u78c1\u632f\u7167\u5f71\u986f\u793a\u5de6\u5074\u6d77\u7dbf\u7ac7\uff08cavernous sinus\uff09\u6709\u4e0d\u6b63\u5e38\u986f\u5f71\uff0c\u81e8\u5e8a\u8a3a\u65b7\u70ba\u773c\u7aa9\u9802\u75c7\u5019\u7fa4\uff08orbital apex syndrome\uff09\uff0c\u90a3\u4e00\u689d\u9871\u795e\u7d93\u5b78\u4e0d\u6703\u53d7\u5f71\u97ff\uff1f\nA. \u7b2c\u4e8c\u9871\u795e\u7d93\nB. \u7b2c\u4e09\u9871\u795e\u7d93\nC. \u7b2c\u56db\u9871\u795e\u7d93\nD. \u7b2c\u516d\u9871\u795e\u7d93\nE. \u7b2c\u4e03\u9871\u795e\u7d93\n": "(E)", "103-2.\n25\u6b72\u5973\u6027\uff0c\u56e0\u7a81\u7136\u8907\u8996\u8207\u53f3\u5074\u80a2\u9ad4\u7121\u529b\u5c31\u8a3a\uff0c\u4e4b\u524d\u6709\u5fc3\u96dc\u97f3\u3001\u6700\u8fd13\u500b\u6708\u6709\u8f15\u5ea6\u767c\u71d2\u3001\u5026\u6020\u3001\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\uff0c\u6aa2\u67e5\u6642\u9808\u6ce8\u610f\u54ea\u4e9b\u5fb5\u5019\uff1f(1) Gottron's sign (2) Janeway's lesion (3) Heliotrope sign (4) Roth's spot (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "103-3.\n40\u6b72\u5973\u6027\u56e0\u9663\u767c\u6027\u982d\u75db\u5c31\u91ab\uff0c\u982d\u75db\u4f4d\u5728\u5de6\u5074\u9873\u8449\u8207\u773c\u7736\u9644\u8fd1\uff0c\u6bcf\u6b21\u75db10\u81f320\u5206\u9418\uff0c\u6bcf\u5929\u75db8-10\u6b21\uff0c\u8166\u96fb\u5716\u8207\u8166\u90e8\u5f71\u50cf\u6aa2\u67e5\u6b63\u5e38\uff0c\u61c9\u512a\u5148\u9078\u64c7\u4f55\u7a2e\u85e5\u7269\u6cbb\u7642\uff1f\nA. Verapamil\nB. Sumatriptan\nC. Topiramide\nD. Indomethacin\nE. Propranolol\n": "(D)", "103-4.\n40\u6b72\u7537\u6027\u525b\u88ab\u8a3a\u65b7\u6709\u7672\u7647\u75be\u75c5\uff0c\u904e\u53bb\u4e26\u7121\u8166\u708e\u3001\u8166\u5916\u50b7\u3001\u6216\u7279\u6b8a\u75c5\u53f2\uff0c\u6700\u6709\u53ef\u80fd\u662f\u4f55\u7a2e\u7672\u7647\u578b\u614b\uff1f\nA. \u5927\u767c\u4f5c\u7672\u7647\uff08Grand mal seizure\uff09\nB. \u5931\u795e\u7672\u7647\uff08Absence seizure\uff09\nC. \u8907\u96dc\u5c40\u90e8\u7672\u7647\uff08Complex partial seizure\uff09\nD. \u808c\u8e8d\u6027\u7672\u7647\uff08Myoclonic seizure\uff09\nE. \u7672\u7647\u5f8c\u7671\u7613\uff08Todd paralysis\uff09\n": "(C)", "103-5.\n70\u6b72\u7537\u6027\u6709\u53f3\u5074\u7684\u6a4b\u8166\u6897\u585e\uff08pons infarction\uff09\uff0c\u7522\u751f1\u53c81/2\u75c7\u5019\u7fa4\uff08One-and-a-half syndrome\uff09\uff0c\u5247\u4e0b\u5217\u773c\u7403\u52d5\u4f5c\u4f55\u8005\u70ba\u975e\uff1f\nA. \u53f3\u773c\u7403\u7121\u6cd5\u5411\u5916\u8f49\u52d5\nB. \u53f3\u773c\u7403\u7121\u6cd5\u5411\u5167\u8f49\u52d5\nC. \u5de6\u773c\u7403\u7121\u6cd5\u5411\u5167\u8f49\u52d5\nD. \u5de6\u773c\u7403\u7121\u6cd5\u5411\u5916\u8f49\u52d5\nE. \u53f3\u773c\u7403\u53ef\u5411\u4e0b\u8f49\u52d5\n": "(D)", "103-6.\n25\u6b72\u7537\u6027\uff0c\u56e0\u56b4\u91cd\u8e81\u52d5\u8207\u80a2\u9ad4\u986b\u52d5\u5c31\u91ab\uff0c\u75c5\u60a3\u6709\u7cbe\u795e\u75be\u75c5\uff0c\u4f7f\u7528lithium\u3001clozapine\u3001valproic acid\u7b49\u85e5\u7269\uff0c\u75c5\u60a3\u610f\u8b58\u6df7\u4e82\uff0c\u9ad4\u6eab39\u2103\uff0c\u8840\u58d3 120/82 mmHg\uff0c\u8108\u640f 105/\u5206\u9418\uff0c\u5168\u8eab\u50f5\u786c\uff08rigidity\uff09\u8207\u986b\u6296\uff08tremor\uff09\uff0c\u808c\u9150\u9178\ufffdC\uff08creatine kinase\uff09\u70ba2450 units/L\uff0c\u6700\u53ef\u80fd\u662f\u54ea\u4e00\u8a3a\u65b7\uff1f\nA. \u92f0\u9e7d\u4e2d\u6bd2\nB. valproic acid\u904e\u91cf\nC. \u8840\u6e05\u7d20\u75c7\u5019\u7fa4\uff08serotonin syndrome\uff09\nD. \u60e1\u6027\u9ad8\u9ad4\u6eab\uff08malignant hyperthermia\uff09\nE. \u6297\u7cbe\u795e\u75c5\u85e5\u7269\u60e1\u6027\u75c7\u5019\u7fa4\uff08neuroleptic malignant syndrome\uff09\n": "(E)", "103-7.\n82\u6b72\u5973\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u3001\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c\u56e0\u6025\u6027\u4e2d\u98a8\u5c31\u91ab\uff0c\u8a3a\u65b7\u70ba\u5de6\u5074\u5927\u7bc4\u570d\u4e2d\u5927\u8166\u52d5\u8108\u6897\u585e\uff0c\u7f8e\u570b\u570b\u5bb6\u885b\u751f\u9662\u8166\u4e2d\u98a8\u91cf\u8868\uff08NIHSS\uff09\u5206\u6578\u70ba18\u5206\uff0c\u8840\u7cd6230 mg/dL\uff0c\u73fe\u70ba\u4e2d\u98a8\u767c\u751f\u5f8c6\u5c0f\u6642\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u8f03\u9069\u7576\uff1f(1) \u66ab\u6642\u5148\u4e0d\u8981\u7d66\u4e88\u6297\u8840\u6813\u85e5\u7269 (2) \u53ef\u8003\u616e\u4e00\u5468\u5f8c\u958b\u59cb\u4f7f\u7528\u65b0\u578b\u53e3\u670d\u6297\u51dd\u5291 (3) \u82e5\u8840\u58d3\u70ba190/90 mmHg\u4e0d\u8981\u7acb\u5373\u964d\u58d3 (4) \u53ef\u8003\u616e\u7a4d\u6975\u80f0\u5cf6\u7d20\u8f38\u6ce8\uff08insulin infusion\uff09\u4ee5\u56b4\u683c\u63a7\u5236\u8840\u7cd6\u3002(\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(A)", "104-1.\n20\u6b72\u5973\u6027\u56e0\u5de6\u624b\u7121\u529b\u5c31\u8a3a\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u5de6\u5074\u7684\u624b\u6307\u7121\u6cd5\u5b8c\u5168\u5f35\u958b\u8207\u9589\u5408\uff0c\u638c\u9aa8\u9593\u808c\uff08interossei muscle\uff09\u7121\u529b\u840e\u7e2e\uff0c\u662f\u90a3\u4e00\u689d\u795e\u7d93\u53d7\u640d\uff1f\nA. \u6b63\u4e2d\u795e\u7d93\uff08median nerve\uff09\nB. \u5c3a\u795e\u7d93\uff08ulnar nerve\uff09\nC. \u6a48\u795e\u7d93\uff08radial nerve\uff09\nD. \u808c\u8868\u76ae\u795e\u7d93\uff08musculocutaneous nerve\uff09\nE. \u9577\u80f8\u795e\u7d93\uff08long thoracic nerve\uff09\n": "(B)", "104-2.\n25\u6b72\u5973\u6027\u6709\u7d05\u6591\u6027\u72fc\u7621\uff08systemic lupus erythematosus\uff09\u5408\u4f75\u814e\u708e\u67093\u5e74\uff0c\u4f7f\u7528\u985e\u56fa\u9187\u3001\u514d\u75ab\u6291\u5236\u5291\uff08cyclophosphamide\uff09\uff0c\u56e0\u610f\u8b58\u4e0d\u6e05\u8207\u7672\u7647\u81f3\u6025\u8a3a\uff0c\u7406\u5b78\u6aa2\u67e5\u8840\u58d3200/110 mmHg\u3001\u9ad4\u6eab37\u00b0C\uff0c\u810a\u9ad3\u6db2\u6aa2\u67e5\u986f\u793a\u7121\u767d\u8840\u7403\u3001\u86cb\u767d\u6fc3\u5ea6\u7a0d\u589e\u52a0\uff0c\u8166\u90e8\u78c1\u632f\u7167\u5f71\u986f\u793a\u5169\u5074\u6795\u8449\u6709\u4e0d\u6b63\u5e38\u8a0a\u865f\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u8166\u819c\u8166\u708e\uff08meningoencephalitis\uff09\nB. \u5c3f\u6bd2\u8166\u75c5\u8b8a\uff08uremic encephalopathy\uff09\nC. \u6025\u6027\u53bb\u9ad3\u9798\u8166\u708e\uff08acute demyelinating encephalitis\uff09\nD. \u6025\u6027\u8166\u6897\u585e\uff08acute cerebral infarction\uff09\nE. \u53ef\u9006\u6027\u5f8c\u8166\u75c5\u8b8a\u75c7\u5019\u7fa4\uff08posterior reversible encephalopathy syndrome\uff09\n": "(E)", "104-3.\n25\u6b72\u5973\u6027\uff0c\u56e0\u7a81\u7136\u8907\u8996\u8207\u53f3\u5074\u80a2\u9ad4\u7121\u529b\u5c31\u8a3a\uff0c\u4e4b\u524d\u6709\u5fc3\u96dc\u97f3\u3001\u6700\u8fd13\u500b\u6708\u6709\u8f15\u5ea6\u767c\u71d2\u3001\u5026\u6020\u3001\u9ad4\u91cd\u6e1b\u8f155\u516c\u65a4\uff0c\u6aa2\u67e5\u6642\u9808\u6ce8\u610f\u54ea\u4e9b\u5fb5\u5019\uff1f(1) Gottron's sign\uff1b(2) Janeway's lesion\uff1b(3) Heliotrope sign\uff1b(4) Roth's spot\u3002\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(1)\nE. (2)+(4)\n": "(E)", "104-4.\n55\u6b72\u5973\u6027\u56e0\u98a8\u6fd5\u6027\u5fc3\u81df\u75c5\u3001\u74e3\u819c\u7f6e\u63db\u8207\u5fc3\u623f\u986b\u52d5\uff0c\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u5291\uff0c\u56e0\u8166\u51fa\u8840\u81f3\u6025\u8a3a\uff0cINR\u70ba5.5\uff0c\u4f7f\u7528\u4e0b\u5217\u4f55\u7a2e\u6cbb\u7642\u80fd\u6700\u5feb\u6062\u5fa9\u51dd\u8840\u529f\u80fd\uff1f\r\n(1) Vitamin K\uff1b(2) Fresh frozen plasma\uff1b(3)Platelets\uff1b(4)Prothrombin complex concentrates\uff1b(5) Whole blood\nA. (1)+(2)\nB. (1)+(2)+(3)\nC. (1)+(2)+(4)\nD. (1)+(3)+(5)\nE. (1)+(4)+(5)\n": "(A or B or C or D)", "104-5.\n50\u6b72\u5973\u6027\u7f79\u60a3\u808c\u7121\u529b\uff08myasthenia gravis\uff094\u5e74\uff0c\u56e0\u80ba\u708e\u4f75\u767c\u547c\u5438\u8870\u7aed\u5165\u4f4f\u52a0\u8b77\u75c5\u623f\uff0c\u4e0b\u5217\u90a3\u4e9b\u985e\u5225\u7684\u6297\u751f\u7d20\u8f03\u4e0d\u9069\u5408\u4f7f\u7528\uff1f(1) Quinolones\uff1b(2) Beta-lactam + beta-lactamase inhibitor\uff1b(3) Macrolides\uff1b(4) Cephalosporins\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(A)", "104-6.\n\u76f8\u8f03\u65bc\u808c\u7121\u529b\uff08myasthenia gravis\uff09\uff0c\u85cd\u4f2f-\u4f0a\u9813\u808c\u7121\u529b\u75c7\uff08Lambert-Eaton myasthenic syndrome\uff09\u8f03\u5e38\u51fa\u73fe\u90a3\u4e9b\u75c7\u72c0\uff1f(1) \u773c\u76ae\u4e0b\u5782\u3001\u8907\u8996\uff1b(2) \u808c\u8171\u53cd\u5c04\u4e0b\u964d\uff1b(3) \u53e3\u9f52\u4e0d\u6e05\u53ca\u541e\u56a5\u56f0\u96e3\uff1b(4) \u81ea\u5f8b\u795e\u7d93\u5931\u8abf\u75c7\u72c0\uff0c\u5982\u53e3\u4e7e\u3001\u4fbf\u79d8\u3001\u5c0f\u4fbf\u56f0\u96e3\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "104-7.\n40\u6b72\u5973\u59d3\u56e0\u80a2\u9ad4\u986b\u6296\u5c31\u8a3a\uff0c\u8166\u90e8\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\u986f\u793a\u6709\u660e\u986f\u5169\u5074\u57fa\u5e95\u6838\u9223\u5316\uff0c\u4e0b\u5217\u90a3\u4e9b\u75be\u75c5\u9808\u8003\u616e\uff1f(1) \u4e00\u6c27\u5316\u78b3\u4e2d\u6bd2\uff08carbon monoxide intoxication\uff09\uff1b(2) \u7c92\u7dda\u9ad4\u75be\u75c5\uff08mitochondrial disease\uff09\uff1b(3) \u8166\u56ca\u5c3e\u5e7c\u87f2\u75c7\uff08neurocysticercosis\uff09\uff1b(4) \u526f\u7532\u72c0\u817a\u4f4e\u80fd\u75c7\uff08hypoparathyroidism\uff09\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(E)", "105-1.\n60\u6b72\u7537\u6027\u56e0\u4e3b\u52d5\u8108\u525d\u96e2\u4f4f\u9662\uff0c\u4f4f\u9662\u4e2d\u767c\u751f\u56db\u80a2\u7121\u529b\u8207\u5931\u7981\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u56db\u80a2\u808c\u529b\u70ba1\u5206\uff0c\u56db\u80a2\u808c\u8171\u53cd\u5c04\u589e\u52a0\uff0c\u8e60\u53cd\u5c04\uff08plantar reflex\uff09\u70ba\u5411\u4e0a\uff0c\u91dd\u523a\u611f\u89ba\uff08pin prick sense\uff09\u81ea\u80f8\u90e8\u4ee5\u4e0b\u55aa\u5931\uff0c\u95dc\u7bc0\u6d3b\u52d5\u611f\u89ba\uff08joint position sense\uff09\u5247\u6b63\u5e38\uff0c\u4f55\u7a2e\u75c5\u8b8a\u7684\u53ef\u80fd\u6027\u6700\u9ad8\uff1f\nA. \u786c\u8166\u819c\u5916\u81bf\u760d\uff08epidural abscess\uff09\nB. \u786c\u8166\u819c\u4e0b\u8840\u816b\uff08subdural hematoma\uff09\nC. \u524d\u810a\u690e\u52d5\u8108\u75c7\u5019\u7fa4\uff08anterior spinal artery syndrome\uff09\nD. \u6025\u6027\u6a6b\u8cab\u6027\u810a\u9ad3\u708e\uff08acute transverse myelitis\uff09\nE. \u786c\u8166\u819c\u5916\u8840\u816b\uff08epidural hematoma\uff09\n": "(C)", "105-2.\n20\u6b72\u7537\u6027\uff0c\u56e0\u7761\u7720\u554f\u984c\u770b\u8a3a\uff0c\u4e3b\u8a34\u6709\u4e0b\u5217\u75c7\u72c0\uff0c\u4f55\u8005\u662f\u8a3a\u65b7\u731d\u7761\u75c7\uff08narcolepsy\uff09\u6700\u660e\u78ba\uff08specific\uff09\u7684\u75c7\u72c0\uff1f\nA. \u767d\u5929\u4e0a\u8ab2\u6642\u5f88\u5bb9\u6613\u7761\u8457\nB. \u5927\u7b11\u6642\u6703\u5168\u8eab\u7121\u529b\nC. \u5e38\u4e00\u8eba\u4e0b\u5c31\u7761\u8457\u4e86\nD. \u767d\u5929\u7cbe\u795e\u5e38\u4e0d\u4f73\nE. \u525b\u7761\u9192\u6642\u6709\u5e7b\u89ba\n": "(B)", "105-3.\n40\u6b72\u5973\u6027\u56e0\u5927\u91cf\u6d41\u6c57\u3001\u767c\u71d2\u3001\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u6aa2\u67e5\u986f\u793a\u8108\u640f\u6bcf\u5206\u9418120\u4e0b\u3001\u80a2\u9ad4\u50f5\u76f4(rigidity)\u3001\u808c\u8171\u53cd\u5c04\u589e\u52a0 (hyperreflexia)\u3002\u75c5\u4eba\u6709\u6182\u9b31\u75c7\u75c5\u53f2\uff0c\u5728\u7cbe\u795e\u79d1\u9580\u8a3a\u770b\u8a3a\u7528\u85e5\uff0c\u6700\u6709\u53ef\u80fd\u662f\u4e0b\u5217\u4f55\u8a3a\u65b7\uff1f\nA. \u97cb\u5c3c\u514b\u6c0f\u8166\u75c5\uff08Wernicke's encephalopathy\uff09\nB. \u75c5\u6bd2\u8166\u708e\uff08viral encephalitis\uff09\nC. \u6297\u7cbe\u795e\u85e5\u7269\u60e1\u6027\u75c7\u5019\u7fa4\uff08neuroleptic malignant syndrome\uff09\nD. \u93ae\u975c\u5291\u904e\u91cf\uff08tranquilizer overdose\uff09\nE. \u8840\u6e05\u75c7\u5019\u7fa4\uff08serotonin syndrome\uff09\n": "(E)", "105-4.\n30\u6b72\u5973\u6027\u56e0\u96d9\u4e0b\u80a2\u7121\u529b\u3001\u9ebb\u6728\u8207\u5931\u7981\u5c31\u91ab\uff0c\u810a\u9ad3\u6db2\u6aa2\u67e5\u986f\u793a\u7121\u767d\u8840\u7403\uff0c\u8461\u8404\u7cd6\u70ba70 mg/dL\u3001\u5168\u90e8\u86cb\u767d\u70ba75 mg/dL\u3001\u767d\u86cb\u767d\u70ba50 mg/dL\u3001IgG\u70ba20 mg/dL\uff0c\u8840\u6e05\u7684\u767d\u86cb\u767d\u70ba3000 mg/dL\u3001IgG\u70ba1000 mg/dL\uff0c\u5247\u5979\u7684IgG index\u662f\u591a\u5c11\uff1f\nA. \u22671.20\nB. 1.00~1.19\nC. 0.80~0.99\nD. 0.60~0.79\nE. <0.60\n": "(A)", "105-5.\n55\u6b72\u7537\u6027\uff0c\u9577\u671f\u65bc\u67d0\u4e00\u5de5\u5ee0\u5de5\u4f5c\uff0c\u8fd16\u500b\u6708\u6709\u6f38\u9032\u7684\u6b65\u5c65\u8b8a\u5c0f\u3001\u52d5\u4f5c\u8b8a\u6162\u3001\u5e73\u8861\u8b8a\u5dee\uff0c\u8a3a\u65b7\u70ba\u5df4\u91d1\u68ee\u6c0f\u75c7\uff08parkinsonism\uff09\uff0c\u67092\u4f4d\u5de5\u5ee0\u540c\u4e8b\u6709\u985e\u4f3c\u4f46\u8f03\u8f15\u7684\u75c7\u72c0\uff0c\u6700\u9700\u8981\u61f7\u7591\u70ba\u4f55\u7a2e\u4e2d\u6bd2\uff1f\nA. \u925b\uff08lead\uff09\nB. \u9333\uff08manganese\uff09\nC. \u6c5e\uff08mercury\uff09\nD. \u7837\uff08arsenic\uff09\nE. \u9285\uff08copper\uff09\n": "(B)", "105-6.\n\u6162\u6027\u814e\u81df\u75be\u75c5\uff08chronic kidney disease\uff09\u75c5\u4eba\u63a5\u53d7\u900f\u6790\u6cbb\u7642\u7684\u6642\u5019\uff0c\u767c\u751f\u900f\u6790\u5931\u8861\u75c7\u5019\u7fa4\uff08dialysis disequilibrium syndrome\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u591a\u5728\u900f\u6790\u7d50\u675f\u6642\u767c\u751f\uff0c\u800c\u975e\u900f\u6790\u958b\u59cb\u524d\u767c\u751f\nB. \u6703\u8868\u73fe\u7a81\u773c\u3001\u773c\u58d3\u9ad8\nC. \u6703\u8868\u73fe\u982d\u75db\u3001\u7672\u7647\nD. \u56e0\u6c34\u5206\u81ea\u8166\u90e8\u812b\u51fa\u592a\u591a\u6240\u81f4\nE. \u56e0\u79fb\u9664\u5c3f\u7d20\u592a\u5feb\u6240\u81f4\n": "(D)", "105-7.\n25\u6b72\u7537\u60271\u5e74\u524d\u66fe\u767c\u751f\u8eca\u798d\u81f4\u9396\u9aa8\u9aa8\u6298\uff0c\u534a\u5e74\u524d\u8d77\u6f38\u9032\u53f3\u4e0a\u80a2\u7121\u529b\u3001\u9ebb\u6728\u8207\u51b0\u51b7\u5c31\u8a3a\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u53f3\u4e0a\u80a2\u5167\u5074\u611f\u89ba\u9072\u920d\u3001\u53f3\u624b\u808c\u529b\u8f03\u5dee\uff0c\u53f3\u81c2\u8840\u58d3\u70ba90/60 mmHg\u3001\u5de6\u81c2\u8840\u58d3\u70ba130/80 mmHg\uff0c\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f\nA. \u9838\u795e\u7d93\u6839\u75c5\u8b8a\uff08cervical radiculopathy\uff09\nB. \u80f8\u5ed3\u51fa\u53e3\u75c7\u5019\u7fa4\uff08thoracic outlet syndrome)\nC. \u81c2\u795e\u7d93\u53e2\u75c5\u8b8a\uff08brachial plexopathy\uff09\nD. \u8155\u96a7\u9053\u75c7\u5019\u7fa4\uff08carpal tunnel syndrome\uff09\nE. \u9396\u9aa8\u4e0b\u52d5\u8108\u7aca\u8840\u75c7\u5019\u7fa4\uff08subclavian steal syndrome\uff09\n": "(B)", "106-1.\n75\u6b72\u7537\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u9ad8\u8840\u8102\u3001\u51a0\u5fc3\u75c7\uff0c\u67d0\u65e5\u7a81\u7136\u767c\u73fe\u5de6\u773c\u5e7e\u4e4e\u770b\u4e0d\u898b\uff0c\u75c7\u72c0\u6301\u7e8c\u7d0410\u5206\u9418\u5f8c\u8996\u529b\u9010\u6f38\u6062\u5fa9\uff0c\u61c9\u512a\u5148\u5b89\u6392\u90a3\u4e00\u500b\u6aa2\u67e5\uff1f\nA. \u7d93\u80f8\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\nB. \u7d93\u98df\u9053\u5fc3\u81df\u8d85\u97f3\u6ce2\u6aa2\u67e5\nC. \u8166\u90e8\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\nD. \u9838\u52d5\u8108\u8d85\u97f3\u6ce2\u6aa2\u67e5\nE. \u8996\u91ce\u6aa2\u67e5\n": "(D)", "106-2.\n50\u6b72\u5973\u6027\uff0c\u6bcf\u665a\u525b\u7761\u6642\u6703\u6709\u4e0b\u80a2\u5f88\u4e0d\u8212\u670d\u611f\u89ba\uff0c\u5fc5\u9808\u8981\u52d5\u4e00\u52d5\u8173\u624d\u6703\u8212\u670d\u4e9b\uff0c\u7761\u89ba\u6642\u88ab\u767c\u73fe\u6703\u9663\u767c\u6027\u7684\u77ed\u66ab\u8173\u6296\u52d5\uff0c\u82e5\u9700\u4f7f\u7528\u85e5\u7269\u53ef\u512a\u5148\u8003\u616e\u54ea\u4e00\u985e\u85e5\u6cbb\u7642\uff1f\nA. Dopamine agonist\nB. Dopamine antagonist\nC. Serotonin antagonist\nD. Selective serotonin-reuptake inhibitor (SSRI)\nE. Monoamine oxidase inhibitor (MAOI)\n": "(A)", "106-3.\n40\u6b72\u5973\u6027\uff0c2\u500b\u6708\u524d\u63a5\u53d7\u814e\u81df\u79fb\u690d\uff0c\u4f7f\u7528cyclosporine\uff0c\u7a81\u767c\u982d\u75db\u3001\u7672\u7647\u3001\u610f\u8b58\u4e0d\u6e05\uff0c\u8166\u90e8\u78c1\u632f\u7167\u5f71\u6aa2\u67e5\u6700\u53ef\u80fd\u767c\u73fe\u75c5\u7076\u4f4d\u7f6e\u70ba\u4f55\uff1f\nA. \u984d\u8449\uff08frontal lobe\uff09\nB. \u6a4b\u8166\uff08pons\uff09\nC. \u9873\u8449\uff08temporal lobe\uff09\nD. \u6795\u8449\uff08occipital lobe\uff09\nE. \u4e2d\u8166\uff08midbrain\uff09\n": "(D)", "106-4.\n\u5c0d\u65bc\u4e2d\u98a8\u7684\u4e8c\u6b21\u9810\u9632\u5371\u96aa\u56e0\u5b50\u7684\u63a7\u5236\uff0c\u4e0b\u5217\u54ea\u4e9b\u6cbb\u7642\u6240\u9700\u8981\u7684\u500b\u6848\u6578\u4ee5\u964d\u4f4e\u4e00\u500b\u4e2d\u98a8\u767c\u751f\uff08Number needed to treat, NNT\uff09\uff0cNNT\u7531\u5c0f\u5230\u5927\uff0c\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u5fc3\u623f\u986b\u52d5\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u5291\u3001\u9ad8\u8840\u58d3\u964d\u8840\u58d3\u3001\u9ad8\u8840\u8102\u964d\u8840\u8102\nB. \u9ad8\u8840\u58d3\u964d\u8840\u58d3\u3001\u5fc3\u623f\u986b\u52d5\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u5291\u3001\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\nC. \u5fc3\u623f\u986b\u52d5\u4f7f\u7528\u53e3\u670d\u6297\u51dd\u5291\u3001\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\u3001\u9ad8\u8840\u8102\u964d\u8840\u8102\nD. \u9ad8\u8840\u58d3\u964d\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\u3001\u9ad8\u8840\u8102\u964d\u8840\u8102\nE. \u9ad8\u8840\u8102\u964d\u8840\u8102\u3001\u9ad8\u8840\u58d3\u964d\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\n": "(A)", "106-5.\n25\u6b72\u7537\u6027\uff0c\u8fd13\u65e5\u6709\u6f38\u9032\u56db\u80a2\u7121\u529b\u3001\u80a2\u9ad4\u672b\u7aef\u9ebb\u6728\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u56db\u80a2\u808c\u529b3-4\u5206\u3001\u80a2\u9ad4\u9060\u7aef\u8f03\u8fd1\u7aef\u7121\u529b\u3001\u808c\u8171\u53cd\u5c04\u6d88\u5931\uff0c1\u9031\u524d\u6709\u4e0a\u547c\u5438\u9053\u611f\u67d3\uff0c\u810a\u9ad3\u6db2\u6aa2\u67e5\u7d50\u679c\u6700\u53ef\u80fd\u662f\u4e0b\u8ff0\u4f55\u8005\uff1f\nA. \u86cb\u767d40 mg/dL\u3001\u8461\u8404\u7cd675 mg/dL\u3001\u767d\u8840\u74035/\u03bcL\u3001\u521d\u58d3 200 mmH2O\nB. \u86cb\u767d200 mg/dL\u3001\u8461\u8404\u7cd645 mg/dL\u3001\u767d\u8840\u7403100/\u03bcL\u3001\u521d\u58d3 250 mmH2O\nC. \u86cb\u767d150 mg/dL\u3001\u8461\u8404\u7cd685 mg/dL\u3001\u767d\u8840\u74033/\u03bcL\u3001\u521d\u58d3 120 mmH2O\nD. \u86cb\u767d100 mg/dL\u3001\u8461\u8404\u7cd655 mg/dL\u3001\u767d\u8840\u740320/\u03bcL\u3001\u521d\u58d3 180 mmH2O\nE. \u86cb\u767d80 mg/dL\u3001\u8461\u8404\u7cd665 mg/dL\u3001\u767d\u8840\u740310/\u03bcL\u3001\u521d\u58d3 300 mmH2O\n": "(C)", "106-6.\n60\u6b72\u7537\u6027\u56e0\u4e3b\u52d5\u8108\u525d\u96e2\u4f75\u767c\u80f8\u810a\u9ad3\u6897\u585e\uff0c\u4e0b\u80a2\u611f\u89ba\u529f\u80fd\u90a3\u4e9b\u6700\u53ef\u80fd\u53d7\u5230\u5f71\u97ff(1)\u9707\u52d5\u611f(vibration)\uff1b(2)\u6eab\u5ea6\u611f(temperature)\uff1b(3) \u91dd\u523a\u611f(pin-prick)\uff1b(4) \u95dc\u7bc0\u4f4d\u7f6e\u611f(joint position sense)\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(D)", "106-7.\n\u4e0b\u5217\u75be\u75c5\u4f55\u8005\u5c6c\u65bc\u5c0f\u8840\u7ba1\u75c5\u8b8a\uff1f(1)\u6bdb\u6bdb\u6a23\u75c5(Moya-moya disease)\uff1b(2)\u9ad4\u986f\u6027\u8166\u52d5\u8108\u8840\u7ba1\u75c5\u8b8a\u5408\u4f75\u76ae\u8cea\u4e0b\u8166\u6897\u585e\u53ca\u8166\u767d\u8cea\u75c5\u8b8a(Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CADASIL)\uff1b(3)\u9ad8\u5b89\u6c0f\u52d5\u8108\u708e(Takayasu's arteritis)\uff1b(4)\u9ad8\u8840\u58d3\u8166\u51fa\u8840(Hypertensive intracerebral hemorrhage)\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "107-1.\n25\u6b72\u7537\u6027\uff0c\u9a0e\u8173\u8e0f\u8eca\u6642\u767c\u751f\u8eca\u798d\u6454\u5012\uff0c\u7acb\u5373\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u5165\u6025\u8a3a\u6642\uff0c\u610f\u8b58\u6e05\u695a\uff0c\u8840\u58d3120/70 mmHg\uff0c\u81c9\u8207\u8eab\u9ad4\u6709\u591a\u8655\u64e6\u50b7\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u5927\u8166\u76ae\u8cea\u529f\u80fd\u8207\u9871\u795e\u7d93\u6b63\u5e38\uff0c\u4e0a\u80a2\u808c\u529b5\u5206\uff0c\u96d9\u4e0b\u80a2\u808c\u529b3-4\u5206\uff0c\u4e0b\u80a2\u808c\u9375\u53cd\u5c04\u4e0b\u964d\uff0c\u81ea\u809a\u81cd\u4ee5\u4e0b\u91dd\u523a\u611f\u964d\u4f4e\u3002\u8acb\u554f\u61c9\u7acb\u5373\u9032\u884c\u4e0b\u5217\u4f55\u7a2e\u8655\u7f6e?\nA. \u8166\u90e8\u65b7\u5c64\u6383\u63cf\u6aa2\u67e5\nB. \u80f8\u90e8\u6838\u78c1\u5171\u632f\u6aa2\u67e5\nC. \u9ad4\u611f\u8a98\u767c\u96fb\u4f4d\u6aa2\u67e5\nD. \u975c\u8108\u7d66\u4e88\u9ad8\u5291\u91cfmethylprednisolone\nE. \u975c\u8108\u7d66\u4e88\u6297\u7672\u7647\u85e5\u7269\uff08\u5982\uff1alevetiracetam\uff09\n": "(D)", "107-2.\n75\u6b72\u5973\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c\u5e73\u6642\u672a\u898f\u5247\u7528\u85e5\uff0c\u7a81\u767c\u53f3\u5074\u7121\u529b\u8207\u5931\u8a9e\uff0c\u96a8\u5373\u88ab\u9001\u81f3\u6025\u8a3a\u8655\uff0c\u7f8e\u570b\u570b\u5bb6\u885b\u751f\u9662\u8166\u4e2d\u98a8\u91cf\u8868\u7684\u5206\u6578\u70ba18\u5206\uff0c\u8166\u90e8\u65b7\u5c64\u6383\u63cf\u986f\u793a\u7121\u8166\u5167\u51fa\u8840\uff0c\u81ea\u75c7\u72c0\u767c\u751f\u5df2\u7d93120\u5206\u9418\uff0c\u61c9\u9032\u884c\u4e0b\u5217\u4f55\u8655\u7f6e\u8f03\u9069\u5b9c?\nA. \u7acb\u5373\u7d66\u4e88aspirin 300\u6beb\u514b\nB. \u7acb\u5373\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\uff0c\u65bd\u625360\u5206\u9418\uff0c\u5bc6\u5207\u89c0\u5bdf\u662f\u5426\u6709\u9032\u6b65\nC. \u61f7\u7591\u4e2d\u5927\u8166\u52d5\u8108\u7ba1\u963b\u585e\uff0c\u5b89\u6392\u65b7\u5c64\u6383\u63cf\u8840\u7ba1\u651d\u5f71\u6aa2\u67e5\nD. \u61f7\u7591\u4e2d\u5927\u8166\u52d5\u8108\u7ba1\u963b\u585e\uff0c\u7acb\u5373\u5165\u5c0e\u7ba1\u5ba4\uff0c\u76f4\u63a5\u505a\u8840\u7ba1\u651d\u5f71\nE. \u7acb\u5373\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\uff0c\u4e26\u540c\u6642\u5b89\u6392\u65b7\u5c64\u6383\u63cf\u8840\u7ba1\u651d\u5f71\u6aa2\u67e5\n": "(E)", "107-3.\n\u95dc\u65bc\u8f15\u5ea6\u667a\u80fd\u969c\u7919\uff08mild cognitive impairment, MCI\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e?\nA. \u6bcf\u5e74\u670910-15%\u6703\u9000\u5316\u70ba\u5931\u667a\nB. \u8207apolipoprotein E\uff08APOE epsilon 4\uff09\u57fa\u56e0\u578b\u76f8\u95dc\nC. \u660e\u986f\u81ea\u89ba\u6216\u5bb6\u4eba\u767c\u89ba\u5bb9\u6613\u5065\u5fd8\nD. \u793e\u4ea4\u529f\u80fd\u5df2\u660e\u986f\u53d7\u5f71\u97ff\nE. \u8840\u7ba1\u6027\u7684MCI\u5e38\u5408\u4f75\u52d5\u4f5c\u8b8a\u9072\u7de9\n": "(D)", "107-4.\n\u95dc\u65bc\u6025\u6027\u7f3a\u8840\u4e2d\u98a8\u6642\u7684\u8840\u58d3\u8abf\u63a7\uff0c\u4e0b\u5217\u4f55\u7a2e\u8655\u7f6e\u8f03\u4e0d\u5efa\u8b70\u81e8\u5e8a\u5e38\u898f\u57f7\u884c?\nA. \u975c\u8108\u8840\u6813\u6eb6\u89e3\u524d\uff0c\u8840\u58d3\u8981\u5148\u63a7\u5236\u5728185/110 mmHg\u4ee5\u4e0b\nB. \u975c\u8108\u8840\u6813\u6eb6\u89e3\u5f8c\uff0c\u8840\u58d3\u8981\u5148\u63a7\u5236\u5728180/105 mmHg\u4ee5\u4e0b\nC. \u52d5\u8108\u8840\u6813\u79fb\u9664\u8853\u5f8c\uff0c\u6536\u7e2e\u58d3\u90fd\u61c9\u63a7\u5236\u5728130 mmHg\u4ee5\u4e0b\nD. \u672a\u9032\u884c\u8840\u6813\u6eb6\u89e3\u6216\u8840\u6813\u79fb\u9664\u8853\uff0c\u8840\u58d3\u672a\u8d85\u904e220/120 mmHg\uff0c\u4e0d\u9808\u7acb\u5373\u964d\u8840\u58d3\nE. \u7576\u795e\u7d93\u75c7\u72c0\u7a69\u5b9a\u6642\uff0c\u8840\u58d3\u53ef\u6f38\u63a7\u5236\u5728140/90 mmHg\u4ee5\u4e0b\n": "(C)", "107-5.\n60\u6b72\u5973\u6027\uff0c\u4e3b\u8a34\u5728\u665a\u4e0a\u770b\u96fb\u8996\u6216\u8eba\u5728\u5e8a\u4e0a\u8981\u5165\u7761\u524d\u5e38\u6703\u611f\u5230\u5169\u817f\u5f88\u4e0d\u8212\u670d\uff0c\u8981\u8d77\u4f86\u52d5\u52d5\u817f\u624d\u6703\u7de9\u89e3\uff0c\u8acb\u554f\u9019\u500b\u75be\u75c5\u53ef\u4f7f\u7528\u7684\u6cbb\u7642\u85e5\u7269\uff0c\u4f55\u8005\u9664\u5916?\nA. \u591a\u5df4\u80fa\u63a5\u53d7\u9ad4\u4fc3\u6548\u5291\uff08\u5982ropinirole\uff09\nB. \u6297\u7672\u7647\u85e5\u7269\uff08\u5982gabapentin\uff09\nC. \u591a\u5df4\u80fa\u4fc3\u9032\u85e5\u7269\uff08\u5982levodopa\uff09\nD. \u6297\u6182\u9b31\u5291\uff08\u5982fluxetine\uff09\nE. \u9435\u5291\u88dc\u5145\n": "(D)", "107-6.\n\u4e0b\u5217\u4f55\u8005\u975e\u7dad\u4ed6\u547dB12\u7f3a\u4e4f\u5c0e\u81f4\u7684\u795e\u7d93\u529f\u80fd\u7570\u5e38\u7684\u5178\u578b\u75c7\u72c0\u8207\u5fb5\u5019?\nA. \u8a18\u61b6\u9000\u5316\nB. \u6b65\u5c65\u4e0d\u7a69\nC. \u80a2\u9ad4\u91dd\u523a\u611f\u4e0b\u964d\nD. \u808c\u8171\u53cd\u5c04\u4e0b\u964d\nE. \u80a2\u9ad4\u9707\u52d5\u611f\u4e0b\u964d\n": "(C)", "107-7.\n55\u6b72\u5973\u6027\uff0c\u7d042-3\u9031\u524d\u6709\u8179\u7009\uff0c\u8fd15\u65e5\u6709\u6f38\u9032\u56db\u80a2\u7121\u529b\u3001\u9ebb\u6728\uff0c\u4e26\u4f34\u96a8\u8d70\u52d5\u6703\u5598\uff0c\u88ab\u9001\u81f3\u6025\u8a3a\u8655\u3002\u8840\u58d3140/90 mmHg\u3001\u547c\u5438\u6bcf\u5206\u941816\u6b21\u3001\u5fc3\u8df3\u6bcf\u5206\u941890\u6b21\uff0c\u795e\u7d93\u5b78\u6aa2\u67e5\u986f\u793a\u4e0a\u80a2\u808c\u529b3-4\u3001\u4e0b\u80a2\u808c\u529b4\u5206\u3001\u56db\u80a2\u7121\u808c\u8171\u53cd\u5c04\uff0c\u521d\u6b65\u8a3a\u65b7\u7591\u70ba\u6025\u6027\u795e\u7d93\u708e\u3002\u5f8c\u7e8c\u61c9\u5b89\u6392\u90a3\u4e9b\u8655\u7f6e\u8f03\u9069\u5b9c\uff1a(1). \u8170\u690e\u7a7f\u523a\u6aa2\u67e5 (2). \u8003\u616e\u9ad8\u5291\u91cf\u985e\u56fa\u9187\u6cbb\u7642 (3). \u8a55\u4f30\u5176\u541e\u56a5\u529f\u80fd\u53ca\u547c\u5438\u72c0\u6cc1 (4). \u62bd\u8840\u6aa2\u9a57\u4e4b\u524d\u7684\u611f\u67d3\u662f\u5426\u70ba\u5e38\u898b\u7684\u524d\u9a45\u611f\u67d3\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(A)", "108-1.\n12\u6b72\u7537\u7ae5\uff0c\u88ab\u8001\u5e2b\u767c\u73fe\u4e0a\u8ab2\u6703\u767c\u5446\uff0c\u8ab2\u696d\u8868\u73fe\u9000\u6b65\uff0c\u81f3\u91ab\u9662\u6aa2\u67e5\u8166\u96fb\u5716\u986f\u793a\u6709\u5927\u8166\u96d9\u5074\u5c0d\u7a313 Hz\u7684\u68d8\u6162\u8907\u5408\u6ce2\uff08spike-and-slow-wave discharges\uff09\uff0c\u95dc\u65bc\u6b64\u75be\u75c5\u7684\u767c\u4f5c\u6642\u8868\u73fe\u4e0b\u5217\u4f55\u8005\u70ba\u975e?\nA. \u5e38\u6703\u7728\u773c\nB. \u6709\u5480\u56bc\u52d5\u4f5c\nC. \u591a\u7121\u5026\u6020\u8868\u73fe\nD. \u96d9\u817f\u7121\u529b\u3001\u8dcc\u5750\nE. \u904e\u5ea6\u63db\u6c23\u6703\u8a98\u767c\n": "(D)", "108-2.\n75\u6b72\u5973\u6027\uff0c\u6709\u9ad8\u8840\u58d3\u3001\u5fc3\u623f\u986b\u52d5\u75c5\u53f2\uff0c\u5e73\u6642\u898f\u5247\u670d\u7528dabigatran(110)\uff0c\u7a81\u767c\u53f3\u5074\u7121\u529b\u8207\u8aaa\u8a71\u4e0d\u6e05\u695a\uff0c\u96a8\u5373\u88ab\u9001\u81f3\u67d0\u4e00\u793e\u5340\u91ab\u9662\u6025\u8a3a\uff0c\u7f8e\u570b\u570b\u5bb6\u885b\u751f\u9662\u8166\u4e2d\u98a8\u91cf\u8868\u7684\u5206\u6578\u70ba7\u5206\uff0c\u8166\u90e8\u65b7\u5c64\u6383\u63cf\u986f\u793a\u7121\u8166\u5167\u51fa\u8840\uff0c\u81ea\u75c7\u72c0\u767c\u751f\u5df2\u7d93120\u5206\u9418\uff0c\u61c9\u9032\u884c\u4e0b\u5217\u4f55\u8655\u7f6e\u6700\u9069\u5b9c?\nA. \u7acb\u5373\u7d66\u4e88\u65b0\u9bae\u51b7\u51cd\u8840\u6f3f\uff08Fresh frozen plasma, FFP\uff09\uff0c\u63a5\u7e8c\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\nB. \u7acb\u5373\u7d66\u4e88\u51dd\u8840?\u539f\u8907\u5408\u7269\u6fc3\u7e2e\u7269\uff08Prothrombin Complex Concentrate, PCC\uff09\uff0c\u63a5\u7e8c\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\nC. \u7acb\u5373\u7d66\u4e88dabigatran\u53cd\u8f49\u5291idarucizumab\uff0c\u63a5\u7e8c\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\nD. \u7acb\u5373\u8f49\u9662\u81f3\u53ef\u4ee5\u9032\u884c\u8840\u6813\u79fb\u9664\u7684\u91ab\u9662\nE. \u5148\u5b89\u6392\u65b7\u5c64\u6383\u63cf\u8840\u7ba1\u651d\u5f71\u6aa2\u67e5\uff0c\u518d\u8f49\u9662\u81f3\u53ef\u4ee5\u9032\u884c\u8840\u6813\u79fb\u9664\u7684\u91ab\u9662\n": "(C)", "108-3.\n\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u6613\u6709\u81ea\u4e3b\u5468\u908a\u795e\u7d93\uff08autonomic neuropathy\uff09\u75c7\u72c0\u8868\u73fe?\nA. \u925b\u4e2d\u6bd2\u795e\u7d93\u75c5\u8b8a\uff08lead neuropathy\uff09\nB. \u7cd6\u5c3f\u75c5\u795e\u7d93\u75c5\u8b8a\uff08diabetic neuropathy\uff09\nC. \u6fb1\u7c89\u6a23\u795e\u7d93\u75c5\u8b8a\uff08amyloid neuropathy\uff09\nD. \u6025\u6027\u9593\u6b47\u6027\u7d2b\u8cea\u75c7\uff08acute intermittent porphyria\uff09\nE. \u8089\u6bd2\u687f\u83cc\u4e2d\u6bd2\uff08botulism\uff09\n": "(A)", "108-4.\n22\u6b72\u5973\u6027\uff0c\u8fd13\u500b\u6708\u6709\u6f38\u9032\u7684\u6613\u6012\u3001\u7cbe\u795e\u4e0d\u96c6\u4e2d\u3001\u8a18\u61b6\u529b\u4e0b\u964d\u3001\u7761\u7720\u969c\u7919\uff0c\u751a\u81f3\u6709\u5984\u60f3\u75c7\u72c0\uff0c\u81f3\u7cbe\u795e\u79d1\u5c31\u8a3a\uff0c\u7a81\u767c\u7672\u7647\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u521d\u6b65\u8a3a\u65b7\u70ba\u975e\u611f\u67d3\u6027\u8166\u708e\uff0c\u61c9\u512a\u5148\u8003\u616e\u5b89\u6392\u54ea\u4e9b\u6aa2\u67e5\uff1a(1)\u5fc3\u81df\u8d85\u97f3\u6ce2 (2)\u8179\u90e8\u9aa8\u76c6\u8154\u65b7\u5c64\u6383\u63cf (3)\u51dd\u8840\u76f8\u95dc\u8840\u6db2\u6aa2\u67e5 (4) \u514d\u75ab\u76f8\u95dc\u8840\u6db2\u6aa2\u67e5\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(4)\nD. (2)+(3)\nE. (1)+(2)+(3)+(4)\n": "(B)", "108-5.\n\u4e0b\u5217\u54ea\u4e00\u90e8\u4f4d\u7684\u8166\u6897\u585e\u8f03\u4e0d\u5e38\u662f\u5fc3\u56e0\u6027\u8166\u6897\u585e\u767c\u751f\u4f4d\u7f6e?\nA. \u6795\u8449\uff08occipital lobe\uff09\nB. \u5c0f\u8166\u5916\u5074\uff08lateral cerebellum\uff09\nC. \u96d9\u6e2c\u8996\u4e18\uff08bilateral thalamus\uff09\nD. \u9802\u8449\u76ae\u8cea\u90e8\uff08parietal lobe cortex\uff09\nE. \u6a4b\u8166\u8fd1\u4e2d\u5074\uff08medial pons\uff09\n": "(E)", "108-6.\n50\u6b72\u7537\u6027\uff0c\u8fd1\u4e00\u500b\u6708\u5e7e\u4e4e\u6bcf\u65e5\u982d\u75db\uff0c\u75db\u5728\u9873\u8449\u3001\u773c\u5f8c\u90e8\u4f4d\uff0c\u6bcf\u6b21\u982d\u7684\u6642\u9593\u7d041-2\u5c0f\u6642\uff0c\u75db\u6642\u5019\u5408\u4f75\u6709\u9f3b\u585e\u3001\u6d41\u773c\u6dda\u75c7\u72c0\uff0c2\u5e74\u524d\u6709\u985e\u4f3c\u75c7\u72c0\u6301\u7e8c1-2\u500b\u6708\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u500b\u85e5\u7269\u4e0d\u6703\u9078\u64c7\u70ba\u9810\u9632\u982d\u75db\u767c\u4f5c\u85e5\u7269?\nA. Verapamil\nB. Gabapentin\nC. Indomethacin\nD. Topiramate\nE. Lithium\n": "(C)", "108-7.\n\u95dc\u65bc\u9ad8\u6c99\u53ef\u592b\u75c7\u5019\u7fa4\uff08Korsakoff's syndrome\uff09\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\nA. \u8207\u57fa\u5e95\u6838(basal ganglia)\u53d7\u5f71\u97ff\u76f8\u95dc\nB. \u6700\u4e3b\u8981\u75c7\u72c0\u70ba\u56b4\u91cd\u8a18\u61b6\u7f3a\u640d\nC. \u4e4b\u524d\u4e0d\u6703\u51fa\u73fe\u6709\u97cb\u5c3c\u514b\u6c0f\u8166\u75c5\u8b8a(Wernicke encephalopathy)\u75c7\u72c0\nD. \u7d93\u7dad\u4ed6\u547dB1\u6cbb\u7642\uff0c\u5927\u591a\u6578\u53ef\u4ee5\u660e\u986f\u6062\u5fa9\nE. MRI\u53ef\u898b\u9593\u8166(Diencephalon)\u840e\u7e2e\n": "(D)", "109-180.75\u6b72\u5973\u6027 \uff0c\u904e\u53bb\u6709\u9ad8\u8840\u58d3 \u3001\u7cd6\u5c3f\u75c5\uff0c\u7a81\u767c\u8b1b\u8a71\u8a5e\u4e0d\u9054\u610f \uff0c\u9001\u81f3\u6025\u8a3a\u5f8c\u8166\u90e8\u78c1\u632f\u7167\u5f71\u986f\u793a\u5de6\u5074\u9802\u8449\u90e8\u6025\u6027\u6897\n\u585e\uff0c\u5247\u6703\u51fa\u73fe\u4e0b\u5217\u75c7\u72c0\u4f55\u8005\u9664\u5916 \uff1f   \nA.\u5de6\u53f3\u6df7\u6dc6\uff08right left disorientation\uff09\nB.\u624b\u6307\u8fa8\u8b58\u56f0\u96e3\uff08finger agnosia\uff09\nC.\u4e0d\u6703\u7a7f\u8863\uff08dressing apraxia\uff09\nD.\u8a08\u7b97\u56f0\u96e3\uff08acalculia\uff09   \nE.\u66f8\u5beb\u56f0\u96e3\uff08agraphia\uff09\n": "[C]", "109-181.65\u6b72\u7537\u6027 \uff0c2\u5e74\u524d\u958b\u59cb\u6709\u7126\u616e \u3001\u60c5\u7dd2\u4f4e\u843d \u3001\u7761\u7720\u5dee\u75c7\u72c0 \uff0c\u6f38\u6f38\u767c\u751f\u6b65\u614b\u4e0d\u7a69\u50f5\u786c \u3001\u8a18\u61b6\u8870\u9000 \uff0c\u5076\u6709\u8996\u5e7b\u89ba\n\u8207\u5984\u60f3\u75c7\u72c0 \uff0c\u6700\u53ef\u80fd\u662f\u4e0b\u5217\u4f55\u8a3a\u65b7 \uff1f   \nA.\u76ae\u8cea\u57fa\u5e95\u6838\u9000\u5316\uff08corticobasal ganglion degeneration\uff09\nB.\u591a\u7cfb\u7d71\u840e\u7e2e\uff08multiple system atrophy\uff09\nC.\u6f38\u9032\u6027\u4e0a\u6838\u9ebb\u75fa\uff08progressive supranuclear palsy\uff09\nD.\u8def\u6613\u9ad4\u5931\u667a\u75c7\uff08dementia with Lewy body\uff09\nE.\u984d\u9873\u8449\u5931\u667a\u75c7\uff08frontotemporal dementia\uff09\n": "[D]", "109-182.52\u6b72\u5973\u6027 \uff0c\u539f\u5373\u6709\u63a7\u5236\u4e0d\u5f88\u597d\u7684\u9ad8\u8840\u58d3 \uff0c\u67d0\u65e5\u8207\u4ed6\u4eba\u6fc0\u70c8\u722d\u5435\u5f8c \uff0c\u7a81\u767c\u5287\u70c8\u982d\u75db \uff0c\u5408\u4f75\u610f\u8b58\u6709\u4e9b\u6df7\u6c8c \uff0c\u7dca\n\u6025\u9001\u91ab\u5f8c\u78c1\u632f\u7167\u5f71\u986f\u793a\u8166\u90e8\u7684\u5169\u5074\u6795\u8449\u6709\u816b\u8139 \uff0c\u4f46\u7121\u6897\u585e\u6216\u51fa\u8840 \u3002\u95dc\u65bc\u6b64\u75be\u75c5 \uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u8f03\u6b63\u78ba \uff1f   \nA.\u61c9\u512a\u5148\u8003\u616e\u8166\u8840\u7ba1\u708e\uff08cerebral vasculitis\uff09\nB.\u61c9\u8003\u616e\u5c0e\u7ba1\u662f\u8840\u7ba1\u651d\u5f71\uff08catheter angiography\uff09\nC.\u61c9\u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642\nD.\u61c9\u7d66\u4e88\u975c\u8108\u9223\u96e2\u5b50\u963b\u65b7\u5291\nE.\u61c9\u7d66\u4e88\u6297\u7672\u7647\u85e5\u7269\n": "[D]", "109-183.50\u6b72\u7537\u6027 \uff0c\u6709\u9152\u766e\u8207\u66fe\u6709\u9152\u7cbe\u6212\u65b7\u75c7\u72c0 \uff0c\u56e0\u6025\u6027\u795e\u7d93\u75c7\u72c0 \uff0c\u5305\u62ec\u8907\u8996 \uff08diplopia\uff09\u3001 \u6b65\u5c65\u4e0d\n\u7a69\uff08ataxia\uff09\u3001 \u8a18\u61b6\u55aa\u5931 \uff08memory loss\uff09\u3001 \u6de1\u6f20 \uff08apathy\uff09\u3001 \u6df7\u6c8c \uff08confusion \uff09\u7b49\u5165\u9662\u6cbb\u7642 \uff0c\u521d\u6b65\u8a3a\u65b7\n\u70ba\u7dad\u751f\u7d20 B1\u7f3a\u4e4f\uff0c\u7d66\u4e88thiamine\u6cbb\u7642 \uff0c\u4e0b\u5217\u90a3\u4e00\u500b\u75c7\u72c0\u6062\u5fa9\u8f03\u5feb \uff1f   \nA.\u8907\u8996\nB.\u6b65\u5c65\u4e0d\u7a69\nC.\u8a18\u61b6\u55aa\u5931\nD.\u6de1\u6f20\nE.\u6df7\u6c8c\n": "[A]", "109-184.40\u6b72\u5973\u6027\u6709\u814e\u529f\u80fd\u4e0d\u5168\u53ca\u591a\u7a2e\u75be\u75c5 \uff0c\u6f38\u9032\u767c\u751f\u80a2\u9ad4\u8fd1\u7aef\u7121\u529b \uff0c\u4f46\u6c92\u6709\u75bc\u75db\u8207\u76ae\u819a\u8b8a\u8272 \uff0c\u521d\u6b65\u8a3a\u65b7\u70ba\u808c\u8089\u75c5\n\u8b8a\uff0c\u61f7\u7591\u8207\u4f7f\u7528\u7684\u85e5\u7269\u76f8\u95dc \uff0c\u4e0b\u5217\u54ea\u4e00\u500b\u85e5\u7269\u9808\u512a\u5148\u8003\u616e \uff1f   \nA.Carvedilol\nB.Metformin\nC.Colchicine\nD.Furosemide\nE.Propafenone\n": "[C]", "109-185.25\u6b72\u7537\u6027 \uff0c\u8fd1\u5e7e\u5e74\u6bcf\u5e74\u5728\u51ac\u5b63\u6703\u6709\u53e2\u805a\u982d\u75db (cluster headache )\uff0c\u6bcf\u5929\u982d\u75db 1-2\u5c0f\u6642\uff0c\u9023\u7e8c5-6\u9031\uff0c\u5728\u6025\u6027\n\u5287\u70c8\u982d\u75db\u767c\u751f\u6642 \u3002\u90a3\u4e9b\u6cbb\u7642\u8f03\u80fd\u7de9\u89e3\u982d\u75db \uff1a(1) 100%\u6c27\u6c23\uff0c\u6bcf\u5206\u941810 -12\u5347\uff0c15-20\u5206\u9418\uff1b(2) \nSumatriptan\u53e3\u670d50 -100\u6beb\u514b (3) Verapamil\u53e3\u670d\u6bcf\u65e5160 -960\u6beb\u514b\uff1b(4) Indomethacin\u53e3\u670d25 -75\u6beb\u514b\uff0c\u6bcf\n\u65e53\u6b21\u3002   \nA.(1)+(3)\nB.(2)+(4)\nC.(1)+(4)\nD.(2)+(3)\nE.(1)+(2)+(3)+(4)   \n": "[A]", "109-186.\u95dc\u65bc\u5fc3\u623f\u986b\u52d5 \uff08atrial fibrillation \uff0cAF\uff09\uff0c \u4e0b\u5217\u4f55\u7a2e\u60c5\u5883\u8655\u7f6e\u8f03\u70ba\u6b63\u78ba \uff1a\n(1) 57\u6b72\u7537\u6027 \uff0c\u4e4b\u524d\u7121\u91cd\u5927\u75be\u75c5 \uff0c\u8fd13\u65e5\u6709\u5fc3\u8df3\u904e\u5feb\u4e14\u4e0d\u898f\u5247 \uff0c\u81f3\u6025\u8a3a\u6642\u986f\u793aAF \uff0c\u5fc3\u640f130\u6b21/\u5206\uff0c\u5148\u7d66\u53e3\n\u670d\u6297\u51dd\u5291 \uff0c\u66ab\u6642\u4e0d\u6574\u8108 \uff08cardioversion \uff09\n(2) 70\u6b72\u7537\u6027 \uff0c\u7a81\u767c\u6025\u6027\u8166\u6897\u585e \uff0c\u795e\u7d93\u75c7\u72c0\u8f15\u5fae \uff0c\u4e2d\u98a8\u5f8c\u767c\u73fe\u6709AF \uff0c\u5728\u4e2d\u98a8\u5f8c\u7b2c 3\u65e5\u958b\u59cb\u4f7f\u7528\u76f4\u63a5\u53e3\u670d\u6297\n\u51dd\u8840\u5291\uff08direct oral anticoagulant \uff0cDOAC\uff09\n(3) 80\u6b72\u5973\u6027 \uff0c\u5df2\u77e5\u6709AF\u4e26\u670d\u7528DOAC \uff0c\u56e0\u62d4\u7259\u505c\u7528\u4e86 2\u65e5\uff0c\u7a81\u767c\u77ed\u66ab\u8166\u7f3a\u8840 \uff0c\u7acb\u5373\u52a0\u56deDOAC\n(4) 85\u6b72\u5973\u6027 \uff0c\u5df2\u77e5\u6709AF\u4e26\u670d\u7528warfarin \uff0c\u7a81\u767c\u6025\u6027\u8166\u6897\u585e \uff0cNIHSS\u70ba8\u5206\uff0c\u8ddd\u4e2d\u98a8\u767c\u4f5c 2.5\u5c0f\n\u6642\uff0cINR=1.4\uff0c\u7acb\u5373\u7d66\u4e88\u975c\u8108\u8840\u6813\u6eb6\u89e3\u5291\u6cbb\u7642   \nA.(1)+(3)\nB.(2)+(4)\nC.(1)+(4)\nD.(2)+(3)\nE.(1)+(2)+(3)+(4)\n": "[E]", "110-145.\u95dc\u65bc\u808c\u7121\u529b \uff08myasthenia gravis \uff09\u8207\u5176\u5b83\u7684\u795e\u7d93\u808c\u8089\u4ea4\u754c\u75be\u75c5 \uff08neuromuscular junction disorder\uff09\uff0c \u4e0b\n\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba \uff1a   \nA.\u808c\u7121\u529b\u572850\u6b72\u4e4b\u524d\u767c\u75c5\u5973\u6027\u8f03\u591a\uff0c50\u6b72\u4e4b\u5f8c\u5247\u7537\u5973\u6027\u5dee\u4e0d\u591a\u3002\nB.\u8089\u6bd2\u687f\u83cc\u4e2d\u6bd2\uff08botulism\uff09\u70ba\u7a81\u89f8\u524d\u75c5\u8b8a\u3002\nC.\u808c\u7121\u529b\u5371\u6a5f\uff08myasthenic crisis\uff09\u6642\u4f7f\u7528\u8840\u6f3f\u7f6e\u63db\u8853\u6216\u514d\u75ab\u7403\u86cb\u767d\u6cbb\u7642\u6548\u679c\u76f8\u8fd1\u3002\nD.MuSK\u578b\u7684\u808c\u7121\u529b\u4e00\u822c\u75c7\u72c0\u8f03\u8f15\uff0c\u9032\u5c55\u8f03\u7de9\u3002\nE.Lambert-Eaton\u808c\u7121\u529b\u75c7\u5019\u7fa4\u591a\u8207\u5c0f\u7d30\u80de\u80ba\u764c\u76f8\u95dc\u3002\n": "[D]", "110-146.70\u6b72\u7537\u6027 \uff0c\u56e0\u80f8\u8179\u4e3b\u52d5\u8108\u7624 \uff08thoracic-abdominal aortic aneurysm \uff09\u63a5\u53d7\u624b\u8853 \uff0c\u8853\u5f8c\u7a81\u767c\u96d9\u4e0b\u80a2\u7121\u529b \uff0c\u7406\n\u5b78\u8207\u795e\u7d93\u5b78\u6aa2\u67e5\u8f03\u4e0d\u53ef\u80fd\u51fa\u73fe\u4e0b\u5217\u4f55\u8005 ?   \nA.\u4e0b\u80a2\u75db\u611f\u4e0b\u964d\u3002\nB.\u4e0b\u80a2\u6eab\u5ea6\u611f\u4e0b\u964d\u3002\nC.\u4e0b\u80a2\u9707\u52d5\u611f\u4e0b\u964d\u3002\nD.\u4f4e\u8840\u58d3\u3002\nE.\u5c3f\u5931\u7981\u3002\n": "[C]", "110-147.50\u6b72\u5973\u6027 \uff0c\u56e0\u8166\u52d5\u8108\u7624\u7834\u88c2\u81f4\u8718\u86db\u819c\u4e0b\u8154\u51fa\u8840\u5165\u9662 \uff0c\u63a5\u53d7\u593e\u52d5\u8108\u7624\u624b\u8853 \uff0c\u8853\u5f8c\u7b2c\u4e09\u65e5\u767c\u73fe\u8840\u9209\u504f\u4f4e \uff08124 \nmmol/L\uff09\uff0c \u795e\u7d93\u5b78\u5c1a\u7a69\u5b9a \uff0c\u6aa2\u67e5\u7d50\u679c\u8207\u6cbb\u7642 \uff0c\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba ?   \nA.24\u5c0f\u6642\u5c3f\u4e2d\u7684\u9209\u542b\u91cf\u589e\u52a0\u3002\nB.\u5c3f\u6db2\u6ef2\u900f\u58d3\uff08urine osmolarity\uff09\u589e\u52a0\u3002\nC.\u9ad4\u5167\u5448\u73fe\u4f4e\u5bb9\u7a4d\uff08hypovolemic\uff09\u3002\nD.\u7d66\u4e88\u7b49\u5f35\u6c2f\u5316\u9209\u6eb6\u6db2\u6ef4\u6ce8\u3002\nE.\u7d66\u4e88\u7518\u9732\u9187\uff08Mannitol\uff09\u6ef4\u6ce8\u3002\n": "[E]", "110-148.75\u6b72\u5973\u6027 \uff0c\u56e0\u6557\u8840\u6027\u4f11\u514b\u5165\u4f4f\u52a0\u8b77\u75c5\u623f \uff0c\u7d93\u6cbb\u7642\u5f8c\u610f\u8b58\u6062\u5fa9 \uff0c\u4f46\u4ecd\u70ba\u547c\u5438\u5668\u4f9d\u8cf4 \uff0c\u5169\u9031\u5f8c\u767c\u73fe\u56db\u80a2\u808c\u529b\u660e\n\u986f\u4e0b\u964d\u5408\u4f75\u808c\u8089\u840e\u7e2e \uff0c\u5247\u6b64\u75c5\u4eba\u7684\u6aa2\u67e5\u8207\u6cbb\u7642 \uff0c\u4e0b\u5217\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba ?   \nA.\u56db\u80a2\u808c\u8171\u53cd\u5c04\u4e0b\u964d\u3002\nB.\u795e\u7d93\u50b3\u5c0e\u6aa2\u67e5\u986f\u793a\u50b3\u5c0e\u901f\u5ea6\u660e\u986f\u964d\u4f4e\u3002\nC.\u795e\u7d93\u50b3\u5c0e\u6aa2\u67e5\u986f\u793a\u52d5\u4f5c\u96fb\u4f4d\uff08action potential\uff09\u660e\u986f\u4e0b\u964d\u3002   \nD.\u985e\u56fa\u9187\u6cbb\u7642\u5e6b\u52a9\u4e0d\u5927\u3002\nE.\u808c\u529b\u6062\u5fa9\u81f3\u5c11\u97003\u81f36\u500b\u6708\u6642\u9593\u3002\n": "[B]", "110-149.\u95dc\u65bc\u8166\u975c\u8108\u6813\u585e \uff08cerebral venous thrombosis \uff0cCVT\uff09\uff0c \u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u6b63\u78ba \uff1a\n(1) CVT\u53ea\u4ee5\u55ae\u4e00\u76ae\u8cea\u975c\u8108 \uff08cortical vein \uff09\u6813\u585e\u8868\u73fe\u8f03\u70ba\u5c11\u898b\n(2) \u4ee5\u5931\u8a9e\u8868\u73fe\u4e3b\u8981\u70baTrolard\u76ae\u8cea\u975c\u8108\u6813\u585e\n(3) COVID-19\u611f\u67d3\u4f75\u767cCVT \uff0c\u53ef\u80fd\u8207\u8a98\u767c\u6297\u8840\u5c0f\u677f\u56e0\u5b50 -4\uff08anti-platelet factor 4\uff09\u6297\u9ad4\u76f8\u95dc\n(4) \u8fc4\u4eca\u7814\u7a76 \uff0c\u975e\u7dad\u4ed6\u547d K\u53e3\u670d\u6297\u51dd\u5291\u4e26\u672a\u512a\u65bc\u7dad\u4ed6\u547d K\u53e3\u670d\u6297\u51dd\u5291\u5c0d\u65bcCVT\u518d\u767c\u751f\u7684\u9810\u9632   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[C]", "110-150.\u95dc\u65bc\u5f8c\u8166\u53ef\u9006\u6027\u8166\u75c5\u8b8a\u75c7\u5019\u7fa4 \uff08posterior reversible encephalopathy syndrome \uff0cPRES\uff09\uff0c \u4e0b\u5217\u6558\u8ff0\u4f55\n\u8005\u8f03\u6b63\u78ba \uff1a\n(1) \u8166\u90e8\u78c1\u632f\u9020\u5f71\u986f\u793aFLAIR\u5f71\u50cf\u6709\u9ad8\u5f37\u5ea6\u986f\u5f71 \uff0c\u8868\u793a\u8840\u7ba1\u6e90\u6027\u8166\u6c34\u816b \uff08vasogenic edema \uff09\u5b58\u5728\n(2) \u61c9\u8003\u616e\u7d66\u4e88\u975c\u8108\u8f38\u6ce8nicardipine \u3001labetalol\u3001hydralazine \u7b49\n(3) \u82e5\u8d77\u521d\u6536\u7e2e\u58d3\u70ba200 mmHg \uff0c\u61c9\u5feb\u901f\u65bc 1\u5c0f\u6642\u5167\u5c07\u6536\u7e2e\u58d3\u964d\u81f3140 mmHg\u4ee5\u4e0b\n(4) \u82e5\u70ba\u5b50\u7672\u75c7 \uff08eclampsia\uff09\uff0c \u61c9\u512a\u5148\u4f7f\u7528\u975c\u8108\u8f38\u6ce8magnesium sulphate   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[C]", "111-145.62\u6b72\u5973\u6027 \uff0c\u7121\u9ad8\u8840\u58d3 \u3001\u7cd6\u5c3f\u75c5\u53f2 \uff0c\u767c\u751f\u5de6\u5074\u984d\u8449\u90e8\u51fa\u8840\u81f4\u5931\u8a9e \uff0c4\u500b\u6708\u5f8c\u518d\u767c\u751f\u53f3\u5074\u9802\u8449\u90e8\u51fa\u8840 \uff0c\u95dc\u65bc\u6b64\n\u75be\u75c5\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u6b63\u78ba \uff1a   \nA.\u5177\u6709apolipoprotein E \u025b2 \u6216\u025b3\u8f03\u6613\u767c\u751f\u6b64\u75be\u75c5\u3002\nB.\u8166\u5e79\u4e5f\u662f\u597d\u767c\u751f\u51fa\u8840\u8655\u3002\nC.\u7537\u6027\u8f03\u5973\u6027\u5e38\u898b\u3002\nD.50-70\u6b72\u662f\u4e3b\u8981\u767c\u75c5\u5e74\u9f61\u5c64\u3002\nE.\u591a\u5408\u4f75\u76ae\u8cea\u90e8\u7684\u5fae\u5c0f\u51fa\u8840\u3002\n": "[E]", "111-146.\u6bd4\u8f03\u808c\u7121\u529b \uff08myasthenia gravis, MG \uff09\u8207\u85cd\u4f2f\uff0d\u4f0a\u9813\u808c\u7121\u529b\u75c7\u5019\u7fa4 \uff08Lambert-Eaton myasthenic \nsyndrome, LEMS\uff09\uff0c \u4e0b\u5217\u7684\u81e8\u5e8a\u8868\u73fe\u4f55\u8005\u8f03\u4e0d\u5e38\u767c\u751f\u65bcLEMS ?   \nA.\u8ec0\u5e79\u53ca\u8fd1\u7aef\u808c\u8089\u7684\u7121\u529b\u3002\nB.\u81ea\u5f8b\u795e\u7d93\u5931\u8abf\u7684\u75c7\u72c0\uff0c\u5982\u53e3\u4e7e\u3001\u4fbf\u79d8\u3001\u5c0f\u4fbf\u56f0\u96e3\u53ca\u6027\u7121\u80fd\u3002\nC.\u5408\u4f75\u5c0f\u7d30\u80de\u80ba\u764c\u767c\u751f\u3002\nD.\u96fb\u5b78\u6aa2\u67e5\u4ee5\u9ad8\u983b\u523a\u6fc0\uff08\u6bcf\u79d220-50\u6b21\uff09\uff0c\u904b\u52d5\u96fb\u4f4d\u7684\u632f\u5e45\u660e\u986f\u6e1b\u5c11\u3002\nE.P/Q\u578b\u614b\u7684\u9223\u96e2\u5b50\u901a\u9053\u6297\u9ad4\u3002\n": "[D]", "111-147.\u95dc\u65bc\u9752\u5c11\u5e74\u808c\u9663\u6523\u6027\u7672\u7647\uff08juvenile myoclonic epilepsy\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba?       \nA.\u5e38\u4ee5\u77ed\u66ab\u3001\u96d9\u5074\u5c0d\u7a31\u3001\u540c\u6b65\u3001\u7121\u7bc0\u5f8b\u7684\u808c\u8089\u6536\u7e2e\u8868\u73fe\u3002\nB.\u5e38\u767c\u751f\u65bc\u6e05\u6668\u525b\u8d77\u5e8a\u6642\u3002\nC.\u591a\u6703\u6709\u77ed\u66ab\u610f\u8b58\u55aa\u5931\u3002\nD.\u5e38\u6709\u7672\u7647\u5bb6\u65cf\u53f2\u3002\nE.\u795e\u7d93\u7cfb\u7d71\u767c\u80b2\u5927\u591a\u6b63\u5e38\u3002\n": "[C]", "111-148.\u95dc\u65bc\u97cb\u5c3c\u514b-\u9ad8\u6c99\u53ef\u592b\u75c7\u5019\u7fa4\uff08Wernicke-Korsakoff syndrome\uff09\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u4e0d\u6b63\u78ba?    \nA.\u9ad8\u6c99\u53ef\u592b\u75c7\u5019\u7fa4\u591a\u767c\u751f\u5728\u97cb\u5c3c\u514b\u8166\u75c7\uff08Wernicke encephalopathy\uff09\u4e4b\u5f8c\u3002\nB.\u80a2\u9ad4\u5931\u8abf\uff08limb ataxia\uff09\u8f03\u8ec0\u5e79\u5931\u8abf\uff08truncal ataxia\uff09\u5e38\u898b\u3002\nC.\u773c\u808c\u9ebb\u75f9\uff08ophthalmoplegia\uff09\u5e38\u4ee5\u8907\u8996\uff08diplopia\uff09\u3001\u773c\u77bc\u4e0b\u5782\uff08ptosis\uff09\u8868\u73fe\u3002\nD.\u6b65\u614b\u4e0d\u7a69\u8207\u5408\u4f75\u591a\u767c\u6027\u795e\u7d93\u75c5\u8b8a\u3001\u5c0f\u8166\u75c5\u8b8a\u76f8\u95dc\u3002\nE.\u6cbb\u7642\u5f8c\u773c\u808c\u9ebb\u75f9\u8f03\u6b65\u614b\u4e0d\u7a69\u6062\u5fa9\u5feb\u3002\n": "[C]", "111-149.\u95dc\u65bc\u53e3\u670d\u6297\u51dd\u8840\u5291\u76f8\u95dc\u4e4b\u8166\u5167\u51fa\u8840 \uff08anticoagulant related intracerebral hemorrhage \uff09\u7684\u8655\u7f6e\uff0c\u4e0b\u5217\u6558\u8ff0\n\u4f55\u8005\u8f03\u6b63\u78ba \uff1a\n(1) \u7dad\u4ed6\u547dK\u6297\u51dd\u8840\u5291 \uff08vitamin K antagonists\uff09\uff1a \u5148\u7d66\u65b0\u9bae\u51b7\u51cd\u8840\u6f3f \uff08fresh frozen plasma, FFP\uff09\uff0c \u518d\u7d66\n\u51dd\u8840\u9176\u8907\u5408\u6fc3\u7e2e\u7269 \uff08prothrombin complex concentrate, PCC \uff09\u8207vitamin K\n(2) Dabigatran \uff1a\u7acb\u5373\u7d66\u4e88\u55ae\u682a\u6297\u9ad4idarucizumab\n(3) Factor Xa inhibitors \uff1a\u82e5\u7121andexanet alpha \uff0c\u5247\u7d66\u4e88PCC \n(4) Factor Xa inhibitors \uff1a\u82e5\u7121andexanet alpha \uff0c\u4e5f\u53ef\u8003\u616e\u814e\u81df\u66ff\u4ee3\u7642\u6cd5 \uff08renal replacement therapy \uff09   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[D]", "111-150.\u660f\u53a5\u75c5\u4eba\u9032\u884c\u81ea\u4e3b\u795e\u7d93\u529f\u80fd\u6e2c\u8a66 \uff0c\u4e0b\u5217\u4f55\u8005\u4e3b\u8981\u70ba\u526f\u4ea4\u611f\u795e\u7d93\u529f\u80fd\u6e2c\u8a66 \uff1a\n(1) \u6bcf\u5206\u94186\u6b21\u6df1\u547c\u5438\u6642\u7684\u5fc3\u5f8b\u8b8a\u7570 \uff08heart rate variation with deep breathing \uff09\n(2) \u6d41\u6c57\u6e2c\u8a66 \uff08quantitative sudomotor axon reflex test, QSART \uff09\n(3) \u9589\u6c23\u7528\u529b--\u4f10\u6c0f\u64cd\u4f5c\u6642\u6700\u5feb\u5fc3\u8df3\u6bd4\u6700\u6162\u5fc3\u8df3 \uff08Valsalva ratio \uff09\n(4) \u50be\u659c\u5e8a\u6e2c\u8a66 \uff08head-up tilt table test \uff09   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(2)+(3)\u3002\nE.(1)+(2)+(3)+(4)\u3002\n": "[A]", "100-1.\n\u95dc\u65bc\u8b6b\u5984(delirium)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6f5b\u5728\u8eab\u9ad4\u75be\u75c5\u7d93\u5e38\u662f\u9020\u6210\u8b6b\u5984\u7684\u4e3b\u8981\u539f\u56e0\nB. \u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5\u662f\u6cbb\u7642\u8b6b\u5984\u7684\u5fc5\u8981\u6b65\u9a5f\nC. \u6709\u7814\u7a76\u986f\u793a\u8b6b\u5984\u7684\u767c\u751f\u8207\u65e5\u5f8c\u500b\u6848\u7684\u6b7b\u4ea1\u98a8\u96aa\u76f8\u95dc\nD. Benzodiazepine\u4e5f\u662f\u85e5\u7269\u6cbb\u7642\u8b6b\u5984\u7684\u9078\u9805\u4e4b\u4e00\nE. \u63d0\u4f9b\u5b89\u5168\u7684\u7167\u8b77\u74b0\u5883\u4e5f\u662f\u8655\u7f6e\u8b6b\u5984\u4e0d\u53ef\u6216\u7f3a\u4e4b\u4e00\u74b0\n": "(B)", "100-2.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u7f8e\u570b\u7cbe\u795e\u91ab\u5b78\u6703\u9812\u5e03\u7cbe\u795e\u75be\u75c5\u8a3a\u65b7\u53ca\u7d71\u8a08\u624b\u518a\u4fee\u8a02\u7b2c\u56db\u7248(DSM-IV-TR)\u6240\u5b9a\u7fa9\u7684\u6050\u614c\u767c\u4f5c(panic attack)\u75c7\u72c0\uff1f\nA. \u5fc3\u60b8(palpitation)\nB. \u80f8\u60b6(chest pain)\nC. \u5641\u5fc3(nausea)\nD. \u982d\u6688(dizzy)\nE. \u53e3\u4e7e(dry mouth)\n": "(E)", "100-3.\n\u95dc\u65bc\u908a\u7de3\u6027\u4eba\u683c\u75be\u60a3(borderline personality disorder)\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u500b\u6848\u53ef\u80fd\u56e0\u70ba\u53cd\u8986\u6027\u7684\u81ea\u6bba\u884c\u70ba\u800c\u51fa\u73fe\u5728\u6025\u8a3a\nB. \u500b\u6848\u5c0d\u65bc\u4eba\u969b\u95dc\u4fc2\u5341\u5206\u654f\u611f\uff0c\u7279\u5225\u5bb3\u6015\u88ab\u5176\u6240\u4f9d\u8cf4\u7684\u4eba\u907a\u68c4\nC. \u65b0\u4e00\u4ee3\u6297\u7cbe\u795e\u75c5\u85e5\u53ef\u4ee5\u505a\u70ba\u8f14\u52a9\u6cbb\u7642\u7684\u9078\u9805\nD. \u8fa8\u8b49\u5f0f\u884c\u70ba\u6cbb\u7642(dialectical behavior therapy)\u88ab\u8b49\u5be6\u5c0d\u6b64\u985e\u75c5\u60a3\u6709\u7642\u6548\nE. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u662f\u908a\u7de3\u6027\u4eba\u683c\u75be\u60a3\u7684\u9996\u9078\u6cbb\u7642\u65b9\u5f0f\n": "(E)", "100-4.\n\u95dc\u65bc\u6162\u6027\u975e\u764c\u75c7\u75bc\u75db(chronic non-cancer pain)\u7684\u85e5\u7269\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5728\u773e\u591a\u6297\u6182\u9b31\u85e5\u7576\u4e2d\uff0c\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7684\u6587\u737b\u8b49\u64da\u6700\u70ba\u5145\u8db3\nB. \u76ee\u524d\u8b49\u64da\u986f\u793a\u300c\u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291\u300d(SSRI)\u8981\u6bd4\u300c\u9078\u64c7\u6027\u8840\u6e05\u7d20\u53ca\u65b0\u814e\u4e0a\u817a\u7d20\u518d\u5438\u6536\u6291\u5236\u5291\u300d(SNRI)\u6709\u66f4\u597d\u7684\u6b62\u75db\u6548\u679c\nC. \u6297\u7672\u7647\u85e5\u7269\u4f8b\u5982carbamazepine, gabapentine, \u4ee5\u53capregabalin\u7b49\uff0c\u4e5f\u88ab\u8b49\u5be6\u5c0d\u6162\u6027\u975e\u764c\u75c7\u75bc\u75db\u6709\u7642\u6548\nD. \u6295\u4e88\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u6642\u9808\u6ce8\u610f\u59ff\u52e2\u6027\u4f4e\u8840\u58d3\u4ee5\u53ca\u5fc3\u5f8b\u4e0d\u6574\u7b49\u526f\u4f5c\u7528\nE. \u5c40\u90e8\u5857\u62b9\u8fa3\u6912\u7d20(capsaicin)\u4e5f\u88ab\u8b49\u5be6\u5c0d\u6162\u6027\u975e\u764c\u75c7\u75bc\u75db\u6709\u7642\u6548\n": "(B)", "100-5.\n\u95dc\u65bc\u81ea\u6bba\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u66fe\u7d93\u81ea\u6bba\u672a\u9042\u7684\u500b\u6848\uff0c\u65e5\u5f8c\u4e0d\u5e78\u6b7b\u65bc\u81ea\u6bba\u7684\u98a8\u96aa\u8f03\u4e00\u822c\u4eba\u9ad8\nB. \u4e00\u822c\u800c\u8a00\u7537\u6027\u81ea\u6bba\u8eab\u4ea1\u7684\u98a8\u96aa\u6bd4\u5973\u6027\u9ad8\nC. \u4e00\u822c\u800c\u8a00\u5973\u6027\u81ea\u6bba\u672a\u9042\u7684\u98a8\u96aa\u6bd4\u7537\u6027\u9ad8\nD. \u5728\u53f0\u7063\u5e74\u9f61\u5c64\u8d8a\u9ad8\u81ea\u6bba\u98a8\u96aa\u8d8a\u9ad8\nE. 50%\u5de6\u53f3\u7684\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u60a3\u8005\u6700\u7d42\u6703\u6b7b\u65bc\u81ea\u6bba\n": "(E)", "100-6.\n\u4e0b\u5217\u4f55\u7a2e\u85e5\u7269\u4e26\u975e\u4e00\u822c\u7528\u65bc\u5354\u52a9\u75c5\u60a3\u6212\u9664\u83f8\u766e(nicotine addiction)\u7684\u85e5\u7269\uff1f\nA. Varenicline\nB. Bupropion\nC. Clonidine\nD. Nortriptyline\nE. Fluvoxamine\n": "(E)", "100-7.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1f\r1.\u6297\u6182\u9b31\u85e5\u7269\u7684\u9078\u64c7\u5e38\u4ee5\u526f\u4f5c\u7528\u4f5c\u70ba\u8003\u91cf\u7684\u4f9d\u64da\r2.\u5f9e\u85e5\u7269\u958b\u59cb\u6295\u4e88\u5230\u7642\u6548\u986f\u8457\u9700\u8981\u56db\u81f3\u516d\u9031\r3.\u5c0d\u65bc\u6bcf\u4e00\u7a2e\u6297\u6182\u9b31\u85e5\u7269\u800c\u8a00\u90fd\u5927\u7d04\u670930%\u81f340%\u7684\u60a3\u8005\u7642\u6548\u4e0d\u4f73\r4.\u75c5\u60c5\u7a69\u5b9a\u6216\u75ca\u7652(full remission)\u5f8c\u61c9\u7acb\u5373\u505c\u85e5\u4ee5\u9632\u526f\u4f5c\u7528\r5.\u6297\u6182\u9b31\u85e5\u7269\u7684\u4ee3\u8b1d\u4e26\u7121\u660e\u986f\u7684\u7a2e\u65cf\u5dee\u7570\u3002\nA. 1+2+3\nB. 2+3+5\nC. 1+3+5\nD. 3+4+5\nE. 1+4+5\n": "(A)", "101-1.\n\u95dc\u65bc\u81ea\u6bba\u554f\u984c\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8eab\u9ad4\u75be\u75c5\u8207\u7cbe\u795e\u75be\u75c5\u662f\u81ea\u6bba\u7684\u5371\u96aa\u56e0\u5b50\nB. \u7d55\u5927\u591a\u6578\u81ea\u6bba\u8eab\u4ea1\u8005\u5f9e\u4f86\u6c92\u6709\u900f\u9732\u81ea\u6bba\u7684\u60f3\u6cd5\nC. \u5fc3\u7406\u793e\u6703\u5371\u6a5f\u4e5f\u662f\u81ea\u6bba\u7684\u5371\u96aa\u56e0\u5b50\nD. \u5a92\u9ad4\u4e0d\u9069\u7576\u5831\u5c0e\u81ea\u6bba\u4e8b\u4ef6\u6240\u5f15\u8d77\u7684\u6a21\u4eff\u6548\u61c9\u4e5f\u662f\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nE. \u9650\u5236\u81f4\u547d\u5de5\u5177\u7684\u53ef\u5f97\u6027\u88ab\u8b49\u660e\u53ef\u4ee5\u964d\u4f4e\u81ea\u6bba\u6b7b\u4ea1\u7387\n": "(B)", "101-2.\n\u7576\u4ee3\u91ab\u75c5\u95dc\u4fc2\u7684\u6311\u6230\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u91ab\u7642\u6c7a\u7b56\u5f62\u6210\u904e\u7a0b\u4e2d\u91ab\u5e2b\u8207\u75c5\u4eba\u4e4b\u9593\u6b0a\u529b\u4f4d\u968e\u4e4b\u6539\u8b8a\nB. \u5b58\u5728\u65bc\u91ab\u75c5\u95dc\u4fc2\u4e4b\u5916\u81e8\u5e8a\u7814\u7a76\u53d7\u8a66\u8005\u8207\u7814\u7a76\u8005\u4e4b\u7279\u6b8a\u95dc\u4fc2\nC. \u5e73\u8861\u5065\u5eb7\u4fdd\u96aa\u7cfb\u7d71\u6216\u91ab\u7642\u7b2c\u4e09\u65b9(third party)\u8207\u75c5\u4eba\u6700\u5927\u5229\u76ca\u4e4b\u885d\u7a81\nD. \u500b\u9ad4\u5229\u76ca\u8207\u7fa4\u9ad4\u5229\u76ca\u4e4b\u53d6\u6368\nE. \u4ee5\u4e0a\u7686\u662f\n": "(E)", "101-3.\n\u95dc\u65bc\u8b6b\u5984\u7684\u8a55\u4f30\u8207\u8655\u7f6e\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u78ba\u5b9a\u8a3a\u65b7\u5f8c\u61c9\u7acb\u5373\u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5\u5982 haloperidol\nB. \u6ce8\u610f\u529b\u969c\u7919\u662f\u8b6b\u5984\u7684\u91cd\u8981\u75c7\u72c0\u4e4b\u4e00\nC. \u6295\u4e88haloperidol\u6642\uff0c\u61c9\u6ce8\u610f\u5176\u662f\u5426\u589e\u52a0\u5fc3\u5f8b\u4e0d\u6574\u4e4b\u98a8\u96aa\nD. \u8b6b\u5984\u70ba\u6025\u6027\u767c\u4f5c\u4e14\u75c5\u7a0b\u8d77\u4f0f\nE. \u65e5\u591c\u9031\u671f\u6df7\u4e82\u4e5f\u6709\u53ef\u80fd\u6703\u767c\u751f\u5728\u8b6b\u5984\u75c5\u60a3\u8eab\u4e0a\n": "(A)", "101-4.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u8a3a\u65b7\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u300c\u5c0d\u65bc\u672c\u4f86\u6709\u8208\u8da3\u7684\u4e8b\u60c5\u8b8a\u5f97\u6c92\u8208\u8da3\u300d\u662f\u6838\u5fc3\u75c7\u72c0\u4e4b\u4e00\nB. \u300c\u6301\u7e8c\u6027\u7684\u60c5\u7dd2\u4f4e\u843d\u300d\u4e5f\u662f\u6838\u5fc3\u75c7\u72c0\u4e4b\u4e00\nC. \u7336\u8c6b\u4e0d\u6c7a(undecisiveness)\u4ee5\u53ca\u6ce8\u610f\u529b\u4e0d\u96c6\u4e2d(inattentiveness)\u90fd\u662f\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u8a8d\u77e5\u75c7\u72c0\nD. \u56e0\u6182\u9b31\u60c5\u7dd2\u800c\u9020\u6210\u529f\u80fd\u640d\u5bb3\u4ee5\u53ca\u500b\u4eba\u91cd\u5927\u75db\u82e6\u662f\u5efa\u7acb\u8a3a\u65b7\u7684\u8981\u4ef6\nE. \u6027\u617e\u589e\u52a0\u4ee5\u53ca\u55dc\u7720\u591a\u7720\u4e0d\u53ef\u80fd\u767c\u751f\u5728\u91cd\u5ea6\u6182\u9b31\u75c7\u75c5\u60a3\u8eab\u4e0a\n": "(E)", "101-5.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u751f\u7269\u5b78\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u85e5(selective serotonin reuptake inhibitor)\u7684\u7642\u6548\u986f\u8457\u512a\u65bc\u50b3\u7d71\u4e09\u74b0\u6297\u6182\u9b31\u85e5(tricyclic antidepressant)\nB. \u5f9e\u958b\u59cb\u6295\u85e5\u5230\u6cbb\u7642\u6548\u679c\u660e\u986f\u51fa\u73fe\u5f80\u5f80\u9700\u89814\u81f36\u500b\u6708\nC. \u7167\u5149\u6cbb\u7642(light therapy)\u53ef\u4ee5\u505a\u70ba\u55ae\u7368\u7684\u4e3b\u7dda\u6cbb\u7642\nD. \u6297\u6182\u9b31\u85e5\u7269\u7684\u9078\u64c7\u9700\u8981\u8003\u616e\u60a3\u8005\u5c0d\u65bc\u5404\u7a2e\u85e5\u7269\u526f\u4f5c\u7528\u7684\u8010\u53d7\u7a0b\u5ea6\nE. \u96fb\u6c23\u75d9\u6523\u6cbb\u7642\u6cd5(electroconvulsive therapy)\u5e38\u898b\u7684\u526f\u4f5c\u7528\u70ba\u6c38\u4e45\u6027\u7684\u8a18\u61b6\u529b\u640d\u5bb3\n": "(D)", "101-6.\n\u95dc\u65bc\u5931\u7720\u75c7\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u4e00\u822c\u4eba\u53e3\u7684\u76db\u884c\u7387\u7d041%\u81f32%\nB. \u7761\u7720\u885b\u751f\u6559\u80b2(sleep-hygiene education)\u662f\u6cbb\u7642\u5931\u7720\u53ef\u884c\u7684\u8fa6\u6cd5\u4e4b\u4e00\nC. \u7761\u7720\u8a8d\u77e5\u6cbb\u7642(cognitive therapy)\u7684\u5167\u5bb9\u5305\u62ec\u7834\u9664\u500b\u6848\u5c0d\u65bc\u7761\u7720\u4e4b\u8ff7\u601d\nD. \u6559\u5c0e\u75c5\u60a3\u7761\u4e0d\u8457\u5c31\u8d77\u4f86\uff0c\u6709\u7761\u610f\u518d\u56de\u5e8a\u4e0a\u7761\uff0c\u662f\u5c6c\u65bc\u523a\u6fc0\u63a7\u5236\u6cbb\u7642(stimulation-control therapy)\u4e4b\u4e00\u90e8\u5206\nE. \u6559\u5c0e\u75c5\u60a3\u653e\u9b06(relaxation training)\u4e5f\u6709\u52a9\u65bc\u8655\u7406\u5931\u7720\u7684\u554f\u984c\n": "(A)", "101-7.\n\u95dc\u65bc\u6050\u614c\u75c7(panic disorder)\u7684\u8a3a\u65b7\u8207\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8207\u76f8\u95dc\u8eab\u9ad4\u75be\u75c5\u4e4b\u9451\u5225\u8a3a\u65b7\u662f\u5fc5\u8981\u7684\nB. \u4e0d\u9810\u671f\u7684\u91cd\u8907\u767c\u4f5c\u662f\u5efa\u7acb\u8a3a\u65b7\u7684\u8981\u4ef6\u4e4b\u4e00\nC. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u85e5(SSRI)\u53ef\u4ee5\u4f5c\u70ba\u7b2c\u4e00\u7dda\u6cbb\u7642\u85e5\u7269\nD. \u9577\u671f\u6295\u4e88benzodiazepine\u985e\u6297\u7126\u616e\u85e5\u662f\u6700\u4f73\u7684\u6cbb\u7642\u65b9\u5f0f\nE. \u8a8d\u77e5\u884c\u70ba\u6cbb\u7642\u5c0d\u65bc\u6050\u614c\u75c7\u7684\u6cbb\u7642\u4e5f\u6709\u5e6b\u52a9\n": "(D)", "102-1.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u8b6b\u5984\u75c7(delirium)\u75c5\u60a3\u5e38\u898b\u7684\u60c5\u7dd2\u884c\u70ba\u75c7\u72c0\uff1f\nA. \u610f\u8b58\u4e0d\u6e05(disturbed consciousness)\nB. \u601d\u8003\u6df7\u4e82(disorganization of thought processes)\nC. \u6ce8\u610f\u529b\u4e0d\u96c6\u4e2d(inattentiveness)\nD. \u7cfb\u7d71\u6027\u5984\u60f3(systematized delusion)\nE. \u65e5\u591c\u985b\u5012(sleep-wake cycle reversal)\n": "(D)", "102-2.\n\u95dc\u65bc\u5b89\u7720\u85e5\u7269(hypnotics)\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u6709\u670d\u7528\u5b89\u7720\u85e5\u7269\u7684\u500b\u6848\u9700\u8981\u6ce8\u610f\u5176\u99d5\u99db\u6c7d\u6a5f\u8eca\u7684\u5b89\u5168\u6027\nB. Zolpidem\u4ee3\u8b1d\u901f\u7387\u7684\u5feb\u6162\u6709\u6027\u5225\u5dee\u7570\nC. \u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40(FDA)\u5efa\u8b70\u5973\u6027\u7684Zolpidem\u8d77\u59cb\u7528\u91cf\u8981\u6bd4\u4e00\u822c\u7537\u6027\u5c11\u4e00\u534a\nD. \u500b\u6848\u5c0d\u65bc\u99d5\u99db\u529f\u80fd\u969c\u7919\u6709\u53ef\u9760\u7684\u81ea\u89ba(self-perception)\nE. \u7761\u7720\u4e0d\u8db3\u6216\u662f\u4f75\u7528\u9152\u7cbe\u6216\u5176\u4ed6\u5177\u6709\u93ae\u5b9a\u526f\u4f5c\u7528\u7684\u85e5\u7269\u540c\u6a23\u4e5f\u6703\u5f71\u97ff\u99d5\u99db\u5b89\u5168\n": "(D)", "102-3.\n\u95dc\u65bc\u8b6b\u5984(delirium)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6f5b\u5728\u8eab\u9ad4\u75be\u75c5\u7d93\u5e38\u662f\u9020\u6210\u8b6b\u5984\u7684\u4e3b\u8981\u539f\u56e0\nB. \u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5\u662f\u6cbb\u7642\u8b6b\u5984\u7684\u5fc5\u8981\u6b65\u9a5f\nC. \u0013\u6709\u7814\u7a76\u986f\u793a\u8b6b\u5984\u7684\u767c\u751f\u8207\u65e5\u5f8c\u500b\u6848\u7684\u6b7b\u4ea1\u98a8\u96aa\u76f8\u95dc\nD. Benzodiazepine\u4e5f\u662f\u85e5\u7269\u6cbb\u7642\u8b6b\u5984\u7684\u9078\u9805\u4e4b\u4e00\nE. \u63d0\u4f9b\u5b89\u5168\u7684\u7167\u8b77\u74b0\u5883\u4e5f\u662f\u8655\u7f6e\u8b6b\u5984\u4e0d\u53ef\u6216\u7f3a\u4e4b\u4e00\u74b0\n": "(B)", "102-4.\n\u6839\u64da\u4e16\u754c\u885b\u751f\u7d44\u7e54(WHO)\u6700\u8fd1\u5c0d\u65bc\u91cd\u5927\u707d\u96e3\u3001\u66b4\u529b\u653b\u64ca\u3001\u610f\u5916\u4e8b\u4ef6\u3001\u6216\u662f\u89aa\u53cb\u7a81\u7136\u5f80\u751f\u5f8c\uff0c\u53ef\u80fd\u767c\u751f\u7684\u54c0\u615f\u53cd\u61c9(bereavement)\u6216\u5275\u50b7\u5f8c\u58d3\u529b\u75c7\u5019\u7fa4(post-traumatic stress disorder: PTSD)\uff0c\u5176\u8655\u7f6e\u5efa\u8b70\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u906d\u9022\u5275\u50b7\u4e8b\u4ef6\u5f8c\u7684\u982d\u4e00\u500b\u6708\u5167\uff0c\u5c0d\u65bc\u6b21\u767c\u6027\u6025\u6027\u5931\u7720(secondary acute insomnia)\u554f\u984c\uff0c\u6cbb\u7642\u9996\u9078\u70babenzodiazepines\nB. \u5728\u906d\u9022\u5275\u50b7\u4e8b\u4ef6\u982d\u4e00\u500b\u6708\u5167\u7684\u5b69\u7ae5(children)\uff0c\u82e5\u6709\u904e\u5ea6\u63db\u6c23(hyperventilation)\u554f\u984c\uff0c\u4e0d\u5efa\u8b70\u4f7f\u7528\u7d19\u888b\u518d\u547c\u5438(rebreathing into a paper bag)\u6cd5\nC. \u5728\u906d\u9022\u5275\u50b7\u4e8b\u4ef6\u4e00\u500b\u6708\u5f8c\u4e14\u7b26\u5408PTSD\u8a3a\u65b7\u7684\u6210\u5e74\u4eba\uff0c\u5efa\u8b70\u65bd\u4ee5\u500b\u5225\u6216\u5718\u9ad4\u8a8d\u77e5\u884c\u70ba\u6cbb\u7642\nD. \u5728\u906d\u9022\u5275\u50b7\u4e8b\u4ef6\u4e00\u500b\u6708\u5f8c\u4e14\u7b26\u5408PTSD\u8a3a\u65b7\u7684\u5152\u7ae5\u53ca\u9752\u5c11\u5e74\uff0c\u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u4e26\u975e\u6cbb\u7642\u9996\u9078\nE. \u5c0d\u65bc\u6c92\u6709\u7cbe\u795e\u75be\u60a3\u7684\u500b\u9ad4\uff0c\u4e0d\u5efa\u8b70\u91dd\u5c0d\u54c0\u615f\u53cd\u61c9\uff0c\u65bd\u4ee5\u7d50\u69cb\u6027\u7684\u5fc3\u7406\u5b78\u4ecb\u5165(structured psychological intervention)\n": "(A)", "102-5.\n\u4e0b\u5217\u4f55\u8005\u662fDSM-IV\u5efa\u7acb\u91cd\u5ea6\u6182\u9b31\u75c7(major depression)\u8a3a\u65b7\u7684\u5178\u578b\u75c7\u72c0\uff1f(1)\u60c5\u7dd2\u4f4e\u843d (2)\u5c0d\u65bc\u672c\u4f86\u6709\u8208\u8da3\u7684\u4e8b\u60c5\u4e0d\u611f\u8208\u8da3 (3)\u7336\u8c6b\u4e0d\u6c7a (4)\u65e5\u591c\u985b\u5012 (5)\u7121\u6cd5\u63a7\u5236\u7684\u64d4\u5fc3\nA. (1)+(2)+(5)\nB. (1)+(3)+(4)\nC. (1)+(2)+(3)\nD. (3)+(4)+(5)\nE. (2)+(3)+(5)\n": "(C)", "102-6.\n\u4e0b\u5217\u4f55\u8005\u4e26\u975e\u6050\u614c\u767c\u4f5c(panic attack)\u7684\u5178\u578b\u75c7\u72c0\nA. \u5fc3\u60b8 (palpitation)\nB. \u6613\u6012\u60c5\u7dd2 (irritable mood)\nC. \u5bb3\u6015\u81ea\u5df1\u6703\u6b7b\u6389 (fear of dying)\nD. \u982d\u660f (dizzy)\nE. \u5bb3\u6015\u5931\u53bb\u63a7\u5236\u8207\u767c\u760b (fear of losing control or going crazy)\n": "(B)", "102-7.\n\u95dc\u65bc\u5404\u7a2ebenzodiazepine(BZD)\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(1)Lorazepam\u5c6c\u65bcintermediate onset\u7684BZD (2)Triazolam\u8840\u4e2d\u6fc3\u5ea6\u534a\u8870\u671f\u70ba1.5-5\u5c0f\u6642 (3)Clonazepam\u5c6c\u65bcintermediate onset\u7684BZD (4)Diazepam\u5c6c\u65bcfast onset\u7684BZD (5)Alprazolam\u7684\u8840\u4e2d\u6fc3\u5ea6\u534a\u8870\u671f\u70ba20-70\u5c0f\u6642\nA. (1)+(2)+(4)\nB. (2)+(3)+(5)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(A)", "103-1.\n\u95dc\u65bc\u8b6b\u5984(delirium)\u81e8\u5e8a\u8868\u73fe\u7684\u63cf\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6709\u6642\u6703\u4f34\u96a8\u60c5\u7dd2\u4e0d\u7a69(emotional lability)\u5bb9\u6613\u54ed\u6ce3\u6216\u52d5\u6012\nB. \u75c5\u7a0b\u8d77\u8d77\u4f0f\u4f0f\uff0c\u6642\u597d\u6642\u58de\nC. \u6ce8\u610f\u529b\u4e0d\u96c6\u4e2d\uff1a\u9762\u8ac7\u6642\u5448\u73fe\u5fc3\u4e0d\u5728\u7109\nD. \u65e5\u591c\u898f\u5f8b\u969c\u7919(sleep-wake cycle disturbance)\uff1a\u767d\u5929\u4e00\u76f4\u7761\uff0c\u665a\u4e0a\u4e0d\u7761\nE. \u6f5b\u4f0f\u6027\u800c\u9010\u6f38\u767c\u4f5c\u7684\u610f\u8b58\u6539\u8b8a\n": "(E)", "103-2.\n\u95dc\u65bc\u5f37\u8feb\u6027\u7cbe\u795e\u5b98\u80fd\u75c7(obsessive-compulsive disorder: OCD)\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1f(1)\u7d42\u751f\u76db\u884c\u7387(lifetime prevalence)\u5927\u7d041%\u81f33%\uff1b(2)\u6210\u5e74\u4ebaOCD\u7684\u7537\u5973\u6bd4\u4f8b\u70ba4:1\u5de6\u53f3\uff1b(3)\u6cbb\u7642\u9078\u9805\u5305\u62ec\u66b4\u9732\u7642\u6cd5(exposure therapy)\uff1b(4)\u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u7684\u5efa\u8b70\u5291\u91cf\u901a\u5e38\u6bd4\u6cbb\u7642\u6182\u9b31\u75c7\u7684\u5291\u91cf\u4f86\u7684\u4f4e\uff1b(5)\u5e38\u898b\u75c7\u72c0\u53ef\u5305\u62ec\u8207\u5b97\u6559\u76f8\u95dc\u4e4b\u80cc\u5fb7(immoral)\u6216\u8a5b\u5492(dammation)\u7684\u53cd\u8986\u60f3\u6cd5\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (1)+(4)+(5)\nD. (2)+(3)+(4)\nE. (3)+(4)+(5)\n": "(B)", "103-3.\n\u95dc\u65bc\u4f7f\u7528\u5927\u9ebb(marijuana)\u5c0d\u65bc\u5065\u5eb7\u7684\u5f71\u97ff\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u77ed\u671f\u4f7f\u7528\u6703\u5f71\u97ff\u5224\u65b7\u529b(judgement)\nB. \u77ed\u671f\u4f7f\u7528\u6703\u5f71\u97ff\u52d5\u4f5c\u5354\u8abf\u6027(motor coordination)\nC. \u5438\u98df\u5927\u9ebb\u6709\u6210\u766e(addiction)\u7684\u98a8\u96aa(risk)\uff0c\u4e00\u822c\u4f7f\u7528\u8005\u67099%\u7684\u98a8\u96aa\uff0c\u5f9e\u9752\u5c11\u5e74\u5c31\u4f7f\u7528\u8005\u670917%\u7684\u98a8\u96aa\uff0c\u6bcf\u65e5\u4f7f\u7528\u8005\u98a8\u96aa\u7d0425%\u523050%\nD. \u9577\u671f\u6216\u5927\u91cf\u4f7f\u7528\u8005\uff0c\u5176\u751f\u6d3b\u6eff\u610f\u5ea6(life satisfaction)\u4ee5\u53ca\u6210\u5c31(achievement)\u6703\u964d\u4f4e\nE. \u6709\u9ad8\u53ef\u4fe1\u5ea6\u4e4b\u8b49\u64da(high level of confidence)\u8b49\u660e\u4f7f\u7528\u5927\u9ebb\u6703\u589e\u52a0\u7f79\u60a3\u80ba\u764c\u7684\u98a8\u96aa\n": "(E)", "103-4.\n\u95dc\u65bc\u6050\u614c\u75c7(panic disorder)\u7684\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. Benzodiazepine(BZD)\u5efa\u8b70\u53ef\u4ee5\u9577\u671f\u6301\u7e8c\u4f7f\u7528\nB. \u65bc\u6cbb\u7642\u521d\u671f\u53ef\u4ee5\u8003\u616e\u4f75\u7528Selective Serotonin Reuptake Inhibitor(SSRI)\u4ee5\u53caBZD\nC. \u7b49\u5f85\u56db\u9031\u5230\u516d\u9031SSRI\u6548\u679c\u51fa\u4f86\u5f8c\u9010\u6b65\u964d\u4f4eBZD\nD. SSRI\u7684\u8d77\u59cb\u5291\u91cf\u6700\u597d\u5f9eSSRI\u6cbb\u7642\u6182\u9b31\u75c7\u8d77\u59cb\u5291\u91cf\u7684\u3127\u534a\u958b\u59cb\u6295\u85e5\nE. \u75c5\u60a3\u75ca\u7652\u5f8c\u4ecd\u9700\u8981\u3127\u6bb5\u6642\u9593\u7684\u7dad\u6301\u6027(maintenance)\u85e5\u7269\u6cbb\u7642\n": "(A)", "103-5.\n\u4e0b\u5217\u4f55\u8005\u662f\u7f8e\u570b\u7cbe\u795e\u91ab\u5b78\u6703\u7cbe\u795e\u75be\u75c5\u8a3a\u65b7\u53ca\u7d71\u8a08\u624b\u518a\u7b2c\u56db\u7248(DSM-IV)\u5b9a\u7fa9\u300c\u91cd\u5ea6\u6182\u9b31\u767c\u4f5c\u300d(major depresive episode)\u7684\u5178\u578b\u75c7\u72c0\uff1f(1)\u5c0d\u672c\u4f86\u6709\u8208\u8da3\u7684\u4e8b\u7269\u5931\u53bb\u8208\u8da3(anhedonia) (2)\u5bb9\u6613\u75b2\u7d2f(fatigue) (3)\u601d\u8003\u53ca\u52d5\u4f5c\u8b8a\u6162(psychomotor retardation) (4)\u80f8\u60b6(chest tightness) (5)\u5fc3\u60b8(palpitation)\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(4)\nC. (2)+(3)+(5)\nD. (1)+(4)+(5)\nE. (3)+(4)+(5)\n": "(A)", "103-6.\n\u4e0b\u5217\u6297\u6182\u9b31\u85e5\u7269\u8207\u526f\u4f5c\u7528\u7684\u914d\u5c0d\uff0c\u54ea\u3127\u7d44\u662f\u4e0d\u5e38\u898b\u7684\uff1f\nA. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u6291\u5236\u5291(Selective Serotonin Reuptake Inhbitor: SSRI)\uff1a\u8178\u80c3\u4e0d\u9069(nausea and other GI effects )\nB. \u4e09\u74b0\u6297\u6182\u9b31\u85e5(Tricyclic antidepressants: TCA):\uff1a\u53e3\u4e7e\u4fbf\u79d8(dry mouth and constipation)\nC. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u6291\u5236\u5291(Selective Serotonin Reuptake Inhibitor: SSRI)\uff1a\u982d\u75db(headache)\nD. \u9078\u64c7\u6027\u65b0\u814e\u4e0a\u817a\u7d20\u8207\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(Selective Norepinephrine/Serotonin Reuptake Inhibitors: SNRI): \u9670\u8396\u7570\u5e38\u52c3\u8d77(priapism)\nE. \u4e09\u74b0\u6297\u6182\u9b31\u85e5(Tricyclic antidepressants: TCA)\uff1a\u9ad4\u91cd\u4e0a\u5347(weight gain)\n": "(D)", "103-7.\n\u5c0d\u65bc\u8b6b\u5984(delirium)\u7684\u8655\u7406\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u591a\u6578\u8b49\u64da\u986f\u793a\u91dd\u5c0d\u8b6b\u5984\u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5(antipsychotics)\u6216\u93ae\u5b9a\u5291(sedatives)\u5c0d\u65bc\u5176\u8b6b\u5984\u9810\u5f8c\u6c92\u6709\u6b63\u9762\u5f71\u97ff\nB. \u76ee\u524d\u5c0d\u65bc\u8b6b\u5984\u4e8b\u5148\u9810\u9632(preventive)\u6295\u85e5\u7684\u8af8\u591a\u7814\u7a76\u5747\u986f\u793a\uff1a\u6297\u7cbe\u795e\u75c5\u85e5\u5c0d\u65bc\u9810\u9632\u8b6b\u5984\u767c\u751f\u6709\u986f\u8457\u6548\u679c\nC. \u85e5\u7269\u55ae\u7d14\u5316(drug reduction)\u4e5f\u662f\u8655\u7406\u8b6b\u5984\u7684\u65b9\u6cd5\u4e4b\u3127\nD. \u6297\u7cbe\u795e\u75c5\u85e5\u4ee5\u53ca\u93ae\u5b9a\u5291\u7684\u6295\u4e88\uff0c\u6709\u53ef\u80fd\u5ef6\u9577\u8b6b\u5984\u7684\u75c5\u7a0b\nE. \u907f\u514d\u5c0f\u7761(napping)\u4ee5\u53ca\u589e\u52a0\u767d\u5929\u7167\u5149\u4e5f\u662f\u975e\u85e5\u7269\u6cbb\u7642\u7684\u9078\u9805\n": "(B)", "104-1.\n\u95dc\u65bc\u89aa\u4eba\u904e\u4e16\u4e4b\u5f8c\u54c0\u615f\u53cd\u61c9(grief)\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u6709\u8b49\u64da\u6307\u51fa\u5728\u54c0\u615f\u53cd\u61c9\u7684\u6025\u6027\u671f\u5fc3\u808c\u6897\u585e\u98a8\u96aa\u589e\u52a0\nB. \u5728\u54c0\u615f\u53cd\u61c9\u7684\u6025\u6027\u671f\u8840\u58d3\u5fc3\u8df3\u6703\u589e\u52a0\nC. \u5728\u54c0\u615f\u53cd\u61c9\u7684\u6025\u6027\u671f\u8840\u4e2dcortisol\u6fc3\u5ea6\u964d\u4f4e\nD. \u67092%\u52303%\u5931\u53bb\u89aa\u4eba\u7684\u6c11\u773e\uff0c\u54c0\u615f\u53cd\u61c9\u6301\u7e8c\u592a\u4e45\uff0c\u5f37\u5ea6\u672a\u96a8\u6642\u9593\u6e1b\u5f31\uff0c\u5448\u73fe\u300c\u8907\u96dc\u6027\u300d\u54c0\u615f\u53cd\u61c9(complicated grief)\nE. \u8907\u96dc\u6027\u54c0\u615f\u53cd\u61c9\u9700\u8981\u8ddf\u91cd\u5ea6\u6182\u9b31\u75c7(major depression)\u4ee5\u53ca\u5275\u50b7\u5f8c\u58d3\u529b\u75c7(posttraumatic stress disorder)\u4f5c\u9451\u5225\u8a3a\u65b7\n": "(C)", "104-2.\n\u95dc\u65bc\u8001\u5e74\u6182\u9b31\u75c7(depression in the elderly)\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u7f79\u60a3\u6182\u9b31\u75c7\u6703\u589e\u52a0\u500b\u6848\u7f79\u60a3\u5931\u667a\u75c7\u7684\u98a8\u96aa\nB. \u751f\u6d3b\u4f5c\u606f\u6539\u8b8a(lifestyle changes)\u4e5f\u662f\u6cbb\u7642\u65b9\u5f0f\u4e4b\u4e00\nC. \u4ee5\u751f\u6d3b\u4f5c\u606f\u6539\u8b8a\u4f5c\u70ba\u6cbb\u7642\u65b9\u5f0f\uff0c\u901a\u5e38\u53ef\u4ee5\u55ae\u7368\u9054\u5230\u6cbb\u7642\u6548\u679c\nD. \u85e5\u7269\u6cbb\u7642\u8207\u5fc3\u7406\u6cbb\u7642\u90fd\u53ef\u4ee5\u8003\u616e\u4f5c\u70ba\u7b2c\u4e00\u7dda\u7684\u6cbb\u7642\nE. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(selective serotonin reuptake inhibitor: SSRI)\u88ab\u5efa\u8b70\u7576\u4f5c\u85e5\u7269\u6cbb\u7642\u7684\u9996\u9078\n": "(C)", "104-3.\n\u95dc\u65bc\u8a50\u75c5(malingering)\u8207\u5ea0\u75c5\u75c7(factitious disorder)\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5177\u6709\u300c\u91ab\u7642\u7121\u6cd5\u89e3\u91cb\u7684\u8eab\u9ad4\u75c7\u72c0\u300d(medically unexplained physical symptoms)\u7684\u75c5\u60a3\uff0c\u90fd\u662f\u6709\u7cbe\u795e\u79d1\u8a3a\u65b7\u7684\nB. \u8655\u7406\u5ea0\u75c5\u75c7\u500b\u6848\u7684\u539f\u5247\u5305\u62ec\u300c\u9867\u5168\u500b\u6848\u984f\u9762\u300d(face saving)\u4ee5\u53ca\u300c\u6e1b\u4f4e\u50b7\u5bb3\u300d(harm minimization)\nC. \u9664\u4e86\u91ab\u7642\u4e0a\u8a73\u76e1\u7684\u75c5\u53f2\u8a62\u554f\u8207\u75c5\u6b77\u8cc7\u6599\u56de\u9867\uff0c\u78ba\u8a8d\u8a50\u75c5\u8207\u5ea0\u75c5\u75c7\u4e5f\u9700\u8981\u91ab\u7642\u4ee5\u5916\u7684\u8abf\u67e5\u8cc7\u8a0a(non-medical investigation)\u4f86\u652f\u6301\u8a3a\u65b7\u4e4b\u78ba\u7acb\nD. \u50c5\u4f9d\u9760\u300c\u81e8\u5e8a\u6280\u8853\u300d(clinical skills)\u672c\u8eab\u4e0d\u8db3\u4ee5\u5075\u6e2c(detect)\u6216\u8a3a\u65b7\u8a50\u75c5\nE. \u5373\u4f7f\u6709\u660e\u78ba\u7684\u795e\u7d93\u79d1\u6216\u7cbe\u795e\u79d1\u8a3a\u65b7\u7684\u75c5\u60a3\uff0c\u4ed6\u5011\u7684\u7570\u5e38\u751f\u75c5\u884c\u70ba(abnormal illness behaviors)\uff0c\u4e5f\u4e26\u975e\u5b8c\u5168\u6e90\u81ea\u65bc\u4ed6\u5011\u7f79\u60a3\u7684\u75be\u75c5\u672c\u8eab\n": "(A)", "104-4.\n\u95dc\u65bc\u8001\u5e74\u4eba\u7684\u8b6b\u5984(delirium)\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u6c92\u6709\u8db3\u5920\u7684\u8b49\u64da\u8b49\u660e\u6295\u4e88\u85e5\u7269\u53ef\u4ee5\u6709\u6548\u5730\u300c\u9810\u9632\u300d\u8b6b\u5984\u767c\u751f\nB. \u5728\u4e00\u822c\u91ab\u7642\u60c5\u5883(general medicine)\u7576\u4e2d\uff0c\u6182\u9b31\u75c7(depression)\u66fe\u7d93\u88ab\u8b49\u660e\u662f\u8b6b\u5984\u7684\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nC. Serum urea \u589e\u52a0\u4e5f\u662f\u8b6b\u5984\u7684\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00\nD. \u8166\u6ce2\u6aa2\u67e5 (electroencephalography: EEG)\u5c0d\u65bc\u8a3a\u65b7\u8b6b\u5984\uff0c\u6709\u826f\u597d\u7684\u654f\u611f\u5ea6(sensitivity)\u53ca\u7279\u7570\u5ea6(specificity)\nE. Haloperidol 0.5mg BID \u662f\u5408\u7406\u7684\u85e5\u7269\u6cbb\u7642\u9078\u64c7\n": "(D)", "104-5.\n\u4e0b\u5217\u5408\u8005\u975e\u6050\u614c\u767c\u4f5c(panic attack)\u7684\u5178\u578b\u75c7\u72c0\uff1f\nA. \u5fc3\u60b8 (palpitation)\nB. \u80f8\u75db (chest pain)\nC. \u5bb3\u6015\u81ea\u5df1\u5feb\u8981\u6b7b\u6389 (fear of dying)\nD. \u7570\u7269\u6897\u585e\u611f (feeling of choking)\nE. \u6613\u6012\u60c5\u7dd2 (irritable mood)\n": "(E)", "104-6.\n\u95dc\u65bc\u6297\u6182\u9b31\u85e5\u7269\u526f\u4f5c\u7528\u7684\u8655\u7406\u65b9\u5f0f\uff0c\u4e0b\u5217\u5408\u8005\u70ba\u975e\uff1f\nA. \u5641\u5fc3 (nausea)\uff1a\u6301\u7e8c\u5f88\u4e45\u4e14\u8207\u5291\u91cf\u7121\u95dc\uff0c\u53ef\u4f75\u7528\u5236\u9178\u5291\u5e6b\u52a9\u7de9\u89e3\u6216\u96a8\u9910\u670d\u7528\nB. \u6027\u9ad8\u6f6e\u4e0d\u80fd (anorgasmia)\uff1a\u4f7f\u7528cyproheptadine 4mg to 8mg \u65bc\u6027\u6d3b\u52d5\u524d2\u5c0f\u6642\u670d\u7528\nC. \u9ad4\u91cd\u4e0a\u5347 (weight gain)\uff1a\u904b\u52d5\u7bc0\u98df\u6216\u8003\u616e\u6539\u70ba fluoxetine\nD. \u59ff\u52e2\u6027\u4f4e\u8840\u58d3 (orthostatic hypotension)\uff1a\u4e0d\u5bb9\u6613\u7522\u751f\u8010\u53d7\u6027\u800c\u81ea\u7136\u7de9\u89e3\uff0c\u589e\u52a0\u98f2\u6c34\u91cf\uff0c\u6216\u662f\u4f7f\u7528 fludrocortisone 0.025mg/day\nE. \u6297\u4e59\u91af\u81bd\u9e7c(anticholinergic)\u526f\u4f5c\u7528\uff1a\u7b49\u5f85\u8010\u53d7\u6027\u7522\u751f (wait for tolerance)\n": "(A)", "104-7.\n\u95dc\u65bc\u6cbb\u7642\u96d9\u6975\u6027\u60c5\u611f\u75be\u60a3(bipolar affective disorder)\u7684\u60c5\u7dd2\u7a69\u5b9a\u5291(mood stabilizer)\u7684\u7279\u6027\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u662f\uff1f(1) \u92f0\u9e7d(lithium)\u7684\u6709\u6548\u8840\u4e2d\u6cbb\u7642\u6fc3\u5ea6\u7bc4\u570d\u70ba 8-12 meq/L\uff1b(2) Thiazide\u6703\u6e1b\u5c11\u92f0\u9e7d\u7684\u8840\u4e2d\u6fc3\u5ea6\uff1b(3) Valproic acid\u7684\u6709\u6548\u8840\u4e2d\u6cbb\u7642\u6fc3\u5ea6\u70ba50-125 ug/ml\uff1b(4) \u80f0\u81df\u708e(pancreatitis)\u662fValproic acid\u53ef\u80fd\u7684\u7f55\u898b\u526f\u4f5c\u7528\u4e4b\u4e00\uff1b(5) Lamotrigine\u7684\u7f55\u898b\u526f\u4f5c\u7528\u5305\u62ecStevens-Johnson syndrome\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (1)+(2)+(5)\nE. (3)+(4)+(5)\n": "(E)", "105-1.\n\u95dc\u65bc\u81ea\u6bba\u9632\u6cbb\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5404\u7a2e\u7528\u65bc\u9810\u6e2c\u81ea\u6bba\u98a8\u96aa\u7684\u7be9\u6aa2\u554f\u5377\uff0c\u5c0d\u65bc\u672a\u4f86\u81ea\u6bba\u884c\u70ba\u7684\u967d\u6027\u9810\u6e2c\u7387 (positive predictive value) \u90fd\u4e0d\u9ad8\uff0c\u5f88\u5c11\u8d85\u904e20%\nB. \u66fe\u7d93\u56e0\u70ba\u81ea\u6211\u50b7\u5bb3(self-harm)\u4f86\u6025\u8a3a\u7684\u6c11\u773e\uff0c\u5927\u7d042%\u5728\u672a\u4f86\u4e00\u5e74\u6703\u6b7b\u65bc\u81ea\u6bba\nC. \u66fe\u6709\u7814\u7a76\u6307\u51fa\uff0c\u4e0d\u5e78\u81ea\u6bba\u8eab\u4ea1\u7684\u500b\u6848\u4e2d\uff0c\u670980%\u5728\u4ed6\u5011\u6700\u5f8c\u7684\u8a9e\u8a00\u6e9d\u901a\u4e2d\uff0c\u672a\u66fe\u986f\u9732\u81ea\u6bba\u7684\u610f\u5ff5\u60f3\u6cd5\nD. \u5be6\u8b49\u7814\u7a76\u5747\u986f\u793a\uff1a\u8a62\u554f\u75c5\u60a3\u662f\u5426\u6709\u81ea\u6bba\u610f\u5ff5\uff0c\u6703\u5927\u5e45\u589e\u52a0\u75c5\u60a3\u81ea\u6bba\u98a8\u96aa\nE. \u75c5\u4eba\u5f9e\u7cbe\u795e\u79d1\u75c5\u623f\u51fa\u9662\u5f8c\u4e00\u9031\u5167\u662f\u81ea\u6bba\u7684\u9ad8\u98a8\u96aa\u6642\u6bb5\n": "(D)", "105-2.\n\u95dc\u65bc\u4e0b\u5217\u5404\u7a2e\u6297\u7126\u616e\u85e5\u7269\u7684\u7279\u6027\u63cf\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. Diazepam\u4f5c\u7528\u901f\u5ea6(action of onset)\u5feb\uff0c\u93ae\u975c(sedation)\u6548\u679c\u660e\u986f\nB. Lorazepam\u4f5c\u7528\u901f\u5ea6\u4e2d\u7b49\uff0c\u7121\u6d3b\u6027\u4ee3\u8b1d\u7269(no active metabolites)\nC. Alprazolam\u4f5c\u7528\u901f\u5ea6\u4e2d\u7b49\uff0c\u8f03\u96e3\u6212\u65b7\u505c\u85e5(difficult to withdrawal)\nD. Oxazepam\u4f5c\u7528\u901f\u5ea6\u5feb\uff0c\u5177\u6709\u534a\u8870\u671f\u6975\u9577\u4e4b\u6d3b\u6027\u4ee3\u8b1d\u7269\nE. Clonazepam\u4f5c\u7528\u901f\u5ea6\u6162\uff0c\u7f8e\u570bFDA\u6838\u51c6\u4f7f\u7528\u65bc\u6050\u614c\u75c7(panic disorder)\n": "(D)", "105-3.\n\u95dc\u65bc\u9d09\u7247\u985e(opioid)\u88fd\u5291\u904e\u91cf(overdose)\u7684\u8655\u7f6e\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u7dad\u8b77\u6c23\u9053(establish airway)\u70ba\u9996\u8981\uff0c\u6709\u6642\u9700\u8981\u63d2\u7ba1\u6216\u4f7f\u7528\u547c\u5438\u5668\nB. Naloxone\u4e00\u822c\u5efa\u8b70\u5291\u91cf0.4mg-2.0mg\uff0c\u53ef\u85c9\u7531\u808c\u8089\u6ce8\u5c04\uff0c\u975c\u8108\u6ce8\u5c04\uff0c\u6216\u662f\u6c23\u7ba1\u5167\u7ba1(endotracheal tube)\u7d66\u85e5\nC. Naloxone\u975c\u8108\u7d66\u85e5\u5f8c10\u81f320\u5206\u9418\u898b\u6548\nD. \u82e5\u547c\u5438\u4ecd\u4e0d\u7406\u60f3Naloxone\u9700\u91cd\u8907\u7d66\u85e5\nE. \u7576\u547c\u5438\u6291\u5236\u89e3\u9664\u5f8c\uff0c\u6bcf\u5c0f\u6642\u6295\u8207\u8d77\u59cb\u5291\u91cf\u76841/2\u52302/3\u505a\u70ba\u7dad\u6301\u6cbb\u7642\n": "(C)", "105-4.\n\u95dc\u65bc\u7f8e\u570b\u7cbe\u795e\u91ab\u5b78\u6703\u9812\u5e03\u300c\u7cbe\u795e\u75be\u75c5\u8a3a\u65b7\u7d71\u8a08\u624b\u518a\u7b2c\u4e94\u7248\u300d(Diagnostic and Statistical Manual of Mental DIsorders, Fifth edition: DSM-5)\uff0c\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u9152\u7cbe\u4f7f\u7528\u75be\u60a3(alcohol use disorder)\u7684\u8a3a\u65b7\u5167\u5bb9\nA. \u9152\u7cbe\u7684\u8010\u53d7\u6027(tolerance)\nB. \u6e34\u671b\u98f2\u9152(alcohol craving)\nC. \u559d\u5f97\u6bd4\u9810\u671f\u7684\u9084\u591a\u9084\u4e45(larger amount or longer)\nD. \u53cd\u8986\u60f3\u6212\u9152\u4f46\u6212\u4e0d\u6389\nE. \u98f2\u9152\u5f8c\u7522\u751f\u91cd\u5ea6\u6182\u9b31\u767c\u4f5c\n": "(E)", "105-5.\n\u95dc\u65bc\u5931\u7720\u500b\u6848\u7684\u975e\u85e5\u7269\u8655\u7f6e\u885b\u6559\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u523a\u6fc0\u63a7\u5236(stimulus control)\uff1a\u6709\u7761\u610f\u7684\u6642\u5019\u624d\u53bb\u5e8a\u4e0a\u7761\uff0c\u7761\u4e0d\u8457\u800c\u4e14\u7126\u616e\u7684\u6642\u5019\u5c31\u96e2\u958b\u5e8a\u8216\nB. \u7761\u7720\u885b\u751f(sleep hygiene)\uff1a\u81e5\u5ba4\u5b9c\u6697\u800c\u5b89\u975c\uff0c\u6642\u9418\u5b9c\u79fb\u9664\u65bc\u8996\u7dda\u7bc4\u570d\u5916\nC. \u653e\u9b06\u6cbb\u7642(relaxation therapy)\uff1a\u808c\u8089\u653e\u9b06\uff0c\u547c\u5438\u8a13\u7df4\uff0c\u6c89\u601d\u51a5\u60f3(meditation)\nD. \u8a8d\u77e5\u6cbb\u7642(cognitive therapy)\uff1a\u7dad\u6301\u5c0d\u65bc\u7761\u7720\u7684\u5408\u7406\u671f\u5f85\uff0c\u6311\u6230\u64d4\u5fc3\u5931\u7720\u6703\u5f15\u767c\u707d\u96e3\u6027\u7684\u904e\u5ea6\u9810\u671f\u5fc3\u614b\nE. \u9650\u5236\u7761\u7720(sleep restriction)\uff1a\u6e1b\u5c11\u8eba\u5e8a\u6642\u9593\u81f33\u500b\u5c0f\u6642\uff0c\u4e26\u4e14\u8207\u500b\u6848\u7684\u751f\u7269\u9031\u671f(circadian rhythm)\u53cd\u5411\u64cd\u4f5c\n": "(E)", "105-6.\n\u95dc\u65bc\u8001\u4eba\u8650\u5f85(elder abuse)\u5728\u81e8\u5e8a\u4e0a\u53ef\u80fd\u7684\u7dda\u7d22\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u4e00\u822c\u8001\u5e74\u4eba\u8eab\u4e0a\u9bae\u5c11\u6709\u81ea\u767c\u6027\u7684\u7600\u9752(bruise)\nB. \u8001\u5e74\u4eba\u56e0\u8dcc\u5012\u800c\u9020\u6210\u982d\u90e8\u7684\u9aa8\u6298\u8f03\u5e38\u898b\u65bc\u773c\u7aa9(orbital)\u9aa8\u53ca\u9f3b\u6a11\u9aa8(nasal)\uff0c\u56e0\u70ba\u8650\u5f85\u6bc6\u6253\u8f03\u5e38\u898b\u65bc\u4e0b\u984e(jaw)\u4ee5\u53ca\u9874\u9aa8(zygomatic)\u9aa8\u6298\nC. \u88ab\u8eab\u9ad4\u8650\u5f85(physical abuse)\u7684\u8001\u4eba\uff0c\u8eab\u4e0a\u53ef\u80fd\u6709\u8a31\u591a\u50b7\u53e3\uff0c\u800c\u4e14\u8655\u5728\u4e0d\u540c\u7684\u7652\u5408\u968e\u6bb5\nD. \u5fc3\u7406\u8650\u5f85(psychological abuse)\u7684\u8de1\u8c61\u5305\u62ec\u8001\u4eba\u88ab\u523b\u610f\u9694\u7d55\u65bc\u8ddf\u597d\u670b\u53cb\u6216\u4fe1\u8cf4\u5bb6\u4eba\u7684\u4e92\u52d5\u63a5\u89f8\nE. \u5e38\u7167\u6a5f\u69cb\u5167\u7684\u8001\u4eba\u8650\u5f85\u50b7\u5bb3\uff0c\u6709\u53ef\u80fd\u662f\u6a5f\u69cb\u4f4f\u6c11\u9593\u4e92\u76f8\u653b\u64ca\u6240\u81f4\n": "(A)", "105-7.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7\u7684\u8a3a\u65b7\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u8d77\u59cb\u968e\u6bb5\u4e3b\u8981\u662f\u75c5\u4eba\u885b\u6559\u4ee5\u53ca\u9078\u7528\u53ef\u8010\u53d7\u7684\u85e5\u7269\nB. \u82e5\u6297\u6182\u9b31\u85e5\u7269\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73\uff0c\u9700\u8003\u616e\u500b\u6848\u4e4b\u9451\u5225\u8a3a\u65b7\u662f\u5426\u70ba\u96d9\u6975\u6027\u60c5\u611f\u75be\u60a3\nC. \u5c0d\u65bcSSRI\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73(treatment resistant)\u7684\u91cd\u5ea6\u6182\u9b31\u75c7\u500b\u6848\uff0c\u63db\u6210SNRI\u7684\u9810\u671f\u7642\u6548(efficacy)\uff0c\u6bd4\u63db\u6210mirtazapine\u7684\u9810\u671f\u7642\u6548\u986f\u8457\u70ba\u9ad8\nD. \u6cbb\u7642\u91cd\u5ea6\u6182\u9b31\u75c7\u500b\u6848\u82e5\u6c92\u6709\u9054\u5230\u5b8c\u5168\u7de9\u89e3(full remission)\uff0c\u5fa9\u767c\u98a8\u96aa\u589e\u52a0\uff0c\u81ea\u6bba\u98a8\u96aa\u4e5f\u589e\u9ad8\nE. \u9078\u7528\u85e5\u7269\u7684\u53c3\u8003\u4f9d\u64da\uff0c\u9084\u5305\u62ec\u500b\u6848\u89aa\u4eba\u82e5\u4e5f\u6709\u91cd\u5ea6\u6182\u9b31\u75c7\uff0c\u5176\u89aa\u4eba\u7684\u85e5\u7269\u6cbb\u7642\u53cd\u61c9\n": "(C)", "106-1.\n\u4e0b\u5217\u95dc\u65bc\u81ea\u6bba\u7684\u63cf\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u8eab\u9ad4\u75be\u75c5\u5982\u51a0\u72c0\u52d5\u8108\u5fc3\u81df\u75c5\u53ca\u6162\u6027\u963b\u585e\u6027\u80ba\u75be\u60a3\uff0c\u82e5\u5408\u4f75\u6182\u9b31\u75c7\uff0c\u6703\u589e\u52a0\u81ea\u6bba\u7684\u98a8\u96aa\nB. \u6709\u4e9b\u6162\u6027\u75be\u75c5\u5982\u7672\u7647\u4ee5\u53ca\u767c\u708e\u6027\u8178\u9053\u75be\u75c5 (inflammatory bowel disease)\uff0c\u672c\u8eab\u4e0d\u9700\u8981\u5408\u4f75\u7cbe\u795e\u75be\u75c5\uff0c\u81ea\u6bba\u98a8\u96aa\u5c31\u589e\u52a0\nC. \u5931\u7720\u672c\u8eab\u662f\u81ea\u6bba\u7368\u7acb\u7684\u5371\u96aa\u56e0\u5b50\uff0c\u5176\u6a5f\u8f49\u53ef\u80fd\u900f\u904e\u5931\u7720\u589e\u52a0\u885d\u52d5\u6027\u4ee5\u53ca\u8a8d\u77e5\u7684\u504f\u5dee\nD. \u5275\u50b7\u6027\u8166\u50b7 (traumatic brain injury) \u4e0d\u6703\u589e\u52a0\u81ea\u6bba\u98a8\u96aa\nE. \u591a\u767c\u6027\u786c\u5316\u75c7\u4e5f\u6703\u589e\u52a0\u81ea\u6bba\u98a8\u96aa\n": "(D)", "106-2.\n\u95dc\u65bcbenzodiazepine (BZD) \u985e\u85e5\u7269\u7684\u6210\u766e\u554f\u984c\u53ca\u6212\u6cbb\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. BZD\u7684\u4f9d\u8cf4\u6027(dependence)\u53ef\u4ee5\u767c\u751f\u5728\u4f4e\u5291\u91cf\u800c\u4e14\u6c92\u6709\u7522\u751f\u8010\u53d7\u6027(tolerance)\u7684\u60c5\u6cc1\u4e0b\nB. BZD\u7684\u6212\u65b7\u75c7\u72c0\uff0c\u9577\u6548\u578b\u7684\u85e5\u7269\u767c\u751f\u5728\u65b7\u85e5\u5f8c5-10\u5929\uff0c\u77ed\u6548\u7684\u85e5\u7269\u5927\u7d04\u57282-3\u5929\nC. \u6bcf\u65e5\u4f7f\u7528BZD\u7576\u91cf\u82e5\u8d85\u904e100 mg\u7684diazepam\uff0c\u5efa\u8b70\u4f4f\u9662\u4f86\u6212\u85e5\nD. \u5354\u52a9\u4f7f\u7528\u591a\u7a2eBZD\u500b\u6848\u6212\u85e5\u6642\uff0c\u61c9\u5148\u5c07BZD\u7a2e\u985e\u55ae\u7d14\u5316\u81f3diazepam\u4e00\u7a2e\nE. \u4f9d\u64da\u5be6\u8b49\u91ab\u5b78\u56de\u9867\u7684\u5171\u8b58\uff0c\u6212\u9664\u5927\u65bc30 mg diazepam\u7684BZD\u6210\u766e\uff0c\u53ef\u57284-6\u5929\u5b8c\u6210\n": "(E)", "106-3.\n\u95dc\u65bc\u6182\u9b31\u75c7\u7be9\u6aa2\u8207\u6cbb\u7642\u7684\u6700\u65b0\u5efa\u8b70\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6b63\u78ba\u7684\uff1f(1)\u5b55\u7522\u671f\u5a66\u5973(pregnant and postpartum)\u4e0d\u61c9\u8a72\u7d0d\u5165\u7be9\u6aa2\uff1b(2)\u9577\u671f\u5931\u7720\u4e5f\u662f\u9020\u6210\u8001\u5e74\u4eba\u6182\u9b31\u7684\u5371\u96aa\u56e0\u5b50\uff1b(3)\u5c0d\u65bc\u6210\u4eba\u6182\u9b31\u75c7\u7684\u6cbb\u7642\uff0c\u8207\u5b89\u6170\u5291\u76f8\u8f03\uff0c\u76ee\u524d\u4e26\u7121\u7814\u7a76\u8b49\u5be6\u6297\u6182\u9b31\u85e5\u7269\u5728\u7d71\u8a08\u4e0a\u986f\u8457\u5730\u589e\u52a0\u81ea\u6bba\u6b7b\u4ea1\u98a8\u96aa\uff1b(4)\u8a8d\u77e5\u884c\u70ba\u6cbb\u7642(cognitive behavioral psychotherapy)\u88ab\u8b49\u5be6\u5c0d\u65bc\u9810\u7522\u671f\u5a66\u5973\u7684\u6182\u9b31\u75c7\u6c92\u6709\u7642\u6548\uff1b(5)\u9762\u5c0d\u56f0\u96e3\u990a\u80b2\u5f88\u96e3\u5e36\u7684\u5b30\u5152(difficult infant temperament)\uff0c\u4e5f\u662f\u7522\u5f8c\u6182\u9b31\u7684\u5371\u96aa\u56e0\u5b50\u3002\nA. (2)+(3)+(5)\nB. (1)+(4)+(5)\nC. (1)+(2)+(3)\nD. (2)+(3)+(4)\nE. (1)+(3)+(5)\n": "(A)", "106-4.\n\u95dc\u65bc\u7126\u616e\u75be\u60a3(anxiety disorders)\u7684\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u76ee\u524d\u6c92\u6709\u8db3\u5920\u8b49\u64da\u652f\u6301\u8981\u4ee5\u85e5\u7269\u6cbb\u7642\u6216\u5fc3\u7406\u6cbb\u7642\uff0c\u4f5c\u70ba\u9996\u9078\u6cbb\u7642\u65b9\u5f0f\nB. Inderal \u53ef\u4ee5\u6e1b\u8f15\u793e\u4ea4\u7126\u616e\u75c7(social anxiety disorder)\u7684\u75c7\u72c0\nC. Benzodiazepine\u985e\u85e5\u7269\u53ef\u4ee5\u4f5c\u70ba\u7b2c\u4e00\u7dda\u7684\u55ae\u7368\u6cbb\u7642(monotherapy)\u9078\u9805\nD. \u7528\u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u6cbb\u7642\u7126\u616e\u75be\u60a3\uff0c\u8d77\u59cb\u5291\u91cf\u5efa\u8b70\u7531SSRI\u6cbb\u7642\u6182\u9b31\u75c7\u8d77\u59cb\u5291\u91cf\u7684\u4e00\u534a\u958b\u59cb\nE. \u7576\u7126\u616e\u75be\u60a3\u7528\u85e5\u7269\u6cbb\u7652\u5f8c\uff0c\u9084\u9700\u8981\u85e5\u7269\u505a\u7dad\u6301\u6027\u6cbb\u7642\u4e00\u6bb5\u6642\u9593\n": "(C)", "106-5.\n\u95dc\u65bc\u6050\u614c\u75c7\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u662f\u6c11\u773e\u5c0b\u6c42\u5167\u79d1\u91ab\u5e2b\u8a3a\u6cbb\u7684\u5e38\u898b\u539f\u56e0\u4e4b\u4e00\nB. \u81e8\u5e8a\u8868\u73fe\u70ba\u53cd\u8986\u4e14\u4e0d\u53ef\u9810\u671f\u7684\u7126\u616e\u75c7\u72c0\u767c\u4f5c\nC. \u7406\u5b78\u8207\u5be6\u9a57\u5ba4\u6aa2\u67e5\u7d50\u679c\u6703\u767c\u73fe\u80fd\u89e3\u91cb\u767c\u4f5c\u75c7\u72c0\u4e4b\u539f\u56e0\nD. \u500b\u6848\u6703\u5bb3\u6015\u4e0b\u4e00\u6b21\u767c\u4f5c\uff0c\u6216\u56e0\u5bb3\u6015\u767c\u4f5c\u800c\u81ea\u6211\u9650\u5236\u6d3b\u52d5\u7bc4\u570d\nE. \u7532\u72c0\u817a\u529f\u80fd\u7570\u5e38\u662f\u9451\u5225\u8a3a\u65b7\u4e4b\u4e00\n": "(C)", "106-6.\n\u95dc\u65bc\u5f37\u8feb\u75c7(obsessive-compulsive disorder: OCD)\u7684\u8a3a\u65b7\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u500b\u6848\u53ef\u80fd\u6703\u6301\u7e8c\u61f7\u7591(persistent doubting)\u5927\u9580\u6709\u6c92\u6709\u9396\u597d\uff0c\u800c\u53cd\u8986\u6aa2\u67e5\u9580\u9396\nB. \u500b\u6848\u53ef\u80fd\u6703\u5bb3\u6015\u81ea\u5df1\u4e0d\u5c0f\u5fc3\u9020\u6210\u50b7\u5bb3(fear of causing harm)\uff0c\u800c\u91cd\u8907\u6298\u8fd4\u525b\u525b\u958b\u8eca\u7d93\u904e\u7684\u8def\u6bb5\u6aa2\u67e5\nC. \u91dd\u5c0dOCD\u4f7f\u7528\u85e5\u7269\u6cbb\u7642\u7684\u7642\u6548\uff0c\u7d9c\u5408\u5206\u6790\u5448\u73fe\uff1a\u9700\u6cbb\u4eba\u6578(number needed to treat: NNT)\u5927\u7d045\nD. \u91dd\u5c0dOCD\u4f7f\u7528\u5fc3\u7406\u6cbb\u7642(psychotherapy)\u7684\u7642\u6548\uff0c\u7d9c\u5408\u5206\u6790\u5448\u73feNNT\u5927\u65bc10\nE. \u82e5\u4ee5clomipramine\u6cbb\u7642OCD\uff0c\u6bcf\u65e5\u76ee\u6a19\u5291\u91cf\u70ba250 mg\n": "(D)", "106-7.\n\u95dc\u65bc\u8207\u56b4\u91cd\u81f4\u547d\u6027\u75be\u75c5(serious and life-threatening illness)\u75c5\u60a3\u4e4b\u9593\u7684\u91ab\u75c5\u6e9d\u901a\u7b56\u7565\u8207\u77e5\u80fd\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u963b\u7919\u9019\u985e\u6e9d\u901a\u7684\u539f\u56e0\u4e4b\u4e00\u662f\u75c5\u60a3\u8207\u91ab\u5e2b\u90fd\u7b49\u5f85\u5c0d\u65b9\u5148\u958b\u555f\u9019\u985e\u8a71\u984c\nB. \u91ab\u5e2b\u5728\u9810\u5f8c\u63a8\u6e2c(prognostication)\u7684\u6559\u80b2\u8a13\u7df4\u5145\u8db3\u8207\u5426\uff0c\u4e5f\u662f\u963b\u7919\u6b64\u985e\u6e9d\u901a\u7684\u539f\u56e0\nC. \u7167\u8b77\u9ad4\u7cfb\u5206\u5de5\u592a\u7d30\u7f3a\u4e4f\u5354\u8abf(lack of coordination)\u4e5f\u662f\u5f71\u97ff\u9019\u985e\u6e9d\u901a\u6548\u80fd\u7684\u539f\u56e0\u4e4b\u4e00\nD. \u900f\u904e\u6559\u80b2\u8a13\u7df4\u5efa\u7acb\u77e5\u8b58(knowlege)\u3001\u614b\u5ea6(attitude)\u8207\u6280\u5de7(skill)\u7684\u9023\u7d50\uff0c\u6709\u52a9\u65bc\u589e\u9032\u751f\u547d\u672b\u671f(end-of-life)\u7684\u91ab\u75c5\u6e9d\u901a\u54c1\u8cea\nE. \u5c0d\u91ab\u5e2b\u5c08\u696d\u800c\u8a00\uff0c\u9762\u5c0d\u56b4\u91cd\u81f4\u547d\u75be\u75c5\u7684\u91ab\u75c5\u6e9d\u901a\uff0c\u662f\u4e0d\u6703\u6709\u58d3\u529b\u7684\n": "(E)", "107-1.\n\u95dc\u65bc\u8001\u5e74\u8b6b\u5984(delirium)\u7684\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u5728\u6025\u8a3a\u5c31\u91ab\u7684\u8001\u5e74\u4eba\u767c\u751f\u8b6b\u5984\u7684\u6a5f\u6703\u53ef\u905410%-15%\nB. \u4f4e\u6d3b\u52d5\u5ea6(hypoactive)\u8b6b\u5984\u500b\u6848\u9810\u5f8c\u8f03\u4f73\nC. \u7537\u6027\u8001\u5e74\u75c5\u60a3\u6bd4\u5973\u6027\u8001\u5e74\u75c5\u60a3\u5bb9\u6613\u767c\u751f\u8b6b\u5984\nD. \u6025\u6027\u767c\u751f\u6ce8\u610f\u529b(attention)\u8207\u5c0d\u5468\u906d\u611f\u77e5(awareness)\u7684\u969c\u7919\u662f\u5176\u7279\u5fb5\nE. \u8b6b\u5984\u75c5\u7a0b\u6709\u6642\u5019\u6703\u6301\u7e8c\u5230\u51fa\u9662\u751a\u81f3\u9577\u9054\u4e00\u500b\u6708\n": "(B)", "107-2.\n\u95dc\u65bc\u8001\u5e74\u8b6b\u5984(delirium)\u7684\u85e5\u7269\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. Haloperidol \u8d77\u59cb\u5291\u91cf 0.25-0.5mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5efa\u8b70\u5291\u91cf 30mg\uff0c\u662f\u4f7f\u7528\u7d93\u9a57\u6700\u4e45\u7684\u85e5\u7269\u4e4b\u4e00\nB. Ziprasidone \u8d77\u59cb\u5291\u91cf 5-10mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5efa\u8b70\u5291\u91cf 40mg\uff0c\u4e3b\u8981\u5728ICU\u5167\u4f7f\u7528\nC. Olanzapine \u8d77\u59cb\u5291\u91cf 2.5-5mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5efa\u8b70\u5291\u91cf 20mg\uff0c\u5c0d\u65bc\u6025\u6027\u75c7\u72c0\u7642\u6548\u53e3\u670d\u4f4e\u65bc\u808c\u8089\u6ce8\u5c04\nD. Lorazepam \u8d77\u59cb\u5291\u91cf 0.25-0.5mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5291\u91cf 2mg\uff0c\u662f\u7b2c\u4e8c\u7dda\u7684\u9078\u64c7\nE. Quetiapine \u8d77\u59cb\u5291\u91cf 12.5-25mg\uff0c\u6bcf\u65e5\u6700\u9ad8\u5291\u91cf 50mg\uff0c\u9808\u6ce8\u610f\u4f4e\u8840\u58d3\u554f\u984c\n": "(A)", "107-3.\n\u95dc\u65bc\u7cbe\u795e\u75c5(psychotic disorder)\uff0c\u4e5f\u5c31\u662f\u5305\u62ec\u601d\u89ba\u5931\u8abf\u75c7(schizophrenia)\u8207\u5984\u60f3\u75c7(delusional disorder)\u7b49\u56b4\u91cd\u7684\u7cbe\u795e\u75be\u75c5\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u591a\u5df4\u80fa\u7b2c\u4e8c\u578b\u53d7\u9ad4\u963b\u65b7\u5291\u662f\u5e38\u7528\u7684\u6cbb\u7642\u85e5\u7269\nB. \u96fb\u7642(ECT)\u5c0d\u65bc\u5408\u4f75\u50f5\u76f4\u72c0\u614b\u6216\u6709\u660e\u986f\u60c5\u611f\u75c7\u72c0\u8005\u7642\u6548\u8f03\u4f73\nC. \u53ea\u6709\u4e0d\u5230\u4e00\u6210\u4ee5\u4e0b\u7684\u7cbe\u795e\u75c5(psychotic disorder)\u500b\u6848\u66fe\u7d93\u4f01\u5716\u81ea\u6bba\nD. \u7cbe\u795e\u75c5(psychotic disorder)\u500b\u6848\u5bb9\u6613\u6210\u70ba\u53d7\u5bb3\u8005(victimization by others)\nE. \u7cbe\u795e\u75c5(psychotic disorder)\u66fe\u88ab\u8b49\u660e\u662f\u66b4\u529b\u884c\u70ba(acts of violence)\u7684\u5371\u96aa\u56e0\u5b50\n": "(C)", "107-4.\n\u95dc\u65bc\u81ea\u9589\u75c7\u6216\u6cdb\u81ea\u9589\u75c7\u969c\u7919(autism spectrum disorder, ASD)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u4e9e\u65af\u4f2f\u683c\u75c7(Asperger's disorder)\u5c6c\u65bc\u5176\u4e2d\u7684\u4e00\u500b\u578b\u614b\nB. \u793e\u6703\u4eba\u969b\u6e9d\u901a\u80fd\u529b\u591a\u9762\u5411\u6301\u7e8c\u7684\u7f3a\u640d\u662f\u5176\u7279\u5fb5\nC. \u500b\u6848\u5448\u73fe\u4fb7\u9650\u800c\u91cd\u8907\u7684\u884c\u70ba\u6a21\u5f0f\u8207\u8208\u8da3\nD. \u6ce8\u610f\u529b\u4e0d\u8db3\u904e\u52d5\u75c7(ADHD)\u5f88\u5c11\u8207ASD\u5171\u75c5\nE. \u6559\u5c0e\u96d9\u89aa\u5982\u4f55\u8207ASD\u7684\u5b69\u5b50\u4e92\u52d5\uff0c\u88ab\u8b49\u660e\u53ef\u5feb\u901f\u6539\u5584\u5b69\u7ae5\u7684\u793e\u6703\u884c\u70ba\u8207\u6e9d\u901a\n": "(D)", "107-5.\n\u95dc\u65bc\u5275\u50b7\u5f8c\u58d3\u529b\u75c7(post-traumatic stress disorder, PTSD)\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u81e8\u5e8a\u75c7\u72c0\u4e0a\u5305\u62ec\u91cd\u8907\u51fa\u73fe\u8207\u5275\u50b7\u4e8b\u4ef6\u76f8\u95dc\u7684\u5669\u5922\nB. \u7121\u6545\u6216\u56e0\u7d30\u6545\u6613\u6012(irritable behavior)\u751a\u81f3\u5bb9\u6613\u66b4\u6012(anger outbursts)\u4e5f\u662f\u53ef\u80fd\u7684\u75c7\u72c0\u4e4b\u4e00\nC. Sertraline\u4ee5\u53caparoxetine\u662f\u7f8e\u570bFDA\u6838\u51c6\u7684\u6cbb\u7642\u7528\u85e5\nD. \u7dad\u6301\u6027\u85e5\u7269\u6cbb\u7642\u9700\u90546\u81f312\u500b\u6708\uff0c\u800c\u4e14\u7de9\u6162\u5730\u6e1b\u91cf\uff0c\u4ee5\u9632\u5fa9\u767c\nE. PTSD\u4e0d\u6703\u5728\u5275\u50b7\u4e8b\u4ef6\u767c\u751f\u5f8c\u4e00\u6bb5\u6642\u9593\u624d\u5ef6\u9072\u767c\u751f(delayed expression)\n": "(E)", "107-6.\n\u95dc\u65bc\u5b89\u7720\u85e5\u7269(hypnotics)\u4e0b\u5217\u4f55\u8005\u932f\u8aa4?\nA. \u6709\u670d\u7528\u5b89\u7720\u85e5\u7269\u7684\u500b\u6848\u9700\u8981\u6ce8\u610f\u5176\u99d5\u99db\u6c7d\u6a5f\u8eca\u7684\u5b89\u5168\u6027\nB. Zolpidem\u4ee3\u8b1d\u901f\u7387\u7684\u5feb\u6162\u6709\u6027\u5225\u5dee\u7570\nC. \u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40(FDA)\u5efa\u8b70\u5973\u6027\u7684Zolpidem\u8d77\u59cb\u7528\u91cf\u8981\u6bd4\u4e00\u822c\u7537\u6027\u5c11\u4e00\u534a\nD. \u500b\u6848\u5c0d\u65bc\u99d5\u99db\u529f\u80fd\u969c\u7919\u6709\u53ef\u9760\u7684\u81ea\u89ba(self-perception)\nE. \u7761\u7720\u4e0d\u8db3\u6216\u662f\u4f75\u7528\u9152\u7cbe\u6216\u5176\u4ed6\u5177\u6709\u93ae\u5b9a\u526f\u4f5c\u7528\u7684\u85e5\u7269\u540c\u6a23\u4e5f\u6703\u5f71\u97ff\u99d5\u99db\u5b89\u5168\n": "(D)", "107-7.\n\u4e0b\u5217\u54ea\u4e09\u7a2e\u6297\u6182\u9b31\u85e5\u7269\uff0c\u5728\u8fd1\u671f\u7684\u5927\u898f\u6a21 meta-analysis \u4e2d\uff0c\u5448\u73fe\u51fa\u76f8\u4f3c\u7a0b\u5ea6\u7684\u7642\u6548(efficacy)\uff1f (1). venlafaxine (2). fluvoxamine (3). trazodone (4). sertraline (5). fluoxetine\nA. (1)+(3)+(5)\nB. (2)+(4)+(5)\nC. (2)+(3)+(5)\nD. (1)+(2)+(3)\nE. (3)+(4)+(5)\n": "(C)", "108-1.\n\u95dc\u65bc\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b(intimate partner violence)\u8207\u81e8\u5e8a\u91ab\u5b78\u7684\u95dc\u806f\u6027\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u66b4\u9732\u65bc\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\uff0c\u6703\u589e\u52a0\u7f79\u60a3\u6c23\u5598\u3001\u4e2d\u98a8\u6216\u5fc3\u8840\u7ba1\u75be\u75c5\u7684\u98a8\u96aa\nB. \u500b\u6848\u6709\u7d93\u5e38\u6027\u7684\u982d\u9838\u984f\u9762\u7684\u9aa8\u6298\u6216\u6495\u88c2\u50b7\uff0c\u4e5f\u9700\u8981\u8003\u616e\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\u7684\u53ef\u80fd\u6027\nC. \u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\u4e5f\u53ef\u4ee5\u900f\u904e\u9650\u5236\u53d7\u5bb3\u4f34\u4fb6\u7684\u6c42\u91ab\u884c\u70ba\u4f86\u5448\u73fe\uff0c\u5c0e\u81f4\u53d7\u5bb3\u4f34\u4fb6\u91ab\u7642\u914d\u5408\u5ea6(medical adherence)\u4e0d\u4f73\nD. \u5354\u52a9\u60a3\u8005\u63ed\u9732\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\u7d93\u9a57\uff0c\u4e0d\u9700\u8981\u5728\u96b1\u5bc6\u5b89\u5168\u7684\u60c5\u5883\u4e0b\u8a62\u554f\uff0c\u800c\u4e14\u9996\u6b21\u898b\u9762\u5c31\u53ef\u4ee5\u554f\u5f97\u51fa\u4f86\nE. \u719f\u6089\u4e26\u63d0\u4f9b\u8f49\u4ecb\u8cc7\u6e90\uff0c\u5982113\u5c08\u7dda\u6216\u5404\u7e23\u5e02\u5bb6\u5ead\u66b4\u529b\u8207\u6027\u4fb5\u5bb3\u9632\u6cbb\u4e2d\u5fc3\u806f\u7d61\u65b9\u5f0f\uff0c\u6709\u52a9\u65bc\u9632\u7bc4\u89aa\u5bc6\u95dc\u4fc2\u66b4\u529b\n": "(D)", "108-2.\n\u95dc\u65bc\u91cd\u5ea6\u6182\u9b31\u75c7(major depression)\u7684\u75c5\u56e0\u5b78\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u96d9\u80de\u80ce\u7814\u7a76\u5448\u73fe\u4e2d\u7b49\u7a0b\u5ea6\u7684\u907a\u50b3\u7387 (moderate heritability)\nB. \u6d77\u99ac\u8ff4\u9ad4\u7a4d(hippocampal volume)\u6e1b\u5c11\u662f\u5728\u5927\u8166\u7d50\u69cb\u4e0a\u4e00\u81f4\u7684\u767c\u73fe\nC. \u5728\u529f\u80fd\u6027\u8166\u9020\u5f71\u7814\u7a76\u5e38\u767c\u73fe\u674f\u4ec1\u6838(amygdala)\u6d3b\u6027\u589e\u52a0\nD. \u8fd1\u5e74\u5168\u57fa\u56e0\u7d44\u95dc\u806f\u6027\u5206\u6790(GWAS)\u5df2\u7d93\u627e\u5230\u5927\u91cf\u53ef\u91cd\u8907\u9a57\u8b49\u7684\u81f4\u75c5\u57fa\u56e0\u4f4d\u9ede\nE. \u8fd1\u5e74\u7814\u7a76\u767c\u73fe\u767c\u708e\u53cd\u61c9\u4e5f\u8207\u91cd\u5ea6\u6182\u9b31\u75c7\u75c5\u56e0\u76f8\u95dc\n": "(D)", "108-3.\n\u95dc\u65bc\u6182\u9b31\u75c7\u7684\u5fc3\u7406\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5728\u6182\u9b31\u75c7\u7684\u5fc3\u7406\u6cbb\u7642\u4e2d\uff0c\u8a8d\u77e5\u884c\u70ba\u6cbb\u7642(CBT)\u4ee5\u53ca\u4eba\u969b\u95dc\u4fc2\u6cbb\u7642(IPT)\u662f\u5169\u7a2e\u5e38\u898b\u7684\u6cbb\u7642\u6a21\u5f0f\nB. \u5c0d\u65bc\u75c5\u60c5\u8f03\u56b4\u91cd\u7684\u6182\u9b31\u75c7\u60a3\u8005\uff0c\u75c5\u4eba\u96e3\u4ee5\u6295\u5165(engage)\u5fc3\u7406\u6cbb\u7642\u904e\u7a0b\uff0c\u6545\u50c5\u4f7f\u7528\u5fc3\u7406\u6cbb\u7642\u7684\u7642\u6548\u4e0d\u4f73\nC. \u76ee\u524d\u5b78\u754c\u53ef\u4ee5\u6e05\u695a\u5340\u5206\u4e0d\u540c\u5fc3\u7406\u6cbb\u7642\u6a21\u5f0f\u7642\u6548\u7684\u5dee\u7570\u6240\u5728\nD. \u5c0d\u65bc\u6bd4\u8f03\u8f15\u7684\u6182\u9b31\u75c7\uff0c\u5fc3\u7406\u6cbb\u7642\u8207\u85e5\u7269\u6cbb\u7642\u7684\u6548\u679c\u985e\u4f3c\nE. \u4e0d\u540c\u5fc3\u7406\u6cbb\u7642\u6a21\u5f0f\u5171\u540c\u7684\u7642\u6548\u95dc\u9375\u4e0d\u5916\u4e4e\u8b93\u500b\u6848\u611f\u5230\u6eab\u6696\u3001\u6b63\u5411\u3001\u4ee5\u53ca\u771f\u8aa0\u7684\u7167\u9867\n": "(C)", "108-4.\n\u95dc\u65bc\u6182\u9b31\u75c7\u7684\u751f\u7269\u6027\u6cbb\u7642\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u9078\u64c7\u6027\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291(SSRI)\u5e38\u898b\u7684\u526f\u4f5c\u7528\u53ef\u80fd\u5305\u62ec\u6027\u529f\u80fd\u969c\u7919\u3001\u5641\u5fc3\u3001\u982d\u75db\u3001\u9ad4\u91cd\u4e0a\u5347\nB. \u5927\u7d04\u6709\u4e09\u5206\u4e4b\u4e00\u7684\u75c5\u60a3\uff0c\u53ef\u4ee5\u85c9\u7531\u91ab\u5e2b\u8655\u65b9\u7684\u7b2c\u4e00\u7a2e\u6297\u6182\u9b31\u85e5\u7372\u5f97\u75ca\u7652(full remission)\nC. \u66fe\u6709\u570b\u5916\u5927\u578b\u968e\u6bb5\u6027\u85e5\u7269\u8a66\u9a57\u7814\u7a76\u7d50\u679c\u5448\u73fe\uff0c\u5728\u5617\u8a66\u4e86\u56db\u7a2e\u4e0d\u540c\u7684\u6297\u6182\u9b31\u85e5\u7269\u5f8c\uff0c\u7d2f\u7a4d\u8d77\u4f86\u4e5f\u53ea\u6709\u4e8c\u5206\u4e4b\u4e00\u7684\u75c5\u60a3\u7372\u5f97\u75ca\u7652\nD. \u70ba\u4e86\u56e0\u61c9\u55ae\u4e00\u7dda\u6297\u6182\u9b31\u85e5\u7269\u7642\u6548\u4e0d\u5f70\u7684\u554f\u984c\uff0c\u6709\u6642\u5019\u5f97\u5617\u8a66augmentation\uff0c\u4f8b\u5982\u6297\u6182\u9b31\u85e5\u7269\u5408\u4f75lithium\u6216\u662f\u90e8\u5206atypical antipsychotics\nE. \u591a\u91cd\u85e5\u7269\u6cbb\u7642\u53cd\u61c9\u4e0d\u4f73\u6216\u662f\u81ea\u6bba\u98a8\u96aa\u8f03\u9ad8\u7684\u60a3\u8005\uff0c\u53ef\u4ee5\u8003\u616e\u96fb\u6c23\u75d9\u6523\u6cbb\u7642\u6cd5(ECT)\n": "(C)", "108-5.\n\u95dc\u65bc\u5ee3\u7fa9\u7684\u7cbe\u795e\u75c5(psychotic disorders)\u985e\u7fa4\u5404\u7a2e\u75be\u60a3\u7684\u7d42\u751f\u76db\u884c\u7387(lifetime prevalence)\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u601d\u89ba\u5931\u8abf\u75c7(schizophrenia)\uff1a0.30%-0.87%\nB. \u5e36\u6709\u7cbe\u795e\u75c5\u7279\u5fb5\u7684\u96d9\u6975\u60c5\u611f\u75be\u60a3(bipolar disorder with psychotic feature)\uff1a0.12%\nC. \u5e36\u6709\u7cbe\u795e\u75c5\u7279\u5fb5\u7684\u91cd\u5ea6\u6182\u9b31\u75c7(major depressive disorder with psychotic feature):\uff1a0.33%\nD. \u5984\u60f3\u75c7(delusional disorder)\uff1a0.18%\nE. \u7522\u5f8c\u7cbe\u795e\u75c5(postpartum psychosis)\uff1a7%\n": "(E)", "108-6.\n\u95dc\u65bc\u601d\u89ba\u5931\u8abf\u75c7(schizophrenia)\u7684\u5fc3\u7406\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f\nA. \u76ee\u524d\u5b78\u754c\u652f\u6301\u55ae\u7d14\u4ee5\u5fc3\u7406\u6cbb\u7642\u65b9\u5f0f\u6cbb\u7642\u601d\u89ba\u5931\u8abf\u75c7\nB. \u8a8d\u77e5\u884c\u70ba\u6cbb\u7642(CBT)\u88ab\u8b49\u5be6\u53ef\u4ee5\u6e1b\u8f15\u60a3\u8005\u4f86\u81ea\u5e7b\u807d\u6216\u5984\u60f3\u7684\u75db\u82e6\nC. \u5bb6\u65cf\u7cbe\u795e\u885b\u6559(family psychoeducation)\u6709\u52a9\u65bc\u5bb6\u65cf\u6210\u54e1\u652f\u6301\u75c5\u60a3\u8d70\u5411\u91cd\u5efa\u4e4b\u8def\nD. \u793e\u4ea4\u6280\u5de7\u8a13\u7df4(social skill training)\u9069\u5408\u75c7\u72c0\u56b4\u91cd\u7684\u6025\u6027\u671f\u75c5\u60a3\nE. \u91dd\u5c0d\u6703\u5f15\u767c\u7cbe\u795e\u75c5\u75c7\u72c0\u7684\u523a\u6fc0\uff0c\u65bd\u4ee5\u56b4\u8b39\u7684\u884c\u70ba\u66b4\u9732\u6cbb\u7642(behavioral exposure)\uff0c\u6709\u52a9\u65bc\u5efa\u7acb\u73fe\u5be6\u8003\u9a57\u611f(reality testing)\n": "(A)", "108-7.\n\u4e0b\u5217\u54ea\u5e7e\u500b\u85e5\u7269\u6709\u7372\u5f97\u7f8e\u570bFDA\u6cbb\u7642\u9152\u7cbe\u4f7f\u7528\u75be\u60a3(alcohol use disorder)\u7684\u8a31\u53ef\u8b49\uff1f(1)Vareniciline (2)Naltrexone (3)Disulfiram (4)Baclofen (5)Acamprosate\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (2)+(3)+(5)\nE. (3)+(4)+(5)\n": "(D)", "109-187.\u95dc\u65bc\u9152\u7cbe\u4f7f\u7528\u75be\u60a3(alcohol use disorder, AUD)\u7684\u6cbb\u7642\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u76ee\u524d\u5be6\u8b49\u6709\u6548\u7684\u793e\u6703\u5fc3\u7406\u6cbb\u7642 (psychosocial treatment )\uff0c\u5305\u62ec\u77ed\u671f\u8aee\u5546 (brief counseling )\u3001\u5f37\u5316\u52d5\u6a5f\n\u6cbb\u7642(motivational enhancement therapy )\u3001\u4ee5\u53ca\u884c\u70ba\u7d04\u5b9a (behavioral contract )\u7b49\nB.\u7f8e\u570bFDA\u6216\u6b50\u6d32EMA\u6838\u51c6\u7684AUD\u6cbb\u7642\u85e5\u7269\uff0c\u5305\u62ecNaltrexone\u808c\u8089\u6ce8\u5c04\nC.Disulfiram\u9069\u7528\u65bc\u4ecd\u6301\u7e8c\u5927\u91cf\u98f2\u9152\u7684\u500b\u6848\nD.Topiramate\u6709\u6548\u6212\u9152\u7684\u6a5f\u8f49\uff0c\u8207GluK1\u7684\u57fa\u56e0\u591a\u578b\u6027\u76f8\u95dc\nE.\u6b62\u5410\u5291Ondansetron\u5c0d\u65bc\u65e9\u767c\u578b\u9152\u7cbe\u4f7f\u7528\u75be\u60a3(early-onset AUD)\u5177\u6709\u6cbb\u7642\u6f5b\u529b\n": "[C]", "109-188.\u95dc\u65bcCOVID-19\u5927\u6d41\u884c\u75ab\u60c5\u7684\u5fc3\u7406\u885d\u64ca\u8207\u9632\u6cbb\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u5373\u4f7f\u75ab\u60c5\u904e\u53bb\uff0c\u5fc3\u7406\u885d\u64ca\u53ef\u80fd\u6301\u7e8c\nB.\u8fc5\u901f\u6709\u6548\u7684\u6e9d\u901a (effective and rapid communication )\u4ee5\u53ca\u76e1\u53ef\u80fd\u63d0\u4f9b\u5145\u8db3\u7684\u8cc7\u8a0a\u662f\u964d\u4f4e\u5fc3\u7406\u885d\u64ca\u7684\u91cd\n\u8981\u5143\u7d20\nC.\u81ea\u9858\u6027\u6aa2\u75ab(voluntary quarantine)\u7684\u500b\u6848\u60c5\u7dd2\u75db\u82e6\u8f03\u5c11\nD.\u516c\u5171\u885b\u751f\u5b98\u54e1\u4e0d\u61c9\u8a72\u5f37\u8abf\u81ea\u6211\u9694\u96e2(self-isolating)\u6240\u5c55\u73fe\u7684\u5229\u4ed6(altruism)\u7cbe\u795e\nE.\u91ab\u7642\u6a5f\u69cb\u9700\u8981\u7279\u5225\u95dc\u6ce8\u91ab\u8b77\u4eba\u54e1\u7684\u5fc3\u7406\u5065\u5eb7\u9700\u6c42\n": "[D]", "109-189.\u95dc\u65bc\u53ad\u98df\u75c7(anorexia nervosa)\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u81e8\u5e8a\u8868\u73fe\u70ba\u6975\u5ea6\u5730\u5bb3\u6015\u9ad4\u91cd\u589e\u52a0\uff0c\u81ea\u6211\u9650\u5236\u71b1\u91cf\u651d\u53d6\uff0c\u5c0e\u81f4\u71df\u990a\u4e0d\u826f\nB.\u7cbe\u795e\u4f5c\u7528\u85e5\u7269(psychotropic medications)\u5c0d\u65bc\u5e6b\u52a9\u53ad\u98df\u75c7\u500b\u6848\u589e\u52a0\u9ad4\u91cd\u8207\u964d\u4f4e\u6182\u9b31\u60c5\u7dd2\u6709\u660e\u986f\u7642\u6548\nC.\u61c9\u63d0\u4f9b\u5fc3\u7406\u6cbb\u7642\u4ecb\u5165 (psychotherapeutic approach )\u4ee5\u53ca\u91dd\u5c0d\u5b69\u7ae5\u6216\u9752\u5c11\u5e74\u75c5\u60a3\u7684\u5bb6\u65cf\u6cbb\n\u7642(family-based therapy )\nD.\u56b4\u91cd\u812b\u6c34\uff0c\u96fb\u89e3\u8cea\u4e0d\u5e73\u8861\uff0c\u5fc3\u5f8b\u904e\u6162\uff0c\u81ea\u6bba\u98a8\u96aa\uff0c\u4ee5\u53caBMI\u5c0f\u65bc15\u7b49\uff0c\u5e38\u5e38\u662f\u75c5\u60a3\u9700\u8981\u4f4f\u9662\u7684\u539f\u56e0\nE.\u53ad\u98df\u75c7\u6709\u5169\u500b\u4e9e\u578b \uff0c\u9650\u5236\u98f2\u98df\u578b (restricting type )\u4ee5\u53ca\u66b4\u98df\u50ac\u5410\u578b (binge-eating and purging type )\uff0c\u500b\n\u6848\u8f03\u5e38\u662f\u7531\u9650\u5236\u578b\u8f49\u70ba\u66b4\u98df\u50ac\u5410\u578b\n": "[B]", "109-190.\u95dc\u65bc\u601d\u89ba\u5931\u8abf\u75c7(schizophrenia)\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u5927\u7d04\u67091%\u4eba\u53e3\u7b26\u5408\u9019\u500b\u8a3a\u65b7\nB.\u5984\u60f3(delusion)\u3001\u5e7b\u89ba(hallucination)\u3001\u4ee5\u53ca\u7f3a\u4e4f\u7d44\u7e54\u7684\u8a00\u8a9e(disorganized speech)\u662f\u4e3b\u8981\u75c7\u72c0\nC.\u7814\u7a76\u767c\u73fe\u75c5\u60a3\u53ef\u80fd\u6709\u5927\u8166\u524d\u984d\u8449(prefrontal)\u7070\u8cea\u6e1b\u5c11\u73fe\u8c61   \nD.\u6295\u4e88\u6297\u7cbe\u795e\u75c5\u85e5\u7269(antipsychotic medications)\u5f8c\uff0c\u5e7b\u807d\u5984\u60f3\u5e38\u57282\u5929\u81f34\u5929\u5167\u53ef\u7372\u660e\u986f\u7de9\u89e3\nE.\u5927\u7d04\u670910%\u523030%\u7684\u75c5\u60a3\u5c0d\u65bc\u6297\u7cbe\u795e\u75c5\u85e5\u7269\u6cbb\u7642\u53cd\u61c9\u6709\u9650\n": "[D]", "109-191.\u5728\u9580\u8a3a\u7be9\u6aa2\u500b\u6848\u662f\u5426\u6709\u6182\u9b31\u75c7 \uff0c\u5b78\u8005\u5e38\u7528PHQ -2\u554f\u5377\uff0c\u7be9\u6aa2\u984c\u76ee \u300c\u4e0d\u5305\u62ec\u300d\u4e0b\u5217\u54ea\u4e09\u53e5\uff1f\u300c\u5728\u904e\u53bb\u5169\u5468\u7576\n\u4e2d\uff0c\u60a8\u6709\u591a\u5e38\u88ab\u4e0b\u5217\u7684\u554f\u984c\u56f0\u64fe... \u300d\n(1) \u7121\u6cd5\u96c6\u4e2d\u6ce8\u610f\u529b\n(2) \u96e3\u4ee5\u5165\u7761\u6216\u7761\u5f97\u592a\u591a\n(3) \u505a\u4e8b\u5f88\u5c11\u6709\u52d5\u6a5f\u6216\u6a02\u8da3\n(4) \u98df\u617e\u4e0d\u4f73\u4e0d\u60f3\u5403\u98ef\n(5) \u89ba\u5f97\u60c5\u7dd2\u4f4e\u843d\u6182\u9b31\u6216\u6c92\u6709\u5e0c\u671b   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(1)+(2)+(4)\nD.(3)+(4)+(5)\nE.(1)+(3)+(5)\n": "[C]", "109-192.\u95dc\u65bc\u81ea\u6bba\u9632\u6cbb\u4e0b\u5217\u4f55\u8005\u70ba\u5c0d \uff1f(1) \u5728\u525b\u88ab\u8a3a\u65b7\u7f79\u60a3\u764c\u75c7\u5f8c\u4e00\u5468\u5167\u53ef\u80fd\u6709\u7279\u5225\u9ad8\u7684\u81ea\u6bba\u98a8\u96aa \uff1b(2) \u5efa\u7acb\u4e26\u7dad\u6301\n\u6cbb\u7642\u95dc\u4fc2\u662f\u81ea\u6bba\u9632\u6cbb\u91cd\u8981\u56e0\u7d20\u4e4b\u4e00 \uff1b(3) \u9650\u5236\u81f4\u547d\u5de5\u5177\u53ef\u5f97\u6027 \uff0c\u4f8b\u5982\u7ba1\u5236\u69cd\u679d\u6216\u505c\u6b62\u8ca9\u552e\u5287\u6bd2\u8fb2\u85e5 \uff0c\u5c0d\u9632\n\u6cbb\u81ea\u6bba\u6c92\u6709\u5e6b\u52a9 \uff1b(4) \u76ee\u524d\u6709\u5f88\u5f37\u7684\u8b49\u64da\u652f\u6301\u5728\u4e00\u822c\u91ab\u5b78\u60c5\u5883 (primary care )\u548c\u6025\u8a3a\u5ba4 \uff0c\u4f7f\u7528\u91cf\u8868\u5e38\u898f\u7be9\u6aa2\n\u81ea\u6bba\u98a8\u96aa\u53ef\u4ee5\u6709\u6548\u9632\u6cbb\u81ea\u6bba \uff1b(5) \u92f0\u9e7d(Lithium)\u66fe\u7d93\u88ab\u8b49\u660e\u53ef\u4ee5\u964d\u4f4e\u96d9\u6975\u75c7 (bipolar disorder )\u75c5\u60a3\u7684\u81ea\u6bba\u98a8\n\u96aa\u3002   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(1)+(4)+(5)\nD.(3)+(4)+(5)\nE.(1)+(2)+(5)\n": "[E]", "109-193.\u4e0b\u5217\u6297\u6182\u9b31\u85e5\u7269\u8207\u526f\u4f5c\u7528\u7684\u914d\u5c0d\uff0c\u54ea \u3127\u7d44\u662f\u4e0d\u5e38\u898b\u7684\uff1f    \nA.\u9078\u64c7\u6027\u8840\u6e05\u7d20\u6291\u5236\u5291 (Selective Serotonin Reuptake Inhbitor: SSRI )\uff1a\u8178\u80c3\u4e0d\u9069 (nausea and other GI \neffects )\nB.\u4e09\u74b0\u6297\u6182\u9b31\u85e5(Tricyclic antidepressants: TCA):\uff1a\u53e3\u4e7e\u4fbf\u79d8(dry mouth and constipation)\nC.\u9078\u64c7\u6027\u8840\u6e05\u7d20\u6291\u5236\u5291(Selective Serotonin Reuptake Inhibitor: SSRI)\uff1a\u982d\u75db(headache)\nD.\u9078\u64c7\u6027\u65b0\u814e\u4e0a\u817a\u7d20\u8207\u8840\u6e05\u7d20\u518d\u5438\u6536\u6291\u5236\u5291 (Selective Norepinephrine /Serotonin Reuptake Inhibitors: \nSNRI): \u9670\u8396\u7570\u5e38\u52c3\u8d77 (priapism)\nE.\u4e09\u74b0\u6297\u6182\u9b31\u85e5(Tricyclic antidepressants: TCA)\uff1a\u9ad4\u91cd\u4e0a\u5347(weight gain)\n": "[D]", "110-151.\u95dc\u65bc\u91ab\u7642\u4eba\u54e1\u9762\u5c0d\u56b4\u91cd\u7279\u6b8a\u50b3\u67d3\u6027\u80ba\u708e\u6aa2\u75ab\u9694\u96e2\u7684\u5fc3\u7406\u58d3\u529b\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u9694\u96e2\u6aa2\u75ab\u6642\u9593 (duration of quarantine )\u8d8a\u9577\uff0c\u53ef\u80fd\u589e\u52a0\u5275\u50b7\u5f8c\u58d3\u529b\u75c7\u72c0 (post-traumatic stress \nsymptoms )\u98a8\u96aa\u3002\nB.\u8271\u9245\u5de5\u4f5c\u74b0\u5883\u53ca\u5167\u5728\u50f9\u503c\u885d\u7a81\u662f\u5fc3\u7406\u5c64\u9762\u885d\u64ca\u4f86\u6e90\u4e4b\u4e00\u3002\nC.\u88ab\u6aa2\u75ab\u9694\u96e2\u7684\u91ab\u7642\u4eba\u54e1 \uff0c\u6240\u53d7\u5230\u6a19\u7c64\u5316 (stigmatization )\u8ca0\u9762\u5f71\u97ff\u7a0b\u5ea6 \uff0c\u660e\u986f\u4f4e\u65bc\u88ab\u6aa2\u75ab\u9694\u96e2\u7684\u4e00\u822c\u5927\n\u773e\u3002\nD.\u91ab\u7642\u4eba\u54e1\u82e5\u66fe\u7d93\u6b77\u904e\u6aa2\u75ab\u9694\u96e2\uff0c\u7121\u8ad6\u662f\u5426\u88ab\u78ba\u8a3a\uff0c\u5fc3\u7406\u5c64\u9762\u885d\u64ca\u98a8\u96aa\u53ef\u80fd\u8f03\u4e00\u822c\u65cf\u7fa4\u70ba\u9ad8\u3002\nE.\u5c0d\u65bc\u75ab\u60c5\u671f\u9593\u9577\u671f\u65bc\u7b2c\u4e00\u7dda\u5de5\u4f5c\u4e4b\u91ab\u7642\u4eba\u54e1\uff0c\u5fc3\u7406\u5065\u5eb7\u95dc\u61f7\u9700\u8981\u7279\u5225\u88ab\u91cd\u8996\u3002\n": "[C]", "110-152.\u95dc\u65bc\u7126\u616e\u75be\u60a3(anxiety disorders)\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u9078\u64c7\u6027\u5931\u8a9e\u75c7(selective mutism)\u4e5f\u662f\u4e00\u7a2e\u7126\u616e\u75be\u60a3\u3002\nB.\u793e\u4ea4\u7126\u616e\u75c7(social anxiety disorder)\u7684\u767c\u75c5\u5e74\u9f61\u591a\u5728\u9752\u6625\u671f\u65e9\u671f(early adolescence)\u3002\nC.Selective serotonin reuptake inhibitors (SSRIs) \u4ee5\u53ca Serotonin \u2013noradrenaline reuptake inhibitors \n(SNRIs)\u662f\u5305\u62ec\u793e\u4ea4\u7126\u616e\u75c7\u4ee5\u53ca\u6050\u614c\u75c7\u7b49\u7126\u616e\u75be\u60a3\u7684\u6cbb\u7642\u9078\u9805 \u3002\nD.\u7126\u616e\u75be\u60a3\u7684\u6cbb\u7642\u6548\u679c\uff0c\u76ee\u524d\u8b49\u64da\u50be\u5411\u65bc\u85e5\u7269\u6cbb\u7642\u986f\u8457\u512a\u65bc\u5fc3\u7406\u6cbb\u7642\u3002\nE.\u7672\u7647(epilepsy)\u7684\u524d\u5146(aura)\u6216\u662f\u8d77\u59cb\u75c7\u72c0\uff0c\u4e5f\u6709\u53ef\u80fd\u4ee5\u7126\u616e\u75c7\u72c0\u4f86\u5448\u73fe\u3002\n": "[D]", "110-153.\u95dc\u65bc\u5404\u7a2e\u98f2\u98df\u75be\u60a3(eating disorders)\u7684\u63cf\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u98f2\u98df\u75be\u60a3\u500b\u6848\u5e38\u5171\u75c5\u7126\u616e\u4ee5\u53ca\u6182\u9b31\u75be\u60a3\u3002   \nB.\u53cd\u82bb\u969c\u7919 (rumination disorder) \u662f\u56e0\u70ba\u5641\u5fc3 (nausea)\uff0c\u4e0d\u81ea\u4e3b\u4e7e\u5614 (involuntary retching )\uff0c\u6216\u662f\u53cd\u80c3\u4f5c\n\u5614(disgust)\uff0c\u800c\u5c07\u5403\u9032\u53bb\u7684\u98df\u7269\u53cd\u6d41\u51fa\u4f86 (regurgitation )\u3002\nC.\u53ad\u98df\u75c7(anorexia nervosa )\u60a3\u8005\u65bc\u6d88\u5316\u9053\u7684\u75c7\u72c0\u5305\u62ec\u5ef6\u9072\u6027\u80c3\u6392\u7a7a (delayed gastric emptying )\u4ee5\u53ca\u80c3\u524d\n\u5ead\u8815\u52d5\u7570\u5e38 (altered antral motility )\u3002\nD.\u66b4\u98df\u75c7(bulimia nervosa )\u60a3\u8005\u65bc\u4ee3\u8b1d\u751f\u5316\u6aa2\u9a57\u7684\u7279\u5fb5\u53ef\u80fd\u5305\u62ec\u56e0\u70ba\u7009\u5291\u6feb\u7528\u5f15\u767c\u4e4b\u4ee3\u8b1d\u6027\u9178\u4e2d\n\u6bd2(metabolic acidosis )\u4ee5\u53ca\u904e\u5ea6\u5614\u5410\u9020\u6210\u7684\u4ee3\u8b1d\u6027\u9e7c\u4e2d\u6bd2 (metabolic alkalosis )\u3002\nE.\u8a8d\u77e5\u884c\u70ba\u6cbb\u7642(cognitive behavioural therapy, CBT)\u662f\u98f2\u98df\u75be\u60a3\u6cbb\u7642\u7684\u9996\u9078\u65b9\u5f0f\u4e4b\u4e00\u3002\n": "[B]", "110-154.\u95dc\u65bc\u7cbe\u795e\u79d1\u8a3a\u65b7\u7cfb\u7d71DSM -5\u5b9a\u7fa9\u7684\u8eab\u9ad4\u75c7\u72c0\u75be\u60a3 (somatic symptom disorders )\uff0c\u4e5f\u5c31\u662f\u904e\u53bb\u4fd7\u7a31\u591a\u91cd\u8eab\u9ad4\n\u62b1\u6028(multiple somatic compliants )\uff0c\u6b47\u65af\u5e95\u91cc\u75c7 (hysteria)\uff0c\u6216\u662f\u8eab\u9ad4\u5316\u75c7 (somoatoform disorder )\u500b\n\u6848\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6b63\u78ba \uff1a(1)\u5373\u4f7f\u75c5\u60a3\u8eab\u9ad4\u62b1\u6028\u67e5\u6709\u5be6\u64da \uff0c\u4f46\u500b\u6848\u5c0d\u5065\u5eb7\u6216\u75c7\u72c0\u6709\u6301\u7e8c\u6027\u9ad8\u5ea6\u7126\u616e \uff0c\u6295\u6ce8\u4e86\n\u904e\u591a\u7684\u6642\u9593\u548c\u7cbe\u529b \uff0c\u4e5f\u53ef\u4ee5\u7b26\u5408\u9019\u500b\u8a3a\u65b7 (2)\u5927\u91cf\u63a2\u7d22\u6027\u6aa2\u67e5\u6709\u52a9\u5b89\u64ab\u75c5\u60a3 (3)\u8207\u75c5\u60a3\u5c0d\u8cea (confront)\u8eab\u9ad4\n\u4e0d\u9069\u7684\u771f\u5be6\u6027 \uff0c\u6709\u52a9\u65bc\u6e1b\u7de9\u500b\u6848\u7126\u616e (4)\u90e8\u4efd\u75c5\u60a3\u53ef\u80fd\u5c0d\u65bc\u6297\u6182\u9b31\u85e5\u7269\u6709\u6cbb\u7642\u53cd\u61c9 \uff0c\u4f46\u5be6\u8b49\u6587\u737b\u4ecd\u4e0d\u8db3 \n(5)\u6301\u7e8c\u898f\u5f8b\u7684\u60c5\u7dd2\u652f\u6301 \uff0c\u4e26\u9010\u6f38\u767c\u5c55\u4e0d\u5b8c\u5168\u4ee5\u5c0b\u6c42\u8a3a\u65b7\u4ecb\u5165\u70ba\u76ee\u7684\u4e4b\u898f\u5247\u56de\u8a3a \uff0c\u6709\u52a9\u65bc\u500b\u6848\u8abf\u6574\u884c\u70ba \u3002   \nA.(1)+(2)+(3)\u3002\nB.(2)+(3)+(5)\u3002\nC.(3)+(4)+(5)\u3002\nD.(1)+(3)+(4)\u3002\nE.(1)+(4)+(5)\u3002\n": "[E]", "110-155.\u95dc\u65bc\u6297\u6182\u9b31\u85e5\u7269\u7684\u5e38\u898b\u526f\u4f5c\u7528 \uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u771f \uff1f(1)Fluoxetine (Prozac)\uff1a\u5641\u5fc3 (2)Doxepin \n(Sinequan )\uff1a\u8179\u7009 (3)Mirtazapine (Remeron )\uff1a\u9ad4\u91cd\u4e0a\u5347 (4)Duloxetine (Cymbalta )\uff1a\u982d\u75db (5)Bupropion \n(Wellbutrin )\uff1a\u6027\u529f\u80fd\u969c\u7919 \u3002   \nA.(1)+(2)+(3)\u3002\nB.(1)+(3)+(5)\u3002\nC.(2)+(3)+(4)\u3002\nD.(1)+(3)+(4)\u3002\nE.(3)+(4)+(5)\u3002\n": "[D]", "111-151.\u95dc\u65bc\u81ea\u6bba\u9632\u6cbb\u5de5\u4f5c\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u5f71\u8996\u540d\u4eba\u81ea\u6bba\u7684\u65b0\u805e\u5831\u5c0e\u8207\u81ea\u6bba\u7387\u589e\u52a0\u6709\u95dc\u3002\nB.\u9810\u9632\u81ea\u6bba\u5fc5\u9808\u5305\u62ec\u81e8\u5e8a\u8207\u793e\u6703\u652f\u6301\u7b49\u591a\u9762\u5411\u6295\u5165\u3002\nC.\u6c23\u5019\u8b8a\u9077(climate change)\u5c0e\u81f4\u4e4b\u81ea\u6bba\u548c\u81ea\u6b98\uff0c\u662f\u4e00\u500b\u9010\u6f38\u88ab\u91cd\u8996\u7684\u5168\u7403\u95dc\u9375\u98a8\u96aa\u56e0\u7d20\u3002\nD.\u4f7f\u7528\u85e5\u7269\u4f86\u59a5\u5584\u6cbb\u7642\u6f5b\u5728\u7684\u7cbe\u795e\u75be\u60a3\uff0c\u7121\u52a9\u65bc\u9810\u9632\u81ea\u6bba\u3002\nE.\u5c0d\u91ab\u7642\u4fdd\u5065\u5c08\u696d\u4eba\u54e1\u800c\u8a00 \uff0c\u7576\u6709\u60a3\u8005\u4e0d\u5e78\u81ea\u6bba\u8eab\u4ea1 \uff0c\u53ef\u80fd\u6703\u5728\u60c5\u7dd2\u8207\u5c08\u696d\u5de5\u4f5c\u4e0a\u9020\u6210\u885d\u64ca \uff0c\u70ba\u91ab\u7642\u4fdd\n\u5065\u5c08\u696d\u4eba\u54e1\u63d0\u4f9b\u652f\u6301\u4ee5\u53ca\u8eab\u5fc3\u7167\u9867\u662f\u91cd\u8981\u7684 \u3002   \n": "[D]", "111-152.\u95dc\u65bc\u6cbb\u7642 \u300c\u8ec0\u9ad4\u75c7\u72c0\u75be\u60a3 \u300d(somatic symptom disorder )\uff0c\u4e5f\u5c31\u662f\u904e\u53bb\u7a31\u4e4b\u70ba \u300c\u8eab\u9ad4\u5316\u75c7 \u300d(somatoform \ndisorder)\u9019\u985e\u5177\u6709 \u300c\u67e5\u7121\u5be6\u64da \u300d\u6216\u300c\u8a00\u904e\u5176\u5be6 \u300d\u8eab\u9ad4\u62b1\u6028\u7684\u60a3\u8005 \uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u975e \uff1f   \nA.\u8ec0\u9ad4\u75c7\u72c0\u75be\u60a3\u500b\u6848\uff0c\u7d93\u5e38\u63a5\u53d7\u8a31\u591a\u8a3a\u65b7\u6aa2\u67e5\u548c\u63a2\u7d22\u6027\u624b\u8853\uff0c\u8a66\u5716\u627e\u5230\u4ed6\u5011\u300c\u771f\u6b63\u300d\u7684\u75be\u75c5\u3002\nB.\u6297\u6182\u9b31\u85e5\u7269\u5c0d\u65bc\u8ec0\u9ad4\u75c7\u72c0\u75be\u60a3\u500b\u6848\u7684\u75c7\u72c0\u7de9\u89e3\u5b8c\u5168\u7121\u6548\u3002\nC.\u4efb\u4f55\u8207\u60a3\u8005\u5c0d\u8cea (confrontation )\u5176\u5fc3\u7406\u6b78\u56e0\u7684\u5617\u8a66 \uff0c\u901a\u5e38\u90fd\u6703\u7522\u751f\u7f9e\u8fb1\u611f \uff0c\u5c0e\u81f4\u60a3\u8005\u653e\u68c4\u8a72\u91ab\u7642\u4eba\u54e1\n\u7684\u6cbb\u7642\uff0c\u6301\u7e8c\u904a\u8d70\u5c31\u91ab \u3002\nD.\u6bd4\u8f03\u6709\u5e6b\u52a9\u7684\u7b56\u7565\u662f\u5f15\u5165\u5fc3\u7406\u56e0\u679c\u95dc\u4fc2\u4f5c\u70ba\u8a0e\u8ad6\u9451\u5225\u8a3a\u65b7\u4e2d\u7684\u8a31\u591a\u53ef\u80fd\u89e3\u91cb\u4e4b\u4e00\u3002\nE.\u5728\u907f\u514d\u5c07\u5fc3\u7406\u56e0\u7d20\u4f5c\u70ba\u60a3\u8005\u8eab\u9ad4\u62b1\u6028\u75c5\u56e0\u552f\u4e00\u89e3\u91cb\u7684\u6c1b\u570d\u4e0b \uff0c\u53ef\u4ee5\u70ba\u60a3\u8005\u4fdd\u7559\u9762\u5b50 \uff0c\u901a\u904e\u9019\u7a2e\u9593\u63a5\u7a00\n\u91cb\u5fc3\u7406\u6b78\u56e0\u7684\u65b9\u5f0f \uff0c\u53cd\u800c\u6709\u6a5f\u6703\u767c\u5c55\u51fa\u8abf\u6574\u60a3\u8005\u751f\u6d3b\u58d3\u529b\u6e90\u7684\u65b9\u6cd5 \u3002\n": "[B]", "111-153.\u95dc\u65bc\u6182\u9b31\u75c7\u8207\u8eab\u9ad4\u75be\u75c5\u7684\u95dc\u806f\u6027\uff0c\u9805\u5217\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u5728\u764c\u75c7\u60a3\u8005\u4e2d \uff0c\u6182\u9b31\u75c7\u7684\u5e73\u5747\u7f79\u75c5\u7387\u53ef\u4ee5\u9ad8\u9054 25 %\uff0c\u800c40-50% \u7684\u80f0\u81df\u764c\u6216\u53e3\u54bd\u764c\u60a3\u8005\u6703\u51fa\u73fe\u6182\u9b31\n\u75c7\u3002\nB.\u80f0\u81df\u764c\u8207\u6182\u9b31\u75c7\u7684\u95dc\u806f\u4e0d\u50c5\u50c5\u7531\u65bc\u60e1\u75c5\u8cea (cachexia )\u5f71\u97ff\uff0c\u8207\u665a\u671f\u80c3\u764c\u60a3\u8005\u76f8\u6bd4 \uff0c\u80f0\u81df\u764c\u60a3\u8005\u7684\u6182\u9b31\n\u75c7\u60a3\u75c5\u7387\u660e\u986f\u8f03\u9ad8 \u3002\nC.\u4e0d\u7a69\u5b9a\u578b\u5fc3\u7d5e\u75db \u3001\u5fc3\u808c\u6897\u585e \u3001\u5fc3\u81df\u7e5e\u9053\u624b\u8853\u6216\u5fc3\u81df\u79fb\u690d\u5f8c\u60a3\u8005 \uff0c\u82e5\u767c\u751f\u6182\u9b31\u75c7\u72c0 \uff0c\u88ab\u8b49\u660e\u6703\u5f71\u97ff\u5eb7\n\u5fa9\uff0c\u4e26\u8207\u65e5\u5f8c\u8f03\u9ad8\u7684\u6b7b\u4ea1\u7387 (mortality )\u548c\u91ab\u7642\u767c\u75c5\u7387 (morbidity )\u76f8\u95dc\u3002\nD.\u7cd6\u5c3f\u75c5\u60a3\u8005\u7684\u6182\u9b31\u75c7\u60a3\u75c5\u7387\u5f9e 8% \u5230 27% \u4e0d\u7b49 \uff0c\u6182\u9b31\u60c5\u7dd2\u7684\u56b4\u91cd\u7a0b\u5ea6 \uff0c\u8207\u9ad8\u8840\u7cd6\u7a0b\u5ea6 (level of \nhyperglycemia )\u548c\u7cd6\u5c3f\u75c5\u4f75\u767c\u75c7\u7684\u98a8\u96aa\u76f8\u95dc \u3002\nE.\u4e09\u74b0\u6297\u6182\u9b31\u85e5(TCA)\u6703\u7522\u751f\u4f4e\u8840\u7cd6\u548c\u5c0d\u78b3\u6c34\u5316\u5408\u7269\u7684\u5acc\u60e1\u3002\n": "[E]", "111-154.\u95dc\u65bc\u96fb\u6c23\u75d9\u6523\u6cbb\u7642\u6cd5 (Electroconvulsive Therapy, ECT )\u7684\u6558\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u662f \uff1f\n(1) \u5728\u7279\u5b9a\u65cf\u7fa4\u4e2d \uff0cECT \u53ef\u4ee5\u8fc5\u901f\u6539\u5584\u6182\u9b31 \u3001\u7cbe\u795e\u75c5\u548c\u7dca\u5f35 (catatonia )\u75c7\u72c0\uff0c\u4e26\u53ef\u4ee5\u6e1b\u5c11\u81ea\u6bba\u885d\u52d5\n(2) \u8207 ECT \u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\u5f88\u7f55\u898b \uff0c\u5305\u62ec\u5fc3\u5f8b\u4e0d\u6574\u8207\u547c\u5438\u7a98\u8feb\u7b49\n(3) \u5728\u4e00\u9805\u6d89\u53ca\u96e3\u6cbb\u578b\u7cbe\u795e\u5206\u88c2\u75c7\u60a3\u8005\u7684\u7814\u7a76\u4e2d \uff0cECT \u6709\u6548\u7387\u5728 80% \u5230 90% \u4e4b\u9593\n(4) ECT \u7684\u4f30\u8a08\u6b7b\u4ea1\u7387\u7d04\u70ba\u6bcf 100 ,000 \u6b21\u6cbb\u7642\u4e2d\u6709 21 \u4eba\u6b7b\u4ea1\n(5) \u73fe\u4ee3\u5316\u7684ECT \u7684\u6cbb\u7642\u6d41\u7a0b\u5305\u62ec\u8a98\u5c0e\u77ed\u66ab\u7684\u5168\u8eab\u9ebb\u9189 \uff08\u901a\u5e38\u6301\u7e8c\u4e0d\u5230 10 \u5206\u9418\uff09\u3001 \u85e5\u7269\u6027\u808c\u8089\u653e\u9b06 \uff0c\u4ee5\n\u53ca\u6301\u7e8c\u76e3\u6e2c\u8840\u6c27\u98fd\u548c\u5ea6 \u3001\u8840\u58d3\u3001\u5fc3\u7387\u548c\u7bc0\u5f8b   \nA.(1)+(2)+(3)\u3002\nB.(1)+(3)+(5)\u3002\nC.(2)+(3)+(4)\u3002\nD.(1)+(2)+(5)\u3002\nE.(3)+(4)+(5)\u3002\n": "[D]", "111-155.\u95dc\u65bc\u8b6b\u5984 (delirium)\u4e0b\u5217\u4f55\u8005\u70ba\u662f \uff1f\n(1) \u4f4f\u9662\u75c5\u60a3\u7684\u8b6b\u5984\u98a8\u96aa\u56e0\u5b50\u5305\u62ec \uff1a\u4f7f\u7528\u8180\u80f1\u5c0e\u7ba1\u63d2\u5165\u8853 \u3001\u8eab\u9ad4\u7d04\u675f \u3001\u7761\u7720\u548c\u611f\u89ba\u525d\u596a \uff0c\u4ee5\u53ca\u6dfb\u52a0\u4e09\u7a2e\u6216\n\u66f4\u591a\u7684\u65b0\u85e5\u7269\n(2) \u8b6b\u5984\u60a3\u8005\u7684\u4f4f\u9662\u6b7b\u4ea1\u7387\u4f30\u8a08\u5728 2% \u5230 4% \u4e4b\u9593\uff0c\u9060\u4f4e\u65bc\u6557\u8840\u75c7\u5f15\u8d77\u7684\u6b7b\u4ea1\u7387\n(3) \u85e5\u7269\u4ecd\u7136\u662f\u8b6b\u5984\u7684\u9810\u9632\u53ca\u4fdd\u8b77\u56e0\u5b50 \uff0c\u5c24\u5176\u662f\u5177\u6709\u6297\u81bd\u9e7c\u6216\u93ae\u975c\u7279\u6027\u7684\u85e5\u7269\n(4) \u76f2\u76ee\u5730\u91dd\u5c0d\u8b6b\u5984\u75c7\u72c0\u9032\u884c\u85e5\u7269\u6cbb\u7642\u53ea\u6703\u5ef6\u9577\u60a3\u8005\u8655\u65bc\u6df7\u4e82\u72c0\u614b\u7684\u6642\u9593 \uff0c\u4e26\u53ef\u80fd\u63a9\u84cb\u91cd\u8981\u7684\u6f5b\u5728\u75c5\u56e0\u8a3a\n\u65b7\u7dda\u7d22\n(5) \u61c9\u907f\u514d\u5316\u5b78\u7d04\u675f (chemical restrain )\uff0c\u5fc5\u8981\u6642\u4f7f\u7528\u6975\u4f4e\u5291\u91cf\u7684\u5178\u578b\u6216\u975e\u5178\u578b\u6297\u7cbe\u795e\u75c5\u85e5\u7269 \uff0c\u4e14\u61c9\u8a72\u7559\u7d66\n\u56b4\u91cd\u8e81\u52d5\u548c\u660e\u986f\u53ef\u80fd\u50b7\u5bb3\u81ea\u5df1\u6216\u5de5\u4f5c\u4eba\u54e1\u7684\u60a3\u8005   \nA.(1)+(2)+(3)\u3002\nB.(1)+(3)+(5)\u3002   \nC.(2)+(3)+(4)\u3002\nD.(3)+(4)+(5)\u3002\nE.(1)+(4)+(5)\u3002\n": "[E]", "100-1.\n\u4e00\u4f4d30\u6b72\u7537\u6027\u8d74\u6771\u5357\u4e9e\u65c5\u904a\uff0c\u56de\u570b\u5f8c\u56db\u500b\u6708\u51fa\u73fe\u5982\u5716\u4e4b\u76ae\u75b9\uff0c\u4e0b?\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. \u6885\u6bd2 (syphilis)\nB. \u767b\u9769\u71b1(dengue fever)\nC. \u6dcb\u75c5(gonorrhea)\nD. \u624b\u53e3\u8db3\u75c7(hand-foot-mouth disease)\nE. \u73ab\u7470\u7ce0\u75b9(pityriasis rosea)\n": "(A)", "100-2.\n\u6709\u95dc\u5982\u5716\u6240\u793a\u5287\u7662\u3001\u53cd\u8986\u767c\u751f\u4e4b\u76ae\u819a\u75c5\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u8207\u5bb6\u65cf\u907a\u50b3\u6709\u95dc\nB. \u8840\u6db2\u4e2dIgE\u5e38\u9ad8\u65bc\u6b63\u5e38\u4eba\nC. \u5728\u53f0\u7063\u5e38\u898b\u5c0d\u5875\u9862\u904e\u654f\nD. \u5c45\u4f4f\u74b0\u5883\u8d8a\u4e7e\u71e5\u8d8a\u597d\nE. \u53ef\u7528\u985e\u56fa\u9187\u85e5\u818f\u6cbb\u7642\n": "(D)", "100-3.\n\u5982\u5716\u6240\u793a\u4e4b\u76ae\u819a\u816b\u7624\u662f\uff1f\nA. \u68d8\u7d30\u80de\u764c (squamous cell carcinoma)\nB. \u57fa\u5e95\u7d30\u80de\u764c (basal cell carcinoma)\nC. \u6ce2\u6587\u6c0f\u75c7 (Bowen's disease)\nD. \u60e1\u6027\u9ed1\u7d20\u7624 (malignant melanoma)\nE. \u8840\u7ba1\u8089\u7624 (angiosarcoma)\n": "(B)", "100-4.\n\u4ee5\u4e0b\u6709\u95dc\u5982\u5716\u6240\u793a\u76ae\u819a\u75c5\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f\nA. \u6709Auspitz sign\u548cKoebner phenomenon\nB. \u53e3\u670d\u76ae\u8cea\u985e\u56fa\u9187\u53ef\u5f97\u5f88\u597d\u7684\u6548\u679c\uff0c\u662f\u6cbb\u7642\u7684\u9996\u9078\nC. \u92f0\u9e7d\u3001\u6297\u7627\u5291\u3001\u9152\u7cbe\u53ca\u4e59\u578b\u963b\u65b7\u5291\u7684\u6295\u4e88\u6703\u52a0\u91cd\u75c5\u60c5\nD. \u5354\u52a9\u8005T\u7d30\u80de\u5341\u4e03\u578b(Th17) \u8207 T\u7d30\u80de\u4e00\u578b\uff08Th1\uff09\u4e4b\u6d3b\u5316\u88ab\u8a8d\u70ba\u662f\u5f15\u767c\u4e7e\u766c\u7684\u91cd\u8981\u6a5f\u8f49\nE. \u53ef\u7167\u5c04\u7a84\u6ce2\u7d2b\u5916B\u5149(311nm)\u4f86\u6cbb\u7642\n": "(B)", "100-5.\n\u6709\u95dc\u809d\u6591 (chloasma, melasma)\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u4e3b\u8981\u767c\u751f\u65bc\u984f\u9762\u7684\u5c0d\u7a31\u6027\u8272\u7d20\u6591\nB. \u809d\u529f\u80fd\u7570\u5e38\u8005\u5e38\u898b\nC. \u53e3\u670d\u907f\u5b55\u85e5\u70ba\u53ef\u80fd\u75c5\u56e0\u4e4b\u4e00\nD. \u60a3\u8005\u61c9\u907f\u514d\u967d\u5149\u7167\u5c04\nE. \u7528\u7d05\u5bf6\u77f3\u96f7\u5c04(Ruby laser)\u6cbb\u7642\u53cd\u800c\u6703\u60e1\u5316\u75c5\u60c5\n": "(B)", "100-6.\n\u4e00\u4f4d40\u6b72\u5973\u6027\uff0c\u8fd1\u534a\u5e74\u4f86\u5728\u81c9\u90e8\u3001\u9838\u90e8\u8207\u524d\u80f8\u90e8\u76ae\u819a\uff0c\u51fa\u73fe\u5982\u5716\u4e4b\u8868\u73fe\u3002\u95dc\u65bc\u8a72\u60a3\u8005\u8a3a\u65b7\u8207\u6cbb\u7642\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u76ae\u819a\u75c5\u7406\u6709\u660e\u986f\u767c\u708e\u53cd\u61c9\uff0c\u9020\u6210\u8272\u7d20\u812b\u5931\r2.\u76ae\u819a\u9ed1\u8272\u7d20\u7d30\u80de\u6578\u76ee\u6e1b\u5c11\r3.\u61c9\u505a\u7532\u72c0\u817a\u529f\u80fd\u8207\u6297\u9ad4\u7684\u6aa2\u67e5\r4.UVB1\uff08311nm\uff09\u7a84\u6ce2\u7d2b\u5916\u5149\u53ef\u4fc3\u9032\u8272\u7d20\u56de\u5fa9\nA. 1+3\nB. 2+4\nC. 1+2+3\nD. 2+3+4\nE. 1+2+3+4\n": "(D)", "100-7.\n\u4e0b\u5217\u95dc\u65bc\u8541\u9ebb\u75b9(urticaria)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u662f\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u8541\u9ebb\u75b9\u4e4b\u55ae\u4e00\u75c5\u7076\u5e38\u6301\u7e8c24 \u5c0f\u6642\u4ee5\u4e0a\r2.\u4e5f\u662f\u904e\u654f\u6027\u4f11\u514b(anaphylaxis)\u7684\u76ae\u819a\u8868\u73fe\r3.\u4e00\u5b9a\u662f\u85e5\u7269\u904e\u654f\u6240\u5f15\u8d77\r4.\u4f75\u7528aspirin\uff0c\u53ef\u80fd\u6703\u4f7f\u6b64\u75c5\u60e1\u5316\nA. 1+3\nB. 2+4\nC. 1+2+3\nD. 2+3+4\nE. 1+2+3+4\n": "(B)", "101-1.\n\u4e00\u4f4d30\u6b72\u7537\u6027\u8d74\u6771\u5357\u4e9e\u65c5\u904a\uff0c\u56de\u570b\u5f8c\u56db\u500b\u6708\u51fa\u73fe\u624b\u638c\u8173\u638c\u76ae\u75b9\uff0c\u540c\u6642\uff0c\u5168\u8eab\u4e5f\u6709\u7d05\u75b9(\u5982\u5716\u6240\u793a\uff09\u3002\u4ee5\u4e0b\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. \u5fc3\u5167\u819c\u708e(endocarditis)\nB. \u767b\u9769\u71b1(dengue fever)\nC. \u6dcb\u75c5(gonorrhea)\nD. \u6885\u6bd2 (syphilis)\nE. \u611b\u6ecb\u75c5\uff08AIDS\uff09\n": "(D)", "101-2.\n\u4e00\u4f4d65 \u6b72\u5973\u6027\uff0c\u8eab\u6750\u80a5\u80d6\uff0c\u7f79\u60a3\u7cd6\u5c3f\u75c510\u5e74\uff0c\u4f46\u4e0d\u898f\u5247\u5c31\u91ab\u670d\u85e5\uff0c\u4e00\u661f\u671f\u524d\u5728\u4e73\u623f\u4e0b\u51fa\u73fe\u523a\u7662\u7684\u7d05\u8272\u6591(\u5982\u5716\u6240\u793a)\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. \u81bf\u75c2\u75b9\uff08impetigo\uff09\nB. \u55ae\u7d14\u6027\u76b0\u75b9\u75c5\u6bd2\u611f\u67d3\uff08herpes simplex virus infection\uff09\nC. \u76ae\u819a\u5ff5\u73e0\u83cc\u611f\u67d3\uff08cutaneous candidiasis\uff09\nD. \u6bdb\u56ca\u708e\uff08folliculitis\uff09\nE. \u9ad4\u766c (tinea corporis)\n": "(C)", "101-3.\n\u4e0b\u5217\u95dc\u65bc\u8541\u9ebb\u75b9(urticaria)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5e38\u7528\u6297\u7d44\u7e54\u80fa\u85e5\u7269\u6cbb\u7642\nB. \u6240\u6709\u7684\u75c5\u4eba\u7686\u53ef\u627e\u51fa\u539f\u56e0\nC. \u4f75\u7528aspirin\uff0c\u5e38\u4f7f\u6b64\u75c5\u60e1\u5316\nD. \u8541\u9ebb\u75b9\u4e4b\u55ae\u4e00\u75c5\u7076\u5e38\u572824 \u5c0f\u6642\u5167\u6d88\u5931\nE. \u61c9\u5148\u8a62\u554f\u75c5\u4eba\u7684\u7528\u85e5\u53f2\n": "(B)", "101-4.\n\u5982\u5716\u6240\u793a\u7684\u591a\u767c\u6027\u76ae\u75b9\uff0c \u4ee5\u4e0b\u7684\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u5b83\u6e90\u65bc\u7e96\u7dad\u82bd\u7d30\u80de(fibroblast)\nB. \u597d\u767c\u65bc\u4e0b\u80a2\nC. \u5e38\u898b\u65bc\u9752\u5e74\u4eba\nD. \u77ed\u671f\u5167\u5168\u8eab\u51fa\u73fe\u5f88\u591a\u6642\uff0c\u61c9\u61f7\u7591\u662f\u5426\u5408\u4f75\u5167\u81df\u764c\nE. \u5f88\u5bb9\u6613\u8f49\u8b8a\u6210\u57fa\u5e95\u7d30\u80de\u764c\n": "(D)", "101-5.\n\u5982\u5716\u6240\u793a\u7684\u591a\u767c\u6027\u76ae\u75b9\uff0c \u4ee5\u4e0b\u7684\u6558\u8ff0\u4f55\u8005\u70ba\u932f\u8aa4\uff1f\nA. \u6709Auspitz sign\u548cKoebner phenomenon\nB. \u92f0\u9e7d\u3001\u6297\u7627\u5291\u3001\u9152\u7cbe\u53ca\u4e59\u578b\u963b\u65b7\u5291\u6703\u52a0\u91cd\u75c5\u60c5\nC. \u5354\u52a9\u8005T\u7d30\u80de\u4e00\u578b\uff08Th1\uff09\u8207T\u7d30\u80de\u5341\u4e03\u578b(Th17)\u514d\u75ab\u53cd\u61c9\u88ab\u8a8d\u70ba\u662f\u5f15\u767c\u6b64\u75c5\u7684\u91cd\u8981\u6a5f\u8f49\nD. \u53e3\u670d\u76ae\u8cea\u985e\u56fa\u9187\u53ef\u5f97\u5f88\u597d\u7684\u6548\u679c\uff0c\u662f\u6cbb\u7642\u7684\u9996\u9078\nE. \u75c5\u60a3\u6709\u8f03\u9ad8\u6bd4\u4f8b\u4f75\u6709metabolic syndrome\n": "(D)", "101-6.\n\u6709\u95dc\u5982\u5716\u6240\u793a\u76ae\u819a\u8272\u7d20\u6591\uff0c\u4ee5\u4e0b\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u662f\u8868\u76ae\u5c64\u7684\u9ed1\u8272\u7d20\u589e\u52a0\u9020\u6210\nB. \u809d\u529f\u80fd\u7570\u5e38\u8005\u5e38\u898b\nC. \u53e3\u670d\u907f\u5b55\u85e5\u70ba\u53ef\u80fd\u75c5\u56e0\u4e4b\u4e00\nD. \u60a3\u8005\u61c9\u907f\u514d\u967d\u5149\u7167\u5c04\nE. \u96f7\u5c04\u6703\u4f7f\u4e4b\u60e1\u5316\n": "(B)", "101-7.\n\u4e0b\u5217\u4f55\u8005\u4e0d\u662f\u611b\u6ecb\u75c5\u4e4b\u5e38\u898b\u76ae\u819a\u75c5\u8b8a\uff1f\nA. \u5361\u6ce2\u897f\u6c0f\u8089\u7624\uff08Kaposi's sarcoma\uff09\nB. \u6cdb\u767c\u6027\u8edf\u75a3\uff08disseminated molluscum contagiosum\uff09\nC. \u65e5\u5149\u654f\u611f\u6027\u76ae\u819a\u708e\uff08photosensitive dermatitis\uff09\nD. \u53e3\u8154\u6bdb\u72c0\u9ecf\u819c\u767d\u6591\uff08oral hairy leukoplakia\uff09\nE. \u809b\u9580\u5468\u570d\u5c16\u75a3 \uff08perianal condyloma acuminatum\uff09\n": "(C)", "102-1.\n\u4e00\u4f4d30\u6b72\u7537\u6027\u8d74\u6771\u5357\u4e9e\u65c5\u904a\uff0c\u56de\u570b\u5f8c\u56db\u500b\u6708\u51fa\u73fe\u624b\u638c\u8173\u638c\u76ae\u75b9\uff0c\u540c\u6642\uff0c\u5168\u8eab\u4e5f\u6709\u7d05\u75b9(\u5982\u5716\u793a),\u4ee5\u4e0b\u4f55\u8005\u662f\u5fc5\u8981\u8655\u7f6e? (1)\u8a62\u554f\u7528\u85e5\u53f2 (2)\u8a62\u554f\u6027\u884c\u70ba\u53f2 (3)\u6aa2\u6e2cTPHA\uff0cVDR\u6216RPR (4)\u6aa2\u6e2crubella IgM (5)\u6aa2\u6e2c\u809d\u529f\u80fd\nA. (1)+(3)+(5)\nB. (1)+(4)+(5)\nC. (1)+(2)+(3)\nD. (2)+(3)+(4)\nE. (2)+(3)+(5)\n": "(C)", "102-2.\n\u4e00\u4f4d40\u6b72\u5973\u6027\uff0c\u8fd1\u534a\u5e74\u4f86\u5728\u81c9\u90e8\u3001\u9838\u90e8\u8207\u524d\u80f8\u90e8\u76ae\u819a\uff0c\u51fa\u73fe\u5982\u5716\u4e4b\u8868\u73fe\u3002\u95dc\u65bc\u8a72\u75be\u75c5\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(1) \u8868\u76ae\u9ed1\u8272\u7d20\u7d30\u80de\u6578\u76ee\u6e1b\u5c11\u6216\u6d88\u5931 (2)\u6bdb\u56ca\u9ed1\u8272\u7d20\u7d30\u80de\u6578\u76ee\u6b63\u5e38 (3)\u61c9\u505a\u7532\u72c0\u817a\u529f\u80fd\u8207\u6297\u9ad4\u7684\u6aa2\u67e5 (4)UVB1\uff08311nm\uff09\u7a84\u6ce2\u7d2b\u5916\u5149\u53ef\u4fc3\u9032\u8272\u7d20\u56de\u5fa9 (5)\u76ae\u819a\u75c5\u7406\u6709\u660e\u986f\u767c\u708e\u53cd\u61c9\uff0c\u9020\u6210\u8272\u7d20\u812b\u5931\nA. (1)+(2)+(3)+(5)\nB. (1)+(3)+(4)+(5)\nC. (1)+(2)+(4)+(5)\nD. (1)+(2)+(3)+(4)\nE. (2)+(3)+(4)+(5)\n": "(D)", "102-3.\n\u6b64\u4e0055\u6b72\u7537\u6027\uff0c\u5728\u81c9\u4e0a\u53ca\u4e0a\u8ec0\u5e79\u767c\u751f\u591a\u767c\u6027\u5982\u5716\u793a\u4e4b\u7d05\u75b9\uff0c\u9996\u5148\u8981\u8003\u616e\u4ed6\u6709\u4ee5\u4e0b\u4f55\u7a2e\u75be\u75c5\uff1f\nA. Liver cirrhosis\nB. Erythema multiforma\nC. Photosensitive dermatitis\nD. Systemic lupus erythematosus\nE. Rosacea\n": "(A)", "102-4.\n\u5982\u5716\u793a\u4e4b\u4e0d\u7662\u3001\u4e0d\u75db\u3001\u7121\u9e9f\u5c51\u76ae\u75b9\u767c\u751f\u65bc\u81c9\u4e0a\u5df2\u67092\u500b\u6708\uff0c\u8a3a\u65b7\u662f\uff1f\nA. Systemic lupus erythematosus\nB. Contact dermatitis\nC. Rosacea\nD. Sun burn\nE. Seborrheic dermatitis\n": "(A)", "102-5.\n\u6b64\u75c5\u60a3\u53cd\u8986\u767c\u751f\u5982\u5716\u793a\u76ae\u75b9\u5df2\u67093\u500b\u6708\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u61c9\u8a62\u554f\u662f\u5426\u6b63\u4f7f\u7528NSAID (nonsteroidal antinflammatory drug)\nB. \u61c9\u8a62\u554f\u662f\u5426\u6b63\u4f7f\u7528angiotensin- converting enzyme inhibitors\nC. \u61c9\u8a62\u554f\u500b\u5225\u7684\u76ae\u75b9\u662f\u4e0d\u662f24\u5c0f\u6642\u5167\u6703\u6d88\u5931\nD. \u61c9\u8a62\u554f\u662f\u5426\u6709\u4f34\u96a8\u7684\u75c7\u72c0\nE. \u53ea\u6709\u505aantigen specific IgE \u6aa2\u6e2c\uff0c\u624d\u80fd\u627e\u51fa\u771f\u6b63\u7684\u539f\u56e0\n": "(E)", "102-6.\n\u5982\u5716\u793a\u76ae\u75b9\uff0c\u4f75\u6709\u795e\u7d93\u75db\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u8a3a\u65b7\u662fherpes zoster\nB. \u767c\u751f\u5728cranial nerve V1 branch\nC. \u61c9\u505a\u773c\u79d1\u6aa2\u67e5\nD. \u6700\u4f73\u8655\u7f6e\u662facyclovir\u7684\u76f4\u63a5IV push\nE. 65\u6b72\u4ee5\u4e0a\u8001\u4eba\u5f8c\u907a\u7684\u795e\u7d93\u75db\u4e00\u822c\u8f03\u56b4\u91cd\u4e5f\u8f03\u6301\u4e45\n": "(D)", "102-7.\n\u4e00\u4f4d\u5be6\u7fd2\u91ab\u5e2b\u7a81\u7136\u5728\u81c9\u90e8\u53ca\u8ec0\u5e79\u767c\u751f\u5982\u5716\u793a\u7684\u76ae\u75b9\uff0c\u4f75\u6709\u767c\u71d2\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1f\nA. Varicella\nB. Stevens-Johnson syndrome\nC. Rubella\nD. Sudamina\nE. Pityriasis lichenoides et varioliformis acuta\n": "(A)", "103-1.\n\u4e0024\u6b72\u7537\u6027\uff0c\u56e02 \u661f\u671f\u4ee5\u4f86fever, chills, malaise and fatigue\u81f3\u6025\u8a3a\u5c31\u91ab\u3002\u4ed6\u8fd1\u671f\u66fe\u53bb\u6cf0\u570b\u65c5\u904a\u4e26\u5ad6\u5993\u3002 \u4ed6\u611f\u89ba\u5589\u56a8\u75db\uff0c\u53e3\u8154\u4e26\u6709painful sores; \u5168\u8eab\u53ca\u56db\u80a2\u6709 diffuse erythematous rash\u3002 \u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\uff1a\u9ad4\u6eab38.2\u00b0C, \u8840\u58d3 130/78 mmHg, \u8108\u640f99/min, \u547c\u543812/min\u3002\u5728groins \u53ca supraclavicular region \u6709non-tender lymphadenopathy\u3002\u7121\u95dc\u7bc0\u816b\u8139\u6216\u75bc\u75db\u3002\u4e0b\u4e00\u6b65\u61c9\u505a\u4ee5\u4e0b\u4f55\u7a2e\u6aa2\u67e5\uff1f(1) HIV viral load (2) Parvovirus B19 IgM antibody assay\uff1b(3) Rapid plasma reagin test (4) Heterophile antibody test  (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(2)+(3)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(A)", "103-2.\n\u4e00\u4f4d50\u6b72\u7537\u6027\uff0c\u767c\u751f\u5982\u5716\u6240\u793a\u4e4b\u5168\u8eab\u76ae\u819a\u7d05\u75b9\uff0c\u8986\u84cb\u5168\u8eab\u7d0410%\u9762\u7a4d\u3002\u53cd\u53cd\u8986\u8986\u5df2\u67092\u5e74\uff0c\u8acb\u554f\u4ee5\u4e0b\u4f55\u8005\u70ba\u9069\u7576\u8655\u7f6e\uff1f  (1) \u53e3\u670d\u985e\u56fa\u9187 (2) \u5857\u62b9\u985e\u56fa\u9187\u85e5\u818f (3) \u53e3\u670dcalcipotriol (4) \u5857\u62b9calcipotriol\u85e5\u818f (5) \u7a84\u6ce2311nm\u7d2b\u5916\u7ddaB\u7167\u5c04\u6cbb\u7642\u3002 (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(3)+(5)\nB. (2)+(4)+(5)\nC. (1)+(2)+(3)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)+(4)+(5)\n": "(B)", "103-3.\n\u4e0058\u6b72\u7537\u6027\uff0c\u76ae\u819a\u7662\u53ca\u812b\u5c51\u5df2\u67093\u5e74\u3002\u8fd13\u500b\u6708\u4ee5\u4f86\uff0c\u7531\u6591\u584a\u8b8a\u6210\u5168\u8eab\u767c\u7d05\u3002\u76ae\u819a\u5287\u7662\u81f3\u6703\u5e72\u64fe\u751f\u6d3b\u7684\u7a0b\u5ea6\u3002\u7528\u85e5\u65b9\u9762\u53ea\u6709\u8fd15\u5e74\u4f86\u4f7f\u7528lisinpril\u63a7\u5236\u9ad8\u8840\u58d3\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fevital signs\u90fd\u6b63\u5e38\u3002\u9ad4\u8868\u5982\u5716\u6240\u793a90%\u76ae\u819a\u90fd\u767c\u7d05\u4e26\u812b\u5c51\uff0c\u800c\u4e14\u6709alopecia, thickening of nails, palms and soles, generalized lymphadenopathy\u3002\u4ee5\u4e0b\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. Drug hypersensitivity reaction\nB. Pustular psoriasis\nC. Staphylococcal scalded skin syndrome\nD. Cutaneous T-cell lymphoma\nE. Atopic dermatitis\n": "(D)", "103-4.\n\u5982\u5716\u6240\u793a\u81c9\u90e8\u7684\u6162\u6027\u589e\u5927\u55ae\u4e00\u816b\u584a\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. Basal cell carcinoma\nB. Melanoma\nC. Seborrheic keratosis\nD. Sebaceous carcinoma\nE. Squamous cell carcinoma\n": "(A)", "103-5.\n\u4e00\u4f4f\u5b89\u990a\u9662\u8001\u4eba\u65bc\u8eab\u4e0a\u3001\u56db\u80a2\u53ca\u751f\u6b96\u5668\u767c\u751f(\u5982\u5716A\u53ca\u5716B)\u5287\u7662\u76ae\u75b9\u5df2\u67092\u500b\u6708\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fevital signs\u90fd\u6b63\u5e38\u3002\u61c9\u4f5c\u4f55\u7a2e\u6aa2\u67e5\u4ee5\u78ba\u5b9a\u8a3a\u65b7\uff1f\nA. Complete blood count\nB. Serum tissue transglutaminase level\nC. Skin biopsy for direct immunofluorescence microscopy\nD. Microscopic evaluation of skin scraping\nE. Thyroid function test\n": "(D)", "103-6.\n\u4e0037\u6b72\u7537\u6027\u5728\u53f3\u817f\u767c\u751f\u7d05\u3001\u816b\u3001\u71b1\u3001\u75db\u5df2\u67092\u5929(\u5982\u5716A\u53ca\u5716B)\u3002\u4ed6\u6709\u9999\u6e2f\u8173\uff0c\u7121\u6162\u6027\u817f\u90e8\u6c34\u816b\u75c5\u53f2\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u9ad4\u6eab38.4\u00b0 C; \u5176\u4ed6vital signs\u90fd\u6b63\u5e38\u3002BMI 30 kg/m2. \u8acb\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. Cellulitis\nB. Contact dermatitis\nC. Insect bite reaction\nD. Stasis dermatitis\nE. Erythema nodosum\n": "(A)", "103-7.\n\u4e00\u7537\u6027\u75c5\u60a3\u5728\u80ef\u4e0b\u767c\u751f\u5982\u5716\u6240\u793a\u6703\u7662\u76ae\u75b9\uff0c\u81f3\u897f\u85e5\u623f\u8cb7\u985e\u56fa\u9187\u85e5\u818f\u4f86\u64e6\uff0c\u6bcf\u6b21\u64e6\u5f8c\u7662\u611f\u6703\u6539\u5584\uff0c\u4f46\u76ae\u75b9\u8d8a\u64f4\u8d8a\u5927\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. Atopic dermatitis\nB. Nummular eczema\nC. Psoriasis\nD. Tinea cruris\nE. Candidiasis\n": "(D)", "104-1.\n30\u6b72\u7537\u6027, \u76ae\u819a\u75c5\u8b8a\u5982\u5716, \u4ee5\u4e0b\u4f55\u8005\u70ba\u5fc5\u9700\u4e4b\u8655\u7f6e\uff1f(1) \u62bd\u8840\u6aa2\u67e5\u6709\u7121HIV\u611f\u67d3\uff1b (2) \u8a62\u554f\u6027\u884c\u70ba\u53f2\uff1b(3) \u62bd\u8840\u6aa2\u67e5\u6709\u7121\u6885\u6bd2\uff1b(4) \u5207\u53d6\u7d44\u7e54\u4f5c\u75c5\u7406\u6aa2\u67e5\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(2)+(3)\nD. (4)\nE. (1)+(2)+(3)+(4)\n": "(C)", "104-2.\n\u4e00\u4f4d50\u6b72\u5973\u6027\uff0c\u767c\u751f\u5982\u5716\u6240\u793a\u7684\u76ae\u75b9\u3002\u76ae\u819a\u5207\u7247\u6aa2\u67e5\u767c\u73fe\u6709 acantholysis, keratinocytes necrosis \u53cavacuolar-interface dermatitis\u3002\u76f4\u63a5\u514d\u75ab\u87a2\u5149\u53cd\u61c9\uff08DIF\uff09\u767c\u73feIgG\u53cacomplement\u6c88\u7a4d\u65bc\u89d2\u8cea\u7d30\u80de\u8868\u9762\u53ca\u8868\u76ae\u57fa\u5e95\u819c\u3002\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(1)\u61c9\u505a\u60e1\u6027\u816b\u7624\u7be9\u6aa2; (2)\u61c9\u8a62\u554f\u7528\u85e5\u53f2, \u4e26\u7acb\u523b\u505c\u6b62\u76ee\u524d\u4f7f\u7528\u4e4b\u85e5\u7269 ;(3)\u61c9\u5bc6\u5207\u6ce8\u610f\u75c5\u60a3\u662f\u5426\u767c\u751f\u547c\u5438\u56f0\u96e3 ; (4)\u4ee5\u9ad8\u5291\u91cf\u985e\u56fa\u9187\u6cbb\u7642\uff0c\u4e00\u822c\u90fd\u6703\u5f88\u6709\u6548\u3002\nA. (1)+(3)\nB. (1)+(2)+(4)\nC. (1)+(2)+(3)\nD. (3)+(4)\nE. (1)+(2)+(3)+(4)\n": "(A)", "104-3.\n\u4e0058\u6b72\u7537\u6027\uff0c\u76ae\u819a\u5287\u7662\u53ca\u812b\u5c51\u5df2\u67093\u5e74\u3002\u8fd13\u500b\u6708\u4ee5\u4f86\uff0c\u7531\u6591\u584a\u8b8a\u6210\u5168\u8eab\u767c\u7d05\u3002\u76ae\u819a\u5287\u7662\u81f3\u6703\u5e72\u64fe\u751f\u6d3b\u7684\u7a0b\u5ea6\u3002\u7528\u85e5\u65b9\u9762\u53ea\u6709\u8fd15\u5e74\u4f86\u4f7f\u7528lisinpril\u63a7\u5236\u9ad8\u8840\u58d3\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fevital sign\u90fd\u6b63\u5e38\u3002\u9ad4\u8868\u5982\u5716\u6240\u793a90%\u76ae\u819a\u90fd\u767c\u7d05\u4e26\u812b\u5c51\uff0c\u800c\u4e14\u6709\u5168\u8eab\u6027\u6dcb\u5df4\u7d50\u816b\u5927, \u624b\u638c\u89d2\u638c\u589e\u539a\uff0c\u8dbe\u7532\u8b8a\u539a\u3002\u4ee5\u4e0b\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. Drug hypersensitivity reaction\nB. Pustular psoriasis\nC. Staphylococcal scalded skin syndrome\nD. Cutaneous T-cell lymphoma\nE. Atopic dermatitis\n": "(D)", "104-4.\n\u4e00 68\u6b72\u7537\u6027\uff0c\u6709\u9577\u671f\u7cd6\u5c3f\u75c5\u75c5\u53f2\uff0c3\u5e74\u5169\u5074\u4e0b\u80a2\u611f\u89ba\u7570\u5e38\uff0c\u5169\u5e74\u52c3\u8d77\u969c\u7919\u3002\u8173\u5e95\u767c\u751f\u5982\u5716\u6240\u793a\u4e0d\u75db\u7684\u6f70\u760d\u5df2\u67096\u500b\u6708\u3002BMI 32\u3002\u4ed6\u4e0d\u62bd\u7159\uff0c\u8173\u5e95\u672a\u53d7\u50b7\u904e\uff0c\u7121\u8ddb\u884c(claudication\uff09,\u7121\u591c\u9593\u8db3\u90e8\u75bc\u75db\u3002\u8db3\u90e8\u6aa2\u67e5\uff0c\u986f\u793adorsalis pedis\u8108\u52d5\u8b8a\u5c0f\uff0c\u8173\u8e1d\u4e26\u7121\u8272\u7d20\u6c88\u6fb1\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\u4ec0\u9ebc\uff1f\nA. Venous stasis ulcer\nB. Vasculitic ulcer\nC. Neuropathic ulcer\nD. Ischemic ulcer\nE. Clavus\n": "(C)", "104-5.\n\u4e00\u75c5\u4eba\u56e0leukocytoclastic vasculitis, \u4f7f\u7528dapsone\u6cbb\u7642 25\u5929\u5f8c\u7522\u751ffever\uff0c lymphadenopathy, \u53ca\u5982\u5716\u6240\u793a\u76ae\u75b9\uff0c \u4f46\u7121mucosa ulcer\u3002\u8acb\u554f\u70ba\u78ba\u5b9a\u8a3a\u65b7\uff0c\u4ee5\u4e0b\u6700\u61c9\u7acb\u5373\u505a\u7684\u5169\u9805\u6aa2\u67e5\u662f\u4ec0\u9ebc\uff1f\nA. CBC\uff08\u5305\u62ecdifferential count\uff09\u53caLiver function test\nB. Lymph node biopsy\u53caskin biopy\nC. Blood bacterial culture \u53cafungal culture\nD. MAST \u53caprick test\u6aa2\u6e2c\u904e\u654f\u539f\nE. Patch test\n": "(A)", "104-6.\n\u4e00\u4f4d64\u6b72\u7537\u6027\u56e0\u4e09\u5929\u4ee5\u4f86\u5feb\u901f\u8513\u5ef6\u7684\u5168\u8eab\u767c\u7d05\u3001\u75bc\u75db\u53ca\u878d\u5408\u7684\u81bf\u76b0\u81f3\u6025\u8a3a\u5c31\u8a3a\u3002\u7576\u6642\u9ad4\u6eab\u70ba38.9 C\u3002\u8a62\u554f\u75c5\u53f2\uff0c\u77ad\u89e3\u4ed6\u6709\u8f15\u5fae\u5c0b\u5e38\u6027\u4e7e\u766c\u53ca\u6c23\u5598\u3002\u5c0b\u5e38\u6027\u4e7e\u766c\u7528\u5916\u7528\u85e5\u63a7\u5236\u5f97\u4e0d\u932f\u3002\u4ed6\u56e0\u6c23\u5598\u670d\u7528\u4e86\u5341\u5929\u985e\u56fa\u9187\u81f3\u4e00\u661f\u671f\u524d\u624d\u505c\u85e5\u3002\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\u4ec0\u9ebc\uff1f\nA. Pustular psoriasis\nB. Acute generalized exanthematous pustulosis\nC. Drug reaction with eosinophilia and systemic symptoms\nD. Sweet syndrome\nE. Candida albicans infection\n": "(A)", "104-7.\n\u4e00\u5973\u6027\u75c5\u60a3\u5168\u8eab\u53ca\u81c9\u90e8\u767c\u751f\u5982\u5716\u6240\u793a\u76ae\u819a\u8b8a\u5316\u5df2\u6709\u4e8c\u5e74, \u4ee5\u4e0b\u4f55\u7a2e\u6aa2\u67e5\u5c0d\u6b64\u75c5\u4eba\u6700\u70ba\u6709\u7528\uff1f\nA. Liver function\nB. Renal function\nC. Thyroid function\nD. Pulmonary function\nE. Muscle power test\n": "(C)", "105-1.\n\u4e0027\u6b72\u7537\u6027\uff0c\u56e0\u5c0f\u817f\u4e00\u500b\u5feb\u901f\u8b8a\u5927\u7684\u75bc\u75db\u6f70\u760d(\u5982\u5716)\u5df2\u67092\u9031\uff0c\u81f3\u6025\u8a3a\u5c31\u91ab\u3002\u525b\u958b\u59cb\u50cf\u500b\u75d8\u5b50\u3002\u8fd12\u500b\u6708\u4f86\uff0c\u4ed6\u6709\u8179\u75db\u53ca\u8178\u9053\u8815\u52d5\u589e\u52a0\u7684\u554f\u984c\u3002\u8eab\u9ad4\u6aa2\u67e5\u4e26\u7121\u767c\u71d2\uff0cvital sign \u6b63\u5e38\u3002\u6f70\u760d\u4e0a\u4e26\u7121\u5316\u81bf\uff0c\u4e5f\u7121\u5ed4\u7ba1\u3002\r\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Calciphylaxis\nB. Ecthyma gangrenosum\nC. Necrotizing fasciitis\nD. Pyoderma gangrenosum\nE. Stasis ulcer\n": "(D)", "105-2.\n\u6b6450\u6b72\u5973\u6027\u75c5\u60a3\u5148\u6709\u81c9\u90e8\u6f6e\u7d05\u73fe\u8c61\uff0c\u4e00\u5e74\u5f8c\u5f8c\u6f14\u8b8a\u6210\u5982\u5716\u6240\u793a\u4e4b\u76ae\u75b9\uff0c\u9047\u71b1\u6642\u81c9\u6703\u66f4\u7d05\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Systemic lupus erythematosus\nB. Solar dermatitis\nC. Rosacea\nD. Dermatomyositis\nE. Ofuji disease\n": "(C)", "105-3.\n\u4e00\u4f4d70\u6b72\u5973\u6027\uff0c\u7f79\u60a3\u7cd6\u5c3f\u75c510\u5e74\uff0c\u672a\u898f\u5247\u5c31\u91ab\u670d\u85e5\uff0c\u4e00\u661f\u671f\u524d\u5728\u4e73\u623f\u4e0b\u51fa\u73fe\u523a\u7662\u7684\u7d05\u8272\u6591(\u5982\u5716)\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. \u81bf\u75c2\u75b9\uff08impetigo\uff09\nB. \u55ae\u7d14\u6027\u76b0\u75b9\u75c5\u6bd2\u611f\u67d3\uff08herpes simplex virus infection\uff09\nC. \u76ae\u819a\u5ff5\u73e0\u83cc\u611f\u67d3\uff08cutaneous candidiasis\uff09\nD. \u6bdb\u56ca\u708e\uff08folliculitis\uff09\nE. \u9ad4\u766c (tinea corporis)\n": "(C)", "105-4.\n\u5982\u5716\u6240\u793a\u4e4b\u76ae\u819a\u816b\u7624\u662f\uff1f\nA. \u68d8\u7d30\u80de\u764c (squamous cell carcinoma)\nB. \u6ce2\u6587\u6c0f\u75c7 (Bowen's disease)\nC. \u57fa\u5e95\u7d30\u80de\u764c (basal cell carcinoma)\nD. \u60e1\u6027\u9ed1\u7d20\u7624 (malignant melanoma)\nE. \u8840\u7ba1\u8089\u7624 (angiosarcoma)\n": "(C)", "105-5.\n\u4eca\u5e747\u6708\u9593\uff0c\u4e00\u4f4d33\u6b72\u7537\u6027\uff0c\u7a81\u7136\u767c\u751f\u5982\u5716\u6240\u793a\u4e4b\u5168 \u8eab\u76ae\u819a\u7d05\u75b9, \u611f\u89ba\u65e5\u66ec\u5f8c\u6703\u66f4\u7d05\u66f4\u7662\u3002\u4ee5\u4e0b\u4f55\u8005\u6709\u52a9\u65bc\u8a3a\u65b7\uff1a\nA. \u8a62\u554f\u904e\u53bb2\u5e74\u898f\u5247\u4f7f\u7528\u7684\u85e5\u7269\u540d\u7a31\nB. \u8a62\u554f\u8fd1\u4e8c\u9031\u65b0\u7528\u4e4b\u85e5\u7269\u540d\u7a31\nC. \u505aCBC \u53cadifferential count\nD. \u505a\u809d\u6a5f\u80fd\u6aa2\u67e5\nE. \u505a\u5149\u8cbc\u819a\u8a66\u9a57 (photo-patch test)\n": "(B)", "105-6.\n\u4e00\u4f4d40\u6b72\u5973\u6027\uff0c\u8fd1\u534a\u5e74\u4f86\u5728\u81c9\u90e8\u3001\u9838\u90e8\u8207\u524d\u80f8\u90e8\u76ae \u819a\uff0c\u51fa\u73fe\u5982\u5716\u4e4b\u8868\u73fe\u3002\u95dc\u65bc\u8a72\u60a3\u8005\u8a3a\u65b7\u8207\u6cbb\u7642\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(\u8acb\u9078\u51fa\u5168\u90e8\u7b54\u6848) 1.\u76ae\u819a\u75c5\u7406\u6709\u660e\u986f\u767c\u708e\u53cd\u61c9\uff0c\u9020\u6210\u8272\u7d20\u812b\u5931 2.\u76ae\u819a\u9ed1\u8272\u7d20\u7d30\u80de\u6d88\u5931\u6216\u6e1b\u5c11 3.\u61c9\u505a\u7532\u72c0\u817a\u529f\u80fd\u8207\u6297\u9ad4\u7684\u6aa2\u67e5 4.UVB1 \uff08311nm\uff09\u7a84\u6ce2\u7d2b\u5916\u5149\u53ef\u4fc3\u9032\u8272\u7d20\u56de\u5fa9\u3002\nA. 1+3\nB. 1+4\nC. 1+2+3\nD. 2+3+4\nE. 1+2+3+4\n": "(D)", "105-7.\n\u4e0065\u6b72\u7537\u6027\uff0c\u5148\u6709\u9f3b\u5c16\u75bc\u75db\u7136\u5f8c\u53f3\u773c\u9031\u75bc\u75db\u4f86\u5c31\u8a3a\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fevital sign\u90fd\u6b63\u5e38\u3002\u5728\u9f3b\u5c16\u53ca\u53f3\u773c\u9031\u570d\u6709\u5e95\u90e8\u7d05\u816b\u7684\u6210\u7c07\u5c0f\u6c34\u76b0\u3002\u4ee5\u4e0b\u4f55\u8005\u70ba\u6070\u7576\u8655\u7f6e\uff1f 1. \u5857\u62b9\u985e\u56fa\u9187\u85e5\u818f\uff1b 2. \u7acb\u523b\u505aophthalmic consultation\uff1b 3. \u505abacterial culture, \u4e26\u7d66\u4e88cephalexin\uff1b 4. \u7d66\u4e88\u53e3\u670dvalacyclovir; 5. IV push acyclovir\nA. 1+3\nB. 2+4\nC. 1+2+3\nD. 1+2+5\nE. 1+2+3+4+5\n": "(B)", "106-1.\n\u4e00\u4f4d40\u6b72\u5973\u6027\uff0c\u8fd1\u534a\u5e74\u4f86\u5728\u81c9\u90e8\u3001\u9838\u90e8\u8207\u524d\u80f8\u90e8\u76ae\u819a\uff0c\u51fa\u73fe\u5982\u5716\u4e4b\u8868\u73fe\u3002\u95dc\u65bc\u8a72\u60a3\u8005\u8a3a\u65b7\u8207\u6cbb\u7642\u7684\u63cf\u8ff0\uff0c\u4f55\u8005\u6b63\u78ba\uff1f(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848) (1)\u76ae\u819a\u75c5\u7406\u6709\u660e\u986f\u767c\u708e\u7d30\u80de\u6d78\u6f64\uff0c\u9020\u6210\u8272\u7d20\u812b\u5931; (2) \u6bdb\u56ca\u4e4b\u9ed1\u8272\u7d20\u7d30\u80de\u6d88\u5931; (3) \u8868\u76ae\u57fa\u5e95\u5c64\u4e4b\u9ed1\u8272\u7d20\u7d30\u80de\u6d88\u5931;  (4) \u61c9\u505a\u7532\u72c0\u817a\u529f\u80fd\u8207\u6297\u9ad4\u7684\u6aa2\u67e5; (5) UVB1(311nm)\u7a84\u6ce2\u7d2b\u5916\u5149\u53ef\u4fc3\u9032\u8272\u7d20\u56de\u5fa9\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (2)+(5)\nE. (3)+(4)+(5)\n": "(E)", "106-2.\n\u4e0070\u6b72\u7537\u6027\uff0c\u56e0\u53f3\u773c\u9031\u53ca\u53f3\u5074\u982d\u90e8\u75bc\u75db\u4f86\u5c31\u8a3a\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fevital sign\u90fd\u6b63\u5e38\u3002\u5728\u9f3b\u5c16\u53ca\u53f3\u773c\u9031\u570d\u6709\u5e95\u90e8\u7d05\u816b\u7684\u6210\u7c07\u5c0f\u6c34\u76b0\u3002\u4ee5\u4e0b\u4f55\u8005\u70ba\u6070\u7576\u8655\u7f6e\uff1f(1)\u5857\u62b9\u985e\u56fa\u9187\u85e5\u818f\uff1b(2)\u505abacterial culture, \u4e26\u7d66\u4e88cephalexin\uff1b(3)\u7acb\u523b\u505aophthalmic consultation\uff1b(4)\u505a\u814e\u529f\u80fd\u6aa2\u67e5; (5)\u7d66\u4e88\u53e3\u670dvalacyclovir\u6216\u975c\u8108\u9ede\u6ef4\u6ce8\u5c04acyclovir\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (2)+(5)\nE. (3)+(4)+(5)\n": "(E)", "106-3.\n\u4e00\u4f4d30\u6b72\u7537\u6027\u8d74\u6771\u5357\u4e9e\u65c5\u904a\uff0c\u56de\u570b\u5f8c\u56db\u500b\u6708\u51fa\u73fe\u624b\u638c\u8173\u638c\u53ca\u5168\u8eab\u5e36\u6709\u53e4\u9285\u8272\u7684\u812b\u5c51\u4e18\u75b9\uff0c\u6b64\u76ae\u75b9\u5df2\u6301\u7e8c2\u500b\u6708(\u5982\u5716\u793a)\u3002\u4ee5\u4e0b\u4f55\u8005\u4e0d\u662f\u5fc5\u8981\u8655\u7f6e? (1) \u6aa2\u6e2cmeasles IgM; (2)\u8a62\u554f\u6027\u884c\u70ba\u53f2; (3)\u6aa2\u6e2cTPHA; (4) \u6aa2\u6e2cVDRL\u6216RPR; (5)\u6aa2\u6e2crubella IgM\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(5)\nD. (2)+(5)\nE. (3)+(4)+(5)\n": "(C)", "106-4.\n\u4e0057\u6b72\u6709\u7159\u766e\u7684\u7537\u6027\uff0c10\u5e74\u524d\u6212\u7159\u3002\u4e0b\u5507\u767c\u751f\u5982\u5716\u6240\u793a\u4e4b\u76ae\u819a\u816b\u7624\u5df2\u67093\u500b\u6708\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1f\nA. \u68d8\u7d30\u80de\u764c (squamous cell carcinoma)\nB. \u65e5\u5149\u6027\u53e3\u5507\u708e(actinic chelitis)\nC. \u55ae\u7d14\u76b0\u75b9 (herpes simplex)\nD. \u60e1\u6027\u9ed1\u7d20\u7624 (malignant melanoma)\nE. \u81bf\u75c2\u75b9 (impetigo)\n": "(A)", "106-5.\n\u6b6422\u6b72\u7537\u6027\u75c5\u60a3\u540c\u6642\u6709\u5634\u5507\u6210\u7c07\u5c0f\u6c34\u76b0\uff0c\u53ca\u624b\u638c\u5982\u5716\u6240\u793a\u6a19\u9776\u6a23\u76ae\u75b9\uff0c\u6700\u53ef\u80fd\u7684\u611f\u67d3\u75c5\u539f\u662f\uff1a\nA. Herpes simplex virus\nB. Parvovirus B19\nC. Streptococcus, group A\nD. Varicella zoster virus\nE. Staphylococcus aureus\n": "(A)", "106-6.\n\u5982\u5716\u6240\u793a\u76ae\u75b9\u5df2\u67095\u5e74\uff0c\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5e38\u5728\u982d\u76ae\u767c\u751f\nB. Anti-IL12/IL-23, anti-IL17 \u662f\u6709\u6548\u7684\u751f\u7269\u88fd\u5291\nC. \u53e3\u670d\u985e\u56fa\u9187\u662f\u9996\u9078\u6cbb\u7642\nD. \u6bd4\u4e00\u822c\u4eba\u6613\u4f75\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\nE. \u6bd4\u4e00\u822c\u4eba\u6613\u4f75\u6709\u65b0\u9673\u4ee3\u8b1d\u75c7\u5019\u7fa4\n": "(C)", "106-7.\n\u6b6445\u6b72\u5a66\u5973\u65c5\u884c\u5c45\u4f4f\u65c5\u9928\u5f8c\u65bc\u8179\u90e8\u767c\u751f\u5982\u5716\u6240\u793a3\u9846\u9802\u90e8\u6709\u5c0f\u6c34\u76b0\u7684\u6703\u7662\u76ae\u75b9\uff0c\u8207\u5979\u540c\u884c\u7684\u5148\u751f\u4e26\u672a\u767c\u751f\u540c\u6a23\u76ae\u75b9\u3002\u61c9\u5982\u4f55\u8655\u7f6e\uff1f\nA. \u5857\u62b9\u985e\u56fa\u9187\u85e5\u818f\nB. \u5857\u62b9permethrin \u85e5\u818f\nC. \u5168\u8eab\u5857\u62b9benzyl benzoate \u85e5\u6c34\nD. \u53e3\u670d\u985e\u56fa\u9187\nE. \u53e3\u670divermectin\n": "(A)", "107-1.\n\u4e0038\u6b72\u5973\u6027\u56e0pyelonephritis\u4f7f\u7528trimethoprim-sulfamethoxazole\u6cbb\u76423\u661f\u671f\u5f8c\u767c\u751f\u5168\u8eab\u6027\u76ae\u75b9\u53ca\u81c9\u90e8\u816b\u8139\uff0c\u4f46\u7121\u547c\u5438\u56f0\u96e3\u3002\u5979\u4e26\u672a\u540c\u6642\u4f7f\u7528\u5176\u4ed6\u85e5\u7269\uff0c\u4e5f\u7121\u5176\u4ed6\u75be\u75c5\u3002\u7406\u5b78\u6aa2\u67e5\u767c\u73fe\uff1a\u9ad4\u6eab38.5\u2103, \u7121\u9ecf\u819c\u7834\u640d\uff0c\u5728\u524d\u9838\u53ca\u814b\u4e0b\u67093cm\u5927\u5c0f\u7684\u6dcb\u5df4\u7d50\uff0ccostal margin \u4e0b\u65b94cm\u6478\u5230liver edge\u3002\u76ae\u75b9\u5982\u5716\u6240\u793a\u3002\u8acb\u554f\u5982\u4e0b\u54ea\u4e9b\u6aa2\u67e5\u90fd\u662f\u5fc5\u9808\u505a\u7684\uff1f(1). CBC and differential count (2). Liver chemistry test (3). Lymph node biopsy (4). Skin biopsy (5). Serum IgE\nA. (1)+(2)\nB. (3)+(4)\nC. (4)+(5)\nD. (1)+(2)+(3)\nE. (3)+(4)+(5)\n": "(A)", "107-2.\n\u4e00\u7537\u6027\u75c5\u60a3\u767c\u751f\u65bc\u5168\u8eab(\u5305\u62ec\u624b\u638c\u8173\u638c)\u4e4b\u5982\u5716\u4e0d\u7662\u68d5\u7d05\u8272\u5e36\u5c51\u6591\u72c0\u4e18\u75b9\uff08maculopaules\uff09 \u5df2\u67091\u500b\u6708\uff0c\u7121\u7528\u85e5\u53f2\uff0c\u6709\u5168\u8eab\u6027\u6dcb\u5df4\u7d50\u816b\u5927, \u7d66\u4e88antihistamine\u672a\u898b\u6539\u5584\u3002\u75c5\u60a3\u53ca\u7537\u6027\u6027\u4f34\u4fb6RPR, TPHA\u5747\u70ba\u967d\u6027\uff0c\u4ee5\u4e0b\u4f55\u8005\u4e0d\u6b63\u78ba\uff1f (1). \u65bd\u6253benzathine penicillin G \u6cbb\u7642 (2). \u6aa2\u6e2cTPHA\u6216TPPA\uff0c\u964d\u4f4e4\u500d\u4ee5\u4e0a\u53ef\u4ee5\u78ba\u5b9a\u6cbb\u7642\u6210\u6548 (3). \u6aa2\u6e2cRPR\u6216VDRL\uff0c\u964d\u4f4e4\u500d\u4ee5\u4e0a\u53ef\u4ee5\u78ba\u5b9a\u6cbb\u7642\u6210\u6548 (4). \u6aa2\u6e2c anti-HSV2 IgG \u53ef\u8b49\u660e\u73fe\u5728\u4e5f\u6709HSV2 infection (5). \u5373\u4f7f\u4e0d\u6cbb\u7642\uff0c\u76ae\u75b9\u4e5f\u53ef\u80fd\u81ea\u52d5\u6d88\u5931\nA. (1)+(3)+(5)\nB. (2)+(4)\nC. (3)+(5)\nD. (1)+(3)\nE. (1)+(5)\n": "(B)", "107-3.\n52\u6b72\u7537\u6027\u6709acute myeloid leukemia, \u5728\u958b\u59cb\u5316\u764210\u5929\u5f8c\u767c\u751fneutropenic fever, \u4e14\u5728\u524d\u80f8\u3001\u5f8c\u80cc\u53ca\u624b\u81c2\u767c\u751f\u5e7e\u500b\u76ae\u75b9\u3002\u7406\u5b78\u6aa2\u67e5\u986f\u793a\uff1a\u9ad4\u6eab38.4\u2103\uff0c\u8840\u58d3110/70 mmHg, \u8108\u640f 95/min, \u547c\u543818/min. \u4ee3\u8868\u6027\u76ae\u75b9\u5982\u5716\u6240\u793a\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\uff1aHb 8.2g/dL\u3001WBC 400/ uL with 95% neutrophils\u3001Platelet 10,000/ uL\u3001Metabolic profile: normal\u3001Urine analysis: normal\u3001Chest x-ray: normal\u3001Blood culture: negative\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\u4ec0\u9ebc\uff1f\nA. Candidiasis\nB. Keratoacanthoma\nC. Pyogenic granuloma\nD. Sweet syndrome\nE. Deep fungal infection\n": "(D)", "107-4.\n\u6b64\u4e00\u75c5\u60a3\u767c\u751f\u5982\u5716\u6240\u793a\u7d05\u8272\u812b\u5c51\u76ae\u75b9\u65bc\u7709\u6bdb\u53ca\u7709\u5fc3, \u51ac\u5b63\u589e\u60e1\u3002\r\u8acb\u554f\u4ee5\u4e0b\u4f55\u8005\u70ba\u6700\u9069\u7576\u7684\u8655\u7f6e\uff1f\nA. Benzoyl peroxide\nB. Ketoconazole cream \u53ca low potency steroid cream\nC. Metronidazole gel\nD. Mupirocin ointment\nE. Clobetasol-17-propionate ointment\n": "(B)", "107-5.\n67\u6b72\u7537\u6027\u5e7e\u661f\u671f\u524d\u767c\u751f\u5982\u5716\u6240\u793a\u8173\u8e1d\u5916\u5074\u4e4b\u6f70\u760d\u3002\u6b64\u6f70\u760d\u6703\u75db\uff0c\u800c\u4e14\u5c07\u8173\u62ac\u9ad8\u6642\u66f4\u75db\u3002\u4ed6\u6709\u9ad8\u8840\u58d3\uff0c\u6bcf\u5e74\u62bd\u715940\u5305\uff0camlodipine\u662f\u552f\u4e00\u4f7f\u7528\u7684\u85e5\u7269\u3002\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u9700\u8981\u7684\u8655\u7f6e\uff1f\nA. \u5728\u6f70\u760d\u908a\u7de3\u505a\u5207\u7247\u6aa2\u67e5\nB. \u7a7f\u5f48\u6027\u896a\nC. \u91cf\u6e2c ankle-brachial index\nD. \u53e3\u670d\u6297\u751f\u7d20\nE. \u505a\u7d30\u83cc\u57f9\u990a\n": "(C)", "107-6.\n80\u6b72\u5973\u6027\u5728\u4e00\u9031\u524d\u767c\u73fe\u76ae\u819a\u5f88\u7662\uff0c\u7136\u5f8c\u5728\u524d\u80f8\u3001\u8179\u90e8\u3001\u56db\u80a2\u767c\u751f\u5982\u5716\u6240\u793a\u4e0d\u6613\u7834\u6389\u7684\u6c34\u76b0\uff0c\u53e3\u8154\u9ecf\u819c\u6b63\u5e38\u3002\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\u4ec0\u9ebc\uff1f\nA. Bullous pemphigoid\nB. Pemphigus vulgaris\nC. Pemphigus foliaceus\nD. Toxic epidermal necrolysis\nE. Stevens-Johnson syndrome\n": "(A)", "107-7.\n32\u6b72\u5973\u6027\u5728\u624b\u8098\u3001\u819d\u84cb\u3001\u982d\u76ae\u767c\u751f\u5287\u7662\u7684\u76ae\u75b9\u5df2\u67096\u500b\u6708\uff0c\u4e26\u6709irritable bowel syndrome \u7684\u75c5\u53f2\uff0c\u53e3\u8154\u9ecf\u819c\u6b63\u5e38\uff0c\u8fd16\u500b\u6708\u9ad4\u91cd\u6e1b\u8f154.5kg\uff0c\u7406\u5b78\u6aa2\u67e5\uff1a\u76ae\u75b9\u5982\u5716\u6240\u793a\uff0c\u5176\u9918\u6b63\u5e38\u3002\u6700\u53ef\u80fd\u540c\u6642\u4f75\u6709\u7684\u75be\u75c5\u662f\u90a3\u500b\uff1f\nA. Celiac disease\nB. Hepatitis C\nC. Non-Hodgkin lymphoma\nD. Ulcerative colitis\nE. Diabetes mellitus\n": "(A)", "108-1.\n\u95dc\u65bc\u75a5\u7621(scabies)\u4ee5\u4e0b\u4f55\u8005\u932f\u8aa4? (1)\u611f\u67d3\u4eba\u985e\u4e4b\u75a5\u87f2(Sarcoptes scabei var. hominis)\u751f\u547d\u5468\u671f\u7d04 30 \u5929\uff1b(2)\u75a5\u87f2\u96e2\u958b\u4eba\u9ad4\u76ae\u819a\u6700\u591a\u53ef\u5b58\u6d3b 3 \u5929\uff1b(3)\u6297\u75a5\u85e5\u818f\u5c40\u90e8\u539a\u5857\u65bc\u60a3\u90e8\u5c31\u53ef\u5fb9\u5e95\u6bba\u75a5\u87f2\uff1b(4)\u5982\u78ba\u5b9a\u611f\u67d3\uff0c\u5bb6\u4e2d\u5bf5\u7269(\u5982\u8c93\u72d7)\u4e5f\u9808\u4e00\u4f75\u6cbb\u7642\uff1b(5)\u6210\u4eba\u597d\u767c\u65bc\u624b\u81c2\u3001\u817f\u90e8\u3001\u80cc\u90e8\u53ca\u81c9\u90e8\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(3)\nD. (2)+(4)\nE. (3)+(4)+(5)\n": "(E)", "108-2.\n\u975e\u7622\u75d5\u578b\u843d\u9aee( nonscarring alopecia )\u53ef\u80fd\u4e4b\u539f\u56e0? (1)Alopecia areata\uff1b(2)Syphilis\uff1b(3)Androgenetic alopecia\uff1b(4)Discoid lupus erythematosus\uff1b(5)Lichen planopilaris\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (1)+(3)\nD. (2)+(4)\nE. (3)+(4)+(5)\n": "(A)", "108-3.\n\u4e0b\u5217\u95dc\u65bc\u8541\u9ebb\u75b9(urticaria)\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e\uff1f\nA. \u5e38\u7528\u6297\u7d44\u7e54\u80fa\u85e5\u7269\u6cbb\u7642\nB. \u6240\u6709\u7684\u75c5\u4eba\u7686\u53ef\u627e\u51fa\u539f\u56e0\nC. \u4f75\u7528aspirin\uff0c\u5e38\u4f7f\u6b64\u75c5\u60e1\u5316\nD. \u8541\u9ebb\u75b9\u4e4b\u55ae\u4e00\u75c5\u7076\u5e38\u572824 \u5c0f\u6642\u5167\u6d88\u5931\nE. \u61c9\u5148\u8a62\u554f\u75c5\u4eba\u7684\u7528\u85e5\u53f2\n": "(B)", "108-4.\n\u4e00\u4f4d\u5be6\u7fd2\u91ab\u5e2b\u7a81\u7136\u5728\u81c9\u90e8\u53ca\u8ec0\u5e79\u767c\u751f\u5982\u5716\u793a\u7684\u76ae\u75b9\uff0c\u4f75\u6709\u767c\u71d2\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1f\nA. Varicella\nB. Stevens-Johnson syndrome\nC. Rubella\nD. Sudamina\nE. Pityriasis lichenoides et varioliformis acuta\n": "(A)", "108-5.\n30\u6b72\u7537\u6027, \u76ae\u819a\u75c5\u8b8a\u5982\u5716, \u4ee5\u4e0b\u4f55\u8005\u70ba\u5fc5\u9700\u4e4b\u8655\u7f6e\uff1f(1) \u62bd\u8840\u6aa2\u67e5\u6709\u7121HIV\u611f\u67d3\uff1b (2) \u8a62\u554f\u6027\u884c\u70ba\u53f2\uff1b(3) \u62bd\u8840\u6aa2\u67e5\u6709\u7121\u6885\u6bd2\uff1b(4) \u5207\u53d6\u7d44\u7e54\u4f5c\u75c5\u7406\u6aa2\u67e5\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(2)+(3)\nD. (4)\nE. (1)+(2)+(3)+(4)\n": "(C)", "108-6.\n\u6b6450\u6b72\u5973\u6027\u75c5\u60a3\u5148\u6709\u81c9\u90e8\u6f6e\u7d05\u73fe\u8c61\uff0c\u4e00\u5e74\u5f8c\u5f8c\u6f14\u8b8a\u6210\u5982\u5716\u6240\u793a\u4e4b\u76ae\u75b9\uff0c\u9047\u71b1\u6642\u81c9\u6703\u66f4\u7d05\u3002\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Systemic lupus erythematosus\nB. Solar dermatitis\nC. Rosacea\nD. Dermatomyositis\nE. Ofuji disease\n": "(C)", "108-7.\n\u5982\u5716\u6240\u793a\u81c9\u90e8\u7684\u6162\u6027\u589e\u5927\u55ae\u4e00\u816b\u584a\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\uff1f\nA. Basal cell carcinoma\nB. Melanoma\nC. Seborrheic keratosis\nD. Sebaceous carcinoma\nE. Squamous cell carcinoma\n": "(A)", "109-194.\u4e00\u4f4d36\u6b72\u5973\u6027\u51fa\u73fe\u5982\u5716\u4e4b\u5287\u7662\u76ae\u819a\u75c5\u8b8a \uff0c\u75c5\u7076\u5f80\u5f80\u5728 2-4\u5c0f\u6642\u5019\u6d88\u5931 \uff0c\u4f46\u6703\u53cd\u53cd\u8986\u8986\u767c\u4f5c \uff0c\u90544\u5e74\u4e4b\u4e45\uff0c\u4f7f\n\u5979\u5e38\u5e38\u7121\u6cd5\u5165\u7720 \uff0c\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.\u7570\u4f4d\u6027\u76ae\u819a\u708e (atopic dermatitis)\nB.\u5c0b\u5e38\u6027\u9b5a\u9c57\u766c (ichthyosis vulgaris)\nC.\u6162\u6027\u8541\u9ebb\u75b9 (Chronic urticaria)\nD.\u75a5\u7621 (Scabies)\nE.\u6162\u6027\u6fd5\u75b9 (Chronic eczema)\n": "[C]", "109-195.\u627f\u4e0a\uff0c\u8acb\u554f\u76ee\u524d\u6700\u5efa\u8b70\u7684\u9996\u9078\u6cbb\u7642\u65b9\u5f0f\u70ba\u4f55\uff1f       \nA.\u53e3\u670d\u6297\u7d44\u7e54\u80fa\nB.\u53e3\u670d\u985e\u56fa\u9187\nC.\u5c40\u90e8\u985e\u56fa\u9187\nD.\u514d\u75ab\u6291\u5236\u5291 (\u5982\u74b0\u5b62\u9748cyclosporine)\nE.\u5c40\u90e8\u6297\u7d44\u7e54\u80fa\n": "[A]", "109-196.\u81fa\u7063\u4eba\u6700\u5e38\u898b\u7684\u76ae\u819a\u9ed1\u8272\u7d20\u7d30\u80de\u764c (Cutaneous melanoma) \u662f\u54ea\u4e00\u578b\uff1f    \nA.\u7d50\u7bc0\u578b\u9ed1\u8272\u7d20\u7d30\u80de\u764c (nodular melanoma)\nB.\u80a2\u7aef\u9ed1\u75e3\u578b\u9ed1\u8272\u7d20\u7d30\u80de\u764c (acral lentiginous melanoma)\nC.\u8868\u6dfa\u64f4\u6563\u578b\u9ed1\u8272\u7d20\u7d30\u80de\u764c (superficial spreading melanoma)\nD.\u60e1\u6027\u9ed1\u75e3\u578b\u9ed1\u8272\u7d20\u7d30\u80de\u764c (lentigo maligna melanoma)\nE.\u9ecf\u819c\u578b\u9ed1\u8272\u7d20\u7d30\u80de\u764c (mucousal melanoma)\n": "[B]", "109-197.\u4e0b\u5217\u6709\u95dc\u5224\u65b7\u662f\u5426\u70ba\u76ae\u819a\u9ed1\u8272\u7d20\u7d30\u80de\u764c (Cutaneous melanoma) \u7684ABCDE\u53e3\u8a23 \uff0c\u54ea\u4e9b\u8981\u8003\u616e\u60e1\u6027 \uff1f(1) \nA:\u5c0d\u7a31 (Asymmetry )\uff0c\u75c5\u7076\u672c\u8eab\u5de6\u53f3\u5c0d\u7a31\u7684\u6642\u5019; (2) B\u908a\u7de3 (Border)\uff0c\u75c5\u7076\u908a\u7de3\u898f\u5247\u7684\u6642\u5019; (3) C\u984f\u8272 \n(Color)\uff0c\u75c5\u7076\u8272\u6fa4\u5747\u52fb\u7684\u6642\u5019; (4) D\u76f4\u5f91 (Diameter) \u5927\u65bc6 mm\u7684\u6642\u5019; (5) E\u6f14\u8b8a (Evolving )\uff0c\u75c5\u7076\u5927\n\u5c0f\u3001\u5f62\u72c0\u3001\u984f\u8272\u6709\u8b8a\u5316 \uff0c\u6216\u662f\u9686\u8d77 \u3001\u51fa\u8840\u6642   \nA.(1)+(2)+(3)\nB.(2)+(3)+(4)\nC.(2)+(3)\nD.(4)+(5)\nE.(2)+(5)\n": "[D]", "109-198.\u4e0b\u5217\u6709\u95dc\u57fa\u5e95\u7d30\u80de\u764c (Basal cell carcinoma) \u7684\u81e8\u5e8a\u8868\u73fe \uff0c\u4f55\u8005\u6b63\u78ba \uff1f(1) \u8868\u6dfa\u578b (superficial) \u57fa\u5e95\u7d30\u80de\u764c\n\u6700\u60e1\u6027\uff0c\u597d\u767c\u65bc\u56db\u80a2\u672b\u68a2 \uff0c\u81e8\u5e8a\u4e0a\u50cf\u6fd5\u75b9\u75c5\u7076; (2) \u7d50\u7bc0\u578b (nodular) \u57fa\u5e95\u7d30\u80de\u764c\u81e8\u5e8a\u4e0a\u5e38\u898b\u70ba\u7de9\u6162\u9577\u5927\u7684\n\u7d50\u7bc0\uff0c\u5e36\u6709\u73cd\u73e0\u5149\u6fa4 \uff0c\u908a\u7de3\u9686\u8d77 \uff0c\u4e14\u6709\u64f4\u5f35\u8840\u7d72; (3) \u8272\u7d20\u578b (pigmented) \u57fa\u5e95\u7d30\u80de\u764c\u985e\u4f3c\u9ed1\u8272\u7d20\u7d30\u80de\n\u764c\uff0c\u6975\u6613\u8f49\u79fb; (4) \u786c\u76ae\u578b (morpheaform) \u57fa\u5e95\u7d30\u80de\u764c \uff0c\u81e8\u5e8a\u8868\u73fe\u70ba\u55ae\u4e00 \u3001\u6241\u5e73\u6216\u840e\u7e2e\u50cf\u75a4\u75d5\u822c\u7684\u677f\u584a\u75c5\n\u7076\uff0c\u5177\u4fb5\u8972\u6027   \nA.(1)+(3)\nB.(2)+(4)\nC.(1)+(4)\nD.(2)+(3)\nE.(3)+(4)\n": "[B]", "109-199.\u4e00\u4f4d56\u6b72\u7537\u6027\u51fa\u73fe\u5982\u5716\u75c5\u7076\uff0c\u8acb\u554f\u6700\u53ef\u80fd\u8a3a\u65b7\uff0c\u8207\u6700\u91cd\u8981\u7684\u81e8\u5e8a\u7279\u5fb5\u70ba\u4f55\uff1f    \nA.\u7d05\u6591\u6027\u72fc\u7621 (lupus erythematosus)\uff1b\u51cd\u7621\u578b\u7d05\u6591\u6027\u72fc\u7621 (chilblain lupus erythematosus) \u75c5\u7076\nB.\u76ae\u808c\u708e (dermatomyositis)\uff1bGottron\u6c0f\u5fb5\u5019 (Gottron's sign)\nC.\u985e\u98a8\u6ebc\u6027\u95dc\u7bc0\u708e (rheumatoid arthritis)\uff1b\u985e\u98a8\u6fd5\u6027\u7d50\u7bc0 (rheumatoid nodules)\nD.\u5168\u8eab\u6027\u786c\u76ae\u75c7 (systemic scleroderma)\uff1b\u624b\u6307\u786c\u5316 (sclerodactyly)\u3001\u624b\u6307\u6f70\u760d (digital ulcerations)\nE.\u611f\u67d3\u6027\u5fc3\u5167\u819c\u708e (infective endocarditis)\uff1bJaneway lesions\n": "[D]", "109-200.\u4e00\u4f4d26\u6b72\u7537\u6027\u51fa\u73fe\u5982\u5716\u75c5\u7076\uff0c\u8acb\u554f\u6700\u53ef\u80fd\u8a3a\u65b7\u70ba\u4f55\uff1f    \nA.\u5713\u76e4\u578b\u7d05\u6591\u6027\u72fc\u7621 (discoid lupus erythematosus)   \nB.\u76ae\u808c\u708e (dermatomyositis)\nC.\u6df1\u90e8\u771f\u83cc\u611f\u67d3 (deep fungal infection)\nD.\u786c\u76ae\u75c7 (scleroderma)\nE.\u840e\u7e2e\u6027\u75a4\u75d5 (atrophic scar)": "[A]", "110-156.31\u6b72\u7537\u6027\u4e3b\u8a34\u5168\u8eab\u7121\u75c7\u72c0\u76ae\u75b9 2\u500b\u6708(\u5982\u5716\u793a)\uff0c\u56db\u500b\u6708\u524d\u6709\u6771\u5357\u4e9e\u65c5\u904a\u53f2 \uff0c\u4e26\u66fe\u53c3\u52a0\u7576\u5730\u7684\u5c71\u5340\u5065\u884c \uff0c\u4ee5\n\u4e0b\u4f55\u8005\u662f\u5c0d\u5176\u8a3a\u65b7\u6700\u9700\u8981\u7684\u6aa2\u67e5 ?   \nA.\u76ae\u5c51KOH\u986f\u5fae\u93e1\u6aa2\u67e5\u3002\nB.\u76ae\u819a\u7d44\u7e54\u5207\u7247\u7684\u975e\u5178\u578b\u5206\u679d\u687f\u83cc\u7684\u7d44\u7e54\u67d3\u8272\u53ca\u57f9\u990a\u3002\nC.\u62bd\u8840\u6aa2\u6e2cVDRL/RPR \u53caTPPA/TPHA\u6548\u50f9\u3002\nD.\u62bd\u8840\u6aa2\u6e2cBorrelia burgdorferi IgM \u53caIgG\u8840\u6e05\u6297\u9ad4\u3002\nE.\u4f0d\u6c0f\u71c8(Wood's light)\u6aa2\u67e5\u3002\n": "[C]", "110-157.20\u6b72\u7537\u6027\u51fa\u751f\u6642\u5728\u81c0\u90e8\u5169\u5074\u53ca\u80cc\u90e8\u767c\u73fe\u6578\u500b\u767d\u6591 \uff0c\u5169\u500b\u6708\u5927\u6642\u958b\u59cb\u6709\u7672\u7647\u767c\u4f5c \uff0c\u4e00\u76f4\u4ee5\u6297\u7672\u7647\u85e5\u63a7\u5236 \u3002\u81c9\n\u90e8 (\u5716\u4e00) \u53ca\u4e0b\u80cc\u90e8 (\u5716\u4e8c) \u5728\u5b69\u7ae5\u671f\u51fa\u73fe\u591a\u767c\u6027\u76ae\u819a\u816b\u7624 \uff0c5\u5e74\u524d\u8179\u90e8MRI\u5f71\u50cf\u6aa2\u67e5\u767c\u73fe\u814e\u81df\u816b\u7624\u53ca\u80f0\u81df\u982d\n\u90e8\u816b\u7624\u3002\u80f0\u81df\u816b\u7624\u9010\u6f38\u8b8a\u5927\u52307 cm \uff0c\u4e26\u4f34\u6709\u8179\u75db \uff0c\u7d93\u5167\u8996\u93e1\u8d85\u97f3\u6ce2\u6307\u5f15\u7d30\u91dd\u62bd\u5438\u6aa2\u67e5 \uff0c\u75c5\u7406\u5831\u544a\u986f\u793a\u70ba\n\u795e\u7d93\u5167\u5206\u6ccc\u7624 (neuroendocrine tumor )\u3002\u8acb\u554f\u7d9c\u5408\u4e0a\u8ff0\u6b64\u4f4d\u75c5\u4eba\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.\u795e\u7d93\u7e96\u7dad\u7624\u75c7\u7b2c\u4e00\u578b (Neurofibromatosis type 1)\u3002\nB.\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624\u7b2c\u4e00\u578b (Multiple endocrine neoplasia type 1)\u3002\nC.von Hippel-Lindau\u75c7\u5019\u7fa4 (von Hippel \u2013Lindau disease)\u3002   \nD.\u7d50\u7bc0\u6027\u786c\u5316\u75c7 (Tuberous sclerosis)\u3002\nE.Muir-Torre \u75c7\u5019\u7fa4 (Muir-Torre syndrome)\u3002\n": "[D]", "110-158.62\u6b72\u5973\u6027 3\u5e74\u524d\u958b\u59cb\u5728\u524d\u80f8 \u3001\u4e0a\u80cc (\u5716\u4e00)\u3001\u56db\u80a2\u53ca\u624b\u80cc (\u5716\u4e8c) \u51fa\u73fe\u6414\u7662\u76ae\u75b9 \uff0c\u7121\u53e3\u8154\u9ecf\u819c\u6f70\u760d \uff0c\u6700\u8fd1\u5e7e\u500b\n\u6708\u6709\u4e0b\u80a2\u95dc\u7bc0\u75bc\u75db \uff0c\u722c\u6a13\u68af\u6709\u7121\u529b\u73fe\u8c61 \uff0c\u4e26\u5728\u4e00\u500b\u6708\u524d\u767c\u73fe\u7f79\u60a3\u4e73\u764c \uff0c\u5be6\u9a57\u5ba4\u62bd\u8840\u6aa2\u67e5 \uff1acreatine kinase \n(CK), ALT, AST \u5728\u6b63\u5e38\u7bc4\u570d \uff0cantinuclear antibodies 1:160 (speckled pattern) \u967d\u6027 \uff0canti-Ro/SSA \nantibodies\u9670\u6027 \uff0canti-La/SSB antibodies \u9670\u6027 \u3002\u7d9c\u5408\u4e0a\u8ff0\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.\u4e7e\u766c (Psoriasis vulgaris)\u3002\nB.\u76ae\u808c\u708e (Dermatomyositis)\u3002\nC.\u526f\u816b\u7624\u578b\u5929\u75b1\u7621 (Paraneoplastic pemphigus)\u3002\nD.\u4e9e\u6025\u6027\u76ae\u819a\u7d05\u6591\u72fc\u7621 (Subacute cutaneous lupus erythematosus)\u3002\nE.Lambert-Eaton\u808c\u7121\u529b\u75c7\u5019\u7fa4 (Lambert-Eaton myasthenic syndrome)\u3002\n": "[B]", "110-159.26\u6b72\u7537\u6027\u81ea 2\u6b72\u8d77\u8a3a\u65b7\u70ba\u7570\u4f4d\u6027\u76ae\u819a\u708e \uff0c\u671f\u9593\u65b7\u65b7\u7e8c\u7e8c\u63a5\u53d7\u6cbb\u7642 \uff0c\u4e00\u5468\u524d\u6709\u767c\u71d2\u4e26\u958b\u59cb\u7531\u624b\u524d\u81c2\u51fa\u73fe\u6414\u7662\n\u75bc\u75db\u7684\u76ae\u75b9 (\u5716\u4e00)\uff0c\u6709\u63a5\u53d7\u53e3\u670dcephalexin\u6cbb\u7642 \uff0c\u4f46\u76ae\u819a\u75c5\u7076\u5728\u9019\u4e00\u5468\u4ecd\u64f4\u6563\u81f3\u81c9\u90e8 \u3001\u9838\u90e8\u3001\u8ec0\u5e79 (\u5716\n\u4e8c)\u548c\u4e0b\u80a2\uff0c\u8acb\u554f\u4e0b\u5217\u4f55\u8005\u662f\u6700\u6070\u7576\u7684\u8655\u7f6e \uff1f   \nA.Topical mupirocin\u3002\nB.Systemic prednisolone\u3002\nC.Systemic acyclovir\u3002\nD.Intravenous vancomycin\u3002\nE.Oral fluconazole\u3002\n": "[C]", "110-160.\u95dc\u65bc\u9ed1\u8272\u7d20\u7624 (melanoma) \uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba \uff1f\n(1) \u662f\u76ae\u819a\u764c\u4e2d\u6700\u5e38\u898b\u7684\u985e\u578b\n(2) \u5c31\u7a2e\u65cf\u4e2d\u9ed1\u8272\u7d20\u7624\u7684\u4e9e\u578b\u5206\u5e03\u800c\u8a00 \uff0c\u9ec3\u7a2e\u4eba\u80a2\u7aef\u5c0f\u75e3\u6027\u9ed1\u8272\u7d20\u7624 (acral lentiginous melanoma )\u6240\u5360\u6bd4\n\u4f8b\u6bd4\u767d\u7a2e\u4eba\u591a \uff0c\u767d\u7a2e\u4eba\u9ecf\u819c\u9ed1\u8272\u7d20\u7624 (mucosal melanoma) \u6240\u5360\u6bd4\u4f8b\u6bd4\u9ec3\u7a2e\u4eba\u591a\n(3) \u75e3(nevus)\u662f\u9ed1\u8272\u7d20\u7624\u7684\u5371\u96aa\u56e0\u5b50\u4e4b\u4e00 \uff0c\u7d04\u67097\u6210\u4ee5\u4e0a\u7684\u76ae\u819a\u9ed1\u8272\u7d20\u7624\u662f\u7531\u75e3\u8f49\u8b8a\u800c\u4f86 \u3002\n(4) Breslow\u816b\u7624\u539a\u5ea6\u662f\u9ed1\u8272\u7d20\u7624\u6700\u91cd\u8981\u7684\u9810\u5f8c\u56e0\u5b50\n(5) \u4e00\u4f4d\u7f79\u60a3\u5de6\u8db3\u5e95\u80a2\u7aef\u5c0f\u75e3\u6027\u9ed1\u8272\u7d20\u7624\u768452\u6b72\u5973\u6027 \uff0c\u816b\u7624\u539a\u5ea6\u70ba2 mm\u4f46\u6c92\u6709\u6f70\u760d \uff0c\u5979\u7684\u5de6\u8179\u80a1\u6e9d\u6c92\u6709\u6478\n\u5230\u6dcb\u5df4\u7d50\u816b \uff0c\u4e14\u96fb\u8166\u65b7\u5c64\u6383\u63cf\u6c92\u6709\u770b\u5230\u5168\u8eab\u6027\u8f49\u79fb \uff0c\u6839\u64da\u76ee\u524d\u7684\u6cbb\u7642\u6a19\u6e96 \uff0c\u6b64\u75c5\u60a3\u9664\u4e86\u63a5\u53d7\u76ae\u819a\u816b\u7624\u5ee3\u6cdb\n\u5207\u9664\u5916\u9084\u8981\u65bd\u884c\u524d\u54e8\u6dcb\u5df4\u7d50\u5207\u7247 (sentinel lymph node biopsy )\u3002   \nA.(1)+(2)+(3)+(4)\u3002\nB.(2)+(3)+(4)\u3002\nC.(1)+(3)+(5)\u3002\nD.(4)+(5)\u3002\nE.(3)+(4)+(5)\u3002": "[D]", "111-156.20\u6b72\u7537\u6027\u81ea\u5b69\u7ae5\u671f\u8d77\u8a3a\u65b7\u70ba\u7570\u4f4d\u6027\u76ae\u819a\u708e \uff0c\u671f\u9593\u65b7\u65b7\u7e8c\u7e8c\u63a5\u53d7\u6cbb\u7642 \uff0c\u4e00\u5468\u524d\u6709\u767c\u71d2\u4e26\u5728\u81c9\u9838\u90e8\u51fa\u73fe\u6414\u7662\u75bc\n\u75db\u7684\u76ae\u75b9 (\u5982\u5716)\uff0c\u8acb\u554f\u6700\u53ef\u80fd\u7684\u611f\u67d3\u75c5\u539f\u662f ?   \nA.\u55ae\u7d14\u75b1\u75b9\u75c5\u6bd2 (Herpes simplex virus)\u3002\nB.\u4eba\u985e\u7ec6\u5c0f\u75c5\u6bd2B19 (Human parvovirus B19)\u3002\nC.A\u7fa4\u93c8\u7403\u83cc (Streptococcus, group A)\u3002\nD.\u6c34\u75d8\u5e36\u72c0\u75b1\u75b9\u75c5\u6bd2 (Varicella zoster virus)\u3002\nE.\u91d1\u9ec3\u8272\u8461\u8404\u7403\u83cc (Staphylococcus aureus)\u3002\n": "[A]", "111-157.50\u6b72\u5973\u6027\u6709\u7cd6\u5c3f\u75c5\u53f2 \uff0c4\u5e74\u524d\u56e0\u8179\u75db\u53ca\u6162\u6027\u8179\u7009\u8a3a\u65b7\u70ba\u6f70\u760d\u6027\u7d50\u8178\u708e \uff0c\u4e00\u5468\u524d\u5728\u96d9\u5074\u5c0f\u817f\u7522\u751f\u75bc\u75db\u7684\u76ae\u75b9\n\u53ca\u6f70\u760d\uff0c\u7bc4\u570d\u9010\u6f38\u64f4\u5927 \uff0c\u4e26\u5408\u4f75\u96d9\u4e0b\u80a2\u6c34\u816b (\u5982\u5716)\u3002\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.\u52d5\u8108\u6027\u6f70\u760d (Arterial ulcer)\u3002\nB.\u7d50\u7bc0\u6027\u7d05\u6591 (Erythema nodosum)\u3002\nC.\u975c\u8108\u9b31\u6eef\u6027\u6f70\u760d (Venous stasis ulcer)\u3002\nD.\u58de\u75bd\u6027\u81bf\u76ae\u75c7 (Pyoderma gangrenosum)\u3002\nE.\u8102\u80aa\u76ae\u819a\u786c\u5316\u75c7 (Lipodermatosclerosis)\u3002\n": "[D]", "111-158.45\u6b72\u7537\u6027\u5370\u5c3c\u79fb\u5de5 \uff0c\u4e00\u5e74\u524d\u958b\u59cb\u6ce8\u610f\u5230\u81ea\u5df1\u8eab\u9ad4\u51fa\u73fe\u7d05\u8272\u7a81\u8d77\u4e18\u75b9\u53ca\u6591\u584a \uff0c\u75c5\u7076\u9010\u6f38\u64f4\u5c55\u81f3\u81c9\u90e8\u53ca\u56db\n\u80a2\uff0c\u55ae\u4e00\u75c5\u7076\u9762\u7a4d\u4e5f\u8b8a\u5927 \uff0c\u4e00\u500b\u6708\u524d\u767c\u73fe\u5916\u5074\u7709\u6bdb\u812b\u5931 \uff0c\u75c5\u7076\u89f8\u6478\u6642\u6709\u9ebb\u6728\u611f (\u5716\u4e00\u53ca\u5716\u4e8c )\u3002\u76ae\u819a\u5207\u7247\u75c5\n\u7406\u6aa2\u67e5\u53ef\u898b\u76ae\u819a\u771f\u76ae\u5167\u6709\u6ce1\u6cab\u7d30\u80de (foam cells )\u6d78\u6f64\u53ca\u8a31\u591a\u6297\u9178\u6027\u83cc \u3002\u8acb\u554f\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.\uf9d0\u7d50\u6838\u578b\u6f22\u751f\u75c5 (Tuberculoid leprosy)\u3002\nB.\u5c0b\u5e38\u72fc\u7621 (Lupus vulgaris)\u3002\nC.\u985e\u8089\u7624\u75c5 (Sarcoidosis)\u3002\nD.\u74b0\u5f62\u8089\u82bd\u816b (Granuloma annulare)\u3002\nE.\u816b\u7624\u578b\u6f22\u751f\u75c5 (Lepromatous leprosy)\u3002\n": "[E]", "111-159.\u5982\u5716\u6240\u793a\u7684\u76ae\u75b9\uff0c\u75c5\u53f2\u5df2\u670910\u5e74\uff0c\u95dc\u65bc\u6b64\u75be\u75c5\u4ee5\u4e0b\u6558\u8ff0\u4f55\u8005\u70ba\u975e\uff1f    \nA.\u6703\u9020\u6210\u95dc\u7bc0\u708e\u53ca\u6307\u7532\u75c5\u8b8a\u3002\nB.\u56e0\u5fc3\u8840\u7ba1\u75be\u75c5\u5c0e\u81f4\u6b7b\u4ea1\u7684\u6bd4\u7387\u6bd4\u4e00\u822c\u4eba\u9ad8\u3002\nC.\u670d\u7528\u03b2\u53d7\u9ad4\u963b\u65b7\u5291\u5982propranolol \u53ef\u80fd\u4f7f\u75be\u75c5\u60e1\u5316\u3002\nD.\u53e3\u670d\u985e\u56fa\u9187\u662f\u7b2c\u4e00\u7dda\u6cbb\u7642\u3002\nE.IL-23\u6291\u5236\u5291\u53caIL-17\u6291\u5236\u5291\u662f\u6709\u6548\u7684\u751f\u7269\u88fd\u5291\u6cbb\u7642\u3002\n": "[D]", "111-160.60\u6b72\u5973\u6027 2\u5e74\u524d\u958b\u59cb\u5728\u524d\u80f8 (\u5716\u4e00)\u3001\u4e0a\u80cc \u3001\u56db\u80a2\u53ca\u624b\u80cc (\u5716\u4e8c) \u51fa\u73fe\u6414\u7662\u76ae\u75b9 \uff0c\u7121\u53e3\u8154\u9ecf\u819c\u6f70\u760d \uff0c\u6700\u8fd1\u5e7e\n\u500b\u6708\u6709\u541e\u56a5\u56f0\u96e3 \uff0c\u722c\u6a13\u68af\u7121\u529b\u7684\u73fe\u8c61 \uff0c\u4e26\u5728\u4e00\u500b\u6708\u524d\u767c\u73fe\u7f79\u60a3\u4e73\u764c \uff0c\u5be6\u9a57\u5ba4\u62bd\u8840\u6aa2\u67e5 \uff1a\u808c\u9178\u6fc0\u9176 \n(creatine kinase )\u5728\u6b63\u5e38\u7bc4\u570d \uff0cantinuclear antibodies 1:160 (speckled pattern) \u967d\u6027 \uff0canti-Ro/SSA \nantibodies\u9670\u6027 \uff0canti-La/SSB antibodies \u9670\u6027 \u3002\u7d9c\u5408\u4e0a\u8ff0\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u70ba\u4f55 \uff1f   \nA.\u5168\u8eab\u6027\u786c\u5316\u75c7 (Systemic sclerosis)\u3002\nB.\u76ae\u808c\u708e (Dermatomyositis)\u3002\nC.\u4f34\u816b\u7624\u578b\u5929\u76b0\u7621 (Paraneoplastic pemphigus)\u3002   \nD.\u4e9e\u6025\u6027\u76ae\u819a\u7d05\u6591\u6027\u72fc\u7621 (Subacute cutaneous lupus erythematosus)\u3002\nE.\u5305\u6db5\u9ad4\u808c\u708e (Inclusion body myositis)\u3002": "[B]"}